DrugMAP Full Data Download File
Title - DrugMAP molecular interaction atlas of all drug in raw format
Version 1.01 (2022.07.20)
Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB)
            College of Pharmaceutical Sciences
            Zhejiang University
            https://idrblab.org/
Any question about data provided here, please contact with:
Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn)

DI: Drug ID
DN: Drug Name
MI: Molecule ID
MN: Molecule Name
MT: Molecule Type
MA: Mode of Action
RN: Reference Name
RU: Reference URL

DMMHNU2	DI	DMMHNU2
DMMHNU2	DN	(S)-(+)-Dimethindene maleate
DMMHNU2	MI	TTTIBOJ
DMMHNU2	MN	Histamine H1 receptor (H1R)
DMMHNU2	MT	DTT
DMMHNU2	MA	Antagonist
DMMHNU2	RN	Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93.
DMMHNU2	RU	https://pubmed.ncbi.nlm.nih.gov/19308787

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTG3T6X
DMIAHVU	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Glutamine 161 of Glut1 glucose transporter is critical for transport activity and exofacial ligand binding. J Biol Chem. 1994 Aug 12;269(32):20533-8.
DMIAHVU	RU	http://www.jbc.org/content/269/32/20533.long

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT3BI6S
DMIAHVU	MN	Glucose transporter type 10 (SLC2A10)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab. 2001 Sep-Oct;74(1-2):186-99.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/11592815

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTA5QI0
DMIAHVU	MN	Glucose transporter type 12 (SLC2A12)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The human facilitative glucose transporter GLUT12: Expression and regulation in Caco-2 and 3T3-L1cells.
DMIAHVU	RU	https://2017.febscongress.org/abstract_preview.aspx?idAbstractEnc=4424170093096096098098424170

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT18YD9
DMIAHVU	MN	Glucose transporter type 14 (SLC2A14)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The SLC2A14 gene, encoding the novel glucose/dehydroascorbate transporter GLUT14, is associated with inflammatory bowel disease. Am J Clin Nutr. 2017 Dec;106(6):1508-1513.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/28971850

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTUJPOL
DMIAHVU	MN	Glucose transporter type 2, liver (SLC2A2)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab. 2011 Dec;104(4):648-53.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21920790

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT9SQ3L
DMIAHVU	MN	Glucose transporter type 3, brain (SLC2A3)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J Cell Physiol. 2011 Dec;226(12):3286-94.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21321936

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT4827A
DMIAHVU	MN	Glucose transporter type 4, insulin-responsive (SLC2A4)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. Diabetes. 2002 Sep;51(9):2719-26.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12196464

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTS4MKQ
DMIAHVU	MN	Glucose transporter type 6 (SLC2A6)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT8SQBG
DMIAHVU	MN	Glucose transporter type 7 (SLC2A7)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT2I7BM
DMIAHVU	MN	Glucose transporter type 8 (SLC2A8)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTMSNOU
DMIAHVU	MN	Proton-associated sugar transporter A (SLC45A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	Dysfunction of the Cerebral Glucose Transporter SLC45A1 in Individuals with Intellectual Disability and Epilepsy. Am J Hum Genet. 2017 May 4;100(5):824-830.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/28434495

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTOKC04
DMIAHVU	MN	Sodium/glucose cotransporter 1 (SLC5A1)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/24587162

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTO4FLB
DMIAHVU	MN	Sodium/glucose cotransporter 3 (SLC5A4)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DT1CP40
DMIAHVU	MN	Sodium/glucose cotransporter 4 (SLC5A9)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607332

DMIAHVU	DI	DMIAHVU
DMIAHVU	DN	2-deoxyglucose
DMIAHVU	MI	DTQNIG7
DMIAHVU	MN	Sodium/glucose cotransporter 5 (SLC5A10)
DMIAHVU	MT	DTP
DMIAHVU	MA	Substrate
DMIAHVU	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMIAHVU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMYFBMS	DI	DMYFBMS
DMYFBMS	DN	99mTc-fanolesomab
DMYFBMS	MI	TTNV1KZ
DMYFBMS	MN	Fucosyltransferase IV (CD15)
DMYFBMS	MT	DTT
DMYFBMS	RN	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
DMYFBMS	RU	https://pubmed.ncbi.nlm.nih.gov/15756752

DMVZO01	DI	DMVZO01
DMVZO01	DN	99mTc-sestamibi
DMVZO01	MI	DTSYQGK
DMVZO01	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVZO01	MT	DTP
DMVZO01	MA	Substrate
DMVZO01	RN	99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77(3):353-8.
DMVZO01	RU	https://doi.org/10.1038/bjc.1998.57

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DE017IC
DMMN36E	MN	Alcohol dehydrogenase class-V (ADH6)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
DMMN36E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTI7UX6
DMMN36E	MN	Breast cancer resistance protein (ABCG2)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46.
DMMN36E	RU	https://doi.org/10.1016/j.addr.2008.10.004

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	TT84ETX
DMMN36E	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMN36E	MT	DTT
DMMN36E	MA	Inhibitor
DMMN36E	RN	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
DMMN36E	RU	https://pubmed.ncbi.nlm.nih.gov/19442129

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTCSGPB
DMMN36E	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMMN36E	RU	https://doi.org/10.1007/s11095-012-0935-x

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DTUGYRD
DMMN36E	MN	P-glycoprotein 1 (ABCB1)
DMMN36E	MT	DTP
DMMN36E	MA	Substrate
DMMN36E	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DMMN36E	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DEYGVN4
DMMN36E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71.
DMMN36E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171

DMMN36E	DI	DMMN36E
DMMN36E	DN	Abacavir
DMMN36E	MI	DEB3CV1
DMMN36E	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMMN36E	MT	DME
DMMN36E	MA	Metabolism
DMMN36E	RN	Product characteristics of Triumeq.
DMMN36E	RU	https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf

DMOERGM	DI	DMOERGM
DMOERGM	DN	Abaloparatide
DMOERGM	MI	TTFPD47
DMOERGM	MN	Parathyroid hormone 1 receptor (PTH1R)
DMOERGM	MT	DTT
DMOERGM	MA	Modulator
DMOERGM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOERGM	RU	https://www.fda.gov/

DM2RX0I	DI	DM2RX0I
DM2RX0I	DN	Abametapir
DM2RX0I	MI	TT1GHVO
DM2RX0I	MN	Matrix metalloproteinase (MMP)
DM2RX0I	MT	DTT
DM2RX0I	MA	Inhibitor
DM2RX0I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM2RX0I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf

DM5WFNP	DI	DM5WFNP
DM5WFNP	DN	Abarelix
DM5WFNP	MI	TT8R70G
DM5WFNP	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM5WFNP	MT	DTT
DM5WFNP	MA	Modulator
DM5WFNP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5WFNP	RU	https://www.fda.gov/

DMSA8RU	DI	DMSA8RU
DMSA8RU	DN	Abatacept
DMSA8RU	MI	TTFZDNP
DMSA8RU	MN	Activation B7-1 antigen (CD80)
DMSA8RU	MT	DTT
DMSA8RU	MA	Binder
DMSA8RU	RN	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
DMSA8RU	RU	https://pubmed.ncbi.nlm.nih.gov/19604448

DMSA8RU	DI	DMSA8RU
DMSA8RU	DN	Abatacept
DMSA8RU	MI	TTHGXBU
DMSA8RU	MN	T-lymphocyte activation antigen CD86 (FUN1)
DMSA8RU	MT	DTT
DMSA8RU	MA	Binder
DMSA8RU	RN	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
DMSA8RU	RU	https://pubmed.ncbi.nlm.nih.gov/19604448

DMJO6GV	DI	DMJO6GV
DMJO6GV	DN	Abciximab
DMJO6GV	MI	TT38RM1
DMJO6GV	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMJO6GV	MT	DTT
DMJO6GV	MA	Modulator
DMJO6GV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJO6GV	RU	https://www.fda.gov/

DM8V75C	DI	DM8V75C
DM8V75C	DN	ABIRATERONE
DM8V75C	MI	TTRA5BZ
DM8V75C	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM8V75C	MT	DTT
DM8V75C	MA	Modulator
DM8V75C	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM8V75C	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DE4LYSA
DMANBZI	MN	Cytochrome P450 3A4 (CYP3A4)
DMANBZI	MT	DME
DMANBZI	MA	Metabolism
DMANBZI	RN	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DTPFTEQ
DMANBZI	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMANBZI	MT	DTP
DMANBZI	MA	Substrate
DMANBZI	RN	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311.
DMANBZI	RU	http://www.ncbi.nlm.nih.gov/pubmed/28762529

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	TTRA5BZ
DMANBZI	MN	Steroid 17-alpha-monooxygenase (S17AH)
DMANBZI	MT	DTT
DMANBZI	MA	Modulator
DMANBZI	RN	CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/25560485

DMANBZI	DI	DMANBZI
DMANBZI	DN	Abiraterone acetate
DMANBZI	MI	DE0P6LK
DMANBZI	MN	Sulfotransferase 2A1 (SULT2A1)
DMANBZI	MT	DME
DMANBZI	MA	Metabolism
DMANBZI	RN	Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24.
DMANBZI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819

DMZT2P0	DI	DMZT2P0
DMZT2P0	DN	Abobotulinum toxin A
DMZT2P0	MI	TTZJD1B
DMZT2P0	MN	Acetylcholine release (Ach rele)
DMZT2P0	MT	DTT
DMZT2P0	MA	Modulator
DMZT2P0	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMZT2P0	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	DE4LYSA
DM7GCVW	MN	Cytochrome P450 3A4 (CYP3A4)
DM7GCVW	MT	DME
DM7GCVW	MA	Metabolism
DM7GCVW	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DM7GCVW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	DEIBDNY
DM7GCVW	MN	Cytochrome P450 3A5 (CYP3A5)
DM7GCVW	MT	DME
DM7GCVW	MA	Metabolism
DM7GCVW	RN	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DM7GCVW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf

DM7GCVW	DI	DM7GCVW
DM7GCVW	DN	Acalabrutinib
DM7GCVW	MI	TTGM6VW
DM7GCVW	MN	Tyrosine-protein kinase BTK (ATK)
DM7GCVW	MT	DTT
DM7GCVW	MA	Inhibitor
DM7GCVW	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM7GCVW	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMO381I	DI	DMO381I
DMO381I	DN	Acamprosate
DMO381I	MI	TTAN6JD
DMO381I	MN	Glutamate receptor AMPA (GRIA)
DMO381I	MT	DTT
DMO381I	MA	Agonist
DMO381I	RN	Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.
DMO381I	RU	https://pubmed.ncbi.nlm.nih.gov/19523047

DMRM3AW	DI	DMRM3AW
DMRM3AW	DN	Acarbose
DMRM3AW	MI	TTXWASR
DMRM3AW	MN	Intestinal maltase-glucoamylase (MGAM)
DMRM3AW	MT	DTT
DMRM3AW	MA	Modulator
DMRM3AW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRM3AW	RU	https://www.fda.gov/

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	TTR6W5O
DM0TI4U	MN	Adrenergic receptor beta-1 (ADRB1)
DM0TI4U	MT	DTT
DM0TI4U	MA	Antagonist
DM0TI4U	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DM0TI4U	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DECB0K3
DM0TI4U	MN	Cytochrome P450 2D6 (CYP2D6)
DM0TI4U	MT	DME
DM0TI4U	MA	Metabolism
DM0TI4U	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM0TI4U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTE2B1D
DM0TI4U	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DM0TI4U	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTT79CX
DM0TI4U	MN	Organic cation transporter 1 (SLC22A1)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DM0TI4U	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DM0TI4U	DI	DM0TI4U
DM0TI4U	DN	Acebutolol
DM0TI4U	MI	DTUGYRD
DM0TI4U	MN	P-glycoprotein 1 (ABCB1)
DM0TI4U	MT	DTP
DM0TI4U	MA	Substrate
DM0TI4U	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0TI4U	RU	https://doi.org/10.1007/s11095-012-0935-x

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTZ9SOR
DMOLNCZ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTYEG6Q
DMOLNCZ	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTQ13Z5
DMOLNCZ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTQ3JTF
DMOLNCZ	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMOLNCZ	DI	DMOLNCZ
DMOLNCZ	DN	ACECLIDINE
DMOLNCZ	MI	TTH18TF
DMOLNCZ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMOLNCZ	MT	DTT
DMOLNCZ	MA	Inhibitor
DMOLNCZ	RN	Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
DMOLNCZ	RU	https://pubmed.ncbi.nlm.nih.gov/8464038

DMZDF0B	DI	DMZDF0B
DMZDF0B	DN	Aceclofenac
DMZDF0B	MI	DE5IED8
DMZDF0B	MN	Cytochrome P450 2C9 (CYP2C9)
DMZDF0B	MT	DME
DMZDF0B	MA	Metabolism
DMZDF0B	RN	Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996 Aug;24(8):834-41.
DMZDF0B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8869816

DMZDF0B	DI	DMZDF0B
DMZDF0B	DN	Aceclofenac
DMZDF0B	MI	TTK0943
DMZDF0B	MN	Prostaglandin G/H synthase (COX)
DMZDF0B	MT	DTT
DMZDF0B	MA	Modulator
DMZDF0B	RN	Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
DMZDF0B	RU	https://pubmed.ncbi.nlm.nih.gov/12966366

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DEJGDUW
DMH75KV	MN	Cytochrome P450 1A2 (CYP1A2)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DE5IED8
DMH75KV	MN	Cytochrome P450 2C9 (CYP2C9)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DE4LYSA
DMH75KV	MN	Cytochrome P450 3A4 (CYP3A4)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19843835

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	DEGTFWK
DMH75KV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMH75KV	MT	DME
DMH75KV	MA	Metabolism
DMH75KV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMH75KV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH75KV	DI	DMH75KV
DMH75KV	DN	Acenocoumarol
DMH75KV	MI	TTEUC8H
DMH75KV	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMH75KV	MT	DTT
DMH75KV	MA	Inhibitor
DMH75KV	RN	Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7.
DMH75KV	RU	https://pubmed.ncbi.nlm.nih.gov/19562511

DM1SRQT	DI	DM1SRQT
DM1SRQT	DN	Aceprometazine
DM1SRQT	MI	TTTIBOJ
DM1SRQT	MN	Histamine H1 receptor (H1R)
DM1SRQT	MT	DTT
DM1SRQT	MA	Antagonist
DM1SRQT	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM1SRQT	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4OGUF
DMUIE76	MN	Cytochrome P450 102A1 (cyp102)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE6OQ3W
DMUIE76	MN	Cytochrome P450 1A1 (CYP1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8145237

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEJGDUW
DMUIE76	MN	Cytochrome P450 1A2 (CYP1A2)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26049587

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEJVYAZ
DMUIE76	MN	Cytochrome P450 2A6 (CYP2A6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE5IED8
DMUIE76	MN	Cytochrome P450 2C9 (CYP2C9)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DECB0K3
DMUIE76	MN	Cytochrome P450 2D6 (CYP2D6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEVDYN7
DMUIE76	MN	Cytochrome P450 2E1 (CYP2E1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20166895

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4LYSA
DMUIE76	MN	Cytochrome P450 3A4 (CYP3A4)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEIBDNY
DMUIE76	MN	Cytochrome P450 3A5 (CYP3A5)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620348

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE4ZHS1
DMUIE76	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16157696

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DTFI42L
DMUIE76	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUIE76	MT	DTP
DMUIE76	MA	Substrate
DMUIE76	RN	Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
DMUIE76	RU	http://www.ncbi.nlm.nih.gov/pubmed/15276087

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TTAWNKZ
DMUIE76	MN	Norepinephrine transporter (NET)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TTK0943
DMUIE76	MN	Prostaglandin G/H synthase (COX)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/15662292

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	TT3ROYC
DMUIE76	MN	Serotonin transporter (SERT)
DMUIE76	MT	DTT
DMUIE76	MA	Inhibitor
DMUIE76	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMUIE76	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEYWLRK
DMUIE76	MN	Sulfotransferase 1A1 (SULT1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DEYGVN4
DMUIE76	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28932176

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DESD26P
DMUIE76	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21666065

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DE85D2P
DMUIE76	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DMUIE76	DI	DMUIE76
DMUIE76	DN	Acetaminophen
DMUIE76	MI	DENZ6B1
DMUIE76	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DMUIE76	MT	DME
DMUIE76	MA	Metabolism
DMUIE76	RN	Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52.
DMUIE76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21245288

DM1AF5U	DI	DM1AF5U
DM1AF5U	DN	Acetazolamide
DM1AF5U	MI	TTHQPL7
DM1AF5U	MN	Carbonic anhydrase I (CA-I)
DM1AF5U	MT	DTT
DM1AF5U	MA	Modulator
DM1AF5U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1AF5U	RU	https://www.fda.gov/

DM4SJ5Y	DI	DM4SJ5Y
DM4SJ5Y	DN	Acetic Acid, Glacial
DM4SJ5Y	MI	DEVDYN7
DM4SJ5Y	MN	Cytochrome P450 2E1 (CYP2E1)
DM4SJ5Y	MT	DME
DM4SJ5Y	MA	Metabolism
DM4SJ5Y	RN	Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J Biol Chem. 1999 Aug 20;274(34):23833-40.
DM4SJ5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10446146

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	TTP835K
DMR6N7H	MN	ATP-binding cassette transporter C8 (ABCC8)
DMR6N7H	MT	DTT
DMR6N7H	MA	Modulator
DMR6N7H	RN	Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/16249427

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	DE5IED8
DMR6N7H	MN	Cytochrome P450 2C9 (CYP2C9)
DMR6N7H	MT	DME
DMR6N7H	MA	Metabolism
DMR6N7H	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMR6N7H	DI	DMR6N7H
DMR6N7H	DN	Acetohexamide
DMR6N7H	MI	DEXPVUN
DMR6N7H	MN	Short-chain dehydrogenase/reductase retSDR1 (DHRS3)
DMR6N7H	MT	DME
DMR6N7H	MA	Metabolism
DMR6N7H	RN	Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87.
DMR6N7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25451588

DMYX7NI	DI	DMYX7NI
DMYX7NI	DN	Acetohydroxamic Acid
DMYX7NI	MI	TTAS2UO
DMYX7NI	MN	Bacterial Urease (Bact ureC)
DMYX7NI	MT	DTT
DMYX7NI	MA	Inhibitor
DMYX7NI	RN	Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
DMYX7NI	RU	https://pubmed.ncbi.nlm.nih.gov/18638408

DMZV2PJ	DI	DMZV2PJ
DMZV2PJ	DN	Acetophenazine
DMZV2PJ	MI	TTEX248
DMZV2PJ	MN	Dopamine D2 receptor (D2R)
DMZV2PJ	MT	DTT
DMZV2PJ	MA	Antagonist
DMZV2PJ	RN	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
DMZV2PJ	RU	https://pubmed.ncbi.nlm.nih.gov/11873706

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DEQ2BAJ
DMDF79Z	MN	Acetylcholinesterase (ACHE)
DMDF79Z	MT	DME
DMDF79Z	MA	Metabolism
DMDF79Z	RN	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMDF79Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT8KXR9
DMDF79Z	MN	Choline transporter-like protein 4 (SLC44A4)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J Neurochem. 2013 Aug;126(4):451-61.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23651124

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	TTOXS3C
DMDF79Z	MN	Muscarinic acetylcholine receptor (CHRM)
DMDF79Z	MT	DTT
DMDF79Z	MA	Agonist
DMDF79Z	RN	Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
DMDF79Z	RU	https://pubmed.ncbi.nlm.nih.gov/14722259

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DTT79CX
DMDF79Z	MN	Organic cation transporter 1 (SLC22A1)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res. 2006 Apr 12;7:65.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16608531

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT6201N
DMDF79Z	MN	Organic cation transporter 3 (SLC22A3)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/19702534

DMDF79Z	DI	DMDF79Z
DMDF79Z	DN	Acetylcholine
DMDF79Z	MI	DT3T2K0
DMDF79Z	MN	Vesicular acetylcholine transporter (SLC18A3)
DMDF79Z	MT	DTP
DMDF79Z	MA	Substrate
DMDF79Z	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMDF79Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMHAUO0	DI	DMHAUO0
DMHAUO0	DN	Acetyldigitoxin
DMHAUO0	MI	TTWK8D0
DMHAUO0	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMHAUO0	MT	DTT
DMHAUO0	MA	Modulator
DMHAUO0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHAUO0	RU	https://www.fda.gov/

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTW7AE3
DMYLOVR	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16375689

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTI7UX6
DMYLOVR	MN	Breast cancer resistance protein (ABCG2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80.
DMYLOVR	RU	https://doi.org/10.1139/y11-045

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	TTIU7X1
DMYLOVR	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMYLOVR	MT	DTT
DMYLOVR	MA	Modulator
DMYLOVR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYLOVR	RU	https://www.fda.gov/

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTZGT0P
DMYLOVR	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DT3TX4H
DMYLOVR	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTFI42L
DMYLOVR	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/12750437

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTQ23VB
DMYLOVR	MN	Organic anion transporter 1 (SLC22A6)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DT0OC1Q
DMYLOVR	MN	Organic anion transporter 2 (SLC22A7)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18216183

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTVP67E
DMYLOVR	MN	Organic anion transporter 3 (SLC22A8)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/22190696

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	DTT79CX
DMYLOVR	MN	Organic cation transporter 1 (SLC22A1)
DMYLOVR	MT	DTP
DMYLOVR	MA	Substrate
DMYLOVR	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMYLOVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMYLOVR	DI	DMYLOVR
DMYLOVR	DN	Aciclovir
DMYLOVR	MI	TTHPJTK
DMYLOVR	MN	Varicella-zoster virus DNA polymerase (VZV ORF28)
DMYLOVR	MT	DTT
DMYLOVR	MA	Modulator
DMYLOVR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYLOVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8BKU9	DI	DM8BKU9
DM8BKU9	DN	Acitretin
DM8BKU9	MI	TTH8FZW
DM8BKU9	MN	Signal transducer and activator of transcription 3 (STAT3)
DM8BKU9	MT	DTT
DM8BKU9	MA	Inhibitor
DM8BKU9	RN	Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
DM8BKU9	RU	https://pubmed.ncbi.nlm.nih.gov/16737614

DMLFZHD	DI	DMLFZHD
DMLFZHD	DN	Aclarubicin
DMLFZHD	MI	TT0IHXV
DMLFZHD	MN	DNA topoisomerase II (TOP2)
DMLFZHD	MT	DTT
DMLFZHD	MA	Inhibitor
DMLFZHD	RN	Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.
DMLFZHD	RU	https://pubmed.ncbi.nlm.nih.gov/12375883

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DTE2B1D
DM7JT24	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/10600646

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DT3D8F0
DM7JT24	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DT9C1TS
DM7JT24	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	DTY0QMU
DM7JT24	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DM7JT24	MT	DTP
DM7JT24	MA	Substrate
DM7JT24	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM7JT24	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM7JT24	DI	DM7JT24
DM7JT24	DN	Acocantherin
DM7JT24	MI	TTWK8D0
DM7JT24	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM7JT24	MT	DTT
DM7JT24	MA	Binder
DM7JT24	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7JT24	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMTIGA0	DI	DMTIGA0
DMTIGA0	DN	Acrivastine
DMTIGA0	MI	TTTIBOJ
DMTIGA0	MN	Histamine H1 receptor (H1R)
DMTIGA0	MT	DTT
DMTIGA0	MA	Antagonist
DMTIGA0	RN	Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52.
DMTIGA0	RU	https://pubmed.ncbi.nlm.nih.gov/10384858

DMTIGA0	DI	DMTIGA0
DMTIGA0	DN	Acrivastine
DMTIGA0	MI	DTUGYRD
DMTIGA0	MN	P-glycoprotein 1 (ABCB1)
DMTIGA0	MT	DTP
DMTIGA0	MA	Substrate
DMTIGA0	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMTIGA0	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMQMV1B	DI	DMQMV1B
DMQMV1B	DN	Adalimumab
DMQMV1B	MI	TTF8CQI
DMQMV1B	MN	Tumor necrosis factor (TNF)
DMQMV1B	MT	DTT
DMQMV1B	RN	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
DMQMV1B	RU	https://pubmed.ncbi.nlm.nih.gov/19573024

DMX2358	DI	DMX2358
DMX2358	DN	Adapalene
DMX2358	MI	TTOD7B3
DMX2358	MN	Retinoic acid receptor (RAR)
DMX2358	MT	DTT
DMX2358	MA	Binder
DMX2358	RN	A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4.
DMX2358	RU	https://pubmed.ncbi.nlm.nih.gov/18848668

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTI7UX6
DMM278X	MN	Breast cancer resistance protein (ABCG2)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DMM278X	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTSYQGK
DMM278X	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMM278X	RU	https://doi.org/10.1007/s11095-012-0935-x

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTFI42L
DMM278X	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMM278X	RU	https://doi.org/10.1007/s12033-009-9220-6

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTCSGPB
DMM278X	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27.
DMM278X	RU	http://www.ncbi.nlm.nih.gov/pubmed/17110501

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTQ23VB
DMM278X	MN	Organic anion transporter 1 (SLC22A6)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93.
DMM278X	RU	http://www.ncbi.nlm.nih.gov/pubmed/10703662

DMM278X	DI	DMM278X
DMM278X	DN	Adefovir
DMM278X	MI	DTVP67E
DMM278X	MN	Organic anion transporter 3 (SLC22A8)
DMM278X	MT	DTP
DMM278X	MA	Substrate
DMM278X	RN	FDA Drug Development and Drug Interactions
DMM278X	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMMAWY1	DI	DMMAWY1
DMMAWY1	DN	Adefovir dipivoxil
DMMAWY1	MI	DEY1FJO
DMMAWY1	MN	ATP-AMP transphosphorylase 2 (AK2)
DMMAWY1	MT	DME
DMMAWY1	MA	Metabolism
DMMAWY1	RN	Scientific discussion of Hepsera.
DMMAWY1	RU	https://www.ema.europa.eu/en/documents/scientific-discussion/hepsera-epar-scientific-discussion_en.pdf

DMMAWY1	DI	DMMAWY1
DMMAWY1	DN	Adefovir dipivoxil
DMMAWY1	MI	TT84ETX
DMMAWY1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMAWY1	MT	DTT
DMMAWY1	MA	Modulator
DMMAWY1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMAWY1	RU	https://www.fda.gov/

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	DEVDYN7
DMYQDBO	MN	Cytochrome P450 2E1 (CYP2E1)
DMYQDBO	MT	DME
DMYQDBO	MA	Metabolism
DMYQDBO	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DMYQDBO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	DEFQ8VO
DMYQDBO	MN	Thiopurine methyltransferase (TPMT)
DMYQDBO	MT	DME
DMYQDBO	MA	Metabolism
DMYQDBO	RN	Evolution of putrescine N-methyltransferase from spermidine synthase demanded alterations in substrate binding. FEBS Lett. 2009 Oct 20;583(20):3367-74.
DMYQDBO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19796640

DMYQDBO	DI	DMYQDBO
DMYQDBO	DN	Ademetionine
DMYQDBO	MI	TTX2N1T
DMYQDBO	MN	Transferase unspecific (TF)
DMYQDBO	MT	DTT
DMYQDBO	MA	Modulator
DMYQDBO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2013
DMYQDBO	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf

DMZLHKJ	DI	DMZLHKJ
DMZLHKJ	DN	Adenine
DMZLHKJ	MI	DTLMGFJ
DMZLHKJ	MN	Adenine nucleotide translocator 3 (SLC25A6)
DMZLHKJ	MT	DTP
DMZLHKJ	MA	Substrate
DMZLHKJ	RN	Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell. 2007 Nov;18(11):4681-9.
DMZLHKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17855512

DMZLHKJ	DI	DMZLHKJ
DMZLHKJ	DN	Adenine
DMZLHKJ	MI	TTUTN1I
DMZLHKJ	MN	Human Deoxyribonucleic acid (hDNA)
DMZLHKJ	MT	DTT
DMZLHKJ	MA	Binder
DMZLHKJ	RN	Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410.
DMZLHKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19580332

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	TTNE7KG
DMM2NSK	MN	Adenosine A2b receptor (ADORA2B)
DMM2NSK	MT	DTT
DMM2NSK	MA	Modulator
DMM2NSK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM2NSK	RU	https://www.fda.gov/

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DEDQHBV
DMM2NSK	MN	Adenosine aminohydrolase (ADA)
DMM2NSK	MT	DME
DMM2NSK	MA	Metabolism
DMM2NSK	RN	A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15676-81.
DMM2NSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16221767

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DTXD1TQ
DMM2NSK	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMM2NSK	MT	DTP
DMM2NSK	MA	Substrate
DMM2NSK	RN	Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.
DMM2NSK	RU	http://www.ncbi.nlm.nih.gov/pubmed/16688763

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DTYVM24
DMM2NSK	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMM2NSK	MT	DTP
DMM2NSK	MA	Substrate
DMM2NSK	RN	Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
DMM2NSK	RU	http://www.ncbi.nlm.nih.gov/pubmed/12423063

DMM2NSK	DI	DMM2NSK
DMM2NSK	DN	Adenosine
DMM2NSK	MI	DEYWLRK
DMM2NSK	MN	Sulfotransferase 1A1 (SULT1A1)
DMM2NSK	MT	DME
DMM2NSK	MA	Metabolism
DMM2NSK	RN	Regulation of sulfate assimilation in plants: 7. Cysteine inactivation of adenosine 5'-phosphosulfate sulfotransferase in Lemna minor L. Plant Physiol. 1978 Mar;61(3):342-7.
DMM2NSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16660289

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	DE2MV1R
DMNIJT0	MN	Adenine phosphoribosyltransferase (APRT)
DMNIJT0	MT	DME
DMNIJT0	MA	Metabolism
DMNIJT0	RN	Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. Assay Drug Dev Technol. 2006 Dec;4(6):661-9.
DMNIJT0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17199504

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	TTV1ZSQ
DMNIJT0	MN	Adenylate cyclase type 1 (ADCY1)
DMNIJT0	MT	DTT
DMNIJT0	MA	Binder
DMNIJT0	RN	Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8.
DMNIJT0	RU	https://pubmed.ncbi.nlm.nih.gov/16497164

DMNIJT0	DI	DMNIJT0
DMNIJT0	DN	Adenosine monophosphate
DMNIJT0	MI	DTYR5U7
DMNIJT0	MN	Peroxisomal membrane protein PMP34 (SLC25A17)
DMNIJT0	MT	DTP
DMNIJT0	MA	Substrate
DMNIJT0	RN	The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7.
DMNIJT0	RU	http://www.ncbi.nlm.nih.gov/pubmed/22185573

DM79F6G	DI	DM79F6G
DM79F6G	DN	Adenosine triphosphate
DM79F6G	MI	TT3PJMV
DM79F6G	MN	Tyrosine-protein kinase ABL1 (ABL)
DM79F6G	MT	DTT
DM79F6G	MA	Inhibitor
DM79F6G	RN	Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
DM79F6G	RU	https://pubmed.ncbi.nlm.nih.gov/18056932

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	DE4LYSA
DMBHO9Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMBHO9Y	MT	DME
DMBHO9Y	MA	Metabolism
DMBHO9Y	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DMBHO9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	DEGTFWK
DMBHO9Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBHO9Y	MT	DME
DMBHO9Y	MA	Metabolism
DMBHO9Y	RN	Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
DMBHO9Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717

DMBHO9Y	DI	DMBHO9Y
DMBHO9Y	DN	Adinazolam
DMBHO9Y	MI	TTPTXIN
DMBHO9Y	MN	Translocator protein (TSPO)
DMBHO9Y	MT	DTT
DMBHO9Y	MA	Agonist
DMBHO9Y	RN	Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22.
DMBHO9Y	RU	https://pubmed.ncbi.nlm.nih.gov/10357248

DMVWHTG	DI	DMVWHTG
DMVWHTG	DN	Afamelanotide
DMVWHTG	MI	TT0MV2T
DMVWHTG	MN	Melanocortin receptor 1 (MC1R)
DMVWHTG	MT	DTT
DMVWHTG	MA	Modulator
DMVWHTG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMVWHTG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TT48I1Y
DMT3D5I	MN	Placenta growth factor (PlGF)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TTOHSBA
DMT3D5I	MN	Vascular endothelial growth factor A (VEGFA)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMT3D5I	DI	DMT3D5I
DMT3D5I	DN	Aflibercept
DMT3D5I	MI	TTPJQHE
DMT3D5I	MN	Vascular endothelial growth factor B (VEGFB)
DMT3D5I	MT	DTT
DMT3D5I	MA	Modulator
DMT3D5I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMT3D5I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMPOD47	DI	DMPOD47
DMPOD47	DN	Ajmalicine
DMPOD47	MI	TTR6W5O
DMPOD47	MN	Adrenergic receptor beta-1 (ADRB1)
DMPOD47	MT	DTT
DMPOD47	MA	Modulator
DMPOD47	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMPOD47	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMDJW5K	DI	DMDJW5K
DMDJW5K	DN	Ajmaline
DMDJW5K	MI	DECB0K3
DMDJW5K	MN	Cytochrome P450 2D6 (CYP2D6)
DMDJW5K	MT	DME
DMDJW5K	MA	Metabolism
DMDJW5K	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDJW5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDJW5K	DI	DMDJW5K
DMDJW5K	DN	Ajmaline
DMDJW5K	MI	DTUGYRD
DMDJW5K	MN	P-glycoprotein 1 (ABCB1)
DMDJW5K	MT	DTP
DMDJW5K	MA	Substrate
DMDJW5K	RN	ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 1994 Apr 25;343(2):168-72.
DMDJW5K	RU	http://www.ncbi.nlm.nih.gov/pubmed/7909523

DML6SRO	DI	DML6SRO
DML6SRO	DN	Alacepril
DML6SRO	MI	TTL69WB
DML6SRO	MN	Angiotensin-converting enzyme (ACE)
DML6SRO	MT	DTT
DML6SRO	MA	Modulator
DML6SRO	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DML6SRO	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DEJGDUW
DMYZ57N	MN	Cytochrome P450 1A2 (CYP1A2)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451431

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DE4LYSA
DMYZ57N	MN	Cytochrome P450 3A4 (CYP3A4)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DEGTFWK
DMYZ57N	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMYZ57N	MT	DME
DMYZ57N	MA	Metabolism
DMYZ57N	RN	Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
DMYZ57N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26048912

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	DTUGYRD
DMYZ57N	MN	P-glycoprotein 1 (ABCB1)
DMYZ57N	MT	DTP
DMYZ57N	MA	Substrate
DMYZ57N	RN	The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
DMYZ57N	RU	http://www.ncbi.nlm.nih.gov/pubmed/11901088

DMYZ57N	DI	DMYZ57N
DMYZ57N	DN	Albendazole
DMYZ57N	MI	TTYFKSZ
DMYZ57N	MN	Tubulin beta (TUBB)
DMYZ57N	MT	DTT
DMYZ57N	MA	Binder
DMYZ57N	RN	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
DMYZ57N	RU	https://pubmed.ncbi.nlm.nih.gov/19336257

DM1JEGF	DI	DM1JEGF
DM1JEGF	DN	Albiglutide
DM1JEGF	MI	TTVIMDE
DM1JEGF	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1JEGF	MT	DTT
DM1JEGF	MA	Modulator
DM1JEGF	RN	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
DM1JEGF	RU	https://www.ncbi.nlm.nih.gov/pubmed/22945360

DM5JTPU	DI	DM5JTPU
DM5JTPU	DN	Albumin Human
DM5JTPU	MI	TTFNGC9
DM5JTPU	MN	Serum albumin (ALB)
DM5JTPU	MT	DTT
DM5JTPU	MA	Modulator
DM5JTPU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5JTPU	RU	https://www.fda.gov/

DM5J1NH	DI	DM5J1NH
DM5J1NH	DN	Alcaftadine
DM5J1NH	MI	TTTIBOJ
DM5J1NH	MN	Histamine H1 receptor (H1R)
DM5J1NH	MT	DTT
DM5J1NH	MA	Antagonist
DM5J1NH	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM5J1NH	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMAE84F	DI	DMAE84F
DMAE84F	DN	Alclometasone
DMAE84F	MI	TTJL8VG
DMAE84F	MN	Corticosteroid-binding globulin (SERPINA6)
DMAE84F	MT	DTT
DMAE84F	MA	Binder
DMAE84F	RN	The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.
DMAE84F	RU	https://pubmed.ncbi.nlm.nih.gov/2508442

DMAE84F	DI	DMAE84F
DMAE84F	DN	Alclometasone
DMAE84F	MI	DE4LYSA
DMAE84F	MN	Cytochrome P450 3A4 (CYP3A4)
DMAE84F	MT	DME
DMAE84F	MA	Metabolism
DMAE84F	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMAE84F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DM2U4XQ	DI	DM2U4XQ
DM2U4XQ	DN	ALCURONIUM
DM2U4XQ	MI	TTLA931
DM2U4XQ	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2U4XQ	MT	DTT
DM2U4XQ	MA	Inhibitor
DM2U4XQ	RN	Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
DM2U4XQ	RU	https://pubmed.ncbi.nlm.nih.gov/17722904

DM4YMIS	DI	DM4YMIS
DM4YMIS	DN	Aldesleukin
DM4YMIS	MI	TTF89GD
DM4YMIS	MN	Interleukin-2 (IL2)
DM4YMIS	MT	DTT
DM4YMIS	MA	Modulator
DM4YMIS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4YMIS	RU	https://www.fda.gov/

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DE6TYUK
DM9S2JW	MN	Aldosterone synthase (CYP11B2)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005 Oct 20;48(21):6632-42.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16220979

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DE4LYSA
DM9S2JW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010 Feb 23;121(7):934-9.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20177008

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEIBDNY
DM9S2JW	MN	Cytochrome P450 3A5 (CYP3A5)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	TT26PHO
DM9S2JW	MN	Mineralocorticoid receptor  (MR)
DM9S2JW	MT	DTT
DM9S2JW	MA	Agonist
DM9S2JW	RN	Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
DM9S2JW	RU	https://pubmed.ncbi.nlm.nih.gov/16188378

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DTUGYRD
DM9S2JW	MN	P-glycoprotein 1 (ABCB1)
DM9S2JW	MT	DTP
DM9S2JW	MA	Substrate
DM9S2JW	RN	MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44.
DM9S2JW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17301693

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	TTS087L
DM9S2JW	MN	Solute carrier family 12 member 1 (SLC12A1)
DM9S2JW	MT	DTT
DM9S2JW	MA	Blocker
DM9S2JW	RN	Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
DM9S2JW	RU	https://pubmed.ncbi.nlm.nih.gov/18769054

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEPE0RD
DM9S2JW	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002 Dec;147(6):795-802.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12457455

DM9S2JW	DI	DM9S2JW
DM9S2JW	DN	Aldosterone
DM9S2JW	MI	DEB3CV1
DM9S2JW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9S2JW	MT	DME
DM9S2JW	MA	Metabolism
DM9S2JW	RN	Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68.
DM9S2JW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330

DMP1I6Y	DI	DMP1I6Y
DMP1I6Y	DN	Alectinib
DMP1I6Y	MI	TTPMQSO
DMP1I6Y	MN	ALK tyrosine kinase receptor (ALK)
DMP1I6Y	MT	DTT
DMP1I6Y	MA	Inhibitor
DMP1I6Y	RN	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90.
DMP1I6Y	RU	https://pubmed.ncbi.nlm.nih.gov/21575866

DMP1I6Y	DI	DMP1I6Y
DMP1I6Y	DN	Alectinib
DMP1I6Y	MI	DE4LYSA
DMP1I6Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMP1I6Y	MT	DME
DMP1I6Y	MA	Metabolism
DMP1I6Y	RN	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica. 2018 Jun;48(6):546-554.
DMP1I6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28657423

DMMYPWO	DI	DMMYPWO
DMMYPWO	DN	Alefacept
DMMYPWO	MI	TT5KSBY
DMMYPWO	MN	Surface glycoprotein LFA-3 (CD58)
DMMYPWO	MT	DTT
DMMYPWO	MA	Modulator
DMMYPWO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMYPWO	RU	https://www.fda.gov/

DMZL3IV	DI	DMZL3IV
DMZL3IV	DN	Alemtuzumab
DMZL3IV	MI	TTQT5S9
DMZL3IV	MN	Cambridge pathology 1 antigen (CD52)
DMZL3IV	MT	DTT
DMZL3IV	RN	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49.
DMZL3IV	RU	https://pubmed.ncbi.nlm.nih.gov/19545375

DMY2KX9	DI	DMY2KX9
DMY2KX9	DN	Alendronate
DMY2KX9	MI	TTIKWV4
DMY2KX9	MN	Geranyltranstransferase (FDPS)
DMY2KX9	MT	DTT
DMY2KX9	MA	Modulator
DMY2KX9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMY2KX9	RU	https://www.fda.gov/

DMCKPUR	DI	DMCKPUR
DMCKPUR	DN	Alfaferone
DMCKPUR	MI	TT95SOA
DMCKPUR	MN	Interferon alpha (IFNA)
DMCKPUR	MT	DTT
DMCKPUR	MA	Modulator
DMCKPUR	RN	Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
DMCKPUR	RU	https://pubmed.ncbi.nlm.nih.gov/21739360

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DE4LYSA
DMVO0UB	MN	Cytochrome P450 3A4 (CYP3A4)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6.
DMVO0UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15731592

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DEIBDNY
DMVO0UB	MN	Cytochrome P450 3A5 (CYP3A5)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26.
DMVO0UB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17554244

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	DERD86B
DMVO0UB	MN	Cytochrome P450 3A7 (CYP3A7)
DMVO0UB	MT	DME
DMVO0UB	MA	Metabolism
DMVO0UB	RN	Drug Interactions Flockhart Table
DMVO0UB	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMVO0UB	DI	DMVO0UB
DMVO0UB	DN	Alfentanil
DMVO0UB	MI	TTKWM86
DMVO0UB	MN	Opioid receptor mu (MOP)
DMVO0UB	MT	DTT
DMVO0UB	MA	Agonist
DMVO0UB	RN	Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
DMVO0UB	RU	https://pubmed.ncbi.nlm.nih.gov/11240090

DMZVMKF	DI	DMZVMKF
DMZVMKF	DN	Alfuzosin
DMZVMKF	MI	TT34BHT
DMZVMKF	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMZVMKF	MT	DTT
DMZVMKF	MA	Antagonist
DMZVMKF	RN	Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
DMZVMKF	RU	https://pubmed.ncbi.nlm.nih.gov/11893233

DMZVMKF	DI	DMZVMKF
DMZVMKF	DN	Alfuzosin
DMZVMKF	MI	DTI7UX6
DMZVMKF	MN	Breast cancer resistance protein (ABCG2)
DMZVMKF	MT	DTP
DMZVMKF	MA	Substrate
DMZVMKF	RN	In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
DMZVMKF	RU	https://doi.org/10.1007/978-3-642-14541-4_9

DM4LOD0	DI	DM4LOD0
DM4LOD0	DN	Alglucosidase alfa
DM4LOD0	MI	TT95ICL
DM4LOD0	MN	Mannose-6-phosphate receptor (M6PR)
DM4LOD0	MT	DTT
DM4LOD0	MA	Binder
DM4LOD0	RN	Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35.
DM4LOD0	RU	https://pubmed.ncbi.nlm.nih.gov/19542901

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	TTB2MXP
DM1BV7W	MN	Angiotensinogenase renin (REN)
DM1BV7W	MT	DTT
DM1BV7W	MA	Inhibitor
DM1BV7W	RN	Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67.
DM1BV7W	RU	https://pubmed.ncbi.nlm.nih.gov/19617271

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DE4LYSA
DM1BV7W	MN	Cytochrome P450 3A4 (CYP3A4)
DM1BV7W	MT	DME
DM1BV7W	MA	Metabolism
DM1BV7W	RN	Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31.
DM1BV7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18611061

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DTPFTEQ
DM1BV7W	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM1BV7W	MT	DTP
DM1BV7W	MA	Substrate
DM1BV7W	RN	Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26.
DM1BV7W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21204914

DM1BV7W	DI	DM1BV7W
DM1BV7W	DN	Aliskiren
DM1BV7W	MI	DTUGYRD
DM1BV7W	MN	P-glycoprotein 1 (ABCB1)
DM1BV7W	MT	DTP
DM1BV7W	MA	Substrate
DM1BV7W	RN	Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2015 Jan;36(1):15-33.
DM1BV7W	RU	http://www.ncbi.nlm.nih.gov/pubmed/25264342

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	DE4LYSA
DMME8LH	MN	Cytochrome P450 3A4 (CYP3A4)
DMME8LH	MT	DME
DMME8LH	MA	Metabolism
DMME8LH	RN	Alitretinoin in dermatology-an update. Indian J Dermatol. 2015 Sep-Oct;60(5):520.
DMME8LH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26538721

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTISP28
DMME8LH	MN	Retinoic acid receptor beta (RARB)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TT1Q3IE
DMME8LH	MN	Retinoic acid receptor gamma (RARG)
DMME8LH	MT	DTT
DMME8LH	MA	Modulator
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TT6PEUO
DMME8LH	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTKLV96
DMME8LH	MN	Retinoic acid receptor RXR-beta (RXRB)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMME8LH	DI	DMME8LH
DMME8LH	DN	Alitretinoin
DMME8LH	MI	TTH029C
DMME8LH	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMME8LH	MT	DTT
DMME8LH	MA	Agonist
DMME8LH	RN	Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
DMME8LH	RU	https://pubmed.ncbi.nlm.nih.gov/8380496

DMB4HFI	DI	DMB4HFI
DMB4HFI	DN	Alkavervir
DMB4HFI	MI	TTNZRI3
DMB4HFI	MN	Synaptic vesicle amine transporter (SLC18A2)
DMB4HFI	MT	DTT
DMB4HFI	MA	Modulator
DMB4HFI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HFI	RU	https://www.fda.gov/

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	DE7WS3H
DMNLHAC	MN	Aldo-keto reductase 1B1 (AKR1B1)
DMNLHAC	MT	DME
DMNLHAC	MA	Metabolism
DMNLHAC	RN	FDA Label of Brexanolone. The 2020 official website of the U.S. Food and Drug Administration.
DMNLHAC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TT1MPAY
DMNLHAC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTZA1NY
DMNLHAC	MN	GABA(A) receptor beta-2 (GABRB2)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTGXH6N
DMNLHAC	MN	GABA(A) receptor delta (GABRD)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TT06RH5
DMNLHAC	MN	GABA(A) receptor gamma-2 (GABRG2)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/15828844

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTEX6LM
DMNLHAC	MN	GABA(A) receptor gamma-3 (GABRG3)
DMNLHAC	MT	DTT
DMNLHAC	MA	Modulator
DMNLHAC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNLHAC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMNLHAC	DI	DMNLHAC
DMNLHAC	DN	Allopregnanolone
DMNLHAC	MI	TTNJYV2
DMNLHAC	MN	Gamma-aminobutyric acid receptor (GAR)
DMNLHAC	MT	DTT
DMNLHAC	MA	Inhibitor
DMNLHAC	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DMNLHAC	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DT0OC1Q
DMLPAOB	MN	Organic anion transporter 2 (SLC22A7)
DMLPAOB	MT	DTP
DMLPAOB	MA	Substrate
DMLPAOB	RN	Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
DMLPAOB	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065749

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DTVP67E
DMLPAOB	MN	Organic anion transporter 3 (SLC22A8)
DMLPAOB	MT	DTP
DMLPAOB	MA	Substrate
DMLPAOB	RN	Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83.
DMLPAOB	RU	http://www.ncbi.nlm.nih.gov/pubmed/15100168

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	DEZV4AP
DMLPAOB	MN	RNA cytidine acetyltransferase (hALP)
DMLPAOB	MT	DME
DMLPAOB	MA	Metabolism
DMLPAOB	RN	Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
DMLPAOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10027663

DMLPAOB	DI	DMLPAOB
DMLPAOB	DN	Allopurinol
DMLPAOB	MI	TT7RJY8
DMLPAOB	MN	Xanthine dehydrogenase/oxidase (XDH)
DMLPAOB	MT	DTT
DMLPAOB	MA	Inhibitor
DMLPAOB	RN	Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
DMLPAOB	RU	https://pubmed.ncbi.nlm.nih.gov/5324754

DM0SYAN	DI	DM0SYAN
DM0SYAN	DN	Almitrine
DM0SYAN	MI	TTWK8D0
DM0SYAN	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM0SYAN	MT	DTT
DM0SYAN	MA	Binder
DM0SYAN	RN	Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9.
DM0SYAN	RU	https://pubmed.ncbi.nlm.nih.gov/2527061

DM7I64Z	DI	DM7I64Z
DM7I64Z	DN	Almogran
DM7I64Z	MI	TT6MSOK
DM7I64Z	MN	5-HT 1D receptor (HTR1D)
DM7I64Z	MT	DTT
DM7I64Z	MA	Agonist
DM7I64Z	RN	Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
DM7I64Z	RU	https://pubmed.ncbi.nlm.nih.gov/11768838

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DES5XRU
DMFG5ST	MN	Cytochrome P450 2C8 (CYP2C8)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DECB0K3
DMFG5ST	MN	Cytochrome P450 2D6 (CYP2D6)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEVDYN7
DMFG5ST	MN	Cytochrome P450 2E1 (CYP2E1)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DE4LYSA
DMFG5ST	MN	Cytochrome P450 3A4 (CYP3A4)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEP76YL
DMFG5ST	MN	Dimethylaniline oxidase 3 (FMO3)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DEGTFWK
DMFG5ST	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466

DMFG5ST	DI	DMFG5ST
DMFG5ST	DN	Almotriptan malate
DMFG5ST	MI	DERE4TU
DMFG5ST	MN	Monoamine oxidase type A (MAO-A)
DMFG5ST	MT	DME
DMFG5ST	MA	Metabolism
DMFG5ST	RN	Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.
DMFG5ST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	DECB0K3
DM8WI3R	MN	Cytochrome P450 2D6 (CYP2D6)
DM8WI3R	MT	DME
DM8WI3R	MA	Metabolism
DM8WI3R	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DM8WI3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	DE4LYSA
DM8WI3R	MN	Cytochrome P450 3A4 (CYP3A4)
DM8WI3R	MT	DME
DM8WI3R	MA	Metabolism
DM8WI3R	RN	An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38.
DM8WI3R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204

DM8WI3R	DI	DM8WI3R
DM8WI3R	DN	Alogliptin
DM8WI3R	MI	TTDIGC1
DM8WI3R	MN	Dipeptidyl peptidase 4 (DPP-4)
DM8WI3R	MT	DTT
DM8WI3R	MA	Inhibitor
DM8WI3R	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM8WI3R	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	TTPC4TU
DML2A03	MN	5-HT 3A receptor (HTR3A)
DML2A03	MT	DTT
DML2A03	MA	Antagonist
DML2A03	RN	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
DML2A03	RU	https://pubmed.ncbi.nlm.nih.gov/19471254

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DEJGDUW
DML2A03	MN	Cytochrome P450 1A2 (CYP1A2)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010 May;3(3):165-72.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21180598

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DE5IED8
DML2A03	MN	Cytochrome P450 2C9 (CYP2C9)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001 Apr;41(4):455-8.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304903

DML2A03	DI	DML2A03
DML2A03	DN	Alosetron
DML2A03	MI	DE4LYSA
DML2A03	MN	Cytochrome P450 3A4 (CYP3A4)
DML2A03	MT	DME
DML2A03	MA	Metabolism
DML2A03	RN	Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2001 Apr;41(4):452-4.
DML2A03	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11304902

DMEXMYK	DI	DMEXMYK
DMEXMYK	DN	Alpelisib
DMEXMYK	MI	DE4LYSA
DMEXMYK	MN	Cytochrome P450 3A4 (CYP3A4)
DMEXMYK	MT	DME
DMEXMYK	MA	Metabolism
DMEXMYK	RN	Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907.
DMEXMYK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28566285

DMEXMYK	DI	DMEXMYK
DMEXMYK	DN	Alpelisib
DMEXMYK	MI	TTEUNMR
DMEXMYK	MN	PI3-kinase alpha (PIK3CA)
DMEXMYK	MT	DTT
DMEXMYK	MA	Inhibitor
DMEXMYK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMEXMYK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf

DMXC1K9	DI	DMXC1K9
DMXC1K9	DN	Alpha 1-PI
DMXC1K9	MI	TTN9D8E
DMXC1K9	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMXC1K9	MT	DTT
DMXC1K9	MA	Antagonist
DMXC1K9	RN	NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
DMXC1K9	RU	https://pubmed.ncbi.nlm.nih.gov/19381304

DMXC1K9	DI	DMXC1K9
DMXC1K9	DN	Alpha 1-PI
DMXC1K9	MI	TT3NKIB
DMXC1K9	MN	Pancreatic elastase 1 (CELA1)
DMXC1K9	MT	DTT
DMXC1K9	MA	Inhibitor
DMXC1K9	RN	Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
DMXC1K9	RU	https://pubmed.ncbi.nlm.nih.gov/11723826

DMAS02L	DI	DMAS02L
DMAS02L	DN	Alpha-acetyldigoxin
DMAS02L	MI	TTYHPRQ
DMAS02L	MN	Sodium pump (NaP)
DMAS02L	MT	DTT
DMAS02L	MA	Modulator
DMAS02L	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMAS02L	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMN7Y9K	DI	DMN7Y9K
DMN7Y9K	DN	Alpidem
DMN7Y9K	MI	TTNJYV2
DMN7Y9K	MN	Gamma-aminobutyric acid receptor (GAR)
DMN7Y9K	MT	DTT
DMN7Y9K	MA	Inhibitor
DMN7Y9K	RN	Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
DMN7Y9K	RU	https://pubmed.ncbi.nlm.nih.gov/9301675

DMN7Y9K	DI	DMN7Y9K
DMN7Y9K	DN	Alpidem
DMN7Y9K	MI	TTPTXIN
DMN7Y9K	MN	Translocator protein (TSPO)
DMN7Y9K	MT	DTT
DMN7Y9K	MA	Inhibitor
DMN7Y9K	RN	Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806.
DMN7Y9K	RU	https://pubmed.ncbi.nlm.nih.gov/18729350

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DE5IED8
DMC7XDN	MN	Cytochrome P450 2C9 (CYP2C9)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DE4LYSA
DMC7XDN	MN	Cytochrome P450 3A4 (CYP3A4)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15856409

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DEIBDNY
DMC7XDN	MN	Cytochrome P450 3A5 (CYP3A5)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
DMC7XDN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15903124

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	DERD86B
DMC7XDN	MN	Cytochrome P450 3A7 (CYP3A7)
DMC7XDN	MT	DME
DMC7XDN	MA	Metabolism
DMC7XDN	RN	Drug Interactions Flockhart Table
DMC7XDN	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMC7XDN	DI	DMC7XDN
DMC7XDN	DN	Alprazolam
DMC7XDN	MI	TTPTXIN
DMC7XDN	MN	Translocator protein (TSPO)
DMC7XDN	MT	DTT
DMC7XDN	MA	Agonist
DMC7XDN	RN	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
DMC7XDN	RU	https://pubmed.ncbi.nlm.nih.gov/19443999

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTCSGPB
DMWH7NQ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/12835412

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTQ23VB
DMWH7NQ	MN	Organic anion transporter 1 (SLC22A6)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26692285

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DT021JD
DMWH7NQ	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/8787677

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DTVNRXW
DMWH7NQ	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMWH7NQ	MT	DTP
DMWH7NQ	MA	Substrate
DMWH7NQ	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMWH7NQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	DEHKSC6
DMWH7NQ	MN	Prostaglandin dehydrogenase 1 (HPGD)
DMWH7NQ	MT	DME
DMWH7NQ	MA	Metabolism
DMWH7NQ	RN	Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells. Am J Obstet Gynecol. 2008 Nov;199(5):554.e1-8.
DMWH7NQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18639206

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	TT1ZAVI
DMWH7NQ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMWH7NQ	MT	DTT
DMWH7NQ	MA	Agonist
DMWH7NQ	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMWH7NQ	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMWH7NQ	DI	DMWH7NQ
DMWH7NQ	DN	Alprostadil
DMWH7NQ	MI	TT2O84V
DMWH7NQ	MN	Thromboxane A2 receptor (TBXA2R)
DMWH7NQ	MT	DTT
DMWH7NQ	MA	Modulator
DMWH7NQ	RN	Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
DMWH7NQ	RU	https://pubmed.ncbi.nlm.nih.gov/10509658

DMB47TQ	DI	DMB47TQ
DMB47TQ	DN	Alseroxylon
DMB47TQ	MI	TTNZRI3
DMB47TQ	MN	Synaptic vesicle amine transporter (SLC18A2)
DMB47TQ	MT	DTT
DMB47TQ	MA	Blocker
DMB47TQ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMB47TQ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMRJ3YX	DI	DMRJ3YX
DMRJ3YX	DN	Alteplase
DMRJ3YX	MI	TTP86E2
DMRJ3YX	MN	Plasminogen (PLG)
DMRJ3YX	MT	DTT
DMRJ3YX	MA	Activator
DMRJ3YX	RN	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
DMRJ3YX	RU	https://pubmed.ncbi.nlm.nih.gov/15823070

DMKLAYG	DI	DMKLAYG
DMKLAYG	DN	Altretamine
DMKLAYG	MI	TTUTN1I
DMKLAYG	MN	Human Deoxyribonucleic acid (hDNA)
DMKLAYG	MT	DTT
DMKLAYG	MA	Breaker
DMKLAYG	RN	Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
DMKLAYG	RU	https://pubmed.ncbi.nlm.nih.gov/18305940

DMO9WDS	DI	DMO9WDS
DMO9WDS	DN	Altropane
DMO9WDS	MI	TTVBI8W
DMO9WDS	MN	Dopamine transporter (DAT)
DMO9WDS	MT	DTT
DMO9WDS	MA	Inhibitor
DMO9WDS	RN	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
DMO9WDS	RU	https://pubmed.ncbi.nlm.nih.gov/9593103

DM6ECN9	DI	DM6ECN9
DM6ECN9	DN	Aluminium
DM6ECN9	MI	TTWK8D0
DM6ECN9	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM6ECN9	MT	DTT
DM6ECN9	MA	Binder
DM6ECN9	RN	The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50.
DM6ECN9	RU	https://pubmed.ncbi.nlm.nih.gov/14507470

DMHR8KW	DI	DMHR8KW
DMHR8KW	DN	Alvimopan
DMHR8KW	MI	TTKWM86
DMHR8KW	MN	Opioid receptor mu (MOP)
DMHR8KW	MT	DTT
DMHR8KW	MA	Antagonist
DMHR8KW	RN	Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77.
DMHR8KW	RU	https://pubmed.ncbi.nlm.nih.gov/19574601

DMS3YE9	DI	DMS3YE9
DMS3YE9	DN	Amantadine
DMS3YE9	MI	TTXT3PU
DMS3YE9	MN	Influenza M2 protein (Influ M)
DMS3YE9	MT	DTT
DMS3YE9	MA	Inhibitor
DMS3YE9	RN	Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76.
DMS3YE9	RU	https://pubmed.ncbi.nlm.nih.gov/19469531

DMS3YE9	DI	DMS3YE9
DMS3YE9	DN	Amantadine
DMS3YE9	MI	DT9IDPW
DMS3YE9	MN	Organic cation transporter 2 (SLC22A2)
DMS3YE9	MT	DTP
DMS3YE9	MA	Substrate
DMS3YE9	RN	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
DMS3YE9	RU	http://www.ncbi.nlm.nih.gov/pubmed/9687576

DMOP0BL	DI	DMOP0BL
DMOP0BL	DN	Ambenonium
DMOP0BL	MI	TT1RS9F
DMOP0BL	MN	Acetylcholinesterase (AChE)
DMOP0BL	MT	DTT
DMOP0BL	MA	Inhibitor
DMOP0BL	RN	Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
DMOP0BL	RU	https://pubmed.ncbi.nlm.nih.gov/18033235

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DE4LYSA
DMD1QXW	MN	Cytochrome P450 3A4 (CYP3A4)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	TTKRD0G
DMD1QXW	MN	Endothelin A receptor (EDNRA)
DMD1QXW	MT	DTT
DMD1QXW	MA	Antagonist
DMD1QXW	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMD1QXW	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEGTFWK
DMD1QXW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DTUGYRD
DMD1QXW	MN	P-glycoprotein 1 (ABCB1)
DMD1QXW	MT	DTP
DMD1QXW	MA	Substrate
DMD1QXW	RN	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
DMD1QXW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20811346

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEF2WXN
DMD1QXW	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DE85D2P
DMD1QXW	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMD1QXW	DI	DMD1QXW
DMD1QXW	DN	Ambrisentan
DMD1QXW	MI	DEB3CV1
DMD1QXW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMD1QXW	MT	DME
DMD1QXW	MA	Metabolism
DMD1QXW	RN	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
DMD1QXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719

DMWJE9D	DI	DMWJE9D
DMWJE9D	DN	Ambroxol
DMWJE9D	MI	DE4LYSA
DMWJE9D	MN	Cytochrome P450 3A4 (CYP3A4)
DMWJE9D	MT	DME
DMWJE9D	MA	Metabolism
DMWJE9D	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMWJE9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM1JL9	DI	DMM1JL9
DMM1JL9	DN	Amcinonide
DMM1JL9	MI	DE4LYSA
DMM1JL9	MN	Cytochrome P450 3A4 (CYP3A4)
DMM1JL9	MT	DME
DMM1JL9	MA	Metabolism
DMM1JL9	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMM1JL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMM1JL9	DI	DMM1JL9
DMM1JL9	DN	Amcinonide
DMM1JL9	MI	TTP3UTW
DMM1JL9	MN	Steroid hormone receptor ERR (ESRR)
DMM1JL9	MT	DTT
DMM1JL9	MA	Modulator
DMM1JL9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM1JL9	RU	https://www.fda.gov/

DMIG6FY	DI	DMIG6FY
DMIG6FY	DN	Amdinocillin
DMIG6FY	MI	TTHWB7G
DMIG6FY	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMIG6FY	MT	DTT
DMIG6FY	MA	Inhibitor
DMIG6FY	RN	Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22.
DMIG6FY	RU	https://pubmed.ncbi.nlm.nih.gov/18390656

DM6I2WQ	DI	DM6I2WQ
DM6I2WQ	DN	Amezinium
DM6I2WQ	MI	TT2NUT5
DM6I2WQ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM6I2WQ	MT	DTT
DM6I2WQ	MA	Modulator
DM6I2WQ	RN	Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
DM6I2WQ	RU	https://pubmed.ncbi.nlm.nih.gov/7197970

DM9YSNQ	DI	DM9YSNQ
DM9YSNQ	DN	Amfepramone
DM9YSNQ	MI	TTAWNKZ
DM9YSNQ	MN	Norepinephrine transporter (NET)
DM9YSNQ	MT	DTT
DM9YSNQ	MA	Inhibitor
DM9YSNQ	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM9YSNQ	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DM9YSNQ	DI	DM9YSNQ
DM9YSNQ	DN	Amfepramone
DM9YSNQ	MI	TT3ROYC
DM9YSNQ	MN	Serotonin transporter (SERT)
DM9YSNQ	MT	DTT
DM9YSNQ	MA	Inhibitor
DM9YSNQ	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM9YSNQ	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	DE7OAB3
DMK08L3	MN	N-acetyltransferase 1 (NAT1)
DMK08L3	MT	DME
DMK08L3	MA	Metabolism
DMK08L3	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DMK08L3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	DER7TA0
DMK08L3	MN	N-acetyltransferase 2 (NAT2)
DMK08L3	MT	DME
DMK08L3	MA	Metabolism
DMK08L3	RN	Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
DMK08L3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017

DMK08L3	DI	DMK08L3
DMK08L3	DN	Amifampridine
DMK08L3	MI	TT1VOHK
DMK08L3	MN	Potassium channel unspecific (KC)
DMK08L3	MT	DTT
DMK08L3	MA	Blocker
DMK08L3	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK08L3	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM5FL14	DI	DM5FL14
DM5FL14	DN	Amifostine
DM5FL14	MI	DEVEFKM
DM5FL14	MN	Alkaline phosphatase (ALPL)
DM5FL14	MT	DME
DM5FL14	MA	Metabolism
DM5FL14	RN	Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug;23(4 Suppl 8):18-22.
DM5FL14	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8783662

DM5FL14	DI	DM5FL14
DM5FL14	DN	Amifostine
DM5FL14	MI	TT0C9DV
DM5FL14	MN	Toxic reactive metabolite (TRM)
DM5FL14	MT	DTT
DM5FL14	MA	Modulator
DM5FL14	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM5FL14	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DEWPAJD
DM5PDRB	MN	Aminoglycoside O-phosphotransferase (aphA6)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DE1C8Q4
DM5PDRB	MN	Endoglucanase A (EGA)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	DE2AZTG
DM5PDRB	MN	Endoglucanase Y (EGY)
DM5PDRB	MT	DME
DM5PDRB	MA	Metabolism
DM5PDRB	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5PDRB	DI	DM5PDRB
DM5PDRB	DN	Amikacin
DM5PDRB	MI	TTQ8KVI
DM5PDRB	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM5PDRB	MT	DTT
DM5PDRB	MA	Binder
DM5PDRB	RN	Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9.
DM5PDRB	RU	https://pubmed.ncbi.nlm.nih.gov/10702385

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	TTRJYB6
DMRTSGP	MN	Acid-sensing ion channel 1 (ASIC1)
DMRTSGP	MT	DTT
DMRTSGP	MA	Modulator
DMRTSGP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRTSGP	RU	https://www.fda.gov/

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	DTT79CX
DMRTSGP	MN	Organic cation transporter 1 (SLC22A1)
DMRTSGP	MT	DTP
DMRTSGP	MA	Substrate
DMRTSGP	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMRTSGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMRTSGP	DI	DMRTSGP
DMRTSGP	DN	Amiloride
DMRTSGP	MI	DT9IDPW
DMRTSGP	MN	Organic cation transporter 2 (SLC22A2)
DMRTSGP	MT	DTP
DMRTSGP	MA	Substrate
DMRTSGP	RN	Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31.
DMRTSGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/16394027

DMFGND4	DI	DMFGND4
DMFGND4	DN	Aminocaproic acid
DMFGND4	MI	TTP86E2
DMFGND4	MN	Plasminogen (PLG)
DMFGND4	MT	DTT
DMFGND4	MA	Inhibitor
DMFGND4	RN	The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92.
DMFGND4	RU	https://pubmed.ncbi.nlm.nih.gov/12007600

DMFGND4	DI	DMFGND4
DMFGND4	DN	Aminocaproic acid
DMFGND4	MI	TTXAGYU
DMFGND4	MN	Tissue-type plasminogen activator (PLAT)
DMFGND4	MT	DTT
DMFGND4	MA	Inhibitor
DMFGND4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFGND4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMWFHMZ	DI	DMWFHMZ
DMWFHMZ	DN	Aminoglutethimide
DMWFHMZ	MI	TTSZLWK
DMWFHMZ	MN	Aromatase (CYP19A1)
DMWFHMZ	MT	DTT
DMWFHMZ	MA	Inhibitor
DMWFHMZ	RN	Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
DMWFHMZ	RU	https://pubmed.ncbi.nlm.nih.gov/17602675

DMWFHMZ	DI	DMWFHMZ
DMWFHMZ	DN	Aminoglutethimide
DMWFHMZ	MI	TTSYVO6
DMWFHMZ	MN	Cholesterol desmolase (CYP11A1)
DMWFHMZ	MT	DTT
DMWFHMZ	MA	Inhibitor
DMWFHMZ	RN	Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15.
DMWFHMZ	RU	https://pubmed.ncbi.nlm.nih.gov/11161433

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	TTJHKYD
DMS4BLQ	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DMS4BLQ	MT	DTT
DMS4BLQ	MA	Inhibitor
DMS4BLQ	RN	Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9.
DMS4BLQ	RU	https://pubmed.ncbi.nlm.nih.gov/12665801

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT9G7XN
DMS4BLQ	MN	Peptide transporter 1 (SLC15A1)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther. 2010 Jan;332(1):220-8.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19789362

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT8QKNP
DMS4BLQ	MN	Peptide transporter 2 (SLC15A2)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17034769

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DETBNY4
DMS4BLQ	MN	Porphobilinogen synthase (ALAD)
DMS4BLQ	MT	DME
DMS4BLQ	MA	Metabolism
DMS4BLQ	RN	Modifying effects of delta-Aminolevulinate dehydratase polymorphism on blood lead levels and ALAD activity. Toxicol Lett. 2018 Oct 1;295:351-356.
DMS4BLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30025905

DMS4BLQ	DI	DMS4BLQ
DMS4BLQ	DN	Aminolevulinic acid hci
DMS4BLQ	MI	DT48WEM
DMS4BLQ	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMS4BLQ	MT	DTP
DMS4BLQ	MA	Substrate
DMS4BLQ	RN	Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53.
DMS4BLQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20128809

DMWNHPC	DI	DMWNHPC
DMWNHPC	DN	Aminolevulinic Acid Hydrochloride
DMWNHPC	MI	TTNFMS9
DMWNHPC	MN	Protoporphyrinogen oxidase (PPOX)
DMWNHPC	MT	DTT
DMWNHPC	MA	Modulator
DMWNHPC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWNHPC	RU	https://www.fda.gov/

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	DEJGDUW
DML2NIB	MN	Cytochrome P450 1A2 (CYP1A2)
DML2NIB	MT	DME
DML2NIB	MA	Metabolism
DML2NIB	RN	Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.
DML2NIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9855322

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	DEVDYN7
DML2NIB	MN	Cytochrome P450 2E1 (CYP2E1)
DML2NIB	MT	DME
DML2NIB	MA	Metabolism
DML2NIB	RN	Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7.
DML2NIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786569

DML2NIB	DI	DML2NIB
DML2NIB	DN	Aminophylline
DML2NIB	MI	TT06AWU
DML2NIB	MN	Phosphodiesterase 3A (PDE3A)
DML2NIB	MT	DTT
DML2NIB	MA	Inhibitor
DML2NIB	RN	Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
DML2NIB	RU	https://pubmed.ncbi.nlm.nih.gov/17391155

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TTYZVDJ
DMENSL5	MN	Dihydrofolate reductase (DHFR)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	DER7TA0
DMENSL5	MN	N-acetyltransferase 2 (NAT2)
DMENSL5	MT	DME
DMENSL5	MA	Metabolism
DMENSL5	RN	Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
DMENSL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27416043

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TT8NGED
DMENSL5	MN	Prostaglandin G/H synthase 1 (COX-1)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	TTVKILB
DMENSL5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMENSL5	MT	DTT
DMENSL5	MA	Modulator
DMENSL5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMENSL5	RU	https://www.fda.gov/

DMENSL5	DI	DMENSL5
DMENSL5	DN	Aminosalicylic acid
DMENSL5	MI	DTKWJH3
DMENSL5	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMENSL5	MT	DTP
DMENSL5	MA	Substrate
DMENSL5	RN	Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
DMENSL5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10794727

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE6OQ3W
DMUTEX3	MN	Cytochrome P450 1A1 (CYP1A1)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DEJGDUW
DMUTEX3	MN	Cytochrome P450 1A2 (CYP1A2)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11907638

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DES5XRU
DMUTEX3	MN	Cytochrome P450 2C8 (CYP2C8)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15716363

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE5IED8
DMUTEX3	MN	Cytochrome P450 2C9 (CYP2C9)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DECB0K3
DMUTEX3	MN	Cytochrome P450 2D6 (CYP2D6)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688833

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DE4LYSA
DMUTEX3	MN	Cytochrome P450 3A4 (CYP3A4)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DEGTFWK
DMUTEX3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUTEX3	MT	DME
DMUTEX3	MA	Metabolism
DMUTEX3	RN	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
DMUTEX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	DTUGYRD
DMUTEX3	MN	P-glycoprotein 1 (ABCB1)
DMUTEX3	MT	DTP
DMUTEX3	MA	Substrate
DMUTEX3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUTEX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUTEX3	DI	DMUTEX3
DMUTEX3	DN	Amiodarone
DMUTEX3	MI	TT1VOHK
DMUTEX3	MN	Potassium channel unspecific (KC)
DMUTEX3	MT	DTT
DMUTEX3	MA	Modulator
DMUTEX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUTEX3	RU	https://www.fda.gov/

DMSJVAM	DI	DMSJVAM
DMSJVAM	DN	Amisulpride
DMSJVAM	MI	TTEX248
DMSJVAM	MN	Dopamine D2 receptor (D2R)
DMSJVAM	MT	DTT
DMSJVAM	MA	Antagonist
DMSJVAM	RN	Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
DMSJVAM	RU	https://pubmed.ncbi.nlm.nih.gov/16696579

DMSJVAM	DI	DMSJVAM
DMSJVAM	DN	Amisulpride
DMSJVAM	MI	DTUGYRD
DMSJVAM	MN	P-glycoprotein 1 (ABCB1)
DMSJVAM	MT	DTP
DMSJVAM	MA	Substrate
DMSJVAM	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMSJVAM	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEJGDUW
DMK7F9S	MN	Cytochrome P450 1A2 (CYP1A2)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28344482

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEPKLMQ
DMK7F9S	MN	Cytochrome P450 2B6 (CYP2B6)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259560

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DES5XRU
DMK7F9S	MN	Cytochrome P450 2C8 (CYP2C8)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136296

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DE5IED8
DMK7F9S	MN	Cytochrome P450 2C9 (CYP2C9)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DECB0K3
DMK7F9S	MN	Cytochrome P450 2D6 (CYP2D6)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEVDYN7
DMK7F9S	MN	Cytochrome P450 2E1 (CYP2E1)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9549641

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DE4LYSA
DMK7F9S	MN	Cytochrome P450 3A4 (CYP3A4)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEIBDNY
DMK7F9S	MN	Cytochrome P450 3A5 (CYP3A5)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14637191

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEGTFWK
DMK7F9S	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	TTAWNKZ
DMK7F9S	MN	Norepinephrine transporter (NET)
DMK7F9S	MT	DTT
DMK7F9S	MA	Inhibitor
DMK7F9S	RN	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
DMK7F9S	RU	https://pubmed.ncbi.nlm.nih.gov/18622371

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DTUGYRD
DMK7F9S	MN	P-glycoprotein 1 (ABCB1)
DMK7F9S	MT	DTP
DMK7F9S	MA	Substrate
DMK7F9S	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DMK7F9S	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	TT3ROYC
DMK7F9S	MN	Serotonin transporter (SERT)
DMK7F9S	MT	DTT
DMK7F9S	MA	Inhibitor
DMK7F9S	RN	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
DMK7F9S	RU	https://pubmed.ncbi.nlm.nih.gov/18622371

DMK7F9S	DI	DMK7F9S
DMK7F9S	DN	Amitriptyline
DMK7F9S	MI	DEYGVN4
DMK7F9S	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMK7F9S	MT	DME
DMK7F9S	MA	Metabolism
DMK7F9S	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DMK7F9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DM0DQM5	DI	DM0DQM5
DM0DQM5	DN	Amlexanox
DM0DQM5	MI	TT78R5H
DM0DQM5	MN	Heat shock protein 90 alpha (HSP90A)
DM0DQM5	MT	DTT
DM0DQM5	MA	Inhibitor
DM0DQM5	RN	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
DM0DQM5	RU	https://pubmed.ncbi.nlm.nih.gov/12803546

DMBDAZV	DI	DMBDAZV
DMBDAZV	DN	Amlodipine
DMBDAZV	MI	DE4LYSA
DMBDAZV	MN	Cytochrome P450 3A4 (CYP3A4)
DMBDAZV	MT	DME
DMBDAZV	MA	Metabolism
DMBDAZV	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DMBDAZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DMBDAZV	DI	DMBDAZV
DMBDAZV	DN	Amlodipine
DMBDAZV	MI	TTFK1JQ
DMBDAZV	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMBDAZV	MT	DTT
DMBDAZV	MA	Blocker
DMBDAZV	RN	A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
DMBDAZV	RU	https://pubmed.ncbi.nlm.nih.gov/18217647

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DTU6IF7
DMOEVK6	MN	Ammonium transporter Rh type B (SLC42A2)
DMOEVK6	MT	DTP
DMOEVK6	MA	Substrate
DMOEVK6	RN	Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47.
DMOEVK6	RU	http://www.ncbi.nlm.nih.gov/pubmed/19553567

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DTF3LTV
DMOEVK6	MN	Ammonium transporter Rh type C (SLC42A3)
DMOEVK6	MT	DTP
DMOEVK6	MA	Substrate
DMOEVK6	RN	Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47.
DMOEVK6	RU	http://www.ncbi.nlm.nih.gov/pubmed/19553567

DMOEVK6	DI	DMOEVK6
DMOEVK6	DN	Ammonia
DMOEVK6	MI	DE5UC73
DMOEVK6	MN	Glutamine synthetase (GLUL)
DMOEVK6	MT	DME
DMOEVK6	MA	Metabolism
DMOEVK6	RN	Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):621-7.
DMOEVK6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19073408

DM0GQ8N	DI	DM0GQ8N
DM0GQ8N	DN	Amobarbital
DM0GQ8N	MI	TT1MPAY
DM0GQ8N	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0GQ8N	MT	DTT
DM0GQ8N	MA	Antagonist
DM0GQ8N	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM0GQ8N	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE4OGUF
DME4RA8	MN	Cytochrome P450 102A1 (cyp102)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE6OQ3W
DME4RA8	MN	Cytochrome P450 1A1 (CYP1A1)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DE9QHP6
DME4RA8	MN	Cytochrome P450 1B1 (CYP1B1)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DES5XRU
DME4RA8	MN	Cytochrome P450 2C8 (CYP2C8)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
DME4RA8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361129

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	DERQ52Z
DME4RA8	MN	Glutathione S-transferase mu-4 (GSTM4)
DME4RA8	MT	DME
DME4RA8	MA	Metabolism
DME4RA8	RN	Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017 Jun 5;275:83-91.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/28478157

DME4RA8	DI	DME4RA8
DME4RA8	DN	Amodiaquine
DME4RA8	MI	TT2B6EV
DME4RA8	MN	Histamine N-methyltransferase (HNMT)
DME4RA8	MT	DTT
DME4RA8	MA	Inhibitor
DME4RA8	RN	Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84.
DME4RA8	RU	https://pubmed.ncbi.nlm.nih.gov/17222819

DML8QSZ	DI	DML8QSZ
DML8QSZ	DN	Amosulalol
DML8QSZ	MI	TT2NUT5
DML8QSZ	MN	Adrenergic receptor alpha-2C (ADRA2C)
DML8QSZ	MT	DTT
DML8QSZ	MA	Modulator
DML8QSZ	RN	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
DML8QSZ	RU	https://pubmed.ncbi.nlm.nih.gov/8095542

DML8QSZ	DI	DML8QSZ
DML8QSZ	DN	Amosulalol
DML8QSZ	MI	TTMXGCW
DML8QSZ	MN	Adrenergic receptor beta-3 (ADRB3)
DML8QSZ	MT	DTT
DML8QSZ	MA	Modulator
DML8QSZ	RN	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
DML8QSZ	RU	https://pubmed.ncbi.nlm.nih.gov/8095542

DMKITQE	DI	DMKITQE
DMKITQE	DN	Amoxapine
DMKITQE	MI	DECB0K3
DMKITQE	MN	Cytochrome P450 2D6 (CYP2D6)
DMKITQE	MT	DME
DMKITQE	MA	Metabolism
DMKITQE	RN	Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2.
DMKITQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24294487

DMKITQE	DI	DMKITQE
DMKITQE	DN	Amoxapine
DMKITQE	MI	TTAWNKZ
DMKITQE	MN	Norepinephrine transporter (NET)
DMKITQE	MT	DTT
DMKITQE	MA	Inhibitor
DMKITQE	RN	Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
DMKITQE	RU	https://pubmed.ncbi.nlm.nih.gov/7845548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	TTXT4D5
DMUYNEI	MN	Bacterial Cell membrane (Bact CM)
DMUYNEI	MT	DTT
DMUYNEI	MA	Modulator
DMUYNEI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUYNEI	RU	https://www.fda.gov/

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DED0TBR
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/23349065

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEX8KJO
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg. 1990 Jun;28(3):180-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/1983762

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAYSTX
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30014616

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DERGEVU
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEV0KWQ
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQMISO
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEHFJ4G
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEHPJRC
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEITMS0
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/11036038

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DET9I1W
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE7IH52
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DENJ2SQ
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE5HV8P
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE47ARF
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEG2PK9
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEWHJ7A
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEU1RXB
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DETDS7E
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE37FJH
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEC7JEF
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEP7MN1
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAILCM
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DET4XFN
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEACNTL
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	IncU plasmid harbouring bla CTX-M-8 in multidrug-resistant Shigella sonnei in Brazil. J Glob Antimicrob Resist. 2018 Sep;14:99-100.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29964206

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEE8742
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEY09SU
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQLVCA
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/29737548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE2IL34
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE1NJIW
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Yersinia enterocolitica and Photorhabdus asymbiotica beta-lactamases BlaA are exported by the twin-arginine translocation pathway. Int J Med Microbiol. 2013 Jan;303(1):16-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/23276548

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEDIMN9
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEJ8X2W
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEFEVNH
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEAPGXV
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE0PDVC
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQL32N
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/24013195

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE9HF0I
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DESHI6O
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEZS3N4
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DE5NSUX
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/15621454

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEW193R
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEQ1CTE
DMUYNEI	MN	Beta-lactamase (blaB)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High prevalence of cfxA beta-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol. 2002 Apr;17(2):85-8.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/11929554

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEGTFWK
DMUYNEI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
DMUYNEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14696516

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEPCQ12
DMUYNEI	MN	Metallo-beta-lactamase (blaM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEK9VG2
DMUYNEI	MN	Metallo-beta-lactamase (blaM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/27381397

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEIU0XN
DMUYNEI	MN	N-acylhomoserine lactone acylase (lacA)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DEBGCYQ
DMUYNEI	MN	New delhi metallo-beta-lactamase NDM-1 (blaNDM)
DMUYNEI	MT	DME
DMUYNEI	MA	Metabolism
DMUYNEI	RN	Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
DMUYNEI	RU	https://pubmed.ncbi.nlm.nih.gov/28870291

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DTQ23VB
DMUYNEI	MN	Organic anion transporter 1 (SLC22A6)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/11744606

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DT9G7XN
DMUYNEI	MN	Peptide transporter 1 (SLC15A1)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DT8QKNP
DMUYNEI	MN	Peptide transporter 2 (SLC15A2)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMUYNEI	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMUYNEI	DI	DMUYNEI
DMUYNEI	DN	Amoxicillin
DMUYNEI	MI	DTUGYRD
DMUYNEI	MN	P-glycoprotein 1 (ABCB1)
DMUYNEI	MT	DTP
DMUYNEI	MA	Substrate
DMUYNEI	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMUYNEI	RU	https://doi.org/10.1007/s11095-012-0935-x

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DECB0K3
DMSZQAK	MN	Cytochrome P450 2D6 (CYP2D6)
DMSZQAK	MT	DME
DMSZQAK	MA	Metabolism
DMSZQAK	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DMSZQAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT6201N
DMSZQAK	MN	Organic cation transporter 3 (SLC22A3)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20402963

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT3HUVD
DMSZQAK	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15316089

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT3BA8L
DMSZQAK	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25542076

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DT9JBVI
DMSZQAK	MN	Sodium-dependent noradrenaline transporter (SLC6A2)
DMSZQAK	MT	DTP
DMSZQAK	MA	Substrate
DMSZQAK	RN	Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
DMSZQAK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25542076

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	TTIU98M
DMSZQAK	MN	Trace amine-associated receptor-1 (TAAR1)
DMSZQAK	MT	DTT
DMSZQAK	MA	Modulator
DMSZQAK	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMSZQAK	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMSZQAK	DI	DMSZQAK
DMSZQAK	DN	Amphetamine
DMSZQAK	MI	DEB3TNR
DMSZQAK	MN	Tyramine oxidase (tynA)
DMSZQAK	MT	DME
DMSZQAK	MA	Metabolism
DMSZQAK	RN	Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30.
DMSZQAK	RU	https://pubmed.ncbi.nlm.nih.gov/30701587

DMTAJQE	DI	DMTAJQE
DMTAJQE	DN	Amphotericin B
DMTAJQE	MI	TTQKWA4
DMTAJQE	MN	Fungal Cell membrane ergosterol (Fung CME)
DMTAJQE	MT	DTT
DMTAJQE	MA	Modulator
DMTAJQE	RN	Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78.
DMTAJQE	RU	https://pubmed.ncbi.nlm.nih.gov/12488039

DMTAJQE	DI	DMTAJQE
DMTAJQE	DN	Amphotericin B
DMTAJQE	MI	DTUGYRD
DMTAJQE	MN	P-glycoprotein 1 (ABCB1)
DMTAJQE	MT	DTP
DMTAJQE	MA	Substrate
DMTAJQE	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DMTAJQE	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DERI7LO
DMHWE7P	MN	AmpC beta-lactamase (ampC)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	TTJP4SM
DMHWE7P	MN	Bacterial Penicillin binding protein (Bact PBP)
DMHWE7P	MT	DTT
DMHWE7P	MA	Binder
DMHWE7P	RN	Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/11959556

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DET9I1W
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DE3FVRW
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DETDS7E
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEQX0DG
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEC7JEF
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEXB2A9
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/10837443

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEBKS91
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEWMGC3
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEWYT5M
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DE52KD0
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEG5Y4W
DMHWE7P	MN	Beta-lactamase (blaB)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/15327642

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DTFI42L
DMHWE7P	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DEIU0XN
DMHWE7P	MN	N-acylhomoserine lactone acylase (lacA)
DMHWE7P	MT	DME
DMHWE7P	MA	Metabolism
DMHWE7P	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMHWE7P	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DT9G7XN
DMHWE7P	MN	Peptide transporter 1 (SLC15A1)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/28214542

DMHWE7P	DI	DMHWE7P
DMHWE7P	DN	Ampicillin
DMHWE7P	MI	DT8QKNP
DMHWE7P	MN	Peptide transporter 2 (SLC15A2)
DMHWE7P	MT	DTP
DMHWE7P	MA	Substrate
DMHWE7P	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHWE7P	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM5BS98	DI	DM5BS98
DM5BS98	DN	Ampiroxicam
DM5BS98	MI	TTK0943
DM5BS98	MN	Prostaglandin G/H synthase (COX)
DM5BS98	MT	DTT
DM5BS98	MA	Modulator
DM5BS98	RN	Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7.
DM5BS98	RU	https://pubmed.ncbi.nlm.nih.gov/16540287

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DE5IED8
DMLMXE0	MN	Cytochrome P450 2C9 (CYP2C9)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DECB0K3
DMLMXE0	MN	Cytochrome P450 2D6 (CYP2D6)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DE4LYSA
DMLMXE0	MN	Cytochrome P450 3A4 (CYP3A4)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DEIBDNY
DMLMXE0	MN	Cytochrome P450 3A5 (CYP3A5)
DMLMXE0	MT	DME
DMLMXE0	MA	Metabolism
DMLMXE0	RN	Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
DMLMXE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584153

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	TT5FNQT
DMLMXE0	MN	Human immunodeficiency virus Protease (HIV PR)
DMLMXE0	MT	DTT
DMLMXE0	MA	Inhibitor
DMLMXE0	RN	Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. 
DMLMXE0	RU	https://pubmed.ncbi.nlm.nih.gov/19323590

DMLMXE0	DI	DMLMXE0
DMLMXE0	DN	Amprenavir
DMLMXE0	MI	DTUGYRD
DMLMXE0	MN	P-glycoprotein 1 (ABCB1)
DMLMXE0	MT	DTP
DMLMXE0	MA	Substrate
DMLMXE0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLMXE0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZKYIV	DI	DMZKYIV
DMZKYIV	DN	Amsacrine
DMZKYIV	MI	DECB0K3
DMZKYIV	MN	Cytochrome P450 2D6 (CYP2D6)
DMZKYIV	MT	DME
DMZKYIV	MA	Metabolism
DMZKYIV	RN	Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94.
DMZKYIV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10955788

DMZKYIV	DI	DMZKYIV
DMZKYIV	DN	Amsacrine
DMZKYIV	MI	TT0IHXV
DMZKYIV	MN	DNA topoisomerase II (TOP2)
DMZKYIV	MT	DTT
DMZKYIV	MA	Inhibitor
DMZKYIV	RN	Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
DMZKYIV	RU	https://pubmed.ncbi.nlm.nih.gov/11716434

DMAWU35	DI	DMAWU35
DMAWU35	DN	Amtolmetin guacil
DMAWU35	MI	TTK0943
DMAWU35	MN	Prostaglandin G/H synthase (COX)
DMAWU35	MT	DTT
DMAWU35	MA	Modulator
DMAWU35	RN	Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18.
DMAWU35	RU	https://pubmed.ncbi.nlm.nih.gov/16396699

DMJKO05	DI	DMJKO05
DMJKO05	DN	Amyl nitrite
DMJKO05	MI	DEWYTJB
DMJKO05	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMJKO05	MT	DME
DMJKO05	MA	Metabolism
DMJKO05	RN	Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26.
DMJKO05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20543077

DMJKO05	DI	DMJKO05
DMJKO05	DN	Amyl nitrite
DMJKO05	MI	DE4ZHS1
DMJKO05	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMJKO05	MT	DME
DMJKO05	MA	Metabolism
DMJKO05	RN	Subunit specificity and organ distribution of glutathione transferase-catalysed S-nitrosoglutathione formation from alkyl nitrites in the rat. Biochem Pharmacol. 1997 Jan 10;53(1):117-20.
DMJKO05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8960071

DMJXIC9	DI	DMJXIC9
DMJXIC9	DN	Anagliptin
DMJXIC9	MI	TTDIGC1
DMJXIC9	MN	Dipeptidyl peptidase 4 (DPP-4)
DMJXIC9	MT	DTT
DMJXIC9	MA	Modulator
DMJXIC9	RN	Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
DMJXIC9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/

DMSQ8MD	DI	DMSQ8MD
DMSQ8MD	DN	Anagrelide
DMSQ8MD	MI	DEJGDUW
DMSQ8MD	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQ8MD	MT	DME
DMSQ8MD	MA	Metabolism
DMSQ8MD	RN	Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8.
DMSQ8MD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23378182

DMSQ8MD	DI	DMSQ8MD
DMSQ8MD	DN	Anagrelide
DMSQ8MD	MI	TT06AWU
DMSQ8MD	MN	Phosphodiesterase 3A (PDE3A)
DMSQ8MD	MT	DTT
DMSQ8MD	MA	Inhibitor
DMSQ8MD	RN	Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
DMSQ8MD	RU	https://pubmed.ncbi.nlm.nih.gov/16000354

DMU8KOD	DI	DMU8KOD
DMU8KOD	DN	Anakinra
DMU8KOD	MI	TTWOTEA
DMU8KOD	MN	Interleukin 1 receptor type 1 (IL1R1)
DMU8KOD	MT	DTT
DMU8KOD	MA	Antagonist
DMU8KOD	RN	IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87.
DMU8KOD	RU	https://pubmed.ncbi.nlm.nih.gov/19541594

DMV96ZH	DI	DMV96ZH
DMV96ZH	DN	Anapsos
DMV96ZH	MI	TTXL3MF
DMV96ZH	MN	Lymphoid cell adhesion molecule expression (LCDME)
DMV96ZH	MT	DTT
DMV96ZH	MA	Modulator
DMV96ZH	RN	Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90.
DMV96ZH	RU	https://pubmed.ncbi.nlm.nih.gov/12220959

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	TTSZLWK
DMNP60F	MN	Aromatase (CYP19A1)
DMNP60F	MT	DTT
DMNP60F	MA	Inhibitor
DMNP60F	RN	Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
DMNP60F	RU	https://pubmed.ncbi.nlm.nih.gov/12199354

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DES5XRU
DMNP60F	MN	Cytochrome P450 2C8 (CYP2C8)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DE4LYSA
DMNP60F	MN	Cytochrome P450 3A4 (CYP3A4)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEIBDNY
DMNP60F	MN	Cytochrome P450 3A5 (CYP3A5)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DT2EGUN
DMNP60F	MN	Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7)
DMNP60F	MT	DTP
DMNP60F	MA	Substrate
DMNP60F	RN	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 Jan 16.
DMNP60F	RU	http://www.ncbi.nlm.nih.gov/pubmed/30648747

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEYGVN4
DMNP60F	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEF2WXN
DMNP60F	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMNP60F	DI	DMNP60F
DMNP60F	DN	Anastrozole
DMNP60F	MI	DEB3CV1
DMNP60F	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMNP60F	MT	DME
DMNP60F	MA	Metabolism
DMNP60F	RN	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
DMNP60F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441

DMLWQ27	DI	DMLWQ27
DMLWQ27	DN	Angiotensin Ii
DMLWQ27	MI	TT8DBY3
DMLWQ27	MN	Angiotensin II receptor type-1 (AGTR1)
DMLWQ27	MT	DTT
DMLWQ27	MA	Inhibitor
DMLWQ27	RN	The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75.
DMLWQ27	RU	https://pubmed.ncbi.nlm.nih.gov/20146480

DMLWQ27	DI	DMLWQ27
DMLWQ27	DN	Angiotensin Ii
DMLWQ27	MI	TTQVOEI
DMLWQ27	MN	Angiotensin II receptor type-2 (AGTR2)
DMLWQ27	MT	DTT
DMLWQ27	MA	Inhibitor
DMLWQ27	RN	The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
DMLWQ27	RU	http://www.sciencedirect.com/science/article/pii/S0960894X00806885

DM8QM5U	DI	DM8QM5U
DM8QM5U	DN	Anidulafungin
DM8QM5U	MI	TT0SFXH
DM8QM5U	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DM8QM5U	MT	DTT
DM8QM5U	MA	Modulator
DM8QM5U	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM8QM5U	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMBAUED	DI	DMBAUED
DMBAUED	DN	Anileridine
DMBAUED	MI	TTKWM86
DMBAUED	MN	Opioid receptor mu (MOP)
DMBAUED	MT	DTT
DMBAUED	MA	Agonist
DMBAUED	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMBAUED	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMC128O	DI	DMC128O
DMC128O	DN	Anileridine Hydrochloride
DMC128O	MI	TTKWM86
DMC128O	MN	Opioid receptor mu (MOP)
DMC128O	MT	DTT
DMC128O	MA	Modulator
DMC128O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC128O	RU	https://www.fda.gov/

DMOIFW0	DI	DMOIFW0
DMOIFW0	DN	Aniracetam
DMOIFW0	MI	TTJQOD7
DMOIFW0	MN	5-HT 2A receptor (HTR2A)
DMOIFW0	MT	DTT
DMOIFW0	MA	Inhibitor
DMOIFW0	RN	Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
DMOIFW0	RU	https://pubmed.ncbi.nlm.nih.gov/11412837

DMOIFW0	DI	DMOIFW0
DMOIFW0	DN	Aniracetam
DMOIFW0	MI	TTEX248
DMOIFW0	MN	Dopamine D2 receptor (D2R)
DMOIFW0	MT	DTT
DMOIFW0	MA	Inhibitor
DMOIFW0	RN	Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
DMOIFW0	RU	https://pubmed.ncbi.nlm.nih.gov/11412837

DM2C48U	DI	DM2C48U
DM2C48U	DN	Anisindione
DM2C48U	MI	TT6L509
DM2C48U	MN	Coagulation factor IIa (F2)
DM2C48U	MT	DTT
DM2C48U	MA	Modulator
DM2C48U	RN	Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
DM2C48U	RU	https://pubmed.ncbi.nlm.nih.gov/12680483

DMW51AX	DI	DMW51AX
DMW51AX	DN	Anisodamine
DMW51AX	MI	TTR6W5O
DMW51AX	MN	Adrenergic receptor beta-1 (ADRB1)
DMW51AX	MT	DTT
DMW51AX	MA	Modulator
DMW51AX	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMW51AX	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMW51AX	DI	DMW51AX
DMW51AX	DN	Anisodamine
DMW51AX	MI	DECB0K3
DMW51AX	MN	Cytochrome P450 2D6 (CYP2D6)
DMW51AX	MT	DME
DMW51AX	MA	Metabolism
DMW51AX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMW51AX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNOSWU	DI	DMNOSWU
DMNOSWU	DN	Anisodine
DMNOSWU	MI	TTR6W5O
DMNOSWU	MN	Adrenergic receptor beta-1 (ADRB1)
DMNOSWU	MT	DTT
DMNOSWU	MA	Modulator
DMNOSWU	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNOSWU	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMNOSWU	DI	DMNOSWU
DMNOSWU	DN	Anisodine
DMNOSWU	MI	TTH18TF
DMNOSWU	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMNOSWU	MT	DTT
DMNOSWU	MA	Modulator
DMNOSWU	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNOSWU	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMIJRF0	DI	DMIJRF0
DMIJRF0	DN	Anisotropine Methylbromide
DMIJRF0	MI	TTH18TF
DMIJRF0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMIJRF0	MT	DTT
DMIJRF0	MA	Binder
DMIJRF0	RN	Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8.
DMIJRF0	RU	https://pubmed.ncbi.nlm.nih.gov/13966843

DM6Q4B0	DI	DM6Q4B0
DM6Q4B0	DN	Anistreplase
DM6Q4B0	MI	TTP86E2
DM6Q4B0	MN	Plasminogen (PLG)
DM6Q4B0	MT	DTT
DM6Q4B0	MA	Activator
DM6Q4B0	RN	Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7.
DM6Q4B0	RU	https://pubmed.ncbi.nlm.nih.gov/9360848

DMUMOEV	DI	DMUMOEV
DMUMOEV	DN	Ansuvimab
DMUMOEV	MI	TT2F0AU
DMUMOEV	MN	Ebola virus Envelope glycoprotein (EV GP)
DMUMOEV	MT	DTT
DMUMOEV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMUMOEV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf

DMA04JS	DI	DMA04JS
DMA04JS	DN	Antazoline
DMA04JS	MI	TTTIBOJ
DMA04JS	MN	Histamine H1 receptor (H1R)
DMA04JS	MT	DTT
DMA04JS	MA	Antagonist
DMA04JS	RN	Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6.
DMA04JS	RU	https://pubmed.ncbi.nlm.nih.gov/19205365

DMNC64R	DI	DMNC64R
DMNC64R	DN	Antegren
DMNC64R	MI	TT4BT06
DMNC64R	MN	Integrin alpha-4 (ITGA4)
DMNC64R	MT	DTT
DMNC64R	RN	Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
DMNC64R	RU	https://pubmed.ncbi.nlm.nih.gov/9736917

DMH4CFE	DI	DMH4CFE
DMH4CFE	DN	Antithymocyte globulin
DMH4CFE	MI	TTBGTFN
DMH4CFE	MN	T-cell surface glycoprotein CD1a (CD1A)
DMH4CFE	MT	DTT
DMH4CFE	MA	Binder
DMH4CFE	RN	Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6.
DMH4CFE	RU	https://pubmed.ncbi.nlm.nih.gov/17283492

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DTI7UX6
DM89JLN	MN	Breast cancer resistance protein (ABCG2)
DM89JLN	MT	DTP
DM89JLN	MA	Substrate
DM89JLN	RN	Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
DM89JLN	RU	http://www.ncbi.nlm.nih.gov/pubmed/23382458

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	TTCIHJA
DM89JLN	MN	Coagulation factor Xa (F10)
DM89JLN	MT	DTT
DM89JLN	MA	Inhibitor
DM89JLN	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM89JLN	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEJGDUW
DM89JLN	MN	Cytochrome P450 1A2 (CYP1A2)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DES5XRU
DM89JLN	MN	Cytochrome P450 2C8 (CYP2C8)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DE5IED8
DM89JLN	MN	Cytochrome P450 2C9 (CYP2C9)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DE4LYSA
DM89JLN	MN	Cytochrome P450 3A4 (CYP3A4)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19940026

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEIBDNY
DM89JLN	MN	Cytochrome P450 3A5 (CYP3A5)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23016247

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DEGTFWK
DM89JLN	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM89JLN	MT	DME
DM89JLN	MA	Metabolism
DM89JLN	RN	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
DM89JLN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512

DM89JLN	DI	DM89JLN
DM89JLN	DN	Apixaban
DM89JLN	MI	DTUGYRD
DM89JLN	MN	P-glycoprotein 1 (ABCB1)
DM89JLN	MT	DTP
DM89JLN	MA	Substrate
DM89JLN	RN	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27.
DM89JLN	RU	http://www.ncbi.nlm.nih.gov/pubmed/26749408

DMX38HQ	DI	DMX38HQ
DMX38HQ	DN	Apomorphine
DMX38HQ	MI	TTEX248
DMX38HQ	MN	Dopamine D2 receptor (D2R)
DMX38HQ	MT	DTT
DMX38HQ	MA	Agonist
DMX38HQ	RN	Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89.
DMX38HQ	RU	https://pubmed.ncbi.nlm.nih.gov/19173265

DMX38HQ	DI	DMX38HQ
DMX38HQ	DN	Apomorphine
DMX38HQ	MI	DEYWLRK
DMX38HQ	MN	Sulfotransferase 1A1 (SULT1A1)
DMX38HQ	MT	DME
DMX38HQ	MA	Metabolism
DMX38HQ	RN	Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48.
DMX38HQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14660177

DMO4PVE	DI	DMO4PVE
DMO4PVE	DN	Apraclonidine
DMO4PVE	MI	TTQ8AFT
DMO4PVE	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMO4PVE	MT	DTT
DMO4PVE	MA	Agonist
DMO4PVE	RN	Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents.
DMO4PVE	RU	https://pubmed.ncbi.nlm.nih.gov/11867401

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TT0PG8F
DMTWS9E	MN	Cyclin-dependent kinase 4 (CDK4)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
DMTWS9E	RU	http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TTO0FDJ
DMTWS9E	MN	Cyclin-dependent kinase 6 (CDK6)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
DMTWS9E	RU	http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DEJGDUW
DMTWS9E	MN	Cytochrome P450 1A2 (CYP1A2)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DEJVYAZ
DMTWS9E	MN	Cytochrome P450 2A6 (CYP2A6)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DE4LYSA
DMTWS9E	MN	Cytochrome P450 3A4 (CYP3A4)
DMTWS9E	MT	DME
DMTWS9E	MA	Metabolism
DMTWS9E	RN	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695.
DMTWS9E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27869356

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	DTUGYRD
DMTWS9E	MN	P-glycoprotein 1 (ABCB1)
DMTWS9E	MT	DTP
DMTWS9E	MA	Substrate
DMTWS9E	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMTWS9E	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMTWS9E	DI	DMTWS9E
DMTWS9E	DN	Apremilast
DMTWS9E	MI	TTV5CGO
DMTWS9E	MN	Phosphodiesterase 4 (PDE4)
DMTWS9E	MT	DTT
DMTWS9E	MA	Inhibitor
DMTWS9E	RN	Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26.
DMTWS9E	RU	https://pubmed.ncbi.nlm.nih.gov/17352685

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DEJGDUW
DM053KT	MN	Cytochrome P450 1A2 (CYP1A2)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DE4LYSA
DM053KT	MN	Cytochrome P450 3A4 (CYP3A4)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15723220

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DEGTFWK
DM053KT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM053KT	MT	DME
DM053KT	MA	Metabolism
DM053KT	RN	Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
DM053KT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	DTUGYRD
DM053KT	MN	P-glycoprotein 1 (ABCB1)
DM053KT	MT	DTP
DM053KT	MA	Substrate
DM053KT	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM053KT	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM053KT	DI	DM053KT
DM053KT	DN	Aprepitant
DM053KT	MI	TTZPO1L
DM053KT	MN	Substance-P receptor (TACR1)
DM053KT	MT	DTT
DM053KT	MA	Antagonist
DM053KT	RN	Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
DM053KT	RU	https://pubmed.ncbi.nlm.nih.gov/19354254

DMBXWU8	DI	DMBXWU8
DMBXWU8	DN	Aprindine
DMBXWU8	MI	TTV3NH6
DMBXWU8	MN	Calmodulin (CALM)
DMBXWU8	MT	DTT
DMBXWU8	MA	Inhibitor
DMBXWU8	RN	Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6.
DMBXWU8	RU	https://pubmed.ncbi.nlm.nih.gov/6186851

DMBXWU8	DI	DMBXWU8
DMBXWU8	DN	Aprindine
DMBXWU8	MI	DECB0K3
DMBXWU8	MN	Cytochrome P450 2D6 (CYP2D6)
DMBXWU8	MT	DME
DMBXWU8	MA	Metabolism
DMBXWU8	RN	Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21.
DMBXWU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16508157

DMOWK6B	DI	DMOWK6B
DMOWK6B	DN	Aprobarbital
DMOWK6B	MI	TTAN6JD
DMOWK6B	MN	Glutamate receptor AMPA (GRIA)
DMOWK6B	MT	DTT
DMOWK6B	MA	Binder
DMOWK6B	RN	Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8.
DMOWK6B	RU	https://pubmed.ncbi.nlm.nih.gov/12039632

DM0QD4W	DI	DM0QD4W
DM0QD4W	DN	Aprotinin
DM0QD4W	MI	TTEMV5X
DM0QD4W	MN	Serine protease unspecific (SP)
DM0QD4W	MT	DTT
DM0QD4W	MA	Modulator
DM0QD4W	RN	Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32.
DM0QD4W	RU	https://pubmed.ncbi.nlm.nih.gov/16279145

DMHTXSL	DI	DMHTXSL
DMHTXSL	DN	Arbekacin
DMHTXSL	MI	TTA4FIU
DMHTXSL	MN	Ribosome A (hRA)
DMHTXSL	MT	DTT
DMHTXSL	MA	Modulator
DMHTXSL	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMHTXSL	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMHTXSL	DI	DMHTXSL
DMHTXSL	DN	Arbekacin
DMHTXSL	MI	DEZV4AP
DMHTXSL	MN	RNA cytidine acetyltransferase (hALP)
DMHTXSL	MT	DME
DMHTXSL	MA	Metabolism
DMHTXSL	RN	The novel enzymatic 3''-N-acetylation of arbekacin by an aminoglycoside 3-N-acetyltransferase of Streptomyces origin and the resulting activity. J Antibiot (Tokyo). 1998 Aug;51(8):735-42.
DMHTXSL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9766465

DMOQK8Z	DI	DMOQK8Z
DMOQK8Z	DN	Arbidol
DMOQK8Z	MI	TTF4CAM
DMOQK8Z	MN	Influenza Hemagglutinin (Influ HA)
DMOQK8Z	MT	DTT
DMOQK8Z	MA	Inhibitor
DMOQK8Z	RN	Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92.
DMOQK8Z	RU	https://pubmed.ncbi.nlm.nih.gov/19446151

DMCY8AF	DI	DMCY8AF
DMCY8AF	DN	Arbutamine
DMCY8AF	MI	TTR6W5O
DMCY8AF	MN	Adrenergic receptor beta-1 (ADRB1)
DMCY8AF	MT	DTT
DMCY8AF	MA	Stimulator
DMCY8AF	RN	Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47.
DMCY8AF	RU	https://pubmed.ncbi.nlm.nih.gov/8723169

DM9GH25	DI	DM9GH25
DM9GH25	DN	Arcitumomab
DM9GH25	MI	TTPX7I5
DM9GH25	MN	Carcinoembryonic antigen CGM1 (CD66d)
DM9GH25	MT	DTT
DM9GH25	RN	In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87.
DM9GH25	RU	https://pubmed.ncbi.nlm.nih.gov/18413884

DMYRX8B	DI	DMYRX8B
DMYRX8B	DN	Ardeparin
DMYRX8B	MI	TT4QPUL
DMYRX8B	MN	Antithrombin-III (ATIII)
DMYRX8B	MT	DTT
DMYRX8B	MA	Modulator
DMYRX8B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYRX8B	RU	https://www.fda.gov/

DMVMY7K	DI	DMVMY7K
DMVMY7K	DN	Arepanrix
DMVMY7K	MI	TT3J5ZI
DMVMY7K	MN	Cell mediated immunity response (CMIR)
DMVMY7K	MT	DTT
DMVMY7K	RN	Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57.
DMVMY7K	RU	https://pubmed.ncbi.nlm.nih.gov/25452148

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	TT2CJVK
DMYM974	MN	Adrenergic receptor beta-2 (ADRB2)
DMYM974	MT	DTT
DMYM974	MA	Agonist
DMYM974	RN	Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
DMYM974	RU	https://pubmed.ncbi.nlm.nih.gov/19271027

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DEJVYAZ
DMYM974	MN	Cytochrome P450 2A6 (CYP2A6)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DECB0K3
DMYM974	MN	Cytochrome P450 2D6 (CYP2D6)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMYM974	DI	DMYM974
DMYM974	DN	Arformoterol
DMYM974	MI	DEGTFWK
DMYM974	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMYM974	MT	DME
DMYM974	MA	Metabolism
DMYM974	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMYM974	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	TT6L509
DMFI46A	MN	Coagulation factor IIa (F2)
DMFI46A	MT	DTT
DMFI46A	MA	Inhibitor
DMFI46A	RN	Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
DMFI46A	RU	https://pubmed.ncbi.nlm.nih.gov/12496240

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	DE4LYSA
DMFI46A	MN	Cytochrome P450 3A4 (CYP3A4)
DMFI46A	MT	DME
DMFI46A	MA	Metabolism
DMFI46A	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DMFI46A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DMFI46A	DI	DMFI46A
DMFI46A	DN	Argatroban
DMFI46A	MI	DEIBDNY
DMFI46A	MN	Cytochrome P450 3A5 (CYP3A5)
DMFI46A	MT	DME
DMFI46A	MA	Metabolism
DMFI46A	RN	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
DMFI46A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DTDPJ3F
DMRE4FC	MN	Mitochondrial ornithine transporter 2 (SLC25A2)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2. Amino Acids. 2016 Feb;48(2):427-36.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/26403849

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DT96BT4
DMRE4FC	MN	Mitochondrial ornithine transporter 3 (SLC25A29)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May 9;289(19):13374-84.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24652292

DMRE4FC	DI	DMRE4FC
DMRE4FC	DN	Arginine
DMRE4FC	MI	DTF7MYK
DMRE4FC	MN	Sodium-coupled neutral amino acid transporter 9 (SLC38A9)
DMRE4FC	MT	DTP
DMRE4FC	MA	Substrate
DMRE4FC	RN	Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015 Jan 9;347(6218):188-94.
DMRE4FC	RU	http://www.ncbi.nlm.nih.gov/pubmed/25567906

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DECB0K3
DM3NUMH	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DM3NUMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DE4LYSA
DM3NUMH	MN	Cytochrome P450 3A4 (CYP3A4)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.
DM3NUMH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DEIBDNY
DM3NUMH	MN	Cytochrome P450 3A5 (CYP3A5)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Drug Interactions Flockhart Table
DM3NUMH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	DERD86B
DM3NUMH	MN	Cytochrome P450 3A7 (CYP3A7)
DM3NUMH	MT	DME
DM3NUMH	MA	Metabolism
DM3NUMH	RN	Drug Interactions Flockhart Table
DM3NUMH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NUMH	DI	DM3NUMH
DM3NUMH	DN	Aripiprazole
DM3NUMH	MI	TTEX248
DM3NUMH	MN	Dopamine D2 receptor (D2R)
DM3NUMH	MT	DTT
DM3NUMH	MA	Agonist
DM3NUMH	RN	Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.
DM3NUMH	RU	https://pubmed.ncbi.nlm.nih.gov/17501690

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	TT34BHT
DMGB035	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMGB035	MT	DTT
DMGB035	MA	Agonist
DMGB035	RN	Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
DMGB035	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	DE4LYSA
DMGB035	MN	Cytochrome P450 3A4 (CYP3A4)
DMGB035	MT	DME
DMGB035	MA	Metabolism
DMGB035	RN	Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.
DMGB035	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18076219

DMGB035	DI	DMGB035
DMGB035	DN	Armodafinil
DMGB035	MI	DEIBDNY
DMGB035	MN	Cytochrome P450 3A5 (CYP3A5)
DMGB035	MT	DME
DMGB035	MA	Metabolism
DMGB035	RN	Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
DMGB035	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12537513

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	TTS64P2
DMT81LZ	MN	Androgen receptor (AR)
DMT81LZ	MT	DTT
DMT81LZ	MA	Inhibitor
DMT81LZ	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMT81LZ	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	DES5XRU
DMT81LZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMT81LZ	MT	DME
DMT81LZ	MA	Metabolism
DMT81LZ	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DMT81LZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DMT81LZ	DI	DMT81LZ
DMT81LZ	DN	Arn-509
DMT81LZ	MI	DE4LYSA
DMT81LZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMT81LZ	MT	DME
DMT81LZ	MA	Metabolism
DMT81LZ	RN	Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705.
DMT81LZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DTI7UX6
DM1P6FR	MN	Breast cancer resistance protein (ABCG2)
DM1P6FR	MT	DTP
DM1P6FR	MA	Substrate
DM1P6FR	RN	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28921565

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DEJGDUW
DM1P6FR	MN	Cytochrome P450 1A2 (CYP1A2)
DM1P6FR	MT	DME
DM1P6FR	MA	Metabolism
DM1P6FR	RN	FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration.
DM1P6FR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	TTZCRP3
DM1P6FR	MN	ERK activator kinase (MEK)
DM1P6FR	MT	DTT
DM1P6FR	MA	Inhibitor
DM1P6FR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1P6FR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	TTROQ37
DM1P6FR	MN	MAPK/ERK kinase kinase (MAP3K)
DM1P6FR	MT	DTT
DM1P6FR	MA	Modulator
DM1P6FR	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DTUGYRD
DM1P6FR	MN	P-glycoprotein 1 (ABCB1)
DM1P6FR	MT	DTP
DM1P6FR	MA	Substrate
DM1P6FR	RN	The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391.
DM1P6FR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28921565

DM1P6FR	DI	DM1P6FR
DM1P6FR	DN	Arry-162
DM1P6FR	MI	DEYGVN4
DM1P6FR	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1P6FR	MT	DME
DM1P6FR	MA	Metabolism
DM1P6FR	RN	Binimetinib - European Medicines Agency - European Union
DM1P6FR	RU	https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-balimek-binimetinib_en.pdf

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DE9KJP3
DMTL2Y1	MN	Arsenite methyltransferase (AS3MT)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ Health Perspect. 2011 Feb;119(2):182-8.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21247820

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DEOT0QC
DMTL2Y1	MN	Methylarsonite methyltransferase N6AMT1 (N6AMT1)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Interactive influence of N6AMT1 and As3MT genetic variations on arsenic metabolism in the population of Inner Mongolia, China. Toxicol Sci. 2017 Jan;155(1):124-134.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27637898

DMTL2Y1	DI	DMTL2Y1
DMTL2Y1	DN	Arsenic
DMTL2Y1	MI	DEYLWI6
DMTL2Y1	MN	Serine sulfhydrase (CBS)
DMTL2Y1	MT	DME
DMTL2Y1	MA	Metabolism
DMTL2Y1	RN	Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010 Aug;110(6):580-7.
DMTL2Y1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20670920

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	TTJ3E9X
DM61TA4	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DM61TA4	MT	DTT
DM61TA4	MA	Inhibitor
DM61TA4	RN	How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13.
DM61TA4	RU	https://pubmed.ncbi.nlm.nih.gov/12209159

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	DTFI42L
DM61TA4	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM61TA4	MT	DTP
DM61TA4	MA	Substrate
DM61TA4	RN	MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
DM61TA4	RU	http://www.ncbi.nlm.nih.gov/pubmed/17324950

DM61TA4	DI	DM61TA4
DM61TA4	DN	Arsenic trioxide
DM61TA4	MI	DTUGYRD
DM61TA4	MN	P-glycoprotein 1 (ABCB1)
DM61TA4	MT	DTP
DM61TA4	MA	Substrate
DM61TA4	RN	Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.
DM61TA4	RU	http://www.ncbi.nlm.nih.gov/pubmed/12647012

DMQLX7O	DI	DMQLX7O
DMQLX7O	DN	Arteether
DMQLX7O	MI	TT9X7H4
DMQLX7O	MN	Beta-hematin formation (BHF)
DMQLX7O	MT	DTT
DMQLX7O	MA	Modulator
DMQLX7O	RN	Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52.
DMQLX7O	RU	https://pubmed.ncbi.nlm.nih.gov/22354307

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEPKLMQ
DM48QOT	MN	Cytochrome P450 2B6 (CYP2B6)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DE5IED8
DM48QOT	MN	Cytochrome P450 2C9 (CYP2C9)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23441978

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DECB0K3
DM48QOT	MN	Cytochrome P450 2D6 (CYP2D6)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DE4LYSA
DM48QOT	MN	Cytochrome P450 3A4 (CYP3A4)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999 Oct;66(4):408-14.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10546925

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEIBDNY
DM48QOT	MN	Cytochrome P450 3A5 (CYP3A5)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 3;16(1):267.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28673292

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	DEGTFWK
DM48QOT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM48QOT	MT	DME
DM48QOT	MA	Metabolism
DM48QOT	RN	The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
DM48QOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988

DM48QOT	DI	DM48QOT
DM48QOT	DN	Artemether
DM48QOT	MI	TTWK8D0
DM48QOT	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM48QOT	MT	DTT
DM48QOT	MA	Binder
DM48QOT	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM48QOT	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DEJVYAZ
DMOY7W3	MN	Cytochrome P450 2A6 (CYP2A6)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DEPKLMQ
DMOY7W3	MN	Cytochrome P450 2B6 (CYP2B6)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DE4LYSA
DMOY7W3	MN	Cytochrome P450 3A4 (CYP3A4)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	DE4ZHS1
DMOY7W3	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOY7W3	MT	DME
DMOY7W3	MA	Metabolism
DMOY7W3	RN	Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
DMOY7W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11807801

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	TT3PQ2Y
DMOY7W3	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMOY7W3	MT	DTT
DMOY7W3	MA	Inhibitor
DMOY7W3	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMOY7W3	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOY7W3	DI	DMOY7W3
DMOY7W3	DN	Artemisinin
DMOY7W3	MI	TTZVSJ2
DMOY7W3	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMOY7W3	MT	DTT
DMOY7W3	MA	Inhibitor
DMOY7W3	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMOY7W3	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMFETDK	DI	DMFETDK
DMFETDK	DN	Artemisinin SP
DMFETDK	MI	TTAN6JD
DMFETDK	MN	Glutamate receptor AMPA (GRIA)
DMFETDK	MT	DTT
DMFETDK	MA	Agonist
DMFETDK	RN	GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
DMFETDK	RU	https://pubmed.ncbi.nlm.nih.gov/12171573

DMFETDK	DI	DMFETDK
DMFETDK	DN	Artemisinin SP
DMFETDK	MI	TTZVSJ2
DMFETDK	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMFETDK	MT	DTT
DMFETDK	MA	Inhibitor
DMFETDK	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMFETDK	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMR27C8	DI	DMR27C8
DMR27C8	DN	Artesunate
DMR27C8	MI	DEJVYAZ
DMR27C8	MN	Cytochrome P450 2A6 (CYP2A6)
DMR27C8	MT	DME
DMR27C8	MA	Metabolism
DMR27C8	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMR27C8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMR27C8	DI	DMR27C8
DMR27C8	DN	Artesunate
DMR27C8	MI	TTZVSJ2
DMR27C8	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMR27C8	MT	DTT
DMR27C8	MA	Inhibitor
DMR27C8	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMR27C8	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMOKCVI	DI	DMOKCVI
DMOKCVI	DN	ARZOXIFENE
DMOKCVI	MI	TTZAYWL
DMOKCVI	MN	Estrogen receptor (ESR)
DMOKCVI	MT	DTT
DMOKCVI	MA	Inhibitor
DMOKCVI	RN	Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
DMOKCVI	RU	https://pubmed.ncbi.nlm.nih.gov/17489582

DMOKCVI	DI	DMOKCVI
DMOKCVI	DN	ARZOXIFENE
DMOKCVI	MI	TTOM3J0
DMOKCVI	MN	Estrogen receptor beta (ESR2)
DMOKCVI	MT	DTT
DMOKCVI	MA	Inhibitor
DMOKCVI	RN	Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
DMOKCVI	RU	https://pubmed.ncbi.nlm.nih.gov/17489582

DMV05SW	DI	DMV05SW
DMV05SW	DN	As-1670542
DMV05SW	MI	TTIHYA4
DMV05SW	MN	Thrombopoietin receptor (MPL)
DMV05SW	MT	DTT
DMV05SW	MA	Agonist
DMV05SW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DMV05SW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMCZIHT	DI	DMCZIHT
DMCZIHT	DN	Asasantin
DMCZIHT	MI	TTK0943
DMCZIHT	MN	Prostaglandin G/H synthase (COX)
DMCZIHT	MT	DTT
DMCZIHT	MA	Inhibitor
DMCZIHT	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMCZIHT	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DEJGDUW
DMSQZE2	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DECB0K3
DMSQZE2	MN	Cytochrome P450 2D6 (CYP2D6)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	DE4LYSA
DMSQZE2	MN	Cytochrome P450 3A4 (CYP3A4)
DMSQZE2	MT	DME
DMSQZE2	MA	Metabolism
DMSQZE2	RN	Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504.
DMSQZE2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23356509

DMSQZE2	DI	DMSQZE2
DMSQZE2	DN	Asenapine
DMSQZE2	MI	TTXFI1K
DMSQZE2	MN	Hyaluronidase (HYAL)
DMSQZE2	MT	DTT
DMSQZE2	MA	Modulator
DMSQZE2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSQZE2	RU	https://www.fda.gov/

DMM4FXA	DI	DMM4FXA
DMM4FXA	DN	Asfotase alfa
DMM4FXA	MI	TTMR5UV
DMM4FXA	MN	Alkaline phosphatase tissue-nonspecific (ALPL)
DMM4FXA	MT	DTT
DMM4FXA	MA	Modulator
DMM4FXA	RN	Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13.
DMM4FXA	RU	https://pubmed.ncbi.nlm.nih.gov/22397652

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DE5IED8
DM672AH	MN	Cytochrome P450 2C9 (CYP2C9)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	TTPADOQ
DM672AH	MN	HMG-CoA reductase (HMGCR)
DM672AH	MT	DTT
DM672AH	MA	Inhibitor
DM672AH	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DM672AH	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEGTFWK
DM672AH	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621391

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DER7TA0
DM672AH	MN	N-acetyltransferase 2 (NAT2)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DT0OC1Q
DM672AH	MN	Organic anion transporter 2 (SLC22A7)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/9650585

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DTUGYRD
DM672AH	MN	P-glycoprotein 1 (ABCB1)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DTHE530
DM672AH	MN	Probable small intestine urate exporter (SLC17A4)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	TTK0943
DM672AH	MN	Prostaglandin G/H synthase (COX)
DM672AH	MT	DTT
DM672AH	MA	Inhibitor
DM672AH	RN	Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
DM672AH	RU	https://pubmed.ncbi.nlm.nih.gov/19075637

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DT8ARWJ
DM672AH	MN	Sodium-dependent phosphate transport protein 1 (SLC17A1)
DM672AH	MT	DTP
DM672AH	MA	Substrate
DM672AH	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DM672AH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEYWLRK
DM672AH	MN	Sulfotransferase 1A1 (SULT1A1)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17073578

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DEYGVN4
DM672AH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20214591

DM672AH	DI	DM672AH
DM672AH	DN	Aspirin
DM672AH	MI	DESD26P
DM672AH	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM672AH	MT	DME
DM672AH	MA	Metabolism
DM672AH	RN	Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
DM672AH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DE5IED8
DMSYRBX	MN	Cytochrome P450 2C9 (CYP2C9)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DE4LYSA
DMSYRBX	MN	Cytochrome P450 3A4 (CYP3A4)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DEIBDNY
DMSYRBX	MN	Cytochrome P450 3A5 (CYP3A5)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DERD86B
DMSYRBX	MN	Cytochrome P450 3A7 (CYP3A7)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	TT5FNQT
DMSYRBX	MN	Human immunodeficiency virus Protease (HIV PR)
DMSYRBX	MT	DTT
DMSYRBX	MA	Modulator
DMSYRBX	RN	Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9.
DMSYRBX	RU	https://pubmed.ncbi.nlm.nih.gov/11237841

DMSYRBX	DI	DMSYRBX
DMSYRBX	DN	Atazanavir
DMSYRBX	MI	DEYGVN4
DMSYRBX	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSYRBX	MT	DME
DMSYRBX	MA	Metabolism
DMSYRBX	RN	In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 Nov;33(11):1729-39.
DMSYRBX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118329

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	TTR6W5O
DMNKG1Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMNKG1Z	MT	DTT
DMNKG1Z	MA	Antagonist
DMNKG1Z	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DMNKG1Z	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DECB0K3
DMNKG1Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMNKG1Z	MT	DME
DMNKG1Z	MA	Metabolism
DMNKG1Z	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMNKG1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DE4LYSA
DMNKG1Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMNKG1Z	MT	DME
DMNKG1Z	MA	Metabolism
DMNKG1Z	RN	Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
DMNKG1Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27019

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTE2B1D
DMNKG1Z	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTT79CX
DMNKG1Z	MN	Organic cation transporter 1 (SLC22A1)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMNKG1Z	DI	DMNKG1Z
DMNKG1Z	DN	Atenolol
DMNKG1Z	MI	DTUGYRD
DMNKG1Z	MN	P-glycoprotein 1 (ABCB1)
DMNKG1Z	MT	DTP
DMNKG1Z	MA	Substrate
DMNKG1Z	RN	Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
DMNKG1Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/11895100

DMMF8U0	DI	DMMF8U0
DMMF8U0	DN	Atezolizumab
DMMF8U0	MI	TT8ZLTI
DMMF8U0	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMMF8U0	MT	DTT
DMMF8U0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMF8U0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DECB0K3
DM5L6HI	MN	Cytochrome P450 2D6 (CYP2D6)
DM5L6HI	MT	DME
DM5L6HI	MA	Metabolism
DM5L6HI	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DM5L6HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DEGTFWK
DM5L6HI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5L6HI	MT	DME
DM5L6HI	MA	Metabolism
DM5L6HI	RN	Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
DM5L6HI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	TTAWNKZ
DM5L6HI	MN	Norepinephrine transporter (NET)
DM5L6HI	MT	DTT
DM5L6HI	MA	Inhibitor
DM5L6HI	RN	Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
DM5L6HI	RU	https://pubmed.ncbi.nlm.nih.gov/18568443

DM5L6HI	DI	DM5L6HI
DM5L6HI	DN	Atomoxetine
DM5L6HI	MI	DTUGYRD
DM5L6HI	MN	P-glycoprotein 1 (ABCB1)
DM5L6HI	MT	DTP
DM5L6HI	MA	Substrate
DM5L6HI	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM5L6HI	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DES5XRU
DMF28YC	MN	Cytochrome P450 2C8 (CYP2C8)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DE4LYSA
DMF28YC	MN	Cytochrome P450 3A4 (CYP3A4)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEIBDNY
DMF28YC	MN	Cytochrome P450 3A5 (CYP3A5)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DERD86B
DMF28YC	MN	Cytochrome P450 3A7 (CYP3A7)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
DMF28YC	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	TTPADOQ
DMF28YC	MN	HMG-CoA reductase (HMGCR)
DMF28YC	MT	DTT
DMF28YC	MA	Inhibitor
DMF28YC	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DMF28YC	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT342ZG
DMF28YC	MN	Monocarboxylate transporter 1 (SLC16A1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
DMF28YC	RU	https://doi.org/10.1113/expphysiol.2005.029959

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTLT3UG
DMF28YC	MN	Monocarboxylate transporter 2 (SLC16A7)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMF28YC	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTE2B1D
DMF28YC	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20797388

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT3D8F0
DMF28YC	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19374892

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DT9C1TS
DMF28YC	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	FDA Drug Development and Drug Interactions
DMF28YC	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTPFTEQ
DMF28YC	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
DMF28YC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19237515

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DTUGYRD
DMF28YC	MN	P-glycoprotein 1 (ABCB1)
DMF28YC	MT	DTP
DMF28YC	MA	Substrate
DMF28YC	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMF28YC	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEYGVN4
DMF28YC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17470524

DMF28YC	DI	DMF28YC
DMF28YC	DN	Atorvastatin
DMF28YC	MI	DEF2WXN
DMF28YC	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMF28YC	MT	DME
DMF28YC	MA	Metabolism
DMF28YC	RN	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
DMF28YC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23580084

DMY4UMW	DI	DMY4UMW
DMY4UMW	DN	Atovaquone
DMY4UMW	MI	DE4LYSA
DMY4UMW	MN	Cytochrome P450 3A4 (CYP3A4)
DMY4UMW	MT	DME
DMY4UMW	MA	Metabolism
DMY4UMW	RN	Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27.
DMY4UMW	RU	https://www.ncbi.nlm.nih.gov/pubmed/11956669

DMY4UMW	DI	DMY4UMW
DMY4UMW	DN	Atovaquone
DMY4UMW	MI	TT3PQ2Y
DMY4UMW	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMY4UMW	MT	DTT
DMY4UMW	MA	Inhibitor
DMY4UMW	RN	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
DMY4UMW	RU	https://pubmed.ncbi.nlm.nih.gov/15044733

DM42HXN	DI	DM42HXN
DM42HXN	DN	Atracurium
DM42HXN	MI	TTJSZTB
DM42HXN	MN	Nicotinic acetylcholine receptor (nAChR)
DM42HXN	MT	DTT
DM42HXN	MA	Antagonist
DM42HXN	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DM42HXN	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMEN6X7	DI	DMEN6X7
DMEN6X7	DN	Atropine
DMEN6X7	MI	TTH18TF
DMEN6X7	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEN6X7	MT	DTT
DMEN6X7	MA	Antagonist
DMEN6X7	RN	Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204.
DMEN6X7	RU	https://pubmed.ncbi.nlm.nih.gov/19526284

DMEN6X7	DI	DMEN6X7
DMEN6X7	DN	Atropine
DMEN6X7	MI	DTT79CX
DMEN6X7	MN	Organic cation transporter 1 (SLC22A1)
DMEN6X7	MT	DTP
DMEN6X7	MA	Substrate
DMEN6X7	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMEN6X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM79Y2T	DI	DM79Y2T
DM79Y2T	DN	ATryn antithrombin
DM79Y2T	MI	TT6L509
DM79Y2T	MN	Coagulation factor IIa (F2)
DM79Y2T	MT	DTT
DM79Y2T	MA	Modulator
DM79Y2T	RN	Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.
DM79Y2T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	DTZGT0P
DMWE2N4	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMWE2N4	MT	DTP
DMWE2N4	MA	Substrate
DMWE2N4	RN	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
DMWE2N4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221187

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	DTT79CX
DMWE2N4	MN	Organic cation transporter 1 (SLC22A1)
DMWE2N4	MT	DTP
DMWE2N4	MA	Substrate
DMWE2N4	RN	Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078.
DMWE2N4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221187

DMWE2N4	DI	DMWE2N4
DMWE2N4	DN	Auranofin
DMWE2N4	MI	TTP3UTW
DMWE2N4	MN	Steroid hormone receptor ERR (ESRR)
DMWE2N4	MT	DTT
DMWE2N4	MA	Modulator
DMWE2N4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWE2N4	RU	https://www.fda.gov/

DM75CXN	DI	DM75CXN
DM75CXN	DN	Avanafil
DM75CXN	MI	DE4LYSA
DM75CXN	MN	Cytochrome P450 3A4 (CYP3A4)
DM75CXN	MT	DME
DM75CXN	MA	Metabolism
DM75CXN	RN	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44.
DM75CXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23675780

DM75CXN	DI	DM75CXN
DM75CXN	DN	Avanafil
DM75CXN	MI	TTJ0IQB
DM75CXN	MN	Phosphodiesterase 5A (PDE5A)
DM75CXN	MT	DTT
DM75CXN	MA	Modulator
DM75CXN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM75CXN	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMK2GZX	DI	DMK2GZX
DMK2GZX	DN	Avapritinib
DMK2GZX	MI	TT8FYO9
DMK2GZX	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMK2GZX	MT	DTT
DMK2GZX	MA	Inhibitor
DMK2GZX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMK2GZX	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf

DMSZLJR	DI	DMSZLJR
DMSZLJR	DN	Avelumab
DMSZLJR	MI	TT8ZLTI
DMSZLJR	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSZLJR	MT	DTT
DMSZLJR	RN	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
DMSZLJR	RU	https://pubmed.ncbi.nlm.nih.gov/26014098

DM1AEH4	DI	DM1AEH4
DM1AEH4	DN	Avibactam
DM1AEH4	MI	DE7IH52
DM1AEH4	MN	Beta-lactamase (blaB)
DM1AEH4	MT	DME
DM1AEH4	MA	Metabolism
DM1AEH4	RN	nan
DM1AEH4	RU	nan

DMYHN59	DI	DMYHN59
DMYHN59	DN	Axicabtagene ciloleucel
DMYHN59	MI	TTW640A
DMYHN59	MN	B-lymphocyte surface antigen B4 (CD19)
DMYHN59	MT	DTT
DMYHN59	MA	CAR-T-Cell-Therapy
DMYHN59	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMYHN59	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEJGDUW
DMGVH6N	MN	Cytochrome P450 1A2 (CYP1A2)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DE4LYSA
DMGVH6N	MN	Cytochrome P450 3A4 (CYP3A4)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEIBDNY
DMGVH6N	MN	Cytochrome P450 3A5 (CYP3A5)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEGTFWK
DMGVH6N	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DT3D8F0
DMGVH6N	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGVH6N	MT	DTP
DMGVH6N	MA	Substrate
DMGVH6N	RN	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
DMGVH6N	RU	http://www.ncbi.nlm.nih.gov/pubmed/22170007

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DTUGYRD
DMGVH6N	MN	P-glycoprotein 1 (ABCB1)
DMGVH6N	MT	DTP
DMGVH6N	MA	Substrate
DMGVH6N	RN	Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55.
DMGVH6N	RU	http://www.ncbi.nlm.nih.gov/pubmed/22170007

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	DEYGVN4
DMGVH6N	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGVH6N	MT	DME
DMGVH6N	MA	Metabolism
DMGVH6N	RN	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
DMGVH6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771

DMGVH6N	DI	DMGVH6N
DMGVH6N	DN	Axitinib
DMGVH6N	MI	TTUTJGQ
DMGVH6N	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMGVH6N	MT	DTT
DMGVH6N	MA	Modulator
DMGVH6N	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMGVH6N	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	DEKEDRC
DMTA5OE	MN	Cytidine aminohydrolase (CDA)
DMTA5OE	MT	DME
DMTA5OE	MA	Metabolism
DMTA5OE	RN	A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
DMTA5OE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18548103

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	DEYILK4
DMTA5OE	MN	Cytidine deaminase (cdd)
DMTA5OE	MT	DME
DMTA5OE	MA	Metabolism
DMTA5OE	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMTA5OE	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMTA5OE	DI	DMTA5OE
DMTA5OE	DN	Azacitidine
DMTA5OE	MI	TTHVCUP
DMTA5OE	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMTA5OE	MT	DTT
DMTA5OE	MA	Inhibitor
DMTA5OE	RN	The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
DMTA5OE	RU	https://pubmed.ncbi.nlm.nih.gov/19194470

DMZ80SB	DI	DMZ80SB
DMZ80SB	DN	Azatadine
DMZ80SB	MI	TTTIBOJ
DMZ80SB	MN	Histamine H1 receptor (H1R)
DMZ80SB	MT	DTT
DMZ80SB	MA	Antagonist
DMZ80SB	RN	Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7.
DMZ80SB	RU	https://pubmed.ncbi.nlm.nih.gov/1982614

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	TTZFTY4
DMMZSXQ	MN	Amidophosphoribosyltransferase (PPAT)
DMMZSXQ	MT	DTT
DMMZSXQ	MA	Inhibitor
DMMZSXQ	RN	IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77.
DMMZSXQ	RU	https://pubmed.ncbi.nlm.nih.gov/17662091

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEJGDUW
DMMZSXQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62.
DMMZSXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10837004

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEH49YS
DMMZSXQ	MN	Glutathione S-transferase alpha-2 (GSTA2)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMMZSXQ	RU	https://www.pharmgkb.org/pathway/PA2040

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEYZEJA
DMMZSXQ	MN	Glutathione S-transferase mu-1 (GSTM1)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMMZSXQ	RU	https://www.pharmgkb.org/pathway/PA2040

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DTUGYRD
DMMZSXQ	MN	P-glycoprotein 1 (ABCB1)
DMMZSXQ	MT	DTP
DMMZSXQ	MA	Substrate
DMMZSXQ	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DMMZSXQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMMZSXQ	DI	DMMZSXQ
DMMZSXQ	DN	Azathioprine
DMMZSXQ	MI	DEFQ8VO
DMMZSXQ	MN	Thiopurine methyltransferase (TPMT)
DMMZSXQ	MT	DME
DMMZSXQ	MA	Metabolism
DMMZSXQ	RN	Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
DMMZSXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20726808

DMHVL0J	DI	DMHVL0J
DMHVL0J	DN	Azelaic Acid
DMHVL0J	MI	TT2A0DR
DMHVL0J	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMHVL0J	MT	DTT
DMHVL0J	MA	Inhibitor
DMHVL0J	RN	Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32.
DMHVL0J	RU	https://pubmed.ncbi.nlm.nih.gov/3207614

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEJGDUW
DMXTMBJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEJVYAZ
DMXTMBJ	MN	Cytochrome P450 2A6 (CYP2A6)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DES5XRU
DMXTMBJ	MN	Cytochrome P450 2C8 (CYP2C8)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DE5IED8
DMXTMBJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DECB0K3
DMXTMBJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383922

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DE4LYSA
DMXTMBJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEIBDNY
DMXTMBJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	TTTIBOJ
DMXTMBJ	MN	Histamine H1 receptor (H1R)
DMXTMBJ	MT	DTT
DMXTMBJ	MA	Antagonist
DMXTMBJ	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMXTMBJ	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMXTMBJ	DI	DMXTMBJ
DMXTMBJ	DN	Azelastine
DMXTMBJ	MI	DEGTFWK
DMXTMBJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXTMBJ	MT	DME
DMXTMBJ	MA	Metabolism
DMXTMBJ	RN	In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
DMXTMBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623

DMOIX5S	DI	DMOIX5S
DMOIX5S	DN	Azilsartan
DMOIX5S	MI	TT8DBY3
DMOIX5S	MN	Angiotensin II receptor type-1 (AGTR1)
DMOIX5S	MT	DTT
DMOIX5S	MA	Modulator
DMOIX5S	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMOIX5S	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMIR5QP	DI	DMIR5QP
DMIR5QP	DN	Azlocillin
DMIR5QP	MI	TTJP4SM
DMIR5QP	MN	Bacterial Penicillin binding protein (Bact PBP)
DMIR5QP	MT	DTT
DMIR5QP	MA	Binder
DMIR5QP	RN	Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8.
DMIR5QP	RU	https://pubmed.ncbi.nlm.nih.gov/2515794

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	TT85JMW
DMDNJHG	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMDNJHG	MT	DTT
DMDNJHG	MA	Binder
DMDNJHG	RN	Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/12519203

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEP0IWS
DMDNJHG	MN	Beta-lactamase (blaB)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEEAL81
DMDNJHG	MN	Beta-lactamase (blaB)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
DMDNJHG	RU	https://pubmed.ncbi.nlm.nih.gov/8889716

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DE4LYSA
DMDNJHG	MN	Cytochrome P450 3A4 (CYP3A4)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DEIBDNY
DMDNJHG	MN	Cytochrome P450 3A5 (CYP3A5)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMDNJHG	DI	DMDNJHG
DMDNJHG	DN	Aztreonam
DMDNJHG	MI	DERD86B
DMDNJHG	MN	Cytochrome P450 3A7 (CYP3A7)
DMDNJHG	MT	DME
DMDNJHG	MA	Metabolism
DMDNJHG	RN	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
DMDNJHG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141

DMP54C7	DI	DMP54C7
DMP54C7	DN	Bacampicillin
DMP54C7	MI	TTJP4SM
DMP54C7	MN	Bacterial Penicillin binding protein (Bact PBP)
DMP54C7	MT	DTT
DMP54C7	MA	Binder
DMP54C7	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMP54C7	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMD2871	DI	DMD2871
DMD2871	DN	Bacitracin
DMD2871	MI	DEK9LVM
DMD2871	MN	Endoglucanase A (EGA)
DMD2871	MT	DME
DMD2871	MA	Metabolism
DMD2871	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMD2871	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMD2871	DI	DMD2871
DMD2871	DN	Bacitracin
DMD2871	MI	DE2M583
DMD2871	MN	Endoglucanase Y (EGY)
DMD2871	MT	DME
DMD2871	MA	Metabolism
DMD2871	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMD2871	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DM5OHYE	DI	DM5OHYE
DM5OHYE	DN	Bacitracin
DM5OHYE	MI	TT2EDHU
DM5OHYE	MN	Insulin-degrading enzyme (IDE)
DM5OHYE	MT	DTT
DM5OHYE	MA	Inhibitor
DM5OHYE	RN	Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7.
DM5OHYE	RU	https://pubmed.ncbi.nlm.nih.gov/15509750

DM0QV1J	DI	DM0QV1J
DM0QV1J	DN	Baclofen
DM0QV1J	MI	TTDCVZW
DM0QV1J	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM0QV1J	MT	DTT
DM0QV1J	MA	Modulator
DM0QV1J	RN	Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
DM0QV1J	RU	https://pubmed.ncbi.nlm.nih.gov/10354414

DMPWNDB	DI	DMPWNDB
DMPWNDB	DN	Balofloxacin
DMPWNDB	MI	TTJP4SM
DMPWNDB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPWNDB	MT	DTT
DMPWNDB	MA	Inhibitor
DMPWNDB	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMPWNDB	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	DE4LYSA
DM1UV7F	MN	Cytochrome P450 3A4 (CYP3A4)
DM1UV7F	MT	DME
DM1UV7F	MA	Metabolism
DM1UV7F	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DM1UV7F	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	TTWORX6
DM1UV7F	MN	Influenza Polymerase acidic endonuclease (Influ PA)
DM1UV7F	MT	DTT
DM1UV7F	MA	Inhibitor
DM1UV7F	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1UV7F	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMRJ9EN	DI	DMRJ9EN
DMRJ9EN	DN	Baloxavir marboxil
DMRJ9EN	MI	DTUGYRD
DMRJ9EN	MN	P-glycoprotein 1 (ABCB1)
DMRJ9EN	MT	DTP
DMRJ9EN	MA	Substrate
DMRJ9EN	RN	Baloxavir Marboxil FDA label
DMRJ9EN	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/078/original/Baloxavir_Marboxil_FDA_label.pdf?1543255968

DM1UV7F	DI	DM1UV7F
DM1UV7F	DN	Baloxavir marboxil
DM1UV7F	MI	DEF2WXN
DM1UV7F	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM1UV7F	MT	DME
DM1UV7F	MA	Metabolism
DM1UV7F	RN	FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
DM1UV7F	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf

DM7I1T9	DI	DM7I1T9
DM7I1T9	DN	Balsalazide
DM7I1T9	MI	DEEHWOG
DM7I1T9	MN	Azoreductase (azoR)
DM7I1T9	MT	DME
DM7I1T9	MA	Metabolism
DM7I1T9	RN	Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15.
DM7I1T9	RU	https://pubmed.ncbi.nlm.nih.gov/6345112

DM7I1T9	DI	DM7I1T9
DM7I1T9	DN	Balsalazide
DM7I1T9	MI	DETQAEP
DM7I1T9	MN	FMN-dependent NADH-azoreductase (azoR1)
DM7I1T9	MT	DME
DM7I1T9	MA	Metabolism
DM7I1T9	RN	nan
DM7I1T9	RU	nan

DMO091F	DI	DMO091F
DMO091F	DN	Balsalazide
DMO091F	MI	TT8NGED
DMO091F	MN	Prostaglandin G/H synthase 1 (COX-1)
DMO091F	MT	DTT
DMO091F	MA	Inhibitor
DMO091F	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMO091F	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMKLSHF	DI	DMKLSHF
DMKLSHF	DN	Bambuterol
DMKLSHF	MI	TT2CJVK
DMKLSHF	MN	Adrenergic receptor beta-2 (ADRB2)
DMKLSHF	MT	DTT
DMKLSHF	MA	Agonist
DMKLSHF	RN	Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40.
DMKLSHF	RU	https://pubmed.ncbi.nlm.nih.gov/18065099

DMXLHYN	DI	DMXLHYN
DMXLHYN	DN	Bamifylline
DMXLHYN	MI	DEJGDUW
DMXLHYN	MN	Cytochrome P450 1A2 (CYP1A2)
DMXLHYN	MT	DME
DMXLHYN	MA	Metabolism
DMXLHYN	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMXLHYN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DME1DJX	DI	DME1DJX
DME1DJX	DN	Baquting
DME1DJX	MI	TTWODQF
DME1DJX	MN	Fibrin (FG)
DME1DJX	MT	DTT
DME1DJX	MA	Modulator
DME1DJX	RN	Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals.
DME1DJX	RU	http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm

DMJ8NMC	DI	DMJ8NMC
DMJ8NMC	DN	Barbital
DMJ8NMC	MI	TT1MPAY
DMJ8NMC	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJ8NMC	MT	DTT
DMJ8NMC	MA	Antagonist
DMJ8NMC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMJ8NMC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMJ8NMC	DI	DMJ8NMC
DMJ8NMC	DN	Barbital
DMJ8NMC	MI	DEGTFWK
DMJ8NMC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJ8NMC	MT	DME
DMJ8NMC	MA	Metabolism
DMJ8NMC	RN	Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72.
DMJ8NMC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22331680

DMJIA6T	DI	DMJIA6T
DMJIA6T	DN	Barbiturate
DMJIA6T	MI	TT1MPAY
DMJIA6T	MN	GABA(A) receptor alpha-1 (GABRA1)
DMJIA6T	MT	DTT
DMJIA6T	MA	Antagonist
DMJIA6T	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMJIA6T	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMJIA6T	DI	DMJIA6T
DMJIA6T	DN	Barbiturate
DMJIA6T	MI	TTAN6JD
DMJIA6T	MN	Glutamate receptor AMPA (GRIA)
DMJIA6T	MT	DTT
DMJIA6T	MA	Agonist
DMJIA6T	RN	Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
DMJIA6T	RU	https://pubmed.ncbi.nlm.nih.gov/17073666

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DTI7UX6
DM4ONW5	MN	Breast cancer resistance protein (ABCG2)
DM4ONW5	MT	DTP
DM4ONW5	MA	Substrate
DM4ONW5	RN	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17.
DM4ONW5	RU	http://www.ncbi.nlm.nih.gov/pubmed/28848011

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DE4LYSA
DM4ONW5	MN	Cytochrome P450 3A4 (CYP3A4)
DM4ONW5	MT	DME
DM4ONW5	MA	Metabolism
DM4ONW5	RN	FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
DM4ONW5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TT6DM01
DM4ONW5	MN	Janus kinase 1 (JAK-1)
DM4ONW5	MT	DTT
DM4ONW5	MA	Modulator
DM4ONW5	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TTRMX3V
DM4ONW5	MN	Janus kinase 2 (JAK-2)
DM4ONW5	MT	DTT
DM4ONW5	MA	Modulator
DM4ONW5	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	DTUGYRD
DM4ONW5	MN	P-glycoprotein 1 (ABCB1)
DM4ONW5	MT	DTP
DM4ONW5	MA	Substrate
DM4ONW5	RN	Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519.
DM4ONW5	RU	http://www.ncbi.nlm.nih.gov/pubmed/28749581

DM4ONW5	DI	DM4ONW5
DM4ONW5	DN	Baricitinib
DM4ONW5	MI	TTJSQEF
DM4ONW5	MN	Tyrosine-protein kinase (PTK)
DM4ONW5	MT	DTT
DM4ONW5	MA	Inhibitor
DM4ONW5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM4ONW5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMWNRZT	DI	DMWNRZT
DMWNRZT	DN	Basiliximab
DMWNRZT	MI	TT10Y9E
DMWNRZT	MN	Interleukin 2 receptor alpha (IL2RA)
DMWNRZT	MT	DTT
DMWNRZT	MA	Modulator
DMWNRZT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWNRZT	RU	https://www.fda.gov/

DMU9C8F	DI	DMU9C8F
DMU9C8F	DN	Bavencio
DMU9C8F	MI	TT8ZLTI
DMU9C8F	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMU9C8F	MT	DTT
DMU9C8F	MA	Inhibitor
DMU9C8F	RN	ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
DMU9C8F	RU	https://clinicaltrials.gov/ct2/show/NCT03403777

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	DE6OQ3W
DMLOS5R	MN	Cytochrome P450 1A1 (CYP1A1)
DMLOS5R	MT	DME
DMLOS5R	MA	Metabolism
DMLOS5R	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DMLOS5R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	DE4LYSA
DMLOS5R	MN	Cytochrome P450 3A4 (CYP3A4)
DMLOS5R	MT	DME
DMLOS5R	MA	Metabolism
DMLOS5R	RN	FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.
DMLOS5R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTEUNMR
DMLOS5R	MN	PI3-kinase alpha (PIK3CA)
DMLOS5R	MT	DTT
DMLOS5R	MA	Inhibitor
DMLOS5R	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMLOS5R	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTGBPJE
DMLOS5R	MN	PI3-kinase delta (PIK3CD)
DMLOS5R	MT	DTT
DMLOS5R	MA	Inhibitor
DMLOS5R	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMLOS5R	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMLOS5R	DI	DMLOS5R
DMLOS5R	DN	Bay 80-6946
DMLOS5R	MI	TTHBTOP
DMLOS5R	MN	PI3-kinase gamma (PIK3CG)
DMLOS5R	MT	DTT
DMLOS5R	MA	Modulator
DMLOS5R	RN	BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
DMLOS5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/24170767

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEWTCUK
DMY85QW	MN	Beta-glucuronidase (uidA)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
DMY85QW	RU	https://pubmed.ncbi.nlm.nih.gov/29802368

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	TTZAYWL
DMY85QW	MN	Estrogen receptor (ESR)
DMY85QW	MT	DTT
DMY85QW	MA	Modulator
DMY85QW	RN	Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15.
DMY85QW	RU	https://pubmed.ncbi.nlm.nih.gov/19543129

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEYGVN4
DMY85QW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene. Pharmazie. 2015 Feb;70(2):94-6.
DMY85QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25997248

DMY85QW	DI	DMY85QW
DMY85QW	DN	Bazedoxifene
DMY85QW	MI	DEL5N6Y
DMY85QW	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMY85QW	MT	DME
DMY85QW	MA	Metabolism
DMY85QW	RN	In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
DMY85QW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20516255

DM1R5X4	DI	DM1R5X4
DM1R5X4	DN	Becaplermin
DM1R5X4	MI	TTI7421
DM1R5X4	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM1R5X4	MT	DTT
DM1R5X4	MA	Modulator
DM1R5X4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1R5X4	RU	https://www.fda.gov/

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DEDH7FP
DMZPHIK	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMZPHIK	MT	DME
DMZPHIK	MA	Metabolism
DMZPHIK	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMZPHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DE4LYSA
DMZPHIK	MN	Cytochrome P450 3A4 (CYP3A4)
DMZPHIK	MT	DME
DMZPHIK	MA	Metabolism
DMZPHIK	RN	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16.
DMZPHIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23512537

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	DTUGYRD
DMZPHIK	MN	P-glycoprotein 1 (ABCB1)
DMZPHIK	MT	DTP
DMZPHIK	MA	Substrate
DMZPHIK	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMZPHIK	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMZPHIK	DI	DMZPHIK
DMZPHIK	DN	Beclomethasone
DMZPHIK	MI	TTP3UTW
DMZPHIK	MN	Steroid hormone receptor ERR (ESRR)
DMZPHIK	MT	DTT
DMZPHIK	MA	Modulator
DMZPHIK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZPHIK	RU	https://www.fda.gov/

DM3906J	DI	DM3906J
DM3906J	DN	Bedaquiline
DM3906J	MI	DE4LYSA
DM3906J	MN	Cytochrome P450 3A4 (CYP3A4)
DM3906J	MT	DME
DM3906J	MA	Metabolism
DM3906J	RN	Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
DM3906J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24513655

DM3906J	DI	DM3906J
DM3906J	DN	Bedaquiline
DM3906J	MI	TT19K0L
DM3906J	MN	Mycobacterium Proton pump (MycB Prop)
DM3906J	MT	DTT
DM3906J	MA	Modulator
DM3906J	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM3906J	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8WCXM	DI	DM8WCXM
DM8WCXM	DN	Befunolol hci
DM8WCXM	MI	TTVIREA
DM8WCXM	MN	Adrenergic receptor (ADR)
DM8WCXM	MT	DTT
DM8WCXM	MA	Modulator
DM8WCXM	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM8WCXM	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMBT3AI	DI	DMBT3AI
DMBT3AI	DN	Belantamab mafodotin
DMBT3AI	MI	TTZ3P4W
DMBT3AI	MN	B-cell maturation protein (TNFRSF17)
DMBT3AI	MT	DTT
DMBT3AI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBT3AI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf

DMXLYQF	DI	DMXLYQF
DMXLYQF	DN	Belatacept
DMXLYQF	MI	TTQ13FT
DMXLYQF	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMXLYQF	MT	DTT
DMXLYQF	MA	Inhibitor
DMXLYQF	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DMXLYQF	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DM3OBQF	DI	DM3OBQF
DM3OBQF	DN	Belimumab
DM3OBQF	MI	TTWMIDN
DM3OBQF	MN	B-cell-activating factor (TNFSF13B)
DM3OBQF	MT	DTT
DM3OBQF	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM3OBQF	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2RBWK	DI	DM2RBWK
DM2RBWK	DN	Belladonna
DM2RBWK	MI	TTH18TF
DM2RBWK	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM2RBWK	MT	DTT
DM2RBWK	MA	Modulator
DM2RBWK	RN	Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4.
DM2RBWK	RU	https://pubmed.ncbi.nlm.nih.gov/19586361

DM3SRJZ	DI	DM3SRJZ
DM3SRJZ	DN	Belotecan hydrocholoride
DM3SRJZ	MI	TTGTQHC
DM3SRJZ	MN	DNA topoisomerase I (TOP1)
DM3SRJZ	MT	DTT
DM3SRJZ	MA	Modulator
DM3SRJZ	RN	Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
DM3SRJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19422222

DM1CI9R	DI	DM1CI9R
DM1CI9R	DN	Bempedoic acid
DM1CI9R	MI	TT0Z6Y2
DM1CI9R	MN	ATP-citrate synthase (ACLY)
DM1CI9R	MT	DTT
DM1CI9R	MA	Inhibitor
DM1CI9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1CI9R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf

DM1CI9R	DI	DM1CI9R
DM1CI9R	DN	Bempedoic acid
DM1CI9R	MI	TTRA79S
DM1CI9R	MN	Cholesterol synthesis (Chole synth)
DM1CI9R	MT	DTT
DM1CI9R	MA	Inhibitor
DM1CI9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1CI9R	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	TTL69WB
DMH1M9B	MN	Angiotensin-converting enzyme (ACE)
DMH1M9B	MT	DTT
DMH1M9B	MA	Inhibitor
DMH1M9B	RN	Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83.
DMH1M9B	RU	https://pubmed.ncbi.nlm.nih.gov/19572914

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DEOXTPZ
DMH1M9B	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMH1M9B	MT	DME
DMH1M9B	MA	Metabolism
DMH1M9B	RN	Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7.
DMH1M9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20445573

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DT9G7XN
DMH1M9B	MN	Peptide transporter 1 (SLC15A1)
DMH1M9B	MT	DTP
DMH1M9B	MA	Substrate
DMH1M9B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMH1M9B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMH1M9B	DI	DMH1M9B
DMH1M9B	DN	Benazepril
DMH1M9B	MI	DT8QKNP
DMH1M9B	MN	Peptide transporter 2 (SLC15A2)
DMH1M9B	MT	DTP
DMH1M9B	MA	Substrate
DMH1M9B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMH1M9B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMFH15Z	DI	DMFH15Z
DMFH15Z	DN	Bendamustine hydrochloride
DMFH15Z	MI	DEJGDUW
DMFH15Z	MN	Cytochrome P450 1A2 (CYP1A2)
DMFH15Z	MT	DME
DMFH15Z	MA	Metabolism
DMFH15Z	RN	Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
DMFH15Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25829094

DMFH15Z	DI	DMFH15Z
DMFH15Z	DN	Bendamustine hydrochloride
DMFH15Z	MI	TTUTN1I
DMFH15Z	MN	Human Deoxyribonucleic acid (hDNA)
DMFH15Z	MT	DTT
DMFH15Z	MA	Modulator
DMFH15Z	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMFH15Z	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM7EVLC	DI	DM7EVLC
DM7EVLC	DN	Bendroflumethiazide
DM7EVLC	MI	TTS087L
DM7EVLC	MN	Solute carrier family 12 member 1 (SLC12A1)
DM7EVLC	MT	DTT
DM7EVLC	MA	Blocker
DM7EVLC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7EVLC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7EVLC	DI	DM7EVLC
DM7EVLC	DN	Bendroflumethiazide
DM7EVLC	MI	TTP362L
DM7EVLC	MN	Solute carrier family 12 member 3 (SLC12A3)
DM7EVLC	MT	DTT
DM7EVLC	MA	Blocker
DM7EVLC	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7EVLC	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7P1J4	DI	DM7P1J4
DM7P1J4	DN	Benralizumab
DM7P1J4	MI	TTXH9AD
DM7P1J4	MN	Interleukin 5 receptor alpha (IL5RA)
DM7P1J4	MT	DTT
DM7P1J4	MA	Modulator
DM7P1J4	RN	Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. 
DM7P1J4	RU	https://www.ncbi.nlm.nih.gov/pubmed/22136436

DM7P1J4	DI	DM7P1J4
DM7P1J4	DN	Benralizumab
DM7P1J4	MI	TTPREZD
DM7P1J4	MN	Interleukin-5 (IL5)
DM7P1J4	MT	DTT
DM7P1J4	MA	Modulator
DM7P1J4	RN	Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
DM7P1J4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289

DMRVBWU	DI	DMRVBWU
DMRVBWU	DN	Bentazepam
DMRVBWU	MI	TTEX6LM
DMRVBWU	MN	GABA(A) receptor gamma-3 (GABRG3)
DMRVBWU	MT	DTT
DMRVBWU	MA	Modulator
DMRVBWU	RN	Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96.
DMRVBWU	RU	https://pubmed.ncbi.nlm.nih.gov/20530587

DMF7EXL	DI	DMF7EXL
DMF7EXL	DN	Benzatropine
DMF7EXL	MI	DECB0K3
DMF7EXL	MN	Cytochrome P450 2D6 (CYP2D6)
DMF7EXL	MT	DME
DMF7EXL	MA	Metabolism
DMF7EXL	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMF7EXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMF7EXL	DI	DMF7EXL
DMF7EXL	DN	Benzatropine
DMF7EXL	MI	DEGTFWK
DMF7EXL	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF7EXL	MT	DME
DMF7EXL	MA	Metabolism
DMF7EXL	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMF7EXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	TTOJI4S
DMC3YUA	MN	Calcium-dependent chloride channel anoctamin (ANO)
DMC3YUA	MT	DTT
DMC3YUA	MA	Antagonist
DMC3YUA	RN	Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600.
DMC3YUA	RU	https://pubmed.ncbi.nlm.nih.gov/29471754

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	DE5IED8
DMC3YUA	MN	Cytochrome P450 2C9 (CYP2C9)
DMC3YUA	MT	DME
DMC3YUA	MA	Metabolism
DMC3YUA	RN	Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry. 2004 Jun 8;43(22):6948-58.
DMC3YUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15170332

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	TTOI92F
DMC3YUA	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMC3YUA	MT	DTT
DMC3YUA	MA	Stimulator
DMC3YUA	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMC3YUA	RU	https://pubmed.ncbi.nlm.nih.gov/18845662

DMC3YUA	DI	DMC3YUA
DMC3YUA	DN	Benzbromarone
DMC3YUA	MI	DT582KR
DMC3YUA	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMC3YUA	MT	DTP
DMC3YUA	MA	Substrate
DMC3YUA	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 3.A.1.208.10)
DMC3YUA	RU	http://www.tcdb.org/search/result.php?tc=3.A.1.208.10

DMI18HW	DI	DMI18HW
DMI18HW	DN	Benzocaine
DMI18HW	MI	TTRK8B9
DMI18HW	MN	Sodium channel unspecific (NaC)
DMI18HW	MT	DTT
DMI18HW	MA	Blocker
DMI18HW	RN	Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94.
DMI18HW	RU	https://pubmed.ncbi.nlm.nih.gov/17967784

DMKB9FI	DI	DMKB9FI
DMKB9FI	DN	Benzoic acid
DMKB9FI	MI	TT958S6
DMKB9FI	MN	Ras-related protein Rab-9A (RAB9A)
DMKB9FI	MT	DTT
DMKB9FI	MA	Inhibitor
DMKB9FI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKB9FI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKB9FI	DI	DMKB9FI
DMKB9FI	DN	Benzoic acid
DMKB9FI	MI	DTM301H
DMKB9FI	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DMKB9FI	MT	DTP
DMKB9FI	MA	Substrate
DMKB9FI	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DMKB9FI	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DM9U4FO	DI	DM9U4FO
DM9U4FO	DN	Benzonatate
DM9U4FO	MI	TTZOVE0
DM9U4FO	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM9U4FO	MT	DTT
DM9U4FO	MA	Blocker
DM9U4FO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM9U4FO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DEPKLMQ
DMIJATC	MN	Cytochrome P450 2B6 (CYP2B6)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19144770

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DE4LYSA
DMIJATC	MN	Cytochrome P450 3A4 (CYP3A4)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DEIZLTN
DMIJATC	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DMIJATC	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	DE3N2FM
DMIJATC	MN	NADPH-cytochrome P450 reductase (CPR)
DMIJATC	MT	DME
DMIJATC	MA	Metabolism
DMIJATC	RN	On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
DMIJATC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3924914

DMIJATC	DI	DMIJATC
DMIJATC	DN	Benzphetamine
DMIJATC	MI	TT9IK2Z
DMIJATC	MN	N-methyl-D-aspartate receptor (NMDAR)
DMIJATC	MT	DTT
DMIJATC	MA	Antagonist
DMIJATC	RN	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
DMIJATC	RU	https://pubmed.ncbi.nlm.nih.gov/11861810

DMU4D5Y	DI	DMU4D5Y
DMU4D5Y	DN	Benzquinamide
DMU4D5Y	MI	TT0JLSD
DMU4D5Y	MN	Multidrug resistance protein (MDR)
DMU4D5Y	MT	DTT
DMU4D5Y	MA	Inhibitor
DMU4D5Y	RN	Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65.
DMU4D5Y	RU	https://pubmed.ncbi.nlm.nih.gov/1362504

DMQWZ0H	DI	DMQWZ0H
DMQWZ0H	DN	Benzthiazide
DMQWZ0H	MI	TTANPDJ
DMQWZ0H	MN	Carbonic anhydrase II (CA-II)
DMQWZ0H	MT	DTT
DMQWZ0H	MA	Inhibitor
DMQWZ0H	RN	Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
DMQWZ0H	RU	https://pubmed.ncbi.nlm.nih.gov/13760527

DMGZOVN	DI	DMGZOVN
DMGZOVN	DN	Benztropine
DMGZOVN	MI	TTZ9SOR
DMGZOVN	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMGZOVN	MT	DTT
DMGZOVN	MA	Antagonist
DMGZOVN	RN	Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
DMGZOVN	RU	https://pubmed.ncbi.nlm.nih.gov/18417307

DMGZOVN	DI	DMGZOVN
DMGZOVN	DN	Benztropine
DMGZOVN	MI	DT3BA8L
DMGZOVN	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMGZOVN	MT	DTP
DMGZOVN	MA	Substrate
DMGZOVN	RN	Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15.
DMGZOVN	RU	http://www.ncbi.nlm.nih.gov/pubmed/24194528

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEWYTJB
DMBVYDI	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. Toxicol Appl Pharmacol. 1995 Aug;133(2):295-304.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7645026

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEJGDUW
DMBVYDI	MN	Cytochrome P450 1A2 (CYP1A2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DES5XRU
DMBVYDI	MN	Cytochrome P450 2C8 (CYP2C8)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DECB0K3
DMBVYDI	MN	Cytochrome P450 2D6 (CYP2D6)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717179

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEVDYN7
DMBVYDI	MN	Cytochrome P450 2E1 (CYP2E1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15129551

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DEYWLRK
DMBVYDI	MN	Sulfotransferase 1A1 (SULT1A1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DERUZL7
DMBVYDI	MN	Sulfotransferase 1A2 (SULT1A2)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMBVYDI	DI	DMBVYDI
DMBVYDI	DN	Benzyl alcohol
DMBVYDI	MI	DED5UR3
DMBVYDI	MN	Sulfotransferase 1B1 (SULT1B1)
DMBVYDI	MT	DME
DMBVYDI	MA	Metabolism
DMBVYDI	RN	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
DMBVYDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444

DMDPYI5	DI	DMDPYI5
DMDPYI5	DN	Benzyl benzoate
DMDPYI5	MI	TTLUQ8E
DMDPYI5	MN	Hormone sensitive lipase (LIPE)
DMDPYI5	MT	DTT
DMDPYI5	MA	Modulator
DMDPYI5	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMDPYI5	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMDPYI5	DI	DMDPYI5
DMDPYI5	DN	Benzyl benzoate
DMDPYI5	MI	DE4IY8S
DMDPYI5	MN	Peroxidase (katG)
DMDPYI5	MT	DME
DMDPYI5	MA	Metabolism
DMDPYI5	RN	Peroxidase activity in the sulfate-reducing bacterium Desulfotomaculum acetoxidans DSM 771. Pol J Microbiol. 2010;59(4):249-55.
DMDPYI5	RU	https://pubmed.ncbi.nlm.nih.gov/21466042

DMQHM2D	DI	DMQHM2D
DMQHM2D	DN	Benzylpenicilloyl Polylysine
DMQHM2D	MI	TTDGEC0
DMQHM2D	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMQHM2D	MT	DTT
DMQHM2D	MA	Binder
DMQHM2D	RN	Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.
DMQHM2D	RU	https://pubmed.ncbi.nlm.nih.gov/7436456

DMXDZAQ	DI	DMXDZAQ
DMXDZAQ	DN	Bepotastine
DMXDZAQ	MI	TTTIBOJ
DMXDZAQ	MN	Histamine H1 receptor (H1R)
DMXDZAQ	MT	DTT
DMXDZAQ	MA	Antagonist
DMXDZAQ	RN	Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72.
DMXDZAQ	RU	https://pubmed.ncbi.nlm.nih.gov/18606918

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	TT5HONZ
DM0RKS4	MN	Calcium channel unspecific (CaC)
DM0RKS4	MT	DTT
DM0RKS4	MA	Modulator
DM0RKS4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0RKS4	RU	https://www.fda.gov/

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DECB0K3
DM0RKS4	MN	Cytochrome P450 2D6 (CYP2D6)
DM0RKS4	MT	DME
DM0RKS4	MA	Metabolism
DM0RKS4	RN	Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62.
DM0RKS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26195225

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DE4LYSA
DM0RKS4	MN	Cytochrome P450 3A4 (CYP3A4)
DM0RKS4	MT	DME
DM0RKS4	MA	Metabolism
DM0RKS4	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM0RKS4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM0RKS4	DI	DM0RKS4
DM0RKS4	DN	Bepridil
DM0RKS4	MI	DTUGYRD
DM0RKS4	MN	P-glycoprotein 1 (ABCB1)
DM0RKS4	MT	DTP
DM0RKS4	MA	Substrate
DM0RKS4	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0RKS4	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEBY2D	DI	DMEBY2D
DMEBY2D	DN	Beriplast-P
DMEBY2D	MI	TTWODQF
DMEBY2D	MN	Fibrin (FG)
DMEBY2D	MT	DTT
DMEBY2D	MA	Modulator
DMEBY2D	RN	Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23.
DMEBY2D	RU	https://pubmed.ncbi.nlm.nih.gov/15953052

DMWA2DZ	DI	DMWA2DZ
DMWA2DZ	DN	Berotralstat
DMWA2DZ	MI	TTMF8H9
DMWA2DZ	MN	Plasma kallikrein (KLKB1)
DMWA2DZ	MT	DTT
DMWA2DZ	MA	Inhibitor
DMWA2DZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWA2DZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf

DMPHXMI	DI	DMPHXMI
DMPHXMI	DN	Besifloxacin
DMPHXMI	MI	TTN6J5F
DMPHXMI	MN	Bacterial DNA gyrase (Bact gyrase)
DMPHXMI	MT	DTT
DMPHXMI	MA	Modulator
DMPHXMI	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMPHXMI	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMPHXMI	DI	DMPHXMI
DMPHXMI	DN	Besifloxacin
DMPHXMI	MI	TTIXTO3
DMPHXMI	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMPHXMI	MT	DTT
DMPHXMI	MA	Modulator
DMPHXMI	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMPHXMI	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	TTXZEAJ
DM8L9D4	MN	Leukotriene A-4 hydrolase (LTA4H)
DM8L9D4	MT	DTT
DM8L9D4	MA	Inhibitor
DM8L9D4	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DM8L9D4	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	DT9G7XN
DM8L9D4	MN	Peptide transporter 1 (SLC15A1)
DM8L9D4	MT	DTP
DM8L9D4	MA	Substrate
DM8L9D4	RN	Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol. 1993 Aug;265(2 Pt 1):G289-94.
DM8L9D4	RU	http://www.ncbi.nlm.nih.gov/pubmed/8396335

DM8L9D4	DI	DM8L9D4
DM8L9D4	DN	Bestatin
DM8L9D4	MI	DT8QKNP
DM8L9D4	MN	Peptide transporter 2 (SLC15A2)
DM8L9D4	MT	DTP
DM8L9D4	MA	Substrate
DM8L9D4	RN	Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol. 2008 Jun;294(6):F1422-32.
DM8L9D4	RU	http://www.ncbi.nlm.nih.gov/pubmed/18367661

DMI6GKT	DI	DMI6GKT
DMI6GKT	DN	Beta-acetyldigoxin
DMI6GKT	MI	DTUGYRD
DMI6GKT	MN	P-glycoprotein 1 (ABCB1)
DMI6GKT	MT	DTP
DMI6GKT	MA	Substrate
DMI6GKT	RN	P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43.
DMI6GKT	RU	https://doi.org/10.1007/s002100000354

DMI6GKT	DI	DMI6GKT
DMI6GKT	DN	Beta-acetyldigoxin
DMI6GKT	MI	TTYHPRQ
DMI6GKT	MN	Sodium pump (NaP)
DMI6GKT	MT	DTT
DMI6GKT	MA	Modulator
DMI6GKT	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMI6GKT	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM0RXBT	DI	DM0RXBT
DM0RXBT	DN	Beta-carotene
DM0RXBT	MI	DE6BOK3
DM0RXBT	MN	Beta,beta-carotene 15,15'-dioxygenase (BCO1)
DM0RXBT	MT	DME
DM0RXBT	MA	Metabolism
DM0RXBT	RN	Substrate specificity of purified recombinant human beta-carotene 15,15'-oxygenase (BCO1). J Biol Chem. 2013 Dec 27;288(52):37094-103.
DM0RXBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24187135

DM0RXBT	DI	DM0RXBT
DM0RXBT	DN	Beta-carotene
DM0RXBT	MI	DTUGYRD
DM0RXBT	MN	P-glycoprotein 1 (ABCB1)
DM0RXBT	MT	DTP
DM0RXBT	MA	Substrate
DM0RXBT	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM0RXBT	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMGRZW2	DI	DMGRZW2
DMGRZW2	DN	Betaine
DMGRZW2	MI	DTBPTJF
DMGRZW2	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMGRZW2	MT	DTP
DMGRZW2	MA	Substrate
DMGRZW2	RN	Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011 Jun;95(1-2):70-81.
DMGRZW2	RU	http://www.ncbi.nlm.nih.gov/pubmed/21459558

DMAHJEF	DI	DMAHJEF
DMAHJEF	DN	Betamethasone
DMAHJEF	MI	TTYRL6O
DMAHJEF	MN	Glucocorticoid receptor (NR3C1)
DMAHJEF	MT	DTT
DMAHJEF	MA	Agonist
DMAHJEF	RN	The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83.
DMAHJEF	RU	https://pubmed.ncbi.nlm.nih.gov/16824511

DMAHJEF	DI	DMAHJEF
DMAHJEF	DN	Betamethasone
DMAHJEF	MI	DTUGYRD
DMAHJEF	MN	P-glycoprotein 1 (ABCB1)
DMAHJEF	MT	DTP
DMAHJEF	MA	Substrate
DMAHJEF	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DMAHJEF	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMRMS1A	DI	DMRMS1A
DMRMS1A	DN	Betamethasone Benzoate
DMRMS1A	MI	TTYRL6O
DMRMS1A	MN	Glucocorticoid receptor (NR3C1)
DMRMS1A	MT	DTT
DMRMS1A	MA	Modulator
DMRMS1A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRMS1A	RU	https://www.fda.gov/

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	DEDH7FP
DMMIAXO	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMMIAXO	MT	DME
DMMIAXO	MA	Metabolism
DMMIAXO	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMMIAXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	DE4LYSA
DMMIAXO	MN	Cytochrome P450 3A4 (CYP3A4)
DMMIAXO	MT	DME
DMMIAXO	MA	Metabolism
DMMIAXO	RN	Studies on Drug Interactions between CYP3A4 Inhibitors and Glucocorticoids.
DMMIAXO	RU	https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf

DMMIAXO	DI	DMMIAXO
DMMIAXO	DN	Betamethasone valerate
DMMIAXO	MI	TTYRL6O
DMMIAXO	MN	Glucocorticoid receptor (NR3C1)
DMMIAXO	MT	DTT
DMMIAXO	MA	Modulator
DMMIAXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMIAXO	RU	https://www.fda.gov/

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	TTR6W5O
DM6EUL5	MN	Adrenergic receptor beta-1 (ADRB1)
DM6EUL5	MT	DTT
DM6EUL5	MA	Antagonist
DM6EUL5	RN	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
DM6EUL5	RU	https://pubmed.ncbi.nlm.nih.gov/19439240

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	DEJGDUW
DM6EUL5	MN	Cytochrome P450 1A2 (CYP1A2)
DM6EUL5	MT	DME
DM6EUL5	MA	Metabolism
DM6EUL5	RN	Drugs that may have potential CYP1A2 interactions.
DM6EUL5	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DM6EUL5	DI	DM6EUL5
DM6EUL5	DN	Betaxolol
DM6EUL5	MI	DECB0K3
DM6EUL5	MN	Cytochrome P450 2D6 (CYP2D6)
DM6EUL5	MT	DME
DM6EUL5	MA	Metabolism
DM6EUL5	RN	Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
DM6EUL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635183

DMUFGAY	DI	DMUFGAY
DMUFGAY	DN	Betazole
DMUFGAY	MI	TTQHJ1K
DMUFGAY	MN	Histamine H2 receptor (H2R)
DMUFGAY	MT	DTT
DMUFGAY	MA	Antagonist
DMUFGAY	RN	Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
DMUFGAY	RU	https://pubmed.ncbi.nlm.nih.gov/2892392

DMCLHO0	DI	DMCLHO0
DMCLHO0	DN	Bethanechol
DMCLHO0	MI	TTH18TF
DMCLHO0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMCLHO0	MT	DTT
DMCLHO0	MA	Agonist
DMCLHO0	RN	Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97.
DMCLHO0	RU	https://pubmed.ncbi.nlm.nih.gov/19298254

DM2C4RF	DI	DM2C4RF
DM2C4RF	DN	Betrixaban
DM2C4RF	MI	TTCIHJA
DM2C4RF	MN	Coagulation factor Xa (F10)
DM2C4RF	MT	DTT
DM2C4RF	MA	Modulator
DM2C4RF	RN	Company report (Portola)
DM2C4RF	RU	https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/

DM2C4RF	DI	DM2C4RF
DM2C4RF	DN	Betrixaban
DM2C4RF	MI	DTUGYRD
DM2C4RF	MN	P-glycoprotein 1 (ABCB1)
DM2C4RF	MT	DTP
DM2C4RF	MA	Substrate
DM2C4RF	RN	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.
DM2C4RF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26170684

DMSD1UN	DI	DMSD1UN
DMSD1UN	DN	Bevacizumab
DMSD1UN	MI	TTOHSBA
DMSD1UN	MN	Vascular endothelial growth factor A (VEGFA)
DMSD1UN	MT	DTT
DMSD1UN	MA	Inhibitor
DMSD1UN	RN	FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
DMSD1UN	RU	https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085

DMZFICR	DI	DMZFICR
DMZFICR	DN	Bevantolol
DMZFICR	MI	DECB0K3
DMZFICR	MN	Cytochrome P450 2D6 (CYP2D6)
DMZFICR	MT	DME
DMZFICR	MA	Metabolism
DMZFICR	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMZFICR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMZFICR	DI	DMZFICR
DMZFICR	DN	Bevantolol
DMZFICR	MI	TTEX248
DMZFICR	MN	Dopamine D2 receptor (D2R)
DMZFICR	MT	DTT
DMZFICR	MA	Antagonist
DMZFICR	RN	Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7.
DMZFICR	RU	https://pubmed.ncbi.nlm.nih.gov/17703743

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	DE5IED8
DMOBIKY	MN	Cytochrome P450 2C9 (CYP2C9)
DMOBIKY	MT	DME
DMOBIKY	MA	Metabolism
DMOBIKY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOBIKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	DE4LYSA
DMOBIKY	MN	Cytochrome P450 3A4 (CYP3A4)
DMOBIKY	MT	DME
DMOBIKY	MA	Metabolism
DMOBIKY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOBIKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOBIKY	DI	DMOBIKY
DMOBIKY	DN	Bexarotene
DMOBIKY	MI	TT6PEUO
DMOBIKY	MN	Retinoic acid receptor RXR-alpha (RXRA)
DMOBIKY	MT	DTT
DMOBIKY	MA	Modulator
DMOBIKY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOBIKY	RU	https://www.fda.gov/

DMZDCS0	DI	DMZDCS0
DMZDCS0	DN	Bezafibrate
DMZDCS0	MI	DE4LYSA
DMZDCS0	MN	Cytochrome P450 3A4 (CYP3A4)
DMZDCS0	MT	DME
DMZDCS0	MA	Metabolism
DMZDCS0	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMZDCS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMZDCS0	DI	DMZDCS0
DMZDCS0	DN	Bezafibrate
DMZDCS0	MI	TTJ584C
DMZDCS0	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMZDCS0	MT	DTT
DMZDCS0	MA	Agonist
DMZDCS0	RN	Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
DMZDCS0	RU	https://pubmed.ncbi.nlm.nih.gov/19124612

DMTZC5G	DI	DMTZC5G
DMTZC5G	DN	Bezlotoxumab
DMTZC5G	MI	TTQH65V
DMTZC5G	MN	Clostridium difficile Toxin B (CD toxB)
DMTZC5G	MT	DTT
DMTZC5G	MA	Modulator
DMTZC5G	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMTZC5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	DTI7UX6
DMTKD7Q	MN	Breast cancer resistance protein (ABCG2)
DMTKD7Q	MT	DTP
DMTKD7Q	MA	Substrate
DMTKD7Q	RN	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
DMTKD7Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28288939

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	TTGKNB4
DMTKD7Q	MN	Epidermal growth factor receptor (EGFR)
DMTKD7Q	MT	DTT
DMTKD7Q	MA	Inhibitor
DMTKD7Q	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMTKD7Q	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	TT6EO5L
DMTKD7Q	MN	Erbb2 tyrosine kinase receptor (HER2)
DMTKD7Q	MT	DTT
DMTKD7Q	MA	Inhibitor
DMTKD7Q	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMTKD7Q	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMTKD7Q	DI	DMTKD7Q
DMTKD7Q	DN	BIBW 2992
DMTKD7Q	MI	DTUGYRD
DMTKD7Q	MN	P-glycoprotein 1 (ABCB1)
DMTKD7Q	MT	DTP
DMTKD7Q	MA	Substrate
DMTKD7Q	RN	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50.
DMTKD7Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28288939

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	TTS64P2
DMZMSPF	MN	Androgen receptor (AR)
DMZMSPF	MT	DTT
DMZMSPF	MA	Antagonist
DMZMSPF	RN	Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
DMZMSPF	RU	https://pubmed.ncbi.nlm.nih.gov/19533338

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DTI7UX6
DMZMSPF	MN	Breast cancer resistance protein (ABCG2)
DMZMSPF	MT	DTP
DMZMSPF	MA	Substrate
DMZMSPF	RN	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
DMZMSPF	RU	http://www.ncbi.nlm.nih.gov/pubmed/25124867

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DE4LYSA
DMZMSPF	MN	Cytochrome P450 3A4 (CYP3A4)
DMZMSPF	MT	DME
DMZMSPF	MA	Metabolism
DMZMSPF	RN	Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
DMZMSPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509184

DMZMSPF	DI	DMZMSPF
DMZMSPF	DN	Bicalutamide
DMZMSPF	MI	DTUGYRD
DMZMSPF	MN	P-glycoprotein 1 (ABCB1)
DMZMSPF	MT	DTP
DMZMSPF	MA	Substrate
DMZMSPF	RN	Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
DMZMSPF	RU	http://www.ncbi.nlm.nih.gov/pubmed/25124867

DMG0H8K	DI	DMG0H8K
DMG0H8K	DN	Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K	MI	TT5FH9Y
DMG0H8K	MN	Human immunodeficiency virus Integrase (HIV IN)
DMG0H8K	MT	DTT
DMG0H8K	MA	Inhibitor
DMG0H8K	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMG0H8K	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMG0H8K	DI	DMG0H8K
DMG0H8K	DN	Bictegravir, emtricitabine and tenofovir alafenamide
DMG0H8K	MI	TT84ETX
DMG0H8K	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG0H8K	MT	DTT
DMG0H8K	MA	Inhibitor
DMG0H8K	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMG0H8K	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM3KN7V	DI	DM3KN7V
DM3KN7V	DN	Bifonazole
DM3KN7V	MI	TTTSOUD
DM3KN7V	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM3KN7V	MT	DTT
DM3KN7V	MA	Inhibitor
DM3KN7V	RN	Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
DM3KN7V	RU	https://pubmed.ncbi.nlm.nih.gov/17027909

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	DE4LYSA
DMX0E5B	MN	Cytochrome P450 3A4 (CYP3A4)
DMX0E5B	MT	DME
DMX0E5B	MA	Metabolism
DMX0E5B	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DMX0E5B	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	DEIBDNY
DMX0E5B	MN	Cytochrome P450 3A5 (CYP3A5)
DMX0E5B	MT	DME
DMX0E5B	MA	Metabolism
DMX0E5B	RN	Product monograph: LUMIGAN RC (Bimatoprost).
DMX0E5B	RU	https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf

DMX0E5B	DI	DMX0E5B
DMX0E5B	DN	Bimatoprost
DMX0E5B	MI	TT9B4N3
DMX0E5B	MN	Prostaglandin receptor (PTGR)
DMX0E5B	MT	DTT
DMX0E5B	MA	Modulator
DMX0E5B	RN	Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95.
DMX0E5B	RU	https://pubmed.ncbi.nlm.nih.gov/19274525

DME78OA	DI	DME78OA
DME78OA	DN	Biperiden
DME78OA	MI	TTZ9SOR
DME78OA	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DME78OA	MT	DTT
DME78OA	MA	Antagonist
DME78OA	RN	Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92.
DME78OA	RU	https://pubmed.ncbi.nlm.nih.gov/10907719

DMTKU46	DI	DMTKU46
DMTKU46	DN	Bismuth
DMTKU46	MI	TTFNGC9
DMTKU46	MN	Serum albumin (ALB)
DMTKU46	MT	DTT
DMTKU46	MA	Binder
DMTKU46	RN	Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
DMTKU46	RU	https://pubmed.ncbi.nlm.nih.gov/11110794

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	TTR6W5O
DM3UZ95	MN	Adrenergic receptor beta-1 (ADRB1)
DM3UZ95	MT	DTT
DM3UZ95	MA	Antagonist
DM3UZ95	RN	Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93.
DM3UZ95	RU	https://pubmed.ncbi.nlm.nih.gov/18612186

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	DECB0K3
DM3UZ95	MN	Cytochrome P450 2D6 (CYP2D6)
DM3UZ95	MT	DME
DM3UZ95	MA	Metabolism
DM3UZ95	RN	Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22.
DM3UZ95	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14732961

DM3UZ95	DI	DM3UZ95
DM3UZ95	DN	Bisoprolol
DM3UZ95	MI	DE4LYSA
DM3UZ95	MN	Cytochrome P450 3A4 (CYP3A4)
DM3UZ95	MT	DME
DM3UZ95	MA	Metabolism
DM3UZ95	RN	Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108.
DM3UZ95	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763205

DMK6XAV	DI	DMK6XAV
DMK6XAV	DN	Bitolterol
DMK6XAV	MI	TTMXGCW
DMK6XAV	MN	Adrenergic receptor beta-3 (ADRB3)
DMK6XAV	MT	DTT
DMK6XAV	MA	Modulator
DMK6XAV	RN	Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
DMK6XAV	RU	https://pubmed.ncbi.nlm.nih.gov/3895171

DMECRX1	DI	DMECRX1
DMECRX1	DN	Bivalirudin
DMECRX1	MI	TT6L509
DMECRX1	MN	Coagulation factor IIa (F2)
DMECRX1	MT	DTT
DMECRX1	MA	Inhibitor
DMECRX1	RN	New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
DMECRX1	RU	https://pubmed.ncbi.nlm.nih.gov/11479484

DMECRX1	DI	DMECRX1
DMECRX1	DN	Bivalirudin
DMECRX1	MI	TTRTKPV
DMECRX1	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMECRX1	MT	DTT
DMECRX1	MA	Inhibitor
DMECRX1	RN	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
DMECRX1	RU	https://pubmed.ncbi.nlm.nih.gov/12937775

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTPOI4B
DMR8YD6	MN	Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/8951505

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTLP6GN
DMR8YD6	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMR8YD6	DI	DMR8YD6
DMR8YD6	DN	B-Lactams
DMR8YD6	MI	TTGTQHC
DMR8YD6	MN	DNA topoisomerase I (TOP1)
DMR8YD6	MT	DTT
DMR8YD6	MA	Inhibitor
DMR8YD6	RN	Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
DMR8YD6	RU	https://pubmed.ncbi.nlm.nih.gov/12027807

DMNER5S	DI	DMNER5S
DMNER5S	DN	Bleomycin
DMNER5S	MI	DECH1VP
DMNER5S	MN	Bleomycin hydrolase (BLMH)
DMNER5S	MT	DME
DMNER5S	MA	Metabolism
DMNER5S	RN	The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998 Oct 12;421(1):1-7.
DMNER5S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9748474

DMNER5S	DI	DMNER5S
DMNER5S	DN	Bleomycin
DMNER5S	MI	TTUTN1I
DMNER5S	MN	Human Deoxyribonucleic acid (hDNA)
DMNER5S	MT	DTT
DMNER5S	MA	Breaker
DMNER5S	RN	Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
DMNER5S	RU	https://pubmed.ncbi.nlm.nih.gov/6177398

DMGECIJ	DI	DMGECIJ
DMGECIJ	DN	Blinatumomab
DMGECIJ	MI	TTW640A
DMGECIJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMGECIJ	MT	DTT
DMGECIJ	MA	Modulator
DMGECIJ	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGECIJ	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMGECIJ	DI	DMGECIJ
DMGECIJ	DN	Blinatumomab
DMGECIJ	MI	TTUN7MC
DMGECIJ	MN	T-cell surface glycoprotein CD3 (CD3)
DMGECIJ	MT	DTT
DMGECIJ	MA	Modulator
DMGECIJ	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGECIJ	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMQTAGO	DI	DMQTAGO
DMQTAGO	DN	BMS-201038
DMQTAGO	MI	TTUS1RD
DMQTAGO	MN	Microsomal triglyceride transfer protein (MTTP)
DMQTAGO	MT	DTT
DMQTAGO	MA	Inhibitor
DMQTAGO	RN	Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8.
DMQTAGO	RU	https://pubmed.ncbi.nlm.nih.gov/19276898

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DE4LYSA
DMBSHMF	MN	Cytochrome P450 3A4 (CYP3A4)
DMBSHMF	MT	DME
DMBSHMF	MA	Metabolism
DMBSHMF	RN	Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8.
DMBSHMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23529734

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DEIBDNY
DMBSHMF	MN	Cytochrome P450 3A5 (CYP3A5)
DMBSHMF	MT	DME
DMBSHMF	MA	Metabolism
DMBSHMF	RN	Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
DMBSHMF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23140245

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	TTHC7JD
DMBSHMF	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMBSHMF	MT	DTT
DMBSHMF	MA	Modulator
DMBSHMF	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMBSHMF	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMBSHMF	DI	DMBSHMF
DMBSHMF	DN	Boceprevir
DMBSHMF	MI	DTUGYRD
DMBSHMF	MN	P-glycoprotein 1 (ABCB1)
DMBSHMF	MT	DTP
DMBSHMF	MA	Substrate
DMBSHMF	RN	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
DMBSHMF	RU	http://www.ncbi.nlm.nih.gov/pubmed/24817413

DM2EXC5	DI	DM2EXC5
DM2EXC5	DN	BOL-303259-X
DM2EXC5	MI	DTPFTEQ
DM2EXC5	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM2EXC5	MT	DTP
DM2EXC5	MA	Substrate
DM2EXC5	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DM2EXC5	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DM2EXC5	DI	DM2EXC5
DM2EXC5	DN	BOL-303259-X
DM2EXC5	MI	TTT2ZAR
DM2EXC5	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM2EXC5	MT	DTT
DM2EXC5	MA	Agonist
DM2EXC5	RN	Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.
DM2EXC5	RU	https://pubmed.ncbi.nlm.nih.gov/21396362

DMIFYLX	DI	DMIFYLX
DMIFYLX	DN	Bopindolol
DMIFYLX	MI	TTMXGCW
DMIFYLX	MN	Adrenergic receptor beta-3 (ADRB3)
DMIFYLX	MT	DTT
DMIFYLX	MA	Modulator
DMIFYLX	RN	Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
DMIFYLX	RU	https://pubmed.ncbi.nlm.nih.gov/2439825

DMIFYLX	DI	DMIFYLX
DMIFYLX	DN	Bopindolol
DMIFYLX	MI	DECB0K3
DMIFYLX	MN	Cytochrome P450 2D6 (CYP2D6)
DMIFYLX	MT	DME
DMIFYLX	MA	Metabolism
DMIFYLX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMIFYLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TT2WR1T
DMNO38U	MN	Cationic trypsinogen (PRSS1)
DMNO38U	MT	DTT
DMNO38U	MA	Inhibitor
DMNO38U	RN	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
DMNO38U	RU	https://pubmed.ncbi.nlm.nih.gov/7739010

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DEJGDUW
DMNO38U	MN	Cytochrome P450 1A2 (CYP1A2)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764713

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DE5IED8
DMNO38U	MN	Cytochrome P450 2C9 (CYP2C9)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443666

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DECB0K3
DMNO38U	MN	Cytochrome P450 2D6 (CYP2D6)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DE4LYSA
DMNO38U	MN	Cytochrome P450 3A4 (CYP3A4)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103134

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TT5L2VC
DMNO38U	MN	Kallikrein-related peptidase (KLK)
DMNO38U	MT	DTT
DMNO38U	MA	Inhibitor
DMNO38U	RN	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
DMNO38U	RU	https://pubmed.ncbi.nlm.nih.gov/7739010

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DEGTFWK
DMNO38U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNO38U	MT	DME
DMNO38U	MA	Metabolism
DMNO38U	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMNO38U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	DTUGYRD
DMNO38U	MN	P-glycoprotein 1 (ABCB1)
DMNO38U	MT	DTP
DMNO38U	MA	Substrate
DMNO38U	RN	CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.
DMNO38U	RU	http://www.ncbi.nlm.nih.gov/pubmed/26792401

DMNO38U	DI	DMNO38U
DMNO38U	DN	Bortezomib
DMNO38U	MI	TTU7ZMG
DMNO38U	MN	Proteasome (PS)
DMNO38U	MT	DTT
DMNO38U	MA	Modulator
DMNO38U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNO38U	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DE5IED8
DMIOGBU	MN	Cytochrome P450 2C9 (CYP2C9)
DMIOGBU	MT	DME
DMIOGBU	MA	Metabolism
DMIOGBU	RN	Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.
DMIOGBU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12603176

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DE4LYSA
DMIOGBU	MN	Cytochrome P450 3A4 (CYP3A4)
DMIOGBU	MT	DME
DMIOGBU	MA	Metabolism
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	TTKRD0G
DMIOGBU	MN	Endothelin A receptor (EDNRA)
DMIOGBU	MT	DTT
DMIOGBU	MA	Modulator
DMIOGBU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIOGBU	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	TT3ZTGU
DMIOGBU	MN	Endothelin B receptor (EDNRB)
DMIOGBU	MT	DTT
DMIOGBU	MA	Modulator
DMIOGBU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIOGBU	RU	https://www.fda.gov/

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DT3D8F0
DMIOGBU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DT9C1TS
DMIOGBU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMIOGBU	DI	DMIOGBU
DMIOGBU	DN	Bosentan
DMIOGBU	MI	DTPFTEQ
DMIOGBU	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMIOGBU	MT	DTP
DMIOGBU	MA	Substrate
DMIOGBU	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMIOGBU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	DE4LYSA
DMTI8YE	MN	Cytochrome P450 3A4 (CYP3A4)
DMTI8YE	MT	DME
DMTI8YE	MA	Metabolism
DMTI8YE	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMTI8YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	DTUGYRD
DMTI8YE	MN	P-glycoprotein 1 (ABCB1)
DMTI8YE	MT	DTP
DMTI8YE	MA	Substrate
DMTI8YE	RN	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81.
DMTI8YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/26149173

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	TT6PKBN
DMTI8YE	MN	Proto-oncogene c-Src (SRC)
DMTI8YE	MT	DTT
DMTI8YE	MA	Inhibitor
DMTI8YE	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMTI8YE	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMTI8YE	DI	DMTI8YE
DMTI8YE	DN	Bosutinib
DMTI8YE	MI	TT3PJMV
DMTI8YE	MN	Tyrosine-protein kinase ABL1 (ABL)
DMTI8YE	MT	DTT
DMTI8YE	MA	Inhibitor
DMTI8YE	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMTI8YE	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMW67MU	DI	DMW67MU
DMW67MU	DN	Botulinum Toxin Type A
DMW67MU	MI	TTYQWA0
DMW67MU	MN	Synaptosomal-associated protein 25 (SNAP25)
DMW67MU	MT	DTT
DMW67MU	MA	Inhibitor
DMW67MU	RN	Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71.
DMW67MU	RU	https://pubmed.ncbi.nlm.nih.gov/12381720

DM58QS1	DI	DM58QS1
DM58QS1	DN	Botulinum Toxin Type B
DM58QS1	MI	TTG25NJ
DM58QS1	MN	Vesicle-associated membrane protein (VAMP)
DM58QS1	MT	DTT
DM58QS1	MA	Binder
DM58QS1	RN	Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7.
DM58QS1	RU	https://pubmed.ncbi.nlm.nih.gov/19401804

DM20LIM	DI	DM20LIM
DM20LIM	DN	Bremelanotide
DM20LIM	MI	TT0MV2T
DM20LIM	MN	Melanocortin receptor 1 (MC1R)
DM20LIM	MT	DTT
DM20LIM	MA	Agonist
DM20LIM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20LIM	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

DM20LIM	DI	DM20LIM
DM20LIM	DN	Bremelanotide
DM20LIM	MI	TTD0CIQ
DM20LIM	MN	Melanocortin receptor 4 (MC4R)
DM20LIM	MT	DTT
DM20LIM	MA	Agonist
DM20LIM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20LIM	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

DMWLC57	DI	DMWLC57
DMWLC57	DN	Brentuximab vedotin
DMWLC57	MI	DE4LYSA
DMWLC57	MN	Cytochrome P450 3A4 (CYP3A4)
DMWLC57	MT	DME
DMWLC57	MA	Metabolism
DMWLC57	RN	Brentuximab vedotin.
DMWLC57	RU	https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf

DMWLC57	DI	DMWLC57
DMWLC57	DN	Brentuximab vedotin
DMWLC57	MI	TT2GM5R
DMWLC57	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMWLC57	MT	DTT
DMWLC57	MA	Modulator
DMWLC57	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMWLC57	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM1FX74	DI	DM1FX74
DM1FX74	DN	Bretylium
DM1FX74	MI	TTR6W5O
DM1FX74	MN	Adrenergic receptor beta-1 (ADRB1)
DM1FX74	MT	DTT
DM1FX74	MA	Antagonist
DM1FX74	RN	Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10.
DM1FX74	RU	https://pubmed.ncbi.nlm.nih.gov/2859811

DM1FX74	DI	DM1FX74
DM1FX74	DN	Bretylium
DM1FX74	MI	DT3BA8L
DM1FX74	MN	Sodium-dependent dopamine transporter (SLC6A3)
DM1FX74	MT	DTP
DM1FX74	MA	Substrate
DM1FX74	RN	Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82.
DM1FX74	RU	http://www.ncbi.nlm.nih.gov/pubmed/9988729

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	TTPMQSO
DM7W94S	MN	ALK tyrosine kinase receptor (ALK)
DM7W94S	MT	DTT
DM7W94S	MA	Inhibitor
DM7W94S	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM7W94S	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DTKVEXO
DM7W94S	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DM7W94S	MT	DTP
DM7W94S	MA	Substrate
DM7W94S	RN	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
DM7W94S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DTI7UX6
DM7W94S	MN	Breast cancer resistance protein (ABCG2)
DM7W94S	MT	DTP
DM7W94S	MA	Substrate
DM7W94S	RN	NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
DM7W94S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf

DM7W94S	DI	DM7W94S
DM7W94S	DN	Brigatinib
DM7W94S	MI	DES5XRU
DM7W94S	MN	Cytochrome P450 2C8 (CYP2C8)
DM7W94S	MT	DME
DM7W94S	MA	Metabolism
DM7W94S	RN	Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135.
DM7W94S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28597393

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	DE4LYSA
DMBR01X	MN	Cytochrome P450 3A4 (CYP3A4)
DMBR01X	MT	DME
DMBR01X	MA	Metabolism
DMBR01X	RN	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
DMBR01X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551239

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	TTZ1DT0
DMBR01X	MN	P2Y purinoceptor 12 (P2RY12)
DMBR01X	MT	DTT
DMBR01X	MA	Antagonist
DMBR01X	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMBR01X	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMBR01X	DI	DMBR01X
DMBR01X	DN	Brilinta
DMBR01X	MI	DTUGYRD
DMBR01X	MN	P-glycoprotein 1 (ABCB1)
DMBR01X	MT	DTP
DMBR01X	MA	Substrate
DMBR01X	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMBR01X	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMQLT4N	DI	DMQLT4N
DMQLT4N	DN	Brimonidine
DMQLT4N	MI	TTQ8AFT
DMQLT4N	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMQLT4N	MT	DTT
DMQLT4N	MA	Agonist
DMQLT4N	RN	Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
DMQLT4N	RU	https://pubmed.ncbi.nlm.nih.gov/10943881

DMQLT4N	DI	DMQLT4N
DMQLT4N	DN	Brimonidine
DMQLT4N	MI	TT2NUT5
DMQLT4N	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMQLT4N	MT	DTT
DMQLT4N	MA	Modulator
DMQLT4N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
DMQLT4N	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520

DMBAPFG	DI	DMBAPFG
DMBAPFG	DN	Brinzolamide
DMBAPFG	MI	TTZHA0O
DMBAPFG	MN	Carbonic anhydrase IV (CA-IV)
DMBAPFG	MT	DTT
DMBAPFG	MA	Modulator
DMBAPFG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBAPFG	RU	https://www.fda.gov/

DMBAPFG	DI	DMBAPFG
DMBAPFG	DN	Brinzolamide
DMBAPFG	MI	DE4LYSA
DMBAPFG	MN	Cytochrome P450 3A4 (CYP3A4)
DMBAPFG	MT	DME
DMBAPFG	MA	Metabolism
DMBAPFG	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMBAPFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DEPKLMQ
DMSEPK8	MN	Cytochrome P450 2B6 (CYP2B6)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DE5IED8
DMSEPK8	MN	Cytochrome P450 2C9 (CYP2C9)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22538270

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	DEGTFWK
DMSEPK8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSEPK8	MT	DME
DMSEPK8	MA	Metabolism
DMSEPK8	RN	Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
DMSEPK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923

DMSEPK8	DI	DMSEPK8
DMSEPK8	DN	Brivaracetam
DMSEPK8	MI	TTT3P91
DMSEPK8	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMSEPK8	MT	DTT
DMSEPK8	MA	Inhibitor
DMSEPK8	RN	Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39.
DMSEPK8	RU	https://pubmed.ncbi.nlm.nih.gov/18778117

DMASDQ6	DI	DMASDQ6
DMASDQ6	DN	Brodalumab
DMASDQ6	MI	TT69OHW
DMASDQ6	MN	Interleukin 17 receptor (IL17R)
DMASDQ6	MT	DTT
DMASDQ6	MA	Antagonist
DMASDQ6	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMASDQ6	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMASDQ6	DI	DMASDQ6
DMASDQ6	DN	Brodalumab
DMASDQ6	MI	TTG0MT6
DMASDQ6	MN	Interleukin-17 (IL17)
DMASDQ6	MT	DTT
DMASDQ6	MA	Modulator
DMASDQ6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMASDQ6	RU	https://www.fda.gov/

DMW8QNG	DI	DMW8QNG
DMW8QNG	DN	Brolucizumab
DMW8QNG	MI	TT9HKJA
DMW8QNG	MN	Vascular endothelial growth factor (VEGF)
DMW8QNG	MT	DTT
DMW8QNG	MA	Inhibitor
DMW8QNG	RN	Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
DMW8QNG	RU	https://pubmed.ncbi.nlm.nih.gov/31768932

DMW8QNG	DI	DMW8QNG
DMW8QNG	DN	Brolucizumab
DMW8QNG	MI	TTOHSBA
DMW8QNG	MN	Vascular endothelial growth factor A (VEGFA)
DMW8QNG	MT	DTT
DMW8QNG	MA	Inhibitor
DMW8QNG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMW8QNG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	DEJGDUW
DMY9TCW	MN	Cytochrome P450 1A2 (CYP1A2)
DMY9TCW	MT	DME
DMY9TCW	MA	Metabolism
DMY9TCW	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DMY9TCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	TTAN6JD
DMY9TCW	MN	Glutamate receptor AMPA (GRIA)
DMY9TCW	MT	DTT
DMY9TCW	MA	Binder
DMY9TCW	RN	Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
DMY9TCW	RU	https://pubmed.ncbi.nlm.nih.gov/19099296

DMY9TCW	DI	DMY9TCW
DMY9TCW	DN	Bromazepam
DMY9TCW	MI	DEGTFWK
DMY9TCW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY9TCW	MT	DME
DMY9TCW	MA	Metabolism
DMY9TCW	RN	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
DMY9TCW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DES5XRU
DMKB79O	MN	Cytochrome P450 2C8 (CYP2C8)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DE5IED8
DMKB79O	MN	Cytochrome P450 2C9 (CYP2C9)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DEGTFWK
DMKB79O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DT3D8F0
DMKB79O	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMKB79O	MT	DTP
DMKB79O	MA	Substrate
DMKB79O	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMKB79O	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	TT8NGED
DMKB79O	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKB79O	MT	DTT
DMKB79O	MA	Inhibitor
DMKB79O	RN	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
DMKB79O	RU	https://pubmed.ncbi.nlm.nih.gov/16846546

DMKB79O	DI	DMKB79O
DMKB79O	DN	Bromfenac
DMKB79O	MI	DEB3CV1
DMKB79O	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMKB79O	MT	DME
DMKB79O	MA	Metabolism
DMKB79O	RN	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
DMKB79O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	DE4LYSA
DMVE3TK	MN	Cytochrome P450 3A4 (CYP3A4)
DMVE3TK	MT	DME
DMVE3TK	MA	Metabolism
DMVE3TK	RN	Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13.
DMVE3TK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16229479

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	TTEX248
DMVE3TK	MN	Dopamine D2 receptor (D2R)
DMVE3TK	MT	DTT
DMVE3TK	MA	Agonist
DMVE3TK	RN	Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44.
DMVE3TK	RU	https://pubmed.ncbi.nlm.nih.gov/19303749

DMVE3TK	DI	DMVE3TK
DMVE3TK	DN	Bromocriptine
DMVE3TK	MI	DTUGYRD
DMVE3TK	MN	P-glycoprotein 1 (ABCB1)
DMVE3TK	MT	DTP
DMVE3TK	MA	Substrate
DMVE3TK	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMVE3TK	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMNDJT5	DI	DMNDJT5
DMNDJT5	DN	Bromodiphenhydramine
DMNDJT5	MI	TTTIBOJ
DMNDJT5	MN	Histamine H1 receptor (H1R)
DMNDJT5	MT	DTT
DMNDJT5	MA	Antagonist
DMNDJT5	RN	Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8.
DMNDJT5	RU	https://pubmed.ncbi.nlm.nih.gov/1973150

DM24XYQ	DI	DM24XYQ
DM24XYQ	DN	Bromperidol
DM24XYQ	MI	DE4LYSA
DM24XYQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM24XYQ	MT	DME
DM24XYQ	MA	Metabolism
DM24XYQ	RN	CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20.
DM24XYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11133003

DMFOVSD	DI	DMFOVSD
DMFOVSD	DN	Brompheniramine
DMFOVSD	MI	TTTIBOJ
DMFOVSD	MN	Histamine H1 receptor (H1R)
DMFOVSD	MT	DTT
DMFOVSD	MA	Antagonist
DMFOVSD	RN	Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14.
DMFOVSD	RU	https://pubmed.ncbi.nlm.nih.gov/8151062

DMXKZT3	DI	DMXKZT3
DMXKZT3	DN	Buclizine
DMXKZT3	MI	TTTIBOJ
DMXKZT3	MN	Histamine H1 receptor (H1R)
DMXKZT3	MT	DTT
DMXKZT3	MA	Antagonist
DMXKZT3	RN	Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7.
DMXKZT3	RU	https://pubmed.ncbi.nlm.nih.gov/13294975

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	DE4LYSA
DMJIBAW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJIBAW	MT	DME
DMJIBAW	MA	Metabolism
DMJIBAW	RN	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
DMJIBAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726657

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	TTYRL6O
DMJIBAW	MN	Glucocorticoid receptor (NR3C1)
DMJIBAW	MT	DTT
DMJIBAW	MA	Antagonist
DMJIBAW	RN	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
DMJIBAW	RU	https://pubmed.ncbi.nlm.nih.gov/19138736

DMJIBAW	DI	DMJIBAW
DMJIBAW	DN	Budesonide
DMJIBAW	MI	DEYWLRK
DMJIBAW	MN	Sulfotransferase 1A1 (SULT1A1)
DMJIBAW	MT	DME
DMJIBAW	MA	Metabolism
DMJIBAW	RN	Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
DMJIBAW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11950791

DMODHQI	DI	DMODHQI
DMODHQI	DN	Budipine
DMODHQI	MI	TTGP7BY
DMODHQI	MN	Monoamine oxidase type B (MAO-B)
DMODHQI	MT	DTT
DMODHQI	MA	Modulator
DMODHQI	RN	Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
DMODHQI	RU	https://pubmed.ncbi.nlm.nih.gov/10370904

DMG1OPF	DI	DMG1OPF
DMG1OPF	DN	Buflomedil
DMG1OPF	MI	DECB0K3
DMG1OPF	MN	Cytochrome P450 2D6 (CYP2D6)
DMG1OPF	MT	DME
DMG1OPF	MA	Metabolism
DMG1OPF	RN	DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136.
DMG1OPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10909680

DMG1OPF	DI	DMG1OPF
DMG1OPF	DN	Buflomedil
DMG1OPF	MI	DEGTFWK
DMG1OPF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG1OPF	MT	DME
DMG1OPF	MA	Metabolism
DMG1OPF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMG1OPF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMX82DO	DI	DMX82DO
DMX82DO	DN	Buformin
DMX82DO	MI	DTT79CX
DMX82DO	MN	Organic cation transporter 1 (SLC22A1)
DMX82DO	MT	DTP
DMX82DO	MA	Substrate
DMX82DO	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMX82DO	RU	https://doi.org/10.1007/s11095-012-0935-x

DMJUVE6	DI	DMJUVE6
DMJUVE6	DN	Bulevirtide
DMJUVE6	MI	TTWZRY5
DMJUVE6	MN	Sodium/bile acid cotransporter (SLC10A1)
DMJUVE6	MT	DTT
DMJUVE6	MA	Inhibitor
DMJUVE6	RN	Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605.
DMJUVE6	RU	https://pubmed.ncbi.nlm.nih.gov/32926353

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT3I124
DMRV7H0	MN	Monocarboxylate transporter 6 (SLC16A5)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT0OC1Q
DMRV7H0	MN	Organic anion transporter 2 (SLC22A7)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DTVP67E
DMRV7H0	MN	Organic anion transporter 3 (SLC22A8)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT06JWZ
DMRV7H0	MN	Organic anion transporter 4 (SLC22A11)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	TTS087L
DMRV7H0	MN	Solute carrier family 12 member 1 (SLC12A1)
DMRV7H0	MT	DTT
DMRV7H0	MA	Blocker
DMRV7H0	RN	Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
DMRV7H0	RU	https://pubmed.ncbi.nlm.nih.gov/19141616

DMRV7H0	DI	DMRV7H0
DMRV7H0	DN	Bumetanide
DMRV7H0	MI	DT6MDC9
DMRV7H0	MN	Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)
DMRV7H0	MT	DTP
DMRV7H0	MA	Substrate
DMRV7H0	RN	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
DMRV7H0	RU	http://www.ncbi.nlm.nih.gov/pubmed/17460608

DM4I8O7	DI	DM4I8O7
DM4I8O7	DN	Bunazosin
DM4I8O7	MI	TT34BHT
DM4I8O7	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM4I8O7	MT	DTT
DM4I8O7	MA	Modulator
DM4I8O7	RN	Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
DM4I8O7	RU	https://pubmed.ncbi.nlm.nih.gov/15867947

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DECB0K3
DM4PRFC	MN	Cytochrome P450 2D6 (CYP2D6)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DE4LYSA
DM4PRFC	MN	Cytochrome P450 3A4 (CYP3A4)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	DEGTFWK
DM4PRFC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4PRFC	MT	DME
DM4PRFC	MA	Metabolism
DM4PRFC	RN	Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
DM4PRFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304

DM4PRFC	DI	DM4PRFC
DM4PRFC	DN	Bupivacaine
DM4PRFC	MI	TT90XZ8
DM4PRFC	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM4PRFC	MT	DTT
DM4PRFC	MA	Modulator
DM4PRFC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PRFC	RU	https://www.fda.gov/

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEZMWRE
DMPRI8G	MN	Cytochrome P450 2C18 (CYP2C18)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DES5XRU
DMPRI8G	MN	Cytochrome P450 2C8 (CYP2C8)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16010532

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DE5IED8
DMPRI8G	MN	Cytochrome P450 2C9 (CYP2C9)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DECB0K3
DMPRI8G	MN	Cytochrome P450 2D6 (CYP2D6)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684471

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DE4LYSA
DMPRI8G	MN	Cytochrome P450 3A4 (CYP3A4)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20132117

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEIBDNY
DMPRI8G	MN	Cytochrome P450 3A5 (CYP3A5)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30531584

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DERD86B
DMPRI8G	MN	Cytochrome P450 3A7 (CYP3A7)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	TTKWM86
DMPRI8G	MN	Opioid receptor mu (MOP)
DMPRI8G	MT	DTT
DMPRI8G	MA	Agonist
DMPRI8G	RN	Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
DMPRI8G	RU	https://pubmed.ncbi.nlm.nih.gov/19494155

DMPRI8G	DI	DMPRI8G
DMPRI8G	DN	Buprenorphine
DMPRI8G	MI	DEYGVN4
DMPRI8G	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMPRI8G	MT	DME
DMPRI8G	MA	Metabolism
DMPRI8G	RN	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5.
DMPRI8G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19841060

DMBQEGT	DI	DMBQEGT
DMBQEGT	DN	Buprenorphine + naloxone
DMBQEGT	MI	TTKWM86
DMBQEGT	MN	Opioid receptor mu (MOP)
DMBQEGT	MT	DTT
DMBQEGT	MA	Agonist
DMBQEGT	RN	Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18.
DMBQEGT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DTI7UX6
DM5PCS7	MN	Breast cancer resistance protein (ABCG2)
DM5PCS7	MT	DTP
DM5PCS7	MA	Substrate
DM5PCS7	RN	Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6.
DM5PCS7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20599802

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DEPKLMQ
DM5PCS7	MN	Cytochrome P450 2B6 (CYP2B6)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30916845

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DE5IED8
DM5PCS7	MN	Cytochrome P450 2C9 (CYP2C9)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Product Monograph of Wellbutrin SR(Bupropion Hydrochloride).
DM5PCS7	RU	https://pdf.hres.ca/dpd_pm/00038603.PDF

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DECB0K3
DM5PCS7	MN	Cytochrome P450 2D6 (CYP2D6)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/27836670

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DEVDYN7
DM5PCS7	MN	Cytochrome P450 2E1 (CYP2E1)
DM5PCS7	MT	DME
DM5PCS7	MA	Metabolism
DM5PCS7	RN	Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222-30.
DM5PCS7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997944

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	TTAWNKZ
DM5PCS7	MN	Norepinephrine transporter (NET)
DM5PCS7	MT	DTT
DM5PCS7	MA	Inhibitor
DM5PCS7	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DM5PCS7	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	DTUGYRD
DM5PCS7	MN	P-glycoprotein 1 (ABCB1)
DM5PCS7	MT	DTP
DM5PCS7	MA	Substrate
DM5PCS7	RN	Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4.
DM5PCS7	RU	https://doi.org/10.1248/bpb.31.231

DM5PCS7	DI	DM5PCS7
DM5PCS7	DN	Bupropion
DM5PCS7	MI	TT3ROYC
DM5PCS7	MN	Serotonin transporter (SERT)
DM5PCS7	MT	DTT
DM5PCS7	MA	Inhibitor
DM5PCS7	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DM5PCS7	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMKUOQV	DI	DMKUOQV
DMKUOQV	DN	Burosumab
DMKUOQV	MI	TT2IZ4K
DMKUOQV	MN	Fibroblast growth factor-23 (FGF23)
DMKUOQV	MT	DTT
DMKUOQV	MA	Modulator
DMKUOQV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMKUOQV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	TTSQIFT
DMBS632	MN	5-HT 1A receptor (HTR1A)
DMBS632	MT	DTT
DMBS632	MA	Agonist
DMBS632	RN	Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
DMBS632	RU	https://pubmed.ncbi.nlm.nih.gov/16594259

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DE4OGUF
DMBS632	MN	Cytochrome P450 102A1 (cyp102)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMBS632	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DECB0K3
DMBS632	MN	Cytochrome P450 2D6 (CYP2D6)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DE4LYSA
DMBS632	MN	Cytochrome P450 3A4 (CYP3A4)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17376576

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DEIBDNY
DMBS632	MN	Cytochrome P450 3A5 (CYP3A5)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
DMBS632	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381

DMBS632	DI	DMBS632
DMBS632	DN	Buspirone
DMBS632	MI	DERD86B
DMBS632	MN	Cytochrome P450 3A7 (CYP3A7)
DMBS632	MT	DME
DMBS632	MA	Metabolism
DMBS632	RN	Drug Interactions Flockhart Table
DMBS632	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE4LYSA
DMXYJ9C	MN	Cytochrome P450 3A4 (CYP3A4)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9469685

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE4ZHS1
DMXYJ9C	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15142875

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEH49YS
DMXYJ9C	MN	Glutathione S-transferase alpha-2 (GSTA2)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18194479

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEYZEJA
DMXYJ9C	MN	Glutathione S-transferase mu-1 (GSTM1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DEK6079
DMXYJ9C	MN	Glutathione S-transferase pi (GSTP1)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	TTUTN1I
DMXYJ9C	MN	Human Deoxyribonucleic acid (hDNA)
DMXYJ9C	MT	DTT
DMXYJ9C	MA	Modulator
DMXYJ9C	RN	DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15132775

DMXYJ9C	DI	DMXYJ9C
DMXYJ9C	DN	Busulfan
DMXYJ9C	MI	DE31KMQ
DMXYJ9C	MN	Microsomal glutathione S-transferase 2 (MGST2)
DMXYJ9C	MT	DME
DMXYJ9C	MA	Metabolism
DMXYJ9C	RN	Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 2005;23(1):19-25.
DMXYJ9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15779864

DMC5AST	DI	DMC5AST
DMC5AST	DN	Butabarbital
DMC5AST	MI	TT1MPAY
DMC5AST	MN	GABA(A) receptor alpha-1 (GABRA1)
DMC5AST	MT	DTT
DMC5AST	MA	Antagonist
DMC5AST	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMC5AST	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM584TM	DI	DM584TM
DM584TM	DN	Butacaine
DM584TM	MI	TTRK8B9
DM584TM	MN	Sodium channel unspecific (NaC)
DM584TM	MT	DTT
DM584TM	MA	Modulator
DM584TM	RN	WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
DM584TM	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1

DM9J04X	DI	DM9J04X
DM9J04X	DN	Butalbital
DM9J04X	MI	TT1MPAY
DM9J04X	MN	GABA(A) receptor alpha-1 (GABRA1)
DM9J04X	MT	DTT
DM9J04X	MA	Antagonist
DM9J04X	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM9J04X	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMOJ4ZI	DI	DMOJ4ZI
DMOJ4ZI	DN	Butenafine
DMOJ4ZI	MI	TTM9XSU
DMOJ4ZI	MN	Candida Squalene epoxidase (Candi ERG1)
DMOJ4ZI	MT	DTT
DMOJ4ZI	MA	Modulator
DMOJ4ZI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOJ4ZI	RU	https://www.fda.gov/

DM7JHX0	DI	DM7JHX0
DM7JHX0	DN	Butethal
DM7JHX0	MI	TT1MPAY
DM7JHX0	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7JHX0	MT	DTT
DM7JHX0	MA	Antagonist
DM7JHX0	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7JHX0	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM8SY60	DI	DM8SY60
DM8SY60	DN	Butoconazole
DM8SY60	MI	TTTSOUD
DM8SY60	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM8SY60	MT	DTT
DM8SY60	MA	Inhibitor
DM8SY60	RN	Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5.
DM8SY60	RU	https://pubmed.ncbi.nlm.nih.gov/2184984

DM5KYPJ	DI	DM5KYPJ
DM5KYPJ	DN	Butorphanol
DM5KYPJ	MI	TT27RFC
DM5KYPJ	MN	Opioid receptor delta (OPRD1)
DM5KYPJ	MT	DTT
DM5KYPJ	MA	Agonist
DM5KYPJ	RN	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
DM5KYPJ	RU	https://pubmed.ncbi.nlm.nih.gov/15942128

DMZKXB7	DI	DMZKXB7
DMZKXB7	DN	Butylscopolamine
DMZKXB7	MI	TTH18TF
DMZKXB7	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZKXB7	MT	DTT
DMZKXB7	MA	Modulator
DMZKXB7	RN	Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7.
DMZKXB7	RU	https://pubmed.ncbi.nlm.nih.gov/8036897

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DES5XRU
DMPAZHC	MN	Cytochrome P450 2C8 (CYP2C8)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DE4LYSA
DMPAZHC	MN	Cytochrome P450 3A4 (CYP3A4)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	DEIBDNY
DMPAZHC	MN	Cytochrome P450 3A5 (CYP3A5)
DMPAZHC	MT	DME
DMPAZHC	MA	Metabolism
DMPAZHC	RN	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
DMPAZHC	RU	https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa

DMPAZHC	DI	DMPAZHC
DMPAZHC	DN	Cabazitaxel
DMPAZHC	MI	TTML2WA
DMPAZHC	MN	Tubulin (TUB)
DMPAZHC	MT	DTT
DMPAZHC	MA	Inhibitor
DMPAZHC	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMPAZHC	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	DE4LYSA
DMQ4HIN	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ4HIN	MT	DME
DMQ4HIN	MA	Metabolism
DMQ4HIN	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMQ4HIN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	TTEX248
DMQ4HIN	MN	Dopamine D2 receptor (D2R)
DMQ4HIN	MT	DTT
DMQ4HIN	MA	Agonist
DMQ4HIN	RN	Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7.
DMQ4HIN	RU	https://pubmed.ncbi.nlm.nih.gov/19145338

DMQ4HIN	DI	DMQ4HIN
DMQ4HIN	DN	Cabergoline
DMQ4HIN	MI	DTUGYRD
DMQ4HIN	MN	P-glycoprotein 1 (ABCB1)
DMQ4HIN	MT	DTP
DMQ4HIN	MA	Substrate
DMQ4HIN	RN	Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35.
DMQ4HIN	RU	http://www.ncbi.nlm.nih.gov/pubmed/22672924

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	DE5IED8
DMIYDT4	MN	Cytochrome P450 2C9 (CYP2C9)
DMIYDT4	MT	DME
DMIYDT4	MA	Metabolism
DMIYDT4	RN	FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration.
DMIYDT4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	DE4LYSA
DMIYDT4	MN	Cytochrome P450 3A4 (CYP3A4)
DMIYDT4	MT	DME
DMIYDT4	MA	Metabolism
DMIYDT4	RN	Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064.
DMIYDT4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29089775

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	TTNDSF4
DMIYDT4	MN	Proto-oncogene c-Met (MET)
DMIYDT4	MT	DTT
DMIYDT4	MA	Inhibitor
DMIYDT4	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMIYDT4	RU	http://www.exelixis.com/pipeline

DMIYDT4	DI	DMIYDT4
DMIYDT4	DN	Cabozantinib
DMIYDT4	MI	TTUTJGQ
DMIYDT4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMIYDT4	MT	DTT
DMIYDT4	MA	Inhibitor
DMIYDT4	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DMIYDT4	RU	http://www.exelixis.com/pipeline

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	TTK25J1
DMKBJWP	MN	Adenosine A1 receptor (ADORA1)
DMKBJWP	MT	DTT
DMKBJWP	MA	Antagonist
DMKBJWP	RN	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
DMKBJWP	RU	https://pubmed.ncbi.nlm.nih.gov/15095008

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	TTM2AOE
DMKBJWP	MN	Adenosine A2a receptor (ADORA2A)
DMKBJWP	MT	DTT
DMKBJWP	MA	Antagonist
DMKBJWP	RN	Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
DMKBJWP	RU	https://pubmed.ncbi.nlm.nih.gov/15095008

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEJGDUW
DMKBJWP	MN	Cytochrome P450 1A2 (CYP1A2)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE9QHP6
DMKBJWP	MN	Cytochrome P450 1B1 (CYP1B1)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DES5XRU
DMKBJWP	MN	Cytochrome P450 2C8 (CYP2C8)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE5IED8
DMKBJWP	MN	Cytochrome P450 2C9 (CYP2C9)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23679834

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DECB0K3
DMKBJWP	MN	Cytochrome P450 2D6 (CYP2D6)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9617978

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEVDYN7
DMKBJWP	MN	Cytochrome P450 2E1 (CYP2E1)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 1;459(1):59-69.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17222385

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DE4LYSA
DMKBJWP	MN	Cytochrome P450 3A4 (CYP3A4)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17652830

DMKBJWP	DI	DMKBJWP
DMKBJWP	DN	Caffeine
DMKBJWP	MI	DEZV4AP
DMKBJWP	MN	RNA cytidine acetyltransferase (hALP)
DMKBJWP	MT	DME
DMKBJWP	MA	Metabolism
DMKBJWP	RN	A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
DMKBJWP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8354022

DMQZBXI	DI	DMQZBXI
DMQZBXI	DN	Calaspargase pegol
DMQZBXI	MI	TT4WT91
DMQZBXI	MN	Asparaginase (ASRGL1)
DMQZBXI	MT	DTT
DMQZBXI	MA	Inhibitor
DMQZBXI	RN	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82.
DMQZBXI	RU	https://pubmed.ncbi.nlm.nih.gov/25348002

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	DE3FYEM
DMN4CV5	MN	Calcidiol 1-monooxygenase (CYP27B1)
DMN4CV5	MT	DME
DMN4CV5	MA	Metabolism
DMN4CV5	RN	Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99.
DMN4CV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20619365

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	DEFI12S
DMN4CV5	MN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DMN4CV5	MT	DME
DMN4CV5	MA	Metabolism
DMN4CV5	RN	Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60.
DMN4CV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16600026

DMN4CV5	DI	DMN4CV5
DMN4CV5	DN	Calcidiol
DMN4CV5	MI	TTK59TV
DMN4CV5	MN	Vitamin D3 receptor (VDR)
DMN4CV5	MT	DTT
DMN4CV5	MA	Antagonist
DMN4CV5	RN	Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
DMN4CV5	RU	https://pubmed.ncbi.nlm.nih.gov/18525006

DM03CP7	DI	DM03CP7
DM03CP7	DN	Calcipotriol
DM03CP7	MI	TTK59TV
DM03CP7	MN	Vitamin D3 receptor (VDR)
DM03CP7	MT	DTT
DM03CP7	MA	Antagonist
DM03CP7	RN	Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
DM03CP7	RU	https://pubmed.ncbi.nlm.nih.gov/18393827

DM0N9WA	DI	DM0N9WA
DM0N9WA	DN	Calcitonin Human
DM0N9WA	MI	TTLWS2O
DM0N9WA	MN	Calcitonin receptor (CALCR)
DM0N9WA	MT	DTT
DM0N9WA	MA	Modulator
DM0N9WA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N9WA	RU	https://www.fda.gov/

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DE4LYSA
DM8ZVJ7	MN	Cytochrome P450 3A4 (CYP3A4)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207822

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DELOY3P
DM8ZVJ7	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18177842

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	DEFI12S
DM8ZVJ7	MN	Vitamin D(3) 24-hydroxylase (CYP24A1)
DM8ZVJ7	MT	DME
DM8ZVJ7	MA	Metabolism
DM8ZVJ7	RN	The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57.
DM8ZVJ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24705652

DM8ZVJ7	DI	DM8ZVJ7
DM8ZVJ7	DN	Calcitriol
DM8ZVJ7	MI	TTK59TV
DM8ZVJ7	MN	Vitamin D3 receptor (VDR)
DM8ZVJ7	MT	DTT
DM8ZVJ7	MA	Agonist
DM8ZVJ7	RN	Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94.
DM8ZVJ7	RU	https://pubmed.ncbi.nlm.nih.gov/11050002

DM3W15N	DI	DM3W15N
DM3W15N	DN	Calcium carbimide
DM3W15N	MI	TTCTAOJ
DM3W15N	MN	Acetaldehyde dehydrogenase (ALDH)
DM3W15N	MT	DTT
DM3W15N	MA	Inhibitor
DM3W15N	RN	Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8.
DM3W15N	RU	https://pubmed.ncbi.nlm.nih.gov/2185581

DM3W15N	DI	DM3W15N
DM3W15N	DN	Calcium carbimide
DM3W15N	MI	DE1XPGH
DM3W15N	MN	Catalase (CAT)
DM3W15N	MT	DME
DM3W15N	MA	Metabolism
DM3W15N	RN	Vasiliou V. and Petersen D. (2010). Comprehensive toxicology (2nd ed.). Elsevier.
DM3W15N	RU	https://www.elsevier.com/books/comprehensive-toxicology/mcqueen/978-0-08-100601-6

DMJ3CFY	DI	DMJ3CFY
DMJ3CFY	DN	Calcium phosphate dihydrate
DMJ3CFY	MI	DTKS517
DMJ3CFY	MN	Sodium-dependent phosphate transport protein 2C (SLC34A3)
DMJ3CFY	MT	DTP
DMJ3CFY	MA	Substrate
DMJ3CFY	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMJ3CFY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DE9JBQK
DMWIO46	MN	Cytochrome P450 101D1 (cyp101)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/14578864

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DE7HL3C
DMWIO46	MN	Cytochrome P450 101D2 (cyp101)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/14578864

DMWIO46	DI	DMWIO46
DMWIO46	DN	Camphor
DMWIO46	MI	DEJVYAZ
DMWIO46	MN	Cytochrome P450 2A6 (CYP2A6)
DMWIO46	MT	DME
DMWIO46	MA	Metabolism
DMWIO46	RN	In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6. Biol Pharm Bull. 2007 Feb;30(2):230-3.
DMWIO46	RU	https://pubmed.ncbi.nlm.nih.gov/17268056

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DTI7UX6
DMFRM1I	MN	Breast cancer resistance protein (ABCG2)
DMFRM1I	MT	DTP
DMFRM1I	MA	Substrate
DMFRM1I	RN	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
DMFRM1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27862160

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DE4LYSA
DMFRM1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26185406

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DTUGYRD
DMFRM1I	MN	P-glycoprotein 1 (ABCB1)
DMFRM1I	MT	DTP
DMFRM1I	MA	Substrate
DMFRM1I	RN	In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096.
DMFRM1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27862160

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	TTLWPVF
DMFRM1I	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMFRM1I	MT	DTT
DMFRM1I	MA	Modulator
DMFRM1I	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMFRM1I	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DE85D2P
DMFRM1I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DMFRM1I	DI	DMFRM1I
DMFRM1I	DN	Canagliflozin
DMFRM1I	MI	DENUPDX
DMFRM1I	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMFRM1I	MT	DME
DMFRM1I	MA	Metabolism
DMFRM1I	RN	Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
DMFRM1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255

DM8HLO5	DI	DM8HLO5
DM8HLO5	DN	Canakinumab
DM8HLO5	MI	TTRYK0X
DM8HLO5	MN	Interleukin-1 beta (IL1B)
DM8HLO5	MT	DTT
DM8HLO5	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM8HLO5	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	TT8DBY3
DMRK8OT	MN	Angiotensin II receptor type-1 (AGTR1)
DMRK8OT	MT	DTT
DMRK8OT	MA	Antagonist
DMRK8OT	RN	Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
DMRK8OT	RU	https://pubmed.ncbi.nlm.nih.gov/19563275

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEB30C5
DMRK8OT	MN	Carboxylesterase 1 (CES1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23946449

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DE5IED8
DMRK8OT	MN	Cytochrome P450 2C9 (CYP2C9)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Product Monograph of Atacand.
DMRK8OT	RU	https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/ATACAND%20-%20Product-Monograph_001.pdf

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DE073H6
DMRK8OT	MN	Prostaglandin G/H synthase 1 (COX-1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEYGVN4
DMRK8OT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DMRK8OT	DI	DMRK8OT
DMRK8OT	DN	Candesartan
DMRK8OT	MI	DEF2WXN
DMRK8OT	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRK8OT	MT	DME
DMRK8OT	MA	Metabolism
DMRK8OT	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMRK8OT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMNZSC1	DI	DMNZSC1
DMNZSC1	DN	Candicidin
DMNZSC1	MI	TTQKWA4
DMNZSC1	MN	Fungal Cell membrane ergosterol (Fung CME)
DMNZSC1	MT	DTT
DMNZSC1	MA	Modulator
DMNZSC1	RN	Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans
DMNZSC1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577

DM8JRH0	DI	DM8JRH0
DM8JRH0	DN	Cangrelor
DM8JRH0	MI	TTZ1DT0
DM8JRH0	MN	P2Y purinoceptor 12 (P2RY12)
DM8JRH0	MT	DTT
DM8JRH0	MA	Antagonist
DM8JRH0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
DM8JRH0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	TT94IAG
DM0659E	MN	Cannabinoid receptor (CB)
DM0659E	MT	DTT
DM0659E	MA	Binder
DM0659E	RN	(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106.
DM0659E	RU	https://pubmed.ncbi.nlm.nih.gov/12450575

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DE5IED8
DM0659E	MN	Cytochrome P450 2C9 (CYP2C9)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DECB0K3
DM0659E	MN	Cytochrome P450 2D6 (CYP2D6)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DE4LYSA
DM0659E	MN	Cytochrome P450 3A4 (CYP3A4)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DEIBDNY
DM0659E	MN	Cytochrome P450 3A5 (CYP3A5)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DEGTFWK
DM0659E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0659E	MT	DME
DM0659E	MA	Metabolism
DM0659E	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DM0659E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DM0659E	DI	DM0659E
DM0659E	DN	Cannabidiol
DM0659E	MI	DTUGYRD
DM0659E	MN	P-glycoprotein 1 (ABCB1)
DM0659E	MT	DTP
DM0659E	MA	Substrate
DM0659E	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM0659E	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMBP5N3	DI	DMBP5N3
DMBP5N3	DN	Cantharidin
DMBP5N3	MI	TTFLH0E
DMBP5N3	MN	Serine/threonine PP1-alpha (PPP1CA)
DMBP5N3	MT	DTT
DMBP5N3	MA	Inhibitor
DMBP5N3	RN	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75.
DMBP5N3	RU	https://pubmed.ncbi.nlm.nih.gov/11881984

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	TTU6BFZ
DMTS85L	MN	Candida Thymidylate synthase (Candi TMP1)
DMTS85L	MT	DTT
DMTS85L	MA	Inhibitor
DMTS85L	RN	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
DMTS85L	RU	https://pubmed.ncbi.nlm.nih.gov/15709193

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	DEKEDRC
DMTS85L	MN	Cytidine aminohydrolase (CDA)
DMTS85L	MT	DME
DMTS85L	MA	Metabolism
DMTS85L	RN	Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805.
DMTS85L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12866042

DMTS85L	DI	DMTS85L
DMTS85L	DN	Capecitabine
DMTS85L	MI	DE4HCYL
DMTS85L	MN	Thymidine phosphorylase (TYMP)
DMTS85L	MT	DME
DMTS85L	MA	Metabolism
DMTS85L	RN	Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
DMTS85L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12481438

DMPUKA7	DI	DMPUKA7
DMPUKA7	DN	Caplacizumab
DMPUKA7	MI	TT3SZBT
DMPUKA7	MN	von Willebrand factor (VWF)
DMPUKA7	MT	DTT
DMPUKA7	MA	Inhibitor
DMPUKA7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMPUKA7	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf

DMYCXKL	DI	DMYCXKL
DMYCXKL	DN	Capmatinib
DMYCXKL	MI	TTNDSF4
DMYCXKL	MN	Proto-oncogene c-Met (MET)
DMYCXKL	MT	DTT
DMYCXKL	MA	Modulator
DMYCXKL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMYCXKL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf

DMNZBRY	DI	DMNZBRY
DMNZBRY	DN	Capreomycin
DMNZBRY	MI	TTIA0J5
DMNZBRY	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DMNZBRY	MT	DTT
DMNZBRY	MA	Binder
DMNZBRY	RN	Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15.
DMNZBRY	RU	https://pubmed.ncbi.nlm.nih.gov/17564727

DM346QI	DI	DM346QI
DM346QI	DN	Capreomycin Sulfate
DM346QI	MI	TTIA0J5
DM346QI	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DM346QI	MT	DTT
DM346QI	MA	Modulator
DM346QI	RN	The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93.
DM346QI	RU	https://www.ncbi.nlm.nih.gov/pubmed/20154709

DMHERIJ	DI	DMHERIJ
DMHERIJ	DN	Capromab
DMHERIJ	MI	TT9G4N0
DMHERIJ	MN	Glutamate carboxypeptidase II (GCPII)
DMHERIJ	MT	DTT
DMHERIJ	RN	Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28.
DMHERIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17161036

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE6OQ3W
DMGMF6V	MN	Cytochrome P450 1A1 (CYP1A1)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEJGDUW
DMGMF6V	MN	Cytochrome P450 1A2 (CYP1A2)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEPKLMQ
DMGMF6V	MN	Cytochrome P450 2B6 (CYP2B6)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DES5XRU
DMGMF6V	MN	Cytochrome P450 2C8 (CYP2C8)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE5IED8
DMGMF6V	MN	Cytochrome P450 2C9 (CYP2C9)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DECB0K3
DMGMF6V	MN	Cytochrome P450 2D6 (CYP2D6)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEVDYN7
DMGMF6V	MN	Cytochrome P450 2E1 (CYP2E1)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DE4LYSA
DMGMF6V	MN	Cytochrome P450 3A4 (CYP3A4)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	DEGTFWK
DMGMF6V	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGMF6V	MT	DME
DMGMF6V	MA	Metabolism
DMGMF6V	RN	Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
DMGMF6V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434

DMGMF6V	DI	DMGMF6V
DMGMF6V	DN	Capsaicin
DMGMF6V	MI	TTMI6F5
DMGMF6V	MN	Transient receptor potential cation channel V1 (TRPV1)
DMGMF6V	MT	DTT
DMGMF6V	MA	Agonist
DMGMF6V	RN	Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71.
DMGMF6V	RU	https://pubmed.ncbi.nlm.nih.gov/17217056

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	TTL69WB
DM458UM	MN	Angiotensin-converting enzyme (ACE)
DM458UM	MT	DTT
DM458UM	MA	Inhibitor
DM458UM	RN	Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8.
DM458UM	RU	https://pubmed.ncbi.nlm.nih.gov/12182524

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DECB0K3
DM458UM	MN	Cytochrome P450 2D6 (CYP2D6)
DM458UM	MT	DME
DM458UM	MA	Metabolism
DM458UM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM458UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DT9G7XN
DM458UM	MN	Peptide transporter 1 (SLC15A1)
DM458UM	MT	DTP
DM458UM	MA	Substrate
DM458UM	RN	Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
DM458UM	RU	https://doi.org/10.1038/nrd3028

DM458UM	DI	DM458UM
DM458UM	DN	Captopril
DM458UM	MI	DEFQ8VO
DM458UM	MN	Thiopurine methyltransferase (TPMT)
DM458UM	MT	DME
DM458UM	MA	Metabolism
DM458UM	RN	S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62.
DM458UM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6344869

DMX9K8F	DI	DMX9K8F
DMX9K8F	DN	Carbachol
DMX9K8F	MI	TTF4E0J
DMX9K8F	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMX9K8F	MT	DTT
DMX9K8F	MA	Antagonist
DMX9K8F	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DMX9K8F	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEJGDUW
DMZOLBI	MN	Cytochrome P450 1A2 (CYP1A2)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22332980

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEPKLMQ
DMZOLBI	MN	Cytochrome P450 2B6 (CYP2B6)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DES5XRU
DMZOLBI	MN	Cytochrome P450 2C8 (CYP2C8)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10907977

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DE4LYSA
DMZOLBI	MN	Cytochrome P450 3A4 (CYP3A4)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEIBDNY
DMZOLBI	MN	Cytochrome P450 3A5 (CYP3A5)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DERD86B
DMZOLBI	MN	Cytochrome P450 3A7 (CYP3A7)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos. 2003 Apr;31(4):432-8.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642469

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DELB4KP
DMZOLBI	MN	Epoxide hydrolase 1 (EPHX1)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005 Mar;61(1):25-34.
DMZOLBI	RU	https://pubmed.ncbi.nlm.nih.gov/15692831

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DTFI42L
DMZOLBI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMZOLBI	MT	DTP
DMZOLBI	MA	Substrate
DMZOLBI	RN	A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
DMZOLBI	RU	http://www.ncbi.nlm.nih.gov/pubmed/20216337

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	TTRK8B9
DMZOLBI	MN	Sodium channel unspecific (NaC)
DMZOLBI	MT	DTT
DMZOLBI	MA	Modulator
DMZOLBI	RN	Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
DMZOLBI	RU	https://pubmed.ncbi.nlm.nih.gov/24319110

DMZOLBI	DI	DMZOLBI
DMZOLBI	DN	Carbamazepine
DMZOLBI	MI	DEB3CV1
DMZOLBI	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMZOLBI	MT	DME
DMZOLBI	MA	Metabolism
DMZOLBI	RN	Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
DMZOLBI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23252947

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	TTJP4SM
DMLEDNK	MN	Bacterial Penicillin binding protein (Bact PBP)
DMLEDNK	MT	DTT
DMLEDNK	MA	Binder
DMLEDNK	RN	Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/2112536

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEXB2A9
DMLEDNK	MN	Beta-lactamase (blaB)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/10837443

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEF01WC
DMLEDNK	MN	Beta-lactamase (blaB)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DEIU0XN
DMLEDNK	MN	N-acylhomoserine lactone acylase (lacA)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMLEDNK	DI	DMLEDNK
DMLEDNK	DN	Carbenicillin
DMLEDNK	MI	DE2ARDZ
DMLEDNK	MN	PenA beta-lactamase (penA1)
DMLEDNK	MT	DME
DMLEDNK	MA	Metabolism
DMLEDNK	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMLEDNK	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DME2XG3	DI	DME2XG3
DME2XG3	DN	Carbenicillin Indanyl Sodium
DME2XG3	MI	TTJP4SM
DME2XG3	MN	Bacterial Penicillin binding protein (Bact PBP)
DME2XG3	MT	DTT
DME2XG3	MA	Modulator
DME2XG3	RN	Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61.
DME2XG3	RU	https://www.ncbi.nlm.nih.gov/pubmed/6821456

DMUSLW3	DI	DMUSLW3
DMUSLW3	DN	Carbetocin
DMUSLW3	MI	TTSCIUP
DMUSLW3	MN	Oxytocin receptor (OTR)
DMUSLW3	MT	DTT
DMUSLW3	MA	Agonist
DMUSLW3	RN	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
DMUSLW3	RU	https://pubmed.ncbi.nlm.nih.gov/18655903

DMHRG8Q	DI	DMHRG8Q
DMHRG8Q	DN	Carbidopa
DMHRG8Q	MI	TTN451K
DMHRG8Q	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMHRG8Q	MT	DTT
DMHRG8Q	MA	Inhibitor
DMHRG8Q	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DMHRG8Q	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMULAI4	DI	DMULAI4
DMULAI4	DN	Carbimazole
DMULAI4	MI	TT52XDZ
DMULAI4	MN	Thyroid peroxidase (TPO)
DMULAI4	MT	DTT
DMULAI4	MA	Inhibitor
DMULAI4	RN	Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73.
DMULAI4	RU	https://pubmed.ncbi.nlm.nih.gov/7952157

DMCT31R	DI	DMCT31R
DMCT31R	DN	Carbinoxamine
DMCT31R	MI	TTTIBOJ
DMCT31R	MN	Histamine H1 receptor (H1R)
DMCT31R	MT	DTT
DMCT31R	MA	Antagonist
DMCT31R	RN	Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.
DMCT31R	RU	https://pubmed.ncbi.nlm.nih.gov/7513381

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEYZEJA
DMG281S	MN	Glutathione S-transferase mu-1 (GSTM1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEK6079
DMG281S	MN	Glutathione S-transferase pi (GSTP1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DE3PKUG
DMG281S	MN	Glutathione S-transferase theta-1 (GSTT1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DTP8L4F
DMG281S	MN	High affinity copper uptake protein 1 (SLC31A1)
DMG281S	MT	DTP
DMG281S	MA	Substrate
DMG281S	RN	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
DMG281S	RU	http://www.ncbi.nlm.nih.gov/pubmed/24122978

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	TTUTN1I
DMG281S	MN	Human Deoxyribonucleic acid (hDNA)
DMG281S	MT	DTT
DMG281S	MA	Modulator
DMG281S	RN	Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
DMG281S	RU	https://www.ncbi.nlm.nih.gov/pubmed/20719935

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DE5ME8A
DMG281S	MN	Metallothionein-1A (MT1A)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEFKGT7
DMG281S	MN	Metallothionein-2A (MT2A)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DEA3U9Y
DMG281S	MN	Myeloperoxidase (MPO)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMG281S	DI	DMG281S
DMG281S	DN	Carboplatin
DMG281S	MI	DENP5RY
DMG281S	MN	Quinone reductase 1 (NQO1)
DMG281S	MT	DME
DMG281S	MA	Metabolism
DMG281S	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMG281S	RU	https://www.pharmgkb.org/pathway/PA150642262

DMS3508	DI	DMS3508
DMS3508	DN	Carboprost tromethamine
DMS3508	MI	TTT2ZAR
DMS3508	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMS3508	MT	DTT
DMS3508	MA	Modulator
DMS3508	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS3508	RU	https://www.fda.gov/

DM48K0X	DI	DM48K0X
DM48K0X	DN	Carfilzomib
DM48K0X	MI	DTUGYRD
DM48K0X	MN	P-glycoprotein 1 (ABCB1)
DM48K0X	MT	DTP
DM48K0X	MA	Substrate
DM48K0X	RN	Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72.
DM48K0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23475625

DM48K0X	DI	DM48K0X
DM48K0X	DN	Carfilzomib
DM48K0X	MI	TTU7ZMG
DM48K0X	MN	Proteasome (PS)
DM48K0X	MT	DTT
DM48K0X	MA	Modulator
DM48K0X	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM48K0X	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMCY0TI	DI	DMCY0TI
DMCY0TI	DN	Carglumic acid
DMCY0TI	MI	TT42M75
DMCY0TI	MN	Carbamoyl-phosphate synthetase I (CPS1)
DMCY0TI	MT	DTT
DMCY0TI	MA	Activator
DMCY0TI	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCY0TI	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	DECB0K3
DMJYDVK	MN	Cytochrome P450 2D6 (CYP2D6)
DMJYDVK	MT	DME
DMJYDVK	MA	Metabolism
DMJYDVK	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DMJYDVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	DE4LYSA
DMJYDVK	MN	Cytochrome P450 3A4 (CYP3A4)
DMJYDVK	MT	DME
DMJYDVK	MA	Metabolism
DMJYDVK	RN	Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206.
DMJYDVK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	TTEX248
DMJYDVK	MN	Dopamine D2 receptor (D2R)
DMJYDVK	MT	DTT
DMJYDVK	MA	Modulator
DMJYDVK	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMJYDVK	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMJYDVK	DI	DMJYDVK
DMJYDVK	DN	Cariprazine
DMJYDVK	MI	TT4C8EA
DMJYDVK	MN	Dopamine D3 receptor (D3R)
DMJYDVK	MT	DTT
DMJYDVK	MA	Modulator
DMJYDVK	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMJYDVK	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMWR1JC	DI	DMWR1JC
DMWR1JC	DN	Carisoprodol
DMWR1JC	MI	DEGTFWK
DMWR1JC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWR1JC	MT	DME
DMWR1JC	MA	Metabolism
DMWR1JC	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DMWR1JC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DMHTB31	DI	DMHTB31
DMHTB31	DN	Carphenazine
DMHTB31	MI	TTEX248
DMHTB31	MN	Dopamine D2 receptor (D2R)
DMHTB31	MT	DTT
DMHTB31	MA	Antagonist
DMHTB31	RN	Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38.
DMHTB31	RU	https://pubmed.ncbi.nlm.nih.gov/11873706

DMHMP05	DI	DMHMP05
DMHMP05	DN	Carprofen
DMHMP05	MI	TTVKILB
DMHMP05	MN	Prostaglandin G/H synthase 2 (COX-2)
DMHMP05	MT	DTT
DMHMP05	MA	Inhibitor
DMHMP05	RN	Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91.
DMHMP05	RU	https://pubmed.ncbi.nlm.nih.gov/17181139

DMHMP05	DI	DMHMP05
DMHMP05	DN	Carprofen
DMHMP05	MI	DEB3CV1
DMHMP05	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHMP05	MT	DME
DMHMP05	MA	Metabolism
DMHMP05	RN	Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. Chirality. 2015 Mar;27(3):189-93.
DMHMP05	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502512

DMFMDOB	DI	DMFMDOB
DMFMDOB	DN	Carteolol
DMFMDOB	MI	TTR6W5O
DMFMDOB	MN	Adrenergic receptor beta-1 (ADRB1)
DMFMDOB	MT	DTT
DMFMDOB	MA	Agonist
DMFMDOB	RN	Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92.
DMFMDOB	RU	https://pubmed.ncbi.nlm.nih.gov/11138729

DMFMDOB	DI	DMFMDOB
DMFMDOB	DN	Carteolol
DMFMDOB	MI	DECB0K3
DMFMDOB	MN	Cytochrome P450 2D6 (CYP2D6)
DMFMDOB	MT	DME
DMFMDOB	MA	Metabolism
DMFMDOB	RN	Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9.
DMFMDOB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9413916

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	TTG28O6
DMHTEAO	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMHTEAO	MT	DTT
DMHTEAO	MA	Antagonist
DMHTEAO	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DMHTEAO	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEJGDUW
DMHTEAO	MN	Cytochrome P450 1A2 (CYP1A2)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31086844

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DE5IED8
DMHTEAO	MN	Cytochrome P450 2C9 (CYP2C9)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25476996

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DECB0K3
DMHTEAO	MN	Cytochrome P450 2D6 (CYP2D6)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEVDYN7
DMHTEAO	MN	Cytochrome P450 2E1 (CYP2E1)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9280405

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DE4LYSA
DMHTEAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27354764

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DTUGYRD
DMHTEAO	MN	P-glycoprotein 1 (ABCB1)
DMHTEAO	MT	DTP
DMHTEAO	MA	Substrate
DMHTEAO	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMHTEAO	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEYGVN4
DMHTEAO	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMHTEAO	DI	DMHTEAO
DMHTEAO	DN	Carvedilol
DMHTEAO	MI	DEB3CV1
DMHTEAO	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHTEAO	MT	DME
DMHTEAO	MA	Metabolism
DMHTEAO	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHTEAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMZPXRC	DI	DMZPXRC
DMZPXRC	DN	Carzinophilin
DMZPXRC	MI	TTY1GPO
DMZPXRC	MN	Human Deoxyribonucleic acid major groove (hDNA maj)
DMZPXRC	MT	DTT
DMZPXRC	MA	Modulator
DMZPXRC	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMZPXRC	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMGQIPT	DI	DMGQIPT
DMGQIPT	DN	Caspofungin
DMGQIPT	MI	TT0SFXH
DMGQIPT	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMGQIPT	MT	DTT
DMGQIPT	MA	Modulator
DMGQIPT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQIPT	RU	https://www.fda.gov/

DMGQIPT	DI	DMGQIPT
DMGQIPT	DN	Caspofungin
DMGQIPT	MI	DT3D8F0
DMGQIPT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGQIPT	MT	DTP
DMGQIPT	MA	Substrate
DMGQIPT	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMGQIPT	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMRSZA5	DI	DMRSZA5
DMRSZA5	DN	Cefacetrile
DMRSZA5	MI	TTJP4SM
DMRSZA5	MN	Bacterial Penicillin binding protein (Bact PBP)
DMRSZA5	MT	DTT
DMRSZA5	MA	Binder
DMRSZA5	RN	Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42.
DMRSZA5	RU	https://pubmed.ncbi.nlm.nih.gov/18665871

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	TTJP4SM
DMJXDGC	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJXDGC	MT	DTT
DMJXDGC	MA	Binder
DMJXDGC	RN	Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74.
DMJXDGC	RU	https://pubmed.ncbi.nlm.nih.gov/15747584

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DTQ23VB
DMJXDGC	MN	Organic anion transporter 1 (SLC22A6)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	FDA Drug Development and Drug Interactions
DMJXDGC	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DTVP67E
DMJXDGC	MN	Organic anion transporter 3 (SLC22A8)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DT9G7XN
DMJXDGC	MN	Peptide transporter 1 (SLC15A1)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G895-902.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/21311026

DMJXDGC	DI	DMJXDGC
DMJXDGC	DN	Cefaclor
DMJXDGC	MI	DT8QKNP
DMJXDGC	MN	Peptide transporter 2 (SLC15A2)
DMJXDGC	MT	DTP
DMJXDGC	MA	Substrate
DMJXDGC	RN	Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
DMJXDGC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434549

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	TTJP4SM
DMMC345	MN	Bacterial Penicillin binding protein (Bact PBP)
DMMC345	MT	DTT
DMMC345	MA	Binder
DMMC345	RN	Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
DMMC345	RU	https://pubmed.ncbi.nlm.nih.gov/9352657

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTSYQGK
DMMC345	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTFI42L
DMMC345	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTQ3ZHF
DMMC345	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DTCSGPB
DMMC345	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DEIU0XN
DMMC345	MN	N-acylhomoserine lactone acylase (lacA)
DMMC345	MT	DME
DMMC345	MA	Metabolism
DMMC345	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMMC345	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DT9G7XN
DMMC345	MN	Peptide transporter 1 (SLC15A1)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMMC345	DI	DMMC345
DMMC345	DN	Cefadroxil
DMMC345	MI	DT8QKNP
DMMC345	MN	Peptide transporter 2 (SLC15A2)
DMMC345	MT	DTP
DMMC345	MA	Substrate
DMMC345	RN	Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136.
DMMC345	RU	http://www.ncbi.nlm.nih.gov/pubmed/27836942

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DERI7LO
DMVYSLE	MN	AmpC beta-lactamase (ampC)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	TTLP6GN
DMVYSLE	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMVYSLE	MT	DTT
DMVYSLE	MA	Inhibitor
DMVYSLE	RN	Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/7626623

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DET9I1W
DMVYSLE	MN	Beta-lactamase (blaB)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMVYSLE	DI	DMVYSLE
DMVYSLE	DN	Cefalotin
DMVYSLE	MI	DENJ2SQ
DMVYSLE	MN	Beta-lactamase (blaB)
DMVYSLE	MT	DME
DMVYSLE	MA	Metabolism
DMVYSLE	RN	Antibacterial activity of cefoperazone against anaerobic bacteria (author's transl). Jpn J Antibiot. 1980 Nov;33(11):1171-82.
DMVYSLE	RU	https://pubmed.ncbi.nlm.nih.gov/6454011

DMNEXZF	DI	DMNEXZF
DMNEXZF	DN	Cefamandole
DMNEXZF	MI	TTJP4SM
DMNEXZF	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNEXZF	MT	DTT
DMNEXZF	MA	Binder
DMNEXZF	RN	The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54.
DMNEXZF	RU	https://pubmed.ncbi.nlm.nih.gov/9419181

DMNEXZF	DI	DMNEXZF
DMNEXZF	DN	Cefamandole
DMNEXZF	MI	DT9G7XN
DMNEXZF	MN	Peptide transporter 1 (SLC15A1)
DMNEXZF	MT	DTP
DMNEXZF	MA	Substrate
DMNEXZF	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMNEXZF	RU	https://doi.org/10.1023/A:1018814627484

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	TTJP4SM
DMPDYFR	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPDYFR	MT	DTT
DMPDYFR	MA	Binder
DMPDYFR	RN	Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/18218742

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DEP0IWS
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DE7IH52
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/28711438

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DENJ2SQ
DMPDYFR	MN	Beta-lactamase (blaB)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DMPDYFR	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTCSGPB
DMPDYFR	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTQ23VB
DMPDYFR	MN	Organic anion transporter 1 (SLC22A6)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/14984259

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DTVP67E
DMPDYFR	MN	Organic anion transporter 3 (SLC22A8)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/14984259

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DT3D8F0
DMPDYFR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DT9G7XN
DMPDYFR	MN	Peptide transporter 1 (SLC15A1)
DMPDYFR	MT	DTP
DMPDYFR	MA	Substrate
DMPDYFR	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMPDYFR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMPDYFR	DI	DMPDYFR
DMPDYFR	DN	Cefazolin
DMPDYFR	MI	DEFQ8VO
DMPDYFR	MN	Thiopurine methyltransferase (TPMT)
DMPDYFR	MT	DME
DMPDYFR	MA	Metabolism
DMPDYFR	RN	Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
DMPDYFR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228189

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	TTJP4SM
DMJ7A0H	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJ7A0H	MT	DTT
DMJ7A0H	MA	Binder
DMJ7A0H	RN	Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60.
DMJ7A0H	RU	https://pubmed.ncbi.nlm.nih.gov/17540669

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	DTVP67E
DMJ7A0H	MN	Organic anion transporter 3 (SLC22A8)
DMJ7A0H	MT	DTP
DMJ7A0H	MA	Substrate
DMJ7A0H	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DMJ7A0H	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DMJ7A0H	DI	DMJ7A0H
DMJ7A0H	DN	Cefdinir
DMJ7A0H	MI	DT9G7XN
DMJ7A0H	MN	Peptide transporter 1 (SLC15A1)
DMJ7A0H	MT	DTP
DMJ7A0H	MA	Substrate
DMJ7A0H	RN	Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today. 2004 Aug 15;9(16):712-20.
DMJ7A0H	RU	https://doi.org/10.1016/S1359-6446(04)03198-8

DMSUVM1	DI	DMSUVM1
DMSUVM1	DN	Cefditoren
DMSUVM1	MI	TTJP4SM
DMSUVM1	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSUVM1	MT	DTT
DMSUVM1	MA	Binder
DMSUVM1	RN	Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7.
DMSUVM1	RU	https://pubmed.ncbi.nlm.nih.gov/17724158

DMSUVM1	DI	DMSUVM1
DMSUVM1	DN	Cefditoren
DMSUVM1	MI	DT3D8F0
DMSUVM1	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMSUVM1	MT	DTP
DMSUVM1	MA	Substrate
DMSUVM1	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMSUVM1	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMHVWIK	DI	DMHVWIK
DMHVWIK	DN	Cefepime
DMHVWIK	MI	TTHWB7G
DMHVWIK	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMHVWIK	MT	DTT
DMHVWIK	MA	Modulator
DMHVWIK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHVWIK	RU	https://www.fda.gov/

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	TTJP4SM
DMY60I8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMY60I8	MT	DTT
DMY60I8	MA	Binder
DMY60I8	RN	Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51.
DMY60I8	RU	https://pubmed.ncbi.nlm.nih.gov/19528266

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	DT9G7XN
DMY60I8	MN	Peptide transporter 1 (SLC15A1)
DMY60I8	MT	DTP
DMY60I8	MA	Substrate
DMY60I8	RN	Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J Pharmacol Exp Ther. 2001 Oct;299(1):351-7.
DMY60I8	RU	http://www.ncbi.nlm.nih.gov/pubmed/11561098

DMY60I8	DI	DMY60I8
DMY60I8	DN	Cefixime
DMY60I8	MI	DT8QKNP
DMY60I8	MN	Peptide transporter 2 (SLC15A2)
DMY60I8	MT	DTP
DMY60I8	MA	Substrate
DMY60I8	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMY60I8	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMPLY7B	DI	DMPLY7B
DMPLY7B	DN	Cefmenoxime
DMPLY7B	MI	TT85JMW
DMPLY7B	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMPLY7B	MT	DTT
DMPLY7B	MA	Binder
DMPLY7B	RN	In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701.
DMPLY7B	RU	https://pubmed.ncbi.nlm.nih.gov/3134847

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	TT85JMW
DM42W1B	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DM42W1B	MT	DTT
DM42W1B	MA	Binder
DM42W1B	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DM42W1B	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	DT9C1TS
DM42W1B	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM42W1B	MT	DTP
DM42W1B	MA	Substrate
DM42W1B	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DM42W1B	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DM42W1B	DI	DM42W1B
DM42W1B	DN	Cefmetazole
DM42W1B	MI	DT9G7XN
DM42W1B	MN	Peptide transporter 1 (SLC15A1)
DM42W1B	MT	DTP
DM42W1B	MA	Substrate
DM42W1B	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DM42W1B	RU	https://doi.org/10.1023/A:1018814627484

DMORSGU	DI	DMORSGU
DMORSGU	DN	Cefodizime
DMORSGU	MI	DTFI42L
DMORSGU	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMORSGU	MT	DTP
DMORSGU	MA	Substrate
DMORSGU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMORSGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMTX2BH	DI	DMTX2BH
DMTX2BH	DN	Cefonicid
DMTX2BH	MI	TTJP4SM
DMTX2BH	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTX2BH	MT	DTT
DMTX2BH	MA	Binder
DMTX2BH	RN	Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6.
DMTX2BH	RU	https://pubmed.ncbi.nlm.nih.gov/6376452

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	TTJP4SM
DM53PV8	MN	Bacterial Penicillin binding protein (Bact PBP)
DM53PV8	MT	DTT
DM53PV8	MA	Binder
DM53PV8	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DM53PV8	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DT3D8F0
DM53PV8	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DT9C1TS
DM53PV8	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DM53PV8	DI	DM53PV8
DM53PV8	DN	Cefoperazone
DM53PV8	MI	DTUGYRD
DM53PV8	MN	P-glycoprotein 1 (ABCB1)
DM53PV8	MT	DTP
DM53PV8	MA	Substrate
DM53PV8	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM53PV8	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSQVD6	DI	DMSQVD6
DMSQVD6	DN	Ceforanide
DMSQVD6	MI	TTJP4SM
DMSQVD6	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSQVD6	MT	DTT
DMSQVD6	MA	Binder
DMSQVD6	RN	The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3.
DMSQVD6	RU	https://pubmed.ncbi.nlm.nih.gov/12890292

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE0TCN3
DMEB837	MN	Ampc beta-lactamase (ampC)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26416862

DMMKHBJ	DI	DMMKHBJ
DMMKHBJ	DN	Cefotaxime
DMMKHBJ	MI	TTLP6GN
DMMKHBJ	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMMKHBJ	MT	DTT
DMMKHBJ	MA	Inhibitor
DMMKHBJ	RN	Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307.
DMMKHBJ	RU	https://pubmed.ncbi.nlm.nih.gov/17661704

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEAYSTX
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/30014616

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEITMS0
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/11036038

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEP0IWS
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEEAL81
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE7IH52
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE5HV8P
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE47ARF
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEHJVX4
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEG2PK9
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEWHJ7A
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	nan
DMEB837	RU	nan

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEU1RXB
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEMIUB2
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEYIEO5
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEVHXAU
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against beta-lactam antibiotics. J Antimicrob Chemother. 2015 Mar;70(3):701-9.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/25433011

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEZLFV5
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/26416862

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE5AHG6
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Novel TEM-type extended-spectrum beta-lactamase, TEM-134, in a Citrobacter koseri clinical isolate. Antimicrob Agents Chemother. 2005 Apr;49(4):1564-6.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/15793140

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DEKGVS4
DMEB837	MN	Beta-lactamase (blaB)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017 Jul 14;3(7):502-511.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/28264560

DMEB837	DI	DMEB837
DMEB837	DN	Cefotaxime
DMEB837	MI	DE2ARDZ
DMEB837	MN	PenA beta-lactamase (penA1)
DMEB837	MT	DME
DMEB837	MA	Metabolism
DMEB837	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMEB837	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DM07TX3	DI	DM07TX3
DM07TX3	DN	Cefotetan
DM07TX3	MI	TTJP4SM
DM07TX3	MN	Bacterial Penicillin binding protein (Bact PBP)
DM07TX3	MT	DTT
DM07TX3	MA	Binder
DM07TX3	RN	In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24.
DM07TX3	RU	https://pubmed.ncbi.nlm.nih.gov/17488372

DM07TX3	DI	DM07TX3
DM07TX3	DN	Cefotetan
DM07TX3	MI	DTUGYRD
DM07TX3	MN	P-glycoprotein 1 (ABCB1)
DM07TX3	MT	DTP
DM07TX3	MA	Substrate
DM07TX3	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM07TX3	RU	https://doi.org/10.1007/s11095-012-0935-x

DMF5HU6	DI	DMF5HU6
DMF5HU6	DN	Cefotiam
DMF5HU6	MI	TT85JMW
DMF5HU6	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMF5HU6	MT	DTT
DMF5HU6	MA	Binder
DMF5HU6	RN	Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41.
DMF5HU6	RU	https://pubmed.ncbi.nlm.nih.gov/16495632

DMF5HU6	DI	DMF5HU6
DMF5HU6	DN	Cefotiam
DMF5HU6	MI	DTVP67E
DMF5HU6	MN	Organic anion transporter 3 (SLC22A8)
DMF5HU6	MT	DTP
DMF5HU6	MA	Substrate
DMF5HU6	RN	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol. 2008 Jul;295(1):F247-52.
DMF5HU6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18480179

DMYTXVR	DI	DMYTXVR
DMYTXVR	DN	Cefoxitin
DMYTXVR	MI	TTJP4SM
DMYTXVR	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYTXVR	MT	DTT
DMYTXVR	MA	Binder
DMYTXVR	RN	Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
DMYTXVR	RU	https://pubmed.ncbi.nlm.nih.gov/18725435

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEP0IWS
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEEAL81
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	nan
DMY8NC4	RU	nan

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE7IH52
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/28711438

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE5HV8P
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE47ARF
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEHJVX4
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEG2PK9
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEWHJ7A
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEU1RXB
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/12837513

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEMIUB2
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEQAG48
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/15128725

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DEF01WC
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMY8NC4	DI	DMY8NC4
DMY8NC4	DN	Cefoxitin
DMY8NC4	MI	DE5AHG6
DMY8NC4	MN	Beta-lactamase (blaB)
DMY8NC4	MT	DME
DMY8NC4	MA	Metabolism
DMY8NC4	RN	Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80.
DMY8NC4	RU	https://pubmed.ncbi.nlm.nih.gov/15128725

DMYTXVR	DI	DMYTXVR
DMYTXVR	DN	Cefoxitin
DMYTXVR	MI	DT9G7XN
DMYTXVR	MN	Peptide transporter 1 (SLC15A1)
DMYTXVR	MT	DTP
DMYTXVR	MA	Substrate
DMYTXVR	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMYTXVR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMKBTFG	DI	DMKBTFG
DMKBTFG	DN	Cefozopran
DMKBTFG	MI	TT4ILYC
DMKBTFG	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKBTFG	MT	DTT
DMKBTFG	MA	Inhibitor
DMKBTFG	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMKBTFG	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMZ2WL4	DI	DMZ2WL4
DMZ2WL4	DN	Cefpiramide
DMZ2WL4	MI	TTJP4SM
DMZ2WL4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZ2WL4	MT	DTT
DMZ2WL4	MA	Binder
DMZ2WL4	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMZ2WL4	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	TTJP4SM
DMJUNY5	MN	Bacterial Penicillin binding protein (Bact PBP)
DMJUNY5	MT	DTT
DMJUNY5	MA	Binder
DMJUNY5	RN	Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/16940068

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DEQAG48
DMJUNY5	MN	Beta-lactamase (blaB)
DMJUNY5	MT	DME
DMJUNY5	MA	Metabolism
DMJUNY5	RN	Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/12384364

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DEEQ3RW
DMJUNY5	MN	Beta-lactamase (blaB)
DMJUNY5	MT	DME
DMJUNY5	MA	Metabolism
DMJUNY5	RN	Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60.
DMJUNY5	RU	https://pubmed.ncbi.nlm.nih.gov/12384364

DMJUNY5	DI	DMJUNY5
DMJUNY5	DN	Cefpodoxime
DMJUNY5	MI	DT9G7XN
DMJUNY5	MN	Peptide transporter 1 (SLC15A1)
DMJUNY5	MT	DTP
DMJUNY5	MA	Substrate
DMJUNY5	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMJUNY5	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DM7DSYP	DI	DM7DSYP
DM7DSYP	DN	Cefprozil
DM7DSYP	MI	TTJP4SM
DM7DSYP	MN	Bacterial Penicillin binding protein (Bact PBP)
DM7DSYP	MT	DTT
DM7DSYP	MA	Binder
DM7DSYP	RN	Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8.
DM7DSYP	RU	https://pubmed.ncbi.nlm.nih.gov/15949076

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	TTJP4SM
DMUNSWV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMUNSWV	MT	DTT
DMUNSWV	MA	Binder
DMUNSWV	RN	Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
DMUNSWV	RU	https://pubmed.ncbi.nlm.nih.gov/18725435

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	DT9G7XN
DMUNSWV	MN	Peptide transporter 1 (SLC15A1)
DMUNSWV	MT	DTP
DMUNSWV	MA	Substrate
DMUNSWV	RN	Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11.
DMUNSWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/9374833

DMUNSWV	DI	DMUNSWV
DMUNSWV	DN	Cefradine
DMUNSWV	MI	DT8QKNP
DMUNSWV	MN	Peptide transporter 2 (SLC15A2)
DMUNSWV	MT	DTP
DMUNSWV	MA	Substrate
DMUNSWV	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMUNSWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMQXLF3	DI	DMQXLF3
DMQXLF3	DN	Cefsulodin
DMQXLF3	MI	DT9G7XN
DMQXLF3	MN	Peptide transporter 1 (SLC15A1)
DMQXLF3	MT	DTP
DMQXLF3	MA	Substrate
DMQXLF3	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMQXLF3	RU	https://doi.org/10.1023/A:1018814627484

DM41GRA	DI	DM41GRA
DM41GRA	DN	Ceftazidime
DM41GRA	MI	TTJP4SM
DM41GRA	MN	Bacterial Penicillin binding protein (Bact PBP)
DM41GRA	MT	DTT
DM41GRA	MA	Binder
DM41GRA	RN	New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41.
DM41GRA	RU	https://pubmed.ncbi.nlm.nih.gov/18318877

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	TTJP4SM
DMWV2AG	MN	Bacterial Penicillin binding protein (Bact PBP)
DMWV2AG	MT	DTT
DMWV2AG	MA	Binder
DMWV2AG	RN	Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91.
DMWV2AG	RU	https://pubmed.ncbi.nlm.nih.gov/19532086

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	DT9G7XN
DMWV2AG	MN	Peptide transporter 1 (SLC15A1)
DMWV2AG	MT	DTP
DMWV2AG	MA	Substrate
DMWV2AG	RN	Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G664-70.
DMWV2AG	RU	http://www.ncbi.nlm.nih.gov/pubmed/15528259

DMWV2AG	DI	DMWV2AG
DMWV2AG	DN	Ceftibuten
DMWV2AG	MI	DT8QKNP
DMWV2AG	MN	Peptide transporter 2 (SLC15A2)
DMWV2AG	MT	DTP
DMWV2AG	MA	Substrate
DMWV2AG	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMWV2AG	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE3FVRW
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEYM2D3
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE9ZQ3L
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DE69OXF
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEPYGS9
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/21876048

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEPGFHV
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DENZLGX
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DMR2SOZ	DI	DMR2SOZ
DMR2SOZ	DN	Ceftiofur
DMR2SOZ	MI	DEZAQPD
DMR2SOZ	MN	Beta-lactamase (blaB)
DMR2SOZ	MT	DME
DMR2SOZ	MA	Metabolism
DMR2SOZ	RN	Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96.
DMR2SOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19428193

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	TTJP4SM
DM3VOGS	MN	Bacterial Penicillin binding protein (Bact PBP)
DM3VOGS	MT	DTT
DM3VOGS	MA	Binder
DM3VOGS	RN	Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24.
DM3VOGS	RU	https://pubmed.ncbi.nlm.nih.gov/15716453

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTCSGPB
DM3VOGS	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
DM3VOGS	RU	http://www.ncbi.nlm.nih.gov/pubmed/22166395

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTQ23VB
DM3VOGS	MN	Organic anion transporter 1 (SLC22A6)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	FDA Drug Development and Drug Interactions
DM3VOGS	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM3VOGS	DI	DM3VOGS
DM3VOGS	DN	Ceftizoxime
DM3VOGS	MI	DTVP67E
DM3VOGS	MN	Organic anion transporter 3 (SLC22A8)
DM3VOGS	MT	DTP
DM3VOGS	MA	Substrate
DM3VOGS	RN	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
DM3VOGS	RU	http://www.ncbi.nlm.nih.gov/pubmed/16098483

DM9QWAH	DI	DM9QWAH
DM9QWAH	DN	Ceftolozane/tazobactam
DM9QWAH	MI	TTHI19T
DM9QWAH	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM9QWAH	MT	DTT
DM9QWAH	MA	Modulator
DM9QWAH	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM9QWAH	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	TTJP4SM
DMCEW64	MN	Bacterial Penicillin binding protein (Bact PBP)
DMCEW64	MT	DTT
DMCEW64	MA	Modulator
DMCEW64	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMCEW64	RU	https://www.fda.gov/

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEEAL81
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/8889716

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEYIEO5
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DEBKS91
DMCEW64	MN	Beta-lactamase (blaB)
DMCEW64	MT	DME
DMCEW64	MA	Metabolism
DMCEW64	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMCEW64	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DTFI42L
DMCEW64	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DT9C1TS
DMCEW64	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/21372390

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DT9G7XN
DMCEW64	MN	Peptide transporter 1 (SLC15A1)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DMCEW64	RU	https://doi.org/10.1023/A:1018814627484

DMCEW64	DI	DMCEW64
DMCEW64	DN	Ceftriaxone
DMCEW64	MI	DTUGYRD
DMCEW64	MN	P-glycoprotein 1 (ABCB1)
DMCEW64	MT	DTP
DMCEW64	MA	Substrate
DMCEW64	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCEW64	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSIMD8	DI	DMSIMD8
DMSIMD8	DN	Cefuroxime
DMSIMD8	MI	TTJP4SM
DMSIMD8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMSIMD8	MT	DTT
DMSIMD8	MA	Binder
DMSIMD8	RN	Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30.
DMSIMD8	RU	https://pubmed.ncbi.nlm.nih.gov/12615852

DM4CHN0	DI	DM4CHN0
DM4CHN0	DN	Cefuroxime axetil
DM4CHN0	MI	DT9G7XN
DM4CHN0	MN	Peptide transporter 1 (SLC15A1)
DM4CHN0	MT	DTP
DM4CHN0	MA	Substrate
DM4CHN0	RN	Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
DM4CHN0	RU	https://doi.org/10.1023/A:1018814627484

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DES5XRU
DM6LOQU	MN	Cytochrome P450 2C8 (CYP2C8)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19761371

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DE5IED8
DM6LOQU	MN	Cytochrome P450 2C9 (CYP2C9)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DECB0K3
DM6LOQU	MN	Cytochrome P450 2D6 (CYP2D6)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30219715

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DE4LYSA
DM6LOQU	MN	Cytochrome P450 3A4 (CYP3A4)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10773015

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	TTVKILB
DM6LOQU	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6LOQU	MT	DTT
DM6LOQU	MA	Inhibitor
DM6LOQU	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM6LOQU	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM6LOQU	DI	DM6LOQU
DM6LOQU	DN	Celecoxib
DM6LOQU	MI	DEYWLRK
DM6LOQU	MN	Sulfotransferase 1A1 (SULT1A1)
DM6LOQU	MT	DME
DM6LOQU	MA	Metabolism
DM6LOQU	RN	Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
DM6LOQU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17239972

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	TTVIREA
DMD5LBX	MN	Adrenergic receptor (ADR)
DMD5LBX	MT	DTT
DMD5LBX	MA	Modulator
DMD5LBX	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMD5LBX	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	DTE2B1D
DMD5LBX	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMD5LBX	MT	DTP
DMD5LBX	MA	Substrate
DMD5LBX	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMD5LBX	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMD5LBX	DI	DMD5LBX
DMD5LBX	DN	Celiprolol HCL
DMD5LBX	MI	DTUGYRD
DMD5LBX	MN	P-glycoprotein 1 (ABCB1)
DMD5LBX	MT	DTP
DMD5LBX	MA	Substrate
DMD5LBX	RN	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
DMD5LBX	RU	https://doi.org/10.1111/j.2042-7158.1996.tb05904.x

DMYT2FP	DI	DMYT2FP
DMYT2FP	DN	Cellulose Sodium Phosphate
DMYT2FP	MI	TT8X5NO
DMYT2FP	MN	Calcium (Ca)
DMYT2FP	MT	DTT
DMYT2FP	MA	Modulator
DMYT2FP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYT2FP	RU	https://www.fda.gov/

DMTIUFA	DI	DMTIUFA
DMTIUFA	DN	Celtura
DMTIUFA	MI	TT3J5ZI
DMTIUFA	MN	Cell mediated immunity response (CMIR)
DMTIUFA	MT	DTT
DMTIUFA	RN	A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43.
DMTIUFA	RU	https://pubmed.ncbi.nlm.nih.gov/22902681

DMKMJHE	DI	DMKMJHE
DMKMJHE	DN	Cemiplimab
DMKMJHE	MI	TTNBFWK
DMKMJHE	MN	Programmed cell death protein 1 (PD-1)
DMKMJHE	MT	DTT
DMKMJHE	MA	Modulator
DMKMJHE	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMKMJHE	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM8Y2RU	DI	DM8Y2RU
DM8Y2RU	DN	Cenegermin
DM8Y2RU	MI	TTEDJN4
DM8Y2RU	MN	Low-affinity nerve growth factor receptor (NGFR)
DM8Y2RU	MT	DTT
DM8Y2RU	MA	Agonist
DM8Y2RU	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM8Y2RU	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMXQS7K	DI	DMXQS7K
DMXQS7K	DN	Cenestin
DMXQS7K	MI	TTZAYWL
DMXQS7K	MN	Estrogen receptor (ESR)
DMXQS7K	MT	DTT
DMXQS7K	MA	Agonist
DMXQS7K	RN	Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6.
DMXQS7K	RU	https://pubmed.ncbi.nlm.nih.gov/11887204

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEJVYAZ
DM8KLU9	MN	Cytochrome P450 2A6 (CYP2A6)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEPKLMQ
DM8KLU9	MN	Cytochrome P450 2B6 (CYP2B6)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEVDYN7
DM8KLU9	MN	Cytochrome P450 2E1 (CYP2E1)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DE4LYSA
DM8KLU9	MN	Cytochrome P450 3A4 (CYP3A4)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEIBDNY
DM8KLU9	MN	Cytochrome P450 3A5 (CYP3A5)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEGTFWK
DM8KLU9	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DM8KLU9	DI	DM8KLU9
DM8KLU9	DN	Cenobamate
DM8KLU9	MI	DEB3CV1
DM8KLU9	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM8KLU9	MT	DME
DM8KLU9	MA	Metabolism
DM8KLU9	RN	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
DM8KLU9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf

DMGOVHA	DI	DMGOVHA
DMGOVHA	DN	Cenobamate
DMGOVHA	MI	TTIG65Q
DMGOVHA	MN	Voltage-gated sodium channel (Nav)
DMGOVHA	MT	DTT
DMGOVHA	MA	Inhibitor
DMGOVHA	RN	Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182.
DMGOVHA	RU	https://pubmed.ncbi.nlm.nih.gov/31063770

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	TTJP4SM
DMD5JU8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMD5JU8	MT	DTT
DMD5JU8	MA	Binder
DMD5JU8	RN	Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
DMD5JU8	RU	https://pubmed.ncbi.nlm.nih.gov/14970246

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DECB0K3
DMD5JU8	MN	Cytochrome P450 2D6 (CYP2D6)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80.
DMD5JU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289959

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DE4LYSA
DMD5JU8	MN	Cytochrome P450 3A4 (CYP3A4)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep;16(9):1352-9.
DMD5JU8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10496649

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DTZGT0P
DMD5JU8	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/20484555

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DEIU0XN
DMD5JU8	MN	N-acylhomoserine lactone acylase (lacA)
DMD5JU8	MT	DME
DMD5JU8	MA	Metabolism
DMD5JU8	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMD5JU8	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DT9G7XN
DMD5JU8	MN	Peptide transporter 1 (SLC15A1)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Direct evidence for efficient transport and minimal metabolism of L-cephalexin by oligopeptide transporter 1 in budded baculovirus fraction. Biol Pharm Bull. 2009 Aug;32(8):1459-61.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/19652390

DMD5JU8	DI	DMD5JU8
DMD5JU8	DN	Cephalexin
DMD5JU8	MI	DT8QKNP
DMD5JU8	MN	Peptide transporter 2 (SLC15A2)
DMD5JU8	MT	DTP
DMD5JU8	MA	Substrate
DMD5JU8	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMD5JU8	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMYZITL	DI	DMYZITL
DMYZITL	DN	Cephaloglycin
DMYZITL	MI	TTJP4SM
DMYZITL	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYZITL	MT	DTT
DMYZITL	MA	Modulator
DMYZITL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYZITL	RU	https://www.fda.gov/

DMYZITL	DI	DMYZITL
DMYZITL	DN	Cephaloglycin
DMYZITL	MI	DT9G7XN
DMYZITL	MN	Peptide transporter 1 (SLC15A1)
DMYZITL	MT	DTP
DMYZITL	MA	Substrate
DMYZITL	RN	Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008 May;60(5):543-85.
DMYZITL	RU	https://doi.org/10.1211/jpp.60.5.0002

DM79XDW	DI	DM79XDW
DM79XDW	DN	Cephalosporin
DM79XDW	MI	TTLP6GN
DM79XDW	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DM79XDW	MT	DTT
DM79XDW	MA	Binder
DM79XDW	RN	A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31.
DM79XDW	RU	https://pubmed.ncbi.nlm.nih.gov/11171967

DM79XDW	DI	DM79XDW
DM79XDW	DN	Cephalosporin
DM79XDW	MI	DESIWFO
DM79XDW	MN	Beta-lactamase (blaB)
DM79XDW	MT	DME
DM79XDW	MA	Metabolism
DM79XDW	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DM79XDW	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DM51Z9E	DI	DM51Z9E
DM51Z9E	DN	Cephalothin sodium
DM51Z9E	MI	TTJP4SM
DM51Z9E	MN	Bacterial Penicillin binding protein (Bact PBP)
DM51Z9E	MT	DTT
DM51Z9E	MA	Modulator
DM51Z9E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM51Z9E	RU	https://www.fda.gov/

DM51Z9E	DI	DM51Z9E
DM51Z9E	DN	Cephalothin sodium
DM51Z9E	MI	DTI7UX6
DM51Z9E	MN	Breast cancer resistance protein (ABCG2)
DM51Z9E	MT	DTP
DM51Z9E	MA	Substrate
DM51Z9E	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM51Z9E	RU	https://doi.org/10.1042/BJ20040791

DMV2JNY	DI	DMV2JNY
DMV2JNY	DN	Cephapirin
DMV2JNY	MI	TTJP4SM
DMV2JNY	MN	Bacterial Penicillin binding protein (Bact PBP)
DMV2JNY	MT	DTT
DMV2JNY	MA	Binder
DMV2JNY	RN	The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85.
DMV2JNY	RU	https://pubmed.ncbi.nlm.nih.gov/808545

DM9Y5JB	DI	DM9Y5JB
DM9Y5JB	DN	Cepharanthine
DM9Y5JB	MI	DTUGYRD
DM9Y5JB	MN	P-glycoprotein 1 (ABCB1)
DM9Y5JB	MT	DTP
DM9Y5JB	MA	Substrate
DM9Y5JB	RN	Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8.
DM9Y5JB	RU	http://jpet.aspetjournals.org/content/275/1/73.long

DMB920Z	DI	DMB920Z
DMB920Z	DN	Ceritinib
DMB920Z	MI	TTPMQSO
DMB920Z	MN	ALK tyrosine kinase receptor (ALK)
DMB920Z	MT	DTT
DMB920Z	MA	Modulator
DMB920Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
DMB920Z	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397

DMB920Z	DI	DMB920Z
DMB920Z	DN	Ceritinib
DMB920Z	MI	DTUGYRD
DMB920Z	MN	P-glycoprotein 1 (ABCB1)
DMB920Z	MT	DTP
DMB920Z	MA	Substrate
DMB920Z	RN	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66.
DMB920Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/26870817

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTI7UX6
DMXCM7H	MN	Breast cancer resistance protein (ABCG2)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMXCM7H	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DES5XRU
DMXCM7H	MN	Cytochrome P450 2C8 (CYP2C8)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DE4LYSA
DMXCM7H	MN	Cytochrome P450 3A4 (CYP3A4)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEIBDNY
DMXCM7H	MN	Cytochrome P450 3A5 (CYP3A5)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Drug Interactions Flockhart Table
DMXCM7H	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DERD86B
DMXCM7H	MN	Cytochrome P450 3A7 (CYP3A7)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Drug Interactions Flockhart Table
DMXCM7H	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	TTPADOQ
DMXCM7H	MN	HMG-CoA reductase (HMGCR)
DMXCM7H	MT	DTT
DMXCM7H	MA	Inhibitor
DMXCM7H	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMXCM7H	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTFI42L
DMXCM7H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMXCM7H	RU	https://doi.org/10.1124/jpet.105.085589

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT3D8F0
DMXCM7H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	FDA Drug Development and Drug Interactions
DMXCM7H	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT9C1TS
DMXCM7H	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	FDA Drug Development and Drug Interactions
DMXCM7H	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTPFTEQ
DMXCM7H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
DMXCM7H	RU	https://doi.org/10.1021/mp200103h

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DTUGYRD
DMXCM7H	MN	P-glycoprotein 1 (ABCB1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMXCM7H	RU	https://doi.org/10.1124/jpet.105.085589

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DT56EKP
DMXCM7H	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMXCM7H	MT	DTP
DMXCM7H	MA	Substrate
DMXCM7H	RN	Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
DMXCM7H	RU	http://www.ncbi.nlm.nih.gov/pubmed/20946088

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEYGVN4
DMXCM7H	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DMXCM7H	DI	DMXCM7H
DMXCM7H	DN	Cerivastatin
DMXCM7H	MI	DEF2WXN
DMXCM7H	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMXCM7H	MT	DME
DMXCM7H	MA	Metabolism
DMXCM7H	RN	Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
DMXCM7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/21386754

DM0HAC8	DI	DM0HAC8
DM0HAC8	DN	Cerliponase Alfa
DM0HAC8	MI	TTOVYPT
DM0HAC8	MN	Tripeptidyl-peptidase I (TPP1)
DM0HAC8	MT	DTT
DM0HAC8	MA	Modulator
DM0HAC8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0HAC8	RU	https://www.fda.gov/

DM5CL9Z	DI	DM5CL9Z
DM5CL9Z	DN	Certolizumab
DM5CL9Z	MI	TTF8CQI
DM5CL9Z	MN	Tumor necrosis factor (TNF)
DM5CL9Z	MT	DTT
DM5CL9Z	MA	Inhibitor
DM5CL9Z	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DM5CL9Z	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMUR94J	DI	DMUR94J
DMUR94J	DN	Certoparin sodium
DMUR94J	MI	TTCIHJA
DMUR94J	MN	Coagulation factor Xa (F10)
DMUR94J	MT	DTT
DMUR94J	MA	Modulator
DMUR94J	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUR94J	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM6N4PR	DI	DM6N4PR
DM6N4PR	DN	Cerulenin
DM6N4PR	MI	TT7AOUD
DM6N4PR	MN	Fatty acid synthase (FASN)
DM6N4PR	MT	DTT
DM6N4PR	MA	Inhibitor
DM6N4PR	RN	Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
DM6N4PR	RU	https://pubmed.ncbi.nlm.nih.gov/19382912

DM2WE5K	DI	DM2WE5K
DM2WE5K	DN	Ceruletide
DM2WE5K	MI	TTVFO0U
DM2WE5K	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM2WE5K	MT	DTT
DM2WE5K	MA	Agonist
DM2WE5K	RN	Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
DM2WE5K	RU	https://pubmed.ncbi.nlm.nih.gov/18537882

DMOMP9U	DI	DMOMP9U
DMOMP9U	DN	Cetirizine
DMOMP9U	MI	TTTIBOJ
DMOMP9U	MN	Histamine H1 receptor (H1R)
DMOMP9U	MT	DTT
DMOMP9U	MA	Antagonist
DMOMP9U	RN	Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7.
DMOMP9U	RU	https://pubmed.ncbi.nlm.nih.gov/19537525

DMOMP9U	DI	DMOMP9U
DMOMP9U	DN	Cetirizine
DMOMP9U	MI	DTUGYRD
DMOMP9U	MN	P-glycoprotein 1 (ABCB1)
DMOMP9U	MT	DTP
DMOMP9U	MA	Substrate
DMOMP9U	RN	Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality. 2010 Jul;22(7):684-92.
DMOMP9U	RU	http://www.ncbi.nlm.nih.gov/pubmed/20014242

DMSP4JX	DI	DMSP4JX
DMSP4JX	DN	Cetraxate
DMSP4JX	MI	TT5L2VC
DMSP4JX	MN	Kallikrein-related peptidase (KLK)
DMSP4JX	MT	DTT
DMSP4JX	MA	Modulator
DMSP4JX	RN	A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
DMSP4JX	RU	https://pubmed.ncbi.nlm.nih.gov/4261023

DMFD9Q6	DI	DMFD9Q6
DMFD9Q6	DN	Cetrorelix
DMFD9Q6	MI	TT8R70G
DMFD9Q6	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMFD9Q6	MT	DTT
DMFD9Q6	MA	Antagonist
DMFD9Q6	RN	Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33.
DMFD9Q6	RU	https://pubmed.ncbi.nlm.nih.gov/19301301

DMLNCE0	DI	DMLNCE0
DMLNCE0	DN	Cetuximab
DMLNCE0	MI	TTGKNB4
DMLNCE0	MN	Epidermal growth factor receptor (EGFR)
DMLNCE0	MT	DTT
DMLNCE0	RN	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
DMLNCE0	RU	https://pubmed.ncbi.nlm.nih.gov/12479268

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	DECB0K3
DMWSMND	MN	Cytochrome P450 2D6 (CYP2D6)
DMWSMND	MT	DME
DMWSMND	MA	Metabolism
DMWSMND	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DMWSMND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	DE4LYSA
DMWSMND	MN	Cytochrome P450 3A4 (CYP3A4)
DMWSMND	MT	DME
DMWSMND	MA	Metabolism
DMWSMND	RN	Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.
DMWSMND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011

DMWSMND	DI	DMWSMND
DMWSMND	DN	Cevimeline
DMWSMND	MI	TTQ13Z5
DMWSMND	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMWSMND	MT	DTT
DMWSMND	MA	Agonist
DMWSMND	RN	Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
DMWSMND	RU	https://pubmed.ncbi.nlm.nih.gov/18450949

DMKN345	DI	DMKN345
DMKN345	DN	Charybdotoxin
DMKN345	MI	TTMNI76
DMKN345	MN	Calcium-activated potassium channel (KCN)
DMKN345	MT	DTT
DMKN345	MA	Blocker
DMKN345	RN	Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
DMKN345	RU	https://pubmed.ncbi.nlm.nih.gov/16741254

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DE4LYSA
DMQ8JIK	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
DMQ8JIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18583509

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DETL4WB
DMQ8JIK	MN	Cytochrome P450 8B1 (CYP8B1)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biol Chem. 2019 Apr 24;400(5):625-628.
DMQ8JIK	RU	https://pubmed.ncbi.nlm.nih.gov/30465713

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	TTS4UGC
DMQ8JIK	MN	Farnesoid X-activated receptor (FXR)
DMQ8JIK	MT	DTT
DMQ8JIK	MA	Modulator
DMQ8JIK	RN	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
DMQ8JIK	RU	https://pubmed.ncbi.nlm.nih.gov/12052824

DMQ8JIK	DI	DMQ8JIK
DMQ8JIK	DN	Chenodiol
DMQ8JIK	MI	DEYGVN4
DMQ8JIK	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQ8JIK	MT	DME
DMQ8JIK	MA	Metabolism
DMQ8JIK	RN	Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
DMQ8JIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17058234

DMXGJEI	DI	DMXGJEI
DMXGJEI	DN	Chlophedianol
DMXGJEI	MI	TTTIBOJ
DMXGJEI	MN	Histamine H1 receptor (H1R)
DMXGJEI	MT	DTT
DMXGJEI	MA	Antagonist
DMXGJEI	RN	Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41.
DMXGJEI	RU	https://pubmed.ncbi.nlm.nih.gov/2905706

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	TTABD5E
DMRKE63	MN	DNA replication (DNA repli)
DMRKE63	MT	DTT
DMRKE63	MA	Intercalator
DMRKE63	RN	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
DMRKE63	RU	https://pubmed.ncbi.nlm.nih.gov/19509245

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DEK6079
DMRKE63	MN	Glutathione S-transferase pi (GSTP1)
DMRKE63	MT	DME
DMRKE63	MA	Metabolism
DMRKE63	RN	The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
DMRKE63	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18511072

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DTE2B1D
DMRKE63	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMRKE63	MT	DTP
DMRKE63	MA	Substrate
DMRKE63	RN	Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66.
DMRKE63	RU	https://doi.org/10.1146/annurev.pharmtox.44.101802.121856

DMRKE63	DI	DMRKE63
DMRKE63	DN	Chlorambucil
DMRKE63	MI	DTUGYRD
DMRKE63	MN	P-glycoprotein 1 (ABCB1)
DMRKE63	MT	DTP
DMRKE63	MA	Substrate
DMRKE63	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMRKE63	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	TTLFGBV
DMFXEWT	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMFXEWT	MT	DTT
DMFXEWT	MA	Binder
DMFXEWT	RN	Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/15554968

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DE26V9J
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEMUBWL
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DECMT89
DMFXEWT	MN	Chloramphenicolase (chlR)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60.
DMFXEWT	RU	https://pubmed.ncbi.nlm.nih.gov/4165044

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEFVHQU
DMFXEWT	MN	Glycerol-3-phosphate dehydrogenase (gpsA)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol. 2008 Jan;45(2):386-94.
DMFXEWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/17658606

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DEGTFWK
DMFXEWT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFXEWT	MT	DME
DMFXEWT	MA	Metabolism
DMFXEWT	RN	Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
DMFXEWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14576103

DMFXEWT	DI	DMFXEWT
DMFXEWT	DN	Chloramphenicol
DMFXEWT	MI	DTUGYRD
DMFXEWT	MN	P-glycoprotein 1 (ABCB1)
DMFXEWT	MT	DTP
DMFXEWT	MA	Substrate
DMFXEWT	RN	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
DMFXEWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221992

DMTN5XI	DI	DMTN5XI
DMTN5XI	DN	Chlordiazepoxide
DMTN5XI	MI	TTPTXIN
DMTN5XI	MN	Translocator protein (TSPO)
DMTN5XI	MT	DTT
DMTN5XI	MA	Modulator
DMTN5XI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTN5XI	RU	https://www.fda.gov/

DMQ9MVG	DI	DMQ9MVG
DMQ9MVG	DN	Chlorhexidine
DMQ9MVG	MI	TT4ILYC
DMQ9MVG	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMQ9MVG	MT	DTT
DMQ9MVG	MA	Breaker
DMQ9MVG	RN	The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5.
DMQ9MVG	RU	https://pubmed.ncbi.nlm.nih.gov/1335944

DMSF4PR	DI	DMSF4PR
DMSF4PR	DN	Chlormerodrin
DMSF4PR	MI	TTJUWVB
DMSF4PR	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMSF4PR	MT	DTT
DMSF4PR	MA	Modulator
DMSF4PR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSF4PR	RU	https://www.fda.gov/

DMTWUXR	DI	DMTWUXR
DMTWUXR	DN	Chlormezanone
DMTWUXR	MI	TTPTXIN
DMTWUXR	MN	Translocator protein (TSPO)
DMTWUXR	MT	DTT
DMTWUXR	MA	Agonist
DMTWUXR	RN	Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8.
DMTWUXR	RU	https://pubmed.ncbi.nlm.nih.gov/7105820

DMSOQK1	DI	DMSOQK1
DMSOQK1	DN	Chloroprocaine
DMSOQK1	MI	TTWK8D0
DMSOQK1	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMSOQK1	MT	DTT
DMSOQK1	MA	Blocker
DMSOQK1	RN	Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403.
DMSOQK1	RU	https://pubmed.ncbi.nlm.nih.gov/11352545

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DE6OQ3W
DMSI5CB	MN	Cytochrome P450 1A1 (CYP1A1)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12756207

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DES5XRU
DMSI5CB	MN	Cytochrome P450 2C8 (CYP2C8)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005 Dec;10(12):1271-3.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16359408

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DECB0K3
DMSI5CB	MN	Cytochrome P450 2D6 (CYP2D6)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DE4LYSA
DMSI5CB	MN	Cytochrome P450 3A4 (CYP3A4)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DEIBDNY
DMSI5CB	MN	Cytochrome P450 3A5 (CYP3A5)
DMSI5CB	MT	DME
DMSI5CB	MA	Metabolism
DMSI5CB	RN	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
DMSI5CB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	TTKY2NS
DMSI5CB	MN	Duffy antigen chemokine receptor (ACKR1)
DMSI5CB	MT	DTT
DMSI5CB	MA	Modulator
DMSI5CB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSI5CB	RU	https://www.fda.gov/

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DTZGT0P
DMSI5CB	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMSI5CB	MT	DTP
DMSI5CB	MA	Substrate
DMSI5CB	RN	Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
DMSI5CB	RU	http://www.ncbi.nlm.nih.gov/pubmed/21518836

DMSI5CB	DI	DMSI5CB
DMSI5CB	DN	Chloroquine
DMSI5CB	MI	DTUGYRD
DMSI5CB	MN	P-glycoprotein 1 (ABCB1)
DMSI5CB	MT	DTP
DMSI5CB	MA	Substrate
DMSI5CB	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMSI5CB	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	DTI7UX6
DMLHESP	MN	Breast cancer resistance protein (ABCG2)
DMLHESP	MT	DTP
DMLHESP	MA	Substrate
DMLHESP	RN	ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53.
DMLHESP	RU	https://doi.org/10.2133/dmpk.DMPK-11-NT-068

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	TTANPDJ
DMLHESP	MN	Carbonic anhydrase II (CA-II)
DMLHESP	MT	DTT
DMLHESP	MA	Inhibitor
DMLHESP	RN	Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
DMLHESP	RU	https://pubmed.ncbi.nlm.nih.gov/10731484

DMLHESP	DI	DMLHESP
DMLHESP	DN	Chlorothiazide
DMLHESP	MI	DTVP67E
DMLHESP	MN	Organic anion transporter 3 (SLC22A8)
DMLHESP	MT	DTP
DMLHESP	MA	Substrate
DMLHESP	RN	Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73.
DMLHESP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18216144

DMFZBMQ	DI	DMFZBMQ
DMFZBMQ	DN	Chloroxine
DMFZBMQ	MI	TTQW87Y
DMFZBMQ	MN	Opioid receptor kappa (OPRK1)
DMFZBMQ	MT	DTT
DMFZBMQ	MA	Inhibitor
DMFZBMQ	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMFZBMQ	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DECB0K3
DM5URA2	MN	Cytochrome P450 2D6 (CYP2D6)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DM5URA2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DE4LYSA
DM5URA2	MN	Cytochrome P450 3A4 (CYP3A4)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DEIBDNY
DM5URA2	MN	Cytochrome P450 3A5 (CYP3A5)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DERD86B
DM5URA2	MN	Cytochrome P450 3A7 (CYP3A7)
DM5URA2	MT	DME
DM5URA2	MA	Metabolism
DM5URA2	RN	Drug Interactions Flockhart Table
DM5URA2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	TTTIBOJ
DM5URA2	MN	Histamine H1 receptor (H1R)
DM5URA2	MT	DTT
DM5URA2	MA	Antagonist
DM5URA2	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM5URA2	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DM5URA2	DI	DM5URA2
DM5URA2	DN	Chlorpheniramine
DM5URA2	MI	DTSYQGK
DM5URA2	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM5URA2	MT	DTP
DM5URA2	MA	Substrate
DM5URA2	RN	Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
DM5URA2	RU	http://www.ncbi.nlm.nih.gov/pubmed/15666293

DMQRPOS	DI	DMQRPOS
DMQRPOS	DN	Chlorphentermine hydrochloride
DMQRPOS	MI	TT3ROYC
DMQRPOS	MN	Serotonin transporter (SERT)
DMQRPOS	MT	DTT
DMQRPOS	MA	Modulator
DMQRPOS	RN	Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75.
DMQRPOS	RU	https://www.ncbi.nlm.nih.gov/pubmed/10458725

DM1IFGT	DI	DM1IFGT
DM1IFGT	DN	Chlorproguanil
DM1IFGT	MI	TT9SL3Q
DM1IFGT	MN	Polypeptide deformylase (PDF)
DM1IFGT	MT	DTT
DM1IFGT	MA	Inhibitor
DM1IFGT	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM1IFGT	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DEJGDUW
DMBGZI3	MN	Cytochrome P450 1A2 (CYP1A2)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17611010

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DECB0K3
DMBGZI3	MN	Cytochrome P450 2D6 (CYP2D6)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DE4LYSA
DMBGZI3	MN	Cytochrome P450 3A4 (CYP3A4)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8.
DMBGZI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23406751

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DEIZLTN
DMBGZI3	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DMBGZI3	MT	DME
DMBGZI3	MA	Metabolism
DMBGZI3	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DMBGZI3	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	TTEX248
DMBGZI3	MN	Dopamine D2 receptor (D2R)
DMBGZI3	MT	DTT
DMBGZI3	MA	Antagonist
DMBGZI3	RN	Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
DMBGZI3	RU	https://pubmed.ncbi.nlm.nih.gov/19374860

DMBGZI3	DI	DMBGZI3
DMBGZI3	DN	Chlorpromazine
DMBGZI3	MI	DTUGYRD
DMBGZI3	MN	P-glycoprotein 1 (ABCB1)
DMBGZI3	MT	DTP
DMBGZI3	MA	Substrate
DMBGZI3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMBGZI3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	DE5IED8
DMPHZQE	MN	Cytochrome P450 2C9 (CYP2C9)
DMPHZQE	MT	DME
DMPHZQE	MA	Metabolism
DMPHZQE	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DMPHZQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	TTG140O
DMPHZQE	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMPHZQE	MT	DTT
DMPHZQE	MA	Blocker
DMPHZQE	RN	Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53.
DMPHZQE	RU	https://pubmed.ncbi.nlm.nih.gov/14998554

DMPHZQE	DI	DMPHZQE
DMPHZQE	DN	Chlorpropamide
DMPHZQE	MI	DEGTFWK
DMPHZQE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPHZQE	MT	DME
DMPHZQE	MA	Metabolism
DMPHZQE	RN	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
DMPHZQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554

DMY0KGJ	DI	DMY0KGJ
DMY0KGJ	DN	Chlorprothixene
DMY0KGJ	MI	TTEX248
DMY0KGJ	MN	Dopamine D2 receptor (D2R)
DMY0KGJ	MT	DTT
DMY0KGJ	MA	Antagonist
DMY0KGJ	RN	Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42.
DMY0KGJ	RU	https://pubmed.ncbi.nlm.nih.gov/19091563

DM4DMBT	DI	DM4DMBT
DM4DMBT	DN	Chlorthalidone
DM4DMBT	MI	TTS087L
DM4DMBT	MN	Solute carrier family 12 member 1 (SLC12A1)
DM4DMBT	MT	DTT
DM4DMBT	MA	Blocker
DM4DMBT	RN	The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
DM4DMBT	RU	https://pubmed.ncbi.nlm.nih.gov/15134800

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	TTMNI76
DMCYVDT	MN	Calcium-activated potassium channel (KCN)
DMCYVDT	MT	DTT
DMCYVDT	MA	Activator
DMCYVDT	RN	Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
DMCYVDT	RU	https://pubmed.ncbi.nlm.nih.gov/16859676

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DE4OGUF
DMCYVDT	MN	Cytochrome P450 102A1 (cyp102)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
DMCYVDT	RU	https://pubmed.ncbi.nlm.nih.gov/17235582

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEJGDUW
DMCYVDT	MN	Cytochrome P450 1A2 (CYP1A2)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9825829

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEJVYAZ
DMCYVDT	MN	Cytochrome P450 2A6 (CYP2A6)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DECB0K3
DMCYVDT	MN	Cytochrome P450 2D6 (CYP2D6)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DEVDYN7
DMCYVDT	MN	Cytochrome P450 2E1 (CYP2E1)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DMCYVDT	DI	DMCYVDT
DMCYVDT	DN	Chlorzoxazone
DMCYVDT	MI	DE4LYSA
DMCYVDT	MN	Cytochrome P450 3A4 (CYP3A4)
DMCYVDT	MT	DME
DMCYVDT	MA	Metabolism
DMCYVDT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCYVDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGU74E	DI	DMGU74E
DMGU74E	DN	Cholecalciferol
DMGU74E	MI	TTK59TV
DMGU74E	MN	Vitamin D3 receptor (VDR)
DMGU74E	MT	DTT
DMGU74E	MA	Binder
DMGU74E	RN	[Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20.
DMGU74E	RU	https://pubmed.ncbi.nlm.nih.gov/18406498

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DT7JELC
DM7OKQV	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69.
DM7OKQV	RU	http://ajpgi.physiology.org/content/274/1/G157.long

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTI7UX6
DM7OKQV	MN	Breast cancer resistance protein (ABCG2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
DM7OKQV	RU	https://doi.org/10.1124/mol.111.075143

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TTQ6VF4
DM7OKQV	MN	Ferrochelatase (FECH)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TTMF541
DM7OKQV	MN	Liver carboxylesterase (CES1)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTFI42L
DM7OKQV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
DM7OKQV	RU	https://doi.org/10.1038/sj.bjp.0704560

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTCSGPB
DM7OKQV	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM7OKQV	RU	https://doi.org/10.1007/s11095-012-0935-x

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DTE2B1D
DM7OKQV	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
DM7OKQV	RU	http://www.ncbi.nlm.nih.gov/pubmed/7557095

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DT3D8F0
DM7OKQV	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7OKQV	MT	DTP
DM7OKQV	MA	Substrate
DM7OKQV	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM7OKQV	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	TT9V5JH
DM7OKQV	MN	Phospholipase A2 (PLA2G1B)
DM7OKQV	MT	DTT
DM7OKQV	MA	Inhibitor
DM7OKQV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM7OKQV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM7OKQV	DI	DM7OKQV
DM7OKQV	DN	Cholic acid
DM7OKQV	MI	DEYWLRK
DM7OKQV	MN	Sulfotransferase 1A1 (SULT1A1)
DM7OKQV	MT	DME
DM7OKQV	MA	Metabolism
DM7OKQV	RN	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
DM7OKQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20102295

DMOI1ZF	DI	DMOI1ZF
DMOI1ZF	DN	Choline alfoscerate
DMOI1ZF	MI	TTH18TF
DMOI1ZF	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMOI1ZF	MT	DTT
DMOI1ZF	MA	Modulator
DMOI1ZF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMOI1ZF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DEAHED0
DM8P137	MN	Choline dehydrogenase (CHDH)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	Usual choline and betaine dietary intake and incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. BMC Cardiovasc Disord. 2007 Jul 13;7:20.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17629908

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DE5NGOW
DM8P137	MN	Choline O-acetyltransferase (CHAT)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	The effect of trichlorfon and methylazoxymethanol on the development of guinea pig cerebellum. Toxicol Appl Pharmacol. 2007 Mar;219(2-3):128-35.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17150236

DM8P137	DI	DM8P137
DM8P137	DN	Choline salicylate
DM8P137	MI	DEL87ZT
DM8P137	MN	Choline/ethanolaminephosphotransferase 1 (CEPT1)
DM8P137	MT	DME
DM8P137	MA	Metabolism
DM8P137	RN	PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1). Lipids. 2002 Jul;37(7):663-72.
DM8P137	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12216837

DMFMZ3G	DI	DMFMZ3G
DMFMZ3G	DN	Choriogonadotropin alfa
DMFMZ3G	MI	TT2O4W9
DMFMZ3G	MN	Luteinizing hormone receptor (LHCGR)
DMFMZ3G	MT	DTT
DMFMZ3G	MA	Modulator
DMFMZ3G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFMZ3G	RU	https://www.fda.gov/

DMFT73E	DI	DMFT73E
DMFT73E	DN	Chorionic Gonadotropin
DMFT73E	MI	TT2O4W9
DMFT73E	MN	Luteinizing hormone receptor (LHCGR)
DMFT73E	MT	DTT
DMFT73E	MA	Modulator
DMFT73E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFT73E	RU	https://www.fda.gov/

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	TTJL8VG
DM2NA4K	MN	Corticosteroid-binding globulin (SERPINA6)
DM2NA4K	MT	DTT
DM2NA4K	MA	Binder
DM2NA4K	RN	Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7.
DM2NA4K	RU	https://pubmed.ncbi.nlm.nih.gov/10634411

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DECB0K3
DM2NA4K	MN	Cytochrome P450 2D6 (CYP2D6)
DM2NA4K	MT	DME
DM2NA4K	MA	Metabolism
DM2NA4K	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DM2NA4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DE4LYSA
DM2NA4K	MN	Cytochrome P450 3A4 (CYP3A4)
DM2NA4K	MT	DME
DM2NA4K	MA	Metabolism
DM2NA4K	RN	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86.
DM2NA4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573

DM2NA4K	DI	DM2NA4K
DM2NA4K	DN	Ciclesonide
DM2NA4K	MI	DTUGYRD
DM2NA4K	MN	P-glycoprotein 1 (ABCB1)
DM2NA4K	MT	DTP
DM2NA4K	MA	Substrate
DM2NA4K	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DM2NA4K	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMN5T2A	DI	DMN5T2A
DMN5T2A	DN	Ciclopirox
DMN5T2A	MI	TTJQFBG
DMN5T2A	MN	HIF-prolyl hydroxylase (HPH)
DMN5T2A	MT	DTT
DMN5T2A	MA	Modulator
DMN5T2A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMN5T2A	RU	https://www.fda.gov/

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTI7UX6
DMT2KRV	MN	Breast cancer resistance protein (ABCG2)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMT2KRV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	TTA4LDE
DMT2KRV	MN	Calcineurin (PPP3CA)
DMT2KRV	MT	DTT
DMT2KRV	MA	Inhibitor
DMT2KRV	RN	Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
DMT2KRV	RU	https://pubmed.ncbi.nlm.nih.gov/17414949

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DE4LYSA
DMAZJFX	MN	Cytochrome P450 3A4 (CYP3A4)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction. Pharmacol Rep. 2019 Apr;71(2):201-205.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30785057

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DEIBDNY
DMAZJFX	MN	Cytochrome P450 3A5 (CYP3A5)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25976223

DMAZJFX	DI	DMAZJFX
DMAZJFX	DN	Ciclosporin
DMAZJFX	MI	DERD86B
DMAZJFX	MN	Cytochrome P450 3A7 (CYP3A7)
DMAZJFX	MT	DME
DMAZJFX	MA	Metabolism
DMAZJFX	RN	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008 Dec;30(6):689-99.
DMAZJFX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18978522

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTFI42L
DMT2KRV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
DMT2KRV	RU	https://doi.org/10.1007/s00228-009-0740-6

DMT2KRV	DI	DMT2KRV
DMT2KRV	DN	Ciclosporin
DMT2KRV	MI	DTUGYRD
DMT2KRV	MN	P-glycoprotein 1 (ABCB1)
DMT2KRV	MT	DTP
DMT2KRV	MA	Substrate
DMT2KRV	RN	Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
DMT2KRV	RU	http://www.ncbi.nlm.nih.gov/pubmed/18725544

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	TTIU7X1
DMA13GD	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMA13GD	MT	DTT
DMA13GD	MA	Modulator
DMA13GD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA13GD	RU	https://www.fda.gov/

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTFI42L
DMA13GD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTQ23VB
DMA13GD	MN	Organic anion transporter 1 (SLC22A6)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17372702

DMA13GD	DI	DMA13GD
DMA13GD	DN	Cidofovir
DMA13GD	MI	DTVP67E
DMA13GD	MN	Organic anion transporter 3 (SLC22A8)
DMA13GD	MT	DTP
DMA13GD	MA	Substrate
DMA13GD	RN	Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
DMA13GD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17372702

DME2H5T	DI	DME2H5T
DME2H5T	DN	Cilastatin
DME2H5T	MI	TTYUENF
DME2H5T	MN	Dehydropeptidase I (DPEP1)
DME2H5T	MT	DTT
DME2H5T	MA	Inhibitor
DME2H5T	RN	Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31.
DME2H5T	RU	https://pubmed.ncbi.nlm.nih.gov/16493791

DM4V6JA	DI	DM4V6JA
DM4V6JA	DN	Cilazapril
DM4V6JA	MI	TTL69WB
DM4V6JA	MN	Angiotensin-converting enzyme (ACE)
DM4V6JA	MT	DTT
DM4V6JA	MA	Inhibitor
DM4V6JA	RN	Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93.
DM4V6JA	RU	https://pubmed.ncbi.nlm.nih.gov/18423812

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEJGDUW
DMZMSCT	MN	Cytochrome P450 1A2 (CYP1A2)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DECB0K3
DMZMSCT	MN	Cytochrome P450 2D6 (CYP2D6)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DE4LYSA
DMZMSCT	MN	Cytochrome P450 3A4 (CYP3A4)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEIBDNY
DMZMSCT	MN	Cytochrome P450 3A5 (CYP3A5)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DERD86B
DMZMSCT	MN	Cytochrome P450 3A7 (CYP3A7)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DEGTFWK
DMZMSCT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZMSCT	MT	DME
DMZMSCT	MA	Metabolism
DMZMSCT	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMZMSCT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DTVP67E
DMZMSCT	MN	Organic anion transporter 3 (SLC22A8)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692216

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DT3D8F0
DMZMSCT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/28535976

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	DT9C1TS
DMZMSCT	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMZMSCT	MT	DTP
DMZMSCT	MA	Substrate
DMZMSCT	RN	Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523.
DMZMSCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/28535976

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	TTZCG4L
DMZMSCT	MN	Phosphodiesterase 3 (PDE3)
DMZMSCT	MT	DTT
DMZMSCT	MA	Modulator
DMZMSCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZMSCT	RU	https://www.fda.gov/

DMZMSCT	DI	DMZMSCT
DMZMSCT	DN	Cilostazol
DMZMSCT	MI	TT06AWU
DMZMSCT	MN	Phosphodiesterase 3A (PDE3A)
DMZMSCT	MT	DTT
DMZMSCT	MA	Inhibitor
DMZMSCT	RN	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
DMZMSCT	RU	https://pubmed.ncbi.nlm.nih.gov/2985781

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTI7UX6
DMH61ZB	MN	Breast cancer resistance protein (ABCG2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/18086804

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	TTQHJ1K
DMH61ZB	MN	Histamine H2 receptor (H2R)
DMH61ZB	MT	DTT
DMH61ZB	MA	Antagonist
DMH61ZB	RN	Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
DMH61ZB	RU	https://pubmed.ncbi.nlm.nih.gov/11180002

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTZGT0P
DMH61ZB	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DT3TX4H
DMH61ZB	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTVP67E
DMH61ZB	MN	Organic anion transporter 3 (SLC22A8)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17314201

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTT79CX
DMH61ZB	MN	Organic cation transporter 1 (SLC22A1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DT9IDPW
DMH61ZB	MN	Organic cation transporter 2 (SLC22A2)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814153

DMH61ZB	DI	DMH61ZB
DMH61ZB	DN	Cimetidine
DMH61ZB	MI	DTUGYRD
DMH61ZB	MN	P-glycoprotein 1 (ABCB1)
DMH61ZB	MT	DTP
DMH61ZB	MA	Substrate
DMH61ZB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMH61ZB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZHPNE	DI	DMZHPNE
DMZHPNE	DN	Cimetropium bromide
DMZHPNE	MI	TTH18TF
DMZHPNE	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZHPNE	MT	DTT
DMZHPNE	MA	Modulator
DMZHPNE	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMZHPNE	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DEJGDUW
DMCX0K3	MN	Cytochrome P450 1A2 (CYP1A2)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DECB0K3
DMCX0K3	MN	Cytochrome P450 2D6 (CYP2D6)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	DE4LYSA
DMCX0K3	MN	Cytochrome P450 3A4 (CYP3A4)
DMCX0K3	MT	DME
DMCX0K3	MA	Metabolism
DMCX0K3	RN	Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11.
DMCX0K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113

DMCX0K3	DI	DMCX0K3
DMCX0K3	DN	Cinacalcet
DMCX0K3	MI	TTBUYHA
DMCX0K3	MN	Extracellular calcium-sensing receptor (CASR)
DMCX0K3	MT	DTT
DMCX0K3	MA	Agonist
DMCX0K3	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DMCX0K3	RU	http://www.amgen.com/science/pipe.jsp

DMFIC0M	DI	DMFIC0M
DMFIC0M	DN	Cinalukast
DMFIC0M	MI	TTGKOY9
DMFIC0M	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMFIC0M	MT	DTT
DMFIC0M	MA	Antagonist
DMFIC0M	RN	Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
DMFIC0M	RU	https://pubmed.ncbi.nlm.nih.gov/9042047

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEJGDUW
DM7U5QJ	MN	Cytochrome P450 1A2 (CYP1A2)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19590965

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEJVYAZ
DM7U5QJ	MN	Cytochrome P450 2A6 (CYP2A6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DEPKLMQ
DM7U5QJ	MN	Cytochrome P450 2B6 (CYP2B6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DE5IED8
DM7U5QJ	MN	Cytochrome P450 2C9 (CYP2C9)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DECB0K3
DM7U5QJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	DE4LYSA
DM7U5QJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM7U5QJ	MT	DME
DM7U5QJ	MA	Metabolism
DM7U5QJ	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM7U5QJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM7U5QJ	DI	DM7U5QJ
DM7U5QJ	DN	Cinnarizine
DM7U5QJ	MI	TTTIBOJ
DM7U5QJ	MN	Histamine H1 receptor (H1R)
DM7U5QJ	MT	DTT
DM7U5QJ	MA	Antagonist
DM7U5QJ	RN	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
DM7U5QJ	RU	https://pubmed.ncbi.nlm.nih.gov/12056673

DMDX1ZC	DI	DMDX1ZC
DMDX1ZC	DN	Cinolazepam
DMDX1ZC	MI	TTPTXIN
DMDX1ZC	MN	Translocator protein (TSPO)
DMDX1ZC	MT	DTT
DMDX1ZC	MA	Binder
DMDX1ZC	RN	Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18.
DMDX1ZC	RU	https://pubmed.ncbi.nlm.nih.gov/2889679

DM4EWNS	DI	DM4EWNS
DM4EWNS	DN	Cinoxacin
DM4EWNS	MI	TT0IHXV
DM4EWNS	MN	DNA topoisomerase II (TOP2)
DM4EWNS	MT	DTT
DM4EWNS	MA	Inhibitor
DM4EWNS	RN	The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.
DM4EWNS	RU	https://pubmed.ncbi.nlm.nih.gov/10411577

DMVIKJZ	DI	DMVIKJZ
DMVIKJZ	DN	Cinryze
DMVIKJZ	MI	TTVQ6R9
DMVIKJZ	MN	C1 esterase inhibitor (SERPING1)
DMVIKJZ	MT	DTT
DMVIKJZ	MA	Modulator
DMVIKJZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVIKJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMVIKJZ	DI	DMVIKJZ
DMVIKJZ	DN	Cinryze
DMVIKJZ	MI	TT7LRQH
DMVIKJZ	MN	Complement C1s component (C1S)
DMVIKJZ	MT	DTT
DMVIKJZ	MA	Modulator
DMVIKJZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVIKJZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMGC5DB	DI	DMGC5DB
DMGC5DB	DN	Ciprofibrate
DMGC5DB	MI	DE4LYSA
DMGC5DB	MN	Cytochrome P450 3A4 (CYP3A4)
DMGC5DB	MT	DME
DMGC5DB	MA	Metabolism
DMGC5DB	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMGC5DB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMGC5DB	DI	DMGC5DB
DMGC5DB	DN	Ciprofibrate
DMGC5DB	MI	TTJ584C
DMGC5DB	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMGC5DB	MT	DTT
DMGC5DB	MA	Agonist
DMGC5DB	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMGC5DB	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTN6J5F
DM2NLS9	MN	Bacterial DNA gyrase (Bact gyrase)
DM2NLS9	MT	DTT
DM2NLS9	MA	Modulator
DM2NLS9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2NLS9	RU	https://www.fda.gov/

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTJP4SM
DM2NLS9	MN	Bacterial Penicillin binding protein (Bact PBP)
DM2NLS9	MT	DTT
DM2NLS9	MA	Inhibitor
DM2NLS9	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM2NLS9	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTI7UX6
DM2NLS9	MN	Breast cancer resistance protein (ABCG2)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18200507

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTU6BFZ
DM2NLS9	MN	Candida Thymidylate synthase (Candi TMP1)
DM2NLS9	MT	DTT
DM2NLS9	MA	Inhibitor
DM2NLS9	RN	Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
DM2NLS9	RU	https://pubmed.ncbi.nlm.nih.gov/12494465

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTCSGPB
DM2NLS9	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/19307362

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTVP67E
DM2NLS9	MN	Organic anion transporter 3 (SLC22A8)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol. 2008 Jul;74(1):122-31.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18381565

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	DTE2B1D
DM2NLS9	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2NLS9	MT	DTP
DM2NLS9	MA	Substrate
DM2NLS9	RN	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
DM2NLS9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21039758

DM2NLS9	DI	DM2NLS9
DM2NLS9	DN	Ciprofloxacin XR
DM2NLS9	MI	TTIXTO3
DM2NLS9	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DM2NLS9	MT	DTT
DM2NLS9	MA	Modulator
DM2NLS9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2NLS9	RU	https://www.fda.gov/

DMZR26N	DI	DMZR26N
DMZR26N	DN	Ciprofloxacin+dexamethasone
DMZR26N	MI	TT0IHXV
DMZR26N	MN	DNA topoisomerase II (TOP2)
DMZR26N	MT	DTT
DMZR26N	MA	Binder
DMZR26N	RN	Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
DMZR26N	RU	https://pubmed.ncbi.nlm.nih.gov/16634700

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	TT07C3Y
DMY7PED	MN	5-HT 4 receptor (HTR4)
DMY7PED	MT	DTT
DMY7PED	MA	Agonist
DMY7PED	RN	Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
DMY7PED	RU	https://pubmed.ncbi.nlm.nih.gov/18948374

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEJVYAZ
DMY7PED	MN	Cytochrome P450 2A6 (CYP2A6)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEPKLMQ
DMY7PED	MN	Cytochrome P450 2B6 (CYP2B6)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DES5XRU
DMY7PED	MN	Cytochrome P450 2C8 (CYP2C8)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DE5IED8
DMY7PED	MN	Cytochrome P450 2C9 (CYP2C9)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DE4LYSA
DMY7PED	MN	Cytochrome P450 3A4 (CYP3A4)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12621386

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEIBDNY
DMY7PED	MN	Cytochrome P450 3A5 (CYP3A5)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DERD86B
DMY7PED	MN	Cytochrome P450 3A7 (CYP3A7)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMY7PED	DI	DMY7PED
DMY7PED	DN	Cisapride
DMY7PED	MI	DEGTFWK
DMY7PED	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY7PED	MT	DME
DMY7PED	MA	Metabolism
DMY7PED	RN	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
DMY7PED	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153

DMUZPJ5	DI	DMUZPJ5
DMUZPJ5	DN	Cisatracurium
DMUZPJ5	MI	TTUPDWN
DMUZPJ5	MN	Cholinergic receptor unspecific (CHR)
DMUZPJ5	MT	DTT
DMUZPJ5	MA	Antagonist
DMUZPJ5	RN	Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
DMUZPJ5	RU	https://pubmed.ncbi.nlm.nih.gov/9429048

DMUZPJ5	DI	DMUZPJ5
DMUZPJ5	DN	Cisatracurium
DMUZPJ5	MI	TTF4E0J
DMUZPJ5	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMUZPJ5	MT	DTT
DMUZPJ5	MA	Antagonist
DMUZPJ5	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMUZPJ5	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTI7UX6
DMRHGI9	MN	Breast cancer resistance protein (ABCG2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
DMRHGI9	RU	https://doi.org/10.1016/j.bcp.2008.11.007

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT206GF
DMRHGI9	MN	Copper-transporting ATPase 2 (ATP7B)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/28636017

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEVDYN7
DMRHGI9	MN	Cytochrome P450 2E1 (CYP2E1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12675844

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE4ZHS1
DMRHGI9	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18852128

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEH7XYP
DMRHGI9	MN	Glutathione S-transferase alpha-4 (GSTA4)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150.
DMRHGI9	RU	https://pubmed.ncbi.nlm.nih.gov/31515474

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEYZEJA
DMRHGI9	MN	Glutathione S-transferase mu-1 (GSTM1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEK6079
DMRHGI9	MN	Glutathione S-transferase pi (GSTP1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE3PKUG
DMRHGI9	MN	Glutathione S-transferase theta-1 (GSTT1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTP8L4F
DMRHGI9	MN	High affinity copper uptake protein 1 (SLC31A1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/24122978

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	TTUTN1I
DMRHGI9	MN	Human Deoxyribonucleic acid (hDNA)
DMRHGI9	MT	DTT
DMRHGI9	MA	Modulator
DMRHGI9	RN	Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/8533159

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DE5ME8A
DMRHGI9	MN	Metallothionein-1A (MT1A)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEFKGT7
DMRHGI9	MN	Metallothionein-2A (MT2A)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTSYQGK
DMRHGI9	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/11687904

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTFI42L
DMRHGI9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18834541

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT582KR
DMRHGI9	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/12414644

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEA3U9Y
DMRHGI9	MN	Myeloperoxidase (MPO)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
DMRHGI9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19818462

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTT79CX
DMRHGI9	MN	Organic cation transporter 1 (SLC22A1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/16914559

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT9IDPW
DMRHGI9	MN	Organic cation transporter 2 (SLC22A2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/16314463

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DTUGYRD
DMRHGI9	MN	P-glycoprotein 1 (ABCB1)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DT8Q56F
DMRHGI9	MN	Probable low affinity copper uptake protein 2 (SLC31A2)
DMRHGI9	MT	DTP
DMRHGI9	MA	Substrate
DMRHGI9	RN	Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66.
DMRHGI9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20930109

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DENP5RY
DMRHGI9	MN	Quinone reductase 1 (NQO1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMRHGI9	RU	https://www.pharmgkb.org/pathway/PA150642262

DMRHGI9	DI	DMRHGI9
DMRHGI9	DN	Cisplatin
DMRHGI9	MI	DEUTDON
DMRHGI9	MN	Superoxide dismutase 1 (SOD1)
DMRHGI9	MT	DME
DMRHGI9	MA	Metabolism
DMRHGI9	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMRHGI9	RU	https://www.pharmgkb.org/pathway/PA150642262

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DECB0K3
DM2G9AE	MN	Cytochrome P450 2D6 (CYP2D6)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968657

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DEVDYN7
DM2G9AE	MN	Cytochrome P450 2E1 (CYP2E1)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DE4LYSA
DM2G9AE	MN	Cytochrome P450 3A4 (CYP3A4)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DEGTFWK
DM2G9AE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2G9AE	MT	DME
DM2G9AE	MA	Metabolism
DM2G9AE	RN	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
DM2G9AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10494454

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTSYQGK
DM2G9AE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010 Apr;30(2):116-25.
DM2G9AE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20520284

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTT79CX
DM2G9AE	MN	Organic cation transporter 1 (SLC22A1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DM2G9AE	RU	https://doi.org/10.2133/dmpk.23.243

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	DTUGYRD
DM2G9AE	MN	P-glycoprotein 1 (ABCB1)
DM2G9AE	MT	DTP
DM2G9AE	MA	Substrate
DM2G9AE	RN	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86.
DM2G9AE	RU	http://www.ncbi.nlm.nih.gov/pubmed/23515680

DM2G9AE	DI	DM2G9AE
DM2G9AE	DN	Citalopram
DM2G9AE	MI	TT3ROYC
DM2G9AE	MN	Serotonin transporter (SERT)
DM2G9AE	MT	DTT
DM2G9AE	MA	Modulator
DM2G9AE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2G9AE	RU	https://www.fda.gov/

DMI4XBM	DI	DMI4XBM
DMI4XBM	DN	Citicoline
DMI4XBM	MI	DEQJ8N3
DMI4XBM	MN	ASM-like phosphodiesterase 3a (SMPDL3A)
DMI4XBM	MT	DME
DMI4XBM	MA	Metabolism
DMI4XBM	RN	The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a--an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity. FEBS J. 2016 Mar;283(6):1107-23.
DMI4XBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26783088

DMI4XBM	DI	DMI4XBM
DMI4XBM	DN	Citicoline
DMI4XBM	MI	DEH6S1Q
DMI4XBM	MN	CDP-choline phosphohydrolase (ADPRM)
DMI4XBM	MT	DME
DMI4XBM	MA	Metabolism
DMI4XBM	RN	Molecular bases of catalysis and ADP-ribose preference of human Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase and conversion by mutagenesis to a preferential cyclic ADP-ribose phosphohydrolase. PLoS One. 2015 Feb 18;10(2):e0118680.
DMI4XBM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25692488

DMMEBWR	DI	DMMEBWR
DMMEBWR	DN	Citric acid, magnesium oxide, sodium picosulfate
DMMEBWR	MI	DEHYDG9
DMMEBWR	MN	Arylsulfate sulfotransferase (astA)
DMMEBWR	MT	DME
DMMEBWR	MA	Metabolism
DMMEBWR	RN	The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 1992 May;59(1):1-5.
DMMEBWR	RU	https://pubmed.ncbi.nlm.nih.gov/1507649

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	TTLP57V
DM3JDRP	MN	Adenosine deaminase (ADA)
DM3JDRP	MT	DTT
DM3JDRP	MA	Inhibitor
DM3JDRP	RN	Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57.
DM3JDRP	RU	https://pubmed.ncbi.nlm.nih.gov/15485311

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTI7UX6
DM3JDRP	MN	Breast cancer resistance protein (ABCG2)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
DM3JDRP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18765824

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DE9FGNK
DM3JDRP	MN	Deoxycytidine kinase (DCK)
DM3JDRP	MT	DME
DM3JDRP	MA	Metabolism
DM3JDRP	RN	Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186.
DM3JDRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30785074

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTZAWTH
DM3JDRP	MN	Equilibrative nucleoside transporter 3 (SLC29A3)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7.
DM3JDRP	RU	http://www.ncbi.nlm.nih.gov/pubmed/15701636

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTCSGPB
DM3JDRP	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3JDRP	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3JDRP	DI	DM3JDRP
DM3JDRP	DN	Cladribine
DM3JDRP	MI	DTT79CX
DM3JDRP	MN	Organic cation transporter 1 (SLC22A1)
DM3JDRP	MT	DTP
DM3JDRP	MA	Substrate
DM3JDRP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3JDRP	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	TTUWYEA
DM4M1SG	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4M1SG	MT	DTT
DM4M1SG	MA	Binder
DM4M1SG	RN	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
DM4M1SG	RU	https://pubmed.ncbi.nlm.nih.gov/11677599

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DE4LYSA
DM4M1SG	MN	Cytochrome P450 3A4 (CYP3A4)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85.
DM4M1SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24035278

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DEIBDNY
DM4M1SG	MN	Cytochrome P450 3A5 (CYP3A5)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Drug Interactions Flockhart Table
DM4M1SG	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DEGTFWK
DM4M1SG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4M1SG	MT	DME
DM4M1SG	MA	Metabolism
DM4M1SG	RN	Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
DM4M1SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15952098

DM4M1SG	DI	DM4M1SG
DM4M1SG	DN	Clarithromycin
DM4M1SG	MI	DTUGYRD
DM4M1SG	MN	P-glycoprotein 1 (ABCB1)
DM4M1SG	MT	DTP
DM4M1SG	MA	Substrate
DM4M1SG	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM4M1SG	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPGR1E	DI	DMPGR1E
DMPGR1E	DN	Clascoterone
DMPGR1E	MI	TTS64P2
DMPGR1E	MN	Androgen receptor (AR)
DMPGR1E	MT	DTT
DMPGR1E	MA	Antagonist
DMPGR1E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMPGR1E	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf

DM2FGRT	DI	DM2FGRT
DM2FGRT	DN	Clavulanate
DM2FGRT	MI	TTHI19T
DM2FGRT	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM2FGRT	MT	DTT
DM2FGRT	MA	Inhibitor
DM2FGRT	RN	A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
DM2FGRT	RU	https://pubmed.ncbi.nlm.nih.gov/19505232

DMBZWQL	DI	DMBZWQL
DMBZWQL	DN	Clemastine
DMBZWQL	MI	TTTIBOJ
DMBZWQL	MN	Histamine H1 receptor (H1R)
DMBZWQL	MT	DTT
DMBZWQL	MA	Antagonist
DMBZWQL	RN	Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91.
DMBZWQL	RU	https://pubmed.ncbi.nlm.nih.gov/18548114

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	TT2CJVK
DMCKYZ5	MN	Adrenergic receptor beta-2 (ADRB2)
DMCKYZ5	MT	DTT
DMCKYZ5	MA	Agonist
DMCKYZ5	RN	Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
DMCKYZ5	RU	https://pubmed.ncbi.nlm.nih.gov/19095863

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	DE6OQ3W
DMCKYZ5	MN	Cytochrome P450 1A1 (CYP1A1)
DMCKYZ5	MT	DME
DMCKYZ5	MA	Metabolism
DMCKYZ5	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DMCKYZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DMCKYZ5	DI	DMCKYZ5
DMCKYZ5	DN	Clenbuterol
DMCKYZ5	MI	DEJGDUW
DMCKYZ5	MN	Cytochrome P450 1A2 (CYP1A2)
DMCKYZ5	MT	DME
DMCKYZ5	MA	Metabolism
DMCKYZ5	RN	Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50.
DMCKYZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	TT5HONZ
DMW4M97	MN	Calcium channel unspecific (CaC)
DMW4M97	MT	DTT
DMW4M97	MA	Modulator
DMW4M97	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMW4M97	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DECB0K3
DMW4M97	MN	Cytochrome P450 2D6 (CYP2D6)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DEVDYN7
DMW4M97	MN	Cytochrome P450 2E1 (CYP2E1)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	DE4LYSA
DMW4M97	MN	Cytochrome P450 3A4 (CYP3A4)
DMW4M97	MT	DME
DMW4M97	MA	Metabolism
DMW4M97	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMW4M97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMW4M97	DI	DMW4M97
DMW4M97	DN	Clevidipine butyrate
DMW4M97	MI	TTXHYV6
DMW4M97	MN	Voltage-gated L-type calcium channel (L-CaC)
DMW4M97	MT	DTT
DMW4M97	MA	Inhibitor
DMW4M97	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMW4M97	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	TTOXS3C
DMUMQZ0	MN	Muscarinic acetylcholine receptor (CHRM)
DMUMQZ0	MT	DTT
DMUMQZ0	MA	Antagonist
DMUMQZ0	RN	Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
DMUMQZ0	RU	https://pubmed.ncbi.nlm.nih.gov/9454790

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	TTZ9SOR
DMUMQZ0	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMUMQZ0	MT	DTT
DMUMQZ0	MA	Antagonist
DMUMQZ0	RN	Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
DMUMQZ0	RU	https://pubmed.ncbi.nlm.nih.gov/19465630

DMUMQZ0	DI	DMUMQZ0
DMUMQZ0	DN	Clidinium
DMUMQZ0	MI	DTT79CX
DMUMQZ0	MN	Organic cation transporter 1 (SLC22A1)
DMUMQZ0	MT	DTP
DMUMQZ0	MA	Substrate
DMUMQZ0	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMUMQZ0	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	TTUWYEA
DM15HL8	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM15HL8	MT	DTT
DM15HL8	MA	Binder
DM15HL8	RN	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
DM15HL8	RU	https://pubmed.ncbi.nlm.nih.gov/11677599

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	DEMSNER
DM15HL8	MN	Beta-lactamase (blaB)
DM15HL8	MT	DME
DM15HL8	MA	Metabolism
DM15HL8	RN	Comparison of antimicrobial susceptibility, beta-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol. 1993 Oct;39(4):273-81.
DM15HL8	RU	https://pubmed.ncbi.nlm.nih.gov/8411088

DM15HL8	DI	DM15HL8
DM15HL8	DN	Clindamycin
DM15HL8	MI	DE4LYSA
DM15HL8	MN	Cytochrome P450 3A4 (CYP3A4)
DM15HL8	MT	DME
DM15HL8	MA	Metabolism
DM15HL8	RN	In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
DM15HL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814964

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEPKLMQ
DMW1OQ0	MN	Cytochrome P450 2B6 (CYP2B6)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEZMWRE
DMW1OQ0	MN	Cytochrome P450 2C18 (CYP2C18)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DE4LYSA
DMW1OQ0	MN	Cytochrome P450 3A4 (CYP3A4)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	TT1MPAY
DMW1OQ0	MN	GABA(A) receptor alpha-1 (GABRA1)
DMW1OQ0	MT	DTT
DMW1OQ0	MA	Antagonist
DMW1OQ0	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMW1OQ0	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	TTEX6LM
DMW1OQ0	MN	GABA(A) receptor gamma-3 (GABRG3)
DMW1OQ0	MT	DTT
DMW1OQ0	MA	Modulator
DMW1OQ0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW1OQ0	RU	https://www.fda.gov/

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DEGTFWK
DMW1OQ0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMW1OQ0	MT	DME
DMW1OQ0	MA	Metabolism
DMW1OQ0	RN	A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
DMW1OQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15533655

DMW1OQ0	DI	DMW1OQ0
DMW1OQ0	DN	Clobazam - Lundbeck
DMW1OQ0	MI	DTUGYRD
DMW1OQ0	MN	P-glycoprotein 1 (ABCB1)
DMW1OQ0	MT	DTP
DMW1OQ0	MA	Substrate
DMW1OQ0	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMW1OQ0	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMUXP52	DI	DMUXP52
DMUXP52	DN	Clobetasol
DMUXP52	MI	TT9V5JH
DMUXP52	MN	Phospholipase A2 (PLA2G1B)
DMUXP52	MT	DTT
DMUXP52	MA	Inhibitor
DMUXP52	RN	Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
DMUXP52	RU	https://pubmed.ncbi.nlm.nih.gov/6743552

DM9ZMQH	DI	DM9ZMQH
DM9ZMQH	DN	Clocortolone
DM9ZMQH	MI	TT9V5JH
DM9ZMQH	MN	Phospholipase A2 (PLA2G1B)
DM9ZMQH	MT	DTT
DM9ZMQH	MA	Inducer
DM9ZMQH	RN	Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
DM9ZMQH	RU	https://pubmed.ncbi.nlm.nih.gov/6986236

DM9Y6X7	DI	DM9Y6X7
DM9Y6X7	DN	Clodronate
DM9Y6X7	MI	TTU5A6Q
DM9Y6X7	MN	Adenine nucleotide translocator 1 (SLC25A4)
DM9Y6X7	MT	DTT
DM9Y6X7	MA	Inhibitor
DM9Y6X7	RN	Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.
DM9Y6X7	RU	https://pubmed.ncbi.nlm.nih.gov/11961144

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	TTJP4SM
DMCVJ86	MN	Bacterial Penicillin binding protein (Bact PBP)
DMCVJ86	MT	DTT
DMCVJ86	MA	Binder
DMCVJ86	RN	Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
DMCVJ86	RU	https://pubmed.ncbi.nlm.nih.gov/17852710

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTI7UX6
DMCVJ86	MN	Breast cancer resistance protein (ABCG2)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/18765824

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DT4YL5R
DMCVJ86	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DE9FGNK
DMCVJ86	MN	Deoxycytidine kinase (DCK)
DMCVJ86	MT	DME
DMCVJ86	MA	Metabolism
DMCVJ86	RN	FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
DMCVJ86	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021673s024lbl.pdf

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTXD1TQ
DMCVJ86	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	DTW78DQ
DMCVJ86	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMCVJ86	MT	DTP
DMCVJ86	MA	Substrate
DMCVJ86	RN	Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
DMCVJ86	RU	http://www.ncbi.nlm.nih.gov/pubmed/24692694

DMCVJ86	DI	DMCVJ86
DMCVJ86	DN	Clofarabine
DMCVJ86	MI	TTX09M4
DMCVJ86	MN	Ribonucleotide reductase (RIR)
DMCVJ86	MT	DTT
DMCVJ86	MA	Inhibitor
DMCVJ86	RN	Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
DMCVJ86	RU	https://pubmed.ncbi.nlm.nih.gov/17852710

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	TTS1W4A
DMEBOFW	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMEBOFW	MT	DTT
DMEBOFW	MA	Modulator
DMEBOFW	RN	The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
DMEBOFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/945233

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	DE4LYSA
DMEBOFW	MN	Cytochrome P450 3A4 (CYP3A4)
DMEBOFW	MT	DME
DMEBOFW	MA	Metabolism
DMEBOFW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMEBOFW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMEBOFW	DI	DMEBOFW
DMEBOFW	DN	Clofazimine
DMEBOFW	MI	DTUGYRD
DMEBOFW	MN	P-glycoprotein 1 (ABCB1)
DMEBOFW	MT	DTP
DMEBOFW	MA	Substrate
DMEBOFW	RN	Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
DMEBOFW	RU	http://www.ncbi.nlm.nih.gov/pubmed/26472768

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE6OQ3W
DMPC1J7	MN	Cytochrome P450 1A1 (CYP1A1)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEJGDUW
DMPC1J7	MN	Cytochrome P450 1A2 (CYP1A2)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEJVYAZ
DMPC1J7	MN	Cytochrome P450 2A6 (CYP2A6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DEPKLMQ
DMPC1J7	MN	Cytochrome P450 2B6 (CYP2B6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE5IED8
DMPC1J7	MN	Cytochrome P450 2C9 (CYP2C9)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DECB0K3
DMPC1J7	MN	Cytochrome P450 2D6 (CYP2D6)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE4LYSA
DMPC1J7	MN	Cytochrome P450 3A4 (CYP3A4)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE4ZHS1
DMPC1J7	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7720514

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	DE2XQGW
DMPC1J7	MN	Lauric acid omega-hydroxylase (CYP4A11)
DMPC1J7	MT	DME
DMPC1J7	MA	Metabolism
DMPC1J7	RN	Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41.
DMPC1J7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056802

DMPC1J7	DI	DMPC1J7
DMPC1J7	DN	Clofibrate
DMPC1J7	MI	TTOF3WZ
DMPC1J7	MN	Lipoprotein lipase (LPL)
DMPC1J7	MT	DTT
DMPC1J7	MA	Activator
DMPC1J7	RN	Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95.
DMPC1J7	RU	https://pubmed.ncbi.nlm.nih.gov/17495091

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	DECB0K3
DMKI7RB	MN	Cytochrome P450 2D6 (CYP2D6)
DMKI7RB	MT	DME
DMKI7RB	MA	Metabolism
DMKI7RB	RN	CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5.
DMKI7RB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445989

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	TTZAYWL
DMKI7RB	MN	Estrogen receptor (ESR)
DMKI7RB	MT	DTT
DMKI7RB	MA	Modulator
DMKI7RB	RN	The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34.
DMKI7RB	RU	https://pubmed.ncbi.nlm.nih.gov/17448265

DMKI7RB	DI	DMKI7RB
DMKI7RB	DN	Clomifene
DMKI7RB	MI	DTUGYRD
DMKI7RB	MN	P-glycoprotein 1 (ABCB1)
DMKI7RB	MT	DTP
DMKI7RB	MA	Substrate
DMKI7RB	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMKI7RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMS51VC	DI	DMS51VC
DMS51VC	DN	Clomiphene citrate
DMS51VC	MI	TTZAYWL
DMS51VC	MN	Estrogen receptor (ESR)
DMS51VC	MT	DTT
DMS51VC	MA	Modulator
DMS51VC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS51VC	RU	https://www.fda.gov/

DMS51VC	DI	DMS51VC
DMS51VC	DN	Clomiphene citrate
DMS51VC	MI	DTUGYRD
DMS51VC	MN	P-glycoprotein 1 (ABCB1)
DMS51VC	MT	DTP
DMS51VC	MA	Substrate
DMS51VC	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMS51VC	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMINRKW	DI	DMINRKW
DMINRKW	DN	Clomipramine
DMINRKW	MI	DTUGYRD
DMINRKW	MN	P-glycoprotein 1 (ABCB1)
DMINRKW	MT	DTP
DMINRKW	MA	Substrate
DMINRKW	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMINRKW	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMINRKW	DI	DMINRKW
DMINRKW	DN	Clomipramine
DMINRKW	MI	TT3ROYC
DMINRKW	MN	Serotonin transporter (SERT)
DMINRKW	MT	DTT
DMINRKW	MA	Inhibitor
DMINRKW	RN	Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13.
DMINRKW	RU	https://pubmed.ncbi.nlm.nih.gov/19366379

DM0ZRMQ	DI	DM0ZRMQ
DM0ZRMQ	DN	Clomocycline
DM0ZRMQ	MI	TTQ8KVI
DM0ZRMQ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM0ZRMQ	MT	DTT
DM0ZRMQ	MA	Binder
DM0ZRMQ	RN	Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
DM0ZRMQ	RU	https://pubmed.ncbi.nlm.nih.gov/18219717

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DE4LYSA
DMTO13J	MN	Cytochrome P450 3A4 (CYP3A4)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
DMTO13J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	TTNJYV2
DMTO13J	MN	Gamma-aminobutyric acid receptor (GAR)
DMTO13J	MT	DTT
DMTO13J	MA	Agonist
DMTO13J	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMTO13J	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DE0QLUZ
DMTO13J	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103.
DMTO13J	RU	https://pubmed.ncbi.nlm.nih.gov/19447228

DMTO13J	DI	DMTO13J
DMTO13J	DN	Clonazepam
DMTO13J	MI	DEZV4AP
DMTO13J	MN	RNA cytidine acetyltransferase (hALP)
DMTO13J	MT	DME
DMTO13J	MA	Metabolism
DMTO13J	RN	Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
DMTO13J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356010

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	TTQ8AFT
DM6RZ9Q	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM6RZ9Q	MT	DTT
DM6RZ9Q	MA	Agonist
DM6RZ9Q	RN	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
DM6RZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/11164065

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DEJGDUW
DM6RZ9Q	MN	Cytochrome P450 1A2 (CYP1A2)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DECB0K3
DM6RZ9Q	MN	Cytochrome P450 2D6 (CYP2D6)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DE4LYSA
DM6RZ9Q	MN	Cytochrome P450 3A4 (CYP3A4)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DEIBDNY
DM6RZ9Q	MN	Cytochrome P450 3A5 (CYP3A5)
DM6RZ9Q	MT	DME
DM6RZ9Q	MA	Metabolism
DM6RZ9Q	RN	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
DM6RZ9Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	TT7HC21
DM6RZ9Q	MN	Membrane copper amine oxidase (AOC3)
DM6RZ9Q	MT	DTT
DM6RZ9Q	MA	Inhibitor
DM6RZ9Q	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM6RZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DTT79CX
DM6RZ9Q	MN	Organic cation transporter 1 (SLC22A1)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DT9IDPW
DM6RZ9Q	MN	Organic cation transporter 2 (SLC22A2)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DT6201N
DM6RZ9Q	MN	Organic cation transporter 3 (SLC22A3)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM6RZ9Q	DI	DM6RZ9Q
DM6RZ9Q	DN	Clonidine
DM6RZ9Q	MI	DTUGYRD
DM6RZ9Q	MN	P-glycoprotein 1 (ABCB1)
DM6RZ9Q	MT	DTP
DM6RZ9Q	MA	Substrate
DM6RZ9Q	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM6RZ9Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEJGDUW
DMOL54H	MN	Cytochrome P450 1A2 (CYP1A2)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25559342

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEPKLMQ
DMOL54H	MN	Cytochrome P450 2B6 (CYP2B6)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20440227

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DE5IED8
DMOL54H	MN	Cytochrome P450 2C9 (CYP2C9)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DE4LYSA
DMOL54H	MN	Cytochrome P450 3A4 (CYP3A4)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEIBDNY
DMOL54H	MN	Cytochrome P450 3A5 (CYP3A5)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DEGTFWK
DMOL54H	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOL54H	MT	DME
DMOL54H	MA	Metabolism
DMOL54H	RN	Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
DMOL54H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28164572

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	TTZ1DT0
DMOL54H	MN	P2Y purinoceptor 12 (P2RY12)
DMOL54H	MT	DTT
DMOL54H	MA	Antagonist
DMOL54H	RN	P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
DMOL54H	RU	https://pubmed.ncbi.nlm.nih.gov/15199474

DMOL54H	DI	DMOL54H
DMOL54H	DN	Clopidogrel
DMOL54H	MI	DTUGYRD
DMOL54H	MN	P-glycoprotein 1 (ABCB1)
DMOL54H	MT	DTP
DMOL54H	MA	Substrate
DMOL54H	RN	Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501.
DMOL54H	RU	http://www.ncbi.nlm.nih.gov/pubmed/17112805

DMC3JST	DI	DMC3JST
DMC3JST	DN	Clorazepate
DMC3JST	MI	DE4LYSA
DMC3JST	MN	Cytochrome P450 3A4 (CYP3A4)
DMC3JST	MT	DME
DMC3JST	MA	Metabolism
DMC3JST	RN	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.
DMC3JST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11251565

DMC3JST	DI	DMC3JST
DMC3JST	DN	Clorazepate
DMC3JST	MI	TTPTXIN
DMC3JST	MN	Translocator protein (TSPO)
DMC3JST	MT	DTT
DMC3JST	MA	Modulator
DMC3JST	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC3JST	RU	https://www.fda.gov/

DMCEUJD	DI	DMCEUJD
DMCEUJD	DN	Clorgyline
DMCEUJD	MI	TT32XQJ
DMCEUJD	MN	Monoamine oxidase (MAO)
DMCEUJD	MT	DTT
DMCEUJD	MA	Inhibitor
DMCEUJD	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMCEUJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMCEUJD	DI	DMCEUJD
DMCEUJD	DN	Clorgyline
DMCEUJD	MI	TT3WG5C
DMCEUJD	MN	Monoamine oxidase type A (MAO-A)
DMCEUJD	MT	DTT
DMCEUJD	MA	Inhibitor
DMCEUJD	RN	Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
DMCEUJD	RU	https://pubmed.ncbi.nlm.nih.gov/19423952

DM6K1OA	DI	DM6K1OA
DM6K1OA	DN	Clothiapine
DM6K1OA	MI	DERD86B
DM6K1OA	MN	Cytochrome P450 3A7 (CYP3A7)
DM6K1OA	MT	DME
DM6K1OA	MA	Metabolism
DM6K1OA	RN	Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000 May;38(5):393-414.
DM6K1OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10843459

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEPKLMQ
DM59AZT	MN	Cytochrome P450 2B6 (CYP2B6)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEZMWRE
DM59AZT	MN	Cytochrome P450 2C18 (CYP2C18)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DE4LYSA
DM59AZT	MN	Cytochrome P450 3A4 (CYP3A4)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	DEGTFWK
DM59AZT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM59AZT	MT	DME
DM59AZT	MA	Metabolism
DM59AZT	RN	Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
DM59AZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545

DM59AZT	DI	DM59AZT
DM59AZT	DN	Clotiazepam
DM59AZT	MI	TTPTXIN
DM59AZT	MN	Translocator protein (TSPO)
DM59AZT	MT	DTT
DM59AZT	MA	Agonist
DM59AZT	RN	Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
DM59AZT	RU	https://pubmed.ncbi.nlm.nih.gov/2574062

DMMFCIH	DI	DMMFCIH
DMMFCIH	DN	Clotrimazole
DMMFCIH	MI	TT30C9G
DMMFCIH	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMMFCIH	MT	DTT
DMMFCIH	MA	Modulator
DMMFCIH	RN	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
DMMFCIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/3895959

DMMFCIH	DI	DMMFCIH
DMMFCIH	DN	Clotrimazole
DMMFCIH	MI	DE4LYSA
DMMFCIH	MN	Cytochrome P450 3A4 (CYP3A4)
DMMFCIH	MT	DME
DMMFCIH	MA	Metabolism
DMMFCIH	RN	Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9.
DMMFCIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21037909

DMUTL7O	DI	DMUTL7O
DMUTL7O	DN	Cloxacillin
DMUTL7O	MI	TTJP4SM
DMUTL7O	MN	Bacterial Penicillin binding protein (Bact PBP)
DMUTL7O	MT	DTT
DMUTL7O	MA	Binder
DMUTL7O	RN	Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303.
DMUTL7O	RU	https://pubmed.ncbi.nlm.nih.gov/17386727

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEJGDUW
DMFC71L	MN	Cytochrome P450 1A2 (CYP1A2)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEJVYAZ
DMFC71L	MN	Cytochrome P450 2A6 (CYP2A6)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23297297

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DES5XRU
DMFC71L	MN	Cytochrome P450 2C8 (CYP2C8)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DE5IED8
DMFC71L	MN	Cytochrome P450 2C9 (CYP2C9)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DECB0K3
DMFC71L	MN	Cytochrome P450 2D6 (CYP2D6)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DE4LYSA
DMFC71L	MN	Cytochrome P450 3A4 (CYP3A4)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	TTE0A2F
DMFC71L	MN	Dopamine D4 receptor (D4R)
DMFC71L	MT	DTT
DMFC71L	MA	Modulator
DMFC71L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFC71L	RU	https://www.fda.gov/

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DEGTFWK
DMFC71L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFC71L	MT	DME
DMFC71L	MA	Metabolism
DMFC71L	RN	Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
DMFC71L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890

DMFC71L	DI	DMFC71L
DMFC71L	DN	Clozapine
DMFC71L	MI	DTUGYRD
DMFC71L	MN	P-glycoprotein 1 (ABCB1)
DMFC71L	MT	DTP
DMFC71L	MA	Substrate
DMFC71L	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMFC71L	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMPC2QY	DI	DMPC2QY
DMPC2QY	DN	CNTO-1959
DMPC2QY	MI	TTC1GLB
DMPC2QY	MN	Interleukin-23 (IL23)
DMPC2QY	MT	DTT
DMPC2QY	RN	Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
DMPC2QY	RU	https://pubmed.ncbi.nlm.nih.gov/25807335

DM8HBJI	DI	DM8HBJI
DM8HBJI	DN	Coagulation Factor IX
DM8HBJI	MI	TTCIHJA
DM8HBJI	MN	Coagulation factor Xa (F10)
DM8HBJI	MT	DTT
DM8HBJI	MA	Activator
DM8HBJI	RN	Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
DM8HBJI	RU	https://pubmed.ncbi.nlm.nih.gov/16086639

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DECB0K3
DM6L4H2	MN	Cytochrome P450 2D6 (CYP2D6)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8.
DM6L4H2	RU	https://academic.oup.com/jac/article/71/7/1755/1750409

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	TTIJQ3O
DM6L4H2	MN	Cytochrome P450 3A (CYP3A)
DM6L4H2	MT	DTT
DM6L4H2	MA	Modulator
DM6L4H2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535).
DM6L4H2	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DE4LYSA
DM6L4H2	MN	Cytochrome P450 3A4 (CYP3A4)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017 Apr 24;31(7):917-952.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28060009

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DEIBDNY
DM6L4H2	MN	Cytochrome P450 3A5 (CYP3A5)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DM6L4H2	DI	DM6L4H2
DM6L4H2	DN	Cobicistat
DM6L4H2	MI	DERD86B
DM6L4H2	MN	Cytochrome P450 3A7 (CYP3A7)
DM6L4H2	MT	DME
DM6L4H2	MA	Metabolism
DM6L4H2	RN	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
DM6L4H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009

DMDKXTO	DI	DMDKXTO
DMDKXTO	DN	Cobicistat/darunavir
DMDKXTO	MI	TTIJQ3O
DMDKXTO	MN	Cytochrome P450 3A (CYP3A)
DMDKXTO	MT	DTT
DMDKXTO	MA	Modulator
DMDKXTO	RN	Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206.
DMDKXTO	RU	https://pubmed.ncbi.nlm.nih.gov/24343782

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DEIHSMD
DMSOX7I	MN	Butyrylcholine esterase (BCHE)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25;175(1-3):83-7.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18514640

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DECB0K3
DMSOX7I	MN	Cytochrome P450 2D6 (CYP2D6)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DE4LYSA
DMSOX7I	MN	Cytochrome P450 3A4 (CYP3A4)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DEIBDNY
DMSOX7I	MN	Cytochrome P450 3A5 (CYP3A5)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23.
DMSOX7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8617431

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	DERD86B
DMSOX7I	MN	Cytochrome P450 3A7 (CYP3A7)
DMSOX7I	MT	DME
DMSOX7I	MA	Metabolism
DMSOX7I	RN	Drug Interactions Flockhart Table
DMSOX7I	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TTVBI8W
DMSOX7I	MN	Dopamine transporter (DAT)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TTAWNKZ
DMSOX7I	MN	Norepinephrine transporter (NET)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMSOX7I	DI	DMSOX7I
DMSOX7I	DN	Cocaine
DMSOX7I	MI	TT3ROYC
DMSOX7I	MN	Serotonin transporter (SERT)
DMSOX7I	MT	DTT
DMSOX7I	MA	Inhibitor
DMSOX7I	RN	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
DMSOX7I	RU	https://pubmed.ncbi.nlm.nih.gov/19376154

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DECB0K3
DMJX6ZG	MN	Cytochrome P450 2D6 (CYP2D6)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DE4LYSA
DMJX6ZG	MN	Cytochrome P450 3A4 (CYP3A4)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DERD86B
DMJX6ZG	MN	Cytochrome P450 3A7 (CYP3A7)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	TT27RFC
DMJX6ZG	MN	Opioid receptor delta (OPRD1)
DMJX6ZG	MT	DTT
DMJX6ZG	MA	Agonist
DMJX6ZG	RN	Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
DMJX6ZG	RU	https://pubmed.ncbi.nlm.nih.gov/15942128

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DTT79CX
DMJX6ZG	MN	Organic cation transporter 1 (SLC22A1)
DMJX6ZG	MT	DTP
DMJX6ZG	MA	Substrate
DMJX6ZG	RN	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93.
DMJX6ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/25510240

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DEYGVN4
DMJX6ZG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920168

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DENUPDX
DMJX6ZG	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22092298

DMJX6ZG	DI	DMJX6ZG
DMJX6ZG	DN	Codeine
DMJX6ZG	MI	DEB3CV1
DMJX6ZG	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMJX6ZG	MT	DME
DMJX6ZG	MA	Metabolism
DMJX6ZG	RN	Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.
DMJX6ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9010622

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DE4LYSA
DM2POTE	MN	Cytochrome P450 3A4 (CYP3A4)
DM2POTE	MT	DME
DM2POTE	MA	Metabolism
DM2POTE	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DM2POTE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DTSYQGK
DM2POTE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2POTE	MT	DTP
DM2POTE	MA	Substrate
DM2POTE	RN	Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
DM2POTE	RU	http://molpharm.aspetjournals.org/content/52/3/344

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	DTUGYRD
DM2POTE	MN	P-glycoprotein 1 (ABCB1)
DM2POTE	MT	DTP
DM2POTE	MA	Substrate
DM2POTE	RN	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
DM2POTE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19427995

DM2POTE	DI	DM2POTE
DM2POTE	DN	Colchicine
DM2POTE	MI	TTML2WA
DM2POTE	MN	Tubulin (TUB)
DM2POTE	MT	DTT
DM2POTE	MA	Binder
DM2POTE	RN	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
DM2POTE	RU	https://pubmed.ncbi.nlm.nih.gov/19527023

DMJ01D8	DI	DMJ01D8
DMJ01D8	DN	Colforsin daropate hci
DMJ01D8	MI	TTULOB6
DMJ01D8	MN	Cathelicidin antimicrobial peptide (CAMP)
DMJ01D8	MT	DTT
DMJ01D8	MA	Modulator
DMJ01D8	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJ01D8	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMZ9BMU	DI	DMZ9BMU
DMZ9BMU	DN	Colistimethate
DMZ9BMU	MI	TT4ILYC
DMZ9BMU	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMZ9BMU	MT	DTT
DMZ9BMU	MA	Binder
DMZ9BMU	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMZ9BMU	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	TT4ILYC
DMMD9QE	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMMD9QE	MT	DTT
DMMD9QE	MA	Binder
DMMD9QE	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	DE2M583
DMMD9QE	MN	Endoglucanase Y (EGY)
DMMD9QE	MT	DME
DMMD9QE	MA	Metabolism
DMMD9QE	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMMD9QE	DI	DMMD9QE
DMMD9QE	DN	Colistin
DMMD9QE	MI	DE2AZTG
DMMD9QE	MN	Endoglucanase Y (EGY)
DMMD9QE	MT	DME
DMMD9QE	MA	Metabolism
DMMD9QE	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMMD9QE	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMFJ2OG	DI	DMFJ2OG
DMFJ2OG	DN	Collagenase
DMFJ2OG	MI	TTK982E
DMFJ2OG	MN	Collagen (CO)
DMFJ2OG	MT	DTT
DMFJ2OG	MA	Breaker
DMFJ2OG	RN	Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2.
DMFJ2OG	RU	https://pubmed.ncbi.nlm.nih.gov/17577383

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	DE4LYSA
DM1V329	MN	Cytochrome P450 3A4 (CYP3A4)
DM1V329	MT	DME
DM1V329	MA	Metabolism
DM1V329	RN	Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.
DM1V329	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17919259

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	TT4TFGN
DM1V329	MN	Vasopressin V1a receptor (V1AR)
DM1V329	MT	DTT
DM1V329	MA	Modulator
DM1V329	RN	Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
DM1V329	RU	https://pubmed.ncbi.nlm.nih.gov/11705818

DM1V329	DI	DM1V329
DM1V329	DN	Conivaptan
DM1V329	MI	TTK8R02
DM1V329	MN	Vasopressin V2 receptor (V2R)
DM1V329	MT	DTT
DM1V329	MA	Modulator
DM1V329	RN	Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
DM1V329	RU	https://pubmed.ncbi.nlm.nih.gov/11705818

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DE9RA0I
DMLT0E1	MN	Beta-glucuronidase (uidA)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
DMLT0E1	RU	https://pubmed.ncbi.nlm.nih.gov/29802368

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DEJGDUW
DMLT0E1	MN	Cytochrome P450 1A2 (CYP1A2)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006 Nov;46(11):1299-307.
DMLT0E1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050794

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	DE4LYSA
DMLT0E1	MN	Cytochrome P450 3A4 (CYP3A4)
DMLT0E1	MT	DME
DMLT0E1	MA	Metabolism
DMLT0E1	RN	Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115.
DMLT0E1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28798519

DMLT0E1	DI	DMLT0E1
DMLT0E1	DN	Conjugated estrogens
DMLT0E1	MI	TTOM3J0
DMLT0E1	MN	Estrogen receptor beta (ESR2)
DMLT0E1	MT	DTT
DMLT0E1	MA	Antagonist
DMLT0E1	RN	Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
DMLT0E1	RU	https://pubmed.ncbi.nlm.nih.gov/19036900

DMTPIZC	DI	DMTPIZC
DMTPIZC	DN	Conjugated estrogens a
DMTPIZC	MI	TTZAYWL
DMTPIZC	MN	Estrogen receptor (ESR)
DMTPIZC	MT	DTT
DMTPIZC	MA	Modulator
DMTPIZC	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMTPIZC	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMU7SF8	DI	DMU7SF8
DMU7SF8	DN	Conjugated estrogens b
DMU7SF8	MI	TTZAYWL
DMU7SF8	MN	Estrogen receptor (ESR)
DMU7SF8	MT	DTT
DMU7SF8	MA	Modulator
DMU7SF8	RN	Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13.
DMU7SF8	RU	https://pubmed.ncbi.nlm.nih.gov/326277

DMF29Q5	DI	DMF29Q5
DMF29Q5	DN	Connexyn
DMF29Q5	MI	TTWG9A4
DMF29Q5	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMF29Q5	MT	DTT
DMF29Q5	MA	Agonist
DMF29Q5	RN	alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
DMF29Q5	RU	https://pubmed.ncbi.nlm.nih.gov/19527774

DMF29Q5	DI	DMF29Q5
DMF29Q5	DN	Connexyn
DMF29Q5	MI	DE4LYSA
DMF29Q5	MN	Cytochrome P450 3A4 (CYP3A4)
DMF29Q5	MT	DME
DMF29Q5	MA	Metabolism
DMF29Q5	RN	Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.
DMF29Q5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9396389

DM26KR1	DI	DM26KR1
DM26KR1	DN	Copper dotatate Cu-64
DM26KR1	MI	TTZ6T9E
DM26KR1	MN	Somatostatin receptor type 2 (SSTR2)
DM26KR1	MT	DTT
DM26KR1	MA	Binder
DM26KR1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM26KR1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf

DMP9TWZ	DI	DMP9TWZ
DMP9TWZ	DN	Corticotropin
DMP9TWZ	MI	DE4LYSA
DMP9TWZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMP9TWZ	MT	DME
DMP9TWZ	MA	Metabolism
DMP9TWZ	RN	Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6.
DMP9TWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151

DMU5QZX	DI	DMU5QZX
DMU5QZX	DN	Cortisone
DMU5QZX	MI	DTUGYRD
DMU5QZX	MN	P-glycoprotein 1 (ABCB1)
DMU5QZX	MT	DTP
DMU5QZX	MA	Substrate
DMU5QZX	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DMU5QZX	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEZDRQO
DMG8K57	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEDH7FP
DMG8K57	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DE4LYSA
DMG8K57	MN	Cytochrome P450 3A4 (CYP3A4)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26924289

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEIBDNY
DMG8K57	MN	Cytochrome P450 3A5 (CYP3A5)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DERD86B
DMG8K57	MN	Cytochrome P450 3A7 (CYP3A7)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
DMG8K57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	DEEXSKI
DMG8K57	MN	Short-chain dehydrogenase/reductase retSDR4 (DHRS7)
DMG8K57	MT	DME
DMG8K57	MA	Metabolism
DMG8K57	RN	Human DHRS7, promising enzyme in metabolism of steroids and retinoids? J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):112-9.
DMG8K57	RU	https://pubmed.ncbi.nlm.nih.gov/26466768

DMG8K57	DI	DMG8K57
DMG8K57	DN	Cortisone acetate
DMG8K57	MI	TTP3UTW
DMG8K57	MN	Steroid hormone receptor ERR (ESRR)
DMG8K57	MT	DTT
DMG8K57	MA	Modulator
DMG8K57	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMG8K57	RU	https://www.fda.gov/

DMUIASK	DI	DMUIASK
DMUIASK	DN	Cosyntropin
DMUIASK	MI	TTPWFDX
DMUIASK	MN	Melanocortin receptor 2 (MC2R)
DMUIASK	MT	DTT
DMUIASK	MA	Antagonist
DMUIASK	RN	Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12.
DMUIASK	RU	https://pubmed.ncbi.nlm.nih.gov/19496914

DMCEZ1B	DI	DMCEZ1B
DMCEZ1B	DN	Cotinine
DMCEZ1B	MI	TTJSZTB
DMCEZ1B	MN	Nicotinic acetylcholine receptor (nAChR)
DMCEZ1B	MT	DTT
DMCEZ1B	MA	Modulator
DMCEZ1B	RN	Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
DMCEZ1B	RU	https://pubmed.ncbi.nlm.nih.gov/12008000

DMCEZ1B	DI	DMCEZ1B
DMCEZ1B	DN	Cotinine
DMCEZ1B	MI	DEI8NGH
DMCEZ1B	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DMCEZ1B	MT	DME
DMCEZ1B	MA	Metabolism
DMCEZ1B	RN	Human UDP-glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by UGT enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metab Dispos. 2016 Mar;44(3):378-88.
DMCEZ1B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26669329

DMJ7IQX	DI	DMJ7IQX
DMJ7IQX	DN	Crestor/TriLipix
DMJ7IQX	MI	TTPADOQ
DMJ7IQX	MN	HMG-CoA reductase (HMGCR)
DMJ7IQX	MT	DTT
DMJ7IQX	MA	Inhibitor
DMJ7IQX	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMJ7IQX	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMNVKU6	DI	DMNVKU6
DMNVKU6	DN	Crisaborole
DMNVKU6	MI	TTV5CGO
DMNVKU6	MN	Phosphodiesterase 4 (PDE4)
DMNVKU6	MT	DTT
DMNVKU6	MA	Modulator
DMNVKU6	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMNVKU6	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMAHOVJ	DI	DMAHOVJ
DMAHOVJ	DN	Crizanlizumab
DMAHOVJ	MI	TTE5VG0
DMAHOVJ	MN	P-selectin (SELP)
DMAHOVJ	MT	DTT
DMAHOVJ	MA	Inhibitor
DMAHOVJ	RN	Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
DMAHOVJ	RU	https://pubmed.ncbi.nlm.nih.gov/31933169

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTPMQSO
DM4F29C	MN	ALK tyrosine kinase receptor (ALK)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DE4LYSA
DM4F29C	MN	Cytochrome P450 3A4 (CYP3A4)
DM4F29C	MT	DME
DM4F29C	MA	Metabolism
DM4F29C	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DM4F29C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DEIBDNY
DM4F29C	MN	Cytochrome P450 3A5 (CYP3A5)
DM4F29C	MT	DME
DM4F29C	MA	Metabolism
DM4F29C	RN	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
DM4F29C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTKA5LP
DM4F29C	MN	HGF/Met signaling pathway (HGF/Met pathway)
DM4F29C	MT	DTT
DM4F29C	MA	Inhibitor
DM4F29C	RN	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
DM4F29C	RU	https://pubmed.ncbi.nlm.nih.gov/26345996

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DT3D8F0
DM4F29C	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DT9C1TS
DM4F29C	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	DTUGYRD
DM4F29C	MN	P-glycoprotein 1 (ABCB1)
DM4F29C	MT	DTP
DM4F29C	MA	Substrate
DM4F29C	RN	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
DM4F29C	RU	http://www.ncbi.nlm.nih.gov/pubmed/24037730

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTNDSF4
DM4F29C	MN	Proto-oncogene c-Met (MET)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4F29C	DI	DM4F29C
DM4F29C	DN	Crizotinib
DM4F29C	MI	TTSZ6Y3
DM4F29C	MN	Proto-oncogene c-Ros (ROS1)
DM4F29C	MT	DTT
DM4F29C	MA	Modulator
DM4F29C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM4F29C	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM4AMQZ	DI	DM4AMQZ
DM4AMQZ	DN	Crofelemer
DM4AMQZ	MI	TTOJI4S
DM4AMQZ	MN	Calcium-dependent chloride channel anoctamin (ANO)
DM4AMQZ	MT	DTT
DM4AMQZ	MA	Modulator
DM4AMQZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM4AMQZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM4AMQZ	DI	DM4AMQZ
DM4AMQZ	DN	Crofelemer
DM4AMQZ	MI	TTRLZHP
DM4AMQZ	MN	cAMP-dependent chloride channel (CFTR)
DM4AMQZ	MT	DTT
DM4AMQZ	MA	Modulator
DM4AMQZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM4AMQZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM74LZK	DI	DM74LZK
DM74LZK	DN	Cromoglicate
DM74LZK	MI	TT78R5H
DM74LZK	MN	Heat shock protein 90 alpha (HSP90A)
DM74LZK	MT	DTT
DM74LZK	MA	Inhibitor
DM74LZK	RN	Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
DM74LZK	RU	https://pubmed.ncbi.nlm.nih.gov/12803546

DMHCTAL	DI	DMHCTAL
DMHCTAL	DN	Cryptenamine Acetates
DMHCTAL	MI	TTH18TF
DMHCTAL	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHCTAL	MT	DTT
DMHCTAL	MA	Modulator
DMHCTAL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHCTAL	RU	https://www.fda.gov/

DMB8PF3	DI	DMB8PF3
DMB8PF3	DN	CT-102
DMB8PF3	MI	TTI2WET
DMB8PF3	MN	Platelet-derived growth factor receptor (PDGFR)
DMB8PF3	MT	DTT
DMB8PF3	MA	Activator
DMB8PF3	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMB8PF3	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMP0NFQ	DI	DMP0NFQ
DMP0NFQ	DN	Cupric Sulfate
DMP0NFQ	MI	DTP8L4F
DMP0NFQ	MN	High affinity copper uptake protein 1 (SLC31A1)
DMP0NFQ	MT	DTP
DMP0NFQ	MA	Substrate
DMP0NFQ	RN	Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
DMP0NFQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20631178

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	TTJP4SM
DMHSJB4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMHSJB4	MT	DTT
DMHSJB4	MA	Binder
DMHSJB4	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMHSJB4	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	DT9G7XN
DMHSJB4	MN	Peptide transporter 1 (SLC15A1)
DMHSJB4	MT	DTP
DMHSJB4	MA	Substrate
DMHSJB4	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHSJB4	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMHSJB4	DI	DMHSJB4
DMHSJB4	DN	Cyclacillin
DMHSJB4	MI	DT8QKNP
DMHSJB4	MN	Peptide transporter 2 (SLC15A2)
DMHSJB4	MT	DTP
DMHSJB4	MA	Substrate
DMHSJB4	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMHSJB4	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMO0R76	DI	DMO0R76
DMO0R76	DN	Cyclandelate
DMO0R76	MI	DE4LYSA
DMO0R76	MN	Cytochrome P450 3A4 (CYP3A4)
DMO0R76	MT	DME
DMO0R76	MA	Metabolism
DMO0R76	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMO0R76	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM9G7BS	DI	DM9G7BS
DM9G7BS	DN	Cyclizine
DM9G7BS	MI	TTTIBOJ
DM9G7BS	MN	Histamine H1 receptor (H1R)
DM9G7BS	MT	DTT
DM9G7BS	MA	Antagonist
DM9G7BS	RN	Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6.
DM9G7BS	RU	https://pubmed.ncbi.nlm.nih.gov/12657913

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	TTYSN63
DM1YBRM	MN	5-HT 2 receptor (5HT2R)
DM1YBRM	MT	DTT
DM1YBRM	MA	Antagonist
DM1YBRM	RN	Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
DM1YBRM	RU	https://pubmed.ncbi.nlm.nih.gov/19590258

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DEJGDUW
DM1YBRM	MN	Cytochrome P450 1A2 (CYP1A2)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DECB0K3
DM1YBRM	MN	Cytochrome P450 2D6 (CYP2D6)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DM1YBRM	DI	DM1YBRM
DM1YBRM	DN	Cyclobenzaprine
DM1YBRM	MI	DE4LYSA
DM1YBRM	MN	Cytochrome P450 3A4 (CYP3A4)
DM1YBRM	MT	DME
DM1YBRM	MA	Metabolism
DM1YBRM	RN	Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.
DM1YBRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577

DMT5RMB	DI	DMT5RMB
DMT5RMB	DN	Cyclofenil
DMT5RMB	MI	TTZAYWL
DMT5RMB	MN	Estrogen receptor (ESR)
DMT5RMB	MT	DTT
DMT5RMB	MA	Modulator
DMT5RMB	RN	Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511.
DMT5RMB	RU	https://pubmed.ncbi.nlm.nih.gov/16610793

DMA8LM5	DI	DMA8LM5
DMA8LM5	DN	Cyclopentolate
DMA8LM5	MI	TTH18TF
DMA8LM5	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMA8LM5	MT	DTT
DMA8LM5	MA	Antagonist
DMA8LM5	RN	High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76.
DMA8LM5	RU	https://pubmed.ncbi.nlm.nih.gov/19486927

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEJVYAZ
DM4O2Z7	MN	Cytochrome P450 2A6 (CYP2A6)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEPKLMQ
DM4O2Z7	MN	Cytochrome P450 2B6 (CYP2B6)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065440

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEZMWRE
DM4O2Z7	MN	Cytochrome P450 2C18 (CYP2C18)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DES5XRU
DM4O2Z7	MN	Cytochrome P450 2C8 (CYP2C8)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DE5IED8
DM4O2Z7	MN	Cytochrome P450 2C9 (CYP2C9)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DE4LYSA
DM4O2Z7	MN	Cytochrome P450 3A4 (CYP3A4)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29129847

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DERD86B
DM4O2Z7	MN	Cytochrome P450 3A7 (CYP3A7)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	TTUTN1I
DM4O2Z7	MN	Human Deoxyribonucleic acid (hDNA)
DM4O2Z7	MT	DTT
DM4O2Z7	MA	Modulator
DM4O2Z7	RN	O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/9714064

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DEGTFWK
DM4O2Z7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4O2Z7	MT	DME
DM4O2Z7	MA	Metabolism
DM4O2Z7	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DM4O2Z7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DM4O2Z7	DI	DM4O2Z7
DM4O2Z7	DN	Cyclophosphamide
DM4O2Z7	MI	DTCSGPB
DM4O2Z7	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4O2Z7	MT	DTP
DM4O2Z7	MA	Substrate
DM4O2Z7	RN	Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
DM4O2Z7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20405259

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TTLD29N
DMT1I52	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TT6TMZU
DMT1I52	MN	Mycobacterium Biosynthetic alanine racemase (MycB alr)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TTCS3P1
DMT1I52	MN	Mycobacterium D-alanine-D-alanine ligase A (MycB ddl)
DMT1I52	MT	DTT
DMT1I52	MA	Inhibitor
DMT1I52	RN	Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/15302885

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	TT9IK2Z
DMT1I52	MN	N-methyl-D-aspartate receptor (NMDAR)
DMT1I52	MT	DTT
DMT1I52	MA	Agonist
DMT1I52	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMT1I52	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	DT48WEM
DMT1I52	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMT1I52	MT	DTP
DMT1I52	MA	Substrate
DMT1I52	RN	Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13.
DMT1I52	RU	http://www.ncbi.nlm.nih.gov/pubmed/15754324

DMT1I52	DI	DMT1I52
DMT1I52	DN	Cycloserine
DMT1I52	MI	DTAOPTV
DMT1I52	MN	Proton-coupled amino acid transporter 2 (SLC36A2)
DMT1I52	MT	DTP
DMT1I52	MA	Substrate
DMT1I52	RN	Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2). Br J Pharmacol. 2005 Jan;144(1):28-41.
DMT1I52	RU	http://www.ncbi.nlm.nih.gov/pubmed/15644866

DMJ4AWC	DI	DMJ4AWC
DMJ4AWC	DN	Cyclothiazide
DMJ4AWC	MI	TTANPDJ
DMJ4AWC	MN	Carbonic anhydrase II (CA-II)
DMJ4AWC	MT	DTT
DMJ4AWC	MA	Inhibitor
DMJ4AWC	RN	Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
DMJ4AWC	RU	https://pubmed.ncbi.nlm.nih.gov/8914012

DM8C43Q	DI	DM8C43Q
DM8C43Q	DN	Cycrimine
DM8C43Q	MI	TTZ9SOR
DM8C43Q	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM8C43Q	MT	DTT
DM8C43Q	MA	Binder
DM8C43Q	RN	Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
DM8C43Q	RU	https://pubmed.ncbi.nlm.nih.gov/2573609

DMUY2OR	DI	DMUY2OR
DMUY2OR	DN	Cynarin
DMUY2OR	MI	TTLOQ79
DMUY2OR	MN	Taste receptor (TASR)
DMUY2OR	MT	DTT
DMUY2OR	MA	Modulator
DMUY2OR	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMUY2OR	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	TTTIBOJ
DM92AH3	MN	Histamine H1 receptor (H1R)
DM92AH3	MT	DTT
DM92AH3	MA	Antagonist
DM92AH3	RN	Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9.
DM92AH3	RU	https://pubmed.ncbi.nlm.nih.gov/18502826

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	DEYGVN4
DM92AH3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM92AH3	MT	DME
DM92AH3	MA	Metabolism
DM92AH3	RN	Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):486-93.
DM92AH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726413

DM92AH3	DI	DM92AH3
DM92AH3	DN	Cyproheptadine
DM92AH3	MI	DEF2WXN
DM92AH3	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM92AH3	MT	DME
DM92AH3	MA	Metabolism
DM92AH3	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DM92AH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DMQXLD2	DI	DMQXLD2
DMQXLD2	DN	Cyproterone
DMQXLD2	MI	TTS64P2
DMQXLD2	MN	Androgen receptor (AR)
DMQXLD2	MT	DTT
DMQXLD2	MA	Antagonist
DMQXLD2	RN	Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74.
DMQXLD2	RU	https://pubmed.ncbi.nlm.nih.gov/19463689

DMSYFM8	DI	DMSYFM8
DMSYFM8	DN	Cysteamine
DMSYFM8	MI	DEA3U9Y
DMSYFM8	MN	Myeloperoxidase (MPO)
DMSYFM8	MT	DME
DMSYFM8	MA	Metabolism
DMSYFM8	RN	Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
DMSYFM8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8381104

DMSYFM8	DI	DMSYFM8
DMSYFM8	DN	Cysteamine
DMSYFM8	MI	TTWF7UG
DMSYFM8	MN	Somatostatin (SST)
DMSYFM8	MT	DTT
DMSYFM8	MA	Binder
DMSYFM8	RN	Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61.
DMSYFM8	RU	https://pubmed.ncbi.nlm.nih.gov/19595735

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DT0EQPW
DMZD5QR	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEKEDRC
DMZD5QR	MN	Cytidine aminohydrolase (CDA)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEYILK4
DMZD5QR	MN	Cytidine deaminase (cdd)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMZD5QR	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DE4LYSA
DMZD5QR	MN	Cytochrome P450 3A4 (CYP3A4)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181153

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DEXL3P2
DMZD5QR	MN	Deoxycytidylate deaminase (DCTD)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DE3Z9HM
DMZD5QR	MN	Ecto-5'-nucleotidase (NT5E)
DMZD5QR	MT	DME
DMZD5QR	MA	Metabolism
DMZD5QR	RN	Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74.
DMZD5QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTXD1TQ
DMZD5QR	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTW78DQ
DMZD5QR	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27391351

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	TTIU7X1
DMZD5QR	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMZD5QR	MT	DTT
DMZD5QR	MA	Inhibitor
DMZD5QR	RN	Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
DMZD5QR	RU	https://pubmed.ncbi.nlm.nih.gov/19372559

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTT79CX
DMZD5QR	MN	Organic cation transporter 1 (SLC22A1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMZD5QR	RU	https://doi.org/10.1007/s11095-012-0935-x

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DT2EG60
DMZD5QR	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28209616

DMZD5QR	DI	DMZD5QR
DMZD5QR	DN	Cytarabine
DMZD5QR	MI	DTUGYRD
DMZD5QR	MN	P-glycoprotein 1 (ABCB1)
DMZD5QR	MT	DTP
DMZD5QR	MA	Substrate
DMZD5QR	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZD5QR	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMDI6R4	DI	DMDI6R4
DMDI6R4	DN	Dabigatran
DMDI6R4	MI	TT6L509
DMDI6R4	MN	Coagulation factor IIa (F2)
DMDI6R4	MT	DTT
DMDI6R4	MA	Inhibitor
DMDI6R4	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMDI6R4	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMDI6R4	DI	DMDI6R4
DMDI6R4	DN	Dabigatran
DMDI6R4	MI	DTUGYRD
DMDI6R4	MN	P-glycoprotein 1 (ABCB1)
DMDI6R4	MT	DTP
DMDI6R4	MA	Substrate
DMDI6R4	RN	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
DMDI6R4	RU	http://www.ncbi.nlm.nih.gov/pubmed/29091211

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DTI7UX6
DMX6OE3	MN	Breast cancer resistance protein (ABCG2)
DMX6OE3	MT	DTP
DMX6OE3	MA	Substrate
DMX6OE3	RN	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
DMX6OE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/23249624

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DES5XRU
DMX6OE3	MN	Cytochrome P450 2C8 (CYP2C8)
DMX6OE3	MT	DME
DMX6OE3	MA	Metabolism
DMX6OE3	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMX6OE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DE4LYSA
DMX6OE3	MN	Cytochrome P450 3A4 (CYP3A4)
DMX6OE3	MT	DME
DMX6OE3	MA	Metabolism
DMX6OE3	RN	Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228.
DMX6OE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29574693

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	DTUGYRD
DMX6OE3	MN	P-glycoprotein 1 (ABCB1)
DMX6OE3	MT	DTP
DMX6OE3	MA	Substrate
DMX6OE3	RN	Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64.
DMX6OE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/23249624

DMX6OE3	DI	DMX6OE3
DMX6OE3	DN	Dabrafenib
DMX6OE3	MI	TTWCGQT
DMX6OE3	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMX6OE3	MT	DTT
DMX6OE3	MA	Inhibitor
DMX6OE3	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2011).
DMX6OE3	RU	http://www.gsk.com/

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DE6OQ3W
DMNPZL4	MN	Cytochrome P450 1A1 (CYP1A1)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10473105

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DEJGDUW
DMNPZL4	MN	Cytochrome P450 1A2 (CYP1A2)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19954661

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	DEVDYN7
DMNPZL4	MN	Cytochrome P450 2E1 (CYP2E1)
DMNPZL4	MT	DME
DMNPZL4	MA	Metabolism
DMNPZL4	RN	Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
DMNPZL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11751525

DMNPZL4	DI	DMNPZL4
DMNPZL4	DN	Dacarbazine
DMNPZL4	MI	TTUTN1I
DMNPZL4	MN	Human Deoxyribonucleic acid (hDNA)
DMNPZL4	MT	DTT
DMNPZL4	MA	Breaker
DMNPZL4	RN	Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
DMNPZL4	RU	https://pubmed.ncbi.nlm.nih.gov/19561552

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DE4LYSA
DMSFK9V	MN	Cytochrome P450 3A4 (CYP3A4)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DEIBDNY
DMSFK9V	MN	Cytochrome P450 3A5 (CYP3A5)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DERD86B
DMSFK9V	MN	Cytochrome P450 3A7 (CYP3A7)
DMSFK9V	MT	DME
DMSFK9V	MA	Metabolism
DMSFK9V	RN	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
DMSFK9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	TTCJ2X8
DMSFK9V	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMSFK9V	MT	DTT
DMSFK9V	MA	Inhibitor
DMSFK9V	RN	2011 Pipeline of Bristol-Myers Squibb.
DMSFK9V	RU	http://www.bms.com/pages/default.aspx

DMSFK9V	DI	DMSFK9V
DMSFK9V	DN	Daclatasvir
DMSFK9V	MI	DTUGYRD
DMSFK9V	MN	P-glycoprotein 1 (ABCB1)
DMSFK9V	MT	DTP
DMSFK9V	MA	Substrate
DMSFK9V	RN	Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849.
DMSFK9V	RU	http://www.ncbi.nlm.nih.gov/pubmed/29091211

DM6OZQV	DI	DM6OZQV
DM6OZQV	DN	Daclizumab
DM6OZQV	MI	TTF89GD
DM6OZQV	MN	Interleukin-2 (IL2)
DM6OZQV	MT	DTT
DM6OZQV	MA	Modulator
DM6OZQV	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM6OZQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DE5IED8
DMOH8VY	MN	Cytochrome P450 2C9 (CYP2C9)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DECB0K3
DMOH8VY	MN	Cytochrome P450 2D6 (CYP2D6)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	DE4LYSA
DMOH8VY	MN	Cytochrome P450 3A4 (CYP3A4)
DMOH8VY	MT	DME
DMOH8VY	MA	Metabolism
DMOH8VY	RN	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466.
DMOH8VY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TTGKNB4
DMOH8VY	MN	Epidermal growth factor receptor (EGFR)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TT6EO5L
DMOH8VY	MN	Erbb2 tyrosine kinase receptor (HER2)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422

DMOH8VY	DI	DMOH8VY
DMOH8VY	DN	Dacomitinib
DMOH8VY	MI	TT0JESD
DMOH8VY	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMOH8VY	MT	DTT
DMOH8VY	MA	Antagonist
DMOH8VY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
DMOH8VY	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTI7UX6
DM2YGNW	MN	Breast cancer resistance protein (ABCG2)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72.
DM2YGNW	RU	https://doi.org/10.1124/mol.63.1.65

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	TTUTN1I
DM2YGNW	MN	Human Deoxyribonucleic acid (hDNA)
DM2YGNW	MT	DTT
DM2YGNW	MA	Breaker
DM2YGNW	RN	Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
DM2YGNW	RU	https://pubmed.ncbi.nlm.nih.gov/10576292

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTSYQGK
DM2YGNW	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342-7.
DM2YGNW	RU	http://cancerres.aacrjournals.org/content/55/22/5342

DM2YGNW	DI	DM2YGNW
DM2YGNW	DN	Dactinomycin
DM2YGNW	MI	DTUGYRD
DM2YGNW	MN	P-glycoprotein 1 (ABCB1)
DM2YGNW	MT	DTP
DM2YGNW	MA	Substrate
DM2YGNW	RN	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
DM2YGNW	RU	https://doi.org/10.1111/j.0013-9580.2005.31904.x

DMGMNH3	DI	DMGMNH3
DMGMNH3	DN	Dalbavancin
DMGMNH3	MI	TTXMY0J
DMGMNH3	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMGMNH3	MT	DTT
DMGMNH3	MA	Inhibitor
DMGMNH3	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMGMNH3	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMM0PDO	DI	DMM0PDO
DMM0PDO	DN	Dalfampridine
DMM0PDO	MI	DEVDYN7
DMM0PDO	MN	Cytochrome P450 2E1 (CYP2E1)
DMM0PDO	MT	DME
DMM0PDO	MA	Metabolism
DMM0PDO	RN	Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5.
DMM0PDO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22764324

DMM0PDO	DI	DMM0PDO
DMM0PDO	DN	Dalfampridine
DMM0PDO	MI	TT1VOHK
DMM0PDO	MN	Potassium channel unspecific (KC)
DMM0PDO	MT	DTT
DMM0PDO	MA	Modulator
DMM0PDO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMM0PDO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM4LTKV	DI	DM4LTKV
DM4LTKV	DN	Dalfopristin
DM4LTKV	MI	TTUWYEA
DM4LTKV	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4LTKV	MT	DTT
DM4LTKV	MA	Binder
DM4LTKV	RN	The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
DM4LTKV	RU	https://pubmed.ncbi.nlm.nih.gov/15991995

DM6CLBN	DI	DM6CLBN
DM6CLBN	DN	Danaparoid
DM6CLBN	MI	TTCIHJA
DM6CLBN	MN	Coagulation factor Xa (F10)
DM6CLBN	MT	DTT
DM6CLBN	MA	Inhibitor
DM6CLBN	RN	Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
DM6CLBN	RU	https://pubmed.ncbi.nlm.nih.gov/12402196

DML8KTN	DI	DML8KTN
DML8KTN	DN	Danazol
DML8KTN	MI	TTZAYWL
DML8KTN	MN	Estrogen receptor (ESR)
DML8KTN	MT	DTT
DML8KTN	MA	Antagonist
DML8KTN	RN	Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7.
DML8KTN	RU	https://pubmed.ncbi.nlm.nih.gov/2326286

DM1D8XY	DI	DM1D8XY
DM1D8XY	DN	Dantrolene
DM1D8XY	MI	DE4LYSA
DM1D8XY	MN	Cytochrome P450 3A4 (CYP3A4)
DM1D8XY	MT	DME
DM1D8XY	MA	Metabolism
DM1D8XY	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1D8XY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1D8XY	DI	DM1D8XY
DM1D8XY	DN	Dantrolene
DM1D8XY	MI	TT9YXM1
DM1D8XY	MN	Ryanodine receptor (RYR)
DM1D8XY	MT	DTT
DM1D8XY	MA	Modulator
DM1D8XY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1D8XY	RU	https://www.fda.gov/

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEJGDUW
DM28UJG	MN	Cytochrome P450 1A2 (CYP1A2)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEJVYAZ
DM28UJG	MN	Cytochrome P450 2A6 (CYP2A6)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE5IED8
DM28UJG	MN	Cytochrome P450 2C9 (CYP2C9)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DECB0K3
DM28UJG	MN	Cytochrome P450 2D6 (CYP2D6)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE4LYSA
DM28UJG	MN	Cytochrome P450 3A4 (CYP3A4)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	TTLWPVF
DM28UJG	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM28UJG	MT	DTT
DM28UJG	MA	Modulator
DM28UJG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM28UJG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DE85D2P
DM28UJG	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM28UJG	DI	DM28UJG
DM28UJG	DN	Dapagliflozin
DM28UJG	MI	DEB3CV1
DM28UJG	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM28UJG	MT	DME
DM28UJG	MA	Metabolism
DM28UJG	RN	Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27.
DM28UJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299

DM34TXO	DI	DM34TXO
DM34TXO	DN	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO	MI	TTDIGC1
DM34TXO	MN	Dipeptidyl peptidase 4 (DPP-4)
DM34TXO	MT	DTT
DM34TXO	MA	Modulator
DM34TXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM34TXO	RU	https://www.fda.gov/

DM34TXO	DI	DM34TXO
DM34TXO	DN	Dapagliflozin Propanediol; Saxagliptin Hydrochloride
DM34TXO	MI	TTLWPVF
DM34TXO	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM34TXO	MT	DTT
DM34TXO	MA	Modulator
DM34TXO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM34TXO	RU	https://www.fda.gov/

DMOXJKF	DI	DMOXJKF
DMOXJKF	DN	Dapiprazole
DMOXJKF	MI	TTEX248
DMOXJKF	MN	Dopamine D2 receptor (D2R)
DMOXJKF	MT	DTT
DMOXJKF	MA	Antagonist
DMOXJKF	RN	Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8.
DMOXJKF	RU	https://pubmed.ncbi.nlm.nih.gov/14578408

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEZMWRE
DM4LT8A	MN	Cytochrome P450 2C18 (CYP2C18)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DES5XRU
DM4LT8A	MN	Cytochrome P450 2C8 (CYP2C8)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE5IED8
DM4LT8A	MN	Cytochrome P450 2C9 (CYP2C9)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15130760

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEVDYN7
DM4LT8A	MN	Cytochrome P450 2E1 (CYP2E1)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE4LYSA
DM4LT8A	MN	Cytochrome P450 3A4 (CYP3A4)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8742227

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEIBDNY
DM4LT8A	MN	Cytochrome P450 3A5 (CYP3A5)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Drug Interactions Flockhart Table
DM4LT8A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DERD86B
DM4LT8A	MN	Cytochrome P450 3A7 (CYP3A7)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Drug Interactions Flockhart Table
DM4LT8A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEGTFWK
DM4LT8A	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DEA3U9Y
DM4LT8A	MN	Myeloperoxidase (MPO)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	TT6NHYC
DM4LT8A	MN	Pneumocystis carinii Dihydropteroate synthase (PC DHPS)
DM4LT8A	MT	DTT
DM4LT8A	MA	Modulator
DM4LT8A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4LT8A	RU	https://www.fda.gov/

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE073H6
DM4LT8A	MN	Prostaglandin G/H synthase 1 (COX-1)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4LT8A	DI	DM4LT8A
DM4LT8A	DN	Dapsone
DM4LT8A	MI	DE492CE
DM4LT8A	MN	Prostaglandin G/H synthase 2 (COX-2)
DM4LT8A	MT	DME
DM4LT8A	MA	Metabolism
DM4LT8A	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4LT8A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKDU16	DI	DMKDU16
DMKDU16	DN	Daptomycin
DMKDU16	MI	TT4ILYC
DMKDU16	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKDU16	MT	DTT
DMKDU16	MA	Binder
DMKDU16	RN	Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57.
DMKDU16	RU	https://pubmed.ncbi.nlm.nih.gov/15271353

DMFDQ3I	DI	DMFDQ3I
DMFDQ3I	DN	Daptomycin
DMFDQ3I	MI	DE49HWX
DMFDQ3I	MN	CDP-alcohol phosphatidyltransferase (pgsA)
DMFDQ3I	MT	DME
DMFDQ3I	MA	Metabolism
DMFDQ3I	RN	Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18.
DMFDQ3I	RU	https://pubmed.ncbi.nlm.nih.gov/30509945

DMFDQ3I	DI	DMFDQ3I
DMFDQ3I	DN	Daptomycin
DMFDQ3I	MI	DETMA7Z
DMFDQ3I	MN	CDP-alcohol phosphatidyltransferase (pgsA)
DMFDQ3I	MT	DME
DMFDQ3I	MA	Metabolism
DMFDQ3I	RN	Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18.
DMFDQ3I	RU	https://pubmed.ncbi.nlm.nih.gov/30509945

DMKCIUZ	DI	DMKCIUZ
DMKCIUZ	DN	Daratumumab
DMKCIUZ	MI	TTPURFN
DMKCIUZ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMKCIUZ	MT	DTT
DMKCIUZ	RN	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
DMKCIUZ	RU	https://pubmed.ncbi.nlm.nih.gov/26308596

DMMJTYW	DI	DMMJTYW
DMMJTYW	DN	Darbepoetin alfa
DMMJTYW	MI	TTAUX24
DMMJTYW	MN	Erythropoietin Receptor (EPOR)
DMMJTYW	MT	DTT
DMMJTYW	MA	Agonist
DMMJTYW	RN	A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
DMMJTYW	RU	https://pubmed.ncbi.nlm.nih.gov/10406949

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	DECB0K3
DMWXLYZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMWXLYZ	MT	DME
DMWXLYZ	MA	Metabolism
DMWXLYZ	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DMWXLYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	DE4LYSA
DMWXLYZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWXLYZ	MT	DME
DMWXLYZ	MA	Metabolism
DMWXLYZ	RN	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
DMWXLYZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	TTOXS3C
DMWXLYZ	MN	Muscarinic acetylcholine receptor (CHRM)
DMWXLYZ	MT	DTT
DMWXLYZ	MA	Antagonist
DMWXLYZ	RN	Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
DMWXLYZ	RU	https://pubmed.ncbi.nlm.nih.gov/9029489

DMWXLYZ	DI	DMWXLYZ
DMWXLYZ	DN	Darifenacin
DMWXLYZ	MI	TTQ13Z5
DMWXLYZ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMWXLYZ	MT	DTT
DMWXLYZ	MA	Antagonist
DMWXLYZ	RN	M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
DMWXLYZ	RU	https://pubmed.ncbi.nlm.nih.gov/19416629

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	TTS64P2
DMV7YFT	MN	Androgen receptor (AR)
DMV7YFT	MT	DTT
DMV7YFT	MA	Antagonist
DMV7YFT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMV7YFT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE4LYSA
DMV7YFT	MN	Cytochrome P450 3A4 (CYP3A4)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEYGVN4
DMV7YFT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEF2WXN
DMV7YFT	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE2GB8N
DMV7YFT	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DE85D2P
DMV7YFT	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMV7YFT	DI	DMV7YFT
DMV7YFT	DN	Darolutamide
DMV7YFT	MI	DEAZDL8
DMV7YFT	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMV7YFT	MT	DME
DMV7YFT	MA	Metabolism
DMV7YFT	RN	Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
DMV7YFT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DE4LYSA
DMN3GCH	MN	Cytochrome P450 3A4 (CYP3A4)
DMN3GCH	MT	DME
DMN3GCH	MA	Metabolism
DMN3GCH	RN	Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41.
DMN3GCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19492868

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	TT5FNQT
DMN3GCH	MN	Human immunodeficiency virus Protease (HIV PR)
DMN3GCH	MT	DTT
DMN3GCH	MA	Modulator
DMN3GCH	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMN3GCH	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DTE2B1D
DMN3GCH	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93.
DMN3GCH	RU	https://doi.org/10.1248/bpb.32.1588

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DT3D8F0
DMN3GCH	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMN3GCH	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMN3GCH	DI	DMN3GCH
DMN3GCH	DN	Darunavir
DMN3GCH	MI	DTUGYRD
DMN3GCH	MN	P-glycoprotein 1 (ABCB1)
DMN3GCH	MT	DTP
DMN3GCH	MA	Substrate
DMN3GCH	RN	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28.
DMN3GCH	RU	https://doi.org/10.1093/jac/dkq324

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DTI7UX6
DMJV2EK	MN	Breast cancer resistance protein (ABCG2)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEJGDUW
DMJV2EK	MN	Cytochrome P450 1A2 (CYP1A2)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DE4LYSA
DMJV2EK	MN	Cytochrome P450 3A4 (CYP3A4)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEIBDNY
DMJV2EK	MN	Cytochrome P450 3A5 (CYP3A5)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DEP76YL
DMJV2EK	MN	Dimethylaniline oxidase 3 (FMO3)
DMJV2EK	MT	DME
DMJV2EK	MA	Metabolism
DMJV2EK	RN	Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39.
DMJV2EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18556438

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TTS7G69
DMJV2EK	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT2B9KF
DMJV2EK	MN	Fyn tyrosine protein kinase (FYN)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT860QF
DMJV2EK	MN	LCK tyrosine protein kinase (LCK)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DT3D8F0
DMJV2EK	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DT9C1TS
DMJV2EK	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	DTUGYRD
DMJV2EK	MN	P-glycoprotein 1 (ABCB1)
DMJV2EK	MT	DTP
DMJV2EK	MA	Substrate
DMJV2EK	RN	Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80.
DMJV2EK	RU	http://www.ncbi.nlm.nih.gov/pubmed/20423956

DMJV2EK	DI	DMJV2EK
DMJV2EK	DN	Dasatinib
DMJV2EK	MI	TT6PKBN
DMJV2EK	MN	Proto-oncogene c-Src (SRC)
DMJV2EK	MT	DTT
DMJV2EK	MA	Inhibitor
DMJV2EK	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMJV2EK	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM74SVE	DI	DM74SVE
DM74SVE	DN	Dasiglucagon
DM74SVE	MI	TT9O6WS
DM74SVE	MN	Glucagon receptor (GCGR)
DM74SVE	MT	DTT
DM74SVE	MA	Agonist
DM74SVE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DM74SVE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TTVBI8W
DMLDQFV	MN	Dopamine transporter (DAT)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TTAWNKZ
DMLDQFV	MN	Norepinephrine transporter (NET)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TT3ROYC
DMLDQFV	MN	Serotonin transporter (SERT)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
DMLDQFV	RU	https://pubmed.ncbi.nlm.nih.gov/25948101

DMLDQFV	DI	DMLDQFV
DMLDQFV	DN	Dasotraline
DMLDQFV	MI	TT8G3Z7
DMLDQFV	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMLDQFV	MT	DTT
DMLDQFV	MA	Inhibitor
DMLDQFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLDQFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTI7UX6
DMQUSBT	MN	Breast cancer resistance protein (ABCG2)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/11437380

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE6OQ3W
DMQUSBT	MN	Cytochrome P450 1A1 (CYP1A1)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DEJGDUW
DMQUSBT	MN	Cytochrome P450 1A2 (CYP1A2)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE4LYSA
DMQUSBT	MN	Cytochrome P450 3A4 (CYP3A4)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	TTABD5E
DMQUSBT	MN	DNA replication (DNA repli)
DMQUSBT	MT	DTT
DMQUSBT	MA	Modulator
DMQUSBT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQUSBT	RU	https://www.fda.gov/

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	TTUTN1I
DMQUSBT	MN	Human Deoxyribonucleic acid (hDNA)
DMQUSBT	MT	DTT
DMQUSBT	MA	Intercalator
DMQUSBT	RN	31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
DMQUSBT	RU	https://pubmed.ncbi.nlm.nih.gov/2472832

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTSYQGK
DMQUSBT	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/10917554

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DT582KR
DMQUSBT	MN	Multidrug resistance-associated protein 6 (ABCC6)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/12414644

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE3N2FM
DMQUSBT	MN	NADPH-cytochrome P450 reductase (CPR)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10543722

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DE9JFMC
DMQUSBT	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18579125

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DEIVKZ8
DMQUSBT	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMQUSBT	MT	DME
DMQUSBT	MA	Metabolism
DMQUSBT	RN	Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
DMQUSBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20007405

DMQUSBT	DI	DMQUSBT
DMQUSBT	DN	Daunorubicin
DMQUSBT	MI	DTUGYRD
DMQUSBT	MN	P-glycoprotein 1 (ABCB1)
DMQUSBT	MT	DTP
DMQUSBT	MA	Substrate
DMQUSBT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMQUSBT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	TTT04VN
DMC50ME	MN	Adrenergic neuron (AD neuro)
DMC50ME	MT	DTT
DMC50ME	MA	Blocker
DMC50ME	RN	Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604.
DMC50ME	RU	https://pubmed.ncbi.nlm.nih.gov/5431666

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DE6OQ3W
DMC50ME	MN	Cytochrome P450 1A1 (CYP1A1)
DMC50ME	MT	DME
DMC50ME	MA	Metabolism
DMC50ME	RN	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32.
DMC50ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023534

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DECB0K3
DMC50ME	MN	Cytochrome P450 2D6 (CYP2D6)
DMC50ME	MT	DME
DMC50ME	MA	Metabolism
DMC50ME	RN	Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46.
DMC50ME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15726636

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DTT79CX
DMC50ME	MN	Organic cation transporter 1 (SLC22A1)
DMC50ME	MT	DTP
DMC50ME	MA	Substrate
DMC50ME	RN	The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34.
DMC50ME	RU	https://doi.org/10.1016/j.bcp.2012.01.032

DMC50ME	DI	DMC50ME
DMC50ME	DN	Debrisoquin
DMC50ME	MI	DTUGYRD
DMC50ME	MN	P-glycoprotein 1 (ABCB1)
DMC50ME	MT	DTP
DMC50ME	MA	Substrate
DMC50ME	RN	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.
DMC50ME	RU	http://www.ncbi.nlm.nih.gov/pubmed/10213372

DMSBRUW	DI	DMSBRUW
DMSBRUW	DN	Decamethonium
DMSBRUW	MI	TT54JVQ
DMSBRUW	MN	Neuronal acetylcholine receptor alpha-1 (CHRNA1)
DMSBRUW	MT	DTT
DMSBRUW	MA	Modulator
DMSBRUW	RN	Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6.
DMSBRUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/21102480

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	DEKEDRC
DMQL8XJ	MN	Cytidine aminohydrolase (CDA)
DMQL8XJ	MT	DME
DMQL8XJ	MA	Metabolism
DMQL8XJ	RN	Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. Sci Rep. 2019 Mar 14;9(1):4558.
DMQL8XJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30872721

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	DEYILK4
DMQL8XJ	MN	Cytidine deaminase (cdd)
DMQL8XJ	MT	DME
DMQL8XJ	MA	Metabolism
DMQL8XJ	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMQL8XJ	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMQL8XJ	DI	DMQL8XJ
DMQL8XJ	DN	Decitabine
DMQL8XJ	MI	TTUTN1I
DMQL8XJ	MN	Human Deoxyribonucleic acid (hDNA)
DMQL8XJ	MT	DTT
DMQL8XJ	MA	Modulator
DMQL8XJ	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMQL8XJ	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DM6ETS0	DI	DM6ETS0
DM6ETS0	DN	Deferasirox
DM6ETS0	MI	DEYGVN4
DM6ETS0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6ETS0	MT	DME
DM6ETS0	MA	Metabolism
DM6ETS0	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DM6ETS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DM6ETS0	DI	DM6ETS0
DM6ETS0	DN	Deferasirox
DM6ETS0	MI	DEF2WXN
DM6ETS0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM6ETS0	MT	DME
DM6ETS0	MA	Metabolism
DM6ETS0	RN	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
DM6ETS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059

DMS2M7O	DI	DMS2M7O
DMS2M7O	DN	Deferiprone
DMS2M7O	MI	TTUDR0C
DMS2M7O	MN	Iron (Fe)
DMS2M7O	MT	DTT
DMS2M7O	MA	Modulator
DMS2M7O	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMS2M7O	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMS2M7O	DI	DMS2M7O
DMS2M7O	DN	Deferiprone
DMS2M7O	MI	DESD26P
DMS2M7O	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMS2M7O	MT	DME
DMS2M7O	MA	Metabolism
DMS2M7O	RN	Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
DMS2M7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18971318

DMTUKZH	DI	DMTUKZH
DMTUKZH	DN	Deferoxamine mesylate
DMTUKZH	MI	TTUDR0C
DMTUKZH	MN	Iron (Fe)
DMTUKZH	MT	DTT
DMTUKZH	MA	Modulator
DMTUKZH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTUKZH	RU	https://www.fda.gov/

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	DE4LYSA
DMV0RNS	MN	Cytochrome P450 3A4 (CYP3A4)
DMV0RNS	MT	DME
DMV0RNS	MA	Metabolism
DMV0RNS	RN	Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos. 2019 Feb;47(2):135-144.
DMV0RNS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30442649

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	TTYRL6O
DMV0RNS	MN	Glucocorticoid receptor (NR3C1)
DMV0RNS	MT	DTT
DMV0RNS	MA	Modulator
DMV0RNS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMV0RNS	RU	https://www.fda.gov/

DMV0RNS	DI	DMV0RNS
DMV0RNS	DN	Deflazacort
DMV0RNS	MI	DTUGYRD
DMV0RNS	MN	P-glycoprotein 1 (ABCB1)
DMV0RNS	MT	DTP
DMV0RNS	MA	Substrate
DMV0RNS	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMV0RNS	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM3O8QY	DI	DM3O8QY
DM3O8QY	DN	Degarelix
DM3O8QY	MI	TT8R70G
DM3O8QY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM3O8QY	MT	DTT
DM3O8QY	MA	Inhibitor
DM3O8QY	RN	Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60.
DM3O8QY	RU	https://pubmed.ncbi.nlm.nih.gov/16033265

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTI7UX6
DM4Q80H	MN	Breast cancer resistance protein (ABCG2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DM4Q80H	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTSYQGK
DM4Q80H	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTFI42L
DM4Q80H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/15652233

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTQ3ZHF
DM4Q80H	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 Apr;27(5):447-86.
DM4Q80H	RU	https://doi.org/10.1016/j.ejps.2005.12.007

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTCSGPB
DM4Q80H	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTE2B1D
DM4Q80H	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36.
DM4Q80H	RU	https://doi.org/10.1038/nrd3028

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DT3D8F0
DM4Q80H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DT9C1TS
DM4Q80H	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM4Q80H	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM4Q80H	DI	DM4Q80H
DM4Q80H	DN	Dehydroepiandrosterone sulfate
DM4Q80H	MI	DTPFTEQ
DM4Q80H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4Q80H	MT	DTP
DM4Q80H	MA	Substrate
DM4Q80H	RN	Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372.
DM4Q80H	RU	https://doi.org/10.1371/journal.pone.0020372

DMVTU5Q	DI	DMVTU5Q
DMVTU5Q	DN	Delafloxacin Meglumine
DMVTU5Q	MI	TTZ82MR
DMVTU5Q	MN	Plasmodium DNA gyrase (Malaria gyrase)
DMVTU5Q	MT	DTT
DMVTU5Q	MA	Inhibitor
DMVTU5Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMVTU5Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMVTU5Q	DI	DMVTU5Q
DMVTU5Q	DN	Delafloxacin Meglumine
DMVTU5Q	MI	TTIXTO3
DMVTU5Q	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMVTU5Q	MT	DTT
DMVTU5Q	MA	Inhibitor
DMVTU5Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMVTU5Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMXE76K	DI	DMXE76K
DMXE76K	DN	Delamanid
DMXE76K	MI	TTXT4D5
DMXE76K	MN	Bacterial Cell membrane (Bact CM)
DMXE76K	MT	DTT
DMXE76K	MA	Inhibitor
DMXE76K	RN	Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483.
DMXE76K	RU	https://pubmed.ncbi.nlm.nih.gov/33243846

DMXE76K	DI	DMXE76K
DMXE76K	DN	Delamanid
DMXE76K	MI	DE4LYSA
DMXE76K	MN	Cytochrome P450 3A4 (CYP3A4)
DMXE76K	MT	DME
DMXE76K	MA	Metabolism
DMXE76K	RN	Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76.
DMXE76K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26055620

DM7EUK3	DI	DM7EUK3
DM7EUK3	DN	Delapril
DM7EUK3	MI	TTL69WB
DM7EUK3	MN	Angiotensin-converting enzyme (ACE)
DM7EUK3	MT	DTT
DM7EUK3	MA	Modulator
DM7EUK3	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM7EUK3	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DTI7UX6
DM3NF5G	MN	Breast cancer resistance protein (ABCG2)
DM3NF5G	MT	DTP
DM3NF5G	MA	Substrate
DM3NF5G	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM3NF5G	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DECB0K3
DM3NF5G	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DM3NF5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DE4LYSA
DM3NF5G	MN	Cytochrome P450 3A4 (CYP3A4)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26.
DM3NF5G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11327199

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DEIBDNY
DM3NF5G	MN	Cytochrome P450 3A5 (CYP3A5)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Drug Interactions Flockhart Table
DM3NF5G	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DERD86B
DM3NF5G	MN	Cytochrome P450 3A7 (CYP3A7)
DM3NF5G	MT	DME
DM3NF5G	MA	Metabolism
DM3NF5G	RN	Drug Interactions Flockhart Table
DM3NF5G	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	TT84ETX
DM3NF5G	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM3NF5G	MT	DTT
DM3NF5G	MA	Modulator
DM3NF5G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3NF5G	RU	https://www.fda.gov/

DM3NF5G	DI	DM3NF5G
DM3NF5G	DN	Delavirdine
DM3NF5G	MI	DTUGYRD
DM3NF5G	MN	P-glycoprotein 1 (ABCB1)
DM3NF5G	MT	DTP
DM3NF5G	MA	Substrate
DM3NF5G	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DM3NF5G	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DMAYEU1	DI	DMAYEU1
DMAYEU1	DN	Demecarium bromide
DMAYEU1	MI	TT1RS9F
DMAYEU1	MN	Acetylcholinesterase (AChE)
DMAYEU1	MT	DTT
DMAYEU1	MA	Inhibitor
DMAYEU1	RN	The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
DMAYEU1	RU	https://pubmed.ncbi.nlm.nih.gov/12641839

DMZEPFJ	DI	DMZEPFJ
DMZEPFJ	DN	Demeclocycline
DMZEPFJ	MI	TTQ8KVI
DMZEPFJ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMZEPFJ	MT	DTT
DMZEPFJ	MA	Binder
DMZEPFJ	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMZEPFJ	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMCZQGK	DI	DMCZQGK
DMCZQGK	DN	Demecolcine
DMCZQGK	MI	TT1EDJZ
DMCZQGK	MN	Microtubule-associated protein (MAP)
DMCZQGK	MT	DTT
DMCZQGK	MA	Modulator
DMCZQGK	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMCZQGK	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMMHR1U	DI	DMMHR1U
DMMHR1U	DN	Denileukin diftitox
DMMHR1U	MI	TTAJU0S
DMMHR1U	MN	Interleukin 2 receptor (IL2R)
DMMHR1U	MT	DTT
DMMHR1U	MA	Binder
DMMHR1U	RN	Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69.
DMMHR1U	RU	https://pubmed.ncbi.nlm.nih.gov/18684057

DM8C3GN	DI	DM8C3GN
DM8C3GN	DN	Denopamine
DM8C3GN	MI	TTEX248
DM8C3GN	MN	Dopamine D2 receptor (D2R)
DM8C3GN	MT	DTT
DM8C3GN	MA	Modulator
DM8C3GN	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM8C3GN	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM8C3GN	DI	DM8C3GN
DM8C3GN	DN	Denopamine
DM8C3GN	MI	DEAZDL8
DM8C3GN	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DM8C3GN	MT	DME
DM8C3GN	MA	Metabolism
DM8C3GN	RN	Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12.
DM8C3GN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15608137

DMNI0KO	DI	DMNI0KO
DMNI0KO	DN	Denosumab
DMNI0KO	MI	TT9E8HR
DMNI0KO	MN	Osteoclast differentiation factor (ODF)
DMNI0KO	MT	DTT
DMNI0KO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMNI0KO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM3GYAL	DI	DM3GYAL
DM3GYAL	DN	Deoxycholic acid
DM3GYAL	MI	DT7JELC
DM3GYAL	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM3GYAL	MT	DTP
DM3GYAL	MA	Substrate
DM3GYAL	RN	Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23.
DM3GYAL	RU	http://www.ncbi.nlm.nih.gov/pubmed/29055774

DM3GYAL	DI	DM3GYAL
DM3GYAL	DN	Deoxycholic acid
DM3GYAL	MI	DTI7UX6
DM3GYAL	MN	Breast cancer resistance protein (ABCG2)
DM3GYAL	MT	DTP
DM3GYAL	MA	Substrate
DM3GYAL	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM3GYAL	RU	https://doi.org/10.1042/BJ20040791

DMYE5LJ	DI	DMYE5LJ
DMYE5LJ	DN	DEOXYCYTIDINE
DMYE5LJ	MI	TTP3QRF
DMYE5LJ	MN	Thymidine kinase 1 (TK1)
DMYE5LJ	MT	DTT
DMYE5LJ	MA	Inhibitor
DMYE5LJ	RN	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
DMYE5LJ	RU	https://pubmed.ncbi.nlm.nih.gov/7097717

DMRH7CV	DI	DMRH7CV
DMRH7CV	DN	Deserpidine
DMRH7CV	MI	TTL69WB
DMRH7CV	MN	Angiotensin-converting enzyme (ACE)
DMRH7CV	MT	DTT
DMRH7CV	MA	Inhibitor
DMRH7CV	RN	Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906.
DMRH7CV	RU	https://pubmed.ncbi.nlm.nih.gov/12651915

DM2TO9R	DI	DM2TO9R
DM2TO9R	DN	Desflurane
DM2TO9R	MI	TTAN6JD
DM2TO9R	MN	Glutamate receptor AMPA (GRIA)
DM2TO9R	MT	DTT
DM2TO9R	MA	Antagonist
DM2TO9R	RN	Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91.
DM2TO9R	RU	https://pubmed.ncbi.nlm.nih.gov/11323344

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEJGDUW
DMT2FDC	MN	Cytochrome P450 1A2 (CYP1A2)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEPKLMQ
DMT2FDC	MN	Cytochrome P450 2B6 (CYP2B6)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Drugs that may have potential CYP2B6 interactions.
DMT2FDC	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DECB0K3
DMT2FDC	MN	Cytochrome P450 2D6 (CYP2D6)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8880055

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DE4LYSA
DMT2FDC	MN	Cytochrome P450 3A4 (CYP3A4)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DEGTFWK
DMT2FDC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT2FDC	MT	DME
DMT2FDC	MA	Metabolism
DMT2FDC	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DMT2FDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	TTAWNKZ
DMT2FDC	MN	Norepinephrine transporter (NET)
DMT2FDC	MT	DTT
DMT2FDC	MA	Inhibitor
DMT2FDC	RN	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
DMT2FDC	RU	https://pubmed.ncbi.nlm.nih.gov/19517098

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DTT79CX
DMT2FDC	MN	Organic cation transporter 1 (SLC22A1)
DMT2FDC	MT	DTP
DMT2FDC	MA	Substrate
DMT2FDC	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMT2FDC	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMT2FDC	DI	DMT2FDC
DMT2FDC	DN	Desipramine
DMT2FDC	MI	DTUGYRD
DMT2FDC	MN	P-glycoprotein 1 (ABCB1)
DMT2FDC	MT	DTP
DMT2FDC	MA	Substrate
DMT2FDC	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMT2FDC	RU	https://doi.org/10.1007/s00210-008-0345-0

DM2BTFN	DI	DM2BTFN
DM2BTFN	DN	Desirudin Recombinant
DM2BTFN	MI	TT6L509
DM2BTFN	MN	Coagulation factor IIa (F2)
DM2BTFN	MT	DTT
DM2BTFN	MA	Modulator
DM2BTFN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2BTFN	RU	https://www.fda.gov/

DMB3ZSK	DI	DMB3ZSK
DMB3ZSK	DN	Deslanoside
DMB3ZSK	MI	TTWK8D0
DMB3ZSK	MN	Sodium pump subunit alpha-1 (ATP1A1)
DMB3ZSK	MT	DTT
DMB3ZSK	MA	Binder
DMB3ZSK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMB3ZSK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DES5XRU
DM56YN7	MN	Cytochrome P450 2C8 (CYP2C8)
DM56YN7	MT	DME
DM56YN7	MA	Metabolism
DM56YN7	RN	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
DM56YN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	TTTIBOJ
DM56YN7	MN	Histamine H1 receptor (H1R)
DM56YN7	MT	DTT
DM56YN7	MA	Antagonist
DM56YN7	RN	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. 
DM56YN7	RU	https://pubmed.ncbi.nlm.nih.gov/19236123

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DTUGYRD
DM56YN7	MN	P-glycoprotein 1 (ABCB1)
DM56YN7	MT	DTP
DM56YN7	MA	Substrate
DM56YN7	RN	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
DM56YN7	RU	http://www.ncbi.nlm.nih.gov/pubmed/12584158

DM56YN7	DI	DM56YN7
DM56YN7	DN	Desloratadine
DM56YN7	MI	DEI8NGH
DM56YN7	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DM56YN7	MT	DME
DM56YN7	MA	Metabolism
DM56YN7	RN	Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302.
DM56YN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTSCIUP
DMS3GVE	MN	Oxytocin receptor (OTR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTYCILE
DMS3GVE	MN	Vasopressin receptor (VR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Modulator
DMS3GVE	RN	Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/10594321

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TT4TFGN
DMS3GVE	MN	Vasopressin V1a receptor (V1AR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTL9MHW
DMS3GVE	MN	Vasopressin V1b receptor (V1BR)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DMS3GVE	DI	DMS3GVE
DMS3GVE	DN	Desmopressin
DMS3GVE	MI	TTK8R02
DMS3GVE	MN	Vasopressin V2 receptor (V2R)
DMS3GVE	MT	DTT
DMS3GVE	MA	Agonist
DMS3GVE	RN	Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
DMS3GVE	RU	https://pubmed.ncbi.nlm.nih.gov/15084136

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DE5IED8
DM27U4Y	MN	Cytochrome P450 2C9 (CYP2C9)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DE4LYSA
DM27U4Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	DEGTFWK
DM27U4Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM27U4Y	MT	DME
DM27U4Y	MA	Metabolism
DM27U4Y	RN	The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
DM27U4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282

DM27U4Y	DI	DM27U4Y
DM27U4Y	DN	Desogestrel
DM27U4Y	MI	TTUV8G9
DM27U4Y	MN	Progesterone receptor (PGR)
DM27U4Y	MT	DTT
DM27U4Y	MA	Modulator
DM27U4Y	RN	Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
DM27U4Y	RU	https://pubmed.ncbi.nlm.nih.gov/11108884

DMTP2NJ	DI	DMTP2NJ
DMTP2NJ	DN	Desonide
DMTP2NJ	MI	DE4LYSA
DMTP2NJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMTP2NJ	MT	DME
DMTP2NJ	MA	Metabolism
DMTP2NJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTP2NJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTP2NJ	DI	DMTP2NJ
DMTP2NJ	DN	Desonide
DMTP2NJ	MI	TTP3UTW
DMTP2NJ	MN	Steroid hormone receptor ERR (ESRR)
DMTP2NJ	MT	DTT
DMTP2NJ	MA	Modulator
DMTP2NJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTP2NJ	RU	https://www.fda.gov/

DM4PXF6	DI	DM4PXF6
DM4PXF6	DN	Desoximetasone
DM4PXF6	MI	TTP3UTW
DM4PXF6	MN	Steroid hormone receptor ERR (ESRR)
DM4PXF6	MT	DTT
DM4PXF6	MA	Modulator
DM4PXF6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PXF6	RU	https://www.fda.gov/

DMS0AFE	DI	DMS0AFE
DMS0AFE	DN	Desoxycorticosterone acetate
DMS0AFE	MI	DE4LYSA
DMS0AFE	MN	Cytochrome P450 3A4 (CYP3A4)
DMS0AFE	MT	DME
DMS0AFE	MA	Metabolism
DMS0AFE	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DMS0AFE	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DMS0AFE	DI	DMS0AFE
DMS0AFE	DN	Desoxycorticosterone acetate
DMS0AFE	MI	TT26PHO
DMS0AFE	MN	Mineralocorticoid receptor  (MR)
DMS0AFE	MT	DTT
DMS0AFE	MA	Modulator
DMS0AFE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS0AFE	RU	https://www.fda.gov/

DMSA4B3	DI	DMSA4B3
DMSA4B3	DN	Desoxycorticosterone pivalate
DMSA4B3	MI	DE4LYSA
DMSA4B3	MN	Cytochrome P450 3A4 (CYP3A4)
DMSA4B3	MT	DME
DMSA4B3	MA	Metabolism
DMSA4B3	RN	Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207.
DMSA4B3	RU	https://www.sciencedirect.com/science/article/pii/S0079612308810114

DMSA4B3	DI	DMSA4B3
DMSA4B3	DN	Desoxycorticosterone pivalate
DMSA4B3	MI	TT26PHO
DMSA4B3	MN	Mineralocorticoid receptor  (MR)
DMSA4B3	MT	DTT
DMSA4B3	MA	Binder
DMSA4B3	RN	Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
DMSA4B3	RU	https://pubmed.ncbi.nlm.nih.gov/6227474

DMEZFXR	DI	DMEZFXR
DMEZFXR	DN	Desoxyribonuclease
DMEZFXR	MI	TT3C1VN
DMEZFXR	MN	Enzyme unspecific (Enz)
DMEZFXR	MT	DTT
DMEZFXR	MA	Modulator
DMEZFXR	RN	Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52.
DMEZFXR	RU	https://pubmed.ncbi.nlm.nih.gov/486431

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	DECB0K3
DMJE6KO	MN	Cytochrome P450 2D6 (CYP2D6)
DMJE6KO	MT	DME
DMJE6KO	MA	Metabolism
DMJE6KO	RN	Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3.
DMJE6KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10233212

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	DE4LYSA
DMJE6KO	MN	Cytochrome P450 3A4 (CYP3A4)
DMJE6KO	MT	DME
DMJE6KO	MA	Metabolism
DMJE6KO	RN	Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8.
DMJE6KO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22098230

DMJE6KO	DI	DMJE6KO
DMJE6KO	DN	Desvenalfaxine succinate
DMJE6KO	MI	TTAWNKZ
DMJE6KO	MN	Norepinephrine transporter (NET)
DMJE6KO	MT	DTT
DMJE6KO	MA	Inhibitor
DMJE6KO	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMJE6KO	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMHD4PE	DI	DMHD4PE
DMHD4PE	DN	Desvenlafaxine
DMHD4PE	MI	TT3ROYC
DMHD4PE	MN	Serotonin transporter (SERT)
DMHD4PE	MT	DTT
DMHD4PE	MA	Modulator
DMHD4PE	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMHD4PE	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	DEJGDUW
DMUPFLI	MN	Cytochrome P450 1A2 (CYP1A2)
DMUPFLI	MT	DME
DMUPFLI	MA	Metabolism
DMUPFLI	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DMUPFLI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	DECB0K3
DMUPFLI	MN	Cytochrome P450 2D6 (CYP2D6)
DMUPFLI	MT	DME
DMUPFLI	MA	Metabolism
DMUPFLI	RN	FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
DMUPFLI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf

DMUPFLI	DI	DMUPFLI
DMUPFLI	DN	Deutetrabenazine
DMUPFLI	MI	TTNZRI3
DMUPFLI	MN	Synaptic vesicle amine transporter (SLC18A2)
DMUPFLI	MT	DTT
DMUPFLI	MA	Modulator
DMUPFLI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUPFLI	RU	https://www.fda.gov/

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DETHCPD
DMMWZET	MN	Carboxylesterase 2 (CES2)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21657966

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DEDH7FP
DMMWZET	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DE4LYSA
DMMWZET	MN	Cytochrome P450 3A4 (CYP3A4)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DEIBDNY
DMMWZET	MN	Cytochrome P450 3A5 (CYP3A5)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12538830

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DERD86B
DMMWZET	MN	Cytochrome P450 3A7 (CYP3A7)
DMMWZET	MT	DME
DMMWZET	MA	Metabolism
DMMWZET	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DMMWZET	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	TTYRL6O
DMMWZET	MN	Glucocorticoid receptor (NR3C1)
DMMWZET	MT	DTT
DMMWZET	MA	Agonist
DMMWZET	RN	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
DMMWZET	RU	https://pubmed.ncbi.nlm.nih.gov/19375647

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DT9G7XN
DMMWZET	MN	Peptide transporter 1 (SLC15A1)
DMMWZET	MT	DTP
DMMWZET	MA	Substrate
DMMWZET	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMMWZET	RU	https://doi.org/10.1007/BF02980227

DMMWZET	DI	DMMWZET
DMMWZET	DN	Dexamethasone
DMMWZET	MI	DTUGYRD
DMMWZET	MN	P-glycoprotein 1 (ABCB1)
DMMWZET	MT	DTP
DMMWZET	MA	Substrate
DMMWZET	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMMWZET	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DMIG8DW	DI	DMIG8DW
DMIG8DW	DN	Dexamethasone sodium phosphate
DMIG8DW	MI	DE4LYSA
DMIG8DW	MN	Cytochrome P450 3A4 (CYP3A4)
DMIG8DW	MT	DME
DMIG8DW	MA	Metabolism
DMIG8DW	RN	Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
DMIG8DW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917

DMIG8DW	DI	DMIG8DW
DMIG8DW	DN	Dexamethasone sodium phosphate
DMIG8DW	MI	TTYRL6O
DMIG8DW	MN	Glucocorticoid receptor (NR3C1)
DMIG8DW	MT	DTT
DMIG8DW	MA	Agonist
DMIG8DW	RN	Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505.
DMIG8DW	RU	https://pubmed.ncbi.nlm.nih.gov/23936221

DMKVWGE	DI	DMKVWGE
DMKVWGE	DN	Dexbrompheniramine
DMKVWGE	MI	TTTIBOJ
DMKVWGE	MN	Histamine H1 receptor (H1R)
DMKVWGE	MT	DTT
DMKVWGE	MA	Antagonist
DMKVWGE	RN	H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13.
DMKVWGE	RU	https://pubmed.ncbi.nlm.nih.gov/9811372

DMA8DPN	DI	DMA8DPN
DMA8DPN	DN	Dexchlorpheniramine maleate
DMA8DPN	MI	DECB0K3
DMA8DPN	MN	Cytochrome P450 2D6 (CYP2D6)
DMA8DPN	MT	DME
DMA8DPN	MA	Metabolism
DMA8DPN	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DMA8DPN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DMA8DPN	DI	DMA8DPN
DMA8DPN	DN	Dexchlorpheniramine maleate
DMA8DPN	MI	TTTIBOJ
DMA8DPN	MN	Histamine H1 receptor (H1R)
DMA8DPN	MT	DTT
DMA8DPN	MA	Modulator
DMA8DPN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA8DPN	RU	https://www.fda.gov/

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEGKWJB
DMFYBD0	MN	Alpha-methylacyl-CoA racemase (AMACR)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Alpha-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013 Apr;52(2):220-30.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23376124

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DES5XRU
DMFYBD0	MN	Cytochrome P450 2C8 (CYP2C8)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DE5IED8
DMFYBD0	MN	Cytochrome P450 2C9 (CYP2C9)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEGTFWK
DMFYBD0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	TTK0943
DMFYBD0	MN	Prostaglandin G/H synthase (COX)
DMFYBD0	MT	DTT
DMFYBD0	MA	Modulator
DMFYBD0	RN	Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
DMFYBD0	RU	https://pubmed.ncbi.nlm.nih.gov/12708604

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEYGVN4
DMFYBD0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEF2WXN
DMFYBD0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DE85D2P
DMFYBD0	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFYBD0	DI	DMFYBD0
DMFYBD0	DN	Dexibuprofen
DMFYBD0	MI	DEB3CV1
DMFYBD0	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMFYBD0	MT	DME
DMFYBD0	MA	Metabolism
DMFYBD0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFYBD0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DE4LYSA
DM1DBV5	MN	Cytochrome P450 3A4 (CYP3A4)
DM1DBV5	MT	DME
DM1DBV5	MA	Metabolism
DM1DBV5	RN	Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32.
DM1DBV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22455762

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	TTLOKXP
DM1DBV5	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM1DBV5	MT	DTT
DM1DBV5	MA	Modulator
DM1DBV5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1DBV5	RU	https://www.fda.gov/

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	TTF1QVM
DM1DBV5	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM1DBV5	MT	DTT
DM1DBV5	MA	Inhibitor
DM1DBV5	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM1DBV5	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DEGTFWK
DM1DBV5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1DBV5	MT	DME
DM1DBV5	MA	Metabolism
DM1DBV5	RN	Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.
DM1DBV5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26932927

DM1DBV5	DI	DM1DBV5
DM1DBV5	DN	Dexlansoprazole
DM1DBV5	MI	DTUGYRD
DM1DBV5	MN	P-glycoprotein 1 (ABCB1)
DM1DBV5	MT	DTP
DM1DBV5	MA	Substrate
DM1DBV5	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM1DBV5	RU	https://doi.org/10.1007/s00210-008-0345-0

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	TTQ8AFT
DM93L4X	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM93L4X	MT	DTT
DM93L4X	MA	Agonist
DM93L4X	RN	Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
DM93L4X	RU	https://pubmed.ncbi.nlm.nih.gov/12503262

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEJGDUW
DM93L4X	MN	Cytochrome P450 1A2 (CYP1A2)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17973897

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEJVYAZ
DM93L4X	MN	Cytochrome P450 2A6 (CYP2A6)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert Rev Clin Pharmacol. 2018 Sep;11(9):917-922.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30092666

DM93L4X	DI	DM93L4X
DM93L4X	DN	Dexmedetomidine
DM93L4X	MI	DEVDYN7
DM93L4X	MN	Cytochrome P450 2E1 (CYP2E1)
DM93L4X	MT	DME
DM93L4X	MA	Metabolism
DM93L4X	RN	Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77.
DM93L4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20020418

DMUQE2A	DI	DMUQE2A
DMUQE2A	DN	Dexmethylphenidate
DMUQE2A	MI	DEB30C5
DMUQE2A	MN	Carboxylesterase 1 (CES1)
DMUQE2A	MT	DME
DMUQE2A	MA	Metabolism
DMUQE2A	RN	Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.
DMUQE2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19412495

DM8WBAH	DI	DM8WBAH
DM8WBAH	DN	Dexmethylphenidate hydrochloride
DM8WBAH	MI	TTVBI8W
DM8WBAH	MN	Dopamine transporter (DAT)
DM8WBAH	MT	DTT
DM8WBAH	MA	Inhibitor
DM8WBAH	RN	Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
DM8WBAH	RU	https://pubmed.ncbi.nlm.nih.gov/17489581

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	DE0EUXB
DMD7X1O	MN	Dihydropyrimidinase-related protein 1 (DRP1)
DMD7X1O	MT	DME
DMD7X1O	MA	Metabolism
DMD7X1O	RN	Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos. 2005 Jun;33(6):719-25.
DMD7X1O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764716

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	TT0IHXV
DMD7X1O	MN	DNA topoisomerase II (TOP2)
DMD7X1O	MT	DTT
DMD7X1O	MA	Modulator
DMD7X1O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMD7X1O	RU	https://www.fda.gov/

DMD7X1O	DI	DMD7X1O
DMD7X1O	DN	Dexrazoxane
DMD7X1O	MI	TT4NVEM
DMD7X1O	MN	DNA topoisomerase II beta (TOP2B)
DMD7X1O	MT	DTT
DMD7X1O	MA	Inhibitor
DMD7X1O	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD7X1O	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMMIHVP	DI	DMMIHVP
DMMIHVP	DN	Dextroamphetamine
DMMIHVP	MI	DECB0K3
DMMIHVP	MN	Cytochrome P450 2D6 (CYP2D6)
DMMIHVP	MT	DME
DMMIHVP	MA	Metabolism
DMMIHVP	RN	Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32.
DMMIHVP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690

DMMIHVP	DI	DMMIHVP
DMMIHVP	DN	Dextroamphetamine
DMMIHVP	MI	TTIU98M
DMMIHVP	MN	Trace amine-associated receptor-1 (TAAR1)
DMMIHVP	MT	DTT
DMMIHVP	MA	Modulator
DMMIHVP	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMMIHVP	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEKP5HX
DMUDJZM	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE4OGUF
DMUDJZM	MN	Cytochrome P450 102A1 (cyp102)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/17532492

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE6CQ0I
DMUDJZM	MN	Cytochrome P450 130A1 (cyp130)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEPKLMQ
DMUDJZM	MN	Cytochrome P450 2B6 (CYP2B6)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE5IED8
DMUDJZM	MN	Cytochrome P450 2C9 (CYP2C9)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DECB0K3
DMUDJZM	MN	Cytochrome P450 2D6 (CYP2D6)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DE4LYSA
DMUDJZM	MN	Cytochrome P450 3A4 (CYP3A4)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11602530

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEIBDNY
DMUDJZM	MN	Cytochrome P450 3A5 (CYP3A5)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DERD86B
DMUDJZM	MN	Cytochrome P450 3A7 (CYP3A7)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8043020

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	DEGTFWK
DMUDJZM	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUDJZM	MT	DME
DMUDJZM	MA	Metabolism
DMUDJZM	RN	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
DMUDJZM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160

DMUDJZM	DI	DMUDJZM
DMUDJZM	DN	Dextromethorphan
DMUDJZM	MI	TT5TPI6
DMUDJZM	MN	Opioid receptor sigma 1 (OPRS1)
DMUDJZM	MT	DTT
DMUDJZM	MA	Agonist
DMUDJZM	RN	Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
DMUDJZM	RU	https://pubmed.ncbi.nlm.nih.gov/15869321

DMEHCY5	DI	DMEHCY5
DMEHCY5	DN	Dextromethorphan polistirex
DMEHCY5	MI	TT5TPI6
DMEHCY5	MN	Opioid receptor sigma 1 (OPRS1)
DMEHCY5	MT	DTT
DMEHCY5	MA	Modulator
DMEHCY5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEHCY5	RU	https://www.fda.gov/

DMEHCY5	DI	DMEHCY5
DMEHCY5	DN	Dextromethorphan polistirex
DMEHCY5	MI	TT3ROYC
DMEHCY5	MN	Serotonin transporter (SERT)
DMEHCY5	MT	DTT
DMEHCY5	MA	Modulator
DMEHCY5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEHCY5	RU	https://www.fda.gov/

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	DECB0K3
DM23HCX	MN	Cytochrome P450 2D6 (CYP2D6)
DM23HCX	MT	DME
DM23HCX	MA	Metabolism
DM23HCX	RN	Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
DM23HCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9143866

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	DE4LYSA
DM23HCX	MN	Cytochrome P450 3A4 (CYP3A4)
DM23HCX	MT	DME
DM23HCX	MA	Metabolism
DM23HCX	RN	CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
DM23HCX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15764408

DM23HCX	DI	DM23HCX
DM23HCX	DN	Dextropropoxyphene
DM23HCX	MI	TTN4QDT
DM23HCX	MN	Opioid receptor (OPR)
DM23HCX	MT	DTT
DM23HCX	MA	Agonist
DM23HCX	RN	Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
DM23HCX	RU	https://pubmed.ncbi.nlm.nih.gov/19021937

DMBVEC7	DI	DMBVEC7
DMBVEC7	DN	Dextrothyroxine Sodium
DMBVEC7	MI	TTTSEPU
DMBVEC7	MN	Thyroid hormone receptor alpha (THRA)
DMBVEC7	MT	DTT
DMBVEC7	MA	Modulator
DMBVEC7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBVEC7	RU	https://www.fda.gov/

DMBVEC7	DI	DMBVEC7
DMBVEC7	DN	Dextrothyroxine Sodium
DMBVEC7	MI	TTGER3L
DMBVEC7	MN	Thyroid hormone receptor beta (THRB)
DMBVEC7	MT	DTT
DMBVEC7	MA	Modulator
DMBVEC7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBVEC7	RU	https://www.fda.gov/

DMJDB0Y	DI	DMJDB0Y
DMJDB0Y	DN	Dezocine
DMJDB0Y	MI	TTQW87Y
DMJDB0Y	MN	Opioid receptor kappa (OPRK1)
DMJDB0Y	MT	DTT
DMJDB0Y	MA	Antagonist
DMJDB0Y	RN	Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
DMJDB0Y	RU	https://pubmed.ncbi.nlm.nih.gov/16433932

DMU3FGB	DI	DMU3FGB
DMU3FGB	DN	Dhaq diacetate
DMU3FGB	MI	TT0IHXV
DMU3FGB	MN	DNA topoisomerase II (TOP2)
DMU3FGB	MT	DTT
DMU3FGB	MA	Inhibitor
DMU3FGB	RN	The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7.
DMU3FGB	RU	https://pubmed.ncbi.nlm.nih.gov/19176397

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEJGDUW
DM08E9O	MN	Cytochrome P450 1A2 (CYP1A2)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEPKLMQ
DM08E9O	MN	Cytochrome P450 2B6 (CYP2B6)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEZMWRE
DM08E9O	MN	Cytochrome P450 2C18 (CYP2C18)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9028867

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DES5XRU
DM08E9O	MN	Cytochrome P450 2C8 (CYP2C8)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10771285

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE5IED8
DM08E9O	MN	Cytochrome P450 2C9 (CYP2C9)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12708941

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE4LYSA
DM08E9O	MN	Cytochrome P450 3A4 (CYP3A4)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487724

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEIBDNY
DM08E9O	MN	Cytochrome P450 3A5 (CYP3A5)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DERD86B
DM08E9O	MN	Cytochrome P450 3A7 (CYP3A7)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Drug Interactions Flockhart Table
DM08E9O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DEGTFWK
DM08E9O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DTUGYRD
DM08E9O	MN	P-glycoprotein 1 (ABCB1)
DM08E9O	MT	DTP
DM08E9O	MA	Substrate
DM08E9O	RN	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
DM08E9O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11785684

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	DE073H6
DM08E9O	MN	Prostaglandin G/H synthase 1 (COX-1)
DM08E9O	MT	DME
DM08E9O	MA	Metabolism
DM08E9O	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM08E9O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM08E9O	DI	DM08E9O
DM08E9O	DN	Diazepam
DM08E9O	MI	TTPTXIN
DM08E9O	MN	Translocator protein (TSPO)
DM08E9O	MT	DTT
DM08E9O	MA	Agonist
DM08E9O	RN	Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
DM08E9O	RU	https://pubmed.ncbi.nlm.nih.gov/19782064

DML1538	DI	DML1538
DML1538	DN	Diazoxide
DML1538	MI	TT1VOHK
DML1538	MN	Potassium channel unspecific (KC)
DML1538	MT	DTT
DML1538	MA	Modulator
DML1538	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DML1538	RU	https://www.fda.gov/

DMF9G7L	DI	DMF9G7L
DMF9G7L	DN	Dibucaine
DMF9G7L	MI	TTZOVE0
DMF9G7L	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMF9G7L	MT	DTT
DMF9G7L	MA	Blocker
DMF9G7L	RN	Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
DMF9G7L	RU	https://pubmed.ncbi.nlm.nih.gov/12354567

DMH7IDQ	DI	DMH7IDQ
DMH7IDQ	DN	Dichlorphenamide
DMH7IDQ	MI	TTHQPL7
DMH7IDQ	MN	Carbonic anhydrase I (CA-I)
DMH7IDQ	MT	DTT
DMH7IDQ	MA	Modulator
DMH7IDQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMH7IDQ	RU	https://www.fda.gov/

DMH7IDQ	DI	DMH7IDQ
DMH7IDQ	DN	Dichlorphenamide
DMH7IDQ	MI	TTANPDJ
DMH7IDQ	MN	Carbonic anhydrase II (CA-II)
DMH7IDQ	MT	DTT
DMH7IDQ	MA	Inhibitor
DMH7IDQ	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMH7IDQ	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DTI7UX6
DMPIHLS	MN	Breast cancer resistance protein (ABCG2)
DMPIHLS	MT	DTP
DMPIHLS	MA	Substrate
DMPIHLS	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMPIHLS	RU	http://www.ncbi.nlm.nih.gov/pubmed/18845662

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEKP5HX
DMPIHLS	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE4OGUF
DMPIHLS	MN	Cytochrome P450 102A1 (cyp102)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DECV2ME
DMPIHLS	MN	Cytochrome P450 105D7 (cyp105)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/29270447

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE6OQ3W
DMPIHLS	MN	Cytochrome P450 1A1 (CYP1A1)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEJGDUW
DMPIHLS	MN	Cytochrome P450 1A2 (CYP1A2)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27034690

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEPKLMQ
DMPIHLS	MN	Cytochrome P450 2B6 (CYP2B6)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10449188

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEZMWRE
DMPIHLS	MN	Cytochrome P450 2C18 (CYP2C18)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DES5XRU
DMPIHLS	MN	Cytochrome P450 2C8 (CYP2C8)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15581350

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE5IED8
DMPIHLS	MN	Cytochrome P450 2C9 (CYP2C9)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE4LYSA
DMPIHLS	MN	Cytochrome P450 3A4 (CYP3A4)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950847

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEGTFWK
DMPIHLS	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DT9C1TS
DMPIHLS	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMPIHLS	MT	DTP
DMPIHLS	MA	Substrate
DMPIHLS	RN	Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
DMPIHLS	RU	http://www.ncbi.nlm.nih.gov/pubmed/21389119

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	TTK0943
DMPIHLS	MN	Prostaglandin G/H synthase (COX)
DMPIHLS	MT	DTT
DMPIHLS	MA	Modulator
DMPIHLS	RN	Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
DMPIHLS	RU	https://pubmed.ncbi.nlm.nih.gov/11221916

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEF2WXN
DMPIHLS	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DE85D2P
DMPIHLS	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492

DMPIHLS	DI	DMPIHLS
DMPIHLS	DN	Diclofenac
DMPIHLS	MI	DEB3CV1
DMPIHLS	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPIHLS	MT	DME
DMPIHLS	MA	Metabolism
DMPIHLS	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPIHLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	TTJP4SM
DM8EU0Z	MN	Bacterial Penicillin binding protein (Bact PBP)
DM8EU0Z	MT	DTT
DM8EU0Z	MA	Binder
DM8EU0Z	RN	Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71.
DM8EU0Z	RU	https://pubmed.ncbi.nlm.nih.gov/6335600

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DT9G7XN
DM8EU0Z	MN	Peptide transporter 1 (SLC15A1)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DT8QKNP
DM8EU0Z	MN	Peptide transporter 2 (SLC15A2)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DM8EU0Z	DI	DM8EU0Z
DM8EU0Z	DN	Dicloxacillin
DM8EU0Z	MI	DTUGYRD
DM8EU0Z	MN	P-glycoprotein 1 (ABCB1)
DM8EU0Z	MT	DTP
DM8EU0Z	MA	Substrate
DM8EU0Z	RN	Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62.
DM8EU0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/12033380

DMFQCB1	DI	DMFQCB1
DMFQCB1	DN	Dicumarol
DMFQCB1	MI	DE5IED8
DMFQCB1	MN	Cytochrome P450 2C9 (CYP2C9)
DMFQCB1	MT	DME
DMFQCB1	MA	Metabolism
DMFQCB1	RN	Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5.
DMFQCB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25866574

DMFQCB1	DI	DMFQCB1
DMFQCB1	DN	Dicumarol
DMFQCB1	MI	TTEUC8H
DMFQCB1	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMFQCB1	MT	DTT
DMFQCB1	MA	Inhibitor
DMFQCB1	RN	Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9.
DMFQCB1	RU	https://pubmed.ncbi.nlm.nih.gov/2424118

DMZSDGX	DI	DMZSDGX
DMZSDGX	DN	Dicyclomine
DMZSDGX	MI	TTZ9SOR
DMZSDGX	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMZSDGX	MT	DTT
DMZSDGX	MA	Antagonist
DMZSDGX	RN	[Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11.
DMZSDGX	RU	https://pubmed.ncbi.nlm.nih.gov/19627722

DMI2QPE	DI	DMI2QPE
DMI2QPE	DN	Didanosine
DMI2QPE	MI	DT82KPY
DMI2QPE	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMI2QPE	MT	DTP
DMI2QPE	MA	Substrate
DMI2QPE	RN	Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals.
DMI2QPE	RU	https://books.google.co.jp/books?id=cYBGAAAAQBAJ&pg=PA59&lpg=PA59&dq=SLC15A1%09Didanosine&source=bl&ots=CeeUnMnW6Z&sig=ACfU3U10UhN6m18-AuKuLOfFeDKtUo5VYw&hl=zh-CN&sa=X&ved=2ahUKEwjh_IyK9KHiAhVIzbwKHZKiDoMQ6AEwAXoECAgQAQ#v=onepage&q=SLC15A1%09Didanosine&f=false

DMI2QPE	DI	DMI2QPE
DMI2QPE	DN	Didanosine
DMI2QPE	MI	TT84ETX
DMI2QPE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI2QPE	MT	DTT
DMI2QPE	MA	Inhibitor
DMI2QPE	RN	The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
DMI2QPE	RU	https://pubmed.ncbi.nlm.nih.gov/19412117

DMBSXI0	DI	DMBSXI0
DMBSXI0	DN	Dienestrol
DMBSXI0	MI	TTZAYWL
DMBSXI0	MN	Estrogen receptor (ESR)
DMBSXI0	MT	DTT
DMBSXI0	MA	Agonist
DMBSXI0	RN	Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12.
DMBSXI0	RU	https://pubmed.ncbi.nlm.nih.gov/18976723

DM1TJ8F	DI	DM1TJ8F
DM1TJ8F	DN	Diethylcarbamazine
DM1TJ8F	MI	TT2J34L
DM1TJ8F	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1TJ8F	MT	DTT
DM1TJ8F	MA	Inhibitor
DM1TJ8F	RN	Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
DM1TJ8F	RU	https://pubmed.ncbi.nlm.nih.gov/10518442

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DES5XRU
DMN3UXQ	MN	Cytochrome P450 2C8 (CYP2C8)
DMN3UXQ	MT	DME
DMN3UXQ	MA	Metabolism
DMN3UXQ	RN	Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21.
DMN3UXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21553654

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DE4LYSA
DMN3UXQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMN3UXQ	MT	DME
DMN3UXQ	MA	Metabolism
DMN3UXQ	RN	Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. Reprod Toxicol. 2013 Jun;37:24-30.
DMN3UXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23384967

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	TTZAYWL
DMN3UXQ	MN	Estrogen receptor (ESR)
DMN3UXQ	MT	DTT
DMN3UXQ	MA	Agonist
DMN3UXQ	RN	Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9.
DMN3UXQ	RU	https://pubmed.ncbi.nlm.nih.gov/19553606

DMN3UXQ	DI	DMN3UXQ
DMN3UXQ	DN	Diethylstilbestrol
DMN3UXQ	MI	DTUGYRD
DMN3UXQ	MN	P-glycoprotein 1 (ABCB1)
DMN3UXQ	MT	DTP
DMN3UXQ	MA	Substrate
DMN3UXQ	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMN3UXQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMI9PRJ	DI	DMI9PRJ
DMI9PRJ	DN	Diflorasone
DMI9PRJ	MI	TT9V5JH
DMI9PRJ	MN	Phospholipase A2 (PLA2G1B)
DMI9PRJ	MT	DTT
DMI9PRJ	MA	Inhibitor
DMI9PRJ	RN	Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
DMI9PRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19013475

DM7EN8I	DI	DM7EN8I
DM7EN8I	DN	Diflunisal
DM7EN8I	MI	TTVKILB
DM7EN8I	MN	Prostaglandin G/H synthase 2 (COX-2)
DM7EN8I	MT	DTT
DM7EN8I	MA	Inhibitor
DM7EN8I	RN	Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6.
DM7EN8I	RU	https://pubmed.ncbi.nlm.nih.gov/11315375

DM7EN8I	DI	DM7EN8I
DM7EN8I	DN	Diflunisal
DM7EN8I	MI	DEYGVN4
DM7EN8I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7EN8I	MT	DME
DM7EN8I	MA	Metabolism
DM7EN8I	RN	Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. J Pharmacol Exp Ther. 1987 Sep;242(3):1013-8.
DM7EN8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3656106

DMMFVB3	DI	DMMFVB3
DMMFVB3	DN	Difluprednate
DMMFVB3	MI	DE4LYSA
DMMFVB3	MN	Cytochrome P450 3A4 (CYP3A4)
DMMFVB3	MT	DME
DMMFVB3	MA	Metabolism
DMMFVB3	RN	Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52.
DMMFVB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27084892

DMMFVB3	DI	DMMFVB3
DMMFVB3	DN	Difluprednate
DMMFVB3	MI	TTUCK4B
DMMFVB3	MN	Phospholipase A2 inhibitory protein (PA2IP)
DMMFVB3	MT	DTT
DMMFVB3	MA	Agonist
DMMFVB3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMMFVB3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DE4LYSA
DMWVIGP	MN	Cytochrome P450 3A4 (CYP3A4)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1944247

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DTUGYRD
DMWVIGP	MN	P-glycoprotein 1 (ABCB1)
DMWVIGP	MT	DTP
DMWVIGP	MA	Substrate
DMWVIGP	RN	The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. Eur J Clin Pharmacol. 2008 Apr;64(4):367-72.
DMWVIGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/18080812

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	TTQ38E9
DMWVIGP	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMWVIGP	MT	DTT
DMWVIGP	MA	Inhibitor
DMWVIGP	RN	Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7.
DMWVIGP	RU	https://pubmed.ncbi.nlm.nih.gov/11525233

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DEYWLRK
DMWVIGP	MN	Sulfotransferase 1A1 (SULT1A1)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Hydroxysteroid sulfotransferase and a specific UDP-glucuronosyltransferase are involved in the metabolism of digitoxin in man. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):226-33.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1448185

DMWVIGP	DI	DMWVIGP
DMWVIGP	DN	Digitoxin
DMWVIGP	MI	DEYGVN4
DMWVIGP	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWVIGP	MT	DME
DMWVIGP	MA	Metabolism
DMWVIGP	RN	Use of a human liver microsome bank in drug glucuronidation studies. Toxicol In Vitro. 1991;5(5-6):559-62.
DMWVIGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20732077

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE84PFW
DMQCTIH	MN	Cardiac glycoside reductase 1 (cgr1)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/24637603

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE9VSLW
DMQCTIH	MN	Cardiac glycoside reductase 2 (cgr2)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/24637603

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DE4LYSA
DMQCTIH	MN	Cytochrome P450 3A4 (CYP3A4)
DMQCTIH	MT	DME
DMQCTIH	MA	Metabolism
DMQCTIH	RN	Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2.
DMQCTIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458401

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTZRMK5
DMQCTIH	MN	Multidrug resistance protein 3 (ABCB4)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	TTACFNR
DMQCTIH	MN	Organic anion transporter M1 (SLCO4C1)
DMQCTIH	MT	DTT
DMQCTIH	MA	Modulator
DMQCTIH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227).
DMQCTIH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DT9C1TS
DMQCTIH	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTPFTEQ
DMQCTIH	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Drug Interactions in Infectious Diseases.
DMQCTIH	RU	http://www.springer.com/medicine/internal/book/978-1-61779-212-0

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTY0QMU
DMQCTIH	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTMEQ32
DMQCTIH	MN	Organic solute transporter subunit alpha (SLC51A)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DT1V9AJ
DMQCTIH	MN	Organic solute transporter subunit beta (SLC51B)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	DTUGYRD
DMQCTIH	MN	P-glycoprotein 1 (ABCB1)
DMQCTIH	MT	DTP
DMQCTIH	MA	Substrate
DMQCTIH	RN	MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12.
DMQCTIH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20510202

DMQCTIH	DI	DMQCTIH
DMQCTIH	DN	Digoxin
DMQCTIH	MI	TTQ38E9
DMQCTIH	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMQCTIH	MT	DTT
DMQCTIH	MA	Inhibitor
DMQCTIH	RN	Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33.
DMQCTIH	RU	https://pubmed.ncbi.nlm.nih.gov/15554746

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DEJGDUW
DMZIXU9	MN	Cytochrome P450 1A2 (CYP1A2)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol. 1999 Oct;12(10):1028-32.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10525281

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DE4LYSA
DMZIXU9	MN	Cytochrome P450 3A4 (CYP3A4)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770

DMZIXU9	DI	DMZIXU9
DMZIXU9	DN	Dihydralazine
DMZIXU9	MI	DEZV4AP
DMZIXU9	MN	RNA cytidine acetyltransferase (hALP)
DMZIXU9	MT	DME
DMZIXU9	MA	Metabolism
DMZIXU9	RN	The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23 Suppl 1:S74-8.
DMZIXU9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3842694

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	TTZVSJ2
DMBXVMZ	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMBXVMZ	MT	DTT
DMBXVMZ	MA	Inhibitor
DMBXVMZ	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMBXVMZ	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	DE85D2P
DMBXVMZ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMBXVMZ	MT	DME
DMBXVMZ	MA	Metabolism
DMBXVMZ	RN	Eurartesim - European Medicines Agency
DMBXVMZ	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DMBXVMZ	DI	DMBXVMZ
DMBXVMZ	DN	Dihydroartemisinin
DMBXVMZ	MI	DEB3CV1
DMBXVMZ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMBXVMZ	MT	DME
DMBXVMZ	MA	Metabolism
DMBXVMZ	RN	Eurartesim - European Medicines Agency
DMBXVMZ	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DM5SQ1G	DI	DM5SQ1G
DM5SQ1G	DN	Dihydroergocristine
DM5SQ1G	MI	TT2NUT5
DM5SQ1G	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM5SQ1G	MT	DTT
DM5SQ1G	MA	Modulator
DM5SQ1G	RN	Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
DM5SQ1G	RU	https://pubmed.ncbi.nlm.nih.gov/6321209

DM5SQ1G	DI	DM5SQ1G
DM5SQ1G	DN	Dihydroergocristine
DM5SQ1G	MI	DTUGYRD
DM5SQ1G	MN	P-glycoprotein 1 (ABCB1)
DM5SQ1G	MT	DTP
DM5SQ1G	MA	Substrate
DM5SQ1G	RN	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.
DM5SQ1G	RU	https://doi.org/10.1124/jpet.102.037549

DM5IKUF	DI	DM5IKUF
DM5IKUF	DN	Dihydroergotamine
DM5IKUF	MI	DE4LYSA
DM5IKUF	MN	Cytochrome P450 3A4 (CYP3A4)
DM5IKUF	MT	DME
DM5IKUF	MA	Metabolism
DM5IKUF	RN	CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
DM5IKUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14998425

DM5IKUF	DI	DM5IKUF
DM5IKUF	DN	Dihydroergotamine
DM5IKUF	MI	TTEX248
DM5IKUF	MN	Dopamine D2 receptor (D2R)
DM5IKUF	MT	DTT
DM5IKUF	MA	Agonist
DM5IKUF	RN	Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94.
DM5IKUF	RU	https://pubmed.ncbi.nlm.nih.gov/18626630

DM5D6WZ	DI	DM5D6WZ
DM5D6WZ	DN	Dihydroergotoxine
DM5D6WZ	MI	TTEX248
DM5D6WZ	MN	Dopamine D2 receptor (D2R)
DM5D6WZ	MT	DTT
DM5D6WZ	MA	Agonist
DM5D6WZ	RN	Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
DM5D6WZ	RU	https://pubmed.ncbi.nlm.nih.gov/10084415

DM5D6WZ	DI	DM5D6WZ
DM5D6WZ	DN	Dihydroergotoxine
DM5D6WZ	MI	TTAN6JD
DM5D6WZ	MN	Glutamate receptor AMPA (GRIA)
DM5D6WZ	MT	DTT
DM5D6WZ	MA	Agonist
DM5D6WZ	RN	Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
DM5D6WZ	RU	https://pubmed.ncbi.nlm.nih.gov/10084415

DMFB97P	DI	DMFB97P
DMFB97P	DN	Dihydrotachysterol
DMFB97P	MI	TTK59TV
DMFB97P	MN	Vitamin D3 receptor (VDR)
DMFB97P	MT	DTT
DMFB97P	MA	Antagonist
DMFB97P	RN	In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92.
DMFB97P	RU	https://pubmed.ncbi.nlm.nih.gov/8380156

DMM1LG2	DI	DMM1LG2
DMM1LG2	DN	Dihydroxyacetone
DMM1LG2	MI	DEX9ZJQ
DMM1LG2	MN	Triokinase/FMN cyclase (TKFC)
DMM1LG2	MT	DME
DMM1LG2	MA	Metabolism
DMM1LG2	RN	Bifunctional homodimeric triokinase/FMN cyclase: contribution of protein domains to the activities of the human enzyme and molecular dynamics simulation of domain movements. J Biol Chem. 2014 Apr 11;289(15):10620-36.
DMM1LG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24569995

DM8YXKW	DI	DM8YXKW
DM8YXKW	DN	Dihydroxyaluminium
DM8YXKW	MI	TT8RDXP
DM8YXKW	MN	Troponin C (TN-C)
DM8YXKW	MT	DTT
DM8YXKW	MA	Stimulator
DM8YXKW	RN	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12.
DM8YXKW	RU	https://pubmed.ncbi.nlm.nih.gov/19350363

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DES5XRU
DMAI7ZV	MN	Cytochrome P450 2C8 (CYP2C8)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9223567

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DE5IED8
DMAI7ZV	MN	Cytochrome P450 2C9 (CYP2C9)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DECB0K3
DMAI7ZV	MN	Cytochrome P450 2D6 (CYP2D6)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DE4LYSA
DMAI7ZV	MN	Cytochrome P450 3A4 (CYP3A4)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124305

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DEIBDNY
DMAI7ZV	MN	Cytochrome P450 3A5 (CYP3A5)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27149910

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DERD86B
DMAI7ZV	MN	Cytochrome P450 3A7 (CYP3A7)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	FDA Drug Development and Drug Interactions
DMAI7ZV	RU	https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DEGTFWK
DMAI7ZV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMAI7ZV	MT	DME
DMAI7ZV	MA	Metabolism
DMAI7ZV	RN	Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
DMAI7ZV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560871

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	DTUGYRD
DMAI7ZV	MN	P-glycoprotein 1 (ABCB1)
DMAI7ZV	MT	DTP
DMAI7ZV	MA	Substrate
DMAI7ZV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMAI7ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMAI7ZV	DI	DMAI7ZV
DMAI7ZV	DN	Diltiazem
DMAI7ZV	MI	TTFK1JQ
DMAI7ZV	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMAI7ZV	MT	DTT
DMAI7ZV	MA	Blocker
DMAI7ZV	RN	Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
DMAI7ZV	RU	https://pubmed.ncbi.nlm.nih.gov/19590189

DM264B3	DI	DM264B3
DM264B3	DN	Dimenhydrinate
DM264B3	MI	TTTIBOJ
DM264B3	MN	Histamine H1 receptor (H1R)
DM264B3	MT	DTT
DM264B3	MA	Antagonist
DM264B3	RN	Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6.
DM264B3	RU	https://pubmed.ncbi.nlm.nih.gov/18849063

DM32YAI	DI	DM32YAI
DM32YAI	DN	Dimethindene
DM32YAI	MI	TTTIBOJ
DM32YAI	MN	Histamine H1 receptor (H1R)
DM32YAI	MT	DTT
DM32YAI	MA	Antagonist
DM32YAI	RN	Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93.
DM32YAI	RU	https://pubmed.ncbi.nlm.nih.gov/19308787

DMXQKSL	DI	DMXQKSL
DMXQKSL	DN	Dinoprost Tromethamine
DMXQKSL	MI	TTOFYT1
DMXQKSL	MN	Prostacyclin receptor (PTGIR)
DMXQKSL	MT	DTT
DMXQKSL	MA	Antagonist
DMXQKSL	RN	Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
DMXQKSL	RU	https://pubmed.ncbi.nlm.nih.gov/12488443

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DEJGDUW
DMTYOPD	MN	Cytochrome P450 1A2 (CYP1A2)
DMTYOPD	MT	DME
DMTYOPD	MA	Metabolism
DMTYOPD	RN	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15224350

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DE3GT9C
DMTYOPD	MN	Cytochrome P450 4F2 (CYP4F2)
DMTYOPD	MT	DME
DMTYOPD	MA	Metabolism
DMTYOPD	RN	Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11370662

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTFI42L
DMTYOPD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
DMTYOPD	RU	https://doi.org/10.1111/j.1478-3231.2005.01234.x

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTCSGPB
DMTYOPD	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12835412

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTQ23VB
DMTYOPD	MN	Organic anion transporter 1 (SLC22A6)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT0OC1Q
DMTYOPD	MN	Organic anion transporter 2 (SLC22A7)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTVP67E
DMTYOPD	MN	Organic anion transporter 3 (SLC22A8)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT06JWZ
DMTYOPD	MN	Organic anion transporter 4 (SLC22A11)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11907186

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTE2B1D
DMTYOPD	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/11713643

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT3D8F0
DMTYOPD	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTPYCQ4
DMTYOPD	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12351693

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT021JD
DMTYOPD	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTPFTEQ
DMTYOPD	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTVNRXW
DMTYOPD	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT8H2IC
DMTYOPD	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTYVQ5M
DMTYOPD	MN	Organic anion transporting polypeptide 5A1 (SLCO5A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Expression and regulation of prostaglandin transporters, ATP-binding cassette, subfamily C, member 1 and 9, and solute carrier organic anion transporter family, member 2A1 and 5A1 in the uterine endometrium during the estrous cycle and pregnancy in pigs. Asian-Australas J Anim Sci. 2017 May;30(5):643-652.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/27764917

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTT79CX
DMTYOPD	MN	Organic cation transporter 1 (SLC22A1)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16211406

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT9IDPW
DMTYOPD	MN	Organic cation transporter 2 (SLC22A2)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16211406

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DTMEQ32
DMTYOPD	MN	Organic solute transporter subunit alpha (SLC51A)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	DT1V9AJ
DMTYOPD	MN	Organic solute transporter subunit beta (SLC51B)
DMTYOPD	MT	DTP
DMTYOPD	MA	Substrate
DMTYOPD	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMTYOPD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	TT1ZAVI
DMTYOPD	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMTYOPD	MT	DTT
DMTYOPD	MA	Antagonist
DMTYOPD	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMTYOPD	DI	DMTYOPD
DMTYOPD	DN	Dinoprostone
DMTYOPD	MI	TTT2ZAR
DMTYOPD	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMTYOPD	MT	DTT
DMTYOPD	MA	Antagonist
DMTYOPD	RN	Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
DMTYOPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25772215

DMXVU6D	DI	DMXVU6D
DMXVU6D	DN	Diphemanil Methylsulfate
DMXVU6D	MI	TTZ9SOR
DMXVU6D	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMXVU6D	MT	DTT
DMXVU6D	MA	Modulator
DMXVU6D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMXVU6D	RU	https://www.fda.gov/

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DE5IED8
DMKQTBA	MN	Cytochrome P450 2C9 (CYP2C9)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/25185985

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DECB0K3
DMKQTBA	MN	Cytochrome P450 2D6 (CYP2D6)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020955

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	TTTIBOJ
DMKQTBA	MN	Histamine H1 receptor (H1R)
DMKQTBA	MT	DTT
DMKQTBA	MA	Antagonist
DMKQTBA	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMKQTBA	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	TT2B6EV
DMKQTBA	MN	Histamine N-methyltransferase (HNMT)
DMKQTBA	MT	DTT
DMKQTBA	MA	Inhibitor
DMKQTBA	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKQTBA	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DEGTFWK
DMKQTBA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMKQTBA	DI	DMKQTBA
DMKQTBA	DN	Diphenhydramine
DMKQTBA	MI	DE073H6
DMKQTBA	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKQTBA	MT	DME
DMKQTBA	MA	Metabolism
DMKQTBA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKQTBA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMHPWOM	DI	DMHPWOM
DMHPWOM	DN	Diphenidol
DMHPWOM	MI	TTQ3JTF
DMHPWOM	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMHPWOM	MT	DTT
DMHPWOM	MA	Antagonist
DMHPWOM	RN	Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6.
DMHPWOM	RU	https://pubmed.ncbi.nlm.nih.gov/18395442

DMO5SZX	DI	DMO5SZX
DMO5SZX	DN	Diphenoxylate
DMO5SZX	MI	TTKWM86
DMO5SZX	MN	Opioid receptor mu (MOP)
DMO5SZX	MT	DTT
DMO5SZX	MA	Agonist
DMO5SZX	RN	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
DMO5SZX	RU	https://pubmed.ncbi.nlm.nih.gov/18192961

DMW4X37	DI	DMW4X37
DMW4X37	DN	Diphenylpyraline
DMW4X37	MI	TTTIBOJ
DMW4X37	MN	Histamine H1 receptor (H1R)
DMW4X37	MT	DTT
DMW4X37	MA	Antagonist
DMW4X37	RN	Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9.
DMW4X37	RU	https://pubmed.ncbi.nlm.nih.gov/7920432

DM0FSIM	DI	DM0FSIM
DM0FSIM	DN	Diphtheria-tetanus vaccine
DM0FSIM	MI	TTXT4D5
DM0FSIM	MN	Bacterial Cell membrane (Bact CM)
DM0FSIM	MT	DTT
DM0FSIM	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM0FSIM	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMH5W0G	DI	DMH5W0G
DMH5W0G	DN	Dipivefrin
DMH5W0G	MI	TTR6W5O
DMH5W0G	MN	Adrenergic receptor beta-1 (ADRB1)
DMH5W0G	MT	DTT
DMH5W0G	MA	Antagonist
DMH5W0G	RN	Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53.
DMH5W0G	RU	https://pubmed.ncbi.nlm.nih.gov/8803576

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	DTI7UX6
DMXY30O	MN	Breast cancer resistance protein (ABCG2)
DMXY30O	MT	DTP
DMXY30O	MA	Substrate
DMXY30O	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DMXY30O	RU	https://doi.org/10.1016/j.addr.2008.11.003

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	DTUGYRD
DMXY30O	MN	P-glycoprotein 1 (ABCB1)
DMXY30O	MT	DTP
DMXY30O	MA	Substrate
DMXY30O	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMXY30O	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMXY30O	DI	DMXY30O
DMXY30O	DN	Dipyridamole
DMXY30O	MI	TTJ0IQB
DMXY30O	MN	Phosphodiesterase 5A (PDE5A)
DMXY30O	MT	DTT
DMXY30O	MA	Modulator
DMXY30O	RN	Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
DMXY30O	RU	https://www.ncbi.nlm.nih.gov/pubmed/21649691

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	TTUWYEA
DM0D9YJ	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM0D9YJ	MT	DTT
DM0D9YJ	MA	Binder
DM0D9YJ	RN	Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
DM0D9YJ	RU	https://pubmed.ncbi.nlm.nih.gov/11324679

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	DTI7UX6
DM0D9YJ	MN	Breast cancer resistance protein (ABCG2)
DM0D9YJ	MT	DTP
DM0D9YJ	MA	Substrate
DM0D9YJ	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DM0D9YJ	RU	https://doi.org/10.1042/BJ20040791

DM0D9YJ	DI	DM0D9YJ
DM0D9YJ	DN	Dirithromycin
DM0D9YJ	MI	DE4LYSA
DM0D9YJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM0D9YJ	MT	DME
DM0D9YJ	MA	Metabolism
DM0D9YJ	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DM0D9YJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DEJGDUW
DM5SYZP	MN	Cytochrome P450 1A2 (CYP1A2)
DM5SYZP	MT	DME
DM5SYZP	MA	Metabolism
DM5SYZP	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DM5SYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DE4LYSA
DM5SYZP	MN	Cytochrome P450 3A4 (CYP3A4)
DM5SYZP	MT	DME
DM5SYZP	MA	Metabolism
DM5SYZP	RN	Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.
DM5SYZP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	DTT79CX
DM5SYZP	MN	Organic cation transporter 1 (SLC22A1)
DM5SYZP	MT	DTP
DM5SYZP	MA	Substrate
DM5SYZP	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM5SYZP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM5SYZP	DI	DM5SYZP
DM5SYZP	DN	Disopyramide
DM5SYZP	MI	TTZOVE0
DM5SYZP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM5SYZP	MT	DTT
DM5SYZP	MA	Blocker
DM5SYZP	RN	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
DM5SYZP	RU	https://pubmed.ncbi.nlm.nih.gov/11196553

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DEVDYN7
DMCL2OK	MN	Cytochrome P450 2E1 (CYP2E1)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther. 1999 Oct;291(1):213-9.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490907

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DE4LYSA
DMCL2OK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24118434

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	DEIBDNY
DMCL2OK	MN	Cytochrome P450 3A5 (CYP3A5)
DMCL2OK	MT	DME
DMCL2OK	MA	Metabolism
DMCL2OK	RN	Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
DMCL2OK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9756035

DMCL2OK	DI	DMCL2OK
DMCL2OK	DN	Disulfiram
DMCL2OK	MI	TTB6UM0
DMCL2OK	MN	Fatty aldehyde dehydrogenase (ALDH3A2)
DMCL2OK	MT	DTT
DMCL2OK	MA	Inhibitor
DMCL2OK	RN	Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76.
DMCL2OK	RU	https://pubmed.ncbi.nlm.nih.gov/16545872

DM4RK0G	DI	DM4RK0G
DM4RK0G	DN	Divalproex sodium
DM4RK0G	MI	TTT2LD9
DM4RK0G	MN	GABA transaminase (ABAT)
DM4RK0G	MT	DTT
DM4RK0G	MA	Inhibitor
DM4RK0G	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM4RK0G	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMD1B8Z	DI	DMD1B8Z
DMD1B8Z	DN	Dobutamine
DMD1B8Z	MI	TTR6W5O
DMD1B8Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMD1B8Z	MT	DTT
DMD1B8Z	MA	Agonist
DMD1B8Z	RN	Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16.
DMD1B8Z	RU	https://pubmed.ncbi.nlm.nih.gov/18275933

DMD1B8Z	DI	DMD1B8Z
DMD1B8Z	DN	Dobutamine
DMD1B8Z	MI	DEV3T4A
DMD1B8Z	MN	Catechol O-methyltransferase (COMT)
DMD1B8Z	MT	DME
DMD1B8Z	MA	Metabolism
DMD1B8Z	RN	Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52.
DMD1B8Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2868577

DMS5IEB	DI	DMS5IEB
DMS5IEB	DN	Docarpamine
DMS5IEB	MI	TTEX248
DMS5IEB	MN	Dopamine D2 receptor (D2R)
DMS5IEB	MT	DTT
DMS5IEB	MA	Modulator
DMS5IEB	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMS5IEB	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTI7UX6
DMDI269	MN	Breast cancer resistance protein (ABCG2)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DE4LYSA
DMDI269	MN	Cytochrome P450 3A4 (CYP3A4)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
DMDI269	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15657405

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DEIBDNY
DMDI269	MN	Cytochrome P450 3A5 (CYP3A5)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Drug Interactions Flockhart Table
DMDI269	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DERD86B
DMDI269	MN	Cytochrome P450 3A7 (CYP3A7)
DMDI269	MT	DME
DMDI269	MA	Metabolism
DMDI269	RN	Drug Interactions Flockhart Table
DMDI269	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTSYQGK
DMDI269	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDI269	RU	https://doi.org/10.1007/s11095-012-0935-x

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTFI42L
DMDI269	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/18845662

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTPS120
DMDI269	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT3D8F0
DMDI269	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	FDA Drug Development and Drug Interactions
DMDI269	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT9C1TS
DMDI269	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/18082941

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DTUGYRD
DMDI269	MN	P-glycoprotein 1 (ABCB1)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/20628376

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	DT68UV2
DMDI269	MN	TAP-like protein (ABCB9)
DMDI269	MT	DTP
DMDI269	MA	Substrate
DMDI269	RN	RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
DMDI269	RU	http://www.ncbi.nlm.nih.gov/pubmed/28825433

DMDI269	DI	DMDI269
DMDI269	DN	Docetaxel
DMDI269	MI	TTML2WA
DMDI269	MN	Tubulin (TUB)
DMDI269	MT	DTT
DMDI269	MA	Inhibitor
DMDI269	RN	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
DMDI269	RU	https://pubmed.ncbi.nlm.nih.gov/16296875

DMOHK1E	DI	DMOHK1E
DMOHK1E	DN	Docosanol
DMOHK1E	MI	TT1JL7D
DMOHK1E	MN	Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1)
DMOHK1E	MT	DTT
DMOHK1E	MA	Modulator
DMOHK1E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOHK1E	RU	https://www.fda.gov/

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DE4LYSA
DMPN1TW	MN	Cytochrome P450 3A4 (CYP3A4)
DMPN1TW	MT	DME
DMPN1TW	MA	Metabolism
DMPN1TW	RN	Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55.
DMPN1TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8801060

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DTZGT0P
DMPN1TW	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DT3TX4H
DMPN1TW	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	DT9IDPW
DMPN1TW	MN	Organic cation transporter 2 (SLC22A2)
DMPN1TW	MT	DTP
DMPN1TW	MA	Substrate
DMPN1TW	RN	FDA Drug Development and Drug Interactions
DMPN1TW	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMPN1TW	DI	DMPN1TW
DMPN1TW	DN	Dofetilide
DMPN1TW	MI	TT1VOHK
DMPN1TW	MN	Potassium channel unspecific (KC)
DMPN1TW	MT	DTT
DMPN1TW	MA	Modulator
DMPN1TW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPN1TW	RU	https://www.fda.gov/

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	TTPC4TU
DMMG26Z	MN	5-HT 3A receptor (HTR3A)
DMMG26Z	MT	DTT
DMMG26Z	MA	Antagonist
DMMG26Z	RN	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
DMMG26Z	RU	https://pubmed.ncbi.nlm.nih.gov/19135415

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DE5IED8
DMMG26Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DECB0K3
DMMG26Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22427733

DMMG26Z	DI	DMMG26Z
DMMG26Z	DN	Dolasetron
DMMG26Z	MI	DE4LYSA
DMMG26Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMMG26Z	MT	DME
DMMG26Z	MA	Metabolism
DMMG26Z	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMMG26Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DE4LYSA
DMCZGRE	MN	Cytochrome P450 3A4 (CYP3A4)
DMCZGRE	MT	DME
DMCZGRE	MA	Metabolism
DMCZGRE	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DMCZGRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	TT5FH9Y
DMCZGRE	MN	Human immunodeficiency virus Integrase (HIV IN)
DMCZGRE	MT	DTT
DMCZGRE	MA	Modulator
DMCZGRE	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMCZGRE	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DTUGYRD
DMCZGRE	MN	P-glycoprotein 1 (ABCB1)
DMCZGRE	MT	DTP
DMCZGRE	MA	Substrate
DMCZGRE	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMCZGRE	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMCZGRE	DI	DMCZGRE
DMCZGRE	DN	Dolutegravir
DMCZGRE	MI	DEYGVN4
DMCZGRE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCZGRE	MT	DME
DMCZGRE	MA	Metabolism
DMCZGRE	RN	Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8.
DMCZGRE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEJGDUW
DMBDPY0	MN	Cytochrome P450 1A2 (CYP1A2)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEPKLMQ
DMBDPY0	MN	Cytochrome P450 2B6 (CYP2B6)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DES5XRU
DMBDPY0	MN	Cytochrome P450 2C8 (CYP2C8)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DECB0K3
DMBDPY0	MN	Cytochrome P450 2D6 (CYP2D6)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DE4LYSA
DMBDPY0	MN	Cytochrome P450 3A4 (CYP3A4)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103.
DMBDPY0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21281268

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DEIBDNY
DMBDPY0	MN	Cytochrome P450 3A5 (CYP3A5)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Drug Interactions Flockhart Table
DMBDPY0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DERD86B
DMBDPY0	MN	Cytochrome P450 3A7 (CYP3A7)
DMBDPY0	MT	DME
DMBDPY0	MA	Metabolism
DMBDPY0	RN	Drug Interactions Flockhart Table
DMBDPY0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	TTEX248
DMBDPY0	MN	Dopamine D2 receptor (D2R)
DMBDPY0	MT	DTT
DMBDPY0	MA	Antagonist
DMBDPY0	RN	Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
DMBDPY0	RU	https://pubmed.ncbi.nlm.nih.gov/18970411

DMBDPY0	DI	DMBDPY0
DMBDPY0	DN	Domperidone
DMBDPY0	MI	DTUGYRD
DMBDPY0	MN	P-glycoprotein 1 (ABCB1)
DMBDPY0	MT	DTP
DMBDPY0	MA	Substrate
DMBDPY0	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMBDPY0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	TT1RS9F
DMIYG7Z	MN	Acetylcholinesterase (AChE)
DMIYG7Z	MT	DTT
DMIYG7Z	MA	Modulator
DMIYG7Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMIYG7Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DE5IED8
DMIYG7Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26603528

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DECB0K3
DMIYG7Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DMIYG7Z	DI	DMIYG7Z
DMIYG7Z	DN	Donepezil
DMIYG7Z	MI	DE4LYSA
DMIYG7Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMIYG7Z	MT	DME
DMIYG7Z	MA	Metabolism
DMIYG7Z	RN	Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7.
DMIYG7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEV3T4A
DMPGUCF	MN	Catechol O-methyltransferase (COMT)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21656904

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEJGDUW
DMPGUCF	MN	Cytochrome P450 1A2 (CYP1A2)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9682270

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DE5IED8
DMPGUCF	MN	Cytochrome P450 2C9 (CYP2C9)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DECB0K3
DMPGUCF	MN	Cytochrome P450 2D6 (CYP2D6)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	TTEX248
DMPGUCF	MN	Dopamine D2 receptor (D2R)
DMPGUCF	MT	DTT
DMPGUCF	MA	Agonist
DMPGUCF	RN	The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
DMPGUCF	RU	https://pubmed.ncbi.nlm.nih.gov/17301410

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEL0D64
DMPGUCF	MN	Dopamine dehydroxylase (dadH)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
DMPGUCF	RU	https://pubmed.ncbi.nlm.nih.gov/31196984

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DEGTFWK
DMPGUCF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DET2NXO
DMPGUCF	MN	Monoamine oxidase type B (MAO-B)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20869994

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTT79CX
DMPGUCF	MN	Organic cation transporter 1 (SLC22A1)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DMPGUCF	RU	https://doi.org/10.2133/dmpk.23.243

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT9IDPW
DMPGUCF	MN	Organic cation transporter 2 (SLC22A2)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT3BA8L
DMPGUCF	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28055236

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DED5UR3
DMPGUCF	MN	Sulfotransferase 1B1 (SULT1B1)
DMPGUCF	MT	DME
DMPGUCF	MA	Metabolism
DMPGUCF	RN	Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
DMPGUCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9647753

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DT7A9GF
DMPGUCF	MN	Synaptic vesicle glycoprotein 2C (SLC22B3)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28246328

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTM953D
DMPGUCF	MN	Vesicular amine transporter 1 (SLC18A1)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMPGUCF	DI	DMPGUCF
DMPGUCF	DN	Dopamine
DMPGUCF	MI	DTT7VPB
DMPGUCF	MN	Vesicular amine transporter 2 (SLC18A2)
DMPGUCF	MT	DTP
DMPGUCF	MA	Substrate
DMPGUCF	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMPGUCF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMSCIKZ	DI	DMSCIKZ
DMSCIKZ	DN	Dopexamine
DMSCIKZ	MI	TTEX248
DMSCIKZ	MN	Dopamine D2 receptor (D2R)
DMSCIKZ	MT	DTT
DMSCIKZ	MA	Modulator
DMSCIKZ	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMSCIKZ	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	TT4ILYC
DM9UCJK	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM9UCJK	MT	DTT
DM9UCJK	MA	Inhibitor
DM9UCJK	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM9UCJK	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	DEC3G7M
DM9UCJK	MN	Beta-lactamase (blaB)
DM9UCJK	MT	DME
DM9UCJK	MA	Metabolism
DM9UCJK	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM9UCJK	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM9UCJK	DI	DM9UCJK
DM9UCJK	DN	Doripenem
DM9UCJK	MI	DEAMVR3
DM9UCJK	MN	Dehydropeptidase-I (DPEP1)
DM9UCJK	MT	DME
DM9UCJK	MA	Metabolism
DM9UCJK	RN	Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother. 2008 Oct;52(10):3478-83.
DM9UCJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18644951

DM3XU74	DI	DM3XU74
DM3XU74	DN	Dornase Alfa
DM3XU74	MI	TTUTN1I
DM3XU74	MN	Human Deoxyribonucleic acid (hDNA)
DM3XU74	MT	DTT
DM3XU74	MA	Breaker
DM3XU74	RN	Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45.
DM3XU74	RU	https://pubmed.ncbi.nlm.nih.gov/18031106

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	TTANPDJ
DMA17D0	MN	Carbonic anhydrase II (CA-II)
DMA17D0	MT	DTT
DMA17D0	MA	Inhibitor
DMA17D0	RN	Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
DMA17D0	RU	https://pubmed.ncbi.nlm.nih.gov/19520577

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DE5IED8
DMA17D0	MN	Cytochrome P450 2C9 (CYP2C9)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DEVDYN7
DMA17D0	MN	Cytochrome P450 2E1 (CYP2E1)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos. 1994 Nov-Dec;22(6):916-21.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895610

DMA17D0	DI	DMA17D0
DMA17D0	DN	Dorzolamide
DMA17D0	MI	DE4LYSA
DMA17D0	MN	Cytochrome P450 3A4 (CYP3A4)
DMA17D0	MT	DME
DMA17D0	MA	Metabolism
DMA17D0	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA17D0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM78NWP	DI	DM78NWP
DM78NWP	DN	Dostarlimab
DM78NWP	MI	TTNBFWK
DM78NWP	MN	Programmed cell death protein 1 (PD-1)
DM78NWP	MT	DTT
DM78NWP	MA	Inhibitor
DM78NWP	RN	Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
DM78NWP	RU	https://pubmed.ncbi.nlm.nih.gov/33251877

DMKE7L9	DI	DMKE7L9
DMKE7L9	DN	Doxacurium
DMKE7L9	MI	TTS5WZF
DMKE7L9	MN	Neuronal acetylcholine receptor alpha (NACHRA)
DMKE7L9	MT	DTT
DMKE7L9	MA	Antagonist
DMKE7L9	RN	Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61.
DMKE7L9	RU	https://pubmed.ncbi.nlm.nih.gov/8572329

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	DE4LYSA
DMCYANK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCYANK	MT	DME
DMCYANK	MA	Metabolism
DMCYANK	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DMCYANK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	DEIBDNY
DMCYANK	MN	Cytochrome P450 3A5 (CYP3A5)
DMCYANK	MT	DME
DMCYANK	MA	Metabolism
DMCYANK	RN	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
DMCYANK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340

DMCYANK	DI	DMCYANK
DMCYANK	DN	Doxapram
DMCYANK	MI	TT6EYVN
DMCYANK	MN	Peripheral carotid chemoreceptor (PCC)
DMCYANK	MT	DTT
DMCYANK	MA	Stimulator
DMCYANK	RN	Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8.
DMCYANK	RU	https://pubmed.ncbi.nlm.nih.gov/16024517

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	TT34BHT
DM9PLRH	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM9PLRH	MT	DTT
DM9PLRH	MA	Antagonist
DM9PLRH	RN	The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
DM9PLRH	RU	https://pubmed.ncbi.nlm.nih.gov/19002123

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DE5IED8
DM9PLRH	MN	Cytochrome P450 2C9 (CYP2C9)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Product monograph: CARDURA (Doxazosin mesylate).
DM9PLRH	RU	https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DECB0K3
DM9PLRH	MN	Cytochrome P450 2D6 (CYP2D6)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DE4LYSA
DM9PLRH	MN	Cytochrome P450 3A4 (CYP3A4)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DM9PLRH	DI	DM9PLRH
DM9PLRH	DN	Doxazosin
DM9PLRH	MI	DEGTFWK
DM9PLRH	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9PLRH	MT	DME
DM9PLRH	MA	Metabolism
DM9PLRH	RN	Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
DM9PLRH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DEJGDUW
DMPI98T	MN	Cytochrome P450 1A2 (CYP1A2)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DE5IED8
DMPI98T	MN	Cytochrome P450 2C9 (CYP2C9)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DECB0K3
DMPI98T	MN	Cytochrome P450 2D6 (CYP2D6)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15520506

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DE4LYSA
DMPI98T	MN	Cytochrome P450 3A4 (CYP3A4)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	TTTIBOJ
DMPI98T	MN	Histamine H1 receptor (H1R)
DMPI98T	MT	DTT
DMPI98T	MA	Inhibitor
DMPI98T	RN	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
DMPI98T	RU	https://pubmed.ncbi.nlm.nih.gov/17685877

DMPI98T	DI	DMPI98T
DMPI98T	DN	Doxepin
DMPI98T	MI	DEGTFWK
DMPI98T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPI98T	MT	DME
DMPI98T	MA	Metabolism
DMPI98T	RN	Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
DMPI98T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109

DM6FG1P	DI	DM6FG1P
DM6FG1P	DN	Doxercalciferol
DM6FG1P	MI	DEBS639
DM6FG1P	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DM6FG1P	MT	DME
DM6FG1P	MA	Metabolism
DM6FG1P	RN	Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4. Indian J Nephrol. 2013 Jul;23(4):271-5.
DM6FG1P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960343

DM6FG1P	DI	DM6FG1P
DM6FG1P	DN	Doxercalciferol
DM6FG1P	MI	TTK59TV
DM6FG1P	MN	Vitamin D3 receptor (VDR)
DM6FG1P	MT	DTT
DM6FG1P	MA	Antagonist
DM6FG1P	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DM6FG1P	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMEDKZH	DI	DMEDKZH
DMEDKZH	DN	Doxofylline
DMEDKZH	MI	DEJGDUW
DMEDKZH	MN	Cytochrome P450 1A2 (CYP1A2)
DMEDKZH	MT	DME
DMEDKZH	MA	Metabolism
DMEDKZH	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMEDKZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DED2FW3
DMVP5YE	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18635746

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEGQTXO
DMVP5YE	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18616992

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTKVEXO
DMVP5YE	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899824

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DT0KQND
DMVP5YE	MN	ATP-binding cassette sub-family B member 8 (ABCB8)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19147539

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTI7UX6
DMVP5YE	MN	Breast cancer resistance protein (ABCG2)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17273774

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DECB0K3
DMVP5YE	MN	Cytochrome P450 2D6 (CYP2D6)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE4LYSA
DMVP5YE	MN	Cytochrome P450 3A4 (CYP3A4)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17279585

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEIBDNY
DMVP5YE	MN	Cytochrome P450 3A5 (CYP3A5)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	TT0IHXV
DMVP5YE	MN	DNA topoisomerase II (TOP2)
DMVP5YE	MT	DTT
DMVP5YE	MA	Modulator
DMVP5YE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVP5YE	RU	https://www.fda.gov/

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTPATLS
DMVP5YE	MN	Fly-like putative transporter 2 (SLC22A16)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20179710

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE6NIY9
DMVP5YE	MN	Methionine synthase reductase (MTRR)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEYSOD0
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE1QMDG
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEME01W
DMVP5YE	MN	Molybdopterin-dependent enzyme (molD)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/29160065

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DT342ZG
DMVP5YE	MN	Monocarboxylate transporter 1 (SLC16A1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
DMVP5YE	RU	https://doi.org/10.1016/j.addr.2010.05.009

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTSYQGK
DMVP5YE	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/15942634

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTFI42L
DMVP5YE	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/16377671

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEAMEF2
DMVP5YE	MN	NADH dehydrogenase (nuoE)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
DMVP5YE	RU	https://pubmed.ncbi.nlm.nih.gov/23102220

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEIW03B
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE741FI
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEKX5CD
DMVP5YE	MN	NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE3N2FM
DMVP5YE	MN	NADPH-cytochrome P450 reductase (CPR)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6305277

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DEYEK78
DMVP5YE	MN	Nitric oxide synthase brain (NOS1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE708H2
DMVP5YE	MN	Nitric oxide synthase endothelial (NOS3)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE3C1JY
DMVP5YE	MN	Nitric oxide synthase inducible (NOS2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DTUGYRD
DMVP5YE	MN	P-glycoprotein 1 (ABCB1)
DMVP5YE	MT	DTP
DMVP5YE	MA	Substrate
DMVP5YE	RN	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
DMVP5YE	RU	http://www.ncbi.nlm.nih.gov/pubmed/19123050

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DENP5RY
DMVP5YE	MN	Quinone reductase 1 (NQO1)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DE4G629
DMVP5YE	MN	Succinic semialdehyde reductase (AKR7A2)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20837989

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	TTQY2EJ
DMVP5YE	MN	TERT messenger RNA (TERT mRNA)
DMVP5YE	MT	DTT
DMVP5YE	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMVP5YE	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMVP5YE	DI	DMVP5YE
DMVP5YE	DN	Doxorubicin
DMVP5YE	MI	DECG04O
DMVP5YE	MN	Xanthine dehydrogenase/oxidase (XDH)
DMVP5YE	MT	DME
DMVP5YE	MA	Metabolism
DMVP5YE	RN	Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
DMVP5YE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27458036

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	TTOVFH2
DM7ICNU	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM7ICNU	MT	DTT
DM7ICNU	MA	Modulator
DM7ICNU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7ICNU	RU	https://www.fda.gov/

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	DE4LYSA
DM7ICNU	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ICNU	MT	DME
DM7ICNU	MA	Metabolism
DM7ICNU	RN	A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.
DM7ICNU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10716067

DM7ICNU	DI	DM7ICNU
DM7ICNU	DN	Doxycycline
DM7ICNU	MI	DTUGYRD
DM7ICNU	MN	P-glycoprotein 1 (ABCB1)
DM7ICNU	MT	DTP
DM7ICNU	MA	Substrate
DM7ICNU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM7ICNU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMKOXFE	DI	DMKOXFE
DMKOXFE	DN	Doxylamine
DMKOXFE	MI	TTTIBOJ
DMKOXFE	MN	Histamine H1 receptor (H1R)
DMKOXFE	MT	DTT
DMKOXFE	MA	Antagonist
DMKOXFE	RN	First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22.
DMKOXFE	RU	https://pubmed.ncbi.nlm.nih.gov/17539447

DMGOXPQ	DI	DMGOXPQ
DMGOXPQ	DN	DP-VPA
DMGOXPQ	MI	TTNJYV2
DMGOXPQ	MN	Gamma-aminobutyric acid receptor (GAR)
DMGOXPQ	MT	DTT
DMGOXPQ	MA	Modulator
DMGOXPQ	RN	DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
DMGOXPQ	RU	https://pubmed.ncbi.nlm.nih.gov/12137414

DMF2JDG	DI	DMF2JDG
DMF2JDG	DN	Dromostanolone
DMF2JDG	MI	TTS64P2
DMF2JDG	MN	Androgen receptor (AR)
DMF2JDG	MT	DTT
DMF2JDG	MA	Binder
DMF2JDG	RN	Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34.
DMF2JDG	RU	https://pubmed.ncbi.nlm.nih.gov/15351799

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DECB0K3
DMA8FS5	MN	Cytochrome P450 2D6 (CYP2D6)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28942006

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DE4LYSA
DMA8FS5	MN	Cytochrome P450 3A4 (CYP3A4)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22971242

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	DEIBDNY
DMA8FS5	MN	Cytochrome P450 3A5 (CYP3A5)
DMA8FS5	MT	DME
DMA8FS5	MA	Metabolism
DMA8FS5	RN	Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
DMA8FS5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26490246

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	TT1VOHK
DMA8FS5	MN	Potassium channel unspecific (KC)
DMA8FS5	MT	DTT
DMA8FS5	MA	Inhibitor
DMA8FS5	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMA8FS5	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMA8FS5	DI	DMA8FS5
DMA8FS5	DN	Dronedarone
DMA8FS5	MI	TTW0CMT
DMA8FS5	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMA8FS5	MT	DTT
DMA8FS5	MA	Blocker
DMA8FS5	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMA8FS5	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DM0DXA8	DI	DM0DXA8
DM0DXA8	DN	Droperidol
DM0DXA8	MI	TTEX248
DM0DXA8	MN	Dopamine D2 receptor (D2R)
DM0DXA8	MT	DTT
DM0DXA8	MA	Binder
DM0DXA8	RN	Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.
DM0DXA8	RU	https://pubmed.ncbi.nlm.nih.gov/12505540

DM1A9W3	DI	DM1A9W3
DM1A9W3	DN	Drospirenone
DM1A9W3	MI	DE4LYSA
DM1A9W3	MN	Cytochrome P450 3A4 (CYP3A4)
DM1A9W3	MT	DME
DM1A9W3	MA	Metabolism
DM1A9W3	RN	Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018 May;11(3):251-260.
DM1A9W3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986954

DM1A9W3	DI	DM1A9W3
DM1A9W3	DN	Drospirenone
DM1A9W3	MI	TT26PHO
DM1A9W3	MN	Mineralocorticoid receptor  (MR)
DM1A9W3	MT	DTT
DM1A9W3	MA	Binder
DM1A9W3	RN	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
DM1A9W3	RU	https://pubmed.ncbi.nlm.nih.gov/16719803

DM59JCN	DI	DM59JCN
DM59JCN	DN	Drotrecogin alfa
DM59JCN	MI	TT1O264
DM59JCN	MN	Coagulation factor Va (F5)
DM59JCN	MT	DTT
DM59JCN	MA	Inhibitor
DM59JCN	RN	Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
DM59JCN	RU	https://pubmed.ncbi.nlm.nih.gov/19498123

DM59JCN	DI	DM59JCN
DM59JCN	DN	Drotrecogin alfa
DM59JCN	MI	TT1290U
DM59JCN	MN	Coagulation factor VIII (F8)
DM59JCN	MT	DTT
DM59JCN	MA	Inhibitor
DM59JCN	RN	Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
DM59JCN	RU	https://pubmed.ncbi.nlm.nih.gov/19498123

DM5YF4M	DI	DM5YF4M
DM5YF4M	DN	Droxidopa
DM5YF4M	MI	DETK9CN
DM5YF4M	MN	DOPA decarboxylase (DDC)
DM5YF4M	MT	DME
DM5YF4M	MA	Metabolism
DM5YF4M	RN	L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203.
DM5YF4M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17214596

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	DEJGDUW
DMXZRW0	MN	Cytochrome P450 1A2 (CYP1A2)
DMXZRW0	MT	DME
DMXZRW0	MA	Metabolism
DMXZRW0	RN	Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35.
DMXZRW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7967709

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	DE4ZHS1
DMXZRW0	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMXZRW0	MT	DME
DMXZRW0	MA	Metabolism
DMXZRW0	RN	Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207.
DMXZRW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16874663

DMXZRW0	DI	DMXZRW0
DMXZRW0	DN	DTI-015
DMXZRW0	MI	TTUTN1I
DMXZRW0	MN	Human Deoxyribonucleic acid (hDNA)
DMXZRW0	MT	DTT
DMXZRW0	MA	Binder
DMXZRW0	RN	Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
DMXZRW0	RU	https://pubmed.ncbi.nlm.nih.gov/1664221

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	TTCIHJA
DMCIJBH	MN	Coagulation factor Xa (F10)
DMCIJBH	MT	DTT
DMCIJBH	MA	Modulator
DMCIJBH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
DMCIJBH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	DE4LYSA
DMCIJBH	MN	Cytochrome P450 3A4 (CYP3A4)
DMCIJBH	MT	DME
DMCIJBH	MA	Metabolism
DMCIJBH	RN	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
DMCIJBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27530188

DMCIJBH	DI	DMCIJBH
DMCIJBH	DN	DU-176B
DMCIJBH	MI	DTUGYRD
DMCIJBH	MN	P-glycoprotein 1 (ABCB1)
DMCIJBH	MT	DTP
DMCIJBH	MA	Substrate
DMCIJBH	RN	Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600.
DMCIJBH	RU	http://www.ncbi.nlm.nih.gov/pubmed/27530188

DMYXBV3	DI	DMYXBV3
DMYXBV3	DN	Dulaglutide
DMYXBV3	MI	TTVIMDE
DMYXBV3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMYXBV3	MT	DTT
DMYXBV3	MA	Agonist
DMYXBV3	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMYXBV3	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DEJGDUW
DM9BI7M	MN	Cytochrome P450 1A2 (CYP1A2)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DE5IED8
DM9BI7M	MN	Cytochrome P450 2C9 (CYP2C9)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	DECB0K3
DM9BI7M	MN	Cytochrome P450 2D6 (CYP2D6)
DM9BI7M	MT	DME
DM9BI7M	MA	Metabolism
DM9BI7M	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DM9BI7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	TTAWNKZ
DM9BI7M	MN	Norepinephrine transporter (NET)
DM9BI7M	MT	DTT
DM9BI7M	MA	Inhibitor
DM9BI7M	RN	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
DM9BI7M	RU	https://pubmed.ncbi.nlm.nih.gov/17198971

DM9BI7M	DI	DM9BI7M
DM9BI7M	DN	Duloxetine
DM9BI7M	MI	TT3ROYC
DM9BI7M	MN	Serotonin transporter (SERT)
DM9BI7M	MT	DTT
DM9BI7M	MA	Inhibitor
DM9BI7M	RN	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
DM9BI7M	RU	https://pubmed.ncbi.nlm.nih.gov/17198971

DMOAD2Y	DI	DMOAD2Y
DMOAD2Y	DN	Dupilumab
DMOAD2Y	MI	TTDWHC3
DMOAD2Y	MN	Interleukin 4 receptor alpha (IL4R)
DMOAD2Y	MT	DTT
DMOAD2Y	RN	Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
DMOAD2Y	RU	https://pubmed.ncbi.nlm.nih.gov/23688323

DM4PVDY	DI	DM4PVDY
DM4PVDY	DN	Durvalumab
DM4PVDY	MI	TT8ZLTI
DM4PVDY	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM4PVDY	MT	DTT
DM4PVDY	MA	Modulator
DM4PVDY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4PVDY	RU	https://www.fda.gov/

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	DECB0K3
DMQ4TJK	MN	Cytochrome P450 2D6 (CYP2D6)
DMQ4TJK	MT	DME
DMQ4TJK	MA	Metabolism
DMQ4TJK	RN	Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94.
DMQ4TJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	DEIBDNY
DMQ4TJK	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ4TJK	MT	DME
DMQ4TJK	MA	Metabolism
DMQ4TJK	RN	Product monograph: Avodart (dutasteride capsules).
DMQ4TJK	RU	https://ca.gsk.com/media/588688/avodart.pdf

DMQ4TJK	DI	DMQ4TJK
DMQ4TJK	DN	Dutasteride
DMQ4TJK	MI	TT2A0DR
DMQ4TJK	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMQ4TJK	MT	DTT
DMQ4TJK	MA	Inhibitor
DMQ4TJK	RN	The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
DMQ4TJK	RU	https://pubmed.ncbi.nlm.nih.gov/19543428

DMU6OFP	DI	DMU6OFP
DMU6OFP	DN	Dyclonine
DMU6OFP	MI	TTZOVE0
DMU6OFP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMU6OFP	MT	DTT
DMU6OFP	MA	Blocker
DMU6OFP	RN	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
DMU6OFP	RU	https://pubmed.ncbi.nlm.nih.gov/9476974

DMAKIDV	DI	DMAKIDV
DMAKIDV	DN	Dydrogesterone
DMAKIDV	MI	DE4LYSA
DMAKIDV	MN	Cytochrome P450 3A4 (CYP3A4)
DMAKIDV	MT	DME
DMAKIDV	MA	Metabolism
DMAKIDV	RN	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74.
DMAKIDV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26796435

DMAKIDV	DI	DMAKIDV
DMAKIDV	DN	Dydrogesterone
DMAKIDV	MI	TTUV8G9
DMAKIDV	MN	Progesterone receptor (PGR)
DMAKIDV	MT	DTT
DMAKIDV	MA	Agonist
DMAKIDV	RN	Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
DMAKIDV	RU	https://pubmed.ncbi.nlm.nih.gov/18061638

DM8DZC1	DI	DM8DZC1
DM8DZC1	DN	Dyphylline
DM8DZC1	MI	TTZ97H5
DM8DZC1	MN	Phosphodiesterase 4A (PDE4A)
DM8DZC1	MT	DTT
DM8DZC1	MA	Inhibitor
DM8DZC1	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DM8DZC1	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DEJGDUW
DMJDYNQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698.
DMJDYNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27904300

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DE4LYSA
DMJDYNQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
DMJDYNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25495693

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	DEIBDNY
DMJDYNQ	MN	Cytochrome P450 3A5 (CYP3A5)
DMJDYNQ	MT	DME
DMJDYNQ	MA	Metabolism
DMJDYNQ	RN	FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
DMJDYNQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTAN6JD
DMJDYNQ	MN	Glutamate receptor AMPA (GRIA)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Modulator
DMJDYNQ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTVPQTF
DMJDYNQ	MN	Glutamate receptor AMPA 1 (GRIA1)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TT9HLZ0
DMJDYNQ	MN	Glutamate receptor AMPA 2 (GRIA2)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TT82EZV
DMJDYNQ	MN	Glutamate receptor AMPA 3 (GRIA3)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJDYNQ	DI	DMJDYNQ
DMJDYNQ	DN	E-2007
DMJDYNQ	MI	TTPJR0G
DMJDYNQ	MN	Glutamate receptor AMPA 4 (GRIA4)
DMJDYNQ	MT	DTT
DMJDYNQ	MA	Inhibitor
DMJDYNQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJDYNQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMOF2C6	DI	DMOF2C6
DMOF2C6	DN	Ecallantide
DMOF2C6	MI	TT5L2VC
DMOF2C6	MN	Kallikrein-related peptidase (KLK)
DMOF2C6	MT	DTT
DMOF2C6	MA	Inhibitor
DMOF2C6	RN	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
DMOF2C6	RU	https://pubmed.ncbi.nlm.nih.gov/18613770

DMOF2C6	DI	DMOF2C6
DMOF2C6	DN	Ecallantide
DMOF2C6	MI	TTMF8H9
DMOF2C6	MN	Plasma kallikrein (KLKB1)
DMOF2C6	MT	DTT
DMOF2C6	MA	Inhibitor
DMOF2C6	RN	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
DMOF2C6	RU	https://pubmed.ncbi.nlm.nih.gov/18613770

DMSNVGB	DI	DMSNVGB
DMSNVGB	DN	Echothiophate Iodide
DMSNVGB	MI	TT1RS9F
DMSNVGB	MN	Acetylcholinesterase (AChE)
DMSNVGB	MT	DTT
DMSNVGB	MA	Modulator
DMSNVGB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSNVGB	RU	https://www.fda.gov/

DMFSWGH	DI	DMFSWGH
DMFSWGH	DN	Econazole
DMFSWGH	MI	TTTSOUD
DMFSWGH	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMFSWGH	MT	DTT
DMFSWGH	MA	Inhibitor
DMFSWGH	RN	Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
DMFSWGH	RU	https://pubmed.ncbi.nlm.nih.gov/18694951

DMCRQHB	DI	DMCRQHB
DMCRQHB	DN	Edrophonium
DMCRQHB	MI	TT1RS9F
DMCRQHB	MN	Acetylcholinesterase (AChE)
DMCRQHB	MT	DTT
DMCRQHB	MA	Inhibitor
DMCRQHB	RN	Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
DMCRQHB	RU	https://pubmed.ncbi.nlm.nih.gov/19472276

DMCKL5V	DI	DMCKL5V
DMCKL5V	DN	Efalizumab
DMCKL5V	MI	TT48WR6
DMCKL5V	MN	Integrin alpha-L (ITGAL)
DMCKL5V	MT	DTT
DMCKL5V	RN	[Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9.
DMCKL5V	RU	https://pubmed.ncbi.nlm.nih.gov/19436973

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DEJGDUW
DMC0GSJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31339646

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DEPKLMQ
DMC0GSJ	MN	Cytochrome P450 2B6 (CYP2B6)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DE4LYSA
DMC0GSJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMC0GSJ	MT	DME
DMC0GSJ	MA	Metabolism
DMC0GSJ	RN	Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81.
DMC0GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15496645

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	TT84ETX
DMC0GSJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMC0GSJ	MT	DTT
DMC0GSJ	MA	Modulator
DMC0GSJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMC0GSJ	RU	https://www.fda.gov/

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DTQ3ZHF
DMC0GSJ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMC0GSJ	MT	DTP
DMC0GSJ	MA	Substrate
DMC0GSJ	RN	Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
DMC0GSJ	RU	https://doi.org/10.1254/jphs.08209FP

DMC0GSJ	DI	DMC0GSJ
DMC0GSJ	DN	Efavirenz
DMC0GSJ	MI	DTUGYRD
DMC0GSJ	MN	P-glycoprotein 1 (ABCB1)
DMC0GSJ	MT	DTP
DMC0GSJ	MA	Substrate
DMC0GSJ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMC0GSJ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMFA9MV	DI	DMFA9MV
DMFA9MV	DN	Efinaconazole
DMFA9MV	MI	TTTSOUD
DMFA9MV	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMFA9MV	MT	DTT
DMFA9MV	MA	Inhibitor
DMFA9MV	RN	Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25.
DMFA9MV	RU	https://pubmed.ncbi.nlm.nih.gov/25527861

DMJOQM3	DI	DMJOQM3
DMJOQM3	DN	Eflornithine
DMJOQM3	MI	TTUMGNO
DMJOQM3	MN	Ornithine decarboxylase (ODC1)
DMJOQM3	MT	DTT
DMJOQM3	MA	Inhibitor
DMJOQM3	RN	Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43.
DMJOQM3	RU	https://pubmed.ncbi.nlm.nih.gov/3115816

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE5IED8
DMMUCG4	MN	Cytochrome P450 2C9 (CYP2C9)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21945326

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DT5G94L
DMMUCG4	MN	Major facilitator superfamily domain-containing protein 2A (SLC59A1)
DMMUCG4	MT	DTP
DMMUCG4	MA	Substrate
DMMUCG4	RN	Mfsd2a Is a Transporter for the Essential -3 Fatty Acid Docosahexaenoic Acid (DHA) in Eye and Is Important for Photoreceptor Cell Development. J Biol Chem. 2016 May 13;291(20):10501-14.
DMMUCG4	RU	http://www.ncbi.nlm.nih.gov/pubmed/27008858

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	TT8NGED
DMMUCG4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMUCG4	MT	DTT
DMMUCG4	MA	Inhibitor
DMMUCG4	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMMUCG4	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE073H6
DMMUCG4	MN	Prostaglandin G/H synthase 1 (COX-1)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	TTVKILB
DMMUCG4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMUCG4	MT	DTT
DMMUCG4	MA	Inhibitor
DMMUCG4	RN	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
DMMUCG4	RU	https://pubmed.ncbi.nlm.nih.gov/11421736

DMMUCG4	DI	DMMUCG4
DMMUCG4	DN	Eicosapentaenoic acid/docosa-hexaenoic acid
DMMUCG4	MI	DE492CE
DMMUCG4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMMUCG4	MT	DME
DMMUCG4	MA	Metabolism
DMMUCG4	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMMUCG4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMRDUC0	DI	DMRDUC0
DMRDUC0	DN	Elagolix sodium
DMRDUC0	MI	TT8R70G
DMRDUC0	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMRDUC0	MT	DTT
DMRDUC0	MA	Antagonist
DMRDUC0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMRDUC0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMS7OU8	DI	DMS7OU8
DMS7OU8	DN	Elapegademase
DMS7OU8	MI	TTLP57V
DMS7OU8	MN	Adenosine deaminase (ADA)
DMS7OU8	MT	DTT
DMS7OU8	MA	Modulator
DMS7OU8	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMS7OU8	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMJLE18	DI	DMJLE18
DMJLE18	DN	Elbasvir
DMJLE18	MI	DE4LYSA
DMJLE18	MN	Cytochrome P450 3A4 (CYP3A4)
DMJLE18	MT	DME
DMJLE18	MA	Metabolism
DMJLE18	RN	Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531.
DMJLE18	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557529

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	TTK8CXU
DMW649X	MN	5-HT 1B receptor (HTR1B)
DMW649X	MT	DTT
DMW649X	MA	Modulator
DMW649X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW649X	RU	https://www.fda.gov/

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	TT6MSOK
DMW649X	MN	5-HT 1D receptor (HTR1D)
DMW649X	MT	DTT
DMW649X	MA	Modulator
DMW649X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW649X	RU	https://www.fda.gov/

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE5IED8
DMW649X	MN	Cytochrome P450 2C9 (CYP2C9)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27582896

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DECB0K3
DMW649X	MN	Cytochrome P450 2D6 (CYP2D6)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814962

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE4LYSA
DMW649X	MN	Cytochrome P450 3A4 (CYP3A4)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DTUGYRD
DMW649X	MN	P-glycoprotein 1 (ABCB1)
DMW649X	MT	DTP
DMW649X	MA	Substrate
DMW649X	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMW649X	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMW649X	DI	DMW649X
DMW649X	DN	Eletriptan
DMW649X	MI	DE073H6
DMW649X	MN	Prostaglandin G/H synthase 1 (COX-1)
DMW649X	MT	DME
DMW649X	MA	Metabolism
DMW649X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMW649X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	TTPHEX3
DMSRZAO	MN	Ceramide glucosyltransferase (UGCG)
DMSRZAO	MT	DTT
DMSRZAO	MA	Modulator
DMSRZAO	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSRZAO	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DECB0K3
DMSRZAO	MN	Cytochrome P450 2D6 (CYP2D6)
DMSRZAO	MT	DME
DMSRZAO	MA	Metabolism
DMSRZAO	RN	Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36.
DMSRZAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25239269

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DE4LYSA
DMSRZAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMSRZAO	MT	DME
DMSRZAO	MA	Metabolism
DMSRZAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSRZAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSRZAO	DI	DMSRZAO
DMSRZAO	DN	Eliglustat tartrate
DMSRZAO	MI	DTUGYRD
DMSRZAO	MN	P-glycoprotein 1 (ABCB1)
DMSRZAO	MT	DTP
DMSRZAO	MA	Substrate
DMSRZAO	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMSRZAO	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMZC6GT	DI	DMZC6GT
DMZC6GT	DN	Elliptinium acetate
DMZC6GT	MI	TTABD5E
DMZC6GT	MN	DNA replication (DNA repli)
DMZC6GT	MT	DTT
DMZC6GT	MA	Modulator
DMZC6GT	RN	Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.
DMZC6GT	RU	https://pubmed.ncbi.nlm.nih.gov/91123

DMRCX8K	DI	DMRCX8K
DMRCX8K	DN	Eloctate
DMRCX8K	MI	TT1290U
DMRCX8K	MN	Coagulation factor VIII (F8)
DMRCX8K	MT	DTT
DMRCX8K	MA	Modulator
DMRCX8K	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMRCX8K	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMA9REV	DI	DMA9REV
DMA9REV	DN	Elosulfase alfa
DMA9REV	MI	TTT9YPO
DMA9REV	MN	N-acetylgalactosamine 6 sulfatase (GALNS)
DMA9REV	MT	DTT
DMA9REV	MA	Modulator
DMA9REV	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMA9REV	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMEYHG9	DI	DMEYHG9
DMEYHG9	DN	Elotuzumab
DMEYHG9	MI	TT7ILZ1
DMEYHG9	MN	SLAM family member 7 SLAMF7 (CS1)
DMEYHG9	MT	DTT
DMEYHG9	RN	Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
DMEYHG9	RU	https://pubmed.ncbi.nlm.nih.gov/25764988

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DTI7UX6
DMOGFIX	MN	Breast cancer resistance protein (ABCG2)
DMOGFIX	MT	DTP
DMOGFIX	MA	Substrate
DMOGFIX	RN	Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51.
DMOGFIX	RU	https://doi.org/10.1128/AAC.05214-11

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DEJGDUW
DMOGFIX	MN	Cytochrome P450 1A2 (CYP1A2)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 Feb 27;2(4):454-461.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29487060

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DES5XRU
DMOGFIX	MN	Cytochrome P450 2C8 (CYP2C8)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DTPFTEQ
DMOGFIX	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMOGFIX	MT	DTP
DMOGFIX	MA	Substrate
DMOGFIX	RN	Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
DMOGFIX	RU	http://www.ncbi.nlm.nih.gov/pubmed/21422191

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	TTIHYA4
DMOGFIX	MN	Thrombopoietin receptor (MPL)
DMOGFIX	MT	DTT
DMOGFIX	MA	Agonist
DMOGFIX	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMOGFIX	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMOGFIX	DI	DMOGFIX
DMOGFIX	DN	Eltrombopag
DMOGFIX	MI	DEYGVN4
DMOGFIX	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOGFIX	MT	DME
DMOGFIX	MA	Metabolism
DMOGFIX	RN	Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388.
DMOGFIX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	TT27RFC
DMYZ0P1	MN	Opioid receptor delta (OPRD1)
DMYZ0P1	MT	DTT
DMYZ0P1	MA	Modulator
DMYZ0P1	RN	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
DMYZ0P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25261794

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	TTKWM86
DMYZ0P1	MN	Opioid receptor mu (MOP)
DMYZ0P1	MT	DTT
DMYZ0P1	MA	Modulator
DMYZ0P1	RN	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
DMYZ0P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25261794

DMYZ0P1	DI	DMYZ0P1
DMYZ0P1	DN	Eluxadoline
DMYZ0P1	MI	DT3D8F0
DMYZ0P1	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMYZ0P1	MT	DTP
DMYZ0P1	MA	Substrate
DMYZ0P1	RN	Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42.
DMYZ0P1	RU	http://www.ncbi.nlm.nih.gov/pubmed/25491493

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	DE4LYSA
DMG9B1U	MN	Cytochrome P450 3A4 (CYP3A4)
DMG9B1U	MT	DME
DMG9B1U	MA	Metabolism
DMG9B1U	RN	FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration.
DMG9B1U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203100s030lbl.pdf

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	TT5FH9Y
DMG9B1U	MN	Human immunodeficiency virus Integrase (HIV IN)
DMG9B1U	MT	DTT
DMG9B1U	MA	Modulator
DMG9B1U	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMG9B1U	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMG9B1U	DI	DMG9B1U
DMG9B1U	DN	Elvitegravir
DMG9B1U	MI	DEYGVN4
DMG9B1U	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMG9B1U	MT	DME
DMG9B1U	MA	Metabolism
DMG9B1U	RN	Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17.
DMG9B1U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24696866

DMZG5WL	DI	DMZG5WL
DMZG5WL	DN	Emapalumab
DMZG5WL	MI	TT93WF5
DMZG5WL	MN	Interferon-gamma (IFNG)
DMZG5WL	MT	DTT
DMZG5WL	MA	Modulator
DMZG5WL	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMZG5WL	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM36LAJ	DI	DM36LAJ
DM36LAJ	DN	Emedastine
DM36LAJ	MI	TTTIBOJ
DM36LAJ	MN	Histamine H1 receptor (H1R)
DM36LAJ	MT	DTT
DM36LAJ	MA	Antagonist
DM36LAJ	RN	Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.
DM36LAJ	RU	https://pubmed.ncbi.nlm.nih.gov/19558341

DMCOAVT	DI	DMCOAVT
DMCOAVT	DN	Emepronium
DMCOAVT	MI	TTH18TF
DMCOAVT	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMCOAVT	MT	DTT
DMCOAVT	MA	Modulator
DMCOAVT	RN	Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68.
DMCOAVT	RU	https://pubmed.ncbi.nlm.nih.gov/7616431

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DECB0K3
DMCT2YF	MN	Cytochrome P450 2D6 (CYP2D6)
DMCT2YF	MT	DME
DMCT2YF	MA	Metabolism
DMCT2YF	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DMCT2YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DE4LYSA
DMCT2YF	MN	Cytochrome P450 3A4 (CYP3A4)
DMCT2YF	MT	DME
DMCT2YF	MA	Metabolism
DMCT2YF	RN	Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82.
DMCT2YF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558

DMCT2YF	DI	DMCT2YF
DMCT2YF	DN	Emetine
DMCT2YF	MI	DTUGYRD
DMCT2YF	MN	P-glycoprotein 1 (ABCB1)
DMCT2YF	MT	DTP
DMCT2YF	MA	Substrate
DMCT2YF	RN	Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35.
DMCT2YF	RU	https://doi.org/10.1111/j.0013-9580.2005.31904.x

DM0AQ83	DI	DM0AQ83
DM0AQ83	DN	Emicizumab
DM0AQ83	MI	TTFEZ5Q
DM0AQ83	MN	Coagulation factor IX (F9)
DM0AQ83	MT	DTT
DM0AQ83	MA	Modulator
DM0AQ83	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0AQ83	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM0AQ83	DI	DM0AQ83
DM0AQ83	DN	Emicizumab
DM0AQ83	MI	TTCIHJA
DM0AQ83	MN	Coagulation factor Xa (F10)
DM0AQ83	MT	DTT
DM0AQ83	MA	Modulator
DM0AQ83	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0AQ83	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DTI7UX6
DMRF9YK	MN	Breast cancer resistance protein (ABCG2)
DMRF9YK	MT	DTP
DMRF9YK	MA	Substrate
DMRF9YK	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMRF9YK	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DTUGYRD
DMRF9YK	MN	P-glycoprotein 1 (ABCB1)
DMRF9YK	MT	DTP
DMRF9YK	MA	Substrate
DMRF9YK	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMRF9YK	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	TTLWPVF
DMRF9YK	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMRF9YK	MT	DTT
DMRF9YK	MA	Modulator
DMRF9YK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMRF9YK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DEF2WXN
DMRF9YK	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DE2GB8N
DMRF9YK	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DE85D2P
DMRF9YK	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMRF9YK	DI	DMRF9YK
DMRF9YK	DN	Empagliflozin
DMRF9YK	MI	DEB3CV1
DMRF9YK	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRF9YK	MT	DME
DMRF9YK	MA	Metabolism
DMRF9YK	RN	Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
DMRF9YK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645

DMBMUWZ	DI	DMBMUWZ
DMBMUWZ	DN	Emtricitabine
DMBMUWZ	MI	TT84ETX
DMBMUWZ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBMUWZ	MT	DTT
DMBMUWZ	MA	Modulator
DMBMUWZ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMBMUWZ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMBMUWZ	DI	DMBMUWZ
DMBMUWZ	DN	Emtricitabine
DMBMUWZ	MI	DTZGT0P
DMBMUWZ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMBMUWZ	MT	DTP
DMBMUWZ	MA	Substrate
DMBMUWZ	RN	Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
DMBMUWZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27052107

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	TTL69WB
DMNFUZR	MN	Angiotensin-converting enzyme (ACE)
DMNFUZR	MT	DTT
DMNFUZR	MA	Inhibitor
DMNFUZR	RN	Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8.
DMNFUZR	RU	https://pubmed.ncbi.nlm.nih.gov/19557238

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DEB30C5
DMNFUZR	MN	Carboxylesterase 1 (CES1)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
DMNFUZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25832562

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DE4LYSA
DMNFUZR	MN	Cytochrome P450 3A4 (CYP3A4)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNFUZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DEQMBHW
DMNFUZR	MN	Dipeptidase (pepV)
DMNFUZR	MT	DME
DMNFUZR	MA	Metabolism
DMNFUZR	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DMNFUZR	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DTFI42L
DMNFUZR	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16627748

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DTE2B1D
DMNFUZR	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/10859154

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT3D8F0
DMNFUZR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/9794920

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT9C1TS
DMNFUZR	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/16627748

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT9G7XN
DMNFUZR	MN	Peptide transporter 1 (SLC15A1)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
DMNFUZR	RU	https://doi.org/10.1016/S0928-0987(03)00142-8

DMNFUZR	DI	DMNFUZR
DMNFUZR	DN	Enalapril
DMNFUZR	MI	DT8QKNP
DMNFUZR	MN	Peptide transporter 2 (SLC15A2)
DMNFUZR	MT	DTP
DMNFUZR	MA	Substrate
DMNFUZR	RN	Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84.
DMNFUZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18336632

DMPRBQV	DI	DMPRBQV
DMPRBQV	DN	Enalaprilat
DMPRBQV	MI	TTL69WB
DMPRBQV	MN	Angiotensin-converting enzyme (ACE)
DMPRBQV	MT	DTT
DMPRBQV	MA	Inhibitor
DMPRBQV	RN	Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687.
DMPRBQV	RU	https://pubmed.ncbi.nlm.nih.gov/11862223

DMFYAM1	DI	DMFYAM1
DMFYAM1	DN	Enalaprilat
DMFYAM1	MI	DEQMBHW
DMFYAM1	MN	Dipeptidase (pepV)
DMFYAM1	MT	DME
DMFYAM1	MA	Metabolism
DMFYAM1	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DMFYAM1	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DMPRBQV	DI	DMPRBQV
DMPRBQV	DN	Enalaprilat
DMPRBQV	MI	DT9G7XN
DMPRBQV	MN	Peptide transporter 1 (SLC15A1)
DMPRBQV	MT	DTP
DMPRBQV	MA	Substrate
DMPRBQV	RN	Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74.
DMPRBQV	RU	https://doi.org/10.2133/dmpk.17.253

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEJGDUW
DM8QXOC	MN	Cytochrome P450 1A2 (CYP1A2)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEPKLMQ
DM8QXOC	MN	Cytochrome P450 2B6 (CYP2B6)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DES5XRU
DM8QXOC	MN	Cytochrome P450 2C8 (CYP2C8)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DE5IED8
DM8QXOC	MN	Cytochrome P450 2C9 (CYP2C9)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration.
DM8QXOC	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf

DM8QXOC	DI	DM8QXOC
DM8QXOC	DN	Enasidenib
DM8QXOC	MI	DEGTFWK
DM8QXOC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8QXOC	MT	DME
DM8QXOC	MA	Metabolism
DM8QXOC	RN	Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760.
DM8QXOC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29770715

DMPOU5H	DI	DMPOU5H
DMPOU5H	DN	ENASIDENIB MESYLATE
DMPOU5H	MI	TTDTWV0
DMPOU5H	MN	Isocitrate dehydrogenase (IDH)
DMPOU5H	MT	DTT
DMPOU5H	MA	Inhibitor
DMPOU5H	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMPOU5H	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM7RNP3	DI	DM7RNP3
DM7RNP3	DN	Enbrel
DM7RNP3	MI	TTF8CQI
DM7RNP3	MN	Tumor necrosis factor (TNF)
DM7RNP3	MT	DTT
DM7RNP3	MA	Modulator
DM7RNP3	RN	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
DM7RNP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11451976

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	DEVDYN7
DM0YJSB	MN	Cytochrome P450 2E1 (CYP2E1)
DM0YJSB	MT	DME
DM0YJSB	MA	Metabolism
DM0YJSB	RN	Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos. 1995 Dec;23(12):1426-30.
DM0YJSB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8689955

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	DED5AT3
DM0YJSB	MN	Cytochrome P450 2F1 (CYP2F1)
DM0YJSB	MT	DME
DM0YJSB	MA	Metabolism
DM0YJSB	RN	Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther. 1994 Apr;55(4):434-40.
DM0YJSB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8162670

DM0YJSB	DI	DM0YJSB
DM0YJSB	DN	Enflurane
DM0YJSB	MI	TTAN6JD
DM0YJSB	MN	Glutamate receptor AMPA (GRIA)
DM0YJSB	MT	DTT
DM0YJSB	MA	Suppressor
DM0YJSB	RN	Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
DM0YJSB	RU	https://pubmed.ncbi.nlm.nih.gov/11020764

DMFS63G	DI	DMFS63G
DMFS63G	DN	Enfortumab
DMFS63G	MI	TTPO9EG
DMFS63G	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DMFS63G	MT	DTT
DMFS63G	MA	Inhibitor
DMFS63G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMFS63G	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	DEVDYN7
DM7YPM1	MN	Cytochrome P450 2E1 (CYP2E1)
DM7YPM1	MT	DME
DM7YPM1	MA	Metabolism
DM7YPM1	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DM7YPM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	TTG90S6
DM7YPM1	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DM7YPM1	MT	DTT
DM7YPM1	MA	Modulator
DM7YPM1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7YPM1	RU	https://www.fda.gov/

DM7YPM1	DI	DM7YPM1
DM7YPM1	DN	Enfuvirtide
DM7YPM1	MI	DEGTFWK
DM7YPM1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7YPM1	MT	DME
DM7YPM1	MA	Metabolism
DM7YPM1	RN	Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
DM7YPM1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	TT0IHXV
DMYTE6L	MN	DNA topoisomerase II (TOP2)
DMYTE6L	MT	DTT
DMYTE6L	MA	Inhibitor
DMYTE6L	RN	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
DMYTE6L	RU	https://pubmed.ncbi.nlm.nih.gov/3282749

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	DTZGT0P
DMYTE6L	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMYTE6L	MT	DTP
DMYTE6L	MA	Substrate
DMYTE6L	RN	Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
DMYTE6L	RU	http://www.ncbi.nlm.nih.gov/pubmed/19004926

DMYTE6L	DI	DMYTE6L
DMYTE6L	DN	Enoxacin
DMYTE6L	MI	DTE2B1D
DMYTE6L	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMYTE6L	MT	DTP
DMYTE6L	MA	Substrate
DMYTE6L	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMYTE6L	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMQVZJD	DI	DMQVZJD
DMQVZJD	DN	Enoximone
DMQVZJD	MI	TTZCG4L
DMQVZJD	MN	Phosphodiesterase 3 (PDE3)
DMQVZJD	MT	DTT
DMQVZJD	MA	Modulator
DMQVZJD	RN	In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
DMQVZJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/12657857

DMQVZJD	DI	DMQVZJD
DMQVZJD	DN	Enoximone
DMQVZJD	MI	TT06AWU
DMQVZJD	MN	Phosphodiesterase 3A (PDE3A)
DMQVZJD	MT	DTT
DMQVZJD	MA	Inhibitor
DMQVZJD	RN	Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
DMQVZJD	RU	https://pubmed.ncbi.nlm.nih.gov/3027339

DMFYZKN	DI	DMFYZKN
DMFYZKN	DN	Enprofylline
DMFYZKN	MI	TTZ97H5
DMFYZKN	MN	Phosphodiesterase 4A (PDE4A)
DMFYZKN	MT	DTT
DMFYZKN	MA	Inhibitor
DMFYZKN	RN	Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62.
DMFYZKN	RU	https://pubmed.ncbi.nlm.nih.gov/3034059

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DTI7UX6
DMLBVKQ	MN	Breast cancer resistance protein (ABCG2)
DMLBVKQ	MT	DTP
DMLBVKQ	MA	Substrate
DMLBVKQ	RN	Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291.
DMLBVKQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28916530

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	TTKWFB8
DMLBVKQ	MN	Catechol-O-methyl-transferase (COMT)
DMLBVKQ	MT	DTT
DMLBVKQ	MA	Inhibitor
DMLBVKQ	RN	Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771.
DMLBVKQ	RU	https://pubmed.ncbi.nlm.nih.gov/11440283

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DT3D8F0
DMLBVKQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLBVKQ	MT	DTP
DMLBVKQ	MA	Substrate
DMLBVKQ	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMLBVKQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMLBVKQ	DI	DMLBVKQ
DMLBVKQ	DN	Entacapone
DMLBVKQ	MI	DE85D2P
DMLBVKQ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMLBVKQ	MT	DME
DMLBVKQ	MA	Metabolism
DMLBVKQ	RN	Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26.
DMLBVKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15802387

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTI7UX6
DM7VTQO	MN	Breast cancer resistance protein (ABCG2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT4YL5R
DM7VTQO	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT82KPY
DM7VTQO	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTXD1TQ
DM7VTQO	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DTW78DQ
DM7VTQO	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	TTS5K1M
DM7VTQO	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM7VTQO	MT	DTT
DM7VTQO	MA	Modulator
DM7VTQO	RN	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7.
DM7VTQO	RU	https://pubmed.ncbi.nlm.nih.gov/24610871

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT0OC1Q
DM7VTQO	MN	Organic anion transporter 2 (SLC22A7)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/27916488

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT6201N
DM7VTQO	MN	Organic cation transporter 3 (SLC22A3)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT3HUVD
DM7VTQO	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/28062543

DM7VTQO	DI	DM7VTQO
DM7VTQO	DN	Entecavir
DM7VTQO	MI	DT8QKNP
DM7VTQO	MN	Peptide transporter 2 (SLC15A2)
DM7VTQO	MT	DTP
DM7VTQO	MA	Substrate
DM7VTQO	RN	The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.
DM7VTQO	RU	http://www.ncbi.nlm.nih.gov/pubmed/24184752

DMK659W	DI	DMK659W
DMK659W	DN	Enteric-coated mycophenolate sodium
DMK659W	MI	TTCAQMW
DMK659W	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DMK659W	MT	DTT
DMK659W	MA	Inhibitor
DMK659W	RN	Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8.
DMK659W	RU	https://pubmed.ncbi.nlm.nih.gov/14723604

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTPMQSO
DMMPTLH	MN	ALK tyrosine kinase receptor (ALK)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTKN7QR
DMMPTLH	MN	BDNF/NT-3 growth factors receptor (TrkB)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	DE4LYSA
DMMPTLH	MN	Cytochrome P450 3A4 (CYP3A4)
DMMPTLH	MT	DME
DMMPTLH	MA	Metabolism
DMMPTLH	RN	Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483.
DMMPTLH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31372957

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTXABCW
DMMPTLH	MN	NT-3 growth factor receptor (TrkC)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTSZ6Y3
DMMPTLH	MN	Proto-oncogene c-Ros (ROS1)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMMPTLH	DI	DMMPTLH
DMMPTLH	DN	Entrectinib
DMMPTLH	MI	TTTDVOJ
DMMPTLH	MN	Tropomyosin-related kinase A (TrkA)
DMMPTLH	MT	DTT
DMMPTLH	MA	Inhibitor
DMMPTLH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMMPTLH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf

DMGL19D	DI	DMGL19D
DMGL19D	DN	Enzalutamide
DMGL19D	MI	TTS64P2
DMGL19D	MN	Androgen receptor (AR)
DMGL19D	MT	DTT
DMGL19D	MA	Modulator
DMGL19D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMGL19D	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5OGK0	DI	DM5OGK0
DM5OGK0	DN	Epalrestat
DM5OGK0	MI	TTFBNVI
DM5OGK0	MN	Aldose reductase (AKR1B1)
DM5OGK0	MT	DTT
DM5OGK0	MA	Inhibitor
DM5OGK0	RN	Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
DM5OGK0	RU	https://pubmed.ncbi.nlm.nih.gov/11522497

DM5OGK0	DI	DM5OGK0
DM5OGK0	DN	Epalrestat
DM5OGK0	MI	TTXHYV6
DM5OGK0	MN	Voltage-gated L-type calcium channel (L-CaC)
DM5OGK0	MT	DTT
DM5OGK0	MA	Blocker
DM5OGK0	RN	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
DM5OGK0	RU	https://pubmed.ncbi.nlm.nih.gov/19442208

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DE87OZS
DMHEAGL	MN	Arachidonate 5-lipoxygenase (ALOX5)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Omega-3 fatty acids and inflammatory processes. Nutrients. 2010 Mar;2(3):355-74.
DMHEAGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22254027

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DEIPST6
DMHEAGL	MN	Cytochrome P450 147G1 (cyp147)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Selective Omega-1 oxidation of fatty acids by CYP147G1 from Mycobacterium marinum. Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):408-417.
DMHEAGL	RU	https://pubmed.ncbi.nlm.nih.gov/30476524

DMHEAGL	DI	DMHEAGL
DMHEAGL	DN	Epanova
DMHEAGL	MI	DE492CE
DMHEAGL	MN	Prostaglandin G/H synthase 2 (COX-2)
DMHEAGL	MT	DME
DMHEAGL	MA	Metabolism
DMHEAGL	RN	Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
DMHEAGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20463020

DMMV0KW	DI	DMMV0KW
DMMV0KW	DN	Ephedrine
DMMV0KW	MI	TTEX248
DMMV0KW	MN	Dopamine D2 receptor (D2R)
DMMV0KW	MT	DTT
DMMV0KW	MA	Agonist
DMMV0KW	RN	The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7.
DMMV0KW	RU	https://pubmed.ncbi.nlm.nih.gov/17159617

DMMV0KW	DI	DMMV0KW
DMMV0KW	DN	Ephedrine
DMMV0KW	MI	DEYWLRK
DMMV0KW	MN	Sulfotransferase 1A1 (SULT1A1)
DMMV0KW	MT	DME
DMMV0KW	MA	Metabolism
DMMV0KW	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DMMV0KW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	DE1TNRG
DMVONE6	MN	Carboxypeptidase M (CPM)
DMVONE6	MT	DME
DMVONE6	MA	Metabolism
DMVONE6	RN	Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J Biol Chem. 1995 Jul 21;270(29):17154-8.
DMVONE6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7615511

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	TTED8JB
DMVONE6	MN	Epidermal growth factor (EGF)
DMVONE6	MT	DTT
DMVONE6	MA	Modulator
DMVONE6	RN	Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52.
DMVONE6	RU	http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html

DMVONE6	DI	DMVONE6
DMVONE6	DN	Epidermal growth factor
DMVONE6	MI	TTGKNB4
DMVONE6	MN	Epidermal growth factor receptor (EGFR)
DMVONE6	MT	DTT
DMVONE6	MA	Modulator
DMVONE6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMVONE6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DEPKLMQ
DMX0K3Q	MN	Cytochrome P450 2B6 (CYP2B6)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DECB0K3
DMX0K3Q	MN	Cytochrome P450 2D6 (CYP2D6)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DE4LYSA
DMX0K3Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMX0K3Q	MT	DME
DMX0K3Q	MA	Metabolism
DMX0K3Q	RN	Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.
DMX0K3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	TTTIBOJ
DMX0K3Q	MN	Histamine H1 receptor (H1R)
DMX0K3Q	MT	DTT
DMX0K3Q	MA	Antagonist
DMX0K3Q	RN	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
DMX0K3Q	RU	https://pubmed.ncbi.nlm.nih.gov/19381339

DMX0K3Q	DI	DMX0K3Q
DMX0K3Q	DN	Epinastine
DMX0K3Q	MI	DTUGYRD
DMX0K3Q	MN	P-glycoprotein 1 (ABCB1)
DMX0K3Q	MT	DTP
DMX0K3Q	MA	Substrate
DMX0K3Q	RN	Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24.
DMX0K3Q	RU	https://doi.org/10.1124/dmd.32.5.519

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	TTR6W5O
DM3KJBC	MN	Adrenergic receptor beta-1 (ADRB1)
DM3KJBC	MT	DTT
DM3KJBC	MA	Agonist
DM3KJBC	RN	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
DM3KJBC	RU	https://pubmed.ncbi.nlm.nih.gov/19460844

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEV3T4A
DM3KJBC	MN	Catechol O-methyltransferase (COMT)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther. 1994 Mar;268(3):1242-51.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8138937

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DERE4TU
DM3KJBC	MN	Monoamine oxidase type A (MAO-A)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31556016

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DTT79CX
DM3KJBC	MN	Organic cation transporter 1 (SLC22A1)
DM3KJBC	MT	DTP
DM3KJBC	MA	Substrate
DM3KJBC	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3KJBC	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DT6201N
DM3KJBC	MN	Organic cation transporter 3 (SLC22A3)
DM3KJBC	MT	DTP
DM3KJBC	MA	Substrate
DM3KJBC	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DM3KJBC	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEYWLRK
DM3KJBC	MN	Sulfotransferase 1A1 (SULT1A1)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16083857

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEFQ8VO
DM3KJBC	MN	Thiopurine methyltransferase (TPMT)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6859813

DM3KJBC	DI	DM3KJBC
DM3KJBC	DN	Epinephrine
DM3KJBC	MI	DEYGVN4
DM3KJBC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3KJBC	MT	DME
DM3KJBC	MA	Metabolism
DM3KJBC	RN	Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J Steroid Biochem Mol Biol. 1991;40(4-6):593-8.
DM3KJBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1835648

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTI7UX6
DMPDW6T	MN	Breast cancer resistance protein (ABCG2)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	TT0IHXV
DMPDW6T	MN	DNA topoisomerase II (TOP2)
DMPDW6T	MT	DTT
DMPDW6T	MA	Modulator
DMPDW6T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPDW6T	RU	https://www.fda.gov/

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTSYQGK
DMPDW6T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/28276667

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTFI42L
DMPDW6T	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DTUGYRD
DMPDW6T	MN	P-glycoprotein 1 (ABCB1)
DMPDW6T	MT	DTP
DMPDW6T	MA	Substrate
DMPDW6T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPDW6T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMPDW6T	DI	DMPDW6T
DMPDW6T	DN	Epirubicin
DMPDW6T	MI	DEB3CV1
DMPDW6T	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPDW6T	MT	DME
DMPDW6T	MA	Metabolism
DMPDW6T	RN	Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101.
DMPDW6T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16985101

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	DE4LYSA
DMF0NQR	MN	Cytochrome P450 3A4 (CYP3A4)
DMF0NQR	MT	DME
DMF0NQR	MA	Metabolism
DMF0NQR	RN	Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63.
DMF0NQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14503934

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	DEIBDNY
DMF0NQR	MN	Cytochrome P450 3A5 (CYP3A5)
DMF0NQR	MT	DME
DMF0NQR	MA	Metabolism
DMF0NQR	RN	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
DMF0NQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31408697

DMF0NQR	DI	DMF0NQR
DMF0NQR	DN	Eplerenone
DMF0NQR	MI	TT26PHO
DMF0NQR	MN	Mineralocorticoid receptor  (MR)
DMF0NQR	MT	DTT
DMF0NQR	MA	Modulator
DMF0NQR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMF0NQR	RU	https://www.fda.gov/

DMKWB73	DI	DMKWB73
DMKWB73	DN	Epoetin alfa
DMKWB73	MI	TTAUX24
DMKWB73	MN	Erythropoietin Receptor (EPOR)
DMKWB73	MT	DTT
DMKWB73	MA	Agonist
DMKWB73	RN	2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
DMKWB73	RU	https://pubmed.ncbi.nlm.nih.gov/19229970

DMUTYR2	DI	DMUTYR2
DMUTYR2	DN	Epoprostenol
DMUTYR2	MI	DE5IED8
DMUTYR2	MN	Cytochrome P450 2C9 (CYP2C9)
DMUTYR2	MT	DME
DMUTYR2	MA	Metabolism
DMUTYR2	RN	Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):321-6.
DMUTYR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15569819

DMUTYR2	DI	DMUTYR2
DMUTYR2	DN	Epoprostenol
DMUTYR2	MI	TTOFYT1
DMUTYR2	MN	Prostacyclin receptor (PTGIR)
DMUTYR2	MT	DTT
DMUTYR2	MA	Agonist
DMUTYR2	RN	Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
DMUTYR2	RU	https://pubmed.ncbi.nlm.nih.gov/19302827

DM07K2I	DI	DM07K2I
DM07K2I	DN	Eprosartan
DM07K2I	MI	TT8DBY3
DM07K2I	MN	Angiotensin II receptor type-1 (AGTR1)
DM07K2I	MT	DTT
DM07K2I	MA	Antagonist
DM07K2I	RN	Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7.
DM07K2I	RU	https://pubmed.ncbi.nlm.nih.gov/18855637

DM07K2I	DI	DM07K2I
DM07K2I	DN	Eprosartan
DM07K2I	MI	DT9G7XN
DM07K2I	MN	Peptide transporter 1 (SLC15A1)
DM07K2I	MT	DTP
DM07K2I	MA	Substrate
DM07K2I	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DM07K2I	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMQXTJS	DI	DMQXTJS
DMQXTJS	DN	Eptifibatide
DMQXTJS	MI	TT38RM1
DMQXTJS	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMQXTJS	MT	DTT
DMQXTJS	MA	Modulator
DMQXTJS	RN	Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
DMQXTJS	RU	https://pubmed.ncbi.nlm.nih.gov/2033037

DM5LJCI	DI	DM5LJCI
DM5LJCI	DN	Eptinezumab
DM5LJCI	MI	TTAFORY
DM5LJCI	MN	Calcitonin gene-related peptide (CALC)
DM5LJCI	MT	DTT
DM5LJCI	MA	Inhibitor
DM5LJCI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM5LJCI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	DE5IED8
DMI782S	MN	Cytochrome P450 2C9 (CYP2C9)
DMI782S	MT	DME
DMI782S	MA	Metabolism
DMI782S	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	DE4LYSA
DMI782S	MN	Cytochrome P450 3A4 (CYP3A4)
DMI782S	MT	DME
DMI782S	MA	Metabolism
DMI782S	RN	FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration.
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf

DMI782S	DI	DMI782S
DMI782S	DN	Erdafitinib
DMI782S	MI	TT0LF7H
DMI782S	MN	Fibroblast growth factor receptor (FGFR)
DMI782S	MT	DTT
DMI782S	MA	Inhibitor
DMI782S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMI782S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf

DM6QFSV	DI	DM6QFSV
DM6QFSV	DN	Erdosteine
DM6QFSV	MI	TT3NKIB
DM6QFSV	MN	Pancreatic elastase 1 (CELA1)
DM6QFSV	MT	DTT
DM6QFSV	MA	Modulator
DM6QFSV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM6QFSV	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMWMCN0	DI	DMWMCN0
DMWMCN0	DN	Erenumab
DMWMCN0	MI	TTY6O0Q
DMWMCN0	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMWMCN0	MT	DTT
DMWMCN0	MA	Modulator
DMWMCN0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMWMCN0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DE98XPV
DMHO0AR	MN	Cholesterol desmolase (CYP11A1)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	Vitamin D: mechanisms of action and clinical applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29080648

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DERSX5P
DMHO0AR	MN	Cytochrome P450 2J2 (CYP2J2)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DE4LYSA
DMHO0AR	MN	Cytochrome P450 3A4 (CYP3A4)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005856

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	DEBIHM3
DMHO0AR	MN	Vitamin D 25-hydroxylase (CYP2R1)
DMHO0AR	MT	DME
DMHO0AR	MA	Metabolism
DMHO0AR	RN	CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6.
DMHO0AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17607662

DMHO0AR	DI	DMHO0AR
DMHO0AR	DN	Ergocalciferol
DMHO0AR	MI	TTK59TV
DMHO0AR	MN	Vitamin D3 receptor (VDR)
DMHO0AR	MT	DTT
DMHO0AR	MA	Antagonist
DMHO0AR	RN	Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41.
DMHO0AR	RU	https://pubmed.ncbi.nlm.nih.gov/18525006

DMORPBA	DI	DMORPBA
DMORPBA	DN	Ergoloid mesylate
DMORPBA	MI	TT32XQJ
DMORPBA	MN	Monoamine oxidase (MAO)
DMORPBA	MT	DTT
DMORPBA	MA	Modulator
DMORPBA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMORPBA	RU	https://www.fda.gov/

DM0VEC1	DI	DM0VEC1
DM0VEC1	DN	Ergonovine
DM0VEC1	MI	DE4LYSA
DM0VEC1	MN	Cytochrome P450 3A4 (CYP3A4)
DM0VEC1	MT	DME
DM0VEC1	MA	Metabolism
DM0VEC1	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DM0VEC1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DM0VEC1	DI	DM0VEC1
DM0VEC1	DN	Ergonovine
DM0VEC1	MI	TTEX248
DM0VEC1	MN	Dopamine D2 receptor (D2R)
DM0VEC1	MT	DTT
DM0VEC1	MA	Agonist
DM0VEC1	RN	Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9.
DM0VEC1	RU	https://pubmed.ncbi.nlm.nih.gov/2897449

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	TTG28O6
DMKR3C5	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMKR3C5	MT	DTT
DMKR3C5	MA	Agonist
DMKR3C5	RN	Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6.
DMKR3C5	RU	https://pubmed.ncbi.nlm.nih.gov/18763151

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DEJGDUW
DMKR3C5	MN	Cytochrome P450 1A2 (CYP1A2)
DMKR3C5	MT	DME
DMKR3C5	MA	Metabolism
DMKR3C5	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DMKR3C5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DE4LYSA
DMKR3C5	MN	Cytochrome P450 3A4 (CYP3A4)
DMKR3C5	MT	DME
DMKR3C5	MA	Metabolism
DMKR3C5	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DMKR3C5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DMKR3C5	DI	DMKR3C5
DMKR3C5	DN	Ergotamine
DMKR3C5	MI	DTUGYRD
DMKR3C5	MN	P-glycoprotein 1 (ABCB1)
DMKR3C5	MT	DTP
DMKR3C5	MA	Substrate
DMKR3C5	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMKR3C5	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DETECWH
DM78IME	MN	Amiloride-sensitive amine oxidase (AOC1)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Human kidney diamine oxidase: heterologous expression, purification, and characterization. J Biol Inorg Chem. 2002 Jun;7(6):565-79.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12072962

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE5IED8
DM78IME	MN	Cytochrome P450 2C9 (CYP2C9)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE4LYSA
DM78IME	MN	Cytochrome P450 3A4 (CYP3A4)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT3EAQP
DM78IME	MN	Equilibrative nucleoside transporter 4 (SLC29A4)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 2019 Apr 15;849:75-83.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/30707958

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	TTTIBOJ
DM78IME	MN	Histamine H1 receptor (H1R)
DM78IME	MT	DTT
DM78IME	MA	Agonist
DM78IME	RN	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
DM78IME	RU	https://pubmed.ncbi.nlm.nih.gov/11179434

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DE3PZ0I
DM78IME	MN	Histamine N-methyltransferase (HNMT)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Histamine pharmacogenomics. Pharmacogenomics. 2009 May;10(5):867-83.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19450133

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT9IDPW
DM78IME	MN	Organic cation transporter 2 (SLC22A2)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/17393420

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DT6201N
DM78IME	MN	Organic cation transporter 3 (SLC22A3)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DEFQ8VO
DM78IME	MN	Thiopurine methyltransferase (TPMT)
DM78IME	MT	DME
DM78IME	MA	Metabolism
DM78IME	RN	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
DM78IME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19538200

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DTM953D
DM78IME	MN	Vesicular amine transporter 1 (SLC18A1)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	Gastrin-producing endocrine cells: a novel source of histamine in the rat stomach. Endocrinology. 1998 Oct;139(10):4404-15.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/9751525

DM78IME	DI	DM78IME
DM78IME	DN	Ergotidine
DM78IME	MI	DTT7VPB
DM78IME	MN	Vesicular amine transporter 2 (SLC18A2)
DM78IME	MT	DTP
DM78IME	MA	Substrate
DM78IME	RN	The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97.
DM78IME	RU	http://www.ncbi.nlm.nih.gov/pubmed/24398404

DM1DX4Q	DI	DM1DX4Q
DM1DX4Q	DN	Eribulin
DM1DX4Q	MI	DE4LYSA
DM1DX4Q	MN	Cytochrome P450 3A4 (CYP3A4)
DM1DX4Q	MT	DME
DM1DX4Q	MA	Metabolism
DM1DX4Q	RN	Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
DM1DX4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18431572

DM1DX4Q	DI	DM1DX4Q
DM1DX4Q	DN	Eribulin
DM1DX4Q	MI	TTML2WA
DM1DX4Q	MN	Tubulin (TUB)
DM1DX4Q	MT	DTT
DM1DX4Q	MA	Inhibitor
DM1DX4Q	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM1DX4Q	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DTI7UX6
DMCMBHA	MN	Breast cancer resistance protein (ABCG2)
DMCMBHA	MT	DTP
DMCMBHA	MA	Substrate
DMCMBHA	RN	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
DMCMBHA	RU	https://doi.org/10.1016/j.addr.2008.07.003

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DEJGDUW
DMCMBHA	MN	Cytochrome P450 1A2 (CYP1A2)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DECB0K3
DMCMBHA	MN	Cytochrome P450 2D6 (CYP2D6)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DE4LYSA
DMCMBHA	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DEIBDNY
DMCMBHA	MN	Cytochrome P450 3A5 (CYP3A5)
DMCMBHA	MT	DME
DMCMBHA	MA	Metabolism
DMCMBHA	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DMCMBHA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	TTGKNB4
DMCMBHA	MN	Epidermal growth factor receptor (EGFR)
DMCMBHA	MT	DTT
DMCMBHA	MA	Inhibitor
DMCMBHA	RN	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
DMCMBHA	RU	https://pubmed.ncbi.nlm.nih.gov/19627157

DMCMBHA	DI	DMCMBHA
DMCMBHA	DN	Erlotinib
DMCMBHA	MI	DTUGYRD
DMCMBHA	MN	P-glycoprotein 1 (ABCB1)
DMCMBHA	MT	DTP
DMCMBHA	MA	Substrate
DMCMBHA	RN	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
DMCMBHA	RU	https://doi.org/10.1158/1535-7163.MCT-07-2250

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	TTJP4SM
DM4S3O8	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4S3O8	MT	DTT
DM4S3O8	MA	Binder
DM4S3O8	RN	Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/15716453

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DEC3G7M
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DEMIUB2
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/25870058

DM4S3O8	DI	DM4S3O8
DM4S3O8	DN	Ertapenem
DM4S3O8	MI	DECWSA9
DM4S3O8	MN	Beta-lactamase (blaB)
DM4S3O8	MT	DME
DM4S3O8	MA	Metabolism
DM4S3O8	RN	War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62.
DM4S3O8	RU	https://pubmed.ncbi.nlm.nih.gov/25870058

DMFGQ2S	DI	DMFGQ2S
DMFGQ2S	DN	Erythrityl Tetranitrate
DMFGQ2S	MI	TT6HPVC
DMFGQ2S	MN	Guanylate cyclase (GC)
DMFGQ2S	MT	DTT
DMFGQ2S	MA	Stimulator
DMFGQ2S	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMFGQ2S	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	TTUWYEA
DM4K7GQ	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM4K7GQ	MT	DTT
DM4K7GQ	MA	Binder
DM4K7GQ	RN	A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/1945852

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE7IQ34
DM4K7GQ	MN	Beta-glucuronidase (uidA)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/17308175

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTI7UX6
DM4K7GQ	MN	Breast cancer resistance protein (ABCG2)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DM4K7GQ	RU	https://doi.org/10.1016/j.addr.2008.11.003

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE6OQ3W
DM4K7GQ	MN	Cytochrome P450 1A1 (CYP1A1)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEJGDUW
DM4K7GQ	MN	Cytochrome P450 1A2 (CYP1A2)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9806945

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE9QHP6
DM4K7GQ	MN	Cytochrome P450 1B1 (CYP1B1)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DE4LYSA
DM4K7GQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEIBDNY
DM4K7GQ	MN	Cytochrome P450 3A5 (CYP3A5)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DERD86B
DM4K7GQ	MN	Cytochrome P450 3A7 (CYP3A7)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DM4K7GQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DEIZLTN
DM4K7GQ	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DM4K7GQ	MT	DME
DM4K7GQ	MA	Metabolism
DM4K7GQ	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DM4K7GQ	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTFI42L
DM4K7GQ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/21451505

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DT0OC1Q
DM4K7GQ	MN	Organic anion transporter 2 (SLC22A7)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15708966

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DT9C1TS
DM4K7GQ	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DM4K7GQ	DI	DM4K7GQ
DM4K7GQ	DN	Erythromycin
DM4K7GQ	MI	DTUGYRD
DM4K7GQ	MN	P-glycoprotein 1 (ABCB1)
DM4K7GQ	MT	DTP
DM4K7GQ	MA	Substrate
DM4K7GQ	RN	Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
DM4K7GQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18958406

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DECB0K3
DMFK9HG	MN	Cytochrome P450 2D6 (CYP2D6)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24302953

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DE4LYSA
DMFK9HG	MN	Cytochrome P450 3A4 (CYP3A4)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	DEGTFWK
DMFK9HG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFK9HG	MT	DME
DMFK9HG	MA	Metabolism
DMFK9HG	RN	Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
DMFK9HG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313485

DMFK9HG	DI	DMFK9HG
DMFK9HG	DN	Escitalopram
DMFK9HG	MI	TT3ROYC
DMFK9HG	MN	Serotonin transporter (SERT)
DMFK9HG	MT	DTT
DMFK9HG	MA	Inhibitor
DMFK9HG	RN	Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7.
DMFK9HG	RU	https://pubmed.ncbi.nlm.nih.gov/19566691

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTRK8B9
DMZREFQ	MN	Sodium channel unspecific (NaC)
DMZREFQ	MT	DTT
DMZREFQ	MA	Blocker
DMZREFQ	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	DEYGVN4
DMZREFQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZREFQ	MT	DME
DMZREFQ	MA	Metabolism
DMZREFQ	RN	Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94.
DMZREFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21673130

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTIG65Q
DMZREFQ	MN	Voltage-gated sodium channel (Nav)
DMZREFQ	MT	DTT
DMZREFQ	MA	Inhibitor
DMZREFQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZREFQ	DI	DMZREFQ
DMZREFQ	DN	Eslicarbazepine
DMZREFQ	MI	TTN9VTF
DMZREFQ	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMZREFQ	MT	DTT
DMZREFQ	MA	Inhibitor
DMZREFQ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZREFQ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMREUZV	DI	DMREUZV
DMREUZV	DN	Eslicarbazepine acetate
DMREUZV	MI	DTUGYRD
DMREUZV	MN	P-glycoprotein 1 (ABCB1)
DMREUZV	MT	DTP
DMREUZV	MA	Substrate
DMREUZV	RN	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
DMREUZV	RU	https://doi.org/10.1111/j.1528-1167.2011.03140.x

DM51TYR	DI	DM51TYR
DM51TYR	DN	Esmolol
DM51TYR	MI	TTR6W5O
DM51TYR	MN	Adrenergic receptor beta-1 (ADRB1)
DM51TYR	MT	DTT
DM51TYR	MA	Antagonist
DM51TYR	RN	Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55.
DM51TYR	RU	https://pubmed.ncbi.nlm.nih.gov/19150530

DM51TYR	DI	DM51TYR
DM51TYR	DN	Esmolol
DM51TYR	MI	DECB0K3
DM51TYR	MN	Cytochrome P450 2D6 (CYP2D6)
DM51TYR	MT	DME
DM51TYR	MA	Metabolism
DM51TYR	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM51TYR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM7BN0X	DI	DM7BN0X
DM7BN0X	DN	Esomeprazole
DM7BN0X	MI	TTLOKXP
DM7BN0X	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM7BN0X	MT	DTT
DM7BN0X	MA	Modulator
DM7BN0X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7BN0X	RU	https://www.fda.gov/

DM7BN0X	DI	DM7BN0X
DM7BN0X	DN	Esomeprazole
DM7BN0X	MI	DEGTFWK
DM7BN0X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7BN0X	MT	DME
DM7BN0X	MA	Metabolism
DM7BN0X	RN	Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
DM7BN0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027194

DMZGXUM	DI	DMZGXUM
DMZGXUM	DN	Estazolam
DMZGXUM	MI	DE4LYSA
DMZGXUM	MN	Cytochrome P450 3A4 (CYP3A4)
DMZGXUM	MT	DME
DMZGXUM	MA	Metabolism
DMZGXUM	RN	Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65.
DMZGXUM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16012077

DMZGXUM	DI	DMZGXUM
DMZGXUM	DN	Estazolam
DMZGXUM	MI	TTPTXIN
DMZGXUM	MN	Translocator protein (TSPO)
DMZGXUM	MT	DTT
DMZGXUM	MA	Agonist
DMZGXUM	RN	Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9.
DMZGXUM	RU	https://pubmed.ncbi.nlm.nih.gov/15876530

DM9KZDO	DI	DM9KZDO
DM9KZDO	DN	Esterified estrogens
DM9KZDO	MI	TTZAYWL
DM9KZDO	MN	Estrogen receptor (ESR)
DM9KZDO	MT	DTT
DM9KZDO	MA	Modulator
DM9KZDO	RN	Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8.
DM9KZDO	RU	https://pubmed.ncbi.nlm.nih.gov/20850731

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DTI7UX6
DMUNTE3	MN	Breast cancer resistance protein (ABCG2)
DMUNTE3	MT	DTP
DMUNTE3	MA	Substrate
DMUNTE3	RN	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
DMUNTE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/12668685

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE6OQ3W
DMUNTE3	MN	Cytochrome P450 1A1 (CYP1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEJGDUW
DMUNTE3	MN	Cytochrome P450 1A2 (CYP1A2)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15217502

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE9QHP6
DMUNTE3	MN	Cytochrome P450 1B1 (CYP1B1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DES5XRU
DMUNTE3	MN	Cytochrome P450 2C8 (CYP2C8)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE5IED8
DMUNTE3	MN	Cytochrome P450 2C9 (CYP2C9)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DE4LYSA
DMUNTE3	MN	Cytochrome P450 3A4 (CYP3A4)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22837389

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEIBDNY
DMUNTE3	MN	Cytochrome P450 3A5 (CYP3A5)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Drug Interactions Flockhart Table
DMUNTE3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DERD86B
DMUNTE3	MN	Cytochrome P450 3A7 (CYP3A7)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Drug Interactions Flockhart Table
DMUNTE3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEGTB1K
DMUNTE3	MN	Dehydrogenase/reductase retSDR3 (HSD17B14)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/22864907

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	TTZAYWL
DMUNTE3	MN	Estrogen receptor (ESR)
DMUNTE3	MT	DTT
DMUNTE3	MA	Agonist
DMUNTE3	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DER0XCH
DMUNTE3	MN	Farnesol dehydrogenase (AKR1B15)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEHX1DZ
DMUNTE3	MN	Lactoperoxidase (LPO)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 1994 Nov;15(11):2637-43.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7955118

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEGTFWK
DMUNTE3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18521743

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DTUGYRD
DMUNTE3	MN	P-glycoprotein 1 (ABCB1)
DMUNTE3	MT	DTP
DMUNTE3	MA	Substrate
DMUNTE3	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMUNTE3	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEYWLRK
DMUNTE3	MN	Sulfotransferase 1A1 (SULT1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21669803

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEFQ8VO
DMUNTE3	MN	Thiopurine methyltransferase (TPMT)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8055052

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEYGVN4
DMUNTE3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DMUNTE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DMUNTE3	DI	DMUNTE3
DMUNTE3	DN	Estradiol
DMUNTE3	MI	DEB7I4M
DMUNTE3	MN	UDP-glucuronosyltransferase 2B28 (UGT2B28)
DMUNTE3	MT	DME
DMUNTE3	MA	Metabolism
DMUNTE3	RN	Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001 Apr 3;40(13):3869-81.
DMUNTE3	RU	https://pubmed.ncbi.nlm.nih.gov/11300766

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEJGDUW
DM07U2A	MN	Cytochrome P450 1A2 (CYP1A2)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DES5XRU
DM07U2A	MN	Cytochrome P450 2C8 (CYP2C8)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DE5IED8
DM07U2A	MN	Cytochrome P450 2C9 (CYP2C9)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DE4LYSA
DM07U2A	MN	Cytochrome P450 3A4 (CYP3A4)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEIBDNY
DM07U2A	MN	Cytochrome P450 3A5 (CYP3A5)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Drug Interactions Flockhart Table
DM07U2A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DERD86B
DM07U2A	MN	Cytochrome P450 3A7 (CYP3A7)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Drug Interactions Flockhart Table
DM07U2A	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	TTZAYWL
DM07U2A	MN	Estrogen receptor (ESR)
DM07U2A	MT	DTT
DM07U2A	MA	Modulator
DM07U2A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM07U2A	RU	https://www.fda.gov/

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEGTFWK
DM07U2A	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM07U2A	DI	DM07U2A
DM07U2A	DN	Estradiol acetate
DM07U2A	MI	DEYGVN4
DM07U2A	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM07U2A	MT	DME
DM07U2A	MA	Metabolism
DM07U2A	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM07U2A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEJGDUW
DM27Z5T	MN	Cytochrome P450 1A2 (CYP1A2)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DES5XRU
DM27Z5T	MN	Cytochrome P450 2C8 (CYP2C8)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DE5IED8
DM27Z5T	MN	Cytochrome P450 2C9 (CYP2C9)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DE4LYSA
DM27Z5T	MN	Cytochrome P450 3A4 (CYP3A4)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEIBDNY
DM27Z5T	MN	Cytochrome P450 3A5 (CYP3A5)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Drug Interactions Flockhart Table
DM27Z5T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DERD86B
DM27Z5T	MN	Cytochrome P450 3A7 (CYP3A7)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Drug Interactions Flockhart Table
DM27Z5T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	TTZAYWL
DM27Z5T	MN	Estrogen receptor (ESR)
DM27Z5T	MT	DTT
DM27Z5T	MA	Modulator
DM27Z5T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM27Z5T	RU	https://www.fda.gov/

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEGTFWK
DM27Z5T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM27Z5T	DI	DM27Z5T
DM27Z5T	DN	Estradiol cypionate
DM27Z5T	MI	DEYGVN4
DM27Z5T	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM27Z5T	MT	DME
DM27Z5T	MA	Metabolism
DM27Z5T	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM27Z5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEJGDUW
DM8MC6O	MN	Cytochrome P450 1A2 (CYP1A2)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DES5XRU
DM8MC6O	MN	Cytochrome P450 2C8 (CYP2C8)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DE5IED8
DM8MC6O	MN	Cytochrome P450 2C9 (CYP2C9)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DE4LYSA
DM8MC6O	MN	Cytochrome P450 3A4 (CYP3A4)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEIBDNY
DM8MC6O	MN	Cytochrome P450 3A5 (CYP3A5)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Drug Interactions Flockhart Table
DM8MC6O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DERD86B
DM8MC6O	MN	Cytochrome P450 3A7 (CYP3A7)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Drug Interactions Flockhart Table
DM8MC6O	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	TTZAYWL
DM8MC6O	MN	Estrogen receptor (ESR)
DM8MC6O	MT	DTT
DM8MC6O	MA	Modulator
DM8MC6O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8MC6O	RU	https://www.fda.gov/

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEGTFWK
DM8MC6O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520

DM8MC6O	DI	DM8MC6O
DM8MC6O	DN	Estradiol valerate
DM8MC6O	MI	DEYGVN4
DM8MC6O	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8MC6O	MT	DME
DM8MC6O	MA	Metabolism
DM8MC6O	RN	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
DM8MC6O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155

DMLNMEA	DI	DMLNMEA
DMLNMEA	DN	Estradiol valerate/dienogest
DMLNMEA	MI	TTUV8G9
DMLNMEA	MN	Progesterone receptor (PGR)
DMLNMEA	MT	DTT
DMLNMEA	MA	Modulator
DMLNMEA	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMLNMEA	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMWTAOI	DI	DMWTAOI
DMWTAOI	DN	Estramustine
DMWTAOI	MI	DE4LYSA
DMWTAOI	MN	Cytochrome P450 3A4 (CYP3A4)
DMWTAOI	MT	DME
DMWTAOI	MA	Metabolism
DMWTAOI	RN	Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34.
DMWTAOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12686819

DMWTAOI	DI	DMWTAOI
DMWTAOI	DN	Estramustine
DMWTAOI	MI	TTSBFYK
DMWTAOI	MN	Estramustine binding protein (EMBP)
DMWTAOI	MT	DTT
DMWTAOI	MA	Binder
DMWTAOI	RN	Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.
DMWTAOI	RU	https://pubmed.ncbi.nlm.nih.gov/7703721

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DERD86B
DMOEM2I	MN	Cytochrome P450 3A7 (CYP3A7)
DMOEM2I	MT	DME
DMOEM2I	MA	Metabolism
DMOEM2I	RN	Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003 Jan;31(1):1-6.
DMOEM2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485945

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	TTZAYWL
DMOEM2I	MN	Estrogen receptor (ESR)
DMOEM2I	MT	DTT
DMOEM2I	MA	Agonist
DMOEM2I	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DMOEM2I	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DTUGYRD
DMOEM2I	MN	P-glycoprotein 1 (ABCB1)
DMOEM2I	MT	DTP
DMOEM2I	MA	Substrate
DMOEM2I	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DMOEM2I	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMOEM2I	DI	DMOEM2I
DMOEM2I	DN	Estriol
DMOEM2I	MI	DEYGVN4
DMOEM2I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOEM2I	MT	DME
DMOEM2I	MA	Metabolism
DMOEM2I	RN	Stimulation of microsomal uridine diphosphate glucuronyltransferase by glucuronic acid derivatives. Biochem J. 1974 Apr;139(1):243-9.
DMOEM2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4219139

DMGY0UT	DI	DMGY0UT
DMGY0UT	DN	Estrogen
DMGY0UT	MI	TTZAYWL
DMGY0UT	MN	Estrogen receptor (ESR)
DMGY0UT	MT	DTT
DMGY0UT	MA	Agonist
DMGY0UT	RN	Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74.
DMGY0UT	RU	https://pubmed.ncbi.nlm.nih.gov/11919305

DMGY0UT	DI	DMGY0UT
DMGY0UT	DN	Estrogen
DMGY0UT	MI	TTOM3J0
DMGY0UT	MN	Estrogen receptor beta (ESR2)
DMGY0UT	MT	DTT
DMGY0UT	MA	Agonist
DMGY0UT	RN	Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
DMGY0UT	RU	https://pubmed.ncbi.nlm.nih.gov/10611350

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE6OQ3W
DM5T6US	MN	Cytochrome P450 1A1 (CYP1A1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEJGDUW
DM5T6US	MN	Cytochrome P450 1A2 (CYP1A2)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10930541

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE9QHP6
DM5T6US	MN	Cytochrome P450 1B1 (CYP1B1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEPKLMQ
DM5T6US	MN	Cytochrome P450 2B6 (CYP2B6)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE5IED8
DM5T6US	MN	Cytochrome P450 2C9 (CYP2C9)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEVDYN7
DM5T6US	MN	Cytochrome P450 2E1 (CYP2E1)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640505

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE4LYSA
DM5T6US	MN	Cytochrome P450 3A4 (CYP3A4)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25678418

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEIBDNY
DM5T6US	MN	Cytochrome P450 3A5 (CYP3A5)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9635876

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEBMFZ8
DM5T6US	MN	Estradiol 17-beta-dehydrogenase 2 (HSD17B2)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	TTZAYWL
DM5T6US	MN	Estrogen receptor (ESR)
DM5T6US	MT	DTT
DM5T6US	MA	Agonist
DM5T6US	RN	Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
DM5T6US	RU	https://pubmed.ncbi.nlm.nih.gov/19434891

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DER0XCH
DM5T6US	MN	Farnesol dehydrogenase (AKR1B15)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE915QP
DM5T6US	MN	Ketoacyl-CoA reductase (HSD17B12)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006 Feb;20(2):437-43.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16166196

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEDMWFX
DM5T6US	MN	Keto-steroid reductase (HSD17B7)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DE2XQGW
DM5T6US	MN	Lauric acid omega-hydroxylase (CYP4A11)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DEJHG19
DM5T6US	MN	Peroxisomal multifunctional enzyme 2 (HSD17B4)
DM5T6US	MT	DME
DM5T6US	MA	Metabolism
DM5T6US	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM5T6US	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM5T6US	DI	DM5T6US
DM5T6US	DN	Estrone
DM5T6US	MI	DTUGYRD
DM5T6US	MN	P-glycoprotein 1 (ABCB1)
DM5T6US	MT	DTP
DM5T6US	MA	Substrate
DM5T6US	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DM5T6US	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT9NXMV
DMVBIZL	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTI7UX6
DMVBIZL	MN	Breast cancer resistance protein (ABCG2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12682043

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTI7UX6
DMVBIZL	MN	Breast cancer resistance protein (ABCG2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
DMVBIZL	RU	https://doi.org/10.1002/jps.23069

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTZGT0P
DMVBIZL	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT3TX4H
DMVBIZL	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTSYQGK
DMVBIZL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12867490

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTFI42L
DMVBIZL	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16046661

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTVP67E
DMVBIZL	MN	Organic anion transporter 3 (SLC22A8)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Involvement of tyrosine kinase and PI3K in the regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1057-64.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15956776

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT06JWZ
DMVBIZL	MN	Organic anion transporter 4 (SLC22A11)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17132213

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTT3IKQ
DMVBIZL	MN	Organic anion transporter 6 (SLC22A20)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal Physiol. 2006 Aug;291(2):F314-21.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16478971

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTE2B1D
DMVBIZL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21605667

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT3D8F0
DMVBIZL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci. 2009 Nov;18(11):2298-306.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19760661

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT9C1TS
DMVBIZL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTPFTEQ
DMVBIZL	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTVNRXW
DMVBIZL	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT8H2IC
DMVBIZL	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):1032-7.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15328376

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTY0QMU
DMVBIZL	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet. 2010;25(3):314-7.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20610891

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTMEQ32
DMVBIZL	MN	Organic solute transporter subunit alpha (SLC51A)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT1V9AJ
DMVBIZL	MN	Organic solute transporter subunit beta (SLC51B)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT1V9AJ
DMVBIZL	MN	Organic solute transporter subunit beta (SLC51B)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DTUGYRD
DMVBIZL	MN	P-glycoprotein 1 (ABCB1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
DMVBIZL	RU	https://doi.org/10.1124/jpet.105.085589

DMVBIZL	DI	DMVBIZL
DMVBIZL	DN	Estrone sulfate
DMVBIZL	MI	DT56EKP
DMVBIZL	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMVBIZL	MT	DTP
DMVBIZL	MA	Substrate
DMVBIZL	RN	Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
DMVBIZL	RU	http://www.ncbi.nlm.nih.gov/pubmed/14660639

DMRMDWA	DI	DMRMDWA
DMRMDWA	DN	Estropipate
DMRMDWA	MI	DE4LYSA
DMRMDWA	MN	Cytochrome P450 3A4 (CYP3A4)
DMRMDWA	MT	DME
DMRMDWA	MA	Metabolism
DMRMDWA	RN	Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35.
DMRMDWA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264

DMRMDWA	DI	DMRMDWA
DMRMDWA	DN	Estropipate
DMRMDWA	MI	TTZAYWL
DMRMDWA	MN	Estrogen receptor (ESR)
DMRMDWA	MT	DTT
DMRMDWA	MA	Modulator
DMRMDWA	RN	US patent application no. 5,004,651, Stabilizing system for solid dosage forms.
DMRMDWA	RU	http://www.google.com/patents/US5004651

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DES5XRU
DM8RZ9H	MN	Cytochrome P450 2C8 (CYP2C8)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DEVDYN7
DM8RZ9H	MN	Cytochrome P450 2E1 (CYP2E1)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	DE4LYSA
DM8RZ9H	MN	Cytochrome P450 3A4 (CYP3A4)
DM8RZ9H	MT	DME
DM8RZ9H	MA	Metabolism
DM8RZ9H	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8RZ9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8RZ9H	DI	DM8RZ9H
DM8RZ9H	DN	Eszopiclone
DM8RZ9H	MI	TTPTXIN
DM8RZ9H	MN	Translocator protein (TSPO)
DM8RZ9H	MT	DTT
DM8RZ9H	MA	Agonist
DM8RZ9H	RN	New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
DM8RZ9H	RU	https://pubmed.ncbi.nlm.nih.gov/18265473

DMCV109	DI	DMCV109
DMCV109	DN	Etanercept
DMCV109	MI	TTF8CQI
DMCV109	MN	Tumor necrosis factor (TNF)
DMCV109	MT	DTT
DMCV109	MA	Modulator
DMCV109	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMCV109	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMHP9BL	DI	DMHP9BL
DMHP9BL	DN	Etelcalcetide
DMHP9BL	MI	TTBUYHA
DMHP9BL	MN	Extracellular calcium-sensing receptor (CASR)
DMHP9BL	MT	DTT
DMHP9BL	MA	Modulator
DMHP9BL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHP9BL	RU	https://www.fda.gov/

DM2QBHP	DI	DM2QBHP
DM2QBHP	DN	Eteplirsen
DM2QBHP	MI	TTWLFXU
DM2QBHP	MN	Dystrophin messenger RNA (DMD mRNA)
DM2QBHP	MT	DTT
DM2QBHP	MA	Modulator
DM2QBHP	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM2QBHP	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM5M4NT	DI	DM5M4NT
DM5M4NT	DN	Ethacrynate sodium
DM5M4NT	MI	TTS087L
DM5M4NT	MN	Solute carrier family 12 member 1 (SLC12A1)
DM5M4NT	MT	DTT
DM5M4NT	MA	Modulator
DM5M4NT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5M4NT	RU	https://www.fda.gov/

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DE6OQ3W
DM60QMR	MN	Cytochrome P450 1A1 (CYP1A1)
DM60QMR	MT	DME
DM60QMR	MA	Metabolism
DM60QMR	RN	Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500.
DM60QMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10323333

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DE4ZHS1
DM60QMR	MN	Glutathione S-transferase alpha-1 (GSTA1)
DM60QMR	MT	DME
DM60QMR	MA	Metabolism
DM60QMR	RN	Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
DM60QMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15826502

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	DTSYQGK
DM60QMR	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM60QMR	MT	DTP
DM60QMR	MA	Substrate
DM60QMR	RN	Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160-6.
DM60QMR	RU	http://www.ncbi.nlm.nih.gov/pubmed/12391280

DM60QMR	DI	DM60QMR
DM60QMR	DN	Ethacrynic acid
DM60QMR	MI	TTS087L
DM60QMR	MN	Solute carrier family 12 member 1 (SLC12A1)
DM60QMR	MT	DTT
DM60QMR	MA	Blocker
DM60QMR	RN	Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
DM60QMR	RU	https://pubmed.ncbi.nlm.nih.gov/7733229

DMR87LC	DI	DMR87LC
DMR87LC	DN	Ethambutol
DMR87LC	MI	TT1Q8GP
DMR87LC	MN	Mycobacterium Arabinosyltransferase C (MycB embC)
DMR87LC	MT	DTT
DMR87LC	MA	Inhibitor
DMR87LC	RN	The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46.
DMR87LC	RU	https://pubmed.ncbi.nlm.nih.gov/19596878

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEG8NJD
DMDRQZU	MN	Alcohol dehydrogenase (ADH)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
DMDRQZU	RU	https://pubmed.ncbi.nlm.nih.gov/30034639

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEE5M8O
DMDRQZU	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEEN9RD
DMDRQZU	MN	Alcohol dehydrogenase class-I beta (ADH1B)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEM1HNL
DMDRQZU	MN	Alcohol dehydrogenase class-I gamma (ADH1C)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEOCWU3
DMDRQZU	MN	Alcohol dehydrogenase class-II (ADH4)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEIOH6A
DMDRQZU	MN	Alcohol dehydrogenase class-III (ADH5)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DE017IC
DMDRQZU	MN	Alcohol dehydrogenase class-V (ADH6)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DED2FW3
DMDRQZU	MN	Aldo-keto reductase 1A1 (AKR1A1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEJGDUW
DMDRQZU	MN	Cytochrome P450 1A2 (CYP1A2)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEVDYN7
DMDRQZU	MN	Cytochrome P450 2E1 (CYP2E1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12707490

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DE4LYSA
DMDRQZU	MN	Cytochrome P450 3A4 (CYP3A4)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	TT1MPAY
DMDRQZU	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDRQZU	MT	DTT
DMDRQZU	MA	Antagonist
DMDRQZU	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMDRQZU	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEZMAHX
DMDRQZU	MN	Gastric alcohol dehydrogenase (ADH7)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560

DMDRQZU	DI	DMDRQZU
DMDRQZU	DN	Ethanol
DMDRQZU	MI	DEYGVN4
DMDRQZU	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDRQZU	MT	DME
DMDRQZU	MA	Metabolism
DMDRQZU	RN	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
DMDRQZU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553666

DM3B654	DI	DM3B654
DM3B654	DN	Ethanolamine oleate
DM3B654	MI	DEVDYN7
DM3B654	MN	Cytochrome P450 2E1 (CYP2E1)
DM3B654	MT	DME
DM3B654	MA	Metabolism
DM3B654	RN	CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med. 2006 Jul;73(4):657-72.
DM3B654	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16878272

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	DE4LYSA
DM53IP1	MN	Cytochrome P450 3A4 (CYP3A4)
DM53IP1	MT	DME
DM53IP1	MA	Metabolism
DM53IP1	RN	Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 1982 Oct;25(10):1174-9.
DM53IP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7143353

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	TT1MPAY
DM53IP1	MN	GABA(A) receptor alpha-1 (GABRA1)
DM53IP1	MT	DTT
DM53IP1	MA	Antagonist
DM53IP1	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM53IP1	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM53IP1	DI	DM53IP1
DM53IP1	DN	Ethchlorvynol
DM53IP1	MI	TTZA1NY
DM53IP1	MN	GABA(A) receptor beta-2 (GABRB2)
DM53IP1	MT	DTT
DM53IP1	MA	Antagonist
DM53IP1	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM53IP1	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMK57GB	DI	DMK57GB
DMK57GB	DN	Ethinamate
DMK57GB	MI	TTANPDJ
DMK57GB	MN	Carbonic anhydrase II (CA-II)
DMK57GB	MT	DTT
DMK57GB	MA	Inhibitor
DMK57GB	RN	Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
DMK57GB	RU	https://pubmed.ncbi.nlm.nih.gov/1460006

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE6OQ3W
DMODJ40	MN	Cytochrome P450 1A1 (CYP1A1)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DES5XRU
DMODJ40	MN	Cytochrome P450 2C8 (CYP2C8)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE5IED8
DMODJ40	MN	Cytochrome P450 2C9 (CYP2C9)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DE4LYSA
DMODJ40	MN	Cytochrome P450 3A4 (CYP3A4)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15554232

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	TTZAYWL
DMODJ40	MN	Estrogen receptor (ESR)
DMODJ40	MT	DTT
DMODJ40	MA	Agonist
DMODJ40	RN	17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
DMODJ40	RU	https://pubmed.ncbi.nlm.nih.gov/19237207

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DEGTFWK
DMODJ40	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12895199

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DTUGYRD
DMODJ40	MN	P-glycoprotein 1 (ABCB1)
DMODJ40	MT	DTP
DMODJ40	MA	Substrate
DMODJ40	RN	P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.
DMODJ40	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290871

DMODJ40	DI	DMODJ40
DMODJ40	DN	Ethinyl estradiol
DMODJ40	MI	DEYGVN4
DMODJ40	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMODJ40	MT	DME
DMODJ40	MA	Metabolism
DMODJ40	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMODJ40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	TTVTX4N
DM8K3EI	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM8K3EI	MT	DTT
DM8K3EI	MA	Inhibitor
DM8K3EI	RN	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
DM8K3EI	RU	https://pubmed.ncbi.nlm.nih.gov/17227913

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	DEIASEZ
DM8K3EI	MN	Dimethylaniline oxidase 2 (FMO2)
DM8K3EI	MT	DME
DM8K3EI	MA	Metabolism
DM8K3EI	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM8K3EI	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM8K3EI	DI	DM8K3EI
DM8K3EI	DN	Ethionamide
DM8K3EI	MI	DEP76YL
DM8K3EI	MN	Dimethylaniline oxidase 3 (FMO3)
DM8K3EI	MT	DME
DM8K3EI	MA	Metabolism
DM8K3EI	RN	Physiologically based pharmacokinetic modeling approach to predict drug-drug interactions with ethionamide involving impact of genetic polymorphism on FMO3. J Clin Pharmacol. 2019 Jun;59(6):880-889.
DM8K3EI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30690726

DM0N3L7	DI	DM0N3L7
DM0N3L7	DN	Ethopropazine
DM0N3L7	MI	TTTIBOJ
DM0N3L7	MN	Histamine H1 receptor (H1R)
DM0N3L7	MT	DTT
DM0N3L7	MA	Modulator
DM0N3L7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N3L7	RU	https://www.fda.gov/

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEVDYN7
DMDZ9LT	MN	Cytochrome P450 2E1 (CYP2E1)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DE4LYSA
DMDZ9LT	MN	Cytochrome P450 3A4 (CYP3A4)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEO1IE3
DMDZ9LT	MN	Cytochrome P450 3A43 (CYP3A43)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DEIBDNY
DMDZ9LT	MN	Cytochrome P450 3A5 (CYP3A5)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	DERD86B
DMDZ9LT	MN	Cytochrome P450 3A7 (CYP3A7)
DMDZ9LT	MT	DME
DMDZ9LT	MA	Metabolism
DMDZ9LT	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
DMDZ9LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244

DMDZ9LT	DI	DMDZ9LT
DMDZ9LT	DN	Ethosuximide
DMDZ9LT	MI	TT729IR
DMDZ9LT	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMDZ9LT	MT	DTT
DMDZ9LT	MA	Blocker
DMDZ9LT	RN	Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
DMDZ9LT	RU	https://pubmed.ncbi.nlm.nih.gov/19005061

DMXWOCP	DI	DMXWOCP
DMXWOCP	DN	Ethotoin
DMXWOCP	MI	TTZOVE0
DMXWOCP	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMXWOCP	MT	DTT
DMXWOCP	MA	Blocker
DMXWOCP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMXWOCP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVO4ED	DI	DMVO4ED
DMVO4ED	DN	Ethoxzolamide
DMVO4ED	MI	TTHQPL7
DMVO4ED	MN	Carbonic anhydrase I (CA-I)
DMVO4ED	MT	DTT
DMVO4ED	MA	Modulator
DMVO4ED	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVO4ED	RU	https://www.fda.gov/

DMVO4ED	DI	DMVO4ED
DMVO4ED	DN	Ethoxzolamide
DMVO4ED	MI	TTANPDJ
DMVO4ED	MN	Carbonic anhydrase II (CA-II)
DMVO4ED	MT	DTT
DMVO4ED	MA	Inhibitor
DMVO4ED	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMVO4ED	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM20VMW	DI	DM20VMW
DM20VMW	DN	Ethylestrenol
DM20VMW	MI	TTS64P2
DM20VMW	MN	Androgen receptor (AR)
DM20VMW	MT	DTT
DM20VMW	MA	Modulator
DM20VMW	RN	Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6.
DM20VMW	RU	https://www.ncbi.nlm.nih.gov/pubmed/6539197

DMZM84R	DI	DMZM84R
DMZM84R	DN	Ethynodiol diacetate
DMZM84R	MI	DE4LYSA
DMZM84R	MN	Cytochrome P450 3A4 (CYP3A4)
DMZM84R	MT	DME
DMZM84R	MA	Metabolism
DMZM84R	RN	News and information in drug research: Ethynodiol diacetate.
DMZM84R	RU	http://genelabs.com/drugsdb/details/ethynodiol-diacetate/

DMZM84R	DI	DMZM84R
DMZM84R	DN	Ethynodiol diacetate
DMZM84R	MI	TTUV8G9
DMZM84R	MN	Progesterone receptor (PGR)
DMZM84R	MT	DTT
DMZM84R	MA	Binder
DMZM84R	RN	Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
DMZM84R	RU	https://pubmed.ncbi.nlm.nih.gov/858280

DMBIYNH	DI	DMBIYNH
DMBIYNH	DN	ETI-204
DMBIYNH	MI	TTRLPUB
DMBIYNH	MN	Bacillus anthracis Protective antigen (Anthrax PA)
DMBIYNH	MT	DTT
DMBIYNH	RN	Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14.
DMBIYNH	RU	https://pubmed.ncbi.nlm.nih.gov/25645849

DMAWJIN	DI	DMAWJIN
DMAWJIN	DN	Etidronate Disodium
DMAWJIN	MI	TT8X5NO
DMAWJIN	MN	Calcium (Ca)
DMAWJIN	MT	DTT
DMAWJIN	MA	Modulator
DMAWJIN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAWJIN	RU	https://www.fda.gov/

DMAWJIN	DI	DMAWJIN
DMAWJIN	DN	Etidronate Disodium
DMAWJIN	MI	TTUDR0C
DMAWJIN	MN	Iron (Fe)
DMAWJIN	MT	DTT
DMAWJIN	MA	Modulator
DMAWJIN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAWJIN	RU	https://www.fda.gov/

DM1XHYJ	DI	DM1XHYJ
DM1XHYJ	DN	Etidronic acid
DM1XHYJ	MI	TTCWXFA
DM1XHYJ	MN	Protein-tyrosine phosphatase sigma (R-PTP-sigma)
DM1XHYJ	MT	DTT
DM1XHYJ	MA	Inhibitor
DM1XHYJ	RN	Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
DM1XHYJ	RU	https://pubmed.ncbi.nlm.nih.gov/8992885

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DE5IED8
DM6WJO9	MN	Cytochrome P450 2C9 (CYP2C9)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	TTVKILB
DM6WJO9	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6WJO9	MT	DTT
DM6WJO9	MA	Inhibitor
DM6WJO9	RN	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
DM6WJO9	RU	https://pubmed.ncbi.nlm.nih.gov/17603251

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEYGVN4
DM6WJO9	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEL5N6Y
DM6WJO9	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEF2WXN
DM6WJO9	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DE85D2P
DM6WJO9	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6WJO9	DI	DM6WJO9
DM6WJO9	DN	Etodolac
DM6WJO9	MI	DEB3CV1
DM6WJO9	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM6WJO9	MT	DME
DM6WJO9	MA	Metabolism
DM6WJO9	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6WJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZI3WO	DI	DMZI3WO
DMZI3WO	DN	Etomidate
DMZI3WO	MI	TTEX6LM
DMZI3WO	MN	GABA(A) receptor gamma-3 (GABRG3)
DMZI3WO	MT	DTT
DMZI3WO	MA	Modulator
DMZI3WO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMZI3WO	RU	https://www.fda.gov/

DMKA8J4	DI	DMKA8J4
DMKA8J4	DN	Etonogestrel
DMKA8J4	MI	DE4LYSA
DMKA8J4	MN	Cytochrome P450 3A4 (CYP3A4)
DMKA8J4	MT	DME
DMKA8J4	MA	Metabolism
DMKA8J4	RN	The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75.
DMKA8J4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096

DMKA8J4	DI	DMKA8J4
DMKA8J4	DN	Etonogestrel
DMKA8J4	MI	TTUV8G9
DMKA8J4	MN	Progesterone receptor (PGR)
DMKA8J4	MT	DTT
DMKA8J4	MA	Binder
DMKA8J4	RN	Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
DMKA8J4	RU	https://pubmed.ncbi.nlm.nih.gov/19434887

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTI7UX6
DMNH3PG	MN	Breast cancer resistance protein (ABCG2)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/25128152

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEJGDUW
DMNH3PG	MN	Cytochrome P450 1A2 (CYP1A2)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEVDYN7
DMNH3PG	MN	Cytochrome P450 2E1 (CYP2E1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732391

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE4LYSA
DMNH3PG	MN	Cytochrome P450 3A4 (CYP3A4)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEIBDNY
DMNH3PG	MN	Cytochrome P450 3A5 (CYP3A5)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319341

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	TT0IHXV
DMNH3PG	MN	DNA topoisomerase II (TOP2)
DMNH3PG	MT	DTT
DMNH3PG	MA	Modulator
DMNH3PG	RN	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/16101488

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEK6079
DMNH3PG	MN	Glutathione S-transferase pi (GSTP1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE3PKUG
DMNH3PG	MN	Glutathione S-transferase theta-1 (GSTT1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTSYQGK
DMNH3PG	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504821

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTFI42L
DMNH3PG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11901101

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTQ3ZHF
DMNH3PG	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/19334674

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DT3D8F0
DMNH3PG	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
DMNH3PG	RU	https://doi.org/10.1111/j.1476-5381.2011.01672.x

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DT9C1TS
DMNH3PG	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTPFTEQ
DMNH3PG	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
DMNH3PG	RU	https://doi.org/10.1111/j.1476-5381.2011.01672.x

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DTUGYRD
DMNH3PG	MN	P-glycoprotein 1 (ABCB1)
DMNH3PG	MT	DTP
DMNH3PG	MA	Substrate
DMNH3PG	RN	Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
DMNH3PG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12948018

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE073H6
DMNH3PG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DE492CE
DMNH3PG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680

DMNH3PG	DI	DMNH3PG
DMNH3PG	DN	Etoposide
DMNH3PG	MI	DEYGVN4
DMNH3PG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNH3PG	MT	DME
DMNH3PG	MA	Metabolism
DMNH3PG	RN	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
DMNH3PG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151191

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DEJGDUW
DM6A4NW	MN	Cytochrome P450 1A2 (CYP1A2)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DE5IED8
DM6A4NW	MN	Cytochrome P450 2C9 (CYP2C9)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	DE4LYSA
DM6A4NW	MN	Cytochrome P450 3A4 (CYP3A4)
DM6A4NW	MT	DME
DM6A4NW	MA	Metabolism
DM6A4NW	RN	Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20.
DM6A4NW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749

DM6A4NW	DI	DM6A4NW
DM6A4NW	DN	Etoricoxib
DM6A4NW	MI	TTVKILB
DM6A4NW	MN	Prostaglandin G/H synthase 2 (COX-2)
DM6A4NW	MT	DTT
DM6A4NW	MA	Inhibitor
DM6A4NW	RN	The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17.
DM6A4NW	RU	https://pubmed.ncbi.nlm.nih.gov/19470170

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DE5IED8
DMGV8QU	MN	Cytochrome P450 2C9 (CYP2C9)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DE4LYSA
DMGV8QU	MN	Cytochrome P450 3A4 (CYP3A4)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	TT84ETX
DMGV8QU	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMGV8QU	MT	DTT
DMGV8QU	MA	Modulator
DMGV8QU	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMGV8QU	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DEGTFWK
DMGV8QU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGV8QU	MT	DME
DMGV8QU	MA	Metabolism
DMGV8QU	RN	Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
DMGV8QU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22269145

DMGV8QU	DI	DMGV8QU
DMGV8QU	DN	Etravirine
DMGV8QU	MI	DTQ3ZHF
DMGV8QU	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMGV8QU	MT	DTP
DMGV8QU	MA	Substrate
DMGV8QU	RN	Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4.
DMGV8QU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21189339

DM2CZFA	DI	DM2CZFA
DM2CZFA	DN	Etretinate
DM2CZFA	MI	DEZT8FM
DM2CZFA	MN	Retinoic acid 4-hydroxylase 26B1 (CYP26B1)
DM2CZFA	MT	DME
DM2CZFA	MA	Metabolism
DM2CZFA	RN	Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1029-36.
DM2CZFA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17185629

DM5GT1M	DI	DM5GT1M
DM5GT1M	DN	EVANS BLUE
DM5GT1M	MI	TTFNGC9
DM5GT1M	MN	Serum albumin (ALB)
DM5GT1M	MT	DTT
DM5GT1M	MA	Modulator
DM5GT1M	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM5GT1M	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	DE4LYSA
DM8X2EH	MN	Cytochrome P450 3A4 (CYP3A4)
DM8X2EH	MT	DME
DM8X2EH	MA	Metabolism
DM8X2EH	RN	The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S.
DM8X2EH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15041395

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	DTUGYRD
DM8X2EH	MN	P-glycoprotein 1 (ABCB1)
DM8X2EH	MT	DTP
DM8X2EH	MA	Substrate
DM8X2EH	RN	Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. Ther Drug Monit. 2015 Oct;37(5):675-80.
DM8X2EH	RU	http://www.ncbi.nlm.nih.gov/pubmed/25565673

DM8X2EH	DI	DM8X2EH
DM8X2EH	DN	Everolimus
DM8X2EH	MI	TTCJG29
DM8X2EH	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM8X2EH	MT	DTT
DM8X2EH	MA	Inhibitor
DM8X2EH	RN	Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
DM8X2EH	RU	https://pubmed.ncbi.nlm.nih.gov/19620795

DMBLX7U	DI	DMBLX7U
DMBLX7U	DN	Evinacumab
DMBLX7U	MI	TTUO98L
DMBLX7U	MN	Angiopoietin-related protein 3 (ANGPTL3)
DMBLX7U	MT	DTT
DMBLX7U	MA	Inhibitor
DMBLX7U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMBLX7U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf

DM9HPW3	DI	DM9HPW3
DM9HPW3	DN	Exemestane
DM9HPW3	MI	TTSZLWK
DM9HPW3	MN	Aromatase (CYP19A1)
DM9HPW3	MT	DTT
DM9HPW3	MA	Inhibitor
DM9HPW3	RN	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
DM9HPW3	RU	https://pubmed.ncbi.nlm.nih.gov/14505258

DM9HPW3	DI	DM9HPW3
DM9HPW3	DN	Exemestane
DM9HPW3	MI	DE4LYSA
DM9HPW3	MN	Cytochrome P450 3A4 (CYP3A4)
DM9HPW3	MT	DME
DM9HPW3	MA	Metabolism
DM9HPW3	RN	In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314.
DM9HPW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28603633

DMYHBKN	DI	DMYHBKN
DMYHBKN	DN	Exenatide
DMYHBKN	MI	DEKZQY6
DMYHBKN	MN	Dipeptidyl peptidase IV (DPP4)
DMYHBKN	MT	DME
DMYHBKN	MA	Metabolism
DMYHBKN	RN	In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805.
DMYHBKN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25723538

DMYHBKN	DI	DMYHBKN
DMYHBKN	DN	Exenatide
DMYHBKN	MI	TTVIMDE
DMYHBKN	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMYHBKN	MT	DTT
DMYHBKN	MA	Binder
DMYHBKN	RN	Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
DMYHBKN	RU	https://pubmed.ncbi.nlm.nih.gov/19459763

DMHPRWG	DI	DMHPRWG
DMHPRWG	DN	Exjade
DMHPRWG	MI	TTUDR0C
DMHPRWG	MN	Iron (Fe)
DMHPRWG	MT	DTT
DMHPRWG	MA	Modulator
DMHPRWG	RN	Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
DMHPRWG	RU	https://pubmed.ncbi.nlm.nih.gov/17927285

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTJ0EW4
DM7A8TW	MN	Bile salt export pump (ABCB11)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTI7UX6
DM7A8TW	MN	Breast cancer resistance protein (ABCG2)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19443695

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DE4LYSA
DM7A8TW	MN	Cytochrome P450 3A4 (CYP3A4)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTFI42L
DM7A8TW	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/16513445

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTQ3ZHF
DM7A8TW	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19443695

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	TTPD1CN
DM7A8TW	MN	Niemann-Pick C1-like protein 1 (NPC1L1)
DM7A8TW	MT	DTT
DM7A8TW	MA	Inhibitor
DM7A8TW	RN	Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107.
DM7A8TW	RU	https://pubmed.ncbi.nlm.nih.gov/19552506

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DT3D8F0
DM7A8TW	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/16280261

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DTUGYRD
DM7A8TW	MN	P-glycoprotein 1 (ABCB1)
DM7A8TW	MT	DTP
DM7A8TW	MA	Substrate
DM7A8TW	RN	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
DM7A8TW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20220747

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEYGVN4
DM7A8TW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEF2WXN
DM7A8TW	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21368751

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DENZ6B1
DM7A8TW	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DM7A8TW	DI	DM7A8TW
DM7A8TW	DN	Ezetimibe
DM7A8TW	MI	DEB3CV1
DM7A8TW	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM7A8TW	MT	DME
DM7A8TW	MA	Metabolism
DM7A8TW	RN	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
DM7A8TW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634

DMAB6PM	DI	DMAB6PM
DMAB6PM	DN	Factor 8
DMAB6PM	MI	TT1290U
DMAB6PM	MN	Coagulation factor VIII (F8)
DMAB6PM	MT	DTT
DMAB6PM	MA	Modulator
DMAB6PM	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DMAB6PM	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMZUW6P	DI	DMZUW6P
DMZUW6P	DN	Factor viia
DMZUW6P	MI	TTF0EGX
DMZUW6P	MN	Coagulation factor VII (F7)
DMZUW6P	MT	DTT
DMZUW6P	MA	Modulator
DMZUW6P	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMZUW6P	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM3C5GZ	DI	DM3C5GZ
DM3C5GZ	DN	FADROZOLE
DM3C5GZ	MI	TTSZLWK
DM3C5GZ	MN	Aromatase (CYP19A1)
DM3C5GZ	MT	DTT
DM3C5GZ	MA	Inhibitor
DM3C5GZ	RN	Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
DM3C5GZ	RU	https://pubmed.ncbi.nlm.nih.gov/16279787

DM3C5GZ	DI	DM3C5GZ
DM3C5GZ	DN	FADROZOLE
DM3C5GZ	MI	TTIQUX7
DM3C5GZ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DM3C5GZ	MT	DTT
DM3C5GZ	MA	Inhibitor
DM3C5GZ	RN	Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25.
DM3C5GZ	RU	https://pubmed.ncbi.nlm.nih.gov/20121113

DMBI9ZJ	DI	DMBI9ZJ
DMBI9ZJ	DN	Falecalcitrol
DMBI9ZJ	MI	TTK59TV
DMBI9ZJ	MN	Vitamin D3 receptor (VDR)
DMBI9ZJ	MT	DTT
DMBI9ZJ	MA	Agonist
DMBI9ZJ	RN	Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66.
DMBI9ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/11003160

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	DE4LYSA
DMJHLSD	MN	Cytochrome P450 3A4 (CYP3A4)
DMJHLSD	MT	DME
DMJHLSD	MA	Metabolism
DMJHLSD	RN	Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23.
DMJHLSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8095215

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	TTIU7X1
DMJHLSD	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMJHLSD	MT	DTT
DMJHLSD	MA	Inhibitor
DMJHLSD	RN	Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
DMJHLSD	RU	https://pubmed.ncbi.nlm.nih.gov/15452407

DMJHLSD	DI	DMJHLSD
DMJHLSD	DN	Famciclovir
DMJHLSD	MI	DTUGYRD
DMJHLSD	MN	P-glycoprotein 1 (ABCB1)
DMJHLSD	MT	DTP
DMJHLSD	MA	Substrate
DMJHLSD	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMJHLSD	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	TTQHJ1K
DMRL3AB	MN	Histamine H2 receptor (H2R)
DMRL3AB	MT	DTT
DMRL3AB	MA	Antagonist
DMRL3AB	RN	Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
DMRL3AB	RU	https://pubmed.ncbi.nlm.nih.gov/11180002

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DEGTFWK
DMRL3AB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMRL3AB	MT	DME
DMRL3AB	MA	Metabolism
DMRL3AB	RN	Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
DMRL3AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112810

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DTQ23VB
DMRL3AB	MN	Organic anion transporter 1 (SLC22A6)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/15496291

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DTVP67E
DMRL3AB	MN	Organic anion transporter 3 (SLC22A8)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DMRL3AB	DI	DMRL3AB
DMRL3AB	DN	Famotidine
DMRL3AB	MI	DT9IDPW
DMRL3AB	MN	Organic cation transporter 2 (SLC22A2)
DMRL3AB	MT	DTP
DMRL3AB	MA	Substrate
DMRL3AB	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DMRL3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DMX7A5V	DI	DMX7A5V
DMX7A5V	DN	Faropenem
DMX7A5V	MI	TT4ILYC
DMX7A5V	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMX7A5V	MT	DTT
DMX7A5V	MA	Inhibitor
DMX7A5V	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DMX7A5V	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMDEXQ0	DI	DMDEXQ0
DMDEXQ0	DN	Febuxostat
DMDEXQ0	MI	DEYGVN4
DMDEXQ0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDEXQ0	MT	DME
DMDEXQ0	MA	Metabolism
DMDEXQ0	RN	In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510.
DMDEXQ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18421623

DMDEXQ0	DI	DMDEXQ0
DMDEXQ0	DN	Febuxostat
DMDEXQ0	MI	TT7RJY8
DMDEXQ0	MN	Xanthine dehydrogenase/oxidase (XDH)
DMDEXQ0	MT	DTT
DMDEXQ0	MA	Inhibitor
DMDEXQ0	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMDEXQ0	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM4ZBK6	DI	DM4ZBK6
DM4ZBK6	DN	Fedratinib
DM4ZBK6	MI	TTRMX3V
DM4ZBK6	MN	Janus kinase 2 (JAK-2)
DM4ZBK6	MT	DTT
DM4ZBK6	MA	Inhibitor
DM4ZBK6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM4ZBK6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DE4LYSA
DML2DCR	MN	Cytochrome P450 3A4 (CYP3A4)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DEP76YL
DML2DCR	MN	Dimethylaniline oxidase 3 (FMO3)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DML2DCR	DI	DML2DCR
DML2DCR	DN	Fedratinib hydrochloride
DML2DCR	MI	DEGTFWK
DML2DCR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DML2DCR	MT	DME
DML2DCR	MA	Metabolism
DML2DCR	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DML2DCR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	DEVDYN7
DM1V5ZS	MN	Cytochrome P450 2E1 (CYP2E1)
DM1V5ZS	MT	DME
DM1V5ZS	MA	Metabolism
DM1V5ZS	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1V5ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	DE4LYSA
DM1V5ZS	MN	Cytochrome P450 3A4 (CYP3A4)
DM1V5ZS	MT	DME
DM1V5ZS	MA	Metabolism
DM1V5ZS	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DM1V5ZS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DM1V5ZS	DI	DM1V5ZS
DM1V5ZS	DN	Felbamate
DM1V5ZS	MI	TT9IK2Z
DM1V5ZS	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1V5ZS	MT	DTT
DM1V5ZS	MA	Antagonist
DM1V5ZS	RN	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
DM1V5ZS	RU	https://pubmed.ncbi.nlm.nih.gov/18311896

DMKZEIB	DI	DMKZEIB
DMKZEIB	DN	Felbinac
DMKZEIB	MI	TTK0943
DMKZEIB	MN	Prostaglandin G/H synthase (COX)
DMKZEIB	MT	DTT
DMKZEIB	MA	Modulator
DMKZEIB	RN	A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7.
DMKZEIB	RU	https://pubmed.ncbi.nlm.nih.gov/6254545

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	TT5HONZ
DMOSW35	MN	Calcium channel unspecific (CaC)
DMOSW35	MT	DTT
DMOSW35	MA	Blocker
DMOSW35	RN	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
DMOSW35	RU	https://pubmed.ncbi.nlm.nih.gov/18974361

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DE4LYSA
DMOSW35	MN	Cytochrome P450 3A4 (CYP3A4)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMOSW35	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DEIBDNY
DMOSW35	MN	Cytochrome P450 3A5 (CYP3A5)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug Interactions Flockhart Table
DMOSW35	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DERD86B
DMOSW35	MN	Cytochrome P450 3A7 (CYP3A7)
DMOSW35	MT	DME
DMOSW35	MA	Metabolism
DMOSW35	RN	Drug Interactions Flockhart Table
DMOSW35	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMOSW35	DI	DMOSW35
DMOSW35	DN	Felodipine
DMOSW35	MI	DTUGYRD
DMOSW35	MN	P-glycoprotein 1 (ABCB1)
DMOSW35	MT	DTP
DMOSW35	MA	Substrate
DMOSW35	RN	The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
DMOSW35	RU	http://www.ncbi.nlm.nih.gov/pubmed/28244604

DMHLP9C	DI	DMHLP9C
DMHLP9C	DN	Felypressin
DMHLP9C	MI	TT4TFGN
DMHLP9C	MN	Vasopressin V1a receptor (V1AR)
DMHLP9C	MT	DTT
DMHLP9C	MA	Agonist
DMHLP9C	RN	Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
DMHLP9C	RU	https://pubmed.ncbi.nlm.nih.gov/18655903

DMXGDFK	DI	DMXGDFK
DMXGDFK	DN	Fenbufen
DMXGDFK	MI	TT8NGED
DMXGDFK	MN	Prostaglandin G/H synthase 1 (COX-1)
DMXGDFK	MT	DTT
DMXGDFK	MA	Inhibitor
DMXGDFK	RN	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
DMXGDFK	RU	https://pubmed.ncbi.nlm.nih.gov/19457595

DMXGDFK	DI	DMXGDFK
DMXGDFK	DN	Fenbufen
DMXGDFK	MI	TTVKILB
DMXGDFK	MN	Prostaglandin G/H synthase 2 (COX-2)
DMXGDFK	MT	DTT
DMXGDFK	MA	Inhibitor
DMXGDFK	RN	Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
DMXGDFK	RU	https://pubmed.ncbi.nlm.nih.gov/19457595

DM0LRU9	DI	DM0LRU9
DM0LRU9	DN	Fendrix
DM0LRU9	MI	TT3J5ZI
DM0LRU9	MN	Cell mediated immunity response (CMIR)
DM0LRU9	MT	DTT
DM0LRU9	RN	Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7.
DM0LRU9	RU	https://pubmed.ncbi.nlm.nih.gov/22981848

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	DE4LYSA
DMFKXDY	MN	Cytochrome P450 3A4 (CYP3A4)
DMFKXDY	MT	DME
DMFKXDY	MA	Metabolism
DMFKXDY	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMFKXDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	TTJ584C
DMFKXDY	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFKXDY	MT	DTT
DMFKXDY	MA	Agonist
DMFKXDY	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMFKXDY	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DMFKXDY	DI	DMFKXDY
DMFKXDY	DN	Fenofibrate
DMFKXDY	MI	DE85D2P
DMFKXDY	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMFKXDY	MT	DME
DMFKXDY	MA	Metabolism
DMFKXDY	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMFKXDY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE7WS3H
DMGO2MC	MN	Aldo-keto reductase 1B1 (AKR1B1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE7P2FB
DMGO2MC	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DEOY5ZM
DMGO2MC	MN	Aldo-keto reductase 1C2 (AKR1C2)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DEGQTXO
DMGO2MC	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DT61TWI
DMGO2MC	MN	ATP-binding cassette sub-family A member 1 (ABCA1)
DMGO2MC	MT	DTP
DMGO2MC	MA	Substrate
DMGO2MC	RN	Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7.
DMGO2MC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15790930

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	TTIV96N
DMGO2MC	MN	Fatty acid-binding protein 1 (FABP1)
DMGO2MC	MT	DTT
DMGO2MC	MA	Inhibitor
DMGO2MC	RN	Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
DMGO2MC	RU	https://pubmed.ncbi.nlm.nih.gov/18533710

DMGO2MC	DI	DMGO2MC
DMGO2MC	DN	Fenofibric acid
DMGO2MC	MI	DE9JFMC
DMGO2MC	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMGO2MC	MT	DME
DMGO2MC	MA	Metabolism
DMGO2MC	RN	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
DMGO2MC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626

DMFAOKP	DI	DMFAOKP
DMFAOKP	DN	Fenoldopam
DMFAOKP	MI	TTZFYLI
DMFAOKP	MN	Dopamine D1 receptor (D1R)
DMFAOKP	MT	DTT
DMFAOKP	MA	Agonist
DMFAOKP	RN	Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
DMFAOKP	RU	https://pubmed.ncbi.nlm.nih.gov/18591870

DML5VQ0	DI	DML5VQ0
DML5VQ0	DN	Fenoprofen
DML5VQ0	MI	TTK0943
DML5VQ0	MN	Prostaglandin G/H synthase (COX)
DML5VQ0	MT	DTT
DML5VQ0	MA	Inhibitor
DML5VQ0	RN	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
DML5VQ0	RU	https://pubmed.ncbi.nlm.nih.gov/17409433

DMIP3ZV	DI	DMIP3ZV
DMIP3ZV	DN	Fenoterol
DMIP3ZV	MI	TT2CJVK
DMIP3ZV	MN	Adrenergic receptor beta-2 (ADRB2)
DMIP3ZV	MT	DTT
DMIP3ZV	MA	Agonist
DMIP3ZV	RN	Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
DMIP3ZV	RU	https://pubmed.ncbi.nlm.nih.gov/19334040

DMIP3ZV	DI	DMIP3ZV
DMIP3ZV	DN	Fenoterol
DMIP3ZV	MI	DTT79CX
DMIP3ZV	MN	Organic cation transporter 1 (SLC22A1)
DMIP3ZV	MT	DTP
DMIP3ZV	MA	Substrate
DMIP3ZV	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMIP3ZV	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DE4LYSA
DM8WAHT	MN	Cytochrome P450 3A4 (CYP3A4)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10490933

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DEIBDNY
DM8WAHT	MN	Cytochrome P450 3A5 (CYP3A5)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DERD86B
DM8WAHT	MN	Cytochrome P450 3A7 (CYP3A7)
DM8WAHT	MT	DME
DM8WAHT	MA	Metabolism
DM8WAHT	RN	Drug Interactions Flockhart Table
DM8WAHT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	TTKWM86
DM8WAHT	MN	Opioid receptor mu (MOP)
DM8WAHT	MT	DTT
DM8WAHT	MA	Modulator
DM8WAHT	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DM8WAHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DM8WAHT	DI	DM8WAHT
DM8WAHT	DN	Fentanyl
DM8WAHT	MI	DTUGYRD
DM8WAHT	MN	P-glycoprotein 1 (ABCB1)
DM8WAHT	MT	DTP
DM8WAHT	MA	Substrate
DM8WAHT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM8WAHT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DECB0K3
DM13495	MN	Cytochrome P450 2D6 (CYP2D6)
DM13495	MT	DME
DM13495	MA	Metabolism
DM13495	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DM13495	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DE4LYSA
DM13495	MN	Cytochrome P450 3A4 (CYP3A4)
DM13495	MT	DME
DM13495	MA	Metabolism
DM13495	RN	Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9.
DM13495	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	TTZ9SOR
DM13495	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM13495	MT	DTT
DM13495	MA	Modulator
DM13495	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM13495	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM13495	DI	DM13495
DM13495	DN	Fesoterodine fumarate
DM13495	MI	DTUGYRD
DM13495	MN	P-glycoprotein 1 (ABCB1)
DM13495	MT	DTP
DM13495	MA	Substrate
DM13495	RN	Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73.
DM13495	RU	http://www.ncbi.nlm.nih.gov/pubmed/22390261

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	TTTIBOJ
DM17ONX	MN	Histamine H1 receptor (H1R)
DM17ONX	MT	DTT
DM17ONX	MA	Antagonist
DM17ONX	RN	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
DM17ONX	RU	https://pubmed.ncbi.nlm.nih.gov/19210904

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTQ3ZHF
DM17ONX	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/18245269

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTE2B1D
DM17ONX	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/20797388

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DT9C1TS
DM17ONX	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16014768

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTPFTEQ
DM17ONX	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/21280267

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTT79CX
DM17ONX	MN	Organic cation transporter 1 (SLC22A1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70.
DM17ONX	RU	https://doi.org/10.1038/sj.clpt.6100056

DM17ONX	DI	DM17ONX
DM17ONX	DN	Fexofenadine
DM17ONX	MI	DTUGYRD
DM17ONX	MN	P-glycoprotein 1 (ABCB1)
DM17ONX	MT	DTP
DM17ONX	MA	Substrate
DM17ONX	RN	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.
DM17ONX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16084853

DM9Q8SO	DI	DM9Q8SO
DM9Q8SO	DN	Fibrinolysin
DM9Q8SO	MI	TTWODQF
DM9Q8SO	MN	Fibrin (FG)
DM9Q8SO	MT	DTT
DM9Q8SO	MA	Modulator
DM9Q8SO	RN	FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2.
DM9Q8SO	RU	https://pubmed.ncbi.nlm.nih.gov/14075642

DMFP6MV	DI	DMFP6MV
DMFP6MV	DN	Fidaxomicin
DMFP6MV	MI	TTIJ5EB
DMFP6MV	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMFP6MV	MT	DTT
DMFP6MV	MA	Modulator
DMFP6MV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMFP6MV	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZEONG	DI	DMZEONG
DMZEONG	DN	Finafloxacin
DMZEONG	MI	TTN6J5F
DMZEONG	MN	Bacterial DNA gyrase (Bact gyrase)
DMZEONG	MT	DTT
DMZEONG	MA	Modulator
DMZEONG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMZEONG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMZEONG	DI	DMZEONG
DMZEONG	DN	Finafloxacin
DMZEONG	MI	TTIXTO3
DMZEONG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMZEONG	MT	DTT
DMZEONG	MA	Modulator
DMZEONG	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMZEONG	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DE4LYSA
DMWV3TZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMWV3TZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DEIBDNY
DMWV3TZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Drug Interactions Flockhart Table
DMWV3TZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	DERD86B
DMWV3TZ	MN	Cytochrome P450 3A7 (CYP3A7)
DMWV3TZ	MT	DME
DMWV3TZ	MA	Metabolism
DMWV3TZ	RN	Drug Interactions Flockhart Table
DMWV3TZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	TT2A0DR
DMWV3TZ	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMWV3TZ	MT	DTT
DMWV3TZ	MA	Inhibitor
DMWV3TZ	RN	The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.
DMWV3TZ	RU	https://pubmed.ncbi.nlm.nih.gov/19543428

DMWV3TZ	DI	DMWV3TZ
DMWV3TZ	DN	Finasteride
DMWV3TZ	MI	TTT02K8
DMWV3TZ	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMWV3TZ	MT	DTT
DMWV3TZ	MA	Inhibitor
DMWV3TZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV3TZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	DED26GV
DM5JVAN	MN	Cytochrome P450 4F12 (CYP4F12)
DM5JVAN	MT	DME
DM5JVAN	MA	Metabolism
DM5JVAN	RN	CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
DM5JVAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	DE3GT9C
DM5JVAN	MN	Cytochrome P450 4F2 (CYP4F2)
DM5JVAN	MT	DME
DM5JVAN	MA	Metabolism
DM5JVAN	RN	CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8.
DM5JVAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201

DM5JVAN	DI	DM5JVAN
DM5JVAN	DN	Fingolimod
DM5JVAN	MI	TT9JZCK
DM5JVAN	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM5JVAN	MT	DTT
DM5JVAN	MA	Modulator
DM5JVAN	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM5JVAN	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMKV4NL	DI	DMKV4NL
DMKV4NL	DN	Flavoxate
DMKV4NL	MI	TTH18TF
DMKV4NL	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMKV4NL	MT	DTT
DMKV4NL	MA	Antagonist
DMKV4NL	RN	Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8.
DMKV4NL	RU	https://pubmed.ncbi.nlm.nih.gov/8842386

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	DEJGDUW
DMSQDLE	MN	Cytochrome P450 1A2 (CYP1A2)
DMSQDLE	MT	DME
DMSQDLE	MA	Metabolism
DMSQDLE	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DMSQDLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	DECB0K3
DMSQDLE	MN	Cytochrome P450 2D6 (CYP2D6)
DMSQDLE	MT	DME
DMSQDLE	MA	Metabolism
DMSQDLE	RN	Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85.
DMSQDLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	TT05DLS
DMSQDLE	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMSQDLE	MT	DTT
DMSQDLE	MA	Modulator
DMSQDLE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSQDLE	RU	https://www.fda.gov/

DMSQDLE	DI	DMSQDLE
DMSQDLE	DN	Flecainide
DMSQDLE	MI	TTN9VTF
DMSQDLE	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMSQDLE	MT	DTT
DMSQDLE	MA	Blocker
DMSQDLE	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMSQDLE	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMXGQYZ	DI	DMXGQYZ
DMXGQYZ	DN	Fleroxacin
DMXGQYZ	MI	TT0IHXV
DMXGQYZ	MN	DNA topoisomerase II (TOP2)
DMXGQYZ	MT	DTT
DMXGQYZ	MA	Inhibitor
DMXGQYZ	RN	Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9.
DMXGQYZ	RU	https://pubmed.ncbi.nlm.nih.gov/8861529

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	TTSQIFT
DM70DTN	MN	5-HT 1A receptor (HTR1A)
DM70DTN	MT	DTT
DM70DTN	MA	Modulator
DM70DTN	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM70DTN	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	TTJQOD7
DM70DTN	MN	5-HT 2A receptor (HTR2A)
DM70DTN	MT	DTT
DM70DTN	MA	Modulator
DM70DTN	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM70DTN	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	DE4LYSA
DM70DTN	MN	Cytochrome P450 3A4 (CYP3A4)
DM70DTN	MT	DME
DM70DTN	MA	Metabolism
DM70DTN	RN	Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22.
DM70DTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26412054

DM70DTN	DI	DM70DTN
DM70DTN	DN	Flibanserin
DM70DTN	MI	DEGTFWK
DM70DTN	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70DTN	MT	DME
DM70DTN	MA	Metabolism
DM70DTN	RN	Flibanserin therapy and CYP2C19 genotype.
DM70DTN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31550099

DMJ8A3Z	DI	DMJ8A3Z
DMJ8A3Z	DN	Florbetapir F-18
DMJ8A3Z	MI	TTE4KHA
DMJ8A3Z	MN	Amyloid beta A4 protein (APP)
DMJ8A3Z	MT	DTT
DMJ8A3Z	MA	Modulator
DMJ8A3Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMJ8A3Z	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM04LR2	DI	DM04LR2
DM04LR2	DN	Floxuridine
DM04LR2	MI	TTU6BFZ
DM04LR2	MN	Candida Thymidylate synthase (Candi TMP1)
DM04LR2	MT	DTT
DM04LR2	MA	Inhibitor
DM04LR2	RN	Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
DM04LR2	RU	https://pubmed.ncbi.nlm.nih.gov/10482907

DM04LR2	DI	DM04LR2
DM04LR2	DN	Floxuridine
DM04LR2	MI	DE4HCYL
DM04LR2	MN	Thymidine phosphorylase (TYMP)
DM04LR2	MT	DME
DM04LR2	MA	Metabolism
DM04LR2	RN	Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
DM04LR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18652477

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	TTJP4SM
DMNUWST	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNUWST	MT	DTT
DMNUWST	MA	Binder
DMNUWST	RN	Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71.
DMNUWST	RU	https://pubmed.ncbi.nlm.nih.gov/6335600

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	DE4LYSA
DMNUWST	MN	Cytochrome P450 3A4 (CYP3A4)
DMNUWST	MT	DME
DMNUWST	MA	Metabolism
DMNUWST	RN	Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477.
DMNUWST	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30447161

DMNUWST	DI	DMNUWST
DMNUWST	DN	Flucloxacillin
DMNUWST	MI	DT9G7XN
DMNUWST	MN	Peptide transporter 1 (SLC15A1)
DMNUWST	MT	DTP
DMNUWST	MA	Substrate
DMNUWST	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMNUWST	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMOWZ6B	DI	DMOWZ6B
DMOWZ6B	DN	Fluconazole
DMOWZ6B	MI	TTTSOUD
DMOWZ6B	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMOWZ6B	MT	DTT
DMOWZ6B	MA	Modulator
DMOWZ6B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOWZ6B	RU	https://www.fda.gov/

DMOWZ6B	DI	DMOWZ6B
DMOWZ6B	DN	Fluconazole
DMOWZ6B	MI	DE5IED8
DMOWZ6B	MN	Cytochrome P450 2C9 (CYP2C9)
DMOWZ6B	MT	DME
DMOWZ6B	MA	Metabolism
DMOWZ6B	RN	Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9.
DMOWZ6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10952477

DM13VTW	DI	DM13VTW
DM13VTW	DN	Flucytosine
DM13VTW	MI	TTU6BFZ
DM13VTW	MN	Candida Thymidylate synthase (Candi TMP1)
DM13VTW	MT	DTT
DM13VTW	MA	Inhibitor
DM13VTW	RN	Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
DM13VTW	RU	https://pubmed.ncbi.nlm.nih.gov/16964330

DMVRLT7	DI	DMVRLT7
DMVRLT7	DN	Fludarabine
DMVRLT7	MI	TTLP57V
DMVRLT7	MN	Adenosine deaminase (ADA)
DMVRLT7	MT	DTT
DMVRLT7	MA	Inhibitor
DMVRLT7	RN	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
DMVRLT7	RU	https://pubmed.ncbi.nlm.nih.gov/10887639

DMD2K4I	DI	DMD2K4I
DMD2K4I	DN	Fludiazepam
DMD2K4I	MI	TTPTXIN
DMD2K4I	MN	Translocator protein (TSPO)
DMD2K4I	MT	DTT
DMD2K4I	MA	Agonist
DMD2K4I	RN	Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.
DMD2K4I	RU	https://pubmed.ncbi.nlm.nih.gov/2857046

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	TTS64P2
DMUDIR8	MN	Androgen receptor (AR)
DMUDIR8	MT	DTT
DMUDIR8	MA	Inhibitor
DMUDIR8	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMUDIR8	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	DE4LYSA
DMUDIR8	MN	Cytochrome P450 3A4 (CYP3A4)
DMUDIR8	MT	DME
DMUDIR8	MA	Metabolism
DMUDIR8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUDIR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUDIR8	DI	DMUDIR8
DMUDIR8	DN	Fludrocortisone
DMUDIR8	MI	TT26PHO
DMUDIR8	MN	Mineralocorticoid receptor  (MR)
DMUDIR8	MT	DTT
DMUDIR8	MA	Agonist
DMUDIR8	RN	Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
DMUDIR8	RU	https://pubmed.ncbi.nlm.nih.gov/14570856

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TTS64P2
DMC8VNH	MN	Androgen receptor (AR)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TT5ZWB6
DMC8VNH	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TT8NGED
DMC8VNH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMC8VNH	DI	DMC8VNH
DMC8VNH	DN	Flufenamic Acid
DMC8VNH	MI	TTVKILB
DMC8VNH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMC8VNH	MT	DTT
DMC8VNH	MA	Inhibitor
DMC8VNH	RN	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
DMC8VNH	RU	https://pubmed.ncbi.nlm.nih.gov/7864817

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTBMV1G
DMPCG2L	MN	GABA(A) receptor alpha-2 (GABRA2)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TT37EDJ
DMPCG2L	MN	GABA(A) receptor alpha-3 (GABRA3)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTNZPQ1
DMPCG2L	MN	GABA(A) receptor alpha-5 (GABRA5)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTEX6LM
DMPCG2L	MN	GABA(A) receptor gamma-3 (GABRG3)
DMPCG2L	MT	DTT
DMPCG2L	MA	Modulator (allosteric modulator)
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMPCG2L	DI	DMPCG2L
DMPCG2L	DN	Flumazenil
DMPCG2L	MI	TTPTXIN
DMPCG2L	MN	Translocator protein (TSPO)
DMPCG2L	MT	DTT
DMPCG2L	MA	Antagonist
DMPCG2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMPCG2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DMUNG4A	DI	DMUNG4A
DMUNG4A	DN	Flumethasone
DMUNG4A	MI	DE4LYSA
DMUNG4A	MN	Cytochrome P450 3A4 (CYP3A4)
DMUNG4A	MT	DME
DMUNG4A	MA	Metabolism
DMUNG4A	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMUNG4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DMU0YP6	DI	DMU0YP6
DMU0YP6	DN	Flumethasone Pivalate
DMU0YP6	MI	TTP3UTW
DMU0YP6	MN	Steroid hormone receptor ERR (ESRR)
DMU0YP6	MT	DTT
DMU0YP6	MA	Modulator
DMU0YP6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU0YP6	RU	https://www.fda.gov/

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DE6OQ3W
DMZU5JP	MN	Cytochrome P450 1A1 (CYP1A1)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DEJGDUW
DMZU5JP	MN	Cytochrome P450 1A2 (CYP1A2)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DEJVYAZ
DMZU5JP	MN	Cytochrome P450 2A6 (CYP2A6)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DE5IED8
DMZU5JP	MN	Cytochrome P450 2C9 (CYP2C9)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	DECB0K3
DMZU5JP	MN	Cytochrome P450 2D6 (CYP2D6)
DMZU5JP	MT	DME
DMZU5JP	MA	Metabolism
DMZU5JP	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZU5JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	TTX4QDJ
DMZU5JP	MN	Voltage-gated calcium channel alpha Cav2.1 (CACNA1A)
DMZU5JP	MT	DTT
DMZU5JP	MA	Inhibitor
DMZU5JP	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZU5JP	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZU5JP	DI	DMZU5JP
DMZU5JP	DN	Flunarizine
DMZU5JP	MI	TTZPWGN
DMZU5JP	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMZU5JP	MT	DTT
DMZU5JP	MA	Blocker
DMZU5JP	RN	Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
DMZU5JP	RU	https://pubmed.ncbi.nlm.nih.gov/19582593

DMZSWQC	DI	DMZSWQC
DMZSWQC	DN	Flunisolide
DMZSWQC	MI	DE4LYSA
DMZSWQC	MN	Cytochrome P450 3A4 (CYP3A4)
DMZSWQC	MT	DME
DMZSWQC	MA	Metabolism
DMZSWQC	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DMZSWQC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DMZSWQC	DI	DMZSWQC
DMZSWQC	DN	Flunisolide
DMZSWQC	MI	TTYRL6O
DMZSWQC	MN	Glucocorticoid receptor (NR3C1)
DMZSWQC	MT	DTT
DMZSWQC	MA	Agonist
DMZSWQC	RN	The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7.
DMZSWQC	RU	https://pubmed.ncbi.nlm.nih.gov/19254810

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEJGDUW
DMGR5Z3	MN	Cytochrome P450 1A2 (CYP1A2)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEJVYAZ
DMGR5Z3	MN	Cytochrome P450 2A6 (CYP2A6)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEPKLMQ
DMGR5Z3	MN	Cytochrome P450 2B6 (CYP2B6)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE5IED8
DMGR5Z3	MN	Cytochrome P450 2C9 (CYP2C9)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE4LYSA
DMGR5Z3	MN	Cytochrome P450 3A4 (CYP3A4)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi. 2003;105(5):631-42.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12875231

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DEGTFWK
DMGR5Z3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75.
DMGR5Z3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12640218

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	DE0QLUZ
DMGR5Z3	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMGR5Z3	MT	DME
DMGR5Z3	MA	Metabolism
DMGR5Z3	RN	Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9.
DMGR5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/22445794

DMGR5Z3	DI	DMGR5Z3
DMGR5Z3	DN	Flunitrazepam
DMGR5Z3	MI	TTPTXIN
DMGR5Z3	MN	Translocator protein (TSPO)
DMGR5Z3	MT	DTT
DMGR5Z3	MA	Agonist
DMGR5Z3	RN	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
DMGR5Z3	RU	https://pubmed.ncbi.nlm.nih.gov/19443999

DMG2KI4	DI	DMG2KI4
DMG2KI4	DN	Fluocinolone acetonide
DMG2KI4	MI	DE4LYSA
DMG2KI4	MN	Cytochrome P450 3A4 (CYP3A4)
DMG2KI4	MT	DME
DMG2KI4	MA	Metabolism
DMG2KI4	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DMG2KI4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DMG2KI4	DI	DMG2KI4
DMG2KI4	DN	Fluocinolone acetonide
DMG2KI4	MI	TTYRL6O
DMG2KI4	MN	Glucocorticoid receptor (NR3C1)
DMG2KI4	MT	DTT
DMG2KI4	MA	Modulator
DMG2KI4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMG2KI4	RU	https://www.fda.gov/

DM65KL8	DI	DM65KL8
DM65KL8	DN	Fluocinonide
DM65KL8	MI	DE4LYSA
DM65KL8	MN	Cytochrome P450 3A4 (CYP3A4)
DM65KL8	MT	DME
DM65KL8	MA	Metabolism
DM65KL8	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM65KL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM65KL8	DI	DM65KL8
DM65KL8	DN	Fluocinonide
DM65KL8	MI	TTP3UTW
DM65KL8	MN	Steroid hormone receptor ERR (ESRR)
DM65KL8	MT	DTT
DM65KL8	MA	Modulator
DM65KL8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM65KL8	RU	https://www.fda.gov/

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	TTHQZV7
DMQTFAO	MN	Mothers against decapentaplegic homolog 3 (SMAD3)
DMQTFAO	MT	DTT
DMQTFAO	MA	Inhibitor
DMQTFAO	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMQTFAO	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTSYQGK
DMQTFAO	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/11409873

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTFI42L
DMQTFAO	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/20815017

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTYVM24
DMQTFAO	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/17540771

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DTQ23VB
DMQTFAO	MN	Organic anion transporter 1 (SLC22A6)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/15107594

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DT3D8F0
DMQTFAO	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	DT9C1TS
DMQTFAO	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMQTFAO	MT	DTP
DMQTFAO	MA	Substrate
DMQTFAO	RN	Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.
DMQTFAO	RU	http://www.ncbi.nlm.nih.gov/pubmed/20448812

DMQTFAO	DI	DMQTFAO
DMQTFAO	DN	Fluorescein
DMQTFAO	MI	TTTQR47
DMQTFAO	MN	Solute carrier family 22 member 8 (SLC22A8)
DMQTFAO	MT	DTT
DMQTFAO	MA	Inhibitor
DMQTFAO	RN	Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
DMQTFAO	RU	https://pubmed.ncbi.nlm.nih.gov/17553798

DM2HKC4	DI	DM2HKC4
DM2HKC4	DN	Fluorometholone
DM2HKC4	MI	DE4LYSA
DM2HKC4	MN	Cytochrome P450 3A4 (CYP3A4)
DM2HKC4	MT	DME
DM2HKC4	MA	Metabolism
DM2HKC4	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM2HKC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DM2HKC4	DI	DM2HKC4
DM2HKC4	DN	Fluorometholone
DM2HKC4	MI	TTYRL6O
DM2HKC4	MN	Glucocorticoid receptor (NR3C1)
DM2HKC4	MT	DTT
DM2HKC4	MA	Binder
DM2HKC4	RN	Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.
DM2HKC4	RU	https://pubmed.ncbi.nlm.nih.gov/12861354

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEMJ7R2
DMUM7HZ	MN	Amidophosphoribosyltransferase (GPAT)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150653776)
DMUM7HZ	RU	https://www.pharmgkb.org/pathway/PA150653776

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTI7UX6
DMUM7HZ	MN	Breast cancer resistance protein (ABCG2)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18820913

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTU6BFZ
DMUM7HZ	MN	Candida Thymidylate synthase (Candi TMP1)
DMUM7HZ	MT	DTT
DMUM7HZ	MA	Inhibitor
DMUM7HZ	RN	The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
DMUM7HZ	RU	https://pubmed.ncbi.nlm.nih.gov/14689231

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEJGDUW
DMUM7HZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEJVYAZ
DMUM7HZ	MN	Cytochrome P450 2A6 (CYP2A6)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DES5XRU
DMUM7HZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTZPS91
DMUM7HZ	MN	Dihydrothymine dehydrogenase (DPYD)
DMUM7HZ	MT	DTT
DMUM7HZ	MA	Inhibitor
DMUM7HZ	RN	Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
DMUM7HZ	RU	https://pubmed.ncbi.nlm.nih.gov/12044515

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DESOEW1
DMUM7HZ	MN	Dihydrothymine dehydrogenase (DPYD)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18443386

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTXD1TQ
DMUM7HZ	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17695509

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEOXTPZ
DMUM7HZ	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTFI42L
DMUM7HZ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27602148

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTQ3ZHF
DMUM7HZ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTCSGPB
DMUM7HZ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTYVM24
DMUM7HZ	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/19077464

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DT0OC1Q
DMUM7HZ	MN	Organic anion transporter 2 (SLC22A7)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DTUGYRD
DMUM7HZ	MN	P-glycoprotein 1 (ABCB1)
DMUM7HZ	MT	DTP
DMUM7HZ	MA	Substrate
DMUM7HZ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUM7HZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTQY2EJ
DMUM7HZ	MN	TERT messenger RNA (TERT mRNA)
DMUM7HZ	MT	DTT
DMUM7HZ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUM7HZ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DE4HCYL
DMUM7HZ	MN	Thymidine phosphorylase (TYMP)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEASG0Q
DMUM7HZ	MN	Thymidylate synthase (TYMS)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	TTP1UKZ
DMUM7HZ	MN	Thymidylate synthase messenger RNA (TYMS mRNA)
DMUM7HZ	MT	DTT
DMUM7HZ	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUM7HZ	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DE20ETR
DMUM7HZ	MN	Uracil phosphoribosyltransferase (UPRT)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000 Jul;7(7):1015-22.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917204

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEWJYTE
DMUM7HZ	MN	Uridine 5'-monophosphate synthase (UMPS)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis. 2016 Apr 5;4(1):e1165909.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27274438

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEFZWAX
DMUM7HZ	MN	Uridine phosphorylase 1 (UPP1)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348

DMUM7HZ	DI	DMUM7HZ
DMUM7HZ	DN	Fluorouracil
DMUM7HZ	MI	DEBQ2WU
DMUM7HZ	MN	Uridine phosphorylase 2 (UPP2)
DMUM7HZ	MT	DME
DMUM7HZ	MA	Metabolism
DMUM7HZ	RN	Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66.
DMUM7HZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEJGDUW
DM3PD2C	MN	Cytochrome P450 1A2 (CYP1A2)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEPKLMQ
DM3PD2C	MN	Cytochrome P450 2B6 (CYP2B6)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537573

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DE5IED8
DM3PD2C	MN	Cytochrome P450 2C9 (CYP2C9)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19442216

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DECB0K3
DM3PD2C	MN	Cytochrome P450 2D6 (CYP2D6)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEVDYN7
DM3PD2C	MN	Cytochrome P450 2E1 (CYP2E1)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DE4LYSA
DM3PD2C	MN	Cytochrome P450 3A4 (CYP3A4)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752104

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEIBDNY
DM3PD2C	MN	Cytochrome P450 3A5 (CYP3A5)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DEGTFWK
DM3PD2C	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3PD2C	MT	DME
DM3PD2C	MA	Metabolism
DM3PD2C	RN	Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
DM3PD2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11730569

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	DTUGYRD
DM3PD2C	MN	P-glycoprotein 1 (ABCB1)
DM3PD2C	MT	DTP
DM3PD2C	MA	Substrate
DM3PD2C	RN	Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7.
DM3PD2C	RU	https://doi.org/10.1016/j.canlet.2005.06.003

DM3PD2C	DI	DM3PD2C
DM3PD2C	DN	Fluoxetine
DM3PD2C	MI	TT3ROYC
DM3PD2C	MN	Serotonin transporter (SERT)
DM3PD2C	MT	DTT
DM3PD2C	MA	Modulator
DM3PD2C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3PD2C	RU	https://www.fda.gov/

DMUHCF1	DI	DMUHCF1
DMUHCF1	DN	Fluoxymesterone
DMUHCF1	MI	TTS64P2
DMUHCF1	MN	Androgen receptor (AR)
DMUHCF1	MT	DTT
DMUHCF1	MA	Agonist
DMUHCF1	RN	An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
DMUHCF1	RU	https://pubmed.ncbi.nlm.nih.gov/17023534

DMUHCF1	DI	DMUHCF1
DMUHCF1	DN	Fluoxymesterone
DMUHCF1	MI	DE4LYSA
DMUHCF1	MN	Cytochrome P450 3A4 (CYP3A4)
DMUHCF1	MT	DME
DMUHCF1	MA	Metabolism
DMUHCF1	RN	Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43.
DMUHCF1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2880590

DM0DJ9O	DI	DM0DJ9O
DM0DJ9O	DN	Flupentixol
DM0DJ9O	MI	DTUGYRD
DM0DJ9O	MN	P-glycoprotein 1 (ABCB1)
DM0DJ9O	MT	DTP
DM0DJ9O	MA	Substrate
DM0DJ9O	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM0DJ9O	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	TTK8CXU
DMIT8LX	MN	5-HT 1B receptor (HTR1B)
DMIT8LX	MT	DTT
DMIT8LX	MA	Modulator
DMIT8LX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIT8LX	RU	https://www.fda.gov/

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	DECB0K3
DMIT8LX	MN	Cytochrome P450 2D6 (CYP2D6)
DMIT8LX	MT	DME
DMIT8LX	MA	Metabolism
DMIT8LX	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMIT8LX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMIT8LX	DI	DMIT8LX
DMIT8LX	DN	Fluphenazine
DMIT8LX	MI	DTUGYRD
DMIT8LX	MN	P-glycoprotein 1 (ABCB1)
DMIT8LX	MT	DTP
DMIT8LX	MA	Substrate
DMIT8LX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMIT8LX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMZWBKG	DI	DMZWBKG
DMZWBKG	DN	Fluprednisolone
DMZWBKG	MI	DE4LYSA
DMZWBKG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZWBKG	MT	DME
DMZWBKG	MA	Metabolism
DMZWBKG	RN	NCIthesaurus: Fluprednisolone
DMZWBKG	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DMHCI9S	DI	DMHCI9S
DMHCI9S	DN	Flurandrenolide
DMHCI9S	MI	DE4LYSA
DMHCI9S	MN	Cytochrome P450 3A4 (CYP3A4)
DMHCI9S	MT	DME
DMHCI9S	MA	Metabolism
DMHCI9S	RN	Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8.
DMHCI9S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097

DMHCI9S	DI	DMHCI9S
DMHCI9S	DN	Flurandrenolide
DMHCI9S	MI	TTP3UTW
DMHCI9S	MN	Steroid hormone receptor ERR (ESRR)
DMHCI9S	MT	DTT
DMHCI9S	MA	Modulator
DMHCI9S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHCI9S	RU	https://www.fda.gov/

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	DEJVYAZ
DMAL4G0	MN	Cytochrome P450 2A6 (CYP2A6)
DMAL4G0	MT	DME
DMAL4G0	MA	Metabolism
DMAL4G0	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DMAL4G0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	DE4LYSA
DMAL4G0	MN	Cytochrome P450 3A4 (CYP3A4)
DMAL4G0	MT	DME
DMAL4G0	MA	Metabolism
DMAL4G0	RN	Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
DMAL4G0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109

DMAL4G0	DI	DMAL4G0
DMAL4G0	DN	Flurazepam
DMAL4G0	MI	TTPTXIN
DMAL4G0	MN	Translocator protein (TSPO)
DMAL4G0	MT	DTT
DMAL4G0	MA	Modulator
DMAL4G0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAL4G0	RU	https://www.fda.gov/

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DE5IED8
DMGN4BY	MN	Cytochrome P450 2C9 (CYP2C9)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25144335

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	TTVKILB
DMGN4BY	MN	Prostaglandin G/H synthase 2 (COX-2)
DMGN4BY	MT	DTT
DMGN4BY	MA	Modulator
DMGN4BY	RN	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/22714712

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEYGVN4
DMGN4BY	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17446261

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEF2WXN
DMGN4BY	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DE85D2P
DMGN4BY	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMGN4BY	DI	DMGN4BY
DMGN4BY	DN	Flurbiprofen
DMGN4BY	MI	DEB3CV1
DMGN4BY	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMGN4BY	MT	DME
DMGN4BY	MA	Metabolism
DMGN4BY	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMGN4BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFO843	DI	DMFO843
DMFO843	DN	Fluspirilene
DMFO843	MI	DE4LYSA
DMFO843	MN	Cytochrome P450 3A4 (CYP3A4)
DMFO843	MT	DME
DMFO843	MA	Metabolism
DMFO843	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMFO843	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMFO843	DI	DMFO843
DMFO843	DN	Fluspirilene
DMFO843	MI	TTEX248
DMFO843	MN	Dopamine D2 receptor (D2R)
DMFO843	MT	DTT
DMFO843	MA	Antagonist
DMFO843	RN	Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41.
DMFO843	RU	https://pubmed.ncbi.nlm.nih.gov/11842444

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	TTS64P2
DMK0O7U	MN	Androgen receptor (AR)
DMK0O7U	MT	DTT
DMK0O7U	MA	Antagonist
DMK0O7U	RN	Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
DMK0O7U	RU	https://pubmed.ncbi.nlm.nih.gov/12231070

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE6OQ3W
DMK0O7U	MN	Cytochrome P450 1A1 (CYP1A1)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEJGDUW
DMK0O7U	MN	Cytochrome P450 1A2 (CYP1A2)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1298-303.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9351907

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE9QHP6
DMK0O7U	MN	Cytochrome P450 1B1 (CYP1B1)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160641

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DE4LYSA
DMK0O7U	MN	Cytochrome P450 3A4 (CYP3A4)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEIBDNY
DMK0O7U	MN	Cytochrome P450 3A5 (CYP3A5)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DEGTFWK
DMK0O7U	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK0O7U	MT	DME
DMK0O7U	MA	Metabolism
DMK0O7U	RN	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
DMK0O7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17403914

DMK0O7U	DI	DMK0O7U
DMK0O7U	DN	Flutamide
DMK0O7U	MI	DTSYQGK
DMK0O7U	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMK0O7U	MT	DTP
DMK0O7U	MA	Substrate
DMK0O7U	RN	The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
DMK0O7U	RU	https://doi.org/10.1016/S0378-4274(02)00485-X

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DE4LYSA
DMGCSVF	MN	Cytochrome P450 3A4 (CYP3A4)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DEIBDNY
DMGCSVF	MN	Cytochrome P450 3A5 (CYP3A5)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	DERD86B
DMGCSVF	MN	Cytochrome P450 3A7 (CYP3A7)
DMGCSVF	MT	DME
DMGCSVF	MA	Metabolism
DMGCSVF	RN	Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40.
DMGCSVF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16565171

DMGCSVF	DI	DMGCSVF
DMGCSVF	DN	Fluticasone
DMGCSVF	MI	TTYRL6O
DMGCSVF	MN	Glucocorticoid receptor (NR3C1)
DMGCSVF	MT	DTT
DMGCSVF	MA	Antagonist
DMGCSVF	RN	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
DMGCSVF	RU	https://pubmed.ncbi.nlm.nih.gov/18536783

DMRWLB2	DI	DMRWLB2
DMRWLB2	DN	Fluticasone propionate
DMRWLB2	MI	DTUGYRD
DMRWLB2	MN	P-glycoprotein 1 (ABCB1)
DMRWLB2	MT	DTP
DMRWLB2	MA	Substrate
DMRWLB2	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMRWLB2	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMU54C3	DI	DMU54C3
DMU54C3	DN	Flutropium bromide
DMU54C3	MI	TTH18TF
DMU54C3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMU54C3	MT	DTT
DMU54C3	MA	Modulator
DMU54C3	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMU54C3	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTI7UX6
DM4MDJY	MN	Breast cancer resistance protein (ABCG2)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates. Pharm Res. 2015 May;32(5):1634-47.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/25380981

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE6OQ3W
DM4MDJY	MN	Cytochrome P450 1A1 (CYP1A1)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver. Drug Metab Dispos. 1996 Nov;24(11):1197-204.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937853

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DES5XRU
DM4MDJY	MN	Cytochrome P450 2C8 (CYP2C8)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005 Aug;97(2):104-8.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15998357

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE5IED8
DM4MDJY	MN	Cytochrome P450 2C9 (CYP2C9)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 1;6(2):94-101.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22594566

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DECB0K3
DM4MDJY	MN	Cytochrome P450 2D6 (CYP2D6)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet. 2001;40(4):263-81.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368292

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DE4LYSA
DM4MDJY	MN	Cytochrome P450 3A4 (CYP3A4)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Effects of fluvastatin on the pharmacokinetics of eepaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by fluvastatin. Korean J Physiol Pharmacol. 2013 Jun;17(3):245-51.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23776402

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DEIBDNY
DM4MDJY	MN	Cytochrome P450 3A5 (CYP3A5)
DM4MDJY	MT	DME
DM4MDJY	MA	Metabolism
DM4MDJY	RN	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004 Aug;14(8):523-5.
DM4MDJY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284534

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	TTPADOQ
DM4MDJY	MN	HMG-CoA reductase (HMGCR)
DM4MDJY	MT	DTT
DM4MDJY	MA	Inhibitor
DM4MDJY	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DM4MDJY	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DT3D8F0
DM4MDJY	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther. 2006 Oct;80(4):356-66.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17015053

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DT9C1TS
DM4MDJY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTPFTEQ
DM4MDJY	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14.
DM4MDJY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17470528

DM4MDJY	DI	DM4MDJY
DM4MDJY	DN	Fluvastatin
DM4MDJY	MI	DTUGYRD
DM4MDJY	MN	P-glycoprotein 1 (ABCB1)
DM4MDJY	MT	DTP
DM4MDJY	MA	Substrate
DM4MDJY	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM4MDJY	RU	https://doi.org/10.1007/s00210-008-0345-0

DMQTJSX	DI	DMQTJSX
DMQTJSX	DN	Fluvoxamine
DMQTJSX	MI	DTUGYRD
DMQTJSX	MN	P-glycoprotein 1 (ABCB1)
DMQTJSX	MT	DTP
DMQTJSX	MA	Substrate
DMQTJSX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMQTJSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMQTJSX	DI	DMQTJSX
DMQTJSX	DN	Fluvoxamine
DMQTJSX	MI	TT3ROYC
DMQTJSX	MN	Serotonin transporter (SERT)
DMQTJSX	MT	DTT
DMQTJSX	MA	Inhibitor
DMQTJSX	RN	Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4.
DMQTJSX	RU	https://pubmed.ncbi.nlm.nih.gov/19568609

DM2PSBE	DI	DM2PSBE
DM2PSBE	DN	Focetria A(H1N1)
DM2PSBE	MI	TT3J5ZI
DM2PSBE	MN	Cell mediated immunity response (CMIR)
DM2PSBE	MT	DTT
DM2PSBE	RN	Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393.
DM2PSBE	RU	https://pubmed.ncbi.nlm.nih.gov/23381200

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTI7UX6
DMEMBJC	MN	Breast cancer resistance protein (ABCG2)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/17032904

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEVDYN7
DMEMBJC	MN	Cytochrome P450 2E1 (CYP2E1)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15705656

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE4EGMZ
DMEMBJC	MN	Dihydrofolate reductase (DHFR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	The dihydrofolate reductase 19 bp polymorphism is not associated with biomarkers of folate status in healthy young adults, irrespective of folic acid intake. J Nutr. 2015 Oct;145(10):2207-11.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26269242

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DERGIEC
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Measurement of the uptake of radioactive para-aminobenzoic acid monitors folate biosynthesis in Escherichia coli K-12. Anal Biochem. 1994 Feb 1;216(2):427-30.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/8179200

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEEBFXM
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Molecular cloning of the gene for dihydrofolate reductase from Lactobacillus casei. Gene. 1982 Feb;17(2):229-33.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/6282715

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE1GYMX
DMEMBJC	MN	Dihydrofolate reductase (folA)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Biophysical principles predict fitness landscapes of drug resistance. Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1470-8.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/26929328

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TTQOD3G
DMEMBJC	MN	Folate receptor (FOLR)
DMEMBJC	MT	DTT
DMEMBJC	MA	Binder
DMEMBJC	RN	Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/16859665

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTOSN46
DMEMBJC	MN	Folate transporter 1 (SLC19A1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEW0GI5
DMEMBJC	MN	Folylpolyglutamate synthetase (fpgS)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Mutagenesis of folylpolyglutamate synthetase indicates that dihydropteroate and tetrahydrofolate bind to the same site. Biochemistry. 2008 Feb 26;47(8):2388-96.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/18232714

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEU7MWJ
DMEMBJC	MN	Gamma-Glu-X carboxypeptidase (GGH)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Optimization of the trienzyme extraction for the microbiological assay of folate in vegetables. J Agric Food Chem. 2007 May 16;55(10):3884-8.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17439143

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DE6NIY9
DMEMBJC	MN	Methionine synthase reductase (MTRR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B. 2008 Feb;9(2):93-9.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18257130

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEOXTPZ
DMEMBJC	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Genetic variation: impact on folate (and choline) bioefficacy. Int J Vitam Nutr Res. 2010 Oct;80(4-5):319-29.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21462116

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTM8E7H
DMEMBJC	MN	Mitochondrial folate transporter/carrier (SLC25A32)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Polymorphism of SLC25A32, the folate transporter gene, is associated with plasma folate levels and bone fractures in Japanese postmenopausal women. Geriatr Gerontol Int. 2014 Oct;14(4):942-6.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24354357

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTSYQGK
DMEMBJC	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15041471

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTFI42L
DMEMBJC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
DMEMBJC	RU	https://doi.org/10.1042/bse0500179

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTQ3ZHF
DMEMBJC	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTCSGPB
DMEMBJC	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/12036927

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTYVM24
DMEMBJC	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899835

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTUGYRD
DMEMBJC	MN	P-glycoprotein 1 (ABCB1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/26105097

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TTY8Z2E
DMEMBJC	MN	Proton-coupled folate transporter (SLC46A1)
DMEMBJC	MT	DTT
DMEMBJC	MA	Modulator
DMEMBJC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DMEMBJC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTDJEMI
DMEMBJC	MN	Proton-coupled folate transporter (SLC46A1)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Characterization of uptake of folates by rat and human blood-brain barrier endothelial cells. Biofactors. 2010 May-Jun;36(3):201-9.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20232349

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEZV4AP
DMEMBJC	MN	RNA cytidine acetyltransferase (hALP)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1329759

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DTKWJH3
DMEMBJC	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMEMBJC	MT	DTP
DMEMBJC	MA	Substrate
DMEMBJC	RN	Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.
DMEMBJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/7598738

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	TT09I7D
DMEMBJC	MN	Solute carrier family 19 member 1 (SLC19A1)
DMEMBJC	MT	DTT
DMEMBJC	MA	Modulator
DMEMBJC	RN	Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
DMEMBJC	RU	https://pubmed.ncbi.nlm.nih.gov/9525913

DMEMBJC	DI	DMEMBJC
DMEMBJC	DN	Folic acid
DMEMBJC	MI	DEWSHL5
DMEMBJC	MN	Vitamin B12 methionine synthase (MTR)
DMEMBJC	MT	DME
DMEMBJC	MA	Metabolism
DMEMBJC	RN	Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab. 2007 May;91(1):85-97.
DMEMBJC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17369066

DM2JTS5	DI	DM2JTS5
DM2JTS5	DN	Follitropin beta
DM2JTS5	MI	TTZFDBT
DM2JTS5	MN	Follicle-stimulating hormone receptor (FSHR)
DM2JTS5	MT	DTT
DM2JTS5	MA	Binder
DM2JTS5	RN	Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5.
DM2JTS5	RU	https://pubmed.ncbi.nlm.nih.gov/18851846

DM6VOWQ	DI	DM6VOWQ
DM6VOWQ	DN	Fomepizole
DM6VOWQ	MI	TT5AHZ0
DM6VOWQ	MN	Alcohol dehydrogenase 1A (ADH1A)
DM6VOWQ	MT	DTT
DM6VOWQ	MA	Modulator
DM6VOWQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6VOWQ	RU	https://www.fda.gov/

DM6VOWQ	DI	DM6VOWQ
DM6VOWQ	DN	Fomepizole
DM6VOWQ	MI	DEVDYN7
DM6VOWQ	MN	Cytochrome P450 2E1 (CYP2E1)
DM6VOWQ	MT	DME
DM6VOWQ	MA	Metabolism
DM6VOWQ	RN	Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole. Open Access Emerg Med. 2010 Aug 24;2:67-75.
DM6VOWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27147840

DMBEP7G	DI	DMBEP7G
DMBEP7G	DN	Fomivirsen sodium
DMBEP7G	MI	TT4SCBE
DMBEP7G	MN	Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA)
DMBEP7G	MT	DTT
DMBEP7G	MA	Modulator
DMBEP7G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBEP7G	RU	https://www.fda.gov/

DMWS3FH	DI	DMWS3FH
DMWS3FH	DN	Fondaparinux sodium
DMWS3FH	MI	TTCIHJA
DMWS3FH	MN	Coagulation factor Xa (F10)
DMWS3FH	MT	DTT
DMWS3FH	MA	Inhibitor
DMWS3FH	RN	Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
DMWS3FH	RU	https://pubmed.ncbi.nlm.nih.gov/13679646

DMRBJNZ	DI	DMRBJNZ
DMRBJNZ	DN	Forasartan
DMRBJNZ	MI	TT8DBY3
DMRBJNZ	MN	Angiotensin II receptor type-1 (AGTR1)
DMRBJNZ	MT	DTT
DMRBJNZ	MA	Antagonist
DMRBJNZ	RN	Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26.
DMRBJNZ	RU	https://pubmed.ncbi.nlm.nih.gov/12593652

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	TT2CJVK
DMSOURV	MN	Adrenergic receptor beta-2 (ADRB2)
DMSOURV	MT	DTT
DMSOURV	MA	Agonist
DMSOURV	RN	Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
DMSOURV	RU	https://pubmed.ncbi.nlm.nih.gov/12137617

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DE5IED8
DMSOURV	MN	Cytochrome P450 2C9 (CYP2C9)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	FDA Label of Formoterol. The 2020 official website of the U.S. Food and Drug Administration.
DMSOURV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020831s028lbl.pdf

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DECB0K3
DMSOURV	MN	Cytochrome P450 2D6 (CYP2D6)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMSOURV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DEGTFWK
DMSOURV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSOURV	MT	DME
DMSOURV	MA	Metabolism
DMSOURV	RN	A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
DMSOURV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976

DMSOURV	DI	DMSOURV
DMSOURV	DN	Formoterol
DMSOURV	MI	DTT79CX
DMSOURV	MN	Organic cation transporter 1 (SLC22A1)
DMSOURV	MT	DTP
DMSOURV	MA	Substrate
DMSOURV	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMSOURV	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	DE4LYSA
DM4W9B3	MN	Cytochrome P450 3A4 (CYP3A4)
DM4W9B3	MT	DME
DM4W9B3	MA	Metabolism
DM4W9B3	RN	Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.
DM4W9B3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16485915

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	TT5FNQT
DM4W9B3	MN	Human immunodeficiency virus Protease (HIV PR)
DM4W9B3	MT	DTT
DM4W9B3	MA	Inhibitor
DM4W9B3	RN	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410.
DM4W9B3	RU	https://pubmed.ncbi.nlm.nih.gov/19515730

DM4W9B3	DI	DM4W9B3
DM4W9B3	DN	Fosamprenavir
DM4W9B3	MI	DTUGYRD
DM4W9B3	MN	P-glycoprotein 1 (ABCB1)
DM4W9B3	MT	DTP
DM4W9B3	MA	Substrate
DM4W9B3	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM4W9B3	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM9KJLZ	DI	DM9KJLZ
DM9KJLZ	DN	Foscavir
DM9KJLZ	MI	TTIU7X1
DM9KJLZ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM9KJLZ	MT	DTT
DM9KJLZ	MA	Inhibitor
DM9KJLZ	RN	Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
DM9KJLZ	RU	https://pubmed.ncbi.nlm.nih.gov/19275707

DMR0TYK	DI	DMR0TYK
DMR0TYK	DN	Fosdenopterin
DMR0TYK	MI	TT7RJY8
DMR0TYK	MN	Xanthine dehydrogenase/oxidase (XDH)
DMR0TYK	MT	DTT
DMR0TYK	MA	Cofactor
DMR0TYK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMR0TYK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf

DMD072M	DI	DMD072M
DMD072M	DN	Fosfestrol
DMD072M	MI	TTZAYWL
DMD072M	MN	Estrogen receptor (ESR)
DMD072M	MT	DTT
DMD072M	MA	Modulator
DMD072M	RN	Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
DMD072M	RU	https://pubmed.ncbi.nlm.nih.gov/19422222

DMVGPMX	DI	DMVGPMX
DMVGPMX	DN	Fosfomycin
DMVGPMX	MI	TTICX3S
DMVGPMX	MN	Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA)
DMVGPMX	MT	DTT
DMVGPMX	MA	Inhibitor
DMVGPMX	RN	Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005 Feb 4;280(5):3757-63.
DMVGPMX	RU	https://pubmed.ncbi.nlm.nih.gov/15531591

DMVGPMX	DI	DMVGPMX
DMVGPMX	DN	Fosfomycin
DMVGPMX	MI	DE4ZHS1
DMVGPMX	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMVGPMX	MT	DME
DMVGPMX	MA	Metabolism
DMVGPMX	RN	Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother. 1988 Oct;32(10):1552-6.
DMVGPMX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3056239

DMDIC39	DI	DMDIC39
DMDIC39	DN	Fosfosal
DMDIC39	MI	TTK0943
DMDIC39	MN	Prostaglandin G/H synthase (COX)
DMDIC39	MT	DTT
DMDIC39	MA	Modulator
DMDIC39	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMDIC39	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	TTL69WB
DM9NJ52	MN	Angiotensin-converting enzyme (ACE)
DM9NJ52	MT	DTT
DM9NJ52	MA	Inhibitor
DM9NJ52	RN	Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8.
DM9NJ52	RU	https://pubmed.ncbi.nlm.nih.gov/19185642

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	DT9G7XN
DM9NJ52	MN	Peptide transporter 1 (SLC15A1)
DM9NJ52	MT	DTP
DM9NJ52	MA	Substrate
DM9NJ52	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM9NJ52	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM9NJ52	DI	DM9NJ52
DM9NJ52	DN	Fosinopril
DM9NJ52	MI	DT8QKNP
DM9NJ52	MN	Peptide transporter 2 (SLC15A2)
DM9NJ52	MT	DTP
DM9NJ52	MA	Substrate
DM9NJ52	RN	Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. Drug Metab Dispos. 2001 Oct;29(10):1307-15.
DM9NJ52	RU	http://www.ncbi.nlm.nih.gov/pubmed/11560874

DM7G0EP	DI	DM7G0EP
DM7G0EP	DN	Fosmidomycin
DM7G0EP	MI	TTLH4J3
DM7G0EP	MN	Plasmodium DOXP reductoisomerase (Malaria DXR)
DM7G0EP	MT	DTT
DM7G0EP	MA	Binder
DM7G0EP	RN	Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7.
DM7G0EP	RU	https://pubmed.ncbi.nlm.nih.gov/12621040

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DE5IED8
DMOX3LB	MN	Cytochrome P450 2C9 (CYP2C9)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DE4LYSA
DMOX3LB	MN	Cytochrome P450 3A4 (CYP3A4)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013 Jul;4(4):263-8.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25032007

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	DEGTFWK
DMOX3LB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOX3LB	MT	DME
DMOX3LB	MA	Metabolism
DMOX3LB	RN	CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
DMOX3LB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19617466

DMOX3LB	DI	DMOX3LB
DMOX3LB	DN	Fosphenytoin
DMOX3LB	MI	TTZOVE0
DMOX3LB	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMOX3LB	MT	DTT
DMOX3LB	MA	Blocker
DMOX3LB	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DMOX3LB	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DM8J5XT	DI	DM8J5XT
DM8J5XT	DN	Fospropofol
DM8J5XT	MI	DEVEFKM
DM8J5XT	MN	Alkaline phosphatase (ALPL)
DM8J5XT	MT	DME
DM8J5XT	MA	Metabolism
DM8J5XT	RN	A double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of fospropofol disodium as an intravenous sedative for colonoscopy in high-risk populations. Am J Ther. 2013 Mar-Apr;20(2):163-71.
DM8J5XT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22820718

DMKLJRD	DI	DMKLJRD
DMKLJRD	DN	Fospropofol disodium
DMKLJRD	MI	TTAN6JD
DMKLJRD	MN	Glutamate receptor AMPA (GRIA)
DMKLJRD	MT	DTT
DMKLJRD	MA	Modulator
DMKLJRD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMKLJRD	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	DTKVEXO
DM6AUHV	MN	ATP-binding cassette sub-family B member 5 (ABCB5)
DM6AUHV	MT	DTP
DM6AUHV	MA	Substrate
DM6AUHV	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
DM6AUHV	RU	https://www.drugbank.ca/drugs/DB12010

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	DE4LYSA
DM6AUHV	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AUHV	MT	DME
DM6AUHV	MA	Metabolism
DM6AUHV	RN	Effects of CYP3A4 inhibitors ketoconazole and verapamil and the CYP3A4 inducer rifampicin on the pharmacokinetic parameters of fostamatinib: results from In vitro and phase I clinical studies. Drugs R D. 2016 Mar;16(1):81-92.
DM6AUHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26739683

DM6AUHV	DI	DM6AUHV
DM6AUHV	DN	Fostamatinib
DM6AUHV	MI	TTOU65C
DM6AUHV	MN	Tyrosine-protein kinase SYK (SYK)
DM6AUHV	MT	DTT
DM6AUHV	MA	Modulator
DM6AUHV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
DM6AUHV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230

DM50ILT	DI	DM50ILT
DM50ILT	DN	Fostemsavir
DM50ILT	MI	TTBYP1X
DM50ILT	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DM50ILT	MT	DTT
DM50ILT	MA	Inhibitor
DM50ILT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
DM50ILT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf

DMV62ED	DI	DMV62ED
DMV62ED	DN	Fotemustine
DMV62ED	MI	TTR7UJ3
DMV62ED	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMV62ED	MT	DTT
DMV62ED	MA	Inhibitor
DMV62ED	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMV62ED	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	DEJADS9
DMF8DNE	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMF8DNE	MT	DME
DMF8DNE	MA	Metabolism
DMF8DNE	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	DEWPAJD
DMF8DNE	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMF8DNE	MT	DME
DMF8DNE	MA	Metabolism
DMF8DNE	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	TT38DW5
DMF8DNE	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMF8DNE	MT	DTT
DMF8DNE	MA	Binder
DMF8DNE	RN	Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/1105242

DMF8DNE	DI	DMF8DNE
DMF8DNE	DN	Framycetin
DMF8DNE	MI	TTQ8KVI
DMF8DNE	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMF8DNE	MT	DTT
DMF8DNE	MA	Binder
DMF8DNE	RN	Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9.
DMF8DNE	RU	https://pubmed.ncbi.nlm.nih.gov/18060665

DMDZY54	DI	DMDZY54
DMDZY54	DN	Fremanezumab
DMDZY54	MI	TTY6O0Q
DMDZY54	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMDZY54	MT	DTT
DMDZY54	MA	Modulator
DMDZY54	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMDZY54	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	TTK8CXU
DM7RE8P	MN	5-HT 1B receptor (HTR1B)
DM7RE8P	MT	DTT
DM7RE8P	MA	Modulator
DM7RE8P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7RE8P	RU	https://www.fda.gov/

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	TT6MSOK
DM7RE8P	MN	5-HT 1D receptor (HTR1D)
DM7RE8P	MT	DTT
DM7RE8P	MA	Modulator
DM7RE8P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7RE8P	RU	https://www.fda.gov/

DM7RE8P	DI	DM7RE8P
DM7RE8P	DN	Frovatriptan
DM7RE8P	MI	DEJGDUW
DM7RE8P	MN	Cytochrome P450 1A2 (CYP1A2)
DM7RE8P	MT	DME
DM7RE8P	MA	Metabolism
DM7RE8P	RN	Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73.
DM7RE8P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	TTMS54D
DM43AN2	MN	Fragile histidine triad protein (FHIT)
DM43AN2	MT	DTT
DM43AN2	MA	Inhibitor
DM43AN2	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM43AN2	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DTOR02F
DM43AN2	MN	Glucose transporter type 5, small intestine (SLC2A5)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	Dexamethasone sensitizes the neonatal intestine to fructose induction of intestinal fructose transporter (Slc2A5) function. Endocrinology. 2008 Jan;149(1):409-23.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/17947353

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DT8SQBG
DM43AN2	MN	Glucose transporter type 7 (SLC2A7)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18660845

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DT1CP40
DM43AN2	MN	Sodium/glucose cotransporter 4 (SLC5A9)
DM43AN2	MT	DTP
DM43AN2	MA	Substrate
DM43AN2	RN	SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50.
DM43AN2	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607332

DM43AN2	DI	DM43AN2
DM43AN2	DN	Fructose
DM43AN2	MI	DEWU03P
DM43AN2	MN	Sorbitol dehydrogenase (SORD)
DM43AN2	MT	DME
DM43AN2	MA	Metabolism
DM43AN2	RN	Isolation, characterization and evaluation of the Pichia pastoris sorbitol dehydrogenase promoter for expression of heterologous proteins. Protein Expr Purif. 2013 Nov;92(1):128-33.
DM43AN2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24075932

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	DE4LYSA
DM0YZC6	MN	Cytochrome P450 3A4 (CYP3A4)
DM0YZC6	MT	DME
DM0YZC6	MA	Metabolism
DM0YZC6	RN	Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006 Sep;40(9):1572-83.
DM0YZC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16912252

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	TTZAYWL
DM0YZC6	MN	Estrogen receptor (ESR)
DM0YZC6	MT	DTT
DM0YZC6	MA	Antagonist
DM0YZC6	RN	Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88.
DM0YZC6	RU	https://pubmed.ncbi.nlm.nih.gov/19466750

DM0YZC6	DI	DM0YZC6
DM0YZC6	DN	Fulvestrant
DM0YZC6	MI	DEYGVN4
DM0YZC6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0YZC6	MT	DME
DM0YZC6	MA	Metabolism
DM0YZC6	RN	Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol. 2006 Mar;69(3):908-20.
DM0YZC6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16339389

DM3P6V7	DI	DM3P6V7
DM3P6V7	DN	Furazolidone
DM3P6V7	MI	TTS1W4A
DM3P6V7	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DM3P6V7	MT	DTT
DM3P6V7	MA	Modulator
DM3P6V7	RN	Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
DM3P6V7	RU	https://www.ncbi.nlm.nih.gov/pubmed/1174533

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DEVDYN7
DMMQ8ZG	MN	Cytochrome P450 2E1 (CYP2E1)
DMMQ8ZG	MT	DME
DMMQ8ZG	MA	Metabolism
DMMQ8ZG	RN	Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009 Jan;61(1):47-54.
DMMQ8ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19126296

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DTQ23VB
DMMQ8ZG	MN	Organic anion transporter 1 (SLC22A6)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMMQ8ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DTVP67E
DMMQ8ZG	MN	Organic anion transporter 3 (SLC22A8)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
DMMQ8ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610216

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DT9G7XN
DMMQ8ZG	MN	Peptide transporter 1 (SLC15A1)
DMMQ8ZG	MT	DTP
DMMQ8ZG	MA	Substrate
DMMQ8ZG	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMMQ8ZG	RU	https://doi.org/10.1007/BF02980227

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	TTS087L
DMMQ8ZG	MN	Solute carrier family 12 member 1 (SLC12A1)
DMMQ8ZG	MT	DTT
DMMQ8ZG	MA	Blocker
DMMQ8ZG	RN	Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
DMMQ8ZG	RU	https://pubmed.ncbi.nlm.nih.gov/17414583

DMMQ8ZG	DI	DMMQ8ZG
DMMQ8ZG	DN	Furosemide
DMMQ8ZG	MI	DEYGVN4
DMMQ8ZG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMQ8ZG	MT	DME
DMMQ8ZG	MA	Metabolism
DMMQ8ZG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMMQ8ZG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	DECB0K3
DMWVCF3	MN	Cytochrome P450 2D6 (CYP2D6)
DMWVCF3	MT	DME
DMWVCF3	MA	Metabolism
DMWVCF3	RN	The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in in vivo bioaccumulation. Xenobiotica. 2018 Oct;48(10):999-1005.
DMWVCF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29027845

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	TT6HP1T
DMWVCF3	MN	Streptococcus Elongation factor G (Stre-coc fusA)
DMWVCF3	MT	DTT
DMWVCF3	MA	Inhibitor
DMWVCF3	RN	Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65.
DMWVCF3	RU	https://pubmed.ncbi.nlm.nih.gov/19289529

DMWVCF3	DI	DMWVCF3
DMWVCF3	DN	Fusidic acid
DMWVCF3	MI	DEYGVN4
DMWVCF3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWVCF3	MT	DME
DMWVCF3	MA	Metabolism
DMWVCF3	RN	Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94.
DMWVCF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27458210

DMZ0P95	DI	DMZ0P95
DMZ0P95	DN	Ga-68-DOTATOC
DMZ0P95	MI	TTZ6T9E
DMZ0P95	MN	Somatostatin receptor type 2 (SSTR2)
DMZ0P95	MT	DTT
DMZ0P95	MA	Binder
DMZ0P95	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMZ0P95	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	TTDCVZW
DM6T924	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM6T924	MT	DTT
DM6T924	MA	Antagonist
DM6T924	RN	Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
DM6T924	RU	https://pubmed.ncbi.nlm.nih.gov/16871066

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT48T0N
DM6T924	MN	L-type amino acid transporter 1 (SLC7A5)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013 Jun 1;85(11):1672-83.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/23567998

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT9IDPW
DM6T924	MN	Organic cation transporter 2 (SLC22A2)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DM6T924	DI	DM6T924
DM6T924	DN	Gabapentin
DM6T924	MI	DT2EG60
DM6T924	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DM6T924	MT	DTP
DM6T924	MA	Substrate
DM6T924	RN	Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008 Mar;83(3):416-21.
DM6T924	RU	http://www.ncbi.nlm.nih.gov/pubmed/17609685

DMU9D2F	DI	DMU9D2F
DMU9D2F	DN	Gabexate
DMU9D2F	MI	TTEMV5X
DMU9D2F	MN	Serine protease unspecific (SP)
DMU9D2F	MT	DTT
DMU9D2F	MA	Inhibitor
DMU9D2F	RN	Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
DMU9D2F	RU	https://pubmed.ncbi.nlm.nih.gov/19513558

DMI53FU	DI	DMI53FU
DMI53FU	DN	Gaboxadol
DMI53FU	MI	TTGXH6N
DMI53FU	MN	GABA(A) receptor delta (GABRD)
DMI53FU	MT	DTT
DMI53FU	MA	Modulator
DMI53FU	RN	Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6.
DMI53FU	RU	https://www.ncbi.nlm.nih.gov/pubmed/16368265

DMI53FU	DI	DMI53FU
DMI53FU	DN	Gaboxadol
DMI53FU	MI	DT48WEM
DMI53FU	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMI53FU	MT	DTP
DMI53FU	MA	Substrate
DMI53FU	RN	Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan. Br J Pharmacol. 2009 Aug;157(8):1380-9.
DMI53FU	RU	http://www.ncbi.nlm.nih.gov/pubmed/19594759

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DTFI42L
DM4VAOG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DT3D8F0
DM4VAOG	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	DT9C1TS
DM4VAOG	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM4VAOG	MT	DTP
DM4VAOG	MA	Substrate
DM4VAOG	RN	Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
DM4VAOG	RU	http://www.ncbi.nlm.nih.gov/pubmed/27778300

DM4VAOG	DI	DM4VAOG
DM4VAOG	DN	Gadobenate dimeglumine
DM4VAOG	MI	TTFNGC9
DM4VAOG	MN	Serum albumin (ALB)
DM4VAOG	MT	DTT
DM4VAOG	MA	Binder
DM4VAOG	RN	Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
DM4VAOG	RU	https://pubmed.ncbi.nlm.nih.gov/18655261

DM5V9U1	DI	DM5V9U1
DM5V9U1	DN	Gadofosveset
DM5V9U1	MI	TTFNGC9
DM5V9U1	MN	Serum albumin (ALB)
DM5V9U1	MT	DTT
DM5V9U1	MA	Modulator
DM5V9U1	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DM5V9U1	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	TT1RS9F
DMEO794	MN	Acetylcholinesterase (AChE)
DMEO794	MT	DTT
DMEO794	MA	Inhibitor
DMEO794	RN	[From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
DMEO794	RU	https://pubmed.ncbi.nlm.nih.gov/19504422

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	DECB0K3
DMEO794	MN	Cytochrome P450 2D6 (CYP2D6)
DMEO794	MT	DME
DMEO794	MA	Metabolism
DMEO794	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DMEO794	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DMEO794	DI	DMEO794
DMEO794	DN	Galantamine
DMEO794	MI	DE4LYSA
DMEO794	MN	Cytochrome P450 3A4 (CYP3A4)
DMEO794	MT	DME
DMEO794	MA	Metabolism
DMEO794	RN	Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
DMEO794	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14674789

DMIZ1E8	DI	DMIZ1E8
DMIZ1E8	DN	Galcanezumab
DMIZ1E8	MI	TTY6O0Q
DMIZ1E8	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMIZ1E8	MT	DTT
DMIZ1E8	MA	Modulator
DMIZ1E8	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMIZ1E8	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMPO0MS	DI	DMPO0MS
DMPO0MS	DN	Gallamine Triethiodide
DMPO0MS	MI	TTYEG6Q
DMPO0MS	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMPO0MS	MT	DTT
DMPO0MS	MA	Antagonist
DMPO0MS	RN	Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
DMPO0MS	RU	https://pubmed.ncbi.nlm.nih.gov/11921079

DMF9O6B	DI	DMF9O6B
DMF9O6B	DN	Gallium nitrate
DMF9O6B	MI	TTRYK0X
DMF9O6B	MN	Interleukin-1 beta (IL1B)
DMF9O6B	MT	DTT
DMF9O6B	MA	Inhibitor
DMF9O6B	RN	Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41.
DMF9O6B	RU	https://pubmed.ncbi.nlm.nih.gov/16122880

DMER9YA	DI	DMER9YA
DMER9YA	DN	Galsulfase
DMER9YA	MI	TTESQTG
DMER9YA	MN	N-acetylgalactosamine-4-sulfatase (G4S)
DMER9YA	MT	DTT
DMER9YA	MA	Modulator
DMER9YA	RN	Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94.
DMER9YA	RU	https://pubmed.ncbi.nlm.nih.gov/22669363

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	TTDCVZW
DMGBKVD	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMGBKVD	MT	DTT
DMGBKVD	MA	Modulator
DMGBKVD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGBKVD	RU	https://www.fda.gov/

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	DT342ZG
DMGBKVD	MN	Monocarboxylate transporter 1 (SLC16A1)
DMGBKVD	MT	DTP
DMGBKVD	MA	Substrate
DMGBKVD	RN	Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
DMGBKVD	RU	http://www.ncbi.nlm.nih.gov/pubmed/17108059

DMGBKVD	DI	DMGBKVD
DMGBKVD	DN	Gamma hydroxybutyric acid
DMGBKVD	MI	DTM301H
DMGBKVD	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DMGBKVD	MT	DTP
DMGBKVD	MA	Substrate
DMGBKVD	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DMGBKVD	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	TT8NGED
DMSXKYG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSXKYG	MT	DTT
DMSXKYG	MA	Inhibitor
DMSXKYG	RN	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
DMSXKYG	RU	https://pubmed.ncbi.nlm.nih.gov/11939906

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	DE073H6
DMSXKYG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMSXKYG	MT	DME
DMSXKYG	MA	Metabolism
DMSXKYG	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMSXKYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMSXKYG	DI	DMSXKYG
DMSXKYG	DN	Gamma-homolinolenic acid
DMSXKYG	MI	DE492CE
DMSXKYG	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSXKYG	MT	DME
DMSXKYG	MA	Metabolism
DMSXKYG	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMSXKYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMQN30Z	DI	DMQN30Z
DMQN30Z	DN	Gamolenic acid
DMQN30Z	MI	DE073H6
DMQN30Z	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQN30Z	MT	DME
DMQN30Z	MA	Metabolism
DMQN30Z	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMQN30Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DMQN30Z	DI	DMQN30Z
DMQN30Z	DN	Gamolenic acid
DMQN30Z	MI	DE492CE
DMQN30Z	MN	Prostaglandin G/H synthase 2 (COX-2)
DMQN30Z	MT	DME
DMQN30Z	MA	Metabolism
DMQN30Z	RN	Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
DMQN30Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTW7AE3
DM1MBYQ	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/16375689

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTI7UX6
DM1MBYQ	MN	Breast cancer resistance protein (ABCG2)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Side populations of glioblastoma cells are less sensitive to HSV-TK/GCV suicide gene therapy system than the non-side population. In Vitro Cell Dev Biol Anim. 2010 Jun;46(6):497-501.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20135358

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	TTIU7X1
DM1MBYQ	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM1MBYQ	MT	DTT
DM1MBYQ	MA	Inhibitor
DM1MBYQ	RN	Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
DM1MBYQ	RU	https://pubmed.ncbi.nlm.nih.gov/19563015

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTZGT0P
DM1MBYQ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DT3TX4H
DM1MBYQ	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTCSGPB
DM1MBYQ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM1MBYQ	RU	https://doi.org/10.1007/s11095-012-0935-x

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTYVM24
DM1MBYQ	MN	Multidrug resistance-associated protein 5 (ABCC5)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15747503

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTQ23VB
DM1MBYQ	MN	Organic anion transporter 1 (SLC22A6)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTVP67E
DM1MBYQ	MN	Organic anion transporter 3 (SLC22A8)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	FDA Drug Development and Drug Interactions
DM1MBYQ	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM1MBYQ	DI	DM1MBYQ
DM1MBYQ	DN	Ganciclovir
DM1MBYQ	MI	DTT79CX
DM1MBYQ	MN	Organic cation transporter 1 (SLC22A1)
DM1MBYQ	MT	DTP
DM1MBYQ	MA	Substrate
DM1MBYQ	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM1MBYQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMGMB30	DI	DMGMB30
DMGMB30	DN	Ganirelix
DMGMB30	MI	TT8R70G
DMGMB30	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMGMB30	MT	DTT
DMGMB30	MA	Antagonist
DMGMB30	RN	Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32.
DMGMB30	RU	https://pubmed.ncbi.nlm.nih.gov/17579202

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	TTN6J5F
DMSL679	MN	Bacterial DNA gyrase (Bact gyrase)
DMSL679	MT	DTT
DMSL679	MA	Modulator
DMSL679	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSL679	RU	https://www.fda.gov/

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTFI42L
DMSL679	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573571

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTE2B1D
DMSL679	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	DTUGYRD
DMSL679	MN	P-glycoprotein 1 (ABCB1)
DMSL679	MT	DTP
DMSL679	MA	Substrate
DMSL679	RN	Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm. 2010 Aug 16;395(1-2):114-21.
DMSL679	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573570

DMSL679	DI	DMSL679
DMSL679	DN	Gatifloxacin
DMSL679	MI	TTIXTO3
DMSL679	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMSL679	MT	DTT
DMSL679	MA	Modulator
DMSL679	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSL679	RU	https://www.fda.gov/

DMH0QKA	DI	DMH0QKA
DMH0QKA	DN	GDC-0199
DMH0QKA	MI	TTJGNVC
DMH0QKA	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMH0QKA	MT	DTT
DMH0QKA	MA	Modulator
DMH0QKA	RN	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
DMH0QKA	RU	https://pubmed.ncbi.nlm.nih.gov/23291630

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DTI7UX6
DM15F0X	MN	Breast cancer resistance protein (ABCG2)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DECB0K3
DM15F0X	MN	Cytochrome P450 2D6 (CYP2D6)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067-81.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176119

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DE4LYSA
DM15F0X	MN	Cytochrome P450 3A4 (CYP3A4)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DEIBDNY
DM15F0X	MN	Cytochrome P450 3A5 (CYP3A5)
DM15F0X	MT	DME
DM15F0X	MA	Metabolism
DM15F0X	RN	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
DM15F0X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17575239

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	TTGKNB4
DM15F0X	MN	Epidermal growth factor receptor (EGFR)
DM15F0X	MT	DTT
DM15F0X	MA	Inhibitor
DM15F0X	RN	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
DM15F0X	RU	https://pubmed.ncbi.nlm.nih.gov/14760365

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DT3D8F0
DM15F0X	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DT9C1TS
DM15F0X	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM15F0X	DI	DM15F0X
DM15F0X	DN	Gefitinib
DM15F0X	MI	DTUGYRD
DM15F0X	MN	P-glycoprotein 1 (ABCB1)
DM15F0X	MT	DTP
DM15F0X	MA	Substrate
DM15F0X	RN	Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):226-37.
DM15F0X	RU	http://www.ncbi.nlm.nih.gov/pubmed/19694743

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DT0EQPW
DMSE3I7	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
DMSE3I7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29144412

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEKEDRC
DMSE3I7	MN	Cytidine aminohydrolase (CDA)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
DMSE3I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21284703

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DETX3A5
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/28912244

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEFVABT
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/28912244

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEYILK4
DMSE3I7	MN	Cytidine deaminase (cdd)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
DMSE3I7	RU	https://pubmed.ncbi.nlm.nih.gov/26322268

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DTYVM24
DMSE3I7	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
DMSE3I7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20824050

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DTUGYRD
DMSE3I7	MN	P-glycoprotein 1 (ABCB1)
DMSE3I7	MT	DTP
DMSE3I7	MA	Substrate
DMSE3I7	RN	Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
DMSE3I7	RU	https://doi.org/10.1038/sj.bjc.6601011

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	TTBWDI0
DMSE3I7	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMSE3I7	MT	DTT
DMSE3I7	MA	Modulator
DMSE3I7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSE3I7	RU	https://www.fda.gov/

DMSE3I7	DI	DMSE3I7
DMSE3I7	DN	Gemcitabine
DMSE3I7	MI	DEMPH4I
DMSE3I7	MN	Uridine/cytidine monophosphate kinase (UMPK)
DMSE3I7	MT	DME
DMSE3I7	MA	Metabolism
DMSE3I7	RN	Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
DMSE3I7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18556440

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEFKSVZ
DMD8Q3J	MN	Catechol-2,3-dioxygenase (caD)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Genomic, proteomic, and metabolite characterization of gemfibrozil-degrading organism Bacillus sp. GeD10. Environ Sci Technol. 2016 Jan 19;50(2):744-55.
DMD8Q3J	RU	https://pubmed.ncbi.nlm.nih.gov/26683816

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DE4LYSA
DMD8Q3J	MN	Cytochrome P450 3A4 (CYP3A4)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	TTOF3WZ
DMD8Q3J	MN	Lipoprotein lipase (LPL)
DMD8Q3J	MT	DTT
DMD8Q3J	MA	Activator
DMD8Q3J	RN	Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64.
DMD8Q3J	RU	https://pubmed.ncbi.nlm.nih.gov/16511610

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEYGVN4
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEF2WXN
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28940478

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DE85D2P
DMD8Q3J	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMD8Q3J	DI	DMD8Q3J
DMD8Q3J	DN	Gemfibrozil
DMD8Q3J	MI	DEB3CV1
DMD8Q3J	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMD8Q3J	MT	DME
DMD8Q3J	MA	Metabolism
DMD8Q3J	RN	The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos. 2007 Nov;35(11):2040-4.
DMD8Q3J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17670842

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	TTN6J5F
DMHT34O	MN	Bacterial DNA gyrase (Bact gyrase)
DMHT34O	MT	DTT
DMHT34O	MA	Modulator
DMHT34O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHT34O	RU	https://www.fda.gov/

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	DTFI42L
DMHT34O	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHT34O	MT	DTP
DMHT34O	MA	Substrate
DMHT34O	RN	Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
DMHT34O	RU	http://www.ncbi.nlm.nih.gov/pubmed/21864659

DMHT34O	DI	DMHT34O
DMHT34O	DN	Gemifloxacin
DMHT34O	MI	TTIXTO3
DMHT34O	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMHT34O	MT	DTT
DMHT34O	MA	Modulator
DMHT34O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHT34O	RU	https://www.fda.gov/

DMJ2O7B	DI	DMJ2O7B
DMJ2O7B	DN	Gemtuzumab ozogamicin
DMJ2O7B	MI	DE4LYSA
DMJ2O7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ2O7B	MT	DME
DMJ2O7B	MA	Metabolism
DMJ2O7B	RN	Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
DMJ2O7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185

DMJ2O7B	DI	DMJ2O7B
DMJ2O7B	DN	Gemtuzumab ozogamicin
DMJ2O7B	MI	TTJVYO3
DMJ2O7B	MN	Myeloid cell surface antigen CD33 (CD33)
DMJ2O7B	MT	DTT
DMJ2O7B	RN	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
DMJ2O7B	RU	https://pubmed.ncbi.nlm.nih.gov/19503782

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE48UAX
DMKINJO	MN	Aminoglycoside 6'-N-acetyltransferase (aacA)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Detection of multidrug-resistant Enterobacteriaceae isolated from river waters flowing to the Guanabara Bay and from clinical samples of hospitals in Rio de Janeiro, Brazil. Biomedica. 2019 May 1;39(s1):135-149.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/31529856

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DEWPAJD
DMKINJO	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE5WGIM
DMKINJO	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	TTOVFH2
DMKINJO	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMKINJO	MT	DTT
DMKINJO	MA	Modulator
DMKINJO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKINJO	RU	https://www.fda.gov/

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE2M583
DMKINJO	MN	Endoglucanase Y (EGY)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DE2AZTG
DMKINJO	MN	Endoglucanase Y (EGY)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMKINJO	DI	DMKINJO
DMKINJO	DN	Gentamicin
DMKINJO	MI	DECXWN8
DMKINJO	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMKINJO	MT	DME
DMKINJO	MA	Metabolism
DMKINJO	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMKINJO	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMBT7MI	DI	DMBT7MI
DMBT7MI	DN	Gentamicine sulfate
DMBT7MI	MI	TTUWYEA
DMBT7MI	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMBT7MI	MT	DTT
DMBT7MI	MA	Binder
DMBT7MI	RN	The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
DMBT7MI	RU	https://pubmed.ncbi.nlm.nih.gov/12217690

DMP0OVQ	DI	DMP0OVQ
DMP0OVQ	DN	Gestrinone
DMP0OVQ	MI	DE4LYSA
DMP0OVQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMP0OVQ	MT	DME
DMP0OVQ	MA	Metabolism
DMP0OVQ	RN	Adverse drug interactions: a handbook for prescribers. Taylor and Francis group.2010.
DMP0OVQ	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040554/

DMP0OVQ	DI	DMP0OVQ
DMP0OVQ	DN	Gestrinone
DMP0OVQ	MI	TTZAYWL
DMP0OVQ	MN	Estrogen receptor (ESR)
DMP0OVQ	MT	DTT
DMP0OVQ	MA	Modulator
DMP0OVQ	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMP0OVQ	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMKGH0R	DI	DMKGH0R
DMKGH0R	DN	GHRP-2
DMKGH0R	MI	TTWDC17
DMKGH0R	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMKGH0R	MT	DTT
DMKGH0R	MA	Agonist
DMKGH0R	RN	GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68.
DMKGH0R	RU	https://pubmed.ncbi.nlm.nih.gov/11796511

DMKGH0R	DI	DMKGH0R
DMKGH0R	DN	GHRP-2
DMKGH0R	MI	TTZ3IFB
DMKGH0R	MN	Phosphogluconate dehydrogenase (PGD)
DMKGH0R	MT	DTT
DMKGH0R	MA	Inhibitor
DMKGH0R	RN	Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14.
DMKGH0R	RU	https://pubmed.ncbi.nlm.nih.gov/12818683

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	DE4LYSA
DMWQ4MZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQ4MZ	MT	DME
DMWQ4MZ	MA	Metabolism
DMWQ4MZ	RN	ClinicalTrials.gov (NCT02456883) Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors.
DMWQ4MZ	RU	https://clinicaltrials.gov/ct2/show/NCT02456883

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	TTGJCWZ
DMWQ4MZ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMWQ4MZ	MT	DTT
DMWQ4MZ	MA	Inhibitor
DMWQ4MZ	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMWQ4MZ	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMTI0ZO	DI	DMTI0ZO
DMTI0ZO	DN	Gilteritinib
DMTI0ZO	MI	DTUGYRD
DMTI0ZO	MN	P-glycoprotein 1 (ABCB1)
DMTI0ZO	MT	DTP
DMTI0ZO	MA	Substrate
DMTI0ZO	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMTI0ZO	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMWQ4MZ	DI	DMWQ4MZ
DMWQ4MZ	DN	Gilteritinib
DMWQ4MZ	MI	TTZPY6J
DMWQ4MZ	MN	Tyrosine-protein kinase UFO (AXL)
DMWQ4MZ	MT	DTT
DMWQ4MZ	MA	Inhibitor
DMWQ4MZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWQ4MZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5PFIJ	DI	DM5PFIJ
DM5PFIJ	DN	Givosiran
DM5PFIJ	MI	TTG1FXO
DM5PFIJ	MN	ALAS1 messenger RNA (ALAS1 mRNA)
DM5PFIJ	MT	DTT
DM5PFIJ	MA	Inhibitor
DM5PFIJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM5PFIJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf

DM83MOK	DI	DM83MOK
DM83MOK	DN	Glassia
DM83MOK	MI	TTA7UJC
DM83MOK	MN	Alpha-1-antitrypsin (SERPINA1)
DM83MOK	MT	DTT
DM83MOK	MA	Inhibitor
DM83MOK	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM83MOK	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMAPV1B	DI	DMAPV1B
DMAPV1B	DN	Glatiramer acetate
DMAPV1B	MI	TTLCMWF
DMAPV1B	MN	MHC class II antigen DRB1*1 (HLA-DRB1)
DMAPV1B	MT	DTT
DMAPV1B	MA	Binder
DMAPV1B	RN	Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8.
DMAPV1B	RU	https://pubmed.ncbi.nlm.nih.gov/15371592

DM31YVO	DI	DM31YVO
DM31YVO	DN	Glecaprevir
DM31YVO	MI	DE4LYSA
DM31YVO	MN	Cytochrome P450 3A4 (CYP3A4)
DM31YVO	MT	DME
DM31YVO	MA	Metabolism
DM31YVO	RN	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030.
DM31YVO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30199279

DMF6Z5T	DI	DMF6Z5T
DMF6Z5T	DN	Glecaprevir; pibrentasvir
DMF6Z5T	MI	TTCJ2X8
DMF6Z5T	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMF6Z5T	MT	DTT
DMF6Z5T	MA	Inhibitor
DMF6Z5T	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMF6Z5T	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMF6Z5T	DI	DMF6Z5T
DMF6Z5T	DN	Glecaprevir; pibrentasvir
DMF6Z5T	MI	TTHC7JD
DMF6Z5T	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMF6Z5T	MT	DTT
DMF6Z5T	MA	Inhibitor
DMF6Z5T	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMF6Z5T	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	TTP835K
DM8JXPZ	MN	ATP-binding cassette transporter C8 (ABCC8)
DM8JXPZ	MT	DTT
DM8JXPZ	MA	Modulator
DM8JXPZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8JXPZ	RU	https://www.fda.gov/

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTI7UX6
DM8JXPZ	MN	Breast cancer resistance protein (ABCG2)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Glyburide transport across the human placenta. Obstet Gynecol. 2015 Mar;125(3):583-8.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/25730219

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DE5IED8
DM8JXPZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos. 2010 May;31(4):228-42.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20437462

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DE4LYSA
DM8JXPZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEIBDNY
DM8JXPZ	MN	Cytochrome P450 3A5 (CYP3A5)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DERD86B
DM8JXPZ	MN	Cytochrome P450 3A7 (CYP3A7)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25450675

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEGTFWK
DM8JXPZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTQ3ZHF
DM8JXPZ	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/16460798

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DTPFTEQ
DM8JXPZ	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM8JXPZ	MT	DTP
DM8JXPZ	MA	Substrate
DM8JXPZ	RN	Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23.
DM8JXPZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15640378

DM8JXPZ	DI	DM8JXPZ
DM8JXPZ	DN	Glibenclamide
DM8JXPZ	MI	DEYGVN4
DM8JXPZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8JXPZ	MT	DME
DM8JXPZ	MA	Metabolism
DM8JXPZ	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DM8JXPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	TTP835K
DMN6QO5	MN	ATP-binding cassette transporter C8 (ABCC8)
DMN6QO5	MT	DTT
DMN6QO5	MA	Blocker
DMN6QO5	RN	Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9.
DMN6QO5	RU	https://pubmed.ncbi.nlm.nih.gov/11574406

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	DE5IED8
DMN6QO5	MN	Cytochrome P450 2C9 (CYP2C9)
DMN6QO5	MT	DME
DMN6QO5	MA	Metabolism
DMN6QO5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMN6QO5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMN6QO5	DI	DMN6QO5
DMN6QO5	DN	Gliclazide
DMN6QO5	MI	DEGTFWK
DMN6QO5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMN6QO5	MT	DME
DMN6QO5	MA	Metabolism
DMN6QO5	RN	The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.
DMN6QO5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18541345

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	TTP835K
DM5FSJA	MN	ATP-binding cassette transporter C8 (ABCC8)
DM5FSJA	MT	DTT
DM5FSJA	MA	Blocker
DM5FSJA	RN	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
DM5FSJA	RU	https://pubmed.ncbi.nlm.nih.gov/19125764

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	TTEF5MJ
DM5FSJA	MN	ATP-binding cassette transporter C9 (ABCC9)
DM5FSJA	MT	DTT
DM5FSJA	MA	Blocker
DM5FSJA	RN	Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8.
DM5FSJA	RU	https://pubmed.ncbi.nlm.nih.gov/19125764

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	DTJ0EW4
DM5FSJA	MN	Bile salt export pump (ABCB11)
DM5FSJA	MT	DTP
DM5FSJA	MA	Substrate
DM5FSJA	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DM5FSJA	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DM5FSJA	DI	DM5FSJA
DM5FSJA	DN	Glimepiride
DM5FSJA	MI	DE5IED8
DM5FSJA	MN	Cytochrome P450 2C9 (CYP2C9)
DM5FSJA	MT	DME
DM5FSJA	MA	Metabolism
DM5FSJA	RN	Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006 May;72(2):148-54.
DM5FSJA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16325295

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DTJ0EW4
DMZA5PQ	MN	Bile salt export pump (ABCB11)
DMZA5PQ	MT	DTP
DMZA5PQ	MA	Substrate
DMZA5PQ	RN	Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
DMZA5PQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/24014644

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DE5IED8
DMZA5PQ	MN	Cytochrome P450 2C9 (CYP2C9)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15637526

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DE4LYSA
DMZA5PQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics. 2004;22(6):389-411.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15099124

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	TTG140O
DMZA5PQ	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMZA5PQ	MT	DTT
DMZA5PQ	MA	Blocker
DMZA5PQ	RN	Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6.
DMZA5PQ	RU	https://pubmed.ncbi.nlm.nih.gov/19233162

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DEGTFWK
DMZA5PQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10208645

DMZA5PQ	DI	DMZA5PQ
DMZA5PQ	DN	Glipizide
DMZA5PQ	MI	DEYGVN4
DMZA5PQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZA5PQ	MT	DME
DMZA5PQ	MA	Metabolism
DMZA5PQ	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMZA5PQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMB0EUX	DI	DMB0EUX
DMB0EUX	DN	Gliquidone
DMB0EUX	MI	DE5IED8
DMB0EUX	MN	Cytochrome P450 2C9 (CYP2C9)
DMB0EUX	MT	DME
DMB0EUX	MA	Metabolism
DMB0EUX	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMB0EUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMB0EUX	DI	DMB0EUX
DMB0EUX	DN	Gliquidone
DMB0EUX	MI	TTG140O
DMB0EUX	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMB0EUX	MT	DTT
DMB0EUX	MA	Binder
DMB0EUX	RN	Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113.
DMB0EUX	RU	https://pubmed.ncbi.nlm.nih.gov/12670661

DMJPR2B	DI	DMJPR2B
DMJPR2B	DN	Glisoxepide
DMJPR2B	MI	DE5IED8
DMJPR2B	MN	Cytochrome P450 2C9 (CYP2C9)
DMJPR2B	MT	DME
DMJPR2B	MA	Metabolism
DMJPR2B	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMJPR2B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMJPR2B	DI	DMJPR2B
DMJPR2B	DN	Glisoxepide
DMJPR2B	MI	TTG140O
DMJPR2B	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMJPR2B	MT	DTT
DMJPR2B	MA	Blocker
DMJPR2B	RN	Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8.
DMJPR2B	RU	https://pubmed.ncbi.nlm.nih.gov/16174795

DMFLUTR	DI	DMFLUTR
DMFLUTR	DN	Glucagon recombinant
DMFLUTR	MI	TT9O6WS
DMFLUTR	MN	Glucagon receptor (GCGR)
DMFLUTR	MT	DTT
DMFLUTR	MA	Binder
DMFLUTR	RN	Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
DMFLUTR	RU	https://pubmed.ncbi.nlm.nih.gov/17462598

DM6EL5Q	DI	DM6EL5Q
DM6EL5Q	DN	Glucarpidase
DM6EL5Q	MI	TTX81QL
DM6EL5Q	MN	Toxic methotrexate (TM)
DM6EL5Q	MT	DTT
DM6EL5Q	MA	Modulator
DM6EL5Q	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM6EL5Q	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	DEVDYN7
DM4ZLFD	MN	Cytochrome P450 2E1 (CYP2E1)
DM4ZLFD	MT	DME
DM4ZLFD	MA	Metabolism
DM4ZLFD	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DM4ZLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	TTRYK0X
DM4ZLFD	MN	Interleukin-1 beta (IL1B)
DM4ZLFD	MT	DTT
DM4ZLFD	MA	Inhibitor
DM4ZLFD	RN	Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98.
DM4ZLFD	RU	https://pubmed.ncbi.nlm.nih.gov/19626664

DM4ZLFD	DI	DM4ZLFD
DM4ZLFD	DN	Glucosamine
DM4ZLFD	MI	DEGTFWK
DM4ZLFD	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4ZLFD	MT	DME
DM4ZLFD	MA	Metabolism
DM4ZLFD	RN	Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
DM4ZLFD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11531003

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTI7UX6
DMAHMT9	MN	Breast cancer resistance protein (ABCG2)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J Biol Chem. 2010 May 28;285(22):16582-7.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20332504

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	TT3C1VN
DMAHMT9	MN	Enzyme unspecific (Enz)
DMAHMT9	MT	DTT
DMAHMT9	MA	Modulator
DMAHMT9	RN	Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/9372907

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEKW6PB
DMAHMT9	MN	Gamma-glutamylcyclotransferase (GGCT)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Characterization of the mechanism of thioredoxin-dependent activation of gamma-glutamylcyclotransferase, RipAY, from Ralstonia solanacearum. Biochem Biophys Res Commun. 2020 Mar 12;523(3):759-765.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/31948763

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEB4JZV
DMAHMT9	MN	Gamma-glutamylcyclotransferase 2 (CHAC2)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	ChaC2, an enzyme for slow turnover of cytosolic glutathione. J Biol Chem. 2017 Jan 13;292(2):638-651.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27913623

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEH6CAO
DMAHMT9	MN	Gamma-glutamyltranspeptidase 5 (GGT5)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011 Jul 15;414(2):208-14.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21447318

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEOS3FD
DMAHMT9	MN	Glutathione peroxidase 6 (GPX6)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Metabolomics reveals a role for the chromatin-binding protein HMGN5 in glutathione metabolism. PLoS One. 2014 Jan 2;9(1):e84583.
DMAHMT9	RU	https://pubmed.ncbi.nlm.nih.gov/24392144

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEZSNJD
DMAHMT9	MN	Glutathione S-transferase omega-1 (GSTO1)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DEHMPZR
DMAHMT9	MN	Glutathione S-transferase omega-2 (GSTO2)
DMAHMT9	MT	DME
DMAHMT9	MA	Metabolism
DMAHMT9	RN	Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases. J Mol Biol. 2012 Jul 13;420(3):190-203.
DMAHMT9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22522127

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTSYQGK
DMAHMT9	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/18775981

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTFI42L
DMAHMT9	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17668877

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTCSGPB
DMAHMT9	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
DMAHMT9	RU	https://doi.org/10.1042/0264-6021:3610497

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DT9C1TS
DMAHMT9	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DMAHMT9	DI	DMAHMT9
DMAHMT9	DN	Glutathione
DMAHMT9	MI	DTUGYRD
DMAHMT9	MN	P-glycoprotein 1 (ABCB1)
DMAHMT9	MT	DTP
DMAHMT9	MA	Substrate
DMAHMT9	RN	Upregulation of cellular glutathione levels in human ABCB5- and murine Abcb5-transfected cells. BMC Pharmacol Toxicol. 2015 Dec 15;16:37.
DMAHMT9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26666373

DMGE0CW	DI	DMGE0CW
DMGE0CW	DN	Glutethimide
DMGE0CW	MI	TTVG215
DMGE0CW	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMGE0CW	MT	DTT
DMGE0CW	MA	Inducer
DMGE0CW	RN	A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78.
DMGE0CW	RU	https://pubmed.ncbi.nlm.nih.gov/18818183

DMGE0CW	DI	DMGE0CW
DMGE0CW	DN	Glutethimide
DMGE0CW	MI	DEA3U9Y
DMGE0CW	MN	Myeloperoxidase (MPO)
DMGE0CW	MT	DME
DMGE0CW	MA	Metabolism
DMGE0CW	RN	Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
DMGE0CW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26102013

DMDGRQO	DI	DMDGRQO
DMDGRQO	DN	Glycerol phenylbutyrate
DMDGRQO	MI	DEVOTU4
DMDGRQO	MN	Aquaporin adipose (AQP7)
DMDGRQO	MT	DME
DMDGRQO	MA	Metabolism
DMDGRQO	RN	Aquaporins in the human testis and spermatozoa - identification, involvement in sperm volume regulation and clinical relevance. Int J Androl. 2010 Aug 1;33(4):629-41.
DMDGRQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19840149

DMDGRQO	DI	DMDGRQO
DMDGRQO	DN	Glycerol phenylbutyrate
DMDGRQO	MI	DEDI8VX
DMDGRQO	MN	Propanediol dehydrogenase (dhaT)
DMDGRQO	MT	DME
DMDGRQO	MA	Metabolism
DMDGRQO	RN	Expression and characterization of a novel 1,3-propanediol dehydrogenase from Lactobacillus brevis. Appl Biochem Biotechnol. 2016 Jul;179(6):959-72.
DMDGRQO	RU	https://pubmed.ncbi.nlm.nih.gov/26961082

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTW7AE3
DMIOZ29	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/17855766

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DERA3OF
DMIOZ29	MN	Bile acid-CoA thioesterase (BAAT)
DMIOZ29	MT	DME
DMIOZ29	MA	Metabolism
DMIOZ29	RN	Bile acid coenzyme A: amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 2005;400:374-94.
DMIOZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16399361

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DE437BY
DMIOZ29	MN	Delta-aminolevulinate synthase 2 (ALAS2)
DMIOZ29	MT	DME
DMIOZ29	MA	Metabolism
DMIOZ29	RN	Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. Mol Med. 2013 Mar 5;19:18-25.
DMIOZ29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23348515

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	TTKJEMQ
DMIOZ29	MN	Glutamate receptor ionotropic NMDA 2A (NMDAR2A)
DMIOZ29	MT	DTT
DMIOZ29	MA	Antagonist
DMIOZ29	RN	Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
DMIOZ29	RU	https://pubmed.ncbi.nlm.nih.gov/19562643

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTJF3DX
DMIOZ29	MN	L-type amino acid transporter 2 (SLC7A8)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMIOZ29	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTBPTJF
DMIOZ29	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/20195502

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DT48WEM
DMIOZ29	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008 Sep 2;35(1-2):86-95.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/18621125

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DT2CFQ5
DMIOZ29	MN	Sodium- and chloride-dependent glycine transporter 1 (SLC6A9)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016 Nov;135(11):1263-1268.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/27481395

DMIOZ29	DI	DMIOZ29
DMIOZ29	DN	Glycine
DMIOZ29	MI	DTE8R17
DMIOZ29	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DMIOZ29	MT	DTP
DMIOZ29	MA	Substrate
DMIOZ29	RN	Mutations in the GlyT2 gene (SLC6A5) are a second major cause of startle disease. J Biol Chem. 2012 Aug 17;287(34):28975-85.
DMIOZ29	RU	http://www.ncbi.nlm.nih.gov/pubmed/22700964

DM1WL9O	DI	DM1WL9O
DM1WL9O	DN	Glycodiazine
DM1WL9O	MI	TTG140O
DM1WL9O	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DM1WL9O	MT	DTT
DM1WL9O	MA	Binder
DM1WL9O	RN	Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52.
DM1WL9O	RU	https://pubmed.ncbi.nlm.nih.gov/141035

DM2M3ZA	DI	DM2M3ZA
DM2M3ZA	DN	Glycopyrrolate
DM2M3ZA	MI	TTZ9SOR
DM2M3ZA	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2M3ZA	MT	DTT
DM2M3ZA	MA	Antagonist
DM2M3ZA	RN	Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
DM2M3ZA	RU	https://pubmed.ncbi.nlm.nih.gov/17687267

DM2M3ZA	DI	DM2M3ZA
DM2M3ZA	DN	Glycopyrrolate
DM2M3ZA	MI	DTT79CX
DM2M3ZA	MN	Organic cation transporter 1 (SLC22A1)
DM2M3ZA	MT	DTP
DM2M3ZA	MA	Substrate
DM2M3ZA	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM2M3ZA	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMGVJLB	DI	DMGVJLB
DMGVJLB	DN	GMA-161
DMGVJLB	MI	TT7KTSR
DMGVJLB	MN	Immunoglobulin gamma Fc receptor III (FCGR3)
DMGVJLB	MT	DTT
DMGVJLB	MA	Antagonist
DMGVJLB	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMGVJLB	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMHZV7X	DI	DMHZV7X
DMHZV7X	DN	Golimumab
DMHZV7X	MI	TTF8CQI
DMHZV7X	MN	Tumor necrosis factor (TNF)
DMHZV7X	MT	DTT
DMHZV7X	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHZV7X	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	TT8R70G
DMAQ469	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAQ469	MT	DTT
DMAQ469	MA	Agonist
DMAQ469	RN	Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29.
DMAQ469	RU	https://pubmed.ncbi.nlm.nih.gov/17308138

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DEYCUQ2
DMAQ469	MN	Metallo-endopeptidase-like 1 (MMEL1)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J. 2002 May 1;363(Pt 3):697-705.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11964170

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DEVSCNZ
DMAQ469	MN	Prolyl endopeptidase (PREP)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Ion-exchange chromatography: basic principles and application to the partial purification of soluble mammalian prolyl oligopeptidase. Methods Mol Biol. 2011;681:215-28.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20978968

DMAQ469	DI	DMAQ469
DMAQ469	DN	Gonadorelin
DMAQ469	MI	DE95LJC
DMAQ469	MN	Thimet oligopeptidase (THOP1)
DMAQ469	MT	DME
DMAQ469	MA	Metabolism
DMAQ469	RN	Sleep deprivation changes thimet oligopeptidase (THOP1) expression and activity in rat brain. Heliyon. 2019 Nov 26;5(11):e02896.
DMAQ469	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31828230

DMAT8CG	DI	DMAT8CG
DMAT8CG	DN	Goserelin
DMAT8CG	MI	TT0ID4A
DMAT8CG	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMAT8CG	MT	DTT
DMAT8CG	MA	Activator
DMAT8CG	RN	Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9.
DMAT8CG	RU	https://pubmed.ncbi.nlm.nih.gov/19244174

DMPT74U	DI	DMPT74U
DMPT74U	DN	Gramicidin D
DMPT74U	MI	TT4ILYC
DMPT74U	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMPT74U	MT	DTT
DMPT74U	MA	Binder
DMPT74U	RN	Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
DMPT74U	RU	https://pubmed.ncbi.nlm.nih.gov/11570868

DMPT74U	DI	DMPT74U
DMPT74U	DN	Gramicidin D
DMPT74U	MI	DTUGYRD
DMPT74U	MN	P-glycoprotein 1 (ABCB1)
DMPT74U	MT	DTP
DMPT74U	MA	Substrate
DMPT74U	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPT74U	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	TTNXLKE
DMIUW25	MN	5-HT 3 receptor (5HT3R)
DMIUW25	MT	DTT
DMIUW25	MA	Antagonist
DMIUW25	RN	New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7.
DMIUW25	RU	https://pubmed.ncbi.nlm.nih.gov/17034670

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DE6OQ3W
DMIUW25	MN	Cytochrome P450 1A1 (CYP1A1)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DEJGDUW
DMIUW25	MN	Cytochrome P450 1A2 (CYP1A2)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Heterogeneity in systemic availability of ondansetron and granisetron following oral administration. Drug Metab Dispos. 1999 Jan;27(1):110-2.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9884318

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DECB0K3
DMIUW25	MN	Cytochrome P450 2D6 (CYP2D6)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12943486

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DE4LYSA
DMIUW25	MN	Cytochrome P450 3A4 (CYP3A4)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16248838

DMIUW25	DI	DMIUW25
DMIUW25	DN	Granisetron
DMIUW25	MI	DEIBDNY
DMIUW25	MN	Cytochrome P450 3A5 (CYP3A5)
DMIUW25	MT	DME
DMIUW25	MA	Metabolism
DMIUW25	RN	Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
DMIUW25	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7888294

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	TTN6J5F
DMGLX0T	MN	Bacterial DNA gyrase (Bact gyrase)
DMGLX0T	MT	DTT
DMGLX0T	MA	Modulator
DMGLX0T	RN	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/11796384

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTI7UX6
DMGLX0T	MN	Breast cancer resistance protein (ABCG2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones. Drug Metab Dispos. 2007 Oct;35(10):1873-9.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17639028

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DEJGDUW
DMGLX0T	MN	Cytochrome P450 1A2 (CYP1A2)
DMGLX0T	MT	DME
DMGLX0T	MA	Metabolism
DMGLX0T	RN	Quantitative prediction of drug interactions caused by CYP1A2 inhibitors and inducers. Clin Pharmacokinet. 2016 Aug;55(8):977-90.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26936044

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DE4LYSA
DMGLX0T	MN	Cytochrome P450 3A4 (CYP3A4)
DMGLX0T	MT	DME
DMGLX0T	MA	Metabolism
DMGLX0T	RN	MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39.
DMGLX0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18040809

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTSYQGK
DMGLX0T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 2000 Oct;295(1):146-52.
DMGLX0T	RU	http://jpet.aspetjournals.org/content/295/1/146.long

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTFI42L
DMGLX0T	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/18200507

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTE2B1D
DMGLX0T	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMGLX0T	DI	DMGLX0T
DMGLX0T	DN	Grepafloxacin
DMGLX0T	MI	DTUGYRD
DMGLX0T	MN	P-glycoprotein 1 (ABCB1)
DMGLX0T	MT	DTP
DMGLX0T	MA	Substrate
DMGLX0T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMGLX0T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMK54YG	DI	DMK54YG
DMK54YG	DN	Griseofulvin
DMK54YG	MI	DEJGDUW
DMK54YG	MN	Cytochrome P450 1A2 (CYP1A2)
DMK54YG	MT	DME
DMK54YG	MA	Metabolism
DMK54YG	RN	Kinetic mechanism of the activation of human plasminogen by streptokinase. Biochemistry. 1975 Oct 7;14(20):4459-65.
DMK54YG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=126078

DMK54YG	DI	DMK54YG
DMK54YG	DN	Griseofulvin
DMK54YG	MI	TT7PBUD
DMK54YG	MN	Fungal Microtubule (Fung MicroTU)
DMK54YG	MT	DTT
DMK54YG	MA	Inducer
DMK54YG	RN	Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8.
DMK54YG	RU	https://pubmed.ncbi.nlm.nih.gov/12537173

DM1ECNJ	DI	DM1ECNJ
DM1ECNJ	DN	GS-7340
DM1ECNJ	MI	TT84ETX
DM1ECNJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1ECNJ	MT	DTT
DM1ECNJ	MA	Inhibitor
DM1ECNJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
DM1ECNJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf

DM8QB0T	DI	DM8QB0T
DM8QB0T	DN	GSK2592984A
DM8QB0T	MI	TT3J5ZI
DM8QB0T	MN	Cell mediated immunity response (CMIR)
DM8QB0T	MT	DTT
DM8QB0T	RN	Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.
DM8QB0T	RU	https://pubmed.ncbi.nlm.nih.gov/20941447

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	TTQ8AFT
DM5QWEL	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM5QWEL	MT	DTT
DM5QWEL	MA	Agonist
DM5QWEL	RN	Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
DM5QWEL	RU	https://pubmed.ncbi.nlm.nih.gov/9284427

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	DEJGDUW
DM5QWEL	MN	Cytochrome P450 1A2 (CYP1A2)
DM5QWEL	MT	DME
DM5QWEL	MA	Metabolism
DM5QWEL	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM5QWEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM5QWEL	DI	DM5QWEL
DM5QWEL	DN	Guanabenz
DM5QWEL	MI	DTUGYRD
DM5QWEL	MN	P-glycoprotein 1 (ABCB1)
DM5QWEL	MT	DTP
DM5QWEL	MA	Substrate
DM5QWEL	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM5QWEL	RU	https://doi.org/10.1007/s00210-008-0345-0

DM6S157	DI	DM6S157
DM6S157	DN	Guanadrel Sulfate
DM6S157	MI	TTVIREA
DM6S157	MN	Adrenergic receptor (ADR)
DM6S157	MT	DTT
DM6S157	MA	Modulator
DM6S157	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6S157	RU	https://www.fda.gov/

DM9NSWT	DI	DM9NSWT
DM9NSWT	DN	Guanethidine
DM9NSWT	MI	TTT04VN
DM9NSWT	MN	Adrenergic neuron (AD neuro)
DM9NSWT	MT	DTT
DM9NSWT	MA	Blocker
DM9NSWT	RN	Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70.
DM9NSWT	RU	https://pubmed.ncbi.nlm.nih.gov/19646091

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTQ8AFT
DMB1CZ8	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17874970

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTMSFAW
DMB1CZ8	MN	Cannabinoid receptor 2 (CB2)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/18524639

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TT7QNVC
DMB1CZ8	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
DMB1CZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126

DMB1CZ8	DI	DMB1CZ8
DMB1CZ8	DN	Guanfacine extended release
DMB1CZ8	MI	TTNET8J
DMB1CZ8	MN	G-protein coupled receptor 55 (GPR55)
DMB1CZ8	MT	DTT
DMB1CZ8	MA	Agonist
DMB1CZ8	RN	The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
DMB1CZ8	RU	https://pubmed.ncbi.nlm.nih.gov/17876302

DM0P63W	DI	DM0P63W
DM0P63W	DN	Guanidine Hydrochloride
DM0P63W	MI	TTQ8AFT
DM0P63W	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM0P63W	MT	DTT
DM0P63W	MA	Modulator
DM0P63W	RN	Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54.
DM0P63W	RU	https://www.ncbi.nlm.nih.gov/pubmed/24908653

DMP7LK1	DI	DMP7LK1
DMP7LK1	DN	Guggulsterone
DMP7LK1	MI	TTS4UGC
DMP7LK1	MN	Farnesoid X-activated receptor (FXR)
DMP7LK1	MT	DTT
DMP7LK1	MA	Antagonist
DMP7LK1	RN	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
DMP7LK1	RU	https://pubmed.ncbi.nlm.nih.gov/19102680

DMP7LK1	DI	DMP7LK1
DMP7LK1	DN	Guggulsterone
DMP7LK1	MI	DTUGYRD
DMP7LK1	MN	P-glycoprotein 1 (ABCB1)
DMP7LK1	MT	DTP
DMP7LK1	MA	Substrate
DMP7LK1	RN	Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun. 2008 May 2;369(2):363-8.
DMP7LK1	RU	https://doi.org/10.1016/j.bbrc.2008.02.026

DMV4KOA	DI	DMV4KOA
DMV4KOA	DN	GW642444
DMV4KOA	MI	TT2CJVK
DMV4KOA	MN	Adrenergic receptor beta-2 (ADRB2)
DMV4KOA	MT	DTT
DMV4KOA	MA	Agonist
DMV4KOA	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMV4KOA	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DML72VJ	DI	DML72VJ
DML72VJ	DN	GW685698X
DML72VJ	MI	TTYRL6O
DML72VJ	MN	Glucocorticoid receptor (NR3C1)
DML72VJ	MT	DTT
DML72VJ	MA	Agonist
DML72VJ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DML72VJ	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMFUAXT	DI	DMFUAXT
DMFUAXT	DN	H1N1 pandemic influenza A vaccine
DMFUAXT	MI	TT3J5ZI
DMFUAXT	MN	Cell mediated immunity response (CMIR)
DMFUAXT	MT	DTT
DMFUAXT	RN	How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014.
DMFUAXT	RU	http://www.flu.gov/about_the_flu/h1n1/

DMMHYLB	DI	DMMHYLB
DMMHYLB	DN	H5N1 influenza vaccine
DMMHYLB	MI	TT3J5ZI
DMMHYLB	MN	Cell mediated immunity response (CMIR)
DMMHYLB	MT	DTT
DMMHYLB	RN	Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6.
DMMHYLB	RU	https://pubmed.ncbi.nlm.nih.gov/17672124

DM7JNTV	DI	DM7JNTV
DM7JNTV	DN	Halaven
DM7JNTV	MI	DE4LYSA
DM7JNTV	MN	Cytochrome P450 3A4 (CYP3A4)
DM7JNTV	MT	DME
DM7JNTV	MA	Metabolism
DM7JNTV	RN	Eribulin, a microtubule inhibitor for metastatic breast cancer. Oncology (Williston Park). 2011 Feb;25(2 Suppl Nurse Ed):46-8.
DM7JNTV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25373284

DMPFWO6	DI	DMPFWO6
DMPFWO6	DN	Halazepam
DMPFWO6	MI	TTPTXIN
DMPFWO6	MN	Translocator protein (TSPO)
DMPFWO6	MT	DTT
DMPFWO6	MA	Modulator
DMPFWO6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPFWO6	RU	https://www.fda.gov/

DMGLAX1	DI	DMGLAX1
DMGLAX1	DN	Halcinonide
DMGLAX1	MI	DE4LYSA
DMGLAX1	MN	Cytochrome P450 3A4 (CYP3A4)
DMGLAX1	MT	DME
DMGLAX1	MA	Metabolism
DMGLAX1	RN	NCIthesaurus: Halcinonide
DMGLAX1	RU	https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47552&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null

DMGLAX1	DI	DMGLAX1
DMGLAX1	DN	Halcinonide
DMGLAX1	MI	TTP3UTW
DMGLAX1	MN	Steroid hormone receptor ERR (ESRR)
DMGLAX1	MT	DTT
DMGLAX1	MA	Modulator
DMGLAX1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGLAX1	RU	https://www.fda.gov/

DM3GB6S	DI	DM3GB6S
DM3GB6S	DN	Halobetasol propionate
DM3GB6S	MI	TTP3UTW
DM3GB6S	MN	Steroid hormone receptor ERR (ESRR)
DM3GB6S	MT	DTT
DM3GB6S	MA	Modulator
DM3GB6S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM3GB6S	RU	https://www.fda.gov/

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	TTV3NH6
DMOMK1V	MN	Calmodulin (CALM)
DMOMK1V	MT	DTT
DMOMK1V	MA	Modulator
DMOMK1V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOMK1V	RU	https://www.fda.gov/

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DES5XRU
DMOMK1V	MN	Cytochrome P450 2C8 (CYP2C8)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DECB0K3
DMOMK1V	MN	Cytochrome P450 2D6 (CYP2D6)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DE4LYSA
DMOMK1V	MN	Cytochrome P450 3A4 (CYP3A4)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426515

DMOMK1V	DI	DMOMK1V
DMOMK1V	DN	Halofantrine
DMOMK1V	MI	DEIBDNY
DMOMK1V	MN	Cytochrome P450 3A5 (CYP3A5)
DMOMK1V	MT	DME
DMOMK1V	MA	Metabolism
DMOMK1V	RN	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
DMOMK1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10385214

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE6OQ3W
DM96SE0	MN	Cytochrome P450 1A1 (CYP1A1)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEJGDUW
DM96SE0	MN	Cytochrome P450 1A2 (CYP1A2)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE5IED8
DM96SE0	MN	Cytochrome P450 2C9 (CYP2C9)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DECB0K3
DM96SE0	MN	Cytochrome P450 2D6 (CYP2D6)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE4LYSA
DM96SE0	MN	Cytochrome P450 3A4 (CYP3A4)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEIBDNY
DM96SE0	MN	Cytochrome P450 3A5 (CYP3A5)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584149

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DERD86B
DM96SE0	MN	Cytochrome P450 3A7 (CYP3A7)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Drug Interactions Flockhart Table
DM96SE0	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	TTEX248
DM96SE0	MN	Dopamine D2 receptor (D2R)
DM96SE0	MT	DTT
DM96SE0	MA	Antagonist
DM96SE0	RN	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
DM96SE0	RU	https://pubmed.ncbi.nlm.nih.gov/12112400

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DEGTFWK
DM96SE0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11717183

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DTUGYRD
DM96SE0	MN	P-glycoprotein 1 (ABCB1)
DM96SE0	MT	DTP
DM96SE0	MA	Substrate
DM96SE0	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM96SE0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM96SE0	DI	DM96SE0
DM96SE0	DN	Haloperidol
DM96SE0	MI	DE85D2P
DM96SE0	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM96SE0	MT	DME
DM96SE0	MA	Metabolism
DM96SE0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM96SE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH4IVU	DI	DMH4IVU
DMH4IVU	DN	Haloprogin
DMH4IVU	MI	TTAH0B3
DMH4IVU	MN	Fungal Cell membrane (Fung CM)
DMH4IVU	MT	DTT
DMH4IVU	MA	Binder
DMH4IVU	RN	Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5.
DMH4IVU	RU	https://pubmed.ncbi.nlm.nih.gov/4608935

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEJVYAZ
DM80OZ5	MN	Cytochrome P450 2A6 (CYP2A6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology. 2001 Aug;95(2):509-14.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11506127

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEPKLMQ
DM80OZ5	MN	Cytochrome P450 2B6 (CYP2B6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE5IED8
DM80OZ5	MN	Cytochrome P450 2C9 (CYP2C9)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DECB0K3
DM80OZ5	MN	Cytochrome P450 2D6 (CYP2D6)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DEVDYN7
DM80OZ5	MN	Cytochrome P450 2E1 (CYP2E1)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiol Scand. 2003 Jul;47(6):765-70.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12803597

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE4LYSA
DM80OZ5	MN	Cytochrome P450 3A4 (CYP3A4)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8886607

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	TTAN6JD
DM80OZ5	MN	Glutamate receptor AMPA (GRIA)
DM80OZ5	MT	DTT
DM80OZ5	MA	Antagonist
DM80OZ5	RN	Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
DM80OZ5	RU	https://pubmed.ncbi.nlm.nih.gov/17828284

DM80OZ5	DI	DM80OZ5
DM80OZ5	DN	Halothane
DM80OZ5	MI	DE9A2LB
DM80OZ5	MN	Microsomal cytochrome MCB5 (CYB5A)
DM80OZ5	MT	DME
DM80OZ5	MA	Metabolism
DM80OZ5	RN	Modulation of the reductive metabolism of halothane by microsomal cytochrome b5 in rat liver. Biochim Biophys Acta. 1987 Dec 7;926(3):231-8.
DM80OZ5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3689822

DMN0S1G	DI	DMN0S1G
DMN0S1G	DN	HEGF
DMN0S1G	MI	TTGKNB4
DMN0S1G	MN	Epidermal growth factor receptor (EGFR)
DMN0S1G	MT	DTT
DMN0S1G	MA	Activator
DMN0S1G	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMN0S1G	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMEVXY6	DI	DMEVXY6
DMEVXY6	DN	Heparin Calcium
DMEVXY6	MI	TT4QPUL
DMEVXY6	MN	Antithrombin-III (ATIII)
DMEVXY6	MT	DTT
DMEVXY6	MA	Modulator
DMEVXY6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEVXY6	RU	https://www.fda.gov/

DM9KHZL	DI	DM9KHZL
DM9KHZL	DN	Heparin Sodium
DM9KHZL	MI	TT4QPUL
DM9KHZL	MN	Antithrombin-III (ATIII)
DM9KHZL	MT	DTT
DM9KHZL	MA	Modulator
DM9KHZL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632).
DM9KHZL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632

DMOB2F3	DI	DMOB2F3
DMOB2F3	DN	Heptabarbital
DMOB2F3	MI	TTAN6JD
DMOB2F3	MN	Glutamate receptor AMPA (GRIA)
DMOB2F3	MT	DTT
DMOB2F3	MA	Antagonist
DMOB2F3	RN	A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15.
DMOB2F3	RU	https://pubmed.ncbi.nlm.nih.gov/9008265

DM6YWBF	DI	DM6YWBF
DM6YWBF	DN	Herbimycin A
DM6YWBF	MI	TT6PKBN
DM6YWBF	MN	Proto-oncogene c-Src (SRC)
DM6YWBF	MT	DTT
DM6YWBF	MA	Inhibitor
DM6YWBF	RN	In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
DM6YWBF	RU	https://pubmed.ncbi.nlm.nih.gov/7967714

DMDBWHY	DI	DMDBWHY
DMDBWHY	DN	Heroin diacetylmorphine
DMDBWHY	MI	DEQ2BAJ
DMDBWHY	MN	Acetylcholinesterase (ACHE)
DMDBWHY	MT	DME
DMDBWHY	MA	Metabolism
DMDBWHY	RN	Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chem Biol Interact. 2018 Sep 25;293:107-114.
DMDBWHY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30080993

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	DTI7UX6
DMKER83	MN	Breast cancer resistance protein (ABCG2)
DMKER83	MT	DTP
DMKER83	MA	Substrate
DMKER83	RN	Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004 Apr 23;317(1):269-75.
DMKER83	RU	https://doi.org/10.1016/j.bbrc.2004.03.040

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	DEJGDUW
DMKER83	MN	Cytochrome P450 1A2 (CYP1A2)
DMKER83	MT	DME
DMKER83	MA	Metabolism
DMKER83	RN	In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol. 2002 May;40(5):609-16.
DMKER83	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11955666

DMKER83	DI	DMKER83
DMKER83	DN	Hesperetin
DMKER83	MI	TTF8P9I
DMKER83	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMKER83	MT	DTT
DMKER83	MA	Inhibitor
DMKER83	RN	In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60.
DMKER83	RU	https://pubmed.ncbi.nlm.nih.gov/15114505

DMI5DW1	DI	DMI5DW1
DMI5DW1	DN	Hesperidin
DMI5DW1	MI	TT4FDG6
DMI5DW1	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMI5DW1	MT	DTT
DMI5DW1	MA	Inhibitor
DMI5DW1	RN	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
DMI5DW1	RU	https://pubmed.ncbi.nlm.nih.gov/21074425

DMPXITB	DI	DMPXITB
DMPXITB	DN	Hetacillin
DMPXITB	MI	TTJP4SM
DMPXITB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMPXITB	MT	DTT
DMPXITB	MA	Modulator
DMPXITB	RN	JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051.
DMPXITB	RU	https://www.ncbi.nlm.nih.gov/pubmed/23846595

DMGUC9T	DI	DMGUC9T
DMGUC9T	DN	HEV-239
DMGUC9T	MI	TT3J5ZI
DMGUC9T	MN	Cell mediated immunity response (CMIR)
DMGUC9T	MT	DTT
DMGUC9T	RN	The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14.
DMGUC9T	RU	https://pubmed.ncbi.nlm.nih.gov/25714510

DMLKSE0	DI	DMLKSE0
DMLKSE0	DN	Hexachlorophene
DMLKSE0	MI	TTAO7YK
DMLKSE0	MN	Plasmodium Glutamate dehydrogenase (Malaria gdh)
DMLKSE0	MT	DTT
DMLKSE0	MA	Inhibitor
DMLKSE0	RN	Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000.
DMLKSE0	RU	https://pubmed.ncbi.nlm.nih.gov/19531491

DMFY307	DI	DMFY307
DMFY307	DN	Hexafluronium bromide
DMFY307	MI	TTEB0GD
DMFY307	MN	Cholinesterase (BCHE)
DMFY307	MT	DTT
DMFY307	MA	Inhibitor
DMFY307	RN	Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90.
DMFY307	RU	https://pubmed.ncbi.nlm.nih.gov/6711267

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DEJGDUW
DMQ314B	MN	Cytochrome P450 1A2 (CYP1A2)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE5IED8
DMQ314B	MN	Cytochrome P450 2C9 (CYP2C9)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE4LYSA
DMQ314B	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	TT1MPAY
DMQ314B	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQ314B	MT	DTT
DMQ314B	MA	Antagonist
DMQ314B	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMQ314B	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DEGTFWK
DMQ314B	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality. 2007 Jul;19(7):550-8.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17487889

DMQ314B	DI	DMQ314B
DMQ314B	DN	Hexobarbital
DMQ314B	MI	DE073H6
DMQ314B	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQ314B	MT	DME
DMQ314B	MA	Metabolism
DMQ314B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMQ314B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMEADRK	DI	DMEADRK
DMEADRK	DN	Hexylcaine
DMEADRK	MI	TTZOVE0
DMEADRK	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMEADRK	MT	DTT
DMEADRK	MA	Blocker
DMEADRK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMEADRK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMV7IM6	DI	DMV7IM6
DMV7IM6	DN	Histamine Phosphate
DMV7IM6	MI	TT7CXIM
DMV7IM6	MN	Histamine receptor (HR)
DMV7IM6	MT	DTT
DMV7IM6	MA	Modulator
DMV7IM6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMV7IM6	RU	https://www.fda.gov/

DMGBPSH	DI	DMGBPSH
DMGBPSH	DN	Homatropine Methylbromide
DMGBPSH	MI	TTH18TF
DMGBPSH	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMGBPSH	MT	DTT
DMGBPSH	MA	Antagonist
DMGBPSH	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMGBPSH	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM78G6F	DI	DM78G6F
DM78G6F	DN	HTF 919
DM78G6F	MI	TT07C3Y
DM78G6F	MN	5-HT 4 receptor (HTR4)
DM78G6F	MT	DTT
DM78G6F	MA	Agonist
DM78G6F	RN	5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
DM78G6F	RU	https://pubmed.ncbi.nlm.nih.gov/11874527

DMA5OBU	DI	DMA5OBU
DMA5OBU	DN	Human neutral insulin
DMA5OBU	MI	TTCBFJO
DMA5OBU	MN	Insulin receptor (INSR)
DMA5OBU	MT	DTT
DMA5OBU	MA	Binder
DMA5OBU	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMA5OBU	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMPHVQ1	DI	DMPHVQ1
DMPHVQ1	DN	Human prothrombin complex concentrate
DMPHVQ1	MI	TT6L509
DMPHVQ1	MN	Coagulation factor IIa (F2)
DMPHVQ1	MT	DTT
DMPHVQ1	MA	Modulator
DMPHVQ1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMPHVQ1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMMAWLU	DI	DMMAWLU
DMMAWLU	DN	Huperzine A
DMMAWLU	MI	TT1RS9F
DMMAWLU	MN	Acetylcholinesterase (AChE)
DMMAWLU	MT	DTT
DMMAWLU	MA	Inhibitor
DMMAWLU	RN	Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
DMMAWLU	RU	https://pubmed.ncbi.nlm.nih.gov/12213312

DMMAWLU	DI	DMMAWLU
DMMAWLU	DN	Huperzine A
DMMAWLU	MI	TT9IK2Z
DMMAWLU	MN	N-methyl-D-aspartate receptor (NMDAR)
DMMAWLU	MT	DTT
DMMAWLU	MA	Antagonist
DMMAWLU	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DMMAWLU	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	DEH31BC
DMX8M26	MN	Hyaluronate lyase (hyaL)
DMX8M26	MT	DME
DMX8M26	MA	Metabolism
DMX8M26	RN	A bacterial ABC transporter enables import of mammalian host glycosaminoglycans. Sci Rep. 2017 Apr 21;7(1):1069.
DMX8M26	RU	https://pubmed.ncbi.nlm.nih.gov/28432302

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	TTG8DNU
DMX8M26	MN	Hyaluronic acid receptor (LYVE1)
DMX8M26	MT	DTT
DMX8M26	MA	Modulator
DMX8M26	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4954).
DMX8M26	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954

DMX8M26	DI	DMX8M26
DMX8M26	DN	Hyaluronate sodium
DMX8M26	MI	DEWP153
DMX8M26	MN	Hyaluronidase (hyl)
DMX8M26	MT	DME
DMX8M26	MA	Metabolism
DMX8M26	RN	A novel hyaluronidase produced by Bacillus sp. A50. PLoS One. 2014 Apr 15;9(4):e94156.
DMX8M26	RU	https://pubmed.ncbi.nlm.nih.gov/24736576

DMETWAU	DI	DMETWAU
DMETWAU	DN	Hyaluronidase (ovine)
DMETWAU	MI	TTYTVXF
DMETWAU	MN	Hyaluronic acid (HA)
DMETWAU	MT	DTT
DMETWAU	MA	Modulator
DMETWAU	RN	Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97.
DMETWAU	RU	https://pubmed.ncbi.nlm.nih.gov/16226510

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	TT7HC21
DMU8JGH	MN	Membrane copper amine oxidase (AOC3)
DMU8JGH	MT	DTT
DMU8JGH	MA	Modulator
DMU8JGH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8JGH	RU	https://www.fda.gov/

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DE7OAB3
DMU8JGH	MN	N-acetyltransferase 1 (NAT1)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DER7TA0
DMU8JGH	MN	N-acetyltransferase 2 (NAT2)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29018032

DMU8JGH	DI	DMU8JGH
DMU8JGH	DN	Hydralazine
DMU8JGH	MI	DEZV4AP
DMU8JGH	MN	RNA cytidine acetyltransferase (hALP)
DMU8JGH	MT	DME
DMU8JGH	MA	Metabolism
DMU8JGH	RN	Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
DMU8JGH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6111409

DMUSZHD	DI	DMUSZHD
DMUSZHD	DN	Hydrochlorothiazide
DMUSZHD	MI	TTL69WB
DMUSZHD	MN	Angiotensin-converting enzyme (ACE)
DMUSZHD	MT	DTT
DMUSZHD	MA	Modulator
DMUSZHD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMUSZHD	RU	https://www.fda.gov/

DMQ2JO5	DI	DMQ2JO5
DMQ2JO5	DN	Hydrocodone
DMQ2JO5	MI	TTKWM86
DMQ2JO5	MN	Opioid receptor mu (MOP)
DMQ2JO5	MT	DTT
DMQ2JO5	MA	Modulator
DMQ2JO5	RN	Clinical pipeline report, company report or official report of kempharm.
DMQ2JO5	RU	http://www.kempharm.com/pages/pipeline/pain.php

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DEPKLMQ
DMIAPBE	MN	Cytochrome P450 2B6 (CYP2B6)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	FDA label of Hydrocodone bitartrate. The 2020 official website of the U.S. Food and Drug Administration.
DMIAPBE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DECB0K3
DMIAPBE	MN	Cytochrome P450 2D6 (CYP2D6)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DE4LYSA
DMIAPBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. Acad Emerg Med. 2014 Aug;21(8):879-85.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25156930

DMIAPBE	DI	DMIAPBE
DMIAPBE	DN	Hydrocodone bitartrate
DMIAPBE	MI	DEYGVN4
DMIAPBE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMIAPBE	MT	DME
DMIAPBE	MA	Metabolism
DMIAPBE	RN	Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics. 2003 Nov-Dec;44(6):515-20.
DMIAPBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14597688

DM8K1XO	DI	DM8K1XO
DM8K1XO	DN	Hydrocortamate
DM8K1XO	MI	TTYRL6O
DM8K1XO	MN	Glucocorticoid receptor (NR3C1)
DM8K1XO	MT	DTT
DM8K1XO	MA	Modulator
DM8K1XO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8K1XO	RU	https://www.fda.gov/

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DE6TYUK
DMGEMB7	MN	Aldosterone synthase (CYP11B2)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DE4LYSA
DMGEMB7	MN	Cytochrome P450 3A4 (CYP3A4)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos. 2000 May;28(5):493-6.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10772626

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DEIBDNY
DMGEMB7	MN	Cytochrome P450 3A5 (CYP3A5)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DERD86B
DMGEMB7	MN	Cytochrome P450 3A7 (CYP3A7)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	TTYRL6O
DMGEMB7	MN	Glucocorticoid receptor (NR3C1)
DMGEMB7	MT	DTT
DMGEMB7	MA	Modulator
DMGEMB7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGEMB7	RU	https://www.fda.gov/

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DTUGYRD
DMGEMB7	MN	P-glycoprotein 1 (ABCB1)
DMGEMB7	MT	DTP
DMGEMB7	MA	Substrate
DMGEMB7	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DMGEMB7	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMGEMB7	DI	DMGEMB7
DMGEMB7	DN	Hydrocortisone
DMGEMB7	MI	DEPE0RD
DMGEMB7	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMGEMB7	MT	DME
DMGEMB7	MA	Metabolism
DMGEMB7	RN	Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33.
DMGEMB7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15356073

DMVPUQI	DI	DMVPUQI
DMVPUQI	DN	Hydroflumethiazide
DMVPUQI	MI	TTS087L
DMVPUQI	MN	Solute carrier family 12 member 1 (SLC12A1)
DMVPUQI	MT	DTT
DMVPUQI	MA	Blocker
DMVPUQI	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMVPUQI	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DE1XPGH
DM1NG5W	MN	Catalase (CAT)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes. Blood. 1989 Jan;73(1):334-9.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2491951

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DESZ5G9
DM1NG5W	MN	Cellular glutathione peroxidase (GPX1)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Catalase and glutathione peroxidase are equally active in detoxification of hydrogen peroxide in human erythrocytes. Blood. 1989 Jan;73(1):334-9.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2491951

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DE9QHP6
DM1NG5W	MN	Cytochrome P450 1B1 (CYP1B1)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	NADPH- and hydroperoxide-supported 17beta-estradiol hydroxylation catalyzed by a variant form (432L, 453S) of human cytochrome P450 1B1. J Steroid Biochem Mol Biol. 2000 Sep;74(1-2):11-8.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11074351

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	DECB0K3
DM1NG5W	MN	Cytochrome P450 2D6 (CYP2D6)
DM1NG5W	MT	DME
DM1NG5W	MA	Metabolism
DM1NG5W	RN	Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos. 2006 Dec;34(12):1958-65.
DM1NG5W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16987939

DM1NG5W	DI	DM1NG5W
DM1NG5W	DN	Hydrogen peroxide
DM1NG5W	MI	TTELIN2
DM1NG5W	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM1NG5W	MT	DTT
DM1NG5W	MA	Inhibitor
DM1NG5W	RN	Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
DM1NG5W	RU	https://pubmed.ncbi.nlm.nih.gov/10091683

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DE5IED8
DMHP21E	MN	Cytochrome P450 2C9 (CYP2C9)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.;
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15268978

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DECB0K3
DMHP21E	MN	Cytochrome P450 2D6 (CYP2D6)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9067326

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DE4LYSA
DMHP21E	MN	Cytochrome P450 3A4 (CYP3A4)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16718649

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	TT27RFC
DMHP21E	MN	Opioid receptor delta (OPRD1)
DMHP21E	MT	DTT
DMHP21E	MA	Binder
DMHP21E	RN	Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
DMHP21E	RU	https://pubmed.ncbi.nlm.nih.gov/14998329

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	TTKWM86
DMHP21E	MN	Opioid receptor mu (MOP)
DMHP21E	MT	DTT
DMHP21E	MA	Inhibitor
DMHP21E	RN	Clinical pipeline report, company report or official report of signaturerx.
DMHP21E	RU	http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEYGVN4
DMHP21E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012 Jan;50(1):1-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22148986

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEF2WXN
DMHP21E	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DMHP21E	DI	DMHP21E
DMHP21E	DN	Hydromorphone
DMHP21E	MI	DEB3CV1
DMHP21E	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMHP21E	MT	DME
DMHP21E	MA	Metabolism
DMHP21E	RN	Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
DMHP21E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23218233

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	DE4LYSA
DM6AVR4	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AVR4	MT	DME
DM6AVR4	MA	Metabolism
DM6AVR4	RN	Metabolism of (S)-5,6-difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a non-nucleoside reverse transcriptase inhibitor, in human liver microsomes. Metabolic activation and enzyme kinetics. Drug Metab Dispos. 2003 Jan;31(1):122-32.
DM6AVR4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12485961

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	DEQUXZ5
DM6AVR4	MN	Fumarate reductase flavoprotein (frdA)
DM6AVR4	MT	DME
DM6AVR4	MA	Metabolism
DM6AVR4	RN	Wolinella succinogenes quinol:fumarate reductase and its comparison to E. coli succinate:quinone reductase. FEBS Lett. 2003 Nov 27;555(1):21-8.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/14630313

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	TT38RM1
DM6AVR4	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM6AVR4	MT	DTT
DM6AVR4	MA	Antagonist
DM6AVR4	RN	Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/9787163

DM6AVR4	DI	DM6AVR4
DM6AVR4	DN	Hydroquinone
DM6AVR4	MI	TTULVH8
DM6AVR4	MN	Tyrosinase (TYR)
DM6AVR4	MT	DTT
DM6AVR4	MA	Inhibitor
DM6AVR4	RN	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
DM6AVR4	RU	https://pubmed.ncbi.nlm.nih.gov/19159217

DMGKV9D	DI	DMGKV9D
DMGKV9D	DN	Hydroxocobalamin
DMGKV9D	MI	TTCQ21Y
DMGKV9D	MN	Methylmalonyl-CoA mutase (MMUT)
DMGKV9D	MT	DTT
DMGKV9D	MA	Cofactor
DMGKV9D	RN	Vitamin B12. Nippon Rinsho. 1999 Oct;57(10):2205-10.
DMGKV9D	RU	https://pubmed.ncbi.nlm.nih.gov/10540863

DMJAS3O	DI	DMJAS3O
DMJAS3O	DN	Hydroxyamphetamine
DMJAS3O	MI	DE4LYSA
DMJAS3O	MN	Cytochrome P450 3A4 (CYP3A4)
DMJAS3O	MT	DME
DMJAS3O	MA	Metabolism
DMJAS3O	RN	Stereoselective method development and validation for determination of concentrations of amphetamine-type stimulants and metabolites in human urine using a simultaneous extraction-chiral derivatization approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jan 1;879(1):8-16.
DMJAS3O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21147046

DMQSGM0	DI	DMQSGM0
DMQSGM0	DN	Hydroxyamphetamine Hydrobromide
DMQSGM0	MI	TTIU98M
DMQSGM0	MN	Trace amine-associated receptor-1 (TAAR1)
DMQSGM0	MT	DTT
DMQSGM0	MA	Modulator
DMQSGM0	RN	Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37.
DMQSGM0	RU	https://www.ncbi.nlm.nih.gov/pubmed/3884149

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	DTI7UX6
DMSIVND	MN	Breast cancer resistance protein (ABCG2)
DMSIVND	MT	DTP
DMSIVND	MA	Substrate
DMSIVND	RN	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
DMSIVND	RU	http://www.ncbi.nlm.nih.gov/pubmed/23711386

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	DE4LYSA
DMSIVND	MN	Cytochrome P450 3A4 (CYP3A4)
DMSIVND	MT	DME
DMSIVND	MA	Metabolism
DMSIVND	RN	Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther. 2018 Jun;365(3):447-459.
DMSIVND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29438998

DMSIVND	DI	DMSIVND
DMSIVND	DN	Hydroxychloroquine
DMSIVND	MI	TTRJ1K4
DMSIVND	MN	Toll-like receptor 7 (TLR7)
DMSIVND	MT	DTT
DMSIVND	MA	Antagonist
DMSIVND	RN	TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
DMSIVND	RU	https://pubmed.ncbi.nlm.nih.gov/18220957

DMGIZF5	DI	DMGIZF5
DMGIZF5	DN	Hydroxyflutamide
DMGIZF5	MI	TTS64P2
DMGIZF5	MN	Androgen receptor (AR)
DMGIZF5	MT	DTT
DMGIZF5	MA	Antagonist
DMGIZF5	RN	Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
DMGIZF5	RU	https://pubmed.ncbi.nlm.nih.gov/17392714

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DE4LYSA
DMIKQH5	MN	Cytochrome P450 3A4 (CYP3A4)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DEIBDNY
DMIKQH5	MN	Cytochrome P450 3A5 (CYP3A5)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25256193

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DE0JMZ5
DMIKQH5	MN	Steroid 21-hydroxylase (CYP21A2)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	Functional characterization of two novel point mutations in the CYP21 gene causing simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2005 Jan;90(1):445-54.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15483094

DMIKQH5	DI	DMIKQH5
DMIKQH5	DN	Hydroxyprogesterone
DMIKQH5	MI	DEYGVN4
DMIKQH5	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMIKQH5	MT	DME
DMIKQH5	MA	Metabolism
DMIKQH5	RN	The glucuronidation of Delta4-3-Keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6alpha- and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab Dispos. 2007 Mar;35(3):363-70.
DMIKQH5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17151189

DMR5QS6	DI	DMR5QS6
DMR5QS6	DN	Hydroxystilbamidine Isethionate
DMR5QS6	MI	TTS1W4A
DMR5QS6	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMR5QS6	MT	DTT
DMR5QS6	MA	Modulator
DMR5QS6	RN	Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42.
DMR5QS6	RU	https://www.ncbi.nlm.nih.gov/pubmed/1242363

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DTE2B1D
DMOQVU9	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DT3D8F0
DMOQVU9	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DT9C1TS
DMOQVU9	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	DTUGYRD
DMOQVU9	MN	P-glycoprotein 1 (ABCB1)
DMOQVU9	MT	DTP
DMOQVU9	MA	Substrate
DMOQVU9	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMOQVU9	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMOQVU9	DI	DMOQVU9
DMOQVU9	DN	Hydroxyurea
DMOQVU9	MI	TTBWDI0
DMOQVU9	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMOQVU9	MT	DTT
DMOQVU9	MA	Modulator
DMOQVU9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOQVU9	RU	https://www.fda.gov/

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	DE4LYSA
DMF8Y74	MN	Cytochrome P450 3A4 (CYP3A4)
DMF8Y74	MT	DME
DMF8Y74	MA	Metabolism
DMF8Y74	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DMF8Y74	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	DEIBDNY
DMF8Y74	MN	Cytochrome P450 3A5 (CYP3A5)
DMF8Y74	MT	DME
DMF8Y74	MA	Metabolism
DMF8Y74	RN	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
DMF8Y74	RU	https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf

DMF8Y74	DI	DMF8Y74
DMF8Y74	DN	Hydroxyzine
DMF8Y74	MI	TTTIBOJ
DMF8Y74	MN	Histamine H1 receptor (H1R)
DMF8Y74	MT	DTT
DMF8Y74	MA	Antagonist
DMF8Y74	RN	Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71.
DMF8Y74	RU	https://pubmed.ncbi.nlm.nih.gov/19057127

DMVAIH4	DI	DMVAIH4
DMVAIH4	DN	Hylenex
DMVAIH4	MI	TTYTVXF
DMVAIH4	MN	Hyaluronic acid (HA)
DMVAIH4	MT	DTT
DMVAIH4	MA	Modulator
DMVAIH4	RN	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.
DMVAIH4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/

DM804UR	DI	DM804UR
DM804UR	DN	Hyoscyamine
DM804UR	MI	TTH18TF
DM804UR	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM804UR	MT	DTT
DM804UR	MA	Antagonist
DM804UR	RN	Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82.
DM804UR	RU	https://pubmed.ncbi.nlm.nih.gov/3126798

DM0RXF5	DI	DM0RXF5
DM0RXF5	DN	Hyqvia
DM0RXF5	MI	TTXFI1K
DM0RXF5	MN	Hyaluronidase (HYAL)
DM0RXF5	MT	DTT
DM0RXF5	MA	Modulator
DM0RXF5	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM0RXF5	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMV67QO	DI	DMV67QO
DMV67QO	DN	Ibalizumab 
DMV67QO	MI	TTN2JFW
DMV67QO	MN	T-cell surface glycoprotein CD4 (CD4)
DMV67QO	MT	DTT
DMV67QO	MA	Modulator
DMV67QO	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMV67QO	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM0QZBN	DI	DM0QZBN
DM0QZBN	DN	Ibandronate
DM0QZBN	MI	TTIKWV4
DM0QZBN	MN	Geranyltranstransferase (FDPS)
DM0QZBN	MT	DTT
DM0QZBN	MA	Modulator
DM0QZBN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0QZBN	RU	https://www.fda.gov/

DMGUX67	DI	DMGUX67
DMGUX67	DN	Ibopamine hci
DMGUX67	MI	TTEX248
DMGUX67	MN	Dopamine D2 receptor (D2R)
DMGUX67	MT	DTT
DMGUX67	MA	Modulator
DMGUX67	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMGUX67	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMG594T	DI	DMG594T
DMG594T	DN	Ibritumomab
DMG594T	MI	TTUE541
DMG594T	MN	Leukocyte surface antigen Leu-16 (CD20)
DMG594T	MT	DTT
DMG594T	RN	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
DMG594T	RU	https://pubmed.ncbi.nlm.nih.gov/19427037

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DECB0K3
DMHZCPO	MN	Cytochrome P450 2D6 (CYP2D6)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DE4LYSA
DMHZCPO	MN	Cytochrome P450 3A4 (CYP3A4)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DEIBDNY
DMHZCPO	MN	Cytochrome P450 3A5 (CYP3A5)
DMHZCPO	MT	DME
DMHZCPO	MA	Metabolism
DMHZCPO	RN	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
DMHZCPO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25488930

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	DTUGYRD
DMHZCPO	MN	P-glycoprotein 1 (ABCB1)
DMHZCPO	MT	DTP
DMHZCPO	MA	Substrate
DMHZCPO	RN	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Mol Pharm. 2018 Nov 5;15(11):5124-5134.
DMHZCPO	RU	http://www.ncbi.nlm.nih.gov/pubmed/30247919

DMHZCPO	DI	DMHZCPO
DMHZCPO	DN	Ibrutinib
DMHZCPO	MI	TTGM6VW
DMHZCPO	MN	Tyrosine-protein kinase BTK (ATK)
DMHZCPO	MT	DTT
DMHZCPO	MA	Inhibitor
DMHZCPO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
DMHZCPO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948

DM4LSPN	DI	DM4LSPN
DM4LSPN	DN	Ibudilast
DM4LSPN	MI	TTZCG4L
DM4LSPN	MN	Phosphodiesterase 3 (PDE3)
DM4LSPN	MT	DTT
DM4LSPN	MA	Inhibitor
DM4LSPN	RN	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
DM4LSPN	RU	https://pubmed.ncbi.nlm.nih.gov/31388135

DM4LSPN	DI	DM4LSPN
DM4LSPN	DN	Ibudilast
DM4LSPN	MI	TTV5CGO
DM4LSPN	MN	Phosphodiesterase 4 (PDE4)
DM4LSPN	MT	DTT
DM4LSPN	MA	Inhibitor
DM4LSPN	RN	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
DM4LSPN	RU	https://pubmed.ncbi.nlm.nih.gov/31388135

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEMEPVJ
DM8VCBE	MN	Acyl-CoA thioesterase 2 (ACOT2)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	A study on the chiral inversion of mandelic acid in humans. Org Biomol Chem. 2014 Sep 14;12(34):6737-44.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25050409

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEGKWJB
DM8VCBE	MN	Alpha-methylacyl-CoA racemase (AMACR)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009 Dec;17(6):275-342.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19949916

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTMWT8Z
DM8VCBE	MN	C-X-C chemokine receptor type 1 (CXCR1)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TT30C9G
DM8VCBE	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DES5XRU
DM8VCBE	MN	Cytochrome P450 2C8 (CYP2C8)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE5IED8
DM8VCBE	MN	Cytochrome P450 2C9 (CYP2C9)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE4LYSA
DM8VCBE	MN	Cytochrome P450 3A4 (CYP3A4)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTCTE1G
DM8VCBE	MN	Interleukin-8 (IL8)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/19560921

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEGTFWK
DM8VCBE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DTLT3UG
DM8VCBE	MN	Monocarboxylate transporter 2 (SLC16A7)
DM8VCBE	MT	DTP
DM8VCBE	MA	Substrate
DM8VCBE	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DM8VCBE	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DTHE530
DM8VCBE	MN	Probable small intestine urate exporter (SLC17A4)
DM8VCBE	MT	DTP
DM8VCBE	MA	Substrate
DM8VCBE	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM8VCBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	TTVKILB
DM8VCBE	MN	Prostaglandin G/H synthase 2 (COX-2)
DM8VCBE	MT	DTT
DM8VCBE	MA	Inhibitor
DM8VCBE	RN	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
DM8VCBE	RU	https://pubmed.ncbi.nlm.nih.gov/19379806

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEF2WXN
DM8VCBE	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DE85D2P
DM8VCBE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8VCBE	DI	DM8VCBE
DM8VCBE	DN	Ibuprofen
DM8VCBE	MI	DEB3CV1
DM8VCBE	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM8VCBE	MT	DME
DM8VCBE	MA	Metabolism
DM8VCBE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM8VCBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFJ8LT	DI	DMFJ8LT
DMFJ8LT	DN	Ibutamoren
DMFJ8LT	MI	TTWDC17
DMFJ8LT	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMFJ8LT	MT	DTT
DMFJ8LT	MA	Modulator
DMFJ8LT	RN	Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.
DMFJ8LT	RU	https://www.ncbi.nlm.nih.gov/pubmed/7624358

DMKXY2R	DI	DMKXY2R
DMKXY2R	DN	Ibutilide
DMKXY2R	MI	TT1VOHK
DMKXY2R	MN	Potassium channel unspecific (KC)
DMKXY2R	MT	DTT
DMKXY2R	MA	Modulator
DMKXY2R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKXY2R	RU	https://www.fda.gov/

DMQPTOZ	DI	DMQPTOZ
DMQPTOZ	DN	Icatibant
DMQPTOZ	MI	TTGY8IW
DMQPTOZ	MN	B2 bradykinin receptor (BDKRB2)
DMQPTOZ	MT	DTT
DMQPTOZ	MA	Antagonist
DMQPTOZ	RN	Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41.
DMQPTOZ	RU	https://pubmed.ncbi.nlm.nih.gov/19552510

DM648X9	DI	DM648X9
DM648X9	DN	Icodextrin
DM648X9	MI	DET64RG
DM648X9	MN	Pancreatic alpha-amylase (AMY2A)
DM648X9	MT	DME
DM648X9	MA	Metabolism
DM648X9	RN	Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int. 2009 Jul-Aug;29(4):377-83.
DM648X9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19602602

DMJHN0A	DI	DMJHN0A
DMJHN0A	DN	Icosapent
DMJHN0A	MI	TTK0943
DMJHN0A	MN	Prostaglandin G/H synthase (COX)
DMJHN0A	MT	DTT
DMJHN0A	MA	Binder
DMJHN0A	RN	Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86.
DMJHN0A	RU	https://pubmed.ncbi.nlm.nih.gov/12562875

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTI7UX6
DMM0XGL	MN	Breast cancer resistance protein (ABCG2)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
DMM0XGL	RU	https://doi.org/10.1038/leu.2008.87

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DE5IED8
DMM0XGL	MN	Cytochrome P450 2C9 (CYP2C9)
DMM0XGL	MT	DME
DMM0XGL	MA	Metabolism
DMM0XGL	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DMM0XGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DECB0K3
DMM0XGL	MN	Cytochrome P450 2D6 (CYP2D6)
DMM0XGL	MT	DME
DMM0XGL	MA	Metabolism
DMM0XGL	RN	In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
DMM0XGL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15204103

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	TT0IHXV
DMM0XGL	MN	DNA topoisomerase II (TOP2)
DMM0XGL	MT	DTT
DMM0XGL	MA	Modulator
DMM0XGL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM0XGL	RU	https://www.fda.gov/

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTSYQGK
DMM0XGL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMM0XGL	RU	https://doi.org/10.1007/s11095-012-0935-x

DMM0XGL	DI	DMM0XGL
DMM0XGL	DN	Idarubicin
DMM0XGL	MI	DTUGYRD
DMM0XGL	MN	P-glycoprotein 1 (ABCB1)
DMM0XGL	MT	DTP
DMM0XGL	MA	Substrate
DMM0XGL	RN	Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
DMM0XGL	RU	https://doi.org/10.1038/leu.2008.87

DMXEACF	DI	DMXEACF
DMXEACF	DN	Idarucizumab
DMXEACF	MI	TTFDXCO
DMXEACF	MN	Dabigatran (Dabi)
DMXEACF	MT	DTT
DMXEACF	MA	Binder
DMXEACF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2015
DMXEACF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf

DMQFDRC	DI	DMQFDRC
DMQFDRC	DN	Idebenone
DMQFDRC	MI	DEJGDUW
DMQFDRC	MN	Cytochrome P450 1A2 (CYP1A2)
DMQFDRC	MT	DME
DMQFDRC	MA	Metabolism
DMQFDRC	RN	Pharmacokinetic evaluation of idebenone. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1437-44.
DMQFDRC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20955109

DMP1QTS	DI	DMP1QTS
DMP1QTS	DN	Idecabtagene vicleucel
DMP1QTS	MI	TTZ3P4W
DMP1QTS	MN	B-cell maturation protein (TNFRSF17)
DMP1QTS	MT	DTT
DMP1QTS	MA	CAR-T-Cell-Therapy
DMP1QTS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMP1QTS	RU	https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	DTI7UX6
DM602WT	MN	Breast cancer resistance protein (ABCG2)
DM602WT	MT	DTP
DM602WT	MA	Substrate
DM602WT	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
DM602WT	RU	https://www.drugbank.ca/drugs/DB09054

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	DE4LYSA
DM602WT	MN	Cytochrome P450 3A4 (CYP3A4)
DM602WT	MT	DME
DM602WT	MA	Metabolism
DM602WT	RN	FDA label of Idelalisib. The 2020 official website of the U.S. Food and Drug Administration.
DM602WT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf

DM602WT	DI	DM602WT
DM602WT	DN	Idelalisib
DM602WT	MI	TTGBPJE
DM602WT	MN	PI3-kinase delta (PIK3CD)
DM602WT	MT	DTT
DM602WT	MA	Inhibitor
DM602WT	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM602WT	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMDRT0E	DI	DMDRT0E
DMDRT0E	DN	Idoxuridine
DMDRT0E	MI	TT4823K
DMDRT0E	MN	Virus Deoxyribonucleic acid (Viru DNA)
DMDRT0E	MT	DTT
DMDRT0E	MA	Binder
DMDRT0E	RN	Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7.
DMDRT0E	RU	https://pubmed.ncbi.nlm.nih.gov/10392098

DM30SXV	DI	DM30SXV
DM30SXV	DN	Idursulfase
DM30SXV	MI	TTNY2AP
DM30SXV	MN	Iduronate 2-sulfatase (IDS)
DM30SXV	MT	DTT
DM30SXV	MA	Modulator
DM30SXV	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DM30SXV	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEJVYAZ
DMCT3I8	MN	Cytochrome P450 2A6 (CYP2A6)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12136253

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEPKLMQ
DMCT3I8	MN	Cytochrome P450 2B6 (CYP2B6)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12571232

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEZMWRE
DMCT3I8	MN	Cytochrome P450 2C18 (CYP2C18)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DES5XRU
DMCT3I8	MN	Cytochrome P450 2C8 (CYP2C8)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE5IED8
DMCT3I8	MN	Cytochrome P450 2C9 (CYP2C9)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE4LYSA
DMCT3I8	MN	Cytochrome P450 3A4 (CYP3A4)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEIBDNY
DMCT3I8	MN	Cytochrome P450 3A5 (CYP3A5)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DERD86B
DMCT3I8	MN	Cytochrome P450 3A7 (CYP3A7)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	TTUTN1I
DMCT3I8	MN	Human Deoxyribonucleic acid (hDNA)
DMCT3I8	MT	DTT
DMCT3I8	MA	Modulator
DMCT3I8	RN	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15827549

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DEGTFWK
DMCT3I8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794

DMCT3I8	DI	DMCT3I8
DMCT3I8	DN	Ifosfamide
DMCT3I8	MI	DE073H6
DMCT3I8	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCT3I8	MT	DME
DMCT3I8	MA	Metabolism
DMCT3I8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCT3I8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	TTJQOD7
DM6AUFY	MN	5-HT 2A receptor (HTR2A)
DM6AUFY	MT	DTT
DM6AUFY	MA	Antagonist
DM6AUFY	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6AUFY	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DECB0K3
DM6AUFY	MN	Cytochrome P450 2D6 (CYP2D6)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DE4LYSA
DM6AUFY	MN	Cytochrome P450 3A4 (CYP3A4)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis. Acta Pharmacol Sin. 2016 Nov;37(11):1499-1508.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27665849

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DEIBDNY
DM6AUFY	MN	Cytochrome P450 3A5 (CYP3A5)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	DERD86B
DM6AUFY	MN	Cytochrome P450 3A7 (CYP3A7)
DM6AUFY	MT	DME
DM6AUFY	MA	Metabolism
DM6AUFY	RN	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
DM6AUFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732390

DM6AUFY	DI	DM6AUFY
DM6AUFY	DN	Iloperidone
DM6AUFY	MI	TTEX248
DM6AUFY	MN	Dopamine D2 receptor (D2R)
DM6AUFY	MT	DTT
DM6AUFY	MA	Antagonist
DM6AUFY	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6AUFY	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	DT021JD
DMVPZBE	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMVPZBE	MT	DTP
DMVPZBE	MA	Substrate
DMVPZBE	RN	Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
DMVPZBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/8787677

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	DTVNRXW
DMVPZBE	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMVPZBE	MT	DTP
DMVPZBE	MA	Substrate
DMVPZBE	RN	Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
DMVPZBE	RU	http://www.ncbi.nlm.nih.gov/pubmed/14631946

DMVPZBE	DI	DMVPZBE
DMVPZBE	DN	Iloprost
DMVPZBE	MI	TT1ZAVI
DMVPZBE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMVPZBE	MT	DTT
DMVPZBE	MA	Agonist
DMVPZBE	RN	Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
DMVPZBE	RU	https://pubmed.ncbi.nlm.nih.gov/17408863

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTI7UX6
DM7RJXL	MN	Breast cancer resistance protein (ABCG2)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15251980

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DEJGDUW
DM7RJXL	MN	Cytochrome P450 1A2 (CYP1A2)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24369535

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DES5XRU
DM7RJXL	MN	Cytochrome P450 2C8 (CYP2C8)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE5IED8
DM7RJXL	MN	Cytochrome P450 2C9 (CYP2C9)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27749579

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DECB0K3
DM7RJXL	MN	Cytochrome P450 2D6 (CYP2D6)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE4LYSA
DM7RJXL	MN	Cytochrome P450 3A4 (CYP3A4)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22014153

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DEIBDNY
DM7RJXL	MN	Cytochrome P450 3A5 (CYP3A5)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16122278

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DERD86B
DM7RJXL	MN	Cytochrome P450 3A7 (CYP3A7)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Drug Interactions Flockhart Table
DM7RJXL	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTS7G69
DM7RJXL	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTN6ORK
DM7RJXL	MN	Mcl-1 messenger RNA (MCL-1 mRNA)
DM7RJXL	MT	DTT
DM7RJXL	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM7RJXL	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTE2B1D
DM7RJXL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21508937

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DT3D8F0
DM7RJXL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DT9C1TS
DM7RJXL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTT79CX
DM7RJXL	MN	Organic cation transporter 1 (SLC22A1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/18398725

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DTUGYRD
DM7RJXL	MN	P-glycoprotein 1 (ABCB1)
DM7RJXL	MT	DTP
DM7RJXL	MA	Substrate
DM7RJXL	RN	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
DM7RJXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21311410

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTI2WET
DM7RJXL	MN	Platelet-derived growth factor receptor (PDGFR)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	DE073H6
DM7RJXL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM7RJXL	MT	DME
DM7RJXL	MA	Metabolism
DM7RJXL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM7RJXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7RJXL	DI	DM7RJXL
DM7RJXL	DN	Imatinib
DM7RJXL	MI	TTX41N9
DM7RJXL	MN	Tyrosine-protein kinase Kit (KIT)
DM7RJXL	MT	DTT
DM7RJXL	MA	Inhibitor
DM7RJXL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM7RJXL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMUL7T1	DI	DMUL7T1
DMUL7T1	DN	Imidapril
DMUL7T1	MI	TTL69WB
DMUL7T1	MN	Angiotensin-converting enzyme (ACE)
DMUL7T1	MT	DTT
DMUL7T1	MA	Modulator
DMUL7T1	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUL7T1	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM3VS7Z	DI	DM3VS7Z
DM3VS7Z	DN	Imidazole salicylate
DM3VS7Z	MI	TTTEJMY
DM3VS7Z	MN	Tromboxane A2 synthesis (TA2 synth)
DM3VS7Z	MT	DTT
DM3VS7Z	MA	Modulator
DM3VS7Z	RN	Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4.
DM3VS7Z	RU	https://pubmed.ncbi.nlm.nih.gov/8566739

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DERI7LO
DMI9FBP	MN	AmpC beta-lactamase (ampC)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30012762

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	TTHWB7G
DMI9FBP	MN	Bacterial Penicillin binding protein 2 (Bact mrdA)
DMI9FBP	MT	DTT
DMI9FBP	MA	Binder
DMI9FBP	RN	A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/11061029

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEC3G7M
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE7IH52
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEYIEO5
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEBKS91
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30592758

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEUHIQS
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	AmpC beta-lactamase-producing Enterobacterales: what a clinician should know. Infection. 2019 Jun;47(3):363-375.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30840201

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DECWSA9
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/27236395

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DECB2MX
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Whole-genome sequence of Chryseobacterium oranimense, a colistin-resistant bacterium isolated from a cystic fibrosis patient in France. Antimicrob Agents Chemother. 2015 Mar;59(3):1696-706.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/25583710

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEEQ3RW
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEQ0K5J
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE7MYGB
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Antibiotic therapy for inducible AmpC beta-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents. 2012 Oct;40(4):297-305.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/22824371

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEL6894
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Hospital sewage water: a reservoir for variants of New Delhi metallo-beta-lactamase (NDM)- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Int J Antimicrob Agents. 2018 Jan;51(1):82-88.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28887202

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE8KH4C
DMI9FBP	MN	Beta-lactamase (blaB)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Carbapenemase VCC-1-producing Vibrio cholerae in coastal waters of Germany. Emerg Infect Dis. 2017 Oct;23(10):1735-1737.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/28930017

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEB90AL
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/30289383

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DETRKSD
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans. Sci Rep. 2018 May 25;8(1):8181.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/29802257

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DEQ4LIN
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett. 2001 Jan 1;194(1):53-7.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/11150665

DMI9FBP	DI	DMI9FBP
DMI9FBP	DN	Imipenem
DMI9FBP	MI	DE9QNXV
DMI9FBP	MN	Carbapenemase (cphA)
DMI9FBP	MT	DME
DMI9FBP	MA	Metabolism
DMI9FBP	RN	Pseudocitrobacter gen. nov., a novel genus of the Enterobacteriaceae with two new species Pseudocitrobacter faecalis sp. nov., and Pseudocitrobacter anthropi sp. nov, isolated from fecal samples from hospitalized patients in Pakistan. Syst Appl Microbiol. 2014 Feb;37(1):17-22.
DMI9FBP	RU	https://pubmed.ncbi.nlm.nih.gov/24182752

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEJGDUW
DM2NUH3	MN	Cytochrome P450 1A2 (CYP1A2)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEPKLMQ
DM2NUH3	MN	Cytochrome P450 2B6 (CYP2B6)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEZMWRE
DM2NUH3	MN	Cytochrome P450 2C18 (CYP2C18)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9190854

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DECB0K3
DM2NUH3	MN	Cytochrome P450 2D6 (CYP2D6)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother. 2005 Mar;39(3):543-6.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15687478

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DE4LYSA
DM2NUH3	MN	Cytochrome P450 3A4 (CYP3A4)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DERD86B
DM2NUH3	MN	Cytochrome P450 3A7 (CYP3A7)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos. 1999 Nov;27(11):1306-8.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534316

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEIZLTN
DM2NUH3	MN	Docosahexaenoic acid omega-hydroxylase (CYP4F11)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
DM2NUH3	RU	https://pubmed.ncbi.nlm.nih.gov/15364545

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEGTFWK
DM2NUH3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12228186

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	TTAWNKZ
DM2NUH3	MN	Norepinephrine transporter (NET)
DM2NUH3	MT	DTT
DM2NUH3	MA	Inhibitor
DM2NUH3	RN	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
DM2NUH3	RU	https://pubmed.ncbi.nlm.nih.gov/19059298

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DTUGYRD
DM2NUH3	MN	P-glycoprotein 1 (ABCB1)
DM2NUH3	MT	DTP
DM2NUH3	MA	Substrate
DM2NUH3	RN	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
DM2NUH3	RU	http://www.ncbi.nlm.nih.gov/pubmed/12954186

DM2NUH3	DI	DM2NUH3
DM2NUH3	DN	Imipramine
DM2NUH3	MI	DEYGVN4
DM2NUH3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM2NUH3	MT	DME
DM2NUH3	MA	Metabolism
DM2NUH3	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DM2NUH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	DEJGDUW
DM1TMA3	MN	Cytochrome P450 1A2 (CYP1A2)
DM1TMA3	MT	DME
DM1TMA3	MA	Metabolism
DM1TMA3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1TMA3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	DE4LYSA
DM1TMA3	MN	Cytochrome P450 3A4 (CYP3A4)
DM1TMA3	MT	DME
DM1TMA3	MA	Metabolism
DM1TMA3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1TMA3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1TMA3	DI	DM1TMA3
DM1TMA3	DN	Imiquimod
DM1TMA3	MI	TTRJ1K4
DM1TMA3	MN	Toll-like receptor 7 (TLR7)
DM1TMA3	MT	DTT
DM1TMA3	MA	Agonist
DM1TMA3	RN	Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
DM1TMA3	RU	https://pubmed.ncbi.nlm.nih.gov/19516264

DMRMFP4	DI	DMRMFP4
DMRMFP4	DN	Inamrinone Lactate
DMRMFP4	MI	TTZCG4L
DMRMFP4	MN	Phosphodiesterase 3 (PDE3)
DMRMFP4	MT	DTT
DMRMFP4	MA	Inhibitor
DMRMFP4	RN	Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
DMRMFP4	RU	https://pubmed.ncbi.nlm.nih.gov/12076859

DM3DSVJ	DI	DM3DSVJ
DM3DSVJ	DN	Incadronate
DM3DSVJ	MI	TTIKWV4
DM3DSVJ	MN	Geranyltranstransferase (FDPS)
DM3DSVJ	MT	DTT
DM3DSVJ	MA	Inhibitor
DM3DSVJ	RN	Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
DM3DSVJ	RU	https://pubmed.ncbi.nlm.nih.gov/11160603

DMKE6YT	DI	DMKE6YT
DMKE6YT	DN	Incobotulinum toxin A
DMKE6YT	MI	TTZJD1B
DMKE6YT	MN	Acetylcholine release (Ach rele)
DMKE6YT	MT	DTT
DMKE6YT	MA	Modulator
DMKE6YT	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMKE6YT	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM32GSJ	DI	DM32GSJ
DM32GSJ	DN	Incruse ellipta
DM32GSJ	MI	DECB0K3
DM32GSJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM32GSJ	MT	DME
DM32GSJ	MA	Metabolism
DM32GSJ	RN	The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013 Dec;7(6):311-9.
DM32GSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24004659

DM32GSJ	DI	DM32GSJ
DM32GSJ	DN	Incruse ellipta
DM32GSJ	MI	TTOXS3C
DM32GSJ	MN	Muscarinic acetylcholine receptor (CHRM)
DM32GSJ	MT	DTT
DM32GSJ	MA	Antagonist
DM32GSJ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM32GSJ	RU	http://www.gsk.ca/english/html/media-centre/2014-04-17.html

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	TT2CJVK
DMQJHR7	MN	Adrenergic receptor beta-2 (ADRB2)
DMQJHR7	MT	DTT
DMQJHR7	MA	Agonist
DMQJHR7	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMQJHR7	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DE4LYSA
DMQJHR7	MN	Cytochrome P450 3A4 (CYP3A4)
DMQJHR7	MT	DME
DMQJHR7	MA	Metabolism
DMQJHR7	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DMQJHR7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DTT79CX
DMQJHR7	MN	Organic cation transporter 1 (SLC22A1)
DMQJHR7	MT	DTP
DMQJHR7	MA	Substrate
DMQJHR7	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMQJHR7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DTUGYRD
DMQJHR7	MN	P-glycoprotein 1 (ABCB1)
DMQJHR7	MT	DTP
DMQJHR7	MA	Substrate
DMQJHR7	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMQJHR7	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMQJHR7	DI	DMQJHR7
DMQJHR7	DN	Indacaterol
DMQJHR7	MI	DEYGVN4
DMQJHR7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQJHR7	MT	DME
DMQJHR7	MA	Metabolism
DMQJHR7	RN	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37.
DMQJHR7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24295085

DMGN1PW	DI	DMGN1PW
DMGN1PW	DN	Indapamide
DMGN1PW	MI	DE4LYSA
DMGN1PW	MN	Cytochrome P450 3A4 (CYP3A4)
DMGN1PW	MT	DME
DMGN1PW	MA	Metabolism
DMGN1PW	RN	Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84.
DMGN1PW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19074530

DMGN1PW	DI	DMGN1PW
DMGN1PW	DN	Indapamide
DMGN1PW	MI	TT846HF
DMGN1PW	MN	Voltage-gated potassium channel Kv7.1 (KCNQ1)
DMGN1PW	MT	DTT
DMGN1PW	MA	Blocker
DMGN1PW	RN	Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84.
DMGN1PW	RU	https://pubmed.ncbi.nlm.nih.gov/16556441

DMUV8OR	DI	DMUV8OR
DMUV8OR	DN	Indecainide
DMUV8OR	MI	TTZOVE0
DMUV8OR	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMUV8OR	MT	DTT
DMUV8OR	MA	Blocker
DMUV8OR	RN	Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21.
DMUV8OR	RU	https://pubmed.ncbi.nlm.nih.gov/6206315

DMWO3N6	DI	DMWO3N6
DMWO3N6	DN	Indeloxazine
DMWO3N6	MI	TTGP7BY
DMWO3N6	MN	Monoamine oxidase type B (MAO-B)
DMWO3N6	MT	DTT
DMWO3N6	MA	Modulator
DMWO3N6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMWO3N6	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DECB0K3
DM0T3YH	MN	Cytochrome P450 2D6 (CYP2D6)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DE4LYSA
DM0T3YH	MN	Cytochrome P450 3A4 (CYP3A4)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DEIBDNY
DM0T3YH	MN	Cytochrome P450 3A5 (CYP3A5)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DERD86B
DM0T3YH	MN	Cytochrome P450 3A7 (CYP3A7)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	TT5FNQT
DM0T3YH	MN	Human immunodeficiency virus Protease (HIV PR)
DM0T3YH	MT	DTT
DM0T3YH	MA	Inhibitor
DM0T3YH	RN	Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80.
DM0T3YH	RU	https://pubmed.ncbi.nlm.nih.gov/19168402

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTSYQGK
DM0T3YH	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0T3YH	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTFI42L
DM0T3YH	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
DM0T3YH	RU	http://www.ncbi.nlm.nih.gov/pubmed/20238377

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DTUGYRD
DM0T3YH	MN	P-glycoprotein 1 (ABCB1)
DM0T3YH	MT	DTP
DM0T3YH	MA	Substrate
DM0T3YH	RN	HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 1998 Mar 17;37(11):3594-601.
DM0T3YH	RU	http://www.ncbi.nlm.nih.gov/pubmed/9530286

DM0T3YH	DI	DM0T3YH
DM0T3YH	DN	Indinavir
DM0T3YH	MI	DEYGVN4
DM0T3YH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0T3YH	MT	DME
DM0T3YH	MA	Metabolism
DM0T3YH	RN	Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R738-43.
DM0T3YH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19571206

DMOPGHQ	DI	DMOPGHQ
DMOPGHQ	DN	Indiplon
DMOPGHQ	MI	TT1MPAY
DMOPGHQ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMOPGHQ	MT	DTT
DMOPGHQ	MA	Agonist
DMOPGHQ	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMOPGHQ	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DM2NQUY	DI	DM2NQUY
DM2NQUY	DN	Indocyanine green
DM2NQUY	MI	DT9C1TS
DM2NQUY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2NQUY	MT	DTP
DM2NQUY	MA	Substrate
DM2NQUY	RN	Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.
DM2NQUY	RU	https://doi.org/10.1016/j.jhep.2012.01.031

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DE5IED8
DMSC4A7	MN	Cytochrome P450 2C9 (CYP2C9)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEGTFWK
DMSC4A7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DTUGYRD
DMSC4A7	MN	P-glycoprotein 1 (ABCB1)
DMSC4A7	MT	DTP
DMSC4A7	MA	Substrate
DMSC4A7	RN	Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Br J Cancer. 2007 Oct 22;97(8):1077-83.
DMSC4A7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17940500

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	TTVKILB
DMSC4A7	MN	Prostaglandin G/H synthase 2 (COX-2)
DMSC4A7	MT	DTT
DMSC4A7	MA	Modulator
DMSC4A7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSC4A7	RU	https://www.fda.gov/

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEYGVN4
DMSC4A7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DE85D2P
DMSC4A7	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMSC4A7	DI	DMSC4A7
DMSC4A7	DN	Indomethacin
DMSC4A7	MI	DEB3CV1
DMSC4A7	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMSC4A7	MT	DME
DMSC4A7	MA	Metabolism
DMSC4A7	RN	Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol. 2007 Mar;63(3):289-96.
DMSC4A7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17245571

DMI0RHA	DI	DMI0RHA
DMI0RHA	DN	Inebilizumab
DMI0RHA	MI	TTW640A
DMI0RHA	MN	B-lymphocyte surface antigen B4 (CD19)
DMI0RHA	MT	DTT
DMI0RHA	MA	Inhibitor
DMI0RHA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMI0RHA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf

DMH7OIA	DI	DMH7OIA
DMH7OIA	DN	Infliximab
DMH7OIA	MI	TTF8CQI
DMH7OIA	MN	Tumor necrosis factor (TNF)
DMH7OIA	MT	DTT
DMH7OIA	RN	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
DMH7OIA	RU	https://pubmed.ncbi.nlm.nih.gov/18414459

DMK1CZJ	DI	DMK1CZJ
DMK1CZJ	DN	Ingenol mebutate
DMK1CZJ	MI	DTUGYRD
DMK1CZJ	MN	P-glycoprotein 1 (ABCB1)
DMK1CZJ	MT	DTP
DMK1CZJ	MA	Substrate
DMK1CZJ	RN	The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010 Jun 1;70(11):4509-19.
DMK1CZJ	RU	https://doi.org/10.1158/0008-5472.CAN-09-4303

DMJ93CT	DI	DMJ93CT
DMJ93CT	DN	Inotersen
DMJ93CT	MI	TTC1I86
DMJ93CT	MN	Transthyretin (TTR)
DMJ93CT	MT	DTT
DMJ93CT	MA	Antisense 
DMJ93CT	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMJ93CT	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMAC130	DI	DMAC130
DMAC130	DN	Inotuzumab ozogamicin
DMAC130	MI	TTM6QSK
DMAC130	MN	B-cell receptor CD22 (CD22)
DMAC130	MT	DTT
DMAC130	RN	Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
DMAC130	RU	https://pubmed.ncbi.nlm.nih.gov/23633004

DMB7CE0	DI	DMB7CE0
DMB7CE0	DN	Insulin
DMB7CE0	MI	DE9OSW8
DMB7CE0	MN	Insulin-degrading enzyme (IDE)
DMB7CE0	MT	DME
DMB7CE0	MA	Metabolism
DMB7CE0	RN	Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 2005 May 3;44(17):6513-25.
DMB7CE0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15850385

DMB7CE0	DI	DMB7CE0
DMB7CE0	DN	Insulin
DMB7CE0	MI	DE0QGHP
DMB7CE0	MN	Insulin-degrading enzyme (ide)
DMB7CE0	MT	DME
DMB7CE0	MA	Metabolism
DMB7CE0	RN	Vibrio vulnificus secretes an insulin-degrading enzyme that promotes bacterial proliferation in vivo. J Biol Chem. 2015 Jul 24;290(30):18708-20.
DMB7CE0	RU	https://pubmed.ncbi.nlm.nih.gov/26041774

DMPL395	DI	DMPL395
DMPL395	DN	Insulin degludec
DMPL395	MI	TTZOPHG
DMPL395	MN	Insulin (INS)
DMPL395	MT	DTT
DMPL395	MA	Modulator
DMPL395	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMPL395	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM79NZ5	DI	DM79NZ5
DM79NZ5	DN	Insulin determir
DM79NZ5	MI	TTZOPHG
DM79NZ5	MN	Insulin (INS)
DM79NZ5	MT	DTT
DM79NZ5	MA	Modulator
DM79NZ5	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DM79NZ5	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM5XHVR	DI	DM5XHVR
DM5XHVR	DN	Insulin Lyspro recombinant
DM5XHVR	MI	TTCBFJO
DM5XHVR	MN	Insulin receptor (INSR)
DM5XHVR	MT	DTT
DM5XHVR	MA	Binder
DM5XHVR	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM5XHVR	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMYVP5G	DI	DMYVP5G
DMYVP5G	DN	Insulin recombinant
DMYVP5G	MI	TTCBFJO
DMYVP5G	MN	Insulin receptor (INSR)
DMYVP5G	MT	DTT
DMYVP5G	MA	Binder
DMYVP5G	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMYVP5G	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DMW8KI7	DI	DMW8KI7
DMW8KI7	DN	Insulin Susp Isophane Recombinant Human
DMW8KI7	MI	TTZOPHG
DMW8KI7	MN	Insulin (INS)
DMW8KI7	MT	DTT
DMW8KI7	MA	Modulator
DMW8KI7	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW8KI7	RU	https://www.fda.gov/

DM0NATE	DI	DM0NATE
DM0NATE	DN	Insulin Susp Protamine Zinc Beef/Pork
DM0NATE	MI	TTZOPHG
DM0NATE	MN	Insulin (INS)
DM0NATE	MT	DTT
DM0NATE	MA	Modulator
DM0NATE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0NATE	RU	https://www.fda.gov/

DM6MO9X	DI	DM6MO9X
DM6MO9X	DN	Insulin Zinc Susp Recombinant Human
DM6MO9X	MI	TTZOPHG
DM6MO9X	MN	Insulin (INS)
DM6MO9X	MT	DTT
DM6MO9X	MA	Modulator
DM6MO9X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6MO9X	RU	https://www.fda.gov/

DMO95XI	DI	DMO95XI
DMO95XI	DN	Insulin, porcine
DMO95XI	MI	TTCBFJO
DMO95XI	MN	Insulin receptor (INSR)
DMO95XI	MT	DTT
DMO95XI	MA	Binder
DMO95XI	RN	Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
DMO95XI	RU	https://pubmed.ncbi.nlm.nih.gov/12038982

DMX7V28	DI	DMX7V28
DMX7V28	DN	Insulin-aspart
DMX7V28	MI	TTZOPHG
DMX7V28	MN	Insulin (INS)
DMX7V28	MT	DTT
DMX7V28	MA	Modulator
DMX7V28	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMX7V28	RU	https://www.fda.gov/

DMOA4VW	DI	DMOA4VW
DMOA4VW	DN	Insulin-detemir
DMOA4VW	MI	TTZOPHG
DMOA4VW	MN	Insulin (INS)
DMOA4VW	MT	DTT
DMOA4VW	MA	Modulator
DMOA4VW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOA4VW	RU	https://www.fda.gov/

DMR4HIW	DI	DMR4HIW
DMR4HIW	DN	Insulin-glargine
DMR4HIW	MI	TTZOPHG
DMR4HIW	MN	Insulin (INS)
DMR4HIW	MT	DTT
DMR4HIW	MA	Modulator
DMR4HIW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMR4HIW	RU	https://www.fda.gov/

DMQI0FU	DI	DMQI0FU
DMQI0FU	DN	Insulin-glulisine
DMQI0FU	MI	TTCBFJO
DMQI0FU	MN	Insulin receptor (INSR)
DMQI0FU	MT	DTT
DMQI0FU	MA	Binder
DMQI0FU	RN	Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. 
DMQI0FU	RU	https://pubmed.ncbi.nlm.nih.gov/19496630

DM4O90W	DI	DM4O90W
DM4O90W	DN	Insulin-lispro
DM4O90W	MI	TTCBFJO
DM4O90W	MN	Insulin receptor (INSR)
DM4O90W	MT	DTT
DM4O90W	MA	Binder
DM4O90W	RN	Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
DM4O90W	RU	https://pubmed.ncbi.nlm.nih.gov/10601956

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTRLW2X
DMSTA36	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTGJCWZ
DMSTA36	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMSTA36	MT	DTT
DMSTA36	MA	Inhibitor
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	DTUGYRD
DMSTA36	MN	P-glycoprotein 1 (ABCB1)
DMSTA36	MT	DTP
DMSTA36	MA	Substrate
DMSTA36	RN	Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541.
DMSTA36	RU	http://www.ncbi.nlm.nih.gov/pubmed/29500603

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTI2WET
DMSTA36	MN	Platelet-derived growth factor receptor (PDGFR)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSTA36	DI	DMSTA36
DMSTA36	DN	Intedanib
DMSTA36	MI	TTVJ1D8
DMSTA36	MN	Vascular endothelial growth factor receptor (VEGFR)
DMSTA36	MT	DTT
DMSTA36	MA	Modulator
DMSTA36	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMSTA36	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMUTZ8S	DI	DMUTZ8S
DMUTZ8S	DN	Interferon Alfa-2a, Recombinant
DMUTZ8S	MI	TTGJVQM
DMUTZ8S	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMUTZ8S	MT	DTT
DMUTZ8S	MA	Binder
DMUTZ8S	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMUTZ8S	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMWCQP4	DI	DMWCQP4
DMWCQP4	DN	Interferon alfa-2B
DMWCQP4	MI	TTSIUJ9
DMWCQP4	MN	Interferon-alpha 2 (IFNA2)
DMWCQP4	MT	DTT
DMWCQP4	MA	Modulator
DMWCQP4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWCQP4	RU	https://www.fda.gov/

DM3TPY8	DI	DM3TPY8
DM3TPY8	DN	Interferon Alfa-2b, Recombinant
DM3TPY8	MI	TTMQB37
DM3TPY8	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM3TPY8	MT	DTT
DM3TPY8	MA	Binder
DM3TPY8	RN	Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3.
DM3TPY8	RU	https://pubmed.ncbi.nlm.nih.gov/19362369

DM90WJH	DI	DM90WJH
DM90WJH	DN	Interferon alfacon-1
DM90WJH	MI	TTMQB37
DM90WJH	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM90WJH	MT	DTT
DM90WJH	MA	Binder
DM90WJH	RN	Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46.
DM90WJH	RU	https://pubmed.ncbi.nlm.nih.gov/19291790

DM4AK0Q	DI	DM4AK0Q
DM4AK0Q	DN	Interferon alfa-n1
DM4AK0Q	MI	TTMQB37
DM4AK0Q	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM4AK0Q	MT	DTT
DM4AK0Q	MA	Binder
DM4AK0Q	RN	Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7.
DM4AK0Q	RU	https://pubmed.ncbi.nlm.nih.gov/9537453

DMTZNQ9	DI	DMTZNQ9
DMTZNQ9	DN	Interferon alfa-n3
DMTZNQ9	MI	TT95SOA
DMTZNQ9	MN	Interferon alpha (IFNA)
DMTZNQ9	MT	DTT
DMTZNQ9	MA	Modulator
DMTZNQ9	RN	Clinical pipeline report, company report or official report of Hemispherx Biopharma.
DMTZNQ9	RU	http://www.hemispherx.net/content/rnd/

DM1A6RV	DI	DM1A6RV
DM1A6RV	DN	Interferon beta-1a
DM1A6RV	MI	TT4TZ8J
DM1A6RV	MN	Interferon-beta (IFNB1)
DM1A6RV	MT	DTT
DM1A6RV	MA	Modulator
DM1A6RV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1A6RV	RU	https://www.fda.gov/

DMCN61Z	DI	DMCN61Z
DMCN61Z	DN	Interferon beta-1b
DMCN61Z	MI	TTMQB37
DMCN61Z	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DMCN61Z	MT	DTT
DMCN61Z	MA	Binder
DMCN61Z	RN	Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170.
DMCN61Z	RU	https://pubmed.ncbi.nlm.nih.gov/19590215

DMWUMRL	DI	DMWUMRL
DMWUMRL	DN	Interferon gamma-1b
DMWUMRL	MI	TT13TL0
DMWUMRL	MN	Interferon gamma receptor (IFNGR2)
DMWUMRL	MT	DTT
DMWUMRL	MA	Binder
DMWUMRL	RN	Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9.
DMWUMRL	RU	https://pubmed.ncbi.nlm.nih.gov/17251453

DM1Y69Q	DI	DM1Y69Q
DM1Y69Q	DN	Interleukin-3
DM1Y69Q	MI	TT5TQ2W
DM1Y69Q	MN	Granulocyte colony-stimulating factor (CSF3)
DM1Y69Q	MT	DTT
DM1Y69Q	MA	Modulator
DM1Y69Q	RN	Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30.
DM1Y69Q	RU	https://pubmed.ncbi.nlm.nih.gov/1618595

DMS6ZI0	DI	DMS6ZI0
DMS6ZI0	DN	Inulin
DMS6ZI0	MI	DE4EX78
DMS6ZI0	MN	Beta-fructofuranosidase (BFRU)
DMS6ZI0	MT	DME
DMS6ZI0	MA	Metabolism
DMS6ZI0	RN	Substrate-driven gene expression in Roseburia inulinivorans: importance of inducible enzymes in the utilization of inulin and starch. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4672-9.
DMS6ZI0	RU	https://pubmed.ncbi.nlm.nih.gov/20679207

DM1Y2JH	DI	DM1Y2JH
DM1Y2JH	DN	Inulin
DM1Y2JH	MI	TTZOPHG
DM1Y2JH	MN	Insulin (INS)
DM1Y2JH	MT	DTT
DM1Y2JH	MA	Modulator
DM1Y2JH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1Y2JH	RU	https://www.fda.gov/

DM80OEZ	DI	DM80OEZ
DM80OEZ	DN	Iobenguane I-123
DM80OEZ	MI	TTAWNKZ
DM80OEZ	MN	Norepinephrine transporter (NET)
DM80OEZ	MT	DTT
DM80OEZ	MA	Inhibitor
DM80OEZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DM80OEZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DMXIQYS	DI	DMXIQYS
DMXIQYS	DN	Iodipamide
DMXIQYS	MI	TTFNGC9
DMXIQYS	MN	Serum albumin (ALB)
DMXIQYS	MT	DTT
DMXIQYS	MA	Binder
DMXIQYS	RN	Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
DMXIQYS	RU	https://pubmed.ncbi.nlm.nih.gov/18436441

DMNARJT	DI	DMNARJT
DMNARJT	DN	Ioflupane I-123
DMNARJT	MI	TTVBI8W
DMNARJT	MN	Dopamine transporter (DAT)
DMNARJT	MT	DTT
DMNARJT	MA	Modulator
DMNARJT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMNARJT	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMLZTP9	DI	DMLZTP9
DMLZTP9	DN	Ipecac
DMLZTP9	MI	DECB0K3
DMLZTP9	MN	Cytochrome P450 2D6 (CYP2D6)
DMLZTP9	MT	DME
DMLZTP9	MA	Metabolism
DMLZTP9	RN	Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. doi: 10.1002/9781118105955.ch13
DMLZTP9	RU	https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118105955.ch13

DMWA24P	DI	DMWA24P
DMWA24P	DN	IPI-145
DMWA24P	MI	TTGBPJE
DMWA24P	MN	PI3-kinase delta (PIK3CD)
DMWA24P	MT	DTT
DMWA24P	MA	Modulator
DMWA24P	RN	PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
DMWA24P	RU	https://pubmed.ncbi.nlm.nih.gov/24211136

DMWA24P	DI	DMWA24P
DMWA24P	DN	IPI-145
DMWA24P	MI	TTHBTOP
DMWA24P	MN	PI3-kinase gamma (PIK3CG)
DMWA24P	MT	DTT
DMWA24P	MA	Modulator
DMWA24P	RN	PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
DMWA24P	RU	https://pubmed.ncbi.nlm.nih.gov/24211136

DMJTIYK	DI	DMJTIYK
DMJTIYK	DN	Ipilimumab
DMJTIYK	MI	TTI2S1D
DMJTIYK	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJTIYK	MT	DTT
DMJTIYK	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMJTIYK	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	TTQ13Z5
DMFQ320	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMFQ320	MT	DTT
DMFQ320	MA	Modulator
DMFQ320	RN	Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
DMFQ320	RU	https://www.ncbi.nlm.nih.gov/pubmed/22767057

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DTT79CX
DMFQ320	MN	Organic cation transporter 1 (SLC22A1)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DT2EG60
DMFQ320	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DMFQ320	DI	DMFQ320
DMFQ320	DN	Ipratropium
DMFQ320	MI	DT3HUVD
DMFQ320	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMFQ320	MT	DTP
DMFQ320	MA	Substrate
DMFQ320	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFQ320	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DE6OQ3W
DM0IO13	MN	Cytochrome P450 1A1 (CYP1A1)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol. 2006 Apr;58(4):449-57.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16597362

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DEJGDUW
DM0IO13	MN	Cytochrome P450 1A2 (CYP1A2)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes. Xenobiotica. 2007 Mar;37(3):246-59.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17624023

DM0IO13	DI	DM0IO13
DM0IO13	DN	Ipriflavone
DM0IO13	MI	DE4LYSA
DM0IO13	MN	Cytochrome P450 3A4 (CYP3A4)
DM0IO13	MT	DME
DM0IO13	MA	Metabolism
DM0IO13	RN	Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet. Am J Ther. 1997 Jul-Aug;4(7-8):229-38.
DM0IO13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10423615

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	TT8DBY3
DMTP1DC	MN	Angiotensin II receptor type-1 (AGTR1)
DMTP1DC	MT	DTT
DMTP1DC	MA	Antagonist
DMTP1DC	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DMTP1DC	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DES5XRU
DMTP1DC	MN	Cytochrome P450 2C8 (CYP2C8)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE5IED8
DMTP1DC	MN	Cytochrome P450 2C9 (CYP2C9)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol. 2003 Jun;9(6):1342-6.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12800253

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE4LYSA
DMTP1DC	MN	Cytochrome P450 3A4 (CYP3A4)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Drug interactions with irbesartan. Clin Pharmacokinet. 2001;40(8):605-14.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11523726

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DT9G7XN
DMTP1DC	MN	Peptide transporter 1 (SLC15A1)
DMTP1DC	MT	DTP
DMTP1DC	MA	Substrate
DMTP1DC	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMTP1DC	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DE073H6
DMTP1DC	MN	Prostaglandin G/H synthase 1 (COX-1)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMTP1DC	DI	DMTP1DC
DMTP1DC	DN	Irbesartan
DMTP1DC	MI	DEF2WXN
DMTP1DC	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMTP1DC	MT	DME
DMTP1DC	MA	Metabolism
DMTP1DC	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMTP1DC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DE9RA0I
DMP6SC2	MN	Beta-glucuronidase (uidA)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
DMP6SC2	RU	https://pubmed.ncbi.nlm.nih.gov/8706020

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTI7UX6
DMP6SC2	MN	Breast cancer resistance protein (ABCG2)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16404634

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEB30C5
DMP6SC2	MN	Carboxylesterase 1 (CES1)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19852077

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DETHCPD
DMP6SC2	MN	Carboxylesterase 2 (CES2)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15100172

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEMI4VE
DMP6SC2	MN	Carboxylesterase 3 (CES3)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15100172

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEPKLMQ
DMP6SC2	MN	Cytochrome P450 2B6 (CYP2B6)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Drugs that may have potential CYP2B6 interactions.
DMP6SC2	RU	https://drug-interactions.medicine.iu.edu/MainTable.aspx

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DE4LYSA
DMP6SC2	MN	Cytochrome P450 3A4 (CYP3A4)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19852077

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DEIBDNY
DMP6SC2	MN	Cytochrome P450 3A5 (CYP3A5)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
DMP6SC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16271446

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DERD86B
DMP6SC2	MN	Cytochrome P450 3A7 (CYP3A7)
DMP6SC2	MT	DME
DMP6SC2	MA	Metabolism
DMP6SC2	RN	Drug Interactions Flockhart Table
DMP6SC2	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	TTGTQHC
DMP6SC2	MN	DNA topoisomerase I (TOP1)
DMP6SC2	MT	DTT
DMP6SC2	MA	Modulator
DMP6SC2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMP6SC2	RU	https://www.fda.gov/

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTSYQGK
DMP6SC2	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
DMP6SC2	RU	http://molpharm.aspetjournals.org/content/55/5/921

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTFI42L
DMP6SC2	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065434

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTCSGPB
DMP6SC2	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/20583968

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTYVM24
DMP6SC2	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18690847

DMP6SC2	DI	DMP6SC2
DMP6SC2	DN	Irinotecan
DMP6SC2	MI	DTUGYRD
DMP6SC2	MN	P-glycoprotein 1 (ABCB1)
DMP6SC2	MT	DTP
DMP6SC2	MA	Substrate
DMP6SC2	RN	Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
DMP6SC2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12065434

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DEXVHDB
DMAP8MV	MN	Friedreich ataxia protein (FXN)
DMAP8MV	MT	DME
DMAP8MV	MA	Metabolism
DMAP8MV	RN	Iron dysregulation in Friedreich ataxia. Semin Pediatr Neurol. 2006 Sep;13(3):166-75.
DMAP8MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17101455

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	TTQO71U
DMAP8MV	MN	Hemoglobin (HB)
DMAP8MV	MT	DTT
DMAP8MV	MA	Activator
DMAP8MV	RN	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
DMAP8MV	RU	https://pubmed.ncbi.nlm.nih.gov/18760066

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DTVKMHD
DMAP8MV	MN	Natural resistance-associated macrophage protein 2 (SLC11A2)
DMAP8MV	MT	DTP
DMAP8MV	MA	Substrate
DMAP8MV	RN	Transmembrane topology of the mammalian Slc11a2 iron transporter. Biochemistry. 2009 Sep 8;48(35):8422-34.
DMAP8MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/19621945

DMAP8MV	DI	DMAP8MV
DMAP8MV	DN	Iron
DMAP8MV	MI	DTG1RJO
DMAP8MV	MN	Sodium/bile acid cotransporter 7 (SLC10A7)
DMAP8MV	MT	DTP
DMAP8MV	MA	Substrate
DMAP8MV	RN	Modulation of macrophage iron transport by Nramp1 (Slc11a1). Immunobiology. 2007;212(9-10):751-7.
DMAP8MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/18086376

DM5OY70	DI	DM5OY70
DM5OY70	DN	Iron Dextran
DM5OY70	MI	TTQO71U
DM5OY70	MN	Hemoglobin (HB)
DM5OY70	MT	DTT
DM5OY70	MA	Activator
DM5OY70	RN	Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
DM5OY70	RU	https://pubmed.ncbi.nlm.nih.gov/18760066

DMD45S9	DI	DMD45S9
DMD45S9	DN	Isavuconazonium
DMD45S9	MI	DE4LYSA
DMD45S9	MN	Cytochrome P450 3A4 (CYP3A4)
DMD45S9	MT	DME
DMD45S9	MA	Metabolism
DMD45S9	RN	Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent. Pharmacotherapy. 2015 Nov;35(11):1037-51.
DMD45S9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26598096

DMJ9G23	DI	DMJ9G23
DMJ9G23	DN	ISIS 1570
DMJ9G23	MI	TTA1L39
DMJ9G23	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMJ9G23	MT	DTT
DMJ9G23	RN	US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.
DMJ9G23	RU	http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true

DMAF1NB	DI	DMAF1NB
DMAF1NB	DN	Isocarboxazid
DMAF1NB	MI	TT3WG5C
DMAF1NB	MN	Monoamine oxidase type A (MAO-A)
DMAF1NB	MT	DTT
DMAF1NB	MA	Inhibitor
DMAF1NB	RN	MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
DMAF1NB	RU	https://pubmed.ncbi.nlm.nih.gov/7612154

DMITSEH	DI	DMITSEH
DMITSEH	DN	Isoetharine
DMITSEH	MI	TT2CJVK
DMITSEH	MN	Adrenergic receptor beta-2 (ADRB2)
DMITSEH	MT	DTT
DMITSEH	MA	Modulator
DMITSEH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMITSEH	RU	https://www.fda.gov/

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	DEPKLMQ
DMY6T31	MN	Cytochrome P450 2B6 (CYP2B6)
DMY6T31	MT	DME
DMY6T31	MA	Metabolism
DMY6T31	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY6T31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	DEVDYN7
DMY6T31	MN	Cytochrome P450 2E1 (CYP2E1)
DMY6T31	MT	DME
DMY6T31	MA	Metabolism
DMY6T31	RN	Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology. 1999 Mar;90(3):766-71.
DMY6T31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10078678

DMY6T31	DI	DMY6T31
DMY6T31	DN	Isoflurane
DMY6T31	MI	TTAN6JD
DMY6T31	MN	Glutamate receptor AMPA (GRIA)
DMY6T31	MT	DTT
DMY6T31	MA	Agonist
DMY6T31	RN	Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
DMY6T31	RU	https://pubmed.ncbi.nlm.nih.gov/15680938

DMBSK7X	DI	DMBSK7X
DMBSK7X	DN	Isoflurophate
DMBSK7X	MI	TT1RS9F
DMBSK7X	MN	Acetylcholinesterase (AChE)
DMBSK7X	MT	DTT
DMBSK7X	MA	Inhibitor
DMBSK7X	RN	Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
DMBSK7X	RU	https://pubmed.ncbi.nlm.nih.gov/12837382

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEXCQTM
DM5JVS3	MN	Arylamine N-acetyltransferase (NAT)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog. World J Microbiol Biotechnol. 2019 Oct 31;35(11):174.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/31673919

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	TTVTX4N
DM5JVS3	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM5JVS3	MT	DTT
DM5JVS3	MA	Inhibitor
DM5JVS3	RN	Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/19151923

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEAGY5M
DM5JVS3	MN	Catalase-peroxidase (katG)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	Crystal structure of the catalase-peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro-drug isoniazid. FEBS Lett. 2015 Jan 2;589(1):131-7.
DM5JVS3	RU	https://pubmed.ncbi.nlm.nih.gov/25479089

DM5JVS3	DI	DM5JVS3
DM5JVS3	DN	Isoniazid
DM5JVS3	MI	DEVDYN7
DM5JVS3	MN	Cytochrome P450 2E1 (CYP2E1)
DM5JVS3	MT	DME
DM5JVS3	MA	Metabolism
DM5JVS3	RN	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
DM5JVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544

DMQYV60	DI	DMQYV60
DMQYV60	DN	Isopropamide iodide
DMQYV60	MI	TTOXS3C
DMQYV60	MN	Muscarinic acetylcholine receptor (CHRM)
DMQYV60	MT	DTT
DMQYV60	MA	Modulator
DMQYV60	RN	Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
DMQYV60	RU	https://pubmed.ncbi.nlm.nih.gov/3580704

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TTR6W5O
DMK7MEY	MN	Adrenergic receptor beta-1 (ADRB1)
DMK7MEY	MT	DTT
DMK7MEY	MA	Agonist
DMK7MEY	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TT2CJVK
DMK7MEY	MN	Adrenergic receptor beta-2 (ADRB2)
DMK7MEY	MT	DTT
DMK7MEY	MA	Modulator
DMK7MEY	RN	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/9551698

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	TTGW72V
DMK7MEY	MN	Interleukin-12 beta (IL12B)
DMK7MEY	MT	DTT
DMK7MEY	MA	Modulator
DMK7MEY	RN	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
DMK7MEY	RU	https://pubmed.ncbi.nlm.nih.gov/21447719

DMK7MEY	DI	DMK7MEY
DMK7MEY	DN	Isoproterenol
DMK7MEY	MI	DEFQ8VO
DMK7MEY	MN	Thiopurine methyltransferase (TPMT)
DMK7MEY	MT	DME
DMK7MEY	MA	Metabolism
DMK7MEY	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DMK7MEY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	DE4LYSA
DMBI4JG	MN	Cytochrome P450 3A4 (CYP3A4)
DMBI4JG	MT	DME
DMBI4JG	MA	Metabolism
DMBI4JG	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DMBI4JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	DE4ZHS1
DMBI4JG	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMBI4JG	MT	DME
DMBI4JG	MA	Metabolism
DMBI4JG	RN	Nitroglycerin and isosorbide dinitrate stimulation of glutathione disulfide efflux from perfused rat liver. Biochem Pharmacol. 1989 Nov 1;38(21):3807-10.
DMBI4JG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2512927

DMBI4JG	DI	DMBI4JG
DMBI4JG	DN	Isosorbide dinitrate
DMBI4JG	MI	TT6HPVC
DMBI4JG	MN	Guanylate cyclase (GC)
DMBI4JG	MT	DTT
DMBI4JG	MA	Stimulator
DMBI4JG	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMBI4JG	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DMYLMU0	DI	DMYLMU0
DMYLMU0	DN	Isosorbide mononitrate
DMYLMU0	MI	DE4LYSA
DMYLMU0	MN	Cytochrome P450 3A4 (CYP3A4)
DMYLMU0	MT	DME
DMYLMU0	MA	Metabolism
DMYLMU0	RN	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
DMYLMU0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10386583

DMYLMU0	DI	DMYLMU0
DMYLMU0	DN	Isosorbide mononitrate
DMYLMU0	MI	TT6HPVC
DMYLMU0	MN	Guanylate cyclase (GC)
DMYLMU0	MT	DTT
DMYLMU0	MA	Stimulator
DMYLMU0	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DMYLMU0	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM4QTBN	DI	DM4QTBN
DM4QTBN	DN	Isotretinoin
DM4QTBN	MI	DE4LYSA
DM4QTBN	MN	Cytochrome P450 3A4 (CYP3A4)
DM4QTBN	MT	DME
DM4QTBN	MA	Metabolism
DM4QTBN	RN	The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 2004 May;75(5):464-75.
DM4QTBN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15116059

DM4QTBN	DI	DM4QTBN
DM4QTBN	DN	Isotretinoin
DM4QTBN	MI	TTOD7B3
DM4QTBN	MN	Retinoic acid receptor (RAR)
DM4QTBN	MT	DTT
DM4QTBN	MA	Agonist
DM4QTBN	RN	Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402.
DM4QTBN	RU	https://pubmed.ncbi.nlm.nih.gov/14501777

DMX7LKS	DI	DMX7LKS
DMX7LKS	DN	Isovanillin
DMX7LKS	MI	TT3MOS2
DMX7LKS	MN	Aldehyde oxidase (AOX1)
DMX7LKS	MT	DTT
DMX7LKS	MA	Inhibitor
DMX7LKS	RN	Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56.
DMX7LKS	RU	https://pubmed.ncbi.nlm.nih.gov/16543721

DMJL10P	DI	DMJL10P
DMJL10P	DN	Isoxyl
DMJL10P	MI	TT6RIOV
DMJL10P	MN	Acyl-CoA desaturase (SCD)
DMJL10P	MT	DTT
DMJL10P	MA	Binder
DMJL10P	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DMJL10P	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMWCRN1	DI	DMWCRN1
DMWCRN1	DN	Ispaghula
DMWCRN1	MI	TTH18TF
DMWCRN1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMWCRN1	MT	DTT
DMWCRN1	MA	Antagonist
DMWCRN1	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMWCRN1	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMA5XGH	DI	DMA5XGH
DMA5XGH	DN	Isradipine
DMA5XGH	MI	TT5HONZ
DMA5XGH	MN	Calcium channel unspecific (CaC)
DMA5XGH	MT	DTT
DMA5XGH	MA	Modulator
DMA5XGH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA5XGH	RU	https://www.fda.gov/

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	TTM2AOE
DM20VSK	MN	Adenosine A2a receptor (ADORA2A)
DM20VSK	MT	DTT
DM20VSK	MA	Modulator
DM20VSK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM20VSK	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEJGDUW
DM20VSK	MN	Cytochrome P450 1A2 (CYP1A2)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEPKLMQ
DM20VSK	MN	Cytochrome P450 2B6 (CYP2B6)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEZMWRE
DM20VSK	MN	Cytochrome P450 2C18 (CYP2C18)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DES5XRU
DM20VSK	MN	Cytochrome P450 2C8 (CYP2C8)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DE5IED8
DM20VSK	MN	Cytochrome P450 2C9 (CYP2C9)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DECB0K3
DM20VSK	MN	Cytochrome P450 2D6 (CYP2D6)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DE4LYSA
DM20VSK	MN	Cytochrome P450 3A4 (CYP3A4)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DM20VSK	DI	DM20VSK
DM20VSK	DN	Istradefylline
DM20VSK	MI	DEIBDNY
DM20VSK	MN	Cytochrome P450 3A5 (CYP3A5)
DM20VSK	MT	DME
DM20VSK	MA	Metabolism
DM20VSK	RN	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
DM20VSK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28881378

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	TTTSOUD
DMCR1MV	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMCR1MV	MT	DTT
DMCR1MV	MA	Modulator
DMCR1MV	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMCR1MV	RU	https://www.fda.gov/

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DE4LYSA
DMCR1MV	MN	Cytochrome P450 3A4 (CYP3A4)
DMCR1MV	MT	DME
DMCR1MV	MA	Metabolism
DMCR1MV	RN	Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
DMCR1MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16418697

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	TT4LXBC
DMCR1MV	MN	Hedgehog signaling pathway (HS pathway)
DMCR1MV	MT	DTT
DMCR1MV	MA	Inhibitor
DMCR1MV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCR1MV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DTUGYRD
DMCR1MV	MN	P-glycoprotein 1 (ABCB1)
DMCR1MV	MT	DTP
DMCR1MV	MA	Substrate
DMCR1MV	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCR1MV	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCR1MV	DI	DMCR1MV
DMCR1MV	DN	Itraconazole
DMCR1MV	MI	DEYGVN4
DMCR1MV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCR1MV	MT	DME
DMCR1MV	MA	Metabolism
DMCR1MV	RN	Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
DMCR1MV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20304965

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	DE4LYSA
DM0L594	MN	Cytochrome P450 3A4 (CYP3A4)
DM0L594	MT	DME
DM0L594	MA	Metabolism
DM0L594	RN	Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007 Apr;16(88):53-6.
DM0L594	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17458043

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	TTKLW9S
DM0L594	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DM0L594	MT	DTT
DM0L594	MA	Inhibitor
DM0L594	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0L594	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0L594	DI	DM0L594
DM0L594	DN	Ivabradine
DM0L594	MI	TTFCQYU
DM0L594	MN	Sinus node I(f) channel (SA node IfC)
DM0L594	MT	DTT
DM0L594	MA	Modulator
DM0L594	RN	Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228.
DM0L594	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448693/

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	TTRLZHP
DMZC1HS	MN	cAMP-dependent chloride channel (CFTR)
DMZC1HS	MT	DTT
DMZC1HS	MA	Modulator
DMZC1HS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMZC1HS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DE4LYSA
DMZC1HS	MN	Cytochrome P450 3A4 (CYP3A4)
DMZC1HS	MT	DME
DMZC1HS	MA	Metabolism
DMZC1HS	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DMZC1HS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DEIBDNY
DMZC1HS	MN	Cytochrome P450 3A5 (CYP3A5)
DMZC1HS	MT	DME
DMZC1HS	MA	Metabolism
DMZC1HS	RN	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
DMZC1HS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29488691

DMZC1HS	DI	DMZC1HS
DMZC1HS	DN	Ivacaftor
DMZC1HS	MI	DTUGYRD
DMZC1HS	MN	P-glycoprotein 1 (ABCB1)
DMZC1HS	MT	DTP
DMZC1HS	MA	Substrate
DMZC1HS	RN	Investigation of the effects of the CFTR potentiator ivacaftor on human P-glycoprotein (ABCB1). Sci Rep. 2017 Dec 13;7(1):17481.
DMZC1HS	RU	http://www.ncbi.nlm.nih.gov/pubmed/29235532

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DE4LYSA
DMDBX5F	MN	Cytochrome P450 3A4 (CYP3A4)
DMDBX5F	MT	DME
DMDBX5F	MA	Metabolism
DMDBX5F	RN	Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica. 1998 Mar;28(3):313-21.
DMDBX5F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9574819

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DTSYQGK
DMDBX5F	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMDBX5F	MT	DTP
DMDBX5F	MA	Substrate
DMDBX5F	RN	Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79.
DMDBX5F	RU	http://www.ncbi.nlm.nih.gov/pubmed/16384552

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	TTSNVHO
DMDBX5F	MN	Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)
DMDBX5F	MT	DTT
DMDBX5F	MA	Activator
DMDBX5F	RN	Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95.
DMDBX5F	RU	https://pubmed.ncbi.nlm.nih.gov/18755283

DMDBX5F	DI	DMDBX5F
DMDBX5F	DN	Ivermectin
DMDBX5F	MI	DTUGYRD
DMDBX5F	MN	P-glycoprotein 1 (ABCB1)
DMDBX5F	MT	DTP
DMDBX5F	MA	Substrate
DMDBX5F	RN	MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91.
DMDBX5F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12559367

DM8S6T7	DI	DM8S6T7
DM8S6T7	DN	Ivosidenib
DM8S6T7	MI	TTV2A1R
DM8S6T7	MN	Oxalosuccinate decarboxylase (IDH1)
DM8S6T7	MT	DTT
DM8S6T7	MA	Inhibitor
DM8S6T7	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM8S6T7	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMRVITQ	DI	DMRVITQ
DMRVITQ	DN	Ivosidenib
DMRVITQ	MI	DTUGYRD
DMRVITQ	MN	P-glycoprotein 1 (ABCB1)
DMRVITQ	MT	DTP
DMRVITQ	MA	Substrate
DMRVITQ	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB14568)
DMRVITQ	RU	https://www.drugbank.ca/drugs/DB14568

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	DE4LYSA
DM2OZ3G	MN	Cytochrome P450 3A4 (CYP3A4)
DM2OZ3G	MT	DME
DM2OZ3G	MA	Metabolism
DM2OZ3G	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
DM2OZ3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18451235

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	DTUGYRD
DM2OZ3G	MN	P-glycoprotein 1 (ABCB1)
DM2OZ3G	MT	DTP
DM2OZ3G	MA	Substrate
DM2OZ3G	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DM2OZ3G	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DM2OZ3G	DI	DM2OZ3G
DM2OZ3G	DN	Ixabepilone
DM2OZ3G	MI	TTML2WA
DM2OZ3G	MN	Tubulin (TUB)
DM2OZ3G	MT	DTT
DM2OZ3G	MA	Stablizer
DM2OZ3G	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM2OZ3G	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMXW92T	DI	DMXW92T
DMXW92T	DN	Ixekizumab
DMXW92T	MI	TTG0MT6
DMXW92T	MN	Interleukin-17 (IL17)
DMXW92T	MT	DTT
DMXW92T	MA	Modulator
DMXW92T	RN	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
DMXW92T	RU	https://pubmed.ncbi.nlm.nih.gov/23013312

DMKJ8LB	DI	DMKJ8LB
DMKJ8LB	DN	Josamycin
DMKJ8LB	MI	TTUWYEA
DMKJ8LB	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMKJ8LB	MT	DTT
DMKJ8LB	MA	Binder
DMKJ8LB	RN	The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14.
DMKJ8LB	RU	https://pubmed.ncbi.nlm.nih.gov/12860123

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DEWPAJD
DMITFB8	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE5WGIM
DMITFB8	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE2M583
DMITFB8	MN	Endoglucanase Y (EGY)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DE2AZTG
DMITFB8	MN	Endoglucanase Y (EGY)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMITFB8	DI	DMITFB8
DMITFB8	DN	Kanamycin
DMITFB8	MI	DECXWN8
DMITFB8	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMITFB8	MT	DME
DMITFB8	MA	Metabolism
DMITFB8	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMITFB8	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DM2DMPO	DI	DM2DMPO
DM2DMPO	DN	Kanamycin
DM2DMPO	MI	TTQ8KVI
DM2DMPO	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM2DMPO	MT	DTT
DM2DMPO	MA	Binder
DM2DMPO	RN	SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38.
DM2DMPO	RU	https://pubmed.ncbi.nlm.nih.gov/12081641

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DEPKLMQ
DMT5HA4	MN	Cytochrome P450 2B6 (CYP2B6)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DE5IED8
DMT5HA4	MN	Cytochrome P450 2C9 (CYP2C9)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	DE4LYSA
DMT5HA4	MN	Cytochrome P450 3A4 (CYP3A4)
DMT5HA4	MT	DME
DMT5HA4	MA	Metabolism
DMT5HA4	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMT5HA4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMT5HA4	DI	DMT5HA4
DMT5HA4	DN	Ketamine
DMT5HA4	MI	TT9IK2Z
DMT5HA4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMT5HA4	MT	DTT
DMT5HA4	MA	Antagonist
DMT5HA4	RN	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
DMT5HA4	RU	https://pubmed.ncbi.nlm.nih.gov/19583475

DMVLMW6	DI	DMVLMW6
DMVLMW6	DN	Ketanserin
DMVLMW6	MI	TTYSN63
DMVLMW6	MN	5-HT 2 receptor (5HT2R)
DMVLMW6	MT	DTT
DMVLMW6	MA	Antagonist
DMVLMW6	RN	Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
DMVLMW6	RU	https://pubmed.ncbi.nlm.nih.gov/14607779

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DEPKLMQ
DMM3L6Z	MN	Cytochrome P450 2B6 (CYP2B6)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DES5XRU
DMM3L6Z	MN	Cytochrome P450 2C8 (CYP2C8)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE5IED8
DMM3L6Z	MN	Cytochrome P450 2C9 (CYP2C9)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE4LYSA
DMM3L6Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DEGTFWK
DMM3L6Z	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278191

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	TTN4QDT
DMM3L6Z	MN	Opioid receptor (OPR)
DMM3L6Z	MT	DTT
DMM3L6Z	MA	Modulator
DMM3L6Z	RN	The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
DMM3L6Z	RU	https://pubmed.ncbi.nlm.nih.gov/8878254

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE073H6
DMM3L6Z	MN	Prostaglandin G/H synthase 1 (COX-1)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMM3L6Z	DI	DMM3L6Z
DMM3L6Z	DN	Ketobemidone
DMM3L6Z	MI	DE85D2P
DMM3L6Z	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMM3L6Z	MT	DME
DMM3L6Z	MA	Metabolism
DMM3L6Z	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMM3L6Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	TTTSOUD
DMPZI3Q	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMPZI3Q	MT	DTT
DMPZI3Q	MA	Inhibitor
DMPZI3Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. 
DMPZI3Q	RU	https://pubmed.ncbi.nlm.nih.gov/19566112

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	DE4LYSA
DMPZI3Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMPZI3Q	MT	DME
DMPZI3Q	MA	Metabolism
DMPZI3Q	RN	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
DMPZI3Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370

DMPZI3Q	DI	DMPZI3Q
DMPZI3Q	DN	Ketoconazole
DMPZI3Q	MI	DTUGYRD
DMPZI3Q	MN	P-glycoprotein 1 (ABCB1)
DMPZI3Q	MT	DTP
DMPZI3Q	MA	Substrate
DMPZI3Q	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPZI3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	DE5IED8
DMRKXPT	MN	Cytochrome P450 2C9 (CYP2C9)
DMRKXPT	MT	DME
DMRKXPT	MA	Metabolism
DMRKXPT	RN	Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis. Eur J Drug Metab Pharmacokinet. 2011 Sep;36(3):167-73.
DMRKXPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21516380

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	TTVKILB
DMRKXPT	MN	Prostaglandin G/H synthase 2 (COX-2)
DMRKXPT	MT	DTT
DMRKXPT	MA	Inhibitor
DMRKXPT	RN	Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62.
DMRKXPT	RU	https://pubmed.ncbi.nlm.nih.gov/17588732

DMRKXPT	DI	DMRKXPT
DMRKXPT	DN	Ketoprofen
DMRKXPT	MI	DEYGVN4
DMRKXPT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRKXPT	MT	DME
DMRKXPT	MA	Metabolism
DMRKXPT	RN	Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis. Biosci Rep. 2019 May 2;39(5). pii: BSR20182105.
DMRKXPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/30962262

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	DES5XRU
DMI4EL5	MN	Cytochrome P450 2C8 (CYP2C8)
DMI4EL5	MT	DME
DMI4EL5	MA	Metabolism
DMI4EL5	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DMI4EL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	TTK0943
DMI4EL5	MN	Prostaglandin G/H synthase (COX)
DMI4EL5	MT	DTT
DMI4EL5	MA	Inhibitor
DMI4EL5	RN	Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
DMI4EL5	RU	https://pubmed.ncbi.nlm.nih.gov/17369458

DMI4EL5	DI	DMI4EL5
DMI4EL5	DN	Ketorolac
DMI4EL5	MI	DEB3CV1
DMI4EL5	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMI4EL5	MT	DME
DMI4EL5	MA	Metabolism
DMI4EL5	RN	Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol. 2017 Sep;83(9):1966-1975.
DMI4EL5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28429492

DMOVY05	DI	DMOVY05
DMOVY05	DN	Ketotifen
DMOVY05	MI	TTTIBOJ
DMOVY05	MN	Histamine H1 receptor (H1R)
DMOVY05	MT	DTT
DMOVY05	MA	Antagonist
DMOVY05	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DMOVY05	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DM74XKS	DI	DM74XKS
DM74XKS	DN	Ketotifen
DM74XKS	MI	DE1LZID
DM74XKS	MN	Short-chain dehydrogenase/reductase SDR19C1 (DHRS1)
DM74XKS	MT	DME
DM74XKS	MA	Metabolism
DM74XKS	RN	Initial characterization of human DHRS1 (SDR19C1), a member of the short-chain dehydrogenase/reductase superfamily. J Steroid Biochem Mol Biol. 2019 Jan;185:80-89.
DM74XKS	RU	https://pubmed.ncbi.nlm.nih.gov/30031147

DM0KAE6	DI	DM0KAE6
DM0KAE6	DN	Kombiglyze XR/Komboglyze FDC
DM0KAE6	MI	TTDIGC1
DM0KAE6	MN	Dipeptidyl peptidase 4 (DPP-4)
DM0KAE6	MT	DTT
DM0KAE6	MA	Modulator
DM0KAE6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).
DM0KAE6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612

DMSA4HZ	DI	DMSA4HZ
DMSA4HZ	DN	KU-0058948
DMSA4HZ	MI	TTVDSZ0
DMSA4HZ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMSA4HZ	MT	DTT
DMSA4HZ	MA	Inhibitor
DMSA4HZ	RN	Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
DMSA4HZ	RU	https://pubmed.ncbi.nlm.nih.gov/19354255

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	TTG28O6
DMK8U72	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMK8U72	MT	DTT
DMK8U72	MA	Antagonist
DMK8U72	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DMK8U72	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DECB0K3
DMK8U72	MN	Cytochrome P450 2D6 (CYP2D6)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992 Feb;32(2):176-83.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1613128

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEGTFWK
DMK8U72	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Drug Interactions Flockhart Table
DMK8U72	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DTE2B1D
DMK8U72	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMK8U72	MT	DTP
DMK8U72	MA	Substrate
DMK8U72	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMK8U72	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DTUGYRD
DMK8U72	MN	P-glycoprotein 1 (ABCB1)
DMK8U72	MT	DTP
DMK8U72	MA	Substrate
DMK8U72	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMK8U72	RU	https://doi.org/10.1007/s11095-012-0935-x

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEYGVN4
DMK8U72	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DE85D2P
DMK8U72	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DENUPDX
DMK8U72	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMK8U72	DI	DMK8U72
DMK8U72	DN	Labetalol
DMK8U72	MI	DEB3CV1
DMK8U72	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMK8U72	MT	DME
DMK8U72	MA	Metabolism
DMK8U72	RN	Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
DMK8U72	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18098064

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	DE5IED8
DMVM6QR	MN	Cytochrome P450 2C9 (CYP2C9)
DMVM6QR	MT	DME
DMVM6QR	MA	Metabolism
DMVM6QR	RN	Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr. 2009 Sep-Oct;9(5):133-4.
DMVM6QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19826503

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTZCW3T
DMVM6QR	MN	Dihydropyrimidinase related protein 2 (DPYSL2)
DMVM6QR	MT	DTT
DMVM6QR	MA	Modulator
DMVM6QR	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	DEGTFWK
DMVM6QR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMVM6QR	MT	DME
DMVM6QR	MA	Metabolism
DMVM6QR	RN	Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
DMVM6QR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23942540

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTIG65Q
DMVM6QR	MN	Voltage-gated sodium channel (Nav)
DMVM6QR	MT	DTT
DMVM6QR	MA	Inhibitor
DMVM6QR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMVM6QR	DI	DMVM6QR
DMVM6QR	DN	Lacosamide
DMVM6QR	MI	TTN9VTF
DMVM6QR	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMVM6QR	MT	DTT
DMVM6QR	MA	Inhibitor
DMVM6QR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMVM6QR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMA7QTC	DI	DMA7QTC
DMA7QTC	DN	Lactoferrin
DMA7QTC	MI	TTM1TDX
DMA7QTC	MN	Tryptase alpha/beta-1 (Tryptase)
DMA7QTC	MT	DTT
DMA7QTC	MA	Inhibitor
DMA7QTC	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DMA7QTC	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DEIEY19
DMV7OPN	MN	Beta-galactosidase (bgaB)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DE235K6
DMV7OPN	MN	Beta-glucosidase (bglA)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMV7OPN	DI	DMV7OPN
DMV7OPN	DN	Lactulose
DMV7OPN	MI	DEPB9C2
DMV7OPN	MN	Glycosyl hydrolase (glyH)
DMV7OPN	MT	DME
DMV7OPN	MA	Metabolism
DMV7OPN	RN	In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
DMV7OPN	RU	https://pubmed.ncbi.nlm.nih.gov/25340538

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTC54PX
DMZDN4W	MN	Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	TTT2LD9
DMZDN4W	MN	GABA transaminase (ABAT)
DMZDN4W	MT	DTT
DMZDN4W	MA	Inhibitor
DMZDN4W	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMZDN4W	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTJF3DX
DMZDN4W	MN	L-type amino acid transporter 2 (SLC7A8)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMZDN4W	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTD815L
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 1 (SLC38A1)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTTWL58
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 2 (SLC38A2)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTKWJH3
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTPJBD5
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 4 (SLC38A4)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMZDN4W	DI	DMZDN4W
DMZDN4W	DN	L-alanine
DMZDN4W	MI	DTLX28N
DMZDN4W	MN	Sodium-coupled neutral amino acid transporter 5 (SLC38A5)
DMZDN4W	MT	DTP
DMZDN4W	MA	Substrate
DMZDN4W	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DMZDN4W	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMANBR7	DI	DMANBR7
DMANBR7	DN	L-alanyl-l-glutamine
DMANBR7	MI	TTI7S12
DMANBR7	MN	Glutamine receptor (GluR)
DMANBR7	MT	DTT
DMANBR7	MA	Modulator
DMANBR7	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMANBR7	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DTI7UX6
DMI347A	MN	Breast cancer resistance protein (ABCG2)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol. 2007 Nov;64(5):645-54.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509035

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DE4E31Z
DMI347A	MN	Deoxy-5'-nucleotidase 1 (NT5C)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 2010 Jan;85(1):39-58.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19887088

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	TT84ETX
DMI347A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMI347A	MT	DTT
DMI347A	MA	Modulator
DMI347A	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMI347A	RU	https://www.fda.gov/

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DTT79CX
DMI347A	MN	Organic cation transporter 1 (SLC22A1)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/18490433

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DT9IDPW
DMI347A	MN	Organic cation transporter 2 (SLC22A2)
DMI347A	MT	DTP
DMI347A	MA	Substrate
DMI347A	RN	Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos. 2012 Apr;33(3):170-8.
DMI347A	RU	http://www.ncbi.nlm.nih.gov/pubmed/22415520

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DEQYXD4
DMI347A	MN	Phosphorylcholine transferase A (PCYT1A)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug;50(8):2686-94.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16870759

DMI347A	DI	DMI347A
DMI347A	DN	Lamivudine
DMI347A	MI	DEIX1PO
DMI347A	MN	Phosphorylethanolamine transferase (PCYT2)
DMI347A	MT	DME
DMI347A	MA	Metabolism
DMI347A	RN	Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother. 2006 Aug;50(8):2686-94.
DMI347A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16870759

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DTT79CX
DM8SXYG	MN	Organic cation transporter 1 (SLC22A1)
DM8SXYG	MT	DTP
DM8SXYG	MA	Substrate
DM8SXYG	RN	Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14.
DM8SXYG	RU	https://doi.org/10.1016/j.bcp.2011.12.032

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DTUGYRD
DM8SXYG	MN	P-glycoprotein 1 (ABCB1)
DM8SXYG	MT	DTP
DM8SXYG	MA	Substrate
DM8SXYG	RN	Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75.
DM8SXYG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824002

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DEYGVN4
DM8SXYG	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DEF2WXN
DM8SXYG	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19387891

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	DELOY3P
DM8SXYG	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DM8SXYG	MT	DME
DM8SXYG	MA	Metabolism
DM8SXYG	RN	Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35.
DM8SXYG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19845433

DM8SXYG	DI	DM8SXYG
DM8SXYG	DN	Lamotrigine
DM8SXYG	MI	TTN9VTF
DM8SXYG	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DM8SXYG	MT	DTT
DM8SXYG	MA	Blocker
DM8SXYG	RN	The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9.
DM8SXYG	RU	https://pubmed.ncbi.nlm.nih.gov/19579915

DMEH7YU	DI	DMEH7YU
DMEH7YU	DN	Lanadelumab
DMEH7YU	MI	TTMF8H9
DMEH7YU	MN	Plasma kallikrein (KLKB1)
DMEH7YU	MT	DTT
DMEH7YU	MA	Modulator
DMEH7YU	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMEH7YU	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMG6ZU4	DI	DMG6ZU4
DMG6ZU4	DN	Lanreotide acetate
DMG6ZU4	MI	TTZ6T9E
DMG6ZU4	MN	Somatostatin receptor type 2 (SSTR2)
DMG6ZU4	MT	DTT
DMG6ZU4	MA	Modulator
DMG6ZU4	RN	Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90.
DMG6ZU4	RU	https://pubmed.ncbi.nlm.nih.gov/16262568

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DEZMWRE
DMXYLQ3	MN	Cytochrome P450 2C18 (CYP2C18)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7870052

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DES5XRU
DMXYLQ3	MN	Cytochrome P450 2C8 (CYP2C8)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627562

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DE5IED8
DMXYLQ3	MN	Cytochrome P450 2C9 (CYP2C9)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DE4LYSA
DMXYLQ3	MN	Cytochrome P450 3A4 (CYP3A4)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact. 1998 Jul 3;114(1-2):1-13.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9744552

DMXYLQ3	DI	DMXYLQ3
DMXYLQ3	DN	Lansoprazole
DMXYLQ3	MI	DEGTFWK
DMXYLQ3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXYLQ3	MT	DME
DMXYLQ3	MA	Metabolism
DMXYLQ3	RN	Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
DMXYLQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752376

DMMJQSH	DI	DMMJQSH
DMMJQSH	DN	Lanthanum carbonate
DMMJQSH	MI	TTHOTF6
DMMJQSH	MN	Phosphate (PHO)
DMMJQSH	MT	DTT
DMMJQSH	MA	Modulator
DMMJQSH	RN	2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
DMMJQSH	RU	https://pubmed.ncbi.nlm.nih.gov/15756752

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DTI7UX6
DM3BH1Y	MN	Breast cancer resistance protein (ABCG2)
DM3BH1Y	MT	DTP
DM3BH1Y	MA	Substrate
DM3BH1Y	RN	The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
DM3BH1Y	RU	https://doi.org/10.1124/dmd.107.018374

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DES5XRU
DM3BH1Y	MN	Cytochrome P450 2C8 (CYP2C8)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DE4LYSA
DM3BH1Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20624855

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DEIBDNY
DM3BH1Y	MN	Cytochrome P450 3A5 (CYP3A5)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TTGKNB4
DM3BH1Y	MN	Epidermal growth factor receptor (EGFR)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19365520

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TT6EO5L
DM3BH1Y	MN	Erbb2 tyrosine kinase receptor (HER2)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19365520

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	TT1QFLA
DM3BH1Y	MN	Eukaryotic elongation factor 2 kinase (eEF-2K)
DM3BH1Y	MT	DTT
DM3BH1Y	MA	Inhibitor
DM3BH1Y	RN	Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
DM3BH1Y	RU	https://pubmed.ncbi.nlm.nih.gov/27756261

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DEGTFWK
DM3BH1Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3BH1Y	MT	DME
DM3BH1Y	MA	Metabolism
DM3BH1Y	RN	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
DM3BH1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976

DM3BH1Y	DI	DM3BH1Y
DM3BH1Y	DN	Lapatinib
DM3BH1Y	MI	DTUGYRD
DM3BH1Y	MN	P-glycoprotein 1 (ABCB1)
DM3BH1Y	MT	DTP
DM3BH1Y	MA	Substrate
DM3BH1Y	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM3BH1Y	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTKN7QR
DM26CQR	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTXABCW
DM26CQR	MN	NT-3 growth factor receptor (TrkC)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM26CQR	DI	DM26CQR
DM26CQR	DN	Larotrectinib
DM26CQR	MI	TTTDVOJ
DM26CQR	MN	Tropomyosin-related kinase A (TrkA)
DM26CQR	MT	DTT
DM26CQR	MA	Inhibitor
DM26CQR	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM26CQR	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMSQ1JV	DI	DMSQ1JV
DMSQ1JV	DN	LAS-34273
DMSQ1JV	MI	TTQ13Z5
DMSQ1JV	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSQ1JV	MT	DTT
DMSQ1JV	MA	Antagonist
DMSQ1JV	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMSQ1JV	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMXLVDT	DI	DMXLVDT
DMXLVDT	DN	Lasmiditan
DMXLVDT	MI	TT0MI3F
DMXLVDT	MN	5-HT 1F receptor (HTR1F)
DMXLVDT	MT	DTT
DMXLVDT	MA	Agonist
DMXLVDT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMXLVDT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf

DMHA18P	DI	DMHA18P
DMHA18P	DN	Lasofoxifene
DMHA18P	MI	TTZAYWL
DMHA18P	MN	Estrogen receptor (ESR)
DMHA18P	MT	DTT
DMHA18P	MA	Modulator
DMHA18P	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMHA18P	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMHA18P	DI	DMHA18P
DMHA18P	DN	Lasofoxifene
DMHA18P	MI	TT57ID8
DMHA18P	MN	Respiratory syncytial virus protein F (RSV F)
DMHA18P	MT	DTT
DMHA18P	MA	Modulator
DMHA18P	RN	Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
DMHA18P	RU	https://pubmed.ncbi.nlm.nih.gov/19562644

DMANL0D	DI	DMANL0D
DMANL0D	DN	Latamoxef
DMANL0D	MI	TT85JMW
DMANL0D	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMANL0D	MT	DTT
DMANL0D	MA	Binder
DMANL0D	RN	Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
DMANL0D	RU	https://pubmed.ncbi.nlm.nih.gov/9841767

DMANL0D	DI	DMANL0D
DMANL0D	DN	Latamoxef
DMANL0D	MI	DT8QKNP
DMANL0D	MN	Peptide transporter 2 (SLC15A2)
DMANL0D	MT	DTP
DMANL0D	MA	Substrate
DMANL0D	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DMANL0D	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	DT021JD
DMI5OXG	MN	Organic anion transporting polypeptide 2A1 (SLCO2A1)
DMI5OXG	MT	DTP
DMI5OXG	MA	Substrate
DMI5OXG	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DMI5OXG	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	DTPFTEQ
DMI5OXG	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMI5OXG	MT	DTP
DMI5OXG	MA	Substrate
DMI5OXG	RN	The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.
DMI5OXG	RU	http://www.ncbi.nlm.nih.gov/pubmed/20019365

DMI5OXG	DI	DMI5OXG
DMI5OXG	DN	Latanoprost
DMI5OXG	MI	TTT2ZAR
DMI5OXG	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMI5OXG	MT	DTT
DMI5OXG	MA	Agonist
DMI5OXG	RN	PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70.
DMI5OXG	RU	https://pubmed.ncbi.nlm.nih.gov/19384589

DMLFX7K	DI	DMLFX7K
DMLFX7K	DN	LCZ696
DMLFX7K	MI	TT5TKPM
DMLFX7K	MN	Neutral endopeptidase (MME)
DMLFX7K	MT	DTT
DMLFX7K	MA	Modulator
DMLFX7K	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMLFX7K	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DME6G97	DI	DME6G97
DME6G97	DN	Lefamulin
DME6G97	MI	TTLFGBV
DME6G97	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DME6G97	MT	DTT
DME6G97	MA	Inhibitor
DME6G97	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DME6G97	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf

DME6G97	DI	DME6G97
DME6G97	DN	Lefamulin
DME6G97	MI	DE4LYSA
DME6G97	MN	Cytochrome P450 3A4 (CYP3A4)
DME6G97	MT	DME
DME6G97	MA	Metabolism
DME6G97	RN	Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946.
DME6G97	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30019769

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DTI7UX6
DMR8ONJ	MN	Breast cancer resistance protein (ABCG2)
DMR8ONJ	MT	DTP
DMR8ONJ	MA	Substrate
DMR8ONJ	RN	Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7.
DMR8ONJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18397960

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DEJGDUW
DMR8ONJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DE5IED8
DMR8ONJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004 Jan;36(1):82-4.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14971821

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	DE4LYSA
DMR8ONJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMR8ONJ	MT	DME
DMR8ONJ	MA	Metabolism
DMR8ONJ	RN	Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes. Chem Res Toxicol. 2015 May 18;28(5):872-85.
DMR8ONJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25860621

DMR8ONJ	DI	DMR8ONJ
DMR8ONJ	DN	Leflunomide
DMR8ONJ	MI	TT3PQ2Y
DMR8ONJ	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMR8ONJ	MT	DTT
DMR8ONJ	MA	Inhibitor
DMR8ONJ	RN	Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
DMR8ONJ	RU	https://pubmed.ncbi.nlm.nih.gov/10583416

DM6Q7U4	DI	DM6Q7U4
DM6Q7U4	DN	Lenalidomide
DM6Q7U4	MI	DTUGYRD
DM6Q7U4	MN	P-glycoprotein 1 (ABCB1)
DM6Q7U4	MT	DTP
DM6Q7U4	MA	Substrate
DM6Q7U4	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
DM6Q7U4	RU	https://www.drugbank.ca/drugs/DB00480

DM6Q7U4	DI	DM6Q7U4
DM6Q7U4	DN	Lenalidomide
DM6Q7U4	MI	TTF8CQI
DM6Q7U4	MN	Tumor necrosis factor (TNF)
DM6Q7U4	MT	DTT
DM6Q7U4	MA	Inhibitor
DM6Q7U4	RN	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
DM6Q7U4	RU	https://pubmed.ncbi.nlm.nih.gov/19370685

DMB1IU4	DI	DMB1IU4
DMB1IU4	DN	Lenvatinib
DMB1IU4	MI	DTUGYRD
DMB1IU4	MN	P-glycoprotein 1 (ABCB1)
DMB1IU4	MT	DTP
DMB1IU4	MA	Substrate
DMB1IU4	RN	Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
DMB1IU4	RU	http://www.ncbi.nlm.nih.gov/pubmed/30931962

DMB1IU4	DI	DMB1IU4
DMB1IU4	DN	Lenvatinib
DMB1IU4	MI	TTUTJGQ
DMB1IU4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMB1IU4	MT	DTT
DMB1IU4	MA	Inhibitor
DMB1IU4	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DMB1IU4	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DM1I3D5	DI	DM1I3D5
DM1I3D5	DN	Lepirudin
DM1I3D5	MI	TT6L509
DM1I3D5	MN	Coagulation factor IIa (F2)
DM1I3D5	MT	DTT
DM1I3D5	MA	Inhibitor
DM1I3D5	RN	Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
DM1I3D5	RU	https://pubmed.ncbi.nlm.nih.gov/10560805

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DE4LYSA
DMPWSEM	MN	Cytochrome P450 3A4 (CYP3A4)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1(3):173-82.
DMPWSEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319103

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DEIBDNY
DMPWSEM	MN	Cytochrome P450 3A5 (CYP3A5)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Drug Interactions Flockhart Table
DMPWSEM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	DERD86B
DMPWSEM	MN	Cytochrome P450 3A7 (CYP3A7)
DMPWSEM	MT	DME
DMPWSEM	MA	Metabolism
DMPWSEM	RN	Drug Interactions Flockhart Table
DMPWSEM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMPWSEM	DI	DMPWSEM
DMPWSEM	DN	Lercanidipine
DMPWSEM	MI	TTFK1JQ
DMPWSEM	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMPWSEM	MT	DTT
DMPWSEM	MA	Blocker
DMPWSEM	RN	Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
DMPWSEM	RU	https://pubmed.ncbi.nlm.nih.gov/19619074

DMUR64T	DI	DMUR64T
DMUR64T	DN	Lesinurad
DMUR64T	MI	DE5IED8
DMUR64T	MN	Cytochrome P450 2C9 (CYP2C9)
DMUR64T	MT	DME
DMUR64T	MA	Metabolism
DMUR64T	RN	FDA Label of Lesinurad. The 2020 official website of the U.S. Food and Drug Administration.
DMUR64T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf

DMUR64T	DI	DMUR64T
DMUR64T	DN	Lesinurad
DMUR64T	MI	TTA592U
DMUR64T	MN	Urate anion exchanger 1 (URAT1)
DMUR64T	MT	DTT
DMUR64T	MA	Modulator
DMUR64T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
DMUR64T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031

DMQ2AIJ	DI	DMQ2AIJ
DMQ2AIJ	DN	Lestaurtinib
DMQ2AIJ	MI	TTGJCWZ
DMQ2AIJ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMQ2AIJ	MT	DTT
DMQ2AIJ	MA	Modulator
DMQ2AIJ	RN	Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
DMQ2AIJ	RU	https://pubmed.ncbi.nlm.nih.gov/17984313

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	TTSZLWK
DMH07Y3	MN	Aromatase (CYP19A1)
DMH07Y3	MT	DTT
DMH07Y3	MA	Inhibitor
DMH07Y3	RN	Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
DMH07Y3	RU	https://pubmed.ncbi.nlm.nih.gov/14505258

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DEQX145
DMH07Y3	MN	Aromatase (CYP19A1)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10448261

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DEJVYAZ
DMH07Y3	MN	Cytochrome P450 2A6 (CYP2A6)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30094551

DMH07Y3	DI	DMH07Y3
DMH07Y3	DN	Letrozole
DMH07Y3	MI	DE4LYSA
DMH07Y3	MN	Cytochrome P450 3A4 (CYP3A4)
DMH07Y3	MT	DME
DMH07Y3	MA	Metabolism
DMH07Y3	RN	Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75.
DMH07Y3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19198839

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTFI42L
DMUAZWG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12874005

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTQ3ZHF
DMUAZWG	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DMUAZWG	DI	DMUAZWG
DMUAZWG	DN	Leucovorin
DMUAZWG	MI	DTCSGPB
DMUAZWG	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMUAZWG	MT	DTP
DMUAZWG	MA	Substrate
DMUAZWG	RN	Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
DMUAZWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12036927

DMNWZJG	DI	DMNWZJG
DMNWZJG	DN	Leucovorin Calcium
DMNWZJG	MI	TTYZVDJ
DMNWZJG	MN	Dihydrofolate reductase (DHFR)
DMNWZJG	MT	DTT
DMNWZJG	MA	Modulator
DMNWZJG	RN	Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
DMNWZJG	RU	https://www.ncbi.nlm.nih.gov/pubmed/2448654

DMZT4N7	DI	DMZT4N7
DMZT4N7	DN	Leucovorin/5-fluorouracil
DMZT4N7	MI	TTU6BFZ
DMZT4N7	MN	Candida Thymidylate synthase (Candi TMP1)
DMZT4N7	MT	DTT
DMZT4N7	MA	Inhibitor
DMZT4N7	RN	Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
DMZT4N7	RU	https://pubmed.ncbi.nlm.nih.gov/19383847

DM5XPIJ	DI	DM5XPIJ
DM5XPIJ	DN	Leuprolide
DM5XPIJ	MI	TT0ID4A
DM5XPIJ	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DM5XPIJ	MT	DTT
DM5XPIJ	MA	Activator
DM5XPIJ	RN	Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22.
DM5XPIJ	RU	https://pubmed.ncbi.nlm.nih.gov/19025432

DM15HAT	DI	DM15HAT
DM15HAT	DN	Leuprorelin acetate
DM15HAT	MI	TT8R70G
DM15HAT	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM15HAT	MT	DTT
DM15HAT	MA	Agonist
DM15HAT	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DM15HAT	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTW7AE3
DMJBOCR	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18771654

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DEIGQCY
DMJBOCR	MN	Carnitine O-acetyltransferase (CRAT)
DMJBOCR	MT	DME
DMJBOCR	MA	Metabolism
DMJBOCR	RN	Structural and mutational characterization of L-carnitine binding to human carnitine acetyltransferase. J Struct Biol. 2004 Jun;146(3):416-24.
DMJBOCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15099582

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	TTDL0NY
DMJBOCR	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMJBOCR	MT	DTT
DMJBOCR	MA	Activator
DMJBOCR	RN	Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
DMJBOCR	RU	https://pubmed.ncbi.nlm.nih.gov/19608647

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTQOUM4
DMJBOCR	MN	Carnitine/acylcarnitine translocase (SLC25A20)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004 Oct;24(4):312-20.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/15365988

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DEVDYN7
DMJBOCR	MN	Cytochrome P450 2E1 (CYP2E1)
DMJBOCR	MT	DME
DMJBOCR	MA	Metabolism
DMJBOCR	RN	Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. Biol Pharm Bull. 1993 Dec;16(12):1240-3.
DMJBOCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8130774

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTPATLS
DMJBOCR	MN	Fly-like putative transporter 2 (SLC22A16)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20037140

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DTQK5O9
DMJBOCR	MN	Monocarboxylate transporter 9 (SLC16A9)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Histological characterization of orphan transporter MCT14 (SLC16A14) shows abundant expression in mouse CNS and kidney. BMC Neurosci. 2016 Jul 1;17(1):43.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/27364523

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DT2EG60
DMJBOCR	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab. 2007 Dec;92(4):315-24.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/17884651

DMJBOCR	DI	DMJBOCR
DMJBOCR	DN	Levacecarnine HCL
DMJBOCR	MI	DT3HUVD
DMJBOCR	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMJBOCR	MT	DTP
DMJBOCR	MA	Substrate
DMJBOCR	RN	Colistin is substrate of the carnitine/organic cation transporter 2 (OCTN2, SLC22A5). Drug Metab Dispos. 2017 Dec;45(12):1240-1244.
DMJBOCR	RU	http://www.ncbi.nlm.nih.gov/pubmed/28986476

DM5YBO1	DI	DM5YBO1
DM5YBO1	DN	Levalbuterol
DM5YBO1	MI	TT2CJVK
DM5YBO1	MN	Adrenergic receptor beta-2 (ADRB2)
DM5YBO1	MT	DTT
DM5YBO1	MA	Antagonist
DM5YBO1	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DM5YBO1	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DMCOLUP	DI	DMCOLUP
DMCOLUP	DN	Levallorphan
DMCOLUP	MI	TTF4E0J
DMCOLUP	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMCOLUP	MT	DTT
DMCOLUP	MA	Antagonist
DMCOLUP	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DMCOLUP	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DM5EN79	DI	DM5EN79
DM5EN79	DN	Levamisole
DM5EN79	MI	TTMR5UV
DM5EN79	MN	Alkaline phosphatase tissue-nonspecific (ALPL)
DM5EN79	MT	DTT
DM5EN79	MA	Inhibitor
DM5EN79	RN	Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9.
DM5EN79	RU	https://pubmed.ncbi.nlm.nih.gov/18719742

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	TTPC4TU
DMTGDN8	MN	5-HT 3A receptor (HTR3A)
DMTGDN8	MT	DTT
DMTGDN8	MA	Antagonist
DMTGDN8	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMTGDN8	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	DTUGYRD
DMTGDN8	MN	P-glycoprotein 1 (ABCB1)
DMTGDN8	MT	DTP
DMTGDN8	MA	Substrate
DMTGDN8	RN	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46.
DMTGDN8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17045309

DMTGDN8	DI	DMTGDN8
DMTGDN8	DN	Levetiracetam
DMTGDN8	MI	TTT3P91
DMTGDN8	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMTGDN8	MT	DTT
DMTGDN8	MA	Modulator
DMTGDN8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTGDN8	RU	https://www.fda.gov/

DMSREPX	DI	DMSREPX
DMSREPX	DN	Levobetaxolol
DMSREPX	MI	TTR6W5O
DMSREPX	MN	Adrenergic receptor beta-1 (ADRB1)
DMSREPX	MT	DTT
DMSREPX	MA	Antagonist
DMSREPX	RN	Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9.
DMSREPX	RU	https://pubmed.ncbi.nlm.nih.gov/15117564

DMSREPX	DI	DMSREPX
DMSREPX	DN	Levobetaxolol
DMSREPX	MI	DECB0K3
DMSREPX	MN	Cytochrome P450 2D6 (CYP2D6)
DMSREPX	MT	DME
DMSREPX	MA	Metabolism
DMSREPX	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMSREPX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMTNFCQ	DI	DMTNFCQ
DMTNFCQ	DN	Levobunolol
DMTNFCQ	MI	TTR6W5O
DMTNFCQ	MN	Adrenergic receptor beta-1 (ADRB1)
DMTNFCQ	MT	DTT
DMTNFCQ	MA	Antagonist
DMTNFCQ	RN	Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84.
DMTNFCQ	RU	https://pubmed.ncbi.nlm.nih.gov/6147147

DMTNFCQ	DI	DMTNFCQ
DMTNFCQ	DN	Levobunolol
DMTNFCQ	MI	DECB0K3
DMTNFCQ	MN	Cytochrome P450 2D6 (CYP2D6)
DMTNFCQ	MT	DME
DMTNFCQ	MA	Metabolism
DMTNFCQ	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMTNFCQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	DEJGDUW
DM783CH	MN	Cytochrome P450 1A2 (CYP1A2)
DM783CH	MT	DME
DM783CH	MA	Metabolism
DM783CH	RN	Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. Br J Anaesth. 2005 Oct;95(4):524-9.
DM783CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16100236

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	DE4LYSA
DM783CH	MN	Cytochrome P450 3A4 (CYP3A4)
DM783CH	MT	DME
DM783CH	MA	Metabolism
DM783CH	RN	Clinical profile of levobupivacaine in regional anesthesia: A systematic review. J Anaesthesiol Clin Pharmacol. 2013 Oct;29(4):530-9.
DM783CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24249993

DM783CH	DI	DM783CH
DM783CH	DN	Levobupivacaine
DM783CH	MI	TTRK8B9
DM783CH	MN	Sodium channel unspecific (NaC)
DM783CH	MT	DTT
DM783CH	MA	Blocker
DM783CH	RN	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
DM783CH	RU	https://pubmed.ncbi.nlm.nih.gov/11094008

DMMZPWT	DI	DMMZPWT
DMMZPWT	DN	Levocabastine
DMMZPWT	MI	TTTIBOJ
DMMZPWT	MN	Histamine H1 receptor (H1R)
DMMZPWT	MT	DTT
DMMZPWT	MA	Antagonist
DMMZPWT	RN	Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62.
DMMZPWT	RU	https://pubmed.ncbi.nlm.nih.gov/18680729

DMQYLGP	DI	DMQYLGP
DMQYLGP	DN	Levocetirizine
DMQYLGP	MI	DT06JWZ
DMQYLGP	MN	Organic anion transporter 4 (SLC22A11)
DMQYLGP	MT	DTP
DMQYLGP	MA	Substrate
DMQYLGP	RN	Cellular Uptake of Levocetirizine by Organic Anion Transporter 4. J Pharm Sci. 2017 Sep;106(9):2895-2898.
DMQYLGP	RU	http://www.ncbi.nlm.nih.gov/pubmed/28385546

DMW6ZJI	DI	DMW6ZJI
DMW6ZJI	DN	Levocetirizine dihydrochloride
DMW6ZJI	MI	DE4LYSA
DMW6ZJI	MN	Cytochrome P450 3A4 (CYP3A4)
DMW6ZJI	MT	DME
DMW6ZJI	MA	Metabolism
DMW6ZJI	RN	FDA label of Levocetirizine dihydrochloride. The 2020 official website of the U.S. Food and Drug Administration.
DMW6ZJI	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf

DMW6ZJI	DI	DMW6ZJI
DMW6ZJI	DN	Levocetirizine dihydrochloride
DMW6ZJI	MI	TTTIBOJ
DMW6ZJI	MN	Histamine H1 receptor (H1R)
DMW6ZJI	MT	DTT
DMW6ZJI	MA	Antagonist
DMW6ZJI	RN	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
DMW6ZJI	RU	https://pubmed.ncbi.nlm.nih.gov/19210904

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DECB0K3
DMN3E57	MN	Cytochrome P450 2D6 (CYP2D6)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433806

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DETK9CN
DMN3E57	MN	DOPA decarboxylase (DDC)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Complexity of dopamine metabolism. Cell Commun Signal. 2013 May 17;11(1):34.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23683503

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	TTEX248
DMN3E57	MN	Dopamine D2 receptor (D2R)
DMN3E57	MT	DTT
DMN3E57	MA	Modulator
DMN3E57	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
DMN3E57	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DT48T0N
DMN3E57	MN	L-type amino acid transporter 1 (SLC7A5)
DMN3E57	MT	DTP
DMN3E57	MA	Substrate
DMN3E57	RN	Modulation of LAT1 (SLC7A5) transporter activity and stability by membrane cholesterol. Sci Rep. 2017 Mar 8;7:43580.
DMN3E57	RU	http://www.ncbi.nlm.nih.gov/pubmed/28272458

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DTUGYRD
DMN3E57	MN	P-glycoprotein 1 (ABCB1)
DMN3E57	MT	DTP
DMN3E57	MA	Substrate
DMN3E57	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMN3E57	RU	https://doi.org/10.1007/s11095-012-0935-x

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DEFQ8VO
DMN3E57	MN	Thiopurine methyltransferase (TPMT)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
DMN3E57	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19676096

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DE3HL9N
DMN3E57	MN	Tyrosine decarboxylase (tdc)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
DMN3E57	RU	https://pubmed.ncbi.nlm.nih.gov/31196984

DMN3E57	DI	DMN3E57
DMN3E57	DN	Levodopa
DMN3E57	MI	DEX2ZLF
DMN3E57	MN	Tyrosine decarboxylase (tdc)
DMN3E57	MT	DME
DMN3E57	MA	Metabolism
DMN3E57	RN	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 Jan 18;10(1):310.
DMN3E57	RU	https://pubmed.ncbi.nlm.nih.gov/30659181

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	TTN6J5F
DMS60RB	MN	Bacterial DNA gyrase (Bact gyrase)
DMS60RB	MT	DTT
DMS60RB	MA	Modulator
DMS60RB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS60RB	RU	https://www.fda.gov/

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DEP0IWS
DMS60RB	MN	Beta-lactamase (blaB)
DMS60RB	MT	DME
DMS60RB	MA	Metabolism
DMS60RB	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMS60RB	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DTE2B1D
DMS60RB	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMS60RB	MT	DTP
DMS60RB	MA	Substrate
DMS60RB	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMS60RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	DTUGYRD
DMS60RB	MN	P-glycoprotein 1 (ABCB1)
DMS60RB	MT	DTP
DMS60RB	MA	Substrate
DMS60RB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMS60RB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMS60RB	DI	DMS60RB
DMS60RB	DN	Levofloxacin
DMS60RB	MI	TTIXTO3
DMS60RB	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMS60RB	MT	DTT
DMS60RB	MA	Modulator
DMS60RB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMS60RB	RU	https://www.fda.gov/

DMUV5JB	DI	DMUV5JB
DMUV5JB	DN	Levomefolic acid
DMUV5JB	MI	DEWSHL5
DMUV5JB	MN	Vitamin B12 methionine synthase (MTR)
DMUV5JB	MT	DME
DMUV5JB	MA	Metabolism
DMUV5JB	RN	Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48.
DMUV5JB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20608755

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	DECB0K3
DMIKFEL	MN	Cytochrome P450 2D6 (CYP2D6)
DMIKFEL	MT	DME
DMIKFEL	MA	Metabolism
DMIKFEL	RN	Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS One. 2014 Nov 4;9(11):e90453.
DMIKFEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25369508

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	TTEX248
DMIKFEL	MN	Dopamine D2 receptor (D2R)
DMIKFEL	MT	DTT
DMIKFEL	MA	Modulator
DMIKFEL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIKFEL	RU	https://www.fda.gov/

DMIKFEL	DI	DMIKFEL
DMIKFEL	DN	Levomepromazine
DMIKFEL	MI	DTUGYRD
DMIKFEL	MN	P-glycoprotein 1 (ABCB1)
DMIKFEL	MT	DTP
DMIKFEL	MA	Substrate
DMIKFEL	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMIKFEL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM06HG5	DI	DM06HG5
DM06HG5	DN	Levomethadyl Acetate
DM06HG5	MI	TTKWM86
DM06HG5	MN	Opioid receptor mu (MOP)
DM06HG5	MT	DTT
DM06HG5	MA	Agonist
DM06HG5	RN	Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
DM06HG5	RU	https://pubmed.ncbi.nlm.nih.gov/10911931

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DEQX145
DM429AE	MN	Aromatase (CYP19A1)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol. 2004 Mar 1;67(5):885-92.
DM429AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15104241

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DE4LYSA
DM429AE	MN	Cytochrome P450 3A4 (CYP3A4)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clin Pharmacokinet. 2005;44(7):731-51.
DM429AE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15966756

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DEIBDNY
DM429AE	MN	Cytochrome P450 3A5 (CYP3A5)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Drug Interactions Flockhart Table
DM429AE	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM429AE	DI	DM429AE
DM429AE	DN	Levomethadyl acetate hydrochloride
DM429AE	MI	DERD86B
DM429AE	MN	Cytochrome P450 3A7 (CYP3A7)
DM429AE	MT	DME
DM429AE	MA	Metabolism
DM429AE	RN	Drug Interactions Flockhart Table
DM429AE	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	DES5XRU
DMV26S8	MN	Cytochrome P450 2C8 (CYP2C8)
DMV26S8	MT	DME
DMV26S8	MA	Metabolism
DMV26S8	RN	The role of levomilnacipran in the management of major depressive disorder: a comprehensive review. Curr Neuropharmacol. 2016;14(2):191-9.
DMV26S8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26572745

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	TTAWNKZ
DMV26S8	MN	Norepinephrine transporter (NET)
DMV26S8	MT	DTT
DMV26S8	MA	Modulator
DMV26S8	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMV26S8	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	DTUGYRD
DMV26S8	MN	P-glycoprotein 1 (ABCB1)
DMV26S8	MT	DTP
DMV26S8	MA	Substrate
DMV26S8	RN	P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier inivo. Neuropharmacology. 2016 Apr;103:104-11.
DMV26S8	RU	http://www.ncbi.nlm.nih.gov/pubmed/26700248

DMV26S8	DI	DMV26S8
DMV26S8	DN	Levomilnacipran
DMV26S8	MI	TT3ROYC
DMV26S8	MN	Serotonin transporter (SERT)
DMV26S8	MT	DTT
DMV26S8	MA	Modulator
DMV26S8	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMV26S8	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM1DP7T	DI	DM1DP7T
DM1DP7T	DN	Levonorgestrel
DM1DP7T	MI	TTUV8G9
DM1DP7T	MN	Progesterone receptor (PGR)
DM1DP7T	MT	DTT
DM1DP7T	MA	Binder
DM1DP7T	RN	Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24.
DM1DP7T	RU	https://pubmed.ncbi.nlm.nih.gov/19289570

DMECB4H	DI	DMECB4H
DMECB4H	DN	Levopropoxyphene Napsylate Anhydrous
DMECB4H	MI	TT35UGH
DMECB4H	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DMECB4H	MT	DTT
DMECB4H	MA	Modulator
DMECB4H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMECB4H	RU	https://www.fda.gov/

DMECB4H	DI	DMECB4H
DMECB4H	DN	Levopropoxyphene Napsylate Anhydrous
DMECB4H	MI	TTKWM86
DMECB4H	MN	Opioid receptor mu (MOP)
DMECB4H	MT	DTT
DMECB4H	MA	Modulator
DMECB4H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMECB4H	RU	https://www.fda.gov/

DM2XVNI	DI	DM2XVNI
DM2XVNI	DN	Levormeloxifene
DM2XVNI	MI	TTZAYWL
DM2XVNI	MN	Estrogen receptor (ESR)
DM2XVNI	MT	DTT
DM2XVNI	MA	Modulator
DM2XVNI	RN	Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001 Jul;21(4):302-47.
DM2XVNI	RU	https://pubmed.ncbi.nlm.nih.gov/11410933

DMGS80V	DI	DMGS80V
DMGS80V	DN	Levorphanol
DMGS80V	MI	TT9IK2Z
DMGS80V	MN	N-methyl-D-aspartate receptor (NMDAR)
DMGS80V	MT	DTT
DMGS80V	MA	Antagonist
DMGS80V	RN	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
DMGS80V	RU	https://pubmed.ncbi.nlm.nih.gov/12507405

DMGS80V	DI	DMGS80V
DMGS80V	DN	Levorphanol
DMGS80V	MI	TTN4QDT
DMGS80V	MN	Opioid receptor (OPR)
DMGS80V	MT	DTT
DMGS80V	MA	Agonist
DMGS80V	RN	Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
DMGS80V	RU	https://pubmed.ncbi.nlm.nih.gov/14742749

DMKBOS2	DI	DMKBOS2
DMKBOS2	DN	Levosimendan
DMKBOS2	MI	TT8RDXP
DMKBOS2	MN	Troponin C (TN-C)
DMKBOS2	MT	DTT
DMKBOS2	MA	Stimulator
DMKBOS2	RN	Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30.
DMKBOS2	RU	https://pubmed.ncbi.nlm.nih.gov/19520657

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DE4LYSA
DMHN027	MN	Cytochrome P450 3A4 (CYP3A4)
DMHN027	MT	DME
DMHN027	MA	Metabolism
DMHN027	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DMHN027	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DTE2B1D
DMHN027	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DT3D8F0
DMHN027	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DTPYCQ4
DMHN027	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DMHN027	MT	DTP
DMHN027	MA	Substrate
DMHN027	RN	Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.
DMHN027	RU	http://www.ncbi.nlm.nih.gov/pubmed/12351693

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	TTTSEPU
DMHN027	MN	Thyroid hormone receptor alpha (THRA)
DMHN027	MT	DTT
DMHN027	MA	Antagonist
DMHN027	RN	Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23.
DMHN027	RU	https://pubmed.ncbi.nlm.nih.gov/18816177

DMHN027	DI	DMHN027
DMHN027	DN	Levothyroxine
DMHN027	MI	DEYGVN4
DMHN027	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHN027	MT	DME
DMHN027	MA	Metabolism
DMHN027	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMHN027	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT85HYR
DM4PUDW	MN	Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/25663199

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTDSYAQ
DM4PUDW	MN	Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/30321589

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTKLMH6
DM4PUDW	MN	Cystine/glutamate transporter (SLC7A11)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28630042

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT9U216
DM4PUDW	MN	Excitatory amino acid transporter 1 (SLC1A3)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT0VAI5
DM4PUDW	MN	Excitatory amino acid transporter 2 (SLC1A2)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/25274824

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTJIRMD
DM4PUDW	MN	Excitatory amino acid transporter 3 (SLC1A1)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/21123949

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTV2AOB
DM4PUDW	MN	Excitatory amino acid transporter 4 (SLC1A6)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTBGZ8H
DM4PUDW	MN	Excitatory amino acid transporter 5 (SLC1A7)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506861

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTJCWP8
DM4PUDW	MN	Mitochondrial glutamate carrier 1 (SLC25A22)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15592994

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT3VZJO
DM4PUDW	MN	Mitochondrial glutamate carrier 2 (SLC25A18)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18)
DM4PUDW	RU	http://slc.bioparadigms.org/protein?GeneName=SLC25A18

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	TT9IK2Z
DM4PUDW	MN	N-methyl-D-aspartate receptor (NMDAR)
DM4PUDW	MT	DTT
DM4PUDW	MA	Antagonist
DM4PUDW	RN	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
DM4PUDW	RU	https://pubmed.ncbi.nlm.nih.gov/18923069

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT06JWZ
DM4PUDW	MN	Organic anion transporter 4 (SLC22A11)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The role of the intracellular glutamate gradient in driving organic anion transporter function.
DM4PUDW	RU	http://www.physoc.org/proceedings/abstract/Proc%20Physiol%20Soc%2034C12

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTPFTEQ
DM4PUDW	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
DM4PUDW	RU	http://www.tcdb.org/search/result.php?tc=2.A.60.1.20

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT38SZL
DM4PUDW	MN	Organic cation transporter-like 3 (SLC22A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/24147638

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT2LGOY
DM4PUDW	MN	Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28593130

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT0UQDA
DM4PUDW	MN	Putative sodium-coupled neutral amino acid transporter 8 (SLC38A8)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/28546991

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTMWE5P
DM4PUDW	MN	Sodium-independent aspartate/glutamate transporter 1 (SLC7A13)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/26739563

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTNK0FR
DM4PUDW	MN	Vesicular glutamate transporter 1 (SLC17A7)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DT5LHCR
DM4PUDW	MN	Vesicular glutamate transporter 2 (SLC17A6)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM4PUDW	DI	DM4PUDW
DM4PUDW	DN	L-glutamic acid
DM4PUDW	MI	DTAGDH7
DM4PUDW	MN	Vesicular glutamate transporter 3 (SLC17A8)
DM4PUDW	MT	DTP
DM4PUDW	MA	Substrate
DM4PUDW	RN	Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
DM4PUDW	RU	http://www.ncbi.nlm.nih.gov/pubmed/15210307

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTW7AE3
DM69G8X	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/16516348

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DT48T0N
DM69G8X	MN	L-type amino acid transporter 1 (SLC7A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/19203585

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DT2EGUN
DM69G8X	MN	Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTD815L
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 1 (SLC38A1)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTTWL58
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 2 (SLC38A2)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTKWJH3
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 3 (SLC38A3)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTPJBD5
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 4 (SLC38A4)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DM69G8X	DI	DM69G8X
DM69G8X	DN	L-glutamine
DM69G8X	MI	DTLX28N
DM69G8X	MN	Sodium-coupled neutral amino acid transporter 5 (SLC38A5)
DM69G8X	MT	DTP
DM69G8X	MA	Substrate
DM69G8X	RN	Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
DM69G8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/21511949

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	DE4LYSA
DMNQXV8	MN	Cytochrome P450 3A4 (CYP3A4)
DMNQXV8	MT	DME
DMNQXV8	MA	Metabolism
DMNQXV8	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	DEGTFWK
DMNQXV8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNQXV8	MT	DME
DMNQXV8	MA	Metabolism
DMNQXV8	RN	Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29356698

DMNQXV8	DI	DMNQXV8
DMNQXV8	DN	LGX818
DMNQXV8	MI	TTWCGQT
DMNQXV8	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMNQXV8	MT	DTT
DMNQXV8	MA	Modulator
DMNQXV8	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNQXV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEJGDUW
DML4ZOT	MN	Cytochrome P450 1A2 (CYP1A2)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEJVYAZ
DML4ZOT	MN	Cytochrome P450 2A6 (CYP2A6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEPKLMQ
DML4ZOT	MN	Cytochrome P450 2B6 (CYP2B6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEZMWRE
DML4ZOT	MN	Cytochrome P450 2C18 (CYP2C18)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DES5XRU
DML4ZOT	MN	Cytochrome P450 2C8 (CYP2C8)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DE5IED8
DML4ZOT	MN	Cytochrome P450 2C9 (CYP2C9)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DECB0K3
DML4ZOT	MN	Cytochrome P450 2D6 (CYP2D6)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10901707

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DE4LYSA
DML4ZOT	MN	Cytochrome P450 3A4 (CYP3A4)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Pharmacokinetics of lidocaine hydrochloride metabolized by CYP3A4 in Chinese Han volunteers living at low altitude and in native Han and Tibetan Chinese volunteers living at high altitude. Pharmacology. 2016;97(3-4):107-13.
DML4ZOT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26730802

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DEIBDNY
DML4ZOT	MN	Cytochrome P450 3A5 (CYP3A5)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Drug Interactions Flockhart Table
DML4ZOT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DERD86B
DML4ZOT	MN	Cytochrome P450 3A7 (CYP3A7)
DML4ZOT	MT	DME
DML4ZOT	MA	Metabolism
DML4ZOT	RN	Drug Interactions Flockhart Table
DML4ZOT	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	DTUGYRD
DML4ZOT	MN	P-glycoprotein 1 (ABCB1)
DML4ZOT	MT	DTP
DML4ZOT	MA	Substrate
DML4ZOT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DML4ZOT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DML4ZOT	DI	DML4ZOT
DML4ZOT	DN	Lidocaine
DML4ZOT	MI	TTN9VTF
DML4ZOT	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DML4ZOT	MT	DTT
DML4ZOT	MA	Blocker
DML4ZOT	RN	Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6.
DML4ZOT	RU	https://pubmed.ncbi.nlm.nih.gov/19378524

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	DE4LYSA
DMV23GL	MN	Cytochrome P450 3A4 (CYP3A4)
DMV23GL	MT	DME
DMV23GL	MA	Metabolism
DMV23GL	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMV23GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTRK8B9
DMV23GL	MN	Sodium channel unspecific (NaC)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/8295214

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTLXAKE
DMV23GL	MN	Solute carrier family 29 member 1 (SLC29A1)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/17636949

DMV23GL	DI	DMV23GL
DMV23GL	DN	Lidoflazine
DMV23GL	MI	TTAXZ0K
DMV23GL	MN	Voltage-gated sodium channel alpha Nav1.3 (SCN3A)
DMV23GL	MT	DTT
DMV23GL	MA	Inhibitor
DMV23GL	RN	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
DMV23GL	RU	https://pubmed.ncbi.nlm.nih.gov/8295214

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	TT48WR6
DM4WVC5	MN	Integrin alpha-L (ITGAL)
DM4WVC5	MT	DTT
DM4WVC5	MA	Modulator
DM4WVC5	RN	Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.
DM4WVC5	RU	https://pubmed.ncbi.nlm.nih.gov/23215542

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	TTCT6F7
DM4WVC5	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DM4WVC5	MT	DTT
DM4WVC5	MA	Inhibitor
DM4WVC5	RN	Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6.
DM4WVC5	RU	https://pubmed.ncbi.nlm.nih.gov/24900456

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	DTE2B1D
DM4WVC5	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM4WVC5	MT	DTP
DM4WVC5	MA	Substrate
DM4WVC5	RN	Clinical Pharmacology and Biopharmaceutics review(s)
DM4WVC5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf

DM4WVC5	DI	DM4WVC5
DM4WVC5	DN	Lifitegrast
DM4WVC5	MI	DTPFTEQ
DM4WVC5	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM4WVC5	MT	DTP
DM4WVC5	MA	Substrate
DM4WVC5	RN	Clinical Pharmacology and Biopharmaceutics review(s)
DM4WVC5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf

DM4EGV0	DI	DM4EGV0
DM4EGV0	DN	Linaclotide
DM4EGV0	MI	TTLDPRG
DM4EGV0	MN	Guanylyl cyclase C (GUCY2C)
DM4EGV0	MT	DTT
DM4EGV0	MA	Activator
DM4EGV0	RN	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
DM4EGV0	RU	https://pubmed.ncbi.nlm.nih.gov/17979603

DMWFJTR	DI	DMWFJTR
DMWFJTR	DN	Linagliptin
DMWFJTR	MI	TTDIGC1
DMWFJTR	MN	Dipeptidyl peptidase 4 (DPP-4)
DMWFJTR	MT	DTT
DMWFJTR	MA	Inhibitor
DMWFJTR	RN	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
DMWFJTR	RU	http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp

DMWFJTR	DI	DMWFJTR
DMWFJTR	DN	Linagliptin
DMWFJTR	MI	DTUGYRD
DMWFJTR	MN	P-glycoprotein 1 (ABCB1)
DMWFJTR	MT	DTP
DMWFJTR	MA	Substrate
DMWFJTR	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMWFJTR	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMVTHER	DI	DMVTHER
DMVTHER	DN	Lincomycin
DMVTHER	MI	TTUWYEA
DMVTHER	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMVTHER	MT	DTT
DMVTHER	MA	Inhibitor
DMVTHER	RN	Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35.
DMVTHER	RU	https://pubmed.ncbi.nlm.nih.gov/10856379

DMB8CNL	DI	DMB8CNL
DMB8CNL	DN	Lindane
DMB8CNL	MI	TTAN6JD
DMB8CNL	MN	Glutamate receptor AMPA (GRIA)
DMB8CNL	MT	DTT
DMB8CNL	MA	Antagonist
DMB8CNL	RN	NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20.
DMB8CNL	RU	https://pubmed.ncbi.nlm.nih.gov/18834901

DMGFPU2	DI	DMGFPU2
DMGFPU2	DN	Linezolid
DMGFPU2	MI	TTLFGBV
DMGFPU2	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMGFPU2	MT	DTT
DMGFPU2	MA	Binder
DMGFPU2	RN	Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
DMGFPU2	RU	https://pubmed.ncbi.nlm.nih.gov/19351617

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTE2B1D
DM6IR3P	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT3D8F0
DM6IR3P	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT9C1TS
DM6IR3P	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTPYCQ4
DM6IR3P	MN	Organic anion transporting polypeptide 1C1 (SLCO1C1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/15166123

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT8H2IC
DM6IR3P	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DTY0QMU
DM6IR3P	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/14993604

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DT56EKP
DM6IR3P	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM6IR3P	MT	DTP
DM6IR3P	MA	Substrate
DM6IR3P	RN	Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
DM6IR3P	RU	http://www.ncbi.nlm.nih.gov/pubmed/9918867

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DEYWLRK
DM6IR3P	MN	Sulfotransferase 1A1 (SULT1A1)
DM6IR3P	MT	DME
DM6IR3P	MA	Metabolism
DM6IR3P	RN	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
DM6IR3P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11739018

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	TTTSEPU
DM6IR3P	MN	Thyroid hormone receptor alpha (THRA)
DM6IR3P	MT	DTT
DM6IR3P	MA	Antagonist
DM6IR3P	RN	Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32.
DM6IR3P	RU	https://pubmed.ncbi.nlm.nih.gov/17827792

DM6IR3P	DI	DM6IR3P
DM6IR3P	DN	Liothyronine
DM6IR3P	MI	DEYGVN4
DM6IR3P	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6IR3P	MT	DME
DM6IR3P	MA	Metabolism
DM6IR3P	RN	FDA Label of Liothyronine sodium. The 2020 official website of the U.S. Food and Drug Administration.
DM6IR3P	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/010379s054lbl.pdf

DMSTXWR	DI	DMSTXWR
DMSTXWR	DN	Liotrix
DMSTXWR	MI	DE4LYSA
DMSTXWR	MN	Cytochrome P450 3A4 (CYP3A4)
DMSTXWR	MT	DME
DMSTXWR	MA	Metabolism
DMSTXWR	RN	A basic conceptual and practical overview of interactions with highly prescribed drugs. Can J Clin Pharmacol. 2002 Winter;9(4):191-8.
DMSTXWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12584577

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	DEKZQY6
DM3FXPS	MN	Dipeptidyl peptidase IV (DPP4)
DM3FXPS	MT	DME
DM3FXPS	MA	Metabolism
DM3FXPS	RN	Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53.
DM3FXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20709939

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	TTVIMDE
DM3FXPS	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM3FXPS	MT	DTT
DM3FXPS	MA	Agonist
DM3FXPS	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM3FXPS	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DM3FXPS	DI	DM3FXPS
DM3FXPS	DN	Liraglutide
DM3FXPS	MI	DEVN830
DM3FXPS	MN	Neprilysin (MME)
DM3FXPS	MT	DME
DM3FXPS	MA	Metabolism
DM3FXPS	RN	Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944-53.
DM3FXPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20709939

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	DECB0K3
DM6W8V5	MN	Cytochrome P450 2D6 (CYP2D6)
DM6W8V5	MT	DME
DM6W8V5	MA	Metabolism
DM6W8V5	RN	Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
DM6W8V5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24594478

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	DT9G7XN
DM6W8V5	MN	Peptide transporter 1 (SLC15A1)
DM6W8V5	MT	DTP
DM6W8V5	MA	Substrate
DM6W8V5	RN	Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010 Jun 24;6:317-27.
DM6W8V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/20628632

DM6W8V5	DI	DM6W8V5
DM6W8V5	DN	Lisdexamfetamine
DM6W8V5	MI	TTIU98M
DM6W8V5	MN	Trace amine-associated receptor-1 (TAAR1)
DM6W8V5	MT	DTT
DM6W8V5	MA	Modulator
DM6W8V5	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM6W8V5	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMUOK4C	DI	DMUOK4C
DMUOK4C	DN	Lisinopril
DMUOK4C	MI	TTL69WB
DMUOK4C	MN	Angiotensin-converting enzyme (ACE)
DMUOK4C	MT	DTT
DMUOK4C	MA	Inhibitor
DMUOK4C	RN	Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71.
DMUOK4C	RU	https://pubmed.ncbi.nlm.nih.gov/19556720

DMUOK4C	DI	DMUOK4C
DMUOK4C	DN	Lisinopril
DMUOK4C	MI	DT9G7XN
DMUOK4C	MN	Peptide transporter 1 (SLC15A1)
DMUOK4C	MT	DTP
DMUOK4C	MA	Substrate
DMUOK4C	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMUOK4C	RU	https://doi.org/10.1007/BF02980227

DMP45ME	DI	DMP45ME
DMP45ME	DN	Lisocabtagene maraleucel
DMP45ME	MI	TTW640A
DMP45ME	MN	B-lymphocyte surface antigen B4 (CD19)
DMP45ME	MT	DTT
DMP45ME	MA	CAR-T-Cell-Therapy
DMP45ME	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMP45ME	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	DECB0K3
DMCME17	MN	Cytochrome P450 2D6 (CYP2D6)
DMCME17	MT	DME
DMCME17	MA	Metabolism
DMCME17	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DMCME17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	DE4LYSA
DMCME17	MN	Cytochrome P450 3A4 (CYP3A4)
DMCME17	MT	DME
DMCME17	MA	Metabolism
DMCME17	RN	Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol. 1995 Oct 6;293(3):183-90.
DMCME17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8666035

DMCME17	DI	DMCME17
DMCME17	DN	Lisuride
DMCME17	MI	TTEX248
DMCME17	MN	Dopamine D2 receptor (D2R)
DMCME17	MT	DTT
DMCME17	MA	Agonist
DMCME17	RN	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9.
DMCME17	RU	https://pubmed.ncbi.nlm.nih.gov/17706566

DMX9PIA	DI	DMX9PIA
DMX9PIA	DN	Live attenuated influenza vaccine
DMX9PIA	MI	TT3J5ZI
DMX9PIA	MN	Cell mediated immunity response (CMIR)
DMX9PIA	MT	DTT
DMX9PIA	RN	Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84.
DMX9PIA	RU	https://pubmed.ncbi.nlm.nih.gov/18174020

DM0QJDC	DI	DM0QJDC
DM0QJDC	DN	Lixisenatide
DM0QJDC	MI	TTVIMDE
DM0QJDC	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0QJDC	MT	DTT
DM0QJDC	MA	Modulator
DM0QJDC	RN	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
DM0QJDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22945360

DMJPD06	DI	DMJPD06
DMJPD06	DN	Lmw heparin
DMJPD06	MI	TTCIHJA
DMJPD06	MN	Coagulation factor Xa (F10)
DMJPD06	MT	DTT
DMJPD06	MA	Modulator
DMJPD06	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJPD06	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	DES5XRU
DMHY3IP	MN	Cytochrome P450 2C8 (CYP2C8)
DMHY3IP	MT	DME
DMHY3IP	MA	Metabolism
DMHY3IP	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMHY3IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	DE4LYSA
DMHY3IP	MN	Cytochrome P450 3A4 (CYP3A4)
DMHY3IP	MT	DME
DMHY3IP	MA	Metabolism
DMHY3IP	RN	Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on the pharmacokinetics and pharmacodynamics of warfarin. Drug Des Devel Ther. 2015 Mar 2;9:737-43.
DMHY3IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25767371

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	TTJ584C
DMHY3IP	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMHY3IP	MT	DTT
DMHY3IP	MA	Agonist
DMHY3IP	RN	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
DMHY3IP	RU	https://pubmed.ncbi.nlm.nih.gov/24802657

DMHY3IP	DI	DMHY3IP
DMHY3IP	DN	Lobeglitazone
DMHY3IP	MI	TTZMAO3
DMHY3IP	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMHY3IP	MT	DTT
DMHY3IP	MA	Agonist
DMHY3IP	RN	Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
DMHY3IP	RU	https://pubmed.ncbi.nlm.nih.gov/24802657

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	TTQ8AFT
DM1WXA6	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM1WXA6	MT	DTT
DM1WXA6	MA	Agonist
DM1WXA6	RN	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
DM1WXA6	RU	https://pubmed.ncbi.nlm.nih.gov/18821454

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	TTWG9A4
DM1WXA6	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM1WXA6	MT	DTT
DM1WXA6	MA	Agonist
DM1WXA6	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1WXA6	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DEJGDUW
DM1WXA6	MN	Cytochrome P450 1A2 (CYP1A2)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	The Drugs.com International Drug Name Database: Lofexidine
DM1WXA6	RU	https://www.drugs.com/ppa/lofexidine.html

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DECB0K3
DM1WXA6	MN	Cytochrome P450 2D6 (CYP2D6)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DM1WXA6	RU	https://www.fda.gov/media/111903/download

DM1WXA6	DI	DM1WXA6
DM1WXA6	DN	Lofexidine
DM1WXA6	MI	DEGTFWK
DM1WXA6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1WXA6	MT	DME
DM1WXA6	MA	Metabolism
DM1WXA6	RN	Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
DM1WXA6	RU	https://www.fda.gov/media/111903/download

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	DEJGDUW
DMVRH9C	MN	Cytochrome P450 1A2 (CYP1A2)
DMVRH9C	MT	DME
DMVRH9C	MA	Metabolism
DMVRH9C	RN	Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
DMVRH9C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510417

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	TT0IHXV
DMVRH9C	MN	DNA topoisomerase II (TOP2)
DMVRH9C	MT	DTT
DMVRH9C	MA	Inhibitor
DMVRH9C	RN	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
DMVRH9C	RU	https://pubmed.ncbi.nlm.nih.gov/12215656

DMVRH9C	DI	DMVRH9C
DMVRH9C	DN	Lomefloxacin
DMVRH9C	MI	DTE2B1D
DMVRH9C	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMVRH9C	MT	DTP
DMVRH9C	MA	Substrate
DMVRH9C	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMVRH9C	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	DE4LYSA
DME0TC8	MN	Cytochrome P450 3A4 (CYP3A4)
DME0TC8	MT	DME
DME0TC8	MA	Metabolism
DME0TC8	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DME0TC8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TTRK8B9
DME0TC8	MN	Sodium channel unspecific (NaC)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TT4FDG6
DME0TC8	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/17134896

DME0TC8	DI	DME0TC8
DME0TC8	DN	Lomerizine
DME0TC8	MI	TTZOVE0
DME0TC8	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DME0TC8	MT	DTT
DME0TC8	MA	Inhibitor
DME0TC8	RN	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
DME0TC8	RU	https://pubmed.ncbi.nlm.nih.gov/11170622

DMLB4PE	DI	DMLB4PE
DMLB4PE	DN	Lomitapide mesylate
DMLB4PE	MI	DE4LYSA
DMLB4PE	MN	Cytochrome P450 3A4 (CYP3A4)
DMLB4PE	MT	DME
DMLB4PE	MA	Metabolism
DMLB4PE	RN	Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2016 Jan;56(1):47-55.
DMLB4PE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26120010

DMMWSUL	DI	DMMWSUL
DMMWSUL	DN	Lomustine
DMMWSUL	MI	TTUTN1I
DMMWSUL	MN	Human Deoxyribonucleic acid (hDNA)
DMMWSUL	MT	DTT
DMMWSUL	MA	Inhibitor
DMMWSUL	RN	Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33.
DMMWSUL	RU	https://pubmed.ncbi.nlm.nih.gov/17665847

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	DE4LYSA
DMGM2Z6	MN	Cytochrome P450 3A4 (CYP3A4)
DMGM2Z6	MT	DME
DMGM2Z6	MA	Metabolism
DMGM2Z6	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DMGM2Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	DEIBDNY
DMGM2Z6	MN	Cytochrome P450 3A5 (CYP3A5)
DMGM2Z6	MT	DME
DMGM2Z6	MA	Metabolism
DMGM2Z6	RN	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
DMGM2Z6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16443667

DMGM2Z6	DI	DMGM2Z6
DMGM2Z6	DN	Lonafarnib
DMGM2Z6	MI	TTXQKM3
DMGM2Z6	MN	Farnesyl protein transferase (Ftase)
DMGM2Z6	MT	DTT
DMGM2Z6	MA	Modulator
DMGM2Z6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMGM2Z6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf

DMXSVGI	DI	DMXSVGI
DMXSVGI	DN	Loncastuximab tesirine
DMXSVGI	MI	TTW640A
DMXSVGI	MN	B-lymphocyte surface antigen B4 (CD19)
DMXSVGI	MT	DTT
DMXSVGI	MA	Inhibitor
DMXSVGI	RN	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
DMXSVGI	RU	https://pubmed.ncbi.nlm.nih.gov/33211842

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DEPKLMQ
DMOJZQ9	MN	Cytochrome P450 2B6 (CYP2B6)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DES5XRU
DMOJZQ9	MN	Cytochrome P450 2C8 (CYP2C8)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DECB0K3
DMOJZQ9	MN	Cytochrome P450 2D6 (CYP2D6)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004 Oct;60(8):575-81.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15365656

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DE4LYSA
DMOJZQ9	MN	Cytochrome P450 3A4 (CYP3A4)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8.
DMOJZQ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18192961

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	TT27RFC
DMOJZQ9	MN	Opioid receptor delta (OPRD1)
DMOJZQ9	MT	DTT
DMOJZQ9	MA	Binder
DMOJZQ9	RN	Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
DMOJZQ9	RU	https://pubmed.ncbi.nlm.nih.gov/6319884

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DEDPI65
DMOJZQ9	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMOJZQ9	MT	DME
DMOJZQ9	MA	Metabolism
DMOJZQ9	RN	Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995 Mar;23(3):354-62.
DMOJZQ9	RU	https://pubmed.ncbi.nlm.nih.gov/7628301

DMOJZQ9	DI	DMOJZQ9
DMOJZQ9	DN	Loperamide
DMOJZQ9	MI	DTUGYRD
DMOJZQ9	MN	P-glycoprotein 1 (ABCB1)
DMOJZQ9	MT	DTP
DMOJZQ9	MA	Substrate
DMOJZQ9	RN	In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008 Feb;36(2):268-75.
DMOJZQ9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17962372

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	TTLFGBV
DMITQS0	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMITQS0	MT	DTT
DMITQS0	MA	Modulator
DMITQS0	RN	Company report (JMI Laboratories)
DMITQS0	RU	http://www.jmilabs.com/data/posters/ICAAC2013%5CE-144.pdf

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTI7UX6
DMITQS0	MN	Breast cancer resistance protein (ABCG2)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DE4LYSA
DMITQS0	MN	Cytochrome P450 3A4 (CYP3A4)
DMITQS0	MT	DME
DMITQS0	MA	Metabolism
DMITQS0	RN	Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3.
DMITQS0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11378352

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTSYQGK
DMITQS0	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007 Nov;60(5):987-93.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/17890284

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTFI42L
DMITQS0	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/20590614

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DT3D8F0
DMITQS0	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMITQS0	DI	DMITQS0
DMITQS0	DN	Lopinavir
DMITQS0	MI	DTUGYRD
DMITQS0	MN	P-glycoprotein 1 (ABCB1)
DMITQS0	MT	DTP
DMITQS0	MA	Substrate
DMITQS0	RN	Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
DMITQS0	RU	http://www.ncbi.nlm.nih.gov/pubmed/20590614

DM4L8H3	DI	DM4L8H3
DM4L8H3	DN	Loracarbef
DM4L8H3	MI	TTJP4SM
DM4L8H3	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4L8H3	MT	DTT
DM4L8H3	MA	Binder
DM4L8H3	RN	Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45.
DM4L8H3	RU	https://pubmed.ncbi.nlm.nih.gov/16940068

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEJGDUW
DMF3AN7	MN	Cytochrome P450 1A2 (CYP1A2)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEPKLMQ
DMF3AN7	MN	Cytochrome P450 2B6 (CYP2B6)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DES5XRU
DMF3AN7	MN	Cytochrome P450 2C8 (CYP2C8)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DE5IED8
DMF3AN7	MN	Cytochrome P450 2C9 (CYP2C9)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10597902

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DECB0K3
DMF3AN7	MN	Cytochrome P450 2D6 (CYP2D6)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1173-5.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11502723

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DE4LYSA
DMF3AN7	MN	Cytochrome P450 3A4 (CYP3A4)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEIBDNY
DMF3AN7	MN	Cytochrome P450 3A5 (CYP3A5)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19702548

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	TTTIBOJ
DMF3AN7	MN	Histamine H1 receptor (H1R)
DMF3AN7	MT	DTT
DMF3AN7	MA	Antagonist
DMF3AN7	RN	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
DMF3AN7	RU	https://pubmed.ncbi.nlm.nih.gov/19452709

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DEGTFWK
DMF3AN7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF3AN7	MT	DME
DMF3AN7	MA	Metabolism
DMF3AN7	RN	Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
DMF3AN7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27460981

DMF3AN7	DI	DMF3AN7
DMF3AN7	DN	Loratadine
DMF3AN7	MI	DTUGYRD
DMF3AN7	MN	P-glycoprotein 1 (ABCB1)
DMF3AN7	MT	DTP
DMF3AN7	MA	Substrate
DMF3AN7	RN	P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8.
DMF3AN7	RU	http://www.ncbi.nlm.nih.gov/pubmed/12584158

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	TTPTXIN
DM84ZXF	MN	Translocator protein (TSPO)
DM84ZXF	MT	DTT
DM84ZXF	MA	Modulator
DM84ZXF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM84ZXF	RU	https://www.fda.gov/

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	DENZ6B1
DM84ZXF	MN	UDP-glucuronosyltransferase 2B15 (UGT2B15)
DM84ZXF	MT	DME
DM84ZXF	MA	Metabolism
DM84ZXF	RN	Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
DM84ZXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15961980

DM84ZXF	DI	DM84ZXF
DM84ZXF	DN	Lorazepam
DM84ZXF	MI	DEB3CV1
DM84ZXF	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM84ZXF	MT	DME
DM84ZXF	MA	Metabolism
DM84ZXF	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DM84ZXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	TTWJBZ5
DMG6OYJ	MN	5-HT 2C receptor (HTR2C)
DMG6OYJ	MT	DTT
DMG6OYJ	MA	Agonist
DMG6OYJ	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMG6OYJ	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEJGDUW
DMG6OYJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEJVYAZ
DMG6OYJ	MN	Cytochrome P450 2A6 (CYP2A6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEPKLMQ
DMG6OYJ	MN	Cytochrome P450 2B6 (CYP2B6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DECB0K3
DMG6OYJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DE4LYSA
DMG6OYJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMG6OYJ	DI	DMG6OYJ
DMG6OYJ	DN	Lorcaserin
DMG6OYJ	MI	DEGTFWK
DMG6OYJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG6OYJ	MT	DME
DMG6OYJ	MA	Metabolism
DMG6OYJ	RN	Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
DMG6OYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22266842

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	TTPMQSO
DMICDLV	MN	ALK tyrosine kinase receptor (ALK)
DMICDLV	MT	DTT
DMICDLV	MA	Inhibitor
DMICDLV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMICDLV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DES5XRU
DMICDLV	MN	Cytochrome P450 2C8 (CYP2C8)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DE4LYSA
DMICDLV	MN	Cytochrome P450 3A4 (CYP3A4)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEIBDNY
DMICDLV	MN	Cytochrome P450 3A5 (CYP3A5)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DERD86B
DMICDLV	MN	Cytochrome P450 3A7 (CYP3A7)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	Product characteristics of Lorviqua.
DMICDLV	RU	https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEGTFWK
DMICDLV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	TTSZ6Y3
DMICDLV	MN	Proto-oncogene c-Ros (ROS1)
DMICDLV	MT	DTT
DMICDLV	MA	Inhibitor
DMICDLV	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMICDLV	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DEF2WXN
DMICDLV	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMICDLV	DI	DMICDLV
DMICDLV	DN	Lorlatinib
DMICDLV	MI	DELOY3P
DMICDLV	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMICDLV	MT	DME
DMICDLV	MA	Metabolism
DMICDLV	RN	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
DMICDLV	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf

DMYZFXN	DI	DMYZFXN
DMYZFXN	DN	Lornoxicam
DMYZFXN	MI	DE5IED8
DMYZFXN	MN	Cytochrome P450 2C9 (CYP2C9)
DMYZFXN	MT	DME
DMYZFXN	MA	Metabolism
DMYZFXN	RN	Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8.
DMYZFXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513

DMYZFXN	DI	DMYZFXN
DMYZFXN	DN	Lornoxicam
DMYZFXN	MI	TTK0943
DMYZFXN	MN	Prostaglandin G/H synthase (COX)
DMYZFXN	MT	DTT
DMYZFXN	MA	Modulator
DMYZFXN	RN	The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
DMYZFXN	RU	https://pubmed.ncbi.nlm.nih.gov/10450786

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	TT8DBY3
DM72JXH	MN	Angiotensin II receptor type-1 (AGTR1)
DM72JXH	MT	DTT
DM72JXH	MA	Antagonist
DM72JXH	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DM72JXH	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DES5XRU
DM72JXH	MN	Cytochrome P450 2C8 (CYP2C8)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25424246

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DE5IED8
DM72JXH	MN	Cytochrome P450 2C9 (CYP2C9)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DE4LYSA
DM72JXH	MN	Cytochrome P450 3A4 (CYP3A4)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEIBDNY
DM72JXH	MN	Cytochrome P450 3A5 (CYP3A5)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DT9G7XN
DM72JXH	MN	Peptide transporter 1 (SLC15A1)
DM72JXH	MT	DTP
DM72JXH	MA	Substrate
DM72JXH	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DM72JXH	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DTUGYRD
DM72JXH	MN	P-glycoprotein 1 (ABCB1)
DM72JXH	MT	DTP
DM72JXH	MA	Substrate
DM72JXH	RN	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
DM72JXH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10725273

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEYGVN4
DM72JXH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEL5N6Y
DM72JXH	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEF2WXN
DM72JXH	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM72JXH	DI	DM72JXH
DM72JXH	DN	Losartan
DM72JXH	MI	DEB3CV1
DM72JXH	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM72JXH	MT	DME
DM72JXH	MA	Metabolism
DM72JXH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM72JXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	DE4LYSA
DM8QTJI	MN	Cytochrome P450 3A4 (CYP3A4)
DM8QTJI	MT	DME
DM8QTJI	MA	Metabolism
DM8QTJI	RN	EMC: Lotemax 0.5% w/v Eye Drops, Suspension.
DM8QTJI	RU	https://www.medicines.org.uk/emc/product/6212

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	DESDN74
DM8QTJI	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM8QTJI	MT	DME
DM8QTJI	MA	Metabolism
DM8QTJI	RN	Identification of esterase involved in the metabolism of two corticosteroid soft drugs. Biochem Pharmacol. 2017 Mar 1;127:82-89.
DM8QTJI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28017774

DM8QTJI	DI	DM8QTJI
DM8QTJI	DN	Loteprednol etabonate
DM8QTJI	MI	TTP3UTW
DM8QTJI	MN	Steroid hormone receptor ERR (ESRR)
DM8QTJI	MT	DTT
DM8QTJI	MA	Modulator
DM8QTJI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8QTJI	RU	https://www.fda.gov/

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DES5XRU
DM9OZWQ	MN	Cytochrome P450 2C8 (CYP2C8)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DE4LYSA
DM9OZWQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11475198

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	TTPADOQ
DM9OZWQ	MN	HMG-CoA reductase (HMGCR)
DM9OZWQ	MT	DTT
DM9OZWQ	MA	Inhibitor
DM9OZWQ	RN	Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
DM9OZWQ	RU	https://pubmed.ncbi.nlm.nih.gov/12082550

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEGTFWK
DM9OZWQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DT3D8F0
DM9OZWQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM9OZWQ	MT	DTP
DM9OZWQ	MA	Substrate
DM9OZWQ	RN	A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
DM9OZWQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/10601278

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DTUGYRD
DM9OZWQ	MN	P-glycoprotein 1 (ABCB1)
DM9OZWQ	MT	DTP
DM9OZWQ	MA	Substrate
DM9OZWQ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM9OZWQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DETXQZ1
DM9OZWQ	MN	Serum paraoxonase/lactonase 3 (PON3)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27238723

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEYGVN4
DM9OZWQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEF2WXN
DM9OZWQ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM9OZWQ	DI	DM9OZWQ
DM9OZWQ	DN	Lovastatin
DM9OZWQ	MI	DEB3CV1
DM9OZWQ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9OZWQ	MT	DME
DM9OZWQ	MA	Metabolism
DM9OZWQ	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM9OZWQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DMGCQ4E	DI	DMGCQ4E
DMGCQ4E	DN	Lovastatin acid
DMGCQ4E	MI	DTUGYRD
DMGCQ4E	MN	P-glycoprotein 1 (ABCB1)
DMGCQ4E	MT	DTP
DMGCQ4E	MA	Substrate
DMGCQ4E	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMGCQ4E	RU	https://doi.org/10.1007/s11095-012-0935-x

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DEJGDUW
DM8AI9U	MN	Cytochrome P450 1A2 (CYP1A2)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DECB0K3
DM8AI9U	MN	Cytochrome P450 2D6 (CYP2D6)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	DE4LYSA
DM8AI9U	MN	Cytochrome P450 3A4 (CYP3A4)
DM8AI9U	MT	DME
DM8AI9U	MA	Metabolism
DM8AI9U	RN	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
DM8AI9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21826677

DM8AI9U	DI	DM8AI9U
DM8AI9U	DN	Loxapine
DM8AI9U	MI	TTEX248
DM8AI9U	MN	Dopamine D2 receptor (D2R)
DM8AI9U	MT	DTT
DM8AI9U	MA	Antagonist
DM8AI9U	RN	Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45.
DM8AI9U	RU	https://pubmed.ncbi.nlm.nih.gov/8665533

DMQMGXV	DI	DMQMGXV
DMQMGXV	DN	Loxoprofen gel
DMQMGXV	MI	TTK0943
DMQMGXV	MN	Prostaglandin G/H synthase (COX)
DMQMGXV	MT	DTT
DMQMGXV	MA	Inhibitor
DMQMGXV	RN	Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9.
DMQMGXV	RU	https://pubmed.ncbi.nlm.nih.gov/24261771

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTJF3DX
DMQXI9F	MN	L-type amino acid transporter 2 (SLC7A8)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/28091567

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTBMSWG
DMQXI9F	MN	L-type amino acid transporter 3 (SLC43A1)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003 Oct 31;278(44):43838-45.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12930836

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DTK02I1
DMQXI9F	MN	L-type amino acid transporter 4 (SLC43A2)
DMQXI9F	MT	DTP
DMQXI9F	MA	Substrate
DMQXI9F	RN	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. J Physiol. 2019 Jan;597(2):521-542.
DMQXI9F	RU	http://www.ncbi.nlm.nih.gov/pubmed/30379325

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	DE0WGR8
DMQXI9F	MN	Phenylalanine--tRNA ligase mitochondrial (FARS2)
DMQXI9F	MT	DME
DMQXI9F	MA	Metabolism
DMQXI9F	RN	Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase. J Mol Biol. 1999 May 14;288(4):567-77.
DMQXI9F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10329163

DMQXI9F	DI	DMQXI9F
DMQXI9F	DN	L-Phenylalanine
DMQXI9F	MI	TTUHP71
DMQXI9F	MN	Tyrosine 3-monooxygenase (TH)
DMQXI9F	MT	DTT
DMQXI9F	MA	Binder
DMQXI9F	RN	Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
DMQXI9F	RU	https://pubmed.ncbi.nlm.nih.gov/17305546

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTJF3DX
DMKSTWR	MN	L-type amino acid transporter 2 (SLC7A8)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMKSTWR	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTBPTJF
DMKSTWR	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	Interpreting metabolomic profiles using unbiased pathway models. PLoS Comput Biol. 2010 Feb 26;6(2):e1000692.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20195502

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DT48WEM
DMKSTWR	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats. Am J Physiol Endocrinol Metab. 2014 Jan 1;306(1):E65-74.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/24222668

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTBS49U
DMKSTWR	MN	Proton-coupled amino acid transporter 4 (SLC36A4)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/21097500

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	TTL2ADK
DMKSTWR	MN	Rotamase A (PPIA)
DMKSTWR	MT	DTT
DMKSTWR	MA	Binder
DMKSTWR	RN	Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009 Jan 14;131(1):147-52.
DMKSTWR	RU	https://pubmed.ncbi.nlm.nih.gov/19128175

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	TT6ZFQ4
DMKSTWR	MN	Rotamase B (PPIB)
DMKSTWR	MT	DTT
DMKSTWR	MA	Binder
DMKSTWR	RN	Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803.
DMKSTWR	RU	https://pubmed.ncbi.nlm.nih.gov/15355356

DMKSTWR	DI	DMKSTWR
DMKSTWR	DN	L-Proline
DMKSTWR	MI	DTH1GEL
DMKSTWR	MN	Sodium-dependent proline transporter (SLC6A7)
DMKSTWR	MT	DTP
DMKSTWR	MA	Substrate
DMKSTWR	RN	A new association between polymorphisms of the SLC6A7 gene in the chromosome 5q31-32 region and asthma. J Hum Genet. 2010 Jun;55(6):358-65.
DMKSTWR	RU	http://www.ncbi.nlm.nih.gov/pubmed/20431603

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DETK9CN
DMIBH7M	MN	DOPA decarboxylase (DDC)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S1-7.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1369709

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	TTZJYKH
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIBH7M	MT	DTT
DMIBH7M	MA	Binder
DMIBH7M	RN	Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
DMIBH7M	RU	https://pubmed.ncbi.nlm.nih.gov/16834326

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DE43MW5
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26970015

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DE8BVKA
DMIBH7M	MN	Indoleamine 2,3-dioxygenase 2 (IDO2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology. 2017 Jan;112(Pt B):331-345.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26970015

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTJF3DX
DMIBH7M	MN	L-type amino acid transporter 2 (SLC7A8)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DMIBH7M	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTPAQJO
DMIBH7M	MN	Monocarboxylate transporter 10 (SLC16A10)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Phosphatidylserine synthesis required for the maximal tryptophan transport activity in Saccharomyces cerevisiae. Biosci Biotechnol Biochem. 2000 Jan;64(1):167-72.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/10705462

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTVP67E
DMIBH7M	MN	Organic anion transporter 3 (SLC22A8)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/15944205

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTUGYRD
DMIBH7M	MN	P-glycoprotein 1 (ABCB1)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	Pharmacogenetics of antidepressants. Front Pharmacol. 2011 Feb 16;2:6.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21687501

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DTBS49U
DMIBH7M	MN	Proton-coupled amino acid transporter 4 (SLC36A4)
DMIBH7M	MT	DTP
DMIBH7M	MA	Substrate
DMIBH7M	RN	SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytes. J Biol Chem. 2011 Jan 28;286(4):2455-60.
DMIBH7M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21097500

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEP5BDK
DMIBH7M	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol. 2007 Feb;35(1):45-54.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17519505

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DER6XYF
DMIBH7M	MN	Tryptophan 5-hydroxylase 2 (TPH2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. J Neurochem. 2007 Nov;103(3):1111-20.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17666043

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEGH1QU
DMIBH7M	MN	Tryptophan oxygenase (TRPO)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Reaction pathway of tryptophanase-catalyzed L-tryptophan synthesis from D-serine. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 1;879(29):3289-95.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21601540

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEPVE0M
DMIBH7M	MN	Tryptophanyl-tRNA synthetase cytoplasmic (WARS1)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007 Oct;55(13):1385-96.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17661345

DMIBH7M	DI	DMIBH7M
DMIBH7M	DN	L-tryptophan
DMIBH7M	MI	DEPTKBQ
DMIBH7M	MN	Tryptophanyl-tRNA synthetase mitochondrial (WARS2)
DMIBH7M	MT	DME
DMIBH7M	MA	Metabolism
DMIBH7M	RN	Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28.
DMIBH7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17428498

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	DTJF3DX
DM9O8DT	MN	L-type amino acid transporter 2 (SLC7A8)
DM9O8DT	MT	DTP
DM9O8DT	MA	Substrate
DM9O8DT	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
DM9O8DT	RU	http://www.tcdb.org/search/result.php?tc=2.A.3.8.20

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	TTUHP71
DM9O8DT	MN	Tyrosine 3-monooxygenase (TH)
DM9O8DT	MT	DTT
DM9O8DT	MA	Binder
DM9O8DT	RN	Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
DM9O8DT	RU	https://pubmed.ncbi.nlm.nih.gov/16581181

DM9O8DT	DI	DM9O8DT
DM9O8DT	DN	L-tyrosine
DM9O8DT	MI	DEX2ZLF
DM9O8DT	MN	Tyrosine decarboxylase (tdc)
DM9O8DT	MT	DME
DM9O8DT	MA	Metabolism
DM9O8DT	RN	Tyrosine decarboxylase from Lactobacillus brevis: soluble expression and characterization. Protein Expr Purif. 2014 Feb;94:33-9.
DM9O8DT	RU	https://pubmed.ncbi.nlm.nih.gov/24211777

DMMJVXZ	DI	DMMJVXZ
DMMJVXZ	DN	LU302146
DMMJVXZ	MI	TTKRD0G
DMMJVXZ	MN	Endothelin A receptor (EDNRA)
DMMJVXZ	MT	DTT
DMMJVXZ	MA	Antagonist
DMMJVXZ	RN	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
DMMJVXZ	RU	https://pubmed.ncbi.nlm.nih.gov/12193103

DMJTEMW	DI	DMJTEMW
DMJTEMW	DN	Lubiprostone
DMJTEMW	MI	TT30NW6
DMJTEMW	MN	Chloride channel protein 2 (CLC-2)
DMJTEMW	MT	DTT
DMJTEMW	MA	Activator
DMJTEMW	RN	Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24.
DMJTEMW	RU	https://pubmed.ncbi.nlm.nih.gov/19233902

DMZLBUO	DI	DMZLBUO
DMZLBUO	DN	Lucanthone
DMZLBUO	MI	TT0IHXV
DMZLBUO	MN	DNA topoisomerase II (TOP2)
DMZLBUO	MT	DTT
DMZLBUO	MA	Inhibitor
DMZLBUO	RN	Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45.
DMZLBUO	RU	https://pubmed.ncbi.nlm.nih.gov/15832946

DMT73J8	DI	DMT73J8
DMT73J8	DN	Luliconazole
DMT73J8	MI	TTTSOUD
DMT73J8	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMT73J8	MT	DTT
DMT73J8	MA	Inhibitor
DMT73J8	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMT73J8	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMUPOGR	DI	DMUPOGR
DMUPOGR	DN	Lumacaftor + Ivacaftor
DMUPOGR	MI	TTRLZHP
DMUPOGR	MN	cAMP-dependent chloride channel (CFTR)
DMUPOGR	MT	DTT
DMUPOGR	MA	Enhancer
DMUPOGR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUPOGR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUPOGR	DI	DMUPOGR
DMUPOGR	DN	Lumacaftor + Ivacaftor
DMUPOGR	MI	TTFPKRB
DMUPOGR	MN	cAMP-dependent chloride channel F508 deletion (CFTR del F508)
DMUPOGR	MT	DTT
DMUPOGR	MA	Enhancer
DMUPOGR	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUPOGR	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMEBQAO	DI	DMEBQAO
DMEBQAO	DN	Lumasiran
DMEBQAO	MI	TTS58YO
DMEBQAO	MN	HAO1 messenger RNA (HAO1 mRNA)
DMEBQAO	MT	DTT
DMEBQAO	MA	Inhibitor
DMEBQAO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEBQAO	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf

DMQ8HOJ	DI	DMQ8HOJ
DMQ8HOJ	DN	lumateperone tosylate
DMQ8HOJ	MI	TTJQOD7
DMQ8HOJ	MN	5-HT 2A receptor (HTR2A)
DMQ8HOJ	MT	DTT
DMQ8HOJ	MA	Antagonist
DMQ8HOJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMQ8HOJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf

DMQ8HOJ	DI	DMQ8HOJ
DMQ8HOJ	DN	lumateperone tosylate
DMQ8HOJ	MI	TTEX248
DMQ8HOJ	MN	Dopamine D2 receptor (D2R)
DMQ8HOJ	MT	DTT
DMQ8HOJ	MA	Antagonist
DMQ8HOJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMQ8HOJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf

DM29GAD	DI	DM29GAD
DM29GAD	DN	Lumefantrine
DM29GAD	MI	DE4LYSA
DM29GAD	MN	Cytochrome P450 3A4 (CYP3A4)
DM29GAD	MT	DME
DM29GAD	MA	Metabolism
DM29GAD	RN	Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017 Aug 30;106:20-33.
DM29GAD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28546104

DM29GAD	DI	DM29GAD
DM29GAD	DN	Lumefantrine
DM29GAD	MI	TTWK8D0
DM29GAD	MN	Sodium pump subunit alpha-1 (ATP1A1)
DM29GAD	MT	DTT
DM29GAD	MA	Binder
DM29GAD	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM29GAD	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DEJGDUW
DM1S4AG	MN	Cytochrome P450 1A2 (CYP1A2)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DE5IED8
DM1S4AG	MN	Cytochrome P450 2C9 (CYP2C9)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DEGTFWK
DM1S4AG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372823

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	TTVKILB
DM1S4AG	MN	Prostaglandin G/H synthase 2 (COX-2)
DM1S4AG	MT	DTT
DM1S4AG	MA	Inhibitor
DM1S4AG	RN	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
DM1S4AG	RU	https://pubmed.ncbi.nlm.nih.gov/19251789

DM1S4AG	DI	DM1S4AG
DM1S4AG	DN	Lumiracoxib
DM1S4AG	MI	DE85D2P
DM1S4AG	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM1S4AG	MT	DME
DM1S4AG	MA	Metabolism
DM1S4AG	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM1S4AG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	TTJQOD7
DMCVPXO	MN	5-HT 2A receptor (HTR2A)
DMCVPXO	MT	DTT
DMCVPXO	MA	Modulator
DMCVPXO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCVPXO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	DE4LYSA
DMCVPXO	MN	Cytochrome P450 3A4 (CYP3A4)
DMCVPXO	MT	DME
DMCVPXO	MA	Metabolism
DMCVPXO	RN	Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017 May;56(5):493-503.
DMCVPXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27722855

DMCVPXO	DI	DMCVPXO
DMCVPXO	DN	Lurasidone hydrochloride
DMCVPXO	MI	TTEX248
DMCVPXO	MN	Dopamine D2 receptor (D2R)
DMCVPXO	MT	DTT
DMCVPXO	MA	Modulator
DMCVPXO	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCVPXO	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMEFRTZ	DI	DMEFRTZ
DMEFRTZ	DN	Lurbinectedin
DMEFRTZ	MI	TTUTN1I
DMEFRTZ	MN	Human Deoxyribonucleic acid (hDNA)
DMEFRTZ	MT	DTT
DMEFRTZ	MA	Inhibitor
DMEFRTZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEFRTZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

DMEFRTZ	DI	DMEFRTZ
DMEFRTZ	DN	Lurbinectedin
DMEFRTZ	MI	TTOVXHF
DMEFRTZ	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMEFRTZ	MT	DTT
DMEFRTZ	MA	Inhibitor
DMEFRTZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMEFRTZ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

DMH6IKO	DI	DMH6IKO
DMH6IKO	DN	Lusutrombopag
DMH6IKO	MI	TTIHYA4
DMH6IKO	MN	Thrombopoietin receptor (MPL)
DMH6IKO	MT	DTT
DMH6IKO	MA	Agonist
DMH6IKO	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMH6IKO	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMN1XVC	DI	DMN1XVC
DMN1XVC	DN	Lutetium Lu 177 dotatate
DMN1XVC	MI	TTIND6G
DMN1XVC	MN	Somatostatin receptor type 1 (SSTR1)
DMN1XVC	MT	DTT
DMN1XVC	MA	Antagonist
DMN1XVC	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMN1XVC	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7K5GD	DI	DM7K5GD
DM7K5GD	DN	Lutropin alfa
DM7K5GD	MI	TT2O4W9
DM7K5GD	MN	Luteinizing hormone receptor (LHCGR)
DM7K5GD	MT	DTT
DM7K5GD	MA	Binder
DM7K5GD	RN	Lutropin alfa. Drugs. 2008;68(11):1529-40.
DM7K5GD	RU	https://pubmed.ncbi.nlm.nih.gov/18627209

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DEJGDUW
DMJKROX	MN	Cytochrome P450 1A2 (CYP1A2)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. Clin Pharmacokinet. 2007;46(7):613-22.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17596106

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DECB0K3
DMJKROX	MN	Cytochrome P450 2D6 (CYP2D6)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10774624

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	DEVDYN7
DMJKROX	MN	Cytochrome P450 2E1 (CYP2E1)
DMJKROX	MT	DME
DMJKROX	MA	Metabolism
DMJKROX	RN	Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778

DMJKROX	DI	DMJKROX
DMJKROX	DN	Luvox
DMJKROX	MI	TT3ROYC
DMJKROX	MN	Serotonin transporter (SERT)
DMJKROX	MT	DTT
DMJKROX	MA	Modulator
DMJKROX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJKROX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	TT0PG8F
DM93VBZ	MN	Cyclin-dependent kinase 4 (CDK4)
DM93VBZ	MT	DTT
DM93VBZ	MA	Modulator
DM93VBZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	TTO0FDJ
DM93VBZ	MN	Cyclin-dependent kinase 6 (CDK6)
DM93VBZ	MT	DTT
DM93VBZ	MA	Modulator
DM93VBZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DE4LYSA
DM93VBZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM93VBZ	MT	DME
DM93VBZ	MA	Metabolism
DM93VBZ	RN	LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]-Abemaciclib.
DM93VBZ	RU	https://www.ncbi.nlm.nih.gov/books/NBK548807/

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DTZGT0P
DM93VBZ	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DT3TX4H
DM93VBZ	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DM93VBZ	DI	DM93VBZ
DM93VBZ	DN	LY2835219
DM93VBZ	MI	DT9IDPW
DM93VBZ	MN	Organic cation transporter 2 (SLC22A2)
DM93VBZ	MT	DTP
DM93VBZ	MA	Substrate
DM93VBZ	RN	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
DM93VBZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30449032

DMOMLHJ	DI	DMOMLHJ
DMOMLHJ	DN	Lymecycline
DMOMLHJ	MI	TTQ8KVI
DMOMLHJ	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMOMLHJ	MT	DTT
DMOMLHJ	MA	Binder
DMOMLHJ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMOMLHJ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM154EB	DI	DM154EB
DM154EB	DN	Lypressin
DM154EB	MI	TTPFZJ1
DM154EB	MN	Vasopressin V1 receptor (V1R)
DM154EB	MT	DTT
DM154EB	MA	Modulator
DM154EB	RN	Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9.
DM154EB	RU	https://pubmed.ncbi.nlm.nih.gov/3628176

DMQYJIR	DI	DMQYJIR
DMQYJIR	DN	Macimorelin
DMQYJIR	MI	TTWDC17
DMQYJIR	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMQYJIR	MT	DTT
DMQYJIR	MA	Agonist
DMQYJIR	RN	National Cancer Institute Drug Dictionary (drug id 735530).
DMQYJIR	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=735530

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	DE4LYSA
DMP79A1	MN	Cytochrome P450 3A4 (CYP3A4)
DMP79A1	MT	DME
DMP79A1	MA	Metabolism
DMP79A1	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DMP79A1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	TTKRD0G
DMP79A1	MN	Endothelin A receptor (EDNRA)
DMP79A1	MT	DTT
DMP79A1	MA	Modulator
DMP79A1	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMP79A1	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	TT3ZTGU
DMP79A1	MN	Endothelin B receptor (EDNRB)
DMP79A1	MT	DTT
DMP79A1	MA	Modulator
DMP79A1	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMP79A1	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMP79A1	DI	DMP79A1
DMP79A1	DN	Macitentan
DMP79A1	MI	DEGTFWK
DMP79A1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMP79A1	MT	DME
DMP79A1	MA	Metabolism
DMP79A1	RN	Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
DMP79A1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23568224

DM3BS97	DI	DM3BS97
DM3BS97	DN	Macrolides
DM3BS97	MI	TTLFGBV
DM3BS97	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM3BS97	MT	DTT
DM3BS97	MA	Binder
DM3BS97	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DM3BS97	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMU4ORS	DI	DMU4ORS
DMU4ORS	DN	Magnesium
DMU4ORS	MI	TT9IK2Z
DMU4ORS	MN	N-methyl-D-aspartate receptor (NMDAR)
DMU4ORS	MT	DTT
DMU4ORS	MA	Antagonist
DMU4ORS	RN	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
DMU4ORS	RU	https://pubmed.ncbi.nlm.nih.gov/19249986

DMVEK07	DI	DMVEK07
DMVEK07	DN	Magnesium Sulfate
DMVEK07	MI	TT9IK2Z
DMVEK07	MN	N-methyl-D-aspartate receptor (NMDAR)
DMVEK07	MT	DTT
DMVEK07	MA	Antagonist
DMVEK07	RN	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
DMVEK07	RU	https://pubmed.ncbi.nlm.nih.gov/17720112

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	TT1RS9F
DMXZ84M	MN	Acetylcholinesterase (AChE)
DMXZ84M	MT	DTT
DMXZ84M	MA	Inhibitor
DMXZ84M	RN	Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
DMXZ84M	RU	https://pubmed.ncbi.nlm.nih.gov/19444631

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	DEJGDUW
DMXZ84M	MN	Cytochrome P450 1A2 (CYP1A2)
DMXZ84M	MT	DME
DMXZ84M	MA	Metabolism
DMXZ84M	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DMXZ84M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DMXZ84M	DI	DMXZ84M
DMXZ84M	DN	Malathion
DMXZ84M	MI	DEPKLMQ
DMXZ84M	MN	Cytochrome P450 2B6 (CYP2B6)
DMXZ84M	MT	DME
DMXZ84M	MA	Metabolism
DMXZ84M	RN	Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms. Drug Metab Dispos. 2005 Mar;33(3):295-302.
DMXZ84M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15557345

DMSCDY9	DI	DMSCDY9
DMSCDY9	DN	Mannitol
DMSCDY9	MI	TTTX5M8
DMSCDY9	MN	Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)
DMSCDY9	MT	DTT
DMSCDY9	MA	Activator
DMSCDY9	RN	Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82.
DMSCDY9	RU	https://pubmed.ncbi.nlm.nih.gov/18983992

DMSCDY9	DI	DMSCDY9
DMSCDY9	DN	Mannitol
DMSCDY9	MI	TTV0PE2
DMSCDY9	MN	Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA)
DMSCDY9	MT	DTT
DMSCDY9	MA	Activator
DMSCDY9	RN	Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82.
DMSCDY9	RU	https://pubmed.ncbi.nlm.nih.gov/18983992

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	DEJGDUW
DMPWB7T	MN	Cytochrome P450 1A2 (CYP1A2)
DMPWB7T	MT	DME
DMPWB7T	MA	Metabolism
DMPWB7T	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DMPWB7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	DECB0K3
DMPWB7T	MN	Cytochrome P450 2D6 (CYP2D6)
DMPWB7T	MT	DME
DMPWB7T	MA	Metabolism
DMPWB7T	RN	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9.
DMPWB7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12071336

DMPWB7T	DI	DMPWB7T
DMPWB7T	DN	Maprotiline
DMPWB7T	MI	TTAWNKZ
DMPWB7T	MN	Norepinephrine transporter (NET)
DMPWB7T	MT	DTT
DMPWB7T	MA	Inhibitor
DMPWB7T	RN	Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
DMPWB7T	RU	https://pubmed.ncbi.nlm.nih.gov/15900091

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	TT2CEJG
DMTL94F	MN	C-C chemokine receptor type 5 (CCR5)
DMTL94F	MT	DTT
DMTL94F	MA	Antagonist
DMTL94F	RN	Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
DMTL94F	RU	https://pubmed.ncbi.nlm.nih.gov/19501260

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	TTJIH8Q
DMTL94F	MN	CCR5 messenger RNA (CCR5 mRNA)
DMTL94F	MT	DTT
DMTL94F	MA	Antagonist
DMTL94F	RN	Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72.
DMTL94F	RU	https://pubmed.ncbi.nlm.nih.gov/16298345

DMTL94F	DI	DMTL94F
DMTL94F	DN	Maraviroc
DMTL94F	MI	DTUGYRD
DMTL94F	MN	P-glycoprotein 1 (ABCB1)
DMTL94F	MT	DTP
DMTL94F	MA	Substrate
DMTL94F	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMTL94F	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMKEY6S	DI	DMKEY6S
DMKEY6S	DN	Margetuximab
DMKEY6S	MI	TT6EO5L
DMKEY6S	MN	Erbb2 tyrosine kinase receptor (HER2)
DMKEY6S	MT	DTT
DMKEY6S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMKEY6S	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	TT6OEDT
DM70IK5	MN	Cannabinoid receptor 1 (CB1)
DM70IK5	MT	DTT
DM70IK5	MA	Agonist
DM70IK5	RN	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
DM70IK5	RU	https://pubmed.ncbi.nlm.nih.gov/19226257

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE6OQ3W
DM70IK5	MN	Cytochrome P450 1A1 (CYP1A1)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):696-704.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15714209

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DEJVYAZ
DM70IK5	MN	Cytochrome P450 2A6 (CYP2A6)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Health control over the feeding of troops on the Western and 3d Belorussian Fronts during the Great Patriotic War years. Voen Med Zh. 1975 Jun;(6):86-8.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1103455

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE5IED8
DM70IK5	MN	Cytochrome P450 2C9 (CYP2C9)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005 Oct 1;70(7):1096-103.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16112652

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE4LYSA
DM70IK5	MN	Cytochrome P450 3A4 (CYP3A4)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DEGTFWK
DM70IK5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8730919

DM70IK5	DI	DM70IK5
DM70IK5	DN	Marinol
DM70IK5	MI	DE073H6
DM70IK5	MN	Prostaglandin G/H synthase 1 (COX-1)
DM70IK5	MT	DME
DM70IK5	MA	Metabolism
DM70IK5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70IK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMVNZ0	DI	DMMVNZ0
DMMVNZ0	DN	Masoprocol
DMMVNZ0	MI	TT6EO5L
DMMVNZ0	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMVNZ0	MT	DTT
DMMVNZ0	MA	Modulator
DMMVNZ0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMVNZ0	RU	https://www.fda.gov/

DMZ36RN	DI	DMZ36RN
DMZ36RN	DN	Mazindol
DMZ36RN	MI	TTAWNKZ
DMZ36RN	MN	Norepinephrine transporter (NET)
DMZ36RN	MT	DTT
DMZ36RN	MA	Modulator
DMZ36RN	RN	Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
DMZ36RN	RU	https://pubmed.ncbi.nlm.nih.gov/15300361

DM0R4Z5	DI	DM0R4Z5
DM0R4Z5	DN	MCB-3837
DM0R4Z5	MI	TT9SL3Q
DM0R4Z5	MN	Polypeptide deformylase (PDF)
DM0R4Z5	MT	DTT
DM0R4Z5	MA	Inhibitor
DM0R4Z5	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM0R4Z5	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	TTJGNVC
DM8ZHP1	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM8ZHP1	MT	DTT
DM8ZHP1	MA	Regulator (upregulator)
DM8ZHP1	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DM8ZHP1	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DTQ23VB
DM8ZHP1	MN	Organic anion transporter 1 (SLC22A6)
DM8ZHP1	MT	DTP
DM8ZHP1	MA	Substrate
DM8ZHP1	RN	Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34.
DM8ZHP1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17502342

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DTVP67E
DM8ZHP1	MN	Organic anion transporter 3 (SLC22A8)
DM8ZHP1	MT	DTP
DM8ZHP1	MA	Substrate
DM8ZHP1	RN	Human organic anion transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate. Drug Metab Dispos. 2007 Aug;35(8):1429-34.
DM8ZHP1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17502342

DM8ZHP1	DI	DM8ZHP1
DM8ZHP1	DN	MCI-186
DM8ZHP1	MI	DEYGVN4
DM8ZHP1	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8ZHP1	MT	DME
DM8ZHP1	MA	Metabolism
DM8ZHP1	RN	A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone. Int J Pharm. 2009 May 8;372(1-2):33-8.
DM8ZHP1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19166920

DM4IAKR	DI	DM4IAKR
DM4IAKR	DN	MD-1100
DM4IAKR	MI	TTLDPRG
DM4IAKR	MN	Guanylyl cyclase C (GUCY2C)
DM4IAKR	MT	DTT
DM4IAKR	MA	Activator
DM4IAKR	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM4IAKR	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMO14SG	DI	DMO14SG
DMO14SG	DN	Mebendazole
DMO14SG	MI	DE4LYSA
DMO14SG	MN	Cytochrome P450 3A4 (CYP3A4)
DMO14SG	MT	DME
DMO14SG	MA	Metabolism
DMO14SG	RN	Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. Infection. 2004 Oct;32(5):299-302.
DMO14SG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15624896

DMO14SG	DI	DMO14SG
DMO14SG	DN	Mebendazole
DMO14SG	MI	TTYFKSZ
DMO14SG	MN	Tubulin beta (TUBB)
DMO14SG	MT	DTT
DMO14SG	MA	Binder
DMO14SG	RN	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
DMO14SG	RU	https://pubmed.ncbi.nlm.nih.gov/19336257

DMNOBFQ	DI	DMNOBFQ
DMNOBFQ	DN	Mebeverine
DMNOBFQ	MI	TTH18TF
DMNOBFQ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMNOBFQ	MT	DTT
DMNOBFQ	MA	Antagonist
DMNOBFQ	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMNOBFQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM0KYI4	DI	DM0KYI4
DM0KYI4	DN	Mebutamate
DM0KYI4	MI	TTEX6LM
DM0KYI4	MN	GABA(A) receptor gamma-3 (GABRG3)
DM0KYI4	MT	DTT
DM0KYI4	MA	Modulator
DM0KYI4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0KYI4	RU	https://www.fda.gov/

DMGQFYB	DI	DMGQFYB
DMGQFYB	DN	Mecamylamine
DMGQFYB	MI	TTJSZTB
DMGQFYB	MN	Nicotinic acetylcholine receptor (nAChR)
DMGQFYB	MT	DTT
DMGQFYB	MA	Antagonist
DMGQFYB	RN	Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
DMGQFYB	RU	https://pubmed.ncbi.nlm.nih.gov/12080428

DM1O3BY	DI	DM1O3BY
DM1O3BY	DN	Mecasermin
DM1O3BY	MI	TTHRID2
DM1O3BY	MN	Insulin-like growth factor I receptor (IGF1R)
DM1O3BY	MT	DTT
DM1O3BY	MA	Inhibitor
DM1O3BY	RN	IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
DM1O3BY	RU	https://pubmed.ncbi.nlm.nih.gov/12845531

DM0CVXA	DI	DM0CVXA
DM0CVXA	DN	Mechlorethamine
DM0CVXA	MI	TTUTN1I
DM0CVXA	MN	Human Deoxyribonucleic acid (hDNA)
DM0CVXA	MT	DTT
DM0CVXA	MA	Intercalator
DM0CVXA	RN	Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62.
DM0CVXA	RU	https://pubmed.ncbi.nlm.nih.gov/19480393

DMS7T13	DI	DMS7T13
DMS7T13	DN	Meclizine
DMS7T13	MI	DECB0K3
DMS7T13	MN	Cytochrome P450 2D6 (CYP2D6)
DMS7T13	MT	DME
DMS7T13	MA	Metabolism
DMS7T13	RN	Meclizine metabolism and pharmacokinetics: formulation on its absorption. J Clin Pharmacol. 2012 Sep;52(9):1343-9.
DMS7T13	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21903894

DMS7T13	DI	DMS7T13
DMS7T13	DN	Meclizine
DMS7T13	MI	TTRANFM
DMS7T13	MN	Orphan nuclear receptor NR1I3 (NR1I3)
DMS7T13	MT	DTT
DMS7T13	MA	Modulator
DMS7T13	RN	Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73.
DMS7T13	RU	https://pubmed.ncbi.nlm.nih.gov/16684648

DMSFQ8I	DI	DMSFQ8I
DMSFQ8I	DN	Meclocycline
DMSFQ8I	MI	TTQ8KVI
DMSFQ8I	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMSFQ8I	MT	DTT
DMSFQ8I	MA	Binder
DMSFQ8I	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMSFQ8I	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMNL98G	DI	DMNL98G
DMNL98G	DN	Meclofenamate sodium
DMNL98G	MI	TT8NGED
DMNL98G	MN	Prostaglandin G/H synthase 1 (COX-1)
DMNL98G	MT	DTT
DMNL98G	MA	Modulator
DMNL98G	RN	Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
DMNL98G	RU	https://www.ncbi.nlm.nih.gov/pubmed/11592955

DMNL98G	DI	DMNL98G
DMNL98G	DN	Meclofenamate sodium
DMNL98G	MI	TTVKILB
DMNL98G	MN	Prostaglandin G/H synthase 2 (COX-2)
DMNL98G	MT	DTT
DMNL98G	MA	Modulator
DMNL98G	RN	Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82.
DMNL98G	RU	https://www.ncbi.nlm.nih.gov/pubmed/11592955

DM05FXR	DI	DM05FXR
DM05FXR	DN	Meclofenamic acid
DM05FXR	MI	DE4OGUF
DM05FXR	MN	Cytochrome P450 102A1 (cyp102)
DM05FXR	MT	DME
DM05FXR	MA	Metabolism
DM05FXR	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DM05FXR	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DM05FXR	DI	DM05FXR
DM05FXR	DN	Meclofenamic acid
DM05FXR	MI	TTK0943
DM05FXR	MN	Prostaglandin G/H synthase (COX)
DM05FXR	MT	DTT
DM05FXR	MA	Inhibitor
DM05FXR	RN	Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
DM05FXR	RU	https://pubmed.ncbi.nlm.nih.gov/7825862

DMBGWPH	DI	DMBGWPH
DMBGWPH	DN	Medroxyprogesterone
DMBGWPH	MI	DE4LYSA
DMBGWPH	MN	Cytochrome P450 3A4 (CYP3A4)
DMBGWPH	MT	DME
DMBGWPH	MA	Metabolism
DMBGWPH	RN	Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8.
DMBGWPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18725509

DMBGWPH	DI	DMBGWPH
DMBGWPH	DN	Medroxyprogesterone
DMBGWPH	MI	TTUV8G9
DMBGWPH	MN	Progesterone receptor (PGR)
DMBGWPH	MT	DTT
DMBGWPH	MA	Agonist
DMBGWPH	RN	Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
DMBGWPH	RU	https://pubmed.ncbi.nlm.nih.gov/18061638

DMJ90O5	DI	DMJ90O5
DMJ90O5	DN	Medrysone
DMJ90O5	MI	DE4LYSA
DMJ90O5	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ90O5	MT	DME
DMJ90O5	MA	Metabolism
DMJ90O5	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMJ90O5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMJ90O5	DI	DMJ90O5
DMJ90O5	DN	Medrysone
DMJ90O5	MI	TTP3UTW
DMJ90O5	MN	Steroid hormone receptor ERR (ESRR)
DMJ90O5	MT	DTT
DMJ90O5	MA	Modulator
DMJ90O5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJ90O5	RU	https://www.fda.gov/

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DE4OGUF
DMK7HFI	MN	Cytochrome P450 102A1 (cyp102)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DMK7HFI	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DES5XRU
DMK7HFI	MN	Cytochrome P450 2C8 (CYP2C8)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMK7HFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	DE5IED8
DMK7HFI	MN	Cytochrome P450 2C9 (CYP2C9)
DMK7HFI	MT	DME
DMK7HFI	MA	Metabolism
DMK7HFI	RN	Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014 Dec 15;27(12):2071-81.
DMK7HFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25372302

DMK7HFI	DI	DMK7HFI
DMK7HFI	DN	Mefenamic acid
DMK7HFI	MI	TTVKILB
DMK7HFI	MN	Prostaglandin G/H synthase 2 (COX-2)
DMK7HFI	MT	DTT
DMK7HFI	MA	Inhibitor
DMK7HFI	RN	Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62.
DMK7HFI	RU	https://pubmed.ncbi.nlm.nih.gov/9758208

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	DE4LYSA
DMWT905	MN	Cytochrome P450 3A4 (CYP3A4)
DMWT905	MT	DME
DMWT905	MA	Metabolism
DMWT905	RN	Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. J Pharm Pharmacol. 2000 Oct;52(10):1265-9.
DMWT905	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11092571

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	DTUGYRD
DMWT905	MN	P-glycoprotein 1 (ABCB1)
DMWT905	MT	DTP
DMWT905	MA	Substrate
DMWT905	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMWT905	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMWT905	DI	DMWT905
DMWT905	DN	Mefloquine
DMWT905	MI	TTT28H3
DMWT905	MN	Plasmodium 80S ribosome (Malaria 80S)
DMWT905	MT	DTT
DMWT905	MA	Binder
DMWT905	RN	An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14.
DMWT905	RU	https://pubmed.ncbi.nlm.nih.gov/3544894

DMDH9KX	DI	DMDH9KX
DMDH9KX	DN	Megestrol
DMDH9KX	MI	DE4LYSA
DMDH9KX	MN	Cytochrome P450 3A4 (CYP3A4)
DMDH9KX	MT	DME
DMDH9KX	MA	Metabolism
DMDH9KX	RN	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct;48(10):973-983.
DMDH9KX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29050522

DMDH9KX	DI	DMDH9KX
DMDH9KX	DN	Megestrol
DMDH9KX	MI	TTUV8G9
DMDH9KX	MN	Progesterone receptor (PGR)
DMDH9KX	MT	DTT
DMDH9KX	MA	Binder
DMDH9KX	RN	Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
DMDH9KX	RU	https://pubmed.ncbi.nlm.nih.gov/14687437

DM1OFHN	DI	DM1OFHN
DM1OFHN	DN	Meglitinides
DM1OFHN	MI	TTEX248
DM1OFHN	MN	Dopamine D2 receptor (D2R)
DM1OFHN	MT	DTT
DM1OFHN	MA	Antagonist
DM1OFHN	RN	Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9.
DM1OFHN	RU	https://pubmed.ncbi.nlm.nih.gov/4015674

DM1OFHN	DI	DM1OFHN
DM1OFHN	DN	Meglitinides
DM1OFHN	MI	TTCBFJO
DM1OFHN	MN	Insulin receptor (INSR)
DM1OFHN	MT	DTT
DM1OFHN	MA	Stimulator
DM1OFHN	RN	New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
DM1OFHN	RU	https://pubmed.ncbi.nlm.nih.gov/18840004

DMGUZ0W	DI	DMGUZ0W
DMGUZ0W	DN	MELARSOPROL
DMGUZ0W	MI	TT2SUAQ
DMGUZ0W	MN	Cysteine protease (CYP)
DMGUZ0W	MT	DTT
DMGUZ0W	MA	Inhibitor
DMGUZ0W	RN	On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide s... J Med Chem. 2009 Sep 24;52(18):5662-72.
DMGUZ0W	RU	https://pubmed.ncbi.nlm.nih.gov/19715342

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE6OQ3W
DMKWFBT	MN	Cytochrome P450 1A1 (CYP1A1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEJGDUW
DMKWFBT	MN	Cytochrome P450 1A2 (CYP1A2)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15626586

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE9QHP6
DMKWFBT	MN	Cytochrome P450 1B1 (CYP1B1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15616152

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE5IED8
DMKWFBT	MN	Cytochrome P450 2C9 (CYP2C9)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEHGR57
DMKWFBT	MN	Hydroxyindole O-methyltransferase (ASMT)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	The pharmacology of the pineal gland. Annu Rev Pharmacol Toxicol. 1976;16:33-51.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=180879

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DE43MW5
DMKWFBT	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J. 2005 May 15;388(Pt 1):205-15.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15636586

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	TT0WAIE
DMKWFBT	MN	Melatonin receptor type 1A (MTNR1A)
DMKWFBT	MT	DTT
DMKWFBT	MA	Binder
DMKWFBT	RN	The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8.
DMKWFBT	RU	https://pubmed.ncbi.nlm.nih.gov/15796769

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	DEGTFWK
DMKWFBT	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMKWFBT	MT	DME
DMKWFBT	MA	Metabolism
DMKWFBT	RN	The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.
DMKWFBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003850

DMKWFBT	DI	DMKWFBT
DMKWFBT	DN	Melatonin
DMKWFBT	MI	TTJLP0R
DMKWFBT	MN	Quinone reductase 2 (NQO2)
DMKWFBT	MT	DTT
DMKWFBT	MA	Inhibitor
DMKWFBT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMKWFBT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DES5XRU
DM2AR7L	MN	Cytochrome P450 2C8 (CYP2C8)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DE5IED8
DM2AR7L	MN	Cytochrome P450 2C9 (CYP2C9)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	DE4LYSA
DM2AR7L	MN	Cytochrome P450 3A4 (CYP3A4)
DM2AR7L	MT	DME
DM2AR7L	MA	Metabolism
DM2AR7L	RN	Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.
DM2AR7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10381752

DM2AR7L	DI	DM2AR7L
DM2AR7L	DN	Meloxicam
DM2AR7L	MI	TTVKILB
DM2AR7L	MN	Prostaglandin G/H synthase 2 (COX-2)
DM2AR7L	MT	DTT
DM2AR7L	MA	Inhibitor
DM2AR7L	RN	Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7.
DM2AR7L	RU	https://pubmed.ncbi.nlm.nih.gov/9219316

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	DE4ZHS1
DMOLNHF	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOLNHF	MT	DME
DMOLNHF	MA	Metabolism
DMOLNHF	RN	Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact. 2005 Apr 15;152(2-3):101-6.
DMOLNHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15840383

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	TTUTN1I
DMOLNHF	MN	Human Deoxyribonucleic acid (hDNA)
DMOLNHF	MT	DTT
DMOLNHF	MA	Modulator
DMOLNHF	RN	Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
DMOLNHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/2155711

DMOLNHF	DI	DMOLNHF
DMOLNHF	DN	Melphalan
DMOLNHF	MI	DTUGYRD
DMOLNHF	MN	P-glycoprotein 1 (ABCB1)
DMOLNHF	MT	DTP
DMOLNHF	MA	Substrate
DMOLNHF	RN	Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77(2):201-9.
DMOLNHF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9460989

DMWF5R4	DI	DMWF5R4
DMWF5R4	DN	Melphalan flufenamide
DMWF5R4	MI	TTUTN1I
DMWF5R4	MN	Human Deoxyribonucleic acid (hDNA)
DMWF5R4	MT	DTT
DMWF5R4	MA	Binder
DMWF5R4	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMWF5R4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf

DMD9WSC	DI	DMD9WSC
DMD9WSC	DN	Memantine
DMD9WSC	MI	TT9IK2Z
DMD9WSC	MN	N-methyl-D-aspartate receptor (NMDAR)
DMD9WSC	MT	DTT
DMD9WSC	MA	Modulator
DMD9WSC	RN	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
DMD9WSC	RU	https://pubmed.ncbi.nlm.nih.gov/12973747

DMD9WSC	DI	DMD9WSC
DMD9WSC	DN	Memantine
DMD9WSC	MI	DT9IDPW
DMD9WSC	MN	Organic cation transporter 2 (SLC22A2)
DMD9WSC	MT	DTP
DMD9WSC	MA	Substrate
DMD9WSC	RN	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
DMD9WSC	RU	http://www.ncbi.nlm.nih.gov/pubmed/9687576

DMP9N85	DI	DMP9N85
DMP9N85	DN	Menadiol sodium diphosphate
DMP9N85	MI	DE3N2FM
DMP9N85	MN	NADPH-cytochrome P450 reductase (CPR)
DMP9N85	MT	DME
DMP9N85	MA	Metabolism
DMP9N85	RN	Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
DMP9N85	RU	https://www.ndrugs.com/?s=creatinine%20sulfate/esculoside/hesperidin%20methyl%20chalcone/menadiol%20sodium%20phosphate/tranexamic%20acid&t=actions#doctor_pharmacology

DMP9N85	DI	DMP9N85
DMP9N85	DN	Menadiol sodium diphosphate
DMP9N85	MI	DEVRYQN
DMP9N85	MN	Vitamin K1 2,3-epoxide reductase 1 (VKOR)
DMP9N85	MT	DME
DMP9N85	MA	Metabolism
DMP9N85	RN	SMPDB database: Vitamin K Metabolism
DMP9N85	RU	http://smpdb.ca/view/SMP00464

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	TT3MOS2
DMSJDTY	MN	Aldehyde oxidase (AOX1)
DMSJDTY	MT	DTT
DMSJDTY	MA	Inhibitor
DMSJDTY	RN	Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/8512597

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DTI7UX6
DMSJDTY	MN	Breast cancer resistance protein (ABCG2)
DMSJDTY	MT	DTP
DMSJDTY	MA	Substrate
DMSJDTY	RN	The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3279-86.
DMSJDTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18065489

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE6OQ3W
DMSJDTY	MN	Cytochrome P450 1A1 (CYP1A1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEJGDUW
DMSJDTY	MN	Cytochrome P450 1A2 (CYP1A2)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Rat hepatic CYP1A1 and CYP1A2 induction by menadione. Toxicol Lett. 2005 Feb 15;155(2):253-8.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15603920

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEVDYN7
DMSJDTY	MN	Cytochrome P450 2E1 (CYP2E1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology. 2004 Feb;39(2):444-55.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14767997

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE6NIY9
DMSJDTY	MN	Methionine synthase reductase (MTRR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEOXTPZ
DMSJDTY	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Purification and properties of 5,10-methylenetetrahydrofolate reductase, an iron-sulfur flavoprotein from Clostridium formicoaceticum. J Biol Chem. 1984 Sep 10;259(17):10845-9.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6381490

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE8RYV5
DMSJDTY	MN	NADPH:quinone reductase (CRYZ)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Role of glutathione reductase during menadione-induced NADPH oxidation in isolated rat hepatocytes. Biochem Pharmacol. 1987 Nov 15;36(22):3879-84.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3689427

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DE9JFMC
DMSJDTY	MN	NADPH-dependent carbonyl reductase 1 (CBR1)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Polycyclic aromatic hydrocarbon quinones and glutathione thioethers as substrates and inhibitors of the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase. J Biol Chem. 1987 Sep 15;262(26):12448-51.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3624267

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEIVKZ8
DMSJDTY	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18493841

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEPG9C0
DMSJDTY	MN	Nitroreductase (NTR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	DEJVDAT
DMSJDTY	MN	Sepiapterin reductase (SPR)
DMSJDTY	MT	DME
DMSJDTY	MA	Metabolism
DMSJDTY	RN	Sepiapterin reductase mediates chemical redox cycling in lung epithelial cells. J Biol Chem. 2013 Jun 28;288(26):19221-37.
DMSJDTY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23640889

DMSJDTY	DI	DMSJDTY
DMSJDTY	DN	Menadione
DMSJDTY	MI	TTPFZJ1
DMSJDTY	MN	Vasopressin V1 receptor (V1R)
DMSJDTY	MT	DTT
DMSJDTY	MA	Agonist
DMSJDTY	RN	Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10.
DMSJDTY	RU	https://pubmed.ncbi.nlm.nih.gov/8738818

DM2SR1J	DI	DM2SR1J
DM2SR1J	DN	Meningococcal groups A, C, Y and W-135 conjugate vaccine
DM2SR1J	MI	TTY4IQ9
DM2SR1J	MN	Corynebacterium Mutated CRM197 (Cory mTOX)
DM2SR1J	MT	DTT
DM2SR1J	MA	Binder
DM2SR1J	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM2SR1J	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM4CF18	DI	DM4CF18
DM4CF18	DN	Menotropins
DM4CF18	MI	TTZFDBT
DM4CF18	MN	Follicle-stimulating hormone receptor (FSHR)
DM4CF18	MT	DTT
DM4CF18	MA	Binder
DM4CF18	RN	The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65.
DM4CF18	RU	https://pubmed.ncbi.nlm.nih.gov/7872378

DMG2KW7	DI	DMG2KW7
DMG2KW7	DN	Menthol
DMG2KW7	MI	TTXDKTO
DMG2KW7	MN	Long transient receptor potential channel 8 (TRPM8)
DMG2KW7	MT	DTT
DMG2KW7	MA	Activator
DMG2KW7	RN	TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
DMG2KW7	RU	https://pubmed.ncbi.nlm.nih.gov/19220220

DMG2KW7	DI	DMG2KW7
DMG2KW7	DN	Menthol
DMG2KW7	MI	TTELV3W
DMG2KW7	MN	Transformation-sensitive protein p120 (TRPA1)
DMG2KW7	MT	DTT
DMG2KW7	MA	Activator
DMG2KW7	RN	TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10.
DMG2KW7	RU	https://pubmed.ncbi.nlm.nih.gov/19220220

DM8YU2F	DI	DM8YU2F
DM8YU2F	DN	Mepenzolate
DM8YU2F	MI	TTH18TF
DM8YU2F	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8YU2F	MT	DTT
DM8YU2F	MA	Antagonist
DM8YU2F	RN	Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22.
DM8YU2F	RU	https://pubmed.ncbi.nlm.nih.gov/7623487

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	TTQ8AFT
DMX4GND	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMX4GND	MT	DTT
DMX4GND	MA	Agonist
DMX4GND	RN	Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
DMX4GND	RU	https://pubmed.ncbi.nlm.nih.gov/18234187

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DEPKLMQ
DMX4GND	MN	Cytochrome P450 2B6 (CYP2B6)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DECB0K3
DMX4GND	MN	Cytochrome P450 2D6 (CYP2D6)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15319333

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DE4LYSA
DMX4GND	MN	Cytochrome P450 3A4 (CYP3A4)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Is meperidine the drug that just won't die? J Pediatr Pharmacol Ther. 2011 Jul;16(3):167-9.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22479158

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DEGTFWK
DMX4GND	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMX4GND	MT	DME
DMX4GND	MA	Metabolism
DMX4GND	RN	Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
DMX4GND	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30902024

DMX4GND	DI	DMX4GND
DMX4GND	DN	Meperidine
DMX4GND	MI	DTUGYRD
DMX4GND	MN	P-glycoprotein 1 (ABCB1)
DMX4GND	MT	DTP
DMX4GND	MA	Substrate
DMX4GND	RN	Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40.
DMX4GND	RU	http://www.ncbi.nlm.nih.gov/pubmed/18499452

DMFJH5Q	DI	DMFJH5Q
DMFJH5Q	DN	Mephentermine
DMFJH5Q	MI	TTEX248
DMFJH5Q	MN	Dopamine D2 receptor (D2R)
DMFJH5Q	MT	DTT
DMFJH5Q	MA	Agonist
DMFJH5Q	RN	Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.
DMFJH5Q	RU	https://pubmed.ncbi.nlm.nih.gov/10722

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEJGDUW
DM5UGDK	MN	Cytochrome P450 1A2 (CYP1A2)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEPKLMQ
DM5UGDK	MN	Cytochrome P450 2B6 (CYP2B6)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEZMWRE
DM5UGDK	MN	Cytochrome P450 2C18 (CYP2C18)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DES5XRU
DM5UGDK	MN	Cytochrome P450 2C8 (CYP2C8)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 1994 Feb 22;33(7):1743-52.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8110777

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DE5IED8
DM5UGDK	MN	Cytochrome P450 2C9 (CYP2C9)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes. Carcinogenesis. 1996 Sep;17(9):2029-34.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8824531

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DECB0K3
DM5UGDK	MN	Cytochrome P450 2D6 (CYP2D6)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. 2004 Apr;19(2):83-95.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499174

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DE4LYSA
DM5UGDK	MN	Cytochrome P450 3A4 (CYP3A4)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEIBDNY
DM5UGDK	MN	Cytochrome P450 3A5 (CYP3A5)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8423554

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	DEGTFWK
DM5UGDK	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5UGDK	MT	DME
DM5UGDK	MA	Metabolism
DM5UGDK	RN	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
DM5UGDK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945

DM5UGDK	DI	DM5UGDK
DM5UGDK	DN	Mephenytoin
DM5UGDK	MI	TTZOVE0
DM5UGDK	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DM5UGDK	MT	DTT
DM5UGDK	MA	Blocker
DM5UGDK	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DM5UGDK	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DMUDWP9	DI	DMUDWP9
DMUDWP9	DN	Mepindolol
DMUDWP9	MI	TTMXGCW
DMUDWP9	MN	Adrenergic receptor beta-3 (ADRB3)
DMUDWP9	MT	DTT
DMUDWP9	MA	Modulator
DMUDWP9	RN	Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
DMUDWP9	RU	https://pubmed.ncbi.nlm.nih.gov/2873820

DMUDWP9	DI	DMUDWP9
DMUDWP9	DN	Mepindolol
DMUDWP9	MI	DECB0K3
DMUDWP9	MN	Cytochrome P450 2D6 (CYP2D6)
DMUDWP9	MT	DME
DMUDWP9	MA	Metabolism
DMUDWP9	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMUDWP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMH2NMY	DI	DMH2NMY
DMH2NMY	DN	Mepivacaine
DMH2NMY	MI	TTRK8B9
DMH2NMY	MN	Sodium channel unspecific (NaC)
DMH2NMY	MT	DTT
DMH2NMY	MA	Blocker
DMH2NMY	RN	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
DMH2NMY	RU	https://pubmed.ncbi.nlm.nih.gov/11094008

DMW2GEJ	DI	DMW2GEJ
DMW2GEJ	DN	Mepolizumab
DMW2GEJ	MI	TTPREZD
DMW2GEJ	MN	Interleukin-5 (IL5)
DMW2GEJ	MT	DTT
DMW2GEJ	MA	Modulator
DMW2GEJ	RN	Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
DMW2GEJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/18298130

DMTL9IP	DI	DMTL9IP
DMTL9IP	DN	Meprednisone
DMTL9IP	MI	DE4LYSA
DMTL9IP	MN	Cytochrome P450 3A4 (CYP3A4)
DMTL9IP	MT	DME
DMTL9IP	MA	Metabolism
DMTL9IP	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMTL9IP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMTL9IP	DI	DMTL9IP
DMTL9IP	DN	Meprednisone
DMTL9IP	MI	TTYRL6O
DMTL9IP	MN	Glucocorticoid receptor (NR3C1)
DMTL9IP	MT	DTT
DMTL9IP	MA	Modulator
DMTL9IP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTL9IP	RU	https://www.fda.gov/

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEVDYN7
DMHM93Y	MN	Cytochrome P450 2E1 (CYP2E1)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Mechanisms of circadian rhythmicity of carbon tetrachloride hepatotoxicity. J Pharmacol Exp Ther. 2002 Jan;300(1):273-81.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11752126

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TT1MPAY
DMHM93Y	MN	GABA(A) receptor alpha-1 (GABRA1)
DMHM93Y	MT	DTT
DMHM93Y	MA	Antagonist
DMHM93Y	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMHM93Y	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEGTFWK
DMHM93Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TT9SL3Q
DMHM93Y	MN	Polypeptide deformylase (PDF)
DMHM93Y	MT	DTT
DMHM93Y	MA	Inhibitor
DMHM93Y	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMHM93Y	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	TTBZ7OD
DMHM93Y	MN	Protein kinase C epsilon (PRKCE)
DMHM93Y	MT	DTT
DMHM93Y	MA	Stimulator
DMHM93Y	RN	Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957.
DMHM93Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760692/

DMHM93Y	DI	DMHM93Y
DMHM93Y	DN	Meprobamate
DMHM93Y	MI	DEYGVN4
DMHM93Y	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMHM93Y	MT	DME
DMHM93Y	MA	Metabolism
DMHM93Y	RN	Solid-phase synthesis of drug glucuronides by immobilized glucuronosyltransferase. J Med Chem. 1976 May;19(5):679-83.
DMHM93Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=818382

DMPSB8F	DI	DMPSB8F
DMPSB8F	DN	MEPTAZINOL
DMPSB8F	MI	TTEB0GD
DMPSB8F	MN	Cholinesterase (BCHE)
DMPSB8F	MT	DTT
DMPSB8F	MA	Inhibitor
DMPSB8F	RN	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
DMPSB8F	RU	https://pubmed.ncbi.nlm.nih.gov/18333606

DMB4SFH	DI	DMB4SFH
DMB4SFH	DN	Mepyramine
DMB4SFH	MI	TTTIBOJ
DMB4SFH	MN	Histamine H1 receptor (H1R)
DMB4SFH	MT	DTT
DMB4SFH	MA	Antagonist
DMB4SFH	RN	Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
DMB4SFH	RU	https://pubmed.ncbi.nlm.nih.gov/19552055

DMB4SFH	DI	DMB4SFH
DMB4SFH	DN	Mepyramine
DMB4SFH	MI	DT3HUVD
DMB4SFH	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMB4SFH	MT	DTP
DMB4SFH	MA	Substrate
DMB4SFH	RN	Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharm Drug Dispos. 2009 Dec;30(9):495-507.
DMB4SFH	RU	http://www.ncbi.nlm.nih.gov/pubmed/19821448

DM7F5OW	DI	DM7F5OW
DM7F5OW	DN	Mepyramine maleate
DM7F5OW	MI	TTTIBOJ
DM7F5OW	MN	Histamine H1 receptor (H1R)
DM7F5OW	MT	DTT
DM7F5OW	MA	Antagonist
DM7F5OW	RN	Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
DM7F5OW	RU	https://pubmed.ncbi.nlm.nih.gov/19552055

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	DECB0K3
DMAFBCY	MN	Cytochrome P450 2D6 (CYP2D6)
DMAFBCY	MT	DME
DMAFBCY	MA	Metabolism
DMAFBCY	RN	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
DMAFBCY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9454781

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	TTTIBOJ
DMAFBCY	MN	Histamine H1 receptor (H1R)
DMAFBCY	MT	DTT
DMAFBCY	MA	Antagonist
DMAFBCY	RN	Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9.
DMAFBCY	RU	https://pubmed.ncbi.nlm.nih.gov/18697448

DMAFBCY	DI	DMAFBCY
DMAFBCY	DN	Mequitazine
DMAFBCY	MI	DTUGYRD
DMAFBCY	MN	P-glycoprotein 1 (ABCB1)
DMAFBCY	MT	DTP
DMAFBCY	MA	Substrate
DMAFBCY	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMAFBCY	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	TTZFTY4
DMTM2IK	MN	Amidophosphoribosyltransferase (PPAT)
DMTM2IK	MT	DTT
DMTM2IK	MA	Breaker
DMTM2IK	RN	6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202.
DMTM2IK	RU	https://pubmed.ncbi.nlm.nih.gov/19281843

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTI7UX6
DMTM2IK	MN	Breast cancer resistance protein (ABCG2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DMTM2IK	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DT4YL5R
DMTM2IK	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/16530731

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DT82KPY
DMTM2IK	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DE6OQ3W
DMTM2IK	MN	Cytochrome P450 1A1 (CYP1A1)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTGBPR5
DMTM2IK	MN	Equilibrative nucleobase transporter 1 (SLC43A3)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter. Mol Pharmacol. 2019 Jun;95(6):584-596.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/30910793

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTXD1TQ
DMTM2IK	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTW78DQ
DMTM2IK	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
DMTM2IK	RU	https://www.pharmgkb.org/pathway/PA2040

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	TTL7C8Q
DMTM2IK	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMTM2IK	MT	DTT
DMTM2IK	MA	Inhibitor
DMTM2IK	RN	Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
DMTM2IK	RU	https://pubmed.ncbi.nlm.nih.gov/18506437

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTCSGPB
DMTM2IK	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/19515727

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTYVM24
DMTM2IK	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/25674464

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DTVP67E
DMTM2IK	MN	Organic anion transporter 3 (SLC22A8)
DMTM2IK	MT	DTP
DMTM2IK	MA	Substrate
DMTM2IK	RN	Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
DMTM2IK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15287899

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DEFQ8VO
DMTM2IK	MN	Thiopurine methyltransferase (TPMT)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20130603

DMTM2IK	DI	DMTM2IK
DMTM2IK	DN	Mercaptopurine
DMTM2IK	MI	DEYGVN4
DMTM2IK	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMTM2IK	MT	DME
DMTM2IK	MA	Metabolism
DMTM2IK	RN	Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
DMTM2IK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17691917

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TTGKNB4
DM0HS92	MN	Epidermal growth factor receptor (EGFR)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0HS92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TT6EO5L
DM0HS92	MN	Erbb2 tyrosine kinase receptor (HER2)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0HS92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0HS92	DI	DM0HS92
DM0HS92	DN	Merimepodib
DM0HS92	MI	TTL7C8Q
DM0HS92	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM0HS92	MT	DTT
DM0HS92	MA	Inhibitor
DM0HS92	RN	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
DM0HS92	RU	https://pubmed.ncbi.nlm.nih.gov/11288107

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	TTJP4SM
DM62UHC	MN	Bacterial Penicillin binding protein (Bact PBP)
DM62UHC	MT	DTT
DM62UHC	MA	Modulator
DM62UHC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM62UHC	RU	https://www.fda.gov/

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEC3G7M
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30060114

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DENJ2SQ
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30802650

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEBKS91
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018 Dec 28;13(12):e0209367.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30592758

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DECWSA9
DM62UHC	MN	Beta-lactamase (blaB)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Molecular investigation of extended-spectrum beta-lactamase genes and potential drug resistance in clinical isolates of Morganella morganii. Ann Saudi Med. 2016 May-Jun;36(3):223-8.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/27236395

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEB90AL
DM62UHC	MN	Carbapenemase (cphA)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 beta-lactamase. J Med Microbiol. 2018 Nov;67(11):1535-1537.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/30289383

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DEBGCYQ
DM62UHC	MN	New delhi metallo-beta-lactamase NDM-1 (blaNDM)
DM62UHC	MT	DME
DM62UHC	MA	Metabolism
DM62UHC	RN	Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54.
DM62UHC	RU	https://pubmed.ncbi.nlm.nih.gov/28870291

DM62UHC	DI	DM62UHC
DM62UHC	DN	Meropenem
DM62UHC	MI	DTQ23VB
DM62UHC	MN	Organic anion transporter 1 (SLC22A6)
DM62UHC	MT	DTP
DM62UHC	MA	Substrate
DM62UHC	RN	Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007 Feb 25;22(1):41-7.
DM62UHC	RU	http://www.ncbi.nlm.nih.gov/pubmed/17329910

DMOVAIX	DI	DMOVAIX
DMOVAIX	DN	Meropenem + vaborbactam
DMOVAIX	MI	TTHI19T
DMOVAIX	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMOVAIX	MT	DTT
DMOVAIX	MA	Inhibitor
DMOVAIX	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMOVAIX	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DTFI42L
DMOL5IU	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/16944117

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DT3D8F0
DMOL5IU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DT9C1TS
DMOL5IU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DTPFTEQ
DMOL5IU	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMOL5IU	MT	DTP
DMOL5IU	MA	Substrate
DMOL5IU	RN	Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake. Drug Metab Dispos. 2011 Jun;39(6):1097-102.
DMOL5IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/21430235

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	TT8NGED
DMOL5IU	MN	Prostaglandin G/H synthase 1 (COX-1)
DMOL5IU	MT	DTT
DMOL5IU	MA	Inhibitor
DMOL5IU	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOL5IU	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMOL5IU	DI	DMOL5IU
DMOL5IU	DN	Mesalazine
DMOL5IU	MI	DEZV4AP
DMOL5IU	MN	RNA cytidine acetyltransferase (hALP)
DMOL5IU	MT	DME
DMOL5IU	MA	Metabolism
DMOL5IU	RN	NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
DMOL5IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18322880

DM2ZGAN	DI	DM2ZGAN
DM2ZGAN	DN	Mesoridazine
DM2ZGAN	MI	DECB0K3
DM2ZGAN	MN	Cytochrome P450 2D6 (CYP2D6)
DM2ZGAN	MT	DME
DM2ZGAN	MA	Metabolism
DM2ZGAN	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DM2ZGAN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DM2ZGAN	DI	DM2ZGAN
DM2ZGAN	DN	Mesoridazine
DM2ZGAN	MI	TTEX248
DM2ZGAN	MN	Dopamine D2 receptor (D2R)
DM2ZGAN	MT	DTT
DM2ZGAN	MA	Agonist
DM2ZGAN	RN	Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87.
DM2ZGAN	RU	https://pubmed.ncbi.nlm.nih.gov/16135699

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DES5XRU
DMG3F94	MN	Cytochrome P450 2C8 (CYP2C8)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Loss of orally administered drugs in GI tract. Saudi Pharm J. 2012 Oct;20(4):331-44.
DMG3F94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23960808

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DE5IED8
DMG3F94	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMG3F94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	DE4LYSA
DMG3F94	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3F94	MT	DME
DMG3F94	MA	Metabolism
DMG3F94	RN	Prescribrt's digital referenve - Ethinyl estradiol/norethindrone; mestranol/norethindrone - Drug Summary
DMG3F94	RU	http://www.pdr.net/drug-summary/Necon-ethinyl-estradiol-norethindrone----mestranol-norethindrone-2049

DMG3F94	DI	DMG3F94
DMG3F94	DN	Mestranol
DMG3F94	MI	TTZAYWL
DMG3F94	MN	Estrogen receptor (ESR)
DMG3F94	MT	DTT
DMG3F94	MA	Agonist
DMG3F94	RN	Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9.
DMG3F94	RU	https://pubmed.ncbi.nlm.nih.gov/18374427

DMM4QOJ	DI	DMM4QOJ
DMM4QOJ	DN	Metadoxine
DMM4QOJ	MI	TTPRKM0
DMM4QOJ	MN	GABA transporter GAT-1 (SLC6A1)
DMM4QOJ	MT	DTT
DMM4QOJ	MA	Modulator
DMM4QOJ	RN	Company report (Alcobra pharma)
DMM4QOJ	RU	http://www.alcobra-pharma.com/products.cfm?productID=163127

DMTQS9A	DI	DMTQS9A
DMTQS9A	DN	Metaproterenol sulfate
DMTQS9A	MI	TT2CJVK
DMTQS9A	MN	Adrenergic receptor beta-2 (ADRB2)
DMTQS9A	MT	DTT
DMTQS9A	MA	Modulator
DMTQS9A	RN	Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9.
DMTQS9A	RU	https://pubmed.ncbi.nlm.nih.gov/18037507

DMWIX23	DI	DMWIX23
DMWIX23	DN	Metaraminol
DMWIX23	MI	TTEX248
DMWIX23	MN	Dopamine D2 receptor (D2R)
DMWIX23	MT	DTT
DMWIX23	MA	Agonist
DMWIX23	RN	Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9.
DMWIX23	RU	https://pubmed.ncbi.nlm.nih.gov/9663612

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTK8CXU
DMJFP6G	MN	5-HT 1B receptor (HTR1B)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/8863519

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT6MSOK
DMJFP6G	MN	5-HT 1D receptor (HTR1D)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/1652050

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTCPG9S
DMJFP6G	MN	5-HT 1E receptor (HTR1E)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/14744596

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT0MI3F
DMJFP6G	MN	5-HT 1F receptor (HTR1F)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/9225282

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTJQOD7
DMJFP6G	MN	5-HT 2A receptor (HTR2A)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT0K1SC
DMJFP6G	MN	5-HT 2B receptor (HTR2B)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTWJBZ5
DMJFP6G	MN	5-HT 2C receptor (HTR2C)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/15322733

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TTRUFDT
DMJFP6G	MN	5-HT 5A receptor (HTR5A)
DMJFP6G	MT	DTT
DMJFP6G	MA	Antagonist
DMJFP6G	RN	Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/7988681

DMJFP6G	DI	DMJFP6G
DMJFP6G	DN	Metergolin
DMJFP6G	MI	TT85JO3
DMJFP6G	MN	5-HT receptor (5HTR)
DMJFP6G	MT	DTT
DMJFP6G	MA	Modulator
DMJFP6G	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMJFP6G	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	TTY84UG
DM89QE1	MN	Acetyl-CoA carboxylase 2 (ACACB)
DM89QE1	MT	DTT
DM89QE1	MA	Activator
DM89QE1	RN	AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93.
DM89QE1	RU	https://pubmed.ncbi.nlm.nih.gov/19428322

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTI7UX6
DM89QE1	MN	Breast cancer resistance protein (ABCG2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20350646

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT3EAQP
DM89QE1	MN	Equilibrative nucleoside transporter 4 (SLC29A4)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin: from mechanisms of action to therapies. Cell Metab. 2014 Dec 2;20(6):953-66.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/25456737

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTZGT0P
DM89QE1	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20053795

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT3TX4H
DM89QE1	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTT79CX
DM89QE1	MN	Organic cation transporter 1 (SLC22A1)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/16272756

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT9IDPW
DM89QE1	MN	Organic cation transporter 2 (SLC22A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/16272756

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT6201N
DM89QE1	MN	Organic cation transporter 3 (SLC22A3)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/19591196

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	TTMHCGA
DM89QE1	MN	Solute carrier family 47 member 1 (SLC47A1)
DM89QE1	MT	DTT
DM89QE1	MA	Modulator
DM89QE1	RN	Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701.
DM89QE1	RU	https://pubmed.ncbi.nlm.nih.gov/16850272

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DTLA4Q2
DM89QE1	MN	Thiamine transporter 1 (SLC19A2)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm. 2015 Dec 7;12(12):4301-10.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/26528626

DM89QE1	DI	DM89QE1
DM89QE1	DN	Metformin
DM89QE1	MI	DT39CEA
DM89QE1	MN	Thiamine transporter 2 (SLC19A3)
DM89QE1	MT	DTP
DM89QE1	MA	Substrate
DM89QE1	RN	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm. 2015 Dec 7;12(12):4301-10.
DM89QE1	RU	http://www.ncbi.nlm.nih.gov/pubmed/26528626

DMTPAM3	DI	DMTPAM3
DMTPAM3	DN	Metformin arginine-hemisuccinimide
DMTPAM3	MI	TTCBFJO
DMTPAM3	MN	Insulin receptor (INSR)
DMTPAM3	MT	DTT
DMTPAM3	MA	Inhibitor
DMTPAM3	RN	Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
DMTPAM3	RU	https://pubmed.ncbi.nlm.nih.gov/15135305

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTYEG6Q
DMGS4QH	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMGS4QH	MT	DTT
DMGS4QH	MA	Inhibitor
DMGS4QH	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTQ13Z5
DMGS4QH	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMGS4QH	MT	DTT
DMGS4QH	MA	Modulator
DMGS4QH	RN	Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/12540494

DMGS4QH	DI	DMGS4QH
DMGS4QH	DN	Methacholine Chloride
DMGS4QH	MI	TTQ3JTF
DMGS4QH	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DMGS4QH	MT	DTT
DMGS4QH	MA	Inhibitor
DMGS4QH	RN	6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
DMGS4QH	RU	https://pubmed.ncbi.nlm.nih.gov/9622546

DMAY96V	DI	DMAY96V
DMAY96V	DN	Methacycline
DMAY96V	MI	TTQ8KVI
DMAY96V	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMAY96V	MT	DTT
DMAY96V	MA	Binder
DMAY96V	RN	Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6.
DMAY96V	RU	https://pubmed.ncbi.nlm.nih.gov/18220943

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEQX145
DMTW6IU	MN	Aromatase (CYP19A1)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005 Jan 1;69(1):187-97.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15588727

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEJGDUW
DMTW6IU	MN	Cytochrome P450 1A2 (CYP1A2)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15501692

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEPKLMQ
DMTW6IU	MN	Cytochrome P450 2B6 (CYP2B6)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEZMWRE
DMTW6IU	MN	Cytochrome P450 2C18 (CYP2C18)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8839037

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DES5XRU
DMTW6IU	MN	Cytochrome P450 2C8 (CYP2C8)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DE5IED8
DMTW6IU	MN	Cytochrome P450 2C9 (CYP2C9)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DECB0K3
DMTW6IU	MN	Cytochrome P450 2D6 (CYP2D6)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DE4LYSA
DMTW6IU	MN	Cytochrome P450 3A4 (CYP3A4)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DERD86B
DMTW6IU	MN	Cytochrome P450 3A7 (CYP3A7)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DEGTFWK
DMTW6IU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMTW6IU	MT	DME
DMTW6IU	MA	Metabolism
DMTW6IU	RN	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
DMTW6IU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30205091

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	TTN4QDT
DMTW6IU	MN	Opioid receptor (OPR)
DMTW6IU	MT	DTT
DMTW6IU	MA	Agonist
DMTW6IU	RN	Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
DMTW6IU	RU	https://pubmed.ncbi.nlm.nih.gov/19535889

DMTW6IU	DI	DMTW6IU
DMTW6IU	DN	Methadone
DMTW6IU	MI	DTUGYRD
DMTW6IU	MN	P-glycoprotein 1 (ABCB1)
DMTW6IU	MT	DTP
DMTW6IU	MA	Substrate
DMTW6IU	RN	In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolites. Pharmacology. 2007;80(4):304-11.
DMTW6IU	RU	http://www.ncbi.nlm.nih.gov/pubmed/17690563

DMIRMVB	DI	DMIRMVB
DMIRMVB	DN	Methadyl Acetate
DMIRMVB	MI	TTKWM86
DMIRMVB	MN	Opioid receptor mu (MOP)
DMIRMVB	MT	DTT
DMIRMVB	MA	Agonist
DMIRMVB	RN	Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9.
DMIRMVB	RU	https://pubmed.ncbi.nlm.nih.gov/6268422

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	TTBRKXS
DMPM4SK	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMPM4SK	MT	DTT
DMPM4SK	MA	Antagonist
DMPM4SK	RN	Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
DMPM4SK	RU	https://pubmed.ncbi.nlm.nih.gov/18945553

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	DECB0K3
DMPM4SK	MN	Cytochrome P450 2D6 (CYP2D6)
DMPM4SK	MT	DME
DMPM4SK	MA	Metabolism
DMPM4SK	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DMPM4SK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	TTEX248
DMPM4SK	MN	Dopamine D2 receptor (D2R)
DMPM4SK	MT	DTT
DMPM4SK	MA	Agonist
DMPM4SK	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DMPM4SK	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMPM4SK	DI	DMPM4SK
DMPM4SK	DN	Methamphetamine
DMPM4SK	MI	DTT7VPB
DMPM4SK	MN	Vesicular amine transporter 2 (SLC18A2)
DMPM4SK	MT	DTP
DMPM4SK	MA	Substrate
DMPM4SK	RN	Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem. 2018 Oct 25;61(20):9121-9131.
DMPM4SK	RU	http://www.ncbi.nlm.nih.gov/pubmed/30240563

DMO2JBC	DI	DMO2JBC
DMO2JBC	DN	Methamphetamine hydrochloride
DMO2JBC	MI	DECB0K3
DMO2JBC	MN	Cytochrome P450 2D6 (CYP2D6)
DMO2JBC	MT	DME
DMO2JBC	MA	Metabolism
DMO2JBC	RN	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
DMO2JBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11505218

DM8X4A1	DI	DM8X4A1
DM8X4A1	DN	Methantheline
DM8X4A1	MI	TTH18TF
DM8X4A1	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM8X4A1	MT	DTT
DM8X4A1	MA	Antagonist
DM8X4A1	RN	Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193.
DM8X4A1	RU	https://pubmed.ncbi.nlm.nih.gov/19160231

DM5A38V	DI	DM5A38V
DM5A38V	DN	Metharbital
DM5A38V	MI	TTEX6LM
DM5A38V	MN	GABA(A) receptor gamma-3 (GABRG3)
DM5A38V	MT	DTT
DM5A38V	MA	Modulator
DM5A38V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5A38V	RU	https://www.fda.gov/

DM7J2TA	DI	DM7J2TA
DM7J2TA	DN	Methazolamide
DM7J2TA	MI	TTHQPL7
DM7J2TA	MN	Carbonic anhydrase I (CA-I)
DM7J2TA	MT	DTT
DM7J2TA	MA	Modulator
DM7J2TA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
DM7J2TA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597

DMAUHQX	DI	DMAUHQX
DMAUHQX	DN	Methdilazine
DMAUHQX	MI	TTTIBOJ
DMAUHQX	MN	Histamine H1 receptor (H1R)
DMAUHQX	MT	DTT
DMAUHQX	MA	Antagonist
DMAUHQX	RN	Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4.
DMAUHQX	RU	https://pubmed.ncbi.nlm.nih.gov/2858829

DM3Z217	DI	DM3Z217
DM3Z217	DN	Methimazole
DM3Z217	MI	DEIASEZ
DM3Z217	MN	Dimethylaniline oxidase 2 (FMO2)
DM3Z217	MT	DME
DM3Z217	MA	Metabolism
DM3Z217	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM3Z217	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM25FL8	DI	DM25FL8
DM25FL8	DN	Methimazole
DM25FL8	MI	TT52XDZ
DM25FL8	MN	Thyroid peroxidase (TPO)
DM25FL8	MT	DTT
DM25FL8	MA	Inhibitor
DM25FL8	RN	Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73.
DM25FL8	RU	https://pubmed.ncbi.nlm.nih.gov/7952157

DM7YMIT	DI	DM7YMIT
DM7YMIT	DN	Methohexital
DM7YMIT	MI	TT1MPAY
DM7YMIT	MN	GABA(A) receptor alpha-1 (GABRA1)
DM7YMIT	MT	DTT
DM7YMIT	MA	Antagonist
DM7YMIT	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7YMIT	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTI7UX6
DM2TEOL	MN	Breast cancer resistance protein (ABCG2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/14500392

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DE4EGMZ
DM2TEOL	MN	Dihydrofolate reductase (DHFR)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTOSN46
DM2TEOL	MN	Folate transporter 1 (SLC19A1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DECWT2V
DM2TEOL	MN	Folylpolyglutamate synthase (FPGS)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEU7MWJ
DM2TEOL	MN	Gamma-Glu-X carboxypeptidase (GGH)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEN8V7Z
DM2TEOL	MN	Glutamate carboxypeptidase II (FOLH1)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006 Jun;11(6):694-703.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16794248

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEOXTPZ
DM2TEOL	MN	Methylenetetrahydrofolate reductase (MTHFR)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTSYQGK
DM2TEOL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11585759

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTFI42L
DM2TEOL	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/21841039

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTQ3ZHF
DM2TEOL	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12731885

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTCSGPB
DM2TEOL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17005917

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTYVM24
DM2TEOL	MN	Multidrug resistance-associated protein 5 (ABCC5)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15899835

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTWN7FC
DM2TEOL	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20718756

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTQ23VB
DM2TEOL	MN	Organic anion transporter 1 (SLC22A6)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20460822

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT0OC1Q
DM2TEOL	MN	Organic anion transporter 2 (SLC22A7)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12605306

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTVP67E
DM2TEOL	MN	Organic anion transporter 3 (SLC22A8)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/15548848

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT06JWZ
DM2TEOL	MN	Organic anion transporter 4 (SLC22A11)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12130730

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTE2B1D
DM2TEOL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16702441

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT3D8F0
DM2TEOL	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/26474710

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DT9C1TS
DM2TEOL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTUGYRD
DM2TEOL	MN	P-glycoprotein 1 (ABCB1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	TTY8Z2E
DM2TEOL	MN	Proton-coupled folate transporter (SLC46A1)
DM2TEOL	MT	DTT
DM2TEOL	MA	Modulator
DM2TEOL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213).
DM2TEOL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DTDJEMI
DM2TEOL	MN	Proton-coupled folate transporter (SLC46A1)
DM2TEOL	MT	DTP
DM2TEOL	MA	Substrate
DM2TEOL	RN	Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2009 Jul;61(7):911-8.
DM2TEOL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19589233

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	TT09I7D
DM2TEOL	MN	Solute carrier family 19 member 1 (SLC19A1)
DM2TEOL	MT	DTT
DM2TEOL	MA	Modulator
DM2TEOL	RN	Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11.
DM2TEOL	RU	https://pubmed.ncbi.nlm.nih.gov/9525913

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEFQ8VO
DM2TEOL	MN	Thiopurine methyltransferase (TPMT)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16438485

DM2TEOL	DI	DM2TEOL
DM2TEOL	DN	Methotrexate
DM2TEOL	MI	DEASG0Q
DM2TEOL	MN	Thymidylate synthase (TYMS)
DM2TEOL	MT	DME
DM2TEOL	MA	Metabolism
DM2TEOL	RN	The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4.
DM2TEOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17586865

DM5XH2C	DI	DM5XH2C
DM5XH2C	DN	Methotrexate Sodium
DM5XH2C	MI	TTYZVDJ
DM5XH2C	MN	Dihydrofolate reductase (DHFR)
DM5XH2C	MT	DTT
DM5XH2C	MA	Modulator
DM5XH2C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5XH2C	RU	https://www.fda.gov/

DMF5XQH	DI	DMF5XQH
DMF5XQH	DN	Methoxamine
DMF5XQH	MI	TTBRKXS
DMF5XQH	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMF5XQH	MT	DTT
DMF5XQH	MA	Stimulator
DMF5XQH	RN	Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
DMF5XQH	RU	https://pubmed.ncbi.nlm.nih.gov/19373756

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	TTAQ6ZW
DME8FZ9	MN	Cytochrome P450 2A6 (CYP2A6)
DME8FZ9	MT	DTT
DME8FZ9	MA	Binder
DME8FZ9	RN	Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9.
DME8FZ9	RU	https://pubmed.ncbi.nlm.nih.gov/6372701

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	DEJVYAZ
DME8FZ9	MN	Cytochrome P450 2A6 (CYP2A6)
DME8FZ9	MT	DME
DME8FZ9	MA	Metabolism
DME8FZ9	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
DME8FZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023

DME8FZ9	DI	DME8FZ9
DME8FZ9	DN	Methoxsalen
DME8FZ9	MI	DE4LYSA
DME8FZ9	MN	Cytochrome P450 3A4 (CYP3A4)
DME8FZ9	MT	DME
DME8FZ9	MA	Metabolism
DME8FZ9	RN	Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
DME8FZ9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003103

DMK1LZD	DI	DMK1LZD
DMK1LZD	DN	Methoxy polyethylene glycol-epoetin beta
DMK1LZD	MI	TTAUX24
DMK1LZD	MN	Erythropoietin Receptor (EPOR)
DMK1LZD	MT	DTT
DMK1LZD	MA	Activator
DMK1LZD	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMK1LZD	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEJGDUW
DML0RAE	MN	Cytochrome P450 1A2 (CYP1A2)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEJVYAZ
DML0RAE	MN	Cytochrome P450 2A6 (CYP2A6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEPKLMQ
DML0RAE	MN	Cytochrome P450 2B6 (CYP2B6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DE5IED8
DML0RAE	MN	Cytochrome P450 2C9 (CYP2C9)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DECB0K3
DML0RAE	MN	Cytochrome P450 2D6 (CYP2D6)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DEVDYN7
DML0RAE	MN	Cytochrome P450 2E1 (CYP2E1)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	DE4LYSA
DML0RAE	MN	Cytochrome P450 3A4 (CYP3A4)
DML0RAE	MT	DME
DML0RAE	MA	Metabolism
DML0RAE	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DML0RAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DML0RAE	DI	DML0RAE
DML0RAE	DN	Methoxyflurane
DML0RAE	MI	TT1MPAY
DML0RAE	MN	GABA(A) receptor alpha-1 (GABRA1)
DML0RAE	MT	DTT
DML0RAE	MA	Antagonist
DML0RAE	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DML0RAE	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMHP8FI	DI	DMHP8FI
DMHP8FI	DN	Methscopolamine bromide
DMHP8FI	MI	TTQ13Z5
DMHP8FI	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMHP8FI	MT	DTT
DMHP8FI	MA	Modulator
DMHP8FI	RN	Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43.
DMHP8FI	RU	https://www.ncbi.nlm.nih.gov/pubmed/7693670

DM6L5VO	DI	DM6L5VO
DM6L5VO	DN	Methsuximide
DM6L5VO	MI	DEGTFWK
DM6L5VO	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM6L5VO	MT	DME
DM6L5VO	MA	Metabolism
DM6L5VO	RN	The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
DM6L5VO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7640152

DM6L5VO	DI	DM6L5VO
DM6L5VO	DN	Methsuximide
DM6L5VO	MI	TT729IR
DM6L5VO	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM6L5VO	MT	DTT
DM6L5VO	MA	Blocker
DM6L5VO	RN	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
DM6L5VO	RU	https://pubmed.ncbi.nlm.nih.gov/11641441

DMN7SDE	DI	DMN7SDE
DMN7SDE	DN	Methyclothiazide
DMN7SDE	MI	TTS087L
DMN7SDE	MN	Solute carrier family 12 member 1 (SLC12A1)
DMN7SDE	MT	DTT
DMN7SDE	MA	Blocker
DMN7SDE	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMN7SDE	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMIUX3D	DI	DMIUX3D
DMIUX3D	DN	Methyl aminolevulinate
DMIUX3D	MI	TTQ6VF4
DMIUX3D	MN	Ferrochelatase (FECH)
DMIUX3D	MT	DTT
DMIUX3D	MA	Activator
DMIUX3D	RN	Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43.
DMIUX3D	RU	https://pubmed.ncbi.nlm.nih.gov/19447864

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEJGDUW
DM5I621	MN	Cytochrome P450 1A2 (CYP1A2)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DECB0K3
DM5I621	MN	Cytochrome P450 2D6 (CYP2D6)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. J Clin Pharmacol. 2002 Mar;42(3):342-6.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11865972

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	TTEX248
DM5I621	MN	Dopamine D2 receptor (D2R)
DM5I621	MT	DTT
DM5I621	MA	Agonist
DM5I621	RN	Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405.
DM5I621	RU	https://pubmed.ncbi.nlm.nih.gov/17485976

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEYWLRK
DM5I621	MN	Sulfotransferase 1A1 (SULT1A1)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther. 1984 Jan;35(1):55-63.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=6580988

DM5I621	DI	DM5I621
DM5I621	DN	Methyldopa
DM5I621	MI	DEFQ8VO
DM5I621	MN	Thiopurine methyltransferase (TPMT)
DM5I621	MT	DME
DM5I621	MA	Metabolism
DM5I621	RN	Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
DM5I621	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21371608

DM8XI09	DI	DM8XI09
DM8XI09	DN	Methyldopate Hydrochloride
DM8XI09	MI	TTQ8AFT
DM8XI09	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM8XI09	MT	DTT
DM8XI09	MA	Modulator
DM8XI09	RN	Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders
DM8XI09	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447877

DMJAPE7	DI	DMJAPE7
DMJAPE7	DN	Methylene blue
DMJAPE7	MI	TT6HPVC
DMJAPE7	MN	Guanylate cyclase (GC)
DMJAPE7	MT	DTT
DMJAPE7	MA	Inhibitor
DMJAPE7	RN	Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82.
DMJAPE7	RU	https://pubmed.ncbi.nlm.nih.gov/19473193

DMJAPE7	DI	DMJAPE7
DMJAPE7	DN	Methylene blue
DMJAPE7	MI	TT32XQJ
DMJAPE7	MN	Monoamine oxidase (MAO)
DMJAPE7	MT	DTT
DMJAPE7	RN	Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
DMJAPE7	RU	https://pubmed.ncbi.nlm.nih.gov/19562136

DMBEX4O	DI	DMBEX4O
DMBEX4O	DN	Methylergonovine
DMBEX4O	MI	DE4LYSA
DMBEX4O	MN	Cytochrome P450 3A4 (CYP3A4)
DMBEX4O	MT	DME
DMBEX4O	MA	Metabolism
DMBEX4O	RN	Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9.
DMBEX4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687

DMBEX4O	DI	DMBEX4O
DMBEX4O	DN	Methylergonovine
DMBEX4O	MI	TTZFYLI
DMBEX4O	MN	Dopamine D1 receptor (D1R)
DMBEX4O	MT	DTT
DMBEX4O	MA	Antagonist
DMBEX4O	RN	Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20.
DMBEX4O	RU	https://pubmed.ncbi.nlm.nih.gov/15930499

DMZTGN2	DI	DMZTGN2
DMZTGN2	DN	Methylnaltrexone bromide
DMZTGN2	MI	TTD0CIQ
DMZTGN2	MN	Melanocortin receptor 4 (MC4R)
DMZTGN2	MT	DTT
DMZTGN2	MA	Agonist
DMZTGN2	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMZTGN2	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMZTGN2	DI	DMZTGN2
DMZTGN2	DN	Methylnaltrexone bromide
DMZTGN2	MI	TTKWM86
DMZTGN2	MN	Opioid receptor mu (MOP)
DMZTGN2	MT	DTT
DMZTGN2	MA	Modulator
DMZTGN2	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMZTGN2	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	DEB30C5
DM7SJD6	MN	Carboxylesterase 1 (CES1)
DM7SJD6	MT	DME
DM7SJD6	MA	Metabolism
DM7SJD6	RN	Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76.
DM7SJD6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15082749

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	TTVBI8W
DM7SJD6	MN	Dopamine transporter (DAT)
DM7SJD6	MT	DTT
DM7SJD6	MA	Blocker
DM7SJD6	RN	Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
DM7SJD6	RU	https://pubmed.ncbi.nlm.nih.gov/15950015

DM7SJD6	DI	DM7SJD6
DM7SJD6	DN	Methylphenidate
DM7SJD6	MI	DTE8R17
DM7SJD6	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DM7SJD6	MT	DTP
DM7SJD6	MA	Substrate
DM7SJD6	RN	SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med. 2013 Apr-Jun;34(2-3):197-219.
DM7SJD6	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506866

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	DEPKLMQ
DMDSWAG	MN	Cytochrome P450 2B6 (CYP2B6)
DMDSWAG	MT	DME
DMDSWAG	MA	Metabolism
DMDSWAG	RN	Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics. 2004 Aug;14(8):549-56.
DMDSWAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284537

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	TT1MPAY
DMDSWAG	MN	GABA(A) receptor alpha-1 (GABRA1)
DMDSWAG	MT	DTT
DMDSWAG	MA	Antagonist
DMDSWAG	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMDSWAG	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDSWAG	DI	DMDSWAG
DMDSWAG	DN	Methylphenobarbital
DMDSWAG	MI	DEGTFWK
DMDSWAG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMDSWAG	MT	DME
DMDSWAG	MA	Metabolism
DMDSWAG	RN	A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
DMDSWAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15499191

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	DE4LYSA
DM4BDON	MN	Cytochrome P450 3A4 (CYP3A4)
DM4BDON	MT	DME
DM4BDON	MA	Metabolism
DM4BDON	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DM4BDON	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	TTYRL6O
DM4BDON	MN	Glucocorticoid receptor (NR3C1)
DM4BDON	MT	DTT
DM4BDON	MA	Modulator
DM4BDON	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4BDON	RU	https://www.fda.gov/

DM4BDON	DI	DM4BDON
DM4BDON	DN	Methylprednisolone
DM4BDON	MI	DTUGYRD
DM4BDON	MN	P-glycoprotein 1 (ABCB1)
DM4BDON	MT	DTP
DM4BDON	MA	Substrate
DM4BDON	RN	Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
DM4BDON	RU	http://www.ncbi.nlm.nih.gov/pubmed/11913542

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTOXS3C
DM5VWOB	MN	Muscarinic acetylcholine receptor (CHRM)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/12235229

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTYEG6Q
DM5VWOB	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/19565307

DM5VWOB	DI	DM5VWOB
DM5VWOB	DN	Methylscopolamine
DM5VWOB	MI	TTQ13Z5
DM5VWOB	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM5VWOB	MT	DTT
DM5VWOB	MA	Antagonist
DM5VWOB	RN	Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
DM5VWOB	RU	https://pubmed.ncbi.nlm.nih.gov/9846649

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DEPKLMQ
DMWLFGO	MN	Cytochrome P450 2B6 (CYP2B6)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DMWLFGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DE4LYSA
DMWLFGO	MN	Cytochrome P450 3A4 (CYP3A4)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Metabolism of anabolic steroids by recombinant human cytochrome P450 enzymes. Gas chromatographic-mass spectrometric determination of metabolites. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):73-83.
DMWLFGO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10630892

DMWLFGO	DI	DMWLFGO
DMWLFGO	DN	Methyltestosterone
DMWLFGO	MI	DEGKRXT
DMWLFGO	MN	UDP-glucuronosyltransferase 2A1 (UGT2A1)
DMWLFGO	MT	DME
DMWLFGO	MA	Metabolism
DMWLFGO	RN	Hepatic expression patterns of aryl hydrocarbon receptor, pregnane X receptor, two cytochrome P450s and five phase II metabolism genes responsive to 17alpha-methyltestosterone in rare minnow Gobiocypris rarus. Environ Toxicol Pharmacol. 2014 May;37(3):1157-68.
DMWLFGO	RU	https://pubmed.ncbi.nlm.nih.gov/24814259

DMBW7VH	DI	DMBW7VH
DMBW7VH	DN	Methyprylon
DMBW7VH	MI	DECB0K3
DMBW7VH	MN	Cytochrome P450 2D6 (CYP2D6)
DMBW7VH	MT	DME
DMBW7VH	MA	Metabolism
DMBW7VH	RN	Drugs and steatohepatitis. Semin Liver Dis. 2002;22(2):185-94.
DMBW7VH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12016549

DMBW7VH	DI	DMBW7VH
DMBW7VH	DN	Methyprylon
DMBW7VH	MI	TT1MPAY
DMBW7VH	MN	GABA(A) receptor alpha-1 (GABRA1)
DMBW7VH	MT	DTT
DMBW7VH	MA	Antagonist
DMBW7VH	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMBW7VH	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM1EF73	DI	DM1EF73
DM1EF73	DN	Methysergide
DM1EF73	MI	TTWJBZ5
DM1EF73	MN	5-HT 2C receptor (HTR2C)
DM1EF73	MT	DTT
DM1EF73	MA	Antagonist
DM1EF73	RN	Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
DM1EF73	RU	https://pubmed.ncbi.nlm.nih.gov/18396470

DM1EF73	DI	DM1EF73
DM1EF73	DN	Methysergide
DM1EF73	MI	DTUGYRD
DM1EF73	MN	P-glycoprotein 1 (ABCB1)
DM1EF73	MT	DTP
DM1EF73	MA	Substrate
DM1EF73	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DM1EF73	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMIKHN0	DI	DMIKHN0
DMIKHN0	DN	Meticillin
DMIKHN0	MI	TTJP4SM
DMIKHN0	MN	Bacterial Penicillin binding protein (Bact PBP)
DMIKHN0	MT	DTT
DMIKHN0	MA	Binder
DMIKHN0	RN	A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58.
DMIKHN0	RU	https://pubmed.ncbi.nlm.nih.gov/16946250

DMJMVKI	DI	DMJMVKI
DMJMVKI	DN	Metipranolol
DMJMVKI	MI	TTR6W5O
DMJMVKI	MN	Adrenergic receptor beta-1 (ADRB1)
DMJMVKI	MT	DTT
DMJMVKI	MA	Antagonist
DMJMVKI	RN	Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81.
DMJMVKI	RU	https://pubmed.ncbi.nlm.nih.gov/15969634

DMJMVKI	DI	DMJMVKI
DMJMVKI	DN	Metipranolol
DMJMVKI	MI	DECB0K3
DMJMVKI	MN	Cytochrome P450 2D6 (CYP2D6)
DMJMVKI	MT	DME
DMJMVKI	MA	Metabolism
DMJMVKI	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMJMVKI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM0JE6N	DI	DM0JE6N
DM0JE6N	DN	Metixene
DM0JE6N	MI	TTZ9SOR
DM0JE6N	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0JE6N	MT	DTT
DM0JE6N	MA	Modulator
DM0JE6N	RN	Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603.
DM0JE6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/22135383

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DEJGDUW
DMFA5MY	MN	Cytochrome P450 1A2 (CYP1A2)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DECB0K3
DMFA5MY	MN	Cytochrome P450 2D6 (CYP2D6)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DE4LYSA
DMFA5MY	MN	Cytochrome P450 3A4 (CYP3A4)
DMFA5MY	MT	DME
DMFA5MY	MA	Metabolism
DMFA5MY	RN	Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica. 2014 Apr;44(4):309-319.
DMFA5MY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24010633

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	TTEX248
DMFA5MY	MN	Dopamine D2 receptor (D2R)
DMFA5MY	MT	DTT
DMFA5MY	MA	Antagonist
DMFA5MY	RN	Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6.
DMFA5MY	RU	https://pubmed.ncbi.nlm.nih.gov/18457824

DMFA5MY	DI	DMFA5MY
DMFA5MY	DN	Metoclopramide
DMFA5MY	MI	DTT79CX
DMFA5MY	MN	Organic cation transporter 1 (SLC22A1)
DMFA5MY	MT	DTP
DMFA5MY	MA	Substrate
DMFA5MY	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFA5MY	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMZJYBW	DI	DMZJYBW
DMZJYBW	DN	Metocurine Iodide
DMZJYBW	MI	TTL1ATN
DMZJYBW	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMZJYBW	MT	DTT
DMZJYBW	MA	Modulator
DMZJYBW	RN	NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8.
DMZJYBW	RU	https://www.ncbi.nlm.nih.gov/pubmed/17993502

DMB39LO	DI	DMB39LO
DMB39LO	DN	Metolazone
DMB39LO	MI	TTP362L
DMB39LO	MN	Solute carrier family 12 member 3 (SLC12A3)
DMB39LO	MT	DTT
DMB39LO	MA	Blocker
DMB39LO	RN	The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
DMB39LO	RU	https://pubmed.ncbi.nlm.nih.gov/11457874

DMB39LO	DI	DMB39LO
DMB39LO	DN	Metolazone
DMB39LO	MI	DT6MDC9
DMB39LO	MN	Thiazide-sensitive sodium-chloride cotransporter (SLC12A3)
DMB39LO	MT	DTP
DMB39LO	MA	Substrate
DMB39LO	RN	Inhibition of binding of [3H]metolazone to rat kidney membrane by stilbene disulfonates. Biochem Pharmacol. 1991 Jun 1;41(11):1745-50.
DMB39LO	RU	http://www.ncbi.nlm.nih.gov/pubmed/2043163

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	TTR6W5O
DMOJ0V6	MN	Adrenergic receptor beta-1 (ADRB1)
DMOJ0V6	MT	DTT
DMOJ0V6	MA	Antagonist
DMOJ0V6	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DMOJ0V6	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DECB0K3
DMOJ0V6	MN	Cytochrome P450 2D6 (CYP2D6)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715.
DMOJ0V6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30248178

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DE4LYSA
DMOJ0V6	MN	Cytochrome P450 3A4 (CYP3A4)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	Chemical stability-indicating HPLC study of fixed-dosage combination containing metoprolol tartrate and hydrochlorothiazide.
DMOJ0V6	RU	https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DEGTFWK
DMOJ0V6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOJ0V6	MT	DME
DMOJ0V6	MA	Metabolism
DMOJ0V6	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOJ0V6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOJ0V6	DI	DMOJ0V6
DMOJ0V6	DN	Metoprolol
DMOJ0V6	MI	DT9G7XN
DMOJ0V6	MN	Peptide transporter 1 (SLC15A1)
DMOJ0V6	MT	DTP
DMOJ0V6	MA	Substrate
DMOJ0V6	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMOJ0V6	RU	https://doi.org/10.1007/BF02980227

DM1NOEK	DI	DM1NOEK
DM1NOEK	DN	Metreleptin
DM1NOEK	MI	TT0HD6V
DM1NOEK	MN	Leptin receptor (LEPR)
DM1NOEK	MT	DTT
DM1NOEK	MA	Modulator
DM1NOEK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM1NOEK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	TTS1W4A
DMTIVEN	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMTIVEN	MT	DTT
DMTIVEN	MA	Modulator
DMTIVEN	RN	DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/11406179

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEJVYAZ
DMTIVEN	MN	Cytochrome P450 2A6 (CYP2A6)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE5IED8
DMTIVEN	MN	Cytochrome P450 2C9 (CYP2C9)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE4LYSA
DMTIVEN	MN	Cytochrome P450 3A4 (CYP3A4)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17374625

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEIBDNY
DMTIVEN	MN	Cytochrome P450 3A5 (CYP3A5)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DERD86B
DMTIVEN	MN	Cytochrome P450 3A7 (CYP3A7)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23813797

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE8R7QY
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE2VSMT
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEQGIMN
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/19015349

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEP7ECA
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol. 1979 Dec 15;28(24):3611-5.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/231450

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEAN5EW
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DE3U2Y6
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEUW4J0
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DELAPDY
DMTIVEN	MN	Nitroreductase (NTR)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol. 2004 Sep;42(9):4127-9. Case Reports
DMTIVEN	RU	https://pubmed.ncbi.nlm.nih.gov/15364999

DMTIVEN	DI	DMTIVEN
DMTIVEN	DN	Metronidazole
DMTIVEN	MI	DEYGVN4
DMTIVEN	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMTIVEN	MT	DME
DMTIVEN	MA	Metabolism
DMTIVEN	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMTIVEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMI7FVQ	DI	DMI7FVQ
DMI7FVQ	DN	Metyrapone
DMI7FVQ	MI	TTIQUX7
DMI7FVQ	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMI7FVQ	MT	DTT
DMI7FVQ	MA	Inhibitor
DMI7FVQ	RN	Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21.
DMI7FVQ	RU	https://pubmed.ncbi.nlm.nih.gov/11869873

DMBYCU0	DI	DMBYCU0
DMBYCU0	DN	Metyrosine
DMBYCU0	MI	TTUHP71
DMBYCU0	MN	Tyrosine 3-monooxygenase (TH)
DMBYCU0	MT	DTT
DMBYCU0	MA	Binder
DMBYCU0	RN	Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
DMBYCU0	RU	https://pubmed.ncbi.nlm.nih.gov/1677640

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEJGDUW
DMCTE9R	MN	Cytochrome P450 1A2 (CYP1A2)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide. J Pharmacol Exp Ther. 1999 May;289(2):853-8.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215663

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEPKLMQ
DMCTE9R	MN	Cytochrome P450 2B6 (CYP2B6)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DECB0K3
DMCTE9R	MN	Cytochrome P450 2D6 (CYP2D6)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. Eur J Clin Pharmacol. 2003 Sep;59(5-6):395-9.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12937870

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DEVDYN7
DMCTE9R	MN	Cytochrome P450 2E1 (CYP2E1)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003 Jan;33(1):13-25.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519691

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	DE4LYSA
DMCTE9R	MN	Cytochrome P450 3A4 (CYP3A4)
DMCTE9R	MT	DME
DMCTE9R	MA	Metabolism
DMCTE9R	RN	Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings. Clin Pharmacol Ther. 2000 Jul;68(1):44-57.
DMCTE9R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10945315

DMCTE9R	DI	DMCTE9R
DMCTE9R	DN	Mexiletine
DMCTE9R	MI	TTZOVE0
DMCTE9R	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMCTE9R	MT	DTT
DMCTE9R	MA	Blocker
DMCTE9R	RN	Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
DMCTE9R	RU	https://pubmed.ncbi.nlm.nih.gov/11196553

DMY5JEP	DI	DMY5JEP
DMY5JEP	DN	Mezlocillin
DMY5JEP	MI	TT85JMW
DMY5JEP	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMY5JEP	MT	DTT
DMY5JEP	MA	Binder
DMY5JEP	RN	Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302.
DMY5JEP	RU	https://pubmed.ncbi.nlm.nih.gov/2949271

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	TTYSN63
DMVKA4O	MN	5-HT 2 receptor (5HT2R)
DMVKA4O	MT	DTT
DMVKA4O	MA	Antagonist
DMVKA4O	RN	5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
DMVKA4O	RU	https://pubmed.ncbi.nlm.nih.gov/18155835

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DEJGDUW
DMVKA4O	MN	Cytochrome P450 1A2 (CYP1A2)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther. 1996 Jul;278(1):21-30.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8764331

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DEPKLMQ
DMVKA4O	MN	Cytochrome P450 2B6 (CYP2B6)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DECB0K3
DMVKA4O	MN	Cytochrome P450 2D6 (CYP2D6)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy. Psychiatr Pol. 2004 Nov-Dec;38(6):1093-104.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15779673

DMVKA4O	DI	DMVKA4O
DMVKA4O	DN	Mianserin
DMVKA4O	MI	DE4LYSA
DMVKA4O	MN	Cytochrome P450 3A4 (CYP3A4)
DMVKA4O	MT	DME
DMVKA4O	MA	Metabolism
DMVKA4O	RN	[Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.
DMVKA4O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12143142

DM6Y3AN	DI	DM6Y3AN
DM6Y3AN	DN	Micafungin
DM6Y3AN	MI	DEJ6FSR
DM6Y3AN	MN	Arylsulfatase A (ARSA)
DM6Y3AN	MT	DME
DM6Y3AN	MA	Metabolism
DM6Y3AN	RN	The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.
DM6Y3AN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17516879

DM6Y3AN	DI	DM6Y3AN
DM6Y3AN	DN	Micafungin
DM6Y3AN	MI	TT0SFXH
DM6Y3AN	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DM6Y3AN	MT	DTT
DM6Y3AN	MA	Modulator
DM6Y3AN	RN	An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74.
DM6Y3AN	RU	https://pubmed.ncbi.nlm.nih.gov/24265229

DM3O6CY	DI	DM3O6CY
DM3O6CY	DN	Micardis telmisartan
DM3O6CY	MI	TT8DBY3
DM3O6CY	MN	Angiotensin II receptor type-1 (AGTR1)
DM3O6CY	MT	DTT
DM3O6CY	MA	Antagonist
DM3O6CY	RN	The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61.
DM3O6CY	RU	https://pubmed.ncbi.nlm.nih.gov/16208149

DMPMYE8	DI	DMPMYE8
DMPMYE8	DN	Miconazole
DMPMYE8	MI	TTTSOUD
DMPMYE8	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMPMYE8	MT	DTT
DMPMYE8	MA	Modulator
DMPMYE8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPMYE8	RU	https://www.fda.gov/

DMPMYE8	DI	DMPMYE8
DMPMYE8	DN	Miconazole
DMPMYE8	MI	DE4LYSA
DMPMYE8	MN	Cytochrome P450 3A4 (CYP3A4)
DMPMYE8	MT	DME
DMPMYE8	MA	Metabolism
DMPMYE8	RN	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
DMPMYE8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15135088

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEPKLMQ
DMXOELT	MN	Cytochrome P450 2B6 (CYP2B6)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9732386

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DE4LYSA
DMXOELT	MN	Cytochrome P450 3A4 (CYP3A4)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20203109

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEIBDNY
DMXOELT	MN	Cytochrome P450 3A5 (CYP3A5)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DERD86B
DMXOELT	MN	Cytochrome P450 3A7 (CYP3A7)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DEMF740
DMXOELT	MN	Cytochrome P450 4B1 (CYP4B1)
DMXOELT	MT	DME
DMXOELT	MA	Metabolism
DMXOELT	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMXOELT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	DTUGYRD
DMXOELT	MN	P-glycoprotein 1 (ABCB1)
DMXOELT	MT	DTP
DMXOELT	MA	Substrate
DMXOELT	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMXOELT	RU	https://doi.org/10.1007/s00210-008-0345-0

DMXOELT	DI	DMXOELT
DMXOELT	DN	Midazolam
DMXOELT	MI	TTPTXIN
DMXOELT	MN	Translocator protein (TSPO)
DMXOELT	MT	DTT
DMXOELT	MA	Modulator
DMXOELT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMXOELT	RU	https://www.fda.gov/

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	TTG28O6
DME2PY5	MN	Adrenergic receptor Alpha-1 (ADRA1)
DME2PY5	MT	DTT
DME2PY5	MA	Agonist
DME2PY5	RN	Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.
DME2PY5	RU	https://pubmed.ncbi.nlm.nih.gov/11482743

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	DECB0K3
DME2PY5	MN	Cytochrome P450 2D6 (CYP2D6)
DME2PY5	MT	DME
DME2PY5	MA	Metabolism
DME2PY5	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DME2PY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DME2PY5	DI	DME2PY5
DME2PY5	DN	Midodrine
DME2PY5	MI	DT9G7XN
DME2PY5	MN	Peptide transporter 1 (SLC15A1)
DME2PY5	MT	DTP
DME2PY5	MA	Substrate
DME2PY5	RN	Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.
DME2PY5	RU	http://www.ncbi.nlm.nih.gov/pubmed/16597710

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	DE4LYSA
DMI6E0R	MN	Cytochrome P450 3A4 (CYP3A4)
DMI6E0R	MT	DME
DMI6E0R	MA	Metabolism
DMI6E0R	RN	Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos. 2017 May;45(5):540-555.
DMI6E0R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28270565

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	TTGJCWZ
DMI6E0R	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMI6E0R	MT	DTT
DMI6E0R	MA	Inhibitor
DMI6E0R	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMI6E0R	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	DTUGYRD
DMI6E0R	MN	P-glycoprotein 1 (ABCB1)
DMI6E0R	MT	DTP
DMI6E0R	MA	Substrate
DMI6E0R	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMI6E0R	RU	https://doi.org/10.1007/s11095-012-0935-x

DMI6E0R	DI	DMI6E0R
DMI6E0R	DN	Midostaurin
DMI6E0R	MI	TTRFOXJ
DMI6E0R	MN	Protein kinase C gamma (PRKCG)
DMI6E0R	MT	DTT
DMI6E0R	MA	Inhibitor
DMI6E0R	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMI6E0R	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	DE4LYSA
DMGZQEF	MN	Cytochrome P450 3A4 (CYP3A4)
DMGZQEF	MT	DME
DMGZQEF	MA	Metabolism
DMGZQEF	RN	Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
DMGZQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29785610

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	DEIBDNY
DMGZQEF	MN	Cytochrome P450 3A5 (CYP3A5)
DMGZQEF	MT	DME
DMGZQEF	MA	Metabolism
DMGZQEF	RN	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
DMGZQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16684709

DMGZQEF	DI	DMGZQEF
DMGZQEF	DN	Mifepristone
DMGZQEF	MI	TTYRL6O
DMGZQEF	MN	Glucocorticoid receptor (NR3C1)
DMGZQEF	MT	DTT
DMGZQEF	MA	Modulator
DMGZQEF	RN	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
DMGZQEF	RU	https://pubmed.ncbi.nlm.nih.gov/17509631

DMFIQ2H	DI	DMFIQ2H
DMFIQ2H	DN	Migalastat
DMFIQ2H	MI	TTIS03D
DMFIQ2H	MN	Alpha-galactosidase A (GLA)
DMFIQ2H	MT	DTT
DMFIQ2H	MA	Modulator
DMFIQ2H	RN	AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45.
DMFIQ2H	RU	https://pubmed.ncbi.nlm.nih.gov/25440006

DMXBQAM	DI	DMXBQAM
DMXBQAM	DN	Miglitol
DMXBQAM	MI	TTXWASR
DMXBQAM	MN	Intestinal maltase-glucoamylase (MGAM)
DMXBQAM	MT	DTT
DMXBQAM	MA	Inhibitor
DMXBQAM	RN	Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
DMXBQAM	RU	https://pubmed.ncbi.nlm.nih.gov/9951949

DM5J64S	DI	DM5J64S
DM5J64S	DN	Miglustat
DM5J64S	MI	TTPHEX3
DM5J64S	MN	Ceramide glucosyltransferase (UGCG)
DM5J64S	MT	DTT
DM5J64S	MA	Inhibitor
DM5J64S	RN	Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54.
DM5J64S	RU	https://pubmed.ncbi.nlm.nih.gov/17919546

DMBFE74	DI	DMBFE74
DMBFE74	DN	Milnacipran
DMBFE74	MI	TTAWNKZ
DMBFE74	MN	Norepinephrine transporter (NET)
DMBFE74	MT	DTT
DMBFE74	MA	Inhibitor
DMBFE74	RN	Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63.
DMBFE74	RU	https://pubmed.ncbi.nlm.nih.gov/19620845

DM8TUPF	DI	DM8TUPF
DM8TUPF	DN	Milrinone
DM8TUPF	MI	TTZCG4L
DM8TUPF	MN	Phosphodiesterase 3 (PDE3)
DM8TUPF	MT	DTT
DM8TUPF	MA	Modulator
DM8TUPF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8TUPF	RU	https://www.fda.gov/

DMND304	DI	DMND304
DMND304	DN	Miltefosine
DMND304	MI	DEB2ZMT
DMND304	MN	Choline phosphatase 1 (PLD1)
DMND304	MT	DME
DMND304	MA	Metabolism
DMND304	RN	Development of miltefosine as an oral treatment for leishmaniasis. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S17-20.
DMND304	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16730362

DMND304	DI	DMND304
DMND304	DN	Miltefosine
DMND304	MI	TT9V5JH
DMND304	MN	Phospholipase A2 (PLA2G1B)
DMND304	MT	DTT
DMND304	MA	Inhibitor
DMND304	RN	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
DMND304	RU	https://pubmed.ncbi.nlm.nih.gov/19463273

DM0EP7M	DI	DM0EP7M
DM0EP7M	DN	Minaprine
DM0EP7M	MI	TT0K1SC
DM0EP7M	MN	5-HT 2B receptor (HTR2B)
DM0EP7M	MT	DTT
DM0EP7M	MA	Antagonist
DM0EP7M	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DM0EP7M	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DM0EP7M	DI	DM0EP7M
DM0EP7M	DN	Minaprine
DM0EP7M	MI	DECB0K3
DM0EP7M	MN	Cytochrome P450 2D6 (CYP2D6)
DM0EP7M	MT	DME
DM0EP7M	MA	Metabolism
DM0EP7M	RN	Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6. Bioorg Med Chem. 2003 Dec 1;11(24):5545-54.
DM0EP7M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642599

DMVN5OH	DI	DMVN5OH
DMVN5OH	DN	Minocycline
DMVN5OH	MI	TTQ8KVI
DMVN5OH	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMVN5OH	MT	DTT
DMVN5OH	MA	Binder
DMVN5OH	RN	Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
DMVN5OH	RU	https://pubmed.ncbi.nlm.nih.gov/16723578

DM50PMY	DI	DM50PMY
DM50PMY	DN	Minodronate
DM50PMY	MI	TTIKWV4
DM50PMY	MN	Geranyltranstransferase (FDPS)
DM50PMY	MT	DTT
DM50PMY	MA	Inhibitor
DM50PMY	RN	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
DM50PMY	RU	https://pubmed.ncbi.nlm.nih.gov/20394422

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	TT1VOHK
DMA2Z4F	MN	Potassium channel unspecific (KC)
DMA2Z4F	MT	DTT
DMA2Z4F	MA	Modulator
DMA2Z4F	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA2Z4F	RU	https://www.fda.gov/

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	DEYWLRK
DMA2Z4F	MN	Sulfotransferase 1A1 (SULT1A1)
DMA2Z4F	MT	DME
DMA2Z4F	MA	Metabolism
DMA2Z4F	RN	Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact. 1998 Feb 20;109(1-3):53-67.
DMA2Z4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9566733

DMA2Z4F	DI	DMA2Z4F
DMA2Z4F	DN	Minoxidil
DMA2Z4F	MI	DEYGVN4
DMA2Z4F	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMA2Z4F	MT	DME
DMA2Z4F	MA	Metabolism
DMA2Z4F	RN	Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 2004 Apr;32(4):413-23.
DMA2Z4F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15039294

DMGSRN1	DI	DMGSRN1
DMGSRN1	DN	Mipomersen
DMGSRN1	MI	TTN1IE2
DMGSRN1	MN	APOB messenger RNA (APOB mRNA)
DMGSRN1	MT	DTT
DMGSRN1	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMGSRN1	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	TTMXGCW
DMS1GYT	MN	Adrenergic receptor beta-3 (ADRB3)
DMS1GYT	MT	DTT
DMS1GYT	MA	Modulator
DMS1GYT	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMS1GYT	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	DECB0K3
DMS1GYT	MN	Cytochrome P450 2D6 (CYP2D6)
DMS1GYT	MT	DME
DMS1GYT	MA	Metabolism
DMS1GYT	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DMS1GYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DMS1GYT	DI	DMS1GYT
DMS1GYT	DN	Mirabegron
DMS1GYT	MI	DE4LYSA
DMS1GYT	MN	Cytochrome P450 3A4 (CYP3A4)
DMS1GYT	MT	DME
DMS1GYT	MA	Metabolism
DMS1GYT	RN	Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta-3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40.
DMS1GYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23625188

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	TTWJBZ5
DML53ZJ	MN	5-HT 2C receptor (HTR2C)
DML53ZJ	MT	DTT
DML53ZJ	MA	Antagonist
DML53ZJ	RN	Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
DML53ZJ	RU	https://pubmed.ncbi.nlm.nih.gov/18083778

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DEJGDUW
DML53ZJ	MN	Cytochrome P450 1A2 (CYP1A2)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol. 2004 Dec;24(6):647-52.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15538128

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DES5XRU
DML53ZJ	MN	Cytochrome P450 2C8 (CYP2C8)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DE5IED8
DML53ZJ	MN	Cytochrome P450 2C9 (CYP2C9)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DECB0K3
DML53ZJ	MN	Cytochrome P450 2D6 (CYP2D6)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DML53ZJ	DI	DML53ZJ
DML53ZJ	DN	Mirtazapine
DML53ZJ	MI	DE4LYSA
DML53ZJ	MN	Cytochrome P450 3A4 (CYP3A4)
DML53ZJ	MT	DME
DML53ZJ	MA	Metabolism
DML53ZJ	RN	A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64.
DML53ZJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11607047

DMHVJFK	DI	DMHVJFK
DMHVJFK	DN	Misoprostol
DMHVJFK	MI	TTOFYT1
DMHVJFK	MN	Prostacyclin receptor (PTGIR)
DMHVJFK	MT	DTT
DMHVJFK	MA	Antagonist
DMHVJFK	RN	Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
DMHVJFK	RU	https://pubmed.ncbi.nlm.nih.gov/12488443

DMP8HEL	DI	DMP8HEL
DMP8HEL	DN	Mitiglinide
DMP8HEL	MI	TTG140O
DMP8HEL	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMP8HEL	MT	DTT
DMP8HEL	MA	Blocker
DMP8HEL	RN	Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51.
DMP8HEL	RU	https://pubmed.ncbi.nlm.nih.gov/17359941

DMP8HEL	DI	DMP8HEL
DMP8HEL	DN	Mitiglinide
DMP8HEL	MI	DEF2WXN
DMP8HEL	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMP8HEL	MT	DME
DMP8HEL	MA	Metabolism
DMP8HEL	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMP8HEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH0ZJE	DI	DMH0ZJE
DMH0ZJE	DN	Mitomycin
DMH0ZJE	MI	TTUTN1I
DMH0ZJE	MN	Human Deoxyribonucleic acid (hDNA)
DMH0ZJE	MT	DTT
DMH0ZJE	MA	Binder
DMH0ZJE	RN	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
DMH0ZJE	RU	https://pubmed.ncbi.nlm.nih.gov/19608391

DMH0ZJE	DI	DMH0ZJE
DMH0ZJE	DN	Mitomycin
DMH0ZJE	MI	DTUGYRD
DMH0ZJE	MN	P-glycoprotein 1 (ABCB1)
DMH0ZJE	MT	DTP
DMH0ZJE	MA	Substrate
DMH0ZJE	RN	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
DMH0ZJE	RU	http://www.ncbi.nlm.nih.gov/pubmed/20533531

DM4PF81	DI	DM4PF81
DM4PF81	DN	Mitomycin A
DM4PF81	MI	TTUTN1I
DM4PF81	MN	Human Deoxyribonucleic acid (hDNA)
DM4PF81	MT	DTT
DM4PF81	RN	Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42.
DM4PF81	RU	https://pubmed.ncbi.nlm.nih.gov/11495594

DMU1GX0	DI	DMU1GX0
DMU1GX0	DN	Mitotane
DMU1GX0	MI	TTZAYWL
DMU1GX0	MN	Estrogen receptor (ESR)
DMU1GX0	MT	DTT
DMU1GX0	MA	Binder
DMU1GX0	RN	Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94.
DMU1GX0	RU	https://pubmed.ncbi.nlm.nih.gov/15898346

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DT2T6VQ
DMM39BF	MN	ATP-binding cassette sub-family A member 3 (ABCA3)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/15381773

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTI7UX6
DMM39BF	MN	Breast cancer resistance protein (ABCG2)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/11437380

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DEVDYN7
DMM39BF	MN	Cytochrome P450 2E1 (CYP2E1)
DMM39BF	MT	DME
DMM39BF	MA	Metabolism
DMM39BF	RN	FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
DMM39BF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	TT0IHXV
DMM39BF	MN	DNA topoisomerase II (TOP2)
DMM39BF	MT	DTT
DMM39BF	MA	Modulator
DMM39BF	RN	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
DMM39BF	RU	https://pubmed.ncbi.nlm.nih.gov/9450803

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTSYQGK
DMM39BF	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
DMM39BF	RU	https://doi.org/10.1124/mol.105.017988

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTFI42L
DMM39BF	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMM39BF	DI	DMM39BF
DMM39BF	DN	Mitoxantrone
DMM39BF	MI	DTUGYRD
DMM39BF	MN	P-glycoprotein 1 (ABCB1)
DMM39BF	MT	DTP
DMM39BF	MA	Substrate
DMM39BF	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMM39BF	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM473VD	DI	DM473VD
DM473VD	DN	Mivacurium
DM473VD	MI	TTF4E0J
DM473VD	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM473VD	MT	DTT
DM473VD	MA	Antagonist
DM473VD	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DM473VD	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DM1FDN8	DI	DM1FDN8
DM1FDN8	DN	Mizolastine
DM1FDN8	MI	TTTIBOJ
DM1FDN8	MN	Histamine H1 receptor (H1R)
DM1FDN8	MT	DTT
DM1FDN8	MA	Antagonist
DM1FDN8	RN	Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56.
DM1FDN8	RU	https://pubmed.ncbi.nlm.nih.gov/18498541

DMW6F0S	DI	DMW6F0S
DMW6F0S	DN	Mizoribine
DMW6F0S	MI	TTL7C8Q
DMW6F0S	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMW6F0S	MT	DTT
DMW6F0S	MA	Inhibitor
DMW6F0S	RN	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
DMW6F0S	RU	https://pubmed.ncbi.nlm.nih.gov/11288107

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	DE4LYSA
DM215WE	MN	Cytochrome P450 3A4 (CYP3A4)
DM215WE	MT	DME
DM215WE	MA	Metabolism
DM215WE	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DM215WE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	DEIBDNY
DM215WE	MN	Cytochrome P450 3A5 (CYP3A5)
DM215WE	MT	DME
DM215WE	MA	Metabolism
DM215WE	RN	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
DM215WE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557716

DM215WE	DI	DM215WE
DM215WE	DN	MK-1439
DM215WE	MI	TT84ETX
DM215WE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM215WE	MT	DTT
DM215WE	MA	Inhibitor
DM215WE	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM215WE	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMBYNW0	DI	DMBYNW0
DMBYNW0	DN	MK-3475
DMBYNW0	MI	TTNBFWK
DMBYNW0	MN	Programmed cell death protein 1 (PD-1)
DMBYNW0	MT	DTT
DMBYNW0	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMBYNW0	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	TTZHSBO
DMOB58Q	MN	Cytomegalovirus Terminase (CMV TRM)
DMOB58Q	MT	DTT
DMOB58Q	MA	Inhibitor
DMOB58Q	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMOB58Q	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	TTOGPL1
DMOB58Q	MN	Cytomegalovirus Terminase UL56 (CMV TRM1)
DMOB58Q	MT	DTT
DMOB58Q	MA	Inhibitor
DMOB58Q	RN	The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93.
DMOB58Q	RU	https://pubmed.ncbi.nlm.nih.gov/21752907

DMOB58Q	DI	DMOB58Q
DMOB58Q	DN	MK-8228
DMOB58Q	MI	DEYGVN4
DMOB58Q	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMOB58Q	MT	DME
DMOB58Q	MA	Metabolism
DMOB58Q	RN	Pharmacogenetic analysis of OATP1B1, UGT1A1, and BCRP variants in relation to the pharmacokinetics of letermovir in previously conducted clinical studies. J Clin Pharmacol. 2019 Sep;59(9):1236-1243.
DMOB58Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31022310

DMP2LZ8	DI	DMP2LZ8
DMP2LZ8	DN	MLN0002
DMP2LZ8	MI	TT7ZMI1
DMP2LZ8	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DMP2LZ8	MT	DTT
DMP2LZ8	MA	Modulator
DMP2LZ8	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMP2LZ8	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DEJGDUW
DMCMETN	MN	Cytochrome P450 1A2 (CYP1A2)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30;8(8):70.
DMCMETN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30061664

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DEPKLMQ
DMCMETN	MN	Cytochrome P450 2B6 (CYP2B6)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	NINLARO- European Medicines Agency - European Union
DMCMETN	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	DES5XRU
DMCMETN	MN	Cytochrome P450 2C8 (CYP2C8)
DMCMETN	MT	DME
DMCMETN	MA	Metabolism
DMCMETN	RN	Ninlaro- European Medicines Agency - European Union
DMCMETN	RU	https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf

DMCMETN	DI	DMCMETN
DMCMETN	DN	MLN9708
DMCMETN	MI	TTU7ZMG
DMCMETN	MN	Proteasome (PS)
DMCMETN	MT	DTT
DMCMETN	MA	Modulator
DMCMETN	RN	Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.
DMCMETN	RU	https://pubmed.ncbi.nlm.nih.gov/20160034

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DE5IED8
DMNZWL7	MN	Cytochrome P450 2C9 (CYP2C9)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DECB0K3
DMNZWL7	MN	Cytochrome P450 2D6 (CYP2D6)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7781267

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	DEGTFWK
DMNZWL7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNZWL7	MT	DME
DMNZWL7	MA	Metabolism
DMNZWL7	RN	Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11309556

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	TT32XQJ
DMNZWL7	MN	Monoamine oxidase (MAO)
DMNZWL7	MT	DTT
DMNZWL7	MA	Inhibitor
DMNZWL7	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMNZWL7	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMNZWL7	DI	DMNZWL7
DMNZWL7	DN	Moclobemide
DMNZWL7	MI	TT3WG5C
DMNZWL7	MN	Monoamine oxidase type A (MAO-A)
DMNZWL7	MT	DTT
DMNZWL7	MA	Inhibitor
DMNZWL7	RN	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
DMNZWL7	RU	https://pubmed.ncbi.nlm.nih.gov/12457375

DMYILBE	DI	DMYILBE
DMYILBE	DN	Modafinil
DMYILBE	MI	DE4LYSA
DMYILBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMYILBE	MT	DME
DMYILBE	MA	Metabolism
DMYILBE	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMYILBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMYILBE	DI	DMYILBE
DMYILBE	DN	Modafinil
DMYILBE	MI	TTVBI8W
DMYILBE	MN	Dopamine transporter (DAT)
DMYILBE	MT	DTT
DMYILBE	MA	Modulator
DMYILBE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYILBE	RU	https://www.fda.gov/

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	TTL69WB
DM26E4B	MN	Angiotensin-converting enzyme (ACE)
DM26E4B	MT	DTT
DM26E4B	MA	Inhibitor
DM26E4B	RN	Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83.
DM26E4B	RU	https://pubmed.ncbi.nlm.nih.gov/19255851

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	DT9G7XN
DM26E4B	MN	Peptide transporter 1 (SLC15A1)
DM26E4B	MT	DTP
DM26E4B	MA	Substrate
DM26E4B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM26E4B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM26E4B	DI	DM26E4B
DM26E4B	DN	Moexipril
DM26E4B	MI	DT8QKNP
DM26E4B	MN	Peptide transporter 2 (SLC15A2)
DM26E4B	MT	DTP
DM26E4B	MA	Substrate
DM26E4B	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM26E4B	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMISH0Z	DI	DMISH0Z
DMISH0Z	DN	Mogamulizumab
DMISH0Z	MI	TT7HQD0
DMISH0Z	MN	C-C chemokine receptor type 4 (CCR4)
DMISH0Z	MT	DTT
DMISH0Z	MA	Inhibitor
DMISH0Z	RN	Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
DMISH0Z	RU	https://pubmed.ncbi.nlm.nih.gov/21154168

DMAH70G	DI	DMAH70G
DMAH70G	DN	Molindone
DMAH70G	MI	TTEX248
DMAH70G	MN	Dopamine D2 receptor (D2R)
DMAH70G	MT	DTT
DMAH70G	MA	Binder
DMAH70G	RN	Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083.
DMAH70G	RU	https://pubmed.ncbi.nlm.nih.gov/17253473

DM9MA8O	DI	DM9MA8O
DM9MA8O	DN	Molsidomine
DM9MA8O	MI	DE37ABY
DM9MA8O	MN	Phosphodiesterase 5A (PDE5A)
DM9MA8O	MT	DME
DM9MA8O	MA	Metabolism
DM9MA8O	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (id: DB09282)
DM9MA8O	RU	https://www.drugbank.ca/drugs/DB09282

DM45OJN	DI	DM45OJN
DM45OJN	DN	Mometasone
DM45OJN	MI	DE4LYSA
DM45OJN	MN	Cytochrome P450 3A4 (CYP3A4)
DM45OJN	MT	DME
DM45OJN	MA	Metabolism
DM45OJN	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM45OJN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DM45OJN	DI	DM45OJN
DM45OJN	DN	Mometasone
DM45OJN	MI	TTYRL6O
DM45OJN	MN	Glucocorticoid receptor (NR3C1)
DM45OJN	MT	DTT
DM45OJN	MA	Agonist
DM45OJN	RN	Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92.
DM45OJN	RU	https://pubmed.ncbi.nlm.nih.gov/12503693

DMVJS2K	DI	DMVJS2K
DMVJS2K	DN	Monobenzone
DMVJS2K	MI	TTULVH8
DMVJS2K	MN	Tyrosinase (TYR)
DMVJS2K	MT	DTT
DMVJS2K	MA	Inhibitor
DMVJS2K	RN	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
DMVJS2K	RU	https://pubmed.ncbi.nlm.nih.gov/19159217

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DEJVYAZ
DMD157S	MN	Cytochrome P450 2A6 (CYP2A6)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DES5XRU
DMD157S	MN	Cytochrome P450 2C8 (CYP2C8)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18413310

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DE5IED8
DMD157S	MN	Cytochrome P450 2C9 (CYP2C9)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26374173

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DE4LYSA
DMD157S	MN	Cytochrome P450 3A4 (CYP3A4)
DMD157S	MT	DME
DMD157S	MA	Metabolism
DMD157S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMD157S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	TTGKOY9
DMD157S	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMD157S	MT	DTT
DMD157S	MA	Antagonist
DMD157S	RN	Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
DMD157S	RU	https://pubmed.ncbi.nlm.nih.gov/19515388

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DTE2B1D
DMD157S	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMD157S	MT	DTP
DMD157S	MA	Substrate
DMD157S	RN	Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
DMD157S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20974993

DMD157S	DI	DMD157S
DMD157S	DN	Montelukast
DMD157S	MI	DTPFTEQ
DMD157S	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMD157S	MT	DTP
DMD157S	MA	Substrate
DMD157S	RN	Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.
DMD157S	RU	http://www.ncbi.nlm.nih.gov/pubmed/23970434

DM560Y3	DI	DM560Y3
DM560Y3	DN	Morantel tartrate
DM560Y3	MI	TTHDSE2
DM560Y3	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM560Y3	MT	DTT
DM560Y3	MA	Inhibitor
DM560Y3	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DM560Y3	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DMOMBJW	DI	DMOMBJW
DMOMBJW	DN	Moricizine
DMOMBJW	MI	TTZOVE0
DMOMBJW	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMOMBJW	MT	DTT
DMOMBJW	MA	Blocker
DMOMBJW	RN	From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
DMOMBJW	RU	https://pubmed.ncbi.nlm.nih.gov/8780326

DM9UTDE	DI	DM9UTDE
DM9UTDE	DN	Morniflumate
DM9UTDE	MI	TTK0943
DM9UTDE	MN	Prostaglandin G/H synthase (COX)
DM9UTDE	MT	DTT
DM9UTDE	MA	Modulator
DM9UTDE	RN	Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
DM9UTDE	RU	https://pubmed.ncbi.nlm.nih.gov/1659152

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DES5XRU
DMRMS0L	MN	Cytochrome P450 2C8 (CYP2C8)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DECB0K3
DMRMS0L	MN	Cytochrome P450 2D6 (CYP2D6)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600248

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DE4LYSA
DMRMS0L	MN	Cytochrome P450 3A4 (CYP3A4)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16204972

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DTQ3ZHF
DMRMS0L	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMRMS0L	MT	DTP
DMRMS0L	MA	Substrate
DMRMS0L	RN	Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
DMRMS0L	RU	http://www.ncbi.nlm.nih.gov/pubmed/16586096

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	TTKWM86
DMRMS0L	MN	Opioid receptor mu (MOP)
DMRMS0L	MT	DTT
DMRMS0L	MA	Modulator
DMRMS0L	RN	Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/15901793

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DTUGYRD
DMRMS0L	MN	P-glycoprotein 1 (ABCB1)
DMRMS0L	MT	DTP
DMRMS0L	MA	Substrate
DMRMS0L	RN	Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
DMRMS0L	RU	http://www.ncbi.nlm.nih.gov/pubmed/16045647

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEYGVN4
DMRMS0L	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18187562

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEF2WXN
DMRMS0L	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184

DMRMS0L	DI	DMRMS0L
DMRMS0L	DN	Morphine
DMRMS0L	MI	DEB3CV1
DMRMS0L	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRMS0L	MT	DME
DMRMS0L	MA	Metabolism
DMRMS0L	RN	Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
DMRMS0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071451

DMEJKRF	DI	DMEJKRF
DMEJKRF	DN	Motexafin gadolinium
DMEJKRF	MI	TTLPJWH
DMEJKRF	MN	Thioredoxin reductase (PRDX5)
DMEJKRF	MT	DTT
DMEJKRF	MA	Modulator
DMEJKRF	RN	Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9.
DMEJKRF	RU	https://pubmed.ncbi.nlm.nih.gov/19121624

DMYKUNR	DI	DMYKUNR
DMYKUNR	DN	Moxalactam Disodium
DMYKUNR	MI	TT85JMW
DMYKUNR	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMYKUNR	MT	DTT
DMYKUNR	MA	Modulator
DMYKUNR	RN	Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.
DMYKUNR	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283783 

DMN63DZ	DI	DMN63DZ
DMN63DZ	DN	Moxetumomab pasudotox
DMN63DZ	MI	TTM6QSK
DMN63DZ	MN	B-cell receptor CD22 (CD22)
DMN63DZ	MT	DTT
DMN63DZ	MA	Modulator
DMN63DZ	RN	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
DMN63DZ	RU	https://pubmed.ncbi.nlm.nih.gov/22003067

DMYGHX5	DI	DMYGHX5
DMYGHX5	DN	Moxidectin 
DMYGHX5	MI	TTNJYV2
DMYGHX5	MN	Gamma-aminobutyric acid receptor (GAR)
DMYGHX5	MT	DTT
DMYGHX5	MA	Modulator
DMYGHX5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMYGHX5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMYGHX5	DI	DMYGHX5
DMYGHX5	DN	Moxidectin 
DMYGHX5	MI	TTSNVHO
DMYGHX5	MN	Onchocerca Glutamate-gated chloride channel (Onchoc GluCl)
DMYGHX5	MT	DTT
DMYGHX5	MA	Modulator
DMYGHX5	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMYGHX5	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMU8V4S	DI	DMU8V4S
DMU8V4S	DN	Moxifloxacin
DMU8V4S	MI	TTN6J5F
DMU8V4S	MN	Bacterial DNA gyrase (Bact gyrase)
DMU8V4S	MT	DTT
DMU8V4S	MA	Modulator
DMU8V4S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8V4S	RU	https://www.fda.gov/

DMU8V4S	DI	DMU8V4S
DMU8V4S	DN	Moxifloxacin
DMU8V4S	MI	TTIXTO3
DMU8V4S	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMU8V4S	MT	DTT
DMU8V4S	MA	Modulator
DMU8V4S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMU8V4S	RU	https://www.fda.gov/

DMFCLYW	DI	DMFCLYW
DMFCLYW	DN	Moxisylyte
DMFCLYW	MI	TT34BHT
DMFCLYW	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMFCLYW	MT	DTT
DMFCLYW	MA	Modulator
DMFCLYW	RN	Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
DMFCLYW	RU	https://pubmed.ncbi.nlm.nih.gov/8866639

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TTWG9A4
DMGFB0E	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TTWM4TY
DMGFB0E	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMGFB0E	DI	DMGFB0E
DMGFB0E	DN	MOXONIDINE
DMGFB0E	MI	TT2NUT5
DMGFB0E	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMGFB0E	MT	DTT
DMGFB0E	MA	Inhibitor
DMGFB0E	RN	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
DMGFB0E	RU	https://pubmed.ncbi.nlm.nih.gov/8632424

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTPFZJ1
DMZ905C	MN	Vasopressin V1 receptor (V1R)
DMZ905C	MT	DTT
DMZ905C	MA	Antagonist
DMZ905C	RN	Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/1337114

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TT4TFGN
DMZ905C	MN	Vasopressin V1a receptor (V1AR)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/10376439

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTL9MHW
DMZ905C	MN	Vasopressin V1b receptor (V1BR)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/7241506

DMZ905C	DI	DMZ905C
DMZ905C	DN	Mozavaptan
DMZ905C	MI	TTK8R02
DMZ905C	MN	Vasopressin V2 receptor (V2R)
DMZ905C	MT	DTT
DMZ905C	MA	Inhibitor
DMZ905C	RN	Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
DMZ905C	RU	https://pubmed.ncbi.nlm.nih.gov/12436936

DMWX683	DI	DMWX683
DMWX683	DN	Mupirocin
DMWX683	MI	TT6KYJ5
DMWX683	MN	Bacterial Isoleucyl-tRNA synthetase (Bact ileS)
DMWX683	MT	DTT
DMWX683	MA	Modulator
DMWX683	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMWX683	RU	https://www.fda.gov/

DM8ANCF	DI	DM8ANCF
DM8ANCF	DN	Muromonab
DM8ANCF	MI	TTZAT79
DM8ANCF	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DM8ANCF	MT	DTT
DM8ANCF	MA	Binder
DM8ANCF	RN	Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
DM8ANCF	RU	https://pubmed.ncbi.nlm.nih.gov/14664658

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTI7UX6
DMPQAGE	MN	Breast cancer resistance protein (ABCG2)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/18695635

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DES5XRU
DMPQAGE	MN	Cytochrome P450 2C8 (CYP2C8)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DE4LYSA
DMPQAGE	MN	Cytochrome P450 3A4 (CYP3A4)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEIBDNY
DMPQAGE	MN	Cytochrome P450 3A5 (CYP3A5)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	TTTB4UP
DMPQAGE	MN	Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)
DMPQAGE	MT	DTT
DMPQAGE	MA	Inhibitor
DMPQAGE	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMPQAGE	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTFI42L
DMPQAGE	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DT3D8F0
DMPQAGE	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DT9C1TS
DMPQAGE	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17906856

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DTUGYRD
DMPQAGE	MN	P-glycoprotein 1 (ABCB1)
DMPQAGE	MT	DTP
DMPQAGE	MA	Substrate
DMPQAGE	RN	Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
DMPQAGE	RU	http://www.ncbi.nlm.nih.gov/pubmed/18695635

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	TT1ZAVI
DMPQAGE	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMPQAGE	MT	DTT
DMPQAGE	MA	Modulator
DMPQAGE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
DMPQAGE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEYGVN4
DMPQAGE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790558

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEL5N6Y
DMPQAGE	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	[Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11817210

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DESD26P
DMPQAGE	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16790558

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DE85D2P
DMPQAGE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21142265

DMPQAGE	DI	DMPQAGE
DMPQAGE	DN	Mycophenolate mofetil
DMPQAGE	MI	DEB3CV1
DMPQAGE	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMPQAGE	MT	DME
DMPQAGE	MA	Metabolism
DMPQAGE	RN	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
DMPQAGE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24220207

DMYTN18	DI	DMYTN18
DMYTN18	DN	Mycophenolic acid
DMYTN18	MI	DTFI42L
DMYTN18	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMYTN18	MT	DTP
DMYTN18	MA	Substrate
DMYTN18	RN	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
DMYTN18	RU	http://www.ncbi.nlm.nih.gov/pubmed/17924828

DMYTN18	DI	DMYTN18
DMYTN18	DN	Mycophenolic acid
DMYTN18	MI	DTQ23VB
DMYTN18	MN	Organic anion transporter 1 (SLC22A6)
DMYTN18	MT	DTP
DMYTN18	MA	Substrate
DMYTN18	RN	Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3. Biochem Pharmacol. 2007 Jun 30;74(1):161-8.
DMYTN18	RU	http://www.ncbi.nlm.nih.gov/pubmed/17462604

DMRBMAU	DI	DMRBMAU
DMRBMAU	DN	Mycophenolic acid
DMRBMAU	MI	DE85D2P
DMRBMAU	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRBMAU	MT	DME
DMRBMAU	MA	Metabolism
DMRBMAU	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DMRBMAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DMRBMAU	DI	DMRBMAU
DMRBMAU	DN	Mycophenolic acid
DMRBMAU	MI	DEB3CV1
DMRBMAU	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRBMAU	MT	DME
DMRBMAU	MA	Metabolism
DMRBMAU	RN	Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55.
DMRBMAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123165

DMSOAJ2	DI	DMSOAJ2
DMSOAJ2	DN	N-0923
DMSOAJ2	MI	TTEX248
DMSOAJ2	MN	Dopamine D2 receptor (D2R)
DMSOAJ2	MT	DTT
DMSOAJ2	MA	Agonist
DMSOAJ2	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMSOAJ2	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMHJVOL	DI	DMHJVOL
DMHJVOL	DN	Nabi-HB
DMHJVOL	MI	TT6KSF7
DMHJVOL	MN	Hepatitis B virus Large envelope protein (HBV S)
DMHJVOL	MT	DTT
DMHJVOL	MA	Modulator
DMHJVOL	RN	Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report.
DMHJVOL	RU	http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117658.pdf

DMVRYT2	DI	DMVRYT2
DMVRYT2	DN	Nabilone
DMVRYT2	MI	TT6OEDT
DMVRYT2	MN	Cannabinoid receptor 1 (CB1)
DMVRYT2	MT	DTT
DMVRYT2	MA	Inhibitor
DMVRYT2	RN	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
DMVRYT2	RU	https://pubmed.ncbi.nlm.nih.gov/20925434

DMVRYT2	DI	DMVRYT2
DMVRYT2	DN	Nabilone
DMVRYT2	MI	TTMSFAW
DMVRYT2	MN	Cannabinoid receptor 2 (CB2)
DMVRYT2	MT	DTT
DMVRYT2	MA	Inhibitor
DMVRYT2	RN	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
DMVRYT2	RU	https://pubmed.ncbi.nlm.nih.gov/20925434

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DE7P2FB
DMAT2XH	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEAJN47
DMAT2XH	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEZDRQO
DMAT2XH	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24659525

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DEJGDUW
DMAT2XH	MN	Cytochrome P450 1A2 (CYP1A2)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos. 2009 May;37(5):1017-24.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19204080

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	DE5IED8
DMAT2XH	MN	Cytochrome P450 2C9 (CYP2C9)
DMAT2XH	MT	DME
DMAT2XH	MA	Metabolism
DMAT2XH	RN	In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. Biol Pharm Bull. 2011;34(5):734-9.
DMAT2XH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21532165

DMAT2XH	DI	DMAT2XH
DMAT2XH	DN	Nabumetone
DMAT2XH	MI	TTVKILB
DMAT2XH	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAT2XH	MT	DTT
DMAT2XH	MA	Inhibitor
DMAT2XH	RN	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
DMAT2XH	RU	https://pubmed.ncbi.nlm.nih.gov/11701998

DM1XBWR	DI	DM1XBWR
DM1XBWR	DN	N-acetyl-D-glucosamine
DM1XBWR	MI	TTDM6HZ
DM1XBWR	MN	Alpha-N-acetylglucosaminidase (NAGLU)
DM1XBWR	MT	DTT
DM1XBWR	MA	Activator
DM1XBWR	RN	Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51.
DM1XBWR	RU	https://pubmed.ncbi.nlm.nih.gov/19622275

DM1XBWR	DI	DM1XBWR
DM1XBWR	DN	N-acetyl-D-glucosamine
DM1XBWR	MI	DEROYHE
DM1XBWR	MN	N-acetyl-D-glucosamine 2-epimerase (AGE)
DM1XBWR	MT	DME
DM1XBWR	MA	Metabolism
DM1XBWR	RN	Production of N-acetyl-d-neuraminic acid by whole cells expressing Bacteroides thetaiotaomicron N-acetyl-d-glucosamine 2-epimerase and Escherichia coli N-acetyl-d-neuraminic acid aldolase. J Agric Food Chem. 2019 Jun 5;67(22):6285-6291.
DM1XBWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31117501

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEE5M8O
DM5NM6E	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEEN9RD
DM5NM6E	MN	Alcohol dehydrogenase class-I beta (ADH1B)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEIOH6A
DM5NM6E	MN	Alcohol dehydrogenase class-III (ADH5)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DE017IC
DM5NM6E	MN	Alcohol dehydrogenase class-V (ADH6)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DED2FW3
DM5NM6E	MN	Aldo-keto reductase 1A1 (AKR1A1)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DE4A3BL
DM5NM6E	MN	Diaphorase-1 (CYB5R3)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Expression of a novel P275L variant of NADH:cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. Arch Biochem Biophys. 2006 Mar 1;447(1):59-67.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16469290

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEZMAHX
DM5NM6E	MN	Gastric alcohol dehydrogenase (ADH7)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19583966

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEGSPC9
DM5NM6E	MN	Hydroxyacyl-CoA dehydrogenase 2 (HSD17B10)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J Biol Chem. 1998 Apr 24;273(17):10741-6.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9553139

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	TTTJF7V
DM5NM6E	MN	NADH dehydrogenase (MT-ND3)
DM5NM6E	MT	DTT
DM5NM6E	MA	Binder
DM5NM6E	RN	Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47.
DM5NM6E	RU	https://pubmed.ncbi.nlm.nih.gov/1472079

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DESICUZ
DM5NM6E	MN	Retinol dehydrogenase 13 (RDH13)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Human retinol dehydrogenase 13 (RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity. FEBS J. 2008 Jan;275(1):138-47.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18039331

DM5NM6E	DI	DM5NM6E
DM5NM6E	DN	NADH
DM5NM6E	MI	DEWDJU4
DM5NM6E	MN	Retinol dehydrogenase 14 (RDH14)
DM5NM6E	MT	DME
DM5NM6E	MA	Metabolism
DM5NM6E	RN	Human pancreas protein 2 (PAN2) has a retinal reductase activity and is ubiquitously expressed in human tissues. FEBS Lett. 2002 Nov 20;531(3):489-93.
DM5NM6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12435598

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	TTR6W5O
DMW6GVL	MN	Adrenergic receptor beta-1 (ADRB1)
DMW6GVL	MT	DTT
DMW6GVL	MA	Modulator
DMW6GVL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMW6GVL	RU	https://www.fda.gov/

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	DTE2B1D
DMW6GVL	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMW6GVL	MT	DTP
DMW6GVL	MA	Substrate
DMW6GVL	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DMW6GVL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMW6GVL	DI	DMW6GVL
DMW6GVL	DN	Nadolol
DMW6GVL	MI	DTUGYRD
DMW6GVL	MN	P-glycoprotein 1 (ABCB1)
DMW6GVL	MT	DTP
DMW6GVL	MA	Substrate
DMW6GVL	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMW6GVL	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMBNKST	DI	DMBNKST
DMBNKST	DN	Nadroparin calcium
DMBNKST	MI	TTCIHJA
DMBNKST	MN	Coagulation factor Xa (F10)
DMBNKST	MT	DTT
DMBNKST	MA	Modulator
DMBNKST	RN	Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
DMBNKST	RU	https://pubmed.ncbi.nlm.nih.gov/113585

DMU1XOD	DI	DMU1XOD
DMU1XOD	DN	Nafamostat
DMU1XOD	MI	TTEMV5X
DMU1XOD	MN	Serine protease unspecific (SP)
DMU1XOD	MT	DTT
DMU1XOD	MA	Inhibitor
DMU1XOD	RN	Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
DMU1XOD	RU	https://pubmed.ncbi.nlm.nih.gov/19513558

DMU1XOD	DI	DMU1XOD
DMU1XOD	DN	Nafamostat
DMU1XOD	MI	TTF8CQI
DMU1XOD	MN	Tumor necrosis factor (TNF)
DMU1XOD	MT	DTT
DMU1XOD	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMU1XOD	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMAHEFY	DI	DMAHEFY
DMAHEFY	DN	Nafarelin
DMAHEFY	MI	TT8R70G
DMAHEFY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAHEFY	MT	DTT
DMAHEFY	MA	Agonist
DMAHEFY	RN	Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45.
DMAHEFY	RU	https://pubmed.ncbi.nlm.nih.gov/19233456

DMN9RPO	DI	DMN9RPO
DMN9RPO	DN	Nafcillin
DMN9RPO	MI	TTJP4SM
DMN9RPO	MN	Bacterial Penicillin binding protein (Bact PBP)
DMN9RPO	MT	DTT
DMN9RPO	MA	Binder
DMN9RPO	RN	Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10.
DMN9RPO	RU	https://pubmed.ncbi.nlm.nih.gov/2387996

DMN9RPO	DI	DMN9RPO
DMN9RPO	DN	Nafcillin
DMN9RPO	MI	DT3D8F0
DMN9RPO	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMN9RPO	MT	DTP
DMN9RPO	MA	Substrate
DMN9RPO	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMN9RPO	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMVMQ1L	DI	DMVMQ1L
DMVMQ1L	DN	Nafronyl
DMVMQ1L	MI	TT85JO3
DMVMQ1L	MN	5-HT receptor (5HTR)
DMVMQ1L	MT	DTT
DMVMQ1L	MA	Modulator
DMVMQ1L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMVMQ1L	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHVBG1	DI	DMHVBG1
DMHVBG1	DN	Naftifine
DMHVBG1	MI	TTE14XG
DMHVBG1	MN	Squalene monooxygenase (SQLE)
DMHVBG1	MT	DTT
DMHVBG1	MA	Inhibitor
DMHVBG1	RN	Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
DMHVBG1	RU	https://pubmed.ncbi.nlm.nih.gov/8834895

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	TTNGILX
DMQ8R4E	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMQ8R4E	MT	DTT
DMQ8R4E	MA	Inhibitor
DMQ8R4E	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMQ8R4E	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	DE5IED8
DMQ8R4E	MN	Cytochrome P450 2C9 (CYP2C9)
DMQ8R4E	MT	DME
DMQ8R4E	MA	Metabolism
DMQ8R4E	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DMQ8R4E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DMQ8R4E	DI	DMQ8R4E
DMQ8R4E	DN	Naftopidil
DMQ8R4E	MI	DEGTFWK
DMQ8R4E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQ8R4E	MT	DME
DMQ8R4E	MA	Metabolism
DMQ8R4E	RN	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
DMQ8R4E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24944083

DMOSQGU	DI	DMOSQGU
DMOSQGU	DN	Nalbuphine
DMOSQGU	MI	TTQW87Y
DMOSQGU	MN	Opioid receptor kappa (OPRK1)
DMOSQGU	MT	DTT
DMOSQGU	MA	Modulator
DMOSQGU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOSQGU	RU	https://www.fda.gov/

DMOSQGU	DI	DMOSQGU
DMOSQGU	DN	Nalbuphine
DMOSQGU	MI	DTUGYRD
DMOSQGU	MN	P-glycoprotein 1 (ABCB1)
DMOSQGU	MT	DTP
DMOSQGU	MA	Substrate
DMOSQGU	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMOSQGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMGD3YH	DI	DMGD3YH
DMGD3YH	DN	Naldemedine Tosylate
DMGD3YH	MI	TTKWM86
DMGD3YH	MN	Opioid receptor mu (MOP)
DMGD3YH	MT	DTT
DMGD3YH	MA	Antagonist
DMGD3YH	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMGD3YH	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMA9DHW	DI	DMA9DHW
DMA9DHW	DN	Nalfurafine hcl
DMA9DHW	MI	TTQW87Y
DMA9DHW	MN	Opioid receptor kappa (OPRK1)
DMA9DHW	MT	DTT
DMA9DHW	MA	Inhibitor
DMA9DHW	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DMA9DHW	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DMA9DHW	DI	DMA9DHW
DMA9DHW	DN	Nalfurafine hcl
DMA9DHW	MI	TTKWM86
DMA9DHW	MN	Opioid receptor mu (MOP)
DMA9DHW	MT	DTT
DMA9DHW	MA	Inhibitor
DMA9DHW	RN	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
DMA9DHW	RU	https://pubmed.ncbi.nlm.nih.gov/19962305

DMRM0JV	DI	DMRM0JV
DMRM0JV	DN	Nalidixic acid
DMRM0JV	MI	TT0IHXV
DMRM0JV	MN	DNA topoisomerase II (TOP2)
DMRM0JV	MT	DTT
DMRM0JV	MA	Inhibitor
DMRM0JV	RN	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
DMRM0JV	RU	https://pubmed.ncbi.nlm.nih.gov/2847647

DM4YWCZ	DI	DM4YWCZ
DM4YWCZ	DN	Nalmefene
DM4YWCZ	MI	TTN4QDT
DM4YWCZ	MN	Opioid receptor (OPR)
DM4YWCZ	MT	DTT
DM4YWCZ	MA	Antagonist
DM4YWCZ	RN	Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
DM4YWCZ	RU	https://pubmed.ncbi.nlm.nih.gov/19001155

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	DE4LYSA
DML0B41	MN	Cytochrome P450 3A4 (CYP3A4)
DML0B41	MT	DME
DML0B41	MA	Metabolism
DML0B41	RN	Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5.
DML0B41	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25471070

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	TTKWM86
DML0B41	MN	Opioid receptor mu (MOP)
DML0B41	MT	DTT
DML0B41	MA	Modulator
DML0B41	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DML0B41	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DML0B41	DI	DML0B41
DML0B41	DN	Naloxegol
DML0B41	MI	DTUGYRD
DML0B41	MN	P-glycoprotein 1 (ABCB1)
DML0B41	MT	DTP
DML0B41	MA	Substrate
DML0B41	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DML0B41	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM3FXMA	DI	DM3FXMA
DM3FXMA	DN	Naloxone
DM3FXMA	MI	TTKWM86
DM3FXMA	MN	Opioid receptor mu (MOP)
DM3FXMA	MT	DTT
DM3FXMA	MA	Antagonist
DM3FXMA	RN	OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7.
DM3FXMA	RU	https://pubmed.ncbi.nlm.nih.gov/19332974

DMUL45H	DI	DMUL45H
DMUL45H	DN	Naltrexone
DMUL45H	MI	TTN4QDT
DMUL45H	MN	Opioid receptor (OPR)
DMUL45H	MT	DTT
DMUL45H	MA	Antagonist
DMUL45H	RN	An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
DMUL45H	RU	https://pubmed.ncbi.nlm.nih.gov/18250251

DMUL45H	DI	DMUL45H
DMUL45H	DN	Naltrexone
DMUL45H	MI	DEYGVN4
DMUL45H	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUL45H	MT	DME
DMUL45H	MA	Metabolism
DMUL45H	RN	In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
DMUL45H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18639530

DMFWKG1	DI	DMFWKG1
DMFWKG1	DN	Nandrolone
DMFWKG1	MI	TTS64P2
DMFWKG1	MN	Androgen receptor (AR)
DMFWKG1	MT	DTT
DMFWKG1	MA	Agonist
DMFWKG1	RN	Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
DMFWKG1	RU	https://pubmed.ncbi.nlm.nih.gov/15931869

DMFWKG1	DI	DMFWKG1
DMFWKG1	DN	Nandrolone
DMFWKG1	MI	DEQX145
DMFWKG1	MN	Aromatase (CYP19A1)
DMFWKG1	MT	DME
DMFWKG1	MA	Metabolism
DMFWKG1	RN	Aromatization of testosterone and 19-nortestosterone by a single enzyme from equine testicular microsomes. Differences from human placental aromatase. J Steroid Biochem. 1988 Jan;29(1):119-25.
DMFWKG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=3347045

DMJFZDL	DI	DMJFZDL
DMJFZDL	DN	Naphazoline
DMJFZDL	MI	TTEX248
DMJFZDL	MN	Dopamine D2 receptor (D2R)
DMJFZDL	MT	DTT
DMJFZDL	MA	Agonist
DMJFZDL	RN	Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52.
DMJFZDL	RU	https://pubmed.ncbi.nlm.nih.gov/10481510

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEJGDUW
DMZ5RGV	MN	Cytochrome P450 1A2 (CYP1A2)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DES5XRU
DMZ5RGV	MN	Cytochrome P450 2C8 (CYP2C8)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DE5IED8
DMZ5RGV	MN	Cytochrome P450 2C9 (CYP2C9)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	TT8NGED
DMZ5RGV	MN	Prostaglandin G/H synthase 1 (COX-1)
DMZ5RGV	MT	DTT
DMZ5RGV	MA	Inhibitor
DMZ5RGV	RN	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
DMZ5RGV	RU	https://pubmed.ncbi.nlm.nih.gov/11028250

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	TTVKILB
DMZ5RGV	MN	Prostaglandin G/H synthase 2 (COX-2)
DMZ5RGV	MT	DTT
DMZ5RGV	MA	Inhibitor
DMZ5RGV	RN	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
DMZ5RGV	RU	https://pubmed.ncbi.nlm.nih.gov/11028250

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEYGVN4
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18004206

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEL5N6Y
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEF2WXN
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DESD26P
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DE85D2P
DMZ5RGV	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187975

DMZ5RGV	DI	DMZ5RGV
DMZ5RGV	DN	Naproxen
DMZ5RGV	MI	DEB3CV1
DMZ5RGV	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMZ5RGV	MT	DME
DMZ5RGV	MA	Metabolism
DMZ5RGV	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZ5RGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	TTK8CXU
DMO50U2	MN	5-HT 1B receptor (HTR1B)
DMO50U2	MT	DTT
DMO50U2	MA	Agonist
DMO50U2	RN	Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
DMO50U2	RU	https://pubmed.ncbi.nlm.nih.gov/18223456

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	DERE4TU
DMO50U2	MN	Monoamine oxidase type A (MAO-A)
DMO50U2	MT	DME
DMO50U2	MA	Metabolism
DMO50U2	RN	Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.
DMO50U2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11249525

DMO50U2	DI	DMO50U2
DMO50U2	DN	Naratriptan
DMO50U2	MI	DTT79CX
DMO50U2	MN	Organic cation transporter 1 (SLC22A1)
DMO50U2	MT	DTP
DMO50U2	MA	Substrate
DMO50U2	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DMO50U2	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DMFEHXD	DI	DMFEHXD
DMFEHXD	DN	Natamycin
DMFEHXD	MI	TTAH0B3
DMFEHXD	MN	Fungal Cell membrane (Fung CM)
DMFEHXD	MT	DTT
DMFEHXD	MA	Binder
DMFEHXD	RN	Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401.
DMFEHXD	RU	https://pubmed.ncbi.nlm.nih.gov/18165687

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE5IED8
DMLK2QH	MN	Cytochrome P450 2C9 (CYP2C9)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DECB0K3
DMLK2QH	MN	Cytochrome P450 2D6 (CYP2D6)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43(4):267-78.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15005635

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE4LYSA
DMLK2QH	MN	Cytochrome P450 3A4 (CYP3A4)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DEIBDNY
DMLK2QH	MN	Cytochrome P450 3A5 (CYP3A5)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug Interactions Flockhart Table
DMLK2QH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DERD86B
DMLK2QH	MN	Cytochrome P450 3A7 (CYP3A7)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Drug Interactions Flockhart Table
DMLK2QH	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT3I124
DMLK2QH	MN	Monocarboxylate transporter 6 (SLC16A5)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMLK2QH	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT3D8F0
DMLK2QH	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
DMLK2QH	RU	http://www.ncbi.nlm.nih.gov/pubmed/30135178

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DT9C1TS
DMLK2QH	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMLK2QH	MT	DTP
DMLK2QH	MA	Substrate
DMLK2QH	RN	FDA Drug Development and Drug Interactions
DMLK2QH	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	TT1VOHK
DMLK2QH	MN	Potassium channel unspecific (KC)
DMLK2QH	MT	DTT
DMLK2QH	MA	Modulator
DMLK2QH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLK2QH	RU	https://www.fda.gov/

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE073H6
DMLK2QH	MN	Prostaglandin G/H synthase 1 (COX-1)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMLK2QH	DI	DMLK2QH
DMLK2QH	DN	Nateglinide
DMLK2QH	MI	DE85D2P
DMLK2QH	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMLK2QH	MT	DME
DMLK2QH	MA	Metabolism
DMLK2QH	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMLK2QH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	TTR6W5O
DM7F1PA	MN	Adrenergic receptor beta-1 (ADRB1)
DM7F1PA	MT	DTT
DM7F1PA	MA	Antagonist
DM7F1PA	RN	Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27.
DM7F1PA	RU	https://pubmed.ncbi.nlm.nih.gov/19443516

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	DECB0K3
DM7F1PA	MN	Cytochrome P450 2D6 (CYP2D6)
DM7F1PA	MT	DME
DM7F1PA	MA	Metabolism
DM7F1PA	RN	Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
DM7F1PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16961165

DM7F1PA	DI	DM7F1PA
DM7F1PA	DN	Nebivolol
DM7F1PA	MI	DEGTFWK
DM7F1PA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7F1PA	MT	DME
DM7F1PA	MA	Metabolism
DM7F1PA	RN	Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
DM7F1PA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27538917

DMKOJSN	DI	DMKOJSN
DMKOJSN	DN	Necitumumab
DMKOJSN	MI	TTGKNB4
DMKOJSN	MN	Epidermal growth factor receptor (EGFR)
DMKOJSN	MT	DTT
DMKOJSN	MA	Modulator
DMKOJSN	RN	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
DMKOJSN	RU	https://pubmed.ncbi.nlm.nih.gov/21154166

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	TTWJBZ5
DM4ZS8M	MN	5-HT 2C receptor (HTR2C)
DM4ZS8M	MT	DTT
DM4ZS8M	MA	Antagonist
DM4ZS8M	RN	Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
DM4ZS8M	RU	https://pubmed.ncbi.nlm.nih.gov/16433010

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	DECB0K3
DM4ZS8M	MN	Cytochrome P450 2D6 (CYP2D6)
DM4ZS8M	MT	DME
DM4ZS8M	MA	Metabolism
DM4ZS8M	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DM4ZS8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DM4ZS8M	DI	DM4ZS8M
DM4ZS8M	DN	Nefazodone
DM4ZS8M	MI	DE4LYSA
DM4ZS8M	MN	Cytochrome P450 3A4 (CYP3A4)
DM4ZS8M	MT	DME
DM4ZS8M	MA	Metabolism
DM4ZS8M	RN	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.
DM4ZS8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10445380

DMB6VEG	DI	DMB6VEG
DMB6VEG	DN	Nelarabine
DMB6VEG	MI	DEDQHBV
DMB6VEG	MN	Adenosine aminohydrolase (ADA)
DMB6VEG	MT	DME
DMB6VEG	MA	Metabolism
DMB6VEG	RN	Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia. Onco Targets Ther. 2009 Feb 18;2:219-28.
DMB6VEG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20616909

DMB6VEG	DI	DMB6VEG
DMB6VEG	DN	Nelarabine
DMB6VEG	MI	TTUBNVO
DMB6VEG	MN	DNA synthesis (DNA synth)
DMB6VEG	MT	DTT
DMB6VEG	MA	Binder
DMB6VEG	RN	Nelarabine. Drugs. 2008;68(4):439-47.
DMB6VEG	RU	https://pubmed.ncbi.nlm.nih.gov/18318562

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DE4LYSA
DMFX6G8	MN	Cytochrome P450 3A4 (CYP3A4)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DEIBDNY
DMFX6G8	MN	Cytochrome P450 3A5 (CYP3A5)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DERD86B
DMFX6G8	MN	Cytochrome P450 3A7 (CYP3A7)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMFX6G8	DI	DMFX6G8
DMFX6G8	DN	Nelfinavir mesylate
DMFX6G8	MI	DEGTFWK
DMFX6G8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFX6G8	MT	DME
DMFX6G8	MA	Metabolism
DMFX6G8	RN	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol. 2015 Aug;80(2):267-75.
DMFX6G8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25752914

DMY0EKH	DI	DMY0EKH
DMY0EKH	DN	Nemonapride
DMY0EKH	MI	TTEX248
DMY0EKH	MN	Dopamine D2 receptor (D2R)
DMY0EKH	MT	DTT
DMY0EKH	MA	Agonist
DMY0EKH	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMY0EKH	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM0S9Z1	DI	DM0S9Z1
DM0S9Z1	DN	Nemonoxacin
DM0S9Z1	MI	TTN6J5F
DM0S9Z1	MN	Bacterial DNA gyrase (Bact gyrase)
DM0S9Z1	MT	DTT
DM0S9Z1	MA	Inhibitor
DM0S9Z1	RN	Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53.
DM0S9Z1	RU	https://pubmed.ncbi.nlm.nih.gov/25079302

DMPWCTH	DI	DMPWCTH
DMPWCTH	DN	Neocarzinostatin
DMPWCTH	MI	TTUTN1I
DMPWCTH	MN	Human Deoxyribonucleic acid (hDNA)
DMPWCTH	MT	DTT
DMPWCTH	MA	Modulator
DMPWCTH	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMPWCTH	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM6T2J3	DI	DM6T2J3
DM6T2J3	DN	Neostigmine
DM6T2J3	MI	TT1RS9F
DM6T2J3	MN	Acetylcholinesterase (AChE)
DM6T2J3	MT	DTT
DM6T2J3	MA	Inhibitor
DM6T2J3	RN	Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
DM6T2J3	RU	https://pubmed.ncbi.nlm.nih.gov/19472276

DM6T2J3	DI	DM6T2J3
DM6T2J3	DN	Neostigmine
DM6T2J3	MI	DTUGYRD
DM6T2J3	MN	P-glycoprotein 1 (ABCB1)
DM6T2J3	MT	DTP
DM6T2J3	MA	Substrate
DM6T2J3	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM6T2J3	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMYK490	DI	DMYK490
DMYK490	DN	Nepafenac
DMYK490	MI	TTK0943
DMYK490	MN	Prostaglandin G/H synthase (COX)
DMYK490	MT	DTT
DMYK490	MA	Inhibitor
DMYK490	RN	Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
DMYK490	RU	https://pubmed.ncbi.nlm.nih.gov/12506103

DMEDU7B	DI	DMEDU7B
DMEDU7B	DN	NERATINIB MALEATE
DMEDU7B	MI	TTGKNB4
DMEDU7B	MN	Epidermal growth factor receptor (EGFR)
DMEDU7B	MT	DTT
DMEDU7B	MA	Antagonist
DMEDU7B	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMEDU7B	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMEDU7B	DI	DMEDU7B
DMEDU7B	DN	NERATINIB MALEATE
DMEDU7B	MI	TT6EO5L
DMEDU7B	MN	Erbb2 tyrosine kinase receptor (HER2)
DMEDU7B	MT	DTT
DMEDU7B	MA	Antagonist
DMEDU7B	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMEDU7B	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMMPG5V	DI	DMMPG5V
DMMPG5V	DN	NERIDRONIC ACID
DMMPG5V	MI	TTIKWV4
DMMPG5V	MN	Geranyltranstransferase (FDPS)
DMMPG5V	MT	DTT
DMMPG5V	MA	Inhibitor
DMMPG5V	RN	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
DMMPG5V	RU	https://pubmed.ncbi.nlm.nih.gov/18327899

DMFOIA8	DI	DMFOIA8
DMFOIA8	DN	Nesiritide
DMFOIA8	MI	TTJME02
DMFOIA8	MN	Atrial natriuretic peptide receptor A (NPR1)
DMFOIA8	MT	DTT
DMFOIA8	MA	Binder
DMFOIA8	RN	The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9.
DMFOIA8	RU	https://pubmed.ncbi.nlm.nih.gov/14736964

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTAWNKZ
DM0LPI9	MN	Norepinephrine transporter (NET)
DM0LPI9	MT	DTT
DM0LPI9	MA	Modulator
DM0LPI9	RN	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/25535688

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTMQO60
DM0LPI9	MN	Rho-associated protein kinase (ROCK)
DM0LPI9	MT	DTT
DM0LPI9	MA	Modulator
DM0LPI9	RN	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/25535688

DM0LPI9	DI	DM0LPI9
DM0LPI9	DN	Netarsudil
DM0LPI9	MI	TTZN7RP
DM0LPI9	MN	Rho-associated protein kinase 1 (ROCK1)
DM0LPI9	MT	DTT
DM0LPI9	MA	Inhibitor
DM0LPI9	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0LPI9	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEJADS9
DMRD1QK	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEWPAJD
DMRD1QK	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	DEZV4AP
DMRD1QK	MN	RNA cytidine acetyltransferase (hALP)
DMRD1QK	MT	DME
DMRD1QK	MA	Metabolism
DMRD1QK	RN	Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
DMRD1QK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12709325

DMRD1QK	DI	DMRD1QK
DMRD1QK	DN	Netilmicin
DMRD1QK	MI	TTQ8KVI
DMRD1QK	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMRD1QK	MT	DTT
DMRD1QK	MA	Binder
DMRD1QK	RN	Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6.
DMRD1QK	RU	https://pubmed.ncbi.nlm.nih.gov/6927285

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEJVYAZ
DM6HX9B	MN	Cytochrome P450 2A6 (CYP2A6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEPKLMQ
DM6HX9B	MN	Cytochrome P450 2B6 (CYP2B6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):423-31.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003847

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DE5IED8
DM6HX9B	MN	Cytochrome P450 2C9 (CYP2C9)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DECB0K3
DM6HX9B	MN	Cytochrome P450 2D6 (CYP2D6)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DE4LYSA
DM6HX9B	MN	Cytochrome P450 3A4 (CYP3A4)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10570031

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DEIBDNY
DM6HX9B	MN	Cytochrome P450 3A5 (CYP3A5)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DERD86B
DM6HX9B	MN	Cytochrome P450 3A7 (CYP3A7)
DM6HX9B	MT	DME
DM6HX9B	MA	Metabolism
DM6HX9B	RN	Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	TT84ETX
DM6HX9B	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6HX9B	MT	DTT
DM6HX9B	MA	Modulator
DM6HX9B	RN	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
DM6HX9B	RU	https://www.ncbi.nlm.nih.gov/pubmed/22266819

DM6HX9B	DI	DM6HX9B
DM6HX9B	DN	Nevirapine
DM6HX9B	MI	DTUGYRD
DM6HX9B	MN	P-glycoprotein 1 (ABCB1)
DM6HX9B	MT	DTP
DM6HX9B	MA	Substrate
DM6HX9B	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM6HX9B	RU	https://doi.org/10.1007/s11095-012-0935-x

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DTI7UX6
DMCDYW7	MN	Breast cancer resistance protein (ABCG2)
DMCDYW7	MT	DTP
DMCDYW7	MA	Substrate
DMCDYW7	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMCDYW7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	TT5HONZ
DMCDYW7	MN	Calcium channel unspecific (CaC)
DMCDYW7	MT	DTT
DMCDYW7	MA	Blocker
DMCDYW7	RN	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
DMCDYW7	RU	https://pubmed.ncbi.nlm.nih.gov/19569065

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DES5XRU
DMCDYW7	MN	Cytochrome P450 2C8 (CYP2C8)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DECB0K3
DMCDYW7	MN	Cytochrome P450 2D6 (CYP2D6)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DEVDYN7
DMCDYW7	MN	Cytochrome P450 2E1 (CYP2E1)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DE4LYSA
DMCDYW7	MN	Cytochrome P450 3A4 (CYP3A4)
DMCDYW7	MT	DME
DMCDYW7	MA	Metabolism
DMCDYW7	RN	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
DMCDYW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15863898

DMCDYW7	DI	DMCDYW7
DMCDYW7	DN	Nicardipine
DMCDYW7	MI	DTUGYRD
DMCDYW7	MN	P-glycoprotein 1 (ABCB1)
DMCDYW7	MT	DTP
DMCDYW7	MA	Substrate
DMCDYW7	RN	Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
DMCDYW7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17029589

DMBCM8L	DI	DMBCM8L
DMBCM8L	DN	Nicergoline
DMBCM8L	MI	TTQ8AFT
DMBCM8L	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMBCM8L	MT	DTT
DMBCM8L	MA	Antagonist
DMBCM8L	RN	Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35.
DMBCM8L	RU	https://pubmed.ncbi.nlm.nih.gov/16201147

DMBCM8L	DI	DMBCM8L
DMBCM8L	DN	Nicergoline
DMBCM8L	MI	DECB0K3
DMBCM8L	MN	Cytochrome P450 2D6 (CYP2D6)
DMBCM8L	MT	DME
DMBCM8L	MA	Metabolism
DMBCM8L	RN	Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol. 1996 Dec;42(6):707-11.
DMBCM8L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8971425

DMJAGXQ	DI	DMJAGXQ
DMJAGXQ	DN	Niclosamide
DMJAGXQ	MI	DE5IED8
DMJAGXQ	MN	Cytochrome P450 2C9 (CYP2C9)
DMJAGXQ	MT	DME
DMJAGXQ	MA	Metabolism
DMJAGXQ	RN	Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87.
DMJAGXQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557374

DMJAGXQ	DI	DMJAGXQ
DMJAGXQ	DN	Niclosamide
DMJAGXQ	MI	DE0K82S
DMJAGXQ	MN	Nitroreductase (NTR)
DMJAGXQ	MT	DME
DMJAGXQ	MA	Metabolism
DMJAGXQ	RN	CYP1A1 and Cnr nitroreductase bioactivated niclosamide in vitro. Mutagenesis. 2013 Nov;28(6):645-51.
DMJAGXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23956140

DMIYJFV	DI	DMIYJFV
DMIYJFV	DN	Nicorandil
DMIYJFV	MI	TTEF5MJ
DMIYJFV	MN	ATP-binding cassette transporter C9 (ABCC9)
DMIYJFV	MT	DTT
DMIYJFV	MA	Activator
DMIYJFV	RN	A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6.
DMIYJFV	RU	https://pubmed.ncbi.nlm.nih.gov/15978900

DMUPE07	DI	DMUPE07
DMUPE07	DN	Nicotinamide
DMUPE07	MI	DEVDYN7
DMUPE07	MN	Cytochrome P450 2E1 (CYP2E1)
DMUPE07	MT	DME
DMUPE07	MA	Metabolism
DMUPE07	RN	Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab Dispos. 2013 Mar;41(3):550-3.
DMUPE07	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23418369

DMUPE07	DI	DMUPE07
DMUPE07	DN	Nicotinamide
DMUPE07	MI	TTVDSZ0
DMUPE07	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMUPE07	MT	DTT
DMUPE07	MA	Binder
DMUPE07	RN	beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
DMUPE07	RU	https://pubmed.ncbi.nlm.nih.gov/19333861

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE6OQ3W
DMWX5CO	MN	Cytochrome P450 1A1 (CYP1A1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEJGDUW
DMWX5CO	MN	Cytochrome P450 1A2 (CYP1A2)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEXZA9U
DMWX5CO	MN	Cytochrome P450 2A13 (CYP2A13)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther. 2006 Jan;316(1):295-303.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16188955

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEJVYAZ
DMWX5CO	MN	Cytochrome P450 2A6 (CYP2A6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22869927

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEPKLMQ
DMWX5CO	MN	Cytochrome P450 2B6 (CYP2B6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16174803

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DES5XRU
DMWX5CO	MN	Cytochrome P450 2C8 (CYP2C8)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE5IED8
DMWX5CO	MN	Cytochrome P450 2C9 (CYP2C9)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DECB0K3
DMWX5CO	MN	Cytochrome P450 2D6 (CYP2D6)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEVDYN7
DMWX5CO	MN	Cytochrome P450 2E1 (CYP2E1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20233178

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE4LYSA
DMWX5CO	MN	Cytochrome P450 3A4 (CYP3A4)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEGTFWK
DMWX5CO	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10350185

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DE4AMLP
DMWX5CO	MN	Nicotinate dehydrogenase (nicA)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction. BMC Biotechnol. 2019 Aug 2;19(1):56.
DMWX5CO	RU	https://pubmed.ncbi.nlm.nih.gov/31375100

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	TTJSZTB
DMWX5CO	MN	Nicotinic acetylcholine receptor (nAChR)
DMWX5CO	MT	DTT
DMWX5CO	MA	Antagonist
DMWX5CO	RN	Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
DMWX5CO	RU	https://pubmed.ncbi.nlm.nih.gov/19481556

DMWX5CO	DI	DMWX5CO
DMWX5CO	DN	Nicotine
DMWX5CO	MI	DEYGVN4
DMWX5CO	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWX5CO	MT	DME
DMWX5CO	MA	Metabolism
DMWX5CO	RN	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
DMWX5CO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DE4OGUF
DMSVOZT	MN	Cytochrome P450 102A1 (cyp102)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
DMSVOZT	RU	https://pubmed.ncbi.nlm.nih.gov/17235582

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DEJGDUW
DMSVOZT	MN	Cytochrome P450 1A2 (CYP1A2)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805063

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DECB0K3
DMSVOZT	MN	Cytochrome P450 2D6 (CYP2D6)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Molecular basis of polymorphic drug metabolism. J Mol Med (Berl). 1995 Nov;73(11):539-53.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8751138

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DE4LYSA
DMSVOZT	MN	Cytochrome P450 3A4 (CYP3A4)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9384469

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DEIBDNY
DMSVOZT	MN	Cytochrome P450 3A5 (CYP3A5)
DMSVOZT	MT	DME
DMSVOZT	MA	Metabolism
DMSVOZT	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMSVOZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	DTUGYRD
DMSVOZT	MN	P-glycoprotein 1 (ABCB1)
DMSVOZT	MT	DTP
DMSVOZT	MA	Substrate
DMSVOZT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMSVOZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMSVOZT	DI	DMSVOZT
DMSVOZT	DN	Nifedipine
DMSVOZT	MI	TTXHYV6
DMSVOZT	MN	Voltage-gated L-type calcium channel (L-CaC)
DMSVOZT	MT	DTT
DMSVOZT	MA	Modulator
DMSVOZT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSVOZT	RU	https://www.fda.gov/

DMJ3I1Q	DI	DMJ3I1Q
DMJ3I1Q	DN	Niflumic acid
DMJ3I1Q	MI	TTVKILB
DMJ3I1Q	MN	Prostaglandin G/H synthase 2 (COX-2)
DMJ3I1Q	MT	DTT
DMJ3I1Q	MA	Inhibitor
DMJ3I1Q	RN	Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42.
DMJ3I1Q	RU	https://pubmed.ncbi.nlm.nih.gov/17485303

DMJ3I1Q	DI	DMJ3I1Q
DMJ3I1Q	DN	Niflumic acid
DMJ3I1Q	MI	DEYGVN4
DMJ3I1Q	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJ3I1Q	MT	DME
DMJ3I1Q	MA	Metabolism
DMJ3I1Q	RN	Identification of human UDP-glucuronosyltransferase responsible for the glucuronidation of niflumic acid in human liver. Pharm Res. 2006 Jul;23(7):1502-8.
DMJ3I1Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783480

DMSQLZJ	DI	DMSQLZJ
DMSQLZJ	DN	Nifurtimox
DMSQLZJ	MI	DTI7UX6
DMSQLZJ	MN	Breast cancer resistance protein (ABCG2)
DMSQLZJ	MT	DTP
DMSQLZJ	MA	Substrate
DMSQLZJ	RN	The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein. Brain Res. 2012 Feb 3;1436:111-21.
DMSQLZJ	RU	https://doi.org/10.1016/j.brainres.2011.11.053

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTI7UX6
DM7HXWT	MN	Breast cancer resistance protein (ABCG2)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DES5XRU
DM7HXWT	MN	Cytochrome P450 2C8 (CYP2C8)
DM7HXWT	MT	DME
DM7HXWT	MA	Metabolism
DM7HXWT	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM7HXWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DE4LYSA
DM7HXWT	MN	Cytochrome P450 3A4 (CYP3A4)
DM7HXWT	MT	DME
DM7HXWT	MA	Metabolism
DM7HXWT	RN	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
DM7HXWT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20810928

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	TTS7G69
DM7HXWT	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7HXWT	MT	DTT
DM7HXWT	MA	Modulator
DM7HXWT	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM7HXWT	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTFI42L
DM7HXWT	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785662

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DT3D8F0
DM7HXWT	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DT9C1TS
DM7HXWT	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM7HXWT	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM7HXWT	DI	DM7HXWT
DM7HXWT	DN	Nilotinib
DM7HXWT	MI	DTUGYRD
DM7HXWT	MN	P-glycoprotein 1 (ABCB1)
DM7HXWT	MT	DTP
DM7HXWT	MA	Substrate
DM7HXWT	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM7HXWT	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	TTS64P2
DMFN07X	MN	Androgen receptor (AR)
DMFN07X	MT	DTT
DMFN07X	MA	Antagonist
DMFN07X	RN	CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
DMFN07X	RU	https://pubmed.ncbi.nlm.nih.gov/18339851

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	DEGTFWK
DMFN07X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFN07X	MT	DME
DMFN07X	MA	Metabolism
DMFN07X	RN	Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
DMFN07X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1785203

DMFN07X	DI	DMFN07X
DMFN07X	DN	Nilutamide
DMFN07X	MI	DE3N2FM
DMFN07X	MN	NADPH-cytochrome P450 reductase (CPR)
DMFN07X	MT	DME
DMFN07X	MA	Metabolism
DMFN07X	RN	Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
DMFN07X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1311586

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	TT5HONZ
DMQ0RKZ	MN	Calcium channel unspecific (CaC)
DMQ0RKZ	MT	DTT
DMQ0RKZ	MA	Blocker
DMQ0RKZ	RN	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
DMQ0RKZ	RU	https://pubmed.ncbi.nlm.nih.gov/19443934

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DE4LYSA
DMQ0RKZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ0RKZ	MT	DME
DMQ0RKZ	MA	Metabolism
DMQ0RKZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMQ0RKZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DEIBDNY
DMQ0RKZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ0RKZ	MT	DME
DMQ0RKZ	MA	Metabolism
DMQ0RKZ	RN	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
DMQ0RKZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501176

DMQ0RKZ	DI	DMQ0RKZ
DMQ0RKZ	DN	Nimodipine
DMQ0RKZ	MI	DTUGYRD
DMQ0RKZ	MN	P-glycoprotein 1 (ABCB1)
DMQ0RKZ	MT	DTP
DMQ0RKZ	MA	Substrate
DMQ0RKZ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMQ0RKZ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMA65ER	DI	DMA65ER
DMA65ER	DN	Nipradilol
DMA65ER	MI	TTMXGCW
DMA65ER	MN	Adrenergic receptor beta-3 (ADRB3)
DMA65ER	MT	DTT
DMA65ER	MA	Modulator
DMA65ER	RN	Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
DMA65ER	RU	https://pubmed.ncbi.nlm.nih.gov/6150128

DMLPSWQ	DI	DMLPSWQ
DMLPSWQ	DN	Niraparib Tosylate
DMLPSWQ	MI	TTVDSZ0
DMLPSWQ	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMLPSWQ	MT	DTT
DMLPSWQ	MA	Modulator
DMLPSWQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLPSWQ	RU	https://www.fda.gov/

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	TT5HONZ
DM7ISKJ	MN	Calcium channel unspecific (CaC)
DM7ISKJ	MT	DTT
DM7ISKJ	MA	Blocker
DM7ISKJ	RN	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
DM7ISKJ	RU	https://pubmed.ncbi.nlm.nih.gov/19536471

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DE4LYSA
DM7ISKJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM7ISKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DEIBDNY
DM7ISKJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Drug Interactions Flockhart Table
DM7ISKJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DERD86B
DM7ISKJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM7ISKJ	MT	DME
DM7ISKJ	MA	Metabolism
DM7ISKJ	RN	Drug Interactions Flockhart Table
DM7ISKJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM7ISKJ	DI	DM7ISKJ
DM7ISKJ	DN	Nisoldipine
DM7ISKJ	MI	DTUGYRD
DM7ISKJ	MN	P-glycoprotein 1 (ABCB1)
DM7ISKJ	MT	DTP
DM7ISKJ	MA	Substrate
DM7ISKJ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM7ISKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMOWLVG	DI	DMOWLVG
DMOWLVG	DN	Nitazoxanide
DMOWLVG	MI	TT0F5P8
DMOWLVG	MN	Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO)
DMOWLVG	MT	DTT
DMOWLVG	MA	Modulator
DMOWLVG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOWLVG	RU	https://www.fda.gov/

DMVS9WQ	DI	DMVS9WQ
DMVS9WQ	DN	Nitisinone
DMVS9WQ	MI	TT8DSFC
DMVS9WQ	MN	Hydroxyphenylpyruvate dioxygenase (HPD)
DMVS9WQ	MT	DTT
DMVS9WQ	MA	Inhibitor
DMVS9WQ	RN	Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.
DMVS9WQ	RU	https://pubmed.ncbi.nlm.nih.gov/18422479

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE4LYSA
DMEGIQ6	MN	Cytochrome P450 3A4 (CYP3A4)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. Xenobiotica. 2008 Apr;38(4):353-67.
DMEGIQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18340561

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	TT1MPAY
DMEGIQ6	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEGIQ6	MT	DTT
DMEGIQ6	MA	Antagonist
DMEGIQ6	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEAVXGM
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Reduction of nitrazepam by Clostridium leptum, a nitroreductase-producing bacterium isolated from the human intestinal tract. Clin Infect Dis. 1997 Sep;25 Suppl 2:S121-2.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9310649

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEGV7K0
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets. Cell Host Microbe. 2019 Mar 13;25(3):444-453.e3.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/30799264

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE0K82S
DMEGIQ6	MN	Nitroreductase (NTR)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEDPI65
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8755878

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DEX5D46
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Identification and characterization of SnrA, an inducible oxygen-insensitive nitroreductase in Salmonella enterica serovar Typhimurium TA1535. Mutat Res. 2002 Oct 31;508(1-2):59-70.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/12379462

DMEGIQ6	DI	DMEGIQ6
DMEGIQ6	DN	Nitrazepam
DMEGIQ6	MI	DE0QLUZ
DMEGIQ6	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMEGIQ6	MT	DME
DMEGIQ6	MA	Metabolism
DMEGIQ6	RN	Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
DMEGIQ6	RU	https://pubmed.ncbi.nlm.nih.gov/8755909

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DE4LYSA
DM21C09	MN	Cytochrome P450 3A4 (CYP3A4)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM21C09	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DEIBDNY
DM21C09	MN	Cytochrome P450 3A5 (CYP3A5)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Drug Interactions Flockhart Table
DM21C09	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DERD86B
DM21C09	MN	Cytochrome P450 3A7 (CYP3A7)
DM21C09	MT	DME
DM21C09	MA	Metabolism
DM21C09	RN	Drug Interactions Flockhart Table
DM21C09	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	DTUGYRD
DM21C09	MN	P-glycoprotein 1 (ABCB1)
DM21C09	MT	DTP
DM21C09	MA	Substrate
DM21C09	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM21C09	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM21C09	DI	DM21C09
DM21C09	DN	Nitrendipine
DM21C09	MI	TTFK1JQ
DM21C09	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM21C09	MT	DTT
DM21C09	MA	Blocker
DM21C09	RN	Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
DM21C09	RU	https://pubmed.ncbi.nlm.nih.gov/19408308

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	DTW7AE3
DM1RBYG	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM1RBYG	MT	DTP
DM1RBYG	MA	Substrate
DM1RBYG	RN	Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.
DM1RBYG	RU	http://www.ncbi.nlm.nih.gov/pubmed/15848195

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	TT6HPVC
DM1RBYG	MN	Guanylate cyclase (GC)
DM1RBYG	MT	DTT
DM1RBYG	MA	Stimulator
DM1RBYG	RN	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
DM1RBYG	RU	https://pubmed.ncbi.nlm.nih.gov/19618122

DM1RBYG	DI	DM1RBYG
DM1RBYG	DN	Nitric Oxide
DM1RBYG	MI	TT23PYC
DM1RBYG	MN	Soluble guanylate cyclase (GCS)
DM1RBYG	MT	DTT
DM1RBYG	MA	Stimulator
DM1RBYG	RN	Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
DM1RBYG	RU	https://pubmed.ncbi.nlm.nih.gov/8638522

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	TTS1W4A
DM7PQIK	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DM7PQIK	MT	DTT
DM7PQIK	MA	Breaker
DM7PQIK	RN	On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/8607796

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DTI7UX6
DM7PQIK	MN	Breast cancer resistance protein (ABCG2)
DM7PQIK	MT	DTP
DM7PQIK	MA	Substrate
DM7PQIK	RN	The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol. 2005 May;67(5):1758-64.
DM7PQIK	RU	http://www.ncbi.nlm.nih.gov/pubmed/15709111

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE3N2FM
DM7PQIK	MN	NADPH-cytochrome P450 reductase (CPR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
DM7PQIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18206659

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE21PLI
DM7PQIK	MN	NADPH-dependent nitroreductase (nfrA1)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE82GV7
DM7PQIK	MN	NADPH-dependent oxidoreductase (nfrA)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEAVXGM
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE7XBKW
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEP7ECA
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEH3ABM
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/9593138

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE3U2Y6
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DEUW4J0
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DM7PQIK	DI	DM7PQIK
DM7PQIK	DN	Nitrofurantoin
DM7PQIK	MI	DE5LYXF
DM7PQIK	MN	Nitroreductase (NTR)
DM7PQIK	MT	DME
DM7PQIK	MA	Metabolism
DM7PQIK	RN	Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
DM7PQIK	RU	https://pubmed.ncbi.nlm.nih.gov/7167066

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	TTOVFH2
DMSM2KE	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMSM2KE	MT	DTT
DMSM2KE	MA	Inhibitor
DMSM2KE	RN	The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/22941660

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DECB0K3
DMSM2KE	MN	Cytochrome P450 2D6 (CYP2D6)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 2000 Aug;39(8):1008-16.
DMSM2KE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10939229

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE21PLI
DMSM2KE	MN	NADPH-dependent nitroreductase (nfrA1)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE82GV7
DMSM2KE	MN	NADPH-dependent oxidoreductase (nfrA)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE3U2Y6
DMSM2KE	MN	Nitroreductase (NTR)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DEUW4J0
DMSM2KE	MN	Nitroreductase (NTR)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/12951241

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DEDPI65
DMSM2KE	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol. 1996 Aug;178(15):4508-14.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/8755878

DMSM2KE	DI	DMSM2KE
DMSM2KE	DN	Nitrofurazone
DMSM2KE	MI	DE0QLUZ
DMSM2KE	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMSM2KE	MT	DME
DMSM2KE	MA	Metabolism
DMSM2KE	RN	Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
DMSM2KE	RU	https://pubmed.ncbi.nlm.nih.gov/8755909

DMQ2491	DI	DMQ2491
DMQ2491	DN	Nitroglycerin
DMQ2491	MI	TTGKNB4
DMQ2491	MN	Epidermal growth factor receptor (EGFR)
DMQ2491	MT	DTT
DMQ2491	MA	Activator
DMQ2491	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMQ2491	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMQ2491	DI	DMQ2491
DMQ2491	DN	Nitroglycerin
DMQ2491	MI	TT23PYC
DMQ2491	MN	Soluble guanylate cyclase (GCS)
DMQ2491	MT	DTT
DMQ2491	MA	Modulator
DMQ2491	RN	Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
DMQ2491	RU	https://pubmed.ncbi.nlm.nih.gov/11896472

DMM765C	DI	DMM765C
DMM765C	DN	Nitroprusside
DMM765C	MI	TTC9IZL
DMM765C	MN	Inositol 1,4,5-trisphosphate receptor (ITPR)
DMM765C	MT	DTT
DMM765C	MA	Antagonist
DMM765C	RN	Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem. 1996 Mar 8;271(10):5545-51.
DMM765C	RU	https://pubmed.ncbi.nlm.nih.gov/8621413

DMLUA2J	DI	DMLUA2J
DMLUA2J	DN	Nitroprusside
DMLUA2J	MI	DEAH3PE
DMLUA2J	MN	S-(hydroxymethyl)glutathione dehydrogenase (adh)
DMLUA2J	MT	DME
DMLUA2J	MA	Metabolism
DMLUA2J	RN	Nitrosative stress response in Vibrio cholerae: role of S-nitrosoglutathione reductase. Appl Biochem Biotechnol. 2017 Jul;182(3):871-884.
DMLUA2J	RU	https://pubmed.ncbi.nlm.nih.gov/28000045

DMTHWBI	DI	DMTHWBI
DMTHWBI	DN	Nitrous oxide
DMTHWBI	MI	TT9IK2Z
DMTHWBI	MN	N-methyl-D-aspartate receptor (NMDAR)
DMTHWBI	MT	DTT
DMTHWBI	MA	Antagonist
DMTHWBI	RN	Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
DMTHWBI	RU	https://pubmed.ncbi.nlm.nih.gov/17073666

DMAB9QE	DI	DMAB9QE
DMAB9QE	DN	Nivolumab
DMAB9QE	MI	TTNBFWK
DMAB9QE	MN	Programmed cell death protein 1 (PD-1)
DMAB9QE	MT	DTT
DMAB9QE	MA	Modulator
DMAB9QE	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAB9QE	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	TTQHJ1K
DMGFV3Z	MN	Histamine H2 receptor (H2R)
DMGFV3Z	MT	DTT
DMGFV3Z	MA	Antagonist
DMGFV3Z	RN	Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
DMGFV3Z	RU	https://pubmed.ncbi.nlm.nih.gov/18979143

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	DTT79CX
DMGFV3Z	MN	Organic cation transporter 1 (SLC22A1)
DMGFV3Z	MT	DTP
DMGFV3Z	MA	Substrate
DMGFV3Z	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMGFV3Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMGFV3Z	DI	DMGFV3Z
DMGFV3Z	DN	Nizatidine
DMGFV3Z	MI	DTUGYRD
DMGFV3Z	MN	P-glycoprotein 1 (ABCB1)
DMGFV3Z	MT	DTP
DMGFV3Z	MA	Substrate
DMGFV3Z	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00585)
DMGFV3Z	RU	https://www.drugbank.ca/drugs/DB00585

DMRJ7D1	DI	DMRJ7D1
DMRJ7D1	DN	Nomegestrol acetate
DMRJ7D1	MI	TTZAYWL
DMRJ7D1	MN	Estrogen receptor (ESR)
DMRJ7D1	MT	DTT
DMRJ7D1	MA	Modulator
DMRJ7D1	RN	Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61.
DMRJ7D1	RU	https://pubmed.ncbi.nlm.nih.gov/2918478

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	TTR6W5O
DMOUC09	MN	Adrenergic receptor beta-1 (ADRB1)
DMOUC09	MT	DTT
DMOUC09	MA	Stimulator
DMOUC09	RN	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
DMOUC09	RU	https://pubmed.ncbi.nlm.nih.gov/10075057

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTT79CX
DMOUC09	MN	Organic cation transporter 1 (SLC22A1)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
DMOUC09	RU	https://doi.org/10.2133/dmpk.23.243

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT9IDPW
DMOUC09	MN	Organic cation transporter 2 (SLC22A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT6201N
DMOUC09	MN	Organic cation transporter 3 (SLC22A3)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16581093

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTE8R17
DMOUC09	MN	Sodium- and chloride-dependent glycine transporter 2 (SLC6A5)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC6A2 Gene (Protein Coding).
DMOUC09	RU	https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC6A2

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DT9JBVI
DMOUC09	MN	Sodium-dependent noradrenaline transporter (SLC6A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/16573647

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTM953D
DMOUC09	MN	Vesicular amine transporter 1 (SLC18A1)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMOUC09	DI	DMOUC09
DMOUC09	DN	Norepinephrine
DMOUC09	MI	DTT7VPB
DMOUC09	MN	Vesicular amine transporter 2 (SLC18A2)
DMOUC09	MT	DTP
DMOUC09	MA	Substrate
DMOUC09	RN	SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
DMOUC09	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506877

DMTY169	DI	DMTY169
DMTY169	DN	Norethindrone
DMTY169	MI	TTUV8G9
DMTY169	MN	Progesterone receptor (PGR)
DMTY169	MT	DTT
DMTY169	MA	Agonist
DMTY169	RN	Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7.
DMTY169	RU	https://pubmed.ncbi.nlm.nih.gov/15189034

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEAJN47
DMDGCQP	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEVON3M
DMDGCQP	MN	Aldo-keto reductase 1D1 (AKR1D1)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEN0GVQ
DMDGCQP	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162927

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEJGDUW
DMDGCQP	MN	Cytochrome P450 1A2 (CYP1A2)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEJVYAZ
DMDGCQP	MN	Cytochrome P450 2A6 (CYP2A6)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DE4LYSA
DMDGCQP	MN	Cytochrome P450 3A4 (CYP3A4)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEIBDNY
DMDGCQP	MN	Cytochrome P450 3A5 (CYP3A5)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DERD86B
DMDGCQP	MN	Cytochrome P450 3A7 (CYP3A7)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
DMDGCQP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14663455

DMDGCQP	DI	DMDGCQP
DMDGCQP	DN	Norethindrone acetate
DMDGCQP	MI	DEGTFWK
DMDGCQP	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMDGCQP	MT	DME
DMDGCQP	MA	Metabolism
DMDGCQP	RN	Drug Interactions Flockhart Table
DMDGCQP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	TTN6J5F
DMIZ6W2	MN	Bacterial DNA gyrase (Bact gyrase)
DMIZ6W2	MT	DTT
DMIZ6W2	MA	Modulator
DMIZ6W2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIZ6W2	RU	https://www.fda.gov/

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTI7UX6
DMIZ6W2	MN	Breast cancer resistance protein (ABCG2)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
DMIZ6W2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16434544

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DEJGDUW
DMIZ6W2	MN	Cytochrome P450 1A2 (CYP1A2)
DMIZ6W2	MT	DME
DMIZ6W2	MA	Metabolism
DMIZ6W2	RN	Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
DMIZ6W2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTE2B1D
DMIZ6W2	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
DMIZ6W2	RU	http://www.ncbi.nlm.nih.gov/pubmed/17274666

DMIZ6W2	DI	DMIZ6W2
DMIZ6W2	DN	Norfloxacin
DMIZ6W2	MI	DTUGYRD
DMIZ6W2	MN	P-glycoprotein 1 (ABCB1)
DMIZ6W2	MT	DTP
DMIZ6W2	MA	Substrate
DMIZ6W2	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMIZ6W2	RU	https://doi.org/10.1007/s11095-012-0935-x

DMYP4XC	DI	DMYP4XC
DMYP4XC	DN	Norgestimate
DMYP4XC	MI	DE4LYSA
DMYP4XC	MN	Cytochrome P450 3A4 (CYP3A4)
DMYP4XC	MT	DME
DMYP4XC	MA	Metabolism
DMYP4XC	RN	Metabolite identification, reaction phenotyping, and retrospective drug-drug interaction predictions of 17-deacetylnorgestimate, the active component of the oral contraceptive norgestimate. Drug Metab Dispos. 2017 Jun;45(6):676-685.
DMYP4XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28283499

DMYP4XC	DI	DMYP4XC
DMYP4XC	DN	Norgestimate
DMYP4XC	MI	TTUV8G9
DMYP4XC	MN	Progesterone receptor (PGR)
DMYP4XC	MT	DTT
DMYP4XC	MA	Agonist
DMYP4XC	RN	Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
DMYP4XC	RU	https://pubmed.ncbi.nlm.nih.gov/19434887

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEJGDUW
DM4KDYJ	MN	Cytochrome P450 1A2 (CYP1A2)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9193876

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DECB0K3
DM4KDYJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DE4LYSA
DM4KDYJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Cytochrome P-450 activities in human and rat brain microsomes. Brain Res. 2000 Feb 14;855(2):235-43.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10677595

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEIBDNY
DM4KDYJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DEGTFWK
DM4KDYJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9867310

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	DE073H6
DM4KDYJ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM4KDYJ	MT	DME
DM4KDYJ	MA	Metabolism
DM4KDYJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM4KDYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM4KDYJ	DI	DM4KDYJ
DM4KDYJ	DN	Nortriptyline
DM4KDYJ	MI	TT3ROYC
DM4KDYJ	MN	Serotonin transporter (SERT)
DM4KDYJ	MT	DTT
DM4KDYJ	MA	Modulator
DM4KDYJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4KDYJ	RU	https://www.fda.gov/

DMRFWGK	DI	DMRFWGK
DMRFWGK	DN	Novobiocin
DMRFWGK	MI	TT0IHXV
DMRFWGK	MN	DNA topoisomerase II (TOP2)
DMRFWGK	MT	DTT
DMRFWGK	MA	Inhibitor
DMRFWGK	RN	Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9.
DMRFWGK	RU	https://pubmed.ncbi.nlm.nih.gov/19082504

DM6ZPLQ	DI	DM6ZPLQ
DM6ZPLQ	DN	Novolimus
DM6ZPLQ	MI	TTCJG29
DM6ZPLQ	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM6ZPLQ	MT	DTT
DM6ZPLQ	MA	Inhibitor
DM6ZPLQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DM6ZPLQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMRSX53	DI	DMRSX53
DMRSX53	DN	nusinersen
DMRSX53	MI	TTSVGQ5
DMRSX53	MN	SMN1 messenger RNA (SMN1 mRNA)
DMRSX53	MT	DTT
DMRSX53	MA	Modulator
DMRSX53	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DMRSX53	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM63QS9	DI	DM63QS9
DM63QS9	DN	Nystatin
DM63QS9	MI	TTQKWA4
DM63QS9	MN	Fungal Cell membrane ergosterol (Fung CME)
DM63QS9	MT	DTT
DM63QS9	MA	Modulator
DM63QS9	RN	Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation
DM63QS9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304795

DM3Q1SM	DI	DM3Q1SM
DM3Q1SM	DN	Obeticholic acid
DM3Q1SM	MI	DERA3OF
DM3Q1SM	MN	Bile acid-CoA thioesterase (BAAT)
DM3Q1SM	MT	DME
DM3Q1SM	MA	Metabolism
DM3Q1SM	RN	Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem. 1994 Jul 29;269(30):19375-9.
DM3Q1SM	RU	http://www.jbc.org/content/269/30/19375.full.pdf

DM3Q1SM	DI	DM3Q1SM
DM3Q1SM	DN	Obeticholic acid
DM3Q1SM	MI	TTS4UGC
DM3Q1SM	MN	Farnesoid X-activated receptor (FXR)
DM3Q1SM	MT	DTT
DM3Q1SM	MA	Modulator
DM3Q1SM	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM3Q1SM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DM3BVAE	DI	DM3BVAE
DM3BVAE	DN	Obinutuzumab
DM3BVAE	MI	TTUE541
DM3BVAE	MN	Leukocyte surface antigen Leu-16 (CD20)
DM3BVAE	MT	DTT
DM3BVAE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DM3BVAE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DMEZ2KH	DI	DMEZ2KH
DMEZ2KH	DN	Ocrelizumab
DMEZ2KH	MI	TTUE541
DMEZ2KH	MN	Leukocyte surface antigen Leu-16 (CD20)
DMEZ2KH	MT	DTT
DMEZ2KH	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMEZ2KH	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DM7AVGW	DI	DM7AVGW
DM7AVGW	DN	Ocriplasmin
DM7AVGW	MI	TTPJ921
DM7AVGW	MN	Fibronectin (FN1)
DM7AVGW	MT	DTT
DM7AVGW	MA	Inhibitor
DM7AVGW	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM7AVGW	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMHIDCJ	DI	DMHIDCJ
DMHIDCJ	DN	Octreotide
DMHIDCJ	MI	DTFI42L
DMHIDCJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHIDCJ	MT	DTP
DMHIDCJ	MA	Substrate
DMHIDCJ	RN	P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
DMHIDCJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/10694230

DMHIDCJ	DI	DMHIDCJ
DMHIDCJ	DN	Octreotide
DMHIDCJ	MI	TTZ6T9E
DMHIDCJ	MN	Somatostatin receptor type 2 (SSTR2)
DMHIDCJ	MT	DTT
DMHIDCJ	MA	Binder
DMHIDCJ	RN	Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31.
DMHIDCJ	RU	https://pubmed.ncbi.nlm.nih.gov/19537708

DMZK0FQ	DI	DMZK0FQ
DMZK0FQ	DN	Oestradiol valerate and dienogest
DMZK0FQ	MI	DE4LYSA
DMZK0FQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZK0FQ	MT	DME
DMZK0FQ	MA	Metabolism
DMZK0FQ	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMZK0FQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DM295PR	DI	DM295PR
DM295PR	DN	Ofatumumab
DM295PR	MI	TTUE541
DM295PR	MN	Leukocyte surface antigen Leu-16 (CD20)
DM295PR	MT	DTT
DM295PR	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM295PR	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM0VQN3	DI	DM0VQN3
DM0VQN3	DN	Ofloxacin
DM0VQN3	MI	TTN6J5F
DM0VQN3	MN	Bacterial DNA gyrase (Bact gyrase)
DM0VQN3	MT	DTT
DM0VQN3	MA	Modulator
DM0VQN3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0VQN3	RU	https://www.fda.gov/

DM0VQN3	DI	DM0VQN3
DM0VQN3	DN	Ofloxacin
DM0VQN3	MI	DTI7UX6
DM0VQN3	MN	Breast cancer resistance protein (ABCG2)
DM0VQN3	MT	DTP
DM0VQN3	MA	Substrate
DM0VQN3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0VQN3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMQ4PKA	DI	DMQ4PKA
DMQ4PKA	DN	Olamufloxacin
DMQ4PKA	MI	DTFI42L
DMQ4PKA	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQ4PKA	MT	DTP
DMQ4PKA	MA	Substrate
DMQ4PKA	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMQ4PKA	RU	https://doi.org/10.1007/s11095-012-0935-x

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DEJGDUW
DMPFN6Y	MN	Cytochrome P450 1A2 (CYP1A2)
DMPFN6Y	MT	DME
DMPFN6Y	MA	Metabolism
DMPFN6Y	RN	Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci. 2003 Mar;28(2):99-112.
DMPFN6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12670127

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DECB0K3
DMPFN6Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMPFN6Y	MT	DME
DMPFN6Y	MA	Metabolism
DMPFN6Y	RN	[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring]. Fortschr Neurol Psychiatr. 2001 Nov;69(11):510-7.
DMPFN6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11704898

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	TTEX248
DMPFN6Y	MN	Dopamine D2 receptor (D2R)
DMPFN6Y	MT	DTT
DMPFN6Y	MA	Agonist
DMPFN6Y	RN	Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
DMPFN6Y	RU	https://pubmed.ncbi.nlm.nih.gov/11217867

DMPFN6Y	DI	DMPFN6Y
DMPFN6Y	DN	Olanzapine
DMPFN6Y	MI	DTUGYRD
DMPFN6Y	MN	P-glycoprotein 1 (ABCB1)
DMPFN6Y	MT	DTP
DMPFN6Y	MA	Substrate
DMPFN6Y	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMPFN6Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM0Y49P	DI	DM0Y49P
DM0Y49P	DN	Olanzapine/fluoxetine combination
DM0Y49P	MI	TT8G3Z7
DM0Y49P	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DM0Y49P	MT	DTT
DM0Y49P	MA	Antagonist
DM0Y49P	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM0Y49P	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	DE4LYSA
DM8QB1D	MN	Cytochrome P450 3A4 (CYP3A4)
DM8QB1D	MT	DME
DM8QB1D	MA	Metabolism
DM8QB1D	RN	Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015 Sep;116(3):358-65.
DM8QB1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25981132

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	DTUGYRD
DM8QB1D	MN	P-glycoprotein 1 (ABCB1)
DM8QB1D	MT	DTP
DM8QB1D	MA	Substrate
DM8QB1D	RN	Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 May 7;12(7):871-878.
DM8QB1D	RU	http://www.ncbi.nlm.nih.gov/pubmed/31075528

DM8QB1D	DI	DM8QB1D
DM8QB1D	DN	Olaparib
DM8QB1D	MI	TTEBCY8
DM8QB1D	MN	Poly [ADP-ribose] polymerase (PARP)
DM8QB1D	MT	DTT
DM8QB1D	MA	Modulator
DM8QB1D	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM8QB1D	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMNYOIX	DI	DMNYOIX
DMNYOIX	DN	Olaratumab
DMNYOIX	MI	TT8FYO9
DMNYOIX	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMNYOIX	MT	DTT
DMNYOIX	MA	Modulator
DMNYOIX	RN	A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
DMNYOIX	RU	https://pubmed.ncbi.nlm.nih.gov/24452395

DM6MDCF	DI	DM6MDCF
DM6MDCF	DN	Oliceridine
DM6MDCF	MI	DECB0K3
DM6MDCF	MN	Cytochrome P450 2D6 (CYP2D6)
DM6MDCF	MT	DME
DM6MDCF	MA	Metabolism
DM6MDCF	RN	First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
DM6MDCF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24122908

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	TT8DBY3
DMWBHRY	MN	Angiotensin II receptor type-1 (AGTR1)
DMWBHRY	MT	DTT
DMWBHRY	MA	Antagonist
DMWBHRY	RN	Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56.
DMWBHRY	RU	https://pubmed.ncbi.nlm.nih.gov/19528815

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTI7UX6
DMWBHRY	MN	Breast cancer resistance protein (ABCG2)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMWBHRY	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTFI42L
DMWBHRY	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTCSGPB
DMWBHRY	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTQ23VB
DMWBHRY	MN	Organic anion transporter 1 (SLC22A6)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTVP67E
DMWBHRY	MN	Organic anion transporter 3 (SLC22A8)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DT3D8F0
DMWBHRY	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006 May;34(5):862-9.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/16501004

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DT9C1TS
DMWBHRY	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
DMWBHRY	RU	http://www.ncbi.nlm.nih.gov/pubmed/17823233

DMWBHRY	DI	DMWBHRY
DMWBHRY	DN	Olmesartan medoxomil
DMWBHRY	MI	DTUGYRD
DMWBHRY	MN	P-glycoprotein 1 (ABCB1)
DMWBHRY	MT	DTP
DMWBHRY	MA	Substrate
DMWBHRY	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMWBHRY	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM62B78	DI	DM62B78
DM62B78	DN	Olodaterol
DM62B78	MI	TT2CJVK
DM62B78	MN	Adrenergic receptor beta-2 (ADRB2)
DM62B78	MT	DTT
DM62B78	MA	Modulator
DM62B78	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM62B78	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM62B78	DI	DM62B78
DM62B78	DN	Olodaterol
DM62B78	MI	DE5IED8
DM62B78	MN	Cytochrome P450 2C9 (CYP2C9)
DM62B78	MT	DME
DM62B78	MA	Metabolism
DM62B78	RN	FDA Label of Olodaterol. The 2020 official website of the U.S. Food and Drug Administration.
DM62B78	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203108s006lbl.pdf

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	DE4LYSA
DMKMWQG	MN	Cytochrome P450 3A4 (CYP3A4)
DMKMWQG	MT	DME
DMKMWQG	MA	Metabolism
DMKMWQG	RN	Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
DMKMWQG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433826

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	TTTIBOJ
DMKMWQG	MN	Histamine H1 receptor (H1R)
DMKMWQG	MT	DTT
DMKMWQG	MA	Antagonist
DMKMWQG	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMKMWQG	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DMKMWQG	DI	DMKMWQG
DMKMWQG	DN	Olopatadine
DMKMWQG	MI	DTUGYRD
DMKMWQG	MN	P-glycoprotein 1 (ABCB1)
DMKMWQG	MT	DTP
DMKMWQG	MA	Substrate
DMKMWQG	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMKMWQG	RU	https://doi.org/10.1007/s11095-012-0935-x

DMWBQKU	DI	DMWBQKU
DMWBQKU	DN	Olprinone
DMWBQKU	MI	TTZCG4L
DMWBQKU	MN	Phosphodiesterase 3 (PDE3)
DMWBQKU	MT	DTT
DMWBQKU	MA	Inhibitor
DMWBQKU	RN	Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
DMWBQKU	RU	https://pubmed.ncbi.nlm.nih.gov/12397365

DMZW9HA	DI	DMZW9HA
DMZW9HA	DN	Olsalazine
DMZW9HA	MI	TTPZ7AG
DMZW9HA	MN	Oxidoreductase unspecific (OR)
DMZW9HA	MT	DTT
DMZW9HA	MA	Modulator
DMZW9HA	RN	Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90.
DMZW9HA	RU	https://pubmed.ncbi.nlm.nih.gov/21203919

DMPU2WX	DI	DMPU2WX
DMPU2WX	DN	Omacetaxine mepesuccinate
DMPU2WX	MI	TTA4FIU
DMPU2WX	MN	Ribosome A (hRA)
DMPU2WX	MT	DTT
DMPU2WX	MA	Modulator
DMPU2WX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMPU2WX	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMR2J95	DI	DMR2J95
DMR2J95	DN	Omadacycline
DMR2J95	MI	TTOVFH2
DMR2J95	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMR2J95	MT	DTT
DMR2J95	MA	Inhibitor
DMR2J95	RN	Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204. 
DMR2J95	RU	https://pubmed.ncbi.nlm.nih.gov/30290000

DMU5G01	DI	DMU5G01
DMU5G01	DN	Omadacycline
DMU5G01	MI	DTUGYRD
DMU5G01	MN	P-glycoprotein 1 (ABCB1)
DMU5G01	MT	DTP
DMU5G01	MA	Substrate
DMU5G01	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12455)
DMU5G01	RU	https://www.drugbank.ca/drugs/DB12455

DMETVFJ	DI	DMETVFJ
DMETVFJ	DN	Omalizumab
DMETVFJ	MI	TTDGEC0
DMETVFJ	MN	Immunoglobulin epsilon Fc receptor gamma (FCERG)
DMETVFJ	MT	DTT
DMETVFJ	MA	Modulator
DMETVFJ	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMETVFJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DML9TI0	DI	DML9TI0
DML9TI0	DN	Ombitasvir + paritaprevir + ritonavir
DML9TI0	MI	TTWXB3E
DML9TI0	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DML9TI0	MT	DTT
DML9TI0	MA	Modulator
DML9TI0	RN	HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
DML9TI0	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632384

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEZMWRE
DM471KJ	MN	Cytochrome P450 2C18 (CYP2C18)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DES5XRU
DM471KJ	MN	Cytochrome P450 2C8 (CYP2C8)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 Oct;24(10):1081-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8894508

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DE5IED8
DM471KJ	MN	Cytochrome P450 2C9 (CYP2C9)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258107

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DE4LYSA
DM471KJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEIBDNY
DM471KJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19139162

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	TTLOKXP
DM471KJ	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM471KJ	MT	DTT
DM471KJ	MA	Modulator
DM471KJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM471KJ	RU	https://www.fda.gov/

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DEGTFWK
DM471KJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM471KJ	MT	DME
DM471KJ	MA	Metabolism
DM471KJ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM471KJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM471KJ	DI	DM471KJ
DM471KJ	DN	Omeprazole
DM471KJ	MI	DTUGYRD
DM471KJ	MN	P-glycoprotein 1 (ABCB1)
DM471KJ	MT	DTP
DM471KJ	MA	Substrate
DM471KJ	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM471KJ	RU	https://doi.org/10.1007/s00210-008-0345-0

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	TTNXLKE
DMOTQ1I	MN	5-HT 3 receptor (5HT3R)
DMOTQ1I	MT	DTT
DMOTQ1I	MA	Agonist
DMOTQ1I	RN	Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
DMOTQ1I	RU	https://pubmed.ncbi.nlm.nih.gov/9831410

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEJGDUW
DMOTQ1I	MN	Cytochrome P450 1A2 (CYP1A2)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2006 Sep;29(9):1931-5.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16946512

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DE5IED8
DMOTQ1I	MN	Cytochrome P450 2C9 (CYP2C9)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DECB0K3
DMOTQ1I	MN	Cytochrome P450 2D6 (CYP2D6)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEVDYN7
DMOTQ1I	MN	Cytochrome P450 2E1 (CYP2E1)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DE4LYSA
DMOTQ1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223773

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DEIBDNY
DMOTQ1I	MN	Cytochrome P450 3A5 (CYP3A5)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DERD86B
DMOTQ1I	MN	Cytochrome P450 3A7 (CYP3A7)
DMOTQ1I	MT	DME
DMOTQ1I	MA	Metabolism
DMOTQ1I	RN	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
DMOTQ1I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8591723

DMOTQ1I	DI	DMOTQ1I
DMOTQ1I	DN	Ondansetron
DMOTQ1I	MI	DTUGYRD
DMOTQ1I	MN	P-glycoprotein 1 (ABCB1)
DMOTQ1I	MT	DTP
DMOTQ1I	MA	Substrate
DMOTQ1I	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMOTQ1I	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	TTSQIFT
DMHG57U	MN	5-HT 1A receptor (HTR1A)
DMHG57U	MT	DTT
DMHG57U	MA	Modulator
DMHG57U	RN	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24955861

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DECB0K3
DMHG57U	MN	Cytochrome P450 2D6 (CYP2D6)
DMHG57U	MT	DME
DMHG57U	MA	Metabolism
DMHG57U	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DE4LYSA
DMHG57U	MN	Cytochrome P450 3A4 (CYP3A4)
DMHG57U	MT	DME
DMHG57U	MA	Metabolism
DMHG57U	RN	Brexpiprazole: first global approval. Drugs. 2015 Sep;75(14):1687-97.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26310190

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	TTEX248
DMHG57U	MN	Dopamine D2 receptor (D2R)
DMHG57U	MT	DTT
DMHG57U	MA	Modulator
DMHG57U	RN	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
DMHG57U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24955861

DMHG57U	DI	DMHG57U
DMHG57U	DN	OPC-34712
DMHG57U	MI	DT3BA8L
DMHG57U	MN	Sodium-dependent dopamine transporter (SLC6A3)
DMHG57U	MT	DTP
DMHG57U	MA	Substrate
DMHG57U	RN	Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania. Psychopharmacology (Berl). 2017 Mar;234(6):1017-1028.
DMHG57U	RU	http://www.ncbi.nlm.nih.gov/pubmed/28160035

DM1BKA6	DI	DM1BKA6
DM1BKA6	DN	Opicapone
DM1BKA6	MI	TTKWFB8
DM1BKA6	MN	Catechol-O-methyl-transferase (COMT)
DM1BKA6	MT	DTT
DM1BKA6	MA	Inhibitor
DM1BKA6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM1BKA6	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf

DMPUOXF	DI	DMPUOXF
DMPUOXF	DN	Opipramol
DMPUOXF	MI	DECB0K3
DMPUOXF	MN	Cytochrome P450 2D6 (CYP2D6)
DMPUOXF	MT	DME
DMPUOXF	MA	Metabolism
DMPUOXF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMPUOXF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTSRI6	DI	DMTSRI6
DMTSRI6	DN	Oprelvekin
DMTSRI6	MI	TTZPLJS
DMTSRI6	MN	Interleukin 11 receptor alpha (IL11RA)
DMTSRI6	MT	DTT
DMTSRI6	MA	Binder
DMTSRI6	RN	Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.
DMTSRI6	RU	https://pubmed.ncbi.nlm.nih.gov/18020592

DM28D05	DI	DM28D05
DM28D05	DN	Oritavancin
DM28D05	MI	TT4ILYC
DM28D05	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM28D05	MT	DTT
DM28D05	MA	Inhibitor
DM28D05	RN	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
DM28D05	RU	https://pubmed.ncbi.nlm.nih.gov/15934867

DMRJSP8	DI	DMRJSP8
DMRJSP8	DN	Orlistat
DMRJSP8	MI	TT6OEDT
DMRJSP8	MN	Cannabinoid receptor 1 (CB1)
DMRJSP8	MT	DTT
DMRJSP8	MA	Inhibitor
DMRJSP8	RN	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
DMRJSP8	RU	https://pubmed.ncbi.nlm.nih.gov/18831576

DMRJSP8	DI	DMRJSP8
DMRJSP8	DN	Orlistat
DMRJSP8	MI	TTXMY0J
DMRJSP8	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMRJSP8	MT	DTT
DMRJSP8	MA	Modulator
DMRJSP8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRJSP8	RU	https://www.fda.gov/

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE4LYSA
DM6QHDJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEIBDNY
DM6QHDJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DERD86B
DM6QHDJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
DM6QHDJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17152348

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE90ZBW
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEXG57F
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE5CJFM
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DE9WXYE
DM6QHDJ	MN	Flavin adenine dinucleotide dehydrogenase (fadd)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Reduction of azo dyes and nitroaromatic compounds by bacterial enzymes from the human intestinal tract. Environ Health Perspect. 1995 Jun;103 Suppl 5:17-9.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/8565901

DM6QHDJ	DI	DM6QHDJ
DM6QHDJ	DN	Ornidazole
DM6QHDJ	MI	DEX5D46
DM6QHDJ	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DM6QHDJ	MT	DME
DM6QHDJ	MA	Metabolism
DM6QHDJ	RN	Identification and characterization of SnrA, an inducible oxygen-insensitive nitroreductase in Salmonella enterica serovar Typhimurium TA1535. Mutat Res. 2002 Oct 31;508(1-2):59-70.
DM6QHDJ	RU	https://pubmed.ncbi.nlm.nih.gov/12379462

DMW542E	DI	DMW542E
DMW542E	DN	Orphenadrine
DMW542E	MI	TT9IK2Z
DMW542E	MN	N-methyl-D-aspartate receptor (NMDAR)
DMW542E	MT	DTT
DMW542E	MA	Antagonist
DMW542E	RN	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
DMW542E	RU	https://pubmed.ncbi.nlm.nih.gov/19217209

DMFIQ20	DI	DMFIQ20
DMFIQ20	DN	Orphenadrine citrate
DMFIQ20	MI	DE4LYSA
DMFIQ20	MN	Cytochrome P450 3A4 (CYP3A4)
DMFIQ20	MT	DME
DMFIQ20	MA	Metabolism
DMFIQ20	RN	Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
DMFIQ20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9172960

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	TT50QJ3
DMGO72P	MN	Influenza Neuraminidase (Influ NA)
DMGO72P	MT	DTT
DMGO72P	MA	Inhibitor
DMGO72P	RN	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
DMGO72P	RU	https://pubmed.ncbi.nlm.nih.gov/18328578

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTCSGPB
DMGO72P	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009 Feb;37(2):315-21.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19029202

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTQ23VB
DMGO72P	MN	Organic anion transporter 1 (SLC22A6)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	FDA Drug Development and Drug Interactions
DMGO72P	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTVP67E
DMGO72P	MN	Organic anion transporter 3 (SLC22A8)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	FDA Drug Development and Drug Interactions
DMGO72P	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DT9G7XN
DMGO72P	MN	Peptide transporter 1 (SLC15A1)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos. 2009 Aug;37(8):1676-81.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19439487

DMGO72P	DI	DMGO72P
DMGO72P	DN	Oseltamivir
DMGO72P	MI	DTUGYRD
DMGO72P	MN	P-glycoprotein 1 (ABCB1)
DMGO72P	MT	DTP
DMGO72P	MA	Substrate
DMGO72P	RN	Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61.
DMGO72P	RU	http://www.ncbi.nlm.nih.gov/pubmed/19721074

DMIJC9X	DI	DMIJC9X
DMIJC9X	DN	Osilodrostat
DMIJC9X	MI	TTIQUX7
DMIJC9X	MN	Steroid 11-beta-hydroxylase (CYP11B1)
DMIJC9X	MT	DTT
DMIJC9X	MA	Modulator
DMIJC9X	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMIJC9X	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf

DMRJLAT	DI	DMRJLAT
DMRJLAT	DN	Osimertinib
DMRJLAT	MI	TTGKNB4
DMRJLAT	MN	Epidermal growth factor receptor (EGFR)
DMRJLAT	MT	DTT
DMRJLAT	MA	Inhibitor
DMRJLAT	RN	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
DMRJLAT	RU	https://pubmed.ncbi.nlm.nih.gov/24893891

DMF5ZB3	DI	DMF5ZB3
DMF5ZB3	DN	OspA lipoprotein
DMF5ZB3	MI	TTM6QSK
DMF5ZB3	MN	B-cell receptor CD22 (CD22)
DMF5ZB3	MT	DTT
DMF5ZB3	MA	Binder
DMF5ZB3	RN	Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
DMF5ZB3	RU	https://pubmed.ncbi.nlm.nih.gov/10067697

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DEPKLMQ
DMC4GEI	MN	Cytochrome P450 2B6 (CYP2B6)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DE5IED8
DMC4GEI	MN	Cytochrome P450 2C9 (CYP2C9)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DE4LYSA
DMC4GEI	MN	Cytochrome P450 3A4 (CYP3A4)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	TTZAYWL
DMC4GEI	MN	Estrogen receptor (ESR)
DMC4GEI	MT	DTT
DMC4GEI	MA	Modulator
DMC4GEI	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMC4GEI	RU	http://www.shionogi.co.jp/index_e.html

DMC4GEI	DI	DMC4GEI
DMC4GEI	DN	Ospemifene
DMC4GEI	MI	DEGTFWK
DMC4GEI	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC4GEI	MT	DME
DMC4GEI	MA	Metabolism
DMC4GEI	RN	Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
DMC4GEI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23729558

DM05968	DI	DM05968
DM05968	DN	Otilonium bromide
DM05968	MI	TTXHYV6
DM05968	MN	Voltage-gated L-type calcium channel (L-CaC)
DM05968	MT	DTT
DM05968	MA	Blocker
DM05968	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM05968	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMQNI7O	DI	DMQNI7O
DMQNI7O	DN	OTL-200
DMQNI7O	MI	TTYQANR
DMQNI7O	MN	Cerebroside-sulfatase (ARSA)
DMQNI7O	MT	DTT
DMQNI7O	MA	Replacement
DMQNI7O	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMQNI7O	RU	https://www.orchard-tx.com/approach/pipeline/

DME0F98	DI	DME0F98
DME0F98	DN	Ovine corticotropin-releasing hormone
DME0F98	MI	TTVIREA
DME0F98	MN	Adrenergic receptor (ADR)
DME0F98	MT	DTT
DME0F98	MA	Modulator
DME0F98	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME0F98	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTAFY4	DI	DMTAFY4
DMTAFY4	DN	Oxacillin
DMTAFY4	MI	TTJP4SM
DMTAFY4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTAFY4	MT	DTT
DMTAFY4	MA	Binder
DMTAFY4	RN	Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8.
DMTAFY4	RU	https://pubmed.ncbi.nlm.nih.gov/19433567

DMTAFY4	DI	DMTAFY4
DMTAFY4	DN	Oxacillin
DMTAFY4	MI	DE2ARDZ
DMTAFY4	MN	PenA beta-lactamase (penA1)
DMTAFY4	MT	DME
DMTAFY4	MA	Metabolism
DMTAFY4	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMTAFY4	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTI7UX6
DMQNWRD	MN	Breast cancer resistance protein (ABCG2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
DMQNWRD	RU	https://doi.org/10.1016/j.tiv.2008.09.001

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE6OQ3W
DMQNWRD	MN	Cytochrome P450 1A1 (CYP1A1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEJGDUW
DMQNWRD	MN	Cytochrome P450 1A2 (CYP1A2)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE9QHP6
DMQNWRD	MN	Cytochrome P450 1B1 (CYP1B1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEVDYN7
DMQNWRD	MN	Cytochrome P450 2E1 (CYP2E1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17498780

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEYZEJA
DMQNWRD	MN	Glutathione S-transferase mu-1 (GSTM1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEK6079
DMQNWRD	MN	Glutathione S-transferase pi (GSTP1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE3PKUG
DMQNWRD	MN	Glutathione S-transferase theta-1 (GSTT1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTP8L4F
DMQNWRD	MN	High affinity copper uptake protein 1 (SLC31A1)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/15607932

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	TTUTN1I
DMQNWRD	MN	Human Deoxyribonucleic acid (hDNA)
DMQNWRD	MT	DTT
DMQNWRD	MA	Modulator
DMQNWRD	RN	Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
DMQNWRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/23019159

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DE5ME8A
DMQNWRD	MN	Metallothionein-1A (MT1A)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEFKGT7
DMQNWRD	MN	Metallothionein-2A (MT2A)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTFI42L
DMQNWRD	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/26131551

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEA3U9Y
DMQNWRD	MN	Myeloperoxidase (MPO)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DTT79CX
DMQNWRD	MN	Organic cation transporter 1 (SLC22A1)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/16951202

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DT9IDPW
DMQNWRD	MN	Organic cation transporter 2 (SLC22A2)
DMQNWRD	MT	DTP
DMQNWRD	MA	Substrate
DMQNWRD	RN	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
DMQNWRD	RU	http://www.ncbi.nlm.nih.gov/pubmed/29417972

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DENP5RY
DMQNWRD	MN	Quinone reductase 1 (NQO1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DMQNWRD	DI	DMQNWRD
DMQNWRD	DN	Oxaliplatin
DMQNWRD	MI	DEUTDON
DMQNWRD	MN	Superoxide dismutase 1 (SOD1)
DMQNWRD	MT	DME
DMQNWRD	MA	Metabolism
DMQNWRD	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
DMQNWRD	RU	https://www.pharmgkb.org/pathway/PA150642262

DM2QDX1	DI	DM2QDX1
DM2QDX1	DN	Oxamniquine
DM2QDX1	MI	DECB0K3
DM2QDX1	MN	Cytochrome P450 2D6 (CYP2D6)
DM2QDX1	MT	DME
DM2QDX1	MA	Metabolism
DM2QDX1	RN	Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol. 1995;48(1):35-8.
DM2QDX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7621845

DM2QDX1	DI	DM2QDX1
DM2QDX1	DN	Oxamniquine
DM2QDX1	MI	TTB1TZG
DM2QDX1	MN	Schistosoma Deoxyribonucleic acid (Schist DNA)
DM2QDX1	MT	DTT
DM2QDX1	MA	Modulator
DM2QDX1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2QDX1	RU	https://www.fda.gov/

DMU9MYJ	DI	DMU9MYJ
DMU9MYJ	DN	Oxandrolone
DMU9MYJ	MI	TTS64P2
DMU9MYJ	MN	Androgen receptor (AR)
DMU9MYJ	MT	DTT
DMU9MYJ	MA	Agonist
DMU9MYJ	RN	The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
DMU9MYJ	RU	https://pubmed.ncbi.nlm.nih.gov/17364004

DMZ30JT	DI	DMZ30JT
DMZ30JT	DN	Oxantel pamoate
DMZ30JT	MI	TTHDSE2
DMZ30JT	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DMZ30JT	MT	DTT
DMZ30JT	MA	Inhibitor
DMZ30JT	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DMZ30JT	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DM9UB0P	DI	DM9UB0P
DM9UB0P	DN	Oxaprozin
DM9UB0P	MI	DE5IED8
DM9UB0P	MN	Cytochrome P450 2C9 (CYP2C9)
DM9UB0P	MT	DME
DM9UB0P	MA	Metabolism
DM9UB0P	RN	Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
DM9UB0P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9115051

DM9UB0P	DI	DM9UB0P
DM9UB0P	DN	Oxaprozin
DM9UB0P	MI	TTK0943
DM9UB0P	MN	Prostaglandin G/H synthase (COX)
DM9UB0P	MT	DTT
DM9UB0P	MA	Inhibitor
DM9UB0P	RN	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
DM9UB0P	RU	https://pubmed.ncbi.nlm.nih.gov/17409433

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	DECB0K3
DM1F42Z	MN	Cytochrome P450 2D6 (CYP2D6)
DM1F42Z	MT	DME
DM1F42Z	MA	Metabolism
DM1F42Z	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DM1F42Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	DE4LYSA
DM1F42Z	MN	Cytochrome P450 3A4 (CYP3A4)
DM1F42Z	MT	DME
DM1F42Z	MA	Metabolism
DM1F42Z	RN	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
DM1F42Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15684493

DM1F42Z	DI	DM1F42Z
DM1F42Z	DN	Oxatomide
DM1F42Z	MI	TTTIBOJ
DM1F42Z	MN	Histamine H1 receptor (H1R)
DM1F42Z	MT	DTT
DM1F42Z	MA	Antagonist
DM1F42Z	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM1F42Z	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DE4LYSA
DMXNZM4	MN	Cytochrome P450 3A4 (CYP3A4)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng. 2000 Apr;2(2):115-25.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10935727

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEO1IE3
DMXNZM4	MN	Cytochrome P450 3A43 (CYP3A43)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEIBDNY
DMXNZM4	MN	Cytochrome P450 3A5 (CYP3A5)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DERD86B
DMXNZM4	MN	Cytochrome P450 3A7 (CYP3A7)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659949

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	TTPTXIN
DMXNZM4	MN	Translocator protein (TSPO)
DMXNZM4	MT	DTT
DMXNZM4	MA	Agonist
DMXNZM4	RN	Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
DMXNZM4	RU	https://pubmed.ncbi.nlm.nih.gov/18692521

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEYGVN4
DMXNZM4	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19916996

DMXNZM4	DI	DMXNZM4
DMXNZM4	DN	Oxazepam
DMXNZM4	MI	DEB3CV1
DMXNZM4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMXNZM4	MT	DME
DMXNZM4	MA	Metabolism
DMXNZM4	RN	Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65.
DMXNZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12386133

DM5PU6O	DI	DM5PU6O
DM5PU6O	DN	Oxcarbazepine
DM5PU6O	MI	DTUGYRD
DM5PU6O	MN	P-glycoprotein 1 (ABCB1)
DM5PU6O	MT	DTP
DM5PU6O	MA	Substrate
DM5PU6O	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DM5PU6O	RU	https://doi.org/10.1016/j.addr.2011.12.003

DM5PU6O	DI	DM5PU6O
DM5PU6O	DN	Oxcarbazepine
DM5PU6O	MI	TTN9VTF
DM5PU6O	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DM5PU6O	MT	DTT
DM5PU6O	MA	Blocker
DM5PU6O	RN	Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24.
DM5PU6O	RU	https://pubmed.ncbi.nlm.nih.gov/19087113

DME7KRM	DI	DME7KRM
DME7KRM	DN	Oxiconazole
DME7KRM	MI	TTTSOUD
DME7KRM	MN	Candida Cytochrome P450 51 (Candi ERG11)
DME7KRM	MT	DTT
DME7KRM	MA	Inhibitor
DME7KRM	RN	Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
DME7KRM	RU	https://pubmed.ncbi.nlm.nih.gov/12823944

DME7KRM	DI	DME7KRM
DME7KRM	DN	Oxiconazole
DME7KRM	MI	DEGTFWK
DME7KRM	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DME7KRM	MT	DME
DME7KRM	MA	Metabolism
DME7KRM	RN	In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702.
DME7KRM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21177487

DM9EQC0	DI	DM9EQC0
DM9EQC0	DN	Oxidized glutathione
DM9EQC0	MI	TTEP6RV
DM9EQC0	MN	Glutathione reductase (GR)
DM9EQC0	MT	DTT
DM9EQC0	MA	Inhibitor
DM9EQC0	RN	The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401.
DM9EQC0	RU	https://pubmed.ncbi.nlm.nih.gov/7788561

DMRKOS1	DI	DMRKOS1
DMRKOS1	DN	Oxilofrine
DMRKOS1	MI	TTVIREA
DMRKOS1	MN	Adrenergic receptor (ADR)
DMRKOS1	MT	DTT
DMRKOS1	MA	Modulator
DMRKOS1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMRKOS1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM9FKSR	DI	DM9FKSR
DM9FKSR	DN	Oxitropium bromide
DM9FKSR	MI	TTH18TF
DM9FKSR	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM9FKSR	MT	DTT
DM9FKSR	MA	Modulator
DM9FKSR	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM9FKSR	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DM51OQW	DI	DM51OQW
DM51OQW	DN	Oxprenolol
DM51OQW	MI	TTR6W5O
DM51OQW	MN	Adrenergic receptor beta-1 (ADRB1)
DM51OQW	MT	DTT
DM51OQW	MA	Antagonist
DM51OQW	RN	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
DM51OQW	RU	https://pubmed.ncbi.nlm.nih.gov/16268148

DM51OQW	DI	DM51OQW
DM51OQW	DN	Oxprenolol
DM51OQW	MI	DECB0K3
DM51OQW	MN	Cytochrome P450 2D6 (CYP2D6)
DM51OQW	MT	DME
DM51OQW	MA	Metabolism
DM51OQW	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM51OQW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	DEJGDUW
DMLHSE3	MN	Cytochrome P450 1A2 (CYP1A2)
DMLHSE3	MT	DME
DMLHSE3	MA	Metabolism
DMLHSE3	RN	PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics. 2012 Jan;22(1):73-7.
DMLHSE3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21989077

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	TTZCG4L
DMLHSE3	MN	Phosphodiesterase 3 (PDE3)
DMLHSE3	MT	DTT
DMLHSE3	MA	Modulator
DMLHSE3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLHSE3	RU	https://www.fda.gov/

DMLHSE3	DI	DMLHSE3
DMLHSE3	DN	Oxtriphylline
DMLHSE3	MI	TTV5CGO
DMLHSE3	MN	Phosphodiesterase 4 (PDE4)
DMLHSE3	MT	DTT
DMLHSE3	MA	Modulator
DMLHSE3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLHSE3	RU	https://www.fda.gov/

DMI0GDH	DI	DMI0GDH
DMI0GDH	DN	Oxybuprocaine
DMI0GDH	MI	TTRK8B9
DMI0GDH	MN	Sodium channel unspecific (NaC)
DMI0GDH	MT	DTT
DMI0GDH	MA	Blocker
DMI0GDH	RN	Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53.
DMI0GDH	RU	https://pubmed.ncbi.nlm.nih.gov/19429093

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	DE4LYSA
DMF2KLU	MN	Cytochrome P450 3A4 (CYP3A4)
DMF2KLU	MT	DME
DMF2KLU	MA	Metabolism
DMF2KLU	RN	A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9.
DMF2KLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20428289

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	DEIBDNY
DMF2KLU	MN	Cytochrome P450 3A5 (CYP3A5)
DMF2KLU	MT	DME
DMF2KLU	MA	Metabolism
DMF2KLU	RN	Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica. 2007 Jan;37(1):59-73.
DMF2KLU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178634

DMF2KLU	DI	DMF2KLU
DMF2KLU	DN	Oxybutynin hydrochloride
DMF2KLU	MI	TTOXS3C
DMF2KLU	MN	Muscarinic acetylcholine receptor (CHRM)
DMF2KLU	MT	DTT
DMF2KLU	MA	Modulator
DMF2KLU	RN	Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
DMF2KLU	RU	https://pubmed.ncbi.nlm.nih.gov/10347840

DMXLKHV	DI	DMXLKHV
DMXLKHV	DN	Oxycodone
DMXLKHV	MI	TT27RFC
DMXLKHV	MN	Opioid receptor delta (OPRD1)
DMXLKHV	MT	DTT
DMXLKHV	MA	Agonist
DMXLKHV	RN	Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
DMXLKHV	RU	https://pubmed.ncbi.nlm.nih.gov/17525040

DMXLKHV	DI	DMXLKHV
DMXLKHV	DN	Oxycodone
DMXLKHV	MI	TTKWM86
DMXLKHV	MN	Opioid receptor mu (MOP)
DMXLKHV	MT	DTT
DMXLKHV	MA	Modulator
DMXLKHV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
DMXLKHV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319

DM8ZXT6	DI	DM8ZXT6
DM8ZXT6	DN	Oxymetazoline
DM8ZXT6	MI	TTQ8AFT
DM8ZXT6	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM8ZXT6	MT	DTT
DM8ZXT6	MA	Agonist
DM8ZXT6	RN	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
DM8ZXT6	RU	https://pubmed.ncbi.nlm.nih.gov/11481271

DM8ZXT6	DI	DM8ZXT6
DM8ZXT6	DN	Oxymetazoline
DM8ZXT6	MI	DEYGVN4
DM8ZXT6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM8ZXT6	MT	DME
DM8ZXT6	MA	Metabolism
DM8ZXT6	RN	Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. J Pharm Sci. 2011 Feb;100(2):784-93.
DM8ZXT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20669329

DMFXUT8	DI	DMFXUT8
DMFXUT8	DN	Oxymetholone
DMFXUT8	MI	DEOG15F
DMFXUT8	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMFXUT8	MT	DME
DMFXUT8	MA	Metabolism
DMFXUT8	RN	Androgen physiology. Semin Reprod Med. 2006 Apr;24(2):71-7.
DMFXUT8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633980

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	DECB0K3
DM65AGJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM65AGJ	MT	DME
DM65AGJ	MA	Metabolism
DM65AGJ	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DM65AGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	DE4LYSA
DM65AGJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM65AGJ	MT	DME
DM65AGJ	MA	Metabolism
DM65AGJ	RN	Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
DM65AGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20642550

DM65AGJ	DI	DM65AGJ
DM65AGJ	DN	Oxymorphone
DM65AGJ	MI	TTN4QDT
DM65AGJ	MN	Opioid receptor (OPR)
DM65AGJ	MT	DTT
DM65AGJ	MA	Modulator
DM65AGJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
DM65AGJ	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7094

DMPZS7U	DI	DMPZS7U
DMPZS7U	DN	Oxyphenbutazone
DMPZS7U	MI	TTFNGC9
DMPZS7U	MN	Serum albumin (ALB)
DMPZS7U	MT	DTT
DMPZS7U	MA	Modulator
DMPZS7U	RN	Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
DMPZS7U	RU	https://www.ncbi.nlm.nih.gov/pubmed/7062254

DM3TABW	DI	DM3TABW
DM3TABW	DN	Oxyphencyclimine
DM3TABW	MI	TTH18TF
DM3TABW	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM3TABW	MT	DTT
DM3TABW	MA	Binder
DM3TABW	RN	Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42.
DM3TABW	RU	https://pubmed.ncbi.nlm.nih.gov/1426023

DMMQHOZ	DI	DMMQHOZ
DMMQHOZ	DN	Oxyphenonium
DMMQHOZ	MI	TTZ9SOR
DMMQHOZ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMMQHOZ	MT	DTT
DMMQHOZ	MA	Antagonist
DMMQHOZ	RN	Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
DMMQHOZ	RU	https://pubmed.ncbi.nlm.nih.gov/10430538

DMMQHOZ	DI	DMMQHOZ
DMMQHOZ	DN	Oxyphenonium
DMMQHOZ	MI	DTT79CX
DMMQHOZ	MN	Organic cation transporter 1 (SLC22A1)
DMMQHOZ	MT	DTP
DMMQHOZ	MA	Substrate
DMMQHOZ	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMMQHOZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMOVH1M	DI	DMOVH1M
DMOVH1M	DN	Oxytetracycline
DMOVH1M	MI	TTQ8KVI
DMOVH1M	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMOVH1M	MT	DTT
DMOVH1M	MA	Binder
DMOVH1M	RN	Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13.
DMOVH1M	RU	https://pubmed.ncbi.nlm.nih.gov/15156014

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTSCIUP
DMDL27I	MN	Oxytocin receptor (OTR)
DMDL27I	MT	DTT
DMDL27I	MA	Modulator
DMDL27I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
DMDL27I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TT4TFGN
DMDL27I	MN	Vasopressin V1a receptor (V1AR)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
DMDL27I	RU	https://pubmed.ncbi.nlm.nih.gov/9334232

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTL9MHW
DMDL27I	MN	Vasopressin V1b receptor (V1BR)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
DMDL27I	RU	https://pubmed.ncbi.nlm.nih.gov/9322919

DMDL27I	DI	DMDL27I
DMDL27I	DN	Oxytocin
DMDL27I	MI	TTK8R02
DMDL27I	MN	Vasopressin V2 receptor (V2R)
DMDL27I	MT	DTT
DMDL27I	MA	Agonist
DMDL27I	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
DMDL27I	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368

DM1YB0R	DI	DM1YB0R
DM1YB0R	DN	OZ277
DM1YB0R	MI	TTZVSJ2
DM1YB0R	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DM1YB0R	MT	DTT
DM1YB0R	MA	Inhibitor
DM1YB0R	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DM1YB0R	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMT6AM2	DI	DMT6AM2
DMT6AM2	DN	Ozanimod
DMT6AM2	MI	TT9JZCK
DMT6AM2	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMT6AM2	MT	DTT
DMT6AM2	MA	Agonist
DMT6AM2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMT6AM2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTN6J5F
DM6KZMG	MN	Bacterial DNA gyrase (Bact gyrase)
DM6KZMG	MT	DTT
DM6KZMG	MA	Modulator
DM6KZMG	RN	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
DM6KZMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/11864945

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTABD5E
DM6KZMG	MN	DNA replication (DNA repli)
DM6KZMG	MT	DTT
DM6KZMG	MA	Inhibitor
DM6KZMG	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM6KZMG	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTRVWAT
DM6KZMG	MN	Staphylococcus DNA gyrase A (Stap-coc gyrA)
DM6KZMG	MT	DTT
DM6KZMG	MA	Inhibitor
DM6KZMG	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM6KZMG	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM6KZMG	DI	DM6KZMG
DM6KZMG	DN	Ozenoxacin
DM6KZMG	MI	TTIXTO3
DM6KZMG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DM6KZMG	MT	DTT
DM6KZMG	MA	Modulator
DM6KZMG	RN	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
DM6KZMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/11864945

DMNKT8Z	DI	DMNKT8Z
DMNKT8Z	DN	Pachycarpine
DMNKT8Z	MI	TTRK8B9
DMNKT8Z	MN	Sodium channel unspecific (NaC)
DMNKT8Z	MT	DTT
DMNKT8Z	MA	Modulator
DMNKT8Z	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMNKT8Z	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTI7UX6
DMLB81S	MN	Breast cancer resistance protein (ABCG2)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTZRMK5
DMLB81S	MN	Multidrug resistance protein 3 (ABCB4)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTSYQGK
DMLB81S	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMLB81S	RU	https://doi.org/10.1007/s11095-012-0935-x

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTFI42L
DMLB81S	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/17062689

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTQ3ZHF
DMLB81S	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008 Jul 1;68(13):5380-9.
DMLB81S	RU	https://doi.org/10.1158/0008-5472.CAN-08-0234

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTPS120
DMLB81S	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT0OC1Q
DMLB81S	MN	Organic anion transporter 2 (SLC22A7)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901346

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT3D8F0
DMLB81S	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds. Eur J Med Chem. 2015 Mar 6;92:723-31.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/25618019

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT9C1TS
DMLB81S	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005 Aug;4(8):815-8.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/16210916

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DTUGYRD
DMLB81S	MN	P-glycoprotein 1 (ABCB1)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504826

DMLB81S	DI	DMLB81S
DMLB81S	DN	Paclitaxel
DMLB81S	MI	DT68UV2
DMLB81S	MN	TAP-like protein (ABCB9)
DMLB81S	MT	DTP
DMLB81S	MA	Substrate
DMLB81S	RN	Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9. Oncol Lett. 2016 Nov;12(5):3905-3911.
DMLB81S	RU	http://www.ncbi.nlm.nih.gov/pubmed/27895747

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DTI7UX6
DMD7L94	MN	Breast cancer resistance protein (ABCG2)
DMD7L94	MT	DTP
DMD7L94	MA	Substrate
DMD7L94	RN	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
DMD7L94	RU	http://www.ncbi.nlm.nih.gov/pubmed/26354993

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	TT0PG8F
DMD7L94	MN	Cyclin-dependent kinase 4 (CDK4)
DMD7L94	MT	DTT
DMD7L94	MA	Modulator
DMD7L94	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
DMD7L94	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	TTO0FDJ
DMD7L94	MN	Cyclin-dependent kinase 6 (CDK6)
DMD7L94	MT	DTT
DMD7L94	MA	Modulator
DMD7L94	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2017
DMD7L94	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DE4LYSA
DMD7L94	MN	Cytochrome P450 3A4 (CYP3A4)
DMD7L94	MT	DME
DMD7L94	MA	Metabolism
DMD7L94	RN	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
DMD7L94	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28203301

DMD7L94	DI	DMD7L94
DMD7L94	DN	Palbociclib
DMD7L94	MI	DTUGYRD
DMD7L94	MN	P-glycoprotein 1 (ABCB1)
DMD7L94	MT	DTP
DMD7L94	MA	Substrate
DMD7L94	RN	Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
DMD7L94	RU	http://www.ncbi.nlm.nih.gov/pubmed/26354993

DM9JOYP	DI	DM9JOYP
DM9JOYP	DN	Palifermin
DM9JOYP	MI	TTGJVQM
DM9JOYP	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM9JOYP	MT	DTT
DM9JOYP	MA	Binder
DM9JOYP	RN	Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
DM9JOYP	RU	https://pubmed.ncbi.nlm.nih.gov/19456212

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	TT85JO3
DM7NPJS	MN	5-HT receptor (5HTR)
DM7NPJS	MT	DTT
DM7NPJS	MA	Antagonist
DM7NPJS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM7NPJS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DECB0K3
DM7NPJS	MN	Cytochrome P450 2D6 (CYP2D6)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	Interpreting serum risperidone concentrations. Pharmacotherapy. 2005 Feb;25(2):299-302.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15767244

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DE4LYSA
DM7NPJS	MN	Cytochrome P450 3A4 (CYP3A4)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18708991

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DEIBDNY
DM7NPJS	MN	Cytochrome P450 3A5 (CYP3A5)
DM7NPJS	MT	DME
DM7NPJS	MA	Metabolism
DM7NPJS	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DM7NPJS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DM7NPJS	DI	DM7NPJS
DM7NPJS	DN	Paliperidone
DM7NPJS	MI	DTUGYRD
DM7NPJS	MN	P-glycoprotein 1 (ABCB1)
DM7NPJS	MT	DTP
DM7NPJS	MA	Substrate
DM7NPJS	RN	Invega (paliperidone) extended release tablets FDA Label
DM7NPJS	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf

DMQM9S0	DI	DMQM9S0
DMQM9S0	DN	Palivizumab
DMQM9S0	MI	TT57ID8
DMQM9S0	MN	Respiratory syncytial virus protein F (RSV F)
DMQM9S0	MT	DTT
DMQM9S0	MA	Modulator
DMQM9S0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQM9S0	RU	https://www.fda.gov/

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	TTPC4TU
DMBHMOX	MN	5-HT 3A receptor (HTR3A)
DMBHMOX	MT	DTT
DMBHMOX	MA	Antagonist
DMBHMOX	RN	Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
DMBHMOX	RU	https://pubmed.ncbi.nlm.nih.gov/19436621

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	DECB0K3
DMBHMOX	MN	Cytochrome P450 2D6 (CYP2D6)
DMBHMOX	MT	DME
DMBHMOX	MA	Metabolism
DMBHMOX	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMBHMOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMBHMOX	DI	DMBHMOX
DMBHMOX	DN	Palonosetron
DMBHMOX	MI	DE4LYSA
DMBHMOX	MN	Cytochrome P450 3A4 (CYP3A4)
DMBHMOX	MT	DME
DMBHMOX	MA	Metabolism
DMBHMOX	RN	Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004 Nov;25(8):329-37.
DMBHMOX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15378559

DMK2PBD	DI	DMK2PBD
DMK2PBD	DN	Palonosetron + fosnetupitant
DMK2PBD	MI	TTPC4TU
DMK2PBD	MN	5-HT 3A receptor (HTR3A)
DMK2PBD	MT	DTT
DMK2PBD	MA	Antagonist
DMK2PBD	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK2PBD	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMK2PBD	DI	DMK2PBD
DMK2PBD	DN	Palonosetron + fosnetupitant
DMK2PBD	MI	TTZPO1L
DMK2PBD	MN	Substance-P receptor (TACR1)
DMK2PBD	MT	DTT
DMK2PBD	MA	Antagonist
DMK2PBD	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMK2PBD	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMB4AVP	DI	DMB4AVP
DMB4AVP	DN	Pamidronate
DMB4AVP	MI	TTIKWV4
DMB4AVP	MN	Geranyltranstransferase (FDPS)
DMB4AVP	MT	DTT
DMB4AVP	MA	Inhibitor
DMB4AVP	RN	Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
DMB4AVP	RU	https://pubmed.ncbi.nlm.nih.gov/18782552

DMB0VY8	DI	DMB0VY8
DMB0VY8	DN	Pancuronium
DMB0VY8	MI	TTJSZTB
DMB0VY8	MN	Nicotinic acetylcholine receptor (nAChR)
DMB0VY8	MT	DTT
DMB0VY8	MA	Antagonist
DMB0VY8	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMB0VY8	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMQPD1F	DI	DMQPD1F
DMQPD1F	DN	Panitumumab
DMQPD1F	MI	TTGKNB4
DMQPD1F	MN	Epidermal growth factor receptor (EGFR)
DMQPD1F	MT	DTT
DMQPD1F	MA	Suppressor
DMQPD1F	RN	Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
DMQPD1F	RU	https://pubmed.ncbi.nlm.nih.gov/19616446

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	DE4LYSA
DM58WKG	MN	Cytochrome P450 3A4 (CYP3A4)
DM58WKG	MT	DME
DM58WKG	MA	Metabolism
DM58WKG	RN	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48.
DM58WKG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26503877

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	TT6R7JZ
DM58WKG	MN	Histone deacetylase 1 (HDAC1)
DM58WKG	MT	DTT
DM58WKG	MA	Inhibitor
DM58WKG	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DM58WKG	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DM58WKG	DI	DM58WKG
DM58WKG	DN	Panobinostat
DM58WKG	MI	DTUGYRD
DM58WKG	MN	P-glycoprotein 1 (ABCB1)
DM58WKG	MT	DTP
DM58WKG	MA	Substrate
DM58WKG	RN	Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76.
DM58WKG	RU	http://www.ncbi.nlm.nih.gov/pubmed/26504410

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DTI7UX6
DMSVOCZ	MN	Breast cancer resistance protein (ABCG2)
DMSVOCZ	MT	DTP
DMSVOCZ	MA	Substrate
DMSVOCZ	RN	Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11.
DMSVOCZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15313923

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEJGDUW
DMSVOCZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DE4LYSA
DMSVOCZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	TTLOKXP
DMSVOCZ	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMSVOCZ	MT	DTT
DMSVOCZ	MA	Modulator
DMSVOCZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSVOCZ	RU	https://www.fda.gov/

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEGTFWK
DMSVOCZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29620484

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DTUGYRD
DMSVOCZ	MN	P-glycoprotein 1 (ABCB1)
DMSVOCZ	MT	DTP
DMSVOCZ	MA	Substrate
DMSVOCZ	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DMSVOCZ	RU	https://doi.org/10.1007/s00210-008-0345-0

DMSVOCZ	DI	DMSVOCZ
DMSVOCZ	DN	Pantoprazole
DMSVOCZ	MI	DEYWLRK
DMSVOCZ	MN	Sulfotransferase 1A1 (SULT1A1)
DMSVOCZ	MT	DME
DMSVOCZ	MA	Metabolism
DMSVOCZ	RN	Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med. 1996 May-Jun;69(3):203-9.
DMSVOCZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9165689

DM091H2	DI	DM091H2
DM091H2	DN	Pantothenic acid
DM091H2	MI	DENRZXT
DM091H2	MN	Pantothenate kinase 3 (PANK3)
DM091H2	MT	DME
DM091H2	MA	Metabolism
DM091H2	RN	Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain. Chem Biol. 2010 Aug 27;17(8):892-902.
DM091H2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20797618

DMCA9QP	DI	DMCA9QP
DMCA9QP	DN	Papaverine
DMCA9QP	MI	TTSKMI8
DMCA9QP	MN	Phosphodiesterase 4D (PDE4D)
DMCA9QP	MT	DTT
DMCA9QP	MA	Inhibitor
DMCA9QP	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMCA9QP	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMCA9QP	DI	DMCA9QP
DMCA9QP	DN	Papaverine
DMCA9QP	MI	TTJ0IQB
DMCA9QP	MN	Phosphodiesterase 5A (PDE5A)
DMCA9QP	MT	DTT
DMCA9QP	MA	Inhibitor
DMCA9QP	RN	Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
DMCA9QP	RU	https://pubmed.ncbi.nlm.nih.gov/12646997

DMOC1BX	DI	DMOC1BX
DMOC1BX	DN	Paraldehyde
DMOC1BX	MI	DEWYTJB
DMOC1BX	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMOC1BX	MT	DME
DMOC1BX	MA	Metabolism
DMOC1BX	RN	Paraldehyde. J Appl Toxicol. 1991 Oct;11(5):379-81.
DMOC1BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1783744

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DE5IED8
DMR5ZUP	MN	Cytochrome P450 2C9 (CYP2C9)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DEVDYN7
DMR5ZUP	MN	Cytochrome P450 2E1 (CYP2E1)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther. 2000 Jun;25(3):165-75.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10886461

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	DE4LYSA
DMR5ZUP	MN	Cytochrome P450 3A4 (CYP3A4)
DMR5ZUP	MT	DME
DMR5ZUP	MA	Metabolism
DMR5ZUP	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DMR5ZUP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DMR5ZUP	DI	DMR5ZUP
DMR5ZUP	DN	Paramethadione
DMR5ZUP	MI	TT729IR
DMR5ZUP	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMR5ZUP	MT	DTT
DMR5ZUP	MA	Blocker
DMR5ZUP	RN	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
DMR5ZUP	RU	https://pubmed.ncbi.nlm.nih.gov/17291698

DM6PR40	DI	DM6PR40
DM6PR40	DN	Paramethasone
DM6PR40	MI	TTJL8VG
DM6PR40	MN	Corticosteroid-binding globulin (SERPINA6)
DM6PR40	MT	DTT
DM6PR40	MA	Binder
DM6PR40	RN	Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7.
DM6PR40	RU	https://pubmed.ncbi.nlm.nih.gov/10634411

DM6PR40	DI	DM6PR40
DM6PR40	DN	Paramethasone
DM6PR40	MI	DE4LYSA
DM6PR40	MN	Cytochrome P450 3A4 (CYP3A4)
DM6PR40	MT	DME
DM6PR40	MA	Metabolism
DM6PR40	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DM6PR40	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMM0HR1	DI	DMM0HR1
DMM0HR1	DN	Pargyline
DMM0HR1	MI	TT32XQJ
DMM0HR1	MN	Monoamine oxidase (MAO)
DMM0HR1	MT	DTT
DMM0HR1	MA	Inhibitor
DMM0HR1	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMM0HR1	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMM0HR1	DI	DMM0HR1
DMM0HR1	DN	Pargyline
DMM0HR1	MI	TTGP7BY
DMM0HR1	MN	Monoamine oxidase type B (MAO-B)
DMM0HR1	MT	DTT
DMM0HR1	MA	Inhibitor
DMM0HR1	RN	Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
DMM0HR1	RU	https://pubmed.ncbi.nlm.nih.gov/19542488

DMYBV3G	DI	DMYBV3G
DMYBV3G	DN	Paricalcitol
DMYBV3G	MI	TTK59TV
DMYBV3G	MN	Vitamin D3 receptor (VDR)
DMYBV3G	MT	DTT
DMYBV3G	MA	Agonist
DMYBV3G	RN	New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226.
DMYBV3G	RU	https://pubmed.ncbi.nlm.nih.gov/19494617

DM1AGXN	DI	DM1AGXN
DM1AGXN	DN	Paromomycin
DM1AGXN	MI	TTQ8KVI
DM1AGXN	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM1AGXN	MT	DTT
DM1AGXN	MA	Binder
DM1AGXN	RN	Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30.
DM1AGXN	RU	https://pubmed.ncbi.nlm.nih.gov/19438282

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DEJGDUW
DM5PVQE	MN	Cytochrome P450 1A2 (CYP1A2)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics. 2010 Nov;11(11):1535-43.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21121774

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DECB0K3
DM5PVQE	MN	Cytochrome P450 2D6 (CYP2D6)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25974703

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DE4LYSA
DM5PVQE	MN	Cytochrome P450 3A4 (CYP3A4)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DEGTFWK
DM5PVQE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5PVQE	MT	DME
DM5PVQE	MA	Metabolism
DM5PVQE	RN	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
DM5PVQE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20007670

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	DTUGYRD
DM5PVQE	MN	P-glycoprotein 1 (ABCB1)
DM5PVQE	MT	DTP
DM5PVQE	MA	Substrate
DM5PVQE	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM5PVQE	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM5PVQE	DI	DM5PVQE
DM5PVQE	DN	Paroxetine
DM5PVQE	MI	TT3ROYC
DM5PVQE	MN	Serotonin transporter (SERT)
DM5PVQE	MT	DTT
DM5PVQE	MA	Modulator
DM5PVQE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5PVQE	RU	https://www.fda.gov/

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTIND6G
DMHM7JS	MN	Somatostatin receptor type 1 (SSTR1)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTZ6T9E
DMHM7JS	MN	Somatostatin receptor type 2 (SSTR2)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TTJX3UE
DMHM7JS	MN	Somatostatin receptor type 3 (SSTR3)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357

DMHM7JS	DI	DMHM7JS
DMHM7JS	DN	Pasireotide
DMHM7JS	MI	TT2BC4G
DMHM7JS	MN	Somatostatin receptor type 5 (SSTR5)
DMHM7JS	MT	DTT
DMHM7JS	MA	Inhibitor
DMHM7JS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359).
DMHM7JS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359

DMMIQ20	DI	DMMIQ20
DMMIQ20	DN	Patiromer calcium
DMMIQ20	MI	TTB0SC6
DMMIQ20	MN	Potassium (K)
DMMIQ20	MT	DTT
DMMIQ20	MA	Binder
DMMIQ20	RN	Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8.
DMMIQ20	RU	https://pubmed.ncbi.nlm.nih.gov/21208974

DMWSA0V	DI	DMWSA0V
DMWSA0V	DN	Patisiran
DMWSA0V	MI	TTPOYU7
DMWSA0V	MN	Transthyretin messenger RNA (TTR mRNA)
DMWSA0V	MT	DTT
DMWSA0V	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DMWSA0V	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DEJGDUW
DMF57DM	MN	Cytochrome P450 1A2 (CYP1A2)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DES5XRU
DMF57DM	MN	Cytochrome P450 2C8 (CYP2C8)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DECB0K3
DMF57DM	MN	Cytochrome P450 2D6 (CYP2D6)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21395357

DMF57DM	DI	DMF57DM
DMF57DM	DN	Pazopanib
DMF57DM	MI	DE4LYSA
DMF57DM	MN	Cytochrome P450 3A4 (CYP3A4)
DMF57DM	MT	DME
DMF57DM	MA	Metabolism
DMF57DM	RN	Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35.
DMF57DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23488774

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DTI7UX6
DM6U9CQ	MN	Breast cancer resistance protein (ABCG2)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23548165

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DT3D8F0
DM6U9CQ	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	DTUGYRD
DM6U9CQ	MN	P-glycoprotein 1 (ABCB1)
DM6U9CQ	MT	DTP
DM6U9CQ	MA	Substrate
DM6U9CQ	RN	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53.
DM6U9CQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23548165

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTI2WET
DM6U9CQ	MN	Platelet-derived growth factor receptor (PDGFR)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTX41N9
DM6U9CQ	MN	Tyrosine-protein kinase Kit (KIT)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6U9CQ	DI	DM6U9CQ
DM6U9CQ	DN	Pazopanib HCl
DM6U9CQ	MI	TTUTJGQ
DM6U9CQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6U9CQ	MT	DTT
DM6U9CQ	MA	Inhibitor
DM6U9CQ	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM6U9CQ	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM49IGF	DI	DM49IGF
DM49IGF	DN	Pefloxacin
DM49IGF	MI	TT0IHXV
DM49IGF	MN	DNA topoisomerase II (TOP2)
DM49IGF	MT	DTT
DM49IGF	MA	Inhibitor
DM49IGF	RN	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
DM49IGF	RU	https://pubmed.ncbi.nlm.nih.gov/3282749

DMOWEBU	DI	DMOWEBU
DMOWEBU	DN	Pegaptanib
DMOWEBU	MI	TTIPJCB
DMOWEBU	MN	Neuropilin-1 (NRP1)
DMOWEBU	MT	DTT
DMOWEBU	RN	Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32.
DMOWEBU	RU	https://pubmed.ncbi.nlm.nih.gov/16518379

DM7UP8X	DI	DM7UP8X
DM7UP8X	DN	Pegfilgrastim
DM7UP8X	MI	TTC70AJ
DM7UP8X	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DM7UP8X	MT	DTT
DM7UP8X	MA	Binder
DM7UP8X	RN	Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
DM7UP8X	RU	https://pubmed.ncbi.nlm.nih.gov/15082029

DMJI3BA	DI	DMJI3BA
DMJI3BA	DN	Peginterferon alfa-2a
DMJI3BA	MI	TTSIUJ9
DMJI3BA	MN	Interferon-alpha 2 (IFNA2)
DMJI3BA	MT	DTT
DMJI3BA	MA	Modulator
DMJI3BA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJI3BA	RU	https://www.fda.gov/

DMAP58Y	DI	DMAP58Y
DMAP58Y	DN	Peginterferon alfa-2b
DMAP58Y	MI	TTSIUJ9
DMAP58Y	MN	Interferon-alpha 2 (IFNA2)
DMAP58Y	MT	DTT
DMAP58Y	MA	Modulator
DMAP58Y	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAP58Y	RU	https://www.fda.gov/

DMCLR6G	DI	DMCLR6G
DMCLR6G	DN	Pegloticase
DMCLR6G	MI	TTZ1SWF
DMCLR6G	MN	Uric acid (URA)
DMCLR6G	MT	DTT
DMCLR6G	MA	Modulator
DMCLR6G	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMCLR6G	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM6NZ2P	DI	DM6NZ2P
DM6NZ2P	DN	Pegvaliase
DM6NZ2P	MI	TTGSVH2
DM6NZ2P	MN	Phenylalanine hydroxylase (PAH)
DM6NZ2P	MT	DTT
DM6NZ2P	MA	Modulator
DM6NZ2P	RN	Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227. 
DM6NZ2P	RU	https://pubmed.ncbi.nlm.nih.gov/30146451

DMDEZI3	DI	DMDEZI3
DMDEZI3	DN	Pegvisomant
DMDEZI3	MI	TTKMAZ6
DMDEZI3	MN	Growth hormone receptor (GHR)
DMDEZI3	MT	DTT
DMDEZI3	MA	Antagonist
DMDEZI3	RN	Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72.
DMDEZI3	RU	https://pubmed.ncbi.nlm.nih.gov/19549743

DMRH0D5	DI	DMRH0D5
DMRH0D5	DN	PEGylated IFN beta 1-a
DMRH0D5	MI	TT4TZ8J
DMRH0D5	MN	Interferon-beta (IFNB1)
DMRH0D5	MT	DTT
DMRH0D5	MA	Modulator
DMRH0D5	RN	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65.
DMRH0D5	RU	https://pubmed.ncbi.nlm.nih.gov/24794721

DM8DQV9	DI	DM8DQV9
DM8DQV9	DN	Pelubiprofen
DM8DQV9	MI	TTK0943
DM8DQV9	MN	Prostaglandin G/H synthase (COX)
DM8DQV9	MT	DTT
DM8DQV9	MA	Modulator
DM8DQV9	RN	Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603.
DM8DQV9	RU	https://pubmed.ncbi.nlm.nih.gov/21809372

DMD1VZL	DI	DMD1VZL
DMD1VZL	DN	Pemafibrate
DMD1VZL	MI	TTJ584C
DMD1VZL	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD1VZL	MT	DTT
DMD1VZL	MA	Agonist
DMD1VZL	RN	Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
DMD1VZL	RU	https://pubmed.ncbi.nlm.nih.gov/28929345

DMFQEA6	DI	DMFQEA6
DMFQEA6	DN	Pembrolizumab
DMFQEA6	MI	TTNBFWK
DMFQEA6	MN	Programmed cell death protein 1 (PD-1)
DMFQEA6	MT	DTT
DMFQEA6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMFQEA6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTI7UX6
DMMX2E6	MN	Breast cancer resistance protein (ABCG2)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos. 2011 Sep;39(9):1478-85.
DMMX2E6	RU	https://doi.org/10.1124/dmd.111.039370

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	TTU6BFZ
DMMX2E6	MN	Candida Thymidylate synthase (Candi TMP1)
DMMX2E6	MT	DTT
DMMX2E6	MA	Inhibitor
DMMX2E6	RN	Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
DMMX2E6	RU	https://pubmed.ncbi.nlm.nih.gov/19362945

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTOSN46
DMMX2E6	MN	Folate transporter 1 (SLC19A1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/24745983

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTFI42L
DMMX2E6	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMMX2E6	RU	https://doi.org/10.1007/s11095-012-0935-x

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTYVM24
DMMX2E6	MN	Multidrug resistance-associated protein 5 (ABCC5)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16337112

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTPFTEQ
DMMX2E6	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol. 2012 Feb;81(2):134-42.
DMMX2E6	RU	https://doi.org/10.1124/mol.111.074823

DMMX2E6	DI	DMMX2E6
DMMX2E6	DN	Pemetrexed
DMMX2E6	MI	DTDJEMI
DMMX2E6	MN	Proton-coupled folate transporter (SLC46A1)
DMMX2E6	MT	DTP
DMMX2E6	MA	Substrate
DMMX2E6	RN	The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol. 2008 Sep;74(3):854-62.
DMMX2E6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18524888

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTRLW2X
DM819JF	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTGJVQM
DM819JF	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DM819JF	DI	DM819JF
DM819JF	DN	Pemigatinib
DM819JF	MI	TTST7KB
DM819JF	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM819JF	MT	DTT
DM819JF	MA	Inhibitor
DM819JF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM819JF	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	TTTIBOJ
DML97WV	MN	Histamine H1 receptor (H1R)
DML97WV	MT	DTT
DML97WV	MA	Antagonist
DML97WV	RN	The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9.
DML97WV	RU	https://pubmed.ncbi.nlm.nih.gov/18463425

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	DTFI42L
DML97WV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DML97WV	MT	DTP
DML97WV	MA	Substrate
DML97WV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DML97WV	RU	https://doi.org/10.1007/s11095-012-0935-x

DML97WV	DI	DML97WV
DML97WV	DN	Pemirolast
DML97WV	MI	DTUGYRD
DML97WV	MN	P-glycoprotein 1 (ABCB1)
DML97WV	MT	DTP
DML97WV	MA	Substrate
DML97WV	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DML97WV	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4ES8F	DI	DM4ES8F
DM4ES8F	DN	Penbutolol
DM4ES8F	MI	TTR6W5O
DM4ES8F	MN	Adrenergic receptor beta-1 (ADRB1)
DM4ES8F	MT	DTT
DM4ES8F	MA	Antagonist
DM4ES8F	RN	beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8.
DM4ES8F	RU	https://pubmed.ncbi.nlm.nih.gov/12058352

DM4ES8F	DI	DM4ES8F
DM4ES8F	DN	Penbutolol
DM4ES8F	MI	DECB0K3
DM4ES8F	MN	Cytochrome P450 2D6 (CYP2D6)
DM4ES8F	MT	DME
DM4ES8F	MA	Metabolism
DM4ES8F	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM4ES8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	TTIU7X1
DMOUMDV	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMOUMDV	MT	DTT
DMOUMDV	MA	Inhibitor
DMOUMDV	RN	Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. 
DMOUMDV	RU	https://pubmed.ncbi.nlm.nih.gov/19228073

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	DT0OC1Q
DMOUMDV	MN	Organic anion transporter 2 (SLC22A7)
DMOUMDV	MT	DTP
DMOUMDV	MA	Substrate
DMOUMDV	RN	In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica. 2018 Oct;48(10):1037-1049.
DMOUMDV	RU	http://www.ncbi.nlm.nih.gov/pubmed/28945155

DMOUMDV	DI	DMOUMDV
DMOUMDV	DN	Penciclovir
DMOUMDV	MI	TTP3QRF
DMOUMDV	MN	Thymidine kinase 1 (TK1)
DMOUMDV	MT	DTT
DMOUMDV	MA	Inhibitor
DMOUMDV	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOUMDV	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG1DTE	DI	DMG1DTE
DMG1DTE	DN	Penfluridol
DMG1DTE	MI	TT729IR
DMG1DTE	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMG1DTE	MT	DTT
DMG1DTE	MA	Blocker
DMG1DTE	RN	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
DMG1DTE	RU	https://pubmed.ncbi.nlm.nih.gov/11784784

DM40EF6	DI	DM40EF6
DM40EF6	DN	Penicillamine
DM40EF6	MI	TTT3ZC9
DM40EF6	MN	Human immunodeficiency virus Tat protein (HIV tat)
DM40EF6	MT	DTT
DM40EF6	MA	Inhibitor
DM40EF6	RN	Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6.
DM40EF6	RU	https://pubmed.ncbi.nlm.nih.gov/11959100

DMNMHBV	DI	DMNMHBV
DMNMHBV	DN	Penicillin
DMNMHBV	MI	TTJP4SM
DMNMHBV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMNMHBV	MT	DTT
DMNMHBV	MA	Modulator
DMNMHBV	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMNMHBV	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DM49VEW	DI	DM49VEW
DM49VEW	DN	Penicillin G Benzathine
DM49VEW	MI	TTJP4SM
DM49VEW	MN	Bacterial Penicillin binding protein (Bact PBP)
DM49VEW	MT	DTT
DM49VEW	MA	Modulator
DM49VEW	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DM49VEW	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMU4JLB	DI	DMU4JLB
DMU4JLB	DN	Penicillin G Procaine
DMU4JLB	MI	TTJP4SM
DMU4JLB	MN	Bacterial Penicillin binding protein (Bact PBP)
DMU4JLB	MT	DTT
DMU4JLB	MA	Modulator
DMU4JLB	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMU4JLB	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMY18XK	DI	DMY18XK
DMY18XK	DN	Penicillin G Sodium
DMY18XK	MI	TTJP4SM
DMY18XK	MN	Bacterial Penicillin binding protein (Bact PBP)
DMY18XK	MT	DTT
DMY18XK	MA	Modulator
DMY18XK	RN	Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
DMY18XK	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 

DMKVOYF	DI	DMKVOYF
DMKVOYF	DN	Penicillin V
DMKVOYF	MI	TTJP4SM
DMKVOYF	MN	Bacterial Penicillin binding protein (Bact PBP)
DMKVOYF	MT	DTT
DMKVOYF	MA	Binder
DMKVOYF	RN	Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40.
DMKVOYF	RU	https://pubmed.ncbi.nlm.nih.gov/7541399

DM8LX76	DI	DM8LX76
DM8LX76	DN	Penicillin V Potassium
DM8LX76	MI	TTJP4SM
DM8LX76	MN	Bacterial Penicillin binding protein (Bact PBP)
DM8LX76	MT	DTT
DM8LX76	MA	Modulator
DM8LX76	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8LX76	RU	https://www.fda.gov/

DMZ9MO5	DI	DMZ9MO5
DMZ9MO5	DN	Pentaerythritol tetranitrate
DMZ9MO5	MI	DEWYTJB
DMZ9MO5	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMZ9MO5	MT	DME
DMZ9MO5	MA	Metabolism
DMZ9MO5	RN	OSHA Occupational Chemical Database: drug information.
DMZ9MO5	RU	https://www.osha.gov/dts/chemicalsampling/data/CH_260110.html

DMRCLZB	DI	DMRCLZB
DMRCLZB	DN	Pentagastrin
DMRCLZB	MI	TTVFO0U
DMRCLZB	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMRCLZB	MT	DTT
DMRCLZB	MA	Agonist
DMRCLZB	RN	Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21.
DMRCLZB	RU	https://pubmed.ncbi.nlm.nih.gov/18580872

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEJGDUW
DMHZJCG	MN	Cytochrome P450 1A2 (CYP1A2)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DES5XRU
DMHZJCG	MN	Cytochrome P450 2C8 (CYP2C8)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DECB0K3
DMHZJCG	MN	Cytochrome P450 2D6 (CYP2D6)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DE4LYSA
DMHZJCG	MN	Cytochrome P450 3A4 (CYP3A4)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEIBDNY
DMHZJCG	MN	Cytochrome P450 3A5 (CYP3A5)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DEGTFWK
DMHZJCG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHZJCG	MT	DME
DMHZJCG	MA	Metabolism
DMHZJCG	RN	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
DMHZJCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21299635

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	DTT79CX
DMHZJCG	MN	Organic cation transporter 1 (SLC22A1)
DMHZJCG	MT	DTP
DMHZJCG	MA	Substrate
DMHZJCG	RN	Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
DMHZJCG	RU	http://www.ncbi.nlm.nih.gov/pubmed/18971316

DMHZJCG	DI	DMHZJCG
DMHZJCG	DN	Pentamidine
DMHZJCG	MI	TTM1TDX
DMHZJCG	MN	Tryptase alpha/beta-1 (Tryptase)
DMHZJCG	MT	DTT
DMHZJCG	MA	Inhibitor
DMHZJCG	RN	Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96.
DMHZJCG	RU	https://pubmed.ncbi.nlm.nih.gov/10197050

DM1XBHS	DI	DM1XBHS
DM1XBHS	DN	Pentazocine
DM1XBHS	MI	TTN4QDT
DM1XBHS	MN	Opioid receptor (OPR)
DM1XBHS	MT	DTT
DM1XBHS	MA	Antagonist
DM1XBHS	RN	Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
DM1XBHS	RU	https://pubmed.ncbi.nlm.nih.gov/10562966

DM1XBHS	DI	DM1XBHS
DM1XBHS	DN	Pentazocine
DM1XBHS	MI	DTUGYRD
DM1XBHS	MN	P-glycoprotein 1 (ABCB1)
DM1XBHS	MT	DTP
DM1XBHS	MA	Substrate
DM1XBHS	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1XBHS	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMFNH7L	DI	DMFNH7L
DMFNH7L	DN	Pentobarbital
DMFNH7L	MI	TT1MPAY
DMFNH7L	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFNH7L	MT	DTT
DMFNH7L	MA	Antagonist
DMFNH7L	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMFNH7L	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMFNH7L	DI	DMFNH7L
DMFNH7L	DN	Pentobarbital
DMFNH7L	MI	DEGTFWK
DMFNH7L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMFNH7L	MT	DME
DMFNH7L	MA	Metabolism
DMFNH7L	RN	CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
DMFNH7L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10805060

DM38VYQ	DI	DM38VYQ
DM38VYQ	DN	Pentolinium
DM38VYQ	MI	TT4H1MQ
DM38VYQ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DM38VYQ	MT	DTT
DM38VYQ	MA	Antagonist
DM38VYQ	RN	Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
DM38VYQ	RU	https://pubmed.ncbi.nlm.nih.gov/8516349

DM2HRKE	DI	DM2HRKE
DM2HRKE	DN	Pentosan polysulfate
DM2HRKE	MI	TTCEKVZ
DM2HRKE	MN	Fibroblast growth factor-4 (FGF4)
DM2HRKE	MT	DTT
DM2HRKE	MA	Modulator
DM2HRKE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2HRKE	RU	https://www.fda.gov/

DM0HXDS	DI	DM0HXDS
DM0HXDS	DN	Pentostatin
DM0HXDS	MI	TTLP57V
DM0HXDS	MN	Adenosine deaminase (ADA)
DM0HXDS	MT	DTT
DM0HXDS	MA	Inhibitor
DM0HXDS	RN	Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
DM0HXDS	RU	https://pubmed.ncbi.nlm.nih.gov/10887639

DMU3DNC	DI	DMU3DNC
DMU3DNC	DN	Pentoxifylline
DMU3DNC	MI	DEJGDUW
DMU3DNC	MN	Cytochrome P450 1A2 (CYP1A2)
DMU3DNC	MT	DME
DMU3DNC	MA	Metabolism
DMU3DNC	RN	Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metab Dispos. 1997 Dec;25(12):1354-8.
DMU3DNC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9394024

DMU3DNC	DI	DMU3DNC
DMU3DNC	DN	Pentoxifylline
DMU3DNC	MI	TTF8CQI
DMU3DNC	MN	Tumor necrosis factor (TNF)
DMU3DNC	MT	DTT
DMU3DNC	RN	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
DMU3DNC	RU	https://pubmed.ncbi.nlm.nih.gov/15190511

DMNXY5K	DI	DMNXY5K
DMNXY5K	DN	Peramivir
DMNXY5K	MI	TT50QJ3
DMNXY5K	MN	Influenza Neuraminidase (Influ NA)
DMNXY5K	MT	DTT
DMNXY5K	MA	Inhibitor
DMNXY5K	RN	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
DMNXY5K	RU	https://pubmed.ncbi.nlm.nih.gov/19067613

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE6OQ3W
DM2AOTZ	MN	Cytochrome P450 1A1 (CYP1A1)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEJGDUW
DM2AOTZ	MN	Cytochrome P450 1A2 (CYP1A2)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Pol J Pharmacol. 2002 Jul-Aug;54(4):407-10.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12523495

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEJVYAZ
DM2AOTZ	MN	Cytochrome P450 2A6 (CYP2A6)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE5IED8
DM2AOTZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DECB0K3
DM2AOTZ	MN	Cytochrome P450 2D6 (CYP2D6)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEVDYN7
DM2AOTZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol. 2001 Nov-Dec;53(6):615-21.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11985335

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DE4LYSA
DM2AOTZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. Eur Neuropsychopharmacol. 2004 May;14(3):199-208.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15056479

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	TTEX248
DM2AOTZ	MN	Dopamine D2 receptor (D2R)
DM2AOTZ	MT	DTT
DM2AOTZ	MA	Modulator
DM2AOTZ	RN	Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
DM2AOTZ	RU	https://pubmed.ncbi.nlm.nih.gov/15582454

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DEGTFWK
DM2AOTZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM2AOTZ	MT	DME
DM2AOTZ	MA	Metabolism
DM2AOTZ	RN	Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
DM2AOTZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11026737

DM2AOTZ	DI	DM2AOTZ
DM2AOTZ	DN	Perazine
DM2AOTZ	MI	DTUGYRD
DM2AOTZ	MN	P-glycoprotein 1 (ABCB1)
DM2AOTZ	MT	DTP
DM2AOTZ	MA	Substrate
DM2AOTZ	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM2AOTZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM14MAE	DI	DM14MAE
DM14MAE	DN	Pergolide
DM14MAE	MI	TTZFYLI
DM14MAE	MN	Dopamine D1 receptor (D1R)
DM14MAE	MT	DTT
DM14MAE	MA	Modulator
DM14MAE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM14MAE	RU	https://www.fda.gov/

DM14MAE	DI	DM14MAE
DM14MAE	DN	Pergolide
DM14MAE	MI	TTEX248
DM14MAE	MN	Dopamine D2 receptor (D2R)
DM14MAE	MT	DTT
DM14MAE	MA	Modulator
DM14MAE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM14MAE	RU	https://www.fda.gov/

DM5GKOV	DI	DM5GKOV
DM5GKOV	DN	Pergolide mesylate
DM5GKOV	MI	DE4LYSA
DM5GKOV	MN	Cytochrome P450 3A4 (CYP3A4)
DM5GKOV	MT	DME
DM5GKOV	MA	Metabolism
DM5GKOV	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DM5GKOV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	TTDL0NY
DMINO7Z	MN	Carnitine O-palmitoyltransferase I (CPT1B)
DMINO7Z	MT	DTT
DMINO7Z	MA	Inhibitor
DMINO7Z	RN	Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
DMINO7Z	RU	https://pubmed.ncbi.nlm.nih.gov/17445089

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DEPKLMQ
DMINO7Z	MN	Cytochrome P450 2B6 (CYP2B6)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DECB0K3
DMINO7Z	MN	Cytochrome P450 2D6 (CYP2D6)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMINO7Z	DI	DMINO7Z
DMINO7Z	DN	Perhexiline
DMINO7Z	MI	DE4LYSA
DMINO7Z	MN	Cytochrome P450 3A4 (CYP3A4)
DMINO7Z	MT	DME
DMINO7Z	MA	Metabolism
DMINO7Z	RN	CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):128-38.
DMINO7Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17050648

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	TTL69WB
DMOPZDT	MN	Angiotensin-converting enzyme (ACE)
DMOPZDT	MT	DTT
DMOPZDT	MA	Inhibitor
DMOPZDT	RN	Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7.
DMOPZDT	RU	https://pubmed.ncbi.nlm.nih.gov/19514543

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	DT9G7XN
DMOPZDT	MN	Peptide transporter 1 (SLC15A1)
DMOPZDT	MT	DTP
DMOPZDT	MA	Substrate
DMOPZDT	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMOPZDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMOPZDT	DI	DMOPZDT
DMOPZDT	DN	Perindopril
DMOPZDT	MI	DT8QKNP
DMOPZDT	MN	Peptide transporter 2 (SLC15A2)
DMOPZDT	MT	DTP
DMOPZDT	MA	Substrate
DMOPZDT	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DMOPZDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	DEPKLMQ
DMZ0Q1G	MN	Cytochrome P450 2B6 (CYP2B6)
DMZ0Q1G	MT	DME
DMZ0Q1G	MA	Metabolism
DMZ0Q1G	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DMZ0Q1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	DE4LYSA
DMZ0Q1G	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ0Q1G	MT	DME
DMZ0Q1G	MA	Metabolism
DMZ0Q1G	RN	Human metabolic interactions of environmental chemicals. J Biochem Mol Toxicol. 2007;21(4):182-6.
DMZ0Q1G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17936932

DMZ0Q1G	DI	DMZ0Q1G
DMZ0Q1G	DN	Permethrin
DMZ0Q1G	MI	TTRK8B9
DMZ0Q1G	MN	Sodium channel unspecific (NaC)
DMZ0Q1G	MT	DTT
DMZ0Q1G	MA	Blocker
DMZ0Q1G	RN	In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
DMZ0Q1G	RU	https://pubmed.ncbi.nlm.nih.gov/14651650

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	TTYSN63
DMVHJLX	MN	5-HT 2 receptor (5HT2R)
DMVHJLX	MT	DTT
DMVHJLX	MA	Modulator
DMVHJLX	RN	Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
DMVHJLX	RU	https://pubmed.ncbi.nlm.nih.gov/7690975

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	DES5XRU
DMVHJLX	MN	Cytochrome P450 2C8 (CYP2C8)
DMVHJLX	MT	DME
DMVHJLX	MA	Metabolism
DMVHJLX	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DMVHJLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DMVHJLX	DI	DMVHJLX
DMVHJLX	DN	Perospirone
DMVHJLX	MI	DECB0K3
DMVHJLX	MN	Cytochrome P450 2D6 (CYP2D6)
DMVHJLX	MT	DME
DMVHJLX	MA	Metabolism
DMVHJLX	RN	Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit. 2004 Aug;26(4):361-5.
DMVHJLX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15257064

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEJGDUW
DMA4MRX	MN	Cytochrome P450 1A2 (CYP1A2)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEZMWRE
DMA4MRX	MN	Cytochrome P450 2C18 (CYP2C18)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DES5XRU
DMA4MRX	MN	Cytochrome P450 2C8 (CYP2C8)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DE5IED8
DMA4MRX	MN	Cytochrome P450 2C9 (CYP2C9)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DECB0K3
DMA4MRX	MN	Cytochrome P450 2D6 (CYP2D6)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DE4LYSA
DMA4MRX	MN	Cytochrome P450 3A4 (CYP3A4)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	TTEX248
DMA4MRX	MN	Dopamine D2 receptor (D2R)
DMA4MRX	MT	DTT
DMA4MRX	MA	Antagonist
DMA4MRX	RN	CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
DMA4MRX	RU	https://pubmed.ncbi.nlm.nih.gov/18075468

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DEGTFWK
DMA4MRX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA4MRX	MT	DME
DMA4MRX	MA	Metabolism
DMA4MRX	RN	Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
DMA4MRX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11136295

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DTT79CX
DMA4MRX	MN	Organic cation transporter 1 (SLC22A1)
DMA4MRX	MT	DTP
DMA4MRX	MA	Substrate
DMA4MRX	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMA4MRX	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMA4MRX	DI	DMA4MRX
DMA4MRX	DN	Perphenazine
DMA4MRX	MI	DTUGYRD
DMA4MRX	MN	P-glycoprotein 1 (ABCB1)
DMA4MRX	MT	DTP
DMA4MRX	MA	Substrate
DMA4MRX	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DMA4MRX	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DMHJV0X	DI	DMHJV0X
DMHJV0X	DN	Pertuzumab
DMHJV0X	MI	TT6EO5L
DMHJV0X	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHJV0X	MT	DTT
DMHJV0X	MA	Inhibitor
DMHJV0X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMHJV0X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TTGJCWZ
DMS2J0Z	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TT7MRDV
DMS2J0Z	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMS2J0Z	DI	DMS2J0Z
DMS2J0Z	DN	Pexidartinib
DMS2J0Z	MI	TTX41N9
DMS2J0Z	MN	Tyrosine-protein kinase Kit (KIT)
DMS2J0Z	MT	DTT
DMS2J0Z	MA	Inhibitor
DMS2J0Z	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMS2J0Z	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	DES5XRU
DMSB068	MN	Cytochrome P450 2C8 (CYP2C8)
DMSB068	MT	DME
DMSB068	MA	Metabolism
DMSB068	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TT4LXBC
DMSB068	MN	Hedgehog signaling pathway (HS pathway)
DMSB068	MT	DTT
DMSB068	MA	Inhibitor
DMSB068	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMSB068	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TTCJG29
DMSB068	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMSB068	MT	DTT
DMSB068	MA	Inhibitor
DMSB068	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSB068	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	TT8J1S3
DMSB068	MN	Smoothened homolog (SMO)
DMSB068	MT	DTT
DMSB068	MA	Modulator
DMSB068	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSB068	DI	DMSB068
DMSB068	DN	PF-04449913
DMSB068	MI	DE85D2P
DMSB068	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMSB068	MT	DME
DMSB068	MA	Metabolism
DMSB068	RN	Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
DMSB068	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27866461

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	TTLWPVF
DM79VXT	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM79VXT	MT	DTT
DM79VXT	MA	Modulator
DM79VXT	RN	Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/25754396

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	DE85D2P
DM79VXT	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM79VXT	MT	DME
DM79VXT	MA	Metabolism
DM79VXT	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DM79VXT	DI	DM79VXT
DM79VXT	DN	PF-04971729
DM79VXT	MI	DEB3CV1
DM79VXT	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM79VXT	MT	DME
DM79VXT	MA	Metabolism
DM79VXT	RN	The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017 Nov;57(11):1432-1443.
DM79VXT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28703316

DMOHS9P	DI	DMOHS9P
DMOHS9P	DN	Phenacemide
DMOHS9P	MI	TTRK8B9
DMOHS9P	MN	Sodium channel unspecific (NaC)
DMOHS9P	MT	DTT
DMOHS9P	MA	Blocker
DMOHS9P	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOHS9P	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM6TS1N	DI	DM6TS1N
DM6TS1N	DN	Phendimetrazine
DM6TS1N	MI	TTBRKXS
DM6TS1N	MN	Adrenergic receptor alpha-1B (ADRA1B)
DM6TS1N	MT	DTT
DM6TS1N	MA	Antagonist
DM6TS1N	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM6TS1N	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DE4LYSA
DMHIDUE	MN	Cytochrome P450 3A4 (CYP3A4)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DEIBDNY
DMHIDUE	MN	Cytochrome P450 3A5 (CYP3A5)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	DEGTFWK
DMHIDUE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHIDUE	MT	DME
DMHIDUE	MA	Metabolism
DMHIDUE	RN	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669850

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	TT32XQJ
DMHIDUE	MN	Monoamine oxidase (MAO)
DMHIDUE	MT	DTT
DMHIDUE	MA	Inhibitor
DMHIDUE	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMHIDUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMHIDUE	DI	DMHIDUE
DMHIDUE	DN	Phenelzine
DMHIDUE	MI	TTGP7BY
DMHIDUE	MN	Monoamine oxidase type B (MAO-B)
DMHIDUE	MT	DTT
DMHIDUE	MA	Inhibitor
DMHIDUE	RN	Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
DMHIDUE	RU	https://pubmed.ncbi.nlm.nih.gov/18539478

DMDTC7R	DI	DMDTC7R
DMDTC7R	DN	Phenindamine
DMDTC7R	MI	TTTIBOJ
DMDTC7R	MN	Histamine H1 receptor (H1R)
DMDTC7R	MT	DTT
DMDTC7R	MA	Antagonist
DMDTC7R	RN	The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60.
DMDTC7R	RU	https://pubmed.ncbi.nlm.nih.gov/7650688

DM2PYNR	DI	DM2PYNR
DM2PYNR	DN	Phenindione
DM2PYNR	MI	TTEUC8H
DM2PYNR	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DM2PYNR	MT	DTT
DM2PYNR	MA	Inhibitor
DM2PYNR	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DM2PYNR	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMCH7RU	DI	DMCH7RU
DMCH7RU	DN	Pheniramine
DMCH7RU	MI	TTTIBOJ
DMCH7RU	MN	Histamine H1 receptor (H1R)
DMCH7RU	MT	DTT
DMCH7RU	MA	Antagonist
DMCH7RU	RN	Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82.
DMCH7RU	RU	https://pubmed.ncbi.nlm.nih.gov/11526976

DMXYTN9	DI	DMXYTN9
DMXYTN9	DN	Phenmetrazine
DMXYTN9	MI	TTVBI8W
DMXYTN9	MN	Dopamine transporter (DAT)
DMXYTN9	MT	DTT
DMXYTN9	MA	Inhibitor
DMXYTN9	RN	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
DMXYTN9	RU	https://pubmed.ncbi.nlm.nih.gov/12106802

DMXYTN9	DI	DMXYTN9
DMXYTN9	DN	Phenmetrazine
DMXYTN9	MI	TTAWNKZ
DMXYTN9	MN	Norepinephrine transporter (NET)
DMXYTN9	MT	DTT
DMXYTN9	MA	Inhibitor
DMXYTN9	RN	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
DMXYTN9	RU	https://pubmed.ncbi.nlm.nih.gov/12106802

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEPKLMQ
DMXZOCG	MN	Cytochrome P450 2B6 (CYP2B6)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEZMWRE
DMXZOCG	MN	Cytochrome P450 2C18 (CYP2C18)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181490

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DES5XRU
DMXZOCG	MN	Cytochrome P450 2C8 (CYP2C8)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DE5IED8
DMXZOCG	MN	Cytochrome P450 2C9 (CYP2C9)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther. 2004 Feb;308(2):495-501.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14600250

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEVDYN7
DMXZOCG	MN	Cytochrome P450 2E1 (CYP2E1)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. Eur J Pharmacol. 2006 Dec 15;552(1-3):151-8.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17049344

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DE4LYSA
DMXZOCG	MN	Cytochrome P450 3A4 (CYP3A4)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 Dec;29(6):687-710.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18043468

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEIBDNY
DMXZOCG	MN	Cytochrome P450 3A5 (CYP3A5)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10696073

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DERD86B
DMXZOCG	MN	Cytochrome P450 3A7 (CYP3A7)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology. 1993 Nov;18(5):1254-62.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8225233

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	TTNJYV2
DMXZOCG	MN	Gamma-aminobutyric acid receptor (GAR)
DMXZOCG	MT	DTT
DMXZOCG	MA	Antagonist
DMXZOCG	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMXZOCG	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DEGTFWK
DMXZOCG	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMXZOCG	MT	DME
DMXZOCG	MA	Metabolism
DMXZOCG	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DMXZOCG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DTFI42L
DMXZOCG	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMXZOCG	MT	DTP
DMXZOCG	MA	Substrate
DMXZOCG	RN	Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
DMXZOCG	RU	http://www.ncbi.nlm.nih.gov/pubmed/11706036

DMXZOCG	DI	DMXZOCG
DMXZOCG	DN	Phenobarbital
DMXZOCG	MI	DTUGYRD
DMXZOCG	MN	P-glycoprotein 1 (ABCB1)
DMXZOCG	MT	DTP
DMXZOCG	MA	Substrate
DMXZOCG	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DMXZOCG	RU	https://doi.org/10.1016/j.addr.2011.12.003

DM8KSQH	DI	DM8KSQH
DM8KSQH	DN	Phenoxybenzamine
DM8KSQH	MI	TTEX248
DM8KSQH	MN	Dopamine D2 receptor (D2R)
DM8KSQH	MT	DTT
DM8KSQH	MA	Antagonist
DM8KSQH	RN	Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6.
DM8KSQH	RU	https://pubmed.ncbi.nlm.nih.gov/19232942

DM8KSQH	DI	DM8KSQH
DM8KSQH	DN	Phenoxybenzamine
DM8KSQH	MI	DTT79CX
DM8KSQH	MN	Organic cation transporter 1 (SLC22A1)
DM8KSQH	MT	DTP
DM8KSQH	MA	Substrate
DM8KSQH	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DM8KSQH	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DES5XRU
DMDO279	MN	Cytochrome P450 2C8 (CYP2C8)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DE5IED8
DMDO279	MN	Cytochrome P450 2C9 (CYP2C9)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica. 2004 Sep;34(9):847-59.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15742978

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DE4LYSA
DMDO279	MN	Cytochrome P450 3A4 (CYP3A4)
DMDO279	MT	DME
DMDO279	MA	Metabolism
DMDO279	RN	Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82.
DMDO279	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15054565

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	DTUGYRD
DMDO279	MN	P-glycoprotein 1 (ABCB1)
DMDO279	MT	DTP
DMDO279	MA	Substrate
DMDO279	RN	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65.
DMDO279	RU	http://www.ncbi.nlm.nih.gov/pubmed/23663291

DMDO279	DI	DMDO279
DMDO279	DN	Phenprocoumon
DMDO279	MI	TTEUC8H
DMDO279	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMDO279	MT	DTT
DMDO279	MA	Inhibitor
DMDO279	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DMDO279	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMG60XN	DI	DMG60XN
DMG60XN	DN	Phentermine
DMG60XN	MI	DE4LYSA
DMG60XN	MN	Cytochrome P450 3A4 (CYP3A4)
DMG60XN	MT	DME
DMG60XN	MA	Metabolism
DMG60XN	RN	FDA Label of Qsymia. The 2020 official website of the U.S. Food and Drug Administration.
DMG60XN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf

DMG60XN	DI	DMG60XN
DMG60XN	DN	Phentermine
DMG60XN	MI	TTAWNKZ
DMG60XN	MN	Norepinephrine transporter (NET)
DMG60XN	MT	DTT
DMG60XN	MA	Inhibitor
DMG60XN	RN	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
DMG60XN	RU	https://pubmed.ncbi.nlm.nih.gov/11060745

DMXYJOB	DI	DMXYJOB
DMXYJOB	DN	Phentolamine
DMXYJOB	MI	TTEX248
DMXYJOB	MN	Dopamine D2 receptor (D2R)
DMXYJOB	MT	DTT
DMXYJOB	MA	Antagonist
DMXYJOB	RN	Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6.
DMXYJOB	RU	https://pubmed.ncbi.nlm.nih.gov/19474390

DMQ95GE	DI	DMQ95GE
DMQ95GE	DN	Phenylacetic acid
DMQ95GE	MI	DT39AOM
DMQ95GE	MN	Monocarboxylate transporter 3 (SLC16A8)
DMQ95GE	MT	DTP
DMQ95GE	MA	Substrate
DMQ95GE	RN	Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metab Dispos. 2013 Feb;41(2):466-74.
DMQ95GE	RU	http://www.ncbi.nlm.nih.gov/pubmed/23169611

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	DE5IED8
DMAYL0T	MN	Cytochrome P450 2C9 (CYP2C9)
DMAYL0T	MT	DME
DMAYL0T	MA	Metabolism
DMAYL0T	RN	Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos. 2001 May;29(5):701-11.
DMAYL0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11302937

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	TTVKILB
DMAYL0T	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAYL0T	MT	DTT
DMAYL0T	MA	Inhibitor
DMAYL0T	RN	COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6.
DMAYL0T	RU	https://pubmed.ncbi.nlm.nih.gov/15939622

DMAYL0T	DI	DMAYL0T
DMAYL0T	DN	Phenylbutazone
DMAYL0T	MI	DEYGVN4
DMAYL0T	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMAYL0T	MT	DME
DMAYL0T	MA	Metabolism
DMAYL0T	RN	Identification of human UDP-glucuronosyltransferase isoform(s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys. 2006 Oct 1;454(1):72-9.
DMAYL0T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16949544

DMZHUO5	DI	DMZHUO5
DMZHUO5	DN	Phenylephrine
DMZHUO5	MI	TTEX248
DMZHUO5	MN	Dopamine D2 receptor (D2R)
DMZHUO5	MT	DTT
DMZHUO5	MA	Agonist
DMZHUO5	RN	MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64.
DMZHUO5	RU	https://pubmed.ncbi.nlm.nih.gov/19482300

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTZFYLI
DMKAEQW	MN	Dopamine D1 receptor (D1R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTEX248
DMKAEQW	MN	Dopamine D2 receptor (D2R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTE0A2F
DMKAEQW	MN	Dopamine D4 receptor (D4R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMKAEQW	DI	DMKAEQW
DMKAEQW	DN	Phenyltoloxamine
DMKAEQW	MI	TTS2PH3
DMKAEQW	MN	Dopamine D5 receptor (D5R)
DMKAEQW	MT	DTT
DMKAEQW	MA	Inhibitor
DMKAEQW	RN	Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
DMKAEQW	RU	https://pubmed.ncbi.nlm.nih.gov/15293986

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEPKLMQ
DMNOKBV	MN	Cytochrome P450 2B6 (CYP2B6)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEZMWRE
DMNOKBV	MN	Cytochrome P450 2C18 (CYP2C18)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DES5XRU
DMNOKBV	MN	Cytochrome P450 2C8 (CYP2C8)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE5IED8
DMNOKBV	MN	Cytochrome P450 2C9 (CYP2C9)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010 Sep;8(3):254-67.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21358975

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE4LYSA
DMNOKBV	MN	Cytochrome P450 3A4 (CYP3A4)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1034-40.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15247556

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEIBDNY
DMNOKBV	MN	Cytochrome P450 3A5 (CYP3A5)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DERD86B
DMNOKBV	MN	Cytochrome P450 3A7 (CYP3A7)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22569204

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DE4ZHS1
DMNOKBV	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2890493

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DEGTFWK
DMNOKBV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMNOKBV	MT	DME
DMNOKBV	MA	Metabolism
DMNOKBV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNOKBV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTSYQGK
DMNOKBV	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
DMNOKBV	RU	http://www.ncbi.nlm.nih.gov/pubmed/20080116

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTFI42L
DMNOKBV	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
DMNOKBV	RU	http://www.ncbi.nlm.nih.gov/pubmed/17437408

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	DTUGYRD
DMNOKBV	MN	P-glycoprotein 1 (ABCB1)
DMNOKBV	MT	DTP
DMNOKBV	MA	Substrate
DMNOKBV	RN	The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42.
DMNOKBV	RU	https://doi.org/10.1016/j.addr.2011.12.003

DMNOKBV	DI	DMNOKBV
DMNOKBV	DN	Phenytoin
DMNOKBV	MI	TTRK8B9
DMNOKBV	MN	Sodium channel unspecific (NaC)
DMNOKBV	MT	DTT
DMNOKBV	MA	Blocker
DMNOKBV	RN	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. 
DMNOKBV	RU	https://pubmed.ncbi.nlm.nih.gov/19552484

DMUKMC8	DI	DMUKMC8
DMUKMC8	DN	Phloroglucinol
DMUKMC8	MI	DE69WKO
DMUKMC8	MN	Phloroglucinol reductase (PHGR)
DMUKMC8	MT	DME
DMUKMC8	MA	Metabolism
DMUKMC8	RN	Purification and properties of phloroglucinol reductase from Eubacterium oxidoreducens G-41. J Biol Chem. 1989 Mar 15;264(8):4423-7.
DMUKMC8	RU	https://pubmed.ncbi.nlm.nih.gov/2925649

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTVAEDK
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-1 (SLC25A24)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	De Novo Mutations in SLC25A24 Cause a Disorder Characterized by Early Aging, Bone Dysplasia, Characteristic Face, and Early Demise. Am J Hum Genet. 2017 Nov 2;101(5):844-855.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29100094

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTN7X5J
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-2 (SLC25A25)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Ketogenic diet induces expression of the muscle circadian gene Slc25a25 via neural pathway that might be involved in muscle thermogenesis. Sci Rep. 2017 Jun 6;7(1):2885.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/28588221

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTLQ0EZ
DMUXQG7	MN	Calcium-binding mitochondrial carrier protein SCaMC-3 (SLC25A23)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Cellular expression and alternative splicing of SLC25A23, a member of the mitochondrial Ca2+-dependent solute carrier gene family. Gene. 2005 Jan 31;345(2):173-82.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/15716113

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DE9P5K7
DMUXQG7	MN	GDP-D-glucose phosphorylase 1 (GDPGP1)
DMUXQG7	MT	DME
DMUXQG7	MA	Metabolism
DMUXQG7	RN	A novel GDP-D-glucose phosphorylase involved in quality control of the nucleoside diphosphate sugar pool in Caenorhabditis elegans and mammals. J Biol Chem. 2011 Jun 17;286(24):21511-23.
DMUXQG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21507950

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTH9SQJ
DMUXQG7	MN	Glycerol-3-phosphate permease (SLC37A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011;6(9):e23157.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/21949678

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTJYKDQ
DMUXQG7	MN	Mitochondrial dicarboxylate carrier (SLC25A10)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC25A10 biallelic mutations in intractable epileptic encephalopathy with complex I deficiency. Hum Mol Genet. 2018 Feb 1;27(3):499-504.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29211846

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTCRIWV
DMUXQG7	MN	Phosphate carrier protein (SLC25A3)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis. J Biol Chem. 2018 Feb 9;293(6):1887-1896.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/29237729

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTHE530
DMUXQG7	MN	Probable small intestine urate exporter (SLC17A4)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DT8ARWJ
DMUXQG7	MN	Sodium-dependent phosphate transport protein 1 (SLC17A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTFOJL7
DMUXQG7	MN	Sodium-dependent phosphate transport protein 4 (SLC17A3)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010 Nov 5;285(45):35123-32.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20810651

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTMULXV
DMUXQG7	MN	Sodium-dependent phosphate transporter 1 (SLC20A1)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTFD4VB
DMUXQG7	MN	Sodium-dependent phosphate transporter 2 (SLC20A2)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DTNK0FR
DMUXQG7	MN	Vesicular glutamate transporter 1 (SLC17A7)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	SLC17: a functionally diverse family of organic anion transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):350-9.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506876

DMUXQG7	DI	DMUXQG7
DMUXQG7	DN	Phosphate
DMUXQG7	MI	DT5LHCR
DMUXQG7	MN	Vesicular glutamate transporter 2 (SLC17A6)
DMUXQG7	MT	DTP
DMUXQG7	MA	Substrate
DMUXQG7	RN	Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
DMUXQG7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20566650

DM8HDOL	DI	DM8HDOL
DM8HDOL	DN	Phytonadione
DM8HDOL	MI	TT76OLR
DM8HDOL	MN	Vitamin K-dependent gamma-carboxylase (GGCX)
DM8HDOL	MT	DTT
DM8HDOL	MA	Cofactor
DM8HDOL	RN	Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85-101.
DM8HDOL	RU	https://pubmed.ncbi.nlm.nih.gov/18374191

DM27BL1	DI	DM27BL1
DM27BL1	DN	Pibrentasvir
DM27BL1	MI	DTUGYRD
DM27BL1	MN	P-glycoprotein 1 (ABCB1)
DM27BL1	MT	DTP
DM27BL1	MA	Substrate
DM27BL1	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM27BL1	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMIBNG2	DI	DMIBNG2
DMIBNG2	DN	Picrotoxin
DMIBNG2	MI	TT1MPAY
DMIBNG2	MN	GABA(A) receptor alpha-1 (GABRA1)
DMIBNG2	MT	DTT
DMIBNG2	MA	Antagonist
DMIBNG2	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMIBNG2	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	DEJVYAZ
DMV9ADG	MN	Cytochrome P450 2A6 (CYP2A6)
DMV9ADG	MT	DME
DMV9ADG	MA	Metabolism
DMV9ADG	RN	Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. FEBS J. 2012 May;279(9):1621-31.
DMV9ADG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22051186

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	DE4LYSA
DMV9ADG	MN	Cytochrome P450 3A4 (CYP3A4)
DMV9ADG	MT	DME
DMV9ADG	MA	Metabolism
DMV9ADG	RN	The inhibition of CYP enzymes in mouse and human liver by pilocarpine. Br J Pharmacol. 1995 Feb;114(4):832-6.
DMV9ADG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7773543

DMV9ADG	DI	DMV9ADG
DMV9ADG	DN	Pilocarpine
DMV9ADG	MI	TTH18TF
DMV9ADG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMV9ADG	MT	DTT
DMV9ADG	MA	Agonist
DMV9ADG	RN	Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6.
DMV9ADG	RU	https://pubmed.ncbi.nlm.nih.gov/19465517

DMZ65K8	DI	DMZ65K8
DMZ65K8	DN	Pilsicainide
DMZ65K8	MI	TTRK8B9
DMZ65K8	MN	Sodium channel unspecific (NaC)
DMZ65K8	MT	DTT
DMZ65K8	MA	Modulator
DMZ65K8	RN	A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42.
DMZ65K8	RU	https://pubmed.ncbi.nlm.nih.gov/21869589

DMR7IVC	DI	DMR7IVC
DMR7IVC	DN	Pimavanserin
DMR7IVC	MI	TTJQOD7
DMR7IVC	MN	5-HT 2A receptor (HTR2A)
DMR7IVC	MT	DTT
DMR7IVC	MA	Modulator
DMR7IVC	RN	Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
DMR7IVC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22954754

DMZLGRB	DI	DMZLGRB
DMZLGRB	DN	Pimecrolimus
DMZLGRB	MI	TTA4LDE
DMZLGRB	MN	Calcineurin (PPP3CA)
DMZLGRB	MT	DTT
DMZLGRB	MA	Inhibitor
DMZLGRB	RN	Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8.
DMZLGRB	RU	https://pubmed.ncbi.nlm.nih.gov/19499228

DMZLGRB	DI	DMZLGRB
DMZLGRB	DN	Pimecrolimus
DMZLGRB	MI	DE4LYSA
DMZLGRB	MN	Cytochrome P450 3A4 (CYP3A4)
DMZLGRB	MT	DME
DMZLGRB	MA	Metabolism
DMZLGRB	RN	Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.
DMZLGRB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16467136

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DEJGDUW
DMW83TP	MN	Cytochrome P450 1A2 (CYP1A2)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DECB0K3
DMW83TP	MN	Cytochrome P450 2D6 (CYP2D6)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	The influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015 Jun;35(3):228-36.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25868121

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DE4LYSA
DMW83TP	MN	Cytochrome P450 3A4 (CYP3A4)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998 May;285(2):428-37.
DMW83TP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9580580

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DEIBDNY
DMW83TP	MN	Cytochrome P450 3A5 (CYP3A5)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Drug Interactions Flockhart Table
DMW83TP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DERD86B
DMW83TP	MN	Cytochrome P450 3A7 (CYP3A7)
DMW83TP	MT	DME
DMW83TP	MA	Metabolism
DMW83TP	RN	Drug Interactions Flockhart Table
DMW83TP	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	TTEX248
DMW83TP	MN	Dopamine D2 receptor (D2R)
DMW83TP	MT	DTT
DMW83TP	MA	Antagonist
DMW83TP	RN	[The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
DMW83TP	RU	https://pubmed.ncbi.nlm.nih.gov/16924461

DMW83TP	DI	DMW83TP
DMW83TP	DN	Pimozide
DMW83TP	MI	DTUGYRD
DMW83TP	MN	P-glycoprotein 1 (ABCB1)
DMW83TP	MT	DTP
DMW83TP	MA	Substrate
DMW83TP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW83TP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMRADYL	DI	DMRADYL
DMRADYL	DN	Pinacidil
DMRADYL	MI	DE4LYSA
DMRADYL	MN	Cytochrome P450 3A4 (CYP3A4)
DMRADYL	MT	DME
DMRADYL	MA	Metabolism
DMRADYL	RN	Cytochrome P450 3A4-mediated oxidative conversion of a cyano to an amide group in the metabolism of pinacidil. Biochemistry. 2002 Feb 26;41(8):2712-8.
DMRADYL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11851418

DMRADYL	DI	DMRADYL
DMRADYL	DN	Pinacidil
DMRADYL	MI	TT1VOHK
DMRADYL	MN	Potassium channel unspecific (KC)
DMRADYL	MT	DTT
DMRADYL	MA	Modulator
DMRADYL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMRADYL	RU	https://www.fda.gov/

DMD2NV7	DI	DMD2NV7
DMD2NV7	DN	Pindolol
DMD2NV7	MI	TTR6W5O
DMD2NV7	MN	Adrenergic receptor beta-1 (ADRB1)
DMD2NV7	MT	DTT
DMD2NV7	MA	Antagonist
DMD2NV7	RN	Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27.
DMD2NV7	RU	https://pubmed.ncbi.nlm.nih.gov/17433471

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DES5XRU
DMKJ485	MN	Cytochrome P450 2C8 (CYP2C8)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic Clin Pharmacol Toxicol. 2009 Dec;105(6):374-9.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19614891

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE5IED8
DMKJ485	MN	Cytochrome P450 2C9 (CYP2C9)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013 Nov 26;4:147.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24324437

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE4LYSA
DMKJ485	MN	Cytochrome P450 3A4 (CYP3A4)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	TTZMAO3
DMKJ485	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMKJ485	MT	DTT
DMKJ485	MA	Agonist
DMKJ485	RN	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
DMKJ485	RU	https://pubmed.ncbi.nlm.nih.gov/12379847

DMKJ485	DI	DMKJ485
DMKJ485	DN	Pioglitazone
DMKJ485	MI	DE073H6
DMKJ485	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKJ485	MT	DME
DMKJ485	MA	Metabolism
DMKJ485	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKJ485	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5F84A	DI	DM5F84A
DM5F84A	DN	Pipecuronium
DM5F84A	MI	TTF4E0J
DM5F84A	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DM5F84A	MT	DTT
DM5F84A	MA	Antagonist
DM5F84A	RN	Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
DM5F84A	RU	https://pubmed.ncbi.nlm.nih.gov/18633030

DMGQU0Y	DI	DMGQU0Y
DMGQU0Y	DN	Piperacetazine
DMGQU0Y	MI	TTEX248
DMGQU0Y	MN	Dopamine D2 receptor (D2R)
DMGQU0Y	MT	DTT
DMGQU0Y	MA	Modulator
DMGQU0Y	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQU0Y	RU	https://www.fda.gov/

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	TTJP4SM
DMTBKF3	MN	Bacterial Penicillin binding protein (Bact PBP)
DMTBKF3	MT	DTT
DMTBKF3	MA	Binder
DMTBKF3	RN	In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/15551215

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DET9I1W
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DEEZ5CV
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/26539828

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DEYIEO5
DMTBKF3	MN	Beta-lactamase (blaB)
DMTBKF3	MT	DME
DMTBKF3	MA	Metabolism
DMTBKF3	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DMTBKF3	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DMTBKF3	DI	DMTBKF3
DMTBKF3	DN	Piperacillin
DMTBKF3	MI	DT9G7XN
DMTBKF3	MN	Peptide transporter 1 (SLC15A1)
DMTBKF3	MT	DTP
DMTBKF3	MA	Substrate
DMTBKF3	RN	Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
DMTBKF3	RU	http://www.ncbi.nlm.nih.gov/pubmed/15974593

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	DE5IED8
DMT70RC	MN	Cytochrome P450 2C9 (CYP2C9)
DMT70RC	MT	DME
DMT70RC	MA	Metabolism
DMT70RC	RN	Eurartesim - European Medicines Agency
DMT70RC	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	DEGTFWK
DMT70RC	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT70RC	MT	DME
DMT70RC	MA	Metabolism
DMT70RC	RN	Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6.
DMT70RC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25267661

DMT70RC	DI	DMT70RC
DMT70RC	DN	Piperaquine
DMT70RC	MI	TTZVSJ2
DMT70RC	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMT70RC	MT	DTT
DMT70RC	MA	Inhibitor
DMT70RC	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMT70RC	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMTY9LU	DI	DMTY9LU
DMTY9LU	DN	Piperazine
DMTY9LU	MI	DECB0K3
DMTY9LU	MN	Cytochrome P450 2D6 (CYP2D6)
DMTY9LU	MT	DME
DMTY9LU	MA	Metabolism
DMTY9LU	RN	Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004 Apr;26(2):127-31.
DMTY9LU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15228152

DMTY9LU	DI	DMTY9LU
DMTY9LU	DN	Piperazine
DMTY9LU	MI	TTNJYV2
DMTY9LU	MN	Gamma-aminobutyric acid receptor (GAR)
DMTY9LU	MT	DTT
DMTY9LU	MA	Antagonist
DMTY9LU	RN	Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
DMTY9LU	RU	https://pubmed.ncbi.nlm.nih.gov/13678839

DMNL0E6	DI	DMNL0E6
DMNL0E6	DN	Pipobroman
DMNL0E6	MI	TTUTN1I
DMNL0E6	MN	Human Deoxyribonucleic acid (hDNA)
DMNL0E6	MT	DTT
DMNL0E6	MA	Binder
DMNL0E6	RN	Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12.
DMNL0E6	RU	https://pubmed.ncbi.nlm.nih.gov/5556760

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DECB0K3
DMC68DF	MN	Cytochrome P450 2D6 (CYP2D6)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19902987

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DE4LYSA
DMC68DF	MN	Cytochrome P450 3A4 (CYP3A4)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DMC68DF	DI	DMC68DF
DMC68DF	DN	Pipotiazine
DMC68DF	MI	DEGTFWK
DMC68DF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC68DF	MT	DME
DMC68DF	MA	Metabolism
DMC68DF	RN	Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
DMC68DF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615392

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	DTI7UX6
DMGTW1I	MN	Breast cancer resistance protein (ABCG2)
DMGTW1I	MT	DTP
DMGTW1I	MA	Substrate
DMGTW1I	RN	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
DMGTW1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/18820913

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	TTUTN1I
DMGTW1I	MN	Human Deoxyribonucleic acid (hDNA)
DMGTW1I	MT	DTT
DMGTW1I	MA	Modulator
DMGTW1I	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMGTW1I	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMGTW1I	DI	DMGTW1I
DMGTW1I	DN	Pirarubicin
DMGTW1I	MI	DTUGYRD
DMGTW1I	MN	P-glycoprotein 1 (ABCB1)
DMGTW1I	MT	DTP
DMGTW1I	MA	Substrate
DMGTW1I	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMGTW1I	RU	https://doi.org/10.1007/s11095-012-0935-x

DMI5678	DI	DMI5678
DMI5678	DN	Pirbuterol
DMI5678	MI	TT2CJVK
DMI5678	MN	Adrenergic receptor beta-2 (ADRB2)
DMI5678	MT	DTT
DMI5678	MA	Agonist
DMI5678	RN	Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32.
DMI5678	RU	https://pubmed.ncbi.nlm.nih.gov/17594727

DMP6M1N	DI	DMP6M1N
DMP6M1N	DN	Pirenzepine
DMP6M1N	MI	TTZ9SOR
DMP6M1N	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMP6M1N	MT	DTT
DMP6M1N	MA	Antagonist
DMP6M1N	RN	Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
DMP6M1N	RU	https://pubmed.ncbi.nlm.nih.gov/19427366

DMP6M1N	DI	DMP6M1N
DMP6M1N	DN	Pirenzepine
DMP6M1N	MI	DTUGYRD
DMP6M1N	MN	P-glycoprotein 1 (ABCB1)
DMP6M1N	MT	DTP
DMP6M1N	MA	Substrate
DMP6M1N	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMP6M1N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DM6VZFQ	DI	DM6VZFQ
DM6VZFQ	DN	Pirfenidone
DM6VZFQ	MI	DEJGDUW
DM6VZFQ	MN	Cytochrome P450 1A2 (CYP1A2)
DM6VZFQ	MT	DME
DM6VZFQ	MA	Metabolism
DM6VZFQ	RN	Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug Metab Dispos. 2018 Jun;46(6):835-845.
DM6VZFQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29572333

DM6VZFQ	DI	DM6VZFQ
DM6VZFQ	DN	Pirfenidone
DM6VZFQ	MI	TTR9XHZ
DM6VZFQ	MN	Transforming growth factor beta 1 (TGFB1)
DM6VZFQ	MT	DTT
DM6VZFQ	MA	Modulator
DM6VZFQ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6VZFQ	RU	https://www.fda.gov/

DMBCYF5	DI	DMBCYF5
DMBCYF5	DN	Pirmenol
DMBCYF5	MI	TTRK8B9
DMBCYF5	MN	Sodium channel unspecific (NaC)
DMBCYF5	MT	DTT
DMBCYF5	MA	Modulator
DMBCYF5	RN	Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71.
DMBCYF5	RU	https://pubmed.ncbi.nlm.nih.gov/2164163

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	DES5XRU
DMTK234	MN	Cytochrome P450 2C8 (CYP2C8)
DMTK234	MT	DME
DMTK234	MA	Metabolism
DMTK234	RN	Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9 J Pain Res. 2017 Jul 6;10:1581-1589.
DMTK234	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28740425

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	DE5IED8
DMTK234	MN	Cytochrome P450 2C9 (CYP2C9)
DMTK234	MT	DME
DMTK234	MA	Metabolism
DMTK234	RN	Functional characterization of human CYP2C9 allelic variants in COS-7 cells. Front Pharmacol. 2016 Apr 25;7:98.
DMTK234	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27199745

DMTK234	DI	DMTK234
DMTK234	DN	Piroxicam
DMTK234	MI	TT8NGED
DMTK234	MN	Prostaglandin G/H synthase 1 (COX-1)
DMTK234	MT	DTT
DMTK234	MA	Modulator
DMTK234	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMTK234	RU	https://www.fda.gov/

DMMOFHT	DI	DMMOFHT
DMMOFHT	DN	Pirprofen
DMMOFHT	MI	DEYGVN4
DMMOFHT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMOFHT	MT	DME
DMMOFHT	MA	Metabolism
DMMOFHT	RN	Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
DMMOFHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1981722

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTI7UX6
DMJH792	MN	Breast cancer resistance protein (ABCG2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
DMJH792	RU	https://doi.org/10.1016/j.addr.2008.11.003

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTFI42L
DMJH792	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/15955871

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTE2B1D
DMJH792	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DT3D8F0
DMJH792	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci. 2012 Aug 30;47(1):244-55.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/22538052

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DT9C1TS
DMJH792	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DMJH792	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DMJH792	DI	DMJH792
DMJH792	DN	Pitavastatin
DMJH792	MI	DTPFTEQ
DMJH792	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMJH792	MT	DTP
DMJH792	MA	Substrate
DMJH792	RN	Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. Drug Metab Pharmacokinet. 2011;26(2):171-9.
DMJH792	RU	https://doi.org/10.2133/dmpk.DMPK-10-RG-073

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTI7UX6
DM1UJO0	MN	Breast cancer resistance protein (ABCG2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15955871

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DES5XRU
DM1UJO0	MN	Cytochrome P450 2C8 (CYP2C8)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J Cardiovasc Pharmacol. 2012 Jul;60(1):42-8.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22472908

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DE5IED8
DM1UJO0	MN	Cytochrome P450 2C9 (CYP2C9)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	TTPADOQ
DM1UJO0	MN	HMG-CoA reductase (HMGCR)
DM1UJO0	MT	DTT
DM1UJO0	MA	Inhibitor
DM1UJO0	RN	Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
DM1UJO0	RU	https://pubmed.ncbi.nlm.nih.gov/11304935

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTFI42L
DM1UJO0	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTVP67E
DM1UJO0	MN	Organic anion transporter 3 (SLC22A8)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTE2B1D
DM1UJO0	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT3D8F0
DM1UJO0	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/18408565

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT9C1TS
DM1UJO0	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/15159445

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DTPFTEQ
DM1UJO0	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16595711

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DT56EKP
DM1UJO0	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM1UJO0	MT	DTP
DM1UJO0	MA	Substrate
DM1UJO0	RN	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
DM1UJO0	RU	http://www.ncbi.nlm.nih.gov/pubmed/16259759

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEYGVN4
DM1UJO0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003 Jan;33(1):27-41.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12519692

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEF2WXN
DM1UJO0	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM1UJO0	DI	DM1UJO0
DM1UJO0	DN	Pitavastatin calcium
DM1UJO0	MI	DEB3CV1
DM1UJO0	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM1UJO0	MT	DME
DM1UJO0	MA	Metabolism
DM1UJO0	RN	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
DM1UJO0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28130659

DM8RFNJ	DI	DM8RFNJ
DM8RFNJ	DN	Pitolisant
DM8RFNJ	MI	TT9JNIC
DM8RFNJ	MN	Histamine H3 receptor (H3R)
DM8RFNJ	MT	DTT
DM8RFNJ	MA	Agonist
DM8RFNJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM8RFNJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf

DMX8CVY	DI	DMX8CVY
DMX8CVY	DN	Pivampicillin
DMX8CVY	MI	TTJP4SM
DMX8CVY	MN	Bacterial Penicillin binding protein (Bact PBP)
DMX8CVY	MT	DTT
DMX8CVY	MA	Binder
DMX8CVY	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMX8CVY	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMDU0BV	DI	DMDU0BV
DMDU0BV	DN	Pivmecillinam
DMDU0BV	MI	TTJP4SM
DMDU0BV	MN	Bacterial Penicillin binding protein (Bact PBP)
DMDU0BV	MT	DTT
DMDU0BV	MA	Binder
DMDU0BV	RN	Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7.
DMDU0BV	RU	https://pubmed.ncbi.nlm.nih.gov/19104012

DMV74ZH	DI	DMV74ZH
DMV74ZH	DN	Pizotyline
DMV74ZH	MI	TT85JO3
DMV74ZH	MN	5-HT receptor (5HTR)
DMV74ZH	MT	DTT
DMV74ZH	MA	Modulator
DMV74ZH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMV74ZH	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMV74ZH	DI	DMV74ZH
DMV74ZH	DN	Pizotyline
DMV74ZH	MI	DEI8NGH
DMV74ZH	MN	UDP-glucuronosyltransferase 2B10 (UGT2B10)
DMV74ZH	MT	DME
DMV74ZH	MA	Metabolism
DMV74ZH	RN	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013 Jul;41(7):1389-97.
DMV74ZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23611809

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	DE69QHT
DMKMBES	MN	Aminoglycoside acetyltransferase (aac)
DMKMBES	MT	DME
DMKMBES	MA	Metabolism
DMKMBES	RN	Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-987.
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29634241

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	DESGYWE
DMKMBES	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMKMBES	MT	DME
DMKMBES	MA	Metabolism
DMKMBES	RN	Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis. 2018 Jun 8;4(6):980-987.
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29634241

DMKMBES	DI	DMKMBES
DMKMBES	DN	Plazomicin
DMKMBES	MI	TTUQ7WN
DMKMBES	MN	Mitochondrial rRNA methyltransferase 2 (MRM2)
DMKMBES	MT	DTT
DMKMBES	MA	Inhibitor
DMKMBES	RN	In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. 
DMKMBES	RU	https://pubmed.ncbi.nlm.nih.gov/29091224

DMKEX7O	DI	DMKEX7O
DMKEX7O	DN	Plecanatide
DMKEX7O	MI	TTLDPRG
DMKEX7O	MN	Guanylyl cyclase C (GUCY2C)
DMKEX7O	MT	DTT
DMKEX7O	MA	Modulator
DMKEX7O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKEX7O	RU	https://www.fda.gov/

DMAKXW9	DI	DMAKXW9
DMAKXW9	DN	PLEGRIDY
DMAKXW9	MI	TT4TZ8J
DMAKXW9	MN	Interferon-beta (IFNB1)
DMAKXW9	MT	DTT
DMAKXW9	MA	Modulator
DMAKXW9	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAKXW9	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMCJN1P	DI	DMCJN1P
DMCJN1P	DN	Plerixafor
DMCJN1P	MI	TTBID49
DMCJN1P	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMCJN1P	MT	DTT
DMCJN1P	MA	Antagonist
DMCJN1P	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMCJN1P	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM7C8YV	DI	DM7C8YV
DM7C8YV	DN	Plicamycin
DM7C8YV	MI	TTX2AYW
DM7C8YV	MN	RNA synthesis (hRNA synth)
DM7C8YV	MT	DTT
DM7C8YV	MA	Modulator
DM7C8YV	RN	Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85.
DM7C8YV	RU	https://pubmed.ncbi.nlm.nih.gov/7827085

DMG8MLJ	DI	DMG8MLJ
DMG8MLJ	DN	Pneumococcal 13-valent conjugate vaccine
DMG8MLJ	MI	TTY4IQ9
DMG8MLJ	MN	Corynebacterium Mutated CRM197 (Cory mTOX)
DMG8MLJ	MT	DTT
DMG8MLJ	MA	Binder
DMG8MLJ	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMG8MLJ	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	DE4LYSA
DMT2EJP	MN	Cytochrome P450 3A4 (CYP3A4)
DMT2EJP	MT	DME
DMT2EJP	MA	Metabolism
DMT2EJP	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DMT2EJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	TT0IHXV
DMT2EJP	MN	DNA topoisomerase II (TOP2)
DMT2EJP	MT	DTT
DMT2EJP	MA	Modulator
DMT2EJP	RN	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
DMT2EJP	RU	https://pubmed.ncbi.nlm.nih.gov/11102564

DMT2EJP	DI	DMT2EJP
DMT2EJP	DN	Podofilox
DMT2EJP	MI	DEGTFWK
DMT2EJP	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMT2EJP	MT	DME
DMT2EJP	MA	Metabolism
DMT2EJP	RN	Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
DMT2EJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18050240

DMF6Y0L	DI	DMF6Y0L
DMF6Y0L	DN	Polatuzumab vedotin
DMF6Y0L	MI	TTBN5I7
DMF6Y0L	MN	B-cell-specific glycoprotein B29 (CD79B)
DMF6Y0L	MT	DTT
DMF6Y0L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMF6Y0L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

DMF6Y0L	DI	DMF6Y0L
DMF6Y0L	DN	Polatuzumab vedotin
DMF6Y0L	MI	DE4LYSA
DMF6Y0L	MN	Cytochrome P450 3A4 (CYP3A4)
DMF6Y0L	MT	DME
DMF6Y0L	MA	Metabolism
DMF6Y0L	RN	FDA label of Polatuzumab vedotin-piiq. The 2020 official website of the U.S. Food and Drug Administration.
DMF6Y0L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf

DMH1KMT	DI	DMH1KMT
DMH1KMT	DN	Polidocanol
DMH1KMT	MI	TTT6K3S
DMH1KMT	MN	Endothelium of blood vessels (Endothelium)
DMH1KMT	MT	DTT
DMH1KMT	MA	Modulator
DMH1KMT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMH1KMT	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMUCWEX	DI	DMUCWEX
DMUCWEX	DN	Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co
DMUCWEX	MI	TT42M75
DMUCWEX	MN	Carbamoyl-phosphate synthetase I (CPS1)
DMUCWEX	MT	DTT
DMUCWEX	MA	Modulator
DMUCWEX	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMUCWEX	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM0PMGJ	DI	DM0PMGJ
DM0PMGJ	DN	Polyestradiol Phosphate
DM0PMGJ	MI	TT2A0DR
DM0PMGJ	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM0PMGJ	MT	DTT
DM0PMGJ	MA	Modulator
DM0PMGJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0PMGJ	RU	https://www.fda.gov/

DM4I1JP	DI	DM4I1JP
DM4I1JP	DN	Polyethylene glycol
DM4I1JP	MI	DEIOH6A
DM4I1JP	MN	Alcohol dehydrogenase class-III (ADH5)
DM4I1JP	MT	DME
DM4I1JP	MA	Metabolism
DM4I1JP	RN	PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16.
DM4I1JP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020954

DMN0LP8	DI	DMN0LP8
DMN0LP8	DN	Polymyxin B Sulfate
DMN0LP8	MI	TT4ILYC
DMN0LP8	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMN0LP8	MT	DTT
DMN0LP8	MA	Binder
DMN0LP8	RN	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
DMN0LP8	RU	https://pubmed.ncbi.nlm.nih.gov/10492501

DMJAOT1	DI	DMJAOT1
DMJAOT1	DN	Polyoxidonium
DMJAOT1	MI	TT3J5ZI
DMJAOT1	MN	Cell mediated immunity response (CMIR)
DMJAOT1	MT	DTT
DMJAOT1	MA	Modulator
DMJAOT1	RN	Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60.
DMJAOT1	RU	https://pubmed.ncbi.nlm.nih.gov/12717555

DMCH80F	DI	DMCH80F
DMCH80F	DN	Polythiazide
DMCH80F	MI	TTP362L
DMCH80F	MN	Solute carrier family 12 member 3 (SLC12A3)
DMCH80F	MT	DTT
DMCH80F	MA	Blocker
DMCH80F	RN	The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
DMCH80F	RU	https://pubmed.ncbi.nlm.nih.gov/11457874

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	TTDIBYJ
DMTGBAX	MN	Angiogenesis/myeloma cell growth (AMCG)
DMTGBAX	MT	DTT
DMTGBAX	MA	Modulator
DMTGBAX	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMTGBAX	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DEJGDUW
DMTGBAX	MN	Cytochrome P450 1A2 (CYP1A2)
DMTGBAX	MT	DME
DMTGBAX	MA	Metabolism
DMTGBAX	RN	Population pharmacokinetics of pomalidomide. J Clin Pharmacol. 2015 May;55(5):563-72.
DMTGBAX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25556560

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DE4LYSA
DMTGBAX	MN	Cytochrome P450 3A4 (CYP3A4)
DMTGBAX	MT	DME
DMTGBAX	MA	Metabolism
DMTGBAX	RN	Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol. 2015 Feb;55(2):168-78.
DMTGBAX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25159194

DMTGBAX	DI	DMTGBAX
DMTGBAX	DN	Pomalidomide
DMTGBAX	MI	DTUGYRD
DMTGBAX	MN	P-glycoprotein 1 (ABCB1)
DMTGBAX	MT	DTP
DMTGBAX	MA	Substrate
DMTGBAX	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08910)
DMTGBAX	RU	https://www.drugbank.ca/drugs/DB08910

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DTI7UX6
DMYGJQO	MN	Breast cancer resistance protein (ABCG2)
DMYGJQO	MT	DTP
DMYGJQO	MA	Substrate
DMYGJQO	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
DMYGJQO	RU	https://www.drugbank.ca/drugs/DB08901

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DECB0K3
DMYGJQO	MN	Cytochrome P450 2D6 (CYP2D6)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther. 2017 Oct;363(1):12-19.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28882992

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DE4LYSA
DMYGJQO	MN	Cytochrome P450 3A4 (CYP3A4)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27137144

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DEIBDNY
DMYGJQO	MN	Cytochrome P450 3A5 (CYP3A5)
DMYGJQO	MT	DME
DMYGJQO	MA	Metabolism
DMYGJQO	RN	Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
DMYGJQO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23986642

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TTGJCWZ
DMYGJQO	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	DTUGYRD
DMYGJQO	MN	P-glycoprotein 1 (ABCB1)
DMYGJQO	MT	DTP
DMYGJQO	MA	Substrate
DMYGJQO	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB08901)
DMYGJQO	RU	https://www.drugbank.ca/drugs/DB08901

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TT4DXQT
DMYGJQO	MN	Proto-oncogene c-Ret (RET)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TT3PJMV
DMYGJQO	MN	Tyrosine-protein kinase ABL1 (ABL)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMYGJQO	DI	DMYGJQO
DMYGJQO	DN	Ponatinib
DMYGJQO	MI	TTX41N9
DMYGJQO	MN	Tyrosine-protein kinase Kit (KIT)
DMYGJQO	MT	DTT
DMYGJQO	MA	Modulator
DMYGJQO	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYGJQO	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMEAOYJ	DI	DMEAOYJ
DMEAOYJ	DN	Ponesimod
DMEAOYJ	MI	TT9JZCK
DMEAOYJ	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMEAOYJ	MT	DTT
DMEAOYJ	MA	Agonist
DMEAOYJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMEAOYJ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf

DM7ZWNY	DI	DM7ZWNY
DM7ZWNY	DN	Porfimer Sodium
DM7ZWNY	MI	TTH0DUS
DM7ZWNY	MN	Low-density lipoprotein receptor (LDL-R)
DM7ZWNY	MT	DTT
DM7ZWNY	MA	Modulator
DM7ZWNY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM7ZWNY	RU	https://www.fda.gov/

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	TTTSOUD
DMUL5EW	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMUL5EW	MT	DTT
DMUL5EW	MA	Inhibitor
DMUL5EW	RN	A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
DMUL5EW	RU	https://pubmed.ncbi.nlm.nih.gov/16961575

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DE4LYSA
DMUL5EW	MN	Cytochrome P450 3A4 (CYP3A4)
DMUL5EW	MT	DME
DMUL5EW	MA	Metabolism
DMUL5EW	RN	Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70.
DMUL5EW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20181649

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DTUGYRD
DMUL5EW	MN	P-glycoprotein 1 (ABCB1)
DMUL5EW	MT	DTP
DMUL5EW	MA	Substrate
DMUL5EW	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMUL5EW	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMUL5EW	DI	DMUL5EW
DMUL5EW	DN	Posaconazole
DMUL5EW	MI	DEYGVN4
DMUL5EW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMUL5EW	MT	DME
DMUL5EW	MA	Metabolism
DMUL5EW	RN	Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004 Feb;32(2):267-71.
DMUL5EW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744950

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTHKL3Q
DMMTAJC	MN	Basolateral Na-K-Cl symporter (SLC12A2)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20458365

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTO1UQY
DMMTAJC	MN	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/24253496 

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTY25IU
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 1 (SLC12A4)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Human potassium chloride cotransporter 1 (SLC12A4) promoter is regulated by AP-2 and contains a functional downstream promoter element. Blood. 2004 Jun 1;103(11):4302-9.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/14976052

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTD62VB
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 2 (SLC12A5)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2. Mol Cell Neurosci. 2010 Oct;45(2):173-9.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20600929

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DTMA4FJ
DMMTAJC	MN	Electroneutral potassium-chloride cotransporter 3 (SLC12A6)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Functional analysis of a potassium-chloride co-transporter 3 (SLC12A6) promoter polymorphism leading to an additional DNA methylation site. Neuropsychopharmacology. 2009 Jan;34(2):458-67.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/18536702

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	DT3HUVD
DMMTAJC	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMMTAJC	MT	DTP
DMMTAJC	MA	Substrate
DMMTAJC	RN	Mutations affecting GABAergic signaling in seizures and epilepsy. Pflugers Arch. 2010 Jul;460(2):505-23.
DMMTAJC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20352446

DMMTAJC	DI	DMMTAJC
DMMTAJC	DN	Potassium chloride
DMMTAJC	MI	TTS087L
DMMTAJC	MN	Solute carrier family 12 member 1 (SLC12A1)
DMMTAJC	MT	DTT
DMMTAJC	MA	Modulator
DMMTAJC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMTAJC	RU	https://www.fda.gov/

DMGLZ26	DI	DMGLZ26
DMGLZ26	DN	Practolol
DMGLZ26	MI	TTR6W5O
DMGLZ26	MN	Adrenergic receptor beta-1 (ADRB1)
DMGLZ26	MT	DTT
DMGLZ26	MA	Antagonist
DMGLZ26	RN	Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412.
DMGLZ26	RU	https://pubmed.ncbi.nlm.nih.gov/1335153

DMGLZ26	DI	DMGLZ26
DMGLZ26	DN	Practolol
DMGLZ26	MI	DECB0K3
DMGLZ26	MN	Cytochrome P450 2D6 (CYP2D6)
DMGLZ26	MT	DME
DMGLZ26	MA	Metabolism
DMGLZ26	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMGLZ26	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DTOSN46
DMAO80I	MN	Folate transporter 1 (SLC19A1)
DMAO80I	MT	DTP
DMAO80I	MA	Substrate
DMAO80I	RN	Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
DMAO80I	RU	http://www.ncbi.nlm.nih.gov/pubmed/22921318

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DECWT2V
DMAO80I	MN	Folylpolyglutamate synthase (FPGS)
DMAO80I	MT	DME
DMAO80I	MA	Metabolism
DMAO80I	RN	Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013 Mar;14(4):515-23.
DMAO80I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23409799

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	TT9SL3Q
DMAO80I	MN	Polypeptide deformylase (PDF)
DMAO80I	MT	DTT
DMAO80I	MA	Inhibitor
DMAO80I	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMAO80I	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMAO80I	DI	DMAO80I
DMAO80I	DN	Pralatrexate
DMAO80I	MI	DTDJEMI
DMAO80I	MN	Proton-coupled folate transporter (SLC46A1)
DMAO80I	MT	DTP
DMAO80I	MA	Substrate
DMAO80I	RN	Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
DMAO80I	RU	http://www.ncbi.nlm.nih.gov/pubmed/22921318

DMGQ0ZI	DI	DMGQ0ZI
DMGQ0ZI	DN	Pralidoxime chloride
DMGQ0ZI	MI	TT1RS9F
DMGQ0ZI	MN	Acetylcholinesterase (AChE)
DMGQ0ZI	MT	DTT
DMGQ0ZI	MA	Modulator
DMGQ0ZI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGQ0ZI	RU	https://www.fda.gov/

DMWU0I2	DI	DMWU0I2
DMWU0I2	DN	Pralsetinib
DMWU0I2	MI	TT4DXQT
DMWU0I2	MN	Proto-oncogene c-Ret (RET)
DMWU0I2	MT	DTT
DMWU0I2	MA	Inhibitor
DMWU0I2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWU0I2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	TTEX248
DMNMW9R	MN	Dopamine D2 receptor (D2R)
DMNMW9R	MT	DTT
DMNMW9R	MA	Modulator
DMNMW9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMW9R	RU	https://www.fda.gov/

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	TT4C8EA
DMNMW9R	MN	Dopamine D3 receptor (D3R)
DMNMW9R	MT	DTT
DMNMW9R	MA	Modulator
DMNMW9R	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMW9R	RU	https://www.fda.gov/

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	DTT79CX
DMNMW9R	MN	Organic cation transporter 1 (SLC22A1)
DMNMW9R	MT	DTP
DMNMW9R	MA	Substrate
DMNMW9R	RN	OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics. 2011 Feb;12(1):79-82.
DMNMW9R	RU	http://www.ncbi.nlm.nih.gov/pubmed/20680652

DMNMW9R	DI	DMNMW9R
DMNMW9R	DN	Pramipexole
DMNMW9R	MI	DT9IDPW
DMNMW9R	MN	Organic cation transporter 2 (SLC22A2)
DMNMW9R	MT	DTP
DMNMW9R	MA	Substrate
DMNMW9R	RN	Uptake of pramipexole by human organic cation transporters. Mol Pharm. 2010 Aug 2;7(4):1342-7.
DMNMW9R	RU	http://www.ncbi.nlm.nih.gov/pubmed/20496886

DM2FHG3	DI	DM2FHG3
DM2FHG3	DN	Pramiracetam
DM2FHG3	MI	TTH18TF
DM2FHG3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM2FHG3	MT	DTT
DM2FHG3	MA	Modulator
DM2FHG3	RN	Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Article first published online: 5 OCT 2004.
DM2FHG3	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430030503/abstract

DM0EZ9Q	DI	DM0EZ9Q
DM0EZ9Q	DN	Pramlintide
DM0EZ9Q	MI	TTVIMDE
DM0EZ9Q	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM0EZ9Q	MT	DTT
DM0EZ9Q	MA	Agonist
DM0EZ9Q	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM0EZ9Q	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMYHDCA	DI	DMYHDCA
DMYHDCA	DN	Pranlukast
DMYHDCA	MI	DE4LYSA
DMYHDCA	MN	Cytochrome P450 3A4 (CYP3A4)
DMYHDCA	MT	DME
DMYHDCA	MA	Metabolism
DMYHDCA	RN	Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. Drug Metab Pharmacokinet. 2008;23(6):428-33.;
DMYHDCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19122337

DMYHDCA	DI	DMYHDCA
DMYHDCA	DN	Pranlukast
DMYHDCA	MI	TTGKOY9
DMYHDCA	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMYHDCA	MT	DTT
DMYHDCA	MA	Antagonist
DMYHDCA	RN	Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
DMYHDCA	RU	https://pubmed.ncbi.nlm.nih.gov/19610262

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	TTS64P2
DM67VKL	MN	Androgen receptor (AR)
DM67VKL	MT	DTT
DM67VKL	MA	Antagonist
DM67VKL	RN	Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/15177053

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEQX145
DM67VKL	MN	Aromatase (CYP19A1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet. 1975 Nov 15;2(7942):943-6.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=53430

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEN0GVQ
DM67VKL	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20736065

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTI7UX6
DM67VKL	MN	Breast cancer resistance protein (ABCG2)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM67VKL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE4LYSA
DM67VKL	MN	Cytochrome P450 3A4 (CYP3A4)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DERD86B
DM67VKL	MN	Cytochrome P450 3A7 (CYP3A7)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE36TMY
DM67VKL	MN	Cytochrome P450 7B1 (CYP7B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta,17beta-diol--potential role(s) for estrogen signaling. FEBS J. 2008 Apr;275(8):1778-89.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/18331353

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DERDQWN
DM67VKL	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Selective inhibition of human 3beta-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer. J Steroid Biochem Mol Biol. 2011 May;125(1-2):57-65.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20736065

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEZS5YK
DM67VKL	MN	Estradiol 17-beta-dehydrogenase 1 (HSD17B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEBMFZ8
DM67VKL	MN	Estradiol 17-beta-dehydrogenase 2 (HSD17B2)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	TTKN8W0
DM67VKL	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DM67VKL	MT	DTT
DM67VKL	MA	Inhibitor
DM67VKL	RN	Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
DM67VKL	RU	https://pubmed.ncbi.nlm.nih.gov/3776114

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTCSGPB
DM67VKL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/12523936

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTWN7FC
DM67VKL	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16359813

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DTVP67E
DM67VKL	MN	Organic anion transporter 3 (SLC22A8)
DM67VKL	MT	DTP
DM67VKL	MA	Substrate
DM67VKL	RN	Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
DM67VKL	RU	http://www.ncbi.nlm.nih.gov/pubmed/11306713

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEJHG19
DM67VKL	MN	Peroxisomal multifunctional enzyme 2 (HSD17B4)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DE0P6LK
DM67VKL	MN	Sulfotransferase 2A1 (SULT2A1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DM67VKL	DI	DM67VKL
DM67VKL	DN	Prasterone
DM67VKL	MI	DEZBN53
DM67VKL	MN	Sulfotransferase 2B1 (SULT2B1)
DM67VKL	MT	DME
DM67VKL	MA	Metabolism
DM67VKL	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM67VKL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DEPKLMQ
DM7MT6E	MN	Cytochrome P450 2B6 (CYP2B6)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DE5IED8
DM7MT6E	MN	Cytochrome P450 2C9 (CYP2C9)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DE4LYSA
DM7MT6E	MN	Cytochrome P450 3A4 (CYP3A4)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	DEGTFWK
DM7MT6E	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7MT6E	MT	DME
DM7MT6E	MA	Metabolism
DM7MT6E	RN	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
DM7MT6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23083110

DM7MT6E	DI	DM7MT6E
DM7MT6E	DN	Prasugrel
DM7MT6E	MI	TTZ1DT0
DM7MT6E	MN	P2Y purinoceptor 12 (P2RY12)
DM7MT6E	MT	DTT
DM7MT6E	MA	Inhibitor
DM7MT6E	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DM7MT6E	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTJ0EW4
DM6A0X7	MN	Bile salt export pump (ABCB11)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901796

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTI7UX6
DM6A0X7	MN	Breast cancer resistance protein (ABCG2)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DE5IED8
DM6A0X7	MN	Cytochrome P450 2C9 (CYP2C9)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8737761

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DE4LYSA
DM6A0X7	MN	Cytochrome P450 3A4 (CYP3A4)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000 Dec;39(6):397-412.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192473

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DEIBDNY
DM6A0X7	MN	Cytochrome P450 3A5 (CYP3A5)
DM6A0X7	MT	DME
DM6A0X7	MA	Metabolism
DM6A0X7	RN	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb;27(2):173-9.
DM6A0X7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9929499

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	TTPADOQ
DM6A0X7	MN	HMG-CoA reductase (HMGCR)
DM6A0X7	MT	DTT
DM6A0X7	MA	Inhibitor
DM6A0X7	RN	A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
DM6A0X7	RU	https://pubmed.ncbi.nlm.nih.gov/11996957

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTFI42L
DM6A0X7	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/11772448

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTVP67E
DM6A0X7	MN	Organic anion transporter 3 (SLC22A8)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT06JWZ
DM6A0X7	MN	Organic anion transporter 4 (SLC22A11)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica. 2007 Apr;37(4):416-26.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/17455113

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTDI5S3
DM6A0X7	MN	Organic anion transporter 7 (SLC22A9)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. Pharmacogenomics J. 2016 Aug;16(4):341-51.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/26239079

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT3D8F0
DM6A0X7	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/18408565

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DT9C1TS
DM6A0X7	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/20100277

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTPFTEQ
DM6A0X7	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTUGYRD
DM6A0X7	MN	P-glycoprotein 1 (ABCB1)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM6A0X7	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DM6A0X7	DI	DM6A0X7
DM6A0X7	DN	Pravastatin
DM6A0X7	MI	DTHE530
DM6A0X7	MN	Probable small intestine urate exporter (SLC17A4)
DM6A0X7	MT	DTP
DM6A0X7	MA	Substrate
DM6A0X7	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM6A0X7	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DMEWC7N	DI	DMEWC7N
DMEWC7N	DN	Prazepam
DMEWC7N	MI	DE4LYSA
DMEWC7N	MN	Cytochrome P450 3A4 (CYP3A4)
DMEWC7N	MT	DME
DMEWC7N	MA	Metabolism
DMEWC7N	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DMEWC7N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DMEWC7N	DI	DMEWC7N
DMEWC7N	DN	Prazepam
DMEWC7N	MI	TTPTXIN
DMEWC7N	MN	Translocator protein (TSPO)
DMEWC7N	MT	DTT
DMEWC7N	MA	Modulator
DMEWC7N	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMEWC7N	RU	https://www.fda.gov/

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEJGDUW
DMOU1PK	MN	Cytochrome P450 1A2 (CYP1A2)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DE4LYSA
DMOU1PK	MN	Cytochrome P450 3A4 (CYP3A4)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4). Acta Pol Pharm. 2006 Sep-Oct;63(5):381-5.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17357589

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEO1IE3
DMOU1PK	MN	Cytochrome P450 3A43 (CYP3A43)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEIBDNY
DMOU1PK	MN	Cytochrome P450 3A5 (CYP3A5)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DERD86B
DMOU1PK	MN	Cytochrome P450 3A7 (CYP3A7)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	TTCYE56
DMOU1PK	MN	Glutathione-dependent PGD synthase (HPGDS)
DMOU1PK	MT	DTT
DMOU1PK	MA	Inhibitor
DMOU1PK	RN	X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5.
DMOU1PK	RU	https://pubmed.ncbi.nlm.nih.gov/16511012

DMOU1PK	DI	DMOU1PK
DMOU1PK	DN	Praziquantel
DMOU1PK	MI	DEGTFWK
DMOU1PK	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOU1PK	MT	DME
DMOU1PK	MA	Metabolism
DMOU1PK	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMOU1PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	TTG28O6
DMCD9YG	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMCD9YG	MT	DTT
DMCD9YG	MA	Antagonist
DMCD9YG	RN	Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33.
DMCD9YG	RU	https://pubmed.ncbi.nlm.nih.gov/19566752

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTI7UX6
DMCD9YG	MN	Breast cancer resistance protein (ABCG2)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
DMCD9YG	RU	http://www.ncbi.nlm.nih.gov/pubmed/21075088

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DE6OQ3W
DMCD9YG	MN	Cytochrome P450 1A1 (CYP1A1)
DMCD9YG	MT	DME
DMCD9YG	MA	Metabolism
DMCD9YG	RN	Role of adrenoceptor-linked signaling pathways in the regulation of CYP1A1 gene expression. Biochem Pharmacol. 2005 Jan 15;69(2):277-87.
DMCD9YG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15627480

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTT79CX
DMCD9YG	MN	Organic cation transporter 1 (SLC22A1)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMCD9YG	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMCD9YG	DI	DMCD9YG
DMCD9YG	DN	Prazosin
DMCD9YG	MI	DTUGYRD
DMCD9YG	MN	P-glycoprotein 1 (ABCB1)
DMCD9YG	MT	DTP
DMCD9YG	MA	Substrate
DMCD9YG	RN	Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.
DMCD9YG	RU	http://www.ncbi.nlm.nih.gov/pubmed/9380680

DMBUNVW	DI	DMBUNVW
DMBUNVW	DN	Prednicarbate
DMBUNVW	MI	DE4LYSA
DMBUNVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMBUNVW	MT	DME
DMBUNVW	MA	Metabolism
DMBUNVW	RN	HEP Drug interaction: daclatasvir and abacavir.
DMBUNVW	RU	https://hep-druginteractions.org/interactions/1205/all

DMBUNVW	DI	DMBUNVW
DMBUNVW	DN	Prednicarbate
DMBUNVW	MI	TTP3UTW
DMBUNVW	MN	Steroid hormone receptor ERR (ESRR)
DMBUNVW	MT	DTT
DMBUNVW	MA	Modulator
DMBUNVW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMBUNVW	RU	https://www.fda.gov/

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DE4LYSA
DMQ8FR2	MN	Cytochrome P450 3A4 (CYP3A4)
DMQ8FR2	MT	DME
DMQ8FR2	MA	Metabolism
DMQ8FR2	RN	Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
DMQ8FR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19795924

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DEIBDNY
DMQ8FR2	MN	Cytochrome P450 3A5 (CYP3A5)
DMQ8FR2	MT	DME
DMQ8FR2	MA	Metabolism
DMQ8FR2	RN	Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
DMQ8FR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10533695

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	TTYRL6O
DMQ8FR2	MN	Glucocorticoid receptor (NR3C1)
DMQ8FR2	MT	DTT
DMQ8FR2	MA	Modulator
DMQ8FR2	RN	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
DMQ8FR2	RU	https://pubmed.ncbi.nlm.nih.gov/11081607

DMQ8FR2	DI	DMQ8FR2
DMQ8FR2	DN	Prednisolone
DMQ8FR2	MI	DTUGYRD
DMQ8FR2	MN	P-glycoprotein 1 (ABCB1)
DMQ8FR2	MT	DTP
DMQ8FR2	MA	Substrate
DMQ8FR2	RN	The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
DMQ8FR2	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379510

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	DE4LYSA
DM2HG4X	MN	Cytochrome P450 3A4 (CYP3A4)
DM2HG4X	MT	DME
DM2HG4X	MA	Metabolism
DM2HG4X	RN	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
DM2HG4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24451000

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	TTYRL6O
DM2HG4X	MN	Glucocorticoid receptor (NR3C1)
DM2HG4X	MT	DTT
DM2HG4X	MA	Agonist
DM2HG4X	RN	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
DM2HG4X	RU	https://pubmed.ncbi.nlm.nih.gov/8619627

DM2HG4X	DI	DM2HG4X
DM2HG4X	DN	Prednisone
DM2HG4X	MI	DTUGYRD
DM2HG4X	MN	P-glycoprotein 1 (ABCB1)
DM2HG4X	MT	DTP
DM2HG4X	MA	Substrate
DM2HG4X	RN	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
DM2HG4X	RU	http://www.ncbi.nlm.nih.gov/pubmed/14661924

DMDVP3B	DI	DMDVP3B
DMDVP3B	DN	Pregabalin
DMDVP3B	MI	DT48T0N
DMDVP3B	MN	L-type amino acid transporter 1 (SLC7A5)
DMDVP3B	MT	DTP
DMDVP3B	MA	Substrate
DMDVP3B	RN	Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246.
DMDVP3B	RU	http://www.ncbi.nlm.nih.gov/pubmed/30374619

DMDVP3B	DI	DMDVP3B
DMDVP3B	DN	Pregabalin
DMDVP3B	MI	TTFK1JQ
DMDVP3B	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMDVP3B	MT	DTT
DMDVP3B	MA	Modulator
DMDVP3B	RN	Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
DMDVP3B	RU	https://pubmed.ncbi.nlm.nih.gov/16641316

DMYQVGN	DI	DMYQVGN
DMYQVGN	DN	Premarin/Trimegestone
DMYQVGN	MI	TTZAYWL
DMYQVGN	MN	Estrogen receptor (ESR)
DMYQVGN	MT	DTT
DMYQVGN	MA	Modulator
DMYQVGN	RN	The Haunting of Medical Journals: How Ghostwriting Sold RT PLoS Med. 2010 September; 7(9): e1000335.
DMYQVGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935455/

DMDYA31	DI	DMDYA31
DMDYA31	DN	Pretomanid
DMDYA31	MI	DE4LYSA
DMDYA31	MN	Cytochrome P450 3A4 (CYP3A4)
DMDYA31	MT	DME
DMDYA31	MA	Metabolism
DMDYA31	RN	FDA briefing document - pretomanid tablet, 200 mg meeting of the antimicrobial drugs advisory committee (AMDAC).
DMDYA31	RU	https://www.fda.gov/media/127592/download

DMDYA31	DI	DMDYA31
DMDYA31	DN	Pretomanid
DMDYA31	MI	TT08ESN
DMDYA31	MN	Mycobacterium Mycolic acid synthase (MycB cma)
DMDYA31	MT	DTT
DMDYA31	MA	Inhibitor
DMDYA31	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMDYA31	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf

DMQ0C2Z	DI	DMQ0C2Z
DMQ0C2Z	DN	Prevnar
DMQ0C2Z	MI	TT9GOIR
DMQ0C2Z	MN	Streptococcus Diphtheria protein (Stre DIPP)
DMQ0C2Z	MT	DTT
DMQ0C2Z	RN	Patent WO2013131983 A1.
DMQ0C2Z	RU	http://www.google.com/patents/WO2013131983A1?cl=en

DMMZB0K	DI	DMMZB0K
DMMZB0K	DN	Prifinium
DMMZB0K	MI	TTH18TF
DMMZB0K	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMMZB0K	MT	DTT
DMMZB0K	MA	Modulator
DMMZB0K	RN	Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther. 1995 Jul;274(1):378-84.
DMMZB0K	RU	https://pubmed.ncbi.nlm.nih.gov/7616422

DMI7DZ2	DI	DMI7DZ2
DMI7DZ2	DN	Prilocaine
DMI7DZ2	MI	TTZOVE0
DMI7DZ2	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMI7DZ2	MT	DTT
DMI7DZ2	MA	Blocker
DMI7DZ2	RN	Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
DMI7DZ2	RU	https://pubmed.ncbi.nlm.nih.gov/9476974

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	DEJGDUW
DMWQ16I	MN	Cytochrome P450 1A2 (CYP1A2)
DMWQ16I	MT	DME
DMWQ16I	MA	Metabolism
DMWQ16I	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMWQ16I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	DE4LYSA
DMWQ16I	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQ16I	MT	DME
DMWQ16I	MA	Metabolism
DMWQ16I	RN	Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
DMWQ16I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1510705

DMWQ16I	DI	DMWQ16I
DMWQ16I	DN	Primaquine
DMWQ16I	MI	TT698WO
DMWQ16I	MN	Plasmodium Deoxyribonucleic acid (Malaria DNA)
DMWQ16I	MT	DTT
DMWQ16I	RN	Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
DMWQ16I	RU	https://pubmed.ncbi.nlm.nih.gov/17686563

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	DE5IED8
DM0WX6I	MN	Cytochrome P450 2C9 (CYP2C9)
DM0WX6I	MT	DME
DM0WX6I	MA	Metabolism
DM0WX6I	RN	Prescribrt's digital referenve - Primidone - Drug Summary.
DM0WX6I	RU	https://www.pdr.net/drug-summary/Mysoline-primidone-775

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	TT1MPAY
DM0WX6I	MN	GABA(A) receptor alpha-1 (GABRA1)
DM0WX6I	MT	DTT
DM0WX6I	MA	Antagonist
DM0WX6I	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM0WX6I	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM0WX6I	DI	DM0WX6I
DM0WX6I	DN	Primidone
DM0WX6I	MI	DEGTFWK
DM0WX6I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0WX6I	MT	DME
DM0WX6I	MA	Metabolism
DM0WX6I	RN	Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
DM0WX6I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10380060

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTMX39J
DM9HOKG	MN	Matrix metalloproteinase-1 (MMP-1)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTLM12X
DM9HOKG	MN	Matrix metalloproteinase-2 (MMP-2)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DM9HOKG	DI	DM9HOKG
DM9HOKG	DN	Prinomastat
DM9HOKG	MI	TTMTWOS
DM9HOKG	MN	Matrix metalloproteinase-7 (MMP-7)
DM9HOKG	MT	DTT
DM9HOKG	MA	Inhibitor
DM9HOKG	RN	AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
DM9HOKG	RU	https://pubmed.ncbi.nlm.nih.gov/16103944

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DT3I124
DMMFWOJ	MN	Monocarboxylate transporter 6 (SLC16A5)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936.
DMMFWOJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28513167

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DTFI42L
DMMFWOJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
DMMFWOJ	RU	https://doi.org/10.1002/ijc.21013

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DTE2B1D
DMMFWOJ	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMMFWOJ	MT	DTP
DMMFWOJ	MA	Substrate
DMMFWOJ	RN	Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22.
DMMFWOJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11408557

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	TTTQR47
DMMFWOJ	MN	Solute carrier family 22 member 8 (SLC22A8)
DMMFWOJ	MT	DTT
DMMFWOJ	MA	Blocker
DMMFWOJ	RN	Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
DMMFWOJ	RU	https://pubmed.ncbi.nlm.nih.gov/12605306

DMMFWOJ	DI	DMMFWOJ
DMMFWOJ	DN	Probenecid
DMMFWOJ	MI	DEYGVN4
DMMFWOJ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMFWOJ	MT	DME
DMMFWOJ	MA	Metabolism
DMMFWOJ	RN	Modulation of 3'-azido-3'-deoxythymidine catabolism by probenecid and acetaminophen in freshly isolated rat hepatocytes. Biochem Pharmacol. 1991 Sep 12;42(7):1475-80.
DMMFWOJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1930271

DMVZQ2M	DI	DMVZQ2M
DMVZQ2M	DN	Probucol
DMVZQ2M	MI	TTJW1GN
DMVZQ2M	MN	ATP-binding cassette transporter A1 (ABCA1)
DMVZQ2M	MT	DTT
DMVZQ2M	MA	Modulator
DMVZQ2M	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMVZQ2M	RU	https://www.fda.gov/

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DECB0K3
DMNMXR8	MN	Cytochrome P450 2D6 (CYP2D6)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10634131

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	TT05DLS
DMNMXR8	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMNMXR8	MT	DTT
DMNMXR8	MA	Modulator
DMNMXR8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMNMXR8	RU	https://www.fda.gov/

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DTZGT0P
DMNMXR8	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DT3TX4H
DMNMXR8	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DE7OAB3
DMNMXR8	MN	N-acetyltransferase 1 (NAT1)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613-20.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8937477

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DER7TA0
DMNMXR8	MN	N-acetyltransferase 2 (NAT2)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10692486

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DTT79CX
DMNMXR8	MN	Organic cation transporter 1 (SLC22A1)
DMNMXR8	MT	DTP
DMNMXR8	MA	Substrate
DMNMXR8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMNMXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMNMXR8	DI	DMNMXR8
DMNMXR8	DN	Procainamide
DMNMXR8	MI	DEZV4AP
DMNMXR8	MN	RNA cytidine acetyltransferase (hALP)
DMNMXR8	MT	DME
DMNMXR8	MA	Metabolism
DMNMXR8	RN	Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
DMNMXR8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1371435

DM4LSNE	DI	DM4LSNE
DM4LSNE	DN	Procaine
DM4LSNE	MI	TTPC4TU
DM4LSNE	MN	5-HT 3A receptor (HTR3A)
DM4LSNE	MT	DTT
DM4LSNE	MA	Antagonist
DM4LSNE	RN	Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
DM4LSNE	RU	https://pubmed.ncbi.nlm.nih.gov/18035290

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DE6OQ3W
DMIK367	MN	Cytochrome P450 1A1 (CYP1A1)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DEJGDUW
DMIK367	MN	Cytochrome P450 1A2 (CYP1A2)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1316811

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	DE9QHP6
DMIK367	MN	Cytochrome P450 1B1 (CYP1B1)
DMIK367	MT	DME
DMIK367	MA	Metabolism
DMIK367	RN	Tumour cytochrome P450 and drug activation. Curr Pharm Des. 2002;8(15):1335-47.
DMIK367	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12052211

DMIK367	DI	DMIK367
DMIK367	DN	Procarbazine
DMIK367	MI	TTUTN1I
DMIK367	MN	Human Deoxyribonucleic acid (hDNA)
DMIK367	MT	DTT
DMIK367	RN	Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
DMIK367	RU	https://pubmed.ncbi.nlm.nih.gov/18840549

DM1M0Q4	DI	DM1M0Q4
DM1M0Q4	DN	Procaterol
DM1M0Q4	MI	TT2CJVK
DM1M0Q4	MN	Adrenergic receptor beta-2 (ADRB2)
DM1M0Q4	MT	DTT
DM1M0Q4	MA	Agonist
DM1M0Q4	RN	Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91.
DM1M0Q4	RU	https://pubmed.ncbi.nlm.nih.gov/17646734

DM1M0Q4	DI	DM1M0Q4
DM1M0Q4	DN	Procaterol
DM1M0Q4	MI	DTT79CX
DM1M0Q4	MN	Organic cation transporter 1 (SLC22A1)
DM1M0Q4	MT	DTP
DM1M0Q4	MA	Substrate
DM1M0Q4	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM1M0Q4	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DM53SRA	DI	DM53SRA
DM53SRA	DN	Prochlorperazine
DM53SRA	MI	DECB0K3
DM53SRA	MN	Cytochrome P450 2D6 (CYP2D6)
DM53SRA	MT	DME
DM53SRA	MA	Metabolism
DM53SRA	RN	Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004 Apr;57(4):464-72.
DM53SRA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15025745

DM53SRA	DI	DM53SRA
DM53SRA	DN	Prochlorperazine
DM53SRA	MI	TTEX248
DM53SRA	MN	Dopamine D2 receptor (D2R)
DM53SRA	MT	DTT
DM53SRA	MA	Antagonist
DM53SRA	RN	In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102.
DM53SRA	RU	https://pubmed.ncbi.nlm.nih.gov/18992311

DMHFJDT	DI	DMHFJDT
DMHFJDT	DN	Procyclidine
DMHFJDT	MI	TTH18TF
DMHFJDT	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMHFJDT	MT	DTT
DMHFJDT	MA	Antagonist
DMHFJDT	RN	Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol. 2004 May 1;196(3):327-36.
DMHFJDT	RU	https://pubmed.ncbi.nlm.nih.gov/15094303

DMF1X5P	DI	DMF1X5P
DMF1X5P	DN	Proflavine
DMF1X5P	MI	TTS1W4A
DMF1X5P	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMF1X5P	MT	DTT
DMF1X5P	MA	Binder
DMF1X5P	RN	Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
DMF1X5P	RU	https://pubmed.ncbi.nlm.nih.gov/19364280

DM671NG	DI	DM671NG
DM671NG	DN	Progabide
DM671NG	MI	TTDCVZW
DM671NG	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM671NG	MT	DTT
DM671NG	MA	Agonist
DM671NG	RN	Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
DM671NG	RU	https://pubmed.ncbi.nlm.nih.gov/9443561

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE7P2FB
DMUY35B	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24434280

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DTI7UX6
DMUY35B	MN	Breast cancer resistance protein (ABCG2)
DMUY35B	MT	DTP
DMUY35B	MA	Substrate
DMUY35B	RN	Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
DMUY35B	RU	http://www.ncbi.nlm.nih.gov/pubmed/12668685

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEKP5HX
DMUY35B	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE6OQ3W
DMUY35B	MN	Cytochrome P450 1A1 (CYP1A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE9QHP6
DMUY35B	MN	Cytochrome P450 1B1 (CYP1B1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEBY951
DMUY35B	MN	Cytochrome P450 21A2 (cyp21)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
DMUY35B	RU	https://pubmed.ncbi.nlm.nih.gov/31427655

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEJVYAZ
DMUY35B	MN	Cytochrome P450 2A6 (CYP2A6)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE5IED8
DMUY35B	MN	Cytochrome P450 2C9 (CYP2C9)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DECB0K3
DMUY35B	MN	Cytochrome P450 2D6 (CYP2D6)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15469888

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE4LYSA
DMUY35B	MN	Cytochrome P450 3A4 (CYP3A4)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9667077

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEIBDNY
DMUY35B	MN	Cytochrome P450 3A5 (CYP3A5)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10403825

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DERD86B
DMUY35B	MN	Cytochrome P450 3A7 (CYP3A7)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8424894

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEMF740
DMUY35B	MN	Cytochrome P450 4B1 (CYP4B1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEZ1H4L
DMUY35B	MN	Cytochrome P450 MEG (cyp106)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Engineering of CYP106A2 for steroid 9alpha- and 6beta-hydroxylation. Steroids. 2017 Apr;120:41-48.
DMUY35B	RU	https://pubmed.ncbi.nlm.nih.gov/28163026

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE4ZHS1
DMUY35B	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11418619

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEGTFWK
DMUY35B	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DTUGYRD
DMUY35B	MN	P-glycoprotein 1 (ABCB1)
DMUY35B	MT	DTP
DMUY35B	MA	Substrate
DMUY35B	RN	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
DMUY35B	RU	http://www.ncbi.nlm.nih.gov/pubmed/11785684

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	TTUV8G9
DMUY35B	MN	Progesterone receptor (PGR)
DMUY35B	MT	DTT
DMUY35B	MA	Agonist
DMUY35B	RN	Clinical pipeline report, company report or official report of lipocine.
DMUY35B	RU	http://www.lipocine.com/pipeline/lpcn-1107/

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DE0JMZ5
DMUY35B	MN	Steroid 21-hydroxylase (CYP21A2)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Human cytochrome P450 21A2, the major steroid 21-hydroxylase: structure of the enzyme progesterone substrate complex and rate-limiting C-H bond cleavage. J Biol Chem. 2015 May 22;290(21):13128-43.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25855791

DMUY35B	DI	DMUY35B
DMUY35B	DN	Progesterone
DMUY35B	MI	DEYWLRK
DMUY35B	MN	Sulfotransferase 1A1 (SULT1A1)
DMUY35B	MT	DME
DMUY35B	MA	Metabolism
DMUY35B	RN	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
DMUY35B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16879988

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEJGDUW
DMBL79I	MN	Cytochrome P450 1A2 (CYP1A2)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DE5IED8
DMBL79I	MN	Cytochrome P450 2C9 (CYP2C9)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEVDYN7
DMBL79I	MN	Cytochrome P450 2E1 (CYP2E1)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br J Clin Pharmacol. 1999 Aug;48(2):158-67.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10417492

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DE4LYSA
DMBL79I	MN	Cytochrome P450 3A4 (CYP3A4)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11501186

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	DEGTFWK
DMBL79I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBL79I	MT	DME
DMBL79I	MA	Metabolism
DMBL79I	RN	Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol. 2002 Nov;58(8):543-5.
DMBL79I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12451432

DMBL79I	DI	DMBL79I
DMBL79I	DN	Proguanil
DMBL79I	MI	TT9SL3Q
DMBL79I	MN	Polypeptide deformylase (PDF)
DMBL79I	MT	DTT
DMBL79I	MA	Inhibitor
DMBL79I	RN	Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6.
DMBL79I	RU	https://pubmed.ncbi.nlm.nih.gov/9380737

DMYSCIL	DI	DMYSCIL
DMYSCIL	DN	Prolastin
DMYSCIL	MI	TTZBFA0
DMYSCIL	MN	Protease unspecific (PRO)
DMYSCIL	MT	DTT
DMYSCIL	MA	Inhibitor
DMYSCIL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYSCIL	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMMJ1IS	DI	DMMJ1IS
DMMJ1IS	DN	Prolixin decanoate
DMMJ1IS	MI	TTK8CXU
DMMJ1IS	MN	5-HT 1B receptor (HTR1B)
DMMJ1IS	MT	DTT
DMMJ1IS	MA	Modulator
DMMJ1IS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMJ1IS	RU	https://www.fda.gov/

DMMJ1IS	DI	DMMJ1IS
DMMJ1IS	DN	Prolixin decanoate
DMMJ1IS	MI	DECB0K3
DMMJ1IS	MN	Cytochrome P450 2D6 (CYP2D6)
DMMJ1IS	MT	DME
DMMJ1IS	MA	Metabolism
DMMJ1IS	RN	Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
DMMJ1IS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DEJGDUW
DMZAL7W	MN	Cytochrome P450 1A2 (CYP1A2)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DE5IED8
DMZAL7W	MN	Cytochrome P450 2C9 (CYP2C9)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DE4LYSA
DMZAL7W	MN	Cytochrome P450 3A4 (CYP3A4)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	DEGTFWK
DMZAL7W	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZAL7W	MT	DME
DMZAL7W	MA	Metabolism
DMZAL7W	RN	Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
DMZAL7W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12721102

DMZAL7W	DI	DMZAL7W
DMZAL7W	DN	Promazine
DMZAL7W	MI	TTH18TF
DMZAL7W	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMZAL7W	MT	DTT
DMZAL7W	MA	Binder
DMZAL7W	RN	Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
DMZAL7W	RU	https://pubmed.ncbi.nlm.nih.gov/2899826

DMK4S8I	DI	DMK4S8I
DMK4S8I	DN	Promegestone
DMK4S8I	MI	DE4LYSA
DMK4S8I	MN	Cytochrome P450 3A4 (CYP3A4)
DMK4S8I	MT	DME
DMK4S8I	MA	Metabolism
DMK4S8I	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMK4S8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMU92F8	DI	DMU92F8
DMU92F8	DN	Promestriene
DMU92F8	MI	TTZAYWL
DMU92F8	MN	Estrogen receptor (ESR)
DMU92F8	MT	DTT
DMU92F8	MA	Modulator
DMU92F8	RN	Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients. Anticancer Drugs. 2013 Nov;24(10):989-98.
DMU92F8	RU	https://pubmed.ncbi.nlm.nih.gov/24080714

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	DEPKLMQ
DM6I5GR	MN	Cytochrome P450 2B6 (CYP2B6)
DM6I5GR	MT	DME
DM6I5GR	MA	Metabolism
DM6I5GR	RN	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
DM6I5GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14515060

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	DECB0K3
DM6I5GR	MN	Cytochrome P450 2D6 (CYP2D6)
DM6I5GR	MT	DME
DM6I5GR	MA	Metabolism
DM6I5GR	RN	Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
DM6I5GR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16670408

DM6I5GR	DI	DM6I5GR
DM6I5GR	DN	Promethazine
DM6I5GR	MI	TTTIBOJ
DM6I5GR	MN	Histamine H1 receptor (H1R)
DM6I5GR	MT	DTT
DM6I5GR	MA	Antagonist
DM6I5GR	RN	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
DM6I5GR	RU	https://pubmed.ncbi.nlm.nih.gov/18446005

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DEJGDUW
DMPIBJK	MN	Cytochrome P450 1A2 (CYP1A2)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol. 1998 Apr;45(4):361-8.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578183

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DECB0K3
DMPIBJK	MN	Cytochrome P450 2D6 (CYP2D6)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DE4LYSA
DMPIBJK	MN	Cytochrome P450 3A4 (CYP3A4)
DMPIBJK	MT	DME
DMPIBJK	MA	Metabolism
DMPIBJK	RN	Effect of selective serotonin reuptake inhibitors on the oxidative metabolism of propafenone: in vitro studies using human liver microsomes. J Clin Psychopharmacol. 2000 Aug;20(4):428-34.
DMPIBJK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10917404

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	TT05DLS
DMPIBJK	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMPIBJK	MT	DTT
DMPIBJK	MA	Modulator
DMPIBJK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMPIBJK	RU	https://www.fda.gov/

DMPIBJK	DI	DMPIBJK
DMPIBJK	DN	Propafenone
DMPIBJK	MI	DTUGYRD
DMPIBJK	MN	P-glycoprotein 1 (ABCB1)
DMPIBJK	MT	DTP
DMPIBJK	MA	Substrate
DMPIBJK	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMPIBJK	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM2EN6G	DI	DM2EN6G
DM2EN6G	DN	Propantheline
DM2EN6G	MI	TTZ9SOR
DM2EN6G	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM2EN6G	MT	DTT
DM2EN6G	MA	Antagonist
DM2EN6G	RN	Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805.
DM2EN6G	RU	https://pubmed.ncbi.nlm.nih.gov/15337834

DMLS39E	DI	DMLS39E
DMLS39E	DN	Proparacaine
DMLS39E	MI	TT90XZ8
DMLS39E	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMLS39E	MT	DTT
DMLS39E	MA	Modulator
DMLS39E	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLS39E	RU	https://www.fda.gov/

DM6JQ2I	DI	DM6JQ2I
DM6JQ2I	DN	Propentofylline propionate
DM6JQ2I	MI	DEJGDUW
DM6JQ2I	MN	Cytochrome P450 1A2 (CYP1A2)
DM6JQ2I	MT	DME
DM6JQ2I	MA	Metabolism
DM6JQ2I	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DM6JQ2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DME9JNL	DI	DME9JNL
DME9JNL	DN	Propericiazine
DME9JNL	MI	TTBRKXS
DME9JNL	MN	Adrenergic receptor alpha-1B (ADRA1B)
DME9JNL	MT	DTT
DME9JNL	MA	Binder
DME9JNL	RN	Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
DME9JNL	RU	https://pubmed.ncbi.nlm.nih.gov/6149771

DMWDHUZ	DI	DMWDHUZ
DMWDHUZ	DN	Propicillin
DMWDHUZ	MI	DTLT3UG
DMWDHUZ	MN	Monocarboxylate transporter 2 (SLC16A7)
DMWDHUZ	MT	DTP
DMWDHUZ	MA	Substrate
DMWDHUZ	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMWDHUZ	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMKY8V1	DI	DMKY8V1
DMKY8V1	DN	Propiomazine
DMKY8V1	MI	TTTIBOJ
DMKY8V1	MN	Histamine H1 receptor (H1R)
DMKY8V1	MT	DTT
DMKY8V1	MA	Antagonist
DMKY8V1	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKY8V1	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMUWBIJ	DI	DMUWBIJ
DMUWBIJ	DN	Propiverine
DMUWBIJ	MI	DE4LYSA
DMUWBIJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMUWBIJ	MT	DME
DMUWBIJ	MA	Metabolism
DMUWBIJ	RN	Product monograph: Mictoryl (Propiverine hydrochloride modified-release capsules).
DMUWBIJ	RU	https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf

DMUWBIJ	DI	DMUWBIJ
DMUWBIJ	DN	Propiverine
DMUWBIJ	MI	TTH18TF
DMUWBIJ	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMUWBIJ	MT	DTT
DMUWBIJ	MA	Antagonist
DMUWBIJ	RN	Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
DMUWBIJ	RU	https://pubmed.ncbi.nlm.nih.gov/10374898

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEJGDUW
DMB4OLE	MN	Cytochrome P450 1A2 (CYP1A2)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEJVYAZ
DMB4OLE	MN	Cytochrome P450 2A6 (CYP2A6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEPKLMQ
DMB4OLE	MN	Cytochrome P450 2B6 (CYP2B6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17620218

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEZMWRE
DMB4OLE	MN	Cytochrome P450 2C18 (CYP2C18)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DES5XRU
DMB4OLE	MN	Cytochrome P450 2C8 (CYP2C8)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE5IED8
DMB4OLE	MN	Cytochrome P450 2C9 (CYP2C9)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DECB0K3
DMB4OLE	MN	Cytochrome P450 2D6 (CYP2D6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9764927

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEVDYN7
DMB4OLE	MN	Cytochrome P450 2E1 (CYP2E1)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE4LYSA
DMB4OLE	MN	Cytochrome P450 3A4 (CYP3A4)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001 Jan;94(1):110-9.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11135730

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	TTDP1UC
DMB4OLE	MN	Fatty acid amide hydrolase (FAAH)
DMB4OLE	MT	DTT
DMB4OLE	MA	Inhibitor
DMB4OLE	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMB4OLE	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEGTFWK
DMB4OLE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9771309

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEUM1EX
DMB4OLE	MN	Oleamide hydrolase 1 (FAAH)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Update of TTD: therapeutic target database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19933260

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DEYGVN4
DMB4OLE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17697043

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DESD26P
DMB4OLE	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19752585

DMB4OLE	DI	DMB4OLE
DMB4OLE	DN	Propofol
DMB4OLE	MI	DE85D2P
DMB4OLE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMB4OLE	MT	DME
DMB4OLE	MA	Metabolism
DMB4OLE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB4OLE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMSOLA	DI	DMMSOLA
DMMSOLA	DN	Propoxyphene Hydrochloride
DMMSOLA	MI	TTKWM86
DMMSOLA	MN	Opioid receptor mu (MOP)
DMMSOLA	MT	DTT
DMMSOLA	MA	Modulator
DMMSOLA	RN	Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78.
DMMSOLA	RU	https://www.ncbi.nlm.nih.gov/pubmed/10690289

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	TTR6W5O
DM79NTF	MN	Adrenergic receptor beta-1 (ADRB1)
DM79NTF	MT	DTT
DM79NTF	MA	Antagonist
DM79NTF	RN	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
DM79NTF	RU	https://pubmed.ncbi.nlm.nih.gov/19491545

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DE4OGUF
DM79NTF	MN	Cytochrome P450 102A1 (cyp102)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
DM79NTF	RU	https://pubmed.ncbi.nlm.nih.gov/31427655

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEJGDUW
DM79NTF	MN	Cytochrome P450 1A2 (CYP1A2)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DECB0K3
DM79NTF	MN	Cytochrome P450 2D6 (CYP2D6)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996013

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DE4LYSA
DM79NTF	MN	Cytochrome P450 3A4 (CYP3A4)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7895609

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEIBDNY
DM79NTF	MN	Cytochrome P450 3A5 (CYP3A5)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DERD86B
DM79NTF	MN	Cytochrome P450 3A7 (CYP3A7)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1487547

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEIASEZ
DM79NTF	MN	Dimethylaniline oxidase 2 (FMO2)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26062974

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DEGTFWK
DM79NTF	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM79NTF	MT	DME
DM79NTF	MA	Metabolism
DM79NTF	RN	Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
DM79NTF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11678778

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DTT79CX
DM79NTF	MN	Organic cation transporter 1 (SLC22A1)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DT9IDPW
DM79NTF	MN	Organic cation transporter 2 (SLC22A2)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DT6201N
DM79NTF	MN	Organic cation transporter 3 (SLC22A3)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
DM79NTF	RU	http://www.ncbi.nlm.nih.gov/pubmed/28768994

DM79NTF	DI	DM79NTF
DM79NTF	DN	Propranolol
DM79NTF	MI	DTUGYRD
DM79NTF	MN	P-glycoprotein 1 (ABCB1)
DM79NTF	MT	DTP
DM79NTF	MA	Substrate
DM79NTF	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM79NTF	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMTBW2O	DI	DMTBW2O
DMTBW2O	DN	Propylhexedrine
DMTBW2O	MI	TT2NUT5
DMTBW2O	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMTBW2O	MT	DTT
DMTBW2O	MA	Modulator
DMTBW2O	RN	Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
DMTBW2O	RU	https://pubmed.ncbi.nlm.nih.gov/7533806

DM6D7N8	DI	DM6D7N8
DM6D7N8	DN	Propylthiouracil
DM6D7N8	MI	TTU3X26
DM6D7N8	MN	Iodothyronine deiodinase type I (DIO1)
DM6D7N8	MT	DTT
DM6D7N8	MA	Inhibitor
DM6D7N8	RN	Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1.
DM6D7N8	RU	https://pubmed.ncbi.nlm.nih.gov/17712320

DM6D7N8	DI	DM6D7N8
DM6D7N8	DN	Propylthiouracil
DM6D7N8	MI	TT52XDZ
DM6D7N8	MN	Thyroid peroxidase (TPO)
DM6D7N8	MT	DTT
DM6D7N8	MA	Inhibitor
DM6D7N8	RN	Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214.
DM6D7N8	RU	https://pubmed.ncbi.nlm.nih.gov/17497002

DMX0EZJ	DI	DMX0EZJ
DMX0EZJ	DN	Prothionamide
DMX0EZJ	MI	TTVTX4N
DMX0EZJ	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DMX0EZJ	MT	DTT
DMX0EZJ	MA	Inhibitor
DMX0EZJ	RN	Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
DMX0EZJ	RU	https://pubmed.ncbi.nlm.nih.gov/17227913

DMGN5QD	DI	DMGN5QD
DMGN5QD	DN	Protirelin
DMGN5QD	MI	DEVDR46
DMGN5QD	MN	Pyrrolidone-carboxylate peptidase (PGPI)
DMGN5QD	MT	DME
DMGN5QD	MA	Metabolism
DMGN5QD	RN	Marginal involvement of pyroglutamyl aminopeptidase I in metabolism of thyrotropin-releasing hormone in rat brain. Biol Pharm Bull. 2004 Aug;27(8):1197-201.
DMGN5QD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15305021

DMGN5QD	DI	DMGN5QD
DMGN5QD	DN	Protirelin
DMGN5QD	MI	TT4J8MF
DMGN5QD	MN	Thyrotropin-releasing hormone receptor (TRHR)
DMGN5QD	MT	DTT
DMGN5QD	MA	Modulator
DMGN5QD	RN	Company report (takeda)
DMGN5QD	RU	https://www.takeda.com/csr/reports/pdf/index/ar2010_04_en.pdf

DMAHZKR	DI	DMAHZKR
DMAHZKR	DN	Protokylol Hydrochloride
DMAHZKR	MI	TTR6W5O
DMAHZKR	MN	Adrenergic receptor beta-1 (ADRB1)
DMAHZKR	MT	DTT
DMAHZKR	MA	Modulator
DMAHZKR	RN	N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver.
DMAHZKR	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668481

DMNHTZI	DI	DMNHTZI
DMNHTZI	DN	Protriptyline
DMNHTZI	MI	TTAWNKZ
DMNHTZI	MN	Norepinephrine transporter (NET)
DMNHTZI	MT	DTT
DMNHTZI	MA	Inhibitor
DMNHTZI	RN	Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
DMNHTZI	RU	https://pubmed.ncbi.nlm.nih.gov/3494977

DMNHTZI	DI	DMNHTZI
DMNHTZI	DN	Protriptyline
DMNHTZI	MI	DTUGYRD
DMNHTZI	MN	P-glycoprotein 1 (ABCB1)
DMNHTZI	MT	DTP
DMNHTZI	MA	Substrate
DMNHTZI	RN	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.
DMNHTZI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12438524

DMGKT2L	DI	DMGKT2L
DMGKT2L	DN	Pro-urokinase
DMGKT2L	MI	TTGY7WI
DMGKT2L	MN	Urokinase-type plasminogen activator (PLAU)
DMGKT2L	MT	DTT
DMGKT2L	MA	Modulator
DMGKT2L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
DMGKT2L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393

DMOK965	DI	DMOK965
DMOK965	DN	Prulifloxacin
DMOK965	MI	TTN6J5F
DMOK965	MN	Bacterial DNA gyrase (Bact gyrase)
DMOK965	MT	DTT
DMOK965	MA	Inhibitor
DMOK965	RN	Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
DMOK965	RU	https://pubmed.ncbi.nlm.nih.gov/16441207

DMOK965	DI	DMOK965
DMOK965	DN	Prulifloxacin
DMOK965	MI	TTFK8YB
DMOK965	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMOK965	MT	DTT
DMOK965	MA	Inhibitor
DMOK965	RN	Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
DMOK965	RU	https://pubmed.ncbi.nlm.nih.gov/16441207

DMIVJ0D	DI	DMIVJ0D
DMIVJ0D	DN	Pseudoephedrine
DMIVJ0D	MI	TTEX248
DMIVJ0D	MN	Dopamine D2 receptor (D2R)
DMIVJ0D	MT	DTT
DMIVJ0D	MA	Stimulator
DMIVJ0D	RN	Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2.
DMIVJ0D	RU	https://pubmed.ncbi.nlm.nih.gov/11772135

DMIVJ0D	DI	DMIVJ0D
DMIVJ0D	DN	Pseudoephedrine
DMIVJ0D	MI	DEYWLRK
DMIVJ0D	MN	Sulfotransferase 1A1 (SULT1A1)
DMIVJ0D	MT	DME
DMIVJ0D	MA	Metabolism
DMIVJ0D	RN	Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11.
DMIVJ0D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	DEWJATF
DMLSUWZ	MN	Adenosine 5'-monophosphoramidase (HINT1)
DMLSUWZ	MT	DME
DMLSUWZ	MA	Metabolism
DMLSUWZ	RN	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
DMLSUWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20801890

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	DEB30C5
DMLSUWZ	MN	Carboxylesterase 1 (CES1)
DMLSUWZ	MT	DME
DMLSUWZ	MA	Metabolism
DMLSUWZ	RN	Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
DMLSUWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20801890

DMLSUWZ	DI	DMLSUWZ
DMLSUWZ	DN	PSI-7977
DMLSUWZ	MI	TTMVBWH
DMLSUWZ	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMLSUWZ	MT	DTT
DMLSUWZ	MA	Modulator
DMLSUWZ	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMLSUWZ	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMWLTU2	DI	DMWLTU2
DMWLTU2	DN	PSMA-11 Ga-68
DMWLTU2	MI	TT9G4N0
DMWLTU2	MN	Glutamate carboxypeptidase II (GCPII)
DMWLTU2	MT	DTT
DMWLTU2	MA	Binder
DMWLTU2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWLTU2	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf

DMG2X3E	DI	DMG2X3E
DMG2X3E	DN	Pyrantel
DMG2X3E	MI	DECB0K3
DMG2X3E	MN	Cytochrome P450 2D6 (CYP2D6)
DMG2X3E	MT	DME
DMG2X3E	MA	Metabolism
DMG2X3E	RN	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
DMG2X3E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	TTVTX4N
DM4IF32	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM4IF32	MT	DTT
DM4IF32	MA	Inhibitor
DM4IF32	RN	Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
DM4IF32	RU	https://pubmed.ncbi.nlm.nih.gov/10973326

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DEJGDUW
DM4IF32	MN	Cytochrome P450 1A2 (CYP1A2)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DM4IF32	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DE4LYSA
DM4IF32	MN	Cytochrome P450 3A4 (CYP3A4)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DM4IF32	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DM4IF32	DI	DM4IF32
DM4IF32	DN	Pyrazinamide
DM4IF32	MI	DERQS6E
DM4IF32	MN	Nicotinamidase (pncA)
DM4IF32	MT	DME
DM4IF32	MA	Metabolism
DM4IF32	RN	Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl. 2009;48(48):9176-9.
DM4IF32	RU	https://pubmed.ncbi.nlm.nih.gov/19859929

DM8HO1L	DI	DM8HO1L
DM8HO1L	DN	Pyridostigmine
DM8HO1L	MI	TT1RS9F
DM8HO1L	MN	Acetylcholinesterase (AChE)
DM8HO1L	MT	DTT
DM8HO1L	MA	Inhibitor
DM8HO1L	RN	Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
DM8HO1L	RU	https://pubmed.ncbi.nlm.nih.gov/19257799

DMO2K0J	DI	DMO2K0J
DMO2K0J	DN	Pyridoxal Phosphate
DMO2K0J	MI	TT6L509
DMO2K0J	MN	Coagulation factor IIa (F2)
DMO2K0J	MT	DTT
DMO2K0J	MA	Inhibitor
DMO2K0J	RN	New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
DMO2K0J	RU	https://pubmed.ncbi.nlm.nih.gov/11794963

DMO2K0J	DI	DMO2K0J
DMO2K0J	DN	Pyridoxal Phosphate
DMO2K0J	MI	TTT2LD9
DMO2K0J	MN	GABA transaminase (ABAT)
DMO2K0J	MT	DTT
DMO2K0J	MA	Inhibitor
DMO2K0J	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMO2K0J	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	DTI7UX6
DM5X7VY	MN	Breast cancer resistance protein (ABCG2)
DM5X7VY	MT	DTP
DM5X7VY	MA	Substrate
DM5X7VY	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM5X7VY	RU	https://doi.org/10.1007/s00280-006-0230-9

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	TTVC37M
DM5X7VY	MN	Folate receptor alpha (FOLR1)
DM5X7VY	MT	DTT
DM5X7VY	MA	Modulator
DM5X7VY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5X7VY	RU	https://www.fda.gov/

DM5X7VY	DI	DM5X7VY
DM5X7VY	DN	Pyrimethamine
DM5X7VY	MI	DTZGT0P
DM5X7VY	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DM5X7VY	MT	DTP
DM5X7VY	MA	Substrate
DM5X7VY	RN	Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
DM5X7VY	RU	http://www.ncbi.nlm.nih.gov/pubmed/29514829

DMNA8HM	DI	DMNA8HM
DMNA8HM	DN	Pyrithione Zinc
DMNA8HM	MI	TTG5TOX
DMNA8HM	MN	Fungal Proton pump (FPPCM)
DMNA8HM	MT	DTT
DMNA8HM	MA	Modulator
DMNA8HM	RN	Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrob Agents Chemother. 1978 Jul;14(1):60-8.
DMNA8HM	RU	https://www.ncbi.nlm.nih.gov/pubmed/28693

DMUWAM2	DI	DMUWAM2
DMUWAM2	DN	Pyronaridine
DMUWAM2	MI	TTZVSJ2
DMUWAM2	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMUWAM2	MT	DTT
DMUWAM2	MA	Inhibitor
DMUWAM2	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMUWAM2	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DM7Q41G	DI	DM7Q41G
DM7Q41G	DN	Pyruvic acid
DM7Q41G	MI	TTT2LD9
DM7Q41G	MN	GABA transaminase (ABAT)
DM7Q41G	MT	DTT
DM7Q41G	MA	Inhibitor
DM7Q41G	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM7Q41G	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DM7Q41G	DI	DM7Q41G
DM7Q41G	DN	Pyruvic acid
DM7Q41G	MI	DT342ZG
DM7Q41G	MN	Monocarboxylate transporter 1 (SLC16A1)
DM7Q41G	MT	DTP
DM7Q41G	MA	Substrate
DM7Q41G	RN	AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
DM7Q41G	RU	https://doi.org/10.1042/BJ20091515

DMGAZHU	DI	DMGAZHU
DMGAZHU	DN	Quattvaxem
DMGAZHU	MI	TT3J5ZI
DMGAZHU	MN	Cell mediated immunity response (CMIR)
DMGAZHU	MT	DTT
DMGAZHU	RN	Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9.
DMGAZHU	RU	https://pubmed.ncbi.nlm.nih.gov/15705477

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DE5IED8
DMY4D87	MN	Cytochrome P450 2C9 (CYP2C9)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DE4LYSA
DMY4D87	MN	Cytochrome P450 3A4 (CYP3A4)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006 Mar;62(3):209-15.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16416305

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	DEGTFWK
DMY4D87	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY4D87	MT	DME
DMY4D87	MA	Metabolism
DMY4D87	RN	In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
DMY4D87	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15801544

DMY4D87	DI	DMY4D87
DMY4D87	DN	Quazepam
DMY4D87	MI	TTPTXIN
DMY4D87	MN	Translocator protein (TSPO)
DMY4D87	MT	DTT
DMY4D87	MA	Modulator
DMY4D87	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMY4D87	RU	https://www.fda.gov/

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	TTPOI4B
DM3NC4M	MN	Acetyl-CoA:lyso-PAF acetyltransferase (PCAT)
DM3NC4M	MT	DTT
DM3NC4M	MA	Inhibitor
DM3NC4M	RN	Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7.
DM3NC4M	RU	https://pubmed.ncbi.nlm.nih.gov/12576520

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTI7UX6
DM3NC4M	MN	Breast cancer resistance protein (ABCG2)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM3NC4M	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTH6X7Q
DM3NC4M	MN	Feline leukemia virus subgroup C receptor-related protein 1 (SLC49A1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.1.28.1)
DM3NC4M	RU	http://www.tcdb.org/search/result.php?tc=2.A.1.28.1

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTG3T6X
DM3NC4M	MN	Glucose transporter type 1, erythrocyte/brain (SLC2A1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Oral Bioavailability and Disposition of Phytochemicals
DM3NC4M	RU	http://cdn.intechweb.org/pdfs/25496.pdf

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTLT3UG
DM3NC4M	MN	Monocarboxylate transporter 2 (SLC16A7)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DM3NC4M	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTSYQGK
DM3NC4M	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3NC4M	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTCSGPB
DM3NC4M	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3NC4M	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3NC4M	DI	DM3NC4M
DM3NC4M	DN	Quercetin
DM3NC4M	MI	DTUGYRD
DM3NC4M	MN	P-glycoprotein 1 (ABCB1)
DM3NC4M	MT	DTP
DM3NC4M	MA	Substrate
DM3NC4M	RN	Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.
DM3NC4M	RU	https://doi.org/10.1016/j.freeradbiomed.2003.11.023

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DECB0K3
DM1N62C	MN	Cytochrome P450 2D6 (CYP2D6)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DE4LYSA
DM1N62C	MN	Cytochrome P450 3A4 (CYP3A4)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22688609

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DEIBDNY
DM1N62C	MN	Cytochrome P450 3A5 (CYP3A5)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24240480

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DERD86B
DM1N62C	MN	Cytochrome P450 3A7 (CYP3A7)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	TTEX248
DM1N62C	MN	Dopamine D2 receptor (D2R)
DM1N62C	MT	DTT
DM1N62C	MA	Agonist
DM1N62C	RN	Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
DM1N62C	RU	https://pubmed.ncbi.nlm.nih.gov/19217900

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DEGTFWK
DM1N62C	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1N62C	MT	DME
DM1N62C	MA	Metabolism
DM1N62C	RN	A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
DM1N62C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15516294

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DTUGYRD
DM1N62C	MN	P-glycoprotein 1 (ABCB1)
DM1N62C	MT	DTP
DM1N62C	MA	Substrate
DM1N62C	RN	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
DM1N62C	RU	http://www.ncbi.nlm.nih.gov/pubmed/15285840

DM1N62C	DI	DM1N62C
DM1N62C	DN	Quetiapine
DM1N62C	MI	DTMJK12
DM1N62C	MN	Solute carrier family 22 member 23 (SLC22A23)
DM1N62C	MT	DTP
DM1N62C	MA	Substrate
DM1N62C	RN	Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012 Apr;12(2):165-72.
DM1N62C	RU	http://www.ncbi.nlm.nih.gov/pubmed/20921969

DM7WI4Q	DI	DM7WI4Q
DM7WI4Q	DN	Quinagolide
DM7WI4Q	MI	TTEX248
DM7WI4Q	MN	Dopamine D2 receptor (D2R)
DM7WI4Q	MT	DTT
DM7WI4Q	MA	Agonist
DM7WI4Q	RN	Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8.
DM7WI4Q	RU	https://pubmed.ncbi.nlm.nih.gov/12055141

DMR8H31	DI	DMR8H31
DMR8H31	DN	Quinapril
DMR8H31	MI	TTL69WB
DMR8H31	MN	Angiotensin-converting enzyme (ACE)
DMR8H31	MT	DTT
DMR8H31	MA	Inhibitor
DMR8H31	RN	An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50.
DMR8H31	RU	https://pubmed.ncbi.nlm.nih.gov/19270231

DMJ6H1Z	DI	DMJ6H1Z
DMJ6H1Z	DN	Quinestrol
DMJ6H1Z	MI	TTZAYWL
DMJ6H1Z	MN	Estrogen receptor (ESR)
DMJ6H1Z	MT	DTT
DMJ6H1Z	MA	Modulator
DMJ6H1Z	RN	The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007 Mar;40(3):674-84.
DMJ6H1Z	RU	https://pubmed.ncbi.nlm.nih.gov/17174166

DMWCOSR	DI	DMWCOSR
DMWCOSR	DN	Quinethazone
DMWCOSR	MI	TTUNARX
DMWCOSR	MN	Carbonic anhydrase (CA)
DMWCOSR	MT	DTT
DMWCOSR	MA	Inhibitor
DMWCOSR	RN	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
DMWCOSR	RU	https://pubmed.ncbi.nlm.nih.gov/18374572

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DES5XRU
DMLPICK	MN	Cytochrome P450 2C8 (CYP2C8)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DE5IED8
DMLPICK	MN	Cytochrome P450 2C9 (CYP2C9)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol. 1999 Dec;48(6):829-38.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10594487

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DECB0K3
DMLPICK	MN	Cytochrome P450 2D6 (CYP2D6)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. J Inorg Biochem. 2012 May;110:46-50.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22459173

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DEVDYN7
DMLPICK	MN	Cytochrome P450 2E1 (CYP2E1)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ther. 1999 Apr;289(1):31-7.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10086984

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DE4LYSA
DMLPICK	MN	Cytochrome P450 3A4 (CYP3A4)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	10th North American ISSX meeting. October 24-28, 2000. Indianapolis, Indiana, USA. Abstracts. Drug Metab Rev. 2000;32 Suppl 2:137-340.
DMLPICK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11057336

DMLPICK	DI	DMLPICK
DMLPICK	DN	Quinidine
DMLPICK	MI	DERD86B
DMLPICK	MN	Cytochrome P450 3A7 (CYP3A7)
DMLPICK	MT	DME
DMLPICK	MA	Metabolism
DMLPICK	RN	Drug Interactions Flockhart Table
DMLPICK	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEJGDUW
DMSWYF5	MN	Cytochrome P450 1A2 (CYP1A2)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther. 1999 Nov;66(5):454-60.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10579472

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DES5XRU
DMSWYF5	MN	Cytochrome P450 2C8 (CYP2C8)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DE5IED8
DMSWYF5	MN	Cytochrome P450 2C9 (CYP2C9)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8968357

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DECB0K3
DMSWYF5	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12703961

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DE4LYSA
DMSWYF5	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Quinine induced simvastatin toxicity through cytochrome inhibition - a case report. BMC Geriatr. 2016 Oct 1;16(1):168.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27716084

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEIBDNY
DMSWYF5	MN	Cytochrome P450 3A5 (CYP3A5)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Drug Interactions Flockhart Table
DMSWYF5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DERD86B
DMSWYF5	MN	Cytochrome P450 3A7 (CYP3A7)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Drug Interactions Flockhart Table
DMSWYF5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	TT05DLS
DMSWYF5	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMSWYF5	MT	DTT
DMSWYF5	MA	Modulator
DMSWYF5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSWYF5	RU	https://www.fda.gov/

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DEGTFWK
DMSWYF5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSWYF5	MT	DME
DMSWYF5	MA	Metabolism
DMSWYF5	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DMSWYF5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159893

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTBPTJF
DMSWYF5	MN	Na(+)/Cl(-) betaine/GABA transporter (SLC6A12)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.22.3.1)
DMSWYF5	RU	http://www.tcdb.org/search/result.php?tc=2.A.22.3.1

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTT79CX
DMSWYF5	MN	Organic cation transporter 1 (SLC22A1)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/11408531

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT9IDPW
DMSWYF5	MN	Organic cation transporter 2 (SLC22A2)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/9260930

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT2EG60
DMSWYF5	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10215651

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DT3HUVD
DMSWYF5	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/10525100

DMSWYF5	DI	DMSWYF5
DMSWYF5	DN	Quinine
DMSWYF5	MI	DTUGYRD
DMSWYF5	MN	P-glycoprotein 1 (ABCB1)
DMSWYF5	MT	DTP
DMSWYF5	MA	Substrate
DMSWYF5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMSWYF5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM5GVHU	DI	DM5GVHU
DM5GVHU	DN	Quinolones
DM5GVHU	MI	TT0IHXV
DM5GVHU	MN	DNA topoisomerase II (TOP2)
DM5GVHU	MT	DTT
DM5GVHU	MA	Inhibitor
DM5GVHU	RN	The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.
DM5GVHU	RU	https://pubmed.ncbi.nlm.nih.gov/15822188

DM5GVHU	DI	DM5GVHU
DM5GVHU	DN	Quinolones
DM5GVHU	MI	DTE2B1D
DM5GVHU	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM5GVHU	MT	DTP
DM5GVHU	MA	Substrate
DM5GVHU	RN	The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.14)
DM5GVHU	RU	http://www.tcdb.org/search/result.php?tc=2.A.60.1.14

DMLKFC4	DI	DMLKFC4
DMLKFC4	DN	Quinupristin
DMLKFC4	MI	TTIB7O8
DMLKFC4	MN	Bacterial Integral membrane LmrP (Bact lmrP)
DMLKFC4	MT	DTT
DMLKFC4	MA	Modulator
DMLKFC4	RN	The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80.
DMLKFC4	RU	https://pubmed.ncbi.nlm.nih.gov/11577166

DMM4U9G	DI	DMM4U9G
DMM4U9G	DN	R0-93877
DMM4U9G	MI	TT07C3Y
DMM4U9G	MN	5-HT 4 receptor (HTR4)
DMM4U9G	MT	DTT
DMM4U9G	MA	Agonist
DMM4U9G	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DMM4U9G	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMM4U9G	DI	DMM4U9G
DMM4U9G	DN	R0-93877
DMM4U9G	MI	DTUGYRD
DMM4U9G	MN	P-glycoprotein 1 (ABCB1)
DMM4U9G	MT	DTP
DMM4U9G	MA	Substrate
DMM4U9G	RN	Resolor, INN-prucalopride
DMM4U9G	RU	https://www.ema.europa.eu/documents/product-information/resolor-epar-product-information_en.pdf

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DTI7UX6
DMMZXIW	MN	Breast cancer resistance protein (ABCG2)
DMMZXIW	MT	DTP
DMMZXIW	MA	Substrate
DMMZXIW	RN	Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9.
DMMZXIW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19076159

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DE4LYSA
DMMZXIW	MN	Cytochrome P450 3A4 (CYP3A4)
DMMZXIW	MT	DME
DMMZXIW	MA	Metabolism
DMMZXIW	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DMMZXIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	TTF1QVM
DMMZXIW	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMMZXIW	MT	DTT
DMMZXIW	MA	Inhibitor
DMMZXIW	RN	Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23.
DMMZXIW	RU	https://pubmed.ncbi.nlm.nih.gov/10555605

DMMZXIW	DI	DMMZXIW
DMMZXIW	DN	Rabeprazole
DMMZXIW	MI	DEGTFWK
DMMZXIW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMMZXIW	MT	DME
DMMZXIW	MA	Metabolism
DMMZXIW	RN	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
DMMZXIW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16783561

DMFOTZ7	DI	DMFOTZ7
DMFOTZ7	DN	Racecadotril
DMFOTZ7	MI	TT8CYO4
DMFOTZ7	MN	Endopeptidase (ENP)
DMFOTZ7	MT	DTT
DMFOTZ7	MA	Modulator
DMFOTZ7	RN	A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol. 2012 May 30;3:93.
DMFOTZ7	RU	https://pubmed.ncbi.nlm.nih.gov/22661949

DMXTCVF	DI	DMXTCVF
DMXTCVF	DN	Radium-223-Dichloride
DMXTCVF	MI	TTUTN1I
DMXTCVF	MN	Human Deoxyribonucleic acid (hDNA)
DMXTCVF	MT	DTT
DMXTCVF	MA	Modulator
DMXTCVF	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMXTCVF	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DE4LYSA
DMDKF3M	MN	Cytochrome P450 3A4 (CYP3A4)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16959878

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	TTZAYWL
DMDKF3M	MN	Estrogen receptor (ESR)
DMDKF3M	MT	DTT
DMDKF3M	MA	Modulator
DMDKF3M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMDKF3M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DTUGYRD
DMDKF3M	MN	P-glycoprotein 1 (ABCB1)
DMDKF3M	MT	DTP
DMDKF3M	MA	Substrate
DMDKF3M	RN	Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
DMDKF3M	RU	https://doi.org/10.1016/j.trsl.2012.03.002

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DEYGVN4
DMDKF3M	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMDKF3M	DI	DMDKF3M
DMDKF3M	DN	Raloxifene
DMDKF3M	MI	DEL5N6Y
DMDKF3M	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMDKF3M	MT	DME
DMDKF3M	MA	Metabolism
DMDKF3M	RN	Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
DMDKF3M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23682072

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	DE6OQ3W
DMYURI6	MN	Cytochrome P450 1A1 (CYP1A1)
DMYURI6	MT	DME
DMYURI6	MA	Metabolism
DMYURI6	RN	Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
DMYURI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20926993

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	TT5FH9Y
DMYURI6	MN	Human immunodeficiency virus Integrase (HIV IN)
DMYURI6	MT	DTT
DMYURI6	MA	Modulator
DMYURI6	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMYURI6	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMYURI6	DI	DMYURI6
DMYURI6	DN	Raltegravir
DMYURI6	MI	DEYGVN4
DMYURI6	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMYURI6	MT	DME
DMYURI6	MA	Metabolism
DMYURI6	RN	Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact. 2011;26(3):139-41.
DMYURI6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21980965

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	DTI7UX6
DMT9K8G	MN	Breast cancer resistance protein (ABCG2)
DMT9K8G	MT	DTP
DMT9K8G	MA	Substrate
DMT9K8G	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMT9K8G	RU	https://doi.org/10.2217/14622416.9.8.1005

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	TTU6BFZ
DMT9K8G	MN	Candida Thymidylate synthase (Candi TMP1)
DMT9K8G	MT	DTT
DMT9K8G	MA	Inhibitor
DMT9K8G	RN	DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
DMT9K8G	RU	https://pubmed.ncbi.nlm.nih.gov/18773878

DMT9K8G	DI	DMT9K8G
DMT9K8G	DN	Raltitrexed
DMT9K8G	MI	DTFI42L
DMT9K8G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMT9K8G	MT	DTP
DMT9K8G	MA	Substrate
DMT9K8G	RN	Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
DMT9K8G	RU	http://cancerres.aacrjournals.org/content/59/11/2532

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DEJGDUW
DM7IW9J	MN	Cytochrome P450 1A2 (CYP1A2)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DE4LYSA
DM7IW9J	MN	Cytochrome P450 3A4 (CYP3A4)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20478852

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	TT0WAIE
DM7IW9J	MN	Melatonin receptor type 1A (MTNR1A)
DM7IW9J	MT	DTT
DM7IW9J	MA	Modulator
DM7IW9J	RN	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
DM7IW9J	RU	https://pubmed.ncbi.nlm.nih.gov/24228714

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	TT32JK8
DM7IW9J	MN	Melatonin receptor type 1B (MTNR1B)
DM7IW9J	MT	DTT
DM7IW9J	MA	Modulator
DM7IW9J	RN	MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85.
DM7IW9J	RU	https://pubmed.ncbi.nlm.nih.gov/24228714

DM7IW9J	DI	DM7IW9J
DM7IW9J	DN	Ramelteon
DM7IW9J	MI	DEGTFWK
DM7IW9J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM7IW9J	MT	DME
DM7IW9J	MA	Metabolism
DM7IW9J	RN	Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
DM7IW9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23861638

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	TTL69WB
DM2R68E	MN	Angiotensin-converting enzyme (ACE)
DM2R68E	MT	DTT
DM2R68E	MA	Inhibitor
DM2R68E	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM2R68E	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	DT9G7XN
DM2R68E	MN	Peptide transporter 1 (SLC15A1)
DM2R68E	MT	DTP
DM2R68E	MA	Substrate
DM2R68E	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM2R68E	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM2R68E	DI	DM2R68E
DM2R68E	DN	Ramipril
DM2R68E	MI	DT8QKNP
DM2R68E	MN	Peptide transporter 2 (SLC15A2)
DM2R68E	MT	DTP
DM2R68E	MA	Substrate
DM2R68E	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM2R68E	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	TTNXLKE
DMH7GN8	MN	5-HT 3 receptor (5HT3R)
DMH7GN8	MT	DTT
DMH7GN8	MA	Modulator
DMH7GN8	RN	Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12.
DMH7GN8	RU	https://pubmed.ncbi.nlm.nih.gov/7498299

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	TT85JO3
DMH7GN8	MN	5-HT receptor (5HTR)
DMH7GN8	MT	DTT
DMH7GN8	MA	Modulator
DMH7GN8	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMH7GN8	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	DEJGDUW
DMH7GN8	MN	Cytochrome P450 1A2 (CYP1A2)
DMH7GN8	MT	DME
DMH7GN8	MA	Metabolism
DMH7GN8	RN	Ondansetron, ramosetron, or palonosetron: which is a better choice of antiemetic to prevent postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy? Anesth Essays Res. 2011 Jul-Dec;5(2):182-6.
DMH7GN8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25885385

DMH7GN8	DI	DMH7GN8
DMH7GN8	DN	Ramosetron
DMH7GN8	MI	DTUGYRD
DMH7GN8	MN	P-glycoprotein 1 (ABCB1)
DMH7GN8	MT	DTP
DMH7GN8	MA	Substrate
DMH7GN8	RN	Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. J Pharm Pharmacol. 2002 Aug;54(8):1055-63.
DMH7GN8	RU	https://doi.org/10.1211/002235702320266208

DMWUFQ4	DI	DMWUFQ4
DMWUFQ4	DN	Ramucirumab
DMWUFQ4	MI	TTUTJGQ
DMWUFQ4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMWUFQ4	MT	DTT
DMWUFQ4	MA	Modulator
DMWUFQ4	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMWUFQ4	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMSYPNW	DI	DMSYPNW
DMSYPNW	DN	Ranibizumab
DMSYPNW	MI	TTOHSBA
DMSYPNW	MN	Vascular endothelial growth factor A (VEGFA)
DMSYPNW	MT	DTT
DMSYPNW	RN	Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
DMSYPNW	RU	https://pubmed.ncbi.nlm.nih.gov/17031284

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEJGDUW
DM0GUSX	MN	Cytochrome P450 1A2 (CYP1A2)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10223772

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DECB0K3
DM0GUSX	MN	Cytochrome P450 2D6 (CYP2D6)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEBMX7C
DM0GUSX	MN	Dimethylaniline oxidase 5 (FMO5)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
DM0GUSX	RU	https://pubmed.ncbi.nlm.nih.gov/27678284

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	TTQHJ1K
DM0GUSX	MN	Histamine H2 receptor (H2R)
DM0GUSX	MT	DTT
DM0GUSX	MA	Antagonist
DM0GUSX	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DM0GUSX	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DEGTFWK
DM0GUSX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0GUSX	MT	DME
DM0GUSX	MA	Metabolism
DM0GUSX	RN	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
DM0GUSX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11128045

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DT0OC1Q
DM0GUSX	MN	Organic anion transporter 2 (SLC22A7)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTVP67E
DM0GUSX	MN	Organic anion transporter 3 (SLC22A8)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTT79CX
DM0GUSX	MN	Organic cation transporter 1 (SLC22A1)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16141367

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DT9IDPW
DM0GUSX	MN	Organic cation transporter 2 (SLC22A2)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/16006492

DM0GUSX	DI	DM0GUSX
DM0GUSX	DN	Ranitidine
DM0GUSX	MI	DTUGYRD
DM0GUSX	MN	P-glycoprotein 1 (ABCB1)
DM0GUSX	MT	DTP
DM0GUSX	MA	Substrate
DM0GUSX	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM0GUSX	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DECB0K3
DM0C9IL	MN	Cytochrome P450 2D6 (CYP2D6)
DM0C9IL	MT	DME
DM0C9IL	MA	Metabolism
DM0C9IL	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DM0C9IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DE4LYSA
DM0C9IL	MN	Cytochrome P450 3A4 (CYP3A4)
DM0C9IL	MT	DME
DM0C9IL	MA	Metabolism
DM0C9IL	RN	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
DM0C9IL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26979079

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	DTUGYRD
DM0C9IL	MN	P-glycoprotein 1 (ABCB1)
DM0C9IL	MT	DTP
DM0C9IL	MA	Substrate
DM0C9IL	RN	Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
DM0C9IL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20876828

DM0C9IL	DI	DM0C9IL
DM0C9IL	DN	Ranolazine
DM0C9IL	MI	TTP86E2
DM0C9IL	MN	Plasminogen (PLG)
DM0C9IL	MT	DTT
DM0C9IL	MA	Modulator
DM0C9IL	RN	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
DM0C9IL	RU	https://pubmed.ncbi.nlm.nih.gov/23694890

DM3WKQ4	DI	DM3WKQ4
DM3WKQ4	DN	Rasagiline
DM3WKQ4	MI	DEJGDUW
DM3WKQ4	MN	Cytochrome P450 1A2 (CYP1A2)
DM3WKQ4	MT	DME
DM3WKQ4	MA	Metabolism
DM3WKQ4	RN	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
DM3WKQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17296539

DM3WKQ4	DI	DM3WKQ4
DM3WKQ4	DN	Rasagiline
DM3WKQ4	MI	TTGP7BY
DM3WKQ4	MN	Monoamine oxidase type B (MAO-B)
DM3WKQ4	MT	DTT
DM3WKQ4	MA	Inhibitor
DM3WKQ4	RN	Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
DM3WKQ4	RU	https://pubmed.ncbi.nlm.nih.gov/19526291

DMWTVAN	DI	DMWTVAN
DMWTVAN	DN	Rauwolfia serpentina root
DMWTVAN	MI	TTZIFHC
DMWTVAN	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMWTVAN	MT	DTT
DMWTVAN	MA	Inhibitor
DMWTVAN	RN	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
DMWTVAN	RU	https://pubmed.ncbi.nlm.nih.gov/7562902

DMSWNJF	DI	DMSWNJF
DMSWNJF	DN	Ravulizumab
DMSWNJF	MI	TTKANGO
DMSWNJF	MN	Complement C5 (CO5)
DMSWNJF	MT	DTT
DMSWNJF	MA	Inhibitor
DMSWNJF	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMSWNJF	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM7QG0M	DI	DM7QG0M
DM7QG0M	DN	Raxibacumab
DM7QG0M	MI	TT3YGCD
DM7QG0M	MN	Bacterial Protective antigen (Bact pagA)
DM7QG0M	MT	DTT
DM7QG0M	MA	Modulator
DM7QG0M	RN	Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
DM7QG0M	RU	https://pubmed.ncbi.nlm.nih.gov/21383241

DM26PRD	DI	DM26PRD
DM26PRD	DN	Reboxetine
DM26PRD	MI	DE4LYSA
DM26PRD	MN	Cytochrome P450 3A4 (CYP3A4)
DM26PRD	MT	DME
DM26PRD	MA	Metabolism
DM26PRD	RN	Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27.
DM26PRD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11192474

DM26PRD	DI	DM26PRD
DM26PRD	DN	Reboxetine
DM26PRD	MI	TTAWNKZ
DM26PRD	MN	Norepinephrine transporter (NET)
DM26PRD	MT	DTT
DM26PRD	MA	Inhibitor
DM26PRD	RN	Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
DM26PRD	RU	https://pubmed.ncbi.nlm.nih.gov/11249515

DMY7ESM	DI	DMY7ESM
DMY7ESM	DN	Recombinant Factor IX
DMY7ESM	MI	TTFEZ5Q
DMY7ESM	MN	Coagulation factor IX (F9)
DMY7ESM	MT	DTT
DMY7ESM	MA	Modulator
DMY7ESM	RN	BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80.
DMY7ESM	RU	https://pubmed.ncbi.nlm.nih.gov/25324957

DMMPCFX	DI	DMMPCFX
DMMPCFX	DN	Recombinant human endostatin
DMMPCFX	MI	TTRPKQG
DMMPCFX	MN	Beta-catenin (CTNNB1)
DMMPCFX	MT	DTT
DMMPCFX	MA	Modulator
DMMPCFX	RN	Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463.
DMMPCFX	RU	https://pubmed.ncbi.nlm.nih.gov/25232946

DM76VHG	DI	DM76VHG
DM76VHG	DN	Regadenoson
DM76VHG	MI	TTM2AOE
DM76VHG	MN	Adenosine A2a receptor (ADORA2A)
DM76VHG	MT	DTT
DM76VHG	MA	Modulator
DM76VHG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM76VHG	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM87XSN	DI	DM87XSN
DM87XSN	DN	REGN-727
DM87XSN	MI	TTBRG7E
DM87XSN	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM87XSN	MT	DTT
DM87XSN	RN	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36.
DM87XSN	RU	https://pubmed.ncbi.nlm.nih.gov/22633824

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTI7UX6
DMHSY1I	MN	Breast cancer resistance protein (ABCG2)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMHSY1I	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DE4LYSA
DMHSY1I	MN	Cytochrome P450 3A4 (CYP3A4)
DMHSY1I	MT	DME
DMHSY1I	MA	Metabolism
DMHSY1I	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DMHSY1I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTFI42L
DMHSY1I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25739790

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DT3D8F0
DMHSY1I	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25739790

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DTUGYRD
DMHSY1I	MN	P-glycoprotein 1 (ABCB1)
DMHSY1I	MT	DTP
DMHSY1I	MA	Substrate
DMHSY1I	RN	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res. 2015 Jul;32(7):2205-16.
DMHSY1I	RU	http://www.ncbi.nlm.nih.gov/pubmed/25563977

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TT4DXQT
DMHSY1I	MN	Proto-oncogene c-Ret (RET)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TTX41N9
DMHSY1I	MN	Tyrosine-protein kinase Kit (KIT)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	DE85D2P
DMHSY1I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMHSY1I	MT	DME
DMHSY1I	MA	Metabolism
DMHSY1I	RN	FDA Label of Regorafenib. The 2020 official website of the U.S. Food and Drug Administration.
DMHSY1I	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf

DMHSY1I	DI	DMHSY1I
DMHSY1I	DN	Regorafenib
DMHSY1I	MI	TTUTJGQ
DMHSY1I	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHSY1I	MT	DTT
DMHSY1I	MA	Modulator
DMHSY1I	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMHSY1I	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMK7IWL	DI	DMK7IWL
DMK7IWL	DN	Relugolix
DMK7IWL	MI	TT8R70G
DMK7IWL	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMK7IWL	MT	DTT
DMK7IWL	MA	Antagonist
DMK7IWL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMK7IWL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf

DMK7IWL	DI	DMK7IWL
DMK7IWL	DN	Relugolix
DMK7IWL	MI	DTUGYRD
DMK7IWL	MN	P-glycoprotein 1 (ABCB1)
DMK7IWL	MT	DTP
DMK7IWL	MA	Substrate
DMK7IWL	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMK7IWL	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMBFZ6L	DI	DMBFZ6L
DMBFZ6L	DN	Remdesivir
DMBFZ6L	MI	TTV1095
DMBFZ6L	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMBFZ6L	MT	DTT
DMBFZ6L	MA	Inhibitor
DMBFZ6L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBFZ6L	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf

DMZTXCH	DI	DMZTXCH
DMZTXCH	DN	Remifentanil
DMZTXCH	MI	TTKWM86
DMZTXCH	MN	Opioid receptor mu (MOP)
DMZTXCH	MT	DTT
DMZTXCH	MA	Agonist
DMZTXCH	RN	The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96.
DMZTXCH	RU	https://pubmed.ncbi.nlm.nih.gov/19058913

DMNAKLY	DI	DMNAKLY
DMNAKLY	DN	Remikiren
DMNAKLY	MI	TTB2MXP
DMNAKLY	MN	Angiotensinogenase renin (REN)
DMNAKLY	MT	DTT
DMNAKLY	MA	Inhibitor
DMNAKLY	RN	Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9.
DMNAKLY	RU	https://pubmed.ncbi.nlm.nih.gov/16189286

DMLVSYX	DI	DMLVSYX
DMLVSYX	DN	Remimazolam
DMLVSYX	MI	TTEX6LM
DMLVSYX	MN	GABA(A) receptor gamma-3 (GABRG3)
DMLVSYX	MT	DTT
DMLVSYX	MA	Agonist
DMLVSYX	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMLVSYX	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	TTP835K
DM5SXUV	MN	ATP-binding cassette transporter C8 (ABCC8)
DM5SXUV	MT	DTT
DM5SXUV	MA	Blocker
DM5SXUV	RN	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
DM5SXUV	RU	https://pubmed.ncbi.nlm.nih.gov/19478691

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	TTEF5MJ
DM5SXUV	MN	ATP-binding cassette transporter C9 (ABCC9)
DM5SXUV	MT	DTT
DM5SXUV	MA	Blocker
DM5SXUV	RN	Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
DM5SXUV	RU	https://pubmed.ncbi.nlm.nih.gov/19478691

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DES5XRU
DM5SXUV	MN	Cytochrome P450 2C8 (CYP2C8)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DE4LYSA
DM5SXUV	MN	Cytochrome P450 3A4 (CYP3A4)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17253883

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DT3D8F0
DM5SXUV	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM5SXUV	MT	DTP
DM5SXUV	MA	Substrate
DM5SXUV	RN	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
DM5SXUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/29756222

DM5SXUV	DI	DM5SXUV
DM5SXUV	DN	Repaglinide
DM5SXUV	MI	DEYGVN4
DM5SXUV	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM5SXUV	MT	DME
DM5SXUV	MA	Metabolism
DM5SXUV	RN	Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
DM5SXUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21175442

DM6KI0D	DI	DM6KI0D
DM6KI0D	DN	Repirinast
DM6KI0D	MI	TT7CXIM
DM6KI0D	MN	Histamine receptor (HR)
DM6KI0D	MT	DTT
DM6KI0D	MA	Modulator
DM6KI0D	RN	Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
DM6KI0D	RU	https://pubmed.ncbi.nlm.nih.gov/1378339

DMG7SQK	DI	DMG7SQK
DMG7SQK	DN	Rescinnamine
DMG7SQK	MI	TTL69WB
DMG7SQK	MN	Angiotensin-converting enzyme (ACE)
DMG7SQK	MT	DTT
DMG7SQK	MA	Inhibitor
DMG7SQK	RN	Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51.
DMG7SQK	RU	https://pubmed.ncbi.nlm.nih.gov/16431399

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	DTI7UX6
DM6VM38	MN	Breast cancer resistance protein (ABCG2)
DM6VM38	MT	DTP
DM6VM38	MA	Substrate
DM6VM38	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM6VM38	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	DTUGYRD
DM6VM38	MN	P-glycoprotein 1 (ABCB1)
DM6VM38	MT	DTP
DM6VM38	MA	Substrate
DM6VM38	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM6VM38	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM6VM38	DI	DM6VM38
DM6VM38	DN	Reserpine
DM6VM38	MI	TTNZRI3
DM6VM38	MN	Synaptic vesicle amine transporter (SLC18A2)
DM6VM38	MT	DTT
DM6VM38	MA	Blocker
DM6VM38	RN	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
DM6VM38	RU	https://pubmed.ncbi.nlm.nih.gov/19571144

DM0AUCH	DI	DM0AUCH
DM0AUCH	DN	Reslizumab
DM0AUCH	MI	TTPREZD
DM0AUCH	MN	Interleukin-5 (IL5)
DM0AUCH	MT	DTT
DM0AUCH	MA	Modulator
DM0AUCH	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DM0AUCH	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DM9JXB7	DI	DM9JXB7
DM9JXB7	DN	Retapamulin
DM9JXB7	MI	TTUWYEA
DM9JXB7	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM9JXB7	MT	DTT
DM9JXB7	MA	Inhibitor
DM9JXB7	RN	Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
DM9JXB7	RU	https://pubmed.ncbi.nlm.nih.gov/17562806

DML0D1P	DI	DML0D1P
DML0D1P	DN	Reteplase
DML0D1P	MI	TTP86E2
DML0D1P	MN	Plasminogen (PLG)
DML0D1P	MT	DTT
DML0D1P	MA	Activator
DML0D1P	RN	Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23.
DML0D1P	RU	https://pubmed.ncbi.nlm.nih.gov/18673235

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DE6OQ3W
DMGNYIH	MN	Cytochrome P450 1A1 (CYP1A1)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DEYGVN4
DMGNYIH	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism. 2006 Jun;55(6):711-21.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16713428

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DEF2WXN
DMGNYIH	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	DE85D2P
DMGNYIH	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMGNYIH	MT	DME
DMGNYIH	MA	Metabolism
DMGNYIH	RN	Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
DMGNYIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10220490

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	TTQ29KF
DMGNYIH	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DMGNYIH	MT	DTT
DMGNYIH	MA	Activator
DMGNYIH	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMGNYIH	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMGNYIH	DI	DMGNYIH
DMGNYIH	DN	Retigabine
DMGNYIH	MI	TTIVDM3
DMGNYIH	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMGNYIH	MT	DTT
DMGNYIH	MA	Modulator
DMGNYIH	RN	The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12.
DMGNYIH	RU	https://pubmed.ncbi.nlm.nih.gov/22428574

DMMP5SI	DI	DMMP5SI
DMMP5SI	DN	Revefenacin
DMMP5SI	MI	DECB0K3
DMMP5SI	MN	Cytochrome P450 2D6 (CYP2D6)
DMMP5SI	MT	DME
DMMP5SI	MA	Metabolism
DMMP5SI	RN	A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir Res. 2017 Nov 2;18(1):182.
DMMP5SI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29096627

DMMP5SI	DI	DMMP5SI
DMMP5SI	DN	Revefenacin
DMMP5SI	MI	TTOXS3C
DMMP5SI	MN	Muscarinic acetylcholine receptor (CHRM)
DMMP5SI	MT	DTT
DMMP5SI	MA	Antagonist
DMMP5SI	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMMP5SI	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM8LRU2	DI	DM8LRU2
DM8LRU2	DN	Revolade/Promacta
DM8LRU2	MI	TTIHYA4
DM8LRU2	MN	Thrombopoietin receptor (MPL)
DM8LRU2	MT	DTT
DM8LRU2	MA	Agonist
DM8LRU2	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM8LRU2	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM69XMQ	DI	DM69XMQ
DM69XMQ	DN	RG-7446
DM69XMQ	MI	TT8ZLTI
DM69XMQ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM69XMQ	MT	DTT
DM69XMQ	RN	PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
DM69XMQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/

DMNF0G8	DI	DMNF0G8
DMNF0G8	DN	Rh-alphaglucosidase
DMNF0G8	MI	TTXWASR
DMNF0G8	MN	Intestinal maltase-glucoamylase (MGAM)
DMNF0G8	MT	DTT
DMNF0G8	MA	Modulator
DMNF0G8	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMNF0G8	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DM3ADGP	DI	DM3ADGP
DM3ADGP	DN	Rhucin
DM3ADGP	MI	TTVQ6R9
DM3ADGP	MN	C1 esterase inhibitor (SERPING1)
DM3ADGP	MT	DTT
DM3ADGP	MA	Modulator
DM3ADGP	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM3ADGP	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM3ADGP	DI	DM3ADGP
DM3ADGP	DN	Rhucin
DM3ADGP	MI	TTJ0IQB
DM3ADGP	MN	Phosphodiesterase 5A (PDE5A)
DM3ADGP	MT	DTT
DM3ADGP	MA	Inhibitor
DM3ADGP	RN	cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
DM3ADGP	RU	https://pubmed.ncbi.nlm.nih.gov/19546307

DMALNG0	DI	DMALNG0
DMALNG0	DN	RHuEPO
DMALNG0	MI	TTAUX24
DMALNG0	MN	Erythropoietin Receptor (EPOR)
DMALNG0	MT	DTT
DMALNG0	MA	Stimulator
DMALNG0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
DMALNG0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT4YL5R
DMEYLH9	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophys Chem. 2010 Mar;147(1-2):59-65.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/20096989

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT82KPY
DMEYLH9	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/17700367

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DE1DOKJ
DMEYLH9	MN	Cytosolic 5'-nucleotidase II (NT5C2)
DMEYLH9	MT	DME
DMEYLH9	MA	Metabolism
DMEYLH9	RN	Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother. 2005 Jun;49(6):2164-71.
DMEYLH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15917509

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DTXD1TQ
DMEYLH9	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet. 2013;28(5):406-10.
DMEYLH9	RU	http://www.ncbi.nlm.nih.gov/pubmed/23459628

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	TTL7C8Q
DMEYLH9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMEYLH9	MT	DTT
DMEYLH9	MA	Inhibitor
DMEYLH9	RN	Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
DMEYLH9	RU	https://pubmed.ncbi.nlm.nih.gov/16293677

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DT9G7XN
DMEYLH9	MN	Peptide transporter 1 (SLC15A1)
DMEYLH9	MT	DTP
DMEYLH9	MA	Substrate
DMEYLH9	RN	Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J Pharm Sci. 2006 Jun;95(6):1318-25.
DMEYLH9	RU	https://doi.org/10.1002/jps.20434

DMEYLH9	DI	DMEYLH9
DMEYLH9	DN	Ribavirin
DMEYLH9	MI	DE2WSAL
DMEYLH9	MN	Purine nucleoside phosphorylase (PNP)
DMEYLH9	MT	DME
DMEYLH9	MA	Metabolism
DMEYLH9	RN	Functional analysis of purine nucleoside phosphorylase as a key enzyme in ribavirin metabolism. Drug Metab Pharmacokinet. 2014;29(2):211-4.
DMEYLH9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24107682

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	TT0PG8F
DM9CIUW	MN	Cyclin-dependent kinase 4 (CDK4)
DM9CIUW	MT	DTT
DM9CIUW	MA	Modulator
DM9CIUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM9CIUW	RU	https://www.fda.gov/

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	TTO0FDJ
DM9CIUW	MN	Cyclin-dependent kinase 6 (CDK6)
DM9CIUW	MT	DTT
DM9CIUW	MA	Modulator
DM9CIUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM9CIUW	RU	https://www.fda.gov/

DM9CIUW	DI	DM9CIUW
DM9CIUW	DN	Ribociclib succinate
DM9CIUW	MI	DE4LYSA
DM9CIUW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9CIUW	MT	DME
DM9CIUW	MA	Metabolism
DM9CIUW	RN	P-glycoprotein limits ribociclib brain exposure and CYP3A4 restricts its oral bioavailability. Mol Pharm. 2019 Sep 3;16(9):3842-3852.
DM9CIUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31329454

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DER6BCE
DM8YMWE	MN	Acid phosphatase-like protein 1 (ACP6)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTI7UX6
DM8YMWE	MN	Breast cancer resistance protein (ABCG2)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007 Feb;27(4):1247-53.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/17145775

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE6OQ3W
DM8YMWE	MN	Cytochrome P450 1A1 (CYP1A1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
DM8YMWE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9512490

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DETE84Z
DM8YMWE	MN	Eosinophil peroxidase (EPX)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE21PLI
DM8YMWE	MN	NADPH-dependent nitroreductase (nfrA1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Conversion of NfsA, the major Escherichia coli nitroreductase, to a flavin reductase with an activity similar to that of Frp, a flavin reductase in Vibrio harveyi, by a single amino acid substitution. J Bacteriol. 1998 Jan;180(2):422-5.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/9440535

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE82GV7
DM8YMWE	MN	NADPH-dependent oxidoreductase (nfrA)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev. 2008 May;32(3):474-500.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/18355273

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE0K82S
DM8YMWE	MN	Nitroreductase (NTR)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	Purification and characterization of wild-type and mutant "classical" nitroreductases of Salmonella typhimurium. L33R mutation greatly diminishes binding of FMN to the nitroreductase of S. typhimurium. J Biol Chem. 1998 Sep 11;273(37):23922-8.
DM8YMWE	RU	https://pubmed.ncbi.nlm.nih.gov/9727006

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DEDW5H6
DM8YMWE	MN	Prostatic acid phosphatase (ACP3)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DT7NOKR
DM8YMWE	MN	Riboflavin transporter 1 (SLC52A1)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTBVQIO
DM8YMWE	MN	Riboflavin transporter 2 (SLC52A3)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DTAVOS6
DM8YMWE	MN	Riboflavin transporter 3 (SLC52A2)
DM8YMWE	MT	DTP
DM8YMWE	MA	Substrate
DM8YMWE	RN	An intronic variation in SLC52A1 causes exon skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Mol Genet Metab. 2017 Dec;122(4):182-188.
DM8YMWE	RU	http://www.ncbi.nlm.nih.gov/pubmed/29122468

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DESITDW
DM8YMWE	MN	Tartrate-resistant acid ATPase (ACP5)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DE3OZT4
DM8YMWE	MN	Testicular acid phosphatase (ACP4)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DM8YMWE	DI	DM8YMWE
DM8YMWE	DN	Riboflavin
DM8YMWE	MI	DEGSUI0
DM8YMWE	MN	Xylosyl phosphatase (PXYLP1)
DM8YMWE	MT	DME
DM8YMWE	MA	Metabolism
DM8YMWE	RN	An atlas of human metabolism. Sci Signal. 2020 Mar 24;13(624). pii: eaaz1482. (Reaction HMR_6507)
DM8YMWE	RU	https://www.metabolicatlas.org/explore/gem-browser/human1/reaction/HMR_6507

DMWH9CN	DI	DMWH9CN
DMWH9CN	DN	Ridogrel
DMWH9CN	MI	TT2O84V
DMWH9CN	MN	Thromboxane A2 receptor (TBXA2R)
DMWH9CN	MT	DTT
DMWH9CN	MA	Binder
DMWH9CN	RN	Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
DMWH9CN	RU	https://pubmed.ncbi.nlm.nih.gov/19337130

DM1YBHK	DI	DM1YBHK
DM1YBHK	DN	Rifabutin
DM1YBHK	MI	DE4LYSA
DM1YBHK	MN	Cytochrome P450 3A4 (CYP3A4)
DM1YBHK	MT	DME
DM1YBHK	MA	Metabolism
DM1YBHK	RN	The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998 Apr;63(4):414-21.
DM1YBHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9585795

DM1YBHK	DI	DM1YBHK
DM1YBHK	DN	Rifabutin
DM1YBHK	MI	TTHKJLN
DM1YBHK	MN	DNA-directed RNA polymerase (RNAP)
DM1YBHK	MT	DTT
DM1YBHK	MA	Modulator
DM1YBHK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1YBHK	RU	https://www.fda.gov/

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEJGDUW
DM5DSFZ	MN	Cytochrome P450 1A2 (CYP1A2)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642468

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEPKLMQ
DM5DSFZ	MN	Cytochrome P450 2B6 (CYP2B6)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity. Clin Pharmacol Ther. 2006 Jul;80(1):75-84.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16815319

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE5IED8
DM5DSFZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DECB0K3
DM5DSFZ	MN	Cytochrome P450 2D6 (CYP2D6)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20035023

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEVDYN7
DM5DSFZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Protective effect of rifampicin against acute liver injury induced by carbon tetrachloride in mice. Jpn J Pharmacol. 1995 Dec;69(4):325-34.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8786635

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE4LYSA
DM5DSFZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 Aug;50(8):951-9.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124517

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DEGTFWK
DM5DSFZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
DM5DSFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12426514

DM5DSFZ	DI	DM5DSFZ
DM5DSFZ	DN	Rifampicin
DM5DSFZ	MI	DE6PKFB
DM5DSFZ	MN	Rifampicin monooxygenase (rox)
DM5DSFZ	MT	DME
DM5DSFZ	MA	Metabolism
DM5DSFZ	RN	Mechanism of rifampicin inactivation in Nocardia farcinica. PLoS One. 2016 Oct 5;11(10):e0162578.
DM5DSFZ	RU	https://pubmed.ncbi.nlm.nih.gov/27706151

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	TTIJ5EB
DMA8J1G	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMA8J1G	MT	DTT
DMA8J1G	MA	Inhibitor
DMA8J1G	RN	Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67.
DMA8J1G	RU	https://pubmed.ncbi.nlm.nih.gov/11751823

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTI7UX6
DMA8J1G	MN	Breast cancer resistance protein (ABCG2)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DMA8J1G	RU	https://doi.org/10.1042/BJ20040791

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTFI42L
DMA8J1G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/19844775

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DT3D8F0
DMA8J1G	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/12490595

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DT9C1TS
DMA8J1G	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/12085361

DMA8J1G	DI	DMA8J1G
DMA8J1G	DN	Rifampin
DMA8J1G	MI	DTUGYRD
DMA8J1G	MN	P-glycoprotein 1 (ABCB1)
DMA8J1G	MT	DTP
DMA8J1G	MA	Substrate
DMA8J1G	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMA8J1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TTR6YA2
DMEH3O7	MN	Bacterial RNA polymerase sigma factor SigA (Bact sigA)
DMEH3O7	MT	DTT
DMEH3O7	MA	Modulator
DMEH3O7	RN	NCBI report
DMEH3O7	RU	http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TT79JGK
DMEH3O7	MN	Mycobacterium RNA polymerase (MycB RNAP)
DMEH3O7	MT	DTT
DMEH3O7	MA	Inhibitor
DMEH3O7	RN	Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. 
DMEH3O7	RU	https://pubmed.ncbi.nlm.nih.gov/28559332

DMEH3O7	DI	DMEH3O7
DMEH3O7	DN	Rifamycin
DMEH3O7	MI	TTS31JH
DMEH3O7	MN	Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB)
DMEH3O7	MT	DTT
DMEH3O7	MA	Modulator
DMEH3O7	RN	NCBI report
DMEH3O7	RU	http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR

DMCHV4I	DI	DMCHV4I
DMCHV4I	DN	Rifapentine
DMCHV4I	MI	DE4LYSA
DMCHV4I	MN	Cytochrome P450 3A4 (CYP3A4)
DMCHV4I	MT	DME
DMCHV4I	MA	Metabolism
DMCHV4I	RN	Inhibitory potential of twenty five anti-tuberculosis drugs on CYP activities in human liver microsomes. Biol Pharm Bull. 2015;38(9):1425-9.
DMCHV4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26094899

DMCHV4I	DI	DMCHV4I
DMCHV4I	DN	Rifapentine
DMCHV4I	MI	TTHKJLN
DMCHV4I	MN	DNA-directed RNA polymerase (RNAP)
DMCHV4I	MT	DTT
DMCHV4I	MA	Binder
DMCHV4I	RN	Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7.
DMCHV4I	RU	https://pubmed.ncbi.nlm.nih.gov/9661035

DMW1TV2	DI	DMW1TV2
DMW1TV2	DN	Rifaximin
DMW1TV2	MI	DE4LYSA
DMW1TV2	MN	Cytochrome P450 3A4 (CYP3A4)
DMW1TV2	MT	DME
DMW1TV2	MA	Metabolism
DMW1TV2	RN	Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011 May;45(5):e25.
DMW1TV2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21505109

DMW1TV2	DI	DMW1TV2
DMW1TV2	DN	Rifaximin
DMW1TV2	MI	DTUGYRD
DMW1TV2	MN	P-glycoprotein 1 (ABCB1)
DMW1TV2	MT	DTP
DMW1TV2	MA	Substrate
DMW1TV2	RN	Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
DMW1TV2	RU	http://www.ncbi.nlm.nih.gov/pubmed/28204967

DM13PQW	DI	DM13PQW
DM13PQW	DN	Rilmenidine
DM13PQW	MI	TT2NUT5
DM13PQW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM13PQW	MT	DTT
DM13PQW	MA	Modulator
DM13PQW	RN	Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
DM13PQW	RU	https://pubmed.ncbi.nlm.nih.gov/8921215

DMGLUQS	DI	DMGLUQS
DMGLUQS	DN	Rilonacept
DMGLUQS	MI	TTRYK0X
DMGLUQS	MN	Interleukin-1 beta (IL1B)
DMGLUQS	MT	DTT
DMGLUQS	MA	Modulator
DMGLUQS	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMGLUQS	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DE4LYSA
DMJ0QOW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23428312

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	TT84ETX
DMJ0QOW	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJ0QOW	MT	DTT
DMJ0QOW	MA	Inhibitor
DMJ0QOW	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMJ0QOW	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DEGTFWK
DMJ0QOW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27799217

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DEYGVN4
DMJ0QOW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	DELOY3P
DMJ0QOW	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMJ0QOW	MT	DME
DMJ0QOW	MA	Metabolism
DMJ0QOW	RN	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
DMJ0QOW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23917319

DMJ0QOW	DI	DMJ0QOW
DMJ0QOW	DN	Rilpivirine
DMJ0QOW	MI	TT90XZ8
DMJ0QOW	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMJ0QOW	MT	DTT
DMJ0QOW	MA	Inhibitor
DMJ0QOW	RN	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
DMJ0QOW	RU	https://pubmed.ncbi.nlm.nih.gov/15044438

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DTI7UX6
DMECBWN	MN	Breast cancer resistance protein (ABCG2)
DMECBWN	MT	DTP
DMECBWN	MA	Substrate
DMECBWN	RN	Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6.
DMECBWN	RU	http://www.ncbi.nlm.nih.gov/pubmed/19146924

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DE6OQ3W
DMECBWN	MN	Cytochrome P450 1A1 (CYP1A1)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DEJGDUW
DMECBWN	MN	Cytochrome P450 1A2 (CYP1A2)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15752377

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	DEYGVN4
DMECBWN	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMECBWN	MT	DME
DMECBWN	MA	Metabolism
DMECBWN	RN	Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997 Sep;282(3):1465-72.
DMECBWN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9316860

DMECBWN	DI	DMECBWN
DMECBWN	DN	Riluzole
DMECBWN	MI	TTN9VTF
DMECBWN	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMECBWN	MT	DTT
DMECBWN	MA	Blocker
DMECBWN	RN	Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90.
DMECBWN	RU	https://pubmed.ncbi.nlm.nih.gov/12440368

DM5DWMU	DI	DM5DWMU
DM5DWMU	DN	Rimantadine
DM5DWMU	MI	TTXT3PU
DM5DWMU	MN	Influenza M2 protein (Influ M)
DM5DWMU	MT	DTT
DM5DWMU	MA	Inhibitor
DM5DWMU	RN	Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.
DM5DWMU	RU	https://pubmed.ncbi.nlm.nih.gov/19215710

DMHOAUG	DI	DMHOAUG
DMHOAUG	DN	Rimegepant
DMHOAUG	MI	TTY6O0Q
DMHOAUG	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMHOAUG	MT	DTT
DMHOAUG	MA	Antagonist
DMHOAUG	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMHOAUG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf

DMTAREC	DI	DMTAREC
DMTAREC	DN	Rimexolone
DMTAREC	MI	DE4LYSA
DMTAREC	MN	Cytochrome P450 3A4 (CYP3A4)
DMTAREC	MT	DME
DMTAREC	MA	Metabolism
DMTAREC	RN	Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011 Jan;39(1):151-9.
DMTAREC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20966043

DMTAREC	DI	DMTAREC
DMTAREC	DN	Rimexolone
DMTAREC	MI	TTPNQAC
DMTAREC	MN	Estrogen-related receptor-alpha (ESRRA)
DMTAREC	MT	DTT
DMTAREC	MA	Modulator
DMTAREC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622).
DMTAREC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622

DMA47C6	DI	DMA47C6
DMA47C6	DN	Rimiterol
DMA47C6	MI	TTMXGCW
DMA47C6	MN	Adrenergic receptor beta-3 (ADRB3)
DMA47C6	MT	DTT
DMA47C6	MA	Modulator
DMA47C6	RN	Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
DMA47C6	RU	https://pubmed.ncbi.nlm.nih.gov/10940

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DTI7UX6
DMXBLMP	MN	Breast cancer resistance protein (ABCG2)
DMXBLMP	MT	DTP
DMXBLMP	MA	Substrate
DMXBLMP	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMXBLMP	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DE6OQ3W
DMXBLMP	MN	Cytochrome P450 1A1 (CYP1A1)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DES5XRU
DMXBLMP	MN	Cytochrome P450 2C8 (CYP2C8)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DERSX5P
DMXBLMP	MN	Cytochrome P450 2J2 (CYP2J2)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DE4LYSA
DMXBLMP	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBLMP	MT	DME
DMXBLMP	MA	Metabolism
DMXBLMP	RN	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
DMXBLMP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25395817

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	DTUGYRD
DMXBLMP	MN	P-glycoprotein 1 (ABCB1)
DMXBLMP	MT	DTP
DMXBLMP	MA	Substrate
DMXBLMP	RN	Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, initro. Pulm Pharmacol Ther. 2014 Aug;28(2):130-7.
DMXBLMP	RU	http://www.ncbi.nlm.nih.gov/pubmed/24657506

DMXBLMP	DI	DMXBLMP
DMXBLMP	DN	Riociguat
DMXBLMP	MI	TTWNFC2
DMXBLMP	MN	Soluble guanylyl cyclase (GUCY2D)
DMXBLMP	MT	DTT
DMXBLMP	MA	Modulator
DMXBLMP	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMXBLMP	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM958QB	DI	DM958QB
DM958QB	DN	Ripretinib
DM958QB	MI	TT8FYO9
DM958QB	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM958QB	MT	DTT
DM958QB	MA	Inhibitor
DM958QB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM958QB	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

DM958QB	DI	DM958QB
DM958QB	DN	Ripretinib
DM958QB	MI	TTX41N9
DM958QB	MN	Tyrosine-protein kinase Kit (KIT)
DM958QB	MT	DTT
DM958QB	MA	Inhibitor
DM958QB	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM958QB	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf

DMM32GT	DI	DMM32GT
DMM32GT	DN	Risankizumab
DMM32GT	MI	TTC1GLB
DMM32GT	MN	Interleukin-23 (IL23)
DMM32GT	MT	DTT
DMM32GT	MA	Inhibitor
DMM32GT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMM32GT	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf

DMIMF8J	DI	DMIMF8J
DMIMF8J	DN	Risdiplam
DMIMF8J	MI	DE4LYSA
DMIMF8J	MN	Cytochrome P450 3A4 (CYP3A4)
DMIMF8J	MT	DME
DMIMF8J	MA	Metabolism
DMIMF8J	RN	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019 Jan;85(1):181-193.
DMIMF8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30302786

DM5FLTY	DI	DM5FLTY
DM5FLTY	DN	Risedronate
DM5FLTY	MI	TTIKWV4
DM5FLTY	MN	Geranyltranstransferase (FDPS)
DM5FLTY	MT	DTT
DM5FLTY	MA	Inhibitor
DM5FLTY	RN	Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
DM5FLTY	RU	https://pubmed.ncbi.nlm.nih.gov/12086478

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DECB0K3
DMN6DXL	MN	Cytochrome P450 2D6 (CYP2D6)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005 Nov;78(5):520-8.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16321618

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DE4LYSA
DMN6DXL	MN	Cytochrome P450 3A4 (CYP3A4)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DEIBDNY
DMN6DXL	MN	Cytochrome P450 3A5 (CYP3A5)
DMN6DXL	MT	DME
DMN6DXL	MA	Metabolism
DMN6DXL	RN	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
DMN6DXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560868

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	TTEX248
DMN6DXL	MN	Dopamine D2 receptor (D2R)
DMN6DXL	MT	DTT
DMN6DXL	MA	Antagonist
DMN6DXL	RN	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8.
DMN6DXL	RU	https://pubmed.ncbi.nlm.nih.gov/19566763

DMN6DXL	DI	DMN6DXL
DMN6DXL	DN	Risperidone
DMN6DXL	MI	DTUGYRD
DMN6DXL	MN	P-glycoprotein 1 (ABCB1)
DMN6DXL	MT	DTP
DMN6DXL	MA	Substrate
DMN6DXL	RN	Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51.
DMN6DXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/16003291

DM4V6RL	DI	DM4V6RL
DM4V6RL	DN	Ritodrine
DM4V6RL	MI	TT2CJVK
DM4V6RL	MN	Adrenergic receptor beta-2 (ADRB2)
DM4V6RL	MT	DTT
DM4V6RL	MA	Modulator
DM4V6RL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM4V6RL	RU	https://www.fda.gov/

DM4V6RL	DI	DM4V6RL
DM4V6RL	DN	Ritodrine
DM4V6RL	MI	DEYWLRK
DM4V6RL	MN	Sulfotransferase 1A1 (SULT1A1)
DM4V6RL	MT	DME
DM4V6RL	MA	Metabolism
DM4V6RL	RN	Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. Pharm Res. 2005 Aug;22(8):1406-10.
DM4V6RL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16078151

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DEPKLMQ
DMU764S	MN	Cytochrome P450 2B6 (CYP2B6)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DECB0K3
DMU764S	MN	Cytochrome P450 2D6 (CYP2D6)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002 Sep-Oct;25(5):251-3.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12410055

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DE4LYSA
DMU764S	MN	Cytochrome P450 3A4 (CYP3A4)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DEIBDNY
DMU764S	MN	Cytochrome P450 3A5 (CYP3A5)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Drug Interactions Flockhart Table
DMU764S	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DERD86B
DMU764S	MN	Cytochrome P450 3A7 (CYP3A7)
DMU764S	MT	DME
DMU764S	MA	Metabolism
DMU764S	RN	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 Mar;79(3):243-54.
DMU764S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513448

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	TT5FNQT
DMU764S	MN	Human immunodeficiency virus Protease (HIV PR)
DMU764S	MT	DTT
DMU764S	MA	Inhibitor
DMU764S	RN	Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20.
DMU764S	RU	https://pubmed.ncbi.nlm.nih.gov/19108994

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTFI42L
DMU764S	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20238377

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTPFTEQ
DMU764S	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther. 2010 Sep 1;334(3):1009-22.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/20507927

DMU764S	DI	DMU764S
DMU764S	DN	Ritonavir
DMU764S	MI	DTUGYRD
DMU764S	MN	P-glycoprotein 1 (ABCB1)
DMU764S	MT	DTP
DMU764S	MA	Substrate
DMU764S	RN	MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS. 2005 Oct 14;19(15):1617-25.
DMU764S	RU	http://www.ncbi.nlm.nih.gov/pubmed/16184031

DMBUH26	DI	DMBUH26
DMBUH26	DN	Rituximab
DMBUH26	MI	TTUE541
DMBUH26	MN	Leukocyte surface antigen Leu-16 (CD20)
DMBUH26	MT	DTT
DMBUH26	RN	[Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
DMBUH26	RU	https://pubmed.ncbi.nlm.nih.gov/19061730

DM1YVZT	DI	DM1YVZT
DM1YVZT	DN	Rituximab
DM1YVZT	MI	TTUE541
DM1YVZT	MN	Leukocyte surface antigen Leu-16 (CD20)
DM1YVZT	MT	DTT
DM1YVZT	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DM1YVZT	RU	http://www.gene.com/gene/pipeline/status/

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DTI7UX6
DMQMBZ1	MN	Breast cancer resistance protein (ABCG2)
DMQMBZ1	MT	DTP
DMQMBZ1	MA	Substrate
DMQMBZ1	RN	Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
DMQMBZ1	RU	http://www.ncbi.nlm.nih.gov/pubmed/22958812

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	TTCIHJA
DMQMBZ1	MN	Coagulation factor Xa (F10)
DMQMBZ1	MT	DTT
DMQMBZ1	MA	Modulator
DMQMBZ1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMQMBZ1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DERSX5P
DMQMBZ1	MN	Cytochrome P450 2J2 (CYP2J2)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DE4LYSA
DMQMBZ1	MN	Cytochrome P450 3A4 (CYP3A4)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20135071

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DEIBDNY
DMQMBZ1	MN	Cytochrome P450 3A5 (CYP3A5)
DMQMBZ1	MT	DME
DMQMBZ1	MA	Metabolism
DMQMBZ1	RN	Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
DMQMBZ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23645472

DMQMBZ1	DI	DMQMBZ1
DMQMBZ1	DN	Rivaroxaban
DMQMBZ1	MI	DTUGYRD
DMQMBZ1	MN	P-glycoprotein 1 (ABCB1)
DMQMBZ1	MT	DTP
DMQMBZ1	MA	Substrate
DMQMBZ1	RN	Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
DMQMBZ1	RU	http://www.ncbi.nlm.nih.gov/pubmed/30725221

DMG629M	DI	DMG629M
DMG629M	DN	Rivastigmine
DMG629M	MI	TT1RS9F
DMG629M	MN	Acetylcholinesterase (AChE)
DMG629M	MT	DTT
DMG629M	MA	Modulator
DMG629M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
DMG629M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465

DMDJMA3	DI	DMDJMA3
DMDJMA3	DN	Rizatriptan
DMDJMA3	MI	TT6MSOK
DMDJMA3	MN	5-HT 1D receptor (HTR1D)
DMDJMA3	MT	DTT
DMDJMA3	MA	Agonist
DMDJMA3	RN	An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
DMDJMA3	RU	https://pubmed.ncbi.nlm.nih.gov/12434581

DMDJMA3	DI	DMDJMA3
DMDJMA3	DN	Rizatriptan
DMDJMA3	MI	DTT79CX
DMDJMA3	MN	Organic cation transporter 1 (SLC22A1)
DMDJMA3	MT	DTP
DMDJMA3	MA	Substrate
DMDJMA3	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DMDJMA3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	TTF4E0J
DMY9BMK	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMY9BMK	MT	DTT
DMY9BMK	MA	Antagonist
DMY9BMK	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMY9BMK	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	DTE2B1D
DMY9BMK	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMY9BMK	MT	DTP
DMY9BMK	MA	Substrate
DMY9BMK	RN	Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther. 1999 Oct;291(1):147-52.
DMY9BMK	RU	http://jpet.aspetjournals.org/content/291/1/147.long

DMY9BMK	DI	DMY9BMK
DMY9BMK	DN	Rocuronium
DMY9BMK	MI	DTPFTEQ
DMY9BMK	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMY9BMK	MT	DTP
DMY9BMK	MA	Substrate
DMY9BMK	RN	Drug Interactions in Infectious Diseases.
DMY9BMK	RU	http://www.springer.com/medicine/internal/book/978-1-61779-212-0

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DEJGDUW
DM3P5DA	MN	Cytochrome P450 1A2 (CYP1A2)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006 Sep;62(3):345-57.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16934051

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DES5XRU
DM3P5DA	MN	Cytochrome P450 2C8 (CYP2C8)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE5IED8
DM3P5DA	MN	Cytochrome P450 2C9 (CYP2C9)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16118328

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE4LYSA
DM3P5DA	MN	Cytochrome P450 3A4 (CYP3A4)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	DE073H6
DM3P5DA	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3P5DA	MT	DME
DM3P5DA	MA	Metabolism
DM3P5DA	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM3P5DA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM3P5DA	DI	DM3P5DA
DM3P5DA	DN	Rofecoxib
DM3P5DA	MI	TTVKILB
DM3P5DA	MN	Prostaglandin G/H synthase 2 (COX-2)
DM3P5DA	MT	DTT
DM3P5DA	MA	Inhibitor
DM3P5DA	RN	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
DM3P5DA	RU	https://pubmed.ncbi.nlm.nih.gov/18045214

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	DEJGDUW
DMPGHY8	MN	Cytochrome P450 1A2 (CYP1A2)
DMPGHY8	MT	DME
DMPGHY8	MA	Metabolism
DMPGHY8	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DMPGHY8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	DE4LYSA
DMPGHY8	MN	Cytochrome P450 3A4 (CYP3A4)
DMPGHY8	MT	DME
DMPGHY8	MA	Metabolism
DMPGHY8	RN	Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
DMPGHY8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20466871

DMPGHY8	DI	DMPGHY8
DMPGHY8	DN	Roflumilast
DMPGHY8	MI	TTV5CGO
DMPGHY8	MN	Phosphodiesterase 4 (PDE4)
DMPGHY8	MT	DTT
DMPGHY8	MA	Modulator
DMPGHY8	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMPGHY8	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMCZWOK	DI	DMCZWOK
DMCZWOK	DN	Rokitamycin
DMCZWOK	MI	DE4LYSA
DMCZWOK	MN	Cytochrome P450 3A4 (CYP3A4)
DMCZWOK	MT	DME
DMCZWOK	MA	Metabolism
DMCZWOK	RN	An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes. Drug Metab Dispos. 1999 Jul;27(7):776-85.
DMCZWOK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10383920

DM8XP26	DI	DM8XP26
DM8XP26	DN	Rolapitant
DM8XP26	MI	DE4LYSA
DM8XP26	MN	Cytochrome P450 3A4 (CYP3A4)
DM8XP26	MT	DME
DM8XP26	MA	Metabolism
DM8XP26	RN	Pharmacokinetic interactions of rolapitant with cytochrome P450 3A substrates in healthy subjects. J Clin Pharmacol. 2019 Apr;59(4):488-499.
DM8XP26	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30422319

DM8XP26	DI	DM8XP26
DM8XP26	DN	Rolapitant
DM8XP26	MI	TTZPO1L
DM8XP26	MN	Substance-P receptor (TACR1)
DM8XP26	MT	DTT
DM8XP26	MA	Antagonist
DM8XP26	RN	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
DM8XP26	RU	https://pubmed.ncbi.nlm.nih.gov/24969614

DMBR5Q7	DI	DMBR5Q7
DMBR5Q7	DN	Rolitetracycline
DMBR5Q7	MI	TTQ8KVI
DMBR5Q7	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMBR5Q7	MT	DTT
DMBR5Q7	MA	Binder
DMBR5Q7	RN	Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16.
DMBR5Q7	RU	https://pubmed.ncbi.nlm.nih.gov/18501371

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DEPKLMQ
DMT5GNL	MN	Cytochrome P450 2B6 (CYP2B6)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
DMT5GNL	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DE4LYSA
DMT5GNL	MN	Cytochrome P450 3A4 (CYP3A4)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
DMT5GNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21377994

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DEIBDNY
DMT5GNL	MN	Cytochrome P450 3A5 (CYP3A5)
DMT5GNL	MT	DME
DMT5GNL	MA	Metabolism
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19228751

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	TT6R7JZ
DMT5GNL	MN	Histone deacetylase 1 (HDAC1)
DMT5GNL	MT	DTT
DMT5GNL	MA	Inhibitor
DMT5GNL	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMT5GNL	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DT9C1TS
DMT5GNL	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMT5GNL	MT	DTP
DMT5GNL	MA	Substrate
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19228751

DMT5GNL	DI	DMT5GNL
DMT5GNL	DN	Romidepsin
DMT5GNL	MI	DTUGYRD
DMT5GNL	MN	P-glycoprotein 1 (ABCB1)
DMT5GNL	MT	DTP
DMT5GNL	MA	Substrate
DMT5GNL	RN	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
DMT5GNL	RU	http://www.ncbi.nlm.nih.gov/pubmed/19228751

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT037IE
DM3U7SZ	MN	Aryl hydrocarbon receptor (AHR)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Modulator
DM3U7SZ	RN	A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/16222321

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTRLW2X
DM3U7SZ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT8FYO9
DM3U7SZ	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTI7421
DM3U7SZ	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12646019

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT4DXQT
DM3U7SZ	MN	Proto-oncogene c-Ret (RET)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/20117004

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTIHYA4
DM3U7SZ	MN	Thrombopoietin receptor (MPL)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Modulator
DM3U7SZ	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTX41N9
DM3U7SZ	MN	Tyrosine-protein kinase Kit (KIT)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/10882357

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TTUTJGQ
DM3U7SZ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/12477352

DM3U7SZ	DI	DM3U7SZ
DM3U7SZ	DN	Romiplostim
DM3U7SZ	MI	TT1VAUK
DM3U7SZ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM3U7SZ	MT	DTT
DM3U7SZ	MA	Inhibitor
DM3U7SZ	RN	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
DM3U7SZ	RU	https://pubmed.ncbi.nlm.nih.gov/10882357

DMFJZN0	DI	DMFJZN0
DMFJZN0	DN	Romosozumab
DMFJZN0	MI	TTYRO4F
DMFJZN0	MN	Sclerostin (SOST)
DMFJZN0	MT	DTT
DMFJZN0	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMFJZN0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	DEJGDUW
DMA6S1D	MN	Cytochrome P450 1A2 (CYP1A2)
DMA6S1D	MT	DME
DMA6S1D	MA	Metabolism
DMA6S1D	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMA6S1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	DE4LYSA
DMA6S1D	MN	Cytochrome P450 3A4 (CYP3A4)
DMA6S1D	MT	DME
DMA6S1D	MA	Metabolism
DMA6S1D	RN	In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997 Jul;25(7):840-4.
DMA6S1D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9224778

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	TTEX248
DMA6S1D	MN	Dopamine D2 receptor (D2R)
DMA6S1D	MT	DTT
DMA6S1D	MA	Modulator
DMA6S1D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA6S1D	RU	https://www.fda.gov/

DMA6S1D	DI	DMA6S1D
DMA6S1D	DN	Ropinirole
DMA6S1D	MI	TT4C8EA
DMA6S1D	MN	Dopamine D3 receptor (D3R)
DMA6S1D	MT	DTT
DMA6S1D	MA	Modulator
DMA6S1D	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMA6S1D	RU	https://www.fda.gov/

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DEJGDUW
DMSPJG2	MN	Cytochrome P450 1A2 (CYP1A2)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther. 1998 Nov;64(5):484-91.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9834040

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DEPKLMQ
DMSPJG2	MN	Cytochrome P450 2B6 (CYP2B6)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DECB0K3
DMSPJG2	MN	Cytochrome P450 2D6 (CYP2D6)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	DE4LYSA
DMSPJG2	MN	Cytochrome P450 3A4 (CYP3A4)
DMSPJG2	MT	DME
DMSPJG2	MA	Metabolism
DMSPJG2	RN	Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology. 1995 Jan;82(1):214-20.
DMSPJG2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7832304

DMSPJG2	DI	DMSPJG2
DMSPJG2	DN	Ropivacaine
DMSPJG2	MI	TT90XZ8
DMSPJG2	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMSPJG2	MT	DTT
DMSPJG2	MA	Modulator
DMSPJG2	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMSPJG2	RU	https://www.fda.gov/

DMILWZR	DI	DMILWZR
DMILWZR	DN	Rosiglitazone
DMILWZR	MI	DTI7UX6
DMILWZR	MN	Breast cancer resistance protein (ABCG2)
DMILWZR	MT	DTP
DMILWZR	MA	Substrate
DMILWZR	RN	ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
DMILWZR	RU	http://www.ncbi.nlm.nih.gov/pubmed/18392808

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DES5XRU
DMY6EAO	MN	Cytochrome P450 2C8 (CYP2C8)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE5IED8
DMY6EAO	MN	Cytochrome P450 2C9 (CYP2C9)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510156

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE4LYSA
DMY6EAO	MN	Cytochrome P450 3A4 (CYP3A4)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMY6EAO	DI	DMY6EAO
DMY6EAO	DN	Rosiglitazone
DMY6EAO	MI	DE073H6
DMY6EAO	MN	Prostaglandin G/H synthase 1 (COX-1)
DMY6EAO	MT	DME
DMY6EAO	MA	Metabolism
DMY6EAO	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMY6EAO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMT45MU	DI	DMT45MU
DMT45MU	DN	Rosiglitazone XR
DMT45MU	MI	TTZMAO3
DMT45MU	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMT45MU	MT	DTT
DMT45MU	MA	Agonist
DMT45MU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMT45MU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMVOIK1	DI	DMVOIK1
DMVOIK1	DN	Rosoxacin
DMVOIK1	MI	TT0IHXV
DMVOIK1	MN	DNA topoisomerase II (TOP2)
DMVOIK1	MT	DTT
DMVOIK1	MA	Inhibitor
DMVOIK1	RN	Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601.
DMVOIK1	RU	https://pubmed.ncbi.nlm.nih.gov/3010848

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTI7UX6
DMMIQ7G	MN	Breast cancer resistance protein (ABCG2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE9QHP6
DMMIQ7G	MN	Cytochrome P450 1B1 (CYP1B1)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691987

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE5IED8
DMMIQ7G	MN	Cytochrome P450 2C9 (CYP2C9)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DE4LYSA
DMMIQ7G	MN	Cytochrome P450 3A4 (CYP3A4)
DMMIQ7G	MT	DME
DMMIQ7G	MA	Metabolism
DMMIQ7G	RN	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
DMMIQ7G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	TTPADOQ
DMMIQ7G	MN	HMG-CoA reductase (HMGCR)
DMMIQ7G	MT	DTT
DMMIQ7G	MA	Inhibitor
DMMIQ7G	RN	New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
DMMIQ7G	RU	https://pubmed.ncbi.nlm.nih.gov/12539816

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTFI42L
DMMIQ7G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTVP67E
DMMIQ7G	MN	Organic anion transporter 3 (SLC22A8)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/17585018

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTE2B1D
DMMIQ7G	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/16697742

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT3D8F0
DMMIQ7G	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT9C1TS
DMMIQ7G	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTPFTEQ
DMMIQ7G	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DTUGYRD
DMMIQ7G	MN	P-glycoprotein 1 (ABCB1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18617601

DMMIQ7G	DI	DMMIQ7G
DMMIQ7G	DN	Rosuvastatin
DMMIQ7G	MI	DT56EKP
DMMIQ7G	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DMMIQ7G	MT	DTP
DMMIQ7G	MA	Substrate
DMMIQ7G	RN	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
DMMIQ7G	RU	http://www.ncbi.nlm.nih.gov/pubmed/16697742

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DE4LYSA
DMP7X6Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEYWLRK
DMP7X6Q	MN	Sulfotransferase 1A1 (SULT1A1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DERUZL7
DMP7X6Q	MN	Sulfotransferase 1A2 (SULT1A2)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEP7E8X
DMP7X6Q	MN	Sulfotransferase 1A3 (SULT1A3)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DED5UR3
DMP7X6Q	MN	Sulfotransferase 1B1 (SULT1B1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DEU3DHN
DMP7X6Q	MN	Sulfotransferase 1C4 (SULT1C4)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DMP7X6Q	DI	DMP7X6Q
DMP7X6Q	DN	Rotigotine
DMP7X6Q	MI	DESTKG6
DMP7X6Q	MN	Sulfotransferase 1E1 (SULT1E1)
DMP7X6Q	MT	DME
DMP7X6Q	MA	Metabolism
DMP7X6Q	RN	Identification of the human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol. 2016 Jun;56(6):754-60.
DMP7X6Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26465778

DM9PVX8	DI	DM9PVX8
DM9PVX8	DN	Rucaparib
DM9PVX8	MI	DEJGDUW
DM9PVX8	MN	Cytochrome P450 1A2 (CYP1A2)
DM9PVX8	MT	DME
DM9PVX8	MA	Metabolism
DM9PVX8	RN	Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017 Jun 19;10:3029-3037.
DM9PVX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28790837

DM9PVX8	DI	DM9PVX8
DM9PVX8	DN	Rucaparib
DM9PVX8	MI	TTEBCY8
DM9PVX8	MN	Poly [ADP-ribose] polymerase (PARP)
DM9PVX8	MT	DTT
DM9PVX8	MA	Modulator
DM9PVX8	RN	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. 
DM9PVX8	RU	https://www.ncbi.nlm.nih.gov/pubmed/28148938

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	DEB30C5
DMWE60C	MN	Carboxylesterase 1 (CES1)
DMWE60C	MT	DME
DMWE60C	MA	Metabolism
DMWE60C	RN	Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
DMWE60C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22022867

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	DETHCPD
DMWE60C	MN	Carboxylesterase 2 (CES2)
DMWE60C	MT	DME
DMWE60C	MA	Metabolism
DMWE60C	RN	Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
DMWE60C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22022867

DMWE60C	DI	DMWE60C
DMWE60C	DN	Rufinamide
DMWE60C	MI	TTRK8B9
DMWE60C	MN	Sodium channel unspecific (NaC)
DMWE60C	MT	DTT
DMWE60C	MA	Blocker
DMWE60C	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DMWE60C	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TT6DM01
DM7Q98D	MN	Janus kinase 1 (JAK-1)
DM7Q98D	MT	DTT
DM7Q98D	MA	Modulator
DM7Q98D	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TTRMX3V
DM7Q98D	MN	Janus kinase 2 (JAK-2)
DM7Q98D	MT	DTT
DM7Q98D	MA	Modulator
DM7Q98D	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM7Q98D	DI	DM7Q98D
DM7Q98D	DN	Ruxolitinib
DM7Q98D	MI	TTPRL03
DM7Q98D	MN	Urokinase plasminogen activator surface receptor (PLAUR)
DM7Q98D	MT	DTT
DM7Q98D	MA	Inhibitor
DM7Q98D	RN	Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69.
DM7Q98D	RU	https://pubmed.ncbi.nlm.nih.gov/24763226

DMOFP18	DI	DMOFP18
DMOFP18	DN	Ryzodeq
DMOFP18	MI	TTCBFJO
DMOFP18	MN	Insulin receptor (INSR)
DMOFP18	MT	DTT
DMOFP18	MA	Modulator
DMOFP18	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMOFP18	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM0YWJC	DI	DM0YWJC
DM0YWJC	DN	Safinamide
DM0YWJC	MI	TTGP7BY
DM0YWJC	MN	Monoamine oxidase type B (MAO-B)
DM0YWJC	MT	DTT
DM0YWJC	MA	Inhibitor
DM0YWJC	RN	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
DM0YWJC	RU	https://pubmed.ncbi.nlm.nih.gov/17874969

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	DE4LYSA
DM0J2ZT	MN	Cytochrome P450 3A4 (CYP3A4)
DM0J2ZT	MT	DME
DM0J2ZT	MA	Metabolism
DM0J2ZT	RN	Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. Pharmacology. 2013;92(3-4):207-16.
DM0J2ZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24136086

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	DERE4TU
DM0J2ZT	MN	Monoamine oxidase type A (MAO-A)
DM0J2ZT	MT	DME
DM0J2ZT	MA	Metabolism
DM0J2ZT	RN	Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem. 2007 Oct 4;50(20):4909-16.
DM0J2ZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17824599

DM0J2ZT	DI	DM0J2ZT
DM0J2ZT	DN	Safinamide mesylate
DM0J2ZT	MI	TTGP7BY
DM0J2ZT	MN	Monoamine oxidase type B (MAO-B)
DM0J2ZT	MT	DTT
DM0J2ZT	MA	Inhibitor
DM0J2ZT	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM0J2ZT	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	TT2CJVK
DMN9CWF	MN	Adrenergic receptor beta-2 (ADRB2)
DMN9CWF	MT	DTT
DMN9CWF	MA	Agonist
DMN9CWF	RN	Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
DMN9CWF	RU	https://pubmed.ncbi.nlm.nih.gov/11772115

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DEB30C5
DMN9CWF	MN	Carboxylesterase 1 (CES1)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25919042

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DE4LYSA
DMN9CWF	MN	Cytochrome P450 3A4 (CYP3A4)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DTT79CX
DMN9CWF	MN	Organic cation transporter 1 (SLC22A1)
DMN9CWF	MT	DTP
DMN9CWF	MA	Substrate
DMN9CWF	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMN9CWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMN9CWF	DI	DMN9CWF
DMN9CWF	DN	Salbutamol
DMN9CWF	MI	DEP7E8X
DMN9CWF	MN	Sulfotransferase 1A3 (SULT1A3)
DMN9CWF	MT	DME
DMN9CWF	MA	Metabolism
DMN9CWF	RN	SULT 1A3 single-nucleotide polymorphism and the single dose pharmacokinetics of inhaled salbutamol enantiomers: are some athletes at risk of higher urine levels? Drug Test Anal. 2015 Feb;7(2):109-13.
DMN9CWF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24692077

DM1T2LS	DI	DM1T2LS
DM1T2LS	DN	Salicin
DM1T2LS	MI	DEFKVZD
DM1T2LS	MN	Phospho-beta-glucosidase (LBA1706)
DM1T2LS	MT	DME
DM1T2LS	MA	Metabolism
DM1T2LS	RN	Microbial unmasking of plant glycosides. mBio. 2018 Jan 30;9(1). pii: e02433-17.
DM1T2LS	RU	https://pubmed.ncbi.nlm.nih.gov/29382739

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTUNARX
DM2F8XZ	MN	Carbonic anhydrase (CA)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18501600

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTHQPL7
DM2F8XZ	MN	Carbonic anhydrase I (CA-I)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTANPDJ
DM2F8XZ	MN	Carbonic anhydrase II (CA-II)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTZHA0O
DM2F8XZ	MN	Carbonic anhydrase IV (CA-IV)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTCFSPE
DM2F8XZ	MN	Carbonic anhydrase VI (CA-VI)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TTSYM0R
DM2F8XZ	MN	Carbonic anhydrase XII (CA-XII)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18579385

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DE5IED8
DM2F8XZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM2F8XZ	MT	DME
DM2F8XZ	MA	Metabolism
DM2F8XZ	RN	Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
DM2F8XZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25840124

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DT342ZG
DM2F8XZ	MN	Monocarboxylate transporter 1 (SLC16A1)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
DM2F8XZ	RU	https://doi.org/10.1113/expphysiol.2005.029959

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTLT3UG
DM2F8XZ	MN	Monocarboxylate transporter 2 (SLC16A7)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/29660777

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTHE530
DM2F8XZ	MN	Probable small intestine urate exporter (SLC17A4)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/22460716

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	TT8NGED
DM2F8XZ	MN	Prostaglandin G/H synthase 1 (COX-1)
DM2F8XZ	MT	DTT
DM2F8XZ	MA	Inhibitor
DM2F8XZ	RN	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
DM2F8XZ	RU	https://pubmed.ncbi.nlm.nih.gov/18612540

DM2F8XZ	DI	DM2F8XZ
DM2F8XZ	DN	Salicyclic acid
DM2F8XZ	MI	DTM301H
DM2F8XZ	MN	Sodium-coupled monocarboxylate transporter 2 (SLC5A12)
DM2F8XZ	MT	DTP
DM2F8XZ	MA	Substrate
DM2F8XZ	RN	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
DM2F8XZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/18446519

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	TT2CJVK
DMIEU69	MN	Adrenergic receptor beta-2 (ADRB2)
DMIEU69	MT	DTT
DMIEU69	MA	Agonist
DMIEU69	RN	Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
DMIEU69	RU	https://pubmed.ncbi.nlm.nih.gov/19059068

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DE4LYSA
DMIEU69	MN	Cytochrome P450 3A4 (CYP3A4)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
DMIEU69	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11825095

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DEIBDNY
DMIEU69	MN	Cytochrome P450 3A5 (CYP3A5)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Drug Interactions Flockhart Table
DMIEU69	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMIEU69	DI	DMIEU69
DMIEU69	DN	Salmeterol
DMIEU69	MI	DERD86B
DMIEU69	MN	Cytochrome P450 3A7 (CYP3A7)
DMIEU69	MT	DME
DMIEU69	MA	Metabolism
DMIEU69	RN	Drug Interactions Flockhart Table
DMIEU69	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMEWUPF	DI	DMEWUPF
DMEWUPF	DN	Salmon Calcitonin
DMEWUPF	MI	TTLWS2O
DMEWUPF	MN	Calcitonin receptor (CALCR)
DMEWUPF	MT	DTT
DMEWUPF	MA	Binder
DMEWUPF	RN	Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95.
DMEWUPF	RU	https://pubmed.ncbi.nlm.nih.gov/19540427

DM13P4C	DI	DM13P4C
DM13P4C	DN	Salsalate
DM13P4C	MI	TT8NGED
DM13P4C	MN	Prostaglandin G/H synthase 1 (COX-1)
DM13P4C	MT	DTT
DM13P4C	MA	Inhibitor
DM13P4C	RN	New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15.
DM13P4C	RU	https://pubmed.ncbi.nlm.nih.gov/9711054

DM62MUZ	DI	DM62MUZ
DM62MUZ	DN	Samarium Sm-153 Lexidronam Pentasodium
DM62MUZ	MI	TTGXKP7
DM62MUZ	MN	Samarium (SAM)
DM62MUZ	MT	DTT
DM62MUZ	MA	Modulator
DM62MUZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM62MUZ	RU	https://www.fda.gov/

DMDINFS	DI	DMDINFS
DMDINFS	DN	Sanguinarine
DMDINFS	MI	TTQ38E9
DMDINFS	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMDINFS	MT	DTT
DMDINFS	MA	Modulator
DMDINFS	RN	Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81.
DMDINFS	RU	https://pubmed.ncbi.nlm.nih.gov/3879679

DM5VP0F	DI	DM5VP0F
DM5VP0F	DN	Saphris
DM5VP0F	MI	DTUGYRD
DM5VP0F	MN	P-glycoprotein 1 (ABCB1)
DM5VP0F	MT	DTP
DM5VP0F	MA	Substrate
DM5VP0F	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM5VP0F	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4087K	DI	DM4087K
DM4087K	DN	Saprisartan
DM4087K	MI	TT8DBY3
DM4087K	MN	Angiotensin II receptor type-1 (AGTR1)
DM4087K	MT	DTT
DM4087K	MA	Antagonist
DM4087K	RN	Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F.
DM4087K	RU	https://pubmed.ncbi.nlm.nih.gov/10579749

DM90TJP	DI	DM90TJP
DM90TJP	DN	Sapropterin hydrochloride
DM90TJP	MI	TTGSVH2
DM90TJP	MN	Phenylalanine hydroxylase (PAH)
DM90TJP	MT	DTT
DM90TJP	MA	Modulator
DM90TJP	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DM90TJP	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTI7UX6
DMG814N	MN	Breast cancer resistance protein (ABCG2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem. 2010 Dec;115(6):1495-507.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/20950334

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DECB0K3
DMG814N	MN	Cytochrome P450 2D6 (CYP2D6)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9758674

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DE4LYSA
DMG814N	MN	Cytochrome P450 3A4 (CYP3A4)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19792991

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DEIBDNY
DMG814N	MN	Cytochrome P450 3A5 (CYP3A5)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DERD86B
DMG814N	MN	Cytochrome P450 3A7 (CYP3A7)
DMG814N	MT	DME
DMG814N	MA	Metabolism
DMG814N	RN	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
DMG814N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	TT5FNQT
DMG814N	MN	Human immunodeficiency virus Protease (HIV PR)
DMG814N	MT	DTT
DMG814N	MA	Inhibitor
DMG814N	RN	PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63.
DMG814N	RU	https://pubmed.ncbi.nlm.nih.gov/19040279

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTSYQGK
DMG814N	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12384350

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTFI42L
DMG814N	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/12702717

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTE2B1D
DMG814N	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/15832500

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DT3D8F0
DMG814N	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMG814N	DI	DMG814N
DMG814N	DN	Saquinavir
DMG814N	MI	DTUGYRD
DMG814N	MN	P-glycoprotein 1 (ABCB1)
DMG814N	MT	DTP
DMG814N	MA	Substrate
DMG814N	RN	Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.
DMG814N	RU	http://www.ncbi.nlm.nih.gov/pubmed/15180340

DMKS1DV	DI	DMKS1DV
DMKS1DV	DN	SARALASIN
DMKS1DV	MI	TT8DBY3
DMKS1DV	MN	Angiotensin II receptor type-1 (AGTR1)
DMKS1DV	MT	DTT
DMKS1DV	MA	Inhibitor
DMKS1DV	RN	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
DMKS1DV	RU	https://pubmed.ncbi.nlm.nih.gov/18588282

DMKS1DV	DI	DMKS1DV
DMKS1DV	DN	SARALASIN
DMKS1DV	MI	TTQVOEI
DMKS1DV	MN	Angiotensin II receptor type-2 (AGTR2)
DMKS1DV	MT	DTT
DMKS1DV	MA	Inhibitor
DMKS1DV	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMKS1DV	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DMKZROL	DI	DMKZROL
DMKZROL	DN	Saralasin Acetate
DMKZROL	MI	TT8DBY3
DMKZROL	MN	Angiotensin II receptor type-1 (AGTR1)
DMKZROL	MT	DTT
DMKZROL	MA	Modulator
DMKZROL	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKZROL	RU	https://www.fda.gov/

DMLZNIQ	DI	DMLZNIQ
DMLZNIQ	DN	Sarecycline 
DMLZNIQ	MI	TTOVFH2
DMLZNIQ	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMLZNIQ	MT	DTT
DMLZNIQ	MA	Inhibitor
DMLZNIQ	RN	Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. 
DMLZNIQ	RU	https://pubmed.ncbi.nlm.nih.gov/30397052

DMY0M8J	DI	DMY0M8J
DMY0M8J	DN	Sargramostim
DMY0M8J	MI	TT6MP2Z
DMY0M8J	MN	GMCSFR-alpha (CSF2RA)
DMY0M8J	MT	DTT
DMY0M8J	MA	Binder
DMY0M8J	RN	Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
DMY0M8J	RU	https://pubmed.ncbi.nlm.nih.gov/12901131

DMOGNXY	DI	DMOGNXY
DMOGNXY	DN	Sarilumab
DMOGNXY	MI	TT0E5SK
DMOGNXY	MN	Interleukin 6 receptor (IL6R)
DMOGNXY	MT	DTT
DMOGNXY	MA	Modulator
DMOGNXY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMOGNXY	RU	https://www.fda.gov/

DMGLP6S	DI	DMGLP6S
DMGLP6S	DN	Sarpogrelate
DMGLP6S	MI	TTJQOD7
DMGLP6S	MN	5-HT 2A receptor (HTR2A)
DMGLP6S	MT	DTT
DMGLP6S	MA	Antagonist
DMGLP6S	RN	Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
DMGLP6S	RU	https://pubmed.ncbi.nlm.nih.gov/19557588

DMRSKMZ	DI	DMRSKMZ
DMRSKMZ	DN	Satumomab Pendetide
DMRSKMZ	MI	TTX35ZM
DMRSKMZ	MN	Tumor-associated glycoprotein 72 (TAG-72)
DMRSKMZ	MT	DTT
DMRSKMZ	MA	Binder
DMRSKMZ	RN	Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1.
DMRSKMZ	RU	https://pubmed.ncbi.nlm.nih.gov/9755434

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DE4LYSA
DMGXENV	MN	Cytochrome P450 3A4 (CYP3A4)
DMGXENV	MT	DME
DMGXENV	MA	Metabolism
DMGXENV	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DMGXENV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DEIBDNY
DMGXENV	MN	Cytochrome P450 3A5 (CYP3A5)
DMGXENV	MT	DME
DMGXENV	MA	Metabolism
DMGXENV	RN	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
DMGXENV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21651615

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	TTDIGC1
DMGXENV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGXENV	MT	DTT
DMGXENV	MA	Inhibitor
DMGXENV	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMGXENV	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTSYQGK
DMGXENV	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010 Sep;49(9):573-88.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/20690781

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTVP67E
DMGXENV	MN	Organic anion transporter 3 (SLC22A8)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/22686547

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTY0QMU
DMGXENV	MN	Organic anion transporting polypeptide 4C1 (SLCO4C1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
DMGXENV	RU	http://www.ncbi.nlm.nih.gov/pubmed/22686547

DMGXENV	DI	DMGXENV
DMGXENV	DN	Saxagliptin
DMGXENV	MI	DTUGYRD
DMGXENV	MN	P-glycoprotein 1 (ABCB1)
DMGXENV	MT	DTP
DMGXENV	MA	Substrate
DMGXENV	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMGXENV	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMDK7T9	DI	DMDK7T9
DMDK7T9	DN	SBC-102
DMDK7T9	MI	TTS8T1M
DMDK7T9	MN	Lysosomal acid lipase (LIPA)
DMDK7T9	MT	DTT
DMDK7T9	MA	Modulator
DMDK7T9	RN	A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20.
DMDK7T9	RU	https://pubmed.ncbi.nlm.nih.gov/26352813

DMOM8AL	DI	DMOM8AL
DMOM8AL	DN	Scopolamine
DMOM8AL	MI	TTOXS3C
DMOM8AL	MN	Muscarinic acetylcholine receptor (CHRM)
DMOM8AL	MT	DTT
DMOM8AL	MA	Antagonist
DMOM8AL	RN	The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
DMOM8AL	RU	https://pubmed.ncbi.nlm.nih.gov/19272427

DMJ18YL	DI	DMJ18YL
DMJ18YL	DN	Secnidazole
DMJ18YL	MI	DEAN5EW
DMJ18YL	MN	Nitroreductase (NTR)
DMJ18YL	MT	DME
DMJ18YL	MA	Metabolism
DMJ18YL	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMJ18YL	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DM14RF5	DI	DM14RF5
DM14RF5	DN	Secobarbital
DM14RF5	MI	TT1MPAY
DM14RF5	MN	GABA(A) receptor alpha-1 (GABRA1)
DM14RF5	MT	DTT
DM14RF5	MA	Antagonist
DM14RF5	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DM14RF5	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMDKE4N	DI	DMDKE4N
DMDKE4N	DN	Secretin
DMDKE4N	MI	TTOBVIN
DMDKE4N	MN	Secretin receptor (SCT)
DMDKE4N	MT	DTT
DMDKE4N	MA	Binder
DMDKE4N	RN	False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2.
DMDKE4N	RU	https://pubmed.ncbi.nlm.nih.gov/19245850

DMFEGB0	DI	DMFEGB0
DMFEGB0	DN	Segesterone acetate; ethinyl estradiol
DMFEGB0	MI	TTDSB34
DMFEGB0	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMFEGB0	MT	DTT
DMFEGB0	MA	Modulator
DMFEGB0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMFEGB0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMFEGB0	DI	DMFEGB0
DMFEGB0	DN	Segesterone acetate; ethinyl estradiol
DMFEGB0	MI	TTUV8G9
DMFEGB0	MN	Progesterone receptor (PGR)
DMFEGB0	MT	DTT
DMFEGB0	MA	Modulator
DMFEGB0	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMFEGB0	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TT32XQJ
DM6034S	MN	Monoamine oxidase (MAO)
DM6034S	MT	DTT
DM6034S	MA	Inhibitor
DM6034S	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DM6034S	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TTGP7BY
DM6034S	MN	Monoamine oxidase type B (MAO-B)
DM6034S	MT	DTT
DM6034S	MA	Inhibitor
DM6034S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
DM6034S	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490

DM6034S	DI	DM6034S
DM6034S	DN	Selegiline
DM6034S	MI	TTZPO1L
DM6034S	MN	Substance-P receptor (TACR1)
DM6034S	MT	DTT
DM6034S	MA	Antagonist
DM6034S	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6034S	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEJGDUW
DM3VR1L	MN	Cytochrome P450 1A2 (CYP1A2)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEJVYAZ
DM3VR1L	MN	Cytochrome P450 2A6 (CYP2A6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Variation in CYP2A6 activity and personalized medicine. J Pers Med. 2017 Dec 1;7(4). pii: E18.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29194389

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEPKLMQ
DM3VR1L	MN	Cytochrome P450 2B6 (CYP2B6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25656918

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DES5XRU
DM3VR1L	MN	Cytochrome P450 2C8 (CYP2C8)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DE5IED8
DM3VR1L	MN	Cytochrome P450 2C9 (CYP2C9)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DECB0K3
DM3VR1L	MN	Cytochrome P450 2D6 (CYP2D6)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease. Rinsho Shinkeigaku. 2005 Nov;45(11):895-8.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16447756

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DE4LYSA
DM3VR1L	MN	Cytochrome P450 3A4 (CYP3A4)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17495414

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	DEGTFWK
DM3VR1L	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3VR1L	MT	DME
DM3VR1L	MA	Metabolism
DM3VR1L	RN	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
DM3VR1L	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12920164

DM3VR1L	DI	DM3VR1L
DM3VR1L	DN	Selegiline hydrochloride
DM3VR1L	MI	TTGP7BY
DM3VR1L	MN	Monoamine oxidase type B (MAO-B)
DM3VR1L	MT	DTT
DM3VR1L	MA	Modulator
DM3VR1L	RN	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
DM3VR1L	RU	https://pubmed.ncbi.nlm.nih.gov/16939381

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEGDPL2
DM25CGV	MN	Glutathione reductase (GSR)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEH4TD6
DM25CGV	MN	Selenocysteine lyase (SCLY)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DM25CGV	DI	DM25CGV
DM25CGV	DN	Selenium
DM25CGV	MI	DEUP4DA
DM25CGV	MN	Thioredoxin reductase TR1 (TXNRD1)
DM25CGV	MT	DME
DM25CGV	MA	Metabolism
DM25CGV	RN	Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis. 1999 Sep;20(9):1657-66.
DM25CGV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10469608

DMAHSU0	DI	DMAHSU0
DMAHSU0	DN	Selexipag
DMAHSU0	MI	DES5XRU
DMAHSU0	MN	Cytochrome P450 2C8 (CYP2C8)
DMAHSU0	MT	DME
DMAHSU0	MA	Metabolism
DMAHSU0	RN	FDA Label of Uptravi. The 2020 official website of the U.S. Food and Drug Administration.
DMAHSU0	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207947s005lbl.pdf

DMAHSU0	DI	DMAHSU0
DMAHSU0	DN	Selexipag
DMAHSU0	MI	TTOFYT1
DMAHSU0	MN	Prostacyclin receptor (PTGIR)
DMAHSU0	MT	DTT
DMAHSU0	MA	Agonist
DMAHSU0	RN	Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
DMAHSU0	RU	https://pubmed.ncbi.nlm.nih.gov/22362844

DMZR15V	DI	DMZR15V
DMZR15V	DN	Selpercatinib
DMZR15V	MI	TT4DXQT
DMZR15V	MN	Proto-oncogene c-Ret (RET)
DMZR15V	MT	DTT
DMZR15V	MA	Inhibitor
DMZR15V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMZR15V	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	DEKZQY6
DMAGFOD	MN	Dipeptidyl peptidase IV (DPP4)
DMAGFOD	MT	DME
DMAGFOD	MA	Metabolism
DMAGFOD	RN	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41.
DMAGFOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28323117

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	TTVIMDE
DMAGFOD	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMAGFOD	MT	DTT
DMAGFOD	MA	Agonist
DMAGFOD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMAGFOD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMAGFOD	DI	DMAGFOD
DMAGFOD	DN	Semaglutide
DMAGFOD	MI	DEVN830
DMAGFOD	MN	Neprilysin (MME)
DMAGFOD	MT	DME
DMAGFOD	MA	Metabolism
DMAGFOD	RN	Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017 Jun 15;104:31-41.
DMAGFOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28323117

DM25HP1	DI	DM25HP1
DM25HP1	DN	Sermorelin
DM25HP1	MI	TTG4R8V
DM25HP1	MN	Growth hormone-releasing hormone receptor (GHRHR)
DM25HP1	MT	DTT
DM25HP1	MA	Binder
DM25HP1	RN	Sermorelin: a better approach to management of adult-onset growth hormone insufficiency Clin Interv Aging. 2006;1(4):307-8.
DM25HP1	RU	https://pubmed.ncbi.nlm.nih.gov/18046908

DM1A9XO	DI	DM1A9XO
DM1A9XO	DN	Sertaconazole
DM1A9XO	MI	TTTSOUD
DM1A9XO	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1A9XO	MT	DTT
DM1A9XO	MA	Inhibitor
DM1A9XO	RN	Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. 
DM1A9XO	RU	https://pubmed.ncbi.nlm.nih.gov/19275277

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEJGDUW
DM0FB1J	MN	Cytochrome P450 1A2 (CYP1A2)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001 Spring;7(1):1-24.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11420570

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEPKLMQ
DM0FB1J	MN	Cytochrome P450 2B6 (CYP2B6)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DE5IED8
DM0FB1J	MN	Cytochrome P450 2C9 (CYP2C9)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15547048

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DECB0K3
DM0FB1J	MN	Cytochrome P450 2D6 (CYP2D6)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004 Jan-Feb;59(1):5-12.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15199661

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEVDYN7
DM0FB1J	MN	Cytochrome P450 2E1 (CYP2E1)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166181117)
DM0FB1J	RU	https://www.pharmgkb.org/pathway/PA166181117

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DE4LYSA
DM0FB1J	MN	Cytochrome P450 3A4 (CYP3A4)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag. 2014 Jun 13;10:423-36.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24966680

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DEGTFWK
DM0FB1J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0FB1J	MT	DME
DM0FB1J	MA	Metabolism
DM0FB1J	RN	Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
DM0FB1J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26830411

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	DTUGYRD
DM0FB1J	MN	P-glycoprotein 1 (ABCB1)
DM0FB1J	MT	DTP
DM0FB1J	MA	Substrate
DM0FB1J	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM0FB1J	RU	https://doi.org/10.1016/j.addr.2011.12.008

DM0FB1J	DI	DM0FB1J
DM0FB1J	DN	Sertraline
DM0FB1J	MI	TT3ROYC
DM0FB1J	MN	Serotonin transporter (SERT)
DM0FB1J	MT	DTT
DM0FB1J	MA	Inhibitor
DM0FB1J	RN	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
DM0FB1J	RU	https://pubmed.ncbi.nlm.nih.gov/17877739

DMPVRN9	DI	DMPVRN9
DMPVRN9	DN	Setmelanotide
DMPVRN9	MI	TTD0CIQ
DMPVRN9	MN	Melanocortin receptor 4 (MC4R)
DMPVRN9	MT	DTT
DMPVRN9	MA	Agonist
DMPVRN9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMPVRN9	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEJVYAZ
DMC9O43	MN	Cytochrome P450 2A6 (CYP2A6)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7879937

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEPKLMQ
DMC9O43	MN	Cytochrome P450 2B6 (CYP2B6)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DEVDYN7
DMC9O43	MN	Cytochrome P450 2E1 (CYP2E1)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12234619

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	DE4LYSA
DMC9O43	MN	Cytochrome P450 3A4 (CYP3A4)
DMC9O43	MT	DME
DMC9O43	MA	Metabolism
DMC9O43	RN	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
DMC9O43	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8214760

DMC9O43	DI	DMC9O43
DMC9O43	DN	Sevoflurane
DMC9O43	MI	TTAN6JD
DMC9O43	MN	Glutamate receptor AMPA (GRIA)
DMC9O43	MT	DTT
DMC9O43	MA	Antagonist
DMC9O43	RN	Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
DMC9O43	RU	https://pubmed.ncbi.nlm.nih.gov/19247760

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	DE4LYSA
DMFJTDI	MN	Cytochrome P450 3A4 (CYP3A4)
DMFJTDI	MT	DME
DMFJTDI	MA	Metabolism
DMFJTDI	RN	Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
DMFJTDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10492502

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	TTAWNKZ
DMFJTDI	MN	Norepinephrine transporter (NET)
DMFJTDI	MT	DTT
DMFJTDI	MA	Modulator
DMFJTDI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFJTDI	RU	https://www.fda.gov/

DMFJTDI	DI	DMFJTDI
DMFJTDI	DN	Sibutramine
DMFJTDI	MI	TT3ROYC
DMFJTDI	MN	Serotonin transporter (SERT)
DMFJTDI	MT	DTT
DMFJTDI	MA	Modulator
DMFJTDI	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMFJTDI	RU	https://www.fda.gov/

DM1BS03	DI	DM1BS03
DM1BS03	DN	Sifalimumab
DM1BS03	MI	TTMQB37
DM1BS03	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM1BS03	MT	DTT
DM1BS03	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM1BS03	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DE5IED8
DMSWJ5X	MN	Cytochrome P450 2C9 (CYP2C9)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DECB0K3
DMSWJ5X	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEVDYN7
DMSWJ5X	MN	Cytochrome P450 2E1 (CYP2E1)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DE4LYSA
DMSWJ5X	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEIBDNY
DMSWJ5X	MN	Cytochrome P450 3A5 (CYP3A5)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DERD86B
DMSWJ5X	MN	Cytochrome P450 3A7 (CYP3A7)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Drug Interactions Flockhart Table
DMSWJ5X	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMSWJ5X	DI	DMSWJ5X
DMSWJ5X	DN	Sildenafil citrate
DMSWJ5X	MI	DEGTFWK
DMSWJ5X	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSWJ5X	MT	DME
DMSWJ5X	MA	Metabolism
DMSWJ5X	RN	Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48.
DMSWJ5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11298070

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	TTNGILX
DMJSBT6	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMJSBT6	MT	DTT
DMJSBT6	MA	Inhibitor
DMJSBT6	RN	Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
DMJSBT6	RU	https://pubmed.ncbi.nlm.nih.gov/15664832

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEE5M8O
DMJSBT6	MN	Alcohol dehydrogenase class-I alpha (ADH1A)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEWYTJB
DMJSBT6	MN	Aldehyde dehydrogenase 2 (ALDH2)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DE4LYSA
DMJSBT6	MN	Cytochrome P450 3A4 (CYP3A4)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20071497

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DTZRMK5
DMJSBT6	MN	Multidrug resistance protein 3 (ABCB4)
DMJSBT6	MT	DTP
DMJSBT6	MA	Substrate
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16518089

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DTUGYRD
DMJSBT6	MN	P-glycoprotein 1 (ABCB1)
DMJSBT6	MT	DTP
DMJSBT6	MA	Substrate
DMJSBT6	RN	The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43.
DMJSBT6	RU	http://www.ncbi.nlm.nih.gov/pubmed/23257391

DMJSBT6	DI	DMJSBT6
DMJSBT6	DN	Silodosin
DMJSBT6	MI	DEB3CV1
DMJSBT6	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMJSBT6	MT	DME
DMJSBT6	MA	Metabolism
DMJSBT6	RN	Pharmacokinetics and disposition of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
DMJSBT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16518089

DMGEATB	DI	DMGEATB
DMGEATB	DN	Siltuximab
DMGEATB	MI	TTT1V78
DMGEATB	MN	Interleukin-6 (IL6)
DMGEATB	MT	DTT
DMGEATB	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMGEATB	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMVTHWQ	DI	DMVTHWQ
DMVTHWQ	DN	Silver sulfadiazine
DMVTHWQ	MI	TT4ILYC
DMVTHWQ	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMVTHWQ	MT	DTT
DMVTHWQ	MA	Binder
DMVTHWQ	RN	Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4.
DMVTHWQ	RU	https://pubmed.ncbi.nlm.nih.gov/16921417

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DE4LYSA
DMLUA9D	MN	Cytochrome P450 3A4 (CYP3A4)
DMLUA9D	MT	DME
DMLUA9D	MA	Metabolism
DMLUA9D	RN	Hepatitis C virus direct-acting antiviral drug interactions and use in renal and hepatic impairment. Top Antivir Med. 2015 May-Jun;23(2):92-6.
DMLUA9D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26200709

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	TTHC7JD
DMLUA9D	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMLUA9D	MT	DTT
DMLUA9D	MA	Modulator
DMLUA9D	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMLUA9D	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DT3D8F0
DMLUA9D	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMLUA9D	MT	DTP
DMLUA9D	MA	Substrate
DMLUA9D	RN	Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir. Clin Pharmacokinet. 2016 Feb;55(2):197-208.
DMLUA9D	RU	http://www.ncbi.nlm.nih.gov/pubmed/26353895

DMLUA9D	DI	DMLUA9D
DMLUA9D	DN	Simeprevir
DMLUA9D	MI	DTUGYRD
DMLUA9D	MN	P-glycoprotein 1 (ABCB1)
DMLUA9D	MT	DTP
DMLUA9D	MA	Substrate
DMLUA9D	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMLUA9D	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DTI7UX6
DM30SGU	MN	Breast cancer resistance protein (ABCG2)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM30SGU	RU	https://doi.org/10.1007/s11095-012-0935-x

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DES5XRU
DM30SGU	MN	Cytochrome P450 2C8 (CYP2C8)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6):565-81.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17178259

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DECB0K3
DM30SGU	MN	Cytochrome P450 2D6 (CYP2D6)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs. 2004;4(4):247-55.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15285699

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DE4LYSA
DM30SGU	MN	Cytochrome P450 3A4 (CYP3A4)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEIBDNY
DM30SGU	MN	Cytochrome P450 3A5 (CYP3A5)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9321523

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	TTPADOQ
DM30SGU	MN	HMG-CoA reductase (HMGCR)
DM30SGU	MT	DTT
DM30SGU	MA	Inhibitor
DM30SGU	RN	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
DM30SGU	RU	https://pubmed.ncbi.nlm.nih.gov/11523064

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEGTFWK
DM30SGU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DT3D8F0
DM30SGU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
DM30SGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/19785645

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DTUGYRD
DM30SGU	MN	P-glycoprotein 1 (ABCB1)
DM30SGU	MT	DTP
DM30SGU	MA	Substrate
DM30SGU	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM30SGU	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEYGVN4
DM30SGU	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEF2WXN
DM30SGU	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DM30SGU	DI	DM30SGU
DM30SGU	DN	Simvastatin
DM30SGU	MI	DEB3CV1
DM30SGU	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM30SGU	MT	DME
DM30SGU	MA	Metabolism
DM30SGU	RN	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
DM30SGU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27757045

DMGWR0C	DI	DMGWR0C
DMGWR0C	DN	Sintilimab
DMGWR0C	MI	TTNBFWK
DMGWR0C	MN	Programmed cell death protein 1 (PD-1)
DMGWR0C	MT	DTT
DMGWR0C	MA	Inhibitor
DMGWR0C	RN	Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
DMGWR0C	RU	https://pubmed.ncbi.nlm.nih.gov/30742278

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	DE5IED8
DM2R86O	MN	Cytochrome P450 2C9 (CYP2C9)
DM2R86O	MT	DME
DM2R86O	MA	Metabolism
DM2R86O	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DM2R86O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DMVCMUJ	DI	DMVCMUJ
DMVCMUJ	DN	Siponimod
DMVCMUJ	MI	DE5IED8
DMVCMUJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMVCMUJ	MT	DME
DMVCMUJ	MA	Metabolism
DMVCMUJ	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DMVCMUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	DE4LYSA
DM2R86O	MN	Cytochrome P450 3A4 (CYP3A4)
DM2R86O	MT	DME
DM2R86O	MA	Metabolism
DM2R86O	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DM2R86O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DMVCMUJ	DI	DMVCMUJ
DMVCMUJ	DN	Siponimod
DMVCMUJ	MI	DE4LYSA
DMVCMUJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMVCMUJ	MT	DME
DMVCMUJ	MA	Metabolism
DMVCMUJ	RN	Metabolism and disposition of siponimod, a novel selective S1P1/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-1013.
DMVCMUJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29735753

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	TT7BQRM
DM2R86O	MN	Sphingosine-1 phosphate receptor (S1PR)
DM2R86O	MT	DTT
DM2R86O	MA	Modulator
DM2R86O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM2R86O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf

DM2R86O	DI	DM2R86O
DM2R86O	DN	Siponimod
DM2R86O	MI	TT9JZCK
DM2R86O	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM2R86O	MT	DTT
DM2R86O	MA	Modulator
DM2R86O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM2R86O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DE4LYSA
DMGW1ID	MN	Cytochrome P450 3A4 (CYP3A4)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMGW1ID	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DEIBDNY
DMGW1ID	MN	Cytochrome P450 3A5 (CYP3A5)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Drug Interactions Flockhart Table
DMGW1ID	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DERD86B
DMGW1ID	MN	Cytochrome P450 3A7 (CYP3A7)
DMGW1ID	MT	DME
DMGW1ID	MA	Metabolism
DMGW1ID	RN	Drug Interactions Flockhart Table
DMGW1ID	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DT3D8F0
DMGW1ID	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMGW1ID	MT	DTP
DMGW1ID	MA	Substrate
DMGW1ID	RN	Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7.
DMGW1ID	RU	http://www.ncbi.nlm.nih.gov/pubmed/20220747

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	DTUGYRD
DMGW1ID	MN	P-glycoprotein 1 (ABCB1)
DMGW1ID	MT	DTP
DMGW1ID	MA	Substrate
DMGW1ID	RN	Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. Transplant Proc. 2007 Sep;39(7):2142-4.
DMGW1ID	RU	http://www.ncbi.nlm.nih.gov/pubmed/17889118

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	TTGQUFK
DMGW1ID	MN	PI3K/AKT/mTOR pathway (PAm pathway)
DMGW1ID	MT	DTT
DMGW1ID	MA	Inhibitor
DMGW1ID	RN	The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71.
DMGW1ID	RU	https://pubmed.ncbi.nlm.nih.gov/24952746

DMGW1ID	DI	DMGW1ID
DMGW1ID	DN	Sirolimus
DMGW1ID	MI	TTCJG29
DMGW1ID	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMGW1ID	MT	DTT
DMGW1ID	MA	Inhibitor
DMGW1ID	RN	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
DMGW1ID	RU	https://pubmed.ncbi.nlm.nih.gov/12509758

DM92P0F	DI	DM92P0F
DM92P0F	DN	Sisomicin
DM92P0F	MI	DE5WGIM
DM92P0F	MN	Aminoglycoside phosphotransferase (aph-Ib)
DM92P0F	MT	DME
DM92P0F	MA	Metabolism
DM92P0F	RN	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
DM92P0F	RU	https://pubmed.ncbi.nlm.nih.gov/23129050

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DES5XRU
DMGDKXN	MN	Cytochrome P450 2C8 (CYP2C8)
DMGDKXN	MT	DME
DMGDKXN	MA	Metabolism
DMGDKXN	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMGDKXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DE4LYSA
DMGDKXN	MN	Cytochrome P450 3A4 (CYP3A4)
DMGDKXN	MT	DME
DMGDKXN	MA	Metabolism
DMGDKXN	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMGDKXN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20590741

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	TTDIGC1
DMGDKXN	MN	Dipeptidyl peptidase 4 (DPP-4)
DMGDKXN	MT	DTT
DMGDKXN	MA	Inhibitor
DMGDKXN	RN	Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
DMGDKXN	RU	https://pubmed.ncbi.nlm.nih.gov/19545590

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTVP67E
DMGDKXN	MN	Organic anion transporter 3 (SLC22A8)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
DMGDKXN	RU	http://www.ncbi.nlm.nih.gov/pubmed/17314201

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTT79CX
DMGDKXN	MN	Organic cation transporter 1 (SLC22A1)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	265 effect of dietary cholesterol on gallbladder bile lithogenicity and gene expression in the enterohepatic axis of non-obese gallstone and control women. Journal of Hepatology, 2009, 50(09):S105-S106.
DMGDKXN	RU	https://doi.org/10.1016/S0168-8278(09)60267-1

DMGDKXN	DI	DMGDKXN
DMGDKXN	DN	Sitagliptin
DMGDKXN	MI	DTUGYRD
DMGDKXN	MN	P-glycoprotein 1 (ABCB1)
DMGDKXN	MT	DTP
DMGDKXN	MA	Substrate
DMGDKXN	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMGDKXN	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TTGKNB4
DMQ8E9R	MN	Epidermal growth factor receptor (EGFR)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TT6PKBN
DMQ8E9R	MN	Proto-oncogene c-Src (SRC)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMQ8E9R	DI	DMQ8E9R
DMQ8E9R	DN	SKI-758
DMQ8E9R	MI	TT3PJMV
DMQ8E9R	MN	Tyrosine-protein kinase ABL1 (ABL)
DMQ8E9R	MT	DTT
DMQ8E9R	MA	Inhibitor
DMQ8E9R	RN	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
DMQ8E9R	RU	https://pubmed.ncbi.nlm.nih.gov/17181170

DMDIZCS	DI	DMDIZCS
DMDIZCS	DN	S-licarbazepine
DMDIZCS	MI	DTUGYRD
DMDIZCS	MN	P-glycoprotein 1 (ABCB1)
DMDIZCS	MT	DTP
DMDIZCS	MA	Substrate
DMDIZCS	RN	In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904.
DMDIZCS	RU	https://doi.org/10.1111/j.1528-1167.2011.03140.x

DMFX9O6	DI	DMFX9O6
DMFX9O6	DN	SM-101
DMFX9O6	MI	TTXT21W
DMFX9O6	MN	Immunoglobulin gamma Fc receptor IIA (FCGR2A)
DMFX9O6	MT	DTT
DMFX9O6	MA	Antagonist
DMFX9O6	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DMFX9O6	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMFX9O6	DI	DMFX9O6
DMFX9O6	DN	SM-101
DMFX9O6	MI	TTYT93M
DMFX9O6	MN	MAP kinase p38 (MAPK12)
DMFX9O6	MT	DTT
DMFX9O6	MA	Inhibitor
DMFX9O6	RN	Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
DMFX9O6	RU	https://pubmed.ncbi.nlm.nih.gov/18764722

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTZ9SOR
DM1I93C	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTYEG6Q
DM1I93C	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DM1I93C	DI	DM1I93C
DM1I93C	DN	SMT-D002
DM1I93C	MI	TTQ13Z5
DM1I93C	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM1I93C	MT	DTT
DM1I93C	MA	Agonist
DM1I93C	RN	Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
DM1I93C	RU	https://pubmed.ncbi.nlm.nih.gov/15540789

DMH21E0	DI	DMH21E0
DMH21E0	DN	Sodium acetate anhydrous
DMH21E0	MI	DEE76VW
DMH21E0	MN	Acetyl-CoA synthetase (ACSS2)
DMH21E0	MT	DME
DMH21E0	MA	Metabolism
DMH21E0	RN	Sodium acetate induces a metabolic alkalosis but not the increase in fatty acid oxidation observed following bicarbonate ingestion in humans. J Nutr. 2007 Jul;137(7):1750-6.
DMH21E0	RU	http://jn.nutrition.org/content/137/7/1750.full

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTSQY0W
DMMU6BJ	MN	Anion exchange protein 4 (SLC4A9)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	A novel sodium bicarbonate cotransporter-like gene in an ancient duplicated region: SLC4A9 at 5q31. Genome Biol. 2001;2(4):RESEARCH0011.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/11305939

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTWDEIL
DMMU6BJ	MN	Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter (NBCe1) is essential for normal development of mouse dentition. J Biol Chem. 2010 Aug 6;285(32):24432-8.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/20529845

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTCL4P8
DMMU6BJ	MN	Electrogenic sodium bicarbonate cotransporter 4 (SLC4A5)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DTW40Z7
DMMU6BJ	MN	Electroneutral sodium bicarbonate exchanger 1 (SLC4A8)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DT03V27
DMMU6BJ	MN	Sodium bicarbonate cotransporter 3 (SLC4A7)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17071329

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	DT7RYVF
DMMU6BJ	MN	Sodium-driven chloride bicarbonate exchanger (SLC4A10)
DMMU6BJ	MT	DTP
DMMU6BJ	MA	Substrate
DMMU6BJ	RN	Molecular mechanisms of electrogenic sodium bicarbonate cotransport: structural and equilibrium thermodynamic considerations. J Membr Biol. 2004 Jan 15;197(2):77-90.
DMMU6BJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/15014910

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	TTZPWGN
DMMU6BJ	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMMU6BJ	MT	DTT
DMMU6BJ	MA	Blocker
DMMU6BJ	RN	Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
DMMU6BJ	RU	https://pubmed.ncbi.nlm.nih.gov/19445797

DMMU6BJ	DI	DMMU6BJ
DMMU6BJ	DN	Sodium bicarbonate
DMMU6BJ	MI	TTPLQO0
DMMU6BJ	MN	Voltage-gated potassium channel Kv4.3 (KCND3)
DMMU6BJ	MT	DTT
DMMU6BJ	MA	Blocker
DMMU6BJ	RN	Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23.
DMMU6BJ	RU	https://pubmed.ncbi.nlm.nih.gov/18815938

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	TTQ8AFT
DMM3950	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMM3950	MT	DTT
DMM3950	MA	Agonist
DMM3950	RN	Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
DMM3950	RU	https://pubmed.ncbi.nlm.nih.gov/11164065

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DTHKL3Q
DMM3950	MN	Basolateral Na-K-Cl symporter (SLC12A2)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Expression of the sodium potassium chloride cotransporter (NKCC1) and sodium chloride cotransporter (NCC) and their effects on rat lens transparency. Mol Vis. 2010 May 4;16:800-12.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/20458365

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DTO1UQY
DMM3950	MN	Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2 (SLC12A1)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Upregulation of renal sodium transporters in D5 dopamine receptor-deficient mice. Hypertension. 2010 Jun;55(6):1431-7.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/20404220

DMM3950	DI	DMM3950
DMM3950	DN	Sodium chloride
DMM3950	MI	DT6201N
DMM3950	MN	Organic cation transporter 3 (SLC22A3)
DMM3950	MT	DTP
DMM3950	MA	Substrate
DMM3950	RN	Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
DMM3950	RU	http://www.ncbi.nlm.nih.gov/pubmed/15028779

DMLJ634	DI	DMLJ634
DMLJ634	DN	Sodium lauryl sulfate
DMLJ634	MI	TTFNGC9
DMLJ634	MN	Serum albumin (ALB)
DMLJ634	MT	DTT
DMLJ634	MA	Binder
DMLJ634	RN	Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
DMLJ634	RU	https://pubmed.ncbi.nlm.nih.gov/16085141

DMGA9X0	DI	DMGA9X0
DMGA9X0	DN	Sodium nitroprusside
DMGA9X0	MI	TT23PYC
DMGA9X0	MN	Soluble guanylate cyclase (GCS)
DMGA9X0	MT	DTT
DMGA9X0	MA	Modulator
DMGA9X0	RN	Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
DMGA9X0	RU	https://www.ncbi.nlm.nih.gov/pubmed/22482042

DMCIWZL	DI	DMCIWZL
DMCIWZL	DN	Sodium oxybate
DMCIWZL	MI	DE8RJ3F
DMCIWZL	MN	Hydroxyacid-oxoacid transhydrogenase (ADHFE1)
DMCIWZL	MT	DME
DMCIWZL	MA	Metabolism
DMCIWZL	RN	Kinetic characterization of human hydroxyacid-oxoacid transhydrogenase: relevance to D-2-hydroxyglutaric and gamma-hydroxybutyric acidurias. J Inherit Metab Dis. 2005;28(6):921-30.
DMCIWZL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16435184

DMCIWZL	DI	DMCIWZL
DMCIWZL	DN	Sodium oxybate
DMCIWZL	MI	DE5KEWZ
DMCIWZL	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMCIWZL	MT	DME
DMCIWZL	MA	Metabolism
DMCIWZL	RN	Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68.
DMCIWZL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19300440

DMXLBCQ	DI	DMXLBCQ
DMXLBCQ	DN	Sodium phenylbutyrate
DMXLBCQ	MI	TTBH0VX
DMXLBCQ	MN	Histone deacetylase (HDAC)
DMXLBCQ	MT	DTT
DMXLBCQ	MA	Inhibitor
DMXLBCQ	RN	Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
DMXLBCQ	RU	https://pubmed.ncbi.nlm.nih.gov/20583972

DMXLBCQ	DI	DMXLBCQ
DMXLBCQ	DN	Sodium phenylbutyrate
DMXLBCQ	MI	TTFJ8Q1
DMXLBCQ	MN	Protein kinase C alpha (PRKCA)
DMXLBCQ	MT	DTT
DMXLBCQ	MA	Modulator
DMXLBCQ	RN	Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
DMXLBCQ	RU	https://pubmed.ncbi.nlm.nih.gov/23686835

DMKY27B	DI	DMKY27B
DMKY27B	DN	Sodium phosphate dibasic/sodium phosphate monobasic
DMKY27B	MI	DTWFOPY
DMKY27B	MN	Sodium-dependent phosphate transport protein 2B (SLC34A2)
DMKY27B	MT	DTP
DMKY27B	MA	Substrate
DMKY27B	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMKY27B	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DM4QFXJ	DI	DM4QFXJ
DM4QFXJ	DN	Sodium Tetradecyl Sulfate
DM4QFXJ	MI	TTZUXYS
DM4QFXJ	MN	Vitamin K-dependent protein C (PROC)
DM4QFXJ	MT	DTT
DM4QFXJ	MA	Inhibitor
DM4QFXJ	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DM4QFXJ	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DMCSLZ4	DI	DMCSLZ4
DMCSLZ4	DN	Sodium zirconium cyclosilicate
DMCSLZ4	MI	TTB0SC6
DMCSLZ4	MN	Potassium (K)
DMCSLZ4	MT	DTT
DMCSLZ4	MA	Binder
DMCSLZ4	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMCSLZ4	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMQI86A	DI	DMQI86A
DMQI86A	DN	Sofosbuvir
DMQI86A	MI	DTI7UX6
DMQI86A	MN	Breast cancer resistance protein (ABCG2)
DMQI86A	MT	DTP
DMQI86A	MA	Substrate
DMQI86A	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DMQI86A	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DMQI86A	DI	DMQI86A
DMQI86A	DN	Sofosbuvir
DMQI86A	MI	DTUGYRD
DMQI86A	MN	P-glycoprotein 1 (ABCB1)
DMQI86A	MT	DTP
DMQI86A	MA	Substrate
DMQI86A	RN	Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine. Clin Pharmacol Ther. 2018 Dec;104(6):1191-1198.
DMQI86A	RU	http://www.ncbi.nlm.nih.gov/pubmed/29569712

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTCJ2X8
DM5F47O	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTMVBWH
DM5F47O	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DM5F47O	DI	DM5F47O
DM5F47O	DN	Sofosbuvir + velpatasvir + voxilaprevir
DM5F47O	MI	TTHC7JD
DM5F47O	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DM5F47O	MT	DTT
DM5F47O	MA	Inhibitor
DM5F47O	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM5F47O	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	DECB0K3
DMG592Q	MN	Cytochrome P450 2D6 (CYP2D6)
DMG592Q	MT	DME
DMG592Q	MA	Metabolism
DMG592Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DMG592Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	DE4LYSA
DMG592Q	MN	Cytochrome P450 3A4 (CYP3A4)
DMG592Q	MT	DME
DMG592Q	MA	Metabolism
DMG592Q	RN	Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
DMG592Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19566112

DMG592Q	DI	DMG592Q
DMG592Q	DN	Solifenacin
DMG592Q	MI	TTQ13Z5
DMG592Q	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMG592Q	MT	DTT
DMG592Q	MA	Antagonist
DMG592Q	RN	Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
DMG592Q	RU	https://pubmed.ncbi.nlm.nih.gov/19446545

DMZ9FAO	DI	DMZ9FAO
DMZ9FAO	DN	Somatomedin-1
DMZ9FAO	MI	TTHRID2
DMZ9FAO	MN	Insulin-like growth factor I receptor (IGF1R)
DMZ9FAO	MT	DTT
DMZ9FAO	MA	Modulator
DMZ9FAO	RN	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
DMZ9FAO	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DMF3GM2	DI	DMF3GM2
DMF3GM2	DN	Somatropin recombinant
DMF3GM2	MI	TTKMAZ6
DMF3GM2	MN	Growth hormone receptor (GHR)
DMF3GM2	MT	DTT
DMF3GM2	MA	Binder
DMF3GM2	RN	Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7.
DMF3GM2	RU	https://pubmed.ncbi.nlm.nih.gov/16466607

DM72409	DI	DM72409
DM72409	DN	Sonidegib phosphate
DM72409	MI	DE4LYSA
DM72409	MN	Cytochrome P450 3A4 (CYP3A4)
DM72409	MT	DME
DM72409	MA	Metabolism
DM72409	RN	Sonidegib: first global approval. Drugs. 2015 Sep;75(13):1559-66.
DM72409	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26323341

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTI7UX6
DMS8IFC	MN	Breast cancer resistance protein (ABCG2)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
DMS8IFC	RU	https://doi.org/10.1021/mp1003898

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DEJGDUW
DMS8IFC	MN	Cytochrome P450 1A2 (CYP1A2)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22927483

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DES5XRU
DMS8IFC	MN	Cytochrome P450 2C8 (CYP2C8)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DE4LYSA
DMS8IFC	MN	Cytochrome P450 3A4 (CYP3A4)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21350850

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DEIBDNY
DMS8IFC	MN	Cytochrome P450 3A5 (CYP3A5)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Drug Interactions Flockhart Table
DMS8IFC	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DERD86B
DMS8IFC	MN	Cytochrome P450 3A7 (CYP3A7)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Drug Interactions Flockhart Table
DMS8IFC	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTGKNB4
DMS8IFC	MN	Epidermal growth factor receptor (EGFR)
DMS8IFC	MT	DTT
DMS8IFC	MA	Inhibitor
DMS8IFC	RN	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
DMS8IFC	RU	http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTFI42L
DMS8IFC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
DMS8IFC	RU	https://doi.org/10.1248/bpb.34.433

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DT3D8F0
DMS8IFC	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DT9C1TS
DMS8IFC	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTT79CX
DMS8IFC	MN	Organic cation transporter 1 (SLC22A1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	nan
DMS8IFC	RU	nan

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTUGYRD
DMS8IFC	MN	P-glycoprotein 1 (ABCB1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/20103600

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTI7421
DMS8IFC	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DTYEM9B
DMS8IFC	MN	RalBP1-associated Eps domain-containing protein 2 (RALBP1)
DMS8IFC	MT	DTP
DMS8IFC	MA	Substrate
DMS8IFC	RN	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
DMS8IFC	RU	http://www.ncbi.nlm.nih.gov/pubmed/19626587

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTX41N9
DMS8IFC	MN	Tyrosine-protein kinase Kit (KIT)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	DE85D2P
DMS8IFC	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMS8IFC	MT	DME
DMS8IFC	MA	Metabolism
DMS8IFC	RN	Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20706860

DMS8IFC	DI	DMS8IFC
DMS8IFC	DN	Sorafenib
DMS8IFC	MI	TTUTJGQ
DMS8IFC	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS8IFC	MT	DTT
DMS8IFC	MA	Modulator
DMS8IFC	RN	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
DMS8IFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/18852116

DMAN0DE	DI	DMAN0DE
DMAN0DE	DN	Sorbitol
DMAN0DE	MI	DEWU03P
DMAN0DE	MN	Sorbitol dehydrogenase (SORD)
DMAN0DE	MT	DME
DMAN0DE	MA	Metabolism
DMAN0DE	RN	Plasma concentration of iditol dehydrogenase (sorbitol dehydrogenase) in ponies treated with aflatoxin B1. Am J Vet Res. 1980 Jun;41(6):925-7.
DMAN0DE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7436081

DMUJGR1	DI	DMUJGR1
DMUJGR1	DN	Sorivudine
DMUJGR1	MI	TT84ETX
DMUJGR1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMUJGR1	MT	DTT
DMUJGR1	MA	Modulator
DMUJGR1	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMUJGR1	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	TTR6W5O
DML60TN	MN	Adrenergic receptor beta-1 (ADRB1)
DML60TN	MT	DTT
DML60TN	MA	Antagonist
DML60TN	RN	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
DML60TN	RU	https://pubmed.ncbi.nlm.nih.gov/19259968

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	DECB0K3
DML60TN	MN	Cytochrome P450 2D6 (CYP2D6)
DML60TN	MT	DME
DML60TN	MA	Metabolism
DML60TN	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DML60TN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DML60TN	DI	DML60TN
DML60TN	DN	Sotalol
DML60TN	MI	DTE2B1D
DML60TN	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DML60TN	MT	DTP
DML60TN	MA	Substrate
DML60TN	RN	Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
DML60TN	RU	http://www.ncbi.nlm.nih.gov/pubmed/19067419

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	TTN6J5F
DMB4HCT	MN	Bacterial DNA gyrase (Bact gyrase)
DMB4HCT	MT	DTT
DMB4HCT	MA	Modulator
DMB4HCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HCT	RU	https://www.fda.gov/

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	DTUGYRD
DMB4HCT	MN	P-glycoprotein 1 (ABCB1)
DMB4HCT	MT	DTP
DMB4HCT	MA	Substrate
DMB4HCT	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMB4HCT	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMB4HCT	DI	DMB4HCT
DMB4HCT	DN	Sparfloxacin
DMB4HCT	MI	TTIXTO3
DMB4HCT	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMB4HCT	MT	DTT
DMB4HCT	MA	Modulator
DMB4HCT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMB4HCT	RU	https://www.fda.gov/

DM6CMJD	DI	DM6CMJD
DM6CMJD	DN	Spectinomycin
DM6CMJD	MI	DEYWTIQ
DM6CMJD	MN	Aminoglycoside adenylyltransferase (aadA1a)
DM6CMJD	MT	DME
DM6CMJD	MA	Metabolism
DM6CMJD	RN	Structural mechanism of AadA, a dual-specificity aminoglycoside adenylyltransferase from Salmonella enterica. J Biol Chem. 2018 Jul 20;293(29):11481-11490.
DM6CMJD	RU	https://pubmed.ncbi.nlm.nih.gov/29871922

DM0MQ35	DI	DM0MQ35
DM0MQ35	DN	Spectinomycin
DM0MQ35	MI	TTQ8KVI
DM0MQ35	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DM0MQ35	MT	DTT
DM0MQ35	MA	Binder
DM0MQ35	RN	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
DM0MQ35	RU	https://pubmed.ncbi.nlm.nih.gov/11014183

DM6XFHS	DI	DM6XFHS
DM6XFHS	DN	SPI-1005
DM6XFHS	MI	TTFNGC9
DM6XFHS	MN	Serum albumin (ALB)
DM6XFHS	MT	DTT
DM6XFHS	MA	Binder
DM6XFHS	RN	Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
DM6XFHS	RU	https://pubmed.ncbi.nlm.nih.gov/7945407

DM0BQRS	DI	DM0BQRS
DM0BQRS	DN	Spinosad
DM0BQRS	MI	TT9JZPU
DM0BQRS	MN	Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR)
DM0BQRS	MT	DTT
DM0BQRS	MA	Modulator
DM0BQRS	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM0BQRS	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM20R5F	DI	DM20R5F
DM20R5F	DN	Spiramycin
DM20R5F	MI	TTLFGBV
DM20R5F	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM20R5F	MT	DTT
DM20R5F	MA	Binder
DM20R5F	RN	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
DM20R5F	RU	https://pubmed.ncbi.nlm.nih.gov/11768328

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	TTL69WB
DM5XLTY	MN	Angiotensin-converting enzyme (ACE)
DM5XLTY	MT	DTT
DM5XLTY	MA	Inhibitor
DM5XLTY	RN	Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81.
DM5XLTY	RU	https://pubmed.ncbi.nlm.nih.gov/16126915

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DEQMBHW
DM5XLTY	MN	Dipeptidase (pepV)
DM5XLTY	MT	DME
DM5XLTY	MA	Metabolism
DM5XLTY	RN	Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45.
DM5XLTY	RU	https://pubmed.ncbi.nlm.nih.gov/16962986

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DT9G7XN
DM5XLTY	MN	Peptide transporter 1 (SLC15A1)
DM5XLTY	MT	DTP
DM5XLTY	MA	Substrate
DM5XLTY	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM5XLTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM5XLTY	DI	DM5XLTY
DM5XLTY	DN	Spirapril
DM5XLTY	MI	DT8QKNP
DM5XLTY	MN	Peptide transporter 2 (SLC15A2)
DM5XLTY	MT	DTP
DM5XLTY	MA	Substrate
DM5XLTY	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM5XLTY	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM2AQ5N	DI	DM2AQ5N
DM2AQ5N	DN	Spironolactone
DM2AQ5N	MI	TT26PHO
DM2AQ5N	MN	Mineralocorticoid receptor  (MR)
DM2AQ5N	MT	DTT
DM2AQ5N	MA	Modulator
DM2AQ5N	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM2AQ5N	RU	https://www.fda.gov/

DMCO5JZ	DI	DMCO5JZ
DMCO5JZ	DN	SR141716A
DMCO5JZ	MI	TT6OEDT
DMCO5JZ	MN	Cannabinoid receptor 1 (CB1)
DMCO5JZ	MT	DTT
DMCO5JZ	MA	Antagonist
DMCO5JZ	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMCO5JZ	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DM6DEK9	DI	DM6DEK9
DM6DEK9	DN	Stavudine
DM6DEK9	MI	TT84ETX
DM6DEK9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6DEK9	MT	DTT
DM6DEK9	MA	Inhibitor
DM6DEK9	RN	Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
DM6DEK9	RU	https://pubmed.ncbi.nlm.nih.gov/15183338

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DEJGDUW
DMMSDOY	MN	Cytochrome P450 1A2 (CYP1A2)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
DMMSDOY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16022579

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DE4LYSA
DMMSDOY	MN	Cytochrome P450 3A4 (CYP3A4)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	Product characteristics of Diacomit.
DMMSDOY	RU	http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	TTEX6LM
DMMSDOY	MN	GABA(A) receptor gamma-3 (GABRG3)
DMMSDOY	MT	DTT
DMMSDOY	MA	Modulator
DMMSDOY	RN	Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16.
DMMSDOY	RU	https://pubmed.ncbi.nlm.nih.gov/16650136

DMMSDOY	DI	DMMSDOY
DMMSDOY	DN	Stiripentol
DMMSDOY	MI	DEGTFWK
DMMSDOY	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMMSDOY	MT	DME
DMMSDOY	MA	Metabolism
DMMSDOY	RN	FDA Label of Diacomit. The 2020 official website of the U.S. Food and Drug Administration.
DMMSDOY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf

DM5JQ0D	DI	DM5JQ0D
DM5JQ0D	DN	Streptokinase
DM5JQ0D	MI	TTP86E2
DM5JQ0D	MN	Plasminogen (PLG)
DM5JQ0D	MT	DTT
DM5JQ0D	MA	Activator
DM5JQ0D	RN	Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61.
DM5JQ0D	RU	https://pubmed.ncbi.nlm.nih.gov/19123085

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEYWTIQ
DMSRXVM	MN	Aminoglycoside adenylyltransferase (aadA1a)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Structural mechanism of AadA, a dual-specificity aminoglycoside adenylyltransferase from Salmonella enterica. J Biol Chem. 2018 Jul 20;293(29):11481-11490.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/29871922

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEWPAJD
DMSRXVM	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DE2M583
DMSRXVM	MN	Endoglucanase Y (EGY)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DE2AZTG
DMSRXVM	MN	Endoglucanase Y (EGY)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/10688695

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEMVXEA
DMSRXVM	MN	Phosphotransferase enzyme strA (strA)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Genetic analysis of streptomycin-resistant (Sm(R)) strains of Erwinia amylovora suggests that dissemination of two genotypes is responsible for the current distribution of Sm(R) E. amylovora in Michigan. Phytopathology. 2011 Feb;101(2):182-91.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/20923367

DMSRXVM	DI	DMSRXVM
DMSRXVM	DN	Streptomycin
DMSRXVM	MI	DEXCHR2
DMSRXVM	MN	Phosphotransferase enzyme strB (strB)
DMSRXVM	MT	DME
DMSRXVM	MA	Metabolism
DMSRXVM	RN	Genetic analysis of streptomycin-resistant (Sm(R)) strains of Erwinia amylovora suggests that dissemination of two genotypes is responsible for the current distribution of Sm(R) E. amylovora in Michigan. Phytopathology. 2011 Feb;101(2):182-91.
DMSRXVM	RU	https://pubmed.ncbi.nlm.nih.gov/20923367

DME1LQN	DI	DME1LQN
DME1LQN	DN	Streptomycin
DME1LQN	MI	TTQ8KVI
DME1LQN	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DME1LQN	MT	DTT
DME1LQN	MA	Binder
DME1LQN	RN	Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8.
DME1LQN	RU	https://pubmed.ncbi.nlm.nih.gov/11014183

DMOF7AT	DI	DMOF7AT
DMOF7AT	DN	Streptozocin
DMOF7AT	MI	TTUTN1I
DMOF7AT	MN	Human Deoxyribonucleic acid (hDNA)
DMOF7AT	MT	DTT
DMOF7AT	MA	Breaker
DMOF7AT	RN	Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90.
DMOF7AT	RU	https://pubmed.ncbi.nlm.nih.gov/19561381

DME81IY	DI	DME81IY
DME81IY	DN	Succimer
DME81IY	MI	DTFI42L
DME81IY	MN	Multidrug resistance-associated protein 2 (ABCC2)
DME81IY	MT	DTP
DME81IY	MA	Substrate
DME81IY	RN	MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
DME81IY	RU	http://www.ncbi.nlm.nih.gov/pubmed/19063911

DMDWICP	DI	DMDWICP
DMDWICP	DN	Succinic acid
DMDWICP	MI	TTJUWVB
DMDWICP	MN	Succinate-semialdehyde dehydrogenase (ALDH5A1)
DMDWICP	MT	DTT
DMDWICP	MA	Inhibitor
DMDWICP	RN	Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68.
DMDWICP	RU	https://pubmed.ncbi.nlm.nih.gov/19300440

DM2ET1M	DI	DM2ET1M
DM2ET1M	DN	Succinylcholine
DM2ET1M	MI	TTQ13Z5
DM2ET1M	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM2ET1M	MT	DTT
DM2ET1M	MA	Antagonist
DM2ET1M	RN	The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906.
DM2ET1M	RU	https://pubmed.ncbi.nlm.nih.gov/19020136

DMP9HBO	DI	DMP9HBO
DMP9HBO	DN	Sucralfate
DMP9HBO	MI	TTGKIED
DMP9HBO	MN	Fibroblast growth factor-2 (FGF2)
DMP9HBO	MT	DTT
DMP9HBO	MA	Modulator
DMP9HBO	RN	Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
DMP9HBO	RU	https://pubmed.ncbi.nlm.nih.gov/7720996

DMU7YEL	DI	DMU7YEL
DMU7YEL	DN	Sufentanil
DMU7YEL	MI	DE4LYSA
DMU7YEL	MN	Cytochrome P450 3A4 (CYP3A4)
DMU7YEL	MT	DME
DMU7YEL	MA	Metabolism
DMU7YEL	RN	Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol. 1997 Jun 1;53(11):1613-9.
DMU7YEL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9264313

DMU7YEL	DI	DMU7YEL
DMU7YEL	DN	Sufentanil
DMU7YEL	MI	TTN4QDT
DMU7YEL	MN	Opioid receptor (OPR)
DMU7YEL	MT	DTT
DMU7YEL	MA	Antagonist
DMU7YEL	RN	mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
DMU7YEL	RU	https://pubmed.ncbi.nlm.nih.gov/19519662

DMZ6VEY	DI	DMZ6VEY
DMZ6VEY	DN	Sulfacetamide
DMZ6VEY	MI	TT915ZD
DMZ6VEY	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMZ6VEY	MT	DTT
DMZ6VEY	MA	Inhibitor
DMZ6VEY	RN	Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54.
DMZ6VEY	RU	https://pubmed.ncbi.nlm.nih.gov/18475922

DMKI2XC	DI	DMKI2XC
DMKI2XC	DN	Sulfacytine
DMKI2XC	MI	TT4ILYC
DMKI2XC	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKI2XC	MT	DTT
DMKI2XC	MA	Inhibitor
DMKI2XC	RN	Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. Urology. 1976 Mar;7(3):267-71.
DMKI2XC	RU	https://pubmed.ncbi.nlm.nih.gov/769287

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	TT4ILYC
DMTW3R8	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMTW3R8	MT	DTT
DMTW3R8	MA	Inhibitor
DMTW3R8	RN	Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
DMTW3R8	RU	https://pubmed.ncbi.nlm.nih.gov/18434167

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DES5XRU
DMTW3R8	MN	Cytochrome P450 2C8 (CYP2C8)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DE5IED8
DMTW3R8	MN	Cytochrome P450 2C9 (CYP2C9)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DEVDYN7
DMTW3R8	MN	Cytochrome P450 2E1 (CYP2E1)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DE4LYSA
DMTW3R8	MN	Cytochrome P450 3A4 (CYP3A4)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMTW3R8	DI	DMTW3R8
DMTW3R8	DN	Sulfadiazine
DMTW3R8	MI	DEZV4AP
DMTW3R8	MN	RNA cytidine acetyltransferase (hALP)
DMTW3R8	MT	DME
DMTW3R8	MA	Metabolism
DMTW3R8	RN	Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
DMTW3R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15843491

DMKM3SX	DI	DMKM3SX
DMKM3SX	DN	Sulfamerazine
DMKM3SX	MI	TT4ILYC
DMKM3SX	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMKM3SX	MT	DTT
DMKM3SX	MA	Inhibitor
DMKM3SX	RN	A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
DMKM3SX	RU	https://pubmed.ncbi.nlm.nih.gov/19586630

DMRGZ16	DI	DMRGZ16
DMRGZ16	DN	Sulfamethazine
DMRGZ16	MI	TT4ILYC
DMRGZ16	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMRGZ16	MT	DTT
DMRGZ16	MA	Inhibitor
DMRGZ16	RN	A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80.
DMRGZ16	RU	https://pubmed.ncbi.nlm.nih.gov/19505691

DMGCHDS	DI	DMGCHDS
DMGCHDS	DN	Sulfamethizole
DMGCHDS	MI	TT4ILYC
DMGCHDS	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMGCHDS	MT	DTT
DMGCHDS	MA	Inhibitor
DMGCHDS	RN	Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34.
DMGCHDS	RU	https://pubmed.ncbi.nlm.nih.gov/2372557

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	TT4ILYC
DMB08GE	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMB08GE	MT	DTT
DMB08GE	MA	Inhibitor
DMB08GE	RN	In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
DMB08GE	RU	https://pubmed.ncbi.nlm.nih.gov/7786001

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DES5XRU
DMB08GE	MN	Cytochrome P450 2C8 (CYP2C8)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signaling. J Immunol. 2007 May 1;178(9):5533-42.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17442935

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE5IED8
DMB08GE	MN	Cytochrome P450 2C9 (CYP2C9)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes. Life Sci. 2005 May 27;77(2):205-19.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15862605

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE4LYSA
DMB08GE	MN	Cytochrome P450 3A4 (CYP3A4)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	The effect of cimetidine on the formation of sulfamethoxazole hydroxylamine in patients with human immunodeficiency virus. J Clin Pharmacol. 1998 May;38(5):463-6.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9602961

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE073H6
DMB08GE	MN	Prostaglandin G/H synthase 1 (COX-1)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DEZV4AP
DMB08GE	MN	RNA cytidine acetyltransferase (hALP)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17909290

DMB08GE	DI	DMB08GE
DMB08GE	DN	Sulfamethoxazole
DMB08GE	MI	DE85D2P
DMB08GE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMB08GE	MT	DME
DMB08GE	MA	Metabolism
DMB08GE	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMB08GE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTUNARX
DMIO1K0	MN	Carbonic anhydrase (CA)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTANPDJ
DMIO1K0	MN	Carbonic anhydrase II (CA-II)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/20201556

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTZHA0O
DMIO1K0	MN	Carbonic anhydrase IV (CA-IV)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/15686931

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTCFSPE
DMIO1K0	MN	Carbonic anhydrase VI (CA-VI)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/19193158

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTSYM0R
DMIO1K0	MN	Carbonic anhydrase XII (CA-XII)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/20201556

DMIO1K0	DI	DMIO1K0
DMIO1K0	DN	Sulfamylon
DMIO1K0	MI	TTEYTKG
DMIO1K0	MN	Carbonic anhydrase XIV (CA-XIV)
DMIO1K0	MT	DTT
DMIO1K0	MA	Inhibitor
DMIO1K0	RN	Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
DMIO1K0	RU	https://pubmed.ncbi.nlm.nih.gov/16039848

DMABVE9	DI	DMABVE9
DMABVE9	DN	Sulfanilamide
DMABVE9	MI	TT4ILYC
DMABVE9	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMABVE9	MT	DTT
DMABVE9	MA	Modulator
DMABVE9	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMABVE9	RU	https://www.fda.gov/

DMFNAEM	DI	DMFNAEM
DMFNAEM	DN	Sulfaphenazole
DMFNAEM	MI	TTR40YJ
DMFNAEM	MN	S-mephenytoin 4-hydroxylase (CYP2C9)
DMFNAEM	MT	DTT
DMFNAEM	MA	Modulator
DMFNAEM	RN	Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9.
DMFNAEM	RU	https://www.ncbi.nlm.nih.gov/pubmed/9819219

DMIUYFH	DI	DMIUYFH
DMIUYFH	DN	Sulfapyridine
DMIUYFH	MI	TT4ILYC
DMIUYFH	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMIUYFH	MT	DTT
DMIUYFH	MA	Inhibitor
DMIUYFH	RN	A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
DMIUYFH	RU	https://pubmed.ncbi.nlm.nih.gov/19586630

DMIUYFH	DI	DMIUYFH
DMIUYFH	DN	Sulfapyridine
DMIUYFH	MI	DEZV4AP
DMIUYFH	MN	RNA cytidine acetyltransferase (hALP)
DMIUYFH	MT	DME
DMIUYFH	MA	Metabolism
DMIUYFH	RN	Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009 Sep;407(1-2):30-5.
DMIUYFH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19560446

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	TTIMJ02
DMICA9H	MN	ATP-binding cassette transporter G2 (ABCG2)
DMICA9H	MT	DTT
DMICA9H	MA	Inhibitor
DMICA9H	RN	The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/8596047

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE5CAX1
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEGTKHL
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE3UF6Z
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DE6GHJ5
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEEISQ2
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEI2PC5
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DETEMAH
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972 Jun;181(3):555-62.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/4402374

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEM1BHT
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIKZOU
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/31158845

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DENLBG3
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIHK8V
DMICA9H	MN	Azoreductase (azoR)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica. 2012 Aug;42(8):791-7.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/22348441

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTI7UX6
DMICA9H	MN	Breast cancer resistance protein (ABCG2)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/18841445

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DEIBDNY
DMICA9H	MN	Cytochrome P450 3A5 (CYP3A5)
DMICA9H	MT	DME
DMICA9H	MA	Metabolism
DMICA9H	RN	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
DMICA9H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9117175

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTFI42L
DMICA9H	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/19541926

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	TTSXVID
DMICA9H	MN	Nuclear factor NF-kappa-B (NFKB)
DMICA9H	MT	DTT
DMICA9H	MA	Activator
DMICA9H	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMICA9H	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DTPFTEQ
DMICA9H	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
DMICA9H	RU	http://www.ncbi.nlm.nih.gov/pubmed/28322941

DMICA9H	DI	DMICA9H
DMICA9H	DN	Sulfasalazine
DMICA9H	MI	DT9G7XN
DMICA9H	MN	Peptide transporter 1 (SLC15A1)
DMICA9H	MT	DTP
DMICA9H	MA	Substrate
DMICA9H	RN	Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
DMICA9H	RU	https://doi.org/10.1007/BF02980227

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DES5XRU
DMEV954	MN	Cytochrome P450 2C8 (CYP2C8)
DMEV954	MT	DME
DMEV954	MA	Metabolism
DMEV954	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMEV954	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DE4LYSA
DMEV954	MN	Cytochrome P450 3A4 (CYP3A4)
DMEV954	MT	DME
DMEV954	MA	Metabolism
DMEV954	RN	CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
DMEV954	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065438

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	TTOI92F
DMEV954	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMEV954	MT	DTT
DMEV954	MA	Modulator
DMEV954	RN	Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40.
DMEV954	RU	https://pubmed.ncbi.nlm.nih.gov/18180270

DMEV954	DI	DMEV954
DMEV954	DN	Sulfinpyrazone
DMEV954	MI	DTFI42L
DMEV954	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMEV954	MT	DTP
DMEV954	MA	Substrate
DMEV954	RN	Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
DMEV954	RU	http://www.ncbi.nlm.nih.gov/pubmed/10917554

DMXLT8C	DI	DMXLT8C
DMXLT8C	DN	Sulfisoxazole
DMXLT8C	MI	TT4ILYC
DMXLT8C	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMXLT8C	MT	DTT
DMXLT8C	MA	Inhibitor
DMXLT8C	RN	Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
DMXLT8C	RU	https://pubmed.ncbi.nlm.nih.gov/7486915

DMXLT8C	DI	DMXLT8C
DMXLT8C	DN	Sulfisoxazole
DMXLT8C	MI	DE5IED8
DMXLT8C	MN	Cytochrome P450 2C9 (CYP2C9)
DMXLT8C	MT	DME
DMXLT8C	MA	Metabolism
DMXLT8C	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DMXLT8C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DM1YA7M	DI	DM1YA7M
DM1YA7M	DN	Sulfonamides
DM1YA7M	MI	TT4ILYC
DM1YA7M	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DM1YA7M	MT	DTT
DM1YA7M	MA	Binder
DM1YA7M	RN	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
DM1YA7M	RU	https://pubmed.ncbi.nlm.nih.gov/18804175

DMAYX6P	DI	DMAYX6P
DMAYX6P	DN	Sulfoxone
DMAYX6P	MI	TT915ZD
DMAYX6P	MN	Candida Mannose-6-phosphate isomerase (Candi PMI1)
DMAYX6P	MT	DTT
DMAYX6P	MA	Inhibitor
DMAYX6P	RN	Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54.
DMAYX6P	RU	https://pubmed.ncbi.nlm.nih.gov/18475922

DM2QHZU	DI	DM2QHZU
DM2QHZU	DN	Sulindac
DM2QHZU	MI	TTFBNVI
DM2QHZU	MN	Aldose reductase (AKR1B1)
DM2QHZU	MT	DTT
DM2QHZU	MA	Inhibitor
DM2QHZU	RN	Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
DM2QHZU	RU	https://pubmed.ncbi.nlm.nih.gov/6409111

DM2QHZU	DI	DM2QHZU
DM2QHZU	DN	Sulindac
DM2QHZU	MI	DTCSGPB
DM2QHZU	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2QHZU	MT	DTP
DM2QHZU	MA	Substrate
DM2QHZU	RN	Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
DM2QHZU	RU	http://www.ncbi.nlm.nih.gov/pubmed/20649844

DMNUC42	DI	DMNUC42
DMNUC42	DN	Sulodexide
DMNUC42	MI	TT4QPUL
DMNUC42	MN	Antithrombin-III (ATIII)
DMNUC42	MT	DTT
DMNUC42	MA	Activator
DMNUC42	RN	Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20.
DMNUC42	RU	https://pubmed.ncbi.nlm.nih.gov/9436179

DMZI2UF	DI	DMZI2UF
DMZI2UF	DN	Sulphadoxine
DMZI2UF	MI	TT4ILYC
DMZI2UF	MN	Bacterial Dihydropteroate synthetase (Bact folP)
DMZI2UF	MT	DTT
DMZI2UF	MA	Binder
DMZI2UF	RN	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
DMZI2UF	RU	https://pubmed.ncbi.nlm.nih.gov/18220771

DMZI2UF	DI	DMZI2UF
DMZI2UF	DN	Sulphadoxine
DMZI2UF	MI	TTGP7BY
DMZI2UF	MN	Monoamine oxidase type B (MAO-B)
DMZI2UF	MT	DTT
DMZI2UF	MA	Inhibitor
DMZI2UF	RN	Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
DMZI2UF	RU	https://pubmed.ncbi.nlm.nih.gov/11928718

DMF54ZG	DI	DMF54ZG
DMF54ZG	DN	Sulpiride
DMF54ZG	MI	TTEX248
DMF54ZG	MN	Dopamine D2 receptor (D2R)
DMF54ZG	MT	DTT
DMF54ZG	MA	Antagonist
DMF54ZG	RN	The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
DMF54ZG	RU	https://pubmed.ncbi.nlm.nih.gov/12083990

DMF54ZG	DI	DMF54ZG
DMF54ZG	DN	Sulpiride
DMF54ZG	MI	DT9G7XN
DMF54ZG	MN	Peptide transporter 1 (SLC15A1)
DMF54ZG	MT	DTP
DMF54ZG	MA	Substrate
DMF54ZG	RN	Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Oct;25(10):1345-50.
DMF54ZG	RU	http://www.ncbi.nlm.nih.gov/pubmed/12392092

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	TT6MSOK
DMVYXR8	MN	5-HT 1D receptor (HTR1D)
DMVYXR8	MT	DTT
DMVYXR8	MA	Agonist
DMVYXR8	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DMVYXR8	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	DTT79CX
DMVYXR8	MN	Organic cation transporter 1 (SLC22A1)
DMVYXR8	MT	DTP
DMVYXR8	MA	Substrate
DMVYXR8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMVYXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMVYXR8	DI	DMVYXR8
DMVYXR8	DN	Sumatriptan
DMVYXR8	MI	DTUGYRD
DMVYXR8	MN	P-glycoprotein 1 (ABCB1)
DMVYXR8	MT	DTP
DMVYXR8	MA	Substrate
DMVYXR8	RN	HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci. 2001 Oct;90(10):1608-19. Comparative Study
DMVYXR8	RU	http://www.ncbi.nlm.nih.gov/pubmed/11745719

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTI7UX6
DMCBJSR	MN	Breast cancer resistance protein (ABCG2)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
DMCBJSR	RU	https://doi.org/10.1021/mp1003898

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DE4LYSA
DMCBJSR	MN	Cytochrome P450 3A4 (CYP3A4)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
DMCBJSR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DEIBDNY
DMCBJSR	MN	Cytochrome P450 3A5 (CYP3A5)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	Drug Interactions Flockhart Table
DMCBJSR	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DERD86B
DMCBJSR	MN	Cytochrome P450 3A7 (CYP3A7)
DMCBJSR	MT	DME
DMCBJSR	MA	Metabolism
DMCBJSR	RN	Drug Interactions Flockhart Table
DMCBJSR	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DT3D8F0
DMCBJSR	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DT9C1TS
DMCBJSR	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTUGYRD
DMCBJSR	MN	P-glycoprotein 1 (ABCB1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/19773380

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	DTYEM9B
DMCBJSR	MN	RalBP1-associated Eps domain-containing protein 2 (RALBP1)
DMCBJSR	MT	DTP
DMCBJSR	MA	Substrate
DMCBJSR	RN	Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
DMCBJSR	RU	http://www.ncbi.nlm.nih.gov/pubmed/19626587

DMCBJSR	DI	DMCBJSR
DMCBJSR	DN	Sunitinib
DMCBJSR	MI	TTUTJGQ
DMCBJSR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMCBJSR	MT	DTT
DMCBJSR	MA	Modulator
DMCBJSR	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMCBJSR	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMN8E5D	DI	DMN8E5D
DMN8E5D	DN	Sunitinib malate
DMN8E5D	MI	DTUGYRD
DMN8E5D	MN	P-glycoprotein 1 (ABCB1)
DMN8E5D	MT	DTP
DMN8E5D	MA	Substrate
DMN8E5D	RN	JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.
DMN8E5D	RU	http://www.ncbi.nlm.nih.gov/pubmed/30121250

DMOGREH	DI	DMOGREH
DMOGREH	DN	Suplatast tosilate
DMOGREH	MI	TTGPK5Y
DMOGREH	MN	T(H2) cytokine production (TH2 produ)
DMOGREH	MT	DTT
DMOGREH	MA	Modulator
DMOGREH	RN	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45.
DMOGREH	RU	https://pubmed.ncbi.nlm.nih.gov/10756224

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	DE5IED8
DMKXJZ7	MN	Cytochrome P450 2C9 (CYP2C9)
DMKXJZ7	MT	DME
DMKXJZ7	MA	Metabolism
DMKXJZ7	RN	Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
DMKXJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14570769

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	TT8NGED
DMKXJZ7	MN	Prostaglandin G/H synthase 1 (COX-1)
DMKXJZ7	MT	DTT
DMKXJZ7	MA	Inhibitor
DMKXJZ7	RN	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
DMKXJZ7	RU	https://pubmed.ncbi.nlm.nih.gov/11885959

DMKXJZ7	DI	DMKXJZ7
DMKXJZ7	DN	Suprofen
DMKXJZ7	MI	DEYGVN4
DMKXJZ7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKXJZ7	MT	DME
DMKXJZ7	MA	Metabolism
DMKXJZ7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMKXJZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM0E6S3	DI	DM0E6S3
DM0E6S3	DN	Suvorexant
DM0E6S3	MI	DE4LYSA
DM0E6S3	MN	Cytochrome P450 3A4 (CYP3A4)
DM0E6S3	MT	DME
DM0E6S3	MA	Metabolism
DM0E6S3	RN	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
DM0E6S3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26955275

DM0E6S3	DI	DM0E6S3
DM0E6S3	DN	Suvorexant
DM0E6S3	MI	TT9N02I
DM0E6S3	MN	Orexin receptor type 2 (HCRTR2)
DM0E6S3	MT	DTT
DM0E6S3	MA	Modulator
DM0E6S3	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DM0E6S3	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM6S0HB	DI	DM6S0HB
DM6S0HB	DN	TachoComb
DM6S0HB	MI	TTWODQF
DM6S0HB	MN	Fibrin (FG)
DM6S0HB	MT	DTT
DM6S0HB	MA	Modulator
DM6S0HB	RN	Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2011 Jan-Feb;58(105):187-91.
DM6S0HB	RU	https://pubmed.ncbi.nlm.nih.gov/21510312

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	TT1RS9F
DM51FY6	MN	Acetylcholinesterase (AChE)
DM51FY6	MT	DTT
DM51FY6	MA	Inhibitor
DM51FY6	RN	Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
DM51FY6	RU	https://pubmed.ncbi.nlm.nih.gov/12139368

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DEJGDUW
DM51FY6	MN	Cytochrome P450 1A2 (CYP1A2)
DM51FY6	MT	DME
DM51FY6	MA	Metabolism
DM51FY6	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM51FY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DE4ZHS1
DM51FY6	MN	Glutathione S-transferase alpha-1 (GSTA1)
DM51FY6	MT	DME
DM51FY6	MA	Metabolism
DM51FY6	RN	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
DM51FY6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10801254

DM51FY6	DI	DM51FY6
DM51FY6	DN	Tacrine
DM51FY6	MI	DTUGYRD
DM51FY6	MN	P-glycoprotein 1 (ABCB1)
DM51FY6	MT	DTP
DM51FY6	MA	Substrate
DM51FY6	RN	Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes. J Pharm Pharm Sci. 2014;17(3):427-38.
DM51FY6	RU	http://www.ncbi.nlm.nih.gov/pubmed/25224352

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	TTA4LDE
DMZ7XNQ	MN	Calcineurin (PPP3CA)
DMZ7XNQ	MT	DTT
DMZ7XNQ	MA	Inhibitor
DMZ7XNQ	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DE4LYSA
DMZ7XNQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEIBDNY
DMZ7XNQ	MN	Cytochrome P450 3A5 (CYP3A5)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635182

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DE3N2FM
DMZ7XNQ	MN	NADPH-cytochrome P450 reductase (CPR)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
DMZ7XNQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28731962

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DTUGYRD
DMZ7XNQ	MN	P-glycoprotein 1 (ABCB1)
DMZ7XNQ	MT	DTP
DMZ7XNQ	MA	Substrate
DMZ7XNQ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZ7XNQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEW6V07
DMZ7XNQ	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMZ7XNQ	DI	DMZ7XNQ
DMZ7XNQ	DN	Tacrolimus
DMZ7XNQ	MI	DEA65D8
DMZ7XNQ	MN	Ribosomal 23S RNA methyltransferase Erm (erm)
DMZ7XNQ	MT	DME
DMZ7XNQ	MA	Metabolism
DMZ7XNQ	RN	High frequency of macrolide resistance mechanisms in clinical isolates of Corynebacterium species. Microb Drug Resist. 2010 Dec;16(4):273-7.
DMZ7XNQ	RU	https://pubmed.ncbi.nlm.nih.gov/20624090

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DE4LYSA
DMJZHT1	MN	Cytochrome P450 3A4 (CYP3A4)
DMJZHT1	MT	DME
DMJZHT1	MA	Metabolism
DMJZHT1	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DMJZHT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DEIBDNY
DMJZHT1	MN	Cytochrome P450 3A5 (CYP3A5)
DMJZHT1	MT	DME
DMJZHT1	MA	Metabolism
DMJZHT1	RN	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
DMJZHT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25744459

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	DTUGYRD
DMJZHT1	MN	P-glycoprotein 1 (ABCB1)
DMJZHT1	MT	DTP
DMJZHT1	MA	Substrate
DMJZHT1	RN	In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319.
DMJZHT1	RU	http://www.ncbi.nlm.nih.gov/pubmed/28769012

DMJZHT1	DI	DMJZHT1
DMJZHT1	DN	Tadalafil
DMJZHT1	MI	TTJ0IQB
DMJZHT1	MN	Phosphodiesterase 5A (PDE5A)
DMJZHT1	MT	DTT
DMJZHT1	MA	Inhibitor
DMJZHT1	RN	Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
DMJZHT1	RU	https://pubmed.ncbi.nlm.nih.gov/19487219

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	DECB0K3
DM1XT4N	MN	Cytochrome P450 2D6 (CYP2D6)
DM1XT4N	MT	DME
DM1XT4N	MA	Metabolism
DM1XT4N	RN	Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99.
DM1XT4N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27528800

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	TTB8JQ7
DM1XT4N	MN	Electron transport complex III (Complex III)
DM1XT4N	MT	DTT
DM1XT4N	MA	Inhibitor
DM1XT4N	RN	Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. 
DM1XT4N	RU	https://pubmed.ncbi.nlm.nih.gov/30229442

DM1XT4N	DI	DM1XT4N
DM1XT4N	DN	Tafenoquine
DM1XT4N	MI	TTULV0X
DM1XT4N	MN	Reactive oxygen species (ROS)
DM1XT4N	MT	DTT
DM1XT4N	MA	Modulator
DM1XT4N	RN	Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. 
DM1XT4N	RU	https://pubmed.ncbi.nlm.nih.gov/30229442

DMFC41K	DI	DMFC41K
DMFC41K	DN	Tafluprost
DMFC41K	MI	TTT2ZAR
DMFC41K	MN	Prostaglandin F2-alpha receptor (PTGFR)
DMFC41K	MT	DTT
DMFC41K	MA	Modulator
DMFC41K	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMFC41K	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM9HQ5U	DI	DM9HQ5U
DM9HQ5U	DN	Tagraxofusp
DM9HQ5U	MI	TTENHJ0
DM9HQ5U	MN	Interleukin 3 receptor alpha (IL3RA)
DM9HQ5U	MT	DTT
DM9HQ5U	MA	Modulator
DM9HQ5U	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM9HQ5U	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM2M3OC	DI	DM2M3OC
DM2M3OC	DN	Talazoparib
DM2M3OC	MI	DTI7UX6
DM2M3OC	MN	Breast cancer resistance protein (ABCG2)
DM2M3OC	MT	DTP
DM2M3OC	MA	Substrate
DM2M3OC	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
DM2M3OC	RU	https://www.drugbank.ca/drugs/DB11760

DM2M3OC	DI	DM2M3OC
DM2M3OC	DN	Talazoparib
DM2M3OC	MI	DTUGYRD
DM2M3OC	MN	P-glycoprotein 1 (ABCB1)
DM2M3OC	MT	DTP
DM2M3OC	MA	Substrate
DM2M3OC	RN	DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
DM2M3OC	RU	https://www.drugbank.ca/drugs/DB11760

DM1KS78	DI	DM1KS78
DM1KS78	DN	Talazoparib
DM1KS78	MI	TTEBCY8
DM1KS78	MN	Poly [ADP-ribose] polymerase (PARP)
DM1KS78	MT	DTT
DM1KS78	MA	Inhibitor
DM1KS78	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DM1KS78	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM214Q8	DI	DM214Q8
DM214Q8	DN	Talbutal
DM214Q8	MI	TTEX6LM
DM214Q8	MN	GABA(A) receptor gamma-3 (GABRG3)
DM214Q8	MT	DTT
DM214Q8	MA	Modulator
DM214Q8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM214Q8	RU	https://www.fda.gov/

DM3PZXN	DI	DM3PZXN
DM3PZXN	DN	Taliglucerase alfa
DM3PZXN	MI	TT1B5PU
DM3PZXN	MN	Glucosylceramidase (GBA)
DM3PZXN	MT	DTT
DM3PZXN	MA	Modulator
DM3PZXN	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM3PZXN	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMKBW5C	DI	DMKBW5C
DMKBW5C	DN	Talimogene Laherparepvec
DMKBW5C	MI	TTNYZG2
DMKBW5C	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMKBW5C	MT	DTT
DMKBW5C	MA	Modulator
DMKBW5C	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKBW5C	RU	https://www.fda.gov/

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTI7UX6
DMLB0EZ	MN	Breast cancer resistance protein (ABCG2)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/27033456

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE6OQ3W
DMLB0EZ	MN	Cytochrome P450 1A1 (CYP1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12124303

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEJGDUW
DMLB0EZ	MN	Cytochrome P450 1A2 (CYP1A2)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25157097

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEJVYAZ
DMLB0EZ	MN	Cytochrome P450 2A6 (CYP2A6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEPKLMQ
DMLB0EZ	MN	Cytochrome P450 2B6 (CYP2B6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12023523

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE5IED8
DMLB0EZ	MN	Cytochrome P450 2C9 (CYP2C9)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17024799

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DECB0K3
DMLB0EZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20425602

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEVDYN7
DMLB0EZ	MN	Cytochrome P450 2E1 (CYP2E1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8293548

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DE4LYSA
DMLB0EZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15159443

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEIBDNY
DMLB0EZ	MN	Cytochrome P450 3A5 (CYP3A5)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15596297

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DERD86B
DMLB0EZ	MN	Cytochrome P450 3A7 (CYP3A7)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Drug Interactions Flockhart Table
DMLB0EZ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	TTZAYWL
DMLB0EZ	MN	Estrogen receptor (ESR)
DMLB0EZ	MT	DTT
DMLB0EZ	MA	Antagonist
DMLB0EZ	RN	Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
DMLB0EZ	RU	https://pubmed.ncbi.nlm.nih.gov/18991792

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEGTFWK
DMLB0EZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTPS120
DMLB0EZ	MN	Multidrug resistance-associated protein 7 (ABCC10)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23087055

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DTUGYRD
DMLB0EZ	MN	P-glycoprotein 1 (ABCB1)
DMLB0EZ	MT	DTP
DMLB0EZ	MA	Substrate
DMLB0EZ	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLB0EZ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEYWLRK
DMLB0EZ	MN	Sulfotransferase 1A1 (SULT1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19812351

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEFQ8VO
DMLB0EZ	MN	Thiopurine methyltransferase (TPMT)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15288375

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEYGVN4
DMLB0EZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19244109

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEL5N6Y
DMLB0EZ	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMLB0EZ	DI	DMLB0EZ
DMLB0EZ	DN	Tamoxifen
DMLB0EZ	MI	DEB3CV1
DMLB0EZ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMLB0EZ	MT	DME
DMLB0EZ	MA	Metabolism
DMLB0EZ	RN	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
DMLB0EZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24328412

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	TTNGILX
DM5QF9V	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM5QF9V	MT	DTT
DM5QF9V	MA	Modulator
DM5QF9V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5QF9V	RU	https://www.fda.gov/

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	DECB0K3
DM5QF9V	MN	Cytochrome P450 2D6 (CYP2D6)
DM5QF9V	MT	DME
DM5QF9V	MA	Metabolism
DM5QF9V	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DM5QF9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DM5QF9V	DI	DM5QF9V
DM5QF9V	DN	Tamsulosin
DM5QF9V	MI	DE4LYSA
DM5QF9V	MN	Cytochrome P450 3A4 (CYP3A4)
DM5QF9V	MT	DME
DM5QF9V	MA	Metabolism
DM5QF9V	RN	Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998 Oct;28(10):909-22.
DM5QF9V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9849639

DMPHWU6	DI	DMPHWU6
DMPHWU6	DN	Tandospirone
DMPHWU6	MI	TT85JO3
DMPHWU6	MN	5-HT receptor (5HTR)
DMPHWU6	MT	DTT
DMPHWU6	MA	Modulator
DMPHWU6	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMPHWU6	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DE5IED8
DMXLSH3	MN	Cytochrome P450 2C9 (CYP2C9)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DECB0K3
DMXLSH3	MN	Cytochrome P450 2D6 (CYP2D6)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	TTAWNKZ
DMXLSH3	MN	Norepinephrine transporter (NET)
DMXLSH3	MT	DTT
DMXLSH3	MA	Modulator
DMXLSH3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMXLSH3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	TTKWM86
DMXLSH3	MN	Opioid receptor mu (MOP)
DMXLSH3	MT	DTT
DMXLSH3	MA	Modulator
DMXLSH3	RN	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
DMXLSH3	RU	https://pubmed.ncbi.nlm.nih.gov/19180096

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DE85D2P
DMXLSH3	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMXLSH3	DI	DMXLSH3
DMXLSH3	DN	Tapentadol hydrochloride
DMXLSH3	MI	DEB3CV1
DMXLSH3	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMXLSH3	MT	DME
DMXLSH3	MA	Metabolism
DMXLSH3	RN	Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75.
DMXLSH3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19356073

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	DEJGDUW
DMLOQ1V	MN	Cytochrome P450 1A2 (CYP1A2)
DMLOQ1V	MT	DME
DMLOQ1V	MA	Metabolism
DMLOQ1V	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DMLOQ1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	DE4LYSA
DMLOQ1V	MN	Cytochrome P450 3A4 (CYP3A4)
DMLOQ1V	MT	DME
DMLOQ1V	MA	Metabolism
DMLOQ1V	RN	Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J Clin Pharmacol. 2015 Sep;55(9):1004-11.
DMLOQ1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25851638

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	TT0WAIE
DMLOQ1V	MN	Melatonin receptor type 1A (MTNR1A)
DMLOQ1V	MT	DTT
DMLOQ1V	MA	Agonist
DMLOQ1V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
DMLOQ1V	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393

DMLOQ1V	DI	DMLOQ1V
DMLOQ1V	DN	Tasimelteon
DMLOQ1V	MI	TT32JK8
DMLOQ1V	MN	Melatonin receptor type 1B (MTNR1B)
DMLOQ1V	MT	DTT
DMLOQ1V	MA	Agonist
DMLOQ1V	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393).
DMLOQ1V	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393

DMM13DI	DI	DMM13DI
DMM13DI	DN	Tasosartan
DMM13DI	MI	TT8DBY3
DMM13DI	MN	Angiotensin II receptor type-1 (AGTR1)
DMM13DI	MT	DTT
DMM13DI	MA	Antagonist
DMM13DI	RN	Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.
DMM13DI	RU	https://pubmed.ncbi.nlm.nih.gov/11046101

DMM13DI	DI	DMM13DI
DMM13DI	DN	Tasosartan
DMM13DI	MI	DE4LYSA
DMM13DI	MN	Cytochrome P450 3A4 (CYP3A4)
DMM13DI	MT	DME
DMM13DI	MA	Metabolism
DMM13DI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM13DI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM3ED1A	DI	DM3ED1A
DM3ED1A	DN	Tavaborole
DM3ED1A	MI	TT37GL6
DM3ED1A	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DM3ED1A	MT	DTT
DM3ED1A	MA	Inhibitor
DM3ED1A	RN	An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007 Jun 22;316(5832):1759-61.
DM3ED1A	RU	https://pubmed.ncbi.nlm.nih.gov/17588934

DMUOT9V	DI	DMUOT9V
DMUOT9V	DN	Taxol
DMUOT9V	MI	TTJGNVC
DMUOT9V	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMUOT9V	MT	DTT
DMUOT9V	MA	Modulator
DMUOT9V	RN	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
DMUOT9V	RU	https://pubmed.ncbi.nlm.nih.gov/19671798

DMUOT9V	DI	DMUOT9V
DMUOT9V	DN	Taxol
DMUOT9V	MI	TTYFKSZ
DMUOT9V	MN	Tubulin beta (TUBB)
DMUOT9V	MT	DTT
DMUOT9V	MA	Modulator
DMUOT9V	RN	Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
DMUOT9V	RU	https://pubmed.ncbi.nlm.nih.gov/19671798

DM8SMD1	DI	DM8SMD1
DM8SMD1	DN	Tazarotene
DM8SMD1	MI	DES5XRU
DM8SMD1	MN	Cytochrome P450 2C8 (CYP2C8)
DM8SMD1	MT	DME
DM8SMD1	MA	Metabolism
DM8SMD1	RN	Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos. 2003 Apr;31(4):476-81.
DM8SMD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642475

DM8SMD1	DI	DM8SMD1
DM8SMD1	DN	Tazarotene
DM8SMD1	MI	TT1Q3IE
DM8SMD1	MN	Retinoic acid receptor gamma (RARG)
DM8SMD1	MT	DTT
DM8SMD1	MA	Binder
DM8SMD1	RN	Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31.
DM8SMD1	RU	https://pubmed.ncbi.nlm.nih.gov/10828316

DMWP1BH	DI	DMWP1BH
DMWP1BH	DN	Tazemetostat
DMWP1BH	MI	TT9MZCQ
DMWP1BH	MN	Enhancer of zeste homolog 2 (EZH2)
DMWP1BH	MT	DTT
DMWP1BH	MA	Inhibitor
DMWP1BH	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMWP1BH	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	DEEZ5CV
DM3XNUI	MN	Beta-lactamase (blaB)
DM3XNUI	MT	DME
DM3XNUI	MA	Metabolism
DM3XNUI	RN	Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/26539828

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	DEYIEO5
DM3XNUI	MN	Beta-lactamase (blaB)
DM3XNUI	MT	DME
DM3XNUI	MA	Metabolism
DM3XNUI	RN	Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/30666031

DM3XNUI	DI	DM3XNUI
DM3XNUI	DN	Tazobactam
DM3XNUI	MI	TTHI19T
DM3XNUI	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM3XNUI	MT	DTT
DM3XNUI	MA	Inhibitor
DM3XNUI	RN	Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
DM3XNUI	RU	https://pubmed.ncbi.nlm.nih.gov/19576305

DML6OE7	DI	DML6OE7
DML6OE7	DN	Tbo-Filgrastim
DML6OE7	MI	TTC70AJ
DML6OE7	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DML6OE7	MT	DTT
DML6OE7	MA	Modulator
DML6OE7	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DML6OE7	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMQ5S6C	DI	DMQ5S6C
DMQ5S6C	DN	Tebipenem pivoxil
DMQ5S6C	MI	TTJP4SM
DMQ5S6C	MN	Bacterial Penicillin binding protein (Bact PBP)
DMQ5S6C	MT	DTT
DMQ5S6C	MA	Binder
DMQ5S6C	RN	In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
DMQ5S6C	RU	https://pubmed.ncbi.nlm.nih.gov/30718255

DMYQCWT	DI	DMYQCWT
DMYQCWT	DN	Tecartus
DMYQCWT	MI	TTW640A
DMYQCWT	MN	B-lymphocyte surface antigen B4 (CD19)
DMYQCWT	MT	DTT
DMYQCWT	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMYQCWT	RU	https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel

DM2OVDT	DI	DM2OVDT
DM2OVDT	DN	Tecfidera
DM2OVDT	MI	TTK3Q4W
DM2OVDT	MN	NFE2-related factor 2 pathway (Nrf2 pathway)
DM2OVDT	MT	DTT
DM2OVDT	MA	Inhibitor
DM2OVDT	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM2OVDT	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DTFI42L
DMUEWM3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DTQ3ZHF
DMUEWM3	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DT3D8F0
DMUEWM3	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/29756222

DMUEWM3	DI	DMUEWM3
DMUEWM3	DN	Technetium (99MTC) mebrofenin
DMUEWM3	MI	DT9C1TS
DMUEWM3	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMUEWM3	MT	DTP
DMUEWM3	MA	Substrate
DMUEWM3	RN	Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011 Apr;54(4):738-45.
DMUEWM3	RU	http://www.ncbi.nlm.nih.gov/pubmed/21163547

DMW5ML9	DI	DMW5ML9
DMW5ML9	DN	Tecovirimat 
DMW5ML9	MI	TTG7UOF
DMW5ML9	MN	Variola virus Envelope phospholipase F13 (VARV p37)
DMW5ML9	MT	DTT
DMW5ML9	MA	Inhibitor
DMW5ML9	RN	Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review
DMW5ML9	RU	https://pubmed.ncbi.nlm.nih.gov/20191435

DMG2SKR	DI	DMG2SKR
DMG2SKR	DN	Tedizolid
DMG2SKR	MI	TTUWYEA
DMG2SKR	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMG2SKR	MT	DTT
DMG2SKR	MA	Modulator
DMG2SKR	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMG2SKR	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMYOAKS	DI	DMYOAKS
DMYOAKS	DN	Teduglutide
DMYOAKS	MI	TT1YWO5
DMYOAKS	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMYOAKS	MT	DTT
DMYOAKS	MA	Modulator
DMYOAKS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMYOAKS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEJGDUW
DM31ZQM	MN	Cytochrome P450 1A2 (CYP1A2)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEJVYAZ
DM31ZQM	MN	Cytochrome P450 2A6 (CYP2A6)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:117-20.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16897985

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DES5XRU
DM31ZQM	MN	Cytochrome P450 2C8 (CYP2C8)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEVDYN7
DM31ZQM	MN	Cytochrome P450 2E1 (CYP2E1)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM31ZQM	DI	DM31ZQM
DM31ZQM	DN	Tegafur
DM31ZQM	MI	DEIBDNY
DM31ZQM	MN	Cytochrome P450 3A5 (CYP3A5)
DM31ZQM	MT	DME
DM31ZQM	MA	Metabolism
DM31ZQM	RN	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
DM31ZQM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583

DM3XYD1	DI	DM3XYD1
DM3XYD1	DN	Tegaserod
DM3XYD1	MI	TT07C3Y
DM3XYD1	MN	5-HT 4 receptor (HTR4)
DM3XYD1	MT	DTT
DM3XYD1	MA	Agonist
DM3XYD1	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM3XYD1	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM3XYD1	DI	DM3XYD1
DM3XYD1	DN	Tegaserod
DM3XYD1	MI	DECB0K3
DM3XYD1	MN	Cytochrome P450 2D6 (CYP2D6)
DM3XYD1	MT	DME
DM3XYD1	MA	Metabolism
DM3XYD1	RN	In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
DM3XYD1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11560869

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	TTXT4D5
DMAQ2LK	MN	Bacterial Cell membrane (Bact CM)
DMAQ2LK	MT	DTT
DMAQ2LK	MA	Inhibitor
DMAQ2LK	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEYWLRK
DMAQ2LK	MN	Sulfotransferase 1A1 (SULT1A1)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
DMAQ2LK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21123867

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEOFMQ7
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEO97D6
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEO8E75
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DEN6VO0
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/7979308

DMAQ2LK	DI	DMAQ2LK
DMAQ2LK	DN	Teicoplanin
DMAQ2LK	MI	DESOXHP
DMAQ2LK	MN	VanA ligase (vanA)
DMAQ2LK	MT	DME
DMAQ2LK	MA	Metabolism
DMAQ2LK	RN	vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009 Nov;6(9):1107-11.
DMAQ2LK	RU	https://pubmed.ncbi.nlm.nih.gov/19694552

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	DE4LYSA
DMMRV29	MN	Cytochrome P450 3A4 (CYP3A4)
DMMRV29	MT	DME
DMMRV29	MA	Metabolism
DMMRV29	RN	Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Dis (Hoboken). 2012 Apr 26;1(2):36-40.
DMMRV29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31186844

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	TTHC7JD
DMMRV29	MN	Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A)
DMMRV29	MT	DTT
DMMRV29	MA	Modulator
DMMRV29	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMMRV29	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMMRV29	DI	DMMRV29
DMMRV29	DN	Telaprevir
DMMRV29	MI	DTUGYRD
DMMRV29	MN	P-glycoprotein 1 (ABCB1)
DMMRV29	MT	DTP
DMMRV29	MA	Substrate
DMMRV29	RN	Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89.
DMMRV29	RU	http://www.ncbi.nlm.nih.gov/pubmed/24817413

DM58VQX	DI	DM58VQX
DM58VQX	DN	Telavancin
DM58VQX	MI	TT7EFHR
DM58VQX	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM58VQX	MT	DTT
DM58VQX	MA	Antagonist
DM58VQX	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DM58VQX	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMSWUGE	DI	DMSWUGE
DMSWUGE	DN	Telbivudine
DMSWUGE	MI	TTT4SY6
DMSWUGE	MN	Hepatitis B virus Polymerase (HBV P)
DMSWUGE	MT	DTT
DMSWUGE	MA	Inhibitor
DMSWUGE	RN	Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.
DMSWUGE	RU	https://pubmed.ncbi.nlm.nih.gov/19187868

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	TTUWYEA
DMZ4P3A	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMZ4P3A	MT	DTT
DMZ4P3A	MA	Binder
DMZ4P3A	RN	An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
DMZ4P3A	RU	https://pubmed.ncbi.nlm.nih.gov/15386111

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DE4LYSA
DMZ4P3A	MN	Cytochrome P450 3A4 (CYP3A4)
DMZ4P3A	MT	DME
DMZ4P3A	MA	Metabolism
DMZ4P3A	RN	Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 Apr;7(6):639-51.
DMZ4P3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16556082

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DEIBDNY
DMZ4P3A	MN	Cytochrome P450 3A5 (CYP3A5)
DMZ4P3A	MT	DME
DMZ4P3A	MA	Metabolism
DMZ4P3A	RN	Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
DMZ4P3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15598962

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DTFI42L
DMZ4P3A	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMZ4P3A	MT	DTP
DMZ4P3A	MA	Substrate
DMZ4P3A	RN	Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
DMZ4P3A	RU	http://www.ncbi.nlm.nih.gov/pubmed/16377671

DMZ4P3A	DI	DMZ4P3A
DMZ4P3A	DN	Telithromycin
DMZ4P3A	MI	DTUGYRD
DMZ4P3A	MN	P-glycoprotein 1 (ABCB1)
DMZ4P3A	MT	DTP
DMZ4P3A	MA	Substrate
DMZ4P3A	RN	Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci. 2010 Sep 11;41(1):86-95.
DMZ4P3A	RU	https://doi.org/10.1016/j.ejps.2010.05.016

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	TT8DBY3
DMS3GX2	MN	Angiotensin II receptor type-1 (AGTR1)
DMS3GX2	MT	DTT
DMS3GX2	MA	Antagonist
DMS3GX2	RN	Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35.
DMS3GX2	RU	https://pubmed.ncbi.nlm.nih.gov/19395110

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DTE2B1D
DMS3GX2	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16611857

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DT9C1TS
DMS3GX2	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos. 2006 Jul;34(7):1109-15.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/16611857

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DTPFTEQ
DMS3GX2	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMS3GX2	MT	DTP
DMS3GX2	MA	Substrate
DMS3GX2	RN	Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos. 2008 Apr;36(4):796-805.
DMS3GX2	RU	http://www.ncbi.nlm.nih.gov/pubmed/18180273

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DEYGVN4
DMS3GX2	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMS3GX2	MT	DME
DMS3GX2	MA	Metabolism
DMS3GX2	RN	The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 2011 Sep;21(9):523-30.
DMS3GX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21829131

DMS3GX2	DI	DMS3GX2
DMS3GX2	DN	Telmisartan
DMS3GX2	MI	DEF2WXN
DMS3GX2	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMS3GX2	MT	DME
DMS3GX2	MA	Metabolism
DMS3GX2	RN	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35.
DMS3GX2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22275465

DMDIYFZ	DI	DMDIYFZ
DMDIYFZ	DN	Telotristat ethyl
DMDIYFZ	MI	TTDJBV3
DMDIYFZ	MN	Tryptophan hydroxylase (TPH)
DMDIYFZ	MT	DTT
DMDIYFZ	MA	Modulator
DMDIYFZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMDIYFZ	RU	https://www.fda.gov/

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DEPKLMQ
DM02A65	MN	Cytochrome P450 2B6 (CYP2B6)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DES5XRU
DM02A65	MN	Cytochrome P450 2C8 (CYP2C8)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DE5IED8
DM02A65	MN	Cytochrome P450 2C9 (CYP2C9)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol. 1998 Mar 15;55(6):889-96.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9586962

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DE4LYSA
DM02A65	MN	Cytochrome P450 3A4 (CYP3A4)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	DEGTFWK
DM02A65	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM02A65	MT	DME
DM02A65	MA	Metabolism
DM02A65	RN	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
DM02A65	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948091

DM02A65	DI	DM02A65
DM02A65	DN	Temazepam
DM02A65	MI	TTPTXIN
DM02A65	MN	Translocator protein (TSPO)
DM02A65	MT	DTT
DM02A65	MA	Modulator
DM02A65	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM02A65	RU	https://www.fda.gov/

DM1A79H	DI	DM1A79H
DM1A79H	DN	Temocapril
DM1A79H	MI	DT3D8F0
DM1A79H	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM1A79H	MT	DTP
DM1A79H	MA	Substrate
DM1A79H	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM1A79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM1A79H	DI	DM1A79H
DM1A79H	DN	Temocapril
DM1A79H	MI	DT9G7XN
DM1A79H	MN	Peptide transporter 1 (SLC15A1)
DM1A79H	MT	DTP
DM1A79H	MA	Substrate
DM1A79H	RN	The role of transporters in drug interactions. Eur J Pharm Sci. 2006 Apr;27(5):501-17.
DM1A79H	RU	https://doi.org/10.1016/j.ejps.2005.11.002

DM0JXFL	DI	DM0JXFL
DM0JXFL	DN	Temocapril hydrochloride
DM0JXFL	MI	TTL69WB
DM0JXFL	MN	Angiotensin-converting enzyme (ACE)
DM0JXFL	MT	DTT
DM0JXFL	MA	Modulator
DM0JXFL	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DM0JXFL	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DTFI42L
DMNX2QI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMNX2QI	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DTFI42L
DMNX2QI	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMNX2QI	RU	https://doi.org/10.1007/s12033-009-9220-6

DMNX2QI	DI	DMNX2QI
DMNX2QI	DN	Temocaprilate
DMNX2QI	MI	DT9G7XN
DMNX2QI	MN	Peptide transporter 1 (SLC15A1)
DMNX2QI	MT	DTP
DMNX2QI	MA	Substrate
DMNX2QI	RN	Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74.
DMNX2QI	RU	https://doi.org/10.2133/dmpk.17.253

DMKECZD	DI	DMKECZD
DMKECZD	DN	Temozolomide
DMKECZD	MI	TTUTN1I
DMKECZD	MN	Human Deoxyribonucleic acid (hDNA)
DMKECZD	MT	DTT
DMKECZD	MA	Modulator
DMKECZD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMKECZD	RU	https://www.fda.gov/

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DE4LYSA
DMS104F	MN	Cytochrome P450 3A4 (CYP3A4)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DEIBDNY
DMS104F	MN	Cytochrome P450 3A5 (CYP3A5)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DERD86B
DMS104F	MN	Cytochrome P450 3A7 (CYP3A7)
DMS104F	MT	DME
DMS104F	MA	Metabolism
DMS104F	RN	Drug Interactions Flockhart Table
DMS104F	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	DTUGYRD
DMS104F	MN	P-glycoprotein 1 (ABCB1)
DMS104F	MT	DTP
DMS104F	MA	Substrate
DMS104F	RN	Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017 Sep;80(3):653-659.
DMS104F	RU	http://www.ncbi.nlm.nih.gov/pubmed/28676933

DMS104F	DI	DMS104F
DMS104F	DN	Temsirolimus
DMS104F	MI	TTCJG29
DMS104F	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMS104F	MT	DTT
DMS104F	MA	Inhibitor
DMS104F	RN	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
DMS104F	RU	https://pubmed.ncbi.nlm.nih.gov/25312588

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	DE4LYSA
DMCOZJY	MN	Cytochrome P450 3A4 (CYP3A4)
DMCOZJY	MT	DME
DMCOZJY	MA	Metabolism
DMCOZJY	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	DEIBDNY
DMCOZJY	MN	Cytochrome P450 3A5 (CYP3A5)
DMCOZJY	MT	DME
DMCOZJY	MA	Metabolism
DMCOZJY	RN	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMCOZJY	DI	DMCOZJY
DMCOZJY	DN	Tenapanor
DMCOZJY	MI	TTFZVPO
DMCOZJY	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMCOZJY	MT	DTT
DMCOZJY	MA	Modulator
DMCOZJY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMCOZJY	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf

DMJYN25	DI	DMJYN25
DMJYN25	DN	Tenecteplase
DMJYN25	MI	TTP86E2
DMJYN25	MN	Plasminogen (PLG)
DMJYN25	MT	DTT
DMJYN25	MA	Activator
DMJYN25	RN	Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32.
DMJYN25	RU	https://pubmed.ncbi.nlm.nih.gov/15823070

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTI7UX6
DMLW57T	MN	Breast cancer resistance protein (ABCG2)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DE4LYSA
DMLW57T	MN	Cytochrome P450 3A4 (CYP3A4)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
DMLW57T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11770832

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DEIBDNY
DMLW57T	MN	Cytochrome P450 3A5 (CYP3A5)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
DMLW57T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8114683

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	TT0IHXV
DMLW57T	MN	DNA topoisomerase II (TOP2)
DMLW57T	MT	DTT
DMLW57T	MA	Modulator
DMLW57T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMLW57T	RU	https://www.fda.gov/

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DEGTFWK
DMLW57T	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMLW57T	MT	DME
DMLW57T	MA	Metabolism
DMLW57T	RN	Drug Interactions Flockhart Table
DMLW57T	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTQ3ZHF
DMLW57T	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/11581266

DMLW57T	DI	DMLW57T
DMLW57T	DN	Teniposide
DMLW57T	MI	DTUGYRD
DMLW57T	MN	P-glycoprotein 1 (ABCB1)
DMLW57T	MT	DTP
DMLW57T	MA	Substrate
DMLW57T	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMLW57T	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTI7UX6
DM1IS6U	MN	Breast cancer resistance protein (ABCG2)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913)
DM1IS6U	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	TT84ETX
DM1IS6U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1IS6U	MT	DTT
DM1IS6U	MA	Inhibitor
DM1IS6U	RN	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
DM1IS6U	RU	https://pubmed.ncbi.nlm.nih.gov/15125867

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTCSGPB
DM1IS6U	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/17110501

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTPS120
DM1IS6U	MN	Multidrug resistance-associated protein 7 (ABCC10)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/21628669

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTWN7FC
DM1IS6U	MN	Multidrug resistance-associated protein 8 (ABCC11)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01725-16.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/28167562

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTQ23VB
DM1IS6U	MN	Organic anion transporter 1 (SLC22A6)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/11563082

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTVP67E
DM1IS6U	MN	Organic anion transporter 3 (SLC22A8)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687-92.
DM1IS6U	RU	http://www.ncbi.nlm.nih.gov/pubmed/24699134

DM1IS6U	DI	DM1IS6U
DM1IS6U	DN	Tenofovir
DM1IS6U	MI	DTUGYRD
DM1IS6U	MN	P-glycoprotein 1 (ABCB1)
DM1IS6U	MT	DTP
DM1IS6U	MA	Substrate
DM1IS6U	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DM1IS6U	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMTQF4A	DI	DMTQF4A
DMTQF4A	DN	Tenofovir alafenamide
DMTQF4A	MI	DE14JZK
DMTQF4A	MN	Cathepsin A (CTSA)
DMTQF4A	MT	DME
DMTQF4A	MA	Metabolism
DMTQF4A	RN	Bictegravir/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection. Drugs. 2018 Nov;78(17):1817-1828.
DMTQF4A	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30460547

DMTQF4A	DI	DMTQF4A
DMTQF4A	DN	Tenofovir alafenamide
DMTQF4A	MI	DE4LYSA
DMTQF4A	MN	Cytochrome P450 3A4 (CYP3A4)
DMTQF4A	MT	DME
DMTQF4A	MA	Metabolism
DMTQF4A	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DMTQF4A	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMSY4ZG	DI	DMSY4ZG
DMSY4ZG	DN	Tenofovir disoproxil fumarate
DMSY4ZG	MI	DE4LYSA
DMSY4ZG	MN	Cytochrome P450 3A4 (CYP3A4)
DMSY4ZG	MT	DME
DMSY4ZG	MA	Metabolism
DMSY4ZG	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DMSY4ZG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMSY4ZG	DI	DMSY4ZG
DMSY4ZG	DN	Tenofovir disoproxil fumarate
DMSY4ZG	MI	TT84ETX
DMSY4ZG	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSY4ZG	MT	DTT
DMSY4ZG	MA	Modulator
DMSY4ZG	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMSY4ZG	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	DE5IED8
DMVAZP9	MN	Cytochrome P450 2C9 (CYP2C9)
DMVAZP9	MT	DME
DMVAZP9	MA	Metabolism
DMVAZP9	RN	CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther. 2004 Jul;76(1):18-26.
DMVAZP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15229460

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	DTUGYRD
DMVAZP9	MN	P-glycoprotein 1 (ABCB1)
DMVAZP9	MT	DTP
DMVAZP9	MA	Substrate
DMVAZP9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVAZP9	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVAZP9	DI	DMVAZP9
DMVAZP9	DN	Tenoxicam
DMVAZP9	MI	TTVKILB
DMVAZP9	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVAZP9	MT	DTT
DMVAZP9	MA	Inhibitor
DMVAZP9	RN	The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42.
DMVAZP9	RU	https://pubmed.ncbi.nlm.nih.gov/16245223

DMUQ0E8	DI	DMUQ0E8
DMUQ0E8	DN	Tepotinib
DMUQ0E8	MI	TTNDSF4
DMUQ0E8	MN	Proto-oncogene c-Met (MET)
DMUQ0E8	MT	DTT
DMUQ0E8	MA	Modulator
DMUQ0E8	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMUQ0E8	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf

DM4L59B	DI	DM4L59B
DM4L59B	DN	Teprotumumab
DM4L59B	MI	TTHRID2
DM4L59B	MN	Insulin-like growth factor I receptor (IGF1R)
DM4L59B	MT	DTT
DM4L59B	MA	Antagonist
DM4L59B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DM4L59B	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf

DM3JCVS	DI	DM3JCVS
DM3JCVS	DN	Terazosin
DM3JCVS	MI	TT34BHT
DM3JCVS	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM3JCVS	MT	DTT
DM3JCVS	MA	Antagonist
DM3JCVS	RN	Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
DM3JCVS	RU	https://pubmed.ncbi.nlm.nih.gov/12496995

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	TTM9XSU
DMI6HUW	MN	Candida Squalene epoxidase (Candi ERG1)
DMI6HUW	MT	DTT
DMI6HUW	MA	Modulator
DMI6HUW	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMI6HUW	RU	https://www.fda.gov/

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DEJGDUW
DMI6HUW	MN	Cytochrome P450 1A2 (CYP1A2)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DES5XRU
DMI6HUW	MN	Cytochrome P450 2C8 (CYP2C8)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE5IED8
DMI6HUW	MN	Cytochrome P450 2C9 (CYP2C9)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE4LYSA
DMI6HUW	MN	Cytochrome P450 3A4 (CYP3A4)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DEGTFWK
DMI6HUW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460803

DMI6HUW	DI	DMI6HUW
DMI6HUW	DN	Terbinafine
DMI6HUW	MI	DE073H6
DMI6HUW	MN	Prostaglandin G/H synthase 1 (COX-1)
DMI6HUW	MT	DME
DMI6HUW	MA	Metabolism
DMI6HUW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMI6HUW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMD4381	DI	DMD4381
DMD4381	DN	Terbutaline
DMD4381	MI	TT2CJVK
DMD4381	MN	Adrenergic receptor beta-2 (ADRB2)
DMD4381	MT	DTT
DMD4381	MA	Agonist
DMD4381	RN	Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11.
DMD4381	RU	https://pubmed.ncbi.nlm.nih.gov/239414

DMD4381	DI	DMD4381
DMD4381	DN	Terbutaline
DMD4381	MI	DTT79CX
DMD4381	MN	Organic cation transporter 1 (SLC22A1)
DMD4381	MT	DTP
DMD4381	MA	Substrate
DMD4381	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMD4381	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMVPWLZ	DI	DMVPWLZ
DMVPWLZ	DN	Terbutyline
DMVPWLZ	MI	TTVIREA
DMVPWLZ	MN	Adrenergic receptor (ADR)
DMVPWLZ	MT	DTT
DMVPWLZ	MA	Modulator
DMVPWLZ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMVPWLZ	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMJ13KI	DI	DMJ13KI
DMJ13KI	DN	Terconazole
DMJ13KI	MI	TTTSOUD
DMJ13KI	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMJ13KI	MT	DTT
DMJ13KI	MA	Inhibitor
DMJ13KI	RN	Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
DMJ13KI	RU	https://pubmed.ncbi.nlm.nih.gov/1951574

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	DTI7UX6
DMQ2FKJ	MN	Breast cancer resistance protein (ABCG2)
DMQ2FKJ	MT	DTP
DMQ2FKJ	MA	Substrate
DMQ2FKJ	RN	MDR-ABC transporters: biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):779-87.
DMQ2FKJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23711386

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TTLVP78
DMQ2FKJ	MN	Dihydroorotate dehydrogenase (DHODH)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Modulator
DMQ2FKJ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TTPADOQ
DMQ2FKJ	MN	HMG-CoA reductase (HMGCR)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Inhibitor
DMQ2FKJ	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMQ2FKJ	DI	DMQ2FKJ
DMQ2FKJ	DN	Teriflunomide
DMQ2FKJ	MI	TT3PQ2Y
DMQ2FKJ	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMQ2FKJ	MT	DTT
DMQ2FKJ	MA	Inhibitor
DMQ2FKJ	RN	Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
DMQ2FKJ	RU	https://pubmed.ncbi.nlm.nih.gov/10941801

DMMC45B	DI	DMMC45B
DMMC45B	DN	Teriparatide
DMMC45B	MI	TT6F7GZ
DMMC45B	MN	Parathyroid hormone (PTH)
DMMC45B	MT	DTT
DMMC45B	MA	Modulator
DMMC45B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMMC45B	RU	https://www.fda.gov/

DMT9FH3	DI	DMT9FH3
DMT9FH3	DN	Terlipressin
DMT9FH3	MI	TT4TFGN
DMT9FH3	MN	Vasopressin V1a receptor (V1AR)
DMT9FH3	MT	DTT
DMT9FH3	MA	Stimulator
DMT9FH3	RN	Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
DMT9FH3	RU	https://pubmed.ncbi.nlm.nih.gov/19589090

DM2L3D5	DI	DM2L3D5
DM2L3D5	DN	Tertatolol
DM2L3D5	MI	TTSQIFT
DM2L3D5	MN	5-HT 1A receptor (HTR1A)
DM2L3D5	MT	DTT
DM2L3D5	MA	Inhibitor
DM2L3D5	RN	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
DM2L3D5	RU	http://www.sciencedirect.com/science/article/pii/S0960894X0181009X

DM2L3D5	DI	DM2L3D5
DM2L3D5	DN	Tertatolol
DM2L3D5	MI	DECB0K3
DM2L3D5	MN	Cytochrome P450 2D6 (CYP2D6)
DM2L3D5	MT	DME
DM2L3D5	MA	Metabolism
DM2L3D5	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM2L3D5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM9GP85	DI	DM9GP85
DM9GP85	DN	Tesamorelin
DM9GP85	MI	TTG4R8V
DM9GP85	MN	Growth hormone-releasing hormone receptor (GHRHR)
DM9GP85	MT	DTT
DM9GP85	MA	Binder
DM9GP85	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM9GP85	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMVY4GN	DI	DMVY4GN
DMVY4GN	DN	Testolactone
DMVY4GN	MI	TTSZLWK
DMVY4GN	MN	Aromatase (CYP19A1)
DMVY4GN	MT	DTT
DMVY4GN	MA	Inhibitor
DMVY4GN	RN	Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
DMVY4GN	RU	https://pubmed.ncbi.nlm.nih.gov/11792932

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	TTS64P2
DM7HUNW	MN	Androgen receptor (AR)
DM7HUNW	MT	DTT
DM7HUNW	MA	Agonist
DM7HUNW	RN	Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
DM7HUNW	RU	https://pubmed.ncbi.nlm.nih.gov/18406296

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DTI7UX6
DM7HUNW	MN	Breast cancer resistance protein (ABCG2)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival. BJU Int. 2008 Dec;102(11):1694-9.
DM7HUNW	RU	http://www.ncbi.nlm.nih.gov/pubmed/18710444

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DT9C1TS
DM7HUNW	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008 Jun 1;14(11):3312-8.
DM7HUNW	RU	http://www.ncbi.nlm.nih.gov/pubmed/18519758

DM7HUNW	DI	DM7HUNW
DM7HUNW	DN	Testosterone
DM7HUNW	MI	DTUGYRD
DM7HUNW	MN	P-glycoprotein 1 (ABCB1)
DM7HUNW	MT	DTP
DM7HUNW	MA	Substrate
DM7HUNW	RN	A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.
DM7HUNW	RU	https://doi.org/10.1007/s00210-008-0345-0

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEQX145
DMC1TEV	MN	Aromatase (CYP19A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease? Brain Res Rev. 2008 Mar;57(2):431-43.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18063054

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEKP5HX
DMC1TEV	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEHDW40
DMC1TEV	MN	Cytochrome P450 154C2 (cyp154)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	nan
DMC1TEV	RU	nan

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE6OQ3W
DMC1TEV	MN	Cytochrome P450 1A1 (CYP1A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10975606

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE9QHP6
DMC1TEV	MN	Cytochrome P450 1B1 (CYP1B1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10426814

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEXZA9U
DMC1TEV	MN	Cytochrome P450 2A13 (CYP2A13)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis. 2005 Mar;26(3):621-9.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15579482

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEPKLMQ
DMC1TEV	MN	Cytochrome P450 2B6 (CYP2B6)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DES5XRU
DMC1TEV	MN	Cytochrome P450 2C8 (CYP2C8)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE5IED8
DMC1TEV	MN	Cytochrome P450 2C9 (CYP2C9)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DE4LYSA
DMC1TEV	MN	Cytochrome P450 3A4 (CYP3A4)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Digging deeper into CYP3A testosterone metabolism: kinetic, regioselectivity, and stereoselectivity differences between CYP3A4/5 and CYP3A7. Drug Metab Dispos. 2017 Dec;45(12):1266-1275.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28986474

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEO1IE3
DMC1TEV	MN	Cytochrome P450 3A43 (CYP3A43)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11160876

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEIBDNY
DMC1TEV	MN	Cytochrome P450 3A5 (CYP3A5)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DERD86B
DMC1TEV	MN	Cytochrome P450 3A7 (CYP3A7)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEMF740
DMC1TEV	MN	Cytochrome P450 4B1 (CYP4B1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch Biochem Biophys. 1991 Oct;290(1):160-6.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1898086

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEZ1H4L
DMC1TEV	MN	Cytochrome P450 MEG (cyp106)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	nan
DMC1TEV	RU	nan

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEGTB1K
DMC1TEV	MN	Dehydrogenase/reductase retSDR3 (HSD17B14)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56.
DMC1TEV	RU	https://pubmed.ncbi.nlm.nih.gov/22864907

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DER0XCH
DMC1TEV	MN	Farnesol dehydrogenase (AKR1B15)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEGTFWK
DMC1TEV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEOG15F
DMC1TEV	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEPTJ3D
DMC1TEV	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMC1TEV	DI	DMC1TEV
DMC1TEV	DN	Testosterone cypionate
DMC1TEV	MI	DEZGVDW
DMC1TEV	MN	Steroid 5-alpha-reductase 3 (SRD5A3)
DMC1TEV	MT	DME
DMC1TEV	MA	Metabolism
DMC1TEV	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMC1TEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEPKLMQ
DMB6871	MN	Cytochrome P450 2B6 (CYP2B6)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DES5XRU
DMB6871	MN	Cytochrome P450 2C8 (CYP2C8)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DE5IED8
DMB6871	MN	Cytochrome P450 2C9 (CYP2C9)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEIBDNY
DMB6871	MN	Cytochrome P450 3A5 (CYP3A5)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DERD86B
DMB6871	MN	Cytochrome P450 3A7 (CYP3A7)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEGTFWK
DMB6871	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEON3ED
DMB6871	MN	Phosphodiesterase 7B (PDE7B)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	PDE7B is involved in nandrolone decanoate hydrolysis in liver cytosol and its transcription is up-regulated by androgens in HepG2. Front Pharmacol. 2014 May 30;5:132.
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24910615

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEOG15F
DMB6871	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEPTJ3D
DMB6871	MN	Steroid 5-alpha-reductase 2 (SRD5A2)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMB6871	DI	DMB6871
DMB6871	DN	Testosterone enanthate
DMB6871	MI	DEZGVDW
DMB6871	MN	Steroid 5-alpha-reductase 3 (SRD5A3)
DMB6871	MT	DME
DMB6871	MA	Metabolism
DMB6871	RN	Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).
DMB6871	RU	https://www.ncbi.nlm.nih.gov/pubmed/29084161

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEPKLMQ
DMZO10Y	MN	Cytochrome P450 2B6 (CYP2B6)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DES5XRU
DMZO10Y	MN	Cytochrome P450 2C8 (CYP2C8)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DE5IED8
DMZO10Y	MN	Cytochrome P450 2C9 (CYP2C9)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEIBDNY
DMZO10Y	MN	Cytochrome P450 3A5 (CYP3A5)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DERD86B
DMZO10Y	MN	Cytochrome P450 3A7 (CYP3A7)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Steroid hydroxylation by human fetal CYP3A7 and human NADPH-cytochrome P450 reductase coexpressed in insect cells using baculovirus. Res Commun Mol Pathol Pharmacol. 1998 Apr;100(1):15-28.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9644715

DMZO10Y	DI	DMZO10Y
DMZO10Y	DN	Testosterone Undecanoate
DMZO10Y	MI	DEGTFWK
DMZO10Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMZO10Y	MT	DME
DMZO10Y	MA	Metabolism
DMZO10Y	RN	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
DMZO10Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9328296

DMYWQ0O	DI	DMYWQ0O
DMYWQ0O	DN	Tetrabenazine
DMYWQ0O	MI	DECB0K3
DMYWQ0O	MN	Cytochrome P450 2D6 (CYP2D6)
DMYWQ0O	MT	DME
DMYWQ0O	MA	Metabolism
DMYWQ0O	RN	Role of tetrabenazine for Huntington's disease-associated chorea. Ann Pharmacother. 2010 Jun;44(6):1080-9.
DMYWQ0O	RU	http://www.ncbi.nlm.nih.gov/pubmed/20442355

DMYWQ0O	DI	DMYWQ0O
DMYWQ0O	DN	Tetrabenazine
DMYWQ0O	MI	TTNZRI3
DMYWQ0O	MN	Synaptic vesicle amine transporter (SLC18A2)
DMYWQ0O	MT	DTT
DMYWQ0O	MA	Blocker
DMYWQ0O	RN	Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
DMYWQ0O	RU	https://pubmed.ncbi.nlm.nih.gov/19571144

DM9J6C2	DI	DM9J6C2
DM9J6C2	DN	Tetracaine
DM9J6C2	MI	TT90XZ8
DM9J6C2	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM9J6C2	MT	DTT
DM9J6C2	MA	Inhibitor
DM9J6C2	RN	Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
DM9J6C2	RU	https://pubmed.ncbi.nlm.nih.gov/14975698

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTI7UX6
DMZA017	MN	Breast cancer resistance protein (ABCG2)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
DMZA017	RU	https://doi.org/10.1042/BJ20040791

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DT0OC1Q
DMZA017	MN	Organic anion transporter 2 (SLC22A7)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTVP67E
DMZA017	MN	Organic anion transporter 3 (SLC22A8)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DT06JWZ
DMZA017	MN	Organic anion transporter 4 (SLC22A11)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/11855680

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	DTUGYRD
DMZA017	MN	P-glycoprotein 1 (ABCB1)
DMZA017	MT	DTP
DMZA017	MA	Substrate
DMZA017	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZA017	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZA017	DI	DMZA017
DMZA017	DN	Tetracycline
DMZA017	MI	TTQ8KVI
DMZA017	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMZA017	MT	DTT
DMZA017	MA	Binder
DMZA017	RN	The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88.
DMZA017	RU	https://pubmed.ncbi.nlm.nih.gov/14723559

DMINZ4W	DI	DMINZ4W
DMINZ4W	DN	Tetrahydrobiopterin
DMINZ4W	MI	DER6XYF
DMINZ4W	MN	Tryptophan 5-hydroxylase 2 (TPH2)
DMINZ4W	MT	DME
DMINZ4W	MA	Metabolism
DMINZ4W	RN	Characterization of wild-type and mutant forms of human tryptophan hydroxylase 2. J Neurochem. 2007 Mar;100(6):1648-57.
DMINZ4W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17181551

DMINZ4W	DI	DMINZ4W
DMINZ4W	DN	Tetrahydrobiopterin
DMINZ4W	MI	TTUHP71
DMINZ4W	MN	Tyrosine 3-monooxygenase (TH)
DMINZ4W	MT	DTT
DMINZ4W	MA	Cofactor
DMINZ4W	RN	Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
DMINZ4W	RU	https://pubmed.ncbi.nlm.nih.gov/17982884

DMH15UV	DI	DMH15UV
DMH15UV	DN	Tetrahydrofolic acid
DMH15UV	MI	TTQOD3G
DMH15UV	MN	Folate receptor (FOLR)
DMH15UV	MT	DTT
DMH15UV	MA	Binder
DMH15UV	RN	Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001 Apr 15;102(2):115-20.
DMH15UV	RU	https://pubmed.ncbi.nlm.nih.gov/11323021

DMT57WC	DI	DMT57WC
DMT57WC	DN	Tetrahydrozoline
DMT57WC	MI	TT2NUT5
DMT57WC	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMT57WC	MT	DTT
DMT57WC	MA	Modulator
DMT57WC	RN	Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
DMT57WC	RU	https://pubmed.ncbi.nlm.nih.gov/18259967

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTRK8B9
DMWMPRG	MN	Sodium channel unspecific (NaC)
DMWMPRG	MT	DTT
DMWMPRG	MA	Antagonist
DMWMPRG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWMPRG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTIG65Q
DMWMPRG	MN	Voltage-gated sodium channel (Nav)
DMWMPRG	MT	DTT
DMWMPRG	MA	Inhibitor
DMWMPRG	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMWMPRG	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMWMPRG	DI	DMWMPRG
DMWMPRG	DN	Tetrodotoxin
DMWMPRG	MI	TTZOVE0
DMWMPRG	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMWMPRG	MT	DTT
DMWMPRG	MA	Blocker
DMWMPRG	RN	Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
DMWMPRG	RU	https://pubmed.ncbi.nlm.nih.gov/12354567

DMY62FC	DI	DMY62FC
DMY62FC	DN	Tezacaftor And Ivacaftor
DMY62FC	MI	TTRLZHP
DMY62FC	MN	cAMP-dependent chloride channel (CFTR)
DMY62FC	MT	DTT
DMY62FC	MA	Binder
DMY62FC	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMY62FC	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEJVYAZ
DM70BU5	MN	Cytochrome P450 2A6 (CYP2A6)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEPKLMQ
DM70BU5	MN	Cytochrome P450 2B6 (CYP2B6)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients. J Biochem Mol Toxicol. 2000;14(3):140-7.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10711629

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEZMWRE
DM70BU5	MN	Cytochrome P450 2C18 (CYP2C18)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DES5XRU
DM70BU5	MN	Cytochrome P450 2C8 (CYP2C8)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DE5IED8
DM70BU5	MN	Cytochrome P450 2C9 (CYP2C9)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res. 2002 Jun;8(6):1964-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12060642

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEVDYN7
DM70BU5	MN	Cytochrome P450 2E1 (CYP2E1)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEIBDNY
DM70BU5	MN	Cytochrome P450 3A5 (CYP3A5)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20443640

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DEGTFWK
DM70BU5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12642692

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	DE073H6
DM70BU5	MN	Prostaglandin G/H synthase 1 (COX-1)
DM70BU5	MT	DME
DM70BU5	MA	Metabolism
DM70BU5	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM70BU5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM70BU5	DI	DM70BU5
DM70BU5	DN	Thalidomide
DM70BU5	MI	TTF8CQI
DM70BU5	MN	Tumor necrosis factor (TNF)
DM70BU5	MT	DTT
DM70BU5	MA	Inhibitor
DM70BU5	RN	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
DM70BU5	RU	https://pubmed.ncbi.nlm.nih.gov/19099634

DMM8D3F	DI	DMM8D3F
DMM8D3F	DN	Theobromine
DMM8D3F	MI	DEJGDUW
DMM8D3F	MN	Cytochrome P450 1A2 (CYP1A2)
DMM8D3F	MT	DME
DMM8D3F	MA	Metabolism
DMM8D3F	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DMM8D3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DMM8D3F	DI	DMM8D3F
DMM8D3F	DN	Theobromine
DMM8D3F	MI	DEVDYN7
DMM8D3F	MN	Cytochrome P450 2E1 (CYP2E1)
DMM8D3F	MT	DME
DMM8D3F	MA	Metabolism
DMM8D3F	RN	Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol. 1999 Mar;47(3):299-305.
DMM8D3F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10215755

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	TTSLI08
DMRJFN9	MN	Adenosine receptor (ADOR)
DMRJFN9	MT	DTT
DMRJFN9	MA	Antagonist
DMRJFN9	RN	Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92.
DMRJFN9	RU	https://pubmed.ncbi.nlm.nih.gov/17874974

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE6OQ3W
DMRJFN9	MN	Cytochrome P450 1A1 (CYP1A1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8474022

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DEJGDUW
DMRJFN9	MN	Cytochrome P450 1A2 (CYP1A2)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):257-63.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23167834

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE9QHP6
DMRJFN9	MN	Cytochrome P450 1B1 (CYP1B1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DECB0K3
DMRJFN9	MN	Cytochrome P450 2D6 (CYP2D6)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DEVDYN7
DMRJFN9	MN	Cytochrome P450 2E1 (CYP2E1)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12699383

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DE4LYSA
DMRJFN9	MN	Cytochrome P450 3A4 (CYP3A4)
DMRJFN9	MT	DME
DMRJFN9	MA	Metabolism
DMRJFN9	RN	Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol. 1995 Jul 17;50(2):205-11.
DMRJFN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7632164

DMRJFN9	DI	DMRJFN9
DMRJFN9	DN	Theophylline
DMRJFN9	MI	DT0OC1Q
DMRJFN9	MN	Organic anion transporter 2 (SLC22A7)
DMRJFN9	MT	DTP
DMRJFN9	MA	Substrate
DMRJFN9	RN	Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
DMRJFN9	RU	http://www.ncbi.nlm.nih.gov/pubmed/15708966

DM7YCK3	DI	DM7YCK3
DM7YCK3	DN	Thiabendazole
DM7YCK3	MI	TTHDSE2
DM7YCK3	MN	Bacterial Fumarate reductase flavoprotein (Bact frdA)
DM7YCK3	MT	DTT
DM7YCK3	MA	Inhibitor
DM7YCK3	RN	Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
DM7YCK3	RU	https://pubmed.ncbi.nlm.nih.gov/11031122

DM7YCK3	DI	DM7YCK3
DM7YCK3	DN	Thiabendazole
DM7YCK3	MI	DEJGDUW
DM7YCK3	MN	Cytochrome P450 1A2 (CYP1A2)
DM7YCK3	MT	DME
DM7YCK3	MA	Metabolism
DM7YCK3	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DM7YCK3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMDRKH2	DI	DMDRKH2
DMDRKH2	DN	Thiamphenicol
DMDRKH2	MI	TTLFGBV
DMDRKH2	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMDRKH2	MT	DTT
DMDRKH2	MA	Modulator
DMDRKH2	RN	The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13.
DMDRKH2	RU	https://pubmed.ncbi.nlm.nih.gov/18646313

DMDRKH2	DI	DMDRKH2
DMDRKH2	DN	Thiamphenicol
DMDRKH2	MI	DTUGYRD
DMDRKH2	MN	P-glycoprotein 1 (ABCB1)
DMDRKH2	MT	DTP
DMDRKH2	MA	Substrate
DMDRKH2	RN	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184.
DMDRKH2	RU	http://www.ncbi.nlm.nih.gov/pubmed/29221992

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DE5IED8
DMHDF7B	MN	Cytochrome P450 2C9 (CYP2C9)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DEVDYN7
DMHDF7B	MN	Cytochrome P450 2E1 (CYP2E1)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):181-3.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16445592

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	DE4LYSA
DMHDF7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMHDF7B	MT	DME
DMHDF7B	MA	Metabolism
DMHDF7B	RN	Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40.
DMHDF7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10960410

DMHDF7B	DI	DMHDF7B
DMHDF7B	DN	Thiamylal
DMHDF7B	MI	TTEX6LM
DMHDF7B	MN	GABA(A) receptor gamma-3 (GABRG3)
DMHDF7B	MT	DTT
DMHDF7B	MA	Modulator
DMHDF7B	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMHDF7B	RU	https://www.fda.gov/

DMC1NBW	DI	DMC1NBW
DMC1NBW	DN	Thiazolidinedione
DMC1NBW	MI	TTZMAO3
DMC1NBW	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMC1NBW	MT	DTT
DMC1NBW	MA	Agonist
DMC1NBW	RN	Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
DMC1NBW	RU	https://pubmed.ncbi.nlm.nih.gov/12379847

DMU3IET	DI	DMU3IET
DMU3IET	DN	Thiethylperazine
DMU3IET	MI	TTEX248
DMU3IET	MN	Dopamine D2 receptor (D2R)
DMU3IET	MT	DTT
DMU3IET	MA	Antagonist
DMU3IET	RN	Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3.
DMU3IET	RU	https://pubmed.ncbi.nlm.nih.gov/6130555

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TT1MPAY
DMEPWYA	MN	GABA(A) receptor alpha-1 (GABRA1)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTZA1NY
DMEPWYA	MN	GABA(A) receptor beta-2 (GABRB2)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TT06RH5
DMEPWYA	MN	GABA(A) receptor gamma-2 (GABRG2)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTNJYV2
DMEPWYA	MN	Gamma-aminobutyric acid receptor (GAR)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTZ8EM9
DMEPWYA	MN	Glycine receptor (GlyR)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMEPWYA	DI	DMEPWYA
DMEPWYA	DN	THIOCOLCHICOSIDE
DMEPWYA	MI	TTF45NW
DMEPWYA	MN	Strychnine-binding glycine receptor (GLRA1)
DMEPWYA	MT	DTT
DMEPWYA	MA	Inhibitor
DMEPWYA	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMEPWYA	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DTI7UX6
DM7NKEV	MN	Breast cancer resistance protein (ABCG2)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83.
DM7NKEV	RU	https://doi.org/10.1016/j.bcp.2011.12.042

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DT4YL5R
DM7NKEV	MN	Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun. 2006 Apr 28;343(1):208-15.
DM7NKEV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16530731

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DEVXTP5
DM7NKEV	MN	Hypoxanthine phosphoribosyltransferase (HPRT1)
DM7NKEV	MT	DME
DM7NKEV	MA	Metabolism
DM7NKEV	RN	Qualitative and quantitative difference in mutation induction between carbon- and neon-ion beams in normal human cells. Biol Sci Space. 2003 Dec;17(4):302-6.
DM7NKEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15136753

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	TTCAQMW
DM7NKEV	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DM7NKEV	MT	DTT
DM7NKEV	MA	Intercalator
DM7NKEV	RN	Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
DM7NKEV	RU	https://pubmed.ncbi.nlm.nih.gov/19244103

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DTCSGPB
DM7NKEV	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM7NKEV	MT	DTP
DM7NKEV	MA	Substrate
DM7NKEV	RN	Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57.
DM7NKEV	RU	http://www.ncbi.nlm.nih.gov/pubmed/14643890

DM7NKEV	DI	DM7NKEV
DM7NKEV	DN	Thioguanine
DM7NKEV	MI	DEFQ8VO
DM7NKEV	MN	Thiopurine methyltransferase (TPMT)
DM7NKEV	MT	DME
DM7NKEV	MA	Metabolism
DM7NKEV	RN	Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
DM7NKEV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21086934

DMGP8AX	DI	DMGP8AX
DMGP8AX	DN	Thiopental
DMGP8AX	MI	TTDP1UC
DMGP8AX	MN	Fatty acid amide hydrolase (FAAH)
DMGP8AX	MT	DTT
DMGP8AX	MA	Inhibitor
DMGP8AX	RN	The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
DMGP8AX	RU	https://pubmed.ncbi.nlm.nih.gov/12839875

DMGP8AX	DI	DMGP8AX
DMGP8AX	DN	Thiopental
DMGP8AX	MI	DEGTFWK
DMGP8AX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMGP8AX	MT	DME
DMGP8AX	MA	Metabolism
DMGP8AX	RN	Lerman J. (2014). Neonatal Anesthesia. Springer.
DMGP8AX	RU	https://link.springer.com/book/10.1007%2F978-1-4419-6041-2

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DECB0K3
DM35M8J	MN	Cytochrome P450 2D6 (CYP2D6)
DM35M8J	MT	DME
DM35M8J	MA	Metabolism
DM35M8J	RN	Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003 May;59(1):45-50.
DM35M8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12682803

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	TTEX248
DM35M8J	MN	Dopamine D2 receptor (D2R)
DM35M8J	MT	DTT
DM35M8J	MA	Antagonist
DM35M8J	RN	Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.
DM35M8J	RU	https://pubmed.ncbi.nlm.nih.gov/15695070

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DEGTFWK
DM35M8J	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM35M8J	MT	DME
DM35M8J	MA	Metabolism
DM35M8J	RN	CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
DM35M8J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23959307

DM35M8J	DI	DM35M8J
DM35M8J	DN	Thioridazine
DM35M8J	MI	DTUGYRD
DM35M8J	MN	P-glycoprotein 1 (ABCB1)
DM35M8J	MT	DTP
DM35M8J	MA	Substrate
DM35M8J	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM35M8J	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMIZKOP	DI	DMIZKOP
DMIZKOP	DN	Thiotepa
DMIZKOP	MI	DE4LYSA
DMIZKOP	MN	Cytochrome P450 3A4 (CYP3A4)
DMIZKOP	MT	DME
DMIZKOP	MA	Metabolism
DMIZKOP	RN	Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol. 2002 Jun;49(6):461-7.
DMIZKOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12107550

DMIZKOP	DI	DMIZKOP
DMIZKOP	DN	Thiotepa
DMIZKOP	MI	DE4ZHS1
DMIZKOP	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMIZKOP	MT	DME
DMIZKOP	MA	Metabolism
DMIZKOP	RN	Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys. 1999 Jun 1;366(1):89-94.
DMIZKOP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10334868

DMDINC4	DI	DMDINC4
DMDINC4	DN	Thiothixene
DMDINC4	MI	DEJGDUW
DMDINC4	MN	Cytochrome P450 1A2 (CYP1A2)
DMDINC4	MT	DME
DMDINC4	MA	Metabolism
DMDINC4	RN	In vitro analysis of factors influencing CYP1A2 expression as potential determinants of interindividual variation. Pharmacol Res Perspect. 2017 Mar 2;5(2):e00299.
DMDINC4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28357125

DMDINC4	DI	DMDINC4
DMDINC4	DN	Thiothixene
DMDINC4	MI	TTEX248
DMDINC4	MN	Dopamine D2 receptor (D2R)
DMDINC4	MT	DTT
DMDINC4	MA	Antagonist
DMDINC4	RN	Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64.
DMDINC4	RU	https://pubmed.ncbi.nlm.nih.gov/3039860

DM2P6VD	DI	DM2P6VD
DM2P6VD	DN	Thrombin/fibrinogen matrix patch
DM2P6VD	MI	TTWODQF
DM2P6VD	MN	Fibrin (FG)
DM2P6VD	MT	DTT
DM2P6VD	MA	Modulator
DM2P6VD	RN	Fibrin sealant patch for repair of acute type a aortic dissection. J Card Surg. 2013 Nov;28(6):736-41.
DM2P6VD	RU	https://pubmed.ncbi.nlm.nih.gov/23957708

DMJ47QC	DI	DMJ47QC
DMJ47QC	DN	Thyrotropin
DMJ47QC	MI	TT6NYJA
DMJ47QC	MN	Thyrotropin receptor (TSHR)
DMJ47QC	MT	DTT
DMJ47QC	MA	Modulator
DMJ47QC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJ47QC	RU	https://www.fda.gov/

DMMYLTI	DI	DMMYLTI
DMMYLTI	DN	Thyrotropin Alfa
DMMYLTI	MI	TT6NYJA
DMMYLTI	MN	Thyrotropin receptor (TSHR)
DMMYLTI	MT	DTT
DMMYLTI	MA	Binder
DMMYLTI	RN	Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34.
DMMYLTI	RU	https://pubmed.ncbi.nlm.nih.gov/19602784

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	DE4LYSA
DMKSQG0	MN	Cytochrome P450 3A4 (CYP3A4)
DMKSQG0	MT	DME
DMKSQG0	MA	Metabolism
DMKSQG0	RN	Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):301-19.
DMKSQG0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11030437

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	TTPRKM0
DMKSQG0	MN	GABA transporter GAT-1 (SLC6A1)
DMKSQG0	MT	DTT
DMKSQG0	MA	Inhibitor
DMKSQG0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929).
DMKSQG0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	TTV9MQG
DMKSQG0	MN	Gamma-aminobutyric acid uptake (GABAU)
DMKSQG0	MT	DTT
DMKSQG0	MA	Inhibitor
DMKSQG0	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMKSQG0	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DMKSQG0	DI	DMKSQG0
DMKSQG0	DN	Tiagabine
DMKSQG0	MI	DEYGVN4
DMKSQG0	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKSQG0	MT	DME
DMKSQG0	MA	Metabolism
DMKSQG0	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DMKSQG0	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DMYN8MA	DI	DMYN8MA
DMYN8MA	DN	Tianeptine
DMYN8MA	MI	DE4LYSA
DMYN8MA	MN	Cytochrome P450 3A4 (CYP3A4)
DMYN8MA	MT	DME
DMYN8MA	MA	Metabolism
DMYN8MA	RN	Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant? J Psychiatr Pract. 2004 Sep;10(5):323-30.
DMYN8MA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15361747

DMYN8MA	DI	DMYN8MA
DMYN8MA	DN	Tianeptine
DMYN8MA	MI	TT3ROYC
DMYN8MA	MN	Serotonin transporter (SERT)
DMYN8MA	MT	DTT
DMYN8MA	MA	Inhibitor
DMYN8MA	RN	Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
DMYN8MA	RU	https://pubmed.ncbi.nlm.nih.gov/17109609

DMN6CAG	DI	DMN6CAG
DMN6CAG	DN	Tiapride
DMN6CAG	MI	TTEX248
DMN6CAG	MN	Dopamine D2 receptor (D2R)
DMN6CAG	MT	DTT
DMN6CAG	MA	Antagonist
DMN6CAG	RN	The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914.
DMN6CAG	RU	https://pubmed.ncbi.nlm.nih.gov/12083990

DMN6CAG	DI	DMN6CAG
DMN6CAG	DN	Tiapride
DMN6CAG	MI	TT90XZ8
DMN6CAG	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMN6CAG	MT	DTT
DMN6CAG	MA	Inhibitor
DMN6CAG	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMN6CAG	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM23D7J	DI	DM23D7J
DM23D7J	DN	Tiaprofenic acid
DM23D7J	MI	TTVKILB
DM23D7J	MN	Prostaglandin G/H synthase 2 (COX-2)
DM23D7J	MT	DTT
DM23D7J	MA	Inhibitor
DM23D7J	RN	Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14.
DM23D7J	RU	https://pubmed.ncbi.nlm.nih.gov/2277128

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	TTL7C8Q
DM5JWV9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DM5JWV9	MT	DTT
DM5JWV9	MA	Inhibitor
DM5JWV9	RN	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
DM5JWV9	RU	https://pubmed.ncbi.nlm.nih.gov/9703919

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	DENV24I
DM5JWV9	MN	Nicotinamide riboside kinase 1 (NRK1)
DM5JWV9	MT	DME
DM5JWV9	MA	Metabolism
DM5JWV9	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DM5JWV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DM5JWV9	DI	DM5JWV9
DM5JWV9	DN	Tiazofurin
DM5JWV9	MI	DE8DJ3N
DM5JWV9	MN	Nicotinamide riboside kinase 2 (NRK2)
DM5JWV9	MT	DME
DM5JWV9	MA	Metabolism
DM5JWV9	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DM5JWV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DEN0GVQ
DM78XFG	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
DM78XFG	RU	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DERDQWN
DM78XFG	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Tibolone: a unique version of hormone replacement therapy. Ann Pharmacother. 2004 May;38(5):874-81.
DM78XFG	RU	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf

DM78XFG	DI	DM78XFG
DM78XFG	DN	Tibolone
DM78XFG	MI	DEYWLRK
DM78XFG	MN	Sulfotransferase 1A1 (SULT1A1)
DM78XFG	MT	DME
DM78XFG	MA	Metabolism
DM78XFG	RN	Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids. 2006 May;71(5):343-51.
DM78XFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16360722

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	TTJP4SM
DM4ME02	MN	Bacterial Penicillin binding protein (Bact PBP)
DM4ME02	MT	DTT
DM4ME02	MA	Binder
DM4ME02	RN	Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8360977

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DED0TBR
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DERGEVU
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEQMISO
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEHFJ4G
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEHPJRC
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrob Agents Chemother. 1994 Feb;38(2):211-6.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/8192445

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DE37FJH
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/2221864

DM4ME02	DI	DM4ME02
DM4ME02	DN	Ticarcillin
DM4ME02	MI	DEF01WC
DM4ME02	MN	Beta-lactamase (blaB)
DM4ME02	MT	DME
DM4ME02	MA	Metabolism
DM4ME02	RN	Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3.
DM4ME02	RU	https://pubmed.ncbi.nlm.nih.gov/977998

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DECB0K3
DMO946V	MN	Cytochrome P450 2D6 (CYP2D6)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Effect of health foods on cytochrome P450-mediated drug metabolism. J Pharm Health Care Sci. 2017 May 10;3:14.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28496987

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DEGTFWK
DMO946V	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	DEA3U9Y
DMO946V	MN	Myeloperoxidase (MPO)
DMO946V	MT	DME
DMO946V	MA	Metabolism
DMO946V	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMO946V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMO946V	DI	DMO946V
DMO946V	DN	Ticlopidine
DMO946V	MI	TTQL5VC
DMO946V	MN	Platelet-activating factor receptor (PTAFR)
DMO946V	MT	DTT
DMO946V	MA	Modulator
DMO946V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMO946V	RU	https://www.fda.gov/

DMLE7IO	DI	DMLE7IO
DMLE7IO	DN	Tigecycline
DMLE7IO	MI	TTQ8KVI
DMLE7IO	MN	Staphylococcus 30S ribosomal subunit (Stap-coc pbp2)
DMLE7IO	MT	DTT
DMLE7IO	MA	Binder
DMLE7IO	RN	Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110.
DMLE7IO	RU	https://pubmed.ncbi.nlm.nih.gov/16863487

DMLW9HG	DI	DMLW9HG
DMLW9HG	DN	Tildrakizumab
DMLW9HG	MI	TTC1GLB
DMLW9HG	MN	Interleukin-23 (IL23)
DMLW9HG	MT	DTT
DMLW9HG	MA	Modulator
DMLW9HG	RN	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. 
DMLW9HG	RU	https://pubmed.ncbi.nlm.nih.gov/30710142

DMLW9HG	DI	DMLW9HG
DMLW9HG	DN	Tildrakizumab
DMLW9HG	MI	TTQTX98
DMLW9HG	MN	Interleukin-37 (IL37)
DMLW9HG	MT	DTT
DMLW9HG	MA	Inhibitor
DMLW9HG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLW9HG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMJW0VS	DI	DMJW0VS
DMJW0VS	DN	Tilidine
DMJW0VS	MI	TTN4QDT
DMJW0VS	MN	Opioid receptor (OPR)
DMJW0VS	MT	DTT
DMJW0VS	MA	Modulator
DMJW0VS	RN	Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
DMJW0VS	RU	https://pubmed.ncbi.nlm.nih.gov/15627429

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	TTR6W5O
DM3NXRU	MN	Adrenergic receptor beta-1 (ADRB1)
DM3NXRU	MT	DTT
DM3NXRU	MA	Antagonist
DM3NXRU	RN	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
DM3NXRU	RU	https://pubmed.ncbi.nlm.nih.gov/17154662

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DECB0K3
DM3NXRU	MN	Cytochrome P450 2D6 (CYP2D6)
DM3NXRU	MT	DME
DM3NXRU	MA	Metabolism
DM3NXRU	RN	Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
DM3NXRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27534869

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DEGTFWK
DM3NXRU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3NXRU	MT	DME
DM3NXRU	MA	Metabolism
DM3NXRU	RN	Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
DM3NXRU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21385322

DM3NXRU	DI	DM3NXRU
DM3NXRU	DN	Timolol
DM3NXRU	MI	DTUGYRD
DM3NXRU	MN	P-glycoprotein 1 (ABCB1)
DM3NXRU	MT	DTP
DM3NXRU	MA	Substrate
DM3NXRU	RN	Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
DM3NXRU	RU	https://doi.org/10.1111/j.2042-7158.1996.tb05904.x

DM3OWT4	DI	DM3OWT4
DM3OWT4	DN	Tindamax
DM3OWT4	MI	DE4LYSA
DM3OWT4	MN	Cytochrome P450 3A4 (CYP3A4)
DM3OWT4	MT	DME
DM3OWT4	MA	Metabolism
DM3OWT4	RN	FDA label of Tinidazole. The 2020 official website of the U.S. Food and Drug Administration.
DM3OWT4	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf

DM3OWT4	DI	DM3OWT4
DM3OWT4	DN	Tindamax
DM3OWT4	MI	DEAN5EW
DM3OWT4	MN	Nitroreductase (NTR)
DM3OWT4	MT	DME
DM3OWT4	MA	Metabolism
DM3OWT4	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DM3OWT4	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMNYPGS	DI	DMNYPGS
DMNYPGS	DN	Tioconazole
DMNYPGS	MI	TTTSOUD
DMNYPGS	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMNYPGS	MT	DTT
DMNYPGS	MA	Inhibitor
DMNYPGS	RN	Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
DMNYPGS	RU	https://pubmed.ncbi.nlm.nih.gov/15625110

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	TTOXS3C
DMFDC0Q	MN	Muscarinic acetylcholine receptor (CHRM)
DMFDC0Q	MT	DTT
DMFDC0Q	MA	Antagonist
DMFDC0Q	RN	Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
DMFDC0Q	RU	https://pubmed.ncbi.nlm.nih.gov/23435542

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	TTQ13Z5
DMFDC0Q	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMFDC0Q	MT	DTT
DMFDC0Q	MA	Antagonist
DMFDC0Q	RN	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
DMFDC0Q	RU	https://pubmed.ncbi.nlm.nih.gov/18048412

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	DTT79CX
DMFDC0Q	MN	Organic cation transporter 1 (SLC22A1)
DMFDC0Q	MT	DTP
DMFDC0Q	MA	Substrate
DMFDC0Q	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMFDC0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMFDC0Q	DI	DMFDC0Q
DMFDC0Q	DN	Tiotropium
DMFDC0Q	MI	DT3HUVD
DMFDC0Q	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMFDC0Q	MT	DTP
DMFDC0Q	MA	Substrate
DMFDC0Q	RN	Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95.
DMFDC0Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/20020740

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DECB0K3
DM8HJX6	MN	Cytochrome P450 2D6 (CYP2D6)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DE4LYSA
DM8HJX6	MN	Cytochrome P450 3A4 (CYP3A4)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	TT5FNQT
DM8HJX6	MN	Human immunodeficiency virus Protease (HIV PR)
DM8HJX6	MT	DTT
DM8HJX6	MA	Modulator
DM8HJX6	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM8HJX6	RU	https://www.fda.gov/

DM8HJX6	DI	DM8HJX6
DM8HJX6	DN	Tipranavir
DM8HJX6	MI	DEGTFWK
DM8HJX6	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8HJX6	MT	DME
DM8HJX6	MA	Metabolism
DM8HJX6	RN	A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
DM8HJX6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20147896

DMJNV4O	DI	DMJNV4O
DMJNV4O	DN	Tirbanibulin
DMJNV4O	MI	TTHVQ4N
DMJNV4O	MN	Tubulin polymerization (TubP)
DMJNV4O	MT	DTT
DMJNV4O	MA	Inhibitor
DMJNV4O	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMJNV4O	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf

DMQG17S	DI	DMQG17S
DMQG17S	DN	Tirofiban
DMQG17S	MI	TT38RM1
DMQG17S	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMQG17S	MT	DTT
DMQG17S	MA	Modulator
DMQG17S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQG17S	RU	https://www.fda.gov/

DMM9BJD	DI	DMM9BJD
DMM9BJD	DN	Tisagenlecleucel
DMM9BJD	MI	TTW640A
DMM9BJD	MN	B-lymphocyte surface antigen B4 (CD19)
DMM9BJD	MT	DTT
DMM9BJD	MA	Immunostimulant
DMM9BJD	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DMM9BJD	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMM9BJD	DI	DMM9BJD
DMM9BJD	DN	Tisagenlecleucel
DMM9BJD	MI	TTUE541
DMM9BJD	MN	Leukocyte surface antigen Leu-16 (CD20)
DMM9BJD	MT	DTT
DMM9BJD	MA	Immunostimulant
DMM9BJD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM9BJD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGVUO5	DI	DMGVUO5
DMGVUO5	DN	Tislelizumab
DMGVUO5	MI	TTNBFWK
DMGVUO5	MN	Programmed cell death protein 1 (PD-1)
DMGVUO5	MT	DTT
DMGVUO5	RN	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
DMGVUO5	RU	https://pubmed.ncbi.nlm.nih.gov/33044117

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TT2Q6G1
DMUKC5L	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMUKC5L	MT	DTT
DMUKC5L	MA	Inhibitor
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TTUTJGQ
DMUKC5L	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUKC5L	MT	DTT
DMUKC5L	MA	Modulator
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMUKC5L	DI	DMUKC5L
DMUKC5L	DN	Tivozanib
DMUKC5L	MI	TTDCBX5
DMUKC5L	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMUKC5L	MT	DTT
DMUKC5L	MA	Modulator
DMUKC5L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services
DMUKC5L	RU	https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

DMR2IQ4	DI	DMR2IQ4
DMR2IQ4	DN	Tizanidine
DMR2IQ4	MI	TTQ8AFT
DMR2IQ4	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMR2IQ4	MT	DTT
DMR2IQ4	MA	Agonist
DMR2IQ4	RN	Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
DMR2IQ4	RU	https://pubmed.ncbi.nlm.nih.gov/9074844

DMR2IQ4	DI	DMR2IQ4
DMR2IQ4	DN	Tizanidine
DMR2IQ4	MI	DEJGDUW
DMR2IQ4	MN	Cytochrome P450 1A2 (CYP1A2)
DMR2IQ4	MT	DME
DMR2IQ4	MA	Metabolism
DMR2IQ4	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMR2IQ4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEJADS9
DMUI0CH	MN	Aminoglycoside N-acetyltransferase (aacC2)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEWPAJD
DMUI0CH	MN	Aminoglycoside O-phosphotransferase (aphA6)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/15667800

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DE5WGIM
DMUI0CH	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	TTOVFH2
DMUI0CH	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DMUI0CH	MT	DTT
DMUI0CH	MA	Modulator
DMUI0CH	RN	Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81.
DMUI0CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/391568

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DECXWN8
DMUI0CH	MN	Kanamycin/gentamycin-resistance enzyme (aacA)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Cloning and expression of novel aminoglycoside phosphotransferase genes from Campylobacter and their role in the resistance to six aminoglycosides. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01682-17.
DMUI0CH	RU	https://pubmed.ncbi.nlm.nih.gov/29109167

DMUI0CH	DI	DMUI0CH
DMUI0CH	DN	Tobramycin
DMUI0CH	MI	DEZV4AP
DMUI0CH	MN	RNA cytidine acetyltransferase (hALP)
DMUI0CH	MT	DME
DMUI0CH	MA	Metabolism
DMUI0CH	RN	Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
DMUI0CH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1577689

DMYNMDP	DI	DMYNMDP
DMYNMDP	DN	Tocainide
DMYNMDP	MI	DEJGDUW
DMYNMDP	MN	Cytochrome P450 1A2 (CYP1A2)
DMYNMDP	MT	DME
DMYNMDP	MA	Metabolism
DMYNMDP	RN	The effect of tocainide on theophylline metabolism. Br J Clin Pharmacol. 1993 Apr;35(4):437-40.
DMYNMDP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8485025

DMYNMDP	DI	DMYNMDP
DMYNMDP	DN	Tocainide
DMYNMDP	MI	TT05DLS
DMYNMDP	MN	E3 ubiquitin-protein ligase COP1 (RFWD2)
DMYNMDP	MT	DTT
DMYNMDP	MA	Modulator
DMYNMDP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMYNMDP	RU	https://www.fda.gov/

DM7J6OR	DI	DM7J6OR
DM7J6OR	DN	Tocilizumab
DM7J6OR	MI	TT0E5SK
DM7J6OR	MN	Interleukin 6 receptor (IL6R)
DM7J6OR	MT	DTT
DM7J6OR	MA	Modulator
DM7J6OR	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM7J6OR	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DM1UE67	DI	DM1UE67
DM1UE67	DN	TOCOTRIENOL
DM1UE67	MI	TTPADOQ
DM1UE67	MN	HMG-CoA reductase (HMGCR)
DM1UE67	MT	DTT
DM1UE67	MA	Inhibitor
DM1UE67	RN	Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7.
DM1UE67	RU	https://pubmed.ncbi.nlm.nih.gov/12656204

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	DE4LYSA
DMBS370	MN	Cytochrome P450 3A4 (CYP3A4)
DMBS370	MT	DME
DMBS370	MA	Metabolism
DMBS370	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DMBS370	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	TTT7PJU
DMBS370	MN	Janus kinase 3 (JAK-3)
DMBS370	MT	DTT
DMBS370	MA	Modulator
DMBS370	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMBS370	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMBS370	DI	DMBS370
DMBS370	DN	Tofacitinib
DMBS370	MI	DEGTFWK
DMBS370	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMBS370	MT	DME
DMBS370	MA	Metabolism
DMBS370	RN	The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
DMBS370	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24464803

DMIHRNA	DI	DMIHRNA
DMIHRNA	DN	Tolazamide
DMIHRNA	MI	DE5IED8
DMIHRNA	MN	Cytochrome P450 2C9 (CYP2C9)
DMIHRNA	MT	DME
DMIHRNA	MA	Metabolism
DMIHRNA	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMIHRNA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMIHRNA	DI	DMIHRNA
DMIHRNA	DN	Tolazamide
DMIHRNA	MI	TTG140O
DMIHRNA	MN	Inward rectifier potassium channel Kir1.2 (KCNJ10)
DMIHRNA	MT	DTT
DMIHRNA	MA	Blocker
DMIHRNA	RN	Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4.
DMIHRNA	RU	https://pubmed.ncbi.nlm.nih.gov/8799949

DMI40NL	DI	DMI40NL
DMI40NL	DN	Tolazoline
DMI40NL	MI	TTEX248
DMI40NL	MN	Dopamine D2 receptor (D2R)
DMI40NL	MT	DTT
DMI40NL	MA	Antagonist
DMI40NL	RN	Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31.
DMI40NL	RU	https://pubmed.ncbi.nlm.nih.gov/16368348

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	TTP835K
DM02AWV	MN	ATP-binding cassette transporter C8 (ABCC8)
DM02AWV	MT	DTT
DM02AWV	MA	Blocker
DM02AWV	RN	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. 
DM02AWV	RU	https://pubmed.ncbi.nlm.nih.gov/19065048

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	TTEF5MJ
DM02AWV	MN	ATP-binding cassette transporter C9 (ABCC9)
DM02AWV	MT	DTT
DM02AWV	MA	Blocker
DM02AWV	RN	Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. 
DM02AWV	RU	https://pubmed.ncbi.nlm.nih.gov/19065048

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DEZMWRE
DM02AWV	MN	Cytochrome P450 2C18 (CYP2C18)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DES5XRU
DM02AWV	MN	Cytochrome P450 2C8 (CYP2C8)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab Dispos. 2000 Apr;28(4):475-81.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10725317

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DE5IED8
DM02AWV	MN	Cytochrome P450 2C9 (CYP2C9)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	Effects of organic solvents on the activities of cytochrome P450 isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos. 2001 Feb;29(2):141-4.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11159803

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DEGTFWK
DM02AWV	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM02AWV	MT	DME
DM02AWV	MA	Metabolism
DM02AWV	RN	CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
DM02AWV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681382

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DTI58LU
DM02AWV	MN	Sulfonylurea receptor 1 (ABCC8)
DM02AWV	MT	DTP
DM02AWV	MA	Substrate
DM02AWV	RN	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
DM02AWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16897043

DM02AWV	DI	DM02AWV
DM02AWV	DN	Tolbutamide
DM02AWV	MI	DT3JCE6
DM02AWV	MN	Sulfonylurea receptor 2 (ABCC9)
DM02AWV	MT	DTP
DM02AWV	MA	Substrate
DM02AWV	RN	ABCC8 and ABCC9: ABC transporters that regulate K+ channels. Pflugers Arch. 2007 Feb;453(5):703-18.
DM02AWV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16897043

DM8MNVO	DI	DM8MNVO
DM8MNVO	DN	Tolcapone
DM8MNVO	MI	TTKWFB8
DM8MNVO	MN	Catechol-O-methyl-transferase (COMT)
DM8MNVO	MT	DTT
DM8MNVO	MA	Inhibitor
DM8MNVO	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DM8MNVO	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMWUIJE	DI	DMWUIJE
DMWUIJE	DN	Tolmetin
DMWUIJE	MI	TTVKILB
DMWUIJE	MN	Prostaglandin G/H synthase 2 (COX-2)
DMWUIJE	MT	DTT
DMWUIJE	MA	Inhibitor
DMWUIJE	RN	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
DMWUIJE	RU	https://pubmed.ncbi.nlm.nih.gov/19379806

DM28MU7	DI	DM28MU7
DM28MU7	DN	Tolnaftate
DM28MU7	MI	TTE14XG
DM28MU7	MN	Squalene monooxygenase (SQLE)
DM28MU7	MT	DTT
DM28MU7	MA	Inhibitor
DM28MU7	RN	Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
DM28MU7	RU	https://pubmed.ncbi.nlm.nih.gov/1416865

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DEJGDUW
DMA2GHJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DECB0K3
DMA2GHJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	DEGTFWK
DMA2GHJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA2GHJ	MT	DME
DMA2GHJ	MA	Metabolism
DMA2GHJ	RN	Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
DMA2GHJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12695352

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	TTCRJKY
DMA2GHJ	MN	Voltage-gated calcium channel (Cav)
DMA2GHJ	MT	DTT
DMA2GHJ	MA	Modulator
DMA2GHJ	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DMA2GHJ	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMA2GHJ	DI	DMA2GHJ
DMA2GHJ	DN	Tolperisone
DMA2GHJ	MI	TTN9VTF
DMA2GHJ	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMA2GHJ	MT	DTT
DMA2GHJ	MA	Modulator
DMA2GHJ	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DMA2GHJ	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DE5IED8
DMSHPW8	MN	Cytochrome P450 2C9 (CYP2C9)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DECB0K3
DMSHPW8	MN	Cytochrome P450 2D6 (CYP2D6)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics. Drug Metab Dispos. 2010 Sep;38(9):1456-63.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20530222

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DE4LYSA
DMSHPW8	MN	Cytochrome P450 3A4 (CYP3A4)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	DEGTFWK
DMSHPW8	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSHPW8	MT	DME
DMSHPW8	MA	Metabolism
DMSHPW8	RN	Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
DMSHPW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9531513

DMSHPW8	DI	DMSHPW8
DMSHPW8	DN	Tolterodine
DMSHPW8	MI	TTQ13Z5
DMSHPW8	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSHPW8	MT	DTT
DMSHPW8	MA	Antagonist
DMSHPW8	RN	Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
DMSHPW8	RU	https://pubmed.ncbi.nlm.nih.gov/14769832

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	DE4LYSA
DMIWFRL	MN	Cytochrome P450 3A4 (CYP3A4)
DMIWFRL	MT	DME
DMIWFRL	MA	Metabolism
DMIWFRL	RN	Tolvaptan: a new therapeutic agent. Rev Recent Clin Trials. 2011 May;6(2):177-88.
DMIWFRL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20868352

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	DTUGYRD
DMIWFRL	MN	P-glycoprotein 1 (ABCB1)
DMIWFRL	MT	DTP
DMIWFRL	MA	Substrate
DMIWFRL	RN	In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol. 2011 May;51(5):761-9.
DMIWFRL	RU	http://www.ncbi.nlm.nih.gov/pubmed/20679500

DMIWFRL	DI	DMIWFRL
DMIWFRL	DN	Tolvaptan
DMIWFRL	MI	TTK8R02
DMIWFRL	MN	Vasopressin V2 receptor (V2R)
DMIWFRL	MT	DTT
DMIWFRL	MA	Antagonist
DMIWFRL	RN	Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
DMIWFRL	RU	https://pubmed.ncbi.nlm.nih.gov/19196236

DMAE6LK	DI	DMAE6LK
DMAE6LK	DN	Topetecan
DMAE6LK	MI	TTGTQHC
DMAE6LK	MN	DNA topoisomerase I (TOP1)
DMAE6LK	MT	DTT
DMAE6LK	MA	Inhibitor
DMAE6LK	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMAE6LK	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	DE4LYSA
DM82Z30	MN	Cytochrome P450 3A4 (CYP3A4)
DM82Z30	MT	DME
DM82Z30	MA	Metabolism
DM82Z30	RN	Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003 Dec;44(12):1521-8.
DM82Z30	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14636322

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	TT0MYE2
DM82Z30	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM82Z30	MT	DTT
DM82Z30	MA	Antagonist
DM82Z30	RN	Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
DM82Z30	RU	https://pubmed.ncbi.nlm.nih.gov/15934870

DM82Z30	DI	DM82Z30
DM82Z30	DN	Topiramate
DM82Z30	MI	DTUGYRD
DM82Z30	MN	P-glycoprotein 1 (ABCB1)
DM82Z30	MT	DTP
DM82Z30	MA	Substrate
DM82Z30	RN	The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009 Nov;26(11):2464-70.
DM82Z30	RU	https://doi.org/10.1007/s11095-009-9961-8

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTI7UX6
DMP6G8T	MN	Breast cancer resistance protein (ABCG2)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/20655304

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	TTGTQHC
DMP6G8T	MN	DNA topoisomerase I (TOP1)
DMP6G8T	MT	DTT
DMP6G8T	MA	Modulator
DMP6G8T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMP6G8T	RU	https://www.fda.gov/

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTZGT0P
DMP6G8T	MN	Multidrug and toxin extrusion protein 1 (SLC47A1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DT3TX4H
DMP6G8T	MN	Multidrug and toxin extrusion protein 2 (SLC47A2)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/17509534

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTSYQGK
DMP6G8T	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMP6G8T	RU	https://doi.org/10.1007/s11095-012-0935-x

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTCSGPB
DMP6G8T	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/16454695

DMP6G8T	DI	DMP6G8T
DMP6G8T	DN	Topotecan
DMP6G8T	MI	DTUGYRD
DMP6G8T	MN	P-glycoprotein 1 (ABCB1)
DMP6G8T	MT	DTP
DMP6G8T	MA	Substrate
DMP6G8T	RN	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
DMP6G8T	RU	http://www.ncbi.nlm.nih.gov/pubmed/18654741

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DES5XRU
DMXKJ6C	MN	Cytochrome P450 2C8 (CYP2C8)
DMXKJ6C	MT	DME
DMXKJ6C	MA	Metabolism
DMXKJ6C	RN	Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther. 2004 Dec;311(3):996-1007.
DMXKJ6C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304522

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DE5IED8
DMXKJ6C	MN	Cytochrome P450 2C9 (CYP2C9)
DMXKJ6C	MT	DME
DMXKJ6C	MA	Metabolism
DMXKJ6C	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMXKJ6C	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	DT3D8F0
DMXKJ6C	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMXKJ6C	MT	DTP
DMXKJ6C	MA	Substrate
DMXKJ6C	RN	Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
DMXKJ6C	RU	http://www.doc88.com/p-7415211358030.html

DMXKJ6C	DI	DMXKJ6C
DMXKJ6C	DN	Torasemide
DMXKJ6C	MI	TTS087L
DMXKJ6C	MN	Solute carrier family 12 member 1 (SLC12A1)
DMXKJ6C	MT	DTT
DMXKJ6C	MA	Blocker
DMXKJ6C	RN	Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
DMXKJ6C	RU	https://pubmed.ncbi.nlm.nih.gov/17460608

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DE6OQ3W
DMQYUWG	MN	Cytochrome P450 1A1 (CYP1A1)
DMQYUWG	MT	DME
DMQYUWG	MA	Metabolism
DMQYUWG	RN	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
DMQYUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8204106

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DE4LYSA
DMQYUWG	MN	Cytochrome P450 3A4 (CYP3A4)
DMQYUWG	MT	DME
DMQYUWG	MA	Metabolism
DMQYUWG	RN	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62.
DMQYUWG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21726172

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	TTZAYWL
DMQYUWG	MN	Estrogen receptor (ESR)
DMQYUWG	MT	DTT
DMQYUWG	MA	Modulator
DMQYUWG	RN	Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
DMQYUWG	RU	https://pubmed.ncbi.nlm.nih.gov/19468285

DMQYUWG	DI	DMQYUWG
DMQYUWG	DN	Toremifene
DMQYUWG	MI	DTUGYRD
DMQYUWG	MN	P-glycoprotein 1 (ABCB1)
DMQYUWG	MT	DTP
DMQYUWG	MA	Substrate
DMQYUWG	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMQYUWG	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMMYZ3D	DI	DMMYZ3D
DMMYZ3D	DN	Tositumomab
DMMYZ3D	MI	TTUE541
DMMYZ3D	MN	Leukocyte surface antigen Leu-16 (CD20)
DMMYZ3D	MT	DTT
DMMYZ3D	RN	Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
DMMYZ3D	RU	https://pubmed.ncbi.nlm.nih.gov/19427037

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	TTOVFH2
DM5A31S	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM5A31S	MT	DTT
DM5A31S	MA	Inhibitor
DM5A31S	RN	The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. 
DM5A31S	RU	https://pubmed.ncbi.nlm.nih.gov/30346216

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	TTND3XS
DM5A31S	MN	Bacterial Ribosome (Bact RIBS)
DM5A31S	MT	DTT
DM5A31S	MA	Modulator
DM5A31S	RN	Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64.
DM5A31S	RU	https://pubmed.ncbi.nlm.nih.gov/22354310

DM5A31S	DI	DM5A31S
DM5A31S	DN	TP-434
DM5A31S	MI	DE4LYSA
DM5A31S	MN	Cytochrome P450 3A4 (CYP3A4)
DM5A31S	MT	DME
DM5A31S	MA	Metabolism
DM5A31S	RN	Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01810-18.
DM5A31S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30559132

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE5IED8
DMG3Y89	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DECB0K3
DMG3Y89	MN	Cytochrome P450 2D6 (CYP2D6)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DEVDYN7
DMG3Y89	MN	Cytochrome P450 2E1 (CYP2E1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE4LYSA
DMG3Y89	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE4ZHS1
DMG3Y89	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DEGTFWK
DMG3Y89	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16379042

DMG3Y89	DI	DMG3Y89
DMG3Y89	DN	Trabectedin
DMG3Y89	MI	DE073H6
DMG3Y89	MN	Prostaglandin G/H synthase 1 (COX-1)
DMG3Y89	MT	DME
DMG3Y89	MA	Metabolism
DMG3Y89	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMG3Y89	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	TTWJBZ5
DMRQD04	MN	5-HT 2C receptor (HTR2C)
DMRQD04	MT	DTT
DMRQD04	MA	Modulator
DMRQD04	RN	The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
DMRQD04	RU	https://pubmed.ncbi.nlm.nih.gov/15105221

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DEPKLMQ
DMRQD04	MN	Cytochrome P450 2B6 (CYP2B6)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DECB0K3
DMRQD04	MN	Cytochrome P450 2D6 (CYP2D6)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DE4LYSA
DMRQD04	MN	Cytochrome P450 3A4 (CYP3A4)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15509185

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DTUGYRD
DMRQD04	MN	P-glycoprotein 1 (ABCB1)
DMRQD04	MT	DTP
DMRQD04	MA	Substrate
DMRQD04	RN	Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed Pharmacother. 2015 Mar;70:234-8.
DMRQD04	RU	http://www.ncbi.nlm.nih.gov/pubmed/25776506

DMRQD04	DI	DMRQD04
DMRQD04	DN	Tramadol
DMRQD04	MI	DEYGVN4
DMRQD04	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMRQD04	MT	DME
DMRQD04	MA	Metabolism
DMRQD04	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMRQD04	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DM2JGQ3	DI	DM2JGQ3
DM2JGQ3	DN	Trametinib
DM2JGQ3	MI	TTROQ37
DM2JGQ3	MN	MAPK/ERK kinase kinase (MAP3K)
DM2JGQ3	MT	DTT
DM2JGQ3	MA	Modulator
DM2JGQ3	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM2JGQ3	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	TTL69WB
DM4L6EU	MN	Angiotensin-converting enzyme (ACE)
DM4L6EU	MT	DTT
DM4L6EU	MA	Inhibitor
DM4L6EU	RN	Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7.
DM4L6EU	RU	https://pubmed.ncbi.nlm.nih.gov/19424161

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	DT9G7XN
DM4L6EU	MN	Peptide transporter 1 (SLC15A1)
DM4L6EU	MT	DTP
DM4L6EU	MA	Substrate
DM4L6EU	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM4L6EU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DM4L6EU	DI	DM4L6EU
DM4L6EU	DN	Trandolapril
DM4L6EU	MI	DT8QKNP
DM4L6EU	MN	Peptide transporter 2 (SLC15A2)
DM4L6EU	MT	DTP
DM4L6EU	MA	Substrate
DM4L6EU	RN	Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41.
DM4L6EU	RU	http://www.ncbi.nlm.nih.gov/pubmed/18713951

DMFI8A7	DI	DMFI8A7
DMFI8A7	DN	Tranexamic acid
DMFI8A7	MI	TTP86E2
DMFI8A7	MN	Plasminogen (PLG)
DMFI8A7	MT	DTT
DMFI8A7	MA	Inhibitor
DMFI8A7	RN	Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8.
DMFI8A7	RU	https://pubmed.ncbi.nlm.nih.gov/17666018

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	DE5IED8
DME5Y64	MN	Cytochrome P450 2C9 (CYP2C9)
DME5Y64	MT	DME
DME5Y64	MA	Metabolism
DME5Y64	RN	Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos. 2007 Apr;35(4):583-9.
DME5Y64	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17220234

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	DE4LYSA
DME5Y64	MN	Cytochrome P450 3A4 (CYP3A4)
DME5Y64	MT	DME
DME5Y64	MA	Metabolism
DME5Y64	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DME5Y64	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	TTTIBOJ
DME5Y64	MN	Histamine H1 receptor (H1R)
DME5Y64	MT	DTT
DME5Y64	MA	Antagonist
DME5Y64	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DME5Y64	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DME5Y64	DI	DME5Y64
DME5Y64	DN	Tranilast
DME5Y64	MI	TTHM0R1
DME5Y64	MN	Steryl-sulfatase (STS)
DME5Y64	MT	DTT
DME5Y64	MA	Inhibitor
DME5Y64	RN	Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73.
DME5Y64	RU	https://pubmed.ncbi.nlm.nih.gov/11860358

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TT32XQJ
DMGB5RE	MN	Monoamine oxidase (MAO)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
DMGB5RE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25399762

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TT3WG5C
DMGB5RE	MN	Monoamine oxidase type A (MAO-A)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
DMGB5RE	RU	https://pubmed.ncbi.nlm.nih.gov/19275775

DMGB5RE	DI	DMGB5RE
DMGB5RE	DN	Tranylcypromine
DMGB5RE	MI	TTGP7BY
DMGB5RE	MN	Monoamine oxidase type B (MAO-B)
DMGB5RE	MT	DTT
DMGB5RE	MA	Inhibitor
DMGB5RE	RN	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
DMGB5RE	RU	https://pubmed.ncbi.nlm.nih.gov/16927039

DMZQOUX	DI	DMZQOUX
DMZQOUX	DN	Trastuzumab
DMZQOUX	MI	TT6EO5L
DMZQOUX	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZQOUX	MT	DTT
DMZQOUX	RN	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
DMZQOUX	RU	https://pubmed.ncbi.nlm.nih.gov/15179190

DM20K91	DI	DM20K91
DM20K91	DN	Travoprost
DM20K91	MI	TTT2ZAR
DM20K91	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM20K91	MT	DTT
DM20K91	MA	Agonist
DM20K91	RN	Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8.
DM20K91	RU	https://pubmed.ncbi.nlm.nih.gov/19232013

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	TTSQIFT
DMK1GBJ	MN	5-HT 1A receptor (HTR1A)
DMK1GBJ	MT	DTT
DMK1GBJ	MA	Modulator
DMK1GBJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMK1GBJ	RU	https://www.fda.gov/

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DECB0K3
DMK1GBJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Evaluating the role of drug metabolism and reactive intermediates in trazodone-induced cytotoxicity toward freshly-isolated rat hepatocytes. Drug Res (Stuttg). 2016 Nov;66(11):592-596.
DMK1GBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27643409

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DE4LYSA
DMK1GBJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20.
DMK1GBJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15978881

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DEIBDNY
DMK1GBJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Drug Interactions Flockhart Table
DMK1GBJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	DERD86B
DMK1GBJ	MN	Cytochrome P450 3A7 (CYP3A7)
DMK1GBJ	MT	DME
DMK1GBJ	MA	Metabolism
DMK1GBJ	RN	Drug Interactions Flockhart Table
DMK1GBJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMK1GBJ	DI	DMK1GBJ
DMK1GBJ	DN	Trazodone
DMK1GBJ	MI	TT3ROYC
DMK1GBJ	MN	Serotonin transporter (SERT)
DMK1GBJ	MT	DTT
DMK1GBJ	MA	Modulator
DMK1GBJ	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMK1GBJ	RU	https://www.fda.gov/

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	DES5XRU
DMTIQF3	MN	Cytochrome P450 2C8 (CYP2C8)
DMTIQF3	MT	DME
DMTIQF3	MA	Metabolism
DMTIQF3	RN	FDA label of Treprostinil. The 2020 official website of the U.S. Food and Drug Administration.
DMTIQF3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021272s026lbl.pdf

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	DE5IED8
DMTIQF3	MN	Cytochrome P450 2C9 (CYP2C9)
DMTIQF3	MT	DME
DMTIQF3	MA	Metabolism
DMTIQF3	RN	Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010 Jul;50(7):829-34.
DMTIQF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133511

DMTIQF3	DI	DMTIQF3
DMTIQF3	DN	Treprostinil
DMTIQF3	MI	TTOFYT1
DMTIQF3	MN	Prostacyclin receptor (PTGIR)
DMTIQF3	MT	DTT
DMTIQF3	MA	Agonist
DMTIQF3	RN	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
DMTIQF3	RU	https://pubmed.ncbi.nlm.nih.gov/19332188

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEXNDR0
DM49DUI	MN	Cytochrome P450 26C1 (CYP26C1)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	CYP26C1 is a hydroxylase of multiple active retinoids and interacts with cellular retinoic acid binding proteins. Mol Pharmacol. 2018 May;93(5):489-503.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/29476041

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEJVYAZ
DM49DUI	MN	Cytochrome P450 2A6 (CYP2A6)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEPKLMQ
DM49DUI	MN	Cytochrome P450 2B6 (CYP2B6)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEZMWRE
DM49DUI	MN	Cytochrome P450 2C18 (CYP2C18)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DES5XRU
DM49DUI	MN	Cytochrome P450 2C8 (CYP2C8)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DE5IED8
DM49DUI	MN	Cytochrome P450 2C9 (CYP2C9)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DE4LYSA
DM49DUI	MN	Cytochrome P450 3A4 (CYP3A4)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DEIBDNY
DM49DUI	MN	Cytochrome P450 3A5 (CYP3A5)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DERD86B
DM49DUI	MN	Cytochrome P450 3A7 (CYP3A7)
DM49DUI	MT	DME
DM49DUI	MA	Metabolism
DM49DUI	RN	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
DM49DUI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11093772

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	DTUGYRD
DM49DUI	MN	P-glycoprotein 1 (ABCB1)
DM49DUI	MT	DTP
DM49DUI	MA	Substrate
DM49DUI	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM49DUI	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	TTOD7B3
DM49DUI	MN	Retinoic acid receptor (RAR)
DM49DUI	MT	DTT
DM49DUI	MA	Binder
DM49DUI	RN	Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/11586072

DM49DUI	DI	DM49DUI
DM49DUI	DN	Tretinoin
DM49DUI	MI	TT1Q3IE
DM49DUI	MN	Retinoic acid receptor gamma (RARG)
DM49DUI	MT	DTT
DM49DUI	MA	Agonist
DM49DUI	RN	Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9.
DM49DUI	RU	https://pubmed.ncbi.nlm.nih.gov/15615532

DMU54QB	DI	DMU54QB
DMU54QB	DN	Treximet
DMU54QB	MI	TTSQIFT
DMU54QB	MN	5-HT 1A receptor (HTR1A)
DMU54QB	MT	DTT
DMU54QB	MA	Antagonist
DMU54QB	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMU54QB	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0AEPG	DI	DM0AEPG
DM0AEPG	DN	Triacetin
DM0AEPG	MI	DEQU4N2
DM0AEPG	MN	Carboxyl ester lipase (CEL)
DM0AEPG	MT	DME
DM0AEPG	MA	Metabolism
DM0AEPG	RN	Lipoamidase activity in normal and mutagenized pancreatic cholesterol esterase (bile salt-stimulated lipase). Biochem J. 1993 Apr 1;291 ( Pt 1):65-9.
DM0AEPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8471055

DM98IXF	DI	DM98IXF
DM98IXF	DN	Triamcinolone
DM98IXF	MI	TTYRL6O
DM98IXF	MN	Glucocorticoid receptor (NR3C1)
DM98IXF	MT	DTT
DM98IXF	MA	Modulator
DM98IXF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM98IXF	RU	https://www.fda.gov/

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DE4LYSA
DM7LRKD	MN	Cytochrome P450 3A4 (CYP3A4)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20456080

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DEIBDNY
DM7LRKD	MN	Cytochrome P450 3A5 (CYP3A5)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM7LRKD	DI	DM7LRKD
DM7LRKD	DN	Triamcinolone diacetate
DM7LRKD	MI	DERD86B
DM7LRKD	MN	Cytochrome P450 3A7 (CYP3A7)
DM7LRKD	MT	DME
DM7LRKD	MA	Metabolism
DM7LRKD	RN	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
DM7LRKD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	TTQM7TE
DM2HU9I	MN	Amiloride-sensitive sodium channel (ENaC)
DM2HU9I	MT	DTT
DM2HU9I	MA	Blocker
DM2HU9I	RN	Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18.
DM2HU9I	RU	https://pubmed.ncbi.nlm.nih.gov/11509829

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	DEJGDUW
DM2HU9I	MN	Cytochrome P450 1A2 (CYP1A2)
DM2HU9I	MT	DME
DM2HU9I	MA	Metabolism
DM2HU9I	RN	Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.
DM2HU9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16035375

DM2HU9I	DI	DM2HU9I
DM2HU9I	DN	Triamterene
DM2HU9I	MI	DTT79CX
DM2HU9I	MN	Organic cation transporter 1 (SLC22A1)
DM2HU9I	MT	DTP
DM2HU9I	MA	Substrate
DM2HU9I	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DM2HU9I	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DE4LYSA
DMETYK5	MN	Cytochrome P450 3A4 (CYP3A4)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMETYK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DEIBDNY
DMETYK5	MN	Cytochrome P450 3A5 (CYP3A5)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
DMETYK5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12814972

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	DERD86B
DMETYK5	MN	Cytochrome P450 3A7 (CYP3A7)
DMETYK5	MT	DME
DMETYK5	MA	Metabolism
DMETYK5	RN	Drug Interactions Flockhart Table
DMETYK5	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMETYK5	DI	DMETYK5
DMETYK5	DN	Triazolam
DMETYK5	MI	TTPTXIN
DMETYK5	MN	Translocator protein (TSPO)
DMETYK5	MT	DTT
DMETYK5	MA	Modulator
DMETYK5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMETYK5	RU	https://www.fda.gov/

DMHAQCO	DI	DMHAQCO
DMHAQCO	DN	Trichlormethiazide
DMHAQCO	MI	DTVP67E
DMHAQCO	MN	Organic anion transporter 3 (SLC22A8)
DMHAQCO	MT	DTP
DMHAQCO	MA	Substrate
DMHAQCO	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMHAQCO	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMHAQCO	DI	DMHAQCO
DMHAQCO	DN	Trichlormethiazide
DMHAQCO	MI	TTS087L
DMHAQCO	MN	Solute carrier family 12 member 1 (SLC12A1)
DMHAQCO	MT	DTT
DMHAQCO	MA	Blocker
DMHAQCO	RN	Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
DMHAQCO	RU	https://pubmed.ncbi.nlm.nih.gov/17414671

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DEJGDUW
DMPWGBR	MN	Cytochrome P450 1A2 (CYP1A2)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DE5IED8
DMPWGBR	MN	Cytochrome P450 2C9 (CYP2C9)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DECB0K3
DMPWGBR	MN	Cytochrome P450 2D6 (CYP2D6)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	FDA Label of Egaten. The 2020 official website of the U.S. Food and Drug Administration.
DMPWGBR	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DE4LYSA
DMPWGBR	MN	Cytochrome P450 3A4 (CYP3A4)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	DEGTFWK
DMPWGBR	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPWGBR	MT	DME
DMPWGBR	MA	Metabolism
DMPWGBR	RN	In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
DMPWGBR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30117405

DMPWGBR	DI	DMPWGBR
DMPWGBR	DN	Triclabendazole
DMPWGBR	MI	TTEAID7
DMPWGBR	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMPWGBR	MT	DTT
DMPWGBR	MA	Inhibitor
DMPWGBR	RN	Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
DMPWGBR	RU	https://pubmed.ncbi.nlm.nih.gov/20426472

DMZUR4N	DI	DMZUR4N
DMZUR4N	DN	Triclosan
DMZUR4N	MI	TTNX2CS
DMZUR4N	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMZUR4N	MT	DTT
DMZUR4N	MA	Binder
DMZUR4N	RN	Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
DMZUR4N	RU	https://pubmed.ncbi.nlm.nih.gov/18298458

DMVLHNI	DI	DMVLHNI
DMVLHNI	DN	Tridihexethyl
DMVLHNI	MI	TTH18TF
DMVLHNI	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMVLHNI	MT	DTT
DMVLHNI	MA	Binder
DMVLHNI	RN	Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991 Nov;41(11):1737-41.
DMVLHNI	RU	https://pubmed.ncbi.nlm.nih.gov/1944902

DMD2WPG	DI	DMD2WPG
DMD2WPG	DN	Trientine
DMD2WPG	MI	TTEYTKG
DMD2WPG	MN	Carbonic anhydrase XIV (CA-XIV)
DMD2WPG	MT	DTT
DMD2WPG	MA	Inhibitor
DMD2WPG	RN	Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
DMD2WPG	RU	https://pubmed.ncbi.nlm.nih.gov/20590092

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DEPKLMQ
DMOL793	MN	Cytochrome P450 2B6 (CYP2B6)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DES5XRU
DMOL793	MN	Cytochrome P450 2C8 (CYP2C8)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DE5IED8
DMOL793	MN	Cytochrome P450 2C9 (CYP2C9)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	DE4LYSA
DMOL793	MN	Cytochrome P450 3A4 (CYP3A4)
DMOL793	MT	DME
DMOL793	MA	Metabolism
DMOL793	RN	FDA label of Trifarotene. The 2020 official website of the U.S. Food and Drug Administration.
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMOL793	DI	DMOL793
DMOL793	DN	Trifarotene
DMOL793	MI	TT1Q3IE
DMOL793	MN	Retinoic acid receptor gamma (RARG)
DMOL793	MT	DTT
DMOL793	MA	Agonist
DMOL793	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMOL793	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	TTV3NH6
DMKBYWI	MN	Calmodulin (CALM)
DMKBYWI	MT	DTT
DMKBYWI	MA	Inhibitor
DMKBYWI	RN	Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5.
DMKBYWI	RU	https://pubmed.ncbi.nlm.nih.gov/14531016

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DEJGDUW
DMKBYWI	MN	Cytochrome P450 1A2 (CYP1A2)
DMKBYWI	MT	DME
DMKBYWI	MA	Metabolism
DMKBYWI	RN	Psychotropic Medications Metabolized by Cytochromes P450 (CYP) 1A2 Enzyme and Relevant Drug Interactions: Review of Articles
DMKBYWI	RU	https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v4-id1085.php

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DEIASEZ
DMKBYWI	MN	Dimethylaniline oxidase 2 (FMO2)
DMKBYWI	MT	DME
DMKBYWI	MA	Metabolism
DMKBYWI	RN	Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
DMKBYWI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26062974

DMKBYWI	DI	DMKBYWI
DMKBYWI	DN	Trifluoperazine
DMKBYWI	MI	DTUGYRD
DMKBYWI	MN	P-glycoprotein 1 (ABCB1)
DMKBYWI	MT	DTP
DMKBYWI	MA	Substrate
DMKBYWI	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMKBYWI	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMKFQJP	DI	DMKFQJP
DMKFQJP	DN	Triflupromazine
DMKFQJP	MI	TT0K1SC
DMKFQJP	MN	5-HT 2B receptor (HTR2B)
DMKFQJP	MT	DTT
DMKFQJP	MA	Antagonist
DMKFQJP	RN	Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
DMKFQJP	RU	https://pubmed.ncbi.nlm.nih.gov/497523

DMKFQJP	DI	DMKFQJP
DMKFQJP	DN	Triflupromazine
DMKFQJP	MI	DTUGYRD
DMKFQJP	MN	P-glycoprotein 1 (ABCB1)
DMKFQJP	MT	DTP
DMKFQJP	MA	Substrate
DMKFQJP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMKFQJP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	TTU6BFZ
DMG2YBD	MN	Candida Thymidylate synthase (Candi TMP1)
DMG2YBD	MT	DTT
DMG2YBD	MA	Inhibitor
DMG2YBD	RN	Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
DMG2YBD	RU	https://pubmed.ncbi.nlm.nih.gov/18600528

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DT0EQPW
DMG2YBD	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTXD1TQ
DMG2YBD	MN	Equilibrative nucleoside transporter 1 (SLC29A1)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTW78DQ
DMG2YBD	MN	Equilibrative nucleoside transporter 2 (SLC29A2)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Lonsurf, INN-trifluridine/tipiracil.
DMG2YBD	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/649/original/WC500206246.pdf?1531845997

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DTQ23VB
DMG2YBD	MN	Organic anion transporter 1 (SLC22A6)
DMG2YBD	MT	DTP
DMG2YBD	MA	Substrate
DMG2YBD	RN	Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9.
DMG2YBD	RU	http://www.ncbi.nlm.nih.gov/pubmed/10945832

DMG2YBD	DI	DMG2YBD
DMG2YBD	DN	Trifluridine
DMG2YBD	MI	DE4HCYL
DMG2YBD	MN	Thymidine phosphorylase (TYMP)
DMG2YBD	MT	DME
DMG2YBD	MA	Metabolism
DMG2YBD	RN	Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.
DMG2YBD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18798063

DMB19L8	DI	DMB19L8
DMB19L8	DN	Trihexyphenidyl
DMB19L8	MI	TTMXGCW
DMB19L8	MN	Adrenergic receptor beta-3 (ADRB3)
DMB19L8	MT	DTT
DMB19L8	MA	Agonist
DMB19L8	RN	Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
DMB19L8	RU	https://pubmed.ncbi.nlm.nih.gov/19199918

DMB19L8	DI	DMB19L8
DMB19L8	DN	Trihexyphenidyl
DMB19L8	MI	TTZ9SOR
DMB19L8	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMB19L8	MT	DTT
DMB19L8	MA	Antagonist
DMB19L8	RN	The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
DMB19L8	RU	https://pubmed.ncbi.nlm.nih.gov/18685832

DMP5A4T	DI	DMP5A4T
DMP5A4T	DN	Trilaciclib
DMP5A4T	MI	TT0PG8F
DMP5A4T	MN	Cyclin-dependent kinase 4 (CDK4)
DMP5A4T	MT	DTT
DMP5A4T	MA	Inhibitor
DMP5A4T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMP5A4T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf

DMP5A4T	DI	DMP5A4T
DMP5A4T	DN	Trilaciclib
DMP5A4T	MI	TTO0FDJ
DMP5A4T	MN	Cyclin-dependent kinase 6 (CDK6)
DMP5A4T	MT	DTT
DMP5A4T	MA	Inhibitor
DMP5A4T	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMP5A4T	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf

DMQZ9GF	DI	DMQZ9GF
DMQZ9GF	DN	Trilostane
DMQZ9GF	MI	DE4LYSA
DMQZ9GF	MN	Cytochrome P450 3A4 (CYP3A4)
DMQZ9GF	MT	DME
DMQZ9GF	MA	Metabolism
DMQZ9GF	RN	Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2014;2014:140083.
DMQZ9GF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25535576

DMQZ9GF	DI	DMQZ9GF
DMQZ9GF	DN	Trilostane
DMQZ9GF	MI	TTOM3J0
DMQZ9GF	MN	Estrogen receptor beta (ESR2)
DMQZ9GF	MT	DTT
DMQZ9GF	MA	Modulator
DMQZ9GF	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQZ9GF	RU	https://www.fda.gov/

DM1QLST	DI	DM1QLST
DM1QLST	DN	Trimazosin
DM1QLST	MI	TT34BHT
DM1QLST	MN	Adrenergic receptor alpha-1D (ADRA1D)
DM1QLST	MT	DTT
DM1QLST	MA	Modulator
DM1QLST	RN	The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
DM1QLST	RU	https://pubmed.ncbi.nlm.nih.gov/6199597

DMPYQ7B	DI	DMPYQ7B
DMPYQ7B	DN	Trimebutine
DMPYQ7B	MI	DE4LYSA
DMPYQ7B	MN	Cytochrome P450 3A4 (CYP3A4)
DMPYQ7B	MT	DME
DMPYQ7B	MA	Metabolism
DMPYQ7B	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMPYQ7B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMEMV9D	DI	DMEMV9D
DMEMV9D	DN	Trimeprazine
DMEMV9D	MI	TTTIBOJ
DMEMV9D	MN	Histamine H1 receptor (H1R)
DMEMV9D	MT	DTT
DMEMV9D	MA	Antagonist
DMEMV9D	RN	Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40.
DMEMV9D	RU	https://pubmed.ncbi.nlm.nih.gov/16291162

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DES5XRU
DM0Q8MZ	MN	Cytochrome P450 2C8 (CYP2C8)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DE5IED8
DM0Q8MZ	MN	Cytochrome P450 2C9 (CYP2C9)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DEVDYN7
DM0Q8MZ	MN	Cytochrome P450 2E1 (CYP2E1)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DE4LYSA
DM0Q8MZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14651673

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	DEGTFWK
DM0Q8MZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0Q8MZ	MT	DME
DM0Q8MZ	MA	Metabolism
DM0Q8MZ	RN	Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
DM0Q8MZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11896285

DM0Q8MZ	DI	DM0Q8MZ
DM0Q8MZ	DN	Trimethadione
DM0Q8MZ	MI	TT729IR
DM0Q8MZ	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DM0Q8MZ	MT	DTT
DM0Q8MZ	MA	Blocker
DM0Q8MZ	RN	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
DM0Q8MZ	RU	https://pubmed.ncbi.nlm.nih.gov/17291698

DMHF4IQ	DI	DMHF4IQ
DMHF4IQ	DN	Trimethaphan
DMHF4IQ	MI	TT4H1MQ
DMHF4IQ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMHF4IQ	MT	DTT
DMHF4IQ	MA	Antagonist
DMHF4IQ	RN	Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
DMHF4IQ	RU	https://pubmed.ncbi.nlm.nih.gov/7963258

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DES5XRU
DMM7CHK	MN	Cytochrome P450 2C8 (CYP2C8)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DE5IED8
DMM7CHK	MN	Cytochrome P450 2C9 (CYP2C9)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos. 2002 Jun;30(6):631-5.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12019187

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DE4LYSA
DMM7CHK	MN	Cytochrome P450 3A4 (CYP3A4)
DMM7CHK	MT	DME
DMM7CHK	MA	Metabolism
DMM7CHK	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMM7CHK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	TTYZVDJ
DMM7CHK	MN	Dihydrofolate reductase (DHFR)
DMM7CHK	MT	DTT
DMM7CHK	MA	Modulator
DMM7CHK	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMM7CHK	RU	https://www.fda.gov/

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DTT79CX
DMM7CHK	MN	Organic cation transporter 1 (SLC22A1)
DMM7CHK	MT	DTP
DMM7CHK	MA	Substrate
DMM7CHK	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMM7CHK	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMM7CHK	DI	DMM7CHK
DMM7CHK	DN	Trimethoprim
DMM7CHK	MI	DTUGYRD
DMM7CHK	MN	P-glycoprotein 1 (ABCB1)
DMM7CHK	MT	DTP
DMM7CHK	MA	Substrate
DMM7CHK	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMM7CHK	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMDEA85	DI	DMDEA85
DMDEA85	DN	Trimetrexate
DMDEA85	MI	DTI7UX6
DMDEA85	MN	Breast cancer resistance protein (ABCG2)
DMDEA85	MT	DTP
DMDEA85	MA	Substrate
DMDEA85	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMDEA85	RU	https://doi.org/10.1007/s00280-006-0230-9

DMDEA85	DI	DMDEA85
DMDEA85	DN	Trimetrexate
DMDEA85	MI	TT9SL3Q
DMDEA85	MN	Polypeptide deformylase (PDF)
DMDEA85	MT	DTT
DMDEA85	MA	Inhibitor
DMDEA85	RN	Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6.
DMDEA85	RU	https://pubmed.ncbi.nlm.nih.gov/11036028

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DE5IED8
DM1SC8M	MN	Cytochrome P450 2C9 (CYP2C9)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DECB0K3
DM1SC8M	MN	Cytochrome P450 2D6 (CYP2D6)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16342006

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DEGTFWK
DM1SC8M	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14520122

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	TTAWNKZ
DM1SC8M	MN	Norepinephrine transporter (NET)
DM1SC8M	MT	DTT
DM1SC8M	MA	Inhibitor
DM1SC8M	RN	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
DM1SC8M	RU	https://pubmed.ncbi.nlm.nih.gov/16388933

DM1SC8M	DI	DM1SC8M
DM1SC8M	DN	Trimipramine
DM1SC8M	MI	DEYGVN4
DM1SC8M	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1SC8M	MT	DME
DM1SC8M	MA	Metabolism
DM1SC8M	RN	Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
DM1SC8M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20133892

DMZBU15	DI	DMZBU15
DMZBU15	DN	Tripelennamine
DMZBU15	MI	TTTIBOJ
DMZBU15	MN	Histamine H1 receptor (H1R)
DMZBU15	MT	DTT
DMZBU15	MA	Antagonist
DMZBU15	RN	Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309.
DMZBU15	RU	https://pubmed.ncbi.nlm.nih.gov/15914334

DM7SWIA	DI	DM7SWIA
DM7SWIA	DN	Triprolidine
DM7SWIA	MI	TTTIBOJ
DM7SWIA	MN	Histamine H1 receptor (H1R)
DM7SWIA	MT	DTT
DM7SWIA	MA	Antagonist
DM7SWIA	RN	Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9.
DM7SWIA	RU	https://pubmed.ncbi.nlm.nih.gov/18938221

DM7SWIA	DI	DM7SWIA
DM7SWIA	DN	Triprolidine
DM7SWIA	MI	DTUGYRD
DM7SWIA	MN	P-glycoprotein 1 (ABCB1)
DM7SWIA	MT	DTP
DM7SWIA	MA	Substrate
DM7SWIA	RN	Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metab Dispos. 2007 Aug;35(8):1341-9.
DM7SWIA	RU	https://doi.org/10.1124/dmd.106.013953

DMTK4LS	DI	DMTK4LS
DMTK4LS	DN	Triptorelin
DMTK4LS	MI	TT8R70G
DMTK4LS	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMTK4LS	MT	DTT
DMTK4LS	MA	Modulator
DMTK4LS	RN	Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.
DMTK4LS	RU	https://pubmed.ncbi.nlm.nih.gov/17185802

DMHB2C3	DI	DMHB2C3
DMHB2C3	DN	Trofosfamide
DMHB2C3	MI	DEPKLMQ
DMHB2C3	MN	Cytochrome P450 2B6 (CYP2B6)
DMHB2C3	MT	DME
DMHB2C3	MA	Metabolism
DMHB2C3	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DMHB2C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DMHB2C3	DI	DMHB2C3
DMHB2C3	DN	Trofosfamide
DMHB2C3	MI	DE4LYSA
DMHB2C3	MN	Cytochrome P450 3A4 (CYP3A4)
DMHB2C3	MT	DME
DMHB2C3	MA	Metabolism
DMHB2C3	RN	Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44(4):327-34.
DMHB2C3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10447581

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE6OQ3W
DM3VFPD	MN	Cytochrome P450 1A1 (CYP1A1)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1260-6.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534310

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DES5XRU
DM3VFPD	MN	Cytochrome P450 2C8 (CYP2C8)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE5IED8
DM3VFPD	MN	Cytochrome P450 2C9 (CYP2C9)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE4LYSA
DM3VFPD	MN	Cytochrome P450 3A4 (CYP3A4)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-25.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16372821

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEGTFWK
DM3VFPD	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10659951

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	TTZMAO3
DM3VFPD	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM3VFPD	MT	DTT
DM3VFPD	MA	Agonist
DM3VFPD	RN	Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
DM3VFPD	RU	https://pubmed.ncbi.nlm.nih.gov/12594814

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEYGVN4
DM3VFPD	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEL5N6Y
DM3VFPD	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEF2WXN
DM3VFPD	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DESD26P
DM3VFPD	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DE85D2P
DM3VFPD	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12582161

DM3VFPD	DI	DM3VFPD
DM3VFPD	DN	Troglitazone
DM3VFPD	MI	DEB3CV1
DM3VFPD	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM3VFPD	MT	DME
DM3VFPD	MA	Metabolism
DM3VFPD	RN	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
DM3VFPD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12433820

DMUZNIG	DI	DMUZNIG
DMUZNIG	DN	Troleandomycin
DMUZNIG	MI	TTUWYEA
DMUZNIG	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMUZNIG	MT	DTT
DMUZNIG	MA	Binder
DMUZNIG	RN	Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
DMUZNIG	RU	https://pubmed.ncbi.nlm.nih.gov/6972981

DMUZNIG	DI	DMUZNIG
DMUZNIG	DN	Troleandomycin
DMUZNIG	MI	DE4LYSA
DMUZNIG	MN	Cytochrome P450 3A4 (CYP3A4)
DMUZNIG	MT	DME
DMUZNIG	MA	Metabolism
DMUZNIG	RN	Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes. Xenobiotica. 1996 Nov;26(11):1143-53.
DMUZNIG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8948090

DMOBLGK	DI	DMOBLGK
DMOBLGK	DN	Tromethamine
DMOBLGK	MI	TTBFROQ
DMOBLGK	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMOBLGK	MT	DTT
DMOBLGK	MA	Inhibitor
DMOBLGK	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMOBLGK	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM1D90W	DI	DM1D90W
DM1D90W	DN	Tropicamide
DM1D90W	MI	TTQ3JTF
DM1D90W	MN	Muscarinic acetylcholine receptor M4 (CHRM4)
DM1D90W	MT	DTT
DM1D90W	MA	Antagonist
DM1D90W	RN	The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59.
DM1D90W	RU	https://pubmed.ncbi.nlm.nih.gov/17594079

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	TTPC4TU
DMNSJ7V	MN	5-HT 3A receptor (HTR3A)
DMNSJ7V	MT	DTT
DMNSJ7V	MA	Antagonist
DMNSJ7V	RN	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
DMNSJ7V	RU	https://pubmed.ncbi.nlm.nih.gov/18321148

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DE5IED8
DMNSJ7V	MN	Cytochrome P450 2C9 (CYP2C9)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DECB0K3
DMNSJ7V	MN	Cytochrome P450 2D6 (CYP2D6)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16192915

DMNSJ7V	DI	DMNSJ7V
DMNSJ7V	DN	Tropisetron
DMNSJ7V	MI	DE4LYSA
DMNSJ7V	MN	Cytochrome P450 3A4 (CYP3A4)
DMNSJ7V	MT	DME
DMNSJ7V	MA	Metabolism
DMNSJ7V	RN	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
DMNSJ7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743

DMX6RTG	DI	DMX6RTG
DMX6RTG	DN	Trospium
DMX6RTG	MI	TTH18TF
DMX6RTG	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMX6RTG	MT	DTT
DMX6RTG	MA	Antagonist
DMX6RTG	RN	Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
DMX6RTG	RU	https://pubmed.ncbi.nlm.nih.gov/17016423

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTE2B1D
DM32XZT	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTT79CX
DM32XZT	MN	Organic cation transporter 1 (SLC22A1)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM32XZT	DI	DM32XZT
DM32XZT	DN	Trospium chloride
DM32XZT	MI	DTUGYRD
DM32XZT	MN	P-glycoprotein 1 (ABCB1)
DM32XZT	MT	DTP
DM32XZT	MA	Substrate
DM32XZT	RN	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
DM32XZT	RU	http://www.ncbi.nlm.nih.gov/pubmed/25466967

DM6AN32	DI	DM6AN32
DM6AN32	DN	Trovafloxacin
DM6AN32	MI	TTN6J5F
DM6AN32	MN	Bacterial DNA gyrase (Bact gyrase)
DM6AN32	MT	DTT
DM6AN32	MA	Modulator
DM6AN32	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM6AN32	RU	https://www.fda.gov/

DMDHCK9	DI	DMDHCK9
DMDHCK9	DN	Trumenba
DMDHCK9	MI	TTUW6OP
DMDHCK9	MN	Complement factor H (CFH)
DMDHCK9	MT	DTT
DMDHCK9	RN	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
DMDHCK9	RU	https://pubmed.ncbi.nlm.nih.gov/25633781

DM4NTMO	DI	DM4NTMO
DM4NTMO	DN	TRYPAN BLUE
DM4NTMO	MI	TTELIN2
DM4NTMO	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4NTMO	MT	DTT
DM4NTMO	MA	Inhibitor
DM4NTMO	RN	Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
DM4NTMO	RU	https://pubmed.ncbi.nlm.nih.gov/15050628

DMBZIVP	DI	DMBZIVP
DMBZIVP	DN	Tubocurarine
DMBZIVP	MI	TTF4E0J
DMBZIVP	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMBZIVP	MT	DTT
DMBZIVP	MA	Antagonist
DMBZIVP	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMBZIVP	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMBZIVP	DI	DMBZIVP
DMBZIVP	DN	Tubocurarine
DMBZIVP	MI	DTT79CX
DMBZIVP	MN	Organic cation transporter 1 (SLC22A1)
DMBZIVP	MT	DTP
DMBZIVP	MA	Substrate
DMBZIVP	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMBZIVP	RU	https://doi.org/10.1007/s11095-012-0935-x

DMBESUA	DI	DMBESUA
DMBESUA	DN	Tucatinib
DMBESUA	MI	TT6EO5L
DMBESUA	MN	Erbb2 tyrosine kinase receptor (HER2)
DMBESUA	MT	DTT
DMBESUA	MA	Inhibitor
DMBESUA	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMBESUA	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf

DM749I3	DI	DM749I3
DM749I3	DN	Ubrogepant
DM749I3	MI	TTY6O0Q
DM749I3	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM749I3	MT	DTT
DM749I3	MA	Antagonist
DM749I3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM749I3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	DE4LYSA
DM1IQRP	MN	Cytochrome P450 3A4 (CYP3A4)
DM1IQRP	MT	DME
DM1IQRP	MA	Metabolism
DM1IQRP	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DM1IQRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	DEIBDNY
DM1IQRP	MN	Cytochrome P450 3A5 (CYP3A5)
DM1IQRP	MT	DME
DM1IQRP	MA	Metabolism
DM1IQRP	RN	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011 Dec;21(12):820-8.
DM1IQRP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21934637

DM1IQRP	DI	DM1IQRP
DM1IQRP	DN	Udenafil
DM1IQRP	MI	TTJ0IQB
DM1IQRP	MN	Phosphodiesterase 5A (PDE5A)
DM1IQRP	MT	DTT
DM1IQRP	MA	Inhibitor
DM1IQRP	RN	Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
DM1IQRP	RU	https://pubmed.ncbi.nlm.nih.gov/19465935

DMX3O0D	DI	DMX3O0D
DMX3O0D	DN	UFT
DMX3O0D	MI	DEJVYAZ
DMX3O0D	MN	Cytochrome P450 2A6 (CYP2A6)
DMX3O0D	MT	DME
DMX3O0D	MA	Metabolism
DMX3O0D	RN	UFT Capsules (uracil-tegafur).
DMX3O0D	RU	https://hemonc.org/docs/packageinsert/uraciltegafur.pdf

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	DEJGDUW
DMBNI20	MN	Cytochrome P450 1A2 (CYP1A2)
DMBNI20	MT	DME
DMBNI20	MA	Metabolism
DMBNI20	RN	The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476-83.
DMBNI20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25228633

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	DE4LYSA
DMBNI20	MN	Cytochrome P450 3A4 (CYP3A4)
DMBNI20	MT	DME
DMBNI20	MA	Metabolism
DMBNI20	RN	Emergency contraception. Gynecol Endocrinol. 2013 Mar;29 Suppl 1:1-14.
DMBNI20	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23437846

DMBNI20	DI	DMBNI20
DMBNI20	DN	Ulipristal
DMBNI20	MI	TTUV8G9
DMBNI20	MN	Progesterone receptor (PGR)
DMBNI20	MT	DTT
DMBNI20	MA	Modulator
DMBNI20	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DMBNI20	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMYRBO1	DI	DMYRBO1
DMYRBO1	DN	Umbralisib
DMYRBO1	MI	TTA8PLI
DMYRBO1	MN	Casein kinase I epsilon (CSNK1E)
DMYRBO1	MT	DTT
DMYRBO1	MA	Inhibitor
DMYRBO1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMYRBO1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf

DMYRBO1	DI	DMYRBO1
DMYRBO1	DN	Umbralisib
DMYRBO1	MI	TTGBPJE
DMYRBO1	MN	PI3-kinase delta (PIK3CD)
DMYRBO1	MT	DTT
DMYRBO1	MA	Inhibitor
DMYRBO1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMYRBO1	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf

DM4E8O9	DI	DM4E8O9
DM4E8O9	DN	Umeclidinium
DM4E8O9	MI	TTH18TF
DM4E8O9	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DM4E8O9	MT	DTT
DM4E8O9	MA	Modulator
DM4E8O9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354).
DM4E8O9	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354

DMXNR04	DI	DMXNR04
DMXNR04	DN	Unoprostone
DMXNR04	MI	TT9B4N3
DMXNR04	MN	Prostaglandin receptor (PTGR)
DMXNR04	MT	DTT
DMXNR04	MA	Modulator
DMXNR04	RN	Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504.
DMXNR04	RU	https://pubmed.ncbi.nlm.nih.gov/11381053

DM8T2OI	DI	DM8T2OI
DM8T2OI	DN	Upadacitinib
DM8T2OI	MI	DECB0K3
DM8T2OI	MN	Cytochrome P450 2D6 (CYP2D6)
DM8T2OI	MT	DME
DM8T2OI	MA	Metabolism
DM8T2OI	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DM8T2OI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DM8T2OI	DI	DM8T2OI
DM8T2OI	DN	Upadacitinib
DM8T2OI	MI	DE4LYSA
DM8T2OI	MN	Cytochrome P450 3A4 (CYP3A4)
DM8T2OI	MT	DME
DM8T2OI	MA	Metabolism
DM8T2OI	RN	Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019 Aug;58(8):1045-1058.
DM8T2OI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30945116

DM32B5U	DI	DM32B5U
DM32B5U	DN	Upadacitinib
DM32B5U	MI	TT6DM01
DM32B5U	MN	Janus kinase 1 (JAK-1)
DM32B5U	MT	DTT
DM32B5U	MA	Modulator
DM32B5U	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DM32B5U	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf

DMHL7OB	DI	DMHL7OB
DMHL7OB	DN	Uracil mustard
DMHL7OB	MI	TTUTN1I
DMHL7OB	MN	Human Deoxyribonucleic acid (hDNA)
DMHL7OB	MT	DTT
DMHL7OB	MA	Modulator
DMHL7OB	RN	Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
DMHL7OB	RU	https://pubmed.ncbi.nlm.nih.gov/8625472

DMD59GI	DI	DMD59GI
DMD59GI	DN	Urapidil
DMD59GI	MI	TTSQIFT
DMD59GI	MN	5-HT 1A receptor (HTR1A)
DMD59GI	MT	DTT
DMD59GI	MA	Agonist
DMD59GI	RN	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
DMD59GI	RU	https://pubmed.ncbi.nlm.nih.gov/9829161

DMD59GI	DI	DMD59GI
DMD59GI	DN	Urapidil
DMD59GI	MI	TTG28O6
DMD59GI	MN	Adrenergic receptor Alpha-1 (ADRA1)
DMD59GI	MT	DTT
DMD59GI	MA	Antagonist
DMD59GI	RN	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
DMD59GI	RU	https://pubmed.ncbi.nlm.nih.gov/9829161

DMUK75B	DI	DMUK75B
DMUK75B	DN	Urea
DMUK75B	MI	DTE2B1D
DMUK75B	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMUK75B	MT	DTP
DMUK75B	MA	Substrate
DMUK75B	RN	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
DMUK75B	RU	http://www.ncbi.nlm.nih.gov/pubmed/21256917

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DT0EQPW
DMQTREB	MN	Concentrative nucleoside transporter 1 (SLC28A1)
DMQTREB	MT	DTP
DMQTREB	MA	Substrate
DMQTREB	RN	Electrophysiological recordings of CNT1 (SLC28A1) activity on Nanions SURFE2R N1.
DMQTREB	RU	https://www.nanion.de/images/phocadownloadpap/Application_Notes/Nanion_APP_Note_SURFE2R_CNT1_09003.pdf

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DT82KPY
DMQTREB	MN	Concentrative nucleoside transporter 2 (SLC28A2)
DMQTREB	MT	DTP
DMQTREB	MA	Substrate
DMQTREB	RN	Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochem Pharmacol. 2019 May;163:60-70.
DMQTREB	RU	http://www.ncbi.nlm.nih.gov/pubmed/30716294

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DENV24I
DMQTREB	MN	Nicotinamide riboside kinase 1 (NRK1)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DE8DJ3N
DMQTREB	MN	Nicotinamide riboside kinase 2 (NRK2)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17914902

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	TTO0IB8
DMQTREB	MN	Thymidine phosphorylase (TYMP)
DMQTREB	MT	DTT
DMQTREB	MA	Inhibitor
DMQTREB	RN	Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell. 2007 Nov;20(4):107-10.
DMQTREB	RU	https://pubmed.ncbi.nlm.nih.gov/17949350

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DE478BP
DMQTREB	MN	Uridine-cytidine kinase 1 (UCK1)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMQTREB	DI	DMQTREB
DMQTREB	DN	Uridine
DMQTREB	MI	DETN1O0
DMQTREB	MN	Uridine-cytidine kinase 2 (UCK2)
DMQTREB	MT	DME
DMQTREB	MA	Metabolism
DMQTREB	RN	Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol. 2001 May;59(5):1181-6.
DMQTREB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11306702

DMG9HIA	DI	DMG9HIA
DMG9HIA	DN	Urofollitropin
DMG9HIA	MI	TTZFDBT
DMG9HIA	MN	Follicle-stimulating hormone receptor (FSHR)
DMG9HIA	MT	DTT
DMG9HIA	MA	Binder
DMG9HIA	RN	Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71.
DMG9HIA	RU	https://pubmed.ncbi.nlm.nih.gov/16026112

DM0GOUD	DI	DM0GOUD
DM0GOUD	DN	Urokinase
DM0GOUD	MI	TTGY7WI
DM0GOUD	MN	Urokinase-type plasminogen activator (PLAU)
DM0GOUD	MT	DTT
DM0GOUD	MA	Modulator
DM0GOUD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0GOUD	RU	https://www.fda.gov/

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	DEOMLHG
DMCUT21	MN	Beta-hydroxysteroid dehydrogenase (hdhB)
DMCUT21	MT	DME
DMCUT21	MA	Metabolism
DMCUT21	RN	Identification, cloning, heterologous expression, and characterization of a NADPH-dependent 7beta-hydroxysteroid dehydrogenase from Collinsella aerofaciens. Appl Microbiol Biotechnol. 2011 Apr;90(1):127-35.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/21181147

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	TTJBPN3
DMCUT21	MN	Biliverdin reductase A (BLVRA)
DMCUT21	MT	DTT
DMCUT21	MA	Activator
DMCUT21	RN	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/18706437

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	DT3D8F0
DMCUT21	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCUT21	MT	DTP
DMCUT21	MA	Substrate
DMCUT21	RN	Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
DMCUT21	RU	http://www.ncbi.nlm.nih.gov/pubmed/16534140

DMCUT21	DI	DMCUT21
DMCUT21	DN	Ursodeoxycholic acid
DMCUT21	MI	TTOP832
DMCUT21	MN	Solute carrier family 23 member 2 (SLC23A2)
DMCUT21	MT	DTT
DMCUT21	MA	Activator
DMCUT21	RN	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
DMCUT21	RU	https://pubmed.ncbi.nlm.nih.gov/18706437

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TTRTK6Y
DMHTYK3	MN	Interleukin-12 alpha (IL12A)
DMHTYK3	MT	DTT
DMHTYK3	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TTC1GLB
DMHTYK3	MN	Interleukin-23 (IL23)
DMHTYK3	MT	DTT
DMHTYK3	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMHTYK3	DI	DMHTYK3
DMHTYK3	DN	Ustekinumab
DMHTYK3	MI	TT9SL3Q
DMHTYK3	MN	Polypeptide deformylase (PDF)
DMHTYK3	MT	DTT
DMHTYK3	MA	Inhibitor
DMHTYK3	RN	Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
DMHTYK3	RU	https://pubmed.ncbi.nlm.nih.gov/12384337

DMA630M	DI	DMA630M
DMA630M	DN	Vaccinia immune globulin
DMA630M	MI	TTOP3CH
DMA630M	MN	Immunoglobulin unspecific (Ig)
DMA630M	MT	DTT
DMA630M	MA	Modulator
DMA630M	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMA630M	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DTW7AE3
DMHKS94	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/14617696

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	TTIU7X1
DMHKS94	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMHKS94	MT	DTT
DMHKS94	MA	Inhibitor
DMHKS94	RN	Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
DMHKS94	RU	https://pubmed.ncbi.nlm.nih.gov/19239637

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DTVP67E
DMHKS94	MN	Organic anion transporter 3 (SLC22A8)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DT9G7XN
DMHKS94	MN	Peptide transporter 1 (SLC15A1)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/9610386

DMHKS94	DI	DMHKS94
DMHKS94	DN	Valaciclovir
DMHKS94	MI	DT8QKNP
DMHKS94	MN	Peptide transporter 2 (SLC15A2)
DMHKS94	MT	DTP
DMHKS94	MA	Substrate
DMHKS94	RN	Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun. 1998 May 19;246(2):470-5.
DMHKS94	RU	http://www.ncbi.nlm.nih.gov/pubmed/9610386

DM5I1CE	DI	DM5I1CE
DM5I1CE	DN	Valacyclovir Hydrochloride
DM5I1CE	MI	TTIU7X1
DM5I1CE	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM5I1CE	MT	DTT
DM5I1CE	MA	Modulator
DM5I1CE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM5I1CE	RU	https://www.fda.gov/

DMQSA2V	DI	DMQSA2V
DMQSA2V	DN	Valbenazine tosylate
DMQSA2V	MI	TTNZRI3
DMQSA2V	MN	Synaptic vesicle amine transporter (SLC18A2)
DMQSA2V	MT	DTT
DMQSA2V	MA	Modulator
DMQSA2V	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMQSA2V	RU	https://www.fda.gov/

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE5IED8
DMAY7H4	MN	Cytochrome P450 2C9 (CYP2C9)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19422321

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE4LYSA
DMAY7H4	MN	Cytochrome P450 3A4 (CYP3A4)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12657846

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	TTVKILB
DMAY7H4	MN	Prostaglandin G/H synthase 2 (COX-2)
DMAY7H4	MT	DTT
DMAY7H4	MA	Inhibitor
DMAY7H4	RN	Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
DMAY7H4	RU	https://pubmed.ncbi.nlm.nih.gov/16719803

DMAY7H4	DI	DMAY7H4
DMAY7H4	DN	Valdecoxib
DMAY7H4	MI	DE85D2P
DMAY7H4	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMAY7H4	MT	DME
DMAY7H4	MA	Metabolism
DMAY7H4	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMAY7H4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	DTW7AE3
DMS2IUH	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DMS2IUH	MT	DTP
DMS2IUH	MA	Substrate
DMS2IUH	RN	Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
DMS2IUH	RU	http://www.ncbi.nlm.nih.gov/pubmed/15290873

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	TTIU7X1
DMS2IUH	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMS2IUH	MT	DTT
DMS2IUH	MA	Inhibitor
DMS2IUH	RN	Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
DMS2IUH	RU	https://pubmed.ncbi.nlm.nih.gov/19275707

DMS2IUH	DI	DMS2IUH
DMS2IUH	DN	Valganciclovir
DMS2IUH	MI	DT9G7XN
DMS2IUH	MN	Peptide transporter 1 (SLC15A1)
DMS2IUH	MT	DTP
DMS2IUH	MA	Substrate
DMS2IUH	RN	Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
DMS2IUH	RU	http://www.ncbi.nlm.nih.gov/pubmed/10824137

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEJVYAZ
DMCFE9I	MN	Cytochrome P450 2A6 (CYP2A6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15795555

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEPKLMQ
DMCFE9I	MN	Cytochrome P450 2B6 (CYP2B6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE5IED8
DMCFE9I	MN	Cytochrome P450 2C9 (CYP2C9)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEIBDNY
DMCFE9I	MN	Cytochrome P450 3A5 (CYP3A5)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	TTRZQE3
DMCFE9I	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMCFE9I	MT	DTT
DMCFE9I	MA	Inhibitor
DMCFE9I	RN	Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
DMCFE9I	RU	https://pubmed.ncbi.nlm.nih.gov/18851693

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	TTBH0VX
DMCFE9I	MN	Histone deacetylase (HDAC)
DMCFE9I	MT	DTT
DMCFE9I	MA	Inhibitor
DMCFE9I	RN	Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
DMCFE9I	RU	https://pubmed.ncbi.nlm.nih.gov/19564914

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEGTFWK
DMCFE9I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DTLT3UG
DMCFE9I	MN	Monocarboxylate transporter 2 (SLC16A7)
DMCFE9I	MT	DTP
DMCFE9I	MA	Substrate
DMCFE9I	RN	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
DMCFE9I	RU	https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DTFI42L
DMCFE9I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMCFE9I	MT	DTP
DMCFE9I	MA	Substrate
DMCFE9I	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DMCFE9I	RU	https://doi.org/10.1007/s12033-009-9220-6

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE073H6
DMCFE9I	MN	Prostaglandin G/H synthase 1 (COX-1)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEYGVN4
DMCFE9I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEL5N6Y
DMCFE9I	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761113

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEF2WXN
DMCFE9I	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18838507

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DESD26P
DMCFE9I	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15761113

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DE85D2P
DMCFE9I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMCFE9I	DI	DMCFE9I
DMCFE9I	DN	Valproate
DMCFE9I	MI	DEB3CV1
DMCFE9I	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMCFE9I	MT	DME
DMCFE9I	MA	Metabolism
DMCFE9I	RN	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
DMCFE9I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17687269

DMOYJFK	DI	DMOYJFK
DMOYJFK	DN	Valrubicin
DMOYJFK	MI	TT0IHXV
DMOYJFK	MN	DNA topoisomerase II (TOP2)
DMOYJFK	MT	DTT
DMOYJFK	MA	Inhibitor
DMOYJFK	RN	Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5.
DMOYJFK	RU	https://pubmed.ncbi.nlm.nih.gov/3041237

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	TT8DBY3
DMREUQ6	MN	Angiotensin II receptor type-1 (AGTR1)
DMREUQ6	MT	DTT
DMREUQ6	MA	Antagonist
DMREUQ6	RN	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
DMREUQ6	RU	https://pubmed.ncbi.nlm.nih.gov/19513646

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DE5IED8
DMREUQ6	MN	Cytochrome P450 2C9 (CYP2C9)
DMREUQ6	MT	DME
DMREUQ6	MA	Metabolism
DMREUQ6	RN	In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 2000 May;56(2):135-40.
DMREUQ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10877007

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DTFI42L
DMREUQ6	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16624871

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DTVP67E
DMREUQ6	MN	Organic anion transporter 3 (SLC22A8)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT3D8F0
DMREUQ6	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT9C1TS
DMREUQ6	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/16624871

DMREUQ6	DI	DMREUQ6
DMREUQ6	DN	Valsartan
DMREUQ6	MI	DT9G7XN
DMREUQ6	MN	Peptide transporter 1 (SLC15A1)
DMREUQ6	MT	DTP
DMREUQ6	MA	Substrate
DMREUQ6	RN	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
DMREUQ6	RU	http://www.ncbi.nlm.nih.gov/pubmed/18824524

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE035GU
DMK7T1Q	MN	D-alanylalanine synthetase (ddl)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEOFMQ7
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEO97D6
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEO8E75
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEN6VO0
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother. 1994 Jul;38(7):1675-7.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/7979308

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DESOXHP
DMK7T1Q	MN	VanA ligase (vanA)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	nan
DMK7T1Q	RU	nan

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE27YVU
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DER7KFQ
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563-71.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/8215264

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEMDEJ8
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25042042

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DE2GMEK
DMK7T1Q	MN	VanB ligase (vanB)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanI: a novel D-Ala-D-Lac vancomycin resistance gene cluster found in Desulfitobacterium hafniense. Microb Biotechnol. 2014 Sep;7(5):456-66.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25042042

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEIF4P9
DMK7T1Q	MN	VanC2 ligase (vanC)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine:D-alanine ligase-related protein necessary for vancomycin resistance. Gene. 1992 Mar 1;112(1):53-8.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/1551598

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEH73ZC
DMK7T1Q	MN	VanC2 ligase (vanC)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a D-Ala-D-Ser ligase. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10040-4.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/9294159

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEPH3S7
DMK7T1Q	MN	VanG ligase (vanG)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMK7T1Q	DI	DMK7T1Q
DMK7T1Q	DN	Vancomycin
DMK7T1Q	MI	DEPN8F9
DMK7T1Q	MN	VanG ligase (vanG)
DMK7T1Q	MT	DME
DMK7T1Q	MA	Metabolism
DMK7T1Q	RN	vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014 Jul 22;5(4):e01386-14.
DMK7T1Q	RU	https://pubmed.ncbi.nlm.nih.gov/25053786

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DTI7UX6
DMRICNP	MN	Breast cancer resistance protein (ABCG2)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
DMRICNP	RU	https://doi.org/10.1007/s00280-009-1039-0

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DE4LYSA
DMRICNP	MN	Cytochrome P450 3A4 (CYP3A4)
DMRICNP	MT	DME
DMRICNP	MA	Metabolism
DMRICNP	RN	FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
DMRICNP	RU	http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TTGKNB4
DMRICNP	MN	Epidermal growth factor receptor (EGFR)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DT3D8F0
DMRICNP	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMRICNP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	DT9C1TS
DMRICNP	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMRICNP	MT	DTP
DMRICNP	MA	Substrate
DMRICNP	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DMRICNP	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TT4DXQT
DMRICNP	MN	Proto-oncogene c-Ret (RET)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMRICNP	DI	DMRICNP
DMRICNP	DN	Vandetanib
DMRICNP	MI	TTUTJGQ
DMRICNP	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMRICNP	MT	DTT
DMRICNP	MA	Inhibitor
DMRICNP	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMRICNP	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	DE4LYSA
DMTBGW8	MN	Cytochrome P450 3A4 (CYP3A4)
DMTBGW8	MT	DME
DMTBGW8	MA	Metabolism
DMTBGW8	RN	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
DMTBGW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27800121

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	DEIBDNY
DMTBGW8	MN	Cytochrome P450 3A5 (CYP3A5)
DMTBGW8	MT	DME
DMTBGW8	MA	Metabolism
DMTBGW8	RN	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
DMTBGW8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18308836

DMTBGW8	DI	DMTBGW8
DMTBGW8	DN	Vardenafil
DMTBGW8	MI	TTJ0IQB
DMTBGW8	MN	Phosphodiesterase 5A (PDE5A)
DMTBGW8	MT	DTT
DMTBGW8	MA	Binder
DMTBGW8	RN	The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
DMTBGW8	RU	https://pubmed.ncbi.nlm.nih.gov/12475462

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	TTL1ATN
DMMUOLJ	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMMUOLJ	MT	DTT
DMMUOLJ	MA	Modulator
DMMUOLJ	RN	2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
DMMUOLJ	RU	https://pubmed.ncbi.nlm.nih.gov/17342860

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	DTT79CX
DMMUOLJ	MN	Organic cation transporter 1 (SLC22A1)
DMMUOLJ	MT	DTP
DMMUOLJ	MA	Substrate
DMMUOLJ	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMMUOLJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMMUOLJ	DI	DMMUOLJ
DMMUOLJ	DN	Varenicline
DMMUOLJ	MI	DT9IDPW
DMMUOLJ	MN	Organic cation transporter 2 (SLC22A2)
DMMUOLJ	MT	DTP
DMMUOLJ	MA	Substrate
DMMUOLJ	RN	Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008 Apr;83(4):567-76.
DMMUOLJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/17971819

DMQ2FPC	DI	DMQ2FPC
DMQ2FPC	DN	Vasopressin
DMQ2FPC	MI	DTFI42L
DMQ2FPC	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMQ2FPC	MT	DTP
DMQ2FPC	MA	Substrate
DMQ2FPC	RN	Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
DMQ2FPC	RU	http://www.ncbi.nlm.nih.gov/pubmed/10692506

DMQ2FPC	DI	DMQ2FPC
DMQ2FPC	DN	Vasopressin
DMQ2FPC	MI	TTK8R02
DMQ2FPC	MN	Vasopressin V2 receptor (V2R)
DMQ2FPC	MT	DTT
DMQ2FPC	MA	Agonist
DMQ2FPC	RN	Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
DMQ2FPC	RU	https://pubmed.ncbi.nlm.nih.gov/16738530

DMP0UK2	DI	DMP0UK2
DMP0UK2	DN	Vecuronium
DMP0UK2	MI	TTF4E0J
DMP0UK2	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMP0UK2	MT	DTT
DMP0UK2	MA	Antagonist
DMP0UK2	RN	Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
DMP0UK2	RU	https://pubmed.ncbi.nlm.nih.gov/19417616

DMP0UK2	DI	DMP0UK2
DMP0UK2	DN	Vecuronium
DMP0UK2	MI	DTUGYRD
DMP0UK2	MN	P-glycoprotein 1 (ABCB1)
DMP0UK2	MT	DTP
DMP0UK2	MA	Substrate
DMP0UK2	RN	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
DMP0UK2	RU	https://doi.org/10.1016/j.clpt.2003.09.012

DMV3YMX	DI	DMV3YMX
DMV3YMX	DN	Vedolizmab
DMV3YMX	MI	TT4BT06
DMV3YMX	MN	Integrin alpha-4 (ITGA4)
DMV3YMX	MT	DTT
DMV3YMX	MA	Antagonist
DMV3YMX	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMV3YMX	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DMV3YMX	DI	DMV3YMX
DMV3YMX	DN	Vedolizmab
DMV3YMX	MI	TTLT9XQ
DMV3YMX	MN	Integrin beta-7 (ITGB7)
DMV3YMX	MT	DTT
DMV3YMX	MA	Antagonist
DMV3YMX	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMV3YMX	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM4BOAS	DI	DM4BOAS
DM4BOAS	DN	Velaglucerase alfa
DM4BOAS	MI	TT1B5PU
DM4BOAS	MN	Glucosylceramidase (GBA)
DM4BOAS	MT	DTT
DM4BOAS	MA	Modulator
DM4BOAS	RN	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
DM4BOAS	RU	https://pubmed.ncbi.nlm.nih.gov/21283092

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DEPKLMQ
DMGF8ZQ	MN	Cytochrome P450 2B6 (CYP2B6)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	Epclusa- European Medicines Agency - European Union
DMGF8ZQ	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_de.pdf

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DES5XRU
DMGF8ZQ	MN	Cytochrome P450 2C8 (CYP2C8)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DMGF8ZQ	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DMGF8ZQ	DI	DMGF8ZQ
DMGF8ZQ	DN	Velpatasvir
DMGF8ZQ	MI	DE4LYSA
DMGF8ZQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMGF8ZQ	MT	DME
DMGF8ZQ	MA	Metabolism
DMGF8ZQ	RN	Product characteristics of Epclusa.
DMGF8ZQ	RU	https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information_en.pdf

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DE4LYSA
DM62UG5	MN	Cytochrome P450 3A4 (CYP3A4)
DM62UG5	MT	DME
DM62UG5	MA	Metabolism
DM62UG5	RN	Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012 Dec;13(17):2533-43.
DM62UG5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23094782

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DT3D8F0
DM62UG5	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DT9C1TS
DM62UG5	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/23340295

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	DTUGYRD
DM62UG5	MN	P-glycoprotein 1 (ABCB1)
DM62UG5	MT	DTP
DM62UG5	MA	Substrate
DM62UG5	RN	Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci. 2014;17(1):154-68.
DM62UG5	RU	http://www.ncbi.nlm.nih.gov/pubmed/24735766

DM62UG5	DI	DM62UG5
DM62UG5	DN	Vemurafenib
DM62UG5	MI	TTWCGQT
DM62UG5	MN	Serine/threonine-protein kinase B-raf (BRAF)
DM62UG5	MT	DTT
DM62UG5	MA	Modulator
DM62UG5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM62UG5	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM8I94Y	DI	DM8I94Y
DM8I94Y	DN	Venetoclax
DM8I94Y	MI	DTUGYRD
DM8I94Y	MN	P-glycoprotein 1 (ABCB1)
DM8I94Y	MT	DTP
DM8I94Y	MA	Substrate
DM8I94Y	RN	Venclexta FDA label
DM8I94Y	RU	https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/127/original/Venclexta_FDA_label.pdf?1543869212

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DE5IED8
DMR6QH0	MN	Cytochrome P450 2C9 (CYP2C9)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DECB0K3
DMR6QH0	MN	Cytochrome P450 2D6 (CYP2D6)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry. 2019 Sep;52(5):222-231.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30485867

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DE4LYSA
DMR6QH0	MN	Cytochrome P450 3A4 (CYP3A4)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	DEGTFWK
DMR6QH0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMR6QH0	MT	DME
DMR6QH0	MA	Metabolism
DMR6QH0	RN	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
DMR6QH0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10192828

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	TTAWNKZ
DMR6QH0	MN	Norepinephrine transporter (NET)
DMR6QH0	MT	DTT
DMR6QH0	MA	Inhibitor
DMR6QH0	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DMR6QH0	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMR6QH0	DI	DMR6QH0
DMR6QH0	DN	Venlafaxine
DMR6QH0	MI	TT3ROYC
DMR6QH0	MN	Serotonin transporter (SERT)
DMR6QH0	MT	DTT
DMR6QH0	MA	Inhibitor
DMR6QH0	RN	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
DMR6QH0	RU	https://pubmed.ncbi.nlm.nih.gov/19496045

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEJGDUW
DMA7PEW	MN	Cytochrome P450 1A2 (CYP1A2)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8232610

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEPKLMQ
DMA7PEW	MN	Cytochrome P450 2B6 (CYP2B6)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEZMWRE
DMA7PEW	MN	Cytochrome P450 2C18 (CYP2C18)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DES5XRU
DMA7PEW	MN	Cytochrome P450 2C8 (CYP2C8)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12972955

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DE5IED8
DMA7PEW	MN	Cytochrome P450 2C9 (CYP2C9)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEVDYN7
DMA7PEW	MN	Cytochrome P450 2E1 (CYP2E1)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DE4LYSA
DMA7PEW	MN	Cytochrome P450 3A4 (CYP3A4)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEIBDNY
DMA7PEW	MN	Cytochrome P450 3A5 (CYP3A5)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15689501

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DERD86B
DMA7PEW	MN	Cytochrome P450 3A7 (CYP3A7)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14744949

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DEGTFWK
DMA7PEW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMA7PEW	MT	DME
DMA7PEW	MA	Metabolism
DMA7PEW	RN	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
DMA7PEW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8750925

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTZRMK5
DMA7PEW	MN	Multidrug resistance protein 3 (ABCB4)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTSYQGK
DMA7PEW	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMA7PEW	RU	https://doi.org/10.1007/s11095-012-0935-x

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTT79CX
DMA7PEW	MN	Organic cation transporter 1 (SLC22A1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
DMA7PEW	RU	https://doi.org/10.1016/j.canlet.2005.06.051

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DT2EG60
DMA7PEW	MN	Organic cation/carnitine transporter 1 (SLC22A4)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/10215651

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DT3HUVD
DMA7PEW	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Genetic variations of the SLC22A5 gene in the Chinese and Indian populations of Singapore. Drug Metab Pharmacokinet. 2010;25(1):112-9.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/20208395

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	DTUGYRD
DMA7PEW	MN	P-glycoprotein 1 (ABCB1)
DMA7PEW	MT	DTP
DMA7PEW	MA	Substrate
DMA7PEW	RN	Improved expression and purification of human multidrug resistance protein MDR1 from baculovirus-infected insect cells. Protein Expr Purif. 2009 Jul;66(1):7-14.
DMA7PEW	RU	http://www.ncbi.nlm.nih.gov/pubmed/19233288

DMA7PEW	DI	DMA7PEW
DMA7PEW	DN	Verapamil
DMA7PEW	MI	TT729IR
DMA7PEW	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMA7PEW	MT	DTT
DMA7PEW	MA	Blocker
DMA7PEW	RN	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
DMA7PEW	RU	https://pubmed.ncbi.nlm.nih.gov/15821157

DM7MDBE	DI	DM7MDBE
DM7MDBE	DN	Vericiguat
DM7MDBE	MI	TTWNFC2
DM7MDBE	MN	Soluble guanylyl cyclase (GUCY2D)
DM7MDBE	MT	DTT
DM7MDBE	MA	Modulator
DM7MDBE	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DM7MDBE	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf

DMIY6DB	DI	DMIY6DB
DMIY6DB	DN	Verteporfin
DMIY6DB	MI	DTF9Y2V
DMIY6DB	MN	ATP-binding cassette sub-family B member 6 (ABCB6)
DMIY6DB	MT	DTP
DMIY6DB	MA	Substrate
DMIY6DB	RN	Efficient purification and reconstitution of ATP binding cassette transporter B6 (ABCB6) for functional and structural studies. J Biol Chem. 2013 Aug 2;288(31):22658-69.
DMIY6DB	RU	http://www.ncbi.nlm.nih.gov/pubmed/23792964

DMIY6DB	DI	DMIY6DB
DMIY6DB	DN	Verteporfin
DMIY6DB	MI	DTI7UX6
DMIY6DB	MN	Breast cancer resistance protein (ABCG2)
DMIY6DB	MT	DTP
DMIY6DB	MA	Substrate
DMIY6DB	RN	The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res. 2007 Apr 15;13(8):2463-70.
DMIY6DB	RU	https://doi.org/10.1158/1078-0432.CCR-06-1599

DMBKX3C	DI	DMBKX3C
DMBKX3C	DN	VESNARINONE
DMBKX3C	MI	TT06AWU
DMBKX3C	MN	Phosphodiesterase 3A (PDE3A)
DMBKX3C	MT	DTT
DMBKX3C	MA	Inhibitor
DMBKX3C	RN	Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
DMBKX3C	RU	https://pubmed.ncbi.nlm.nih.gov/20005117

DMBKX3C	DI	DMBKX3C
DMBKX3C	DN	VESNARINONE
DMBKX3C	MI	TTQ6VDM
DMBKX3C	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMBKX3C	MT	DTT
DMBKX3C	MA	Inhibitor
DMBKX3C	RN	Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
DMBKX3C	RU	https://pubmed.ncbi.nlm.nih.gov/12873512

DM4UHZF	DI	DM4UHZF
DM4UHZF	DN	Vestronidase alfa
DM4UHZF	MI	TTHS7CM
DM4UHZF	MN	Beta-glucuronidase (GUSB)
DM4UHZF	MT	DTT
DM4UHZF	MA	Modulator
DM4UHZF	RN	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. 
DM4UHZF	RU	https://pubmed.ncbi.nlm.nih.gov/29348678

DMFR201	DI	DMFR201
DMFR201	DN	Vibegron
DMFR201	MI	TTMXGCW
DMFR201	MN	Adrenergic receptor beta-3 (ADRB3)
DMFR201	MT	DTT
DMFR201	MA	Agonist
DMFR201	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2020
DMFR201	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf

DM0N85H	DI	DM0N85H
DM0N85H	DN	Vidarabine
DM0N85H	MI	TTNE7KG
DM0N85H	MN	Adenosine A2b receptor (ADORA2B)
DM0N85H	MT	DTT
DM0N85H	MA	Modulator
DM0N85H	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM0N85H	RU	https://www.fda.gov/

DMYT0OG	DI	DMYT0OG
DMYT0OG	DN	Vigabatrin
DMYT0OG	MI	TTT2LD9
DMYT0OG	MN	GABA transaminase (ABAT)
DMYT0OG	MT	DTT
DMYT0OG	MA	Inhibitor
DMYT0OG	RN	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
DMYT0OG	RU	https://pubmed.ncbi.nlm.nih.gov/20118952

DMYT0OG	DI	DMYT0OG
DMYT0OG	DN	Vigabatrin
DMYT0OG	MI	DT48WEM
DMYT0OG	MN	Proton-coupled amino acid transporter 1 (SLC36A1)
DMYT0OG	MT	DTP
DMYT0OG	MA	Substrate
DMYT0OG	RN	Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats. Pharm Res. 2012 Apr;29(4):1134-42.
DMYT0OG	RU	http://www.ncbi.nlm.nih.gov/pubmed/22234618

DMF5EK1	DI	DMF5EK1
DMF5EK1	DN	Vilanterol
DMF5EK1	MI	TT2CJVK
DMF5EK1	MN	Adrenergic receptor beta-2 (ADRB2)
DMF5EK1	MT	DTT
DMF5EK1	MA	Modulator
DMF5EK1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
DMF5EK1	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353

DMF5EK1	DI	DMF5EK1
DMF5EK1	DN	Vilanterol
DMF5EK1	MI	DE4LYSA
DMF5EK1	MN	Cytochrome P450 3A4 (CYP3A4)
DMF5EK1	MT	DME
DMF5EK1	MA	Metabolism
DMF5EK1	RN	The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013 Jun;75(6):1478-87.
DMF5EK1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23116485

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	TTSQIFT
DM4LECQ	MN	5-HT 1A receptor (HTR1A)
DM4LECQ	MT	DTT
DM4LECQ	MA	Modulator
DM4LECQ	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM4LECQ	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DECB0K3
DM4LECQ	MN	Cytochrome P450 2D6 (CYP2D6)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DE4LYSA
DM4LECQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	DEGTFWK
DM4LECQ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4LECQ	MT	DME
DM4LECQ	MA	Metabolism
DM4LECQ	RN	Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
DM4LECQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22346333

DM4LECQ	DI	DM4LECQ
DM4LECQ	DN	Vilazodone
DM4LECQ	MI	TT3ROYC
DM4LECQ	MN	Serotonin transporter (SERT)
DM4LECQ	MT	DTT
DM4LECQ	MA	Modulator
DM4LECQ	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DM4LECQ	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DMYN59P	DI	DMYN59P
DMYN59P	DN	Vildagliptin
DMYN59P	MI	TTDIGC1
DMYN59P	MN	Dipeptidyl peptidase 4 (DPP-4)
DMYN59P	MT	DTT
DMYN59P	MA	Inhibitor
DMYN59P	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMYN59P	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMYN59P	DI	DMYN59P
DMYN59P	DN	Vildagliptin
DMYN59P	MI	DTUGYRD
DMYN59P	MN	P-glycoprotein 1 (ABCB1)
DMYN59P	MT	DTP
DMYN59P	MA	Substrate
DMYN59P	RN	Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58.
DMYN59P	RU	https://doi.org/10.1111/j.1463-1326.2010.01212.x

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTI7UX6
DM5TVS3	MN	Breast cancer resistance protein (ABCG2)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/21262849

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DECB0K3
DM5TVS3	MN	Cytochrome P450 2D6 (CYP2D6)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DE4LYSA
DM5TVS3	MN	Cytochrome P450 3A4 (CYP3A4)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20959500

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DEIBDNY
DM5TVS3	MN	Cytochrome P450 3A5 (CYP3A5)
DM5TVS3	MT	DME
DM5TVS3	MA	Metabolism
DM5TVS3	RN	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
DM5TVS3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTZRMK5
DM5TVS3	MN	Multidrug resistance protein 3 (ABCB4)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/10918072

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTSYQGK
DM5TVS3	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/15198509

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTFI42L
DM5TVS3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/28403692

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	DTUGYRD
DM5TVS3	MN	P-glycoprotein 1 (ABCB1)
DM5TVS3	MT	DTP
DM5TVS3	MA	Substrate
DM5TVS3	RN	Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
DM5TVS3	RU	http://www.ncbi.nlm.nih.gov/pubmed/19631272

DM5TVS3	DI	DM5TVS3
DM5TVS3	DN	Vinblastine
DM5TVS3	MI	TTJ2PTI
DM5TVS3	MN	Tubulin beta-2 chain (TUBB2)
DM5TVS3	MT	DTT
DM5TVS3	MA	Inhibitor
DM5TVS3	RN	Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
DM5TVS3	RU	https://pubmed.ncbi.nlm.nih.gov/12795526

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DEJGDUW
DMK1ZOR	MN	Cytochrome P450 1A2 (CYP1A2)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DECB0K3
DMK1ZOR	MN	Cytochrome P450 2D6 (CYP2D6)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DEVDYN7
DMK1ZOR	MN	Cytochrome P450 2E1 (CYP2E1)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMK1ZOR	DI	DMK1ZOR
DMK1ZOR	DN	Vincamine
DMK1ZOR	MI	DE4LYSA
DMK1ZOR	MN	Cytochrome P450 3A4 (CYP3A4)
DMK1ZOR	MT	DME
DMK1ZOR	MA	Metabolism
DMK1ZOR	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMK1ZOR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTI7UX6
DMINOX3	MN	Breast cancer resistance protein (ABCG2)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMINOX3	RU	https://doi.org/10.1007/s00280-006-0230-9

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DE4LYSA
DMINOX3	MN	Cytochrome P450 3A4 (CYP3A4)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DMINOX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DEIBDNY
DMINOX3	MN	Cytochrome P450 3A5 (CYP3A5)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
DMINOX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28697165

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DERD86B
DMINOX3	MN	Cytochrome P450 3A7 (CYP3A7)
DMINOX3	MT	DME
DMINOX3	MA	Metabolism
DMINOX3	RN	Drug Interactions Flockhart Table
DMINOX3	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTSYQGK
DMINOX3	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/18619955

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTFI42L
DMINOX3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	DTUGYRD
DMINOX3	MN	P-glycoprotein 1 (ABCB1)
DMINOX3	MT	DTP
DMINOX3	MA	Substrate
DMINOX3	RN	L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18.
DMINOX3	RU	http://www.ncbi.nlm.nih.gov/pubmed/19944135

DMINOX3	DI	DMINOX3
DMINOX3	DN	Vincristine
DMINOX3	MI	TTYFKSZ
DMINOX3	MN	Tubulin beta (TUBB)
DMINOX3	MT	DTT
DMINOX3	MA	Modulator
DMINOX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMINOX3	RU	https://www.fda.gov/

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DE4LYSA
DMVR628	MN	Cytochrome P450 3A4 (CYP3A4)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61.
DMVR628	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8452560

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DEIBDNY
DMVR628	MN	Cytochrome P450 3A5 (CYP3A5)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DMVR628	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DERD86B
DMVR628	MN	Cytochrome P450 3A7 (CYP3A7)
DMVR628	MT	DME
DMVR628	MA	Metabolism
DMVR628	RN	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
DMVR628	RU	https://www.sciencedirect.com/science/article/pii/S2542568419300431

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	DTUGYRD
DMVR628	MN	P-glycoprotein 1 (ABCB1)
DMVR628	MT	DTP
DMVR628	MA	Substrate
DMVR628	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVR628	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVR628	DI	DMVR628
DMVR628	DN	Vindesine
DMVR628	MI	TTYFKSZ
DMVR628	MN	Tubulin beta (TUBB)
DMVR628	MT	DTT
DMVR628	MA	Binder
DMVR628	RN	Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
DMVR628	RU	https://pubmed.ncbi.nlm.nih.gov/17465195

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DECB0K3
DMVXFYE	MN	Cytochrome P450 2D6 (CYP2D6)
DMVXFYE	MT	DME
DMVXFYE	MA	Metabolism
DMVXFYE	RN	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
DMVXFYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DE4LYSA
DMVXFYE	MN	Cytochrome P450 3A4 (CYP3A4)
DMVXFYE	MT	DME
DMVXFYE	MA	Metabolism
DMVXFYE	RN	Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
DMVXFYE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16176333

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	DTUGYRD
DMVXFYE	MN	P-glycoprotein 1 (ABCB1)
DMVXFYE	MT	DTP
DMVXFYE	MA	Substrate
DMVXFYE	RN	Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
DMVXFYE	RU	http://www.ncbi.nlm.nih.gov/pubmed/11602674

DMVXFYE	DI	DMVXFYE
DMVXFYE	DN	Vinorelbine
DMVXFYE	MI	TTML2WA
DMVXFYE	MN	Tubulin (TUB)
DMVXFYE	MT	DTT
DMVXFYE	MA	Inhibitor
DMVXFYE	RN	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
DMVXFYE	RU	https://pubmed.ncbi.nlm.nih.gov/18633246

DMVN2E6	DI	DMVN2E6
DMVN2E6	DN	Vinpocetine
DMVN2E6	MI	DE4LYSA
DMVN2E6	MN	Cytochrome P450 3A4 (CYP3A4)
DMVN2E6	MT	DME
DMVN2E6	MA	Metabolism
DMVN2E6	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMVN2E6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMVN2E6	DI	DMVN2E6
DMVN2E6	DN	Vinpocetine
DMVN2E6	MI	TTHQENC
DMVN2E6	MN	Phosphodiesterase 1 (PDE1)
DMVN2E6	MT	DTT
DMVN2E6	MA	Inhibitor
DMVN2E6	RN	Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
DMVN2E6	RU	https://pubmed.ncbi.nlm.nih.gov/19285714

DMZYLFC	DI	DMZYLFC
DMZYLFC	DN	Viomycin sulfate
DMZYLFC	MI	TTIA0J5
DMZYLFC	MN	Bacterial 70S ribosomal RNA (Bact 70S rRNA)
DMZYLFC	MT	DTT
DMZYLFC	MA	Modulator
DMZYLFC	RN	The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7.
DMZYLFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/17515906

DM0REZS	DI	DM0REZS
DM0REZS	DN	Virulizin
DM0REZS	MI	TTD2MLN
DM0REZS	MN	Natural killer cell activation (NKA)
DM0REZS	MT	DTT
DM0REZS	MA	Modulator
DM0REZS	RN	Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26.
DM0REZS	RU	https://pubmed.ncbi.nlm.nih.gov/15891881

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	DE5IED8
DM5IXKQ	MN	Cytochrome P450 2C9 (CYP2C9)
DM5IXKQ	MT	DME
DM5IXKQ	MA	Metabolism
DM5IXKQ	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DM5IXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	DE4LYSA
DM5IXKQ	MN	Cytochrome P450 3A4 (CYP3A4)
DM5IXKQ	MT	DME
DM5IXKQ	MA	Metabolism
DM5IXKQ	RN	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
DM5IXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23662017

DM5IXKQ	DI	DM5IXKQ
DM5IXKQ	DN	Vismodegib
DM5IXKQ	MI	TT8J1S3
DM5IXKQ	MN	Smoothened homolog (SMO)
DM5IXKQ	MT	DTT
DM5IXKQ	MA	Modulator
DM5IXKQ	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DM5IXKQ	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEJGDUW
DMJ2AH4	MN	Cytochrome P450 1A2 (CYP1A2)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Carotenoids as regulators for inter-species difference in cytochrome P450 1A expression and activity in ungulates and rats. Food Chem Toxicol. 2010 Nov;48(11):3201-8.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20797421

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE9QHP6
DMJ2AH4	MN	Cytochrome P450 1B1 (CYP1B1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15258110

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DES5XRU
DMJ2AH4	MN	Cytochrome P450 2C8 (CYP2C8)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEVDYN7
DMJ2AH4	MN	Cytochrome P450 2E1 (CYP2E1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	The role of inflammatory cells and cytochrome P450 in the potentiation of CCl4-induced liver injury by a single dose of retinol. Toxicol Appl Pharmacol. 1996 Dec;141(2):507-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8975775

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE6NMGO
DMJ2AH4	MN	Cytochrome P450 2S1 (CYP2S1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochim Biophys Acta. 2009 Mar;1791(3):220-8.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19171200

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DE4LYSA
DMJ2AH4	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes. Drug Metab Dispos. 2000 Mar;28(3):315-22.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10681376

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEKN1H4
DMJ2AH4	MN	Retinal dehydrogenase 2 (ALDH1A2)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Vitamin A metabolism by dendritic cells triggers an antimicrobial response against Mycobacterium tuberculosis. mSphere. 2019 Jun 5;4(3). pii: e00327-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31167948

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEOVJF2
DMJ2AH4	MN	Retinoic acid 4-hydroxylase 26A1 (CYP26A1)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids. Mol Pharmacol. 2015;87(3):430-41.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25492813

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTOD7B3
DMJ2AH4	MN	Retinoic acid receptor (RAR)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTH029C
DMJ2AH4	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DESI4OK
DMJ2AH4	MN	Retinol dehydrogenase 5 (RDH5)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Generation of retinaldehyde for retinoic acid biosynthesis. Biomolecules. 2019 Dec 18;10(1). pii: E5.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31861321

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	DEGTU5I
DMJ2AH4	MN	Short-chain dehydrogenase/reductase retSDR8 (DHRS9)
DMJ2AH4	MT	DME
DMJ2AH4	MA	Metabolism
DMJ2AH4	RN	Vitamin A metabolism by dendritic cells triggers an antimicrobial response against Mycobacterium tuberculosis. mSphere. 2019 Jun 5;4(3). pii: e00327-19.
DMJ2AH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31167948

DMJ2AH4	DI	DMJ2AH4
DMJ2AH4	DN	Vitamin A
DMJ2AH4	MI	TTRTKPV
DMJ2AH4	MN	Trypanosoma Trypanothione reductase (Trypano TPR)
DMJ2AH4	MT	DTT
DMJ2AH4	MA	Binder
DMJ2AH4	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMJ2AH4	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	TT8RHGB
DMZ1WXJ	MN	Bacterial Pyruvate decarboxylase (Bact aceE)
DMZ1WXJ	MT	DTT
DMZ1WXJ	MA	Cofactor
DMZ1WXJ	RN	Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3.
DMZ1WXJ	RU	https://pubmed.ncbi.nlm.nih.gov/19620989

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DT8KXR9
DMZ1WXJ	MN	Choline transporter-like protein 4 (SLC44A4)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. J Biol Chem. 2017 Oct 6;292(40):16526.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/28986434

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DTEHSG0
DMZ1WXJ	MN	Putative thiamine transporter SLC35F3 (SLC35F3)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Genetic implication of a novel thiamine transporter in human hypertension. J Am Coll Cardiol. 2014 Apr 22;63(15):1542-55.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/24509276

DMZ1WXJ	DI	DMZ1WXJ
DMZ1WXJ	DN	Vitamin B1
DMZ1WXJ	MI	DT39CEA
DMZ1WXJ	MN	Thiamine transporter 2 (SLC19A3)
DMZ1WXJ	MT	DTP
DMZ1WXJ	MA	Substrate
DMZ1WXJ	RN	Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med. 2013 Apr-Jun;34(2-3):373-85.
DMZ1WXJ	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506878

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	DEGF70S
DMQVRZH	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMQVRZH	MT	DME
DMQVRZH	MA	Metabolism
DMQVRZH	RN	ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995 Dec 22;270(51):30327-33.
DMQVRZH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8530456

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	TTRHEQ4
DMQVRZH	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DMQVRZH	MT	DTT
DMQVRZH	MA	Inhibitor
DMQVRZH	RN	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
DMQVRZH	RU	https://pubmed.ncbi.nlm.nih.gov/12100180

DMQVRZH	DI	DMQVRZH
DMQVRZH	DN	Vitamin B3
DMQVRZH	MI	TTWNV8U
DMQVRZH	MN	Nicotinic acid receptor (HCAR2)
DMQVRZH	MT	DTT
DMQVRZH	MA	Agonist
DMQVRZH	RN	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
DMQVRZH	RU	https://pubmed.ncbi.nlm.nih.gov/12100180

DMDBZMV	DI	DMDBZMV
DMDBZMV	DN	Vitamin B6
DMDBZMV	MI	TTN451K
DMDBZMV	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMDBZMV	MT	DTT
DMDBZMV	MA	Cofactor
DMDBZMV	RN	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
DMDBZMV	RU	https://pubmed.ncbi.nlm.nih.gov/15965967

DMDBZMV	DI	DMDBZMV
DMDBZMV	DN	Vitamin B6
DMDBZMV	MI	DE2UNSW
DMDBZMV	MN	Pyridoxal phosphate phosphatase (PDXP)
DMDBZMV	MT	DME
DMDBZMV	MA	Metabolism
DMDBZMV	RN	Purification and characterization of vitamin B6-phosphate phosphatase from human erythrocytes. J Biol Chem. 1992 Aug 5;267(22):15978-83.
DMDBZMV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1322411

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TTK982E
DMXJ7O8	MN	Collagen (CO)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Activator
DMXJ7O8	RN	Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7.
DMXJ7O8	RU	https://pubmed.ncbi.nlm.nih.gov/19626722

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DEWO724
DMXJ7O8	MN	HIF-prolyl hydroxylase 2 (EGLN1)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003 Aug 15;278(33):30772-80.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12788921

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DESO5ZY
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-1 (P4HA1)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DE5EGK0
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-2 (P4HA2)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003 Mar;22(1):15-24.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12714038

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DE2L4RX
DMXJ7O8	MN	Prolyl 4-hydroxylase alpha-3 (P4HA3)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003 Nov 28;278(48):47685-93.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14500733

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DT3KH2X
DMXJ7O8	MN	Sodium-dependent vitamin C transporter 1 (SLC23A1)
DMXJ7O8	MT	DTP
DMXJ7O8	MA	Substrate
DMXJ7O8	RN	A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5.
DMXJ7O8	RU	http://www.ncbi.nlm.nih.gov/pubmed/10331392

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DTVY9PJ
DMXJ7O8	MN	Sodium-dependent vitamin C transporter 2 (SLC23A2)
DMXJ7O8	MT	DTP
DMXJ7O8	MA	Substrate
DMXJ7O8	RN	Molecular characterization and transcriptional regulation of the sodium-dependent vitamin C transporter genes (slc23a1 and slc23a2) in a teleost fish, the Senegalese sole (Solea senegalensis). Comp Biochem Physiol B Biochem Mol Biol. 2012 Mar;161(3):208-18.
DMXJ7O8	RU	http://www.ncbi.nlm.nih.gov/pubmed/22142801

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TT6XAGK
DMXJ7O8	MN	Solute carrier family 23 member 1 (SLC23A1)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Modulator
DMXJ7O8	RN	Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100.
DMXJ7O8	RU	https://pubmed.ncbi.nlm.nih.gov/11895172

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	TTOP832
DMXJ7O8	MN	Solute carrier family 23 member 2 (SLC23A2)
DMXJ7O8	MT	DTT
DMXJ7O8	MA	Modulator
DMXJ7O8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042).
DMXJ7O8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042

DMXJ7O8	DI	DMXJ7O8
DMXJ7O8	DN	Vitamin C
DMXJ7O8	MI	DEFQ8VO
DMXJ7O8	MN	Thiopurine methyltransferase (TPMT)
DMXJ7O8	MT	DME
DMXJ7O8	MA	Metabolism
DMXJ7O8	RN	Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
DMXJ7O8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9054258

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE98XPV
DMWQUC9	MN	Cholesterol desmolase (CYP11A1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Metabolism of 1alpha-hydroxyvitamin D3 by cytochrome P450scc to biologically active 1alpha,20-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2008 Dec;112(4-5):213-9.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19000766

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE28NZ9
DMWQUC9	MN	Cytochrome P450 124 (cyp124)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Identification of Mycobacterium tuberculosis enzyme involved in vitamin D and 7-dehydrocholesterol metabolism. J Steroid Biochem Mol Biol. 2017 May;169:202-209.
DMWQUC9	RU	https://pubmed.ncbi.nlm.nih.gov/27289046

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DERSX5P
DMWQUC9	MN	Cytochrome P450 2J2 (CYP2J2)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DE4LYSA
DMWQUC9	MN	Cytochrome P450 3A4 (CYP3A4)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013 Jul;136:54-8.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/22985909

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DEBIHM3
DMWQUC9	MN	Vitamin D 25-hydroxylase (CYP2R1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Placental vitamin D metabolism and its associations with circulating vitamin D metabolites in pregnant women. Am J Clin Nutr. 2017 Dec;106(6):1439-1448.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29021285

DMWQUC9	DI	DMWQUC9
DMWQUC9	DN	Vitamin D
DMWQUC9	MI	DEBS639
DMWQUC9	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DMWQUC9	MT	DME
DMWQUC9	MA	Metabolism
DMWQUC9	RN	Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin Exp Metastasis. 2005;22(3):265-73.
DMWQUC9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16158254

DMZC90K	DI	DMZC90K
DMZC90K	DN	Vitamin E
DMZC90K	MI	DE4LYSA
DMZC90K	MN	Cytochrome P450 3A4 (CYP3A4)
DMZC90K	MT	DME
DMZC90K	MA	Metabolism
DMZC90K	RN	Adverse effects of vitamin E by induction of drug metabolism. Genes Nutr. 2007 Dec;2(3):249-56.
DMZC90K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18850180

DMWIJTN	DI	DMWIJTN
DMWIJTN	DN	Voclosporin
DMWIJTN	MI	TTA4LDE
DMWIJTN	MN	Calcineurin (PPP3CA)
DMWIJTN	MT	DTT
DMWIJTN	MA	Inhibitor
DMWIJTN	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2021
DMWIJTN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf

DMUBP9O	DI	DMUBP9O
DMUBP9O	DN	Voglibose
DMUBP9O	MI	TTXWASR
DMUBP9O	MN	Intestinal maltase-glucoamylase (MGAM)
DMUBP9O	MT	DTT
DMUBP9O	MA	Inhibitor
DMUBP9O	RN	Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
DMUBP9O	RU	https://pubmed.ncbi.nlm.nih.gov/19568704

DM1YEPS	DI	DM1YEPS
DM1YEPS	DN	Volanesorsen
DM1YEPS	MI	TTXOZQ1
DM1YEPS	MN	ApoC-III messenger RNA (APOC3 mRNA)
DM1YEPS	MT	DTT
DM1YEPS	MA	Inhibitor
DM1YEPS	RN	Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173.
DM1YEPS	RU	https://pubmed.ncbi.nlm.nih.gov/31350288

DMO6315	DI	DMO6315
DMO6315	DN	Vonoprazan
DMO6315	MI	TTLOKXP
DMO6315	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMO6315	MT	DTT
DMO6315	MA	Modulator
DMO6315	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2008
DMO6315	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020973s022lbl.pdf

DMI783H	DI	DMI783H
DMI783H	DN	Vonvendi
DMI783H	MI	TT3SZBT
DMI783H	MN	von Willebrand factor (VWF)
DMI783H	MT	DTT
DMI783H	MA	Replacement
DMI783H	RN	Clinical pipeline report, company report or official report of Vonvendi.
DMI783H	RU	https://www.vonvendi.com/

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	DERSX5P
DMA16BR	MN	Cytochrome P450 2J2 (CYP2J2)
DMA16BR	MT	DME
DMA16BR	MA	Metabolism
DMA16BR	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DMA16BR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	DE4LYSA
DMA16BR	MN	Cytochrome P450 3A4 (CYP3A4)
DMA16BR	MT	DME
DMA16BR	MA	Metabolism
DMA16BR	RN	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
DMA16BR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28781465

DMA16BR	DI	DMA16BR
DMA16BR	DN	Vorapaxar
DMA16BR	MI	TTL935N
DMA16BR	MN	Proteinase activated receptor 1 (F2R)
DMA16BR	MT	DTT
DMA16BR	MA	Antagonist
DMA16BR	RN	In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
DMA16BR	RU	https://pubmed.ncbi.nlm.nih.gov/19572350

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	TTTSOUD
DMAOL2S	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMAOL2S	MT	DTT
DMAOL2S	MA	Modulator
DMAOL2S	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMAOL2S	RU	https://www.fda.gov/

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE5IED8
DMAOL2S	MN	Cytochrome P450 2C9 (CYP2C9)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE4LYSA
DMAOL2S	MN	Cytochrome P450 3A4 (CYP3A4)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17433262

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DEGTFWK
DMAOL2S	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18034666

DMAOL2S	DI	DMAOL2S
DMAOL2S	DN	Voriconazole
DMAOL2S	MI	DE073H6
DMAOL2S	MN	Prostaglandin G/H synthase 1 (COX-1)
DMAOL2S	MT	DME
DMAOL2S	MA	Metabolism
DMAOL2S	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMAOL2S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	TT6R7JZ
DMWMPD4	MN	Histone deacetylase 1 (HDAC1)
DMWMPD4	MT	DTT
DMWMPD4	MA	Inhibitor
DMWMPD4	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DMWMPD4	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEYGVN4
DMWMPD4	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct;20(10):638-41.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20729791

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEF2WXN
DMWMPD4	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEZO4N3
DMWMPD4	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DE2GB8N
DMWMPD4	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20373870

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DE85D2P
DMWMPD4	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEAZDL8
DMWMPD4	MN	UDP-glucuronosyltransferase 2B17 (UGT2B17)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DMWMPD4	DI	DMWMPD4
DMWMPD4	DN	Vorinostat
DMWMPD4	MI	DEB3CV1
DMWMPD4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMWMPD4	MT	DME
DMWMPD4	MA	Metabolism
DMWMPD4	RN	Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
DMWMPD4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27899892

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEJVYAZ
DM6F1PU	MN	Cytochrome P450 2A6 (CYP2A6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEPKLMQ
DM6F1PU	MN	Cytochrome P450 2B6 (CYP2B6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DES5XRU
DM6F1PU	MN	Cytochrome P450 2C8 (CYP2C8)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DE5IED8
DM6F1PU	MN	Cytochrome P450 2C9 (CYP2C9)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DECB0K3
DM6F1PU	MN	Cytochrome P450 2D6 (CYP2D6)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DE4LYSA
DM6F1PU	MN	Cytochrome P450 3A4 (CYP3A4)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEIBDNY
DM6F1PU	MN	Cytochrome P450 3A5 (CYP3A5)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22496396

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	DEGTFWK
DM6F1PU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM6F1PU	MT	DME
DM6F1PU	MA	Metabolism
DM6F1PU	RN	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
DM6F1PU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29189941

DM6F1PU	DI	DM6F1PU
DM6F1PU	DN	Vortioxetine
DM6F1PU	MI	TT3ROYC
DM6F1PU	MN	Serotonin transporter (SERT)
DM6F1PU	MT	DTT
DM6F1PU	MA	Inhibitor
DM6F1PU	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DM6F1PU	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DEPKLMQ
DMCS6M5	MN	Cytochrome P450 2B6 (CYP2B6)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DE5IED8
DMCS6M5	MN	Cytochrome P450 2C9 (CYP2C9)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DE4LYSA
DMCS6M5	MN	Cytochrome P450 3A4 (CYP3A4)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	TTQO71U
DMCS6M5	MN	Hemoglobin (HB)
DMCS6M5	MT	DTT
DMCS6M5	MA	Modulator
DMCS6M5	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf

DMCS6M5	DI	DMCS6M5
DMCS6M5	DN	Voxelotor
DMCS6M5	MI	DEGTFWK
DMCS6M5	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCS6M5	MT	DME
DMCS6M5	MA	Metabolism
DMCS6M5	RN	FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
DMCS6M5	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf

DMAI83D	DI	DMAI83D
DMAI83D	DN	Voxilaprevir
DMAI83D	MI	DEJGDUW
DMAI83D	MN	Cytochrome P450 1A2 (CYP1A2)
DMAI83D	MT	DME
DMAI83D	MA	Metabolism
DMAI83D	RN	Management of Unique Populations with HCV Infection
DMAI83D	RU	https://www.hcvguidelines.org/unique-populations

DMAI83D	DI	DMAI83D
DMAI83D	DN	Voxilaprevir
DMAI83D	MI	DES5XRU
DMAI83D	MN	Cytochrome P450 2C8 (CYP2C8)
DMAI83D	MT	DME
DMAI83D	MA	Metabolism
DMAI83D	RN	FDA Label of Vosevi. The 2020 official website of the U.S. Food and Drug Administration.
DMAI83D	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTI7UX6
DMIO4V5	MN	Breast cancer resistance protein (ABCG2)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	TTXVOJ5
DMIO4V5	MN	Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA)
DMIO4V5	MT	DTT
DMIO4V5	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMIO4V5	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTFI42L
DMIO4V5	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMIO4V5	DI	DMIO4V5
DMIO4V5	DN	VRX496
DMIO4V5	MI	DTUGYRD
DMIO4V5	MN	P-glycoprotein 1 (ABCB1)
DMIO4V5	MT	DTP
DMIO4V5	MA	Substrate
DMIO4V5	RN	Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42.
DMIO4V5	RU	http://www.ncbi.nlm.nih.gov/pubmed/16267764

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEJGDUW
DMJYCVW	MN	Cytochrome P450 1A2 (CYP1A2)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEZMWRE
DMJYCVW	MN	Cytochrome P450 2C18 (CYP2C18)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67-74.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9014207

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DES5XRU
DMJYCVW	MN	Cytochrome P450 2C8 (CYP2C8)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9248768

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DE5IED8
DMJYCVW	MN	Cytochrome P450 2C9 (CYP2C9)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29283396

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DE4LYSA
DMJYCVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20615193

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEGTFWK
DMJYCVW	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23331088

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DT9C1TS
DMJYCVW	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMJYCVW	MT	DTP
DMJYCVW	MA	Substrate
DMJYCVW	RN	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
DMJYCVW	RU	http://www.ncbi.nlm.nih.gov/pubmed/17496208

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEYWLRK
DMJYCVW	MN	Sulfotransferase 1A1 (SULT1A1)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11824526

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	DEYGVN4
DMJYCVW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJYCVW	MT	DME
DMJYCVW	MA	Metabolism
DMJYCVW	RN	Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul;22(7):1239-45.
DMJYCVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19408964

DMJYCVW	DI	DMJYCVW
DMJYCVW	DN	Warfarin
DMJYCVW	MI	TTEUC8H
DMJYCVW	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMJYCVW	MT	DTT
DMJYCVW	MA	Inhibitor
DMJYCVW	RN	[Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
DMJYCVW	RU	https://pubmed.ncbi.nlm.nih.gov/17955831

DMLHOA0	DI	DMLHOA0
DMLHOA0	DN	Xatral
DMLHOA0	MI	TTNGILX
DMLHOA0	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMLHOA0	MT	DTT
DMLHOA0	MA	Antagonist
DMLHOA0	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMLHOA0	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMLHOA0	DI	DMLHOA0
DMLHOA0	DN	Xatral
DMLHOA0	MI	DE4LYSA
DMLHOA0	MN	Cytochrome P450 3A4 (CYP3A4)
DMLHOA0	MT	DME
DMLHOA0	MA	Metabolism
DMLHOA0	RN	Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.
DMLHOA0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15555475

DMU8ANS	DI	DMU8ANS
DMU8ANS	DN	Ximelegatran
DMU8ANS	MI	TT6L509
DMU8ANS	MN	Coagulation factor IIa (F2)
DMU8ANS	MT	DTT
DMU8ANS	MA	Inhibitor
DMU8ANS	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMU8ANS	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMU8ANS	DI	DMU8ANS
DMU8ANS	DN	Ximelegatran
DMU8ANS	MI	TTMQO60
DMU8ANS	MN	Rho-associated protein kinase (ROCK)
DMU8ANS	MT	DTT
DMU8ANS	MA	Modulator
DMU8ANS	RN	Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
DMU8ANS	RU	https://www.ncbi.nlm.nih.gov/pubmed/10779382

DMAR467	DI	DMAR467
DMAR467	DN	Xylose
DMAR467	MI	DE86CHA
DMAR467	MN	Xylose isomerase (xylA)
DMAR467	MT	DME
DMAR467	MA	Metabolism
DMAR467	RN	Purification and characterization of D-xylose isomerase from Bifidobacterium adolescentis. Biosci Biotechnol Biochem. 1994 Apr;58(4):691-4.
DMAR467	RU	https://pubmed.ncbi.nlm.nih.gov/7764860

DMAR467	DI	DMAR467
DMAR467	DN	Xylose
DMAR467	MI	DEMZ1HA
DMAR467	MN	Xylose isomerase (xylA)
DMAR467	MT	DME
DMAR467	MA	Metabolism
DMAR467	RN	Bacterial xylose isomerases from the mammal gut Bacteroidetes cluster function in Saccharomyces cerevisiae for effective xylose fermentation. Microb Cell Fact. 2015 May 17;14:70.
DMAR467	RU	https://pubmed.ncbi.nlm.nih.gov/25981595

DMDPM7R	DI	DMDPM7R
DMDPM7R	DN	Y-25130
DMDPM7R	MI	TTNXLKE
DMDPM7R	MN	5-HT 3 receptor (5HT3R)
DMDPM7R	MT	DTT
DMDPM7R	MA	Antagonist
DMDPM7R	RN	The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305.
DMDPM7R	RU	https://pubmed.ncbi.nlm.nih.gov/1654255

DMDPM7R	DI	DMDPM7R
DMDPM7R	DN	Y-25130
DMDPM7R	MI	DTUGYRD
DMDPM7R	MN	P-glycoprotein 1 (ABCB1)
DMDPM7R	MT	DTP
DMDPM7R	MA	Substrate
DMDPM7R	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDPM7R	RU	https://doi.org/10.1007/s11095-012-0935-x

DMNZCI1	DI	DMNZCI1
DMNZCI1	DN	YM443
DMNZCI1	MI	TT1RS9F
DMNZCI1	MN	Acetylcholinesterase (AChE)
DMNZCI1	MT	DTT
DMNZCI1	MA	Modulator
DMNZCI1	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMNZCI1	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMMP3Y2	DI	DMMP3Y2
DMMP3Y2	DN	Yn-968D1
DMMP3Y2	MI	DTI7UX6
DMMP3Y2	MN	Breast cancer resistance protein (ABCG2)
DMMP3Y2	MT	DTP
DMMP3Y2	MA	Substrate
DMMP3Y2	RN	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010 Oct 15;70(20):7981-91.
DMMP3Y2	RU	https://doi.org/10.1158/0008-5472.CAN-10-0111

DMMP3Y2	DI	DMMP3Y2
DMMP3Y2	DN	Yn-968D1
DMMP3Y2	MI	TTUTJGQ
DMMP3Y2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMMP3Y2	MT	DTT
DMMP3Y2	MA	Inhibitor
DMMP3Y2	RN	YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80.
DMMP3Y2	RU	https://pubmed.ncbi.nlm.nih.gov/21443688

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	TTQ8AFT
DMJCP1Y	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMJCP1Y	MT	DTT
DMJCP1Y	MA	Antagonist
DMJCP1Y	RN	Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
DMJCP1Y	RU	https://pubmed.ncbi.nlm.nih.gov/19640235

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	DECB0K3
DMJCP1Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMJCP1Y	MT	DME
DMJCP1Y	MA	Metabolism
DMJCP1Y	RN	Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. 2008 Aug;20(8):891-9.
DMJCP1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18433425

DMJCP1Y	DI	DMJCP1Y
DMJCP1Y	DN	Yohimbine
DMJCP1Y	MI	DE4LYSA
DMJCP1Y	MN	Cytochrome P450 3A4 (CYP3A4)
DMJCP1Y	MT	DME
DMJCP1Y	MA	Metabolism
DMJCP1Y	RN	Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004 Aug;76(2):139-53.
DMJCP1Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15289791

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DES5XRU
DMHNQOG	MN	Cytochrome P450 2C8 (CYP2C8)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16867170

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE5IED8
DMHNQOG	MN	Cytochrome P450 2C9 (CYP2C9)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15370959

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE4LYSA
DMHNQOG	MN	Cytochrome P450 3A4 (CYP3A4)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol. 2012 May;68(5):681-8.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22108774

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	TTGKOY9
DMHNQOG	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMHNQOG	MT	DTT
DMHNQOG	MA	Antagonist
DMHNQOG	RN	Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
DMHNQOG	RU	https://pubmed.ncbi.nlm.nih.gov/12512231

DMHNQOG	DI	DMHNQOG
DMHNQOG	DN	Zafirlukast
DMHNQOG	MI	DE073H6
DMHNQOG	MN	Prostaglandin G/H synthase 1 (COX-1)
DMHNQOG	MT	DME
DMHNQOG	MA	Metabolism
DMHNQOG	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMHNQOG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DE5IED8
DMH7MUV	MN	Cytochrome P450 2C9 (CYP2C9)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DECB0K3
DMH7MUV	MN	Cytochrome P450 2D6 (CYP2D6)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DE4LYSA
DMH7MUV	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DEO1IE3
DMH7MUV	MN	Cytochrome P450 3A43 (CYP3A43)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DEIBDNY
DMH7MUV	MN	Cytochrome P450 3A5 (CYP3A5)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DERD86B
DMH7MUV	MN	Cytochrome P450 3A7 (CYP3A7)
DMH7MUV	MT	DME
DMH7MUV	MA	Metabolism
DMH7MUV	RN	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
DMH7MUV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9084959

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	TT84ETX
DMH7MUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMH7MUV	MT	DTT
DMH7MUV	MA	Inhibitor
DMH7MUV	RN	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
DMH7MUV	RU	https://pubmed.ncbi.nlm.nih.gov/9833673

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DTWN7FC
DMH7MUV	MN	Multidrug resistance-associated protein 8 (ABCC11)
DMH7MUV	MT	DTP
DMH7MUV	MA	Substrate
DMH7MUV	RN	MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14.
DMH7MUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/12764137

DMH7MUV	DI	DMH7MUV
DMH7MUV	DN	Zalcitabine
DMH7MUV	MI	DTQ23VB
DMH7MUV	MN	Organic anion transporter 1 (SLC22A6)
DMH7MUV	MT	DTP
DMH7MUV	MA	Substrate
DMH7MUV	RN	Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
DMH7MUV	RU	http://www.ncbi.nlm.nih.gov/pubmed/16724555

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DEAWHS8
DMGFWSM	MN	Aldehyde oxidase (AOX1)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 2012 Feb;40(2):267-75.
DMGFWSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22031625

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DE4LYSA
DMGFWSM	MN	Cytochrome P450 3A4 (CYP3A4)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47.
DMGFWSM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12419014

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DEIBDNY
DMGFWSM	MN	Cytochrome P450 3A5 (CYP3A5)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Drug Interactions Flockhart Table
DMGFWSM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	DERD86B
DMGFWSM	MN	Cytochrome P450 3A7 (CYP3A7)
DMGFWSM	MT	DME
DMGFWSM	MA	Metabolism
DMGFWSM	RN	Drug Interactions Flockhart Table
DMGFWSM	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DMGFWSM	DI	DMGFWSM
DMGFWSM	DN	Zaleplon
DMGFWSM	MI	TT1MPAY
DMGFWSM	MN	GABA(A) receptor alpha-1 (GABRA1)
DMGFWSM	MT	DTT
DMGFWSM	MA	Modulator
DMGFWSM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMGFWSM	RU	https://www.fda.gov/

DMFMBZ4	DI	DMFMBZ4
DMFMBZ4	DN	Zanamivir
DMFMBZ4	MI	TT50QJ3
DMFMBZ4	MN	Influenza Neuraminidase (Influ NA)
DMFMBZ4	MT	DTT
DMFMBZ4	MA	Inhibitor
DMFMBZ4	RN	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
DMFMBZ4	RU	https://pubmed.ncbi.nlm.nih.gov/18328578

DMUR5NG	DI	DMUR5NG
DMUR5NG	DN	Zanubrutinib
DMUR5NG	MI	DE4LYSA
DMUR5NG	MN	Cytochrome P450 3A4 (CYP3A4)
DMUR5NG	MT	DME
DMUR5NG	MA	Metabolism
DMUR5NG	RN	FDA label of Zanubrutinib. The 2020 official website of the U.S. Food and Drug Administration.
DMUR5NG	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf

DMJWRQP	DI	DMJWRQP
DMJWRQP	DN	Zanubrutinib
DMJWRQP	MI	TTGM6VW
DMJWRQP	MN	Tyrosine-protein kinase BTK (ATK)
DMJWRQP	MT	DTT
DMJWRQP	MA	Inhibitor
DMJWRQP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services. 2019
DMJWRQP	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf

DMA5QPM	DI	DMA5QPM
DMA5QPM	DN	Zemaira
DMA5QPM	MI	TTA7UJC
DMA5QPM	MN	Alpha-1-antitrypsin (SERPINA1)
DMA5QPM	MT	DTT
DMA5QPM	MA	Inhibitor
DMA5QPM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DMA5QPM	RU	https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira

DMSLJP4	DI	DMSLJP4
DMSLJP4	DN	Ziconotide
DMSLJP4	MI	DE4LYSA
DMSLJP4	MN	Cytochrome P450 3A4 (CYP3A4)
DMSLJP4	MT	DME
DMSLJP4	MA	Metabolism
DMSLJP4	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMSLJP4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMSLJP4	DI	DMSLJP4
DMSLJP4	DN	Ziconotide
DMSLJP4	MI	TT4FDG6
DMSLJP4	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMSLJP4	MT	DTT
DMSLJP4	MA	Blocker
DMSLJP4	RN	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
DMSLJP4	RU	https://pubmed.ncbi.nlm.nih.gov/19249984

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTI7UX6
DM4KI7O	MN	Breast cancer resistance protein (ABCG2)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEJVYAZ
DM4KI7O	MN	Cytochrome P450 2A6 (CYP2A6)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DES5XRU
DM4KI7O	MN	Cytochrome P450 2C8 (CYP2C8)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DE5IED8
DM4KI7O	MN	Cytochrome P450 2C9 (CYP2C9)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DE4LYSA
DM4KI7O	MN	Cytochrome P450 3A4 (CYP3A4)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8053924

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	TTGJCWZ
DM4KI7O	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM4KI7O	MT	DTT
DM4KI7O	MA	Binder
DM4KI7O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
DM4KI7O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	TT84ETX
DM4KI7O	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4KI7O	MT	DTT
DM4KI7O	MA	Inhibitor
DM4KI7O	RN	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
DM4KI7O	RU	https://pubmed.ncbi.nlm.nih.gov/15125867

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEGTFWK
DM4KI7O	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTCSGPB
DM4KI7O	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4KI7O	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTQ23VB
DM4KI7O	MN	Organic anion transporter 1 (SLC22A6)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DT0OC1Q
DM4KI7O	MN	Organic anion transporter 2 (SLC22A7)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTVP67E
DM4KI7O	MN	Organic anion transporter 3 (SLC22A8)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DT06JWZ
DM4KI7O	MN	Organic anion transporter 4 (SLC22A11)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
DM4KI7O	RU	http://www.ncbi.nlm.nih.gov/pubmed/11861798

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTT79CX
DM4KI7O	MN	Organic cation transporter 1 (SLC22A1)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4KI7O	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DTUGYRD
DM4KI7O	MN	P-glycoprotein 1 (ABCB1)
DM4KI7O	MT	DTP
DM4KI7O	MA	Substrate
DM4KI7O	RN	The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109.
DM4KI7O	RU	https://doi.org/10.1016/j.antiviral.2008.12.013

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEYGVN4
DM4KI7O	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19628728

DM4KI7O	DI	DM4KI7O
DM4KI7O	DN	Zidovudine
DM4KI7O	MI	DEB3CV1
DM4KI7O	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM4KI7O	MT	DME
DM4KI7O	MA	Metabolism
DM4KI7O	RN	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
DM4KI7O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18573701

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	TT2J34L
DMVRIC2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVRIC2	MT	DTT
DMVRIC2	MA	Inhibitor
DMVRIC2	RN	5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
DMVRIC2	RU	https://pubmed.ncbi.nlm.nih.gov/19309543

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DEJGDUW
DMVRIC2	MN	Cytochrome P450 1A2 (CYP1A2)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19754423

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE5IED8
DMVRIC2	MN	Cytochrome P450 2C9 (CYP2C9)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8654206

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE4LYSA
DMVRIC2	MN	Cytochrome P450 3A4 (CYP3A4)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE073H6
DMVRIC2	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMVRIC2	DI	DMVRIC2
DMVRIC2	DN	Zileuton
DMVRIC2	MI	DE85D2P
DMVRIC2	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMVRIC2	MT	DME
DMVRIC2	MA	Metabolism
DMVRIC2	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMVRIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTD3FHQ
DMZ4R3Q	MN	Iron-regulated transporter 1 (SLC40A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta. 2012 Sep;1823(9):1426-33.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/22440327

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT1BO38
DMZ4R3Q	MN	Zinc transporter 1 (SLC30A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporters ZnT1 (Slc30a1), Zip8 (Slc39a8), and Zip10 (Slc39a10) in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency. J Nutr. 2008 Nov;138(11):2076-83.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/18936201

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTYBI73
DMZ4R3Q	MN	Zinc transporter 10 (SLC30A10)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012 Mar 9;90(3):467-77.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/22341971

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTIAF6C
DMZ4R3Q	MN	Zinc transporter 2 (SLC30A2)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Compound heterozygous mutations in SLC30A2/ZnT2 results in low milk zinc concentrations: a novel mechanism for zinc deficiency in a breast-fed infant. PLoS One. 2013 May 31;8(5):e64045.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23741301

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTKMECW
DMZ4R3Q	MN	Zinc transporter 3 (SLC30A3)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Loss of synaptic Zn2+ transporter function increases risk of febrile seizures. Sci Rep. 2015 Dec 9;5:17816.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26647834

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT280XI
DMZ4R3Q	MN	Zinc transporter 4 (SLC30A4)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Mutation analysis of the zinc transporter gene SLC30A4 reveals no association with periodic catatonia on chromosome 15q15. J Neural Transm (Vienna). 2003 Nov;110(11):1329-32.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/14628196

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTVHQT2
DMZ4R3Q	MN	Zinc transporter 5 (SLC30A5)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Altered expression of two zinc transporters, SLC30A5 and SLC30A6, underlies a mammary gland disorder of reduced zinc secretion into milk. Genes Nutr. 2015 Sep;10(5):487.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26319140

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTKPRIL
DMZ4R3Q	MN	Zinc transporter 6 (SLC30A6)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Altered expression of two zinc transporters, SLC30A5 and SLC30A6, underlies a mammary gland disorder of reduced zinc secretion into milk. Genes Nutr. 2015 Sep;10(5):487.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26319140

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTQK38X
DMZ4R3Q	MN	Zinc transporter 7 (SLC30A7)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Znt7 (Slc30a7)-deficient mice display reduced body zinc status and body fat accumulation. J Biol Chem. 2007 Dec 21;282(51):37053-63.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/17954933

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT7NVLY
DMZ4R3Q	MN	Zinc transporter 8 (SLC30A8)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporter 8 (ZnT8) and cell function. Trends Endocrinol Metab. 2014 Aug;25(8):415-24.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24751356

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT2I79L
DMZ4R3Q	MN	Zinc transporter 9 (SLC30A9)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC30A9 mutation affecting intracellular zinc homeostasis causes a novel cerebro-renal syndrome. Brain. 2017 Apr 1;140(4):928-939.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28334855

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTDQSAM
DMZ4R3Q	MN	Zinc transporter SLC39A7 (SLC39A7)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTLWPXS
DMZ4R3Q	MN	Zinc transporter ZIP1 (SLC39A1)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J. 2016 May 1;473(9):1113-24.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/27118869

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTK02RZ
DMZ4R3Q	MN	Zinc transporter ZIP10 (SLC39A10)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporter SLC39A10/ZIP10 facilitates antiapoptotic signaling during early B-cell development. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11780-5.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/25074913

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTEOAND
DMZ4R3Q	MN	Zinc transporter ZIP11 (SLC39A11)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Gastric and colonic zinc transporter ZIP11 (Slc39a11) in mice responds to dietary zinc and exhibits nuclear localization. J Nutr. 2013 Dec;143(12):1882-8.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24089422

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DT1UIT5
DMZ4R3Q	MN	Zinc transporter ZIP12 (SLC39A12)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature. 2015 Aug 20;524(7565):356-60.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26258299

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTOTKBS
DMZ4R3Q	MN	Zinc transporter ZIP13 (SLC39A13)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Promotion of vesicular zinc efflux by ZIP13 and its implications for spondylocheiro dysplastic Ehlers-Danlos syndrome. Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3530-8.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23213233

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTZ6IJW
DMZ4R3Q	MN	Zinc transporter ZIP14 (SLC39A14)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1769-E1778.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/29437953

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTL8VXO
DMZ4R3Q	MN	Zinc transporter ZIP2 (SLC39A2)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Reassessment of the Transport Mechanism of the Human Zinc Transporter SLC39A2. Biochemistry. 2018 Jul 3;57(26):3976-3986.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/29791142

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTH08M7
DMZ4R3Q	MN	Zinc transporter ZIP3 (SLC39A3)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The SLC39 family of zinc transporters. Mol Aspects Med. 2013 Apr-Jun;34(2-3):612-9.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/23506894

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTEZCUM
DMZ4R3Q	MN	Zinc transporter ZIP4 (SLC39A4)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Extreme population differences in the human zinc transporter ZIP4 (SLC39A4) are explained by positive selection in Sub-Saharan Africa. PLoS Genet. 2014 Feb 20;10(2):e1004128.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/24586184

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTN9ACR
DMZ4R3Q	MN	Zinc transporter ZIP5 (SLC39A5)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells. J Biol Chem. 2004 Dec 3;279(49):51433-41.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/15322118

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTT1S93
DMZ4R3Q	MN	Zinc transporter ZIP6 (SLC39A6)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTLPQGT
DMZ4R3Q	MN	Zinc transporter ZIP8 (SLC39A8)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	Zinc transporters ZnT1 (Slc30a1), Zip8 (Slc39a8), and Zip10 (Slc39a10) in mouse red blood cells are differentially regulated during erythroid development and by dietary zinc deficiency. J Nutr. 2008 Nov;138(11):2076-83.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/18936201

DMZ4R3Q	DI	DMZ4R3Q
DMZ4R3Q	DN	Zinc salts
DMZ4R3Q	MI	DTJH79E
DMZ4R3Q	MN	Zinc transporter ZIP9 (SLC39A9)
DMZ4R3Q	MT	DTP
DMZ4R3Q	MA	Substrate
DMZ4R3Q	RN	A ZIP6-ZIP10 heteromer controls NCAM1 phosphorylation and integration into focal adhesion complexes during epithelial-to-mesenchymal transition. Sci Rep. 2017 Jan 18;7:40313.
DMZ4R3Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/28098160

DMK4OL7	DI	DMK4OL7
DMK4OL7	DN	Zinostatin stimalamer
DMK4OL7	MI	TTUTN1I
DMK4OL7	MN	Human Deoxyribonucleic acid (hDNA)
DMK4OL7	MT	DTT
DMK4OL7	MA	Modulator
DMK4OL7	RN	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
DMK4OL7	RU	https://pubmed.ncbi.nlm.nih.gov/17309302

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	DE4LYSA
DMM58JY	MN	Cytochrome P450 3A4 (CYP3A4)
DMM58JY	MT	DME
DMM58JY	MA	Metabolism
DMM58JY	RN	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
DMM58JY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18537577

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	TTEX248
DMM58JY	MN	Dopamine D2 receptor (D2R)
DMM58JY	MT	DTT
DMM58JY	MA	Agonist
DMM58JY	RN	Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17.
DMM58JY	RU	https://pubmed.ncbi.nlm.nih.gov/19011428

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	TTLA931
DMM58JY	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMM58JY	MT	DTT
DMM58JY	MA	Binder
DMM58JY	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMM58JY	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMM58JY	DI	DMM58JY
DMM58JY	DN	Ziprasidone
DMM58JY	MI	DTUGYRD
DMM58JY	MN	P-glycoprotein 1 (ABCB1)
DMM58JY	MT	DTP
DMM58JY	MA	Substrate
DMM58JY	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DMM58JY	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMN4H2O	DI	DMN4H2O
DMN4H2O	DN	Zithromax
DMN4H2O	MI	TTUWYEA
DMN4H2O	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMN4H2O	MT	DTT
DMN4H2O	MA	Modulator
DMN4H2O	RN	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
DMN4H2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/27899562

DMN4H2O	DI	DMN4H2O
DMN4H2O	DN	Zithromax
DMN4H2O	MI	DE4LYSA
DMN4H2O	MN	Cytochrome P450 3A4 (CYP3A4)
DMN4H2O	MT	DME
DMN4H2O	MA	Metabolism
DMN4H2O	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMN4H2O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMIXC7G	DI	DMIXC7G
DMIXC7G	DN	Zoledronate
DMIXC7G	MI	TTIKWV4
DMIXC7G	MN	Geranyltranstransferase (FDPS)
DMIXC7G	MT	DTT
DMIXC7G	MA	Modulator
DMIXC7G	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMIXC7G	RU	https://www.fda.gov/

DMIXC7G	DI	DMIXC7G
DMIXC7G	DN	Zoledronate
DMIXC7G	MI	DTSYQGK
DMIXC7G	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMIXC7G	MT	DTP
DMIXC7G	MA	Substrate
DMIXC7G	RN	Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82.
DMIXC7G	RU	https://doi.org/10.1016/j.cellbi.2005.11.008

DM57O90	DI	DM57O90
DM57O90	DN	Zolgensma
DM57O90	MI	TT8QL6X
DM57O90	MN	Survival motor neuron protein (SMN1)
DM57O90	MT	DTT
DM57O90	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health  Human Services.
DM57O90	RU	https://www.fda.gov/vaccines-blood-biologics/zolgensma

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	TTK8CXU
DM1IB4Q	MN	5-HT 1B receptor (HTR1B)
DM1IB4Q	MT	DTT
DM1IB4Q	MA	Modulator
DM1IB4Q	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1IB4Q	RU	https://www.fda.gov/

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	TT6MSOK
DM1IB4Q	MN	5-HT 1D receptor (HTR1D)
DM1IB4Q	MT	DTT
DM1IB4Q	MA	Modulator
DM1IB4Q	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DM1IB4Q	RU	https://www.fda.gov/

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DEJGDUW
DM1IB4Q	MN	Cytochrome P450 1A2 (CYP1A2)
DM1IB4Q	MT	DME
DM1IB4Q	MA	Metabolism
DM1IB4Q	RN	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
DM1IB4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DERE4TU
DM1IB4Q	MN	Monoamine oxidase type A (MAO-A)
DM1IB4Q	MT	DME
DM1IB4Q	MA	Metabolism
DM1IB4Q	RN	Med-psych drug-drug interactions update. Psychosomatics. 2002 May;43(3):245-7.
DM1IB4Q	RU	https://www.ncbi.nlm.nih.gov/pubmed/12075043

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DTT79CX
DM1IB4Q	MN	Organic cation transporter 1 (SLC22A1)
DM1IB4Q	MT	DTP
DM1IB4Q	MA	Substrate
DM1IB4Q	RN	OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016 Jun;99(6):633-41.
DM1IB4Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/26659468

DM1IB4Q	DI	DM1IB4Q
DM1IB4Q	DN	Zolmitriptan
DM1IB4Q	MI	DTUGYRD
DM1IB4Q	MN	P-glycoprotein 1 (ABCB1)
DM1IB4Q	MT	DTP
DM1IB4Q	MA	Substrate
DM1IB4Q	RN	Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
DM1IB4Q	RU	https://doi.org/10.1016/j.addr.2011.12.008

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEJGDUW
DMWOSKJ	MN	Cytochrome P450 1A2 (CYP1A2)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010;12(6). pii: PCC.09r00849.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21494350

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DE5IED8
DMWOSKJ	MN	Cytochrome P450 2C9 (CYP2C9)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30178440

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DECB0K3
DMWOSKJ	MN	Cytochrome P450 2D6 (CYP2D6)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002 Dec;23(9):361-7.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12469329

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DE4LYSA
DMWOSKJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010 Sep;66(9):955.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20552178

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEIBDNY
DMWOSKJ	MN	Cytochrome P450 3A5 (CYP3A5)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
DMWOSKJ	RU	https://www.pharmgkb.org/vip/PA166170041/relationships

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DERD86B
DMWOSKJ	MN	Cytochrome P450 3A7 (CYP3A7)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Principles of Clinical Pharmacology (Third Edition). 2012, Pages 417-436
DMWOSKJ	RU	https://doi.org/10.1016/B978-0-12-385471-1.00025-8

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	TT1MPAY
DMWOSKJ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMWOSKJ	MT	DTT
DMWOSKJ	MA	Modulator
DMWOSKJ	RN	Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/17113947

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	TTEX6LM
DMWOSKJ	MN	GABA(A) receptor gamma-3 (GABRG3)
DMWOSKJ	MT	DTT
DMWOSKJ	MA	Modulator (allosteric modulator)
DMWOSKJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMWOSKJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DMWOSKJ	DI	DMWOSKJ
DMWOSKJ	DN	Zolpidem
DMWOSKJ	MI	DEGTFWK
DMWOSKJ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWOSKJ	MT	DME
DMWOSKJ	MA	Metabolism
DMWOSKJ	RN	Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
DMWOSKJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17515707

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DE8UGTM
DM0DTF7	MN	Aldehyde oxidase (AOX)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997 Mar;49(3):253-6.
DM0DTF7	RU	https://pubmed.ncbi.nlm.nih.gov/9231340

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DE4LYSA
DM0DTF7	MN	Cytochrome P450 3A4 (CYP3A4)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17319920

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEIBDNY
DM0DTF7	MN	Cytochrome P450 3A5 (CYP3A5)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9626925

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DERD86B
DM0DTF7	MN	Cytochrome P450 3A7 (CYP3A7)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9555064

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEGTFWK
DM0DTF7	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
DM0DTF7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	TTRK8B9
DM0DTF7	MN	Sodium channel unspecific (NaC)
DM0DTF7	MT	DTT
DM0DTF7	MA	Blocker
DM0DTF7	RN	Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
DM0DTF7	RU	https://pubmed.ncbi.nlm.nih.gov/18782687

DM0DTF7	DI	DM0DTF7
DM0DTF7	DN	Zonisamide
DM0DTF7	MI	DEYGVN4
DM0DTF7	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM0DTF7	MT	DME
DM0DTF7	MA	Metabolism
DM0DTF7	RN	Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
DM0DTF7	RU	https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DES5XRU
DMPI6Z0	MN	Cytochrome P450 2C8 (CYP2C8)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE5IED8
DMPI6Z0	MN	Cytochrome P450 2C9 (CYP2C9)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos. 1999 Sep;27(9):1068-73.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10460808

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DEVDYN7
DMPI6Z0	MN	Cytochrome P450 2E1 (CYP2E1)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE4LYSA
DMPI6Z0	MN	Cytochrome P450 3A4 (CYP3A4)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	TTAN6JD
DMPI6Z0	MN	Glutamate receptor AMPA (GRIA)
DMPI6Z0	MT	DTT
DMPI6Z0	MA	Binder
DMPI6Z0	RN	Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
DMPI6Z0	RU	https://pubmed.ncbi.nlm.nih.gov/19300573

DMPI6Z0	DI	DMPI6Z0
DMPI6Z0	DN	Zopiclone
DMPI6Z0	MI	DE073H6
DMPI6Z0	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPI6Z0	MT	DME
DMPI6Z0	MA	Metabolism
DMPI6Z0	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMPI6Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMRMCXW	DI	DMRMCXW
DMRMCXW	DN	Zotarolimus
DMRMCXW	MI	TTCJG29
DMRMCXW	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMRMCXW	MT	DTT
DMRMCXW	MA	Modulator
DMRMCXW	RN	Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
DMRMCXW	RU	https://pubmed.ncbi.nlm.nih.gov/18497896

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	TTJQOD7
DMF3VXA	MN	5-HT 2A receptor (HTR2A)
DMF3VXA	MT	DTT
DMF3VXA	MA	Inhibitor
DMF3VXA	RN	Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
DMF3VXA	RU	https://pubmed.ncbi.nlm.nih.gov/11170639

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DE6OQ3W
DMF3VXA	MN	Cytochrome P450 1A1 (CYP1A1)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEJGDUW
DMF3VXA	MN	Cytochrome P450 1A2 (CYP1A2)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEPKLMQ
DMF3VXA	MN	Cytochrome P450 2B6 (CYP2B6)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DECB0K3
DMF3VXA	MN	Cytochrome P450 2D6 (CYP2D6)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DE4LYSA
DMF3VXA	MN	Cytochrome P450 3A4 (CYP3A4)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	New antipsychotic agents for schizophrenia: pharmacokinetics and metabolism update. Curr Opin Investig Drugs. 2002 Jul;3(7):1073-80.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12186270

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEIBDNY
DMF3VXA	MN	Cytochrome P450 3A5 (CYP3A5)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMF3VXA	DI	DMF3VXA
DMF3VXA	DN	Zotepine
DMF3VXA	MI	DEGTFWK
DMF3VXA	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF3VXA	MT	DME
DMF3VXA	MA	Metabolism
DMF3VXA	RN	Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
DMF3VXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219963

DMKYD5N	DI	DMKYD5N
DMKYD5N	DN	Zuclopenthixol
DMKYD5N	MI	DECB0K3
DMKYD5N	MN	Cytochrome P450 2D6 (CYP2D6)
DMKYD5N	MT	DME
DMKYD5N	MA	Metabolism
DMKYD5N	RN	Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84.
DMKYD5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26514968

DMKYD5N	DI	DMKYD5N
DMKYD5N	DN	Zuclopenthixol
DMKYD5N	MI	TTEX248
DMKYD5N	MN	Dopamine D2 receptor (D2R)
DMKYD5N	MT	DTT
DMKYD5N	MA	Antagonist
DMKYD5N	RN	An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5.
DMKYD5N	RU	https://pubmed.ncbi.nlm.nih.gov/10222441

DMRCOU5	DI	DMRCOU5
DMRCOU5	DN	Dicycloplatin
DMRCOU5	MI	TTUTN1I
DMRCOU5	MN	Human Deoxyribonucleic acid (hDNA)
DMRCOU5	MT	DTT
DMRCOU5	MA	Inhibitor
DMRCOU5	RN	Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63.
DMRCOU5	RU	https://pubmed.ncbi.nlm.nih.gov/24403501

DMBZ27L	DI	DMBZ27L
DMBZ27L	DN	Favipiravir
DMBZ27L	MI	TT79JGK
DMBZ27L	MN	Mycobacterium RNA polymerase (MycB RNAP)
DMBZ27L	MT	DTT
DMBZ27L	MA	Modulator
DMBZ27L	RN	Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
DMBZ27L	RU	https://www.ncbi.nlm.nih.gov/pubmed/24084488

DMDWYUN	DI	DMDWYUN
DMDWYUN	DN	HBI-8000
DMDWYUN	MI	TTBH0VX
DMDWYUN	MN	Histone deacetylase (HDAC)
DMDWYUN	MT	DTT
DMDWYUN	MA	Inhibitor
DMDWYUN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDWYUN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDWYUN	DI	DMDWYUN
DMDWYUN	DN	HBI-8000
DMDWYUN	MI	TT6R7JZ
DMDWYUN	MN	Histone deacetylase 1 (HDAC1)
DMDWYUN	MT	DTT
DMDWYUN	MA	Modulator
DMDWYUN	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDWYUN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DEJGDUW
DM5GFIK	MN	Cytochrome P450 1A2 (CYP1A2)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DE4LYSA
DM5GFIK	MN	Cytochrome P450 3A4 (CYP3A4)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	DEIBDNY
DM5GFIK	MN	Cytochrome P450 3A5 (CYP3A5)
DM5GFIK	MT	DME
DM5GFIK	MA	Metabolism
DM5GFIK	RN	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
DM5GFIK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29247736

DM5GFIK	DI	DM5GFIK
DM5GFIK	DN	Icotinib hydrochloride
DM5GFIK	MI	TTGKNB4
DM5GFIK	MN	Epidermal growth factor receptor (EGFR)
DM5GFIK	MT	DTT
DM5GFIK	MA	Antagonist
DM5GFIK	RN	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
DM5GFIK	RU	https://pubmed.ncbi.nlm.nih.gov/21144613

DM5GIWZ	DI	DM5GIWZ
DM5GIWZ	DN	Mirogabalin
DM5GIWZ	MI	TTFK1JQ
DM5GIWZ	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DM5GIWZ	MT	DTT
DM5GIWZ	MA	Modulator
DM5GIWZ	RN	Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
DM5GIWZ	RU	https://pubmed.ncbi.nlm.nih.gov/25231896

DMY67U8	DI	DMY67U8
DMY67U8	DN	Trapidil
DMY67U8	MI	TTST7KB
DMY67U8	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMY67U8	MT	DTT
DMY67U8	MA	Inhibitor
DMY67U8	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMY67U8	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMY67U8	DI	DMY67U8
DMY67U8	DN	Trapidil
DMY67U8	MI	TTI2WET
DMY67U8	MN	Platelet-derived growth factor receptor (PDGFR)
DMY67U8	MT	DTT
DMY67U8	MA	Inhibitor
DMY67U8	RN	Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46.
DMY67U8	RU	https://pubmed.ncbi.nlm.nih.gov/18635661

DMVZL26	DI	DMVZL26
DMVZL26	DN	3,4-Dihydroxycinnamic Acid
DMVZL26	MI	TT2J34L
DMVZL26	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVZL26	MT	DTT
DMVZL26	MA	Inhibitor
DMVZL26	RN	Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
DMVZL26	RU	https://pubmed.ncbi.nlm.nih.gov/18760329

DMVZL26	DI	DMVZL26
DMVZL26	DN	3,4-Dihydroxycinnamic Acid
DMVZL26	MI	TT2AST1
DMVZL26	MN	Macrophage migration inhibitory factor (MIF)
DMVZL26	MT	DTT
DMVZL26	MA	Inhibitor
DMVZL26	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVZL26	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DML6CN4	DI	DML6CN4
DML6CN4	DN	Acemetacin
DML6CN4	MI	DEB3CV1
DML6CN4	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DML6CN4	MT	DME
DML6CN4	MA	Metabolism
DML6CN4	RN	Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
DML6CN4	RU	https://link.springer.com/content/pdf/bfm%3A978-94-011-3804-8%2F1.pdf

DM4UE3K	DI	DM4UE3K
DM4UE3K	DN	Acetylcarnitine
DM4UE3K	MI	DT3HUVD
DM4UE3K	MN	Organic cation/carnitine transporter 2 (SLC22A5)
DM4UE3K	MT	DTP
DM4UE3K	MA	Substrate
DM4UE3K	RN	Cloning and functional characterization of a novel up-regulator, cartregulin, of carnitine transporter, OCTN2. Arch Biochem Biophys. 2006 Aug 1;452(1):29-37.
DM4UE3K	RU	http://www.ncbi.nlm.nih.gov/pubmed/16839516

DM1237M	DI	DM1237M
DM1237M	DN	Alfacalcidol
DM1237M	MI	DERSX5P
DM1237M	MN	Cytochrome P450 2J2 (CYP2J2)
DM1237M	MT	DME
DM1237M	MA	Metabolism
DM1237M	RN	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
DM1237M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832

DM1237M	DI	DM1237M
DM1237M	DN	Alfacalcidol
DM1237M	MI	DEBS639
DM1237M	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DM1237M	MT	DME
DM1237M	MA	Metabolism
DM1237M	RN	Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development. Biochim Biophys Acta. 2002 Feb 28;1580(2-3):133-44.
DM1237M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11880238

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEJGDUW
DMY2AH1	MN	Cytochrome P450 1A2 (CYP1A2)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEZMWRE
DMY2AH1	MN	Cytochrome P450 2C18 (CYP2C18)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DES5XRU
DMY2AH1	MN	Cytochrome P450 2C8 (CYP2C8)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DE5IED8
DMY2AH1	MN	Cytochrome P450 2C9 (CYP2C9)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DECB0K3
DMY2AH1	MN	Cytochrome P450 2D6 (CYP2D6)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DE4LYSA
DMY2AH1	MN	Cytochrome P450 3A4 (CYP3A4)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DERD86B
DMY2AH1	MN	Cytochrome P450 3A7 (CYP3A7)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEGTFWK
DMY2AH1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11853173

DMY2AH1	DI	DMY2AH1
DMY2AH1	DN	Aminophenazone
DMY2AH1	MI	DEX2KIA
DMY2AH1	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DMY2AH1	MT	DME
DMY2AH1	MA	Metabolism
DMY2AH1	RN	Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica. 1999 Feb;29(2):187-93.
DMY2AH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10199594

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	DE0LW4X
DMWDEN0	MN	Matrix metalloproteinase-2 (MMP-2)
DMWDEN0	MT	DME
DMWDEN0	MA	Metabolism
DMWDEN0	RN	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
DMWDEN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23229548

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	DEA0BDX
DMWDEN0	MN	Matrix metalloproteinase-9 (MMP-9)
DMWDEN0	MT	DME
DMWDEN0	MA	Metabolism
DMWDEN0	RN	Matrix metalloproteinase-9 reduces islet amyloid formation by degrading islet amyloid polypeptide. J Biol Chem. 2013 Feb 1;288(5):3553-9.
DMWDEN0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23229548

DMWDEN0	DI	DMWDEN0
DMWDEN0	DN	Amylin
DMWDEN0	MI	TTD0CIQ
DMWDEN0	MN	Melanocortin receptor 4 (MC4R)
DMWDEN0	MT	DTT
DMWDEN0	MA	Agonist
DMWDEN0	RN	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
DMWDEN0	RU	https://pubmed.ncbi.nlm.nih.gov/11060745

DM8EKSV	DI	DM8EKSV
DM8EKSV	DN	Anti-MIF antibodies
DM8EKSV	MI	TT2AST1
DM8EKSV	MN	Macrophage migration inhibitory factor (MIF)
DM8EKSV	MT	DTT
DM8EKSV	MA	Inhibitor
DM8EKSV	RN	Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455.
DM8EKSV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293543/

DML1VXW	DI	DML1VXW
DML1VXW	DN	Arotinolol
DML1VXW	MI	DECB0K3
DML1VXW	MN	Cytochrome P450 2D6 (CYP2D6)
DML1VXW	MT	DME
DML1VXW	MA	Metabolism
DML1VXW	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DML1VXW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTSCIUP
DMB7WYM	MN	Oxytocin receptor (OTR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/16297621

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TT4TFGN
DMB7WYM	MN	Vasopressin V1a receptor (V1AR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTL9MHW
DMB7WYM	MN	Vasopressin V1b receptor (V1BR)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMB7WYM	DI	DMB7WYM
DMB7WYM	DN	ATOSIBAN
DMB7WYM	MI	TTK8R02
DMB7WYM	MN	Vasopressin V2 receptor (V2R)
DMB7WYM	MT	DTT
DMB7WYM	MA	Inhibitor
DMB7WYM	RN	The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
DMB7WYM	RU	https://pubmed.ncbi.nlm.nih.gov/18032036

DMA12HL	DI	DMA12HL
DMA12HL	DN	Azelnidipine
DMA12HL	MI	DE4LYSA
DMA12HL	MN	Cytochrome P450 3A4 (CYP3A4)
DMA12HL	MT	DME
DMA12HL	MA	Metabolism
DMA12HL	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
DMA12HL	RU	http://www.genome.jp/dbget-bin/www_bget?D01145

DMJSDBE	DI	DMJSDBE
DMJSDBE	DN	Barnidipine
DMJSDBE	MI	DE4LYSA
DMJSDBE	MN	Cytochrome P450 3A4 (CYP3A4)
DMJSDBE	MT	DME
DMJSDBE	MA	Metabolism
DMJSDBE	RN	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica. 1997 Sep;27(9):885-900.
DMJSDBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9381730

DMLKUG7	DI	DMLKUG7
DMLKUG7	DN	Beclabuvir
DMLKUG7	MI	DE4LYSA
DMLKUG7	MN	Cytochrome P450 3A4 (CYP3A4)
DMLKUG7	MT	DME
DMLKUG7	MA	Metabolism
DMLKUG7	RN	Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos. 2016 Aug;44(8):1372-80.
DMLKUG7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27226352

DM5NW1E	DI	DM5NW1E
DM5NW1E	DN	Beclomethasone dipropionate
DM5NW1E	MI	DTUGYRD
DM5NW1E	MN	P-glycoprotein 1 (ABCB1)
DM5NW1E	MT	DTP
DM5NW1E	MA	Substrate
DM5NW1E	RN	Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
DM5NW1E	RU	https://doi.org/10.1016/j.taap.2012.03.008

DMWNP6B	DI	DMWNP6B
DMWNP6B	DN	Benidipine
DMWNP6B	MI	DE4LYSA
DMWNP6B	MN	Cytochrome P450 3A4 (CYP3A4)
DMWNP6B	MT	DME
DMWNP6B	MA	Metabolism
DMWNP6B	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DMWNP6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DMWNP6B	DI	DMWNP6B
DMWNP6B	DN	Benidipine
DMWNP6B	MI	DEIBDNY
DMWNP6B	MN	Cytochrome P450 3A5 (CYP3A5)
DMWNP6B	MT	DME
DMWNP6B	MA	Metabolism
DMWNP6B	RN	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
DMWNP6B	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17537876

DMHKZX1	DI	DMHKZX1
DMHKZX1	DN	Benzethonium
DMHKZX1	MI	DECB0K3
DMHKZX1	MN	Cytochrome P450 2D6 (CYP2D6)
DMHKZX1	MT	DME
DMHKZX1	MA	Metabolism
DMHKZX1	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMHKZX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DMHKZX1	DI	DMHKZX1
DMHKZX1	DN	Benzethonium
DMHKZX1	MI	DEGTFWK
DMHKZX1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHKZX1	MT	DME
DMHKZX1	MA	Metabolism
DMHKZX1	RN	Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
DMHKZX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230

DML634R	DI	DML634R
DML634R	DN	Beraprost
DML634R	MI	DES5XRU
DML634R	MN	Cytochrome P450 2C8 (CYP2C8)
DML634R	MT	DME
DML634R	MA	Metabolism
DML634R	RN	Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65.
DML634R	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18827466

DMWL182	DI	DMWL182
DMWL182	DN	Beraprost
DMWL182	MI	TTOFYT1
DMWL182	MN	Prostacyclin receptor (PTGIR)
DMWL182	MT	DTT
DMWL182	MA	Agonist
DMWL182	RN	Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
DMWL182	RU	https://pubmed.ncbi.nlm.nih.gov/25584359

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	DTT79CX
DMC5Q8X	MN	Organic cation transporter 1 (SLC22A1)
DMC5Q8X	MT	DTP
DMC5Q8X	MA	Substrate
DMC5Q8X	RN	Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61.
DMC5Q8X	RU	https://doi.org/10.1007/s00210-007-0219-x

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	DTUGYRD
DMC5Q8X	MN	P-glycoprotein 1 (ABCB1)
DMC5Q8X	MT	DTP
DMC5Q8X	MA	Substrate
DMC5Q8X	RN	P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002 Dec;91(12):2614-21.
DMC5Q8X	RU	http://www.ncbi.nlm.nih.gov/pubmed/12434406

DMC5Q8X	DI	DMC5Q8X
DMC5Q8X	DN	Berberine
DMC5Q8X	MI	TTUJFD0
DMC5Q8X	MN	Telomerase reverse transcriptase (TERT)
DMC5Q8X	MT	DTT
DMC5Q8X	MA	Inhibitor
DMC5Q8X	RN	Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
DMC5Q8X	RU	https://pubmed.ncbi.nlm.nih.gov/11880232

DMGXD5T	DI	DMGXD5T
DMGXD5T	DN	Brotizolam
DMGXD5T	MI	DE4LYSA
DMGXD5T	MN	Cytochrome P450 3A4 (CYP3A4)
DMGXD5T	MT	DME
DMGXD5T	MA	Metabolism
DMGXD5T	RN	Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005 Aug;60(2):172-5.
DMGXD5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16042670

DMXZU73	DI	DMXZU73
DMXZU73	DN	Carbapenem
DMXZU73	MI	DESIWFO
DMXZU73	MN	Beta-lactamase (blaB)
DMXZU73	MT	DME
DMXZU73	MA	Metabolism
DMXZU73	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DMXZU73	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DMXZU73	DI	DMXZU73
DMXZU73	DN	Carbapenem
DMXZU73	MI	DEBKS91
DMXZU73	MN	Beta-lactamase (blaB)
DMXZU73	MT	DME
DMXZU73	MA	Metabolism
DMXZU73	RN	Investigation of carbapenemases and aminoglycoside modifying enzymes of Acinetobacter baumannii isolates recovered from patients admitted to intensive care units in a tertiary-care hospital in Brazil. Rev Soc Bras Med Trop. 2019 Dec 20;53:e20190044.
DMXZU73	RU	https://pubmed.ncbi.nlm.nih.gov/31859941

DMJKWPZ	DI	DMJKWPZ
DMJKWPZ	DN	Cefpirome
DMJKWPZ	MI	DEEAL81
DMJKWPZ	MN	Beta-lactamase (blaB)
DMJKWPZ	MT	DME
DMJKWPZ	MA	Metabolism
DMJKWPZ	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMJKWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMJKWPZ	DI	DMJKWPZ
DMJKWPZ	DN	Cefpirome
DMJKWPZ	MI	DEMIUB2
DMJKWPZ	MN	Beta-lactamase (blaB)
DMJKWPZ	MT	DME
DMJKWPZ	MA	Metabolism
DMJKWPZ	RN	Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5.
DMJKWPZ	RU	https://pubmed.ncbi.nlm.nih.gov/17438917

DMPZTRC	DI	DMPZTRC
DMPZTRC	DN	Ceftazidine
DMPZTRC	MI	DEBKS91
DMPZTRC	MN	Beta-lactamase (blaB)
DMPZTRC	MT	DME
DMPZTRC	MA	Metabolism
DMPZTRC	RN	Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5.
DMPZTRC	RU	https://pubmed.ncbi.nlm.nih.gov/21034630

DMYGEH7	DI	DMYGEH7
DMYGEH7	DN	Ceftolozane sulfate
DMYGEH7	MI	TTJP4SM
DMYGEH7	MN	Bacterial Penicillin binding protein (Bact PBP)
DMYGEH7	MT	DTT
DMYGEH7	MA	Modulator
DMYGEH7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYGEH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYTGW0	DI	DMYTGW0
DMYTGW0	DN	Celiprolol
DMYTGW0	MI	DECB0K3
DMYTGW0	MN	Cytochrome P450 2D6 (CYP2D6)
DMYTGW0	MT	DME
DMYTGW0	MA	Metabolism
DMYTGW0	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMYTGW0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DECB0K3
DM6C4YJ	MN	Cytochrome P450 2D6 (CYP2D6)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25.
DM6C4YJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DE4LYSA
DM6C4YJ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DEIBDNY
DM6C4YJ	MN	Cytochrome P450 3A5 (CYP3A5)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM6C4YJ	DI	DM6C4YJ
DM6C4YJ	DN	Chlorphenamine
DM6C4YJ	MI	DERD86B
DM6C4YJ	MN	Cytochrome P450 3A7 (CYP3A7)
DM6C4YJ	MT	DME
DM6C4YJ	MA	Metabolism
DM6C4YJ	RN	Drug Interactions Flockhart Table
DM6C4YJ	RU	https://drug-interactions.medicine.iu.edu/Main-Table.aspx

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DELTYX6
DM0N19Y	MN	Alpha-L-iduronidase (IDUA)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEHKRDS
DM0N19Y	MN	Arylsulfatase B (ARSB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEP54UE
DM0N19Y	MN	Beta-glucuronidase (GUSB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEQIZP2
DM0N19Y	MN	Chondroitin 6-sulfotransferase (CHST3)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thromb Res. 2018 Jan;161:43-51.
DM0N19Y	RU	https://pubmed.ncbi.nlm.nih.gov/29178990

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEH31BC
DM0N19Y	MN	Hyaluronate lyase (hyaL)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	nan
DM0N19Y	RU	nan

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEV7UZD
DM0N19Y	MN	Hyaluronoglucosaminidase (nagH)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	nan
DM0N19Y	RU	nan

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DEL45C2
DM0N19Y	MN	Iduronate 2-sulfatase (IDS)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DM0N19Y	DI	DM0N19Y
DM0N19Y	DN	Chondroitin sulfate
DM0N19Y	MI	DE6AY40
DM0N19Y	MN	N-acetyl-beta-glucosaminidase beta (HEXB)
DM0N19Y	MT	DME
DM0N19Y	MA	Metabolism
DM0N19Y	RN	MFN human ref: Chondroitin sulfate degradation.
DM0N19Y	RU	http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png

DMBG0N4	DI	DMBG0N4
DMBG0N4	DN	Cibenzoline
DMBG0N4	MI	DECB0K3
DMBG0N4	MN	Cytochrome P450 2D6 (CYP2D6)
DMBG0N4	MT	DME
DMBG0N4	MA	Metabolism
DMBG0N4	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DMBG0N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DMBG0N4	DI	DMBG0N4
DMBG0N4	DN	Cibenzoline
DMBG0N4	MI	DE4LYSA
DMBG0N4	MN	Cytochrome P450 3A4 (CYP3A4)
DMBG0N4	MT	DME
DMBG0N4	MA	Metabolism
DMBG0N4	RN	Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A. Drug Metab Dispos. 2000 Sep;28(9):1128-34.
DMBG0N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10950860

DMSW5QP	DI	DMSW5QP
DMSW5QP	DN	Cotrimoxazole
DMSW5QP	MI	DEP0IWS
DMSW5QP	MN	Beta-lactamase (blaB)
DMSW5QP	MT	DME
DMSW5QP	MA	Metabolism
DMSW5QP	RN	Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8.
DMSW5QP	RU	https://pubmed.ncbi.nlm.nih.gov/26505351

DMLMOIJ	DI	DMLMOIJ
DMLMOIJ	DN	Cyproterone acetate
DMLMOIJ	MI	DE4LYSA
DMLMOIJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMLMOIJ	MT	DME
DMLMOIJ	MA	Metabolism
DMLMOIJ	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMLMOIJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DECB0K3
DMV6KFY	MN	Cytochrome P450 2D6 (CYP2D6)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.
DMV6KFY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23024705

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DE4LYSA
DMV6KFY	MN	Cytochrome P450 3A4 (CYP3A4)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
DMV6KFY	RU	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2003.11.123

DMV6KFY	DI	DMV6KFY
DMV6KFY	DN	Dapoxetine
DMV6KFY	MI	DEJ73Q9
DMV6KFY	MN	Dimethylaniline oxidase 1 (FMO1)
DMV6KFY	MT	DME
DMV6KFY	MA	Metabolism
DMV6KFY	RN	Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
DMV6KFY	RU	https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/j.clpt.2003.11.123

DMV5KTJ	DI	DMV5KTJ
DMV5KTJ	DN	Demegestone
DMV5KTJ	MI	DE4LYSA
DMV5KTJ	MN	Cytochrome P450 3A4 (CYP3A4)
DMV5KTJ	MT	DME
DMV5KTJ	MA	Metabolism
DMV5KTJ	RN	Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811.
DMV5KTJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29130574

DMN2Q5I	DI	DMN2Q5I
DMN2Q5I	DN	Diacerein
DMN2Q5I	MI	TTRYK0X
DMN2Q5I	MN	Interleukin-1 beta (IL1B)
DMN2Q5I	MT	DTT
DMN2Q5I	MA	Inhibitor
DMN2Q5I	RN	Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86.
DMN2Q5I	RU	https://pubmed.ncbi.nlm.nih.gov/19247594

DMTX0PZ	DI	DMTX0PZ
DMTX0PZ	DN	Dibekacin
DMTX0PZ	MI	DE5WGIM
DMTX0PZ	MN	Aminoglycoside phosphotransferase (aph-Ib)
DMTX0PZ	MT	DME
DMTX0PZ	MA	Metabolism
DMTX0PZ	RN	Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Antimicrob Agents Chemother. 2013 Jan;57(1):452-7.
DMTX0PZ	RU	https://pubmed.ncbi.nlm.nih.gov/23129050

DMZ5Y1P	DI	DMZ5Y1P
DMZ5Y1P	DN	Dichloroacetate
DMZ5Y1P	MI	TTCZOF2
DMZ5Y1P	MN	Pyruvate dehydrogenase kinase 1 (PDHK1)
DMZ5Y1P	MT	DTT
DMZ5Y1P	MA	Inhibitor
DMZ5Y1P	RN	Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.
DMZ5Y1P	RU	https://pubmed.ncbi.nlm.nih.gov/31768777

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DECB0K3
DMB0FWL	MN	Cytochrome P450 2D6 (CYP2D6)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther. 2003 Mar;41(3):95-106.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12665158

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DE4LYSA
DMB0FWL	MN	Cytochrome P450 3A4 (CYP3A4)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol. 1999 Sep;48(3):317-22.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10510141

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	TTN4QDT
DMB0FWL	MN	Opioid receptor (OPR)
DMB0FWL	MT	DTT
DMB0FWL	MA	Modulator
DMB0FWL	RN	Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
DMB0FWL	RU	https://pubmed.ncbi.nlm.nih.gov/12420793

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DENUPDX
DMB0FWL	MN	UDP-glucuronosyltransferase 2B4 (UGT2B4)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DMB0FWL	DI	DMB0FWL
DMB0FWL	DN	Dihydrocodeine
DMB0FWL	MI	DEB3CV1
DMB0FWL	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMB0FWL	MT	DME
DMB0FWL	MA	Metabolism
DMB0FWL	RN	Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
DMB0FWL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31691978

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DE7P2FB
DM3S8XC	MN	Aldo-keto reductase 1C1 (AKR1C1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24434280

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	TTS64P2
DM3S8XC	MN	Androgen receptor (AR)
DM3S8XC	MT	DTT
DM3S8XC	MA	Modulator
DM3S8XC	RN	Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/12089345

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	TTKPW01
DM3S8XC	MN	Androgen receptor messenger RNA (AR mRNA)
DM3S8XC	MT	DTT
DM3S8XC	MA	Agonist
DM3S8XC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628).
DM3S8XC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEQX145
DM3S8XC	MN	Aromatase (CYP19A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DTUGYRD
DM3S8XC	MN	P-glycoprotein 1 (ABCB1)
DM3S8XC	MT	DTP
DM3S8XC	MA	Substrate
DM3S8XC	RN	P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.
DM3S8XC	RU	https://doi.org/10.1002/pros.10354

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEX2KIA
DM3S8XC	MN	Steroid 17-alpha-monooxygenase (CYP17A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16103457

DM3S8XC	DI	DM3S8XC
DM3S8XC	DN	Dihydrotestosterone
DM3S8XC	MI	DEYGVN4
DM3S8XC	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM3S8XC	MT	DME
DM3S8XC	MA	Metabolism
DM3S8XC	RN	UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem. 2007 Nov 16;282(46):33466-74.
DM3S8XC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17848572

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DTC54PX
DM3YH4I	MN	Alanine/serine/cysteine/threonine transporter 1 (SLC1A4)
DM3YH4I	MT	DTP
DM3YH4I	MA	Substrate
DM3YH4I	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DM3YH4I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DTW7AE3
DM3YH4I	MN	Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
DM3YH4I	MT	DTP
DM3YH4I	MA	Substrate
DM3YH4I	RN	D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
DM3YH4I	RU	http://www.ncbi.nlm.nih.gov/pubmed/27272177

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DERZQ2Y
DM3YH4I	MN	D-amino-acid oxidase (DAO)
DM3YH4I	MT	DME
DM3YH4I	MA	Metabolism
DM3YH4I	RN	Focus on the role of D-serine and D-amino acid oxidase in amyotrophic lateral sclerosis/motor neuron disease (ALS). Front Mol Biosci. 2018 Feb 13;5:8.
DM3YH4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29487852

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	TTLD29N
DM3YH4I	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DM3YH4I	MT	DTT
DM3YH4I	MA	Inhibitor
DM3YH4I	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DM3YH4I	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	DEKOQX7
DM3YH4I	MN	Serine racemase (SRR)
DM3YH4I	MT	DME
DM3YH4I	MA	Metabolism
DM3YH4I	RN	D-Serine made by serine racemase in Drosophila intestine plays a physiological role in sleep. Nat Commun. 2019 May 7;10(1):1986.
DM3YH4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31064979

DM3YH4I	DI	DM3YH4I
DM3YH4I	DN	D-Serine
DM3YH4I	MI	TTF45NW
DM3YH4I	MN	Strychnine-binding glycine receptor (GLRA1)
DM3YH4I	MT	DTT
DM3YH4I	MA	Inhibitor
DM3YH4I	RN	Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
DM3YH4I	RU	https://pubmed.ncbi.nlm.nih.gov/11752352

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DERSX5P
DMQRX24	MN	Cytochrome P450 2J2 (CYP2J2)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22328583

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DE4LYSA
DMQRX24	MN	Cytochrome P450 3A4 (CYP3A4)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMQRX24	DI	DMQRX24
DMQRX24	DN	Ebastine
DMQRX24	MI	DE3GT9C
DMQRX24	MN	Cytochrome P450 4F2 (CYP4F2)
DMQRX24	MT	DME
DMQRX24	MA	Metabolism
DMQRX24	RN	cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1135-41.
DMQRX24	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11162645

DMH21D9	DI	DMH21D9
DMH21D9	DN	Ebastine
DMH21D9	MI	DTUGYRD
DMH21D9	MN	P-glycoprotein 1 (ABCB1)
DMH21D9	MT	DTP
DMH21D9	MA	Substrate
DMH21D9	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMH21D9	RU	https://doi.org/10.1007/s11095-012-0935-x

DM9WPIH	DI	DM9WPIH
DM9WPIH	DN	Ergonovine maleate
DM9WPIH	MI	DE4LYSA
DM9WPIH	MN	Cytochrome P450 3A4 (CYP3A4)
DM9WPIH	MT	DME
DM9WPIH	MA	Metabolism
DM9WPIH	RN	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28.
DM9WPIH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937

DMKEGI3	DI	DMKEGI3
DMKEGI3	DN	Esmirtazapine
DMKEGI3	MI	DECB0K3
DMKEGI3	MN	Cytochrome P450 2D6 (CYP2D6)
DMKEGI3	MT	DME
DMKEGI3	MA	Metabolism
DMKEGI3	RN	Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. Psychopharmacology (Berl). 2011 May;215(2):321-32.
DMKEGI3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21246188

DM7ITZK	DI	DM7ITZK
DM7ITZK	DN	Ethinylestradiol propanesulfonate
DM7ITZK	MI	DE4LYSA
DM7ITZK	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ITZK	MT	DME
DM7ITZK	MA	Metabolism
DM7ITZK	RN	The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12.
DM7ITZK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DEZMWRE
DM8TNX3	MN	Cytochrome P450 2C18 (CYP2C18)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Etizolam (INN) Pre-Review Report.
DM8TNX3	RU	https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DE4LYSA
DM8TNX3	MN	Cytochrome P450 3A4 (CYP3A4)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol. 2004 Aug;60(6):427-30.
DM8TNX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15232663

DM8TNX3	DI	DM8TNX3
DM8TNX3	DN	Etizolam
DM8TNX3	MI	DEGTFWK
DM8TNX3	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM8TNX3	MT	DME
DM8TNX3	MA	Metabolism
DM8TNX3	RN	Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
DM8TNX3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17635335

DMR7U8F	DI	DMR7U8F
DMR7U8F	DN	Etoperidone
DMR7U8F	MI	DE4LYSA
DMR7U8F	MN	Cytochrome P450 3A4 (CYP3A4)
DMR7U8F	MT	DME
DMR7U8F	MA	Metabolism
DMR7U8F	RN	In vitro identification of metabolic pathways and cytochrome P450 enzymes involved in the metabolism of etoperidone. Xenobiotica. 2002 Nov;32(11):949-62.
DMR7U8F	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487725

DM9R1YU	DI	DM9R1YU
DM9R1YU	DN	Gestodene
DM9R1YU	MI	DE4LYSA
DM9R1YU	MN	Cytochrome P450 3A4 (CYP3A4)
DM9R1YU	MT	DME
DM9R1YU	MA	Metabolism
DM9R1YU	RN	Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation. Br J Clin Pharmacol. 2000 Oct;50(4):333-7.
DM9R1YU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11012556

DMDN4A1	DI	DMDN4A1
DMDN4A1	DN	Glitazone
DMDN4A1	MI	TTZMAO3
DMDN4A1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMDN4A1	MT	DTT
DMDN4A1	MA	Agonist
DMDN4A1	RN	Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
DMDN4A1	RU	https://pubmed.ncbi.nlm.nih.gov/10828060

DMF72W3	DI	DMF72W3
DMF72W3	DN	Glyceryl trinitrate
DMF72W3	MI	DEAPJSO
DMF72W3	MN	Microsomal glutathione S-transferase 1 (MGST1)
DMF72W3	MT	DME
DMF72W3	MA	Metabolism
DMF72W3	RN	Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev. 2011 May;43(2):300-6.
DMF72W3	RU	https://pubmed.ncbi.nlm.nih.gov/21495795

DM0OX31	DI	DM0OX31
DM0OX31	DN	Glypromate
DM0OX31	MI	DEIZ2D9
DM0OX31	MN	Tripeptidase (pepT)
DM0OX31	MT	DME
DM0OX31	MA	Metabolism
DM0OX31	RN	Tripeptidase gene (pepT) of Lactococcus lactis: molecular cloning and nucleotide sequencing of pepT and construction of a chromosomal deletion mutant. J Bacteriol. 1994 May;176(10):2854-61.
DM0OX31	RU	https://pubmed.ncbi.nlm.nih.gov/8188586

DM9BPLW	DI	DM9BPLW
DM9BPLW	DN	Grazoprevir
DM9BPLW	MI	DE4LYSA
DM9BPLW	MN	Cytochrome P450 3A4 (CYP3A4)
DM9BPLW	MT	DME
DM9BPLW	MA	Metabolism
DM9BPLW	RN	FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.
DM9BPLW	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf

DMPN5IH	DI	DMPN5IH
DMPN5IH	DN	Guanfacine
DMPN5IH	MI	DTUGYRD
DMPN5IH	MN	P-glycoprotein 1 (ABCB1)
DMPN5IH	MT	DTP
DMPN5IH	MA	Substrate
DMPN5IH	RN	An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat. 2011;7:501-5.
DMPN5IH	RU	https://doi.org/10.2147/NDT.S24153

DMLYXBF	DI	DMLYXBF
DMLYXBF	DN	Guanoxan
DMLYXBF	MI	DECB0K3
DMLYXBF	MN	Cytochrome P450 2D6 (CYP2D6)
DMLYXBF	MT	DME
DMLYXBF	MA	Metabolism
DMLYXBF	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMLYXBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM4OQRD	DI	DM4OQRD
DM4OQRD	DN	HIF-1alpha
DM4OQRD	MI	TT0LF7H
DM4OQRD	MN	Fibroblast growth factor receptor (FGFR)
DM4OQRD	MT	DTT
DM4OQRD	MA	Antagonist
DM4OQRD	RN	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
DM4OQRD	RU	https://pubmed.ncbi.nlm.nih.gov/11576867

DM4OQRD	DI	DM4OQRD
DM4OQRD	DN	HIF-1alpha
DM4OQRD	MI	TTQHWNA
DM4OQRD	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM4OQRD	MT	DTT
DM4OQRD	MA	Inhibitor
DM4OQRD	RN	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608.
DM4OQRD	RU	https://pubmed.ncbi.nlm.nih.gov/18974394

DMYOC29	DI	DMYOC29
DMYOC29	DN	Hirudin
DMYOC29	MI	TT6L509
DMYOC29	MN	Coagulation factor IIa (F2)
DMYOC29	MT	DTT
DMYOC29	MA	Inhibitor
DMYOC29	RN	Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69.
DMYOC29	RU	https://pubmed.ncbi.nlm.nih.gov/12427016

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DE7PT32
DM0WD1V	MN	Alanyl aminopeptidase (ANPEP)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DELOWRJ
DM0WD1V	MN	Alpha-N-acetylglucosaminidase (NAG)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DM0WD1V	DI	DM0WD1V
DM0WD1V	DN	Human calcitonin
DM0WD1V	MI	DEA3VM1
DM0WD1V	MN	Phosphoglucomutase 1 (PGM1)
DM0WD1V	MT	DME
DM0WD1V	MA	Metabolism
DM0WD1V	RN	Renal metabolism of calcitonin. Am J Physiol. 1988 Apr;254(4 Pt 2):F593-600.
DM0WD1V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2833122

DMABXOZ	DI	DMABXOZ
DMABXOZ	DN	Hyaluronic acid
DMABXOZ	MI	DEV7UZD
DMABXOZ	MN	Hyaluronoglucosaminidase (nagH)
DMABXOZ	MT	DME
DMABXOZ	MA	Metabolism
DMABXOZ	RN	An extracellular enzyme with hyaluronidase and chondroitinase activities from some oral anaerobic spirochaetes. Microbiology. 1996 Sep;142 ( Pt 9):2567-76.
DMABXOZ	RU	https://pubmed.ncbi.nlm.nih.gov/8828225

DM8NWFD	DI	DM8NWFD
DM8NWFD	DN	Hypericum
DM8NWFD	MI	TTAWNKZ
DM8NWFD	MN	Norepinephrine transporter (NET)
DM8NWFD	MT	DTT
DM8NWFD	MA	Inhibitor
DM8NWFD	RN	The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
DM8NWFD	RU	https://pubmed.ncbi.nlm.nih.gov/10483049

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	DE5IED8
DMVXLOD	MN	Cytochrome P450 2C9 (CYP2C9)
DMVXLOD	MT	DME
DMVXLOD	MA	Metabolism
DMVXLOD	RN	Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019 Oct 31;9(1):15774.
DMVXLOD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31673051

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	TT8NGED
DMVXLOD	MN	Prostaglandin G/H synthase 1 (COX-1)
DMVXLOD	MT	DTT
DMVXLOD	MA	Inhibitor
DMVXLOD	RN	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
DMVXLOD	RU	https://pubmed.ncbi.nlm.nih.gov/19286379

DMVXLOD	DI	DMVXLOD
DMVXLOD	DN	Imrecoxib
DMVXLOD	MI	TTVKILB
DMVXLOD	MN	Prostaglandin G/H synthase 2 (COX-2)
DMVXLOD	MT	DTT
DMVXLOD	MA	Inhibitor
DMVXLOD	RN	Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2.
DMVXLOD	RU	https://pubmed.ncbi.nlm.nih.gov/19286379

DM2R496	DI	DM2R496
DM2R496	DN	Indenolol
DM2R496	MI	DECB0K3
DM2R496	MN	Cytochrome P450 2D6 (CYP2D6)
DM2R496	MT	DME
DM2R496	MA	Metabolism
DM2R496	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DM2R496	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DMVPLNC	DI	DMVPLNC
DMVPLNC	DN	Ingrezza
DMVPLNC	MI	TTNZRI3
DMVPLNC	MN	Synaptic vesicle amine transporter (SLC18A2)
DMVPLNC	MT	DTT
DMVPLNC	MA	Antagonist
DMVPLNC	RN	VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
DMVPLNC	RU	https://pubmed.ncbi.nlm.nih.gov/29680151

DM7U58J	DI	DM7U58J
DM7U58J	DN	Isoflavone
DM7U58J	MI	DEUX61H
DM7U58J	MN	Biphenyl dioxygenase (bphC)
DM7U58J	MT	DME
DM7U58J	MA	Metabolism
DM7U58J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DM7U58J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DM7U58J	DI	DM7U58J
DM7U58J	DN	Isoflavone
DM7U58J	MI	DEE76YZ
DM7U58J	MN	Naphthalene dioxygenase (doxB)
DM7U58J	MT	DME
DM7U58J	MA	Metabolism
DM7U58J	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DM7U58J	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DM170OH	DI	DM170OH
DM170OH	DN	Ketazolam
DM170OH	MI	DE4LYSA
DM170OH	MN	Cytochrome P450 3A4 (CYP3A4)
DM170OH	MT	DME
DM170OH	MA	Metabolism
DM170OH	RN	Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects. Drug Metab Rev. 2017 Nov;49(4):451-463.
DM170OH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28903606

DMQP5I3	DI	DMQP5I3
DMQP5I3	DN	Lacidipine
DMQP5I3	MI	DE4LYSA
DMQP5I3	MN	Cytochrome P450 3A4 (CYP3A4)
DMQP5I3	MT	DME
DMQP5I3	MA	Metabolism
DMQP5I3	RN	The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol. 2001 Feb;51(2):147-52.
DMQP5I3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11259986

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTPADOQ
DM5FABJ	MN	HMG-CoA reductase (HMGCR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTOFYT1
DM5FABJ	MN	Prostacyclin receptor (PTGIR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTNVEIR
DM5FABJ	MN	Prostaglandin D2 receptor (PTGDR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTQDMX5
DM5FABJ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TT1ZAVI
DM5FABJ	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TTT2ZAR
DM5FABJ	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM5FABJ	DI	DM5FABJ
DM5FABJ	DN	LAROPIPRANT
DM5FABJ	MI	TT2O84V
DM5FABJ	MN	Thromboxane A2 receptor (TBXA2R)
DM5FABJ	MT	DTT
DM5FABJ	MA	Inhibitor
DM5FABJ	RN	Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
DM5FABJ	RU	https://pubmed.ncbi.nlm.nih.gov/17300164

DM92S6N	DI	DM92S6N
DM92S6N	DN	Levamlodipine
DM92S6N	MI	DE4LYSA
DM92S6N	MN	Cytochrome P450 3A4 (CYP3A4)
DM92S6N	MT	DME
DM92S6N	MA	Metabolism
DM92S6N	RN	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
DM92S6N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608

DM92S6N	DI	DM92S6N
DM92S6N	DN	Levamlodipine
DM92S6N	MI	TTXHYV6
DM92S6N	MN	Voltage-gated L-type calcium channel (L-CaC)
DM92S6N	MT	DTT
DM92S6N	MA	Modulator
DM92S6N	RN	Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
DM92S6N	RU	https://pubmed.ncbi.nlm.nih.gov/18604992

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DE5IED8
DM82JP0	MN	Cytochrome P450 2C9 (CYP2C9)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DE4LYSA
DM82JP0	MN	Cytochrome P450 3A4 (CYP3A4)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM82JP0	DI	DM82JP0
DM82JP0	DN	Lynestrenol
DM82JP0	MI	DEGTFWK
DM82JP0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM82JP0	MT	DME
DM82JP0	MA	Metabolism
DM82JP0	RN	Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
DM82JP0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18356043

DM0UGYX	DI	DM0UGYX
DM0UGYX	DN	Medifoxamine
DM0UGYX	MI	DEJVYAZ
DM0UGYX	MN	Cytochrome P450 2A6 (CYP2A6)
DM0UGYX	MT	DME
DM0UGYX	MA	Metabolism
DM0UGYX	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM0UGYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM0UGYX	DI	DM0UGYX
DM0UGYX	DN	Medifoxamine
DM0UGYX	MI	DE4LYSA
DM0UGYX	MN	Cytochrome P450 3A4 (CYP3A4)
DM0UGYX	MT	DME
DM0UGYX	MA	Metabolism
DM0UGYX	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM0UGYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DME1X96	DI	DME1X96
DME1X96	DN	Mexazolam
DME1X96	MI	DE4LYSA
DME1X96	MN	Cytochrome P450 3A4 (CYP3A4)
DME1X96	MT	DME
DME1X96	MA	Metabolism
DME1X96	RN	A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8.
DME1X96	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11181496

DM2VOQ3	DI	DM2VOQ3
DM2VOQ3	DN	Mosapride
DM2VOQ3	MI	TT07C3Y
DM2VOQ3	MN	5-HT 4 receptor (HTR4)
DM2VOQ3	MT	DTT
DM2VOQ3	MA	Agonist
DM2VOQ3	RN	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
DM2VOQ3	RU	https://pubmed.ncbi.nlm.nih.gov/18415081

DM2VOQ3	DI	DM2VOQ3
DM2VOQ3	DN	Mosapride
DM2VOQ3	MI	DE4LYSA
DM2VOQ3	MN	Cytochrome P450 3A4 (CYP3A4)
DM2VOQ3	MT	DME
DM2VOQ3	MA	Metabolism
DM2VOQ3	RN	The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos. 2000 Oct;28(10):1231-7.
DM2VOQ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10997945

DMVILAD	DI	DMVILAD
DMVILAD	DN	MOTILIN
DMVILAD	MI	TT953CX
DMVILAD	MN	Motilin receptor (MLNR)
DMVILAD	MT	DTT
DMVILAD	MA	Inhibitor
DMVILAD	RN	Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7.
DMVILAD	RU	https://pubmed.ncbi.nlm.nih.gov/17125271

DMHEAB1	DI	DMHEAB1
DMHEAB1	DN	Neupro
DMHEAB1	MI	TTWFZ1N
DMHEAB1	MN	Dopamine receptor (DR)
DMHEAB1	MT	DTT
DMHEAB1	MA	Agonist
DMHEAB1	RN	Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718.
DMHEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/31243728

DMRP8XB	DI	DMRP8XB
DMRP8XB	DN	Nomegestrol
DMRP8XB	MI	DE4LYSA
DMRP8XB	MN	Cytochrome P450 3A4 (CYP3A4)
DMRP8XB	MT	DME
DMRP8XB	MA	Metabolism
DMRP8XB	RN	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
DMRP8XB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26327902

DMVAOME	DI	DMVAOME
DMVAOME	DN	Oleandomycin
DMVAOME	MI	DEYGVN4
DMVAOME	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMVAOME	MT	DME
DMVAOME	MA	Metabolism
DMVAOME	RN	Inversion of the anomeric configuration of the transferred sugar during inactivation of the macrolide antibiotic oleandomycin catalyzed by a macrolide glycosyltransferase. FEBS Lett. 2000 Jul 7;476(3):186-9.
DMVAOME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10913610

DMQIMTK	DI	DMQIMTK
DMQIMTK	DN	Ombitasvir
DMQIMTK	MI	DTUGYRD
DMQIMTK	MN	P-glycoprotein 1 (ABCB1)
DMQIMTK	MT	DTP
DMQIMTK	MA	Substrate
DMQIMTK	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMQIMTK	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMPSKA5	DI	DMPSKA5
DMPSKA5	DN	Ortho-phosphate
DMPSKA5	MI	DEQ3EWA
DMPSKA5	MN	Maltose phosphorylase (malP)
DMPSKA5	MT	DME
DMPSKA5	MA	Metabolism
DMPSKA5	RN	Maltose phosphorylase from Lactobacillus brevis: purification, characterization, and application in a biosensor for ortho-phosphate. Enzyme Microb Technol. 1997 Nov 1;21(6):413-20.
DMPSKA5	RU	https://pubmed.ncbi.nlm.nih.gov/9343859

DMU1JVW	DI	DMU1JVW
DMU1JVW	DN	Otilonium
DMU1JVW	MI	DE4LYSA
DMU1JVW	MN	Cytochrome P450 3A4 (CYP3A4)
DMU1JVW	MT	DME
DMU1JVW	MA	Metabolism
DMU1JVW	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMU1JVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMIGKA1	DI	DMIGKA1
DMIGKA1	DN	Ozagrel
DMIGKA1	MI	TTQBR95
DMIGKA1	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIGKA1	MT	DTT
DMIGKA1	MA	Inhibitor
DMIGKA1	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMIGKA1	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMY2AEF	DI	DMY2AEF
DMY2AEF	DN	PAI-1
DMY2AEF	MI	TTGY7WI
DMY2AEF	MN	Urokinase-type plasminogen activator (PLAU)
DMY2AEF	MT	DTT
DMY2AEF	MA	Inhibitor
DMY2AEF	RN	Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
DMY2AEF	RU	https://pubmed.ncbi.nlm.nih.gov/7563153

DMIV8CT	DI	DMIV8CT
DMIV8CT	DN	Parecoxib
DMIV8CT	MI	DE4LYSA
DMIV8CT	MN	Cytochrome P450 3A4 (CYP3A4)
DMIV8CT	MT	DME
DMIV8CT	MA	Metabolism
DMIV8CT	RN	Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice. J Pharm Biomed Anal. 2018 Sep 5;158:1-7.
DMIV8CT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29843006

DMIV8CT	DI	DMIV8CT
DMIV8CT	DN	Parecoxib
DMIV8CT	MI	TTSZDQU
DMIV8CT	MN	Lactotransferrin (LTF)
DMIV8CT	MT	DTT
DMIV8CT	MA	Inhibitor
DMIV8CT	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMIV8CT	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMQY873	DI	DMQY873
DMQY873	DN	Pentifylline
DMQY873	MI	DEJGDUW
DMQY873	MN	Cytochrome P450 1A2 (CYP1A2)
DMQY873	MT	DME
DMQY873	MA	Metabolism
DMQY873	RN	PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95.
DMQY873	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536

DM4OIMZ	DI	DM4OIMZ
DM4OIMZ	DN	Pinaverium
DM4OIMZ	MI	DE4LYSA
DM4OIMZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM4OIMZ	MT	DME
DM4OIMZ	MA	Metabolism
DM4OIMZ	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM4OIMZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMWRYUH	DI	DMWRYUH
DMWRYUH	DN	Prasterone sulfate
DMWRYUH	MI	DERD86B
DMWRYUH	MN	Cytochrome P450 3A7 (CYP3A7)
DMWRYUH	MT	DME
DMWRYUH	MA	Metabolism
DMWRYUH	RN	CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif Tissue Int. 2007 Mar;80(3):154-9.
DMWRYUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17334880

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DEN0GVQ
DM6VFO1	MN	Beta-HSD adrenal and gonadal type (HSD3B2)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DE4LYSA
DM6VFO1	MN	Cytochrome P450 3A4 (CYP3A4)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos. 2008 Feb;36(2):435-41.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048490

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DERDQWN
DM6VFO1	MN	Dihydrotestosterone oxidoreductase (HSD3B1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem. 2002 Nov 8;277(45):42795-801.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12205101

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	TTPNQAC
DM6VFO1	MN	Estrogen-related receptor-alpha (ESRRA)
DM6VFO1	MT	DTT
DM6VFO1	MA	Agonist
DM6VFO1	RN	Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6.
DM6VFO1	RU	https://pubmed.ncbi.nlm.nih.gov/16597193

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DE0P6LK
DM6VFO1	MN	Sulfotransferase 2A1 (SULT2A1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM6VFO1	DI	DM6VFO1
DM6VFO1	DN	Pregnenolone
DM6VFO1	MI	DEZBN53
DM6VFO1	MN	Sulfotransferase 2B1 (SULT2B1)
DM6VFO1	MT	DME
DM6VFO1	MA	Metabolism
DM6VFO1	RN	Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b). J Steroid Biochem Mol Biol. 2001 Jun;77(4-5):261-9.
DM6VFO1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11457664

DM8PTSY	DI	DM8PTSY
DM8PTSY	DN	Prenylamine
DM8PTSY	MI	DE4LYSA
DM8PTSY	MN	Cytochrome P450 3A4 (CYP3A4)
DM8PTSY	MT	DME
DM8PTSY	MA	Metabolism
DM8PTSY	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM8PTSY	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM37FKA	DI	DM37FKA
DM37FKA	DN	Primovist
DM37FKA	MI	DT3D8F0
DM37FKA	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM37FKA	MT	DTP
DM37FKA	MA	Substrate
DM37FKA	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM37FKA	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM37FKA	DI	DM37FKA
DM37FKA	DN	Primovist
DM37FKA	MI	DT9C1TS
DM37FKA	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM37FKA	MT	DTP
DM37FKA	MA	Substrate
DM37FKA	RN	Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010 Jul;38(7):1024-8.
DM37FKA	RU	http://www.ncbi.nlm.nih.gov/pubmed/20406852

DMXL43T	DI	DMXL43T
DMXL43T	DN	Prulifloxacin
DMXL43T	MI	DESDN74
DMXL43T	MN	Serum paraoxonase/arylesterase 1 (PON1)
DMXL43T	MT	DME
DMXL43T	MA	Metabolism
DMXL43T	RN	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
DMXL43T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27238723

DMF8CJ9	DI	DMF8CJ9
DMF8CJ9	DN	Pyridine
DMF8CJ9	MI	TTKNWZ4
DMF8CJ9	MN	Thromboxane-A synthase (TBXAS1)
DMF8CJ9	MT	DTT
DMF8CJ9	MA	Inhibitor
DMF8CJ9	RN	Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
DMF8CJ9	RU	https://pubmed.ncbi.nlm.nih.gov/7199089

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DE5IED8
DMBPN7T	MN	Cytochrome P450 2C9 (CYP2C9)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	Product Monograph of Xtandi Rupatadine (as rupatadine fumarate).
DMBPN7T	RU	http://www.pedia-pharm.com/en/wp-content/uploads/sites/3/2017/02/RUPALL-monograph-EN.pdf

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DE4LYSA
DMBPN7T	MN	Cytochrome P450 3A4 (CYP3A4)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001.
DMBPN7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17020424

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	DEIBDNY
DMBPN7T	MN	Cytochrome P450 3A5 (CYP3A5)
DMBPN7T	MT	DME
DMBPN7T	MA	Metabolism
DMBPN7T	RN	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):117-24.
DMBPN7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25427746

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	TTTIBOJ
DMBPN7T	MN	Histamine H1 receptor (H1R)
DMBPN7T	MT	DTT
DMBPN7T	MA	Inhibitor
DMBPN7T	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBPN7T	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMBPN7T	DI	DMBPN7T
DMBPN7T	DN	Rupatadine
DMBPN7T	MI	TTQL5VC
DMBPN7T	MN	Platelet-activating factor receptor (PTAFR)
DMBPN7T	MT	DTT
DMBPN7T	MA	Inhibitor
DMBPN7T	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMBPN7T	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMXBYQR	DI	DMXBYQR
DMXBYQR	DN	Silymarin
DMXBYQR	MI	TT2J34L
DMXBYQR	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMXBYQR	MT	DTT
DMXBYQR	MA	Inhibitor
DMXBYQR	RN	Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
DMXBYQR	RU	https://pubmed.ncbi.nlm.nih.gov/10782486

DMXBYQR	DI	DMXBYQR
DMXBYQR	DN	Silymarin
DMXBYQR	MI	DEYGVN4
DMXBYQR	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMXBYQR	MT	DME
DMXBYQR	MA	Metabolism
DMXBYQR	RN	Role of UDP-glucuronosyltransferase 1A1 in the metabolism and pharmacokinetics of silymarin flavonolignans in patients with HCV and NAFLD. Molecules. 2017 Jan 15;22(1). pii: E142.
DMXBYQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28098838

DMOSJD0	DI	DMOSJD0
DMOSJD0	DN	Sivelestat sodium hydrate
DMOSJD0	MI	TTPLTSQ
DMOSJD0	MN	Neutrophil elastase (NE)
DMOSJD0	MT	DTT
DMOSJD0	MA	Inhibitor
DMOSJD0	RN	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
DMOSJD0	RU	https://pubmed.ncbi.nlm.nih.gov/17874973

DMOSJD0	DI	DMOSJD0
DMOSJD0	DN	Sivelestat sodium hydrate
DMOSJD0	MI	TTEMV5X
DMOSJD0	MN	Serine protease unspecific (SP)
DMOSJD0	MT	DTT
DMOSJD0	MA	Inhibitor
DMOSJD0	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMOSJD0	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMTV7XH	DI	DMTV7XH
DMTV7XH	DN	SPN-812
DMTV7XH	MI	TT0K1SC
DMTV7XH	MN	5-HT 2B receptor (HTR2B)
DMTV7XH	MT	DTT
DMTV7XH	MA	Antagonist
DMTV7XH	RN	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
DMTV7XH	RU	https://pubmed.ncbi.nlm.nih.gov/32943948

DMTV7XH	DI	DMTV7XH
DMTV7XH	DN	SPN-812
DMTV7XH	MI	TTAWNKZ
DMTV7XH	MN	Norepinephrine transporter (NET)
DMTV7XH	MT	DTT
DMTV7XH	MA	Antagonist
DMTV7XH	RN	New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
DMTV7XH	RU	https://pubmed.ncbi.nlm.nih.gov/32943948

DM4TX7J	DI	DM4TX7J
DM4TX7J	DN	Talipexole
DM4TX7J	MI	TTEX248
DM4TX7J	MN	Dopamine D2 receptor (D2R)
DM4TX7J	MT	DTT
DM4TX7J	MA	Agonist
DM4TX7J	RN	Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res Commun Mol Pathol Pharmacol. 1997 Jan;95(1):67-82.
DM4TX7J	RU	https://pubmed.ncbi.nlm.nih.gov/9055350

DM62IPN	DI	DM62IPN
DM62IPN	DN	Tenofovir disoproxil
DM62IPN	MI	DE4LYSA
DM62IPN	MN	Cytochrome P450 3A4 (CYP3A4)
DM62IPN	MT	DME
DM62IPN	MA	Metabolism
DM62IPN	RN	FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
DM62IPN	RU	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf

DMC40UY	DI	DMC40UY
DMC40UY	DN	Tenofovir disoproxil
DMC40UY	MI	DTUGYRD
DMC40UY	MN	P-glycoprotein 1 (ABCB1)
DMC40UY	MT	DTP
DMC40UY	MA	Substrate
DMC40UY	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMC40UY	RU	https://doi.org/10.1007/s11095-012-0935-x

DM2M47Y	DI	DM2M47Y
DM2M47Y	DN	TKM-ApoB
DM2M47Y	MI	TTN1IE2
DM2M47Y	MN	APOB messenger RNA (APOB mRNA)
DM2M47Y	MT	DTT
DM2M47Y	RN	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
DM2M47Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/

DM7NSI0	DI	DM7NSI0
DM7NSI0	DN	Urethane
DM7NSI0	MI	DE08Z3W
DM7NSI0	MN	Cytosolic phospholipase A2 (PLA2G4A)
DM7NSI0	MT	DME
DM7NSI0	MA	Metabolism
DM7NSI0	RN	Phospholipase A2 pathway association with macrophage-mediated polycarbonate-urethane biodegradation. Biomaterials. 2005 Jun;26(18):3881-9.
DM7NSI0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15626436

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DEPKLMQ
DMCOJPS	MN	Cytochrome P450 2B6 (CYP2B6)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DECB0K3
DMCOJPS	MN	Cytochrome P450 2D6 (CYP2D6)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DE4LYSA
DMCOJPS	MN	Cytochrome P450 3A4 (CYP3A4)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DEGTFWK
DMCOJPS	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMCOJPS	DI	DMCOJPS
DMCOJPS	DN	Vonoprazan
DMCOJPS	MI	DE0P6LK
DMCOJPS	MN	Sulfotransferase 2A1 (SULT2A1)
DMCOJPS	MT	DME
DMCOJPS	MA	Metabolism
DMCOJPS	RN	In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
DMCOJPS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27414183

DMKV32D	DI	DMKV32D
DMKV32D	DN	Xylometazoline
DMKV32D	MI	TT2NUT5
DMKV32D	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMKV32D	MT	DTT
DMKV32D	MA	Modulator
DMKV32D	RN	Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
DMKV32D	RU	https://pubmed.ncbi.nlm.nih.gov/20030735

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DE5IED8
DM9RJH7	MN	Cytochrome P450 2C9 (CYP2C9)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DE073H6
DM9RJH7	MN	Prostaglandin G/H synthase 1 (COX-1)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DM9RJH7	DI	DM9RJH7
DM9RJH7	DN	Zaltoprofen
DM9RJH7	MI	DEB3CV1
DM9RJH7	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM9RJH7	MT	DME
DM9RJH7	MA	Metabolism
DM9RJH7	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DM9RJH7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMXIRA0	DI	DMXIRA0
DMXIRA0	DN	RLX030
DMXIRA0	MI	TTMAHD1
DMXIRA0	MN	Relaxin receptor 1 (RXFP1)
DMXIRA0	MT	DTT
DMXIRA0	MA	Modulator
DMXIRA0	RN	Design of the RELAXin in acute heart failure study. Am Heart J. 2012 Feb;163(2):149-55.e1.
DMXIRA0	RU	https://pubmed.ncbi.nlm.nih.gov/22305830

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TT7MRGU
DMOML9Q	MN	Chymotrypsin (CTR)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DMOML9Q	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TTCGSZ4
DMOML9Q	MN	Pancreatic alpha-amylase (AMY2A)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	Clinical pipeline report, company report or official report of Digestive Care.
DMOML9Q	RU	http://www.digestivecare.com/release102708.shtm

DMOML9Q	DI	DMOML9Q
DMOML9Q	DN	Pancrecarb
DMOML9Q	MI	TTXMY0J
DMOML9Q	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMOML9Q	MT	DTT
DMOML9Q	MA	Modulator
DMOML9Q	RN	Clinical pipeline report, company report or official report of Digestive Care.
DMOML9Q	RU	http://www.digestivecare.com/release102708.shtm

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT8JRS7
DMF2O4T	MN	Beta-secretase (BACE)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT9W8GU
DMF2O4T	MN	Gamma-secretase (GS)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTZ3S8C
DMF2O4T	MN	Presenilin 1 (PSEN1)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTWN3F4
DMF2O4T	MN	Presenilin 2 (PSEN2)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TT8NGED
DMF2O4T	MN	Prostaglandin G/H synthase 1 (COX-1)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMF2O4T	DI	DMF2O4T
DMF2O4T	DN	(S)-FLURBIPROFEN
DMF2O4T	MI	TTVKILB
DMF2O4T	MN	Prostaglandin G/H synthase 2 (COX-2)
DMF2O4T	MT	DTT
DMF2O4T	MA	Inhibitor
DMF2O4T	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMF2O4T	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMBRFUQ	DI	DMBRFUQ
DMBRFUQ	DN	B-cell lymphoma vaccine
DMBRFUQ	MI	TT6MP2Z
DMBRFUQ	MN	GMCSFR-alpha (CSF2RA)
DMBRFUQ	MT	DTT
DMBRFUQ	RN	Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
DMBRFUQ	RU	http://meeting.ascopubs.org/cgi/content/abstract/27/18S/2?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Idiotype+vaccine+therapy+(BiovaxID)+in+follicular+lymphoma+&searchid=1&FIRSTINDEX=0&volume=27&issue=18S&resourcetype=HWCIT

DMP5O1U	DI	DMP5O1U
DMP5O1U	DN	GSK2696273
DMP5O1U	MI	TTLP57V
DMP5O1U	MN	Adenosine deaminase (ADA)
DMP5O1U	MT	DTT
DMP5O1U	MA	Modulator
DMP5O1U	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMP5O1U	RU	https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

DMXSDJU	DI	DMXSDJU
DMXSDJU	DN	MPL-containing Pollinex allergy desensitization vaccine
DMXSDJU	MI	TTISGCA
DMXSDJU	MN	Toll-like receptor 4 (TLR4)
DMXSDJU	MT	DTT
DMXSDJU	RN	Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
DMXSDJU	RU	http://miranda.hemscott.com/ir/agy/ir.jsp?page=news_regulatory&article=36483600159086

DMLRKJX	DI	DMLRKJX
DMLRKJX	DN	Neugranin
DMLRKJX	MI	TT5TQ2W
DMLRKJX	MN	Granulocyte colony-stimulating factor (CSF3)
DMLRKJX	MT	DTT
DMLRKJX	MA	Modulator
DMLRKJX	RN	Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840.
DMLRKJX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275271/

DMUY09W	DI	DMUY09W
DMUY09W	DN	SK-NBP601
DMUY09W	MI	TT1290U
DMUY09W	MN	Coagulation factor VIII (F8)
DMUY09W	MT	DTT
DMUY09W	MA	Inhibitor
DMUY09W	RN	Clinical pipeline report, company report or official report of SK Chemicals.
DMUY09W	RU	http://www.skchemicals.com/en/about/rd_result.asp

DM26I8H	DI	DM26I8H
DM26I8H	DN	TK-DLI
DM26I8H	MI	TTP3QRF
DM26I8H	MN	Thymidine kinase 1 (TK1)
DM26I8H	MT	DTT
DM26I8H	MA	Modulator
DM26I8H	RN	Company report (Takara Bio)
DM26I8H	RU	http://www.takara-bio.com/news_e/2008/10/07.htm

DMYA6TR	DI	DMYA6TR
DMYA6TR	DN	Human coagulation factor X
DMYA6TR	MI	TTCIHJA
DMYA6TR	MN	Coagulation factor Xa (F10)
DMYA6TR	MT	DTT
DMYA6TR	MA	Modulator
DMYA6TR	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMYA6TR	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMNCY1I	DI	DMNCY1I
DMNCY1I	DN	(-)-Phenserine
DMNCY1I	MI	TT1RS9F
DMNCY1I	MN	Acetylcholinesterase (AChE)
DMNCY1I	MT	DTT
DMNCY1I	MA	Inhibitor
DMNCY1I	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMNCY1I	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMNCY1I	DI	DMNCY1I
DMNCY1I	DN	(-)-Phenserine
DMNCY1I	MI	TTEB0GD
DMNCY1I	MN	Cholinesterase (BCHE)
DMNCY1I	MT	DTT
DMNCY1I	MA	Inhibitor
DMNCY1I	RN	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. 
DMNCY1I	RU	https://pubmed.ncbi.nlm.nih.gov/20627738

DMLRHM5	DI	DMLRHM5
DMLRHM5	DN	[3H](R)-(-)-baclofen
DMLRHM5	MI	TTDCVZW
DMLRHM5	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMLRHM5	MT	DTT
DMLRHM5	MA	Agonist
DMLRHM5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
DMLRHM5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242

DM3YEV0	DI	DM3YEV0
DM3YEV0	DN	131I-labelled aCD45
DM3YEV0	MI	TTUS45N
DM3YEV0	MN	Leukocyte common antigen (PTPRC)
DM3YEV0	MT	DTT
DM3YEV0	RN	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91.
DM3YEV0	RU	https://pubmed.ncbi.nlm.nih.gov/16254140

DMTZ1A5	DI	DMTZ1A5
DMTZ1A5	DN	13-cis-retinoic acid
DMTZ1A5	MI	TTOD7B3
DMTZ1A5	MN	Retinoic acid receptor (RAR)
DMTZ1A5	MT	DTT
DMTZ1A5	MA	Modulator
DMTZ1A5	RN	13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7.
DMTZ1A5	RU	https://pubmed.ncbi.nlm.nih.gov/10951254

DMP5L8S	DI	DMP5L8S
DMP5L8S	DN	177Lu-DOTA-octreotate
DMP5L8S	MI	TTOMNR9
DMP5L8S	MN	Somatostatin receptor (SSTR)
DMP5L8S	MT	DTT
DMP5L8S	MA	Modulator
DMP5L8S	RN	Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
DMP5L8S	RU	https://pubmed.ncbi.nlm.nih.gov/24632546

DMQ0IZ6	DI	DMQ0IZ6
DMQ0IZ6	DN	177Lu-labelled PSMA-617
DMQ0IZ6	MI	TT9G4N0
DMQ0IZ6	MN	Glutamate carboxypeptidase II (GCPII)
DMQ0IZ6	MT	DTT
DMQ0IZ6	RN	[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8.
DMQ0IZ6	RU	https://pubmed.ncbi.nlm.nih.gov/27350005

DMMZS2T	DI	DMMZS2T
DMMZS2T	DN	177-Lu-oxodotreotide
DMMZS2T	MI	TTOMNR9
DMMZS2T	MN	Somatostatin receptor (SSTR)
DMMZS2T	MT	DTT
DMMZS2T	MA	Agonist
DMMZS2T	RN	Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
DMMZS2T	RU	https://pubmed.ncbi.nlm.nih.gov/22388631

DMX178V	DI	DMX178V
DMX178V	DN	177-Lu-PSMA-617
DMX178V	MI	TT9G4N0
DMX178V	MN	Glutamate carboxypeptidase II (GCPII)
DMX178V	MT	DTT
DMX178V	MA	Agonist
DMX178V	RN	Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921.
DMX178V	RU	https://pubmed.ncbi.nlm.nih.gov/32760622

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE6OQ3W
DME2A8X	MN	Cytochrome P450 1A1 (CYP1A1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEJGDUW
DME2A8X	MN	Cytochrome P450 1A2 (CYP1A2)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE9QHP6
DME2A8X	MN	Cytochrome P450 1B1 (CYP1B1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEJVYAZ
DME2A8X	MN	Cytochrome P450 2A6 (CYP2A6)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DEVDYN7
DME2A8X	MN	Cytochrome P450 2E1 (CYP2E1)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity. PLoS One. 2013 Sep 23;8(9):e75494.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24086543

DME2A8X	DI	DME2A8X
DME2A8X	DN	5-methoxypsoralen
DME2A8X	MI	DE4LYSA
DME2A8X	MN	Cytochrome P450 3A4 (CYP3A4)
DME2A8X	MT	DME
DME2A8X	MA	Metabolism
DME2A8X	RN	Metabolism of 5-methoxypsoralen by Saccharomyces cerevisiae. Photochem Photobiol. 1991 Nov;54(5):689-95.
DME2A8X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=1798745

DM4OHMP	DI	DM4OHMP
DM4OHMP	DN	A-3309
DM4OHMP	MI	TTPI1M5
DM4OHMP	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM4OHMP	MT	DTT
DM4OHMP	MA	Inhibitor
DM4OHMP	RN	Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84.
DM4OHMP	RU	https://pubmed.ncbi.nlm.nih.gov/23215781

DMJNSLU	DI	DMJNSLU
DMJNSLU	DN	AAV2-hRPE65v2
DMJNSLU	MI	TTBOH16
DMJNSLU	MN	Retinal pigment epithelium protein (RPE65)
DMJNSLU	MT	DTT
DMJNSLU	MA	Modulator
DMJNSLU	RN	AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012 Feb 8;4(120):120ra15.
DMJNSLU	RU	https://pubmed.ncbi.nlm.nih.gov/22323828

DMPDQ8T	DI	DMPDQ8T
DMPDQ8T	DN	AB-103
DMPDQ8T	MI	TTQ13FT
DMPDQ8T	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMPDQ8T	MT	DTT
DMPDQ8T	MA	Antagonist
DMPDQ8T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPDQ8T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMUES7Y	DI	DMUES7Y
DMUES7Y	DN	AB154
DMUES7Y	MI	TTWNL74
DMUES7Y	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMUES7Y	MT	DTT
DMUES7Y	MA	Inhibitor
DMUES7Y	RN	Clinical pipeline report, company report or official report of Arcus Biosciences.
DMUES7Y	RU	https://arcusbio.com/domvanalimab/

DMMWO7V	DI	DMMWO7V
DMMWO7V	DN	ABBV-951
DMMWO7V	MI	TTWFZ1N
DMMWO7V	MN	Dopamine receptor (DR)
DMMWO7V	MT	DTT
DMMWO7V	MA	Activator
DMMWO7V	RN	Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61.
DMMWO7V	RU	https://pubmed.ncbi.nlm.nih.gov/33772855

DMCKPG4	DI	DMCKPG4
DMCKPG4	DN	ABC294640
DMCKPG4	MI	TTCN0M9
DMCKPG4	MN	Sphingosine kinase 2 (SPHK2)
DMCKPG4	MT	DTT
DMCKPG4	MA	Modulator
DMCKPG4	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMCKPG4	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DM91LGU	DI	DM91LGU
DM91LGU	DN	Abexinostat
DM91LGU	MI	TTBH0VX
DM91LGU	MN	Histone deacetylase (HDAC)
DM91LGU	MT	DTT
DM91LGU	MA	Modulator
DM91LGU	RN	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
DM91LGU	RU	https://pubmed.ncbi.nlm.nih.gov/25600050

DMMF5K4	DI	DMMF5K4
DMMF5K4	DN	ABL 001
DMMF5K4	MI	TTS7G69
DMMF5K4	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMMF5K4	MT	DTT
DMMF5K4	MA	Inhibitor
DMMF5K4	RN	ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125.
DMMF5K4	RU	https://ash.confex.com/ash/2014/webprogram/Paper76344.html

DM7EVUF	DI	DM7EVUF
DM7EVUF	DN	ABL001
DM7EVUF	MI	TTS7G69
DM7EVUF	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7EVUF	MT	DTT
DM7EVUF	MA	Inhibitor
DM7EVUF	RN	Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326.
DM7EVUF	RU	https://pubmed.ncbi.nlm.nih.gov/31826340

DM2J4YB	DI	DM2J4YB
DM2J4YB	DN	ABP 501
DM2J4YB	MI	TTF8CQI
DM2J4YB	MN	Tumor necrosis factor (TNF)
DM2J4YB	MT	DTT
DM2J4YB	RN	Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30.
DM2J4YB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/

DMDXE4I	DI	DMDXE4I
DMDXE4I	DN	ABP959
DMDXE4I	MI	TTKANGO
DMDXE4I	MN	Complement C5 (CO5)
DMDXE4I	MT	DTT
DMDXE4I	MA	Inhibitor
DMDXE4I	RN	A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74.
DMDXE4I	RU	https://pubmed.ncbi.nlm.nih.gov/32196749

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTJGNVC
DMNE56X	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTQ79W8
DMNE56X	MN	Apoptosis regulator Bcl-W (BCL-W)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTU1E82
DMNE56X	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMNE56X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	DE4LYSA
DMNE56X	MN	Cytochrome P450 3A4 (CYP3A4)
DMNE56X	MT	DME
DMNE56X	MA	Metabolism
DMNE56X	RN	Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4.
DMNE56X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25047139

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	TTFCJ7S
DMNE56X	MN	G1/S-specific cyclin-D1 (CCND1)
DMNE56X	MT	DTT
DMNE56X	MA	Inhibitor
DMNE56X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNE56X	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNE56X	DI	DMNE56X
DMNE56X	DN	ABT-263
DMNE56X	MI	DTUGYRD
DMNE56X	MN	P-glycoprotein 1 (ABCB1)
DMNE56X	MT	DTP
DMNE56X	MA	Substrate
DMNE56X	RN	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun. 2011 May 6;408(2):344-9.
DMNE56X	RU	https://doi.org/10.1016/j.bbrc.2011.04.043

DMNQ869	DI	DMNQ869
DMNQ869	DN	ABT-267
DMNQ869	MI	DES5XRU
DMNQ869	MN	Cytochrome P450 2C8 (CYP2C8)
DMNQ869	MT	DME
DMNQ869	MA	Metabolism
DMNQ869	RN	Metabolism and disposition of pan-genotypic inhibitor of hepatitis C virus NS5A ombitasvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1148-57.
DMNQ869	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179128

DMNQ869	DI	DMNQ869
DMNQ869	DN	ABT-267
DMNQ869	MI	TTCJ2X8
DMNQ869	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMNQ869	MT	DTT
DMNQ869	MA	Modulator
DMNQ869	RN	Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57.
DMNQ869	RU	https://pubmed.ncbi.nlm.nih.gov/24400777

DMJFD2I	DI	DMJFD2I
DMJFD2I	DN	ABT-492
DMJFD2I	MI	TTIXTO3
DMJFD2I	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMJFD2I	MT	DTT
DMJFD2I	MA	Modulator
DMJFD2I	RN	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus
DMJFD2I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028753

DMJFD2I	DI	DMJFD2I
DMJFD2I	DN	ABT-492
DMJFD2I	MI	DEYGVN4
DMJFD2I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJFD2I	MT	DME
DMJFD2I	MA	Metabolism
DMJFD2I	RN	Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018 Jun;7(2):197-217.
DMJFD2I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29605887

DM3FIC2	DI	DM3FIC2
DM3FIC2	DN	ABT-761
DM3FIC2	MI	TT2J34L
DM3FIC2	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3FIC2	MT	DTT
DM3FIC2	MA	Inhibitor
DM3FIC2	RN	Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
DM3FIC2	RU	https://pubmed.ncbi.nlm.nih.gov/20190281

DM3FIC2	DI	DM3FIC2
DM3FIC2	DN	ABT-761
DM3FIC2	MI	DE4LYSA
DM3FIC2	MN	Cytochrome P450 3A4 (CYP3A4)
DM3FIC2	MT	DME
DM3FIC2	MA	Metabolism
DM3FIC2	RN	Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos. 1998 Oct;26(10):970-6.
DM3FIC2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9763401

DMREDYP	DI	DMREDYP
DMREDYP	DN	ABT-869
DMREDYP	MI	TTDCBX5
DMREDYP	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMREDYP	MT	DTT
DMREDYP	MA	Modulator
DMREDYP	RN	Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
DMREDYP	RU	https://pubmed.ncbi.nlm.nih.gov/16648571

DMYHSO2	DI	DMYHSO2
DMYHSO2	DN	ABT-874
DMYHSO2	MI	TTGW72V
DMYHSO2	MN	Interleukin-12 beta (IL12B)
DMYHSO2	MT	DTT
DMYHSO2	MA	Modulator
DMYHSO2	RN	Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20.
DMYHSO2	RU	https://www.ncbi.nlm.nih.gov/pubmed/22077474

DM4HYMS	DI	DM4HYMS
DM4HYMS	DN	ABT-888
DM4HYMS	MI	TTEBCY8
DM4HYMS	MN	Poly [ADP-ribose] polymerase (PARP)
DM4HYMS	MT	DTT
DM4HYMS	MA	Modulator
DM4HYMS	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4HYMS	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQRL2Y	DI	DMQRL2Y
DMQRL2Y	DN	AC0010
DMQRL2Y	MI	TTG96HZ
DMQRL2Y	MN	EGFR messenger RNA (EGFR mRNA)
DMQRL2Y	MT	DTT
DMQRL2Y	MA	Inhibitor
DMQRL2Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQRL2Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXZ9T3	DI	DMXZ9T3
DMXZ9T3	DN	AC-170
DMXZ9T3	MI	TTTIBOJ
DMXZ9T3	MN	Histamine H1 receptor (H1R)
DMXZ9T3	MT	DTT
DMXZ9T3	MA	Antagonist
DMXZ9T3	RN	Clinical pipeline report, company report or official report of NicOx SA.
DMXZ9T3	RU	http://www.nicox.com/rd/ac-170/

DM8Y4JS	DI	DM8Y4JS
DM8Y4JS	DN	AC220
DM8Y4JS	MI	TTGJCWZ
DM8Y4JS	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM8Y4JS	MT	DTT
DM8Y4JS	MA	Inhibitor
DM8Y4JS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8Y4JS	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1RMF5	DI	DM1RMF5
DM1RMF5	DN	Acadesine
DM1RMF5	MI	TTLAFZV
DM1RMF5	MN	AMP-activated protein kinase (AMPK)
DM1RMF5	MT	DTT
DM1RMF5	MA	Modulator
DM1RMF5	RN	Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
DM1RMF5	RU	https://pubmed.ncbi.nlm.nih.gov/18671468

DMY96O3	DI	DMY96O3
DMY96O3	DN	acelarin
DMY96O3	MI	TTUBNVO
DMY96O3	MN	DNA synthesis (DNA synth)
DMY96O3	MT	DTT
DMY96O3	MA	Inhibitor
DMY96O3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY96O3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3UQ9K	DI	DM3UQ9K
DM3UQ9K	DN	Acolbifene
DM3UQ9K	MI	TTZAYWL
DM3UQ9K	MN	Estrogen receptor (ESR)
DM3UQ9K	MT	DTT
DM3UQ9K	MA	Modulator
DM3UQ9K	RN	Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82.
DM3UQ9K	RU	https://pubmed.ncbi.nlm.nih.gov/15720121

DMXYRPO	DI	DMXYRPO
DMXYRPO	DN	Act1
DMXYRPO	MI	TT4F7SL
DMXYRPO	MN	Gap junction alpha-1 protein (GJA1)
DMXYRPO	MT	DTT
DMXYRPO	MA	Modulator
DMXYRPO	RN	Company report (FirstString Research)
DMXYRPO	RU	http://firststringresearch.com/platform-technology/

DMVLWG7	DI	DMVLWG7
DMVLWG7	DN	Ad5FGF-4
DMVLWG7	MI	TTCEKVZ
DMVLWG7	MN	Fibroblast growth factor-4 (FGF4)
DMVLWG7	MT	DTT
DMVLWG7	MA	Modulator
DMVLWG7	RN	Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N.
DMVLWG7	RU	https://pubmed.ncbi.nlm.nih.gov/14615023

DMFIP35	DI	DMFIP35
DMFIP35	DN	Adhexil
DMFIP35	MI	TTWODQF
DMFIP35	MN	Fibrin (FG)
DMFIP35	MT	DTT
DMFIP35	MA	Modulator
DMFIP35	RN	Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci. Fertil Steril. 2010 Mar 1;93(4):1045-51.
DMFIP35	RU	https://pubmed.ncbi.nlm.nih.gov/19147133

DMLBYRA	DI	DMLBYRA
DMLBYRA	DN	ADX N05
DMLBYRA	MI	TT5TPI6
DMLBYRA	MN	Opioid receptor sigma 1 (OPRS1)
DMLBYRA	MT	DTT
DMLBYRA	MA	Modulator
DMLBYRA	RN	Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
DMLBYRA	RU	http://www.skbp.com/etc/news_view_14.asp

DMAYO46	DI	DMAYO46
DMAYO46	DN	AEZS-108
DMAYO46	MI	TT8R70G
DMAYO46	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMAYO46	MT	DTT
DMAYO46	MA	Modulator
DMAYO46	RN	Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34.
DMAYO46	RU	https://pubmed.ncbi.nlm.nih.gov/10639165

DMS0ZBI	DI	DMS0ZBI
DMS0ZBI	DN	Ag-221
DMS0ZBI	MI	TTDTWV0
DMS0ZBI	MN	Isocitrate dehydrogenase (IDH)
DMS0ZBI	MT	DTT
DMS0ZBI	MA	Inhibitor
DMS0ZBI	RN	New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213.
DMS0ZBI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323358/

DMIE1WY	DI	DMIE1WY
DMIE1WY	DN	AG-881
DMIE1WY	MI	TTDTWV0
DMIE1WY	MN	Isocitrate dehydrogenase (IDH)
DMIE1WY	MT	DTT
DMIE1WY	MA	Inhibitor
DMIE1WY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIE1WY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYN3IH	DI	DMYN3IH
DMYN3IH	DN	AGI-1067
DMYN3IH	MI	TT1AVS7
DMYN3IH	MN	Second phase insulin secretion (SPI secr)
DMYN3IH	MT	DTT
DMYN3IH	MA	Inhibitor
DMYN3IH	RN	AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55.
DMYN3IH	RU	https://pubmed.ncbi.nlm.nih.gov/20211684

DMJRQDG	DI	DMJRQDG
DMJRQDG	DN	AG-SPT201
DMJRQDG	MI	TTF1QVM
DMJRQDG	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DMJRQDG	MT	DTT
DMJRQDG	MA	Modulator
DMJRQDG	RN	Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7.
DMJRQDG	RU	https://pubmed.ncbi.nlm.nih.gov/10197495

DMS2WV3	DI	DMS2WV3
DMS2WV3	DN	AIDSVAX
DMS2WV3	MI	TTBYP1X
DMS2WV3	MN	Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)
DMS2WV3	MT	DTT
DMS2WV3	RN	HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D. 2003;4(4):249-53.
DMS2WV3	RU	https://pubmed.ncbi.nlm.nih.gov/12848591

DM8SYTE	DI	DM8SYTE
DM8SYTE	DN	AIR-insulin
DM8SYTE	MI	TTF89GD
DM8SYTE	MN	Interleukin-2 (IL2)
DM8SYTE	MT	DTT
DM8SYTE	MA	Modulator
DM8SYTE	RN	The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7.
DM8SYTE	RU	https://pubmed.ncbi.nlm.nih.gov/17563303

DM5K6J4	DI	DM5K6J4
DM5K6J4	DN	AJM-300
DM5K6J4	MI	TT6S84X
DM5K6J4	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM5K6J4	MT	DTT
DM5K6J4	MA	Modulator
DM5K6J4	RN	Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42.
DM5K6J4	RU	https://pubmed.ncbi.nlm.nih.gov/23623333

DM2EJM3	DI	DM2EJM3
DM2EJM3	DN	AKB-6548
DM2EJM3	MI	TTJQFBG
DM2EJM3	MN	HIF-prolyl hydroxylase (HPH)
DM2EJM3	MT	DTT
DM2EJM3	MA	Modulator
DM2EJM3	RN	DOI: 10.1038/nrd4422
DM2EJM3	RU	http://www.nature.com/nrd/journal/v13/n11/fig_tab/nrd4422_T2.html

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	DE4LYSA
DM3WP0N	MN	Cytochrome P450 3A4 (CYP3A4)
DM3WP0N	MT	DME
DM3WP0N	MA	Metabolism
DM3WP0N	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DM3WP0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	DEIBDNY
DM3WP0N	MN	Cytochrome P450 3A5 (CYP3A5)
DM3WP0N	MT	DME
DM3WP0N	MA	Metabolism
DM3WP0N	RN	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
DM3WP0N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30231931

DM3WP0N	DI	DM3WP0N
DM3WP0N	DN	Al3818
DM3WP0N	MI	TT6PKBN
DM3WP0N	MN	Proto-oncogene c-Src (SRC)
DM3WP0N	MT	DTT
DM3WP0N	MA	Inhibitor
DM3WP0N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3WP0N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK0QW6	DI	DMK0QW6
DMK0QW6	DN	Albinterferon alfa-2b
DMK0QW6	MI	TTSIUJ9
DMK0QW6	MN	Interferon-alpha 2 (IFNA2)
DMK0QW6	MT	DTT
DMK0QW6	MA	Modulator
DMK0QW6	RN	Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
DMK0QW6	RU	https://pubmed.ncbi.nlm.nih.gov/19275518

DMWAL73	DI	DMWAL73
DMWAL73	DN	Albutropin
DMWAL73	MI	TTT3YKH
DMWAL73	MN	Somatotropin (GH1)
DMWAL73	MT	DTT
DMWAL73	MA	Modulator
DMWAL73	RN	Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58.
DMWAL73	RU	https://pubmed.ncbi.nlm.nih.gov/12450581

DMHKCIS	DI	DMHKCIS
DMHKCIS	DN	Aldoxorubicin
DMHKCIS	MI	TT0IHXV
DMHKCIS	MN	DNA topoisomerase II (TOP2)
DMHKCIS	MT	DTT
DMHKCIS	MA	Modulator
DMHKCIS	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHKCIS	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPH1RK	DI	DMPH1RK
DMPH1RK	DN	Alferminogene tadenovec
DMPH1RK	MI	TTCEKVZ
DMPH1RK	MN	Fibroblast growth factor-4 (FGF4)
DMPH1RK	MT	DTT
DMPH1RK	MA	Modulator
DMPH1RK	RN	Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93.
DMPH1RK	RU	https://pubmed.ncbi.nlm.nih.gov/18379964

DMVHRL8	DI	DMVHRL8
DMVHRL8	DN	Alfimeprase
DMVHRL8	MI	TTWODQF
DMVHRL8	MN	Fibrin (FG)
DMVHRL8	MT	DTT
DMVHRL8	MA	Modulator
DMVHRL8	RN	Disulfide structure of alfimeprase: A recombinant analog of fibrolase. Protein Sci. 2001 June; 10(6): 1264-1267.
DMVHRL8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374009/

DMBQK0X	DI	DMBQK0X
DMBQK0X	DN	Algenpantucel-L
DMBQK0X	MI	TTPJ1I3
DMBQK0X	MN	Galactosyltransferase (GALT)
DMBQK0X	MT	DTT
DMBQK0X	RN	Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer. 2014; 45(2): 190-201.
DMBQK0X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024386/

DMQ509J	DI	DMQ509J
DMQ509J	DN	Alicaforsen
DMQ509J	MI	TTA1L39
DMQ509J	MN	ICAM1 messenger RNA (ICAM1 mRNA)
DMQ509J	MT	DTT
DMQ509J	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMQ509J	RU	http://www.isispharm.com/Pipeline/index.htm

DMQ509J	DI	DMQ509J
DMQ509J	DN	Alicaforsen
DMQ509J	MI	TTCT6F7
DMQ509J	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMQ509J	MT	DTT
DMQ509J	MA	Antagonist
DMQ509J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ509J	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9R2SD	DI	DM9R2SD
DM9R2SD	DN	Alilusem
DM9R2SD	MI	DTPFTEQ
DM9R2SD	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM9R2SD	MT	DTP
DM9R2SD	MA	Substrate
DM9R2SD	RN	Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 2007 Jan;24(1):90-8.
DM9R2SD	RU	https://doi.org/10.1007/s11095-006-9127-x

DM9R2SD	DI	DM9R2SD
DM9R2SD	DN	Alilusem
DM9R2SD	MI	TTYJL7K
DM9R2SD	MN	Sodium/potassium transport (Na/K trans)
DM9R2SD	MT	DTT
DM9R2SD	MA	Modulator
DM9R2SD	RN	US patent application no. 8,067,031, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use.
DM9R2SD	RU	http://www.google.lv/patents/US8067031

DM83EBP	DI	DM83EBP
DM83EBP	DN	Alisporivir
DM83EBP	MI	TTATDGJ
DM83EBP	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DM83EBP	MT	DTT
DM83EBP	MA	Inhibitor
DM83EBP	RN	DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.
DM83EBP	RU	https://pubmed.ncbi.nlm.nih.gov/21060866

DM83EBP	DI	DM83EBP
DM83EBP	DN	Alisporivir
DM83EBP	MI	DE4LYSA
DM83EBP	MN	Cytochrome P450 3A4 (CYP3A4)
DM83EBP	MT	DME
DM83EBP	MA	Metabolism
DM83EBP	RN	Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 2013;7:105-15.
DM83EBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23440335

DMCHA27	DI	DMCHA27
DMCHA27	DN	Almonertinib
DMCHA27	MI	TTGKNB4
DMCHA27	MN	Epidermal growth factor receptor (EGFR)
DMCHA27	MT	DTT
DMCHA27	MA	Inhibitor
DMCHA27	RN	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918.
DMCHA27	RU	https://pubmed.ncbi.nlm.nih.gov/32916310

DMFUOM7	DI	DMFUOM7
DMFUOM7	DN	ALN-TTRsc
DMFUOM7	MI	TTC1I86
DMFUOM7	MN	Transthyretin (TTR)
DMFUOM7	MT	DTT
DMFUOM7	MA	Inhibitor
DMFUOM7	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DMFUOM7	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/

DMKLBHX	DI	DMKLBHX
DMKLBHX	DN	ALO-02
DMKLBHX	MI	TTN4QDT
DMKLBHX	MN	Opioid receptor (OPR)
DMKLBHX	MT	DTT
DMKLBHX	MA	Modulator
DMKLBHX	RN	Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9.
DMKLBHX	RU	https://pubmed.ncbi.nlm.nih.gov/15943961

DM2RTGP	DI	DM2RTGP
DM2RTGP	DN	Alpha-glucosidase
DM2RTGP	MI	TTXWASR
DM2RTGP	MN	Intestinal maltase-glucoamylase (MGAM)
DM2RTGP	MT	DTT
DM2RTGP	MA	Modulator
DM2RTGP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
DM2RTGP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627

DM7EBH9	DI	DM7EBH9
DM7EBH9	DN	ALX-0081
DM7EBH9	MI	TT3SZBT
DM7EBH9	MN	von Willebrand factor (VWF)
DM7EBH9	MT	DTT
DM7EBH9	MA	Binder
DM7EBH9	RN	Clinical pipeline report, company report or official report of Ablynx
DM7EBH9	RU	http://hugin.info/137912/R/1338761/319541.pdf

DMG5BTD	DI	DMG5BTD
DMG5BTD	DN	ALZT-OP1
DMG5BTD	MI	TTE4KHA
DMG5BTD	MN	Amyloid beta A4 protein (APP)
DMG5BTD	MT	DTT
DMG5BTD	MA	Inhibitor
DMG5BTD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG5BTD	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMGMNUE	DI	DMGMNUE
DMGMNUE	DN	AM0010
DMGMNUE	MI	TTT0Q1F
DMGMNUE	MN	Interleukin-10 (IL10)
DMGMNUE	MT	DTT
DMGMNUE	MA	Modulator
DMGMNUE	RN	Clinical pipeline report, company report or official report of ARMO BioSciences.
DMGMNUE	RU	http://www.armobio.com/drug-development

DM4E9PK	DI	DM4E9PK
DM4E9PK	DN	AM-111
DM4E9PK	MI	TTR2TXZ
DM4E9PK	MN	Jun N terminal kinase (JNK)
DM4E9PK	MT	DTT
DM4E9PK	MA	Modulator
DM4E9PK	RN	The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
DM4E9PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22427801

DMVOY6B	DI	DMVOY6B
DMVOY6B	DN	AMD-070
DMVOY6B	MI	TTBID49
DMVOY6B	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMVOY6B	MT	DTT
DMVOY6B	MA	Antagonist
DMVOY6B	RN	Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65.
DMVOY6B	RU	https://pubmed.ncbi.nlm.nih.gov/18362694

DM4FPM3	DI	DM4FPM3
DM4FPM3	DN	Amediplase
DM4FPM3	MI	TTGY7WI
DM4FPM3	MN	Urokinase-type plasminogen activator (PLAU)
DM4FPM3	MT	DTT
DM4FPM3	MA	Activator
DM4FPM3	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DM4FPM3	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DMG324Y	DI	DMG324Y
DMG324Y	DN	AMG 145
DMG324Y	MI	TTBRG7E
DMG324Y	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMG324Y	MT	DTT
DMG324Y	MA	Modulator
DMG324Y	RN	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40.
DMG324Y	RU	https://pubmed.ncbi.nlm.nih.gov/25282519

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTWNQ1T
DMQJXL4	MN	Angiopoietin-1 (ANGPT1)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTKLQTJ
DMQJXL4	MN	Angiopoietin-2 (ANGPT2)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TT9W8GU
DMQJXL4	MN	Gamma-secretase (GS)
DMQJXL4	MT	DTT
DMQJXL4	MA	Inhibitor
DMQJXL4	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMQJXL4	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTD0CIQ
DMQJXL4	MN	Melanocortin receptor 4 (MC4R)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMQJXL4	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTLA931
DMQJXL4	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMQJXL4	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTN4QDT
DMQJXL4	MN	Opioid receptor (OPR)
DMQJXL4	MT	DTT
DMQJXL4	MA	Agonist
DMQJXL4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQJXL4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQJXL4	DI	DMQJXL4
DMQJXL4	DN	AMG 386
DMQJXL4	MI	TTBW580
DMQJXL4	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DMQJXL4	MT	DTT
DMQJXL4	MA	Modulator
DMQJXL4	RN	Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
DMQJXL4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23334208

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TTVBI8W
DMS1X67	MN	Dopamine transporter (DAT)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TTAWNKZ
DMS1X67	MN	Norepinephrine transporter (NET)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DMS1X67	DI	DMS1X67
DMS1X67	DN	Amitifadine
DMS1X67	MI	TT3ROYC
DMS1X67	MN	Serotonin transporter (SERT)
DMS1X67	MT	DTT
DMS1X67	MA	Inhibitor
DMS1X67	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928).
DMS1X67	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928

DMF50XJ	DI	DMF50XJ
DMF50XJ	DN	Amitriptyline+ketamine
DMF50XJ	MI	TT9IK2Z
DMF50XJ	MN	N-methyl-D-aspartate receptor (NMDAR)
DMF50XJ	MT	DTT
DMF50XJ	MA	Antagonist
DMF50XJ	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMF50XJ	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMZ7AMY	DI	DMZ7AMY
DMZ7AMY	DN	Amivantamab
DMZ7AMY	MI	TTGKNB4
DMZ7AMY	MN	Epidermal growth factor receptor (EGFR)
DMZ7AMY	MT	DTT
DMZ7AMY	MA	Inhibitor
DMZ7AMY	RN	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
DMZ7AMY	RU	https://pubmed.ncbi.nlm.nih.gov/32414908

DMZ7AMY	DI	DMZ7AMY
DMZ7AMY	DN	Amivantamab
DMZ7AMY	MI	TTNDSF4
DMZ7AMY	MN	Proto-oncogene c-Met (MET)
DMZ7AMY	MT	DTT
DMZ7AMY	MA	Inhibitor
DMZ7AMY	RN	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
DMZ7AMY	RU	https://pubmed.ncbi.nlm.nih.gov/32414908

DMB9587	DI	DMB9587
DMB9587	DN	Amocarzine
DMB9587	MI	TT1RS9F
DMB9587	MN	Acetylcholinesterase (AChE)
DMB9587	MT	DTT
DMB9587	MA	Inhibitor
DMB9587	RN	Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211.
DMB9587	RU	https://pubmed.ncbi.nlm.nih.gov/1359747

DM6SGUB	DI	DM6SGUB
DM6SGUB	DN	Amrubicin
DM6SGUB	MI	DE3N2FM
DM6SGUB	MN	NADPH-cytochrome P450 reductase (CPR)
DM6SGUB	MT	DME
DM6SGUB	MA	Metabolism
DM6SGUB	RN	Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
DM6SGUB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16418065

DM8QIRN	DI	DM8QIRN
DM8QIRN	DN	AMT-011
DM8QIRN	MI	TTOF3WZ
DM8QIRN	MN	Lipoprotein lipase (LPL)
DM8QIRN	MT	DTT
DM8QIRN	MA	Modulator
DM8QIRN	RN	Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70.
DM8QIRN	RU	https://pubmed.ncbi.nlm.nih.gov/23527320

DMSO02K	DI	DMSO02K
DMSO02K	DN	AMT-061
DMSO02K	MI	TTFEZ5Q
DMSO02K	MN	Coagulation factor IX (F9)
DMSO02K	MT	DTT
DMSO02K	RN	Clinical pipeline report, company report or official report of uniQure.
DMSO02K	RU	http://uniqure.com/gene-therapy/hemophilia.php

DMP2BFG	DI	DMP2BFG
DMP2BFG	DN	Anacetrapib
DMP2BFG	MI	TTFQAYR
DMP2BFG	MN	Cholesteryl ester transfer protein (CETP)
DMP2BFG	MT	DTT
DMP2BFG	MA	Inhibitor
DMP2BFG	RN	Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6.
DMP2BFG	RU	https://pubmed.ncbi.nlm.nih.gov/19552746

DMP2BFG	DI	DMP2BFG
DMP2BFG	DN	Anacetrapib
DMP2BFG	MI	DE4LYSA
DMP2BFG	MN	Cytochrome P450 3A4 (CYP3A4)
DMP2BFG	MT	DME
DMP2BFG	MA	Metabolism
DMP2BFG	RN	Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos. 2010 Mar;38(3):474-83.
DMP2BFG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20016053

DM2F9YO	DI	DM2F9YO
DM2F9YO	DN	Anakinra
DM2F9YO	MI	TTT7FOP
DM2F9YO	MN	HUMAN interleukin-1 receptor 1 (IL1R1)
DM2F9YO	MT	DTT
DM2F9YO	MA	Antagonist
DM2F9YO	RN	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166.
DM2F9YO	RU	http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_drug_name

DM6HXTS	DI	DM6HXTS
DM6HXTS	DN	Anamorelin
DM6HXTS	MI	TTHCF4J
DM6HXTS	MN	Alpha-glucosidase (GLA)
DM6HXTS	MT	DTT
DM6HXTS	MA	Modulator
DM6HXTS	RN	Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
DM6HXTS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23378626

DM6HXTS	DI	DM6HXTS
DM6HXTS	DN	Anamorelin
DM6HXTS	MI	TTWDC17
DM6HXTS	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM6HXTS	MT	DTT
DM6HXTS	MA	Stimulator
DM6HXTS	RN	Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73.
DM6HXTS	RU	https://pubmed.ncbi.nlm.nih.gov/19196529

DMK2Y4V	DI	DMK2Y4V
DMK2Y4V	DN	Ancrod
DMK2Y4V	MI	TTZUXYS
DMK2Y4V	MN	Vitamin K-dependent protein C (PROC)
DMK2Y4V	MT	DTT
DMK2Y4V	MA	Modulator
DMK2Y4V	RN	Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7.
DMK2Y4V	RU	https://pubmed.ncbi.nlm.nih.gov/2589675

DMLDB1X	DI	DMLDB1X
DMLDB1X	DN	Andecaliximab
DMLDB1X	MI	TT6X50U
DMLDB1X	MN	Matrix metalloproteinase-9 (MMP-9)
DMLDB1X	MT	DTT
DMLDB1X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLDB1X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMX36BH	DI	DMX36BH
DMX36BH	DN	Andolast
DMX36BH	MI	TT1VOHK
DMX36BH	MN	Potassium channel unspecific (KC)
DMX36BH	MT	DTT
DMX36BH	MA	Opener
DMX36BH	RN	BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46.
DMX36BH	RU	https://pubmed.ncbi.nlm.nih.gov/18473808

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DEOCWU3
DMITJAK	MN	Alcohol dehydrogenase class-II (ADH4)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem Biophys Res Commun. 2003 Mar 28;303(1):273-8.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12646198

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DEGQTXO
DMITJAK	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9578563

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DER0XCH
DMITJAK	MN	Farnesol dehydrogenase (AKR1B15)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	TTNJYV2
DMITJAK	MN	Gamma-aminobutyric acid receptor (GAR)
DMITJAK	MT	DTT
DMITJAK	MA	Inhibitor
DMITJAK	RN	Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
DMITJAK	RU	https://pubmed.ncbi.nlm.nih.gov/16854065

DMITJAK	DI	DMITJAK
DMITJAK	DN	Androsterone
DMITJAK	MI	DESD26P
DMITJAK	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMITJAK	MT	DME
DMITJAK	MA	Metabolism
DMITJAK	RN	Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
DMITJAK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10575553

DM76GZ0	DI	DM76GZ0
DM76GZ0	DN	Angiotensin-(1-7)
DM76GZ0	MI	DEGPI81
DM76GZ0	MN	Angiotensin-converting enzyme 2 (ACE2)
DM76GZ0	MT	DME
DM76GZ0	MA	Metabolism
DM76GZ0	RN	Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension. 1998 Jan;31(1 Pt 2):362-7.
DM76GZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9453329

DM76GZ0	DI	DM76GZ0
DM76GZ0	DN	Angiotensin-(1-7)
DM76GZ0	MI	TTOISYB
DM76GZ0	MN	Proto-oncogene Mas (MAS)
DM76GZ0	MT	DTT
DM76GZ0	MA	Agonist
DM76GZ0	RN	New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8.
DM76GZ0	RU	https://pubmed.ncbi.nlm.nih.gov/23166114

DM3FPAQ	DI	DM3FPAQ
DM3FPAQ	DN	Anifrolumab
DM3FPAQ	MI	TTMQB37
DM3FPAQ	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DM3FPAQ	MT	DTT
DM3FPAQ	MA	Antagonist
DM3FPAQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3FPAQ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMX0PWV	DI	DMX0PWV
DMX0PWV	DN	Anti-IL-23
DMX0PWV	MI	TT6H4QR
DMX0PWV	MN	Interleukin 23 receptor (IL23R)
DMX0PWV	MT	DTT
DMX0PWV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293).
DMX0PWV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293

DMUYOC8	DI	DMUYOC8
DMUYOC8	DN	AP12009
DMUYOC8	MI	TTY9TWO
DMUYOC8	MN	Transforming growth factor beta 2 (TGFB2)
DMUYOC8	MT	DTT
DMUYOC8	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMUYOC8	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMD8QTC	DI	DMD8QTC
DMD8QTC	DN	Apadenoson
DMD8QTC	MI	TTM2AOE
DMD8QTC	MN	Adenosine A2a receptor (ADORA2A)
DMD8QTC	MT	DTT
DMD8QTC	MA	Agonist
DMD8QTC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
DMD8QTC	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290

DMVY0BU	DI	DMVY0BU
DMVY0BU	DN	Apaziquone
DMVY0BU	MI	TTUTN1I
DMVY0BU	MN	Human Deoxyribonucleic acid (hDNA)
DMVY0BU	MT	DTT
DMVY0BU	MA	Modulator
DMVY0BU	RN	EO9 (Apaziquone): from the clinic to the laboratory and back again
DMVY0BU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569998

DMT0A3Y	DI	DMT0A3Y
DMT0A3Y	DN	APD-334
DMT0A3Y	MI	TT9JZCK
DMT0A3Y	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMT0A3Y	MT	DTT
DMT0A3Y	MA	Agonist
DMT0A3Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT0A3Y	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM4HQ52	DI	DM4HQ52
DM4HQ52	DN	APL-2
DM4HQ52	MI	TTJGY7A
DM4HQ52	MN	Complement C3 (CO3)
DM4HQ52	MT	DTT
DM4HQ52	MA	Inhibitor
DM4HQ52	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DM4HQ52	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMBRQF5	DI	DMBRQF5
DMBRQF5	DN	ApoC-III
DMBRQF5	MI	TT3GKN5
DMBRQF5	MN	Lipase unspecific (LIP)
DMBRQF5	MT	DTT
DMBRQF5	MA	Inhibitor
DMBRQF5	RN	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor Int J Clin Pract. 2008 May;62(5):799-809.
DMBRQF5	RU	https://pubmed.ncbi.nlm.nih.gov/18201179

DM1K78U	DI	DM1K78U
DM1K78U	DN	Apricitabine
DM1K78U	MI	TT84ETX
DM1K78U	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM1K78U	MT	DTT
DM1K78U	MA	Modulator
DM1K78U	RN	Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
DM1K78U	RU	https://www.ncbi.nlm.nih.gov/pubmed/18211121

DM2YQK8	DI	DM2YQK8
DM2YQK8	DN	AR-301
DM2YQK8	MI	TT5FLYB
DM2YQK8	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DM2YQK8	MT	DTT
DM2YQK8	MA	Inhibitor
DM2YQK8	RN	Clinical pipeline report, company report or official report of Aridis Pharmaceuticals.
DM2YQK8	RU	https://www.aridispharma.com/ar-301/

DMZB9RI	DI	DMZB9RI
DMZB9RI	DN	Arabaclofen
DMZB9RI	MI	TTDCVZW
DMZB9RI	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMZB9RI	MT	DTT
DMZB9RI	MA	Agonist
DMZB9RI	RN	Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
DMZB9RI	RU	https://pubmed.ncbi.nlm.nih.gov/23436129

DMO628K	DI	DMO628K
DMO628K	DN	Arbaclofen placarbil
DMO628K	MI	TTEX6LM
DMO628K	MN	GABA(A) receptor gamma-3 (GABRG3)
DMO628K	MT	DTT
DMO628K	MA	Agonist
DMO628K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO628K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMO628K	DI	DMO628K
DMO628K	DN	Arbaclofen placarbil
DMO628K	MI	TTDCVZW
DMO628K	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMO628K	MT	DTT
DMO628K	MA	Modulator
DMO628K	RN	Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
DMO628K	RU	https://www.ncbi.nlm.nih.gov/pubmed/19502531

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	DEVDYN7
DMYNJHI	MN	Cytochrome P450 2E1 (CYP2E1)
DMYNJHI	MT	DME
DMYNJHI	MA	Metabolism
DMYNJHI	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DMYNJHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	DE4LYSA
DMYNJHI	MN	Cytochrome P450 3A4 (CYP3A4)
DMYNJHI	MT	DME
DMYNJHI	MA	Metabolism
DMYNJHI	RN	Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull. 2004 Mar;27(3):415-7.
DMYNJHI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14993813

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	TTZIFHC
DMYNJHI	MN	Voltage-gated calcium channel alpha Cav1.2 (CACNA1C)
DMYNJHI	MT	DTT
DMYNJHI	MA	Inhibitor
DMYNJHI	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DMYNJHI	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DMYNJHI	DI	DMYNJHI
DMYNJHI	DN	Arc029
DMYNJHI	MI	TT7RGTM
DMYNJHI	MN	Voltage-gated calcium channel alpha Cav1.3 (CACNA1D)
DMYNJHI	MT	DTT
DMYNJHI	MA	Inhibitor
DMYNJHI	RN	Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
DMYNJHI	RU	https://pubmed.ncbi.nlm.nih.gov/2552119

DM180DM	DI	DM180DM
DM180DM	DN	ARGX-113
DM180DM	MI	TTKLPHO
DM180DM	MN	Neonatal Fc receptor (FCGRT)
DM180DM	MT	DTT
DM180DM	MA	Antagonist
DM180DM	RN	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.
DM180DM	RU	https://pubmed.ncbi.nlm.nih.gov/31118245

DM84AD1	DI	DM84AD1
DM84AD1	DN	Arofylline
DM84AD1	MI	TTV5CGO
DM84AD1	MN	Phosphodiesterase 4 (PDE4)
DM84AD1	MT	DTT
DM84AD1	MA	Inhibitor
DM84AD1	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM84AD1	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM02BVQ	DI	DM02BVQ
DM02BVQ	DN	ARQ-087
DM02BVQ	MI	TT0LF7H
DM02BVQ	MN	Fibroblast growth factor receptor (FGFR)
DM02BVQ	MT	DTT
DM02BVQ	MA	Antagonist
DM02BVQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM02BVQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM02BVQ	DI	DM02BVQ
DM02BVQ	DN	ARQ-087
DM02BVQ	MI	TTRLW2X
DM02BVQ	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM02BVQ	MT	DTT
DM02BVQ	MA	Inhibitor
DM02BVQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808).
DM02BVQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808

DML61S4	DI	DML61S4
DML61S4	DN	ARQ-151
DML61S4	MI	TTV5CGO
DML61S4	MN	Phosphodiesterase 4 (PDE4)
DML61S4	MT	DTT
DML61S4	MA	Inhibitor
DML61S4	RN	Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.
DML61S4	RU	https://pubmed.ncbi.nlm.nih.gov/32668113

DMD7XWS	DI	DMD7XWS
DMD7XWS	DN	AS-013
DMD7XWS	MI	TTG1QMU
DMD7XWS	MN	Prostaglandin E2 receptor EP1 (PTGER1)
DMD7XWS	MT	DTT
DMD7XWS	MA	Agonist
DMD7XWS	RN	Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
DMD7XWS	RU	https://pubmed.ncbi.nlm.nih.gov/9844994

DMIV1WR	DI	DMIV1WR
DMIV1WR	DN	AS-12141
DMIV1WR	MI	DEVSIE6
DMIV1WR	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DMIV1WR	MT	DME
DMIV1WR	MA	Metabolism
DMIV1WR	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DMIV1WR	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DMK09D4	DI	DMK09D4
DMK09D4	DN	ASC09 + ritonavir
DMK09D4	MI	TT1D53B
DMK09D4	MN	COVID-19 3C-like protease (3CLpro)
DMK09D4	MT	DTT
DMK09D4	MA	Inhibitor
DMK09D4	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMK09D4	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMWE3SC	DI	DMWE3SC
DMWE3SC	DN	ASC09 + ritonavir + oseltamivir
DMWE3SC	MI	TT1D53B
DMWE3SC	MN	COVID-19 3C-like protease (3CLpro)
DMWE3SC	MT	DTT
DMWE3SC	MA	Inhibitor
DMWE3SC	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMWE3SC	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMND3AB	DI	DMND3AB
DMND3AB	DN	Asimadoline
DMND3AB	MI	TTQW87Y
DMND3AB	MN	Opioid receptor kappa (OPRK1)
DMND3AB	MT	DTT
DMND3AB	MA	Agonist
DMND3AB	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMND3AB	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMND3AB	DI	DMND3AB
DMND3AB	DN	Asimadoline
DMND3AB	MI	DTUGYRD
DMND3AB	MN	P-glycoprotein 1 (ABCB1)
DMND3AB	MT	DTP
DMND3AB	MA	Substrate
DMND3AB	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMND3AB	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMVA8KU	DI	DMVA8KU
DMVA8KU	DN	ASP0113
DMVA8KU	MI	TTK938H
DMVA8KU	MN	Cytomegalovirus Deoxyribonucleic acid (CMV DNA)
DMVA8KU	MT	DTT
DMVA8KU	RN	VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009 Oct;11(5):572-8.
DMVA8KU	RU	https://pubmed.ncbi.nlm.nih.gov/19806506

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TT6DM01
DMZ1UOI	MN	Janus kinase 1 (JAK-1)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
DMZ1UOI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TTT7PJU
DMZ1UOI	MN	Janus kinase 3 (JAK-3)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
DMZ1UOI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	DECVGJ3
DMZ1UOI	MN	Nicotinamide N-methyltransferase (NNMT)
DMZ1UOI	MT	DME
DMZ1UOI	MA	Metabolism
DMZ1UOI	RN	Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
DMZ1UOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25986538

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	DE0P6LK
DMZ1UOI	MN	Sulfotransferase 2A1 (SULT2A1)
DMZ1UOI	MT	DME
DMZ1UOI	MA	Metabolism
DMZ1UOI	RN	Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica. 2015;45(10):887-902.
DMZ1UOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25986538

DMZ1UOI	DI	DMZ1UOI
DMZ1UOI	DN	Asp-015K
DMZ1UOI	MI	TTJSQEF
DMZ1UOI	MN	Tyrosine-protein kinase (PTK)
DMZ1UOI	MT	DTT
DMZ1UOI	MA	Inhibitor
DMZ1UOI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ1UOI	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMR71ST	DI	DMR71ST
DMR71ST	DN	ASP1929
DMR71ST	MI	TTGKNB4
DMR71ST	MN	Epidermal growth factor receptor (EGFR)
DMR71ST	MT	DTT
DMR71ST	MA	Inhibitor
DMR71ST	RN	ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
DMR71ST	RU	https://clinicaltrials.gov/ct2/show/NCT04305795

DMGQ1TV	DI	DMGQ1TV
DMGQ1TV	DN	ASP1941
DMGQ1TV	MI	TTLWPVF
DMGQ1TV	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMGQ1TV	MT	DTT
DMGQ1TV	MA	Modulator
DMGQ1TV	RN	Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
DMGQ1TV	RU	https://www.ncbi.nlm.nih.gov/pubmed/25685284

DM5N1OB	DI	DM5N1OB
DM5N1OB	DN	Asp-2151
DM5N1OB	MI	DE4LYSA
DM5N1OB	MN	Cytochrome P450 3A4 (CYP3A4)
DM5N1OB	MT	DME
DM5N1OB	MA	Metabolism
DM5N1OB	RN	Amenamevir: studies of potential CYP3A-mediated pharmacokinetic interactions with midazolam, cyclosporine, and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2018 Nov;7(8):844-859.
DM5N1OB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30044899

DM5N1OB	DI	DM5N1OB
DM5N1OB	DN	Asp-2151
DM5N1OB	MI	TTKCVJR
DM5N1OB	MN	Herpes simplex virus Helicase-primase (HSV UL8)
DM5N1OB	MT	DTT
DM5N1OB	MA	Inhibitor
DM5N1OB	RN	Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4.
DM5N1OB	RU	https://pubmed.ncbi.nlm.nih.gov/22155691

DMLY0H5	DI	DMLY0H5
DMLY0H5	DN	Astuprotimut-R
DMLY0H5	MI	TTWSKHD
DMLY0H5	MN	Melanoma-associated antigen 3 (MAGEA3)
DMLY0H5	MT	DTT
DMLY0H5	MA	Modulator
DMLY0H5	RN	National Cancer Institute Drug Dictionary (drug id 600553).
DMLY0H5	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600553

DM4HK8Z	DI	DM4HK8Z
DM4HK8Z	DN	ASTX727
DM4HK8Z	MI	TTHVCUP
DM4HK8Z	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DM4HK8Z	MT	DTT
DM4HK8Z	MA	Inhibitor
DM4HK8Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4HK8Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRV4DT	DI	DMRV4DT
DMRV4DT	DN	AT1001
DMRV4DT	MI	TTLC8E1
DMRV4DT	MN	Haptoglobin (HP)
DMRV4DT	MT	DTT
DMRV4DT	MA	Modulator
DMRV4DT	RN	Zonulin, regulation of tight junctions, and autoimmune diseases
DMRV4DT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384703

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTQ5LRD
DMVJW0S	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTIRY6K
DMVJW0S	MN	Cellular inhibitor of apoptosis 2 (BIRC3)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTS74QB
DMVJW0S	MN	Inhibitor of apoptosis protein (hIAP)
DMVJW0S	MT	DTT
DMVJW0S	MA	Modulator
DMVJW0S	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729).
DMVJW0S	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7729

DMVJW0S	DI	DMVJW0S
DMVJW0S	DN	AT-406
DMVJW0S	MI	TTR7B60
DMVJW0S	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMVJW0S	MT	DTT
DMVJW0S	MA	Inhibitor
DMVJW0S	RN	Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51.
DMVJW0S	RU	https://pubmed.ncbi.nlm.nih.gov/25520882

DMQ94CT	DI	DMQ94CT
DMQ94CT	DN	AT9283
DMQ94CT	MI	TTPS3C0
DMQ94CT	MN	Aurora kinase A (AURKA)
DMQ94CT	MT	DTT
DMQ94CT	MA	Modulator
DMQ94CT	RN	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
DMQ94CT	RU	https://pubmed.ncbi.nlm.nih.gov/25370467

DMQ94CT	DI	DMQ94CT
DMQ94CT	DN	AT9283
DMQ94CT	MI	TT5LS6T
DMQ94CT	MN	Aurora kinase B (AURKB)
DMQ94CT	MT	DTT
DMQ94CT	MA	Modulator
DMQ94CT	RN	A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
DMQ94CT	RU	https://pubmed.ncbi.nlm.nih.gov/25370467

DM8GFEV	DI	DM8GFEV
DM8GFEV	DN	Atacicept
DM8GFEV	MI	TTOI1RM
DM8GFEV	MN	A proliferation-inducing ligand (APRIL)
DM8GFEV	MT	DTT
DM8GFEV	MA	Modulator
DM8GFEV	RN	Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72.
DM8GFEV	RU	https://pubmed.ncbi.nlm.nih.gov/19779889

DM4GXW3	DI	DM4GXW3
DM4GXW3	DN	Ataluren
DM4GXW3	MI	TT2TNRM
DM4GXW3	MN	Dystrophin nonsense mutant (DMD)
DM4GXW3	MT	DTT
DM4GXW3	MA	Modulator
DM4GXW3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341).
DM4GXW3	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7341

DM4GXW3	DI	DM4GXW3
DM4GXW3	DN	Ataluren
DM4GXW3	MI	DE85D2P
DM4GXW3	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM4GXW3	MT	DME
DM4GXW3	MA	Metabolism
DM4GXW3	RN	Ataluren pharmacokinetics in healthy Japanese and Caucasian subjects. Clin Pharmacol Drug Dev. 2019 Feb;8(2):172-178.
DM4GXW3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30629861

DM3QLK2	DI	DM3QLK2
DM3QLK2	DN	Atamestane + Toremifene
DM3QLK2	MI	TTSZLWK
DM3QLK2	MN	Aromatase (CYP19A1)
DM3QLK2	MT	DTT
DM3QLK2	MA	Modulator
DM3QLK2	RN	Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
DM3QLK2	RU	https://pubmed.ncbi.nlm.nih.gov/17942301

DM4VJ5Q	DI	DM4VJ5Q
DM4VJ5Q	DN	ATG-Fresenius S
DM4VJ5Q	MI	TTXQYT6
DM4VJ5Q	MN	T-cells (T-cells)
DM4VJ5Q	MT	DTT
DM4VJ5Q	RN	Clinical pipeline report, company report or official report of Neovii Biotech.
DM4VJ5Q	RU	http://www.neoviibiotech.com/products-and-pipeline/atg-fresenius.html

DMBR0QK	DI	DMBR0QK
DMBR0QK	DN	Atorvastatin
DMBR0QK	MI	TTDJB68
DMBR0QK	MN	HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)
DMBR0QK	MT	DTT
DMBR0QK	MA	Inhibitor
DMBR0QK	RN	Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
DMBR0QK	RU	https://pubmed.ncbi.nlm.nih.gov/32347925

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DE4LYSA
DMM74PK	MN	Cytochrome P450 3A4 (CYP3A4)
DMM74PK	MT	DME
DMM74PK	MA	Metabolism
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16513443

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	TTKRD0G
DMM74PK	MN	Endothelin A receptor (EDNRA)
DMM74PK	MT	DTT
DMM74PK	MA	Antagonist
DMM74PK	RN	Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
DMM74PK	RU	https://pubmed.ncbi.nlm.nih.gov/12193124

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DTE2B1D
DMM74PK	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://doi.org/10.1016/j.clpt.2005.11.003

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DT3D8F0
DMM74PK	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMM74PK	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMM74PK	DI	DMM74PK
DMM74PK	DN	Atrasentan
DMM74PK	MI	DT9C1TS
DMM74PK	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMM74PK	MT	DTP
DMM74PK	MA	Substrate
DMM74PK	RN	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther. 2006 Mar;79(3):186-96.
DMM74PK	RU	https://doi.org/10.1016/j.clpt.2005.11.003

DM64WYC	DI	DM64WYC
DM64WYC	DN	Atx-101
DM64WYC	MI	TTLG1PD
DM64WYC	MN	Proliferating cell nuclear antigen (PCNA)
DM64WYC	MT	DTT
DM64WYC	MA	Immunomodulator
DM64WYC	RN	Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430.
DM64WYC	RU	https://pubmed.ncbi.nlm.nih.gov/23936203

DM0EQ9X	DI	DM0EQ9X
DM0EQ9X	DN	Av 133
DM0EQ9X	MI	TTNZRI3
DM0EQ9X	MN	Synaptic vesicle amine transporter (SLC18A2)
DM0EQ9X	MT	DTT
DM0EQ9X	MA	Enhancer
DM0EQ9X	RN	Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
DM0EQ9X	RU	https://pubmed.ncbi.nlm.nih.gov/24098749

DMPW5UF	DI	DMPW5UF
DMPW5UF	DN	Avalglucosidase alfa
DMPW5UF	MI	TTLPC70
DMPW5UF	MN	Lysosomal alpha-glucosidase (GAA)
DMPW5UF	MT	DTT
DMPW5UF	MA	Replacement
DMPW5UF	RN	ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
DMPW5UF	RU	https://clinicaltrials.gov/ct2/show/NCT02782741

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TT2J34L
DMA86FL	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/9371243

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTG8HIM
DMA86FL	MN	Dual specificity protein phosphatase 1 (DUSP1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTZJYKH
DMA86FL	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/18318466

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTR0SWN
DMA86FL	MN	M-phase inducer phosphatase 2 (MPIP2)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/19028102

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TT3PQ2Y
DMA86FL	MN	Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/10658902

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTJNTSI
DMA86FL	MN	Rotamase Pin1 (PIN1)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833. 
DMA86FL	RU	https://pubmed.ncbi.nlm.nih.gov/27258148

DMA86FL	DI	DMA86FL
DMA86FL	DN	Avastin+/-Tarceva
DMA86FL	MI	TTOHSBA
DMA86FL	MN	Vascular endothelial growth factor A (VEGFA)
DMA86FL	MT	DTT
DMA86FL	MA	Inhibitor
DMA86FL	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMA86FL	RU	http://www.gene.com/gene/pipeline/status/

DMRJK3U	DI	DMRJK3U
DMRJK3U	DN	Avotermin
DMRJK3U	MI	TTWOMY8
DMRJK3U	MN	Transforming growth factor beta 3 (TGFB3)
DMRJK3U	MT	DTT
DMRJK3U	MA	Modulator
DMRJK3U	RN	Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48.
DMRJK3U	RU	https://pubmed.ncbi.nlm.nih.gov/21793965

DMV1SOR	DI	DMV1SOR
DMV1SOR	DN	AVP-786
DMV1SOR	MI	TT5TPI6
DMV1SOR	MN	Opioid receptor sigma 1 (OPRS1)
DMV1SOR	MT	DTT
DMV1SOR	MA	Modulator
DMV1SOR	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMV1SOR	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DMV1SOR	DI	DMV1SOR
DMV1SOR	DN	AVP-786
DMV1SOR	MI	TT3ROYC
DMV1SOR	MN	Serotonin transporter (SERT)
DMV1SOR	MT	DTT
DMV1SOR	MA	Modulator
DMV1SOR	RN	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
DMV1SOR	RU	https://pubmed.ncbi.nlm.nih.gov/24648790

DM6WZG8	DI	DM6WZG8
DM6WZG8	DN	AXS-05
DM6WZG8	MI	TT9IK2Z
DM6WZG8	MN	N-methyl-D-aspartate receptor (NMDAR)
DM6WZG8	MT	DTT
DM6WZG8	MA	Antagonist
DM6WZG8	RN	Clinical pipeline report, company report or official report of Axsome Therapeutics.
DM6WZG8	RU	https://axsome.com/axs-pipeline/about-axs-05/

DMM6G5D	DI	DMM6G5D
DMM6G5D	DN	AZD0914
DMM6G5D	MI	TTN6J5F
DMM6G5D	MN	Bacterial DNA gyrase (Bact gyrase)
DMM6G5D	MT	DTT
DMM6G5D	MA	Modulator
DMM6G5D	RN	High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.Antimicrob Agents Chemother.2014 Sep;58(9):5585-8.
DMM6G5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/24982070

DM9SKW8	DI	DM9SKW8
DM9SKW8	DN	AZD5363
DM9SKW8	MI	TTWTSCV
DM9SKW8	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM9SKW8	MT	DTT
DM9SKW8	MA	Inhibitor
DM9SKW8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SKW8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9SKW8	DI	DM9SKW8
DM9SKW8	DN	AZD5363
DM9SKW8	MI	TTAZ05C
DM9SKW8	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM9SKW8	MT	DTT
DM9SKW8	MA	Modulator
DM9SKW8	RN	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5.
DM9SKW8	RU	https://pubmed.ncbi.nlm.nih.gov/25075128

DMLY9F1	DI	DMLY9F1
DMLY9F1	DN	Azetirelin
DMLY9F1	MI	TT4J8MF
DMLY9F1	MN	Thyrotropin-releasing hormone receptor (TRHR)
DMLY9F1	MT	DTT
DMLY9F1	MA	Modulator
DMLY9F1	RN	Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull. 1995 Jul;18(7):976-9.
DMLY9F1	RU	https://pubmed.ncbi.nlm.nih.gov/7581253

DMLY9F1	DI	DMLY9F1
DMLY9F1	DN	Azetirelin
DMLY9F1	MI	DEIZ2D9
DMLY9F1	MN	Tripeptidase (pepT)
DMLY9F1	MT	DME
DMLY9F1	MA	Metabolism
DMLY9F1	RN	Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms. Pharm Res. 1997 Aug;14(8):1004-7.
DMLY9F1	RU	https://pubmed.ncbi.nlm.nih.gov/9279880

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DECB0K3
DMUIBV8	MN	Cytochrome P450 2D6 (CYP2D6)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DE4LYSA
DMUIBV8	MN	Cytochrome P450 3A4 (CYP3A4)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	DEIBDNY
DMUIBV8	MN	Cytochrome P450 3A5 (CYP3A5)
DMUIBV8	MT	DME
DMUIBV8	MA	Metabolism
DMUIBV8	RN	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16052551

DMUIBV8	DI	DMUIBV8
DMUIBV8	DN	Azimilide
DMUIBV8	MI	TT1VOHK
DMUIBV8	MN	Potassium channel unspecific (KC)
DMUIBV8	MT	DTT
DMUIBV8	MA	Modulator
DMUIBV8	RN	Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
DMUIBV8	RU	https://www.ncbi.nlm.nih.gov/pubmed/10730550

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TTZGK1R
DM5Y4Q2	MN	HUMAN glycosylation of host receptor (GHR)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TTD16BI
DM5Y4Q2	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5Y4Q2	DI	DM5Y4Q2
DM5Y4Q2	DN	Azithromycin + hydroxychloroquine
DM5Y4Q2	MI	TT3A1EZ
DM5Y4Q2	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DM5Y4Q2	MT	DTT
DM5Y4Q2	MA	Inhibitor
DM5Y4Q2	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DM5Y4Q2	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMPV6B2	DI	DMPV6B2
DMPV6B2	DN	BA-058
DMPV6B2	MI	TTEPJL5
DMPV6B2	MN	Parathyroid hormone receptor (PTH2R)
DMPV6B2	MT	DTT
DMPV6B2	MA	Modulator
DMPV6B2	RN	Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul-Sep; 4(3): 147-152.
DMPV6B2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952405/

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	DES5XRU
DMXBHR6	MN	Cytochrome P450 2C8 (CYP2C8)
DMXBHR6	MT	DME
DMXBHR6	MA	Metabolism
DMXBHR6	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	DE4LYSA
DMXBHR6	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBHR6	MT	DME
DMXBHR6	MA	Metabolism
DMXBHR6	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMXBHR6	DI	DMXBHR6
DMXBHR6	DN	Balaglitazone
DMXBHR6	MI	TTZMAO3
DMXBHR6	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMXBHR6	MT	DTT
DMXBHR6	MA	Modulator
DMXBHR6	RN	Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
DMXBHR6	RU	https://www.ncbi.nlm.nih.gov/pubmed/22372600

DMUOFAC	DI	DMUOFAC
DMUOFAC	DN	Balixafortide
DMUOFAC	MI	TTBID49
DMUOFAC	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMUOFAC	MT	DTT
DMUOFAC	MA	Antagonist
DMUOFAC	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMUOFAC	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMKMTDG	DI	DMKMTDG
DMKMTDG	DN	Balovaptan
DMKMTDG	MI	TT4TFGN
DMKMTDG	MN	Vasopressin V1a receptor (V1AR)
DMKMTDG	MT	DTT
DMKMTDG	MA	Antagonist
DMKMTDG	RN	Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
DMKMTDG	RU	https://pubmed.ncbi.nlm.nih.gov/31951127

DMHQ5GK	DI	DMHQ5GK
DMHQ5GK	DN	Bapineuzumab
DMHQ5GK	MI	TTE4KHA
DMHQ5GK	MN	Amyloid beta A4 protein (APP)
DMHQ5GK	MT	DTT
DMHQ5GK	RN	Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
DMHQ5GK	RU	https://pubmed.ncbi.nlm.nih.gov/21091109

DMODA2X	DI	DMODA2X
DMODA2X	DN	Bardoxolone methyl
DMODA2X	MI	TTT2SVW
DMODA2X	MN	PPAR-gamma messenger RNA (PPARG mRNA)
DMODA2X	MT	DTT
DMODA2X	MA	Antagonist
DMODA2X	RN	A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
DMODA2X	RU	https://pubmed.ncbi.nlm.nih.gov/11043571

DMPRI14	DI	DMPRI14
DMPRI14	DN	Baricitinib
DMPRI14	MI	TTN9A16
DMPRI14	MN	HUMAN adaptor-associated kinase 1 (AAK1)
DMPRI14	MT	DTT
DMPRI14	MA	Inhibitor
DMPRI14	RN	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
DMPRI14	RU	https://pubmed.ncbi.nlm.nih.gov/32032529

DMPRI14	DI	DMPRI14
DMPRI14	DN	Baricitinib
DMPRI14	MI	TT0AGBL
DMPRI14	MN	HUMAN cyclin G-associated kinase (GAK)
DMPRI14	MT	DTT
DMPRI14	MA	Inhibitor
DMPRI14	RN	Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31.
DMPRI14	RU	https://pubmed.ncbi.nlm.nih.gov/32032529

DMB147A	DI	DMB147A
DMB147A	DN	BAX-817
DMB147A	MI	TTF0EGX
DMB147A	MN	Coagulation factor VII (F7)
DMB147A	MT	DTT
DMB147A	MA	Inhibitor
DMB147A	RN	Clinical pipeline report, company report or official report of Baxter.
DMB147A	RU	http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2025563

DM407I6	DI	DM407I6
DM407I6	DN	BAY 853934
DM407I6	MI	TTJQFBG
DM407I6	MN	HIF-prolyl hydroxylase (HPH)
DM407I6	MT	DTT
DM407I6	MA	Inhibitor
DM407I6	RN	Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
DM407I6	RU	https://pubmed.ncbi.nlm.nih.gov/29485740

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	DE4LYSA
DMPW5SB	MN	Cytochrome P450 3A4 (CYP3A4)
DMPW5SB	MT	DME
DMPW5SB	MA	Metabolism
DMPW5SB	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	TTROQ37
DMPW5SB	MN	MAPK/ERK kinase kinase (MAP3K)
DMPW5SB	MT	DTT
DMPW5SB	MA	Modulator
DMPW5SB	RN	RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/19706763

DMPW5SB	DI	DMPW5SB
DMPW5SB	DN	Bay 86-9766
DMPW5SB	MI	DEGTFWK
DMPW5SB	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMPW5SB	MT	DME
DMPW5SB	MA	Metabolism
DMPW5SB	RN	Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
DMPW5SB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23434733

DM09M3H	DI	DM09M3H
DM09M3H	DN	BAY 94-9027
DM09M3H	MI	TT1290U
DM09M3H	MN	Coagulation factor VIII (F8)
DM09M3H	MT	DTT
DM09M3H	MA	Modulator
DM09M3H	RN	Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.
DM09M3H	RU	https://pubmed.ncbi.nlm.nih.gov/24843882

DMWYPZF	DI	DMWYPZF
DMWYPZF	DN	BAY-35-3377
DMWYPZF	MI	TTN6J5F
DMWYPZF	MN	Bacterial DNA gyrase (Bact gyrase)
DMWYPZF	MT	DTT
DMWYPZF	MA	Inhibitor
DMWYPZF	RN	Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013 Oct;66(10):571-91. 
DMWYPZF	RU	https://pubmed.ncbi.nlm.nih.gov/24002361

DMQG7ZM	DI	DMQG7ZM
DMQG7ZM	DN	Belagenpumatucel-L
DMQG7ZM	MI	TTI0KH6
DMQG7ZM	MN	TGF beta-2 messenger RNA (TGFB2 mRNA)
DMQG7ZM	MT	DTT
DMQG7ZM	RN	National Cancer Institute Drug Dictionary (drug id 590662).
DMQG7ZM	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=590662

DM71CK8	DI	DM71CK8
DM71CK8	DN	Beloranib
DM71CK8	MI	TTZL0OI
DM71CK8	MN	Methionine aminopeptidase 2 (METAP2)
DM71CK8	MT	DTT
DM71CK8	MA	Inhibitor
DM71CK8	RN	2011 Pipeline of Zafgen.
DM71CK8	RU	http://www.zafgen.com/approach-pipeline.html

DMLU8NX	DI	DMLU8NX
DMLU8NX	DN	Benserazide
DMLU8NX	MI	TTN451K
DMLU8NX	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMLU8NX	MT	DTT
DMLU8NX	MA	Inhibitor
DMLU8NX	RN	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
DMLU8NX	RU	https://pubmed.ncbi.nlm.nih.gov/11346021

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	TTTKCMH
DMS9503	MN	Bacterial Penicillin binding protein 1 (Bact pbp)
DMS9503	MT	DTT
DMS9503	MA	Binder
DMS9503	RN	Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/11802794

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	TT85JMW
DMS9503	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DMS9503	MT	DTT
DMS9503	MA	Binder
DMS9503	RN	Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/11353613

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEV0KWQ
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DET9I1W
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/7492085

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DENJ2SQ
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DESIWFO
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/12234848

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEQX0DG
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. Antimicrob Agents Chemother. 1999 May;43(5):1270-3.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10223950

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DE37FJH
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Antimicrobial drugs used in the management of anaerobic infections in children. Drugs. 1983 Dec;26(6):520-9.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/6360636

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEAILCM
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10508011

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DERPJ4F
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/9371340

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEBAZ7H
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents. Antimicrob Agents Chemother. 1999 Oct;43(10):2383-8.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/10508011

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEA5OYT
DMS9503	MN	Beta-lactamase (blaB)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	Genetic and biochemical characterization of CGB-1, an Ambler class B carbapenem-hydrolyzing beta-lactamase from Chryseobacterium gleum. Antimicrob Agents Chemother. 2002 Sep;46(9):2791-6.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/12183230

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DEIU0XN
DMS9503	MN	N-acylhomoserine lactone acylase (lacA)
DMS9503	MT	DME
DMS9503	MA	Metabolism
DMS9503	RN	A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17.
DMS9503	RU	https://pubmed.ncbi.nlm.nih.gov/28455333

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTVP67E
DMS9503	MN	Organic anion transporter 3 (SLC22A8)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/21383204

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT3D8F0
DMS9503	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT9C1TS
DMS9503	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006 May;91(1):140-9.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/16495352

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTPFTEQ
DMS9503	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DTVNRXW
DMS9503	MN	Organic anion transporting polypeptide 3A1 (SLCO3A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT8H2IC
DMS9503	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
DMS9503	RU	http://www.ncbi.nlm.nih.gov/pubmed/10873595

DMS9503	DI	DMS9503
DMS9503	DN	Benzylpenicillin
DMS9503	MI	DT9G7XN
DMS9503	MN	Peptide transporter 1 (SLC15A1)
DMS9503	MT	DTP
DMS9503	MA	Substrate
DMS9503	RN	Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1136-63.
DMS9503	RU	https://doi.org/10.1016/j.addr.2006.07.024

DM6RWBN	DI	DM6RWBN
DM6RWBN	DN	Beperminogene perplasmid
DM6RWBN	MI	TTNDSF4
DM6RWBN	MN	Proto-oncogene c-Met (MET)
DM6RWBN	MT	DTT
DM6RWBN	MA	Modulator
DM6RWBN	RN	Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
DM6RWBN	RU	https://pubmed.ncbi.nlm.nih.gov/25190335

DMLVNTA	DI	DMLVNTA
DMLVNTA	DN	Besipirdine
DMLVNTA	MI	TTNGILX
DMLVNTA	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMLVNTA	MT	DTT
DMLVNTA	MA	Antagonist
DMLVNTA	RN	Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
DMLVNTA	RU	https://pubmed.ncbi.nlm.nih.gov/9103515

DM0MI81	DI	DM0MI81
DM0MI81	DN	Bevacizumab + Erlotinib
DM0MI81	MI	TTGKNB4
DM0MI81	MN	Epidermal growth factor receptor (EGFR)
DM0MI81	MT	DTT
DM0MI81	MA	Inhibitor
DM0MI81	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM0MI81	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM0MI81	DI	DM0MI81
DM0MI81	DN	Bevacizumab + Erlotinib
DM0MI81	MI	TTOHSBA
DM0MI81	MN	Vascular endothelial growth factor A (VEGFA)
DM0MI81	MT	DTT
DM0MI81	MA	Inhibitor
DM0MI81	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM0MI81	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9EXGI	DI	DM9EXGI
DM9EXGI	DN	Bevacizumab + Rituximab
DM9EXGI	MI	TTUE541
DM9EXGI	MN	Leukocyte surface antigen Leu-16 (CD20)
DM9EXGI	MT	DTT
DM9EXGI	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9EXGI	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9EXGI	DI	DM9EXGI
DM9EXGI	DN	Bevacizumab + Rituximab
DM9EXGI	MI	TTOHSBA
DM9EXGI	MN	Vascular endothelial growth factor A (VEGFA)
DM9EXGI	MT	DTT
DM9EXGI	MA	Inhibitor
DM9EXGI	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9EXGI	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TT6EO5L
DM9CEI5	MN	Erbb2 tyrosine kinase receptor (HER2)
DM9CEI5	MT	DTT
DM9CEI5	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9CEI5	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TTS4UGC
DM9CEI5	MN	Farnesoid X-activated receptor (FXR)
DM9CEI5	MT	DTT
DM9CEI5	MA	Antagonist
DM9CEI5	RN	Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
DM9CEI5	RU	https://pubmed.ncbi.nlm.nih.gov/12052824

DM9CEI5	DI	DM9CEI5
DM9CEI5	DN	Bevacizumab + Trastuzumab
DM9CEI5	MI	TTOHSBA
DM9CEI5	MN	Vascular endothelial growth factor A (VEGFA)
DM9CEI5	MT	DTT
DM9CEI5	MA	Inhibitor
DM9CEI5	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM9CEI5	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMK56G0	DI	DMK56G0
DMK56G0	DN	Bexagliflozin
DMK56G0	MI	TTF8JAT
DMK56G0	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMK56G0	MT	DTT
DMK56G0	MA	Inhibitor
DMK56G0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK56G0	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM7NJYC	DI	DM7NJYC
DM7NJYC	DN	BGB-A317
DM7NJYC	MI	TTNBFWK
DM7NJYC	MN	Programmed cell death protein 1 (PD-1)
DM7NJYC	MT	DTT
DM7NJYC	MA	Inhibitor
DM7NJYC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7NJYC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMNKBEC	DI	DMNKBEC
DMNKBEC	DN	BGJ398
DMNKBEC	MI	TT0LF7H
DMNKBEC	MN	Fibroblast growth factor receptor (FGFR)
DMNKBEC	MT	DTT
DMNKBEC	MA	Inhibitor
DMNKBEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNKBEC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNKBEC	DI	DMNKBEC
DMNKBEC	DN	BGJ398
DMNKBEC	MI	TTRLW2X
DMNKBEC	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMNKBEC	MT	DTT
DMNKBEC	MA	Modulator
DMNKBEC	RN	Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911.
DMNKBEC	RU	https://pubmed.ncbi.nlm.nih.gov/23129509

DM3MXT8	DI	DM3MXT8
DM3MXT8	DN	BI 201335
DM3MXT8	MI	TT5FNQT
DM3MXT8	MN	Human immunodeficiency virus Protease (HIV PR)
DM3MXT8	MT	DTT
DM3MXT8	MA	Inhibitor
DM3MXT8	RN	2011 Pipeline of Boehringer Ingelheim Pharma.
DM3MXT8	RU	http://www.boehringer-ingelheim.com/

DMH3XDR	DI	DMH3XDR
DMH3XDR	DN	BI 425809
DMH3XDR	MI	TTHJTF7
DMH3XDR	MN	Glycine transporter GlyT-1 (SLC6A9)
DMH3XDR	MT	DTT
DMH3XDR	MA	Inhibitor
DMH3XDR	RN	Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201.
DMH3XDR	RU	https://pubmed.ncbi.nlm.nih.gov/33610228

DMBH4FL	DI	DMBH4FL
DMBH4FL	DN	BI 655066
DMBH4FL	MI	TTC1GLB
DMBH4FL	MN	Interleukin-23 (IL23)
DMBH4FL	MT	DTT
DMBH4FL	RN	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
DMBH4FL	RU	https://pubmed.ncbi.nlm.nih.gov/25769911

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	DEJGDUW
DM42GP9	MN	Cytochrome P450 1A2 (CYP1A2)
DM42GP9	MT	DME
DM42GP9	MA	Metabolism
DM42GP9	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DM42GP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	DECB0K3
DM42GP9	MN	Cytochrome P450 2D6 (CYP2D6)
DM42GP9	MT	DME
DM42GP9	MA	Metabolism
DM42GP9	RN	In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab Dispos. 2007 Dec;35(12):2232-41.
DM42GP9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17881661

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	TTAWNKZ
DM42GP9	MN	Norepinephrine transporter (NET)
DM42GP9	MT	DTT
DM42GP9	MA	Modulator
DM42GP9	RN	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
DM42GP9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431

DM42GP9	DI	DM42GP9
DM42GP9	DN	Bicifadine
DM42GP9	MI	TT3ROYC
DM42GP9	MN	Serotonin transporter (SERT)
DM42GP9	MT	DTT
DM42GP9	MA	Modulator
DM42GP9	RN	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
DM42GP9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431

DM57B9J	DI	DM57B9J
DM57B9J	DN	Biferonex
DM57B9J	MI	TT4TZ8J
DM57B9J	MN	Interferon-beta (IFNB1)
DM57B9J	MT	DTT
DM57B9J	MA	Modulator
DM57B9J	RN	Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62.
DM57B9J	RU	https://pubmed.ncbi.nlm.nih.gov/19480465

DM51JW4	DI	DM51JW4
DM51JW4	DN	BIIB037
DM51JW4	MI	TTE4KHA
DM51JW4	MN	Amyloid beta A4 protein (APP)
DM51JW4	MT	DTT
DM51JW4	MA	Modulator
DM51JW4	RN	Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
DM51JW4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/

DM0AEDT	DI	DM0AEDT
DM0AEDT	DN	BIIB067
DM0AEDT	MI	TT6RVLG
DM0AEDT	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DM0AEDT	MT	DTT
DM0AEDT	MA	Inhibitor
DM0AEDT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0AEDT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMR9TF1	DI	DMR9TF1
DMR9TF1	DN	Bimekizumab
DMR9TF1	MI	TT2B6PS
DMR9TF1	MN	Cytokine ML-1 (IL17F)
DMR9TF1	MT	DTT
DMR9TF1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR9TF1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMR9TF1	DI	DMR9TF1
DMR9TF1	DN	Bimekizumab
DMR9TF1	MI	TTG0MT6
DMR9TF1	MN	Interleukin-17 (IL17)
DMR9TF1	MT	DTT
DMR9TF1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR9TF1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMS2GA1	DI	DMS2GA1
DMS2GA1	DN	Bindarit
DMS2GA1	MI	TTNAY0P
DMS2GA1	MN	Monocyte chemotactic and activating factor (CCL2)
DMS2GA1	MT	DTT
DMS2GA1	MA	Inhibitor
DMS2GA1	RN	Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
DMS2GA1	RU	https://pubmed.ncbi.nlm.nih.gov/22189654

DMVHF8G	DI	DMVHF8G
DMVHF8G	DN	Binodenoson
DMVHF8G	MI	TTM2AOE
DMVHF8G	MN	Adenosine A2a receptor (ADORA2A)
DMVHF8G	MT	DTT
DMVHF8G	MA	Agonist
DMVHF8G	RN	Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
DMVHF8G	RU	https://pubmed.ncbi.nlm.nih.gov/17531571

DME76AP	DI	DME76AP
DME76AP	DN	Bis(olanzapine) pamoate monohydrate
DME76AP	MI	TTYSN63
DME76AP	MN	5-HT 2 receptor (5HT2R)
DME76AP	MT	DTT
DME76AP	MA	Modulator
DME76AP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME76AP	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DME76AP	DI	DME76AP
DME76AP	DN	Bis(olanzapine) pamoate monohydrate
DME76AP	MI	TTEX248
DME76AP	MN	Dopamine D2 receptor (D2R)
DME76AP	MT	DTT
DME76AP	MA	Modulator
DME76AP	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DME76AP	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMW34B1	DI	DMW34B1
DMW34B1	DN	BL-8040
DMW34B1	MI	TTBID49
DMW34B1	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMW34B1	MT	DTT
DMW34B1	MA	Antagonist
DMW34B1	RN	The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).
DMW34B1	RU	http://www.bloodjournal.org/content/122/21/3939?sso-checked=true

DM7V9LH	DI	DM7V9LH
DM7V9LH	DN	Blisibimod
DM7V9LH	MI	TTWMIDN
DM7V9LH	MN	B-cell-activating factor (TNFSF13B)
DM7V9LH	MT	DTT
DM7V9LH	MA	Inhibitor
DM7V9LH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7V9LH	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	TTJQOD7
DM36C17	MN	5-HT 2A receptor (HTR2A)
DM36C17	MT	DTT
DM36C17	MA	Antagonist
DM36C17	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM36C17	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	DE4LYSA
DM36C17	MN	Cytochrome P450 3A4 (CYP3A4)
DM36C17	MT	DME
DM36C17	MA	Metabolism
DM36C17	RN	Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587-94.
DM36C17	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23766647

DM36C17	DI	DM36C17
DM36C17	DN	Blonanserin
DM36C17	MI	TTEX248
DM36C17	MN	Dopamine D2 receptor (D2R)
DM36C17	MT	DTT
DM36C17	MA	Antagonist
DM36C17	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM36C17	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMBXR23	DI	DMBXR23
DMBXR23	DN	BMN-110
DMBXR23	MI	TTT9YPO
DMBXR23	MN	N-acetylgalactosamine 6 sulfatase (GALNS)
DMBXR23	MT	DTT
DMBXR23	MA	Modulator
DMBXR23	RN	Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90.
DMBXR23	RU	https://pubmed.ncbi.nlm.nih.gov/24810369

DMM9XL2	DI	DMM9XL2
DMM9XL2	DN	BMN-111
DMM9XL2	MI	TTRK0B9
DMM9XL2	MN	C-type natriuretic peptide (NPPC)
DMM9XL2	MT	DTT
DMM9XL2	MA	Modulator
DMM9XL2	RN	Clinical pipeline report, company report or official report of Biomarin.
DMM9XL2	RU	https://www.bmrn.com/pipeline/clinical-trials/achondroplasia.php

DM94Y6O	DI	DM94Y6O
DM94Y6O	DN	BMN-701
DM94Y6O	MI	TTLPC70
DM94Y6O	MN	Lysosomal alpha-glucosidase (GAA)
DM94Y6O	MT	DTT
DM94Y6O	MA	Modulator
DM94Y6O	RN	Clinical pipeline report, company report or official report of BioMarin Pharma.
DM94Y6O	RU	https://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php

DMDAN8H	DI	DMDAN8H
DMDAN8H	DN	BMS-582664
DMDAN8H	MI	TTST7KB
DMDAN8H	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMDAN8H	MT	DTT
DMDAN8H	MA	Inhibitor
DMDAN8H	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMDAN8H	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMAR1YS	DI	DMAR1YS
DMAR1YS	DN	BMS-986165
DMAR1YS	MI	TTBYWP2
DMAR1YS	MN	TYK2 tyrosine kinase (TYK2)
DMAR1YS	MT	DTT
DMAR1YS	MA	Inhibitor
DMAR1YS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAR1YS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM3MAYQ	DI	DM3MAYQ
DM3MAYQ	DN	BMS-986205
DM3MAYQ	MI	TTZJYKH
DM3MAYQ	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM3MAYQ	MT	DTT
DM3MAYQ	MA	Inhibitor
DM3MAYQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3MAYQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2OBNW	DI	DM2OBNW
DM2OBNW	DN	Bococizumab
DM2OBNW	MI	TTBRG7E
DM2OBNW	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM2OBNW	MT	DTT
DM2OBNW	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DM2OBNW	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM6KRLW	DI	DM6KRLW
DM6KRLW	DN	BQ788
DM6KRLW	MI	TT3ZTGU
DM6KRLW	MN	Endothelin B receptor (EDNRB)
DM6KRLW	MT	DTT
DM6KRLW	MA	Antagonist
DM6KRLW	RN	BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71.
DM6KRLW	RU	https://pubmed.ncbi.nlm.nih.gov/10340767

DM942HP	DI	DM942HP
DM942HP	DN	Brivanib
DM942HP	MI	TTUTJGQ
DM942HP	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM942HP	MT	DTT
DM942HP	MA	Modulator
DM942HP	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM942HP	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMM0VO3	DI	DMM0VO3
DMM0VO3	DN	BSI-201
DMM0VO3	MI	TTEBCY8
DMM0VO3	MN	Poly [ADP-ribose] polymerase (PARP)
DMM0VO3	MT	DTT
DMM0VO3	MA	Modulator
DMM0VO3	RN	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
DMM0VO3	RU	https://pubmed.ncbi.nlm.nih.gov/22291137

DM50SNX	DI	DM50SNX
DM50SNX	DN	Bucelipase alfa
DM50SNX	MI	TTTRNQW
DM50SNX	MN	Bile-salt-activated lipase (CEL)
DM50SNX	MT	DTT
DM50SNX	MA	Modulator
DM50SNX	RN	ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health.
DM50SNX	RU	https://clinicaltrials.gov/ct2/show/NCT00743483

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTEUNMR
DM1WEHC	MN	PI3-kinase alpha (PIK3CA)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTTHBCA
DM1WEHC	MN	PI3-kinase beta (PIK3CB)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTGBPJE
DM1WEHC	MN	PI3-kinase delta (PIK3CD)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DM1WEHC	DI	DM1WEHC
DM1WEHC	DN	Buparlisib
DM1WEHC	MI	TTHBTOP
DM1WEHC	MN	PI3-kinase gamma (PIK3CG)
DM1WEHC	MT	DTT
DM1WEHC	MA	Inhibitor
DM1WEHC	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1WEHC	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTVBI8W
DMAR9ND	MN	Dopamine transporter (DAT)
DMAR9ND	MT	DTT
DMAR9ND	MA	Inhibitor
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTAWNKZ
DMAR9ND	MN	Norepinephrine transporter (NET)
DMAR9ND	MT	DTT
DMAR9ND	MA	Inhibitor
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMAR9ND	DI	DMAR9ND
DMAR9ND	DN	Bupropion+Naltrexone
DMAR9ND	MI	TTN4QDT
DMAR9ND	MN	Opioid receptor (OPR)
DMAR9ND	MT	DTT
DMAR9ND	MA	Antagonist
DMAR9ND	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMAR9ND	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DM6RUKX	DI	DM6RUKX
DM6RUKX	DN	BVT.2733
DM6RUKX	MI	TTN7BL9
DM6RUKX	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM6RUKX	MT	DTT
DM6RUKX	MA	Inhibitor
DM6RUKX	RN	Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62.
DM6RUKX	RU	https://pubmed.ncbi.nlm.nih.gov/12960099

DM1ARHT	DI	DM1ARHT
DM1ARHT	DN	BYM338
DM1ARHT	MI	TTX2DRI
DM1ARHT	MN	Activin receptor type IIA (ACVR2A)
DM1ARHT	MT	DTT
DM1ARHT	MA	Inhibitor
DM1ARHT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1ARHT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTY7ZHS
DMPTCYB	MN	Toll-like receptor 2 (TLR2)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTISGCA
DMPTCYB	MN	Toll-like receptor 4 (TLR4)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DMPTCYB	DI	DMPTCYB
DMPTCYB	DN	Cadi-05
DMPTCYB	MI	TTSHG0T
DMPTCYB	MN	Toll-like receptor 9 (TLR9)
DMPTCYB	MT	DTT
DMPTCYB	RN	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
DMPTCYB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTI7UX6
DM6CHNJ	MN	Breast cancer resistance protein (ABCG2)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells. Phytother Res. 2010 Jan;24(1):146-9.
DM6CHNJ	RU	https://doi.org/10.1002/ptr.2860

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	TTGTQHC
DM6CHNJ	MN	DNA topoisomerase I (TOP1)
DM6CHNJ	MT	DTT
DM6CHNJ	MA	Modulator
DM6CHNJ	RN	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
DM6CHNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16990856

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTFI42L
DM6CHNJ	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
DM6CHNJ	RU	https://doi.org/10.1007/s12033-009-9220-6

DM6CHNJ	DI	DM6CHNJ
DM6CHNJ	DN	Camptothecin
DM6CHNJ	MI	DTCSGPB
DM6CHNJ	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM6CHNJ	MT	DTP
DM6CHNJ	MA	Substrate
DM6CHNJ	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM6CHNJ	RU	https://doi.org/10.1007/s11095-012-0935-x

DMHJCGV	DI	DMHJCGV
DMHJCGV	DN	Candoxatril
DMHJCGV	MI	TT5TKPM
DMHJCGV	MN	Neutral endopeptidase (MME)
DMHJCGV	MT	DTT
DMHJCGV	MA	Inhibitor
DMHJCGV	RN	Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13.
DMHJCGV	RU	https://pubmed.ncbi.nlm.nih.gov/18379655

DM4FHQR	DI	DM4FHQR
DM4FHQR	DN	Canfosfamide
DM4FHQR	MI	TT40K12
DM4FHQR	MN	Glutathione S-transferase P (GSTP1)
DM4FHQR	MT	DTT
DM4FHQR	MA	Modulator
DM4FHQR	RN	Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78.
DM4FHQR	RU	https://pubmed.ncbi.nlm.nih.gov/24066958

DMMZDJ6	DI	DMMZDJ6
DMMZDJ6	DN	Captopril
DMMZDJ6	MI	TTGFNPD
DMMZDJ6	MN	HUMAN angiotensin-converting enzyme (ACE)
DMMZDJ6	MT	DTT
DMMZDJ6	MA	Inhibitor
DMMZDJ6	RN	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
DMMZDJ6	RU	https://pubmed.ncbi.nlm.nih.gov/32291526

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	DERSX5P
DMUVMWZ	MN	Cytochrome P450 2J2 (CYP2J2)
DMUVMWZ	MT	DME
DMUVMWZ	MA	Metabolism
DMUVMWZ	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMUVMWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	DE4LYSA
DMUVMWZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMUVMWZ	MT	DME
DMUVMWZ	MA	Metabolism
DMUVMWZ	RN	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
DMUVMWZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16896065

DMUVMWZ	DI	DMUVMWZ
DMUVMWZ	DN	Carebastine
DMUVMWZ	MI	TTTIBOJ
DMUVMWZ	MN	Histamine H1 receptor (H1R)
DMUVMWZ	MT	DTT
DMUVMWZ	MA	Antagonist
DMUVMWZ	RN	Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
DMUVMWZ	RU	https://pubmed.ncbi.nlm.nih.gov/16083326

DM4Y1SP	DI	DM4Y1SP
DM4Y1SP	DN	Carisbamate
DM4Y1SP	MI	TTRK8B9
DM4Y1SP	MN	Sodium channel unspecific (NaC)
DM4Y1SP	MT	DTT
DM4Y1SP	MA	Blocker
DM4Y1SP	RN	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
DM4Y1SP	RU	https://pubmed.ncbi.nlm.nih.gov/19008076

DM4Y1SP	DI	DM4Y1SP
DM4Y1SP	DN	Carisbamate
DM4Y1SP	MI	DEYGVN4
DM4Y1SP	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM4Y1SP	MT	DME
DM4Y1SP	MA	Metabolism
DM4Y1SP	RN	Carisbamate addon therapy for drugresistant partial epilepsy. The Cochrane Library. John Wiley Sons, Ltd, 2016.
DM4Y1SP	RU	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012121/full

DMPG4OM	DI	DMPG4OM
DMPG4OM	DN	CAZ AVI
DMPG4OM	MI	TTHI19T
DMPG4OM	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMPG4OM	MT	DTT
DMPG4OM	MA	Modulator
DMPG4OM	RN	NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
DMPG4OM	RU	https://pubmed.ncbi.nlm.nih.gov/22587688

DM097UP	DI	DM097UP
DM097UP	DN	CBT-1
DM097UP	MI	TT3OT40
DM097UP	MN	Multidrug resistance protein 1 (ABCB1)
DM097UP	MT	DTT
DM097UP	MA	Modulator
DM097UP	RN	A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512.
DM097UP	RU	https://www.ncbi.nlm.nih.gov/pubmed/22416063

DMV7WSN	DI	DMV7WSN
DMV7WSN	DN	CC-25430
DMV7WSN	MI	DE4LYSA
DMV7WSN	MN	Cytochrome P450 3A4 (CYP3A4)
DMV7WSN	MT	DME
DMV7WSN	MA	Metabolism
DMV7WSN	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMV7WSN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMTNQB0	DI	DMTNQB0
DMTNQB0	DN	CC-486
DMTNQB0	MI	TT6S2FE
DMTNQB0	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMTNQB0	MT	DTT
DMTNQB0	MA	Inhibitor
DMTNQB0	RN	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
DMTNQB0	RU	https://pubmed.ncbi.nlm.nih.gov/26442612

DMTNQB0	DI	DMTNQB0
DMTNQB0	DN	CC-486
DMTNQB0	MI	TTVDSZ0
DMTNQB0	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMTNQB0	MT	DTT
DMTNQB0	MA	Inhibitor
DMTNQB0	RN	Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
DMTNQB0	RU	https://pubmed.ncbi.nlm.nih.gov/12519059

DM5LQHB	DI	DM5LQHB
DM5LQHB	DN	CCX-168
DM5LQHB	MI	TTHXFA1
DM5LQHB	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DM5LQHB	MT	DTT
DM5LQHB	MA	Antagonist
DM5LQHB	RN	Clinical pipeline report, company report or official report of ChemoCentryx.
DM5LQHB	RU	http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/

DMWO5ZR	DI	DMWO5ZR
DMWO5ZR	DN	Cediranib
DMWO5ZR	MI	DE4LYSA
DMWO5ZR	MN	Cytochrome P450 3A4 (CYP3A4)
DMWO5ZR	MT	DME
DMWO5ZR	MA	Metabolism
DMWO5ZR	RN	In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010 Oct;38(10):1688-97.
DMWO5ZR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20634336

DMWO5ZR	DI	DMWO5ZR
DMWO5ZR	DN	Cediranib
DMWO5ZR	MI	TTUTJGQ
DMWO5ZR	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMWO5ZR	MT	DTT
DMWO5ZR	MA	Inhibitor
DMWO5ZR	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMWO5ZR	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMLWIU4	DI	DMLWIU4
DMLWIU4	DN	Cefluprenam
DMLWIU4	MI	TTJP4SM
DMLWIU4	MN	Bacterial Penicillin binding protein (Bact PBP)
DMLWIU4	MT	DTT
DMLWIU4	MA	Inhibitor
DMLWIU4	RN	Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7.
DMLWIU4	RU	https://pubmed.ncbi.nlm.nih.gov/1804003

DMM76GL	DI	DMM76GL
DMM76GL	DN	Ceftobiprole
DMM76GL	MI	TTJP4SM
DMM76GL	MN	Bacterial Penicillin binding protein (Bact PBP)
DMM76GL	MT	DTT
DMM76GL	MA	Modulator
DMM76GL	RN	Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4.
DMM76GL	RU	https://www.ncbi.nlm.nih.gov/pubmed/17470659

DMWLF2X	DI	DMWLF2X
DMWLF2X	DN	Ceftobiprole medocaril
DMWLF2X	MI	TTJP4SM
DMWLF2X	MN	Bacterial Penicillin binding protein (Bact PBP)
DMWLF2X	MT	DTT
DMWLF2X	MA	Binder
DMWLF2X	RN	Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509.
DMWLF2X	RU	https://pubmed.ncbi.nlm.nih.gov/30198789

DMIGX84	DI	DMIGX84
DMIGX84	DN	Cethromycin
DMIGX84	MI	TTLFGBV
DMIGX84	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMIGX84	MT	DTT
DMIGX84	MA	Inhibitor
DMIGX84	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMIGX84	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMIGX84	DI	DMIGX84
DMIGX84	DN	Cethromycin
DMIGX84	MI	DEIBDNY
DMIGX84	MN	Cytochrome P450 3A5 (CYP3A5)
DMIGX84	MT	DME
DMIGX84	MA	Metabolism
DMIGX84	RN	CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004 Jun;75(6):516-28.
DMIGX84	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15179406

DMWAHTN	DI	DMWAHTN
DMWAHTN	DN	Cetilistat
DMWAHTN	MI	TTKYZA9
DMWAHTN	MN	Gastric triacylglycerol lipase (LIPF)
DMWAHTN	MT	DTT
DMWAHTN	MA	Modulator
DMWAHTN	RN	Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9.
DMWAHTN	RU	https://pubmed.ncbi.nlm.nih.gov/16953261

DMX9K3W	DI	DMX9K3W
DMX9K3W	DN	Cetraxal Otic
DMX9K3W	MI	TTE72ID
DMX9K3W	MN	Haemophilus influenzae DNA gyrase A (Hae-influ gyrA)
DMX9K3W	MT	DTT
DMX9K3W	MA	Modulator
DMX9K3W	RN	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
DMX9K3W	RU	https://pubmed.ncbi.nlm.nih.gov/20534341

DMX9K3W	DI	DMX9K3W
DMX9K3W	DN	Cetraxal Otic
DMX9K3W	MI	TT1WJCI
DMX9K3W	MN	Streptococcus Topoisomerase IV A (Stre-coc parC)
DMX9K3W	MT	DTT
DMX9K3W	MA	Modulator
DMX9K3W	RN	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.
DMX9K3W	RU	https://pubmed.ncbi.nlm.nih.gov/20534341

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTHQPL7
DMIKMA9	MN	Carbonic anhydrase I (CA-I)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/26095375

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTANPDJ
DMIKMA9	MN	Carbonic anhydrase II (CA-II)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/26095375

DMIKMA9	DI	DMIKMA9
DMIKMA9	DN	CG-100649
DMIKMA9	MI	TTVKILB
DMIKMA9	MN	Prostaglandin G/H synthase 2 (COX-2)
DMIKMA9	MT	DTT
DMIKMA9	MA	Inhibitor
DMIKMA9	RN	Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210.
DMIKMA9	RU	https://pubmed.ncbi.nlm.nih.gov/25097102

DM1TJXA	DI	DM1TJXA
DM1TJXA	DN	Chloride
DM1TJXA	MI	TTTSOUD
DM1TJXA	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1TJXA	MT	DTT
DM1TJXA	MA	Modulator
DM1TJXA	RN	Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22.
DM1TJXA	RU	https://pubmed.ncbi.nlm.nih.gov/25902926

DM1TJXA	DI	DM1TJXA
DM1TJXA	DN	Chloride
DM1TJXA	MI	DE4LYSA
DM1TJXA	MN	Cytochrome P450 3A4 (CYP3A4)
DM1TJXA	MT	DME
DM1TJXA	MA	Metabolism
DM1TJXA	RN	Metabolism of benzalkonium chlorides by human hepatic cytochromes P450. Chem Res Toxicol. 2019 Dec 16;32(12):2466-2478.
DM1TJXA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31730751

DMORSFB	DI	DMORSFB
DMORSFB	DN	Chloroquine
DMORSFB	MI	TTZGK1R
DMORSFB	MN	HUMAN glycosylation of host receptor (GHR)
DMORSFB	MT	DTT
DMORSFB	MA	Inhibitor
DMORSFB	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMORSFB	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMORSFB	DI	DMORSFB
DMORSFB	DN	Chloroquine
DMORSFB	MI	TTD16BI
DMORSFB	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMORSFB	MT	DTT
DMORSFB	MA	Inhibitor
DMORSFB	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMORSFB	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM5X7DJ	DI	DM5X7DJ
DM5X7DJ	DN	Chlorpromazine
DM5X7DJ	MI	TTAIY2U
DM5X7DJ	MN	HUMAN clathrin-mediated endocytosis (RME)
DM5X7DJ	MT	DTT
DM5X7DJ	MA	Inhibitor
DM5X7DJ	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DM5X7DJ	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM0Q6CM	DI	DM0Q6CM
DM0Q6CM	DN	CIGB-300
DM0Q6CM	MI	TTZ5NI7
DM0Q6CM	MN	Casein kinase II (CSNK2)
DM0Q6CM	MT	DTT
DM0Q6CM	MA	Modulator
DM0Q6CM	RN	Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944.
DM0Q6CM	RU	https://pubmed.ncbi.nlm.nih.gov/25279177

DMP0NGX	DI	DMP0NGX
DMP0NGX	DN	Cilansetron
DMP0NGX	MI	TTPC4TU
DMP0NGX	MN	5-HT 3A receptor (HTR3A)
DMP0NGX	MT	DTT
DMP0NGX	MA	Modulator
DMP0NGX	RN	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
DMP0NGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15757394

DMEAOZ0	DI	DMEAOZ0
DMEAOZ0	DN	Cilengitide
DMEAOZ0	MI	TT69TQN
DMEAOZ0	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMEAOZ0	MT	DTT
DMEAOZ0	MA	Modulator
DMEAOZ0	RN	The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449.
DMEAOZ0	RU	https://www.ncbi.nlm.nih.gov/pubmed/19212436

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	DE4LYSA
DM1975O	MN	Cytochrome P450 3A4 (CYP3A4)
DM1975O	MT	DME
DM1975O	MA	Metabolism
DM1975O	RN	Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin. 2003 Mar;24(3):263-8.
DM1975O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12617777

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	TT4FDG6
DM1975O	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DM1975O	MT	DTT
DM1975O	MA	Blocker
DM1975O	RN	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
DM1975O	RU	https://pubmed.ncbi.nlm.nih.gov/12011661

DM1975O	DI	DM1975O
DM1975O	DN	Cilnidipine
DM1975O	MI	TTXHYV6
DM1975O	MN	Voltage-gated L-type calcium channel (L-CaC)
DM1975O	MT	DTT
DM1975O	MA	Blocker
DM1975O	RN	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
DM1975O	RU	https://pubmed.ncbi.nlm.nih.gov/12011661

DMU2J7Y	DI	DMU2J7Y
DMU2J7Y	DN	Ciltacabtagene autoleucel
DMU2J7Y	MI	TTZ3P4W
DMU2J7Y	MN	B-cell maturation protein (TNFRSF17)
DMU2J7Y	MT	DTT
DMU2J7Y	RN	ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
DMU2J7Y	RU	https://clinicaltrials.gov/ct2/show/NCT04181827

DMEGFYD	DI	DMEGFYD
DMEGFYD	DN	Cinitapride
DMEGFYD	MI	DES5XRU
DMEGFYD	MN	Cytochrome P450 2C8 (CYP2C8)
DMEGFYD	MT	DME
DMEGFYD	MA	Metabolism
DMEGFYD	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DMEGFYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DMEGFYD	DI	DMEGFYD
DMEGFYD	DN	Cinitapride
DMEGFYD	MI	DE4LYSA
DMEGFYD	MN	Cytochrome P450 3A4 (CYP3A4)
DMEGFYD	MT	DME
DMEGFYD	MA	Metabolism
DMEGFYD	RN	The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 Jul;35(7):1149-56.
DMEGFYD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17437965

DM803GL	DI	DM803GL
DM803GL	DN	CIPEMASTAT
DM803GL	MI	TTMX39J
DM803GL	MN	Matrix metalloproteinase-1 (MMP-1)
DM803GL	MT	DTT
DM803GL	MA	Modulator
DM803GL	RN	Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
DM803GL	RU	https://pubmed.ncbi.nlm.nih.gov/24491581

DM803GL	DI	DM803GL
DM803GL	DN	CIPEMASTAT
DM803GL	MI	TTGA1IV
DM803GL	MN	Matrix metalloproteinase-8 (MMP-8)
DM803GL	MT	DTT
DM803GL	MA	Modulator
DM803GL	RN	Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
DM803GL	RU	https://pubmed.ncbi.nlm.nih.gov/24491581

DMJ9ZIY	DI	DMJ9ZIY
DMJ9ZIY	DN	CK-2017357
DMJ9ZIY	MI	TTYUMF5
DMJ9ZIY	MN	Fast skeletal muscle troponin complex (TNNC2)
DMJ9ZIY	MT	DTT
DMJ9ZIY	MA	Modulator
DMJ9ZIY	RN	Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5.
DMJ9ZIY	RU	https://pubmed.ncbi.nlm.nih.gov/22344294

DMTSONL	DI	DMTSONL
DMTSONL	DN	Claritin/Singulair
DMTSONL	MI	TTGKOY9
DMTSONL	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMTSONL	MT	DTT
DMTSONL	MA	Modulator
DMTSONL	RN	Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48.
DMTSONL	RU	https://pubmed.ncbi.nlm.nih.gov/11533366

DMPQR1D	DI	DMPQR1D
DMPQR1D	DN	Claudiximab
DMPQR1D	MI	TT6PKBX
DMPQR1D	MN	Claudin-18 (CLDN18)
DMPQR1D	MT	DTT
DMPQR1D	RN	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9.
DMPQR1D	RU	https://pubmed.ncbi.nlm.nih.gov/23900716

DMQSBX4	DI	DMQSBX4
DMQSBX4	DN	Clazosentan
DMQSBX4	MI	TTKRD0G
DMQSBX4	MN	Endothelin A receptor (EDNRA)
DMQSBX4	MT	DTT
DMQSBX4	MA	Antagonist
DMQSBX4	RN	Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
DMQSBX4	RU	https://pubmed.ncbi.nlm.nih.gov/17700991

DMQSBX4	DI	DMQSBX4
DMQSBX4	DN	Clazosentan
DMQSBX4	MI	TTCV6O0
DMQSBX4	MN	Endothelin receptor (EDNR)
DMQSBX4	MT	DTT
DMQSBX4	MA	Antagonist
DMQSBX4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSBX4	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMR21Q3	DI	DMR21Q3
DMR21Q3	DN	Clevudine
DMR21Q3	MI	TTS5K1M
DMR21Q3	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DMR21Q3	MT	DTT
DMR21Q3	MA	Inhibitor
DMR21Q3	RN	2011 Pipeline of Bukwang.
DMR21Q3	RU	http://bkmedical.en.ecplaza.net/

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEJVYAZ
DMSPN58	MN	Cytochrome P450 2A6 (CYP2A6)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEPKLMQ
DMSPN58	MN	Cytochrome P450 2B6 (CYP2B6)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DE4LYSA
DMSPN58	MN	Cytochrome P450 3A4 (CYP3A4)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	TTEX6LM
DMSPN58	MN	GABA(A) receptor gamma-3 (GABRG3)
DMSPN58	MT	DTT
DMSPN58	MA	Modulator
DMSPN58	RN	Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/12359265

DMSPN58	DI	DMSPN58
DMSPN58	DN	Clomethiazole
DMSPN58	MI	DEGTFWK
DMSPN58	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMSPN58	MT	DME
DMSPN58	MA	Metabolism
DMSPN58	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMSPN58	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMFQ1WX	DI	DMFQ1WX
DMFQ1WX	DN	CLS006
DMFQ1WX	MI	TTL3N71
DMFQ1WX	MN	Virus Replication (Viru Repli)
DMFQ1WX	MT	DTT
DMFQ1WX	MA	Inhibitor
DMFQ1WX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFQ1WX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TTSQIFT
DMASPWR	MN	5-HT 1A receptor (HTR1A)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TT4C8EA
DMASPWR	MN	Dopamine D3 receptor (D3R)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TTE0A2F
DMASPWR	MN	Dopamine D4 receptor (D4R)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMASPWR	DI	DMASPWR
DMASPWR	DN	CM-2395
DMASPWR	MI	TT5TPI6
DMASPWR	MN	Opioid receptor sigma 1 (OPRS1)
DMASPWR	MT	DTT
DMASPWR	MA	Agonist
DMASPWR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
DMASPWR	RU	http://adisinsight.springer.com/drugs/800031127

DMLMN2F	DI	DMLMN2F
DMLMN2F	DN	CM-AT
DMLMN2F	MI	TT7MRGU
DMLMN2F	MN	Chymotrypsin (CTR)
DMLMN2F	MT	DTT
DMLMN2F	MA	Modulator
DMLMN2F	RN	Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4.
DMLMN2F	RU	https://pubmed.ncbi.nlm.nih.gov/20697394

DMC4X7L	DI	DMC4X7L
DMC4X7L	DN	CMS-024-02
DMC4X7L	MI	TTBH0VX
DMC4X7L	MN	Histone deacetylase (HDAC)
DMC4X7L	MT	DTT
DMC4X7L	MA	Modulator
DMC4X7L	RN	US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
DMC4X7L	RU	http://www.google.com/patents/US20120302505

DM9Y3B5	DI	DM9Y3B5
DM9Y3B5	DN	CMX-001
DM9Y3B5	MI	TTATL6Y
DM9Y3B5	MN	DNA-dependent DNA polymerase (DPOL)
DM9Y3B5	MT	DTT
DM9Y3B5	MA	Inhibitor
DM9Y3B5	RN	Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797.
DM9Y3B5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274371/

DMB4JPG	DI	DMB4JPG
DMB4JPG	DN	CNTX-4975
DMB4JPG	MI	TTMI6F5
DMB4JPG	MN	Transient receptor potential cation channel V1 (TRPV1)
DMB4JPG	MT	DTT
DMB4JPG	MA	Agonist
DMB4JPG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB4JPG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWZ2TU	DI	DMWZ2TU
DMWZ2TU	DN	CO-1686
DMWZ2TU	MI	TTGKNB4
DMWZ2TU	MN	Epidermal growth factor receptor (EGFR)
DMWZ2TU	MT	DTT
DMWZ2TU	MA	Modulator
DMWZ2TU	RN	Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
DMWZ2TU	RU	https://pubmed.ncbi.nlm.nih.gov/25923550

DMN9ETB	DI	DMN9ETB
DMN9ETB	DN	Contusugene ladenovec
DMN9ETB	MI	TT7SBF5
DMN9ETB	MN	Cellular tumor antigen p53 (TP53)
DMN9ETB	MT	DTT
DMN9ETB	MA	Modulator
DMN9ETB	RN	A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
DMN9ETB	RU	https://pubmed.ncbi.nlm.nih.gov/19169960

DMA0WEK	DI	DMA0WEK
DMA0WEK	DN	Coprexa
DMA0WEK	MI	TT6RVLG
DMA0WEK	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMA0WEK	MT	DTT
DMA0WEK	MA	Inhibitor
DMA0WEK	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMA0WEK	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMBS3UG	DI	DMBS3UG
DMBS3UG	DN	CORT-125134
DMBS3UG	MI	TTYRL6O
DMBS3UG	MN	Glucocorticoid receptor (NR3C1)
DMBS3UG	MT	DTT
DMBS3UG	MA	Antagonist
DMBS3UG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBS3UG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMEAOL	DI	DMMEAOL
DMMEAOL	DN	Coversin
DMMEAOL	MI	TTKANGO
DMMEAOL	MN	Complement C5 (CO5)
DMMEAOL	MT	DTT
DMMEAOL	MA	Inhibitor
DMMEAOL	RN	Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258.
DMMEAOL	RU	https://pubmed.ncbi.nlm.nih.gov/29296765

DMZIM37	DI	DMZIM37
DMZIM37	DN	CP-868596
DMZIM37	MI	TT8FYO9
DMZIM37	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMZIM37	MT	DTT
DMZIM37	MA	Modulator
DMZIM37	RN	The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
DMZIM37	RU	https://www.ncbi.nlm.nih.gov/pubmed/25597754

DMZIM37	DI	DMZIM37
DMZIM37	DN	CP-868596
DMZIM37	MI	TT6PKBN
DMZIM37	MN	Proto-oncogene c-Src (SRC)
DMZIM37	MT	DTT
DMZIM37	MA	Inhibitor
DMZIM37	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZIM37	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2EO5M	DI	DM2EO5M
DM2EO5M	DN	CPC-211
DM2EO5M	MI	DEQPEMB
DM2EO5M	MN	Glutathione S-transferase zeta-1 (GSTZ1)
DM2EO5M	MT	DME
DM2EO5M	MA	Metabolism
DM2EO5M	RN	Personalized dosing of dichloroacetate using GSTZ1 clinical genotyping assay. Genet Test Mol Biomarkers. 2018 Apr;22(4):266-269.
DM2EO5M	RU	https://pubmed.ncbi.nlm.nih.gov/29641284

DMPXOYJ	DI	DMPXOYJ
DMPXOYJ	DN	CPI-0610
DMPXOYJ	MI	TTE4BSY
DMPXOYJ	MN	Bromodomain and extraterminal domain protein (BET)
DMPXOYJ	MT	DTT
DMPXOYJ	MA	Inhibitor
DMPXOYJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXOYJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPXOYJ	DI	DMPXOYJ
DMPXOYJ	DN	CPI-0610
DMPXOYJ	MI	TTRA6BO
DMPXOYJ	MN	Bromodomain-containing protein 4 (BRD4)
DMPXOYJ	MT	DTT
DMPXOYJ	MA	Modulator
DMPXOYJ	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMPXOYJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DM5XUQL	DI	DM5XUQL
DM5XUQL	DN	CPI-613
DM5XUQL	MI	TTH8T6I
DM5XUQL	MN	Alpha-ketoglutarate dehydrogenase (OGDH)
DM5XUQL	MT	DTT
DM5XUQL	MA	Modulator
DM5XUQL	RN	A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4.
DM5XUQL	RU	https://pubmed.ncbi.nlm.nih.gov/24612826

DM62E7C	DI	DM62E7C
DM62E7C	DN	CPL-7075
DM62E7C	MI	TTF8CQI
DM62E7C	MN	Tumor necrosis factor (TNF)
DM62E7C	MT	DTT
DM62E7C	MA	Inhibitor
DM62E7C	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM62E7C	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM60TVK	DI	DM60TVK
DM60TVK	DN	CQA 206-291
DM60TVK	MI	TTEX248
DM60TVK	MN	Dopamine D2 receptor (D2R)
DM60TVK	MT	DTT
DM60TVK	MA	Agonist
DM60TVK	RN	The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9.
DM60TVK	RU	https://pubmed.ncbi.nlm.nih.gov/2565766

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	DTPKTHL
DMKD2BQ	MN	Creatine transporter 1 (SLC6A8)
DMKD2BQ	MT	DTP
DMKD2BQ	MA	Substrate
DMKD2BQ	RN	Astrocytic -aminobutyric acid (GABA) transporters mediate guanidinoacetate transport in rat brain. 2018 Feb;113:1-7.
DMKD2BQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/29175673

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	TTZ1DV7
DMKD2BQ	MN	Mitochondrial function (MF)
DMKD2BQ	MT	DTT
DMKD2BQ	MA	Modulator
DMKD2BQ	RN	The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207.
DMKD2BQ	RU	https://pubmed.ncbi.nlm.nih.gov/16055197

DMKD2BQ	DI	DMKD2BQ
DMKD2BQ	DN	Creatine ALS-08
DMKD2BQ	MI	DTZOKFJ
DMKD2BQ	MN	Monocarboxylate transporter 12 (SLC16A12)
DMKD2BQ	MT	DTP
DMKD2BQ	MA	Substrate
DMKD2BQ	RN	Mutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria. J Am Soc Nephrol. 2016 May;27(5):1426-36.
DMKD2BQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/26376857

DM7QI29	DI	DM7QI29
DM7QI29	DN	Crenezumab
DM7QI29	MI	TTE4KHA
DM7QI29	MN	Amyloid beta A4 protein (APP)
DM7QI29	MT	DTT
DM7QI29	MA	Modulator
DM7QI29	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM7QI29	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DM5F24X	DI	DM5F24X
DM5F24X	DN	Crocin
DM5F24X	MI	DTUGYRD
DM5F24X	MN	P-glycoprotein 1 (ABCB1)
DM5F24X	MT	DTP
DM5F24X	MA	Substrate
DM5F24X	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DM5F24X	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DM67P0F	DI	DM67P0F
DM67P0F	DN	CS-038
DM67P0F	MI	TTJ584C
DM67P0F	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM67P0F	MT	DTT
DM67P0F	MA	Modulator
DM67P0F	RN	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
DM67P0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/18065097

DM67P0F	DI	DM67P0F
DM67P0F	DN	CS-038
DM67P0F	MI	TTZMAO3
DM67P0F	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM67P0F	MT	DTT
DM67P0F	MA	Modulator
DM67P0F	RN	Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
DM67P0F	RU	https://www.ncbi.nlm.nih.gov/pubmed/18065097

DMSY0NE	DI	DMSY0NE
DMSY0NE	DN	CS1001
DMSY0NE	MI	TT8ZLTI
DMSY0NE	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSY0NE	MT	DTT
DMSY0NE	RN	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
DMSY0NE	RU	https://pubmed.ncbi.nlm.nih.gov/33209620

DM1PV4Y	DI	DM1PV4Y
DM1PV4Y	DN	CS-600G
DM1PV4Y	MI	DEB3CV1
DM1PV4Y	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DM1PV4Y	MT	DME
DM1PV4Y	MA	Metabolism
DM1PV4Y	RN	Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
DM1PV4Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30072626

DM4CSDH	DI	DM4CSDH
DM4CSDH	DN	CS-8958
DM4CSDH	MI	TT50QJ3
DM4CSDH	MN	Influenza Neuraminidase (Influ NA)
DM4CSDH	MT	DTT
DM4CSDH	MA	Inhibitor
DM4CSDH	RN	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
DM4CSDH	RU	https://pubmed.ncbi.nlm.nih.gov/19067613

DMV574J	DI	DMV574J
DMV574J	DN	CSL312
DMV574J	MI	TTMXD0O
DMV574J	MN	Coagulation factor XII (F12)
DMV574J	MT	DTT
DMV574J	MA	Inhibitor
DMV574J	RN	Clinical pipeline report, company report or official report of CSL Behring.
DMV574J	RU	https://www.cslbehring.com/r-and-d/product-pipeline

DMZJGVL	DI	DMZJGVL
DMZJGVL	DN	CSL-654
DMZJGVL	MI	TTFEZ5Q
DMZJGVL	MN	Coagulation factor IX (F9)
DMZJGVL	MT	DTT
DMZJGVL	MA	Modulator
DMZJGVL	RN	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411.
DMZJGVL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448255/

DMU2ZFK	DI	DMU2ZFK
DMU2ZFK	DN	CT-2584
DMU2ZFK	MI	TTUAIKM
DMU2ZFK	MN	Cholinephosphate cytidylyltransferase (PCYT1B)
DMU2ZFK	MT	DTT
DMU2ZFK	MA	Modulator
DMU2ZFK	RN	Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13.
DMU2ZFK	RU	https://pubmed.ncbi.nlm.nih.gov/11016649

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTXV4FI
DMQPH29	MN	Albendazole monooxygenase (CYP3A4)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18249473

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTE4KHA
DMQPH29	MN	Amyloid beta A4 protein (APP)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/17004725

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTUNARX
DMQPH29	MN	Carbonic anhydrase (CA)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHQPL7
DMQPH29	MN	Carbonic anhydrase I (CA-I)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTANPDJ
DMQPH29	MN	Carbonic anhydrase II (CA-II)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTZHA0O
DMQPH29	MN	Carbonic anhydrase IV (CA-IV)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT2LVK8
DMQPH29	MN	Carbonic anhydrase IX (CA-IX)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTCFSPE
DMQPH29	MN	Carbonic anhydrase VI (CA-VI)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTSYM0R
DMQPH29	MN	Carbonic anhydrase XII (CA-XII)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTEYTKG
DMQPH29	MN	Carbonic anhydrase XIV (CA-XIV)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHVCUP
DMQPH29	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT6VZ78
DMQPH29	MN	DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/20006515

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTHY57M
DMQPH29	MN	Matrix metalloproteinase-13 (MMP-13)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18358729

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT6X50U
DMQPH29	MN	Matrix metalloproteinase-9 (MMP-9)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19128977

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT0JLSD
DMQPH29	MN	Multidrug resistance protein (MDR)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEZWDKE
DMQPH29	MN	NADPH-dependent curcumin reductase (curA)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/21467222

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTF10I9
DMQPH29	MN	Nitric-oxide synthase inducible (NOS2)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/18077363

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DTUGYRD
DMQPH29	MN	P-glycoprotein 1 (ABCB1)
DMQPH29	MT	DTP
DMQPH29	MA	Substrate
DMQPH29	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMQPH29	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT8NGED
DMQPH29	MN	Prostaglandin G/H synthase 1 (COX-1)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/15780608

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TTVKILB
DMQPH29	MN	Prostaglandin G/H synthase 2 (COX-2)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/15780608

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEYGVN4
DMQPH29	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DEZO4N3
DMQPH29	MN	UDP-glucuronosyltransferase 1A7 (UGT1A7)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DE2GB8N
DMQPH29	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	DE85D2P
DMQPH29	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMQPH29	MT	DME
DMQPH29	MA	Metabolism
DMQPH29	RN	Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
DMQPH29	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14557274

DMQPH29	DI	DMQPH29
DMQPH29	DN	Curcumin
DMQPH29	MI	TT7RJY8
DMQPH29	MN	Xanthine dehydrogenase/oxidase (XDH)
DMQPH29	MT	DTT
DMQPH29	MA	Inhibitor
DMQPH29	RN	Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
DMQPH29	RU	https://pubmed.ncbi.nlm.nih.gov/19388706

DMIQ31Y	DI	DMIQ31Y
DMIQ31Y	DN	Custirsen
DMIQ31Y	MI	TTRL76H
DMIQ31Y	MN	Clusterin messenger RNA (Clusterin mRNA)
DMIQ31Y	MT	DTT
DMIQ31Y	RN	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54.
DMIQ31Y	RU	https://pubmed.ncbi.nlm.nih.gov/19342222

DM0JA9N	DI	DM0JA9N
DM0JA9N	DN	Cyrtominetin
DM0JA9N	MI	TT5FLYB
DM0JA9N	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DM0JA9N	MT	DTT
DM0JA9N	MA	Modulator
DM0JA9N	RN	Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8.
DM0JA9N	RU	https://pubmed.ncbi.nlm.nih.gov/23376250

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTF4E0J
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-2 (CHRNA2)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16640326

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TT4H1MQ
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-4 (CHRNA4)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTLA931
DMUF0BJ	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16171993

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TT5KPZR
DMUF0BJ	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/16934977

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTTVAFQ
DMUF0BJ	MN	Neuronal acetylcholine receptor beta-4 (CHRNB4)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Inhibitor
DMUF0BJ	RN	Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2316-9.
DMUF0BJ	RU	https://pubmed.ncbi.nlm.nih.gov/18356044

DMUF0BJ	DI	DMUF0BJ
DMUF0BJ	DN	CYTISINE
DMUF0BJ	MI	TTJSZTB
DMUF0BJ	MN	Nicotinic acetylcholine receptor (nAChR)
DMUF0BJ	MT	DTT
DMUF0BJ	MA	Antagonist
DMUF0BJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUF0BJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMYJ2QB	DI	DMYJ2QB
DMYJ2QB	DN	D2A21
DMYJ2QB	MI	TTXT4D5
DMYJ2QB	MN	Bacterial Cell membrane (Bact CM)
DMYJ2QB	MT	DTT
DMYJ2QB	MA	Modulator
DMYJ2QB	RN	In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41.
DMYJ2QB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126975/

DM9FAJM	DI	DM9FAJM
DM9FAJM	DN	D-5519
DM9FAJM	MI	TTPNQAC
DM9FAJM	MN	Estrogen-related receptor-alpha (ESRRA)
DM9FAJM	MT	DTT
DM9FAJM	MA	Modulator
DM9FAJM	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199)
DM9FAJM	RU	http://adisinsight.springer.com/drugs/800007199

DM6S4R2	DI	DM6S4R2
DM6S4R2	DN	DA-3031
DM6S4R2	MI	TT5TQ2W
DM6S4R2	MN	Granulocyte colony-stimulating factor (CSF3)
DM6S4R2	MT	DTT
DM6S4R2	MA	Modulator
DM6S4R2	RN	A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6.
DM6S4R2	RU	https://www.ncbi.nlm.nih.gov/pubmed/23677653

DMP2SGN	DI	DMP2SGN
DMP2SGN	DN	Dabelotine
DMP2SGN	MI	TTVIREA
DMP2SGN	MN	Adrenergic receptor (ADR)
DMP2SGN	MT	DTT
DMP2SGN	MA	Modulator
DMP2SGN	RN	US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation.
DMP2SGN	RU	http://www.google.nl/patents/US20070049576

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DEB30C5
DMRDZ4X	MN	Carboxylesterase 1 (CES1)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30658513

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DETHCPD
DMRDZ4X	MN	Carboxylesterase 2 (CES2)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30658513

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DE85D2P
DMRDZ4X	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DMRDZ4X	DI	DMRDZ4X
DMRDZ4X	DN	Dabigatran etexilate
DMRDZ4X	MI	DEB3CV1
DMRDZ4X	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMRDZ4X	MT	DME
DMRDZ4X	MA	Metabolism
DMRDZ4X	RN	Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75.
DMRDZ4X	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20551237

DMKNCVM	DI	DMKNCVM
DMKNCVM	DN	Dalcetrapib
DMKNCVM	MI	TTFQAYR
DMKNCVM	MN	Cholesteryl ester transfer protein (CETP)
DMKNCVM	MT	DTT
DMKNCVM	MA	Inhibitor
DMKNCVM	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMKNCVM	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMKNCVM	DI	DMKNCVM
DMKNCVM	DN	Dalcetrapib
DMKNCVM	MI	DE4LYSA
DMKNCVM	MN	Cytochrome P450 3A4 (CYP3A4)
DMKNCVM	MT	DME
DMKNCVM	MA	Metabolism
DMKNCVM	RN	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin. 2009 Apr;25(4):891-902.
DMKNCVM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19245299

DM1C95G	DI	DM1C95G
DM1C95G	DN	DARE-BV1
DM1C95G	MI	TTUWYEA
DM1C95G	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM1C95G	MT	DTT
DM1C95G	RN	Characterization of Escherichia coli 50S ribosomal protein L31. FEMS Microbiol Lett. 1999 Nov 15;180(2):345-9.
DM1C95G	RU	https://pubmed.ncbi.nlm.nih.gov/10556732

DMR2JD4	DI	DMR2JD4
DMR2JD4	DN	Darotropium + 642444
DMR2JD4	MI	TTZ9SOR
DMR2JD4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMR2JD4	MT	DTT
DMR2JD4	MA	Agonist
DMR2JD4	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMR2JD4	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2FV5N	DI	DM2FV5N
DM2FV5N	DN	Darunavir + cobicistat
DM2FV5N	MI	TT1D53B
DM2FV5N	MN	COVID-19 3C-like protease (3CLpro)
DM2FV5N	MT	DTT
DM2FV5N	MA	Inhibitor
DM2FV5N	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DM2FV5N	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TTZGK1R
DMF3V01	MN	HUMAN glycosylation of host receptor (GHR)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TTD16BI
DMF3V01	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMF3V01	DI	DMF3V01
DMF3V01	DN	Darunavir + ritonavir + favipiravir + hydroxychloroquine
DMF3V01	MI	TT3A1EZ
DMF3V01	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMF3V01	MT	DTT
DMF3V01	MA	Inhibitor
DMF3V01	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMF3V01	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TTZGK1R
DMN9BO3	MN	HUMAN glycosylation of host receptor (GHR)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TTD16BI
DMN9BO3	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMN9BO3	DI	DMN9BO3
DMN9BO3	DN	Darunavir + ritonavir + oseltamivir + hydroxychloroquine
DMN9BO3	MI	TT3A1EZ
DMN9BO3	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMN9BO3	MT	DTT
DMN9BO3	MA	Inhibitor
DMN9BO3	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMN9BO3	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMN8DQH	DI	DMN8DQH
DMN8DQH	DN	Darusentan
DMN8DQH	MI	TTKRD0G
DMN8DQH	MN	Endothelin A receptor (EDNRA)
DMN8DQH	MT	DTT
DMN8DQH	MA	Antagonist
DMN8DQH	RN	Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
DMN8DQH	RU	https://pubmed.ncbi.nlm.nih.gov/16633090

DMD7K9X	DI	DMD7K9X
DMD7K9X	DN	Davunetide
DMD7K9X	MI	TTS87KH
DMD7K9X	MN	Microtubule-associated protein tau (MAPT)
DMD7K9X	MT	DTT
DMD7K9X	MA	Modulator
DMD7K9X	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DMD7K9X	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMUX7Z8	DI	DMUX7Z8
DMUX7Z8	DN	DE-117
DMUX7Z8	MI	TT1ZAVI
DMUX7Z8	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMUX7Z8	MT	DTT
DMUX7Z8	MA	Agonist
DMUX7Z8	RN	Clinical pipeline report, company report or official report of Santen Pharmaceutical.
DMUX7Z8	RU	http://www.santeninc.com/research/moa/

DM0GUV2	DI	DM0GUV2
DM0GUV2	DN	DE-766
DM0GUV2	MI	TTGKNB4
DM0GUV2	MN	Epidermal growth factor receptor (EGFR)
DM0GUV2	MT	DTT
DM0GUV2	MA	Modulator
DM0GUV2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM0GUV2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTZ97H5
DM2R15Q	MN	Phosphodiesterase 4A (PDE4A)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTVIAT9
DM2R15Q	MN	Phosphodiesterase 4B (PDE4B)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2R15Q	DI	DM2R15Q
DM2R15Q	DN	DENBUFYLLINE
DM2R15Q	MI	TTSKMI8
DM2R15Q	MN	Phosphodiesterase 4D (PDE4D)
DM2R15Q	MT	DTT
DM2R15Q	MA	Inhibitor
DM2R15Q	RN	Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
DM2R15Q	RU	https://pubmed.ncbi.nlm.nih.gov/12014973

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTHCF4J
DM2ATZB	MN	Alpha-glucosidase (GLA)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/7966130

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTXWASR
DM2ATZB	MN	Intestinal maltase-glucoamylase (MGAM)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/7966130

DM2ATZB	DI	DM2ATZB
DM2ATZB	DN	Deoxynojirimycin
DM2ATZB	MI	TTLPC70
DM2ATZB	MN	Lysosomal alpha-glucosidase (GAA)
DM2ATZB	MT	DTT
DM2ATZB	MA	Inhibitor
DM2ATZB	RN	In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
DM2ATZB	RU	https://pubmed.ncbi.nlm.nih.gov/18595718

DMDLU4Z	DI	DMDLU4Z
DMDLU4Z	DN	Desmoteplase
DMDLU4Z	MI	TTP86E2
DMDLU4Z	MN	Plasminogen (PLG)
DMDLU4Z	MT	DTT
DMDLU4Z	MA	Activator
DMDLU4Z	RN	Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
DMDLU4Z	RU	https://pubmed.ncbi.nlm.nih.gov/12574572

DMRH291	DI	DMRH291
DMRH291	DN	Dexanabinol
DMRH291	MI	TT9IK2Z
DMRH291	MN	N-methyl-D-aspartate receptor (NMDAR)
DMRH291	MT	DTT
DMRH291	MA	Antagonist
DMRH291	RN	Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
DMRH291	RU	https://pubmed.ncbi.nlm.nih.gov/19249984

DM1WNGJ	DI	DM1WNGJ
DM1WNGJ	DN	DFP-10917
DM1WNGJ	MI	TTABD5E
DM1WNGJ	MN	DNA replication (DNA repli)
DM1WNGJ	MT	DTT
DM1WNGJ	MA	Inhibitor
DM1WNGJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1WNGJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOUGX1	DI	DMOUGX1
DMOUGX1	DN	Diamyd
DMOUGX1	MI	TT7UY6K
DMOUGX1	MN	Glutamate decarboxylase 2 (GAD2)
DMOUGX1	MT	DTT
DMOUGX1	MA	Immunomodulator
DMOUGX1	RN	Clinical pipeline report, company report or official report of Diamyd Medical.
DMOUGX1	RU	http://www.diamyd.com/docs/gadProducts.aspx?section=products

DM4XBM7	DI	DM4XBM7
DM4XBM7	DN	DiaPep-277
DM4XBM7	MI	TT9HL5R
DM4XBM7	MN	Mitochondrial matrix protein P1 (HSPD1)
DM4XBM7	MT	DTT
DM4XBM7	MA	Modulator
DM4XBM7	RN	Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75.
DM4XBM7	RU	https://pubmed.ncbi.nlm.nih.gov/17024692

DMHZBEO	DI	DMHZBEO
DMHZBEO	DN	Difelikefalin
DMHZBEO	MI	TTQW87Y
DMHZBEO	MN	Opioid receptor kappa (OPRK1)
DMHZBEO	MT	DTT
DMHZBEO	MA	Agonist
DMHZBEO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHZBEO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU4T9Y	DI	DMU4T9Y
DMU4T9Y	DN	Dimesna
DMU4T9Y	MI	DTQ23VB
DMU4T9Y	MN	Organic anion transporter 1 (SLC22A6)
DMU4T9Y	MT	DTP
DMU4T9Y	MA	Substrate
DMU4T9Y	RN	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
DMU4T9Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/21505084

DMU4T9Y	DI	DMU4T9Y
DMU4T9Y	DN	Dimesna
DMU4T9Y	MI	DTVP67E
DMU4T9Y	MN	Organic anion transporter 3 (SLC22A8)
DMU4T9Y	MT	DTP
DMU4T9Y	MA	Substrate
DMU4T9Y	RN	In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. J Clin Pharmacol. 2012 Apr;52(4):530-42.
DMU4T9Y	RU	http://www.ncbi.nlm.nih.gov/pubmed/21505084

DM19CFZ	DI	DM19CFZ
DM19CFZ	DN	DIMS-0150
DM19CFZ	MI	TTKLNRV
DM19CFZ	MN	NFKB messenger RNA (NFKB mRNA)
DM19CFZ	MT	DTT
DM19CFZ	RN	News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013).
DM19CFZ	RU	http://www.nature.com/nrd/journal/v12/n3/full/nrd3963.html

DMG8U6M	DI	DMG8U6M
DMG8U6M	DN	DIPROTEVERINE HYDROCHLORIDE
DMG8U6M	MI	TT5HONZ
DMG8U6M	MN	Calcium channel unspecific (CaC)
DMG8U6M	MT	DTT
DMG8U6M	MA	Antagonist
DMG8U6M	RN	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
DMG8U6M	RU	https://pubmed.ncbi.nlm.nih.gov/8998385

DM64QG9	DI	DM64QG9
DM64QG9	DN	Diquafosol
DM64QG9	MI	TTOZHQC
DM64QG9	MN	P2Y purinoceptor 2 (P2RY2)
DM64QG9	MT	DTT
DM64QG9	MA	Agonist
DM64QG9	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM64QG9	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMJS8V3	DI	DMJS8V3
DMJS8V3	DN	Disufenton sodium
DMJS8V3	MI	TT8E7Z0
DMJS8V3	MN	Free radical (FRD)
DMJS8V3	MT	DTT
DMJS8V3	MA	Modulator
DMJS8V3	RN	NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8.
DMJS8V3	RU	https://pubmed.ncbi.nlm.nih.gov/11136936

DMMKGBP	DI	DMMKGBP
DMMKGBP	DN	D-Methionine
DMMKGBP	MI	TTZL0OI
DMMKGBP	MN	Methionine aminopeptidase 2 (METAP2)
DMMKGBP	MT	DTT
DMMKGBP	MA	Inhibitor
DMMKGBP	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMMKGBP	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMO7BQS	DI	DMO7BQS
DMO7BQS	DN	DMP-444
DMO7BQS	MI	TT38RM1
DMO7BQS	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMO7BQS	MT	DTT
DMO7BQS	MA	Modulator
DMO7BQS	RN	Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
DMO7BQS	RU	https://pubmed.ncbi.nlm.nih.gov/12911097

DMQLSMB	DI	DMQLSMB
DMQLSMB	DN	Dociparstat sodium
DMQLSMB	MI	TTSG7Q5
DMQLSMB	MN	Platelet factor 4 (PF4)
DMQLSMB	MT	DTT
DMQLSMB	MA	Inhibitor
DMQLSMB	RN	Clinical pipeline report, company report or official report of Chimerix.
DMQLSMB	RU	https://www.chimerix.com/our-science/dstat/

DMQLSMB	DI	DMQLSMB
DMQLSMB	DN	Dociparstat sodium
DMQLSMB	MI	TT4UGTF
DMQLSMB	MN	Stromal cell-derived factor 1 (CXCL12)
DMQLSMB	MT	DTT
DMQLSMB	MA	Inhibitor
DMQLSMB	RN	Clinical pipeline report, company report or official report of Chimerix.
DMQLSMB	RU	https://www.chimerix.com/our-science/dstat/

DMH8IT5	DI	DMH8IT5
DMH8IT5	DN	Donaperminogene seltoplasmid
DMH8IT5	MI	TT4V2JM
DMH8IT5	MN	Hepatocyte growth factor (HGF)
DMH8IT5	MT	DTT
DMH8IT5	MA	Replacement
DMH8IT5	RN	Clinical pipeline report, company report or official report of ViroMed.
DMH8IT5	RU	http://menu.itooza.com/cmsupload/contdown.php?sn=20190912100403_fd_image_119_65_142__1669.pdf&rsn=ViroMed_May_30_2018.pdf

DM97S10	DI	DM97S10
DM97S10	DN	DP-b99
DM97S10	MI	TT6X50U
DM97S10	MN	Matrix metalloproteinase-9 (MMP-9)
DM97S10	MT	DTT
DM97S10	MA	Inhibitor
DM97S10	RN	DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
DM97S10	RU	https://pubmed.ncbi.nlm.nih.gov/24918931

DMWUN1S	DI	DMWUN1S
DMWUN1S	DN	Drisapersen
DMWUN1S	MI	TTWLFXU
DMWUN1S	MN	Dystrophin messenger RNA (DMD mRNA)
DMWUN1S	MT	DTT
DMWUN1S	RN	PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther. 2010 Aug;12(4):478-86.
DMWUN1S	RU	https://pubmed.ncbi.nlm.nih.gov/20677099

DMM0HAE	DI	DMM0HAE
DMM0HAE	DN	DSC-127
DMM0HAE	MI	TTOISYB
DMM0HAE	MN	Proto-oncogene Mas (MAS)
DMM0HAE	MT	DTT
DMM0HAE	MA	Agonist
DMM0HAE	RN	New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8.
DMM0HAE	RU	https://pubmed.ncbi.nlm.nih.gov/23166114

DM6P8HU	DI	DM6P8HU
DM6P8HU	DN	Dutasteride + tamsulosin
DM6P8HU	MI	TTNGILX
DM6P8HU	MN	Adrenergic receptor alpha-1A (ADRA1A)
DM6P8HU	MT	DTT
DM6P8HU	MA	Antagonist
DM6P8HU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6P8HU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM6P8HU	DI	DM6P8HU
DM6P8HU	DN	Dutasteride + tamsulosin
DM6P8HU	MI	TT2A0DR
DM6P8HU	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM6P8HU	MT	DTT
DM6P8HU	MA	Inhibitor
DM6P8HU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM6P8HU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMM5VTA	DI	DMM5VTA
DMM5VTA	DN	Dutogliptin
DMM5VTA	MI	TTDIGC1
DMM5VTA	MN	Dipeptidyl peptidase 4 (DPP-4)
DMM5VTA	MT	DTT
DMM5VTA	MA	Inhibitor
DMM5VTA	RN	Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
DMM5VTA	RU	https://pubmed.ncbi.nlm.nih.gov/20380656

DMAFUIR	DI	DMAFUIR
DMAFUIR	DN	DWP-431
DMAFUIR	MI	TTP3IGX
DMAFUIR	MN	Bone morphogenetic protein 2 (BMP2)
DMAFUIR	MT	DTT
DMAFUIR	MA	Modulator
DMAFUIR	RN	Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9.
DMAFUIR	RU	https://pubmed.ncbi.nlm.nih.gov/24412416

DMM1YC4	DI	DMM1YC4
DMM1YC4	DN	E-101
DMM1YC4	MI	TTVCZPI
DMM1YC4	MN	Myeloperoxidase (MPO)
DMM1YC4	MT	DTT
DMM1YC4	MA	Modulator
DMM1YC4	RN	In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42.
DMM1YC4	RU	https://pubmed.ncbi.nlm.nih.gov/21118915

DMTNUJ8	DI	DMTNUJ8
DMTNUJ8	DN	E-2609
DMTNUJ8	MI	TT8JRS7
DMTNUJ8	MN	Beta-secretase (BACE)
DMTNUJ8	MT	DTT
DMTNUJ8	MA	Inhibitor
DMTNUJ8	RN	Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
DMTNUJ8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086426/

DMTNUJ8	DI	DMTNUJ8
DMTNUJ8	DN	E-2609
DMTNUJ8	MI	TTJUNZF
DMTNUJ8	MN	Beta-secretase 1 (BACE1)
DMTNUJ8	MT	DTT
DMTNUJ8	MA	Inhibitor
DMTNUJ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTNUJ8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTRLW2X
DM42PFT	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTGJVQM
DM42PFT	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTST7KB
DM42PFT	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TT8FYO9
DM42PFT	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTI7421
DM42PFT	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TT2Q6G1
DM42PFT	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTUTJGQ
DM42PFT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DM42PFT	DI	DM42PFT
DM42PFT	DN	E-3810
DM42PFT	MI	TTDCBX5
DM42PFT	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM42PFT	MT	DTT
DM42PFT	MA	Inhibitor
DM42PFT	RN	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. 
DM42PFT	RU	https://pubmed.ncbi.nlm.nih.gov/21212416

DMUHS5Q	DI	DMUHS5Q
DMUHS5Q	DN	E-913
DMUHS5Q	MI	TT2CEJG
DMUHS5Q	MN	C-C chemokine receptor type 5 (CCR5)
DMUHS5Q	MT	DTT
DMUHS5Q	MA	Antagonist
DMUHS5Q	RN	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
DMUHS5Q	RU	https://pubmed.ncbi.nlm.nih.gov/17920529

DMLA1ER	DI	DMLA1ER
DMLA1ER	DN	EC20
DMLA1ER	MI	TTVC37M
DMLA1ER	MN	Folate receptor alpha (FOLR1)
DMLA1ER	MT	DTT
DMLA1ER	MA	Modulator
DMLA1ER	RN	EP patent application no. 2822386, Folate receptor alpha binding ligands.
DMLA1ER	RU	http://www.google.com/patents/EP2822386A1?cl=en

DMS9R43	DI	DMS9R43
DMS9R43	DN	Ecopipam
DMS9R43	MI	TTZFYLI
DMS9R43	MN	Dopamine D1 receptor (D1R)
DMS9R43	MT	DTT
DMS9R43	MA	Modulator
DMS9R43	RN	A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30.
DMS9R43	RU	https://www.ncbi.nlm.nih.gov/pubmed/24434529

DMRLXAI	DI	DMRLXAI
DMRLXAI	DN	ED-71
DMRLXAI	MI	DE5FUD0
DMRLXAI	MN	Methylsterol monooxygenase 1 (MSMO1)
DMRLXAI	MT	DME
DMRLXAI	MA	Metabolism
DMRLXAI	RN	Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase. Pharmacol Res Perspect. 2015 Mar;3(2):e00120.
DMRLXAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26038696

DMYVBF6	DI	DMYVBF6
DMYVBF6	DN	Edasalonexent
DMYVBF6	MI	TTSXVID
DMYVBF6	MN	Nuclear factor NF-kappa-B (NFKB)
DMYVBF6	MT	DTT
DMYVBF6	MA	Inhibitor
DMYVBF6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYVBF6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM3ZL7D	DI	DM3ZL7D
DM3ZL7D	DN	Edotecarin
DM3ZL7D	MI	DTI7UX6
DM3ZL7D	MN	Breast cancer resistance protein (ABCG2)
DM3ZL7D	MT	DTP
DM3ZL7D	MA	Substrate
DM3ZL7D	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DM3ZL7D	RU	https://doi.org/10.2217/14622416.9.8.1005

DM3ZL7D	DI	DM3ZL7D
DM3ZL7D	DN	Edotecarin
DM3ZL7D	MI	TTGTQHC
DM3ZL7D	MN	DNA topoisomerase I (TOP1)
DM3ZL7D	MT	DTT
DM3ZL7D	MA	Inhibitor
DM3ZL7D	RN	Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
DM3ZL7D	RU	https://pubmed.ncbi.nlm.nih.gov/15929804

DMX7BM4	DI	DMX7BM4
DMX7BM4	DN	Efaproxyn
DMX7BM4	MI	TTQO71U
DMX7BM4	MN	Hemoglobin (HB)
DMX7BM4	MT	DTT
DMX7BM4	MA	Inhibitor
DMX7BM4	RN	Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
DMX7BM4	RU	https://pubmed.ncbi.nlm.nih.gov/15817356

DMKA2PI	DI	DMKA2PI
DMKA2PI	DN	Efpeglenatide
DMKA2PI	MI	TTVIMDE
DMKA2PI	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKA2PI	MT	DTT
DMKA2PI	MA	Agonist
DMKA2PI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKA2PI	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMCMJRA	DI	DMCMJRA
DMCMJRA	DN	EGF816
DMCMJRA	MI	TTGKNB4
DMCMJRA	MN	Epidermal growth factor receptor (EGFR)
DMCMJRA	MT	DTT
DMCMJRA	MA	Inhibitor
DMCMJRA	RN	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
DMCMJRA	RU	https://pubmed.ncbi.nlm.nih.gov/24065731

DMB2C0E	DI	DMB2C0E
DMB2C0E	DN	Elagolix
DMB2C0E	MI	TT8R70G
DMB2C0E	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMB2C0E	MT	DTT
DMB2C0E	MA	Antagonist
DMB2C0E	RN	Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28.
DMB2C0E	RU	https://pubmed.ncbi.nlm.nih.gov/25581052

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTSQIFT
DMW6C81	MN	5-HT 1A receptor (HTR1A)
DMW6C81	MT	DTT
DMW6C81	MA	Agonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTK8CXU
DMW6C81	MN	5-HT 1B receptor (HTR1B)
DMW6C81	MT	DTT
DMW6C81	MA	Agonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMW6C81	DI	DMW6C81
DMW6C81	DN	Eltoprazine
DMW6C81	MI	TTWJBZ5
DMW6C81	MN	5-HT 2C receptor (HTR2C)
DMW6C81	MT	DTT
DMW6C81	MA	Antagonist
DMW6C81	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMW6C81	RU	http://www.jazzpharma.com/products/

DMZKTYJ	DI	DMZKTYJ
DMZKTYJ	DN	Enmetazobactam
DMZKTYJ	MI	TTHI19T
DMZKTYJ	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMZKTYJ	MT	DTT
DMZKTYJ	MA	Inhibitor
DMZKTYJ	RN	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
DMZKTYJ	RU	https://pubmed.ncbi.nlm.nih.gov/32253209

DMIKDCQ	DI	DMIKDCQ
DMIKDCQ	DN	Ensartinib
DMIKDCQ	MI	TTPMQSO
DMIKDCQ	MN	ALK tyrosine kinase receptor (ALK)
DMIKDCQ	MT	DTT
DMIKDCQ	MA	Inhibitor
DMIKDCQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIKDCQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7EOBQ	DI	DM7EOBQ
DM7EOBQ	DN	Entacapone+levodopa+carbidopa
DM7EOBQ	MI	TTKWFB8
DM7EOBQ	MN	Catechol-O-methyl-transferase (COMT)
DM7EOBQ	MT	DTT
DM7EOBQ	MA	Inhibitor
DM7EOBQ	RN	Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52.
DM7EOBQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083328

DM7EOBQ	DI	DM7EOBQ
DM7EOBQ	DN	Entacapone+levodopa+carbidopa
DM7EOBQ	MI	TTEX248
DM7EOBQ	MN	Dopamine D2 receptor (D2R)
DM7EOBQ	MT	DTT
DM7EOBQ	MA	Agonist
DM7EOBQ	RN	Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52.
DM7EOBQ	RU	https://pubmed.ncbi.nlm.nih.gov/16083328

DMTWLXY	DI	DMTWLXY
DMTWLXY	DN	Entresto
DMTWLXY	MI	DE4LYSA
DMTWLXY	MN	Cytochrome P450 3A4 (CYP3A4)
DMTWLXY	MT	DME
DMTWLXY	MA	Metabolism
DMTWLXY	RN	FDA label of Sacubitril and valsartan. The 2020 official website of the U.S. Food and Drug Administration.
DMTWLXY	RU	https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	DE4LYSA
DM5H0R9	MN	Cytochrome P450 3A4 (CYP3A4)
DM5H0R9	MT	DME
DM5H0R9	MA	Metabolism
DM5H0R9	RN	Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Invest New Drugs. 2013 Jun;31(3):653-60.
DM5H0R9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22766773

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTHBTOP
DM5H0R9	MN	PI3-kinase gamma (PIK3CG)
DM5H0R9	MT	DTT
DM5H0R9	MA	Inhibitor
DM5H0R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5H0R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTYPXQF
DM5H0R9	MN	Protein kinase C beta (PRKCB)
DM5H0R9	MT	DTT
DM5H0R9	MA	Modulator
DM5H0R9	RN	The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
DM5H0R9	RU	https://pubmed.ncbi.nlm.nih.gov/18452078

DM5H0R9	DI	DM5H0R9
DM5H0R9	DN	Enzastaurin
DM5H0R9	MI	TTWTSCV
DM5H0R9	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM5H0R9	MT	DTT
DM5H0R9	MA	Inhibitor
DM5H0R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5H0R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEX86V	DI	DMEX86V
DMEX86V	DN	Epcoritamab
DMEX86V	MI	TTUE541
DMEX86V	MN	Leukocyte surface antigen Leu-16 (CD20)
DMEX86V	MT	DTT
DMEX86V	MA	Inhibitor
DMEX86V	RN	Clinical pipeline report, company report or official report of Genmab.
DMEX86V	RU	https://www.genmab.com/pipeline/

DMEX86V	DI	DMEX86V
DMEX86V	DN	Epcoritamab
DMEX86V	MI	TTUN7MC
DMEX86V	MN	T-cell surface glycoprotein CD3 (CD3)
DMEX86V	MT	DTT
DMEX86V	MA	Inhibitor
DMEX86V	RN	Clinical pipeline report, company report or official report of Genmab.
DMEX86V	RU	https://www.genmab.com/pipeline/

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	DERSX5P
DM1SMAI	MN	Cytochrome P450 2J2 (CYP2J2)
DM1SMAI	MT	DME
DM1SMAI	MA	Metabolism
DM1SMAI	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DM1SMAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	DE4LYSA
DM1SMAI	MN	Cytochrome P450 3A4 (CYP3A4)
DM1SMAI	MT	DME
DM1SMAI	MA	Metabolism
DM1SMAI	RN	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
DM1SMAI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19219743

DM1SMAI	DI	DM1SMAI
DM1SMAI	DN	Eperisone
DM1SMAI	MI	TTCRJKY
DM1SMAI	MN	Voltage-gated calcium channel (Cav)
DM1SMAI	MT	DTT
DM1SMAI	MA	Modulator
DM1SMAI	RN	Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.
DM1SMAI	RU	https://pubmed.ncbi.nlm.nih.gov/2555204

DM08XIN	DI	DM08XIN
DM08XIN	DN	EPIANDROSTERONE
DM08XIN	MI	TTKN8W0
DM08XIN	MN	Glucose-6-phosphate dehydrogenase (G6PD)
DM08XIN	MT	DTT
DM08XIN	MA	Inhibitor
DM08XIN	RN	Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9.
DM08XIN	RU	https://pubmed.ncbi.nlm.nih.gov/19231202

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TT7AOUD
DMCGWBJ	MN	Fatty acid synthase (FASN)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TT84ETX
DMCGWBJ	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/11591519

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTJ4QE7
DMCGWBJ	MN	Matrix metalloproteinase-14 (MMP-14)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/19524436

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTLM12X
DMCGWBJ	MN	Matrix metalloproteinase-2 (MMP-2)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/19524436

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTPLTSQ
DMCGWBJ	MN	Neutrophil elastase (NE)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/20004577

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTHPFTS
DMCGWBJ	MN	Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTNX2CS
DMCGWBJ	MN	Plasmodium Enoyl-ACP reductase (Malaria fabI)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/17263522

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTBE4IR
DMCGWBJ	MN	Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/16722653

DMCGWBJ	DI	DMCGWBJ
DMCGWBJ	DN	Epigallocatechin gallate
DMCGWBJ	MI	TTE14XG
DMCGWBJ	MN	Squalene monooxygenase (SQLE)
DMCGWBJ	MT	DTT
DMCGWBJ	MA	Inhibitor
DMCGWBJ	RN	Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
DMCGWBJ	RU	https://pubmed.ncbi.nlm.nih.gov/11520216

DM9QPOU	DI	DM9QPOU
DM9QPOU	DN	Epoetin zeta
DM9QPOU	MI	TTAUX24
DM9QPOU	MN	Erythropoietin Receptor (EPOR)
DM9QPOU	MT	DTT
DM9QPOU	MA	Modulator
DM9QPOU	RN	Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
DM9QPOU	RU	https://pubmed.ncbi.nlm.nih.gov/18931828

DMITJRU	DI	DMITJRU
DMITJRU	DN	Epothilon
DMITJRU	MI	TTML2WA
DMITJRU	MN	Tubulin (TUB)
DMITJRU	MT	DTT
DMITJRU	MA	Stablizer
DMITJRU	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DMITJRU	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DMI1ZXV	DI	DMI1ZXV
DMI1ZXV	DN	Epratuzumab
DMI1ZXV	MI	TTM6QSK
DMI1ZXV	MN	B-cell receptor CD22 (CD22)
DMI1ZXV	MT	DTT
DMI1ZXV	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DMI1ZXV	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DM35T1O	DI	DM35T1O
DM35T1O	DN	Epristeride
DM35T1O	MI	TT2A0DR
DM35T1O	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM35T1O	MT	DTT
DM35T1O	MA	Inhibitor
DM35T1O	RN	Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8.
DM35T1O	RU	https://pubmed.ncbi.nlm.nih.gov/21094046

DMTV7ZM	DI	DMTV7ZM
DMTV7ZM	DN	Eptastigmine
DMTV7ZM	MI	TT1RS9F
DMTV7ZM	MN	Acetylcholinesterase (AChE)
DMTV7ZM	MT	DTT
DMTV7ZM	MA	Inhibitor
DMTV7ZM	RN	Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86.
DMTV7ZM	RU	https://pubmed.ncbi.nlm.nih.gov/11830755

DMTV7ZM	DI	DMTV7ZM
DMTV7ZM	DN	Eptastigmine
DMTV7ZM	MI	TTEB0GD
DMTV7ZM	MN	Cholinesterase (BCHE)
DMTV7ZM	MT	DTT
DMTV7ZM	MA	Inhibitor
DMTV7ZM	RN	Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85.
DMTV7ZM	RU	https://pubmed.ncbi.nlm.nih.gov/16570913

DM6BU57	DI	DM6BU57
DM6BU57	DN	Eraxis/Vfend
DM6BU57	MI	TTZMS1L
DM6BU57	MN	Fungal Papulacandin B resistance protein 1 (Fung FKS1)
DM6BU57	MT	DTT
DM6BU57	MA	Inhibitor
DM6BU57	RN	Pfizer. Product Development Pipeline. March 31 2009.
DM6BU57	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM9YI2C	DI	DM9YI2C
DM9YI2C	DN	ErepoXen
DM9YI2C	MI	TTAUX24
DM9YI2C	MN	Erythropoietin Receptor (EPOR)
DM9YI2C	MT	DTT
DM9YI2C	MA	Agonist
DM9YI2C	RN	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
DM9YI2C	RU	https://pubmed.ncbi.nlm.nih.gov/16885048

DMKQZ0L	DI	DMKQZ0L
DMKQZ0L	DN	ERITORAN
DMKQZ0L	MI	TTISGCA
DMKQZ0L	MN	Toll-like receptor 4 (TLR4)
DMKQZ0L	MT	DTT
DMKQZ0L	MA	Inhibitor
DMKQZ0L	RN	Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
DMKQZ0L	RU	https://pubmed.ncbi.nlm.nih.gov/18828583

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DEPKLMQ
DMVU687	MN	Cytochrome P450 2B6 (CYP2B6)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DE5IED8
DMVU687	MN	Cytochrome P450 2C9 (CYP2C9)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DE4LYSA
DMVU687	MN	Cytochrome P450 3A4 (CYP3A4)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12065445

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	DEGTFWK
DMVU687	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMVU687	MT	DME
DMVU687	MA	Metabolism
DMVU687	RN	Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017 Feb 20;2(1):2-10.
DMVU687	RU	https://www.ncbi.nlm.nih.gov/pubmed/30483613

DMVU687	DI	DMVU687
DMVU687	DN	Esketamine
DMVU687	MI	TT9IK2Z
DMVU687	MN	N-methyl-D-aspartate receptor (NMDAR)
DMVU687	MT	DTT
DMVU687	MA	Antagonist
DMVU687	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVU687	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM8RBHJ	DI	DM8RBHJ
DM8RBHJ	DN	Esomeprazole magnesium + Aspirin
DM8RBHJ	MI	TTF1QVM
DM8RBHJ	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM8RBHJ	MT	DTT
DM8RBHJ	MA	Inhibitor
DM8RBHJ	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM8RBHJ	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM4YGWA	DI	DM4YGWA
DM4YGWA	DN	Esonarimod
DM4YGWA	MI	TTGD6BY
DM4YGWA	MN	TNF-alpha/IL-1 beta production (TNFA/IL1B produ)
DM4YGWA	MT	DTT
DM4YGWA	MA	Modulator
DM4YGWA	RN	KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res. 2002;28(5):197-205.
DM4YGWA	RU	https://pubmed.ncbi.nlm.nih.gov/12635495

DMXLGED	DI	DMXLGED
DMXLGED	DN	esuberaprost
DMXLGED	MI	TTOFYT1
DMXLGED	MN	Prostacyclin receptor (PTGIR)
DMXLGED	MT	DTT
DMXLGED	MA	Agonist
DMXLGED	RN	Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
DMXLGED	RU	https://pubmed.ncbi.nlm.nih.gov/2665758

DMQHX1Y	DI	DMQHX1Y
DMQHX1Y	DN	Etirinotecan pegol
DMQHX1Y	MI	TTGTQHC
DMQHX1Y	MN	DNA topoisomerase I (TOP1)
DMQHX1Y	MT	DTT
DMQHX1Y	MA	Inhibitor
DMQHX1Y	RN	Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37.
DMQHX1Y	RU	https://pubmed.ncbi.nlm.nih.gov/25228368

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	TTFQAYR
DMCDZ15	MN	Cholesteryl ester transfer protein (CETP)
DMCDZ15	MT	DTT
DMCDZ15	MA	Inhibitor
DMCDZ15	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMCDZ15	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	DES5XRU
DMCDZ15	MN	Cytochrome P450 2C8 (CYP2C8)
DMCDZ15	MT	DME
DMCDZ15	MA	Metabolism
DMCDZ15	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DMCDZ15	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DMCDZ15	DI	DMCDZ15
DMCDZ15	DN	Evacetrapib
DMCDZ15	MI	DE4LYSA
DMCDZ15	MN	Cytochrome P450 3A4 (CYP3A4)
DMCDZ15	MT	DME
DMCDZ15	MA	Metabolism
DMCDZ15	RN	Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98.
DMCDZ15	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14555336

DMG4UJ6	DI	DMG4UJ6
DMG4UJ6	DN	EVK-001
DMG4UJ6	MI	TTWFZ1N
DMG4UJ6	MN	Dopamine receptor (DR)
DMG4UJ6	MT	DTT
DMG4UJ6	MA	Antagonist
DMG4UJ6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG4UJ6	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMLQO7F	DI	DMLQO7F
DMLQO7F	DN	EVP-6124
DMLQO7F	MI	TTLA931
DMLQO7F	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMLQO7F	MT	DTT
DMLQO7F	MA	Modulator
DMLQO7F	RN	Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
DMLQO7F	RU	https://pubmed.ncbi.nlm.nih.gov/24419307

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	DTI7UX6
DMCA7FN	MN	Breast cancer resistance protein (ABCG2)
DMCA7FN	MT	DTP
DMCA7FN	MA	Substrate
DMCA7FN	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMCA7FN	RU	https://doi.org/10.2217/14622416.9.8.1005

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	DE4LYSA
DMCA7FN	MN	Cytochrome P450 3A4 (CYP3A4)
DMCA7FN	MT	DME
DMCA7FN	MA	Metabolism
DMCA7FN	RN	Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clin Cancer Res. 2001 Oct;7(10):3056-64.
DMCA7FN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11595695

DMCA7FN	DI	DMCA7FN
DMCA7FN	DN	Exatecan
DMCA7FN	MI	TTGTQHC
DMCA7FN	MN	DNA topoisomerase I (TOP1)
DMCA7FN	MT	DTT
DMCA7FN	MA	Inhibitor
DMCA7FN	RN	Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
DMCA7FN	RU	https://pubmed.ncbi.nlm.nih.gov/11751488

DMBY56U	DI	DMBY56U
DMBY56U	DN	EXISULIND
DMBY56U	MI	TTJ0IQB
DMBY56U	MN	Phosphodiesterase 5A (PDE5A)
DMBY56U	MT	DTT
DMBY56U	MA	Modulator
DMBY56U	RN	Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
DMBY56U	RU	https://pubmed.ncbi.nlm.nih.gov/10910034

DMOKT7Y	DI	DMOKT7Y
DMOKT7Y	DN	FARGLITAZAR
DMOKT7Y	MI	TTZMAO3
DMOKT7Y	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMOKT7Y	MT	DTT
DMOKT7Y	MA	Modulator
DMOKT7Y	RN	Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84.
DMOKT7Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/10393202

DM83SEB	DI	DM83SEB
DM83SEB	DN	Faricimab
DM83SEB	MI	TTKLQTJ
DM83SEB	MN	Angiopoietin-2 (ANGPT2)
DM83SEB	MT	DTT
DM83SEB	RN	Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
DM83SEB	RU	https://pubmed.ncbi.nlm.nih.gov/33471572

DM83SEB	DI	DM83SEB
DM83SEB	DN	Faricimab
DM83SEB	MI	TTOHSBA
DM83SEB	MN	Vascular endothelial growth factor A (VEGFA)
DM83SEB	MT	DTT
DM83SEB	RN	Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
DM83SEB	RU	https://pubmed.ncbi.nlm.nih.gov/33471572

DMFLWX1	DI	DMFLWX1
DMFLWX1	DN	Farletuzumab
DMFLWX1	MI	TTVC37M
DMFLWX1	MN	Folate receptor alpha (FOLR1)
DMFLWX1	MT	DTT
DMFLWX1	MA	Modulator
DMFLWX1	RN	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8.
DMFLWX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/23474348

DMTGYSO	DI	DMTGYSO
DMTGYSO	DN	Fasiglifam hemihydrate
DMTGYSO	MI	TTB8FUC
DMTGYSO	MN	Free fatty acid receptor 1 (GPR40)
DMTGYSO	MT	DTT
DMTGYSO	MA	Modulator
DMTGYSO	RN	A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
DMTGYSO	RU	https://pubmed.ncbi.nlm.nih.gov/24130766

DM5PRLA	DI	DM5PRLA
DM5PRLA	DN	Fasinumab
DM5PRLA	MI	TTDN3LF
DM5PRLA	MN	Nerve growth factor (NGF)
DM5PRLA	MT	DTT
DM5PRLA	MA	Inhibitor
DM5PRLA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5PRLA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8E51L	DI	DM8E51L
DM8E51L	DN	FASORACETAM
DM8E51L	MI	TTAN6JD
DM8E51L	MN	Glutamate receptor AMPA (GRIA)
DM8E51L	MT	DTT
DM8E51L	MA	Modulator
DM8E51L	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM8E51L	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM35GBS	DI	DM35GBS
DM35GBS	DN	Favipiravir
DM35GBS	MI	TTV1095
DM35GBS	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DM35GBS	MT	DTT
DM35GBS	MA	Inhibitor
DM35GBS	RN	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.
DM35GBS	RU	https://doi.org/10.1101/2020.03.17.20037432

DM0762O	DI	DM0762O
DM0762O	DN	Fenfluramine
DM0762O	MI	TT85JO3
DM0762O	MN	5-HT receptor (5HTR)
DM0762O	MT	DTT
DM0762O	MA	Antagonist
DM0762O	RN	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
DM0762O	RU	https://pubmed.ncbi.nlm.nih.gov/15977970

DMRD5SP	DI	DMRD5SP
DMRD5SP	DN	Fenretinide
DMRD5SP	MI	DES5XRU
DMRD5SP	MN	Cytochrome P450 2C8 (CYP2C8)
DMRD5SP	MT	DME
DMRD5SP	MA	Metabolism
DMRD5SP	RN	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
DMRD5SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21054342

DMRD5SP	DI	DMRD5SP
DMRD5SP	DN	Fenretinide
DMRD5SP	MI	TTOD7B3
DMRD5SP	MN	Retinoic acid receptor (RAR)
DMRD5SP	MT	DTT
DMRD5SP	MA	Modulator
DMRD5SP	RN	National Cancer Institute Drug Dictionary (drug id 39582).
DMRD5SP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39582

DM4NX0C	DI	DM4NX0C
DM4NX0C	DN	Fevipiprant
DM4NX0C	MI	TTQDMX5
DM4NX0C	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM4NX0C	MT	DTT
DM4NX0C	MA	Antagonist
DM4NX0C	RN	Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
DM4NX0C	RU	https://pubmed.ncbi.nlm.nih.gov/29363343

DM4XSQ2	DI	DM4XSQ2
DM4XSQ2	DN	FG-4592
DM4XSQ2	MI	TTMHFRY
DM4XSQ2	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DM4XSQ2	MT	DTT
DM4XSQ2	MA	Inhibitor
DM4XSQ2	RN	The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54.
DM4XSQ2	RU	https://pubmed.ncbi.nlm.nih.gov/18301799

DM4XSQ2	DI	DM4XSQ2
DM4XSQ2	DN	FG-4592
DM4XSQ2	MI	TT9ISBX
DM4XSQ2	MN	HIF-prolyl hydroxylase 2 (HPH-2)
DM4XSQ2	MT	DTT
DM4XSQ2	MA	Inhibitor
DM4XSQ2	RN	Crystalline forms of a prolyl hydroxylase inhibitor. US9115085.
DM4XSQ2	RU	http://www.freepatentsonline.com/US9115085.html

DMFZ81T	DI	DMFZ81T
DMFZ81T	DN	Fidanacogene elaparvovec
DMFZ81T	MI	TTFEZ5Q
DMFZ81T	MN	Coagulation factor IX (F9)
DMFZ81T	MT	DTT
DMFZ81T	MA	Replacement
DMFZ81T	RN	Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218.
DMFZ81T	RU	https://pubmed.ncbi.nlm.nih.gov/33636038

DMZL1I8	DI	DMZL1I8
DMZL1I8	DN	Fidarestat
DMZL1I8	MI	TTFBNVI
DMZL1I8	MN	Aldose reductase (AKR1B1)
DMZL1I8	MT	DTT
DMZL1I8	MA	Inhibitor
DMZL1I8	RN	Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
DMZL1I8	RU	https://pubmed.ncbi.nlm.nih.gov/11574441

DMM4FJ3	DI	DMM4FJ3
DMM4FJ3	DN	Finerenone
DMM4FJ3	MI	TT26PHO
DMM4FJ3	MN	Mineralocorticoid receptor  (MR)
DMM4FJ3	MT	DTT
DMM4FJ3	MA	Antagonist
DMM4FJ3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM4FJ3	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMMQ7BY	DI	DMMQ7BY
DMMQ7BY	DN	Fitusiran
DMMQ7BY	MI	TTZ4MD5
DMMQ7BY	MN	SERPINC1 messenger RNA (SERPINC1 mRNA)
DMMQ7BY	MT	DTT
DMMQ7BY	MA	Inhibitor
DMMQ7BY	RN	Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828.
DMMQ7BY	RU	https://pubmed.ncbi.nlm.nih.gov/28691885

DM6R2XF	DI	DM6R2XF
DM6R2XF	DN	FKB238
DM6R2XF	MI	TT9HKJA
DM6R2XF	MN	Vascular endothelial growth factor (VEGF)
DM6R2XF	MT	DTT
DM6R2XF	MA	Inhibitor
DM6R2XF	RN	Clinical pipeline report, company report or official report of Fujifilm.
DM6R2XF	RU	https://fujifilmkyowakirin-biologics.com/en/pipeline/

DMPSG4D	DI	DMPSG4D
DMPSG4D	DN	Flobufen
DMPSG4D	MI	TT2J34L
DMPSG4D	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMPSG4D	MT	DTT
DMPSG4D	MA	Modulator
DMPSG4D	RN	Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
DMPSG4D	RU	https://pubmed.ncbi.nlm.nih.gov/9205780

DMKL5AT	DI	DMKL5AT
DMKL5AT	DN	Flurpiridaz F 18
DMKL5AT	MI	TTRU1NG
DMKL5AT	MN	Mitochondrial complex I (NDUFA13)
DMKL5AT	MT	DTT
DMKL5AT	MA	Inhibitor
DMKL5AT	RN	The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011 Jul;41(4):305-13.
DMKL5AT	RU	https://pubmed.ncbi.nlm.nih.gov/21624564

DM5S4DL	DI	DM5S4DL
DM5S4DL	DN	Forigerimod
DM5S4DL	MI	TTPVYKI
DM5S4DL	MN	Signal transduction unspecific (ST)
DM5S4DL	MT	DTT
DM5S4DL	MA	Modulator
DM5S4DL	RN	Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83.
DM5S4DL	RU	https://pubmed.ncbi.nlm.nih.gov/19035498

DM8L3JU	DI	DM8L3JU
DM8L3JU	DN	Fosclin
DM8L3JU	MI	TTLH4J3
DM8L3JU	MN	Plasmodium DOXP reductoisomerase (Malaria DXR)
DM8L3JU	MT	DTT
DM8L3JU	MA	Inhibitor
DM8L3JU	RN	Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8.
DM8L3JU	RU	https://pubmed.ncbi.nlm.nih.gov/14976608

DM3274D	DI	DM3274D
DM3274D	DN	Fostamatinib disodium
DM3274D	MI	TTOU65C
DM3274D	MN	Tyrosine-protein kinase SYK (SYK)
DM3274D	MT	DTT
DM3274D	MA	Inhibitor
DM3274D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3274D	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM823WQ	DI	DM823WQ
DM823WQ	DN	FP-1201
DM823WQ	MI	TT4TZ8J
DM823WQ	MN	Interferon-beta (IFNB1)
DM823WQ	MT	DTT
DM823WQ	MA	Modulator
DM823WQ	RN	The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107.
DM823WQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24503265

DMGF8MZ	DI	DMGF8MZ
DMGF8MZ	DN	FPL-62064
DMGF8MZ	MI	TT2J34L
DMGF8MZ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMGF8MZ	MT	DTT
DMGF8MZ	MA	Modulator
DMGF8MZ	RN	FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
DMGF8MZ	RU	https://pubmed.ncbi.nlm.nih.gov/2117338

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTVJ1D8
DMHOSCQ	MN	Vascular endothelial growth factor receptor (VEGFR)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHOSCQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TT2Q6G1
DMHOSCQ	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTUTJGQ
DMHOSCQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DMHOSCQ	DI	DMHOSCQ
DMHOSCQ	DN	Fruquintinib
DMHOSCQ	MI	TTDCBX5
DMHOSCQ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMHOSCQ	MT	DTT
DMHOSCQ	MA	Inhibitor
DMHOSCQ	RN	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
DMHOSCQ	RU	https://pubmed.ncbi.nlm.nih.gov/25482937

DM1YVLM	DI	DM1YVLM
DM1YVLM	DN	FST-201
DM1YVLM	MI	TTYRL6O
DM1YVLM	MN	Glucocorticoid receptor (NR3C1)
DM1YVLM	MT	DTT
DM1YVLM	MA	Agonist
DM1YVLM	RN	A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83.
DM1YVLM	RU	https://pubmed.ncbi.nlm.nih.gov/19756415

DMDKYVE	DI	DMDKYVE
DMDKYVE	DN	FT-0624878
DMDKYVE	MI	DEI2XLV
DMDKYVE	MN	Phosphoenolpyruvate carboxykinase (pckG)
DMDKYVE	MT	DME
DMDKYVE	MA	Metabolism
DMDKYVE	RN	nan
DMDKYVE	RU	nan

DMF4I1V	DI	DMF4I1V
DMF4I1V	DN	FT-0710230
DMF4I1V	MI	DECB0K3
DMF4I1V	MN	Cytochrome P450 2D6 (CYP2D6)
DMF4I1V	MT	DME
DMF4I1V	MA	Metabolism
DMF4I1V	RN	Interpretation of opiate urine drug screens.
DMF4I1V	RU	https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf

DMK38MV	DI	DMK38MV
DMK38MV	DN	Fulranumab
DMK38MV	MI	TTEDJN4
DMK38MV	MN	Low-affinity nerve growth factor receptor (NGFR)
DMK38MV	MT	DTT
DMK38MV	MA	Antagonist
DMK38MV	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
DMK38MV	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888

DMP83UZ	DI	DMP83UZ
DMP83UZ	DN	Fumaric acid
DMP83UZ	MI	TT93WF5
DMP83UZ	MN	Interferon-gamma (IFNG)
DMP83UZ	MT	DTT
DMP83UZ	MA	Binder
DMP83UZ	RN	Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
DMP83UZ	RU	https://pubmed.ncbi.nlm.nih.gov/18764723

DMZARP1	DI	DMZARP1
DMZARP1	DN	FV-100
DMZARP1	MI	TTP3QRF
DMZARP1	MN	Thymidine kinase 1 (TK1)
DMZARP1	MT	DTT
DMZARP1	MA	Inhibitor
DMZARP1	RN	Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
DMZARP1	RU	https://pubmed.ncbi.nlm.nih.gov/11809847

DMMNP2F	DI	DMMNP2F
DMMNP2F	DN	G17DT
DMMNP2F	MI	TT4LRVO
DMMNP2F	MN	Gastrin (GAST)
DMMNP2F	MT	DTT
DMMNP2F	RN	G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404.
DMMNP2F	RU	https://pubmed.ncbi.nlm.nih.gov/17309331

DMXJMKF	DI	DMXJMKF
DMXJMKF	DN	Ganaxolone
DMXJMKF	MI	TTGXH6N
DMXJMKF	MN	GABA(A) receptor delta (GABRD)
DMXJMKF	MT	DTT
DMXJMKF	MA	Modulator
DMXJMKF	RN	Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91.
DMXJMKF	RU	https://www.ncbi.nlm.nih.gov/pubmed/9778270

DMXJMKF	DI	DMXJMKF
DMXJMKF	DN	Ganaxolone
DMXJMKF	MI	TTEX6LM
DMXJMKF	MN	GABA(A) receptor gamma-3 (GABRG3)
DMXJMKF	MT	DTT
DMXJMKF	MA	Agonist
DMXJMKF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXJMKF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWX90U	DI	DMWX90U
DMWX90U	DN	Gantenerumab
DMWX90U	MI	TTE4KHA
DMWX90U	MN	Amyloid beta A4 protein (APP)
DMWX90U	MT	DTT
DMWX90U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWX90U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMO3ITF	DI	DMO3ITF
DMO3ITF	DN	GASTRAZOLE
DMO3ITF	MI	TTVFO0U
DMO3ITF	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMO3ITF	MT	DTT
DMO3ITF	MA	Antagonist
DMO3ITF	RN	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115.
DMO3ITF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/

DMT4QHD	DI	DMT4QHD
DMT4QHD	DN	GDC-0032
DMT4QHD	MI	TTEUNMR
DMT4QHD	MN	PI3-kinase alpha (PIK3CA)
DMT4QHD	MT	DTT
DMT4QHD	MA	Modulator
DMT4QHD	RN	Company report (BioOncology)
DMT4QHD	RU	http://www.biooncology.com/pipeline-molecules/taselisib-gdc-0032

DMT4QHD	DI	DMT4QHD
DMT4QHD	DN	GDC-0032
DMT4QHD	MI	TTHBTOP
DMT4QHD	MN	PI3-kinase gamma (PIK3CG)
DMT4QHD	MT	DTT
DMT4QHD	MA	Inhibitor
DMT4QHD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT4QHD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWBZJD	DI	DMWBZJD
DMWBZJD	DN	GDC-0068
DMWBZJD	MI	TTWTSCV
DMWBZJD	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMWBZJD	MT	DTT
DMWBZJD	MA	Inhibitor
DMWBZJD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWBZJD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBEL3Q	DI	DMBEL3Q
DMBEL3Q	DN	GDC-0853
DMBEL3Q	MI	TTGM6VW
DMBEL3Q	MN	Tyrosine-protein kinase BTK (ATK)
DMBEL3Q	MT	DTT
DMBEL3Q	MA	Inhibitor
DMBEL3Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBEL3Q	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMTUV7L	DI	DMTUV7L
DMTUV7L	DN	GED-0301
DMTUV7L	MI	TTW06P4
DMTUV7L	MN	Mothers against decapentaplegic homolog 7 (SMAD7)
DMTUV7L	MT	DTT
DMTUV7L	MA	Inhibitor
DMTUV7L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTUV7L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMTUV7L	DI	DMTUV7L
DMTUV7L	DN	GED-0301
DMTUV7L	MI	TT0J32Z
DMTUV7L	MN	Smad7 messenger RNA (Smad7 mRNA)
DMTUV7L	MT	DTT
DMTUV7L	MA	Inhibitor
DMTUV7L	RN	A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7.
DMTUV7L	RU	https://pubmed.ncbi.nlm.nih.gov/22971085

DM4GWL7	DI	DM4GWL7
DM4GWL7	DN	Gefapixant
DM4GWL7	MI	TT2THBD
DM4GWL7	MN	P2X purinoceptor 3 (P2RX3)
DM4GWL7	MT	DTT
DM4GWL7	MA	Inhibitor
DM4GWL7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM4GWL7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZKGPV	DI	DMZKGPV
DMZKGPV	DN	Gemigliptin
DMZKGPV	MI	TTDIGC1
DMZKGPV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZKGPV	MT	DTT
DMZKGPV	MA	Inhibitor
DMZKGPV	RN	Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41.
DMZKGPV	RU	https://pubmed.ncbi.nlm.nih.gov/25350224

DM1WMOK	DI	DM1WMOK
DM1WMOK	DN	Generx
DM1WMOK	MI	TTCEKVZ
DM1WMOK	MN	Fibroblast growth factor-4 (FGF4)
DM1WMOK	MT	DTT
DM1WMOK	MA	Replacement
DM1WMOK	RN	Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46.
DM1WMOK	RU	https://pubmed.ncbi.nlm.nih.gov/17825712

DM7ZOAE	DI	DM7ZOAE
DM7ZOAE	DN	GFT-505
DM7ZOAE	MI	TTJ584C
DM7ZOAE	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7ZOAE	MT	DTT
DM7ZOAE	MA	Modulator
DM7ZOAE	RN	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
DM7ZOAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/23715754

DM7ZOAE	DI	DM7ZOAE
DM7ZOAE	DN	GFT-505
DM7ZOAE	MI	TT2JWF6
DM7ZOAE	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM7ZOAE	MT	DTT
DM7ZOAE	MA	Modulator
DM7ZOAE	RN	Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
DM7ZOAE	RU	https://www.ncbi.nlm.nih.gov/pubmed/23715754

DMR6YH3	DI	DMR6YH3
DMR6YH3	DN	GLP-1
DMR6YH3	MI	TTVIMDE
DMR6YH3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMR6YH3	MT	DTT
DMR6YH3	MA	Modulator
DMR6YH3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMR6YH3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMEFCTP	DI	DMEFCTP
DMEFCTP	DN	Glufosfamide
DMEFCTP	MI	TTUBNVO
DMEFCTP	MN	DNA synthesis (DNA synth)
DMEFCTP	MT	DTT
DMEFCTP	MA	Inhibitor
DMEFCTP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFCTP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEFCTP	DI	DMEFCTP
DMEFCTP	DN	Glufosfamide
DMEFCTP	MI	TTUTN1I
DMEFCTP	MN	Human Deoxyribonucleic acid (hDNA)
DMEFCTP	MT	DTT
DMEFCTP	MA	Modulator
DMEFCTP	RN	A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33.
DMEFCTP	RU	https://www.ncbi.nlm.nih.gov/pubmed/17786181

DMOUT89	DI	DMOUT89
DMOUT89	DN	Glutamic acid
DMOUT89	MI	DE8PQ7T
DMOUT89	MN	D-aspartate oxidase (DDO)
DMOUT89	MT	DME
DMOUT89	MA	Metabolism
DMOUT89	RN	Secreted d-aspartate oxidase functions in C. elegans reproduction and development. FEBS J. 2019 Jan;286(1):124-138.
DMOUT89	RU	https://pubmed.ncbi.nlm.nih.gov/30387556

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	TTN7BL9
DM8M2N3	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM8M2N3	MT	DTT
DM8M2N3	MA	Inhibitor
DM8M2N3	RN	Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32.
DM8M2N3	RU	https://pubmed.ncbi.nlm.nih.gov/19574056

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DE4LYSA
DM8M2N3	MN	Cytochrome P450 3A4 (CYP3A4)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DEIBDNY
DM8M2N3	MN	Cytochrome P450 3A5 (CYP3A5)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DERD86B
DM8M2N3	MN	Cytochrome P450 3A7 (CYP3A7)
DM8M2N3	MT	DME
DM8M2N3	MA	Metabolism
DM8M2N3	RN	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
DM8M2N3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20393696

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DTFI42L
DM8M2N3	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM8M2N3	MT	DTP
DM8M2N3	MA	Substrate
DM8M2N3	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM8M2N3	RU	https://doi.org/10.1007/s11095-012-0935-x

DM8M2N3	DI	DM8M2N3
DM8M2N3	DN	Glycyrrhizin
DM8M2N3	MI	DTQ3ZHF
DM8M2N3	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM8M2N3	MT	DTP
DM8M2N3	MA	Substrate
DM8M2N3	RN	The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007 Dec;31(6):1465-72.
DM8M2N3	RU	http://www.spandidos-publications.com/ijo/31/6/1465

DMQCZ4N	DI	DMQCZ4N
DMQCZ4N	DN	Glyminox
DMQCZ4N	MI	TT84ETX
DMQCZ4N	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQCZ4N	MT	DTT
DMQCZ4N	MA	Inhibitor
DMQCZ4N	RN	Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31.
DMQCZ4N	RU	https://pubmed.ncbi.nlm.nih.gov/15043398

DMOHUR2	DI	DMOHUR2
DMOHUR2	DN	GLYX-13
DMOHUR2	MI	TT9IK2Z
DMOHUR2	MN	N-methyl-D-aspartate receptor (NMDAR)
DMOHUR2	MT	DTT
DMOHUR2	MA	Agonist
DMOHUR2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOHUR2	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQIE7U	DI	DMQIE7U
DMQIE7U	DN	GMA102
DMQIE7U	MI	TTVIMDE
DMQIE7U	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQIE7U	MT	DTT
DMQIE7U	MA	Inhibitor
DMQIE7U	RN	Clinical pipeline report, company report or official report of Gmax Biopharm.
DMQIE7U	RU	http://www.gmaxbiopharm.com/wap_product_detailen/id/2.html

DM2XSG0	DI	DM2XSG0
DM2XSG0	DN	GMA105
DM2XSG0	MI	TTVIMDE
DM2XSG0	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM2XSG0	MT	DTT
DM2XSG0	MA	Inhibitor
DM2XSG0	RN	Clinical pipeline report, company report or official report of Gmax Biopharm.
DM2XSG0	RU	http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTAU4D6
DMJ432G	MN	E-selectin (SELE)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TT2IYXF
DMJ432G	MN	L-selectin (SELL)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTE5VG0
DMJ432G	MN	P-selectin (SELP)
DMJ432G	MT	DTT
DMJ432G	MA	Inhibitor
DMJ432G	RN	Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
DMJ432G	RU	https://pubmed.ncbi.nlm.nih.gov/22129980

DMJ432G	DI	DMJ432G
DMJ432G	DN	GMI-1070
DMJ432G	MI	TTBGONL
DMJ432G	MN	Selectin (SEL)
DMJ432G	MT	DTT
DMJ432G	MA	Antagonist
DMJ432G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ432G	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMDTGWQ	DI	DMDTGWQ
DMDTGWQ	DN	GMI-1271
DMDTGWQ	MI	TTAU4D6
DMDTGWQ	MN	E-selectin (SELE)
DMDTGWQ	MT	DTT
DMDTGWQ	MA	Inhibitor
DMDTGWQ	RN	Clinical pipeline report, company report or official report of glycomimetics.
DMDTGWQ	RU	http://www.glycomimetics.com/programs-pipeline/gmi-1271/

DM0LQ94	DI	DM0LQ94
DM0LQ94	DN	GnRH
DM0LQ94	MI	TT8R70G
DM0LQ94	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM0LQ94	MT	DTT
DM0LQ94	MA	Modulator
DM0LQ94	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DM0LQ94	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DMKWV4B	DI	DMKWV4B
DMKWV4B	DN	Golnerminogene pradenovac
DMKWV4B	MI	TTF8CQI
DMKWV4B	MN	Tumor necrosis factor (TNF)
DMKWV4B	MT	DTT
DMKWV4B	MA	Modulator
DMKWV4B	RN	TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
DMKWV4B	RU	https://pubmed.ncbi.nlm.nih.gov/16132372

DMZS2R7	DI	DMZS2R7
DMZS2R7	DN	Granexin gel
DMZS2R7	MI	TT4F7SL
DMZS2R7	MN	Gap junction alpha-1 protein (GJA1)
DMZS2R7	MT	DTT
DMZS2R7	MA	Modulator
DMZS2R7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMZS2R7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM4Y7WV	DI	DM4Y7WV
DM4Y7WV	DN	GRASPA
DM4Y7WV	MI	TT4WT91
DM4Y7WV	MN	Asparaginase (ASRGL1)
DM4Y7WV	MT	DTT
DM4Y7WV	MA	Modulator
DM4Y7WV	RN	l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65.
DM4Y7WV	RU	https://pubmed.ncbi.nlm.nih.gov/21332712

DM71GPM	DI	DM71GPM
DM71GPM	DN	Grippol Plus
DM71GPM	MI	TT3J5ZI
DM71GPM	MN	Cell mediated immunity response (CMIR)
DM71GPM	MT	DTT
DM71GPM	RN	Clinical pipeline report, company report or official report of Petrovax.
DM71GPM	RU	http://petrovax.com/medication/catalog/grippallplus/

DMB34TZ	DI	DMB34TZ
DMB34TZ	DN	Grippol TC
DMB34TZ	MI	TT3J5ZI
DMB34TZ	MN	Cell mediated immunity response (CMIR)
DMB34TZ	MT	DTT
DMB34TZ	RN	Clinical pipeline report, company report or official report of Petrovax.
DMB34TZ	RU	http://petrovax.com/medication/catalog/grippallplus/

DMHN3PG	DI	DMHN3PG
DMHN3PG	DN	GRT-6005
DMHN3PG	MI	TTKWM86
DMHN3PG	MN	Opioid receptor mu (MOP)
DMHN3PG	MT	DTT
DMHN3PG	MA	Modulator
DMHN3PG	RN	Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6.
DMHN3PG	RU	https://pubmed.ncbi.nlm.nih.gov/25248647

DMNZO7M	DI	DMNZO7M
DMNZO7M	DN	GS-441524
DMNZO7M	MI	TTS824E
DMNZO7M	MN	COVID-19 replicase polyprotein 1ab (pp1ab)
DMNZO7M	MT	DTT
DMNZO7M	MA	Inhibitor
DMNZO7M	RN	Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128.
DMNZO7M	RU	https://pubmed.ncbi.nlm.nih.gov/32258351

DMP8MDW	DI	DMP8MDW
DMP8MDW	DN	GS-5745
DMP8MDW	MI	TT6X50U
DMP8MDW	MN	Matrix metalloproteinase-9 (MMP-9)
DMP8MDW	MT	DTT
DMP8MDW	MA	Modulator
DMP8MDW	RN	National Cancer Institute Drug Dictionary (drug id 747683).
DMP8MDW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747683

DMGJQVI	DI	DMGJQVI
DMGJQVI	DN	GS-6615
DMGJQVI	MI	TT40BO8
DMGJQVI	MN	Late inward sodium current (LISC)
DMGJQVI	MT	DTT
DMGJQVI	MA	Modulator
DMGJQVI	RN	Clinical pipeline report, company report or official report of Gilead.
DMGJQVI	RU	http://www.gilead.com/news/press-releases/2014/5/gilead-announces-phase-1-data-for-investigational-therapy-gs6615-in-patients-with-long-qt3-syndrome

DM936V7	DI	DM936V7
DM936V7	DN	GS-9674
DM936V7	MI	TTS4UGC
DM936V7	MN	Farnesoid X-activated receptor (FXR)
DM936V7	MT	DTT
DM936V7	MA	Agonist
DM936V7	RN	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
DM936V7	RU	https://pubmed.ncbi.nlm.nih.gov/30661255

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	TT5FH9Y
DMT8J0I	MN	Human immunodeficiency virus Integrase (HIV IN)
DMT8J0I	MT	DTT
DMT8J0I	MA	Inhibitor
DMT8J0I	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMT8J0I	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	DEYGVN4
DMT8J0I	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMT8J0I	MT	DME
DMT8J0I	MA	Metabolism
DMT8J0I	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DMT8J0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DMT8J0I	DI	DMT8J0I
DMT8J0I	DN	GSK1265744
DMT8J0I	MI	DE85D2P
DMT8J0I	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMT8J0I	MT	DME
DMT8J0I	MA	Metabolism
DMT8J0I	RN	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-62.
DMT8J0I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26134155

DMRNGD2	DI	DMRNGD2
DMRNGD2	DN	GSK1278863
DMRNGD2	MI	DES5XRU
DMRNGD2	MN	Cytochrome P450 2C8 (CYP2C8)
DMRNGD2	MT	DME
DMRNGD2	MA	Metabolism
DMRNGD2	RN	Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410-8.
DMRNGD2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26643993

DMRNGD2	DI	DMRNGD2
DMRNGD2	DN	GSK1278863
DMRNGD2	MI	TTMHFRY
DMRNGD2	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DMRNGD2	MT	DTT
DMRNGD2	MA	Inhibitor
DMRNGD2	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMRNGD2	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMSMFN2	DI	DMSMFN2
DMSMFN2	DN	GSK2140944
DMSMFN2	MI	TT0IHXV
DMSMFN2	MN	DNA topoisomerase II (TOP2)
DMSMFN2	MT	DTT
DMSMFN2	MA	Inhibitor
DMSMFN2	RN	Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32.
DMSMFN2	RU	https://pubmed.ncbi.nlm.nih.gov/24759716

DMWL2XD	DI	DMWL2XD
DMWL2XD	DN	GSK2402968
DMWL2XD	MI	TTWLFXU
DMWL2XD	MN	Dystrophin messenger RNA (DMD mRNA)
DMWL2XD	MT	DTT
DMWL2XD	MA	Modulator
DMWL2XD	RN	Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96.
DMWL2XD	RU	https://pubmed.ncbi.nlm.nih.gov/25209738

DMUVZAO	DI	DMUVZAO
DMUVZAO	DN	GSK642444
DMUVZAO	MI	TT2CJVK
DMUVZAO	MN	Adrenergic receptor beta-2 (ADRB2)
DMUVZAO	MT	DTT
DMUVZAO	MA	Agonist
DMUVZAO	RN	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
DMUVZAO	RU	https://pubmed.ncbi.nlm.nih.gov/28919714

DMPS7U2	DI	DMPS7U2
DMPS7U2	DN	GTPL-9088
DMPS7U2	MI	DE4LYSA
DMPS7U2	MN	Cytochrome P450 3A4 (CYP3A4)
DMPS7U2	MT	DME
DMPS7U2	MA	Metabolism
DMPS7U2	RN	Product Information of Eumovate.
DMPS7U2	RU	https://www.medsafe.govt.nz/Profs/Datasheet/e/Eumovatecrm.pdf

DM9Y3EG	DI	DM9Y3EG
DM9Y3EG	DN	Guadecitabine
DM9Y3EG	MI	TT6S2FE
DM9Y3EG	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM9Y3EG	MT	DTT
DM9Y3EG	MA	Inhibitor
DM9Y3EG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Y3EG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMN4E7T	DI	DMN4E7T
DMN4E7T	DN	Guaiacol
DMN4E7T	MI	TTANPDJ
DMN4E7T	MN	Carbonic anhydrase II (CA-II)
DMN4E7T	MT	DTT
DMN4E7T	MA	Inhibitor
DMN4E7T	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMN4E7T	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DMN4E7T	DI	DMN4E7T
DMN4E7T	DN	Guaiacol
DMN4E7T	MI	DEXL6TZ
DMN4E7T	MN	Thyroid peroxidase (TPO)
DMN4E7T	MT	DME
DMN4E7T	MA	Metabolism
DMN4E7T	RN	Kinetic characterization of human thyroperoxidase. Normal and pathological enzyme expression in Baculovirus system: a molecular model of functional expression. Mol Cell Endocrinol. 2015 Mar 15;404:9-15.
DMN4E7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25576858

DMIWLJE	DI	DMIWLJE
DMIWLJE	DN	Guanine
DMIWLJE	MI	TTLSWP6
DMIWLJE	MN	GTP cyclohydrolase-I (GCH1)
DMIWLJE	MT	DTT
DMIWLJE	MA	Inhibitor
DMIWLJE	RN	GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73.
DMIWLJE	RU	https://pubmed.ncbi.nlm.nih.gov/11361142

DMHULRK	DI	DMHULRK
DMHULRK	DN	GV1001
DMHULRK	MI	TTUJFD0
DMHULRK	MN	Telomerase reverse transcriptase (TERT)
DMHULRK	MT	DTT
DMHULRK	RN	Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82.
DMHULRK	RU	https://pubmed.ncbi.nlm.nih.gov/17060934

DMAXTFO	DI	DMAXTFO
DMAXTFO	DN	H1N1 influenza vaccine
DMAXTFO	MI	TT3J5ZI
DMAXTFO	MN	Cell mediated immunity response (CMIR)
DMAXTFO	MT	DTT
DMAXTFO	RN	Clinical pipeline report, company report or official report of Sanofi Pasteur.
DMAXTFO	RU	http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency.aspx

DM9CMI3	DI	DM9CMI3
DM9CMI3	DN	H5N1 influenza vaccine
DM9CMI3	MI	TT3J5ZI
DM9CMI3	MN	Cell mediated immunity response (CMIR)
DM9CMI3	MT	DTT
DM9CMI3	RN	Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008.
DM9CMI3	RU	http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2008.00066.x/full

DMQ38JZ	DI	DMQ38JZ
DMQ38JZ	DN	HB-AS02V
DMQ38JZ	MI	TT3J5ZI
DMQ38JZ	MN	Cell mediated immunity response (CMIR)
DMQ38JZ	MT	DTT
DMQ38JZ	RN	Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84.
DMQ38JZ	RU	https://pubmed.ncbi.nlm.nih.gov/20523113

DMB06MU	DI	DMB06MU
DMB06MU	DN	HC-1119
DMB06MU	MI	TTS64P2
DMB06MU	MN	Androgen receptor (AR)
DMB06MU	MT	DTT
DMB06MU	MA	Inhibitor
DMB06MU	RN	Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.
DMB06MU	RU	http://www.hinovapharma.com/en/chanpinxianguan.html

DMB9U5E	DI	DMB9U5E
DMB9U5E	DN	HE3286
DMB9U5E	MI	DE4LYSA
DMB9U5E	MN	Cytochrome P450 3A4 (CYP3A4)
DMB9U5E	MT	DME
DMB9U5E	MA	Metabolism
DMB9U5E	RN	Studies of the pharmacology of 17alpha-ethynyl-androst-5-ene-3beta,7beta,17beta-triol, a synthetic anti-inflammatory androstene. Int J Clin Exp Med. 2011;4(2):119-35.
DMB9U5E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21686136

DMQTLVB	DI	DMQTLVB
DMQTLVB	DN	Hebergel
DMQTLVB	MI	TTSIUJ9
DMQTLVB	MN	Interferon-alpha 2 (IFNA2)
DMQTLVB	MT	DTT
DMQTLVB	MA	Modulator
DMQTLVB	RN	Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7.
DMQTLVB	RU	https://pubmed.ncbi.nlm.nih.gov/16316735

DMUE843	DI	DMUE843
DMUE843	DN	Hematide
DMUE843	MI	TTAUX24
DMUE843	MN	Erythropoietin Receptor (EPOR)
DMUE843	MT	DTT
DMUE843	MA	Agonist
DMUE843	RN	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
DMUE843	RU	https://pubmed.ncbi.nlm.nih.gov/23370234

DMGFULM	DI	DMGFULM
DMGFULM	DN	Heparin low molecular weight
DMGFULM	MI	TT4QPUL
DMGFULM	MN	Antithrombin-III (ATIII)
DMGFULM	MT	DTT
DMGFULM	MA	Modulator
DMGFULM	RN	Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8.
DMGFULM	RU	https://pubmed.ncbi.nlm.nih.gov/8588200

DMXAZ47	DI	DMXAZ47
DMXAZ47	DN	HGH-CTP
DMXAZ47	MI	TTT3YKH
DMXAZ47	MN	Somatotropin (GH1)
DMXAZ47	MT	DTT
DMXAZ47	MA	Agonist
DMXAZ47	RN	Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538.
DMXAZ47	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122423/

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	DE4LYSA
DM6QOVN	MN	Cytochrome P450 3A4 (CYP3A4)
DM6QOVN	MT	DME
DM6QOVN	MA	Metabolism
DM6QOVN	RN	Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57.
DM6QOVN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27284682

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTGKNB4
DM6QOVN	MN	Epidermal growth factor receptor (EGFR)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTR5TV4
DM6QOVN	MN	ERBB2 messenger RNA (HER2 mRNA)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/18077425

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TT6EO5L
DM6QOVN	MN	Erbb2 tyrosine kinase receptor (HER2)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM6QOVN	DI	DM6QOVN
DM6QOVN	DN	HKI-272
DM6QOVN	MI	TTUTJGQ
DM6QOVN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6QOVN	MT	DTT
DM6QOVN	MA	Inhibitor
DM6QOVN	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DM6QOVN	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DM29XGY	DI	DM29XGY
DM29XGY	DN	HMPL-004
DM29XGY	MI	TTBD054
DM29XGY	MN	Inflammation pathogenesis (IP)
DM29XGY	MT	DTT
DM29XGY	MA	Antagonist
DM29XGY	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DM29XGY	RU	http://www.hmplglobal.com/en/hmpl-004/

DMAVIPZ	DI	DMAVIPZ
DMAVIPZ	DN	HSR-803
DMAVIPZ	MI	DEP76YL
DMAVIPZ	MN	Dimethylaniline oxidase 3 (FMO3)
DMAVIPZ	MT	DME
DMAVIPZ	MA	Metabolism
DMAVIPZ	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DMAVIPZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DMBER0Q	DI	DMBER0Q
DMBER0Q	DN	Hu5F9-G4
DMBER0Q	MI	TT28S46
DMBER0Q	MN	Leukocyte surface antigen CD47 (CD47)
DMBER0Q	MT	DTT
DMBER0Q	MA	Inhibitor
DMBER0Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBER0Q	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TTZGK1R
DMXZAL2	MN	HUMAN glycosylation of host receptor (GHR)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TTD16BI
DMXZAL2	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMXZAL2	DI	DMXZAL2
DMXZAL2	DN	Hydroxychloroquine
DMXZAL2	MI	TT3A1EZ
DMXZAL2	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMXZAL2	MT	DTT
DMXZAL2	MA	Inhibitor
DMXZAL2	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMXZAL2	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMIGFOR	DI	DMIGFOR
DMIGFOR	DN	I3C
DMIGFOR	MI	TTSHAEB
DMIGFOR	MN	NF-kappa-B inhibitor alpha (NFKBIA)
DMIGFOR	MT	DTT
DMIGFOR	MA	Inhibitor
DMIGFOR	RN	Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137.
DMIGFOR	RU	https://pubmed.ncbi.nlm.nih.gov/32800927

DM5KL8E	DI	DM5KL8E
DM5KL8E	DN	IBI-308
DM5KL8E	MI	TTNBFWK
DM5KL8E	MN	Programmed cell death protein 1 (PD-1)
DM5KL8E	MT	DTT
DM5KL8E	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM5KL8E	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM9G5XD	DI	DM9G5XD
DM9G5XD	DN	IB-MECA
DM9G5XD	MI	TTJFY5U
DM9G5XD	MN	Adenosine A3 receptor (ADORA3)
DM9G5XD	MT	DTT
DM9G5XD	MA	Agonist
DM9G5XD	RN	A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
DM9G5XD	RU	https://pubmed.ncbi.nlm.nih.gov/8262217

DMT67EH	DI	DMT67EH
DMT67EH	DN	Ibodutant
DMT67EH	MI	TTYO0A3
DMT67EH	MN	Substance-K receptor (TACR2)
DMT67EH	MT	DTT
DMT67EH	MA	Antagonist
DMT67EH	RN	Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5.
DMT67EH	RU	https://pubmed.ncbi.nlm.nih.gov/24436990

DMOJQGT	DI	DMOJQGT
DMOJQGT	DN	ICARIIN
DMOJQGT	MI	TTJ0IQB
DMOJQGT	MN	Phosphodiesterase 5A (PDE5A)
DMOJQGT	MT	DTT
DMOJQGT	MA	Inhibitor
DMOJQGT	RN	Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
DMOJQGT	RU	https://pubmed.ncbi.nlm.nih.gov/18778098

DM3OU54	DI	DM3OU54
DM3OU54	DN	ICI 118,551
DM3OU54	MI	TT2CJVK
DM3OU54	MN	Adrenergic receptor beta-2 (ADRB2)
DM3OU54	MT	DTT
DM3OU54	MA	Antagonist
DM3OU54	RN	Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5.
DM3OU54	RU	https://pubmed.ncbi.nlm.nih.gov/2907563

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TTV8DM2
DM7YNV9	MN	Bacterial Dihydrofolate reductase (Bact DHFR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Modulator
DM7YNV9	RN	Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/19257839

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DE5IED8
DM7YNV9	MN	Cytochrome P450 2C9 (CYP2C9)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DECB0K3
DM7YNV9	MN	Cytochrome P450 2D6 (CYP2D6)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	DE4LYSA
DM7YNV9	MN	Cytochrome P450 3A4 (CYP3A4)
DM7YNV9	MT	DME
DM7YNV9	MA	Metabolism
DM7YNV9	RN	An updated review of iclaprim: a potent and rapidly bactericidal antibiotic for the treatment of skin and skin structure infections and nosocomial pneumonia caused by gram-positive including multidrug-resistant bacteria. Open Forum Infect Dis. 2018 Jan 6;5(2):ofy003.
DM7YNV9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29423421

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TTYZVDJ
DM7YNV9	MN	Dihydrofolate reductase (DHFR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Inhibitor
DM7YNV9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7YNV9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7YNV9	DI	DM7YNV9
DM7YNV9	DN	Iclaprim
DM7YNV9	MI	TT9B4N3
DM7YNV9	MN	Prostaglandin receptor (PTGR)
DM7YNV9	MT	DTT
DM7YNV9	MA	Modulator
DM7YNV9	RN	Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
DM7YNV9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/

DMU72KL	DI	DMU72KL
DMU72KL	DN	ICP-022
DMU72KL	MI	TTGM6VW
DMU72KL	MN	Tyrosine-protein kinase BTK (ATK)
DMU72KL	MT	DTT
DMU72KL	MA	Inhibitor
DMU72KL	RN	Clinical pipeline report, company report or official report of InnoCare Pharma.
DMU72KL	RU	https://www.innocarepharma.com/en/pipeline/our-pipeline/

DMBIZ7H	DI	DMBIZ7H
DMBIZ7H	DN	ICT-107
DMBIZ7H	MI	TTMPZ7V
DMBIZ7H	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DMBIZ7H	MT	DTT
DMBIZ7H	RN	Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
DMBIZ7H	RU	http://www.imuc.com/pipeline/ict-107

DMSP0X8	DI	DMSP0X8
DMSP0X8	DN	IDAZOXAN HYDROCHLORIDE
DMSP0X8	MI	TT2NUT5
DMSP0X8	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMSP0X8	MT	DTT
DMSP0X8	MA	Modulator
DMSP0X8	RN	Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.
DMSP0X8	RU	https://pubmed.ncbi.nlm.nih.gov/1354730

DMV3DHQ	DI	DMV3DHQ
DMV3DHQ	DN	IDDBCP161883
DMV3DHQ	MI	TTDIGC1
DMV3DHQ	MN	Dipeptidyl peptidase 4 (DPP-4)
DMV3DHQ	MT	DTT
DMV3DHQ	MA	Inhibitor
DMV3DHQ	RN	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95.
DMV3DHQ	RU	https://pubmed.ncbi.nlm.nih.gov/23671395

DM3A701	DI	DM3A701
DM3A701	DN	IDP-122
DM3A701	MI	TTP3UTW
DM3A701	MN	Steroid hormone receptor ERR (ESRR)
DM3A701	MT	DTT
DM3A701	MA	Agonist
DM3A701	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3A701	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRLVUD	DI	DMRLVUD
DMRLVUD	DN	Imagabalin
DMRLVUD	MI	TTFK1JQ
DMRLVUD	MN	Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)
DMRLVUD	MT	DTT
DMRLVUD	MA	Agonist
DMRLVUD	RN	Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
DMRLVUD	RU	https://pubmed.ncbi.nlm.nih.gov/21664606

DMM9JEF	DI	DMM9JEF
DMM9JEF	DN	Imatinib
DMM9JEF	MI	TTE63HY
DMM9JEF	MN	HUMAN fusion protein Bcr-Abl (Bcr-Abl)
DMM9JEF	MT	DTT
DMM9JEF	MA	Inhibitor
DMM9JEF	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMM9JEF	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DM7BCWT	DI	DM7BCWT
DM7BCWT	DN	Imiglitazar
DM7BCWT	MI	TTJ584C
DM7BCWT	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM7BCWT	MT	DTT
DM7BCWT	MA	Modulator
DM7BCWT	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM7BCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DM7BCWT	DI	DM7BCWT
DM7BCWT	DN	Imiglitazar
DM7BCWT	MI	TTZMAO3
DM7BCWT	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM7BCWT	MT	DTT
DM7BCWT	MA	Modulator
DM7BCWT	RN	A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
DM7BCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15219816

DM735FA	DI	DM735FA
DM735FA	DN	IMO-2125
DM735FA	MI	TTSHG0T
DM735FA	MN	Toll-like receptor 9 (TLR9)
DM735FA	MT	DTT
DM735FA	MA	Agonist
DM735FA	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
DM735FA	RU	http://www.iderapharma.com/

DMIJGT9	DI	DMIJGT9
DMIJGT9	DN	INCB24360
DMIJGT9	MI	TTZJYKH
DMIJGT9	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMIJGT9	MT	DTT
DMIJGT9	MA	Inhibitor
DMIJGT9	RN	Incyte. Product Development Pipeline.
DMIJGT9	RU	http://www.incyte.com/drugs_product_pipeline.html

DMZA2K0	DI	DMZA2K0
DMZA2K0	DN	INCSHR1210
DMZA2K0	MI	TTNBFWK
DMZA2K0	MN	Programmed cell death protein 1 (PD-1)
DMZA2K0	MT	DTT
DMZA2K0	MA	Inhibitor
DMZA2K0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZA2K0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLG96Z	DI	DMLG96Z
DMLG96Z	DN	INM-176
DMLG96Z	MI	TT1RS9F
DMLG96Z	MN	Acetylcholinesterase (AChE)
DMLG96Z	MT	DTT
DMLG96Z	MA	Inhibitor
DMLG96Z	RN	The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Abeta(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012 Sep 28;143(2):611-20.
DMLG96Z	RU	https://pubmed.ncbi.nlm.nih.gov/22846435

DM5L8QT	DI	DM5L8QT
DM5L8QT	DN	INO-1001
DM5L8QT	MI	TTEBCY8
DM5L8QT	MN	Poly [ADP-ribose] polymerase (PARP)
DM5L8QT	MT	DTT
DM5L8QT	MA	Modulator
DM5L8QT	RN	Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
DM5L8QT	RU	https://pubmed.ncbi.nlm.nih.gov/20395771

DMUS1F8	DI	DMUS1F8
DMUS1F8	DN	Inolimomab
DMUS1F8	MI	TT10Y9E
DMUS1F8	MN	Interleukin 2 receptor alpha (IL2RA)
DMUS1F8	MT	DTT
DMUS1F8	MA	Modulator
DMUS1F8	RN	Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41.
DMUS1F8	RU	https://www.ncbi.nlm.nih.gov/pubmed/17085306

DMOTH6V	DI	DMOTH6V
DMOTH6V	DN	Interferon alpha 2a
DMOTH6V	MI	TTSIUJ9
DMOTH6V	MN	Interferon-alpha 2 (IFNA2)
DMOTH6V	MT	DTT
DMOTH6V	MA	Modulator
DMOTH6V	RN	Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.
DMOTH6V	RU	https://pubmed.ncbi.nlm.nih.gov/2840988

DMZA47Y	DI	DMZA47Y
DMZA47Y	DN	Iomab-B
DMZA47Y	MI	TTUS45N
DMZA47Y	MN	Leukocyte common antigen (PTPRC)
DMZA47Y	MT	DTT
DMZA47Y	RN	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
DMZA47Y	RU	http://www.actiniumpharma.com/products/pipeline/iomab-b/

DMSV12M	DI	DMSV12M
DMSV12M	DN	Isavuconazole
DMSV12M	MI	DE4LYSA
DMSV12M	MN	Cytochrome P450 3A4 (CYP3A4)
DMSV12M	MT	DME
DMSV12M	MA	Metabolism
DMSV12M	RN	Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53.
DMSV12M	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27273461

DMQZI7K	DI	DMQZI7K
DMQZI7K	DN	ISIS 23722
DMQZI7K	MI	TTTPU1G
DMQZI7K	MN	Apoptosis inhibitor survivin (BIRC5)
DMQZI7K	MT	DTT
DMQZI7K	MA	Modulator
DMQZI7K	RN	Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71.
DMQZI7K	RU	https://www.ncbi.nlm.nih.gov/pubmed/22088485

DMKWBJR	DI	DMKWBJR
DMKWBJR	DN	ISIS-PKK
DMKWBJR	MI	TTN0PCX
DMKWBJR	MN	Plasma kallikrein messenger RNA (KLKB1 mRNA)
DMKWBJR	MT	DTT
DMKWBJR	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMKWBJR	RU	https://www.isispharm.com/pipeline/isis-pkkrx/

DM4U5NF	DI	DM4U5NF
DM4U5NF	DN	ISIS-TTR
DM4U5NF	MI	TTPOYU7
DM4U5NF	MN	Transthyretin messenger RNA (TTR mRNA)
DM4U5NF	MT	DTT
DM4U5NF	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DM4U5NF	RU	http://www.isispharm.com/index.htm

DMBJTVL	DI	DMBJTVL
DMBJTVL	DN	Isotretinoin
DMBJTVL	MI	TTNHMO8
DMBJTVL	MN	COVID-19 papain-like proteinase (PL-PRO)
DMBJTVL	MT	DTT
DMBJTVL	MA	Inhibitor
DMBJTVL	RN	ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health.
DMBJTVL	RU	https://clinicaltrials.gov/ct2/show/NCT04361422

DMP61YB	DI	DMP61YB
DMP61YB	DN	ISRAPAFANT
DMP61YB	MI	TTQL5VC
DMP61YB	MN	Platelet-activating factor receptor (PTAFR)
DMP61YB	MT	DTT
DMP61YB	MA	Antagonist
DMP61YB	RN	Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
DMP61YB	RU	https://pubmed.ncbi.nlm.nih.gov/20007715

DMNDGWE	DI	DMNDGWE
DMNDGWE	DN	IT-101
DMNDGWE	MI	TTQHWNA
DMNDGWE	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DMNDGWE	MT	DTT
DMNDGWE	MA	Inhibitor
DMNDGWE	RN	CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67.
DMNDGWE	RU	https://pubmed.ncbi.nlm.nih.gov/25833208

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TTBH0VX
DMFZBNE	MN	Histone deacetylase (HDAC)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFZBNE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TT6R7JZ
DMFZBNE	MN	Histone deacetylase 1 (HDAC1)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMFZBNE	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMFZBNE	DI	DMFZBNE
DMFZBNE	DN	ITF2357
DMFZBNE	MI	TTRMX3V
DMFZBNE	MN	Janus kinase 2 (JAK-2)
DMFZBNE	MT	DTT
DMFZBNE	MA	Inhibitor
DMFZBNE	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMFZBNE	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TTJQOD7
DMUQ1DO	MN	5-HT 2A receptor (HTR2A)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
DMUQ1DO	RU	http://www.intracellulartherapies.com/products-technology/iti-007.html

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TT85JO3
DMUQ1DO	MN	5-HT receptor (5HTR)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUQ1DO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMUQ1DO	DI	DMUQ1DO
DMUQ1DO	DN	ITI-007
DMUQ1DO	MI	TT3ROYC
DMUQ1DO	MN	Serotonin transporter (SERT)
DMUQ1DO	MT	DTT
DMUQ1DO	MA	Antagonist
DMUQ1DO	RN	Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc.
DMUQ1DO	RU	http://www.intracellulartherapies.com/products-technology/iti-007.html

DMGWVLX	DI	DMGWVLX
DMGWVLX	DN	Itolizumab
DMGWVLX	MI	TTMF6KC
DMGWVLX	MN	T-cell differentiation antigen CD6 (TP120)
DMGWVLX	MT	DTT
DMGWVLX	RN	Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014 Sep;71(3):484-92.
DMGWVLX	RU	https://pubmed.ncbi.nlm.nih.gov/24703722

DM7MLTR	DI	DM7MLTR
DM7MLTR	DN	Itopride
DM7MLTR	MI	DEP76YL
DM7MLTR	MN	Dimethylaniline oxidase 3 (FMO3)
DM7MLTR	MT	DME
DM7MLTR	MA	Metabolism
DM7MLTR	RN	Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharm Drug Dispos. 2017 Sep;38(6):389-393.
DM7MLTR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28255999

DMNORK8	DI	DMNORK8
DMNORK8	DN	Jakafi
DMNORK8	MI	DE4LYSA
DMNORK8	MN	Cytochrome P450 3A4 (CYP3A4)
DMNORK8	MT	DME
DMNORK8	MA	Metabolism
DMNORK8	RN	Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27.
DMNORK8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23061804

DM8FSPV	DI	DM8FSPV
DM8FSPV	DN	JTZ-951
DM8FSPV	MI	TTJQFBG
DM8FSPV	MN	HIF-prolyl hydroxylase (HPH)
DM8FSPV	MT	DTT
DM8FSPV	MA	Modulator
DM8FSPV	RN	DOI: 10.1038/nrneph.2015.82
DM8FSPV	RU	http://www.nature.com/nrneph/journal/v11/n7/fig_tab/nrneph.2015.82_T1.html

DM5WCV4	DI	DM5WCV4
DM5WCV4	DN	JX-594
DM5WCV4	MI	TTNYZG2
DM5WCV4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM5WCV4	MT	DTT
DM5WCV4	MA	Modulator
DM5WCV4	RN	Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70.
DM5WCV4	RU	https://pubmed.ncbi.nlm.nih.gov/16905462

DM9J0KD	DI	DM9J0KD
DM9J0KD	DN	K-103-IP
DM9J0KD	MI	TTK0943
DM9J0KD	MN	Prostaglandin G/H synthase (COX)
DM9J0KD	MT	DTT
DM9J0KD	MA	Modulator
DM9J0KD	RN	ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health.
DM9J0KD	RU	https://clinicaltrials.gov/ct2/show/NCT02089425

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DTI7UX6
DMCRGY4	MN	Breast cancer resistance protein (ABCG2)
DMCRGY4	MT	DTP
DMCRGY4	MA	Substrate
DMCRGY4	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMCRGY4	RU	https://doi.org/10.2217/14622416.9.8.1005

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DES5XRU
DMCRGY4	MN	Cytochrome P450 2C8 (CYP2C8)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DECB0K3
DMCRGY4	MN	Cytochrome P450 2D6 (CYP2D6)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DE4LYSA
DMCRGY4	MN	Cytochrome P450 3A4 (CYP3A4)
DMCRGY4	MT	DME
DMCRGY4	MA	Metabolism
DMCRGY4	RN	Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
DMCRGY4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12971034

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	TT2GPK3
DMCRGY4	MN	DNA topoisomerase (TOP)
DMCRGY4	MT	DTT
DMCRGY4	MA	Inhibitor
DMCRGY4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCRGY4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	TTGTQHC
DMCRGY4	MN	DNA topoisomerase I (TOP1)
DMCRGY4	MT	DTT
DMCRGY4	MA	Inhibitor
DMCRGY4	RN	Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
DMCRGY4	RU	https://pubmed.ncbi.nlm.nih.gov/10692484

DMCRGY4	DI	DMCRGY4
DMCRGY4	DN	Karenitecin
DMCRGY4	MI	DT3D8F0
DMCRGY4	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMCRGY4	MT	DTP
DMCRGY4	MA	Substrate
DMCRGY4	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMCRGY4	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM8VO16	DI	DM8VO16
DM8VO16	DN	KH-902
DM8VO16	MI	TTVJ1D8
DM8VO16	MN	Vascular endothelial growth factor receptor (VEGFR)
DM8VO16	MT	DTT
DM8VO16	MA	Modulator
DM8VO16	RN	Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
DM8VO16	RU	https://pubmed.ncbi.nlm.nih.gov/22340191

DMSDBPG	DI	DMSDBPG
DMSDBPG	DN	KN046
DMSDBPG	MI	TTI2S1D
DMSDBPG	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMSDBPG	MT	DTT
DMSDBPG	MA	Inhibitor
DMSDBPG	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMSDBPG	RU	http://www.alphamabonc.com/pipeline/kn046.html

DMSDBPG	DI	DMSDBPG
DMSDBPG	DN	KN046
DMSDBPG	MI	TT8ZLTI
DMSDBPG	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMSDBPG	MT	DTT
DMSDBPG	MA	Inhibitor
DMSDBPG	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMSDBPG	RU	http://www.alphamabonc.com/pipeline/kn046.html

DMP5G1K	DI	DMP5G1K
DMP5G1K	DN	KPS-0373
DMP5G1K	MI	TT2Z39D
DMP5G1K	MN	Thyrotropin-releasing hormone (TRH)
DMP5G1K	MT	DTT
DMP5G1K	MA	Modulator
DMP5G1K	RN	DOI: 10.1002/mdc3.12057
DMP5G1K	RU	http://www.movementdisorders.org/MDS/Journals/Clinical-Practice-E-Journal-Overview/Movement-Disorders-Clinical-Practice-E-Journal-Volume-1-Issue-4/Treatment-Options-in-Degenerative-Cerebellar-Ataxia-A-Systematic-Review.htm

DMM2LTC	DI	DMM2LTC
DMM2LTC	DN	KSI-301
DMM2LTC	MI	TT9HKJA
DMM2LTC	MN	Vascular endothelial growth factor (VEGF)
DMM2LTC	MT	DTT
DMM2LTC	MA	Inhibitor
DMM2LTC	RN	Clinical pipeline report, company report or official report of Kodiak Sciences.
DMM2LTC	RU	https://kodiak.com/our-pipeline/

DMP3GI2	DI	DMP3GI2
DMP3GI2	DN	KW-3357
DMP3GI2	MI	TT4QPUL
DMP3GI2	MN	Antithrombin-III (ATIII)
DMP3GI2	MT	DTT
DMP3GI2	MA	Modulator
DMP3GI2	RN	Company report (kyowa-kirin)
DMP3GI2	RU	http://www.kyowa-kirin.com/news_releases/2014/e20140801_01.html

DMF0NA9	DI	DMF0NA9
DMF0NA9	DN	KX-01
DMF0NA9	MI	TT6PKBN
DMF0NA9	MN	Proto-oncogene c-Src (SRC)
DMF0NA9	MT	DTT
DMF0NA9	MA	Inhibitor
DMF0NA9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF0NA9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWTPCA	DI	DMWTPCA
DMWTPCA	DN	L-651582
DMWTPCA	MI	DE4LYSA
DMWTPCA	MN	Cytochrome P450 3A4 (CYP3A4)
DMWTPCA	MT	DME
DMWTPCA	MA	Metabolism
DMWTPCA	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMWTPCA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMWTPCA	DI	DMWTPCA
DMWTPCA	DN	L-651582
DMWTPCA	MI	TTH18TF
DMWTPCA	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMWTPCA	MT	DTT
DMWTPCA	MA	Modulator
DMWTPCA	RN	The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther. 1991 Jun;257(3):967-71.
DMWTPCA	RU	https://pubmed.ncbi.nlm.nih.gov/1646332

DMI3YLK	DI	DMI3YLK
DMI3YLK	DN	LA-EP2006
DMI3YLK	MI	TT5TQ2W
DMI3YLK	MN	Granulocyte colony-stimulating factor (CSF3)
DMI3YLK	MT	DTT
DMI3YLK	MA	Modulator
DMI3YLK	RN	National Cancer Institute Drug Dictionary (drug id 724518).
DMI3YLK	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724518

DMA2NYS	DI	DMA2NYS
DMA2NYS	DN	Lampalizumab
DMA2NYS	MI	TT8D13I
DMA2NYS	MN	Complement factor D (CFD)
DMA2NYS	MT	DTT
DMA2NYS	MA	Inhibitor
DMA2NYS	RN	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95.
DMA2NYS	RU	https://pubmed.ncbi.nlm.nih.gov/30444371

DMFJLB6	DI	DMFJLB6
DMFJLB6	DN	Lanabecestat
DMFJLB6	MI	TT8JRS7
DMFJLB6	MN	Beta-secretase (BACE)
DMFJLB6	MT	DTT
DMFJLB6	MA	Inhibitor
DMFJLB6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFJLB6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4EGPN	DI	DM4EGPN
DM4EGPN	DN	Lanperisone
DM4EGPN	MI	TT84DRB
DM4EGPN	MN	Voltage-gated sodium channel alpha Nav1.4 (SCN4A)
DM4EGPN	MT	DTT
DM4EGPN	MA	Modulator
DM4EGPN	RN	Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46.
DM4EGPN	RU	https://pubmed.ncbi.nlm.nih.gov/16126840

DMMA0C7	DI	DMMA0C7
DMMA0C7	DN	Laquinamod
DMMA0C7	MI	TTZF0K2
DMMA0C7	MN	C-X-C motif chemokine 2 (CXCL2)
DMMA0C7	MT	DTT
DMMA0C7	MA	Modulator
DMMA0C7	RN	Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9.
DMMA0C7	RU	https://pubmed.ncbi.nlm.nih.gov/18220950

DM3IWS8	DI	DM3IWS8
DM3IWS8	DN	Laquinimod
DM3IWS8	MI	DE4LYSA
DM3IWS8	MN	Cytochrome P450 3A4 (CYP3A4)
DM3IWS8	MT	DME
DM3IWS8	MA	Metabolism
DM3IWS8	RN	Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011 Mar;26(2):111-7.
DM3IWS8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21163185

DM3IWS8	DI	DM3IWS8
DM3IWS8	DN	Laquinimod
DM3IWS8	MI	TTSXVID
DM3IWS8	MN	Nuclear factor NF-kappa-B (NFKB)
DM3IWS8	MT	DTT
DM3IWS8	MA	Modulator
DM3IWS8	RN	Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
DM3IWS8	RU	https://pubmed.ncbi.nlm.nih.gov/22766690

DMH2EA1	DI	DMH2EA1
DMH2EA1	DN	Laromustine
DMH2EA1	MI	TTUTN1I
DMH2EA1	MN	Human Deoxyribonucleic acid (hDNA)
DMH2EA1	MT	DTT
DMH2EA1	MA	Binder
DMH2EA1	RN	Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6.
DMH2EA1	RU	https://pubmed.ncbi.nlm.nih.gov/20511167

DMAJM12	DI	DMAJM12
DMAJM12	DN	LATIN T1D
DMAJM12	MI	TTVIMDE
DMAJM12	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMAJM12	MT	DTT
DMAJM12	MA	Agonist
DMAJM12	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMAJM12	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DM09RKB	DI	DM09RKB
DM09RKB	DN	LC-150444
DM09RKB	MI	TTDIGC1
DM09RKB	MN	Dipeptidyl peptidase 4 (DPP-4)
DM09RKB	MT	DTT
DM09RKB	MA	Inhibitor
DM09RKB	RN	Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
DM09RKB	RU	http://www.apischemical.com/APIsproducts4/850649-62-6,Alogliptin(SYR-322).htm

DMT4K0Z	DI	DMT4K0Z
DMT4K0Z	DN	L-citrulline
DMT4K0Z	MI	DTP7AEQ
DMT4K0Z	MN	Glycoprotein-associated amino acid transporter b0, +AT1 (SLC7A9)
DMT4K0Z	MT	DTP
DMT4K0Z	MA	Substrate
DMT4K0Z	RN	Transport characteristics of L-citrulline in renal apical membrane of proximal tubular cells. Biopharm Drug Dispos. 2009 Apr;30(3):126-37.
DMT4K0Z	RU	http://www.ncbi.nlm.nih.gov/pubmed/19322909

DMT4K0Z	DI	DMT4K0Z
DMT4K0Z	DN	L-citrulline
DMT4K0Z	MI	TTI1PRE
DMT4K0Z	MN	G-protein coupled receptor GPCR33 (GPRC6A)
DMT4K0Z	MT	DTT
DMT4K0Z	MA	Agonist
DMT4K0Z	RN	Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97.
DMT4K0Z	RU	https://pubmed.ncbi.nlm.nih.gov/15576628

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	TTF8P9I
DMFLJHQ	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMFLJHQ	MT	DTT
DMFLJHQ	MA	Modulator
DMFLJHQ	RN	DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.
DMFLJHQ	RU	https://pubmed.ncbi.nlm.nih.gov/20597032

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEYGVN4
DMFLJHQ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEF2WXN
DMFLJHQ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMFLJHQ	DI	DMFLJHQ
DMFLJHQ	DN	LCQ908
DMFLJHQ	MI	DEB3CV1
DMFLJHQ	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMFLJHQ	MT	DME
DMFLJHQ	MA	Metabolism
DMFLJHQ	RN	Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
DMFLJHQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27855567

DMQP0X5	DI	DMQP0X5
DMQP0X5	DN	Lebrikizumab
DMQP0X5	MI	TT0GVCH
DMQP0X5	MN	Interleukin-13 (IL13)
DMQP0X5	MT	DTT
DMQP0X5	MA	Modulator
DMQP0X5	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMQP0X5	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMMX75K	DI	DMMX75K
DMMX75K	DN	LEE011
DMMX75K	MI	TT0PG8F
DMMX75K	MN	Cyclin-dependent kinase 4 (CDK4)
DMMX75K	MT	DTT
DMMX75K	MA	Modulator
DMMX75K	RN	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
DMMX75K	RU	https://pubmed.ncbi.nlm.nih.gov/24045179

DMMX75K	DI	DMMX75K
DMMX75K	DN	LEE011
DMMX75K	MI	TTO0FDJ
DMMX75K	MN	Cyclin-dependent kinase 6 (CDK6)
DMMX75K	MT	DTT
DMMX75K	MA	Modulator
DMMX75K	RN	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
DMMX75K	RU	https://pubmed.ncbi.nlm.nih.gov/24045179

DMSCGM8	DI	DMSCGM8
DMSCGM8	DN	LentiGlobin
DMSCGM8	MI	TTM6HK1
DMSCGM8	MN	Hemoglobin subunit beta (HBB)
DMSCGM8	MT	DTT
DMSCGM8	MA	Modulator
DMSCGM8	RN	Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81.
DMSCGM8	RU	https://pubmed.ncbi.nlm.nih.gov/25429463

DMSRIT4	DI	DMSRIT4
DMSRIT4	DN	Lenzilumab
DMSRIT4	MI	TTPZGYX
DMSRIT4	MN	HUMAN colony-stimulating factor (GM-CSF)
DMSRIT4	MT	DTT
DMSRIT4	MA	Inhibitor
DMSRIT4	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DMSRIT4	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMOTCIU	DI	DMOTCIU
DMOTCIU	DN	Lerisetron
DMOTCIU	MI	TTNXLKE
DMOTCIU	MN	5-HT 3 receptor (5HT3R)
DMOTCIU	MT	DTT
DMOTCIU	MA	Antagonist
DMOTCIU	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMOTCIU	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMAYC76	DI	DMAYC76
DMAYC76	DN	Levomequitazine
DMAYC76	MI	TT7CXIM
DMAYC76	MN	Histamine receptor (HR)
DMAYC76	MT	DTT
DMAYC76	MA	Antagonist
DMAYC76	RN	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
DMAYC76	RU	https://pubmed.ncbi.nlm.nih.gov/9454781

DM103O8	DI	DM103O8
DM103O8	DN	Ligelizumab
DM103O8	MI	TTYJQTF
DM103O8	MN	Immunoglobulin E (IgE)
DM103O8	MT	DTT
DM103O8	MA	Inhibitor
DM103O8	RN	Clinical pipeline report, company report or official report of Novartis.
DM103O8	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=Ligelizumab&field_pipeline_filing_date=All

DMNM93X	DI	DMNM93X
DMNM93X	DN	Linagliptin
DMNM93X	MI	TTF928K
DMNM93X	MN	HUMAN dipeptidyl peptidase 4 (DPP-4)
DMNM93X	MT	DTT
DMNM93X	MA	Inhibitor
DMNM93X	RN	DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26.
DMNM93X	RU	https://pubmed.ncbi.nlm.nih.gov/32336007

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DE4LYSA
DM0ZOGX	MN	Cytochrome P450 3A4 (CYP3A4)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DEIBDNY
DM0ZOGX	MN	Cytochrome P450 3A5 (CYP3A5)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	DERD86B
DM0ZOGX	MN	Cytochrome P450 3A7 (CYP3A7)
DM0ZOGX	MT	DME
DM0ZOGX	MA	Metabolism
DM0ZOGX	RN	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
DM0ZOGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8149892

DM0ZOGX	DI	DM0ZOGX
DM0ZOGX	DN	Linopirdine
DM0ZOGX	MI	TTIVDM3
DM0ZOGX	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DM0ZOGX	MT	DTT
DM0ZOGX	MA	Modulator
DM0ZOGX	RN	The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40.
DM0ZOGX	RU	https://pubmed.ncbi.nlm.nih.gov/21099148

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TT7MRGU
DMNF4UH	MN	Chymotrypsin (CTR)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TTCGSZ4
DMNF4UH	MN	Pancreatic alpha-amylase (AMY2A)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMNF4UH	DI	DMNF4UH
DMNF4UH	DN	Liprotamase
DMNF4UH	MI	TTXMY0J
DMNF4UH	MN	Pancreatic triacylglycerol lipase (PNLIP)
DMNF4UH	MT	DTT
DMNF4UH	MA	Modulator
DMNF4UH	RN	Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
DMNF4UH	RU	http://investor.anthera.com/releasedetail.cfm?releaseid=859598

DMKZRBP	DI	DMKZRBP
DMKZRBP	DN	Litoxetine
DMKZRBP	MI	TTNXLKE
DMKZRBP	MN	5-HT 3 receptor (5HT3R)
DMKZRBP	MT	DTT
DMKZRBP	MA	Modulator
DMKZRBP	RN	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
DMKZRBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/8385615

DMKZRBP	DI	DMKZRBP
DMKZRBP	DN	Litoxetine
DMKZRBP	MI	TT3ROYC
DMKZRBP	MN	Serotonin transporter (SERT)
DMKZRBP	MT	DTT
DMKZRBP	MA	Modulator
DMKZRBP	RN	Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45.
DMKZRBP	RU	https://www.ncbi.nlm.nih.gov/pubmed/8385615

DMDN4ZP	DI	DMDN4ZP
DMDN4ZP	DN	Lixivaptan
DMDN4ZP	MI	TTV9GOF
DMDN4ZP	MN	Histidine decarboxylase (HDC)
DMDN4ZP	MT	DTT
DMDN4ZP	MA	Inhibitor
DMDN4ZP	RN	Clinical pipeline report, company report or official report of Biofrontera (2009).
DMDN4ZP	RU	http://www.biofrontera.com/index.php?id=5

DMDN4ZP	DI	DMDN4ZP
DMDN4ZP	DN	Lixivaptan
DMDN4ZP	MI	TTK8R02
DMDN4ZP	MN	Vasopressin V2 receptor (V2R)
DMDN4ZP	MT	DTT
DMDN4ZP	MA	Antagonist
DMDN4ZP	RN	Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
DMDN4ZP	RU	https://pubmed.ncbi.nlm.nih.gov/17355215

DM4OAIU	DI	DM4OAIU
DM4OAIU	DN	LMI070
DM4OAIU	MI	TT8QL6X
DM4OAIU	MN	Survival motor neuron protein (SMN1)
DM4OAIU	MT	DTT
DM4OAIU	MA	Modulator
DM4OAIU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4OAIU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TTS87KH
DMOFIBM	MN	Microtubule-associated protein tau (MAPT)
DMOFIBM	MT	DTT
DMOFIBM	MA	Inhibitor
DMOFIBM	RN	Clinical pipeline report, company report or official report of TauRx.
DMOFIBM	RU	http://taurx.com/press-releases-announcements.html

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TT9RZ03
DMOFIBM	MN	TAR DNA binding protein 43 (TARDBP)
DMOFIBM	MT	DTT
DMOFIBM	MA	Inhibitor
DMOFIBM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOFIBM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOFIBM	DI	DMOFIBM
DMOFIBM	DN	LMT-X
DMOFIBM	MI	TTZGF8B
DMOFIBM	MN	Tau protein aggregation (TauA)
DMOFIBM	MT	DTT
DMOFIBM	MA	Modulator
DMOFIBM	RN	Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81.
DMOFIBM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000701/

DM9EZM0	DI	DM9EZM0
DM9EZM0	DN	LNP023
DM9EZM0	MI	TTA0P7K
DM9EZM0	MN	Complement factor B (CFB)
DM9EZM0	MT	DTT
DM9EZM0	MA	Inhibitor
DM9EZM0	RN	Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722.
DM9EZM0	RU	https://pubmed.ncbi.nlm.nih.gov/32073845

DMQNVR8	DI	DMQNVR8
DMQNVR8	DN	Lopinavir + ritonavir
DMQNVR8	MI	TT1D53B
DMQNVR8	MN	COVID-19 3C-like protease (3CLpro)
DMQNVR8	MT	DTT
DMQNVR8	MA	Inhibitor
DMQNVR8	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMQNVR8	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMX0O9U	DI	DMX0O9U
DMX0O9U	DN	Lopinavir + ritonavir + favipiravir
DMX0O9U	MI	TT1D53B
DMX0O9U	MN	COVID-19 3C-like protease (3CLpro)
DMX0O9U	MT	DTT
DMX0O9U	MA	Inhibitor
DMX0O9U	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMX0O9U	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMNY05F	DI	DMNY05F
DMNY05F	DN	Lopinavir + ritonavir + oseltamivir
DMNY05F	MI	TT1D53B
DMNY05F	MN	COVID-19 3C-like protease (3CLpro)
DMNY05F	MT	DTT
DMNY05F	MA	Inhibitor
DMNY05F	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMNY05F	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMTL5Q0	DI	DMTL5Q0
DMTL5Q0	DN	Losartan
DMTL5Q0	MI	TTPKMXQ
DMTL5Q0	MN	HUMAN type-1 angiotensin II receptor (AGTR1)
DMTL5Q0	MT	DTT
DMTL5Q0	MA	Blocker
DMTL5Q0	RN	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
DMTL5Q0	RU	https://pubmed.ncbi.nlm.nih.gov/32246101

DMIL37Z	DI	DMIL37Z
DMIL37Z	DN	Losmapimod
DMIL37Z	MI	TTQBR95
DMIL37Z	MN	Stress-activated protein kinase 2a (p38 alpha)
DMIL37Z	MT	DTT
DMIL37Z	MA	Inhibitor
DMIL37Z	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMIL37Z	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	TTJS8PY
DMWGRQD	MN	5-HT 6 receptor (HTR6)
DMWGRQD	MT	DTT
DMWGRQD	MA	Enhancer
DMWGRQD	RN	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
DMWGRQD	RU	https://pubmed.ncbi.nlm.nih.gov/20569520

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	DECB0K3
DMWGRQD	MN	Cytochrome P450 2D6 (CYP2D6)
DMWGRQD	MT	DME
DMWGRQD	MA	Metabolism
DMWGRQD	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DMWGRQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DMWGRQD	DI	DMWGRQD
DMWGRQD	DN	LU AE58054
DMWGRQD	MI	DE4LYSA
DMWGRQD	MN	Cytochrome P450 3A4 (CYP3A4)
DMWGRQD	MT	DME
DMWGRQD	MA	Metabolism
DMWGRQD	RN	Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2015;24(7):981-7.
DMWGRQD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26022777

DMNAYUJ	DI	DMNAYUJ
DMNAYUJ	DN	Lu AF35700
DMNAYUJ	MI	TTEX248
DMNAYUJ	MN	Dopamine D2 receptor (D2R)
DMNAYUJ	MT	DTT
DMNAYUJ	MA	Modulator
DMNAYUJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNAYUJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMMLXA9	DI	DMMLXA9
DMMLXA9	DN	LX-4211
DMMLXA9	MI	TT2UE56
DMMLXA9	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMMLXA9	MT	DTT
DMMLXA9	MA	Modulator
DMMLXA9	RN	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
DMMLXA9	RU	https://pubmed.ncbi.nlm.nih.gov/22739142

DMMLXA9	DI	DMMLXA9
DMMLXA9	DN	LX-4211
DMMLXA9	MI	TTLWPVF
DMMLXA9	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMMLXA9	MT	DTT
DMMLXA9	MA	Modulator
DMMLXA9	RN	LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
DMMLXA9	RU	https://pubmed.ncbi.nlm.nih.gov/22739142

DM1BXMY	DI	DM1BXMY
DM1BXMY	DN	LY2605541
DM1BXMY	MI	TTZOPHG
DM1BXMY	MN	Insulin (INS)
DM1BXMY	MT	DTT
DM1BXMY	MA	Modulator
DM1BXMY	RN	LY2605541--a preferential hepato-specific insulin analogue. Diabetes. 2014 Feb;63(2):390-2.
DM1BXMY	RU	https://pubmed.ncbi.nlm.nih.gov/24464715

DMEZ0H5	DI	DMEZ0H5
DMEZ0H5	DN	LY2963016
DMEZ0H5	MI	TTZOPHG
DMEZ0H5	MN	Insulin (INS)
DMEZ0H5	MT	DTT
DMEZ0H5	MA	Agonist
DMEZ0H5	RN	Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33.
DMEZ0H5	RU	https://pubmed.ncbi.nlm.nih.gov/25974640

DMWZIRJ	DI	DMWZIRJ
DMWZIRJ	DN	LY404039
DMWZIRJ	MI	TT8A9EF
DMWZIRJ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMWZIRJ	MT	DTT
DMWZIRJ	MA	Agonist
DMWZIRJ	RN	Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
DMWZIRJ	RU	https://pubmed.ncbi.nlm.nih.gov/19552508

DM7WORZ	DI	DM7WORZ
DM7WORZ	DN	LY-686017
DM7WORZ	MI	TTZPO1L
DM7WORZ	MN	Substance-P receptor (TACR1)
DM7WORZ	MT	DTT
DM7WORZ	MA	Antagonist
DM7WORZ	RN	Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
DM7WORZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804869/

DM6LVCQ	DI	DM6LVCQ
DM6LVCQ	DN	LY-CoV555
DM6LVCQ	MI	TTZ3COY
DM6LVCQ	MN	COVID-19 spike glycoprotein (S)
DM6LVCQ	MT	DTT
DM6LVCQ	MA	Inhibitor
DM6LVCQ	RN	Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189.
DM6LVCQ	RU	https://pubmed.ncbi.nlm.nih.gov/33378611

DMGNC6T	DI	DMGNC6T
DMGNC6T	DN	M-0011
DMGNC6T	MI	TTT2KE3
DMGNC6T	MN	Alpha-mannosidase (MANA)
DMGNC6T	MT	DTT
DMGNC6T	MA	Modulator
DMGNC6T	RN	ClinicalTrials.gov (NCT01681953) A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis. U.S. National Institutes of Health.
DMGNC6T	RU	https://clinicaltrials.gov/ct2/show/NCT01681953

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTJQOD7
DM7ZFBA	MN	5-HT 2A receptor (HTR2A)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Antagonist
DM7ZFBA	RN	Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/11259563

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTWJBZ5
DM7ZFBA	MN	5-HT 2C receptor (HTR2C)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Inhibitor
DM7ZFBA	RN	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/20493697

DM7ZFBA	DI	DM7ZFBA
DM7ZFBA	DN	M100907
DM7ZFBA	MI	TTQ6VDM
DM7ZFBA	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DM7ZFBA	MT	DTT
DM7ZFBA	MA	Inhibitor
DM7ZFBA	RN	Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
DM7ZFBA	RU	https://pubmed.ncbi.nlm.nih.gov/20493697

DMZ6VD5	DI	DMZ6VD5
DMZ6VD5	DN	M-518101
DMZ6VD5	MI	TTUST1O
DMZ6VD5	MN	Phosphodiesterase (PDE)
DMZ6VD5	MT	DTT
DMZ6VD5	MA	Inhibitor
DMZ6VD5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6VD5	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM1PRT6	DI	DM1PRT6
DM1PRT6	DN	M710
DM1PRT6	MI	TT9HKJA
DM1PRT6	MN	Vascular endothelial growth factor (VEGF)
DM1PRT6	MT	DTT
DM1PRT6	MA	Inhibitor
DM1PRT6	RN	ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
DM1PRT6	RU	https://clinicaltrials.gov/ct2/show/NCT03610646

DM8D13S	DI	DM8D13S
DM8D13S	DN	MABp1
DM8D13S	MI	TTPM6HI
DM8D13S	MN	Interleukin-1 alpha (IL1A)
DM8D13S	MT	DTT
DM8D13S	MA	Inhibitor
DM8D13S	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8D13S	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMVXUR0	DI	DMVXUR0
DMVXUR0	DN	Magrolimab
DMVXUR0	MI	TTN2JFW
DMVXUR0	MN	T-cell surface glycoprotein CD4 (CD4)
DMVXUR0	MT	DTT
DMVXUR0	MA	Inhibitor
DMVXUR0	RN	Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
DMVXUR0	RU	https://pubmed.ncbi.nlm.nih.gov/33423844

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	DERSX5P
DMJPGUA	MN	Cytochrome P450 2J2 (CYP2J2)
DMJPGUA	MT	DME
DMJPGUA	MA	Metabolism
DMJPGUA	RN	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
DMJPGUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30965050

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	DE4LYSA
DMJPGUA	MN	Cytochrome P450 3A4 (CYP3A4)
DMJPGUA	MT	DME
DMJPGUA	MA	Metabolism
DMJPGUA	RN	Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol. 2006 May;61(5):533-7.
DMJPGUA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16669846

DMJPGUA	DI	DMJPGUA
DMJPGUA	DN	Manidipine
DMJPGUA	MI	TTEAID7
DMJPGUA	MN	Trypanosoma Cruzipain (Trypano CYSP)
DMJPGUA	MT	DTT
DMJPGUA	MA	Inhibitor
DMJPGUA	RN	Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
DMJPGUA	RU	https://pubmed.ncbi.nlm.nih.gov/20426472

DMR23M1	DI	DMR23M1
DMR23M1	DN	Mapracorat
DMR23M1	MI	TTYRL6O
DMR23M1	MN	Glucocorticoid receptor (NR3C1)
DMR23M1	MT	DTT
DMR23M1	MA	Agonist
DMR23M1	RN	Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103.
DMR23M1	RU	https://pubmed.ncbi.nlm.nih.gov/19422381

DMJCF1O	DI	DMJCF1O
DMJCF1O	DN	Maralixibat
DMJCF1O	MI	TTPI1M5
DMJCF1O	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMJCF1O	MT	DTT
DMJCF1O	MA	Inhibitor
DMJCF1O	RN	Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
DMJCF1O	RU	https://pubmed.ncbi.nlm.nih.gov/32653991

DM3GTAL	DI	DM3GTAL
DM3GTAL	DN	Maribavir
DM3GTAL	MI	DE4LYSA
DM3GTAL	MN	Cytochrome P450 3A4 (CYP3A4)
DM3GTAL	MT	DME
DM3GTAL	MA	Metabolism
DM3GTAL	RN	Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.
DM3GTAL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16569820

DM3GTAL	DI	DM3GTAL
DM3GTAL	DN	Maribavir
DM3GTAL	MI	TTXQ04B
DM3GTAL	MN	Cytomegalovirus Ganciclovir kinase (CMV UL97)
DM3GTAL	MT	DTT
DM3GTAL	MA	Inhibitor
DM3GTAL	RN	The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14.
DM3GTAL	RU	https://pubmed.ncbi.nlm.nih.gov/12502806

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTMX39J
DM6V34C	MN	Matrix metalloproteinase-1 (MMP-1)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTLM12X
DM6V34C	MN	Matrix metalloproteinase-2 (MMP-2)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DM6V34C	DI	DM6V34C
DM6V34C	DN	Marimastat
DM6V34C	MI	TTMTWOS
DM6V34C	MN	Matrix metalloproteinase-7 (MMP-7)
DM6V34C	MT	DTT
DM6V34C	MA	Inhibitor
DM6V34C	RN	Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
DM6V34C	RU	https://pubmed.ncbi.nlm.nih.gov/17234180

DME9QGW	DI	DME9QGW
DME9QGW	DN	Marizomib
DME9QGW	MI	TTU7ZMG
DME9QGW	MN	Proteasome (PS)
DME9QGW	MT	DTT
DME9QGW	MA	Inhibitor
DME9QGW	RN	Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.
DME9QGW	RU	https://pubmed.ncbi.nlm.nih.gov/21247382

DMRSNEU	DI	DMRSNEU
DMRSNEU	DN	Masitinib
DMRSNEU	MI	TT6PKBN
DMRSNEU	MN	Proto-oncogene c-Src (SRC)
DMRSNEU	MT	DTT
DMRSNEU	MA	Inhibitor
DMRSNEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRSNEU	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRSNEU	DI	DMRSNEU
DMRSNEU	DN	Masitinib
DMRSNEU	MI	TTJSQEF
DMRSNEU	MN	Tyrosine-protein kinase (PTK)
DMRSNEU	MT	DTT
DMRSNEU	MA	Inhibitor
DMRSNEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRSNEU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK9BP2	DI	DMK9BP2
DMK9BP2	DN	Mavacamten
DMK9BP2	MI	TTITSMB
DMK9BP2	MN	Myosin (MYO)
DMK9BP2	MT	DTT
DMK9BP2	MA	Inhibitor
DMK9BP2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK9BP2	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMBPY9Z	DI	DMBPY9Z
DMBPY9Z	DN	MBG453
DMBPY9Z	MI	TT1RWL7
DMBPY9Z	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMBPY9Z	MT	DTT
DMBPY9Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBPY9Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVZ57G	DI	DMVZ57G
DMVZ57G	DN	MD1003
DMVZ57G	MI	TTSXVID
DMVZ57G	MN	Nuclear factor NF-kappa-B (NFKB)
DMVZ57G	MT	DTT
DMVZ57G	MA	Inhibitor
DMVZ57G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVZ57G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5X849	DI	DM5X849
DM5X849	DN	MEDI4736
DM5X849	MI	TT8ZLTI
DM5X849	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5X849	MT	DTT
DM5X849	MA	Modulator
DM5X849	RN	National Cancer Institute Drug Dictionary (drug id 740856).
DM5X849	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TT2WR1T
DM4W8RE	MN	Cationic trypsinogen (PRSS1)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TT6L509
DM4W8RE	MN	Coagulation factor IIa (F2)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16460939

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TTCIHJA
DM4W8RE	MN	Coagulation factor Xa (F10)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	DTUGYRD
DM4W8RE	MN	P-glycoprotein 1 (ABCB1)
DM4W8RE	MT	DTP
DM4W8RE	MA	Substrate
DM4W8RE	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM4W8RE	RU	https://doi.org/10.1007/s11095-012-0935-x

DM4W8RE	DI	DM4W8RE
DM4W8RE	DN	Melagatran
DM4W8RE	MI	TTP86E2
DM4W8RE	MN	Plasminogen (PLG)
DM4W8RE	MT	DTT
DM4W8RE	MA	Inhibitor
DM4W8RE	RN	Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7.
DM4W8RE	RU	https://pubmed.ncbi.nlm.nih.gov/16517159

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TT362RB
DMQEC6Z	MN	MART-1 melanoma antigen (MLANA)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TT8MK59
DMQEC6Z	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DMQEC6Z	DI	DMQEC6Z
DMQEC6Z	DN	Melanoma vaccine
DMQEC6Z	MI	TTULVH8
DMQEC6Z	MN	Tyrosinase (TYR)
DMQEC6Z	MT	DTT
DMQEC6Z	RN	National Cancer Institute Drug Dictionary (drug id 685201).
DMQEC6Z	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201

DM8Z0I3	DI	DM8Z0I3
DM8Z0I3	DN	MF-101
DM8Z0I3	MI	TTOM3J0
DM8Z0I3	MN	Estrogen receptor beta (ESR2)
DM8Z0I3	MT	DTT
DM8Z0I3	MA	Antagonist
DM8Z0I3	RN	MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
DM8Z0I3	RU	https://pubmed.ncbi.nlm.nih.gov/19182698

DMRKTCP	DI	DMRKTCP
DMRKTCP	DN	MGA012
DMRKTCP	MI	TTNBFWK
DMRKTCP	MN	Programmed cell death protein 1 (PD-1)
DMRKTCP	MT	DTT
DMRKTCP	MA	Inhibitor
DMRKTCP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRKTCP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMCJRL1	DI	DMCJRL1
DMCJRL1	DN	MGN-1703
DMCJRL1	MI	TTSHG0T
DMCJRL1	MN	Toll-like receptor 9 (TLR9)
DMCJRL1	MT	DTT
DMCJRL1	MA	Agonist
DMCJRL1	RN	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
DMCJRL1	RU	https://pubmed.ncbi.nlm.nih.gov/24816725

DMZHN5B	DI	DMZHN5B
DMZHN5B	DN	MIM-D3
DMZHN5B	MI	TTTDVOJ
DMZHN5B	MN	Tropomyosin-related kinase A (TrkA)
DMZHN5B	MT	DTT
DMZHN5B	MA	Agonist
DMZHN5B	RN	Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
DMZHN5B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/

DMCJY35	DI	DMCJY35
DMCJY35	DN	MIN-101
DMCJY35	MI	TTJQOD7
DMCJY35	MN	5-HT 2A receptor (HTR2A)
DMCJY35	MT	DTT
DMCJY35	MA	Antagonist
DMCJY35	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMCJY35	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMCJY35	DI	DMCJY35
DMCJY35	DN	MIN-101
DMCJY35	MI	TT9NXW4
DMCJY35	MN	Sigma intracellular receptor 2 (TMEM97)
DMCJY35	MT	DTT
DMCJY35	MA	Antagonist
DMCJY35	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCJY35	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM7R3N5	DI	DM7R3N5
DM7R3N5	DN	Mirikizumab
DM7R3N5	MI	TTRTK6Y
DM7R3N5	MN	Interleukin-12 alpha (IL12A)
DM7R3N5	MT	DTT
DM7R3N5	MA	Inhibitor
DM7R3N5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7R3N5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5S4LX	DI	DM5S4LX
DM5S4LX	DN	Mirvetuximab soravtansine
DM5S4LX	MI	TTVC37M
DM5S4LX	MN	Folate receptor alpha (FOLR1)
DM5S4LX	MT	DTT
DM5S4LX	MA	Antagonist
DM5S4LX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5S4LX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PSUF	DI	DM3PSUF
DM3PSUF	DN	MK-3102
DM3PSUF	MI	TTDIGC1
DM3PSUF	MN	Dipeptidyl peptidase 4 (DPP-4)
DM3PSUF	MT	DTT
DM3PSUF	MA	Modulator
DM3PSUF	RN	Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.
DM3PSUF	RU	https://pubmed.ncbi.nlm.nih.gov/24660890

DMQBF7O	DI	DMQBF7O
DMQBF7O	DN	MK-3222
DMQBF7O	MI	TTC1GLB
DMQBF7O	MN	Interleukin-23 (IL23)
DMQBF7O	MT	DTT
DMQBF7O	RN	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
DMQBF7O	RU	https://pubmed.ncbi.nlm.nih.gov/26042589

DMGNHC2	DI	DMGNHC2
DMGNHC2	DN	MK-3415A
DMGNHC2	MI	TT64H8L
DMGNHC2	MN	Clostridium difficile Toxin A (CD toxA)
DMGNHC2	MT	DTT
DMGNHC2	RN	ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
DMGNHC2	RU	https://clinicaltrials.gov/ct2/show/NCT01513239

DMGNHC2	DI	DMGNHC2
DMGNHC2	DN	MK-3415A
DMGNHC2	MI	TTQH65V
DMGNHC2	MN	Clostridium difficile Toxin B (CD toxB)
DMGNHC2	MT	DTT
DMGNHC2	RN	ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
DMGNHC2	RU	https://clinicaltrials.gov/ct2/show/NCT01513239

DMA25NO	DI	DMA25NO
DMA25NO	DN	MK-4214
DMA25NO	MI	TT5TQ2W
DMA25NO	MN	Granulocyte colony-stimulating factor (CSF3)
DMA25NO	MT	DTT
DMA25NO	MA	Modulator
DMA25NO	RN	DOI: 10.1038/nbt0710-636a
DMA25NO	RU	http://www.nature.com/nbt/journal/v28/n7/full/nbt0710-636a.html

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DEP54UE
DMLYGH4	MN	Beta-glucuronidase (GUSB)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
DMLYGH4	RU	https://www.mdpi.com/2073-4409/8/9/1013/s1

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DEB30C5
DMLYGH4	MN	Carboxylesterase 1 (CES1)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
DMLYGH4	RU	https://www.mdpi.com/2073-4409/8/9/1013/s1

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	DE6OQ3W
DMLYGH4	MN	Cytochrome P450 1A1 (CYP1A1)
DMLYGH4	MT	DME
DMLYGH4	MA	Metabolism
DMLYGH4	RN	Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.
DMLYGH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19873981

DMLYGH4	DI	DMLYGH4
DMLYGH4	DN	MK-4827
DMLYGH4	MI	TTEBCY8
DMLYGH4	MN	Poly [ADP-ribose] polymerase (PARP)
DMLYGH4	MT	DTT
DMLYGH4	MA	Modulator
DMLYGH4	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMLYGH4	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM84LO5	DI	DM84LO5
DM84LO5	DN	MK-8109
DM84LO5	MI	TTVC37M
DM84LO5	MN	Folate receptor alpha (FOLR1)
DM84LO5	MT	DTT
DM84LO5	MA	Modulator
DM84LO5	RN	A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996.
DM84LO5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560517/

DMK301H	DI	DMK301H
DMK301H	DN	MK-8742
DMK301H	MI	TTCJ2X8
DMK301H	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMK301H	MT	DTT
DMK301H	MA	Modulator
DMK301H	RN	Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40.
DMK301H	RU	https://pubmed.ncbi.nlm.nih.gov/24127258

DMT8IAJ	DI	DMT8IAJ
DMT8IAJ	DN	MK-8808
DMT8IAJ	MI	TTUE541
DMT8IAJ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMT8IAJ	MT	DTT
DMT8IAJ	MA	Agonist
DMT8IAJ	RN	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68.
DMT8IAJ	RU	https://pubmed.ncbi.nlm.nih.gov/14576843

DMP36KD	DI	DMP36KD
DMP36KD	DN	MLN4924
DMP36KD	MI	TTVKOPM
DMP36KD	MN	NEDD8-activating enzyme (NAE)
DMP36KD	MT	DTT
DMP36KD	MA	Modulator
DMP36KD	RN	Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Cell Death Dis.2012 Sep 6;3:e386.
DMP36KD	RU	https://www.ncbi.nlm.nih.gov/pubmed/22951983

DMP36KD	DI	DMP36KD
DMP36KD	DN	MLN4924
DMP36KD	MI	TTNDC4K
DMP36KD	MN	Ubiquitin-like protein Nedd8 (NEDD8)
DMP36KD	MT	DTT
DMP36KD	MA	Inhibitor
DMP36KD	RN	Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834. 
DMP36KD	RU	https://pubmed.ncbi.nlm.nih.gov/28569775

DMO8PT9	DI	DMO8PT9
DMO8PT9	DN	MLN8237
DMO8PT9	MI	TTPS3C0
DMO8PT9	MN	Aurora kinase A (AURKA)
DMO8PT9	MT	DTT
DMO8PT9	MA	Inhibitor
DMO8PT9	RN	Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
DMO8PT9	RU	http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8553

DMFWE9S	DI	DMFWE9S
DMFWE9S	DN	Mobocertinib
DMFWE9S	MI	TT2M7YX
DMFWE9S	MN	EGFR Exon20ins mutant (EGFR Exon20ins)
DMFWE9S	MT	DTT
DMFWE9S	MA	Inhibitor
DMFWE9S	RN	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Feb 25;candisc.1683.2020.
DMFWE9S	RU	https://pubmed.ncbi.nlm.nih.gov/33632773

DM2TNJ1	DI	DM2TNJ1
DM2TNJ1	DN	Molgramostim
DM2TNJ1	MI	TT6MP2Z
DM2TNJ1	MN	GMCSFR-alpha (CSF2RA)
DM2TNJ1	MT	DTT
DM2TNJ1	MA	Agonist
DM2TNJ1	RN	Clinical pipeline report, company report or official report of gensci-china.
DM2TNJ1	RU	http://www.gensci-china.com/gensci/cp1_somatropinAQ.asp?MaxID=3

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DEJGDUW
DMF98Q0	MN	Cytochrome P450 1A2 (CYP1A2)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DES5XRU
DMF98Q0	MN	Cytochrome P450 2C8 (CYP2C8)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DE5IED8
DMF98Q0	MN	Cytochrome P450 2C9 (CYP2C9)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DE4LYSA
DMF98Q0	MN	Cytochrome P450 3A4 (CYP3A4)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	TTRMX3V
DMF98Q0	MN	Janus kinase 2 (JAK-2)
DMF98Q0	MT	DTT
DMF98Q0	MA	Modulator
DMF98Q0	RN	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25322686

DMF98Q0	DI	DMF98Q0
DMF98Q0	DN	Momelotinib
DMF98Q0	MI	DEGTFWK
DMF98Q0	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMF98Q0	MT	DME
DMF98Q0	MA	Metabolism
DMF98Q0	RN	Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
DMF98Q0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29311136

DMQ1FU8	DI	DMQ1FU8
DMQ1FU8	DN	Montelukast
DMQ1FU8	MI	TTSB6CA
DMQ1FU8	MN	HUMAN cysteinyl leukotriene receptor (CysLTR)
DMQ1FU8	MT	DTT
DMQ1FU8	MA	Antagonist
DMQ1FU8	RN	As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828.
DMQ1FU8	RU	https://pubmed.ncbi.nlm.nih.gov/32416408

DMPVW6H	DI	DMPVW6H
DMPVW6H	DN	Morphine-6-glucuronide
DMPVW6H	MI	TTKWM86
DMPVW6H	MN	Opioid receptor mu (MOP)
DMPVW6H	MT	DTT
DMPVW6H	MA	Agonist
DMPVW6H	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DMPVW6H	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMPVW6H	DI	DMPVW6H
DMPVW6H	DN	Morphine-6-glucuronide
DMPVW6H	MI	DTUGYRD
DMPVW6H	MN	P-glycoprotein 1 (ABCB1)
DMPVW6H	MT	DTP
DMPVW6H	MA	Substrate
DMPVW6H	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMPVW6H	RU	https://doi.org/10.1007/s11095-012-0935-x

DM15ZIB	DI	DM15ZIB
DM15ZIB	DN	Mosunetuzumab
DM15ZIB	MI	TTUE541
DM15ZIB	MN	Leukocyte surface antigen Leu-16 (CD20)
DM15ZIB	MT	DTT
DM15ZIB	MA	Inhibitor
DM15ZIB	RN	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
DM15ZIB	RU	https://pubmed.ncbi.nlm.nih.gov/32859946

DM15ZIB	DI	DM15ZIB
DM15ZIB	DN	Mosunetuzumab
DM15ZIB	MI	TTUN7MC
DM15ZIB	MN	T-cell surface glycoprotein CD3 (CD3)
DM15ZIB	MT	DTT
DM15ZIB	MA	Inhibitor
DM15ZIB	RN	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
DM15ZIB	RU	https://pubmed.ncbi.nlm.nih.gov/32859946

DMB24H7	DI	DMB24H7
DMB24H7	DN	Motavizumab
DMB24H7	MI	TT57ID8
DMB24H7	MN	Respiratory syncytial virus protein F (RSV F)
DMB24H7	MT	DTT
DMB24H7	MA	Modulator
DMB24H7	RN	Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
DMB24H7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/

DM8K5Z6	DI	DM8K5Z6
DM8K5Z6	DN	Motexafin lutetium
DM8K5Z6	MI	TTS78AZ
DM8K5Z6	MN	Prostate specific antigen (KLK3)
DM8K5Z6	MT	DTT
DM8K5Z6	MA	Modulator
DM8K5Z6	RN	Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76.
DM8K5Z6	RU	https://pubmed.ncbi.nlm.nih.gov/18676760

DM9K3LM	DI	DM9K3LM
DM9K3LM	DN	MPDL-3280A
DM9K3LM	MI	TT8ZLTI
DM9K3LM	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM9K3LM	MT	DTT
DM9K3LM	MA	Modulator
DM9K3LM	RN	Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
DM9K3LM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014795/

DMNDCFY	DI	DMNDCFY
DMNDCFY	DN	MPL-S
DMNDCFY	MI	TTF10I9
DMNDCFY	MN	Nitric-oxide synthase inducible (NOS2)
DMNDCFY	MT	DTT
DMNDCFY	MA	Modulator
DMNDCFY	RN	Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
DMNDCFY	RU	https://pubmed.ncbi.nlm.nih.gov/9234781

DMDV4EP	DI	DMDV4EP
DMDV4EP	DN	MRTX849
DMDV4EP	MI	TT3LH46
DMDV4EP	MN	KRAS G12C mutant (KRAS G12C)
DMDV4EP	MT	DTT
DMDV4EP	MA	Inhibitor
DMDV4EP	RN	Clinical pipeline report, company report or official report of Mirati Therapeutics.
DMDV4EP	RU	https://www.mirati.com/science/pipeline/

DMUNBMA	DI	DMUNBMA
DMUNBMA	DN	MT-1621
DMUNBMA	MI	TT7KNZQ
DMUNBMA	MN	Thymidine kinase 2 (Mt-TK2)
DMUNBMA	MT	DTT
DMUNBMA	MA	Replacement
DMUNBMA	RN	Clinical pipeline report, company report or official report of Modis Therapeutics.
DMUNBMA	RU	https://www.modistx.com/product/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TT362RB
DMZPEHY	MN	MART-1 melanoma antigen (MLANA)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TT8MK59
DMZPEHY	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMZPEHY	DI	DMZPEHY
DMZPEHY	DN	Multi-epitope peptide melanoma vaccine
DMZPEHY	MI	TTULVH8
DMZPEHY	MN	Tyrosinase (TYR)
DMZPEHY	MT	DTT
DMZPEHY	RN	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
DMZPEHY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DES5XRU
DMG3NFZ	MN	Cytochrome P450 2C8 (CYP2C8)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE5IED8
DMG3NFZ	MN	Cytochrome P450 2C9 (CYP2C9)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DECB0K3
DMG3NFZ	MN	Cytochrome P450 2D6 (CYP2D6)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE4LYSA
DMG3NFZ	MN	Cytochrome P450 3A4 (CYP3A4)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEGTFWK
DMG3NFZ	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	TTJ584C
DMG3NFZ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMG3NFZ	MT	DTT
DMG3NFZ	MA	Modulator
DMG3NFZ	RN	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/16199244

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	TTZMAO3
DMG3NFZ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMG3NFZ	MT	DTT
DMG3NFZ	MA	Modulator
DMG3NFZ	RN	Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/16199244

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEYGVN4
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DEF2WXN
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17898154

DMG3NFZ	DI	DMG3NFZ
DMG3NFZ	DN	Muraglitazar
DMG3NFZ	MI	DE85D2P
DMG3NFZ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMG3NFZ	MT	DME
DMG3NFZ	MA	Metabolism
DMG3NFZ	RN	Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
DMG3NFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17062778

DMUQ390	DI	DMUQ390
DMUQ390	DN	Murepavadin
DMUQ390	MI	TTJZ7GF
DMUQ390	MN	Pseudomonas LPS-assembly protein LptD (Pseudo lptD)
DMUQ390	MT	DTT
DMUQ390	MA	Antagonist
DMUQ390	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMUQ390	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMS9GE1	DI	DMS9GE1
DMS9GE1	DN	MyoCell SDF-1
DMS9GE1	MI	TT4UGTF
DMS9GE1	MN	Stromal cell-derived factor 1 (CXCL12)
DMS9GE1	MT	DTT
DMS9GE1	MA	Modulator
DMS9GE1	RN	Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97.
DMS9GE1	RU	https://pubmed.ncbi.nlm.nih.gov/21219236

DMY60DT	DI	DMY60DT
DMY60DT	DN	N8-GP
DMY60DT	MI	TT1290U
DMY60DT	MN	Coagulation factor VIII (F8)
DMY60DT	MT	DTT
DMY60DT	MA	Modulator
DMY60DT	RN	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8.
DMY60DT	RU	https://pubmed.ncbi.nlm.nih.gov/23398640

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DE5IED8
DMHKJ5I	MN	Cytochrome P450 2C9 (CYP2C9)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DECB0K3
DMHKJ5I	MN	Cytochrome P450 2D6 (CYP2D6)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DE4LYSA
DMHKJ5I	MN	Cytochrome P450 3A4 (CYP3A4)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1219-28.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23621668

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DEIBDNY
DMHKJ5I	MN	Cytochrome P450 3A5 (CYP3A5)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757

DMHKJ5I	DI	DMHKJ5I
DMHKJ5I	DN	Nabiximols
DMHKJ5I	MI	DEGTFWK
DMHKJ5I	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMHKJ5I	MT	DME
DMHKJ5I	MA	Metabolism
DMHKJ5I	RN	Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
DMHKJ5I	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914

DMDZ6Q3	DI	DMDZ6Q3
DMDZ6Q3	DN	Napabucasin
DMDZ6Q3	MI	TTH8FZW
DMDZ6Q3	MN	Signal transducer and activator of transcription 3 (STAT3)
DMDZ6Q3	MT	DTT
DMDZ6Q3	MA	Inhibitor
DMDZ6Q3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDZ6Q3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKP45D	DI	DMKP45D
DMKP45D	DN	Naproxcinod
DMKP45D	MI	TTK0943
DMKP45D	MN	Prostaglandin G/H synthase (COX)
DMKP45D	MT	DTT
DMKP45D	MA	Modulator
DMKP45D	RN	Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57.
DMKP45D	RU	https://pubmed.ncbi.nlm.nih.gov/19392579

DMIC56X	DI	DMIC56X
DMIC56X	DN	NASVAC
DMIC56X	MI	TT6KSF7
DMIC56X	MN	Hepatitis B virus Large envelope protein (HBV S)
DMIC56X	MT	DTT
DMIC56X	RN	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7.
DMIC56X	RU	https://pubmed.ncbi.nlm.nih.gov/25193323

DMIC56X	DI	DMIC56X
DMIC56X	DN	NASVAC
DMIC56X	MI	TTRF7Q8
DMIC56X	MN	Natural killer cell receptor (NKCR)
DMIC56X	MT	DTT
DMIC56X	RN	In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7.
DMIC56X	RU	https://pubmed.ncbi.nlm.nih.gov/25193323

DMRSI1M	DI	DMRSI1M
DMRSI1M	DN	NAV5001
DMRSI1M	MI	TTVBI8W
DMRSI1M	MN	Dopamine transporter (DAT)
DMRSI1M	MT	DTT
DMRSI1M	MA	Modulator
DMRSI1M	RN	Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
DMRSI1M	RU	https://pubmed.ncbi.nlm.nih.gov/9593103

DMVO1C0	DI	DMVO1C0
DMVO1C0	DN	NBI-98854
DMVO1C0	MI	DECB0K3
DMVO1C0	MN	Cytochrome P450 2D6 (CYP2D6)
DMVO1C0	MT	DME
DMVO1C0	MA	Metabolism
DMVO1C0	RN	Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018 Apr;18(4):323-332.
DMVO1C0	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557243

DMVO1C0	DI	DMVO1C0
DMVO1C0	DN	NBI-98854
DMVO1C0	MI	TTNZRI3
DMVO1C0	MN	Synaptic vesicle amine transporter (SLC18A2)
DMVO1C0	MT	DTT
DMVO1C0	MA	Inhibitor
DMVO1C0	RN	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
DMVO1C0	RU	https://pubmed.ncbi.nlm.nih.gov/26346941

DMFD249	DI	DMFD249
DMFD249	DN	Nebracetam
DMFD249	MI	TTZ9SOR
DMFD249	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFD249	MT	DTT
DMFD249	MA	Agonist
DMFD249	RN	Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80.
DMFD249	RU	https://pubmed.ncbi.nlm.nih.gov/2041225

DMDBY30	DI	DMDBY30
DMDBY30	DN	Nelipepimut S
DMDBY30	MI	TT6EO5L
DMDBY30	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDBY30	MT	DTT
DMDBY30	MA	Inhibitor
DMDBY30	RN	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
DMDBY30	RU	https://pubmed.ncbi.nlm.nih.gov/24896623

DMH9EUA	DI	DMH9EUA
DMH9EUA	DN	Nemolizumab
DMH9EUA	MI	TT9HPX0
DMH9EUA	MN	Interleukin 31 receptor (IL31R)
DMH9EUA	MT	DTT
DMH9EUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH9EUA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIPNBG	DI	DMIPNBG
DMIPNBG	DN	Nemonaxacin
DMIPNBG	MI	TTIXTO3
DMIPNBG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMIPNBG	MT	DTT
DMIPNBG	MA	Modulator
DMIPNBG	RN	In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9.
DMIPNBG	RU	https://www.ncbi.nlm.nih.gov/pubmed/19833635

DMVP7HI	DI	DMVP7HI
DMVP7HI	DN	Nestorone
DMVP7HI	MI	TTUV8G9
DMVP7HI	MN	Progesterone receptor (PGR)
DMVP7HI	MT	DTT
DMVP7HI	MA	Agonist
DMVP7HI	RN	Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97.
DMVP7HI	RU	https://pubmed.ncbi.nlm.nih.gov/25200475

DMTKRY1	DI	DMTKRY1
DMTKRY1	DN	Netivudine
DMTKRY1	MI	TTIU7X1
DMTKRY1	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMTKRY1	MT	DTT
DMTKRY1	MA	Modulator
DMTKRY1	RN	Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206.
DMTKRY1	RU	https://pubmed.ncbi.nlm.nih.gov/10188760

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DE5IED8
DMEKAYI	MN	Cytochrome P450 2C9 (CYP2C9)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DECB0K3
DMEKAYI	MN	Cytochrome P450 2D6 (CYP2D6)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Effect of netupitant, a highly selective NK?receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23748441

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	DE4LYSA
DMEKAYI	MN	Cytochrome P450 3A4 (CYP3A4)
DMEKAYI	MT	DME
DMEKAYI	MA	Metabolism
DMEKAYI	RN	Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019 Apr;59(4):472-487.
DMEKAYI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30412271

DMEKAYI	DI	DMEKAYI
DMEKAYI	DN	Netupitant
DMEKAYI	MI	TTZPO1L
DMEKAYI	MN	Substance-P receptor (TACR1)
DMEKAYI	MT	DTT
DMEKAYI	MA	Antagonist
DMEKAYI	RN	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
DMEKAYI	RU	https://pubmed.ncbi.nlm.nih.gov/24969614

DME617W	DI	DME617W
DME617W	DN	Neucardin
DME617W	MI	TTEH395
DME617W	MN	Pro-neuregulin-1 (Pro-NRG1)
DME617W	MT	DTT
DME617W	MA	Modulator
DME617W	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DME617W	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYTC4I	DI	DMYTC4I
DMYTC4I	DN	NeuVax
DMYTC4I	MI	TT6EO5L
DMYTC4I	MN	Erbb2 tyrosine kinase receptor (HER2)
DMYTC4I	MT	DTT
DMYTC4I	RN	The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31.
DMYTC4I	RU	https://pubmed.ncbi.nlm.nih.gov/24896623

DMJ2KIE	DI	DMJ2KIE
DMJ2KIE	DN	NI-101
DMJ2KIE	MI	TTE4KHA
DMJ2KIE	MN	Amyloid beta A4 protein (APP)
DMJ2KIE	MT	DTT
DMJ2KIE	RN	Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479.
DMJ2KIE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862506/

DMFBNA3	DI	DMFBNA3
DMFBNA3	DN	Nicaraven
DMFBNA3	MI	TTVDSZ0
DMFBNA3	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMFBNA3	MT	DTT
DMFBNA3	MA	Modulator
DMFBNA3	RN	Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
DMFBNA3	RU	https://pubmed.ncbi.nlm.nih.gov/17094462

DM376WT	DI	DM376WT
DM376WT	DN	NKTR 214
DM376WT	MI	TT9721Y
DM376WT	MN	Interleukin 2 receptor beta (IL2RB)
DM376WT	MT	DTT
DM376WT	MA	Agonist
DM376WT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM376WT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM45DS8	DI	DM45DS8
DM45DS8	DN	NKTR-181
DM45DS8	MI	TTKWM86
DM45DS8	MN	Opioid receptor mu (MOP)
DM45DS8	MT	DTT
DM45DS8	MA	Agonist
DM45DS8	RN	A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418.
DM45DS8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411218/

DMACYW6	DI	DMACYW6
DMACYW6	DN	NKTR-214
DMACYW6	MI	TT9721Y
DMACYW6	MN	Interleukin 2 receptor beta (IL2RB)
DMACYW6	MT	DTT
DMACYW6	MA	Agonist
DMACYW6	RN	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661.
DMACYW6	RU	https://pubmed.ncbi.nlm.nih.gov/32005826

DMDJLY9	DI	DMDJLY9
DMDJLY9	DN	NM-702
DMDJLY9	MI	TTUST1O
DMDJLY9	MN	Phosphodiesterase (PDE)
DMDJLY9	MT	DTT
DMDJLY9	MA	Inhibitor
DMDJLY9	RN	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
DMDJLY9	RU	https://pubmed.ncbi.nlm.nih.gov/17174195

DMDJLY9	DI	DMDJLY9
DMDJLY9	DN	NM-702
DMDJLY9	MI	TTKNWZ4
DMDJLY9	MN	Thromboxane-A synthase (TBXAS1)
DMDJLY9	MT	DTT
DMDJLY9	MA	Inhibitor
DMDJLY9	RN	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
DMDJLY9	RU	https://pubmed.ncbi.nlm.nih.gov/17174195

DMDGK83	DI	DMDGK83
DMDGK83	DN	NN1841
DMDGK83	MI	TTAXGIP
DMDGK83	MN	Coagulation factor XIII (F13B)
DMDGK83	MT	DTT
DMDGK83	MA	Modulator
DMDGK83	RN	Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13.
DMDGK83	RU	https://pubmed.ncbi.nlm.nih.gov/25031548

DM0QV27	DI	DM0QV27
DM0QV27	DN	NN5401
DM0QV27	MI	TTCBFJO
DM0QV27	MN	Insulin receptor (INSR)
DM0QV27	MT	DTT
DM0QV27	MA	Modulator
DM0QV27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM0QV27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM1PI9G	DI	DM1PI9G
DM1PI9G	DN	NN8717
DM1PI9G	MI	TTAXGIP
DM1PI9G	MN	Coagulation factor XIII (F13B)
DM1PI9G	MT	DTT
DM1PI9G	MA	Modulator
DM1PI9G	RN	Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14.
DM1PI9G	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786906/

DMOF0CA	DI	DMOF0CA
DMOF0CA	DN	Nolatrexed
DMOF0CA	MI	DTI7UX6
DMOF0CA	MN	Breast cancer resistance protein (ABCG2)
DMOF0CA	MT	DTP
DMOF0CA	MA	Substrate
DMOF0CA	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DMOF0CA	RU	https://doi.org/10.1007/s00280-006-0230-9

DMOF0CA	DI	DMOF0CA
DMOF0CA	DN	Nolatrexed
DMOF0CA	MI	TTU6BFZ
DMOF0CA	MN	Candida Thymidylate synthase (Candi TMP1)
DMOF0CA	MT	DTT
DMOF0CA	MA	Inhibitor
DMOF0CA	RN	A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
DMOF0CA	RU	https://pubmed.ncbi.nlm.nih.gov/10070890

DMMC3Y8	DI	DMMC3Y8
DMMC3Y8	DN	NPC-01
DMMC3Y8	MI	TTZAYWL
DMMC3Y8	MN	Estrogen receptor (ESR)
DMMC3Y8	MT	DTT
DMMC3Y8	MA	Modulator
DMMC3Y8	RN	ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
DMMC3Y8	RU	https://clinicaltrials.gov/ct2/show/NCT01246791

DMMC3Y8	DI	DMMC3Y8
DMMC3Y8	DN	NPC-01
DMMC3Y8	MI	TTUV8G9
DMMC3Y8	MN	Progesterone receptor (PGR)
DMMC3Y8	MT	DTT
DMMC3Y8	MA	Agonist
DMMC3Y8	RN	ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
DMMC3Y8	RU	https://clinicaltrials.gov/ct2/show/NCT01246791

DMCMIJ1	DI	DMCMIJ1
DMCMIJ1	DN	NT0202
DMCMIJ1	MI	TTIU98M
DMCMIJ1	MN	Trace amine-associated receptor-1 (TAAR1)
DMCMIJ1	MT	DTT
DMCMIJ1	MA	Agonist
DMCMIJ1	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DMCMIJ1	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMA16IL	DI	DMA16IL
DMA16IL	DN	NU-100
DMA16IL	MI	TT4TZ8J
DMA16IL	MN	Interferon-beta (IFNB1)
DMA16IL	MT	DTT
DMA16IL	MA	Modulator
DMA16IL	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DMA16IL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DM8JWNA	DI	DM8JWNA
DM8JWNA	DN	NVP-LAQ824
DM8JWNA	MI	TTBH0VX
DM8JWNA	MN	Histone deacetylase (HDAC)
DM8JWNA	MT	DTT
DM8JWNA	MA	Inhibitor
DM8JWNA	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM8JWNA	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM8JWNA	DI	DM8JWNA
DM8JWNA	DN	NVP-LAQ824
DM8JWNA	MI	TT6R7JZ
DM8JWNA	MN	Histone deacetylase 1 (HDAC1)
DM8JWNA	MT	DTT
DM8JWNA	MA	Inhibitor
DM8JWNA	RN	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
DM8JWNA	RU	https://pubmed.ncbi.nlm.nih.gov/12816865

DM3L2GT	DI	DM3L2GT
DM3L2GT	DN	O6-Benzylguanine alkylade
DM3L2GT	MI	TTJ8DV7
DM3L2GT	MN	O-6-methylguanine-DNA-alkyltransferase (MGMT)
DM3L2GT	MT	DTT
DM3L2GT	MA	Modulator
DM3L2GT	RN	Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7.
DM3L2GT	RU	https://pubmed.ncbi.nlm.nih.gov/19204199

DMENDP6	DI	DMENDP6
DMENDP6	DN	OBI-1
DMENDP6	MI	TT1290U
DMENDP6	MN	Coagulation factor VIII (F8)
DMENDP6	MT	DTT
DMENDP6	MA	Modulator
DMENDP6	RN	Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70.
DMENDP6	RU	https://pubmed.ncbi.nlm.nih.gov/25623166

DM7KI4E	DI	DM7KI4E
DM7KI4E	DN	Oblimersen
DM7KI4E	MI	TTJGNVC
DM7KI4E	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM7KI4E	MT	DTT
DM7KI4E	MA	Inhibitor
DM7KI4E	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM7KI4E	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMEDSVJ	DI	DMEDSVJ
DMEDSVJ	DN	Ociperlimab
DMEDSVJ	MI	TTWNL74
DMEDSVJ	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMEDSVJ	MT	DTT
DMEDSVJ	MA	Inhibitor
DMEDSVJ	RN	Clinical pipeline report, company report or official report of BeiGene.
DMEDSVJ	RU	https://www.beigene.com/science-and-product-portfolio/pipeline/ociperlimab

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	TTDZN01
DM1EO3G	MN	Cathepsin K (CTSK)
DM1EO3G	MT	DTT
DM1EO3G	MA	Inhibitor
DM1EO3G	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM1EO3G	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	DES5XRU
DM1EO3G	MN	Cytochrome P450 2C8 (CYP2C8)
DM1EO3G	MT	DME
DM1EO3G	MA	Metabolism
DM1EO3G	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DM1EO3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DM1EO3G	DI	DM1EO3G
DM1EO3G	DN	Odanacatib
DM1EO3G	MI	DE4LYSA
DM1EO3G	MN	Cytochrome P450 3A4 (CYP3A4)
DM1EO3G	MT	DME
DM1EO3G	MA	Metabolism
DM1EO3G	RN	Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.
DM1EO3G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24553380

DMYN391	DI	DMYN391
DMYN391	DN	Odevixibat
DMYN391	MI	TTPI1M5
DMYN391	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMYN391	MT	DTT
DMYN391	MA	Inhibitor
DMYN391	RN	Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689.
DMYN391	RU	https://pubmed.ncbi.nlm.nih.gov/32653991

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTIND6G
DMBWO5T	MN	Somatostatin receptor type 1 (SSTR1)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTZ6T9E
DMBWO5T	MN	Somatostatin receptor type 2 (SSTR2)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTJX3UE
DMBWO5T	MN	Somatostatin receptor type 3 (SSTR3)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TTAE1BR
DMBWO5T	MN	Somatostatin receptor type 4 (SSTR4)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DMBWO5T	DI	DMBWO5T
DMBWO5T	DN	ODT-8
DMBWO5T	MI	TT2BC4G
DMBWO5T	MN	Somatostatin receptor type 5 (SSTR5)
DMBWO5T	MT	DTT
DMBWO5T	MA	Inhibitor
DMBWO5T	RN	Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22.
DMBWO5T	RU	https://pubmed.ncbi.nlm.nih.gov/15658865

DM1FBZ7	DI	DM1FBZ7
DM1FBZ7	DN	Olodaterol/tiotropium bromide
DM1FBZ7	MI	DECB0K3
DM1FBZ7	MN	Cytochrome P450 2D6 (CYP2D6)
DM1FBZ7	MT	DME
DM1FBZ7	MA	Metabolism
DM1FBZ7	RN	Tiotropium rromide/olodaterol (Stiolto Respimat): once-daily combination therapy for the maintenance of COPD. P T. 2016 Feb;41(2):97-102.
DM1FBZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26908999

DM1FBZ7	DI	DM1FBZ7
DM1FBZ7	DN	Olodaterol/tiotropium bromide
DM1FBZ7	MI	DE4LYSA
DM1FBZ7	MN	Cytochrome P450 3A4 (CYP3A4)
DM1FBZ7	MT	DME
DM1FBZ7	MA	Metabolism
DM1FBZ7	RN	Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.
DM1FBZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15350163

DM4Z9QI	DI	DM4Z9QI
DM4Z9QI	DN	Olokizumab
DM4Z9QI	MI	TTT1V78
DM4Z9QI	MN	Interleukin-6 (IL6)
DM4Z9QI	MT	DTT
DM4Z9QI	MA	Modulator
DM4Z9QI	RN	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615.
DM4Z9QI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/

DM624TW	DI	DM624TW
DM624TW	DN	Omecamtiv mecarbil
DM624TW	MI	TT9WOBN
DM624TW	MN	Cardiac myosin (MYBPC3)
DM624TW	MT	DTT
DM624TW	MA	Modulator
DM624TW	RN	CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009 Apr;12(4):243-51.
DM624TW	RU	https://pubmed.ncbi.nlm.nih.gov/19350469

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE87OZS
DMBWY8V	MN	Arachidonate 5-lipoxygenase (ALOX5)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE05S8C
DMBWY8V	MN	Fatty acid desaturase 1 (FADS1)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DEDI4B8
DMBWY8V	MN	Fatty acid desaturase 2 (FADS2)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMBWY8V	DI	DMBWY8V
DMBWY8V	DN	Omega-6-FA
DMBWY8V	MI	DE492CE
DMBWY8V	MN	Prostaglandin G/H synthase 2 (COX-2)
DMBWY8V	MT	DME
DMBWY8V	MA	Metabolism
DMBWY8V	RN	Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
DMBWY8V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22570770

DMK6QBZ	DI	DMK6QBZ
DMK6QBZ	DN	OMS721
DMK6QBZ	MI	TTR01E9
DMK6QBZ	MN	Mannan-binding lectin serine protease-2 (MASP2)
DMK6QBZ	MT	DTT
DMK6QBZ	MA	Inhibitor
DMK6QBZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK6QBZ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU86DM	DI	DMU86DM
DMU86DM	DN	ONO-1101
DMU86DM	MI	DECB0K3
DMU86DM	MN	Cytochrome P450 2D6 (CYP2D6)
DMU86DM	MT	DME
DMU86DM	MA	Metabolism
DMU86DM	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMU86DM	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM06KRC	DI	DM06KRC
DM06KRC	DN	Oregovomab
DM06KRC	MI	TTC1PS3
DM06KRC	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM06KRC	MT	DTT
DM06KRC	RN	MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129.
DM06KRC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TTZGK1R
DMWD3IV	MN	HUMAN glycosylation of host receptor (GHR)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TTD16BI
DMWD3IV	MN	HUMAN pH-dependent viral fusion/replication (pH-DVF/R)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DMWD3IV	DI	DMWD3IV
DMWD3IV	DN	Oseltamivir + hydroxychloroquine
DMWD3IV	MI	TT3A1EZ
DMWD3IV	MN	HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway)
DMWD3IV	MT	DTT
DMWD3IV	MA	Inhibitor
DMWD3IV	RN	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166.
DMWD3IV	RU	https://pubmed.ncbi.nlm.nih.gov/32034323

DMHKZLF	DI	DMHKZLF
DMHKZLF	DN	OSI-906
DMHKZLF	MI	TTHRID2
DMHKZLF	MN	Insulin-like growth factor I receptor (IGF1R)
DMHKZLF	MT	DTT
DMHKZLF	MA	Inhibitor
DMHKZLF	RN	Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
DMHKZLF	RU	https://pubmed.ncbi.nlm.nih.gov/20346655

DM7R145	DI	DM7R145
DM7R145	DN	Otesaconazole
DM7R145	MI	TTTSOUD
DM7R145	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM7R145	MT	DTT
DM7R145	MA	Inhibitor
DM7R145	RN	Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73.
DM7R145	RU	https://pubmed.ncbi.nlm.nih.gov/26124165

DMLMS6J	DI	DMLMS6J
DMLMS6J	DN	OTL-101
DMLMS6J	MI	TTLP57V
DMLMS6J	MN	Adenosine deaminase (ADA)
DMLMS6J	MT	DTT
DMLMS6J	MA	Replacement
DMLMS6J	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMLMS6J	RU	https://www.orchard-tx.com/approach/pipeline/

DM3BK2Y	DI	DM3BK2Y
DM3BK2Y	DN	OTL-103
DM3BK2Y	MI	TTE8T73
DM3BK2Y	MN	Wiskott-Aldrich syndrome protein (WAS)
DM3BK2Y	MT	DTT
DM3BK2Y	MA	Replacement
DM3BK2Y	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DM3BK2Y	RU	https://www.orchard-tx.com/approach/pipeline/

DM5DRMY	DI	DM5DRMY
DM5DRMY	DN	P1101
DM5DRMY	MI	TT95SOA
DM5DRMY	MN	Interferon alpha (IFNA)
DM5DRMY	MT	DTT
DM5DRMY	MA	Inhibitor
DM5DRMY	RN	Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
DM5DRMY	RU	https://pubmed.ncbi.nlm.nih.gov/25545244

DM7WYXJ	DI	DM7WYXJ
DM7WYXJ	DN	P-1101
DM7WYXJ	MI	TTSIUJ9
DM7WYXJ	MN	Interferon-alpha 2 (IFNA2)
DM7WYXJ	MT	DTT
DM7WYXJ	MA	Modulator
DM7WYXJ	RN	Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.
DM7WYXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20486736

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TTEX248
DM9PVHX	MN	Dopamine D2 receptor (D2R)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/9617505

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TT4C8EA
DM9PVHX	MN	Dopamine D3 receptor (D3R)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/9617505

DM9PVHX	DI	DM9PVHX
DM9PVHX	DN	P2B-001
DM9PVHX	MI	TTGP7BY
DM9PVHX	MN	Monoamine oxidase type B (MAO-B)
DM9PVHX	MT	DTT
DM9PVHX	MA	Inhibitor
DM9PVHX	RN	Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.
DM9PVHX	RU	https://pubmed.ncbi.nlm.nih.gov/17296539

DM1T6ZN	DI	DM1T6ZN
DM1T6ZN	DN	Pacritinib
DM1T6ZN	MI	TTGJCWZ
DM1T6ZN	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM1T6ZN	MT	DTT
DM1T6ZN	MA	Modulator
DM1T6ZN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
DM1T6ZN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807

DM1T6ZN	DI	DM1T6ZN
DM1T6ZN	DN	Pacritinib
DM1T6ZN	MI	TTRMX3V
DM1T6ZN	MN	Janus kinase 2 (JAK-2)
DM1T6ZN	MT	DTT
DM1T6ZN	MA	Modulator
DM1T6ZN	RN	National Cancer Institute Drug Dictionary (drug id 609888).
DM1T6ZN	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=609888

DMFKOR9	DI	DMFKOR9
DMFKOR9	DN	Pafuramidine
DMFKOR9	MI	DE3GT9C
DMFKOR9	MN	Cytochrome P450 4F2 (CYP4F2)
DMFKOR9	MT	DME
DMFKOR9	MA	Metabolism
DMFKOR9	RN	Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine. Drug Metab Dispos. 2007 Nov;35(11):2067-75.
DMFKOR9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17709372

DMFKOR9	DI	DMFKOR9
DMFKOR9	DN	Pafuramidine
DMFKOR9	MI	TTUTN1I
DMFKOR9	MN	Human Deoxyribonucleic acid (hDNA)
DMFKOR9	MT	DTT
DMFKOR9	MA	Modulator
DMFKOR9	RN	DNA Minor Groove Induced Dimerization of Heterocyclic Cations: Compound Structure, Binding Affinity and Specificity for a TTAA Site
DMFKOR9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988403

DMAD2OZ	DI	DMAD2OZ
DMAD2OZ	DN	Palovarotene
DMAD2OZ	MI	TT1Q3IE
DMAD2OZ	MN	Retinoic acid receptor gamma (RARG)
DMAD2OZ	MT	DTT
DMAD2OZ	MA	Agonist
DMAD2OZ	RN	Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12.
DMAD2OZ	RU	https://pubmed.ncbi.nlm.nih.gov/22282548

DM4SKYI	DI	DM4SKYI
DM4SKYI	DN	PAMAQUESIDE
DM4SKYI	MI	TT61VTP
DM4SKYI	MN	Cholesterol uptake (Chole uptake)
DM4SKYI	MT	DTT
DM4SKYI	MA	Modulator
DM4SKYI	RN	Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. J Lipid Res. 1999 Mar;40(3):464-74.
DM4SKYI	RU	https://pubmed.ncbi.nlm.nih.gov/10064735

DMIRYU9	DI	DMIRYU9
DMIRYU9	DN	Pancopride
DMIRYU9	MI	TTNXLKE
DMIRYU9	MN	5-HT 3 receptor (5HT3R)
DMIRYU9	MT	DTT
DMIRYU9	MA	Inhibitor
DMIRYU9	RN	Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64.
DMIRYU9	RU	https://pubmed.ncbi.nlm.nih.gov/1451737

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTUNARX
DMEW5Z8	MN	Carbonic anhydrase (CA)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTHQPL7
DMEW5Z8	MN	Carbonic anhydrase I (CA-I)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTANPDJ
DMEW5Z8	MN	Carbonic anhydrase II (CA-II)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTZHA0O
DMEW5Z8	MN	Carbonic anhydrase IV (CA-IV)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TT2LVK8
DMEW5Z8	MN	Carbonic anhydrase IX (CA-IX)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTCFSPE
DMEW5Z8	MN	Carbonic anhydrase VI (CA-VI)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTSYM0R
DMEW5Z8	MN	Carbonic anhydrase XII (CA-XII)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DMEW5Z8	DI	DMEW5Z8
DMEW5Z8	DN	PARABEN
DMEW5Z8	MI	TTEYTKG
DMEW5Z8	MN	Carbonic anhydrase XIV (CA-XIV)
DMEW5Z8	MT	DTT
DMEW5Z8	MA	Inhibitor
DMEW5Z8	RN	Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
DMEW5Z8	RU	https://pubmed.ncbi.nlm.nih.gov/20185318

DM3H2U4	DI	DM3H2U4
DM3H2U4	DN	Patrome
DM3H2U4	MI	TTN451K
DM3H2U4	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DM3H2U4	MT	DTT
DM3H2U4	MA	Modulator
DM3H2U4	RN	The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
DM3H2U4	RU	https://pubmed.ncbi.nlm.nih.gov/11106255

DMHXTAQ	DI	DMHXTAQ
DMHXTAQ	DN	Pazufloxacin
DMHXTAQ	MI	TTN6J5F
DMHXTAQ	MN	Bacterial DNA gyrase (Bact gyrase)
DMHXTAQ	MT	DTT
DMHXTAQ	MA	Inhibitor
DMHXTAQ	RN	Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
DMHXTAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11709337

DMHXTAQ	DI	DMHXTAQ
DMHXTAQ	DN	Pazufloxacin
DMHXTAQ	MI	TTFK8YB
DMHXTAQ	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMHXTAQ	MT	DTT
DMHXTAQ	MA	Inhibitor
DMHXTAQ	RN	Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
DMHXTAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/11709337

DMP3G0W	DI	DMP3G0W
DMP3G0W	DN	Pazufloxacin
DMP3G0W	MI	DTUGYRD
DMP3G0W	MN	P-glycoprotein 1 (ABCB1)
DMP3G0W	MT	DTP
DMP3G0W	MA	Substrate
DMP3G0W	RN	Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol. 2004 Oct 6;501(1-3):151-9.
DMP3G0W	RU	https://doi.org/10.1016/j.ejphar.2004.08.013

DMJBHO0	DI	DMJBHO0
DMJBHO0	DN	PC-DAC:Insulin
DMJBHO0	MI	TTZOPHG
DMJBHO0	MN	Insulin (INS)
DMJBHO0	MT	DTT
DMJBHO0	MA	Modulator
DMJBHO0	RN	Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539.
DMJBHO0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901028/

DMMBC5W	DI	DMMBC5W
DMMBC5W	DN	PDGF-BB
DMMBC5W	MI	TTQA6SX
DMMBC5W	MN	Platelet-derived growth factor B (PDGFB)
DMMBC5W	MT	DTT
DMMBC5W	MA	Modulator
DMMBC5W	RN	Clinical pipeline report, company report or official report of Adocia.
DMMBC5W	RU	http://www.adocia.fr/WP/products/bc-pdgf-bb-en/

DM53J6B	DI	DM53J6B
DM53J6B	DN	PDR001
DM53J6B	MI	TTNBFWK
DM53J6B	MN	Programmed cell death protein 1 (PD-1)
DM53J6B	MT	DTT
DM53J6B	MA	Antagonist
DM53J6B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM53J6B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMBKWAF	DI	DMBKWAF
DMBKWAF	DN	Peg-G-CSF
DMBKWAF	MI	TTC70AJ
DMBKWAF	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMBKWAF	MT	DTT
DMBKWAF	MA	Stimulator
DMBKWAF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMBKWAF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMK6OFY	DI	DMK6OFY
DMK6OFY	DN	Peginterferon lambda-1a
DMK6OFY	MI	TTM624L
DMK6OFY	MN	Interleukin-29 (IL29)
DMK6OFY	MT	DTT
DMK6OFY	MA	Agonist
DMK6OFY	RN	Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.
DMK6OFY	RU	https://pubmed.ncbi.nlm.nih.gov/20645873

DMESAZK	DI	DMESAZK
DMESAZK	DN	Peretinoin
DMESAZK	MI	TTOD7B3
DMESAZK	MN	Retinoic acid receptor (RAR)
DMESAZK	MT	DTT
DMESAZK	MA	Modulator
DMESAZK	RN	Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191.
DMESAZK	RU	https://pubmed.ncbi.nlm.nih.gov/23587162

DMUP5Z0	DI	DMUP5Z0
DMUP5Z0	DN	PF-03084014
DMUP5Z0	MI	TTE4KHA
DMUP5Z0	MN	Amyloid beta A4 protein (APP)
DMUP5Z0	MT	DTT
DMUP5Z0	MA	Inhibitor
DMUP5Z0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUP5Z0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUP5Z0	DI	DMUP5Z0
DMUP5Z0	DN	PF-03084014
DMUP5Z0	MI	TT9W8GU
DMUP5Z0	MN	Gamma-secretase (GS)
DMUP5Z0	MT	DTT
DMUP5Z0	MA	Modulator
DMUP5Z0	RN	Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
DMUP5Z0	RU	https://www.ncbi.nlm.nih.gov/pubmed/20363853

DM0TWCY	DI	DM0TWCY
DM0TWCY	DN	PF-04950615
DM0TWCY	MI	TTBRG7E
DM0TWCY	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DM0TWCY	MT	DTT
DM0TWCY	RN	Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.
DM0TWCY	RU	https://pubmed.ncbi.nlm.nih.gov/24316621

DM8J29L	DI	DM8J29L
DM8J29L	DN	PF-04965842
DM8J29L	MI	TTJSQEF
DM8J29L	MN	Tyrosine-protein kinase (PTK)
DM8J29L	MT	DTT
DM8J29L	MA	Inhibitor
DM8J29L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8J29L	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM23BUP	DI	DM23BUP
DM23BUP	DN	PF-05280014
DM23BUP	MI	TT6EO5L
DM23BUP	MN	Erbb2 tyrosine kinase receptor (HER2)
DM23BUP	MT	DTT
DM23BUP	MA	Antagonist
DM23BUP	RN	Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9.
DM23BUP	RU	https://pubmed.ncbi.nlm.nih.gov/25001079

DMNZOCK	DI	DMNZOCK
DMNZOCK	DN	PF-05280586
DMNZOCK	MI	TTUE541
DMNZOCK	MN	Leukocyte surface antigen Leu-16 (CD20)
DMNZOCK	MT	DTT
DMNZOCK	MA	Antagonist
DMNZOCK	RN	Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81.
DMNZOCK	RU	https://pubmed.ncbi.nlm.nih.gov/24604381

DM2GF14	DI	DM2GF14
DM2GF14	DN	PF-06410293
DM2GF14	MI	TTF8CQI
DM2GF14	MN	Tumor necrosis factor (TNF)
DM2GF14	MT	DTT
DM2GF14	RN	Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20.
DM2GF14	RU	https://pubmed.ncbi.nlm.nih.gov/25114503

DMM4C95	DI	DMM4C95
DMM4C95	DN	PF-06438179
DMM4C95	MI	TTF8CQI
DMM4C95	MN	Tumor necrosis factor (TNF)
DMM4C95	MT	DTT
DMM4C95	MA	Inhibitor
DMM4C95	RN	Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7.
DMM4C95	RU	https://pubmed.ncbi.nlm.nih.gov/24722561

DMVHZDP	DI	DMVHZDP
DMVHZDP	DN	PF-06439535
DMVHZDP	MI	TT9HKJA
DMVHZDP	MN	Vascular endothelial growth factor (VEGF)
DMVHZDP	MT	DTT
DMVHZDP	RN	National Cancer Institute Drug Dictionary (drug id 43234).
DMVHZDP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43234

DMW63TQ	DI	DMW63TQ
DMW63TQ	DN	PF-06741086
DMW63TQ	MI	TT068JH
DMW63TQ	MN	Tissue factor pathway inhibitor (TFPI)
DMW63TQ	MT	DTT
DMW63TQ	MA	Inhibitor
DMW63TQ	RN	Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46.
DMW63TQ	RU	https://pubmed.ncbi.nlm.nih.gov/30927117

DMWPA4L	DI	DMWPA4L
DMWPA4L	DN	PF-07055480
DMWPA4L	MI	TT1290U
DMWPA4L	MN	Coagulation factor VIII (F8)
DMWPA4L	MT	DTT
DMWPA4L	MA	Replacement
DMWPA4L	RN	Clinical pipeline report, company report or official report of Pfizer.
DMWPA4L	RU	https://www.pfizer.com/science/rare-diseases/pipeline

DMS1EQ7	DI	DMS1EQ7
DMS1EQ7	DN	PF-1228305
DMS1EQ7	MI	TTKRD0G
DMS1EQ7	MN	Endothelin A receptor (EDNRA)
DMS1EQ7	MT	DTT
DMS1EQ7	MA	Antagonist
DMS1EQ7	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMS1EQ7	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMJ7IKW	DI	DMJ7IKW
DMJ7IKW	DN	PF-4494700
DMJ7IKW	MI	TTMO9HF
DMJ7IKW	MN	Advanced glycosylation end product receptor (AGER)
DMJ7IKW	MT	DTT
DMJ7IKW	MA	Antagonist
DMJ7IKW	RN	Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
DMJ7IKW	RU	https://pubmed.ncbi.nlm.nih.gov/25586103

DM5DAP3	DI	DM5DAP3
DM5DAP3	DN	PGF2ALPHA-IE
DM5DAP3	MI	TTT2ZAR
DM5DAP3	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5DAP3	MT	DTT
DM5DAP3	MA	Modulator
DM5DAP3	RN	Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7.
DM5DAP3	RU	https://pubmed.ncbi.nlm.nih.gov/7532135

DM8Y12A	DI	DM8Y12A
DM8Y12A	DN	PH-80
DM8Y12A	MI	TTOASGR
DM8Y12A	MN	Neuroepithelial receptor (NR)
DM8Y12A	MT	DTT
DM8Y12A	MA	Modulator
DM8Y12A	RN	Patents by Assignee Pherin Corporation.
DM8Y12A	RU	http://patents.justia.com/assignee/pherin-corporation

DMDC7OH	DI	DMDC7OH
DMDC7OH	DN	PH94B NS
DMDC7OH	MI	TTCI43M
DMDC7OH	MN	GABA(A) receptor (GABAR)
DMDC7OH	MT	DTT
DMDC7OH	MA	Modulator
DMDC7OH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDC7OH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMVEHM4	DI	DMVEHM4
DMVEHM4	DN	Phentermine+topiramate
DMVEHM4	MI	TTUNARX
DMVEHM4	MN	Carbonic anhydrase (CA)
DMVEHM4	MT	DTT
DMVEHM4	MA	Inhibitor
DMVEHM4	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMVEHM4	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMVEHM4	DI	DMVEHM4
DMVEHM4	DN	Phentermine+topiramate
DMVEHM4	MI	TTNJYV2
DMVEHM4	MN	Gamma-aminobutyric acid receptor (GAR)
DMVEHM4	MT	DTT
DMVEHM4	MA	Modulator
DMVEHM4	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMVEHM4	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMGZPX6	DI	DMGZPX6
DMGZPX6	DN	PI-88
DMGZPX6	MI	TTDCBX5
DMGZPX6	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMGZPX6	MT	DTT
DMGZPX6	MA	Modulator
DMGZPX6	RN	Company report (Medigen)
DMGZPX6	RU	http://www.medigen.com.tw/en/muparfostat-pi-88/

DM7OSHC	DI	DM7OSHC
DM7OSHC	DN	Pinaverium bromide
DM7OSHC	MI	TTXHYV6
DM7OSHC	MN	Voltage-gated L-type calcium channel (L-CaC)
DM7OSHC	MT	DTT
DM7OSHC	MA	Blocker
DM7OSHC	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM7OSHC	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMRG1X3	DI	DMRG1X3
DMRG1X3	DN	Pirtobrutinib
DMRG1X3	MI	TTGM6VW
DMRG1X3	MN	Tyrosine-protein kinase BTK (ATK)
DMRG1X3	MT	DTT
DMRG1X3	MA	Inhibitor
DMRG1X3	RN	Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205.
DMRG1X3	RU	https://pubmed.ncbi.nlm.nih.gov/31028669

DMQGR45	DI	DMQGR45
DMQGR45	DN	Pixantrone
DMQGR45	MI	TT0IHXV
DMQGR45	MN	DNA topoisomerase II (TOP2)
DMQGR45	MT	DTT
DMQGR45	MA	Modulator
DMQGR45	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQGR45	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCA6BW	DI	DMCA6BW
DMCA6BW	DN	Pixykine
DMCA6BW	MI	TT6MP2Z
DMCA6BW	MN	GMCSFR-alpha (CSF2RA)
DMCA6BW	MT	DTT
DMCA6BW	MA	Modulator
DMCA6BW	RN	Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
DMCA6BW	RU	https://www.ncbi.nlm.nih.gov/pubmed/9827896

DM1RWMY	DI	DM1RWMY
DM1RWMY	DN	Plasma derived factor VIII PEGylated liposomal
DM1RWMY	MI	TT1290U
DM1RWMY	MN	Coagulation factor VIII (F8)
DM1RWMY	MT	DTT
DM1RWMY	MA	Modulator
DM1RWMY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM1RWMY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMD7L48	DI	DMD7L48
DMD7L48	DN	Plinabulin
DMD7L48	MI	TTKIGZF
DMD7L48	MN	Guanine nucleotide exchange factor (GNEF)
DMD7L48	MT	DTT
DMD7L48	MA	Stimulator
DMD7L48	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD7L48	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMD7L48	DI	DMD7L48
DMD7L48	DN	Plinabulin
DMD7L48	MI	TTYFKSZ
DMD7L48	MN	Tubulin beta (TUBB)
DMD7L48	MT	DTT
DMD7L48	MA	Modulator
DMD7L48	RN	NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
DMD7L48	RU	https://www.ncbi.nlm.nih.gov/pubmed/16317287

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DEJVYAZ
DMJ8AUE	MN	Cytochrome P450 2A6 (CYP2A6)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DEVDYN7
DMJ8AUE	MN	Cytochrome P450 2E1 (CYP2E1)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	DE4LYSA
DMJ8AUE	MN	Cytochrome P450 3A4 (CYP3A4)
DMJ8AUE	MT	DME
DMJ8AUE	MA	Metabolism
DMJ8AUE	RN	In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19.
DMJ8AUE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16633717

DMJ8AUE	DI	DMJ8AUE
DMJ8AUE	DN	Plitidepsin
DMJ8AUE	MI	TTSQC14
DMJ8AUE	MN	Palmitoyl-protein thioesterase 1 (PPT1)
DMJ8AUE	MT	DTT
DMJ8AUE	MA	Modulator
DMJ8AUE	RN	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
DMJ8AUE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765

DMV8EXG	DI	DMV8EXG
DMV8EXG	DN	PolyHeme
DMV8EXG	MI	TTQO71U
DMV8EXG	MN	Hemoglobin (HB)
DMV8EXG	MT	DTT
DMV8EXG	MA	Modulator
DMV8EXG	RN	Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
DMV8EXG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322929/

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	DEJGDUW
DMTD7AB	MN	Cytochrome P450 1A2 (CYP1A2)
DMTD7AB	MT	DME
DMTD7AB	MA	Metabolism
DMTD7AB	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DMTD7AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	DE4LYSA
DMTD7AB	MN	Cytochrome P450 3A4 (CYP3A4)
DMTD7AB	MT	DME
DMTD7AB	MA	Metabolism
DMTD7AB	RN	Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011 Dec;39(12):2219-32.
DMTD7AB	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21873472

DMTD7AB	DI	DMTD7AB
DMTD7AB	DN	Pracinostat
DMTD7AB	MI	TTBH0VX
DMTD7AB	MN	Histone deacetylase (HDAC)
DMTD7AB	MT	DTT
DMTD7AB	MA	Modulator
DMTD7AB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
DMTD7AB	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8365

DM2ZYX9	DI	DM2ZYX9
DM2ZYX9	DN	Pradaxa
DM2ZYX9	MI	DEB30C5
DM2ZYX9	MN	Carboxylesterase 1 (CES1)
DM2ZYX9	MT	DME
DM2ZYX9	MA	Metabolism
DM2ZYX9	RN	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
DM2ZYX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23239178

DM2ZYX9	DI	DM2ZYX9
DM2ZYX9	DN	Pradaxa
DM2ZYX9	MI	DETHCPD
DM2ZYX9	MN	Carboxylesterase 2 (CES2)
DM2ZYX9	MT	DME
DM2ZYX9	MA	Metabolism
DM2ZYX9	RN	Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
DM2ZYX9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23239178

DMOMDXI	DI	DMOMDXI
DMOMDXI	DN	Pratosartan
DMOMDXI	MI	TT8DBY3
DMOMDXI	MN	Angiotensin II receptor type-1 (AGTR1)
DMOMDXI	MT	DTT
DMOMDXI	MA	Antagonist
DMOMDXI	RN	Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7.
DMOMDXI	RU	https://pubmed.ncbi.nlm.nih.gov/18360048

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTZAYWL
DMLSOB7	MN	Estrogen receptor (ESR)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTOM3J0
DMLSOB7	MN	Estrogen receptor beta (ESR2)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMLSOB7	DI	DMLSOB7
DMLSOB7	DN	Premarin/Pravachol
DMLSOB7	MI	TTPADOQ
DMLSOB7	MN	HMG-CoA reductase (HMGCR)
DMLSOB7	MT	DTT
DMLSOB7	MA	Modulator
DMLSOB7	RN	Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26.
DMLSOB7	RU	https://pubmed.ncbi.nlm.nih.gov/12815379

DMX9YLR	DI	DMX9YLR
DMX9YLR	DN	Pridopidine
DMX9YLR	MI	TTEX248
DMX9YLR	MN	Dopamine D2 receptor (D2R)
DMX9YLR	MT	DTT
DMX9YLR	MA	Modulator
DMX9YLR	RN	Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4.
DMX9YLR	RU	https://pubmed.ncbi.nlm.nih.gov/20616707

DMD1FTP	DI	DMD1FTP
DMD1FTP	DN	PRO-140
DMD1FTP	MI	TT2CEJG
DMD1FTP	MN	C-C chemokine receptor type 5 (CCR5)
DMD1FTP	MT	DTT
DMD1FTP	MA	Antagonist
DMD1FTP	RN	Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
DMD1FTP	RU	https://pubmed.ncbi.nlm.nih.gov/21389095

DM5FZH4	DI	DM5FZH4
DM5FZH4	DN	ProstaVac
DM5FZH4	MI	TTS78AZ
DM5FZH4	MN	Prostate specific antigen (KLK3)
DM5FZH4	MT	DTT
DM5FZH4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DM5FZH4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMVU8RW	DI	DMVU8RW
DMVU8RW	DN	PRT4445
DMVU8RW	MI	TTCIHJA
DMVU8RW	MN	Coagulation factor Xa (F10)
DMVU8RW	MT	DTT
DMVU8RW	MA	Modulator
DMVU8RW	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMVU8RW	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMEH641	DI	DMEH641
DMEH641	DN	PRX-302
DMEH641	MI	TTS78AZ
DMEH641	MN	Prostate specific antigen (KLK3)
DMEH641	MT	DTT
DMEH641	MA	Modulator
DMEH641	RN	Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54.
DMEH641	RU	https://pubmed.ncbi.nlm.nih.gov/21129846

DMIZJ8M	DI	DMIZJ8M
DMIZJ8M	DN	Psoralen
DMIZJ8M	MI	TT3WG5C
DMIZJ8M	MN	Monoamine oxidase type A (MAO-A)
DMIZJ8M	MT	DTT
DMIZJ8M	MA	Inhibitor
DMIZJ8M	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMIZJ8M	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMIZJ8M	DI	DMIZJ8M
DMIZJ8M	DN	Psoralen
DMIZJ8M	MI	TTGP7BY
DMIZJ8M	MN	Monoamine oxidase type B (MAO-B)
DMIZJ8M	MT	DTT
DMIZJ8M	MA	Inhibitor
DMIZJ8M	RN	Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
DMIZJ8M	RU	https://pubmed.ncbi.nlm.nih.gov/11169165

DMTSN8L	DI	DMTSN8L
DMTSN8L	DN	PT005
DMTSN8L	MI	TT2CJVK
DMTSN8L	MN	Adrenergic receptor beta-2 (ADRB2)
DMTSN8L	MT	DTT
DMTSN8L	MA	Agonist
DMTSN8L	RN	Clinical pipeline report, company report or official report of Pearl Therapeutics.
DMTSN8L	RU	http://www.pearltherapeutics.com/PT005

DML1KTO	DI	DML1KTO
DML1KTO	DN	PT2977
DML1KTO	MI	TTDMLNT
DML1KTO	MN	Hypoxia-inducible factor 2 alpha (HIF-2A)
DML1KTO	MT	DTT
DML1KTO	MA	Inhibitor
DML1KTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML1KTO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMJ63A	DI	DMMJ63A
DMMJ63A	DN	PT-304
DMMJ63A	MI	TT84ETX
DMMJ63A	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMJ63A	MT	DTT
DMMJ63A	MA	Inhibitor
DMMJ63A	RN	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
DMMJ63A	RU	https://pubmed.ncbi.nlm.nih.gov/8523406

DMVDCGZ	DI	DMVDCGZ
DMVDCGZ	DN	Pyridoxamine
DMVDCGZ	MI	TTMO9HF
DMVDCGZ	MN	Advanced glycosylation end product receptor (AGER)
DMVDCGZ	MT	DTT
DMVDCGZ	MA	Inhibitor
DMVDCGZ	RN	Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
DMVDCGZ	RU	https://pubmed.ncbi.nlm.nih.gov/20441560

DMVDCGZ	DI	DMVDCGZ
DMVDCGZ	DN	Pyridoxamine
DMVDCGZ	MI	DE3Z1RA
DMVDCGZ	MN	Pyridoxamine-phosphate oxidase (PNPO)
DMVDCGZ	MT	DME
DMVDCGZ	MA	Metabolism
DMVDCGZ	RN	An LC-MS/MS-based method for the quantification of pyridox(am)ine 5'-phosphate oxidase activity in dried blood spots from patients with epilepsy. Anal Chem. 2017 Sep 5;89(17):8892-8900.
DMVDCGZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28782931

DMPCFXN	DI	DMPCFXN
DMPCFXN	DN	QAW-039
DMPCFXN	MI	TTNVEIR
DMPCFXN	MN	Prostaglandin D2 receptor (PTGDR)
DMPCFXN	MT	DTT
DMPCFXN	MA	Antagonist
DMPCFXN	RN	Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
DMPCFXN	RU	http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A6361

DMDU5Y2	DI	DMDU5Y2
DMDU5Y2	DN	QPI-1002
DMDU5Y2	MI	TT7SBF5
DMDU5Y2	MN	Cellular tumor antigen p53 (TP53)
DMDU5Y2	MT	DTT
DMDU5Y2	MA	Modulator
DMDU5Y2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDU5Y2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUWXEB	DI	DMUWXEB
DMUWXEB	DN	QPI-1007
DMUWXEB	MI	TT12VNG
DMUWXEB	MN	Caspase 2 messenger RNA (CASP2 mRNA)
DMUWXEB	MT	DTT
DMUWXEB	RN	Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66.
DMUWXEB	RU	https://pubmed.ncbi.nlm.nih.gov/25054518

DMDCQW0	DI	DMDCQW0
DMDCQW0	DN	Quinotolast
DMDCQW0	MI	TT7KY5U
DMDCQW0	MN	Histamine/peptide leukotriene release (His/p-LT rele)
DMDCQW0	MT	DTT
DMDCQW0	MA	Modulator
DMDCQW0	RN	Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol. 1993 Sep;63(1):73-81.
DMDCQW0	RU	https://pubmed.ncbi.nlm.nih.gov/7505860

DMSFX75	DI	DMSFX75
DMSFX75	DN	QVA-149
DMSFX75	MI	TT2CJVK
DMSFX75	MN	Adrenergic receptor beta-2 (ADRB2)
DMSFX75	MT	DTT
DMSFX75	MA	Agonist
DMSFX75	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMSFX75	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DM4K9WH	DI	DM4K9WH
DM4K9WH	DN	R1678
DM4K9WH	MI	TTHJTF7
DM4K9WH	MN	Glycine transporter GlyT-1 (SLC6A9)
DM4K9WH	MT	DTT
DM4K9WH	MA	Blocker
DM4K9WH	RN	Clinical pipeline report, company report or official report of Roche (2009).
DM4K9WH	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DM9Z4N5	DI	DM9Z4N5
DM9Z4N5	DN	RA101495
DM9Z4N5	MI	TTKANGO
DM9Z4N5	MN	Complement C5 (CO5)
DM9Z4N5	MT	DTT
DM9Z4N5	MA	Inhibitor
DM9Z4N5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Z4N5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8RLJ5	DI	DM8RLJ5
DM8RLJ5	DN	RAD-1901
DM8RLJ5	MI	TTZAYWL
DM8RLJ5	MN	Estrogen receptor (ESR)
DM8RLJ5	MT	DTT
DM8RLJ5	MA	Modulator
DM8RLJ5	RN	RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56.
DM8RLJ5	RU	https://pubmed.ncbi.nlm.nih.gov/26164151

DMN1ZEU	DI	DMN1ZEU
DMN1ZEU	DN	Radiosensitizer gene therapy
DMN1ZEU	MI	TTP3QRF
DMN1ZEU	MN	Thymidine kinase 1 (TK1)
DMN1ZEU	MT	DTT
DMN1ZEU	MA	Inhibitor
DMN1ZEU	RN	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
DMN1ZEU	RU	https://pubmed.ncbi.nlm.nih.gov/9815600

DMWA74Y	DI	DMWA74Y
DMWA74Y	DN	Radotinib
DMWA74Y	MI	TTS7G69
DMWA74Y	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMWA74Y	MT	DTT
DMWA74Y	MA	Modulator
DMWA74Y	RN	Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93.
DMWA74Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/22242557

DMFSHEM	DI	DMFSHEM
DMFSHEM	DN	Ragaglitazar
DMFSHEM	MI	TTJ584C
DMFSHEM	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFSHEM	MT	DTT
DMFSHEM	MA	Modulator
DMFSHEM	RN	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
DMFSHEM	RU	https://pubmed.ncbi.nlm.nih.gov/14551179

DMFSHEM	DI	DMFSHEM
DMFSHEM	DN	Ragaglitazar
DMFSHEM	MI	TTZMAO3
DMFSHEM	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMFSHEM	MT	DTT
DMFSHEM	MA	Modulator
DMFSHEM	RN	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
DMFSHEM	RU	https://pubmed.ncbi.nlm.nih.gov/14551179

DMUNMY0	DI	DMUNMY0
DMUNMY0	DN	Ralfinamide
DMUNMY0	MI	TTRK8B9
DMUNMY0	MN	Sodium channel unspecific (NaC)
DMUNMY0	MT	DTT
DMUNMY0	MA	Blocker
DMUNMY0	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMUNMY0	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMUNMY0	DI	DMUNMY0
DMUNMY0	DN	Ralfinamide
DMUNMY0	MI	TT4FDG6
DMUNMY0	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMUNMY0	MT	DTT
DMUNMY0	MA	Blocker
DMUNMY0	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMUNMY0	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMD5QRS	DI	DMD5QRS
DMD5QRS	DN	Ranirestat
DMD5QRS	MI	TTFBNVI
DMD5QRS	MN	Aldose reductase (AKR1B1)
DMD5QRS	MT	DTT
DMD5QRS	MA	Inhibitor
DMD5QRS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMD5QRS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMVKL3B	DI	DMVKL3B
DMVKL3B	DN	Ravulizumab
DMVKL3B	MI	TTN0GJ5
DMVKL3B	MN	HUMAN complement C5 protein (C5)
DMVKL3B	MT	DTT
DMVKL3B	MA	Inhibitor
DMVKL3B	RN	Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.
DMVKL3B	RU	https://pubmed.ncbi.nlm.nih.gov/32327719

DMPJTZ1	DI	DMPJTZ1
DMPJTZ1	DN	RBP-7000
DMPJTZ1	MI	TTEX248
DMPJTZ1	MN	Dopamine D2 receptor (D2R)
DMPJTZ1	MT	DTT
DMPJTZ1	MA	Modulator
DMPJTZ1	RN	Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43.
DMPJTZ1	RU	https://pubmed.ncbi.nlm.nih.gov/24464285

DMDZW8K	DI	DMDZW8K
DMDZW8K	DN	RBT-101
DMDZW8K	MI	TTX4GLS
DMDZW8K	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMDZW8K	MT	DTT
DMDZW8K	MA	Inhibitor
DMDZW8K	RN	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
DMDZW8K	RU	https://pubmed.ncbi.nlm.nih.gov/30057410

DM2GHCR	DI	DM2GHCR
DM2GHCR	DN	Rebamipide
DM2GHCR	MI	DE4LYSA
DM2GHCR	MN	Cytochrome P450 3A4 (CYP3A4)
DM2GHCR	MT	DME
DM2GHCR	MA	Metabolism
DM2GHCR	RN	Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573-86.
DM2GHCR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12162853

DM2GHCR	DI	DM2GHCR
DM2GHCR	DN	Rebamipide
DM2GHCR	MI	TT5Y4EM
DM2GHCR	MN	N-formyl peptide receptor (FPR1)
DM2GHCR	MT	DTT
DM2GHCR	MA	Antagonist
DM2GHCR	RN	Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.
DM2GHCR	RU	https://pubmed.ncbi.nlm.nih.gov/11259567

DM8HVNR	DI	DM8HVNR
DM8HVNR	DN	Recombinant acidic fibroblast growth factor
DM8HVNR	MI	TT5HU6Z
DM8HVNR	MN	Fibroblast growth factor (FGF)
DM8HVNR	MT	DTT
DM8HVNR	MA	Modulator
DM8HVNR	RN	Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79.
DM8HVNR	RU	https://pubmed.ncbi.nlm.nih.gov/1700280

DMOWQAF	DI	DMOWQAF
DMOWQAF	DN	Recombinant human iduronate-2-sulfatase
DMOWQAF	MI	TTNY2AP
DMOWQAF	MN	Iduronate 2-sulfatase (IDS)
DMOWQAF	MT	DTT
DMOWQAF	MA	Modulator
DMOWQAF	RN	The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074.
DMOWQAF	RU	https://pubmed.ncbi.nlm.nih.gov/24454794

DM7JFDO	DI	DM7JFDO
DM7JFDO	DN	Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO	MI	TT1290U
DM7JFDO	MN	Coagulation factor VIII (F8)
DM7JFDO	MT	DTT
DM7JFDO	MA	Modulator
DM7JFDO	RN	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
DM7JFDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/

DM7JFDO	DI	DM7JFDO
DM7JFDO	DN	Recombinant von Willebrand factor/recombinant Factor VIII complex
DM7JFDO	MI	TT3SZBT
DM7JFDO	MN	von Willebrand factor (VWF)
DM7JFDO	MT	DTT
DM7JFDO	MA	Modulator
DM7JFDO	RN	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
DM7JFDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/

DM34GOF	DI	DM34GOF
DM34GOF	DN	REL-1017
DM34GOF	MI	TT9IK2Z
DM34GOF	MN	N-methyl-D-aspartate receptor (NMDAR)
DM34GOF	MT	DTT
DM34GOF	MA	Antagonist
DM34GOF	RN	N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238.
DM34GOF	RU	https://pubmed.ncbi.nlm.nih.gov/31454827

DMOWINT	DI	DMOWINT
DMOWINT	DN	Reloxaliase
DMOWINT	MI	TTMDQIJ
DMOWINT	MN	Oxalate absorption (Oxalate absor)
DMOWINT	MT	DTT
DMOWINT	MA	Replacement
DMOWINT	RN	Clinical pipeline report, company report or official report of Allena Pharmaceuticals.
DMOWINT	RU	https://www.allenapharma.com/reloxaliase

DM3YXP8	DI	DM3YXP8
DM3YXP8	DN	Remacemide
DM3YXP8	MI	DE4LYSA
DM3YXP8	MN	Cytochrome P450 3A4 (CYP3A4)
DM3YXP8	MT	DME
DM3YXP8	MA	Metabolism
DM3YXP8	RN	Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride. Epilepsy Res. 2002 May;49(3):247-54.
DM3YXP8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12076846

DM3YXP8	DI	DM3YXP8
DM3YXP8	DN	Remacemide
DM3YXP8	MI	TT9IK2Z
DM3YXP8	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3YXP8	MT	DTT
DM3YXP8	MA	Agonist
DM3YXP8	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DM3YXP8	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTV1095
DM49IGE	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/32020029

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTOA6YT
DM49IGE	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/31924756

DM49IGE	DI	DM49IGE
DM49IGE	DN	Remdesivir
DM49IGE	MI	TTKXI53
DM49IGE	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DM49IGE	MT	DTT
DM49IGE	MA	Inhibitor
DM49IGE	RN	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
DM49IGE	RU	https://pubmed.ncbi.nlm.nih.gov/31924756

DM7HQNX	DI	DM7HQNX
DM7HQNX	DN	Renzapride
DM7HQNX	MI	TTNXLKE
DM7HQNX	MN	5-HT 3 receptor (5HT3R)
DM7HQNX	MT	DTT
DM7HQNX	MA	Modulator
DM7HQNX	RN	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
DM7HQNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/18095752

DM7HQNX	DI	DM7HQNX
DM7HQNX	DN	Renzapride
DM7HQNX	MI	TT07C3Y
DM7HQNX	MN	5-HT 4 receptor (HTR4)
DM7HQNX	MT	DTT
DM7HQNX	MA	Modulator
DM7HQNX	RN	Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
DM7HQNX	RU	https://www.ncbi.nlm.nih.gov/pubmed/18095752

DMVBA7I	DI	DMVBA7I
DMVBA7I	DN	Reparixin
DMVBA7I	MI	TTMWT8Z
DMVBA7I	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMVBA7I	MT	DTT
DMVBA7I	MA	Modulator
DMVBA7I	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMVBA7I	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMVBA7I	DI	DMVBA7I
DMVBA7I	DN	Reparixin
DMVBA7I	MI	TT30C9G
DMVBA7I	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMVBA7I	MT	DTT
DMVBA7I	MA	Modulator
DMVBA7I	RN	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
DMVBA7I	RU	https://pubmed.ncbi.nlm.nih.gov/15974585

DMDEJX9	DI	DMDEJX9
DMDEJX9	DN	Reproxalap
DMDEJX9	MI	TTZEX7Y
DMDEJX9	MN	Malondialdehyde (MDA)
DMDEJX9	MT	DTT
DMDEJX9	MA	Inhibitor
DMDEJX9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDEJX9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMFMWYC	DI	DMFMWYC
DMFMWYC	DN	Resatorvid
DMFMWYC	MI	TTISGCA
DMFMWYC	MN	Toll-like receptor 4 (TLR4)
DMFMWYC	MT	DTT
DMFMWYC	MA	Antagonist
DMFMWYC	RN	Clinical pipeline report, company report or official report of Takeda (2009).
DMFMWYC	RU	http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTI7UX6
DM3RWXL	MN	Breast cancer resistance protein (ABCG2)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
DM3RWXL	RU	http://www.ncbi.nlm.nih.gov/pubmed/17032904

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEJGDUW
DM3RWXL	MN	Cytochrome P450 1A2 (CYP1A2)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82.
DM3RWXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15276085

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTSYQGK
DM3RWXL	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3RWXL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DTCSGPB
DM3RWXL	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM3RWXL	MT	DTP
DM3RWXL	MA	Substrate
DM3RWXL	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM3RWXL	RU	https://doi.org/10.1007/s11095-012-0935-x

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	TTUF2HO
DM3RWXL	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DM3RWXL	MT	DTT
DM3RWXL	MA	Inhibitor
DM3RWXL	RN	Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15.
DM3RWXL	RU	https://www.ncbi.nlm.nih.gov/pubmed/25435179

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEZWDKE
DM3RWXL	MN	NADPH-dependent curcumin reductase (curA)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6615-20.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/21467222

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	TT8NGED
DM3RWXL	MN	Prostaglandin G/H synthase 1 (COX-1)
DM3RWXL	MT	DTT
DM3RWXL	MA	Modulator
DM3RWXL	RN	Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/15020596

DM3RWXL	DI	DM3RWXL
DM3RWXL	DN	Resveratrol
DM3RWXL	MI	DEYMAD4
DM3RWXL	MN	Sulfotransferase 1C2 (SULT1C2)
DM3RWXL	MT	DME
DM3RWXL	MA	Metabolism
DM3RWXL	RN	Correlation of reactive oxygen species levels with resveratrol sensitivities of anaplastic thyroid cancer cells. Oxid Med Cell Longev. 2018 Jul 10;2018:6235417.
DM3RWXL	RU	https://pubmed.ncbi.nlm.nih.gov/30116486

DMOYGZF	DI	DMOYGZF
DMOYGZF	DN	Retosiban
DMOYGZF	MI	TTSCIUP
DMOYGZF	MN	Oxytocin receptor (OTR)
DMOYGZF	MT	DTT
DMOYGZF	MA	Modulator
DMOYGZF	RN	The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
DMOYGZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/26207346

DM5E73H	DI	DM5E73H
DM5E73H	DN	Revusiran
DM5E73H	MI	TTPOYU7
DM5E73H	MN	Transthyretin messenger RNA (TTR mRNA)
DM5E73H	MT	DTT
DM5E73H	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
DM5E73H	RU	http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/

DMQ4CSX	DI	DMQ4CSX
DMQ4CSX	DN	Rezafungin
DMQ4CSX	MI	TT0SFXH
DMQ4CSX	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMQ4CSX	MT	DTT
DMQ4CSX	MA	Inhibitor
DMQ4CSX	RN	Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343.
DMQ4CSX	RU	https://pubmed.ncbi.nlm.nih.gov/31292663

DMTQJE0	DI	DMTQJE0
DMTQJE0	DN	RG3638
DMTQJE0	MI	TTNDSF4
DMTQJE0	MN	Proto-oncogene c-Met (MET)
DMTQJE0	MT	DTT
DMTQJE0	MA	Modulator
DMTQJE0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMTQJE0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMER75Y	DI	DMER75Y
DMER75Y	DN	RG6013
DMER75Y	MI	TTFEZ5Q
DMER75Y	MN	Coagulation factor IX (F9)
DMER75Y	MT	DTT
DMER75Y	RN	Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13.
DMER75Y	RU	https://pubmed.ncbi.nlm.nih.gov/24738137

DMJRFYB	DI	DMJRFYB
DMJRFYB	DN	RG7201
DMJRFYB	MI	TTN7Y4P
DMJRFYB	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMJRFYB	MT	DTT
DMJRFYB	MA	Modulator
DMJRFYB	RN	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
DMJRFYB	RU	https://pubmed.ncbi.nlm.nih.gov/24678906

DMF5GZI	DI	DMF5GZI
DMF5GZI	DN	RG7388
DMF5GZI	MI	TT0JESD
DMF5GZI	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMF5GZI	MT	DTT
DMF5GZI	MA	Inhibitor
DMF5GZI	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799).
DMF5GZI	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799

DMF5GZI	DI	DMF5GZI
DMF5GZI	DN	RG7388
DMF5GZI	MI	TT08GJW
DMF5GZI	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMF5GZI	MT	DTT
DMF5GZI	MA	Modulator
DMF5GZI	RN	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
DMF5GZI	RU	https://pubmed.ncbi.nlm.nih.gov/25844600

DMDVAFP	DI	DMDVAFP
DMDVAFP	DN	RG7601
DMDVAFP	MI	TTJGNVC
DMDVAFP	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDVAFP	MT	DTT
DMDVAFP	MA	Modulator
DMDVAFP	RN	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
DMDVAFP	RU	https://pubmed.ncbi.nlm.nih.gov/23291630

DMGOTK4	DI	DMGOTK4
DMGOTK4	DN	Rhumab Beta7
DMGOTK4	MI	TTLT9XQ
DMGOTK4	MN	Integrin beta-7 (ITGB7)
DMGOTK4	MT	DTT
DMGOTK4	RN	A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30.
DMGOTK4	RU	https://pubmed.ncbi.nlm.nih.gov/22717454

DMLHEU7	DI	DMLHEU7
DMLHEU7	DN	Ridaforolimus
DMLHEU7	MI	TTCJG29
DMLHEU7	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMLHEU7	MT	DTT
DMLHEU7	MA	Inhibitor
DMLHEU7	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DMLHEU7	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMYXOHV	DI	DMYXOHV
DMYXOHV	DN	Rifalazil
DMYXOHV	MI	TTIJ5EB
DMYXOHV	MN	Bacterial RNA polymerase switch region (Bact RNAP-SR)
DMYXOHV	MT	DTT
DMYXOHV	MA	Inhibitor
DMYXOHV	RN	Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
DMYXOHV	RU	https://pubmed.ncbi.nlm.nih.gov/17691942

DMYXOHV	DI	DMYXOHV
DMYXOHV	DN	Rifalazil
DMYXOHV	MI	DE4LYSA
DMYXOHV	MN	Cytochrome P450 3A4 (CYP3A4)
DMYXOHV	MT	DME
DMYXOHV	MA	Metabolism
DMYXOHV	RN	Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74.
DMYXOHV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10923859

DMKTS2M	DI	DMKTS2M
DMKTS2M	DN	Rifaximin DR
DMKTS2M	MI	TTHKJLN
DMKTS2M	MN	DNA-directed RNA polymerase (RNAP)
DMKTS2M	MT	DTT
DMKTS2M	MA	Inhibitor
DMKTS2M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKTS2M	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMOSTXF	DI	DMOSTXF
DMOSTXF	DN	Rigosertib
DMOSTXF	MI	TTHBTOP
DMOSTXF	MN	PI3-kinase gamma (PIK3CG)
DMOSTXF	MT	DTT
DMOSTXF	MA	Modulator
DMOSTXF	RN	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
DMOSTXF	RU	https://pubmed.ncbi.nlm.nih.gov/24493827

DMOSTXF	DI	DMOSTXF
DMOSTXF	DN	Rigosertib
DMOSTXF	MI	TTIYVQP
DMOSTXF	MN	Polo-like kinase 1 (PLK1)
DMOSTXF	MT	DTT
DMOSTXF	MA	Modulator
DMOSTXF	RN	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
DMOSTXF	RU	https://pubmed.ncbi.nlm.nih.gov/24493827

DMGTCI0	DI	DMGTCI0
DMGTCI0	DN	Rilimogene galvacirepvec
DMGTCI0	MI	TTS78AZ
DMGTCI0	MN	Prostate specific antigen (KLK3)
DMGTCI0	MT	DTT
DMGTCI0	MA	Modulator
DMGTCI0	RN	Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105.
DMGTCI0	RU	https://pubmed.ncbi.nlm.nih.gov/20100959

DMP6IMQ	DI	DMP6IMQ
DMP6IMQ	DN	Rindopepimut
DMP6IMQ	MI	TTGKNB4
DMP6IMQ	MN	Epidermal growth factor receptor (EGFR)
DMP6IMQ	MT	DTT
DMP6IMQ	MA	Modulator
DMP6IMQ	RN	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
DMP6IMQ	RU	https://pubmed.ncbi.nlm.nih.gov/21154166

DMYX7VI	DI	DMYX7VI
DMYX7VI	DN	Rintatolimod
DMYX7VI	MI	TTD24Y0
DMYX7VI	MN	Toll-like receptor 3 (TLR3)
DMYX7VI	MT	DTT
DMYX7VI	RN	A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334.
DMYX7VI	RU	https://pubmed.ncbi.nlm.nih.gov/22431963

DM13V0P	DI	DM13V0P
DM13V0P	DN	Rivoceranib
DM13V0P	MI	TTUTJGQ
DM13V0P	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM13V0P	MT	DTT
DM13V0P	MA	Antagonist
DM13V0P	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM13V0P	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DES5XRU
DMBY31K	MN	Cytochrome P450 2C8 (CYP2C8)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DE4LYSA
DMBY31K	MN	Cytochrome P450 3A4 (CYP3A4)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	TTZMAO3
DMBY31K	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMBY31K	MT	DTT
DMBY31K	MA	Agonist
DMBY31K	RN	A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
DMBY31K	RU	https://pubmed.ncbi.nlm.nih.gov/21492364

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DEF2WXN
DMBY31K	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMBY31K	DI	DMBY31K
DMBY31K	DN	Rivoglitazone
DMBY31K	MI	DEB3CV1
DMBY31K	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMBY31K	MT	DME
DMBY31K	MA	Metabolism
DMBY31K	RN	In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
DMBY31K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21511943

DMVQ5X1	DI	DMVQ5X1
DMVQ5X1	DN	Roclatan
DMVQ5X1	MI	TTAWNKZ
DMVQ5X1	MN	Norepinephrine transporter (NET)
DMVQ5X1	MT	DTT
DMVQ5X1	MA	Modulator
DMVQ5X1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVQ5X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVQ5X1	DI	DMVQ5X1
DMVQ5X1	DN	Roclatan
DMVQ5X1	MI	TTMQO60
DMVQ5X1	MN	Rho-associated protein kinase (ROCK)
DMVQ5X1	MT	DTT
DMVQ5X1	MA	Modulator
DMVQ5X1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVQ5X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSZPR3	DI	DMSZPR3
DMSZPR3	DN	Rolofylline
DMSZPR3	MI	TTK25J1
DMSZPR3	MN	Adenosine A1 receptor (ADORA1)
DMSZPR3	MT	DTT
DMSZPR3	MA	Antagonist
DMSZPR3	RN	Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
DMSZPR3	RU	https://pubmed.ncbi.nlm.nih.gov/19196240

DMSZPR3	DI	DMSZPR3
DMSZPR3	DN	Rolofylline
DMSZPR3	MI	DE4LYSA
DMSZPR3	MN	Cytochrome P450 3A4 (CYP3A4)
DMSZPR3	MT	DME
DMSZPR3	MA	Metabolism
DMSZPR3	RN	Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J. 2013 Apr;15(2):498-504.
DMSZPR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23355301

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTPS3C0
DMPIDXT	MN	Aurora kinase A (AURKA)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TT5LS6T
DMPIDXT	MN	Aurora kinase B (AURKB)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTRLW2X
DMPIDXT	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTZMAO3
DMPIDXT	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMPIDXT	MT	DTT
DMPIDXT	MA	Agonist
DMPIDXT	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMPIDXT	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTI2WET
DMPIDXT	MN	Platelet-derived growth factor receptor (PDGFR)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMPIDXT	DI	DMPIDXT
DMPIDXT	DN	Rosiglitazone + metformin
DMPIDXT	MI	TTUTJGQ
DMPIDXT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPIDXT	MT	DTT
DMPIDXT	MA	Inhibitor
DMPIDXT	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMPIDXT	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM18B72	DI	DM18B72
DM18B72	DN	Rosiglitazone + simvastatin
DM18B72	MI	TTZMAO3
DM18B72	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM18B72	MT	DTT
DM18B72	MA	Agonist
DM18B72	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM18B72	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMNGCAD	DI	DMNGCAD
DMNGCAD	DN	Rova-T
DMNGCAD	MI	TT1C9K6
DMNGCAD	MN	Delta-like protein 3 (DLL3)
DMNGCAD	MT	DTT
DMNGCAD	MA	Inhibitor
DMNGCAD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNGCAD	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM9T8OF	DI	DM9T8OF
DM9T8OF	DN	RQ-00000004
DM9T8OF	MI	TTLOKXP
DM9T8OF	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DM9T8OF	MT	DTT
DM9T8OF	MA	Modulator
DM9T8OF	RN	N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
DM9T8OF	RU	https://pubmed.ncbi.nlm.nih.gov/18981288

DMQM2FH	DI	DMQM2FH
DMQM2FH	DN	RRx-001
DMQM2FH	MI	TT8E7Z0
DMQM2FH	MN	Free radical (FRD)
DMQM2FH	MT	DTT
DMQM2FH	MA	Modulator
DMQM2FH	RN	Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8.
DMQM2FH	RU	https://pubmed.ncbi.nlm.nih.gov/22589277

DM62QTW	DI	DM62QTW
DM62QTW	DN	RTB101
DM62QTW	MI	TT4GO0F
DM62QTW	MN	CREB-regulated transcription coactivator 1 (TORC1)
DM62QTW	MT	DTT
DM62QTW	MA	Inhibitor
DM62QTW	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DM62QTW	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMDWU1S	DI	DMDWU1S
DMDWU1S	DN	Rubitecan
DMDWU1S	MI	TTGTQHC
DMDWU1S	MN	DNA topoisomerase I (TOP1)
DMDWU1S	MT	DTT
DMDWU1S	MA	Inhibitor
DMDWU1S	RN	Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
DMDWU1S	RU	https://pubmed.ncbi.nlm.nih.gov/16370935

DMDWU1S	DI	DMDWU1S
DMDWU1S	DN	Rubitecan
DMDWU1S	MI	DTCSGPB
DMDWU1S	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMDWU1S	MT	DTP
DMDWU1S	MA	Substrate
DMDWU1S	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMDWU1S	RU	https://doi.org/10.1007/s11095-012-0935-x

DMQOCD8	DI	DMQOCD8
DMQOCD8	DN	RUBOXISTAURIN HYDROCHLORIDE
DMQOCD8	MI	TTYPXQF
DMQOCD8	MN	Protein kinase C beta (PRKCB)
DMQOCD8	MT	DTT
DMQOCD8	MA	Modulator
DMQOCD8	RN	Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
DMQOCD8	RU	https://pubmed.ncbi.nlm.nih.gov/17472415

DM25TMP	DI	DM25TMP
DM25TMP	DN	Rubraca rucaparib
DM25TMP	MI	TTEBCY8
DM25TMP	MN	Poly [ADP-ribose] polymerase (PARP)
DM25TMP	MT	DTT
DM25TMP	MA	Inhibitor
DM25TMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM25TMP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM20KYR	DI	DM20KYR
DM20KYR	DN	Ruxolitinib
DM20KYR	MI	TTWKB01
DM20KYR	MN	HUMAN janus kinase 1 (JAK-1)
DM20KYR	MT	DTT
DM20KYR	MA	Inhibitor
DM20KYR	RN	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
DM20KYR	RU	https://pubmed.ncbi.nlm.nih.gov/32222466

DM20KYR	DI	DM20KYR
DM20KYR	DN	Ruxolitinib
DM20KYR	MI	TT0F5HE
DM20KYR	MN	HUMAN janus kinase 2 (JAK-2)
DM20KYR	MT	DTT
DM20KYR	MA	Inhibitor
DM20KYR	RN	The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393.
DM20KYR	RU	https://pubmed.ncbi.nlm.nih.gov/32222466

DMAYTIH	DI	DMAYTIH
DMAYTIH	DN	S-06911
DMAYTIH	MI	TTK59TV
DMAYTIH	MN	Vitamin D3 receptor (VDR)
DMAYTIH	MT	DTT
DMAYTIH	MA	Inhibitor
DMAYTIH	RN	Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73.
DMAYTIH	RU	https://pubmed.ncbi.nlm.nih.gov/12520525

DMXY34J	DI	DMXY34J
DMXY34J	DN	S-110
DMXY34J	MI	TTHVCUP
DMXY34J	MN	DNA [cytosine-5]-methyltransferase (DNMT)
DMXY34J	MT	DTT
DMXY34J	MA	Inhibitor
DMXY34J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXY34J	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMXY34J	DI	DMXY34J
DMXY34J	DN	S-110
DMXY34J	MI	TT6S2FE
DMXY34J	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMXY34J	MT	DTT
DMXY34J	MA	Inhibitor
DMXY34J	RN	S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
DMXY34J	RU	https://pubmed.ncbi.nlm.nih.gov/20442312

DM408GM	DI	DM408GM
DM408GM	DN	S-474474
DM408GM	MI	TT8DBY3
DM408GM	MN	Angiotensin II receptor type-1 (AGTR1)
DM408GM	MT	DTT
DM408GM	MA	Blocker
DM408GM	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM408GM	RU	http://www.shionogi.co.jp/index_e.html

DM7F2VG	DI	DM7F2VG
DM7F2VG	DN	SA-237
DM7F2VG	MI	TT0E5SK
DM7F2VG	MN	Interleukin 6 receptor (IL6R)
DM7F2VG	MT	DTT
DM7F2VG	MA	Antagonist
DM7F2VG	RN	IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
DM7F2VG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893229/

DMGR98T	DI	DMGR98T
DMGR98T	DN	SAGE-217
DMGR98T	MI	TTEX6LM
DMGR98T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMGR98T	MT	DTT
DMGR98T	MA	Modulator
DMGR98T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGR98T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMI1R5S	DI	DMI1R5S
DMI1R5S	DN	SAIT101
DMI1R5S	MI	TTUE541
DMI1R5S	MN	Leukocyte surface antigen Leu-16 (CD20)
DMI1R5S	MT	DTT
DMI1R5S	RN	Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163.
DMI1R5S	RU	https://pubmed.ncbi.nlm.nih.gov/29915719

DMKHLRT	DI	DMKHLRT
DMKHLRT	DN	SAND-26
DMKHLRT	MI	TTDIGC1
DMKHLRT	MN	Dipeptidyl peptidase 4 (DPP-4)
DMKHLRT	MT	DTT
DMKHLRT	RN	Clinical pipeline report, company report or official report of Siesonline.
DMKHLRT	RU	http://www.siesonline.it/en/wp-content/uploads/2013/05/21.pdf

DMXAO4J	DI	DMXAO4J
DMXAO4J	DN	SAR153191
DMXAO4J	MI	TT0E5SK
DMXAO4J	MN	Interleukin 6 receptor (IL6R)
DMXAO4J	MT	DTT
DMXAO4J	MA	Antagonist
DMXAO4J	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMXAO4J	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMHFBOG	DI	DMHFBOG
DMHFBOG	DN	SAR231893
DMHFBOG	MI	TTDWHC3
DMHFBOG	MN	Interleukin 4 receptor alpha (IL4R)
DMHFBOG	MT	DTT
DMHFBOG	MA	Modulator
DMHFBOG	RN	Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
DMHFBOG	RU	https://pubmed.ncbi.nlm.nih.gov/23688323

DMR0EWV	DI	DMR0EWV
DMR0EWV	DN	SAR342434
DMR0EWV	MI	TTZOPHG
DMR0EWV	MN	Insulin (INS)
DMR0EWV	MT	DTT
DMR0EWV	MA	Modulator
DMR0EWV	RN	Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451.
DMR0EWV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403967/

DMXGE3O	DI	DMXGE3O
DMXGE3O	DN	SAR408701
DMXGE3O	MI	TTY6DTE
DMXGE3O	MN	Carcinoembryonic antigen CEA (CD66e)
DMXGE3O	MT	DTT
DMXGE3O	RN	ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
DMXGE3O	RU	https://clinicaltrials.gov/ct2/show/NCT02187848

DMDMAE4	DI	DMDMAE4
DMDMAE4	DN	SAR438584
DMDMAE4	MI	TT57ID8
DMDMAE4	MN	Respiratory syncytial virus protein F (RSV F)
DMDMAE4	MT	DTT
DMDMAE4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470)
DMDMAE4	RU	http://adisinsight.springer.com/drugs/800040470

DM8HCFD	DI	DM8HCFD
DM8HCFD	DN	Sarilumab
DM8HCFD	MI	TTDVAKP
DM8HCFD	MN	HUMAN interleukin-6 receptor (IL6R)
DM8HCFD	MT	DTT
DM8HCFD	MA	Blocker
DM8HCFD	RN	IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57.
DM8HCFD	RU	https://pubmed.ncbi.nlm.nih.gov/25898198

DMUVSG4	DI	DMUVSG4
DMUVSG4	DN	Sasanlimab
DMUVSG4	MI	TTNBFWK
DMUVSG4	MN	Programmed cell death protein 1 (PD-1)
DMUVSG4	MT	DTT
DMUVSG4	RN	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116.
DMUVSG4	RU	https://pubmed.ncbi.nlm.nih.gov/32847983

DME5PN3	DI	DME5PN3
DME5PN3	DN	Satavaptan
DME5PN3	MI	TTK8R02
DME5PN3	MN	Vasopressin V2 receptor (V2R)
DME5PN3	MT	DTT
DME5PN3	MA	Antagonist
DME5PN3	RN	Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
DME5PN3	RU	https://pubmed.ncbi.nlm.nih.gov/19196237

DMALFKX	DI	DMALFKX
DMALFKX	DN	Savolitinib
DMALFKX	MI	TTNDSF4
DMALFKX	MN	Proto-oncogene c-Met (MET)
DMALFKX	MT	DTT
DMALFKX	MA	Inhibitor
DMALFKX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMALFKX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAPRWV	DI	DMAPRWV
DMAPRWV	DN	SaxaDapa FDC
DMAPRWV	MI	TTDIGC1
DMAPRWV	MN	Dipeptidyl peptidase 4 (DPP-4)
DMAPRWV	MT	DTT
DMAPRWV	MA	Modulator
DMAPRWV	RN	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
DMAPRWV	RU	https://pubmed.ncbi.nlm.nih.gov/20539105

DMAPRWV	DI	DMAPRWV
DMAPRWV	DN	SaxaDapa FDC
DMAPRWV	MI	TTN7Y4P
DMAPRWV	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMAPRWV	MT	DTT
DMAPRWV	MA	Modulator
DMAPRWV	RN	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
DMAPRWV	RU	https://pubmed.ncbi.nlm.nih.gov/20539105

DMME6GJ	DI	DMME6GJ
DMME6GJ	DN	SB12
DMME6GJ	MI	TTKANGO
DMME6GJ	MN	Complement C5 (CO5)
DMME6GJ	MT	DTT
DMME6GJ	MA	Inhibitor
DMME6GJ	RN	Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729.
DMME6GJ	RU	https://pubmed.ncbi.nlm.nih.gov/31324874

DM6L4ZT	DI	DM6L4ZT
DM6L4ZT	DN	SB-742457
DM6L4ZT	MI	TTJS8PY
DM6L4ZT	MN	5-HT 6 receptor (HTR6)
DM6L4ZT	MT	DTT
DM6L4ZT	MA	Antagonist
DM6L4ZT	RN	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
DM6L4ZT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DEUO7V8
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DE4LKZ9
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull. 2000 Dec;23(12):1481-5.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/11145182

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DEM6GYO
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	nan
DM6XNJR	RU	nan

DM6XNJR	DI	DM6XNJR
DM6XNJR	DN	SC-46553
DM6XNJR	MI	DE9N4OU
DM6XNJR	MN	Beta-glucosidase (bglA)
DM6XNJR	MT	DME
DM6XNJR	MA	Metabolism
DM6XNJR	RN	Characterization of the ginsenoside-transforming recombinant beta-glucosidase from Actinosynnema mirum and bioconversion of major ginsenosides into minor ginsenosides. Appl Microbiol Biotechnol. 2013 Jan;97(2):649-59.
DM6XNJR	RU	https://pubmed.ncbi.nlm.nih.gov/22911093

DMK1IPV	DI	DMK1IPV
DMK1IPV	DN	SCY-078
DMK1IPV	MI	TT0SFXH
DMK1IPV	MN	Fungal 1,3-beta-glucan synthase (Fung GSC2)
DMK1IPV	MT	DTT
DMK1IPV	MA	Inhibitor
DMK1IPV	RN	Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72.
DMK1IPV	RU	https://pubmed.ncbi.nlm.nih.gov/25512406

DMAMTGI	DI	DMAMTGI
DMAMTGI	DN	SD-101
DMAMTGI	MI	TTSHG0T
DMAMTGI	MN	Toll-like receptor 9 (TLR9)
DMAMTGI	MT	DTT
DMAMTGI	RN	Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
DMAMTGI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303062/

DM9DEYL	DI	DM9DEYL
DM9DEYL	DN	SD-6010
DM9DEYL	MI	TTF10I9
DM9DEYL	MN	Nitric-oxide synthase inducible (NOS2)
DM9DEYL	MT	DTT
DM9DEYL	MA	Inhibitor
DM9DEYL	RN	A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
DM9DEYL	RU	https://pubmed.ncbi.nlm.nih.gov/23144445

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DE4LYSA
DMBD4K3	MN	Cytochrome P450 3A4 (CYP3A4)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	TTCJUR4
DMBD4K3	MN	Exportin-1 (XPO1)
DMBD4K3	MT	DTT
DMBD4K3	MA	Inhibitor
DMBD4K3	RN	Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
DMBD4K3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DE4ZHS1
DMBD4K3	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMBD4K3	DI	DMBD4K3
DMBD4K3	DN	Selinexor
DMBD4K3	MI	DEYGVN4
DMBD4K3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMBD4K3	MT	DME
DMBD4K3	MA	Metabolism
DMBD4K3	RN	FDA label of Selinexor. The 2020 official website of the U.S. Food and Drug Administration.
DMBD4K3	RU	https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTIDAPM
DMC7W6R	MN	ERK activator kinase 1 (MEK1)
DMC7W6R	MT	DTT
DMC7W6R	MA	Inhibitor
DMC7W6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC7W6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTTW2NY
DMC7W6R	MN	ERK activator kinase 2 (MEK2)
DMC7W6R	MT	DTT
DMC7W6R	MA	Inhibitor
DMC7W6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC7W6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC7W6R	DI	DMC7W6R
DMC7W6R	DN	Selumetinib
DMC7W6R	MI	TTROQ37
DMC7W6R	MN	MAPK/ERK kinase kinase (MAP3K)
DMC7W6R	MT	DTT
DMC7W6R	MA	Modulator
DMC7W6R	RN	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59.
DMC7W6R	RU	https://www.ncbi.nlm.nih.gov/pubmed/22569000

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	DE4LYSA
DML83IW	MN	Cytochrome P450 3A4 (CYP3A4)
DML83IW	MT	DME
DML83IW	MA	Metabolism
DML83IW	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DML83IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	DEIBDNY
DML83IW	MN	Cytochrome P450 3A5 (CYP3A5)
DML83IW	MT	DME
DML83IW	MA	Metabolism
DML83IW	RN	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
DML83IW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20075192

DML83IW	DI	DML83IW
DML83IW	DN	Semagacestat
DML83IW	MI	TT9W8GU
DML83IW	MN	Gamma-secretase (GS)
DML83IW	MT	DTT
DML83IW	MA	Modulator
DML83IW	RN	A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
DML83IW	RU	https://pubmed.ncbi.nlm.nih.gov/23883379

DMKL9QO	DI	DMKL9QO
DMKL9QO	DN	Seocalcitol
DMKL9QO	MI	TTK59TV
DMKL9QO	MN	Vitamin D3 receptor (VDR)
DMKL9QO	MT	DTT
DMKL9QO	MA	Inhibitor
DMKL9QO	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKL9QO	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMG2QP4	DI	DMG2QP4
DMG2QP4	DN	SEP-363856
DMG2QP4	MI	TTSQIFT
DMG2QP4	MN	5-HT 1A receptor (HTR1A)
DMG2QP4	MT	DTT
DMG2QP4	MA	Agonist
DMG2QP4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG2QP4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMG2QP4	DI	DMG2QP4
DMG2QP4	DN	SEP-363856
DMG2QP4	MI	TTIU98M
DMG2QP4	MN	Trace amine-associated receptor-1 (TAAR1)
DMG2QP4	MT	DTT
DMG2QP4	MA	Agonist
DMG2QP4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG2QP4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5VH6U	DI	DM5VH6U
DM5VH6U	DN	Serlopitant
DM5VH6U	MI	TTZPO1L
DM5VH6U	MN	Substance-P receptor (TACR1)
DM5VH6U	MT	DTT
DM5VH6U	MA	Antagonist
DM5VH6U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5VH6U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ61IA	DI	DMZ61IA
DMZ61IA	DN	Setipiprant
DMZ61IA	MI	TTNVEIR
DMZ61IA	MN	Prostaglandin D2 receptor (PTGDR)
DMZ61IA	MT	DTT
DMZ61IA	MA	Antagonist
DMZ61IA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ61IA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ61IA	DI	DMZ61IA
DMZ61IA	DN	Setipiprant
DMZ61IA	MI	TTQDMX5
DMZ61IA	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMZ61IA	MT	DTT
DMZ61IA	MA	Antagonist
DMZ61IA	RN	Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
DMZ61IA	RU	https://pubmed.ncbi.nlm.nih.gov/24964348

DM1NQDW	DI	DM1NQDW
DM1NQDW	DN	SGI110
DM1NQDW	MI	TT6S2FE
DM1NQDW	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DM1NQDW	MT	DTT
DM1NQDW	MA	Modulator
DM1NQDW	RN	Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
DM1NQDW	RU	https://pubmed.ncbi.nlm.nih.gov/25793777

DM4N1SP	DI	DM4N1SP
DM4N1SP	DN	Shigamabs
DM4N1SP	MI	TT1HYOF
DM4N1SP	MN	Bacterial Shiga toxin 2 subunit B (Bact stxII)
DM4N1SP	MT	DTT
DM4N1SP	MA	Modulator
DM4N1SP	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DM4N1SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMEWRXA	DI	DMEWRXA
DMEWRXA	DN	SHP647
DMEWRXA	MI	TTBD6I7
DMEWRXA	MN	Mucosal addressin cell adhesion molecule 1 (MADCAM1)
DMEWRXA	MT	DTT
DMEWRXA	MA	Inhibitor
DMEWRXA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWRXA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMMIWCE	DI	DMMIWCE
DMMIWCE	DN	Sifuvirtide
DMMIWCE	MI	TTG90S6
DMMIWCE	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMMIWCE	MT	DTT
DMMIWCE	MA	Modulator
DMMIWCE	RN	Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
DMMIWCE	RU	https://www.ncbi.nlm.nih.gov/pubmed/22228771

DM4YDAJ	DI	DM4YDAJ
DM4YDAJ	DN	Sildenafil
DM4YDAJ	MI	TTRYFSB
DM4YDAJ	MN	HUMAN phosphodiesterase type 5 (PDE5)
DM4YDAJ	MT	DTT
DM4YDAJ	MA	Inhibitor
DM4YDAJ	RN	Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005.
DM4YDAJ	RU	https://pubmed.ncbi.nlm.nih.gov/15650225

DMVO7UW	DI	DMVO7UW
DMVO7UW	DN	Siltuximab
DMVO7UW	MI	TTJH4Y5
DMVO7UW	MN	HUMAN interleukin 6 (IL6)
DMVO7UW	MT	DTT
DMVO7UW	MA	Inhibitor
DMVO7UW	RN	Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3.
DMVO7UW	RU	https://pubmed.ncbi.nlm.nih.gov/29999789

DM18QHT	DI	DM18QHT
DM18QHT	DN	Simvastatin acid
DM18QHT	MI	DTUGYRD
DM18QHT	MN	P-glycoprotein 1 (ABCB1)
DM18QHT	MT	DTP
DM18QHT	MA	Substrate
DM18QHT	RN	Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004 Sep;21(9):1686-91.
DM18QHT	RU	https://doi.org/10.1023/B:PHAM.0000041466.84653.8c

DMK8AQP	DI	DMK8AQP
DMK8AQP	DN	Sirukumab
DMK8AQP	MI	TT0E5SK
DMK8AQP	MN	Interleukin 6 receptor (IL6R)
DMK8AQP	MT	DTT
DMK8AQP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
DMK8AQP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310

DMK8AQP	DI	DMK8AQP
DMK8AQP	DN	Sirukumab
DMK8AQP	MI	TTT1V78
DMK8AQP	MN	Interleukin-6 (IL6)
DMK8AQP	MT	DTT
DMK8AQP	MA	Inhibitor
DMK8AQP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK8AQP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6BZCV	DI	DM6BZCV
DM6BZCV	DN	Sivelestat
DM6BZCV	MI	TTPLTSQ
DM6BZCV	MN	Neutrophil elastase (NE)
DM6BZCV	MT	DTT
DM6BZCV	MA	Inhibitor
DM6BZCV	RN	Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
DM6BZCV	RU	https://pubmed.ncbi.nlm.nih.gov/19169649

DM6BZCV	DI	DM6BZCV
DM6BZCV	DN	Sivelestat
DM6BZCV	MI	TT3NKIB
DM6BZCV	MN	Pancreatic elastase 1 (CELA1)
DM6BZCV	MT	DTT
DM6BZCV	MA	Inhibitor
DM6BZCV	RN	Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
DM6BZCV	RU	https://pubmed.ncbi.nlm.nih.gov/19487982

DMWOF1E	DI	DMWOF1E
DMWOF1E	DN	SKY59
DMWOF1E	MI	TTKANGO
DMWOF1E	MN	Complement C5 (CO5)
DMWOF1E	MT	DTT
DMWOF1E	MA	Inhibitor
DMWOF1E	RN	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.
DMWOF1E	RU	https://pubmed.ncbi.nlm.nih.gov/31978221

DMH7W9X	DI	DMH7W9X
DMH7W9X	DN	SNDX-275
DMH7W9X	MI	TTBH0VX
DMH7W9X	MN	Histone deacetylase (HDAC)
DMH7W9X	MT	DTT
DMH7W9X	MA	Inhibitor
DMH7W9X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH7W9X	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH7W9X	DI	DMH7W9X
DMH7W9X	DN	SNDX-275
DMH7W9X	MI	TT6R7JZ
DMH7W9X	MN	Histone deacetylase 1 (HDAC1)
DMH7W9X	MT	DTT
DMH7W9X	MA	Inhibitor
DMH7W9X	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMH7W9X	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMOQKAD	DI	DMOQKAD
DMOQKAD	DN	SNF472
DMOQKAD	MI	TTGUHMF
DMOQKAD	MN	Hydroxyapatite (HA)
DMOQKAD	MT	DTT
DMOQKAD	MA	Binder
DMOQKAD	RN	Clinical pipeline report, company report or official report of Sanifit.
DMOQKAD	RU	https://www.sanifit.com/lead-compound-snf472/

DMZE2JO	DI	DMZE2JO
DMZE2JO	DN	SNS-595
DMZE2JO	MI	TT0IHXV
DMZE2JO	MN	DNA topoisomerase II (TOP2)
DMZE2JO	MT	DTT
DMZE2JO	MA	Modulator
DMZE2JO	RN	A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.Haematologica.2015 Feb;100(2):231-7.
DMZE2JO	RU	https://www.ncbi.nlm.nih.gov/pubmed/25381131

DMPBA0D	DI	DMPBA0D
DMPBA0D	DN	Sofpironium bromide
DMPBA0D	MI	TTUPDWN
DMPBA0D	MN	Cholinergic receptor unspecific (CHR)
DMPBA0D	MT	DTT
DMPBA0D	MA	Antagonist
DMPBA0D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPBA0D	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM0HIU5	DI	DM0HIU5
DM0HIU5	DN	Solanezumab
DM0HIU5	MI	TTE4KHA
DM0HIU5	MN	Amyloid beta A4 protein (APP)
DM0HIU5	MT	DTT
DM0HIU5	MA	Modulator
DM0HIU5	RN	Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
DM0HIU5	RU	https://pubmed.ncbi.nlm.nih.gov/24450890

DM6QZIA	DI	DM6QZIA
DM6QZIA	DN	Solithromycin
DM6QZIA	MI	TTUWYEA
DM6QZIA	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM6QZIA	MT	DTT
DM6QZIA	MA	Modulator
DM6QZIA	RN	Company report (cempra)
DM6QZIA	RU	http://www.cempra.com/products/Solithromycin-cem-101/

DMLAYTP	DI	DMLAYTP
DMLAYTP	DN	Soluble ferric pyrophosphate
DMLAYTP	MI	TTUDR0C
DMLAYTP	MN	Iron (Fe)
DMLAYTP	MT	DTT
DMLAYTP	MA	Modulator
DMLAYTP	RN	A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
DMLAYTP	RU	https://pubmed.ncbi.nlm.nih.gov/14748943

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTZ97H5
DMIG4OX	MN	Phosphodiesterase 4A (PDE4A)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTVIAT9
DMIG4OX	MN	Phosphodiesterase 4B (PDE4B)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DMIG4OX	DI	DMIG4OX
DMIG4OX	DN	SOTB07
DMIG4OX	MI	TTSKMI8
DMIG4OX	MN	Phosphodiesterase 4D (PDE4D)
DMIG4OX	MT	DTT
DMIG4OX	MA	Inhibitor
DMIG4OX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DMIG4OX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DMLSV74	DI	DMLSV74
DMLSV74	DN	Sotorasib
DMLSV74	MI	TT3LH46
DMLSV74	MN	KRAS G12C mutant (KRAS G12C)
DMLSV74	MT	DTT
DMLSV74	MA	Inhibitor
DMLSV74	RN	Clinical pipeline report, company report or official report of Amgen.
DMLSV74	RU	https://www.amgenpipeline.com/

DMMP51W	DI	DMMP51W
DMMP51W	DN	sparsentan
DMMP51W	MI	TT8DBY3
DMMP51W	MN	Angiotensin II receptor type-1 (AGTR1)
DMMP51W	MT	DTT
DMMP51W	MA	Antagonist
DMMP51W	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMMP51W	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DMMP51W	DI	DMMP51W
DMMP51W	DN	sparsentan
DMMP51W	MI	TTKRD0G
DMMP51W	MN	Endothelin A receptor (EDNRA)
DMMP51W	MT	DTT
DMMP51W	MA	Antagonist
DMMP51W	RN	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
DMMP51W	RU	https://pubmed.ncbi.nlm.nih.gov/16220969

DM4TOEQ	DI	DM4TOEQ
DM4TOEQ	DN	Spartalizumab
DM4TOEQ	MI	TTNBFWK
DM4TOEQ	MN	Programmed cell death protein 1 (PD-1)
DM4TOEQ	MT	DTT
DM4TOEQ	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM4TOEQ	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM7NV1I	DI	DM7NV1I
DM7NV1I	DN	SPD-465
DM7NV1I	MI	TTIU98M
DM7NV1I	MN	Trace amine-associated receptor-1 (TAAR1)
DM7NV1I	MT	DTT
DM7NV1I	MA	Agonist
DM7NV1I	RN	Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507.
DM7NV1I	RU	https://pubmed.ncbi.nlm.nih.gov/24950453

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	TTR7UJ3
DMVJNFI	MN	Cytoplasmic thioredoxin reductase (TXNRD1)
DMVJNFI	MT	DTT
DMVJNFI	MA	Inhibitor
DMVJNFI	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMVJNFI	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DTOFXP5
DMVJNFI	MN	MFS-type transporter SLC18B1 (SLC18B1)
DMVJNFI	MT	DTP
DMVJNFI	MA	Substrate
DMVJNFI	RN	Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014 Oct 30;4:6836.
DMVJNFI	RU	http://www.ncbi.nlm.nih.gov/pubmed/25355561

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DTT79CX
DMVJNFI	MN	Organic cation transporter 1 (SLC22A1)
DMVJNFI	MT	DTP
DMVJNFI	MA	Substrate
DMVJNFI	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMVJNFI	RU	https://doi.org/10.1007/s11095-012-0935-x

DMVJNFI	DI	DMVJNFI
DMVJNFI	DN	Spermidine
DMVJNFI	MI	DEMWO83
DMVJNFI	MN	Putrescine acetyltransferase (SSAT1)
DMVJNFI	MT	DME
DMVJNFI	MA	Metabolism
DMVJNFI	RN	The use of novel C-methylated spermidine derivatives to investigate the regulation of polyamine metabolism. J Med Chem. 2011 Jul 14;54(13):4611-8.
DMVJNFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21639123

DMACVEI	DI	DMACVEI
DMACVEI	DN	SPI-2012
DMACVEI	MI	TT5TQ2W
DMACVEI	MN	Granulocyte colony-stimulating factor (CSF3)
DMACVEI	MT	DTT
DMACVEI	MA	Modulator
DMACVEI	RN	Company report (Sppirx)
DMACVEI	RU	http://www.sppirx.com/338-spectrum-products-development-spi2012.html

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TTGKIED
DM3PS2E	MN	Fibroblast growth factor-2 (FGF2)
DM3PS2E	MT	DTT
DM3PS2E	MA	Modulator
DM3PS2E	RN	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
DM3PS2E	RU	http://www.ohrpharmaceutical.com/research/squalamine

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TTSM78N
DM3PS2E	MN	Platelet-derived growth factor A (PDGFA)
DM3PS2E	MT	DTT
DM3PS2E	MA	Inhibitor
DM3PS2E	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PS2E	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3PS2E	DI	DM3PS2E
DM3PS2E	DN	Squalamine
DM3PS2E	MI	TT9HKJA
DM3PS2E	MN	Vascular endothelial growth factor (VEGF)
DM3PS2E	MT	DTT
DM3PS2E	MA	Modulator
DM3PS2E	RN	Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
DM3PS2E	RU	http://www.ohrpharmaceutical.com/research/squalamine

DM1ODMR	DI	DM1ODMR
DM1ODMR	DN	SR46349B
DM1ODMR	MI	TTJQOD7
DM1ODMR	MN	5-HT 2A receptor (HTR2A)
DM1ODMR	MT	DTT
DM1ODMR	MA	Modulator
DM1ODMR	RN	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
DM1ODMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/12225700

DM1ODMR	DI	DM1ODMR
DM1ODMR	DN	SR46349B
DM1ODMR	MI	TTWJBZ5
DM1ODMR	MN	5-HT 2C receptor (HTR2C)
DM1ODMR	MT	DTT
DM1ODMR	MA	Modulator
DM1ODMR	RN	SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
DM1ODMR	RU	https://www.ncbi.nlm.nih.gov/pubmed/12225700

DMT71EX	DI	DMT71EX
DMT71EX	DN	SSR-126517E
DMT71EX	MI	TTCIHJA
DMT71EX	MN	Coagulation factor Xa (F10)
DMT71EX	MT	DTT
DMT71EX	MA	Inhibitor
DMT71EX	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMT71EX	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMVLKDX	DI	DMVLKDX
DMVLKDX	DN	Streptokinase rectal suppository
DMVLKDX	MI	TT2VCLI
DMVLKDX	MN	Streptococcus Streptokinase (Stre-coc skc)
DMVLKDX	MT	DTT
DMVLKDX	MA	Modulator
DMVLKDX	RN	Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 2005 Nov 2;5:5.
DMVLKDX	RU	https://www.ncbi.nlm.nih.gov/pubmed/16262910

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTRLW2X
DMPOTM4	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TT7MRDV
DMPOTM4	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPOTM4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTVJ1D8
DMPOTM4	MN	Vascular endothelial growth factor receptor (VEGFR)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPOTM4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TT2Q6G1
DMPOTM4	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTUTJGQ
DMPOTM4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMPOTM4	DI	DMPOTM4
DMPOTM4	DN	Sulfatinib
DMPOTM4	MI	TTDCBX5
DMPOTM4	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMPOTM4	MT	DTT
DMPOTM4	MA	Inhibitor
DMPOTM4	RN	Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
DMPOTM4	RU	http://www.hmplglobal.com/en/sulfatinib/

DMMD856	DI	DMMD856
DMMD856	DN	Sulopenem
DMMD856	MI	TTJP4SM
DMMD856	MN	Bacterial Penicillin binding protein (Bact PBP)
DMMD856	MT	DTT
DMMD856	MA	Modulator
DMMD856	RN	In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37.
DMMD856	RU	https://pubmed.ncbi.nlm.nih.gov/8786624

DM07653	DI	DM07653
DM07653	DN	SULTHIAME
DM07653	MI	TTANPDJ
DM07653	MN	Carbonic anhydrase II (CA-II)
DM07653	MT	DTT
DM07653	MA	Inhibitor
DM07653	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM07653	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DMYHV17	DI	DMYHV17
DMYHV17	DN	Sumanirole
DMYHV17	MI	DEJGDUW
DMYHV17	MN	Cytochrome P450 1A2 (CYP1A2)
DMYHV17	MT	DME
DMYHV17	MA	Metabolism
DMYHV17	RN	Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019 Jan 1;180(1):31-40.
DMYHV17	RU	http://www.ncbi.nlm.nih.gov/pubmed/30400048

DMYHV17	DI	DMYHV17
DMYHV17	DN	Sumanirole
DMYHV17	MI	TTEX248
DMYHV17	MN	Dopamine D2 receptor (D2R)
DMYHV17	MT	DTT
DMYHV17	MA	Agonist
DMYHV17	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DMYHV17	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMXNZQK	DI	DMXNZQK
DMXNZQK	DN	SUN-101
DMXNZQK	MI	TTOXS3C
DMXNZQK	MN	Muscarinic acetylcholine receptor (CHRM)
DMXNZQK	MT	DTT
DMXNZQK	MA	Inhibitor
DMXNZQK	RN	Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120.
DMXNZQK	RU	http://breathe.ersjournals.com/content/10/2/110

DMH2FN1	DI	DMH2FN1
DMH2FN1	DN	Suronacrine maleate
DMH2FN1	MI	TT1RS9F
DMH2FN1	MN	Acetylcholinesterase (AChE)
DMH2FN1	MT	DTT
DMH2FN1	MA	Modulator
DMH2FN1	RN	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
DMH2FN1	RU	https://www.ncbi.nlm.nih.gov/pubmed/1776748

DMH2FN1	DI	DMH2FN1
DMH2FN1	DN	Suronacrine maleate
DMH2FN1	MI	TTAWNKZ
DMH2FN1	MN	Norepinephrine transporter (NET)
DMH2FN1	MT	DTT
DMH2FN1	MA	Modulator
DMH2FN1	RN	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
DMH2FN1	RU	https://www.ncbi.nlm.nih.gov/pubmed/1776748

DMY7WH1	DI	DMY7WH1
DMY7WH1	DN	Sutimlimab
DMY7WH1	MI	TT7LRQH
DMY7WH1	MN	Complement C1s component (C1S)
DMY7WH1	MT	DTT
DMY7WH1	MA	Inhibitor
DMY7WH1	RN	Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531.
DMY7WH1	RU	https://pubmed.ncbi.nlm.nih.gov/31847708

DM3BO8G	DI	DM3BO8G
DM3BO8G	DN	SUVN-G3031
DM3BO8G	MI	TT9JNIC
DM3BO8G	MN	Histamine H3 receptor (H3R)
DM3BO8G	MT	DTT
DM3BO8G	MA	Antagonist
DM3BO8G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3BO8G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMOVEDH	DI	DMOVEDH
DMOVEDH	DN	SYM-004
DMOVEDH	MI	TTGKNB4
DMOVEDH	MN	Epidermal growth factor receptor (EGFR)
DMOVEDH	MT	DTT
DMOVEDH	RN	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
DMOVEDH	RU	https://pubmed.ncbi.nlm.nih.gov/24204198

DMRUEKC	DI	DMRUEKC
DMRUEKC	DN	Synthetic conjugated estrogen
DMRUEKC	MI	TTZAYWL
DMRUEKC	MN	Estrogen receptor (ESR)
DMRUEKC	MT	DTT
DMRUEKC	MA	Modulator
DMRUEKC	RN	Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol. 2004 Feb;103(2):245-53.
DMRUEKC	RU	https://pubmed.ncbi.nlm.nih.gov/14754691

DMXU4ON	DI	DMXU4ON
DMXU4ON	DN	Synthetic hypericin
DMXU4ON	MI	DTI7UX6
DMXU4ON	MN	Breast cancer resistance protein (ABCG2)
DMXU4ON	MT	DTP
DMXU4ON	MA	Substrate
DMXU4ON	RN	Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009 Dec;8(12):1716-23.
DMXU4ON	RU	https://doi.org/10.1039/b9pp00086k

DMXU4ON	DI	DMXU4ON
DMXU4ON	DN	Synthetic hypericin
DMXU4ON	MI	TTYVX59
DMXU4ON	MN	Protein kinase C (PRKC)
DMXU4ON	MT	DTT
DMXU4ON	MA	Inhibitor
DMXU4ON	RN	Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8.
DMXU4ON	RU	https://pubmed.ncbi.nlm.nih.gov/16396605

DM9L1AC	DI	DM9L1AC
DM9L1AC	DN	SYR-472
DM9L1AC	MI	TTDIGC1
DM9L1AC	MN	Dipeptidyl peptidase 4 (DPP-4)
DM9L1AC	MT	DTT
DM9L1AC	MA	Inhibitor
DM9L1AC	RN	SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.
DM9L1AC	RU	https://pubmed.ncbi.nlm.nih.gov/24622716

DMR32KN	DI	DMR32KN
DMR32KN	DN	TA-6366
DMR32KN	MI	DEB30C5
DMR32KN	MN	Carboxylesterase 1 (CES1)
DMR32KN	MT	DME
DMR32KN	MA	Metabolism
DMR32KN	RN	Inhibition of human liver carboxylesterase (hCE1) by organophosphate ester flame retardants and plasticizers: implications for pharmacotherapy. Toxicol Sci. 2019 Jul 3. pii: kfz149.
DMR32KN	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31268531

DMKSAG1	DI	DMKSAG1
DMKSAG1	DN	Tabalumab
DMKSAG1	MI	TTWMIDN
DMKSAG1	MN	B-cell-activating factor (TNFSF13B)
DMKSAG1	MT	DTT
DMKSAG1	MA	Modulator
DMKSAG1	RN	Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8.
DMKSAG1	RU	https://pubmed.ncbi.nlm.nih.gov/23268367

DMW5PHL	DI	DMW5PHL
DMW5PHL	DN	Taberminogene vadenovec
DMW5PHL	MI	TTDCBX5
DMW5PHL	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMW5PHL	MT	DTT
DMW5PHL	MA	Modulator
DMW5PHL	RN	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
DMW5PHL	RU	https://pubmed.ncbi.nlm.nih.gov/25312588

DM1NTVQ	DI	DM1NTVQ
DM1NTVQ	DN	Tadekinig alfa
DM1NTVQ	MI	TTRICUF
DM1NTVQ	MN	Interleukin-18 (IL18)
DM1NTVQ	MT	DTT
DM1NTVQ	MA	Inhibitor
DM1NTVQ	RN	Clinical pipeline report, company report or official report of AB2 Bio.
DM1NTVQ	RU	http://www.ab2bio.com/en/products.36.html

DMCF6SX	DI	DMCF6SX
DMCF6SX	DN	TAK-491
DMCF6SX	MI	TT8DBY3
DMCF6SX	MN	Angiotensin II receptor type-1 (AGTR1)
DMCF6SX	MT	DTT
DMCF6SX	MA	Modulator
DMCF6SX	RN	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
DMCF6SX	RU	https://pubmed.ncbi.nlm.nih.gov/22293555

DM2H8FZ	DI	DM2H8FZ
DM2H8FZ	DN	TAK-700
DM2H8FZ	MI	TTRA5BZ
DM2H8FZ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2H8FZ	MT	DTT
DM2H8FZ	MA	Modulator
DM2H8FZ	RN	Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
DM2H8FZ	RU	https://pubmed.ncbi.nlm.nih.gov/22249003

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DE4LYSA
DMIM5AP	MN	Cytochrome P450 3A4 (CYP3A4)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DEIBDNY
DMIM5AP	MN	Cytochrome P450 3A5 (CYP3A5)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	TTB8FUC
DMIM5AP	MN	Free fatty acid receptor 1 (GPR40)
DMIM5AP	MT	DTT
DMIM5AP	MA	Modulator
DMIM5AP	RN	Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
DMIM5AP	RU	https://pubmed.ncbi.nlm.nih.gov/25787200

DMIM5AP	DI	DMIM5AP
DMIM5AP	DN	TAK-875
DMIM5AP	MI	DEF2WXN
DMIM5AP	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DMIM5AP	MT	DME
DMIM5AP	MA	Metabolism
DMIM5AP	RN	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
DMIM5AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29557709

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTJGLZF
DM1IZ5D	MN	Dipeptidyl peptidase 8 (DPP-8)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1IZ5D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTNDUL7
DM1IZ5D	MN	Dipeptidyl peptidase 9 (DPP-9)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1IZ5D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1IZ5D	DI	DM1IZ5D
DM1IZ5D	DN	Talabostat
DM1IZ5D	MI	TTGPQ0F
DM1IZ5D	MN	Prolyl endopeptidase FAP (FAP)
DM1IZ5D	MT	DTT
DM1IZ5D	MA	Inhibitor
DM1IZ5D	RN	Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
DM1IZ5D	RU	https://pubmed.ncbi.nlm.nih.gov/18032930

DMV7T64	DI	DMV7T64
DMV7T64	DN	Talactoferrin
DMV7T64	MI	TTSZDQU
DMV7T64	MN	Lactotransferrin (LTF)
DMV7T64	MT	DTT
DMV7T64	MA	Modulator
DMV7T64	RN	Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54.
DMV7T64	RU	https://pubmed.ncbi.nlm.nih.gov/17188087

DM3G74J	DI	DM3G74J
DM3G74J	DN	Tamibarotene
DM3G74J	MI	TTW38KT
DM3G74J	MN	Retinoic acid receptor alpha (RARA)
DM3G74J	MT	DTT
DM3G74J	MA	Modulator
DM3G74J	RN	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
DM3G74J	RU	https://pubmed.ncbi.nlm.nih.gov/22863914

DM3G74J	DI	DM3G74J
DM3G74J	DN	Tamibarotene
DM3G74J	MI	TTISP28
DM3G74J	MN	Retinoic acid receptor beta (RARB)
DM3G74J	MT	DTT
DM3G74J	MA	Modulator
DM3G74J	RN	Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
DM3G74J	RU	https://pubmed.ncbi.nlm.nih.gov/22863914

DMJKWMA	DI	DMJKWMA
DMJKWMA	DN	Tanezumab
DMJKWMA	MI	TTDN3LF
DMJKWMA	MN	Nerve growth factor (NGF)
DMJKWMA	MT	DTT
DMJKWMA	MA	Inhibitor
DMJKWMA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJKWMA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWM4D0	DI	DMWM4D0
DMWM4D0	DN	TAS-120
DMWM4D0	MI	TT5HU6Z
DMWM4D0	MN	Fibroblast growth factor (FGF)
DMWM4D0	MT	DTT
DMWM4D0	MA	Inhibitor
DMWM4D0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWM4D0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWM4D0	DI	DMWM4D0
DMWM4D0	DN	TAS-120
DMWM4D0	MI	TT0LF7H
DMWM4D0	MN	Fibroblast growth factor receptor (FGFR)
DMWM4D0	MT	DTT
DMWM4D0	MA	Antagonist
DMWM4D0	RN	TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
DMWM4D0	RU	http://mct.aacrjournals.org/content/12/11_Supplement/A270.short

DMPYET9	DI	DMPYET9
DMPYET9	DN	Taspoglutide
DMPYET9	MI	TTVIMDE
DMPYET9	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMPYET9	MT	DTT
DMPYET9	MA	Agonist
DMPYET9	RN	Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64.
DMPYET9	RU	https://pubmed.ncbi.nlm.nih.gov/19929995

DM9GSVQ	DI	DM9GSVQ
DM9GSVQ	DN	Tasquinimod
DM9GSVQ	MI	TT0TMQG
DM9GSVQ	MN	Calgranulin B (S100A9)
DM9GSVQ	MT	DTT
DM9GSVQ	MA	Modulator
DM9GSVQ	RN	Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014; 73(1): 1-8.
DM9GSVQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889691/

DMD6AUX	DI	DMD6AUX
DMD6AUX	DN	Tat-NR2B9c
DMD6AUX	MI	TT9PB26
DMD6AUX	MN	Presynaptic density protein 95 (DLG4)
DMD6AUX	MT	DTT
DMD6AUX	MA	Inhibitor
DMD6AUX	RN	Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7.
DMD6AUX	RU	https://pubmed.ncbi.nlm.nih.gov/22388811

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TTJGNVC
DML6GAN	MN	Apoptosis regulator Bcl-2 (BCL-2)
DML6GAN	MT	DTT
DML6GAN	MA	Modulator
DML6GAN	RN	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16381626

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TT6EO5L
DML6GAN	MN	Erbb2 tyrosine kinase receptor (HER2)
DML6GAN	MT	DTT
DML6GAN	MA	Inhibitor
DML6GAN	RN	Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16381626

DML6GAN	DI	DML6GAN
DML6GAN	DN	Taxol/Paraplatin/Herceptin
DML6GAN	MI	TTUTN1I
DML6GAN	MN	Human Deoxyribonucleic acid (hDNA)
DML6GAN	MT	DTT
DML6GAN	MA	Binder
DML6GAN	RN	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92.
DML6GAN	RU	https://pubmed.ncbi.nlm.nih.gov/16782917

DMGKBZH	DI	DMGKBZH
DMGKBZH	DN	TD-1792
DMGKBZH	MI	TTLP6GN
DMGKBZH	MN	Bacterial DD-carboxypeptidase (Bact vanYB)
DMGKBZH	MT	DTT
DMGKBZH	MA	Inhibitor
DMGKBZH	RN	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
DMGKBZH	RU	https://pubmed.ncbi.nlm.nih.gov/18621146

DMVSX6O	DI	DMVSX6O
DMVSX6O	DN	Tebipenem
DMVSX6O	MI	TT6OEDT
DMVSX6O	MN	Cannabinoid receptor 1 (CB1)
DMVSX6O	MT	DTT
DMVSX6O	MA	Antagonist
DMVSX6O	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMVSX6O	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMTCR2O	DI	DMTCR2O
DMTCR2O	DN	Tecarfarin
DMTCR2O	MI	TTEUC8H
DMTCR2O	MN	Vitamin K epoxide reductase complex 1 (VKORC1)
DMTCR2O	MT	DTT
DMTCR2O	MA	Inhibitor
DMTCR2O	RN	Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74.
DMTCR2O	RU	https://pubmed.ncbi.nlm.nih.gov/20622200

DMKE187	DI	DMKE187
DMKE187	DN	Telmisartan
DMKE187	MI	TTPKMXQ
DMKE187	MN	HUMAN type-1 angiotensin II receptor (AGTR1)
DMKE187	MT	DTT
DMKE187	MA	Blocker
DMKE187	RN	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
DMKE187	RU	https://pubmed.ncbi.nlm.nih.gov/32246101

DMHQRYE	DI	DMHQRYE
DMHQRYE	DN	Tenidap
DMHQRYE	MI	TT2J34L
DMHQRYE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHQRYE	MT	DTT
DMHQRYE	MA	Modulator
DMHQRYE	RN	The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
DMHQRYE	RU	https://pubmed.ncbi.nlm.nih.gov/18475454

DMHOV7D	DI	DMHOV7D
DMHOV7D	DN	Tenofovir alafenamide
DMHOV7D	MI	DTI7UX6
DMHOV7D	MN	Breast cancer resistance protein (ABCG2)
DMHOV7D	MT	DTP
DMHOV7D	MA	Substrate
DMHOV7D	RN	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
DMHOV7D	RU	http://www.ncbi.nlm.nih.gov/pubmed/29649076

DMHOV7D	DI	DMHOV7D
DMHOV7D	DN	Tenofovir alafenamide
DMHOV7D	MI	DTUGYRD
DMHOV7D	MN	P-glycoprotein 1 (ABCB1)
DMHOV7D	MT	DTP
DMHOV7D	MA	Substrate
DMHOV7D	RN	Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):465-472.
DMHOV7D	RU	http://www.ncbi.nlm.nih.gov/pubmed/29649076

DMZ3P6C	DI	DMZ3P6C
DMZ3P6C	DN	Teplizumab
DMZ3P6C	MI	TTBMAOZ
DMZ3P6C	MN	Regulatory protein unspecific (RGP)
DMZ3P6C	MT	DTT
DMZ3P6C	RN	Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901.
DMZ3P6C	RU	https://pubmed.ncbi.nlm.nih.gov/21038470

DMZ3P6C	DI	DMZ3P6C
DMZ3P6C	DN	Teplizumab
DMZ3P6C	MI	TTV3XPL
DMZ3P6C	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMZ3P6C	MT	DTT
DMZ3P6C	MA	Inhibitor
DMZ3P6C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ3P6C	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM4MZXE	DI	DM4MZXE
DM4MZXE	DN	Terodiline
DM4MZXE	MI	DE4LYSA
DM4MZXE	MN	Cytochrome P450 3A4 (CYP3A4)
DM4MZXE	MT	DME
DM4MZXE	MA	Metabolism
DM4MZXE	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM4MZXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMGRBN5	DI	DMGRBN5
DMGRBN5	DN	TESAGLITAZAR
DMGRBN5	MI	TTJ584C
DMGRBN5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMGRBN5	MT	DTT
DMGRBN5	MA	Modulator
DMGRBN5	RN	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
DMGRBN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/22131108

DMGRBN5	DI	DMGRBN5
DMGRBN5	DN	TESAGLITAZAR
DMGRBN5	MI	TTZMAO3
DMGRBN5	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMGRBN5	MT	DTT
DMGRBN5	MA	Modulator
DMGRBN5	RN	Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
DMGRBN5	RU	https://www.ncbi.nlm.nih.gov/pubmed/22131108

DMMTKC6	DI	DMMTKC6
DMMTKC6	DN	TEV-48125
DMMTKC6	MI	TTAFORY
DMMTKC6	MN	Calcitonin gene-related peptide (CALC)
DMMTKC6	MT	DTT
DMMTKC6	RN	TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8.
DMMTKC6	RU	https://pubmed.ncbi.nlm.nih.gov/27281531

DM9R5J6	DI	DM9R5J6
DM9R5J6	DN	Tezepelumab
DM9R5J6	MI	TTHMW3T
DM9R5J6	MN	Thymic stromal lymphopoietin (TSLP)
DM9R5J6	MT	DTT
DM9R5J6	RN	Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946.
DM9R5J6	RU	https://pubmed.ncbi.nlm.nih.gov/28877011

DMLCXPD	DI	DMLCXPD
DMLCXPD	DN	TG-C
DMLCXPD	MI	TTR9XHZ
DMLCXPD	MN	Transforming growth factor beta 1 (TGFB1)
DMLCXPD	MT	DTT
DMLCXPD	MA	Modulator
DMLCXPD	RN	Clinical pipeline report, company report or official report of Tissue Gene, Inc.
DMLCXPD	RU	http://www.tissuegene.com/products/cartilage.html

DMPGH7N	DI	DMPGH7N
DMPGH7N	DN	ThermoProfen
DMPGH7N	MI	TT8NGED
DMPGH7N	MN	Prostaglandin G/H synthase 1 (COX-1)
DMPGH7N	MT	DTT
DMPGH7N	MA	Inhibitor
DMPGH7N	RN	Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
DMPGH7N	RU	https://pubmed.ncbi.nlm.nih.gov/20210866

DMPGH7N	DI	DMPGH7N
DMPGH7N	DN	ThermoProfen
DMPGH7N	MI	TTVKILB
DMPGH7N	MN	Prostaglandin G/H synthase 2 (COX-2)
DMPGH7N	MT	DTT
DMPGH7N	MA	Inhibitor
DMPGH7N	RN	Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49.
DMPGH7N	RU	https://pubmed.ncbi.nlm.nih.gov/20210866

DM3PA8H	DI	DM3PA8H
DM3PA8H	DN	THVD-201
DM3PA8H	MI	TTOXS3C
DM3PA8H	MN	Muscarinic acetylcholine receptor (CHRM)
DM3PA8H	MT	DTT
DM3PA8H	MA	Agonist
DM3PA8H	RN	Future therapies: Early trials and basic science. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10 Suppl 4): S179-S180.
DM3PA8H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919188/

DM3DG5C	DI	DM3DG5C
DM3DG5C	DN	THX-TS01
DM3DG5C	MI	TT94IAG
DM3DG5C	MN	Cannabinoid receptor (CB)
DM3DG5C	MT	DTT
DM3DG5C	MA	Modulator
DM3DG5C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3DG5C	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMMO6P0	DI	DMMO6P0
DMMO6P0	DN	Tifacogin
DMMO6P0	MI	TT068JH
DMMO6P0	MN	Tissue factor pathway inhibitor (TFPI)
DMMO6P0	MT	DTT
DMMO6P0	MA	Inhibitor
DMMO6P0	RN	Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
DMMO6P0	RU	https://pubmed.ncbi.nlm.nih.gov/12851279

DMZBGI8	DI	DMZBGI8
DMZBGI8	DN	Tilarginine acetate
DMZBGI8	MI	TTCM4B3
DMZBGI8	MN	Nitric-oxide synthase endothelial (NOS3)
DMZBGI8	MT	DTT
DMZBGI8	MA	Modulator
DMZBGI8	RN	Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
DMZBGI8	RU	https://pubmed.ncbi.nlm.nih.gov/17387132

DMGYK2N	DI	DMGYK2N
DMGYK2N	DN	Tilsotolimod
DMGYK2N	MI	TTSHG0T
DMGYK2N	MN	Toll-like receptor 9 (TLR9)
DMGYK2N	MT	DTT
DMGYK2N	MA	Agonist
DMGYK2N	RN	Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
DMGYK2N	RU	https://pubmed.ncbi.nlm.nih.gov/33707233

DMBFE4K	DI	DMBFE4K
DMBFE4K	DN	Tirapazamine
DMBFE4K	MI	DEVDYN7
DMBFE4K	MN	Cytochrome P450 2E1 (CYP2E1)
DMBFE4K	MT	DME
DMBFE4K	MA	Metabolism
DMBFE4K	RN	Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br J Cancer. 1995 Apr;71(4):780-5.
DMBFE4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=7710944

DMBFE4K	DI	DMBFE4K
DMBFE4K	DN	Tirapazamine
DMBFE4K	MI	TT0IHXV
DMBFE4K	MN	DNA topoisomerase II (TOP2)
DMBFE4K	MT	DTT
DMBFE4K	MA	Modulator
DMBFE4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBFE4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQNMAT	DI	DMQNMAT
DMQNMAT	DN	Tirzepatide
DMQNMAT	MI	TTVIMDE
DMQNMAT	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMQNMAT	MT	DTT
DMQNMAT	MA	Agonist
DMQNMAT	RN	Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
DMQNMAT	RU	https://pubmed.ncbi.nlm.nih.gov/33236115

DM95IPS	DI	DM95IPS
DM95IPS	DN	Tivanisiran
DM95IPS	MI	TT50OG3
DM95IPS	MN	TRPV1 messenger RNA (TRPV1 mRNA)
DM95IPS	MT	DTT
DM95IPS	MA	Inhibitor
DM95IPS	RN	Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.
DM95IPS	RU	https://pubmed.ncbi.nlm.nih.gov/29569947

DMNVP8Q	DI	DMNVP8Q
DMNVP8Q	DN	Tivantinib
DMNVP8Q	MI	TTNDSF4
DMNVP8Q	MN	Proto-oncogene c-Met (MET)
DMNVP8Q	MT	DTT
DMNVP8Q	MA	Inhibitor
DMNVP8Q	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
DMNVP8Q	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	DEJGDUW
DMYLT67	MN	Cytochrome P450 1A2 (CYP1A2)
DMYLT67	MT	DME
DMYLT67	MA	Metabolism
DMYLT67	RN	A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 Jan;81(1):73-80.
DMYLT67	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29101463

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	TTST7KB
DMYLT67	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMYLT67	MT	DTT
DMYLT67	MA	Inhibitor
DMYLT67	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYLT67	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMYLT67	DI	DMYLT67
DMYLT67	DN	TKI258
DMYLT67	MI	TTI2WET
DMYLT67	MN	Platelet-derived growth factor receptor (PDGFR)
DMYLT67	MT	DTT
DMYLT67	MA	Inhibitor
DMYLT67	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYLT67	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMO1234	DI	DMO1234
DMO1234	DN	TNX-102
DMO1234	MI	TTJQOD7
DMO1234	MN	5-HT 2A receptor (HTR2A)
DMO1234	MT	DTT
DMO1234	MA	Antagonist
DMO1234	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMO1234	RU	http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia

DMO1234	DI	DMO1234
DMO1234	DN	TNX-102
DMO1234	MI	TT2NUT5
DMO1234	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMO1234	MT	DTT
DMO1234	MA	Antagonist
DMO1234	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMO1234	RU	http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia

DMYA41S	DI	DMYA41S
DMYA41S	DN	TNX-355
DMYA41S	MI	TTN2JFW
DMYA41S	MN	T-cell surface glycoprotein CD4 (CD4)
DMYA41S	MT	DTT
DMYA41S	MA	Binder
DMYA41S	RN	Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
DMYA41S	RU	https://pubmed.ncbi.nlm.nih.gov/16182193

DMFDNT0	DI	DMFDNT0
DMFDNT0	DN	Tocilizumab
DMFDNT0	MI	TTDVAKP
DMFDNT0	MN	HUMAN interleukin-6 receptor (IL6R)
DMFDNT0	MT	DTT
DMFDNT0	MA	Inhibitor
DMFDNT0	RN	Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0.
DMFDNT0	RU	https://pubmed.ncbi.nlm.nih.gov/32247642

DMATC14	DI	DMATC14
DMATC14	DN	Tozadenant
DMATC14	MI	TTM2AOE
DMATC14	MN	Adenosine A2a receptor (ADORA2A)
DMATC14	MT	DTT
DMATC14	MA	Antagonist
DMATC14	RN	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
DMATC14	RU	https://pubmed.ncbi.nlm.nih.gov/25008546

DMLKI2B	DI	DMLKI2B
DMLKI2B	DN	Trafermin
DMLKI2B	MI	TTGJVQM
DMLKI2B	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMLKI2B	MT	DTT
DMLKI2B	MA	Activator
DMLKI2B	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMLKI2B	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DM6ENSJ	DI	DM6ENSJ
DM6ENSJ	DN	Tralokinumab
DM6ENSJ	MI	TTMPZ7V
DM6ENSJ	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DM6ENSJ	MT	DTT
DM6ENSJ	MA	Modulator
DM6ENSJ	RN	Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
DM6ENSJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24325475

DM6ENSJ	DI	DM6ENSJ
DM6ENSJ	DN	Tralokinumab
DM6ENSJ	MI	TT0GVCH
DM6ENSJ	MN	Interleukin-13 (IL13)
DM6ENSJ	MT	DTT
DM6ENSJ	MA	Inhibitor
DM6ENSJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6ENSJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7BSRH	DI	DM7BSRH
DM7BSRH	DN	Tramiprosate
DM7BSRH	MI	TTE4KHA
DM7BSRH	MN	Amyloid beta A4 protein (APP)
DM7BSRH	MT	DTT
DM7BSRH	MA	Antagonist
DM7BSRH	RN	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
DM7BSRH	RU	https://pubmed.ncbi.nlm.nih.gov/16675063

DMLB3I4	DI	DMLB3I4
DMLB3I4	DN	Trastuzumab-DM1
DMLB3I4	MI	TT6EO5L
DMLB3I4	MN	Erbb2 tyrosine kinase receptor (HER2)
DMLB3I4	MT	DTT
DMLB3I4	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMLB3I4	RU	http://www.gene.com/gene/pipeline/status/

DM1874J	DI	DM1874J
DM1874J	DN	TRC105
DM1874J	MI	TTB30LE
DM1874J	MN	Endoglin CD105 (ENG)
DM1874J	MT	DTT
DM1874J	MA	Modulator
DM1874J	RN	An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26.
DM1874J	RU	https://pubmed.ncbi.nlm.nih.gov/25261556

DMOG2X1	DI	DMOG2X1
DMOG2X1	DN	Trebananib
DMOG2X1	MI	TTWNQ1T
DMOG2X1	MN	Angiopoietin-1 (ANGPT1)
DMOG2X1	MT	DTT
DMOG2X1	MA	Inhibitor
DMOG2X1	RN	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
DMOG2X1	RU	https://pubmed.ncbi.nlm.nih.gov/28751444

DMOG2X1	DI	DMOG2X1
DMOG2X1	DN	Trebananib
DMOG2X1	MI	TTKLQTJ
DMOG2X1	MN	Angiopoietin-2 (ANGPT2)
DMOG2X1	MT	DTT
DMOG2X1	MA	Inhibitor
DMOG2X1	RN	Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069.
DMOG2X1	RU	https://pubmed.ncbi.nlm.nih.gov/28751444

DMOQ9H1	DI	DMOQ9H1
DMOQ9H1	DN	Tremelimumab
DMOQ9H1	MI	TTI2S1D
DMOQ9H1	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMOQ9H1	MT	DTT
DMOQ9H1	MA	Modulator
DMOQ9H1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
DMOQ9H1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743

DMS57DJ	DI	DMS57DJ
DMS57DJ	DN	Trimegestone/ethinyl estradiol
DMS57DJ	MI	TTZAYWL
DMS57DJ	MN	Estrogen receptor (ESR)
DMS57DJ	MT	DTT
DMS57DJ	MA	Modulator
DMS57DJ	RN	Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol. 2005 Mar;94(4):361-8.
DMS57DJ	RU	https://pubmed.ncbi.nlm.nih.gov/15857755

DMCMDVR	DI	DMCMDVR
DMCMDVR	DN	Triptolide
DMCMDVR	MI	DE4LYSA
DMCMDVR	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMDVR	MT	DME
DMCMDVR	MA	Metabolism
DMCMDVR	RN	Preclinical pharmacokinetics of triptolide: a potential antitumor drug. Curr Drug Metab. 2019;20(2):147-154.
DMCMDVR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30112986

DMCMDVR	DI	DMCMDVR
DMCMDVR	DN	Triptolide
DMCMDVR	MI	TTSXVID
DMCMDVR	MN	Nuclear factor NF-kappa-B (NFKB)
DMCMDVR	MT	DTT
DMCMDVR	MA	Inhibitor
DMCMDVR	RN	Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
DMCMDVR	RU	https://pubmed.ncbi.nlm.nih.gov/11753684

DMHDNK0	DI	DMHDNK0
DMHDNK0	DN	TroVax
DMHDNK0	MI	TT70MLA
DMHDNK0	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMHDNK0	MT	DTT
DMHDNK0	RN	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
DMHDNK0	RU	https://pubmed.ncbi.nlm.nih.gov/20881001

DM0QNF4	DI	DM0QNF4
DM0QNF4	DN	TRx0237
DM0QNF4	MI	TTS87KH
DM0QNF4	MN	Microtubule-associated protein tau (MAPT)
DM0QNF4	MT	DTT
DM0QNF4	MA	Inhibitor
DM0QNF4	RN	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
DM0QNF4	RU	https://pubmed.ncbi.nlm.nih.gov/32091331

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TTJQOD7
DMAFPHB	MN	5-HT 2A receptor (HTR2A)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/3543362

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TT3WG5C
DMAFPHB	MN	Monoamine oxidase type A (MAO-A)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMAFPHB	DI	DMAFPHB
DMAFPHB	DN	TRYPTAMINE
DMAFPHB	MI	TTGP7BY
DMAFPHB	MN	Monoamine oxidase type B (MAO-B)
DMAFPHB	MT	DTT
DMAFPHB	MA	Inhibitor
DMAFPHB	RN	Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
DMAFPHB	RU	https://pubmed.ncbi.nlm.nih.gov/15013009

DMPBJ8W	DI	DMPBJ8W
DMPBJ8W	DN	Turoctocog alfa
DMPBJ8W	MI	TT1290U
DMPBJ8W	MN	Coagulation factor VIII (F8)
DMPBJ8W	MT	DTT
DMPBJ8W	MA	Modulator
DMPBJ8W	RN	The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9.
DMPBJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/25495795

DM71ZL6	DI	DM71ZL6
DM71ZL6	DN	TZTX-001
DM71ZL6	MI	TTZAYWL
DM71ZL6	MN	Estrogen receptor (ESR)
DM71ZL6	MT	DTT
DM71ZL6	MA	Modulator
DM71ZL6	RN	Clinical pipeline report, company report or official report of Pharmabiz.
DM71ZL6	RU	http://www.pharmabiz.com/PrintArticle.aspx?aid=77569&sid=2

DMN72OM	DI	DMN72OM
DMN72OM	DN	U300
DMN72OM	MI	TTZOPHG
DMN72OM	MN	Insulin (INS)
DMN72OM	MT	DTT
DMN72OM	MA	Modulator
DMN72OM	RN	U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014 Dec;14(12):1849-60.
DMN72OM	RU	https://pubmed.ncbi.nlm.nih.gov/25311556

DMHTY9W	DI	DMHTY9W
DMHTY9W	DN	Ublituximab
DMHTY9W	MI	TTUE541
DMHTY9W	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHTY9W	MT	DTT
DMHTY9W	RN	The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
DMHTY9W	RU	https://pubmed.ncbi.nlm.nih.gov/25552707

DMKUOVP	DI	DMKUOVP
DMKUOVP	DN	Ublituximab + umbralisib
DMKUOVP	MI	TTUE541
DMKUOVP	MN	Leukocyte surface antigen Leu-16 (CD20)
DMKUOVP	MT	DTT
DMKUOVP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUOVP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM90AG2	DI	DM90AG2
DM90AG2	DN	Ularitide
DM90AG2	MI	TTJME02
DM90AG2	MN	Atrial natriuretic peptide receptor A (NPR1)
DM90AG2	MT	DTT
DM90AG2	MA	Modulator
DM90AG2	RN	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23.
DM90AG2	RU	https://pubmed.ncbi.nlm.nih.gov/25670819

DMIQCFG	DI	DMIQCFG
DMIQCFG	DN	Ulinastatin
DMIQCFG	MI	TT2WR1T
DMIQCFG	MN	Cationic trypsinogen (PRSS1)
DMIQCFG	MT	DTT
DMIQCFG	MA	Modulator
DMIQCFG	RN	Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8.
DMIQCFG	RU	https://pubmed.ncbi.nlm.nih.gov/24737258

DM6PMNR	DI	DM6PMNR
DM6PMNR	DN	Ulocuplumab
DM6PMNR	MI	TTBID49
DM6PMNR	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM6PMNR	MT	DTT
DM6PMNR	MA	Antagonist
DM6PMNR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6PMNR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMCWM03	DI	DMCWM03
DMCWM03	DN	Unfractionated heparin
DMCWM03	MI	TT4QPUL
DMCWM03	MN	Antithrombin-III (ATIII)
DMCWM03	MT	DTT
DMCWM03	MA	Modulator
DMCWM03	RN	Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97.
DMCWM03	RU	https://pubmed.ncbi.nlm.nih.gov/7164033

DM0DIEZ	DI	DM0DIEZ
DM0DIEZ	DN	UNI-rhIL-11
DM0DIEZ	MI	TTZPLJS
DM0DIEZ	MN	Interleukin 11 receptor alpha (IL11RA)
DM0DIEZ	MT	DTT
DM0DIEZ	MA	Modulator
DM0DIEZ	RN	Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5.
DM0DIEZ	RU	https://pubmed.ncbi.nlm.nih.gov/12478901

DMM2OZH	DI	DMM2OZH
DMM2OZH	DN	Ushercell
DMM2OZH	MI	TTAUG8D
DMM2OZH	MN	Human immunodeficiency virus Transmission (HIV Tran)
DMM2OZH	MT	DTT
DMM2OZH	MA	Modulator
DMM2OZH	RN	Short Communication: Enhancement of HIV Infection by Cellulose Sulfate. AIDS Res Hum Retroviruses. 2008 July; 24(7): 925-929.
DMM2OZH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927036/

DMD2O0L	DI	DMD2O0L
DMD2O0L	DN	UX-001
DMD2O0L	MI	TTQ8J1V
DMD2O0L	MN	Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB)
DMD2O0L	MT	DTT
DMD2O0L	MA	Inhibitor
DMD2O0L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD2O0L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMD2O0L	DI	DMD2O0L
DMD2O0L	DN	UX-001
DMD2O0L	MI	TT50QJ3
DMD2O0L	MN	Influenza Neuraminidase (Influ NA)
DMD2O0L	MT	DTT
DMD2O0L	MA	Inhibitor
DMD2O0L	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMD2O0L	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDCFXJ	DI	DMDCFXJ
DMDCFXJ	DN	Vaborbactam
DMDCFXJ	MI	TTHI19T
DMDCFXJ	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMDCFXJ	MT	DTT
DMDCFXJ	MA	Inhibitor
DMDCFXJ	RN	Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
DMDCFXJ	RU	https://pubmed.ncbi.nlm.nih.gov/28848018

DM9LH10	DI	DM9LH10
DM9LH10	DN	Vadastuximab talirine
DM9LH10	MI	TTJVYO3
DM9LH10	MN	Myeloid cell surface antigen CD33 (CD33)
DM9LH10	MT	DTT
DM9LH10	MA	Antagonist
DM9LH10	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LH10	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9J5Q4	DI	DM9J5Q4
DM9J5Q4	DN	VAL-083
DM9J5Q4	MI	TTUTN1I
DM9J5Q4	MN	Human Deoxyribonucleic acid (hDNA)
DM9J5Q4	MT	DTT
DM9J5Q4	MA	Modulator
DM9J5Q4	RN	Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3.
DM9J5Q4	RU	https://pubmed.ncbi.nlm.nih.gov/6487788

DMMKE2H	DI	DMMKE2H
DMMKE2H	DN	Valoctocogene roxaparvovec
DMMKE2H	MI	TT1290U
DMMKE2H	MN	Coagulation factor VIII (F8)
DMMKE2H	MT	DTT
DMMKE2H	MA	Replacement
DMMKE2H	RN	Clinical pipeline report, company report or official report of BioMarin Pharmaceutical.
DMMKE2H	RU	https://www.biomarin.com/our-treatments/pipeline/

DMQL0KF	DI	DMQL0KF
DMQL0KF	DN	Vanadate
DMQL0KF	MI	TTZVSJ2
DMQL0KF	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)
DMQL0KF	MT	DTT
DMQL0KF	MA	Inhibitor
DMQL0KF	RN	Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7.
DMQL0KF	RU	https://pubmed.ncbi.nlm.nih.gov/11145964

DMLIMEA	DI	DMLIMEA
DMLIMEA	DN	Varespladib methyl
DMLIMEA	MI	TT2XHSJ
DMLIMEA	MN	Secretory phospholipase A2 (sPLA2)
DMLIMEA	MT	DTT
DMLIMEA	MA	Modulator
DMLIMEA	RN	Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43.
DMLIMEA	RU	https://pubmed.ncbi.nlm.nih.gov/21446779

DMANKTO	DI	DMANKTO
DMANKTO	DN	Vatreptacog alfa (activated)
DMANKTO	MI	TTF0EGX
DMANKTO	MN	Coagulation factor VII (F7)
DMANKTO	MT	DTT
DMANKTO	MA	Modulator
DMANKTO	RN	Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.
DMANKTO	RU	https://pubmed.ncbi.nlm.nih.gov/22470921

DMX04CA	DI	DMX04CA
DMX04CA	DN	VB-111
DMX04CA	MI	TTF0RCZ
DMX04CA	MN	Apoptosis mediating surface antigen FAS (FAS)
DMX04CA	MT	DTT
DMX04CA	MA	Modulator
DMX04CA	RN	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
DMX04CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/23589178

DMX04CA	DI	DMX04CA
DMX04CA	DN	VB-111
DMX04CA	MI	TTG043C
DMX04CA	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMX04CA	MT	DTT
DMX04CA	MA	Modulator
DMX04CA	RN	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
DMX04CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/23589178

DMXHI89	DI	DMXHI89
DMXHI89	DN	Velac Gel
DMXHI89	MI	TTOD7B3
DMXHI89	MN	Retinoic acid receptor (RAR)
DMXHI89	MT	DTT
DMXHI89	MA	Inhibitor
DMXHI89	RN	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74.
DMXHI89	RU	https://pubmed.ncbi.nlm.nih.gov/1652368

DMJBU9V	DI	DMJBU9V
DMJBU9V	DN	Velimogene aliplasmid
DMJBU9V	MI	TTGS10J
DMJBU9V	MN	HLA class I antigen B-7 (HLA-B)
DMJBU9V	MT	DTT
DMJBU9V	MA	Modulator
DMJBU9V	RN	Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51.
DMJBU9V	RU	https://pubmed.ncbi.nlm.nih.gov/20367461

DM6L5ZQ	DI	DM6L5ZQ
DM6L5ZQ	DN	Vercirnon
DM6L5ZQ	MI	TTIPS8B
DM6L5ZQ	MN	C-C chemokine receptor type 9 (CCR9)
DM6L5ZQ	MT	DTT
DM6L5ZQ	MA	Modulator
DM6L5ZQ	RN	GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81.
DM6L5ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/20582872

DMOQ81Y	DI	DMOQ81Y
DMOQ81Y	DN	Vernakalant
DMOQ81Y	MI	DECB0K3
DMOQ81Y	MN	Cytochrome P450 2D6 (CYP2D6)
DMOQ81Y	MT	DME
DMOQ81Y	MA	Metabolism
DMOQ81Y	RN	Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009 Jan;49(1):17-29.
DMOQ81Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18927241

DM4CGH5	DI	DM4CGH5
DM4CGH5	DN	verubecestat
DM4CGH5	MI	TT8JRS7
DM4CGH5	MN	Beta-secretase (BACE)
DM4CGH5	MT	DTT
DM4CGH5	MA	Modulator
DM4CGH5	RN	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
DM4CGH5	RU	https://pubmed.ncbi.nlm.nih.gov/25621019

DM4CGH5	DI	DM4CGH5
DM4CGH5	DN	verubecestat
DM4CGH5	MI	TTJUNZF
DM4CGH5	MN	Beta-secretase 1 (BACE1)
DM4CGH5	MT	DTT
DM4CGH5	MA	Inhibitor
DM4CGH5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4CGH5	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMMQ2U9	DI	DMMQ2U9
DMMQ2U9	DN	VGX-3100
DMMQ2U9	MI	TTE2N95
DMMQ2U9	MN	Human papillomavirus protein E6 (HPV E6)
DMMQ2U9	MT	DTT
DMMQ2U9	MA	Modulator
DMMQ2U9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMQ2U9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMMQ2U9	DI	DMMQ2U9
DMMQ2U9	DN	VGX-3100
DMMQ2U9	MI	TT3CPZW
DMMQ2U9	MN	Human papillomavirus protein E7 (HPV E7)
DMMQ2U9	MT	DTT
DMMQ2U9	MA	Modulator
DMMQ2U9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMQ2U9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCWNZG	DI	DMCWNZG
DMCWNZG	DN	Vibegron
DMCWNZG	MI	DTUGYRD
DMCWNZG	MN	P-glycoprotein 1 (ABCB1)
DMCWNZG	MT	DTP
DMCWNZG	MA	Substrate
DMCWNZG	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMCWNZG	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMLO0KD	DI	DMLO0KD
DMLO0KD	DN	Vicineum
DMLO0KD	MI	TTZ8WH4
DMLO0KD	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMLO0KD	MT	DTT
DMLO0KD	RN	Clinical pipeline report, company report or official report of Sesen Bio.
DMLO0KD	RU	https://sesenbio.com/our-programs/

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	TT2CEJG
DMMTW9K	MN	C-C chemokine receptor type 5 (CCR5)
DMMTW9K	MT	DTT
DMMTW9K	MA	Antagonist
DMMTW9K	RN	HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
DMMTW9K	RU	https://pubmed.ncbi.nlm.nih.gov/19532079

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DE5IED8
DMMTW9K	MN	Cytochrome P450 2C9 (CYP2C9)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DE4LYSA
DMMTW9K	MN	Cytochrome P450 3A4 (CYP3A4)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMMTW9K	DI	DMMTW9K
DMMTW9K	DN	Vicriviroc
DMMTW9K	MI	DEIBDNY
DMMTW9K	MN	Cytochrome P450 3A5 (CYP3A5)
DMMTW9K	MT	DME
DMMTW9K	MA	Metabolism
DMMTW9K	RN	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
DMMTW9K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014

DMJFNR9	DI	DMJFNR9
DMJFNR9	DN	Viramidine
DMJFNR9	MI	TTL7C8Q
DMJFNR9	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DMJFNR9	MT	DTT
DMJFNR9	MA	Inhibitor
DMJFNR9	RN	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
DMJFNR9	RU	https://pubmed.ncbi.nlm.nih.gov/17139286

DMXYM1H	DI	DMXYM1H
DMXYM1H	DN	Visilizumab
DMXYM1H	MI	TTBMAOZ
DMXYM1H	MN	Regulatory protein unspecific (RGP)
DMXYM1H	MT	DTT
DMXYM1H	RN	Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.
DMXYM1H	RU	https://pubmed.ncbi.nlm.nih.gov/18424236

DMQGV5P	DI	DMQGV5P
DMQGV5P	DN	VLB-01
DMQGV5P	MI	TT32JK8
DMQGV5P	MN	Melatonin receptor type 1B (MTNR1B)
DMQGV5P	MT	DTT
DMQGV5P	MA	Modulator
DMQGV5P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQGV5P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMSW80U	DI	DMSW80U
DMSW80U	DN	VM-202
DMSW80U	MI	TT4V2JM
DMSW80U	MN	Hepatocyte growth factor (HGF)
DMSW80U	MT	DTT
DMSW80U	MA	Modulator
DMSW80U	RN	Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
DMSW80U	RU	https://pubmed.ncbi.nlm.nih.gov/18620865

DM4P5UJ	DI	DM4P5UJ
DM4P5UJ	DN	VM-501
DM4P5UJ	MI	TTGUYTR
DM4P5UJ	MN	Interleukin-11 (IL11)
DM4P5UJ	MT	DTT
DM4P5UJ	MA	Agonist
DM4P5UJ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052)
DM4P5UJ	RU	http://adisinsight.springer.com/drugs/800033052

DMOFH1M	DI	DMOFH1M
DMOFH1M	DN	Volasertib
DMOFH1M	MI	TTIYVQP
DMOFH1M	MN	Polo-like kinase 1 (PLK1)
DMOFH1M	MT	DTT
DMOFH1M	MA	Modulator
DMOFH1M	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
DMOFH1M	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168

DM5T4IS	DI	DM5T4IS
DM5T4IS	DN	VP-102
DM5T4IS	MI	TTLA7IX
DM5T4IS	MN	Protein phosphatase 1A (PPM1A)
DM5T4IS	MT	DTT
DM5T4IS	MA	Inhibitor
DM5T4IS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5T4IS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5T4IS	DI	DM5T4IS
DM5T4IS	DN	VP-102
DM5T4IS	MI	TTHTKNY
DM5T4IS	MN	Serine/threonine PP2A-alpha (PPP2CA)
DM5T4IS	MT	DTT
DM5T4IS	MA	Inhibitor
DM5T4IS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5T4IS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWMT5N	DI	DMWMT5N
DMWMT5N	DN	VRS-317
DMWMT5N	MI	TTT3YKH
DMWMT5N	MN	Somatotropin (GH1)
DMWMT5N	MT	DTT
DMWMT5N	MA	Modulator
DMWMT5N	RN	Company report (Versartis)
DMWMT5N	RU	http://www.versartis.com/content/productpipeline/vrs-317.htm

DMM1Z9G	DI	DMM1Z9G
DMM1Z9G	DN	Vutrisiran
DMM1Z9G	MI	TTPOYU7
DMM1Z9G	MN	Transthyretin messenger RNA (TTR mRNA)
DMM1Z9G	MT	DTT
DMM1Z9G	MA	Inhibitor
DMM1Z9G	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
DMM1Z9G	RU	https://www.alnylam.com/alnylam-rnai-pipeline/

DMJBXO3	DI	DMJBXO3
DMJBXO3	DN	VX-661
DMJBXO3	MI	TTRLZHP
DMJBXO3	MN	cAMP-dependent chloride channel (CFTR)
DMJBXO3	MT	DTT
DMJBXO3	MA	Regulator
DMJBXO3	RN	CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11.
DMJBXO3	RU	https://pubmed.ncbi.nlm.nih.gov/25083129

DMJBXO3	DI	DMJBXO3
DMJBXO3	DN	VX-661
DMJBXO3	MI	DEIBDNY
DMJBXO3	MN	Cytochrome P450 3A5 (CYP3A5)
DMJBXO3	MT	DME
DMJBXO3	MA	Metabolism
DMJBXO3	RN	Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 2019 May;12(3):267-275.
DMJBXO3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30694595

DMM2JXP	DI	DMM2JXP
DMM2JXP	DN	VX-787
DMM2JXP	MI	TT62KQV
DMM2JXP	MN	Influenza Polymerase basic protein 2 (Influ PB2)
DMM2JXP	MT	DTT
DMM2JXP	MA	Inhibitor
DMM2JXP	RN	Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014 Aug 14;57(15):6668-78.
DMM2JXP	RU	https://pubmed.ncbi.nlm.nih.gov/25019388

DM1JCW8	DI	DM1JCW8
DM1JCW8	DN	Xaliproden
DM1JCW8	MI	TTSQIFT
DM1JCW8	MN	5-HT 1A receptor (HTR1A)
DM1JCW8	MT	DTT
DM1JCW8	MA	Antagonist
DM1JCW8	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM1JCW8	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMK34MZ	DI	DMK34MZ
DMK34MZ	DN	Xilonix
DMK34MZ	MI	TTPM6HI
DMK34MZ	MN	Interleukin-1 alpha (IL1A)
DMK34MZ	MT	DTT
DMK34MZ	MA	Modulator
DMK34MZ	RN	Clinical pipeline report, company report or official report of xbiotech.
DMK34MZ	RU	http://www.xbiotech.com/clinical/oncology.html

DMJ6F5C	DI	DMJ6F5C
DMJ6F5C	DN	XL019
DMJ6F5C	MI	TTRMX3V
DMJ6F5C	MN	Janus kinase 2 (JAK-2)
DMJ6F5C	MT	DTT
DMJ6F5C	MA	Inhibitor
DMJ6F5C	RN	Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
DMJ6F5C	RU	https://pubmed.ncbi.nlm.nih.gov/19552608

DMOKQV7	DI	DMOKQV7
DMOKQV7	DN	XOMA 052
DMOKQV7	MI	TTRYK0X
DMOKQV7	MN	Interleukin-1 beta (IL1B)
DMOKQV7	MT	DTT
DMOKQV7	RN	Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69.
DMOKQV7	RU	https://pubmed.ncbi.nlm.nih.gov/21154167

DMOLR5W	DI	DMOLR5W
DMOLR5W	DN	Yttrium (90Y) clivatuzumab tetraxetan
DMOLR5W	MI	TTBHFYQ
DMOLR5W	MN	Mucin-1 (MUC1)
DMOLR5W	MT	DTT
DMOLR5W	RN	Clinical pipeline report, company report or official report of Immunomedics.
DMOLR5W	RU	http://www.immunomedics.com/clivatuzumab-demo.shtml

DMEY1F3	DI	DMEY1F3
DMEY1F3	DN	Zabofloxacin
DMEY1F3	MI	TTN6J5F
DMEY1F3	MN	Bacterial DNA gyrase (Bact gyrase)
DMEY1F3	MT	DTT
DMEY1F3	MA	Modulator
DMEY1F3	RN	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
DMEY1F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/20403681

DMEY1F3	DI	DMEY1F3
DMEY1F3	DN	Zabofloxacin
DMEY1F3	MI	TTIXTO3
DMEY1F3	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMEY1F3	MT	DTT
DMEY1F3	MA	Modulator
DMEY1F3	RN	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
DMEY1F3	RU	https://www.ncbi.nlm.nih.gov/pubmed/20403681

DM52QEZ	DI	DM52QEZ
DM52QEZ	DN	Zalutumumab
DM52QEZ	MI	TTGKNB4
DM52QEZ	MN	Epidermal growth factor receptor (EGFR)
DM52QEZ	MT	DTT
DM52QEZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DM52QEZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMKB4ZY	DI	DMKB4ZY
DMKB4ZY	DN	Zanolimumab
DMKB4ZY	MI	TTN2JFW
DMKB4ZY	MN	T-cell surface glycoprotein CD4 (CD4)
DMKB4ZY	MT	DTT
DMKB4ZY	RN	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
DMKB4ZY	RU	https://pubmed.ncbi.nlm.nih.gov/17311990

DM9HUYP	DI	DM9HUYP
DM9HUYP	DN	ZANOTERONE
DM9HUYP	MI	TTS64P2
DM9HUYP	MN	Androgen receptor (AR)
DM9HUYP	MT	DTT
DM9HUYP	MA	Inhibitor
DM9HUYP	RN	Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70.
DM9HUYP	RU	https://pubmed.ncbi.nlm.nih.gov/1588549

DMF30HL	DI	DMF30HL
DMF30HL	DN	Zarnestra
DMF30HL	MI	TTXQKM3
DMF30HL	MN	Farnesyl protein transferase (Ftase)
DMF30HL	MT	DTT
DMF30HL	MA	Modulator
DMF30HL	RN	Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500.
DMF30HL	RU	https://www.ncbi.nlm.nih.gov/pubmed/19707379

DMF30HL	DI	DMF30HL
DMF30HL	DN	Zarnestra
DMF30HL	MI	TTIKWV4
DMF30HL	MN	Geranyltranstransferase (FDPS)
DMF30HL	MT	DTT
DMF30HL	MA	Inhibitor
DMF30HL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF30HL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWDEFC	DI	DMWDEFC
DMWDEFC	DN	Zatosetron maleate
DMWDEFC	MI	TTNXLKE
DMWDEFC	MN	5-HT 3 receptor (5HT3R)
DMWDEFC	MT	DTT
DMWDEFC	MA	Modulator
DMWDEFC	RN	Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31.
DMWDEFC	RU	https://www.ncbi.nlm.nih.gov/pubmed/10211913

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTJQOD7
DMP8ESD	MN	5-HT 2A receptor (HTR2A)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTZFYLI
DMP8ESD	MN	Dopamine D1 receptor (D1R)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DMP8ESD	DI	DMP8ESD
DMP8ESD	DN	Zicronapine
DMP8ESD	MI	TTEX248
DMP8ESD	MN	Dopamine D2 receptor (D2R)
DMP8ESD	MT	DTT
DMP8ESD	MA	Modulator
DMP8ESD	RN	Clinical pipeline report, company report or official report of Lundbeck.
DMP8ESD	RU	http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605

DM09TVB	DI	DM09TVB
DM09TVB	DN	Zimura
DM09TVB	MI	TTKANGO
DM09TVB	MN	Complement C5 (CO5)
DM09TVB	MT	DTT
DM09TVB	MA	Inhibitor
DM09TVB	RN	C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586.
DM09TVB	RU	https://pubmed.ncbi.nlm.nih.gov/32882310

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TT1MPAY
DMFWMKZ	MN	GABA(A) receptor alpha-1 (GABRA1)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TTZA1NY
DMFWMKZ	MN	GABA(A) receptor beta-2 (GABRB2)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TT06RH5
DMFWMKZ	MN	GABA(A) receptor gamma-2 (GABRG2)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DMFWMKZ	DI	DMFWMKZ
DMFWMKZ	DN	ZK-93423
DMFWMKZ	MI	TTNJYV2
DMFWMKZ	MN	Gamma-aminobutyric acid receptor (GAR)
DMFWMKZ	MT	DTT
DMFWMKZ	MA	Inhibitor
DMFWMKZ	RN	Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
DMFWMKZ	RU	https://pubmed.ncbi.nlm.nih.gov/1968513

DM5ST9Z	DI	DM5ST9Z
DM5ST9Z	DN	Zolbetuximab
DM5ST9Z	MI	TT6PKBX
DM5ST9Z	MN	Claudin-18 (CLDN18)
DM5ST9Z	MT	DTT
DM5ST9Z	RN	FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.
DM5ST9Z	RU	https://pubmed.ncbi.nlm.nih.gov/33610734

DM8L7JD	DI	DM8L7JD
DM8L7JD	DN	Zoniporide hydrochloride
DM8L7JD	MI	TTGSEFH
DM8L7JD	MN	Sodium/hydrogen exchanger 1 (SLC9A1)
DM8L7JD	MT	DTT
DM8L7JD	MA	Inhibitor
DM8L7JD	RN	Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32.
DM8L7JD	RU	https://pubmed.ncbi.nlm.nih.gov/12595915

DMMBJYC	DI	DMMBJYC
DMMBJYC	DN	ZYH-1
DMMBJYC	MI	TTJ584C
DMMBJYC	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMMBJYC	MT	DTT
DMMBJYC	MA	Modulator
DMMBJYC	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DMMBJYC	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DMMBJYC	DI	DMMBJYC
DMMBJYC	DN	ZYH-1
DMMBJYC	MI	TTZMAO3
DMMBJYC	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMBJYC	MT	DTT
DMMBJYC	MA	Modulator
DMMBJYC	RN	Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
DMMBJYC	RU	https://pubmed.ncbi.nlm.nih.gov/24062180

DM12UX6	DI	DM12UX6
DM12UX6	DN	131 I-omburtamab
DM12UX6	MI	TT6CQUM
DM12UX6	MN	B7 homolog 3 (CD276)
DM12UX6	MT	DTT
DM12UX6	MA	Inhibitor
DM12UX6	RN	IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
DM12UX6	RU	https://pubmed.ncbi.nlm.nih.gov/33047248

DMZ0T24	DI	DMZ0T24
DMZ0T24	DN	Abagovomab
DMZ0T24	MI	TTC1PS3
DMZ0T24	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMZ0T24	MT	DTT
DMZ0T24	RN	Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62.
DMZ0T24	RU	https://pubmed.ncbi.nlm.nih.gov/21322756

DMKY9GI	DI	DMKY9GI
DMKY9GI	DN	Activated recombinant FVII-albumin fusion protein
DMKY9GI	MI	TTF0EGX
DMKY9GI	MN	Coagulation factor VII (F7)
DMKY9GI	MT	DTT
DMKY9GI	MA	Modulator
DMKY9GI	RN	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
DMKY9GI	RU	https://clinicaltrials.gov/ct2/show/NCT01542619

DMKY9GI	DI	DMKY9GI
DMKY9GI	DN	Activated recombinant FVII-albumin fusion protein
DMKY9GI	MI	TTFNGC9
DMKY9GI	MN	Serum albumin (ALB)
DMKY9GI	MT	DTT
DMKY9GI	MA	Modulator
DMKY9GI	RN	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
DMKY9GI	RU	https://clinicaltrials.gov/ct2/show/NCT01542619

DM6GTMD	DI	DM6GTMD
DM6GTMD	DN	ADX-48621
DM6GTMD	MI	TTHS256
DM6GTMD	MN	Metabotropic glutamate receptor 5 (mGluR5)
DM6GTMD	MT	DTT
DM6GTMD	MA	Modulator
DM6GTMD	RN	Pipeline of Addex Pharma. Addex Pharma. 2009.
DM6GTMD	RU	http://www.addexpharma.com/pipeline-old/adx48621/

DMMHSLC	DI	DMMHSLC
DMMHSLC	DN	Afq056
DMMHSLC	MI	DE6OQ3W
DMMHSLC	MN	Cytochrome P450 1A1 (CYP1A1)
DMMHSLC	MT	DME
DMMHSLC	MA	Metabolism
DMMHSLC	RN	Methods to Assess Pulmonary Metabolism.
DMMHSLC	RU	https://edoc.unibas.ch/69409/1/110219_Doctoral_Thesis_Yildiz_Yilmaz.pdf

DMMHSLC	DI	DMMHSLC
DMMHSLC	DN	Afq056
DMMHSLC	MI	TTHS256
DMMHSLC	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMMHSLC	MT	DTT
DMMHSLC	MA	Modulator
DMMHSLC	RN	Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41.
DMMHSLC	RU	https://pubmed.ncbi.nlm.nih.gov/23775850

DMGC970	DI	DMGC970
DMGC970	DN	AG-013
DMGC970	MI	TTNOJIZ
DMGC970	MN	Trefoil factor-1 (TFF1)
DMGC970	MT	DTT
DMGC970	MA	Modulator
DMGC970	RN	AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70.
DMGC970	RU	https://pubmed.ncbi.nlm.nih.gov/20542722

DMD741P	DI	DMD741P
DMD741P	DN	Alagebrium chloride
DMD741P	MI	TTMO9HF
DMD741P	MN	Advanced glycosylation end product receptor (AGER)
DMD741P	MT	DTT
DMD741P	MA	Breaker
DMD741P	RN	Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
DMD741P	RU	https://pubmed.ncbi.nlm.nih.gov/20126491

DM36HBS	DI	DM36HBS
DM36HBS	DN	ALXN1101
DM36HBS	MI	TTH13AB
DM36HBS	MN	Cyclic pyranopterin monophosphate synthase (MOCS1)
DM36HBS	MT	DTT
DM36HBS	MA	Modulator
DM36HBS	RN	ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health.
DM36HBS	RU	https://clinicaltrials.gov/ct2/show/NCT02047461

DMBFOAZ	DI	DMBFOAZ
DMBFOAZ	DN	AMG520
DMBFOAZ	MI	TTJUNZF
DMBFOAZ	MN	Beta-secretase 1 (BACE1)
DMBFOAZ	MT	DTT
DMBFOAZ	MA	Inhibitor
DMBFOAZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBFOAZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMN6F1W	DI	DMN6F1W
DMN6F1W	DN	Amiodarone
DMN6F1W	MI	TTHQJ2Y
DMN6F1W	MN	HUMAN two pore channel subtype 2 (TPC2)
DMN6F1W	MT	DTT
DMN6F1W	MA	Blocker
DMN6F1W	RN	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
DMN6F1W	RU	https://pubmed.ncbi.nlm.nih.gov/32221306

DMJRU3A	DI	DMJRU3A
DMJRU3A	DN	AMO-02
DMJRU3A	MI	TTRSMW9
DMJRU3A	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMJRU3A	MT	DTT
DMJRU3A	MA	Inhibitor
DMJRU3A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJRU3A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDLGRO	DI	DMDLGRO
DMDLGRO	DN	Aramchol
DMDLGRO	MI	TT6RIOV
DMDLGRO	MN	Acyl-CoA desaturase (SCD)
DMDLGRO	MT	DTT
DMDLGRO	MA	Inhibitor
DMDLGRO	RN	The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1.
DMDLGRO	RU	https://pubmed.ncbi.nlm.nih.gov/24815326

DMS8QF9	DI	DMS8QF9
DMS8QF9	DN	Arimoclomol
DMS8QF9	MI	TTG91S4
DMS8QF9	MN	Heat shock protein (HSP)
DMS8QF9	MT	DTT
DMS8QF9	MA	Modulator
DMS8QF9	RN	Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96.
DMS8QF9	RU	https://pubmed.ncbi.nlm.nih.gov/20582873

DM15VBJ	DI	DM15VBJ
DM15VBJ	DN	Artemisone
DM15VBJ	MI	TT9X7H4
DM15VBJ	MN	Beta-hematin formation (BHF)
DM15VBJ	MT	DTT
DM15VBJ	MA	Modulator
DM15VBJ	RN	Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS One. 2013; 8(12): e82962.
DM15VBJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877007/

DMZGKXW	DI	DMZGKXW
DMZGKXW	DN	Atogepant
DMZGKXW	MI	TTQ4ESF
DMZGKXW	MN	Calgranulin D (S100A12)
DMZGKXW	MT	DTT
DMZGKXW	MA	Antagonist
DMZGKXW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZGKXW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMVB4OS	DI	DMVB4OS
DMVB4OS	DN	AVN 211
DMVB4OS	MI	TTJS8PY
DMVB4OS	MN	5-HT 6 receptor (HTR6)
DMVB4OS	MT	DTT
DMVB4OS	MA	Modulator
DMVB4OS	RN	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
DMVB4OS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/

DM5YHU2	DI	DM5YHU2
DM5YHU2	DN	Avoralstat
DM5YHU2	MI	TTDJ4MY
DM5YHU2	MN	Kininogen (KNG1)
DM5YHU2	MT	DTT
DM5YHU2	MA	Inhibitor
DM5YHU2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5YHU2	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM5YHU2	DI	DM5YHU2
DM5YHU2	DN	Avoralstat
DM5YHU2	MI	TTJLNAW
DM5YHU2	MN	Tissue kallikrein (KLK2)
DM5YHU2	MT	DTT
DM5YHU2	MA	Inhibitor
DM5YHU2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5YHU2	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMJQHXD	DI	DMJQHXD
DMJQHXD	DN	AZD3293
DMJQHXD	MI	TT8JRS7
DMJQHXD	MN	Beta-secretase (BACE)
DMJQHXD	MT	DTT
DMJQHXD	MA	Modulator
DMJQHXD	RN	AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
DMJQHXD	RU	http://www.neurobiologyofaging.org/article/S0197-4580(08)00131-0/abstract

DM3827C	DI	DM3827C
DM3827C	DN	AZD4547
DM3827C	MI	TT0LF7H
DM3827C	MN	Fibroblast growth factor receptor (FGFR)
DM3827C	MT	DTT
DM3827C	MA	Inhibitor
DM3827C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3827C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3827C	DI	DM3827C
DM3827C	DN	AZD4547
DM3827C	MI	TTRLW2X
DM3827C	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM3827C	MT	DTT
DM3827C	MA	Modulator
DM3827C	RN	AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56.
DM3827C	RU	https://pubmed.ncbi.nlm.nih.gov/22369928

DMHWE5R	DI	DMHWE5R
DMHWE5R	DN	Batabulin
DMHWE5R	MI	TTYFKSZ
DMHWE5R	MN	Tubulin beta (TUBB)
DMHWE5R	MT	DTT
DMHWE5R	MA	Inhibitor
DMHWE5R	RN	Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
DMHWE5R	RU	https://pubmed.ncbi.nlm.nih.gov/11606124

DMKT16N	DI	DMKT16N
DMKT16N	DN	Bevacizumab
DMKT16N	MI	TT140V6
DMKT16N	MN	HUMAN vascular endothelial growth factor (VEGF)
DMKT16N	MT	DTT
DMKT16N	MA	Inhibitor
DMKT16N	RN	ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
DMKT16N	RU	https://clinicaltrials.gov/ct2/show/NCT04275414

DMUSJ3D	DI	DMUSJ3D
DMUSJ3D	DN	BIIB-088
DMUSJ3D	MI	TTHBDA9
DMUSJ3D	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DMUSJ3D	MT	DTT
DMUSJ3D	RN	ClinicalTrials.gov (NCT04850118) A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
DMUSJ3D	RU	https://clinicaltrials.gov/ct2/show/NCT04850118

DMYFQJL	DI	DMYFQJL
DMYFQJL	DN	BNV-222
DMYFQJL	MI	TTFBNVI
DMYFQJL	MN	Aldose reductase (AKR1B1)
DMYFQJL	MT	DTT
DMYFQJL	MA	Inhibitor
DMYFQJL	RN	ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
DMYFQJL	RU	https://clinicaltrials.gov/ct2/show/NCT02332005

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	TTR6W5O
DMV52CP	MN	Adrenergic receptor beta-1 (ADRB1)
DMV52CP	MT	DTT
DMV52CP	MA	Modulator
DMV52CP	RN	Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/2412063

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	TT2CJVK
DMV52CP	MN	Adrenergic receptor beta-2 (ADRB2)
DMV52CP	MT	DTT
DMV52CP	MA	Modulator
DMV52CP	RN	Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/2412063

DMV52CP	DI	DMV52CP
DMV52CP	DN	Bucindolol
DMV52CP	MI	DECB0K3
DMV52CP	MN	Cytochrome P450 2D6 (CYP2D6)
DMV52CP	MT	DME
DMV52CP	MA	Metabolism
DMV52CP	RN	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
DMV52CP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712

DM31VZT	DI	DM31VZT
DM31VZT	DN	CAD-106
DM31VZT	MI	TTE4KHA
DM31VZT	MN	Amyloid beta A4 protein (APP)
DM31VZT	MT	DTT
DM31VZT	RN	The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.
DM31VZT	RU	https://pubmed.ncbi.nlm.nih.gov/21697382

DMVLXMG	DI	DMVLXMG
DMVLXMG	DN	Camostat mesylate
DMVLXMG	MI	TT3FDB1
DMVLXMG	MN	HUMAN transmembrane protease serine 2 (TMPRSS2)
DMVLXMG	MT	DTT
DMVLXMG	MA	Inhibitor
DMVLXMG	RN	SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
DMVLXMG	RU	https://pubmed.ncbi.nlm.nih.gov/32142651

DMST3FM	DI	DMST3FM
DMST3FM	DN	CART-19
DMST3FM	MI	TTW640A
DMST3FM	MN	B-lymphocyte surface antigen B4 (CD19)
DMST3FM	MT	DTT
DMST3FM	MA	CAR-T-Cell-Therapy
DMST3FM	RN	ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
DMST3FM	RU	https://clinicaltrials.gov/ct2/show/NCT03027739

DM45Z3P	DI	DM45Z3P
DM45Z3P	DN	CD123/CLL1 CAR-T Cells
DM45Z3P	MI	TTENHJ0
DM45Z3P	MN	Interleukin 3 receptor alpha (IL3RA)
DM45Z3P	MT	DTT
DM45Z3P	MA	CAR-T-Cell-Therapy(Dual specific)
DM45Z3P	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DM45Z3P	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DM45Z3P	DI	DM45Z3P
DM45Z3P	DN	CD123/CLL1 CAR-T Cells
DM45Z3P	MI	TT70N8V
DM45Z3P	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM45Z3P	MT	DTT
DM45Z3P	MA	CAR-T-Cell-Therapy(Dual specific)
DM45Z3P	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DM45Z3P	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DM32148	DI	DM32148
DM32148	DN	CD19 CAR T cells
DM32148	MI	TTW640A
DM32148	MN	B-lymphocyte surface antigen B4 (CD19)
DM32148	MT	DTT
DM32148	MA	CAR-T-Cell-Therapy
DM32148	RN	ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
DM32148	RU	https://clinicaltrials.gov/ct2/show/NCT03391726

DMFCLT6	DI	DMFCLT6
DMFCLT6	DN	CE-224535
DMFCLT6	MI	TT473XN
DMFCLT6	MN	P2X purinoceptor 7 (P2RX7)
DMFCLT6	MT	DTT
DMFCLT6	MA	Antagonist
DMFCLT6	RN	Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7.
DMFCLT6	RU	https://pubmed.ncbi.nlm.nih.gov/22382341

DMXCD69	DI	DMXCD69
DMXCD69	DN	CEP1347
DMXCD69	MI	TTUNSIX
DMXCD69	MN	Mixed lineage kinase 1 (MAP3K9)
DMXCD69	MT	DTT
DMXCD69	MA	Inhibitor
DMXCD69	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMXCD69	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMUOMBZ	DI	DMUOMBZ
DMUOMBZ	DN	CLL1 CAR-T Cell
DMUOMBZ	MI	TT70N8V
DMUOMBZ	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMUOMBZ	MT	DTT
DMUOMBZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMUOMBZ	RN	ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
DMUOMBZ	RU	https://clinicaltrials.gov/ct2/show/NCT03631576

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	TTFBNVI
DMX9V8K	MN	Aldose reductase (AKR1B1)
DMX9V8K	MT	DTT
DMX9V8K	MA	Inhibitor
DMX9V8K	RN	Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/8699190

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	TTL69WB
DMX9V8K	MN	Angiotensin-converting enzyme (ACE)
DMX9V8K	MT	DTT
DMX9V8K	MA	Inhibitor
DMX9V8K	RN	Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/3430165

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DEXLYGD
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DEZXOEW
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMX9V8K	DI	DMX9V8K
DMX9V8K	DN	Contigoside B
DMX9V8K	MI	DE4WCJL
DMX9V8K	MN	Beta-glucosidase (bglA)
DMX9V8K	MT	DME
DMX9V8K	MA	Metabolism
DMX9V8K	RN	Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:95-100.
DMX9V8K	RU	https://pubmed.ncbi.nlm.nih.gov/22583754

DMJYTUQ	DI	DMJYTUQ
DMJYTUQ	DN	CR-845
DMJYTUQ	MI	TTQW87Y
DMJYTUQ	MN	Opioid receptor kappa (OPRK1)
DMJYTUQ	MT	DTT
DMJYTUQ	MA	Agonist
DMJYTUQ	RN	Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
DMJYTUQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691465/

DMSR7D2	DI	DMSR7D2
DMSR7D2	DN	CX-516
DMSR7D2	MI	TTAN6JD
DMSR7D2	MN	Glutamate receptor AMPA (GRIA)
DMSR7D2	MT	DTT
DMSR7D2	MA	Modulator
DMSR7D2	RN	Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36.
DMSR7D2	RU	https://pubmed.ncbi.nlm.nih.gov/16083327

DML906E	DI	DML906E
DML906E	DN	CY-1503
DML906E	MI	TTAU4D6
DML906E	MN	E-selectin (SELE)
DML906E	MT	DTT
DML906E	MA	Modulator
DML906E	RN	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
DML906E	RU	https://pubmed.ncbi.nlm.nih.gov/7543381

DML906E	DI	DML906E
DML906E	DN	CY-1503
DML906E	MI	TTE5VG0
DML906E	MN	P-selectin (SELP)
DML906E	MT	DTT
DML906E	MA	Modulator
DML906E	RN	Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
DML906E	RU	https://pubmed.ncbi.nlm.nih.gov/7543381

DMYVKM5	DI	DMYVKM5
DMYVKM5	DN	Darbufelone
DMYVKM5	MI	TT2J34L
DMYVKM5	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMYVKM5	MT	DTT
DMYVKM5	MA	Modulator
DMYVKM5	RN	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
DMYVKM5	RU	https://pubmed.ncbi.nlm.nih.gov/23517721

DMYVKM5	DI	DMYVKM5
DMYVKM5	DN	Darbufelone
DMYVKM5	MI	TTVKILB
DMYVKM5	MN	Prostaglandin G/H synthase 2 (COX-2)
DMYVKM5	MT	DTT
DMYVKM5	MA	Modulator
DMYVKM5	RN	Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
DMYVKM5	RU	https://pubmed.ncbi.nlm.nih.gov/23517721

DMZV3SY	DI	DMZV3SY
DMZV3SY	DN	Denagliptin
DMZV3SY	MI	TTDIGC1
DMZV3SY	MN	Dipeptidyl peptidase 4 (DPP-4)
DMZV3SY	MT	DTT
DMZV3SY	MA	Inhibitor
DMZV3SY	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMZV3SY	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMVSIN2	DI	DMVSIN2
DMVSIN2	DN	Emapalumab
DMVSIN2	MI	TTR10KI
DMVSIN2	MN	HUMAN interferon gamma (IFNG)
DMVSIN2	MT	DTT
DMVSIN2	MA	Inhibitor
DMVSIN2	RN	Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
DMVSIN2	RU	https://pubmed.ncbi.nlm.nih.gov/15476870

DMH8VMP	DI	DMH8VMP
DMH8VMP	DN	Emixustat
DMH8VMP	MI	TTBOH16
DMH8VMP	MN	Retinal pigment epithelium protein (RPE65)
DMH8VMP	MT	DTT
DMH8VMP	MA	Inhibitor
DMH8VMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH8VMP	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEJGDUW
DMOYE70	MN	Cytochrome P450 1A2 (CYP1A2)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEPKLMQ
DMOYE70	MN	Cytochrome P450 2B6 (CYP2B6)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DECB0K3
DMOYE70	MN	Cytochrome P450 2D6 (CYP2D6)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DE4LYSA
DMOYE70	MN	Cytochrome P450 3A4 (CYP3A4)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEIBDNY
DMOYE70	MN	Cytochrome P450 3A5 (CYP3A5)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMOYE70	DI	DMOYE70
DMOYE70	DN	Fexinidazole
DMOYE70	MI	DEGTFWK
DMOYE70	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMOYE70	MT	DME
DMOYE70	MA	Metabolism
DMOYE70	RN	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
DMOYE70	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21200426

DMH7CSQ	DI	DMH7CSQ
DMH7CSQ	DN	Gavilimomab
DMH7CSQ	MI	TT5UJWD
DMH7CSQ	MN	Basigin (BSG)
DMH7CSQ	MT	DTT
DMH7CSQ	RN	National Cancer Institute Drug Dictionary (drug id 38221).
DMH7CSQ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38221

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DTI7UX6
DM0JETC	MN	Breast cancer resistance protein (ABCG2)
DM0JETC	MT	DTP
DM0JETC	MA	Substrate
DM0JETC	RN	Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97.
DM0JETC	RU	https://doi.org/10.1002/jps.23069

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DEJGDUW
DM0JETC	MN	Cytochrome P450 1A2 (CYP1A2)
DM0JETC	MT	DME
DM0JETC	MA	Metabolism
DM0JETC	RN	Differential mechanisms for the inhibition of human cytochrome P450 1A2 by apigenin and genistein. J Biochem Mol Toxicol. 2010 Jul-Aug;24(4):230-4.
DM0JETC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20806393

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	TTOM3J0
DM0JETC	MN	Estrogen receptor beta (ESR2)
DM0JETC	MT	DTT
DM0JETC	MA	Modulator
DM0JETC	RN	Company report (Axcentua)
DM0JETC	RU	http://axcentua.com/science/genistein/

DM0JETC	DI	DM0JETC
DM0JETC	DN	Genistein
DM0JETC	MI	DE0P6LK
DM0JETC	MN	Sulfotransferase 2A1 (SULT2A1)
DM0JETC	MT	DME
DM0JETC	MA	Metabolism
DM0JETC	RN	Sulfation of environmental estrogens by cytosolic human sulfotransferases. Drug Metab Pharmacokinet. 2002;17(3):221-8.
DM0JETC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15618673

DMW7TZV	DI	DMW7TZV
DMW7TZV	DN	GS-6207
DMW7TZV	MI	TTTWS2G
DMW7TZV	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DMW7TZV	MT	DTT
DMW7TZV	MA	Inhibitor
DMW7TZV	RN	Clinical pipeline report, company report or official report of Gilead Sciences.
DMW7TZV	RU	https://www.gilead.com/science-and-medicine/pipeline

DMMTL7V	DI	DMMTL7V
DMMTL7V	DN	Hemoglobin raffimer
DMMTL7V	MI	TTQO71U
DMMTL7V	MN	Hemoglobin (HB)
DMMTL7V	MT	DTT
DMMTL7V	MA	Modulator
DMMTL7V	RN	Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
DMMTL7V	RU	https://pubmed.ncbi.nlm.nih.gov/15814750

DMPLQ1V	DI	DMPLQ1V
DMPLQ1V	DN	IFX-1
DMPLQ1V	MI	TTRJ91Q
DMPLQ1V	MN	HUMAN complement C5 alpha (C5A)
DMPLQ1V	MT	DTT
DMPLQ1V	MA	Inhibitor
DMPLQ1V	RN	03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology
DMPLQ1V	RU	https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html

DMONWJ4	DI	DMONWJ4
DMONWJ4	DN	Imetelstat
DMONWJ4	MI	TTUJFD0
DMONWJ4	MN	Telomerase reverse transcriptase (TERT)
DMONWJ4	MT	DTT
DMONWJ4	MA	Inhibitor
DMONWJ4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMONWJ4	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMIUA3M	DI	DMIUA3M
DMIUA3M	DN	Imprime PGG
DMIUA3M	MI	TTJGY7A
DMIUA3M	MN	Complement C3 (CO3)
DMIUA3M	MT	DTT
DMIUA3M	MA	Modulator
DMIUA3M	RN	National Cancer Institute Drug Dictionary (drug id 599816).
DMIUA3M	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816

DM5UJ9P	DI	DM5UJ9P
DM5UJ9P	DN	IMU-838
DM5UJ9P	MI	TT3UY29
DM5UJ9P	MN	HUMAN dihydroorotate dehydrogenase (DHODH)
DM5UJ9P	MT	DTT
DM5UJ9P	MA	Inhibitor
DM5UJ9P	RN	IMU-838 Targeting DHODH
DM5UJ9P	RU	https://www.immunic-therapeutics.com/imu838/

DMC3794	DI	DMC3794
DMC3794	DN	Indium-111
DMC3794	MI	TTGKNB4
DMC3794	MN	Epidermal growth factor receptor (EGFR)
DMC3794	MT	DTT
DMC3794	RN	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
DMC3794	RU	https://pubmed.ncbi.nlm.nih.gov/25731184

DMGPJ5U	DI	DMGPJ5U
DMGPJ5U	DN	JNJ-54861911
DMGPJ5U	MI	TT8JRS7
DMGPJ5U	MN	Beta-secretase (BACE)
DMGPJ5U	MT	DTT
DMGPJ5U	MA	Inhibitor
DMGPJ5U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGPJ5U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMBJ4IZ	DI	DMBJ4IZ
DMBJ4IZ	DN	LECOZOTAN HYDROCHLORIDE
DMBJ4IZ	MI	TTSQIFT
DMBJ4IZ	MN	5-HT 1A receptor (HTR1A)
DMBJ4IZ	MT	DTT
DMBJ4IZ	MA	Antagonist
DMBJ4IZ	RN	A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in... Clin Pharmacol Ther. 2008 Jan;83(1):86-96.
DMBJ4IZ	RU	https://pubmed.ncbi.nlm.nih.gov/17507923

DMEUGZL	DI	DMEUGZL
DMEUGZL	DN	Legumain-cleavable doxorubicin prodrugs
DMEUGZL	MI	TTPTWV5
DMEUGZL	MN	Legumain (LGMN)
DMEUGZL	MT	DTT
DMEUGZL	MA	Modulator
DMEUGZL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2380).
DMEUGZL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2380

DM4OYXE	DI	DM4OYXE
DM4OYXE	DN	LIAROZOLE
DM4OYXE	MI	TTSZLWK
DM4OYXE	MN	Aromatase (CYP19A1)
DM4OYXE	MT	DTT
DM4OYXE	MA	Inhibitor
DM4OYXE	RN	Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
DM4OYXE	RU	https://pubmed.ncbi.nlm.nih.gov/20413308

DM4OYXE	DI	DM4OYXE
DM4OYXE	DN	LIAROZOLE
DM4OYXE	MI	TTD7Q0R
DM4OYXE	MN	Cytochrome P450 26 (CYP26A1)
DM4OYXE	MT	DTT
DM4OYXE	MA	Inhibitor
DM4OYXE	RN	Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
DM4OYXE	RU	https://pubmed.ncbi.nlm.nih.gov/18722776

DMI215P	DI	DMI215P
DMI215P	DN	Lopinavir + ritonavir + interferon beta-1b
DMI215P	MI	TTWOH4Q
DMI215P	MN	MERS-CoV 3C-like proteinase (3CLpro)
DMI215P	MT	DTT
DMI215P	MA	Inhibitor
DMI215P	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMI215P	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMP8HW1	DI	DMP8HW1
DMP8HW1	DN	LY2157299
DMP8HW1	MI	TTP4520
DMP8HW1	MN	TGF-beta receptor type I (TGFBR1)
DMP8HW1	MT	DTT
DMP8HW1	MA	Modulator
DMP8HW1	RN	Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
DMP8HW1	RU	https://pubmed.ncbi.nlm.nih.gov/25488804

DMP8HW1	DI	DMP8HW1
DMP8HW1	DN	LY2157299
DMP8HW1	MI	TTR9XHZ
DMP8HW1	MN	Transforming growth factor beta 1 (TGFB1)
DMP8HW1	MT	DTT
DMP8HW1	MA	Inhibitor
DMP8HW1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP8HW1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUQWRD	DI	DMUQWRD
DMUQWRD	DN	LYS-SAF302
DMUQWRD	MI	TTPJ2SH
DMUQWRD	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMUQWRD	MT	DTT
DMUQWRD	MA	Replacement
DMUQWRD	RN	Clinical pipeline report, company report or official report of Lysogene.
DMUQWRD	RU	https://www.lysogene.com/lys-saf302/

DM948AP	DI	DM948AP
DM948AP	DN	MAb114
DM948AP	MI	TT2F0AU
DM948AP	MN	Ebola virus Envelope glycoprotein (EV GP)
DM948AP	MT	DTT
DM948AP	RN	Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598.
DM948AP	RU	https://pubmed.ncbi.nlm.nih.gov/33751449

DMONYS9	DI	DMONYS9
DMONYS9	DN	MBX-102
DMONYS9	MI	TTZMAO3
DMONYS9	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMONYS9	MT	DTT
DMONYS9	MA	Agonist
DMONYS9	RN	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
DMONYS9	RU	https://pubmed.ncbi.nlm.nih.gov/19389808

DMNTCV4	DI	DMNTCV4
DMNTCV4	DN	MBX-8025
DMNTCV4	MI	TT2JWF6
DMNTCV4	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMNTCV4	MT	DTT
DMNTCV4	MA	Agonist
DMNTCV4	RN	ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
DMNTCV4	RU	https://clinicaltrials.gov/ct2/show/NCT00701883

DMBIO6E	DI	DMBIO6E
DMBIO6E	DN	Meclinertant
DMBIO6E	MI	TTTUMEP
DMBIO6E	MN	Neurotensin receptor type 1 (NTSR1)
DMBIO6E	MT	DTT
DMBIO6E	MA	Antagonist
DMBIO6E	RN	Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23.
DMBIO6E	RU	https://pubmed.ncbi.nlm.nih.gov/19118604

DMFE0P1	DI	DMFE0P1
DMFE0P1	DN	Metformin glycinate
DMFE0P1	MI	TTCBFJO
DMFE0P1	MN	Insulin receptor (INSR)
DMFE0P1	MT	DTT
DMFE0P1	MA	Inhibitor
DMFE0P1	RN	Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144.
DMFE0P1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521136/

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTU8W4S
DM752PU	MN	Protein kinase (PK)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM752PU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTNDSF4
DM752PU	MN	Proto-oncogene c-Met (MET)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TT4DXQT
DM752PU	MN	Proto-oncogene c-Ret (RET)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTUTJGQ
DM752PU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DM752PU	DI	DM752PU
DM752PU	DN	MGCD516
DM752PU	MI	TTDCBX5
DM752PU	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM752PU	MT	DTT
DM752PU	MA	Inhibitor
DM752PU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
DM752PU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814

DM2YNMI	DI	DM2YNMI
DM2YNMI	DN	MK-1654
DM2YNMI	MI	TT57ID8
DM2YNMI	MN	Respiratory syncytial virus protein F (RSV F)
DM2YNMI	MT	DTT
DM2YNMI	MA	Inhibitor
DM2YNMI	RN	A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153.
DM2YNMI	RU	https://pubmed.ncbi.nlm.nih.gov/31515478

DMDQOWT	DI	DMDQOWT
DMDQOWT	DN	MOR-208
DMDQOWT	MI	TTW640A
DMDQOWT	MN	B-lymphocyte surface antigen B4 (CD19)
DMDQOWT	MT	DTT
DMDQOWT	RN	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
DMDQOWT	RU	https://pubmed.ncbi.nlm.nih.gov/25301708

DMKMZW2	DI	DMKMZW2
DMKMZW2	DN	MTC-DOX
DMKMZW2	MI	TT0IHXV
DMKMZW2	MN	DNA topoisomerase II (TOP2)
DMKMZW2	MT	DTT
DMKMZW2	MA	Modulator
DMKMZW2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMKMZW2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM16PWF	DI	DM16PWF
DM16PWF	DN	N1-methylnicotinamide
DM16PWF	MI	DTT79CX
DM16PWF	MN	Organic cation transporter 1 (SLC22A1)
DM16PWF	MT	DTP
DM16PWF	MA	Substrate
DM16PWF	RN	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
DM16PWF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9260930

DM8D6O2	DI	DM8D6O2
DM8D6O2	DN	Nafamostat
DM8D6O2	MI	TTZ3COY
DM8D6O2	MN	COVID-19 spike glycoprotein (S)
DM8D6O2	MT	DTT
DM8D6O2	MA	Inhibitor
DM8D6O2	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DM8D6O2	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DM8D6O2	DI	DM8D6O2
DM8D6O2	DN	Nafamostat
DM8D6O2	MI	TT85VHW
DM8D6O2	MN	MERS-CoV spike glycoprotein (S)
DM8D6O2	MT	DTT
DM8D6O2	MA	Inhibitor
DM8D6O2	RN	Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539.
DM8D6O2	RU	https://pubmed.ncbi.nlm.nih.gov/27550352

DMD5AEB	DI	DMD5AEB
DMD5AEB	DN	NAL-GLU
DMD5AEB	MI	TT0ID4A
DMD5AEB	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMD5AEB	MT	DTT
DMD5AEB	RN	The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7.
DMD5AEB	RU	https://pubmed.ncbi.nlm.nih.gov/1750480

DM901ZW	DI	DM901ZW
DM901ZW	DN	Naptumomab estafenatox
DM901ZW	MI	TT70MLA
DM901ZW	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DM901ZW	MT	DTT
DM901ZW	MA	Immunomodulator
DM901ZW	RN	Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
DM901ZW	RU	https://pubmed.ncbi.nlm.nih.gov/24445502

DM3MJUS	DI	DM3MJUS
DM3MJUS	DN	NBTX-001
DM3MJUS	MI	TT9IK2Z
DM3MJUS	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3MJUS	MT	DTT
DM3MJUS	MA	Antagonist
DM3MJUS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3MJUS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM0798Z	DI	DM0798Z
DM0798Z	DN	NLG8189
DM0798Z	MI	TTZJYKH
DM0798Z	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DM0798Z	MT	DTT
DM0798Z	MA	Inhibitor
DM0798Z	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0798Z	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4H78P	DI	DM4H78P
DM4H78P	DN	NT-501
DM4H78P	MI	TTT2F9E
DM4H78P	MN	Ciliary neurotrophic factor receptor alpha (CNTFR)
DM4H78P	MT	DTT
DM4H78P	MA	Modulator
DM4H78P	RN	Clinical pipeline report, company report or official report of Neurotech.
DM4H78P	RU	http://www.neurotechusa.com/cntfrenexus.html

DMT13UA	DI	DMT13UA
DMT13UA	DN	Olokizumab
DMT13UA	MI	TTJH4Y5
DMT13UA	MN	HUMAN interleukin 6 (IL6)
DMT13UA	MT	DTT
DMT13UA	MA	Inhibitor
DMT13UA	RN	Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82.
DMT13UA	RU	https://pubmed.ncbi.nlm.nih.gov/24670876

DMTIESG	DI	DMTIESG
DMTIESG	DN	Omburtamab
DMTIESG	MI	TT6CQUM
DMTIESG	MN	B7 homolog 3 (CD276)
DMTIESG	MT	DTT
DMTIESG	MA	Inhibitor
DMTIESG	RN	Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
DMTIESG	RU	https://pubmed.ncbi.nlm.nih.gov/33533945

DMPDA17	DI	DMPDA17
DMPDA17	DN	Omburtamab I-131
DMPDA17	MI	TT6CQUM
DMPDA17	MN	B7 homolog 3 (CD276)
DMPDA17	MT	DTT
DMPDA17	MA	Inhibitor
DMPDA17	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPDA17	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCA2PJ	DI	DMCA2PJ
DMCA2PJ	DN	ONO-2506
DMCA2PJ	MI	TTMXGCW
DMCA2PJ	MN	Adrenergic receptor beta-3 (ADRB3)
DMCA2PJ	MT	DTT
DMCA2PJ	MA	Agonist
DMCA2PJ	RN	FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
DMCA2PJ	RU	https://pubmed.ncbi.nlm.nih.gov/9195306

DMCA2PJ	DI	DMCA2PJ
DMCA2PJ	DN	ONO-2506
DMCA2PJ	MI	TTQ0V86
DMCA2PJ	MN	S100 calcium-binding protein B (S100B)
DMCA2PJ	MT	DTT
DMCA2PJ	MA	Modulator
DMCA2PJ	RN	Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42.
DMCA2PJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15857298

DMCTRLN	DI	DMCTRLN
DMCTRLN	DN	OT-101
DMCTRLN	MI	TTI0KH6
DMCTRLN	MN	TGF beta-2 messenger RNA (TGFB2 mRNA)
DMCTRLN	MT	DTT
DMCTRLN	MA	Inhibitor
DMCTRLN	RN	Clinical pipeline report, company report or official report of Oncotelic.
DMCTRLN	RU	https://www.oncotelic.com/pipeline/

DMURH4X	DI	DMURH4X
DMURH4X	DN	Oxypurinol
DMURH4X	MI	DT2WLAD
DMURH4X	MN	Urate anion exchanger 1 (SLC22A12)
DMURH4X	MT	DTP
DMURH4X	MA	Substrate
DMURH4X	RN	Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
DMURH4X	RU	http://www.ncbi.nlm.nih.gov/pubmed/16135657

DMURH4X	DI	DMURH4X
DMURH4X	DN	Oxypurinol
DMURH4X	MI	TT7RJY8
DMURH4X	MN	Xanthine dehydrogenase/oxidase (XDH)
DMURH4X	MT	DTT
DMURH4X	MA	Inhibitor
DMURH4X	RN	Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
DMURH4X	RU	https://pubmed.ncbi.nlm.nih.gov/2829916

DM0NZDT	DI	DM0NZDT
DM0NZDT	DN	Pactimibe
DM0NZDT	MI	DECB0K3
DM0NZDT	MN	Cytochrome P450 2D6 (CYP2D6)
DM0NZDT	MT	DME
DM0NZDT	MA	Metabolism
DM0NZDT	RN	Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528. Drug Metab Dispos. 2008 Sep;36(9):1938-43.
DM0NZDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18524873

DM0NZDT	DI	DM0NZDT
DM0NZDT	DN	Pactimibe
DM0NZDT	MI	TTMF541
DM0NZDT	MN	Liver carboxylesterase (CES1)
DM0NZDT	MT	DTT
DM0NZDT	MA	Inhibitor
DM0NZDT	RN	Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33.
DM0NZDT	RU	https://pubmed.ncbi.nlm.nih.gov/18620381

DMRZ1F2	DI	DMRZ1F2
DMRZ1F2	DN	Padsevonil
DMRZ1F2	MI	TTCI43M
DMRZ1F2	MN	GABA(A) receptor (GABAR)
DMRZ1F2	MT	DTT
DMRZ1F2	MA	Inhibitor
DMRZ1F2	RN	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
DMRZ1F2	RU	https://pubmed.ncbi.nlm.nih.gov/31619464

DMRZ1F2	DI	DMRZ1F2
DMRZ1F2	DN	Padsevonil
DMRZ1F2	MI	TTT3P91
DMRZ1F2	MN	Synaptic vesicle glycoprotein 2A (SV2A)
DMRZ1F2	MT	DTT
DMRZ1F2	MA	Inhibitor
DMRZ1F2	RN	Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20.
DMRZ1F2	RU	https://pubmed.ncbi.nlm.nih.gov/31619464

DMHWY2G	DI	DMHWY2G
DMHWY2G	DN	Pagoclone
DMHWY2G	MI	TTEX6LM
DMHWY2G	MN	GABA(A) receptor gamma-3 (GABRG3)
DMHWY2G	MT	DTT
DMHWY2G	MA	Modulator
DMHWY2G	RN	Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73.
DMHWY2G	RU	https://pubmed.ncbi.nlm.nih.gov/16702891

DMBJ15R	DI	DMBJ15R
DMBJ15R	DN	Pexacerfont
DMBJ15R	MI	TT7EFHR
DMBJ15R	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMBJ15R	MT	DTT
DMBJ15R	MA	Antagonist
DMBJ15R	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMBJ15R	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMYKNME	DI	DMYKNME
DMYKNME	DN	PF-06651600
DMYKNME	MI	TTT7PJU
DMYKNME	MN	Janus kinase 3 (JAK-3)
DMYKNME	MT	DTT
DMYKNME	MA	Inhibitor
DMYKNME	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYKNME	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTUNARX
DM1QSM3	MN	Carbonic anhydrase (CA)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTHQPL7
DM1QSM3	MN	Carbonic anhydrase I (CA-I)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTANPDJ
DM1QSM3	MN	Carbonic anhydrase II (CA-II)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTZHA0O
DM1QSM3	MN	Carbonic anhydrase IV (CA-IV)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TT2LVK8
DM1QSM3	MN	Carbonic anhydrase IX (CA-IX)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTSYM0R
DM1QSM3	MN	Carbonic anhydrase XII (CA-XII)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	TTEYTKG
DM1QSM3	MN	Carbonic anhydrase XIV (CA-XIV)
DM1QSM3	MT	DTT
DM1QSM3	MA	Inhibitor
DM1QSM3	RN	Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
DM1QSM3	RU	https://pubmed.ncbi.nlm.nih.gov/20674354

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DEVDYN7
DM1QSM3	MN	Cytochrome P450 2E1 (CYP2E1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DED5AT3
DM1QSM3	MN	Cytochrome P450 2F1 (CYP2F1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite. Toxicol Lett. 2001 Dec 15;125(1-3):117-23.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11701230

DM1QSM3	DI	DM1QSM3
DM1QSM3	DN	Phenol
DM1QSM3	MI	DEYGVN4
DM1QSM3	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM1QSM3	MT	DME
DM1QSM3	MA	Metabolism
DM1QSM3	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DM1QSM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DM1SV8I	DI	DM1SV8I
DM1SV8I	DN	PHN-131
DM1SV8I	MI	TTQW87Y
DM1SV8I	MN	Opioid receptor kappa (OPRK1)
DM1SV8I	MT	DTT
DM1SV8I	MA	Agonist
DM1SV8I	RN	Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
DM1SV8I	RU	https://pubmed.ncbi.nlm.nih.gov/2826773

DMPWH30	DI	DMPWH30
DMPWH30	DN	Pimagedine HCl
DMPWH30	MI	TTF10I9
DMPWH30	MN	Nitric-oxide synthase inducible (NOS2)
DMPWH30	MT	DTT
DMPWH30	MA	Inhibitor
DMPWH30	RN	Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
DMPWH30	RU	https://pubmed.ncbi.nlm.nih.gov/18639532

DM0EFQS	DI	DM0EFQS
DM0EFQS	DN	Plasminogen
DM0EFQS	MI	TTP86E2
DM0EFQS	MN	Plasminogen (PLG)
DM0EFQS	MT	DTT
DM0EFQS	MA	Modulator
DM0EFQS	RN	Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54.
DM0EFQS	RU	https://pubmed.ncbi.nlm.nih.gov/15841308

DMCGK6X	DI	DMCGK6X
DMCGK6X	DN	PRO 140
DMCGK6X	MI	TT2CEJG
DMCGK6X	MN	C-C chemokine receptor type 5 (CCR5)
DMCGK6X	MT	DTT
DMCGK6X	MA	Inhibitor
DMCGK6X	RN	The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
DMCGK6X	RU	https://pubmed.ncbi.nlm.nih.gov/29708899

DMZI4OV	DI	DMZI4OV
DMZI4OV	DN	QLT-091001
DMZI4OV	MI	DES5XRU
DMZI4OV	MN	Cytochrome P450 2C8 (CYP2C8)
DMZI4OV	MT	DME
DMZI4OV	MA	Metabolism
DMZI4OV	RN	Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica. 1999 Mar;29(3):231-41.
DMZI4OV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10219964

DMB8UQ3	DI	DMB8UQ3
DMB8UQ3	DN	Ramatroban
DMB8UQ3	MI	TTQDMX5
DMB8UQ3	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMB8UQ3	MT	DTT
DMB8UQ3	MA	Antagonist
DMB8UQ3	RN	CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
DMB8UQ3	RU	https://pubmed.ncbi.nlm.nih.gov/16256979

DMB8UQ3	DI	DMB8UQ3
DMB8UQ3	DN	Ramatroban
DMB8UQ3	MI	TT2O84V
DMB8UQ3	MN	Thromboxane A2 receptor (TBXA2R)
DMB8UQ3	MT	DTT
DMB8UQ3	MA	Antagonist
DMB8UQ3	RN	Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
DMB8UQ3	RU	https://pubmed.ncbi.nlm.nih.gov/17761352

DM1LFUN	DI	DM1LFUN
DM1LFUN	DN	Ravidasvir
DM1LFUN	MI	TTCJ2X8
DM1LFUN	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM1LFUN	MT	DTT
DM1LFUN	MA	Inhibitor
DM1LFUN	RN	Clinical pipeline report, company report or official report of Presidio Pharmaceuticals.
DM1LFUN	RU	http://www.presidiopharma.com/

DML9FD4	DI	DML9FD4
DML9FD4	DN	Rinfabate
DML9FD4	MI	TTHRID2
DML9FD4	MN	Insulin-like growth factor I receptor (IGF1R)
DML9FD4	MT	DTT
DML9FD4	MA	Modulator
DML9FD4	RN	Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
DML9FD4	RU	https://pubmed.ncbi.nlm.nih.gov/15777106

DMWZ6DK	DI	DMWZ6DK
DMWZ6DK	DN	Roledumab
DMWZ6DK	MI	TTLCKI8
DMWZ6DK	MN	Blood group Rh(D) polypeptide (RHD)
DMWZ6DK	MT	DTT
DMWZ6DK	RN	Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. Vox Sang. 2012 Oct;103(3):213-22.
DMWZ6DK	RU	https://pubmed.ncbi.nlm.nih.gov/22568808

DMNIYSZ	DI	DMNIYSZ
DMNIYSZ	DN	RP101
DMNIYSZ	MI	TTP3QRF
DMNIYSZ	MN	Thymidine kinase 1 (TK1)
DMNIYSZ	MT	DTT
DMNIYSZ	MA	Inhibitor
DMNIYSZ	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMNIYSZ	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMOJLCV	DI	DMOJLCV
DMOJLCV	DN	SAR164877
DMOJLCV	MI	TTDN3LF
DMOJLCV	MN	Nerve growth factor (NGF)
DMOJLCV	MT	DTT
DMOJLCV	MA	Modulator
DMOJLCV	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DMOJLCV	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	TTSQIFT
DMH7IPW	MN	5-HT 1A receptor (HTR1A)
DMH7IPW	MT	DTT
DMH7IPW	MA	Modulator
DMH7IPW	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DEJGDUW
DMH7IPW	MN	Cytochrome P450 1A2 (CYP1A2)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DES5XRU
DMH7IPW	MN	Cytochrome P450 2C8 (CYP2C8)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DE5IED8
DMH7IPW	MN	Cytochrome P450 2C9 (CYP2C9)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	DE4LYSA
DMH7IPW	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7IPW	MT	DME
DMH7IPW	MA	Metabolism
DMH7IPW	RN	In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition. Drug Metab Dispos. 2010 Jun;38(6):905-16.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20219851

DMH7IPW	DI	DMH7IPW
DMH7IPW	DN	Sarizotan
DMH7IPW	MI	TTEX248
DMH7IPW	MN	Dopamine D2 receptor (D2R)
DMH7IPW	MT	DTT
DMH7IPW	MA	Modulator
DMH7IPW	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMH7IPW	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DM31L9K	DI	DM31L9K
DM31L9K	DN	Sepofarsen
DM31L9K	MI	TT3XBOV
DM31L9K	MN	CEP290 messenger RNA (CEP290 mRNA)
DM31L9K	MT	DTT
DM31L9K	MA	Inhibitor
DM31L9K	RN	Clinical pipeline report, company report or official report of ProQR Therapeutics.
DM31L9K	RU	https://www.proqr.com/pipeline

DMTV5XC	DI	DMTV5XC
DMTV5XC	DN	Sitafloxacin
DMTV5XC	MI	DTUGYRD
DMTV5XC	MN	P-glycoprotein 1 (ABCB1)
DMTV5XC	MT	DTP
DMTV5XC	MA	Substrate
DMTV5XC	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMTV5XC	RU	https://doi.org/10.1007/s11095-012-0935-x

DM30JWZ	DI	DM30JWZ
DM30JWZ	DN	SM04554
DM30JWZ	MI	TTFPSHI
DM30JWZ	MN	Wnt signaling pathway (Wnt pathway)
DM30JWZ	MT	DTT
DM30JWZ	MA	Modulator
DM30JWZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM30JWZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMD9ISG	DI	DMD9ISG
DMD9ISG	DN	SM-88
DMD9ISG	MI	TT8E7Z0
DMD9ISG	MN	Free radical (FRD)
DMD9ISG	MT	DTT
DMD9ISG	MA	Stimulator
DMD9ISG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD9ISG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5WQ2U	DI	DM5WQ2U
DM5WQ2U	DN	SR-123781A
DM5WQ2U	MI	TT6L509
DM5WQ2U	MN	Coagulation factor IIa (F2)
DM5WQ2U	MT	DTT
DM5WQ2U	MA	Modulator
DM5WQ2U	RN	SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
DM5WQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/11372679

DM5WQ2U	DI	DM5WQ2U
DM5WQ2U	DN	SR-123781A
DM5WQ2U	MI	TTCIHJA
DM5WQ2U	MN	Coagulation factor Xa (F10)
DM5WQ2U	MT	DTT
DM5WQ2U	MA	Modulator
DM5WQ2U	RN	SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60.
DM5WQ2U	RU	https://pubmed.ncbi.nlm.nih.gov/11372679

DMKGQF0	DI	DMKGQF0
DMKGQF0	DN	Suvodirsen
DMKGQF0	MI	TTWLFXU
DMKGQF0	MN	Dystrophin messenger RNA (DMD mRNA)
DMKGQF0	MT	DTT
DMKGQF0	MA	Inhibitor
DMKGQF0	RN	Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694.
DMKGQF0	RU	https://pubmed.ncbi.nlm.nih.gov/32782413

DMWE3GB	DI	DMWE3GB
DMWE3GB	DN	TG-4010
DMWE3GB	MI	TTF89GD
DMWE3GB	MN	Interleukin-2 (IL2)
DMWE3GB	MT	DTT
DMWE3GB	MA	Modulator
DMWE3GB	RN	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
DMWE3GB	RU	https://pubmed.ncbi.nlm.nih.gov/18594319

DMWE3GB	DI	DMWE3GB
DMWE3GB	DN	TG-4010
DMWE3GB	MI	TTBHFYQ
DMWE3GB	MN	Mucin-1 (MUC1)
DMWE3GB	MT	DTT
DMWE3GB	MA	Modulator
DMWE3GB	RN	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
DMWE3GB	RU	https://pubmed.ncbi.nlm.nih.gov/18594319

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TTQ57WJ
DMVDTR2	MN	Apoptosis regulator BAX (BAX)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TTJGNVC
DMVDTR2	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DMVDTR2	DI	DMVDTR2
DMVDTR2	DN	Thymoquinone
DMVDTR2	MI	TT7SBF5
DMVDTR2	MN	Cellular tumor antigen p53 (TP53)
DMVDTR2	MT	DTT
DMVDTR2	MA	Inhibitor
DMVDTR2	RN	Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
DMVDTR2	RU	https://pubmed.ncbi.nlm.nih.gov/32389641

DM23ARP	DI	DM23ARP
DM23ARP	DN	V-710
DM23ARP	MI	TTE0AHP
DM23ARP	MN	Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB)
DM23ARP	MT	DTT
DM23ARP	RN	Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013 Apr 3;309(13):1368-78.
DM23ARP	RU	https://pubmed.ncbi.nlm.nih.gov/23549582

DMDG8Q3	DI	DMDG8Q3
DMDG8Q3	DN	Varlitinib
DMDG8Q3	MI	TTGKNB4
DMDG8Q3	MN	Epidermal growth factor receptor (EGFR)
DMDG8Q3	MT	DTT
DMDG8Q3	MA	Modulator
DMDG8Q3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDG8Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMDG8Q3	DI	DMDG8Q3
DMDG8Q3	DN	Varlitinib
DMDG8Q3	MI	TT6EO5L
DMDG8Q3	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDG8Q3	MT	DTT
DMDG8Q3	MA	Modulator
DMDG8Q3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDG8Q3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMTROUI	DI	DMTROUI
DMTROUI	DN	Vazegepant
DMTROUI	MI	TT67OLB
DMTROUI	MN	HUMAN calcitonin gene-related peptide type 1 receptor (CALCRL)
DMTROUI	MT	DTT
DMTROUI	MA	Inhibitor
DMTROUI	RN	Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
DMTROUI	RU	https://clinicaltrials.gov/ct2/show/NCT04346615

DMGKRAJ	DI	DMGKRAJ
DMGKRAJ	DN	VB4-845
DMGKRAJ	MI	TTZ8WH4
DMGKRAJ	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMGKRAJ	MT	DTT
DMGKRAJ	RN	A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249.
DMGKRAJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994189/

DM0ASTP	DI	DM0ASTP
DM0ASTP	DN	Verapamil
DM0ASTP	MI	TTHQJ2Y
DM0ASTP	MN	HUMAN two pore channel subtype 2 (TPC2)
DM0ASTP	MT	DTT
DM0ASTP	MA	Blocker
DM0ASTP	RN	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
DM0ASTP	RU	https://pubmed.ncbi.nlm.nih.gov/32221306

DM4WQBO	DI	DM4WQBO
DM4WQBO	DN	VM-1500
DM4WQBO	MI	TT84ETX
DM4WQBO	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4WQBO	MT	DTT
DM4WQBO	MA	Inhibitor
DM4WQBO	RN	127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52.
DM4WQBO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149639/

DM5G1NT	DI	DM5G1NT
DM5G1NT	DN	VX-210
DM5G1NT	MI	TTXEVN8
DM5G1NT	MN	Transforming protein Rho (RHO)
DM5G1NT	MT	DTT
DM5G1NT	MA	Inhibitor
DM5G1NT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5G1NT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2U3MX	DI	DM2U3MX
DM2U3MX	DN	VX-509
DM2U3MX	MI	TTT7PJU
DM2U3MX	MN	Janus kinase 3 (JAK-3)
DM2U3MX	MT	DTT
DM2U3MX	MA	Inhibitor
DM2U3MX	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DM2U3MX	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMHXJ68	DI	DMHXJ68
DMHXJ68	DN	WVE-210201
DMHXJ68	MI	TT48MP6
DMHXJ68	MN	Dystrophin (DMD)
DMHXJ68	MT	DTT
DMHXJ68	MA	Modulator
DMHXJ68	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHXJ68	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM78DOT	DI	DM78DOT
DM78DOT	DN	AllerB
DM78DOT	MI	TT9V5JH
DM78DOT	MN	Phospholipase A2 (PLA2G1B)
DM78DOT	MT	DTT
DM78DOT	MA	Inhibitor
DM78DOT	RN	Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
DM78DOT	RU	https://pubmed.ncbi.nlm.nih.gov/9648701

DMJM9LZ	DI	DMJM9LZ
DMJM9LZ	DN	LB80380
DMJM9LZ	MI	TTS5K1M
DMJM9LZ	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DMJM9LZ	MT	DTT
DMJM9LZ	MA	Inhibitor
DMJM9LZ	RN	2011 Pipeline of LG Life Sciences.
DMJM9LZ	RU	http://www.lgls.com/

DMXB4NL	DI	DMXB4NL
DMXB4NL	DN	MEDI4893
DMXB4NL	MI	TT5FLYB
DMXB4NL	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DMXB4NL	MT	DTT
DMXB4NL	RN	Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.
DMXB4NL	RU	https://pubmed.ncbi.nlm.nih.gov/25210036

DMEARCM	DI	DMEARCM
DMEARCM	DN	OrM3
DMEARCM	MI	TTH18TF
DMEARCM	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMEARCM	MT	DTT
DMEARCM	MA	Antagonist
DMEARCM	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMEARCM	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMOE582	DI	DMOE582
DMOE582	DN	TZP-101
DMOE582	MI	TTWDC17
DMOE582	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMOE582	MT	DTT
DMOE582	MA	Agonist
DMOE582	RN	Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18. 
DMOE582	RU	https://pubmed.ncbi.nlm.nih.gov/19432500

DMUB8WN	DI	DMUB8WN
DMUB8WN	DN	Aerovant
DMUB8WN	MI	TTDWHC3
DMUB8WN	MN	Interleukin 4 receptor alpha (IL4R)
DMUB8WN	MT	DTT
DMUB8WN	MA	Antagonist
DMUB8WN	RN	Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009.
DMUB8WN	RU	http://www.news-medical.net/news/2009/03/03/46411.aspx

DMSC8YW	DI	DMSC8YW
DMSC8YW	DN	ANA773
DMSC8YW	MI	TTRJ1K4
DMSC8YW	MN	Toll-like receptor 7 (TLR7)
DMSC8YW	MT	DTT
DMSC8YW	MA	Agonist
DMSC8YW	RN	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
DMSC8YW	RU	http://www.anadyspharma.com/

DMJBDL0	DI	DMJBDL0
DMJBDL0	DN	BIIB104
DMJBDL0	MI	TTAN6JD
DMJBDL0	MN	Glutamate receptor AMPA (GRIA)
DMJBDL0	MT	DTT
DMJBDL0	MA	Activator
DMJBDL0	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJBDL0	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0TH9A	DI	DM0TH9A
DM0TH9A	DN	Bimosiamose
DM0TH9A	MI	TTAU4D6
DM0TH9A	MN	E-selectin (SELE)
DM0TH9A	MT	DTT
DM0TH9A	MA	Inhibitor
DM0TH9A	RN	Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
DM0TH9A	RU	https://pubmed.ncbi.nlm.nih.gov/18598003

DMR6LXM	DI	DMR6LXM
DMR6LXM	DN	CAP-232
DMR6LXM	MI	TT4LOT8
DMR6LXM	MN	Pyruvate kinase M2 (PKM)
DMR6LXM	MT	DTT
DMR6LXM	MA	Modulator
DMR6LXM	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMR6LXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLQ3PO	DI	DMLQ3PO
DMLQ3PO	DN	INCB13739
DMLQ3PO	MI	TTN7BL9
DMLQ3PO	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMLQ3PO	MT	DTT
DMLQ3PO	MA	Inhibitor
DMLQ3PO	RN	Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008.
DMLQ3PO	RU	http://www.medicalnewstoday.com/articles/110647.php

DMLQ3PO	DI	DMLQ3PO
DMLQ3PO	DN	INCB13739
DMLQ3PO	MI	TTWC6MY
DMLQ3PO	MN	Protein tyrosine phosphatase (PTP)
DMLQ3PO	MT	DTT
DMLQ3PO	MA	Inhibitor
DMLQ3PO	RN	Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9.
DMLQ3PO	RU	https://pubmed.ncbi.nlm.nih.gov/9341756

DMMWC6F	DI	DMMWC6F
DMMWC6F	DN	INCB9471
DMMWC6F	MI	TT2CEJG
DMMWC6F	MN	C-C chemokine receptor type 5 (CCR5)
DMMWC6F	MT	DTT
DMMWC6F	MA	Antagonist
DMMWC6F	RN	Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
DMMWC6F	RU	https://pubmed.ncbi.nlm.nih.gov/17920529

DMYZU6G	DI	DMYZU6G
DMYZU6G	DN	MEM-1003
DMYZU6G	MI	TTXHYV6
DMYZU6G	MN	Voltage-gated L-type calcium channel (L-CaC)
DMYZU6G	MT	DTT
DMYZU6G	MA	Modulator
DMYZU6G	RN	Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
DMYZU6G	RU	https://pubmed.ncbi.nlm.nih.gov/16621170

DMGM1IR	DI	DMGM1IR
DMGM1IR	DN	RhuDex
DMGM1IR	MI	TTFZDNP
DMGM1IR	MN	Activation B7-1 antigen (CD80)
DMGM1IR	MT	DTT
DMGM1IR	MA	Inhibitor
DMGM1IR	RN	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
DMGM1IR	RU	https://pubmed.ncbi.nlm.nih.gov/21447719

DMKJDR6	DI	DMKJDR6
DMKJDR6	DN	VX-702
DMKJDR6	MI	TTQBR95
DMKJDR6	MN	Stress-activated protein kinase 2a (p38 alpha)
DMKJDR6	MT	DTT
DMKJDR6	MA	Modulator
DMKJDR6	RN	Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
DMKJDR6	RU	https://pubmed.ncbi.nlm.nih.gov/19404957

DMAV426	DI	DMAV426
DMAV426	DN	(S)-oxybutynin
DMAV426	MI	TTZ9SOR
DMAV426	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMAV426	MT	DTT
DMAV426	MA	Antagonist
DMAV426	RN	Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7.
DMAV426	RU	https://pubmed.ncbi.nlm.nih.gov/1993995

DMGDOS2	DI	DMGDOS2
DMGDOS2	DN	(Z)-endoxifen
DMGDOS2	MI	DTUGYRD
DMGDOS2	MN	P-glycoprotein 1 (ABCB1)
DMGDOS2	MT	DTP
DMGDOS2	MA	Substrate
DMGDOS2	RN	P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration. J Pharmacol Exp Ther. 2011 Jun;337(3):710-7.
DMGDOS2	RU	https://doi.org/10.1124/jpet.110.178301

DMV86DY	DI	DMV86DY
DMV86DY	DN	[131I]-BC8
DMV86DY	MI	TTUS45N
DMV86DY	MN	Leukocyte common antigen (PTPRC)
DMV86DY	MT	DTT
DMV86DY	RN	Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
DMV86DY	RU	https://pubmed.ncbi.nlm.nih.gov/7849300

DM4VWXI	DI	DM4VWXI
DM4VWXI	DN	[131I]-Metuximab
DM4VWXI	MI	TT5UJWD
DM4VWXI	MN	Basigin (BSG)
DM4VWXI	MT	DTT
DM4VWXI	RN	Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44.
DM4VWXI	RU	https://pubmed.ncbi.nlm.nih.gov/16690431

DMSLMY7	DI	DMSLMY7
DMSLMY7	DN	11C-PBR-28
DMSLMY7	MI	TTPTXIN
DMSLMY7	MN	Translocator protein (TSPO)
DMSLMY7	MT	DTT
DMSLMY7	MA	Binder
DMSLMY7	RN	PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett. 2007 Jan 16;411(3):200-5.
DMSLMY7	RU	https://pubmed.ncbi.nlm.nih.gov/17127001

DMTIED1	DI	DMTIED1
DMTIED1	DN	131I-TM-601
DMTIED1	MI	TTCYAXN
DMTIED1	MN	Chloride channel unspecific (ClC)
DMTIED1	MT	DTT
DMTIED1	MA	Inhibitor
DMTIED1	RN	Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6.
DMTIED1	RU	https://pubmed.ncbi.nlm.nih.gov/15809479

DM4EP6Y	DI	DM4EP6Y
DM4EP6Y	DN	13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y	MI	TT0IHXV
DM4EP6Y	MN	DNA topoisomerase II (TOP2)
DM4EP6Y	MT	DTT
DM4EP6Y	MA	Modulator
DM4EP6Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EP6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM4EP6Y	DI	DM4EP6Y
DM4EP6Y	DN	13-DEOXYADRIAMYCIN HYDROCHLORIDE
DM4EP6Y	MI	TTUTN1I
DM4EP6Y	MN	Human Deoxyribonucleic acid (hDNA)
DM4EP6Y	MT	DTT
DM4EP6Y	MA	Modulator
DM4EP6Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EP6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TT1ZAVI
DMNF38S	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TTPNGDE
DMNF38S	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMNF38S	DI	DMNF38S
DMNF38S	DN	16,16-dimethyl-PGE2
DMNF38S	MI	TT79WV3
DMNF38S	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMNF38S	MT	DTT
DMNF38S	MA	Agonist
DMNF38S	RN	Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
DMNF38S	RU	https://pubmed.ncbi.nlm.nih.gov/9313928

DMT8GVU	DI	DMT8GVU
DMT8GVU	DN	177Lu-DOTATATE
DMT8GVU	MI	TTOMNR9
DMT8GVU	MN	Somatostatin receptor (SSTR)
DMT8GVU	MT	DTT
DMT8GVU	MA	Modulator
DMT8GVU	RN	Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
DMT8GVU	RU	https://pubmed.ncbi.nlm.nih.gov/24632546

DMT8GVU	DI	DMT8GVU
DMT8GVU	DN	177Lu-DOTATATE
DMT8GVU	MI	TTAE1BR
DMT8GVU	MN	Somatostatin receptor type 4 (SSTR4)
DMT8GVU	MT	DTT
DMT8GVU	MA	Inhibitor
DMT8GVU	RN	New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors
DMT8GVU	RU	https://www.cancercommons.org/tag/177lu-dotatate/

DM2TSMD	DI	DM2TSMD
DM2TSMD	DN	177Lu-labelled NeoBOMB1
DM2TSMD	MI	TTC1MVT
DM2TSMD	MN	Gastrin-releasing peptide receptor (GRPR)
DM2TSMD	MT	DTT
DM2TSMD	RN	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
DM2TSMD	RU	https://pubmed.ncbi.nlm.nih.gov/27609789

DM8JVIB	DI	DM8JVIB
DM8JVIB	DN	18F-LMI-1195
DM8JVIB	MI	TTAWNKZ
DM8JVIB	MN	Norepinephrine transporter (NET)
DM8JVIB	MT	DTT
DM8JVIB	MA	Enhancer
DM8JVIB	RN	Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
DM8JVIB	RU	https://pubmed.ncbi.nlm.nih.gov/23670901

DMZWNQF	DI	DMZWNQF
DMZWNQF	DN	2'3'-Dideoxyinosine
DMZWNQF	MI	TTMCF1Y
DMZWNQF	MN	Purine nucleoside phosphorylase (PNP)
DMZWNQF	MT	DTT
DMZWNQF	MA	Inhibitor
DMZWNQF	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMZWNQF	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMBOL4K	DI	DMBOL4K
DMBOL4K	DN	264W94
DMBOL4K	MI	TTPI1M5
DMBOL4K	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMBOL4K	MT	DTT
DMBOL4K	MA	Modulator
DMBOL4K	RN	Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76.
DMBOL4K	RU	https://pubmed.ncbi.nlm.nih.gov/21934041

DMGBPME	DI	DMGBPME
DMGBPME	DN	2-Methoxyestradiol
DMGBPME	MI	DE6OQ3W
DMGBPME	MN	Cytochrome P450 1A1 (CYP1A1)
DMGBPME	MT	DME
DMGBPME	MA	Metabolism
DMGBPME	RN	Role of 2-methoxyestradiol, an Endogenous Estrogen Metabolite, in Health and Disease. Mini Rev Med Chem. 2015;15(5):427-38.
DMGBPME	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25723461

DMGBPME	DI	DMGBPME
DMGBPME	DN	2-Methoxyestradiol
DMGBPME	MI	TTQHWNA
DMGBPME	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DMGBPME	MT	DTT
DMGBPME	MA	Modulator
DMGBPME	RN	2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73.
DMGBPME	RU	https://www.ncbi.nlm.nih.gov/pubmed/15623651

DMX9MSL	DI	DMX9MSL
DMX9MSL	DN	2X-121
DMX9MSL	MI	TTEBCY8
DMX9MSL	MN	Poly [ADP-ribose] polymerase (PARP)
DMX9MSL	MT	DTT
DMX9MSL	MA	Inhibitor
DMX9MSL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX9MSL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX9MSL	DI	DMX9MSL
DMX9MSL	DN	2X-121
DMX9MSL	MI	TTKSAQZ
DMX9MSL	MN	Tankyrase (TNKS)
DMX9MSL	MT	DTT
DMX9MSL	MA	Inhibitor
DMX9MSL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX9MSL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML8M5T	DI	DML8M5T
DML8M5T	DN	3,5-diiodothyropropionic acid
DML8M5T	MI	DE4LYSA
DML8M5T	MN	Cytochrome P450 3A4 (CYP3A4)
DML8M5T	MT	DME
DML8M5T	MA	Metabolism
DML8M5T	RN	Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751.
DML8M5T	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25266247

DMTLR6Y	DI	DMTLR6Y
DMTLR6Y	DN	3K3A-APC
DMTLR6Y	MI	TTZUXYS
DMTLR6Y	MN	Vitamin K-dependent protein C (PROC)
DMTLR6Y	MT	DTT
DMTLR6Y	MA	Modulator
DMTLR6Y	RN	Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22.
DMTLR6Y	RU	https://pubmed.ncbi.nlm.nih.gov/22632606

DMPFVJB	DI	DMPFVJB
DMPFVJB	DN	5-hydroxymethyl-2-furfural
DMPFVJB	MI	TTQO71U
DMPFVJB	MN	Hemoglobin (HB)
DMPFVJB	MT	DTT
DMPFVJB	MA	Modulator
DMPFVJB	RN	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.
DMPFVJB	RU	https://pubmed.ncbi.nlm.nih.gov/15686467

DMHBN8X	DI	DMHBN8X
DMHBN8X	DN	60P002
DMHBN8X	MI	TTQL5VC
DMHBN8X	MN	Platelet-activating factor receptor (PTAFR)
DMHBN8X	MT	DTT
DMHBN8X	MA	Antagonist
DMHBN8X	RN	Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
DMHBN8X	RU	https://60degreespharma.com/research-development/clinical-pipeline/

DMOV0AP	DI	DMOV0AP
DMOV0AP	DN	842166X
DMOV0AP	MI	TTMSFAW
DMOV0AP	MN	Cannabinoid receptor 2 (CB2)
DMOV0AP	MT	DTT
DMOV0AP	MA	Agonist
DMOV0AP	RN	The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
DMOV0AP	RU	https://pubmed.ncbi.nlm.nih.gov/24358778

DML4GU1	DI	DML4GU1
DML4GU1	DN	99mTc-MIP-1404
DML4GU1	MI	TT9G4N0
DML4GU1	MN	Glutamate carboxypeptidase II (GCPII)
DML4GU1	MT	DTT
DML4GU1	MA	Modulator
DML4GU1	RN	99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
DML4GU1	RU	https://pubmed.ncbi.nlm.nih.gov/23733925

DMX2LO3	DI	DMX2LO3
DMX2LO3	DN	99mTc-RP-128
DMX2LO3	MI	TTYG378
DMX2LO3	MN	Tuftsin receptor (TR)
DMX2LO3	MT	DTT
DMX2LO3	MA	Modulator
DMX2LO3	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMX2LO3	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DTI7UX6
DMQXYRG	MN	Breast cancer resistance protein (ABCG2)
DMQXYRG	MT	DTP
DMQXYRG	MA	Substrate
DMQXYRG	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMQXYRG	RU	https://doi.org/10.2217/14622416.9.8.1005

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DE6OQ3W
DMQXYRG	MN	Cytochrome P450 1A1 (CYP1A1)
DMQXYRG	MT	DME
DMQXYRG	MA	Metabolism
DMQXYRG	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DMQXYRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	DE4LYSA
DMQXYRG	MN	Cytochrome P450 3A4 (CYP3A4)
DMQXYRG	MT	DME
DMQXYRG	MA	Metabolism
DMQXYRG	RN	Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
DMQXYRG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24889073

DMQXYRG	DI	DMQXYRG
DMQXYRG	DN	9-AMINOCAMPTOTHECIN
DMQXYRG	MI	TTGTQHC
DMQXYRG	MN	DNA topoisomerase I (TOP1)
DMQXYRG	MT	DTT
DMQXYRG	MA	Inhibitor
DMQXYRG	RN	Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87.
DMQXYRG	RU	https://pubmed.ncbi.nlm.nih.gov/11193893

DM57TY3	DI	DM57TY3
DM57TY3	DN	9-ING-41
DM57TY3	MI	TTRSMW9
DM57TY3	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DM57TY3	MT	DTT
DM57TY3	MA	Inhibitor
DM57TY3	RN	9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
DM57TY3	RU	https://pubmed.ncbi.nlm.nih.gov/31882719

DM6ZIES	DI	DM6ZIES
DM6ZIES	DN	A-6
DM6ZIES	MI	TTWFBT7
DM6ZIES	MN	Extracellular matrix receptor III (CD44)
DM6ZIES	MT	DTT
DM6ZIES	MA	Modulator
DM6ZIES	RN	Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135.
DM6ZIES	RU	https://www.ncbi.nlm.nih.gov/pubmed/25870596

DMHOLB7	DI	DMHOLB7
DMHOLB7	DN	A-85380
DMHOLB7	MI	TTJSZTB
DMHOLB7	MN	Nicotinic acetylcholine receptor (nAChR)
DMHOLB7	MT	DTT
DMHOLB7	MA	Agonist
DMHOLB7	RN	The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
DMHOLB7	RU	https://pubmed.ncbi.nlm.nih.gov/11772288

DMOGDCQ	DI	DMOGDCQ
DMOGDCQ	DN	Ab-01
DMOGDCQ	MI	TTZO9B0
DMOGDCQ	MN	Interleukin 21 receptor (IL21R)
DMOGDCQ	MT	DTT
DMOGDCQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2304).
DMOGDCQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2304

DMEW62S	DI	DMEW62S
DMEW62S	DN	AB-106
DMEW62S	MI	TTSZ6Y3
DMEW62S	MN	Proto-oncogene c-Ros (ROS1)
DMEW62S	MT	DTT
DMEW62S	MA	Inhibitor
DMEW62S	RN	Clinical pipeline report, company report or official report of AnHeart Therapeutics.
DMEW62S	RU	https://anhearttherapeutics.com/pipeline/

DMEW62S	DI	DMEW62S
DMEW62S	DN	AB-106
DMEW62S	MI	TTJOCTY
DMEW62S	MN	Tropomyosin receptor kinase (Trk)
DMEW62S	MT	DTT
DMEW62S	MA	Inhibitor
DMEW62S	RN	Clinical pipeline report, company report or official report of AnHeart Therapeutics.
DMEW62S	RU	https://anhearttherapeutics.com/pipeline/

DM48DPS	DI	DM48DPS
DM48DPS	DN	AB-729
DM48DPS	MI	TT43YWN
DM48DPS	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM48DPS	MT	DTT
DM48DPS	MA	Inhibitor
DM48DPS	RN	Clinical pipeline report, company report or official report of Arbutus Biopharma.
DM48DPS	RU	http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php

DM4ZLTY	DI	DM4ZLTY
DM4ZLTY	DN	ABBV-2222
DM4ZLTY	MI	TTRLZHP
DM4ZLTY	MN	cAMP-dependent chloride channel (CFTR)
DM4ZLTY	MT	DTT
DM4ZLTY	MA	Modulator
DM4ZLTY	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM4ZLTY	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMT6H3J	DI	DMT6H3J
DMT6H3J	DN	AbGn-168
DMT6H3J	MI	TTS5K8U
DMT6H3J	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMT6H3J	MT	DTT
DMT6H3J	RN	Clinical pipeline report, company report or official report of Avarx.
DMT6H3J	RU	http://www.avarx.com/AvaRx/SubDomains/bucket3739906636580370793/Listings/bucket460336945731305549/Public.Listing.display.html

DMQ6KZM	DI	DMQ6KZM
DMQ6KZM	DN	ABI-009
DMQ6KZM	MI	TTCJG29
DMQ6KZM	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMQ6KZM	MT	DTT
DMQ6KZM	MA	Inhibitor
DMQ6KZM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ6KZM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM59OJ2	DI	DM59OJ2
DM59OJ2	DN	Abicipar pegol
DM59OJ2	MI	TTOHSBA
DM59OJ2	MN	Vascular endothelial growth factor A (VEGFA)
DM59OJ2	MT	DTT
DM59OJ2	MA	Inhibitor
DM59OJ2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM59OJ2	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMX1KDM	DI	DMX1KDM
DMX1KDM	DN	ABI-H0731
DMX1KDM	MI	TTM42UJ
DMX1KDM	MN	Hepatitis B virus Capsid protein (HBV C)
DMX1KDM	MT	DTT
DMX1KDM	MA	Inhibitor
DMX1KDM	RN	Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166.
DMX1KDM	RU	https://pubmed.ncbi.nlm.nih.gov/31711752

DM6X70G	DI	DM6X70G
DM6X70G	DN	ABI-H2158
DM6X70G	MI	TTM42UJ
DM6X70G	MN	Hepatitis B virus Capsid protein (HBV C)
DM6X70G	MT	DTT
DM6X70G	MA	Inhibitor
DM6X70G	RN	Clinical pipeline report, company report or official report of Assembly Biosciences.
DM6X70G	RU	https://www.assemblybio.com/pipeline/

DMTCXSG	DI	DMTCXSG
DMTCXSG	DN	Abituzumab
DMTCXSG	MI	TTT1R2L
DMTCXSG	MN	Integrin alpha-V (ITGAV)
DMTCXSG	MT	DTT
DMTCXSG	RN	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
DMTCXSG	RU	https://pubmed.ncbi.nlm.nih.gov/25319061

DM23UQ9	DI	DM23UQ9
DM23UQ9	DN	ABT-122
DM23UQ9	MI	TTG0MT6
DM23UQ9	MN	Interleukin-17 (IL17)
DM23UQ9	MT	DTT
DM23UQ9	MA	Modulator
DM23UQ9	RN	DOI: 10.1136/annrheumdis-2015-eular.4042
DM23UQ9	RU	http://ard.bmj.com/content/74/Suppl_2/479.2.abstract

DM23UQ9	DI	DM23UQ9
DM23UQ9	DN	ABT-122
DM23UQ9	MI	TTF8CQI
DM23UQ9	MN	Tumor necrosis factor (TNF)
DM23UQ9	MT	DTT
DM23UQ9	MA	Modulator
DM23UQ9	RN	DOI: 10.1136/annrheumdis-2015-eular.4042
DM23UQ9	RU	http://ard.bmj.com/content/74/Suppl_2/479.2.abstract

DM2OS51	DI	DM2OS51
DM2OS51	DN	ABT-126
DM2OS51	MI	TTLA931
DM2OS51	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DM2OS51	MT	DTT
DM2OS51	MA	Modulator
DM2OS51	RN	A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
DM2OS51	RU	http://www.sciencedirect.com/science/article/pii/S2352873715000104

DMN3S1B	DI	DMN3S1B
DMN3S1B	DN	ABT-229
DMN3S1B	MI	TTQ6VDM
DMN3S1B	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMN3S1B	MT	DTT
DMN3S1B	MA	Inhibitor
DMN3S1B	RN	9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
DMN3S1B	RU	https://pubmed.ncbi.nlm.nih.gov/20869254

DM7X54F	DI	DM7X54F
DM7X54F	DN	ABT-288
DM7X54F	MI	TT9JNIC
DM7X54F	MN	Histamine H3 receptor (H3R)
DM7X54F	MT	DTT
DM7X54F	MA	Modulator
DM7X54F	RN	A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
DM7X54F	RU	https://www.ncbi.nlm.nih.gov/pubmed/25024314

DM6WN2D	DI	DM6WN2D
DM6WN2D	DN	ABT-308
DM6WN2D	MI	TTMPZ7V
DM6WN2D	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DM6WN2D	MT	DTT
DM6WN2D	MA	Antagonist
DM6WN2D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6WN2D	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TTPS3C0
DMMZOYN	MN	Aurora kinase A (AURKA)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TT5LS6T
DMMZOYN	MN	Aurora kinase B (AURKB)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DMMZOYN	DI	DMMZOYN
DMMZOYN	DN	ABT-348
DMMZOYN	MI	TTLYXIT
DMMZOYN	MN	Aurora kinase C (AURKC)
DMMZOYN	MT	DTT
DMMZOYN	MA	Modulator
DMMZOYN	RN	Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
DMMZOYN	RU	https://pubmed.ncbi.nlm.nih.gov/22935731

DM7XW5Y	DI	DM7XW5Y
DM7XW5Y	DN	ABT-384
DM7XW5Y	MI	DE4LYSA
DM7XW5Y	MN	Cytochrome P450 3A4 (CYP3A4)
DM7XW5Y	MT	DME
DM7XW5Y	MA	Metabolism
DM7XW5Y	RN	Effect of ketoconazole on the pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study. Drug Metab Dispos. 2013 May;41(5):1035-45.
DM7XW5Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23431112

DMGUTPN	DI	DMGUTPN
DMGUTPN	DN	ABT-414
DMGUTPN	MI	TTGKNB4
DMGUTPN	MN	Epidermal growth factor receptor (EGFR)
DMGUTPN	MT	DTT
DMGUTPN	RN	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
DMGUTPN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/

DMNAU1V	DI	DMNAU1V
DMNAU1V	DN	ABT-436
DMNAU1V	MI	TTL9MHW
DMNAU1V	MN	Vasopressin V1b receptor (V1BR)
DMNAU1V	MT	DTT
DMNAU1V	MA	Modulator
DMNAU1V	RN	The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
DMNAU1V	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016603/

DMFW860	DI	DMFW860
DMFW860	DN	ABT-450
DMFW860	MI	TT5FNQT
DMFW860	MN	Human immunodeficiency virus Protease (HIV PR)
DMFW860	MT	DTT
DMFW860	MA	Inhibitor
DMFW860	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DMFW860	RU	http://www.abbott.com/index2.htm

DMPDVM8	DI	DMPDVM8
DMPDVM8	DN	ABT-510
DMPDVM8	MI	TTKI0H1
DMPDVM8	MN	Thrombospondin-1 (THBS1)
DMPDVM8	MT	DTT
DMPDVM8	MA	Modulator
DMPDVM8	RN	A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9.
DMPDVM8	RU	https://pubmed.ncbi.nlm.nih.gov/17551310

DMEWQ4X	DI	DMEWQ4X
DMEWQ4X	DN	ABT-639
DMEWQ4X	MI	TTZPWGN
DMEWQ4X	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMEWQ4X	MT	DTT
DMEWQ4X	MA	Modulator
DMEWQ4X	RN	Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
DMEWQ4X	RU	https://pubmed.ncbi.nlm.nih.gov/26035253

DMLEO2Z	DI	DMLEO2Z
DMLEO2Z	DN	ABT-652
DMLEO2Z	MI	TT9JNIC
DMLEO2Z	MN	Histamine H3 receptor (H3R)
DMLEO2Z	MT	DTT
DMLEO2Z	MA	Modulator
DMLEO2Z	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
DMLEO2Z	RU	http://adisinsight.springer.com/drugs/800032225

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	DED5UR3
DMNG35S	MN	Sulfotransferase 1B1 (SULT1B1)
DMNG35S	MT	DME
DMNG35S	MA	Metabolism
DMNG35S	RN	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23670235

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	TTYFKSZ
DMNG35S	MN	Tubulin beta (TUBB)
DMNG35S	MT	DTT
DMNG35S	MA	Modulator
DMNG35S	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNG35S	DI	DMNG35S
DMNG35S	DN	ABT-751
DMNG35S	MI	DEYGVN4
DMNG35S	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMNG35S	MT	DME
DMNG35S	MA	Metabolism
DMNG35S	RN	Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul;23(7):374-81.
DMNG35S	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23670235

DM6PTIX	DI	DM6PTIX
DM6PTIX	DN	ABT-981
DM6PTIX	MI	TTPM6HI
DM6PTIX	MN	Interleukin-1 alpha (IL1A)
DM6PTIX	MT	DTT
DM6PTIX	MA	Modulator
DM6PTIX	RN	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
DM6PTIX	RU	https://pubmed.ncbi.nlm.nih.gov/25764208

DM6PTIX	DI	DM6PTIX
DM6PTIX	DN	ABT-981
DM6PTIX	MI	TTRYK0X
DM6PTIX	MN	Interleukin-1 beta (IL1B)
DM6PTIX	MT	DTT
DM6PTIX	MA	Modulator
DM6PTIX	RN	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
DM6PTIX	RU	https://pubmed.ncbi.nlm.nih.gov/25764208

DM9Y1XB	DI	DM9Y1XB
DM9Y1XB	DN	ABT-RTA-408
DM9Y1XB	MI	TTA6ZN2
DM9Y1XB	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DM9Y1XB	MT	DTT
DM9Y1XB	MA	Modulator
DM9Y1XB	RN	National Cancer Institute Drug Dictionary (drug id 756624).
DM9Y1XB	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756624

DM91U0R	DI	DM91U0R
DM91U0R	DN	ABX-EGF
DM91U0R	MI	TTGKNB4
DM91U0R	MN	Epidermal growth factor receptor (EGFR)
DM91U0R	MT	DTT
DM91U0R	RN	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
DM91U0R	RU	https://pubmed.ncbi.nlm.nih.gov/11920518

DMCZFMS	DI	DMCZFMS
DMCZFMS	DN	ABX-IL8
DMCZFMS	MI	TTCTE1G
DMCZFMS	MN	Interleukin-8 (IL8)
DMCZFMS	MT	DTT
DMCZFMS	RN	Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34.
DMCZFMS	RU	https://pubmed.ncbi.nlm.nih.gov/12107097

DMNVFZA	DI	DMNVFZA
DMNVFZA	DN	AC-1202
DMNVFZA	MI	TTNHYJL
DMNVFZA	MN	Ketogenesis (KG)
DMNVFZA	MT	DTT
DMNVFZA	MA	Modulator
DMNVFZA	RN	Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31.
DMNVFZA	RU	https://pubmed.ncbi.nlm.nih.gov/19664276

DMB0TNL	DI	DMB0TNL
DMB0TNL	DN	AC-201
DMB0TNL	MI	TTCQIBE
DMB0TNL	MN	Caspase-1 (CASP1)
DMB0TNL	MT	DTT
DMB0TNL	MA	Inhibitor
DMB0TNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0TNL	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB0TNL	DI	DMB0TNL
DMB0TNL	DN	AC-201
DMB0TNL	MI	TTRYK0X
DMB0TNL	MN	Interleukin-1 beta (IL1B)
DMB0TNL	MT	DTT
DMB0TNL	MA	Inhibitor
DMB0TNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0TNL	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3TUBR	DI	DM3TUBR
DM3TUBR	DN	Acalabrutinib
DM3TUBR	MI	TTOWPER
DM3TUBR	MN	HUMAN bruton tyrosine kinase (BTK)
DM3TUBR	MT	DTT
DM3TUBR	MA	Inhibitor
DM3TUBR	RN	AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
DM3TUBR	RU	https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html

DM0FGDO	DI	DM0FGDO
DM0FGDO	DN	ACCLAIM
DM0FGDO	MI	TTCM4B3
DM0FGDO	MN	Nitric-oxide synthase endothelial (NOS3)
DM0FGDO	MT	DTT
DM0FGDO	MA	Stimulator
DM0FGDO	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DM0FGDO	RU	http://www.centerwatch.com/

DMZ8PY0	DI	DMZ8PY0
DMZ8PY0	DN	ACE-031
DMZ8PY0	MI	TTSWPH8
DMZ8PY0	MN	Growth/differentiation factor 8 (GDF-8)
DMZ8PY0	MT	DTT
DMZ8PY0	MA	Inhibitor
DMZ8PY0	RN	A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.
DMZ8PY0	RU	https://pubmed.ncbi.nlm.nih.gov/23169607

DMIVUFL	DI	DMIVUFL
DMIVUFL	DN	ACH-1625
DMIVUFL	MI	TT5FNQT
DMIVUFL	MN	Human immunodeficiency virus Protease (HIV PR)
DMIVUFL	MT	DTT
DMIVUFL	MA	Inhibitor
DMIVUFL	RN	Clinical pipeline report, company report or official report of Achillion (2011).
DMIVUFL	RU	http://www.achillion.com/main.aspx?pn=ProductPipeline&fl=l

DM0RPY5	DI	DM0RPY5
DM0RPY5	DN	ACH-3102
DM0RPY5	MI	TTCJ2X8
DM0RPY5	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM0RPY5	MT	DTT
DM0RPY5	MA	Modulator
DM0RPY5	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0RPY5	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLVCZR	DI	DMLVCZR
DMLVCZR	DN	ACH-4471
DMLVCZR	MI	TT8D13I
DMLVCZR	MN	Complement factor D (CFD)
DMLVCZR	MT	DTT
DMLVCZR	MA	Inhibitor
DMLVCZR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLVCZR	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPR8E9	DI	DMPR8E9
DMPR8E9	DN	ACP-001
DMPR8E9	MI	TTT3YKH
DMPR8E9	MN	Somatotropin (GH1)
DMPR8E9	MT	DTT
DMPR8E9	MA	Modulator
DMPR8E9	RN	ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.
DMPR8E9	RU	https://clinicaltrials.gov/ct2/show/NCT01947907

DMMG61B	DI	DMMG61B
DMMG61B	DN	ACT-GRO-777
DMMG61B	MI	TTCSZH7
DMMG61B	MN	Nucleolin (NCL)
DMMG61B	MT	DTT
DMMG61B	RN	Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890.
DMMG61B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104705/

DMKBIPR	DI	DMKBIPR
DMKBIPR	DN	Actimab-A
DMKBIPR	MI	TTJVYO3
DMKBIPR	MN	Myeloid cell surface antigen CD33 (CD33)
DMKBIPR	MT	DTT
DMKBIPR	MA	Inhibitor
DMKBIPR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKBIPR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9GRTK	DI	DM9GRTK
DM9GRTK	DN	ACYLINE
DM9GRTK	MI	TT8R70G
DM9GRTK	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM9GRTK	MT	DTT
DM9GRTK	MA	Inhibitor
DM9GRTK	RN	Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77.
DM9GRTK	RU	https://pubmed.ncbi.nlm.nih.gov/17402723

DMLV9GS	DI	DMLV9GS
DMLV9GS	DN	AD04
DMLV9GS	MI	TTNXLKE
DMLV9GS	MN	5-HT 3 receptor (5HT3R)
DMLV9GS	MT	DTT
DMLV9GS	MA	Antagonist
DMLV9GS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLV9GS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMMFLXN	DI	DMMFLXN
DMMFLXN	DN	AD-452
DMMFLXN	MI	TTXM6JN
DMMFLXN	MN	Cytokine receptor unspecific (CRF)
DMMFLXN	MT	DTT
DMMFLXN	MA	Modulator
DMMFLXN	RN	Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9.
DMMFLXN	RU	http://www.sciencedirect.com/science/article/pii/S1672293011500017

DM8GHIX	DI	DM8GHIX
DM8GHIX	DN	ADC-3680
DM8GHIX	MI	TTQDMX5
DM8GHIX	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM8GHIX	MT	DTT
DM8GHIX	MA	Antagonist
DM8GHIX	RN	Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
DM8GHIX	RU	https://pubmed.ncbi.nlm.nih.gov/24073896

DM821BS	DI	DM821BS
DM821BS	DN	Adipiplon
DM821BS	MI	TT37EDJ
DM821BS	MN	GABA(A) receptor alpha-3 (GABRA3)
DM821BS	MT	DTT
DM821BS	MA	Modulator
DM821BS	RN	Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
DM821BS	RU	https://pubmed.ncbi.nlm.nih.gov/21762686

DMMUPTN	DI	DMMUPTN
DMMUPTN	DN	ADL-5747
DMMUPTN	MI	TT27RFC
DMMUPTN	MN	Opioid receptor delta (OPRD1)
DMMUPTN	MT	DTT
DMMUPTN	MA	Agonist
DMMUPTN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMMUPTN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DMDQH9A	DI	DMDQH9A
DMDQH9A	DN	ADL-5859
DMDQH9A	MI	TT27RFC
DMDQH9A	MN	Opioid receptor delta (OPRD1)
DMDQH9A	MT	DTT
DMDQH9A	MA	Agonist
DMDQH9A	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
DMDQH9A	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317

DM819CO	DI	DM819CO
DM819CO	DN	ADMVA
DM819CO	MI	TTFBNVI
DM819CO	MN	Aldose reductase (AKR1B1)
DM819CO	MT	DTT
DM819CO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DM819CO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DMJSWXL	DI	DMJSWXL
DMJSWXL	DN	Ad-p53
DMJSWXL	MI	TT7SBF5
DMJSWXL	MN	Cellular tumor antigen p53 (TP53)
DMJSWXL	MT	DTT
DMJSWXL	MA	Modulator
DMJSWXL	RN	Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38.
DMJSWXL	RU	https://pubmed.ncbi.nlm.nih.gov/12637944

DMRYH3M	DI	DMRYH3M
DMRYH3M	DN	ADP-A2M4
DMRYH3M	MI	TT9EQUY
DMRYH3M	MN	Melanoma-associated antigen 4 (MAGEA4)
DMRYH3M	MT	DTT
DMRYH3M	RN	Clinical pipeline report, company report or official report of Adaptimmune.
DMRYH3M	RU	https://www.adaptimmune.com/pipeline/adp-a2m4

DME384W	DI	DME384W
DME384W	DN	AdPEDR
DME384W	MI	TTR59S1
DME384W	MN	Pigment epithelium-derived factor (SERPINF1)
DME384W	MT	DTT
DME384W	MA	Inhibitor
DME384W	RN	Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35.
DME384W	RU	https://pubmed.ncbi.nlm.nih.gov/15757408

DMCNTFW	DI	DMCNTFW
DMCNTFW	DN	Ad-RTS-hIL-12
DMCNTFW	MI	TTG68FB
DMCNTFW	MN	Interleukine 12 (IL-12)
DMCNTFW	MT	DTT
DMCNTFW	MA	Replacement
DMCNTFW	RN	Clinical pipeline report, company report or official report of Ziopharm Oncology.
DMCNTFW	RU	https://ziopharm.com/controlled-il-12/

DMM6B2Y	DI	DMM6B2Y
DMM6B2Y	DN	ADU- S100
DMM6B2Y	MI	TTT402Y
DMM6B2Y	MN	Stimulator of interferon genes protein (TMEM173)
DMM6B2Y	MT	DTT
DMM6B2Y	MA	Agonist
DMM6B2Y	RN	Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5.
DMM6B2Y	RU	https://pubmed.ncbi.nlm.nih.gov/30540940

DM8HBUI	DI	DM8HBUI
DM8HBUI	DN	ADU-S100
DM8HBUI	MI	TTT402Y
DM8HBUI	MN	Stimulator of interferon genes protein (TMEM173)
DM8HBUI	MT	DTT
DM8HBUI	MA	Activator
DM8HBUI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8HBUI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGVKHQ	DI	DMGVKHQ
DMGVKHQ	DN	ADX10059
DMGVKHQ	MI	TTHS256
DMGVKHQ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMGVKHQ	MT	DTT
DMGVKHQ	MA	Modulator
DMGVKHQ	RN	A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9.
DMGVKHQ	RU	https://pubmed.ncbi.nlm.nih.gov/19460767

DMC8NAO	DI	DMC8NAO
DMC8NAO	DN	ADXS-HPV
DMC8NAO	MI	TT3CPZW
DMC8NAO	MN	Human papillomavirus protein E7 (HPV E7)
DMC8NAO	MT	DTT
DMC8NAO	RN	ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231.
DMC8NAO	RU	http://www.immunotherapyofcancer.org/content/1/S1/P231

DMJVN89	DI	DMJVN89
DMJVN89	DN	AEB07
DMJVN89	MI	TTYVX59
DMJVN89	MN	Protein kinase C (PRKC)
DMJVN89	MT	DTT
DMJVN89	MA	Inhibitor
DMJVN89	RN	What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
DMJVN89	RU	https://pubmed.ncbi.nlm.nih.gov/18828764

DMQ1GH4	DI	DMQ1GH4
DMQ1GH4	DN	AEF0117
DMQ1GH4	MI	TT6OEDT
DMQ1GH4	MN	Cannabinoid receptor 1 (CB1)
DMQ1GH4	MT	DTT
DMQ1GH4	MA	Antagonist
DMQ1GH4	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMQ1GH4	RU	https://brain.labex.u-bordeaux.fr/Actions/Focus/CannaPreg-i6901.html

DMSBLOU	DI	DMSBLOU
DMSBLOU	DN	AEG-33773
DMSBLOU	MI	TTHYBIX
DMSBLOU	MN	Heat shock protein 70 (HSP70)
DMSBLOU	MT	DTT
DMSBLOU	MA	Inhibitor
DMSBLOU	RN	Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009
DMSBLOU	RU	http://www.nature.com/scibx/journal/v2/n11/full/scibx.2009.462.html

DMI5TXZ	DI	DMI5TXZ
DMI5TXZ	DN	AEM-28
DMI5TXZ	MI	TTKS9CB
DMI5TXZ	MN	Apolipoprotein E (APOE)
DMI5TXZ	MT	DTT
DMI5TXZ	MA	Modulator
DMI5TXZ	RN	Clinical pipeline report, company report or official report of LipimetiX.
DMI5TXZ	RU	http://www.lipimetix.com/technology.html

DMNO7BC	DI	DMNO7BC
DMNO7BC	DN	AeroLEF
DMNO7BC	MI	TTN4QDT
DMNO7BC	MN	Opioid receptor (OPR)
DMNO7BC	MT	DTT
DMNO7BC	MA	Agonist
DMNO7BC	RN	Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246.
DMNO7BC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371376/

DMFO2G5	DI	DMFO2G5
DMFO2G5	DN	Afabicin
DMFO2G5	MI	TTZBRVL
DMFO2G5	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMFO2G5	MT	DTT
DMFO2G5	MA	Inhibitor
DMFO2G5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFO2G5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	TTZAYWL
DMFORDT	MN	Estrogen receptor (ESR)
DMFORDT	MT	DTT
DMFORDT	MA	Modulator
DMFORDT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMFORDT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DTUGYRD
DMFORDT	MN	P-glycoprotein 1 (ABCB1)
DMFORDT	MT	DTP
DMFORDT	MA	Substrate
DMFORDT	RN	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
DMFORDT	RU	http://www.ncbi.nlm.nih.gov/pubmed/7914405

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DEYGVN4
DMFORDT	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMFORDT	MT	DME
DMFORDT	MA	Metabolism
DMFORDT	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMFORDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMFORDT	DI	DMFORDT
DMFORDT	DN	Afimoxifene
DMFORDT	MI	DE2GB8N
DMFORDT	MN	UDP-glucuronosyltransferase 1A8 (UGT1A8)
DMFORDT	MT	DME
DMFORDT	MA	Metabolism
DMFORDT	RN	Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
DMFORDT	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17664247

DMN45IC	DI	DMN45IC
DMN45IC	DN	AFM13
DMN45IC	MI	TTIFOC0
DMN45IC	MN	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
DMN45IC	MT	DTT
DMN45IC	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMN45IC	RU	https://www.affimed.com/rock-platform/pipeline/

DMN45IC	DI	DMN45IC
DMN45IC	DN	AFM13
DMN45IC	MI	TT2GM5R
DMN45IC	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMN45IC	MT	DTT
DMN45IC	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMN45IC	RU	https://www.affimed.com/rock-platform/pipeline/

DMTFE9Y	DI	DMTFE9Y
DMTFE9Y	DN	AFN-1252
DMTFE9Y	MI	TTZBRVL
DMTFE9Y	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMTFE9Y	MT	DTT
DMTFE9Y	MA	Inhibitor
DMTFE9Y	RN	Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
DMTFE9Y	RU	https://pubmed.ncbi.nlm.nih.gov/23433442

DM6AJKC	DI	DM6AJKC
DM6AJKC	DN	AFN-1720
DM6AJKC	MI	TTVTX4N
DM6AJKC	MN	Bacterial Fatty acid synthetase I (Bact inhA)
DM6AJKC	MT	DTT
DM6AJKC	MA	Inhibitor
DM6AJKC	RN	Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
DM6AJKC	RU	http://www.virtualizationconference.com/node/2779672

DM1FJ2B	DI	DM1FJ2B
DM1FJ2B	DN	AFP464
DM1FJ2B	MI	TT2QPV9
DM1FJ2B	MN	Aryl hydrocarbon receptor signaling pathway (AhR pathway)
DM1FJ2B	MT	DTT
DM1FJ2B	MA	Suppressor
DM1FJ2B	RN	Clinical pipeline report, company report or official report of AFP464.
DM1FJ2B	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afp464

DMD3XMG	DI	DMD3XMG
DMD3XMG	DN	AFTVac
DMD3XMG	MI	TT6MP2Z
DMD3XMG	MN	GMCSFR-alpha (CSF2RA)
DMD3XMG	MT	DTT
DMD3XMG	RN	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
DMD3XMG	RU	https://pubmed.ncbi.nlm.nih.gov/15014006

DMD3XMG	DI	DMD3XMG
DMD3XMG	DN	AFTVac
DMD3XMG	MI	TT9721Y
DMD3XMG	MN	Interleukin 2 receptor beta (IL2RB)
DMD3XMG	MT	DTT
DMD3XMG	RN	Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
DMD3XMG	RU	https://pubmed.ncbi.nlm.nih.gov/15014006

DMA9FKY	DI	DMA9FKY
DMA9FKY	DN	AG140699
DMA9FKY	MI	TTVDSZ0
DMA9FKY	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMA9FKY	MT	DTT
DMA9FKY	MA	Inhibitor
DMA9FKY	RN	Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
DMA9FKY	RU	https://pubmed.ncbi.nlm.nih.gov/15864271

DMNQ5T2	DI	DMNQ5T2
DMNQ5T2	DN	AG-858
DMNQ5T2	MI	TTHYBIX
DMNQ5T2	MN	Heat shock protein 70 (HSP70)
DMNQ5T2	MT	DTT
DMNQ5T2	RN	Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265.
DMNQ5T2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088345/

DMPO7UG	DI	DMPO7UG
DMPO7UG	DN	AGEN2034
DMPO7UG	MI	TTNBFWK
DMPO7UG	MN	Programmed cell death protein 1 (PD-1)
DMPO7UG	MT	DTT
DMPO7UG	MA	Inhibitor
DMPO7UG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPO7UG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMP5Y1A	DI	DMP5Y1A
DMP5Y1A	DN	AGN-199981
DMP5Y1A	MI	TTWM4TY
DMP5Y1A	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMP5Y1A	MT	DTT
DMP5Y1A	MA	Agonist
DMP5Y1A	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMP5Y1A	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM4KOAC	DI	DM4KOAC
DM4KOAC	DN	AGN-241751
DM4KOAC	MI	TT9IK2Z
DM4KOAC	MN	N-methyl-D-aspartate receptor (NMDAR)
DM4KOAC	MT	DTT
DM4KOAC	MA	Modulator
DM4KOAC	RN	Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799-808.
DM4KOAC	RU	https://pubmed.ncbi.nlm.nih.gov/33059355

DMLQRFO	DI	DMLQRFO
DMLQRFO	DN	AGN-2979
DMLQRFO	MI	TTZSJHV
DMLQRFO	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMLQRFO	MT	DTT
DMLQRFO	MA	Modulator
DMLQRFO	RN	Antidepressant-like action of AGN 2979, a tryptophan hydroxylase activation inhibitor, in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol. 2001 Oct;11(5):351-7.
DMLQRFO	RU	https://pubmed.ncbi.nlm.nih.gov/11597821

DMMGAUK	DI	DMMGAUK
DMMGAUK	DN	AGN-XX/YY
DMMGAUK	MI	TT2NUT5
DMMGAUK	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMMGAUK	MT	DTT
DMMGAUK	MA	Agonist
DMMGAUK	RN	Patent WO2008058220 A2.
DMMGAUK	RU	http://www.google.com/patents/WO2008058220A2?cl=en

DM2POHA	DI	DM2POHA
DM2POHA	DN	AGS-16C3F
DM2POHA	MI	TTD4TKP
DM2POHA	MN	Phosphodiesterase I beta (ENPP3)
DM2POHA	MT	DTT
DM2POHA	MA	Inhibitor
DM2POHA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2POHA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMMKASG	DI	DMMKASG
DMMKASG	DN	AGTC-0106
DMMKASG	MI	TTA7UJC
DMMKASG	MN	Alpha-1-antitrypsin (SERPINA1)
DMMKASG	MT	DTT
DMMKASG	MA	Modulator
DMMKASG	RN	First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9.
DMMKASG	RU	https://pubmed.ncbi.nlm.nih.gov/22965030

DMXJ8Z4	DI	DMXJ8Z4
DMXJ8Z4	DN	AK104
DMXJ8Z4	MI	TTI2S1D
DMXJ8Z4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMXJ8Z4	MT	DTT
DMXJ8Z4	MA	Inhibitor
DMXJ8Z4	RN	Clinical pipeline report, company report or official report of Akeso Biopharma.
DMXJ8Z4	RU	https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/

DMXJ8Z4	DI	DMXJ8Z4
DMXJ8Z4	DN	AK104
DMXJ8Z4	MI	TTNBFWK
DMXJ8Z4	MN	Programmed cell death protein 1 (PD-1)
DMXJ8Z4	MT	DTT
DMXJ8Z4	MA	Inhibitor
DMXJ8Z4	RN	Clinical pipeline report, company report or official report of Akeso Biopharma.
DMXJ8Z4	RU	https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/

DMKNRYH	DI	DMKNRYH
DMKNRYH	DN	AKB-9778
DMKNRYH	MI	TT9VGXW
DMKNRYH	MN	Angiopoietin 1 receptor (TEK)
DMKNRYH	MT	DTT
DMKNRYH	MA	Activator
DMKNRYH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKNRYH	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMKNRYH	DI	DMKNRYH
DMKNRYH	DN	AKB-9778
DMKNRYH	MI	TT64I9Q
DMKNRYH	MN	Protein tyrosine phosphatase beta (PTPRB)
DMKNRYH	MT	DTT
DMKNRYH	MA	Modulator
DMKNRYH	RN	Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201.
DMKNRYH	RU	https://www.ncbi.nlm.nih.gov/pubmed/23899555

DMR8W7Y	DI	DMR8W7Y
DMR8W7Y	DN	AKCEA-ANGPTL3-LRX
DMR8W7Y	MI	TTUO98L
DMR8W7Y	MN	Angiopoietin-related protein 3 (ANGPTL3)
DMR8W7Y	MT	DTT
DMR8W7Y	MA	Inhibitor
DMR8W7Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR8W7Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMCTWIB	DI	DMCTWIB
DMCTWIB	DN	AL102
DMCTWIB	MI	TT9W8GU
DMCTWIB	MN	Gamma-secretase (GS)
DMCTWIB	MT	DTT
DMCTWIB	MA	Inhibitor
DMCTWIB	RN	Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.
DMCTWIB	RU	https://www.ayalapharma.com/pipeline/investigational-therapies-al101-and-al102

DM3P91Z	DI	DM3P91Z
DM3P91Z	DN	Alacizumab pegol
DM3P91Z	MI	TTUTJGQ
DM3P91Z	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM3P91Z	MT	DTT
DM3P91Z	RN	Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007 Dec 1;13(23):7113-8.
DM3P91Z	RU	https://pubmed.ncbi.nlm.nih.gov/18056191

DM2U530	DI	DM2U530
DM2U530	DN	ALD-401
DM2U530	MI	TTFLN4T
DM2U530	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM2U530	MT	DTT
DM2U530	MA	Modulator
DM2U530	RN	A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72.
DM2U530	RU	https://pubmed.ncbi.nlm.nih.gov/21998334

DM6RBYT	DI	DM6RBYT
DM6RBYT	DN	ALD-403
DM6RBYT	MI	TTAFORY
DM6RBYT	MN	Calcitonin gene-related peptide (CALC)
DM6RBYT	MT	DTT
DM6RBYT	MA	Modulator
DM6RBYT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM6RBYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPWSBL	DI	DMPWSBL
DMPWSBL	DN	ALD-518
DMPWSBL	MI	TTT1V78
DMPWSBL	MN	Interleukin-6 (IL6)
DMPWSBL	MT	DTT
DMPWSBL	MA	Modulator
DMPWSBL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMPWSBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUA0XC	DI	DMUA0XC
DMUA0XC	DN	ALF-5755
DMUA0XC	MI	TTL4H8N
DMUA0XC	MN	Regenerating human pro-islet peptide (REG3A)
DMUA0XC	MT	DTT
DMUA0XC	MA	Modulator
DMUA0XC	RN	HIP/PAP prevents excitotoxic neuronal death and promotes plasticity. Ann Clin Transl Neurol. 2014 October; 1(10): 739-754.
DMUA0XC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241802/

DMR2YPF	DI	DMR2YPF
DMR2YPF	DN	ALG-1001
DMR2YPF	MI	TT9HKJA
DMR2YPF	MN	Vascular endothelial growth factor (VEGF)
DMR2YPF	MT	DTT
DMR2YPF	MA	Modulator
DMR2YPF	RN	Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
DMR2YPF	RU	https://pubmed.ncbi.nlm.nih.gov/25802751

DME3ZYC	DI	DME3ZYC
DME3ZYC	DN	ALKS 4230
DME3ZYC	MI	TTAJU0S
DME3ZYC	MN	Interleukin 2 receptor (IL2R)
DME3ZYC	MT	DTT
DME3ZYC	MA	Agonist
DME3ZYC	RN	ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
DME3ZYC	RU	https://pubmed.ncbi.nlm.nih.gov/32317293

DMF3QN1	DI	DMF3QN1
DMF3QN1	DN	ALKS33
DMF3QN1	MI	TTKWM86
DMF3QN1	MN	Opioid receptor mu (MOP)
DMF3QN1	MT	DTT
DMF3QN1	MA	Inhibitor
DMF3QN1	RN	Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
DMF3QN1	RU	https://pubmed.ncbi.nlm.nih.gov/19282177

DMWYMJN	DI	DMWYMJN
DMWYMJN	DN	ALN-CC5
DMWYMJN	MI	TT2LJRF
DMWYMJN	MN	C5 messenger RNA (C5 mRNA)
DMWYMJN	MT	DTT
DMWYMJN	MA	Inhibitor
DMWYMJN	RN	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492.
DMWYMJN	RU	https://pubmed.ncbi.nlm.nih.gov/31193726

DMEYNQA	DI	DMEYNQA
DMEYNQA	DN	ALN-RSV01
DMEYNQA	MI	TTWSF5D
DMEYNQA	MN	HRSV Nucleoprotein messenger RNA (HRSV N mRNA)
DMEYNQA	MT	DTT
DMEYNQA	MA	Inhibitor
DMEYNQA	RN	Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31.
DMEYNQA	RU	https://pubmed.ncbi.nlm.nih.gov/18242722

DMJPV5X	DI	DMJPV5X
DMJPV5X	DN	Alovudine
DMJPV5X	MI	TT84ETX
DMJPV5X	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJPV5X	MT	DTT
DMJPV5X	MA	Modulator
DMJPV5X	RN	Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38.
DMJPV5X	RU	https://www.ncbi.nlm.nih.gov/pubmed/18211121

DM5EFXZ	DI	DM5EFXZ
DM5EFXZ	DN	Alpha-1 antitrypsin
DM5EFXZ	MI	TT2WR1T
DM5EFXZ	MN	Cationic trypsinogen (PRSS1)
DM5EFXZ	MT	DTT
DM5EFXZ	MA	Modulator
DM5EFXZ	RN	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
DM5EFXZ	RU	http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true

DMLBWT1	DI	DMLBWT1
DMLBWT1	DN	ALRN-6924
DMLBWT1	MI	TT9OUDQ
DMLBWT1	MN	p53-binding protein Mdm4 (MDM4)
DMLBWT1	MT	DTT
DMLBWT1	MA	Inhibitor
DMLBWT1	RN	Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
DMLBWT1	RU	https://pubmed.ncbi.nlm.nih.gov/30072728

DMLBWT1	DI	DMLBWT1
DMLBWT1	DN	ALRN-6924
DMLBWT1	MI	TT08GJW
DMLBWT1	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMLBWT1	MT	DTT
DMLBWT1	MA	Antagonist
DMLBWT1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLBWT1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9KL7P	DI	DM9KL7P
DM9KL7P	DN	ALT-801
DM9KL7P	MI	TT7SBF5
DM9KL7P	MN	Cellular tumor antigen p53 (TP53)
DM9KL7P	MT	DTT
DM9KL7P	MA	Immunomodulator (Immunostimulant)
DM9KL7P	RN	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75.
DM9KL7P	RU	https://pubmed.ncbi.nlm.nih.gov/21994418

DMK3U1X	DI	DMK3U1X
DMK3U1X	DN	ALT-803
DMK3U1X	MI	TTGN89I
DMK3U1X	MN	Interleukin 15 receptor alpha (IL15RA)
DMK3U1X	MT	DTT
DMK3U1X	MA	Agonist
DMK3U1X	RN	Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86.
DMK3U1X	RU	https://pubmed.ncbi.nlm.nih.gov/23644531

DMGJ71F	DI	DMGJ71F
DMGJ71F	DN	ALT-836
DMGJ71F	MI	TT38MDJ
DMGJ71F	MN	Tissue factor (F3)
DMGJ71F	MT	DTT
DMGJ71F	MA	Inhibitor
DMGJ71F	RN	ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303.
DMGJ71F	RU	https://pubmed.ncbi.nlm.nih.gov/25801992

DMLSK01	DI	DMLSK01
DMLSK01	DN	Altrakincept
DMLSK01	MI	TTDWHC3
DMLSK01	MN	Interleukin 4 receptor alpha (IL4R)
DMLSK01	MT	DTT
DMLSK01	MA	Modulator
DMLSK01	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMLSK01	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMXSFA0	DI	DMXSFA0
DMXSFA0	DN	ALV-003
DMXSFA0	MI	TTNGKET
DMXSFA0	MN	Prolyl endopeptidase (PREP)
DMXSFA0	MT	DTT
DMXSFA0	MA	Modulator
DMXSFA0	RN	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
DMXSFA0	RU	https://pubmed.ncbi.nlm.nih.gov/19942485

DMO1VHC	DI	DMO1VHC
DMO1VHC	DN	ALX-0061
DMO1VHC	MI	TT0E5SK
DMO1VHC	MN	Interleukin 6 receptor (IL6R)
DMO1VHC	MT	DTT
DMO1VHC	RN	The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
DMO1VHC	RU	https://pubmed.ncbi.nlm.nih.gov/25994180

DMCAFXM	DI	DMCAFXM
DMCAFXM	DN	ALX-101
DMCAFXM	MI	TTM1EQF
DMCAFXM	MN	Oxysterols receptor LXR (NR1H)
DMCAFXM	MT	DTT
DMCAFXM	MA	Agonist
DMCAFXM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCAFXM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMV934L	DI	DMV934L
DMV934L	DN	ALX-40-4C
DMV934L	MI	TTT3ZC9
DMV934L	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMV934L	MT	DTT
DMV934L	MA	Modulator
DMV934L	RN	Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31.
DMV934L	RU	https://pubmed.ncbi.nlm.nih.gov/8627756

DMH5LFR	DI	DMH5LFR
DMH5LFR	DN	ALXN6000
DMH5LFR	MI	TT0BE68
DMH5LFR	MN	Membrane glycoprotein OX2 (CD200)
DMH5LFR	MT	DTT
DMH5LFR	RN	American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103.
DMH5LFR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086088/

DM7ZQAT	DI	DM7ZQAT
DM7ZQAT	DN	ALZ-801
DM7ZQAT	MI	TTE4KHA
DM7ZQAT	MN	Amyloid beta A4 protein (APP)
DM7ZQAT	MT	DTT
DM7ZQAT	MA	Inhibitor
DM7ZQAT	RN	Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012.
DM7ZQAT	RU	http://www.alzheon.com/?page_id=280

DM9UMSJ	DI	DM9UMSJ
DM9UMSJ	DN	AM001
DM9UMSJ	MI	TTOE7I0
DM9UMSJ	MN	Rap guanine nucleotide exchange factor 3 (RAPGEF3)
DM9UMSJ	MT	DTT
DM9UMSJ	MA	Inhibitor
DM9UMSJ	RN	Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Cardiovasc Res. 2019 Oct 1;115(12):1766-1777.
DM9UMSJ	RU	https://pubmed.ncbi.nlm.nih.gov/30873562

DMGVQI8	DI	DMGVQI8
DMGVQI8	DN	AM-001
DMGVQI8	MI	TTRLW2X
DMGVQI8	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMGVQI8	MT	DTT
DMGVQI8	MA	Antagonist
DMGVQI8	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917)
DMGVQI8	RU	http://adisinsight.springer.com/drugs/800029917

DMBWNX5	DI	DMBWNX5
DMBWNX5	DN	AMA-76
DMBWNX5	MI	TTMQO60
DMBWNX5	MN	Rho-associated protein kinase (ROCK)
DMBWNX5	MT	DTT
DMBWNX5	MA	Modulator
DMBWNX5	RN	AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
DMBWNX5	RU	https://pubmed.ncbi.nlm.nih.gov/24474276

DMEB3T9	DI	DMEB3T9
DMEB3T9	DN	Amdoxovir
DMEB3T9	MI	TT84ETX
DMEB3T9	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMEB3T9	MT	DTT
DMEB3T9	MA	Modulator
DMEB3T9	RN	Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23.
DMEB3T9	RU	https://www.ncbi.nlm.nih.gov/pubmed/16964830

DMIVZ3M	DI	DMIVZ3M
DMIVZ3M	DN	AME-133v
DMIVZ3M	MI	TTUE541
DMIVZ3M	MN	Leukocyte surface antigen Leu-16 (CD20)
DMIVZ3M	MT	DTT
DMIVZ3M	RN	Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403.
DMIVZ3M	RU	https://pubmed.ncbi.nlm.nih.gov/22223529

DMUMCB9	DI	DMUMCB9
DMUMCB9	DN	Amelubant
DMUMCB9	MI	TTN53ZF
DMUMCB9	MN	Leukotriene B4 receptor 1 (LTB4R)
DMUMCB9	MT	DTT
DMUMCB9	MA	Antagonist
DMUMCB9	RN	Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
DMUMCB9	RU	https://pubmed.ncbi.nlm.nih.gov/16356023

DMGOFL3	DI	DMGOFL3
DMGOFL3	DN	AMG 151
DMGOFL3	MI	TTDLNGZ
DMGOFL3	MN	Glucokinase (GCK)
DMGOFL3	MT	DTT
DMGOFL3	MA	Inhibitor
DMGOFL3	RN	This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
DMGOFL3	RU	http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf

DMPQHOR	DI	DMPQHOR
DMPQHOR	DN	AMG 208
DMPQHOR	MI	TTNDSF4
DMPQHOR	MN	Proto-oncogene c-Met (MET)
DMPQHOR	MT	DTT
DMPQHOR	MA	Modulator
DMPQHOR	RN	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.
DMPQHOR	RU	https://pubmed.ncbi.nlm.nih.gov/26155941

DM65PTO	DI	DM65PTO
DM65PTO	DN	AMG 232
DM65PTO	MI	TT08GJW
DM65PTO	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM65PTO	MT	DTT
DM65PTO	MA	Modulator
DM65PTO	RN	Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
DM65PTO	RU	https://pubmed.ncbi.nlm.nih.gov/24967612

DMO72IF	DI	DMO72IF
DMO72IF	DN	AMG 301
DMO72IF	MI	TT5OREU
DMO72IF	MN	PACAP type I receptor (PAC1R)
DMO72IF	MT	DTT
DMO72IF	MA	Inhibitor
DMO72IF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO72IF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMI3WFG	DI	DMI3WFG
DMI3WFG	DN	AMG 334
DMI3WFG	MI	TTY6O0Q
DMI3WFG	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMI3WFG	MT	DTT
DMI3WFG	MA	Modulator
DMI3WFG	RN	EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
DMI3WFG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182181/

DMIOUEY	DI	DMIOUEY
DMIOUEY	DN	AMG 337
DMIOUEY	MI	TTNDSF4
DMIOUEY	MN	Proto-oncogene c-Met (MET)
DMIOUEY	MT	DTT
DMIOUEY	MA	Modulator
DMIOUEY	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).
DMIOUEY	RU	http://meetinglibrary.asco.org/content/127112-144

DM0DRAZ	DI	DM0DRAZ
DM0DRAZ	DN	AMG 479
DM0DRAZ	MI	TTHRID2
DM0DRAZ	MN	Insulin-like growth factor I receptor (IGF1R)
DM0DRAZ	MT	DTT
DM0DRAZ	MA	Inhibitor
DM0DRAZ	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DM0DRAZ	RU	http://www.amgen.com/science/pipe.jsp

DME6QH1	DI	DME6QH1
DME6QH1	DN	AMG 557
DME6QH1	MI	TTB9Z8R
DME6QH1	MN	B7-related protein 1 (B7RP1)
DME6QH1	MT	DTT
DME6QH1	MA	Modulator
DME6QH1	RN	Administration Of AMG 557, A Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. San Diego, CA October 25-30, 2013
DME6QH1	RU	http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109110

DMY1XJH	DI	DMY1XJH
DMY1XJH	DN	AMG 570
DMY1XJH	MI	TTB9Z8R
DMY1XJH	MN	B7-related protein 1 (B7RP1)
DMY1XJH	MT	DTT
DMY1XJH	MA	Inhibitor
DMY1XJH	RN	Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
DMY1XJH	RU	https://pubmed.ncbi.nlm.nih.gov/30789152

DMY1XJH	DI	DMY1XJH
DMY1XJH	DN	AMG 570
DMY1XJH	MI	TTWMIDN
DMY1XJH	MN	B-cell-activating factor (TNFSF13B)
DMY1XJH	MT	DTT
DMY1XJH	MA	Inhibitor
DMY1XJH	RN	Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914.
DMY1XJH	RU	https://pubmed.ncbi.nlm.nih.gov/30789152

DMFXN2T	DI	DMFXN2T
DMFXN2T	DN	AMG 745
DMFXN2T	MI	TTSWPH8
DMFXN2T	MN	Growth/differentiation factor 8 (GDF-8)
DMFXN2T	MT	DTT
DMFXN2T	MA	Antagonist
DMFXN2T	RN	The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
DMFXN2T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177043/

DMWPGB8	DI	DMWPGB8
DMWPGB8	DN	Amg 747
DMWPGB8	MI	TTHJTF7
DMWPGB8	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWPGB8	MT	DTT
DMWPGB8	MA	Modulator
DMWPGB8	RN	Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
DMWPGB8	RU	https://pubmed.ncbi.nlm.nih.gov/24172334

DM973N4	DI	DM973N4
DM973N4	DN	AMG 853
DM973N4	MI	TTNVEIR
DM973N4	MN	Prostaglandin D2 receptor (PTGDR)
DM973N4	MT	DTT
DM973N4	MA	Modulator
DM973N4	RN	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
DM973N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23174659

DM973N4	DI	DM973N4
DM973N4	DN	AMG 853
DM973N4	MI	TTQDMX5
DM973N4	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM973N4	MT	DTT
DM973N4	MA	Modulator
DM973N4	RN	Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
DM973N4	RU	https://www.ncbi.nlm.nih.gov/pubmed/23174659

DM3H0IX	DI	DM3H0IX
DM3H0IX	DN	AMG 890
DM3H0IX	MI	TTU9LGY
DM3H0IX	MN	Apolipoprotein A messenger RNA (LPA mRNA)
DM3H0IX	MT	DTT
DM3H0IX	MA	Inhibitor
DM3H0IX	RN	Clinical pipeline report, company report or official report of Amgen.
DM3H0IX	RU	https://www.amgenpipeline.com/

DMODJTX	DI	DMODJTX
DMODJTX	DN	AMG-181
DMODJTX	MI	TT4BT06
DMODJTX	MN	Integrin alpha-4 (ITGA4)
DMODJTX	MT	DTT
DMODJTX	MA	Inhibitor
DMODJTX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMODJTX	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMODJTX	DI	DMODJTX
DMODJTX	DN	AMG-181
DMODJTX	MI	TTLT9XQ
DMODJTX	MN	Integrin beta-7 (ITGB7)
DMODJTX	MT	DTT
DMODJTX	RN	Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68.
DMODJTX	RU	https://pubmed.ncbi.nlm.nih.gov/23425116

DM1T3KQ	DI	DM1T3KQ
DM1T3KQ	DN	AMG-714
DM1T3KQ	MI	TTJFA35
DM1T3KQ	MN	Interleukin-15 (IL15)
DM1T3KQ	MT	DTT
DM1T3KQ	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DM1T3KQ	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMJ4GPR	DI	DMJ4GPR
DMJ4GPR	DN	AMP-579
DMJ4GPR	MI	TTK25J1
DMJ4GPR	MN	Adenosine A1 receptor (ADORA1)
DMJ4GPR	MT	DTT
DMJ4GPR	MA	Modulator
DMJ4GPR	RN	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
DMJ4GPR	RU	https://pubmed.ncbi.nlm.nih.gov/15271662

DMJ4GPR	DI	DMJ4GPR
DMJ4GPR	DN	AMP-579
DMJ4GPR	MI	TTM2AOE
DMJ4GPR	MN	Adenosine A2a receptor (ADORA2A)
DMJ4GPR	MT	DTT
DMJ4GPR	MA	Modulator
DMJ4GPR	RN	Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
DMJ4GPR	RU	https://pubmed.ncbi.nlm.nih.gov/15271662

DMGE8FK	DI	DMGE8FK
DMGE8FK	DN	AMR-001
DMGE8FK	MI	TTZAVYN
DMGE8FK	MN	Hematopoietic progenitor cell antigen CD34 (CD34)
DMGE8FK	MT	DTT
DMGE8FK	MA	Modulator
DMGE8FK	RN	National Cancer Institute Drug Dictionary (drug id 743421).
DMGE8FK	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=743421

DMOB01U	DI	DMOB01U
DMOB01U	DN	Amsilarotene
DMOB01U	MI	TTOD7B3
DMOB01U	MN	Retinoic acid receptor (RAR)
DMOB01U	MT	DTT
DMOB01U	MA	Antagonist
DMOB01U	RN	Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32.
DMOB01U	RU	https://pubmed.ncbi.nlm.nih.gov/12177113

DMS0GA6	DI	DMS0GA6
DMS0GA6	DN	AMY-101
DMS0GA6	MI	TTJGY7A
DMS0GA6	MN	Complement C3 (CO3)
DMS0GA6	MT	DTT
DMS0GA6	MA	Inhibitor
DMS0GA6	RN	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
DMS0GA6	RU	https://pubmed.ncbi.nlm.nih.gov/32360516

DMT3S10	DI	DMT3S10
DMT3S10	DN	AN0128
DMT3S10	MI	TTF8CQI
DMT3S10	MN	Tumor necrosis factor (TNF)
DMT3S10	MT	DTT
DMT3S10	MA	Inhibitor
DMT3S10	RN	Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52.
DMT3S10	RU	https://pubmed.ncbi.nlm.nih.gov/18218841

DMJ7QP8	DI	DMJ7QP8
DMJ7QP8	DN	AN-019
DMJ7QP8	MI	TTS7G69
DMJ7QP8	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMJ7QP8	MT	DTT
DMJ7QP8	MA	Inhibitor
DMJ7QP8	RN	Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78.
DMJ7QP8	RU	https://pubmed.ncbi.nlm.nih.gov/23151973

DM3JNXS	DI	DM3JNXS
DM3JNXS	DN	AN-1792
DM3JNXS	MI	TTE4KHA
DM3JNXS	MN	Amyloid beta A4 protein (APP)
DM3JNXS	MT	DTT
DM3JNXS	MA	Inhibitor
DM3JNXS	RN	Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63.
DM3JNXS	RU	https://pubmed.ncbi.nlm.nih.gov/16936277

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTZ97H5
DMDK7CL	MN	Phosphodiesterase 4A (PDE4A)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTVIAT9
DMDK7CL	MN	Phosphodiesterase 4B (PDE4B)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMDK7CL	DI	DMDK7CL
DMDK7CL	DN	AN-2898
DMDK7CL	MI	TTSKMI8
DMDK7CL	MN	Phosphodiesterase 4D (PDE4D)
DMDK7CL	MT	DTT
DMDK7CL	MA	Inhibitor
DMDK7CL	RN	An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
DMDK7CL	RU	https://pubmed.ncbi.nlm.nih.gov/23625818

DMG7IEN	DI	DMG7IEN
DMG7IEN	DN	Anatibant
DMG7IEN	MI	TTGY8IW
DMG7IEN	MN	B2 bradykinin receptor (BDKRB2)
DMG7IEN	MT	DTT
DMG7IEN	MA	Antagonist
DMG7IEN	RN	Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34.
DMG7IEN	RU	https://pubmed.ncbi.nlm.nih.gov/19487935

DMTG2O0	DI	DMTG2O0
DMTG2O0	DN	Anrukinzumab
DMTG2O0	MI	TT0GVCH
DMTG2O0	MN	Interleukin-13 (IL13)
DMTG2O0	MT	DTT
DMTG2O0	MA	Modulator
DMTG2O0	RN	Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
DMTG2O0	RU	https://www.ncbi.nlm.nih.gov/pubmed/25567115

DMHVZ27	DI	DMHVZ27
DMHVZ27	DN	Anti-CD137
DMHVZ27	MI	TTPW9LJ
DMHVZ27	MN	Co-stimulatory molecule 4-1BB (CD137)
DMHVZ27	MT	DTT
DMHVZ27	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
DMHVZ27	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878

DMPRIHK	DI	DMPRIHK
DMPRIHK	DN	Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells
DMPRIHK	MI	TT6EO5L
DMPRIHK	MN	Erbb2 tyrosine kinase receptor (HER2)
DMPRIHK	MT	DTT
DMPRIHK	RN	Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.
DMPRIHK	RU	https://pubmed.ncbi.nlm.nih.gov/11359672

DMVQHBK	DI	DMVQHBK
DMVQHBK	DN	Anti-GD2 CART
DMVQHBK	MI	TT80ARU
DMVQHBK	MN	Ganglioside GD2 (GD2)
DMVQHBK	MT	DTT
DMVQHBK	MA	CAR-T-Cell-Therapy
DMVQHBK	RN	ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
DMVQHBK	RU	https://clinicaltrials.gov/ct2/show/NCT02765243

DMVRNAO	DI	DMVRNAO
DMVRNAO	DN	Anti-IP10
DMVRNAO	MI	TTQOVYA
DMVRNAO	MN	C-X-C motif chemokine 10 (CXCL10)
DMVRNAO	MT	DTT
DMVRNAO	RN	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
DMVRNAO	RU	https://pubmed.ncbi.nlm.nih.gov/23461895

DMJO402	DI	DMJO402
DMJO402	DN	Anti-LAG3
DMJO402	MI	TTNVXAW
DMJO402	MN	Lymphocyte activation gene 3 protein (LAG3)
DMJO402	MT	DTT
DMJO402	MA	Inhibitor
DMJO402	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJO402	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQ58YH	DI	DMQ58YH
DMQ58YH	DN	Anti-LT alpha
DMQ58YH	MI	TTP73TM
DMQ58YH	MN	Lymphotoxin-alpha (LTA)
DMQ58YH	MT	DTT
DMQ58YH	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMQ58YH	RU	http://www.gene.com/gene/index.jsp

DMQFU1R	DI	DMQFU1R
DMQFU1R	DN	Anti-M1 prime
DMQFU1R	MI	TTA5LWY
DMQFU1R	MN	M1-prime segment of membrane-expressed IgE (M1 IgE)
DMQFU1R	MT	DTT
DMQFU1R	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMQFU1R	RU	http://www.gene.com/gene/index.jsp

DMJPZDC	DI	DMJPZDC
DMJPZDC	DN	Anti-PSCA mab
DMJPZDC	MI	TT9T4AV
DMJPZDC	MN	Prostate stem cell antigen (PSCA)
DMJPZDC	MT	DTT
DMJPZDC	MA	Modulator
DMJPZDC	RN	Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71.
DMJPZDC	RU	https://pubmed.ncbi.nlm.nih.gov/22020316

DMDKRS3	DI	DMDKRS3
DMDKRS3	DN	Antistasin
DMDKRS3	MI	TTCIHJA
DMDKRS3	MN	Coagulation factor Xa (F10)
DMDKRS3	MT	DTT
DMDKRS3	MA	Inhibitor
DMDKRS3	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DMDKRS3	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DMRGQVZ	DI	DMRGQVZ
DMRGQVZ	DN	Antroquinonol
DMRGQVZ	MI	TT6S2FE
DMRGQVZ	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMRGQVZ	MT	DTT
DMRGQVZ	MA	Inhibitor
DMRGQVZ	RN	Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.
DMRGQVZ	RU	https://pubmed.ncbi.nlm.nih.gov/24784321

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEKP5HX
DMMJOZD	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DE98XPV
DMMJOZD	MN	Cholesterol desmolase (CYP11A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DELIXR8
DMMJOZD	MN	Cytochrome P450 125A1 (cyp125)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DE6ZDK4
DMMJOZD	MN	Cytochrome P450 125A3 (cyp125)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol ester oxidation by mycobacterial cytochrome P450. J Biol Chem. 2014 Oct 31;289(44):30417-25.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/25210044

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEMQ20F
DMMJOZD	MN	Cytochrome P450 142A1 (cyp142)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/30810776

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEPUK4S
DMMJOZD	MN	Cytochrome P450 142A2 (cyp142)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol ester oxidation by mycobacterial cytochrome P450. J Biol Chem. 2014 Oct 31;289(44):30417-25.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/25210044

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEDZRQ1
DMMJOZD	MN	Cytochrome P450 7A1 (CYP7A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMMJOZD	DI	DMMJOZD
DMMJOZD	DN	ANW-32821
DMMJOZD	MI	DEBS639
DMMJOZD	MN	Vitamin D(3) 25-hydroxylase (CYP27A1)
DMMJOZD	MT	DME
DMMJOZD	MA	Metabolism
DMMJOZD	RN	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
DMMJOZD	RU	https://pubmed.ncbi.nlm.nih.gov/16434543

DMYBQEF	DI	DMYBQEF
DMYBQEF	DN	AP26113
DMYBQEF	MI	TTPMQSO
DMYBQEF	MN	ALK tyrosine kinase receptor (ALK)
DMYBQEF	MT	DTT
DMYBQEF	MA	Modulator
DMYBQEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYBQEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM3ICYL	DI	DM3ICYL
DM3ICYL	DN	AP-301-IH
DM3ICYL	MI	TTF8CQI
DM3ICYL	MN	Tumor necrosis factor (TNF)
DM3ICYL	MT	DTT
DM3ICYL	MA	Inhibitor
DM3ICYL	RN	AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63.
DM3ICYL	RU	https://pubmed.ncbi.nlm.nih.gov/23313096

DMISQOZ	DI	DMISQOZ
DMISQOZ	DN	AP-761
DMISQOZ	MI	TTQDMX5
DMISQOZ	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMISQOZ	MT	DTT
DMISQOZ	MA	Antagonist
DMISQOZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
DMISQOZ	RU	http://adisinsight.springer.com/drugs/800028464

DM1B8IT	DI	DM1B8IT
DM1B8IT	DN	Apadoline
DM1B8IT	MI	TTQW87Y
DM1B8IT	MN	Opioid receptor kappa (OPRK1)
DM1B8IT	MT	DTT
DM1B8IT	MA	Agonist
DM1B8IT	RN	Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68.
DM1B8IT	RU	https://pubmed.ncbi.nlm.nih.gov/15989506

DMQMV9F	DI	DMQMV9F
DMQMV9F	DN	Apaxifylline
DMQMV9F	MI	TTK25J1
DMQMV9F	MN	Adenosine A1 receptor (ADORA1)
DMQMV9F	MT	DTT
DMQMV9F	MA	Antagonist
DMQMV9F	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
DMQMV9F	RU	http://adisinsight.springer.com/drugs/800004779

DM3VP19	DI	DM3VP19
DM3VP19	DN	APC-8015F
DM3VP19	MI	TTCT6F7
DM3VP19	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DM3VP19	MT	DTT
DM3VP19	MA	Modulator
DM3VP19	RN	National Cancer Institute Drug Dictionary (drug id 561410).
DM3VP19	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561410

DMNQ7DV	DI	DMNQ7DV
DMNQ7DV	DN	APD-209
DMNQ7DV	MI	TT2CJVK
DMNQ7DV	MN	Adrenergic receptor beta-2 (ADRB2)
DMNQ7DV	MT	DTT
DMNQ7DV	MA	Agonist
DMNQ7DV	RN	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385.
DMNQ7DV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746778/

DM3XT5V	DI	DM3XT5V
DM3XT5V	DN	APD371
DM3XT5V	MI	TTMSFAW
DM3XT5V	MN	Cannabinoid receptor 2 (CB2)
DM3XT5V	MT	DTT
DM3XT5V	MA	Agonist
DM3XT5V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3XT5V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM1VITS	DI	DM1VITS
DM1VITS	DN	APD-403
DM1VITS	MI	TTEX248
DM1VITS	MN	Dopamine D2 receptor (D2R)
DM1VITS	MT	DTT
DM1VITS	MA	Antagonist
DM1VITS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215).
DM1VITS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215

DM9LZ0M	DI	DM9LZ0M
DM9LZ0M	DN	APD-515
DM9LZ0M	MI	TTOXS3C
DM9LZ0M	MN	Muscarinic acetylcholine receptor (CHRM)
DM9LZ0M	MT	DTT
DM9LZ0M	MA	Agonist
DM9LZ0M	RN	Clinical pipeline report, company report or official report of Acacia Pharma.
DM9LZ0M	RU	http://www.acaciapharma.com/pipeline/apd515

DM0FXMZ	DI	DM0FXMZ
DM0FXMZ	DN	APG-101
DM0FXMZ	MI	TTF0RCZ
DM0FXMZ	MN	Apoptosis mediating surface antigen FAS (FAS)
DM0FXMZ	MT	DTT
DM0FXMZ	MA	Inhibitor
DM0FXMZ	RN	Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.
DM0FXMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22446296

DMIFA0L	DI	DMIFA0L
DMIFA0L	DN	APG-115
DMIFA0L	MI	TT7SBF5
DMIFA0L	MN	Cellular tumor antigen p53 (TP53)
DMIFA0L	MT	DTT
DMIFA0L	MA	Inhibitor
DMIFA0L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFA0L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIFA0L	DI	DMIFA0L
DMIFA0L	DN	APG-115
DMIFA0L	MI	TT08GJW
DMIFA0L	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMIFA0L	MT	DTT
DMIFA0L	MA	Inhibitor
DMIFA0L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFA0L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM756GE	DI	DM756GE
DM756GE	DN	APH-0812
DM756GE	MI	TTBH0VX
DM756GE	MN	Histone deacetylase (HDAC)
DM756GE	MT	DTT
DM756GE	MA	Inhibitor
DM756GE	RN	Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
DM756GE	RU	https://pubmed.ncbi.nlm.nih.gov/17585335

DM756GE	DI	DM756GE
DM756GE	DN	APH-0812
DM756GE	MI	TTYVX59
DM756GE	MN	Protein kinase C (PRKC)
DM756GE	MT	DTT
DM756GE	MA	Inhibitor
DM756GE	RN	Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
DM756GE	RU	https://pubmed.ncbi.nlm.nih.gov/17585335

DMHIS6Z	DI	DMHIS6Z
DMHIS6Z	DN	Apilimod
DMHIS6Z	MI	TT0S3MP
DMHIS6Z	MN	HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve)
DMHIS6Z	MT	DTT
DMHIS6Z	MA	Inhibitor
DMHIS6Z	RN	A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020.
DMHIS6Z	RU	https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1

DM4N2O0	DI	DM4N2O0
DM4N2O0	DN	Apilimod dimesylate
DM4N2O0	MI	TTA4M1N
DM4N2O0	MN	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
DM4N2O0	MT	DTT
DM4N2O0	MA	Inhibitor
DM4N2O0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4N2O0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7IGO9	DI	DM7IGO9
DM7IGO9	DN	Apimostinel
DM7IGO9	MI	TT9IK2Z
DM7IGO9	MN	N-methyl-D-aspartate receptor (NMDAR)
DM7IGO9	MT	DTT
DM7IGO9	MA	Partial agonist
DM7IGO9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IGO9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMP0LST	DI	DMP0LST
DMP0LST	DN	APL-101
DMP0LST	MI	TTNDSF4
DMP0LST	MN	Proto-oncogene c-Met (MET)
DMP0LST	MT	DTT
DMP0LST	MA	Inhibitor
DMP0LST	RN	Clinical pipeline report, company report or official report of Apollomics.
DMP0LST	RU	https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-101/

DMGJ1X2	DI	DMGJ1X2
DMGJ1X2	DN	Aplindore fumarate
DMGJ1X2	MI	TTEX248
DMGJ1X2	MN	Dopamine D2 receptor (D2R)
DMGJ1X2	MT	DTT
DMGJ1X2	MA	Agonist
DMGJ1X2	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMGJ1X2	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMGNFBC	DI	DMGNFBC
DMGNFBC	DN	APN301
DMGNFBC	MI	TT80ARU
DMGNFBC	MN	Ganglioside GD2 (GD2)
DMGNFBC	MT	DTT
DMGNFBC	MA	Inhibitor
DMGNFBC	RN	Clinical pipeline report, company report or official report of Apeiron Biologics.
DMGNFBC	RU	https://www.apeiron-biologics.com/childrens-oncology-group-and-apeiron-to-jointly-conduct-phase-ii-study-in-neuroblastoma-with-hu14-18-il2-apn301/

DM32YTJ	DI	DM32YTJ
DM32YTJ	DN	APN-301
DM32YTJ	MI	TTF89GD
DM32YTJ	MN	Interleukin-2 (IL2)
DM32YTJ	MT	DTT
DM32YTJ	MA	Modulator
DM32YTJ	RN	Clinical pipeline report, company report or official report of APEIRON Biologics.
DM32YTJ	RU	http://www.apeiron-biologics.com/index.php/projects/apn301-hu14-18-il2.html

DMEXN7V	DI	DMEXN7V
DMEXN7V	DN	APN401
DMEXN7V	MI	TTHRAIJ
DMEXN7V	MN	CBLB messenger RNA (CBLB mRNA)
DMEXN7V	MT	DTT
DMEXN7V	MA	Inhibitor
DMEXN7V	RN	Clinical pipeline report, company report or official report of Apeiron Biologics.
DMEXN7V	RU	https://www.apeiron-biologics.com/science/#apn401

DMKVP7E	DI	DMKVP7E
DMKVP7E	DN	Apolizumab
DMKVP7E	MI	TTYA75N
DMKVP7E	MN	MHC class II antigen DR (HLA-DR)
DMKVP7E	MT	DTT
DMKVP7E	MA	Modulator
DMKVP7E	RN	A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
DMKVP7E	RU	https://www.ncbi.nlm.nih.gov/pubmed/17071489

DM6B9HP	DI	DM6B9HP
DM6B9HP	DN	Apomine
DM6B9HP	MI	TTS4UGC
DM6B9HP	MN	Farnesoid X-activated receptor (FXR)
DM6B9HP	MT	DTT
DM6B9HP	MA	Agonist
DM6B9HP	RN	The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
DM6B9HP	RU	https://pubmed.ncbi.nlm.nih.gov/11254888

DMNFADH	DI	DMNFADH
DMNFADH	DN	APR-246
DMNFADH	MI	TT7SBF5
DMNFADH	MN	Cellular tumor antigen p53 (TP53)
DMNFADH	MT	DTT
DMNFADH	MA	Stimulator
DMNFADH	RN	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. 
DMNFADH	RU	https://pubmed.ncbi.nlm.nih.gov/24157875

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TTMX39J
DM8W4N9	MN	Matrix metalloproteinase-1 (MMP-1)
DM8W4N9	MT	DTT
DM8W4N9	MA	Inhibitor
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TTHY57M
DM8W4N9	MN	Matrix metalloproteinase-13 (MMP-13)
DM8W4N9	MT	DTT
DM8W4N9	MA	Modulator
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DM8W4N9	DI	DM8W4N9
DM8W4N9	DN	Apratastat
DM8W4N9	MI	TT6AZXG
DM8W4N9	MN	TNF alpha converting enzyme (ADAM17)
DM8W4N9	MT	DTT
DM8W4N9	MA	Modulator
DM8W4N9	RN	Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
DM8W4N9	RU	https://pubmed.ncbi.nlm.nih.gov/16426848

DMEJICQ	DI	DMEJICQ
DMEJICQ	DN	Aprocitentan
DMEJICQ	MI	TTCV6O0
DMEJICQ	MN	Endothelin receptor (EDNR)
DMEJICQ	MT	DTT
DMEJICQ	MA	Antagonist
DMEJICQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEJICQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMX2P5G	DI	DMX2P5G
DMX2P5G	DN	APX005M
DMX2P5G	MI	TTN6Y9A
DMX2P5G	MN	CD40L receptor (CD40)
DMX2P5G	MT	DTT
DMX2P5G	MA	Agonist
DMX2P5G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX2P5G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMU6NBO	DI	DMU6NBO
DMU6NBO	DN	APX3330
DMU6NBO	MI	TTHGL48
DMU6NBO	MN	AP endonuclease 1 (APEX1)
DMU6NBO	MT	DTT
DMU6NBO	MA	Inhibitor
DMU6NBO	RN	Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19.
DMU6NBO	RU	https://pubmed.ncbi.nlm.nih.gov/28825044

DM1USXR	DI	DM1USXR
DM1USXR	DN	AQ-13
DM1USXR	MI	TTKY2NS
DM1USXR	MN	Duffy antigen chemokine receptor (ACKR1)
DM1USXR	MT	DTT
DM1USXR	MA	Modulator
DM1USXR	RN	From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420.
DM1USXR	RU	http://www.sciencedirect.com/science/article/pii/S1995764510601010

DMD2RFO	DI	DMD2RFO
DMD2RFO	DN	AQW-051
DMD2RFO	MI	TTLA931
DMD2RFO	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMD2RFO	MT	DTT
DMD2RFO	MA	Agonist
DMD2RFO	RN	AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
DMD2RFO	RU	https://pubmed.ncbi.nlm.nih.gov/25172125

DMCH3G5	DI	DMCH3G5
DMCH3G5	DN	AQX-1125
DMCH3G5	MI	TTTP2Z1
DMCH3G5	MN	SH2 domain inositol 5'-phosphatase 1 (INPP5D)
DMCH3G5	MT	DTT
DMCH3G5	MA	Agonist
DMCH3G5	RN	Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol. 2013 Mar;168(6):1519-29.
DMCH3G5	RU	https://pubmed.ncbi.nlm.nih.gov/23121409

DM93CTQ	DI	DM93CTQ
DM93CTQ	DN	AR08
DM93CTQ	MI	TTVIREA
DM93CTQ	MN	Adrenergic receptor (ADR)
DM93CTQ	MT	DTT
DM93CTQ	MA	Modulator
DM93CTQ	RN	Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594.
DM93CTQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287224/

DM5TC43	DI	DM5TC43
DM5TC43	DN	AR-12286
DM5TC43	MI	TTMQO60
DM5TC43	MN	Rho-associated protein kinase (ROCK)
DM5TC43	MT	DTT
DM5TC43	MA	Modulator
DM5TC43	RN	Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
DM5TC43	RU	https://pubmed.ncbi.nlm.nih.gov/21794845

DM8A71F	DI	DM8A71F
DM8A71F	DN	AR-67
DM8A71F	MI	TTGTQHC
DM8A71F	MN	DNA topoisomerase I (TOP1)
DM8A71F	MT	DTT
DM8A71F	MA	Inhibitor
DM8A71F	RN	Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54.
DM8A71F	RU	https://pubmed.ncbi.nlm.nih.gov/24807458

DMJHA6Q	DI	DMJHA6Q
DMJHA6Q	DN	Ar9281
DMJHA6Q	MI	TT7WVHI
DMJHA6Q	MN	Soluble epoxide hydrolase (EPHX2)
DMJHA6Q	MT	DTT
DMJHA6Q	MA	Inhibitor
DMJHA6Q	RN	Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
DMJHA6Q	RU	https://pubmed.ncbi.nlm.nih.gov/17616115

DM7PCLY	DI	DM7PCLY
DM7PCLY	DN	ARC1779
DM7PCLY	MI	TT3SZBT
DM7PCLY	MN	von Willebrand factor (VWF)
DM7PCLY	MT	DTT
DM7PCLY	MA	Inhibitor
DM7PCLY	RN	Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037.
DM7PCLY	RU	https://pubmed.ncbi.nlm.nih.gov/31315441

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TTRHEQ4
DM9LNXS	MN	Diacylglycerol O-acyltransferase 2 (DGAT2)
DM9LNXS	MT	DTT
DM9LNXS	MA	Inhibitor
DM9LNXS	RN	2011 Pipeline of Arisaph Pharmaceuticals.
DM9LNXS	RU	http://www.arisaph.com/

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TT8WFXV
DM9LNXS	MN	Hydroxycarboxylic acid receptor 3 (HCAR3)
DM9LNXS	MT	DTT
DM9LNXS	MA	Agonist
DM9LNXS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LNXS	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM9LNXS	DI	DM9LNXS
DM9LNXS	DN	ARI-3037MO
DM9LNXS	MI	TTWNV8U
DM9LNXS	MN	Nicotinic acid receptor (HCAR2)
DM9LNXS	MT	DTT
DM9LNXS	MA	Agonist
DM9LNXS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9LNXS	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DML3PJF	DI	DML3PJF
DML3PJF	DN	ARN-810
DML3PJF	MI	TTZAYWL
DML3PJF	MN	Estrogen receptor (ESR)
DML3PJF	MT	DTT
DML3PJF	MA	Modulator
DML3PJF	RN	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem.2015 Jun 25;58(12):4888-904.
DML3PJF	RU	https://pubmed.ncbi.nlm.nih.gov/25879485

DM2UP6Z	DI	DM2UP6Z
DM2UP6Z	DN	ARO-AAT
DM2UP6Z	MI	TT2L4TV
DM2UP6Z	MN	SERPINA1 messenger RNA (SERPINA1 mRNA)
DM2UP6Z	MT	DTT
DM2UP6Z	RN	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
DM2UP6Z	RU	https://arrowheadpharma.com/pipeline/

DM5WK0J	DI	DM5WK0J
DM5WK0J	DN	ARQ 092
DM5WK0J	MI	TTWTSCV
DM5WK0J	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM5WK0J	MT	DTT
DM5WK0J	MA	Inhibitor
DM5WK0J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5WK0J	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM5WK0J	DI	DM5WK0J
DM5WK0J	DN	ARQ 092
DM5WK0J	MI	TTAZ05C
DM5WK0J	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM5WK0J	MT	DTT
DM5WK0J	MA	Modulator
DM5WK0J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5WK0J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRG0A3	DI	DMRG0A3
DMRG0A3	DN	ARQ 531
DMRG0A3	MI	TTGM6VW
DMRG0A3	MN	Tyrosine-protein kinase BTK (ATK)
DMRG0A3	MT	DTT
DMRG0A3	MA	Inhibitor
DMRG0A3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRG0A3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH5CAL	DI	DMH5CAL
DMH5CAL	DN	ARQ 761
DMH5CAL	MI	TT8XK6L
DMH5CAL	MN	Quinone reductase 1 (NQO1)
DMH5CAL	MT	DTT
DMH5CAL	MA	Inhibitor
DMH5CAL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH5CAL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYEIOH	DI	DMYEIOH
DMYEIOH	DN	ARQ-154
DMYEIOH	MI	TTV5CGO
DMYEIOH	MN	Phosphodiesterase 4 (PDE4)
DMYEIOH	MT	DTT
DMYEIOH	MA	Inhibitor
DMYEIOH	RN	Clinical pipeline report, company report or official report of Arcutis Biotherapeutics.
DMYEIOH	RU	https://arcutis.com/trial/arq-154/

DM0VGDC	DI	DM0VGDC
DM0VGDC	DN	ARRY-382
DM0VGDC	MI	TT731LW
DM0VGDC	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM0VGDC	MT	DTT
DM0VGDC	MA	Modulator
DM0VGDC	RN	Company report (Array)
DM0VGDC	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-382/

DM0VGDC	DI	DM0VGDC
DM0VGDC	DN	ARRY-382
DM0VGDC	MI	TT7MRDV
DM0VGDC	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM0VGDC	MT	DTT
DM0VGDC	MA	Inhibitor
DM0VGDC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0VGDC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM17469	DI	DM17469
DM17469	DN	ARRY-502
DM17469	MI	TTQDMX5
DM17469	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM17469	MT	DTT
DM17469	MA	Modulator
DM17469	RN	Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
DM17469	RU	http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-502/

DMTOI7S	DI	DMTOI7S
DMTOI7S	DN	ARRY-520
DMTOI7S	MI	TTTRP0H
DMTOI7S	MN	Kinesin-like protein KIF11 (KIF11)
DMTOI7S	MT	DTT
DMTOI7S	MA	Inhibitor
DMTOI7S	RN	Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct;23(10):1755-62.
DMTOI7S	RU	https://pubmed.ncbi.nlm.nih.gov/19458629

DMJ48AB	DI	DMJ48AB
DMJ48AB	DN	ARRY-797
DMJ48AB	MI	TTYT93M
DMJ48AB	MN	MAP kinase p38 (MAPK12)
DMJ48AB	MT	DTT
DMJ48AB	MA	Inhibitor
DMJ48AB	RN	Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs
DMJ48AB	RU	http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1720505&highlight=

DMJ48AB	DI	DMJ48AB
DMJ48AB	DN	ARRY-797
DMJ48AB	MI	TTWELHI
DMJ48AB	MN	Stress-activated protein kinase (p38)
DMJ48AB	MT	DTT
DMJ48AB	MA	Inhibitor
DMJ48AB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ48AB	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DML27AE	DI	DML27AE
DML27AE	DN	Arverapamil
DML27AE	MI	TT5HONZ
DML27AE	MN	Calcium channel unspecific (CaC)
DML27AE	MT	DTT
DML27AE	MA	Modulator
DML27AE	RN	BJMP 2010;3(4):a342
DML27AE	RU	http://bjmp.org/files/2010-3-4/bjmp-2010-3-4-a342.pdf

DML27AE	DI	DML27AE
DML27AE	DN	Arverapamil
DML27AE	MI	DTUGYRD
DML27AE	MN	P-glycoprotein 1 (ABCB1)
DML27AE	MT	DTP
DML27AE	MA	Substrate
DML27AE	RN	Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.
DML27AE	RU	http://jpet.aspetjournals.org/content/293/2/376.long

DMMX1EJ	DI	DMMX1EJ
DMMX1EJ	DN	AS-1402
DMMX1EJ	MI	TTBHFYQ
DMMX1EJ	MN	Mucin-1 (MUC1)
DMMX1EJ	MT	DTT
DMMX1EJ	RN	Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
DMMX1EJ	RU	https://pubmed.ncbi.nlm.nih.gov/19811637

DMTUMYX	DI	DMTUMYX
DMTUMYX	DN	AS-902330
DMTUMYX	MI	TT6ICRA
DMTUMYX	MN	Fibroblast growth factor-18 (FGF18)
DMTUMYX	MT	DTT
DMTUMYX	MA	Modulator
DMTUMYX	RN	Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014 Jul;66(7):1820-31.
DMTUMYX	RU	https://pubmed.ncbi.nlm.nih.gov/24740822

DMNVU28	DI	DMNVU28
DMNVU28	DN	ASB17061
DMNVU28	MI	TT8VUE0
DMNVU28	MN	Chymase (CYM)
DMNVU28	MT	DTT
DMNVU28	MA	Modulator
DMNVU28	RN	Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
DMNVU28	RU	https://pubmed.ncbi.nlm.nih.gov/23889510

DMMBVCJ	DI	DMMBVCJ
DMMBVCJ	DN	ASCJ-9
DMMBVCJ	MI	TTS64P2
DMMBVCJ	MN	Androgen receptor (AR)
DMMBVCJ	MT	DTT
DMMBVCJ	MA	Enhancer
DMMBVCJ	RN	Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764.
DMMBVCJ	RU	https://pubmed.ncbi.nlm.nih.gov/23928703

DMDQS4W	DI	DMDQS4W
DMDQS4W	DN	ASC-J9
DMDQS4W	MI	TTS64P2
DMDQS4W	MN	Androgen receptor (AR)
DMDQS4W	MT	DTT
DMDQS4W	MA	Inhibitor
DMDQS4W	RN	New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73.
DMDQS4W	RU	https://pubmed.ncbi.nlm.nih.gov/23219429

DMZF68E	DI	DMZF68E
DMZF68E	DN	Ascrolimus
DMZF68E	MI	TTFH2RS
DMZF68E	MN	FK506-binding protein (FKBP)
DMZF68E	MT	DTT
DMZF68E	MA	Modulator
DMZF68E	RN	Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91.
DMZF68E	RU	https://pubmed.ncbi.nlm.nih.gov/8588225

DM1CLKO	DI	DM1CLKO
DM1CLKO	DN	ASKP-1240
DM1CLKO	MI	TTN6Y9A
DM1CLKO	MN	CD40L receptor (CD40)
DM1CLKO	MT	DTT
DM1CLKO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
DM1CLKO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874

DM35S2I	DI	DM35S2I
DM35S2I	DN	ASM-024
DM35S2I	MI	TTJSZTB
DM35S2I	MN	Nicotinic acetylcholine receptor (nAChR)
DM35S2I	MT	DTT
DM35S2I	MA	Agonist
DM35S2I	RN	Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
DM35S2I	RU	https://pubmed.ncbi.nlm.nih.gov/26252534

DMTHR4U	DI	DMTHR4U
DMTHR4U	DN	ASM8
DMTHR4U	MI	TTU3Y87
DMTHR4U	MN	CCR3 messenger RNA (CCR3 mRNA)
DMTHR4U	MT	DTT
DMTHR4U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60).
DMTHR4U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60

DM92X7N	DI	DM92X7N
DM92X7N	DN	ASN002
DM92X7N	MI	TT2HUPM
DM92X7N	MN	SYK messenger RNA (SYK mRNA)
DM92X7N	MT	DTT
DM92X7N	MA	Inhibitor
DM92X7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM92X7N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWPGLS	DI	DMWPGLS
DMWPGLS	DN	ASN100
DMWPGLS	MI	TT5FLYB
DMWPGLS	MN	Staphylococcus Alpha-hemolysin (Stap-coc hly)
DMWPGLS	MT	DTT
DMWPGLS	MA	Modulator
DMWPGLS	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMWPGLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMWPGLS	DI	DMWPGLS
DMWPGLS	DN	ASN100
DMWPGLS	MI	TTKE96O
DMWPGLS	MN	Staphylococcus Five leukocidin toxins (Stap-coc lukF)
DMWPGLS	MT	DTT
DMWPGLS	MA	Modulator
DMWPGLS	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMWPGLS	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DM6HJ3V	DI	DM6HJ3V
DM6HJ3V	DN	ASP0819
DM6HJ3V	MI	TT7M9I6
DM6HJ3V	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DM6HJ3V	MT	DTT
DM6HJ3V	MA	Activator
DM6HJ3V	RN	Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
DM6HJ3V	RU	https://pubmed.ncbi.nlm.nih.gov/33328761

DME8XD7	DI	DME8XD7
DME8XD7	DN	ASP-1707
DME8XD7	MI	TT8R70G
DME8XD7	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DME8XD7	MT	DTT
DME8XD7	MA	Antagonist
DME8XD7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032657)
DME8XD7	RU	http://adisinsight.springer.com/drugs/800032657

DMBADQV	DI	DMBADQV
DMBADQV	DN	ASP-3291
DMBADQV	MI	TTEOSZT
DMBADQV	MN	Melanocortin receptor (MCR)
DMBADQV	MT	DTT
DMBADQV	MA	Modulator
DMBADQV	RN	Clinical pipeline report, company report or official report of Drais Pharmaceuticals.
DMBADQV	RU	http://www.draispharma.com/press.php

DM4KTN6	DI	DM4KTN6
DM4KTN6	DN	ASP-3652
DM4KTN6	MI	TTMXGCW
DM4KTN6	MN	Adrenergic receptor beta-3 (ADRB3)
DM4KTN6	MT	DTT
DM4KTN6	MA	Agonist
DM4KTN6	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029610)
DM4KTN6	RU	http://adisinsight.springer.com/drugs/800029610

DMZUAH2	DI	DMZUAH2
DMZUAH2	DN	ASP-4901
DMZUAH2	MI	TTZOEBC
DMZUAH2	MN	Phosphodiesterase 9 (PDE9)
DMZUAH2	MT	DTT
DMZUAH2	MA	Inhibitor
DMZUAH2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070)
DMZUAH2	RU	http://adisinsight.springer.com/drugs/800033070

DMTF24A	DI	DMTF24A
DMTF24A	DN	ASP-7035
DMTF24A	MI	TTK8R02
DMTF24A	MN	Vasopressin V2 receptor (V2R)
DMTF24A	MT	DTT
DMTF24A	MA	Agonist
DMTF24A	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
DMTF24A	RU	http://adisinsight.springer.com/drugs/800030285

DMGDF2X	DI	DMGDF2X
DMGDF2X	DN	ASP-7147
DMGDF2X	MI	TTC1MVT
DMGDF2X	MN	Gastrin-releasing peptide receptor (GRPR)
DMGDF2X	MT	DTT
DMGDF2X	MA	Antagonist
DMGDF2X	RN	Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
DMGDF2X	RU	http://www.astellas.com/en/corporate/news/detail/astellas-and-drais-partner-to-.html

DM3TN1A	DI	DM3TN1A
DM3TN1A	DN	ASP7991
DM3TN1A	MI	TTBUYHA
DM3TN1A	MN	Extracellular calcium-sensing receptor (CASR)
DM3TN1A	MT	DTT
DM3TN1A	MA	Agonist
DM3TN1A	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
DM3TN1A	RU	http://adisinsight.springer.com/drugs/800035616

DMR1MIV	DI	DMR1MIV
DMR1MIV	DN	ASP8062
DMR1MIV	MI	TTDCVZW
DMR1MIV	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMR1MIV	MT	DTT
DMR1MIV	MA	Modulator
DMR1MIV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR1MIV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMYK1JU	DI	DMYK1JU
DMYK1JU	DN	ASP8232
DMYK1JU	MI	TT7HC21
DMYK1JU	MN	Membrane copper amine oxidase (AOC3)
DMYK1JU	MT	DTT
DMYK1JU	MA	Inhibitor
DMYK1JU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYK1JU	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMHLXUY	DI	DMHLXUY
DMHLXUY	DN	ASP8273
DMHLXUY	MI	TTGKNB4
DMHLXUY	MN	Epidermal growth factor receptor (EGFR)
DMHLXUY	MT	DTT
DMHLXUY	MA	Inhibitor
DMHLXUY	RN	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
DMHLXUY	RU	http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8083

DMBZQS7	DI	DMBZQS7
DMBZQS7	DN	ASP-8477
DMBZQS7	MI	TTVJ1D8
DMBZQS7	MN	Vascular endothelial growth factor receptor (VEGFR)
DMBZQS7	MT	DTT
DMBZQS7	MA	Modulator
DMBZQS7	RN	ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
DMBZQS7	RU	https://clinicaltrials.gov/ct2/show/NCT02065349

DM2MSGF	DI	DM2MSGF
DM2MSGF	DN	ASP9831
DM2MSGF	MI	TTV5CGO
DM2MSGF	MN	Phosphodiesterase 4 (PDE4)
DM2MSGF	MT	DTT
DM2MSGF	MA	Inhibitor
DM2MSGF	RN	Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5.
DM2MSGF	RU	https://pubmed.ncbi.nlm.nih.gov/24530600

DMMKW8L	DI	DMMKW8L
DMMKW8L	DN	ASTX660
DMMKW8L	MI	TTK3WBU
DMMKW8L	MN	XIAP messenger RNA (XIAP mRNA)
DMMKW8L	MT	DTT
DMMKW8L	MA	Inhibitor
DMMKW8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMKW8L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMARIQK	DI	DMARIQK
DMARIQK	DN	AT-527
DMARIQK	MI	TTSUKYD
DMARIQK	MN	Virus RNA-dependent RNA polymerase (Viru RdRP)
DMARIQK	MT	DTT
DMARIQK	MA	Inhibitor
DMARIQK	RN	AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02479-20.
DMARIQK	RU	https://pubmed.ncbi.nlm.nih.gov/33558299

DM35KDA	DI	DM35KDA
DM35KDA	DN	Ataciguat
DM35KDA	MI	TTJME02
DM35KDA	MN	Atrial natriuretic peptide receptor A (NPR1)
DM35KDA	MT	DTT
DM35KDA	MA	Activator
DM35KDA	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM35KDA	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DM6ABD9	DI	DM6ABD9
DM6ABD9	DN	ATHX-105
DM6ABD9	MI	TTWJBZ5
DM6ABD9	MN	5-HT 2C receptor (HTR2C)
DM6ABD9	MT	DTT
DM6ABD9	MA	Agonist
DM6ABD9	RN	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
DM6ABD9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TT5HONZ
DMWP59B	MN	Calcium channel unspecific (CaC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TTM7WCE
DMWP59B	MN	Ion channel unspecific (IC)
DMWP59B	MT	DTT
DMWP59B	MA	Antagonist
DMWP59B	RN	A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.
DMWP59B	RU	https://pubmed.ncbi.nlm.nih.gov/22205496

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TT1VOHK
DMWP59B	MN	Potassium channel unspecific (KC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMWP59B	DI	DMWP59B
DMWP59B	DN	ATI-2042
DMWP59B	MI	TTRK8B9
DMWP59B	MN	Sodium channel unspecific (NaC)
DMWP59B	MT	DTT
DMWP59B	MA	Agonist
DMWP59B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWP59B	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMT5QYJ	DI	DMT5QYJ
DMT5QYJ	DN	ATI-2173
DMT5QYJ	MI	TTT4SY6
DMT5QYJ	MN	Hepatitis B virus Polymerase (HBV P)
DMT5QYJ	MT	DTT
DMT5QYJ	MA	Inhibitor
DMT5QYJ	RN	ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20.
DMT5QYJ	RU	https://pubmed.ncbi.nlm.nih.gov/32540975

DMTY6OF	DI	DMTY6OF
DMTY6OF	DN	ATI-501
DMTY6OF	MI	TT6DM01
DMTY6OF	MN	Janus kinase 1 (JAK-1)
DMTY6OF	MT	DTT
DMTY6OF	MA	Inhibitor
DMTY6OF	RN	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
DMTY6OF	RU	https://www.aclaristx.com/pipeline/

DMTY6OF	DI	DMTY6OF
DMTY6OF	DN	ATI-501
DMTY6OF	MI	TTT7PJU
DMTY6OF	MN	Janus kinase 3 (JAK-3)
DMTY6OF	MT	DTT
DMTY6OF	MA	Inhibitor
DMTY6OF	RN	Clinical pipeline report, company report or official report of Aclaris Therapeutics.
DMTY6OF	RU	https://www.aclaristx.com/pipeline/

DM8NODR	DI	DM8NODR
DM8NODR	DN	ATI-502
DM8NODR	MI	TT6DM01
DM8NODR	MN	Janus kinase 1 (JAK-1)
DM8NODR	MT	DTT
DM8NODR	MA	Inhibitor
DM8NODR	RN	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
DM8NODR	RU	https://clinicaltrials.gov/ct2/show/NCT03759340

DM8NODR	DI	DM8NODR
DM8NODR	DN	ATI-502
DM8NODR	MI	TTT7PJU
DM8NODR	MN	Janus kinase 3 (JAK-3)
DM8NODR	MT	DTT
DM8NODR	MA	Inhibitor
DM8NODR	RN	ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
DM8NODR	RU	https://clinicaltrials.gov/ct2/show/NCT03759340

DMK3VYU	DI	DMK3VYU
DMK3VYU	DN	ATI-502
DMK3VYU	MI	TTJSQEF
DMK3VYU	MN	Tyrosine-protein kinase (PTK)
DMK3VYU	MT	DTT
DMK3VYU	MA	Inhibitor
DMK3VYU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK3VYU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMYAQV2	DI	DMYAQV2
DMYAQV2	DN	ATL101
DMYAQV2	MI	TT9G4N0
DMYAQV2	MN	Glutamate carboxypeptidase II (GCPII)
DMYAQV2	MT	DTT
DMYAQV2	MA	Modulator
DMYAQV2	RN	Clinical pipeline report, company report or official report of Atlab pharma.
DMYAQV2	RU	http://www.atlab-pharma.com/pipeline_atl101.html

DMD0I29	DI	DMD0I29
DMD0I29	DN	ATL-104
DMD0I29	MI	TTDB5IS
DMD0I29	MN	Receptor unspecific (Rec)
DMD0I29	MT	DTT
DMD0I29	MA	Modulator
DMD0I29	RN	Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9.
DMD0I29	RU	https://pubmed.ncbi.nlm.nih.gov/18997832

DM3POT6	DI	DM3POT6
DM3POT6	DN	ATL1102
DM3POT6	MI	TTJMF9P
DM3POT6	MN	ITGA4 messenger RNA (ITGA4 mRNA)
DM3POT6	MT	DTT
DM3POT6	MA	Modulator
DM3POT6	RN	CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8.
DM3POT6	RU	https://www.ncbi.nlm.nih.gov/pubmed/25239835

DM7I56B	DI	DM7I56B
DM7I56B	DN	ATM AVI
DM7I56B	MI	TTUE541
DM7I56B	MN	Leukocyte surface antigen Leu-16 (CD20)
DM7I56B	MT	DTT
DM7I56B	MA	Modulator
DM7I56B	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
DM7I56B	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628

DM4T9RS	DI	DM4T9RS
DM4T9RS	DN	ATN-161
DM4T9RS	MI	TTH4QIS
DM4T9RS	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DM4T9RS	MT	DTT
DM4T9RS	MA	Antagonist
DM4T9RS	RN	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
DM4T9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16985061

DM4T9RS	DI	DM4T9RS
DM4T9RS	DN	ATN-161
DM4T9RS	MI	TT69TQN
DM4T9RS	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4T9RS	MT	DTT
DM4T9RS	MA	Antagonist
DM4T9RS	RN	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
DM4T9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16985061

DMQJ5DV	DI	DMQJ5DV
DMQJ5DV	DN	ATN-224
DMQJ5DV	MI	TT6RVLG
DMQJ5DV	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMQJ5DV	MT	DTT
DMQJ5DV	MA	Inhibitor
DMQJ5DV	RN	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
DMQJ5DV	RU	https://pubmed.ncbi.nlm.nih.gov/16914587

DMUXO3Z	DI	DMUXO3Z
DMUXO3Z	DN	AUS-131
DMUXO3Z	MI	DEUX61H
DMUXO3Z	MN	Biphenyl dioxygenase (bphC)
DMUXO3Z	MT	DME
DMUXO3Z	MA	Metabolism
DMUXO3Z	RN	Flavonoids biotransformation by bacterial non-heme dioxygenases, biphenyl and naphthalene dioxygenase. Appl Microbiol Biotechnol. 2011 Jul;91(2):219-28.
DMUXO3Z	RU	https://pubmed.ncbi.nlm.nih.gov/21626021

DMZMSQJ	DI	DMZMSQJ
DMZMSQJ	DN	AUS-131
DMZMSQJ	MI	TTOM3J0
DMZMSQJ	MN	Estrogen receptor beta (ESR2)
DMZMSQJ	MT	DTT
DMZMSQJ	MA	Agonist
DMZMSQJ	RN	S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
DMZMSQJ	RU	https://pubmed.ncbi.nlm.nih.gov/15883431

DMN7VK1	DI	DMN7VK1
DMN7VK1	DN	AV-101
DMN7VK1	MI	TT9IK2Z
DMN7VK1	MN	N-methyl-D-aspartate receptor (NMDAR)
DMN7VK1	MT	DTT
DMN7VK1	MA	Antagonist
DMN7VK1	RN	Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc.
DMN7VK1	RU	http://www.vistagen.com/?page_id=198

DMDL9WU	DI	DMDL9WU
DMDL9WU	DN	AV-201
DMDL9WU	MI	TTN451K
DMDL9WU	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMDL9WU	MT	DTT
DMDL9WU	MA	Modulator
DMDL9WU	RN	UCSF report
DMDL9WU	RU	http://pdcenter.neurology.ucsf.edu/research/learn-about-closed-studies/gene-therapy-aadc-phase-i

DMASRP3	DI	DMASRP3
DMASRP3	DN	AVA-101
DMASRP3	MI	TT9HKJA
DMASRP3	MN	Vascular endothelial growth factor (VEGF)
DMASRP3	MT	DTT
DMASRP3	MA	Modulator
DMASRP3	RN	Clinical pipeline report, company report or official report of Avalanche Biotechnologies.
DMASRP3	RU	http://www.avalanchebiotech.com/

DMORJD4	DI	DMORJD4
DMORJD4	DN	AVB-500
DMORJD4	MI	TT69QD2
DMORJD4	MN	AXL receptor tyrosine kinase ligand (GAS6)
DMORJD4	MT	DTT
DMORJD4	MA	Inhibitor
DMORJD4	RN	Clinical pipeline report, company report or official report of Aravive.
DMORJD4	RU	https://aravive.com/pipeline/

DMLAOHX	DI	DMLAOHX
DMLAOHX	DN	Avdoralimab
DMLAOHX	MI	TTQLO2H
DMLAOHX	MN	HUMAN C5a receptor (C5aR)
DMLAOHX	MT	DTT
DMLAOHX	MA	Inhibitor
DMLAOHX	RN	Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77.
DMLAOHX	RU	https://pubmed.ncbi.nlm.nih.gov/29691378

DMESMHU	DI	DMESMHU
DMESMHU	DN	AVE-0657
DMESMHU	MI	TTFZVPO
DMESMHU	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMESMHU	MT	DTT
DMESMHU	MA	Inhibitor
DMESMHU	RN	Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53.
DMESMHU	RU	https://pubmed.ncbi.nlm.nih.gov/24384423

DMA42BV	DI	DMA42BV
DMA42BV	DN	AVE-2268
DMA42BV	MI	TTLWPVF
DMA42BV	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMA42BV	MT	DTT
DMA42BV	MA	Modulator
DMA42BV	RN	Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
DMA42BV	RU	https://pubmed.ncbi.nlm.nih.gov/19137908

DMQGI73	DI	DMQGI73
DMQGI73	DN	AVI-4557
DMQGI73	MI	TTWP7HQ
DMQGI73	MN	CYP3A4 messenger RNA (CYP3A4 mRNA)
DMQGI73	MT	DTT
DMQGI73	RN	Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002 Jul;30(7):757-62.
DMQGI73	RU	https://pubmed.ncbi.nlm.nih.gov/12065433

DMUOYQR	DI	DMUOYQR
DMUOYQR	DN	AVI-5126
DMUOYQR	MI	TTNQ5ZP
DMUOYQR	MN	Myc messenger RNA (MYC mRNA)
DMUOYQR	MT	DTT
DMUOYQR	RN	Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201.
DMUOYQR	RU	https://pubmed.ncbi.nlm.nih.gov/22149555

DMJFLBC	DI	DMJFLBC
DMJFLBC	DN	AVN 101
DMJFLBC	MI	TTJS8PY
DMJFLBC	MN	5-HT 6 receptor (HTR6)
DMJFLBC	MT	DTT
DMJFLBC	MA	Modulator
DMJFLBC	RN	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
DMJFLBC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/

DMK2LGM	DI	DMK2LGM
DMK2LGM	DN	AVN 322
DMK2LGM	MI	TTJS8PY
DMK2LGM	MN	5-HT 6 receptor (HTR6)
DMK2LGM	MT	DTT
DMK2LGM	MA	Modulator
DMK2LGM	RN	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
DMK2LGM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/

DMOGFNI	DI	DMOGFNI
DMOGFNI	DN	AVN-101
DMOGFNI	MI	TTO9X1H
DMOGFNI	MN	5-HT 7 receptor (HTR7)
DMOGFNI	MT	DTT
DMOGFNI	MA	Antagonist
DMOGFNI	RN	AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
DMOGFNI	RU	https://pubmed.ncbi.nlm.nih.gov/27232215

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTZ97H5
DMVADGZ	MN	Phosphodiesterase 4A (PDE4A)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTVIAT9
DMVADGZ	MN	Phosphodiesterase 4B (PDE4B)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMVADGZ	DI	DMVADGZ
DMVADGZ	DN	AWD-12-281
DMVADGZ	MI	TTSKMI8
DMVADGZ	MN	Phosphodiesterase 4D (PDE4D)
DMVADGZ	MT	DTT
DMVADGZ	MA	Inhibitor
DMVADGZ	RN	The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
DMVADGZ	RU	https://pubmed.ncbi.nlm.nih.gov/16354405

DMTAEMB	DI	DMTAEMB
DMTAEMB	DN	AX-200
DMTAEMB	MI	TTC70AJ
DMTAEMB	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMTAEMB	MT	DTT
DMTAEMB	MA	Modulator
DMTAEMB	RN	Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
DMTAEMB	RU	https://pubmed.ncbi.nlm.nih.gov/23963331

DMTQ1Y3	DI	DMTQ1Y3
DMTQ1Y3	DN	AXL-1717
DMTQ1Y3	MI	TTHRID2
DMTQ1Y3	MN	Insulin-like growth factor I receptor (IGF1R)
DMTQ1Y3	MT	DTT
DMTQ1Y3	MA	Inhibitor
DMTQ1Y3	RN	Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
DMTQ1Y3	RU	https://pubmed.ncbi.nlm.nih.gov/20698809

DM4CJNE	DI	DM4CJNE
DM4CJNE	DN	AYX-1
DM4CJNE	MI	TTUQREN
DM4CJNE	MN	Early growth response protein 1 (EGR-1)
DM4CJNE	MT	DTT
DM4CJNE	MA	Inhibitor
DM4CJNE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4CJNE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMHFUJT	DI	DMHFUJT
DMHFUJT	DN	AZ-01, PEGylated interferon-beta
DMHFUJT	MI	TT4TZ8J
DMHFUJT	MN	Interferon-beta (IFNB1)
DMHFUJT	MT	DTT
DMHFUJT	MA	Modulator
DMHFUJT	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DMHFUJT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DM9LKYP	DI	DM9LKYP
DM9LKYP	DN	AZ-40140
DM9LKYP	MI	TTMXGCW
DM9LKYP	MN	Adrenergic receptor beta-3 (ADRB3)
DM9LKYP	MT	DTT
DM9LKYP	MA	Agonist
DM9LKYP	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DM9LKYP	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMM0N1F	DI	DMM0N1F
DMM0N1F	DN	AZD-0865
DMM0N1F	MI	TTLOKXP
DMM0N1F	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMM0N1F	MT	DTT
DMM0N1F	MA	Modulator
DMM0N1F	RN	Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
DMM0N1F	RU	https://pubmed.ncbi.nlm.nih.gov/17081503

DM7B1AR	DI	DM7B1AR
DM7B1AR	DN	AZD-1446
DM7B1AR	MI	TTL1ATN
DM7B1AR	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM7B1AR	MT	DTT
DM7B1AR	MA	Modulator
DM7B1AR	RN	A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65.
DM7B1AR	RU	https://www.ncbi.nlm.nih.gov/pubmed/23640072

DMLK59M	DI	DMLK59M
DMLK59M	DN	AZD1480
DMLK59M	MI	TTRMX3V
DMLK59M	MN	Janus kinase 2 (JAK-2)
DMLK59M	MT	DTT
DMLK59M	MA	Modulator
DMLK59M	RN	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97.
DMLK59M	RU	https://pubmed.ncbi.nlm.nih.gov/19962667

DMUE90I	DI	DMUE90I
DMUE90I	DN	AZD1656
DMUE90I	MI	TTDLNGZ
DMUE90I	MN	Glucokinase (GCK)
DMUE90I	MT	DTT
DMUE90I	MA	Activator
DMUE90I	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMUE90I	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMX5SG7	DI	DMX5SG7
DMX5SG7	DN	AZD1772//RDX5791
DMX5SG7	MI	TTFZVPO
DMX5SG7	MN	Sodium/hydrogen exchanger 3 (SLC9A3)
DMX5SG7	MT	DTT
DMX5SG7	MA	Modulator
DMX5SG7	RN	RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.
DMX5SG7	RU	http://www.gastrojournal.org/article/S0016-5085(11)60405-8/pdf

DMMCL9F	DI	DMMCL9F
DMMCL9F	DN	AZD1981
DMMCL9F	MI	TTQDMX5
DMMCL9F	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMMCL9F	MT	DTT
DMMCL9F	MA	Antagonist
DMMCL9F	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMMCL9F	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DES5XRU
DMOEARH	MN	Cytochrome P450 2C8 (CYP2C8)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DE4LYSA
DMOEARH	MN	Cytochrome P450 3A4 (CYP3A4)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	DEIBDNY
DMOEARH	MN	Cytochrome P450 3A5 (CYP3A5)
DMOEARH	MT	DME
DMOEARH	MA	Metabolism
DMOEARH	RN	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
DMOEARH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25805799

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTX4GLS
DMOEARH	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOEARH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTCJG29
DMOEARH	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
DMOEARH	RU	https://pubmed.ncbi.nlm.nih.gov/24309100

DMOEARH	DI	DMOEARH
DMOEARH	DN	Azd2014
DMOEARH	MI	TTWDKCL
DMOEARH	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DMOEARH	MT	DTT
DMOEARH	MA	Inhibitor
DMOEARH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOEARH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGQSVX	DI	DMGQSVX
DMGQSVX	DN	AZD-2115
DMGQSVX	MI	TT2CJVK
DMGQSVX	MN	Adrenergic receptor beta-2 (ADRB2)
DMGQSVX	MT	DTT
DMGQSVX	MA	Agonist
DMGQSVX	RN	Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83.
DMGQSVX	RU	https://pubmed.ncbi.nlm.nih.gov/22917191

DMGQSVX	DI	DMGQSVX
DMGQSVX	DN	AZD-2115
DMGQSVX	MI	TTOXS3C
DMGQSVX	MN	Muscarinic acetylcholine receptor (CHRM)
DMGQSVX	MT	DTT
DMGQSVX	MA	Agonist
DMGQSVX	RN	Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83.
DMGQSVX	RU	https://pubmed.ncbi.nlm.nih.gov/22917191

DM8FZOG	DI	DM8FZOG
DM8FZOG	DN	AZD-2327
DM8FZOG	MI	TT27RFC
DM8FZOG	MN	Opioid receptor delta (OPRD1)
DM8FZOG	MT	DTT
DM8FZOG	MA	Agonist
DM8FZOG	RN	Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
DM8FZOG	RU	https://pubmed.ncbi.nlm.nih.gov/21444630

DMF34UY	DI	DMF34UY
DMF34UY	DN	AZD-2423
DMF34UY	MI	TTFZYTO
DMF34UY	MN	C-C chemokine receptor type 2 (CCR2)
DMF34UY	MT	DTT
DMF34UY	MA	Antagonist
DMF34UY	RN	CA patent application no. 841416, Method of selecting therapeutic indications.
DMF34UY	RU	http://www.google.com/patents/CA2841416A1?cl=en

DMZLGQV	DI	DMZLGQV
DMZLGQV	DN	AZD2624
DMZLGQV	MI	TTBPGLU
DMZLGQV	MN	Neuromedin-K receptor (TACR3)
DMZLGQV	MT	DTT
DMZLGQV	MA	Modulator
DMZLGQV	RN	The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204.
DMZLGQV	RU	https://www.ncbi.nlm.nih.gov/pubmed/24525659

DMYUNXP	DI	DMYUNXP
DMYUNXP	DN	AZD2811
DMYUNXP	MI	TTCY4SB
DMYUNXP	MN	Aurora kinase (AURK)
DMYUNXP	MT	DTT
DMYUNXP	MA	Inhibitor
DMYUNXP	RN	Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17.
DMYUNXP	RU	https://pubmed.ncbi.nlm.nih.gov/26865565

DM6AI9N	DI	DM6AI9N
DM6AI9N	DN	AZD-2927
DM6AI9N	MI	TTM7WCE
DM6AI9N	MN	Ion channel unspecific (IC)
DM6AI9N	MT	DTT
DM6AI9N	MA	Modulator
DM6AI9N	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
DM6AI9N	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7704

DME8Z5M	DI	DME8Z5M
DME8Z5M	DN	AZD-3199
DME8Z5M	MI	TT2CJVK
DME8Z5M	MN	Adrenergic receptor beta-2 (ADRB2)
DME8Z5M	MT	DTT
DME8Z5M	MA	Agonist
DME8Z5M	RN	Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762.
DME8Z5M	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/

DMANC59	DI	DMANC59
DMANC59	DN	AZD-3241
DMANC59	MI	TTVCZPI
DMANC59	MN	Myeloperoxidase (MPO)
DMANC59	MT	DTT
DMANC59	MA	Inhibitor
DMANC59	RN	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
DMANC59	RU	https://pubmed.ncbi.nlm.nih.gov/26137956

DML9M5S	DI	DML9M5S
DML9M5S	DN	AZD-4017
DML9M5S	MI	TTN7BL9
DML9M5S	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DML9M5S	MT	DTT
DML9M5S	MA	Inhibitor
DML9M5S	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DML9M5S	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DM8SVIY	DI	DM8SVIY
DM8SVIY	DN	AZD4635
DM8SVIY	MI	TTM2AOE
DM8SVIY	MN	Adenosine A2a receptor (ADORA2A)
DM8SVIY	MT	DTT
DM8SVIY	MA	Antagonist
DM8SVIY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8SVIY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFVL5J	DI	DMFVL5J
DMFVL5J	DN	AZD-4877
DMFVL5J	MI	TTTRP0H
DMFVL5J	MN	Kinesin-like protein KIF11 (KIF11)
DMFVL5J	MT	DTT
DMFVL5J	MA	Inhibitor
DMFVL5J	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMFVL5J	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DM3JSFK	DI	DM3JSFK
DM3JSFK	DN	AZD-5069
DM3JSFK	MI	TT30C9G
DM3JSFK	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM3JSFK	MT	DTT
DM3JSFK	MA	Inhibitor
DM3JSFK	RN	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
DM3JSFK	RU	https://pubmed.ncbi.nlm.nih.gov/25736418

DMOZ04X	DI	DMOZ04X
DMOZ04X	DN	AZD-5213
DMOZ04X	MI	TT9JNIC
DMOZ04X	MN	Histamine H3 receptor (H3R)
DMOZ04X	MT	DTT
DMOZ04X	MA	Antagonist
DMOZ04X	RN	SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
DMOZ04X	RU	https://pubmed.ncbi.nlm.nih.gov/22542742

DMJ8V3K	DI	DMJ8V3K
DMJ8V3K	DN	AZD5312
DMJ8V3K	MI	TTS64P2
DMJ8V3K	MN	Androgen receptor (AR)
DMJ8V3K	MT	DTT
DMJ8V3K	MA	Modulator
DMJ8V3K	RN	Company report (Astrazeneca)
DMJ8V3K	RU	https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html

DM0PFNC	DI	DM0PFNC
DM0PFNC	DN	AZD6738
DM0PFNC	MI	TT8ZYBQ
DM0PFNC	MN	Serine/threonine-protein kinase ATR (FRP1)
DM0PFNC	MT	DTT
DM0PFNC	MA	Inhibitor
DM0PFNC	RN	National Cancer Institute Drug Dictionary (drug id 754022).
DM0PFNC	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754022

DMIBXK0	DI	DMIBXK0
DMIBXK0	DN	AZD-7009
DMIBXK0	MI	TT1VOHK
DMIBXK0	MN	Potassium channel unspecific (KC)
DMIBXK0	MT	DTT
DMIBXK0	MA	Modulator
DMIBXK0	RN	Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23.
DMIBXK0	RU	https://pubmed.ncbi.nlm.nih.gov/24508473

DMC48SP	DI	DMC48SP
DMC48SP	DN	AZD-7268
DMC48SP	MI	TTN4QDT
DMC48SP	MN	Opioid receptor (OPR)
DMC48SP	MT	DTT
DMC48SP	MA	Modulator
DMC48SP	RN	EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
DMC48SP	RU	http://www.google.com/patents/EP2774991A1?cl=en

DMXF26Y	DI	DMXF26Y
DMXF26Y	DN	AZD7325
DMXF26Y	MI	TTAN6JD
DMXF26Y	MN	Glutamate receptor AMPA (GRIA)
DMXF26Y	MT	DTT
DMXF26Y	MA	Agonist
DMXF26Y	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMXF26Y	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMEW3K9	DI	DMEW3K9
DMEW3K9	DN	AZD7624
DMEW3K9	MI	TTWELHI
DMEW3K9	MN	Stress-activated protein kinase (p38)
DMEW3K9	MT	DTT
DMEW3K9	MA	Inhibitor
DMEW3K9	RN	Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
DMEW3K9	RU	https://pubmed.ncbi.nlm.nih.gov/25599809

DMLXFM6	DI	DMLXFM6
DMLXFM6	DN	AZD-8683
DMLXFM6	MI	TTOXS3C
DMLXFM6	MN	Muscarinic acetylcholine receptor (CHRM)
DMLXFM6	MT	DTT
DMLXFM6	MA	Antagonist
DMLXFM6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17).
DMLXFM6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17

DM0M7QW	DI	DM0M7QW
DM0M7QW	DN	AZD-8848
DM0M7QW	MI	TTRJ1K4
DM0M7QW	MN	Toll-like receptor 7 (TLR7)
DM0M7QW	MT	DTT
DM0M7QW	MA	Agonist
DM0M7QW	RN	Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
DM0M7QW	RU	https://pubmed.ncbi.nlm.nih.gov/22726593

DMFLCW4	DI	DMFLCW4
DMFLCW4	DN	AZD8931
DMFLCW4	MI	TT6EO5L
DMFLCW4	MN	Erbb2 tyrosine kinase receptor (HER2)
DMFLCW4	MT	DTT
DMFLCW4	MA	Inhibitor
DMFLCW4	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMFLCW4	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMJGYPK	DI	DMJGYPK
DMJGYPK	DN	AZD9056
DMJGYPK	MI	TT473XN
DMJGYPK	MN	P2X purinoceptor 7 (P2RX7)
DMJGYPK	MT	DTT
DMJGYPK	MA	Antagonist
DMJGYPK	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMJGYPK	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMVKPEZ	DI	DMVKPEZ
DMVKPEZ	DN	AZD-9164
DMVKPEZ	MI	TTOXS3C
DMVKPEZ	MN	Muscarinic acetylcholine receptor (CHRM)
DMVKPEZ	MT	DTT
DMVKPEZ	MA	Antagonist
DMVKPEZ	RN	The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6.
DMVKPEZ	RU	https://pubmed.ncbi.nlm.nih.gov/22047691

DMB87M3	DI	DMB87M3
DMB87M3	DN	AZD9668
DMB87M3	MI	TTPLTSQ
DMB87M3	MN	Neutrophil elastase (NE)
DMB87M3	MT	DTT
DMB87M3	MA	Inhibitor
DMB87M3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMB87M3	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMQOTHP	DI	DMQOTHP
DMQOTHP	DN	AZD9833
DMQOTHP	MI	TTZAYWL
DMQOTHP	MN	Estrogen receptor (ESR)
DMQOTHP	MT	DTT
DMQOTHP	MA	Degrader
DMQOTHP	RN	Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. J Med Chem. 2020 Dec 10;63(23):14530-14559.
DMQOTHP	RU	https://pubmed.ncbi.nlm.nih.gov/32910656

DME0JMV	DI	DME0JMV
DME0JMV	DN	AZX-100
DME0JMV	MI	TT5IP87
DME0JMV	MN	Heat shock protein 20 (HSP20)
DME0JMV	MT	DTT
DME0JMV	MA	Modulator
DME0JMV	RN	Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21.
DME0JMV	RU	https://pubmed.ncbi.nlm.nih.gov/20140957

DMOMDA4	DI	DMOMDA4
DMOMDA4	DN	B-701
DMOMDA4	MI	TTST7KB
DMOMDA4	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMOMDA4	MT	DTT
DMOMDA4	MA	Antagonist
DMOMDA4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOMDA4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7586F	DI	DM7586F
DM7586F	DN	Bafetinib
DM7586F	MI	TTS7G69
DM7586F	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM7586F	MT	DTT
DM7586F	MA	Modulator
DM7586F	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7586F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7586F	DI	DM7586F
DM7586F	DN	Bafetinib
DM7586F	MI	TT1RWNJ
DM7586F	MN	Tyrosine-protein kinase Lyn (JTK8)
DM7586F	MT	DTT
DM7586F	MA	Modulator
DM7586F	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM7586F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT2J34L
DM4C7E6	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/1848292

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTV9A7R
DM4C7E6	MN	Lactoylglutathione lyase (GLO1)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/18258440

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT2IYXF
DM4C7E6	MN	L-selectin (SELL)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTNGKET
DM4C7E6	MN	Prolyl endopeptidase (PREP)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/18650094

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTE5VG0
DM4C7E6	MN	P-selectin (SELP)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/17302397

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TTF8CQI
DM4C7E6	MN	Tumor necrosis factor (TNF)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/20850306

DM4C7E6	DI	DM4C7E6
DM4C7E6	DN	BAICALEIN
DM4C7E6	MI	TT7RJY8
DM4C7E6	MN	Xanthine dehydrogenase/oxidase (XDH)
DM4C7E6	MT	DTT
DM4C7E6	MA	Inhibitor
DM4C7E6	RN	Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
DM4C7E6	RU	https://pubmed.ncbi.nlm.nih.gov/3379415

DM3WCL4	DI	DM3WCL4
DM3WCL4	DN	Baltaleucel-T
DM3WCL4	MI	TTXQYT6
DM3WCL4	MN	T-cells (T-cells)
DM3WCL4	MT	DTT
DM3WCL4	MA	Immunomodulator
DM3WCL4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3WCL4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMSZOXQ	DI	DMSZOXQ
DMSZOXQ	DN	Baminercept
DMSZOXQ	MI	TTFO0PM
DMSZOXQ	MN	Lymphotoxin beta receptor (LTBR)
DMSZOXQ	MT	DTT
DMSZOXQ	MA	Antagonist
DMSZOXQ	RN	ClinicalTrials.gov (NCT01552681) Baminercept in Sj ren's Syndrome. U.S. National Institutes of Health.
DMSZOXQ	RU	https://clinicaltrials.gov/ct2/show/NCT01552681

DM0TZEP	DI	DM0TZEP
DM0TZEP	DN	Bamosiran
DM0TZEP	MI	TTG8ZWP
DM0TZEP	MN	ADRB2 messenger RNA (ADRB2 mRNA)
DM0TZEP	MT	DTT
DM0TZEP	MA	Inhibitor
DM0TZEP	RN	Clinical pipeline report, company report or official report of Sylentis.
DM0TZEP	RU	https://www.sylentis.com/index.php/en/pipeline/bamosiran

DMW03YD	DI	DMW03YD
DMW03YD	DN	BAN2401
DMW03YD	MI	TTE4KHA
DMW03YD	MN	Amyloid beta A4 protein (APP)
DMW03YD	MT	DTT
DMW03YD	MA	Modulator
DMW03YD	RN	The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
DMW03YD	RU	https://pubmed.ncbi.nlm.nih.gov/25096615

DMWI0X3	DI	DMWI0X3
DMWI0X3	DN	Barusiban
DMWI0X3	MI	TTSCIUP
DMWI0X3	MN	Oxytocin receptor (OTR)
DMWI0X3	MT	DTT
DMWI0X3	MA	Antagonist
DMWI0X3	RN	The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
DMWI0X3	RU	https://pubmed.ncbi.nlm.nih.gov/19306963

DMQ8J0U	DI	DMQ8J0U
DMQ8J0U	DN	Basmisanil
DMQ8J0U	MI	TTNZPQ1
DMQ8J0U	MN	GABA(A) receptor alpha-5 (GABRA5)
DMQ8J0U	MT	DTT
DMQ8J0U	MA	Modulator
DMQ8J0U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ8J0U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM6CVZ5	DI	DM6CVZ5
DM6CVZ5	DN	Bavisant
DM6CVZ5	MI	TT9JNIC
DM6CVZ5	MN	Histamine H3 receptor (H3R)
DM6CVZ5	MT	DTT
DM6CVZ5	MA	Antagonist
DM6CVZ5	RN	Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
DM6CVZ5	RU	https://pubmed.ncbi.nlm.nih.gov/22519922

DM4JGNH	DI	DM4JGNH
DM4JGNH	DN	BAY 1067197
DM4JGNH	MI	TTK25J1
DM4JGNH	MN	Adenosine A1 receptor (ADORA1)
DM4JGNH	MT	DTT
DM4JGNH	MA	Modulator
DM4JGNH	RN	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.
DM4JGNH	RU	http://www.pnas.org/content/111/12/4614

DMHKTGX	DI	DMHKTGX
DMHKTGX	DN	BAY 1142524
DMHKTGX	MI	TT8VUE0
DMHKTGX	MN	Chymase (CYM)
DMHKTGX	MT	DTT
DMHKTGX	MA	Inhibitor
DMHKTGX	RN	Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
DMHKTGX	RU	https://pubmed.ncbi.nlm.nih.gov/29878583

DM8SNEM	DI	DM8SNEM
DM8SNEM	DN	BAY 11-42524
DM8SNEM	MI	TT8VUE0
DM8SNEM	MN	Chymase (CYM)
DM8SNEM	MT	DTT
DM8SNEM	MA	Inhibitor
DM8SNEM	RN	ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
DM8SNEM	RU	https://clinicaltrials.gov/ct2/show/NCT02452515

DM450XS	DI	DM450XS
DM450XS	DN	BAY 2253651
DM450XS	MI	TTGR91N
DM450XS	MN	TWIK-related acid-sensitive potassium channel 1 (TASK1)
DM450XS	MT	DTT
DM450XS	MA	Inhibitor
DM450XS	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM450XS	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSUB64	DI	DMSUB64
DMSUB64	DN	BAY 57-1293
DMSUB64	MI	TTKCVJR
DMSUB64	MN	Herpes simplex virus Helicase-primase (HSV UL8)
DMSUB64	MT	DTT
DMSUB64	MA	Inhibitor
DMSUB64	RN	Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40.
DMSUB64	RU	https://pubmed.ncbi.nlm.nih.gov/15266895

DMA75FG	DI	DMA75FG
DMA75FG	DN	BAY 794980
DMA75FG	MI	TT1290U
DMA75FG	MN	Coagulation factor VIII (F8)
DMA75FG	MT	DTT
DMA75FG	MA	Modulator
DMA75FG	RN	Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost. 2012 Nov;108(5):913-22.
DMA75FG	RU	https://pubmed.ncbi.nlm.nih.gov/23014711

DMCPUKG	DI	DMCPUKG
DMCPUKG	DN	BAY 85-8501
DMCPUKG	MI	TTPLTSQ
DMCPUKG	MN	Neutrophil elastase (NE)
DMCPUKG	MT	DTT
DMCPUKG	MA	Modulator
DMCPUKG	RN	Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
DMCPUKG	RU	https://pubmed.ncbi.nlm.nih.gov/26083237

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTKPW01
DMRZLU4	MN	Androgen receptor messenger RNA (AR mRNA)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTYRL6O
DMRZLU4	MN	Glucocorticoid receptor (NR3C1)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTHL6YX
DMRZLU4	MN	Progesterone (PG)
DMRZLU4	MT	DTT
DMRZLU4	MA	Antagonist
DMRZLU4	RN	Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/23788750

DMRZLU4	DI	DMRZLU4
DMRZLU4	DN	BAY 86-5044
DMRZLU4	MI	TTUV8G9
DMRZLU4	MN	Progesterone receptor (PGR)
DMRZLU4	MT	DTT
DMRZLU4	MA	Inhibitor
DMRZLU4	RN	Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6.
DMRZLU4	RU	https://pubmed.ncbi.nlm.nih.gov/11150172

DMCSGJ2	DI	DMCSGJ2
DMCSGJ2	DN	BAY1163877
DMCSGJ2	MI	TT0LF7H
DMCSGJ2	MN	Fibroblast growth factor receptor (FGFR)
DMCSGJ2	MT	DTT
DMCSGJ2	MA	Antagonist
DMCSGJ2	RN	Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
DMCSGJ2	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/1739

DM83IYE	DI	DM83IYE
DM83IYE	DN	BAY1193397
DM83IYE	MI	TT2NUT5
DM83IYE	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM83IYE	MT	DTT
DM83IYE	MA	Antagonist
DM83IYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM83IYE	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMYSQMW	DI	DMYSQMW
DMYSQMW	DN	BAY-1902607
DMYSQMW	MI	TT2THBD
DMYSQMW	MN	P2X purinoceptor 3 (P2RX3)
DMYSQMW	MT	DTT
DMYSQMW	MA	Inhibitor
DMYSQMW	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMYSQMW	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMM7Q68	DI	DMM7Q68
DMM7Q68	DN	BAY-2253651
DMM7Q68	MI	TTGR91N
DMM7Q68	MN	TWIK-related acid-sensitive potassium channel 1 (TASK1)
DMM7Q68	MT	DTT
DMM7Q68	MA	Inhibitor
DMM7Q68	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMM7Q68	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTI2WET
DMVA5NS	MN	Platelet-derived growth factor receptor (PDGFR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMVA5NS	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTVJ1D8
DMVA5NS	MN	Vascular endothelial growth factor receptor (VEGFR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVA5NS	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMVA5NS	DI	DMVA5NS
DMVA5NS	DN	BAY-57-9352
DMVA5NS	MI	TTUTJGQ
DMVA5NS	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMVA5NS	MT	DTT
DMVA5NS	MA	Inhibitor
DMVA5NS	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMVA5NS	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM7NHLC	DI	DM7NHLC
DM7NHLC	DN	BAY-85-3934
DM7NHLC	MI	TTMHFRY
DM7NHLC	MN	HIF-prolyl hydroxylase 1 (HPH-1)
DM7NHLC	MT	DTT
DM7NHLC	MA	Inhibitor
DM7NHLC	RN	Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838.
DM7NHLC	RU	https://pubmed.ncbi.nlm.nih.gov/25392999

DM2XE80	DI	DM2XE80
DM2XE80	DN	BAY-X-7195
DM2XE80	MI	TTGKOY9
DM2XE80	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DM2XE80	MT	DTT
DM2XE80	MA	Modulator
DM2XE80	RN	The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
DM2XE80	RU	https://www.ncbi.nlm.nih.gov/pubmed/8838238

DM2XE80	DI	DM2XE80
DM2XE80	DN	BAY-X-7195
DM2XE80	MI	TT0PZR5
DM2XE80	MN	Leukotriene CysLT2 receptor (CYSLTR2)
DM2XE80	MT	DTT
DM2XE80	MA	Modulator
DM2XE80	RN	The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
DM2XE80	RU	https://www.ncbi.nlm.nih.gov/pubmed/8838238

DMLO18H	DI	DMLO18H
DMLO18H	DN	BAY-Y-5959
DMLO18H	MI	TTXHYV6
DMLO18H	MN	Voltage-gated L-type calcium channel (L-CaC)
DMLO18H	MT	DTT
DMLO18H	MA	Modulator
DMLO18H	RN	Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.
DMLO18H	RU	https://pubmed.ncbi.nlm.nih.gov/9694931

DMB0UF9	DI	DMB0UF9
DMB0UF9	DN	Bb2121
DMB0UF9	MI	TTZ3P4W
DMB0UF9	MN	B-cell maturation protein (TNFRSF17)
DMB0UF9	MT	DTT
DMB0UF9	MA	Immunomodulator
DMB0UF9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0UF9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMR59I4	DI	DMR59I4
DMR59I4	DN	BBI-5000
DMR59I4	MI	TTQDMX5
DMR59I4	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMR59I4	MT	DTT
DMR59I4	MA	Antagonist
DMR59I4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR59I4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMDSNIR	DI	DMDSNIR
DMDSNIR	DN	BBI503
DMDSNIR	MI	TTPV9O1
DMDSNIR	MN	Cancer stemness kinase (CSK)
DMDSNIR	MT	DTT
DMDSNIR	MA	Inhibitor
DMDSNIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDSNIR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDSNIR	DI	DMDSNIR
DMDSNIR	DN	BBI503
DMDSNIR	MI	TTPMIQ9
DMDSNIR	MN	Serine/threonine-protein kinase (STK)
DMDSNIR	MT	DTT
DMDSNIR	MA	Inhibitor
DMDSNIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDSNIR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY1UGV	DI	DMY1UGV
DMY1UGV	DN	Bc-3781 intravenous
DMY1UGV	MI	TT2VX74
DMY1UGV	MN	Bacterial Protein synthesis (Bact PROS)
DMY1UGV	MT	DTT
DMY1UGV	MA	Modulator
DMY1UGV	RN	Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95.
DMY1UGV	RU	https://pubmed.ncbi.nlm.nih.gov/23836172

DMY1UGV	DI	DMY1UGV
DMY1UGV	DN	Bc-3781 intravenous
DMY1UGV	MI	DE4LYSA
DMY1UGV	MN	Cytochrome P450 3A4 (CYP3A4)
DMY1UGV	MT	DME
DMY1UGV	MA	Metabolism
DMY1UGV	RN	BC-3781: Evaluation of the CYP3A Interaction Potential.
DMY1UGV	RU	https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2011-bc-3781-and-cyp3a-interaction-potential.pdf

DMMKCJ6	DI	DMMKCJ6
DMMKCJ6	DN	BC-7013
DMMKCJ6	MI	TTUWYEA
DMMKCJ6	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMMKCJ6	MT	DTT
DMMKCJ6	MA	Modulator
DMMKCJ6	RN	Company report (briva)
DMMKCJ6	RU	http://www.nabriva.com/fileadmin/content/ICAAC_2009/F1-1521_In_vitro_antibacterial_spectrum_of_BC-7013.pdf

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEJGDUW
DM2BO9W	MN	Cytochrome P450 1A2 (CYP1A2)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989 Jun;271(2):270-83.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2729995

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DECB0K3
DM2BO9W	MN	Cytochrome P450 2D6 (CYP2D6)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEVDYN7
DM2BO9W	MN	Cytochrome P450 2E1 (CYP2E1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000 Dec;28(12):1397-400.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11095574

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DE0P6LK
DM2BO9W	MN	Sulfotransferase 2A1 (SULT2A1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEYGVN4
DM2BO9W	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases. Biochem Pharmacol. 1993 May 5;45(9):1809-14.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8494539

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DEL5N6Y
DM2BO9W	MN	UDP-glucuronosyltransferase 1A10 (UGT1A10)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15781124

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DESD26P
DM2BO9W	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15284531

DM2BO9W	DI	DM2BO9W
DM2BO9W	DN	BCP-13498
DM2BO9W	MI	DE85D2P
DM2BO9W	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DM2BO9W	MT	DME
DM2BO9W	MA	Metabolism
DM2BO9W	RN	Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
DM2BO9W	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492

DMUFY4K	DI	DMUFY4K
DMUFY4K	DN	BCT303
DMUFY4K	MI	TTTSEPU
DMUFY4K	MN	Thyroid hormone receptor alpha (THRA)
DMUFY4K	MT	DTT
DMUFY4K	MA	Modulator
DMUFY4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUFY4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUFY4K	DI	DMUFY4K
DMUFY4K	DN	BCT303
DMUFY4K	MI	TTGER3L
DMUFY4K	MN	Thyroid hormone receptor beta (THRB)
DMUFY4K	MT	DTT
DMUFY4K	MA	Modulator
DMUFY4K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUFY4K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRSG31	DI	DMRSG31
DMRSG31	DN	BCX-3408
DMRSG31	MI	TTMCF1Y
DMRSG31	MN	Purine nucleoside phosphorylase (PNP)
DMRSG31	MT	DTT
DMRSG31	MA	Inhibitor
DMRSG31	RN	BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008.
DMRSG31	RU	http://ash.confex.com/ash/2008/webprogram/Paper7315.html

DMKFJXP	DI	DMKFJXP
DMKFJXP	DN	BDB001
DMKFJXP	MI	TTOK0LR
DMKFJXP	MN	Toll-like receptor (TLR)
DMKFJXP	MT	DTT
DMKFJXP	MA	Agonist
DMKFJXP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKFJXP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2Q50G	DI	DM2Q50G
DM2Q50G	DN	Belnacasan
DM2Q50G	MI	TTCQIBE
DM2Q50G	MN	Caspase-1 (CASP1)
DM2Q50G	MT	DTT
DM2Q50G	MA	Inhibitor
DM2Q50G	RN	(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16.
DM2Q50G	RU	https://pubmed.ncbi.nlm.nih.gov/17289835

DMWNYIE	DI	DMWNYIE
DMWNYIE	DN	Bemarituzumab
DMWNYIE	MI	TTGKIED
DMWNYIE	MN	Fibroblast growth factor-2 (FGF2)
DMWNYIE	MT	DTT
DMWNYIE	MA	Antagonist
DMWNYIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWNYIE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0YCPL	DI	DM0YCPL
DM0YCPL	DN	Bemcentinib
DM0YCPL	MI	TTZPY6J
DM0YCPL	MN	Tyrosine-protein kinase UFO (AXL)
DM0YCPL	MT	DTT
DM0YCPL	MA	Inhibitor
DM0YCPL	RN	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
DM0YCPL	RU	https://pubmed.ncbi.nlm.nih.gov/32018052

DMUL6GY	DI	DMUL6GY
DMUL6GY	DN	BEMORADAN
DMUL6GY	MI	TT06AWU
DMUL6GY	MN	Phosphodiesterase 3A (PDE3A)
DMUL6GY	MT	DTT
DMUL6GY	MA	Inhibitor
DMUL6GY	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMUL6GY	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMRC0EQ	DI	DMRC0EQ
DMRC0EQ	DN	Bertilimumab
DMRC0EQ	MI	TTCF05Y
DMRC0EQ	MN	Small-inducible cytokine A11 (CCL11)
DMRC0EQ	MT	DTT
DMRC0EQ	MA	Modulator
DMRC0EQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRC0EQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ2REU	DI	DMJ2REU
DMJ2REU	DN	Berubicin
DMJ2REU	MI	TT0IHXV
DMJ2REU	MN	DNA topoisomerase II (TOP2)
DMJ2REU	MT	DTT
DMJ2REU	MA	Modulator
DMJ2REU	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJ2REU	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7583A	DI	DM7583A
DM7583A	DN	Beta-caryophyllene
DM7583A	MI	TTMSFAW
DM7583A	MN	Cannabinoid receptor 2 (CB2)
DM7583A	MT	DTT
DM7583A	MA	Agonist
DM7583A	RN	The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
DM7583A	RU	https://pubmed.ncbi.nlm.nih.gov/24210682

DMMI84K	DI	DMMI84K
DMMI84K	DN	Beta-lapachone
DMMI84K	MI	TTGTQHC
DMMI84K	MN	DNA topoisomerase I (TOP1)
DMMI84K	MT	DTT
DMMI84K	MA	Modulator
DMMI84K	RN	Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42.
DMMI84K	RU	https://pubmed.ncbi.nlm.nih.gov/12188909

DMMI84K	DI	DMMI84K
DMMI84K	DN	Beta-lapachone
DMMI84K	MI	DENP5RY
DMMI84K	MN	Quinone reductase 1 (NQO1)
DMMI84K	MT	DME
DMMI84K	MA	Metabolism
DMMI84K	RN	Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
DMMI84K	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23071729

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	TTFGZB6
DML2D8Q	MN	Human immunodeficiency virus GAG protein (HIV gag)
DML2D8Q	MT	DTT
DML2D8Q	MA	Inhibitor
DML2D8Q	RN	Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65.
DML2D8Q	RU	https://pubmed.ncbi.nlm.nih.gov/23399723

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DEF2WXN
DML2D8Q	MN	UDP-glucuronosyltransferase 1A3 (UGT1A3)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DELOY3P
DML2D8Q	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DML2D8Q	DI	DML2D8Q
DML2D8Q	DN	Bevirimat
DML2D8Q	MI	DEB3CV1
DML2D8Q	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DML2D8Q	MT	DME
DML2D8Q	MA	Metabolism
DML2D8Q	RN	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
DML2D8Q	RU	https://www.intmedpress.com/serveFile.cfm?sUID=ebccbb0b-de4a-42d4-ae2b-ca2304d75f56

DMKBRDL	DI	DMKBRDL
DMKBRDL	DN	BEZ235
DMKBRDL	MI	TTHBTOP
DMKBRDL	MN	PI3-kinase gamma (PIK3CG)
DMKBRDL	MT	DTT
DMKBRDL	MA	Modulator
DMKBRDL	RN	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
DMKBRDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/22355272

DMKBRDL	DI	DMKBRDL
DMKBRDL	DN	BEZ235
DMKBRDL	MI	TTCJG29
DMKBRDL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMKBRDL	MT	DTT
DMKBRDL	MA	Modulator
DMKBRDL	RN	The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43.
DMKBRDL	RU	https://www.ncbi.nlm.nih.gov/pubmed/22355272

DMVUX1C	DI	DMVUX1C
DMVUX1C	DN	BFH-772
DMVUX1C	MI	TTVJ1D8
DMVUX1C	MN	Vascular endothelial growth factor receptor (VEGFR)
DMVUX1C	MT	DTT
DMVUX1C	MA	Agonist
DMVUX1C	RN	CA patent application no. 841416, Method of selecting therapeutic indications.
DMVUX1C	RU	http://www.google.com/patents/CA2841416A1?cl=en

DMRO6XT	DI	DMRO6XT
DMRO6XT	DN	BGB-290
DMRO6XT	MI	TTEBCY8
DMRO6XT	MN	Poly [ADP-ribose] polymerase (PARP)
DMRO6XT	MT	DTT
DMRO6XT	MA	Inhibitor
DMRO6XT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRO6XT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRO6XT	DI	DMRO6XT
DMRO6XT	DN	BGB-290
DMRO6XT	MI	TTKSAQZ
DMRO6XT	MN	Tankyrase (TNKS)
DMRO6XT	MT	DTT
DMRO6XT	MA	Modulator
DMRO6XT	RN	National Cancer Institute Drug Dictionary (drug id 769217).
DMRO6XT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=769217

DMQCFSM	DI	DMQCFSM
DMQCFSM	DN	BGB-3112
DMQCFSM	MI	TTGM6VW
DMQCFSM	MN	Tyrosine-protein kinase BTK (ATK)
DMQCFSM	MT	DTT
DMQCFSM	MA	Inhibitor
DMQCFSM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQCFSM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDI43Y	DI	DMDI43Y
DMDI43Y	DN	BGB-324
DMDI43Y	MI	TTZPY6J
DMDI43Y	MN	Tyrosine-protein kinase UFO (AXL)
DMDI43Y	MT	DTT
DMDI43Y	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
DMDI43Y	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835

DM1X3L0	DI	DM1X3L0
DM1X3L0	DN	BGB-3245
DM1X3L0	MI	TTB18GJ
DM1X3L0	MN	Proto-oncogene c-RAF (c-RAF)
DM1X3L0	MT	DTT
DM1X3L0	MA	Inhibitor
DM1X3L0	RN	Clinical pipeline report, company report or official report of BeiGene.
DM1X3L0	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMS2MQ5	DI	DMS2MQ5
DMS2MQ5	DN	BGC-20-1531
DMS2MQ5	MI	TT79WV3
DMS2MQ5	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMS2MQ5	MT	DTT
DMS2MQ5	MA	Antagonist
DMS2MQ5	RN	BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
DMS2MQ5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697835/

DMYDM68	DI	DMYDM68
DMYDM68	DN	BGP-15
DMYDM68	MI	TTR2TXZ
DMYDM68	MN	Jun N terminal kinase (JNK)
DMYDM68	MT	DTT
DMYDM68	MA	Inhibitor
DMYDM68	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYDM68	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMYDM68	DI	DMYDM68
DMYDM68	DN	BGP-15
DMYDM68	MI	TTEBCY8
DMYDM68	MN	Poly [ADP-ribose] polymerase (PARP)
DMYDM68	MT	DTT
DMYDM68	MA	Modulator
DMYDM68	RN	BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
DMYDM68	RU	https://pubmed.ncbi.nlm.nih.gov/22350755

DMO4MNQ	DI	DMO4MNQ
DMO4MNQ	DN	BGS-649
DMO4MNQ	MI	TTSZLWK
DMO4MNQ	MN	Aromatase (CYP19A1)
DMO4MNQ	MT	DTT
DMO4MNQ	MA	Inhibitor
DMO4MNQ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
DMO4MNQ	RU	http://adisinsight.springer.com/drugs/800032111

DMSROM4	DI	DMSROM4
DMSROM4	DN	BHQ880
DMSROM4	MI	TTE3RAC
DMSROM4	MN	Dickkopf-related protein 1 (DKK1)
DMSROM4	MT	DTT
DMSROM4	MA	Inhibitor
DMSROM4	RN	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9.
DMSROM4	RU	https://pubmed.ncbi.nlm.nih.gov/19417213

DM7ZM1H	DI	DM7ZM1H
DM7ZM1H	DN	BHT-3009
DM7ZM1H	MI	TT2RY5P
DM7ZM1H	MN	Myelin basic protein (MBP)
DM7ZM1H	MT	DTT
DM7ZM1H	RN	BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70.
DM7ZM1H	RU	https://pubmed.ncbi.nlm.nih.gov/19649992

DM740BS	DI	DM740BS
DM740BS	DN	BI 1358894
DM740BS	MI	TTX0H5W
DM740BS	MN	Short transient receptor potential channel 4 (TRPC4)
DM740BS	MT	DTT
DM740BS	MA	Inhibitor
DM740BS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM740BS	RU	https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop

DM740BS	DI	DM740BS
DM740BS	DN	BI 1358894
DM740BS	MI	TT32NQ1
DM740BS	MN	Short transient receptor potential channel 5 (TRPC5)
DM740BS	MT	DTT
DM740BS	MA	Inhibitor
DM740BS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM740BS	RU	https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop

DMMSGAT	DI	DMMSGAT
DMMSGAT	DN	BI 207127
DMMSGAT	MI	TTMVBWH
DMMSGAT	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMMSGAT	MT	DTT
DMMSGAT	MA	Inhibitor
DMMSGAT	RN	2011 Pipeline of Boehringer Ingelheim Pharma.
DMMSGAT	RU	http://www.boehringer-ingelheim.com/

DMJSADP	DI	DMJSADP
DMJSADP	DN	BI 2536
DMJSADP	MI	TTIYVQP
DMJSADP	MN	Polo-like kinase 1 (PLK1)
DMJSADP	MT	DTT
DMJSADP	MA	Inhibitor
DMJSADP	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DMJSADP	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DM1NMGJ	DI	DM1NMGJ
DM1NMGJ	DN	BI 456906
DM1NMGJ	MI	TTVIMDE
DM1NMGJ	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM1NMGJ	MT	DTT
DM1NMGJ	MA	Agonist
DM1NMGJ	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DM1NMGJ	RU	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi

DMF86P2	DI	DMF86P2
DMF86P2	DN	BI 655064
DMF86P2	MI	TTN6Y9A
DMF86P2	MN	CD40L receptor (CD40)
DMF86P2	MT	DTT
DMF86P2	MA	Inhibitor
DMF86P2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF86P2	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMF86P2	DI	DMF86P2
DMF86P2	DN	BI 655064
DMF86P2	MI	TTIJP3Q
DMF86P2	MN	TNF related activation protein (CD40LG)
DMF86P2	MT	DTT
DMF86P2	RN	FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
DMF86P2	RU	http://ard.bmj.com/content/74/Suppl_2/483.3.abstract

DMJFDS0	DI	DMJFDS0
DMJFDS0	DN	BI-409306
DMJFDS0	MI	TTZOEBC
DMJFDS0	MN	Phosphodiesterase 9 (PDE9)
DMJFDS0	MT	DTT
DMJFDS0	MA	Inhibitor
DMJFDS0	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline.
DMJFDS0	RU	https://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html

DMZR9OU	DI	DMZR9OU
DMZR9OU	DN	BI-44370
DMZR9OU	MI	TTY6O0Q
DMZR9OU	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMZR9OU	MT	DTT
DMZR9OU	MA	Antagonist
DMZR9OU	RN	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
DMZR9OU	RU	https://pubmed.ncbi.nlm.nih.gov/21172952

DMSZQHX	DI	DMSZQHX
DMSZQHX	DN	BI-505
DMSZQHX	MI	TTCT6F7
DMSZQHX	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMSZQHX	MT	DTT
DMSZQHX	RN	A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15.
DMSZQHX	RU	https://pubmed.ncbi.nlm.nih.gov/23597564

DMSZQHX	DI	DMSZQHX
DMSZQHX	DN	BI-505
DMSZQHX	MI	TTZPY6J
DMSZQHX	MN	Tyrosine-protein kinase UFO (AXL)
DMSZQHX	MT	DTT
DMSZQHX	MA	Inhibitor
DMSZQHX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSZQHX	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM9FZYT	DI	DM9FZYT
DM9FZYT	DN	BI-655130
DM9FZYT	MI	TTUS18T
DM9FZYT	MN	IL-1 receptor-like 2 (IL1RL2)
DM9FZYT	MT	DTT
DM9FZYT	MA	Antagonist
DM9FZYT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FZYT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWH7Z5	DI	DMWH7Z5
DMWH7Z5	DN	BI-836826
DMWH7Z5	MI	TTFCW29
DMWH7Z5	MN	Leukocyte antigen CD37 (CD37)
DMWH7Z5	MT	DTT
DMWH7Z5	RN	Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61.
DMWH7Z5	RU	https://pubmed.ncbi.nlm.nih.gov/24555705

DMUVMY9	DI	DMUVMY9
DMUVMY9	DN	BI-836858
DMUVMY9	MI	TTJVYO3
DMUVMY9	MN	Myeloid cell surface antigen CD33 (CD33)
DMUVMY9	MT	DTT
DMUVMY9	RN	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
DMUVMY9	RU	https://pubmed.ncbi.nlm.nih.gov/24809231

DMG3ON2	DI	DMG3ON2
DMG3ON2	DN	BIA 3-202
DMG3ON2	MI	TTKWFB8
DMG3ON2	MN	Catechol-O-methyl-transferase (COMT)
DMG3ON2	MT	DTT
DMG3ON2	MA	Inhibitor
DMG3ON2	RN	Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8.
DMG3ON2	RU	https://pubmed.ncbi.nlm.nih.gov/12236793

DMHYZEK	DI	DMHYZEK
DMHYZEK	DN	BIBH 1
DMHYZEK	MI	TTGPQ0F
DMHYZEK	MN	Prolyl endopeptidase FAP (FAP)
DMHYZEK	MT	DTT
DMHYZEK	RN	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
DMHYZEK	RU	https://pubmed.ncbi.nlm.nih.gov/12738716

DM9OXEJ	DI	DM9OXEJ
DM9OXEJ	DN	BIIB 023
DM9OXEJ	MI	TTBTDM1
DM9OXEJ	MN	TNF-related weak inducer of apoptosis (TWEAK)
DM9OXEJ	MT	DTT
DM9OXEJ	MA	Modulator
DM9OXEJ	RN	ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health.
DM9OXEJ	RU	https://clinicaltrials.gov/ct2/show/NCT00771329

DM293JT	DI	DM293JT
DM293JT	DN	BIIB 033
DM293JT	MI	TTZYQ80
DM293JT	MN	Leucine-rich repeat neuronal protein 1 (LINGO1)
DM293JT	MT	DTT
DM293JT	RN	Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18.
DM293JT	RU	https://pubmed.ncbi.nlm.nih.gov/25340070

DMH7RJ1	DI	DMH7RJ1
DMH7RJ1	DN	BIIB014
DMH7RJ1	MI	TTM2AOE
DMH7RJ1	MN	Adenosine A2a receptor (ADORA2A)
DMH7RJ1	MT	DTT
DMH7RJ1	MA	Antagonist
DMH7RJ1	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DMH7RJ1	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DMH7RJ1	DI	DMH7RJ1
DMH7RJ1	DN	BIIB014
DMH7RJ1	MI	DE4LYSA
DMH7RJ1	MN	Cytochrome P450 3A4 (CYP3A4)
DMH7RJ1	MT	DME
DMH7RJ1	MA	Metabolism
DMH7RJ1	RN	Frontiers in CNS Drug Discovery. Edited by Atta-ur Rahman, M. Iqbal Choudhary. Page: 318.
DMH7RJ1	RU	https://books.google.nl/books?id=ip-Pz5C3_loC&pg=PA318&lpg=PA318&dq=BIIB014++metabolizing+enzyme&source=bl&ots=G8YeDCzw5_&sig=ACfU3U1ZkEaPcDy58jtvOlzdzR-s3sNz4g&hl=zh-CN&sa=X&ved=2ahUKEwiGkem-7rnnAhVP4qQKHfNzAi4Q6AEwFXoECAwQAQ#v=onepage&q=BIIB014%20%20metabolizing%20enzyme&f=false

DMPAJ41	DI	DMPAJ41
DMPAJ41	DN	BIIB-021
DMPAJ41	MI	TT78R5H
DMPAJ41	MN	Heat shock protein 90 alpha (HSP90A)
DMPAJ41	MT	DTT
DMPAJ41	MA	Inhibitor
DMPAJ41	RN	BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
DMPAJ41	RU	https://pubmed.ncbi.nlm.nih.gov/19372565

DMZO2SY	DI	DMZO2SY
DMZO2SY	DN	BIIB054
DMZO2SY	MI	TT08OSU
DMZO2SY	MN	Synuclein alpha (SNCA)
DMZO2SY	MT	DTT
DMZO2SY	MA	Inhibitor
DMZO2SY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZO2SY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMLV1ET	DI	DMLV1ET
DMLV1ET	DN	BIIB074
DMLV1ET	MI	TT4G2JS
DMLV1ET	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMLV1ET	MT	DTT
DMLV1ET	MA	Inhibitor
DMLV1ET	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMLV1ET	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM263RP	DI	DM263RP
DM263RP	DN	BIIB092
DM263RP	MI	TTS87KH
DM263RP	MN	Microtubule-associated protein tau (MAPT)
DM263RP	MT	DTT
DM263RP	MA	Inhibitor
DM263RP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM263RP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2J36F	DI	DM2J36F
DM2J36F	DN	BILN-2061
DM2J36F	MI	TTWXB3E
DM2J36F	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DM2J36F	MT	DTT
DM2J36F	MA	Inhibitor
DM2J36F	RN	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
DM2J36F	RU	https://pubmed.ncbi.nlm.nih.gov/15732092

DMAG4SX	DI	DMAG4SX
DMAG4SX	DN	BILR-355
DMAG4SX	MI	TT84ETX
DMAG4SX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMAG4SX	MT	DTT
DMAG4SX	MA	Inhibitor
DMAG4SX	RN	Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8.
DMAG4SX	RU	https://pubmed.ncbi.nlm.nih.gov/21128991

DM6EIZG	DI	DM6EIZG
DM6EIZG	DN	BIM23A760
DM6EIZG	MI	TT2J34L
DM6EIZG	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM6EIZG	MT	DTT
DM6EIZG	MA	Inhibitor
DM6EIZG	RN	Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45.
DM6EIZG	RU	https://pubmed.ncbi.nlm.nih.gov/10940813

DM6EIZG	DI	DM6EIZG
DM6EIZG	DN	BIM23A760
DM6EIZG	MI	TTEX248
DM6EIZG	MN	Dopamine D2 receptor (D2R)
DM6EIZG	MT	DTT
DM6EIZG	MA	Modulator
DM6EIZG	RN	BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7.
DM6EIZG	RU	https://pubmed.ncbi.nlm.nih.gov/16625841

DMH7Q4E	DI	DMH7Q4E
DMH7Q4E	DN	Bimagrumab
DMH7Q4E	MI	TTRG4QN
DMH7Q4E	MN	Activin receptor type II (ACVR2)
DMH7Q4E	MT	DTT
DMH7Q4E	MA	Inhibitor
DMH7Q4E	RN	Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919.
DMH7Q4E	RU	https://pubmed.ncbi.nlm.nih.gov/29566437

DMBRL19	DI	DMBRL19
DMBRL19	DN	Bimakalim
DMBRL19	MI	TT1VOHK
DMBRL19	MN	Potassium channel unspecific (KC)
DMBRL19	MT	DTT
DMBRL19	MA	Agonist
DMBRL19	RN	Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.
DMBRL19	RU	https://pubmed.ncbi.nlm.nih.gov/15115902

DMB9LRJ	DI	DMB9LRJ
DMB9LRJ	DN	Bintrafusp alfa
DMB9LRJ	MI	TT8ZLTI
DMB9LRJ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMB9LRJ	MT	DTT
DMB9LRJ	RN	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
DMB9LRJ	RU	https://pubmed.ncbi.nlm.nih.gov/32173464

DMB9LRJ	DI	DMB9LRJ
DMB9LRJ	DN	Bintrafusp alfa
DMB9LRJ	MI	TTO3HT7
DMB9LRJ	MN	Transforming growth factor beta (TGFB)
DMB9LRJ	MT	DTT
DMB9LRJ	RN	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
DMB9LRJ	RU	https://pubmed.ncbi.nlm.nih.gov/32173464

DM6N05H	DI	DM6N05H
DM6N05H	DN	BIO-11006
DM6N05H	MI	TTHRM39
DM6N05H	MN	Myristoylated alanine-rich C-kinase substrate (MARCKS)
DM6N05H	MT	DTT
DM6N05H	MA	Inhibitor
DM6N05H	RN	Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation. Exp Lung Res. 2010 Mar;36(2):75-84.
DM6N05H	RU	https://pubmed.ncbi.nlm.nih.gov/20205598

DMPNYXQ	DI	DMPNYXQ
DMPNYXQ	DN	BIO-11006
DMPNYXQ	MI	TTHRM39
DMPNYXQ	MN	Myristoylated alanine-rich C-kinase substrate (MARCKS)
DMPNYXQ	MT	DTT
DMPNYXQ	MA	Inhibitor
DMPNYXQ	RN	An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol. 2016 Nov;55(5):617-622.
DMPNYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/27556883

DMKICA3	DI	DMKICA3
DMKICA3	DN	BIO-1211
DMKICA3	MI	TT4BT06
DMKICA3	MN	Integrin alpha-4 (ITGA4)
DMKICA3	MT	DTT
DMKICA3	MA	Antagonist
DMKICA3	RN	A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
DMKICA3	RU	https://pubmed.ncbi.nlm.nih.gov/10934094

DM7PT8R	DI	DM7PT8R
DM7PT8R	DN	BioE-743
DM7PT8R	MI	TT8XK6L
DM7PT8R	MN	Quinone reductase 1 (NQO1)
DM7PT8R	MT	DTT
DM7PT8R	MA	Modulator
DM7PT8R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7PT8R	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6PBUM	DI	DM6PBUM
DM6PBUM	DN	Birinapant
DM6PBUM	MI	TTQ5LRD
DM6PBUM	MN	Cellular inhibitor of apoptosis 1 (BIRC2)
DM6PBUM	MT	DTT
DM6PBUM	MA	Modulator
DM6PBUM	RN	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
DM6PBUM	RU	https://pubmed.ncbi.nlm.nih.gov/24497535

DM6PBUM	DI	DM6PBUM
DM6PBUM	DN	Birinapant
DM6PBUM	MI	TTR7B60
DM6PBUM	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM6PBUM	MT	DTT
DM6PBUM	MA	Modulator
DM6PBUM	RN	cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72.
DM6PBUM	RU	https://pubmed.ncbi.nlm.nih.gov/24497535

DMW76V0	DI	DMW76V0
DMW76V0	DN	Bisantrene
DMW76V0	MI	DTI7UX6
DMW76V0	MN	Breast cancer resistance protein (ABCG2)
DMW76V0	MT	DTP
DMW76V0	MA	Substrate
DMW76V0	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMW76V0	RU	https://doi.org/10.2217/14622416.9.8.1005

DMW76V0	DI	DMW76V0
DMW76V0	DN	Bisantrene
DMW76V0	MI	DTUGYRD
DMW76V0	MN	P-glycoprotein 1 (ABCB1)
DMW76V0	MT	DTP
DMW76V0	MA	Substrate
DMW76V0	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMW76V0	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMVDO93	DI	DMVDO93
DMVDO93	DN	BL-1020
DMVDO93	MI	TTEX248
DMVDO93	MN	Dopamine D2 receptor (D2R)
DMVDO93	MT	DTT
DMVDO93	MA	Antagonist
DMVDO93	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMVDO93	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMVDO93	DI	DMVDO93
DMVDO93	DN	BL-1020
DMVDO93	MI	TTNJYV2
DMVDO93	MN	Gamma-aminobutyric acid receptor (GAR)
DMVDO93	MT	DTT
DMVDO93	MA	Agonist
DMVDO93	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMVDO93	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM8R71T	DI	DM8R71T
DM8R71T	DN	BL-22
DM8R71T	MI	TTM6QSK
DM8R71T	MN	B-cell receptor CD22 (CD22)
DM8R71T	MT	DTT
DM8R71T	RN	Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
DM8R71T	RU	https://pubmed.ncbi.nlm.nih.gov/20215554

DMSBPJI	DI	DMSBPJI
DMSBPJI	DN	BL-7040
DMSBPJI	MI	TTSHG0T
DMSBPJI	MN	Toll-like receptor 9 (TLR9)
DMSBPJI	MT	DTT
DMSBPJI	MA	Activator
DMSBPJI	RN	Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
DMSBPJI	RU	https://pubmed.ncbi.nlm.nih.gov/26003847

DMKO0BQ	DI	DMKO0BQ
DMKO0BQ	DN	BLD-2660
DMKO0BQ	MI	TT45V0U
DMKO0BQ	MN	HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1)
DMKO0BQ	MT	DTT
DMKO0BQ	MA	Inhibitor
DMKO0BQ	RN	ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health.
DMKO0BQ	RU	https://clinicaltrials.gov/ct2/show/NCT04334460

DMKO0BQ	DI	DMKO0BQ
DMKO0BQ	DN	BLD-2660
DMKO0BQ	MI	TTO361H
DMKO0BQ	MN	HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1)
DMKO0BQ	MT	DTT
DMKO0BQ	MA	Inhibitor
DMKO0BQ	RN	ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health.
DMKO0BQ	RU	https://clinicaltrials.gov/ct2/show/NCT04334460

DMYK1DR	DI	DMYK1DR
DMYK1DR	DN	BLI-1005
DMYK1DR	MI	TTAWNKZ
DMYK1DR	MN	Norepinephrine transporter (NET)
DMYK1DR	MT	DTT
DMYK1DR	MA	Inhibitor
DMYK1DR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYK1DR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMG1LVA	DI	DMG1LVA
DMG1LVA	DN	BLZ-945
DMG1LVA	MI	TTC70AJ
DMG1LVA	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMG1LVA	MT	DTT
DMG1LVA	MA	Inhibitor
DMG1LVA	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
DMG1LVA	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719

DMG1LVA	DI	DMG1LVA
DMG1LVA	DN	BLZ-945
DMG1LVA	MI	TT7MRDV
DMG1LVA	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMG1LVA	MT	DTT
DMG1LVA	MA	Antagonist
DMG1LVA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG1LVA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEJVYAZ
DMQI43G	MN	Cytochrome P450 2A6 (CYP2A6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEPKLMQ
DMQI43G	MN	Cytochrome P450 2B6 (CYP2B6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DE5IED8
DMQI43G	MN	Cytochrome P450 2C9 (CYP2C9)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DECB0K3
DMQI43G	MN	Cytochrome P450 2D6 (CYP2D6)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions. Clin Pharmacokinet. 2015 Dec;54(12):1205-22.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26177803

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DE4LYSA
DMQI43G	MN	Cytochrome P450 3A4 (CYP3A4)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEIBDNY
DMQI43G	MN	Cytochrome P450 3A5 (CYP3A5)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
DMQI43G	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26153443

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	TT5FNQT
DMQI43G	MN	Human immunodeficiency virus Protease (HIV PR)
DMQI43G	MT	DTT
DMQI43G	MA	Inhibitor
DMQI43G	RN	2011 Pipeline of Bristol-Myers Squibb.
DMQI43G	RU	http://www.bms.com/pages/default.aspx

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DEGTFWK
DMQI43G	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMQI43G	MT	DME
DMQI43G	MA	Metabolism
DMQI43G	RN	Australian Public Assessment Report for asunaprevir.
DMQI43G	RU	https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf

DMQI43G	DI	DMQI43G
DMQI43G	DN	BMS 650032
DMQI43G	MI	DTUGYRD
DMQI43G	MN	P-glycoprotein 1 (ABCB1)
DMQI43G	MT	DTP
DMQI43G	MA	Substrate
DMQI43G	RN	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
DMQI43G	RU	https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665

DMKH4PI	DI	DMKH4PI
DMKH4PI	DN	BMS 791325
DMKH4PI	MI	TTMVBWH
DMKH4PI	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMKH4PI	MT	DTT
DMKH4PI	MA	Inhibitor
DMKH4PI	RN	2011 Pipeline of Bristol-Myers Squibb.
DMKH4PI	RU	http://www.bms.com/pages/default.aspx

DMDPLEM	DI	DMDPLEM
DMDPLEM	DN	BMS-184476
DMDPLEM	MI	TTML2WA
DMDPLEM	MN	Tubulin (TUB)
DMDPLEM	MT	DTT
DMDPLEM	MA	Inhibitor
DMDPLEM	RN	Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218.
DMDPLEM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/

DML1CK2	DI	DML1CK2
DML1CK2	DN	BMS-188797
DML1CK2	MI	TTML2WA
DML1CK2	MN	Tubulin (TUB)
DML1CK2	MT	DTT
DML1CK2	MA	Inhibitor
DML1CK2	RN	Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
DML1CK2	RU	https://pubmed.ncbi.nlm.nih.gov/14613998

DMJUV6C	DI	DMJUV6C
DMJUV6C	DN	BMS-223131
DMJUV6C	MI	TT1AQ50
DMJUV6C	MN	Charybdotoxin receptor beta-4 (BKbeta4)
DMJUV6C	MT	DTT
DMJUV6C	MA	Modulator
DMJUV6C	RN	Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7.
DMJUV6C	RU	https://pubmed.ncbi.nlm.nih.gov/15701710

DMQL3VS	DI	DMQL3VS
DMQL3VS	DN	BMS-275183
DMQL3VS	MI	TTML2WA
DMQL3VS	MN	Tubulin (TUB)
DMQL3VS	MT	DTT
DMQL3VS	MA	Inhibitor
DMQL3VS	RN	A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31.
DMQL3VS	RU	https://pubmed.ncbi.nlm.nih.gov/20680660

DMGYXFP	DI	DMGYXFP
DMGYXFP	DN	BMS-582949
DMGYXFP	MI	TTGFK5X
DMGYXFP	MN	Protein kinase unspecific (PK)
DMGYXFP	MT	DTT
DMGYXFP	MA	Modulator
DMGYXFP	RN	Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
DMGYXFP	RU	https://pubmed.ncbi.nlm.nih.gov/23578688

DMGYXFP	DI	DMGYXFP
DMGYXFP	DN	BMS-582949
DMGYXFP	MI	TTWELHI
DMGYXFP	MN	Stress-activated protein kinase (p38)
DMGYXFP	MT	DTT
DMGYXFP	MA	Inhibitor
DMGYXFP	RN	Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
DMGYXFP	RU	https://pubmed.ncbi.nlm.nih.gov/23578688

DMDPQV5	DI	DMDPQV5
DMDPQV5	DN	BMS-599626
DMDPQV5	MI	TTGKNB4
DMDPQV5	MN	Epidermal growth factor receptor (EGFR)
DMDPQV5	MT	DTT
DMDPQV5	MA	Inhibitor
DMDPQV5	RN	AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
DMDPQV5	RU	https://pubmed.ncbi.nlm.nih.gov/20119866

DMDPQV5	DI	DMDPQV5
DMDPQV5	DN	BMS-599626
DMDPQV5	MI	TT6EO5L
DMDPQV5	MN	Erbb2 tyrosine kinase receptor (HER2)
DMDPQV5	MT	DTT
DMDPQV5	MA	Inhibitor
DMDPQV5	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMDPQV5	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTGKNB4
DMX302C	MN	Epidermal growth factor receptor (EGFR)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTR5TV4
DMX302C	MN	ERBB2 messenger RNA (HER2 mRNA)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTGJCWZ
DMX302C	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DMX302C	DI	DMX302C
DMX302C	DN	BMS-690514
DMX302C	MI	TTUTJGQ
DMX302C	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMX302C	MT	DTT
DMX302C	MA	Inhibitor
DMX302C	RN	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
DMX302C	RU	https://pubmed.ncbi.nlm.nih.gov/20166197

DM51LTG	DI	DM51LTG
DM51LTG	DN	BMS-708163
DM51LTG	MI	TT9W8GU
DM51LTG	MN	Gamma-secretase (GS)
DM51LTG	MT	DTT
DM51LTG	MA	Modulator
DM51LTG	RN	Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
DM51LTG	RU	https://pubmed.ncbi.nlm.nih.gov/22892585

DMTVGY7	DI	DMTVGY7
DMTVGY7	DN	BMS-770767
DMTVGY7	MI	TTN7BL9
DMTVGY7	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTVGY7	MT	DTT
DMTVGY7	MA	Modulator
DMTVGY7	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMTVGY7	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMKY638	DI	DMKY638
DMKY638	DN	BMS-813160
DMKY638	MI	TTFZYTO
DMKY638	MN	C-C chemokine receptor type 2 (CCR2)
DMKY638	MT	DTT
DMKY638	MA	Modulator
DMKY638	RN	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
DMKY638	RU	https://pubmed.ncbi.nlm.nih.gov/21936726

DMKY638	DI	DMKY638
DMKY638	DN	BMS-813160
DMKY638	MI	TT2CEJG
DMKY638	MN	C-C chemokine receptor type 5 (CCR5)
DMKY638	MT	DTT
DMKY638	MA	Modulator
DMKY638	RN	A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
DMKY638	RU	https://pubmed.ncbi.nlm.nih.gov/21936726

DMT8L6P	DI	DMT8L6P
DMT8L6P	DN	BMS-817399
DMT8L6P	MI	TTC24WT
DMT8L6P	MN	C-C chemokine receptor type 1 (CCR1)
DMT8L6P	MT	DTT
DMT8L6P	MA	Modulator
DMT8L6P	RN	Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64.
DMT8L6P	RU	https://pubmed.ncbi.nlm.nih.gov/25101488

DMF46PD	DI	DMF46PD
DMF46PD	DN	BMS-911543
DMF46PD	MI	TTRMX3V
DMF46PD	MN	Janus kinase 2 (JAK-2)
DMF46PD	MT	DTT
DMF46PD	MA	Modulator
DMF46PD	RN	Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8.
DMF46PD	RU	https://pubmed.ncbi.nlm.nih.gov/22015772

DMN28WK	DI	DMN28WK
DMN28WK	DN	BMS-919373
DMN28WK	MI	TTW0CMT
DMN28WK	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMN28WK	MT	DTT
DMN28WK	MA	Inhibitor
DMN28WK	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
DMN28WK	RU	http://adisinsight.springer.com/drugs/800035504

DMUTS1W	DI	DMUTS1W
DMUTS1W	DN	BMS-936557
DMUTS1W	MI	TTQOVYA
DMUTS1W	MN	C-X-C motif chemokine 10 (CXCL10)
DMUTS1W	MT	DTT
DMUTS1W	RN	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
DMUTS1W	RU	https://pubmed.ncbi.nlm.nih.gov/23461895

DM7XV4R	DI	DM7XV4R
DM7XV4R	DN	BMS-954561
DM7XV4R	MI	TTJSZTB
DM7XV4R	MN	Nicotinic acetylcholine receptor (nAChR)
DM7XV4R	MT	DTT
DM7XV4R	MA	Modulator
DM7XV4R	RN	EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
DM7XV4R	RU	http://www.google.com/patents/EP2774991A1?cl=en

DMMEAGO	DI	DMMEAGO
DMMEAGO	DN	BMS-955176
DMMEAGO	MI	TT5TOX7
DMMEAGO	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMMEAGO	MT	DTT
DMMEAGO	MA	Inhibitor
DMMEAGO	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMMEAGO	RU	http://news.bms.com/press-release/study-next-generation-investigational-hiv-1-maturation-inhibitor-shows-positive-result

DMVJXOH	DI	DMVJXOH
DMVJXOH	DN	BMS-986012
DMVJXOH	MI	TTW7KYV
DMVJXOH	MN	Fucosyl GM1 (FucGM1)
DMVJXOH	MT	DTT
DMVJXOH	MA	Inhibitor
DMVJXOH	RN	A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189.
DMVJXOH	RU	https://pubmed.ncbi.nlm.nih.gov/30021910

DMHMV6E	DI	DMHMV6E
DMHMV6E	DN	BMS-986020
DMHMV6E	MI	TTQ6S1K
DMHMV6E	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMHMV6E	MT	DTT
DMHMV6E	MA	Antagonist
DMHMV6E	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHMV6E	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMIZKEC	DI	DMIZKEC
DMIZKEC	DN	BMS-986036
DMIZKEC	MI	TTQ916P
DMIZKEC	MN	Fibroblast growth factor-21 (FGF21)
DMIZKEC	MT	DTT
DMIZKEC	MA	Agonist
DMIZKEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIZKEC	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMTKDIP	DI	DMTKDIP
DMTKDIP	DN	BMS-986141
DMTKDIP	MI	TT3I4WV
DMTKDIP	MN	Prostate apoptosis response-4 (PAWR)
DMTKDIP	MT	DTT
DMTKDIP	MA	Antagonist
DMTKDIP	RN	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. Eur J Med Chem. 2021 Jan 1;209:112893.
DMTKDIP	RU	https://pubmed.ncbi.nlm.nih.gov/33049608

DMZB8AJ	DI	DMZB8AJ
DMZB8AJ	DN	BMS-986142
DMZB8AJ	MI	TTGM6VW
DMZB8AJ	MN	Tyrosine-protein kinase BTK (ATK)
DMZB8AJ	MT	DTT
DMZB8AJ	MA	Inhibitor
DMZB8AJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZB8AJ	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM4QHZS	DI	DM4QHZS
DM4QHZS	DN	BMS-986177
DM4QHZS	MI	TTDM4ZU
DM4QHZS	MN	Factor XI messenger RNA (F11 mRNA)
DM4QHZS	MT	DTT
DM4QHZS	MA	Inhibitor
DM4QHZS	RN	Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205.
DM4QHZS	RU	https://pubmed.ncbi.nlm.nih.gov/28952381

DM5OU2W	DI	DM5OU2W
DM5OU2W	DN	BMS-986253
DM5OU2W	MI	TT3JF7X
DM5OU2W	MN	HUMAN interleukin 8 (IL8)
DM5OU2W	MT	DTT
DM5OU2W	MA	Inhibitor
DM5OU2W	RN	ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.
DM5OU2W	RU	https://clinicaltrials.gov/ct2/show/NCT04347226

DM42B0C	DI	DM42B0C
DM42B0C	DN	BMS-986253
DM42B0C	MI	TTCTE1G
DM42B0C	MN	Interleukin-8 (IL8)
DM42B0C	MT	DTT
DM42B0C	MA	Inhibitor
DM42B0C	RN	Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240.
DM42B0C	RU	https://pubmed.ncbi.nlm.nih.gov/31488216

DMSRVXO	DI	DMSRVXO
DMSRVXO	DN	BMS-986263
DMSRVXO	MI	TTPSWQG
DMSRVXO	MN	SERPINH1 messenger RNA (SERPINH1 mRNA)
DMSRVXO	MT	DTT
DMSRVXO	MA	Inhibitor
DMSRVXO	RN	A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. AAPS J. 2019 Jul 22;21(5):92.
DMSRVXO	RU	https://pubmed.ncbi.nlm.nih.gov/31332587

DMUM2KA	DI	DMUM2KA
DMUM2KA	DN	BN82451
DMUM2KA	MI	TTK0943
DMUM2KA	MN	Prostaglandin G/H synthase (COX)
DMUM2KA	MT	DTT
DMUM2KA	MA	Inhibitor
DMUM2KA	RN	Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
DMUM2KA	RU	https://pubmed.ncbi.nlm.nih.gov/19453283

DMUM2KA	DI	DMUM2KA
DMUM2KA	DN	BN82451
DMUM2KA	MI	TTRK8B9
DMUM2KA	MN	Sodium channel unspecific (NaC)
DMUM2KA	MT	DTT
DMUM2KA	MA	Blocker
DMUM2KA	RN	Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97.
DMUM2KA	RU	https://pubmed.ncbi.nlm.nih.gov/19453283

DMJC8DR	DI	DMJC8DR
DMJC8DR	DN	BNC-105
DMJC8DR	MI	TTYFKSZ
DMJC8DR	MN	Tubulin beta (TUBB)
DMJC8DR	MT	DTT
DMJC8DR	MA	Modulator
DMJC8DR	RN	The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
DMJC8DR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25482941

DMEGDWA	DI	DMEGDWA
DMEGDWA	DN	BNC-210
DMEGDWA	MI	TTNJYV2
DMEGDWA	MN	Gamma-aminobutyric acid receptor (GAR)
DMEGDWA	MT	DTT
DMEGDWA	MA	Modulator
DMEGDWA	RN	50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. 
DMEGDWA	RU	https://pubmed.ncbi.nlm.nih.gov/23989795

DMRWG8B	DI	DMRWG8B
DMRWG8B	DN	BNT321
DMRWG8B	MI	TTD9I12
DMRWG8B	MN	Carbohydrate antigen 19-9 (CA 19-9)
DMRWG8B	MT	DTT
DMRWG8B	MA	Inhibitor
DMRWG8B	RN	Clinical pipeline report, company report or official report of BioNTech.
DMRWG8B	RU	https://biontech.de/science/pipeline

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TTJFA35
DM8JQZC	MN	Interleukin-15 (IL15)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TTF89GD
DM8JQZC	MN	Interleukin-2 (IL2)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DM8JQZC	DI	DM8JQZC
DM8JQZC	DN	BNZ-1
DM8JQZC	MI	TT0JTFD
DM8JQZC	MN	Interleukin-9 (IL9)
DM8JQZC	MT	DTT
DM8JQZC	MA	Inhibitor
DM8JQZC	RN	Clinical pipeline report, company report or official report of Bioniz Therapeutics.
DM8JQZC	RU	https://bioniz.com/pipeline/bnz-1/

DMZ70GE	DI	DMZ70GE
DMZ70GE	DN	BOS-228
DMZ70GE	MI	TTJP4SM
DMZ70GE	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZ70GE	MT	DTT
DMZ70GE	MA	Inhibitor
DMZ70GE	RN	Clinical pipeline report, company report or official report of Boston Pharmaceuticals.
DMZ70GE	RU	https://www.bostonpharmaceuticals.com/infectious-disease

DMKDGI8	DI	DMKDGI8
DMKDGI8	DN	BP-100-1-01
DMKDGI8	MI	TTEYRJ9
DMKDGI8	MN	GRB2 messenger RNA (GRB2 mRNA)
DMKDGI8	MT	DTT
DMKDGI8	MA	Modulator
DMKDGI8	RN	ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health.
DMKDGI8	RU	https://clinicaltrials.gov/ct2/show/NCT01159028

DMWVPO0	DI	DMWVPO0
DMWVPO0	DN	BPN14770
DMWVPO0	MI	TTSKMI8
DMWVPO0	MN	Phosphodiesterase 4D (PDE4D)
DMWVPO0	MT	DTT
DMWVPO0	MA	Inhibitor
DMWVPO0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWVPO0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDYZRS	DI	DMDYZRS
DMDYZRS	DN	BPS-804
DMDYZRS	MI	TTYRO4F
DMDYZRS	MN	Sclerostin (SOST)
DMDYZRS	MT	DTT
DMDYZRS	RN	WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery.
DMDYZRS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100910&CC=WO&NR=2010100179A2&KC=A2

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	TTKRD0G
DM0MO8I	MN	Endothelin A receptor (EDNRA)
DM0MO8I	MT	DTT
DM0MO8I	MA	Antagonist
DM0MO8I	RN	Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
DM0MO8I	RU	https://pubmed.ncbi.nlm.nih.gov/9068384

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DTFI42L
DM0MO8I	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM0MO8I	RU	https://doi.org/10.1007/s11095-012-0935-x

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DTE2B1D
DM0MO8I	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DT3D8F0
DM0MO8I	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM0MO8I	DI	DM0MO8I
DM0MO8I	DN	BQ-123
DM0MO8I	MI	DT9C1TS
DM0MO8I	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM0MO8I	MT	DTP
DM0MO8I	MA	Substrate
DM0MO8I	RN	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
DM0MO8I	RU	http://www.ncbi.nlm.nih.gov/pubmed/11159893

DMNFKVW	DI	DMNFKVW
DMNFKVW	DN	BR-4628
DMNFKVW	MI	TT26PHO
DMNFKVW	MN	Mineralocorticoid receptor  (MR)
DMNFKVW	MT	DTT
DMNFKVW	MA	Antagonist
DMNFKVW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMNFKVW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DM3TRF7	DI	DM3TRF7
DM3TRF7	DN	Brasofensine
DM3TRF7	MI	TT3ROYC
DM3TRF7	MN	Serotonin transporter (SERT)
DM3TRF7	MT	DTT
DM3TRF7	MA	Modulator
DM3TRF7	RN	Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7.
DM3TRF7	RU	https://pubmed.ncbi.nlm.nih.gov/11249705

DMKGM42	DI	DMKGM42
DMKGM42	DN	BREQUINAR
DMKGM42	MI	TTLVP78
DMKGM42	MN	Dihydroorotate dehydrogenase (DHODH)
DMKGM42	MT	DTT
DMKGM42	MA	Modulator
DMKGM42	RN	DOI: 10.1203/00006450-198807000-00137
DMKGM42	RU	http://www.nature.com/pr/journal/v24/n1/abs/pr1988506a.html

DMXI9BP	DI	DMXI9BP
DMXI9BP	DN	Brilacidin
DMXI9BP	MI	TTXT4D5
DMXI9BP	MN	Bacterial Cell membrane (Bact CM)
DMXI9BP	MT	DTT
DMXI9BP	MA	Enhancer
DMXI9BP	RN	Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45.
DMXI9BP	RU	https://pubmed.ncbi.nlm.nih.gov/24936592

DMLD80M	DI	DMLD80M
DMLD80M	DN	Brivoligide
DMLD80M	MI	TTE8LGD
DMLD80M	MN	EGR1 messenger RNA (EGR1 mRNA)
DMLD80M	MT	DTT
DMLD80M	MA	Inhibitor
DMLD80M	RN	ClinicalTrials.gov (NCT04104919) Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores. U.S. National Institutes of Health.
DMLD80M	RU	https://clinicaltrials.gov/ct2/show/NCT04104919

DMLFGHX	DI	DMLFGHX
DMLFGHX	DN	BRL 35135
DMLFGHX	MI	TTR6W5O
DMLFGHX	MN	Adrenergic receptor beta-1 (ADRB1)
DMLFGHX	MT	DTT
DMLFGHX	MA	Agonist
DMLFGHX	RN	Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300.
DMLFGHX	RU	https://pubmed.ncbi.nlm.nih.gov/8877018

DMUI5PA	DI	DMUI5PA
DMUI5PA	DN	Brostallicin
DMUI5PA	MI	TTOVXHF
DMUI5PA	MN	Human Deoxyribonucleic acid minor groove (hDNA min)
DMUI5PA	MT	DTT
DMUI5PA	MA	Inhibitor
DMUI5PA	RN	Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46.
DMUI5PA	RU	https://pubmed.ncbi.nlm.nih.gov/19938904

DM1ZOCK	DI	DM1ZOCK
DM1ZOCK	DN	Bryostatin-1
DM1ZOCK	MI	TTBZ7OD
DM1ZOCK	MN	Protein kinase C epsilon (PRKCE)
DM1ZOCK	MT	DTT
DM1ZOCK	MA	Activator
DM1ZOCK	RN	Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8.
DM1ZOCK	RU	https://pubmed.ncbi.nlm.nih.gov/11490365

DM2LZIY	DI	DM2LZIY
DM2LZIY	DN	BT-061
DM2LZIY	MI	TTN2JFW
DM2LZIY	MN	T-cell surface glycoprotein CD4 (CD4)
DM2LZIY	MT	DTT
DM2LZIY	RN	Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
DM2LZIY	RU	https://pubmed.ncbi.nlm.nih.gov/25666094

DMYO185	DI	DMYO185
DMYO185	DN	BT-062
DMYO185	MI	TTYDSVG
DMYO185	MN	Syndecan-1 (SDC1)
DMYO185	MT	DTT
DMYO185	RN	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
DMYO185	RU	https://pubmed.ncbi.nlm.nih.gov/19509164

DMDWP0U	DI	DMDWP0U
DMDWP0U	DN	BTA-798
DMDWP0U	MI	TT8R3VP
DMDWP0U	MN	Rhinovirus Capsid protein (HRV VP)
DMDWP0U	MT	DTT
DMDWP0U	MA	Inhibitor
DMDWP0U	RN	Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012 Jan 15;83(2):185-92.
DMDWP0U	RU	https://pubmed.ncbi.nlm.nih.gov/21889497

DMS6ZA0	DI	DMS6ZA0
DMS6ZA0	DN	BTD-001
DMS6ZA0	MI	TTCI43M
DMS6ZA0	MN	GABA(A) receptor (GABAR)
DMS6ZA0	MT	DTT
DMS6ZA0	MA	Antagonist
DMS6ZA0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS6ZA0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMY5IX4	DI	DMY5IX4
DMY5IX4	DN	BTL-TML-001
DMY5IX4	MI	TTL3N71
DMY5IX4	MN	Virus Replication (Viru Repli)
DMY5IX4	MT	DTT
DMY5IX4	MA	Inhibitor
DMY5IX4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY5IX4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMA9238	DI	DMA9238
DMA9238	DN	BTRX-246040
DMA9238	MI	TTNT7K8
DMA9238	MN	Nociceptin receptor (OPRL1)
DMA9238	MT	DTT
DMA9238	MA	Antagonist
DMA9238	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA9238	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWPDUZ	DI	DMWPDUZ
DMWPDUZ	DN	BTRX-335140
DMWPDUZ	MI	TTQW87Y
DMWPDUZ	MN	Opioid receptor kappa (OPRK1)
DMWPDUZ	MT	DTT
DMWPDUZ	MA	Antagonist
DMWPDUZ	RN	Clinical pipeline report, company report or official report of BlackThorn Therapeutics.
DMWPDUZ	RU	https://www.blackthornrx.com/btrx-335140-kappa-opioid-receptor-antagonist/

DMIEPJG	DI	DMIEPJG
DMIEPJG	DN	BTT-1023
DMIEPJG	MI	TT7HC21
DMIEPJG	MN	Membrane copper amine oxidase (AOC3)
DMIEPJG	MT	DTT
DMIEPJG	RN	Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.
DMIEPJG	RU	https://pubmed.ncbi.nlm.nih.gov/23847292

DMZC4V0	DI	DMZC4V0
DMZC4V0	DN	Buproprion+zonisamide
DMZC4V0	MI	TTTQR47
DMZC4V0	MN	Solute carrier family 22 member 8 (SLC22A8)
DMZC4V0	MT	DTT
DMZC4V0	MA	Blocker
DMZC4V0	RN	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
DMZC4V0	RU	https://pubmed.ncbi.nlm.nih.gov/18473708

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TTKPV6O
DMNB4XK	MN	Ephrin type-B receptor 2 (EPHB2)
DMNB4XK	MT	DTT
DMNB4XK	MA	Inhibitor
DMNB4XK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNB4XK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TT1MG9E
DMNB4XK	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMNB4XK	MT	DTT
DMNB4XK	MA	Modulator
DMNB4XK	RN	DOI: 10.1158/1538-7445.AM2015-4693
DMNB4XK	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693

DMNB4XK	DI	DMNB4XK
DMNB4XK	DN	BVD-523
DMNB4XK	MI	TT4TQBX
DMNB4XK	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMNB4XK	MT	DTT
DMNB4XK	MA	Modulator
DMNB4XK	RN	DOI: 10.1158/1538-7445.AM2015-4693
DMNB4XK	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693

DM8CWL0	DI	DM8CWL0
DM8CWL0	DN	BVT.28949
DM8CWL0	MI	TTJQOD7
DM8CWL0	MN	5-HT 2A receptor (HTR2A)
DM8CWL0	MT	DTT
DM8CWL0	MA	Antagonist
DM8CWL0	RN	Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677.
DM8CWL0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/

DMD8GNB	DI	DMD8GNB
DMD8GNB	DN	BXT-51072
DMD8GNB	MI	TTF10I9
DMD8GNB	MN	Nitric-oxide synthase inducible (NOS2)
DMD8GNB	MT	DTT
DMD8GNB	MA	Modulator
DMD8GNB	RN	Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
DMD8GNB	RU	https://pubmed.ncbi.nlm.nih.gov/11078703

DMTRONK	DI	DMTRONK
DMTRONK	DN	BZL-101
DMTRONK	MI	TT34ECM
DMTRONK	MN	Cell cycle (CC)
DMTRONK	MT	DTT
DMTRONK	MA	Inhibitor
DMTRONK	RN	BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405.
DMTRONK	RU	https://www.ncbi.nlm.nih.gov/pubmed/20574166

DMGE058	DI	DMGE058
DMGE058	DN	Cabiralizumab
DMGE058	MI	TTNYZG2
DMGE058	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMGE058	MT	DTT
DMGE058	MA	Antagonist
DMGE058	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE058	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGE058	DI	DMGE058
DMGE058	DN	Cabiralizumab
DMGE058	MI	TT7MRDV
DMGE058	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMGE058	MT	DTT
DMGE058	MA	Antagonist
DMGE058	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE058	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMGXCY9	DI	DMGXCY9
DMGXCY9	DN	Calcium phosphate
DMGXCY9	MI	DT42EWA
DMGXCY9	MN	Sodium-dependent phosphate transport protein 2A (SLC34A1)
DMGXCY9	MT	DTP
DMGXCY9	MA	Substrate
DMGXCY9	RN	Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50.
DMGXCY9	RU	http://www.ncbi.nlm.nih.gov/pubmed/23398154

DMDV8MK	DI	DMDV8MK
DMDV8MK	DN	CALDARET HYDRATE
DMDV8MK	MI	TT619TC
DMDV8MK	MN	Sodium/calcium exchanger (SLC)
DMDV8MK	MT	DTT
DMDV8MK	MA	Modulator
DMDV8MK	RN	Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33.
DMDV8MK	RU	https://pubmed.ncbi.nlm.nih.gov/17299242

DMAKSMX	DI	DMAKSMX
DMAKSMX	DN	Camicinal
DMAKSMX	MI	TT953CX
DMAKSMX	MN	Motilin receptor (MLNR)
DMAKSMX	MT	DTT
DMAKSMX	MA	Modulator
DMAKSMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
DMAKSMX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297

DMQ7UL8	DI	DMQ7UL8
DMQ7UL8	DN	Camostat
DMQ7UL8	MI	DTT79CX
DMQ7UL8	MN	Organic cation transporter 1 (SLC22A1)
DMQ7UL8	MT	DTP
DMQ7UL8	MA	Substrate
DMQ7UL8	RN	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
DMQ7UL8	RU	http://www.ncbi.nlm.nih.gov/pubmed/23984907

DMQ7UL8	DI	DMQ7UL8
DMQ7UL8	DN	Camostat
DMQ7UL8	MI	TTEMV5X
DMQ7UL8	MN	Serine protease unspecific (SP)
DMQ7UL8	MT	DTT
DMQ7UL8	MA	Inhibitor
DMQ7UL8	RN	Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
DMQ7UL8	RU	https://pubmed.ncbi.nlm.nih.gov/19145783

DMEZLFT	DI	DMEZLFT
DMEZLFT	DN	Camsirubicin
DMEZLFT	MI	TTCGY2K
DMEZLFT	MN	DNA topoisomerase II alpha (TOP2A)
DMEZLFT	MT	DTT
DMEZLFT	MA	Inhibitor
DMEZLFT	RN	Clinical pipeline report, company report or official report of Monopar Therapeutics.
DMEZLFT	RU	https://www.monopartx.com/pipeline/Camsirubicin

DMEYIVW	DI	DMEYIVW
DMEYIVW	DN	CAP1-6D
DMEYIVW	MI	TTY6DTE
DMEYIVW	MN	Carcinoembryonic antigen CEA (CD66e)
DMEYIVW	MT	DTT
DMEYIVW	MA	Modulator
DMEYIVW	RN	Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
DMEYIVW	RU	https://pubmed.ncbi.nlm.nih.gov/9377571

DMJKLHU	DI	DMJKLHU
DMJKLHU	DN	CAP-7.1
DMJKLHU	MI	TT0IHXV
DMJKLHU	MN	DNA topoisomerase II (TOP2)
DMJKLHU	MT	DTT
DMJKLHU	MA	Modulator
DMJKLHU	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJKLHU	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYWO62	DI	DMYWO62
DMYWO62	DN	Capadenoson
DMYWO62	MI	TTK25J1
DMYWO62	MN	Adenosine A1 receptor (ADORA1)
DMYWO62	MT	DTT
DMYWO62	MA	Agonist
DMYWO62	RN	A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
DMYWO62	RU	https://pubmed.ncbi.nlm.nih.gov/19012505

DMY4OMS	DI	DMY4OMS
DMY4OMS	DN	Carabersat
DMY4OMS	MI	TTSB7ZR
DMY4OMS	MN	Trigeminal ganglion stimulation-induced response (TGSR)
DMY4OMS	MT	DTT
DMY4OMS	MA	Modulator
DMY4OMS	RN	Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001 April; 132(7): 1549-1557.
DMY4OMS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572685/

DMN5JCX	DI	DMN5JCX
DMN5JCX	DN	Carboxyamidotriazole orotate
DMN5JCX	MI	TTF89GD
DMN5JCX	MN	Interleukin-2 (IL2)
DMN5JCX	MT	DTT
DMN5JCX	MA	Inhibitor
DMN5JCX	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2071).
DMN5JCX	RU	http://meetinglibrary.asco.org/content/132006-144

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	DE2PJF5
DM7ADGX	MN	Acid cholesteryl ester hydrolase (LIPA)
DM7ADGX	MT	DME
DM7ADGX	MA	Metabolism
DM7ADGX	RN	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
DM7ADGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27495118

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	DE4LYSA
DM7ADGX	MN	Cytochrome P450 3A4 (CYP3A4)
DM7ADGX	MT	DME
DM7ADGX	MA	Metabolism
DM7ADGX	RN	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
DM7ADGX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27495118

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TT27RFC
DM7ADGX	MN	Opioid receptor delta (OPRD1)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TTQW87Y
DM7ADGX	MN	Opioid receptor kappa (OPRK1)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DM7ADGX	DI	DM7ADGX
DM7ADGX	DN	Carfentanil
DM7ADGX	MI	TTKWM86
DM7ADGX	MN	Opioid receptor mu (MOP)
DM7ADGX	MT	DTT
DM7ADGX	MA	Agonist
DM7ADGX	RN	Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
DM7ADGX	RU	https://pubmed.ncbi.nlm.nih.gov/12712038

DMAUN15	DI	DMAUN15
DMAUN15	DN	Carlumab
DMAUN15	MI	TTNAY0P
DMAUN15	MN	Monocyte chemotactic and activating factor (CCL2)
DMAUN15	MT	DTT
DMAUN15	RN	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
DMAUN15	RU	https://pubmed.ncbi.nlm.nih.gov/24928772

DMN6TKI	DI	DMN6TKI
DMN6TKI	DN	Carmoterol
DMN6TKI	MI	TT2CJVK
DMN6TKI	MN	Adrenergic receptor beta-2 (ADRB2)
DMN6TKI	MT	DTT
DMN6TKI	MA	Agonist
DMN6TKI	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMN6TKI	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMTBFXW	DI	DMTBFXW
DMTBFXW	DN	CART 19
DMTBFXW	MI	TTW640A
DMTBFXW	MN	B-lymphocyte surface antigen B4 (CD19)
DMTBFXW	MT	DTT
DMTBFXW	MA	CAR-T-Cell-Therapy
DMTBFXW	RN	ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
DMTBFXW	RU	https://clinicaltrials.gov/ct2/show/NCT02935543

DM28A5D	DI	DM28A5D
DM28A5D	DN	CAR-T cells targeting CD19
DM28A5D	MI	TTW640A
DM28A5D	MN	B-lymphocyte surface antigen B4 (CD19)
DM28A5D	MT	DTT
DM28A5D	MA	CAR-T-Cell-Therapy
DM28A5D	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM28A5D	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DM3RU0A	DI	DM3RU0A
DM3RU0A	DN	CAR-T cells targeting CD20
DM3RU0A	MI	TTUE541
DM3RU0A	MN	Leukocyte surface antigen Leu-16 (CD20)
DM3RU0A	MT	DTT
DM3RU0A	MA	CAR-T-Cell-Therapy
DM3RU0A	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM3RU0A	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DM6XN4C	DI	DM6XN4C
DM6XN4C	DN	CAR-T cells targeting CD22
DM6XN4C	MI	TTM6QSK
DM6XN4C	MN	B-cell receptor CD22 (CD22)
DM6XN4C	MT	DTT
DM6XN4C	MA	CAR-T-Cell-Therapy
DM6XN4C	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DM6XN4C	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DML0KWM	DI	DML0KWM
DML0KWM	DN	CAR-T cells targeting CD30
DML0KWM	MI	TT2GM5R
DML0KWM	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DML0KWM	MT	DTT
DML0KWM	MA	CAR-T-Cell-Therapy
DML0KWM	RN	ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
DML0KWM	RU	https://clinicaltrials.gov/ct2/show/NCT03196830

DMHQKN6	DI	DMHQKN6
DMHQKN6	DN	CART-19
DMHQKN6	MI	TTW640A
DMHQKN6	MN	B-lymphocyte surface antigen B4 (CD19)
DMHQKN6	MT	DTT
DMHQKN6	MA	CAR-T-Cell-Therapy
DMHQKN6	RN	ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
DMHQKN6	RU	https://clinicaltrials.gov/ct2/show/NCT01029366

DMZUV7T	DI	DMZUV7T
DMZUV7T	DN	CART-19 cells
DMZUV7T	MI	TTW640A
DMZUV7T	MN	B-lymphocyte surface antigen B4 (CD19)
DMZUV7T	MT	DTT
DMZUV7T	MA	CAR-T-Cell-Therapy
DMZUV7T	RN	ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol
DMZUV7T	RU	https://clinicaltrials.gov/ct2/show/NCT01551043

DMQBP7R	DI	DMQBP7R
DMQBP7R	DN	CAT 1004
DMQBP7R	MI	TTUIZKC
DMQBP7R	MN	DNA-binding factor KBF1 (p105)
DMQBP7R	MT	DTT
DMQBP7R	MA	Inhibitor
DMQBP7R	RN	Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc.
DMQBP7R	RU	http://www.catabasis.com/clinical-trials-cat-1004-movedmd.php

DMQBP7R	DI	DMQBP7R
DMQBP7R	DN	CAT 1004
DMQBP7R	MI	TTSXVID
DMQBP7R	MN	Nuclear factor NF-kappa-B (NFKB)
DMQBP7R	MT	DTT
DMQBP7R	MA	Inhibitor
DMQBP7R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBP7R	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM2IFYZ	DI	DM2IFYZ
DM2IFYZ	DN	CB-10-01
DM2IFYZ	MI	TTUJFD0
DM2IFYZ	MN	Telomerase reverse transcriptase (TERT)
DM2IFYZ	MT	DTT
DM2IFYZ	RN	Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12.
DM2IFYZ	RU	https://pubmed.ncbi.nlm.nih.gov/17324292

DM094UH	DI	DM094UH
DM094UH	DN	CB-839
DM094UH	MI	TTCW0KX
DM094UH	MN	Glutaminase (GLS)
DM094UH	MT	DTT
DM094UH	MA	Modulator
DM094UH	RN	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.
DM094UH	RU	https://pubmed.ncbi.nlm.nih.gov/24523301

DMK4FRU	DI	DMK4FRU
DMK4FRU	DN	CBLB-502
DMK4FRU	MI	TTCXP8J
DMK4FRU	MN	Toll-like receptor 5 (TLR5)
DMK4FRU	MT	DTT
DMK4FRU	MA	Agonist
DMK4FRU	RN	Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One. 2014 May 30;9(5):e96165.
DMK4FRU	RU	https://pubmed.ncbi.nlm.nih.gov/24879439

DMSBNTZ	DI	DMSBNTZ
DMSBNTZ	DN	CBX-129801
DMSBNTZ	MI	TTKF4WV
DMSBNTZ	MN	Connecting peptide (C-peptide)
DMSBNTZ	MT	DTT
DMSBNTZ	MA	Modulator
DMSBNTZ	RN	ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health.
DMSBNTZ	RU	https://clinicaltrials.gov/ct2/show/NCT01681290

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTZ97H5
DMQ874W	MN	Phosphodiesterase 4A (PDE4A)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTVIAT9
DMQ874W	MN	Phosphodiesterase 4B (PDE4B)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMQ874W	DI	DMQ874W
DMQ874W	DN	CC-1088
DMQ874W	MI	TTSKMI8
DMQ874W	MN	Phosphodiesterase 4D (PDE4D)
DMQ874W	MT	DTT
DMQ874W	MA	Inhibitor
DMQ874W	RN	Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74.
DMQ874W	RU	https://pubmed.ncbi.nlm.nih.gov/9873600

DMNE7L3	DI	DMNE7L3
DMNE7L3	DN	CC-220
DMNE7L3	MI	TTDKGTC
DMNE7L3	MN	Protein cereblon (CRBN)
DMNE7L3	MT	DTT
DMNE7L3	MA	Inhibitor
DMNE7L3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNE7L3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJR9H0	DI	DMJR9H0
DMJR9H0	DN	CC-292
DMJR9H0	MI	TTGM6VW
DMJR9H0	MN	Tyrosine-protein kinase BTK (ATK)
DMJR9H0	MT	DTT
DMJR9H0	MA	Modulator
DMJR9H0	RN	Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28.
DMJR9H0	RU	https://pubmed.ncbi.nlm.nih.gov/23709115

DMPMO6G	DI	DMPMO6G
DMPMO6G	DN	CC-401
DMPMO6G	MI	TTR2TXZ
DMPMO6G	MN	Jun N terminal kinase (JNK)
DMPMO6G	MT	DTT
DMPMO6G	MA	Modulator
DMPMO6G	RN	Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
DMPMO6G	RU	https://www.ncbi.nlm.nih.gov/pubmed/19629069

DM0EDHJ	DI	DM0EDHJ
DM0EDHJ	DN	CC-90011
DM0EDHJ	MI	TTNR0UQ
DM0EDHJ	MN	Lysine-specific histone demethylase 1 (LSD)
DM0EDHJ	MT	DTT
DM0EDHJ	MA	Inhibitor
DM0EDHJ	RN	Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
DM0EDHJ	RU	https://pubmed.ncbi.nlm.nih.gov/33034194

DMHVEGJ	DI	DMHVEGJ
DMHVEGJ	DN	CC-930
DMHVEGJ	MI	TTR2TXZ
DMHVEGJ	MN	Jun N terminal kinase (JNK)
DMHVEGJ	MT	DTT
DMHVEGJ	MA	Modulator
DMHVEGJ	RN	In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
DMHVEGJ	RU	https://pubmed.ncbi.nlm.nih.gov/25475995

DMJ9XCO	DI	DMJ9XCO
DMJ9XCO	DN	CCX-140
DMJ9XCO	MI	TTFZYTO
DMJ9XCO	MN	C-C chemokine receptor type 2 (CCR2)
DMJ9XCO	MT	DTT
DMJ9XCO	MA	Antagonist
DMJ9XCO	RN	Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348.
DMJ9XCO	RU	https://pubmed.ncbi.nlm.nih.gov/25945357

DMSHV9C	DI	DMSHV9C
DMSHV9C	DN	CCX-354
DMSHV9C	MI	TTC24WT
DMSHV9C	MN	C-C chemokine receptor type 1 (CCR1)
DMSHV9C	MT	DTT
DMSHV9C	MA	Antagonist
DMSHV9C	RN	Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.
DMSHV9C	RU	https://pubmed.ncbi.nlm.nih.gov/22589376

DMPVAUT	DI	DMPVAUT
DMPVAUT	DN	CCX872
DMPVAUT	MI	TTFZYTO
DMPVAUT	MN	C-C chemokine receptor type 2 (CCR2)
DMPVAUT	MT	DTT
DMPVAUT	MA	Inhibitor
DMPVAUT	RN	Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78.
DMPVAUT	RU	http://www.sciencedirect.com/science/article/pii/S014067361460341X

DMEK580	DI	DMEK580
DMEK580	DN	CD19 CAR T cells
DMEK580	MI	TTW640A
DMEK580	MN	B-lymphocyte surface antigen B4 (CD19)
DMEK580	MT	DTT
DMEK580	MA	CAR-T-Cell-Therapy
DMEK580	RN	ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
DMEK580	RU	https://clinicaltrials.gov/ct2/show/NCT02846584

DMQJBUK	DI	DMQJBUK
DMQJBUK	DN	CD19-targeting CAR T cells
DMQJBUK	MI	TTW640A
DMQJBUK	MN	B-lymphocyte surface antigen B4 (CD19)
DMQJBUK	MT	DTT
DMQJBUK	MA	CAR-T-Cell-Therapy
DMQJBUK	RN	ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
DMQJBUK	RU	https://clinicaltrials.gov/ct2/show/NCT02132624

DMQGI8R	DI	DMQGI8R
DMQGI8R	DN	CD20 CAR T cells
DMQGI8R	MI	TTUE541
DMQGI8R	MN	Leukocyte surface antigen Leu-16 (CD20)
DMQGI8R	MT	DTT
DMQGI8R	MA	CAR-T-Cell-Therapy
DMQGI8R	RN	ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
DMQGI8R	RU	https://clinicaltrials.gov/ct2/show/NCT02846584

DMXYLTI	DI	DMXYLTI
DMXYLTI	DN	CDP323
DMXYLTI	MI	TT6S84X
DMXYLTI	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMXYLTI	MT	DTT
DMXYLTI	MA	Modulator
DMXYLTI	RN	Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438.
DMXYLTI	RU	https://www.ncbi.nlm.nih.gov/pubmed/23472197

DM3YB2C	DI	DM3YB2C
DM3YB2C	DN	CDP-6038
DM3YB2C	MI	TTT1V78
DM3YB2C	MN	Interleukin-6 (IL6)
DM3YB2C	MT	DTT
DM3YB2C	MA	Modulator
DM3YB2C	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM3YB2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8UQJG	DI	DM8UQJG
DM8UQJG	DN	CDX-1307
DM8UQJG	MI	TTUH273
DM8UQJG	MN	Choriogonadotropin beta (CG-beta)
DM8UQJG	MT	DTT
DM8UQJG	RN	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733-42.
DM8UQJG	RU	https://pubmed.ncbi.nlm.nih.gov/21692696

DMCGNJ6	DI	DMCGNJ6
DMCGNJ6	DN	CDX-1401
DMCGNJ6	MI	TTE5ITK
DMCGNJ6	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMCGNJ6	MT	DTT
DMCGNJ6	MA	Modulator
DMCGNJ6	RN	National Cancer Institute Drug Dictionary (drug id 651880).
DMCGNJ6	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=651880

DMKRFCO	DI	DMKRFCO
DMKRFCO	DN	CDX-301
DMKRFCO	MI	TTGJCWZ
DMKRFCO	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMKRFCO	MT	DTT
DMKRFCO	MA	Inhibitor
DMKRFCO	RN	Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30.
DMKRFCO	RU	https://pubmed.ncbi.nlm.nih.gov/25915810

DM5GKYD	DI	DM5GKYD
DM5GKYD	DN	CDX-3379
DM5GKYD	MI	TTDC8N2
DM5GKYD	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM5GKYD	MT	DTT
DM5GKYD	MA	Antagonist
DM5GKYD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5GKYD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM6Z9BV	DI	DM6Z9BV
DM6Z9BV	DN	CeaVac
DM6Z9BV	MI	TTY6DTE
DM6Z9BV	MN	Carcinoembryonic antigen CEA (CD66e)
DM6Z9BV	MT	DTT
DM6Z9BV	RN	Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
DM6Z9BV	RU	https://pubmed.ncbi.nlm.nih.gov/10561367

DM1S2FZ	DI	DM1S2FZ
DM1S2FZ	DN	Cemdisiran
DM1S2FZ	MI	TT2LJRF
DM1S2FZ	MN	C5 messenger RNA (C5 mRNA)
DM1S2FZ	MT	DTT
DM1S2FZ	MA	Inhibitor
DM1S2FZ	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
DM1S2FZ	RU	https://www.alnylam.com/alnylam-rnai-pipeline/

DMCT8EY	DI	DMCT8EY
DMCT8EY	DN	Cenderitide
DMCT8EY	MI	TTJME02
DMCT8EY	MN	Atrial natriuretic peptide receptor A (NPR1)
DMCT8EY	MT	DTT
DMCT8EY	MA	Agonist
DMCT8EY	RN	2011 Pipeline of Nile Therapeutics.
DMCT8EY	RU	http://www.nilethera.com/pipeline.html

DMU3P1K	DI	DMU3P1K
DMU3P1K	DN	Cenerimod
DMU3P1K	MI	TT2DLFI
DMU3P1K	MN	Lysosphingolipid receptor (LSPR)
DMU3P1K	MT	DTT
DMU3P1K	MA	Agonist
DMU3P1K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU3P1K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMMN21R	DI	DMMN21R
DMMN21R	DN	Cenersen
DMMN21R	MI	TT12KOD
DMMN21R	MN	P53 messenger RNA (TP53 mRNA)
DMMN21R	MT	DTT
DMMN21R	RN	Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27.
DMMN21R	RU	https://pubmed.ncbi.nlm.nih.gov/21717444

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	TTFZYTO
DM4V8WF	MN	C-C chemokine receptor type 2 (CCR2)
DM4V8WF	MT	DTT
DM4V8WF	MA	Antagonist
DM4V8WF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4V8WF	RU	http://phrma-docs.phrma.org/files/dmfile/2017-HIV-AIDS-MID-Drug-List.pdf

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	TT2CEJG
DM4V8WF	MN	C-C chemokine receptor type 5 (CCR5)
DM4V8WF	MT	DTT
DM4V8WF	MA	Modulator
DM4V8WF	RN	The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
DM4V8WF	RU	https://pubmed.ncbi.nlm.nih.gov/25433008

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	DES5XRU
DM4V8WF	MN	Cytochrome P450 2C8 (CYP2C8)
DM4V8WF	MT	DME
DM4V8WF	MA	Metabolism
DM4V8WF	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DM4V8WF	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DM4V8WF	DI	DM4V8WF
DM4V8WF	DN	Cenicriviroc
DM4V8WF	MI	DE4LYSA
DM4V8WF	MN	Cytochrome P450 3A4 (CYP3A4)
DM4V8WF	MT	DME
DM4V8WF	MA	Metabolism
DM4V8WF	RN	Pharmacokinetics, safety, and CCR2/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment. Clin Transl Sci. 2016 Jun;9(3):139-48.
DM4V8WF	RU	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12397

DMWUQI9	DI	DMWUQI9
DMWUQI9	DN	CER-001
DMWUQI9	MI	TT7GN3U
DMWUQI9	MN	Apolipoprotein A-I (APOA1)
DMWUQI9	MT	DTT
DMWUQI9	MA	Modulator
DMWUQI9	RN	Clinical pipeline report, company report or official report of Cerenis.
DMWUQI9	RU	http://www.cerenis.com/en/our-therapies/cer-001

DMSABRI	DI	DMSABRI
DMSABRI	DN	CERC-301
DMSABRI	MI	TTN9D8E
DMSABRI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMSABRI	MT	DTT
DMSABRI	MA	Antagonist
DMSABRI	RN	Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
DMSABRI	RU	https://pubmed.ncbi.nlm.nih.gov/26325093

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DE3OP9S
DM3SZ7P	MN	Galactose kinase (GALK1)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact. 2010 Dec 5;188(3):376-85.
DM3SZ7P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20696150

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEVSIE6
DM3SZ7P	MN	Glyceraldehyde-3-phosphate dehydrogenase (gap)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Cloning, expression and characterization of a mucin-binding GAPDH from Lactobacillus acidophilus. Int J Biol Macromol. 2016 Oct;91:338-46.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/27180300

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DETP28W
DM3SZ7P	MN	L-arabinose isomerase (araA)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	The acid tolerant L-arabinose isomerase from the food grade Lactobacillus sakei 23K is an attractive D-tagatose producer. Bioresour Technol. 2010 Dec;101(23):9171-7.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/20688514

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEU37LK
DM3SZ7P	MN	L-arabinose isomerase (araA)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Biochemical properties of L-arabinose isomerase from Clostridium hylemonae to produce D-tagatose as a functional sweetener. PLoS One. 2018 Apr 23;13(4):e0196099.
DM3SZ7P	RU	https://pubmed.ncbi.nlm.nih.gov/29684065

DM3SZ7P	DI	DM3SZ7P
DM3SZ7P	DN	CERC-801
DM3SZ7P	MI	DEYWLRK
DM3SZ7P	MN	Sulfotransferase 1A1 (SULT1A1)
DM3SZ7P	MT	DME
DM3SZ7P	MA	Metabolism
DM3SZ7P	RN	Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase-1. J Biol Chem. 2008 Oct 10;283(41):27438-43.
DM3SZ7P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18697746

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TT6DM01
DMSCR2H	MN	Janus kinase 1 (JAK-1)
DMSCR2H	MT	DTT
DMSCR2H	MA	Inhibitor
DMSCR2H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSCR2H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTRMX3V
DMSCR2H	MN	Janus kinase 2 (JAK-2)
DMSCR2H	MT	DTT
DMSCR2H	MA	Modulator
DMSCR2H	RN	Company report (Portola Pharmaceuticals)
DMSCR2H	RU	https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTT7PJU
DMSCR2H	MN	Janus kinase 3 (JAK-3)
DMSCR2H	MT	DTT
DMSCR2H	MA	Inhibitor
DMSCR2H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSCR2H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMSCR2H	DI	DMSCR2H
DMSCR2H	DN	Cerdulatinib
DMSCR2H	MI	TTOU65C
DMSCR2H	MN	Tyrosine-protein kinase SYK (SYK)
DMSCR2H	MT	DTT
DMSCR2H	MA	Modulator
DMSCR2H	RN	Company report (Portola Pharmaceuticals)
DMSCR2H	RU	https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/

DMNW5I9	DI	DMNW5I9
DMNW5I9	DN	CERE-110
DMNW5I9	MI	TTDN3LF
DMNW5I9	MN	Nerve growth factor (NGF)
DMNW5I9	MT	DTT
DMNW5I9	MA	Modulator
DMNW5I9	RN	CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7.
DMNW5I9	RU	https://pubmed.ncbi.nlm.nih.gov/20373268

DMS01AX	DI	DMS01AX
DMS01AX	DN	CERE-120
DMS01AX	MI	TTWFC4G
DMS01AX	MN	Netrin (NET)
DMS01AX	MT	DTT
DMS01AX	MA	Modulator
DMS01AX	RN	Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007 Jan;15(1):62-8.
DMS01AX	RU	https://pubmed.ncbi.nlm.nih.gov/17164776

DMAWKSM	DI	DMAWKSM
DMAWKSM	DN	CetuGEX
DMAWKSM	MI	TTGKNB4
DMAWKSM	MN	Epidermal growth factor receptor (EGFR)
DMAWKSM	MT	DTT
DMAWKSM	RN	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
DMAWKSM	RU	https://pubmed.ncbi.nlm.nih.gov/21293176

DMP56WJ	DI	DMP56WJ
DMP56WJ	DN	CF102
DMP56WJ	MI	TTJFY5U
DMP56WJ	MN	Adenosine A3 receptor (ADORA3)
DMP56WJ	MT	DTT
DMP56WJ	MA	Agonist
DMP56WJ	RN	2011 Pipeline of Can-Fite BioPharm.
DMP56WJ	RU	http://www.canfite.com/pipeline.html

DM3BN4W	DI	DM3BN4W
DM3BN4W	DN	CFI-400945
DM3BN4W	MI	TTGPNZQ
DM3BN4W	MN	Polo-like kinase 4 (PLK4)
DM3BN4W	MT	DTT
DM3BN4W	MA	Inhibitor
DM3BN4W	RN	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76.
DM3BN4W	RU	https://pubmed.ncbi.nlm.nih.gov/25043604

DM1TWIE	DI	DM1TWIE
DM1TWIE	DN	CFZ533
DM1TWIE	MI	TTN6Y9A
DM1TWIE	MN	CD40L receptor (CD40)
DM1TWIE	MT	DTT
DM1TWIE	MA	Inhibitor
DM1TWIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1TWIE	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWY609	DI	DMWY609
DMWY609	DN	CG201
DMWY609	MI	TT0ID4A
DMWY609	MN	Leutinizing-hormone-releasing hormone (GNRH1)
DMWY609	MT	DTT
DMWY609	MA	Modulator
DMWY609	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWY609	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFAKGR	DI	DMFAKGR
DMFAKGR	DN	CG-400549
DMFAKGR	MI	TTZBRVL
DMFAKGR	MN	Staphylococcus Enoyl ACP reductase (Stap-coc fabI)
DMFAKGR	MT	DTT
DMFAKGR	MA	Inhibitor
DMFAKGR	RN	In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3.
DMFAKGR	RU	https://pubmed.ncbi.nlm.nih.gov/17420210

DM17JSI	DI	DM17JSI
DM17JSI	DN	CGC-11047
DM17JSI	MI	TTUTN1I
DM17JSI	MN	Human Deoxyribonucleic acid (hDNA)
DM17JSI	MT	DTT
DM17JSI	MA	Modulator
DM17JSI	RN	Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75.
DM17JSI	RU	https://pubmed.ncbi.nlm.nih.gov/19487545

DMYNTQV	DI	DMYNTQV
DMYNTQV	DN	CGP-28014
DMYNTQV	MI	TTKWFB8
DMYNTQV	MN	Catechol-O-methyl-transferase (COMT)
DMYNTQV	MT	DTT
DMYNTQV	MA	Modulator
DMYNTQV	RN	CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11.
DMYNTQV	RU	https://pubmed.ncbi.nlm.nih.gov/1980718

DMKS7RJ	DI	DMKS7RJ
DMKS7RJ	DN	CGS-15873A
DMKS7RJ	MI	TTEX248
DMKS7RJ	MN	Dopamine D2 receptor (D2R)
DMKS7RJ	MT	DTT
DMKS7RJ	MA	Modulator
DMKS7RJ	RN	Biochemical and pharmacological characterization of the putative dopamine autoreceptor agonist benzopyranopyridine, CGS 15873A. Article first published online: 5 OCT 2004.
DMKS7RJ	RU	http://onlinelibrary.wiley.com/doi/10.1002/ddr.430180303/abstract

DMLQRYH	DI	DMLQRYH
DMLQRYH	DN	CH-4051
DMLQRYH	MI	TTYZVDJ
DMLQRYH	MN	Dihydrofolate reductase (DHFR)
DMLQRYH	MT	DTT
DMLQRYH	MA	Inhibitor
DMLQRYH	RN	CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
DMLQRYH	RU	https://pubmed.ncbi.nlm.nih.gov/20721827

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TT3WG5C
DMQ2O8V	MN	Monoamine oxidase type A (MAO-A)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Inhibitor
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TTGP7BY
DMQ2O8V	MN	Monoamine oxidase type B (MAO-B)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Inhibitor
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMQ2O8V	DI	DMQ2O8V
DMQ2O8V	DN	CHF-3381
DMQ2O8V	MI	TT9IK2Z
DMQ2O8V	MN	N-methyl-D-aspartate receptor (NMDAR)
DMQ2O8V	MT	DTT
DMQ2O8V	MA	Antagonist
DMQ2O8V	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMQ2O8V	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMTE071	DI	DMTE071
DMTE071	DN	CHF-5074
DMTE071	MI	TT9W8GU
DMTE071	MN	Gamma-secretase (GS)
DMTE071	MT	DTT
DMTE071	MA	Modulator
DMTE071	RN	CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
DMTE071	RU	https://www.ncbi.nlm.nih.gov/pubmed/19239474

DMALN2M	DI	DMALN2M
DMALN2M	DN	Cholyl lysyl fluorescein
DMALN2M	MI	DTQ3ZHF
DMALN2M	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMALN2M	MT	DTP
DMALN2M	MA	Substrate
DMALN2M	RN	The emerging role of transport systems in liver function tests. Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5.
DMALN2M	RU	https://doi.org/10.1016/j.ejphar.2011.11.048

DMALN2M	DI	DMALN2M
DMALN2M	DN	Cholyl lysyl fluorescein
DMALN2M	MI	DT3D8F0
DMALN2M	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMALN2M	MT	DTP
DMALN2M	MA	Substrate
DMALN2M	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMALN2M	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMULZ4W	DI	DMULZ4W
DMULZ4W	DN	CHR-2797
DMULZ4W	MI	TTWLEZV
DMULZ4W	MN	Aminopeptidase (AMP)
DMULZ4W	MT	DTT
DMULZ4W	MA	Inhibitor
DMULZ4W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMULZ4W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMULZ4W	DI	DMULZ4W
DMULZ4W	DN	CHR-2797
DMULZ4W	MI	TT371QC
DMULZ4W	MN	Puromycin-sensitive aminopeptidase (NPEPPS)
DMULZ4W	MT	DTT
DMULZ4W	MA	Inhibitor
DMULZ4W	RN	CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79.
DMULZ4W	RU	https://pubmed.ncbi.nlm.nih.gov/18701491

DMMRKPF	DI	DMMRKPF
DMMRKPF	DN	CHS-131
DMMRKPF	MI	TTZMAO3
DMMRKPF	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMRKPF	MT	DTT
DMMRKPF	MA	Modulator
DMMRKPF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMRKPF	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMLRTN1	DI	DMLRTN1
DMLRTN1	DN	CI-1012
DMLRTN1	MI	TT3NH7G
DMLRTN1	MN	Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA)
DMLRTN1	MT	DTT
DMLRTN1	MA	Inhibitor
DMLRTN1	RN	WO patent application no. 2006,0835,53, Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase.
DMLRTN1	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060810&CC=WO&NR=2006083553A2&KC=A2

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TTGKNB4
DMSI8N3	MN	Epidermal growth factor receptor (EGFR)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TT6EO5L
DMSI8N3	MN	Erbb2 tyrosine kinase receptor (HER2)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TT0JESD
DMSI8N3	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMSI8N3	DI	DMSI8N3
DMSI8N3	DN	CI-1033
DMSI8N3	MI	TTWTSCV
DMSI8N3	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMSI8N3	MT	DTT
DMSI8N3	MA	Inhibitor
DMSI8N3	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMSI8N3	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMCFLRH	DI	DMCFLRH
DMCFLRH	DN	Cibinetide
DMCFLRH	MI	TTAUX24
DMCFLRH	MN	Erythropoietin Receptor (EPOR)
DMCFLRH	MT	DTT
DMCFLRH	MA	Agonist
DMCFLRH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCFLRH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMGTZLW	DI	DMGTZLW
DMGTZLW	DN	Cicletanine
DMGTZLW	MI	DEYGVN4
DMGTZLW	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMGTZLW	MT	DME
DMGTZLW	MA	Metabolism
DMGTZLW	RN	Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats. Fundam Clin Pharmacol. 2000 Sep-Oct;14(5):509-18.
DMGTZLW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11129092

DMTKSVA	DI	DMTKSVA
DMTKSVA	DN	CIMICOXIB
DMTKSVA	MI	TTVKILB
DMTKSVA	MN	Prostaglandin G/H synthase 2 (COX-2)
DMTKSVA	MT	DTT
DMTKSVA	MA	Modulator
DMTKSVA	RN	Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81.
DMTKSVA	RU	https://www.ncbi.nlm.nih.gov/pubmed/24461644

DMGEAM6	DI	DMGEAM6
DMGEAM6	DN	Cinaciguat
DMGEAM6	MI	TTLBYH1
DMGEAM6	MN	Guanylate cyclase soluble beta-1 (GUCY1B1)
DMGEAM6	MT	DTT
DMGEAM6	MA	Activator
DMGEAM6	RN	Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 Jun 2;119(21):2781-8.
DMGEAM6	RU	https://pubmed.ncbi.nlm.nih.gov/19451356

DM98RW0	DI	DM98RW0
DM98RW0	DN	Cirmtuzumab
DM98RW0	MI	TTDEJAU
DM98RW0	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DM98RW0	MT	DTT
DM98RW0	MA	Antagonist
DM98RW0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM98RW0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNRYPF	DI	DMNRYPF
DMNRYPF	DN	Cixutumumab
DMNRYPF	MI	TTHRID2
DMNRYPF	MN	Insulin-like growth factor I receptor (IGF1R)
DMNRYPF	MT	DTT
DMNRYPF	MA	Modulator
DMNRYPF	RN	Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64.
DMNRYPF	RU	https://pubmed.ncbi.nlm.nih.gov/25858498

DMOFTRE	DI	DMOFTRE
DMOFTRE	DN	Cizolirtine
DMOFTRE	MI	TTVSFJW
DMOFTRE	MN	Calcitonin gene-related peptide 1 (CALCA)
DMOFTRE	MT	DTT
DMOFTRE	MA	Inhibitor
DMOFTRE	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMOFTRE	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMTSVJM	DI	DMTSVJM
DMTSVJM	DN	CJM112
DMTSVJM	MI	TTG0MT6
DMTSVJM	MN	Interleukin-17 (IL17)
DMTSVJM	MT	DTT
DMTSVJM	MA	Inhibitor
DMTSVJM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTSVJM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FHV8	DI	DM9FHV8
DM9FHV8	DN	CK-2127107
DM9FHV8	MI	TTYUMF5
DM9FHV8	MN	Fast skeletal muscle troponin complex (TNNC2)
DM9FHV8	MT	DTT
DM9FHV8	MA	Modulator
DM9FHV8	RN	Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5.
DM9FHV8	RU	https://pubmed.ncbi.nlm.nih.gov/22344294

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTI7UX6
DMW9F1G	MN	Breast cancer resistance protein (ABCG2)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
DMW9F1G	RU	http://www.ncbi.nlm.nih.gov/pubmed/18654741

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	TTGTQHC
DMW9F1G	MN	DNA topoisomerase I (TOP1)
DMW9F1G	MT	DTT
DMW9F1G	MA	Inhibitor
DMW9F1G	RN	Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998 Oct;21(5):581-90.
DMW9F1G	RU	https://pubmed.ncbi.nlm.nih.gov/9875499

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTFI42L
DMW9F1G	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW9F1G	RU	https://doi.org/10.1007/s11095-012-0935-x

DMW9F1G	DI	DMW9F1G
DMW9F1G	DN	CKD602
DMW9F1G	MI	DTUGYRD
DMW9F1G	MN	P-glycoprotein 1 (ABCB1)
DMW9F1G	MT	DTP
DMW9F1G	MA	Substrate
DMW9F1G	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW9F1G	RU	https://doi.org/10.1007/s11095-012-0935-x

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTMXGCW
DMXH1KC	MN	Adrenergic receptor beta-3 (ADRB3)
DMXH1KC	MT	DTT
DMXH1KC	MA	Agonist
DMXH1KC	RN	Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/11472270

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTI12YJ
DMXH1KC	MN	Mitochondrial uncoupling protein 1 (UCP1)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TTSC2YM
DMXH1KC	MN	Mitochondrial uncoupling protein 2 (UCP2)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMXH1KC	DI	DMXH1KC
DMXH1KC	DN	CL-316,243
DMXH1KC	MI	TT12RJK
DMXH1KC	MN	Mitochondrial uncoupling protein 3 (UCP3)
DMXH1KC	MT	DTT
DMXH1KC	MA	Inducer
DMXH1KC	RN	Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37.
DMXH1KC	RU	https://pubmed.ncbi.nlm.nih.gov/9150705

DMSF7WJ	DI	DMSF7WJ
DMSF7WJ	DN	CL-329167
DMSF7WJ	MI	TT8DBY3
DMSF7WJ	MN	Angiotensin II receptor type-1 (AGTR1)
DMSF7WJ	MT	DTT
DMSF7WJ	MA	Antagonist
DMSF7WJ	RN	Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52.
DMSF7WJ	RU	https://pubmed.ncbi.nlm.nih.gov/8067441

DM6ZOUV	DI	DM6ZOUV
DM6ZOUV	DN	Clazakizumab
DM6ZOUV	MI	TTJH4Y5
DM6ZOUV	MN	HUMAN interleukin 6 (IL6)
DM6ZOUV	MT	DTT
DM6ZOUV	MA	Inhibitor
DM6ZOUV	RN	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452.
DM6ZOUV	RU	https://pubmed.ncbi.nlm.nih.gov/32291137

DMAIW6C	DI	DMAIW6C
DMAIW6C	DN	Clazakizumab
DMAIW6C	MI	TTT1V78
DMAIW6C	MN	Interleukin-6 (IL6)
DMAIW6C	MT	DTT
DMAIW6C	MA	Inhibitor
DMAIW6C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAIW6C	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU6R3O	DI	DMU6R3O
DMU6R3O	DN	CLG561
DMU6R3O	MI	TTLA0VS
DMU6R3O	MN	Complement factor P (CFP)
DMU6R3O	MT	DTT
DMU6R3O	MA	Inhibitor
DMU6R3O	RN	Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342.
DMU6R3O	RU	https://pubmed.ncbi.nlm.nih.gov/30686077

DMH2VS0	DI	DMH2VS0
DMH2VS0	DN	CLP-1001
DMH2VS0	MI	TTWN7KV
DMH2VS0	MN	Na-K-Cl cotransporter (NKCC)
DMH2VS0	MT	DTT
DMH2VS0	MA	Modulator
DMH2VS0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446)
DMH2VS0	RU	http://adisinsight.springer.com/drugs/800034446

DMAW4EL	DI	DMAW4EL
DMAW4EL	DN	CLR-1404
DMAW4EL	MI	TTHBTOP
DMAW4EL	MN	PI3-kinase gamma (PIK3CG)
DMAW4EL	MT	DTT
DMAW4EL	MA	Inhibitor
DMAW4EL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMAW4EL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM3Z6IQ	DI	DM3Z6IQ
DM3Z6IQ	DN	CLR-3001
DM3Z6IQ	MI	TTEX248
DM3Z6IQ	MN	Dopamine D2 receptor (D2R)
DM3Z6IQ	MT	DTT
DM3Z6IQ	MA	Modulator
DM3Z6IQ	RN	Clinical pipeline report, company report or official report of Clera Inc.
DM3Z6IQ	RU	http://clera.com/cognition/

DM3Z6IQ	DI	DM3Z6IQ
DM3Z6IQ	DN	CLR-3001
DM3Z6IQ	MI	TT3ROYC
DM3Z6IQ	MN	Serotonin transporter (SERT)
DM3Z6IQ	MT	DTT
DM3Z6IQ	MA	Inhibitor
DM3Z6IQ	RN	Clinical pipeline report, company report or official report of Clera Inc.
DM3Z6IQ	RU	http://clera.com/cognition/

DMQSIY1	DI	DMQSIY1
DMQSIY1	DN	CLS003
DMQSIY1	MI	TTL3N71
DMQSIY1	MN	Virus Replication (Viru Repli)
DMQSIY1	MT	DTT
DMQSIY1	MA	Inhibitor
DMQSIY1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSIY1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM1NCUY	DI	DM1NCUY
DM1NCUY	DN	CMI-392
DM1NCUY	MI	TT2J34L
DM1NCUY	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM1NCUY	MT	DTT
DM1NCUY	MA	Modulator
DM1NCUY	RN	Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
DM1NCUY	RU	https://pubmed.ncbi.nlm.nih.gov/11529688

DM1NCUY	DI	DM1NCUY
DM1NCUY	DN	CMI-392
DM1NCUY	MI	TTQL5VC
DM1NCUY	MN	Platelet-activating factor receptor (PTAFR)
DM1NCUY	MT	DTT
DM1NCUY	MA	Modulator
DM1NCUY	RN	Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
DM1NCUY	RU	https://pubmed.ncbi.nlm.nih.gov/11529688

DM7GELO	DI	DM7GELO
DM7GELO	DN	CMVpp65-A0201
DM7GELO	MI	TTNDHVE
DM7GELO	MN	Cytomegalovirus 65kDa phosphoprotein (HCV UL83)
DM7GELO	MT	DTT
DM7GELO	RN	National Cancer Institute Drug Dictionary (drug id 599982).
DM7GELO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599982

DMPSCVY	DI	DMPSCVY
DMPSCVY	DN	CMX-2043
DMPSCVY	MI	TTNDSF4
DMPSCVY	MN	Proto-oncogene c-Met (MET)
DMPSCVY	MT	DTT
DMPSCVY	MA	Modulator
DMPSCVY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPSCVY	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMPSCVY	DI	DMPSCVY
DMPSCVY	DN	CMX-2043
DMPSCVY	MI	TTWTSCV
DMPSCVY	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMPSCVY	MT	DTT
DMPSCVY	MA	Modulator
DMPSCVY	RN	Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
DMPSCVY	RU	https://pubmed.ncbi.nlm.nih.gov/24751172

DM0MTP8	DI	DM0MTP8
DM0MTP8	DN	CN-105
DM0MTP8	MI	TTKS9CB
DM0MTP8	MN	Apolipoprotein E (APOE)
DM0MTP8	MT	DTT
DM0MTP8	MA	Agonist
DM0MTP8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0MTP8	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM16KJ3	DI	DM16KJ3
DM16KJ3	DN	CNS-5161
DM16KJ3	MI	TT9IK2Z
DM16KJ3	MN	N-methyl-D-aspartate receptor (NMDAR)
DM16KJ3	MT	DTT
DM16KJ3	MA	Antagonist
DM16KJ3	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM16KJ3	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM2PEU5	DI	DM2PEU5
DM2PEU5	DN	CNSB-001
DM2PEU5	MI	TTN4QDT
DM2PEU5	MN	Opioid receptor (OPR)
DM2PEU5	MT	DTT
DM2PEU5	MA	Agonist
DM2PEU5	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM2PEU5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM2PEU5	DI	DM2PEU5
DM2PEU5	DN	CNSB-001
DM2PEU5	MI	TTQ29KF
DM2PEU5	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DM2PEU5	MT	DTT
DM2PEU5	MA	Agonist
DM2PEU5	RN	The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
DM2PEU5	RU	https://pubmed.ncbi.nlm.nih.gov/20433607

DMOR8SY	DI	DMOR8SY
DMOR8SY	DN	CNT0-1959
DMOR8SY	MI	TTC1GLB
DMOR8SY	MN	Interleukin-23 (IL23)
DMOR8SY	MT	DTT
DMOR8SY	RN	Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
DMOR8SY	RU	https://pubmed.ncbi.nlm.nih.gov/25807335

DM6RQXB	DI	DM6RQXB
DM6RQXB	DN	CNTO-6785
DM6RQXB	MI	TT69OHW
DM6RQXB	MN	Interleukin 17 receptor (IL17R)
DM6RQXB	MT	DTT
DM6RQXB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RQXB	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6RQXB	DI	DM6RQXB
DM6RQXB	DN	CNTO-6785
DM6RQXB	MI	TTG0MT6
DM6RQXB	MN	Interleukin-17 (IL17)
DM6RQXB	MT	DTT
DM6RQXB	RN	Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. 
DM6RQXB	RU	https://pubmed.ncbi.nlm.nih.gov/25549584

DMLT7JV	DI	DMLT7JV
DMLT7JV	DN	CNV-2197944
DMLT7JV	MI	TT4FDG6
DMLT7JV	MN	Voltage-gated calcium channel alpha Cav2.2 (CACNA1B)
DMLT7JV	MT	DTT
DMLT7JV	MA	Blocker
DMLT7JV	RN	Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd.
DMLT7JV	RU	http://www.convergencepharma.com/index.asp?page_id=30

DMH5GQU	DI	DMH5GQU
DMH5GQU	DN	CO-101
DMH5GQU	MI	TTUTN1I
DMH5GQU	MN	Human Deoxyribonucleic acid (hDNA)
DMH5GQU	MT	DTT
DMH5GQU	MA	Inhibitor
DMH5GQU	RN	Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
DMH5GQU	RU	https://pubmed.ncbi.nlm.nih.gov/16807468

DMH5GQU	DI	DMH5GQU
DMH5GQU	DN	CO-101
DMH5GQU	MI	TTBWDI0
DMH5GQU	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMH5GQU	MT	DTT
DMH5GQU	MA	Inhibitor
DMH5GQU	RN	Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.
DMH5GQU	RU	https://pubmed.ncbi.nlm.nih.gov/16807468

DMF4MX9	DI	DMF4MX9
DMF4MX9	DN	Cobomarsen
DMF4MX9	MI	TT1GNRQ
DMF4MX9	MN	microRNA hsa-miR-155 (MIR155)
DMF4MX9	MT	DTT
DMF4MX9	MA	Inhibitor
DMF4MX9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF4MX9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDWG36	DI	DMDWG36
DMDWG36	DN	Codrituzumab
DMDWG36	MI	TTJTSX4
DMDWG36	MN	Glypican-3 (GPC3)
DMDWG36	MT	DTT
DMDWG36	MA	Inhibitor
DMDWG36	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDWG36	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMO0VGH	DI	DMO0VGH
DMO0VGH	DN	Coenzyme Q10 analog
DMO0VGH	MI	TT8XK6L
DMO0VGH	MN	Quinone reductase 1 (NQO1)
DMO0VGH	MT	DTT
DMO0VGH	MA	Modulator
DMO0VGH	RN	Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
DMO0VGH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204556/

DMNC76I	DI	DMNC76I
DMNC76I	DN	COL-1077
DMNC76I	MI	TTRK8B9
DMNC76I	MN	Sodium channel unspecific (NaC)
DMNC76I	MT	DTT
DMNC76I	MA	Antagonist
DMNC76I	RN	Clinical pipeline report, company report or official report of Columbia Laboratories.
DMNC76I	RU	http://companies.einnews.com/news/columbia-laboratories-news

DMSGFOY	DI	DMSGFOY
DMSGFOY	DN	Coltuximab ravtansine
DMSGFOY	MI	TTW640A
DMSGFOY	MN	B-lymphocyte surface antigen B4 (CD19)
DMSGFOY	MT	DTT
DMSGFOY	MA	Inhibitor
DMSGFOY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSGFOY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMI2GSK	DI	DMI2GSK
DMI2GSK	DN	Coluracetam
DMI2GSK	MI	TTAN6JD
DMI2GSK	MN	Glutamate receptor AMPA (GRIA)
DMI2GSK	MT	DTT
DMI2GSK	MA	Modulator
DMI2GSK	RN	MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm. 2008 Jul;115(7):1027-35.
DMI2GSK	RU	https://pubmed.ncbi.nlm.nih.gov/18446264

DMGCTX5	DI	DMGCTX5
DMGCTX5	DN	Combined PR1/WT1 vaccine
DMGCTX5	MI	TT5MLC4
DMGCTX5	MN	Leukocyte proteinase-3 (PRTN3)
DMGCTX5	MT	DTT
DMGCTX5	RN	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
DMGCTX5	RU	https://pubmed.ncbi.nlm.nih.gov/17875804

DMGCTX5	DI	DMGCTX5
DMGCTX5	DN	Combined PR1/WT1 vaccine
DMGCTX5	MI	TTZ8UT4
DMGCTX5	MN	Wilms tumor protein (WT1)
DMGCTX5	MT	DTT
DMGCTX5	RN	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
DMGCTX5	RU	https://pubmed.ncbi.nlm.nih.gov/17875804

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TT6OEDT
DM2UOSN	MN	Cannabinoid receptor 1 (CB1)
DM2UOSN	MT	DTT
DM2UOSN	MA	Agonist
DM2UOSN	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM2UOSN	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TTW20TU
DM2UOSN	MN	TRAIL receptor 2 (TRAIL-R2)
DM2UOSN	MT	DTT
DM2UOSN	MA	Agonist
DM2UOSN	RN	Clinical pipeline report, company report or official report of Amgen (2009).
DM2UOSN	RU	http://www.amgen.com/science/pipe.jsp

DM2UOSN	DI	DM2UOSN
DM2UOSN	DN	Conatumumab
DM2UOSN	MI	TT90XZ8
DM2UOSN	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM2UOSN	MT	DTT
DM2UOSN	MA	Binder
DM2UOSN	RN	Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
DM2UOSN	RU	https://pubmed.ncbi.nlm.nih.gov/10762603

DMZ0F65	DI	DMZ0F65
DMZ0F65	DN	Contezolid
DMZ0F65	MI	TTLIZBJ
DMZ0F65	MN	Protein synthesis (hPRO synth)
DMZ0F65	MT	DTT
DMZ0F65	MA	Inhibitor
DMZ0F65	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ0F65	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMOHUA	DI	DMMOHUA
DMMOHUA	DN	Contezolid acefosamil
DMMOHUA	MI	TTLIZBJ
DMMOHUA	MN	Protein synthesis (hPRO synth)
DMMOHUA	MT	DTT
DMMOHUA	MA	Inhibitor
DMMOHUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMOHUA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMER82Z	DI	DMER82Z
DMER82Z	DN	COR-1
DMER82Z	MI	TTR6W5O
DMER82Z	MN	Adrenergic receptor beta-1 (ADRB1)
DMER82Z	MT	DTT
DMER82Z	MA	Antagonist
DMER82Z	RN	Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9.
DMER82Z	RU	https://pubmed.ncbi.nlm.nih.gov/22968742

DMHBOUX	DI	DMHBOUX
DMHBOUX	DN	CORT125281
DMHBOUX	MI	TTOZRK6
DMHBOUX	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMHBOUX	MT	DTT
DMHBOUX	MA	Antagonist
DMHBOUX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBOUX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTSZLWK
DMVKW0N	MN	Aromatase (CYP19A1)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTUNARX
DMVKW0N	MN	Carbonic anhydrase (CA)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTHQPL7
DMVKW0N	MN	Carbonic anhydrase I (CA-I)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTANPDJ
DMVKW0N	MN	Carbonic anhydrase II (CA-II)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTZHA0O
DMVKW0N	MN	Carbonic anhydrase IV (CA-IV)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TT2LVK8
DMVKW0N	MN	Carbonic anhydrase IX (CA-IX)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTCFSPE
DMVKW0N	MN	Carbonic anhydrase VI (CA-VI)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTSYM0R
DMVKW0N	MN	Carbonic anhydrase XII (CA-XII)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTEYTKG
DMVKW0N	MN	Carbonic anhydrase XIV (CA-XIV)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/18640037

DMVKW0N	DI	DMVKW0N
DMVKW0N	DN	Coumate
DMVKW0N	MI	TTHM0R1
DMVKW0N	MN	Steryl-sulfatase (STS)
DMVKW0N	MT	DTT
DMVKW0N	MA	Inhibitor
DMVKW0N	RN	Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
DMVKW0N	RU	https://pubmed.ncbi.nlm.nih.gov/20148564

DM2K5VP	DI	DM2K5VP
DM2K5VP	DN	Coxsackievirus A21
DM2K5VP	MI	TT5Z9WY
DM2K5VP	MN	Complement decay-accelerating factor (CD55)
DM2K5VP	MT	DTT
DM2K5VP	MA	Inhibitor
DM2K5VP	RN	Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41.
DM2K5VP	RU	https://pubmed.ncbi.nlm.nih.gov/17391493

DM8X5Q1	DI	DM8X5Q1
DM8X5Q1	DN	CP101
DM8X5Q1	MI	TT9IK2Z
DM8X5Q1	MN	N-methyl-D-aspartate receptor (NMDAR)
DM8X5Q1	MT	DTT
DM8X5Q1	MA	Antagonist
DM8X5Q1	RN	The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17.
DM8X5Q1	RU	https://pubmed.ncbi.nlm.nih.gov/9219855

DMIU19E	DI	DMIU19E
DMIU19E	DN	CP-101,606
DMIU19E	MI	TTN9D8E
DMIU19E	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMIU19E	MT	DTT
DMIU19E	MA	Antagonist
DMIU19E	RN	NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
DMIU19E	RU	https://pubmed.ncbi.nlm.nih.gov/11698028

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DECB0K3
DMSWLM5	MN	Cytochrome P450 2D6 (CYP2D6)
DMSWLM5	MT	DME
DMSWLM5	MA	Metabolism
DMSWLM5	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DMSWLM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DE4LYSA
DMSWLM5	MN	Cytochrome P450 3A4 (CYP3A4)
DMSWLM5	MT	DME
DMSWLM5	MA	Metabolism
DMSWLM5	RN	In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab Pharmacokinet. 2007 Oct;22(5):336-49.
DMSWLM5	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17965517

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	DTUGYRD
DMSWLM5	MN	P-glycoprotein 1 (ABCB1)
DMSWLM5	MT	DTP
DMSWLM5	MA	Substrate
DMSWLM5	RN	P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9.
DMSWLM5	RU	http://www.ncbi.nlm.nih.gov/pubmed/11504828

DMSWLM5	DI	DMSWLM5
DMSWLM5	DN	CP-122721
DMSWLM5	MI	TTZPO1L
DMSWLM5	MN	Substance-P receptor (TACR1)
DMSWLM5	MT	DTT
DMSWLM5	MA	Antagonist
DMSWLM5	RN	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
DMSWLM5	RU	https://pubmed.ncbi.nlm.nih.gov/17109611

DMVO5DR	DI	DMVO5DR
DMVO5DR	DN	CP-331684
DMVO5DR	MI	TTMXGCW
DMVO5DR	MN	Adrenergic receptor beta-3 (ADRB3)
DMVO5DR	MT	DTT
DMVO5DR	MA	Agonist
DMVO5DR	RN	CN patent application no. 1717230, Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor.
DMVO5DR	RU	https://www.google.com/patents/CN1717230A?cl=en

DMEYMTX	DI	DMEYMTX
DMEYMTX	DN	CP-461
DMEYMTX	MI	TTJGW1Z
DMEYMTX	MN	Phosphodiesterase 2A (PDE2A)
DMEYMTX	MT	DTT
DMEYMTX	MA	Inhibitor
DMEYMTX	RN	Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
DMEYMTX	RU	https://pubmed.ncbi.nlm.nih.gov/11569947

DMZEJLB	DI	DMZEJLB
DMZEJLB	DN	CP-533536
DMZEJLB	MI	TT1ZAVI
DMZEJLB	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DMZEJLB	MT	DTT
DMZEJLB	MA	Agonist
DMZEJLB	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMZEJLB	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DMX054A	DI	DMX054A
DMX054A	DN	CP-547632
DMX054A	MI	TTUTJGQ
DMX054A	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMX054A	MT	DTT
DMX054A	MA	Inhibitor
DMX054A	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMX054A	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMKJFDM	DI	DMKJFDM
DMKJFDM	DN	CP-601927
DMKJFDM	MI	TTL1ATN
DMKJFDM	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMKJFDM	MT	DTT
DMKJFDM	MA	Modulator
DMKJFDM	RN	Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32.
DMKJFDM	RU	https://pubmed.ncbi.nlm.nih.gov/21594972

DMUJ0W7	DI	DMUJ0W7
DMUJ0W7	DN	CP-724714
DMUJ0W7	MI	DTI7UX6
DMUJ0W7	MN	Breast cancer resistance protein (ABCG2)
DMUJ0W7	MT	DTP
DMUJ0W7	MA	Substrate
DMUJ0W7	RN	Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem. 2009 Feb;4(2):188-95.
DMUJ0W7	RU	https://doi.org/10.1002/cmdc.200800329

DMUJ0W7	DI	DMUJ0W7
DMUJ0W7	DN	CP-724714
DMUJ0W7	MI	TT6EO5L
DMUJ0W7	MN	Erbb2 tyrosine kinase receptor (HER2)
DMUJ0W7	MT	DTT
DMUJ0W7	MA	Inhibitor
DMUJ0W7	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMUJ0W7	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMT3ORQ	DI	DMT3ORQ
DMT3ORQ	DN	CP-80794
DMT3ORQ	MI	TTB2MXP
DMT3ORQ	MN	Angiotensinogenase renin (REN)
DMT3ORQ	MT	DTT
DMT3ORQ	MA	Inhibitor
DMT3ORQ	RN	Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1992 Jul;20(1):75-82.
DMT3ORQ	RU	https://pubmed.ncbi.nlm.nih.gov/1383634

DM6MUCX	DI	DM6MUCX
DM6MUCX	DN	CpG-10101
DM6MUCX	MI	TTSHG0T
DM6MUCX	MN	Toll-like receptor 9 (TLR9)
DM6MUCX	MT	DTT
DM6MUCX	MA	Agonist
DM6MUCX	RN	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
DM6MUCX	RU	https://pubmed.ncbi.nlm.nih.gov/17713157

DMK9NQI	DI	DMK9NQI
DMK9NQI	DN	CPP-115
DMK9NQI	MI	TTT2LD9
DMK9NQI	MN	GABA transaminase (ABAT)
DMK9NQI	MT	DTT
DMK9NQI	MA	Inhibitor
DMK9NQI	RN	Clinical pipeline report, company report or official report of Catalyst Pharma.
DMK9NQI	RU	http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588

DMK7DFM	DI	DMK7DFM
DMK7DFM	DN	CPX-POM
DMK7DFM	MI	TTX09M4
DMK7DFM	MN	Ribonucleotide reductase (RIR)
DMK7DFM	MT	DTT
DMK7DFM	MA	Inhibitor
DMK7DFM	RN	Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159.
DMK7DFM	RU	https://pubmed.ncbi.nlm.nih.gov/31113837

DMHJEZS	DI	DMHJEZS
DMHJEZS	DN	CR-3294
DMHJEZS	MI	TTF10I9
DMHJEZS	MN	Nitric-oxide synthase inducible (NOS2)
DMHJEZS	MT	DTT
DMHJEZS	MA	Inhibitor
DMHJEZS	RN	Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
DMHJEZS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926937/

DMNC1AF	DI	DMNC1AF
DMNC1AF	DN	CR-665
DMNC1AF	MI	TTQW87Y
DMNC1AF	MN	Opioid receptor kappa (OPRK1)
DMNC1AF	MT	DTT
DMNC1AF	MA	Agonist
DMNC1AF	RN	Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24.
DMNC1AF	RU	https://pubmed.ncbi.nlm.nih.gov/19672186

DMQ47U6	DI	DMQ47U6
DMQ47U6	DN	CR8020
DMQ47U6	MI	TTF4CAM
DMQ47U6	MN	Influenza Hemagglutinin (Influ HA)
DMQ47U6	MT	DTT
DMQ47U6	RN	Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92.
DMQ47U6	RU	https://pubmed.ncbi.nlm.nih.gov/25210195

DMO1ZGX	DI	DMO1ZGX
DMO1ZGX	DN	CRILVASTATIN
DMO1ZGX	MI	TTPADOQ
DMO1ZGX	MN	HMG-CoA reductase (HMGCR)
DMO1ZGX	MT	DTT
DMO1ZGX	MA	Inhibitor
DMO1ZGX	RN	Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8.
DMO1ZGX	RU	https://pubmed.ncbi.nlm.nih.gov/8842455

DMQUWXY	DI	DMQUWXY
DMQUWXY	DN	CRLX101
DMQUWXY	MI	TTGTQHC
DMQUWXY	MN	DNA topoisomerase I (TOP1)
DMQUWXY	MT	DTT
DMQUWXY	MA	Modulator
DMQUWXY	RN	Company report (Ceruleanrx)
DMQUWXY	RU	http://ceruleanrx.com/platform-pipeline/crlx101.php

DM85WID	DI	DM85WID
DM85WID	DN	Crobenetine
DM85WID	MI	TTRK8B9
DM85WID	MN	Sodium channel unspecific (NaC)
DM85WID	MT	DTT
DM85WID	MA	Antagonist
DM85WID	RN	Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8.
DM85WID	RU	https://pubmed.ncbi.nlm.nih.gov/11739251

DM129T7	DI	DM129T7
DM129T7	DN	CROMOGLYCATE LISETIL HYDROCHLORIDE
DM129T7	MI	TTE87WJ
DM129T7	MN	Calcium-activated potassium channel KCa1.1 (KCNMA1)
DM129T7	MT	DTT
DM129T7	MA	Modulator
DM129T7	RN	The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochim Biophys Acta. 2011 Sep;1810(9):867-74.
DM129T7	RU	https://pubmed.ncbi.nlm.nih.gov/21635937

DMXU5LZ	DI	DMXU5LZ
DMXU5LZ	DN	CRS-207
DMXU5LZ	MI	TT4RXME
DMXU5LZ	MN	Mesothelin (MSLN)
DMXU5LZ	MT	DTT
DMXU5LZ	RN	Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.
DMXU5LZ	RU	https://pubmed.ncbi.nlm.nih.gov/25584002

DM16IMT	DI	DM16IMT
DM16IMT	DN	CRYPTOPHYCIN 52
DM16IMT	MI	TTML2WA
DM16IMT	MN	Tubulin (TUB)
DM16IMT	MT	DTT
DM16IMT	MA	Inhibitor
DM16IMT	RN	Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9.
DM16IMT	RU	https://pubmed.ncbi.nlm.nih.gov/12581573

DMZCG91	DI	DMZCG91
DMZCG91	DN	CSL-112
DMZCG91	MI	TT7GN3U
DMZCG91	MN	Apolipoprotein A-I (APOA1)
DMZCG91	MT	DTT
DMZCG91	MA	Modulator
DMZCG91	RN	CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014 Jan;232(1):110-8.
DMZCG91	RU	https://pubmed.ncbi.nlm.nih.gov/24401224

DMQXL1T	DI	DMQXL1T
DMQXL1T	DN	CT 327
DMQXL1T	MI	TTTDVOJ
DMQXL1T	MN	Tropomyosin-related kinase A (TrkA)
DMQXL1T	MT	DTT
DMQXL1T	MA	Inhibitor
DMQXL1T	RN	Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
DMQXL1T	RU	https://pubmed.ncbi.nlm.nih.gov/25594427

DMBRKZ7	DI	DMBRKZ7
DMBRKZ7	DN	CT1812
DMBRKZ7	MI	TT9NXW4
DMBRKZ7	MN	Sigma intracellular receptor 2 (TMEM97)
DMBRKZ7	MT	DTT
DMBRKZ7	MA	Antagonist
DMBRKZ7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBRKZ7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEEHWOG
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	The role of the gut flora in the metabolism of prontosil and neoprontosil in the rat. Xenobiotica. 1971 Mar;1(2):143-56.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/5173017

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEPF49Q
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DEMW0RC
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMSGYNP	DI	DMSGYNP
DMSGYNP	DN	CTK0H-9987
DMSGYNP	MI	DETP059
DMSGYNP	MN	Azoreductase (azoR)
DMSGYNP	MT	DME
DMSGYNP	MA	Metabolism
DMSGYNP	RN	Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013 Mar;69(1):21-31.
DMSGYNP	RU	https://pubmed.ncbi.nlm.nih.gov/22902524

DMMPC6W	DI	DMMPC6W
DMMPC6W	DN	CTL019
DMMPC6W	MI	TTW640A
DMMPC6W	MN	B-lymphocyte surface antigen B4 (CD19)
DMMPC6W	MT	DTT
DMMPC6W	MA	CAR-T-Cell-Therapy
DMMPC6W	RN	ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
DMMPC6W	RU	https://clinicaltrials.gov/ct2/show/NCT02445248

DM3SYOK	DI	DM3SYOK
DM3SYOK	DN	CTP-543
DM3SYOK	MI	TT6DM01
DM3SYOK	MN	Janus kinase 1 (JAK-1)
DM3SYOK	MT	DTT
DM3SYOK	MA	Inhibitor
DM3SYOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3SYOK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMBT46Y	DI	DMBT46Y
DMBT46Y	DN	CTP-543
DMBT46Y	MI	TT6DM01
DMBT46Y	MN	Janus kinase 1 (JAK-1)
DMBT46Y	MT	DTT
DMBT46Y	MA	Inhibitor
DMBT46Y	RN	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
DMBT46Y	RU	https://www.concertpharma.com/product-pipeline/ctp-543/

DM3SYOK	DI	DM3SYOK
DM3SYOK	DN	CTP-543
DM3SYOK	MI	TTRMX3V
DM3SYOK	MN	Janus kinase 2 (JAK-2)
DM3SYOK	MT	DTT
DM3SYOK	MA	Inhibitor
DM3SYOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3SYOK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMBT46Y	DI	DMBT46Y
DMBT46Y	DN	CTP-543
DMBT46Y	MI	TTRMX3V
DMBT46Y	MN	Janus kinase 2 (JAK-2)
DMBT46Y	MT	DTT
DMBT46Y	MA	Inhibitor
DMBT46Y	RN	Clinical pipeline report, company report or official report of Concert Pharmaceuticals.
DMBT46Y	RU	https://www.concertpharma.com/product-pipeline/ctp-543/

DMYPXQ2	DI	DMYPXQ2
DMYPXQ2	DN	CVBT-141H
DMYPXQ2	MI	TTMY81X
DMYPXQ2	MN	Heparin-binding growth factor 1 (FGF1)
DMYPXQ2	MT	DTT
DMYPXQ2	MA	Modulator
DMYPXQ2	RN	Clinical pipeline report, company report or official report of CVBT.
DMYPXQ2	RU	http://cvbt.com/index.php?pr=Severe_CHD

DMCN9GX	DI	DMCN9GX
DMCN9GX	DN	CVX-045
DMCN9GX	MI	TTKI0H1
DMCN9GX	MN	Thrombospondin-1 (THBS1)
DMCN9GX	MT	DTT
DMCN9GX	MA	Agonist
DMCN9GX	RN	Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl Oncol. 2011 Aug;4(4):249-57.
DMCN9GX	RU	https://pubmed.ncbi.nlm.nih.gov/21804921

DMVZT2I	DI	DMVZT2I
DMVZT2I	DN	CX-072
DMVZT2I	MI	TT8ZLTI
DMVZT2I	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMVZT2I	MT	DTT
DMVZT2I	MA	Inhibitor
DMVZT2I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVZT2I	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMS2WB5	DI	DMS2WB5
DMS2WB5	DN	CX157
DMS2WB5	MI	TT3WG5C
DMS2WB5	MN	Monoamine oxidase type A (MAO-A)
DMS2WB5	MT	DTT
DMS2WB5	MA	Inhibitor
DMS2WB5	RN	Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
DMS2WB5	RU	https://pubmed.ncbi.nlm.nih.gov/19890267

DMJD7H4	DI	DMJD7H4
DMJD7H4	DN	CX-1739
DMJD7H4	MI	TTAN6JD
DMJD7H4	MN	Glutamate receptor AMPA (GRIA)
DMJD7H4	MT	DTT
DMJD7H4	MA	Agonist
DMJD7H4	RN	AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82.
DMJD7H4	RU	https://pubmed.ncbi.nlm.nih.gov/22801296

DMA5D6T	DI	DMA5D6T
DMA5D6T	DN	CX1789
DMA5D6T	MI	TTAN6JD
DMA5D6T	MN	Glutamate receptor AMPA (GRIA)
DMA5D6T	MT	DTT
DMA5D6T	MA	Agonist
DMA5D6T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA5D6T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMU62I8	DI	DMU62I8
DMU62I8	DN	CX2009
DMU62I8	MI	TT2AFT6
DMU62I8	MN	Activated leukocyte cell adhesionmolecule (ALCAM)
DMU62I8	MT	DTT
DMU62I8	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMU62I8	RU	https://cytomx.com/pipeline/

DMWE7B9	DI	DMWE7B9
DMWE7B9	DN	CX-4945
DMWE7B9	MI	TTZ5NI7
DMWE7B9	MN	Casein kinase II (CSNK2)
DMWE7B9	MT	DTT
DMWE7B9	MA	Modulator
DMWE7B9	RN	CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6.
DMWE7B9	RU	https://pubmed.ncbi.nlm.nih.gov/23900138

DMWE7B9	DI	DMWE7B9
DMWE7B9	DN	CX-4945
DMWE7B9	MI	TTER6YH
DMWE7B9	MN	Casein kinase II alpha (CSNK2A1)
DMWE7B9	MT	DTT
DMWE7B9	MA	Inhibitor
DMWE7B9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWE7B9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM65W1	DI	DMM65W1
DMM65W1	DN	CX-717
DMM65W1	MI	TTAN6JD
DMM65W1	MN	Glutamate receptor AMPA (GRIA)
DMM65W1	MT	DTT
DMM65W1	MA	Modulator
DMM65W1	RN	Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol. 2012 Aug;26(8):1047-57.
DMM65W1	RU	https://pubmed.ncbi.nlm.nih.gov/21940760

DM3GEHC	DI	DM3GEHC
DM3GEHC	DN	CX-8998
DM3GEHC	MI	TTT6NKW
DM3GEHC	MN	Voltage-gated T-type calcium channel (T-CaC)
DM3GEHC	MT	DTT
DM3GEHC	MA	Modulator
DM3GEHC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3GEHC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMM7Z6K	DI	DMM7Z6K
DMM7Z6K	DN	CXA10
DMM7Z6K	MI	TT3Z6Y9
DMM7Z6K	MN	Cysteines of Keap1 (KEAP1 Cysteines)
DMM7Z6K	MT	DTT
DMM7Z6K	MA	Inactivator
DMM7Z6K	RN	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
DMM7Z6K	RU	https://pubmed.ncbi.nlm.nih.gov/28510041

DMM7Z6K	DI	DMM7Z6K
DMM7Z6K	DN	CXA10
DMM7Z6K	MI	TTA6ZN2
DMM7Z6K	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMM7Z6K	MT	DTT
DMM7Z6K	MA	Activator
DMM7Z6K	RN	The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56.
DMM7Z6K	RU	https://pubmed.ncbi.nlm.nih.gov/28510041

DM3JFZ2	DI	DM3JFZ2
DM3JFZ2	DN	CXL
DM3JFZ2	MI	TTHI19T
DM3JFZ2	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DM3JFZ2	MT	DTT
DM3JFZ2	MA	Modulator
DM3JFZ2	RN	Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
DM3JFZ2	RU	http://www.mdpi.com/2079-6382/3/2/193

DMXR8WN	DI	DMXR8WN
DMXR8WN	DN	CYCLOPLATAM
DMXR8WN	MI	TTYVX59
DMXR8WN	MN	Protein kinase C (PRKC)
DMXR8WN	MT	DTT
DMXR8WN	MA	Inhibitor
DMXR8WN	RN	Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73.
DMXR8WN	RU	https://pubmed.ncbi.nlm.nih.gov/9011234

DM0DT45	DI	DM0DT45
DM0DT45	DN	CYSTEMUSTINE
DM0DT45	MI	TTUTN1I
DM0DT45	MN	Human Deoxyribonucleic acid (hDNA)
DM0DT45	MT	DTT
DM0DT45	MA	Binder
DM0DT45	RN	A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7.
DM0DT45	RU	https://pubmed.ncbi.nlm.nih.gov/18411412

DMMWIHC	DI	DMMWIHC
DMMWIHC	DN	CYT 99007
DMMWIHC	MI	TTAWI51
DMMWIHC	MN	Interleukin 7 receptor alpha (IL7R)
DMMWIHC	MT	DTT
DMMWIHC	MA	Binder
DMMWIHC	RN	Perspectives on interleukin-7 therapy in HIV infection. Curr Opin HIV AIDS. 2007 May;2(3):228-33.
DMMWIHC	RU	https://pubmed.ncbi.nlm.nih.gov/19372891

DM4LJH8	DI	DM4LJH8
DM4LJH8	DN	CYT003
DM4LJH8	MI	TTSHG0T
DM4LJH8	MN	Toll-like receptor 9 (TLR9)
DM4LJH8	MT	DTT
DM4LJH8	MA	Agonist
DM4LJH8	RN	CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
DM4LJH8	RU	https://pubmed.ncbi.nlm.nih.gov/26042362

DMIRSWE	DI	DMIRSWE
DMIRSWE	DN	CYT-006-AngQb
DMIRSWE	MI	TTGN1ZA
DMIRSWE	MN	Angiotensin II receptor (AGTR)
DMIRSWE	MT	DTT
DMIRSWE	RN	CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75.
DMIRSWE	RU	https://pubmed.ncbi.nlm.nih.gov/19333885

DMUDMHA	DI	DMUDMHA
DMUDMHA	DN	CZEN-002
DMUDMHA	MI	TTSXVID
DMUDMHA	MN	Nuclear factor NF-kappa-B (NFKB)
DMUDMHA	MT	DTT
DMUDMHA	MA	Modulator
DMUDMHA	RN	US patent application no. US20100278784 A1.
DMUDMHA	RU	https://www.google.com.ar/patents/US20100278784

DMP6MH9	DI	DMP6MH9
DMP6MH9	DN	DA-8031
DMP6MH9	MI	TT3ROYC
DMP6MH9	MN	Serotonin transporter (SERT)
DMP6MH9	MT	DTT
DMP6MH9	MA	Inhibitor
DMP6MH9	RN	Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior. Int J Urol. 2014 Mar;21(3):325-9.
DMP6MH9	RU	https://pubmed.ncbi.nlm.nih.gov/23968141

DMACTBM	DI	DMACTBM
DMACTBM	DN	DAC-060
DMACTBM	MI	TTBH0VX
DMACTBM	MN	Histone deacetylase (HDAC)
DMACTBM	MT	DTT
DMACTBM	MA	Inhibitor
DMACTBM	RN	Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.
DMACTBM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341130/

DM2U45Q	DI	DM2U45Q
DM2U45Q	DN	Danegaptide
DM2U45Q	MI	TTJO6E9
DM2U45Q	MN	Gap junction protein (GJP)
DM2U45Q	MT	DTT
DM2U45Q	MA	Modulator
DM2U45Q	RN	The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33.
DM2U45Q	RU	https://pubmed.ncbi.nlm.nih.gov/19252062

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DE4LYSA
DM20MDU	MN	Cytochrome P450 3A4 (CYP3A4)
DM20MDU	MT	DME
DM20MDU	MA	Metabolism
DM20MDU	RN	Comprehensive Medicinal Chemistry III. Page: 569.
DM20MDU	RU	https://books.google.fr/books?id=iZHUDQAAQBAJ&pg=RA1-PA569&lpg=RA1-PA569&dq=Danoprevir+metabolizing+enzyme+metabolize&source=bl&ots=PaQ6yPgIDJ&sig=ACfU3U1Rask-Lef8fItwvzwnqUH9ud6e2Q&hl=zh-CN&sa=X&ved=2ahUKEwi8oo2mxrfnAhUQyxoKHV0GBtAQ6AEwCHoECAsQAQ

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	TT5FNQT
DM20MDU	MN	Human immunodeficiency virus Protease (HIV PR)
DM20MDU	MT	DTT
DM20MDU	MA	Inhibitor
DM20MDU	RN	2011 Pipeline of InterMune.
DM20MDU	RU	http://www.intermune.com/pipeline

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DT3D8F0
DM20MDU	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM20MDU	MT	DTP
DM20MDU	MA	Substrate
DM20MDU	RN	FDA Drug Development and Drug Interactions
DM20MDU	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM20MDU	DI	DM20MDU
DM20MDU	DN	Danoprevir
DM20MDU	MI	DT9C1TS
DM20MDU	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM20MDU	MT	DTP
DM20MDU	MA	Substrate
DM20MDU	RN	FDA Drug Development and Drug Interactions
DM20MDU	RU	https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2

DM7IH48	DI	DM7IH48
DM7IH48	DN	Dapansutrile
DM7IH48	MI	TT4EN8X
DM7IH48	MN	Caterpiller protein 1.1 (NLRP3)
DM7IH48	MT	DTT
DM7IH48	MA	Inhibitor
DM7IH48	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IH48	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMIYFWA	DI	DMIYFWA
DMIYFWA	DN	Dapirolizumab pegol
DMIYFWA	MI	TTIJP3Q
DMIYFWA	MN	TNF related activation protein (CD40LG)
DMIYFWA	MT	DTT
DMIYFWA	MA	Inhibitor
DMIYFWA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIYFWA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMR5J6K	DI	DMR5J6K
DMR5J6K	DN	DAPITANT
DMR5J6K	MI	TTZPO1L
DMR5J6K	MN	Substance-P receptor (TACR1)
DMR5J6K	MT	DTT
DMR5J6K	MA	Antagonist
DMR5J6K	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225)
DMR5J6K	RU	http://adisinsight.springer.com/drugs/800004225

DMCU74R	DI	DMCU74R
DMCU74R	DN	Daporinad
DMCU74R	MI	TTD1WIG
DMCU74R	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMCU74R	MT	DTT
DMCU74R	MA	Inhibitor
DMCU74R	RN	Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
DMCU74R	RU	https://pubmed.ncbi.nlm.nih.gov/18201551

DM0Y8JP	DI	DM0Y8JP
DM0Y8JP	DN	DAS-181
DM0Y8JP	MI	TT50QJ3
DM0Y8JP	MN	Influenza Neuraminidase (Influ NA)
DM0Y8JP	MT	DTT
DM0Y8JP	MA	Inhibitor
DM0Y8JP	RN	Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
DM0Y8JP	RU	https://pubmed.ncbi.nlm.nih.gov/19893749

DMM3BPL	DI	DMM3BPL
DMM3BPL	DN	DAS-431
DMM3BPL	MI	TTZFYLI
DMM3BPL	MN	Dopamine D1 receptor (D1R)
DMM3BPL	MT	DTT
DMM3BPL	MA	Agonist
DMM3BPL	RN	Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16.
DMM3BPL	RU	https://pubmed.ncbi.nlm.nih.gov/11607045

DM7JV4O	DI	DM7JV4O
DM7JV4O	DN	DB-041901
DM7JV4O	MI	DEOHI3U
DM7JV4O	MN	Beta-glucosidase (bglA)
DM7JV4O	MT	DME
DM7JV4O	MA	Metabolism
DM7JV4O	RN	Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos. 2015 Oct;43(10):1581-9.
DM7JV4O	RU	https://pubmed.ncbi.nlm.nih.gov/25926432

DMQRCX5	DI	DMQRCX5
DMQRCX5	DN	DCDS-4501A
DMQRCX5	MI	TTBN5I7
DMQRCX5	MN	B-cell-specific glycoprotein B29 (CD79B)
DMQRCX5	MT	DTT
DMQRCX5	RN	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
DMQRCX5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/

DMCHWX1	DI	DMCHWX1
DMCHWX1	DN	DCR-PHXC
DMCHWX1	MI	TTW76JE
DMCHWX1	MN	LDHA messenger RNA (LDHA mRNA)
DMCHWX1	MT	DTT
DMCHWX1	MA	Inhibitor
DMCHWX1	RN	Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098.
DMCHWX1	RU	https://pubmed.ncbi.nlm.nih.gov/33912759

DM9REBL	DI	DM9REBL
DM9REBL	DN	DDP-225
DM9REBL	MI	TTNXLKE
DM9REBL	MN	5-HT 3 receptor (5HT3R)
DM9REBL	MT	DTT
DM9REBL	MA	Modulator
DM9REBL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM9REBL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5XT3G	DI	DM5XT3G
DM5XT3G	DN	DE-098
DM5XT3G	MI	TTF0RCZ
DM5XT3G	MN	Apoptosis mediating surface antigen FAS (FAS)
DM5XT3G	MT	DTT
DM5XT3G	RN	ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
DM5XT3G	RU	http://www.biomedcentral.com/1471-2474/11/221

DMCQL5I	DI	DMCQL5I
DMCQL5I	DN	DE-110
DMCQL5I	MI	TTYRL6O
DMCQL5I	MN	Glucocorticoid receptor (NR3C1)
DMCQL5I	MT	DTT
DMCQL5I	MA	Agonist
DMCQL5I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031667)
DMCQL5I	RU	http://adisinsight.springer.com/drugs/800031667

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TT0LF7H
DMZW50O	MN	Fibroblast growth factor receptor (FGFR)
DMZW50O	MT	DTT
DMZW50O	MA	Modulator
DMZW50O	RN	The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
DMZW50O	RU	https://pubmed.ncbi.nlm.nih.gov/25169980

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTRLW2X
DMZW50O	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTGJVQM
DMZW50O	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZW50O	DI	DMZW50O
DMZW50O	DN	Debio 1347
DMZW50O	MI	TTST7KB
DMZW50O	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMZW50O	MT	DTT
DMZW50O	MA	Inhibitor
DMZW50O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZW50O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1H7UK	DI	DM1H7UK
DM1H7UK	DN	Dectrekumab
DM1H7UK	MI	TT0GVCH
DM1H7UK	MN	Interleukin-13 (IL13)
DM1H7UK	MT	DTT
DM1H7UK	MA	Inhibitor
DM1H7UK	RN	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
DM1H7UK	RU	https://pubmed.ncbi.nlm.nih.gov/25226850

DMX4DQH	DI	DMX4DQH
DMX4DQH	DN	Delanzomib
DMX4DQH	MI	TTU7ZMG
DMX4DQH	MN	Proteasome (PS)
DMX4DQH	MT	DTT
DMX4DQH	MA	Modulator
DMX4DQH	RN	Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
DMX4DQH	RU	https://pubmed.ncbi.nlm.nih.gov/22178195

DMS2WIN	DI	DMS2WIN
DMS2WIN	DN	Delphinidin
DMS2WIN	MI	TTUTJGQ
DMS2WIN	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMS2WIN	MT	DTT
DMS2WIN	MA	Modulator
DMS2WIN	RN	Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis. 2006 May;27(5):989-96.
DMS2WIN	RU	https://pubmed.ncbi.nlm.nih.gov/16308314

DM5CB8U	DI	DM5CB8U
DM5CB8U	DN	DELTIBANT
DM5CB8U	MI	TTGY8IW
DM5CB8U	MN	B2 bradykinin receptor (BDKRB2)
DM5CB8U	MT	DTT
DM5CB8U	MA	Modulator
DM5CB8U	RN	CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20.
DM5CB8U	RU	https://pubmed.ncbi.nlm.nih.gov/1462875

DML4PMG	DI	DML4PMG
DML4PMG	DN	Dendritic cell vaccine
DML4PMG	MI	TTUJFD0
DML4PMG	MN	Telomerase reverse transcriptase (TERT)
DML4PMG	MT	DTT
DML4PMG	RN	In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8.
DML4PMG	RU	https://pubmed.ncbi.nlm.nih.gov/19908943

DM7GPMB	DI	DM7GPMB
DM7GPMB	DN	Depatuxizumab
DM7GPMB	MI	TTGKNB4
DM7GPMB	MN	Epidermal growth factor receptor (EGFR)
DM7GPMB	MT	DTT
DM7GPMB	MA	Antagonist
DM7GPMB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7GPMB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMH96JW	DI	DMH96JW
DMH96JW	DN	Dersalazine
DMH96JW	MI	TTQL5VC
DMH96JW	MN	Platelet-activating factor receptor (PTAFR)
DMH96JW	MT	DTT
DMH96JW	MA	Inhibitor
DMH96JW	RN	The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
DMH96JW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315044/

DM63P1W	DI	DM63P1W
DM63P1W	DN	Descartes-08
DM63P1W	MI	TTZ3P4W
DM63P1W	MN	B-cell maturation protein (TNFRSF17)
DM63P1W	MT	DTT
DM63P1W	MA	CAR-T-Cell-Therapy
DM63P1W	RN	ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
DM63P1W	RU	https://clinicaltrials.gov/ct2/show/NCT03448978

DM1UO4S	DI	DM1UO4S
DM1UO4S	DN	Descartes-11
DM1UO4S	MI	TTZ3P4W
DM1UO4S	MN	B-cell maturation protein (TNFRSF17)
DM1UO4S	MT	DTT
DM1UO4S	RN	Clinical pipeline report, company report or official report of Cartesian Therapeutics.
DM1UO4S	RU	https://www.cartesiantherapeutics.com/clinical-trials/

DMTY4KN	DI	DMTY4KN
DMTY4KN	DN	Dexefaroxan
DMTY4KN	MI	TTM2AOE
DMTY4KN	MN	Adenosine A2a receptor (ADORA2A)
DMTY4KN	MT	DTT
DMTY4KN	MA	Agonist
DMTY4KN	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTY4KN	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMTY4KN	DI	DMTY4KN
DMTY4KN	DN	Dexefaroxan
DMTY4KN	MI	TTJSZTB
DMTY4KN	MN	Nicotinic acetylcholine receptor (nAChR)
DMTY4KN	MT	DTT
DMTY4KN	MA	Agonist
DMTY4KN	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMTY4KN	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	TTCG0AL
DM52HUD	MN	Cholecystokinin receptor type A (CCKAR)
DM52HUD	MT	DTT
DM52HUD	MA	Inhibitor
DM52HUD	RN	Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9.
DM52HUD	RU	https://pubmed.ncbi.nlm.nih.gov/2464062

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DEPKLMQ
DM52HUD	MN	Cytochrome P450 2B6 (CYP2B6)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide. Br J Clin Pharmacol. 2005 Nov;60(5):498-507.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16236040

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DE5IED8
DM52HUD	MN	Cytochrome P450 2C9 (CYP2C9)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DE4LYSA
DM52HUD	MN	Cytochrome P450 3A4 (CYP3A4)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	DEIBDNY
DM52HUD	MN	Cytochrome P450 3A5 (CYP3A5)
DM52HUD	MT	DME
DM52HUD	MA	Metabolism
DM52HUD	RN	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
DM52HUD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17112294

DM52HUD	DI	DM52HUD
DM52HUD	DN	Dexloxiglumide
DM52HUD	MI	TTVFO0U
DM52HUD	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM52HUD	MT	DTT
DM52HUD	MA	Inhibitor
DM52HUD	RN	Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7.
DM52HUD	RU	https://pubmed.ncbi.nlm.nih.gov/9341915

DM9L15R	DI	DM9L15R
DM9L15R	DN	Dextofisopam
DM9L15R	MI	TTNJYV2
DM9L15R	MN	Gamma-aminobutyric acid receptor (GAR)
DM9L15R	MT	DTT
DM9L15R	MA	Agonist
DM9L15R	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM9L15R	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM9L15R	DI	DM9L15R
DM9L15R	DN	Dextofisopam
DM9L15R	MI	TTPTXIN
DM9L15R	MN	Translocator protein (TSPO)
DM9L15R	MT	DTT
DM9L15R	MA	Agonist
DM9L15R	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DM9L15R	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DMFI5J4	DI	DMFI5J4
DMFI5J4	DN	Dextromethorphan+quinidine
DMFI5J4	MI	TTSZLWK
DMFI5J4	MN	Aromatase (CYP19A1)
DMFI5J4	MT	DTT
DMFI5J4	MA	Inhibitor
DMFI5J4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMFI5J4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMFI5J4	DI	DMFI5J4
DMFI5J4	DN	Dextromethorphan+quinidine
DMFI5J4	MI	TT9IK2Z
DMFI5J4	MN	N-methyl-D-aspartate receptor (NMDAR)
DMFI5J4	MT	DTT
DMFI5J4	MA	Antagonist
DMFI5J4	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMFI5J4	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMS9Y1T	DI	DMS9Y1T
DMS9Y1T	DN	DG-17
DMS9Y1T	MI	TT5FNQT
DMS9Y1T	MN	Human immunodeficiency virus Protease (HIV PR)
DMS9Y1T	MT	DTT
DMS9Y1T	MA	Inhibitor
DMS9Y1T	RN	Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999 April 16; 13(6): 661-667.
DMS9Y1T	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566777/

DMK6FYR	DI	DMK6FYR
DMK6FYR	DN	DiabeCell
DMK6FYR	MI	TTXQYT6
DMK6FYR	MN	T-cells (T-cells)
DMK6FYR	MT	DTT
DMK6FYR	MA	Modulator
DMK6FYR	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMK6FYR	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTJOEL	DI	DMTJOEL
DMTJOEL	DN	DIADENOSINE TETRAPHOSPHATE
DMTJOEL	MI	TTSLI08
DMTJOEL	MN	Adenosine receptor (ADOR)
DMTJOEL	MT	DTT
DMTJOEL	MA	Modulator
DMTJOEL	RN	Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44.
DMTJOEL	RU	https://pubmed.ncbi.nlm.nih.gov/8922729

DM7AFJ8	DI	DM7AFJ8
DM7AFJ8	DN	Diannexin
DM7AFJ8	MI	TT2Z83I
DM7AFJ8	MN	Annexin A5 (ANXA5)
DM7AFJ8	MT	DTT
DM7AFJ8	MA	Modulator
DM7AFJ8	RN	Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000 Nov;30(4):305-12.
DM7AFJ8	RU	https://pubmed.ncbi.nlm.nih.gov/11065275

DM20ATW	DI	DM20ATW
DM20ATW	DN	Diflomotecan
DM20ATW	MI	DTI7UX6
DM20ATW	MN	Breast cancer resistance protein (ABCG2)
DM20ATW	MT	DTP
DM20ATW	MA	Substrate
DM20ATW	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DM20ATW	RU	https://doi.org/10.2217/14622416.9.8.1005

DM20ATW	DI	DM20ATW
DM20ATW	DN	Diflomotecan
DM20ATW	MI	TTGTQHC
DM20ATW	MN	DNA topoisomerase I (TOP1)
DM20ATW	MT	DTT
DM20ATW	MA	Inhibitor
DM20ATW	RN	Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75.
DM20ATW	RU	https://pubmed.ncbi.nlm.nih.gov/19053883

DMTLB92	DI	DMTLB92
DMTLB92	DN	DI-Leu16-IL2
DMTLB92	MI	TTUE541
DMTLB92	MN	Leukocyte surface antigen Leu-16 (CD20)
DMTLB92	MT	DTT
DMTLB92	MA	Modulator
DMTLB92	RN	National Cancer Institute Drug Dictionary (drug id 599668).
DMTLB92	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599668

DMBYJ92	DI	DMBYJ92
DMBYJ92	DN	Dilmapimod
DMBYJ92	MI	TTQBR95
DMBYJ92	MN	Stress-activated protein kinase 2a (p38 alpha)
DMBYJ92	MT	DTT
DMBYJ92	MA	Inhibitor
DMBYJ92	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMBYJ92	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMCATH2	DI	DMCATH2
DMCATH2	DN	Dilpacimab
DMCATH2	MI	TTV23LH
DMCATH2	MN	Delta-like protein 4 (DLL4)
DMCATH2	MT	DTT
DMCATH2	RN	Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
DMCATH2	RU	https://pubmed.ncbi.nlm.nih.gov/21473903

DMCATH2	DI	DMCATH2
DMCATH2	DN	Dilpacimab
DMCATH2	MI	TT9HKJA
DMCATH2	MN	Vascular endothelial growth factor (VEGF)
DMCATH2	MT	DTT
DMCATH2	RN	Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
DMCATH2	RU	https://pubmed.ncbi.nlm.nih.gov/21473903

DM96NHM	DI	DM96NHM
DM96NHM	DN	Dimiracetam
DM96NHM	MI	TT9IK2Z
DM96NHM	MN	N-methyl-D-aspartate receptor (NMDAR)
DM96NHM	MT	DTT
DM96NHM	MA	Antagonist
DM96NHM	RN	Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94.
DM96NHM	RU	https://pubmed.ncbi.nlm.nih.gov/24486381

DM2QBDS	DI	DM2QBDS
DM2QBDS	DN	Disitertide
DM2QBDS	MI	TTR9XHZ
DM2QBDS	MN	Transforming growth factor beta 1 (TGFB1)
DM2QBDS	MT	DTT
DM2QBDS	MA	Inhibitor
DM2QBDS	RN	Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94.
DM2QBDS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960190/

DMYC2LE	DI	DMYC2LE
DMYC2LE	DN	Disufenton
DMYC2LE	MI	TTLQTHB
DMYC2LE	MN	Extracellular sulfatase Sulf-2 (SULF2)
DMYC2LE	MT	DTT
DMYC2LE	MA	Inhibitor
DMYC2LE	RN	The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36.
DMYC2LE	RU	https://pubmed.ncbi.nlm.nih.gov/23109092

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTNHMO8
DMBMKV8	MN	COVID-19 papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTYJOLE
DMBMKV8	MN	MERS-CoV papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMBMKV8	DI	DMBMKV8
DMBMKV8	DN	Disulfiram
DMBMKV8	MI	TTRGHB2
DMBMKV8	MN	SARS-CoV papain-like proteinase (PL-PRO)
DMBMKV8	MT	DTT
DMBMKV8	MA	Inhibitor
DMBMKV8	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMBMKV8	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DMOHT5V	DI	DMOHT5V
DMOHT5V	DN	DKN-01
DMOHT5V	MI	TTE3RAC
DMOHT5V	MN	Dickkopf-related protein 1 (DKK1)
DMOHT5V	MT	DTT
DMOHT5V	MA	Inhibitor
DMOHT5V	RN	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644.
DMOHT5V	RU	https://pubmed.ncbi.nlm.nih.gov/32408777

DMDJUWG	DI	DMDJUWG
DMDJUWG	DN	DLX-105
DMDJUWG	MI	TTF8CQI
DMDJUWG	MN	Tumor necrosis factor (TNF)
DMDJUWG	MT	DTT
DMDJUWG	RN	Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8.
DMDJUWG	RU	https://pubmed.ncbi.nlm.nih.gov/12606779

DM0157T	DI	DM0157T
DM0157T	DN	DM199
DM0157T	MI	TTGY8IW
DM0157T	MN	B2 bradykinin receptor (BDKRB2)
DM0157T	MT	DTT
DM0157T	MA	Activator
DM0157T	RN	Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119.
DM0157T	RU	https://pubmed.ncbi.nlm.nih.gov/26038695

DMMSIG7	DI	DMMSIG7
DMMSIG7	DN	DM-71
DMMSIG7	MI	TTCBFJO
DMMSIG7	MN	Insulin receptor (INSR)
DMMSIG7	MT	DTT
DMMSIG7	MA	Modulator
DMMSIG7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMMSIG7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM1HG3U	DI	DM1HG3U
DM1HG3U	DN	DM-99
DM1HG3U	MI	TTCBFJO
DM1HG3U	MN	Insulin receptor (INSR)
DM1HG3U	MT	DTT
DM1HG3U	MA	Agonist
DM1HG3U	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM1HG3U	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMBC7HZ	DI	DMBC7HZ
DMBC7HZ	DN	DM-CHOC-PEN
DMBC7HZ	MI	TTUTN1I
DMBC7HZ	MN	Human Deoxyribonucleic acid (hDNA)
DMBC7HZ	MT	DTT
DMBC7HZ	MA	Modulator
DMBC7HZ	RN	Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835.
DMBC7HZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717391/

DM725UG	DI	DM725UG
DM725UG	DN	DN24-02
DM725UG	MI	TT6EO5L
DM725UG	MN	Erbb2 tyrosine kinase receptor (HER2)
DM725UG	MT	DTT
DM725UG	MA	Modulator
DM725UG	RN	Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7.
DM725UG	RU	https://pubmed.ncbi.nlm.nih.gov/17704416

DMDTVYC	DI	DMDTVYC
DMDTVYC	DN	DNCB
DMDTVYC	MI	DER3H9C
DMDTVYC	MN	Lipocalin-type prostaglandin-D synthase (PTGDS)
DMDTVYC	MT	DME
DMDTVYC	MA	Metabolism
DMDTVYC	RN	Glutathione transferases immobilized on nanoporous alumina: flow system kinetics, screening, and stability. Anal Biochem. 2014 Feb 1;446:59-63.
DMDTVYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24157647

DMDTVYC	DI	DMDTVYC
DMDTVYC	DN	DNCB
DMDTVYC	MI	DE3OALH
DMDTVYC	MN	Prostaglandin E synthase 2 (PTGES2)
DMDTVYC	MT	DME
DMDTVYC	MA	Metabolism
DMDTVYC	RN	Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J Biol Chem. 2003 Jun 20;278(25):22199-209.
DMDTVYC	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12672824

DM89D6C	DI	DM89D6C
DM89D6C	DN	DNL758
DM89D6C	MI	TTAIQSN
DM89D6C	MN	Receptor-interacting protein 1 (RIPK1)
DM89D6C	MT	DTT
DM89D6C	MA	Inhibitor
DM89D6C	RN	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
DM89D6C	RU	https://pubmed.ncbi.nlm.nih.gov/32669658

DM0QDC9	DI	DM0QDC9
DM0QDC9	DN	Dolastatin 10
DM0QDC9	MI	DTUGYRD
DM0QDC9	MN	P-glycoprotein 1 (ABCB1)
DM0QDC9	MT	DTP
DM0QDC9	MA	Substrate
DM0QDC9	RN	Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.
DM0QDC9	RU	http://www.ncbi.nlm.nih.gov/pubmed/8621716

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTML2WA
DMDUV1S	MN	Tubulin (TUB)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/9554885

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTYFKSZ
DMDUV1S	MN	Tubulin beta (TUBB)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMDUV1S	DI	DMDUV1S
DMDUV1S	DN	DOLASTATIN-10
DMDUV1S	MI	TTJ2PTI
DMDUV1S	MN	Tubulin beta-2 chain (TUBB2)
DMDUV1S	MT	DTT
DMDUV1S	MA	Inhibitor
DMDUV1S	RN	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
DMDUV1S	RU	https://pubmed.ncbi.nlm.nih.gov/16837194

DMCT08V	DI	DMCT08V
DMCT08V	DN	Domagrozumab
DMCT08V	MI	TTSWPH8
DMCT08V	MN	Growth/differentiation factor 8 (GDF-8)
DMCT08V	MT	DTT
DMCT08V	MA	Inhibitor
DMCT08V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCT08V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM8VWPH	DI	DM8VWPH
DM8VWPH	DN	Doxorubicin-eluting beads
DM8VWPH	MI	TT0IHXV
DM8VWPH	MN	DNA topoisomerase II (TOP2)
DM8VWPH	MT	DTT
DM8VWPH	MA	Modulator
DM8VWPH	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8VWPH	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM059CZ	DI	DM059CZ
DM059CZ	DN	DPK-060
DM059CZ	MI	TTXT4D5
DM059CZ	MN	Bacterial Cell membrane (Bact CM)
DM059CZ	MT	DTT
DM059CZ	MA	Enhancer
DM059CZ	RN	The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29. 
DM059CZ	RU	https://pubmed.ncbi.nlm.nih.gov/25614221

DMMC3XR	DI	DMMC3XR
DMMC3XR	DN	DPV-001
DMMC3XR	MI	TTOK0LR
DMMC3XR	MN	Toll-like receptor (TLR)
DMMC3XR	MT	DTT
DMMC3XR	MA	Modulator
DMMC3XR	RN	UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013.
DMMC3XR	RU	http://ubivac.com/zap/?page_id=2668

DMGD3XT	DI	DMGD3XT
DMGD3XT	DN	DRL-17822
DMGD3XT	MI	TTFQAYR
DMGD3XT	MN	Cholesteryl ester transfer protein (CETP)
DMGD3XT	MT	DTT
DMGD3XT	MA	Inhibitor
DMGD3XT	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMGD3XT	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM8WU3O	DI	DM8WU3O
DM8WU3O	DN	Drug 2862277
DM8WU3O	MI	TTG043C
DM8WU3O	MN	Tumor necrosis factor receptor type I (TNF-R1)
DM8WU3O	MT	DTT
DM8WU3O	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
DM8WU3O	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

DMI69E5	DI	DMI69E5
DMI69E5	DN	DS-3201b
DMI69E5	MI	TTNJA0C
DMI69E5	MN	Enhancer of zeste homolog 1 (EZH1)
DMI69E5	MT	DTT
DMI69E5	MA	Inhibitor
DMI69E5	RN	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
DMI69E5	RU	https://pubmed.ncbi.nlm.nih.gov/30658046

DMI69E5	DI	DMI69E5
DMI69E5	DN	DS-3201b
DMI69E5	MI	TT9MZCQ
DMI69E5	MN	Enhancer of zeste homolog 2 (EZH2)
DMI69E5	MT	DTT
DMI69E5	MA	Inhibitor
DMI69E5	RN	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
DMI69E5	RU	https://pubmed.ncbi.nlm.nih.gov/30658046

DMUXIRM	DI	DMUXIRM
DMUXIRM	DN	DS-8500
DMUXIRM	MI	TT7QNVC
DMUXIRM	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMUXIRM	MT	DTT
DMUXIRM	MA	Modulator
DMUXIRM	RN	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
DMUXIRM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/

DM6UGHA	DI	DM6UGHA
DM6UGHA	DN	DSP-6952
DM6UGHA	MI	TT07C3Y
DM6UGHA	MN	5-HT 4 receptor (HTR4)
DM6UGHA	MT	DTT
DM6UGHA	MA	Agonist
DM6UGHA	RN	DSP-6952, a high affinity serotonin (5-HT4) receptor partial agonist. Sumitomo Dainippon Pharma Co. Ltd.
DM6UGHA	RU	http://www.biocentury.com/products/dsp-6952

DMU2GP4	DI	DMU2GP4
DMU2GP4	DN	DT-1687
DMU2GP4	MI	TTICZ1O
DMU2GP4	MN	Metabotropic glutamate receptor 4 (mGluR4)
DMU2GP4	MT	DTT
DMU2GP4	MA	Modulator
DMU2GP4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
DMU2GP4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292

DMV84OK	DI	DMV84OK
DMV84OK	DN	DTI-0009
DMV84OK	MI	TTK25J1
DMV84OK	MN	Adenosine A1 receptor (ADORA1)
DMV84OK	MT	DTT
DMV84OK	MA	Agonist
DMV84OK	RN	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
DMV84OK	RU	https://pubmed.ncbi.nlm.nih.gov/21185259

DMX27IT	DI	DMX27IT
DMX27IT	DN	DTRM-555
DMX27IT	MI	TTGM6VW
DMX27IT	MN	Tyrosine-protein kinase BTK (ATK)
DMX27IT	MT	DTT
DMX27IT	MA	Inhibitor
DMX27IT	RN	ClinicalTrials.gov (NCT04305444) Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
DMX27IT	RU	https://clinicaltrials.gov/ct2/show/NCT04305444

DM1ZJYS	DI	DM1ZJYS
DM1ZJYS	DN	Dusigitumab
DM1ZJYS	MI	TTE8WGO
DM1ZJYS	MN	Insulin-like growth factor-II (IGF2)
DM1ZJYS	MT	DTT
DM1ZJYS	MA	Inhibitor
DM1ZJYS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1ZJYS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7USVA	DI	DM7USVA
DM7USVA	DN	Duvelisib
DM7USVA	MI	TTK5FVJ
DM7USVA	MN	HUMAN PI3-kinase delta (PIK3CD)
DM7USVA	MT	DTT
DM7USVA	MA	Inhibitor
DM7USVA	RN	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
DM7USVA	RU	https://clinicaltrials.gov/ct2/show/NCT04372602

DM7USVA	DI	DM7USVA
DM7USVA	DN	Duvelisib
DM7USVA	MI	TTHXGLJ
DM7USVA	MN	HUMAN PI3-kinase gamma (PIK3CG)
DM7USVA	MT	DTT
DM7USVA	MA	Inhibitor
DM7USVA	RN	ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health.
DM7USVA	RU	https://clinicaltrials.gov/ct2/show/NCT04372602

DMUGBQK	DI	DMUGBQK
DMUGBQK	DN	DVC1-0101
DMUGBQK	MI	TTGKIED
DMUGBQK	MN	Fibroblast growth factor-2 (FGF2)
DMUGBQK	MT	DTT
DMUGBQK	MA	Modulator
DMUGBQK	RN	DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
DMUGBQK	RU	https://pubmed.ncbi.nlm.nih.gov/23319060

DMQKU2F	DI	DMQKU2F
DMQKU2F	DN	DWP-05195
DMQKU2F	MI	TTMI6F5
DMQKU2F	MN	Transient receptor potential cation channel V1 (TRPV1)
DMQKU2F	MT	DTT
DMQKU2F	MA	Antagonist
DMQKU2F	RN	TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 .
DMQKU2F	RU	http://benthamopen.com/contents/pdf/TOPAINJ/TOPAINJ-6-108.pdf

DMBFZET	DI	DMBFZET
DMBFZET	DN	DX-890
DMBFZET	MI	TTPLTSQ
DMBFZET	MN	Neutrophil elastase (NE)
DMBFZET	MT	DTT
DMBFZET	MA	Inhibitor
DMBFZET	RN	Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
DMBFZET	RU	https://pubmed.ncbi.nlm.nih.gov/17874973

DMDYWM8	DI	DMDYWM8
DMDYWM8	DN	E-10030
DMDYWM8	MI	TTQA6SX
DMDYWM8	MN	Platelet-derived growth factor B (PDGFB)
DMDYWM8	MT	DTT
DMDYWM8	MA	Antagonist
DMDYWM8	RN	Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50.
DMDYWM8	RU	https://pubmed.ncbi.nlm.nih.gov/20592747

DMLS269	DI	DMLS269
DMLS269	DN	E-1224
DMLS269	MI	TTTSOUD
DMLS269	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMLS269	MT	DTT
DMLS269	MA	Inhibitor
DMLS269	RN	Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242.
DMLS269	RU	https://pubmed.ncbi.nlm.nih.gov/23277882

DMK8SY6	DI	DMK8SY6
DMK8SY6	DN	E2027
DMK8SY6	MI	TTZOEBC
DMK8SY6	MN	Phosphodiesterase 9 (PDE9)
DMK8SY6	MT	DTT
DMK8SY6	MA	Antagonist
DMK8SY6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK8SY6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMC5PB2	DI	DMC5PB2
DMC5PB2	DN	E-4716
DMC5PB2	MI	TTTIBOJ
DMC5PB2	MN	Histamine H1 receptor (H1R)
DMC5PB2	MT	DTT
DMC5PB2	MA	Modulator
DMC5PB2	RN	Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol. 2005 Jan;59(1):43-53.
DMC5PB2	RU	https://pubmed.ncbi.nlm.nih.gov/15606439

DMQERC6	DI	DMQERC6
DMQERC6	DN	E5555
DMQERC6	MI	TTL935N
DMQERC6	MN	Proteinase activated receptor 1 (F2R)
DMQERC6	MT	DTT
DMQERC6	MA	Antagonist
DMQERC6	RN	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53.
DMQERC6	RU	https://pubmed.ncbi.nlm.nih.gov/21502577

DM1S489	DI	DM1S489
DM1S489	DN	E6005
DM1S489	MI	DEB30C5
DM1S489	MN	Carboxylesterase 1 (CES1)
DM1S489	MT	DME
DM1S489	MA	Metabolism
DM1S489	RN	Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014 Jul;41(7):577-85.
DM1S489	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24942594

DM1S489	DI	DM1S489
DM1S489	DN	E6005
DM1S489	MI	TTV5CGO
DM1S489	MN	Phosphodiesterase 4 (PDE4)
DM1S489	MT	DTT
DM1S489	MA	Inhibitor
DM1S489	RN	Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
DM1S489	RU	https://pubmed.ncbi.nlm.nih.gov/23674603

DMOSL9P	DI	DMOSL9P
DMOSL9P	DN	E6201
DMOSL9P	MI	TTROQ37
DMOSL9P	MN	MAPK/ERK kinase kinase (MAP3K)
DMOSL9P	MT	DTT
DMOSL9P	MA	Modulator
DMOSL9P	RN	E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31.
DMOSL9P	RU	https://pubmed.ncbi.nlm.nih.gov/20627998

DMUWJI4	DI	DMUWJI4
DMUWJI4	DN	E-6700
DMUWJI4	MI	TT2J34L
DMUWJI4	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMUWJI4	MT	DTT
DMUWJI4	MA	Modulator
DMUWJI4	RN	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
DMUWJI4	RU	https://pubmed.ncbi.nlm.nih.gov/8759636

DMUWJI4	DI	DMUWJI4
DMUWJI4	DN	E-6700
DMUWJI4	MI	TTKNWZ4
DMUWJI4	MN	Thromboxane-A synthase (TBXAS1)
DMUWJI4	MT	DTT
DMUWJI4	MA	Modulator
DMUWJI4	RN	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
DMUWJI4	RU	https://pubmed.ncbi.nlm.nih.gov/8759636

DMAHGKE	DI	DMAHGKE
DMAHGKE	DN	E7016
DMAHGKE	MI	TTEBCY8
DMAHGKE	MN	Poly [ADP-ribose] polymerase (PARP)
DMAHGKE	MT	DTT
DMAHGKE	MA	Modulator
DMAHGKE	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMAHGKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZRXTL	DI	DMZRXTL
DMZRXTL	DN	E7820
DMZRXTL	MI	TTSJ542
DMZRXTL	MN	Integrin alpha-2 (ITGA2)
DMZRXTL	MT	DTT
DMZRXTL	MA	Inhibitor
DMZRXTL	RN	Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200.
DMZRXTL	RU	https://pubmed.ncbi.nlm.nih.gov/21208908

DM8K5IF	DI	DM8K5IF
DM8K5IF	DN	E7850
DM8K5IF	MI	TT9ABMF
DM8K5IF	MN	Serine/threonine-protein kinase Chk2 (RAD53)
DM8K5IF	MT	DTT
DM8K5IF	MA	Modulator
DM8K5IF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1988).
DM8K5IF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1988

DM753H8	DI	DM753H8
DM753H8	DN	EB8018
DM753H8	MI	TTTCRU2
DM753H8	MN	Bacterial Fimbrin D-mannose adhesin (Bact FimH)
DM753H8	MT	DTT
DM753H8	MA	Inhibitor
DM753H8	RN	Clinical pipeline report, company report or official report of Enterome Biosciences.
DM753H8	RU	https://www.enterome.com/#pipeline

DM0KVJC	DI	DM0KVJC
DM0KVJC	DN	EC-145
DM0KVJC	MI	TTVC37M
DM0KVJC	MN	Folate receptor alpha (FOLR1)
DM0KVJC	MT	DTT
DM0KVJC	MA	Modulator
DM0KVJC	RN	Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30.
DM0KVJC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645936/

DM1LDIP	DI	DM1LDIP
DM1LDIP	DN	Econail
DM1LDIP	MI	TTTSOUD
DM1LDIP	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM1LDIP	MT	DTT
DM1LDIP	MA	Inhibitor
DM1LDIP	RN	Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45.
DM1LDIP	RU	https://pubmed.ncbi.nlm.nih.gov/20625155

DMKAUM9	DI	DMKAUM9
DMKAUM9	DN	Eculizumab
DMKAUM9	MI	TTN0GJ5
DMKAUM9	MN	HUMAN complement C5 protein (C5)
DMKAUM9	MT	DTT
DMKAUM9	MA	Inhibitor
DMKAUM9	RN	Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23.
DMKAUM9	RU	https://pubmed.ncbi.nlm.nih.gov/32327719

DMQ08AJ	DI	DMQ08AJ
DMQ08AJ	DN	Edotreotide
DMQ08AJ	MI	TTOMNR9
DMQ08AJ	MN	Somatostatin receptor (SSTR)
DMQ08AJ	MT	DTT
DMQ08AJ	MA	Modulator
DMQ08AJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQ08AJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMGJYZ8	DI	DMGJYZ8
DMGJYZ8	DN	EDP-305
DMGJYZ8	MI	TTS4UGC
DMGJYZ8	MN	Farnesoid X-activated receptor (FXR)
DMGJYZ8	MT	DTT
DMGJYZ8	MA	Agonist
DMGJYZ8	RN	A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
DMGJYZ8	RU	https://pubmed.ncbi.nlm.nih.gov/32329946

DM5WZ0O	DI	DM5WZ0O
DM5WZ0O	DN	EDP-420
DM5WZ0O	MI	TTLFGBV
DM5WZ0O	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DM5WZ0O	MT	DTT
DM5WZ0O	MA	Inhibitor
DM5WZ0O	RN	EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670.
DM5WZ0O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855536/

DM32UOC	DI	DM32UOC
DM32UOC	DN	EDP-938
DM32UOC	MI	TT25A0I
DM32UOC	MN	Respiratory syncytial virus protein N (RSV N)
DM32UOC	MT	DTT
DM32UOC	MA	Inhibitor
DM32UOC	RN	EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428.
DM32UOC	RU	https://pubmed.ncbi.nlm.nih.gov/33720995

DMX4RSD	DI	DMX4RSD
DMX4RSD	DN	EFEGATRAN SULFATE HYDRATE
DMX4RSD	MI	TT6L509
DMX4RSD	MN	Coagulation factor IIa (F2)
DMX4RSD	MT	DTT
DMX4RSD	MA	Inhibitor
DMX4RSD	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMX4RSD	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMX6RZG	DI	DMX6RZG
DMX6RZG	DN	EFT508
DMX6RZG	MI	TTRECN3
DMX6RZG	MN	MAP kinase signal-integrating kinase 2 (MKNK2)
DMX6RZG	MT	DTT
DMX6RZG	MA	Inhibitor
DMX6RZG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX6RZG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX6RZG	DI	DMX6RZG
DMX6RZG	DN	EFT508
DMX6RZG	MI	TTEZAUX
DMX6RZG	MN	MAPK signal-integrating kinase 1 (MKNK1)
DMX6RZG	MT	DTT
DMX6RZG	MA	Inhibitor
DMX6RZG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX6RZG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBHP56	DI	DMBHP56
DMBHP56	DN	Efungumab
DMBHP56	MI	TT78R5H
DMBHP56	MN	Heat shock protein 90 alpha (HSP90A)
DMBHP56	MT	DTT
DMBHP56	RN	Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
DMBHP56	RU	https://pubmed.ncbi.nlm.nih.gov/19773528

DM6L5TR	DI	DM6L5TR
DM6L5TR	DN	EGEN-001
DM6L5TR	MI	TTGW72V
DM6L5TR	MN	Interleukin-12 beta (IL12B)
DM6L5TR	MT	DTT
DM6L5TR	MA	Modulator
DM6L5TR	RN	National Cancer Institute Drug Dictionary (drug id 454593).
DM6L5TR	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=454593

DMN1SWB	DI	DMN1SWB
DMN1SWB	DN	EGS-21
DMN1SWB	MI	TTCBFJO
DMN1SWB	MN	Insulin receptor (INSR)
DMN1SWB	MT	DTT
DMN1SWB	MA	Modulator
DMN1SWB	RN	Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 2014 Jan 10;289(2):723-34.
DMN1SWB	RU	https://pubmed.ncbi.nlm.nih.gov/24214972

DML7WP0	DI	DML7WP0
DML7WP0	DN	Eldacimibe
DML7WP0	MI	TTMF541
DML7WP0	MN	Liver carboxylesterase (CES1)
DML7WP0	MT	DTT
DML7WP0	MA	Modulator
DML7WP0	RN	Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46.
DML7WP0	RU	https://pubmed.ncbi.nlm.nih.gov/7621974

DMCSXI4	DI	DMCSXI4
DMCSXI4	DN	Elezanumab
DMCSXI4	MI	TTURJV4
DMCSXI4	MN	Repulsive guidance molecule A (RGMA)
DMCSXI4	MT	DTT
DMCSXI4	MA	Inhibitor
DMCSXI4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSXI4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMIOGZM	DI	DMIOGZM
DMIOGZM	DN	ELIPRODIL
DMIOGZM	MI	TTLD29N
DMIOGZM	MN	Glutamate receptor ionotropic NMDA 1 (NMDAR1)
DMIOGZM	MT	DTT
DMIOGZM	MA	Inhibitor
DMIOGZM	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMIOGZM	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMIOGZM	DI	DMIOGZM
DMIOGZM	DN	ELIPRODIL
DMIOGZM	MI	TTN9D8E
DMIOGZM	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMIOGZM	MT	DTT
DMIOGZM	MA	Inhibitor
DMIOGZM	RN	4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
DMIOGZM	RU	https://pubmed.ncbi.nlm.nih.gov/10425109

DMB38KH	DI	DMB38KH
DMB38KH	DN	Elisidepsin
DMB38KH	MI	TTDC8N2
DMB38KH	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMB38KH	MT	DTT
DMB38KH	MA	Inhibitor
DMB38KH	RN	Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64.
DMB38KH	RU	https://pubmed.ncbi.nlm.nih.gov/19346126

DMR50I7	DI	DMR50I7
DMR50I7	DN	Elsamitrucin
DMR50I7	MI	TT0IHXV
DMR50I7	MN	DNA topoisomerase II (TOP2)
DMR50I7	MT	DTT
DMR50I7	MA	Modulator
DMR50I7	RN	Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72.
DMR50I7	RU	https://pubmed.ncbi.nlm.nih.gov/15474012

DMB7CPG	DI	DMB7CPG
DMB7CPG	DN	Elsiglutide
DMB7CPG	MI	TT1YWO5
DMB7CPG	MN	Glucagon-like peptide 2 receptor (GLP2R)
DMB7CPG	MT	DTT
DMB7CPG	MA	Modulator
DMB7CPG	RN	Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.
DMB7CPG	RU	http://onlinelibrary.wiley.com/doi/10.1111/ajco.12305/abstract

DMYOUB6	DI	DMYOUB6
DMYOUB6	DN	EMA-401
DMYOUB6	MI	TTQVOEI
DMYOUB6	MN	Angiotensin II receptor type-2 (AGTR2)
DMYOUB6	MT	DTT
DMYOUB6	MA	Antagonist
DMYOUB6	RN	Clinical pipeline report, company report or official report of Spinifex.
DMYOUB6	RU	http://www.spinifexpharma.com/EMA401-DEVELOPMENT.html

DMCLT2F	DI	DMCLT2F
DMCLT2F	DN	Emepepimut-S
DMCLT2F	MI	TTBHFYQ
DMCLT2F	MN	Mucin-1 (MUC1)
DMCLT2F	MT	DTT
DMCLT2F	RN	Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
DMCLT2F	RU	https://pubmed.ncbi.nlm.nih.gov/21689064

DMT4MKF	DI	DMT4MKF
DMT4MKF	DN	Emibetuzumab
DMT4MKF	MI	TTNDSF4
DMT4MKF	MN	Proto-oncogene c-Met (MET)
DMT4MKF	MT	DTT
DMT4MKF	MA	Inhibitor
DMT4MKF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT4MKF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	DE4LYSA
DMQH1NV	MN	Cytochrome P450 3A4 (CYP3A4)
DMQH1NV	MT	DME
DMQH1NV	MA	Metabolism
DMQH1NV	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	DEIBDNY
DMQH1NV	MN	Cytochrome P450 3A5 (CYP3A5)
DMQH1NV	MT	DME
DMQH1NV	MA	Metabolism
DMQH1NV	RN	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10602732

DMQH1NV	DI	DMQH1NV
DMQH1NV	DN	Emivirine
DMQH1NV	MI	TT84ETX
DMQH1NV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQH1NV	MT	DTT
DMQH1NV	MA	Modulator
DMQH1NV	RN	Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704.
DMQH1NV	RU	https://www.ncbi.nlm.nih.gov/pubmed/19446143

DMDEL3F	DI	DMDEL3F
DMDEL3F	DN	EMZ701
DMDEL3F	MI	TTSYFMA
DMDEL3F	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMDEL3F	MT	DTT
DMDEL3F	MA	Modulator
DMDEL3F	RN	Patent EP2766021 A1.
DMDEL3F	RU	http://www.google.com/patents/EP2766021A1?cl=en

DMGFZOL	DI	DMGFZOL
DMGFZOL	DN	Enadoline
DMGFZOL	MI	TTQW87Y
DMGFZOL	MN	Opioid receptor kappa (OPRK1)
DMGFZOL	MT	DTT
DMGFZOL	MA	Agonist
DMGFZOL	RN	Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9.
DMGFZOL	RU	https://pubmed.ncbi.nlm.nih.gov/10204752

DMM8Z3Q	DI	DMM8Z3Q
DMM8Z3Q	DN	Encequidar
DMM8Z3Q	MI	TTJUXV6
DMM8Z3Q	MN	Multidrug resistance protein 3 (ABCB4)
DMM8Z3Q	MT	DTT
DMM8Z3Q	MA	Inhibitor
DMM8Z3Q	RN	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem. 2021 Apr 8;64(7):3677-3693.
DMM8Z3Q	RU	https://pubmed.ncbi.nlm.nih.gov/33729781

DM8NLDI	DI	DM8NLDI
DM8NLDI	DN	Endostatin
DM8NLDI	MI	TTBPXMA
DM8NLDI	MN	Prolactin receptor (PRLR)
DM8NLDI	MT	DTT
DM8NLDI	MA	Modulator
DM8NLDI	RN	Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604.
DM8NLDI	RU	https://pubmed.ncbi.nlm.nih.gov/12839947

DMTX8IZ	DI	DMTX8IZ
DMTX8IZ	DN	Endoxifen
DMTX8IZ	MI	TTZAYWL
DMTX8IZ	MN	Estrogen receptor (ESR)
DMTX8IZ	MT	DTT
DMTX8IZ	MA	Modulator
DMTX8IZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMTX8IZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DMMIHSO	DI	DMMIHSO
DMMIHSO	DN	ENERGI-F701
DMMIHSO	MI	TTLAFZV
DMMIHSO	MN	AMP-activated protein kinase (AMPK)
DMMIHSO	MT	DTT
DMMIHSO	MA	Activator
DMMIHSO	RN	Clinical pipeline report, company report or official report of Energenesis Biomedical.
DMMIHSO	RU	https://www.energenesis-biomedical.com/_en/tech_detail.php?id=186

DM96NCR	DI	DM96NCR
DM96NCR	DN	Eniluracil
DM96NCR	MI	TTZPS91
DM96NCR	MN	Dihydrothymine dehydrogenase (DPYD)
DM96NCR	MT	DTT
DM96NCR	MA	Modulator
DM96NCR	RN	Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
DM96NCR	RU	https://pubmed.ncbi.nlm.nih.gov/11060767

DMJZVPB	DI	DMJZVPB
DMJZVPB	DN	ENMD-2076
DMJZVPB	MI	TTPS3C0
DMJZVPB	MN	Aurora kinase A (AURKA)
DMJZVPB	MT	DTT
DMJZVPB	MA	Inhibitor
DMJZVPB	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMJZVPB	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMJZVPB	DI	DMJZVPB
DMJZVPB	DN	ENMD-2076
DMJZVPB	MI	TTU8W4S
DMJZVPB	MN	Protein kinase (PK)
DMJZVPB	MT	DTT
DMJZVPB	MA	Inhibitor
DMJZVPB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJZVPB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDS20X	DI	DMDS20X
DMDS20X	DN	Enoblituzumab
DMDS20X	MI	TT6CQUM
DMDS20X	MN	B7 homolog 3 (CD276)
DMDS20X	MT	DTT
DMDS20X	MA	Inhibitor
DMDS20X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDS20X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLPRZJ	DI	DMLPRZJ
DMLPRZJ	DN	Ensaculin hydrochloride
DMLPRZJ	MI	TTSQIFT
DMLPRZJ	MN	5-HT 1A receptor (HTR1A)
DMLPRZJ	MT	DTT
DMLPRZJ	MA	Modulator
DMLPRZJ	RN	Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58.
DMLPRZJ	RU	https://pubmed.ncbi.nlm.nih.gov/12177685

DM69NF1	DI	DM69NF1
DM69NF1	DN	EP-101
DM69NF1	MI	TTOXS3C
DM69NF1	MN	Muscarinic acetylcholine receptor (CHRM)
DM69NF1	MT	DTT
DM69NF1	MA	Antagonist
DM69NF1	RN	Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17.
DM69NF1	RU	https://pubmed.ncbi.nlm.nih.gov/23274274

DMPC4EK	DI	DMPC4EK
DMPC4EK	DN	EP-217609
DMPC4EK	MI	TT6L509
DMPC4EK	MN	Coagulation factor IIa (F2)
DMPC4EK	MT	DTT
DMPC4EK	MA	Modulator
DMPC4EK	RN	Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
DMPC4EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22144183

DMPC4EK	DI	DMPC4EK
DMPC4EK	DN	EP-217609
DMPC4EK	MI	TTCIHJA
DMPC4EK	MN	Coagulation factor Xa (F10)
DMPC4EK	MT	DTT
DMPC4EK	MA	Modulator
DMPC4EK	RN	Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95.
DMPC4EK	RU	https://www.ncbi.nlm.nih.gov/pubmed/22144183

DMZT7EP	DI	DMZT7EP
DMZT7EP	DN	EPI 589
DMZT7EP	MI	TTIB5LO
DMZT7EP	MN	Quinone reductase (NQO)
DMZT7EP	MT	DTT
DMZT7EP	MA	Modulator
DMZT7EP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZT7EP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWK26Q	DI	DMWK26Q
DMWK26Q	DN	EPX-200
DMWK26Q	MI	TT85JO3
DMWK26Q	MN	5-HT receptor (5HTR)
DMWK26Q	MT	DTT
DMWK26Q	MA	Modulator
DMWK26Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWK26Q	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMUXDGZ	DI	DMUXDGZ
DMUXDGZ	DN	EPX-300
DMUXDGZ	MI	TT85JO3
DMUXDGZ	MN	5-HT receptor (5HTR)
DMUXDGZ	MT	DTT
DMUXDGZ	MA	Modulator
DMUXDGZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUXDGZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMD4YRG	DI	DMD4YRG
DMD4YRG	DN	EQ-917
DMD4YRG	MI	TTGTQHC
DMD4YRG	MN	DNA topoisomerase I (TOP1)
DMD4YRG	MT	DTT
DMD4YRG	MA	Inhibitor
DMD4YRG	RN	The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200.
DMD4YRG	RU	https://pubmed.ncbi.nlm.nih.gov/20566426

DMCEPUA	DI	DMCEPUA
DMCEPUA	DN	ERB-041
DMCEPUA	MI	TTOM3J0
DMCEPUA	MN	Estrogen receptor beta (ESR2)
DMCEPUA	MT	DTT
DMCEPUA	MA	Agonist
DMCEPUA	RN	Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
DMCEPUA	RU	https://pubmed.ncbi.nlm.nih.gov/24217507

DMU1XZD	DI	DMU1XZD
DMU1XZD	DN	Erteberel
DMU1XZD	MI	TTOM3J0
DMU1XZD	MN	Estrogen receptor beta (ESR2)
DMU1XZD	MT	DTT
DMU1XZD	MA	Agonist
DMU1XZD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
DMU1XZD	RU	http://adisinsight.springer.com/drugs/800031986

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TT6EO5L
DM5Z3VP	MN	Erbb2 tyrosine kinase receptor (HER2)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TTZAT79
DM5Z3VP	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DM5Z3VP	DI	DM5Z3VP
DM5Z3VP	DN	Ertumaxomab
DM5Z3VP	MI	TTV3XPL
DM5Z3VP	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DM5Z3VP	MT	DTT
DM5Z3VP	RN	Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
DM5Z3VP	RU	https://pubmed.ncbi.nlm.nih.gov/22820509

DMYZWDC	DI	DMYZWDC
DMYZWDC	DN	ESBA-105
DMYZWDC	MI	TTF8CQI
DMYZWDC	MN	Tumor necrosis factor (TNF)
DMYZWDC	MT	DTT
DMYZWDC	RN	Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8.
DMYZWDC	RU	https://pubmed.ncbi.nlm.nih.gov/18757508

DMTB63Q	DI	DMTB63Q
DMTB63Q	DN	Estetrol
DMTB63Q	MI	TTZAYWL
DMTB63Q	MN	Estrogen receptor (ESR)
DMTB63Q	MT	DTT
DMTB63Q	MA	Modulator
DMTB63Q	RN	Clinical pipeline report, company report or official report of Pantarhei Bioscience.
DMTB63Q	RU	http://pantarheibio.com/pipeline/estetrol.htm

DM71BZV	DI	DM71BZV
DM71BZV	DN	Etamicastat
DM71BZV	MI	TTYIP79
DM71BZV	MN	Dopamine beta hydroxylase (DBH)
DM71BZV	MT	DTT
DM71BZV	MA	Inhibitor
DM71BZV	RN	Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42.
DM71BZV	RU	https://pubmed.ncbi.nlm.nih.gov/21171669

DMOCID7	DI	DMOCID7
DMOCID7	DN	Etazolate
DMOCID7	MI	TTEX6LM
DMOCID7	MN	GABA(A) receptor gamma-3 (GABRG3)
DMOCID7	MT	DTT
DMOCID7	MA	Modulator
DMOCID7	RN	Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008 Jul;106(1):392-404.
DMOCID7	RU	https://pubmed.ncbi.nlm.nih.gov/18397369

DM68K39	DI	DM68K39
DM68K39	DN	ETIPREDNOL DICLOACETATE
DM68K39	MI	TTYRL6O
DM68K39	MN	Glucocorticoid receptor (NR3C1)
DM68K39	MT	DTT
DM68K39	MA	Modulator
DM68K39	RN	Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.Int J Inflam.2012;2012:789623.
DM68K39	RU	https://www.ncbi.nlm.nih.gov/pubmed/22536546

DMV96BY	DI	DMV96BY
DMV96BY	DN	ETS-6218
DMV96BY	MI	TT7CXIM
DMV96BY	MN	Histamine receptor (HR)
DMV96BY	MT	DTT
DMV96BY	MA	Modulator
DMV96BY	RN	Clinical pipeline report, company report or official report of e-Therapeutics.
DMV96BY	RU	http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf

DMZOA2L	DI	DMZOA2L
DMZOA2L	DN	ETX-9101
DMZOA2L	MI	TT7CXIM
DMZOA2L	MN	Histamine receptor (HR)
DMZOA2L	MT	DTT
DMZOA2L	MA	Modulator
DMZOA2L	RN	Clinical pipeline report, company report or official report of e-Therapeutics.
DMZOA2L	RU	http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf

DM1FCDH	DI	DM1FCDH
DM1FCDH	DN	EV-077
DM1FCDH	MI	TTKNWZ4
DM1FCDH	MN	Thromboxane-A synthase (TBXAS1)
DM1FCDH	MT	DTT
DM1FCDH	MA	Modulator
DM1FCDH	RN	Company report (Pharmaceuticalintelligence)
DM1FCDH	RU	http://pharmaceuticalintelligence.com/tag/diabetic-nephropathy/

DMWB94K	DI	DMWB94K
DMWB94K	DN	Evenamide
DMWB94K	MI	TTIG65Q
DMWB94K	MN	Voltage-gated sodium channel (Nav)
DMWB94K	MT	DTT
DMWB94K	MA	Blocker
DMWB94K	RN	Clinical pipeline report, company report or official report of Newron Pharmaceuticals.
DMWB94K	RU	https://www.newron.com/science#evenamide

DM8QXEY	DI	DM8QXEY
DM8QXEY	DN	Evt201
DM8QXEY	MI	TTCI43M
DM8QXEY	MN	GABA(A) receptor (GABAR)
DM8QXEY	MT	DTT
DM8QXEY	MA	Modulator
DM8QXEY	RN	The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64.
DM8QXEY	RU	https://pubmed.ncbi.nlm.nih.gov/19345644

DMQGBM1	DI	DMQGBM1
DMQGBM1	DN	EVT-201
DMQGBM1	MI	TT1MPAY
DMQGBM1	MN	GABA(A) receptor alpha-1 (GABRA1)
DMQGBM1	MT	DTT
DMQGBM1	MA	Modulator
DMQGBM1	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMQGBM1	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMQGBM1	DI	DMQGBM1
DMQGBM1	DN	EVT-201
DMQGBM1	MI	TTEX6LM
DMQGBM1	MN	GABA(A) receptor gamma-3 (GABRG3)
DMQGBM1	MT	DTT
DMQGBM1	MA	Modulator
DMQGBM1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMQGBM1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM73XNG	DI	DM73XNG
DM73XNG	DN	EVT302
DM73XNG	MI	TTGP7BY
DM73XNG	MN	Monoamine oxidase type B (MAO-B)
DM73XNG	MT	DTT
DM73XNG	MA	Inhibitor
DM73XNG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM73XNG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4FBUH	DI	DM4FBUH
DM4FBUH	DN	EXC 001
DM4FBUH	MI	TTCJVNE
DM4FBUH	MN	CTGF messenger RNA (CTGF mRNA)
DM4FBUH	MT	DTT
DM4FBUH	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DM4FBUH	RU	http://www.isispharm.com/index.htm

DMC1I56	DI	DMC1I56
DMC1I56	DN	Exherin
DMC1I56	MI	TT1WS0T
DMC1I56	MN	Neural cadherin (CDH2)
DMC1I56	MT	DTT
DMC1I56	MA	Binder
DMC1I56	RN	Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5.
DMC1I56	RU	https://pubmed.ncbi.nlm.nih.gov/19190075

DM5PBLM	DI	DM5PBLM
DM5PBLM	DN	EYP001
DM5PBLM	MI	TTS4UGC
DM5PBLM	MN	Farnesoid X-activated receptor (FXR)
DM5PBLM	MT	DTT
DM5PBLM	MA	Agonist
DM5PBLM	RN	Clinical pipeline report, company report or official report of ENYO Pharma.
DM5PBLM	RU	http://www.enyopharma.com/pipeline/eyp001-in-nash/

DM2L9CO	DI	DM2L9CO
DM2L9CO	DN	Ezatiostat
DM2L9CO	MI	TT40K12
DM2L9CO	MN	Glutathione S-transferase P (GSTP1)
DM2L9CO	MT	DTT
DM2L9CO	MA	Modulator
DM2L9CO	RN	National Cancer Institute Drug Dictionary (drug id 485244).
DM2L9CO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=485244

DMJ4BKT	DI	DMJ4BKT
DMJ4BKT	DN	F-16-IL-2 fusion protein
DMJ4BKT	MI	TTUCPMY
DMJ4BKT	MN	Tenascin (TNC)
DMJ4BKT	MT	DTT
DMJ4BKT	MA	Modulator
DMJ4BKT	RN	National Cancer Institute Drug Dictionary (drug id 674718).
DMJ4BKT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674718

DMKP3SJ	DI	DMKP3SJ
DMKP3SJ	DN	F-351
DMKP3SJ	MI	TTRAXK5
DMKP3SJ	MN	Aminotransferase (AT)
DMKP3SJ	MT	DTT
DMKP3SJ	MA	Inhibitor
DMKP3SJ	RN	Expansion of the clavulanic acid gene cluster: identification and in vivo functional analysis of three new genes required for biosynthesis of clavulanic acid by Streptomyces clavuligerus. J Bacteriol. 2000 Jul;182(14):4087-95.
DMKP3SJ	RU	https://pubmed.ncbi.nlm.nih.gov/10869089

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TTTWS2G
DM6UQNW	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TTI3NXG
DM6UQNW	MN	Human immunodeficiency virus Matrix p17 (HIV MA)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TT4NXYM
DM6UQNW	MN	Human immunodeficiency virus Negative factor (HIV nef)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DM6UQNW	DI	DM6UQNW
DM6UQNW	DN	F4co vaccine
DM6UQNW	MI	TT84ETX
DM6UQNW	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM6UQNW	MT	DTT
DM6UQNW	RN	EP patent application no. 2621528, Vaccine.
DM6UQNW	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1

DMDNJ18	DI	DMDNJ18
DMDNJ18	DN	F-627
DMDNJ18	MI	TT5TQ2W
DMDNJ18	MN	Granulocyte colony-stimulating factor (CSF3)
DMDNJ18	MT	DTT
DMDNJ18	MA	Modulator
DMDNJ18	RN	Clinical pipeline report, company report or official report of Generon (Shanghai) Corporation Ltd.
DMDNJ18	RU	http://www.generonbiomed.com/html/en/index.php?ac=article&at=list&tid=29

DMBFPO1	DI	DMBFPO1
DMBFPO1	DN	F-8-IL-10 fusion protein
DMBFPO1	MI	TTT0Q1F
DMBFPO1	MN	Interleukin-10 (IL10)
DMBFPO1	MT	DTT
DMBFPO1	MA	Modulator
DMBFPO1	RN	Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
DMBFPO1	RU	https://pubmed.ncbi.nlm.nih.gov/19781067

DM2CUS0	DI	DM2CUS0
DM2CUS0	DN	F901318
DM2CUS0	MI	TTTSUI2
DM2CUS0	MN	Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH)
DM2CUS0	MT	DTT
DM2CUS0	MA	Inhibitor
DM2CUS0	RN	Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18.
DM2CUS0	RU	https://pubmed.ncbi.nlm.nih.gov/29891595

DMXB6KG	DI	DMXB6KG
DMXB6KG	DN	FAD-104
DMXB6KG	MI	TTUTN1I
DMXB6KG	MN	Human Deoxyribonucleic acid (hDNA)
DMXB6KG	MT	DTT
DMXB6KG	MA	Binder
DMXB6KG	RN	Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65.
DMXB6KG	RU	https://pubmed.ncbi.nlm.nih.gov/1694165

DM6RKG3	DI	DM6RKG3
DM6RKG3	DN	Fadolmidine
DM6RKG3	MI	TTQ8AFT
DM6RKG3	MN	Adrenergic receptor Alpha-2 (ADRA2)
DM6RKG3	MT	DTT
DM6RKG3	MA	Agonist
DM6RKG3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RKG3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6RKG3	DI	DM6RKG3
DM6RKG3	DN	Fadolmidine
DM6RKG3	MI	TT2NUT5
DM6RKG3	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM6RKG3	MT	DTT
DM6RKG3	MA	Agonist
DM6RKG3	RN	Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26.
DM6RKG3	RU	https://pubmed.ncbi.nlm.nih.gov/15179442

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DE6OQ3W
DMSFWT7	MN	Cytochrome P450 1A1 (CYP1A1)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DEJGDUW
DMSFWT7	MN	Cytochrome P450 1A2 (CYP1A2)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DE4LYSA
DMSFWT7	MN	Cytochrome P450 3A4 (CYP3A4)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	DEIBDNY
DMSFWT7	MN	Cytochrome P450 3A5 (CYP3A5)
DMSFWT7	MT	DME
DMSFWT7	MA	Metabolism
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	http://www.ncbi.nlm.nih.gov/pubmed/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTGJCWZ
DMSFWT7	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TT8FYO9
DMSFWT7	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTI7421
DMSFWT7	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTX41N9
DMSFWT7	MN	Tyrosine-protein kinase Kit (KIT)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TT2Q6G1
DMSFWT7	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTUTJGQ
DMSFWT7	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DMSFWT7	DI	DMSFWT7
DMSFWT7	DN	Famitinib
DMSFWT7	MI	TTDCBX5
DMSFWT7	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMSFWT7	MT	DTT
DMSFWT7	MA	Inhibitor
DMSFWT7	RN	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
DMSFWT7	RU	https://pubmed.ncbi.nlm.nih.gov/23126373

DM563NC	DI	DM563NC
DM563NC	DN	Fasitibant chloride
DM563NC	MI	TTGY8IW
DM563NC	MN	B2 bradykinin receptor (BDKRB2)
DM563NC	MT	DTT
DM563NC	MA	Antagonist
DM563NC	RN	Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10.
DM563NC	RU	https://pubmed.ncbi.nlm.nih.gov/22251015

DMR3952	DI	DMR3952
DMR3952	DN	FBS-0701
DMR3952	MI	TTQO71U
DMR3952	MN	Hemoglobin (HB)
DMR3952	MT	DTT
DMR3952	MA	Modulator
DMR3952	RN	A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
DMR3952	RU	https://pubmed.ncbi.nlm.nih.gov/22919029

DM3CVHQ	DI	DM3CVHQ
DM3CVHQ	DN	FE-202158
DM3CVHQ	MI	TT4TFGN
DM3CVHQ	MN	Vasopressin V1a receptor (V1AR)
DM3CVHQ	MT	DTT
DM3CVHQ	MA	Agonist
DM3CVHQ	RN	The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014 Jul;42(7):e525-33.
DM3CVHQ	RU	https://pubmed.ncbi.nlm.nih.gov/24674922

DMDGZ1C	DI	DMDGZ1C
DMDGZ1C	DN	FE-202767
DMDGZ1C	MI	TTSCIUP
DMDGZ1C	MN	Oxytocin receptor (OTR)
DMDGZ1C	MT	DTT
DMDGZ1C	MA	Agonist
DMDGZ1C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
DMDGZ1C	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DE5IED8
DMICMXE	MN	Cytochrome P450 2C9 (CYP2C9)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DECB0K3
DMICMXE	MN	Cytochrome P450 2D6 (CYP2D6)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DE4LYSA
DMICMXE	MN	Cytochrome P450 3A4 (CYP3A4)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	TT0OV9N
DMICMXE	MN	Haematin (HA)
DMICMXE	MT	DTT
DMICMXE	MA	Inhibitor
DMICMXE	RN	Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005 May-Jun;2(3):185-93.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/15934779

DMICMXE	DI	DMICMXE
DMICMXE	DN	Ferroquine
DMICMXE	MI	DEGTFWK
DMICMXE	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMICMXE	MT	DME
DMICMXE	MA	Metabolism
DMICMXE	RN	In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
DMICMXE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16415117

DMJX2P4	DI	DMJX2P4
DMJX2P4	DN	Fezakinumab
DMJX2P4	MI	TTLDX4N
DMJX2P4	MN	Interleukin-22 (IL22)
DMJX2P4	MT	DTT
DMJX2P4	RN	Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
DMJX2P4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/

DM7RYL4	DI	DM7RYL4
DM7RYL4	DN	FG-2216
DM7RYL4	MI	TTJQFBG
DM7RYL4	MN	HIF-prolyl hydroxylase (HPH)
DM7RYL4	MT	DTT
DM7RYL4	MA	Modulator
DM7RYL4	RN	Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
DM7RYL4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014028

DMXMC8I	DI	DMXMC8I
DMXMC8I	DN	FGF-1
DMXMC8I	MI	TTRLW2X
DMXMC8I	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMXMC8I	MT	DTT
DMXMC8I	MA	Binder
DMXMC8I	RN	Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70.
DMXMC8I	RU	https://pubmed.ncbi.nlm.nih.gov/12085177

DMCIGRB	DI	DMCIGRB
DMCIGRB	DN	Fialuridine
DMCIGRB	MI	TTIU7X1
DMCIGRB	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMCIGRB	MT	DTT
DMCIGRB	MA	Modulator
DMCIGRB	RN	Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7.
DMCIGRB	RU	https://pubmed.ncbi.nlm.nih.gov/8622980

DMG65WH	DI	DMG65WH
DMG65WH	DN	Ficlatuzumab
DMG65WH	MI	TT4V2JM
DMG65WH	MN	Hepatocyte growth factor (HGF)
DMG65WH	MT	DTT
DMG65WH	MA	Inhibitor
DMG65WH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG65WH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNSYXB	DI	DMNSYXB
DMNSYXB	DN	Filibuvir
DMNSYXB	MI	TTMVBWH
DMNSYXB	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMNSYXB	MT	DTT
DMNSYXB	MA	Inhibitor
DMNSYXB	RN	Clinical pipeline report, company report or official report of Pfizer (2011).
DMNSYXB	RU	http://www.pfizer.com/home/

DMG439E	DI	DMG439E
DMG439E	DN	Fipamezole
DMG439E	MI	TTQ8AFT
DMG439E	MN	Adrenergic receptor Alpha-2 (ADRA2)
DMG439E	MT	DTT
DMG439E	MA	Antagonist
DMG439E	RN	Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
DMG439E	RU	https://pubmed.ncbi.nlm.nih.gov/16939381

DMW2QYT	DI	DMW2QYT
DMW2QYT	DN	Firategrast
DMW2QYT	MI	TT6S84X
DMW2QYT	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMW2QYT	MT	DTT
DMW2QYT	MA	Modulator
DMW2QYT	RN	Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9.
DMW2QYT	RU	https://www.ncbi.nlm.nih.gov/pubmed/22226929

DMJSD5W	DI	DMJSD5W
DMJSD5W	DN	FK-070
DMJSD5W	MI	TT2O84V
DMJSD5W	MN	Thromboxane A2 receptor (TBXA2R)
DMJSD5W	MT	DTT
DMJSD5W	MA	Modulator
DMJSD5W	RN	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
DMJSD5W	RU	https://pubmed.ncbi.nlm.nih.gov/8794987

DMJSD5W	DI	DMJSD5W
DMJSD5W	DN	FK-070
DMJSD5W	MI	TTKNWZ4
DMJSD5W	MN	Thromboxane-A synthase (TBXAS1)
DMJSD5W	MT	DTT
DMJSD5W	MA	Modulator
DMJSD5W	RN	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
DMJSD5W	RU	https://pubmed.ncbi.nlm.nih.gov/8794987

DMEL15U	DI	DMEL15U
DMEL15U	DN	FK-143
DMEL15U	MI	TT2A0DR
DMEL15U	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMEL15U	MT	DTT
DMEL15U	MA	Modulator
DMEL15U	RN	FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63.
DMEL15U	RU	https://www.ncbi.nlm.nih.gov/pubmed/7734404

DML5AE4	DI	DML5AE4
DML5AE4	DN	FK-3311
DML5AE4	MI	TTVKILB
DML5AE4	MN	Prostaglandin G/H synthase 2 (COX-2)
DML5AE4	MT	DTT
DML5AE4	MA	Modulator
DML5AE4	RN	Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80.
DML5AE4	RU	https://pubmed.ncbi.nlm.nih.gov/17613692

DMKVXYS	DI	DMKVXYS
DMKVXYS	DN	FK-409
DMKVXYS	MI	TTWNFC2
DMKVXYS	MN	Soluble guanylyl cyclase (GUCY2D)
DMKVXYS	MT	DTT
DMKVXYS	MA	Modulator
DMKVXYS	RN	Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993 Aug 15;246(3):205-12.
DMKVXYS	RU	https://www.ncbi.nlm.nih.gov/pubmed/7901040

DMGROQP	DI	DMGROQP
DMGROQP	DN	FK-505
DMGROQP	MI	TTFH2RS
DMGROQP	MN	FK506-binding protein (FKBP)
DMGROQP	MT	DTT
DMGROQP	MA	Modulator
DMGROQP	RN	Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632.
DMGROQP	RU	http://circres.ahajournals.org/content/84/6/623.full.html

DMY61TJ	DI	DMY61TJ
DMY61TJ	DN	FK-614
DMY61TJ	MI	TTZMAO3
DMY61TJ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMY61TJ	MT	DTT
DMY61TJ	MA	Agonist
DMY61TJ	RN	FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8.
DMY61TJ	RU	https://pubmed.ncbi.nlm.nih.gov/16125538

DMV0MZ3	DI	DMV0MZ3
DMV0MZ3	DN	FK-962
DMV0MZ3	MI	TTOMNR9
DMV0MZ3	MN	Somatostatin receptor (SSTR)
DMV0MZ3	MT	DTT
DMV0MZ3	MA	Modulator
DMV0MZ3	RN	FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
DMV0MZ3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11172755

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TTSQIFT
DM2O7NM	MN	5-HT 1A receptor (HTR1A)
DM2O7NM	MT	DTT
DM2O7NM	MA	Modulator
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TT6MSOK
DM2O7NM	MN	5-HT 1D receptor (HTR1D)
DM2O7NM	MT	DTT
DM2O7NM	MA	Agonist
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM2O7NM	DI	DM2O7NM
DM2O7NM	DN	FKB01MD
DM2O7NM	MI	TTYSN63
DM2O7NM	MN	5-HT 2 receptor (5HT2R)
DM2O7NM	MT	DTT
DM2O7NM	MA	Inhibitor
DM2O7NM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2O7NM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMPXH7N	DI	DMPXH7N
DMPXH7N	DN	FKW00GA
DMPXH7N	MI	TTSQIFT
DMPXH7N	MN	5-HT 1A receptor (HTR1A)
DMPXH7N	MT	DTT
DMPXH7N	MA	Antagonist
DMPXH7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXH7N	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMPXH7N	DI	DMPXH7N
DMPXH7N	DN	FKW00GA
DMPXH7N	MI	TTJQOD7
DMPXH7N	MN	5-HT 2A receptor (HTR2A)
DMPXH7N	MT	DTT
DMPXH7N	MA	Antagonist
DMPXH7N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPXH7N	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DTI7UX6
DMKSUOI	MN	Breast cancer resistance protein (ABCG2)
DMKSUOI	MT	DTP
DMKSUOI	MA	Substrate
DMKSUOI	RN	The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
DMKSUOI	RU	http://www.ncbi.nlm.nih.gov/pubmed/22778153

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TTMBO1Z
DMKSUOI	MN	Cyclin-dependent kinase (CDK)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMKSUOI	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TT1LVF2
DMKSUOI	MN	Cyclin-dependent kinase 9 (CDK9)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKSUOI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	TT31JXP
DMKSUOI	MN	Myophosphorylase (PYGM)
DMKSUOI	MT	DTT
DMKSUOI	MA	Inhibitor
DMKSUOI	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMKSUOI	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DT3D8F0
DMKSUOI	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMKSUOI	MT	DTP
DMKSUOI	MA	Substrate
DMKSUOI	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMKSUOI	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMKSUOI	DI	DMKSUOI
DMKSUOI	DN	Flavopiridol
DMKSUOI	MI	DEYGVN4
DMKSUOI	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMKSUOI	MT	DME
DMKSUOI	MA	Metabolism
DMKSUOI	RN	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
DMKSUOI	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429

DMCN4H6	DI	DMCN4H6
DMCN4H6	DN	Flezelastine
DMCN4H6	MI	TTEWNM1
DMCN4H6	MN	IL-1 synthesis/release (IL-1 synth/rele)
DMCN4H6	MT	DTT
DMCN4H6	MA	Modulator
DMCN4H6	RN	Effects of flezelastine and its enantiomers on LPS-induced IL-1 beta generation in vitro and LPS-induced pyrexia in vivo. Agents Actions. 1994 Mar;41(1-2):99-100.
DMCN4H6	RU	https://pubmed.ncbi.nlm.nih.gov/7915872

DMVR6OM	DI	DMVR6OM
DMVR6OM	DN	Flotetuzumab
DMVR6OM	MI	TTENHJ0
DMVR6OM	MN	Interleukin 3 receptor alpha (IL3RA)
DMVR6OM	MT	DTT
DMVR6OM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVR6OM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMMQ1YU	DI	DMMQ1YU
DMMQ1YU	DN	FLUASTERONE
DMMQ1YU	MI	TT3V81G
DMMQ1YU	MN	Nuclear receptor unspecific (NR)
DMMQ1YU	MT	DTT
DMMQ1YU	MA	Modulator
DMMQ1YU	RN	Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002 Jun 14;277(24):21379-88.
DMMQ1YU	RU	https://pubmed.ncbi.nlm.nih.gov/11934890

DME01HT	DI	DME01HT
DME01HT	DN	Fluciclatide F-18
DME01HT	MI	TT69TQN
DME01HT	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DME01HT	MT	DTT
DME01HT	MA	Modulator
DME01HT	RN	Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22.
DME01HT	RU	https://www.ncbi.nlm.nih.gov/pubmed/19091899

DM0G5O6	DI	DM0G5O6
DM0G5O6	DN	Flumatinib
DM0G5O6	MI	TT3PJMV
DM0G5O6	MN	Tyrosine-protein kinase ABL1 (ABL)
DM0G5O6	MT	DTT
DM0G5O6	MA	Inhibitor
DM0G5O6	RN	Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
DM0G5O6	RU	https://pubmed.ncbi.nlm.nih.gov/24205792

DMCEUOH	DI	DMCEUOH
DMCEUOH	DN	Fluoropeptide vaccine
DMCEUOH	MI	TTN2JFW
DMCEUOH	MN	T-cell surface glycoprotein CD4 (CD4)
DMCEUOH	MT	DTT
DMCEUOH	RN	A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
DMCEUOH	RU	https://pubmed.ncbi.nlm.nih.gov/24928790

DMCEUOH	DI	DMCEUOH
DMCEUOH	DN	Fluoropeptide vaccine
DMCEUOH	MI	TTMHA6L
DMCEUOH	MN	T-cell surface glycoprotein CD8 (CD8)
DMCEUOH	MT	DTT
DMCEUOH	RN	A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
DMCEUOH	RU	https://pubmed.ncbi.nlm.nih.gov/24928790

DMPBV9D	DI	DMPBV9D
DMPBV9D	DN	Flupirtine
DMPBV9D	MI	TTQ29KF
DMPBV9D	MN	Voltage-gated potassium channel Kv7 (KCNQ)
DMPBV9D	MT	DTT
DMPBV9D	MA	Modulator
DMPBV9D	RN	Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.
DMPBV9D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743843/

DMQX5UA	DI	DMQX5UA
DMQX5UA	DN	FLX-787
DMQX5UA	MI	TTFRV98
DMQX5UA	MN	Melanoma antigen gp75 (TYRP1)
DMQX5UA	MT	DTT
DMQX5UA	MA	Activator
DMQX5UA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQX5UA	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQX5UA	DI	DMQX5UA
DMQX5UA	DN	FLX-787
DMQX5UA	MI	TT79AOF
DMQX5UA	MN	Transient receptor potential channel (TRP channel)
DMQX5UA	MT	DTT
DMQX5UA	MA	Agonist
DMQX5UA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQX5UA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMB9ADM	DI	DMB9ADM
DMB9ADM	DN	FolateImmune
DMB9ADM	MI	TTVC37M
DMB9ADM	MN	Folate receptor alpha (FOLR1)
DMB9ADM	MT	DTT
DMB9ADM	MA	Modulator
DMB9ADM	RN	Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91.
DMB9ADM	RU	https://pubmed.ncbi.nlm.nih.gov/19738218

DMJNO3D	DI	DMJNO3D
DMJNO3D	DN	Follicle stimulating hormone
DMJNO3D	MI	TT13GFV
DMJNO3D	MN	Follicle stimulating hormone (FSHB)
DMJNO3D	MT	DTT
DMJNO3D	MA	Modulator
DMJNO3D	RN	Company report (Glycotope)
DMJNO3D	RU	http://www.glycotope.com/glycotopes-fully-human-and-glycooptimized-recombinant-fsh-gextm-showed-superior-activity-and-excellent-tolerability-in-a-phase-ii-clinical-trial-for-in-vitro-fertilisation

DMUAXS5	DI	DMUAXS5
DMUAXS5	DN	FP-1039
DMUAXS5	MI	TTRLW2X
DMUAXS5	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMUAXS5	MT	DTT
DMUAXS5	MA	Antagonist
DMUAXS5	RN	FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927.
DMUAXS5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514973/

DMC1F2T	DI	DMC1F2T
DMC1F2T	DN	FP-1097
DMC1F2T	MI	TTZ9SOR
DMC1F2T	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMC1F2T	MT	DTT
DMC1F2T	MA	Antagonist
DMC1F2T	RN	Clinical pipeline report, company report or official report of FemmePharma.
DMC1F2T	RU	http://femmepharma.com/

DMC1F2T	DI	DMC1F2T
DMC1F2T	DN	FP-1097
DMC1F2T	MI	TTYEG6Q
DMC1F2T	MN	Muscarinic acetylcholine receptor M2 (CHRM2)
DMC1F2T	MT	DTT
DMC1F2T	MA	Antagonist
DMC1F2T	RN	Clinical pipeline report, company report or official report of FemmePharma.
DMC1F2T	RU	http://femmepharma.com/

DMXOTMP	DI	DMXOTMP
DMXOTMP	DN	FPI-01
DMXOTMP	MI	TTZ8UT4
DMXOTMP	MN	Wilms tumor protein (WT1)
DMXOTMP	MT	DTT
DMXOTMP	RN	Clinical pipeline report, company report or official report of Formula Pharmaceuticals.
DMXOTMP	RU	http://www.formulapharma.com/fp1_01/default.asp

DMEL5SV	DI	DMEL5SV
DMEL5SV	DN	FR139317
DMEL5SV	MI	TTKRD0G
DMEL5SV	MN	Endothelin A receptor (EDNRA)
DMEL5SV	MT	DTT
DMEL5SV	MA	Antagonist
DMEL5SV	RN	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505.
DMEL5SV	RU	https://pubmed.ncbi.nlm.nih.gov/12147302

DMEL5SV	DI	DMEL5SV
DMEL5SV	DN	FR139317
DMEL5SV	MI	TTZPO1L
DMEL5SV	MN	Substance-P receptor (TACR1)
DMEL5SV	MT	DTT
DMEL5SV	MA	Antagonist
DMEL5SV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEL5SV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMGO45I	DI	DMGO45I
DMGO45I	DN	FR-146687
DMGO45I	MI	TTTU72V
DMGO45I	MN	Steroid 5-alpha-reductase 1 (SRD5A1)
DMGO45I	MT	DTT
DMGO45I	MA	Inhibitor
DMGO45I	RN	Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94.
DMGO45I	RU	https://pubmed.ncbi.nlm.nih.gov/12236849

DMFZ084	DI	DMFZ084
DMFZ084	DN	Fresolimumab
DMFZ084	MI	TTO3HT7
DMFZ084	MN	Transforming growth factor beta (TGFB)
DMFZ084	MT	DTT
DMFZ084	MA	Inhibitor
DMFZ084	RN	Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
DMFZ084	RU	https://pubmed.ncbi.nlm.nih.gov/29476019

DM9ORUW	DI	DM9ORUW
DM9ORUW	DN	FRM-0962
DM9ORUW	MI	TTE4KHA
DM9ORUW	MN	Amyloid beta A4 protein (APP)
DM9ORUW	MT	DTT
DM9ORUW	MA	Modulator
DM9ORUW	RN	Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014
DM9ORUW	RU	http://www.nature.com/scibx/journal/v7/n40/full/scibx.2014.1175.html

DMZLBAW	DI	DMZLBAW
DMZLBAW	DN	Fucoxanthin
DMZLBAW	MI	TTSHAEB
DMZLBAW	MN	NF-kappa-B inhibitor alpha (NFKBIA)
DMZLBAW	MT	DTT
DMZLBAW	MA	Inhibitor
DMZLBAW	RN	Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75.
DMZLBAW	RU	https://pubmed.ncbi.nlm.nih.gov/20868674

DMPQFTA	DI	DMPQFTA
DMPQFTA	DN	Fucoxanthin
DMPQFTA	MI	DTUGYRD
DMPQFTA	MN	P-glycoprotein 1 (ABCB1)
DMPQFTA	MT	DTP
DMPQFTA	MA	Substrate
DMPQFTA	RN	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
DMPQFTA	RU	https://doi.org/10.1016/j.phymed.2012.05.010

DMKHNXA	DI	DMKHNXA
DMKHNXA	DN	G100
DMKHNXA	MI	TTISGCA
DMKHNXA	MN	Toll-like receptor 4 (TLR4)
DMKHNXA	MT	DTT
DMKHNXA	MA	Antagonist
DMKHNXA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKHNXA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO2IT	DI	DMQO2IT
DMQO2IT	DN	G1T38
DMQO2IT	MI	TT0PG8F
DMQO2IT	MN	Cyclin-dependent kinase 4 (CDK4)
DMQO2IT	MT	DTT
DMQO2IT	MA	Inhibitor
DMQO2IT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO2IT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO2IT	DI	DMQO2IT
DMQO2IT	DN	G1T38
DMQO2IT	MI	TTO0FDJ
DMQO2IT	MN	Cyclin-dependent kinase 6 (CDK6)
DMQO2IT	MT	DTT
DMQO2IT	MA	Inhibitor
DMQO2IT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO2IT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQR9I8	DI	DMQR9I8
DMQR9I8	DN	G-202
DMQR9I8	MI	TT9G4N0
DMQR9I8	MN	Glutamate carboxypeptidase II (GCPII)
DMQR9I8	MT	DTT
DMQR9I8	MA	Inhibitor
DMQR9I8	RN	National Cancer Institute Drug Dictionary (drug id 666090).
DMQR9I8	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=666090

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DT342ZG
DMJY2TM	MN	Monocarboxylate transporter 1 (SLC16A1)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
DMJY2TM	RU	https://doi.org/10.1208/s12248-008-9035-6

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DTE3TAW
DMJY2TM	MN	Sodium-coupled monocarboxylate transporter 1 (SLC5A8)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DMJY2TM	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	TT61XTV
DMJY2TM	MN	Sodium-dependent multivitamin transporter (SLC5A6)
DMJY2TM	MT	DTT
DMJY2TM	MA	Modulator
DMJY2TM	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
DMJY2TM	RU	https://www.fda.gov/

DMJY2TM	DI	DMJY2TM
DMJY2TM	DN	Gabapentin enacarbil
DMJY2TM	MI	DTD5Y4G
DMJY2TM	MN	Sodium-dependent multivitamin transporter (SLC5A6)
DMJY2TM	MT	DTP
DMJY2TM	MA	Substrate
DMJY2TM	RN	Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010 May;69(5):498-507.
DMJY2TM	RU	http://www.ncbi.nlm.nih.gov/pubmed/20573085

DMTXCUS	DI	DMTXCUS
DMTXCUS	DN	Galiximab
DMTXCUS	MI	TTFZDNP
DMTXCUS	MN	Activation B7-1 antigen (CD80)
DMTXCUS	MT	DTT
DMTXCUS	RN	Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.
DMTXCUS	RU	https://pubmed.ncbi.nlm.nih.gov/15994148

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTL69WB
DMXBR27	MN	Angiotensin-converting enzyme (ACE)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	DE4LYSA
DMXBR27	MN	Cytochrome P450 3A4 (CYP3A4)
DMXBR27	MT	DME
DMXBR27	MA	Metabolism
DMXBR27	RN	Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos. 1999 Nov;27(11):1254-9.
DMXBR27	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10534309

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TT5TKPM
DMXBR27	MN	Neutral endopeptidase (MME)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	DTUGYRD
DMXBR27	MN	P-glycoprotein 1 (ABCB1)
DMXBR27	MT	DTP
DMXBR27	MA	Substrate
DMXBR27	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMXBR27	RU	https://doi.org/10.1007/s11095-012-0935-x

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTE6THL
DMXBR27	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
DMXBR27	MT	DTT
DMXBR27	MA	Inhibitor
DMXBR27	RN	Interaction of D-600 with the transmembrane domain of the sarcoplasmic reticulum Ca(2+)-ATPase. Am J Physiol Cell Physiol. 2000 Jul;279(1):C166-72.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/10898728

DMXBR27	DI	DMXBR27
DMXBR27	DN	Gallopamil
DMXBR27	MI	TTXHYV6
DMXBR27	MN	Voltage-gated L-type calcium channel (L-CaC)
DMXBR27	MT	DTT
DMXBR27	MA	Blocker
DMXBR27	RN	Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
DMXBR27	RU	https://pubmed.ncbi.nlm.nih.gov/18258561

DMAEWS1	DI	DMAEWS1
DMAEWS1	DN	GAM-501
DMAEWS1	MI	TTQA6SX
DMAEWS1	MN	Platelet-derived growth factor B (PDGFB)
DMAEWS1	MT	DTT
DMAEWS1	MA	Modulator
DMAEWS1	RN	Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9.
DMAEWS1	RU	https://pubmed.ncbi.nlm.nih.gov/19821960

DM2IFJQ	DI	DM2IFJQ
DM2IFJQ	DN	GBL-310
DM2IFJQ	MI	TTVOE6D
DM2IFJQ	MN	Mitogen-activated protein kinase (MAPK)
DM2IFJQ	MT	DTT
DM2IFJQ	MA	Inhibitor
DM2IFJQ	RN	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
DM2IFJQ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045651A1&KC=A1

DM2VO9T	DI	DM2VO9T
DM2VO9T	DN	GBR 830
DM2VO9T	MI	TTL31H0
DM2VO9T	MN	OX40L receptor (CD134)
DM2VO9T	MT	DTT
DM2VO9T	MA	Antagonist
DM2VO9T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2VO9T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMYS6MW	DI	DMYS6MW
DMYS6MW	DN	GCS-100
DMYS6MW	MI	TTX1OI0
DMYS6MW	MN	Galectin (LGALS)
DMYS6MW	MT	DTT
DMYS6MW	MA	Modulator
DMYS6MW	RN	GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48.
DMYS6MW	RU	https://pubmed.ncbi.nlm.nih.gov/20190189

DMY6WUV	DI	DMY6WUV
DMY6WUV	DN	GDC-0077
DMY6WUV	MI	TTHBTOP
DMY6WUV	MN	PI3-kinase gamma (PIK3CG)
DMY6WUV	MT	DTT
DMY6WUV	MA	Inhibitor
DMY6WUV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY6WUV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA9SEY	DI	DMA9SEY
DMA9SEY	DN	GDC-0084
DMA9SEY	MI	TTHBTOP
DMA9SEY	MN	PI3-kinase gamma (PIK3CG)
DMA9SEY	MT	DTT
DMA9SEY	MA	Inhibitor
DMA9SEY	RN	Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.
DMA9SEY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379803/

DM1YAK6	DI	DM1YAK6
DM1YAK6	DN	GDC0941
DM1YAK6	MI	TTHBTOP
DM1YAK6	MN	PI3-kinase gamma (PIK3CG)
DM1YAK6	MT	DTT
DM1YAK6	MA	Inhibitor
DM1YAK6	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DM1YAK6	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMF3MV1	DI	DMF3MV1
DMF3MV1	DN	GDC-0980/RG7422
DMF3MV1	MI	TTHBTOP
DMF3MV1	MN	PI3-kinase gamma (PIK3CG)
DMF3MV1	MT	DTT
DMF3MV1	MA	Modulator
DMF3MV1	RN	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36.
DMF3MV1	RU	https://pubmed.ncbi.nlm.nih.gov/21998291

DMF3MV1	DI	DMF3MV1
DMF3MV1	DN	GDC-0980/RG7422
DMF3MV1	MI	TTCJG29
DMF3MV1	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMF3MV1	MT	DTT
DMF3MV1	MA	Modulator
DMF3MV1	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMF3MV1	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMMQY0O	DI	DMMQY0O
DMMQY0O	DN	GED-0507-34-Levo
DMMQY0O	MI	TTZMAO3
DMMQY0O	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMMQY0O	MT	DTT
DMMQY0O	MA	Agonist
DMMQY0O	RN	PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7.
DMMQY0O	RU	https://pubmed.ncbi.nlm.nih.gov/23651165

DMJN09S	DI	DMJN09S
DMJN09S	DN	GEN-1
DMJN09S	MI	TTG68FB
DMJN09S	MN	Interleukine 12 (IL-12)
DMJN09S	MT	DTT
DMJN09S	MA	Replacement
DMJN09S	RN	Clinical pipeline report, company report or official report of Celsion.
DMJN09S	RU	https://celsion.com/gen-1/

DMO9WU8	DI	DMO9WU8
DMO9WU8	DN	Gepirone
DMO9WU8	MI	DTUGYRD
DMO9WU8	MN	P-glycoprotein 1 (ABCB1)
DMO9WU8	MT	DTP
DMO9WU8	MA	Substrate
DMO9WU8	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMO9WU8	RU	https://doi.org/10.1007/s11095-012-0935-x

DMD3RU8	DI	DMD3RU8
DMD3RU8	DN	GFT14
DMD3RU8	MI	TTJ584C
DMD3RU8	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD3RU8	MT	DTT
DMD3RU8	MA	Agonist
DMD3RU8	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296)
DMD3RU8	RU	http://adisinsight.springer.com/drugs/800024296

DMTY4PG	DI	DMTY4PG
DMTY4PG	DN	GI-4000
DMTY4PG	MI	TTW2R9X
DMTY4PG	MN	GTPase NRas (NRAS)
DMTY4PG	MT	DTT
DMTY4PG	RN	Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10.
DMTY4PG	RU	https://pubmed.ncbi.nlm.nih.gov/25044103

DMQ0XZE	DI	DMQ0XZE
DMQ0XZE	DN	GI-4000 + gemcitabine
DMQ0XZE	MI	TTRHMTC
DMQ0XZE	MN	Mutated KRAS (mKRAS)
DMQ0XZE	MT	DTT
DMQ0XZE	MA	Modulator
DMQ0XZE	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DMQ0XZE	RU	https://www.globeimmune.com/cancer/gi-4000/

DM72O6F	DI	DM72O6F
DM72O6F	DN	GI-6207
DM72O6F	MI	TTY6DTE
DM72O6F	MN	Carcinoembryonic antigen CEA (CD66e)
DM72O6F	MT	DTT
DM72O6F	MA	Modulator
DM72O6F	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DM72O6F	RU	https://www.globeimmune.com/cancer/gi-6207/

DMOMS7R	DI	DMOMS7R
DMOMS7R	DN	GI-6301
DMOMS7R	MI	TTBXAHS
DMOMS7R	MN	T-box transcription factor T (TBXT)
DMOMS7R	MT	DTT
DMOMS7R	RN	Clinical pipeline report, company report or official report of GlobeImmune.
DMOMS7R	RU	https://www.globeimmune.com/cancer/gi-6301/

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	DTI7UX6
DMSKMET	MN	Breast cancer resistance protein (ABCG2)
DMSKMET	MT	DTP
DMSKMET	MA	Substrate
DMSKMET	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMSKMET	RU	https://doi.org/10.2217/14622416.9.8.1005

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	TTGTQHC
DMSKMET	MN	DNA topoisomerase I (TOP1)
DMSKMET	MT	DTT
DMSKMET	MA	Inhibitor
DMSKMET	RN	Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol. 2013 May 15;85(10):1433-40.
DMSKMET	RU	https://pubmed.ncbi.nlm.nih.gov/23466420

DMSKMET	DI	DMSKMET
DMSKMET	DN	Gimatecan
DMSKMET	MI	DT3D8F0
DMSKMET	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMSKMET	MT	DTP
DMSKMET	MA	Substrate
DMSKMET	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMSKMET	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMG3O2Z	DI	DMG3O2Z
DMG3O2Z	DN	Girentuximab I-124
DMG3O2Z	MI	TT2LVK8
DMG3O2Z	MN	Carbonic anhydrase IX (CA-IX)
DMG3O2Z	MT	DTT
DMG3O2Z	MA	Enhancer
DMG3O2Z	RN	Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
DMG3O2Z	RU	https://pubmed.ncbi.nlm.nih.gov/23204838

DMLFSMX	DI	DMLFSMX
DMLFSMX	DN	GK1-399
DMLFSMX	MI	TTDLNGZ
DMLFSMX	MN	Glucokinase (GCK)
DMLFSMX	MT	DTT
DMLFSMX	MA	Inhibitor
DMLFSMX	RN	Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
DMLFSMX	RU	http://vtvtherapeutics.com/pipeline/ttp399

DMOVB3Y	DI	DMOVB3Y
DMOVB3Y	DN	GKT-137831
DMOVB3Y	MI	TTFQVUT
DMOVB3Y	MN	NADPH oxidase (NOX)
DMOVB3Y	MT	DTT
DMOVB3Y	MA	Modulator
DMOVB3Y	RN	Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327.
DMOVB3Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/

DMOVB3Y	DI	DMOVB3Y
DMOVB3Y	DN	GKT-137831
DMOVB3Y	MI	TTQRBSJ
DMOVB3Y	MN	NADPH oxidase 4 (NOX4)
DMOVB3Y	MT	DTT
DMOVB3Y	MA	Modulator
DMOVB3Y	RN	Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327.
DMOVB3Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/

DM17OZM	DI	DM17OZM
DM17OZM	DN	GL-0817
DM17OZM	MI	TTWSKHD
DM17OZM	MN	Melanoma-associated antigen 3 (MAGEA3)
DM17OZM	MT	DTT
DM17OZM	MA	Immunomodulator
DM17OZM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM17OZM	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSVBND	DI	DMSVBND
DMSVBND	DN	Glecaprevir
DMSVBND	MI	DTUGYRD
DMSVBND	MN	P-glycoprotein 1 (ABCB1)
DMSVBND	MT	DTP
DMSVBND	MA	Substrate
DMSVBND	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMSVBND	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMPHCDL	DI	DMPHCDL
DMPHCDL	DN	GLPG-0634
DMPHCDL	MI	TT6DM01
DMPHCDL	MN	Janus kinase 1 (JAK-1)
DMPHCDL	MT	DTT
DMPHCDL	MA	Modulator
DMPHCDL	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMPHCDL	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMXO4T8	DI	DMXO4T8
DMXO4T8	DN	GLPG0974
DMXO4T8	MI	TT0FYAN
DMXO4T8	MN	Free fatty acid receptor 2 (FFAR2)
DMXO4T8	MT	DTT
DMXO4T8	MA	Antagonist
DMXO4T8	RN	Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57.
DMXO4T8	RU	https://pubmed.ncbi.nlm.nih.gov/25380412

DMOCRYB	DI	DMOCRYB
DMOCRYB	DN	GLPG-1837
DMOCRYB	MI	TTRLZHP
DMOCRYB	MN	cAMP-dependent chloride channel (CFTR)
DMOCRYB	MT	DTT
DMOCRYB	MA	Enhancer
DMOCRYB	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMOCRYB	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTSYQGK
DMJ85FS	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22.
DMJ85FS	RU	http://www.ncbi.nlm.nih.gov/pubmed/9188796

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTFI42L
DMJ85FS	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
DMJ85FS	RU	https://doi.org/10.1046/j.1432-1327.1999.00735.x

DMJ85FS	DI	DMJ85FS
DMJ85FS	DN	Glutathione-S-S-glutathione
DMJ85FS	MI	DTQ3ZHF
DMJ85FS	MN	Multidrug resistance-associated protein 3 (ABCC3)
DMJ85FS	MT	DTP
DMJ85FS	MA	Substrate
DMJ85FS	RN	MRP2 and 3 in health and disease. Cancer Lett. 2006 Mar 8;234(1):51-61.
DMJ85FS	RU	https://doi.org/10.1016/j.canlet.2005.05.051

DML6PO5	DI	DML6PO5
DML6PO5	DN	GM-CSF cancer vaccine
DML6PO5	MI	TT6MP2Z
DML6PO5	MN	GMCSFR-alpha (CSF2RA)
DML6PO5	MT	DTT
DML6PO5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DML6PO5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DMLWKZ7	DI	DMLWKZ7
DMLWKZ7	DN	GO-203-2c
DMLWKZ7	MI	TTBHFYQ
DMLWKZ7	MN	Mucin-1 (MUC1)
DMLWKZ7	MT	DTT
DMLWKZ7	MA	Inhibitor
DMLWKZ7	RN	Clinical pipeline report, company report or official report of Genus Oncology.
DMLWKZ7	RU	http://www.genusoncology.com/phase-1-trial-GO-203-2c.php

DMKZN3A	DI	DMKZN3A
DMKZN3A	DN	Golotimod
DMKZN3A	MI	TTH8FZW
DMKZN3A	MN	Signal transducer and activator of transcription 3 (STAT3)
DMKZN3A	MT	DTT
DMKZN3A	MA	Inhibitor
DMKZN3A	RN	National Cancer Institute Drug Dictionary (drug id 617379).
DMKZN3A	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=617379

DMYWA0Z	DI	DMYWA0Z
DMYWA0Z	DN	GORALATIDE
DMYWA0Z	MI	TTLK6DR
DMYWA0Z	MN	Cyclin D1 synthesis (CCND1 synthesis)
DMYWA0Z	MT	DTT
DMYWA0Z	MA	Modulator
DMYWA0Z	RN	Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP. Br J Haematol. 1997 Dec;99(3):692-8.
DMYWA0Z	RU	https://pubmed.ncbi.nlm.nih.gov/9401086

DMJWE3I	DI	DMJWE3I
DMJWE3I	DN	Gossypol
DMJWE3I	MI	TTJGNVC
DMJWE3I	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMJWE3I	MT	DTT
DMJWE3I	MA	Regulator
DMJWE3I	RN	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
DMJWE3I	RU	https://pubmed.ncbi.nlm.nih.gov/16138106

DM38ARE	DI	DM38ARE
DM38ARE	DN	Gp100:209-217(210M) peptide vaccine
DM38ARE	MI	TT8MK59
DM38ARE	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DM38ARE	MT	DTT
DM38ARE	RN	National Cancer Institute Drug Dictionary (drug id 476335).
DM38ARE	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=476335

DMOHAS2	DI	DMOHAS2
DMOHAS2	DN	GPC-3298306
DMOHAS2	MI	TTJTSX4
DMOHAS2	MN	Glypican-3 (GPC3)
DMOHAS2	MT	DTT
DMOHAS2	RN	Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
DMOHAS2	RU	https://pubmed.ncbi.nlm.nih.gov/18974622

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTZ97H5
DMOQ7YI	MN	Phosphodiesterase 4A (PDE4A)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTVIAT9
DMOQ7YI	MN	Phosphodiesterase 4B (PDE4B)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DMOQ7YI	DI	DMOQ7YI
DMOQ7YI	DN	GPD-1116
DMOQ7YI	MI	TTSKMI8
DMOQ7YI	MN	Phosphodiesterase 4D (PDE4D)
DMOQ7YI	MT	DTT
DMOQ7YI	MA	Inhibitor
DMOQ7YI	RN	Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
DMOQ7YI	RU	https://pubmed.ncbi.nlm.nih.gov/17993591

DM64ZYM	DI	DM64ZYM
DM64ZYM	DN	GPI-1485
DM64ZYM	MI	TTMW94E
DM64ZYM	MN	FK506-binding protein 1A (FKBP1A)
DM64ZYM	MT	DTT
DM64ZYM	MA	Binder
DM64ZYM	RN	Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
DM64ZYM	RU	https://pubmed.ncbi.nlm.nih.gov/18991661

DMHNIGB	DI	DMHNIGB
DMHNIGB	DN	GPX-150D
DMHNIGB	MI	TT0IHXV
DMHNIGB	MN	DNA topoisomerase II (TOP2)
DMHNIGB	MT	DTT
DMHNIGB	MA	Modulator
DMHNIGB	RN	Company report (Gem pharmaceuticals)
DMHNIGB	RU	http://www.gempharmaceuticals.com/targeted-therapy-approach.shtml

DMMZQ7V	DI	DMMZQ7V
DMMZQ7V	DN	Granotapide
DMMZQ7V	MI	TTUS1RD
DMMZQ7V	MN	Microsomal triglyceride transfer protein (MTTP)
DMMZQ7V	MT	DTT
DMMZQ7V	MA	Inhibitor
DMMZQ7V	RN	JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther. 2011 Mar;336(3):850-6.
DMMZQ7V	RU	https://pubmed.ncbi.nlm.nih.gov/21139060

DMWXJSZ	DI	DMWXJSZ
DMWXJSZ	DN	GRC-15300
DMWXJSZ	MI	TTMI6F5
DMWXJSZ	MN	Transient receptor potential cation channel V1 (TRPV1)
DMWXJSZ	MT	DTT
DMWXJSZ	MA	Antagonist
DMWXJSZ	RN	The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759.
DMWXJSZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966322/

DM9QF65	DI	DM9QF65
DM9QF65	DN	GR-MD-02
DM9QF65	MI	TTFPQV7
DM9QF65	MN	Galectin-3 (LGALS3)
DM9QF65	MT	DTT
DM9QF65	MA	Inhibitor
DM9QF65	RN	Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481.
DM9QF65	RU	https://pubmed.ncbi.nlm.nih.gov/24367597

DMAHOEP	DI	DMAHOEP
DMAHOEP	DN	GRNVAC1
DMAHOEP	MI	TTUJFD0
DMAHOEP	MN	Telomerase reverse transcriptase (TERT)
DMAHOEP	MT	DTT
DMAHOEP	RN	Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.
DMAHOEP	RU	https://pubmed.ncbi.nlm.nih.gov/21332640

DMHQV6R	DI	DMHQV6R
DMHQV6R	DN	GS-4059
DMHQV6R	MI	TTGM6VW
DMHQV6R	MN	Tyrosine-protein kinase BTK (ATK)
DMHQV6R	MT	DTT
DMHQV6R	MA	Inhibitor
DMHQV6R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHQV6R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBDFN7	DI	DMBDFN7
DMBDFN7	DN	GS-4977
DMBDFN7	MI	TTOQCD8
DMBDFN7	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DMBDFN7	MT	DTT
DMBDFN7	MA	Inhibitor
DMBDFN7	RN	Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.
DMBDFN7	RU	https://pubmed.ncbi.nlm.nih.gov/25531162

DMNABMU	DI	DMNABMU
DMNABMU	DN	GS-4997
DMNABMU	MI	TTOQCD8
DMNABMU	MN	Apoptosis signal-regulating kinase 1 (MAP3K5)
DMNABMU	MT	DTT
DMNABMU	MA	Inhibitor
DMNABMU	RN	Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33.
DMNABMU	RU	https://pubmed.ncbi.nlm.nih.gov/25531162

DMDAHL6	DI	DMDAHL6
DMDAHL6	DN	GS-5806
DMDAHL6	MI	TT57ID8
DMDAHL6	MN	Respiratory syncytial virus protein F (RSV F)
DMDAHL6	MT	DTT
DMDAHL6	MA	Inhibitor
DMDAHL6	RN	Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43.
DMDAHL6	RU	https://pubmed.ncbi.nlm.nih.gov/25574686

DMSL3DX	DI	DMSL3DX
DMSL3DX	DN	GS-5885
DMSL3DX	MI	TTCJ2X8
DMSL3DX	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMSL3DX	MT	DTT
DMSL3DX	MA	Modulator
DMSL3DX	RN	Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46.
DMSL3DX	RU	https://pubmed.ncbi.nlm.nih.gov/24320933

DMSL3DX	DI	DMSL3DX
DMSL3DX	DN	GS-5885
DMSL3DX	MI	DTUGYRD
DMSL3DX	MN	P-glycoprotein 1 (ABCB1)
DMSL3DX	MT	DTP
DMSL3DX	MA	Substrate
DMSL3DX	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DMSL3DX	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMV7ZU0	DI	DMV7ZU0
DMV7ZU0	DN	GS-6624
DMV7ZU0	MI	TTFSUHX
DMV7ZU0	MN	Lysyl oxidase homolog 2 (LOXL2)
DMV7ZU0	MT	DTT
DMV7ZU0	RN	National Cancer Institute Drug Dictionary (drug id 681814).
DMV7ZU0	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681814

DMCZH5B	DI	DMCZH5B
DMCZH5B	DN	GS-9256
DMCZH5B	MI	TT5FNQT
DMCZH5B	MN	Human immunodeficiency virus Protease (HIV PR)
DMCZH5B	MT	DTT
DMCZH5B	MA	Inhibitor
DMCZH5B	RN	Clinical pipeline report, company report or official report of Gilead (2011).
DMCZH5B	RU	http://www.gilead.com/

DMF910Q	DI	DMF910Q
DMF910Q	DN	GS-9451
DMF910Q	MI	TTWXB3E
DMF910Q	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMF910Q	MT	DTT
DMF910Q	MA	Modulator
DMF910Q	RN	Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
DMF910Q	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457362/

DMG5C8D	DI	DMG5C8D
DMG5C8D	DN	GS-9620
DMG5C8D	MI	DE4LYSA
DMG5C8D	MN	Cytochrome P450 3A4 (CYP3A4)
DMG5C8D	MT	DME
DMG5C8D	MA	Metabolism
DMG5C8D	RN	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015 Aug;63(2):320-8.
DMG5C8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25733157

DMG5C8D	DI	DMG5C8D
DMG5C8D	DN	GS-9620
DMG5C8D	MI	TTRJ1K4
DMG5C8D	MN	Toll-like receptor 7 (TLR7)
DMG5C8D	MT	DTT
DMG5C8D	MA	Modulator
DMG5C8D	RN	Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
DMG5C8D	RU	https://pubmed.ncbi.nlm.nih.gov/24133297

DMYU6P5	DI	DMYU6P5
DMYU6P5	DN	GS-9857
DMYU6P5	MI	TTWXB3E
DMYU6P5	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMYU6P5	MT	DTT
DMYU6P5	MA	Inhibitor
DMYU6P5	RN	Clinical pipeline report, company report or official report of Gilead.
DMYU6P5	RU	http://www.gilead.com/research/pipeline

DM9Q2B6	DI	DM9Q2B6
DM9Q2B6	DN	GS-9876
DM9Q2B6	MI	TTOU65C
DM9Q2B6	MN	Tyrosine-protein kinase SYK (SYK)
DM9Q2B6	MT	DTT
DM9Q2B6	MA	Inhibitor
DM9Q2B6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9Q2B6	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMKWCTR	DI	DMKWCTR
DMKWCTR	DN	GS-9973
DMKWCTR	MI	TTOU65C
DMKWCTR	MN	Tyrosine-protein kinase SYK (SYK)
DMKWCTR	MT	DTT
DMKWCTR	MA	Modulator
DMKWCTR	RN	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43.
DMKWCTR	RU	https://pubmed.ncbi.nlm.nih.gov/25696919

DMQGPLO	DI	DMQGPLO
DMQGPLO	DN	GSK-1070806
DMQGPLO	MI	TTRICUF
DMQGPLO	MN	Interleukin-18 (IL18)
DMQGPLO	MT	DTT
DMQGPLO	RN	Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220.
DMQGPLO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059231/

DMDMXKQ	DI	DMDMXKQ
DMDMXKQ	DN	GSK1292263
DMDMXKQ	MI	TT7QNVC
DMDMXKQ	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMDMXKQ	MT	DTT
DMDMXKQ	MA	Modulator
DMDMXKQ	RN	Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494.
DMDMXKQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24699248

DM1EPMF	DI	DM1EPMF
DM1EPMF	DN	GSK1322322
DM1EPMF	MI	TTICO5G
DM1EPMF	MN	Staphylococcus Peptide deformylase (Stap-coc def)
DM1EPMF	MT	DTT
DM1EPMF	MA	Modulator
DM1EPMF	RN	Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36.
DM1EPMF	RU	https://pubmed.ncbi.nlm.nih.gov/25174923

DMA6RBF	DI	DMA6RBF
DMA6RBF	DN	GSK1325756
DMA6RBF	MI	TT30C9G
DMA6RBF	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMA6RBF	MT	DTT
DMA6RBF	MA	Modulator
DMA6RBF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA6RBF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6HBGN	DI	DM6HBGN
DM6HBGN	DN	GSK-1399686
DM6HBGN	MI	TTUWYEA
DM6HBGN	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DM6HBGN	MT	DTT
DM6HBGN	MA	Modulator
DM6HBGN	RN	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015 March; 8(2): 66-82.
DM6HBGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314302/

DMZHB37	DI	DMZHB37
DMZHB37	DN	GSK2110183
DMZHB37	MI	TTWTSCV
DMZHB37	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMZHB37	MT	DTT
DMZHB37	MA	Modulator
DMZHB37	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMZHB37	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMSHE70	DI	DMSHE70
DMSHE70	DN	GSK2141795
DMSHE70	MI	TTAZ05C
DMSHE70	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMSHE70	MT	DTT
DMSHE70	MA	Modulator
DMSHE70	RN	Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7.
DMSHE70	RU	https://pubmed.ncbi.nlm.nih.gov/21572779

DMBWPZJ	DI	DMBWPZJ
DMBWPZJ	DN	GSK2245035
DMBWPZJ	MI	TTRJ1K4
DMBWPZJ	MN	Toll-like receptor 7 (TLR7)
DMBWPZJ	MT	DTT
DMBWPZJ	MA	Modulator
DMBWPZJ	RN	Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
DMBWPZJ	RU	https://pubmed.ncbi.nlm.nih.gov/26044169

DMG7YQL	DI	DMG7YQL
DMG7YQL	DN	GSK2245840
DMG7YQL	MI	TTUF2HO
DMG7YQL	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMG7YQL	MT	DTT
DMG7YQL	MA	Modulator
DMG7YQL	RN	Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52.
DMG7YQL	RU	https://pubmed.ncbi.nlm.nih.gov/25574479

DMLFI7Q	DI	DMLFI7Q
DMLFI7Q	DN	GSK-2251052
DMLFI7Q	MI	TT37GL6
DMLFI7Q	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DMLFI7Q	MT	DTT
DMLFI7Q	MA	Inhibitor
DMLFI7Q	RN	Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98.
DMLFI7Q	RU	https://pubmed.ncbi.nlm.nih.gov/25348524

DMIN0SV	DI	DMIN0SV
DMIN0SV	DN	GSK2269557
DMIN0SV	MI	TTWELHI
DMIN0SV	MN	Stress-activated protein kinase (p38)
DMIN0SV	MT	DTT
DMIN0SV	MA	Inhibitor
DMIN0SV	RN	Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
DMIN0SV	RU	https://pubmed.ncbi.nlm.nih.gov/22765651

DM4BTH8	DI	DM4BTH8
DM4BTH8	DN	GSK2330672
DM4BTH8	MI	TTPI1M5
DM4BTH8	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM4BTH8	MT	DTT
DM4BTH8	MA	Modulator
DM4BTH8	RN	Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114.
DM4BTH8	RU	https://pubmed.ncbi.nlm.nih.gov/23678871

DMB0CXT	DI	DMB0CXT
DMB0CXT	DN	GSK2330811
DMB0CXT	MI	TTIVXSE
DMB0CXT	MN	Oncostatin-M (OSM)
DMB0CXT	MT	DTT
DMB0CXT	MA	Inhibitor
DMB0CXT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB0CXT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMXUCG3	DI	DMXUCG3
DMXUCG3	DN	GSK233705
DMXUCG3	MI	TTH18TF
DMXUCG3	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMXUCG3	MT	DTT
DMXUCG3	MA	Antagonist
DMXUCG3	RN	Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
DMXUCG3	RU	https://pubmed.ncbi.nlm.nih.gov/19265487

DMRA3T2	DI	DMRA3T2
DMRA3T2	DN	GSK2339345
DMRA3T2	MI	TTRK8B9
DMRA3T2	MN	Sodium channel unspecific (NaC)
DMRA3T2	MT	DTT
DMRA3T2	MA	Modulator
DMRA3T2	RN	ClinicalTrials.gov (NCT01494636) The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects. U.S. National Institutes of Health.
DMRA3T2	RU	https://clinicaltrials.gov/ct2/show/NCT01494636

DMBJMZC	DI	DMBJMZC
DMBJMZC	DN	GSK239512
DMBJMZC	MI	TT9JNIC
DMBJMZC	MN	Histamine H3 receptor (H3R)
DMBJMZC	MT	DTT
DMBJMZC	MA	Antagonist
DMBJMZC	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMBJMZC	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMFAU3Z	DI	DMFAU3Z
DMFAU3Z	DN	GSK249320
DMFAU3Z	MI	TT9XFON
DMFAU3Z	MN	Myelin-associated glycoprotein (MAG)
DMFAU3Z	MT	DTT
DMFAU3Z	RN	First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9.
DMFAU3Z	RU	https://pubmed.ncbi.nlm.nih.gov/23267856

DMMAIY2	DI	DMMAIY2
DMMAIY2	DN	GSK-256073
DMMAIY2	MI	TTWNV8U
DMMAIY2	MN	Nicotinic acid receptor (HCAR2)
DMMAIY2	MT	DTT
DMMAIY2	MA	Agonist
DMMAIY2	RN	GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
DMMAIY2	RU	https://pubmed.ncbi.nlm.nih.gov/23701262

DMA2IXQ	DI	DMA2IXQ
DMA2IXQ	DN	GSK2586184
DMA2IXQ	MI	TT6DM01
DMA2IXQ	MN	Janus kinase 1 (JAK-1)
DMA2IXQ	MT	DTT
DMA2IXQ	MA	Modulator
DMA2IXQ	RN	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9.
DMA2IXQ	RU	https://pubmed.ncbi.nlm.nih.gov/25724932

DMU5EVR	DI	DMU5EVR
DMU5EVR	DN	GSK2586881
DMU5EVR	MI	TTUI5H7
DMU5EVR	MN	Angiotensin-converting enzyme 2 (ACE2)
DMU5EVR	MT	DTT
DMU5EVR	MA	Modulator
DMU5EVR	RN	New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42.
DMU5EVR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/

DM7V96W	DI	DM7V96W
DM7V96W	DN	GSK2798745
DM7V96W	MI	TTKP2SU
DM7V96W	MN	Transient receptor potential cation channel V4 (TRPV4)
DM7V96W	MT	DTT
DM7V96W	MA	Antagonist
DM7V96W	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM7V96W	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMCIGRW	DI	DMCIGRW
DMCIGRW	DN	GSK2838232
DMCIGRW	MI	TT5TOX7
DMCIGRW	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMCIGRW	MT	DTT
DMCIGRW	MA	Modulator
DMCIGRW	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
DMCIGRW	RU	http://adisinsight.springer.com/drugs/800037762

DMT5YK7	DI	DMT5YK7
DMT5YK7	DN	GSK2890457
DMT5YK7	MI	TTF5WCR
DMT5YK7	MN	Endogenous gut peptide (EGP)
DMT5YK7	MT	DTT
DMT5YK7	MA	Modulator
DMT5YK7	RN	Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014 Aug;23(8):1055-66.
DMT5YK7	RU	https://pubmed.ncbi.nlm.nih.gov/25000213

DM25YLM	DI	DM25YLM
DM25YLM	DN	GSK2981278
DM25YLM	MI	TTGV6LY
DM25YLM	MN	Nuclear receptor ROR-gamma (RORG)
DM25YLM	MT	DTT
DM25YLM	MA	Agonist
DM25YLM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM25YLM	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM7HNFV	DI	DM7HNFV
DM7HNFV	DN	GSK2982772
DM7HNFV	MI	TTAIQSN
DM7HNFV	MN	Receptor-interacting protein 1 (RIPK1)
DM7HNFV	MT	DTT
DM7HNFV	MA	Inhibitor
DM7HNFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7HNFV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCDAVK	DI	DMCDAVK
DMCDAVK	DN	GSK3036656
DMCDAVK	MI	TT46T5G
DMCDAVK	MN	Mycobacterium Leucine-tRNA ligase (MycB leuS)
DMCDAVK	MT	DTT
DMCDAVK	MA	Inhibitor
DMCDAVK	RN	Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem. 2017 Oct 12;60(19):8011-8026.
DMCDAVK	RU	https://pubmed.ncbi.nlm.nih.gov/28953378

DMEXKF4	DI	DMEXKF4
DMEXKF4	DN	GSK3196165
DMEXKF4	MI	TTNYZG2
DMEXKF4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMEXKF4	MT	DTT
DMEXKF4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEXKF4	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPBK8N	DI	DMPBK8N
DMPBK8N	DN	GSK3228836
DMPBK8N	MI	TTSJVOI
DMPBK8N	MN	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
DMPBK8N	MT	DTT
DMPBK8N	MA	Inhibitor
DMPBK8N	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMPBK8N	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMJRD7A	DI	DMJRD7A
DMJRD7A	DN	GSK3326595
DMJRD7A	MI	TTR1D7X
DMJRD7A	MN	Protein arginine methyltransferase 5 (PRMT5)
DMJRD7A	MT	DTT
DMJRD7A	MA	Inhibitor
DMJRD7A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJRD7A	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMO5JS3	DI	DMO5JS3
DMO5JS3	DN	GSK3389404
DMO5JS3	MI	TTSJVOI
DMO5JS3	MN	Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA)
DMO5JS3	MT	DTT
DMO5JS3	MA	Inhibitor
DMO5JS3	RN	A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801.
DMO5JS3	RU	https://pubmed.ncbi.nlm.nih.gov/30861337

DMMOWT9	DI	DMMOWT9
DMMOWT9	DN	GSK3640254
DMMOWT9	MI	TT5TOX7
DMMOWT9	MN	Human immunodeficiency virus Maturation (HIV Mat)
DMMOWT9	MT	DTT
DMMOWT9	MA	Inhibitor
DMMOWT9	RN	Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671.
DMMOWT9	RU	https://pubmed.ncbi.nlm.nih.gov/33200887

DMV3TO4	DI	DMV3TO4
DMV3TO4	DN	GSK3810109
DMV3TO4	MI	TT2ISQT
DMV3TO4	MN	Human immunodeficiency virus Attachment (HIV att)
DMV3TO4	MT	DTT
DMV3TO4	MA	Inhibitor
DMV3TO4	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMV3TO4	RU	https://viivhealthcare.com/en-us/medicines-in-development/

DMV6SNU	DI	DMV6SNU
DMV6SNU	DN	GSK4069889
DMV6SNU	MI	TT1RWL7
DMV6SNU	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMV6SNU	MT	DTT
DMV6SNU	MA	Inhibitor
DMV6SNU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMV6SNU	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DM3ZL2O	DI	DM3ZL2O
DM3ZL2O	DN	GSK-557296
DM3ZL2O	MI	TTSCIUP
DM3ZL2O	MN	Oxytocin receptor (OTR)
DM3ZL2O	MT	DTT
DM3ZL2O	MA	Antagonist
DM3ZL2O	RN	Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
DM3ZL2O	RU	https://pubmed.ncbi.nlm.nih.gov/23530818

DMEVARK	DI	DMEVARK
DMEVARK	DN	GSK561679
DMEVARK	MI	TT7EFHR
DMEVARK	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMEVARK	MT	DTT
DMEVARK	MA	Antagonist
DMEVARK	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMEVARK	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMGU05N	DI	DMGU05N
DMGU05N	DN	GSK598809
DMGU05N	MI	TT4C8EA
DMGU05N	MN	Dopamine D3 receptor (D3R)
DMGU05N	MT	DTT
DMGU05N	MA	Antagonist
DMGU05N	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMGU05N	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DECB0K3
DMTW79H	MN	Cytochrome P450 2D6 (CYP2D6)
DMTW79H	MT	DME
DMTW79H	MA	Metabolism
DMTW79H	RN	Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology. 2004 Feb;145(2):699-705.
DMTW79H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14563706

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTPRKM0
DMTW79H	MN	GABA transporter GAT-1 (SLC6A1)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/15509161

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT8RXO5
DMTW79H	MN	GABA transporter-3 (SLC6A11)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/6268788

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT1MPAY
DMTW79H	MN	GABA(A) receptor alpha-1 (GABRA1)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTBMV1G
DMTW79H	MN	GABA(A) receptor alpha-2 (GABRA2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT37EDJ
DMTW79H	MN	GABA(A) receptor alpha-3 (GABRA3)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTNZPQ1
DMTW79H	MN	GABA(A) receptor alpha-5 (GABRA5)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/7392039

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTZA1NY
DMTW79H	MN	GABA(A) receptor beta-2 (GABRB2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT06RH5
DMTW79H	MN	GABA(A) receptor gamma-2 (GABRG2)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTDCVZW
DMTW79H	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/1652022

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TTNJYV2
DMTW79H	MN	Gamma-aminobutyric acid receptor (GAR)
DMTW79H	MT	DTT
DMTW79H	MA	Inhibitor
DMTW79H	RN	3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/16942030

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	TT4BT06
DMTW79H	MN	Integrin alpha-4 (ITGA4)
DMTW79H	MT	DTT
DMTW79H	MA	Binder
DMTW79H	RN	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
DMTW79H	RU	https://pubmed.ncbi.nlm.nih.gov/17355213

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DT8Z563
DMTW79H	MN	Sodium- and chloride-dependent GABA transporter 1 (SLC6A1)
DMTW79H	MT	DTP
DMTW79H	MA	Substrate
DMTW79H	RN	Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic Seizures. Am J Hum Genet. 2015 May 7;96(5):808-15.
DMTW79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/25865495

DMTW79H	DI	DMTW79H
DMTW79H	DN	GSK683699
DMTW79H	MI	DTXQYLR
DMTW79H	MN	Vesicular inhibitory amino acid transporter (SLC32A1)
DMTW79H	MT	DTP
DMTW79H	MA	Substrate
DMTW79H	RN	Wakefulness Is Governed by GABA and Histamine Cotransmission. Neuron. 2015 Jul 1;87(1):164-78.
DMTW79H	RU	http://www.ncbi.nlm.nih.gov/pubmed/26094607

DMPLKAH	DI	DMPLKAH
DMPLKAH	DN	GSK-706769
DMPLKAH	MI	TT2CEJG
DMPLKAH	MN	C-C chemokine receptor type 5 (CCR5)
DMPLKAH	MT	DTT
DMPLKAH	MA	Antagonist
DMPLKAH	RN	Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40.
DMPLKAH	RU	https://pubmed.ncbi.nlm.nih.gov/19483700

DMIEXUM	DI	DMIEXUM
DMIEXUM	DN	GSK768974
DMIEXUM	MI	TTEPJL5
DMIEXUM	MN	Parathyroid hormone receptor (PTH2R)
DMIEXUM	MT	DTT
DMIEXUM	MA	Agonist
DMIEXUM	RN	Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone. 2000 Oct;27(4):471-8.
DMIEXUM	RU	https://pubmed.ncbi.nlm.nih.gov/11033441

DMX27Q1	DI	DMX27Q1
DMX27Q1	DN	GSK933776A
DMX27Q1	MI	TTE4KHA
DMX27Q1	MN	Amyloid beta A4 protein (APP)
DMX27Q1	MT	DTT
DMX27Q1	MA	Modulator
DMX27Q1	RN	Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569.
DMX27Q1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832388/

DM6DKF9	DI	DM6DKF9
DM6DKF9	DN	GSK961081
DM6DKF9	MI	TT2CJVK
DM6DKF9	MN	Adrenergic receptor beta-2 (ADRB2)
DM6DKF9	MT	DTT
DM6DKF9	MA	Modulator
DM6DKF9	RN	Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and 2-adrenoceptor agonist properties.J Pharmacol Exp Ther.2014 Oct;351(1):190-9.
DM6DKF9	RU	https://www.ncbi.nlm.nih.gov/pubmed/25100753

DM8N3OQ	DI	DM8N3OQ
DM8N3OQ	DN	GT-AADC
DM8N3OQ	MI	TTN451K
DM8N3OQ	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DM8N3OQ	MT	DTT
DM8N3OQ	MA	Replacement
DM8N3OQ	RN	Clinical pipeline report, company report or official report of PTC Therapeutics.
DM8N3OQ	RU	https://www.ptcbio.com/our-pipeline/areas-of-interest/additional-areas/

DMN6IDO	DI	DMN6IDO
DMN6IDO	DN	GTP-010
DMN6IDO	MI	TTVIMDE
DMN6IDO	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMN6IDO	MT	DTT
DMN6IDO	MA	Agonist
DMN6IDO	RN	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
DMN6IDO	RU	https://pubmed.ncbi.nlm.nih.gov/16634703

DM03NQS	DI	DM03NQS
DM03NQS	DN	GTP-200
DM03NQS	MI	TTWDC17
DM03NQS	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM03NQS	MT	DTT
DM03NQS	MA	Agonist
DM03NQS	RN	Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346.
DM03NQS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268047/

DMEN5KA	DI	DMEN5KA
DMEN5KA	DN	GTS-21
DMEN5KA	MI	DEJGDUW
DMEN5KA	MN	Cytochrome P450 1A2 (CYP1A2)
DMEN5KA	MT	DME
DMEN5KA	MA	Metabolism
DMEN5KA	RN	Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiotica. 1999 Jul;29(7):747-62.
DMEN5KA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10456692

DMEN5KA	DI	DMEN5KA
DMEN5KA	DN	GTS-21
DMEN5KA	MI	TTLA931
DMEN5KA	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMEN5KA	MT	DTT
DMEN5KA	MA	Agonist
DMEN5KA	RN	The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
DMEN5KA	RU	https://pubmed.ncbi.nlm.nih.gov/10942043

DMDWYZS	DI	DMDWYZS
DMDWYZS	DN	GTx-758
DMDWYZS	MI	TTZAYWL
DMDWYZS	MN	Estrogen receptor (ESR)
DMDWYZS	MT	DTT
DMDWYZS	MA	Modulator
DMDWYZS	RN	Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41.
DMDWYZS	RU	https://pubmed.ncbi.nlm.nih.gov/24968970

DMY53PL	DI	DMY53PL
DMY53PL	DN	GW 597599
DMY53PL	MI	TTZPO1L
DMY53PL	MN	Substance-P receptor (TACR1)
DMY53PL	MT	DTT
DMY53PL	MA	Antagonist
DMY53PL	RN	Application of LC-NMR to the identification of bulk drug impurities in NK1 antagonist GW597599 (vestipitant). Magn Reson Chem. 2010 Jul;48(7):523-30.
DMY53PL	RU	https://pubmed.ncbi.nlm.nih.gov/20535779

DMZMCB1	DI	DMZMCB1
DMZMCB1	DN	GW274150
DMZMCB1	MI	TTF10I9
DMZMCB1	MN	Nitric-oxide synthase inducible (NOS2)
DMZMCB1	MT	DTT
DMZMCB1	MA	Modulator
DMZMCB1	RN	GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
DMZMCB1	RU	https://www.ncbi.nlm.nih.gov/pubmed/12631066

DMY3KSU	DI	DMY3KSU
DMY3KSU	DN	GW-42004
DMY3KSU	MI	TT6OEDT
DMY3KSU	MN	Cannabinoid receptor 1 (CB1)
DMY3KSU	MT	DTT
DMY3KSU	MA	Modulator
DMY3KSU	RN	Company report (Gwpharm)
DMY3KSU	RU	http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx

DMY3KSU	DI	DMY3KSU
DMY3KSU	DN	GW-42004
DMY3KSU	MI	TTMSFAW
DMY3KSU	MN	Cannabinoid receptor 2 (CB2)
DMY3KSU	MT	DTT
DMY3KSU	MA	Modulator
DMY3KSU	RN	Company report (Gwpharm)
DMY3KSU	RU	http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx

DMBX9C0	DI	DMBX9C0
DMBX9C0	DN	GW-427353
DMBX9C0	MI	TTMXGCW
DMBX9C0	MN	Adrenergic receptor beta-3 (ADRB3)
DMBX9C0	MT	DTT
DMBX9C0	MA	Agonist
DMBX9C0	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMBX9C0	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMH0C8J	DI	DMH0C8J
DMH0C8J	DN	GW-813893
DMH0C8J	MI	TTCIHJA
DMH0C8J	MN	Coagulation factor Xa (F10)
DMH0C8J	MT	DTT
DMH0C8J	MA	Inhibitor
DMH0C8J	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMH0C8J	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM489FT	DI	DM489FT
DM489FT	DN	GW-870086-X
DM489FT	MI	TTYRL6O
DM489FT	MN	Glucocorticoid receptor (NR3C1)
DM489FT	MT	DTT
DM489FT	MA	Agonist
DM489FT	RN	Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7.
DM489FT	RU	https://pubmed.ncbi.nlm.nih.gov/23462748

DMQEC9P	DI	DMQEC9P
DMQEC9P	DN	GW-870086-X
DMQEC9P	MI	TTYRL6O
DMQEC9P	MN	Glucocorticoid receptor (NR3C1)
DMQEC9P	MT	DTT
DMQEC9P	MA	Agonist
DMQEC9P	RN	Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7.
DMQEC9P	RU	https://pubmed.ncbi.nlm.nih.gov/23462748

DM8XH3S	DI	DM8XH3S
DM8XH3S	DN	H-1152
DM8XH3S	MI	TTZN7RP
DM8XH3S	MN	Rho-associated protein kinase 1 (ROCK1)
DM8XH3S	MT	DTT
DM8XH3S	MA	Inhibitor
DM8XH3S	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DM8XH3S	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMO4I61	DI	DMO4I61
DMO4I61	DN	H5N1 influenza vaccine
DMO4I61	MI	TT3J5ZI
DMO4I61	MN	Cell mediated immunity response (CMIR)
DMO4I61	MT	DTT
DMO4I61	RN	Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80.
DMO4I61	RU	https://pubmed.ncbi.nlm.nih.gov/20941447

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TT5HONZ
DM74ZKN	MN	Calcium channel unspecific (CaC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Blocker
DM74ZKN	RN	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/20980921

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TT1VOHK
DM74ZKN	MN	Potassium channel unspecific (KC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Blocker
DM74ZKN	RN	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/20980921

DM74ZKN	DI	DM74ZKN
DM74ZKN	DN	HBI-3000
DM74ZKN	MI	TTRK8B9
DM74ZKN	MN	Sodium channel unspecific (NaC)
DM74ZKN	MT	DTT
DM74ZKN	MA	Inhibitor
DM74ZKN	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM74ZKN	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSMCXN	DI	DMSMCXN
DMSMCXN	DN	HBV vaccine
DMSMCXN	MI	TT3J5ZI
DMSMCXN	MN	Cell mediated immunity response (CMIR)
DMSMCXN	MT	DTT
DMSMCXN	RN	ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health.
DMSMCXN	RU	https://clinicaltrials.gov/ct2/show/NCT00508833

DMX8C6J	DI	DMX8C6J
DMX8C6J	DN	HCB1019
DMX8C6J	MI	TT4F7SL
DMX8C6J	MN	Gap junction alpha-1 protein (GJA1)
DMX8C6J	MT	DTT
DMX8C6J	MA	Inhibitor
DMX8C6J	RN	Clinical pipeline report, company report or official report of OcuNexus Therapeutics.
DMX8C6J	RU	https://ocunexus.com/ophthalmic

DMRQGMZ	DI	DMRQGMZ
DMRQGMZ	DN	HD-003
DMRQGMZ	MI	TT20DOQ
DMRQGMZ	MN	Hydroxy radical elimination (HYRE)
DMRQGMZ	MT	DTT
DMRQGMZ	MA	Modulator
DMRQGMZ	RN	Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75.
DMRQGMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22466296

DMAX632	DI	DMAX632
DMAX632	DN	HDV-interferon
DMAX632	MI	TTV2CN0
DMAX632	MN	Interferon receptor (IFNR)
DMAX632	MT	DTT
DMAX632	MA	Modulator
DMAX632	RN	Interferon in HDV infection. Antiviral Res. 1994 Jul;24(2-3):165-74.
DMAX632	RU	https://pubmed.ncbi.nlm.nih.gov/7979316

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	DE4LYSA
DMV50R1	MN	Cytochrome P450 3A4 (CYP3A4)
DMV50R1	MT	DME
DMV50R1	MA	Metabolism
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	DEGTFWK
DMV50R1	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMV50R1	MT	DME
DMV50R1	MA	Metabolism
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	http://www.ncbi.nlm.nih.gov/pubmed/20814732

DMV50R1	DI	DMV50R1
DMV50R1	DN	HE3235
DMV50R1	MI	TTYA7V2
DMV50R1	MN	Prostate cance cell (PCC)
DMV50R1	MT	DTT
DMV50R1	MA	Inhibitor
DMV50R1	RN	17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
DMV50R1	RU	https://pubmed.ncbi.nlm.nih.gov/20814732

DM9OZU5	DI	DM9OZU5
DM9OZU5	DN	Heat shock protein vaccine
DM9OZU5	MI	TTG91S4
DM9OZU5	MN	Heat shock protein (HSP)
DM9OZU5	MT	DTT
DM9OZU5	RN	Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 2012 Nov 1;12(9):1183-97.
DM9OZU5	RU	https://pubmed.ncbi.nlm.nih.gov/22804241

DM8QGPE	DI	DM8QGPE
DM8QGPE	DN	HepaStem
DM8QGPE	MI	TTGSVH2
DM8QGPE	MN	Phenylalanine hydroxylase (PAH)
DM8QGPE	MT	DTT
DM8QGPE	MA	Modulator
DM8QGPE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240).
DM8QGPE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240

DMX6B95	DI	DMX6B95
DMX6B95	DN	HER1-VSSP vaccine
DMX6B95	MI	TTGKNB4
DMX6B95	MN	Epidermal growth factor receptor (EGFR)
DMX6B95	MT	DTT
DMX6B95	RN	Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
DMX6B95	RU	https://pubmed.ncbi.nlm.nih.gov/16841332

DM8TOS0	DI	DM8TOS0
DM8TOS0	DN	HER-2 Protein AutoVac
DM8TOS0	MI	TT6EO5L
DM8TOS0	MN	Erbb2 tyrosine kinase receptor (HER2)
DM8TOS0	MT	DTT
DM8TOS0	MA	Inhibitor
DM8TOS0	RN	Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32.
DM8TOS0	RU	https://pubmed.ncbi.nlm.nih.gov/22124364

DMISETH	DI	DMISETH
DMISETH	DN	HER2/neu peptide vaccine
DMISETH	MI	TT6EO5L
DMISETH	MN	Erbb2 tyrosine kinase receptor (HER2)
DMISETH	MT	DTT
DMISETH	RN	N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35.
DMISETH	RU	https://pubmed.ncbi.nlm.nih.gov/19596910

DMQTREC	DI	DMQTREC
DMQTREC	DN	Her2-targeted autologous T-cell therapy
DMQTREC	MI	TT6EO5L
DMQTREC	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQTREC	MT	DTT
DMQTREC	MA	Inhibitor
DMQTREC	RN	A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545.
DMQTREC	RU	https://pubmed.ncbi.nlm.nih.gov/25009822

DMI4C90	DI	DMI4C90
DMI4C90	DN	HF-0220
DMI4C90	MI	TTCYE56
DMI4C90	MN	Glutathione-dependent PGD synthase (HPGDS)
DMI4C90	MT	DTT
DMI4C90	MA	Stimulator
DMI4C90	RN	US patent application no. 2009,0062,529, Multi-cyclic compounds.
DMI4C90	RU	http://www.google.st/patents/US20090062529

DMDZE3B	DI	DMDZE3B
DMDZE3B	DN	HGT-1111
DMDZE3B	MI	TTYQANR
DMDZE3B	MN	Cerebroside-sulfatase (ARSA)
DMDZE3B	MT	DTT
DMDZE3B	MA	Modulator
DMDZE3B	RN	ClinicalTrials.gov (NCT00681811) Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD. U.S. National Institutes of Health.
DMDZE3B	RU	https://clinicaltrials.gov/ct2/show/NCT00681811

DMHZ4JI	DI	DMHZ4JI
DMHZ4JI	DN	HGT-1410
DMHZ4JI	MI	TTPJ2SH
DMHZ4JI	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMHZ4JI	MT	DTT
DMHZ4JI	MA	Modulator
DMHZ4JI	RN	ClinicalTrials.gov (NCT01155778) Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients. U.S. National Institutes of Health.
DMHZ4JI	RU	https://clinicaltrials.gov/ct2/show/NCT01155778

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TTRP4JT
DM0LA6E	MN	Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TTFP96H
DM0LA6E	MN	Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM0LA6E	DI	DM0LA6E
DM0LA6E	DN	HGTV43
DM0LA6E	MI	TT6S84O
DM0LA6E	MN	Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element)
DM0LA6E	MT	DTT
DM0LA6E	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM0LA6E	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DMO10JI	DI	DMO10JI
DMO10JI	DN	HibTITER
DMO10JI	MI	TTC6JZQ
DMO10JI	MN	Haemophilus influenzae CRM197 (Hae-influ CRM197)
DMO10JI	MT	DTT
DMO10JI	RN	Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. J Microbiol Immunol Infect. 1998 Sep;31(3):180-6.
DMO10JI	RU	https://pubmed.ncbi.nlm.nih.gov/10496155

DMLQDBH	DI	DMLQDBH
DMLQDBH	DN	HM-5016504
DMLQDBH	MI	TTNDSF4
DMLQDBH	MN	Proto-oncogene c-Met (MET)
DMLQDBH	MT	DTT
DMLQDBH	MA	Inhibitor
DMLQDBH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
DMLQDBH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

DMZ3BER	DI	DMZ3BER
DMZ3BER	DN	HM-78136B
DMZ3BER	MI	TTGKNB4
DMZ3BER	MN	Epidermal growth factor receptor (EGFR)
DMZ3BER	MT	DTT
DMZ3BER	MA	Inhibitor
DMZ3BER	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ3BER	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZ3BER	DI	DMZ3BER
DMZ3BER	DN	HM-78136B
DMZ3BER	MI	TT6EO5L
DMZ3BER	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZ3BER	MT	DTT
DMZ3BER	MA	Inhibitor
DMZ3BER	RN	Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.
DMZ3BER	RU	https://pubmed.ncbi.nlm.nih.gov/21732342

DMMQZ3I	DI	DMMQZ3I
DMMQZ3I	DN	HMR59
DMMQZ3I	MI	TTBGTEJ
DMMQZ3I	MN	Membrane inhibitor of reactive lysis (CD59)
DMMQZ3I	MT	DTT
DMMQZ3I	MA	Replacement
DMMQZ3I	RN	Clinical pipeline report, company report or official report of Hemera Biosciences.
DMMQZ3I	RU	https://www.hemerabiosciences.com/hmr59/

DMA6HQJ	DI	DMA6HQJ
DMA6HQJ	DN	HO/03/03
DMA6HQJ	MI	TTYVX59
DMA6HQJ	MN	Protein kinase C (PRKC)
DMA6HQJ	MT	DTT
DMA6HQJ	MA	Modulator
DMA6HQJ	RN	WO patent application no. 2014,0853,81, Pharmaceutical combinations.
DMA6HQJ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140605&CC=WO&NR=2014085381A1&KC=A1

DMNOMV2	DI	DMNOMV2
DMNOMV2	DN	HP-184
DMNOMV2	MI	TTQ6VDM
DMNOMV2	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMNOMV2	MT	DTT
DMNOMV2	MA	Blocker
DMNOMV2	RN	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
DMNOMV2	RU	https://pubmed.ncbi.nlm.nih.gov/18321149

DMNOMV2	DI	DMNOMV2
DMNOMV2	DN	HP-184
DMNOMV2	MI	TTN9VTF
DMNOMV2	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMNOMV2	MT	DTT
DMNOMV2	MA	Blocker
DMNOMV2	RN	Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
DMNOMV2	RU	https://pubmed.ncbi.nlm.nih.gov/18321149

DMNZ35F	DI	DMNZ35F
DMNZ35F	DN	HP-228
DMNZ35F	MI	TTF10I9
DMNZ35F	MN	Nitric-oxide synthase inducible (NOS2)
DMNZ35F	MT	DTT
DMNZ35F	MA	Modulator
DMNZ35F	RN	HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
DMNZ35F	RU	https://pubmed.ncbi.nlm.nih.gov/7473142

DM3WSL2	DI	DM3WSL2
DM3WSL2	DN	HPH-116
DM3WSL2	MI	TT8Z1OP
DM3WSL2	MN	Human immunodeficiency virus Nucleocapsid p7 (HIV p7)
DM3WSL2	MT	DTT
DM3WSL2	MA	Modulator
DM3WSL2	RN	Clinical pipeline report, company report or official report of H-Phar.
DM3WSL2	RU	http://www.h-phar.com/Projects_Projet_1.php

DM25PQB	DI	DM25PQB
DM25PQB	DN	HPPH
DM25PQB	MI	DTI7UX6
DM25PQB	MN	Breast cancer resistance protein (ABCG2)
DM25PQB	MT	DTP
DM25PQB	MA	Substrate
DM25PQB	RN	Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy. Mol Pharm. 2010 Oct 4;7(5):1789-804.
DM25PQB	RU	https://doi.org/10.1021/mp100154j

DM7QUN0	DI	DM7QUN0
DM7QUN0	DN	HQK-1001
DM7QUN0	MI	TTQO71U
DM7QUN0	MN	Hemoglobin (HB)
DM7QUN0	MT	DTT
DM7QUN0	MA	Inducer
DM7QUN0	RN	A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
DM7QUN0	RU	https://pubmed.ncbi.nlm.nih.gov/24224649

DM3WX0K	DI	DM3WX0K
DM3WX0K	DN	HQK-1004
DM3WX0K	MI	TTP3QRF
DM3WX0K	MN	Thymidine kinase 1 (TK1)
DM3WX0K	MT	DTT
DM3WX0K	MA	Modulator
DM3WX0K	RN	Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
DM3WX0K	RU	https://pubmed.ncbi.nlm.nih.gov/11555713

DMQ30X2	DI	DMQ30X2
DMQ30X2	DN	HQP1351
DMQ30X2	MI	TTS7G69
DMQ30X2	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DMQ30X2	MT	DTT
DMQ30X2	MA	Inhibitor
DMQ30X2	RN	Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88.
DMQ30X2	RU	https://pubmed.ncbi.nlm.nih.gov/31673329

DML4RCG	DI	DML4RCG
DML4RCG	DN	HS-110
DML4RCG	MI	TTFZDNP
DML4RCG	MN	Activation B7-1 antigen (CD80)
DML4RCG	MT	DTT
DML4RCG	RN	Clinical pipeline report, company report or official report of Heat Biologics.
DML4RCG	RU	http://www.heatbio.com/product-pipeline/hs-110

DML4RCG	DI	DML4RCG
DML4RCG	DN	HS-110
DML4RCG	MI	TTFPKXQ
DML4RCG	MN	Endoplasmin (HSP90B1)
DML4RCG	MT	DTT
DML4RCG	RN	Clinical pipeline report, company report or official report of Heat Biologics.
DML4RCG	RU	http://www.heatbio.com/product-pipeline/hs-110

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTZ97H5
DM2WP8F	MN	Phosphodiesterase 4A (PDE4A)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTVIAT9
DM2WP8F	MN	Phosphodiesterase 4B (PDE4B)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301

DM2WP8F	DI	DM2WP8F
DM2WP8F	DN	HT-0712
DM2WP8F	MI	TTSKMI8
DM2WP8F	MN	Phosphodiesterase 4D (PDE4D)
DM2WP8F	MT	DTT
DM2WP8F	MA	Inhibitor
DM2WP8F	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303).
DM2WP8F	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303

DM2QIN1	DI	DM2QIN1
DM2QIN1	DN	HT-100
DM2QIN1	MI	TTXYCDZ
DM2QIN1	MN	Bifunctional aminoacyl-tRNA synthetase (EPRS)
DM2QIN1	MT	DTT
DM2QIN1	MA	Modulator
DM2QIN1	RN	Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7.
DM2QIN1	RU	https://pubmed.ncbi.nlm.nih.gov/22327401

DMURXMJ	DI	DMURXMJ
DMURXMJ	DN	HTI-101
DMURXMJ	MI	TT3C1VN
DMURXMJ	MN	Enzyme unspecific (Enz)
DMURXMJ	MT	DTT
DMURXMJ	MA	Antagonist
DMURXMJ	RN	Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006.
DMURXMJ	RU	http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-new-studies-from-hti-101-presented-at-proteoglycan-research-conference-56000982.html

DM9MKQ5	DI	DM9MKQ5
DM9MKQ5	DN	Hu3F8 mAb
DM9MKQ5	MI	TT80ARU
DM9MKQ5	MN	Ganglioside GD2 (GD2)
DM9MKQ5	MT	DTT
DM9MKQ5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9MKQ5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMKQ3MC	DI	DMKQ3MC
DMKQ3MC	DN	Human interferon alpha oral
DMKQ3MC	MI	TT95SOA
DMKQ3MC	MN	Interferon alpha (IFNA)
DMKQ3MC	MT	DTT
DMKQ3MC	MA	Modulator
DMKQ3MC	RN	Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
DMKQ3MC	RU	https://pubmed.ncbi.nlm.nih.gov/1388878

DM0NJWG	DI	DM0NJWG
DM0NJWG	DN	Human interleukin-2
DM0NJWG	MI	TTF89GD
DM0NJWG	MN	Interleukin-2 (IL2)
DM0NJWG	MT	DTT
DM0NJWG	MA	Modulator
DM0NJWG	RN	Clinical pipeline report, company report or official report of Immunservice.
DM0NJWG	RU	http://www.immunservice.com/index.php?page=regulatory

DMOPWSX	DI	DMOPWSX
DMOPWSX	DN	Ibrolipim
DMOPWSX	MI	TTOF3WZ
DMOPWSX	MN	Lipoprotein lipase (LPL)
DMOPWSX	MT	DTT
DMOPWSX	MA	Modulator
DMOPWSX	RN	NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92.
DMOPWSX	RU	https://pubmed.ncbi.nlm.nih.gov/16311090

DM37CX4	DI	DM37CX4
DM37CX4	DN	IC14
DM37CX4	MI	TTCLGZ8
DM37CX4	MN	HUAMN monocyte differentiation antigen CD14 (CD14)
DM37CX4	MT	DTT
DM37CX4	MA	Inhibitor
DM37CX4	RN	IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)
DM37CX4	RU	https://clinicaltrials.gov/ct2/show/NCT04391309

DMUFCQG	DI	DMUFCQG
DMUFCQG	DN	IC14
DMUFCQG	MI	TT6I7DC
DMUFCQG	MN	Monocyte differentiation antigen CD14 (CD14)
DMUFCQG	MT	DTT
DMUFCQG	RN	IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4.
DMUFCQG	RU	https://pubmed.ncbi.nlm.nih.gov/11717588

DMB1UYV	DI	DMB1UYV
DMB1UYV	DN	IC-485
DMB1UYV	MI	TTV5CGO
DMB1UYV	MN	Phosphodiesterase 4 (PDE4)
DMB1UYV	MT	DTT
DMB1UYV	MA	Inhibitor
DMB1UYV	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMB1UYV	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMP925B	DI	DMP925B
DMP925B	DN	ICA-105665
DMP925B	MI	TTIVDM3
DMP925B	MN	Voltage-gated potassium channel Kv7.3 (KCNQ3)
DMP925B	MT	DTT
DMP925B	MA	Activator
DMP925B	RN	New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52.
DMP925B	RU	https://pubmed.ncbi.nlm.nih.gov/18590620

DMRFY7I	DI	DMRFY7I
DMRFY7I	DN	ICA-17043
DMRFY7I	MI	TTMNI76
DMRFY7I	MN	Calcium-activated potassium channel (KCN)
DMRFY7I	MT	DTT
DMRFY7I	MA	Inhibitor
DMRFY7I	RN	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
DMRFY7I	RU	https://pubmed.ncbi.nlm.nih.gov/18232633

DMRFY7I	DI	DMRFY7I
DMRFY7I	DN	ICA-17043
DMRFY7I	MI	TT7M9I6
DMRFY7I	MN	Calcium-activated potassium channel KCa3.1 (KCNN4)
DMRFY7I	MT	DTT
DMRFY7I	MA	Modulator
DMRFY7I	RN	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
DMRFY7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/19236269

DMGHQ37	DI	DMGHQ37
DMGHQ37	DN	Icaritin
DMGHQ37	MI	TTZAYWL
DMGHQ37	MN	Estrogen receptor (ESR)
DMGHQ37	MT	DTT
DMGHQ37	MA	Modulator
DMGHQ37	RN	A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER protein.Carcinogenesis.2012 May;33(5):1089-97.
DMGHQ37	RU	https://www.ncbi.nlm.nih.gov/pubmed/22345291

DMC13BQ	DI	DMC13BQ
DMC13BQ	DN	ICO-25
DMC13BQ	MI	TTBHFYQ
DMC13BQ	MN	Mucin-1 (MUC1)
DMC13BQ	MT	DTT
DMC13BQ	RN	The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
DMC13BQ	RU	https://pubmed.ncbi.nlm.nih.gov/12534220

DMTXNZK	DI	DMTXNZK
DMTXNZK	DN	Icofungipen
DMTXNZK	MI	TT2GPK3
DMTXNZK	MN	DNA topoisomerase (TOP)
DMTXNZK	MT	DTT
DMTXNZK	MA	Inhibitor
DMTXNZK	RN	Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9.
DMTXNZK	RU	https://pubmed.ncbi.nlm.nih.gov/12527422

DMTXNZK	DI	DMTXNZK
DMTXNZK	DN	Icofungipen
DMTXNZK	MI	TTBZHDM
DMTXNZK	MN	Fungal Isoleucyl t-RNA synthetase (Fung ILS1)
DMTXNZK	MT	DTT
DMTXNZK	MA	Modulator
DMTXNZK	RN	Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92.
DMTXNZK	RU	https://pubmed.ncbi.nlm.nih.gov/15855534

DM524GR	DI	DM524GR
DM524GR	DN	ICP-192
DM524GR	MI	TT0LF7H
DM524GR	MN	Fibroblast growth factor receptor (FGFR)
DM524GR	MT	DTT
DM524GR	MA	Inhibitor
DM524GR	RN	Clinical pipeline report, company report or official report of InnoCare Pharma.
DM524GR	RU	https://www.innocarepharma.com/en/pipeline/our-pipeline/

DM7XIAJ	DI	DM7XIAJ
DM7XIAJ	DN	ID-93/GLA-SE
DM7XIAJ	MI	TTVH0YQ
DM7XIAJ	MN	Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens)
DM7XIAJ	MT	DTT
DM7XIAJ	MA	Modulator
DM7XIAJ	RN	US patent application no. US20150182612 A1.
DM7XIAJ	RU	https://www.google.co.in/patents/US20150182612

DMABRXY	DI	DMABRXY
DMABRXY	DN	IDM-2101
DMABRXY	MI	TTY6DTE
DMABRXY	MN	Carcinoembryonic antigen CEA (CD66e)
DMABRXY	MT	DTT
DMABRXY	RN	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
DMABRXY	RU	https://pubmed.ncbi.nlm.nih.gov/18802154

DMABRXY	DI	DMABRXY
DMABRXY	DN	IDM-2101
DMABRXY	MI	TTWSKHD
DMABRXY	MN	Melanoma-associated antigen 3 (MAGEA3)
DMABRXY	MT	DTT
DMABRXY	RN	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
DMABRXY	RU	https://pubmed.ncbi.nlm.nih.gov/18802154

DMSRC5D	DI	DMSRC5D
DMSRC5D	DN	IDX899
DMSRC5D	MI	TT84ETX
DMSRC5D	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSRC5D	MT	DTT
DMSRC5D	MA	Modulator
DMSRC5D	RN	Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78.
DMSRC5D	RU	https://www.ncbi.nlm.nih.gov/pubmed/24158593

DMGWNCJ	DI	DMGWNCJ
DMGWNCJ	DN	Ifabotuzumab
DMGWNCJ	MI	TTHS2LR
DMGWNCJ	MN	Ephrin type-A receptor 3 (EPHA3)
DMGWNCJ	MT	DTT
DMGWNCJ	MA	Antagonist
DMGWNCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGWNCJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZP84Y	DI	DMZP84Y
DMZP84Y	DN	Ifetroban sodium
DMZP84Y	MI	TT2O84V
DMZP84Y	MN	Thromboxane A2 receptor (TBXA2R)
DMZP84Y	MT	DTT
DMZP84Y	MA	Antagonist
DMZP84Y	RN	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
DMZP84Y	RU	https://pubmed.ncbi.nlm.nih.gov/15613065

DM4H8EZ	DI	DM4H8EZ
DM4H8EZ	DN	IFN-alpha
DM4H8EZ	MI	TT95SOA
DM4H8EZ	MN	Interferon alpha (IFNA)
DM4H8EZ	MT	DTT
DM4H8EZ	MA	Modulator
DM4H8EZ	RN	WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
DM4H8EZ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2

DMHI36A	DI	DMHI36A
DMHI36A	DN	IFX-1
DMHI36A	MI	TTKANGO
DMHI36A	MN	Complement C5 (CO5)
DMHI36A	MT	DTT
DMHI36A	MA	Inhibitor
DMHI36A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHI36A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMH97XA	DI	DMH97XA
DMH97XA	DN	Igmesine
DMH97XA	MI	TTA7UJC
DMH97XA	MN	Alpha-1-antitrypsin (SERPINA1)
DMH97XA	MT	DTT
DMH97XA	MA	Modulator
DMH97XA	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMH97XA	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMH97XA	DI	DMH97XA
DMH97XA	DN	Igmesine
DMH97XA	MI	TT5TPI6
DMH97XA	MN	Opioid receptor sigma 1 (OPRS1)
DMH97XA	MT	DTT
DMH97XA	MA	Agonist
DMH97XA	RN	Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
DMH97XA	RU	https://pubmed.ncbi.nlm.nih.gov/16551835

DMIHQ5G	DI	DMIHQ5G
DMIHQ5G	DN	IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G	MI	TTF89GD
DMIHQ5G	MN	Interleukin-2 (IL2)
DMIHQ5G	MT	DTT
DMIHQ5G	RN	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
DMIHQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/16249392

DMIHQ5G	DI	DMIHQ5G
DMIHQ5G	DN	IL-2/CD40L-expressing leukemia vaccine
DMIHQ5G	MI	TTIJP3Q
DMIHQ5G	MN	TNF related activation protein (CD40LG)
DMIHQ5G	MT	DTT
DMIHQ5G	RN	Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
DMIHQ5G	RU	https://pubmed.ncbi.nlm.nih.gov/16249392

DM1E4VP	DI	DM1E4VP
DM1E4VP	DN	IL-21
DM1E4VP	MI	TT9QEJ6
DM1E4VP	MN	Interleukin-21 (IL21)
DM1E4VP	MT	DTT
DM1E4VP	MA	Modulator
DM1E4VP	RN	National Cancer Institute Drug Dictionary (drug id 409696).
DM1E4VP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=409696

DMYEGRH	DI	DMYEGRH
DMYEGRH	DN	IL-4R
DMYEGRH	MI	TTLGTKB
DMYEGRH	MN	Interleukin-4 (IL4)
DMYEGRH	MT	DTT
DMYEGRH	MA	Inhibitor
DMYEGRH	RN	Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
DMYEGRH	RU	https://pubmed.ncbi.nlm.nih.gov/11398072

DMDNHRA	DI	DMDNHRA
DMDNHRA	DN	Ilodecakin
DMDNHRA	MI	TTT0Q1F
DMDNHRA	MN	Interleukin-10 (IL10)
DMDNHRA	MT	DTT
DMDNHRA	MA	Modulator
DMDNHRA	RN	Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
DMDNHRA	RU	https://pubmed.ncbi.nlm.nih.gov/16118714

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TT8MK59
DMUJ1WV	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Modulator
DMUJ1WV	RN	Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
DMUJ1WV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624013

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TT7AKW1
DMUJ1WV	MN	T-cell receptor (TCR)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Modulator
DMUJ1WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUJ1WV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMUJ1WV	DI	DMUJ1WV
DMUJ1WV	DN	IMCgp100
DMUJ1WV	MI	TTV3XPL
DMUJ1WV	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMUJ1WV	MT	DTT
DMUJ1WV	MA	Inhibitor
DMUJ1WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUJ1WV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU1MR9	DI	DMU1MR9
DMU1MR9	DN	IMD-1041
DMU1MR9	MI	TTJ3E9X
DMU1MR9	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMU1MR9	MT	DTT
DMU1MR9	MA	Inhibitor
DMU1MR9	RN	Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45.
DMU1MR9	RU	https://pubmed.ncbi.nlm.nih.gov/23042949

DMMQFG2	DI	DMMQFG2
DMMQFG2	DN	Imeglimin
DMMQFG2	MI	TTLAFZV
DMMQFG2	MN	AMP-activated protein kinase (AMPK)
DMMQFG2	MT	DTT
DMMQFG2	MA	Modulator
DMMQFG2	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
DMMQFG2	RU	http://adisinsight.springer.com/drugs/800032542

DML9AVG	DI	DML9AVG
DML9AVG	DN	IMG-7289
DML9AVG	MI	TTNR0UQ
DML9AVG	MN	Lysine-specific histone demethylase 1 (LSD)
DML9AVG	MT	DTT
DML9AVG	MA	Inhibitor
DML9AVG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML9AVG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNJ491	DI	DMNJ491
DMNJ491	DN	IMGN529
DMNJ491	MI	TTFCW29
DMNJ491	MN	Leukocyte antigen CD37 (CD37)
DMNJ491	MT	DTT
DMNJ491	RN	The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10.
DMNJ491	RU	https://pubmed.ncbi.nlm.nih.gov/24445867

DMIUC3M	DI	DMIUC3M
DMIUC3M	DN	IMGN901
DMIUC3M	MI	TTUBJQ3
DMIUC3M	MN	Neural cell adhesion molecule (NCAM)
DMIUC3M	MT	DTT
DMIUC3M	MA	Modulator
DMIUC3M	RN	Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66.
DMIUC3M	RU	https://pubmed.ncbi.nlm.nih.gov/24492307

DME3POC	DI	DME3POC
DME3POC	DN	Imisopasem manganese
DME3POC	MI	TT9O4C5
DME3POC	MN	Superoxide dismutase Mn (SOD Mn)
DME3POC	MT	DTT
DME3POC	MA	Modulator
DME3POC	RN	The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40.
DME3POC	RU	https://pubmed.ncbi.nlm.nih.gov/20298121

DM6IQ3V	DI	DM6IQ3V
DM6IQ3V	DN	IMO-2055
DM6IQ3V	MI	TTSHG0T
DM6IQ3V	MN	Toll-like receptor 9 (TLR9)
DM6IQ3V	MT	DTT
DM6IQ3V	MA	Agonist
DM6IQ3V	RN	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
DM6IQ3V	RU	http://www.iderapharma.com/

DMM549D	DI	DMM549D
DMM549D	DN	IMO-3100
DMM549D	MI	TTRJ1K4
DMM549D	MN	Toll-like receptor 7 (TLR7)
DMM549D	MT	DTT
DMM549D	MA	Modulator
DMM549D	RN	Company report (Iderapharma)
DMM549D	RU	http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887

DMM549D	DI	DMM549D
DMM549D	DN	IMO-3100
DMM549D	MI	TTSHG0T
DMM549D	MN	Toll-like receptor 9 (TLR9)
DMM549D	MT	DTT
DMM549D	MA	Modulator
DMM549D	RN	Company report (Iderapharma)
DMM549D	RU	http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887

DMDPNCJ	DI	DMDPNCJ
DMDPNCJ	DN	IMO-8400
DMDPNCJ	MI	TTOK0LR
DMDPNCJ	MN	Toll-like receptor (TLR)
DMDPNCJ	MT	DTT
DMDPNCJ	MA	Antagonist
DMDPNCJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDPNCJ	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMTN16K	DI	DMTN16K
DMTN16K	DN	Implitapide
DMTN16K	MI	TTUS1RD
DMTN16K	MN	Microsomal triglyceride transfer protein (MTTP)
DMTN16K	MT	DTT
DMTN16K	MA	Inhibitor
DMTN16K	RN	Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70.
DMTN16K	RU	https://pubmed.ncbi.nlm.nih.gov/19080731

DMB1N6P	DI	DMB1N6P
DMB1N6P	DN	Impoyz
DMB1N6P	MI	DE4LYSA
DMB1N6P	MN	Cytochrome P450 3A4 (CYP3A4)
DMB1N6P	MT	DME
DMB1N6P	MA	Metabolism
DMB1N6P	RN	Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25.
DMB1N6P	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15304077

DM15MRZ	DI	DM15MRZ
DM15MRZ	DN	IMR-687
DM15MRZ	MI	TTZOEBC
DM15MRZ	MN	Phosphodiesterase 9 (PDE9)
DM15MRZ	MT	DTT
DM15MRZ	MA	Inhibitor
DM15MRZ	RN	Clinical pipeline report, company report or official report of Imara.
DM15MRZ	RU	https://imaratx.com/our-programs/

DMNUXKA	DI	DMNUXKA
DMNUXKA	DN	INCAGN01876
DMNUXKA	MI	TTG6LA7
DMNUXKA	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMNUXKA	MT	DTT
DMNUXKA	MA	Agonist
DMNUXKA	RN	Clinical pipeline report, company report or official report of Agenus.
DMNUXKA	RU	https://agenusbio.com/pipeline/

DMK7OHI	DI	DMK7OHI
DMK7OHI	DN	INCAGN01949
DMK7OHI	MI	TTL31H0
DMK7OHI	MN	OX40L receptor (CD134)
DMK7OHI	MT	DTT
DMK7OHI	MA	Agonist
DMK7OHI	RN	Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655.
DMK7OHI	RU	https://pubmed.ncbi.nlm.nih.gov/33083509

DMFG8TI	DI	DMFG8TI
DMFG8TI	DN	INCB00928
DMFG8TI	MI	TTJNBQA
DMFG8TI	MN	Activin receptor-like kinase 2 (ALK-2)
DMFG8TI	MT	DTT
DMFG8TI	MA	Inhibitor
DMFG8TI	RN	Clinical pipeline report, company report or official report of Incyte.
DMFG8TI	RU	https://www.incyte.com/what-we-do/pharmaceutical-portfolio

DMD9RV3	DI	DMD9RV3
DMD9RV3	DN	INCB039110
DMD9RV3	MI	TT6DM01
DMD9RV3	MN	Janus kinase 1 (JAK-1)
DMD9RV3	MT	DTT
DMD9RV3	MA	Inhibitor
DMD9RV3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
DMD9RV3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047

DMD9RV3	DI	DMD9RV3
DMD9RV3	DN	INCB039110
DMD9RV3	MI	TTRMX3V
DMD9RV3	MN	Janus kinase 2 (JAK-2)
DMD9RV3	MT	DTT
DMD9RV3	MA	Inhibitor
DMD9RV3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048).
DMD9RV3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048

DMZJP2T	DI	DMZJP2T
DMZJP2T	DN	INCB50465
DMZJP2T	MI	TTGBPJE
DMZJP2T	MN	PI3-kinase delta (PIK3CD)
DMZJP2T	MT	DTT
DMZJP2T	MA	Inhibitor
DMZJP2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZJP2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDK0HX	DI	DMDK0HX
DMDK0HX	DN	INCB54707
DMDK0HX	MI	TT6DM01
DMDK0HX	MN	Janus kinase 1 (JAK-1)
DMDK0HX	MT	DTT
DMDK0HX	MA	Inhibitor
DMDK0HX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDK0HX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMJN9PU	DI	DMJN9PU
DMJN9PU	DN	INCB86550
DMJN9PU	MI	TT8ZLTI
DMJN9PU	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMJN9PU	MT	DTT
DMJN9PU	MA	Inhibitor
DMJN9PU	RN	National Cancer Institute Drug Dictionary (drug name INCB086550).
DMJN9PU	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pd-l1-inhibitor-incb086550

DM6OFJ8	DI	DM6OFJ8
DM6OFJ8	DN	Indibulin
DM6OFJ8	MI	TTML2WA
DM6OFJ8	MN	Tubulin (TUB)
DM6OFJ8	MT	DTT
DM6OFJ8	MA	Stablizer
DM6OFJ8	RN	2011 Pipeline of ZioPharm.
DM6OFJ8	RU	http://www.ziopharm.com/clinical_dev.php

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	TT2LVK8
DM9SX6Y	MN	Carbonic anhydrase IX (CA-IX)
DM9SX6Y	MT	DTT
DM9SX6Y	MA	Modulator
DM9SX6Y	RN	Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/14684331

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	DE5IED8
DM9SX6Y	MN	Cytochrome P450 2C9 (CYP2C9)
DM9SX6Y	MT	DME
DM9SX6Y	MA	Metabolism
DM9SX6Y	RN	PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther. 2008 Jun;83(6):829-39.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17851564

DM9SX6Y	DI	DM9SX6Y
DM9SX6Y	DN	Indisulam
DM9SX6Y	MI	DEGTFWK
DM9SX6Y	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM9SX6Y	MT	DME
DM9SX6Y	MA	Metabolism
DM9SX6Y	RN	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
DM9SX6Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17504998

DMU5SZP	DI	DMU5SZP
DMU5SZP	DN	Inecalcitol oral
DMU5SZP	MI	TTK59TV
DMU5SZP	MN	Vitamin D3 receptor (VDR)
DMU5SZP	MT	DTT
DMU5SZP	MA	Agonist
DMU5SZP	RN	Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013 Mar 1;12(5):743-52.
DMU5SZP	RU	https://pubmed.ncbi.nlm.nih.gov/23388458

DMEO9Y7	DI	DMEO9Y7
DMEO9Y7	DN	INGAP peptide
DMEO9Y7	MI	TTGMYVE
DMEO9Y7	MN	Phosphofructokinase 2 (PFK2)
DMEO9Y7	MT	DTT
DMEO9Y7	MA	Modulator
DMEO9Y7	RN	A Pentadecapeptide Fragment of Islet Neogenesis-Associated Protein Increases Beta-Cell Mass and Reverses Diabetes in C57BL/6J Mice. Ann Surg. 2004 November; 240(5): 875-884.
DMEO9Y7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356495/

DMF7J6D	DI	DMF7J6D
DMF7J6D	DN	INGN-225
DMF7J6D	MI	TT7SBF5
DMF7J6D	MN	Cellular tumor antigen p53 (TP53)
DMF7J6D	MT	DTT
DMF7J6D	RN	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91.
DMF7J6D	RU	https://pubmed.ncbi.nlm.nih.gov/20420527

DM6P91T	DI	DM6P91T
DM6P91T	DN	INGN-241
DM6P91T	MI	TT1EPXZ
DM6P91T	MN	Interleukin-24 (IL24)
DM6P91T	MT	DTT
DM6P91T	MA	Inhibitor
DM6P91T	RN	Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan;11(1):160-72.
DM6P91T	RU	https://pubmed.ncbi.nlm.nih.gov/15585417

DMGO7QT	DI	DMGO7QT
DMGO7QT	DN	INK128
DMGO7QT	MI	TTCJG29
DMGO7QT	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMGO7QT	MT	DTT
DMGO7QT	MA	Inhibitor
DMGO7QT	RN	2011 Pipeline of Intellikine.
DMGO7QT	RU	http://www.intellikine.com/pipeline/

DMKRGVJ	DI	DMKRGVJ
DMKRGVJ	DN	INS-1
DMKRGVJ	MI	TTZ7WFL
DMKRGVJ	MN	Glucose metabolism (Glucose metab)
DMKRGVJ	MT	DTT
DMKRGVJ	MA	Modulator
DMKRGVJ	RN	Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and beta-cells. Am J Physiol Endocrinol Metab. 2012 April 15; 302(8): E932-E940.
DMKRGVJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330724/

DMF93RQ	DI	DMF93RQ
DMF93RQ	DN	INS-37217
DMF93RQ	MI	TTOZHQC
DMF93RQ	MN	P2Y purinoceptor 2 (P2RY2)
DMF93RQ	MT	DTT
DMF93RQ	MA	Agonist
DMF93RQ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMF93RQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMKZUVC	DI	DMKZUVC
DMKZUVC	DN	INS-50589
DMKZUVC	MI	TTZ1DT0
DMKZUVC	MN	P2Y purinoceptor 12 (P2RY12)
DMKZUVC	MT	DTT
DMKZUVC	MA	Modulator
DMKZUVC	RN	Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
DMKZUVC	RU	https://pubmed.ncbi.nlm.nih.gov/17654304

DMNKAFQ	DI	DMNKAFQ
DMNKAFQ	DN	Instiladrin
DMNKAFQ	MI	TTSIUJ9
DMNKAFQ	MN	Interferon-alpha 2 (IFNA2)
DMNKAFQ	MT	DTT
DMNKAFQ	MA	Modulator
DMNKAFQ	RN	ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
DMNKAFQ	RU	https://clinicaltrials.gov/ct2/show/NCT01687244

DMYTKF5	DI	DMYTKF5
DMYTKF5	DN	Interferon
DMYTKF5	MI	TT6ONYI
DMYTKF5	MN	Interferon (IFN)
DMYTKF5	MT	DTT
DMYTKF5	MA	Modulator
DMYTKF5	RN	Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses. 2013 Sep;7(5):854-62.
DMYTKF5	RU	https://pubmed.ncbi.nlm.nih.gov/23398960

DMVACTU	DI	DMVACTU
DMVACTU	DN	Interferon alpha-2b
DMVACTU	MI	TTSIUJ9
DMVACTU	MN	Interferon-alpha 2 (IFNA2)
DMVACTU	MT	DTT
DMVACTU	MA	Modulator
DMVACTU	RN	Clinical pipeline report, company report or official report of Avarx.
DMVACTU	RU	http://www.avarx.com/AvaRx/SubDomains/Company271/Listings/bucketc9a4f99040669fa206037a416235/Public.Listing.display.html

DMQSA7H	DI	DMQSA7H
DMQSA7H	DN	Interferon beta 1a
DMQSA7H	MI	TT4TZ8J
DMQSA7H	MN	Interferon-beta (IFNB1)
DMQSA7H	MT	DTT
DMQSA7H	MA	Modulator
DMQSA7H	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMQSA7H	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8YF01	DI	DM8YF01
DM8YF01	DN	Interferon-alpha lozenge
DM8YF01	MI	TT95SOA
DM8YF01	MN	Interferon alpha (IFNA)
DM8YF01	MT	DTT
DM8YF01	MA	Modulator
DM8YF01	RN	Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
DM8YF01	RU	https://pubmed.ncbi.nlm.nih.gov/12090541

DMBXEG9	DI	DMBXEG9
DMBXEG9	DN	Intetumumab
DMBXEG9	MI	TT69TQN
DMBXEG9	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMBXEG9	MT	DTT
DMBXEG9	MA	Modulator
DMBXEG9	RN	A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
DMBXEG9	RU	https://pubmed.ncbi.nlm.nih.gov/21750555

DMSTJ6Q	DI	DMSTJ6Q
DMSTJ6Q	DN	INX-189
DMSTJ6Q	MI	TTMVBWH
DMSTJ6Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMSTJ6Q	MT	DTT
DMSTJ6Q	MA	Inhibitor
DMSTJ6Q	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMSTJ6Q	RU	http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa

DMNW0DG	DI	DMNW0DG
DMNW0DG	DN	Iodine-131-tositumomab
DMNW0DG	MI	TTUE541
DMNW0DG	MN	Leukocyte surface antigen Leu-16 (CD20)
DMNW0DG	MT	DTT
DMNW0DG	RN	Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5.
DMNW0DG	RU	https://pubmed.ncbi.nlm.nih.gov/18502830

DM5F0QY	DI	DM5F0QY
DM5F0QY	DN	IONIS-416858
DM5F0QY	MI	TTDM4ZU
DM5F0QY	MN	Factor XI messenger RNA (F11 mRNA)
DM5F0QY	MT	DTT
DM5F0QY	MA	Inhibitor
DM5F0QY	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM5F0QY	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM6PDX2	DI	DM6PDX2
DM6PDX2	DN	IONIS-C9Rx
DM6PDX2	MI	TTA4SHR
DM6PDX2	MN	C9orf72 messenger RNA (C9orf72 mRNA)
DM6PDX2	MT	DTT
DM6PDX2	MA	Inhibitor
DM6PDX2	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM6PDX2	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM5LM3O	DI	DM5LM3O
DM5LM3O	DN	IONIS-DNM2-2.5Rx
DM5LM3O	MI	TTVRA5G
DM5LM3O	MN	DNM2 messenger RNA (DNM2 mRNA)
DM5LM3O	MT	DTT
DM5LM3O	MA	Inhibitor
DM5LM3O	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM5LM3O	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMJ2763	DI	DMJ2763
DMJ2763	DN	IONIS-FB-LRx
DMJ2763	MI	TT3SGK7
DMJ2763	MN	CFB messenger RNA (CFB mRNA)
DMJ2763	MT	DTT
DMJ2763	MA	Inhibitor
DMJ2763	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMJ2763	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMWV2N1	DI	DMWV2N1
DMWV2N1	DN	IONIS-GCCRRX
DMWV2N1	MI	TTYRL6O
DMWV2N1	MN	Glucocorticoid receptor (NR3C1)
DMWV2N1	MT	DTT
DMWV2N1	MA	Antagonist
DMWV2N1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV2N1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB4GD9	DI	DMB4GD9
DMB4GD9	DN	IONIS-GCGR-Rx
DMB4GD9	MI	TTLMJSC
DMB4GD9	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMB4GD9	MT	DTT
DMB4GD9	MA	Inhibitor
DMB4GD9	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMB4GD9	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMGTJUP	DI	DMGTJUP
DMGTJUP	DN	IONIS-PTP1BRX
DMGTJUP	MI	TTMS7KP
DMGTJUP	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMGTJUP	MT	DTT
DMGTJUP	MA	Inhibitor
DMGTJUP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGTJUP	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM7VJE1	DI	DM7VJE1
DM7VJE1	DN	IONIS-TMPRSS6-LRx
DM7VJE1	MI	TTNIUKC
DM7VJE1	MN	TMPRSS6 messenger RNA (TMPRSS6 mRNA)
DM7VJE1	MT	DTT
DM7VJE1	MA	Inhibitor
DM7VJE1	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM7VJE1	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM5TMYC	DI	DM5TMYC
DM5TMYC	DN	iOWH032
DM5TMYC	MI	TTRLZHP
DM5TMYC	MN	cAMP-dependent chloride channel (CFTR)
DM5TMYC	MT	DTT
DM5TMYC	MA	Inhibitor
DM5TMYC	RN	Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25.
DM5TMYC	RU	https://pubmed.ncbi.nlm.nih.gov/21859305

DMANRGW	DI	DMANRGW
DMANRGW	DN	IP10 C8
DMANRGW	MI	TTPHMWB
DMANRGW	MN	Aminopeptidase N (ANPEP)
DMANRGW	MT	DTT
DMANRGW	MA	Modulator
DMANRGW	RN	Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
DMANRGW	RU	https://pubmed.ncbi.nlm.nih.gov/19327105

DMANRGW	DI	DMANRGW
DMANRGW	DN	IP10 C8
DMANRGW	MI	TTDIGC1
DMANRGW	MN	Dipeptidyl peptidase 4 (DPP-4)
DMANRGW	MT	DTT
DMANRGW	MA	Modulator
DMANRGW	RN	Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
DMANRGW	RU	https://pubmed.ncbi.nlm.nih.gov/19327105

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TT4UXPE
DMDUVCZ	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTU0P73
DMDUVCZ	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTEX3SI
DMDUVCZ	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTVWAGF
DMDUVCZ	MN	MHC class I NK cell receptor 2DS1 (CD158h)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMDUVCZ	DI	DMDUVCZ
DMDUVCZ	DN	IPH-2101
DMDUVCZ	MI	TTV3CFI
DMDUVCZ	MN	MHC class I NK cell receptor 2DS2 (CD158j)
DMDUVCZ	MT	DTT
DMDUVCZ	MA	Modulator
DMDUVCZ	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMDUVCZ	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TT4UXPE
DMPBR0D	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TTU0P73
DMPBR0D	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMPBR0D	DI	DMPBR0D
DMPBR0D	DN	IPH-2102
DMPBR0D	MI	TTEX3SI
DMPBR0D	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMPBR0D	MT	DTT
DMPBR0D	MA	Antagonist
DMPBR0D	RN	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
DMPBR0D	RU	https://pubmed.ncbi.nlm.nih.gov/25510242

DMQH2SF	DI	DMQH2SF
DMQH2SF	DN	IPH4102
DMQH2SF	MI	TTQH3N0
DMQH2SF	MN	MHC class I NK cell receptor 3DL2 (CD158k)
DMQH2SF	MT	DTT
DMQH2SF	MA	Antagonist
DMQH2SF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQH2SF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMG5Q7F	DI	DMG5Q7F
DMG5Q7F	DN	IPI-549
DMG5Q7F	MI	TTHBTOP
DMG5Q7F	MN	PI3-kinase gamma (PIK3CG)
DMG5Q7F	MT	DTT
DMG5Q7F	MA	Inhibitor
DMG5Q7F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG5Q7F	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW2IF9	DI	DMW2IF9
DMW2IF9	DN	IR502
DMW2IF9	MI	TT7AKW1
DMW2IF9	MN	T-cell receptor (TCR)
DMW2IF9	MT	DTT
DMW2IF9	MA	Modulator
DMW2IF9	RN	WO patent application no. 2004,0677,06, Production of multimeric proteins.
DMW2IF9	RU	http://www.google.com/patents/WO2004067706A2?cl=en

DMQ3RWN	DI	DMQ3RWN
DMQ3RWN	DN	Iralukast
DMQ3RWN	MI	TTGKOY9
DMQ3RWN	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMQ3RWN	MT	DTT
DMQ3RWN	MA	Modulator
DMQ3RWN	RN	Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
DMQ3RWN	RU	https://pubmed.ncbi.nlm.nih.gov/9504401

DMI874B	DI	DMI874B
DMI874B	DN	Iratumumab
DMI874B	MI	TT2GM5R
DMI874B	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMI874B	MT	DTT
DMI874B	RN	Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
DMI874B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337265/

DMCAFVN	DI	DMCAFVN
DMCAFVN	DN	IRT-102
DMCAFVN	MI	TT6IEYX
DMCAFVN	MN	Opioid receptor zeta (OGFR)
DMCAFVN	MT	DTT
DMCAFVN	MA	Modulator
DMCAFVN	RN	The opiate receptor binding interactions of 3H-methionine enkephalin, an opioid peptide. Eur J Pharmacol. 1978 Feb 1;47(3):319-31.
DMCAFVN	RU	https://pubmed.ncbi.nlm.nih.gov/204498

DMODLN7	DI	DMODLN7
DMODLN7	DN	IRX-2
DMODLN7	MI	TTXM6JN
DMODLN7	MN	Cytokine receptor unspecific (CRF)
DMODLN7	MT	DTT
DMODLN7	MA	Modulator
DMODLN7	RN	Clinical pipeline report, company report or official report of IRX Therapeutics.
DMODLN7	RU	http://www.irxtherapeutics.com/prod_irx2.html

DMHOJ8W	DI	DMHOJ8W
DMHOJ8W	DN	Isatoribine
DMHOJ8W	MI	TTRJ1K4
DMHOJ8W	MN	Toll-like receptor 7 (TLR7)
DMHOJ8W	MT	DTT
DMHOJ8W	MA	Agonist
DMHOJ8W	RN	Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
DMHOJ8W	RU	https://pubmed.ncbi.nlm.nih.gov/18066870

DMBZK3P	DI	DMBZK3P
DMBZK3P	DN	ISF35
DMBZK3P	MI	TTIJP3Q
DMBZK3P	MN	TNF related activation protein (CD40LG)
DMBZK3P	MT	DTT
DMBZK3P	MA	Binder
DMBZK3P	RN	Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
DMBZK3P	RU	https://pubmed.ncbi.nlm.nih.gov/25382101

DMUPD4G	DI	DMUPD4G
DMUPD4G	DN	ISIS 113715
DMUPD4G	MI	TTELIN2
DMUPD4G	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMUPD4G	MT	DTT
DMUPD4G	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMUPD4G	RU	http://www.isispharm.com/Pipeline/index.htm

DMQ3C05	DI	DMQ3C05
DMQ3C05	DN	ISIS-APO(a)
DMQ3C05	MI	TTU9LGY
DMQ3C05	MN	Apolipoprotein A messenger RNA (LPA mRNA)
DMQ3C05	MT	DTT
DMQ3C05	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMQ3C05	RU	https://www.isispharm.com/pipeline/isis-apoarx/

DML84CN	DI	DML84CN
DML84CN	DN	ISIS-CRPRx
DML84CN	MI	TTWRN6M
DML84CN	MN	CRP messenger RNA (CRP mRNA)
DML84CN	MT	DTT
DML84CN	MA	Modulator
DML84CN	RN	Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):49-60.
DML84CN	RU	https://pubmed.ncbi.nlm.nih.gov/24211663

DMRN543	DI	DMRN543
DMRN543	DN	ISIS-EIF4E
DMRN543	MI	TTNBTCW
DMRN543	MN	eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA)
DMRN543	MT	DTT
DMRN543	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMRN543	RU	http://www.isispharm.com/index.htm

DMNVZDT	DI	DMNVZDT
DMNVZDT	DN	ISIS-FGFR4
DMNVZDT	MI	TT1KX2S
DMNVZDT	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMNVZDT	MT	DTT
DMNVZDT	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMNVZDT	RU	http://www.isispharm.com/index.htm

DMHETPI	DI	DMHETPI
DMHETPI	DN	ISIS-FXI
DMHETPI	MI	TTDM4ZU
DMHETPI	MN	Factor XI messenger RNA (F11 mRNA)
DMHETPI	MT	DTT
DMHETPI	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMHETPI	RU	http://www.isispharm.com/index.htm

DMICMNU	DI	DMICMNU
DMICMNU	DN	ISIS-GCCR
DMICMNU	MI	TTOZRK6
DMICMNU	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMICMNU	MT	DTT
DMICMNU	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMICMNU	RU	http://www.isispharm.com/index.htm

DMHNYWP	DI	DMHNYWP
DMHNYWP	DN	ISIS-GCGR
DMHNYWP	MI	TTLMJSC
DMHNYWP	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMHNYWP	MT	DTT
DMHNYWP	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMHNYWP	RU	http://www.isispharm.com/index.htm

DM4RXDQ	DI	DM4RXDQ
DM4RXDQ	DN	ISIS-HBV
DM4RXDQ	MI	TT43YWN
DM4RXDQ	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM4RXDQ	MT	DTT
DM4RXDQ	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM4RXDQ	RU	https://www.isispharm.com/pipeline/isis-hbvrx/

DMJGVXT	DI	DMJGVXT
DMJGVXT	DN	ISIS-PTP1Brx
DMJGVXT	MI	TTELIN2
DMJGVXT	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DMJGVXT	MT	DTT
DMJGVXT	MA	Modulator
DMJGVXT	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMJGVXT	RU	https://www.isispharm.com/pipeline/isis-ptp1brx/

DM2RS0V	DI	DM2RS0V
DM2RS0V	DN	Isofagomine tartrate
DM2RS0V	MI	TT1B5PU
DM2RS0V	MN	Glucosylceramidase (GBA)
DM2RS0V	MT	DTT
DM2RS0V	MA	Inhibitor
DM2RS0V	RN	Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008 Nov 3;9(16):2650-62.
DM2RS0V	RU	https://pubmed.ncbi.nlm.nih.gov/18972510

DMP2BWX	DI	DMP2BWX
DMP2BWX	DN	Ispinesib
DMP2BWX	MI	TTTRP0H
DMP2BWX	MN	Kinesin-like protein KIF11 (KIF11)
DMP2BWX	MT	DTT
DMP2BWX	MA	Inhibitor
DMP2BWX	RN	Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63.
DMP2BWX	RU	https://pubmed.ncbi.nlm.nih.gov/19554570

DMCY9PO	DI	DMCY9PO
DMCY9PO	DN	Itarnafloxin
DMCY9PO	MI	TTCSZH7
DMCY9PO	MN	Nucleolin (NCL)
DMCY9PO	MT	DTT
DMCY9PO	MA	Inhibitor
DMCY9PO	RN	Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275.
DMCY9PO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119469/

DMDZWPL	DI	DMDZWPL
DMDZWPL	DN	ITCA-638
DMDZWPL	MI	TTS2TGF
DMDZWPL	MN	Interferon-omega (IFNW1)
DMDZWPL	MT	DTT
DMDZWPL	MA	Modulator
DMDZWPL	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMDZWPL	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM5UFRO	DI	DM5UFRO
DM5UFRO	DN	Itriglumide
DM5UFRO	MI	TTVFO0U
DM5UFRO	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM5UFRO	MT	DTT
DM5UFRO	MA	Antagonist
DM5UFRO	RN	Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231.
DM5UFRO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718729/

DMCJX79	DI	DMCJX79
DMCJX79	DN	ITV-1
DMCJX79	MI	TTG90S6
DMCJX79	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMCJX79	MT	DTT
DMCJX79	RN	Clinical pipeline report, company report or official report of Immunotech Laboratories.
DMCJX79	RU	http://www.immunotechlab.com/ipf/

DMJV3AX	DI	DMJV3AX
DMJV3AX	DN	IVA337
DMJV3AX	MI	TTRMIZ7
DMJV3AX	MN	Peroxisome proliferator-activated receptor (PPAR)
DMJV3AX	MT	DTT
DMJV3AX	MA	Agonist
DMJV3AX	RN	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940.
DMJV3AX	RU	https://pubmed.ncbi.nlm.nih.gov/28801346

DM0OYLQ	DI	DM0OYLQ
DM0OYLQ	DN	I-vation
DM0OYLQ	MI	TTJL8VG
DM0OYLQ	MN	Corticosteroid-binding globulin (SERPINA6)
DM0OYLQ	MT	DTT
DM0OYLQ	MA	Modulator
DM0OYLQ	RN	Cortisol binding in rat skeletal muscle. J Biol Chem. 1975 Feb 25;250(4):1207-11.
DM0OYLQ	RU	https://pubmed.ncbi.nlm.nih.gov/163248

DM457XO	DI	DM457XO
DM457XO	DN	IW-1701
DM457XO	MI	TT6HPVC
DM457XO	MN	Guanylate cyclase (GC)
DM457XO	MT	DTT
DM457XO	MA	Stimulator 
DM457XO	RN	Clinical pipeline report, company report or official report of Cyclerion Therapeutics.
DM457XO	RU	https://www.cyclerion.com/other-clinical-assets/

DMK2T7J	DI	DMK2T7J
DMK2T7J	DN	IW-1973
DMK2T7J	MI	TT23PYC
DMK2T7J	MN	Soluble guanylate cyclase (GCS)
DMK2T7J	MT	DTT
DMK2T7J	MA	Agonist
DMK2T7J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK2T7J	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMP42W1	DI	DMP42W1
DMP42W1	DN	IW-6118
DMP42W1	MI	TTDP1UC
DMP42W1	MN	Fatty acid amide hydrolase (FAAH)
DMP42W1	MT	DTT
DMP42W1	MA	Modulator
DMP42W1	RN	The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
DMP42W1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581/

DM3WSDR	DI	DM3WSDR
DM3WSDR	DN	IXT-m200
DM3WSDR	MI	TT3UEY0
DM3WSDR	MN	Methamphetamine (Meth)
DM3WSDR	MT	DTT
DM3WSDR	MA	Antagonist
DM3WSDR	RN	Clinical pipeline report, company report or official report of InterveXion Therapeutics.
DM3WSDR	RU	http://intervexion.com/research-development/anti-methamphetamine-products/

DM9XKJU	DI	DM9XKJU
DM9XKJU	DN	J 591 Lu-177
DM9XKJU	MI	TT9G4N0
DM9XKJU	MN	Glutamate carboxypeptidase II (GCPII)
DM9XKJU	MT	DTT
DM9XKJU	MA	Modulator
DM9XKJU	RN	Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91.
DM9XKJU	RU	https://pubmed.ncbi.nlm.nih.gov/23714732

DMKU6MW	DI	DMKU6MW
DMKU6MW	DN	JB991
DMKU6MW	MI	TT9B4N3
DMKU6MW	MN	Prostaglandin receptor (PTGR)
DMKU6MW	MT	DTT
DMKU6MW	MA	Agonist
DMKU6MW	RN	US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis.
DMKU6MW	RU	http://www.google.com/patents/US20060041016

DM89ASO	DI	DM89ASO
DM89ASO	DN	JCAR015
DM89ASO	MI	TTW640A
DM89ASO	MN	B-lymphocyte surface antigen B4 (CD19)
DM89ASO	MT	DTT
DM89ASO	MA	CAR-T-Cell-Therapy
DM89ASO	RN	ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
DM89ASO	RU	https://clinicaltrials.gov/ct2/show/NCT02535364

DMM02VJ	DI	DMM02VJ
DMM02VJ	DN	JI-101
DMM02VJ	MI	TT0JESD
DMM02VJ	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMM02VJ	MT	DTT
DMM02VJ	MA	Modulator
DMM02VJ	RN	A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24.
DMM02VJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/26365907

DMARQ0H	DI	DMARQ0H
DMARQ0H	DN	JKB-122
DMARQ0H	MI	TTN4QDT
DMARQ0H	MN	Opioid receptor (OPR)
DMARQ0H	MT	DTT
DMARQ0H	MA	Modulator
DMARQ0H	RN	WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase.
DMARQ0H	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20111110&CC=WO&NR=2011140190A1&KC=A1

DMJSVRL	DI	DMJSVRL
DMJSVRL	DN	JM216
DMJSVRL	MI	TTUTN1I
DMJSVRL	MN	Human Deoxyribonucleic acid (hDNA)
DMJSVRL	MT	DTT
DMJSVRL	MA	Modulator
DMJSVRL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJSVRL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBXWJ5	DI	DMBXWJ5
DMBXWJ5	DN	JNJ 63723283
DMBXWJ5	MI	TTNBFWK
DMBXWJ5	MN	Programmed cell death protein 1 (PD-1)
DMBXWJ5	MT	DTT
DMBXWJ5	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMBXWJ5	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMY7Q3I	DI	DMY7Q3I
DMY7Q3I	DN	JNJ-10229570
DMY7Q3I	MI	TT6QAJ3
DMY7Q3I	MN	Melanocortin receptor 5 (MC5R)
DMY7Q3I	MT	DTT
DMY7Q3I	MA	Antagonist
DMY7Q3I	RN	A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32.
DMY7Q3I	RU	https://pubmed.ncbi.nlm.nih.gov/21602033

DM7OTQS	DI	DM7OTQS
DM7OTQS	DN	JNJ-10311795
DM7OTQS	MI	TTQAJF1
DM7OTQS	MN	Cathepsin G (CTSG)
DM7OTQS	MT	DTT
DM7OTQS	MA	Inhibitor
DM7OTQS	RN	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
DM7OTQS	RU	https://pubmed.ncbi.nlm.nih.gov/17361995

DM7OTQS	DI	DM7OTQS
DM7OTQS	DN	JNJ-10311795
DM7OTQS	MI	TT8VUE0
DM7OTQS	MN	Chymase (CYM)
DM7OTQS	MT	DTT
DM7OTQS	MA	Inhibitor
DM7OTQS	RN	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
DM7OTQS	RU	https://pubmed.ncbi.nlm.nih.gov/17361995

DMPFG7H	DI	DMPFG7H
DMPFG7H	DN	JNJ-16269110
DMPFG7H	MI	TTUS1RD
DMPFG7H	MN	Microsomal triglyceride transfer protein (MTTP)
DMPFG7H	MT	DTT
DMPFG7H	MA	Inhibitor
DMPFG7H	RN	ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
DMPFG7H	RU	https://clinicaltrials.gov/ct2/show/NCT00672386

DM1GRCU	DI	DM1GRCU
DM1GRCU	DN	JNJ-17216498
DM1GRCU	MI	TT9JNIC
DM1GRCU	MN	Histamine H3 receptor (H3R)
DM1GRCU	MT	DTT
DM1GRCU	MA	Antagonist
DM1GRCU	RN	Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
DM1GRCU	RU	https://pubmed.ncbi.nlm.nih.gov/15466448

DMV1T59	DI	DMV1T59
DMV1T59	DN	JNJ-18038683
DMV1T59	MI	TTO9X1H
DMV1T59	MN	5-HT 7 receptor (HTR7)
DMV1T59	MT	DTT
DMV1T59	MA	Antagonist
DMV1T59	RN	Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
DMV1T59	RU	https://pubmed.ncbi.nlm.nih.gov/25642174

DMKIE9C	DI	DMKIE9C
DMKIE9C	DN	JNJ-26481585
DMKIE9C	MI	TTBH0VX
DMKIE9C	MN	Histone deacetylase (HDAC)
DMKIE9C	MT	DTT
DMKIE9C	MA	Modulator
DMKIE9C	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
DMKIE9C	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503

DMQD1GN	DI	DMQD1GN
DMQD1GN	DN	JNJ-32729463
DMQD1GN	MI	TTN6J5F
DMQD1GN	MN	Bacterial DNA gyrase (Bact gyrase)
DMQD1GN	MT	DTT
DMQD1GN	MA	Inhibitor
DMQD1GN	RN	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
DMQD1GN	RU	https://pubmed.ncbi.nlm.nih.gov/21911562

DMQD1GN	DI	DMQD1GN
DMQD1GN	DN	JNJ-32729463
DMQD1GN	MI	TTFK8YB
DMQD1GN	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMQD1GN	MT	DTT
DMQD1GN	MA	Inhibitor
DMQD1GN	RN	Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
DMQD1GN	RU	https://pubmed.ncbi.nlm.nih.gov/21911562

DMV41P5	DI	DMV41P5
DMV41P5	DN	JNJ-37822681
DMV41P5	MI	DE4LYSA
DMV41P5	MN	Cytochrome P450 3A4 (CYP3A4)
DMV41P5	MT	DME
DMV41P5	MA	Metabolism
DMV41P5	RN	CYP3A4 and 3A5 catalysed alprazolam metabolism in vitro and in vivo. International Clinical Psychopharmacology, 2006, 21(4):A33.
DMV41P5	RU	https://www.researchgate.net/figure/Cloning-and-expression-CYP3A43-and-CYP3A4-and-metabolism-of-alprazolam-in-vitro-by_fig13_5310993

DMV41P5	DI	DMV41P5
DMV41P5	DN	JNJ-37822681
DMV41P5	MI	TTEX248
DMV41P5	MN	Dopamine D2 receptor (D2R)
DMV41P5	MT	DTT
DMV41P5	MA	Agonist
DMV41P5	RN	Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.
DMV41P5	RU	https://pubmed.ncbi.nlm.nih.gov/23754735

DM9UMIO	DI	DM9UMIO
DM9UMIO	DN	JNJ-38518168
DM9UMIO	MI	TTXJ178
DM9UMIO	MN	Histamine H4 receptor (H4R)
DM9UMIO	MT	DTT
DM9UMIO	MA	Antagonist
DM9UMIO	RN	The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65.
DM9UMIO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379874/

DM0WY3H	DI	DM0WY3H
DM0WY3H	DN	JNJ-39220675
DM0WY3H	MI	TT9JNIC
DM0WY3H	MN	Histamine H3 receptor (H3R)
DM0WY3H	MT	DTT
DM0WY3H	MA	Antagonist
DM0WY3H	RN	JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
DM0WY3H	RU	https://pubmed.ncbi.nlm.nih.gov/21086115

DMUOEKM	DI	DMUOEKM
DMUOEKM	DN	JNJ-39393406
DMUOEKM	MI	TTLA931
DMUOEKM	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMUOEKM	MT	DTT
DMUOEKM	MA	Modulator
DMUOEKM	RN	Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
DMUOEKM	RU	https://pubmed.ncbi.nlm.nih.gov/22766391

DM219SF	DI	DM219SF
DM219SF	DN	JNJ-40346527
DM219SF	MI	TT731LW
DM219SF	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM219SF	MT	DTT
DM219SF	MA	Modulator
DM219SF	RN	An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
DM219SF	RU	https://pubmed.ncbi.nlm.nih.gov/25628399

DM72GZO	DI	DM72GZO
DM72GZO	DN	JNJ-42165279
DM72GZO	MI	TTDP1UC
DM72GZO	MN	Fatty acid amide hydrolase (FAAH)
DM72GZO	MT	DTT
DM72GZO	MA	Inhibitor
DM72GZO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM72GZO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMJ1FXL	DI	DMJ1FXL
DMJ1FXL	DN	JNJ-53718678
DMJ1FXL	MI	TT57ID8
DMJ1FXL	MN	Respiratory syncytial virus protein F (RSV F)
DMJ1FXL	MT	DTT
DMJ1FXL	MA	Inhibitor
DMJ1FXL	RN	Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756.
DMJ1FXL	RU	https://pubmed.ncbi.nlm.nih.gov/29684148

DM9RW6H	DI	DM9RW6H
DM9RW6H	DN	JNJ-56136379
DM9RW6H	MI	TTM42UJ
DM9RW6H	MN	Hepatitis B virus Capsid protein (HBV C)
DM9RW6H	MT	DTT
DM9RW6H	MA	Inhibitor
DM9RW6H	RN	JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9.
DM9RW6H	RU	https://pubmed.ncbi.nlm.nih.gov/32343960

DME2S4D	DI	DME2S4D
DME2S4D	DN	JNJ-61393215
DME2S4D	MI	TT60Q8D
DME2S4D	MN	Orexin receptor type 1 (HCRTR1)
DME2S4D	MT	DTT
DME2S4D	MA	Antagonist
DME2S4D	RN	Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
DME2S4D	RU	https://pubmed.ncbi.nlm.nih.gov/32895369

DMVSUH1	DI	DMVSUH1
DMVSUH1	DN	JNJ-64565111
DMVSUH1	MI	TT0NUFM
DMVSUH1	MN	Glucagon (GCG)
DMVSUH1	MT	DTT
DMVSUH1	MA	Agonist
DMVSUH1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVSUH1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM3ICO6	DI	DM3ICO6
DM3ICO6	DN	JNJ-74494550
DM3ICO6	MI	TTNCIE0
DM3ICO6	MN	CD70 antigen (CD27-L)
DM3ICO6	MT	DTT
DM3ICO6	RN	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
DM3ICO6	RU	https://pubmed.ncbi.nlm.nih.gov/32601337

DMXTKCR	DI	DMXTKCR
DMXTKCR	DN	JT02
DMXTKCR	MI	TTQOVYA
DMXTKCR	MN	C-X-C motif chemokine 10 (CXCL10)
DMXTKCR	MT	DTT
DMXTKCR	MA	Inhibitor
DMXTKCR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXTKCR	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM2LBHN	DI	DM2LBHN
DM2LBHN	DN	JTE-051
DM2LBHN	MI	TT3C80U
DM2LBHN	MN	T-cell-specific kinase (ITK)
DM2LBHN	MT	DTT
DM2LBHN	MA	Inhibitor
DM2LBHN	RN	Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490.
DM2LBHN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174519/

DM1945H	DI	DM1945H
DM1945H	DN	JTT-251
DM1945H	MI	TT3UNDH
DM1945H	MN	Pyruvate dehydrogenase kinase (PDHK)
DM1945H	MT	DTT
DM1945H	MA	Inhibitor
DM1945H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1945H	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMGLVBI	DI	DMGLVBI
DMGLVBI	DN	JTT-302
DMGLVBI	MI	TTFQAYR
DMGLVBI	MN	Cholesteryl ester transfer protein (CETP)
DMGLVBI	MT	DTT
DMGLVBI	MA	Inhibitor
DMGLVBI	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMGLVBI	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DM50M2R	DI	DM50M2R
DM50M2R	DN	JTT-654
DM50M2R	MI	TTN7BL9
DM50M2R	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM50M2R	MT	DTT
DM50M2R	MA	Inhibitor
DM50M2R	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DM50M2R	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMED5J6	DI	DMED5J6
DMED5J6	DN	JTT-851
DMED5J6	MI	TTB8FUC
DMED5J6	MN	Free fatty acid receptor 1 (GPR40)
DMED5J6	MT	DTT
DMED5J6	MA	Agonist
DMED5J6	RN	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
DMED5J6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/

DMGXTOP	DI	DMGXTOP
DMGXTOP	DN	JTX-2011
DMGXTOP	MI	TTE5VP6
DMGXTOP	MN	Inducible T-cell costimulator (ICOS)
DMGXTOP	MT	DTT
DMGXTOP	MA	Agonist
DMGXTOP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGXTOP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOT0M7	DI	DMOT0M7
DMOT0M7	DN	JTX-4014
DMOT0M7	MI	TTNBFWK
DMOT0M7	MN	Programmed cell death protein 1 (PD-1)
DMOT0M7	MT	DTT
DMOT0M7	MA	Inhibitor
DMOT0M7	RN	Clinical pipeline report, company report or official report of Jounce Therapeutics.
DMOT0M7	RU	https://jouncetx.com/our-pipeline/

DMZKYNO	DI	DMZKYNO
DMZKYNO	DN	Juvidex
DMZKYNO	MI	TTPNE41
DMZKYNO	MN	CI Man-6-P receptor (IGF2R)
DMZKYNO	MT	DTT
DMZKYNO	MA	Modulator
DMZKYNO	RN	Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125.
DMZKYNO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022978/

DMPMU38	DI	DMPMU38
DMPMU38	DN	JVRS-100
DMPMU38	MI	TTSHG0T
DMPMU38	MN	Toll-like receptor 9 (TLR9)
DMPMU38	MT	DTT
DMPMU38	RN	Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820.
DMPMU38	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690618/

DMD4OK0	DI	DMD4OK0
DMD4OK0	DN	K-134
DMD4OK0	MI	TTZCG4L
DMD4OK0	MN	Phosphodiesterase 3 (PDE3)
DMD4OK0	MT	DTT
DMD4OK0	MA	Modulator
DMD4OK0	RN	A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1.
DMD4OK0	RU	https://pubmed.ncbi.nlm.nih.gov/22119244

DMZCVD7	DI	DMZCVD7
DMZCVD7	DN	K-201
DMZCVD7	MI	TT1VOHK
DMZCVD7	MN	Potassium channel unspecific (KC)
DMZCVD7	MT	DTT
DMZCVD7	MA	Modulator
DMZCVD7	RN	Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy 
DMZCVD7	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340112

DMQVN6P	DI	DMQVN6P
DMQVN6P	DN	K-604
DMQVN6P	MI	TTMF541
DMQVN6P	MN	Liver carboxylesterase (CES1)
DMQVN6P	MT	DTT
DMQVN6P	MA	Inhibitor
DMQVN6P	RN	A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7.
DMQVN6P	RU	https://pubmed.ncbi.nlm.nih.gov/16820149

DMJLNZQ	DI	DMJLNZQ
DMJLNZQ	DN	K-828-AB
DMJLNZQ	MI	TTT2LD9
DMJLNZQ	MN	GABA transaminase (ABAT)
DMJLNZQ	MT	DTT
DMJLNZQ	MA	Inhibitor
DMJLNZQ	RN	Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
DMJLNZQ	RU	http://www.biocentury.com/products/k-828-ab

DMMSTCF	DI	DMMSTCF
DMMSTCF	DN	K-832
DMMSTCF	MI	TTSD92E
DMMSTCF	MN	Interleukin-1 (IL1)
DMMSTCF	MT	DTT
DMMSTCF	MA	Inhibitor
DMMSTCF	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMMSTCF	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMTMCPZ	DI	DMTMCPZ
DMTMCPZ	DN	KB001A
DMTMCPZ	MI	TTLK9NJ
DMTMCPZ	MN	Pseudomonas PcrV protein type III (Pseudo pcrV)
DMTMCPZ	MT	DTT
DMTMCPZ	MA	Inhibitor
DMTMCPZ	RN	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491.
DMTMCPZ	RU	https://pubmed.ncbi.nlm.nih.gov/29292092

DM60G5O	DI	DM60G5O
DM60G5O	DN	KB002/003
DM60G5O	MI	TTNYZG2
DM60G5O	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM60G5O	MT	DTT
DM60G5O	MA	Modulator
DM60G5O	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM60G5O	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM74KIM	DI	DM74KIM
DM74KIM	DN	KB-003
DM74KIM	MI	TTNYZG2
DM74KIM	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM74KIM	MT	DTT
DM74KIM	RN	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
DM74KIM	RU	https://www.google.com/patents/US20100158905

DMZ4MCG	DI	DMZ4MCG
DMZ4MCG	DN	KB-6806
DMZ4MCG	MI	TTNXLKE
DMZ4MCG	MN	5-HT 3 receptor (5HT3R)
DMZ4MCG	MT	DTT
DMZ4MCG	MA	Antagonist
DMZ4MCG	RN	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
DMZ4MCG	RU	https://pubmed.ncbi.nlm.nih.gov/16503832

DMEFW3G	DI	DMEFW3G
DMEFW3G	DN	KD019
DMEFW3G	MI	TTI4ZX2
DMEFW3G	MN	Ephrin type-B receptor 4 (EPHB4)
DMEFW3G	MT	DTT
DMEFW3G	MA	Modulator
DMEFW3G	RN	XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26.
DMEFW3G	RU	https://pubmed.ncbi.nlm.nih.gov/22011666

DMEFW3G	DI	DMEFW3G
DMEFW3G	DN	KD019
DMEFW3G	MI	TTJSQEF
DMEFW3G	MN	Tyrosine-protein kinase (PTK)
DMEFW3G	MT	DTT
DMEFW3G	MA	Inhibitor
DMEFW3G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFW3G	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM548TK	DI	DM548TK
DM548TK	DN	KD025
DM548TK	MI	TTGWKQJ
DM548TK	MN	Rho-associated protein kinase 2 (ROCK2)
DM548TK	MT	DTT
DM548TK	MA	Inhibitor
DM548TK	RN	Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9.
DM548TK	RU	https://pubmed.ncbi.nlm.nih.gov/25385601

DME1WV2	DI	DME1WV2
DME1WV2	DN	KD-7040
DME1WV2	MI	TTF10I9
DME1WV2	MN	Nitric-oxide synthase inducible (NOS2)
DME1WV2	MT	DTT
DME1WV2	MA	Inhibitor
DME1WV2	RN	WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
DME1WV2	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140206&CC=WO&NR=2014021408A1&KC=A1

DMFO6MH	DI	DMFO6MH
DMFO6MH	DN	Kevetrin
DMFO6MH	MI	TT7SBF5
DMFO6MH	MN	Cellular tumor antigen p53 (TP53)
DMFO6MH	MT	DTT
DMFO6MH	MA	Stimulator
DMFO6MH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFO6MH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF6CTI	DI	DMF6CTI
DMF6CTI	DN	KHK-6188
DMF6CTI	MI	TTMSFAW
DMF6CTI	MN	Cannabinoid receptor 2 (CB2)
DMF6CTI	MT	DTT
DMF6CTI	MA	Agonist
DMF6CTI	RN	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
DMF6CTI	RU	http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands

DM40HOY	DI	DM40HOY
DM40HOY	DN	KLH-2109
DM40HOY	MI	TT8R70G
DM40HOY	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DM40HOY	MT	DTT
DM40HOY	MA	Agonist
DM40HOY	RN	Clinical pipeline report, company report or official report of Avarx.
DM40HOY	RU	http://www.avarx.com/AvaRx/SubDomains/bucket2705902527756613996/Listings/bucket5664821816690947691/Public.Listing.display.html

DM05TBE	DI	DM05TBE
DM05TBE	DN	KLS-0611
DM05TBE	MI	TTHBUXE
DM05TBE	MN	Mucin (MUC)
DM05TBE	MT	DTT
DM05TBE	MA	Stimulator
DM05TBE	RN	WO patent application no. 2011,1034,23, Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors.
DM05TBE	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110825&CC=WO&NR=2011103423A1&KC=A1

DMNLH9W	DI	DMNLH9W
DMNLH9W	DN	KN026
DMNLH9W	MI	TT6EO5L
DMNLH9W	MN	Erbb2 tyrosine kinase receptor (HER2)
DMNLH9W	MT	DTT
DMNLH9W	MA	Inhibitor
DMNLH9W	RN	Clinical pipeline report, company report or official report of Alphamab Oncology.
DMNLH9W	RU	http://www.alphamabonc.com/pipeline/kn026.html

DMKLMG6	DI	DMKLMG6
DMKLMG6	DN	KN035
DMKLMG6	MI	TT8ZLTI
DMKLMG6	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMKLMG6	MT	DTT
DMKLMG6	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMKLMG6	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMQZ5HF	DI	DMQZ5HF
DMQZ5HF	DN	KNI-272
DMQZ5HF	MI	DE4LYSA
DMQZ5HF	MN	Cytochrome P450 3A4 (CYP3A4)
DMQZ5HF	MT	DME
DMQZ5HF	MA	Metabolism
DMQZ5HF	RN	Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56.
DMQZ5HF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=10049266

DMQZ5HF	DI	DMQZ5HF
DMQZ5HF	DN	KNI-272
DMQZ5HF	MI	TT5FNQT
DMQZ5HF	MN	Human immunodeficiency virus Protease (HIV PR)
DMQZ5HF	MT	DTT
DMQZ5HF	MA	Modulator
DMQZ5HF	RN	Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activit... Antimicrob Agents Chemother. 2002 Feb;46(2):402-8.
DMQZ5HF	RU	https://www.ncbi.nlm.nih.gov/pubmed/11796349

DMCO8UZ	DI	DMCO8UZ
DMCO8UZ	DN	KP-496
DMCO8UZ	MI	TTGKOY9
DMCO8UZ	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMCO8UZ	MT	DTT
DMCO8UZ	MA	Modulator
DMCO8UZ	RN	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
DMCO8UZ	RU	https://pubmed.ncbi.nlm.nih.gov/17130683

DMCO8UZ	DI	DMCO8UZ
DMCO8UZ	DN	KP-496
DMCO8UZ	MI	TT2O84V
DMCO8UZ	MN	Thromboxane A2 receptor (TBXA2R)
DMCO8UZ	MT	DTT
DMCO8UZ	MA	Modulator
DMCO8UZ	RN	Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
DMCO8UZ	RU	https://pubmed.ncbi.nlm.nih.gov/17130683

DM4WHOS	DI	DM4WHOS
DM4WHOS	DN	KPP203
DM4WHOS	MI	TT7BQRM
DM4WHOS	MN	Sphingosine-1 phosphate receptor (S1PR)
DM4WHOS	MT	DTT
DM4WHOS	MA	Agonist
DM4WHOS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WHOS	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQDLVW	DI	DMQDLVW
DMQDLVW	DN	KRP-104
DMQDLVW	MI	TTDIGC1
DMQDLVW	MN	Dipeptidyl peptidase 4 (DPP-4)
DMQDLVW	MT	DTT
DMQDLVW	MA	Modulator
DMQDLVW	RN	Clinical pipeline report, company report or official report of Activx.
DMQDLVW	RU	http://www.activx.com/press/news_20080821.html

DMOW9X2	DI	DMOW9X2
DMOW9X2	DN	KRP-203
DMOW9X2	MI	TT9JZCK
DMOW9X2	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMOW9X2	MT	DTT
DMOW9X2	MA	Agonist
DMOW9X2	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMOW9X2	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DM08F12	DI	DM08F12
DM08F12	DN	KT6-971
DM08F12	MI	TTNA5ZS
DM08F12	MN	Cholesterol absorption (Chole absorp)
DM08F12	MT	DTT
DM08F12	MA	Inhibitor
DM08F12	RN	Intestinal and Hepatic Niemann-Pick C1-Like 1. Correction in: Diabetes Metab J. 2013 December; 37(6): 486-487.
DM08F12	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753488/

DMZL48U	DI	DMZL48U
DMZL48U	DN	KUR-111
DMZL48U	MI	TT6F7GZ
DMZL48U	MN	Parathyroid hormone (PTH)
DMZL48U	MT	DTT
DMZL48U	MA	Modulator
DMZL48U	RN	Company report (Cytos)
DMZL48U	RU	http://www.cytos.com/kur-111/

DM2N0Z3	DI	DM2N0Z3
DM2N0Z3	DN	KUR-211
DM2N0Z3	MI	TTWODQF
DM2N0Z3	MN	Fibrin (FG)
DM2N0Z3	MT	DTT
DM2N0Z3	MA	Modulator
DM2N0Z3	RN	Clinical pipeline report, company report or official report of Kuros.
DM2N0Z3	RU	http://www.kuros.ch/cms/front_content.php?idcat=78

DMB4HCY	DI	DMB4HCY
DMB4HCY	DN	KUR-212
DMB4HCY	MI	TTWODQF
DMB4HCY	MN	Fibrin (FG)
DMB4HCY	MT	DTT
DMB4HCY	MA	Modulator
DMB4HCY	RN	Clinical pipeline report, company report or official report of Kuros.
DMB4HCY	RU	http://www.kuros.ch/cms/front_content.php?idcat=80

DMK4VOU	DI	DMK4VOU
DMK4VOU	DN	KVD001
DMK4VOU	MI	TTMF8H9
DMK4VOU	MN	Plasma kallikrein (KLKB1)
DMK4VOU	MT	DTT
DMK4VOU	MA	Inhibitor
DMK4VOU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK4VOU	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM5N4OA	DI	DM5N4OA
DM5N4OA	DN	KVD824
DM5N4OA	MI	TTMF8H9
DM5N4OA	MN	Plasma kallikrein (KLKB1)
DM5N4OA	MT	DTT
DM5N4OA	MA	Inhibitor
DM5N4OA	RN	Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
DM5N4OA	RU	https://www.kalvista.com/products-pipeline/kvd824-hae

DMJGL72	DI	DMJGL72
DMJGL72	DN	KW-2478
DMJGL72	MI	TT78R5H
DMJGL72	MN	Heat shock protein 90 alpha (HSP90A)
DMJGL72	MT	DTT
DMJGL72	MA	Modulator
DMJGL72	RN	Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
DMJGL72	RU	https://pubmed.ncbi.nlm.nih.gov/22829970

DM15RZO	DI	DM15RZO
DM15RZO	DN	KYMRIAH
DM15RZO	MI	TTW640A
DM15RZO	MN	B-lymphocyte surface antigen B4 (CD19)
DM15RZO	MT	DTT
DM15RZO	MA	CAR-T-Cell-Therapy
DM15RZO	RN	ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
DM15RZO	RU	https://clinicaltrials.gov/ct2/show/NCT03642626

DMLHPVW	DI	DMLHPVW
DMLHPVW	DN	L1-79
DMLHPVW	MI	TTUHP71
DMLHPVW	MN	Tyrosine 3-monooxygenase (TH)
DMLHPVW	MT	DTT
DMLHPVW	MA	Inhibitor
DMLHPVW	RN	Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
DMLHPVW	RU	https://pubmed.ncbi.nlm.nih.gov/31492568

DMI2XP1	DI	DMI2XP1
DMI2XP1	DN	L19-IL-2 fusion protein
DMI2XP1	MI	TTF89GD
DMI2XP1	MN	Interleukin-2 (IL2)
DMI2XP1	MT	DTT
DMI2XP1	RN	National Cancer Institute Drug Dictionary (drug id 665656).
DMI2XP1	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=665656

DMW6NMP	DI	DMW6NMP
DMW6NMP	DN	L19-TNF-alpha
DMW6NMP	MI	TTPJ921
DMW6NMP	MN	Fibronectin (FN1)
DMW6NMP	MT	DTT
DMW6NMP	RN	National Cancer Institute Drug Dictionary (drug id 686947).
DMW6NMP	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=686947

DMA0DSJ	DI	DMA0DSJ
DMA0DSJ	DN	L-694,458
DMA0DSJ	MI	TTPLTSQ
DMA0DSJ	MN	Neutrophil elastase (NE)
DMA0DSJ	MT	DTT
DMA0DSJ	MA	Inhibitor
DMA0DSJ	RN	Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
DMA0DSJ	RU	https://pubmed.ncbi.nlm.nih.gov/12084007

DMB7WT1	DI	DMB7WT1
DMB7WT1	DN	L-697,661
DMB7WT1	MI	TT84ETX
DMB7WT1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMB7WT1	MT	DTT
DMB7WT1	MA	Modulator
DMB7WT1	RN	Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8.
DMB7WT1	RU	https://www.ncbi.nlm.nih.gov/pubmed/7532595

DMTGR25	DI	DMTGR25
DMTGR25	DN	L-745,870
DMTGR25	MI	TTE0A2F
DMTGR25	MN	Dopamine D4 receptor (D4R)
DMTGR25	MT	DTT
DMTGR25	MA	Antagonist
DMTGR25	RN	Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
DMTGR25	RU	https://pubmed.ncbi.nlm.nih.gov/18604600

DMNO5UE	DI	DMNO5UE
DMNO5UE	DN	Labetuzumab I-131
DMNO5UE	MI	TTY6DTE
DMNO5UE	MN	Carcinoembryonic antigen CEA (CD66e)
DMNO5UE	MT	DTT
DMNO5UE	RN	National Cancer Institute Drug Dictionary (drug id 692828).
DMNO5UE	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=692828

DM7063I	DI	DM7063I
DM7063I	DN	LADIRUBICIN
DM7063I	MI	TTUTN1I
DM7063I	MN	Human Deoxyribonucleic acid (hDNA)
DM7063I	MT	DTT
DM7063I	MA	Binder
DM7063I	RN	The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81.
DM7063I	RU	https://pubmed.ncbi.nlm.nih.gov/16036566

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TT1RS9F
DMJSY3Q	MN	Acetylcholinesterase (AChE)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TT3WG5C
DMJSY3Q	MN	Monoamine oxidase type A (MAO-A)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMJSY3Q	DI	DMJSY3Q
DMJSY3Q	DN	Ladostigil
DMJSY3Q	MI	TTGP7BY
DMJSY3Q	MN	Monoamine oxidase type B (MAO-B)
DMJSY3Q	MT	DTT
DMJSY3Q	MA	Inhibitor
DMJSY3Q	RN	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
DMJSY3Q	RU	https://pubmed.ncbi.nlm.nih.gov/22280345

DMSIGAB	DI	DMSIGAB
DMSIGAB	DN	L-alanosine
DMSIGAB	MI	TTEWTCR
DMSIGAB	MN	Adenine synthesis (Adeni synth)
DMSIGAB	MT	DTT
DMSIGAB	MA	Modulator
DMSIGAB	RN	Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006 Feb;5(2):337-46.
DMSIGAB	RU	https://pubmed.ncbi.nlm.nih.gov/16505107

DMR0N74	DI	DMR0N74
DMR0N74	DN	LAM-002
DMR0N74	MI	TTA4M1N
DMR0N74	MN	Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)
DMR0N74	MT	DTT
DMR0N74	MA	Inhibitor
DMR0N74	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR0N74	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7MBV6	DI	DM7MBV6
DM7MBV6	DN	Lancovutide
DM7MBV6	MI	TTCYAXN
DM7MBV6	MN	Chloride channel unspecific (ClC)
DM7MBV6	MT	DTT
DM7MBV6	MA	Modulator
DM7MBV6	RN	Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59.
DM7MBV6	RU	https://pubmed.ncbi.nlm.nih.gov/21156814

DM1VK96	DI	DM1VK96
DM1VK96	DN	LANEPITANT
DM1VK96	MI	TTZPO1L
DM1VK96	MN	Substance-P receptor (TACR1)
DM1VK96	MT	DTT
DM1VK96	MA	Antagonist
DM1VK96	RN	NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94.
DM1VK96	RU	https://pubmed.ncbi.nlm.nih.gov/25228541

DMPRZX4	DI	DMPRZX4
DMPRZX4	DN	LAS 100977
DMPRZX4	MI	TT2CJVK
DMPRZX4	MN	Adrenergic receptor beta-2 (ADRB2)
DMPRZX4	MT	DTT
DMPRZX4	MA	Agonist
DMPRZX4	RN	Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509.
DMPRZX4	RU	https://pubmed.ncbi.nlm.nih.gov/22588259

DM3WY0B	DI	DM3WY0B
DM3WY0B	DN	LAS-41002
DM3WY0B	MI	TTYRL6O
DM3WY0B	MN	Glucocorticoid receptor (NR3C1)
DM3WY0B	MT	DTT
DM3WY0B	MA	Modulator
DM3WY0B	RN	Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134.
DM3WY0B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432345/

DMC04SR	DI	DMC04SR
DMC04SR	DN	LB-100
DMC04SR	MI	TTRKDL6
DMC04SR	MN	Serine/threonine PP2A (PP2A)
DMC04SR	MT	DTT
DMC04SR	MA	Inhibitor
DMC04SR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC04SR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC04SR	DI	DMC04SR
DMC04SR	DN	LB-100
DMC04SR	MI	TTHTKNY
DMC04SR	MN	Serine/threonine PP2A-alpha (PPP2CA)
DMC04SR	MT	DTT
DMC04SR	MA	Inhibitor
DMC04SR	RN	Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72.
DMC04SR	RU	https://pubmed.ncbi.nlm.nih.gov/24867249

DM0OHX3	DI	DM0OHX3
DM0OHX3	DN	LB-30870
DM0OHX3	MI	TT6L509
DM0OHX3	MN	Coagulation factor IIa (F2)
DM0OHX3	MT	DTT
DM0OHX3	MA	Inhibitor
DM0OHX3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM0OHX3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMQZJNA	DI	DMQZJNA
DMQZJNA	DN	LCAR-B38M CAR-T Cell
DMQZJNA	MI	TTZ3P4W
DMQZJNA	MN	B-cell maturation protein (TNFRSF17)
DMQZJNA	MT	DTT
DMQZJNA	MA	CAR-T-Cell-Therapy
DMQZJNA	RN	ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
DMQZJNA	RU	https://clinicaltrials.gov/ct2/show/NCT03758417

DMY4IWC	DI	DMY4IWC
DMY4IWC	DN	LCB-2183
DMY4IWC	MI	TT7CXIM
DMY4IWC	MN	Histamine receptor (HR)
DMY4IWC	MT	DTT
DMY4IWC	MA	Modulator
DMY4IWC	RN	LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
DMY4IWC	RU	https://pubmed.ncbi.nlm.nih.gov/7989136

DMTM4QA	DI	DMTM4QA
DMTM4QA	DN	LCL161
DMTM4QA	MI	TTS74QB
DMTM4QA	MN	Inhibitor of apoptosis protein (hIAP)
DMTM4QA	MT	DTT
DMTM4QA	MA	Modulator
DMTM4QA	RN	National Cancer Institute Drug Dictionary (drug id 670651).
DMTM4QA	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670651

DMM9F25	DI	DMM9F25
DMM9F25	DN	LDE225
DMM9F25	MI	TT8J1S3
DMM9F25	MN	Smoothened homolog (SMO)
DMM9F25	MT	DTT
DMM9F25	MA	Modulator
DMM9F25	RN	Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
DMM9F25	RU	https://pubmed.ncbi.nlm.nih.gov/25093491

DMIEZUB	DI	DMIEZUB
DMIEZUB	DN	L-DOS47
DMIEZUB	MI	TTUTJGQ
DMIEZUB	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMIEZUB	MT	DTT
DMIEZUB	RN	Clinical pipeline report, company report or official report of Helix BioPharma.
DMIEZUB	RU	https://www.helixbiopharma.com/pipeline/

DMS6E9J	DI	DMS6E9J
DMS6E9J	DN	Lefitolimod
DMS6E9J	MI	TTSHG0T
DMS6E9J	MN	Toll-like receptor 9 (TLR9)
DMS6E9J	MT	DTT
DMS6E9J	MA	Agonist
DMS6E9J	RN	Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096.
DMS6E9J	RU	https://pubmed.ncbi.nlm.nih.gov/31741757

DMV2YDK	DI	DMV2YDK
DMV2YDK	DN	LEISH-F1
DMV2YDK	MI	TT3J5ZI
DMV2YDK	MN	Cell mediated immunity response (CMIR)
DMV2YDK	MT	DTT
DMV2YDK	RN	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7.
DMV2YDK	RU	https://pubmed.ncbi.nlm.nih.gov/21414377

DMZKBMG	DI	DMZKBMG
DMZKBMG	DN	Lenapenem hydrochloride hydrate
DMZKBMG	MI	TTJP4SM
DMZKBMG	MN	Bacterial Penicillin binding protein (Bact PBP)
DMZKBMG	MT	DTT
DMZKBMG	MA	Inhibitor
DMZKBMG	RN	Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42.
DMZKBMG	RU	https://pubmed.ncbi.nlm.nih.gov/9099223

DMWAD93	DI	DMWAD93
DMWAD93	DN	Leniolisib
DMWAD93	MI	TTGBPJE
DMWAD93	MN	PI3-kinase delta (PIK3CD)
DMWAD93	MT	DTT
DMWAD93	MA	Inhibitor
DMWAD93	RN	Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
DMWAD93	RU	https://pubmed.ncbi.nlm.nih.gov/28972011

DMR1MQW	DI	DMR1MQW
DMR1MQW	DN	Lenzilumab
DMR1MQW	MI	TTNYZG2
DMR1MQW	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMR1MQW	MT	DTT
DMR1MQW	MA	Antagonist
DMR1MQW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR1MQW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7W0JE	DI	DM7W0JE
DM7W0JE	DN	LEO 124249
DM7W0JE	MI	TTJSQEF
DM7W0JE	MN	Tyrosine-protein kinase (PTK)
DM7W0JE	MT	DTT
DM7W0JE	MA	Inhibitor
DM7W0JE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7W0JE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMZ6Y0T	DI	DMZ6Y0T
DMZ6Y0T	DN	LEO-32731
DMZ6Y0T	MI	TTV5CGO
DMZ6Y0T	MN	Phosphodiesterase 4 (PDE4)
DMZ6Y0T	MT	DTT
DMZ6Y0T	MA	Inhibitor
DMZ6Y0T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6Y0T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM6DL5K	DI	DM6DL5K
DM6DL5K	DN	Leridistim
DM6DL5K	MI	TTPYS82
DM6DL5K	MN	Interleukin 3 receptor (CSF2RB)
DM6DL5K	MT	DTT
DM6DL5K	MA	Agonist
DM6DL5K	RN	Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33.
DM6DL5K	RU	https://pubmed.ncbi.nlm.nih.gov/11713344

DMMQ6VT	DI	DMMQ6VT
DMMQ6VT	DN	Leronlimab
DMMQ6VT	MI	TTH91NV
DMMQ6VT	MN	HUMAN C-C chemokine receptor 5 (CCR5)
DMMQ6VT	MT	DTT
DMMQ6VT	MA	Inhibitor
DMMQ6VT	RN	Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
DMMQ6VT	RU	https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full.pdf

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	DE4LYSA
DMSEVBH	MN	Cytochrome P450 3A4 (CYP3A4)
DMSEVBH	MT	DME
DMSEVBH	MA	Metabolism
DMSEVBH	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DMSEVBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	TT84ETX
DMSEVBH	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMSEVBH	MT	DTT
DMSEVBH	MA	Inhibitor
DMSEVBH	RN	Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95.
DMSEVBH	RU	https://pubmed.ncbi.nlm.nih.gov/21095483

DMSEVBH	DI	DMSEVBH
DMSEVBH	DN	Lersivirine
DMSEVBH	MI	DEB3CV1
DMSEVBH	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMSEVBH	MT	DME
DMSEVBH	MA	Metabolism
DMSEVBH	RN	Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos. 2010 May;38(5):789-800.
DMSEVBH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20124396

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTI7UX6
DMW50NF	MN	Breast cancer resistance protein (ABCG2)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem Biophys Res Commun. 2001 Nov 9;288(4):827-32.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/11688982

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	TTGTQHC
DMW50NF	MN	DNA topoisomerase I (TOP1)
DMW50NF	MT	DTT
DMW50NF	MA	Inhibitor
DMW50NF	RN	Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012 Nov;32(11):4823-32.
DMW50NF	RU	https://pubmed.ncbi.nlm.nih.gov/23155248

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTSYQGK
DMW50NF	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
DMW50NF	RU	http://molpharm.aspetjournals.org/content/55/5/921

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTFI42L
DMW50NF	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/9823324

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DTCSGPB
DMW50NF	MN	Multidrug resistance-associated protein 4 (ABCC4)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMW50NF	RU	https://doi.org/10.1007/s11095-012-0935-x

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DT3D8F0
DMW50NF	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DT9C1TS
DMW50NF	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DMW50NF	MT	DTP
DMW50NF	MA	Substrate
DMW50NF	RN	Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
DMW50NF	RU	http://www.ncbi.nlm.nih.gov/pubmed/18082941

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DEYGVN4
DMW50NF	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMW50NF	MT	DME
DMW50NF	MA	Metabolism
DMW50NF	RN	Effects of green tea compounds on irinotecan metabolism. Drug Metab Dispos. 2007 Feb;35(2):228-33.
DMW50NF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17108060

DMW50NF	DI	DMW50NF
DMW50NF	DN	LE-SN38
DMW50NF	MI	DE85D2P
DMW50NF	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMW50NF	MT	DME
DMW50NF	MA	Metabolism
DMW50NF	RN	Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett. 2012 Mar;3(3):694-698.
DMW50NF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22740978

DMIFGLY	DI	DMIFGLY
DMIFGLY	DN	Leukemia cancer vaccine
DMIFGLY	MI	TT6MP2Z
DMIFGLY	MN	GMCSFR-alpha (CSF2RA)
DMIFGLY	MT	DTT
DMIFGLY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMIFGLY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM5LQEI	DI	DM5LQEI
DM5LQEI	DN	Leuvectin
DM5LQEI	MI	TTF89GD
DM5LQEI	MN	Interleukin-2 (IL2)
DM5LQEI	MT	DTT
DM5LQEI	MA	Modulator
DM5LQEI	RN	Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6.
DM5LQEI	RU	https://pubmed.ncbi.nlm.nih.gov/10854152

DMOS5JZ	DI	DMOS5JZ
DMOS5JZ	DN	Lexatumumab
DMOS5JZ	MI	TTW20TU
DMOS5JZ	MN	TRAIL receptor 2 (TRAIL-R2)
DMOS5JZ	MT	DTT
DMOS5JZ	RN	National Cancer Institute Drug Dictionary (drug id 528015).
DMOS5JZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=528015

DMLEX1D	DI	DMLEX1D
DMLEX1D	DN	Lexibulin
DMLEX1D	MI	TTYFKSZ
DMLEX1D	MN	Tubulin beta (TUBB)
DMLEX1D	MT	DTT
DMLEX1D	MA	Inhibitor
DMLEX1D	RN	National Cancer Institute Drug Dictionary (drug id 598799).
DMLEX1D	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=598799

DMZ2YBE	DI	DMZ2YBE
DMZ2YBE	DN	Lexipafant
DMZ2YBE	MI	TT84ETX
DMZ2YBE	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMZ2YBE	MT	DTT
DMZ2YBE	MA	Inhibitor
DMZ2YBE	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMZ2YBE	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMZ2YBE	DI	DMZ2YBE
DMZ2YBE	DN	Lexipafant
DMZ2YBE	MI	TTQL5VC
DMZ2YBE	MN	Platelet-activating factor receptor (PTAFR)
DMZ2YBE	MT	DTT
DMZ2YBE	MA	Modulator
DMZ2YBE	RN	Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
DMZ2YBE	RU	https://www.ncbi.nlm.nih.gov/pubmed/12440758

DMCT1RQ	DI	DMCT1RQ
DMCT1RQ	DN	LFG-316
DMCT1RQ	MI	TTKANGO
DMCT1RQ	MN	Complement C5 (CO5)
DMCT1RQ	MT	DTT
DMCT1RQ	RN	Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
DMCT1RQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/

DM9T8A2	DI	DM9T8A2
DM9T8A2	DN	LGD-4665
DM9T8A2	MI	TTIHYA4
DM9T8A2	MN	Thrombopoietin receptor (MPL)
DM9T8A2	MT	DTT
DM9T8A2	MA	Agonist
DM9T8A2	RN	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
DM9T8A2	RU	https://pubmed.ncbi.nlm.nih.gov/18537519

DMPL9KG	DI	DMPL9KG
DMPL9KG	DN	LGD-6972
DMPL9KG	MI	TT9O6WS
DMPL9KG	MN	Glucagon receptor (GCGR)
DMPL9KG	MT	DTT
DMPL9KG	MA	Antagonist
DMPL9KG	RN	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
DMPL9KG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/

DMA0RI9	DI	DMA0RI9
DMA0RI9	DN	LIDORESTAT
DMA0RI9	MI	TTFBNVI
DMA0RI9	MN	Aldose reductase (AKR1B1)
DMA0RI9	MT	DTT
DMA0RI9	MA	Inhibitor
DMA0RI9	RN	Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
DMA0RI9	RU	https://pubmed.ncbi.nlm.nih.gov/15857120

DM32NWD	DI	DM32NWD
DM32NWD	DN	LIK-066
DM32NWD	MI	TT2UE56
DM32NWD	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM32NWD	MT	DTT
DM32NWD	MA	Inhibitor
DM32NWD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
DM32NWD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915

DM32NWD	DI	DM32NWD
DM32NWD	DN	LIK-066
DM32NWD	MI	TTLWPVF
DM32NWD	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM32NWD	MT	DTT
DM32NWD	MA	Inhibitor
DM32NWD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM32NWD	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM9ZHRS	DI	DM9ZHRS
DM9ZHRS	DN	LIM-0705
DM9ZHRS	MI	TTK8XD6
DM9ZHRS	MN	ATP-binding cassette transporter (ABCA)
DM9ZHRS	MT	DTT
DM9ZHRS	MA	Activator
DM9ZHRS	RN	WO patent application no. 2010,0428,86, Pyrone analogs for therapeutic treatment.
DM9ZHRS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100415&CC=WO&NR=2010042886A2&KC=A2

DMSHGWN	DI	DMSHGWN
DMSHGWN	DN	Lintopride
DMSHGWN	MI	TTNXLKE
DMSHGWN	MN	5-HT 3 receptor (5HT3R)
DMSHGWN	MT	DTT
DMSHGWN	MA	Modulator
DMSHGWN	RN	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
DMSHGWN	RU	https://pubmed.ncbi.nlm.nih.gov/8580279

DMSHGWN	DI	DMSHGWN
DMSHGWN	DN	Lintopride
DMSHGWN	MI	TT07C3Y
DMSHGWN	MN	5-HT 4 receptor (HTR4)
DMSHGWN	MT	DTT
DMSHGWN	MA	Modulator
DMSHGWN	RN	The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
DMSHGWN	RU	https://pubmed.ncbi.nlm.nih.gov/8580279

DMWY0V1	DI	DMWY0V1
DMWY0V1	DN	LIPO-5
DMWY0V1	MI	TTFGZB6
DMWY0V1	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMWY0V1	MT	DTT
DMWY0V1	RN	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
DMWY0V1	RU	https://pubmed.ncbi.nlm.nih.gov/25839103

DMWY0V1	DI	DMWY0V1
DMWY0V1	DN	LIPO-5
DMWY0V1	MI	TT4NXYM
DMWY0V1	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMWY0V1	MT	DTT
DMWY0V1	RN	HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9.
DMWY0V1	RU	https://pubmed.ncbi.nlm.nih.gov/25839103

DMNGT89	DI	DMNGT89
DMNGT89	DN	Lirilumab
DMNGT89	MI	TTAZF9M
DMNGT89	MN	RAS-like protein KIR (GEM)
DMNGT89	MT	DTT
DMNGT89	MA	Modulator
DMNGT89	RN	Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40.
DMNGT89	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTZ97H5
DMD4KAU	MN	Phosphodiesterase 4A (PDE4A)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMD4KAU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTVIAT9
DMD4KAU	MN	Phosphodiesterase 4B (PDE4B)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMD4KAU	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMD4KAU	DI	DMD4KAU
DMD4KAU	DN	LIRIMILAST
DMD4KAU	MI	TTSKMI8
DMD4KAU	MN	Phosphodiesterase 4D (PDE4D)
DMD4KAU	MT	DTT
DMD4KAU	MA	Inhibitor
DMD4KAU	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMD4KAU	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMVU9X1	DI	DMVU9X1
DMVU9X1	DN	Lisofylline
DMVU9X1	MI	DEJGDUW
DMVU9X1	MN	Cytochrome P450 1A2 (CYP1A2)
DMVU9X1	MT	DME
DMVU9X1	MA	Metabolism
DMVU9X1	RN	Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):403-12.
DMVU9X1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25663650

DMZ3OU6	DI	DMZ3OU6
DMZ3OU6	DN	Lithium
DMZ3OU6	MI	TTRZQE3
DMZ3OU6	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMZ3OU6	MT	DTT
DMZ3OU6	MA	Inhibitor
DMZ3OU6	RN	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
DMZ3OU6	RU	https://pubmed.ncbi.nlm.nih.gov/29212798

DMZ3OU6	DI	DMZ3OU6
DMZ3OU6	DN	Lithium
DMZ3OU6	MI	TTRSMW9
DMZ3OU6	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMZ3OU6	MT	DTT
DMZ3OU6	MA	Inhibitor
DMZ3OU6	RN	The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
DMZ3OU6	RU	https://pubmed.ncbi.nlm.nih.gov/29212798

DM3XRUH	DI	DM3XRUH
DM3XRUH	DN	LJN452
DM3XRUH	MI	TTS4UGC
DM3XRUH	MN	Farnesoid X-activated receptor (FXR)
DM3XRUH	MT	DTT
DM3XRUH	MA	Agonist
DM3XRUH	RN	FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
DM3XRUH	RU	https://www.ncbi.nlm.nih.gov/pubmed/30259754

DMVM13R	DI	DMVM13R
DMVM13R	DN	LJPC-401
DMVM13R	MI	TTPCG5T
DMVM13R	MN	Hepcidin (HAMP)
DMVM13R	MT	DTT
DMVM13R	MA	Agonist
DMVM13R	RN	ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health.
DMVM13R	RU	https://clinicaltrials.gov/ct2/show/NCT03395704

DMCFGP3	DI	DMCFGP3
DMCFGP3	DN	LKA651
DMCFGP3	MI	TTQG4NR
DMCFGP3	MN	Erythropoietin (EPO)
DMCFGP3	MT	DTT
DMCFGP3	RN	Clinical pipeline report, company report or official report of Novartis.
DMCFGP3	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=LKA651&field_pipeline_filing_date=All

DMSJOE3	DI	DMSJOE3
DMSJOE3	DN	LM-030
DMSJOE3	MI	TT5L2VC
DMSJOE3	MN	Kallikrein-related peptidase (KLK)
DMSJOE3	MT	DTT
DMSJOE3	MA	Inhibitor
DMSJOE3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSJOE3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMW6VA0	DI	DMW6VA0
DMW6VA0	DN	LM-1507.NA
DMW6VA0	MI	TTGKOY9
DMW6VA0	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMW6VA0	MT	DTT
DMW6VA0	MA	Antagonist
DMW6VA0	RN	Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
DMW6VA0	RU	https://pubmed.ncbi.nlm.nih.gov/11996896

DMG7RAV	DI	DMG7RAV
DMG7RAV	DN	LMB-2
DMG7RAV	MI	TT10Y9E
DMG7RAV	MN	Interleukin 2 receptor alpha (IL2RA)
DMG7RAV	MT	DTT
DMG7RAV	MA	Modulator
DMG7RAV	RN	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
DMG7RAV	RU	https://pubmed.ncbi.nlm.nih.gov/10764422

DMQOXNL	DI	DMQOXNL
DMQOXNL	DN	LMB763
DMQOXNL	MI	TTS4UGC
DMQOXNL	MN	Farnesoid X-activated receptor (FXR)
DMQOXNL	MT	DTT
DMQOXNL	MA	Agonist
DMQOXNL	RN	Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
DMQOXNL	RU	https://pubmed.ncbi.nlm.nih.gov/31940200

DM01SR6	DI	DM01SR6
DM01SR6	DN	L-NAME
DM01SR6	MI	TTCM4B3
DM01SR6	MN	Nitric-oxide synthase endothelial (NOS3)
DM01SR6	MT	DTT
DM01SR6	MA	Inhibitor
DM01SR6	RN	Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
DM01SR6	RU	https://pubmed.ncbi.nlm.nih.gov/19586617

DMT3KB4	DI	DMT3KB4
DMT3KB4	DN	Lobeline
DMT3KB4	MI	TTNZRI3
DMT3KB4	MN	Synaptic vesicle amine transporter (SLC18A2)
DMT3KB4	MT	DTT
DMT3KB4	MA	Inhibitor
DMT3KB4	RN	Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
DMT3KB4	RU	https://pubmed.ncbi.nlm.nih.gov/21050177

DMN0VS2	DI	DMN0VS2
DMN0VS2	DN	Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2	MI	TT1D53B
DMN0VS2	MN	COVID-19 3C-like protease (3CLpro)
DMN0VS2	MT	DTT
DMN0VS2	MA	Inhibitor
DMN0VS2	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMN0VS2	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMN0VS2	DI	DMN0VS2
DMN0VS2	DN	Lopinavir + ritonavir + ribavirin + interferon beta-1b
DMN0VS2	MI	TTV1095
DMN0VS2	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMN0VS2	MT	DTT
DMN0VS2	MA	Inhibitor
DMN0VS2	RN	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
DMN0VS2	RU	https://pubmed.ncbi.nlm.nih.gov/32127666

DM0GZTD	DI	DM0GZTD
DM0GZTD	DN	L-ornithine phenylacetate
DM0GZTD	MI	TTSXVID
DM0GZTD	MN	Nuclear factor NF-kappa-B (NFKB)
DM0GZTD	MT	DTT
DM0GZTD	MA	Modulator
DM0GZTD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0GZTD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DME8O5K	DI	DME8O5K
DME8O5K	DN	LOU064
DME8O5K	MI	TTGM6VW
DME8O5K	MN	Tyrosine-protein kinase BTK (ATK)
DME8O5K	MT	DTT
DME8O5K	MA	Inhibitor
DME8O5K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME8O5K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIV9ZE	DI	DMIV9ZE
DMIV9ZE	DN	LOXORIBINE
DMIV9ZE	MI	TTRJ1K4
DMIV9ZE	MN	Toll-like receptor 7 (TLR7)
DMIV9ZE	MT	DTT
DMIV9ZE	MA	Agonist
DMIV9ZE	RN	The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
DMIV9ZE	RU	https://pubmed.ncbi.nlm.nih.gov/14579267

DM7BN5W	DI	DM7BN5W
DM7BN5W	DN	LPN023
DM7BN5W	MI	TTA0P7K
DM7BN5W	MN	Complement factor B (CFB)
DM7BN5W	MT	DTT
DM7BN5W	MA	Inhibitor
DM7BN5W	RN	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166.
DM7BN5W	RU	https://pubmed.ncbi.nlm.nih.gov/31611870

DMZQBCL	DI	DMZQBCL
DMZQBCL	DN	LR3001
DMZQBCL	MI	TT8V13P
DMZQBCL	MN	Myb messenger RNA (MYB mRNA)
DMZQBCL	MT	DTT
DMZQBCL	RN	Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005.
DMZQBCL	RU	http://www.drugs.com/news/genta-obtains-orphan-designation-c-myb-antisense-lr3001-chronic-myelocytic-leukemia-3031.html

DM0TZPL	DI	DM0TZPL
DM0TZPL	DN	LS-71719
DM0TZPL	MI	DEPR1Y7
DM0TZPL	MN	Beta-galactosidase (bgaB)
DM0TZPL	MT	DME
DM0TZPL	MA	Metabolism
DM0TZPL	RN	Diverse galactooligosaccharides consumption by bifidobacteria: implications of beta-galactosidase--LacS operon. Biosci Biotechnol Biochem. 2015;79(4):664-72.
DM0TZPL	RU	https://pubmed.ncbi.nlm.nih.gov/25483279

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	DEFCMPI
DME26RS	MN	Leukotriene B4 omega-hydroxylase (CYP4F3)
DME26RS	MT	DME
DME26RS	MA	Metabolism
DME26RS	RN	Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys. 2001 Jan 15;385(2):231-41.
DME26RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11368003

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	TTN53ZF
DME26RS	MN	Leukotriene B4 receptor 1 (LTB4R)
DME26RS	MT	DTT
DME26RS	MA	Agonist
DME26RS	RN	LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
DME26RS	RU	https://pubmed.ncbi.nlm.nih.gov/25706874

DME26RS	DI	DME26RS
DME26RS	DN	LTB4
DME26RS	MI	TTVJX54
DME26RS	MN	Leukotriene B4 receptor 2 (LTB4R2)
DME26RS	MT	DTT
DME26RS	MA	Inhibitor
DME26RS	RN	Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993).
DME26RS	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810003

DMXEQ0R	DI	DMXEQ0R
DMXEQ0R	DN	LTX-109
DMXEQ0R	MI	TTXT4D5
DMXEQ0R	MN	Bacterial Cell membrane (Bact CM)
DMXEQ0R	MT	DTT
DMXEQ0R	MA	Modulator
DMXEQ0R	RN	A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95.
DMXEQ0R	RU	https://pubmed.ncbi.nlm.nih.gov/21732630

DMJOYNZ	DI	DMJOYNZ
DMJOYNZ	DN	Lu AF11167
DMJOYNZ	MI	TTJW4LU
DMJOYNZ	MN	Phosphodiesterase 10A (PDE10)
DMJOYNZ	MT	DTT
DMJOYNZ	MA	Inhibitor
DMJOYNZ	RN	PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
DMJOYNZ	RU	https://pubmed.ncbi.nlm.nih.gov/33551724

DM2ZUXK	DI	DM2ZUXK
DM2ZUXK	DN	Lu-AA34893
DM2ZUXK	MI	TT85JO3
DM2ZUXK	MN	5-HT receptor (5HTR)
DM2ZUXK	MT	DTT
DM2ZUXK	MA	Modulator
DM2ZUXK	RN	Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
DM2ZUXK	RU	https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false

DM2ZUXK	DI	DM2ZUXK
DM2ZUXK	DN	Lu-AA34893
DM2ZUXK	MI	TT3ROYC
DM2ZUXK	MN	Serotonin transporter (SERT)
DM2ZUXK	MT	DTT
DM2ZUXK	MA	Modulator
DM2ZUXK	RN	Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105).
DM2ZUXK	RU	https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false

DM34FWR	DI	DM34FWR
DM34FWR	DN	Lu-AA39959
DM34FWR	MI	TTM7WCE
DM34FWR	MN	Ion channel unspecific (IC)
DM34FWR	MT	DTT
DM34FWR	MA	Modulator
DM34FWR	RN	Lundbeck: leading the way in the treatment of CNS disorders.
DM34FWR	RU	http://onlinelibrary.wiley.com/doi/10.1002/fps.78/pdf

DMY2L7V	DI	DMY2L7V
DMY2L7V	DN	Lucatumumab
DMY2L7V	MI	TTIJP3Q
DMY2L7V	MN	TNF related activation protein (CD40LG)
DMY2L7V	MT	DTT
DMY2L7V	MA	Modulator
DMY2L7V	RN	Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
DMY2L7V	RU	https://www.ncbi.nlm.nih.gov/pubmed/22475052

DMCKNBA	DI	DMCKNBA
DMCKNBA	DN	Lufironil
DMCKNBA	MI	TTNH25W
DMCKNBA	MN	Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1)
DMCKNBA	MT	DTT
DMCKNBA	MA	Modulator
DMCKNBA	RN	Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994Jul;32(7):515-20.
DMCKNBA	RU	https://pubmed.ncbi.nlm.nih.gov/7981331

DMGWZ93	DI	DMGWZ93
DMGWZ93	DN	Lulizumab pegol
DMGWZ93	MI	TTQ13FT
DMGWZ93	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMGWZ93	MT	DTT
DMGWZ93	MA	Modulator
DMGWZ93	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGWZ93	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQZXDW	DI	DMQZXDW
DMQZXDW	DN	Lum001
DMQZXDW	MI	TTPI1M5
DMQZXDW	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMQZXDW	MT	DTT
DMQZXDW	MA	Inhibitor
DMQZXDW	RN	Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6.
DMQZXDW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322589/

DMQZXDW	DI	DMQZXDW
DMQZXDW	DN	Lum001
DMQZXDW	MI	TTWZRY5
DMQZXDW	MN	Sodium/bile acid cotransporter (SLC10A1)
DMQZXDW	MT	DTT
DMQZXDW	MA	Inhibitor
DMQZXDW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQZXDW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCLWDJ	DI	DMCLWDJ
DMCLWDJ	DN	Lumacaftor
DMCLWDJ	MI	TTRLZHP
DMCLWDJ	MN	cAMP-dependent chloride channel (CFTR)
DMCLWDJ	MT	DTT
DMCLWDJ	MA	Regulator
DMCLWDJ	RN	A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38.
DMCLWDJ	RU	https://pubmed.ncbi.nlm.nih.gov/24973281

DMLTI39	DI	DMLTI39
DMLTI39	DN	Lumiliximab
DMLTI39	MI	TTCH6MU
DMLTI39	MN	Lymphocyte IgE receptor (CD23)
DMLTI39	MT	DTT
DMLTI39	RN	Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8.
DMLTI39	RU	https://pubmed.ncbi.nlm.nih.gov/16210051

DMLRU9I	DI	DMLRU9I
DMLRU9I	DN	Lunacalcipol
DMLRU9I	MI	TT82UI1
DMLRU9I	MN	Cytochrome P450 24 (CYP24A1)
DMLRU9I	MT	DTT
DMLRU9I	MA	Inhibitor
DMLRU9I	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679)
DMLRU9I	RU	http://adisinsight.springer.com/drugs/800022679

DMZ2XAP	DI	DMZ2XAP
DMZ2XAP	DN	LX-1031
DMZ2XAP	MI	TT7ZK9C
DMZ2XAP	MN	Tryptophan 5-hydroxylase (TPH)
DMZ2XAP	MT	DTT
DMZ2XAP	MA	Inhibitor
DMZ2XAP	RN	LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8.
DMZ2XAP	RU	https://pubmed.ncbi.nlm.nih.gov/21154152

DMLA8H3	DI	DMLA8H3
DMLA8H3	DN	LX2931
DMLA8H3	MI	TT618Q2
DMLA8H3	MN	Sphingosine-1-phosphate lyase 1 (SGPL1)
DMLA8H3	MT	DTT
DMLA8H3	MA	Inhibitor
DMLA8H3	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMLA8H3	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMLBD5I	DI	DMLBD5I
DMLBD5I	DN	LXE408
DMLBD5I	MI	TTSVQWU
DMLBD5I	MN	Leishmania major Proteasome (Leishm Proteasome)
DMLBD5I	MT	DTT
DMLBD5I	MA	Inhibitor
DMLBD5I	RN	Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781.
DMLBD5I	RU	https://pubmed.ncbi.nlm.nih.gov/32667203

DM5IX9M	DI	DM5IX9M
DM5IX9M	DN	LY-156735
DM5IX9M	MI	TT0WAIE
DM5IX9M	MN	Melatonin receptor type 1A (MTNR1A)
DM5IX9M	MT	DTT
DM5IX9M	MA	Agonist
DM5IX9M	RN	Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25.
DM5IX9M	RU	https://pubmed.ncbi.nlm.nih.gov/16183237

DMTBFE4	DI	DMTBFE4
DMTBFE4	DN	LY2090314
DMTBFE4	MI	TTRZQE3
DMTBFE4	MN	Glycogen synthase kinase-3 alpha (GSK-3A)
DMTBFE4	MT	DTT
DMTBFE4	MA	Modulator
DMTBFE4	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMTBFE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMTBFE4	DI	DMTBFE4
DMTBFE4	DN	LY2090314
DMTBFE4	MI	TTRSMW9
DMTBFE4	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMTBFE4	MT	DTT
DMTBFE4	MA	Modulator
DMTBFE4	RN	Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
DMTBFE4	RU	https://www.ncbi.nlm.nih.gov/pubmed/27828716

DMU81BH	DI	DMU81BH
DMU81BH	DN	LY-2189102
DMU81BH	MI	TTRYK0X
DMU81BH	MN	Interleukin-1 beta (IL1B)
DMU81BH	MT	DTT
DMU81BH	RN	Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46.
DMU81BH	RU	https://pubmed.ncbi.nlm.nih.gov/23514733

DMH3YKJ	DI	DMH3YKJ
DMH3YKJ	DN	LY2382770
DMH3YKJ	MI	TTO3HT7
DMH3YKJ	MN	Transforming growth factor beta (TGFB)
DMH3YKJ	MT	DTT
DMH3YKJ	MA	Inhibitor
DMH3YKJ	RN	A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
DMH3YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/25270361

DMZOIP4	DI	DMZOIP4
DMZOIP4	DN	LY-2409021
DMZOIP4	MI	TT9O6WS
DMZOIP4	MN	Glucagon receptor (GCGR)
DMZOIP4	MT	DTT
DMZOIP4	MA	Antagonist
DMZOIP4	RN	Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
DMZOIP4	RU	https://pubmed.ncbi.nlm.nih.gov/25656305

DMKYMS2	DI	DMKYMS2
DMKYMS2	DN	LY-2428757
DMKYMS2	MI	TTVIMDE
DMKYMS2	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMKYMS2	MT	DTT
DMKYMS2	MA	Stimulator
DMKYMS2	RN	Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes. 2009; 2: 37-49.
DMKYMS2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818016/

DMLTSDC	DI	DMLTSDC
DMLTSDC	DN	LY-2456302
DMLTSDC	MI	TTQW87Y
DMLTSDC	MN	Opioid receptor kappa (OPRK1)
DMLTSDC	MT	DTT
DMLTSDC	MA	Antagonist
DMLTSDC	RN	LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44.
DMLTSDC	RU	https://pubmed.ncbi.nlm.nih.gov/24071566

DMM5JAN	DI	DMM5JAN
DMM5JAN	DN	LY2495655
DMM5JAN	MI	TTSWPH8
DMM5JAN	MN	Growth/differentiation factor 8 (GDF-8)
DMM5JAN	MT	DTT
DMM5JAN	MA	Modulator
DMM5JAN	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMM5JAN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMCV602	DI	DMCV602
DMCV602	DN	LY2523355
DMCV602	MI	TTTRP0H
DMCV602	MN	Kinesin-like protein KIF11 (KIF11)
DMCV602	MT	DTT
DMCV602	MA	Modulator
DMCV602	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMCV602	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMTVU2Q	DI	DMTVU2Q
DMTVU2Q	DN	LY2541546
DMTVU2Q	MI	TTYRO4F
DMTVU2Q	MN	Sclerostin (SOST)
DMTVU2Q	MT	DTT
DMTVU2Q	RN	Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94.
DMTVU2Q	RU	https://pubmed.ncbi.nlm.nih.gov/22106037

DM81UJW	DI	DM81UJW
DM81UJW	DN	LY-2590443
DM81UJW	MI	TTZPO1L
DM81UJW	MN	Substance-P receptor (TACR1)
DM81UJW	MT	DTT
DM81UJW	MA	Antagonist
DM81UJW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).
DM81UJW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360

DMMI0RH	DI	DMMI0RH
DMMI0RH	DN	LY-2599506
DMMI0RH	MI	TTDLNGZ
DMMI0RH	MN	Glucokinase (GCK)
DMMI0RH	MT	DTT
DMMI0RH	MA	Inhibitor
DMMI0RH	RN	This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
DMMI0RH	RU	http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	TTTU902
DMCXRZF	MN	Checkpoint kinase-1 (CHK1)
DMCXRZF	MT	DTT
DMCXRZF	MA	Modulator
DMCXRZF	RN	Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
DMCXRZF	RU	https://pubmed.ncbi.nlm.nih.gov/24114124

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	DECB0K3
DMCXRZF	MN	Cytochrome P450 2D6 (CYP2D6)
DMCXRZF	MT	DME
DMCXRZF	MA	Metabolism
DMCXRZF	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DMCXRZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DMCXRZF	DI	DMCXRZF
DMCXRZF	DN	LY2603618
DMCXRZF	MI	DE4LYSA
DMCXRZF	MN	Cytochrome P450 3A4 (CYP3A4)
DMCXRZF	MT	DME
DMCXRZF	MA	Metabolism
DMCXRZF	RN	Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors. Xenobiotica. 2014 Sep;44(9):827-41.
DMCXRZF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24666335

DM4XMF7	DI	DM4XMF7
DM4XMF7	DN	LY2606368
DM4XMF7	MI	TTTU902
DM4XMF7	MN	Checkpoint kinase-1 (CHK1)
DM4XMF7	MT	DTT
DM4XMF7	MA	Inhibitor
DM4XMF7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4XMF7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4EF9Y	DI	DM4EF9Y
DM4EF9Y	DN	LY-2608204
DM4EF9Y	MI	TTDLNGZ
DM4EF9Y	MN	Glucokinase (GCK)
DM4EF9Y	MT	DTT
DM4EF9Y	MA	Activator
DM4EF9Y	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DM4EF9Y	RU	http://www.lillytrials.com/initiated/initiated.html

DMFGNB4	DI	DMFGNB4
DMFGNB4	DN	LY-2623091
DMFGNB4	MI	TT26PHO
DMFGNB4	MN	Mineralocorticoid receptor  (MR)
DMFGNB4	MT	DTT
DMFGNB4	MA	Antagonist
DMFGNB4	RN	Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
DMFGNB4	RU	https://pubmed.ncbi.nlm.nih.gov/26083526

DMTPQUA	DI	DMTPQUA
DMTPQUA	DN	LY-2624803
DMTPQUA	MI	TTTIBOJ
DMTPQUA	MN	Histamine H1 receptor (H1R)
DMTPQUA	MT	DTT
DMTPQUA	MA	Modulator
DMTPQUA	RN	Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11.
DMTPQUA	RU	https://pubmed.ncbi.nlm.nih.gov/25423562

DMZASMP	DI	DMZASMP
DMZASMP	DN	LY2784544
DMZASMP	MI	TTRMX3V
DMZASMP	MN	Janus kinase 2 (JAK-2)
DMZASMP	MT	DTT
DMZASMP	MA	Modulator
DMZASMP	RN	Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109.
DMZASMP	RU	https://pubmed.ncbi.nlm.nih.gov/23584399

DM0KJDY	DI	DM0KJDY
DM0KJDY	DN	LY2801653
DM0KJDY	MI	TTU8W4S
DM0KJDY	MN	Protein kinase (PK)
DM0KJDY	MT	DTT
DM0KJDY	MA	Inhibitor
DM0KJDY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0KJDY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0KJDY	DI	DM0KJDY
DM0KJDY	DN	LY2801653
DM0KJDY	MI	TTNDSF4
DM0KJDY	MN	Proto-oncogene c-Met (MET)
DM0KJDY	MT	DTT
DM0KJDY	MA	Modulator
DM0KJDY	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DM0KJDY	RU	http://www.lillyoncologypipeline.com/met-inhibitor.aspx

DMO8IEZ	DI	DMO8IEZ
DMO8IEZ	DN	LY-2828360
DMO8IEZ	MI	TTMSFAW
DMO8IEZ	MN	Cannabinoid receptor 2 (CB2)
DMO8IEZ	MT	DTT
DMO8IEZ	MA	Agonist
DMO8IEZ	RN	Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
DMO8IEZ	RU	http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands

DMZ0DMY	DI	DMZ0DMY
DMZ0DMY	DN	LY2874455
DMZ0DMY	MI	TTGJVQM
DMZ0DMY	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMZ0DMY	MT	DTT
DMZ0DMY	MA	Modulator
DMZ0DMY	RN	Company report (Eli Lilly) (drug: LY2874455)
DMZ0DMY	RU	http://www.lillyoncologypipeline.com/fgfr-inhibitor.aspx

DMQV1OU	DI	DMQV1OU
DMQV1OU	DN	LY-2875358
DMQV1OU	MI	TTNDSF4
DMQV1OU	MN	Proto-oncogene c-Met (MET)
DMQV1OU	MT	DTT
DMQV1OU	RN	Clinical pipeline report, company report or official report of Eli Lilly.
DMQV1OU	RU	http://www.lillyoncologypipeline.com/met-antibody.aspx

DMV14LM	DI	DMV14LM
DMV14LM	DN	LY2886721
DMV14LM	MI	TT8JRS7
DMV14LM	MN	Beta-secretase (BACE)
DMV14LM	MT	DTT
DMV14LM	MA	Modulator
DMV14LM	RN	Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
DMV14LM	RU	https://www.ncbi.nlm.nih.gov/pubmed/24530026

DMRDEKZ	DI	DMRDEKZ
DMRDEKZ	DN	LY2928057
DMRDEKZ	MI	TT6Y1PG
DMRDEKZ	MN	Solute carrier family 40 member 1 (SLC40A1)
DMRDEKZ	MT	DTT
DMRDEKZ	MA	Modulator
DMRDEKZ	RN	Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400.
DMRDEKZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653431/

DM4N6EK	DI	DM4N6EK
DM4N6EK	DN	LY293558
DM4N6EK	MI	TT0MYE2
DM4N6EK	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM4N6EK	MT	DTT
DM4N6EK	MA	Modulator
DM4N6EK	RN	Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
DM4N6EK	RU	https://pubmed.ncbi.nlm.nih.gov/20942817

DMB5L6Q	DI	DMB5L6Q
DMB5L6Q	DN	LY-2940094
DMB5L6Q	MI	TTNT7K8
DMB5L6Q	MN	Nociceptin receptor (OPRL1)
DMB5L6Q	MT	DTT
DMB5L6Q	MA	Modulator
DMB5L6Q	RN	Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97.
DMB5L6Q	RU	http://www.sciencedirect.com/science/article/pii/S0006295215001562

DML6XWR	DI	DML6XWR
DML6XWR	DN	LY2944876
DML6XWR	MI	TT9O6WS
DML6XWR	MN	Glucagon receptor (GCGR)
DML6XWR	MT	DTT
DML6XWR	MA	Modulator
DML6XWR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML6XWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML6XWR	DI	DML6XWR
DML6XWR	DN	LY2944876
DML6XWR	MI	TTVIMDE
DML6XWR	MN	Glucagon-like peptide 1 receptor (GLP1R)
DML6XWR	MT	DTT
DML6XWR	MA	Modulator
DML6XWR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML6XWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRVEHY	DI	DMRVEHY
DMRVEHY	DN	LY3012212
DMRVEHY	MI	TT2Q6G1
DMRVEHY	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMRVEHY	MT	DTT
DMRVEHY	MA	Modulator
DMRVEHY	RN	Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
DMRVEHY	RU	https://pubmed.ncbi.nlm.nih.gov/23903897

DMFMKQ3	DI	DMFMKQ3
DMFMKQ3	DN	LY3015014
DMFMKQ3	MI	TTBRG7E
DMFMKQ3	MN	Proprotein convertase subtilisin/kexin type 9 (PCSK9)
DMFMKQ3	MT	DTT
DMFMKQ3	RN	The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8.
DMFMKQ3	RU	https://pubmed.ncbi.nlm.nih.gov/25323928

DMD9KYF	DI	DMD9KYF
DMD9KYF	DN	LY3023414
DMD9KYF	MI	TTEUNMR
DMD9KYF	MN	PI3-kinase alpha (PIK3CA)
DMD9KYF	MT	DTT
DMD9KYF	MA	Modulator
DMD9KYF	RN	Company report (Lilly)
DMD9KYF	RU	http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx

DMD9KYF	DI	DMD9KYF
DMD9KYF	DN	LY3023414
DMD9KYF	MI	TTCJG29
DMD9KYF	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMD9KYF	MT	DTT
DMD9KYF	MA	Modulator
DMD9KYF	RN	Company report (Lilly)
DMD9KYF	RU	http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx

DMDFZK8	DI	DMDFZK8
DMDFZK8	DN	LY3113593
DMDFZK8	MI	TT07RIB
DMDFZK8	MN	Bone morphogenetic protein 6 (BMP6)
DMDFZK8	MT	DTT
DMDFZK8	MA	Inhibitor
DMDFZK8	RN	Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948.
DMDFZK8	RU	https://pubmed.ncbi.nlm.nih.gov/30677788

DMAC457	DI	DMAC457
DMAC457	DN	LY3127804
DMAC457	MI	TT0APVH
DMAC457	MN	HUMAN angiopoietin-2 (ANG-2)
DMAC457	MT	DTT
DMAC457	MA	Inhibitor
DMAC457	RN	Updates: Lilly's Global COVID-19 Response
DMAC457	RU	https://www.lilly.com/news/stories/coronavirus-covid19-global-response

DM7IFNB	DI	DM7IFNB
DM7IFNB	DN	LY3202626
DM7IFNB	MI	TT8JRS7
DM7IFNB	MN	Beta-secretase (BACE)
DM7IFNB	MT	DTT
DM7IFNB	MA	Inhibitor
DM7IFNB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7IFNB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	DE4LYSA
DMGMC8H	MN	Cytochrome P450 3A4 (CYP3A4)
DMGMC8H	MT	DME
DMGMC8H	MA	Metabolism
DMGMC8H	RN	The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450. Drug Metab Dispos. 2002 Sep;30(9):957-61.
DMGMC8H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12167559

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	TT9SL3Q
DMGMC8H	MN	Polypeptide deformylase (PDF)
DMGMC8H	MT	DTT
DMGMC8H	MA	Inhibitor
DMGMC8H	RN	Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23.
DMGMC8H	RU	https://pubmed.ncbi.nlm.nih.gov/10623528

DMGMC8H	DI	DMGMC8H
DMGMC8H	DN	LY333531
DMGMC8H	MI	TTYPXQF
DMGMC8H	MN	Protein kinase C beta (PRKCB)
DMGMC8H	MT	DTT
DMGMC8H	MA	Inhibitor
DMGMC8H	RN	Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
DMGMC8H	RU	https://pubmed.ncbi.nlm.nih.gov/12540629

DM43O9N	DI	DM43O9N
DM43O9N	DN	LY-334370
DM43O9N	MI	TT0MI3F
DM43O9N	MN	5-HT 1F receptor (HTR1F)
DM43O9N	MT	DTT
DM43O9N	MA	Modulator
DM43O9N	RN	Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
DM43O9N	RU	https://www.ncbi.nlm.nih.gov/pubmed/11675061

DMD09CT	DI	DMD09CT
DMD09CT	DN	LY-362884
DMD09CT	MI	TTMXGCW
DMD09CT	MN	Adrenergic receptor beta-3 (ADRB3)
DMD09CT	MT	DTT
DMD09CT	MA	Agonist
DMD09CT	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMD09CT	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMZCU7I	DI	DMZCU7I
DMZCU7I	DN	LY-377604
DMZCU7I	MI	TTMXGCW
DMZCU7I	MN	Adrenergic receptor beta-3 (ADRB3)
DMZCU7I	MT	DTT
DMZCU7I	MA	Agonist
DMZCU7I	RN	Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Med Chem Lett. 2011 August 11; 2(8): 583-586.
DMZCU7I	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018109/

DM8OG0J	DI	DM8OG0J
DM8OG0J	DN	LY-517717
DM8OG0J	MI	TTCIHJA
DM8OG0J	MN	Coagulation factor Xa (F10)
DM8OG0J	MT	DTT
DM8OG0J	MA	Inhibitor
DM8OG0J	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DM8OG0J	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMBM2I9	DI	DMBM2I9
DMBM2I9	DN	LY-518674
DMBM2I9	MI	TTJ584C
DMBM2I9	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMBM2I9	MT	DTT
DMBM2I9	MA	Agonist
DMBM2I9	RN	Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6.
DMBM2I9	RU	https://pubmed.ncbi.nlm.nih.gov/18988892

DMMSBW5	DI	DMMSBW5
DMMSBW5	DN	LY-545694
DMMSBW5	MI	TTDXZ24
DMMSBW5	MN	Glutamate receptor ionotropic (GRI)
DMMSBW5	MT	DTT
DMMSBW5	MA	Antagonist
DMMSBW5	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019739)
DMMSBW5	RU	http://adisinsight.springer.com/drugs/800019739

DMP05GL	DI	DMP05GL
DMP05GL	DN	LYC-30937
DMP05GL	MI	TT5WKM8
DMP05GL	MN	ATP phosphatase (ATPase)
DMP05GL	MT	DTT
DMP05GL	MA	Modulator
DMP05GL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP05GL	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMV8WU9	DI	DMV8WU9
DMV8WU9	DN	LYC-55716
DMV8WU9	MI	TTGV6LY
DMV8WU9	MN	Nuclear receptor ROR-gamma (RORG)
DMV8WU9	MT	DTT
DMV8WU9	MA	Agonist
DMV8WU9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV8WU9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM23Y6K	DI	DM23Y6K
DM23Y6K	DN	LYS228
DM23Y6K	MI	TT85JMW
DM23Y6K	MN	Bacterial Penicillin binding protein 3 (Bact mrcA)
DM23Y6K	MT	DTT
DM23Y6K	MA	Binder
DM23Y6K	RN	Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18.
DM23Y6K	RU	https://pubmed.ncbi.nlm.nih.gov/30061293

DML0I2Z	DI	DML0I2Z
DML0I2Z	DN	M118
DML0I2Z	MI	TT4QPUL
DML0I2Z	MN	Antithrombin-III (ATIII)
DML0I2Z	MT	DTT
DML0I2Z	MA	Inhibitor
DML0I2Z	RN	Clinical pipeline report, company report or official report of Momentapharma.
DML0I2Z	RU	http://www.momentapharma.com/pipeline/adomiparin.php

DMZ7YX3	DI	DMZ7YX3
DMZ7YX3	DN	M-16209
DMZ7YX3	MI	TTFBNVI
DMZ7YX3	MN	Aldose reductase (AKR1B1)
DMZ7YX3	MT	DTT
DMZ7YX3	MA	Inhibitor
DMZ7YX3	RN	Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.
DMZ7YX3	RU	https://pubmed.ncbi.nlm.nih.gov/1828768

DMC5MQD	DI	DMC5MQD
DMC5MQD	DN	M2951
DMC5MQD	MI	TTGM6VW
DMC5MQD	MN	Tyrosine-protein kinase BTK (ATK)
DMC5MQD	MT	DTT
DMC5MQD	MA	Inhibitor
DMC5MQD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC5MQD	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TT8ZLTI
DMJCULI	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMJCULI	MT	DTT
DMJCULI	MA	Inhibitor
DMJCULI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCULI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TTNBFWK
DMJCULI	MN	Programmed cell death protein 1 (PD-1)
DMJCULI	MT	DTT
DMJCULI	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMJCULI	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMJCULI	DI	DMJCULI
DMJCULI	DN	M7824
DMJCULI	MI	TTO3HT7
DMJCULI	MN	Transforming growth factor beta (TGFB)
DMJCULI	MT	DTT
DMJCULI	MA	Inhibitor
DMJCULI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCULI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TT4UXPE
DMQOBH4	MN	MHC class I NK cell receptor 2DL1 (CD158A)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TTU0P73
DMQOBH4	MN	MHC class I NK cell receptor 2DL2 (CD158b1)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMQOBH4	DI	DMQOBH4
DMQOBH4	DN	mab 1-7F9
DMQOBH4	MI	TTEX3SI
DMQOBH4	MN	MHC class I NK cell receptor 2DL3 (CD158b2)
DMQOBH4	MT	DTT
DMQOBH4	RN	Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
DMQOBH4	RU	https://pubmed.ncbi.nlm.nih.gov/19561305

DMBYDNE	DI	DMBYDNE
DMBYDNE	DN	Managlinat dialanetil
DMBYDNE	MI	TTWHDVK
DMBYDNE	MN	Fructose-1,6-bisphosphatase (FBP)
DMBYDNE	MT	DTT
DMBYDNE	MA	Modulator
DMBYDNE	RN	MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5.
DMBYDNE	RU	https://pubmed.ncbi.nlm.nih.gov/15911772

DMB4A8I	DI	DMB4A8I
DMB4A8I	DN	MANOALIDE
DMB4A8I	MI	TT9V5JH
DMB4A8I	MN	Phospholipase A2 (PLA2G1B)
DMB4A8I	MT	DTT
DMB4A8I	MA	Modulator
DMB4A8I	RN	Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
DMB4A8I	RU	https://www.ncbi.nlm.nih.gov/pubmed/9804280

DMGQ175	DI	DMGQ175
DMGQ175	DN	Mapatumumab
DMGQ175	MI	TT5WLRX
DMGQ175	MN	TRAIL receptor 1 (TRAIL-R1)
DMGQ175	MT	DTT
DMGQ175	MA	Modulator
DMGQ175	RN	National Cancer Institute Drug Dictionary (drug id 486626).
DMGQ175	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=486626

DMDTI0L	DI	DMDTI0L
DMDTI0L	DN	Masilukast
DMDTI0L	MI	TTGKOY9
DMDTI0L	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMDTI0L	MT	DTT
DMDTI0L	MA	Modulator
DMDTI0L	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDTI0L	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2458E	DI	DM2458E
DM2458E	DN	Matuzumab
DM2458E	MI	TTGKNB4
DM2458E	MN	Epidermal growth factor receptor (EGFR)
DM2458E	MT	DTT
DM2458E	RN	Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
DM2458E	RU	https://pubmed.ncbi.nlm.nih.gov/18394559

DMMVFRC	DI	DMMVFRC
DMMVFRC	DN	Mavrilimumab
DMMVFRC	MI	TT6MP2Z
DMMVFRC	MN	GMCSFR-alpha (CSF2RA)
DMMVFRC	MT	DTT
DMMVFRC	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMMVFRC	RU	http://www.medimmune.com/research_pipeline.aspx

DMMVFRC	DI	DMMVFRC
DMMVFRC	DN	Mavrilimumab
DMMVFRC	MI	TTNYZG2
DMMVFRC	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMMVFRC	MT	DTT
DMMVFRC	MA	Antagonist
DMMVFRC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMVFRC	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWLIPJ	DI	DMWLIPJ
DMWLIPJ	DN	MAXY-G34
DMWLIPJ	MI	TTC70AJ
DMWLIPJ	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMWLIPJ	MT	DTT
DMWLIPJ	MA	Agonist
DMWLIPJ	RN	Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
DMWLIPJ	RU	https://pubmed.ncbi.nlm.nih.gov/24276547

DMJKHVX	DI	DMJKHVX
DMJKHVX	DN	Mazapertine succinate
DMJKHVX	MI	TTSQIFT
DMJKHVX	MN	5-HT 1A receptor (HTR1A)
DMJKHVX	MT	DTT
DMJKHVX	MA	Modulator
DMJKHVX	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMJKHVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMJKHVX	DI	DMJKHVX
DMJKHVX	DN	Mazapertine succinate
DMJKHVX	MI	TTEX248
DMJKHVX	MN	Dopamine D2 receptor (D2R)
DMJKHVX	MT	DTT
DMJKHVX	MA	Modulator
DMJKHVX	RN	Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57.
DMJKHVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/24164194

DMHU8SJ	DI	DMHU8SJ
DMHU8SJ	DN	MB07803
DMHU8SJ	MI	TTWHDVK
DMHU8SJ	MN	Fructose-1,6-bisphosphatase (FBP)
DMHU8SJ	MT	DTT
DMHU8SJ	MA	Modulator
DMHU8SJ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHU8SJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6JTSZ	DI	DM6JTSZ
DM6JTSZ	DN	MB-07811
DM6JTSZ	MI	DE4LYSA
DM6JTSZ	MN	Cytochrome P450 3A4 (CYP3A4)
DM6JTSZ	MT	DME
DM6JTSZ	MA	Metabolism
DM6JTSZ	RN	Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos. 2008 Nov;36(11):2393-403.
DM6JTSZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18703645

DM6JTSZ	DI	DM6JTSZ
DM6JTSZ	DN	MB-07811
DM6JTSZ	MI	TTGER3L
DM6JTSZ	MN	Thyroid hormone receptor beta (THRB)
DM6JTSZ	MT	DTT
DM6JTSZ	MA	Modulator
DM6JTSZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589).
DM6JTSZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589

DMLPNVS	DI	DMLPNVS
DMLPNVS	DN	MB-102
DMLPNVS	MI	TTENHJ0
DMLPNVS	MN	Interleukin 3 receptor alpha (IL3RA)
DMLPNVS	MT	DTT
DMLPNVS	MA	CAR-T-Cell-Therapy
DMLPNVS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPNVS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM3RBJW	DI	DM3RBJW
DM3RBJW	DN	MB-11055
DM3RBJW	MI	TTLAFZV
DM3RBJW	MN	AMP-activated protein kinase (AMPK)
DM3RBJW	MT	DTT
DM3RBJW	MA	Modulator
DM3RBJW	RN	Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
DM3RBJW	RU	https://www.ncbi.nlm.nih.gov/pubmed/17429005

DMRSN2C	DI	DMRSN2C
DMRSN2C	DN	MB-12066
DMRSN2C	MI	TTUF2HO
DMRSN2C	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMRSN2C	MT	DTT
DMRSN2C	MA	Modulator
DMRSN2C	RN	Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953.
DMRSN2C	RU	https://www.ncbi.nlm.nih.gov/pubmed/23762270

DM0AOID	DI	DM0AOID
DM0AOID	DN	MB-CART19.1
DM0AOID	MI	TTW640A
DM0AOID	MN	B-lymphocyte surface antigen B4 (CD19)
DM0AOID	MT	DTT
DM0AOID	MA	CAR-T-Cell-Therapy
DM0AOID	RN	ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL
DM0AOID	RU	https://clinicaltrials.gov/ct2/show/NCT03321123

DMJVU7Y	DI	DMJVU7Y
DMJVU7Y	DN	MBL-HCV1
DMJVU7Y	MI	TTDBG95
DMJVU7Y	MN	Hepatitis C virus Envelope glycoprotein E2 (HCV NS1)
DMJVU7Y	MT	DTT
DMJVU7Y	MA	Modulator
DMJVU7Y	RN	Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-54.
DMJVU7Y	RU	https://pubmed.ncbi.nlm.nih.gov/23356386

DMQMTO1	DI	DMQMTO1
DMQMTO1	DN	MBX-2044
DMQMTO1	MI	TTZMAO3
DMQMTO1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMQMTO1	MT	DTT
DMQMTO1	MA	Agonist
DMQMTO1	RN	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88.
DMQMTO1	RU	https://pubmed.ncbi.nlm.nih.gov/19389808

DM0W3R7	DI	DM0W3R7
DM0W3R7	DN	MCLA-128
DM0W3R7	MI	TT6EO5L
DM0W3R7	MN	Erbb2 tyrosine kinase receptor (HER2)
DM0W3R7	MT	DTT
DM0W3R7	MA	Antagonist
DM0W3R7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0W3R7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0CL4I	DI	DM0CL4I
DM0CL4I	DN	MCS-110
DM0CL4I	MI	TT731LW
DM0CL4I	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM0CL4I	MT	DTT
DM0CL4I	MA	Modulator
DM0CL4I	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM0CL4I	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMX4U0B	DI	DMX4U0B
DMX4U0B	DN	MCS-18
DMX4U0B	MI	TTY7ZHS
DMX4U0B	MN	Toll-like receptor 2 (TLR2)
DMX4U0B	MT	DTT
DMX4U0B	MA	Modulator
DMX4U0B	RN	The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
DMX4U0B	RU	https://pubmed.ncbi.nlm.nih.gov/18507149

DMDR2SZ	DI	DMDR2SZ
DMDR2SZ	DN	MCT-125
DMDR2SZ	MI	TTAWNKZ
DMDR2SZ	MN	Norepinephrine transporter (NET)
DMDR2SZ	MT	DTT
DMDR2SZ	MA	Inhibitor
DMDR2SZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
DMDR2SZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926

DM5DSGJ	DI	DM5DSGJ
DM5DSGJ	DN	MD-0727
DM5DSGJ	MI	TTNA5ZS
DM5DSGJ	MN	Cholesterol absorption (Chole absorp)
DM5DSGJ	MT	DTT
DM5DSGJ	MA	Modulator
DM5DSGJ	RN	Th-P16:297 Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects. Atherosclerosis Supplements Volume 7, Issue 3, 2006, Pages 558-559.
DM5DSGJ	RU	http://www.sciencedirect.com/science/article/pii/S1567568806822555

DM9FXU7	DI	DM9FXU7
DM9FXU7	DN	MDL-27192
DM9FXU7	MI	TT9IK2Z
DM9FXU7	MN	N-methyl-D-aspartate receptor (NMDAR)
DM9FXU7	MT	DTT
DM9FXU7	MA	Modulator
DM9FXU7	RN	Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54.
DM9FXU7	RU	https://pubmed.ncbi.nlm.nih.gov/9169290

DMCK8SX	DI	DMCK8SX
DMCK8SX	DN	MDX-1097
DMCK8SX	MI	TT1HM0R
DMCK8SX	MN	Kappa myeloma antigen (KMA)
DMCK8SX	MT	DTT
DMCK8SX	RN	MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43.
DMCK8SX	RU	https://pubmed.ncbi.nlm.nih.gov/25653020

DM0EZWI	DI	DM0EZWI
DM0EZWI	DN	MDX-1100
DM0EZWI	MI	TTQOVYA
DM0EZWI	MN	C-X-C motif chemokine 10 (CXCL10)
DM0EZWI	MT	DTT
DM0EZWI	RN	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
DM0EZWI	RU	https://pubmed.ncbi.nlm.nih.gov/22147649

DMKMSC4	DI	DMKMSC4
DMKMSC4	DN	MDX-1342
DMKMSC4	MI	TTW640A
DMKMSC4	MN	B-lymphocyte surface antigen B4 (CD19)
DMKMSC4	MT	DTT
DMKMSC4	RN	A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65.
DMKMSC4	RU	https://pubmed.ncbi.nlm.nih.gov/19657637

DMO84TL	DI	DMO84TL
DMO84TL	DN	ME-3407
DMO84TL	MI	TT18ETS
DMO84TL	MN	Myosin light kinase (MYLK)
DMO84TL	MT	DTT
DMO84TL	MA	Inhibitor
DMO84TL	RN	ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34.
DMO84TL	RU	https://pubmed.ncbi.nlm.nih.gov/9176222

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTNGILX
DMX9Y7V	MN	Adrenergic receptor alpha-1A (ADRA1A)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTBRKXS
DMX9Y7V	MN	Adrenergic receptor alpha-1B (ADRA1B)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TT34BHT
DMX9Y7V	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTWG9A4
DMX9Y7V	MN	Adrenergic receptor alpha-2A (ADRA2A)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TTWM4TY
DMX9Y7V	MN	Adrenergic receptor alpha-2B (ADRA2B)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMX9Y7V	DI	DMX9Y7V
DMX9Y7V	DN	MEDETOMIDINE
DMX9Y7V	MI	TT2NUT5
DMX9Y7V	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMX9Y7V	MT	DTT
DMX9Y7V	MA	Inhibitor
DMX9Y7V	RN	A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
DMX9Y7V	RU	https://pubmed.ncbi.nlm.nih.gov/7914537

DMSV60C	DI	DMSV60C
DMSV60C	DN	MEDI0382
DMSV60C	MI	TT0NUFM
DMSV60C	MN	Glucagon (GCG)
DMSV60C	MT	DTT
DMSV60C	MA	Agonist
DMSV60C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSV60C	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMOXKIC	DI	DMOXKIC
DMOXKIC	DN	MEDI3902
DMOXKIC	MI	TTLK9NJ
DMOXKIC	MN	Pseudomonas PcrV protein type III (Pseudo pcrV)
DMOXKIC	MT	DTT
DMOXKIC	RN	A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155.
DMOXKIC	RU	https://pubmed.ncbi.nlm.nih.gov/25391481

DMOXKIC	DI	DMOXKIC
DMOXKIC	DN	MEDI3902
DMOXKIC	MI	TTTPDRC
DMOXKIC	MN	Pseudomonas Psl exopolysaccharide (Pseudo pslG)
DMOXKIC	MT	DTT
DMOXKIC	RN	A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155.
DMOXKIC	RU	https://pubmed.ncbi.nlm.nih.gov/25391481

DMDYVN8	DI	DMDYVN8
DMDYVN8	DN	MEDI-528
DMDYVN8	MI	TT0JTFD
DMDYVN8	MN	Interleukin-9 (IL9)
DMDYVN8	MT	DTT
DMDYVN8	MA	Inhibitor
DMDYVN8	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DMDYVN8	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DMPKWR3	DI	DMPKWR3
DMPKWR3	DN	MEDI-546
DMPKWR3	MI	TTSYFMA
DMPKWR3	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMPKWR3	MT	DTT
DMPKWR3	MA	Modulator
DMPKWR3	RN	Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39.
DMPKWR3	RU	https://pubmed.ncbi.nlm.nih.gov/25606664

DMBTVFE	DI	DMBTVFE
DMBTVFE	DN	MEDI-551
DMBTVFE	MI	TTW640A
DMBTVFE	MN	B-lymphocyte surface antigen B4 (CD19)
DMBTVFE	MT	DTT
DMBTVFE	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMBTVFE	RU	http://www.medimmune.com/research_pipeline.aspx

DMI9WVM	DI	DMI9WVM
DMI9WVM	DN	MEDI-575
DMI9WVM	MI	TT8FYO9
DMI9WVM	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMI9WVM	MT	DTT
DMI9WVM	RN	Clinical pipeline report, company report or official report of MedImmune (2011).
DMI9WVM	RU	http://www.medimmune.com/research_pipeline.aspx

DMU4CS8	DI	DMU4CS8
DMU4CS8	DN	MEDI6012
DMU4CS8	MI	TTGZ91P
DMU4CS8	MN	Lecithin-cholesterol acyltransferase (LCAT)
DMU4CS8	MT	DTT
DMU4CS8	MA	Modulator
DMU4CS8	RN	Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria. J Nephropathol. 2015 January; 4(1): 25-28.
DMU4CS8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316582/

DMGD1YP	DI	DMGD1YP
DMGD1YP	DN	MEDI9929
DMGD1YP	MI	TTHMW3T
DMGD1YP	MN	Thymic stromal lymphopoietin (TSLP)
DMGD1YP	MT	DTT
DMGD1YP	MA	Modulator
DMGD1YP	RN	Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929). European medicines agency science medicines health (EMEA-001613-PIP01-14). European Union. 2015.
DMGD1YP	RU	http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001613-PIP01-14/pip_001268.jsp&mid=WC0b01ac058001d129

DM2C1YN	DI	DM2C1YN
DM2C1YN	DN	MEGF0444A
DM2C1YN	MI	TT7WD0H
DM2C1YN	MN	Epidermal growth factor-like protein 7 (EGFL7)
DM2C1YN	MT	DTT
DM2C1YN	MA	Modulator
DM2C1YN	RN	A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.
DM2C1YN	RU	http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2614

DMHOF7T	DI	DMHOF7T
DMHOF7T	DN	MEHD-7945A
DMHOF7T	MI	TTGKNB4
DMHOF7T	MN	Epidermal growth factor receptor (EGFR)
DMHOF7T	MT	DTT
DMHOF7T	MA	Modulator
DMHOF7T	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHOF7T	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHOF7T	DI	DMHOF7T
DMHOF7T	DN	MEHD-7945A
DMHOF7T	MI	TTDC8N2
DMHOF7T	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMHOF7T	MT	DTT
DMHOF7T	MA	Modulator
DMHOF7T	RN	Company report (Biooncology)
DMHOF7T	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMVJ6WS	DI	DMVJ6WS
DMVJ6WS	DN	Melogliptin
DMVJ6WS	MI	TTDIGC1
DMVJ6WS	MN	Dipeptidyl peptidase 4 (DPP-4)
DMVJ6WS	MT	DTT
DMVJ6WS	MA	Inhibitor
DMVJ6WS	RN	Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
DMVJ6WS	RU	https://pubmed.ncbi.nlm.nih.gov/19149538

DMPNDYU	DI	DMPNDYU
DMPNDYU	DN	MEM-3454
DMPNDYU	MI	TTLA931
DMPNDYU	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMPNDYU	MT	DTT
DMPNDYU	MA	Antagonist
DMPNDYU	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMPNDYU	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMUMCWS	DI	DMUMCWS
DMUMCWS	DN	MEMP1972A
DMUMCWS	MI	TTYJQTF
DMUMCWS	MN	Immunoglobulin E (IgE)
DMUMCWS	MT	DTT
DMUMCWS	RN	International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
DMUMCWS	RU	http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf

DMIVR9K	DI	DMIVR9K
DMIVR9K	DN	MER-3001
DMIVR9K	MI	TTZOPHG
DMIVR9K	MN	Insulin (INS)
DMIVR9K	MT	DTT
DMIVR9K	MA	Modulator
DMIVR9K	RN	Clinical pipeline report, company report or official report of Mercia Pharma Inc.
DMIVR9K	RU	http://merciapharma.com/?page_id=81

DM89QXT	DI	DM89QXT
DM89QXT	DN	MET409
DM89QXT	MI	TTS4UGC
DM89QXT	MN	Farnesoid X-activated receptor (FXR)
DM89QXT	MT	DTT
DM89QXT	MA	Agonist
DM89QXT	RN	Clinical pipeline report, company report or official report of Metacrine.
DM89QXT	RU	https://www.metacrine.com/programs/

DMNST69	DI	DMNST69
DMNST69	DN	Metaiodobenzylguanidine I-131
DMNST69	MI	TTAWNKZ
DMNST69	MN	Norepinephrine transporter (NET)
DMNST69	MT	DTT
DMNST69	MA	Modulator
DMNST69	RN	Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
DMNST69	RU	https://pubmed.ncbi.nlm.nih.gov/24573553

DMSZFTP	DI	DMSZFTP
DMSZFTP	DN	Met-enkephalin
DMSZFTP	MI	TT27RFC
DMSZFTP	MN	Opioid receptor delta (OPRD1)
DMSZFTP	MT	DTT
DMSZFTP	MA	Agonist
DMSZFTP	RN	Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
DMSZFTP	RU	https://pubmed.ncbi.nlm.nih.gov/7813576

DMSZFTP	DI	DMSZFTP
DMSZFTP	DN	Met-enkephalin
DMSZFTP	MI	TTKWM86
DMSZFTP	MN	Opioid receptor mu (MOP)
DMSZFTP	MT	DTT
DMSZFTP	MA	Inhibitor
DMSZFTP	RN	Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
DMSZFTP	RU	https://pubmed.ncbi.nlm.nih.gov/17350835

DMS7FRI	DI	DMS7FRI
DMS7FRI	DN	Methanesulfonyl fluoride
DMS7FRI	MI	TT1RS9F
DMS7FRI	MN	Acetylcholinesterase (AChE)
DMS7FRI	MT	DTT
DMS7FRI	MA	Inhibitor
DMS7FRI	RN	A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. Br J Clin Pharmacol. 2013 May;75(5):1231-9.
DMS7FRI	RU	https://pubmed.ncbi.nlm.nih.gov/23116458

DMHSL87	DI	DMHSL87
DMHSL87	DN	Methoxyestradiol
DMHSL87	MI	TT6RVLG
DMHSL87	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMHSL87	MT	DTT
DMHSL87	MA	Inhibitor
DMHSL87	RN	Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14.
DMHSL87	RU	https://pubmed.ncbi.nlm.nih.gov/12409296

DM5GQD7	DI	DM5GQD7
DM5GQD7	DN	Metoprine
DM5GQD7	MI	TT2B6EV
DM5GQD7	MN	Histamine N-methyltransferase (HNMT)
DM5GQD7	MT	DTT
DM5GQD7	MA	Inhibitor
DM5GQD7	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DM5GQD7	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM5GQD7	DI	DM5GQD7
DM5GQD7	DN	Metoprine
DM5GQD7	MI	TT9SL3Q
DM5GQD7	MN	Polypeptide deformylase (PDF)
DM5GQD7	MT	DTT
DM5GQD7	MA	Inhibitor
DM5GQD7	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM5GQD7	RU	https://pubmed.ncbi.nlm.nih.gov/16612649

DMIXT2Y	DI	DMIXT2Y
DMIXT2Y	DN	MGAH22
DMIXT2Y	MI	TT6EO5L
DMIXT2Y	MN	Erbb2 tyrosine kinase receptor (HER2)
DMIXT2Y	MT	DTT
DMIXT2Y	MA	Modulator
DMIXT2Y	RN	Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123.
DMIXT2Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/

DMPBTVK	DI	DMPBTVK
DMPBTVK	DN	MGB-BP-3
DMPBTVK	MI	TTS1W4A
DMPBTVK	MN	Bacterial Deoxyribonucleic acid (Bact DNA)
DMPBTVK	MT	DTT
DMPBTVK	MA	Binder
DMPBTVK	RN	Clinical pipeline report, company report or official report of MGB Biopharma.
DMPBTVK	RU	https://www.mgb-biopharma.com/wp-content/uploads/SMi-MGB-Biopharma-Presentation.pdf

DM726HX	DI	DM726HX
DM726HX	DN	MGCD-0103
DM726HX	MI	TTBH0VX
DM726HX	MN	Histone deacetylase (HDAC)
DM726HX	MT	DTT
DM726HX	MA	Inhibitor
DM726HX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM726HX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM726HX	DI	DM726HX
DM726HX	DN	MGCD-0103
DM726HX	MI	TT6R7JZ
DM726HX	MN	Histone deacetylase 1 (HDAC1)
DM726HX	MT	DTT
DM726HX	MA	Inhibitor
DM726HX	RN	Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
DM726HX	RU	https://pubmed.ncbi.nlm.nih.gov/19721445

DMRPCF2	DI	DMRPCF2
DMRPCF2	DN	MGCD265
DMRPCF2	MI	TTU8W4S
DMRPCF2	MN	Protein kinase (PK)
DMRPCF2	MT	DTT
DMRPCF2	MA	Inhibitor
DMRPCF2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRPCF2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRPCF2	DI	DMRPCF2
DMRPCF2	DN	MGCD265
DMRPCF2	MI	TTZPY6J
DMRPCF2	MN	Tyrosine-protein kinase UFO (AXL)
DMRPCF2	MT	DTT
DMRPCF2	MA	Modulator
DMRPCF2	RN	Company report (Mirati Therapeutics: formerly MethylGene)
DMRPCF2	RU	http://www.mirati.com/programs/mgcd265/

DMRSK2I	DI	DMRSK2I
DMRSK2I	DN	MGCD290
DMRSK2I	MI	TTVO9RI
DMRSK2I	MN	Fungal Probable histone deacetylase HOS2 (Fung HOS2)
DMRSK2I	MT	DTT
DMRSK2I	MA	Inhibitor
DMRSK2I	RN	Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009 Dec;47(12):3797-804.
DMRSK2I	RU	https://pubmed.ncbi.nlm.nih.gov/19794038

DMNYPW7	DI	DMNYPW7
DMNYPW7	DN	MGI-114
DMNYPW7	MI	DE4Q2OE
DMNYPW7	MN	Prostaglandin reductase 1 (PTGR1)
DMNYPW7	MT	DME
DMNYPW7	MA	Metabolism
DMNYPW7	RN	Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent. J Pharmacol Exp Ther. 2012 Nov;343(2):426-33.
DMNYPW7	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22895897

DM1HC9R	DI	DM1HC9R
DM1HC9R	DN	MGL-3196
DM1HC9R	MI	TTGER3L
DM1HC9R	MN	Thyroid hormone receptor beta (THRB)
DM1HC9R	MT	DTT
DM1HC9R	MA	Agonist
DM1HC9R	RN	Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80.
DM1HC9R	RU	https://pubmed.ncbi.nlm.nih.gov/24075770

DME5CSV	DI	DME5CSV
DME5CSV	DN	Mibampator
DME5CSV	MI	TTAN6JD
DME5CSV	MN	Glutamate receptor AMPA (GRIA)
DME5CSV	MT	DTT
DME5CSV	MA	Agonist
DME5CSV	RN	Mibampator (LY451395) Randomized Clinical Trial for Agitation/Aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5): 707-719.
DME5CSV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938603/

DMGCRKY	DI	DMGCRKY
DMGCRKY	DN	Midismase
DMGCRKY	MI	TT6RVLG
DMGCRKY	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMGCRKY	MT	DTT
DMGCRKY	MA	Modulator
DMGCRKY	RN	A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
DMGCRKY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364

DMN45RI	DI	DMN45RI
DMN45RI	DN	MIJ821
DMN45RI	MI	TTN9D8E
DMN45RI	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMN45RI	MT	DTT
DMN45RI	MA	Modulator
DMN45RI	RN	Clinical pipeline report, company report or official report of Cadent Therapeutics.
DMN45RI	RU	https://www.cipherbio.com/data-viz/organization/Cadent%2BTherapeutics/products

DM50Z4U	DI	DM50Z4U
DM50Z4U	DN	Milataxel
DM50Z4U	MI	TTML2WA
DM50Z4U	MN	Tubulin (TUB)
DM50Z4U	MT	DTT
DM50Z4U	MA	Inhibitor
DM50Z4U	RN	J Clin Oncol 28, 2010 (suppl; abstr e13075).
DM50Z4U	RU	http://meetinglibrary.asco.org/content/54296-74

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TTSQIFT
DMSLIW6	MN	5-HT 1A receptor (HTR1A)
DMSLIW6	MT	DTT
DMSLIW6	MA	Antagonist
DMSLIW6	RN	Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015.
DMSLIW6	RU	http://minervaneurosciences.com/

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TT85JO3
DMSLIW6	MN	5-HT receptor (5HTR)
DMSLIW6	MT	DTT
DMSLIW6	MA	Antagonist
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TTVBI8W
DMSLIW6	MN	Dopamine transporter (DAT)
DMSLIW6	MT	DTT
DMSLIW6	MA	Inhibitor
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMSLIW6	DI	DMSLIW6
DMSLIW6	DN	MIN-117
DMSLIW6	MI	TT3ROYC
DMSLIW6	MN	Serotonin transporter (SERT)
DMSLIW6	MT	DTT
DMSLIW6	MA	Inhibitor
DMSLIW6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSLIW6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMZFW8V	DI	DMZFW8V
DMZFW8V	DN	MIN-202
DMZFW8V	MI	TT9N02I
DMZFW8V	MN	Orexin receptor type 2 (HCRTR2)
DMZFW8V	MT	DTT
DMZFW8V	MA	Antagonist
DMZFW8V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFW8V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMWJMFZ	DI	DMWJMFZ
DMWJMFZ	DN	Miravirsen
DMWJMFZ	MI	TTP03CE
DMWJMFZ	MN	Hepatitis C virus microRNA miR-122 (HCV MIR122)
DMWJMFZ	MT	DTT
DMWJMFZ	MA	Modulator
DMWJMFZ	RN	Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic Acids Res.2014 Jan;42(1):609-21.
DMWJMFZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24068553

DM7K4YR	DI	DM7K4YR
DM7K4YR	DN	MIS-416
DM7K4YR	MI	TTYPUHA
DM7K4YR	MN	Pattern recognition receptor NOD2 (NOD2)
DM7K4YR	MT	DTT
DM7K4YR	MA	Modulator
DM7K4YR	RN	DOI: 10.1371/journal.pone.0087712
DM7K4YR	RU	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712

DM7K4YR	DI	DM7K4YR
DM7K4YR	DN	MIS-416
DM7K4YR	MI	TTSHG0T
DM7K4YR	MN	Toll-like receptor 9 (TLR9)
DM7K4YR	MT	DTT
DM7K4YR	MA	Modulator
DM7K4YR	RN	DOI: 10.1371/journal.pone.0087712
DM7K4YR	RU	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712

DMOJ7QA	DI	DMOJ7QA
DMOJ7QA	DN	Mitemcinal fumarate
DMOJ7QA	MI	TT953CX
DMOJ7QA	MN	Motilin receptor (MLNR)
DMOJ7QA	MT	DTT
DMOJ7QA	MA	Agonist
DMOJ7QA	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMOJ7QA	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMIRPSA	DI	DMIRPSA
DMIRPSA	DN	Mitoglitazone
DMIRPSA	MI	TTCBFJO
DMIRPSA	MN	Insulin receptor (INSR)
DMIRPSA	MT	DTT
DMIRPSA	MA	Modulator
DMIRPSA	RN	An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73.
DMIRPSA	RU	https://pubmed.ncbi.nlm.nih.gov/24931567

DMIRPSA	DI	DMIRPSA
DMIRPSA	DN	Mitoglitazone
DMIRPSA	MI	TTSJH2W
DMIRPSA	MN	Mitochondrial protein unspecific (MP)
DMIRPSA	MT	DTT
DMIRPSA	MA	Modulator
DMIRPSA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIRPSA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKPZ0Q	DI	DMKPZ0Q
DMKPZ0Q	DN	Mitoquinone
DMKPZ0Q	MI	TTULV0X
DMKPZ0Q	MN	Reactive oxygen species (ROS)
DMKPZ0Q	MT	DTT
DMKPZ0Q	MA	Inhibitor
DMKPZ0Q	RN	Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192.
DMKPZ0Q	RU	https://pubmed.ncbi.nlm.nih.gov/32867213

DM2NF6X	DI	DM2NF6X
DM2NF6X	DN	MIV-210
DM2NF6X	MI	TTS5K1M
DM2NF6X	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM2NF6X	MT	DTT
DM2NF6X	MA	Modulator
DM2NF6X	RN	Emerging antivirals for the treatment of hepatitis B
DM2NF6X	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069299

DMWFTRJ	DI	DMWFTRJ
DMWFTRJ	DN	MK-0354
DMWFTRJ	MI	TTWNV8U
DMWFTRJ	MN	Nicotinic acid receptor (HCAR2)
DMWFTRJ	MT	DTT
DMWFTRJ	MA	Inhibitor
DMWFTRJ	RN	GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
DMWFTRJ	RU	https://pubmed.ncbi.nlm.nih.gov/20615702

DMLTAES	DI	DMLTAES
DMLTAES	DN	MK-0752
DMLTAES	MI	TT9W8GU
DMLTAES	MN	Gamma-secretase (GS)
DMLTAES	MT	DTT
DMLTAES	MA	Modulator
DMLTAES	RN	Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
DMLTAES	RU	https://pubmed.ncbi.nlm.nih.gov/20702149

DM2CJB4	DI	DM2CJB4
DM2CJB4	DN	MK-0773
DM2CJB4	MI	TTS64P2
DM2CJB4	MN	Androgen receptor (AR)
DM2CJB4	MT	DTT
DM2CJB4	MA	Modulator
DM2CJB4	RN	Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64.
DM2CJB4	RU	https://pubmed.ncbi.nlm.nih.gov/20356837

DMRT8K4	DI	DMRT8K4
DMRT8K4	DN	MK-0812
DMRT8K4	MI	TTFZYTO
DMRT8K4	MN	C-C chemokine receptor type 2 (CCR2)
DMRT8K4	MT	DTT
DMRT8K4	MA	Antagonist
DMRT8K4	RN	Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10.
DMRT8K4	RU	https://pubmed.ncbi.nlm.nih.gov/19913021

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTZ97H5
DM0568C	MN	Phosphodiesterase 4A (PDE4A)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTVIAT9
DM0568C	MN	Phosphodiesterase 4B (PDE4B)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM0568C	DI	DM0568C
DM0568C	DN	MK-0873
DM0568C	MI	TTSKMI8
DM0568C	MN	Phosphodiesterase 4D (PDE4D)
DM0568C	MT	DTT
DM0568C	MA	Inhibitor
DM0568C	RN	MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7.
DM0568C	RU	https://pubmed.ncbi.nlm.nih.gov/18321743

DM8ZTW7	DI	DM8ZTW7
DM8ZTW7	DN	MK-1029
DM8ZTW7	MI	TTNVEIR
DM8ZTW7	MN	Prostaglandin D2 receptor (PTGDR)
DM8ZTW7	MT	DTT
DM8ZTW7	MA	Inhibitor
DM8ZTW7	RN	Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
DM8ZTW7	RU	https://pubmed.ncbi.nlm.nih.gov/24073896

DMEDITW	DI	DMEDITW
DMEDITW	DN	MK-1454
DMEDITW	MI	TTT402Y
DMEDITW	MN	Stimulator of interferon genes protein (TMEM173)
DMEDITW	MT	DTT
DMEDITW	MA	Agonist
DMEDITW	RN	National Cancer Institute Drug Dictionary (drug name MK1454).
DMEDITW	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-1454

DM3WDZ5	DI	DM3WDZ5
DM3WDZ5	DN	MK-1775
DM3WDZ5	MI	TTJFOAL
DM3WDZ5	MN	Wee1-like protein kinase (WEE1)
DM3WDZ5	MT	DTT
DM3WDZ5	MA	Inhibitor
DM3WDZ5	RN	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
DM3WDZ5	RU	https://pubmed.ncbi.nlm.nih.gov/23467907

DMVJB09	DI	DMVJB09
DMVJB09	DN	MK-1903
DMVJB09	MI	TTWNV8U
DMVJB09	MN	Nicotinic acid receptor (HCAR2)
DMVJB09	MT	DTT
DMVJB09	MA	Agonist
DMVJB09	RN	Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
DMVJB09	RU	https://pubmed.ncbi.nlm.nih.gov/22914621

DMT1OZ6	DI	DMT1OZ6
DMT1OZ6	DN	MK-2206
DMT1OZ6	MI	TT0A1R8
DMT1OZ6	MN	E2 ubiquitin-conjugating enzyme T (UBE2T)
DMT1OZ6	MT	DTT
DMT1OZ6	MA	Inhibitor
DMT1OZ6	RN	UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72. 
DMT1OZ6	RU	https://pubmed.ncbi.nlm.nih.gov/26943030

DMT1OZ6	DI	DMT1OZ6
DMT1OZ6	DN	MK-2206
DMT1OZ6	MI	TTAZ05C
DMT1OZ6	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMT1OZ6	MT	DTT
DMT1OZ6	MA	Modulator
DMT1OZ6	RN	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
DMT1OZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/22025163

DM1M57I	DI	DM1M57I
DM1M57I	DN	MK-2578
DM1M57I	MI	TTQG4NR
DM1M57I	MN	Erythropoietin (EPO)
DM1M57I	MT	DTT
DM1M57I	MA	Agonist
DM1M57I	RN	Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
DM1M57I	RU	https://pubmed.ncbi.nlm.nih.gov/20622817

DM6OLGC	DI	DM6OLGC
DM6OLGC	DN	MK-3207
DM6OLGC	MI	TTY6O0Q
DM6OLGC	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM6OLGC	MT	DTT
DM6OLGC	MA	Antagonist
DM6OLGC	RN	Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
DM6OLGC	RU	https://pubmed.ncbi.nlm.nih.gov/20065019

DM347TQ	DI	DM347TQ
DM347TQ	DN	MK-3697
DM347TQ	MI	TT9N02I
DM347TQ	MN	Orexin receptor type 2 (HCRTR2)
DM347TQ	MT	DTT
DM347TQ	MA	Modulator
DM347TQ	RN	Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
DM347TQ	RU	https://pubmed.ncbi.nlm.nih.gov/25248679

DMSPWX6	DI	DMSPWX6
DMSPWX6	DN	MK-5172
DMSPWX6	MI	TT5FNQT
DMSPWX6	MN	Human immunodeficiency virus Protease (HIV PR)
DMSPWX6	MT	DTT
DMSPWX6	MA	Inhibitor
DMSPWX6	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMSPWX6	RU	http://www.merck.com/index.html

DMHTIGU	DI	DMHTIGU
DMHTIGU	DN	MK-5442
DMHTIGU	MI	TTBUYHA
DMHTIGU	MN	Extracellular calcium-sensing receptor (CASR)
DMHTIGU	MT	DTT
DMHTIGU	MA	Modulator
DMHTIGU	RN	Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
DMHTIGU	RU	https://pubmed.ncbi.nlm.nih.gov/21187599

DMLMV0O	DI	DMLMV0O
DMLMV0O	DN	MK-7655
DMLMV0O	MI	TTHI19T
DMLMV0O	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMLMV0O	MT	DTT
DMLMV0O	MA	Inhibitor
DMLMV0O	RN	Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
DMLMV0O	RU	https://pubmed.ncbi.nlm.nih.gov/24433862

DMG6KXB	DI	DMG6KXB
DMG6KXB	DN	MK-8245
DMG6KXB	MI	TT6RIOV
DMG6KXB	MN	Acyl-CoA desaturase (SCD)
DMG6KXB	MT	DTT
DMG6KXB	MA	Inhibitor
DMG6KXB	RN	Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96.
DMG6KXB	RU	https://pubmed.ncbi.nlm.nih.gov/21661758

DMD6E5W	DI	DMD6E5W
DMD6E5W	DN	MK-8342
DMD6E5W	MI	TTUV8G9
DMD6E5W	MN	Progesterone receptor (PGR)
DMD6E5W	MT	DTT
DMD6E5W	MA	Agonist
DMD6E5W	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMD6E5W	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DMVNAYE	DI	DMVNAYE
DMVNAYE	DN	MK-8521
DMVNAYE	MI	TT0NUFM
DMVNAYE	MN	Glucagon (GCG)
DMVNAYE	MT	DTT
DMVNAYE	MA	Co-agonist
DMVNAYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVNAYE	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMVNAYE	DI	DMVNAYE
DMVNAYE	DN	MK-8521
DMVNAYE	MI	TT9O6WS
DMVNAYE	MN	Glucagon receptor (GCGR)
DMVNAYE	MT	DTT
DMVNAYE	MA	Co-agonist
DMVNAYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVNAYE	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMQHS6B	DI	DMQHS6B
DMQHS6B	DN	MK-866
DMQHS6B	MI	TT2J34L
DMQHS6B	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMQHS6B	MT	DTT
DMQHS6B	MA	Modulator
DMQHS6B	RN	Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats
DMQHS6B	RU	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574003

DMXKOW6	DI	DMXKOW6
DMXKOW6	DN	MKC-1106-MT
DMXKOW6	MI	TT362RB
DMXKOW6	MN	MART-1 melanoma antigen (MLANA)
DMXKOW6	MT	DTT
DMXKOW6	MA	Modulator
DMXKOW6	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXKOW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMXKOW6	DI	DMXKOW6
DMXKOW6	DN	MKC-1106-MT
DMXKOW6	MI	TTULVH8
DMXKOW6	MN	Tyrosinase (TYR)
DMXKOW6	MT	DTT
DMXKOW6	MA	Modulator
DMXKOW6	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXKOW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM3I71U	DI	DM3I71U
DM3I71U	DN	MKT-077
DM3I71U	MI	TTMTPG3
DM3I71U	MN	Mortalin (HSPA9)
DM3I71U	MT	DTT
DM3I71U	MA	Modulator
DM3I71U	RN	Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21.
DM3I71U	RU	https://pubmed.ncbi.nlm.nih.gov/11156371

DMQSO4L	DI	DMQSO4L
DMQSO4L	DN	ML-04
DMQSO4L	MI	TT2O4W9
DMQSO4L	MN	Luteinizing hormone receptor (LHCGR)
DMQSO4L	MT	DTT
DMQSO4L	MA	Modulator
DMQSO4L	RN	Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007 Jan;34(1):55-70.
DMQSO4L	RU	https://pubmed.ncbi.nlm.nih.gov/17210462

DMI4E9K	DI	DMI4E9K
DMI4E9K	DN	MLN0264
DMI4E9K	MI	TTLDPRG
DMI4E9K	MN	Guanylyl cyclase C (GUCY2C)
DMI4E9K	MT	DTT
DMI4E9K	MA	Modulator
DMI4E9K	RN	J Clin Oncol 31, 2013 (suppl; abstr TPS3646).
DMI4E9K	RU	http://meetinglibrary.asco.org/content/111779-132

DM24SOL	DI	DM24SOL
DM24SOL	DN	MLN1202
DM24SOL	MI	TTFZYTO
DM24SOL	MN	C-C chemokine receptor type 2 (CCR2)
DM24SOL	MT	DTT
DM24SOL	MA	Antagonist
DM24SOL	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM24SOL	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM24SOL	DI	DM24SOL
DM24SOL	DN	MLN1202
DM24SOL	MI	TTUPB12
DM24SOL	MN	Measles virus Fusion glycoprotein (MeV F)
DM24SOL	MT	DTT
DM24SOL	MA	Inhibitor
DM24SOL	RN	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
DM24SOL	RU	https://pubmed.ncbi.nlm.nih.gov/19453286

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TT0EOB8
DMBR8NF	MN	B-Raf messenger RNA (BRAF mRNA)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
DMBR8NF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TTAN5W2
DMBR8NF	MN	Raf messenger RNA (Raf mRNA)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
DMBR8NF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184

DMBR8NF	DI	DMBR8NF
DMBR8NF	DN	MLN2480
DMBR8NF	MI	TTQ9K3Y
DMBR8NF	MN	Serine/threonine-protein kinase Raf (RAF)
DMBR8NF	MT	DTT
DMBR8NF	MA	Inhibitor
DMBR8NF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBR8NF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJHVZC	DI	DMJHVZC
DMJHVZC	DN	MLN-591RL
DMJHVZC	MI	TT9G4N0
DMJHVZC	MN	Glutamate carboxypeptidase II (GCPII)
DMJHVZC	MT	DTT
DMJHVZC	RN	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28.
DMJHVZC	RU	https://pubmed.ncbi.nlm.nih.gov/25984435

DMXJWNS	DI	DMXJWNS
DMXJWNS	DN	MM-093
DMXJWNS	MI	TTCFEA1
DMXJWNS	MN	Alpha-fetoprotein (AFP)
DMXJWNS	MT	DTT
DMXJWNS	MA	Modulator
DMXJWNS	RN	MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007 Dec;9(6):603-10.
DMXJWNS	RU	https://pubmed.ncbi.nlm.nih.gov/18041671

DMO7MBS	DI	DMO7MBS
DMO7MBS	DN	MM-111
DMO7MBS	MI	TT6EO5L
DMO7MBS	MN	Erbb2 tyrosine kinase receptor (HER2)
DMO7MBS	MT	DTT
DMO7MBS	MA	Modulator
DMO7MBS	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMO7MBS	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMDJRU1	DI	DMDJRU1
DMDJRU1	DN	MM-121
DMDJRU1	MI	TTDC8N2
DMDJRU1	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMDJRU1	MT	DTT
DMDJRU1	MA	Modulator
DMDJRU1	RN	Company report (Merrimack)
DMDJRU1	RU	http://investors.merrimack.com/releasedetail.cfm?releaseid=897168

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTDC8N2
DM2RJ4D	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Modulator
DM2RJ4D	RN	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
DM2RJ4D	RU	https://pubmed.ncbi.nlm.nih.gov/24282274

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTHRID2
DM2RJ4D	MN	Insulin-like growth factor I receptor (IGF1R)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Modulator
DM2RJ4D	RN	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
DM2RJ4D	RU	https://pubmed.ncbi.nlm.nih.gov/24282274

DM2RJ4D	DI	DM2RJ4D
DM2RJ4D	DN	MM-141
DM2RJ4D	MI	TTCJG29
DM2RJ4D	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM2RJ4D	MT	DTT
DM2RJ4D	MA	Inhibitor
DM2RJ4D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2RJ4D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6VPIO	DI	DM6VPIO
DM6VPIO	DN	MM36
DM6VPIO	MI	TT0JLSD
DM6VPIO	MN	Multidrug resistance protein (MDR)
DM6VPIO	MT	DTT
DM6VPIO	MA	Inhibitor
DM6VPIO	RN	Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74.
DM6VPIO	RU	https://pubmed.ncbi.nlm.nih.gov/19442032

DMBX2RE	DI	DMBX2RE
DMBX2RE	DN	MN-221
DMBX2RE	MI	TT2CJVK
DMBX2RE	MN	Adrenergic receptor beta-2 (ADRB2)
DMBX2RE	MT	DTT
DMBX2RE	MA	Agonist
DMBX2RE	RN	Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13.
DMBX2RE	RU	https://pubmed.ncbi.nlm.nih.gov/19527375

DMUGN4B	DI	DMUGN4B
DMUGN4B	DN	MN-305
DMUGN4B	MI	TTSQIFT
DMUGN4B	MN	5-HT 1A receptor (HTR1A)
DMUGN4B	MT	DTT
DMUGN4B	MA	Agonist
DMUGN4B	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMUGN4B	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMQA3MV	DI	DMQA3MV
DMQA3MV	DN	MNX-100
DMQA3MV	MI	TT2MN5K
DMQA3MV	MN	Phosphorylated protein kinase B (pAKT)
DMQA3MV	MT	DTT
DMQA3MV	MA	Modulator
DMQA3MV	RN	Clinical pipeline report, company report or official report of MetronomX.
DMQA3MV	RU	http://www.metronomxgroup.com/mnx-100.php

DMGK1JE	DI	DMGK1JE
DMGK1JE	DN	MORAb-004
DMGK1JE	MI	TTYJWT7
DMGK1JE	MN	Endosialin (CD248)
DMGK1JE	MT	DTT
DMGK1JE	MA	Modulator
DMGK1JE	RN	A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8.
DMGK1JE	RU	https://pubmed.ncbi.nlm.nih.gov/25398449

DMCXNIP	DI	DMCXNIP
DMCXNIP	DN	MORAb-009
DMCXNIP	MI	TT4RXME
DMCXNIP	MN	Mesothelin (MSLN)
DMCXNIP	MT	DTT
DMCXNIP	RN	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.
DMCXNIP	RU	https://pubmed.ncbi.nlm.nih.gov/25231400

DMYCITZ	DI	DMYCITZ
DMYCITZ	DN	MP-101
DMYCITZ	MI	TTXJ47W
DMYCITZ	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMYCITZ	MT	DTT
DMYCITZ	MA	Agonist
DMYCITZ	RN	ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
DMYCITZ	RU	https://clinicaltrials.gov/ct2/show/NCT03044249

DMYCITZ	DI	DMYCITZ
DMYCITZ	DN	MP-101
DMYCITZ	MI	TT8A9EF
DMYCITZ	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMYCITZ	MT	DTT
DMYCITZ	MA	Agonist
DMYCITZ	RN	ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
DMYCITZ	RU	https://clinicaltrials.gov/ct2/show/NCT03044249

DMELUAK	DI	DMELUAK
DMELUAK	DN	MP470
DMELUAK	MI	TT8FYO9
DMELUAK	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMELUAK	MT	DTT
DMELUAK	MA	Modulator
DMELUAK	RN	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
DMELUAK	RU	https://pubmed.ncbi.nlm.nih.gov/24849582

DMELUAK	DI	DMELUAK
DMELUAK	DN	MP470
DMELUAK	MI	TTX41N9
DMELUAK	MN	Tyrosine-protein kinase Kit (KIT)
DMELUAK	MT	DTT
DMELUAK	MA	Modulator
DMELUAK	RN	Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
DMELUAK	RU	https://pubmed.ncbi.nlm.nih.gov/24849582

DMMRYEK	DI	DMMRYEK
DMMRYEK	DN	MPSK3169A
DMMRYEK	MI	TTNIZ2B
DMMRYEK	MN	PCSK9 messenger RNA (PCSK9 mRNA)
DMMRYEK	MT	DTT
DMMRYEK	MA	Modulator
DMMRYEK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).
DMMRYEK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2388

DMQR23W	DI	DMQR23W
DMQR23W	DN	MRE-0094
DMQR23W	MI	TTM2AOE
DMQR23W	MN	Adenosine A2a receptor (ADORA2A)
DMQR23W	MT	DTT
DMQR23W	MA	Agonist
DMQR23W	RN	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
DMQR23W	RU	https://pubmed.ncbi.nlm.nih.gov/17064227

DMJK8L1	DI	DMJK8L1
DMJK8L1	DN	MRG002
DMJK8L1	MI	TT6EO5L
DMJK8L1	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJK8L1	MT	DTT
DMJK8L1	RN	ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health.
DMJK8L1	RU	https://clinicaltrials.gov/ct2/show/NCT04839510

DM9M5WV	DI	DM9M5WV
DM9M5WV	DN	MRG-201
DM9M5WV	MI	TTK982E
DM9M5WV	MN	Collagen (CO)
DM9M5WV	MT	DTT
DM9M5WV	MA	Modulator
DM9M5WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9M5WV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9M5WV	DI	DM9M5WV
DM9M5WV	DN	MRG-201
DM9M5WV	MI	TT1GNRQ
DM9M5WV	MN	microRNA hsa-miR-155 (MIR155)
DM9M5WV	MT	DTT
DM9M5WV	MA	Modulator
DM9M5WV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9M5WV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQZWYE	DI	DMQZWYE
DMQZWYE	DN	MRX-4
DMQZWYE	MI	TT9V5JH
DMQZWYE	MN	Phospholipase A2 (PLA2G1B)
DMQZWYE	MT	DTT
DMQZWYE	MA	Inhibitor
DMQZWYE	RN	Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
DMQZWYE	RU	http://www.nature.com/scibx/journal/v1/n41/full/scibx.2008.999.html

DMLVQKF	DI	DMLVQKF
DMLVQKF	DN	MRX-6
DMLVQKF	MI	TT9V5JH
DMLVQKF	MN	Phospholipase A2 (PLA2G1B)
DMLVQKF	MT	DTT
DMLVQKF	MA	Inhibitor
DMLVQKF	RN	A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.
DMLVQKF	RU	https://pubmed.ncbi.nlm.nih.gov/17346444

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	DE4LYSA
DMH1DYU	MN	Cytochrome P450 3A4 (CYP3A4)
DMH1DYU	MT	DME
DMH1DYU	MA	Metabolism
DMH1DYU	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DMH1DYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	TTROQ37
DMH1DYU	MN	MAPK/ERK kinase kinase (MAP3K)
DMH1DYU	MT	DTT
DMH1DYU	MA	Modulator
DMH1DYU	RN	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101.
DMH1DYU	RU	https://pubmed.ncbi.nlm.nih.gov/23629727

DMH1DYU	DI	DMH1DYU
DMH1DYU	DN	MSC1936369B
DMH1DYU	MI	DEGTFWK
DMH1DYU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMH1DYU	MT	DME
DMH1DYU	MA	Metabolism
DMH1DYU	RN	Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
DMH1DYU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27934635

DMGUI51	DI	DMGUI51
DMGUI51	DN	MSDC-0602
DMGUI51	MI	TTCBFJO
DMGUI51	MN	Insulin receptor (INSR)
DMGUI51	MT	DTT
DMGUI51	MA	Modulator
DMGUI51	RN	Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.
DMGUI51	RU	https://pubmed.ncbi.nlm.nih.gov/22621923

DMUM370	DI	DMUM370
DMUM370	DN	MSH-1001
DMUM370	MI	TT1VOHK
DMUM370	MN	Potassium channel unspecific (KC)
DMUM370	MT	DTT
DMUM370	MA	Opener
DMUM370	RN	KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7.
DMUM370	RU	https://pubmed.ncbi.nlm.nih.gov/19372634

DMSE9TH	DI	DMSE9TH
DMSE9TH	DN	MT-1303
DMSE9TH	MI	TT9JZCK
DMSE9TH	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMSE9TH	MT	DTT
DMSE9TH	MA	Modulator
DMSE9TH	RN	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
DMSE9TH	RU	https://pubmed.ncbi.nlm.nih.gov/26239599

DM7I0MT	DI	DM7I0MT
DM7I0MT	DN	MT203
DM7I0MT	MI	TTNYZG2
DM7I0MT	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM7I0MT	MT	DTT
DM7I0MT	MA	Modulator
DM7I0MT	RN	GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65.
DM7I0MT	RU	https://pubmed.ncbi.nlm.nih.gov/25748625

DMCNL7Z	DI	DMCNL7Z
DMCNL7Z	DN	MT-3724
DMCNL7Z	MI	TTUE541
DMCNL7Z	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCNL7Z	MT	DTT
DMCNL7Z	MA	Inhibitor
DMCNL7Z	RN	Clinical pipeline report, company report or official report of Molecular Templates.
DMCNL7Z	RU	https://www.mtem.com/pipeline/mt-3724

DMXSZA4	DI	DMXSZA4
DMXSZA4	DN	MT-3995
DMXSZA4	MI	TT26PHO
DMXSZA4	MN	Mineralocorticoid receptor  (MR)
DMXSZA4	MT	DTT
DMXSZA4	MA	Antagonist
DMXSZA4	RN	Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
DMXSZA4	RU	https://pubmed.ncbi.nlm.nih.gov/26083526

DM7VG8L	DI	DM7VG8L
DM7VG8L	DN	MTC-896
DM7VG8L	MI	TT6QAJ3
DM7VG8L	MN	Melanocortin receptor 5 (MC5R)
DM7VG8L	MT	DTT
DM7VG8L	MA	Antagonist
DM7VG8L	RN	Clinical pipeline report, company report or official report of Avarx.
DM7VG8L	RU	http://www.avarx.com/AvaRx/SubDomains/Company231/Listings/231/Public.Listing.display.html

DMT0K4F	DI	DMT0K4F
DMT0K4F	DN	MTR105
DMT0K4F	MI	TTCM4B3
DMT0K4F	MN	Nitric-oxide synthase endothelial (NOS3)
DMT0K4F	MT	DTT
DMT0K4F	MA	Inhibitor
DMT0K4F	RN	Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
DMT0K4F	RU	https://pubmed.ncbi.nlm.nih.gov/18434722

DML7N4B	DI	DML7N4B
DML7N4B	DN	MUC1-Poly-ICLC
DML7N4B	MI	TTBHFYQ
DML7N4B	MN	Mucin-1 (MUC1)
DML7N4B	MT	DTT
DML7N4B	RN	Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
DML7N4B	RU	https://pubmed.ncbi.nlm.nih.gov/23802084

DMN68ZL	DI	DMN68ZL
DMN68ZL	DN	Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL	MI	TT8MK59
DMN68ZL	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DMN68ZL	MT	DTT
DMN68ZL	RN	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
DMN68ZL	RU	https://clinicaltrials.gov/ct2/show/NCT00003362

DMN68ZL	DI	DMN68ZL
DMN68ZL	DN	Multi-epitope tyrosinase/gp100 vaccine
DMN68ZL	MI	TTULVH8
DMN68ZL	MN	Tyrosinase (TYR)
DMN68ZL	MT	DTT
DMN68ZL	RN	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
DMN68ZL	RU	https://clinicaltrials.gov/ct2/show/NCT00003362

DMM6KZR	DI	DMM6KZR
DMM6KZR	DN	Mutant ras vaccine
DMM6KZR	MI	TTW2R9X
DMM6KZR	MN	GTPase NRas (NRAS)
DMM6KZR	MT	DTT
DMM6KZR	RN	The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55.
DMM6KZR	RU	https://pubmed.ncbi.nlm.nih.gov/24565030

DMKDN1C	DI	DMKDN1C
DMKDN1C	DN	MVA-85A
DMKDN1C	MI	TTZYJ8U
DMKDN1C	MN	Mycobacterium Antigen complex 85A (MycB fbpA)
DMKDN1C	MT	DTT
DMKDN1C	RN	MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010 Feb;12(1):124-34.
DMKDN1C	RU	https://pubmed.ncbi.nlm.nih.gov/20140824

DMDN6FO	DI	DMDN6FO
DMDN6FO	DN	MVI-816
DMDN6FO	MI	TTBRZQS
DMDN6FO	MN	Prostatic acid phosphatase (ACPP)
DMDN6FO	MT	DTT
DMDN6FO	MA	Modulator
DMDN6FO	RN	Company report (Madisonvaccine)
DMDN6FO	RU	http://www.madisonvaccinesinc.com/Home/News

DM25VY8	DI	DM25VY8
DM25VY8	DN	Mydicar
DM25VY8	MI	TTE6THL
DM25VY8	MN	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)
DM25VY8	MT	DTT
DM25VY8	MA	Modulator
DM25VY8	RN	Clinical pipeline report, company report or official report of Celladon.
DM25VY8	RU	http://www.celladon.com/mydicar/

DMO1XUK	DI	DMO1XUK
DMO1XUK	DN	Myeloma cancer vaccine
DMO1XUK	MI	TT6MP2Z
DMO1XUK	MN	GMCSFR-alpha (CSF2RA)
DMO1XUK	MT	DTT
DMO1XUK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
DMO1XUK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707

DM9BREJ	DI	DM9BREJ
DM9BREJ	DN	MYK-491
DM9BREJ	MI	TTITSMB
DM9BREJ	MN	Myosin (MYO)
DM9BREJ	MT	DTT
DM9BREJ	MA	Activator
DM9BREJ	RN	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658.
DM9BREJ	RU	https://pubmed.ncbi.nlm.nih.gov/32558989

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	TTE4KHA
DMQKSGI	MN	Amyloid beta A4 protein (APP)
DMQKSGI	MT	DTT
DMQKSGI	MA	Inhibitor
DMQKSGI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQKSGI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DE0J45Y
DMQKSGI	MN	Inositol dehydrogenase (idh)
DMQKSGI	MT	DME
DMQKSGI	MA	Metabolism
DMQKSGI	RN	Purification, crystallization and room-temperature X-ray diffraction of inositol dehydrogenase LcIDH2 from Lactobacillus casei BL23. Acta Crystallogr F Struct Biol Commun. 2014 Jul;70(Pt 7):979-83.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/25005103

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DEDUGWF
DMQKSGI	MN	Inositol dehydrogenase (idh)
DMQKSGI	MT	DME
DMQKSGI	MA	Metabolism
DMQKSGI	RN	Purification, crystallization and room-temperature X-ray diffraction of inositol dehydrogenase LcIDH2 from Lactobacillus casei BL23. Acta Crystallogr F Struct Biol Commun. 2014 Jul;70(Pt 7):979-83.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/25005103

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	TTI0TCK
DMQKSGI	MN	Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA)
DMQKSGI	MT	DTT
DMQKSGI	MA	Inhibitor
DMQKSGI	RN	Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50.
DMQKSGI	RU	https://pubmed.ncbi.nlm.nih.gov/9989274

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DT8ACN1
DMQKSGI	MN	Sodium/myo-inositol cotransporter (SLC5A3)
DMQKSGI	MT	DTP
DMQKSGI	MA	Substrate
DMQKSGI	RN	Identification of a novel Na+/myo-inositol cotransporter. J Biol Chem. 2002 Sep 20;277(38):35219-24.
DMQKSGI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12133831

DMQKSGI	DI	DMQKSGI
DMQKSGI	DN	Myo-inositol
DMQKSGI	MI	DT2CAPQ
DMQKSGI	MN	Sodium/myo-inositol cotransporter 2 (SLC5A11)
DMQKSGI	MT	DTP
DMQKSGI	MA	Substrate
DMQKSGI	RN	The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8.
DMQKSGI	RU	http://www.ncbi.nlm.nih.gov/pubmed/12748858

DMUK6HC	DI	DMUK6HC
DMUK6HC	DN	N-5984
DMUK6HC	MI	TTMXGCW
DMUK6HC	MN	Adrenergic receptor beta-3 (ADRB3)
DMUK6HC	MT	DTT
DMUK6HC	MA	Agonist
DMUK6HC	RN	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
DMUK6HC	RU	https://pubmed.ncbi.nlm.nih.gov/16083333

DMN7EUO	DI	DMN7EUO
DMN7EUO	DN	N6022
DMN7EUO	MI	TTVG0SN
DMN7EUO	MN	S-nitrosoglutathione reductase (CBR1)
DMN7EUO	MT	DTT
DMN7EUO	MA	Inhibitor
DMN7EUO	RN	Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012 Mar 13;51(10):2157-68.
DMN7EUO	RU	https://pubmed.ncbi.nlm.nih.gov/22335564

DM7P0WR	DI	DM7P0WR
DM7P0WR	DN	NAI-acne
DM7P0WR	MI	TTYQIFM
DM7P0WR	MN	Staphylococcus Elongation factor Tu (Stap-coc tuf)
DM7P0WR	MT	DTT
DM7P0WR	MA	Modulator
DM7P0WR	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031008)
DM7P0WR	RU	http://adisinsight.springer.com/drugs/800031008

DMSWUNX	DI	DMSWUNX
DMSWUNX	DN	Naratuximab emtansine
DMSWUNX	MI	TTFCW29
DMSWUNX	MN	Leukocyte antigen CD37 (CD37)
DMSWUNX	MT	DTT
DMSWUNX	MA	Inhibitor
DMSWUNX	RN	Clinical pipeline report, company report or official report of Debiopharm.
DMSWUNX	RU	https://www.debiopharm.com/drug-development/pipeline/debio-1562/

DMD0E8U	DI	DMD0E8U
DMD0E8U	DN	Naveglitazar
DMD0E8U	MI	TTJ584C
DMD0E8U	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMD0E8U	MT	DTT
DMD0E8U	MA	Modulator
DMD0E8U	RN	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
DMD0E8U	RU	https://pubmed.ncbi.nlm.nih.gov/17012539

DMD0E8U	DI	DMD0E8U
DMD0E8U	DN	Naveglitazar
DMD0E8U	MI	TTZMAO3
DMD0E8U	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMD0E8U	MT	DTT
DMD0E8U	MA	Modulator
DMD0E8U	RN	The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61.
DMD0E8U	RU	https://pubmed.ncbi.nlm.nih.gov/17012539

DMH9JFZ	DI	DMH9JFZ
DMH9JFZ	DN	NBI-5788
DMH9JFZ	MI	TT2RY5P
DMH9JFZ	MN	Myelin basic protein (MBP)
DMH9JFZ	MT	DTT
DMH9JFZ	MA	Binder
DMH9JFZ	RN	NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65.
DMH9JFZ	RU	https://pubmed.ncbi.nlm.nih.gov/11079539

DMT6O2E	DI	DMT6O2E
DMT6O2E	DN	NC318
DMT6O2E	MI	TTBSZPF
DMT6O2E	MN	Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15)
DMT6O2E	MT	DTT
DMT6O2E	MA	Inhibitor
DMT6O2E	RN	Clinical pipeline report, company report or official report of NextCure.
DMT6O2E	RU	http://www.nextcure.com/pipeline/

DMVQKB3	DI	DMVQKB3
DMVQKB3	DN	NCI-C50000
DMVQKB3	MI	DE4LYSA
DMVQKB3	MN	Cytochrome P450 3A4 (CYP3A4)
DMVQKB3	MT	DME
DMVQKB3	MA	Metabolism
DMVQKB3	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DMVQKB3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DM4W28K	DI	DM4W28K
DM4W28K	DN	NCX 1022
DM4W28K	MI	TTK0943
DM4W28K	MN	Prostaglandin G/H synthase (COX)
DM4W28K	MT	DTT
DM4W28K	MA	Modulator
DM4W28K	RN	Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25.
DM4W28K	RU	https://pubmed.ncbi.nlm.nih.gov/15313880

DM2YIZH	DI	DM2YIZH
DM2YIZH	DN	NCX-1000
DM2YIZH	MI	TTZY5KP
DM2YIZH	MN	Caspase (CASP)
DM2YIZH	MT	DTT
DM2YIZH	MA	Modulator
DM2YIZH	RN	Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42.
DM2YIZH	RU	https://pubmed.ncbi.nlm.nih.gov/15345658

DMOX1CU	DI	DMOX1CU
DMOX1CU	DN	NCX-4016
DMOX1CU	MI	TTK0943
DMOX1CU	MN	Prostaglandin G/H synthase (COX)
DMOX1CU	MT	DTT
DMOX1CU	MA	Inhibitor
DMOX1CU	RN	Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
DMOX1CU	RU	https://pubmed.ncbi.nlm.nih.gov/16503827

DM6S83X	DI	DM6S83X
DM6S83X	DN	NDDP
DM6S83X	MI	TTUTN1I
DM6S83X	MN	Human Deoxyribonucleic acid (hDNA)
DM6S83X	MT	DTT
DM6S83X	MA	Binder
DM6S83X	RN	Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6.
DM6S83X	RU	https://pubmed.ncbi.nlm.nih.gov/8017841

DMVIRN3	DI	DMVIRN3
DMVIRN3	DN	N-DESMETHYLCLOZAPINE
DMVIRN3	MI	TTZ9SOR
DMVIRN3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMVIRN3	MT	DTT
DMVIRN3	MA	Modulator
DMVIRN3	RN	N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95.
DMVIRN3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15900318

DMUPZFO	DI	DMUPZFO
DMUPZFO	DN	Neihulizumab
DMUPZFO	MI	TTS5K8U
DMUPZFO	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMUPZFO	MT	DTT
DMUPZFO	MA	Inhibitor
DMUPZFO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUPZFO	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMSVWI7	DI	DMSVWI7
DMSVWI7	DN	Neladenoson bialanate
DMSVWI7	MI	TT92EIB
DMSVWI7	MN	ADORA1 messenger RNA (ADORA1 mRNA)
DMSVWI7	MT	DTT
DMSVWI7	MA	Agonist
DMSVWI7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSVWI7	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM4LKFO	DI	DM4LKFO
DM4LKFO	DN	NELOTANSERIN
DM4LKFO	MI	TTJQOD7
DM4LKFO	MN	5-HT 2A receptor (HTR2A)
DM4LKFO	MT	DTT
DM4LKFO	MA	Modulator
DM4LKFO	RN	Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90.
DM4LKFO	RU	https://www.ncbi.nlm.nih.gov/pubmed/19841476

DMNM9DZ	DI	DMNM9DZ
DMNM9DZ	DN	Nepicastat oral
DMNM9DZ	MI	TTYIP79
DMNM9DZ	MN	Dopamine beta hydroxylase (DBH)
DMNM9DZ	MT	DTT
DMNM9DZ	MA	Inhibitor
DMNM9DZ	RN	Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9.
DMNM9DZ	RU	https://pubmed.ncbi.nlm.nih.gov/9283721

DM3ORVD	DI	DM3ORVD
DM3ORVD	DN	Neramexane
DM3ORVD	MI	TT9IK2Z
DM3ORVD	MN	N-methyl-D-aspartate receptor (NMDAR)
DM3ORVD	MT	DTT
DM3ORVD	MA	Antagonist
DM3ORVD	RN	Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
DM3ORVD	RU	https://pubmed.ncbi.nlm.nih.gov/15757410

DMBJ3GL	DI	DMBJ3GL
DMBJ3GL	DN	Nerenone
DMBJ3GL	MI	TT26PHO
DMBJ3GL	MN	Mineralocorticoid receptor  (MR)
DMBJ3GL	MT	DTT
DMBJ3GL	MA	Antagonist
DMBJ3GL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
DMBJ3GL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626

DM8H7OA	DI	DM8H7OA
DM8H7OA	DN	Netoglitazone
DM8H7OA	MI	DE4LYSA
DM8H7OA	MN	Cytochrome P450 3A4 (CYP3A4)
DM8H7OA	MT	DME
DM8H7OA	MA	Metabolism
DM8H7OA	RN	Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
DM8H7OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15900286

DM8H7OA	DI	DM8H7OA
DM8H7OA	DN	Netoglitazone
DM8H7OA	MI	TTZMAO3
DM8H7OA	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM8H7OA	MT	DTT
DM8H7OA	MA	Modulator
DM8H7OA	RN	Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84.
DM8H7OA	RU	https://www.ncbi.nlm.nih.gov/pubmed/16137931

DMOZW4C	DI	DMOZW4C
DMOZW4C	DN	Neublastin
DMOZW4C	MI	TT63XRS
DMOZW4C	MN	GDNF receptor alpha-3 (GFRA3)
DMOZW4C	MT	DTT
DMOZW4C	MA	Modulator
DMOZW4C	RN	First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoSOne. 2015 May 11;10(5):e0125034.
DMOZW4C	RU	https://pubmed.ncbi.nlm.nih.gov/25962165

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TTSQIFT
DMIQDFW	MN	5-HT 1A receptor (HTR1A)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
DMIQDFW	RU	http://www.neurim.com/products/

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TT6MSOK
DMIQDFW	MN	5-HT 1D receptor (HTR1D)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
DMIQDFW	RU	http://www.neurim.com/products/

DMIQDFW	DI	DMIQDFW
DMIQDFW	DN	Neu-P11
DMIQDFW	MI	TT0WAIE
DMIQDFW	MN	Melatonin receptor type 1A (MTNR1A)
DMIQDFW	MT	DTT
DMIQDFW	MA	Agonist
DMIQDFW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288).
DMIQDFW	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288

DMINQP1	DI	DMINQP1
DMINQP1	DN	NEUROPEPTIDE-Y
DMINQP1	MI	TTRK9JT
DMINQP1	MN	Neuropeptide Y receptor type 1 (NPY1R)
DMINQP1	MT	DTT
DMINQP1	MA	Inhibitor
DMINQP1	RN	5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
DMINQP1	RU	https://pubmed.ncbi.nlm.nih.gov/19916528

DMINQP1	DI	DMINQP1
DMINQP1	DN	NEUROPEPTIDE-Y
DMINQP1	MI	TTJ6WK9
DMINQP1	MN	Neuropeptide Y receptor type 2 (NPY2R)
DMINQP1	MT	DTT
DMINQP1	MA	Inhibitor
DMINQP1	RN	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
DMINQP1	RU	https://pubmed.ncbi.nlm.nih.gov/18983139

DML5S71	DI	DML5S71
DML5S71	DN	Nexopamil
DML5S71	MI	TTYSN63
DML5S71	MN	5-HT 2 receptor (5HT2R)
DML5S71	MT	DTT
DML5S71	MA	Modulator
DML5S71	RN	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
DML5S71	RU	https://pubmed.ncbi.nlm.nih.gov/7506319

DML5S71	DI	DML5S71
DML5S71	DN	Nexopamil
DML5S71	MI	TT5HONZ
DML5S71	MN	Calcium channel unspecific (CaC)
DML5S71	MT	DTT
DML5S71	MA	Blocker
DML5S71	RN	Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
DML5S71	RU	https://pubmed.ncbi.nlm.nih.gov/7506319

DMJKBAY	DI	DMJKBAY
DMJKBAY	DN	NGX-267
DMJKBAY	MI	TTZ9SOR
DMJKBAY	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMJKBAY	MT	DTT
DMJKBAY	MA	Agonist
DMJKBAY	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMJKBAY	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DMDY01J	DI	DMDY01J
DMDY01J	DN	NHS-IL2-LT
DMDY01J	MI	TTUTN1I
DMDY01J	MN	Human Deoxyribonucleic acid (hDNA)
DMDY01J	MT	DTT
DMDY01J	MA	Modulator
DMDY01J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDY01J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRQUH4	DI	DMRQUH4
DMRQUH4	DN	NI-0801
DMRQUH4	MI	TTQOVYA
DMRQUH4	MN	C-X-C motif chemokine 10 (CXCL10)
DMRQUH4	MT	DTT
DMRQUH4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
DMRQUH4	RU	http://adisinsight.springer.com/drugs/800029267

DMKLJMI	DI	DMKLJMI
DMKLJMI	DN	NIC-002
DMKLJMI	MI	TTJSZTB
DMKLJMI	MN	Nicotinic acetylcholine receptor (nAChR)
DMKLJMI	MT	DTT
DMKLJMI	RN	Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
DMKLJMI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513862/

DMG7XOC	DI	DMG7XOC
DMG7XOC	DN	NIC5-15
DMG7XOC	MI	TTE4KHA
DMG7XOC	MN	Amyloid beta A4 protein (APP)
DMG7XOC	MT	DTT
DMG7XOC	MA	Inhibitor
DMG7XOC	RN	Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20.
DMG7XOC	RU	https://pubmed.ncbi.nlm.nih.gov/25325702

DM21Z68	DI	DM21Z68
DM21Z68	DN	Nimacimab
DM21Z68	MI	TT6OEDT
DM21Z68	MN	Cannabinoid receptor 1 (CB1)
DM21Z68	MT	DTT
DM21Z68	MA	Antagonist
DM21Z68	RN	Clinical pipeline report, company report or official report of Bird Rock Bio.
DM21Z68	RU	http://www.birdrockbio.com/our-pipeline/nimacimab/

DMPER4A	DI	DMPER4A
DMPER4A	DN	NIR178
DMPER4A	MI	TTSLI08
DMPER4A	MN	Adenosine receptor (ADOR)
DMPER4A	MT	DTT
DMPER4A	MA	Antagonist
DMPER4A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPER4A	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM81SDB	DI	DM81SDB
DM81SDB	DN	Niravoline
DM81SDB	MI	TTQW87Y
DM81SDB	MN	Opioid receptor kappa (OPRK1)
DM81SDB	MT	DTT
DM81SDB	MA	Modulator
DM81SDB	RN	Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema. Acta Neurochir (Wien). 1999;141(7):771-8.
DM81SDB	RU	https://www.ncbi.nlm.nih.gov/pubmed/10481790

DM8LBYT	DI	DM8LBYT
DM8LBYT	DN	NIS793
DM8LBYT	MI	TTO3HT7
DM8LBYT	MN	Transforming growth factor beta (TGFB)
DM8LBYT	MT	DTT
DM8LBYT	MA	Inhibitor
DM8LBYT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8LBYT	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQHBSX	DI	DMQHBSX
DMQHBSX	DN	NITD609
DMQHBSX	MI	TTJFY5U
DMQHBSX	MN	Adenosine A3 receptor (ADORA3)
DMQHBSX	MT	DTT
DMQHBSX	MA	Inhibitor
DMQHBSX	RN	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
DMQHBSX	RU	https://pubmed.ncbi.nlm.nih.gov/20813948

DMQHBSX	DI	DMQHBSX
DMQHBSX	DN	NITD609
DMQHBSX	MI	TTQ6VDM
DMQHBSX	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMQHBSX	MT	DTT
DMQHBSX	MA	Inhibitor
DMQHBSX	RN	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
DMQHBSX	RU	https://pubmed.ncbi.nlm.nih.gov/20813948

DMAOUZV	DI	DMAOUZV
DMAOUZV	DN	Nivatrotamab
DMAOUZV	MI	TT80ARU
DMAOUZV	MN	Ganglioside GD2 (GD2)
DMAOUZV	MT	DTT
DMAOUZV	MA	Inhibitor
DMAOUZV	RN	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
DMAOUZV	RU	https://ymabs.com/research-development/pipeline/

DMAOUZV	DI	DMAOUZV
DMAOUZV	DN	Nivatrotamab
DMAOUZV	MI	TTUN7MC
DMAOUZV	MN	T-cell surface glycoprotein CD3 (CD3)
DMAOUZV	MT	DTT
DMAOUZV	MA	Inhibitor
DMAOUZV	RN	Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
DMAOUZV	RU	https://ymabs.com/research-development/pipeline/

DMUX8JZ	DI	DMUX8JZ
DMUX8JZ	DN	Nivocasan
DMUX8JZ	MI	TTCQIBE
DMUX8JZ	MN	Caspase-1 (CASP1)
DMUX8JZ	MT	DTT
DMUX8JZ	MA	Modulator
DMUX8JZ	RN	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91.
DMUX8JZ	RU	https://pubmed.ncbi.nlm.nih.gov/24045874

DMTVGMZ	DI	DMTVGMZ
DMTVGMZ	DN	NKP 608
DMTVGMZ	MI	TTZPO1L
DMTVGMZ	MN	Substance-P receptor (TACR1)
DMTVGMZ	MT	DTT
DMTVGMZ	MA	Antagonist
DMTVGMZ	RN	Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther.2012 Feb;35(3):360-7.
DMTVGMZ	RU	https://pubmed.ncbi.nlm.nih.gov/22221140

DMKD5ZO	DI	DMKD5ZO
DMKD5ZO	DN	NN-8226
DMKD5ZO	MI	TTNZMY2
DMKD5ZO	MN	Interleukin-20 (IL20)
DMKD5ZO	MT	DTT
DMKD5ZO	RN	Handbook of Therapeutic Antibodies. 2014. 1. Page(995).
DMKD5ZO	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false

DM3IEHP	DI	DM3IEHP
DM3IEHP	DN	NN8555
DM3IEHP	MI	TTLRN4A
DM3IEHP	MN	NKG2 D activating NK receptor (KLRK1)
DM3IEHP	MT	DTT
DM3IEHP	MA	Antagonist
DM3IEHP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3IEHP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCFPBE	DI	DMCFPBE
DMCFPBE	DN	NN8765
DMCFPBE	MI	TTC4IMS
DMCFPBE	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMCFPBE	MT	DTT
DMCFPBE	MA	Modulator
DMCFPBE	RN	Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
DMCFPBE	RU	https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA2173&lpg=PA2173&dq=%22NN-8765%22+++drug&source=bl&ots=OSgek3Ubee&sig=uPqJzQ0sfWmrddc5W83GKlUI4JQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI3cTx8NTGyAIVTgWOCh29iQZt

DMDTNOS	DI	DMDTNOS
DMDTNOS	DN	NNC-0123-0000-0338
DMDTNOS	MI	TTZOPHG
DMDTNOS	MN	Insulin (INS)
DMDTNOS	MT	DTT
DMDTNOS	MA	Modulator
DMDTNOS	RN	ClinicalTrials.gov (NCT01334034) Safety of NNC 0123-0000-0338 in Healthy Subjects. U.S. National Institutes of Health.
DMDTNOS	RU	https://clinicaltrials.gov/ct2/show/NCT01334034

DMU3KOH	DI	DMU3KOH
DMU3KOH	DN	NNC-0151-0000-0000
DMU3KOH	MI	TTKANGO
DMU3KOH	MN	Complement C5 (CO5)
DMU3KOH	MT	DTT
DMU3KOH	RN	Complement-targeted therapeutics. Nat Biotechnol. 2007 Nov;25(11):1265-75.
DMU3KOH	RU	https://pubmed.ncbi.nlm.nih.gov/17989689

DMPZ97S	DI	DMPZ97S
DMPZ97S	DN	NNZ-2566
DMPZ97S	MI	TT9RTYG
DMPZ97S	MN	Neuropeptide receptor (NPR)
DMPZ97S	MT	DTT
DMPZ97S	MA	Modulator
DMPZ97S	RN	NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19.
DMPZ97S	RU	https://pubmed.ncbi.nlm.nih.gov/19656406

DME8IFQ	DI	DME8IFQ
DME8IFQ	DN	Noberastine
DME8IFQ	MI	TTTIBOJ
DME8IFQ	MN	Histamine H1 receptor (H1R)
DME8IFQ	MT	DTT
DME8IFQ	MA	Antagonist
DME8IFQ	RN	A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare. Eur J Clin Pharmacol. 1991;40(1):83-5.
DME8IFQ	RU	https://pubmed.ncbi.nlm.nih.gov/1676366

DMEHOI1	DI	DMEHOI1
DMEHOI1	DN	Novaferon
DMEHOI1	MI	TTSIUJ9
DMEHOI1	MN	Interferon-alpha 2 (IFNA2)
DMEHOI1	MT	DTT
DMEHOI1	MA	Modulator
DMEHOI1	RN	Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8.
DMEHOI1	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/

DMHG3UR	DI	DMHG3UR
DMHG3UR	DN	NOX-E36
DMHG3UR	MI	TTNAY0P
DMHG3UR	MN	Monocyte chemotactic and activating factor (CCL2)
DMHG3UR	MT	DTT
DMHG3UR	MA	Inhibitor
DMHG3UR	RN	Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923.
DMHG3UR	RU	https://pubmed.ncbi.nlm.nih.gov/25901662

DM5HPZU	DI	DM5HPZU
DM5HPZU	DN	NOX-H94
DM5HPZU	MI	TTPCG5T
DM5HPZU	MN	Hepcidin (HAMP)
DM5HPZU	MT	DTT
DM5HPZU	MA	Inhibitor
DM5HPZU	RN	The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5.
DM5HPZU	RU	https://pubmed.ncbi.nlm.nih.gov/23349391

DMP1W9Z	DI	DMP1W9Z
DMP1W9Z	DN	NP-01
DMP1W9Z	MI	TTCBFJO
DMP1W9Z	MN	Insulin receptor (INSR)
DMP1W9Z	MT	DTT
DMP1W9Z	MA	Agonist
DMP1W9Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMP1W9Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMLMZ6Q	DI	DMLMZ6Q
DMLMZ6Q	DN	NP-2
DMLMZ6Q	MI	TTN4QDT
DMLMZ6Q	MN	Opioid receptor (OPR)
DMLMZ6Q	MT	DTT
DMLMZ6Q	MA	Antagonist
DMLMZ6Q	RN	Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94.
DMLMZ6Q	RU	https://pubmed.ncbi.nlm.nih.gov/11278319

DME6KAF	DI	DME6KAF
DME6KAF	DN	NPC-15199
DME6KAF	MI	TTW6MKR
DME6KAF	MN	Calcium release (Ca rele)
DME6KAF	MT	DTT
DME6KAF	MA	Modulator
DME6KAF	RN	NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33.
DME6KAF	RU	https://pubmed.ncbi.nlm.nih.gov/10857466

DM9VEAL	DI	DM9VEAL
DM9VEAL	DN	NPC-1C
DM9VEAL	MI	TT34I9F
DM9VEAL	MN	Neoplasm antigen (NA)
DM9VEAL	MT	DTT
DM9VEAL	RN	National Cancer Institute Drug Dictionary (drug id 663436).
DM9VEAL	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436

DM3DQXG	DI	DM3DQXG
DM3DQXG	DN	NPSP-795
DM3DQXG	MI	TTEPJL5
DM3DQXG	MN	Parathyroid hormone receptor (PTH2R)
DM3DQXG	MT	DTT
DM3DQXG	MA	Modulator
DM3DQXG	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332).
DM3DQXG	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332

DMYXOU2	DI	DMYXOU2
DMYXOU2	DN	NRX-4204
DMYXOU2	MI	TTH029C
DMYXOU2	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMYXOU2	MT	DTT
DMYXOU2	MA	Modulator
DMYXOU2	RN	DOI: 10.1038/scibx.2010.766
DMYXOU2	RU	http://www.nature.com/scibx/journal/v3/n25/full/scibx.2010.766.html

DM9EFH0	DI	DM9EFH0
DM9EFH0	DN	NS 1209
DM9EFH0	MI	TT0MYE2
DM9EFH0	MN	Glutamate receptor ionotropic kainate 1 (GRIK1)
DM9EFH0	MT	DTT
DM9EFH0	MA	Modulator
DM9EFH0	RN	The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
DM9EFH0	RU	https://pubmed.ncbi.nlm.nih.gov/19299805

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TTVBI8W
DMI5HFU	MN	Dopamine transporter (DAT)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TTAWNKZ
DMI5HFU	MN	Norepinephrine transporter (NET)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMI5HFU	DI	DMI5HFU
DMI5HFU	DN	NS 2359
DMI5HFU	MI	TT3ROYC
DMI5HFU	MN	Serotonin transporter (SERT)
DMI5HFU	MT	DTT
DMI5HFU	MA	Inhibitor
DMI5HFU	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMI5HFU	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMMUR6V	DI	DMMUR6V
DMMUR6V	DN	NS-2710
DMMUR6V	MI	TT37EDJ
DMMUR6V	MN	GABA(A) receptor alpha-3 (GABRA3)
DMMUR6V	MT	DTT
DMMUR6V	MA	Modulator
DMMUR6V	RN	GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
DMMUR6V	RU	https://pubmed.ncbi.nlm.nih.gov/21050172

DM3H82Q	DI	DM3H82Q
DM3H82Q	DN	NS-7
DM3H82Q	MI	TTRK8B9
DM3H82Q	MN	Sodium channel unspecific (NaC)
DM3H82Q	MT	DTT
DM3H82Q	MA	Modulator
DM3H82Q	RN	Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9.
DM3H82Q	RU	https://pubmed.ncbi.nlm.nih.gov/10773024

DMPJQZG	DI	DMPJQZG
DMPJQZG	DN	NSC-645809
DMPJQZG	MI	DTI7UX6
DMPJQZG	MN	Breast cancer resistance protein (ABCG2)
DMPJQZG	MT	DTP
DMPJQZG	MA	Substrate
DMPJQZG	RN	C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol. 2007 Jun 30;74(1):41-53.
DMPJQZG	RU	https://doi.org/10.1016/j.bcp.2007.03.028

DMPJQZG	DI	DMPJQZG
DMPJQZG	DN	NSC-645809
DMPJQZG	MI	TTJLP0R
DMPJQZG	MN	Quinone reductase 2 (NQO2)
DMPJQZG	MT	DTT
DMPJQZG	MA	Inhibitor
DMPJQZG	RN	Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
DMPJQZG	RU	https://pubmed.ncbi.nlm.nih.gov/20356739

DMRYLBW	DI	DMRYLBW
DMRYLBW	DN	NTO-1151
DMRYLBW	MI	TTRBUYN
DMRYLBW	MN	Ribonuclease (RNase)
DMRYLBW	MT	DTT
DMRYLBW	MA	Modulator
DMRYLBW	RN	Clinical pipeline report, company report or official report of Nanotherapeutics.
DMRYLBW	RU	http://www.nanotherapeutics.com/triapine/

DMORNVB	DI	DMORNVB
DMORNVB	DN	NU-172
DMORNVB	MI	TT6L509
DMORNVB	MN	Coagulation factor IIa (F2)
DMORNVB	MT	DTT
DMORNVB	MA	Inhibitor
DMORNVB	RN	Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214.
DMORNVB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260938/

DMO0C5R	DI	DMO0C5R
DMO0C5R	DN	NU300
DMO0C5R	MI	TTC6JZQ
DMO0C5R	MN	Haemophilus influenzae CRM197 (Hae-influ CRM197)
DMO0C5R	MT	DTT
DMO0C5R	MA	Modulator
DMO0C5R	RN	ClinicalTrials.gov (NCT02140047) Exploratory Clinical Study of MT-2301. U.S. National Institutes of Health.
DMO0C5R	RU	https://clinicaltrials.gov/ct2/show/NCT02140047

DMOJA5G	DI	DMOJA5G
DMOJA5G	DN	Nuplazid
DMOJA5G	MI	TTJQOD7
DMOJA5G	MN	5-HT 2A receptor (HTR2A)
DMOJA5G	MT	DTT
DMOJA5G	MA	Agonist
DMOJA5G	RN	The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
DMOJA5G	RU	https://pubmed.ncbi.nlm.nih.gov/30288594

DMOJA5G	DI	DMOJA5G
DMOJA5G	DN	Nuplazid
DMOJA5G	MI	TTWJBZ5
DMOJA5G	MN	5-HT 2C receptor (HTR2C)
DMOJA5G	MT	DTT
DMOJA5G	MA	Agonist
DMOJA5G	RN	The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091.
DMOJA5G	RU	https://pubmed.ncbi.nlm.nih.gov/30288594

DMTYXQF	DI	DMTYXQF
DMTYXQF	DN	NVP-AUY922
DMTYXQF	MI	TT78R5H
DMTYXQF	MN	Heat shock protein 90 alpha (HSP90A)
DMTYXQF	MT	DTT
DMTYXQF	MA	Inhibitor
DMTYXQF	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMTYXQF	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DM2UJ1H	DI	DM2UJ1H
DM2UJ1H	DN	NW-3509
DM2UJ1H	MI	TTRK8B9
DM2UJ1H	MN	Sodium channel unspecific (NaC)
DM2UJ1H	MT	DTT
DM2UJ1H	MA	Blocker
DM2UJ1H	RN	Clinical pipeline report, company report or official report of Newron.
DM2UJ1H	RU	http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=52

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TTK8CXU
DMMBAIH	MN	5-HT 1B receptor (HTR1B)
DMMBAIH	MT	DTT
DMMBAIH	MA	Modulator
DMMBAIH	RN	Company report (NeurAxon)
DMMBAIH	RU	http://www.neuraxon.com/103110.html

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TT6MSOK
DMMBAIH	MN	5-HT 1D receptor (HTR1D)
DMMBAIH	MT	DTT
DMMBAIH	MA	Modulator
DMMBAIH	RN	Company report (NeurAxon)
DMMBAIH	RU	http://www.neuraxon.com/103110.html

DMMBAIH	DI	DMMBAIH
DMMBAIH	DN	NXN-188
DMMBAIH	MI	TTZUFI5
DMMBAIH	MN	Nitric-oxide synthase brain (NOS1)
DMMBAIH	MT	DTT
DMMBAIH	MA	Inhibitor
DMMBAIH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMBAIH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWVBS2	DI	DMWVBS2
DMWVBS2	DN	NXN-462
DMWVBS2	MI	TTZUFI5
DMWVBS2	MN	Nitric-oxide synthase brain (NOS1)
DMWVBS2	MT	DTT
DMWVBS2	MA	Inhibitor
DMWVBS2	RN	ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
DMWVBS2	RU	https://clinicaltrials.gov/ct2/show/NCT01748877

DM1P60V	DI	DM1P60V
DM1P60V	DN	NYX-2925
DM1P60V	MI	TT9IK2Z
DM1P60V	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1P60V	MT	DTT
DM1P60V	MA	Modulator
DM1P60V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1P60V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX04O8	DI	DMX04O8
DMX04O8	DN	NYX-2925
DMX04O8	MI	TT9IK2Z
DMX04O8	MN	N-methyl-D-aspartate receptor (NMDAR)
DMX04O8	MT	DTT
DMX04O8	MA	Modulator
DMX04O8	RN	NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther. 2018 Sep;366(3):485-497.
DMX04O8	RU	https://pubmed.ncbi.nlm.nih.gov/29986951

DMAVM2E	DI	DMAVM2E
DMAVM2E	DN	NYX-783
DMAVM2E	MI	TT9IK2Z
DMAVM2E	MN	N-methyl-D-aspartate receptor (NMDAR)
DMAVM2E	MT	DTT
DMAVM2E	MA	Modulator
DMAVM2E	RN	Clinical pipeline report, company report or official report of Aptinyx.
DMAVM2E	RU	https://www.aptinyx.com/pipeline/

DMXM34I	DI	DMXM34I
DMXM34I	DN	O-304
DMXM34I	MI	TTLAFZV
DMXM34I	MN	AMP-activated protein kinase (AMPK)
DMXM34I	MT	DTT
DMXM34I	MA	Activator
DMXM34I	RN	Clinical pipeline report, company report or official report of Betagenon.
DMXM34I	RU	https://betagenon.com/research-development/o304-our-ampk-activator

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTJGNVC
DMPF9ZM	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTU1E82
DMPF9ZM	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMPF9ZM	DI	DMPF9ZM
DMPF9ZM	DN	Obatoclax
DMPF9ZM	MI	TTL53M6
DMPF9ZM	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMPF9ZM	MT	DTT
DMPF9ZM	MA	Inhibitor
DMPF9ZM	RN	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
DMPF9ZM	RU	https://pubmed.ncbi.nlm.nih.gov/20709666

DMJIBSG	DI	DMJIBSG
DMJIBSG	DN	OBE-101
DMJIBSG	MI	TTTIBOJ
DMJIBSG	MN	Histamine H1 receptor (H1R)
DMJIBSG	MT	DTT
DMJIBSG	MA	Modulator
DMJIBSG	RN	Betahistine in the treatment of M ni re's disease. Neuropsychiatr Dis Treat. 2007 August; 3(4): 429-440.
DMJIBSG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655085/

DM5D6Y7	DI	DM5D6Y7
DM5D6Y7	DN	OBI-3424
DM5D6Y7	MI	TTUTN1I
DM5D6Y7	MN	Human Deoxyribonucleic acid (hDNA)
DM5D6Y7	MT	DTT
DM5D6Y7	RN	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503.
DM5D6Y7	RU	https://pubmed.ncbi.nlm.nih.gov/31015346

DMVXZC4	DI	DMVXZC4
DMVXZC4	DN	OBP-601
DMVXZC4	MI	TT84ETX
DMVXZC4	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMVXZC4	MT	DTT
DMVXZC4	MA	Inhibitor
DMVXZC4	RN	Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8.
DMVXZC4	RU	https://pubmed.ncbi.nlm.nih.gov/22733071

DM1JBD8	DI	DM1JBD8
DM1JBD8	DN	OC-000459
DM1JBD8	MI	TTQDMX5
DM1JBD8	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM1JBD8	MT	DTT
DM1JBD8	MA	Antagonist
DM1JBD8	RN	Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85.
DM1JBD8	RU	https://pubmed.ncbi.nlm.nih.gov/23379537

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTJQOD7
DMP6B59	MN	5-HT 2A receptor (HTR2A)
DMP6B59	MT	DTT
DMP6B59	MA	Modulator
DMP6B59	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTSECX1
DMP6B59	MN	Connective tissue growth factor (CTGF)
DMP6B59	MT	DTT
DMP6B59	MA	Inhibitor
DMP6B59	RN	Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/17979604

DMP6B59	DI	DMP6B59
DMP6B59	DN	Ocaperidone
DMP6B59	MI	TTEX248
DMP6B59	MN	Dopamine D2 receptor (D2R)
DMP6B59	MT	DTT
DMP6B59	MA	Modulator
DMP6B59	RN	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
DMP6B59	RU	https://pubmed.ncbi.nlm.nih.gov/1370538

DM8TDBY	DI	DM8TDBY
DM8TDBY	DN	OCFENTANIL
DM8TDBY	MI	TTN4QDT
DM8TDBY	MN	Opioid receptor (OPR)
DM8TDBY	MT	DTT
DM8TDBY	MA	Modulator
DM8TDBY	RN	Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6.
DM8TDBY	RU	https://pubmed.ncbi.nlm.nih.gov/1952145

DMT9QI2	DI	DMT9QI2
DMT9QI2	DN	OCV-101
DMT9QI2	MI	TT2Q6G1
DMT9QI2	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMT9QI2	MT	DTT
DMT9QI2	MA	Modulator
DMT9QI2	RN	Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
DMT9QI2	RU	https://www.ncbi.nlm.nih.gov/pubmed/23020774

DMK0MJP	DI	DMK0MJP
DMK0MJP	DN	Odelepran
DMK0MJP	MI	TTN4QDT
DMK0MJP	MN	Opioid receptor (OPR)
DMK0MJP	MT	DTT
DMK0MJP	MA	Antagonist
DMK0MJP	RN	A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20.
DMK0MJP	RU	https://pubmed.ncbi.nlm.nih.gov/24010675

DMJL4A7	DI	DMJL4A7
DMJL4A7	DN	O-desulfated heparin
DMJL4A7	MI	TT4QPUL
DMJL4A7	MN	Antithrombin-III (ATIII)
DMJL4A7	MT	DTT
DMJL4A7	MA	Modulator
DMJL4A7	RN	Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8.
DMJL4A7	RU	https://pubmed.ncbi.nlm.nih.gov/6778897

DMWCBY7	DI	DMWCBY7
DMWCBY7	DN	Odiparcil
DMWCBY7	MI	TT6L509
DMWCBY7	MN	Coagulation factor IIa (F2)
DMWCBY7	MT	DTT
DMWCBY7	MA	Inhibitor
DMWCBY7	RN	A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96.
DMWCBY7	RU	https://pubmed.ncbi.nlm.nih.gov/16961606

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTZ97H5
DMVC90W	MN	Phosphodiesterase 4A (PDE4A)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTVIAT9
DMVC90W	MN	Phosphodiesterase 4B (PDE4B)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMVC90W	DI	DMVC90W
DMVC90W	DN	Oglemilast
DMVC90W	MI	TTSKMI8
DMVC90W	MN	Phosphodiesterase 4D (PDE4D)
DMVC90W	MT	DTT
DMVC90W	MA	Inhibitor
DMVC90W	RN	Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290.
DMVC90W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/

DMJTU8D	DI	DMJTU8D
DMJTU8D	DN	OGX-427
DMJTU8D	MI	TTMG98T
DMJTU8D	MN	Heat shock protein 27 (HSP27)
DMJTU8D	MT	DTT
DMJTU8D	MA	Modulator
DMJTU8D	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJTU8D	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNEHY1	DI	DMNEHY1
DMNEHY1	DN	OI338GT
DMNEHY1	MI	TTVIMDE
DMNEHY1	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMNEHY1	MT	DTT
DMNEHY1	MA	Modulator
DMNEHY1	RN	Clinical pipeline report, company report or official report of Novo Nordisk A/S.
DMNEHY1	RU	http://www.novonordisk.com/bin/getPDF.1781915.pdf

DMVW5KR	DI	DMVW5KR
DMVW5KR	DN	Olcegepant
DMVW5KR	MI	TTY6O0Q
DMVW5KR	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMVW5KR	MT	DTT
DMVW5KR	MA	Modulator
DMVW5KR	RN	Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
DMVW5KR	RU	https://www.ncbi.nlm.nih.gov/pubmed/17665333

DM0RA8F	DI	DM0RA8F
DM0RA8F	DN	Oleoyl-estrone
DM0RA8F	MI	TTXJ47W
DM0RA8F	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM0RA8F	MT	DTT
DM0RA8F	MA	Agonist
DM0RA8F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0RA8F	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM0RA8F	DI	DM0RA8F
DM0RA8F	DN	Oleoyl-estrone
DM0RA8F	MI	TT8A9EF
DM0RA8F	MN	Metabotropic glutamate receptor 3 (mGluR3)
DM0RA8F	MT	DTT
DM0RA8F	MA	Agonist
DM0RA8F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0RA8F	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMXL7HO	DI	DMXL7HO
DMXL7HO	DN	OLX10010
DMXL7HO	MI	TTIL516
DMXL7HO	MN	CCN2 messenger RNA (CCN2 mRNA)
DMXL7HO	MT	DTT
DMXL7HO	MA	Inhibitor
DMXL7HO	RN	Clinical pipeline report, company report or official report of Olix Pharmaceuticals.
DMXL7HO	RU	https://www.olixpharma.com/eng/rnd/rnd03_olx101a.php

DMLMNFX	DI	DMLMNFX
DMLMNFX	DN	Omaveloxolone
DMLMNFX	MI	TTA6ZN2
DMLMNFX	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMLMNFX	MT	DTT
DMLMNFX	MA	Activator
DMLMNFX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLMNFX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMH9RTV	DI	DMH9RTV
DMH9RTV	DN	Omigapil
DMH9RTV	MI	TTUGSWA
DMH9RTV	MN	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
DMH9RTV	MT	DTT
DMH9RTV	MA	Modulator
DMH9RTV	RN	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3887-9.
DMH9RTV	RU	https://pubmed.ncbi.nlm.nih.gov/16505364

DMWC36Y	DI	DMWC36Y
DMWC36Y	DN	OMS405
DMWC36Y	MI	TTZMAO3
DMWC36Y	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMWC36Y	MT	DTT
DMWC36Y	MA	Agonist
DMWC36Y	RN	Clinical pipeline report, company report or official report of Avarx.
DMWC36Y	RU	http://www.avarx.com/AvaRx/SubDomains/bucket4984694478449561395/Listings/bucket4040741479008611375/Public.Listing.display.html

DMA4OGL	DI	DMA4OGL
DMA4OGL	DN	OMS824
DMA4OGL	MI	TTJW4LU
DMA4OGL	MN	Phosphodiesterase 10A (PDE10)
DMA4OGL	MT	DTT
DMA4OGL	MA	Inhibitor
DMA4OGL	RN	New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
DMA4OGL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875261/

DMT6E5N	DI	DMT6E5N
DMT6E5N	DN	Onapristone
DMT6E5N	MI	DE4LYSA
DMT6E5N	MN	Cytochrome P450 3A4 (CYP3A4)
DMT6E5N	MT	DME
DMT6E5N	MA	Metabolism
DMT6E5N	RN	Drug-metabolizing enzymes and transporters: expression in the human prostate and roles in prostate drug disposition. J Androl. 2006 Mar-Apr;27(2):138-50.
DMT6E5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16330661

DMT6E5N	DI	DMT6E5N
DMT6E5N	DN	Onapristone
DMT6E5N	MI	TTUV8G9
DMT6E5N	MN	Progesterone receptor (PGR)
DMT6E5N	MT	DTT
DMT6E5N	MA	Modulator
DMT6E5N	RN	Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8.
DMT6E5N	RU	https://www.ncbi.nlm.nih.gov/pubmed/10448262

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TTEX248
DMM5SCF	MN	Dopamine D2 receptor (D2R)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TT4C8EA
DMM5SCF	MN	Dopamine D3 receptor (D3R)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM5SCF	DI	DMM5SCF
DMM5SCF	DN	ONC201
DMM5SCF	MI	TTWFZ1N
DMM5SCF	MN	Dopamine receptor (DR)
DMM5SCF	MT	DTT
DMM5SCF	MA	Antagonist
DMM5SCF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM5SCF	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKIZAL	DI	DMKIZAL
DMKIZAL	DN	ONO-1603
DMKIZAL	MI	TTNGKET
DMKIZAL	MN	Prolyl endopeptidase (PREP)
DMKIZAL	MT	DTT
DMKIZAL	MA	Modulator
DMKIZAL	RN	ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
DMKIZAL	RU	https://pubmed.ncbi.nlm.nih.gov/8878106

DMOT0WR	DI	DMOT0WR
DMOT0WR	DN	ONO-2333Ms
DMOT0WR	MI	TT7EFHR
DMOT0WR	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMOT0WR	MT	DTT
DMOT0WR	MA	Antagonist
DMOT0WR	RN	Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
DMOT0WR	RU	https://pubmed.ncbi.nlm.nih.gov/23294766

DMOGYQ0	DI	DMOGYQ0
DMOGYQ0	DN	ONO-2952
DMOGYQ0	MI	TTPTXIN
DMOGYQ0	MN	Translocator protein (TSPO)
DMOGYQ0	MT	DTT
DMOGYQ0	MA	Antagonist
DMOGYQ0	RN	Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Jul 17;99:51-66.
DMOGYQ0	RU	https://pubmed.ncbi.nlm.nih.gov/26189762

DMQGO74	DI	DMQGO74
DMQGO74	DN	ONO-3307
DMQGO74	MI	TTZBFA0
DMQGO74	MN	Protease unspecific (PRO)
DMQGO74	MT	DTT
DMQGO74	MA	Modulator
DMQGO74	RN	Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63.
DMQGO74	RU	https://pubmed.ncbi.nlm.nih.gov/2515329

DMX4MVP	DI	DMX4MVP
DMX4MVP	DN	ONO-4053
DMX4MVP	MI	TTNVEIR
DMX4MVP	MN	Prostaglandin D2 receptor (PTGDR)
DMX4MVP	MT	DTT
DMX4MVP	MA	Antagonist
DMX4MVP	RN	Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
DMX4MVP	RU	http://www.sciencedirect.com/science/article/pii/S0091674914034332

DMLUM3Y	DI	DMLUM3Y
DMLUM3Y	DN	ONO-4641
DMLUM3Y	MI	TT9JZCK
DMLUM3Y	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMLUM3Y	MT	DTT
DMLUM3Y	MA	Agonist
DMLUM3Y	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMLUM3Y	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMFX3P1	DI	DMFX3P1
DMFX3P1	DN	ONO-5129
DMFX3P1	MI	TTJ584C
DMFX3P1	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMFX3P1	MT	DTT
DMFX3P1	MA	Modulator
DMFX3P1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFX3P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFX3P1	DI	DMFX3P1
DMFX3P1	DN	ONO-5129
DMFX3P1	MI	TTZMAO3
DMFX3P1	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMFX3P1	MT	DTT
DMFX3P1	MA	Modulator
DMFX3P1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFX3P1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRT28X	DI	DMRT28X
DMRT28X	DN	ONO-6126
DMRT28X	MI	DTUGYRD
DMRT28X	MN	P-glycoprotein 1 (ABCB1)
DMRT28X	MT	DTP
DMRT28X	MA	Substrate
DMRT28X	RN	Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
DMRT28X	RU	https://doi.org/10.1016/j.bmc.2012.03.045

DMRT28X	DI	DMRT28X
DMRT28X	DN	ONO-6126
DMRT28X	MI	TTV5CGO
DMRT28X	MN	Phosphodiesterase 4 (PDE4)
DMRT28X	MT	DTT
DMRT28X	MA	Inhibitor
DMRT28X	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMRT28X	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM5O6GC	DI	DM5O6GC
DM5O6GC	DN	ONO-9054
DM5O6GC	MI	TTPNGDE
DM5O6GC	MN	Prostaglandin E2 receptor EP3 (PTGER3)
DM5O6GC	MT	DTT
DM5O6GC	MA	Modulator
DM5O6GC	RN	IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
DM5O6GC	RU	https://pubmed.ncbi.nlm.nih.gov/25788650

DM5O6GC	DI	DM5O6GC
DM5O6GC	DN	ONO-9054
DM5O6GC	MI	TTT2ZAR
DM5O6GC	MN	Prostaglandin F2-alpha receptor (PTGFR)
DM5O6GC	MT	DTT
DM5O6GC	MA	Modulator
DM5O6GC	RN	IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
DM5O6GC	RU	https://pubmed.ncbi.nlm.nih.gov/25788650

DMCUGI8	DI	DMCUGI8
DMCUGI8	DN	ONO-AE1-437
DMCUGI8	MI	TT79WV3
DMCUGI8	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMCUGI8	MT	DTT
DMCUGI8	MA	Agonist
DMCUGI8	RN	An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
DMCUGI8	RU	https://pubmed.ncbi.nlm.nih.gov/15295094

DMS8Q7A	DI	DMS8Q7A
DMS8Q7A	DN	Ontazolast
DMS8Q7A	MI	TTTWGIX
DMS8Q7A	MN	Leukotriene receptor (LTR)
DMS8Q7A	MT	DTT
DMS8Q7A	MA	Modulator
DMS8Q7A	RN	Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64.
DMS8Q7A	RU	https://pubmed.ncbi.nlm.nih.gov/9110922

DM0FJIE	DI	DM0FJIE
DM0FJIE	DN	Ontuxizumab
DM0FJIE	MI	TTYJWT7
DM0FJIE	MN	Endosialin (CD248)
DM0FJIE	MT	DTT
DM0FJIE	MA	Inhibitor
DM0FJIE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0FJIE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMB1WF3	DI	DMB1WF3
DMB1WF3	DN	OPC-14523
DMB1WF3	MI	TTSQIFT
DMB1WF3	MN	5-HT 1A receptor (HTR1A)
DMB1WF3	MT	DTT
DMB1WF3	MA	Modulator
DMB1WF3	RN	Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
DMB1WF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11747902

DMB1WF3	DI	DMB1WF3
DMB1WF3	DN	OPC-14523
DMB1WF3	MI	TT5TPI6
DMB1WF3	MN	Opioid receptor sigma 1 (OPRS1)
DMB1WF3	MT	DTT
DMB1WF3	MA	Modulator
DMB1WF3	RN	Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
DMB1WF3	RU	https://www.ncbi.nlm.nih.gov/pubmed/11747902

DMIK2AD	DI	DMIK2AD
DMIK2AD	DN	OPC-64005
DMIK2AD	MI	TT8G3Z7
DMIK2AD	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMIK2AD	MT	DTT
DMIK2AD	MA	Inhibitor
DMIK2AD	RN	Clinical pipeline report, company report or official report of Otsuka Pharmaceutical.
DMIK2AD	RU	https://www.otsuka.co.jp/en/research-and-development/pipeline/

DML6TAS	DI	DML6TAS
DML6TAS	DN	OPI-1002
DML6TAS	MI	TT12KOD
DML6TAS	MN	P53 messenger RNA (TP53 mRNA)
DML6TAS	MT	DTT
DML6TAS	RN	2011 Pipeline of Quark Pharm.
DML6TAS	RU	http://www.quarkpharma.com/qbi-en/home/homepage/

DM1IBRT	DI	DM1IBRT
DM1IBRT	DN	OPN-305
DM1IBRT	MI	TTY7ZHS
DM1IBRT	MN	Toll-like receptor 2 (TLR2)
DM1IBRT	MT	DTT
DM1IBRT	RN	Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
DM1IBRT	RU	https://pubmed.ncbi.nlm.nih.gov/22354933

DMYG1ZQ	DI	DMYG1ZQ
DMYG1ZQ	DN	OPNT001
DMYG1ZQ	MI	TTKWM86
DMYG1ZQ	MN	Opioid receptor mu (MOP)
DMYG1ZQ	MT	DTT
DMYG1ZQ	MA	Antagonist
DMYG1ZQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYG1ZQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM16RIC	DI	DM16RIC
DM16RIC	DN	Oprozomib
DM16RIC	MI	TTU7ZMG
DM16RIC	MN	Proteasome (PS)
DM16RIC	MT	DTT
DM16RIC	MA	Modulator
DM16RIC	RN	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.
DM16RIC	RU	https://pubmed.ncbi.nlm.nih.gov/20805366

DMS4XFI	DI	DMS4XFI
DMS4XFI	DN	OPT-302
DMS4XFI	MI	TT0QUFV
DMS4XFI	MN	Vascular endothelial growth factor C (VEGFC)
DMS4XFI	MT	DTT
DMS4XFI	MA	Inhibitor
DMS4XFI	RN	Clinical pipeline report, company report or official report of Opthea.
DMS4XFI	RU	https://opthea.com/

DMS4XFI	DI	DMS4XFI
DMS4XFI	DN	OPT-302
DMS4XFI	MI	TTOM5H4
DMS4XFI	MN	Vascular endothelial growth factor D (VEGFD)
DMS4XFI	MT	DTT
DMS4XFI	MA	Inhibitor
DMS4XFI	RN	Clinical pipeline report, company report or official report of Opthea.
DMS4XFI	RU	https://opthea.com/

DMR3P98	DI	DMR3P98
DMR3P98	DN	ORG 34517/34850
DMR3P98	MI	TTYRL6O
DMR3P98	MN	Glucocorticoid receptor (NR3C1)
DMR3P98	MT	DTT
DMR3P98	MA	Antagonist
DMR3P98	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMR3P98	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMR3P98	DI	DMR3P98
DMR3P98	DN	ORG 34517/34850
DMR3P98	MI	TTBFROQ
DMR3P98	MN	S-adenosylmethionine decarboxylase proenzyme (AMD1)
DMR3P98	MT	DTT
DMR3P98	MA	Inhibitor
DMR3P98	RN	A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601.
DMR3P98	RU	https://pubmed.ncbi.nlm.nih.gov/10944598

DMAWXJT	DI	DMAWXJT
DMAWXJT	DN	ORG-13011
DMAWXJT	MI	TTSQIFT
DMAWXJT	MN	5-HT 1A receptor (HTR1A)
DMAWXJT	MT	DTT
DMAWXJT	MA	Antagonist
DMAWXJT	RN	Antagonism of the 5-HT1A receptor stimulus in a conditioned taste aversion procedure. Eur Neuropsychopharmacol. 1999 Jun;9(4):345-9.
DMAWXJT	RU	https://pubmed.ncbi.nlm.nih.gov/10422896

DMWN2EC	DI	DMWN2EC
DMWN2EC	DN	ORG-25935
DMWN2EC	MI	TTHJTF7
DMWN2EC	MN	Glycine transporter GlyT-1 (SLC6A9)
DMWN2EC	MT	DTT
DMWN2EC	MA	Inhibitor
DMWN2EC	RN	The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8.
DMWN2EC	RU	https://pubmed.ncbi.nlm.nih.gov/24525661

DMDZ4R2	DI	DMDZ4R2
DMDZ4R2	DN	Org-30029
DMDZ4R2	MI	TTZCG4L
DMDZ4R2	MN	Phosphodiesterase 3 (PDE3)
DMDZ4R2	MT	DTT
DMDZ4R2	MA	Modulator
DMDZ4R2	RN	Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
DMDZ4R2	RU	https://pubmed.ncbi.nlm.nih.gov/8431987

DMIO59F	DI	DMIO59F
DMIO59F	DN	ORG-34517
DMIO59F	MI	TTYRL6O
DMIO59F	MN	Glucocorticoid receptor (NR3C1)
DMIO59F	MT	DTT
DMIO59F	MA	Antagonist
DMIO59F	RN	Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann N Y Acad Sci. 2008 Dec;1148:536-41.
DMIO59F	RU	https://pubmed.ncbi.nlm.nih.gov/19120154

DM8ARQW	DI	DM8ARQW
DM8ARQW	DN	ORM-12741
DM8ARQW	MI	TT2NUT5
DM8ARQW	MN	Adrenergic receptor alpha-2C (ADRA2C)
DM8ARQW	MT	DTT
DM8ARQW	MA	Antagonist
DM8ARQW	RN	A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014 May;53(5):948-52.
DM8ARQW	RU	https://pubmed.ncbi.nlm.nih.gov/24489014

DMRIO6D	DI	DMRIO6D
DMRIO6D	DN	ORMD-0901
DMRIO6D	MI	TTVIMDE
DMRIO6D	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMRIO6D	MT	DTT
DMRIO6D	MA	Agonist
DMRIO6D	RN	Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23.
DMRIO6D	RU	https://pubmed.ncbi.nlm.nih.gov/21129350

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	DTI7UX6
DM1EK5D	MN	Breast cancer resistance protein (ABCG2)
DM1EK5D	MT	DTP
DM1EK5D	MA	Substrate
DM1EK5D	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DM1EK5D	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	TT0JLSD
DM1EK5D	MN	Multidrug resistance protein (MDR)
DM1EK5D	MT	DTT
DM1EK5D	MA	Modulator
DM1EK5D	RN	Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
DM1EK5D	RU	http://www.spectrumpharm.com/products_Spectrum.html

DM1EK5D	DI	DM1EK5D
DM1EK5D	DN	Ortataxel
DM1EK5D	MI	TTF8CQI
DM1EK5D	MN	Tumor necrosis factor (TNF)
DM1EK5D	MT	DTT
DM1EK5D	MA	Inhibitor
DM1EK5D	RN	New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
DM1EK5D	RU	https://pubmed.ncbi.nlm.nih.gov/19265486

DMSO846	DI	DMSO846
DMSO846	DN	Orvepitant
DMSO846	MI	TTZPO1L
DMSO846	MN	Substance-P receptor (TACR1)
DMSO846	MT	DTT
DMSO846	MA	Antagonist
DMSO846	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMSO846	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMJX3O8	DI	DMJX3O8
DMJX3O8	DN	OSI-027
DMJX3O8	MI	TTCJG29
DMJX3O8	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMJX3O8	MT	DTT
DMJX3O8	MA	Inhibitor
DMJX3O8	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DMJX3O8	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMBVI6E	DI	DMBVI6E
DMBVI6E	DN	Ostabolin-C
DMBVI6E	MI	TT6F7GZ
DMBVI6E	MN	Parathyroid hormone (PTH)
DMBVI6E	MT	DTT
DMBVI6E	MA	Modulator
DMBVI6E	RN	ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs. 2008 Nov;11(11):827-40.
DMBVI6E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18988128

DMHKIOF	DI	DMHKIOF
DMHKIOF	DN	OT551
DMHKIOF	MI	TTA6ZN2
DMHKIOF	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMHKIOF	MT	DTT
DMHKIOF	MA	Activator
DMHKIOF	RN	Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325.
DMHKIOF	RU	https://pubmed.ncbi.nlm.nih.gov/26594225

DMTNOXQ	DI	DMTNOXQ
DMTNOXQ	DN	OT-551
DMTNOXQ	MI	TTA6ZN2
DMTNOXQ	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMTNOXQ	MT	DTT
DMTNOXQ	MA	Inhibitor
DMTNOXQ	RN	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
DMTNOXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23812264

DMFNDBC	DI	DMFNDBC
DMFNDBC	DN	Otelixizumab
DMFNDBC	MI	TTUN7MC
DMFNDBC	MN	T-cell surface glycoprotein CD3 (CD3)
DMFNDBC	MT	DTT
DMFNDBC	MA	Modulator
DMFNDBC	RN	Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
DMFNDBC	RU	https://www.ncbi.nlm.nih.gov/pubmed/25011949

DM1AQLW	DI	DM1AQLW
DM1AQLW	DN	Otilimab
DM1AQLW	MI	TTPZGYX
DM1AQLW	MN	HUMAN colony-stimulating factor (GM-CSF)
DM1AQLW	MT	DTT
DM1AQLW	MA	Inhibitor
DM1AQLW	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DM1AQLW	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMAZIND	DI	DMAZIND
DMAZIND	DN	Otlertuzumab
DMAZIND	MI	TTFCW29
DMAZIND	MN	Leukocyte antigen CD37 (CD37)
DMAZIND	MT	DTT
DMAZIND	MA	Inhibitor
DMAZIND	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAZIND	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTZ97H5
DM5Q9RY	MN	Phosphodiesterase 4A (PDE4A)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTVIAT9
DM5Q9RY	MN	Phosphodiesterase 4B (PDE4B)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DM5Q9RY	DI	DM5Q9RY
DM5Q9RY	DN	OX-914
DM5Q9RY	MI	TTSKMI8
DM5Q9RY	MN	Phosphodiesterase 4D (PDE4D)
DM5Q9RY	MT	DTT
DM5Q9RY	MA	Inhibitor
DM5Q9RY	RN	Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.
DM5Q9RY	RU	http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf

DMBM47Z	DI	DMBM47Z
DMBM47Z	DN	Oxazolidinones
DMBM47Z	MI	TT38DW5
DMBM47Z	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMBM47Z	MT	DTT
DMBM47Z	MA	Inhibitor
DMBM47Z	RN	Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
DMBM47Z	RU	https://pubmed.ncbi.nlm.nih.gov/10411137

DMBM47Z	DI	DMBM47Z
DMBM47Z	DN	Oxazolidinones
DMBM47Z	MI	TTLFGBV
DMBM47Z	MN	Bacterial 23S ribosomal RNA (Bact 23S rRNA)
DMBM47Z	MT	DTT
DMBM47Z	MA	Inhibitor
DMBM47Z	RN	Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
DMBM47Z	RU	https://pubmed.ncbi.nlm.nih.gov/10411137

DMSNL51	DI	DMSNL51
DMSNL51	DN	Oxfendazole
DMSNL51	MI	DTI7UX6
DMSNL51	MN	Breast cancer resistance protein (ABCG2)
DMSNL51	MT	DTP
DMSNL51	MA	Substrate
DMSNL51	RN	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos. 2005 May;33(5):614-8.
DMSNL51	RU	http://www.ncbi.nlm.nih.gov/pubmed/15703302

DMC3PJS	DI	DMC3PJS
DMC3PJS	DN	Oxytrex
DMC3PJS	MI	TTN4QDT
DMC3PJS	MN	Opioid receptor (OPR)
DMC3PJS	MT	DTT
DMC3PJS	MA	Modulator
DMC3PJS	RN	Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83.
DMC3PJS	RU	https://pubmed.ncbi.nlm.nih.gov/17685875

DMEGTH1	DI	DMEGTH1
DMEGTH1	DN	Ozarelix
DMEGTH1	MI	TT8R70G
DMEGTH1	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMEGTH1	MT	DTT
DMEGTH1	MA	Modulator
DMEGTH1	RN	Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
DMEGTH1	RU	https://pubmed.ncbi.nlm.nih.gov/20623634

DMEYQPN	DI	DMEYQPN
DMEYQPN	DN	P-1736
DMEYQPN	MI	TTB8FUC
DMEYQPN	MN	Free fatty acid receptor 1 (GPR40)
DMEYQPN	MT	DTT
DMEYQPN	MA	Modulator
DMEYQPN	RN	Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
DMEYQPN	RU	https://pubmed.ncbi.nlm.nih.gov/24194903

DMMJUHD	DI	DMMJUHD
DMMJUHD	DN	P-276
DMMJUHD	MI	TTH6V3D
DMMJUHD	MN	Cyclin-dependent kinase 1 (CDK1)
DMMJUHD	MT	DTT
DMMJUHD	MA	Inhibitor
DMMJUHD	RN	P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
DMMJUHD	RU	https://pubmed.ncbi.nlm.nih.gov/17363487

DMMJUHD	DI	DMMJUHD
DMMJUHD	DN	P-276
DMMJUHD	MI	TT0PG8F
DMMJUHD	MN	Cyclin-dependent kinase 4 (CDK4)
DMMJUHD	MT	DTT
DMMJUHD	MA	Inhibitor
DMMJUHD	RN	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
DMMJUHD	RU	https://pubmed.ncbi.nlm.nih.gov/21253554

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TTH6V3D
DM9DJL2	MN	Cyclin-dependent kinase 1 (CDK1)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TT0PG8F
DM9DJL2	MN	Cyclin-dependent kinase 4 (CDK4)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DM9DJL2	DI	DM9DJL2
DM9DJL2	DN	P276-00
DM9DJL2	MI	TT1LVF2
DM9DJL2	MN	Cyclin-dependent kinase 9 (CDK9)
DM9DJL2	MT	DTT
DM9DJL2	MA	Inhibitor
DM9DJL2	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DM9DJL2	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMW1OI6	DI	DMW1OI6
DMW1OI6	DN	P32/98
DMW1OI6	MI	TTDIGC1
DMW1OI6	MN	Dipeptidyl peptidase 4 (DPP-4)
DMW1OI6	MT	DTT
DMW1OI6	MA	Inhibitor
DMW1OI6	RN	Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50.
DMW1OI6	RU	https://pubmed.ncbi.nlm.nih.gov/11916911

DMCBEYH	DI	DMCBEYH
DMCBEYH	DN	P54
DMCBEYH	MI	TTUIZKC
DMCBEYH	MN	DNA-binding factor KBF1 (p105)
DMCBEYH	MT	DTT
DMCBEYH	MA	Modulator
DMCBEYH	RN	Identification of p54(nrb) and the 14-3-3 Protein HS1 as TNF-alpha-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol. 2005 Jul 31;38(4):447-56.
DMCBEYH	RU	https://pubmed.ncbi.nlm.nih.gov/16053712

DMG8NLI	DI	DMG8NLI
DMG8NLI	DN	P-9808
DMG8NLI	MI	TTT0HW3
DMG8NLI	MN	Porphobilinogen deaminase (HMBS)
DMG8NLI	MT	DTT
DMG8NLI	MA	Modulator
DMG8NLI	RN	Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49.
DMG8NLI	RU	https://pubmed.ncbi.nlm.nih.gov/17375984

DM3816P	DI	DM3816P
DM3816P	DN	PAC-14028
DM3816P	MI	TTMI6F5
DM3816P	MN	Transient receptor potential cation channel V1 (TRPV1)
DM3816P	MT	DTT
DM3816P	MA	Antagonist
DM3816P	RN	Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6.
DM3816P	RU	https://pubmed.ncbi.nlm.nih.gov/22477184

DMMIYZ7	DI	DMMIYZ7
DMMIYZ7	DN	Palifosfamide
DMMIYZ7	MI	TT6S2FE
DMMIYZ7	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DMMIYZ7	MT	DTT
DMMIYZ7	MA	Inhibitor
DMMIYZ7	RN	Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
DMMIYZ7	RU	https://pubmed.ncbi.nlm.nih.gov/22027537

DMX8ZAQ	DI	DMX8ZAQ
DMX8ZAQ	DN	Paliroden
DMX8ZAQ	MI	TT9HLZ0
DMX8ZAQ	MN	Glutamate receptor AMPA 2 (GRIA2)
DMX8ZAQ	MT	DTT
DMX8ZAQ	MA	Modulator
DMX8ZAQ	RN	Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44.
DMX8ZAQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/23402301

DMAZ460	DI	DMAZ460
DMAZ460	DN	Pankomab-GEX
DMAZ460	MI	TTBHFYQ
DMAZ460	MN	Mucin-1 (MUC1)
DMAZ460	MT	DTT
DMAZ460	RN	Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
DMAZ460	RU	https://pubmed.ncbi.nlm.nih.gov/23275306

DMV27SP	DI	DMV27SP
DMV27SP	DN	Panobacumab
DMV27SP	MI	TT4ESMB
DMV27SP	MN	Pseudomonas Lipopolysaccharide (Pseudo LPS)
DMV27SP	MT	DTT
DMV27SP	MA	Modulator
DMV27SP	RN	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. 
DMV27SP	RU	https://www.ncbi.nlm.nih.gov/pubmed/26514853

DMPO4M1	DI	DMPO4M1
DMPO4M1	DN	Paquinimod
DMPO4M1	MI	TT0TMQG
DMPO4M1	MN	Calgranulin B (S100A9)
DMPO4M1	MT	DTT
DMPO4M1	MA	Inhibitor
DMPO4M1	RN	Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.
DMPO4M1	RU	https://pubmed.ncbi.nlm.nih.gov/25969431

DMD275X	DI	DMD275X
DMD275X	DN	Pardoprunox
DMD275X	MI	TTEX248
DMD275X	MN	Dopamine D2 receptor (D2R)
DMD275X	MT	DTT
DMD275X	MA	Agonist
DMD275X	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMD275X	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM4N7BT	DI	DM4N7BT
DM4N7BT	DN	Paritaprevir
DM4N7BT	MI	DTUGYRD
DM4N7BT	MN	P-glycoprotein 1 (ABCB1)
DM4N7BT	MT	DTP
DM4N7BT	MA	Substrate
DM4N7BT	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM4N7BT	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMYBIFS	DI	DMYBIFS
DMYBIFS	DN	Parsaclisib
DMYBIFS	MI	TTGBPJE
DMYBIFS	MN	PI3-kinase delta (PIK3CD)
DMYBIFS	MT	DTT
DMYBIFS	MA	Inhibitor
DMYBIFS	RN	Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.
DMYBIFS	RU	https://pubmed.ncbi.nlm.nih.gov/30803990

DMCQBFT	DI	DMCQBFT
DMCQBFT	DN	Parthenolide
DMCQBFT	MI	TTJ3E9X
DMCQBFT	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMCQBFT	MT	DTT
DMCQBFT	MA	Inhibitor
DMCQBFT	RN	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66.
DMCQBFT	RU	https://pubmed.ncbi.nlm.nih.gov/11514225

DMCQBFT	DI	DMCQBFT
DMCQBFT	DN	Parthenolide
DMCQBFT	MI	TTSXVID
DMCQBFT	MN	Nuclear factor NF-kappa-B (NFKB)
DMCQBFT	MT	DTT
DMCQBFT	MA	Inhibitor
DMCQBFT	RN	Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
DMCQBFT	RU	https://pubmed.ncbi.nlm.nih.gov/15630139

DMU3XJP	DI	DMU3XJP
DMU3XJP	DN	Pascolizumab
DMU3XJP	MI	TTLGTKB
DMU3XJP	MN	Interleukin-4 (IL4)
DMU3XJP	MT	DTT
DMU3XJP	MA	Modulator
DMU3XJP	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMU3XJP	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DM2NJYC	DI	DM2NJYC
DM2NJYC	DN	Patidegib
DM2NJYC	MI	TT4LXBC
DM2NJYC	MN	Hedgehog signaling pathway (HS pathway)
DM2NJYC	MT	DTT
DM2NJYC	MA	Inhibitor
DM2NJYC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2NJYC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMU0812	DI	DMU0812
DMU0812	DN	PAZ-320
DMU0812	MI	TTXWASR
DMU0812	MN	Intestinal maltase-glucoamylase (MGAM)
DMU0812	MT	DTT
DMU0812	MA	Modulator
DMU0812	RN	Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
DMU0812	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455361/

DMVJD2W	DI	DMVJD2W
DMVJD2W	DN	Pazopanib + Tyverb/Tykerb
DMVJD2W	MI	TTGKNB4
DMVJD2W	MN	Epidermal growth factor receptor (EGFR)
DMVJD2W	MT	DTT
DMVJD2W	MA	Inhibitor
DMVJD2W	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMVJD2W	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMVJD2W	DI	DMVJD2W
DMVJD2W	DN	Pazopanib + Tyverb/Tykerb
DMVJD2W	MI	TT6EO5L
DMVJD2W	MN	Erbb2 tyrosine kinase receptor (HER2)
DMVJD2W	MT	DTT
DMVJD2W	MA	Inhibitor
DMVJD2W	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMVJD2W	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCI04	DI	DMZCI04
DMZCI04	DN	PB-1023
DMZCI04	MI	TT0NUFM
DMZCI04	MN	Glucagon (GCG)
DMZCI04	MT	DTT
DMZCI04	MA	Agonist
DMZCI04	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZCI04	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMZCI04	DI	DMZCI04
DMZCI04	DN	PB-1023
DMZCI04	MI	TTVIMDE
DMZCI04	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZCI04	MT	DTT
DMZCI04	MA	Modulator
DMZCI04	RN	On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice. Toxicol Pathol February 2013 vol. 41 no. 2 303-309.
DMZCI04	RU	http://tpx.sagepub.com/content/41/2/303.full

DM8MJ3F	DI	DM8MJ3F
DM8MJ3F	DN	PB1046
DM8MJ3F	MI	TT4O5P0
DM8MJ3F	MN	Helodermin-preferring VIP receptor (VIPR2)
DM8MJ3F	MT	DTT
DM8MJ3F	MA	Agonist
DM8MJ3F	RN	Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals.
DM8MJ3F	RU	http://phasebio.com/clinical-development-pipeline/vasomera/

DM05WIU	DI	DM05WIU
DM05WIU	DN	PBI-05204
DM05WIU	MI	TTQ38E9
DM05WIU	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DM05WIU	MT	DTT
DM05WIU	MA	Inhibitor
DM05WIU	RN	First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf- beta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1204-12.
DM05WIU	RU	https://pubmed.ncbi.nlm.nih.gov/24919855

DMPXK27	DI	DMPXK27
DMPXK27	DN	PBI-4050
DMPXK27	MI	TTB8FUC
DMPXK27	MN	Free fatty acid receptor 1 (GPR40)
DMPXK27	MT	DTT
DMPXK27	MA	Agonist
DMPXK27	RN	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
DMPXK27	RU	https://pubmed.ncbi.nlm.nih.gov/30578394

DMPXK27	DI	DMPXK27
DMPXK27	DN	PBI-4050
DMPXK27	MI	TTG0MQD
DMPXK27	MN	Inflammation-related GPCR EX33 (GPR84)
DMPXK27	MT	DTT
DMPXK27	MA	Antagonist
DMPXK27	RN	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
DMPXK27	RU	https://pubmed.ncbi.nlm.nih.gov/30578394

DMKWGS1	DI	DMKWGS1
DMKWGS1	DN	PBT-2
DMKWGS1	MI	TTS87KH
DMKWGS1	MN	Microtubule-associated protein tau (MAPT)
DMKWGS1	MT	DTT
DMKWGS1	MA	Modulator
DMKWGS1	RN	PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
DMKWGS1	RU	https://pubmed.ncbi.nlm.nih.gov/20164561

DMYRIHZ	DI	DMYRIHZ
DMYRIHZ	DN	PCL-016
DMYRIHZ	MI	TT3J1EK
DMYRIHZ	MN	Zinc finger protein (ZNF)
DMYRIHZ	MT	DTT
DMYRIHZ	MA	Modulator
DMYRIHZ	RN	US patent application no. 2005,0239,723, Compositions and methods useful for treatment of acne.
DMYRIHZ	RU	http://www.google.com/patents/US20050239723

DMYFRTB	DI	DMYFRTB
DMYFRTB	DN	PCM-075
DMYFRTB	MI	TTIYVQP
DMYFRTB	MN	Polo-like kinase 1 (PLK1)
DMYFRTB	MT	DTT
DMYFRTB	MA	Inhibitor
DMYFRTB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYFRTB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUHDX3	DI	DMUHDX3
DMUHDX3	DN	PC-SOD
DMUHDX3	MI	TT6RVLG
DMUHDX3	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMUHDX3	MT	DTT
DMUHDX3	MA	Modulator
DMUHDX3	RN	A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis
DMUHDX3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364

DM27D4J	DI	DM27D4J
DM27D4J	DN	PD-0325901
DM27D4J	MI	TTROQ37
DM27D4J	MN	MAPK/ERK kinase kinase (MAP3K)
DM27D4J	MT	DTT
DM27D4J	MA	Modulator
DM27D4J	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DM27D4J	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMXAH4G	DI	DMXAH4G
DMXAH4G	DN	PD-143188
DMXAH4G	MI	TTEX248
DMXAH4G	MN	Dopamine D2 receptor (D2R)
DMXAH4G	MT	DTT
DMXAH4G	MA	Modulator
DMXAH4G	RN	Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 1998;62(7):649-63.
DMXAH4G	RU	https://pubmed.ncbi.nlm.nih.gov/9472724

DMWVBTQ	DI	DMWVBTQ
DMWVBTQ	DN	PD-145065
DMWVBTQ	MI	TTKRD0G
DMWVBTQ	MN	Endothelin A receptor (EDNRA)
DMWVBTQ	MT	DTT
DMWVBTQ	MA	Modulator
DMWVBTQ	RN	Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
DMWVBTQ	RU	https://pubmed.ncbi.nlm.nih.gov/8032643

DMWVBTQ	DI	DMWVBTQ
DMWVBTQ	DN	PD-145065
DMWVBTQ	MI	TT3ZTGU
DMWVBTQ	MN	Endothelin B receptor (EDNRB)
DMWVBTQ	MT	DTT
DMWVBTQ	MA	Modulator
DMWVBTQ	RN	Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
DMWVBTQ	RU	https://pubmed.ncbi.nlm.nih.gov/8032643

DMPW28M	DI	DMPW28M
DMPW28M	DN	PD-200390
DMPW28M	MI	TT729IR
DMPW28M	MN	Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)
DMPW28M	MT	DTT
DMPW28M	MA	Modulator
DMPW28M	RN	Pfizer. Product Development Pipeline. March 31 2009.
DMPW28M	RU	http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf

DM6F5EV	DI	DM6F5EV
DM6F5EV	DN	PD-360324
DM6F5EV	MI	TT731LW
DM6F5EV	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM6F5EV	MT	DTT
DM6F5EV	MA	Modulator
DM6F5EV	RN	Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
DM6F5EV	RU	https://www.ncbi.nlm.nih.gov/pubmed/26376111

DMGP9VN	DI	DMGP9VN
DMGP9VN	DN	PDC-1421
DMGP9VN	MI	TTAWNKZ
DMGP9VN	MN	Norepinephrine transporter (NET)
DMGP9VN	MT	DTT
DMGP9VN	MA	Inhibitor
DMGP9VN	RN	Clinical pipeline report, company report or official report of BioInvent.
DMGP9VN	RU	https://www.biolite.com.tw/tw/medicine/bli1005.html

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	DE4LYSA
DM6OC53	MN	Cytochrome P450 3A4 (CYP3A4)
DM6OC53	MT	DME
DM6OC53	MA	Metabolism
DM6OC53	RN	Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013;8(1):e54522.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23382909

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	TTBH0VX
DM6OC53	MN	Histone deacetylase (HDAC)
DM6OC53	MT	DTT
DM6OC53	MA	Modulator
DM6OC53	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM6OC53	DI	DM6OC53
DM6OC53	DN	PDX-101
DM6OC53	MI	DEYGVN4
DM6OC53	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM6OC53	MT	DME
DM6OC53	MA	Metabolism
DM6OC53	RN	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol. 2016 Apr;56(4):461-73.
DM6OC53	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=26313268

DMFL96Z	DI	DMFL96Z
DMFL96Z	DN	Pegamotecan
DMFL96Z	MI	TTGTQHC
DMFL96Z	MN	DNA topoisomerase I (TOP1)
DMFL96Z	MT	DTT
DMFL96Z	MA	Inhibitor
DMFL96Z	RN	A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70.
DMFL96Z	RU	https://pubmed.ncbi.nlm.nih.gov/18398613

DMPD3X6	DI	DMPD3X6
DMPD3X6	DN	Pegmusirudin
DMPD3X6	MI	TT6L509
DMPD3X6	MN	Coagulation factor IIa (F2)
DMPD3X6	MT	DTT
DMPD3X6	MA	Modulator
DMPD3X6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMPD3X6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM26YJ1	DI	DM26YJ1
DM26YJ1	DN	PEGPH20
DM26YJ1	MI	TTXFI1K
DM26YJ1	MN	Hyaluronidase (HYAL)
DM26YJ1	MT	DTT
DM26YJ1	MA	Modulator
DM26YJ1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM26YJ1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMX9ZM4	DI	DMX9ZM4
DMX9ZM4	DN	PEG-SN38
DMX9ZM4	MI	DE4LYSA
DMX9ZM4	MN	Cytochrome P450 3A4 (CYP3A4)
DMX9ZM4	MT	DME
DMX9ZM4	MA	Metabolism
DMX9ZM4	RN	Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506.
DMX9ZM4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=23543270

DMX9ZM4	DI	DMX9ZM4
DMX9ZM4	DN	PEG-SN38
DMX9ZM4	MI	TTGTQHC
DMX9ZM4	MN	DNA topoisomerase I (TOP1)
DMX9ZM4	MT	DTT
DMX9ZM4	MA	Inhibitor
DMX9ZM4	RN	EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7(9):e45248.
DMX9ZM4	RU	https://pubmed.ncbi.nlm.nih.gov/23028879

DMTDANB	DI	DMTDANB
DMTDANB	DN	Pegsunercept
DMTDANB	MI	TTF8CQI
DMTDANB	MN	Tumor necrosis factor (TNF)
DMTDANB	MT	DTT
DMTDANB	MA	Inhibitor
DMTDANB	RN	Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8.
DMTDANB	RU	https://pubmed.ncbi.nlm.nih.gov/18403591

DMBPJ9U	DI	DMBPJ9U
DMBPJ9U	DN	PEGylated pitrakinra
DMBPJ9U	MI	TT0GVCH
DMBPJ9U	MN	Interleukin-13 (IL13)
DMBPJ9U	MT	DTT
DMBPJ9U	MA	Modulator
DMBPJ9U	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMBPJ9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMBPJ9U	DI	DMBPJ9U
DMBPJ9U	DN	PEGylated pitrakinra
DMBPJ9U	MI	TTLGTKB
DMBPJ9U	MN	Interleukin-4 (IL4)
DMBPJ9U	MT	DTT
DMBPJ9U	MA	Modulator
DMBPJ9U	RN	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. 
DMBPJ9U	RU	https://www.ncbi.nlm.nih.gov/pubmed/23197041

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTI7UX6
DMOMN31	MN	Breast cancer resistance protein (ABCG2)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMOMN31	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DE4ZHS1
DMOMN31	MN	Glutathione S-transferase alpha-1 (GSTA1)
DMOMN31	MT	DME
DMOMN31	MA	Metabolism
DMOMN31	RN	Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS J. 2014 Jul;16(4):705-13.
DMOMN31	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24821055

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTSYQGK
DMOMN31	MN	Multidrug resistance-associated protein 1 (ABCC1)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMOMN31	RU	https://doi.org/10.1007/s11095-012-0935-x

DMOMN31	DI	DMOMN31
DMOMN31	DN	PEITC
DMOMN31	MI	DTFI42L
DMOMN31	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMOMN31	MT	DTP
DMOMN31	MA	Substrate
DMOMN31	RN	Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
DMOMN31	RU	https://doi.org/10.1016/j.bcp.2005.05.025

DMIW453	DI	DMIW453
DMIW453	DN	Pelitinib
DMIW453	MI	TTGKNB4
DMIW453	MN	Epidermal growth factor receptor (EGFR)
DMIW453	MT	DTT
DMIW453	MA	Modulator
DMIW453	RN	EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
DMIW453	RU	https://www.ncbi.nlm.nih.gov/pubmed/23379415

DMR6USG	DI	DMR6USG
DMR6USG	DN	PELITREXOL
DMR6USG	MI	TTEXB9Z
DMR6USG	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMR6USG	MT	DTT
DMR6USG	MA	Inhibitor
DMR6USG	RN	Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075.
DMR6USG	RU	http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3075

DMGY5JC	DI	DMGY5JC
DMGY5JC	DN	Pentacea
DMGY5JC	MI	TTY6DTE
DMGY5JC	MN	Carcinoembryonic antigen CEA (CD66e)
DMGY5JC	MT	DTT
DMGY5JC	RN	Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
DMGY5JC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828581/

DMNU48O	DI	DMNU48O
DMNU48O	DN	Peptide YY 3-36
DMNU48O	MI	TTVFJLX
DMNU48O	MN	Peptide tyrosine tyrosine PYY (PYY)
DMNU48O	MT	DTT
DMNU48O	MA	Modulator
DMNU48O	RN	Clinical pipeline report, company report or official report of Emisphere.
DMNU48O	RU	http://ir.emisphere.com/releasedetail.cfm?releaseid=356364

DMFM6OU	DI	DMFM6OU
DMFM6OU	DN	PerioPatch
DMFM6OU	MI	TTHS7CM
DMFM6OU	MN	Beta-glucuronidase (GUSB)
DMFM6OU	MT	DTT
DMFM6OU	MA	Modulator
DMFM6OU	RN	Clinical pipeline report, company report or official report of Izun Pharmaceuticals.
DMFM6OU	RU	http://izunpharma.com/products/periopatch/

DMNM4CK	DI	DMNM4CK
DMNM4CK	DN	PF-00734200
DMNM4CK	MI	TTDIGC1
DMNM4CK	MN	Dipeptidyl peptidase 4 (DPP-4)
DMNM4CK	MT	DTT
DMNM4CK	MA	Modulator
DMNM4CK	RN	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9.
DMNM4CK	RU	https://www.ncbi.nlm.nih.gov/pubmed/21392067

DMJPE61	DI	DMJPE61
DMJPE61	DN	PF-02545920
DMJPE61	MI	TTJW4LU
DMJPE61	MN	Phosphodiesterase 10A (PDE10)
DMJPE61	MT	DTT
DMJPE61	MA	Inhibitor
DMJPE61	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJPE61	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMTJWNE	DI	DMTJWNE
DMTJWNE	DN	PF-03446962
DMTJWNE	MI	TTGYPTC
DMTJWNE	MN	Activin receptor-like kinase-1 (ACVRL1)
DMTJWNE	MT	DTT
DMTJWNE	MA	Modulator
DMTJWNE	RN	ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006.
DMTJWNE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143549/

DM826SW	DI	DM826SW
DM826SW	DN	PF-04236921
DM826SW	MI	TTF6I40
DM826SW	MN	Interleukin (IL)
DM826SW	MT	DTT
DM826SW	MA	Inhibitor
DM826SW	RN	US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast.
DM826SW	RU	https://www.google.com/patents/US20100158905

DM826SW	DI	DM826SW
DM826SW	DN	PF-04236921
DM826SW	MI	TTT1V78
DM826SW	MN	Interleukin-6 (IL6)
DM826SW	MT	DTT
DM826SW	MA	Inhibitor
DM826SW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM826SW	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPRYU1	DI	DMPRYU1
DMPRYU1	DN	PF-04457845
DMPRYU1	MI	TTDP1UC
DMPRYU1	MN	Fatty acid amide hydrolase (FAAH)
DMPRYU1	MT	DTT
DMPRYU1	MA	Inhibitor
DMPRYU1	RN	Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
DMPRYU1	RU	https://pubmed.ncbi.nlm.nih.gov/21666860

DMZMUIL	DI	DMZMUIL
DMZMUIL	DN	PF-04518600
DMZMUIL	MI	TTL31H0
DMZMUIL	MN	OX40L receptor (CD134)
DMZMUIL	MT	DTT
DMZMUIL	MA	Agonist
DMZMUIL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZMUIL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA9MBR	DI	DMA9MBR
DMA9MBR	DN	PF-04523655
DMA9MBR	MI	TT0AWFK
DMA9MBR	MN	HIF-1 responsive protein RTP801 (DDIT4)
DMA9MBR	MT	DTT
DMA9MBR	RN	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
DMA9MBR	RU	https://pubmed.ncbi.nlm.nih.gov/19568274

DMS610L	DI	DMS610L
DMS610L	DN	PF-04691502
DMS610L	MI	TTHBTOP
DMS610L	MN	PI3-kinase gamma (PIK3CG)
DMS610L	MT	DTT
DMS610L	MA	Modulator
DMS610L	RN	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
DMS610L	RU	https://www.ncbi.nlm.nih.gov/pubmed/21750219

DMS610L	DI	DMS610L
DMS610L	DN	PF-04691502
DMS610L	MI	TTCJG29
DMS610L	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMS610L	MT	DTT
DMS610L	MA	Modulator
DMS610L	RN	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99.
DMS610L	RU	https://www.ncbi.nlm.nih.gov/pubmed/21750219

DMQMF4O	DI	DMQMF4O
DMQMF4O	DN	PF-04937319
DMQMF4O	MI	TTDLNGZ
DMQMF4O	MN	Glucokinase (GCK)
DMQMF4O	MT	DTT
DMQMF4O	MA	Modulator
DMQMF4O	RN	Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
DMQMF4O	RU	https://pubmed.ncbi.nlm.nih.gov/25885172

DMRAFBK	DI	DMRAFBK
DMRAFBK	DN	PF-04958242
DMRAFBK	MI	TTAN6JD
DMRAFBK	MN	Glutamate receptor AMPA (GRIA)
DMRAFBK	MT	DTT
DMRAFBK	MA	Activator
DMRAFBK	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMRAFBK	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM94NBE	DI	DM94NBE
DM94NBE	DN	PF-04991532
DM94NBE	MI	TTDLNGZ
DM94NBE	MN	Glucokinase (GCK)
DM94NBE	MT	DTT
DM94NBE	MA	Activator
DM94NBE	RN	The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
DM94NBE	RU	https://pubmed.ncbi.nlm.nih.gov/24858947

DMD74BJ	DI	DMD74BJ
DMD74BJ	DN	PF-05089771
DMD74BJ	MI	TT4G2JS
DMD74BJ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMD74BJ	MT	DTT
DMD74BJ	MA	Blocker
DMD74BJ	RN	Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
DMD74BJ	RU	https://pubmed.ncbi.nlm.nih.gov/26419464

DMLQ3OK	DI	DMLQ3OK
DMLQ3OK	DN	PF-05175157
DMLQ3OK	MI	TTY84UG
DMLQ3OK	MN	Acetyl-CoA carboxylase 2 (ACACB)
DMLQ3OK	MT	DTT
DMLQ3OK	MA	Inhibitor
DMLQ3OK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264).
DMLQ3OK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264

DMPVQYR	DI	DMPVQYR
DMPVQYR	DN	PF-05212377
DMPVQYR	MI	TTJS8PY
DMPVQYR	MN	5-HT 6 receptor (HTR6)
DMPVQYR	MT	DTT
DMPVQYR	MA	Antagonist
DMPVQYR	RN	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
DMPVQYR	RU	http://www.alzforum.org/therapeutics/pf-05212377

DMBL3VD	DI	DMBL3VD
DMBL3VD	DN	PF-05212384
DMBL3VD	MI	TTHBTOP
DMBL3VD	MN	PI3-kinase gamma (PIK3CG)
DMBL3VD	MT	DTT
DMBL3VD	MA	Modulator
DMBL3VD	RN	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
DMBL3VD	RU	https://pubmed.ncbi.nlm.nih.gov/25652454

DMBL3VD	DI	DMBL3VD
DMBL3VD	DN	PF-05212384
DMBL3VD	MI	TTCJG29
DMBL3VD	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMBL3VD	MT	DTT
DMBL3VD	MA	Modulator
DMBL3VD	RN	First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95.
DMBL3VD	RU	https://pubmed.ncbi.nlm.nih.gov/25652454

DMQLZOF	DI	DMQLZOF
DMQLZOF	DN	PF-06252616
DMQLZOF	MI	TTSWPH8
DMQLZOF	MN	Growth/differentiation factor 8 (GDF-8)
DMQLZOF	MT	DTT
DMQLZOF	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMQLZOF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTE6QWF
DMUAOFM	MN	Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TT4SVB7
DMUAOFM	MN	Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTWGZ64
DMUAOFM	MN	Staphylococcus Clumping factor A (Stap-coc ClfA)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMUAOFM	DI	DMUAOFM
DMUAOFM	DN	PF-06290510
DMUAOFM	MI	TTBWX8P
DMUAOFM	MN	Staphylococcus Manganese transporter C (Stap-coc MntC)
DMUAOFM	MT	DTT
DMUAOFM	RN	ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health.
DMUAOFM	RU	https://clinicaltrials.gov/ct2/show/NCT01364571

DMN94QM	DI	DMN94QM
DMN94QM	DN	PF-06291874
DMN94QM	MI	TT9O6WS
DMN94QM	MN	Glucagon receptor (GCGR)
DMN94QM	MT	DTT
DMN94QM	MA	Antagonist
DMN94QM	RN	Clinical pipeline report, company report or official report of pfizer.
DMN94QM	RU	http://www.pfizer.com/sites/default/files/product-pipeline/110614_Pipeline_Update.pdf

DMKM7EW	DI	DMKM7EW
DMKM7EW	DN	PF-06463922
DMKM7EW	MI	TTPMQSO
DMKM7EW	MN	ALK tyrosine kinase receptor (ALK)
DMKM7EW	MT	DTT
DMKM7EW	MA	Inhibitor
DMKM7EW	RN	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81.
DMKM7EW	RU	https://pubmed.ncbi.nlm.nih.gov/26144315

DM9S3P7	DI	DM9S3P7
DM9S3P7	DN	PF-06473871
DM9S3P7	MI	TTIL516
DM9S3P7	MN	CCN2 messenger RNA (CCN2 mRNA)
DM9S3P7	MT	DTT
DM9S3P7	MA	Inhibitor
DM9S3P7	RN	A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861.
DM9S3P7	RU	https://pubmed.ncbi.nlm.nih.gov/30349773

DMMGSFV	DI	DMMGSFV
DMMGSFV	DN	PF-06700841
DMMGSFV	MI	TT6DM01
DMMGSFV	MN	Janus kinase 1 (JAK-1)
DMMGSFV	MT	DTT
DMMGSFV	MA	Inhibitor
DMMGSFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMGSFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMGSFV	DI	DMMGSFV
DMMGSFV	DN	PF-06700841
DMMGSFV	MI	TTBYWP2
DMMGSFV	MN	TYK2 tyrosine kinase (TYK2)
DMMGSFV	MT	DTT
DMMGSFV	MA	Inhibitor
DMMGSFV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMGSFV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM8C1H4	DI	DM8C1H4
DM8C1H4	DN	PF-06823859
DM8C1H4	MI	TT4TZ8J
DM8C1H4	MN	Interferon-beta (IFNB1)
DM8C1H4	MT	DTT
DM8C1H4	MA	Blocker
DM8C1H4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8C1H4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5H8V1	DI	DM5H8V1
DM5H8V1	DN	PF-06826647
DM5H8V1	MI	TTBYWP2
DM5H8V1	MN	TYK2 tyrosine kinase (TYK2)
DM5H8V1	MT	DTT
DM5H8V1	MA	Inhibitor
DM5H8V1	RN	Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577.
DM5H8V1	RU	https://pubmed.ncbi.nlm.nih.gov/32787094

DM7EJ8S	DI	DM7EJ8S
DM7EJ8S	DN	PF-06882961
DM7EJ8S	MI	TTVIMDE
DM7EJ8S	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM7EJ8S	MT	DTT
DM7EJ8S	MA	Agonist
DM7EJ8S	RN	Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5;80(3):485-500.e7.
DM7EJ8S	RU	https://pubmed.ncbi.nlm.nih.gov/33027691

DM8T6KQ	DI	DM8T6KQ
DM8T6KQ	DN	PF-232798
DM8T6KQ	MI	TT2CEJG
DM8T6KQ	MN	C-C chemokine receptor type 5 (CCR5)
DM8T6KQ	MT	DTT
DM8T6KQ	MA	Antagonist
DM8T6KQ	RN	An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.
DM8T6KQ	RU	https://pubmed.ncbi.nlm.nih.gov/21128663

DMO02LU	DI	DMO02LU
DMO02LU	DN	PF-3463275
DMO02LU	MI	TTHJTF7
DMO02LU	MN	Glycine transporter GlyT-1 (SLC6A9)
DMO02LU	MT	DTT
DMO02LU	MA	Inhibitor
DMO02LU	RN	Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85.
DMO02LU	RU	https://pubmed.ncbi.nlm.nih.gov/24172334

DMC2FAL	DI	DMC2FAL
DMC2FAL	DN	PF-3893787
DMC2FAL	MI	TTXJ178
DMC2FAL	MN	Histamine H4 receptor (H4R)
DMC2FAL	MT	DTT
DMC2FAL	MA	Antagonist
DMC2FAL	RN	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602.
DMC2FAL	RU	https://pubmed.ncbi.nlm.nih.gov/21920751

DM3DWKN	DI	DM3DWKN
DM3DWKN	DN	PF-4191834
DM3DWKN	MI	TT2J34L
DM3DWKN	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3DWKN	MT	DTT
DM3DWKN	MA	Inhibitor
DM3DWKN	RN	Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301.
DM3DWKN	RU	https://pubmed.ncbi.nlm.nih.gov/20378715

DM81D4I	DI	DM81D4I
DM81D4I	DN	PF-4447943
DM81D4I	MI	TTZOEBC
DM81D4I	MN	Phosphodiesterase 9 (PDE9)
DM81D4I	MT	DTT
DM81D4I	MA	Inhibitor
DM81D4I	RN	A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21.
DM81D4I	RU	https://pubmed.ncbi.nlm.nih.gov/24801218

DML38VU	DI	DML38VU
DML38VU	DN	PF-446687
DML38VU	MI	TTD0CIQ
DML38VU	MN	Melanocortin receptor 4 (MC4R)
DML38VU	MT	DTT
DML38VU	MA	Modulator
DML38VU	RN	Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
DML38VU	RU	https://pubmed.ncbi.nlm.nih.gov/25652247

DM3YIKR	DI	DM3YIKR
DM3YIKR	DN	PF-4523655
DM3YIKR	MI	TTVEOY6
DM3YIKR	MN	RTP801 messenger RNA (RTP801 mRNA)
DM3YIKR	MT	DTT
DM3YIKR	RN	DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010
DM3YIKR	RU	http://www.nature.com/scibx/journal/v3/n20/full/scibx.2010.629.html

DM24I0N	DI	DM24I0N
DM24I0N	DN	PF-4878691
DM24I0N	MI	TTRJ1K4
DM24I0N	MN	Toll-like receptor 7 (TLR7)
DM24I0N	MT	DTT
DM24I0N	MA	Agonist
DM24I0N	RN	The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.
DM24I0N	RU	https://pubmed.ncbi.nlm.nih.gov/21451504

DM3C8GQ	DI	DM3C8GQ
DM3C8GQ	DN	PF-489791
DM3C8GQ	MI	TTJ0IQB
DM3C8GQ	MN	Phosphodiesterase 5A (PDE5A)
DM3C8GQ	MT	DTT
DM3C8GQ	MA	Inhibitor
DM3C8GQ	RN	Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
DM3C8GQ	RU	https://www.smr.org.uk/smr/archive/pastmeetings/Downloads/SMR_Dec_09_Report.pdf

DM0KRLJ	DI	DM0KRLJ
DM0KRLJ	DN	PF-885706
DM0KRLJ	MI	TT07C3Y
DM0KRLJ	MN	5-HT 4 receptor (HTR4)
DM0KRLJ	MT	DTT
DM0KRLJ	MA	Agonist
DM0KRLJ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025579)
DM0KRLJ	RU	http://adisinsight.springer.com/drugs/800025579

DMF5YEN	DI	DMF5YEN
DMF5YEN	DN	PG-102
DMF5YEN	MI	TTIJP3Q
DMF5YEN	MN	TNF related activation protein (CD40LG)
DMF5YEN	MT	DTT
DMF5YEN	MA	Modulator
DMF5YEN	RN	Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
DMF5YEN	RU	https://www.ncbi.nlm.nih.gov/pubmed/25795759

DMJTYO4	DI	DMJTYO4
DMJTYO4	DN	PGL-2
DMJTYO4	MI	TTHM0R1
DMJTYO4	MN	Steryl-sulfatase (STS)
DMJTYO4	MT	DTT
DMJTYO4	MA	Inhibitor
DMJTYO4	RN	Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
DMJTYO4	RU	https://pubmed.ncbi.nlm.nih.gov/24604234

DMKA705	DI	DMKA705
DMKA705	DN	PGL-2001
DMKA705	MI	TTHM0R1
DMKA705	MN	Steryl-sulfatase (STS)
DMKA705	MT	DTT
DMKA705	MA	Inhibitor
DMKA705	RN	Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
DMKA705	RU	https://pubmed.ncbi.nlm.nih.gov/24604234

DM9JGTQ	DI	DM9JGTQ
DM9JGTQ	DN	PH10 nasal spray
DM9JGTQ	MI	TT3FOGT
DM9JGTQ	MN	Chemosensory receptor (CheR)
DM9JGTQ	MT	DTT
DM9JGTQ	MA	Modulator
DM9JGTQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9JGTQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM71HVW	DI	DM71HVW
DM71HVW	DN	PH-794428
DM71HVW	MI	TTKMAZ6
DM71HVW	MN	Growth hormone receptor (GHR)
DM71HVW	MT	DTT
DM71HVW	MA	Modulator
DM71HVW	RN	PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51.
DM71HVW	RU	https://www.ncbi.nlm.nih.gov/pubmed/18802875

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TT9RTBL
DMGYBZI	MN	Aurora B messenger RNA (AURKB mRNA)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/15828847

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TTPS3C0
DMGYBZI	MN	Aurora kinase A (AURKA)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TT5LS6T
DMGYBZI	MN	Aurora kinase B (AURKB)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMGYBZI	DI	DMGYBZI
DMGYBZI	DN	PHA-739358
DMGYBZI	MI	TTLYXIT
DMGYBZI	MN	Aurora kinase C (AURKC)
DMGYBZI	MT	DTT
DMGYBZI	MA	Inhibitor
DMGYBZI	RN	Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
DMGYBZI	RU	https://pubmed.ncbi.nlm.nih.gov/15828847

DMS2Q9G	DI	DMS2Q9G
DMS2Q9G	DN	PHA848125
DMS2Q9G	MI	TT7HF4W
DMS2Q9G	MN	Cyclin-dependent kinase 2 (CDK2)
DMS2Q9G	MT	DTT
DMS2Q9G	MA	Inhibitor
DMS2Q9G	RN	Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
DMS2Q9G	RU	https://pubmed.ncbi.nlm.nih.gov/19603809

DMRP3CV	DI	DMRP3CV
DMRP3CV	DN	Phenylalanine hydroxylase
DMRP3CV	MI	TTGSVH2
DMRP3CV	MN	Phenylalanine hydroxylase (PAH)
DMRP3CV	MT	DTT
DMRP3CV	MA	Modulator
DMRP3CV	RN	Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44.
DMRP3CV	RU	https://pubmed.ncbi.nlm.nih.gov/24743000

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TTNJYV2
DMBHPDW	MN	Gamma-aminobutyric acid receptor (GAR)
DMBHPDW	MT	DTT
DMBHPDW	MA	Agonist
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TT6R7JZ
DMBHPDW	MN	Histone deacetylase 1 (HDAC1)
DMBHPDW	MT	DTT
DMBHPDW	MA	Inhibitor
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMBHPDW	DI	DMBHPDW
DMBHPDW	DN	Phenylbutyrate
DMBHPDW	MI	TTRK8B9
DMBHPDW	MN	Sodium channel unspecific (NaC)
DMBHPDW	MT	DTT
DMBHPDW	MA	Blocker
DMBHPDW	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMBHPDW	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTGJFK1
DMJWD62	MN	Calcium-activated potassium channel KCa4.1 (KCNT1)
DMJWD62	MT	DTT
DMJWD62	MA	Activator
DMJWD62	RN	Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/16687497

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTLU5FO
DMJWD62	MN	Calcium-activated potassium channel KCa4.2 (KCNT2)
DMJWD62	MT	DTT
DMJWD62	MA	Inhibitor (gating inhibitor)
DMJWD62	RN	Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/16687497

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTEO25X
DMJWD62	MN	Inward rectifier potassium channel Kir3.4 (KCNJ5)
DMJWD62	MT	DTT
DMJWD62	MA	Inhibitor (gating inhibitor)
DMJWD62	RN	Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1087-92.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/14732702

DMJWD62	DI	DMJWD62
DMJWD62	DN	phorbol 12-myristate 13-acetate
DMJWD62	MI	TTKP2SU
DMJWD62	MN	Transient receptor potential cation channel V4 (TRPV4)
DMJWD62	MT	DTT
DMJWD62	MA	Activator
DMJWD62	RN	Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77.
DMJWD62	RU	https://pubmed.ncbi.nlm.nih.gov/11827975

DM4FIWC	DI	DM4FIWC
DM4FIWC	DN	PI-88/Taxotere
DM4FIWC	MI	TTJGNVC
DM4FIWC	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM4FIWC	MT	DTT
DM4FIWC	MA	Modulator
DM4FIWC	RN	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
DM4FIWC	RU	https://pubmed.ncbi.nlm.nih.gov/19917571

DM4FIWC	DI	DM4FIWC
DM4FIWC	DN	PI-88/Taxotere
DM4FIWC	MI	TT63KYR
DM4FIWC	MN	Tubulin beta-1 chain (TUBB1)
DM4FIWC	MT	DTT
DM4FIWC	MA	Modulator
DM4FIWC	RN	Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
DM4FIWC	RU	https://pubmed.ncbi.nlm.nih.gov/19917571

DM3ZEYL	DI	DM3ZEYL
DM3ZEYL	DN	Piboserod
DM3ZEYL	MI	TT07C3Y
DM3ZEYL	MN	5-HT 4 receptor (HTR4)
DM3ZEYL	MT	DTT
DM3ZEYL	MA	Antagonist
DM3ZEYL	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DM3ZEYL	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTZ97H5
DMYL7VR	MN	Phosphodiesterase 4A (PDE4A)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTVIAT9
DMYL7VR	MN	Phosphodiesterase 4B (PDE4B)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMYL7VR	DI	DMYL7VR
DMYL7VR	DN	Piclamilast
DMYL7VR	MI	TTSKMI8
DMYL7VR	MN	Phosphodiesterase 4D (PDE4D)
DMYL7VR	MT	DTT
DMYL7VR	MA	Inhibitor
DMYL7VR	RN	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77.
DMYL7VR	RU	https://pubmed.ncbi.nlm.nih.gov/15765929

DMMO46E	DI	DMMO46E
DMMO46E	DN	Pidilizumab
DMMO46E	MI	TT8ZLTI
DMMO46E	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMMO46E	MT	DTT
DMMO46E	RN	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18.
DMMO46E	RU	https://pubmed.ncbi.nlm.nih.gov/21577144

DMAFZ84	DI	DMAFZ84
DMAFZ84	DN	PIKAMILONE
DMAFZ84	MI	TTNJYV2
DMAFZ84	MN	Gamma-aminobutyric acid receptor (GAR)
DMAFZ84	MT	DTT
DMAFZ84	MA	Modulator
DMAFZ84	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMAFZ84	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM96VWD	DI	DM96VWD
DM96VWD	DN	PINOCEMBRIN
DM96VWD	MI	TTI84H7
DM96VWD	MN	Cytochrome P450 1B1 (CYP1B1)
DM96VWD	MT	DTT
DM96VWD	MA	Inhibitor
DM96VWD	RN	Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
DM96VWD	RU	https://pubmed.ncbi.nlm.nih.gov/20696580

DM276N1	DI	DM276N1
DM276N1	DN	Piritrexim
DM276N1	MI	DTI7UX6
DM276N1	MN	Breast cancer resistance protein (ABCG2)
DM276N1	MT	DTP
DM276N1	MA	Substrate
DM276N1	RN	Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34.
DM276N1	RU	https://doi.org/10.1007/s00280-006-0230-9

DM276N1	DI	DM276N1
DM276N1	DN	Piritrexim
DM276N1	MI	TTYZVDJ
DM276N1	MN	Dihydrofolate reductase (DHFR)
DM276N1	MT	DTT
DM276N1	MA	Modulator
DM276N1	RN	Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
DM276N1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15571870

DMC3T2S	DI	DMC3T2S
DMC3T2S	DN	PIRODOMAST
DMC3T2S	MI	TTTWGIX
DMC3T2S	MN	Leukotriene receptor (LTR)
DMC3T2S	MT	DTT
DMC3T2S	MA	Modulator
DMC3T2S	RN	Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003.
DMC3T2S	RU	https://pubmed.ncbi.nlm.nih.gov/2462630

DMHI6GE	DI	DMHI6GE
DMHI6GE	DN	Pirsidomine
DMHI6GE	MI	TT6HPVC
DMHI6GE	MN	Guanylate cyclase (GC)
DMHI6GE	MT	DTT
DMHI6GE	MA	Modulator
DMHI6GE	RN	Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12.
DMHI6GE	RU	https://pubmed.ncbi.nlm.nih.gov/9658207

DMKEV7N	DI	DMKEV7N
DMKEV7N	DN	PK1
DMKEV7N	MI	TTCGY2K
DMKEV7N	MN	DNA topoisomerase II alpha (TOP2A)
DMKEV7N	MT	DTT
DMKEV7N	MA	Modulator
DMKEV7N	RN	Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36.
DMKEV7N	RU	https://pubmed.ncbi.nlm.nih.gov/19424581

DMHUCQS	DI	DMHUCQS
DMHUCQS	DN	PL-3994
DMHUCQS	MI	TTJME02
DMHUCQS	MN	Atrial natriuretic peptide receptor A (NPR1)
DMHUCQS	MT	DTT
DMHUCQS	MA	Agonist
DMHUCQS	RN	In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238.
DMHUCQS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070431/

DMYUO6B	DI	DMYUO6B
DMYUO6B	DN	PlaMavax
DMYUO6B	MI	TTDUK07
DMYUO6B	MN	Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP)
DMYUO6B	MT	DTT
DMYUO6B	RN	Lipid kinase enters the malaria stage. SciBX 6(48); doi:10.1038/scibx.2013.1373. Dec. 19 2013
DMYUO6B	RU	http://www.nature.com/scibx/journal/v6/n48/full/scibx.2013.1373.html

DMOB1EM	DI	DMOB1EM
DMOB1EM	DN	Plasmin
DMOB1EM	MI	TTWODQF
DMOB1EM	MN	Fibrin (FG)
DMOB1EM	MT	DTT
DMOB1EM	MA	Modulator
DMOB1EM	RN	ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health.
DMOB1EM	RU	https://clinicaltrials.gov/ct2/show/NCT01014975

DMK10ZC	DI	DMK10ZC
DMK10ZC	DN	PLECONARIL
DMK10ZC	MI	TT87Q2D
DMK10ZC	MN	Picornavirus Capsid protein VP1 (PicVir VP1)
DMK10ZC	MT	DTT
DMK10ZC	MA	Modulator
DMK10ZC	RN	Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9.
DMK10ZC	RU	https://pubmed.ncbi.nlm.nih.gov/16251287

DM7Y60I	DI	DM7Y60I
DM7Y60I	DN	Plevitrexed
DM7Y60I	MI	TTU6BFZ
DM7Y60I	MN	Candida Thymidylate synthase (Candi TMP1)
DM7Y60I	MT	DTT
DM7Y60I	MA	Inhibitor
DM7Y60I	RN	Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
DM7Y60I	RU	https://pubmed.ncbi.nlm.nih.gov/17297914

DMTL39C	DI	DMTL39C
DMTL39C	DN	Plevitrexed (R)-isomer
DMTL39C	MI	TTU6BFZ
DMTL39C	MN	Candida Thymidylate synthase (Candi TMP1)
DMTL39C	MT	DTT
DMTL39C	MA	Inhibitor
DMTL39C	RN	Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
DMTL39C	RU	https://pubmed.ncbi.nlm.nih.gov/17297914

DMTL39C	DI	DMTL39C
DMTL39C	DN	Plevitrexed (R)-isomer
DMTL39C	MI	TT5FOMZ
DMTL39C	MN	Thymidylate synthase (TYMS)
DMTL39C	MT	DTT
DMTL39C	MA	Inhibitor
DMTL39C	RN	Differential effect of 1,10-phenanthroline on mammalian, yeast, and parasite glycosylphosphatidylinositol anchor synthesis. Biochem Biophys Res Commun. 2001 Nov 16;288(5):1112-8.
DMTL39C	RU	https://pubmed.ncbi.nlm.nih.gov/11700026

DMRTD7I	DI	DMRTD7I
DMRTD7I	DN	PLX8394
DMRTD7I	MI	TTWCGQT
DMRTD7I	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMRTD7I	MT	DTT
DMRTD7I	MA	Inhibitor
DMRTD7I	RN	Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62.
DMRTD7I	RU	https://pubmed.ncbi.nlm.nih.gov/24283590

DMMKOPX	DI	DMMKOPX
DMMKOPX	DN	PM-00104
DMMKOPX	MI	TTUTN1I
DMMKOPX	MN	Human Deoxyribonucleic acid (hDNA)
DMMKOPX	MT	DTT
DMMKOPX	MA	Modulator
DMMKOPX	RN	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95.
DMMKOPX	RU	https://pubmed.ncbi.nlm.nih.gov/21330323

DMS34YO	DI	DMS34YO
DMS34YO	DN	PM184
DMS34YO	MI	TTHVQ4N
DMS34YO	MN	Tubulin polymerization (TubP)
DMS34YO	MT	DTT
DMS34YO	MA	Inhibitor
DMS34YO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS34YO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTVDSZ0
DM0OVZ2	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTQ4V96
DM0OVZ2	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTVUSO7
DM0OVZ2	MN	Tankyrase-1 (TNKS-1)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DM0OVZ2	DI	DM0OVZ2
DM0OVZ2	DN	PMID27841036-Compound-37
DM0OVZ2	MI	TTFQI4H
DM0OVZ2	MN	Tankyrase-2 (TNKS-2)
DM0OVZ2	MT	DTT
DM0OVZ2	MA	Inhibitor
DM0OVZ2	RN	PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
DM0OVZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/27841036

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTXV4FI
DMZUAJ4	MN	Albendazole monooxygenase (CYP3A4)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTHXFA1
DMZUAJ4	MN	C5a anaphylatoxin chemotactic receptor (C5AR1)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Modulator
DMZUAJ4	RN	Company report (Arana Therapeutics)
DMZUAJ4	RU	http://www.asx.com.au/asxpdf/20090219/pdf/31g4hr7254nxxr.pdf

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTD0CIQ
DMZUAJ4	MN	Melanocortin receptor 4 (MC4R)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTNT7K8
DMZUAJ4	MN	Nociceptin receptor (OPRL1)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TTYO0A3
DMZUAJ4	MN	Substance-K receptor (TACR2)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMZUAJ4	DI	DMZUAJ4
DMZUAJ4	DN	PMX-53
DMZUAJ4	MI	TT4TFGN
DMZUAJ4	MN	Vasopressin V1a receptor (V1AR)
DMZUAJ4	MT	DTT
DMZUAJ4	MA	Inhibitor
DMZUAJ4	RN	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
DMZUAJ4	RU	https://pubmed.ncbi.nlm.nih.gov/16876401

DMWT73D	DI	DMWT73D
DMWT73D	DN	PMX-60056
DMWT73D	MI	TT4QPUL
DMWT73D	MN	Antithrombin-III (ATIII)
DMWT73D	MT	DTT
DMWT73D	MA	Antagonist
DMWT73D	RN	Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721.
DMWT73D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070/

DMUVON0	DI	DMUVON0
DMUVON0	DN	PNT-2258
DMUVON0	MI	TTFOUV4
DMUVON0	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMUVON0	MT	DTT
DMUVON0	RN	Clinical pipeline report, company report or official report of ProNAi.
DMUVON0	RU	http://pronai.com/pnt2258-targeting-bcl2/

DMM8IAQ	DI	DMM8IAQ
DMM8IAQ	DN	PNU-142731A
DMM8IAQ	MI	TT26HJ8
DMM8IAQ	MN	Eosinophil/lymphocyte-rich accumulation (ELR accum)
DMM8IAQ	MT	DTT
DMM8IAQ	MA	Modulator
DMM8IAQ	RN	Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma. J Pharmacol Exp Ther. 1999 Jul;290(1):188-95.
DMM8IAQ	RU	https://pubmed.ncbi.nlm.nih.gov/10381775

DM4OT29	DI	DM4OT29
DM4OT29	DN	POL-6326
DM4OT29	MI	TTBID49
DM4OT29	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM4OT29	MT	DTT
DM4OT29	MA	Antagonist
DM4OT29	RN	CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64.
DM4OT29	RU	https://pubmed.ncbi.nlm.nih.gov/22376154

DMFCIKN	DI	DMFCIKN
DMFCIKN	DN	Polivy
DMFCIKN	MI	TTBN5I7
DMFCIKN	MN	B-cell-specific glycoprotein B29 (CD79B)
DMFCIKN	MT	DTT
DMFCIKN	MA	Agonist
DMFCIKN	RN	Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475.
DMFCIKN	RU	https://pubmed.ncbi.nlm.nih.gov/31352604

DMUXEBQ	DI	DMUXEBQ
DMUXEBQ	DN	Polyamine
DMUXEBQ	MI	DT01CKS
DMUXEBQ	MN	Lymphocyte activation antigen 4F2 (SLC3A2)
DMUXEBQ	MT	DTP
DMUXEBQ	MA	Substrate
DMUXEBQ	RN	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.
DMUXEBQ	RU	http://www.ncbi.nlm.nih.gov/pubmed/30700572

DMXROM7	DI	DMXROM7
DMXROM7	DN	Polyglutamate camptothecin
DMXROM7	MI	TTGTQHC
DMXROM7	MN	DNA topoisomerase I (TOP1)
DMXROM7	MT	DTT
DMXROM7	MA	Inhibitor
DMXROM7	RN	Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
DMXROM7	RU	https://pubmed.ncbi.nlm.nih.gov/16990856

DM2570B	DI	DM2570B
DM2570B	DN	Poly-ICLC
DM2570B	MI	TTD24Y0
DM2570B	MN	Toll-like receptor 3 (TLR3)
DM2570B	MT	DTT
DM2570B	MA	Inducer
DM2570B	RN	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12;5:10.
DM2570B	RU	https://pubmed.ncbi.nlm.nih.gov/17295916

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TT362RB
DM3QDA6	MN	MART-1 melanoma antigen (MLANA)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TTWSKHD
DM3QDA6	MN	Melanoma-associated antigen 3 (MAGEA3)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DM3QDA6	DI	DM3QDA6
DM3QDA6	DN	Polynoma-1
DM3QDA6	MI	TTULVH8
DM3QDA6	MN	Tyrosinase (TYR)
DM3QDA6	MT	DTT
DM3QDA6	RN	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
DM3QDA6	RU	http://www.polynoma.com/

DMIAZ13	DI	DMIAZ13
DMIAZ13	DN	Ponezumab
DMIAZ13	MI	TTE4KHA
DMIAZ13	MN	Amyloid beta A4 protein (APP)
DMIAZ13	MT	DTT
DMIAZ13	RN	Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36.
DMIAZ13	RU	https://pubmed.ncbi.nlm.nih.gov/22197375

DM5HMTB	DI	DM5HMTB
DM5HMTB	DN	Porphobilinogen
DM5HMTB	MI	TTJHKYD
DM5HMTB	MN	Delta-aminolevulinic acid dehydratase (ALAD)
DM5HMTB	MT	DTT
DM5HMTB	MA	Inhibitor
DM5HMTB	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM5HMTB	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMH0LM2	DI	DMH0LM2
DMH0LM2	DN	POT-4
DMH0LM2	MI	TTJGY7A
DMH0LM2	MN	Complement C3 (CO3)
DMH0LM2	MT	DTT
DMH0LM2	MA	Inhibitor
DMH0LM2	RN	Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
DMH0LM2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700864/

DMTE8DC	DI	DMTE8DC
DMTE8DC	DN	Pozelimab
DMTE8DC	MI	TTKANGO
DMTE8DC	MN	Complement C5 (CO5)
DMTE8DC	MT	DTT
DMTE8DC	MA	Inhibitor
DMTE8DC	RN	Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.
DMTE8DC	RU	https://pubmed.ncbi.nlm.nih.gov/32384086

DM4EHVB	DI	DM4EHVB
DM4EHVB	DN	PPI-668
DM4EHVB	MI	TTCJ2X8
DM4EHVB	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM4EHVB	MT	DTT
DM4EHVB	MA	Modulator
DM4EHVB	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4EHVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMM6J5Z	DI	DMM6J5Z
DMM6J5Z	DN	PQ-912
DMM6J5Z	MI	TTJ7YTV
DMM6J5Z	MN	Glutaminyl cyclase (QPCT)
DMM6J5Z	MT	DTT
DMM6J5Z	MA	Inhibitor
DMM6J5Z	RN	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498.
DMM6J5Z	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763757/

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTTHBCA
DMMCYZ8	MN	PI3-kinase beta (PIK3CB)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTHBTOP
DMMCYZ8	MN	PI3-kinase gamma (PIK3CG)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DMMCYZ8	DI	DMMCYZ8
DMMCYZ8	DN	PQR309
DMMCYZ8	MI	TTCJG29
DMMCYZ8	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMCYZ8	MT	DTT
DMMCYZ8	MA	Inhibitor
DMMCYZ8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMMCYZ8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DM1O0DV	DI	DM1O0DV
DM1O0DV	DN	Pradefovir
DM1O0DV	MI	DE4LYSA
DM1O0DV	MN	Cytochrome P450 3A4 (CYP3A4)
DM1O0DV	MT	DME
DM1O0DV	MA	Metabolism
DM1O0DV	RN	Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother. 2006 Sep;50(9):2926-31.
DM1O0DV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16940083

DM1O0DV	DI	DM1O0DV
DM1O0DV	DN	Pradefovir
DM1O0DV	MI	TTS5K1M
DM1O0DV	MN	Hepatitis B virus Reverse transcriptase (HBV RT)
DM1O0DV	MT	DTT
DM1O0DV	MA	Modulator
DM1O0DV	RN	DOI: 10.1128/AAC.01566-05
DM1O0DV	RU	http://aac.asm.org/content/50/9/2926.full

DMIVMR3	DI	DMIVMR3
DMIVMR3	DN	Prajmaline
DMIVMR3	MI	DECB0K3
DMIVMR3	MN	Cytochrome P450 2D6 (CYP2D6)
DMIVMR3	MT	DME
DMIVMR3	MA	Metabolism
DMIVMR3	RN	Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr. 1985 Nov 15;63(22):1180-6.
DMIVMR3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=4079282

DM73UTG	DI	DM73UTG
DM73UTG	DN	PRALNACASAN
DM73UTG	MI	TTCQIBE
DM73UTG	MN	Caspase-1 (CASP1)
DM73UTG	MT	DTT
DM73UTG	MA	Modulator
DM73UTG	RN	Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46.
DM73UTG	RU	https://pubmed.ncbi.nlm.nih.gov/13129693

DMBH7XI	DI	DMBH7XI
DMBH7XI	DN	Pramiconazole
DMBH7XI	MI	TTTSOUD
DMBH7XI	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMBH7XI	MT	DTT
DMBH7XI	MA	Modulator
DMBH7XI	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBH7XI	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZT8FS	DI	DMZT8FS
DMZT8FS	DN	Preverex
DMZT8FS	MI	TTU5CF1
DMZT8FS	MN	Actin polymerization (Actin poly)
DMZT8FS	MT	DTT
DMZT8FS	MA	Modulator
DMZT8FS	RN	Chronic hypoxia differentially up-regulates protein kinase C-mediated ovine uterine arterial contraction via actin polymerization signaling in pregnancy. Biol Reprod. 2012 Dec 21;87(6):142.
DMZT8FS	RU	https://pubmed.ncbi.nlm.nih.gov/23136295

DMK8PTH	DI	DMK8PTH
DMK8PTH	DN	PRM-151
DMK8PTH	MI	TTNJ5A6
DMK8PTH	MN	Neuronal pentraxin-2 (NPTX2)
DMK8PTH	MT	DTT
DMK8PTH	MA	Modulator
DMK8PTH	RN	PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15.
DMK8PTH	RU	https://pubmed.ncbi.nlm.nih.gov/20603654

DMBZ6CP	DI	DMBZ6CP
DMBZ6CP	DN	PRN1008
DMBZ6CP	MI	TTGM6VW
DMBZ6CP	MN	Tyrosine-protein kinase BTK (ATK)
DMBZ6CP	MT	DTT
DMBZ6CP	MA	Inhibitor
DMBZ6CP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBZ6CP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM5ZTE4	DI	DM5ZTE4
DM5ZTE4	DN	PRO-001
DM5ZTE4	MI	TT2EDHU
DM5ZTE4	MN	Insulin-degrading enzyme (IDE)
DM5ZTE4	MT	DTT
DM5ZTE4	MA	Modulator
DM5ZTE4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2371).
DM5ZTE4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2371

DMFYABR	DI	DMFYABR
DMFYABR	DN	PRO-044
DMFYABR	MI	TTWLFXU
DMFYABR	MN	Dystrophin messenger RNA (DMD mRNA)
DMFYABR	MT	DTT
DMFYABR	RN	Update on neuromuscular disorders in pediatric orthopaedics: Duchenne muscular dystrophy, myelomeningocele, and cerebral palsy. J Pediatr Orthop. 2014 Oct-Nov;34 Suppl 1:S44-8.
DMFYABR	RU	https://pubmed.ncbi.nlm.nih.gov/25207736

DMMEL6B	DI	DMMEL6B
DMMEL6B	DN	PRO22
DMMEL6B	MI	TTSXVID
DMMEL6B	MN	Nuclear factor NF-kappa-B (NFKB)
DMMEL6B	MT	DTT
DMMEL6B	MA	Inhibitor
DMMEL6B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMEL6B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMF9RB4	DI	DMF9RB4
DMF9RB4	DN	Procysteine
DMF9RB4	MI	DEJ1LMB
DMF9RB4	MN	Pyroglutamase (OPLAH)
DMF9RB4	MT	DME
DMF9RB4	MA	Metabolism
DMF9RB4	RN	Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis. 2007 Feb;28(2):378-89.
DMF9RB4	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16950796

DMF9RB4	DI	DMF9RB4
DMF9RB4	DN	Procysteine
DMF9RB4	MI	TTULV0X
DMF9RB4	MN	Reactive oxygen species (ROS)
DMF9RB4	MT	DTT
DMF9RB4	MA	Modulator
DMF9RB4	RN	Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10.
DMF9RB4	RU	https://pubmed.ncbi.nlm.nih.gov/23681269

DM4MF9V	DI	DM4MF9V
DM4MF9V	DN	proglumide
DM4MF9V	MI	TTCG0AL
DM4MF9V	MN	Cholecystokinin receptor type A (CCKAR)
DM4MF9V	MT	DTT
DM4MF9V	MA	Antagonist
DM4MF9V	RN	Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8.
DM4MF9V	RU	https://pubmed.ncbi.nlm.nih.gov/3440035

DMZIQ8G	DI	DMZIQ8G
DMZIQ8G	DN	Prolarix
DMZIQ8G	MI	TTJLP0R
DMZIQ8G	MN	Quinone reductase 2 (NQO2)
DMZIQ8G	MT	DTT
DMZIQ8G	MA	Inhibitor
DMZIQ8G	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMZIQ8G	RU	http://www.centerwatch.com/

DME25TI	DI	DME25TI
DME25TI	DN	Prosaptide TX14(A)
DME25TI	MI	TTDB5IS
DME25TI	MN	Receptor unspecific (Rec)
DME25TI	MT	DTT
DME25TI	MA	Modulator
DME25TI	RN	Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81.
DME25TI	RU	http://www.sciencedirect.com/science/article/pii/S1090380107000584

DMM7F1E	DI	DMM7F1E
DMM7F1E	DN	PRUVANSERIN
DMM7F1E	MI	TTJQOD7
DMM7F1E	MN	5-HT 2A receptor (HTR2A)
DMM7F1E	MT	DTT
DMM7F1E	MA	Modulator
DMM7F1E	RN	5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76.
DMM7F1E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18673166

DMKTP8E	DI	DMKTP8E
DMKTP8E	DN	PRX002
DMKTP8E	MI	TT08OSU
DMKTP8E	MN	Synuclein alpha (SNCA)
DMKTP8E	MT	DTT
DMKTP8E	MA	Inhibitor
DMKTP8E	RN	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214.
DMKTP8E	RU	https://pubmed.ncbi.nlm.nih.gov/29913017

DM1JNDV	DI	DM1JNDV
DM1JNDV	DN	PRX00933
DM1JNDV	MI	TTWJBZ5
DM1JNDV	MN	5-HT 2C receptor (HTR2C)
DM1JNDV	MT	DTT
DM1JNDV	MA	Agonist
DM1JNDV	RN	2011 Pipeline of Proximagen Group plc.
DM1JNDV	RU	http://www.proximagen.com/science/pipeline/

DMR7H2V	DI	DMR7H2V
DMR7H2V	DN	PRX-08066
DMR7H2V	MI	TT0K1SC
DMR7H2V	MN	5-HT 2B receptor (HTR2B)
DMR7H2V	MT	DTT
DMR7H2V	MA	Antagonist
DMR7H2V	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DMR7H2V	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMEVXS1	DI	DMEVXS1
DMEVXS1	DN	PRX-3140
DMEVXS1	MI	TT07C3Y
DMEVXS1	MN	5-HT 4 receptor (HTR4)
DMEVXS1	MT	DTT
DMEVXS1	MA	Modulator
DMEVXS1	RN	Clinical pipeline report, company report or official report of Nanotherapeutics.
DMEVXS1	RU	http://www.nanotherapeutics.com/prx-3140/

DM7YWVT	DI	DM7YWVT
DM7YWVT	DN	PRX-321
DM7YWVT	MI	TTDWHC3
DM7YWVT	MN	Interleukin 4 receptor alpha (IL4R)
DM7YWVT	MT	DTT
DM7YWVT	MA	Agonist
DM7YWVT	RN	Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5.
DM7YWVT	RU	https://pubmed.ncbi.nlm.nih.gov/19478131

DMHZIFJ	DI	DMHZIFJ
DMHZIFJ	DN	PS-938285
DMHZIFJ	MI	TT30C9G
DMHZIFJ	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMHZIFJ	MT	DTT
DMHZIFJ	MA	Antagonist
DMHZIFJ	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMHZIFJ	RU	http://www.centerwatch.com/

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTSN6QU
DMCSN69	MN	HIF1-alpha messenger RNA (HIF1A mRNA)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSN69	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTWPA54
DMCSN69	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCSN69	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMCSN69	DI	DMCSN69
DMCSN69	DN	PT2385
DMCSN69	MI	TTDMLNT
DMCSN69	MN	Hypoxia-inducible factor 2 alpha (HIF-2A)
DMCSN69	MT	DTT
DMCSN69	MA	Inhibitor
DMCSN69	RN	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236. 
DMCSN69	RU	https://pubmed.ncbi.nlm.nih.gov/30089425

DMP9TKE	DI	DMP9TKE
DMP9TKE	DN	PTC299
DMP9TKE	MI	TT2J34L
DMP9TKE	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMP9TKE	MT	DTT
DMP9TKE	MA	Inhibitor
DMP9TKE	RN	Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42.
DMP9TKE	RU	https://pubmed.ncbi.nlm.nih.gov/2124522

DMP9TKE	DI	DMP9TKE
DMP9TKE	DN	PTC299
DMP9TKE	MI	TTOHSBA
DMP9TKE	MN	Vascular endothelial growth factor A (VEGFA)
DMP9TKE	MT	DTT
DMP9TKE	MA	Modulator
DMP9TKE	RN	Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
DMP9TKE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25407389

DMOYS8A	DI	DMOYS8A
DMOYS8A	DN	PTG-300
DMOYS8A	MI	TTPCG5T
DMOYS8A	MN	Hepcidin (HAMP)
DMOYS8A	MT	DTT
DMOYS8A	MA	Replacement
DMOYS8A	RN	Clinical pipeline report, company report or official report of Protagonist Therapeutics.
DMOYS8A	RU	https://www.protagonist-inc.com/pipeline/#overview

DMV17HK	DI	DMV17HK
DMV17HK	DN	PTI-125
DMV17HK	MI	TTSTRZY
DMV17HK	MN	Filamin A (FLNA)
DMV17HK	MT	DTT
DMV17HK	MA	Inhibitor
DMV17HK	RN	Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84.
DMV17HK	RU	https://pubmed.ncbi.nlm.nih.gov/22815492

DM0ZIT2	DI	DM0ZIT2
DM0ZIT2	DN	PTX-200
DM0ZIT2	MI	TTWTSCV
DM0ZIT2	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM0ZIT2	MT	DTT
DM0ZIT2	MA	Inhibitor
DM0ZIT2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0ZIT2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJIMXH	DI	DMJIMXH
DMJIMXH	DN	Puerarin
DMJIMXH	MI	TTWJBZ5
DMJIMXH	MN	5-HT 2C receptor (HTR2C)
DMJIMXH	MT	DTT
DMJIMXH	MA	Modulator
DMJIMXH	RN	NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav. 2003 Jun;75(3):619-25.
DMJIMXH	RU	https://www.ncbi.nlm.nih.gov/pubmed/12895679

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TTAVUMS
DMW7L0Y	MN	HUMAN toll-like receptor 2 (TLR2)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TTLSU52
DMW7L0Y	MN	HUMAN toll-like receptor 6 (TLR6)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMW7L0Y	DI	DMW7L0Y
DMW7L0Y	DN	PUL-042
DMW7L0Y	MI	TT2LBCR
DMW7L0Y	MN	HUMAN toll-like receptor 9 (TLR9)
DMW7L0Y	MT	DTT
DMW7L0Y	MA	Agonist
DMW7L0Y	RN	Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.
DMW7L0Y	RU	https://pulmotect.com/product/

DMBUSNL	DI	DMBUSNL
DMBUSNL	DN	Pumosetrag
DMBUSNL	MI	TTNXLKE
DMBUSNL	MN	5-HT 3 receptor (5HT3R)
DMBUSNL	MT	DTT
DMBUSNL	MA	Modulator
DMBUSNL	RN	Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.Neurogastroenterol Motil.2014 Jan;26(1):13-20.
DMBUSNL	RU	https://www.ncbi.nlm.nih.gov/pubmed/24001105

DMVUGF7	DI	DMVUGF7
DMVUGF7	DN	PUR-0110
DMVUGF7	MI	TT4EWFY
DMVUGF7	MN	TNF/IL-10 release (TNF/IL10 rele)
DMVUGF7	MT	DTT
DMVUGF7	MA	Modulator
DMVUGF7	RN	PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production. Clin Exp Immunol. 2004 Mar;135(3):440-7.
DMVUGF7	RU	https://pubmed.ncbi.nlm.nih.gov/15008976

DM6DK9A	DI	DM6DK9A
DM6DK9A	DN	PVX-410
DM6DK9A	MI	TT7ILZ1
DM6DK9A	MN	SLAM family member 7 SLAMF7 (CS1)
DM6DK9A	MT	DTT
DM6DK9A	MA	Modulator
DM6DK9A	RN	Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
DM6DK9A	RU	https://pubmed.ncbi.nlm.nih.gov/25764988

DMLVHAJ	DI	DMLVHAJ
DMLVHAJ	DN	PX-12
DMLVHAJ	MI	TTZJ5U9
DMLVHAJ	MN	Thioredoxin (TXN)
DMLVHAJ	MT	DTT
DMLVHAJ	MA	Inhibitor
DMLVHAJ	RN	2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51.
DMLVHAJ	RU	https://pubmed.ncbi.nlm.nih.gov/18202017

DMYISJK	DI	DMYISJK
DMYISJK	DN	PX-866
DMYISJK	MI	TTHBTOP
DMYISJK	MN	PI3-kinase gamma (PIK3CG)
DMYISJK	MT	DTT
DMYISJK	MA	Inhibitor
DMYISJK	RN	Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
DMYISJK	RU	https://pubmed.ncbi.nlm.nih.gov/19644473

DMNSRY7	DI	DMNSRY7
DMNSRY7	DN	PXL-770
DMNSRY7	MI	TTLAFZV
DMNSRY7	MN	AMP-activated protein kinase (AMPK)
DMNSRY7	MT	DTT
DMNSRY7	MA	Activator
DMNSRY7	RN	Clinical pipeline report, company report or official report of Poxel SA.
DMNSRY7	RU	https://www.poxelpharma.com/en_us/product-pipeline/pxl770

DMLQK6E	DI	DMLQK6E
DMLQK6E	DN	PYM-50028
DMLQK6E	MI	TTSMLOH
DMLQK6E	MN	Brain-derived neurotrophic factor (BDNF)
DMLQK6E	MT	DTT
DMLQK6E	MA	Agonist
DMLQK6E	RN	PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97.
DMLQK6E	RU	https://pubmed.ncbi.nlm.nih.gov/18364399

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	DEJGDUW
DMSOPAU	MN	Cytochrome P450 1A2 (CYP1A2)
DMSOPAU	MT	DME
DMSOPAU	MA	Metabolism
DMSOPAU	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DMSOPAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	DE4LYSA
DMSOPAU	MN	Cytochrome P450 3A4 (CYP3A4)
DMSOPAU	MT	DME
DMSOPAU	MA	Metabolism
DMSOPAU	RN	The metabolism of pyrazoloacridine (NSC 366140) by cytochromes p450 and flavin monooxygenase in human liver microsomes. Clin Cancer Res. 2004 Feb 15;10(4):1471-80.
DMSOPAU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14977851

DMSOPAU	DI	DMSOPAU
DMSOPAU	DN	Pyrazoloacridine
DMSOPAU	MI	TT0IHXV
DMSOPAU	MN	DNA topoisomerase II (TOP2)
DMSOPAU	MT	DTT
DMSOPAU	MA	Modulator
DMSOPAU	RN	Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91.
DMSOPAU	RU	https://pubmed.ncbi.nlm.nih.gov/9533538

DM1794O	DI	DM1794O
DM1794O	DN	Pyrethroids
DM1794O	MI	DEMI4VE
DM1794O	MN	Carboxylesterase 3 (CES3)
DM1794O	MT	DME
DM1794O	MA	Metabolism
DM1794O	RN	Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
DM1794O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21133409

DM1794O	DI	DM1794O
DM1794O	DN	Pyrethroids
DM1794O	MI	DEVDYN7
DM1794O	MN	Cytochrome P450 2E1 (CYP2E1)
DM1794O	MT	DME
DM1794O	MA	Metabolism
DM1794O	RN	Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
DM1794O	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=21133409

DMU5H3A	DI	DMU5H3A
DMU5H3A	DN	PZ-128
DMU5H3A	MI	TTL935N
DMU5H3A	MN	Proteinase activated receptor 1 (F2R)
DMU5H3A	MT	DTT
DMU5H3A	MA	Antagonist
DMU5H3A	RN	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003.
DMU5H3A	RU	https://pubmed.ncbi.nlm.nih.gov/33028101

DME71WA	DI	DME71WA
DME71WA	DN	Q301
DME71WA	MI	TT2J34L
DME71WA	MN	Arachidonate 5-lipoxygenase (5-LOX)
DME71WA	MT	DTT
DME71WA	MA	Inhibitor
DME71WA	RN	Clinical pipeline report, company report or official report of Qurient.
DME71WA	RU	http://www.qurient.com/bbs/content.php?co_id=q301

DMIZYV1	DI	DMIZYV1
DMIZYV1	DN	QAV-680
DMIZYV1	MI	TTQDMX5
DMIZYV1	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMIZYV1	MT	DTT
DMIZYV1	MA	Antagonist
DMIZYV1	RN	Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
DMIZYV1	RU	https://pubmed.ncbi.nlm.nih.gov/24021582

DMXY0H2	DI	DMXY0H2
DMXY0H2	DN	QAX-028
DMXY0H2	MI	TTOXS3C
DMXY0H2	MN	Muscarinic acetylcholine receptor (CHRM)
DMXY0H2	MT	DTT
DMXY0H2	MA	Antagonist
DMXY0H2	RN	EP patent application no. 2398798, Triazolopyridine derivatives as p38 map kinase inhibitors.
DMXY0H2	RU	http://www.google.com/patents/EP2398798A1?cl=en

DMUWFI7	DI	DMUWFI7
DMUWFI7	DN	QAX-576
DMUWFI7	MI	TT0GVCH
DMUWFI7	MN	Interleukin-13 (IL13)
DMUWFI7	MT	DTT
DMUWFI7	MA	Modulator
DMUWFI7	RN	Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
DMUWFI7	RU	https://pubmed.ncbi.nlm.nih.gov/25226850

DMAFUHK	DI	DMAFUHK
DMAFUHK	DN	QGC-001
DMAFUHK	MI	TTGMFY7
DMAFUHK	MN	Aspartyl aminopeptidase (DNPEP)
DMAFUHK	MT	DTT
DMAFUHK	MA	Inhibitor
DMAFUHK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAFUHK	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMAFUHK	DI	DMAFUHK
DMAFUHK	DN	QGC-001
DMAFUHK	MI	TT9PBIL
DMAFUHK	MN	Glutamyl aminopeptidase (ENPEP)
DMAFUHK	MT	DTT
DMAFUHK	MA	Inhibitor
DMAFUHK	RN	Clinical pipeline report, company report or official report of Quantum Genomics.
DMAFUHK	RU	http://www.quantum-genomics.com/www/en/science/programme-qgc001/

DMKVIWM	DI	DMKVIWM
DMKVIWM	DN	QR-333
DMKVIWM	MI	TTFBNVI
DMKVIWM	MN	Aldose reductase (AKR1B1)
DMKVIWM	MT	DTT
DMKVIWM	MA	Inhibitor
DMKVIWM	RN	A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
DMKVIWM	RU	https://pubmed.ncbi.nlm.nih.gov/16112498

DMIUS5X	DI	DMIUS5X
DMIUS5X	DN	R1507
DMIUS5X	MI	TTHRID2
DMIUS5X	MN	Insulin-like growth factor I receptor (IGF1R)
DMIUS5X	MT	DTT
DMIUS5X	MA	Inhibitor
DMIUS5X	RN	Clinical pipeline report, company report or official report of Roche (2009).
DMIUS5X	RU	http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm

DMP7J0S	DI	DMP7J0S
DMP7J0S	DN	R411
DMP7J0S	MI	TT6S84X
DMP7J0S	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DMP7J0S	MT	DTT
DMP7J0S	MA	Modulator
DMP7J0S	RN	Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20.
DMP7J0S	RU	https://pubmed.ncbi.nlm.nih.gov/20885411

DM79YAS	DI	DM79YAS
DM79YAS	DN	Racotumomab
DM79YAS	MI	TTSFNKW
DM79YAS	MN	Tumor antigen NGcGM3 (NGcGM3)
DM79YAS	MT	DTT
DM79YAS	MA	Modulator
DM79YAS	RN	Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012; 2: 150.
DM79YAS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478665/

DMOI9EL	DI	DMOI9EL
DMOI9EL	DN	Radezolid
DMOI9EL	MI	TT2VX74
DMOI9EL	MN	Bacterial Protein synthesis (Bact PROS)
DMOI9EL	MT	DTT
DMOI9EL	MA	Inhibitor
DMOI9EL	RN	Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo). 2011 Jun;64(6):413-25.
DMOI9EL	RU	https://pubmed.ncbi.nlm.nih.gov/21587262

DMC56T4	DI	DMC56T4
DMC56T4	DN	RAF265
DMC56T4	MI	TTUTJGQ
DMC56T4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMC56T4	MT	DTT
DMC56T4	MA	Modulator
DMC56T4	RN	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5.
DMC56T4	RU	https://pubmed.ncbi.nlm.nih.gov/22773056

DM7G4Y9	DI	DM7G4Y9
DM7G4Y9	DN	Ralinepag
DM7G4Y9	MI	TTOFYT1
DM7G4Y9	MN	Prostacyclin receptor (PTGIR)
DM7G4Y9	MT	DTT
DM7G4Y9	MA	Agonist
DM7G4Y9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7G4Y9	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMBFZSX	DI	DMBFZSX
DMBFZSX	DN	RALURIDINE
DMBFZSX	MI	TT84ETX
DMBFZSX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBFZSX	MT	DTT
DMBFZSX	MA	Inhibitor
DMBFZSX	RN	5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.
DMBFZSX	RU	https://pubmed.ncbi.nlm.nih.gov/7526782

DMP2DNS	DI	DMP2DNS
DMP2DNS	DN	Rambazole
DMP2DNS	MI	TTD7Q0R
DMP2DNS	MN	Cytochrome P450 26 (CYP26A1)
DMP2DNS	MT	DTT
DMP2DNS	MA	Inhibitor
DMP2DNS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DMP2DNS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMP2DNS	DI	DMP2DNS
DMP2DNS	DN	Rambazole
DMP2DNS	MI	TTYO0A3
DMP2DNS	MN	Substance-K receptor (TACR2)
DMP2DNS	MT	DTT
DMP2DNS	MA	Antagonist
DMP2DNS	RN	Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11.
DMP2DNS	RU	https://pubmed.ncbi.nlm.nih.gov/15925360

DMO2TYL	DI	DMO2TYL
DMO2TYL	DN	Ramipril
DMO2TYL	MI	TTGFNPD
DMO2TYL	MN	HUMAN angiotensin-converting enzyme (ACE)
DMO2TYL	MT	DTT
DMO2TYL	MA	Inhibitor
DMO2TYL	RN	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
DMO2TYL	RU	https://pubmed.ncbi.nlm.nih.gov/32291526

DMM15RI	DI	DMM15RI
DMM15RI	DN	Ranpirnase
DMM15RI	MI	TTRBUYN
DMM15RI	MN	Ribonuclease (RNase)
DMM15RI	MT	DTT
DMM15RI	MA	Modulator
DMM15RI	RN	Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27.
DMM15RI	RU	https://pubmed.ncbi.nlm.nih.gov/18476793

DMK2E0N	DI	DMK2E0N
DMK2E0N	DN	RAXOFELAST
DMK2E0N	MI	TTV0YFR
DMK2E0N	MN	Lipid peroxidation (LPO)
DMK2E0N	MT	DTT
DMK2E0N	MA	Modulator
DMK2E0N	RN	Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91.
DMK2E0N	RU	https://pubmed.ncbi.nlm.nih.gov/15988325

DMIG98L	DI	DMIG98L
DMIG98L	DN	RC-3095
DMIG98L	MI	TTC1MVT
DMIG98L	MN	Gastrin-releasing peptide receptor (GRPR)
DMIG98L	MT	DTT
DMIG98L	MA	Inhibitor
DMIG98L	RN	Lipid modification of GRN163, an N3'--&gt;P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8.
DMIG98L	RU	https://pubmed.ncbi.nlm.nih.gov/15940257

DM1TKG4	DI	DM1TKG4
DM1TKG4	DN	RDEA3170
DM1TKG4	MI	TTA592U
DM1TKG4	MN	Urate anion exchanger 1 (URAT1)
DM1TKG4	MT	DTT
DM1TKG4	MA	Modulator
DM1TKG4	RN	The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
DM1TKG4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750299/

DMNWYHD	DI	DMNWYHD
DMNWYHD	DN	RDEA-684
DMNWYHD	MI	TTA592U
DMNWYHD	MN	Urate anion exchanger 1 (URAT1)
DMNWYHD	MT	DTT
DMNWYHD	MA	Inhibitor
DMNWYHD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
DMNWYHD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031

DM4CIKA	DI	DM4CIKA
DM4CIKA	DN	RDP58
DM4CIKA	MI	TTF8CQI
DM4CIKA	MN	Tumor necrosis factor (TNF)
DM4CIKA	MT	DTT
DM4CIKA	MA	Inhibitor
DM4CIKA	RN	RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31.
DM4CIKA	RU	https://pubmed.ncbi.nlm.nih.gov/12540016

DM2CJ4O	DI	DM2CJ4O
DM2CJ4O	DN	Rebmab-100
DM2CJ4O	MI	TTUPAD7
DM2CJ4O	MN	Galactoside 3(4)-L-fucosyltransferase (FUT3)
DM2CJ4O	MT	DTT
DM2CJ4O	RN	A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015 Aug;138(2):272-7.
DM2CJ4O	RU	https://pubmed.ncbi.nlm.nih.gov/26026738

DML8N3Y	DI	DML8N3Y
DML8N3Y	DN	Recifercept
DML8N3Y	MI	TTST7KB
DML8N3Y	MN	Fibroblast growth factor receptor 3 (FGFR3)
DML8N3Y	MT	DTT
DML8N3Y	RN	In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
DML8N3Y	RU	https://pubmed.ncbi.nlm.nih.gov/33370388

DMCSR8I	DI	DMCSR8I
DMCSR8I	DN	Recoflavone
DMCSR8I	MI	TTSXVID
DMCSR8I	MN	Nuclear factor NF-kappa-B (NFKB)
DMCSR8I	MT	DTT
DMCSR8I	MA	Modulator
DMCSR8I	RN	DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
DMCSR8I	RU	https://pubmed.ncbi.nlm.nih.gov/18222973

DMURX4B	DI	DMURX4B
DMURX4B	DN	Recombinant batroxobin
DMURX4B	MI	TTWODQF
DMURX4B	MN	Fibrin (FG)
DMURX4B	MT	DTT
DMURX4B	MA	Modulator
DMURX4B	RN	Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 2004 Jul 30;571(1-3):67-73.
DMURX4B	RU	https://pubmed.ncbi.nlm.nih.gov/15280019

DMV0A28	DI	DMV0A28
DMV0A28	DN	Recombinant RGD-hirudin
DMV0A28	MI	TT6L509
DMV0A28	MN	Coagulation factor IIa (F2)
DMV0A28	MT	DTT
DMV0A28	MA	Modulator
DMV0A28	RN	The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8.
DMV0A28	RU	https://pubmed.ncbi.nlm.nih.gov/17585879

DMSJ3Z5	DI	DMSJ3Z5
DMSJ3Z5	DN	REGN1979
DMSJ3Z5	MI	TTUE541
DMSJ3Z5	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSJ3Z5	MT	DTT
DMSJ3Z5	MA	Inhibitor
DMSJ3Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSJ3Z5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMTBRPO	DI	DMTBRPO
DMTBRPO	DN	REGN910-3
DMTBRPO	MI	TTKLQTJ
DMTBRPO	MN	Angiopoietin-2 (ANGPT2)
DMTBRPO	MT	DTT
DMTBRPO	MA	Inhibitor
DMTBRPO	RN	ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health.
DMTBRPO	RU	https://clinicaltrials.gov/ct2/show/NCT02713204

DM0KBML	DI	DM0KBML
DM0KBML	DN	REGN-COV2
DM0KBML	MI	TTZ3COY
DM0KBML	MN	COVID-19 spike glycoprotein (S)
DM0KBML	MT	DTT
DM0KBML	MA	Inhibitor
DM0KBML	RN	REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251.
DM0KBML	RU	https://pubmed.ncbi.nlm.nih.gov/33332778

DM13OVF	DI	DM13OVF
DM13OVF	DN	REMD 477
DM13OVF	MI	TT9O6WS
DM13OVF	MN	Glucagon receptor (GCGR)
DM13OVF	MT	DTT
DM13OVF	MA	Antagonist
DM13OVF	RN	Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
DM13OVF	RU	https://pubmed.ncbi.nlm.nih.gov/29283470

DMJIB89	DI	DMJIB89
DMJIB89	DN	Remetinostat
DMJIB89	MI	TTBH0VX
DMJIB89	MN	Histone deacetylase (HDAC)
DMJIB89	MT	DTT
DMJIB89	MA	Inhibitor
DMJIB89	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJIB89	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2USXP	DI	DM2USXP
DM2USXP	DN	Remlarsen
DM2USXP	MI	TTO60BY
DM2USXP	MN	microRNA hsa-miR-29b (MIR29b)
DM2USXP	MT	DTT
DM2USXP	MA	Replacement
DM2USXP	RN	A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081.
DM2USXP	RU	https://pubmed.ncbi.nlm.nih.gov/30472058

DMZFV3E	DI	DMZFV3E
DMZFV3E	DN	Remogli ozin-etabonate
DMZFV3E	MI	TTN7Y4P
DMZFV3E	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMZFV3E	MT	DTT
DMZFV3E	MA	Modulator
DMZFV3E	RN	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
DMZFV3E	RU	https://pubmed.ncbi.nlm.nih.gov/23631443

DMW4YK1	DI	DMW4YK1
DMW4YK1	DN	Remogliflozin etabonate
DMW4YK1	MI	TTLWPVF
DMW4YK1	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMW4YK1	MT	DTT
DMW4YK1	MA	Inhibitor
DMW4YK1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW4YK1	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMW4YK1	DI	DMW4YK1
DMW4YK1	DN	Remogliflozin etabonate
DMW4YK1	MI	TTN7Y4P
DMW4YK1	MN	Sodium/glucose cotransporter 2 (SLC5A4)
DMW4YK1	MT	DTT
DMW4YK1	MA	Blocker
DMW4YK1	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW4YK1	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMTGU6K	DI	DMTGU6K
DMTGU6K	DN	REN-1654
DMTGU6K	MI	TTX1JEN
DMTGU6K	MN	JNK signaling pathway (JNK pathway)
DMTGU6K	MT	DTT
DMTGU6K	MA	Modulator
DMTGU6K	RN	US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases.
DMTGU6K	RU	http://www.google.com/patents/US20060270742

DMTGU6K	DI	DMTGU6K
DMTGU6K	DN	REN-1654
DMTGU6K	MI	TT7KPH1
DMTGU6K	MN	MAPK/ERK signaling pathway (MAPK pathway)
DMTGU6K	MT	DTT
DMTGU6K	MA	Modulator
DMTGU6K	RN	US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases.
DMTGU6K	RU	http://www.google.com/patents/US20060270742

DMQ73AY	DI	DMQ73AY
DMQ73AY	DN	Reovirus
DMQ73AY	MI	TTW2R9X
DMQ73AY	MN	GTPase NRas (NRAS)
DMQ73AY	MT	DTT
DMQ73AY	MA	Modulator
DMQ73AY	RN	Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors.
DMQ73AY	RU	http://cancerres.aacrjournals.org/content/72/8_Supplement/2488.short

DMT5QSD	DI	DMT5QSD
DMT5QSD	DN	Resimmune
DMT5QSD	MI	TTZAT79
DMT5QSD	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DMT5QSD	MT	DTT
DMT5QSD	MA	Modulator
DMT5QSD	RN	Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.
DMT5QSD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25795722

DMP62L5	DI	DMP62L5
DMP62L5	DN	Resiniferatoxin
DMP62L5	MI	TTMI6F5
DMP62L5	MN	Transient receptor potential cation channel V1 (TRPV1)
DMP62L5	MT	DTT
DMP62L5	MA	Activator
DMP62L5	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMP62L5	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DML6XSP	DI	DML6XSP
DML6XSP	DN	Resiquimod
DML6XSP	MI	TTRJ1K4
DML6XSP	MN	Toll-like receptor 7 (TLR7)
DML6XSP	MT	DTT
DML6XSP	MA	Modulator
DML6XSP	RN	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
DML6XSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/16081189

DML6XSP	DI	DML6XSP
DML6XSP	DN	Resiquimod
DML6XSP	MI	TT8CWFK
DML6XSP	MN	Toll-like receptor 8 (TLR8)
DML6XSP	MT	DTT
DML6XSP	MA	Modulator
DML6XSP	RN	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
DML6XSP	RU	https://www.ncbi.nlm.nih.gov/pubmed/16081189

DMNE1FR	DI	DMNE1FR
DMNE1FR	DN	Resminostat
DMNE1FR	MI	TT6R7JZ
DMNE1FR	MN	Histone deacetylase 1 (HDAC1)
DMNE1FR	MT	DTT
DMNE1FR	MA	Inhibitor
DMNE1FR	RN	2011 Pipeline of 4SC AG.
DMNE1FR	RU	http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html

DMM4EJI	DI	DMM4EJI
DMM4EJI	DN	Resten-NG
DMM4EJI	MI	TTNQ5ZP
DMM4EJI	MN	Myc messenger RNA (MYC mRNA)
DMM4EJI	MT	DTT
DMM4EJI	RN	Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56.
DMM4EJI	RU	https://pubmed.ncbi.nlm.nih.gov/11590694

DMVXZJ4	DI	DMVXZJ4
DMVXZJ4	DN	RetinoStat
DMVXZJ4	MI	TT63DI9
DMVXZJ4	MN	Endostatin (COL18A1)
DMVXZJ4	MT	DTT
DMVXZJ4	MA	Modulator
DMVXZJ4	RN	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
DMVXZJ4	RU	https://pubmed.ncbi.nlm.nih.gov/22716662

DMVXZJ4	DI	DMVXZJ4
DMVXZJ4	DN	RetinoStat
DMVXZJ4	MI	TTP86E2
DMVXZJ4	MN	Plasminogen (PLG)
DMVXZJ4	MT	DTT
DMVXZJ4	MA	Modulator
DMVXZJ4	RN	Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91.
DMVXZJ4	RU	https://pubmed.ncbi.nlm.nih.gov/22716662

DMJ37UX	DI	DMJ37UX
DMJ37UX	DN	Revacept
DMJ37UX	MI	TTTJUVZ
DMJ37UX	MN	Platelet glycoprotein VI (GP6)
DMJ37UX	MT	DTT
DMJ37UX	MA	Inhibitor
DMJ37UX	RN	Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9.
DMJ37UX	RU	https://pubmed.ncbi.nlm.nih.gov/21502572

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTZ97H5
DM1FS2W	MN	Phosphodiesterase 4A (PDE4A)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTVIAT9
DM1FS2W	MN	Phosphodiesterase 4B (PDE4B)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DM1FS2W	DI	DM1FS2W
DM1FS2W	DN	Revamilast
DM1FS2W	MI	TTSKMI8
DM1FS2W	MN	Phosphodiesterase 4D (PDE4D)
DM1FS2W	MT	DTT
DM1FS2W	MA	Inhibitor
DM1FS2W	RN	WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate .
DM1FS2W	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TT8JRS7
DMFIVSR	MN	Beta-secretase (BACE)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TT9W8GU
DMFIVSR	MN	Gamma-secretase (GS)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TTZ3S8C
DMFIVSR	MN	Presenilin 1 (PSEN1)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMFIVSR	DI	DMFIVSR
DMFIVSR	DN	R-flurbiprofen
DMFIVSR	MI	TTWN3F4
DMFIVSR	MN	Presenilin 2 (PSEN2)
DMFIVSR	MT	DTT
DMFIVSR	MA	Inhibitor
DMFIVSR	RN	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
DMFIVSR	RU	https://pubmed.ncbi.nlm.nih.gov/16455248

DMQ8K93	DI	DMQ8K93
DMQ8K93	DN	RFT-5.dgA
DMQ8K93	MI	TT10Y9E
DMQ8K93	MN	Interleukin 2 receptor alpha (IL2RA)
DMQ8K93	MT	DTT
DMQ8K93	MA	Modulator
DMQ8K93	RN	Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36.
DMQ8K93	RU	https://www.ncbi.nlm.nih.gov/pubmed/12702527

DM2UGT7	DI	DM2UGT7
DM2UGT7	DN	RG-101
DM2UGT7	MI	TTP03CE
DM2UGT7	MN	Hepatitis C virus microRNA miR-122 (HCV MIR122)
DM2UGT7	MT	DTT
DM2UGT7	MA	Modulator
DM2UGT7	RN	Company report (Isis Pharmaceuticals)
DM2UGT7	RU	https://www.isispharm.com/pipeline/rg-101/

DMT1ZX0	DI	DMT1ZX0
DMT1ZX0	DN	RG1577
DMT1ZX0	MI	TTGP7BY
DMT1ZX0	MN	Monoamine oxidase type B (MAO-B)
DMT1ZX0	MT	DTT
DMT1ZX0	MA	Modulator
DMT1ZX0	RN	Sembragiline Alzheimer's Disease (Phase 2). Evotech AG, Roche.
DMT1ZX0	RU	http://www.alzforum.org/therapeutics/sembragiline

DMT4QRD	DI	DMT4QRD
DMT4QRD	DN	RG-4929
DMT4QRD	MI	TTN7BL9
DMT4QRD	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMT4QRD	MT	DTT
DMT4QRD	MA	Inhibitor
DMT4QRD	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMT4QRD	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMEFD0B	DI	DMEFD0B
DMEFD0B	DN	RG6100
DMEFD0B	MI	TTS87KH
DMEFD0B	MN	Microtubule-associated protein tau (MAPT)
DMEFD0B	MT	DTT
DMEFD0B	MA	Inhibitor
DMEFD0B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEFD0B	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX8JYN	DI	DMX8JYN
DMX8JYN	DN	RG-7090
DMX8JYN	MI	TTHS256
DMX8JYN	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMX8JYN	MT	DTT
DMX8JYN	MA	Antagonist
DMX8JYN	RN	The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250.
DMX8JYN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932172/

DM8JMNL	DI	DM8JMNL
DM8JMNL	DN	RG7155
DM8JMNL	MI	TT731LW
DM8JMNL	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM8JMNL	MT	DTT
DM8JMNL	MA	Modulator
DM8JMNL	RN	Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
DM8JMNL	RU	https://pubmed.ncbi.nlm.nih.gov/24898549

DM8JMNL	DI	DM8JMNL
DM8JMNL	DN	RG7155
DM8JMNL	MI	TT0IQER
DM8JMNL	MN	Macrophage colony-stimulating factor 1 (CSF1)
DM8JMNL	MT	DTT
DM8JMNL	MA	Antagonist
DM8JMNL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8JMNL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8J9DC	DI	DM8J9DC
DM8J9DC	DN	RG7221
DM8J9DC	MI	TTKLQTJ
DM8J9DC	MN	Angiopoietin-2 (ANGPT2)
DM8J9DC	MT	DTT
DM8J9DC	MA	Modulator
DM8J9DC	RN	Company report (Roche pipeline: July 27, 2017)
DM8J9DC	RU	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

DM8J9DC	DI	DM8J9DC
DM8J9DC	DN	RG7221
DM8J9DC	MI	TTOHSBA
DM8J9DC	MN	Vascular endothelial growth factor A (VEGFA)
DM8J9DC	MT	DTT
DM8J9DC	MA	Modulator
DM8J9DC	RN	Bispecific antibodies and their applications
DM8J9DC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327

DM5RAB9	DI	DM5RAB9
DM5RAB9	DN	RG-7234
DM5RAB9	MI	TT9H85R
DM5RAB9	MN	Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2)
DM5RAB9	MT	DTT
DM5RAB9	MA	Inhibitor
DM5RAB9	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DM5RAB9	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DMB4M6O	DI	DMB4M6O
DMB4M6O	DN	RG7314
DMB4M6O	MI	TT4TFGN
DMB4M6O	MN	Vasopressin V1a receptor (V1AR)
DMB4M6O	MT	DTT
DMB4M6O	MA	Modulator
DMB4M6O	RN	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
DMB4M6O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/

DMVXGU0	DI	DMVXGU0
DMVXGU0	DN	RG7596
DMVXGU0	MI	TTBN5I7
DMVXGU0	MN	B-cell-specific glycoprotein B29 (CD79B)
DMVXGU0	MT	DTT
DMVXGU0	MA	Modulator
DMVXGU0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
DMVXGU0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852

DMDGPKS	DI	DMDGPKS
DMDGPKS	DN	RG7625
DMDGPKS	MI	TTUMQVO
DMDGPKS	MN	Cathepsin S (CTSS)
DMDGPKS	MT	DTT
DMDGPKS	MA	Antagonist
DMDGPKS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDGPKS	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM6CNFW	DI	DM6CNFW
DM6CNFW	DN	RG7686
DM6CNFW	MI	TTJTSX4
DM6CNFW	MN	Glypican-3 (GPC3)
DM6CNFW	MT	DTT
DM6CNFW	RN	First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
DM6CNFW	RU	https://pubmed.ncbi.nlm.nih.gov/23362325

DMK5PYS	DI	DMK5PYS
DMK5PYS	DN	RG7745
DMK5PYS	MI	TTF4CAM
DMK5PYS	MN	Influenza Hemagglutinin (Influ HA)
DMK5PYS	MT	DTT
DMK5PYS	RN	Clinical pipeline report, company report or official report of Roche.
DMK5PYS	RU	http://www.roche.com/irp2q13e-annex.pdf

DM452RF	DI	DM452RF
DM452RF	DN	RG7880
DM452RF	MI	TTLDX4N
DM452RF	MN	Interleukin-22 (IL22)
DM452RF	MT	DTT
DM452RF	MA	Modulator
DM452RF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM452RF	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM2SWI8	DI	DM2SWI8
DM2SWI8	DN	RG7888
DM2SWI8	MI	TTBW580
DM2SWI8	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DM2SWI8	MT	DTT
DM2SWI8	RN	Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
DM2SWI8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288389/

DME1YMX	DI	DME1YMX
DME1YMX	DN	RG7935
DME1YMX	MI	TT08OSU
DME1YMX	MN	Synuclein alpha (SNCA)
DME1YMX	MT	DTT
DME1YMX	RN	alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399.
DME1YMX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281589/

DMCHZAN	DI	DMCHZAN
DMCHZAN	DN	RGH-896
DMCHZAN	MI	TTN9D8E
DMCHZAN	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMCHZAN	MT	DTT
DMCHZAN	MA	Antagonist
DMCHZAN	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DMCHZAN	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM4AC2F	DI	DM4AC2F
DM4AC2F	DN	RGI-2001
DM4AC2F	MI	TT7AKW1
DM4AC2F	MN	T-cell receptor (TCR)
DM4AC2F	MT	DTT
DM4AC2F	MA	Modulator
DM4AC2F	RN	Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68.
DM4AC2F	RU	https://pubmed.ncbi.nlm.nih.gov/21145405

DMSF10P	DI	DMSF10P
DMSF10P	DN	RGN-259
DMSF10P	MI	TTH5WZF
DMSF10P	MN	Actin (ACT)
DMSF10P	MT	DTT
DMSF10P	MA	Modulator
DMSF10P	RN	Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6.
DMSF10P	RU	https://pubmed.ncbi.nlm.nih.gov/25826322

DMBSXR9	DI	DMBSXR9
DMBSXR9	DN	rhACE2
DMBSXR9	MI	TTYRG7F
DMBSXR9	MN	HUMAN angiotensin-converting enzyme 2 (ACE2)
DMBSXR9	MT	DTT
DMBSXR9	MA	Inhibitor
DMBSXR9	RN	ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
DMBSXR9	RU	https://clinicaltrials.gov/ct2/show/NCT04346797

DMN1EFR	DI	DMN1EFR
DMN1EFR	DN	RhGDF-5
DMN1EFR	MI	TT37XV9
DMN1EFR	MN	Growth/differentiation factor 5 (GDF-5)
DMN1EFR	MT	DTT
DMN1EFR	MA	Modulator
DMN1EFR	RN	Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90.
DMN1EFR	RU	https://pubmed.ncbi.nlm.nih.gov/16945037

DMO9QB8	DI	DMO9QB8
DMO9QB8	DN	R-IFN-1a
DMO9QB8	MI	TTSYFMA
DMO9QB8	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMO9QB8	MT	DTT
DMO9QB8	MA	Modulator
DMO9QB8	RN	Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6.
DMO9QB8	RU	https://pubmed.ncbi.nlm.nih.gov/10526196

DM3L51O	DI	DM3L51O
DM3L51O	DN	Rilopirox
DM3L51O	MI	TT2J34L
DM3L51O	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM3L51O	MT	DTT
DM3L51O	MA	Inhibitor
DM3L51O	RN	Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34 Suppl 1:91-3.
DM3L51O	RU	https://pubmed.ncbi.nlm.nih.gov/1840158

DMSC7TN	DI	DMSC7TN
DMSC7TN	DN	Rimacalib
DMSC7TN	MI	TTFYL58
DMSC7TN	MN	CaM-kinase II (CAMK2)
DMSC7TN	MT	DTT
DMSC7TN	MA	Modulator
DMSC7TN	RN	Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci. 2009 Sep;1173:706-11.
DMSC7TN	RU	https://pubmed.ncbi.nlm.nih.gov/19758219

DM2VO97	DI	DM2VO97
DM2VO97	DN	RK-023
DM2VO97	MI	TT30NW6
DM2VO97	MN	Chloride channel protein 2 (CLC-2)
DM2VO97	MT	DTT
DM2VO97	MA	Modulator
DM2VO97	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2VO97	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVU1R9	DI	DMVU1R9
DMVU1R9	DN	RM-1929
DMVU1R9	MI	TTGKNB4
DMVU1R9	MN	Epidermal growth factor receptor (EGFR)
DMVU1R9	MT	DTT
DMVU1R9	MA	Antagonist
DMVU1R9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVU1R9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM20CIM	DI	DM20CIM
DM20CIM	DN	RNF43-721
DM20CIM	MI	TTD91BL
DM20CIM	MN	RING finger protein 43 (RNF43)
DM20CIM	MT	DTT
DM20CIM	MA	Modulator
DM20CIM	RN	Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011 Jan-Feb; 2(1): 73-79.
DM20CIM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440656/

DMDNRU1	DI	DMDNRU1
DMDNRU1	DN	RNS-60
DMDNRU1	MI	TTO7FVG
DMDNRU1	MN	Heat shock protein 90 (HSP90)
DMDNRU1	MT	DTT
DMDNRU1	MA	Modulator
DMDNRU1	RN	Clinical pipeline report, company report or official report of Revalesio.
DMDNRU1	RU	http://revalesio.com/about-our-technology/

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TTH6V3D
DM83QCL	MN	Cyclin-dependent kinase 1 (CDK1)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TT7HF4W
DM83QCL	MN	Cyclin-dependent kinase 2 (CDK2)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM83QCL	DI	DM83QCL
DM83QCL	DN	Ro 31-7453
DM83QCL	MI	TT0PG8F
DM83QCL	MN	Cyclin-dependent kinase 4 (CDK4)
DM83QCL	MT	DTT
DM83QCL	MA	Inhibitor
DM83QCL	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM83QCL	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMA2UYE	DI	DMA2UYE
DMA2UYE	DN	Ro-24-7429
DMA2UYE	MI	TTT3ZC9
DMA2UYE	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMA2UYE	MT	DTT
DMA2UYE	MA	Modulator
DMA2UYE	RN	A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52.
DMA2UYE	RU	https://pubmed.ncbi.nlm.nih.gov/7594660

DMV319J	DI	DMV319J
DMV319J	DN	RO-4905417
DMV319J	MI	TTS5K8U
DMV319J	MN	P-selectin glycoprotein ligand 1 (SELPLG)
DMV319J	MT	DTT
DMV319J	RN	WO patent application no. 2013,0144,05, Methods.
DMV319J	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130131&CC=WO&NR=2013014405A2&KC=A2

DMXA6B3	DI	DMXA6B3
DMXA6B3	DN	RO-4929097
DMXA6B3	MI	TT9W8GU
DMXA6B3	MN	Gamma-secretase (GS)
DMXA6B3	MT	DTT
DMXA6B3	MA	Modulator
DMXA6B3	RN	Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
DMXA6B3	RU	https://pubmed.ncbi.nlm.nih.gov/22529266

DMNTC7O	DI	DMNTC7O
DMNTC7O	DN	RO-4995819
DMNTC7O	MI	TTXJ47W
DMNTC7O	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMNTC7O	MT	DTT
DMNTC7O	MA	Modulator
DMNTC7O	RN	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
DMNTC7O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/

DMNTC7O	DI	DMNTC7O
DMNTC7O	DN	RO-4995819
DMNTC7O	MI	TT8A9EF
DMNTC7O	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMNTC7O	MT	DTT
DMNTC7O	MA	Modulator
DMNTC7O	RN	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
DMNTC7O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/

DMZJREM	DI	DMZJREM
DMZJREM	DN	RO-4998452
DMZJREM	MI	TTLWPVF
DMZJREM	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMZJREM	MT	DTT
DMZJREM	MA	Modulator
DMZJREM	RN	A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Diabetes Obes Metab.2015 Oct;17(10):984-93.
DMZJREM	RU	https://www.ncbi.nlm.nih.gov/pubmed/26179482

DM3U9BY	DI	DM3U9BY
DM3U9BY	DN	RO-5126766
DM3U9BY	MI	TTROQ37
DM3U9BY	MN	MAPK/ERK kinase kinase (MAP3K)
DM3U9BY	MT	DTT
DM3U9BY	MA	Modulator
DM3U9BY	RN	The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
DM3U9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25422890

DM3U9BY	DI	DM3U9BY
DM3U9BY	DN	RO-5126766
DM3U9BY	MI	TTQ9K3Y
DM3U9BY	MN	Serine/threonine-protein kinase Raf (RAF)
DM3U9BY	MT	DTT
DM3U9BY	MA	Modulator
DM3U9BY	RN	The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217.
DM3U9BY	RU	https://www.ncbi.nlm.nih.gov/pubmed/25422890

DMUB3OY	DI	DMUB3OY
DMUB3OY	DN	RO-5323441
DMUB3OY	MI	TT48I1Y
DMUB3OY	MN	Placenta growth factor (PlGF)
DMUB3OY	MT	DTT
DMUB3OY	MA	Inhibitor
DMUB3OY	RN	RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
DMUB3OY	RU	http://cancerres.aacrjournals.org/content/70/8_Supplement/1370.abstract

DMD3WNP	DI	DMD3WNP
DMD3WNP	DN	RO5520985
DMD3WNP	MI	TTKLQTJ
DMD3WNP	MN	Angiopoietin-2 (ANGPT2)
DMD3WNP	MT	DTT
DMD3WNP	MA	Modulator
DMD3WNP	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMD3WNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMD3WNP	DI	DMD3WNP
DMD3WNP	DN	RO5520985
DMD3WNP	MI	TTOHSBA
DMD3WNP	MN	Vascular endothelial growth factor A (VEGFA)
DMD3WNP	MT	DTT
DMD3WNP	MA	Modulator
DMD3WNP	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMD3WNP	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM8A120	DI	DM8A120
DM8A120	DN	RO7121661
DM8A120	MI	TT1RWL7
DM8A120	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM8A120	MT	DTT
DM8A120	MA	Inhibitor
DM8A120	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM8A120	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM8A120	DI	DM8A120
DM8A120	DN	RO7121661
DM8A120	MI	TTNBFWK
DM8A120	MN	Programmed cell death protein 1 (PD-1)
DM8A120	MT	DTT
DM8A120	MA	Inhibitor
DM8A120	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM8A120	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMSTH01	DI	DMSTH01
DMSTH01	DN	Rocilinostat
DMSTH01	MI	TTBH0VX
DMSTH01	MN	Histone deacetylase (HDAC)
DMSTH01	MT	DTT
DMSTH01	MA	Inhibitor
DMSTH01	RN	National Cancer Institute Drug Dictionary (drug id 698408).
DMSTH01	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=698408

DMYEZ5J	DI	DMYEZ5J
DMYEZ5J	DN	Romilkimab
DMYEZ5J	MI	TT0GVCH
DMYEZ5J	MN	Interleukin-13 (IL13)
DMYEZ5J	MT	DTT
DMYEZ5J	MA	Inhibitor
DMYEZ5J	RN	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
DMYEZ5J	RU	https://pubmed.ncbi.nlm.nih.gov/32963047

DMYEZ5J	DI	DMYEZ5J
DMYEZ5J	DN	Romilkimab
DMYEZ5J	MI	TTLGTKB
DMYEZ5J	MN	Interleukin-4 (IL4)
DMYEZ5J	MT	DTT
DMYEZ5J	MA	Inhibitor
DMYEZ5J	RN	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
DMYEZ5J	RU	https://pubmed.ncbi.nlm.nih.gov/32963047

DMBJN19	DI	DMBJN19
DMBJN19	DN	Rontalizumab
DMBJN19	MI	TT95SOA
DMBJN19	MN	Interferon alpha (IFNA)
DMBJN19	MT	DTT
DMBJN19	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMBJN19	RU	http://www.gene.com/gene/index.jsp

DMKQXDB	DI	DMKQXDB
DMKQXDB	DN	Rostafuroxin
DMKQXDB	MI	TTQ38E9
DMKQXDB	MN	Sodium/potassium-transporting ATPase (SPT ATPase)
DMKQXDB	MT	DTT
DMKQXDB	MA	Modulator
DMKQXDB	RN	Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35.
DMKQXDB	RU	https://pubmed.ncbi.nlm.nih.gov/16467500

DMXB9RS	DI	DMXB9RS
DMXB9RS	DN	ROTIGAPTIDE
DMXB9RS	MI	TTJO6E9
DMXB9RS	MN	Gap junction protein (GJP)
DMXB9RS	MT	DTT
DMXB9RS	MA	Modulator
DMXB9RS	RN	The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95.
DMXB9RS	RU	https://pubmed.ncbi.nlm.nih.gov/16415913

DMIZMYQ	DI	DMIZMYQ
DMIZMYQ	DN	Roxatidine
DMIZMYQ	MI	DEJVYAZ
DMIZMYQ	MN	Cytochrome P450 2A6 (CYP2A6)
DMIZMYQ	MT	DME
DMIZMYQ	MA	Metabolism
DMIZMYQ	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DMIZMYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DMIZMYQ	DI	DMIZMYQ
DMIZMYQ	DN	Roxatidine
DMIZMYQ	MI	DECB0K3
DMIZMYQ	MN	Cytochrome P450 2D6 (CYP2D6)
DMIZMYQ	MT	DME
DMIZMYQ	MA	Metabolism
DMIZMYQ	RN	Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H2)-receptor antagonist roxatidine acetate by human liver microsomes. Arzneimittelforschung. 2001;51(8):651-8.
DMIZMYQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11556126

DM15QL9	DI	DM15QL9
DM15QL9	DN	ROXINDOLE
DM15QL9	MI	TTEX248
DM15QL9	MN	Dopamine D2 receptor (D2R)
DM15QL9	MT	DTT
DM15QL9	MA	Inhibitor
DM15QL9	RN	Indolebutylamines as selective 5-HT(1A) agonists. J Med Chem. 2004 Sep 9;47(19):4677-83.
DM15QL9	RU	https://pubmed.ncbi.nlm.nih.gov/15341483

DMK0NGB	DI	DMK0NGB
DMK0NGB	DN	Rozanolixizumab
DMK0NGB	MI	TTPY4SE
DMK0NGB	MN	Immunoglobulin Fc receptor (FCR)
DMK0NGB	MT	DTT
DMK0NGB	MA	Antagonist
DMK0NGB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK0NGB	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4N6PF	DI	DM4N6PF
DM4N6PF	DN	RP-49356
DM4N6PF	MI	TT1VOHK
DM4N6PF	MN	Potassium channel unspecific (KC)
DM4N6PF	MT	DTT
DM4N6PF	MA	Opener
DM4N6PF	RN	Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92.
DM4N6PF	RU	https://pubmed.ncbi.nlm.nih.gov/2158844

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTSQIFT
DMKUE8O	MN	5-HT 1A receptor (HTR1A)
DMKUE8O	MT	DTT
DMKUE8O	MA	Antagonist
DMKUE8O	RN	Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271
DMKUE8O	RU	http://link.springer.com/article/10.1007%2Fs40290-014-0070-6

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTJQOD7
DMKUE8O	MN	5-HT 2A receptor (HTR2A)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTO9X1H
DMKUE8O	MN	5-HT 7 receptor (HTR7)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTEX248
DMKUE8O	MN	Dopamine D2 receptor (D2R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Antagonist
DMKUE8O	RN	Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271
DMKUE8O	RU	http://link.springer.com/article/10.1007%2Fs40290-014-0070-6

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TT4C8EA
DMKUE8O	MN	Dopamine D3 receptor (D3R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTE0A2F
DMKUE8O	MN	Dopamine D4 receptor (D4R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TTTIBOJ
DMKUE8O	MN	Histamine H1 receptor (H1R)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMKUE8O	DI	DMKUE8O
DMKUE8O	DN	RP5063
DMKUE8O	MI	TT8G3Z7
DMKUE8O	MN	Serotoninnorepinephrinedopamine reuptake (SNDR)
DMKUE8O	MT	DTT
DMKUE8O	MA	Partial agonist
DMKUE8O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKUE8O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMYILGK	DI	DMYILGK
DMYILGK	DN	RP6530
DMYILGK	MI	TTGBPJE
DMYILGK	MN	PI3-kinase delta (PIK3CD)
DMYILGK	MT	DTT
DMYILGK	MA	Inhibitor
DMYILGK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYILGK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4L5VJ	DI	DM4L5VJ
DM4L5VJ	DN	R-phenserine
DM4L5VJ	MI	TT1RS9F
DM4L5VJ	MN	Acetylcholinesterase (AChE)
DM4L5VJ	MT	DTT
DM4L5VJ	MA	Inhibitor
DM4L5VJ	RN	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90.
DM4L5VJ	RU	https://pubmed.ncbi.nlm.nih.gov/15974893

DMSJU5B	DI	DMSJU5B
DMSJU5B	DN	RP-L102
DMSJU5B	MI	TTV5HJS
DMSJU5B	MN	Fanconi anemia group A protein (FANCA)
DMSJU5B	MT	DTT
DMSJU5B	MA	Replacement
DMSJU5B	RN	Clinical pipeline report, company report or official report of Rocket Pharmaceuticals.
DMSJU5B	RU	https://rocketpharma.com/our-disease-focus/

DMLD4VQ	DI	DMLD4VQ
DMLD4VQ	DN	RPL-554
DMLD4VQ	MI	TTZCG4L
DMLD4VQ	MN	Phosphodiesterase 3 (PDE3)
DMLD4VQ	MT	DTT
DMLD4VQ	MA	Modulator
DMLD4VQ	RN	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
DMLD4VQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/24429275

DM0BFJ5	DI	DM0BFJ5
DM0BFJ5	DN	RPSGL-Ig
DM0BFJ5	MI	TTE5VG0
DM0BFJ5	MN	P-selectin (SELP)
DM0BFJ5	MT	DTT
DM0BFJ5	MA	Inhibitor
DM0BFJ5	RN	rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
DM0BFJ5	RU	https://pubmed.ncbi.nlm.nih.gov/25817339

DMBHN4K	DI	DMBHN4K
DMBHN4K	DN	RQ-00000005
DMBHN4K	MI	TTWDC17
DMBHN4K	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMBHN4K	MT	DTT
DMBHN4K	MA	Agonist
DMBHN4K	RN	Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86.
DMBHN4K	RU	https://pubmed.ncbi.nlm.nih.gov/24670149

DMMYTRU	DI	DMMYTRU
DMMYTRU	DN	RQ-00000007 (oral)
DMMYTRU	MI	TT79WV3
DMMYTRU	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMMYTRU	MT	DTT
DMMYTRU	MA	Antagonist
DMMYTRU	RN	Clinical pipeline report, company report or official report of Avarx.
DMMYTRU	RU	http://www.avarx.com/AvaRx/SubDomains/bucket5733245651167129819/Listings/bucket2137138075456035728/Public.Listing.display.html

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTMBO1Z
DMSH108	MN	Cyclin-dependent kinase (CDK)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19470731

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTH6V3D
DMSH108	MN	Cyclin-dependent kinase 1 (CDK1)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TT7HF4W
DMSH108	MN	Cyclin-dependent kinase 2 (CDK2)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	TTQYF7G
DMSH108	MN	Cyclin-dependent kinase 7 (CDK7)
DMSH108	MT	DTT
DMSH108	MA	Inhibitor
DMSH108	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMSH108	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DEPKLMQ
DMSH108	MN	Cytochrome P450 2B6 (CYP2B6)
DMSH108	MT	DME
DMSH108	MA	Metabolism
DMSH108	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DMSH108	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DE4LYSA
DMSH108	MN	Cytochrome P450 3A4 (CYP3A4)
DMSH108	MT	DME
DMSH108	MA	Metabolism
DMSH108	RN	Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 Mar;36(3):561-70.
DMSH108	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18048486

DMSH108	DI	DMSH108
DMSH108	DN	R-roscovitine
DMSH108	MI	DTUGYRD
DMSH108	MN	P-glycoprotein 1 (ABCB1)
DMSH108	MT	DTP
DMSH108	MA	Substrate
DMSH108	RN	ATP-binding cassette B1 transports seliciclib (R-roscovitine), a cyclin-dependent kinase inhibitor. Drug Metab Dispos. 2010 Nov;38(11):2000-6.
DMSH108	RU	https://doi.org/10.1124/dmd.110.032805

DMGLCVU	DI	DMGLCVU
DMGLCVU	DN	R-salbutamol sulphate
DMGLCVU	MI	TT2CJVK
DMGLCVU	MN	Adrenergic receptor beta-2 (ADRB2)
DMGLCVU	MT	DTT
DMGLCVU	MA	Agonist
DMGLCVU	RN	Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52.
DMGLCVU	RU	https://pubmed.ncbi.nlm.nih.gov/9404370

DMAJH75	DI	DMAJH75
DMAJH75	DN	RSV-604
DMAJH75	MI	TT25A0I
DMAJH75	MN	Respiratory syncytial virus protein N (RSV N)
DMAJH75	MT	DTT
DMAJH75	MA	Inhibitor
DMAJH75	RN	Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7.
DMAJH75	RU	https://pubmed.ncbi.nlm.nih.gov/25451060

DM3FS1G	DI	DM3FS1G
DM3FS1G	DN	RT-001
DM3FS1G	MI	TTB52WU
DM3FS1G	MN	Bacterial Botulinum toxin A (Bact botA)
DM3FS1G	MT	DTT
DM3FS1G	MA	Modulator
DM3FS1G	RN	Clinical pipeline report, company report or official report of Revance Therapeutics.
DM3FS1G	RU	http://www.revance.com/mechanism-of-action-rt001/

DM8DVC9	DI	DM8DVC9
DM8DVC9	DN	RT-400
DM8DVC9	MI	TTIY658
DM8DVC9	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM8DVC9	MT	DTT
DM8DVC9	MA	Agonist
DM8DVC9	RN	Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020 Jun;19(6):389-413.
DM8DVC9	RU	https://pubmed.ncbi.nlm.nih.gov/32494050

DM45NHF	DI	DM45NHF
DM45NHF	DN	RTR-003632
DM45NHF	MI	DESDN74
DM45NHF	MN	Serum paraoxonase/arylesterase 1 (PON1)
DM45NHF	MT	DME
DM45NHF	MA	Metabolism
DM45NHF	RN	Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos. 2000 Nov;28(11):1335-42.
DM45NHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11038162

DMVCXZK	DI	DMVCXZK
DMVCXZK	DN	Rupintrivir
DMVCXZK	MI	TTGW0DV
DMVCXZK	MN	Rhinovirus Protease 3C (HRV P3C)
DMVCXZK	MT	DTT
DMVCXZK	MA	Modulator
DMVCXZK	RN	Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011 Oct;85(19):10319-31.
DMVCXZK	RU	https://pubmed.ncbi.nlm.nih.gov/21795339

DMSW5XJ	DI	DMSW5XJ
DMSW5XJ	DN	RV521
DMSW5XJ	MI	TT57ID8
DMSW5XJ	MN	Respiratory syncytial virus protein F (RSV F)
DMSW5XJ	MT	DTT
DMSW5XJ	MA	Inhibitor
DMSW5XJ	RN	Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676.
DMSW5XJ	RU	https://pubmed.ncbi.nlm.nih.gov/33729773

DM652CM	DI	DM652CM
DM652CM	DN	RV-568
DM652CM	MI	TTU8W4S
DM652CM	MN	Protein kinase (PK)
DM652CM	MT	DTT
DM652CM	MA	Inhibitor
DM652CM	RN	Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
DM652CM	RU	https://pubmed.ncbi.nlm.nih.gov/25599809

DM3C9F8	DI	DM3C9F8
DM3C9F8	DN	RVT-505
DM3C9F8	MI	TT037IE
DM3C9F8	MN	Aryl hydrocarbon receptor (AHR)
DM3C9F8	MT	DTT
DM3C9F8	MA	Modulator
DM3C9F8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3C9F8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMTBAV3	DI	DMTBAV3
DMTBAV3	DN	RX-0201
DMTBAV3	MI	TTWTSCV
DMTBAV3	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMTBAV3	MT	DTT
DMTBAV3	MA	Inhibitor
DMTBAV3	RN	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
DMTBAV3	RU	http://www.centerwatch.com/

DME8ARP	DI	DME8ARP
DME8ARP	DN	RX-3117
DME8ARP	MI	TT6S2FE
DME8ARP	MN	DNA [cytosine-5]-methyltransferase 1 (DNMT1)
DME8ARP	MT	DTT
DME8ARP	MA	Inhibitor
DME8ARP	RN	Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
DME8ARP	RU	https://pubmed.ncbi.nlm.nih.gov/24048768

DMBOZPH	DI	DMBOZPH
DMBOZPH	DN	RX-5902
DMBOZPH	MI	TTOTSW1
DMBOZPH	MN	ATP-dependent RNA helicase DDX5 (DDX5)
DMBOZPH	MT	DTT
DMBOZPH	MA	Modulator
DMBOZPH	RN	Company report (Rexahn)
DMBOZPH	RU	http://investors.rexahn.com/releasedetail.cfm?releaseid=895381

DMBOZPH	DI	DMBOZPH
DMBOZPH	DN	RX-5902
DMBOZPH	MI	TTZKPVC
DMBOZPH	MN	Phosphorylated p68 RNA helicase (pDDX5)
DMBOZPH	MT	DTT
DMBOZPH	MA	Inhibitor
DMBOZPH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBOZPH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXG9ES	DI	DMXG9ES
DMXG9ES	DN	RXI-109
DMXG9ES	MI	TTIL516
DMXG9ES	MN	CCN2 messenger RNA (CCN2 mRNA)
DMXG9ES	MT	DTT
DMXG9ES	MA	Inhibitor
DMXG9ES	RN	The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446.
DMXG9ES	RU	https://pubmed.ncbi.nlm.nih.gov/30846871

DM4KWEF	DI	DM4KWEF
DM4KWEF	DN	S-0509
DM4KWEF	MI	TTVFO0U
DM4KWEF	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM4KWEF	MT	DTT
DM4KWEF	MA	Antagonist
DM4KWEF	RN	Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88.
DM4KWEF	RU	https://pubmed.ncbi.nlm.nih.gov/10759628

DM9KTSG	DI	DM9KTSG
DM9KTSG	DN	S-1360
DM9KTSG	MI	TT5FH9Y
DM9KTSG	MN	Human immunodeficiency virus Integrase (HIV IN)
DM9KTSG	MT	DTT
DM9KTSG	MA	Inhibitor
DM9KTSG	RN	HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68.
DM9KTSG	RU	https://pubmed.ncbi.nlm.nih.gov/17472411

DMKTLSD	DI	DMKTLSD
DMKTLSD	DN	S-15535
DMKTLSD	MI	TTSQIFT
DMKTLSD	MN	5-HT 1A receptor (HTR1A)
DMKTLSD	MT	DTT
DMKTLSD	MA	Antagonist
DMKTLSD	RN	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14.
DMKTLSD	RU	https://pubmed.ncbi.nlm.nih.gov/10578133

DML2D30	DI	DML2D30
DML2D30	DN	S-16924
DML2D30	MI	TTSQIFT
DML2D30	MN	5-HT 1A receptor (HTR1A)
DML2D30	MT	DTT
DML2D30	MA	Modulator
DML2D30	RN	S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55.
DML2D30	RU	https://pubmed.ncbi.nlm.nih.gov/9732398

DMTAX8B	DI	DMTAX8B
DMTAX8B	DN	S-2150
DMTAX8B	MI	TT5HONZ
DMTAX8B	MN	Calcium channel unspecific (CaC)
DMTAX8B	MT	DTT
DMTAX8B	MA	Modulator
DMTAX8B	RN	Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
DMTAX8B	RU	https://pubmed.ncbi.nlm.nih.gov/10757414

DM26IH8	DI	DM26IH8
DM26IH8	DN	S-297995
DM26IH8	MI	TTN4QDT
DM26IH8	MN	Opioid receptor (OPR)
DM26IH8	MT	DTT
DM26IH8	MA	Antagonist
DM26IH8	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DM26IH8	RU	http://www.shionogi.co.jp/index_e.html

DMU7ZMH	DI	DMU7ZMH
DMU7ZMH	DN	S-364735
DMU7ZMH	MI	TT5FH9Y
DMU7ZMH	MN	Human immunodeficiency virus Integrase (HIV IN)
DMU7ZMH	MT	DTT
DMU7ZMH	MA	Inhibitor
DMU7ZMH	RN	The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8.
DMU7ZMH	RU	https://pubmed.ncbi.nlm.nih.gov/18160521

DMD8XOY	DI	DMD8XOY
DMD8XOY	DN	S-38093
DMD8XOY	MI	TT9JNIC
DMD8XOY	MN	Histamine H3 receptor (H3R)
DMD8XOY	MT	DTT
DMD8XOY	MA	Antagonist
DMD8XOY	RN	Histamine H3 Receptors and Sleep-Wake Regulation. JPET January 2011 vol. 336 no. 1 17-23.
DMD8XOY	RU	http://jpet.aspetjournals.org/content/336/1/17.full

DMXDVNZ	DI	DMXDVNZ
DMXDVNZ	DN	S-555739
DMXDVNZ	MI	TTNVEIR
DMXDVNZ	MN	Prostaglandin D2 receptor (PTGDR)
DMXDVNZ	MT	DTT
DMXDVNZ	MA	Antagonist
DMXDVNZ	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMXDVNZ	RU	http://www.shionogi.co.jp/index_e.html

DM3GRKY	DI	DM3GRKY
DM3GRKY	DN	S-707106
DM3GRKY	MI	TTCBFJO
DM3GRKY	MN	Insulin receptor (INSR)
DM3GRKY	MT	DTT
DM3GRKY	MA	Modulator
DM3GRKY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM3GRKY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMZGNOJ	DI	DMZGNOJ
DMZGNOJ	DN	S-777469
DMZGNOJ	MI	TTMSFAW
DMZGNOJ	MN	Cannabinoid receptor 2 (CB2)
DMZGNOJ	MT	DTT
DMZGNOJ	MA	Agonist
DMZGNOJ	RN	Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
DMZGNOJ	RU	https://pubmed.ncbi.nlm.nih.gov/19216704

DMRZA6G	DI	DMRZA6G
DMRZA6G	DN	S-8921
DMRZA6G	MI	TTPI1M5
DMRZA6G	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMRZA6G	MT	DTT
DMRZA6G	MA	Inhibitor
DMRZA6G	RN	Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11.
DMRZA6G	RU	https://pubmed.ncbi.nlm.nih.gov/9714138

DMBZO8N	DI	DMBZO8N
DMBZO8N	DN	Sabarubicin
DMBZO8N	MI	TT0IHXV
DMBZO8N	MN	DNA topoisomerase II (TOP2)
DMBZO8N	MT	DTT
DMBZO8N	MA	Modulator
DMBZO8N	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBZO8N	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKDP57	DI	DMKDP57
DMKDP57	DN	Safotibant
DMKDP57	MI	TTG5QIA
DMKDP57	MN	B1 bradykinin receptor (BDKRB1)
DMKDP57	MT	DTT
DMKDP57	MA	Modulator
DMKDP57	RN	The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38.
DMKDP57	RU	http://www.sciencedirect.com/science/article/pii/S030438351300829X

DMRFK0B	DI	DMRFK0B
DMRFK0B	DN	SAGE-217b
DMRFK0B	MI	TTGXH6N
DMRFK0B	MN	GABA(A) receptor delta (GABRD)
DMRFK0B	MT	DTT
DMRFK0B	MA	Immunostimulant
DMRFK0B	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMRFK0B	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM5NC39	DI	DM5NC39
DM5NC39	DN	SAGE-324
DM5NC39	MI	TTCI43M
DM5NC39	MN	GABA(A) receptor (GABAR)
DM5NC39	MT	DTT
DM5NC39	MA	Modulator
DM5NC39	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM5NC39	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM9RC7D	DI	DM9RC7D
DM9RC7D	DN	SAGE-718
DM9RC7D	MI	TT9IK2Z
DM9RC7D	MN	N-methyl-D-aspartate receptor (NMDAR)
DM9RC7D	MT	DTT
DM9RC7D	MA	Modulator
DM9RC7D	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM9RC7D	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMRSU4X	DI	DMRSU4X
DMRSU4X	DN	Salirasib
DMRSU4X	MI	TTW2R9X
DMRSU4X	MN	GTPase NRas (NRAS)
DMRSU4X	MT	DTT
DMRSU4X	MA	Antagonist
DMRSU4X	RN	The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89.
DMRSU4X	RU	https://pubmed.ncbi.nlm.nih.gov/18374183

DMRSU4X	DI	DMRSU4X
DMRSU4X	DN	Salirasib
DMRSU4X	MI	TTCJG29
DMRSU4X	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMRSU4X	MT	DTT
DMRSU4X	MA	Modulator
DMRSU4X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMRSU4X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMQVC3E	DI	DMQVC3E
DMQVC3E	DN	Salvianolic acid B
DMQVC3E	MI	TTZHNQA
DMQVC3E	MN	Insulin-like growth factor-binding protein 3 (IGFBP3)
DMQVC3E	MT	DTT
DMQVC3E	MA	Inhibitor
DMQVC3E	RN	Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020 Feb;139:98-112.
DMQVC3E	RU	https://pubmed.ncbi.nlm.nih.gov/31982427

DM0298B	DI	DM0298B
DM0298B	DN	Salvicine
DM0298B	MI	TT0IHXV
DM0298B	MN	DNA topoisomerase II (TOP2)
DM0298B	MT	DTT
DM0298B	MA	Modulator
DM0298B	RN	Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5.
DM0298B	RU	https://pubmed.ncbi.nlm.nih.gov/17723179

DMHVJZ6	DI	DMHVJZ6
DMHVJZ6	DN	SAM-531
DMHVJZ6	MI	TTJS8PY
DMHVJZ6	MN	5-HT 6 receptor (HTR6)
DMHVJZ6	MT	DTT
DMHVJZ6	MA	Antagonist
DMHVJZ6	RN	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
DMHVJZ6	RU	https://pubmed.ncbi.nlm.nih.gov/23336058

DMXTOVE	DI	DMXTOVE
DMXTOVE	DN	Sampatrilat
DMXTOVE	MI	TT5TKPM
DMXTOVE	MN	Neutral endopeptidase (MME)
DMXTOVE	MT	DTT
DMXTOVE	MA	Modulator
DMXTOVE	RN	Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
DMXTOVE	RU	https://pubmed.ncbi.nlm.nih.gov/10371365

DMP5Z9N	DI	DMP5Z9N
DMP5Z9N	DN	SAN-300
DMP5Z9N	MI	TTPERWV
DMP5Z9N	MN	Integrin alpha-1 (VLA-1)
DMP5Z9N	MT	DTT
DMP5Z9N	MA	Antagonist
DMP5Z9N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMP5Z9N	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMDMQW0	DI	DMDMQW0
DMDMQW0	DN	SAR-100842
DMDMQW0	MI	TTE2YJR
DMDMQW0	MN	Lysophosphatidate-3 receptor (LPAR3)
DMDMQW0	MT	DTT
DMDMQW0	MA	Modulator
DMDMQW0	RN	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
DMDMQW0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/

DMDMQW0	DI	DMDMQW0
DMDMQW0	DN	SAR-100842
DMDMQW0	MI	TTQ6S1K
DMDMQW0	MN	Lysophosphatidic acid receptor 1 (LPAR1)
DMDMQW0	MT	DTT
DMDMQW0	MA	Modulator
DMDMQW0	RN	Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
DMDMQW0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/

DMCLEXM	DI	DMCLEXM
DMCLEXM	DN	SAR-110894
DMCLEXM	MI	TT9JNIC
DMCLEXM	MN	Histamine H3 receptor (H3R)
DMCLEXM	MT	DTT
DMCLEXM	MA	Antagonist
DMCLEXM	RN	SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
DMCLEXM	RU	https://pubmed.ncbi.nlm.nih.gov/22542742

DMMCA9V	DI	DMMCA9V
DMMCA9V	DN	SAR-113945
DMMCA9V	MI	TTJ3E9X
DMMCA9V	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMMCA9V	MT	DTT
DMMCA9V	MA	Inhibitor
DMMCA9V	RN	The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653.
DMMCA9V	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248209/

DMJ34G6	DI	DMJ34G6
DMJ34G6	DN	SAR-125844
DMJ34G6	MI	TTNDSF4
DMJ34G6	MN	Proto-oncogene c-Met (MET)
DMJ34G6	MT	DTT
DMJ34G6	MA	Inhibitor
DMJ34G6	RN	The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.
DMJ34G6	RU	https://pubmed.ncbi.nlm.nih.gov/25504634

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TTDWHC3
DMUICJD	MN	Interleukin 4 receptor alpha (IL4R)
DMUICJD	MT	DTT
DMUICJD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697).
DMUICJD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TT0GVCH
DMUICJD	MN	Interleukin-13 (IL13)
DMUICJD	MT	DTT
DMUICJD	MA	Modulator
DMUICJD	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMUICJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMUICJD	DI	DMUICJD
DMUICJD	DN	SAR-156597
DMUICJD	MI	TTLGTKB
DMUICJD	MN	Interleukin-4 (IL4)
DMUICJD	MT	DTT
DMUICJD	MA	Modulator
DMUICJD	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMUICJD	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMQM7IL	DI	DMQM7IL
DMQM7IL	DN	SAR245409
DMQM7IL	MI	TTHBTOP
DMQM7IL	MN	PI3-kinase gamma (PIK3CG)
DMQM7IL	MT	DTT
DMQM7IL	MA	Inhibitor
DMQM7IL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
DMQM7IL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156

DMQM7IL	DI	DMQM7IL
DMQM7IL	DN	SAR245409
DMQM7IL	MI	TTCJG29
DMQM7IL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMQM7IL	MT	DTT
DMQM7IL	MA	Inhibitor
DMQM7IL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
DMQM7IL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109

DMBJU2G	DI	DMBJU2G
DMBJU2G	DN	SAR-260093
DMBJU2G	MI	TT7QNVC
DMBJU2G	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMBJU2G	MT	DTT
DMBJU2G	MA	Agonist
DMBJU2G	RN	GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
DMBJU2G	RU	https://pubmed.ncbi.nlm.nih.gov/19780700

DMEGNHZ	DI	DMEGNHZ
DMEGNHZ	DN	SAR279356
DMEGNHZ	MI	TTAFD3Y
DMEGNHZ	MN	Poly-N-acetyl glucosamine (PNAG)
DMEGNHZ	MT	DTT
DMEGNHZ	MA	Modulator
DMEGNHZ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMEGNHZ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM63QY0	DI	DM63QY0
DM63QY0	DN	SAR292833
DM63QY0	MI	TT946IA
DM63QY0	MN	Transient receptor potential cation channel V3 (TRPV3)
DM63QY0	MT	DTT
DM63QY0	MA	Modulator
DM63QY0	RN	Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44.
DM63QY0	RU	https://pubmed.ncbi.nlm.nih.gov/23848361

DMJ9RN8	DI	DMJ9RN8
DMJ9RN8	DN	SAR-339658
DMJ9RN8	MI	TTMSB0A
DMJ9RN8	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DMJ9RN8	MT	DTT
DMJ9RN8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578).
DMJ9RN8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578

DMOSCBF	DI	DMOSCBF
DMOSCBF	DN	SAR-3419
DMOSCBF	MI	TTW640A
DMOSCBF	MN	B-lymphocyte surface antigen B4 (CD19)
DMOSCBF	MT	DTT
DMOSCBF	RN	A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20.
DMOSCBF	RU	https://pubmed.ncbi.nlm.nih.gov/24132920

DMS1YPZ	DI	DMS1YPZ
DMS1YPZ	DN	SAR391786
DMS1YPZ	MI	TTSWPH8
DMS1YPZ	MN	Growth/differentiation factor 8 (GDF-8)
DMS1YPZ	MT	DTT
DMS1YPZ	RN	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.
DMS1YPZ	RU	https://pubmed.ncbi.nlm.nih.gov/20190380

DMF95KD	DI	DMF95KD
DMF95KD	DN	SAR-407899
DMF95KD	MI	TTZN7RP
DMF95KD	MN	Rho-associated protein kinase 1 (ROCK1)
DMF95KD	MT	DTT
DMF95KD	MA	Inhibitor
DMF95KD	RN	The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9.
DMF95KD	RU	https://pubmed.ncbi.nlm.nih.gov/22388233

DM6Q295	DI	DM6Q295
DM6Q295	DN	SAR566658
DM6Q295	MI	TTCFSPE
DM6Q295	MN	Carbonic anhydrase VI (CA-VI)
DM6Q295	MT	DTT
DM6Q295	MA	Inhibitor
DM6Q295	RN	An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
DM6Q295	RU	https://pubmed.ncbi.nlm.nih.gov/32451330

DMT4FI5	DI	DMT4FI5
DMT4FI5	DN	SAR-566658
DMT4FI5	MI	TTBHFYQ
DMT4FI5	MN	Mucin-1 (MUC1)
DMT4FI5	MT	DTT
DMT4FI5	RN	Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
DMT4FI5	RU	http://mct.aacrjournals.org/content/12/11_Supplement/A73.short

DMG9MN2	DI	DMG9MN2
DMG9MN2	DN	SAR97276
DMG9MN2	MI	TTQ2GJ0
DMG9MN2	MN	Plasmodial phospholipid metabolism (PPP metab)
DMG9MN2	MT	DTT
DMG9MN2	MA	Antagonist
DMG9MN2	RN	Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276.
DMG9MN2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437492/

DMBLHGP	DI	DMBLHGP
DMBLHGP	DN	Saracatinib
DMBLHGP	MI	TT6PKBN
DMBLHGP	MN	Proto-oncogene c-Src (SRC)
DMBLHGP	MT	DTT
DMBLHGP	MA	Modulator
DMBLHGP	RN	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
DMBLHGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/20557276

DMBLHGP	DI	DMBLHGP
DMBLHGP	DN	Saracatinib
DMBLHGP	MI	TT3PJMV
DMBLHGP	MN	Tyrosine-protein kinase ABL1 (ABL)
DMBLHGP	MT	DTT
DMBLHGP	MA	Modulator
DMBLHGP	RN	Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
DMBLHGP	RU	https://www.ncbi.nlm.nih.gov/pubmed/20557276

DMUE0AK	DI	DMUE0AK
DMUE0AK	DN	Saratin
DMUE0AK	MI	TTE5Q4N
DMUE0AK	MN	VWF-dependent platelet-collagen conversion (VDDPCC)
DMUE0AK	MT	DTT
DMUE0AK	MA	Inhibitor
DMUE0AK	RN	Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200.
DMUE0AK	RU	https://pubmed.ncbi.nlm.nih.gov/15213861

DM5R89X	DI	DM5R89X
DM5R89X	DN	SARIPIDEM
DM5R89X	MI	TTEX6LM
DM5R89X	MN	GABA(A) receptor gamma-3 (GABRG3)
DM5R89X	MT	DTT
DM5R89X	MA	Modulator
DM5R89X	RN	Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol. 1995 Mar;6(2):116-126.
DM5R89X	RU	https://pubmed.ncbi.nlm.nih.gov/11224318

DM1M0PR	DI	DM1M0PR
DM1M0PR	DN	Saruplase
DM1M0PR	MI	TTGY7WI
DM1M0PR	MN	Urokinase-type plasminogen activator (PLAU)
DM1M0PR	MT	DTT
DM1M0PR	MA	Activator
DM1M0PR	RN	Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
DM1M0PR	RU	https://pubmed.ncbi.nlm.nih.gov/7534946

DM27KFY	DI	DM27KFY
DM27KFY	DN	SB-207266A
DM27KFY	MI	TT07C3Y
DM27KFY	MN	5-HT 4 receptor (HTR4)
DM27KFY	MT	DTT
DM27KFY	MA	Antagonist
DM27KFY	RN	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
DM27KFY	RU	https://pubmed.ncbi.nlm.nih.gov/11293643

DM8TKG5	DI	DM8TKG5
DM8TKG5	DN	SB-265610
DM8TKG5	MI	TT30C9G
DM8TKG5	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM8TKG5	MT	DTT
DM8TKG5	MA	Antagonist
DM8TKG5	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DM8TKG5	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DM4NY58	DI	DM4NY58
DM4NY58	DN	SB-623
DM4NY58	MI	TT6R7JZ
DM4NY58	MN	Histone deacetylase 1 (HDAC1)
DM4NY58	MT	DTT
DM4NY58	MA	Inhibitor
DM4NY58	RN	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
DM4NY58	RU	https://pubmed.ncbi.nlm.nih.gov/17896917

DMYLBOU	DI	DMYLBOU
DMYLBOU	DN	SB-649868
DMYLBOU	MI	TT60Q8D
DMYLBOU	MN	Orexin receptor type 1 (HCRTR1)
DMYLBOU	MT	DTT
DMYLBOU	MA	Antagonist
DMYLBOU	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMYLBOU	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMCY785	DI	DMCY785
DMCY785	DN	SB-656933
DMCY785	MI	TT30C9G
DMCY785	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMCY785	MT	DTT
DMCY785	MA	Antagonist
DMCY785	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMCY785	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMRYHWI	DI	DMRYHWI
DMRYHWI	DN	SB-705498
DMRYHWI	MI	TTMI6F5
DMRYHWI	MN	Transient receptor potential cation channel V1 (TRPV1)
DMRYHWI	MT	DTT
DMRYHWI	MA	Blocker
DMRYHWI	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMRYHWI	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DMRWE5D	DI	DMRWE5D
DMRWE5D	DN	SB-728-T
DMRWE5D	MI	TT2CEJG
DMRWE5D	MN	C-C chemokine receptor type 5 (CCR5)
DMRWE5D	MT	DTT
DMRWE5D	MA	Modulator
DMRWE5D	RN	Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
DMRWE5D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084652/

DM6XJ9S	DI	DM6XJ9S
DM6XJ9S	DN	SB-743921
DM6XJ9S	MI	TTTRP0H
DM6XJ9S	MN	Kinesin-like protein KIF11 (KIF11)
DM6XJ9S	MT	DTT
DM6XJ9S	MA	Inhibitor
DM6XJ9S	RN	Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57.
DM6XJ9S	RU	https://pubmed.ncbi.nlm.nih.gov/19357798

DMJRK6D	DI	DMJRK6D
DMJRK6D	DN	SB-9200
DMJRK6D	MI	TTYPUHA
DMJRK6D	MN	Pattern recognition receptor NOD2 (NOD2)
DMJRK6D	MT	DTT
DMJRK6D	MA	Modulator
DMJRK6D	RN	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
DMJRK6D	RU	http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/

DMJRK6D	DI	DMJRK6D
DMJRK6D	DN	SB-9200
DMJRK6D	MI	TTVB0O3
DMJRK6D	MN	Retinoic acid-inducible gene-1 (RIG-1)
DMJRK6D	MT	DTT
DMJRK6D	MA	Modulator
DMJRK6D	RN	Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200)
DMJRK6D	RU	http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/

DMG1VXR	DI	DMG1VXR
DMG1VXR	DN	SBC-014
DMG1VXR	MI	TTC70AJ
DMG1VXR	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMG1VXR	MT	DTT
DMG1VXR	MA	Modulator
DMG1VXR	RN	A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
DMG1VXR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639539/

DMSUQFJ	DI	DMSUQFJ
DMSUQFJ	DN	SBI-087
DMSUQFJ	MI	TTUE541
DMSUQFJ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSUQFJ	MT	DTT
DMSUQFJ	MA	Inhibitor
DMSUQFJ	RN	Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208.
DMSUQFJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730845/

DMGH4Q0	DI	DMGH4Q0
DMGH4Q0	DN	SC-47085
DMGH4Q0	MI	DEEHWOG
DMGH4Q0	MN	Azoreductase (azoR)
DMGH4Q0	MT	DME
DMGH4Q0	MA	Metabolism
DMGH4Q0	RN	Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647-64.
DMGH4Q0	RU	https://pubmed.ncbi.nlm.nih.gov/1711964

DM180VX	DI	DM180VX
DM180VX	DN	SC-49483
DM180VX	MI	TTXWASR
DM180VX	MN	Intestinal maltase-glucoamylase (MGAM)
DM180VX	MT	DTT
DM180VX	MA	Inhibitor
DM180VX	RN	Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
DM180VX	RU	https://pubmed.ncbi.nlm.nih.gov/8923673

DM58HR7	DI	DM58HR7
DM58HR7	DN	SC-75416
DM58HR7	MI	TTVKILB
DM58HR7	MN	Prostaglandin G/H synthase 2 (COX-2)
DM58HR7	MT	DTT
DM58HR7	MA	Inhibitor
DM58HR7	RN	Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66.
DM58HR7	RU	https://pubmed.ncbi.nlm.nih.gov/17882158

DMMWCZS	DI	DMMWCZS
DMMWCZS	DN	SCH 420814
DMMWCZS	MI	TTM2AOE
DMMWCZS	MN	Adenosine A2a receptor (ADORA2A)
DMMWCZS	MT	DTT
DMMWCZS	MA	Antagonist
DMMWCZS	RN	Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
DMMWCZS	RU	https://pubmed.ncbi.nlm.nih.gov/17016425

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TTMWT8Z
DMPUAOE	MN	C-X-C chemokine receptor type 1 (CXCR1)
DMPUAOE	MT	DTT
DMPUAOE	MA	Antagonist
DMPUAOE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPUAOE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TT30C9G
DMPUAOE	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMPUAOE	MT	DTT
DMPUAOE	MA	Modulator
DMPUAOE	RN	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
DMPUAOE	RU	https://www.ncbi.nlm.nih.gov/pubmed/25695403

DMPUAOE	DI	DMPUAOE
DMPUAOE	DN	SCH-527123
DMPUAOE	MI	TTBD6I7
DMPUAOE	MN	Mucosal addressin cell adhesion molecule 1 (MADCAM1)
DMPUAOE	MT	DTT
DMPUAOE	RN	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
DMPUAOE	RU	https://pubmed.ncbi.nlm.nih.gov/17355213

DMBJY1Z	DI	DMBJY1Z
DMBJY1Z	DN	SCH-900271
DMBJY1Z	MI	TTWNV8U
DMBJY1Z	MN	Nicotinic acid receptor (HCAR2)
DMBJY1Z	MT	DTT
DMBJY1Z	MA	Modulator
DMBJY1Z	RN	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
DMBJY1Z	RU	https://pubmed.ncbi.nlm.nih.gov/24900372

DM67EMK	DI	DM67EMK
DM67EMK	DN	SCH-900776
DM67EMK	MI	TTTU902
DM67EMK	MN	Checkpoint kinase-1 (CHK1)
DM67EMK	MT	DTT
DM67EMK	MA	Inhibitor
DM67EMK	RN	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
DM67EMK	RU	https://pubmed.ncbi.nlm.nih.gov/21321066

DMPBKUZ	DI	DMPBKUZ
DMPBKUZ	DN	SCH-900978
DMPBKUZ	MI	TTZPO1L
DMPBKUZ	MN	Substance-P receptor (TACR1)
DMPBKUZ	MT	DTT
DMPBKUZ	MA	Antagonist
DMPBKUZ	RN	Clinical pipeline report, company report or official report of OPKO Health, Inc.
DMPBKUZ	RU	http://investor.opko.com/secfiling.cfm?filingID=950123-10-54487&CIK=944809

DM1C9NQ	DI	DM1C9NQ
DM1C9NQ	DN	SCY-635
DM1C9NQ	MI	TTATDGJ
DM1C9NQ	MN	Calcium signal-modulating cyclophilin ligand (CAML)
DM1C9NQ	MT	DTT
DM1C9NQ	MA	Modulator
DM1C9NQ	RN	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72.
DM1C9NQ	RU	https://pubmed.ncbi.nlm.nih.gov/19933795

DM80HOV	DI	DM80HOV
DM80HOV	DN	SDF-1
DM80HOV	MI	TT4UGTF
DM80HOV	MN	Stromal cell-derived factor 1 (CXCL12)
DM80HOV	MT	DTT
DM80HOV	MA	Inhibitor
DM80HOV	RN	SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7. 
DM80HOV	RU	https://pubmed.ncbi.nlm.nih.gov/22673496

DMPZ67G	DI	DMPZ67G
DMPZ67G	DN	SDZ-281-240
DMPZ67G	MI	TTMW94E
DMPZ67G	MN	FK506-binding protein 1A (FKBP1A)
DMPZ67G	MT	DTT
DMPZ67G	MA	Modulator
DMPZ67G	RN	Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10.
DMPZ67G	RU	https://pubmed.ncbi.nlm.nih.gov/8618008

DM2YIOE	DI	DM2YIOE
DM2YIOE	DN	SDZ-MAR-327
DM2YIOE	MI	TTSQIFT
DM2YIOE	MN	5-HT 1A receptor (HTR1A)
DM2YIOE	MT	DTT
DM2YIOE	MA	Modulator
DM2YIOE	RN	DOI: 10.1038/sj.mp.4002062
DM2YIOE	RU	http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html

DM2YIOE	DI	DM2YIOE
DM2YIOE	DN	SDZ-MAR-327
DM2YIOE	MI	TTEX248
DM2YIOE	MN	Dopamine D2 receptor (D2R)
DM2YIOE	MT	DTT
DM2YIOE	MA	Modulator
DM2YIOE	RN	DOI: 10.1038/sj.mp.4002062
DM2YIOE	RU	http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html

DMTQ2K0	DI	DMTQ2K0
DMTQ2K0	DN	SelG1
DMTQ2K0	MI	TTE5VG0
DMTQ2K0	MN	P-selectin (SELP)
DMTQ2K0	MT	DTT
DMTQ2K0	RN	Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
DMTQ2K0	RU	http://www.selexys.com/product_pipeline.asp

DMST4OR	DI	DMST4OR
DMST4OR	DN	Selgantolimod
DMST4OR	MI	TT8CWFK
DMST4OR	MN	Toll-like receptor 8 (TLR8)
DMST4OR	MT	DTT
DMST4OR	MA	Agonist
DMST4OR	RN	Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
DMST4OR	RU	https://pubmed.ncbi.nlm.nih.gov/32407112

DMDLOBZ	DI	DMDLOBZ
DMDLOBZ	DN	Selinexor oral
DMDLOBZ	MI	TTCJUR4
DMDLOBZ	MN	Exportin-1 (XPO1)
DMDLOBZ	MT	DTT
DMDLOBZ	MA	Inhibitor
DMDLOBZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDLOBZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQM3IX	DI	DMQM3IX
DMQM3IX	DN	SELODENOSON
DMQM3IX	MI	TTK25J1
DMQM3IX	MN	Adenosine A1 receptor (ADORA1)
DMQM3IX	MT	DTT
DMQM3IX	MA	Agonist
DMQM3IX	RN	Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
DMQM3IX	RU	https://pubmed.ncbi.nlm.nih.gov/21185259

DMJH6EL	DI	DMJH6EL
DMJH6EL	DN	Selurampanel
DMJH6EL	MI	TTAN6JD
DMJH6EL	MN	Glutamate receptor AMPA (GRIA)
DMJH6EL	MT	DTT
DMJH6EL	MA	Antagonist
DMJH6EL	RN	BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13.
DMJH6EL	RU	https://pubmed.ncbi.nlm.nih.gov/24147649

DMIJNLG	DI	DMIJNLG
DMIJNLG	DN	Semapimod
DMIJNLG	MI	TTB18GJ
DMIJNLG	MN	Proto-oncogene c-RAF (c-RAF)
DMIJNLG	MT	DTT
DMIJNLG	MA	Modulator
DMIJNLG	RN	Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
DMIJNLG	RU	https://pubmed.ncbi.nlm.nih.gov/16081798

DMLDBQ5	DI	DMLDBQ5
DMLDBQ5	DN	SEN-196
DMLDBQ5	MI	TTUF2HO
DMLDBQ5	MN	NAD-dependent deacetylase sirtuin-1 (SIRT1)
DMLDBQ5	MT	DTT
DMLDBQ5	MA	Inhibitor
DMLDBQ5	RN	Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69.
DMLDBQ5	RU	https://pubmed.ncbi.nlm.nih.gov/22086720

DMOH8LD	DI	DMOH8LD
DMOH8LD	DN	Senktide
DMOH8LD	MI	TT4BT06
DMOH8LD	MN	Integrin alpha-4 (ITGA4)
DMOH8LD	MT	DTT
DMOH8LD	MA	Inhibitor
DMOH8LD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOH8LD	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMOH8LD	DI	DMOH8LD
DMOH8LD	DN	Senktide
DMOH8LD	MI	TTBPGLU
DMOH8LD	MN	Neuromedin-K receptor (TACR3)
DMOH8LD	MT	DTT
DMOH8LD	MA	Agonist
DMOH8LD	RN	Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63.
DMOH8LD	RU	https://pubmed.ncbi.nlm.nih.gov/12598409

DMA12HB	DI	DMA12HB
DMA12HB	DN	SEP--4199
DMA12HB	MI	TT85JO3
DMA12HB	MN	5-HT receptor (5HTR)
DMA12HB	MT	DTT
DMA12HB	MA	Antagonist
DMA12HB	RN	ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
DMA12HB	RU	https://clinicaltrials.gov/ct2/show/NCT03543410

DMA12HB	DI	DMA12HB
DMA12HB	DN	SEP--4199
DMA12HB	MI	TTEX248
DMA12HB	MN	Dopamine D2 receptor (D2R)
DMA12HB	MT	DTT
DMA12HB	MA	Antagonist
DMA12HB	RN	ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health.
DMA12HB	RU	https://clinicaltrials.gov/ct2/show/NCT03543410

DMD8RU0	DI	DMD8RU0
DMD8RU0	DN	SEphB4-HSA
DMD8RU0	MI	TTKPV6O
DMD8RU0	MN	Ephrin type-B receptor 2 (EPHB2)
DMD8RU0	MT	DTT
DMD8RU0	MA	Inhibitor
DMD8RU0	RN	National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
DMD8RU0	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-ephb4-hsa-fusion-protein

DMDW5ZC	DI	DMDW5ZC
DMDW5ZC	DN	SER-100
DMDW5ZC	MI	TTNT7K8
DMDW5ZC	MN	Nociceptin receptor (OPRL1)
DMDW5ZC	MT	DTT
DMDW5ZC	MA	Agonist
DMDW5ZC	RN	Clinical pipeline report, company report or official report of Serodus ASA.
DMDW5ZC	RU	http://www.serodus.com/Pipeline/SER100TRISH

DMYT470	DI	DMYT470
DMYT470	DN	Seribantumab
DMYT470	MI	TTDC8N2
DMYT470	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMYT470	MT	DTT
DMYT470	MA	Antagonist
DMYT470	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYT470	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMTNDM2	DI	DMTNDM2
DMTNDM2	DN	Setrobuvir
DMTNDM2	MI	TTMVBWH
DMTNDM2	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMTNDM2	MT	DTT
DMTNDM2	MA	Inhibitor
DMTNDM2	RN	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
DMTNDM2	RU	http://www.anadyspharma.com/

DM9IMEZ	DI	DM9IMEZ
DM9IMEZ	DN	Seviteronel
DM9IMEZ	MI	TTRA5BZ
DM9IMEZ	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM9IMEZ	MT	DTT
DM9IMEZ	MA	Inhibitor
DM9IMEZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9IMEZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML10K3	DI	DML10K3
DML10K3	DN	SF1126
DML10K3	MI	TTHBTOP
DML10K3	MN	PI3-kinase gamma (PIK3CG)
DML10K3	MT	DTT
DML10K3	MA	Modulator
DML10K3	RN	An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81.
DML10K3	RU	https://www.ncbi.nlm.nih.gov/pubmed/23355037

DML10K3	DI	DML10K3
DML10K3	DN	SF1126
DML10K3	MI	TTCJG29
DML10K3	MN	Serine/threonine-protein kinase mTOR (mTOR)
DML10K3	MT	DTT
DML10K3	MA	Inhibitor
DML10K3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML10K3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMVIWNK	DI	DMVIWNK
DMVIWNK	DN	SFV IL-12 gene therapy
DMVIWNK	MI	TTGW72V
DMVIWNK	MN	Interleukin-12 beta (IL12B)
DMVIWNK	MT	DTT
DMVIWNK	MA	Modulator
DMVIWNK	RN	Clinical pipeline report, company report or official report of Trademarkia.
DMVIWNK	RU	http://www.trademarkia.com/lipovil-12-79009798.html

DMAQW9M	DI	DMAQW9M
DMAQW9M	DN	SFX-01
DMAQW9M	MI	TTA6ZN2
DMAQW9M	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMAQW9M	MT	DTT
DMAQW9M	MA	Activator
DMAQW9M	RN	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
DMAQW9M	RU	https://pubmed.ncbi.nlm.nih.gov/30610225

DMJ9M5D	DI	DMJ9M5D
DMJ9M5D	DN	SGN-30
DMJ9M5D	MI	TT2GM5R
DMJ9M5D	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMJ9M5D	MT	DTT
DMJ9M5D	RN	The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
DMJ9M5D	RU	https://pubmed.ncbi.nlm.nih.gov/12097283

DMA4LNE	DI	DMA4LNE
DMA4LNE	DN	SGN-LIV1A
DMA4LNE	MI	TTZN1CF
DMA4LNE	MN	Solute carrier family 39 member 6 (SLC39A6)
DMA4LNE	MT	DTT
DMA4LNE	RN	SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.
DMA4LNE	RU	https://pubmed.ncbi.nlm.nih.gov/25253783

DM5XYFH	DI	DM5XYFH
DM5XYFH	DN	SGS742
DM5XYFH	MI	TTDCVZW
DM5XYFH	MN	Gamma-aminobutyric acid B receptor (GABBR)
DM5XYFH	MT	DTT
DM5XYFH	MA	Modulator
DM5XYFH	RN	SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
DM5XYFH	RU	https://pubmed.ncbi.nlm.nih.gov/15451390

DMLYIPA	DI	DMLYIPA
DMLYIPA	DN	SGT-53
DMLYIPA	MI	TT7SBF5
DMLYIPA	MN	Cellular tumor antigen p53 (TP53)
DMLYIPA	MT	DTT
DMLYIPA	MA	Stimulator
DMLYIPA	RN	Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8.
DMLYIPA	RU	https://pubmed.ncbi.nlm.nih.gov/23470564

DMGIRM1	DI	DMGIRM1
DMGIRM1	DN	SH-529
DMGIRM1	MI	TT470F3
DMGIRM1	MN	TNF alpha production (TNFA produ)
DMGIRM1	MT	DTT
DMGIRM1	MA	Modulator
DMGIRM1	RN	Particulate beta-glucan induces TNF-alpha production in wound macrophages via a redox-sensitive NF- beta-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9.
DMGIRM1	RU	https://pubmed.ncbi.nlm.nih.gov/21518092

DMIQB13	DI	DMIQB13
DMIQB13	DN	SHAPE
DMIQB13	MI	TTBH0VX
DMIQB13	MN	Histone deacetylase (HDAC)
DMIQB13	MT	DTT
DMIQB13	MA	Inhibitor
DMIQB13	RN	Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
DMIQB13	RU	http://tetralogicpharma.com/shape/

DMT4UC1	DI	DMT4UC1
DMT4UC1	DN	Sibrotuzumab
DMT4UC1	MI	TTGPQ0F
DMT4UC1	MN	Prolyl endopeptidase FAP (FAP)
DMT4UC1	MT	DTT
DMT4UC1	MA	Inhibitor
DMT4UC1	RN	A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
DMT4UC1	RU	https://pubmed.ncbi.nlm.nih.gov/12738716

DM39RXO	DI	DM39RXO
DM39RXO	DN	SiG12D-LODER
DM39RXO	MI	TT9TVNM
DM39RXO	MN	KRAS G12D mutant messenger RNA (KRAS mRNA)
DM39RXO	MT	DTT
DM39RXO	MA	Inhibitor
DM39RXO	RN	Clinical pipeline report, company report or official report of Silenseed.
DM39RXO	RU	https://www.silenseed.com/kras-loder-for-pancreatic-cancer/

DM75RFJ	DI	DM75RFJ
DM75RFJ	DN	Siplizumab
DM75RFJ	MI	TTJDUNO
DM75RFJ	MN	T-cell surface antigen CD2 (CD2)
DM75RFJ	MT	DTT
DM75RFJ	RN	Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
DM75RFJ	RU	https://pubmed.ncbi.nlm.nih.gov/15757402

DMTXHJ9	DI	DMTXHJ9
DMTXHJ9	DN	Sirolimus
DMTXHJ9	MI	TT7HQAF
DMTXHJ9	MN	HUMAN mammalian target of rapamycin (mTOR)
DMTXHJ9	MT	DTT
DMTXHJ9	MA	Inhibitor
DMTXHJ9	RN	Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14.
DMTXHJ9	RU	https://pubmed.ncbi.nlm.nih.gov/32194980

DM90DTM	DI	DM90DTM
DM90DTM	DN	Sirukumab
DM90DTM	MI	TTJH4Y5
DM90DTM	MN	HUMAN interleukin 6 (IL6)
DM90DTM	MT	DTT
DM90DTM	MA	Inhibitor
DM90DTM	RN	Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.
DM90DTM	RU	https://pubmed.ncbi.nlm.nih.gov/27913990

DMA9VGW	DI	DMA9VGW
DMA9VGW	DN	Sitafloxacin
DMA9VGW	MI	TTN6J5F
DMA9VGW	MN	Bacterial DNA gyrase (Bact gyrase)
DMA9VGW	MT	DTT
DMA9VGW	MA	Inhibitor
DMA9VGW	RN	Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
DMA9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/18390884

DMA9VGW	DI	DMA9VGW
DMA9VGW	DN	Sitafloxacin
DMA9VGW	MI	TTFK8YB
DMA9VGW	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DMA9VGW	MT	DTT
DMA9VGW	MA	Inhibitor
DMA9VGW	RN	Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
DMA9VGW	RU	https://pubmed.ncbi.nlm.nih.gov/18390884

DMY3JWO	DI	DMY3JWO
DMY3JWO	DN	Sitamaquine
DMY3JWO	MI	DECB0K3
DMY3JWO	MN	Cytochrome P450 2D6 (CYP2D6)
DMY3JWO	MT	DME
DMY3JWO	MA	Metabolism
DMY3JWO	RN	Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9.
DMY3JWO	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25870069

DMNRHMX	DI	DMNRHMX
DMNRHMX	DN	SKF-110679
DMNRHMX	MI	TTKMAZ6
DMNRHMX	MN	Growth hormone receptor (GHR)
DMNRHMX	MT	DTT
DMNRHMX	MA	Modulator
DMNRHMX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093).
DMNRHMX	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093

DMRHD6B	DI	DMRHD6B
DMRHD6B	DN	SKL-NP
DMRHD6B	MI	TTKLW9S
DMRHD6B	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DMRHD6B	MT	DTT
DMRHD6B	MA	Modulator
DMRHD6B	RN	A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons. Korean J Physiol Pharmacol. 2012 Aug;16(4):237-41.
DMRHD6B	RU	https://pubmed.ncbi.nlm.nih.gov/22915988

DMCDON3	DI	DMCDON3
DMCDON3	DN	SLV 306
DMCDON3	MI	TT1BGDH
DMCDON3	MN	Endothelin-converting enzyme (ECE)
DMCDON3	MT	DTT
DMCDON3	MA	Modulator
DMCDON3	RN	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
DMCDON3	RU	https://pubmed.ncbi.nlm.nih.gov/22480515

DMCDON3	DI	DMCDON3
DMCDON3	DN	SLV 306
DMCDON3	MI	TT5TKPM
DMCDON3	MN	Neutral endopeptidase (MME)
DMCDON3	MT	DTT
DMCDON3	MA	Modulator
DMCDON3	RN	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8.
DMCDON3	RU	https://pubmed.ncbi.nlm.nih.gov/22480515

DM867BJ	DI	DM867BJ
DM867BJ	DN	SLV320
DM867BJ	MI	TTK25J1
DM867BJ	MN	Adenosine A1 receptor (ADORA1)
DM867BJ	MT	DTT
DM867BJ	MA	Antagonist
DM867BJ	RN	Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
DM867BJ	RU	https://pubmed.ncbi.nlm.nih.gov/19196241

DMXCJKY	DI	DMXCJKY
DMXCJKY	DN	SLV-334
DMXCJKY	MI	TT1BGDH
DMXCJKY	MN	Endothelin-converting enzyme (ECE)
DMXCJKY	MT	DTT
DMXCJKY	MA	Modulator
DMXCJKY	RN	Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
DMXCJKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/20129503

DMXCJKY	DI	DMXCJKY
DMXCJKY	DN	SLV-334
DMXCJKY	MI	TT5TKPM
DMXCJKY	MN	Neutral endopeptidase (MME)
DMXCJKY	MT	DTT
DMXCJKY	MA	Modulator
DMXCJKY	RN	Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26.
DMXCJKY	RU	https://www.ncbi.nlm.nih.gov/pubmed/20129503

DMM3AI8	DI	DMM3AI8
DMM3AI8	DN	SLx-4090
DMM3AI8	MI	TTUS1RD
DMM3AI8	MN	Microsomal triglyceride transfer protein (MTTP)
DMM3AI8	MT	DTT
DMM3AI8	MA	Modulator
DMM3AI8	RN	A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85.
DMM3AI8	RU	https://pubmed.ncbi.nlm.nih.gov/21406547

DMOLTAD	DI	DMOLTAD
DMOLTAD	DN	SM-04690
DMOLTAD	MI	TTFPSHI
DMOLTAD	MN	Wnt signaling pathway (Wnt pathway)
DMOLTAD	MT	DTT
DMOLTAD	MA	Modulator
DMOLTAD	RN	Clinical pipeline report, company report or official report of Phrma.org Arthritis 2014.
DMOLTAD	RU	http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-arthritis.pdf

DMTJOQX	DI	DMTJOQX
DMTJOQX	DN	SMP-986
DMTJOQX	MI	TTOXS3C
DMTJOQX	MN	Muscarinic acetylcholine receptor (CHRM)
DMTJOQX	MT	DTT
DMTJOQX	MA	Antagonist
DMTJOQX	RN	DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129.
DMTJOQX	RU	http://www.sciencedirect.com/science/article/pii/S0022534708603717

DMTJOQX	DI	DMTJOQX
DMTJOQX	DN	SMP-986
DMTJOQX	MI	TTRK8B9
DMTJOQX	MN	Sodium channel unspecific (NaC)
DMTJOQX	MT	DTT
DMTJOQX	MA	Antagonist
DMTJOQX	RN	DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129.
DMTJOQX	RU	http://www.sciencedirect.com/science/article/pii/S0022534708603717

DMCD6G1	DI	DMCD6G1
DMCD6G1	DN	SMT-C1100
DMCD6G1	MI	TTNO1VA
DMCD6G1	MN	Utrophin (UTRN)
DMCD6G1	MT	DTT
DMCD6G1	MA	Regulator (upregulator)
DMCD6G1	RN	Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol.2015 Jun;55(6):698-707.
DMCD6G1	RU	https://pubmed.ncbi.nlm.nih.gov/25651188

DMPN314	DI	DMPN314
DMPN314	DN	SNA-120
DMPN314	MI	TTTDVOJ
DMPN314	MN	Tropomyosin-related kinase A (TrkA)
DMPN314	MT	DTT
DMPN314	MA	Inhibitor
DMPN314	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPN314	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMO4EYX	DI	DMO4EYX
DMO4EYX	DN	Soblidotin
DMO4EYX	MI	TTML2WA
DMO4EYX	MN	Tubulin (TUB)
DMO4EYX	MT	DTT
DMO4EYX	MA	Modulator
DMO4EYX	RN	Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81.
DMO4EYX	RU	https://pubmed.ncbi.nlm.nih.gov/16827132

DMKNIVG	DI	DMKNIVG
DMKNIVG	DN	Sodium butyrate
DMKNIVG	MI	TT6R7JZ
DMKNIVG	MN	Histone deacetylase 1 (HDAC1)
DMKNIVG	MT	DTT
DMKNIVG	MA	Inhibitor
DMKNIVG	RN	Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
DMKNIVG	RU	https://pubmed.ncbi.nlm.nih.gov/16955068

DMH5MVE	DI	DMH5MVE
DMH5MVE	DN	Sodium stibogluconate
DMH5MVE	MI	TTNJKC3
DMH5MVE	MN	Leishmania DNA topoisomerase I (Leishm TOP1)
DMH5MVE	MT	DTT
DMH5MVE	MA	Modulator
DMH5MVE	RN	Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62.
DMH5MVE	RU	https://pubmed.ncbi.nlm.nih.gov/15562618

DM157U0	DI	DM157U0
DM157U0	DN	Sofinicline
DM157U0	MI	TTL1ATN
DM157U0	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DM157U0	MT	DTT
DM157U0	MA	Modulator
DM157U0	RN	Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63.
DM157U0	RU	https://pubmed.ncbi.nlm.nih.gov/24965900

DML2ZWR	DI	DML2ZWR
DML2ZWR	DN	Solubilized type 1 native bovine collagen
DML2ZWR	MI	TTUABC1
DML2ZWR	MN	Collagen I (COL1A2)
DML2ZWR	MT	DTT
DML2ZWR	MA	Modulator
DML2ZWR	RN	Company report (Argentisrx)
DML2ZWR	RU	http://www.argentisrx.com/arg201-development-to-date.html

DMKCBSM	DI	DMKCBSM
DMKCBSM	DN	SOM3355
DMKCBSM	MI	TTNZRI3
DMKCBSM	MN	Synaptic vesicle amine transporter (SLC18A2)
DMKCBSM	MT	DTT
DMKCBSM	MA	Inhibitor
DMKCBSM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKCBSM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMTVS3A	DI	DMTVS3A
DMTVS3A	DN	Somatoprim
DMTVS3A	MI	TTOMNR9
DMTVS3A	MN	Somatostatin receptor (SSTR)
DMTVS3A	MT	DTT
DMTVS3A	MA	Modulator
DMTVS3A	RN	DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
DMTVS3A	RU	https://www.ncbi.nlm.nih.gov/pubmed/22065857

DMK3RL8	DI	DMK3RL8
DMK3RL8	DN	Somatropin intranasal rhGH
DMK3RL8	MI	TTT3YKH
DMK3RL8	MN	Somatotropin (GH1)
DMK3RL8	MT	DTT
DMK3RL8	MA	Modulator
DMK3RL8	RN	Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20.
DMK3RL8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15871547

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TTFJ8Q1
DME53YS	MN	Protein kinase C alpha (PRKCA)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TTYPXQF
DME53YS	MN	Protein kinase C beta (PRKCB)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DME53YS	DI	DME53YS
DME53YS	DN	Sotrastaurin acetate
DME53YS	MI	TT8QL1J
DME53YS	MN	Protein kinase C theta (PRKCQ)
DME53YS	MT	DTT
DME53YS	MA	Inhibitor
DME53YS	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DME53YS	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DM2UKJV	DI	DM2UKJV
DM2UKJV	DN	SP-333
DM2UKJV	MI	TTLDPRG
DM2UKJV	MN	Guanylyl cyclase C (GUCY2C)
DM2UKJV	MT	DTT
DM2UKJV	MA	Agonist
DM2UKJV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2UKJV	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM9OPK3	DI	DM9OPK3
DM9OPK3	DN	SPD-556
DM9OPK3	MI	TTK8R02
DM9OPK3	MN	Vasopressin V2 receptor (V2R)
DM9OPK3	MT	DTT
DM9OPK3	MA	Antagonist
DM9OPK3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
DM9OPK3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368

DMJH2AC	DI	DMJH2AC
DMJH2AC	DN	SPD-557
DMJH2AC	MI	TT07C3Y
DMJH2AC	MN	5-HT 4 receptor (HTR4)
DMJH2AC	MT	DTT
DMJH2AC	MA	Agonist
DMJH2AC	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMJH2AC	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMKJ9LU	DI	DMKJ9LU
DMKJ9LU	DN	SPD602
DMKJ9LU	MI	TTUDR0C
DMKJ9LU	MN	Iron (Fe)
DMKJ9LU	MT	DTT
DMKJ9LU	MA	Modulator
DMKJ9LU	RN	ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
DMKJ9LU	RU	https://clinicaltrials.gov/ct2/show/NCT01604941

DM26AHR	DI	DM26AHR
DM26AHR	DN	SPI-1005
DM26AHR	MI	TTNHMO8
DM26AHR	MN	COVID-19 papain-like proteinase (PL-PRO)
DM26AHR	MT	DTT
DM26AHR	MA	Inhibitor
DM26AHR	RN	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
DM26AHR	RU	https://pubmed.ncbi.nlm.nih.gov/32272481

DMNPRMC	DI	DMNPRMC
DMNPRMC	DN	SPI-1620
DMNPRMC	MI	TT3ZTGU
DMNPRMC	MN	Endothelin B receptor (EDNRB)
DMNPRMC	MT	DTT
DMNPRMC	MA	Agonist
DMNPRMC	RN	Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
DMNPRMC	RU	http://www.spectrumpharm.com/products_Spectrum.html

DMHC2AW	DI	DMHC2AW
DMHC2AW	DN	SPI-205
DMHC2AW	MI	TTEDJN4
DMHC2AW	MN	Low-affinity nerve growth factor receptor (NGFR)
DMHC2AW	MT	DTT
DMHC2AW	MA	Modulator
DMHC2AW	RN	AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9.
DMHC2AW	RU	https://www.ncbi.nlm.nih.gov/pubmed/18465624

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTVBI8W
DM7NJWY	MN	Dopamine transporter (DAT)
DM7NJWY	MT	DTT
DM7NJWY	MA	Inhibitor
DM7NJWY	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTVFO0U
DM7NJWY	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM7NJWY	MT	DTT
DM7NJWY	MA	Antagonist
DM7NJWY	RN	Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/8791971

DM7NJWY	DI	DM7NJWY
DM7NJWY	DN	Spiroglumide
DM7NJWY	MI	TTAWNKZ
DM7NJWY	MN	Norepinephrine transporter (NET)
DM7NJWY	MT	DTT
DM7NJWY	MA	Inhibitor
DM7NJWY	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM7NJWY	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DMRXCUQ	DI	DMRXCUQ
DMRXCUQ	DN	SPL-108
DMRXCUQ	MI	TTWFBT7
DMRXCUQ	MN	Extracellular matrix receptor III (CD44)
DMRXCUQ	MT	DTT
DMRXCUQ	MA	Inhibitor
DMRXCUQ	RN	Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
DMRXCUQ	RU	http://www.splashpharma.com/new-page

DMZIC4Q	DI	DMZIC4Q
DMZIC4Q	DN	SPN-812
DMZIC4Q	MI	TTAWNKZ
DMZIC4Q	MN	Norepinephrine transporter (NET)
DMZIC4Q	MT	DTT
DMZIC4Q	MA	Inhibitor
DMZIC4Q	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZIC4Q	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMOVQP8	DI	DMOVQP8
DMOVQP8	DN	SPP-600
DMOVQP8	MI	TTB2MXP
DMOVQP8	MN	Angiotensinogenase renin (REN)
DMOVQP8	MT	DTT
DMOVQP8	MA	Inhibitor
DMOVQP8	RN	Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2012 Jan;94(1):146-9.
DMOVQP8	RU	https://pubmed.ncbi.nlm.nih.gov/22173206

DMFAO5G	DI	DMFAO5G
DMFAO5G	DN	S-PRAnt
DMFAO5G	MI	TTUV8G9
DMFAO5G	MN	Progesterone receptor (PGR)
DMFAO5G	MT	DTT
DMFAO5G	MA	Antagonist
DMFAO5G	RN	BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64.
DMFAO5G	RU	https://pubmed.ncbi.nlm.nih.gov/23739217

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	DECB0K3
DMWK9BX	MN	Cytochrome P450 2D6 (CYP2D6)
DMWK9BX	MT	DME
DMWK9BX	MA	Metabolism
DMWK9BX	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DMWK9BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	DEGTFWK
DMWK9BX	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMWK9BX	MT	DME
DMWK9BX	MA	Metabolism
DMWK9BX	RN	Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
DMWK9BX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16432511

DMWK9BX	DI	DMWK9BX
DMWK9BX	DN	SQ-109
DMWK9BX	MI	TTTLB3R
DMWK9BX	MN	Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
DMWK9BX	MT	DTT
DMWK9BX	MA	Modulator
DMWK9BX	RN	SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809.
DMWK9BX	RU	https://pubmed.ncbi.nlm.nih.gov/22252828

DMRFO34	DI	DMRFO34
DMRFO34	DN	SR 16234
DMRFO34	MI	TTZAYWL
DMRFO34	MN	Estrogen receptor (ESR)
DMRFO34	MT	DTT
DMRFO34	MA	Modulator
DMRFO34	RN	National Cancer Institute Drug Dictionary (drug id 599816).
DMRFO34	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816

DMNAECP	DI	DMNAECP
DMNAECP	DN	SR-147778
DMNAECP	MI	TT6OEDT
DMNAECP	MN	Cannabinoid receptor 1 (CB1)
DMNAECP	MT	DTT
DMNAECP	MA	Modulator
DMNAECP	RN	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
DMNAECP	RU	https://www.ncbi.nlm.nih.gov/pubmed/23278647

DMFDA4Y	DI	DMFDA4Y
DMFDA4Y	DN	SR-2640
DMFDA4Y	MI	TTTWGIX
DMFDA4Y	MN	Leukotriene receptor (LTR)
DMFDA4Y	MT	DTT
DMFDA4Y	MA	Modulator
DMFDA4Y	RN	Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4.
DMFDA4Y	RU	https://pubmed.ncbi.nlm.nih.gov/1677467

DMQSN7B	DI	DMQSN7B
DMQSN7B	DN	SR-31747
DMQSN7B	MI	TT4VQZX
DMQSN7B	MN	Cholestenol delta-isomerase (EBP)
DMQSN7B	MT	DTT
DMQSN7B	MA	Modulator
DMQSN7B	RN	Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302.
DMQSN7B	RU	https://pubmed.ncbi.nlm.nih.gov/9618436

DMTOCIV	DI	DMTOCIV
DMTOCIV	DN	SR-43845
DMTOCIV	MI	TTB2MXP
DMTOCIV	MN	Angiotensinogenase renin (REN)
DMTOCIV	MT	DTT
DMTOCIV	MA	Inhibitor
DMTOCIV	RN	Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens Suppl. 1989 Apr;7(2):S33-5.
DMTOCIV	RU	https://pubmed.ncbi.nlm.nih.gov/2666612

DMW6UA3	DI	DMW6UA3
DMW6UA3	DN	SR-46559A
DMW6UA3	MI	TTZ9SOR
DMW6UA3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMW6UA3	MT	DTT
DMW6UA3	MA	Agonist
DMW6UA3	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMW6UA3	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5GAC4	DI	DM5GAC4
DM5GAC4	DN	SRD-441
DM5GAC4	MI	TTZBFA0
DM5GAC4	MN	Protease unspecific (PRO)
DM5GAC4	MT	DTT
DM5GAC4	MA	Inhibitor
DM5GAC4	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807)
DM5GAC4	RU	http://adisinsight.springer.com/drugs/800029807

DMYAXNM	DI	DMYAXNM
DMYAXNM	DN	SRK-015
DMYAXNM	MI	TTM8I2X
DMYAXNM	MN	Myostatin (MSTN)
DMYAXNM	MT	DTT
DMYAXNM	MA	Inhibitor
DMYAXNM	RN	Clinical pipeline report, company report or official report of Scholar Rock.
DMYAXNM	RU	https://scholarrock.com/our-pipeline/spinal-muscular-atrophy/

DMR09IH	DI	DMR09IH
DMR09IH	DN	SRP-9001
DMR09IH	MI	TT48MP6
DMR09IH	MN	Dystrophin (DMD)
DMR09IH	MT	DTT
DMR09IH	MA	Replacement
DMR09IH	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMR09IH	RU	https://www.sarepta.com/products-pipeline/pipeline

DMKOTUJ	DI	DMKOTUJ
DMKOTUJ	DN	SRX246
DMKOTUJ	MI	TT4TFGN
DMKOTUJ	MN	Vasopressin V1a receptor (V1AR)
DMKOTUJ	MT	DTT
DMKOTUJ	MA	Antagonist
DMKOTUJ	RN	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682.
DMKOTUJ	RU	https://pubmed.ncbi.nlm.nih.gov/33207828

DMMU41F	DI	DMMU41F
DMMU41F	DN	SRX-246
DMMU41F	MI	TT4TFGN
DMMU41F	MN	Vasopressin V1a receptor (V1AR)
DMMU41F	MT	DTT
DMMU41F	MA	Antagonist
DMMU41F	RN	Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43.
DMMU41F	RU	https://pubmed.ncbi.nlm.nih.gov/23471831

DMGJEB8	DI	DMGJEB8
DMGJEB8	DN	SSR125543
DMGJEB8	MI	TT7EFHR
DMGJEB8	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DMGJEB8	MT	DTT
DMGJEB8	MA	Antagonist
DMGJEB8	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMGJEB8	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTSCIUP
DMCMD93	MN	Oxytocin receptor (OTR)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TT4TFGN
DMCMD93	MN	Vasopressin V1a receptor (V1AR)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTL9MHW
DMCMD93	MN	Vasopressin V1b receptor (V1BR)
DMCMD93	MT	DTT
DMCMD93	MA	Antagonist
DMCMD93	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DMCMD93	DI	DMCMD93
DMCMD93	DN	SSR149415
DMCMD93	MI	TTK8R02
DMCMD93	MN	Vasopressin V2 receptor (V2R)
DMCMD93	MT	DTT
DMCMD93	MA	Inhibitor
DMCMD93	RN	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
DMCMD93	RU	https://pubmed.ncbi.nlm.nih.gov/19800231

DMA0QZH	DI	DMA0QZH
DMA0QZH	DN	SSR-180575
DMA0QZH	MI	TTPTXIN
DMA0QZH	MN	Translocator protein (TSPO)
DMA0QZH	MT	DTT
DMA0QZH	MA	Inhibitor
DMA0QZH	RN	SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J PharmacolExp Ther. 2002 Jun;301(3):1067-78.
DMA0QZH	RU	https://pubmed.ncbi.nlm.nih.gov/12023539

DMVZ01T	DI	DMVZ01T
DMVZ01T	DN	SSR240600
DMVZ01T	MI	TTZPO1L
DMVZ01T	MN	Substance-P receptor (TACR1)
DMVZ01T	MT	DTT
DMVZ01T	MA	Antagonist
DMVZ01T	RN	SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9.
DMVZ01T	RU	https://pubmed.ncbi.nlm.nih.gov/12438541

DMFNZPY	DI	DMFNZPY
DMFNZPY	DN	SSR-240612
DMFNZPY	MI	TTG5QIA
DMFNZPY	MN	B1 bradykinin receptor (BDKRB1)
DMFNZPY	MT	DTT
DMFNZPY	MA	Antagonist
DMFNZPY	RN	The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287.
DMFNZPY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978253/

DMGTB2Q	DI	DMGTB2Q
DMGTB2Q	DN	SSR411298
DMGTB2Q	MI	TTDP1UC
DMGTB2Q	MN	Fatty acid amide hydrolase (FAAH)
DMGTB2Q	MT	DTT
DMGTB2Q	MA	Inhibitor
DMGTB2Q	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DMGTB2Q	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMRGTZ2	DI	DMRGTZ2
DMRGTZ2	DN	SSTarbaclofen
DMRGTZ2	MI	TTDCVZW
DMRGTZ2	MN	Gamma-aminobutyric acid B receptor (GABBR)
DMRGTZ2	MT	DTT
DMRGTZ2	MA	Modulator
DMRGTZ2	RN	Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
DMRGTZ2	RU	https://www.ncbi.nlm.nih.gov/pubmed/22993295

DMH4C3M	DI	DMH4C3M
DMH4C3M	DN	STA-5326
DMH4C3M	MI	TTRTK6Y
DMH4C3M	MN	Interleukin-12 alpha (IL12A)
DMH4C3M	MT	DTT
DMH4C3M	MA	Inhibitor
DMH4C3M	RN	Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
DMH4C3M	RU	https://pubmed.ncbi.nlm.nih.gov/18847496

DMEG4TC	DI	DMEG4TC
DMEG4TC	DN	Stannsoporfin
DMEG4TC	MI	TTI6V2A
DMEG4TC	MN	Heme oxygenase 1 (HMOX1)
DMEG4TC	MT	DTT
DMEG4TC	MA	Inhibitor
DMEG4TC	RN	Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. 2004 Oct;28(5):365-8.
DMEG4TC	RU	https://pubmed.ncbi.nlm.nih.gov/15686268

DMJ1DIB	DI	DMJ1DIB
DMJ1DIB	DN	S-tenatoprazole
DMJ1DIB	MI	TTLOKXP
DMJ1DIB	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMJ1DIB	MT	DTT
DMJ1DIB	MA	Modulator
DMJ1DIB	RN	Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
DMJ1DIB	RU	https://www.ncbi.nlm.nih.gov/pubmed/15023167

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTVDSZ0
DMKVBL8	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTQ4V96
DMKVBL8	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTVUSO7
DMKVBL8	MN	Tankyrase-1 (TNKS-1)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMKVBL8	DI	DMKVBL8
DMKVBL8	DN	Stenoparib
DMKVBL8	MI	TTFQI4H
DMKVBL8	MN	Tankyrase-2 (TNKS-2)
DMKVBL8	MT	DTT
DMKVBL8	MA	Inhibitor
DMKVBL8	RN	Clinical pipeline report, company report or official report of Allarity Therapeutics.
DMKVBL8	RU	https://allarity.com/pipeline/stenoparib/

DMR9COG	DI	DMR9COG
DMR9COG	DN	STX-100
DMR9COG	MI	TTIQSVM
DMR9COG	MN	Integrin alpha-V/beta-6 (ITGAV/B6)
DMR9COG	MT	DTT
DMR9COG	MA	Antagonist
DMR9COG	RN	Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896.
DMR9COG	RU	http://www.sciencedirect.com/science/article/pii/S0925443912002281

DMLNKX7	DI	DMLNKX7
DMLNKX7	DN	STX-107
DMLNKX7	MI	TTHS256
DMLNKX7	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMLNKX7	MT	DTT
DMLNKX7	MA	Antagonist
DMLNKX7	RN	Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30.
DMLNKX7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/

DMJK5CT	DI	DMJK5CT
DMJK5CT	DN	STX-140
DMJK5CT	MI	TTANPDJ
DMJK5CT	MN	Carbonic anhydrase II (CA-II)
DMJK5CT	MT	DTT
DMJK5CT	MA	Inhibitor
DMJK5CT	RN	Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308.
DMJK5CT	RU	https://pubmed.ncbi.nlm.nih.gov/18260615

DMJK5CT	DI	DMJK5CT
DMJK5CT	DN	STX-140
DMJK5CT	MI	TTHM0R1
DMJK5CT	MN	Steryl-sulfatase (STS)
DMJK5CT	MT	DTT
DMJK5CT	MA	Inhibitor
DMJK5CT	RN	2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
DMJK5CT	RU	https://pubmed.ncbi.nlm.nih.gov/17181151

DMO9LBE	DI	DMO9LBE
DMO9LBE	DN	SUN N4057
DMO9LBE	MI	TTSQIFT
DMO9LBE	MN	5-HT 1A receptor (HTR1A)
DMO9LBE	MT	DTT
DMO9LBE	MA	Agonist
DMO9LBE	RN	Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia. No To Shinkei. 2001 Sep;53(9):853-8.
DMO9LBE	RU	https://pubmed.ncbi.nlm.nih.gov/11596480

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	TT8VUE0
DMPK34E	MN	Chymase (CYM)
DMPK34E	MT	DTT
DMPK34E	MA	Modulator
DMPK34E	RN	Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
DMPK34E	RU	https://www.ncbi.nlm.nih.gov/pubmed/18996112

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	DECB0K3
DMPK34E	MN	Cytochrome P450 2D6 (CYP2D6)
DMPK34E	MT	DME
DMPK34E	MA	Metabolism
DMPK34E	RN	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
DMPK34E	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015

DMPK34E	DI	DMPK34E
DMPK34E	DN	Sun13834
DMPK34E	MI	TTV5CGO
DMPK34E	MN	Phosphodiesterase 4 (PDE4)
DMPK34E	MT	DTT
DMPK34E	MA	Inhibitor
DMPK34E	RN	Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94.
DMPK34E	RU	https://pubmed.ncbi.nlm.nih.gov/7925603

DMSWPA6	DI	DMSWPA6
DMSWPA6	DN	Superoxide dismutase
DMSWPA6	MI	TT6RVLG
DMSWPA6	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMSWPA6	MT	DTT
DMSWPA6	MA	Modulator
DMSWPA6	RN	Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36.
DMSWPA6	RU	https://www.ncbi.nlm.nih.gov/pubmed/21574914

DMAIGTE	DI	DMAIGTE
DMAIGTE	DN	SurVaxM
DMAIGTE	MI	TTTPU1G
DMAIGTE	MN	Apoptosis inhibitor survivin (BIRC5)
DMAIGTE	MT	DTT
DMAIGTE	MA	Inhibitor
DMAIGTE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAIGTE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2KQ71	DI	DM2KQ71
DM2KQ71	DN	Sutezolid
DM2KQ71	MI	TT2VX74
DM2KQ71	MN	Bacterial Protein synthesis (Bact PROS)
DM2KQ71	MT	DTT
DM2KQ71	MA	Modulator
DM2KQ71	RN	Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59.
DM2KQ71	RU	https://pubmed.ncbi.nlm.nih.gov/20385852

DM2KQ71	DI	DM2KQ71
DM2KQ71	DN	Sutezolid
DM2KQ71	MI	DE4LYSA
DM2KQ71	MN	Cytochrome P450 3A4 (CYP3A4)
DM2KQ71	MT	DME
DM2KQ71	MA	Metabolism
DM2KQ71	RN	TB and HIV therapeutics: pharmacology research priorities. AIDS Res Treat. 2012;2012:874083.
DM2KQ71	RU	https://www.hindawi.com/journals/art/2012/874083/

DMQD753	DI	DMQD753
DMQD753	DN	SUVN-502
DMQD753	MI	TTJS8PY
DMQD753	MN	5-HT 6 receptor (HTR6)
DMQD753	MT	DTT
DMQD753	MA	Antagonist
DMQD753	RN	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
DMQD753	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007800/

DMZV27P	DI	DMZV27P
DMZV27P	DN	SXC-2023
DMZV27P	MI	TTBZMIO
DMZV27P	MN	Cystine/glutamate transporter (SLC7A11)
DMZV27P	MT	DTT
DMZV27P	MA	Activator
DMZV27P	RN	Clinical pipeline report, company report or official report of Promentis Pharmaceuticals.
DMZV27P	RU	https://promentispharma.com/technology/sxc-2023/

DMXLE71	DI	DMXLE71
DMXLE71	DN	SYL-040012
DMXLE71	MI	TTG8ZWP
DMXLE71	MN	ADRB2 messenger RNA (ADRB2 mRNA)
DMXLE71	MT	DTT
DMXLE71	RN	In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91.
DMXLE71	RU	https://pubmed.ncbi.nlm.nih.gov/24025749

DMDF7XB	DI	DMDF7XB
DMDF7XB	DN	SYN120
DMDF7XB	MI	TTJQOD7
DMDF7XB	MN	5-HT 2A receptor (HTR2A)
DMDF7XB	MT	DTT
DMDF7XB	MA	Antagonist
DMDF7XB	RN	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
DMDF7XB	RU	https://pubmed.ncbi.nlm.nih.gov/30262889

DMDF7XB	DI	DMDF7XB
DMDF7XB	DN	SYN120
DMDF7XB	MI	TTJS8PY
DMDF7XB	MN	5-HT 6 receptor (HTR6)
DMDF7XB	MT	DTT
DMDF7XB	MA	Antagonist
DMDF7XB	RN	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
DMDF7XB	RU	https://pubmed.ncbi.nlm.nih.gov/30262889

DMPW0UL	DI	DMPW0UL
DMPW0UL	DN	SYN-120
DMPW0UL	MI	TTJS8PY
DMPW0UL	MN	5-HT 6 receptor (HTR6)
DMPW0UL	MT	DTT
DMPW0UL	MA	Antagonist
DMPW0UL	RN	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
DMPW0UL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268149/

DMF9Z2T	DI	DMF9Z2T
DMF9Z2T	DN	T-2007
DMF9Z2T	MI	TTEX6LM
DMF9Z2T	MN	GABA(A) receptor gamma-3 (GABRG3)
DMF9Z2T	MT	DTT
DMF9Z2T	MA	Agonist
DMF9Z2T	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415).
DMF9Z2T	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415

DM06GDC	DI	DM06GDC
DM06GDC	DN	T2c-001
DM06GDC	MI	TTXQYT6
DM06GDC	MN	T-cells (T-cells)
DM06GDC	MT	DTT
DM06GDC	MA	Modulator
DM06GDC	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DM06GDC	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DM5C70M	DI	DM5C70M
DM5C70M	DN	T-607
DM5C70M	MI	TTYFKSZ
DM5C70M	MN	Tubulin beta (TUBB)
DM5C70M	MT	DTT
DM5C70M	MA	Inhibitor
DM5C70M	RN	Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476.
DM5C70M	RU	http://www.sciencedirect.com/science/article/pii/0040402072880293

DMD72F4	DI	DMD72F4
DMD72F4	DN	T-817MA
DMD72F4	MI	TTE4KHA
DMD72F4	MN	Amyloid beta A4 protein (APP)
DMD72F4	MT	DTT
DMD72F4	MA	Inhibitor
DMD72F4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD72F4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMD72F4	DI	DMD72F4
DMD72F4	DN	T-817MA
DMD72F4	MI	TTV0YFR
DMD72F4	MN	Lipid peroxidation (LPO)
DMD72F4	MT	DTT
DMD72F4	MA	Modulator
DMD72F4	RN	A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60.
DMD72F4	RU	https://pubmed.ncbi.nlm.nih.gov/18573265

DM4JFMZ	DI	DM4JFMZ
DM4JFMZ	DN	T-82
DM4JFMZ	MI	TT1RS9F
DM4JFMZ	MN	Acetylcholinesterase (AChE)
DM4JFMZ	MT	DTT
DM4JFMZ	MA	Inhibitor
DM4JFMZ	RN	Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103.
DM4JFMZ	RU	https://pubmed.ncbi.nlm.nih.gov/12650838

DMMWPSQ	DI	DMMWPSQ
DMMWPSQ	DN	TA-2005
DMMWPSQ	MI	TT2CJVK
DMMWPSQ	MN	Adrenergic receptor beta-2 (ADRB2)
DMMWPSQ	MT	DTT
DMMWPSQ	MA	Agonist
DMMWPSQ	RN	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
DMMWPSQ	RU	https://pubmed.ncbi.nlm.nih.gov/16634702

DMZ7I51	DI	DMZ7I51
DMZ7I51	DN	TA-270
DMZ7I51	MI	TT2J34L
DMZ7I51	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMZ7I51	MT	DTT
DMZ7I51	MA	Inhibitor
DMZ7I51	RN	TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE... J Pharmacol Exp Ther. 2003 Nov;307(2):583-8.
DMZ7I51	RU	https://pubmed.ncbi.nlm.nih.gov/12970384

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTZ97H5
DMZTAJL	MN	Phosphodiesterase 4A (PDE4A)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTVIAT9
DMZTAJL	MN	Phosphodiesterase 4B (PDE4B)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMZTAJL	DI	DMZTAJL
DMZTAJL	DN	TA-7906
DMZTAJL	MI	TTSKMI8
DMZTAJL	MN	Phosphodiesterase 4D (PDE4D)
DMZTAJL	MT	DTT
DMZTAJL	MA	Inhibitor
DMZTAJL	RN	Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
DMZTAJL	RU	https://pubmed.ncbi.nlm.nih.gov/12067300

DMAZHT0	DI	DMAZHT0
DMAZHT0	DN	TA-8995
DMAZHT0	MI	TTFQAYR
DMAZHT0	MN	Cholesteryl ester transfer protein (CETP)
DMAZHT0	MT	DTT
DMAZHT0	MA	Inhibitor
DMAZHT0	RN	Amgen To Acquire Privately-Held Dezima Pharma
DMAZHT0	RU	http://www.amgen.com/media/media_pr_detail.jsp?releaseID=2088272

DMNL9HO	DI	DMNL9HO
DMNL9HO	DN	Tabimorelin
DMNL9HO	MI	TTWDC17
DMNL9HO	MN	Growth hormone secretagogue receptor 1 (GHSR)
DMNL9HO	MT	DTT
DMNL9HO	MA	Modulator
DMNL9HO	RN	Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9.
DMNL9HO	RU	https://pubmed.ncbi.nlm.nih.gov/10427162

DMP1873	DI	DMP1873
DMP1873	DN	TAK-063
DMP1873	MI	TTJW4LU
DMP1873	MN	Phosphodiesterase 10A (PDE10)
DMP1873	MT	DTT
DMP1873	MA	Inhibitor
DMP1873	RN	Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
DMP1873	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/

DMHPEFS	DI	DMHPEFS
DMHPEFS	DN	TAK-128
DMHPEFS	MI	TT2O84V
DMHPEFS	MN	Thromboxane A2 receptor (TBXA2R)
DMHPEFS	MT	DTT
DMHPEFS	MA	Modulator
DMHPEFS	RN	ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
DMHPEFS	RU	https://clinicaltrials.gov/ct2/show/NCT00229437

DM81UAZ	DI	DM81UAZ
DM81UAZ	DN	TAK-272
DM81UAZ	MI	TTB2MXP
DM81UAZ	MN	Angiotensinogenase renin (REN)
DM81UAZ	MT	DTT
DM81UAZ	MA	Modulator
DM81UAZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033655)
DM81UAZ	RU	http://adisinsight.springer.com/drugs/800033655

DMEYKRN	DI	DMEYKRN
DMEYKRN	DN	TAK-379
DMEYKRN	MI	TTCBFJO
DMEYKRN	MN	Insulin receptor (INSR)
DMEYKRN	MT	DTT
DMEYKRN	MA	Modulator
DMEYKRN	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMEYKRN	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMD51RN	DI	DMD51RN
DMD51RN	DN	TAK-448
DMD51RN	MI	TTU2O6T
DMD51RN	MN	Metastasis-suppressor KiSS-1 (KISS1)
DMD51RN	MT	DTT
DMD51RN	MA	Modulator
DMD51RN	RN	Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.Eur J Pharmacol.2014 Jul 15;735:77-85.
DMD51RN	RU	https://www.ncbi.nlm.nih.gov/pubmed/24747751

DMNB4P1	DI	DMNB4P1
DMNB4P1	DN	TAK-653
DMNB4P1	MI	TTAN6JD
DMNB4P1	MN	Glutamate receptor AMPA (GRIA)
DMNB4P1	MT	DTT
DMNB4P1	MA	Activator
DMNB4P1	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNB4P1	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMJH3U0	DI	DMJH3U0
DMJH3U0	DN	TAK-659
DMJH3U0	MI	TTGJCWZ
DMJH3U0	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMJH3U0	MT	DTT
DMJH3U0	MA	Inhibitor
DMJH3U0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJH3U0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJH3U0	DI	DMJH3U0
DMJH3U0	DN	TAK-659
DMJH3U0	MI	TTOU65C
DMJH3U0	MN	Tyrosine-protein kinase SYK (SYK)
DMJH3U0	MT	DTT
DMJH3U0	MA	Inhibitor
DMJH3U0	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 8580).
DMJH3U0	RU	http://meetinglibrary.asco.org/content/134551-144

DMZKPI8	DI	DMZKPI8
DMZKPI8	DN	TAK-715
DMZKPI8	MI	TTWELHI
DMZKPI8	MN	Stress-activated protein kinase (p38)
DMZKPI8	MT	DTT
DMZKPI8	MA	Inhibitor
DMZKPI8	RN	Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
DMZKPI8	RU	https://pubmed.ncbi.nlm.nih.gov/21513885

DMWPSJR	DI	DMWPSJR
DMWPSJR	DN	TAK-831
DMWPSJR	MI	TT7Y3EJ
DMWPSJR	MN	D-amino acid oxidase (DAO)
DMWPSJR	MT	DTT
DMWPSJR	MA	Inhibitor
DMWPSJR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWPSJR	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMZEU6M	DI	DMZEU6M
DMZEU6M	DN	TAK-831
DMZEU6M	MI	TT7Y3EJ
DMZEU6M	MN	D-amino acid oxidase (DAO)
DMZEU6M	MT	DTT
DMZEU6M	MA	Inhibitor
DMZEU6M	RN	Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice. Pharm Res. 2020 Aug 5;37(8):164.
DMZEU6M	RU	https://pubmed.ncbi.nlm.nih.gov/32901384

DMBQD9H	DI	DMBQD9H
DMBQD9H	DN	TAK-906
DMBQD9H	MI	TTEX248
DMBQD9H	MN	Dopamine D2 receptor (D2R)
DMBQD9H	MT	DTT
DMBQD9H	MA	Inhibitor
DMBQD9H	RN	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
DMBQD9H	RU	https://pubmed.ncbi.nlm.nih.gov/33462988

DMBQD9H	DI	DMBQD9H
DMBQD9H	DN	TAK-906
DMBQD9H	MI	TT4C8EA
DMBQD9H	MN	Dopamine D3 receptor (D3R)
DMBQD9H	MT	DTT
DMBQD9H	MA	Inhibitor
DMBQD9H	RN	Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
DMBQD9H	RU	https://pubmed.ncbi.nlm.nih.gov/33462988

DMOZAMN	DI	DMOZAMN
DMOZAMN	DN	TAK-935
DMOZAMN	MI	TT4EB85
DMOZAMN	MN	Cholesterol 24-hydroxylase (CYP46A1)
DMOZAMN	MT	DTT
DMOZAMN	MA	Inhibitor
DMOZAMN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040983)
DMOZAMN	RU	http://adisinsight.springer.com/drugs/800040983

DMARVFG	DI	DMARVFG
DMARVFG	DN	Talacotuzumab
DMARVFG	MI	TTENHJ0
DMARVFG	MN	Interleukin 3 receptor alpha (IL3RA)
DMARVFG	MT	DTT
DMARVFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMARVFG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMJOM5L	DI	DMJOM5L
DMJOM5L	DN	Talampanel
DMJOM5L	MI	TTAN6JD
DMJOM5L	MN	Glutamate receptor AMPA (GRIA)
DMJOM5L	MT	DTT
DMJOM5L	MA	Antagonist
DMJOM5L	RN	Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009 Apr;50(4):694-701.
DMJOM5L	RU	https://pubmed.ncbi.nlm.nih.gov/19220413

DMQKZDT	DI	DMQKZDT
DMQKZDT	DN	Talnetant
DMQKZDT	MI	TTBPGLU
DMQKZDT	MN	Neuromedin-K receptor (TACR3)
DMQKZDT	MT	DTT
DMQKZDT	MA	Antagonist
DMQKZDT	RN	Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67.
DMQKZDT	RU	https://pubmed.ncbi.nlm.nih.gov/19540857

DMNLQHK	DI	DMNLQHK
DMNLQHK	DN	Tanespimycin
DMNLQHK	MI	TT78R5H
DMNLQHK	MN	Heat shock protein 90 alpha (HSP90A)
DMNLQHK	MT	DTT
DMNLQHK	MA	Inhibitor
DMNLQHK	RN	Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
DMNLQHK	RU	https://pubmed.ncbi.nlm.nih.gov/19466875

DM1TSHL	DI	DM1TSHL
DM1TSHL	DN	Taprenepag
DM1TSHL	MI	TT1ZAVI
DM1TSHL	MN	Prostaglandin E2 receptor EP2 (PTGER2)
DM1TSHL	MT	DTT
DM1TSHL	MA	Agonist
DM1TSHL	RN	A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
DM1TSHL	RU	https://pubmed.ncbi.nlm.nih.gov/21851167

DMDB4EJ	DI	DMDB4EJ
DMDB4EJ	DN	Tarafenacin
DMDB4EJ	MI	TTQ13Z5
DMDB4EJ	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMDB4EJ	MT	DTT
DMDB4EJ	MA	Antagonist
DMDB4EJ	RN	In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.
DMDB4EJ	RU	https://pubmed.ncbi.nlm.nih.gov/19222482

DM95FR3	DI	DM95FR3
DM95FR3	DN	Tarextumab
DM95FR3	MI	TT82FVD
DM95FR3	MN	Notch-2 receptor (NOTCH2)
DM95FR3	MT	DTT
DM95FR3	MA	Modulator
DM95FR3	RN	Company report (OncoMed Pharmaceuticals)
DM95FR3	RU	http://www.oncomed.com/Pipeline.html

DM95FR3	DI	DM95FR3
DM95FR3	DN	Tarextumab
DM95FR3	MI	TTVX7IA
DM95FR3	MN	Notch-3 receptor (NOTCH3)
DM95FR3	MT	DTT
DM95FR3	MA	Modulator
DM95FR3	RN	Company report (OncoMed Pharmaceuticals)
DM95FR3	RU	http://www.oncomed.com/Pipeline.html

DMA7ISF	DI	DMA7ISF
DMA7ISF	DN	Tarloxotinib
DMA7ISF	MI	TTGKNB4
DMA7ISF	MN	Epidermal growth factor receptor (EGFR)
DMA7ISF	MT	DTT
DMA7ISF	MA	Inhibitor
DMA7ISF	RN	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
DMA7ISF	RU	https://pubmed.ncbi.nlm.nih.gov/33355298

DMA7ISF	DI	DMA7ISF
DMA7ISF	DN	Tarloxotinib
DMA7ISF	MI	TT6EO5L
DMA7ISF	MN	Erbb2 tyrosine kinase receptor (HER2)
DMA7ISF	MT	DTT
DMA7ISF	MA	Inhibitor
DMA7ISF	RN	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
DMA7ISF	RU	https://pubmed.ncbi.nlm.nih.gov/33355298

DML97KB	DI	DML97KB
DML97KB	DN	TAS-106
DML97KB	MI	TT79JGK
DML97KB	MN	Mycobacterium RNA polymerase (MycB RNAP)
DML97KB	MT	DTT
DML97KB	MA	Modulator
DML97KB	RN	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26.
DML97KB	RU	https://www.ncbi.nlm.nih.gov/pubmed/20839029

DM3D52L	DI	DM3D52L
DM3D52L	DN	TAS-114
DM3D52L	MI	TTH6MBO
DM3D52L	MN	dUTP pyrophosphatase (DUT)
DM3D52L	MT	DTT
DM3D52L	MA	Inhibitor
DM3D52L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3D52L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9QFW2	DI	DM9QFW2
DM9QFW2	DN	Tau-binding PET tracer
DM9QFW2	MI	TTS87KH
DM9QFW2	MN	Microtubule-associated protein tau (MAPT)
DM9QFW2	MT	DTT
DM9QFW2	MA	Modulator
DM9QFW2	RN	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
DM9QFW2	RU	https://pubmed.ncbi.nlm.nih.gov/21902667

DMZX0VF	DI	DMZX0VF
DMZX0VF	DN	Tavokinogene telseplasmid
DMZX0VF	MI	TTG68FB
DMZX0VF	MN	Interleukine 12 (IL-12)
DMZX0VF	MT	DTT
DMZX0VF	MA	Replacement
DMZX0VF	RN	Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540.
DMZX0VF	RU	https://pubmed.ncbi.nlm.nih.gov/32147213

DM4I6XK	DI	DM4I6XK
DM4I6XK	DN	TB-402
DM4I6XK	MI	TT1290U
DM4I6XK	MN	Coagulation factor VIII (F8)
DM4I6XK	MT	DTT
DM4I6XK	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
DM4I6XK	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607

DMDPBMH	DI	DMDPBMH
DMDPBMH	DN	TB-403
DMDPBMH	MI	TT48I1Y
DMDPBMH	MN	Placenta growth factor (PlGF)
DMDPBMH	MT	DTT
DMDPBMH	MA	Inhibitor
DMDPBMH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDPBMH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZTOJ6	DI	DMZTOJ6
DMZTOJ6	DN	TBA-7371
DMZTOJ6	MI	TTLOHU4
DMZTOJ6	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DMZTOJ6	MT	DTT
DMZTOJ6	MA	Inhibitor
DMZTOJ6	RN	Clinical pipeline report, company report or official report of TB Alliance.
DMZTOJ6	RU	https://www.tballiance.org/portfolio/trial/12010

DMZCA0K	DI	DMZCA0K
DMZCA0K	DN	TBC-3711
DMZCA0K	MI	TTKRD0G
DMZCA0K	MN	Endothelin A receptor (EDNRA)
DMZCA0K	MT	DTT
DMZCA0K	MA	Antagonist
DMZCA0K	RN	TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res. 2001 Sep;50(3):374-83.
DMZCA0K	RU	https://pubmed.ncbi.nlm.nih.gov/11518825

DMM5BVG	DI	DMM5BVG
DMM5BVG	DN	TBR-760
DMM5BVG	MI	TTEX248
DMM5BVG	MN	Dopamine D2 receptor (D2R)
DMM5BVG	MT	DTT
DMM5BVG	MA	Agonist
DMM5BVG	RN	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
DMM5BVG	RU	https://pubmed.ncbi.nlm.nih.gov/32591776

DMM5BVG	DI	DMM5BVG
DMM5BVG	DN	TBR-760
DMM5BVG	MI	TTZ6T9E
DMM5BVG	MN	Somatostatin receptor type 2 (SSTR2)
DMM5BVG	MT	DTT
DMM5BVG	MA	Agonist
DMM5BVG	RN	TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.
DMM5BVG	RU	https://pubmed.ncbi.nlm.nih.gov/32591776

DM8AM60	DI	DM8AM60
DM8AM60	DN	TC-5214
DM8AM60	MI	TT35UGH
DM8AM60	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DM8AM60	MT	DTT
DM8AM60	MA	Antagonist
DM8AM60	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8AM60	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM8AM60	DI	DM8AM60
DM8AM60	DN	TC-5214
DM8AM60	MI	TT5KPZR
DM8AM60	MN	Neuronal acetylcholine receptor beta-2 (CHRNB2)
DM8AM60	MT	DTT
DM8AM60	MA	Antagonist
DM8AM60	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8AM60	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMWPI2U	DI	DMWPI2U
DMWPI2U	DN	TC-6499-12
DMWPI2U	MI	TTL1ATN
DMWPI2U	MN	Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2)
DMWPI2U	MT	DTT
DMWPI2U	MA	Modulator
DMWPI2U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMWPI2U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMNFP21	DI	DMNFP21
DMNFP21	DN	TC-6987
DMNFP21	MI	TTLA931
DMNFP21	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMNFP21	MT	DTT
DMNFP21	MA	Modulator
DMNFP21	RN	ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
DMNFP21	RU	https://clinicaltrials.gov/ct2/show/NCT01293669

DM9PVNJ	DI	DM9PVNJ
DM9PVNJ	DN	TCN-032
DM9PVNJ	MI	TTXT3PU
DM9PVNJ	MN	Influenza M2 protein (Influ M)
DM9PVNJ	MT	DTT
DM9PVNJ	RN	Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663.
DM9PVNJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906546/

DMJ3KPO	DI	DMJ3KPO
DMJ3KPO	DN	TD-101
DMJ3KPO	MI	TT2FX8W
DMJ3KPO	MN	Keratin 6A messenger RNA (KRT6A mRNA)
DMJ3KPO	MT	DTT
DMJ3KPO	RN	First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb;18(2):442-6.
DMJ3KPO	RU	https://pubmed.ncbi.nlm.nih.gov/19935778

DMTJMK5	DI	DMTJMK5
DMTJMK5	DN	TD-1211
DMTJMK5	MI	TTKWM86
DMTJMK5	MN	Opioid receptor mu (MOP)
DMTJMK5	MT	DTT
DMTJMK5	MA	Modulator
DMTJMK5	RN	The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91.
DMTJMK5	RU	https://pubmed.ncbi.nlm.nih.gov/23549670

DM6SANW	DI	DM6SANW
DM6SANW	DN	TD-5108
DM6SANW	MI	TT07C3Y
DM6SANW	MN	5-HT 4 receptor (HTR4)
DM6SANW	MT	DTT
DM6SANW	MA	Agonist
DM6SANW	RN	The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
DM6SANW	RU	https://pubmed.ncbi.nlm.nih.gov/18415081

DM3C9NV	DI	DM3C9NV
DM3C9NV	DN	TD-8954
DM3C9NV	MI	TT07C3Y
DM3C9NV	MN	5-HT 4 receptor (HTR4)
DM3C9NV	MT	DTT
DM3C9NV	MA	Modulator
DM3C9NV	RN	The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
DM3C9NV	RU	https://pubmed.ncbi.nlm.nih.gov/21687517

DMQD5NA	DI	DMQD5NA
DMQD5NA	DN	TD-9855
DMQD5NA	MI	TTAWNKZ
DMQD5NA	MN	Norepinephrine transporter (NET)
DMQD5NA	MT	DTT
DMQD5NA	MA	Modulator
DMQD5NA	RN	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
DMQD5NA	RU	https://pubmed.ncbi.nlm.nih.gov/25522383

DMQD5NA	DI	DMQD5NA
DMQD5NA	DN	TD-9855
DMQD5NA	MI	TT3ROYC
DMQD5NA	MN	Serotonin transporter (SERT)
DMQD5NA	MT	DTT
DMQD5NA	MA	Modulator
DMQD5NA	RN	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
DMQD5NA	RU	https://pubmed.ncbi.nlm.nih.gov/25522383

DM6YI5T	DI	DM6YI5T
DM6YI5T	DN	Tegobuvir
DM6YI5T	MI	TTMVBWH
DM6YI5T	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM6YI5T	MT	DTT
DM6YI5T	MA	Inhibitor
DM6YI5T	RN	Clinical pipeline report, company report or official report of Gilead (2011).
DM6YI5T	RU	http://www.gilead.com/

DM9AWSO	DI	DM9AWSO
DM9AWSO	DN	Telapristone
DM9AWSO	MI	TTUV8G9
DM9AWSO	MN	Progesterone receptor (PGR)
DM9AWSO	MT	DTT
DM9AWSO	MA	Antagonist
DM9AWSO	RN	In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88.
DM9AWSO	RU	https://pubmed.ncbi.nlm.nih.gov/15120421

DMFT5D6	DI	DMFT5D6
DMFT5D6	DN	Telcagepant
DMFT5D6	MI	TTY6O0Q
DMFT5D6	MN	Calcitonin gene-related peptide receptor (CGRPR)
DMFT5D6	MT	DTT
DMFT5D6	MA	Antagonist
DMFT5D6	RN	CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
DMFT5D6	RU	https://pubmed.ncbi.nlm.nih.gov/19469188

DM8UCNK	DI	DM8UCNK
DM8UCNK	DN	Telisotuzumab vedotin
DM8UCNK	MI	TTNDSF4
DM8UCNK	MN	Proto-oncogene c-Met (MET)
DM8UCNK	MT	DTT
DM8UCNK	RN	Clinical pipeline report, company report or official report of AbbVie.
DM8UCNK	RU	https://www.abbvie.com/our-science/pipeline/abbv-399.html

DMUQH78	DI	DMUQH78
DMUQH78	DN	Tempol
DMUQH78	MI	TT6RVLG
DMUQH78	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMUQH78	MT	DTT
DMUQH78	MA	Modulator
DMUQH78	RN	The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34.
DMUQH78	RU	https://www.ncbi.nlm.nih.gov/pubmed/15943756

DMVS61L	DI	DMVS61L
DMVS61L	DN	Tepoxalin
DMVS61L	MI	TT2J34L
DMVS61L	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMVS61L	MT	DTT
DMVS61L	MA	Inhibitor
DMVS61L	RN	Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48.
DMVS61L	RU	https://pubmed.ncbi.nlm.nih.gov/8812216

DMVS61L	DI	DMVS61L
DMVS61L	DN	Tepoxalin
DMVS61L	MI	TTLGTKB
DMVS61L	MN	Interleukin-4 (IL4)
DMVS61L	MT	DTT
DMVS61L	MA	Inhibitor
DMVS61L	RN	Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
DMVS61L	RU	https://pubmed.ncbi.nlm.nih.gov/7575347

DMC3P45	DI	DMC3P45
DMC3P45	DN	Terameprocol
DMC3P45	MI	TTZEP6S
DMC3P45	MN	Transcription factor Sp1 (SP1)
DMC3P45	MT	DTT
DMC3P45	MA	Modulator
DMC3P45	RN	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
DMC3P45	RU	https://pubmed.ncbi.nlm.nih.gov/18311658

DMZNFPG	DI	DMZNFPG
DMZNFPG	DN	Terguride
DMZNFPG	MI	DE4LYSA
DMZNFPG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZNFPG	MT	DME
DMZNFPG	MA	Metabolism
DMZNFPG	RN	Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med. 2002 Apr-Jun;6(2):189-98.
DMZNFPG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12169204

DMR4YEG	DI	DMR4YEG
DMR4YEG	DN	Tesidolumab
DMR4YEG	MI	TTKANGO
DMR4YEG	MN	Complement C5 (CO5)
DMR4YEG	MT	DTT
DMR4YEG	MA	Inhibitor
DMR4YEG	RN	Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 Sep;20(9):2581-2588.
DMR4YEG	RU	https://pubmed.ncbi.nlm.nih.gov/32301258

DM1KGS7	DI	DM1KGS7
DM1KGS7	DN	Tesofensine
DM1KGS7	MI	TTCBFJO
DM1KGS7	MN	Insulin receptor (INSR)
DM1KGS7	MT	DTT
DM1KGS7	MA	Inhibitor
DM1KGS7	RN	The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95.
DM1KGS7	RU	https://pubmed.ncbi.nlm.nih.gov/20385125

DMMK6IT	DI	DMMK6IT
DMMK6IT	DN	Testogen TDS
DMMK6IT	MI	TTS64P2
DMMK6IT	MN	Androgen receptor (AR)
DMMK6IT	MT	DTT
DMMK6IT	MA	Modulator
DMMK6IT	RN	Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
DMMK6IT	RU	https://pubmed.ncbi.nlm.nih.gov/2912689

DMR5GSB	DI	DMR5GSB
DMR5GSB	DN	Tetrahydrouridine
DMR5GSB	MI	TTQ12RK
DMR5GSB	MN	Cytidine deaminase (CDA)
DMR5GSB	MT	DTT
DMR5GSB	MA	Modulator
DMR5GSB	RN	Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424.
DMR5GSB	RU	https://pubmed.ncbi.nlm.nih.gov/22616006

DMGNK67	DI	DMGNK67
DMGNK67	DN	TETRAPLATIN TETRANITRATE
DMGNK67	MI	TTUTN1I
DMGNK67	MN	Human Deoxyribonucleic acid (hDNA)
DMGNK67	MT	DTT
DMGNK67	MA	Binder
DMGNK67	RN	Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8.
DMGNK67	RU	https://pubmed.ncbi.nlm.nih.gov/8490203

DM2LBC3	DI	DM2LBC3
DM2LBC3	DN	TEW-7197
DM2LBC3	MI	TTP4520
DM2LBC3	MN	TGF-beta receptor type I (TGFBR1)
DM2LBC3	MT	DTT
DM2LBC3	MA	Modulator
DM2LBC3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM2LBC3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2LBC3	DI	DM2LBC3
DM2LBC3	DN	TEW-7197
DM2LBC3	MI	TTO3HT7
DM2LBC3	MN	Transforming growth factor beta (TGFB)
DM2LBC3	MT	DTT
DM2LBC3	MA	Antagonist
DM2LBC3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2LBC3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMF61ML	DI	DMF61ML
DMF61ML	DN	TF0023
DMF61ML	MI	TT6L509
DMF61ML	MN	Coagulation factor IIa (F2)
DMF61ML	MT	DTT
DMF61ML	MA	Inhibitor
DMF61ML	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMF61ML	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM2ZLWH	DI	DM2ZLWH
DM2ZLWH	DN	TG-0054
DM2ZLWH	MI	TTBID49
DM2ZLWH	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2ZLWH	MT	DTT
DM2ZLWH	MA	Inhibitor
DM2ZLWH	RN	CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28.
DM2ZLWH	RU	https://pubmed.ncbi.nlm.nih.gov/24823505

DMPH1AG	DI	DMPH1AG
DMPH1AG	DN	TG100801
DMPH1AG	MI	TT9HKJA
DMPH1AG	MN	Vascular endothelial growth factor (VEGF)
DMPH1AG	MT	DTT
DMPH1AG	MA	Inhibitor
DMPH1AG	RN	Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
DMPH1AG	RU	https://pubmed.ncbi.nlm.nih.gov/18330892

DMZ571Y	DI	DMZ571Y
DMZ571Y	DN	TG-2349
DMZ571Y	MI	TTRHUKY
DMZ571Y	MN	Hepatitis C virus Serine protease NS4A (HCV NS4A)
DMZ571Y	MT	DTT
DMZ571Y	MA	Modulator
DMZ571Y	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZ571Y	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ2FTU	DI	DMJ2FTU
DMJ2FTU	DN	TGBA01AD
DMJ2FTU	MI	TTSQIFT
DMJ2FTU	MN	5-HT 1A receptor (HTR1A)
DMJ2FTU	MT	DTT
DMJ2FTU	MA	Modulator
DMJ2FTU	RN	Company report (Fabrekramer)
DMJ2FTU	RU	http://www.fabrekramer.com/?page_id=66

DMJ2FTU	DI	DMJ2FTU
DMJ2FTU	DN	TGBA01AD
DMJ2FTU	MI	TT6MSOK
DMJ2FTU	MN	5-HT 1D receptor (HTR1D)
DMJ2FTU	MT	DTT
DMJ2FTU	MA	Modulator
DMJ2FTU	RN	Company report (Fabrekramer)
DMJ2FTU	RU	http://www.fabrekramer.com/?page_id=66

DMNXJ5B	DI	DMNXJ5B
DMNXJ5B	DN	TGFK08AA
DMNXJ5B	MI	TTSQIFT
DMNXJ5B	MN	5-HT 1A receptor (HTR1A)
DMNXJ5B	MT	DTT
DMNXJ5B	MA	Modulator
DMNXJ5B	RN	50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. 
DMNXJ5B	RU	https://pubmed.ncbi.nlm.nih.gov/23989795

DMGWE4H	DI	DMGWE4H
DMGWE4H	DN	TGFK09SD
DMGWE4H	MI	TTSQIFT
DMGWE4H	MN	5-HT 1A receptor (HTR1A)
DMGWE4H	MT	DTT
DMGWE4H	MA	Modulator
DMGWE4H	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032503)
DMGWE4H	RU	http://adisinsight.springer.com/drugs/800032503

DMQ6ANE	DI	DMQ6ANE
DMQ6ANE	DN	TGOF02N
DMQ6ANE	MI	TTYSN63
DMQ6ANE	MN	5-HT 2 receptor (5HT2R)
DMQ6ANE	MT	DTT
DMQ6ANE	MA	Modulator
DMQ6ANE	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMQ6ANE	RU	http://www.fabrekramer.com/?page_id=76

DMI57ZA	DI	DMI57ZA
DMI57ZA	DN	TGWOOAA
DMI57ZA	MI	TTSQIFT
DMI57ZA	MN	5-HT 1A receptor (HTR1A)
DMI57ZA	MT	DTT
DMI57ZA	MA	Antagonist
DMI57ZA	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMI57ZA	RU	http://www.fabrekramer.com/?page_id=70

DMI57ZA	DI	DMI57ZA
DMI57ZA	DN	TGWOOAA
DMI57ZA	MI	TTYSN63
DMI57ZA	MN	5-HT 2 receptor (5HT2R)
DMI57ZA	MT	DTT
DMI57ZA	MA	Antagonist
DMI57ZA	RN	Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
DMI57ZA	RU	http://www.fabrekramer.com/?page_id=70

DMFU0JY	DI	DMFU0JY
DMFU0JY	DN	TH-302
DMFU0JY	MI	TTUTN1I
DMFU0JY	MN	Human Deoxyribonucleic acid (hDNA)
DMFU0JY	MT	DTT
DMFU0JY	MA	Modulator
DMFU0JY	RN	Company report (Threshold Pharmaceuticals)
DMFU0JY	RU	http://www.thresholdpharm.com/what-is-th-302

DMW8X05	DI	DMW8X05
DMW8X05	DN	THR-149
DMW8X05	MI	TTMF8H9
DMW8X05	MN	Plasma kallikrein (KLKB1)
DMW8X05	MT	DTT
DMW8X05	MA	Inhibitor
DMW8X05	RN	Clinical pipeline report, company report or official report of Oxurion.
DMW8X05	RU	https://www.oxurion.com/product/thr-149-pkal-inhibitor

DMBO021	DI	DMBO021
DMBO021	DN	THR-18
DMBO021	MI	TTTO43N
DMBO021	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DMBO021	MT	DTT
DMBO021	MA	Activator
DMBO021	RN	THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models. Neurol Res. 2011 Nov;33(9):983-90.
DMBO021	RU	https://pubmed.ncbi.nlm.nih.gov/22081002

DMAVQR1	DI	DMAVQR1
DMAVQR1	DN	THR-184
DMAVQR1	MI	TTKOBRA
DMAVQR1	MN	Bone morphogenetic protein 7 (BMP7)
DMAVQR1	MT	DTT
DMAVQR1	MA	Agonist
DMAVQR1	RN	Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018 Feb;29(2):670-679.
DMAVQR1	RU	https://pubmed.ncbi.nlm.nih.gov/29203473

DM1BYNF	DI	DM1BYNF
DM1BYNF	DN	THRX-198321
DM1BYNF	MI	TT2CJVK
DM1BYNF	MN	Adrenergic receptor beta-2 (ADRB2)
DM1BYNF	MT	DTT
DM1BYNF	MA	Modulator
DM1BYNF	RN	THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99.
DM1BYNF	RU	https://pubmed.ncbi.nlm.nih.gov/21139051

DM4BLJM	DI	DM4BLJM
DM4BLJM	DN	Thymoctonan
DM4BLJM	MI	TTF89GD
DM4BLJM	MN	Interleukin-2 (IL2)
DM4BLJM	MT	DTT
DM4BLJM	MA	Modulator
DM4BLJM	RN	Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7.
DM4BLJM	RU	https://pubmed.ncbi.nlm.nih.gov/8530805

DME4LA1	DI	DME4LA1
DME4LA1	DN	Tideglusib
DME4LA1	MI	TTRSMW9
DME4LA1	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DME4LA1	MT	DTT
DME4LA1	MA	Inhibitor
DME4LA1	RN	Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
DME4LA1	RU	https://pubmed.ncbi.nlm.nih.gov/22102280

DM5XRMA	DI	DM5XRMA
DM5XRMA	DN	Tipapkinogene sovacivec
DM5XRMA	MI	TTE2N95
DM5XRMA	MN	Human papillomavirus protein E6 (HPV E6)
DM5XRMA	MT	DTT
DM5XRMA	MA	Modulator
DM5XRMA	RN	Immune therapy for human papillomaviruses-related cancers
DM5XRMA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927

DM5XRMA	DI	DM5XRMA
DM5XRMA	DN	Tipapkinogene sovacivec
DM5XRMA	MI	TT3CPZW
DM5XRMA	MN	Human papillomavirus protein E7 (HPV E7)
DM5XRMA	MT	DTT
DM5XRMA	MA	Modulator
DM5XRMA	RN	Immune therapy for human papillomaviruses-related cancers
DM5XRMA	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927

DMS9BDQ	DI	DMS9BDQ
DMS9BDQ	DN	Tipelukast
DMS9BDQ	MI	TT2J34L
DMS9BDQ	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMS9BDQ	MT	DTT
DMS9BDQ	MA	Modulator
DMS9BDQ	RN	Company report (MediciNova)
DMS9BDQ	RU	http://medicinova.com/clinical-development/core/mn-001-nash/

DMS9BDQ	DI	DMS9BDQ
DMS9BDQ	DN	Tipelukast
DMS9BDQ	MI	TTZCG4L
DMS9BDQ	MN	Phosphodiesterase 3 (PDE3)
DMS9BDQ	MT	DTT
DMS9BDQ	MA	Modulator
DMS9BDQ	RN	Company report (MediciNova)
DMS9BDQ	RU	http://medicinova.com/clinical-development/core/mn-001-nash/

DM1SB94	DI	DM1SB94
DM1SB94	DN	Tiprelestat
DM1SB94	MI	TT5MLC4
DM1SB94	MN	Leukocyte proteinase-3 (PRTN3)
DM1SB94	MT	DTT
DM1SB94	MA	Modulator
DM1SB94	RN	Company report (Proteo Biotech AG)
DM1SB94	RU	http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html

DM1SB94	DI	DM1SB94
DM1SB94	DN	Tiprelestat
DM1SB94	MI	TTPLTSQ
DM1SB94	MN	Neutrophil elastase (NE)
DM1SB94	MT	DTT
DM1SB94	MA	Modulator
DM1SB94	RN	Company report (Proteo Biotech AG)
DM1SB94	RU	http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html

DMT8SMO	DI	DMT8SMO
DMT8SMO	DN	TKA-731
DMT8SMO	MI	TTZPO1L
DMT8SMO	MN	Substance-P receptor (TACR1)
DMT8SMO	MT	DTT
DMT8SMO	MA	Antagonist
DMT8SMO	RN	The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71.
DMT8SMO	RU	https://pubmed.ncbi.nlm.nih.gov/16199188

DMGWP8L	DI	DMGWP8L
DMGWP8L	DN	TLC-388
DMGWP8L	MI	TTGTQHC
DMGWP8L	MN	DNA topoisomerase I (TOP1)
DMGWP8L	MT	DTT
DMGWP8L	MA	Inhibitor
DMGWP8L	RN	Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.
DMGWP8L	RU	https://pubmed.ncbi.nlm.nih.gov/9885371

DMVXLQ7	DI	DMVXLQ7
DMVXLQ7	DN	TLN-4601
DMVXLQ7	MI	TTPTXIN
DMVXLQ7	MN	Translocator protein (TSPO)
DMVXLQ7	MT	DTT
DMVXLQ7	MA	Modulator
DMVXLQ7	RN	TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation.Biochem Pharmacol.2010 Nov 15;80(10):1572-9.
DMVXLQ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/20655882

DMKV5UM	DI	DMKV5UM
DMKV5UM	DN	TM-601
DMKV5UM	MI	TTCYAXN
DMKV5UM	MN	Chloride channel unspecific (ClC)
DMKV5UM	MT	DTT
DMKV5UM	MA	Inhibitor
DMKV5UM	RN	NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21.
DMKV5UM	RU	https://pubmed.ncbi.nlm.nih.gov/7819188

DMW145U	DI	DMW145U
DMW145U	DN	TMC-310911
DMW145U	MI	TT5FNQT
DMW145U	MN	Human immunodeficiency virus Protease (HIV PR)
DMW145U	MT	DTT
DMW145U	MA	Inhibitor
DMW145U	RN	Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology Volume 21, Issue 9, 18 September 2014, Pages 1115-1142.
DMW145U	RU	http://www.sciencedirect.com/science/article/pii/S1074552114002890

DME8PFQ	DI	DME8PFQ
DME8PFQ	DN	TMX-049
DME8PFQ	MI	TT7RJY8
DME8PFQ	MN	Xanthine dehydrogenase/oxidase (XDH)
DME8PFQ	MT	DTT
DME8PFQ	MA	Inhibitor
DME8PFQ	RN	Clinical pipeline report, company report or official report of Teijin Pharma.
DME8PFQ	RU	https://www.teijin.com/news/2019/20190920_3737.html

DMH4BFD	DI	DMH4BFD
DMH4BFD	DN	TN-871
DMH4BFD	MI	TTTD45S
DMH4BFD	MN	Neurotransmitter release (NT rele)
DMH4BFD	MT	DTT
DMH4BFD	MA	Modulator
DMH4BFD	RN	Effects of an indene-derivative, TN-871, on synaptic transmission in a sympathetic ganglion: presynaptic actions on neurotransmitter release. Bull Tokyo Med Dent Univ. 1995 Mar;42(1):19-29.
DMH4BFD	RU	https://pubmed.ncbi.nlm.nih.gov/7895315

DM3AIF7	DI	DM3AIF7
DM3AIF7	DN	TNF alpha kinoid
DM3AIF7	MI	TTF8CQI
DM3AIF7	MN	Tumor necrosis factor (TNF)
DM3AIF7	MT	DTT
DM3AIF7	RN	Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703.
DM3AIF7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346328/

DM8DZKI	DI	DM8DZKI
DM8DZKI	DN	TNP-2092
DM8DZKI	MI	TTN6J5F
DM8DZKI	MN	Bacterial DNA gyrase (Bact gyrase)
DM8DZKI	MT	DTT
DM8DZKI	MA	Inhibitor
DM8DZKI	RN	Clinical pipeline report, company report or official report of TenNor Therapeutics.
DM8DZKI	RU	http://www.tennorx.com/en/h-col-158.html

DM8DZKI	DI	DM8DZKI
DM8DZKI	DN	TNP-2092
DM8DZKI	MI	TTFK8YB
DM8DZKI	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DM8DZKI	MT	DTT
DM8DZKI	MA	Inhibitor
DM8DZKI	RN	Clinical pipeline report, company report or official report of TenNor Therapeutics.
DM8DZKI	RU	http://www.tennorx.com/en/h-col-158.html

DMAJ6YL	DI	DMAJ6YL
DMAJ6YL	DN	TNX-1300
DMAJ6YL	MI	TTX7ZJ3
DMAJ6YL	MN	Cocaine (Coca)
DMAJ6YL	MT	DTT
DMAJ6YL	MA	Degrader
DMAJ6YL	RN	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
DMAJ6YL	RU	https://www.tonixpharma.com/pipeline/overview

DMBIJZ6	DI	DMBIJZ6
DMBIJZ6	DN	Tocopherol
DMBIJZ6	MI	DE4LYSA
DMBIJZ6	MN	Cytochrome P450 3A4 (CYP3A4)
DMBIJZ6	MT	DME
DMBIJZ6	MA	Metabolism
DMBIJZ6	RN	A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels. Atherosclerosis. 2007 Jul;193(1):229-33.
DMBIJZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16860808

DMBIJZ6	DI	DMBIJZ6
DMBIJZ6	DN	Tocopherol
DMBIJZ6	MI	DE3GT9C
DMBIJZ6	MN	Cytochrome P450 4F2 (CYP4F2)
DMBIJZ6	MT	DME
DMBIJZ6	MA	Metabolism
DMBIJZ6	RN	Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Ann N Y Acad Sci. 2004 Dec;1031:13-21.
DMBIJZ6	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15753130

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTZ97H5
DMLCUAS	MN	Phosphodiesterase 4A (PDE4A)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54.
DMLCUAS	RU	https://pubmed.ncbi.nlm.nih.gov/21205923

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTVIAT9
DMLCUAS	MN	Phosphodiesterase 4B (PDE4B)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
DMLCUAS	RU	https://pubmed.ncbi.nlm.nih.gov/21948793

DMLCUAS	DI	DMLCUAS
DMLCUAS	DN	TOFIMILAST
DMLCUAS	MI	TTSKMI8
DMLCUAS	MN	Phosphodiesterase 4D (PDE4D)
DMLCUAS	MT	DTT
DMLCUAS	MA	Inhibitor
DMLCUAS	RN	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
DMLCUAS	RU	https://www.accessdata.fda.gov/scripts/cder/drugsatfda/

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTJW4LU
DMTGNWU	MN	Phosphodiesterase 10A (PDE10)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTJGW1Z
DMTGNWU	MN	Phosphodiesterase 2A (PDE2A)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTZCG4L
DMTGNWU	MN	Phosphodiesterase 3 (PDE3)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMTGNWU	DI	DMTGNWU
DMTGNWU	DN	Tofisopam
DMTGNWU	MI	TTZ97H5
DMTGNWU	MN	Phosphodiesterase 4A (PDE4A)
DMTGNWU	MT	DTT
DMTGNWU	MA	Inhibitor
DMTGNWU	RN	The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
DMTGNWU	RU	https://pubmed.ncbi.nlm.nih.gov/20967473

DMVJWPR	DI	DMVJWPR
DMVJWPR	DN	TOK-001
DMVJWPR	MI	TTS64P2
DMVJWPR	MN	Androgen receptor (AR)
DMVJWPR	MT	DTT
DMVJWPR	MA	Inhibitor
DMVJWPR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
DMVJWPR	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638

DMW17KS	DI	DMW17KS
DMW17KS	DN	TOL-3021
DMW17KS	MI	TTUTN1I
DMW17KS	MN	Human Deoxyribonucleic acid (hDNA)
DMW17KS	MT	DTT
DMW17KS	MA	Modulator
DMW17KS	RN	Clinical pipeline report, company report or official report of Tolerion.
DMW17KS	RU	http://www.tolerioninc.com/TOL-3021_press_release.html

DMORFZD	DI	DMORFZD
DMORFZD	DN	Tolamba
DMORFZD	MI	TTSHG0T
DMORFZD	MN	Toll-like receptor 9 (TLR9)
DMORFZD	MT	DTT
DMORFZD	RN	Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291.
DMORFZD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747261/

DMT4OPL	DI	DMT4OPL
DMT4OPL	DN	Tonabersat
DMT4OPL	MI	TT6MSOK
DMT4OPL	MN	5-HT 1D receptor (HTR1D)
DMT4OPL	MT	DTT
DMT4OPL	MA	Agonist
DMT4OPL	RN	The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia. 2000 Jul;20(6):538-45.
DMT4OPL	RU	https://pubmed.ncbi.nlm.nih.gov/11075836

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTK25J1
DMBH316	MN	Adenosine A1 receptor (ADORA1)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTM2AOE
DMBH316	MN	Adenosine A2a receptor (ADORA2A)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTNE7KG
DMBH316	MN	Adenosine A2b receptor (ADORA2B)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMBH316	DI	DMBH316
DMBH316	DN	Tonapofylline
DMBH316	MI	TTJFY5U
DMBH316	MN	Adenosine A3 receptor (ADORA3)
DMBH316	MT	DTT
DMBH316	MA	Inhibitor
DMBH316	RN	2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
DMBH316	RU	https://pubmed.ncbi.nlm.nih.gov/20188574

DMA04DE	DI	DMA04DE
DMA04DE	DN	Topiroxostat
DMA04DE	MI	DE85D2P
DMA04DE	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMA04DE	MT	DME
DMA04DE	MA	Metabolism
DMA04DE	RN	Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug Metab Dispos. 2007 Dec;35(12):2143-8.
DMA04DE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17761779

DMA04DE	DI	DMA04DE
DMA04DE	DN	Topiroxostat
DMA04DE	MI	TT7RJY8
DMA04DE	MN	Xanthine dehydrogenase/oxidase (XDH)
DMA04DE	MT	DTT
DMA04DE	MA	Inhibitor
DMA04DE	RN	QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
DMA04DE	RU	https://pubmed.ncbi.nlm.nih.gov/24214189

DM2HDTM	DI	DM2HDTM
DM2HDTM	DN	Tosagestin
DM2HDTM	MI	TTUV8G9
DM2HDTM	MN	Progesterone receptor (PGR)
DM2HDTM	MT	DTT
DM2HDTM	MA	Agonist
DM2HDTM	RN	Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65.
DM2HDTM	RU	https://pubmed.ncbi.nlm.nih.gov/1616875

DMAWLVB	DI	DMAWLVB
DMAWLVB	DN	TPI ASM8
DMAWLVB	MI	TTPYS82
DMAWLVB	MN	Interleukin 3 receptor (CSF2RB)
DMAWLVB	MT	DTT
DMAWLVB	MA	Modulator
DMAWLVB	RN	Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95.
DMAWLVB	RU	https://www.ncbi.nlm.nih.gov/pubmed/22989709

DMSA2LZ	DI	DMSA2LZ
DMSA2LZ	DN	TPI-1020
DMSA2LZ	MI	TTYRL6O
DMSA2LZ	MN	Glucocorticoid receptor (NR3C1)
DMSA2LZ	MT	DTT
DMSA2LZ	MA	Antagonist
DMSA2LZ	RN	Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br J Pharmacol. 2012 Oct;167(3):515-26.
DMSA2LZ	RU	https://pubmed.ncbi.nlm.nih.gov/22563753

DMC5TV6	DI	DMC5TV6
DMC5TV6	DN	TPI-287
DMC5TV6	MI	TT1WDO0
DMC5TV6	MN	Microtubule (MicroTu)
DMC5TV6	MT	DTT
DMC5TV6	MA	Stabilizer
DMC5TV6	RN	TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012 Sep;11(9):1959-67.
DMC5TV6	RU	https://pubmed.ncbi.nlm.nih.gov/22622283

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TT27RFC
DM4R23C	MN	Opioid receptor delta (OPRD1)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TTQW87Y
DM4R23C	MN	Opioid receptor kappa (OPRK1)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DM4R23C	DI	DM4R23C
DM4R23C	DN	TPM-1/Morphine
DM4R23C	MI	TTKWM86
DM4R23C	MN	Opioid receptor mu (MOP)
DM4R23C	MT	DTT
DM4R23C	MA	Inhibitor
DM4R23C	RN	Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
DM4R23C	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/

DMYP7TO	DI	DMYP7TO
DMYP7TO	DN	Trametinib + 2141795
DMYP7TO	MI	TTWTSCV
DMYP7TO	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMYP7TO	MT	DTT
DMYP7TO	MA	Modulator
DMYP7TO	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMYP7TO	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DE7P2FB
DMU1LXS	MN	Aldo-keto reductase 1C1 (AKR1C1)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEOY5ZM
DMU1LXS	MN	Aldo-keto reductase 1C2 (AKR1C2)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEGQTXO
DMU1LXS	MN	Aldo-keto reductase 1C3 (AKR1C3)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEAJN47
DMU1LXS	MN	Aldo-keto reductase 1C4 (AKR1C4)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DE4LYSA
DMU1LXS	MN	Cytochrome P450 3A4 (CYP3A4)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEIBDNY
DMU1LXS	MN	Cytochrome P450 3A5 (CYP3A5)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25629144

DMU1LXS	DI	DMU1LXS
DMU1LXS	DN	Trastuzumab Emtansine
DMU1LXS	MI	DEIVKZ8
DMU1LXS	MN	NADPH-dependent carbonyl reductase 3 (CBR3)
DMU1LXS	MT	DME
DMU1LXS	MA	Metabolism
DMU1LXS	RN	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
DMU1LXS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25063510

DM1ZQEN	DI	DM1ZQEN
DM1ZQEN	DN	TRAXOPRODIL MESYLATE
DM1ZQEN	MI	TT9IK2Z
DM1ZQEN	MN	N-methyl-D-aspartate receptor (NMDAR)
DM1ZQEN	MT	DTT
DM1ZQEN	MA	Modulator
DM1ZQEN	RN	The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005 Dec;22(12):1428-43.
DM1ZQEN	RU	https://pubmed.ncbi.nlm.nih.gov/16379581

DM7XZY5	DI	DM7XZY5
DM7XZY5	DN	Triapine
DM7XZY5	MI	TTBWDI0
DM7XZY5	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DM7XZY5	MT	DTT
DM7XZY5	MA	Modulator
DM7XZY5	RN	PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9.
DM7XZY5	RU	https://pubmed.ncbi.nlm.nih.gov/19433896

DMWU41P	DI	DMWU41P
DMWU41P	DN	TRIDMAC
DMWU41P	MI	TTJSZTB
DMWU41P	MN	Nicotinic acetylcholine receptor (nAChR)
DMWU41P	MT	DTT
DMWU41P	MA	Antagonist
DMWU41P	RN	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
DMWU41P	RU	https://pubmed.ncbi.nlm.nih.gov/18172433

DM13G5R	DI	DM13G5R
DM13G5R	DN	TRK-170
DM13G5R	MI	TT6S84X
DM13G5R	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM13G5R	MT	DTT
DM13G5R	MA	Modulator
DM13G5R	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM13G5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM13G5R	DI	DM13G5R
DM13G5R	DN	TRK-170
DM13G5R	MI	TT7ZMI1
DM13G5R	MN	Integrin alpha-4/beta-7 (ITGA4/B7)
DM13G5R	MT	DTT
DM13G5R	MA	Modulator
DM13G5R	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM13G5R	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM64NYP	DI	DM64NYP
DM64NYP	DN	TRN-157
DM64NYP	MI	TTQ13Z5
DM64NYP	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DM64NYP	MT	DTT
DM64NYP	MA	Antagonist
DM64NYP	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15).
DM64NYP	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15

DMMQYF6	DI	DMMQYF6
DMMQYF6	DN	TRO-19622
DMMQYF6	MI	TTAN6JD
DMMQYF6	MN	Glutamate receptor AMPA (GRIA)
DMMQYF6	MT	DTT
DMMQYF6	MA	Antagonist
DMMQYF6	RN	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
DMMQYF6	RU	https://pubmed.ncbi.nlm.nih.gov/17604499

DMR8Y4F	DI	DMR8Y4F
DMR8Y4F	DN	Troplasminogen alfa
DMR8Y4F	MI	TTP86E2
DMR8Y4F	MN	Plasminogen (PLG)
DMR8Y4F	MT	DTT
DMR8Y4F	MA	Modulator
DMR8Y4F	RN	V-10153 (Vernalis). Curr Opin Investig Drugs. 2005 Sep;6(9):951-5.
DMR8Y4F	RU	https://pubmed.ncbi.nlm.nih.gov/16187695

DMAZ2L6	DI	DMAZ2L6
DMAZ2L6	DN	TROXACITABINE
DMAZ2L6	MI	TTUTN1I
DMAZ2L6	MN	Human Deoxyribonucleic acid (hDNA)
DMAZ2L6	MT	DTT
DMAZ2L6	MA	Binder
DMAZ2L6	RN	Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8.
DMAZ2L6	RU	https://pubmed.ncbi.nlm.nih.gov/15171046

DMHEWT7	DI	DMHEWT7
DMHEWT7	DN	TRU-015
DMHEWT7	MI	TTUE541
DMHEWT7	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHEWT7	MT	DTT
DMHEWT7	MA	Antagonist
DMHEWT7	RN	TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32.
DMHEWT7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061958/

DMVX6H0	DI	DMVX6H0
DMVX6H0	DN	TRV027
DMVX6H0	MI	TT8DBY3
DMVX6H0	MN	Angiotensin II receptor type-1 (AGTR1)
DMVX6H0	MT	DTT
DMVX6H0	MA	Antagonist
DMVX6H0	RN	First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9.
DMVX6H0	RU	https://pubmed.ncbi.nlm.nih.gov/23813302

DMMNXIW	DI	DMMNXIW
DMMNXIW	DN	TS-022
DMMNXIW	MI	TTNVEIR
DMMNXIW	MN	Prostaglandin D2 receptor (PTGDR)
DMMNXIW	MT	DTT
DMMNXIW	MA	Agonist
DMMNXIW	RN	Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
DMMNXIW	RU	https://pubmed.ncbi.nlm.nih.gov/17141215

DMZE6Y9	DI	DMZE6Y9
DMZE6Y9	DN	TT-100
DMZE6Y9	MI	TTGKNB4
DMZE6Y9	MN	Epidermal growth factor receptor (EGFR)
DMZE6Y9	MT	DTT
DMZE6Y9	MA	Inhibitor
DMZE6Y9	RN	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
DMZE6Y9	RU	http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html

DMZE6Y9	DI	DMZE6Y9
DMZE6Y9	DN	TT-100
DMZE6Y9	MI	TTHRID2
DMZE6Y9	MN	Insulin-like growth factor I receptor (IGF1R)
DMZE6Y9	MT	DTT
DMZE6Y9	MA	Inhibitor
DMZE6Y9	RN	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
DMZE6Y9	RU	http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html

DMSIXG4	DI	DMSIXG4
DMSIXG4	DN	TT-173
DMSIXG4	MI	TT38MDJ
DMSIXG4	MN	Tissue factor (F3)
DMSIXG4	MT	DTT
DMSIXG4	MA	Modulator
DMSIXG4	RN	TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63.
DMSIXG4	RU	https://pubmed.ncbi.nlm.nih.gov/26374745

DMCDMFP	DI	DMCDMFP
DMCDMFP	DN	TT-223
DMCDMFP	MI	TTVFO0U
DMCDMFP	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMCDMFP	MT	DTT
DMCDMFP	MA	Modulator
DMCDMFP	RN	The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.
DMCDMFP	RU	https://pubmed.ncbi.nlm.nih.gov/10757621

DMRQ0SA	DI	DMRQ0SA
DMRQ0SA	DN	TT-401
DMRQ0SA	MI	TT9O6WS
DMRQ0SA	MN	Glucagon receptor (GCGR)
DMRQ0SA	MT	DTT
DMRQ0SA	MA	Agonist
DMRQ0SA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ0SA	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMRQ0SA	DI	DMRQ0SA
DMRQ0SA	DN	TT-401
DMRQ0SA	MI	TTVIMDE
DMRQ0SA	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMRQ0SA	MT	DTT
DMRQ0SA	MA	Modulator
DMRQ0SA	RN	Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83.
DMRQ0SA	RU	https://pubmed.ncbi.nlm.nih.gov/24083687

DM6TAFE	DI	DM6TAFE
DM6TAFE	DN	TTAC-0001
DM6TAFE	MI	TTUTJGQ
DM6TAFE	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM6TAFE	MT	DTT
DM6TAFE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813).
DM6TAFE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813

DMBNU1W	DI	DMBNU1W
DMBNU1W	DN	TTP-054
DMBNU1W	MI	TTVIMDE
DMBNU1W	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMBNU1W	MT	DTT
DMBNU1W	MA	Modulator
DMBNU1W	RN	Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor. Exp Diabetes Res. 2012; 2012: 709893.
DMBNU1W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352573/

DMZ6RG2	DI	DMZ6RG2
DMZ6RG2	DN	TTP273
DMZ6RG2	MI	TTVIMDE
DMZ6RG2	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMZ6RG2	MT	DTT
DMZ6RG2	MA	Agonist
DMZ6RG2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ6RG2	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMBKQSZ	DI	DMBKQSZ
DMBKQSZ	DN	TTP399
DMBKQSZ	MI	TTDLNGZ
DMBKQSZ	MN	Glucokinase (GCK)
DMBKQSZ	MT	DTT
DMBKQSZ	MA	Activator
DMBKQSZ	RN	Clinical pipeline report, company report or official report of vTv Therapeutics.
DMBKQSZ	RU	https://vtvtherapeutics.com/pipeline/ttp399/

DMMNTOW	DI	DMMNTOW
DMMNTOW	DN	TTP435
DMMNTOW	MI	TT4DE1O
DMMNTOW	MN	Agouti-related protein (AGRP)
DMMNTOW	MT	DTT
DMMNTOW	MA	Inhibitor
DMMNTOW	RN	Clinical pipeline report, company report or official report of TransTech Pharma (2011).
DMMNTOW	RU	http://www.ttpharma.com/

DMR37X8	DI	DMR37X8
DMR37X8	DN	TTP-448
DMR37X8	MI	TTMO9HF
DMR37X8	MN	Advanced glycosylation end product receptor (AGER)
DMR37X8	MT	DTT
DMR37X8	MA	Modulator
DMR37X8	RN	Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
DMR37X8	RU	https://pubmed.ncbi.nlm.nih.gov/25586103

DMCQARM	DI	DMCQARM
DMCQARM	DN	TTP889
DMCQARM	MI	TTFEZ5Q
DMCQARM	MN	Coagulation factor IX (F9)
DMCQARM	MT	DTT
DMCQARM	MA	Inhibitor
DMCQARM	RN	Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63.
DMCQARM	RU	https://pubmed.ncbi.nlm.nih.gov/18088349

DMCQARM	DI	DMCQARM
DMCQARM	DN	TTP889
DMCQARM	MI	TTUPB12
DMCQARM	MN	Measles virus Fusion glycoprotein (MeV F)
DMCQARM	MT	DTT
DMCQARM	MA	Inhibitor
DMCQARM	RN	Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17.
DMCQARM	RU	https://pubmed.ncbi.nlm.nih.gov/19453286

DMW7PFS	DI	DMW7PFS
DMW7PFS	DN	Turosteride
DMW7PFS	MI	TT2A0DR
DMW7PFS	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DMW7PFS	MT	DTT
DMW7PFS	MA	Inhibitor
DMW7PFS	RN	Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55.
DMW7PFS	RU	https://pubmed.ncbi.nlm.nih.gov/8240976

DM28M6I	DI	DM28M6I
DM28M6I	DN	TV-1102
DM28M6I	MI	TT2VIZQ
DM28M6I	MN	ITGAV messenger RNA (ITGAV mRNA)
DM28M6I	MT	DTT
DM28M6I	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DM28M6I	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM19GUH	DI	DM19GUH
DM19GUH	DN	TVB-2640
DM19GUH	MI	TT7AOUD
DM19GUH	MN	Fatty acid synthase (FASN)
DM19GUH	MT	DTT
DM19GUH	MA	Inhibitor
DM19GUH	RN	Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
DM19GUH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027139/

DMP30SA	DI	DMP30SA
DMP30SA	DN	TVB-2640
DMP30SA	MI	TT7AOUD
DMP30SA	MN	Fatty acid synthase (FASN)
DMP30SA	MT	DTT
DMP30SA	MA	Inhibitor
DMP30SA	RN	Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
DMP30SA	RU	https://pubmed.ncbi.nlm.nih.gov/31630414

DMGYSZ0	DI	DMGYSZ0
DMGYSZ0	DN	TVI-Kidney-1
DMGYSZ0	MI	TTXQYT6
DMGYSZ0	MN	T-cells (T-cells)
DMGYSZ0	MT	DTT
DMGYSZ0	RN	Clinical pipeline report, company report or official report of TVAX Biomedical.
DMGYSZ0	RU	http://www.tvaxbiomedical.com/tvi-kidney.shtml

DMKJIDU	DI	DMKJIDU
DMKJIDU	DN	TZI-41078
DMKJIDU	MI	TTG3K2U
DMKJIDU	MN	Lipoxygenase (ALOX)
DMKJIDU	MT	DTT
DMKJIDU	MA	Modulator
DMKJIDU	RN	Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
DMKJIDU	RU	https://pubmed.ncbi.nlm.nih.gov/8581424

DMKJIDU	DI	DMKJIDU
DMKJIDU	DN	TZI-41078
DMKJIDU	MI	TTK0943
DMKJIDU	MN	Prostaglandin G/H synthase (COX)
DMKJIDU	MT	DTT
DMKJIDU	MA	Modulator
DMKJIDU	RN	Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10.
DMKJIDU	RU	https://pubmed.ncbi.nlm.nih.gov/8581424

DM4NXWE	DI	DM4NXWE
DM4NXWE	DN	UB-311
DM4NXWE	MI	TTE4KHA
DM4NXWE	MN	Amyloid beta A4 protein (APP)
DM4NXWE	MT	DTT
DM4NXWE	MA	Modulator
DM4NXWE	RN	Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7.
DM4NXWE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979042/

DMXLAPF	DI	DMXLAPF
DMXLAPF	DN	UCB-11056
DMXLAPF	MI	TT0QZ8R
DMXLAPF	MN	cAMP formation (cAMP form)
DMXLAPF	MT	DTT
DMXLAPF	MA	Modulator
DMXLAPF	RN	ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61.
DMXLAPF	RU	https://pubmed.ncbi.nlm.nih.gov/8245976

DM5Z34K	DI	DM5Z34K
DM5Z34K	DN	UCB-35440
DM5Z34K	MI	TT2J34L
DM5Z34K	MN	Arachidonate 5-lipoxygenase (5-LOX)
DM5Z34K	MT	DTT
DM5Z34K	MA	Modulator
DM5Z34K	RN	The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71.
DM5Z34K	RU	https://pubmed.ncbi.nlm.nih.gov/15627437

DM5Z34K	DI	DM5Z34K
DM5Z34K	DN	UCB-35440
DM5Z34K	MI	TTTIBOJ
DM5Z34K	MN	Histamine H1 receptor (H1R)
DM5Z34K	MT	DTT
DM5Z34K	MA	Modulator
DM5Z34K	RN	The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71.
DM5Z34K	RU	https://pubmed.ncbi.nlm.nih.gov/15627437

DMUNJZB	DI	DMUNJZB
DMUNJZB	DN	UCN-01
DMUNJZB	MI	DTI7UX6
DMUNJZB	MN	Breast cancer resistance protein (ABCG2)
DMUNJZB	MT	DTP
DMUNJZB	MA	Substrate
DMUNJZB	RN	Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9.
DMUNJZB	RU	https://doi.org/10.2217/14622416.9.8.1005

DMUNJZB	DI	DMUNJZB
DMUNJZB	DN	UCN-01
DMUNJZB	MI	TTTU902
DMUNJZB	MN	Checkpoint kinase-1 (CHK1)
DMUNJZB	MT	DTT
DMUNJZB	MA	Inhibitor
DMUNJZB	RN	Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
DMUNJZB	RU	https://pubmed.ncbi.nlm.nih.gov/19473860

DMIERPK	DI	DMIERPK
DMIERPK	DN	UE-2343
DMIERPK	MI	TTN7BL9
DMIERPK	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMIERPK	MT	DTT
DMIERPK	MA	Inhibitor
DMIERPK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIERPK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMWDJ15	DI	DMWDJ15
DMWDJ15	DN	UFT/leucovorin calcium
DMWDJ15	MI	TTU6BFZ
DMWDJ15	MN	Candida Thymidylate synthase (Candi TMP1)
DMWDJ15	MT	DTT
DMWDJ15	MA	Modulator
DMWDJ15	RN	Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008-12.
DMWDJ15	RU	https://pubmed.ncbi.nlm.nih.gov/2521810

DM2O4MI	DI	DM2O4MI
DM2O4MI	DN	UK-432097
DM2O4MI	MI	TTM2AOE
DM2O4MI	MN	Adenosine A2a receptor (ADORA2A)
DM2O4MI	MT	DTT
DM2O4MI	MA	Agonist
DM2O4MI	RN	Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7.
DM2O4MI	RU	https://pubmed.ncbi.nlm.nih.gov/21393508

DM8LBUK	DI	DM8LBUK
DM8LBUK	DN	UNI-PH (1-34)
DM8LBUK	MI	TTEPJL5
DM8LBUK	MN	Parathyroid hormone receptor (PTH2R)
DM8LBUK	MT	DTT
DM8LBUK	MA	Modulator
DM8LBUK	RN	Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006 July 4; 175(1): 52-59.
DM8LBUK	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482742/

DMOMI97	DI	DMOMI97
DMOMI97	DN	UNI-rE-4
DMOMI97	MI	TTVIMDE
DMOMI97	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMOMI97	MT	DTT
DMOMI97	MA	Modulator
DMOMI97	RN	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77.
DMOMI97	RU	https://pubmed.ncbi.nlm.nih.gov/19748064

DMFZULI	DI	DMFZULI
DMFZULI	DN	Upamostat
DMFZULI	MI	TTGY7WI
DMFZULI	MN	Urokinase-type plasminogen activator (PLAU)
DMFZULI	MT	DTT
DMFZULI	MA	Inhibitor
DMFZULI	RN	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
DMFZULI	RU	https://pubmed.ncbi.nlm.nih.gov/23412098

DME6X27	DI	DME6X27
DME6X27	DN	UR-63325
DME6X27	MI	TTXJ178
DME6X27	MN	Histamine H4 receptor (H4R)
DME6X27	MT	DTT
DME6X27	MA	Antagonist
DME6X27	RN	Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87.
DME6X27	RU	https://pubmed.ncbi.nlm.nih.gov/22202103

DMY89BN	DI	DMY89BN
DMY89BN	DN	URC102
DMY89BN	MI	TTA592U
DMY89BN	MN	Urate anion exchanger 1 (URAT1)
DMY89BN	MT	DTT
DMY89BN	MA	Inhibitor
DMY89BN	RN	Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
DMY89BN	RU	http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html

DM6RTVG	DI	DM6RTVG
DM6RTVG	DN	Urelumab
DM6RTVG	MI	TTPW9LJ
DM6RTVG	MN	Co-stimulatory molecule 4-1BB (CD137)
DM6RTVG	MT	DTT
DM6RTVG	MA	Agonist
DM6RTVG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6RTVG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM0YO4Q	DI	DM0YO4Q
DM0YO4Q	DN	Urocortin 2
DM0YO4Q	MI	TTIY658
DM0YO4Q	MN	Corticotropin-releasing factor receptor 2 (CRHR2)
DM0YO4Q	MT	DTT
DM0YO4Q	MA	Antagonist
DM0YO4Q	RN	Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies. Ann N Y Acad Sci. 2009 Apr;1163:215-20.
DM0YO4Q	RU	https://pubmed.ncbi.nlm.nih.gov/19456342

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTN7BL9
DM4SOAW	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/20100662

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTZHY6R
DM4SOAW	MN	Glycogen phosphorylase muscle form (GP)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/19642687

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTIU7X1
DM4SOAW	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/10654412

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TT9V5JH
DM4SOAW	MN	Phospholipase A2 (PLA2G1B)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/15993585

DM4SOAW	DI	DM4SOAW
DM4SOAW	DN	URSOLIC ACID
DM4SOAW	MI	TTELIN2
DM4SOAW	MN	PTPN1 messenger RNA (PTPN1 mRNA)
DM4SOAW	MT	DTT
DM4SOAW	MA	Inhibitor
DM4SOAW	RN	Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
DM4SOAW	RU	https://pubmed.ncbi.nlm.nih.gov/19836230

DMDPFTB	DI	DMDPFTB
DMDPFTB	DN	V-101
DMDPFTB	MI	TT2NUT5
DMDPFTB	MN	Adrenergic receptor alpha-2C (ADRA2C)
DMDPFTB	MT	DTT
DMDPFTB	MA	Agonist
DMDPFTB	RN	Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4.
DMDPFTB	RU	https://pubmed.ncbi.nlm.nih.gov/23223767

DM1ODP6	DI	DM1ODP6
DM1ODP6	DN	VA-106483
DM1ODP6	MI	TTK8R02
DM1ODP6	MN	Vasopressin V2 receptor (V2R)
DM1ODP6	MT	DTT
DM1ODP6	MA	Inhibitor
DM1ODP6	RN	New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34.
DM1ODP6	RU	https://pubmed.ncbi.nlm.nih.gov/19053774

DMAYWXD	DI	DMAYWXD
DMAYWXD	DN	VA-111913
DMAYWXD	MI	TT4TFGN
DMAYWXD	MN	Vasopressin V1a receptor (V1AR)
DMAYWXD	MT	DTT
DMAYWXD	MA	Antagonist
DMAYWXD	RN	Clinical pipeline report, company report or official report of Avarx.
DMAYWXD	RU	http://www.avarx.com/AvaRx/SubDomains/bucket304f365f4d5c821c892abf2b5eb4/Listings/bucket3e0f28b94cc197c9e1c49f1451ad/Public.Listing.display.html

DM9GZW6	DI	DM9GZW6
DM9GZW6	DN	Vabicaserin
DM9GZW6	MI	TT0K1SC
DM9GZW6	MN	5-HT 2B receptor (HTR2B)
DM9GZW6	MT	DTT
DM9GZW6	MA	Modulator
DM9GZW6	RN	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
DM9GZW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/24759548

DM9GZW6	DI	DM9GZW6
DM9GZW6	DN	Vabicaserin
DM9GZW6	MI	TTWJBZ5
DM9GZW6	MN	5-HT 2C receptor (HTR2C)
DM9GZW6	MT	DTT
DM9GZW6	MA	Modulator
DM9GZW6	RN	Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
DM9GZW6	RU	https://www.ncbi.nlm.nih.gov/pubmed/24759548

DMDAKZW	DI	DMDAKZW
DMDAKZW	DN	Vacc-4x
DMDAKZW	MI	TTTWS2G
DMDAKZW	MN	Human immunodeficiency virus Capsid p24 (HIV p24)
DMDAKZW	MT	DTT
DMDAKZW	RN	Clinical pipeline report, company report or official report of Bionor Pharma.
DMDAKZW	RU	http://www.bionorpharma.com/en/News/2011/Scientific/Vacc-4x+results+presented+in+Bangkok.b7C_wljS1c.ips

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DEJGDUW
DMK7CYX	MN	Cytochrome P450 1A2 (CYP1A2)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	TTSXVID
DMK7CYX	MN	Nuclear factor NF-kappa-B (NFKB)
DMK7CYX	MT	DTT
DMK7CYX	MA	Modulator
DMK7CYX	RN	Auckland Cancer Society Research Centre report
DMK7CYX	RU	https://www.fmhs.auckland.ac.nz/en/sms/about/our-departments/oncology/cancer-trials-nz/trials-and-research-projects/closed/asa404.html

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DE85D2P
DMK7CYX	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev. 2002 Nov;34(4):751-90.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12487149

DMK7CYX	DI	DMK7CYX
DMK7CYX	DN	Vadimezan
DMK7CYX	MI	DEB3CV1
DMK7CYX	MN	UDP-glucuronosyltransferase 2B7 (UGT2B7)
DMK7CYX	MT	DME
DMK7CYX	MA	Metabolism
DMK7CYX	RN	Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol. 2003 Jun 1;65(11):1853-65.
DMK7CYX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=12781337

DMIKH67	DI	DMIKH67
DMIKH67	DN	Valetizumab
DMIKH67	MI	TTMSB0A
DMIKH67	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DMIKH67	MT	DTT
DMIKH67	RN	Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
DMIKH67	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/

DMAEB9O	DI	DMAEB9O
DMAEB9O	DN	Valomaciclovir stearate
DMAEB9O	MI	TTIU7X1
DMAEB9O	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMAEB9O	MT	DTT
DMAEB9O	MA	Modulator
DMAEB9O	RN	Progress in the Development of New Therapies for Herpesvirus Infections. Curr Opin Virol. 2011 December 1; 1(6): 548-554.
DMAEB9O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230035/

DMFWZ2U	DI	DMFWZ2U
DMFWZ2U	DN	Valopicitabine dihydrochloride
DMFWZ2U	MI	TTMVBWH
DMFWZ2U	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMFWZ2U	MT	DTT
DMFWZ2U	MA	Modulator
DMFWZ2U	RN	Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
DMFWZ2U	RU	https://pubmed.ncbi.nlm.nih.gov/17328231

DMCF5E0	DI	DMCF5E0
DMCF5E0	DN	Vaniprevir
DMCF5E0	MI	TT5FNQT
DMCF5E0	MN	Human immunodeficiency virus Protease (HIV PR)
DMCF5E0	MT	DTT
DMCF5E0	MA	Inhibitor
DMCF5E0	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMCF5E0	RU	http://www.merck.com/index.html

DMNFVKC	DI	DMNFVKC
DMNFVKC	DN	Vapitadine
DMNFVKC	MI	TTTIBOJ
DMNFVKC	MN	Histamine H1 receptor (H1R)
DMNFVKC	MT	DTT
DMNFVKC	MA	Antagonist
DMNFVKC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866)
DMNFVKC	RU	http://adisinsight.springer.com/drugs/800020866

DMQSC5O	DI	DMQSC5O
DMQSC5O	DN	Varlilumab
DMQSC5O	MI	TTDO1MV
DMQSC5O	MN	T-cell activation antigen CD27 (CD27)
DMQSC5O	MT	DTT
DMQSC5O	MA	Inhibitor
DMQSC5O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQSC5O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMKU93J	DI	DMKU93J
DMKU93J	DN	VAS-203
DMKU93J	MI	TTCM4B3
DMKU93J	MN	Nitric-oxide synthase endothelial (NOS3)
DMKU93J	MT	DTT
DMKU93J	MA	Inhibitor
DMKU93J	RN	Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
DMKU93J	RU	https://pubmed.ncbi.nlm.nih.gov/24831445

DMRJ5LP	DI	DMRJ5LP
DMRJ5LP	DN	Vasoactive intestinal peptide
DMRJ5LP	MI	TTCL30I
DMRJ5LP	MN	Vasoactive intestinal polypeptide receptor 1 (VIPR1)
DMRJ5LP	MT	DTT
DMRJ5LP	MA	Antagonist
DMRJ5LP	RN	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
DMRJ5LP	RU	https://pubmed.ncbi.nlm.nih.gov/17064221

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTGKNB4
DMY0UEQ	MN	Epidermal growth factor receptor (EGFR)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTUTJGQ
DMY0UEQ	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/17416531

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TTDCBX5
DMY0UEQ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/15743202

DMY0UEQ	DI	DMY0UEQ
DMY0UEQ	DN	VATALANIB
DMY0UEQ	MI	TT1VAUK
DMY0UEQ	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMY0UEQ	MT	DTT
DMY0UEQ	MA	Inhibitor
DMY0UEQ	RN	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9.
DMY0UEQ	RU	https://pubmed.ncbi.nlm.nih.gov/16460936

DM3V7QO	DI	DM3V7QO
DM3V7QO	DN	Vatelizumab
DM3V7QO	MI	TTMSB0A
DM3V7QO	MN	Integrin alpha-2/beta-1 (ITGA2/B1)
DM3V7QO	MT	DTT
DM3V7QO	RN	Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146.
DM3V7QO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/

DML2CPW	DI	DML2CPW
DML2CPW	DN	VAY736
DML2CPW	MI	TT7NJSE
DML2CPW	MN	B-cell-activating factor receptor (TNFRSF13C)
DML2CPW	MT	DTT
DML2CPW	RN	National Cancer Institute Drug Dictionary (drug id 762784).
DML2CPW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762784

DM0YWQ4	DI	DM0YWQ4
DM0YWQ4	DN	VB 1953
DM0YWQ4	MI	TTN6J5F
DM0YWQ4	MN	Bacterial DNA gyrase (Bact gyrase)
DM0YWQ4	MT	DTT
DM0YWQ4	MA	Inhibitor
DM0YWQ4	RN	Clinical pipeline report, company report or official report of Vyome Therapeutics.
DM0YWQ4	RU	https://www.vyometx.com/platform-strategy.html

DM0YWQ4	DI	DM0YWQ4
DM0YWQ4	DN	VB 1953
DM0YWQ4	MI	TTFK8YB
DM0YWQ4	MN	Bacterial DNA topoisomerase 4A (Bact parC)
DM0YWQ4	MT	DTT
DM0YWQ4	MA	Inhibitor
DM0YWQ4	RN	Clinical pipeline report, company report or official report of Vyome Therapeutics.
DM0YWQ4	RU	https://www.vyometx.com/platform-strategy.html

DM047HI	DI	DM047HI
DM047HI	DN	VBP15
DM047HI	MI	TTOZRK6
DM047HI	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM047HI	MT	DTT
DM047HI	MA	Agonist
DM047HI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM047HI	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMAJ85O	DI	DMAJ85O
DMAJ85O	DN	VDA-1102
DMAJ85O	MI	TTK02H8
DMAJ85O	MN	Hexokinase-2 (HK2)
DMAJ85O	MT	DTT
DMAJ85O	MA	Modulator
DMAJ85O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAJ85O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DME6I03	DI	DME6I03
DME6I03	DN	VDA-1102
DME6I03	MI	TTJLNAW
DME6I03	MN	Tissue kallikrein (KLK2)
DME6I03	MT	DTT
DME6I03	MA	Modulator
DME6I03	RN	Clinical pipeline report, company report or official report of Vidac Pharma.
DME6I03	RU	http://www.vidacpharma.com/vda-1102-iv-vidac-pharma

DME6I03	DI	DME6I03
DME6I03	DN	VDA-1102
DME6I03	MI	TTPZI04
DME6I03	MN	Voltage-dependent anion channel (VDAC)
DME6I03	MT	DTT
DME6I03	MA	Modulator
DME6I03	RN	Clinical pipeline report, company report or official report of Vidac Pharma.
DME6I03	RU	http://www.vidacpharma.com/vda-1102-iv-vidac-pharma

DMAJ85O	DI	DMAJ85O
DMAJ85O	DN	VDA-1102
DMAJ85O	MI	TTAMKGB
DMAJ85O	MN	Voltage-dependent anion-selective channel 1 (VDAC1)
DMAJ85O	MT	DTT
DMAJ85O	MA	Modulator
DMAJ85O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAJ85O	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM5BL4C	DI	DM5BL4C
DM5BL4C	DN	Veltuzumab
DM5BL4C	MI	TTUE541
DM5BL4C	MN	Leukocyte surface antigen Leu-16 (CD20)
DM5BL4C	MT	DTT
DM5BL4C	MA	Modulator
DM5BL4C	RN	Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7.
DM5BL4C	RU	https://pubmed.ncbi.nlm.nih.gov/19330725

DMLPEZS	DI	DMLPEZS
DMLPEZS	DN	Venglustat
DMLPEZS	MI	TTPHEX3
DMLPEZS	MN	Ceramide glucosyltransferase (UGCG)
DMLPEZS	MT	DTT
DMLPEZS	MA	Inhibitor
DMLPEZS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPEZS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFLZPC	DI	DMFLZPC
DMFLZPC	DN	VER 50589
DMFLZPC	MI	TT78R5H
DMFLZPC	MN	Heat shock protein 90 alpha (HSP90A)
DMFLZPC	MT	DTT
DMFLZPC	MA	Inhibitor
DMFLZPC	RN	Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
DMFLZPC	RU	https://pubmed.ncbi.nlm.nih.gov/18855578

DM104SP	DI	DM104SP
DM104SP	DN	Vericigiuat
DM104SP	MI	TTLBYH1
DM104SP	MN	Guanylate cyclase soluble beta-1 (GUCY1B1)
DM104SP	MT	DTT
DM104SP	MA	Modulator
DM104SP	RN	Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38.
DM104SP	RU	https://pubmed.ncbi.nlm.nih.gov/25056511

DMBQC3L	DI	DMBQC3L
DMBQC3L	DN	Verubulin
DMBQC3L	MI	TTYFKSZ
DMBQC3L	MN	Tubulin beta (TUBB)
DMBQC3L	MT	DTT
DMBQC3L	MA	Modulator
DMBQC3L	RN	Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54.
DMBQC3L	RU	https://www.ncbi.nlm.nih.gov/pubmed/24678059

DM0POWG	DI	DM0POWG
DM0POWG	DN	Vidofludimus
DM0POWG	MI	TTLVP78
DM0POWG	MN	Dihydroorotate dehydrogenase (DHODH)
DM0POWG	MT	DTT
DM0POWG	MA	Modulator
DM0POWG	RN	Company report (4SC)
DM0POWG	RU	http://www.4sc.de/product-pipeline/clinical/vidofludimus

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	DE4LYSA
DME7VZD	MN	Cytochrome P450 3A4 (CYP3A4)
DME7VZD	MT	DME
DME7VZD	MA	Metabolism
DME7VZD	RN	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
DME7VZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29330782

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	TTUV8G9
DME7VZD	MN	Progesterone receptor (PGR)
DME7VZD	MT	DTT
DME7VZD	MA	Antagonist
DME7VZD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939)
DME7VZD	RU	http://adisinsight.springer.com/drugs/800033939

DME7VZD	DI	DME7VZD
DME7VZD	DN	Vilaprisan
DME7VZD	MI	DE4G629
DME7VZD	MN	Succinic semialdehyde reductase (AKR7A2)
DME7VZD	MT	DME
DME7VZD	MA	Metabolism
DME7VZD	RN	Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
DME7VZD	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29330782

DM2X0SP	DI	DM2X0SP
DM2X0SP	DN	VIR-2218
DM2X0SP	MI	TTINUYD
DM2X0SP	MN	Hepatitis B virus Large envelope protein (HBV S)
DM2X0SP	MT	DTT
DM2X0SP	MA	Inhibitor
DM2X0SP	RN	Clinical pipeline report, company report or official report of Vir Biotechnology.
DM2X0SP	RU	https://www.vir.bio/pipeline/

DMEXMV5	DI	DMEXMV5
DMEXMV5	DN	Virexxa
DMEXMV5	MI	TTUV8G9
DMEXMV5	MN	Progesterone receptor (PGR)
DMEXMV5	MT	DTT
DMEXMV5	MA	Inducer
DMEXMV5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627).
DMEXMV5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627

DM1G6ME	DI	DM1G6ME
DM1G6ME	DN	VIS410
DM1G6ME	MI	TTF4CAM
DM1G6ME	MN	Influenza Hemagglutinin (Influ HA)
DM1G6ME	MT	DTT
DM1G6ME	MA	Inhibitor
DM1G6ME	RN	Clinical pipeline report, company report or official report of Visterra.
DM1G6ME	RU	http://www.visterrainc.com/#pipeline

DMY5NUR	DI	DMY5NUR
DMY5NUR	DN	VK-2809
DMY5NUR	MI	TTGER3L
DMY5NUR	MN	Thyroid hormone receptor beta (THRB)
DMY5NUR	MT	DTT
DMY5NUR	MA	Agonist
DMY5NUR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY5NUR	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMLT94F	DI	DMLT94F
DMLT94F	DN	VLS-101
DMLT94F	MI	TTDEJAU
DMLT94F	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DMLT94F	MT	DTT
DMLT94F	RN	Clinical pipeline report, company report or official report of VelosBio.
DMLT94F	RU	https://velosbio.com/our-science/pipeline

DM4O17U	DI	DM4O17U
DM4O17U	DN	VLTS-589
DM4O17U	MI	TT69TQN
DM4O17U	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4O17U	MT	DTT
DM4O17U	MA	Modulator
DM4O17U	RN	AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.
DM4O17U	RU	http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1914/html

DM9KNJT	DI	DM9KNJT
DM9KNJT	DN	Vobarilizumab
DM9KNJT	MI	TT0E5SK
DM9KNJT	MN	Interleukin 6 receptor (IL6R)
DM9KNJT	MT	DTT
DM9KNJT	MA	Inhibitor
DM9KNJT	RN	Clinical pipeline report, company report or official report of Ablynx.
DM9KNJT	RU	https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf

DM9KNJT	DI	DM9KNJT
DM9KNJT	DN	Vobarilizumab
DM9KNJT	MI	TTFNGC9
DM9KNJT	MN	Serum albumin (ALB)
DM9KNJT	MT	DTT
DM9KNJT	MA	Inhibitor
DM9KNJT	RN	Clinical pipeline report, company report or official report of Ablynx.
DM9KNJT	RU	https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf

DMQMYP5	DI	DMQMYP5
DMQMYP5	DN	VOFOPITANT HYDROCHLORIDE
DMQMYP5	MI	TTZPO1L
DMQMYP5	MN	Substance-P receptor (TACR1)
DMQMYP5	MT	DTT
DMQMYP5	MA	Antagonist
DMQMYP5	RN	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.
DMQMYP5	RU	https://pubmed.ncbi.nlm.nih.gov/19428297

DMNQG24	DI	DMNQG24
DMNQG24	DN	Volociximab
DMNQG24	MI	TTH4QIS
DMNQG24	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DMNQG24	MT	DTT
DMNQG24	RN	Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
DMNQG24	RU	https://pubmed.ncbi.nlm.nih.gov/17024968

DMIM1U9	DI	DMIM1U9
DMIM1U9	DN	Vorolanib
DMIM1U9	MI	TTI2WET
DMIM1U9	MN	Platelet-derived growth factor receptor (PDGFR)
DMIM1U9	MT	DTT
DMIM1U9	MA	Inhibitor
DMIM1U9	RN	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
DMIM1U9	RU	https://pubmed.ncbi.nlm.nih.gov/33707933

DMIM1U9	DI	DMIM1U9
DMIM1U9	DN	Vorolanib
DMIM1U9	MI	TTVJ1D8
DMIM1U9	MN	Vascular endothelial growth factor receptor (VEGFR)
DMIM1U9	MT	DTT
DMIM1U9	MA	Inhibitor
DMIM1U9	RN	Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
DMIM1U9	RU	https://pubmed.ncbi.nlm.nih.gov/33707933

DMW4LTI	DI	DMW4LTI
DMW4LTI	DN	Votucalis
DMW4LTI	MI	TT7CXIM
DMW4LTI	MN	Histamine receptor (HR)
DMW4LTI	MT	DTT
DMW4LTI	MA	Antagonist
DMW4LTI	RN	CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
DMW4LTI	RU	http://www.google.com.ar/patents/CA2520580A1?cl=en

DMUQZT4	DI	DMUQZT4
DMUQZT4	DN	VPI-2690B
DMUQZT4	MI	TTHRID2
DMUQZT4	MN	Insulin-like growth factor I receptor (IGF1R)
DMUQZT4	MT	DTT
DMUQZT4	MA	Antagonist
DMUQZT4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUQZT4	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMHET8R	DI	DMHET8R
DMHET8R	DN	VRC-HIVDNA016-00-VP
DMHET8R	MI	TTUIFO6
DMHET8R	MN	Human immunodeficiency virus Adenovector Ad35 (HIV Ad35)
DMHET8R	MT	DTT
DMHET8R	RN	ClinicalTrials.gov (NCT00123968) Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults. U.S. National Institutes of Health.
DMHET8R	RU	https://clinicaltrials.gov/ct2/show/NCT00123968

DMGBLI3	DI	DMGBLI3
DMGBLI3	DN	VS-6063
DMGBLI3	MI	TTON5IT
DMGBLI3	MN	Focal adhesion kinase 1 (FAK)
DMGBLI3	MT	DTT
DMGBLI3	MA	Inhibitor
DMGBLI3	RN	Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
DMGBLI3	RU	https://pubmed.ncbi.nlm.nih.gov/24062525

DMY9ZGN	DI	DMY9ZGN
DMY9ZGN	DN	VT-111a
DMY9ZGN	MI	TTEMV5X
DMY9ZGN	MN	Serine protease unspecific (SP)
DMY9ZGN	MT	DTT
DMY9ZGN	MA	Modulator
DMY9ZGN	RN	Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329.
DMY9ZGN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558843/

DMCGK9H	DI	DMCGK9H
DMCGK9H	DN	VT-1129
DMCGK9H	MI	TT3C1VN
DMCGK9H	MN	Enzyme unspecific (Enz)
DMCGK9H	MT	DTT
DMCGK9H	MA	Inhibitor
DMCGK9H	RN	The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7.
DMCGK9H	RU	https://pubmed.ncbi.nlm.nih.gov/25224009

DMCGK9H	DI	DMCGK9H
DMCGK9H	DN	VT-1129
DMCGK9H	MI	TT67TDP
DMCGK9H	MN	Lanosterol 14-alpha demethylase (CYP51A1)
DMCGK9H	MT	DTT
DMCGK9H	MA	Inhibitor
DMCGK9H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCGK9H	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMNY3J0	DI	DMNY3J0
DMNY3J0	DN	VTB-38543
DMNY3J0	MI	TTXA6PH
DMNY3J0	MN	Oxysterols receptor LXR-beta (NR1H2)
DMNY3J0	MT	DTT
DMNY3J0	MA	Agonist
DMNY3J0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNY3J0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMCA8G1	DI	DMCA8G1
DMCA8G1	DN	VTP-43742
DMCA8G1	MI	TTGV6LY
DMCA8G1	MN	Nuclear receptor ROR-gamma (RORG)
DMCA8G1	MT	DTT
DMCA8G1	MA	Inhibitor
DMCA8G1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCA8G1	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMN6J18	DI	DMN6J18
DMN6J18	DN	Vupanorsen
DMN6J18	MI	TT59GO7
DMN6J18	MN	ANGPTL3 messenger RNA (ANGPTL3 mRNA)
DMN6J18	MT	DTT
DMN6J18	MA	Inhibitor
DMN6J18	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMN6J18	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DM6BKG2	DI	DM6BKG2
DM6BKG2	DN	VVP-808
DM6BKG2	MI	TTCBFJO
DM6BKG2	MN	Insulin receptor (INSR)
DM6BKG2	MT	DTT
DM6BKG2	MA	Modulator
DM6BKG2	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DM6BKG2	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMDKWA3	DI	DMDKWA3
DMDKWA3	DN	Vx-001
DMDKWA3	MI	TTUJFD0
DMDKWA3	MN	Telomerase reverse transcriptase (TERT)
DMDKWA3	MT	DTT
DMDKWA3	RN	Clinical pipeline report, company report or official report of Vaxon-biotech.
DMDKWA3	RU	http://vaxon-biotech.com/

DMZ3FE8	DI	DMZ3FE8
DMZ3FE8	DN	VX-135
DMZ3FE8	MI	TTMVBWH
DMZ3FE8	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMZ3FE8	MT	DTT
DMZ3FE8	MA	Inhibitor
DMZ3FE8	RN	All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. 
DMZ3FE8	RU	https://pubmed.ncbi.nlm.nih.gov/23722330

DMLWM4G	DI	DMLWM4G
DMLWM4G	DN	VX-15
DMLWM4G	MI	TT5TKPM
DMLWM4G	MN	Neutral endopeptidase (MME)
DMLWM4G	MT	DTT
DMLWM4G	MA	Inhibitor
DMLWM4G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLWM4G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLWM4G	DI	DMLWM4G
DMLWM4G	DN	VX-15
DMLWM4G	MI	TT5UT28
DMLWM4G	MN	Semaphorin-4D (SEMA4D)
DMLWM4G	MT	DTT
DMLWM4G	RN	Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36.
DMLWM4G	RU	https://pubmed.ncbi.nlm.nih.gov/26446947

DMGDB21	DI	DMGDB21
DMGDB21	DN	VX-150
DMGDB21	MI	TT90XZ8
DMGDB21	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DMGDB21	MT	DTT
DMGDB21	MA	Inhibitor
DMGDB21	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGDB21	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMO3U4W	DI	DMO3U4W
DMO3U4W	DN	VX-222
DMO3U4W	MI	TTMVBWH
DMO3U4W	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMO3U4W	MT	DTT
DMO3U4W	MA	Inhibitor
DMO3U4W	RN	2011 Pipeline of Vertex.
DMO3U4W	RU	http://www.vrtx.com/current-projects.html

DMSTHG1	DI	DMSTHG1
DMSTHG1	DN	VX-371
DMSTHG1	MI	TTQM7TE
DMSTHG1	MN	Amiloride-sensitive sodium channel (ENaC)
DMSTHG1	MT	DTT
DMSTHG1	MA	Inhibitor
DMSTHG1	RN	The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.
DMSTHG1	RU	https://pubmed.ncbi.nlm.nih.gov/29599187

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TTPS3C0
DM93YKJ	MN	Aurora kinase A (AURKA)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TT5LS6T
DM93YKJ	MN	Aurora kinase B (AURKB)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM93YKJ	DI	DM93YKJ
DM93YKJ	DN	VX-680
DM93YKJ	MI	TT860QF
DM93YKJ	MN	LCK tyrosine protein kinase (LCK)
DM93YKJ	MT	DTT
DM93YKJ	MA	Inhibitor
DM93YKJ	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DM93YKJ	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TTYT93M
DMJAEG6	MN	MAP kinase p38 (MAPK12)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/19055838

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TTQBR95
DMJAEG6	MN	Stress-activated protein kinase 2a (p38 alpha)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMJAEG6	DI	DMJAEG6
DMJAEG6	DN	VX-745
DMJAEG6	MI	TT73U6C
DMJAEG6	MN	Stress-activated protein kinase 2b (p38 beta)
DMJAEG6	MT	DTT
DMJAEG6	MA	Inhibitor
DMJAEG6	RN	Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
DMJAEG6	RU	https://pubmed.ncbi.nlm.nih.gov/11804650

DMJUSM8	DI	DMJUSM8
DMJUSM8	DN	VX-759
DMJUSM8	MI	TTMVBWH
DMJUSM8	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMJUSM8	MT	DTT
DMJUSM8	MA	Inhibitor
DMJUSM8	RN	2011 Pipeline of Vertex.
DMJUSM8	RU	http://www.vrtx.com/current-projects.html

DME321B	DI	DME321B
DME321B	DN	VX-944
DME321B	MI	TTCAQMW
DME321B	MN	Inosine-5'-monophosphate dehydrogenase (IMPDH)
DME321B	MT	DTT
DME321B	MA	Inhibitor
DME321B	RN	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96.
DME321B	RU	https://pubmed.ncbi.nlm.nih.gov/15940263

DME321B	DI	DME321B
DME321B	DN	VX-944
DME321B	MI	TTL7C8Q
DME321B	MN	Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)
DME321B	MT	DTT
DME321B	MA	Inhibitor
DME321B	RN	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
DME321B	RU	https://www.ncbi.nlm.nih.gov/pubmed/28074661

DMPSBTL	DI	DMPSBTL
DMPSBTL	DN	VY-AADC
DMPSBTL	MI	TTN451K
DMPSBTL	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMPSBTL	MT	DTT
DMPSBTL	MA	Replacement
DMPSBTL	RN	Clinical pipeline report, company report or official report of Voyager Therapeutics.
DMPSBTL	RU	https://www.voyagertherapeutics.com/our-approach-programs/clinical-trials/

DMH6XJG	DI	DMH6XJG
DMH6XJG	DN	WCK-2349
DMH6XJG	MI	TTIXTO3
DMH6XJG	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMH6XJG	MT	DTT
DMH6XJG	MA	Modulator
DMH6XJG	RN	DOI: 10.1038/ja.2013.86
DMH6XJG	RU	http://www.nature.com/ja/journal/v66/n10/fig_tab/ja201386t3.html

DMVQARP	DI	DMVQARP
DMVQARP	DN	WCK-771
DMVQARP	MI	TTN6J5F
DMVQARP	MN	Bacterial DNA gyrase (Bact gyrase)
DMVQARP	MT	DTT
DMVQARP	MA	Modulator
DMVQARP	RN	Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
DMVQARP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196

DMVQARP	DI	DMVQARP
DMVQARP	DN	WCK-771
DMVQARP	MI	TTIXTO3
DMVQARP	MN	Staphylococcus Topoisomerase IV (Stap-coc parC)
DMVQARP	MT	DTT
DMVQARP	MA	Modulator
DMVQARP	RN	Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
DMVQARP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196

DMZ67Q0	DI	DMZ67Q0
DMZ67Q0	DN	WT1 peptide vaccine
DMZ67Q0	MI	TTZ8UT4
DMZ67Q0	MN	Wilms tumor protein (WT1)
DMZ67Q0	MT	DTT
DMZ67Q0	RN	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22.
DMZ67Q0	RU	https://pubmed.ncbi.nlm.nih.gov/21898091

DMNFZYE	DI	DMNFZYE
DMNFZYE	DN	WT1-targeted autologous dendritic cell vaccine
DMNFZYE	MI	TTZ8UT4
DMNFZYE	MN	Wilms tumor protein (WT1)
DMNFZYE	MT	DTT
DMNFZYE	RN	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
DMNFZYE	RU	https://clinicaltrials.gov/ct2/show/NCT01686334

DMFVNSB	DI	DMFVNSB
DMFVNSB	DN	WY-50295-tromethamine
DMFVNSB	MI	TT2J34L
DMFVNSB	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMFVNSB	MT	DTT
DMFVNSB	MA	Inhibitor
DMFVNSB	RN	WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41.
DMFVNSB	RU	https://pubmed.ncbi.nlm.nih.gov/10319915

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TTI2WET
DMW1NKO	MN	Platelet-derived growth factor receptor (PDGFR)
DMW1NKO	MT	DTT
DMW1NKO	MA	Modulator
DMW1NKO	RN	National Cancer Institute Drug Dictionary (drug id 695817).
DMW1NKO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TTVJ1D8
DMW1NKO	MN	Vascular endothelial growth factor receptor (VEGFR)
DMW1NKO	MT	DTT
DMW1NKO	MA	Inhibitor
DMW1NKO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW1NKO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW1NKO	DI	DMW1NKO
DMW1NKO	DN	X-82
DMW1NKO	MI	TT2Q6G1
DMW1NKO	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMW1NKO	MT	DTT
DMW1NKO	MA	Modulator
DMW1NKO	RN	National Cancer Institute Drug Dictionary (drug id 695817).
DMW1NKO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817

DMXG5WU	DI	DMXG5WU
DMXG5WU	DN	Xanomeline tartrate
DMXG5WU	MI	TTZ9SOR
DMXG5WU	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMXG5WU	MT	DTT
DMXG5WU	MA	Agonist
DMXG5WU	RN	Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6.
DMXG5WU	RU	https://pubmed.ncbi.nlm.nih.gov/19168056

DM0NFMS	DI	DM0NFMS
DM0NFMS	DN	XEN-2174
DM0NFMS	MI	TTAWNKZ
DM0NFMS	MN	Norepinephrine transporter (NET)
DM0NFMS	MT	DTT
DM0NFMS	MA	Inhibitor
DM0NFMS	RN	Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
DM0NFMS	RU	https://pubmed.ncbi.nlm.nih.gov/15661433

DMR69CG	DI	DMR69CG
DMR69CG	DN	XEN-402
DMR69CG	MI	TT4G2JS
DMR69CG	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMR69CG	MT	DTT
DMR69CG	MA	Inhibitor
DMR69CG	RN	Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
DMR69CG	RU	https://pubmed.ncbi.nlm.nih.gov/22035805

DMG7PDY	DI	DMG7PDY
DMG7PDY	DN	XEN-D0501
DMG7PDY	MI	TTMI6F5
DMG7PDY	MN	Transient receptor potential cation channel V1 (TRPV1)
DMG7PDY	MT	DTT
DMG7PDY	MA	Antagonist
DMG7PDY	RN	An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31.
DMG7PDY	RU	https://pubmed.ncbi.nlm.nih.gov/21676011

DM4ZIDH	DI	DM4ZIDH
DM4ZIDH	DN	Xentuzumab
DM4ZIDH	MI	TTT6LOU
DM4ZIDH	MN	Insulin-like growth factor-I (IGF1)
DM4ZIDH	MT	DTT
DM4ZIDH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZIDH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM4ZIDH	DI	DM4ZIDH
DM4ZIDH	DN	Xentuzumab
DM4ZIDH	MI	TTE8WGO
DM4ZIDH	MN	Insulin-like growth factor-II (IGF2)
DM4ZIDH	MT	DTT
DM4ZIDH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZIDH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMML7BE	DI	DMML7BE
DMML7BE	DN	Xl147
DMML7BE	MI	DEAWHS8
DMML7BE	MN	Aldehyde oxidase (AOX1)
DMML7BE	MT	DME
DMML7BE	MA	Metabolism
DMML7BE	RN	Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 2012 Feb;40(2):267-75.
DMML7BE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22031625

DMML7BE	DI	DMML7BE
DMML7BE	DN	Xl147
DMML7BE	MI	TTHBTOP
DMML7BE	MN	PI3-kinase gamma (PIK3CG)
DMML7BE	MT	DTT
DMML7BE	MA	Modulator
DMML7BE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156).
DMML7BE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TT8FYO9
DMMHX9K	MN	Platelet-derived growth factor receptor alpha (PDGFRA)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTI7421
DMMHX9K	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTX41N9
DMMHX9K	MN	Tyrosine-protein kinase Kit (KIT)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMMHX9K	DI	DMMHX9K
DMMHX9K	DN	XL-820
DMMHX9K	MI	TTVJ1D8
DMMHX9K	MN	Vascular endothelial growth factor receptor (VEGFR)
DMMHX9K	MT	DTT
DMMHX9K	MA	Inhibitor
DMMHX9K	RN	National Cancer Institute Drug Dictionary (drug id 452042).
DMMHX9K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042

DMHJTR2	DI	DMHJTR2
DMHJTR2	DN	XL880
DMHJTR2	MI	TTNDSF4
DMHJTR2	MN	Proto-oncogene c-Met (MET)
DMHJTR2	MT	DTT
DMHJTR2	MA	Modulator
DMHJTR2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHJTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHJTR2	DI	DMHJTR2
DMHJTR2	DN	XL880
DMHJTR2	MI	TTUTJGQ
DMHJTR2	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMHJTR2	MT	DTT
DMHJTR2	MA	Modulator
DMHJTR2	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMHJTR2	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVB8EO	DI	DMVB8EO
DMVB8EO	DN	XLCART001
DMVB8EO	MI	TTW640A
DMVB8EO	MN	B-lymphocyte surface antigen B4 (CD19)
DMVB8EO	MT	DTT
DMVB8EO	MA	CAR-T-Cell-Therapy
DMVB8EO	RN	ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
DMVB8EO	RU	https://clinicaltrials.gov/ct2/show/NCT03598179

DMLIPY1	DI	DMLIPY1
DMLIPY1	DN	Xmab 5871
DMLIPY1	MI	TTW640A
DMLIPY1	MN	B-lymphocyte surface antigen B4 (CD19)
DMLIPY1	MT	DTT
DMLIPY1	MA	Modulator
DMLIPY1	RN	Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64.
DMLIPY1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24782179

DMLIPY1	DI	DMLIPY1
DMLIPY1	DN	Xmab 5871
DMLIPY1	MI	TT5RWKQ
DMLIPY1	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMLIPY1	MT	DTT
DMLIPY1	MA	Modulator
DMLIPY1	RN	CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
DMLIPY1	RU	https://pubmed.ncbi.nlm.nih.gov/22820352

DMWEB07	DI	DMWEB07
DMWEB07	DN	XOMA-629
DMWEB07	MI	TTXCSDR
DMWEB07	MN	Protein bactericidal permeability-increasing (BPI)
DMWEB07	MT	DTT
DMWEB07	MA	Inhibitor
DMWEB07	RN	Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54.
DMWEB07	RU	https://pubmed.ncbi.nlm.nih.gov/22421877

DM8N3ZQ	DI	DM8N3ZQ
DM8N3ZQ	DN	XP-21279
DM8N3ZQ	MI	TTEX248
DM8N3ZQ	MN	Dopamine D2 receptor (D2R)
DM8N3ZQ	MT	DTT
DM8N3ZQ	MA	Agonist
DM8N3ZQ	RN	Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82.
DM8N3ZQ	RU	https://pubmed.ncbi.nlm.nih.gov/24339234

DMELUYN	DI	DMELUYN
DMELUYN	DN	XP-23829
DMELUYN	MI	TTSXVID
DMELUYN	MN	Nuclear factor NF-kappa-B (NFKB)
DMELUYN	MT	DTT
DMELUYN	MA	Inhibitor
DMELUYN	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491)
DMELUYN	RU	http://adisinsight.springer.com/drugs/800036491

DMOKUA5	DI	DMOKUA5
DMOKUA5	DN	XR-5000
DMOKUA5	MI	TTGTQHC
DMOKUA5	MN	DNA topoisomerase I (TOP1)
DMOKUA5	MT	DTT
DMOKUA5	MA	Modulator
DMOKUA5	RN	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
DMOKUA5	RU	https://pubmed.ncbi.nlm.nih.gov/12075748

DMOKUA5	DI	DMOKUA5
DMOKUA5	DN	XR-5000
DMOKUA5	MI	TT0IHXV
DMOKUA5	MN	DNA topoisomerase II (TOP2)
DMOKUA5	MT	DTT
DMOKUA5	MA	Modulator
DMOKUA5	RN	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
DMOKUA5	RU	https://pubmed.ncbi.nlm.nih.gov/12075748

DMPI6N0	DI	DMPI6N0
DMPI6N0	DN	XZK-monascus
DMPI6N0	MI	TTPADOQ
DMPI6N0	MN	HMG-CoA reductase (HMGCR)
DMPI6N0	MT	DTT
DMPI6N0	MA	Modulator
DMPI6N0	RN	NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med. 2012 Mar 22;7:8.
DMPI6N0	RU	https://pubmed.ncbi.nlm.nih.gov/22439629

DM54MAJ	DI	DM54MAJ
DM54MAJ	DN	YF-476
DM54MAJ	MI	TTVFO0U
DM54MAJ	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM54MAJ	MT	DTT
DM54MAJ	MA	Inhibitor
DM54MAJ	RN	CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90.
DM54MAJ	RU	https://pubmed.ncbi.nlm.nih.gov/15513388

DMCHFB0	DI	DMCHFB0
DMCHFB0	DN	YH-4808
DMCHFB0	MI	TTLOKXP
DMCHFB0	MN	Gastric H(+)/K(+) ATPase (Proton pump)
DMCHFB0	MT	DTT
DMCHFB0	MA	Modulator
DMCHFB0	RN	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
DMCHFB0	RU	https://www.ncbi.nlm.nih.gov/pubmed/22783985

DM740LV	DI	DM740LV
DM740LV	DN	YKP-GI
DM740LV	MI	TT07C3Y
DM740LV	MN	5-HT 4 receptor (HTR4)
DM740LV	MT	DTT
DM740LV	MA	Agonist
DM740LV	RN	A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
DM740LV	RU	https://pubmed.ncbi.nlm.nih.gov/25148765

DM5Q1W4	DI	DM5Q1W4
DM5Q1W4	DN	Ym155
DM5Q1W4	MI	DTT79CX
DM5Q1W4	MN	Organic cation transporter 1 (SLC22A1)
DM5Q1W4	MT	DTP
DM5Q1W4	MA	Substrate
DM5Q1W4	RN	Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
DM5Q1W4	RU	http://www.ncbi.nlm.nih.gov/pubmed/19833842

DM5Q1W4	DI	DM5Q1W4
DM5Q1W4	DN	Ym155
DM5Q1W4	MI	DT9IDPW
DM5Q1W4	MN	Organic cation transporter 2 (SLC22A2)
DM5Q1W4	MT	DTP
DM5Q1W4	MA	Substrate
DM5Q1W4	RN	Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
DM5Q1W4	RU	http://www.ncbi.nlm.nih.gov/pubmed/19833842

DMAZNVX	DI	DMAZNVX
DMAZNVX	DN	YM-264
DMAZNVX	MI	TTQL5VC
DMAZNVX	MN	Platelet-activating factor receptor (PTAFR)
DMAZNVX	MT	DTT
DMAZNVX	MA	Antagonist
DMAZNVX	RN	Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
DMAZNVX	RU	https://pubmed.ncbi.nlm.nih.gov/2025290

DMS7609	DI	DMS7609
DMS7609	DN	YM-358
DMS7609	MI	TT8DBY3
DMS7609	MN	Angiotensin II receptor type-1 (AGTR1)
DMS7609	MT	DTT
DMS7609	MA	Antagonist
DMS7609	RN	Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81.
DMS7609	RU	https://pubmed.ncbi.nlm.nih.gov/10706380

DMKJF6H	DI	DMKJF6H
DMKJF6H	DN	YM-430
DMKJF6H	MI	TTMXGCW
DMKJF6H	MN	Adrenergic receptor beta-3 (ADRB3)
DMKJF6H	MT	DTT
DMKJF6H	MA	Modulator
DMKJF6H	RN	Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6.
DMKJF6H	RU	https://pubmed.ncbi.nlm.nih.gov/9084878

DMRZBPI	DI	DMRZBPI
DMRZBPI	DN	YM-543
DMRZBPI	MI	TTLWPVF
DMRZBPI	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMRZBPI	MT	DTT
DMRZBPI	MA	Modulator
DMRZBPI	RN	Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.
DMRZBPI	RU	https://www.ncbi.nlm.nih.gov/pubmed/23374077

DMUPJWH	DI	DMUPJWH
DMUPJWH	DN	YM-598
DMUPJWH	MI	TTKRD0G
DMUPJWH	MN	Endothelin A receptor (EDNRA)
DMUPJWH	MT	DTT
DMUPJWH	MA	Antagonist
DMUPJWH	RN	Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233.
DMUPJWH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087127/

DMU79X2	DI	DMU79X2
DMU79X2	DN	Ym-758
DMU79X2	MI	DT3D8F0
DMU79X2	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DMU79X2	MT	DTP
DMU79X2	MA	Substrate
DMU79X2	RN	Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
DMU79X2	RU	http://www.ncbi.nlm.nih.gov/pubmed/21245207

DM7KR4C	DI	DM7KR4C
DM7KR4C	DN	YM-934
DM7KR4C	MI	TT1VOHK
DM7KR4C	MN	Potassium channel unspecific (KC)
DM7KR4C	MT	DTT
DM7KR4C	MA	Blocker
DM7KR4C	RN	Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83.
DM7KR4C	RU	https://pubmed.ncbi.nlm.nih.gov/7524979

DM0K8U7	DI	DM0K8U7
DM0K8U7	DN	YSIL6
DM0K8U7	MI	TTT1V78
DM0K8U7	MN	Interleukin-6 (IL6)
DM0K8U7	MT	DTT
DM0K8U7	MA	Inhibitor
DM0K8U7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380)
DM0K8U7	RU	http://adisinsight.springer.com/drugs/800020380

DM3YVKQ	DI	DM3YVKQ
DM3YVKQ	DN	YT-146
DM3YVKQ	MI	TTNE7KG
DM3YVKQ	MN	Adenosine A2b receptor (ADORA2B)
DM3YVKQ	MT	DTT
DM3YVKQ	MA	Agonist
DM3YVKQ	RN	Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10.
DM3YVKQ	RU	https://pubmed.ncbi.nlm.nih.gov/8135838

DM2M80G	DI	DM2M80G
DM2M80G	DN	Z 360
DM2M80G	MI	TTVFO0U
DM2M80G	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DM2M80G	MT	DTT
DM2M80G	MA	Modulator
DM2M80G	RN	Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22.
DM2M80G	RU	https://www.ncbi.nlm.nih.gov/pubmed/20118543

DMUT9OE	DI	DMUT9OE
DMUT9OE	DN	Zadaxin/lamivudine
DMUT9OE	MI	TTSYFMA
DMUT9OE	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DMUT9OE	MT	DTT
DMUT9OE	MA	Modulator
DMUT9OE	RN	Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7.
DMUT9OE	RU	https://pubmed.ncbi.nlm.nih.gov/15992078

DMUT9OE	DI	DMUT9OE
DMUT9OE	DN	Zadaxin/lamivudine
DMUT9OE	MI	TTSHG0T
DMUT9OE	MN	Toll-like receptor 9 (TLR9)
DMUT9OE	MT	DTT
DMUT9OE	MA	Modulator
DMUT9OE	RN	Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7.
DMUT9OE	RU	https://pubmed.ncbi.nlm.nih.gov/15992078

DMJN3BA	DI	DMJN3BA
DMJN3BA	DN	Zalospirone
DMJN3BA	MI	TTSQIFT
DMJN3BA	MN	5-HT 1A receptor (HTR1A)
DMJN3BA	MT	DTT
DMJN3BA	MA	Agonist
DMJN3BA	RN	The serotonin 5-HT receptor agonist tandospirone improves executive function in common marmosets. Behav Brain Res. 2015 Jul 1;287:120-6.
DMJN3BA	RU	https://pubmed.ncbi.nlm.nih.gov/25804359

DMTYD8Q	DI	DMTYD8Q
DMTYD8Q	DN	ZD2079
DMTYD8Q	MI	TTMXGCW
DMTYD8Q	MN	Adrenergic receptor beta-3 (ADRB3)
DMTYD8Q	MT	DTT
DMTYD8Q	MA	Agonist
DMTYD8Q	RN	Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70.
DMTYD8Q	RU	https://pubmed.ncbi.nlm.nih.gov/10207980

DMH85M0	DI	DMH85M0
DMH85M0	DN	ZD-6126
DMH85M0	MI	TTYFKSZ
DMH85M0	MN	Tubulin beta (TUBB)
DMH85M0	MT	DTT
DMH85M0	MA	Inhibitor
DMH85M0	RN	Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67.
DMH85M0	RU	https://pubmed.ncbi.nlm.nih.gov/18219445

DMPE2B9	DI	DMPE2B9
DMPE2B9	DN	ZD-7288
DMPE2B9	MI	TTKLW9S
DMPE2B9	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DMPE2B9	MT	DTT
DMPE2B9	MA	Modulator
DMPE2B9	RN	ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats. World J Gastroenterol. 2014 Feb 28;20(8):2091-7.
DMPE2B9	RU	https://pubmed.ncbi.nlm.nih.gov/24587682

DM6VQTF	DI	DM6VQTF
DM6VQTF	DN	ZEN-3694
DM6VQTF	MI	TTE4BSY
DM6VQTF	MN	Bromodomain and extraterminal domain protein (BET)
DM6VQTF	MT	DTT
DM6VQTF	MA	Inhibitor
DM6VQTF	RN	Clinical pipeline report, company report or official report of Zenith Epigenetics.
DM6VQTF	RU	https://www.zenithepigenetics.com/programs/pipeline

DM9KB7A	DI	DM9KB7A
DM9KB7A	DN	ZGN-1061
DM9KB7A	MI	TTZL0OI
DM9KB7A	MN	Methionine aminopeptidase 2 (METAP2)
DM9KB7A	MT	DTT
DM9KB7A	MA	Inhibitor
DM9KB7A	RN	The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
DM9KB7A	RU	https://pubmed.ncbi.nlm.nih.gov/32077231

DMJ94L0	DI	DMJ94L0
DMJ94L0	DN	ZK-91587
DMJ94L0	MI	TT26PHO
DMJ94L0	MN	Mineralocorticoid receptor  (MR)
DMJ94L0	MT	DTT
DMJ94L0	MA	Antagonist
DMJ94L0	RN	ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
DMJ94L0	RU	https://pubmed.ncbi.nlm.nih.gov/3193846

DM4MSLY	DI	DM4MSLY
DM4MSLY	DN	ZN-c3
DM4MSLY	MI	TTJFOAL
DM4MSLY	MN	Wee1-like protein kinase (WEE1)
DM4MSLY	MT	DTT
DM4MSLY	MA	Inhibitor
DM4MSLY	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DM4MSLY	RU	https://zentalis.com/our-pipeline/pipeline/

DMG7YI9	DI	DMG7YI9
DMG7YI9	DN	ZYH7
DMG7YI9	MI	TTJ584C
DMG7YI9	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMG7YI9	MT	DTT
DMG7YI9	MA	Agonist
DMG7YI9	RN	Clinical pipeline report, company report or official report of Zydus Cadila.
DMG7YI9	RU	https://zyduscadila.com/public/pdf/investorpresentation/Investor_Presentation_February_2020.pdf

DMTXBUV	DI	DMTXBUV
DMTXBUV	DN	BT1718
DMTXBUV	MI	TTJ4QE7
DMTXBUV	MN	Matrix metalloproteinase-14 (MMP-14)
DMTXBUV	MT	DTT
DMTXBUV	MA	Inhibitor
DMTXBUV	RN	ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
DMTXBUV	RU	https://clinicaltrials.gov/ct2/show/NCT03486730

DM824EG	DI	DM824EG
DM824EG	DN	COVA322
DM824EG	MI	TTG0MT6
DM824EG	MN	Interleukin-17 (IL17)
DM824EG	MT	DTT
DM824EG	MA	Modulator
DM824EG	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM824EG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM824EG	DI	DM824EG
DM824EG	DN	COVA322
DM824EG	MI	TTF8CQI
DM824EG	MN	Tumor necrosis factor (TNF)
DM824EG	MT	DTT
DM824EG	MA	Modulator
DM824EG	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM824EG	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMJ1NG4	DI	DMJ1NG4
DMJ1NG4	DN	Dalazatide
DMJ1NG4	MI	TTY3UE6
DMJ1NG4	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMJ1NG4	MT	DTT
DMJ1NG4	MA	Inhibitor
DMJ1NG4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ1NG4	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMV401D	DI	DMV401D
DMV401D	DN	Debio-0824
DMV401D	MI	TTY3UE6
DMV401D	MN	Voltage-gated potassium channel Kv1.3 (KCNA3)
DMV401D	MT	DTT
DMV401D	MA	Inhibitor
DMV401D	RN	Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
DMV401D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422530/

DMT17XU	DI	DMT17XU
DMT17XU	DN	131I-radretumab
DMT17XU	MI	TTBVIQC
DMT17XU	MN	Integrin beta-1 (ITGB1)
DMT17XU	MT	DTT
DMT17XU	RN	Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
DMT17XU	RU	https://pubmed.ncbi.nlm.nih.gov/24777501

DMVZ9XL	DI	DMVZ9XL
DMVZ9XL	DN	177Lu-labelled DOTA-JR11
DMVZ9XL	MI	TTOMNR9
DMVZ9XL	MN	Somatostatin receptor (SSTR)
DMVZ9XL	MT	DTT
DMVZ9XL	RN	Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
DMVZ9XL	RU	https://pubmed.ncbi.nlm.nih.gov/32859703

DMWPD7N	DI	DMWPD7N
DMWPD7N	DN	177Lu-labelled PSMA-R2
DMWPD7N	MI	TT9G4N0
DMWPD7N	MN	Glutamate carboxypeptidase II (GCPII)
DMWPD7N	MT	DTT
DMWPD7N	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMWPD7N	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM6JLNT	DI	DM6JLNT
DM6JLNT	DN	177-Lu-NeoB
DM6JLNT	MI	TTC1MVT
DM6JLNT	MN	Gastrin-releasing peptide receptor (GRPR)
DM6JLNT	MT	DTT
DM6JLNT	MA	Antagonist
DM6JLNT	RN	68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299.
DM6JLNT	RU	https://pubmed.ncbi.nlm.nih.gov/27609789

DMF4AOE	DI	DMF4AOE
DMF4AOE	DN	177-Lu-PSMA-R2
DMF4AOE	MI	TT9G4N0
DMF4AOE	MN	Glutamate carboxypeptidase II (GCPII)
DMF4AOE	MT	DTT
DMF4AOE	MA	Agonist
DMF4AOE	RN	National Cancer Institute Drug Dictionary (drug name Lu-177-PSMA-R2).
DMF4AOE	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-psma-r2

DMCLKA4	DI	DMCLKA4
DMCLKA4	DN	2-hydroxyoleic acid
DMCLKA4	MI	TTBOE28
DMCLKA4	MN	Sphingomyelin synthase (SMS)
DMCLKA4	MT	DTT
DMCLKA4	MA	Modulator
DMCLKA4	RN	Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19569-74.
DMCLKA4	RU	https://pubmed.ncbi.nlm.nih.gov/22106271

DMYPQT4	DI	DMYPQT4
DMYPQT4	DN	4SCAR19 and 4SCAR123
DMYPQT4	MI	TTW640A
DMYPQT4	MN	B-lymphocyte surface antigen B4 (CD19)
DMYPQT4	MT	DTT
DMYPQT4	MA	CAR-T-Cell-Therapy(Dual specific)
DMYPQT4	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMYPQT4	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMYPQT4	DI	DMYPQT4
DMYPQT4	DN	4SCAR19 and 4SCAR123
DMYPQT4	MI	TTENHJ0
DMYPQT4	MN	Interleukin 3 receptor alpha (IL3RA)
DMYPQT4	MT	DTT
DMYPQT4	MA	CAR-T-Cell-Therapy(Dual specific)
DMYPQT4	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMYPQT4	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMFVTSG	DI	DMFVTSG
DMFVTSG	DN	4SCAR19 and 4SCAR20
DMFVTSG	MI	TTW640A
DMFVTSG	MN	B-lymphocyte surface antigen B4 (CD19)
DMFVTSG	MT	DTT
DMFVTSG	MA	CAR-T-Cell-Therapy(Dual specific)
DMFVTSG	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMFVTSG	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMFVTSG	DI	DMFVTSG
DMFVTSG	DN	4SCAR19 and 4SCAR20
DMFVTSG	MI	TTUE541
DMFVTSG	MN	Leukocyte surface antigen Leu-16 (CD20)
DMFVTSG	MT	DTT
DMFVTSG	MA	CAR-T-Cell-Therapy(Dual specific)
DMFVTSG	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMFVTSG	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DM8CMUW	DI	DM8CMUW
DM8CMUW	DN	4SCAR19 and 4SCAR22
DM8CMUW	MI	TTM6QSK
DM8CMUW	MN	B-cell receptor CD22 (CD22)
DM8CMUW	MT	DTT
DM8CMUW	MA	CAR-T-Cell-Therapy(Dual specific)
DM8CMUW	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DM8CMUW	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DM8CMUW	DI	DM8CMUW
DM8CMUW	DN	4SCAR19 and 4SCAR22
DM8CMUW	MI	TTW640A
DM8CMUW	MN	B-lymphocyte surface antigen B4 (CD19)
DM8CMUW	MT	DTT
DM8CMUW	MA	CAR-T-Cell-Therapy(Dual specific)
DM8CMUW	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DM8CMUW	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMUYFS1	DI	DMUYFS1
DMUYFS1	DN	4SCAR19 and 4SCAR30
DMUYFS1	MI	TTW640A
DMUYFS1	MN	B-lymphocyte surface antigen B4 (CD19)
DMUYFS1	MT	DTT
DMUYFS1	MA	CAR-T-Cell-Therapy(Dual specific)
DMUYFS1	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMUYFS1	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMUYFS1	DI	DMUYFS1
DMUYFS1	DN	4SCAR19 and 4SCAR30
DMUYFS1	MI	TT2GM5R
DMUYFS1	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMUYFS1	MT	DTT
DMUYFS1	MA	CAR-T-Cell-Therapy(Dual specific)
DMUYFS1	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMUYFS1	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMZKFU7	DI	DMZKFU7
DMZKFU7	DN	4SCAR19 and 4SCAR38
DMZKFU7	MI	TTW640A
DMZKFU7	MN	B-lymphocyte surface antigen B4 (CD19)
DMZKFU7	MT	DTT
DMZKFU7	MA	CAR-T-Cell-Therapy(Dual specific)
DMZKFU7	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMZKFU7	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMZKFU7	DI	DMZKFU7
DMZKFU7	DN	4SCAR19 and 4SCAR38
DMZKFU7	MI	TTPURFN
DMZKFU7	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMZKFU7	MT	DTT
DMZKFU7	MA	CAR-T-Cell-Therapy(Dual specific)
DMZKFU7	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMZKFU7	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMKC8F9	DI	DMKC8F9
DMKC8F9	DN	4SCAR19 and 4SCAR70
DMKC8F9	MI	TTW640A
DMKC8F9	MN	B-lymphocyte surface antigen B4 (CD19)
DMKC8F9	MT	DTT
DMKC8F9	MA	CAR-T-Cell-Therapy(Dual specific)
DMKC8F9	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMKC8F9	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMKC8F9	DI	DMKC8F9
DMKC8F9	DN	4SCAR19 and 4SCAR70
DMKC8F9	MI	TTNCIE0
DMKC8F9	MN	CD70 antigen (CD27-L)
DMKC8F9	MT	DTT
DMKC8F9	MA	CAR-T-Cell-Therapy(Dual specific)
DMKC8F9	RN	ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
DMKC8F9	RU	https://clinicaltrials.gov/ct2/show/NCT03125577

DMIY1ZB	DI	DMIY1ZB
DMIY1ZB	DN	4SCAR19 cells
DMIY1ZB	MI	TTW640A
DMIY1ZB	MN	B-lymphocyte surface antigen B4 (CD19)
DMIY1ZB	MT	DTT
DMIY1ZB	MA	CAR-T-Cell-Therapy
DMIY1ZB	RN	ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
DMIY1ZB	RU	https://clinicaltrials.gov/ct2/show/NCT03050190

DMI8TW3	DI	DMI8TW3
DMI8TW3	DN	4SCAR19/22 T cells
DMI8TW3	MI	TTM6QSK
DMI8TW3	MN	B-cell receptor CD22 (CD22)
DMI8TW3	MT	DTT
DMI8TW3	MA	CAR-T-Cell-Therapy(Dual specific)
DMI8TW3	RN	ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
DMI8TW3	RU	https://clinicaltrials.gov/ct2/show/NCT03098355

DMI8TW3	DI	DMI8TW3
DMI8TW3	DN	4SCAR19/22 T cells
DMI8TW3	MI	TTW640A
DMI8TW3	MN	B-lymphocyte surface antigen B4 (CD19)
DMI8TW3	MT	DTT
DMI8TW3	MA	CAR-T-Cell-Therapy(Dual specific)
DMI8TW3	RN	ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
DMI8TW3	RU	https://clinicaltrials.gov/ct2/show/NCT03098355

DMEGSU5	DI	DMEGSU5
DMEGSU5	DN	4SCAR-GD2
DMEGSU5	MI	TT80ARU
DMEGSU5	MN	Ganglioside GD2 (GD2)
DMEGSU5	MT	DTT
DMEGSU5	MA	CAR-T-Cell-Therapy
DMEGSU5	RN	ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
DMEGSU5	RU	https://clinicaltrials.gov/ct2/show/NCT02992210

DMM8J5W	DI	DMM8J5W
DMM8J5W	DN	4SCAR-PSMA
DMM8J5W	MI	TT9G4N0
DMM8J5W	MN	Glutamate carboxypeptidase II (GCPII)
DMM8J5W	MT	DTT
DMM8J5W	MA	CAR-T-Cell-Therapy
DMM8J5W	RN	ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T
DMM8J5W	RU	https://clinicaltrials.gov/ct2/show/NCT03185468

DM129VT	DI	DM129VT
DM129VT	DN	514G3
DM129VT	MI	TTOWKQ9
DM129VT	MN	Staphylococcus IgG binding protein A  (Stap-coc SpA)
DM129VT	MT	DTT
DM129VT	MA	Inhibitor
DM129VT	RN	A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018 Jan 24;13(1):e0190537.
DM129VT	RU	https://pubmed.ncbi.nlm.nih.gov/29364906

DMFAMNH	DI	DMFAMNH
DMFAMNH	DN	99mTc-rBitistatin
DMFAMNH	MI	TT38RM1
DMFAMNH	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMFAMNH	MT	DTT
DMFAMNH	MA	Modulator
DMFAMNH	RN	Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
DMFAMNH	RU	https://pubmed.ncbi.nlm.nih.gov/17921036

DMGTOIX	DI	DMGTOIX
DMGTOIX	DN	A166
DMGTOIX	MI	TT6EO5L
DMGTOIX	MN	Erbb2 tyrosine kinase receptor (HER2)
DMGTOIX	MT	DTT
DMGTOIX	RN	Clinical pipeline report, company report or official report of KLUS Pharma.
DMGTOIX	RU	https://www.kluspharma.com/pipeline

DMAPUZY	DI	DMAPUZY
DMAPUZY	DN	AAV1-FS344
DMAPUZY	MI	TTM8I2X
DMAPUZY	MN	Myostatin (MSTN)
DMAPUZY	MT	DTT
DMAPUZY	MA	Modulator
DMAPUZY	RN	Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med. 2009 November 11; 1(6): 6ra15.
DMAPUZY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852878/

DMI27RF	DI	DMI27RF
DMI27RF	DN	AAV-AQP1
DMI27RF	MI	TTSF1KH
DMI27RF	MN	Aquaporin-1 (AQP1)
DMI27RF	MT	DTT
DMI27RF	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMI27RF	RU	https://meiragtx.com/research-development/pipeline/

DMNZJAE	DI	DMNZJAE
DMNZJAE	DN	AAV-CNGA3
DMNZJAE	MI	TTW0QOV
DMNZJAE	MN	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
DMNZJAE	MT	DTT
DMNZJAE	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMNZJAE	RU	https://meiragtx.com/research-development/pipeline/

DM0CJAN	DI	DM0CJAN
DM0CJAN	DN	AAV-CNGB3
DM0CJAN	MI	TT0LJCG
DM0CJAN	MN	Cyclic nucleotide-gated channel beta-3 (CNGB3)
DM0CJAN	MT	DTT
DM0CJAN	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DM0CJAN	RU	https://meiragtx.com/research-development/pipeline/

DMAH6UJ	DI	DMAH6UJ
DMAH6UJ	DN	AAV-RPE65
DMAH6UJ	MI	TTBOH16
DMAH6UJ	MN	Retinal pigment epithelium protein (RPE65)
DMAH6UJ	MT	DTT
DMAH6UJ	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DMAH6UJ	RU	https://meiragtx.com/research-development/pipeline/

DM7TF49	DI	DM7TF49
DM7TF49	DN	AAV-RPGR
DM7TF49	MI	TTHBDA9
DM7TF49	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DM7TF49	MT	DTT
DM7TF49	RN	Clinical pipeline report, company report or official report of MeiraGTx.
DM7TF49	RU	https://meiragtx.com/research-development/pipeline/

DMDOXMN	DI	DMDOXMN
DMDOXMN	DN	AB928
DMDOXMN	MI	TTM2AOE
DMDOXMN	MN	Adenosine A2a receptor (ADORA2A)
DMDOXMN	MT	DTT
DMDOXMN	MA	Antagonist
DMDOXMN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDOXMN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDOXMN	DI	DMDOXMN
DMDOXMN	DN	AB928
DMDOXMN	MI	TTNE7KG
DMDOXMN	MN	Adenosine A2b receptor (ADORA2B)
DMDOXMN	MT	DTT
DMDOXMN	MA	Antagonist
DMDOXMN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDOXMN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUBLC3	DI	DMUBLC3
DMUBLC3	DN	ABO-101
DMUBLC3	MI	TTDM6HZ
DMUBLC3	MN	Alpha-N-acetylglucosaminidase (NAGLU)
DMUBLC3	MT	DTT
DMUBLC3	RN	Clinical pipeline report, company report or official report of Abeona Therapeutics.
DMUBLC3	RU	https://www.abeonatherapeutics.com/science

DMFJB35	DI	DMFJB35
DMFJB35	DN	ABO-102
DMFJB35	MI	TTPJ2SH
DMFJB35	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMFJB35	MT	DTT
DMFJB35	RN	Clinical pipeline report, company report or official report of Abeona Therapeutics.
DMFJB35	RU	https://www.abeonatherapeutics.com/science

DM31NJU	DI	DM31NJU
DM31NJU	DN	ABY-025
DM31NJU	MI	TT6EO5L
DM31NJU	MN	Erbb2 tyrosine kinase receptor (HER2)
DM31NJU	MT	DTT
DM31NJU	MA	Enhancer
DM31NJU	RN	Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8.
DM31NJU	RU	https://pubmed.ncbi.nlm.nih.gov/20554729

DMIRGTZ	DI	DMIRGTZ
DMIRGTZ	DN	ACHM-CNGA3
DMIRGTZ	MI	TTW0QOV
DMIRGTZ	MN	Cyclic nucleotide-gated channel alpha-3 (CNGA3)
DMIRGTZ	MT	DTT
DMIRGTZ	RN	Clinical pipeline report, company report or official report of Applied Genetic Technologies.
DMIRGTZ	RU	https://agtc.com/programs/achromatopsia/

DMC4ZQD	DI	DMC4ZQD
DMC4ZQD	DN	ACHM-CNGB3
DMC4ZQD	MI	TT0LJCG
DMC4ZQD	MN	Cyclic nucleotide-gated channel beta-3 (CNGB3)
DMC4ZQD	MT	DTT
DMC4ZQD	RN	Clinical pipeline report, company report or official report of Applied Genetic Technologies.
DMC4ZQD	RU	https://agtc.com/programs/achromatopsia/

DM5YDSU	DI	DM5YDSU
DM5YDSU	DN	ACI-24
DM5YDSU	MI	TTE4KHA
DM5YDSU	MN	Amyloid beta A4 protein (APP)
DM5YDSU	MT	DTT
DM5YDSU	RN	Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36.
DM5YDSU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015631/

DM7IWTF	DI	DM7IWTF
DM7IWTF	DN	ACP-319
DM7IWTF	MI	TTGM6VW
DM7IWTF	MN	Tyrosine-protein kinase BTK (ATK)
DM7IWTF	MT	DTT
DM7IWTF	MA	Inhibitor
DM7IWTF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948).
DM7IWTF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948

DMEU86T	DI	DMEU86T
DMEU86T	DN	ACT017
DMEU86T	MI	TTTJUVZ
DMEU86T	MN	Platelet glycoprotein VI (GP6)
DMEU86T	MT	DTT
DMEU86T	MA	Inhibitor
DMEU86T	RN	Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964.
DMEU86T	RU	https://pubmed.ncbi.nlm.nih.gov/31017822

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TTFGZB6
DM4L28K	MN	Human immunodeficiency virus GAG protein (HIV gag)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TT4NXYM
DM4L28K	MN	Human immunodeficiency virus Negative factor (HIV nef)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DM4L28K	DI	DM4L28K
DM4L28K	DN	Ad35-GRIN
DM4L28K	MI	TT84ETX
DM4L28K	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM4L28K	MT	DTT
DM4L28K	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DM4L28K	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMEGPSW	DI	DMEGPSW
DMEGPSW	DN	AdCh63 AMA1
DMEGPSW	MI	TTQZW34
DMEGPSW	MN	Plasmodium Apical membrane protein (Malaria AMA-1)
DMEGPSW	MT	DTT
DMEGPSW	RN	ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health.
DMEGPSW	RU	https://clinicaltrials.gov/ct2/show/NCT01142765

DMBGXH5	DI	DMBGXH5
DMBGXH5	DN	AdCh63-MSP1
DMBGXH5	MI	TT68ZYJ
DMBGXH5	MN	Plasmodium Merozoite surface protein 1 (Malaria MSP-1)
DMBGXH5	MT	DTT
DMBGXH5	RN	Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014 Apr;141(4):628-44.
DMBGXH5	RU	https://pubmed.ncbi.nlm.nih.gov/24303947

DMYOMSC	DI	DMYOMSC
DMYOMSC	DN	Aderbasib
DMYOMSC	MI	TTOMWSY
DMYOMSC	MN	Mammalian disintegrin-metalloprotease (ADAM10)
DMYOMSC	MT	DTT
DMYOMSC	MA	Modulator
DMYOMSC	RN	Company report (Incyte)
DMYOMSC	RU	http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQwNjgzfENoaWxkSUQ9NDYyNTAzfFR5cGU9MQ==&t=1

DMYOMSC	DI	DMYOMSC
DMYOMSC	DN	Aderbasib
DMYOMSC	MI	TT6AZXG
DMYOMSC	MN	TNF alpha converting enzyme (ADAM17)
DMYOMSC	MT	DTT
DMYOMSC	MA	Modulator
DMYOMSC	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMYOMSC	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM87H0S	DI	DM87H0S
DM87H0S	DN	ADG106
DM87H0S	MI	TTPW9LJ
DM87H0S	MN	Co-stimulatory molecule 4-1BB (CD137)
DM87H0S	MT	DTT
DM87H0S	MA	Inhibitor
DM87H0S	RN	Clinical pipeline report, company report or official report of Adagene.
DM87H0S	RU	https://www.adagene.com/pipeline/adg106/

DMB19IO	DI	DMB19IO
DMB19IO	DN	Ad-IL-12 DNA therapeutic
DMB19IO	MI	TTGW72V
DMB19IO	MN	Interleukin-12 beta (IL12B)
DMB19IO	MT	DTT
DMB19IO	MA	Modulator
DMB19IO	RN	National Cancer Institute Drug Dictionary (drug id 710508).
DMB19IO	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710508

DMOPVET	DI	DMOPVET
DMOPVET	DN	ADXS-PSA
DMOPVET	MI	TTS78AZ
DMOPVET	MN	Prostate specific antigen (KLK3)
DMOPVET	MT	DTT
DMOPVET	MA	Modulator
DMOPVET	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373).
DMOPVET	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373

DMEOS5K	DI	DMEOS5K
DMEOS5K	DN	AEE-788
DMEOS5K	MI	TTGJVQM
DMEOS5K	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMEOS5K	MT	DTT
DMEOS5K	MA	Inhibitor
DMEOS5K	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMEOS5K	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMEOS5K	DI	DMEOS5K
DMEOS5K	DN	AEE-788
DMEOS5K	MI	TTST7KB
DMEOS5K	MN	Fibroblast growth factor receptor 3 (FGFR3)
DMEOS5K	MT	DTT
DMEOS5K	MA	Inhibitor
DMEOS5K	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMEOS5K	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM2HRYD	DI	DM2HRYD
DM2HRYD	DN	AEG35156
DM2HRYD	MI	TTK3WBU
DM2HRYD	MN	XIAP messenger RNA (XIAP mRNA)
DM2HRYD	MT	DTT
DM2HRYD	RN	Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6.
DM2HRYD	RU	https://pubmed.ncbi.nlm.nih.gov/19568274

DMMNIBY	DI	DMMNIBY
DMMNIBY	DN	Aflunov
DMMNIBY	MI	TT3J5ZI
DMMNIBY	MN	Cell mediated immunity response (CMIR)
DMMNIBY	MT	DTT
DMMNIBY	RN	Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57.
DMMNIBY	RU	https://pubmed.ncbi.nlm.nih.gov/22309663

DMFTZX0	DI	DMFTZX0
DMFTZX0	DN	AFM24
DMFTZX0	MI	TTGKNB4
DMFTZX0	MN	Epidermal growth factor receptor (EGFR)
DMFTZX0	MT	DTT
DMFTZX0	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMFTZX0	RU	https://www.affimed.com/rock-platform/pipeline/

DMFTZX0	DI	DMFTZX0
DMFTZX0	DN	AFM24
DMFTZX0	MI	TTIFOC0
DMFTZX0	MN	Immunoglobulin gamma Fc receptor IIIA (FCGR3A)
DMFTZX0	MT	DTT
DMFTZX0	RN	Clinical pipeline report, company report or official report of Affimed Therapeutics.
DMFTZX0	RU	https://www.affimed.com/rock-platform/pipeline/

DMRET3H	DI	DMRET3H
DMRET3H	DN	AG-013958
DMRET3H	MI	TTVJ1D8
DMRET3H	MN	Vascular endothelial growth factor receptor (VEGFR)
DMRET3H	MT	DTT
DMRET3H	MA	Inhibitor
DMRET3H	RN	Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
DMRET3H	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995411/

DMEN2L7	DI	DMEN2L7
DMEN2L7	DN	AG019
DMEN2L7	MI	TTT0Q1F
DMEN2L7	MN	Interleukin-10 (IL10)
DMEN2L7	MT	DTT
DMEN2L7	RN	ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
DMEN2L7	RU	https://clinicaltrials.gov/ct2/show/NCT03751007

DMAP5B4	DI	DMAP5B4
DMAP5B4	DN	AGEN1884
DMAP5B4	MI	TTI2S1D
DMAP5B4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMAP5B4	MT	DTT
DMAP5B4	MA	Antagonist
DMAP5B4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAP5B4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMHZUF8	DI	DMHZUF8
DMHZUF8	DN	AGN-208397
DMHZUF8	MI	TT6EO5L
DMHZUF8	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHZUF8	MT	DTT
DMHZUF8	MA	Inhibitor
DMHZUF8	RN	New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2.
DMHZUF8	RU	https://pubmed.ncbi.nlm.nih.gov/23812264

DMTS51C	DI	DMTS51C
DMTS51C	DN	AGTC-501
DMTS51C	MI	TTHBDA9
DMTS51C	MN	X-linked retinitis pigmentosa GTPase regulator (RPGR)
DMTS51C	MT	DTT
DMTS51C	RN	ClinicalTrials.gov (NCT03316560) Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health.
DMTS51C	RU	https://clinicaltrials.gov/ct2/show/NCT03316560

DMJVGIH	DI	DMJVGIH
DMJVGIH	DN	AIGIV
DMJVGIH	MI	TTRLPUB
DMJVGIH	MN	Bacillus anthracis Protective antigen (Anthrax PA)
DMJVGIH	MT	DTT
DMJVGIH	MA	Modulator
DMJVGIH	RN	Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92.
DMJVGIH	RU	https://pubmed.ncbi.nlm.nih.gov/23979731

DML0GIU	DI	DML0GIU
DML0GIU	DN	AIV001
DML0GIU	MI	TTVJ1D8
DML0GIU	MN	Vascular endothelial growth factor receptor (VEGFR)
DML0GIU	MT	DTT
DML0GIU	MA	Inhibitor
DML0GIU	RN	Clinical pipeline report, company report or official report of AiViva BioPharma.
DML0GIU	RU	https://aiviva.com/aiv001

DMNXLOT	DI	DMNXLOT
DMNXLOT	DN	ALAMIFOVIR
DMNXLOT	MI	TTMR83K
DMNXLOT	MN	Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS)
DMNXLOT	MT	DTT
DMNXLOT	MA	Modulator
DMNXLOT	RN	Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine. Correction in: Antimicrob Agents Chemother. 2013 November; 57(11): 5788.
DMNXLOT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754288/

DMGQX0U	DI	DMGQX0U
DMGQX0U	DN	ALX148
DMGQX0U	MI	TT28S46
DMGQX0U	MN	Leukocyte surface antigen CD47 (CD47)
DMGQX0U	MT	DTT
DMGQX0U	MA	Inhibitor
DMGQX0U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGQX0U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEF4L5	DI	DMEF4L5
DMEF4L5	DN	AMG888/U3-1287
DMEF4L5	MI	TTDC8N2
DMEF4L5	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMEF4L5	MT	DTT
DMEF4L5	MA	Modulator
DMEF4L5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DMEF4L5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DM7RNKM	DI	DM7RNKM
DM7RNKM	DN	AMT-060
DM7RNKM	MI	TTFEZ5Q
DM7RNKM	MN	Coagulation factor IX (F9)
DM7RNKM	MT	DTT
DM7RNKM	MA	Modulator
DM7RNKM	RN	Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V.
DM7RNKM	RU	http://www.biocentury.com/products/amt-060

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTU1SOM
DMR9H6B	MN	Microtubule polymerization (MicroTu poly)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTVDSZ0
DMR9H6B	MN	Poly [ADP-ribose] polymerase 1 (PARP1)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMR9H6B	DI	DMR9H6B
DMR9H6B	DN	AMXI 5001
DMR9H6B	MI	TTQ4V96
DMR9H6B	MN	Poly [ADP-ribose] polymerase 2 (PARP2)
DMR9H6B	MT	DTT
DMR9H6B	MA	Inhibitor
DMR9H6B	RN	AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
DMR9H6B	RU	https://pubmed.ncbi.nlm.nih.gov/32905466

DMDHJNV	DI	DMDHJNV
DMDHJNV	DN	Annamycin
DMDHJNV	MI	TTCGY2K
DMDHJNV	MN	DNA topoisomerase II alpha (TOP2A)
DMDHJNV	MT	DTT
DMDHJNV	RN	Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8.
DMDHJNV	RU	https://pubmed.ncbi.nlm.nih.gov/17557149

DM4D3YF	DI	DM4D3YF
DM4D3YF	DN	Anti-BCMA CAR-T cells
DM4D3YF	MI	TTZ3P4W
DM4D3YF	MN	B-cell maturation protein (TNFRSF17)
DM4D3YF	MT	DTT
DM4D3YF	MA	CAR-T-Cell-Therapy
DM4D3YF	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM4D3YF	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMZ18IO	DI	DMZ18IO
DMZ18IO	DN	Anti-BCMA-CAR-transduced T cells
DMZ18IO	MI	TTZ3P4W
DMZ18IO	MN	B-cell maturation protein (TNFRSF17)
DMZ18IO	MT	DTT
DMZ18IO	MA	CAR-T-Cell-Therapy
DMZ18IO	RN	ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
DMZ18IO	RU	https://clinicaltrials.gov/ct2/show/NCT02954445

DMFV6TY	DI	DMFV6TY
DMFV6TY	DN	Anti-CD123-CAR-transduced T cells
DMFV6TY	MI	TTENHJ0
DMFV6TY	MN	Interleukin 3 receptor alpha (IL3RA)
DMFV6TY	MT	DTT
DMFV6TY	MA	CAR-T-Cell-Therapy
DMFV6TY	RN	ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
DMFV6TY	RU	https://clinicaltrials.gov/ct2/show/NCT02937103

DMLFB25	DI	DMLFB25
DMLFB25	DN	Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25	MI	TTW640A
DMLFB25	MN	B-lymphocyte surface antigen B4 (CD19)
DMLFB25	MT	DTT
DMLFB25	MA	CAR-T-Cell-Therapy(Dual specific)
DMLFB25	RN	ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
DMLFB25	RU	https://clinicaltrials.gov/ct2/show/NCT03207178

DMLFB25	DI	DMLFB25
DMLFB25	DN	Anti-CD19 and Anti-CD20 CAR-T Cells
DMLFB25	MI	TTUE541
DMLFB25	MN	Leukocyte surface antigen Leu-16 (CD20)
DMLFB25	MT	DTT
DMLFB25	MA	CAR-T-Cell-Therapy(Dual specific)
DMLFB25	RN	ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
DMLFB25	RU	https://clinicaltrials.gov/ct2/show/NCT03207178

DMS326R	DI	DMS326R
DMS326R	DN	Anti-CD19 CAR T cells
DMS326R	MI	TTW640A
DMS326R	MN	B-lymphocyte surface antigen B4 (CD19)
DMS326R	MT	DTT
DMS326R	MA	CAR-T-Cell-Therapy
DMS326R	RN	ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
DMS326R	RU	https://clinicaltrials.gov/ct2/show/NCT02842138

DMHSLVJ	DI	DMHSLVJ
DMHSLVJ	DN	Anti-CD19 CAR transduced T cells
DMHSLVJ	MI	TTW640A
DMHSLVJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMHSLVJ	MT	DTT
DMHSLVJ	MA	CAR-T-Cell-Therapy
DMHSLVJ	RN	ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
DMHSLVJ	RU	https://clinicaltrials.gov/ct2/show/NCT03191773

DM04HNB	DI	DM04HNB
DM04HNB	DN	Anti-CD19 CAR-T
DM04HNB	MI	TTW640A
DM04HNB	MN	B-lymphocyte surface antigen B4 (CD19)
DM04HNB	MT	DTT
DM04HNB	MA	CAR-T-Cell-Therapy
DM04HNB	RN	ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
DM04HNB	RU	https://clinicaltrials.gov/ct2/show/NCT02685670

DMDRYZK	DI	DMDRYZK
DMDRYZK	DN	Anti-CD19 CAR-T cells
DMDRYZK	MI	TTW640A
DMDRYZK	MN	B-lymphocyte surface antigen B4 (CD19)
DMDRYZK	MT	DTT
DMDRYZK	MA	CAR-T-Cell-Therapy
DMDRYZK	RN	ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
DMDRYZK	RU	https://clinicaltrials.gov/ct2/show/NCT02851589

DMSFEOC	DI	DMSFEOC
DMSFEOC	DN	Anti-CD19 CAR-T cells
DMSFEOC	MI	TTW640A
DMSFEOC	MN	B-lymphocyte surface antigen B4 (CD19)
DMSFEOC	MT	DTT
DMSFEOC	MA	CAR-T-Cell-Therapy
DMSFEOC	RN	ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy
DMSFEOC	RU	https://clinicaltrials.gov/ct2/show/NCT02782351

DM1EH9D	DI	DM1EH9D
DM1EH9D	DN	Anti-CD19 CAR-T cells
DM1EH9D	MI	TTW640A
DM1EH9D	MN	B-lymphocyte surface antigen B4 (CD19)
DM1EH9D	MT	DTT
DM1EH9D	MA	CAR-T-Cell-Therapy
DM1EH9D	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM1EH9D	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM92CUG	DI	DM92CUG
DM92CUG	DN	Anti-CD19 CAR-T cells
DM92CUG	MI	TTW640A
DM92CUG	MN	B-lymphocyte surface antigen B4 (CD19)
DM92CUG	MT	DTT
DM92CUG	MA	CAR-T-Cell-Therapy
DM92CUG	RN	ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
DM92CUG	RU	https://clinicaltrials.gov/ct2/show/NCT03366324

DMMUSHR	DI	DMMUSHR
DMMUSHR	DN	Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR	MI	TTM6QSK
DMMUSHR	MN	B-cell receptor CD22 (CD22)
DMMUSHR	MT	DTT
DMMUSHR	MA	CAR-T-Cell-Therapy(Dual specific)
DMMUSHR	RN	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
DMMUSHR	RU	https://clinicaltrials.gov/ct2/show/NCT03185494

DMMUSHR	DI	DMMUSHR
DMMUSHR	DN	Anti-CD19/22-CAR vector-transduced T cells
DMMUSHR	MI	TTW640A
DMMUSHR	MN	B-lymphocyte surface antigen B4 (CD19)
DMMUSHR	MT	DTT
DMMUSHR	MA	CAR-T-Cell-Therapy(Dual specific)
DMMUSHR	RN	ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
DMMUSHR	RU	https://clinicaltrials.gov/ct2/show/NCT03185494

DM1WB8H	DI	DM1WB8H
DM1WB8H	DN	Anti-CD19-CAR PBL
DM1WB8H	MI	TTW640A
DM1WB8H	MN	B-lymphocyte surface antigen B4 (CD19)
DM1WB8H	MT	DTT
DM1WB8H	MA	CAR-T-Cell-Therapy
DM1WB8H	RN	ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
DM1WB8H	RU	https://clinicaltrials.gov/ct2/show/NCT00924326

DMQXU4C	DI	DMQXU4C
DMQXU4C	DN	Anti-CD19-CAR vector-transduced T cells
DMQXU4C	MI	TTW640A
DMQXU4C	MN	B-lymphocyte surface antigen B4 (CD19)
DMQXU4C	MT	DTT
DMQXU4C	MA	CAR-T-Cell-Therapy
DMQXU4C	RN	ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
DMQXU4C	RU	https://clinicaltrials.gov/ct2/show/NCT02081937

DMNTP23	DI	DMNTP23
DMNTP23	DN	Anti-CD19-CAR-T cells
DMNTP23	MI	TTW640A
DMNTP23	MN	B-lymphocyte surface antigen B4 (CD19)
DMNTP23	MT	DTT
DMNTP23	MA	CAR-T-Cell-Therapy
DMNTP23	RN	ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
DMNTP23	RU	https://clinicaltrials.gov/ct2/show/NCT02672501

DM4WEZL	DI	DM4WEZL
DM4WEZL	DN	Anti-CD20 CAR-T cells
DM4WEZL	MI	TTW640A
DM4WEZL	MN	B-lymphocyte surface antigen B4 (CD19)
DM4WEZL	MT	DTT
DM4WEZL	MA	CAR-T-Cell-Therapy(Dual specific)
DM4WEZL	RN	ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
DM4WEZL	RU	https://clinicaltrials.gov/ct2/show/NCT02737085

DM4WEZL	DI	DM4WEZL
DM4WEZL	DN	Anti-CD20 CAR-T cells
DM4WEZL	MI	TTUE541
DM4WEZL	MN	Leukocyte surface antigen Leu-16 (CD20)
DM4WEZL	MT	DTT
DM4WEZL	MA	CAR-T-Cell-Therapy(Dual specific)
DM4WEZL	RN	ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
DM4WEZL	RU	https://clinicaltrials.gov/ct2/show/NCT02737085

DMCDUJY	DI	DMCDUJY
DMCDUJY	DN	Anti-CD20-CAR vector-transduced autologous T cells
DMCDUJY	MI	TTUE541
DMCDUJY	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCDUJY	MT	DTT
DMCDUJY	MA	CAR-T-Cell-Therapy
DMCDUJY	RN	ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
DMCDUJY	RU	https://clinicaltrials.gov/ct2/show/NCT01735604

DMXMK30	DI	DMXMK30
DMXMK30	DN	Anti-CD20-CAR-transduced T cells
DMXMK30	MI	TTUE541
DMXMK30	MN	Leukocyte surface antigen Leu-16 (CD20)
DMXMK30	MT	DTT
DMXMK30	MA	CAR-T-Cell-Therapy
DMXMK30	RN	ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
DMXMK30	RU	https://clinicaltrials.gov/ct2/show/NCT02710149

DMY6U8R	DI	DMY6U8R
DMY6U8R	DN	Anti-CD22 CAR-T cells
DMY6U8R	MI	TTM6QSK
DMY6U8R	MN	B-cell receptor CD22 (CD22)
DMY6U8R	MT	DTT
DMY6U8R	MA	CAR-T-Cell-Therapy
DMY6U8R	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMY6U8R	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMTO9VF	DI	DMTO9VF
DMTO9VF	DN	Anti-CD22-CAR-transduced T cells
DMTO9VF	MI	TTM6QSK
DMTO9VF	MN	B-cell receptor CD22 (CD22)
DMTO9VF	MT	DTT
DMTO9VF	MA	CAR-T-Cell-Therapy
DMTO9VF	RN	ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
DMTO9VF	RU	https://clinicaltrials.gov/ct2/show/NCT03262298

DM8139V	DI	DM8139V
DM8139V	DN	Anti-CD30 CAR T cells
DM8139V	MI	TT2GM5R
DM8139V	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM8139V	MT	DTT
DM8139V	MA	CAR-T-Cell-Therapy
DM8139V	RN	ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
DM8139V	RU	https://clinicaltrials.gov/ct2/show/NCT02274584

DMTZSPJ	DI	DMTZSPJ
DMTZSPJ	DN	Anti-CD30-CAR-transduced T cells
DMTZSPJ	MI	TT2GM5R
DMTZSPJ	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMTZSPJ	MT	DTT
DMTZSPJ	MA	CAR-T-Cell-Therapy
DMTZSPJ	RN	ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
DMTZSPJ	RU	https://clinicaltrials.gov/ct2/show/NCT02958410

DM9NPF6	DI	DM9NPF6
DM9NPF6	DN	Anti-CD33 CAR-T cells
DM9NPF6	MI	TTJVYO3
DM9NPF6	MN	Myeloid cell surface antigen CD33 (CD33)
DM9NPF6	MT	DTT
DM9NPF6	MA	CAR-T-Cell-Therapy
DM9NPF6	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM9NPF6	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMTVXBY	DI	DMTVXBY
DMTVXBY	DN	Anti-CD38 CAR-T cells
DMTVXBY	MI	TTPURFN
DMTVXBY	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMTVXBY	MT	DTT
DMTVXBY	MA	CAR-T-Cell-Therapy
DMTVXBY	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMTVXBY	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMV5H0S	DI	DMV5H0S
DMV5H0S	DN	Anti-C-met CAR-T cells
DMV5H0S	MI	TTNDSF4
DMV5H0S	MN	Proto-oncogene c-Met (MET)
DMV5H0S	MT	DTT
DMV5H0S	MA	CAR-T-Cell-Therapy
DMV5H0S	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMV5H0S	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMYKZB3	DI	DMYKZB3
DMYKZB3	DN	Anti-DR5 cells
DMYKZB3	MI	TTW20TU
DMYKZB3	MN	TRAIL receptor 2 (TRAIL-R2)
DMYKZB3	MT	DTT
DMYKZB3	MA	CAR-T-Cell-Therapy
DMYKZB3	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DMYKZB3	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM8EAGV	DI	DM8EAGV
DM8EAGV	DN	Anti-EGFR V III CAR-T cells
DM8EAGV	MI	TTZ6B2I
DM8EAGV	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM8EAGV	MT	DTT
DM8EAGV	MA	CAR-T-Cell-Therapy
DM8EAGV	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM8EAGV	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DMDKTYU	DI	DMDKTYU
DMDKTYU	DN	Anti-EGFRvIII CAR transduced PBL
DMDKTYU	MI	TTZ6B2I
DMDKTYU	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMDKTYU	MT	DTT
DMDKTYU	MA	CAR-T-Cell-Therapy
DMDKTYU	RN	ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
DMDKTYU	RU	https://clinicaltrials.gov/ct2/show/NCT01454596

DM8ENKS	DI	DM8ENKS
DM8ENKS	DN	Anti-Factor D
DM8ENKS	MI	TT8D13I
DM8ENKS	MN	Complement factor D (CFD)
DM8ENKS	MT	DTT
DM8ENKS	RN	Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9.
DM8ENKS	RU	https://pubmed.ncbi.nlm.nih.gov/20582862

DMQD6B9	DI	DMQD6B9
DMQD6B9	DN	Anti-HER2 CAR-T
DMQD6B9	MI	TT6EO5L
DMQD6B9	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQD6B9	MT	DTT
DMQD6B9	MA	CAR-T-Cell-Therapy
DMQD6B9	RN	ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
DMQD6B9	RU	https://clinicaltrials.gov/ct2/show/NCT02713984

DMQZJ3B	DI	DMQZJ3B
DMQZJ3B	DN	Anti-HIV ribozyme therapy
DMQZJ3B	MI	TTT3ZC9
DMQZJ3B	MN	Human immunodeficiency virus Tat protein (HIV tat)
DMQZJ3B	MT	DTT
DMQZJ3B	MA	Modulator
DMQZJ3B	RN	Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98.
DMQZJ3B	RU	https://pubmed.ncbi.nlm.nih.gov/15017082

DMXI03L	DI	DMXI03L
DMXI03L	DN	Anti-mesothelin CAR transduced PBL
DMXI03L	MI	TT4RXME
DMXI03L	MN	Mesothelin (MSLN)
DMXI03L	MT	DTT
DMXI03L	MA	CAR-T-Cell-Therapy
DMXI03L	RN	ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
DMXI03L	RU	https://clinicaltrials.gov/ct2/show/NCT01583686

DM4NMBW	DI	DM4NMBW
DM4NMBW	DN	Anti-Mesothelin CAR-T cells
DM4NMBW	MI	TT4RXME
DM4NMBW	MN	Mesothelin (MSLN)
DM4NMBW	MT	DTT
DM4NMBW	MA	CAR-T-Cell-Therapy
DM4NMBW	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM4NMBW	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM0C1IX	DI	DM0C1IX
DM0C1IX	DN	Anti-MUC1 CAR T Cells
DM0C1IX	MI	TTBHFYQ
DM0C1IX	MN	Mucin-1 (MUC1)
DM0C1IX	MT	DTT
DM0C1IX	MA	CAR-T-Cell-Therapy
DM0C1IX	RN	ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
DM0C1IX	RU	https://clinicaltrials.gov/ct2/show/NCT02587689

DMDHKN1	DI	DMDHKN1
DMDHKN1	DN	Anti-MUC1 CAR T Cells
DMDHKN1	MI	TTBHFYQ
DMDHKN1	MN	Mucin-1 (MUC1)
DMDHKN1	MT	DTT
DMDHKN1	MA	CAR-T-Cell-Therapy
DMDHKN1	RN	ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
DMDHKN1	RU	https://clinicaltrials.gov/ct2/show/NCT03525782

DMXYOTP	DI	DMXYOTP
DMXYOTP	DN	Anti-MUC1 CAR-T cells
DMXYOTP	MI	TTBHFYQ
DMXYOTP	MN	Mucin-1 (MUC1)
DMXYOTP	MT	DTT
DMXYOTP	MA	CAR-T-Cell-Therapy
DMXYOTP	RN	ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
DMXYOTP	RU	https://clinicaltrials.gov/ct2/show/NCT03706326

DMTQIB2	DI	DMTQIB2
DMTQIB2	DN	Anti-MUC1 CAR-T cells
DMTQIB2	MI	TTBHFYQ
DMTQIB2	MN	Mucin-1 (MUC1)
DMTQIB2	MT	DTT
DMTQIB2	MA	CAR-T-Cell-Therapy
DMTQIB2	RN	ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
DMTQIB2	RU	https://clinicaltrials.gov/ct2/show/NCT02617134

DM26VCZ	DI	DM26VCZ
DM26VCZ	DN	Anti-NY-ESO-1 CAR-T cells
DM26VCZ	MI	TTE5ITK
DM26VCZ	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM26VCZ	MT	DTT
DM26VCZ	MA	CAR-T-Cell-Therapy
DM26VCZ	RN	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
DM26VCZ	RU	https://clinicaltrials.gov/ct2/show/NCT03638206

DM2910G	DI	DM2910G
DM2910G	DN	Anti-VEGFR2 CD8 cell therapy
DM2910G	MI	TTMHA6L
DM2910G	MN	T-cell surface glycoprotein CD8 (CD8)
DM2910G	MT	DTT
DM2910G	MA	Modulator
DM2910G	RN	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
DM2910G	RU	https://pubmed.ncbi.nlm.nih.gov/23045683

DM2910G	DI	DM2910G
DM2910G	DN	Anti-VEGFR2 CD8 cell therapy
DM2910G	MI	TTUTJGQ
DM2910G	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM2910G	MT	DTT
DM2910G	MA	Modulator
DM2910G	RN	Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
DM2910G	RU	https://pubmed.ncbi.nlm.nih.gov/23045683

DMXU98C	DI	DMXU98C
DMXU98C	DN	AO-176
DMXU98C	MI	TT28S46
DMXU98C	MN	Leukocyte surface antigen CD47 (CD47)
DMXU98C	MT	DTT
DMXU98C	MA	Inhibitor
DMXU98C	RN	Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
DMXU98C	RU	https://pubmed.ncbi.nlm.nih.gov/31879362

DMBGA35	DI	DMBGA35
DMBGA35	DN	AP-1030
DMBGA35	MI	TT0MV2T
DMBGA35	MN	Melanocortin receptor 1 (MC1R)
DMBGA35	MT	DTT
DMBGA35	MA	Modulator
DMBGA35	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBGA35	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBGA35	DI	DMBGA35
DMBGA35	DN	AP-1030
DMBGA35	MI	TTD0CIQ
DMBGA35	MN	Melanocortin receptor 4 (MC4R)
DMBGA35	MT	DTT
DMBGA35	MA	Modulator
DMBGA35	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBGA35	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM2LU8M	DI	DM2LU8M
DM2LU8M	DN	AP1903
DM2LU8M	MI	TTMW94E
DM2LU8M	MN	FK506-binding protein 1A (FKBP1A)
DM2LU8M	MT	DTT
DM2LU8M	MA	Modulator
DM2LU8M	RN	Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64.
DM2LU8M	RU	https://pubmed.ncbi.nlm.nih.gov/18356813

DMJLMEF	DI	DMJLMEF
DMJLMEF	DN	AP-30663
DMJLMEF	MI	TTKU9YD
DMJLMEF	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMJLMEF	MT	DTT
DMJLMEF	MA	Inhibitor
DMJLMEF	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMJLMEF	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM71I53	DI	DM71I53
DM71I53	DN	APC-100
DM71I53	MI	TTS64P2
DM71I53	MN	Androgen receptor (AR)
DM71I53	MT	DTT
DM71I53	MA	Inhibitor
DM71I53	RN	2011 Pipeline of Adamis Pharmaceuticals.
DM71I53	RU	http://www.adamispharmaceuticals.com/

DM8O3R9	DI	DM8O3R9
DM8O3R9	DN	APG-1252
DM8O3R9	MI	TTJGNVC
DM8O3R9	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM8O3R9	MT	DTT
DM8O3R9	MA	Inhibitor
DM8O3R9	RN	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
DM8O3R9	RU	https://pubmed.ncbi.nlm.nih.gov/32346976

DM8O3R9	DI	DM8O3R9
DM8O3R9	DN	APG-1252
DM8O3R9	MI	TTU1E82
DM8O3R9	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DM8O3R9	MT	DTT
DM8O3R9	MA	Inhibitor
DM8O3R9	RN	Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
DM8O3R9	RU	https://pubmed.ncbi.nlm.nih.gov/32346976

DMPWBM2	DI	DMPWBM2
DMPWBM2	DN	APG-2575
DMPWBM2	MI	TTJGNVC
DMPWBM2	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMPWBM2	MT	DTT
DMPWBM2	MA	Inhibitor
DMPWBM2	RN	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344.
DMPWBM2	RU	https://pubmed.ncbi.nlm.nih.gov/32093809

DMV7Q6X	DI	DMV7Q6X
DMV7Q6X	DN	APN-201
DMV7Q6X	MI	TT6RVLG
DMV7Q6X	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMV7Q6X	MT	DTT
DMV7Q6X	MA	Modulator
DMV7Q6X	RN	Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59.
DMV7Q6X	RU	https://pubmed.ncbi.nlm.nih.gov/18650828

DM76S3X	DI	DM76S3X
DM76S3X	DN	ARO-HBV
DM76S3X	MI	TT43YWN
DM76S3X	MN	Hepatitis B virus messenger RNA (HBV mRNA)
DM76S3X	MT	DTT
DM76S3X	MA	Inhibitor
DM76S3X	RN	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
DM76S3X	RU	https://arrowheadpharma.com/pipeline/

DMI17NX	DI	DMI17NX
DMI17NX	DN	ART621
DMI17NX	MI	TTF8CQI
DMI17NX	MN	Tumor necrosis factor (TNF)
DMI17NX	MT	DTT
DMI17NX	MA	Inhibitor
DMI17NX	RN	Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
DMI17NX	RU	https://pubmed.ncbi.nlm.nih.gov/19249988

DMYCID5	DI	DMYCID5
DMYCID5	DN	ARV-110
DMYCID5	MI	TTS64P2
DMYCID5	MN	Androgen receptor (AR)
DMYCID5	MT	DTT
DMYCID5	MA	Degrader
DMYCID5	RN	Clinical pipeline report, company report or official report of Arvinas.
DMYCID5	RU	https://www.arvinas.com/pipeline-programs/androgen-receptor

DM276Y8	DI	DM276Y8
DM276Y8	DN	ARV-471
DM276Y8	MI	TTS64P2
DM276Y8	MN	Androgen receptor (AR)
DM276Y8	MT	DTT
DM276Y8	MA	Degrader
DM276Y8	RN	Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689.
DM276Y8	RU	https://pubmed.ncbi.nlm.nih.gov/32829249

DMVNCSK	DI	DMVNCSK
DMVNCSK	DN	ASC-101
DMVNCSK	MI	TT3C1VN
DMVNCSK	MN	Enzyme unspecific (Enz)
DMVNCSK	MT	DTT
DMVNCSK	MA	Modulator
DMVNCSK	RN	ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health.
DMVNCSK	RU	https://clinicaltrials.gov/ct2/show/NCT01983761

DM8V0UL	DI	DM8V0UL
DM8V0UL	DN	ASP-9521
DM8V0UL	MI	TT5ZWB6
DM8V0UL	MN	Dihydrodiol dehydrogenase type I (AKR1C3)
DM8V0UL	MT	DTT
DM8V0UL	MA	Modulator
DM8V0UL	RN	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
DM8V0UL	RU	https://pubmed.ncbi.nlm.nih.gov/24771350

DMVZXIA	DI	DMVZXIA
DMVZXIA	DN	ASTX029
DMVZXIA	MI	TT1MG9E
DMVZXIA	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMVZXIA	MT	DTT
DMVZXIA	MA	Inhibitor
DMVZXIA	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DMVZXIA	RU	https://astx.com/research-development/clinical-pipeline/

DMVZXIA	DI	DMVZXIA
DMVZXIA	DN	ASTX029
DMVZXIA	MI	TT4TQBX
DMVZXIA	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMVZXIA	MT	DTT
DMVZXIA	MA	Inhibitor
DMVZXIA	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DMVZXIA	RU	https://astx.com/research-development/clinical-pipeline/

DM9EM5G	DI	DM9EM5G
DM9EM5G	DN	ASTX295
DM9EM5G	MI	TT08GJW
DM9EM5G	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM9EM5G	MT	DTT
DM9EM5G	MA	Antagonist
DM9EM5G	RN	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
DM9EM5G	RU	https://astx.com/research-development/clinical-pipeline/astx295-oral-murine-double-minute-2-mdm2-antagonist-solid-tumors/

DMSOQ6E	DI	DMSOQ6E
DMSOQ6E	DN	AT-342
DMSOQ6E	MI	TT34ZAF
DMSOQ6E	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMSOQ6E	MT	DTT
DMSOQ6E	MA	Replacement
DMSOQ6E	RN	ClinicalTrials.gov (NCT03223194) Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS). U.S. National Institutes of Health.
DMSOQ6E	RU	https://clinicaltrials.gov/ct2/show/NCT03223194

DM7O89Q	DI	DM7O89Q
DM7O89Q	DN	AT-777
DM7O89Q	MI	TTMVBWH
DM7O89Q	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7O89Q	MT	DTT
DM7O89Q	MA	Inhibitor
DM7O89Q	RN	Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
DM7O89Q	RU	https://ateapharma.com/about-us/hepatitis-c/

DMB5X7Z	DI	DMB5X7Z
DMB5X7Z	DN	ATG002
DMB5X7Z	MI	TTJSZTB
DMB5X7Z	MN	Nicotinic acetylcholine receptor (nAChR)
DMB5X7Z	MT	DTT
DMB5X7Z	MA	Agonist
DMB5X7Z	RN	Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006.
DMB5X7Z	RU	http://www.prnewswire.com/news-releases/athenagen-advances-angiogenesis-drug-to-clinical-testing-56212977.html

DM84YEC	DI	DM84YEC
DM84YEC	DN	Atiprimod
DM84YEC	MI	TTH8FZW
DM84YEC	MN	Signal transducer and activator of transcription 3 (STAT3)
DM84YEC	MT	DTT
DM84YEC	MA	Inhibitor
DM84YEC	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DM84YEC	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DM75QY9	DI	DM75QY9
DM75QY9	DN	ATL-313
DM75QY9	MI	TTM2AOE
DM75QY9	MN	Adenosine A2a receptor (ADORA2A)
DM75QY9	MT	DTT
DM75QY9	MA	Agonist
DM75QY9	RN	Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12.
DM75QY9	RU	https://pubmed.ncbi.nlm.nih.gov/16622196

DMLAKPI	DI	DMLAKPI
DMLAKPI	DN	AU101
DMLAKPI	MI	TTQ13FT
DMLAKPI	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMLAKPI	MT	DTT
DMLAKPI	MA	Immunomodulator
DMLAKPI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLAKPI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPAZ3U	DI	DMPAZ3U
DMPAZ3U	DN	AU105
DMPAZ3U	MI	TT6EO5L
DMPAZ3U	MN	Erbb2 tyrosine kinase receptor (HER2)
DMPAZ3U	MT	DTT
DMPAZ3U	MA	Immunomodulator
DMPAZ3U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPAZ3U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMG9OAV	DI	DMG9OAV
DMG9OAV	DN	AUTO1
DMG9OAV	MI	TTW640A
DMG9OAV	MN	B-lymphocyte surface antigen B4 (CD19)
DMG9OAV	MT	DTT
DMG9OAV	RN	Clinical pipeline report, company report or official report of Autolus Therapeutics.
DMG9OAV	RU	https://www.autolus.com/pipeline/

DM0PWX2	DI	DM0PWX2
DM0PWX2	DN	AUTO2
DM0PWX2	MI	TTZ3P4W
DM0PWX2	MN	B-cell maturation protein (TNFRSF17)
DM0PWX2	MT	DTT
DM0PWX2	MA	CAR-T-Cell-Therapy(Dual specific)
DM0PWX2	RN	ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
DM0PWX2	RU	https://clinicaltrials.gov/ct2/show/NCT03287804

DM0PWX2	DI	DM0PWX2
DM0PWX2	DN	AUTO2
DM0PWX2	MI	TTL9OD4
DM0PWX2	MN	Transmembrane activator and CAML interactor (TNFRSF13B)
DM0PWX2	MT	DTT
DM0PWX2	MA	CAR-T-Cell-Therapy(Dual specific)
DM0PWX2	RN	ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
DM0PWX2	RU	https://clinicaltrials.gov/ct2/show/NCT03287804

DMC5NSO	DI	DMC5NSO
DMC5NSO	DN	AUTO3
DMC5NSO	MI	TTM6QSK
DMC5NSO	MN	B-cell receptor CD22 (CD22)
DMC5NSO	MT	DTT
DMC5NSO	MA	CAR-T-Cell-Therapy(Dual specific)
DMC5NSO	RN	ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
DMC5NSO	RU	https://clinicaltrials.gov/ct2/show/NCT03289455

DMC5NSO	DI	DMC5NSO
DMC5NSO	DN	AUTO3
DMC5NSO	MI	TTW640A
DMC5NSO	MN	B-lymphocyte surface antigen B4 (CD19)
DMC5NSO	MT	DTT
DMC5NSO	MA	CAR-T-Cell-Therapy(Dual specific)
DMC5NSO	RN	ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
DMC5NSO	RU	https://clinicaltrials.gov/ct2/show/NCT03289455

DM2YTGQ	DI	DM2YTGQ
DM2YTGQ	DN	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
DM2YTGQ	MI	TTW640A
DM2YTGQ	MN	B-lymphocyte surface antigen B4 (CD19)
DM2YTGQ	MT	DTT
DM2YTGQ	MA	CAR-T-Cell-Therapy
DM2YTGQ	RN	ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
DM2YTGQ	RU	https://clinicaltrials.gov/ct2/show/NCT01865617

DMLOGI4	DI	DMLOGI4
DMLOGI4	DN	Autologous CD19-targeting CAR T cells
DMLOGI4	MI	TTW640A
DMLOGI4	MN	B-lymphocyte surface antigen B4 (CD19)
DMLOGI4	MT	DTT
DMLOGI4	MA	CAR-T-Cell-Therapy
DMLOGI4	RN	ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy
DMLOGI4	RU	https://clinicaltrials.gov/ct2/show/NCT02963038

DMRS58M	DI	DMRS58M
DMRS58M	DN	Avrina
DMRS58M	MI	TTSXVID
DMRS58M	MN	Nuclear factor NF-kappa-B (NFKB)
DMRS58M	MT	DTT
DMRS58M	MA	Modulator
DMRS58M	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRS58M	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMC1XHK	DI	DMC1XHK
DMC1XHK	DN	AVR-RD-01
DMC1XHK	MI	TTIS03D
DMC1XHK	MN	Alpha-galactosidase A (GLA)
DMC1XHK	MT	DTT
DMC1XHK	RN	Clinical pipeline report, company report or official report of Avrobio.
DMC1XHK	RU	https://www.avrobio.com/our-pipeline/

DMOPVIQ	DI	DMOPVIQ
DMOPVIQ	DN	AVX701
DMOPVIQ	MI	TTY6DTE
DMOPVIQ	MN	Carcinoembryonic antigen CEA (CD66e)
DMOPVIQ	MT	DTT
DMOPVIQ	MA	Modulator
DMOPVIQ	RN	Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
DMOPVIQ	RU	https://pubmed.ncbi.nlm.nih.gov/21952287

DM7O29W	DI	DM7O29W
DM7O29W	DN	AVX901
DM7O29W	MI	TT6EO5L
DM7O29W	MN	Erbb2 tyrosine kinase receptor (HER2)
DM7O29W	MT	DTT
DM7O29W	MA	Inhibitor
DM7O29W	RN	ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health.
DM7O29W	RU	https://clinicaltrials.gov/ct2/show/NCT01526473

DMWLZI6	DI	DMWLZI6
DMWLZI6	DN	AZD0466
DMWLZI6	MI	TTJGNVC
DMWLZI6	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMWLZI6	MT	DTT
DMWLZI6	MA	Inhibitor
DMWLZI6	RN	Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
DMWLZI6	RU	https://pubmed.ncbi.nlm.nih.gov/33495510

DMWLZI6	DI	DMWLZI6
DMWLZI6	DN	AZD0466
DMWLZI6	MI	TTU1E82
DMWLZI6	MN	Apoptosis regulator Bcl-xL (BCL-xL)
DMWLZI6	MT	DTT
DMWLZI6	MA	Inhibitor
DMWLZI6	RN	Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
DMWLZI6	RU	https://pubmed.ncbi.nlm.nih.gov/33495510

DMT2FAP	DI	DMT2FAP
DMT2FAP	DN	AZD-2836
DMT2FAP	MI	TTCJ2X8
DMT2FAP	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMT2FAP	MT	DTT
DMT2FAP	MA	Modulator
DMT2FAP	RN	TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.
DMT2FAP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/

DMD9Y5T	DI	DMD9Y5T
DMD9Y5T	DN	AZD7648
DMD9Y5T	MI	TTK3PY9
DMD9Y5T	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMD9Y5T	MT	DTT
DMD9Y5T	MA	Inhibitor
DMD9Y5T	RN	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065.
DMD9Y5T	RU	https://pubmed.ncbi.nlm.nih.gov/31699977

DMPFGL8	DI	DMPFGL8
DMPFGL8	DN	BAL-101553
DMPFGL8	MI	TTML2WA
DMPFGL8	MN	Tubulin (TUB)
DMPFGL8	MT	DTT
DMPFGL8	MA	Inhibitor
DMPFGL8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPFGL8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPFGL8	DI	DMPFGL8
DMPFGL8	DN	BAL-101553
DMPFGL8	MI	TTYFKSZ
DMPFGL8	MN	Tubulin beta (TUBB)
DMPFGL8	MT	DTT
DMPFGL8	MA	Inhibitor
DMPFGL8	RN	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9.
DMPFGL8	RU	https://pubmed.ncbi.nlm.nih.gov/25407467

DMFA4CK	DI	DMFA4CK
DMFA4CK	DN	BAY 1902607
DMFA4CK	MI	TT2THBD
DMFA4CK	MN	P2X purinoceptor 3 (P2RX3)
DMFA4CK	MT	DTT
DMFA4CK	MA	Antagonist
DMFA4CK	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFA4CK	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMH70A9	DI	DMH70A9
DMH70A9	DN	BCMA CAR T cells
DMH70A9	MI	TTZ3P4W
DMH70A9	MN	B-cell maturation protein (TNFRSF17)
DMH70A9	MT	DTT
DMH70A9	MA	CAR-T-Cell-Therapy
DMH70A9	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMH70A9	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM1DHPO	DI	DM1DHPO
DM1DHPO	DN	BCMA CAR-T
DM1DHPO	MI	TTZ3P4W
DM1DHPO	MN	B-cell maturation protein (TNFRSF17)
DM1DHPO	MT	DTT
DM1DHPO	MA	CAR-T-Cell-Therapy
DM1DHPO	RN	ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma
DM1DHPO	RU	https://clinicaltrials.gov/ct2/show/NCT03322735

DMZK7IT	DI	DMZK7IT
DMZK7IT	DN	BCT-100
DMZK7IT	MI	TTSANDR
DMZK7IT	MN	Arginase (ARG)
DMZK7IT	MT	DTT
DMZK7IT	MA	Modulator
DMZK7IT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMZK7IT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ5MPG	DI	DMJ5MPG
DMJ5MPG	DN	BDC-1001
DMJ5MPG	MI	TTY6DTE
DMJ5MPG	MN	Carcinoembryonic antigen CEA (CD66e)
DMJ5MPG	MT	DTT
DMJ5MPG	RN	Clinical pipeline report, company report or official report of Bolt Biotherapeutics.
DMJ5MPG	RU	https://www.boltbio.com/pipeline/

DMODTX5	DI	DMODTX5
DMODTX5	DN	BDTX-189
DMODTX5	MI	TTGKNB4
DMODTX5	MN	Epidermal growth factor receptor (EGFR)
DMODTX5	MT	DTT
DMODTX5	MA	Inhibitor
DMODTX5	RN	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
DMODTX5	RU	https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/

DMODTX5	DI	DMODTX5
DMODTX5	DN	BDTX-189
DMODTX5	MI	TT6EO5L
DMODTX5	MN	Erbb2 tyrosine kinase receptor (HER2)
DMODTX5	MT	DTT
DMODTX5	MA	Inhibitor
DMODTX5	RN	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
DMODTX5	RU	https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/

DMXVRI0	DI	DMXVRI0
DMXVRI0	DN	Beclanorsen
DMXVRI0	MI	TTFOUV4
DMXVRI0	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMXVRI0	MT	DTT
DMXVRI0	RN	Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.
DMXVRI0	RU	https://pubmed.ncbi.nlm.nih.gov/25589916

DMVYTG7	DI	DMVYTG7
DMVYTG7	DN	BGB-283
DMVYTG7	MI	TTWCGQT
DMVYTG7	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMVYTG7	MT	DTT
DMVYTG7	MA	Inhibitor
DMVYTG7	RN	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.
DMVYTG7	RU	https://pubmed.ncbi.nlm.nih.gov/26208524

DM5VG6S	DI	DM5VG6S
DM5VG6S	DN	BGB-A333
DM5VG6S	MI	TT8ZLTI
DM5VG6S	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5VG6S	MT	DTT
DM5VG6S	RN	Clinical pipeline report, company report or official report of BeiGene.
DM5VG6S	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMI42Q0	DI	DMI42Q0
DMI42Q0	DN	BGB-A425
DMI42Q0	MI	TT1RWL7
DMI42Q0	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMI42Q0	MT	DTT
DMI42Q0	RN	Clinical pipeline report, company report or official report of BeiGene.
DMI42Q0	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMXKDUL	DI	DMXKDUL
DMXKDUL	DN	BGT226
DMXKDUL	MI	TTHBTOP
DMXKDUL	MN	PI3-kinase gamma (PIK3CG)
DMXKDUL	MT	DTT
DMXKDUL	MA	Modulator
DMXKDUL	RN	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
DMXKDUL	RU	https://pubmed.ncbi.nlm.nih.gov/21959532

DMXKDUL	DI	DMXKDUL
DMXKDUL	DN	BGT226
DMXKDUL	MI	TTCJG29
DMXKDUL	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMXKDUL	MT	DTT
DMXKDUL	MA	Modulator
DMXKDUL	RN	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8.
DMXKDUL	RU	https://pubmed.ncbi.nlm.nih.gov/21959532

DMTOMWB	DI	DMTOMWB
DMTOMWB	DN	BI 1206
DMTOMWB	MI	TT5RWKQ
DMTOMWB	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMTOMWB	MT	DTT
DMTOMWB	RN	Clinical pipeline report, company report or official report of BioInvent.
DMTOMWB	RU	https://www.bioinvent.com/pipeline/bi-1206-in-solid-tumors/

DMR8EPF	DI	DMR8EPF
DMR8EPF	DN	BIIB-087
DMR8EPF	MI	TTT2CZY
DMR8EPF	MN	Retinoschisin (RS1)
DMR8EPF	MT	DTT
DMR8EPF	RN	ClinicalTrials.gov (NCT02416622) Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS). U.S. National Institutes of Health.
DMR8EPF	RU	https://clinicaltrials.gov/ct2/show/NCT02416622

DMV1EA9	DI	DMV1EA9
DMV1EA9	DN	BIL010t
DMV1EA9	MI	TT473XN
DMV1EA9	MN	P2X purinoceptor 7 (P2RX7)
DMV1EA9	MT	DTT
DMV1EA9	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMV1EA9	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMZEA9X	DI	DMZEA9X
DMZEA9X	DN	BIW-8962
DMZEA9X	MI	TTGOFW6
DMZEA9X	MN	Ganglioside GM2 activator (GM2A)
DMZEA9X	MT	DTT
DMZEA9X	RN	Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63.
DMZEA9X	RU	https://pubmed.ncbi.nlm.nih.gov/21895875

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TTCYAXN
DMFKA4G	MN	Chloride channel unspecific (ClC)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TT1GHVO
DMFKA4G	MN	Matrix metalloproteinase (MMP)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMFKA4G	DI	DMFKA4G
DMFKA4G	DN	BLZ-100
DMFKA4G	MI	TT6X50U
DMFKA4G	MN	Matrix metalloproteinase-9 (MMP-9)
DMFKA4G	MT	DTT
DMFKA4G	MA	Inhibitor
DMFKA4G	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMFKA4G	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMDQO0S	DI	DMDQO0S
DMDQO0S	DN	BMS-753493
DMDQO0S	MI	TTVC37M
DMDQO0S	MN	Folate receptor alpha (FOLR1)
DMDQO0S	MT	DTT
DMDQO0S	MA	Modulator
DMDQO0S	RN	A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
DMDQO0S	RU	https://pubmed.ncbi.nlm.nih.gov/25380635

DMGM7QD	DI	DMGM7QD
DMGM7QD	DN	BMS-777607
DMGM7QD	MI	TTNDSF4
DMGM7QD	MN	Proto-oncogene c-Met (MET)
DMGM7QD	MT	DTT
DMGM7QD	MA	Inhibitor
DMGM7QD	RN	Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4.
DMGM7QD	RU	https://pubmed.ncbi.nlm.nih.gov/19260711

DM5HUY8	DI	DM5HUY8
DM5HUY8	DN	BMS-863233
DM5HUY8	MI	TTSMTDI
DM5HUY8	MN	CDC7-related kinase (CDC7)
DM5HUY8	MT	DTT
DM5HUY8	MA	Modulator
DM5HUY8	RN	Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
DM5HUY8	RU	https://pubmed.ncbi.nlm.nih.gov/22560567

DMDCHM7	DI	DMDCHM7
DMDCHM7	DN	BMS-986016
DMDCHM7	MI	TTNVXAW
DMDCHM7	MN	Lymphocyte activation gene 3 protein (LAG3)
DMDCHM7	MT	DTT
DMDCHM7	MA	Modulator
DMDCHM7	RN	Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
DMDCHM7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216/

DM6LDI4	DI	DM6LDI4
DM6LDI4	DN	BMS-986158
DM6LDI4	MI	TTE4BSY
DM6LDI4	MN	Bromodomain and extraterminal domain protein (BET)
DM6LDI4	MT	DTT
DM6LDI4	MA	Inhibitor
DM6LDI4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6LDI4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM10J4	DI	DMM10J4
DMM10J4	DN	BMS-986288
DMM10J4	MI	TTI2S1D
DMM10J4	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMM10J4	MT	DTT
DMM10J4	MA	Inhibitor
DMM10J4	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMM10J4	RU	https://cytomx.com/pipeline/

DMTEY1L	DI	DMTEY1L
DMTEY1L	DN	BMS-986315
DMTEY1L	MI	TTC4IMS
DMTEY1L	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMTEY1L	MT	DTT
DMTEY1L	MA	Inhibitor
DMTEY1L	RN	ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
DMTEY1L	RU	https://clinicaltrials.gov/ct2/show/NCT04349267

DMA9MP5	DI	DMA9MP5
DMA9MP5	DN	BN-2629
DMA9MP5	MI	DTI7UX6
DMA9MP5	MN	Breast cancer resistance protein (ABCG2)
DMA9MP5	MT	DTP
DMA9MP5	MA	Substrate
DMA9MP5	RN	Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters. AAPS J. 2010 Dec;12(4):617-27.
DMA9MP5	RU	https://doi.org/10.1208/s12248-010-9225-x

DMA9MP5	DI	DMA9MP5
DMA9MP5	DN	BN-2629
DMA9MP5	MI	TTUTN1I
DMA9MP5	MN	Human Deoxyribonucleic acid (hDNA)
DMA9MP5	MT	DTT
DMA9MP5	MA	Binder
DMA9MP5	RN	Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226.
DMA9MP5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2620844/

DMGF2PU	DI	DMGF2PU
DMGF2PU	DN	BNT411
DMGF2PU	MI	TTRJ1K4
DMGF2PU	MN	Toll-like receptor 7 (TLR7)
DMGF2PU	MT	DTT
DMGF2PU	MA	Agonist
DMGF2PU	RN	Clinical pipeline report, company report or official report of BioNTech.
DMGF2PU	RU	https://biontech.de/science/pipeline

DMIMA4V	DI	DMIMA4V
DMIMA4V	DN	BPX-501
DMIMA4V	MI	TTXQYT6
DMIMA4V	MN	T-cells (T-cells)
DMIMA4V	MT	DTT
DMIMA4V	MA	Immunomodulator
DMIMA4V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIMA4V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMV9QGW	DI	DMV9QGW
DMV9QGW	DN	BPX-601
DMV9QGW	MI	TT9T4AV
DMV9QGW	MN	Prostate stem cell antigen (PSCA)
DMV9QGW	MT	DTT
DMV9QGW	MA	CAR-T-Cell-Therapy
DMV9QGW	RN	ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
DMV9QGW	RU	https://clinicaltrials.gov/ct2/show/NCT02744287

DMCEGP2	DI	DMCEGP2
DMCEGP2	DN	BrevaRex
DMCEGP2	MI	TTBHFYQ
DMCEGP2	MN	Mucin-1 (MUC1)
DMCEGP2	MT	DTT
DMCEGP2	RN	Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
DMCEGP2	RU	https://pubmed.ncbi.nlm.nih.gov/15550589

DMQKXSW	DI	DMQKXSW
DMQKXSW	DN	BRN-3122594
DMQKXSW	MI	DE4LYSA
DMQKXSW	MN	Cytochrome P450 3A4 (CYP3A4)
DMQKXSW	MT	DME
DMQKXSW	MA	Metabolism
DMQKXSW	RN	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
DMQKXSW	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443

DMYBKMV	DI	DMYBKMV
DMYBKMV	DN	BT5528
DMYBKMV	MI	TTRJB2G
DMYBKMV	MN	Ephrin type-A receptor 2 (EPHA2)
DMYBKMV	MT	DTT
DMYBKMV	RN	MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394.
DMYBKMV	RU	https://pubmed.ncbi.nlm.nih.gov/32398269

DM1FJW6	DI	DM1FJW6
DM1FJW6	DN	BT8009
DM1FJW6	MI	TTPO9EG
DM1FJW6	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DM1FJW6	MT	DTT
DM1FJW6	RN	Clinical pipeline report, company report or official report of Bicycle Therapeutics.
DM1FJW6	RU	https://www.bicycletherapeutics.com/wp-content/uploads/BT8009-AACR-4479-Rigby.pdf

DMEWXFK	DI	DMEWXFK
DMEWXFK	DN	C 82
DMEWXFK	MI	TTRPKQG
DMEWXFK	MN	Beta-catenin (CTNNB1)
DMEWXFK	MT	DTT
DMEWXFK	MA	Inhibitor
DMEWXFK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWXFK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMEWXFK	DI	DMEWXFK
DMEWXFK	DN	C 82
DMEWXFK	MI	TTFRCTK
DMEWXFK	MN	CREB-binding protein (CREBBP)
DMEWXFK	MT	DTT
DMEWXFK	MA	Inhibitor
DMEWXFK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEWXFK	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMPJLS4	DI	DMPJLS4
DMPJLS4	DN	CAD-1883
DMPJLS4	MI	TTKU9YD
DMPJLS4	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMPJLS4	MT	DTT
DMPJLS4	MA	Activator
DMPJLS4	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMPJLS4	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMUZIRY	DI	DMUZIRY
DMUZIRY	DN	Cal-1
DMUZIRY	MI	TT2CEJG
DMUZIRY	MN	C-C chemokine receptor type 5 (CCR5)
DMUZIRY	MT	DTT
DMUZIRY	MA	Modulator
DMUZIRY	RN	Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2014 Feb 12;1:11.
DMUZIRY	RU	https://pubmed.ncbi.nlm.nih.gov/26015947

DM6ZXWY	DI	DM6ZXWY
DM6ZXWY	DN	CAR.CD30 cells
DM6ZXWY	MI	TT2GM5R
DM6ZXWY	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM6ZXWY	MT	DTT
DM6ZXWY	MA	CAR-T-Cell-Therapy
DM6ZXWY	RN	ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
DM6ZXWY	RU	https://clinicaltrials.gov/ct2/show/NCT02663297

DMOI5PB	DI	DMOI5PB
DMOI5PB	DN	CARCIK-CD19
DMOI5PB	MI	TTW640A
DMOI5PB	MN	B-lymphocyte surface antigen B4 (CD19)
DMOI5PB	MT	DTT
DMOI5PB	MA	CAR-T-Cell-Therapy
DMOI5PB	RN	ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
DMOI5PB	RU	https://clinicaltrials.gov/ct2/show/NCT03389035

DMENIQ7	DI	DMENIQ7
DMENIQ7	DN	CAR-T cells targeting BCMA
DMENIQ7	MI	TTZ3P4W
DMENIQ7	MN	B-cell maturation protein (TNFRSF17)
DMENIQ7	MT	DTT
DMENIQ7	MA	CAR-T-Cell-Therapy
DMENIQ7	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMENIQ7	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMIM9TZ	DI	DMIM9TZ
DMIM9TZ	DN	CAR-T cells targeting CD19
DMIM9TZ	MI	TTW640A
DMIM9TZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMIM9TZ	MT	DTT
DMIM9TZ	MA	CAR-T-Cell-Therapy
DMIM9TZ	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMIM9TZ	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMJVENR	DI	DMJVENR
DMJVENR	DN	CAR-T cells targeting CD2
DMJVENR	MI	TT80ARU
DMJVENR	MN	Ganglioside GD2 (GD2)
DMJVENR	MT	DTT
DMJVENR	MA	CAR-T-Cell-Therapy
DMJVENR	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DMJVENR	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DMVFHL9	DI	DMVFHL9
DMVFHL9	DN	CAR-T cells targeting CD22
DMVFHL9	MI	TTM6QSK
DMVFHL9	MN	B-cell receptor CD22 (CD22)
DMVFHL9	MT	DTT
DMVFHL9	MA	CAR-T-Cell-Therapy
DMVFHL9	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMVFHL9	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMZHJV8	DI	DMZHJV8
DMZHJV8	DN	CAR-T cells targeting CD30
DMZHJV8	MI	TT2GM5R
DMZHJV8	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMZHJV8	MT	DTT
DMZHJV8	MA	CAR-T-Cell-Therapy
DMZHJV8	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMZHJV8	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DM6VCPX	DI	DM6VCPX
DM6VCPX	DN	CAR-T cells targeting CEA
DM6VCPX	MI	TTY6DTE
DM6VCPX	MN	Carcinoembryonic antigen CEA (CD66e)
DM6VCPX	MT	DTT
DM6VCPX	MA	CAR-T-Cell-Therapy
DM6VCPX	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DM6VCPX	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DMCPM92	DI	DMCPM92
DMCPM92	DN	CAR-T cells targeting CLL1
DMCPM92	MI	TT70N8V
DMCPM92	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMCPM92	MT	DTT
DMCPM92	MA	CAR-T-Cell-Therapy
DMCPM92	RN	ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMCPM92	RU	https://clinicaltrials.gov/ct2/show/NCT03312205

DMREQCF	DI	DMREQCF
DMREQCF	DN	CAR-T Cells targeting EpCAM
DMREQCF	MI	TTZ8WH4
DMREQCF	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMREQCF	MT	DTT
DMREQCF	MA	CAR-T-Cell-Therapy
DMREQCF	RN	ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
DMREQCF	RU	https://clinicaltrials.gov/ct2/show/NCT03013712

DMN3C2I	DI	DMN3C2I
DMN3C2I	DN	CAR-T cells targeting EphA2
DMN3C2I	MI	TTRJB2G
DMN3C2I	MN	Ephrin type-A receptor 2 (EPHA2)
DMN3C2I	MT	DTT
DMN3C2I	MA	CAR-T-Cell-Therapy
DMN3C2I	RN	ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
DMN3C2I	RU	https://clinicaltrials.gov/ct2/show/NCT02575261

DMFCPG0	DI	DMFCPG0
DMFCPG0	DN	CAR-T cells targeting GD2
DMFCPG0	MI	TT80ARU
DMFCPG0	MN	Ganglioside GD2 (GD2)
DMFCPG0	MT	DTT
DMFCPG0	MA	CAR-T-Cell-Therapy
DMFCPG0	RN	ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
DMFCPG0	RU	https://clinicaltrials.gov/ct2/show/NCT03252171

DMT89K2	DI	DMT89K2
DMT89K2	DN	CAR-T cells targeting GD2
DMT89K2	MI	TT80ARU
DMT89K2	MN	Ganglioside GD2 (GD2)
DMT89K2	MT	DTT
DMT89K2	MA	CAR-T-Cell-Therapy
DMT89K2	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMT89K2	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMDSKR2	DI	DMDSKR2
DMDSKR2	DN	CAR-T cells targeting Glypican-3 (GPC3)
DMDSKR2	MI	TTJTSX4
DMDSKR2	MN	Glypican-3 (GPC3)
DMDSKR2	MT	DTT
DMDSKR2	MA	CAR-T-Cell-Therapy
DMDSKR2	RN	ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3
DMDSKR2	RU	https://clinicaltrials.gov/ct2/show/NCT02723942

DM6H1MQ	DI	DM6H1MQ
DM6H1MQ	DN	CAR-T cells targeting GPC3
DM6H1MQ	MI	TTJTSX4
DM6H1MQ	MN	Glypican-3 (GPC3)
DM6H1MQ	MT	DTT
DM6H1MQ	MA	CAR-T-Cell-Therapy
DM6H1MQ	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DM6H1MQ	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DM1W7LV	DI	DM1W7LV
DM1W7LV	DN	CAR-T cells targeting MAGE-A1
DM1W7LV	MI	TT63M7Q
DM1W7LV	MN	Melanoma-associated antigen 1 (MAGEA1)
DM1W7LV	MT	DTT
DM1W7LV	MA	CAR-T-Cell-Therapy
DM1W7LV	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DM1W7LV	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMUBEX4	DI	DMUBEX4
DMUBEX4	DN	CAR-T cells targeting MAGE-A4
DMUBEX4	MI	TT9EQUY
DMUBEX4	MN	Melanoma-associated antigen 4 (MAGEA4)
DMUBEX4	MT	DTT
DMUBEX4	MA	CAR-T-Cell-Therapy
DMUBEX4	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMUBEX4	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMMAQJ7	DI	DMMAQJ7
DMMAQJ7	DN	CAR-T cells targeting Mesothelin
DMMAQJ7	MI	TT4RXME
DMMAQJ7	MN	Mesothelin (MSLN)
DMMAQJ7	MT	DTT
DMMAQJ7	MA	CAR-T-Cell-Therapy
DMMAQJ7	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMMAQJ7	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMPK35H	DI	DMPK35H
DMPK35H	DN	CAR-T cells targeting mesothelin
DMPK35H	MI	TT4RXME
DMPK35H	MN	Mesothelin (MSLN)
DMPK35H	MT	DTT
DMPK35H	MA	CAR-T-Cell-Therapy
DMPK35H	RN	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
DMPK35H	RU	https://clinicaltrials.gov/ct2/show/NCT02959151

DM5FKU1	DI	DM5FKU1
DM5FKU1	DN	CAR-T cells targeting Muc1
DM5FKU1	MI	TTBHFYQ
DM5FKU1	MN	Mucin-1 (MUC1)
DM5FKU1	MT	DTT
DM5FKU1	MA	CAR-T-Cell-Therapy
DM5FKU1	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DM5FKU1	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DMBPN4K	DI	DMBPN4K
DMBPN4K	DN	CAR-T cells targeting MucI
DMBPN4K	MI	TTBHFYQ
DMBPN4K	MN	Mucin-1 (MUC1)
DMBPN4K	MT	DTT
DMBPN4K	MA	CAR-T-Cell-Therapy
DMBPN4K	RN	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
DMBPN4K	RU	https://clinicaltrials.gov/ct2/show/NCT03356808

DMW340V	DI	DMW340V
DMW340V	DN	CAR-T cells targeting PSMA
DMW340V	MI	TT9G4N0
DMW340V	MN	Glutamate carboxypeptidase II (GCPII)
DMW340V	MT	DTT
DMW340V	MA	CAR-T-Cell-Therapy
DMW340V	RN	ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
DMW340V	RU	https://clinicaltrials.gov/ct2/show/NCT03356795

DM0MCTJ	DI	DM0MCTJ
DM0MCTJ	DN	CART-123 cells
DM0MCTJ	MI	TTENHJ0
DM0MCTJ	MN	Interleukin 3 receptor alpha (IL3RA)
DM0MCTJ	MT	DTT
DM0MCTJ	MA	CAR-T-Cell-Therapy
DM0MCTJ	RN	ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
DM0MCTJ	RU	https://clinicaltrials.gov/ct2/show/NCT03556982

DMUS79V	DI	DMUS79V
DMUS79V	DN	CART-138 cells
DMUS79V	MI	TTYDSVG
DMUS79V	MN	Syndecan-1 (SDC1)
DMUS79V	MT	DTT
DMUS79V	MA	CAR-T-Cell-Therapy
DMUS79V	RN	ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
DMUS79V	RU	https://clinicaltrials.gov/ct2/show/NCT01886976

DMB4HEW	DI	DMB4HEW
DMB4HEW	DN	CART-138 cells
DMB4HEW	MI	TTYDSVG
DMB4HEW	MN	Syndecan-1 (SDC1)
DMB4HEW	MT	DTT
DMB4HEW	MA	CAR-T-Cell-Therapy
DMB4HEW	RN	ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
DMB4HEW	RU	https://clinicaltrials.gov/ct2/show/NCT03196414

DMWYT4K	DI	DMWYT4K
DMWYT4K	DN	CART-19 cells
DMWYT4K	MI	TTW640A
DMWYT4K	MN	B-lymphocyte surface antigen B4 (CD19)
DMWYT4K	MT	DTT
DMWYT4K	MA	CAR-T-Cell-Therapy
DMWYT4K	RN	ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL
DMWYT4K	RU	https://clinicaltrials.gov/ct2/show/NCT03544021

DMX0R1E	DI	DMX0R1E
DMX0R1E	DN	CART-19/22
DMX0R1E	MI	TTM6QSK
DMX0R1E	MN	B-cell receptor CD22 (CD22)
DMX0R1E	MT	DTT
DMX0R1E	MA	CAR-T-Cell-Therapy(Dual specific)
DMX0R1E	RN	ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
DMX0R1E	RU	https://clinicaltrials.gov/ct2/show/NCT03614858

DMX0R1E	DI	DMX0R1E
DMX0R1E	DN	CART-19/22
DMX0R1E	MI	TTW640A
DMX0R1E	MN	B-lymphocyte surface antigen B4 (CD19)
DMX0R1E	MT	DTT
DMX0R1E	MA	CAR-T-Cell-Therapy(Dual specific)
DMX0R1E	RN	ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
DMX0R1E	RU	https://clinicaltrials.gov/ct2/show/NCT03614858

DMVW1GY	DI	DMVW1GY
DMVW1GY	DN	CART-19/BCMA
DMVW1GY	MI	TTZ3P4W
DMVW1GY	MN	B-cell maturation protein (TNFRSF17)
DMVW1GY	MT	DTT
DMVW1GY	MA	CAR-T-Cell-Therapy(Dual specific)
DMVW1GY	RN	ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
DMVW1GY	RU	https://clinicaltrials.gov/ct2/show/NCT03455972

DMVW1GY	DI	DMVW1GY
DMVW1GY	DN	CART-19/BCMA
DMVW1GY	MI	TTW640A
DMVW1GY	MN	B-lymphocyte surface antigen B4 (CD19)
DMVW1GY	MT	DTT
DMVW1GY	MA	CAR-T-Cell-Therapy(Dual specific)
DMVW1GY	RN	ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
DMVW1GY	RU	https://clinicaltrials.gov/ct2/show/NCT03455972

DMKGU5F	DI	DMKGU5F
DMKGU5F	DN	CART20
DMKGU5F	MI	TTUE541
DMKGU5F	MN	Leukocyte surface antigen Leu-16 (CD20)
DMKGU5F	MT	DTT
DMKGU5F	MA	CAR-T-Cell-Therapy
DMKGU5F	RN	ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
DMKGU5F	RU	https://clinicaltrials.gov/ct2/show/NCT02965157

DMLE8T9	DI	DMLE8T9
DMLE8T9	DN	CART30
DMLE8T9	MI	TT2GM5R
DMLE8T9	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMLE8T9	MT	DTT
DMLE8T9	MA	CAR-T-Cell-Therapy
DMLE8T9	RN	ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
DMLE8T9	RU	https://clinicaltrials.gov/ct2/show/NCT02259556

DM81JIT	DI	DM81JIT
DM81JIT	DN	CART33 cells
DM81JIT	MI	TTJVYO3
DM81JIT	MN	Myeloid cell surface antigen CD33 (CD33)
DM81JIT	MT	DTT
DM81JIT	MA	CAR-T-Cell-Therapy
DM81JIT	RN	ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
DM81JIT	RU	https://clinicaltrials.gov/ct2/show/NCT01864902

DMWOYNT	DI	DMWOYNT
DMWOYNT	DN	CART-BCMA cells
DMWOYNT	MI	TTZ3P4W
DMWOYNT	MN	B-cell maturation protein (TNFRSF17)
DMWOYNT	MT	DTT
DMWOYNT	MA	CAR-T-Cell-Therapy
DMWOYNT	RN	ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
DMWOYNT	RU	https://clinicaltrials.gov/ct2/show/NCT03196414

DM3I267	DI	DM3I267
DM3I267	DN	CART-EGFR
DM3I267	MI	TTGKNB4
DM3I267	MN	Epidermal growth factor receptor (EGFR)
DM3I267	MT	DTT
DM3I267	MA	CAR-T-Cell-Therapy
DM3I267	RN	ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
DM3I267	RU	https://clinicaltrials.gov/ct2/show/NCT01869166

DMMTDK1	DI	DMMTDK1
DMMTDK1	DN	CART-HER-2
DMMTDK1	MI	TT6EO5L
DMMTDK1	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMTDK1	MT	DTT
DMMTDK1	MA	CAR-T-Cell-Therapy
DMMTDK1	RN	ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
DMMTDK1	RU	https://clinicaltrials.gov/ct2/show/NCT01935843

DMKCJ75	DI	DMKCJ75
DMKCJ75	DN	CBL0102
DMKCJ75	MI	TTETDKQ
DMKCJ75	MN	Facilitates chromatin transcription complex (FACT)
DMKCJ75	MT	DTT
DMKCJ75	MA	Modulator
DMKCJ75	RN	Company report (Incuron)
DMKCJ75	RU	http://www.incuron.ru/en/news-en/item/2-incuron-announce-cbl0102-orphan-drug-status-for-hepatocellular-carcinoma

DMCWVPU	DI	DMCWVPU
DMCWVPU	DN	CBP-501
DMCWVPU	MI	TTMUG9D
DMCWVPU	MN	MAPK-activated protein kinase 2 (MAPKAPK2)
DMCWVPU	MT	DTT
DMCWVPU	MA	Inhibitor
DMCWVPU	RN	National Cancer Institute Drug Dictionary (drug id 577812).
DMCWVPU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812

DMCWVPU	DI	DMCWVPU
DMCWVPU	DN	CBP-501
DMCWVPU	MI	TT3DCYJ
DMCWVPU	MN	Microtubule affinity regulating kinase 3 (MARK3)
DMCWVPU	MT	DTT
DMCWVPU	MA	Inhibitor
DMCWVPU	RN	National Cancer Institute Drug Dictionary (drug id 577812).
DMCWVPU	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	DE5IED8
DMMQYL9	MN	Cytochrome P450 2C9 (CYP2C9)
DMMQYL9	MT	DME
DMMQYL9	MA	Metabolism
DMMQYL9	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DMMQYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	DE4LYSA
DMMQYL9	MN	Cytochrome P450 3A4 (CYP3A4)
DMMQYL9	MT	DME
DMMQYL9	MA	Metabolism
DMMQYL9	RN	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
DMMQYL9	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29297772

DMMQYL9	DI	DMMQYL9
DMMQYL9	DN	CC-223
DMMQYL9	MI	TTCJG29
DMMQYL9	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMQYL9	MT	DTT
DMMQYL9	MA	Modulator
DMMQYL9	RN	CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305.
DMMQYL9	RU	https://pubmed.ncbi.nlm.nih.gov/25855786

DM9UZM1	DI	DM9UZM1
DM9UZM1	DN	CCS1477
DM9UZM1	MI	TTFRCTK
DM9UZM1	MN	CREB-binding protein (CREBBP)
DM9UZM1	MT	DTT
DM9UZM1	MA	Inhibitor
DM9UZM1	RN	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
DM9UZM1	RU	https://pubmed.ncbi.nlm.nih.gov/33431496

DM9UZM1	DI	DM9UZM1
DM9UZM1	DN	CCS1477
DM9UZM1	MI	TTGH73N
DM9UZM1	MN	Histone acetyltransferase p300 (EP300)
DM9UZM1	MT	DTT
DM9UZM1	MA	Inhibitor
DM9UZM1	RN	Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137.
DM9UZM1	RU	https://pubmed.ncbi.nlm.nih.gov/33431496

DM2B1V0	DI	DM2B1V0
DM2B1V0	DN	CCT301-38 (targeting ROR2)
DM2B1V0	MI	TTUDPCI
DM2B1V0	MN	Neurotrophic tyrosine kinase ROR2 (ROR2)
DM2B1V0	MT	DTT
DM2B1V0	MA	CAR-T-Cell-Therapy
DM2B1V0	RN	ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
DM2B1V0	RU	https://clinicaltrials.gov/ct2/show/NCT03393936

DM0F9CD	DI	DM0F9CD
DM0F9CD	DN	CCT301-59 (targeting ROR2)
DM0F9CD	MI	TTUDPCI
DM0F9CD	MN	Neurotrophic tyrosine kinase ROR2 (ROR2)
DM0F9CD	MT	DTT
DM0F9CD	MA	CAR-T-Cell-Therapy
DM0F9CD	RN	ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
DM0F9CD	RU	https://clinicaltrials.gov/ct2/show/NCT03393936

DMHOWU5	DI	DMHOWU5
DMHOWU5	DN	CD123-specific gene-engineered T cells
DMHOWU5	MI	TTENHJ0
DMHOWU5	MN	Interleukin 3 receptor alpha (IL3RA)
DMHOWU5	MT	DTT
DMHOWU5	MA	CAR-T-Cell-Therapy
DMHOWU5	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMHOWU5	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMHMC19	DI	DMHMC19
DMHMC19	DN	CD137 CAR-T Cell
DMHMC19	MI	TTPW9LJ
DMHMC19	MN	Co-stimulatory molecule 4-1BB (CD137)
DMHMC19	MT	DTT
DMHMC19	MA	CAR-T-Cell-Therapy
DMHMC19	RN	ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
DMHMC19	RU	https://clinicaltrials.gov/ct2/show/NCT02965092

DMCSGNU	DI	DMCSGNU
DMCSGNU	DN	CD138 CAR T cells
DMCSGNU	MI	TTYDSVG
DMCSGNU	MN	Syndecan-1 (SDC1)
DMCSGNU	MT	DTT
DMCSGNU	MA	CAR-T-Cell-Therapy
DMCSGNU	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMCSGNU	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DMRJ3ND	DI	DMRJ3ND
DMRJ3ND	DN	CD19 and CD20 CAR-T Cells
DMRJ3ND	MI	TTW640A
DMRJ3ND	MN	B-lymphocyte surface antigen B4 (CD19)
DMRJ3ND	MT	DTT
DMRJ3ND	MA	CAR-T-Cell-Therapy(Dual specific)
DMRJ3ND	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMRJ3ND	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DMRJ3ND	DI	DMRJ3ND
DMRJ3ND	DN	CD19 and CD20 CAR-T Cells
DMRJ3ND	MI	TTUE541
DMRJ3ND	MN	Leukocyte surface antigen Leu-16 (CD20)
DMRJ3ND	MT	DTT
DMRJ3ND	MA	CAR-T-Cell-Therapy(Dual specific)
DMRJ3ND	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMRJ3ND	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DMQB7SZ	DI	DMQB7SZ
DMQB7SZ	DN	CD19 and CD22 CAR-T Cells
DMQB7SZ	MI	TTM6QSK
DMQB7SZ	MN	B-cell receptor CD22 (CD22)
DMQB7SZ	MT	DTT
DMQB7SZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMQB7SZ	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMQB7SZ	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DM581CS	DI	DM581CS
DM581CS	DN	CD19 and CD22 CAR-T Cells
DM581CS	MI	TTM6QSK
DM581CS	MN	B-cell receptor CD22 (CD22)
DM581CS	MT	DTT
DM581CS	MA	CAR-T-Cell-Therapy(Dual specific)
DM581CS	RN	ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
DM581CS	RU	https://clinicaltrials.gov/ct2/show/NCT03468153

DMQB7SZ	DI	DMQB7SZ
DMQB7SZ	DN	CD19 and CD22 CAR-T Cells
DMQB7SZ	MI	TTW640A
DMQB7SZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMQB7SZ	MT	DTT
DMQB7SZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMQB7SZ	RN	ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
DMQB7SZ	RU	https://clinicaltrials.gov/ct2/show/NCT03398967

DM581CS	DI	DM581CS
DM581CS	DN	CD19 and CD22 CAR-T Cells
DM581CS	MI	TTW640A
DM581CS	MN	B-lymphocyte surface antigen B4 (CD19)
DM581CS	MT	DTT
DM581CS	MA	CAR-T-Cell-Therapy(Dual specific)
DM581CS	RN	ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
DM581CS	RU	https://clinicaltrials.gov/ct2/show/NCT03468153

DMQJ6YL	DI	DMQJ6YL
DMQJ6YL	DN	CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL	MI	TTW640A
DMQJ6YL	MN	B-lymphocyte surface antigen B4 (CD19)
DMQJ6YL	MT	DTT
DMQJ6YL	MA	CAR-T-Cell-Therapy
DMQJ6YL	RN	ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
DMQJ6YL	RU	https://clinicaltrials.gov/ct2/show/NCT02134262

DMMHLJQ	DI	DMMHLJQ
DMMHLJQ	DN	CD19 CAR T cells
DMMHLJQ	MI	TTW640A
DMMHLJQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMHLJQ	MT	DTT
DMMHLJQ	MA	CAR-T-Cell-Therapy
DMMHLJQ	RN	ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
DMMHLJQ	RU	https://clinicaltrials.gov/ct2/show/NCT02772198

DMUARWH	DI	DMUARWH
DMUARWH	DN	CD19 CAR T Cells
DMUARWH	MI	TTW640A
DMUARWH	MN	B-lymphocyte surface antigen B4 (CD19)
DMUARWH	MT	DTT
DMUARWH	MA	CAR-T-Cell-Therapy
DMUARWH	RN	ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
DMUARWH	RU	https://clinicaltrials.gov/ct2/show/NCT01475058

DMU348C	DI	DMU348C
DMU348C	DN	CD19 CART
DMU348C	MI	TTW640A
DMU348C	MN	B-lymphocyte surface antigen B4 (CD19)
DMU348C	MT	DTT
DMU348C	MA	CAR-T-Cell-Therapy
DMU348C	RN	ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
DMU348C	RU	https://clinicaltrials.gov/ct2/show/NCT03146533

DM69A1W	DI	DM69A1W
DM69A1W	DN	CD19 CART
DM69A1W	MI	TTW640A
DM69A1W	MN	B-lymphocyte surface antigen B4 (CD19)
DM69A1W	MT	DTT
DM69A1W	MA	CAR-T-Cell-Therapy
DM69A1W	RN	ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL
DM69A1W	RU	https://clinicaltrials.gov/ct2/show/NCT03232619

DMECGKO	DI	DMECGKO
DMECGKO	DN	CD19 CAR-T Cells
DMECGKO	MI	TTW640A
DMECGKO	MN	B-lymphocyte surface antigen B4 (CD19)
DMECGKO	MT	DTT
DMECGKO	MA	CAR-T-Cell-Therapy
DMECGKO	RN	ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
DMECGKO	RU	https://clinicaltrials.gov/ct2/show/NCT03263208

DM8KESD	DI	DM8KESD
DM8KESD	DN	CD19 CAR-T lymphocytes
DM8KESD	MI	TTW640A
DM8KESD	MN	B-lymphocyte surface antigen B4 (CD19)
DM8KESD	MT	DTT
DM8KESD	MA	CAR-T-Cell-Therapy
DM8KESD	RN	ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
DM8KESD	RU	https://clinicaltrials.gov/ct2/show/NCT03467256

DMGDK9C	DI	DMGDK9C
DMGDK9C	DN	CD19 specific CAR T cells
DMGDK9C	MI	TTW640A
DMGDK9C	MN	B-lymphocyte surface antigen B4 (CD19)
DMGDK9C	MT	DTT
DMGDK9C	MA	CAR-T-Cell-Therapy
DMGDK9C	RN	ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
DMGDK9C	RU	https://clinicaltrials.gov/ct2/show/NCT02028455

DM8RXFB	DI	DM8RXFB
DM8RXFB	DN	CD19 targeted chimeric antigen receptor T cells
DM8RXFB	MI	TTW640A
DM8RXFB	MN	B-lymphocyte surface antigen B4 (CD19)
DM8RXFB	MT	DTT
DM8RXFB	MA	CAR-T-Cell-Therapy
DM8RXFB	RN	ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
DM8RXFB	RU	https://clinicaltrials.gov/ct2/show/NCT03118180

DM79GPF	DI	DM79GPF
DM79GPF	DN	CD19.CAR T Cells
DM79GPF	MI	TTW640A
DM79GPF	MN	B-lymphocyte surface antigen B4 (CD19)
DM79GPF	MT	DTT
DM79GPF	MA	CAR-T-Cell-Therapy
DM79GPF	RN	ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
DM79GPF	RU	https://clinicaltrials.gov/ct2/show/NCT03676504

DMNZ7F2	DI	DMNZ7F2
DMNZ7F2	DN	CD19.CAR-T cells
DMNZ7F2	MI	TTW640A
DMNZ7F2	MN	B-lymphocyte surface antigen B4 (CD19)
DMNZ7F2	MT	DTT
DMNZ7F2	MA	CAR-T-Cell-Therapy
DMNZ7F2	RN	ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
DMNZ7F2	RU	https://clinicaltrials.gov/ct2/show/NCT02652910

DMQE7TW	DI	DMQE7TW
DMQE7TW	DN	CD19-CAR T cell
DMQE7TW	MI	TTW640A
DMQE7TW	MN	B-lymphocyte surface antigen B4 (CD19)
DMQE7TW	MT	DTT
DMQE7TW	MA	CAR-T-Cell-Therapy
DMQE7TW	RN	ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
DMQE7TW	RU	https://clinicaltrials.gov/ct2/show/NCT03373071

DMKQRUJ	DI	DMKQRUJ
DMKQRUJ	DN	CD19-directed CAR-T cells
DMKQRUJ	MI	TTW640A
DMKQRUJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMKQRUJ	MT	DTT
DMKQRUJ	MA	CAR-T-Cell-Therapy
DMKQRUJ	RN	ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
DMKQRUJ	RU	https://clinicaltrials.gov/ct2/show/NCT02537977

DMI2OVA	DI	DMI2OVA
DMI2OVA	DN	CD19-targeting CAR T Cells
DMI2OVA	MI	TTW640A
DMI2OVA	MN	B-lymphocyte surface antigen B4 (CD19)
DMI2OVA	MT	DTT
DMI2OVA	MA	CAR-T-Cell-Therapy
DMI2OVA	RN	ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma
DMI2OVA	RU	https://clinicaltrials.gov/ct2/show/NCT02547948

DM4MBUI	DI	DM4MBUI
DM4MBUI	DN	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI	MI	TTM6QSK
DM4MBUI	MN	B-cell receptor CD22 (CD22)
DM4MBUI	MT	DTT
DM4MBUI	MA	CAR-T-Cell-Therapy(Dual specific)
DM4MBUI	RN	ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
DM4MBUI	RU	https://clinicaltrials.gov/ct2/show/NCT02903810

DM4MBUI	DI	DM4MBUI
DM4MBUI	DN	CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells
DM4MBUI	MI	TTW640A
DM4MBUI	MN	B-lymphocyte surface antigen B4 (CD19)
DM4MBUI	MT	DTT
DM4MBUI	MA	CAR-T-Cell-Therapy(Dual specific)
DM4MBUI	RN	ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
DM4MBUI	RU	https://clinicaltrials.gov/ct2/show/NCT02903810

DMHPZ8G	DI	DMHPZ8G
DMHPZ8G	DN	CD20-Specific CAR T Cells
DMHPZ8G	MI	TTUE541
DMHPZ8G	MN	Leukocyte surface antigen Leu-16 (CD20)
DMHPZ8G	MT	DTT
DMHPZ8G	MA	CAR-T-Cell-Therapy
DMHPZ8G	RN	ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
DMHPZ8G	RU	https://clinicaltrials.gov/ct2/show/NCT03277729

DM40NEB	DI	DM40NEB
DM40NEB	DN	CD22 CAR-T
DM40NEB	MI	TTM6QSK
DM40NEB	MN	B-cell receptor CD22 (CD22)
DM40NEB	MT	DTT
DM40NEB	MA	CAR-T-Cell-Therapy
DM40NEB	RN	ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
DM40NEB	RU	https://clinicaltrials.gov/ct2/show/NCT02794961

DM61MBG	DI	DM61MBG
DM61MBG	DN	CD22-Targeted CAR-T cells
DM61MBG	MI	TTM6QSK
DM61MBG	MN	B-cell receptor CD22 (CD22)
DM61MBG	MT	DTT
DM61MBG	MA	CAR-T-Cell-Therapy
DM61MBG	RN	ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
DM61MBG	RU	https://clinicaltrials.gov/ct2/show/NCT02935153

DMM35D2	DI	DMM35D2
DMM35D2	DN	CD33-specific gene-engineered T cells
DMM35D2	MI	TTJVYO3
DMM35D2	MN	Myeloid cell surface antigen CD33 (CD33)
DMM35D2	MT	DTT
DMM35D2	MA	CAR-T-Cell-Therapy
DMM35D2	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMM35D2	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMFZS8A	DI	DMFZS8A
DMFZS8A	DN	CD38 and BCMA CAR-T Cells
DMFZS8A	MI	TTZ3P4W
DMFZS8A	MN	B-cell maturation protein (TNFRSF17)
DMFZS8A	MT	DTT
DMFZS8A	MA	CAR-T-Cell-Therapy(Dual specific)
DMFZS8A	RN	ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
DMFZS8A	RU	https://clinicaltrials.gov/ct2/show/NCT03767751

DMFZS8A	DI	DMFZS8A
DMFZS8A	DN	CD38 and BCMA CAR-T Cells
DMFZS8A	MI	TTPURFN
DMFZS8A	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMFZS8A	MT	DTT
DMFZS8A	MA	CAR-T-Cell-Therapy(Dual specific)
DMFZS8A	RN	ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
DMFZS8A	RU	https://clinicaltrials.gov/ct2/show/NCT03767751

DMPS3I6	DI	DMPS3I6
DMPS3I6	DN	CD38 CAR T cells
DMPS3I6	MI	TTPURFN
DMPS3I6	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMPS3I6	MT	DTT
DMPS3I6	MA	CAR-T-Cell-Therapy
DMPS3I6	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMPS3I6	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM0USBX	DI	DM0USBX
DM0USBX	DN	CD38 CAR-T Cell
DM0USBX	MI	TTPURFN
DM0USBX	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM0USBX	MT	DTT
DM0USBX	MA	CAR-T-Cell-Therapy
DM0USBX	RN	ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
DM0USBX	RU	https://clinicaltrials.gov/ct2/show/NCT03754764

DMCH98G	DI	DMCH98G
DMCH98G	DN	CD38-specific gene-engineered T cells
DMCH98G	MI	TTPURFN
DMCH98G	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMCH98G	MT	DTT
DMCH98G	MA	CAR-T-Cell-Therapy
DMCH98G	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMCH98G	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMS5OL0	DI	DMS5OL0
DMS5OL0	DN	CD56 CAR T cells
DMS5OL0	MI	TTVXPHT
DMS5OL0	MN	Neural cell adhesion molecule 1 (NCAM1)
DMS5OL0	MT	DTT
DMS5OL0	MA	CAR-T-Cell-Therapy
DMS5OL0	RN	ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
DMS5OL0	RU	https://clinicaltrials.gov/ct2/show/NCT03271632

DM35XCT	DI	DM35XCT
DM35XCT	DN	CD56-specific gene-engineered T cells
DM35XCT	MI	TTVXPHT
DM35XCT	MN	Neural cell adhesion molecule 1 (NCAM1)
DM35XCT	MT	DTT
DM35XCT	MA	CAR-T-Cell-Therapy
DM35XCT	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DM35XCT	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMD1V7I	DI	DMD1V7I
DMD1V7I	DN	Celgosivir
DMD1V7I	MI	TTXWASR
DMD1V7I	MN	Intestinal maltase-glucoamylase (MGAM)
DMD1V7I	MT	DTT
DMD1V7I	MA	Modulator
DMD1V7I	RN	Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.
DMD1V7I	RU	https://www.ncbi.nlm.nih.gov/pubmed/19649930

DMAO04B	DI	DMAO04B
DMAO04B	DN	CEP-32496
DMAO04B	MI	TT4DXQT
DMAO04B	MN	Proto-oncogene c-Ret (RET)
DMAO04B	MT	DTT
DMAO04B	MA	Inhibitor
DMAO04B	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAO04B	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAO04B	DI	DMAO04B
DMAO04B	DN	CEP-32496
DMAO04B	MI	TTWCGQT
DMAO04B	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMAO04B	MT	DTT
DMAO04B	MA	Inhibitor
DMAO04B	RN	Clinical pipeline report, company report or official report of Ambit Biosciences.
DMAO04B	RU	http://www.ambitbio.com/CEP32496

DMY8NUF	DI	DMY8NUF
DMY8NUF	DN	CEP-9722
DMY8NUF	MI	TTEBCY8
DMY8NUF	MN	Poly [ADP-ribose] polymerase (PARP)
DMY8NUF	MT	DTT
DMY8NUF	MA	Modulator
DMY8NUF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMY8NUF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCR7EF	DI	DMCR7EF
DMCR7EF	DN	CEQ-508
DMCR7EF	MI	TTRPKQG
DMCR7EF	MN	Beta-catenin (CTNNB1)
DMCR7EF	MT	DTT
DMCR7EF	RN	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
DMCR7EF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/

DMUW6KP	DI	DMUW6KP
DMUW6KP	DN	CERC-803
DMUW6KP	MI	DEFYE6A
DMUW6KP	MN	L-fucose isomerase (fucI)
DMUW6KP	MT	DME
DMUW6KP	MA	Metabolism
DMUW6KP	RN	nan
DMUW6KP	RU	nan

DMD3XMW	DI	DMD3XMW
DMD3XMW	DN	Cethrin
DMD3XMW	MI	TTMQO60
DMD3XMW	MN	Rho-associated protein kinase (ROCK)
DMD3XMW	MT	DTT
DMD3XMW	MA	Modulator
DMD3XMW	RN	A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
DMD3XMW	RU	https://pubmed.ncbi.nlm.nih.gov/21381984

DMJBQ96	DI	DMJBQ96
DMJBQ96	DN	Cetrelimab
DMJBQ96	MI	TTNBFWK
DMJBQ96	MN	Programmed cell death protein 1 (PD-1)
DMJBQ96	MT	DTT
DMJBQ96	RN	Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924.
DMJBQ96	RU	https://pubmed.ncbi.nlm.nih.gov/30544512

DM2BXDU	DI	DM2BXDU
DM2BXDU	DN	CFG920
DM2BXDU	MI	TTRA5BZ
DM2BXDU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM2BXDU	MT	DTT
DM2BXDU	MA	Inhibitor
DM2BXDU	RN	Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
DM2BXDU	RU	https://pubmed.ncbi.nlm.nih.gov/23880851

DMB5KRA	DI	DMB5KRA
DMB5KRA	DN	CFI-402411
DMB5KRA	MI	TTSHWUP
DMB5KRA	MN	MEK kinase kinase 1 (MAP4K1)
DMB5KRA	MT	DTT
DMB5KRA	MA	Inhibitor
DMB5KRA	RN	Clinical pipeline report, company report or official report of Treadwell Therapeutics.
DMB5KRA	RU	https://treadwelltx.com/pipeline/

DMPYW28	DI	DMPYW28
DMPYW28	DN	CG-806
DMPYW28	MI	TTGM6VW
DMPYW28	MN	Tyrosine-protein kinase BTK (ATK)
DMPYW28	MT	DTT
DMPYW28	MA	Inhibitor
DMPYW28	RN	Clinical pipeline report, company report or official report of Aptose Biosciences.
DMPYW28	RU	https://www.aptose.com/product-pipeline/cg-806-for-b-cell

DMHNFXR	DI	DMHNFXR
DMHNFXR	DN	Chimeric Antigen Receptor Modified T cells Targeting CD19
DMHNFXR	MI	TTW640A
DMHNFXR	MN	B-lymphocyte surface antigen B4 (CD19)
DMHNFXR	MT	DTT
DMHNFXR	MA	CAR-T-Cell-Therapy
DMHNFXR	RN	ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
DMHNFXR	RU	https://clinicaltrials.gov/ct2/show/NCT02349698

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TT6R7JZ
DMIXPNG	MN	Histone deacetylase 1 (HDAC1)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TTSHTOI
DMIXPNG	MN	Histone deacetylase 2 (HDAC2)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DMIXPNG	DI	DMIXPNG
DMIXPNG	DN	CHR-3996
DMIXPNG	MI	TT4YWTO
DMIXPNG	MN	Histone deacetylase 3 (HDAC3)
DMIXPNG	MT	DTT
DMIXPNG	MA	Inhibitor
DMIXPNG	RN	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
DMIXPNG	RU	https://pubmed.ncbi.nlm.nih.gov/22553374

DM90BUD	DI	DM90BUD
DM90BUD	DN	ChronSeal
DM90BUD	MI	TTNDSF4
DM90BUD	MN	Proto-oncogene c-Met (MET)
DM90BUD	MT	DTT
DM90BUD	MA	Inhibitor
DM90BUD	RN	Clinical pipeline report, company report or official report of Kringle Pharma.
DM90BUD	RU	http://www.kringle-pharma.com/en/news.html

DMRSI1O	DI	DMRSI1O
DMRSI1O	DN	ChronVac-C hepatitis C DNA vaccine
DMRSI1O	MI	TTZYW5V
DMRSI1O	MN	Hepatitis C virus Deoxyribonucleic acid (HCV DNA)
DMRSI1O	MT	DTT
DMRSI1O	RN	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
DMRSI1O	RU	http://ir.inovio.com/news/news-releases/news-releases-details/2013/Inovio-Collaborator-ChronTech-Reports-Interim-Phase-II-Clinical-Study-Results-from-ChronVac-C-Vaccine-for-Hepatitis-C-Infection/default.aspx

DMTV4L7	DI	DMTV4L7
DMTV4L7	DN	CHS-828
DMTV4L7	MI	TTD1WIG
DMTV4L7	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMTV4L7	MT	DTT
DMTV4L7	MA	Inhibitor
DMTV4L7	RN	Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
DMTV4L7	RU	https://pubmed.ncbi.nlm.nih.gov/18201551

DMMVWSY	DI	DMMVWSY
DMMVWSY	DN	CK-101
DMMVWSY	MI	TTG96HZ
DMMVWSY	MN	EGFR messenger RNA (EGFR mRNA)
DMMVWSY	MT	DTT
DMMVWSY	MA	Inhibitor
DMMVWSY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMVWSY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML8US9	DI	DML8US9
DML8US9	DN	CLIC-1901
DML8US9	MI	TTW640A
DML8US9	MN	B-lymphocyte surface antigen B4 (CD19)
DML8US9	MT	DTT
DML8US9	MA	CAR-T-Cell-Therapy
DML8US9	RN	ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
DML8US9	RU	https://clinicaltrials.gov/ct2/show/NCT03765177

DMCT917	DI	DMCT917
DMCT917	DN	CLL1-specific gene-engineered T cells
DMCT917	MI	TT70N8V
DMCT917	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DMCT917	MT	DTT
DMCT917	MA	CAR-T-Cell-Therapy
DMCT917	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMCT917	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DM2FSM5	DI	DM2FSM5
DM2FSM5	DN	CLR-1401
DM2FSM5	MI	TTHBTOP
DM2FSM5	MN	PI3-kinase gamma (PIK3CG)
DM2FSM5	MT	DTT
DM2FSM5	MA	Inhibitor
DM2FSM5	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
DM2FSM5	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155

DM64FY7	DI	DM64FY7
DM64FY7	DN	CLR457
DM64FY7	MI	TTHBTOP
DM64FY7	MN	PI3-kinase gamma (PIK3CG)
DM64FY7	MT	DTT
DM64FY7	MA	Modulator
DM64FY7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM64FY7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWZOD7	DI	DMWZOD7
DMWZOD7	DN	CNVN-202
DMWZOD7	MI	TTJ8O14
DMWZOD7	MN	Tumor suppressor candidate 2 (TUSC2)
DMWZOD7	MT	DTT
DMWZOD7	MA	Suppressor
DMWZOD7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766)
DMWZOD7	RU	http://adisinsight.springer.com/drugs/800018766

DM1ZGUX	DI	DM1ZGUX
DM1ZGUX	DN	CPHPC
DM1ZGUX	MI	TTB7VAT
DM1ZGUX	MN	Serum amyloid P-component (APCS)
DM1ZGUX	MT	DTT
DM1ZGUX	MA	Modulator
DM1ZGUX	RN	Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).Acta Crystallogr D Biol Crystallogr.2014 Aug;70(Pt 8):2232-40.
DM1ZGUX	RU	https://www.ncbi.nlm.nih.gov/pubmed/25084341

DMJEXLI	DI	DMJEXLI
DMJEXLI	DN	CPI-0209
DMJEXLI	MI	TT9MZCQ
DMJEXLI	MN	Enhancer of zeste homolog 2 (EZH2)
DMJEXLI	MT	DTT
DMJEXLI	MA	Inhibitor
DMJEXLI	RN	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
DMJEXLI	RU	https://clinicaltrials.gov/ct2/show/NCT04104776

DM3XWJ8	DI	DM3XWJ8
DM3XWJ8	DN	CPI-1205
DM3XWJ8	MI	TT9MZCQ
DM3XWJ8	MN	Enhancer of zeste homolog 2 (EZH2)
DM3XWJ8	MT	DTT
DM3XWJ8	MA	Inhibitor
DM3XWJ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3XWJ8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6078F	DI	DM6078F
DM6078F	DN	CT84.66
DM6078F	MI	TTY6DTE
DM6078F	MN	Carcinoembryonic antigen CEA (CD66e)
DM6078F	MT	DTT
DM6078F	RN	Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.
DM6078F	RU	https://pubmed.ncbi.nlm.nih.gov/15011786

DM95XR8	DI	DM95XR8
DM95XR8	DN	CTCE-9908
DM95XR8	MI	TTBID49
DM95XR8	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM95XR8	MT	DTT
DM95XR8	MA	Modulator
DM95XR8	RN	A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6.
DM95XR8	RU	https://pubmed.ncbi.nlm.nih.gov/19482312

DM90XQC	DI	DM90XQC
DM90XQC	DN	CTX001
DM90XQC	MI	TTR61MW
DM90XQC	MN	B-cell lymphoma/leukemia 11A (BCL11A)
DM90XQC	MT	DTT
DM90XQC	RN	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
DM90XQC	RU	https://pubmed.ncbi.nlm.nih.gov/31900462

DMJ7LP0	DI	DMJ7LP0
DMJ7LP0	DN	CTX110
DMJ7LP0	MI	TTQO71U
DMJ7LP0	MN	Hemoglobin (HB)
DMJ7LP0	MT	DTT
DMJ7LP0	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DMJ7LP0	RU	http://www.crisprtx.com/programs/pipeline

DMHIQDC	DI	DMHIQDC
DMHIQDC	DN	CUDC-907
DMHIQDC	MI	TTBH0VX
DMHIQDC	MN	Histone deacetylase (HDAC)
DMHIQDC	MT	DTT
DMHIQDC	MA	Inhibitor
DMHIQDC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHIQDC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHIQDC	DI	DMHIQDC
DMHIQDC	DN	CUDC-907
DMHIQDC	MI	TTHBTOP
DMHIQDC	MN	PI3-kinase gamma (PIK3CG)
DMHIQDC	MT	DTT
DMHIQDC	MA	Modulator
DMHIQDC	RN	Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res.2012 Aug 1;18(15):4104-13.
DMHIQDC	RU	https://www.ncbi.nlm.nih.gov/pubmed/22693356

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTTPU1G
DMCPZYT	MN	Apoptosis inhibitor survivin (BIRC5)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTE5ITK
DMCPZYT	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TT9M6NA
DMCPZYT	MN	Cancer/testis antigen MAGE-C1/CT7 (MAGEC1)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TTKGUEB
DMCPZYT	MN	Melanoma-associated antigen C2 (MAGEC2)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DMCPZYT	DI	DMCPZYT
DMCPZYT	DN	CV-9201
DMCPZYT	MI	TT70MLA
DMCPZYT	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMCPZYT	MT	DTT
DMCPZYT	RN	National Cancer Institute Drug Dictionary (drug id 648549).
DMCPZYT	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549

DM03LWZ	DI	DM03LWZ
DM03LWZ	DN	CVX-060
DM03LWZ	MI	TTKLQTJ
DM03LWZ	MN	Angiopoietin-2 (ANGPT2)
DM03LWZ	MT	DTT
DM03LWZ	RN	Clinical pipeline report, company report or official report of CovX (2011).
DM03LWZ	RU	http://www.covx.com/pipeline.html

DMBUYIK	DI	DMBUYIK
DMBUYIK	DN	CWP232291
DMBUYIK	MI	TTFPSHI
DMBUYIK	MN	Wnt signaling pathway (Wnt pathway)
DMBUYIK	MT	DTT
DMBUYIK	MA	Inhibitor
DMBUYIK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBUYIK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUGMFN	DI	DMUGMFN
DMUGMFN	DN	CXB-909
DMUGMFN	MI	TTDN3LF
DMUGMFN	MN	Nerve growth factor (NGF)
DMUGMFN	MT	DTT
DMUGMFN	MA	Modulator
DMUGMFN	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUGMFN	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DME6NMJ	DI	DME6NMJ
DME6NMJ	DN	CYT-0851
DME6NMJ	MI	TTC0G1L
DME6NMJ	MN	DNA repair protein RAD51 homolog 1 (RAD51)
DME6NMJ	MT	DTT
DME6NMJ	MA	Inhibitor
DME6NMJ	RN	National Cancer Institute Drug Dictionary (drug name CYT0851).
DME6NMJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rad51-inhibitor-cyt-0851

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	DEIBDNY
DMJPSIL	MN	Cytochrome P450 3A5 (CYP3A5)
DMJPSIL	MT	DME
DMJPSIL	MA	Metabolism
DMJPSIL	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DMJPSIL	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	TT84ETX
DMJPSIL	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMJPSIL	MT	DTT
DMJPSIL	MA	Inhibitor
DMJPSIL	RN	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
DMJPSIL	RU	https://pubmed.ncbi.nlm.nih.gov/18764719

DMJPSIL	DI	DMJPSIL
DMJPSIL	DN	Dapivirine
DMJPSIL	MI	DEYGVN4
DMJPSIL	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMJPSIL	MT	DME
DMJPSIL	MA	Metabolism
DMJPSIL	RN	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
DMJPSIL	RU	https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/39301/TO-DISSERTATION-2014.pdf?sequence=1&isAllowed=y

DMJKFNU	DI	DMJKFNU
DMJKFNU	DN	DCC-2036
DMJKFNU	MI	TT9VGXW
DMJKFNU	MN	Angiopoietin 1 receptor (TEK)
DMJKFNU	MT	DTT
DMJKFNU	MA	Inhibitor
DMJKFNU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJKFNU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJKFNU	DI	DMJKFNU
DMJKFNU	DN	DCC-2036
DMJKFNU	MI	TT3PJMV
DMJKFNU	MN	Tyrosine-protein kinase ABL1 (ABL)
DMJKFNU	MT	DTT
DMJKFNU	MA	Modulator
DMJKFNU	RN	Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
DMJKFNU	RU	http://www.deciphera.com/pipeline

DMHW289	DI	DMHW289
DMHW289	DN	DCC-3014
DMHW289	MI	TT7MRDV
DMHW289	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMHW289	MT	DTT
DMHW289	MA	Inhibitor
DMHW289	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMHW289	RU	https://www.deciphera.com/pipeline/dcc-3014/

DMWE205	DI	DMWE205
DMWE205	DN	DCR-MYC
DMWE205	MI	TTVW4XU
DMWE205	MN	MYCBP messenger RNA (MYCBP mRNA)
DMWE205	MT	DTT
DMWE205	RN	National Cancer Institute Drug Dictionary (drug id 759983).
DMWE205	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=759983

DM0I5LM	DI	DM0I5LM
DM0I5LM	DN	DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells
DM0I5LM	MI	TTJIH8Q
DM0I5LM	MN	CCR5 messenger RNA (CCR5 mRNA)
DM0I5LM	MT	DTT
DM0I5LM	RN	Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980.
DM0I5LM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418169/

DMCMT4V	DI	DMCMT4V
DMCMT4V	DN	Dexamethasone palmitate
DMCMT4V	MI	DE4LYSA
DMCMT4V	MN	Cytochrome P450 3A4 (CYP3A4)
DMCMT4V	MT	DME
DMCMT4V	MA	Metabolism
DMCMT4V	RN	Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
DMCMT4V	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564

DMCMT4V	DI	DMCMT4V
DMCMT4V	DN	Dexamethasone palmitate
DMCMT4V	MI	TTPNQAC
DMCMT4V	MN	Estrogen-related receptor-alpha (ESRRA)
DMCMT4V	MT	DTT
DMCMT4V	MA	Agonist
DMCMT4V	RN	Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8.
DMCMT4V	RU	https://pubmed.ncbi.nlm.nih.gov/12133656

DMACPQO	DI	DMACPQO
DMACPQO	DN	Dihydrexidine
DMACPQO	MI	TTZFYLI
DMACPQO	MN	Dopamine D1 receptor (D1R)
DMACPQO	MT	DTT
DMACPQO	MA	Inhibitor
DMACPQO	RN	trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57.
DMACPQO	RU	https://pubmed.ncbi.nlm.nih.gov/17154515

DM71BFM	DI	DM71BFM
DM71BFM	DN	DNA-Ad
DM71BFM	MI	TTQZW34
DM71BFM	MN	Plasmodium Apical membrane protein (Malaria AMA-1)
DM71BFM	MT	DTT
DM71BFM	RN	Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241.
DM71BFM	RU	https://pubmed.ncbi.nlm.nih.gov/25211344

DMK4VY9	DI	DMK4VY9
DMK4VY9	DN	DS-7300
DMK4VY9	MI	TT6CQUM
DMK4VY9	MN	B7 homolog 3 (CD276)
DMK4VY9	MT	DTT
DMK4VY9	MA	Inhibitor
DMK4VY9	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMK4VY9	RU	https://www.daiichisankyo.com/rd/pipeline/

DMK4VY9	DI	DMK4VY9
DMK4VY9	DN	DS-7300
DMK4VY9	MI	TTGTQHC
DMK4VY9	MN	DNA topoisomerase I (TOP1)
DMK4VY9	MT	DTT
DMK4VY9	MA	Inhibitor
DMK4VY9	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMK4VY9	RU	https://www.daiichisankyo.com/rd/pipeline/

DM7WK6N	DI	DM7WK6N
DM7WK6N	DN	DSP-0509
DM7WK6N	MI	TTRJ1K4
DM7WK6N	MN	Toll-like receptor 7 (TLR7)
DM7WK6N	MT	DTT
DM7WK6N	MA	Agonist
DM7WK6N	RN	Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
DM7WK6N	RU	https://www.ds-pharma.com/rd/clinical/pipeline.html

DM8K0PR	DI	DM8K0PR
DM8K0PR	DN	DSP-107
DM8K0PR	MI	TT28S46
DM8K0PR	MN	Leukocyte surface antigen CD47 (CD47)
DM8K0PR	MT	DTT
DM8K0PR	RN	Clinical pipeline report, company report or official report of KAHR Medical.
DM8K0PR	RU	https://kahrbio.com/technology/#pipeline

DMRXQCL	DI	DMRXQCL
DMRXQCL	DN	DT388IL-3
DMRXQCL	MI	TTPYS82
DMRXQCL	MN	Interleukin 3 receptor (CSF2RB)
DMRXQCL	MT	DTT
DMRXQCL	MA	Inhibitor
DMRXQCL	RN	Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806.
DMRXQCL	RU	https://pubmed.ncbi.nlm.nih.gov/15614527

DM8M71U	DI	DM8M71U
DM8M71U	DN	DTX301
DM8M71U	MI	TT5KIO9
DM8M71U	MN	Ornithine transcarbamylase (OTC)
DM8M71U	MT	DTT
DM8M71U	MA	Replacement
DM8M71U	RN	Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical.
DM8M71U	RU	https://www.ultragenyx.com/pipeline/dtx-301-for-otc/

DM72DU3	DI	DM72DU3
DM72DU3	DN	DZD9008
DM72DU3	MI	TT2M7YX
DM72DU3	MN	EGFR Exon20ins mutant (EGFR Exon20ins)
DM72DU3	MT	DTT
DM72DU3	MA	Inhibitor
DM72DU3	RN	Clinical pipeline report, company report or official report of Dizal Pharmaceuticals.
DM72DU3	RU	http://www.dizalpharma.com/innovation/science

DMH2NKD	DI	DMH2NKD
DMH2NKD	DN	EB-101
DMH2NKD	MI	TTE4KHA
DMH2NKD	MN	Amyloid beta A4 protein (APP)
DMH2NKD	MT	DTT
DMH2NKD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DMH2NKD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMI71FN	DI	DMI71FN
DMI71FN	DN	EDO-S101
DMI71FN	MI	TTBH0VX
DMI71FN	MN	Histone deacetylase (HDAC)
DMI71FN	MT	DTT
DMI71FN	MA	Inhibitor
DMI71FN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI71FN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHRCQI	DI	DMHRCQI
DMHRCQI	DN	eFT226
DMHRCQI	MI	TTIGYVZ
DMHRCQI	MN	HUMAN eukaryotic initiation factor-4A (eIF4A)
DMHRCQI	MT	DTT
DMHRCQI	MA	Inhibitor
DMHRCQI	RN	Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020 Jun 11;63(11):5879-5955.
DMHRCQI	RU	https://pubmed.ncbi.nlm.nih.gov/32470302

DMF7EX8	DI	DMF7EX8
DMF7EX8	DN	EGFR antisense DNA
DMF7EX8	MI	TTG96HZ
DMF7EX8	MN	EGFR messenger RNA (EGFR mRNA)
DMF7EX8	MT	DTT
DMF7EX8	RN	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352.
DMF7EX8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684443/

DMDWCOF	DI	DMDWCOF
DMDWCOF	DN	EGFR CART
DMDWCOF	MI	TTGKNB4
DMDWCOF	MN	Epidermal growth factor receptor (EGFR)
DMDWCOF	MT	DTT
DMDWCOF	MA	CAR-T-Cell-Therapy
DMDWCOF	RN	ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
DMDWCOF	RU	https://clinicaltrials.gov/ct2/show/NCT03152435

DMC284G	DI	DMC284G
DMC284G	DN	EGFRvIII CAR
DMC284G	MI	TTZ6B2I
DMC284G	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMC284G	MT	DTT
DMC284G	MA	Modulator
DMC284G	RN	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84.
DMC284G	RU	https://pubmed.ncbi.nlm.nih.gov/24352643

DM5FCO4	DI	DM5FCO4
DM5FCO4	DN	Elpamotide
DM5FCO4	MI	TTUTJGQ
DM5FCO4	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM5FCO4	MT	DTT
DM5FCO4	RN	Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8.
DM5FCO4	RU	https://pubmed.ncbi.nlm.nih.gov/22957712

DM7CLEZ	DI	DM7CLEZ
DM7CLEZ	DN	Eltanexor oral
DM7CLEZ	MI	TTCJUR4
DM7CLEZ	MN	Exportin-1 (XPO1)
DM7CLEZ	MT	DTT
DM7CLEZ	MA	Inhibitor
DM7CLEZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7CLEZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCAUKW	DI	DMCAUKW
DMCAUKW	DN	EMB-01
DMCAUKW	MI	TTGKNB4
DMCAUKW	MN	Epidermal growth factor receptor (EGFR)
DMCAUKW	MT	DTT
DMCAUKW	MA	Inhibitor
DMCAUKW	RN	Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
DMCAUKW	RU	https://www.epimab.com/en/pipeline/1

DMMD10S	DI	DMMD10S
DMMD10S	DN	EMD 55900
DMMD10S	MI	TTGKNB4
DMMD10S	MN	Epidermal growth factor receptor (EGFR)
DMMD10S	MT	DTT
DMMD10S	RN	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
DMMD10S	RU	https://pubmed.ncbi.nlm.nih.gov/11920518

DMIOUFK	DI	DMIOUFK
DMIOUFK	DN	Emfilermin
DMIOUFK	MI	TTID542
DMIOUFK	MN	Leukemia inhibitory factor receptor (LIFR)
DMIOUFK	MT	DTT
DMIOUFK	MA	Inhibitor
DMIOUFK	RN	Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol. 2004 May; 57(5): 576-585.
DMIOUFK	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884498/

DM1PQJO	DI	DM1PQJO
DM1PQJO	DN	Enapotamab vedotin
DM1PQJO	MI	TTZPY6J
DM1PQJO	MN	Tyrosine-protein kinase UFO (AXL)
DM1PQJO	MT	DTT
DM1PQJO	MA	Inhibitor
DM1PQJO	RN	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
DM1PQJO	RU	https://pubmed.ncbi.nlm.nih.gov/31600169

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TTSJH2W
DMN0EMP	MN	Mitochondrial protein unspecific (MP)
DMN0EMP	MT	DTT
DMN0EMP	MA	Modulator
DMN0EMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMN0EMP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	DTFI42L
DMN0EMP	MN	Multidrug resistance-associated protein 2 (ABCC2)
DMN0EMP	MT	DTP
DMN0EMP	MA	Substrate
DMN0EMP	RN	Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
DMN0EMP	RU	https://doi.org/10.1023/A:1012200805593

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TTPZ7AG
DMN0EMP	MN	Oxidoreductase unspecific (OR)
DMN0EMP	MT	DTT
DMN0EMP	MA	Modulator
DMN0EMP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMN0EMP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMN0EMP	DI	DMN0EMP
DMN0EMP	DN	Epicatechin
DMN0EMP	MI	TT8NGED
DMN0EMP	MN	Prostaglandin G/H synthase 1 (COX-1)
DMN0EMP	MT	DTT
DMN0EMP	MA	Inhibitor
DMN0EMP	RN	Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82.
DMN0EMP	RU	https://pubmed.ncbi.nlm.nih.gov/15568761

DMWSGZU	DI	DMWSGZU
DMWSGZU	DN	Epithalon
DMWSGZU	MI	TTUJFD0
DMWSGZU	MN	Telomerase reverse transcriptase (TERT)
DMWSGZU	MT	DTT
DMWSGZU	MA	Modulator
DMWSGZU	RN	Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2.
DMWSGZU	RU	https://pubmed.ncbi.nlm.nih.gov/12937682

DMTY96S	DI	DMTY96S
DMTY96S	DN	Eptacog beta
DMTY96S	MI	TTLPJWH
DMTY96S	MN	Thioredoxin reductase (PRDX5)
DMTY96S	MT	DTT
DMTY96S	MA	Inhibitor
DMTY96S	RN	APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. 
DMTY96S	RU	https://pubmed.ncbi.nlm.nih.gov/24157875

DMN2FS3	DI	DMN2FS3
DMN2FS3	DN	EPZ-5676
DMN2FS3	MI	TTSZ8T1
DMN2FS3	MN	Histone-lysine N-methyltransferase (HLNM)
DMN2FS3	MT	DTT
DMN2FS3	MA	Modulator
DMN2FS3	RN	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 August 8; 122(6): 1017-1025.
DMN2FS3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739029/

DMNZ6VA	DI	DMNZ6VA
DMNZ6VA	DN	Erythropoietin-transfected autologous cell therapy
DMNZ6VA	MI	TTQG4NR
DMNZ6VA	MN	Erythropoietin (EPO)
DMNZ6VA	MT	DTT
DMNZ6VA	MA	Modulator
DMNZ6VA	RN	Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. 
DMNZ6VA	RU	https://pubmed.ncbi.nlm.nih.gov/19088705

DMUNM4D	DI	DMUNM4D
DMUNM4D	DN	ESR0114
DMUNM4D	MI	TTGV6LY
DMUNM4D	MN	Nuclear receptor ROR-gamma (RORG)
DMUNM4D	MT	DTT
DMUNM4D	MA	Inhibitor
DMUNM4D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUNM4D	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMIREUZ	DI	DMIREUZ
DMIREUZ	DN	Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy
DMIREUZ	MI	TTLP57V
DMIREUZ	MN	Adenosine deaminase (ADA)
DMIREUZ	MT	DTT
DMIREUZ	MA	Modulator
DMIREUZ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMIREUZ	RU	https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

DM64PM7	DI	DM64PM7
DM64PM7	DN	EXO-230
DM64PM7	MI	TT8NGED
DM64PM7	MN	Prostaglandin G/H synthase 1 (COX-1)
DM64PM7	MT	DTT
DM64PM7	MA	Agonist
DM64PM7	RN	Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083.
DM64PM7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831899/

DML6EVJ	DI	DML6EVJ
DML6EVJ	DN	F-14512
DML6EVJ	MI	TT0IHXV
DML6EVJ	MN	DNA topoisomerase II (TOP2)
DML6EVJ	MT	DTT
DML6EVJ	MA	Modulator
DML6EVJ	RN	Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.Apoptosis.2012 Apr;17(4):364-76.
DML6EVJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/22127645

DM49BX1	DI	DM49BX1
DM49BX1	DN	F-16-131I
DM49BX1	MI	TTUCPMY
DM49BX1	MN	Tenascin (TNC)
DM49BX1	MT	DTT
DM49BX1	RN	Tumor-Associated Fibroblasts and their Matrix. Springer. Margareta M. Mueller,Norbert E. Fusenig, 2011. Page(775).
DM49BX1	RU	https://books.google.com.hk/books?id=NthWAAAAcAAJ&pg=PA775&lpg=PA775&dq=%22F-16-131I%22&source=bl&ots=lx9eNOrJ9J&sig=TSJZ44F1Vb9V3iKhqn2bmzR0H4E&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIgayw4crGyAIVDEiOCh1b7Q2U#v=onepage&q=%22F-16-131I%22&f=false

DMQSF5C	DI	DMQSF5C
DMQSF5C	DN	FBT-A05
DMQSF5C	MI	TTUE541
DMQSF5C	MN	Leukocyte surface antigen Leu-16 (CD20)
DMQSF5C	MT	DTT
DMQSF5C	RN	Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160.
DMQSF5C	RU	https://pubmed.ncbi.nlm.nih.gov/23815981

DMQ8VUW	DI	DMQ8VUW
DMQ8VUW	DN	FCN-437
DMQ8VUW	MI	TT0PG8F
DMQ8VUW	MN	Cyclin-dependent kinase 4 (CDK4)
DMQ8VUW	MT	DTT
DMQ8VUW	MA	Inhibitor
DMQ8VUW	RN	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
DMQ8VUW	RU	http://fochon.com/what-we-do/fcn-411/

DMQ8VUW	DI	DMQ8VUW
DMQ8VUW	DN	FCN-437
DMQ8VUW	MI	TTO0FDJ
DMQ8VUW	MN	Cyclin-dependent kinase 6 (CDK6)
DMQ8VUW	MT	DTT
DMQ8VUW	MA	Inhibitor
DMQ8VUW	RN	Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
DMQ8VUW	RU	http://fochon.com/what-we-do/fcn-411/

DMRHOFB	DI	DMRHOFB
DMRHOFB	DN	Ferritarg P
DMRHOFB	MI	TT975ZT
DMRHOFB	MN	Ferritin (FTH1)
DMRHOFB	MT	DTT
DMRHOFB	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019964)
DMRHOFB	RU	http://adisinsight.springer.com/drugs/800019964

DM1XIMU	DI	DM1XIMU
DM1XIMU	DN	FF-10101
DM1XIMU	MI	TTGJCWZ
DM1XIMU	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM1XIMU	MT	DTT
DM1XIMU	MA	Inhibitor
DM1XIMU	RN	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018 Jan 25;131(4):426-438.
DM1XIMU	RU	https://pubmed.ncbi.nlm.nih.gov/29187377

DM0HSJK	DI	DM0HSJK
DM0HSJK	DN	FF-10501-01
DM0HSJK	MI	TTF63Z1
DM0HSJK	MN	Cell differentiation (CD)
DM0HSJK	MT	DTT
DM0HSJK	MA	Stimulator
DM0HSJK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0HSJK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM72JE4	DI	DM72JE4
DM72JE4	DN	FF-10502
DM72JE4	MI	TTA0XPV
DM72JE4	MN	DNA polymerase beta (POLB)
DM72JE4	MT	DTT
DM72JE4	MA	Inhibitor
DM72JE4	RN	FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.
DM72JE4	RU	https://pubmed.ncbi.nlm.nih.gov/29653962

DMWEJ0C	DI	DMWEJ0C
DMWEJ0C	DN	FGF401
DMWEJ0C	MI	TT1KX2S
DMWEJ0C	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMWEJ0C	MT	DTT
DMWEJ0C	MA	Antagonist
DMWEJ0C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWEJ0C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMI7S39	DI	DMI7S39
DMI7S39	DN	FLX475
DMI7S39	MI	TT7HQD0
DMI7S39	MN	C-C chemokine receptor type 4 (CCR4)
DMI7S39	MT	DTT
DMI7S39	MA	Antagonist
DMI7S39	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI7S39	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME2W4T	DI	DME2W4T
DME2W4T	DN	Forodesine
DME2W4T	MI	TTMCF1Y
DME2W4T	MN	Purine nucleoside phosphorylase (PNP)
DME2W4T	MT	DTT
DME2W4T	MA	Inhibitor
DME2W4T	RN	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75.
DME2W4T	RU	https://pubmed.ncbi.nlm.nih.gov/19541822

DM3ZN6Y	DI	DM3ZN6Y
DM3ZN6Y	DN	FPA-008
DM3ZN6Y	MI	TT731LW
DM3ZN6Y	MN	Colony stimulating factor-1 receptor (CSF-1R)
DM3ZN6Y	MT	DTT
DM3ZN6Y	MA	Modulator
DM3ZN6Y	RN	Company report (Five Prime Therapeutics)
DM3ZN6Y	RU	http://www.fiveprime.com/pipeline/fpa008

DM3ZN6Y	DI	DM3ZN6Y
DM3ZN6Y	DN	FPA-008
DM3ZN6Y	MI	TT7MRDV
DM3ZN6Y	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DM3ZN6Y	MT	DTT
DM3ZN6Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3ZN6Y	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMXV6YP	DI	DMXV6YP
DMXV6YP	DN	Fus-1 tumor suppressor gene therapy
DMXV6YP	MI	TTJ8O14
DMXV6YP	MN	Tumor suppressor candidate 2 (TUSC2)
DMXV6YP	MT	DTT
DMXV6YP	MA	Suppressor
DMXV6YP	RN	INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87.
DMXV6YP	RU	https://pubmed.ncbi.nlm.nih.gov/17472413

DMG48WN	DI	DMG48WN
DMG48WN	DN	G0-203-2c
DMG48WN	MI	TTBHFYQ
DMG48WN	MN	Mucin-1 (MUC1)
DMG48WN	MT	DTT
DMG48WN	MA	Modulator
DMG48WN	RN	Clinical pipeline report, company report or official report of Genus Oncology.
DMG48WN	RU	http://www.genusoncology.com/phase-1-trial-GO-203-2c.php

DMTV42K	DI	DMTV42K
DMTV42K	DN	G1
DMTV42K	MI	TTDSB34
DMTV42K	MN	G-protein coupled estrogen receptor 1 (GPER1)
DMTV42K	MT	DTT
DMTV42K	MA	Agonist
DMTV42K	RN	Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12.
DMTV42K	RU	https://pubmed.ncbi.nlm.nih.gov/16520733

DM32AKH	DI	DM32AKH
DM32AKH	DN	G-207 virus construct
DM32AKH	MI	TTX09M4
DM32AKH	MN	Ribonucleotide reductase (RIR)
DM32AKH	MT	DTT
DM32AKH	MA	Inhibitor
DM32AKH	RN	Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011 Dec;30(12):831-41.
DM32AKH	RU	https://pubmed.ncbi.nlm.nih.gov/22059912

DMQU4EI	DI	DMQU4EI
DMQU4EI	DN	Galnobax
DMQU4EI	MI	TTR6W5O
DMQU4EI	MN	Adrenergic receptor beta-1 (ADRB1)
DMQU4EI	MT	DTT
DMQU4EI	MA	Agonist
DMQU4EI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQU4EI	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMN7QBE	DI	DMN7QBE
DMN7QBE	DN	GANTACURIUM CHLORIDE
DMN7QBE	MI	TTJSZTB
DMN7QBE	MN	Nicotinic acetylcholine receptor (nAChR)
DMN7QBE	MT	DTT
DMN7QBE	MA	Modulator
DMN7QBE	RN	Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 April; 112(4): 892-899.
DMN7QBE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854830/

DMCT9NG	DI	DMCT9NG
DMCT9NG	DN	GB1275
DMCT9NG	MI	TTB69FJ
DMCT9NG	MN	Integrin alpha-M (ITGAM)
DMCT9NG	MT	DTT
DMCT9NG	MA	Agonist
DMCT9NG	RN	National Cancer Institute Drug Dictionary (drug name GB1275).
DMCT9NG	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cd11b-agonist-gb1275

DM5VF04	DI	DM5VF04
DM5VF04	DN	GD2-CART01
DM5VF04	MI	TT80ARU
DM5VF04	MN	Ganglioside GD2 (GD2)
DM5VF04	MT	DTT
DM5VF04	MA	CAR-T-Cell-Therapy
DM5VF04	RN	ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
DM5VF04	RU	https://clinicaltrials.gov/ct2/show/NCT03373097

DM8J0MK	DI	DM8J0MK
DM8J0MK	DN	GEA-6414
DM8J0MK	MI	DE4OGUF
DM8J0MK	MN	Cytochrome P450 102A1 (cyp102)
DM8J0MK	MT	DME
DM8J0MK	MA	Metabolism
DM8J0MK	RN	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
DM8J0MK	RU	https://pubmed.ncbi.nlm.nih.gov/30758202

DM8J0MK	DI	DM8J0MK
DM8J0MK	DN	GEA-6414
DM8J0MK	MI	DE4LYSA
DM8J0MK	MN	Cytochrome P450 3A4 (CYP3A4)
DM8J0MK	MT	DME
DM8J0MK	MA	Metabolism
DM8J0MK	RN	Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17.
DM8J0MK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822

DMD8RLY	DI	DMD8RLY
DMD8RLY	DN	GEN3009
DMD8RLY	MI	TTFCW29
DMD8RLY	MN	Leukocyte antigen CD37 (CD37)
DMD8RLY	MT	DTT
DMD8RLY	RN	Clinical pipeline report, company report or official report of AbbVie.
DMD8RLY	RU	https://www.abbvie.com/our-science/pipeline/gen-3009.html

DMZABYH	DI	DMZABYH
DMZABYH	DN	GEN3013
DMZABYH	MI	TTUE541
DMZABYH	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZABYH	MT	DTT
DMZABYH	RN	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
DMZABYH	RU	https://pubmed.ncbi.nlm.nih.gov/31981978

DMZABYH	DI	DMZABYH
DMZABYH	DN	GEN3013
DMZABYH	MI	TTUN7MC
DMZABYH	MN	T-cell surface glycoprotein CD3 (CD3)
DMZABYH	MT	DTT
DMZABYH	RN	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
DMZABYH	RU	https://pubmed.ncbi.nlm.nih.gov/31981978

DMY1CP9	DI	DMY1CP9
DMY1CP9	DN	GLG-801
DMY1CP9	MI	TTH8FZW
DMY1CP9	MN	Signal transducer and activator of transcription 3 (STAT3)
DMY1CP9	MT	DTT
DMY1CP9	MA	Inhibitor
DMY1CP9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY1CP9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7DWLY	DI	DM7DWLY
DM7DWLY	DN	GLR2007
DM7DWLY	MI	TT0PG8F
DM7DWLY	MN	Cyclin-dependent kinase 4 (CDK4)
DM7DWLY	MT	DTT
DM7DWLY	MA	Inhibitor
DM7DWLY	RN	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
DM7DWLY	RU	http://www.ganlee.com/en/index.php?optionid=681&auto_id=68

DM7DWLY	DI	DM7DWLY
DM7DWLY	DN	GLR2007
DM7DWLY	MI	TTO0FDJ
DM7DWLY	MN	Cyclin-dependent kinase 6 (CDK6)
DM7DWLY	MT	DTT
DM7DWLY	MA	Inhibitor
DM7DWLY	RN	Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
DM7DWLY	RU	http://www.ganlee.com/en/index.php?optionid=681&auto_id=68

DMGN679	DI	DMGN679
DMGN679	DN	GPC3-CART cells
DMGN679	MI	TTJTSX4
DMGN679	MN	Glypican-3 (GPC3)
DMGN679	MT	DTT
DMGN679	MA	CAR-T-Cell-Therapy
DMGN679	RN	ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
DMGN679	RU	https://clinicaltrials.gov/ct2/show/NCT03130712

DM1GE67	DI	DM1GE67
DM1GE67	DN	GS-4224
DM1GE67	MI	TT8ZLTI
DM1GE67	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM1GE67	MT	DTT
DM1GE67	MA	Inhibitor
DM1GE67	RN	Clinical pipeline report, company report or official report of Gilead Sciences.
DM1GE67	RU	https://www.gilead.com/science-and-medicine/pipeline

DMTJQ8S	DI	DMTJQ8S
DMTJQ8S	DN	GS-9219
DMTJQ8S	MI	TTIU7X1
DMTJQ8S	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMTJQ8S	MT	DTT
DMTJQ8S	MA	Inhibitor
DMTJQ8S	RN	GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32.
DMTJQ8S	RU	https://pubmed.ncbi.nlm.nih.gov/18451250

DM059OH	DI	DM059OH
DM059OH	DN	GSK3145095
DM059OH	MI	TTAIQSN
DM059OH	MN	Receptor-interacting protein 1 (RIPK1)
DM059OH	MT	DTT
DM059OH	MA	Inhibitor
DM059OH	RN	Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.
DM059OH	RU	https://pubmed.ncbi.nlm.nih.gov/31223438

DMK2RIB	DI	DMK2RIB
DMK2RIB	DN	GTB-3550
DMK2RIB	MI	TT7KTSR
DMK2RIB	MN	Immunoglobulin gamma Fc receptor III (FCGR3)
DMK2RIB	MT	DTT
DMK2RIB	MA	Inhibitor
DMK2RIB	RN	Clinical pipeline report, company report or official report of GT Biopharma.
DMK2RIB	RU	https://www.gtbiopharma.com/product-pipeline/gtb-3550

DMK2RIB	DI	DMK2RIB
DMK2RIB	DN	GTB-3550
DMK2RIB	MI	TTJVYO3
DMK2RIB	MN	Myeloid cell surface antigen CD33 (CD33)
DMK2RIB	MT	DTT
DMK2RIB	MA	Inhibitor
DMK2RIB	RN	Clinical pipeline report, company report or official report of GT Biopharma.
DMK2RIB	RU	https://www.gtbiopharma.com/product-pipeline/gtb-3550

DM0S24D	DI	DM0S24D
DM0S24D	DN	GTU-TB vaccine
DM0S24D	MI	TTUTN1I
DM0S24D	MN	Human Deoxyribonucleic acid (hDNA)
DM0S24D	MT	DTT
DM0S24D	RN	Clinical pipeline report, company report or official report of hightechfinland.
DM0S24D	RU	http://www.hightechfinland.com/wwwdata/pdf/2013/Fitbiotech.pdf

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEJGDUW
DMIFCY2	MN	Cytochrome P450 1A2 (CYP1A2)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEPKLMQ
DMIFCY2	MN	Cytochrome P450 2B6 (CYP2B6)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DES5XRU
DMIFCY2	MN	Cytochrome P450 2C8 (CYP2C8)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DE5IED8
DMIFCY2	MN	Cytochrome P450 2C9 (CYP2C9)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DECB0K3
DMIFCY2	MN	Cytochrome P450 2D6 (CYP2D6)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DERSX5P
DMIFCY2	MN	Cytochrome P450 2J2 (CYP2J2)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DE4LYSA
DMIFCY2	MN	Cytochrome P450 3A4 (CYP3A4)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEIBDNY
DMIFCY2	MN	Cytochrome P450 3A5 (CYP3A5)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	TTZAYWL
DMIFCY2	MN	Estrogen receptor (ESR)
DMIFCY2	MT	DTT
DMIFCY2	MA	Antagonist
DMIFCY2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIFCY2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIFCY2	DI	DMIFCY2
DMIFCY2	DN	H3B-6545
DMIFCY2	MI	DEGTFWK
DMIFCY2	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DMIFCY2	MT	DME
DMIFCY2	MA	Metabolism
DMIFCY2	RN	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
DMIFCY2	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=30386887

DMQWI7V	DI	DMQWI7V
DMQWI7V	DN	Hematopoietic stem cell gene therapy
DMQWI7V	MI	TTE8T73
DMQWI7V	MN	Wiskott-Aldrich syndrome protein (WAS)
DMQWI7V	MT	DTT
DMQWI7V	MA	Modulator
DMQWI7V	RN	Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5.
DMQWI7V	RU	https://pubmed.ncbi.nlm.nih.gov/17078381

DM1U6VX	DI	DM1U6VX
DM1U6VX	DN	HER-2-targeting CAR T Cells
DM1U6VX	MI	TT6EO5L
DM1U6VX	MN	Erbb2 tyrosine kinase receptor (HER2)
DM1U6VX	MT	DTT
DM1U6VX	MA	CAR-T-Cell-Therapy
DM1U6VX	RN	ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
DM1U6VX	RU	https://clinicaltrials.gov/ct2/show/NCT02547961

DM0C5MV	DI	DM0C5MV
DM0C5MV	DN	HH2710
DM0C5MV	MI	TT1MG9E
DM0C5MV	MN	Extracellular signal-regulated kinase 1 (ERK1)
DM0C5MV	MT	DTT
DM0C5MV	MA	Inhibitor
DM0C5MV	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DM0C5MV	RU	https://www.haihepharma.com/en/research

DM0C5MV	DI	DM0C5MV
DM0C5MV	DN	HH2710
DM0C5MV	MI	TT4TQBX
DM0C5MV	MN	Extracellular signal-regulated kinase 2 (ERK2)
DM0C5MV	MT	DTT
DM0C5MV	MA	Inhibitor
DM0C5MV	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DM0C5MV	RU	https://www.haihepharma.com/en/research

DMJDVCW	DI	DMJDVCW
DMJDVCW	DN	HL-085
DMJDVCW	MI	TTZCRP3
DMJDVCW	MN	ERK activator kinase (MEK)
DMJDVCW	MT	DTT
DMJDVCW	MA	Inhibitor
DMJDVCW	RN	Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
DMJDVCW	RU	https://pubmed.ncbi.nlm.nih.gov/28954413

DMDFG1O	DI	DMDFG1O
DMDFG1O	DN	HLF 1-11
DMDFG1O	MI	TTSZDQU
DMDFG1O	MN	Lactotransferrin (LTF)
DMDFG1O	MT	DTT
DMDFG1O	MA	Modulator
DMDFG1O	RN	The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21.
DMDFG1O	RU	https://pubmed.ncbi.nlm.nih.gov/15561882

DMV1SDA	DI	DMV1SDA
DMV1SDA	DN	HM43239
DMV1SDA	MI	TTGJCWZ
DMV1SDA	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMV1SDA	MT	DTT
DMV1SDA	MA	Inhibitor
DMV1SDA	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DMV1SDA	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD

DMV1SDA	DI	DMV1SDA
DMV1SDA	DN	HM43239
DMV1SDA	MI	TTOU65C
DMV1SDA	MN	Tyrosine-protein kinase SYK (SYK)
DMV1SDA	MT	DTT
DMV1SDA	MA	Inhibitor
DMV1SDA	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DMV1SDA	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD

DM1ZHML	DI	DM1ZHML
DM1ZHML	DN	HPN328
DM1ZHML	MI	TT1C9K6
DM1ZHML	MN	Delta-like protein 3 (DLL3)
DM1ZHML	MT	DTT
DM1ZHML	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DM1ZHML	RU	https://www.harpoontx.com/pipeline/

DM86OJ0	DI	DM86OJ0
DM86OJ0	DN	HPN536
DM86OJ0	MI	TT4RXME
DM86OJ0	MN	Mesothelin (MSLN)
DM86OJ0	MT	DTT
DM86OJ0	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DM86OJ0	RU	https://www.harpoontx.com/pipeline/

DMEY1AP	DI	DMEY1AP
DMEY1AP	DN	HSDB-3165
DMEY1AP	MI	DEULQ45
DMEY1AP	MN	Sodium/potassium-transporting ATPase gamma (FXYD2)
DMEY1AP	MT	DME
DMEY1AP	MA	Metabolism
DMEY1AP	RN	Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function. Curr Opin Nephrol Hypertens. 2014 Jan;23(1):1-8.
DMEY1AP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24253496

DM7C1AJ	DI	DM7C1AJ
DM7C1AJ	DN	HT-2157
DM7C1AJ	MI	TTOPAY7
DM7C1AJ	MN	Galanin receptor (GAL-R)
DM7C1AJ	MT	DTT
DM7C1AJ	MA	Antagonist
DM7C1AJ	RN	Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94.
DM7C1AJ	RU	https://pubmed.ncbi.nlm.nih.gov/16287967

DMNHE43	DI	DMNHE43
DMNHE43	DN	HTU-PA
DMNHE43	MI	TTGY7WI
DMNHE43	MN	Urokinase-type plasminogen activator (PLAU)
DMNHE43	MT	DTT
DMNHE43	MA	Activator
DMNHE43	RN	Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
DMNHE43	RU	https://pubmed.ncbi.nlm.nih.gov/2936742

DMIU1HY	DI	DMIU1HY
DMIU1HY	DN	HuM-195-Ac-225
DMIU1HY	MI	TTJVYO3
DMIU1HY	MN	Myeloid cell surface antigen CD33 (CD33)
DMIU1HY	MT	DTT
DMIU1HY	MA	Inhibitor
DMIU1HY	RN	J Clin Oncol 29: 2011 (suppl; abstr 6516).
DMIU1HY	RU	http://meetinglibrary.asco.org/content/77232-102

DMOVF6E	DI	DMOVF6E
DMOVF6E	DN	Humanized CD19 CAR-T cells
DMOVF6E	MI	TTW640A
DMOVF6E	MN	B-lymphocyte surface antigen B4 (CD19)
DMOVF6E	MT	DTT
DMOVF6E	MA	CAR-T-Cell-Therapy
DMOVF6E	RN	ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
DMOVF6E	RU	https://clinicaltrials.gov/ct2/show/NCT03275493

DM7U458	DI	DM7U458
DM7U458	DN	IDX-184
DM7U458	MI	TTE3PC9
DM7U458	MN	Hepatitis C virus Non-structural 5 (HCV NS5)
DM7U458	MT	DTT
DM7U458	MA	Inhibitor
DM7U458	RN	Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrob Agents Chemother. 2012 June; 56(6): 3359-3368.
DM7U458	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370800/

DMLEVFW	DI	DMLEVFW
DMLEVFW	DN	IFN alpha kinoid
DMLEVFW	MI	TT95SOA
DMLEVFW	MN	Interferon alpha (IFNA)
DMLEVFW	MT	DTT
DMLEVFW	MA	Modulator
DMLEVFW	RN	Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
DMLEVFW	RU	https://pubmed.ncbi.nlm.nih.gov/23203821

DM1CG47	DI	DM1CG47
DM1CG47	DN	IL-2 XL
DM1CG47	MI	TTF89GD
DM1CG47	MN	Interleukin-2 (IL2)
DM1CG47	MT	DTT
DM1CG47	MA	Modulator
DM1CG47	RN	Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558.
DM1CG47	RU	http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2558

DMJ9CY4	DI	DMJ9CY4
DMJ9CY4	DN	IL-2/gene-modified lymphocytes
DMJ9CY4	MI	TTF89GD
DMJ9CY4	MN	Interleukin-2 (IL2)
DMJ9CY4	MT	DTT
DMJ9CY4	MA	Modulator
DMJ9CY4	RN	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 November; 97(11): 1622-1631.
DMJ9CY4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487433/

DMKV5D6	DI	DMKV5D6
DMKV5D6	DN	IM19 CAR-T
DMKV5D6	MI	TTW640A
DMKV5D6	MN	B-lymphocyte surface antigen B4 (CD19)
DMKV5D6	MT	DTT
DMKV5D6	MA	CAR-T-Cell-Therapy
DMKV5D6	RN	ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells
DMKV5D6	RU	https://clinicaltrials.gov/ct2/show/NCT03142646

DMHQ2U8	DI	DMHQ2U8
DMHQ2U8	DN	IMC-F106C
DMHQ2U8	MI	TTPH7T0
DMHQ2U8	MN	Tumor expressed melanoma antigen (PRAME)
DMHQ2U8	MT	DTT
DMHQ2U8	RN	Clinical pipeline report, company report or official report of Immunocore.
DMHQ2U8	RU	https://www.immunocore.com/news/immunocore-announces-dosing-first-patient-fourth-immtac

DM09JOZ	DI	DM09JOZ
DM09JOZ	DN	ImMucin
DM09JOZ	MI	TTBHFYQ
DM09JOZ	MN	Mucin-1 (MUC1)
DM09JOZ	MT	DTT
DM09JOZ	RN	Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.
DM09JOZ	RU	https://pubmed.ncbi.nlm.nih.gov/25496030

DM18ZLW	DI	DM18ZLW
DM18ZLW	DN	IMP-321
DM18ZLW	MI	TTNVXAW
DM18ZLW	MN	Lymphocyte activation gene 3 protein (LAG3)
DM18ZLW	MT	DTT
DM18ZLW	MA	Immunomodulator
DM18ZLW	RN	A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
DM18ZLW	RU	https://pubmed.ncbi.nlm.nih.gov/17785860

DM43ICH	DI	DM43ICH
DM43ICH	DN	IMSA101
DM43ICH	MI	TTT402Y
DM43ICH	MN	Stimulator of interferon genes protein (TMEM173)
DM43ICH	MT	DTT
DM43ICH	MA	Agonist
DM43ICH	RN	Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
DM43ICH	RU	http://www.immunesensor.com/

DMNHZS4	DI	DMNHZS4
DMNHZS4	DN	IMX-110
DMNHZS4	MI	TTH8FZW
DMNHZS4	MN	Signal transducer and activator of transcription 3 (STAT3)
DMNHZS4	MT	DTT
DMNHZS4	MA	Inhibitor
DMNHZS4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNHZS4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8XN4A	DI	DM8XN4A
DM8XN4A	DN	INCAGN1876
DM8XN4A	MI	TTG6LA7
DM8XN4A	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DM8XN4A	MT	DTT
DM8XN4A	MA	Agonist
DM8XN4A	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8XN4A	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM7OE3X	DI	DM7OE3X
DM7OE3X	DN	INCAGN1949
DM7OE3X	MI	TTL31H0
DM7OE3X	MN	OX40L receptor (CD134)
DM7OE3X	MT	DTT
DM7OE3X	MA	Agonist
DM7OE3X	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7OE3X	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM8124R	DI	DM8124R
DM8124R	DN	INCB01158
DM8124R	MI	TTSANDR
DM8124R	MN	Arginase (ARG)
DM8124R	MT	DTT
DM8124R	MA	Inhibitor
DM8124R	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8124R	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM7TZL0	DI	DM7TZL0
DM7TZL0	DN	INCB054329
DM7TZL0	MI	TTE4BSY
DM7TZL0	MN	Bromodomain and extraterminal domain protein (BET)
DM7TZL0	MT	DTT
DM7TZL0	MA	Inhibitor
DM7TZL0	RN	The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311.
DM7TZL0	RU	https://pubmed.ncbi.nlm.nih.gov/30206163

DMG65CV	DI	DMG65CV
DMG65CV	DN	INCB057643
DMG65CV	MI	TTE4BSY
DMG65CV	MN	Bromodomain and extraterminal domain protein (BET)
DMG65CV	MT	DTT
DMG65CV	MA	Inhibitor
DMG65CV	RN	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257.
DMG65CV	RU	https://pubmed.ncbi.nlm.nih.gov/31527168

DMED9QV	DI	DMED9QV
DMED9QV	DN	INCB40093
DMED9QV	MI	TTGBPJE
DMED9QV	MN	PI3-kinase delta (PIK3CD)
DMED9QV	MT	DTT
DMED9QV	MA	Inhibitor
DMED9QV	RN	INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors.
DMED9QV	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/4531.short

DMKMSP2	DI	DMKMSP2
DMKMSP2	DN	INCB53914
DMKMSP2	MI	TTA7WGU
DMKMSP2	MN	Serine/threonine-protein kinase pim (PIM)
DMKMSP2	MT	DTT
DMKMSP2	MA	Inhibitor
DMKMSP2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKMSP2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBGU7V	DI	DMBGU7V
DMBGU7V	DN	INCB57643
DMBGU7V	MI	TTRA6BO
DMBGU7V	MN	Bromodomain-containing protein 4 (BRD4)
DMBGU7V	MT	DTT
DMBGU7V	MA	Inhibitor
DMBGU7V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBGU7V	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRLV7G	DI	DMRLV7G
DMRLV7G	DN	INCB59872
DMRLV7G	MI	TTNR0UQ
DMRLV7G	MN	Lysine-specific histone demethylase 1 (LSD)
DMRLV7G	MT	DTT
DMRLV7G	MA	Inhibitor
DMRLV7G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLV7G	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQO5UF	DI	DMQO5UF
DMQO5UF	DN	INCB62079
DMQO5UF	MI	TT5BR7T
DMQO5UF	MN	Fibroblast growth factor receptor 4 (FGFR4)
DMQO5UF	MT	DTT
DMQO5UF	MA	Inhibitor
DMQO5UF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQO5UF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKNA94	DI	DMKNA94
DMKNA94	DN	INO-8875
DMKNA94	MI	TTK25J1
DMKNA94	MN	Adenosine A1 receptor (ADORA1)
DMKNA94	MT	DTT
DMKNA94	MA	Agonist
DMKNA94	RN	INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67.
DMKNA94	RU	https://pubmed.ncbi.nlm.nih.gov/23055540

DMMZSIB	DI	DMMZSIB
DMMZSIB	DN	Interferon alpha 5
DMMZSIB	MI	TTLHGSF
DMMZSIB	MN	Interferon-alpha 5 (IFNA5)
DMMZSIB	MT	DTT
DMMZSIB	MA	Modulator
DMMZSIB	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMMZSIB	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM9PJZT	DI	DM9PJZT
DM9PJZT	DN	Ipamorelin
DM9PJZT	MI	TTWDC17
DM9PJZT	MN	Growth hormone secretagogue receptor 1 (GHSR)
DM9PJZT	MT	DTT
DM9PJZT	MA	Modulator
DM9PJZT	RN	Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6.
DM9PJZT	RU	https://www.ncbi.nlm.nih.gov/pubmed/19289567

DM8E3N6	DI	DM8E3N6
DM8E3N6	DN	IPP-204106
DM8E3N6	MI	TTCSZH7
DM8E3N6	MN	Nucleolin (NCL)
DM8E3N6	MT	DTT
DM8E3N6	MA	Modulator
DM8E3N6	RN	Company report (ImmuPharma)
DM8E3N6	RU	http://www.immupharma.org/cancer-treatment

DM8E3N6	DI	DM8E3N6
DM8E3N6	DN	IPP-204106
DM8E3N6	MI	TTHBS98
DM8E3N6	MN	Nucleophosmin (NPM1)
DM8E3N6	MT	DTT
DM8E3N6	MA	Modulator
DM8E3N6	RN	Company report (ImmuPharma)
DM8E3N6	RU	http://www.immupharma.org/cancer-treatment

DMQ5EYJ	DI	DMQ5EYJ
DMQ5EYJ	DN	ISA-P53-01
DMQ5EYJ	MI	TT7SBF5
DMQ5EYJ	MN	Cellular tumor antigen p53 (TP53)
DMQ5EYJ	MT	DTT
DMQ5EYJ	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMQ5EYJ	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM1WD8F	DI	DM1WD8F
DM1WD8F	DN	ISB 1302
DM1WD8F	MI	TT6EO5L
DM1WD8F	MN	Erbb2 tyrosine kinase receptor (HER2)
DM1WD8F	MT	DTT
DM1WD8F	MA	Inhibitor
DM1WD8F	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DM1WD8F	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DM1WD8F	DI	DM1WD8F
DM1WD8F	DN	ISB 1302
DM1WD8F	MI	TTUN7MC
DM1WD8F	MN	T-cell surface glycoprotein CD3 (CD3)
DM1WD8F	MT	DTT
DM1WD8F	MA	Inhibitor
DM1WD8F	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DM1WD8F	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMG107N	DI	DMG107N
DMG107N	DN	ISB 1342
DMG107N	MI	TTPURFN
DMG107N	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMG107N	MT	DTT
DMG107N	MA	Inhibitor
DMG107N	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DMG107N	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMG107N	DI	DMG107N
DMG107N	DN	ISB 1342
DMG107N	MI	TTUN7MC
DMG107N	MN	T-cell surface glycoprotein CD3 (CD3)
DMG107N	MT	DTT
DMG107N	MA	Inhibitor
DMG107N	RN	Clinical pipeline report, company report or official report of Ichnos Sciences.
DMG107N	RU	https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf

DMH32LC	DI	DMH32LC
DMH32LC	DN	ISIS-DMPK
DMH32LC	MI	TTZQTY2
DMH32LC	MN	DMPK messenger RNA (DMPK mRNA)
DMH32LC	MT	DTT
DMH32LC	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DMH32LC	RU	https://www.isispharm.com/pipeline/isis-dmpkrx/

DMDTNFB	DI	DMDTNFB
DMDTNFB	DN	ISIS-STAT3
DMDTNFB	MI	TTHJT3X
DMDTNFB	MN	STAT3 messenger RNA (STAT3 mRNA)
DMDTNFB	MT	DTT
DMDTNFB	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMDTNFB	RU	http://www.isispharm.com/index.htm

DMA41DO	DI	DMA41DO
DMA41DO	DN	Isunakinra
DMA41DO	MI	TT5BFT0
DMA41DO	MN	Interleukin-1 receptor (IL1R)
DMA41DO	MT	DTT
DMA41DO	MA	Inhibitor
DMA41DO	RN	Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2017 Sep;43(5):287-296.
DMA41DO	RU	https://pubmed.ncbi.nlm.nih.gov/27466718

DM08TH3	DI	DM08TH3
DM08TH3	DN	ITI-214
DM08TH3	MI	TTHQENC
DM08TH3	MN	Phosphodiesterase 1 (PDE1)
DM08TH3	MT	DTT
DM08TH3	MA	Inhibitor
DM08TH3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM08TH3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3KXMG	DI	DM3KXMG
DM3KXMG	DN	IZONSTERIDE
DM3KXMG	MI	TT2A0DR
DM3KXMG	MN	Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A)
DM3KXMG	MT	DTT
DM3KXMG	MA	Modulator
DM3KXMG	RN	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9.
DM3KXMG	RU	https://www.ncbi.nlm.nih.gov/pubmed/14751361

DMNMV0D	DI	DMNMV0D
DMNMV0D	DN	JAB-3312
DMNMV0D	MI	TT7WUAV
DMNMV0D	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMNMV0D	MT	DTT
DMNMV0D	MA	Inhibitor
DMNMV0D	RN	Clinical pipeline report, company report or official report of AbbVie.
DMNMV0D	RU	https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html

DMTMVEW	DI	DMTMVEW
DMTMVEW	DN	JCAR014
DMTMVEW	MI	TTW640A
DMTMVEW	MN	B-lymphocyte surface antigen B4 (CD19)
DMTMVEW	MT	DTT
DMTMVEW	MA	CAR-T-Cell-Therapy
DMTMVEW	RN	ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DMTMVEW	RU	https://clinicaltrials.gov/ct2/show/NCT02706405

DMJV2IF	DI	DMJV2IF
DMJV2IF	DN	JCAR017
DMJV2IF	MI	TTW640A
DMJV2IF	MN	B-lymphocyte surface antigen B4 (CD19)
DMJV2IF	MT	DTT
DMJV2IF	MA	CAR-T-Cell-Therapy
DMJV2IF	RN	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
DMJV2IF	RU	https://clinicaltrials.gov/ct2/show/NCT03436771

DM8P7FC	DI	DM8P7FC
DM8P7FC	DN	JCARH125
DM8P7FC	MI	TTZ3P4W
DM8P7FC	MN	B-cell maturation protein (TNFRSF17)
DM8P7FC	MT	DTT
DM8P7FC	MA	CAR-T-Cell-Therapy
DM8P7FC	RN	ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
DM8P7FC	RU	https://clinicaltrials.gov/ct2/show/NCT03436771

DMD9X6U	DI	DMD9X6U
DMD9X6U	DN	JNJ-68284528
DMD9X6U	MI	TTZ3P4W
DMD9X6U	MN	B-cell maturation protein (TNFRSF17)
DMD9X6U	MT	DTT
DMD9X6U	MA	CAR-T-Cell-Therapy
DMD9X6U	RN	ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
DMD9X6U	RU	https://clinicaltrials.gov/ct2/show/NCT03548207

DMGEZVF	DI	DMGEZVF
DMGEZVF	DN	JS016
DMGEZVF	MI	TTZ3COY
DMGEZVF	MN	COVID-19 spike glycoprotein (S)
DMGEZVF	MT	DTT
DMGEZVF	MA	Inhibitor
DMGEZVF	RN	Clinical pipeline report, company report or official report of Lilly.
DMGEZVF	RU	https://www.lilly.com/discovery/clinical-development-pipeline#

DMELJDI	DI	DMELJDI
DMELJDI	DN	KAI-9803
DMELJDI	MI	TT9WJ8U
DMELJDI	MN	Protein kinase C delta (PRKCD)
DMELJDI	MT	DTT
DMELJDI	MA	Inhibitor
DMELJDI	RN	PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101.
DMELJDI	RU	https://pubmed.ncbi.nlm.nih.gov/19519579

DM5U3IF	DI	DM5U3IF
DM5U3IF	DN	KB-004
DM5U3IF	MI	TTHS2LR
DM5U3IF	MN	Ephrin type-A receptor 3 (EPHA3)
DM5U3IF	MT	DTT
DM5U3IF	RN	Clinical pipeline report, company report or official report of Kalobios.
DM5U3IF	RU	http://kalobios.com/kb004

DMI9FXE	DI	DMI9FXE
DMI9FXE	DN	KBP-5074
DMI9FXE	MI	TT26PHO
DMI9FXE	MN	Mineralocorticoid receptor  (MR)
DMI9FXE	MT	DTT
DMI9FXE	MA	Antagonist
DMI9FXE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI9FXE	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMZ416B	DI	DMZ416B
DMZ416B	DN	KD020
DMZ416B	MI	TTUS1RD
DMZ416B	MN	Microsomal triglyceride transfer protein (MTTP)
DMZ416B	MT	DTT
DMZ416B	MA	Modulator
DMZ416B	RN	Clinical pipeline report, company report or official report of Kadmon Pharmaceuticals.
DMZ416B	RU	http://kadmon.com/press/kadmon-corporation-presents-encouraging-nonclinical-data-on-tesevatinib-kd019-at-aacr-annual-meeting/

DM0NZYC	DI	DM0NZYC
DM0NZYC	DN	KO-539
DM0NZYC	MI	TT0CZBQ
DM0NZYC	MN	Menin-MLL1 interaction (MEN1-KMT2A PPI)
DM0NZYC	MT	DTT
DM0NZYC	MA	Inhibitor
DM0NZYC	RN	Clinical pipeline report, company report or official report of Kura Oncology.
DM0NZYC	RU	https://kuraoncology.com/pipeline/#ko539

DML29RF	DI	DML29RF
DML29RF	DN	KP-100
DML29RF	MI	TTWC6MY
DML29RF	MN	Protein tyrosine phosphatase (PTP)
DML29RF	MT	DTT
DML29RF	MA	Inhibitor
DML29RF	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010512)
DML29RF	RU	http://adisinsight.springer.com/drugs/800010512

DMA5B1S	DI	DMA5B1S
DMA5B1S	DN	KRN-330
DMA5B1S	MI	TT96HUR
DMA5B1S	MN	Cell surface A33 antigen (GPA33)
DMA5B1S	MT	DTT
DMA5B1S	RN	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
DMA5B1S	RU	https://pubmed.ncbi.nlm.nih.gov/24691674

DME8JW1	DI	DME8JW1
DME8JW1	DN	KTE-C19 CAR
DME8JW1	MI	TTW640A
DME8JW1	MN	B-lymphocyte surface antigen B4 (CD19)
DME8JW1	MT	DTT
DME8JW1	MA	Inhibitor
DME8JW1	RN	Clinical pipeline report, company report or official report of Kite Pharma.
DME8JW1	RU	http://ir.kitepharma.com/releasedetail.cfm?releaseid=867609

DMXJ683	DI	DMXJ683
DMXJ683	DN	KY1044
DMXJ683	MI	TTE5VP6
DMXJ683	MN	Inducible T-cell costimulator (ICOS)
DMXJ683	MT	DTT
DMXJ683	MA	Inhibitor
DMXJ683	RN	Clinical pipeline report, company report or official report of Kymab.
DMXJ683	RU	https://www.kymab.com/pipeline/ky1044/

DMBEQ08	DI	DMBEQ08
DMBEQ08	DN	L-377202
DMBEQ08	MI	TT0IHXV
DMBEQ08	MN	DNA topoisomerase II (TOP2)
DMBEQ08	MT	DTT
DMBEQ08	MA	Modulator
DMBEQ08	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBEQ08	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMFHV9L	DI	DMFHV9L
DMFHV9L	DN	Leber's congenital amaurosis gene therapy
DMFHV9L	MI	TTBOH16
DMFHV9L	MN	Retinal pigment epithelium protein (RPE65)
DMFHV9L	MT	DTT
DMFHV9L	MA	Modulator
DMFHV9L	RN	ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health.
DMFHV9L	RU	https://clinicaltrials.gov/ct2/show/NCT00749957

DMQN9ME	DI	DMQN9ME
DMQN9ME	DN	LGH-447
DMQN9ME	MI	TT69J2Z
DMQN9ME	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DMQN9ME	MT	DTT
DMQN9ME	MA	Modulator
DMQN9ME	RN	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014 Apr 1;20(7):1834-45.
DMQN9ME	RU	https://pubmed.ncbi.nlm.nih.gov/24474669

DMENF5K	DI	DMENF5K
DMENF5K	DN	Liatermin
DMENF5K	MI	TTF23ML
DMENF5K	MN	Glial cell line-derived neurotrophic factor (GDNF)
DMENF5K	MT	DTT
DMENF5K	MA	Modulator
DMENF5K	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMENF5K	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMEMRW0	DI	DMEMRW0
DMEMRW0	DN	Lipoteichoic acid
DMEMRW0	MI	TTY7ZHS
DMEMRW0	MN	Toll-like receptor 2 (TLR2)
DMEMRW0	MT	DTT
DMEMRW0	MA	Modulator
DMEMRW0	RN	Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
DMEMRW0	RU	https://pubmed.ncbi.nlm.nih.gov/12594207

DMGTB5N	DI	DMGTB5N
DMGTB5N	DN	LJM716
DMGTB5N	MI	TTDC8N2
DMGTB5N	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMGTB5N	MT	DTT
DMGTB5N	RN	An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.
DMGTB5N	RU	https://pubmed.ncbi.nlm.nih.gov/23928993

DMCJ10K	DI	DMCJ10K
DMCJ10K	DN	LM11A-31
DMCJ10K	MI	TTEDJN4
DMCJ10K	MN	Low-affinity nerve growth factor receptor (NGFR)
DMCJ10K	MT	DTT
DMCJ10K	MA	Modulator
DMCJ10K	RN	Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63.
DMCJ10K	RU	https://www.ncbi.nlm.nih.gov/pubmed/23545424

DM095HQ	DI	DM095HQ
DM095HQ	DN	LM11A-31
DM095HQ	MI	TTEDJN4
DM095HQ	MN	Low-affinity nerve growth factor receptor (NGFR)
DM095HQ	MT	DTT
DM095HQ	MA	Modulator
DM095HQ	RN	Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500.
DM095HQ	RU	https://pubmed.ncbi.nlm.nih.gov/31073629

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DEYGVN4
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9--potent inhibition by niflumic acid. Biopharm Drug Dispos. 2006 Jan;27(1):1-6.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16278927

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DELOY3P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A4 (UGT1A4)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DEPF954
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A5 (UGT1A5)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	A common polymorphic variant of UGT1A5 displays increased activity due to optimized cofactor binding. FEBS Lett. 2018 Jun;592(11):1837-1846.
DMW3QGJ	RU	https://pubmed.ncbi.nlm.nih.gov/29710432

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DESD26P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A6 (UGT1A6)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17956868

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DE85D2P
DMW3QGJ	MN	UDP-glucuronosyltransferase 1A9 (UGT1A9)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62.
DMW3QGJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=18362158

DMW3QGJ	DI	DMW3QGJ
DMW3QGJ	DN	LM-94
DMW3QGJ	MI	DE7TIN4
DMW3QGJ	MN	UDP-glucuronosyltransferase 2B11 (UGT2B11)
DMW3QGJ	MT	DME
DMW3QGJ	MA	Metabolism
DMW3QGJ	RN	cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun. 1993 Jul 15;194(1):496-503.
DMW3QGJ	RU	https://pubmed.ncbi.nlm.nih.gov/8333863

DMYGNDI	DI	DMYGNDI
DMYGNDI	DN	LMP1-CAR-T cells
DMYGNDI	MI	TT0BI4Q
DMYGNDI	MN	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
DMYGNDI	MT	DTT
DMYGNDI	MA	CAR-T-Cell-Therapy
DMYGNDI	RN	ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
DMYGNDI	RU	https://clinicaltrials.gov/ct2/show/NCT02980315

DMZNIAG	DI	DMZNIAG
DMZNIAG	DN	LS-172108
DMZNIAG	MI	DE4LYSA
DMZNIAG	MN	Cytochrome P450 3A4 (CYP3A4)
DMZNIAG	MT	DME
DMZNIAG	MA	Metabolism
DMZNIAG	RN	Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther. 1996 May;277(2):982-90.
DMZNIAG	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=8627581

DM5N04G	DI	DM5N04G
DM5N04G	DN	LT-1951
DM5N04G	MI	TTF10I9
DM5N04G	MN	Nitric-oxide synthase inducible (NOS2)
DM5N04G	MT	DTT
DM5N04G	MA	Modulator
DM5N04G	RN	Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
DM5N04G	RU	https://pubmed.ncbi.nlm.nih.gov/12742995

DM2LYIN	DI	DM2LYIN
DM2LYIN	DN	LX-7101
DM2LYIN	MI	TTU8W4S
DM2LYIN	MN	Protein kinase (PK)
DM2LYIN	MT	DTT
DM2LYIN	MA	Inhibitor
DM2LYIN	RN	Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
DM2LYIN	RU	https://pubmed.ncbi.nlm.nih.gov/26233434

DM65MEL	DI	DM65MEL
DM65MEL	DN	LXS196
DM65MEL	MI	TTYVX59
DM65MEL	MN	Protein kinase C (PRKC)
DM65MEL	MT	DTT
DM65MEL	MA	Inhibitor
DM65MEL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM65MEL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHXTNW	DI	DMHXTNW
DMHXTNW	DN	LY-2228820
DMHXTNW	MI	TTWELHI
DMHXTNW	MN	Stress-activated protein kinase (p38)
DMHXTNW	MT	DTT
DMHXTNW	MA	Inhibitor
DMHXTNW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
DMHXTNW	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959

DMADEHZ	DI	DMADEHZ
DMADEHZ	DN	LY2880070
DMADEHZ	MI	TTTU902
DMADEHZ	MN	Checkpoint kinase-1 (CHK1)
DMADEHZ	MT	DTT
DMADEHZ	MA	Inhibitor
DMADEHZ	RN	A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
DMADEHZ	RU	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3581

DMTJWIQ	DI	DMTJWIQ
DMTJWIQ	DN	LY2940680
DMTJWIQ	MI	DE4LYSA
DMTJWIQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMTJWIQ	MT	DME
DMTJWIQ	MA	Metabolism
DMTJWIQ	RN	Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma. Clin Cancer Res. 2018 May 1;24(9):2082-2091.
DMTJWIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29483143

DMTJWIQ	DI	DMTJWIQ
DMTJWIQ	DN	LY2940680
DMTJWIQ	MI	TT8J1S3
DMTJWIQ	MN	Smoothened homolog (SMO)
DMTJWIQ	MT	DTT
DMTJWIQ	MA	Modulator
DMTJWIQ	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTJWIQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM7T1CR	DI	DM7T1CR
DM7T1CR	DN	LY3016859
DM7T1CR	MI	TTYSB89
DM7T1CR	MN	Epiregulin (EREG)
DM7T1CR	MT	DTT
DM7T1CR	MA	Modulator
DM7T1CR	RN	Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43.
DM7T1CR	RU	https://pubmed.ncbi.nlm.nih.gov/24518034

DM7T1CR	DI	DM7T1CR
DM7T1CR	DN	LY3016859
DM7T1CR	MI	TTTLQFR
DM7T1CR	MN	Transforming growth factor alpha (TGFA)
DM7T1CR	MT	DTT
DM7T1CR	MA	Modulator
DM7T1CR	RN	Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43.
DM7T1CR	RU	https://pubmed.ncbi.nlm.nih.gov/24518034

DMC5SAW	DI	DMC5SAW
DMC5SAW	DN	LY3039478
DMC5SAW	MI	TTB1STW
DMC5SAW	MN	Notch-1 receptor (NOTCH1)
DMC5SAW	MT	DTT
DMC5SAW	MA	Inhibitor
DMC5SAW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC5SAW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMC5SAW	DI	DMC5SAW
DMC5SAW	DN	LY3039478
DMC5SAW	MI	TTXDIK2
DMC5SAW	MN	Notch-4 receptor (NOTCH4)
DMC5SAW	MT	DTT
DMC5SAW	MA	Inhibitor
DMC5SAW	RN	J Clin Oncol 33, 2015 (suppl; abstr 2533).
DMC5SAW	RU	http://meetinglibrary.asco.org/content/144588-156

DM8RJTB	DI	DM8RJTB
DM8RJTB	DN	LY3295668
DM8RJTB	MI	TTPS3C0
DM8RJTB	MN	Aurora kinase A (AURKA)
DM8RJTB	MT	DTT
DM8RJTB	MA	Inhibitor
DM8RJTB	RN	Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
DM8RJTB	RU	https://pubmed.ncbi.nlm.nih.gov/31530649

DMA1CSR	DI	DMA1CSR
DMA1CSR	DN	LY3499446
DMA1CSR	MI	TT3LH46
DMA1CSR	MN	KRAS G12C mutant (KRAS G12C)
DMA1CSR	MT	DTT
DMA1CSR	MA	Inhibitor
DMA1CSR	RN	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
DMA1CSR	RU	https://pubmed.ncbi.nlm.nih.gov/32711246

DMK2L38	DI	DMK2L38
DMK2L38	DN	M3814
DMK2L38	MI	TTK3PY9
DMK2L38	MN	DNA-dependent protein kinase catalytic (PRKDC)
DMK2L38	MT	DTT
DMK2L38	MA	Inhibitor
DMK2L38	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK2L38	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIRG15	DI	DMIRG15
DMIRG15	DN	MaC46/M87o
DMIRG15	MI	TTG90S6
DMIRG15	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMIRG15	MT	DTT
DMIRG15	MA	Modulator
DMIRG15	RN	DOI: 10.1038/mt.sj.6300124
DMIRG15	RU	http://www.nature.com/mt/journal/v15/n5/full/6300124a.html

DM6H3YS	DI	DM6H3YS
DM6H3YS	DN	MAGE-A10 TCR
DM6H3YS	MI	TT7AKW1
DM6H3YS	MN	T-cell receptor (TCR)
DM6H3YS	MT	DTT
DM6H3YS	MA	Immunomodulator
DM6H3YS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6H3YS	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMFK5IX	DI	DMFK5IX
DMFK5IX	DN	MAK683
DMFK5IX	MI	TTFNJ4R
DMFK5IX	MN	Embryonic ectoderm development protein (EED)
DMFK5IX	MT	DTT
DMFK5IX	MA	Inhibitor
DMFK5IX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFK5IX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBZ68C	DI	DMBZ68C
DMBZ68C	DN	MALP-2S
DMBZ68C	MI	TTY7ZHS
DMBZ68C	MN	Toll-like receptor 2 (TLR2)
DMBZ68C	MT	DTT
DMBZ68C	MA	Modulator
DMBZ68C	RN	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
DMBZ68C	RU	https://pubmed.ncbi.nlm.nih.gov/21172450

DMBZ68C	DI	DMBZ68C
DMBZ68C	DN	MALP-2S
DMBZ68C	MI	TTWRI8V
DMBZ68C	MN	Toll-like receptor 6 (TLR6)
DMBZ68C	MT	DTT
DMBZ68C	MA	Modulator
DMBZ68C	RN	Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
DMBZ68C	RU	https://pubmed.ncbi.nlm.nih.gov/21172450

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEST6E5
DMH0ROP	MN	Alpha-glucosidase (aglA)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch. FASEB J. 2010 Oct;24(10):3939-49.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/20581222

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	TTHCF4J
DMH0ROP	MN	Alpha-glucosidase (GLA)
DMH0ROP	MT	DTT
DMH0ROP	MA	Inhibitor
DMH0ROP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEGLW18
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DENTGJO
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE4XLDR
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEGBVKJ
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEDY9F6
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DERDXAF
DMH0ROP	MN	Cellobiose 2-epimerase (CE)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DEBW1FU
DMH0ROP	MN	Fructokinase (scrK)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Sugar metabolism by fusobacteria: regulation of transport, phosphorylation, and polymer formation by Fusobacterium mortiferum ATCC 25557. Infect Immun. 1991 Dec;59(12):4547-54.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/1937813

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	TTXWASR
DMH0ROP	MN	Intestinal maltase-glucoamylase (MGAM)
DMH0ROP	MT	DTT
DMH0ROP	MA	Inhibitor
DMH0ROP	RN	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/21059682

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE7NXHG
DMH0ROP	MN	Maltose phosphorylase (malP)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Rational engineering of Lactobacillus acidophilus NCFM maltose phosphorylase into either trehalose or kojibiose dual specificity phosphorylase. Protein Eng Des Sel. 2010 Oct;23(10):781-7.
DMH0ROP	RU	https://pubmed.ncbi.nlm.nih.gov/20713411

DMH0ROP	DI	DMH0ROP
DMH0ROP	DN	Maltose
DMH0ROP	MI	DE5EO4Y
DMH0ROP	MN	Sucrase-isomaltase intestinal (SI)
DMH0ROP	MT	DME
DMH0ROP	MA	Metabolism
DMH0ROP	RN	Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains. J Biol Chem. 2010 Jun 4;285(23):17763-70.
DMH0ROP	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=20356844

DMXU7P6	DI	DMXU7P6
DMXU7P6	DN	MB-CART20.1
DMXU7P6	MI	TTUE541
DMXU7P6	MN	Leukocyte surface antigen Leu-16 (CD20)
DMXU7P6	MT	DTT
DMXU7P6	MA	CAR-T-Cell-Therapy
DMXU7P6	RN	ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma
DMXU7P6	RU	https://clinicaltrials.gov/ct2/show/NCT03664635

DMS19IH	DI	DMS19IH
DMS19IH	DN	MBO7133
DMS19IH	MI	TTUTN1I
DMS19IH	MN	Human Deoxyribonucleic acid (hDNA)
DMS19IH	MT	DTT
DMS19IH	MA	Binder
DMS19IH	RN	Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004.
DMS19IH	RU	http://www.dtic.mil/get-tr-doc/pdf?AD=ADA431390

DMTCADJ	DI	DMTCADJ
DMTCADJ	DN	McN3377
DMTCADJ	MI	TTHS256
DMTCADJ	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMTCADJ	MT	DTT
DMTCADJ	MA	Modulator
DMTCADJ	RN	Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
DMTCADJ	RU	https://pubmed.ncbi.nlm.nih.gov/16377242

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTX4GLS
DM6JN19	MN	Mammalian target of rapamycin complex 1 (mTORC1)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6JN19	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTCJG29
DM6JN19	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	National Cancer Institute Drug Dictionary (drug id 728650).
DM6JN19	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=728650

DM6JN19	DI	DM6JN19
DM6JN19	DN	ME-344
DM6JN19	MI	TTWDKCL
DM6JN19	MN	Target of rapamycin complex 2 MAPKAP1 (MTORC2)
DM6JN19	MT	DTT
DM6JN19	MA	Inhibitor
DM6JN19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6JN19	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMB5CV	DI	DMMB5CV
DMMB5CV	DN	Medusa IL-2
DMMB5CV	MI	TTF89GD
DMMB5CV	MN	Interleukin-2 (IL2)
DMMB5CV	MT	DTT
DMMB5CV	MA	Modulator
DMMB5CV	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMMB5CV	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJVFK7	DI	DMJVFK7
DMJVFK7	DN	Meplazumab
DMJVFK7	MI	TTG21IS
DMJVFK7	MN	HUMAN basigin (BSG)
DMJVFK7	MT	DTT
DMJVFK7	MA	Inhibitor
DMJVFK7	RN	Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
DMJVFK7	RU	https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1

DMENFD6	DI	DMENFD6
DMENFD6	DN	Metelimumab
DMENFD6	MI	TTP4520
DMENFD6	MN	TGF-beta receptor type I (TGFBR1)
DMENFD6	MT	DTT
DMENFD6	RN	Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
DMENFD6	RU	https://pubmed.ncbi.nlm.nih.gov/15573100

DME6PB0	DI	DME6PB0
DME6PB0	DN	MG7-CART
DME6PB0	MI	TTPW9LJ
DME6PB0	MN	Co-stimulatory molecule 4-1BB (CD137)
DME6PB0	MT	DTT
DME6PB0	MA	CAR-T-Cell-Therapy
DME6PB0	RN	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
DME6PB0	RU	https://clinicaltrials.gov/ct2/show/NCT02862704

DME6PB0	DI	DME6PB0
DME6PB0	DN	MG7-CART
DME6PB0	MI	TTPXOQN
DME6PB0	MN	Gastric carcinoma-associated antigen MG7 (MG7)
DME6PB0	MT	DTT
DME6PB0	MA	CAR-T-Cell-Therapy
DME6PB0	RN	ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
DME6PB0	RU	https://clinicaltrials.gov/ct2/show/NCT02862704

DM1KZW0	DI	DM1KZW0
DM1KZW0	DN	MGC018
DM1KZW0	MI	TT6CQUM
DM1KZW0	MN	B7 homolog 3 (CD276)
DM1KZW0	MT	DTT
DM1KZW0	RN	Clinical pipeline report, company report or official report of MacroGenics.
DM1KZW0	RU	https://www.macrogenics.com/mgc018-b7-h3/

DMAHWLR	DI	DMAHWLR
DMAHWLR	DN	MGD007
DMAHWLR	MI	TT96HUR
DMAHWLR	MN	Cell surface A33 antigen (GPA33)
DMAHWLR	MT	DTT
DMAHWLR	MA	Modulator
DMAHWLR	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMAHWLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMAHWLR	DI	DMAHWLR
DMAHWLR	DN	MGD007
DMAHWLR	MI	TTV3XPL
DMAHWLR	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMAHWLR	MT	DTT
DMAHWLR	MA	Modulator
DMAHWLR	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMAHWLR	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMCVMUL	DI	DMCVMUL
DMCVMUL	DN	MGD013
DMCVMUL	MI	TTNBFWK
DMCVMUL	MN	Programmed cell death protein 1 (PD-1)
DMCVMUL	MT	DTT
DMCVMUL	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMCVMUL	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM4H7UY	DI	DM4H7UY
DM4H7UY	DN	Milatuzumab
DM4H7UY	MI	TTCMYP9
DM4H7UY	MN	HLA-DR antigens-associated invariant (CD74)
DM4H7UY	MT	DTT
DM4H7UY	RN	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41.
DM4H7UY	RU	https://pubmed.ncbi.nlm.nih.gov/21228331

DM25QKC	DI	DM25QKC
DM25QKC	DN	MK-1308
DM25QKC	MI	TTI2S1D
DM25QKC	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM25QKC	MT	DTT
DM25QKC	MA	Inhibitor
DM25QKC	RN	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
DM25QKC	RU	https://pubmed.ncbi.nlm.nih.gov/33276076

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTKN7QR
DM21WBH	MN	BDNF/NT-3 growth factors receptor (TrkB)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTRLW2X
DM21WBH	MN	Fibroblast growth factor receptor 1 (FGFR1)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTGJVQM
DM21WBH	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTST7KB
DM21WBH	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTGJCWZ
DM21WBH	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTBQ3OC
DM21WBH	MN	Macrophage-stimulating protein receptor (RON)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTXABCW
DM21WBH	MN	NT-3 growth factor receptor (TrkC)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTI7421
DM21WBH	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTNDSF4
DM21WBH	MN	Proto-oncogene c-Met (MET)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTO7LKR
DM21WBH	MN	Tyrosine-protein kinase Mer (MERTK)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTUTJGQ
DM21WBH	MN	Vascular endothelial growth factor receptor 2 (KDR)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TTDCBX5
DM21WBH	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DM21WBH	DI	DM21WBH
DM21WBH	DN	MK-2461
DM21WBH	MI	TT1VAUK
DM21WBH	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DM21WBH	MT	DTT
DM21WBH	MA	Inhibitor
DM21WBH	RN	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
DM21WBH	RU	https://pubmed.ncbi.nlm.nih.gov/20145145

DMCVBQD	DI	DMCVBQD
DMCVBQD	DN	MLN1117
DMCVBQD	MI	TTEUNMR
DMCVBQD	MN	PI3-kinase alpha (PIK3CA)
DMCVBQD	MT	DTT
DMCVBQD	MA	Inhibitor
DMCVBQD	RN	National Cancer Institute Drug Dictionary (drug id 714372).
DMCVBQD	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714372

DMGC96P	DI	DMGC96P
DMGC96P	DN	MLN-2704
DMGC96P	MI	TT9G4N0
DMGC96P	MN	Glutamate carboxypeptidase II (GCPII)
DMGC96P	MT	DTT
DMGC96P	RN	Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 1;26(13):2147-54.
DMGC96P	RU	https://pubmed.ncbi.nlm.nih.gov/18362364

DMG7XHE	DI	DMG7XHE
DMG7XHE	DN	Monalizumab
DMG7XHE	MI	TTC4IMS
DMG7XHE	MN	NKG2-A/B-activating NK receptor (NKG2A)
DMG7XHE	MT	DTT
DMG7XHE	MA	Antagonist
DMG7XHE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG7XHE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXVIQN	DI	DMXVIQN
DMXVIQN	DN	MOR-103
DMXVIQN	MI	TT6MP2Z
DMXVIQN	MN	GMCSFR-alpha (CSF2RA)
DMXVIQN	MT	DTT
DMXVIQN	RN	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.
DMXVIQN	RU	https://pubmed.ncbi.nlm.nih.gov/24534756

DMR8AHJ	DI	DMR8AHJ
DMR8AHJ	DN	MOR-202
DMR8AHJ	MI	TTPURFN
DMR8AHJ	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMR8AHJ	MT	DTT
DMR8AHJ	RN	Clinical pipeline report, company report or official report of MorphoSys.
DMR8AHJ	RU	https://www.morphosys.com/pipeline/proprietary-product-portfolio/mor202

DMR3VCY	DI	DMR3VCY
DMR3VCY	DN	MP0250
DMR3VCY	MI	TT4V2JM
DMR3VCY	MN	Hepatocyte growth factor (HGF)
DMR3VCY	MT	DTT
DMR3VCY	MA	Inhibitor
DMR3VCY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3VCY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR3VCY	DI	DMR3VCY
DMR3VCY	DN	MP0250
DMR3VCY	MI	TTOHSBA
DMR3VCY	MN	Vascular endothelial growth factor A (VEGFA)
DMR3VCY	MT	DTT
DMR3VCY	MA	Inhibitor
DMR3VCY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3VCY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME7PBN	DI	DME7PBN
DME7PBN	DN	mRNA-3704
DME7PBN	MI	TTCQ21Y
DME7PBN	MN	Methylmalonyl-CoA mutase (MMUT)
DME7PBN	MT	DTT
DME7PBN	MA	Replacement
DME7PBN	RN	Clinical pipeline report, company report or official report of Moderna Therapeutics.
DME7PBN	RU	https://www.modernatx.com/mrna-3705

DM35YFC	DI	DM35YFC
DM35YFC	DN	MS-1819
DM35YFC	MI	TTXMY0J
DM35YFC	MN	Pancreatic triacylglycerol lipase (PNLIP)
DM35YFC	MT	DTT
DM35YFC	MA	Modulator
DM35YFC	RN	Clinical pipeline report, company report or official report of AzurRx.
DM35YFC	RU	http://www.azurrx.com/news-events/press-releases/10-news-2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit

DMIS75V	DI	DMIS75V
DMIS75V	DN	MTL-CEPBA
DMIS75V	MI	TT5LWG1
DMIS75V	MN	CEBPA messenger RNA (CEBPA mRNA)
DMIS75V	MT	DTT
DMIS75V	MA	Activator
DMIS75V	RN	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946.
DMIS75V	RU	https://pubmed.ncbi.nlm.nih.gov/32357963

DMFUDHM	DI	DMFUDHM
DMFUDHM	DN	MUC-1 CART cell immunotherapy
DMFUDHM	MI	TTBHFYQ
DMFUDHM	MN	Mucin-1 (MUC1)
DMFUDHM	MT	DTT
DMFUDHM	MA	CAR-T-Cell-Therapy
DMFUDHM	RN	ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
DMFUDHM	RU	https://clinicaltrials.gov/ct2/show/NCT03633773

DMPNR0J	DI	DMPNR0J
DMPNR0J	DN	Muc1-specific gene-engineered T cells
DMPNR0J	MI	TTBHFYQ
DMPNR0J	MN	Mucin-1 (MUC1)
DMPNR0J	MT	DTT
DMPNR0J	MA	CAR-T-Cell-Therapy
DMPNR0J	RN	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
DMPNR0J	RU	https://clinicaltrials.gov/ct2/show/NCT03222674

DMU6MJ1	DI	DMU6MJ1
DMU6MJ1	DN	NAHE-001
DMU6MJ1	MI	TTLHGSF
DMU6MJ1	MN	Interferon-alpha 5 (IFNA5)
DMU6MJ1	MT	DTT
DMU6MJ1	MA	Modulator
DMU6MJ1	RN	Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20.
DMU6MJ1	RU	https://pubmed.ncbi.nlm.nih.gov/19319841

DM5O4GR	DI	DM5O4GR
DM5O4GR	DN	NB1011
DM5O4GR	MI	TTU6BFZ
DM5O4GR	MN	Candida Thymidylate synthase (Candi TMP1)
DM5O4GR	MT	DTT
DM5O4GR	MA	Binder
DM5O4GR	RN	Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300.
DM5O4GR	RU	https://pubmed.ncbi.nlm.nih.gov/12859954

DMTAODR	DI	DMTAODR
DMTAODR	DN	NBE-002
DMTAODR	MI	TTDEJAU
DMTAODR	MN	Neurotrophic tyrosine kinase ROR1 (ROR1)
DMTAODR	MT	DTT
DMTAODR	RN	Clinical pipeline report, company report or official report of NBE-Therapeutics.
DMTAODR	RU	https://www.nbe-therapeutics.com/technology/overview

DMZSIV1	DI	DMZSIV1
DMZSIV1	DN	NC410
DMZSIV1	MI	TTSI7A8
DMZSIV1	MN	Leukocyte-associated Ig-like receptor 1 (LAIR1)
DMZSIV1	MT	DTT
DMZSIV1	MA	Inhibitor
DMZSIV1	RN	Clinical pipeline report, company report or official report of NextCure.
DMZSIV1	RU	http://www.nextcure.com/pipeline/

DMCDQX0	DI	DMCDQX0
DMCDQX0	DN	ND-0801
DMCDQX0	MI	TTJSZTB
DMCDQX0	MN	Nicotinic acetylcholine receptor (nAChR)
DMCDQX0	MT	DTT
DMCDQX0	MA	Modulator
DMCDQX0	RN	Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248.
DMCDQX0	RU	http://link.springer.com/article/10.1007/s40290-013-0026-2

DMPMF6L	DI	DMPMF6L
DMPMF6L	DN	Nepadutant
DMPMF6L	MI	TTYO0A3
DMPMF6L	MN	Substance-K receptor (TACR2)
DMPMF6L	MT	DTT
DMPMF6L	MA	Antagonist
DMPMF6L	RN	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
DMPMF6L	RU	https://pubmed.ncbi.nlm.nih.gov/17979603

DMXKOUC	DI	DMXKOUC
DMXKOUC	DN	Neu-120
DMXKOUC	MI	TTRSMW9
DMXKOUC	MN	Glycogen synthase kinase-3 beta (GSK-3B)
DMXKOUC	MT	DTT
DMXKOUC	MA	Modulator
DMXKOUC	RN	Company report (Neurim Pharmaceuticals)
DMXKOUC	RU	http://www.neurim.com/products/

DMXKOUC	DI	DMXKOUC
DMXKOUC	DN	Neu-120
DMXKOUC	MI	TTGP7BY
DMXKOUC	MN	Monoamine oxidase type B (MAO-B)
DMXKOUC	MT	DTT
DMXKOUC	MA	Modulator
DMXKOUC	RN	Company report (Neurim Pharmaceuticals)
DMXKOUC	RU	http://www.neurim.com/products/

DMEOLVP	DI	DMEOLVP
DMEOLVP	DN	NI-0401
DMEOLVP	MI	TTBMAOZ
DMEOLVP	MN	Regulatory protein unspecific (RGP)
DMEOLVP	MT	DTT
DMEOLVP	RN	Clinical pipeline report, company report or official report of NovImmune.
DMEOLVP	RU	http://www.novimmune.com/pipeline/ni-0401.html

DMMOA2X	DI	DMMOA2X
DMMOA2X	DN	Nikkomycin Z
DMMOA2X	MI	TTBGVF1
DMMOA2X	MN	Candida Chitin synthase 3 (Candi CHS3)
DMMOA2X	MT	DTT
DMMOA2X	MA	Modulator
DMMOA2X	RN	Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans. Yeast. 2002 Mar 15;19(4):341-9.
DMMOA2X	RU	https://pubmed.ncbi.nlm.nih.gov/11870857

DM7SMNJ	DI	DM7SMNJ
DM7SMNJ	DN	NKTR-255
DM7SMNJ	MI	TTGN89I
DM7SMNJ	MN	Interleukin 15 receptor alpha (IL15RA)
DM7SMNJ	MT	DTT
DM7SMNJ	MA	Agonist
DM7SMNJ	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DM7SMNJ	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-255

DMYR8LF	DI	DMYR8LF
DMYR8LF	DN	NKTR-262
DMYR8LF	MI	TTRJ1K4
DMYR8LF	MN	Toll-like receptor 7 (TLR7)
DMYR8LF	MT	DTT
DMYR8LF	MA	Agonist
DMYR8LF	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DMYR8LF	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-262

DMYR8LF	DI	DMYR8LF
DMYR8LF	DN	NKTR-262
DMYR8LF	MI	TT8CWFK
DMYR8LF	MN	Toll-like receptor 8 (TLR8)
DMYR8LF	MT	DTT
DMYR8LF	MA	Agonist
DMYR8LF	RN	Clinical pipeline report, company report or official report of Nektar Therapeutics.
DMYR8LF	RU	https://www.nektar.com/pipeline/rd-pipeline/nktr-262

DMDNJP5	DI	DMDNJP5
DMDNJP5	DN	NM21-1480
DMDNJP5	MI	TTPW9LJ
DMDNJP5	MN	Co-stimulatory molecule 4-1BB (CD137)
DMDNJP5	MT	DTT
DMDNJP5	MA	Modulator
DMDNJP5	RN	Clinical pipeline report, company report or official report of Numab Therapeutics.
DMDNJP5	RU	https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf

DMDNJP5	DI	DMDNJP5
DMDNJP5	DN	NM21-1480
DMDNJP5	MI	TT8ZLTI
DMDNJP5	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMDNJP5	MT	DTT
DMDNJP5	MA	Modulator
DMDNJP5	RN	Clinical pipeline report, company report or official report of Numab Therapeutics.
DMDNJP5	RU	https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf

DMDASRW	DI	DMDASRW
DMDASRW	DN	Norleucine
DMDASRW	MI	TT01M3K
DMDASRW	MN	Hepatocyte nuclear factor 1-alpha (HNF1A)
DMDASRW	MT	DTT
DMDASRW	MA	Inhibitor
DMDASRW	RN	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
DMDASRW	RU	https://pubmed.ncbi.nlm.nih.gov/10592235

DM78KMT	DI	DM78KMT
DM78KMT	DN	NPB-001-056
DM78KMT	MI	TTS7G69
DM78KMT	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM78KMT	MT	DTT
DM78KMT	MA	Inhibitor
DM78KMT	RN	NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88.
DM78KMT	RU	https://pubmed.ncbi.nlm.nih.gov/21622134

DMU9BCD	DI	DMU9BCD
DMU9BCD	DN	NS-018
DMU9BCD	MI	TTRMX3V
DMU9BCD	MN	Janus kinase 2 (JAK-2)
DMU9BCD	MT	DTT
DMU9BCD	MA	Modulator
DMU9BCD	RN	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174.
DMU9BCD	RU	https://pubmed.ncbi.nlm.nih.gov/24413068

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTF95B8
DMOYS1N	MN	Insulin receptor substrate 2 (IRS2)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTADRX7
DMOYS1N	MN	Insulin receptor substrate-1 (IRS1)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMOYS1N	DI	DMOYS1N
DMOYS1N	DN	NT219
DMOYS1N	MI	TTH8FZW
DMOYS1N	MN	Signal transducer and activator of transcription 3 (STAT3)
DMOYS1N	MT	DTT
DMOYS1N	MA	Inhibitor
DMOYS1N	RN	Clinical pipeline report, company report or official report of Purple Biotech.
DMOYS1N	RU	https://purple-biotech.com/pipeline/#1NT-219

DMBQRGV	DI	DMBQRGV
DMBQRGV	DN	NT-501 CNTF
DMBQRGV	MI	TTGEM5Q
DMBQRGV	MN	Ciliary neurotrophic factor (CNTF)
DMBQRGV	MT	DTT
DMBQRGV	MA	Modulator
DMBQRGV	RN	Clinical pipeline report, company report or official report of Neurotech.
DMBQRGV	RU	http://www.neurotechusa.com/cntfrenexus.html

DMS0L6J	DI	DMS0L6J
DMS0L6J	DN	NY-ESO-TCR
DMS0L6J	MI	TT7AKW1
DMS0L6J	MN	T-cell receptor (TCR)
DMS0L6J	MT	DTT
DMS0L6J	MA	CAR-T-Cell-Therapy
DMS0L6J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS0L6J	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMD2L1U	DI	DMD2L1U
DMD2L1U	DN	OBI-888
DMD2L1U	MI	TT4UXTG
DMD2L1U	MN	Globohexaosylceramide (Globo H)
DMD2L1U	MT	DTT
DMD2L1U	RN	Clinical pipeline report, company report or official report of OBI Pharma.
DMD2L1U	RU	https://www.obipharma.com/obi-888-mab/

DMPB9OD	DI	DMPB9OD
DMPB9OD	DN	OBI-999
DMPB9OD	MI	TT4UXTG
DMPB9OD	MN	Globohexaosylceramide (Globo H)
DMPB9OD	MT	DTT
DMPB9OD	RN	Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132.
DMPB9OD	RU	https://pubmed.ncbi.nlm.nih.gov/33722855

DM9MF08	DI	DM9MF08
DM9MF08	DN	OBP-301
DM9MF08	MI	TTUJFD0
DM9MF08	MN	Telomerase reverse transcriptase (TERT)
DM9MF08	MT	DTT
DM9MF08	MA	Inhibitor
DM9MF08	RN	Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92.
DM9MF08	RU	https://pubmed.ncbi.nlm.nih.gov/14734481

DMOKVJD	DI	DMOKVJD
DMOKVJD	DN	ODM-207
DMOKVJD	MI	TTE4BSY
DMOKVJD	MN	Bromodomain and extraterminal domain protein (BET)
DMOKVJD	MT	DTT
DMOKVJD	MA	Inhibitor
DMOKVJD	RN	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736.
DMOKVJD	RU	https://pubmed.ncbi.nlm.nih.gov/32989226

DMPLBDF	DI	DMPLBDF
DMPLBDF	DN	Omburtamab I-124
DMPLBDF	MI	TT6CQUM
DMPLBDF	MN	B7 homolog 3 (CD276)
DMPLBDF	MT	DTT
DMPLBDF	MA	Inhibitor
DMPLBDF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPLBDF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2DHJS	DI	DM2DHJS
DM2DHJS	DN	ONC1-13B
DM2DHJS	MI	TTS64P2
DM2DHJS	MN	Androgen receptor (AR)
DM2DHJS	MT	DTT
DM2DHJS	MA	Antagonist
DM2DHJS	RN	Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42.
DM2DHJS	RU	https://pubmed.ncbi.nlm.nih.gov/24494031

DMV6GX7	DI	DMV6GX7
DMV6GX7	DN	ONO-7475
DMV6GX7	MI	TTO7LKR
DMV6GX7	MN	Tyrosine-protein kinase Mer (MERTK)
DMV6GX7	MT	DTT
DMV6GX7	MA	Inhibitor
DMV6GX7	RN	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
DMV6GX7	RU	https://www.ono-pharma.com/ir/library/pipeline.html

DMV6GX7	DI	DMV6GX7
DMV6GX7	DN	ONO-7475
DMV6GX7	MI	TTZPY6J
DMV6GX7	MN	Tyrosine-protein kinase UFO (AXL)
DMV6GX7	MT	DTT
DMV6GX7	MA	Inhibitor
DMV6GX7	RN	Clinical pipeline report, company report or official report of Ono Pharmaceutical.
DMV6GX7	RU	https://www.ono-pharma.com/ir/library/pipeline.html

DMXLPYE	DI	DMXLPYE
DMXLPYE	DN	ONO-7579
DMXLPYE	MI	TTTDVOJ
DMXLPYE	MN	Tropomyosin-related kinase A (TrkA)
DMXLPYE	MT	DTT
DMXLPYE	MA	Inhibitor
DMXLPYE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXLPYE	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMGIN7J	DI	DMGIN7J
DMGIN7J	DN	Onyvax-105
DMGIN7J	MI	TT5Z9WY
DMGIN7J	MN	Complement decay-accelerating factor (CD55)
DMGIN7J	MT	DTT
DMGIN7J	RN	Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72.
DMGIN7J	RU	https://pubmed.ncbi.nlm.nih.gov/14755894

DMIU26T	DI	DMIU26T
DMIU26T	DN	OP-1250
DMIU26T	MI	TTZAYWL
DMIU26T	MN	Estrogen receptor (ESR)
DMIU26T	MT	DTT
DMIU26T	MA	Antagonist
DMIU26T	RN	Clinical pipeline report, company report or official report of Olema Pharmaceuticals.
DMIU26T	RU	https://olema.com/pipeline/

DMELJIV	DI	DMELJIV
DMELJIV	DN	OPA-6566
DMELJIV	MI	TTM2AOE
DMELJIV	MN	Adenosine A2a receptor (ADORA2A)
DMELJIV	MT	DTT
DMELJIV	MA	Agonist
DMELJIV	RN	Clinical pipeline report, company report or official report of Acucela.
DMELJIV	RU	http://www.acucela.com/Read-About-Us/Press-Releases/Acucela-and-Otsuka-Pharmaceutical-Announce-the-(1)

DM6VGO3	DI	DM6VGO3
DM6VGO3	DN	OPB-31121
DM6VGO3	MI	TTH8FZW
DM6VGO3	MN	Signal transducer and activator of transcription 3 (STAT3)
DM6VGO3	MT	DTT
DM6VGO3	MA	Inhibitor
DM6VGO3	RN	OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
DM6VGO3	RU	https://pubmed.ncbi.nlm.nih.gov/23402820

DMZB6LO	DI	DMZB6LO
DMZB6LO	DN	OPC-167832
DMZB6LO	MI	TTLOHU4
DMZB6LO	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DMZB6LO	MT	DTT
DMZB6LO	MA	Inhibitor
DMZB6LO	RN	OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.
DMZB6LO	RU	https://pubmed.ncbi.nlm.nih.gov/32229496

DM471ZH	DI	DM471ZH
DM471ZH	DN	ORE-1001
DM471ZH	MI	TTUI5H7
DM471ZH	MN	Angiotensin-converting enzyme 2 (ACE2)
DM471ZH	MT	DTT
DM471ZH	MA	Inhibitor
DM471ZH	RN	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27.
DM471ZH	RU	https://pubmed.ncbi.nlm.nih.gov/19517214

DM27RXS	DI	DM27RXS
DM27RXS	DN	ORIN1001
DM27RXS	MI	TTOJ9QL
DM27RXS	MN	Endoplasmic reticulum to nucleus signaling 1 (ERN1)
DM27RXS	MT	DTT
DM27RXS	MA	Inhibitor
DM27RXS	RN	Clinical pipeline report, company report or official report of Orinove.
DM27RXS	RU	http://www.orinove.com/about261.html

DMWCJ1F	DI	DMWCJ1F
DMWCJ1F	DN	OT-58
DMWCJ1F	MI	TTVZJ7G
DMWCJ1F	MN	Cystathionine beta-synthase (CBS)
DMWCJ1F	MT	DTT
DMWCJ1F	MA	Replacement
DMWCJ1F	RN	Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020 Jun;173:48-56.
DMWCJ1F	RU	https://pubmed.ncbi.nlm.nih.gov/31857119

DMYGK1D	DI	DMYGK1D
DMYGK1D	DN	OTL-300
DMYGK1D	MI	TTM6HK1
DMYGK1D	MN	Hemoglobin subunit beta (HBB)
DMYGK1D	MT	DTT
DMYGK1D	RN	Clinical pipeline report, company report or official report of Orchard Therapeutics.
DMYGK1D	RU	https://www.orchard-tx.com/approach/pipeline/

DMN0ZQ5	DI	DMN0ZQ5
DMN0ZQ5	DN	OTSGC-A24
DMN0ZQ5	MI	TT2Q6G1
DMN0ZQ5	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMN0ZQ5	MT	DTT
DMN0ZQ5	RN	J Clin Oncol 33, 2015 (suppl 3; abstr 65).
DMN0ZQ5	RU	http://meetinglibrary.asco.org/content/140443-158

DMN0ZQ5	DI	DMN0ZQ5
DMN0ZQ5	DN	OTSGC-A24
DMN0ZQ5	MI	TTUTJGQ
DMN0ZQ5	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMN0ZQ5	MT	DTT
DMN0ZQ5	RN	J Clin Oncol 33, 2015 (suppl 3; abstr 65).
DMN0ZQ5	RU	http://meetinglibrary.asco.org/content/140443-158

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTE4BSY
DMI8RG1	MN	Bromodomain and extraterminal domain protein (BET)
DMI8RG1	MT	DTT
DMI8RG1	MA	Inhibitor
DMI8RG1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI8RG1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTDP48B
DMI8RG1	MN	Bromodomain-containing protein 2 (BRD2)
DMI8RG1	MT	DTT
DMI8RG1	MA	Modulator
DMI8RG1	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMI8RG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMI8RG1	DI	DMI8RG1
DMI8RG1	DN	OTX-015
DMI8RG1	MI	TTRA6BO
DMI8RG1	MN	Bromodomain-containing protein 4 (BRD4)
DMI8RG1	MT	DTT
DMI8RG1	MA	Modulator
DMI8RG1	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMI8RG1	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTN451K
DMXF9DM	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTLSWP6
DMXF9DM	MN	GTP cyclohydrolase-I (GCH1)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMXF9DM	DI	DMXF9DM
DMXF9DM	DN	OXB-102
DMXF9DM	MI	TTUHP71
DMXF9DM	MN	Tyrosine 3-monooxygenase (TH)
DMXF9DM	MT	DTT
DMXF9DM	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMXF9DM	RU	https://www.oxb.com/pipeline

DMTH75R	DI	DMTH75R
DMTH75R	DN	OXY-111A
DMTH75R	MI	TTQO71U
DMTH75R	MN	Hemoglobin (HB)
DMTH75R	MT	DTT
DMTH75R	MA	Enhancer
DMTH75R	RN	Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71.
DMTH75R	RU	https://pubmed.ncbi.nlm.nih.gov/9753039

DM6V5OB	DI	DM6V5OB
DM6V5OB	DN	P-552-02
DM6V5OB	MI	TTRK8B9
DM6V5OB	MN	Sodium channel unspecific (NaC)
DM6V5OB	MT	DTT
DM6V5OB	MA	Blocker
DM6V5OB	RN	US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion.
DM6V5OB	RU	https://www.google.com/patents/US20140221286

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTEUNMR
DMLSYJQ	MN	PI3-kinase alpha (PIK3CA)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTTHBCA
DMLSYJQ	MN	PI3-kinase beta (PIK3CB)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTGBPJE
DMLSYJQ	MN	PI3-kinase delta (PIK3CD)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Inhibitor
DMLSYJQ	RN	The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81.
DMLSYJQ	RU	https://pubmed.ncbi.nlm.nih.gov/21558396

DMLSYJQ	DI	DMLSYJQ
DMLSYJQ	DN	PA-799
DMLSYJQ	MI	TTHBTOP
DMLSYJQ	MN	PI3-kinase gamma (PIK3CG)
DMLSYJQ	MT	DTT
DMLSYJQ	MA	Modulator
DMLSYJQ	RN	Company report (Chugai-pharm)
DMLSYJQ	RU	http://www.chugai-pharm.co.jp/html/meeting/pdf/140424ePresentation.pdf

DMZKFJO	DI	DMZKFJO
DMZKFJO	DN	PAT-SC1
DMZKFJO	MI	TT5Z9WY
DMZKFJO	MN	Complement decay-accelerating factor (CD55)
DMZKFJO	MT	DTT
DMZKFJO	RN	Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep. 2014 Mar;31(3):1059-66.
DMZKFJO	RU	https://pubmed.ncbi.nlm.nih.gov/24452482

DMJC2RU	DI	DMJC2RU
DMJC2RU	DN	PBCAR0191
DMJC2RU	MI	TTW640A
DMJC2RU	MN	B-lymphocyte surface antigen B4 (CD19)
DMJC2RU	MT	DTT
DMJC2RU	MA	CAR-T-Cell-Therapy
DMJC2RU	RN	ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
DMJC2RU	RU	https://clinicaltrials.gov/ct2/show/NCT03666000

DM7NKWQ	DI	DM7NKWQ
DM7NKWQ	DN	PBCAR20A
DM7NKWQ	MI	TTUE541
DM7NKWQ	MN	Leukocyte surface antigen Leu-16 (CD20)
DM7NKWQ	MT	DTT
DM7NKWQ	RN	Clinical pipeline report, company report or official report of Precision Biosciences.
DM7NKWQ	RU	https://precisionbiosciences.com/pipeline/

DMSGM2L	DI	DMSGM2L
DMSGM2L	DN	PBCAR269A
DMSGM2L	MI	TTZ3P4W
DMSGM2L	MN	B-cell maturation protein (TNFRSF17)
DMSGM2L	MT	DTT
DMSGM2L	RN	Clinical pipeline report, company report or official report of Precision Biosciences.
DMSGM2L	RU	https://precisionbiosciences.com/pipeline/

DMGFPQ0	DI	DMGFPQ0
DMGFPQ0	DN	PBF509
DMGFPQ0	MI	TTM2AOE
DMGFPQ0	MN	Adenosine A2a receptor (ADORA2A)
DMGFPQ0	MT	DTT
DMGFPQ0	MA	Antagonist
DMGFPQ0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGFPQ0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSJ54W	DI	DMSJ54W
DMSJ54W	DN	PC14586
DMSJ54W	MI	TTJC50M
DMSJ54W	MN	P53 Y220C mutant (TP53 Y220C)
DMSJ54W	MT	DTT
DMSJ54W	MA	Reactivator
DMSJ54W	RN	Clinical pipeline report, company report or official report of PMV Pharmaceuticals.
DMSJ54W	RU	https://www.pmvpharma.com/pipeline/

DM9DR13	DI	DM9DR13
DM9DR13	DN	PCAR-019
DM9DR13	MI	TTW640A
DM9DR13	MN	B-lymphocyte surface antigen B4 (CD19)
DM9DR13	MT	DTT
DM9DR13	MA	CAR-T-Cell-Therapy
DM9DR13	RN	ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
DM9DR13	RU	https://clinicaltrials.gov/ct2/show/NCT02819583

DM1D6BT	DI	DM1D6BT
DM1D6BT	DN	PEGylated hyaluronidase (human recombinant)
DM1D6BT	MI	TTXFI1K
DM1D6BT	MN	Hyaluronidase (HYAL)
DM1D6BT	MT	DTT
DM1D6BT	MA	Modulator
DM1D6BT	RN	Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296.
DM1D6BT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/

DMMAUOK	DI	DMMAUOK
DMMAUOK	DN	PEN-221
DMMAUOK	MI	TTZ6T9E
DMMAUOK	MN	Somatostatin receptor type 2 (SSTR2)
DMMAUOK	MT	DTT
DMMAUOK	MA	Modulator
DMMAUOK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMAUOK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMLPTOF	DI	DMLPTOF
DMLPTOF	DN	PEN-866
DMLPTOF	MI	TTGTQHC
DMLPTOF	MN	DNA topoisomerase I (TOP1)
DMLPTOF	MT	DTT
DMLPTOF	MA	Inhibitor
DMLPTOF	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLPTOF	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM9L1R	DI	DMM9L1R
DMM9L1R	DN	PEP-223/CoVaccine HT
DMM9L1R	MI	TT8R70G
DMM9L1R	MN	Gonadotropin-releasing hormone receptor (GNRHR)
DMM9L1R	MT	DTT
DMM9L1R	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256).
DMM9L1R	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256

DM03GDJ	DI	DM03GDJ
DM03GDJ	DN	Pepinemab
DM03GDJ	MI	TT5UT28
DM03GDJ	MN	Semaphorin-4D (SEMA4D)
DM03GDJ	MT	DTT
DM03GDJ	MA	Inhibitor
DM03GDJ	RN	Clinical pipeline report, company report or official report of Vaccinex.
DM03GDJ	RU	https://vaccinex.com/pipeline/pepinemab-immuno-oncology/

DMBUJVX	DI	DMBUJVX
DMBUJVX	DN	Phenoxodiol
DMBUJVX	MI	TTOHFIY
DMBUJVX	MN	Sphingosine kinase 1 (SPHK1)
DMBUJVX	MT	DTT
DMBUJVX	MA	Modulator
DMBUJVX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBUJVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMBUJVX	DI	DMBUJVX
DMBUJVX	DN	Phenoxodiol
DMBUJVX	MI	TTR7B60
DMBUJVX	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMBUJVX	MT	DTT
DMBUJVX	MA	Modulator
DMBUJVX	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMBUJVX	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYEAB1	DI	DMYEAB1
DMYEAB1	DN	PIPERINE
DMYEAB1	MI	TT3WG5C
DMYEAB1	MN	Monoamine oxidase type A (MAO-A)
DMYEAB1	MT	DTT
DMYEAB1	MA	Inhibitor
DMYEAB1	RN	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
DMYEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/19969454

DMYEAB1	DI	DMYEAB1
DMYEAB1	DN	PIPERINE
DMYEAB1	MI	TTGP7BY
DMYEAB1	MN	Monoamine oxidase type B (MAO-B)
DMYEAB1	MT	DTT
DMYEAB1	MA	Inhibitor
DMYEAB1	RN	Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
DMYEAB1	RU	https://pubmed.ncbi.nlm.nih.gov/19969454

DMX168L	DI	DMX168L
DMX168L	DN	PLX2853
DMX168L	MI	TTRA6BO
DMX168L	MN	Bromodomain-containing protein 4 (BRD4)
DMX168L	MT	DTT
DMX168L	MA	Inhibitor
DMX168L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX168L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5DZEL	DI	DM5DZEL
DM5DZEL	DN	PLX9486
DM5DZEL	MI	TTX41N9
DM5DZEL	MN	Tyrosine-protein kinase Kit (KIT)
DM5DZEL	MT	DTT
DM5DZEL	MA	Inhibitor
DM5DZEL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5DZEL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQOW0H	DI	DMQOW0H
DMQOW0H	DN	PP-1420
DMQOW0H	MI	TTIB95A
DMQOW0H	MN	Pancreatic hormone (PH)
DMQOW0H	MT	DTT
DMQOW0H	MA	Modulator
DMQOW0H	RN	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9.
DMQOW0H	RU	https://pubmed.ncbi.nlm.nih.gov/21834938

DM0HTEF	DI	DM0HTEF
DM0HTEF	DN	PRI-724
DM0HTEF	MI	TTFRCTK
DM0HTEF	MN	CREB-binding protein (CREBBP)
DM0HTEF	MT	DTT
DM0HTEF	MA	Modulator
DM0HTEF	RN	Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14.
DM0HTEF	RU	https://pubmed.ncbi.nlm.nih.gov/20660310

DM8J5H1	DI	DM8J5H1
DM8J5H1	DN	PRLX93936
DM8J5H1	MI	TTT48SQ
DM8J5H1	MN	Voltage-dependent anion-selective channel 3 (VDAC3)
DM8J5H1	MT	DTT
DM8J5H1	MA	Modulator
DM8J5H1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8J5H1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTN451K
DMJ42E6	MN	Aromatic-L-amino-acid decarboxylase (DDC)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTLSWP6
DMJ42E6	MN	GTP cyclohydrolase-I (GCH1)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMJ42E6	DI	DMJ42E6
DMJ42E6	DN	ProSavin
DMJ42E6	MI	TTUHP71
DMJ42E6	MN	Tyrosine 3-monooxygenase (TH)
DMJ42E6	MT	DTT
DMJ42E6	MA	Modulator
DMJ42E6	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMJ42E6	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/

DMOUW65	DI	DMOUW65
DMOUW65	DN	PRX-102
DMOUW65	MI	TTIS03D
DMOUW65	MN	Alpha-galactosidase A (GLA)
DMOUW65	MT	DTT
DMOUW65	MA	Modulator
DMOUW65	RN	Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.
DMOUW65	RU	https://pubmed.ncbi.nlm.nih.gov/25155442

DM2CDLS	DI	DM2CDLS
DM2CDLS	DN	QLT-091568
DM2CDLS	MI	TTMXGCW
DM2CDLS	MN	Adrenergic receptor beta-3 (ADRB3)
DM2CDLS	MT	DTT
DM2CDLS	MA	Antagonist
DM2CDLS	RN	Clinical pipeline report, company report or official report of QLT Inc.
DM2CDLS	RU	http://www.qltinc.com/newsCenter/2009/091230.htm

DMZD7OA	DI	DMZD7OA
DMZD7OA	DN	Quaratusugene ozeplasmid
DMZD7OA	MI	TTJ8O14
DMZD7OA	MN	Tumor suppressor candidate 2 (TUSC2)
DMZD7OA	MT	DTT
DMZD7OA	RN	Clinical pipeline report, company report or official report of Genprex.
DMZD7OA	RU	https://www.genprex.com/technology/reqorsa/

DM614BA	DI	DM614BA
DM614BA	DN	Re-188-P-2045
DM614BA	MI	TTZ6T9E
DM614BA	MN	Somatostatin receptor type 2 (SSTR2)
DM614BA	MT	DTT
DM614BA	MA	Modulator
DM614BA	RN	The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5.
DM614BA	RU	https://pubmed.ncbi.nlm.nih.gov/25359879

DMY3TAD	DI	DMY3TAD
DMY3TAD	DN	Recombinant factor VIIa PEGylated liposomal
DMY3TAD	MI	TTF0EGX
DMY3TAD	MN	Coagulation factor VII (F7)
DMY3TAD	MT	DTT
DMY3TAD	MA	Modulator
DMY3TAD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DMY3TAD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM7LOSK	DI	DM7LOSK
DM7LOSK	DN	REGN4018
DM7LOSK	MI	TTC1PS3
DM7LOSK	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM7LOSK	MT	DTT
DM7LOSK	MA	Inhibitor
DM7LOSK	RN	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
DM7LOSK	RU	https://pubmed.ncbi.nlm.nih.gov/31217340

DM7LOSK	DI	DM7LOSK
DM7LOSK	DN	REGN4018
DM7LOSK	MI	TTUN7MC
DM7LOSK	MN	T-cell surface glycoprotein CD3 (CD3)
DM7LOSK	MT	DTT
DM7LOSK	MA	Inhibitor
DM7LOSK	RN	A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
DM7LOSK	RU	https://pubmed.ncbi.nlm.nih.gov/31217340

DMAGX0Q	DI	DMAGX0Q
DMAGX0Q	DN	REGN5458
DMAGX0Q	MI	TTZ3P4W
DMAGX0Q	MN	B-cell maturation protein (TNFRSF17)
DMAGX0Q	MT	DTT
DMAGX0Q	MA	Inhibitor
DMAGX0Q	RN	A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
DMAGX0Q	RU	https://pubmed.ncbi.nlm.nih.gov/33651100

DMAGX0Q	DI	DMAGX0Q
DMAGX0Q	DN	REGN5458
DMAGX0Q	MI	TTUN7MC
DMAGX0Q	MN	T-cell surface glycoprotein CD3 (CD3)
DMAGX0Q	MT	DTT
DMAGX0Q	MA	Inhibitor
DMAGX0Q	RN	A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
DMAGX0Q	RU	https://pubmed.ncbi.nlm.nih.gov/33651100

DMRE0LU	DI	DMRE0LU
DMRE0LU	DN	REGN5459
DMRE0LU	MI	TTZ3P4W
DMRE0LU	MN	B-cell maturation protein (TNFRSF17)
DMRE0LU	MT	DTT
DMRE0LU	MA	Inhibitor
DMRE0LU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DMRE0LU	RU	https://www.regeneron.com/science/pipeline

DMRE0LU	DI	DMRE0LU
DMRE0LU	DN	REGN5459
DMRE0LU	MI	TTUN7MC
DMRE0LU	MN	T-cell surface glycoprotein CD3 (CD3)
DMRE0LU	MT	DTT
DMRE0LU	MA	Inhibitor
DMRE0LU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DMRE0LU	RU	https://www.regeneron.com/science/pipeline

DM0Y6WU	DI	DM0Y6WU
DM0Y6WU	DN	REGN5678
DM0Y6WU	MI	TT9G4N0
DM0Y6WU	MN	Glutamate carboxypeptidase II (GCPII)
DM0Y6WU	MT	DTT
DM0Y6WU	MA	Inhibitor
DM0Y6WU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM0Y6WU	RU	https://www.regeneron.com/science/pipeline

DM0Y6WU	DI	DM0Y6WU
DM0Y6WU	DN	REGN5678
DM0Y6WU	MI	TTQ13FT
DM0Y6WU	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DM0Y6WU	MT	DTT
DM0Y6WU	MA	Inhibitor
DM0Y6WU	RN	Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
DM0Y6WU	RU	https://www.regeneron.com/science/pipeline

DM5MFHO	DI	DM5MFHO
DM5MFHO	DN	REIC gene therapy
DM5MFHO	MI	TTY2ZV6
DM5MFHO	MN	Dickkopf-related protein 3 (DKK3)
DM5MFHO	MT	DTT
DM5MFHO	MA	Modulator
DM5MFHO	RN	Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. J Gastroenterol Hepatol. 2014 May;29(5):973-83.
DM5MFHO	RU	https://pubmed.ncbi.nlm.nih.gov/24372695

DMDO6J1	DI	DMDO6J1
DMDO6J1	DN	Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
DMDO6J1	MI	TTJTSX4
DMDO6J1	MN	Glypican-3 (GPC3)
DMDO6J1	MT	DTT
DMDO6J1	MA	CAR-T-Cell-Therapy
DMDO6J1	RN	ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
DMDO6J1	RU	https://clinicaltrials.gov/ct2/show/NCT03084380

DMAGE91	DI	DMAGE91
DMAGE91	DN	RG7800
DMAGE91	MI	TT8QL6X
DMAGE91	MN	Survival motor neuron protein (SMN1)
DMAGE91	MT	DTT
DMAGE91	MA	Modulator
DMAGE91	RN	Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy. Assay Drug Dev Technol. 2014 August 1; 12(6): 315-341.
DMAGE91	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142828/

DM5AIKR	DI	DM5AIKR
DM5AIKR	DN	RGX-104
DM5AIKR	MI	TTM1EQF
DM5AIKR	MN	Oxysterols receptor LXR (NR1H)
DM5AIKR	MT	DTT
DM5AIKR	MA	Agonist
DM5AIKR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5AIKR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMU3PD7	DI	DMU3PD7
DMU3PD7	DN	RGX-121
DMU3PD7	MI	TTNY2AP
DMU3PD7	MN	Iduronate 2-sulfatase (IDS)
DMU3PD7	MT	DTT
DMU3PD7	MA	Replacement
DMU3PD7	RN	Clinical pipeline report, company report or official report of REGENXBIO.
DMU3PD7	RU	https://www.regenxbio.com/rgx-121/

DMSDZ8U	DI	DMSDZ8U
DMSDZ8U	DN	Rintatolimod
DMSDZ8U	MI	TT1CN09
DMSDZ8U	MN	HUMAN toll-like receptor 3 (TLR3)
DMSDZ8U	MT	DTT
DMSDZ8U	MA	Agonist
DMSDZ8U	RN	Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70.
DMSDZ8U	RU	https://pubmed.ncbi.nlm.nih.gov/27045557

DM9FNC8	DI	DM9FNC8
DM9FNC8	DN	RP-3500
DM9FNC8	MI	TT8ZYBQ
DM9FNC8	MN	Serine/threonine-protein kinase ATR (FRP1)
DM9FNC8	MT	DTT
DM9FNC8	MA	Inhibitor
DM9FNC8	RN	Clinical pipeline report, company report or official report of Repare Therapeutics.
DM9FNC8	RU	https://www.reparerx.com/pipeline/

DMKVMWO	DI	DMKVMWO
DMKVMWO	DN	RP-L201
DMKVMWO	MI	TTIJWR7
DMKVMWO	MN	Integrin beta-2 (ITGB2)
DMKVMWO	MT	DTT
DMKVMWO	MA	Replacement
DMKVMWO	RN	Clinical pipeline report, company report or official report of Rocket Pharmaceuticals.
DMKVMWO	RU	https://rocketpharma.com/our-disease-focus/

DMXYHC7	DI	DMXYHC7
DMXYHC7	DN	RU-101
DMXYHC7	MI	TTFNGC9
DMXYHC7	MN	Serum albumin (ALB)
DMXYHC7	MT	DTT
DMXYHC7	MA	Modulator
DMXYHC7	RN	Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283.
DMXYHC7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920766/

DM1LO8K	DI	DM1LO8K
DM1LO8K	DN	RVX-208
DM1LO8K	MI	TTRA6BO
DM1LO8K	MN	Bromodomain-containing protein 4 (BRD4)
DM1LO8K	MT	DTT
DM1LO8K	MA	Modulator
DM1LO8K	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DM1LO8K	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DMCBQTF	DI	DMCBQTF
DMCBQTF	DN	S-3304
DMCBQTF	MI	TT1GHVO
DMCBQTF	MN	Matrix metalloproteinase (MMP)
DMCBQTF	MT	DTT
DMCBQTF	MA	Inhibitor
DMCBQTF	RN	Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
DMCBQTF	RU	https://pubmed.ncbi.nlm.nih.gov/15968885

DMVKQT8	DI	DMVKQT8
DMVKQT8	DN	SALACINOL
DMVKQT8	MI	TTXWASR
DMVKQT8	MN	Intestinal maltase-glucoamylase (MGAM)
DMVKQT8	MT	DTT
DMVKQT8	MA	Inhibitor
DMVKQT8	RN	Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
DMVKQT8	RU	https://pubmed.ncbi.nlm.nih.gov/20970346

DMVKQT8	DI	DMVKQT8
DMVKQT8	DN	SALACINOL
DMVKQT8	MI	TTLPC70
DMVKQT8	MN	Lysosomal alpha-glucosidase (GAA)
DMVKQT8	MT	DTT
DMVKQT8	MA	Inhibitor
DMVKQT8	RN	Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
DMVKQT8	RU	https://pubmed.ncbi.nlm.nih.gov/18547114

DMPXOGD	DI	DMPXOGD
DMPXOGD	DN	SAR-161271
DMPXOGD	MI	TTZOPHG
DMPXOGD	MN	Insulin (INS)
DMPXOGD	MT	DTT
DMPXOGD	MA	Modulator
DMPXOGD	RN	Clinical pipeline report, company report or official report of sanofi-aventis.
DMPXOGD	RU	http://en.sanofi.com/img/content/study/TDU10987_summary.pdf

DM6M8O4	DI	DM6M8O4
DM6M8O4	DN	SAR440234
DM6M8O4	MI	TTENHJ0
DM6M8O4	MN	Interleukin 3 receptor alpha (IL3RA)
DM6M8O4	MT	DTT
DM6M8O4	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM6M8O4	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM6M8O4	DI	DM6M8O4
DM6M8O4	DN	SAR440234
DM6M8O4	MI	TTUN7MC
DM6M8O4	MN	T-cell surface glycoprotein CD3 (CD3)
DM6M8O4	MT	DTT
DM6M8O4	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DM6M8O4	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMD20YH	DI	DMD20YH
DMD20YH	DN	SAR-650984
DMD20YH	MI	TTPURFN
DMD20YH	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMD20YH	MT	DTT
DMD20YH	RN	Clinical pipeline report, company report or official report of Sanofi-Aventis.
DMD20YH	RU	https://www.sanofioncology.com/m/pipeline/SAR650984.aspx

DMA8Z4N	DI	DMA8Z4N
DMA8Z4N	DN	SB-318
DMA8Z4N	MI	TT0IUKX
DMA8Z4N	MN	Alpha-L-iduronidase (IDUA)
DMA8Z4N	MT	DTT
DMA8Z4N	MA	Replacement
DMA8Z4N	RN	ClinicalTrials.gov (NCT02702115) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I. U.S. National Institutes of Health.
DMA8Z4N	RU	https://clinicaltrials.gov/ct2/show/NCT02702115

DM98YFK	DI	DM98YFK
DM98YFK	DN	SB-913
DM98YFK	MI	TTNY2AP
DM98YFK	MN	Iduronate 2-sulfatase (IDS)
DM98YFK	MT	DTT
DM98YFK	MA	Replacement
DM98YFK	RN	ClinicalTrials.gov (NCT03041324) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II. U.S. National Institutes of Health.
DM98YFK	RU	https://clinicaltrials.gov/ct2/show/NCT03041324

DMUP52Y	DI	DMUP52Y
DMUP52Y	DN	SB-FIX
DMUP52Y	MI	TTFEZ5Q
DMUP52Y	MN	Coagulation factor IX (F9)
DMUP52Y	MT	DTT
DMUP52Y	MA	Replacement
DMUP52Y	RN	ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health.
DMUP52Y	RU	https://clinicaltrials.gov/ct2/show/NCT02695160

DMS1NMO	DI	DMS1NMO
DMS1NMO	DN	SCRI-huCAR19v1
DMS1NMO	MI	TTW640A
DMS1NMO	MN	B-lymphocyte surface antigen B4 (CD19)
DMS1NMO	MT	DTT
DMS1NMO	MA	CAR-T-Cell-Therapy
DMS1NMO	RN	ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
DMS1NMO	RU	https://clinicaltrials.gov/ct2/show/NCT03684889

DMBFUOI	DI	DMBFUOI
DMBFUOI	DN	SECTA belomycin
DMBFUOI	MI	TTUTN1I
DMBFUOI	MN	Human Deoxyribonucleic acid (hDNA)
DMBFUOI	MT	DTT
DMBFUOI	MA	Binder
DMBFUOI	RN	Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13.
DMBFUOI	RU	https://pubmed.ncbi.nlm.nih.gov/14624648

DMD37Q5	DI	DMD37Q5
DMD37Q5	DN	SEL24
DMD37Q5	MI	TTGJCWZ
DMD37Q5	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMD37Q5	MT	DTT
DMD37Q5	MA	Inhibitor
DMD37Q5	RN	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
DMD37Q5	RU	https://pubmed.ncbi.nlm.nih.gov/29682194

DMD37Q5	DI	DMD37Q5
DMD37Q5	DN	SEL24
DMD37Q5	MI	TTA7WGU
DMD37Q5	MN	Serine/threonine-protein kinase pim (PIM)
DMD37Q5	MT	DTT
DMD37Q5	MA	Inhibitor
DMD37Q5	RN	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931.
DMD37Q5	RU	https://pubmed.ncbi.nlm.nih.gov/29682194

DMH064K	DI	DMH064K
DMH064K	DN	SEL-24
DMH064K	MI	TTGJCWZ
DMH064K	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMH064K	MT	DTT
DMH064K	MA	Inhibitor
DMH064K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMH064K	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH064K	DI	DMH064K
DMH064K	DN	SEL-24
DMH064K	MI	TTTN5QW
DMH064K	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DMH064K	MT	DTT
DMH064K	MA	Inhibitor
DMH064K	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158).
DMH064K	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158

DM4NK3J	DI	DM4NK3J
DM4NK3J	DN	SF0166
DM4NK3J	MI	TT69TQN
DM4NK3J	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DM4NK3J	MT	DTT
DM4NK3J	MA	Antagonist
DM4NK3J	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4NK3J	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMRC7PI	DI	DMRC7PI
DMRC7PI	DN	SGN-CD33A
DMRC7PI	MI	TTJVYO3
DMRC7PI	MN	Myeloid cell surface antigen CD33 (CD33)
DMRC7PI	MT	DTT
DMRC7PI	RN	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
DMRC7PI	RU	https://pubmed.ncbi.nlm.nih.gov/23770776

DMADNY3	DI	DMADNY3
DMADNY3	DN	SHR-1314
DMADNY3	MI	TTG0MT6
DMADNY3	MN	Interleukin-17 (IL17)
DMADNY3	MT	DTT
DMADNY3	MA	Inhibitor
DMADNY3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMADNY3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMUCH0	DI	DMMUCH0
DMMUCH0	DN	SHR2554
DMMUCH0	MI	TT9MZCQ
DMMUCH0	MN	Enhancer of zeste homolog 2 (EZH2)
DMMUCH0	MT	DTT
DMMUCH0	MA	Inhibitor
DMMUCH0	RN	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
DMMUCH0	RU	https://pubmed.ncbi.nlm.nih.gov/33469207

DMZTQD8	DI	DMZTQD8
DMZTQD8	DN	Sirna-027
DMZTQD8	MI	TT1VAUK
DMZTQD8	MN	VEGFR1 messenger RNA (VEGFR1 mRNA)
DMZTQD8	MT	DTT
DMZTQD8	RN	2011 Pipeline of Sirna Therapeutics.
DMZTQD8	RU	http://www.sirna.com/

DMSOX57	DI	DMSOX57
DMSOX57	DN	SJCAR19
DMSOX57	MI	TTW640A
DMSOX57	MN	B-lymphocyte surface antigen B4 (CD19)
DMSOX57	MT	DTT
DMSOX57	MA	CAR-T-Cell-Therapy
DMSOX57	RN	ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
DMSOX57	RU	https://clinicaltrials.gov/ct2/show/NCT03573700

DMSTEFK	DI	DMSTEFK
DMSTEFK	DN	SKB264
DMSTEFK	MI	TTP2HE5
DMSTEFK	MN	Tumor associated calcium signal transducer 2 (TACSTD2)
DMSTEFK	MT	DTT
DMSTEFK	RN	ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
DMSTEFK	RU	https://clinicaltrials.gov/ct2/show/NCT04152499

DMOCHVE	DI	DMOCHVE
DMOCHVE	DN	SL-401
DMOCHVE	MI	TTPYS82
DMOCHVE	MN	Interleukin 3 receptor (CSF2RB)
DMOCHVE	MT	DTT
DMOCHVE	MA	Inhibitor
DMOCHVE	RN	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92.
DMOCHVE	RU	https://pubmed.ncbi.nlm.nih.gov/24859366

DMEJT5Z	DI	DMEJT5Z
DMEJT5Z	DN	SN-32793
DMEJT5Z	MI	TTGKNB4
DMEJT5Z	MN	Epidermal growth factor receptor (EGFR)
DMEJT5Z	MT	DTT
DMEJT5Z	MA	Inhibitor
DMEJT5Z	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMEJT5Z	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMCGX9Y	DI	DMCGX9Y
DMCGX9Y	DN	SNDX-5613
DMCGX9Y	MI	TT0CZBQ
DMCGX9Y	MN	Menin-MLL1 interaction (MEN1-KMT2A PPI)
DMCGX9Y	MT	DTT
DMCGX9Y	MA	Inhibitor
DMCGX9Y	RN	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
DMCGX9Y	RU	https://syndax.com/pipeline/sndx-5613/

DMNV8SY	DI	DMNV8SY
DMNV8SY	DN	SNN-0029
DMNV8SY	MI	TTOHSBA
DMNV8SY	MN	Vascular endothelial growth factor A (VEGFA)
DMNV8SY	MT	DTT
DMNV8SY	MA	Modulator
DMNV8SY	RN	Clinical pipeline report, company report or official report of Neuronova.
DMNV8SY	RU	http://www.neuronova.com/index.php?option=com_content&task=view&id=40&Itemid=71

DM2X3BR	DI	DM2X3BR
DM2X3BR	DN	SNN-0031
DM2X3BR	MI	TTI7421
DM2X3BR	MN	Platelet-derived growth factor receptor beta (PDGFRB)
DM2X3BR	MT	DTT
DM2X3BR	MA	Modulator
DM2X3BR	RN	Company report (Neuronova)
DM2X3BR	RU	http://www.neuronova.com/index.php?option=com_content&task=view&id=41

DMIU0VP	DI	DMIU0VP
DMIU0VP	DN	SNX-5422
DMIU0VP	MI	TT78R5H
DMIU0VP	MN	Heat shock protein 90 alpha (HSP90A)
DMIU0VP	MT	DTT
DMIU0VP	MA	Inhibitor
DMIU0VP	RN	SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.
DMIU0VP	RU	https://pubmed.ncbi.nlm.nih.gov/18948577

DMIU0VP	DI	DMIU0VP
DMIU0VP	DN	SNX-5422
DMIU0VP	MI	TTH5YN2
DMIU0VP	MN	Heat shock protein 90 beta (HSP90B)
DMIU0VP	MT	DTT
DMIU0VP	MA	Inhibitor
DMIU0VP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIU0VP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXNTR7	DI	DMXNTR7
DMXNTR7	DN	SOBI003
DMXNTR7	MI	TTPJ2SH
DMXNTR7	MN	N-sulphoglucosamine sulphohydrolase (SGSH)
DMXNTR7	MT	DTT
DMXNTR7	MA	Replacement
DMXNTR7	RN	Clinical pipeline report, company report or official report of Swedish Orphan Biovitrum.
DMXNTR7	RU	https://www.sobi.com/en/press-releases/fda-accepts-investigational-new-drug-application-and-grants-fast-track-status

DMST6A3	DI	DMST6A3
DMST6A3	DN	Sodium pyruvate
DMST6A3	MI	TTZHA0O
DMST6A3	MN	Carbonic anhydrase IV (CA-IV)
DMST6A3	MT	DTT
DMST6A3	MA	Inhibitor
DMST6A3	RN	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
DMST6A3	RU	https://pubmed.ncbi.nlm.nih.gov/15664815

DMST6A3	DI	DMST6A3
DMST6A3	DN	Sodium pyruvate
DMST6A3	MI	TTULV0X
DMST6A3	MN	Reactive oxygen species (ROS)
DMST6A3	MT	DTT
DMST6A3	MA	Antagonist
DMST6A3	RN	A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35.
DMST6A3	RU	https://pubmed.ncbi.nlm.nih.gov/16766717

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT7JELC
DM3GO0J	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12475240

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT9NXMV
DM3GO0J	MN	ATP-binding cassette sub-family A member 8 (ABCA8)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTJ0EW4
DM3GO0J	MN	Bile salt export pump (ABCB11)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther. 2005 Aug;314(2):876-82.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/15901796

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	TTSDVTR
DM3GO0J	MN	G-protein coupled bile acid receptor 1 (GPBAR1)
DM3GO0J	MT	DTT
DM3GO0J	MA	Modulator
DM3GO0J	RN	Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157.
DM3GO0J	RU	http://www.sciencedirect.com/science/article/pii/S2211383514001300

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTFI42L
DM3GO0J	MN	Multidrug resistance-associated protein 2 (ABCC2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12379217

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTQ3ZHF
DM3GO0J	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/12924948

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTE2B1D
DM3GO0J	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/7557095

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT3D8F0
DM3GO0J	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/29538325

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT9C1TS
DM3GO0J	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/11375950

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DTPFTEQ
DM3GO0J	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT1V9AJ
DM3GO0J	MN	Organic solute transporter subunit beta (SLC51B)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology. 2005 Dec;42(6):1270-9.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/16317684

DM3GO0J	DI	DM3GO0J
DM3GO0J	DN	Sodium taurocholate
DM3GO0J	MI	DT56EKP
DM3GO0J	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM3GO0J	MT	DTP
DM3GO0J	MA	Substrate
DM3GO0J	RN	Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
DM3GO0J	RU	http://www.ncbi.nlm.nih.gov/pubmed/17374746

DMEVGI9	DI	DMEVGI9
DMEVGI9	DN	SPK-7001
DMEVGI9	MI	TTOA18V
DMEVGI9	MN	Rab proteins geranylgeranyltransferase component A 1 (CHM)
DMEVGI9	MT	DTT
DMEVGI9	MA	Replacement
DMEVGI9	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DMEVGI9	RU	https://sparktx.com/scientific-platform-programs/

DM8K7CN	DI	DM8K7CN
DM8K7CN	DN	SPK-8011
DM8K7CN	MI	TT1290U
DM8K7CN	MN	Coagulation factor VIII (F8)
DM8K7CN	MT	DTT
DM8K7CN	MA	Replacement
DM8K7CN	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DM8K7CN	RU	https://sparktx.com/scientific-platform-programs/

DMCP8F3	DI	DMCP8F3
DMCP8F3	DN	SPK-8016
DMCP8F3	MI	TT1290U
DMCP8F3	MN	Coagulation factor VIII (F8)
DMCP8F3	MT	DTT
DMCP8F3	MA	Replacement
DMCP8F3	RN	Clinical pipeline report, company report or official report of Spark Therapeutics.
DMCP8F3	RU	https://sparktx.com/scientific-platform-programs/

DMJDV0K	DI	DMJDV0K
DMJDV0K	DN	SPR720
DMJDV0K	MI	TTS7LWX
DMJDV0K	MN	Bacterial DNA gyrase B (Bact gyrB)
DMJDV0K	MT	DTT
DMJDV0K	MA	Inhibitor
DMJDV0K	RN	Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.
DMJDV0K	RU	https://pubmed.ncbi.nlm.nih.gov/32183511

DMG8JLC	DI	DMG8JLC
DMG8JLC	DN	SRP-9003
DMG8JLC	MI	TTEDCQ0
DMG8JLC	MN	Beta-sarcoglycan (SGCB)
DMG8JLC	MT	DTT
DMG8JLC	MA	Replacement
DMG8JLC	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMG8JLC	RU	https://www.sarepta.com/products-pipeline/pipeline

DMK095Z	DI	DMK095Z
DMK095Z	DN	SRP-9004
DMK095Z	MI	TTS9Q5V
DMK095Z	MN	Sarcoglycan alpha (SGCA)
DMK095Z	MT	DTT
DMK095Z	MA	Replacement
DMK095Z	RN	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
DMK095Z	RU	https://www.sarepta.com/products-pipeline/pipeline

DMBCIXL	DI	DMBCIXL
DMBCIXL	DN	Stamulumab
DMBCIXL	MI	TTSWPH8
DMBCIXL	MN	Growth/differentiation factor 8 (GDF-8)
DMBCIXL	MT	DTT
DMBCIXL	RN	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
DMBCIXL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/

DMX3CNS	DI	DMX3CNS
DMX3CNS	DN	Stargen
DMX3CNS	MI	TTLB52K
DMX3CNS	MN	ATP-binding cassette transporter A4 (ABCA4)
DMX3CNS	MT	DTT
DMX3CNS	MA	Modulator
DMX3CNS	RN	Clinical pipeline report, company report or official report of Oxford BioMedica.
DMX3CNS	RU	http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-positive-dsmb-review-of-ongoing-retinostat-r-and-stargen-clinical-studies/

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TTGKNB4
DMZM6I2	MN	Epidermal growth factor receptor (EGFR)
DMZM6I2	MT	DTT
DMZM6I2	MA	Antagonist
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TT6EO5L
DMZM6I2	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZM6I2	MT	DTT
DMZM6I2	MA	Inhibitor
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZM6I2	DI	DMZM6I2
DMZM6I2	DN	Sym013
DMZM6I2	MI	TTDC8N2
DMZM6I2	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMZM6I2	MT	DTT
DMZM6I2	MA	Inhibitor
DMZM6I2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM6I2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9B7Z5	DI	DM9B7Z5
DM9B7Z5	DN	Sym015
DM9B7Z5	MI	TTGKNB4
DM9B7Z5	MN	Epidermal growth factor receptor (EGFR)
DM9B7Z5	MT	DTT
DM9B7Z5	MA	Antagonist
DM9B7Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9B7Z5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM9B7Z5	DI	DM9B7Z5
DM9B7Z5	DN	Sym015
DM9B7Z5	MI	TTNDSF4
DM9B7Z5	MN	Proto-oncogene c-Met (MET)
DM9B7Z5	MT	DTT
DM9B7Z5	MA	Inhibitor
DM9B7Z5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9B7Z5	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMB2NP8	DI	DMB2NP8
DMB2NP8	DN	T-1249
DMB2NP8	MI	TTG90S6
DMB2NP8	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMB2NP8	MT	DTT
DMB2NP8	MA	Inhibitor
DMB2NP8	RN	HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
DMB2NP8	RU	https://pubmed.ncbi.nlm.nih.gov/12324253

DMWIH59	DI	DMWIH59
DMWIH59	DN	T2c-003
DMWIH59	MI	TTFBNVI
DMWIH59	MN	Aldose reductase (AKR1B1)
DMWIH59	MT	DTT
DMWIH59	MA	Modulator
DMWIH59	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
DMWIH59	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768

DM1FY97	DI	DM1FY97
DM1FY97	DN	T3D-959
DM1FY97	MI	TT2JWF6
DM1FY97	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DM1FY97	MT	DTT
DM1FY97	MA	Modulator
DM1FY97	RN	Phrma report (2013 Alzheimers disease)
DM1FY97	RU	http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf

DM1FY97	DI	DM1FY97
DM1FY97	DN	T3D-959
DM1FY97	MI	TTZMAO3
DM1FY97	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM1FY97	MT	DTT
DM1FY97	MA	Modulator
DM1FY97	RN	Phrma report (2013 Alzheimers disease)
DM1FY97	RU	http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf

DMCFSZ5	DI	DMCFSZ5
DMCFSZ5	DN	TAI-GPC3-CART cells
DMCFSZ5	MI	TTJTSX4
DMCFSZ5	MN	Glypican-3 (GPC3)
DMCFSZ5	MT	DTT
DMCFSZ5	MA	CAR-T-Cell-Therapy
DMCFSZ5	RN	ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
DMCFSZ5	RU	https://clinicaltrials.gov/ct2/show/NCT02715362

DMJSQXT	DI	DMJSQXT
DMJSQXT	DN	TAK-007
DMJSQXT	MI	TTW640A
DMJSQXT	MN	B-lymphocyte surface antigen B4 (CD19)
DMJSQXT	MT	DTT
DMJSQXT	RN	Clinical pipeline report, company report or official report of Takeda.
DMJSQXT	RU	https://www.takeda.com/newsroom/newsreleases/2020/takeda-opens-new-rd-cell-therapy-manufacturing-facility-to--support-expansion-of-next-generation-clinical-programs/

DM1AB4L	DI	DM1AB4L
DM1AB4L	DN	Talotrexin
DM1AB4L	MI	TTVC37M
DM1AB4L	MN	Folate receptor alpha (FOLR1)
DM1AB4L	MT	DTT
DM1AB4L	MA	Antagonist
DM1AB4L	RN	Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301.
DM1AB4L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033035/

DM13AH8	DI	DM13AH8
DM13AH8	DN	TAS-0728
DM13AH8	MI	TT6EO5L
DM13AH8	MN	Erbb2 tyrosine kinase receptor (HER2)
DM13AH8	MT	DTT
DM13AH8	MA	Inhibitor
DM13AH8	RN	TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742.
DM13AH8	RU	https://pubmed.ncbi.nlm.nih.gov/30787176

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT7JELC
DM2LZ8F	MN	Apical sodium-dependent bile acid transporter (SLC10A2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12475240

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTJ0EW4
DM2LZ8F	MN	Bile salt export pump (ABCB11)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. Biochem Pharmacol. 2002 Jul 1;64(1):151-8.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12106615

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	TTTRNQW
DM2LZ8F	MN	Bile-salt-activated lipase (CEL)
DM2LZ8F	MT	DTT
DM2LZ8F	MA	Inhibitor
DM2LZ8F	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM2LZ8F	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTI7UX6
DM2LZ8F	MN	Breast cancer resistance protein (ABCG2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83.
DM2LZ8F	RU	https://doi.org/10.1124/mol.111.075143

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	TTPI1M5
DM2LZ8F	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DM2LZ8F	MT	DTT
DM2LZ8F	MA	Modulator
DM2LZ8F	RN	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69.
DM2LZ8F	RU	https://pubmed.ncbi.nlm.nih.gov/9458785

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTQ3ZHF
DM2LZ8F	MN	Multidrug resistance-associated protein 3 (ABCC3)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12924948

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTCSGPB
DM2LZ8F	MN	Multidrug resistance-associated protein 4 (ABCC4)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DM2LZ8F	RU	https://doi.org/10.1007/s11095-012-0935-x

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTE2B1D
DM2LZ8F	MN	Organic anion transporting polypeptide 1A2 (SLCO1A2)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2. Drug Metab Dispos. 2013 Mar;41(3):602-7.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/23255551

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT3D8F0
DM2LZ8F	MN	Organic anion transporting polypeptide 1B1 (SLCO1B1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/10358072

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT9C1TS
DM2LZ8F	MN	Organic anion transporting polypeptide 1B3 (SLCO1B3)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/18321482

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTPFTEQ
DM2LZ8F	MN	Organic anion transporting polypeptide 2B1 (SLCO2B1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/14610227

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT8H2IC
DM2LZ8F	MN	Organic anion transporting polypeptide 4A1 (SLCO4A1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/11316767

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DTMEQ32
DM2LZ8F	MN	Organic solute transporter subunit alpha (SLC51A)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT1V9AJ
DM2LZ8F	MN	Organic solute transporter subunit beta (SLC51B)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/12719432

DM2LZ8F	DI	DM2LZ8F
DM2LZ8F	DN	Taurocholic acid
DM2LZ8F	MI	DT56EKP
DM2LZ8F	MN	Sodium/taurocholate cotransporting polypeptide (SLC10A1)
DM2LZ8F	MT	DTP
DM2LZ8F	MA	Substrate
DM2LZ8F	RN	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
DM2LZ8F	RU	http://www.ncbi.nlm.nih.gov/pubmed/10565843

DM5NICF	DI	DM5NICF
DM5NICF	DN	TBI-1501
DM5NICF	MI	TTW640A
DM5NICF	MN	B-lymphocyte surface antigen B4 (CD19)
DM5NICF	MT	DTT
DM5NICF	MA	CAR-T-Cell-Therapy
DM5NICF	RN	ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
DM5NICF	RU	https://clinicaltrials.gov/ct2/show/NCT03155191

DMR65X7	DI	DMR65X7
DMR65X7	DN	TC-110
DMR65X7	MI	TTW640A
DMR65X7	MN	B-lymphocyte surface antigen B4 (CD19)
DMR65X7	MT	DTT
DMR65X7	RN	Clinical pipeline report, company report or official report of TCR2 Therapeutics.
DMR65X7	RU	https://www.tcr2.com/hematological-malignancies#tc110

DM9S5I1	DI	DM9S5I1
DM9S5I1	DN	TC-210
DM9S5I1	MI	TT4RXME
DM9S5I1	MN	Mesothelin (MSLN)
DM9S5I1	MT	DTT
DM9S5I1	RN	Clinical pipeline report, company report or official report of TCR2 Therapeutics.
DM9S5I1	RU	https://www.tcr2.com/solid-tumors#tc210

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TTMBO1Z
DMZFIGQ	MN	Cyclin-dependent kinase (CDK)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Inhibitor
DMZFIGQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFIGQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TT7HF4W
DMZFIGQ	MN	Cyclin-dependent kinase 2 (CDK2)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Modulator
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://pubmed.ncbi.nlm.nih.gov/22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	DEJGDUW
DMZFIGQ	MN	Cytochrome P450 1A2 (CYP1A2)
DMZFIGQ	MT	DME
DMZFIGQ	MA	Metabolism
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	DE4LYSA
DMZFIGQ	MN	Cytochrome P450 3A4 (CYP3A4)
DMZFIGQ	MT	DME
DMZFIGQ	MA	Metabolism
DMZFIGQ	RN	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
DMZFIGQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22372550

DMZFIGQ	DI	DMZFIGQ
DMZFIGQ	DN	TG02
DMZFIGQ	MI	TTU8W4S
DMZFIGQ	MN	Protein kinase (PK)
DMZFIGQ	MT	DTT
DMZFIGQ	MA	Inhibitor
DMZFIGQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZFIGQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMON4IL	DI	DMON4IL
DMON4IL	DN	TG100-115
DMON4IL	MI	TTHBTOP
DMON4IL	MN	PI3-kinase gamma (PIK3CG)
DMON4IL	MT	DTT
DMON4IL	MA	Inhibitor
DMON4IL	RN	Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65.
DMON4IL	RU	https://pubmed.ncbi.nlm.nih.gov/19056934

DMNKLZM	DI	DMNKLZM
DMNKLZM	DN	TgAAG76
DMNKLZM	MI	TTBOH16
DMNKLZM	MN	Retinal pigment epithelium protein (RPE65)
DMNKLZM	MT	DTT
DMNKLZM	MA	Modulator
DMNKLZM	RN	tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7.
DMNKLZM	RU	https://pubmed.ncbi.nlm.nih.gov/20677098

DMDJLX7	DI	DMDJLX7
DMDJLX7	DN	Timcodar dimesilate
DMDJLX7	MI	TTFH2RS
DMDJLX7	MN	FK506-binding protein (FKBP)
DMDJLX7	MT	DTT
DMDJLX7	MA	Modulator
DMDJLX7	RN	Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076.
DMDJLX7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186452/

DM0VXIM	DI	DM0VXIM
DM0VXIM	DN	TJ003234
DM0VXIM	MI	TTPZGYX
DM0VXIM	MN	HUMAN colony-stimulating factor (GM-CSF)
DM0VXIM	MT	DTT
DM0VXIM	MA	Inhibitor
DM0VXIM	RN	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468.
DM0VXIM	RU	https://pubmed.ncbi.nlm.nih.gov/32317220

DMLROMP	DI	DMLROMP
DMLROMP	DN	TKM-PLK1
DMLROMP	MI	TTH4IP0
DMLROMP	MN	PLK1 messenger RNA (PLK1 mRNA)
DMLROMP	MT	DTT
DMLROMP	RN	Clinical pipeline report, company report or official report of Arbutus Biopharma.
DMLROMP	RU	http://arbutusbio.com/portfolio/tkm-plk1.php

DM6AXV9	DI	DM6AXV9
DM6AXV9	DN	TOL-101
DM6AXV9	MI	TT7AKW1
DM6AXV9	MN	T-cell receptor (TCR)
DM6AXV9	MT	DTT
DM6AXV9	RN	First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355.
DM6AXV9	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404309/

DMHTG8P	DI	DMHTG8P
DMHTG8P	DN	TP-0903
DMHTG8P	MI	TTZPY6J
DMHTG8P	MN	Tyrosine-protein kinase UFO (AXL)
DMHTG8P	MT	DTT
DMHTG8P	MA	Inhibitor
DMHTG8P	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHTG8P	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTPMQSO
DM9FB2T	MN	ALK tyrosine kinase receptor (ALK)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTSZ6Y3
DM9FB2T	MN	Proto-oncogene c-Ros (ROS1)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9FB2T	DI	DM9FB2T
DM9FB2T	DN	TPX-0005
DM9FB2T	MI	TTTDVOJ
DM9FB2T	MN	Tropomyosin-related kinase A (TrkA)
DM9FB2T	MT	DTT
DM9FB2T	MA	Inhibitor
DM9FB2T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9FB2T	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMIVE67	DI	DMIVE67
DMIVE67	DN	TPX-0046
DMIVE67	MI	TT4DXQT
DMIVE67	MN	Proto-oncogene c-Ret (RET)
DMIVE67	MT	DTT
DMIVE67	MA	Inhibitor
DMIVE67	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMIVE67	RU	https://tptherapeutics.com/pipeline/tpx-0046/

DMIVE67	DI	DMIVE67
DMIVE67	DN	TPX-0046
DMIVE67	MI	TT6PKBN
DMIVE67	MN	Proto-oncogene c-Src (SRC)
DMIVE67	MT	DTT
DMIVE67	MA	Inhibitor
DMIVE67	RN	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
DMIVE67	RU	https://tptherapeutics.com/pipeline/tpx-0046/

DM8D2LC	DI	DM8D2LC
DM8D2LC	DN	Tractinostat
DM8D2LC	MI	TTBH0VX
DM8D2LC	MN	Histone deacetylase (HDAC)
DM8D2LC	MT	DTT
DM8D2LC	MA	Inhibitor
DM8D2LC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8D2LC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1ZK4W	DI	DM1ZK4W
DM1ZK4W	DN	TRBC1
DM1ZK4W	MI	TT1DHW2
DM1ZK4W	MN	T-cell receptor beta constant 1 (TRBC1)
DM1ZK4W	MT	DTT
DM1ZK4W	MA	CAR-T-Cell-Therapy
DM1ZK4W	RN	ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
DM1ZK4W	RU	https://clinicaltrials.gov/ct2/show/NCT03590574

DMXI8CD	DI	DMXI8CD
DMXI8CD	DN	TRC-253
DMXI8CD	MI	TTKPW01
DMXI8CD	MN	Androgen receptor messenger RNA (AR mRNA)
DMXI8CD	MT	DTT
DMXI8CD	MA	Antagonist
DMXI8CD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXI8CD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DML54PD	DI	DML54PD
DML54PD	DN	TriCAR-T-CD19
DML54PD	MI	TTW640A
DML54PD	MN	B-lymphocyte surface antigen B4 (CD19)
DML54PD	MT	DTT
DML54PD	MA	CAR-T-Cell-Therapy
DML54PD	RN	ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
DML54PD	RU	https://clinicaltrials.gov/ct2/show/NCT03497533

DM8IC5H	DI	DM8IC5H
DM8IC5H	DN	Triciribine
DM8IC5H	MI	DE7T5VX
DM8IC5H	MN	Adenosine kinase (ADK)
DM8IC5H	MT	DME
DM8IC5H	MA	Metabolism
DM8IC5H	RN	Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res Hum Retroviruses. 1998 Oct 10;14(15):1315-22.
DM8IC5H	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=9788672

DM8IC5H	DI	DM8IC5H
DM8IC5H	DN	Triciribine
DM8IC5H	MI	TT84ETX
DM8IC5H	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM8IC5H	MT	DTT
DM8IC5H	MA	Inhibitor
DM8IC5H	RN	Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51.
DM8IC5H	RU	https://pubmed.ncbi.nlm.nih.gov/15916436

DMBN1XS	DI	DMBN1XS
DMBN1XS	DN	Triciribine prodrug
DMBN1XS	MI	TTWTSCV
DMBN1XS	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMBN1XS	MT	DTT
DMBN1XS	MA	Inhibitor
DMBN1XS	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
DMBN1XS	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479

DM9IQ4A	DI	DM9IQ4A
DM9IQ4A	DN	TRU-016
DM9IQ4A	MI	TTFCW29
DM9IQ4A	MN	Leukocyte antigen CD37 (CD37)
DM9IQ4A	MT	DTT
DM9IQ4A	MA	Modulator
DM9IQ4A	RN	TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90.
DM9IQ4A	RU	https://pubmed.ncbi.nlm.nih.gov/19943209

DMQS5DY	DI	DMQS5DY
DMQS5DY	DN	TRX-518
DMQS5DY	MI	TTG6LA7
DMQS5DY	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMQS5DY	MT	DTT
DMQS5DY	RN	Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5.
DMQS5DY	RU	https://pubmed.ncbi.nlm.nih.gov/26153987

DMFOR9Y	DI	DMFOR9Y
DMFOR9Y	DN	TSR-011
DMFOR9Y	MI	TTPMQSO
DMFOR9Y	MN	ALK tyrosine kinase receptor (ALK)
DMFOR9Y	MT	DTT
DMFOR9Y	MA	Inhibitor
DMFOR9Y	RN	Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.
DMFOR9Y	RU	https://pubmed.ncbi.nlm.nih.gov/23020724

DMH9RGV	DI	DMH9RGV
DMH9RGV	DN	TTP-814
DMH9RGV	MI	TTMS7KP
DMH9RGV	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMH9RGV	MT	DTT
DMH9RGV	MA	Inhibitor
DMH9RGV	RN	Protein tyrosine phosphatase 1B (PTP-1B; PTPN1). SciBX 5(7); doi:10.1038/scibx.2012.176. Feb. 16 2012
DMH9RGV	RU	http://www.nature.com/scibx/journal/v5/n7/full/scibx.2012.176.html

DMRJK26	DI	DMRJK26
DMRJK26	DN	UCART019
DMRJK26	MI	TTW640A
DMRJK26	MN	B-lymphocyte surface antigen B4 (CD19)
DMRJK26	MT	DTT
DMRJK26	MA	CAR-T-Cell-Therapy
DMRJK26	RN	ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
DMRJK26	RU	https://clinicaltrials.gov/ct2/show/NCT03166878

DMI0H3B	DI	DMI0H3B
DMI0H3B	DN	UshStat
DMI0H3B	MI	TTNIMDP
DMI0H3B	MN	Myosin-7 (MYH7)
DMI0H3B	MT	DTT
DMI0H3B	MA	Modulator
DMI0H3B	RN	EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One. 2014 Apr 4;9(4):e94272.
DMI0H3B	RU	https://pubmed.ncbi.nlm.nih.gov/24705452

DM6HPEC	DI	DM6HPEC
DM6HPEC	DN	USL311
DM6HPEC	MI	TTBID49
DM6HPEC	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM6HPEC	MT	DTT
DM6HPEC	MA	Antagonist
DM6HPEC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6HPEC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPWHU6	DI	DMPWHU6
DMPWHU6	DN	V81444
DMPWHU6	MI	TTM2AOE
DMPWHU6	MN	Adenosine A2a receptor (ADORA2A)
DMPWHU6	MT	DTT
DMPWHU6	MA	Antagonist
DMPWHU6	RN	Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74.
DMPWHU6	RU	https://pubmed.ncbi.nlm.nih.gov/24687255

DM8A5E0	DI	DM8A5E0
DM8A5E0	DN	Vecabrutinib
DM8A5E0	MI	TTGM6VW
DM8A5E0	MN	Tyrosine-protein kinase BTK (ATK)
DM8A5E0	MT	DTT
DM8A5E0	MA	Inhibitor
DM8A5E0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8A5E0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAN21O	DI	DMAN21O
DMAN21O	DN	VG-101
DMAN21O	MI	TTOM3J0
DMAN21O	MN	Estrogen receptor beta (ESR2)
DMAN21O	MT	DTT
DMAN21O	MA	Agonist
DMAN21O	RN	Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
DMAN21O	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218114/

DMAMIU4	DI	DMAMIU4
DMAMIU4	DN	VIR-201
DMAMIU4	MI	TT93WF5
DMAMIU4	MN	Interferon-gamma (IFNG)
DMAMIU4	MT	DTT
DMAMIU4	MA	Modulator
DMAMIU4	RN	EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
DMAMIU4	RU	http://www.google.com.ar/patents/EP1778251B1?cl=en

DMN62MP	DI	DMN62MP
DMN62MP	DN	WASP gene therapy
DMN62MP	MI	TTE8T73
DMN62MP	MN	Wiskott-Aldrich syndrome protein (WAS)
DMN62MP	MT	DTT
DMN62MP	MA	Modulator
DMN62MP	RN	ClinicalTrials.gov (NCT01347242) Gene Therapy for Wiskott-Aldrich Syndrome (WAS). U.S. National Institutes of Health.
DMN62MP	RU	https://clinicaltrials.gov/ct2/show/NCT01347242

DMUGHWR	DI	DMUGHWR
DMUGHWR	DN	WP-1066
DMUGHWR	MI	TTKAWRQ
DMUGHWR	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMUGHWR	MT	DTT
DMUGHWR	MA	Inhibitor
DMUGHWR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7972).
DMUGHWR	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7972

DMUGHWR	DI	DMUGHWR
DMUGHWR	DN	WP-1066
DMUGHWR	MI	TTH8FZW
DMUGHWR	MN	Signal transducer and activator of transcription 3 (STAT3)
DMUGHWR	MT	DTT
DMUGHWR	MA	Inhibitor
DMUGHWR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUGHWR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3FIMD	DI	DM3FIMD
DM3FIMD	DN	WT-4869
DM3FIMD	MI	TTZ8UT4
DM3FIMD	MN	Wilms tumor protein (WT1)
DM3FIMD	MT	DTT
DM3FIMD	MA	Modulator
DM3FIMD	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
DM3FIMD	RU	http://adisinsight.springer.com/drugs/800033385

DMRABOS	DI	DMRABOS
DMRABOS	DN	WX-554
DMRABOS	MI	TTROQ37
DMRABOS	MN	MAPK/ERK kinase kinase (MAP3K)
DMRABOS	MT	DTT
DMRABOS	MA	Modulator
DMRABOS	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27.
DMRABOS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/

DMZ9VCF	DI	DMZ9VCF
DMZ9VCF	DN	X-396
DMZ9VCF	MI	TTPMQSO
DMZ9VCF	MN	ALK tyrosine kinase receptor (ALK)
DMZ9VCF	MT	DTT
DMZ9VCF	MA	Inhibitor
DMZ9VCF	RN	Clinical pipeline report, company report or official report of Xcovery.
DMZ9VCF	RU	http://www.xcovery.com/our-science/alk-inhibitor/

DMU6TG7	DI	DMU6TG7
DMU6TG7	DN	XMT-1592
DMU6TG7	MI	TTQPZTM
DMU6TG7	MN	Sodium/phosphate cotransporter 2B (SLC34A2)
DMU6TG7	MT	DTT
DMU6TG7	RN	Clinical pipeline report, company report or official report of Mersana Therapeutics.
DMU6TG7	RU	https://www.mersana.com/pipeline/xmt-1592/

DM148HX	DI	DM148HX
DM148HX	DN	XToll
DM148HX	MI	TTWYMFE
DM148HX	MN	Mitochondrial 10kDa heat shock protein (HSPE1)
DM148HX	MT	DTT
DM148HX	MA	Modulator
DM148HX	RN	XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr Opin Investig Drugs. 2008 May;9(5):523-33.
DM148HX	RU	https://pubmed.ncbi.nlm.nih.gov/18465663

DMXSEHF	DI	DMXSEHF
DMXSEHF	DN	Y-39983
DMXSEHF	MI	TTMQO60
DMXSEHF	MN	Rho-associated protein kinase (ROCK)
DMXSEHF	MT	DTT
DMXSEHF	MA	Modulator
DMXSEHF	RN	Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70.
DMXSEHF	RU	https://www.ncbi.nlm.nih.gov/pubmed/21950703

DMIA9JD	DI	DMIA9JD
DMIA9JD	DN	YSCMA
DMIA9JD	MI	TTDIGC1
DMIA9JD	MN	Dipeptidyl peptidase 4 (DPP-4)
DMIA9JD	MT	DTT
DMIA9JD	RN	Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30.
DMIA9JD	RU	https://pubmed.ncbi.nlm.nih.gov/24502396

DMMQGPE	DI	DMMQGPE
DMMQGPE	DN	Zenocutuzomab
DMMQGPE	MI	TT6EO5L
DMMQGPE	MN	Erbb2 tyrosine kinase receptor (HER2)
DMMQGPE	MT	DTT
DMMQGPE	MA	Inhibitor
DMMQGPE	RN	Clinical pipeline report, company report or official report of Merus.
DMMQGPE	RU	https://merus.nl/pipeline/

DMMQGPE	DI	DMMQGPE
DMMQGPE	DN	Zenocutuzomab
DMMQGPE	MI	TTDC8N2
DMMQGPE	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMMQGPE	MT	DTT
DMMQGPE	MA	Inhibitor
DMMQGPE	RN	Clinical pipeline report, company report or official report of Merus.
DMMQGPE	RU	https://merus.nl/pipeline/

DMDJSOH	DI	DMDJSOH
DMDJSOH	DN	ZK-001
DMDJSOH	MI	TTVB0Q9
DMDJSOH	MN	Platelet glycoprotein Ib alpha (CD42b)
DMDJSOH	MT	DTT
DMDJSOH	MA	Modulator
DMDJSOH	RN	Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014 Feb;111(2):279-89.
DMDJSOH	RU	https://pubmed.ncbi.nlm.nih.gov/24172860

DMVG4OC	DI	DMVG4OC
DMVG4OC	DN	ZN-c5
DMVG4OC	MI	TTZAYWL
DMVG4OC	MN	Estrogen receptor (ESR)
DMVG4OC	MT	DTT
DMVG4OC	MA	Degrader
DMVG4OC	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DMVG4OC	RU	https://zentalis.com/our-pipeline/pipeline/

DMLV4U1	DI	DMLV4U1
DMLV4U1	DN	ZN-e4
DMLV4U1	MI	TTGKNB4
DMLV4U1	MN	Epidermal growth factor receptor (EGFR)
DMLV4U1	MT	DTT
DMLV4U1	MA	Inhibitor
DMLV4U1	RN	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
DMLV4U1	RU	https://zentalis.com/our-pipeline/pipeline/

DMPZE2G	DI	DMPZE2G
DMPZE2G	DN	ZPL521
DMPZE2G	MI	TTT1JVS
DMPZE2G	MN	Cytosolic phospholipase A2 (GIVA cPLA2)
DMPZE2G	MT	DTT
DMPZE2G	MA	Inhibitor
DMPZE2G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPZE2G	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM459Q7	DI	DM459Q7
DM459Q7	DN	BMS-833923
DM459Q7	MI	TT8J1S3
DM459Q7	MN	Smoothened homolog (SMO)
DM459Q7	MT	DTT
DM459Q7	MA	Inhibitor
DM459Q7	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DM459Q7	RU	http://www.exelixis.com/pipeline

DMNCOE1	DI	DMNCOE1
DMNCOE1	DN	FRM-6308
DMNCOE1	MI	TTJW4LU
DMNCOE1	MN	Phosphodiesterase 10A (PDE10)
DMNCOE1	MT	DTT
DMNCOE1	MA	Inhibitor
DMNCOE1	RN	Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
DMNCOE1	RU	https://pubmed.ncbi.nlm.nih.gov/25131831

DMVWYOU	DI	DMVWYOU
DMVWYOU	DN	GGF
DMVWYOU	MI	TTEH395
DMVWYOU	MN	Pro-neuregulin-1 (Pro-NRG1)
DMVWYOU	MT	DTT
DMVWYOU	MA	Modulator
DMVWYOU	RN	Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol. 2001 Mar 19;152(6):1289-99.
DMVWYOU	RU	https://pubmed.ncbi.nlm.nih.gov/11257128

DMQGH76	DI	DMQGH76
DMQGH76	DN	S-222611
DMQGH76	MI	TTGKNB4
DMQGH76	MN	Epidermal growth factor receptor (EGFR)
DMQGH76	MT	DTT
DMQGH76	MA	Inhibitor
DMQGH76	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMQGH76	RU	http://www.shionogi.co.jp/index_e.html

DMQGH76	DI	DMQGH76
DMQGH76	DN	S-222611
DMQGH76	MI	TT6EO5L
DMQGH76	MN	Erbb2 tyrosine kinase receptor (HER2)
DMQGH76	MT	DTT
DMQGH76	MA	Inhibitor
DMQGH76	RN	Clinical pipeline report, company report or official report of Shionogi (2011).
DMQGH76	RU	http://www.shionogi.co.jp/index_e.html

DMG74BY	DI	DMG74BY
DMG74BY	DN	(-)-3PPP, Maryland
DMG74BY	MI	TTEX248
DMG74BY	MN	Dopamine D2 receptor (D2R)
DMG74BY	MT	DTT
DMG74BY	MA	Agonist
DMG74BY	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DMG74BY	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TTE4BSY
DM1CZSJ	MN	Bromodomain and extraterminal domain protein (BET)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1CZSJ	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TT7CPI5
DM1CZSJ	MN	Bromodomain testis-specific protein (BRDT)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17;150(4):673-84.
DM1CZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/22901802

DM1CZSJ	DI	DM1CZSJ
DM1CZSJ	DN	(+)-JQ1
DM1CZSJ	MI	TTRA6BO
DM1CZSJ	MN	Bromodomain-containing protein 4 (BRD4)
DM1CZSJ	MT	DTT
DM1CZSJ	MA	Inhibitor
DM1CZSJ	RN	Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73.
DM1CZSJ	RU	https://pubmed.ncbi.nlm.nih.gov/20871596

DMBOXA1	DI	DMBOXA1
DMBOXA1	DN	[3H]fenobam
DMBOXA1	MI	TTHS256
DMBOXA1	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMBOXA1	MT	DTT
DMBOXA1	MA	Modulator (allosteric modulator)
DMBOXA1	RN	Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21.
DMBOXA1	RU	https://pubmed.ncbi.nlm.nih.gov/16040814

DMSCV02	DI	DMSCV02
DMSCV02	DN	[N-methyl-3H(3)]AZ-10419369
DMSCV02	MI	TTK8CXU
DMSCV02	MN	5-HT 1B receptor (HTR1B)
DMSCV02	MT	DTT
DMSCV02	MA	Antagonist
DMSCV02	RN	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
DMSCV02	RU	https://pubmed.ncbi.nlm.nih.gov/25841787

DMSMRC1	DI	DMSMRC1
DMSMRC1	DN	1069C
DMSMRC1	MI	TTYFKSZ
DMSMRC1	MN	Tubulin beta (TUBB)
DMSMRC1	MT	DTT
DMSMRC1	MA	Modulator
DMSMRC1	RN	Patent WO2005108424 A1.
DMSMRC1	RU	http://www.google.com/patents/WO2005108424A1?cl=en

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTSQIFT
DM5IPHE	MN	5-HT 1A receptor (HTR1A)
DM5IPHE	MT	DTT
DM5IPHE	MA	Agonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTJQOD7
DM5IPHE	MN	5-HT 2A receptor (HTR2A)
DM5IPHE	MT	DTT
DM5IPHE	MA	Antagonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DM5IPHE	DI	DM5IPHE
DM5IPHE	DN	1192U90
DM5IPHE	MI	TTEX248
DM5IPHE	MN	Dopamine D2 receptor (D2R)
DM5IPHE	MT	DTT
DM5IPHE	MA	Antagonist
DM5IPHE	RN	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
DM5IPHE	RU	https://pubmed.ncbi.nlm.nih.gov/17667958

DMICUPT	DI	DMICUPT
DMICUPT	DN	11C-6-Me-BTA-1
DMICUPT	MI	TTE4KHA
DMICUPT	MN	Amyloid beta A4 protein (APP)
DMICUPT	MT	DTT
DMICUPT	MA	Modulator
DMICUPT	RN	Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80.
DMICUPT	RU	https://pubmed.ncbi.nlm.nih.gov/18084683

DMYVDXW	DI	DMYVDXW
DMYVDXW	DN	11C-AZD-2184
DMYVDXW	MI	TTE4KHA
DMYVDXW	MN	Amyloid beta A4 protein (APP)
DMYVDXW	MT	DTT
DMYVDXW	MA	Binder
DMYVDXW	RN	Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593.
DMYVDXW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590405/

DMQ0RXA	DI	DMQ0RXA
DMQ0RXA	DN	11C-GSK-215083
DMQ0RXA	MI	TTJS8PY
DMQ0RXA	MN	5-HT 6 receptor (HTR6)
DMQ0RXA	MT	DTT
DMQ0RXA	MA	Antagonist
DMQ0RXA	RN	Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 Feb;53(2):295-303.
DMQ0RXA	RU	https://pubmed.ncbi.nlm.nih.gov/22223878

DMCFPX8	DI	DMCFPX8
DMCFPX8	DN	123-Iodine-labeled MFE-23
DMCFPX8	MI	TTY6DTE
DMCFPX8	MN	Carcinoembryonic antigen CEA (CD66e)
DMCFPX8	MT	DTT
DMCFPX8	RN	Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts.. Biochem J. 2000 March 1; 346(Pt 2): 519-528.
DMCFPX8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220881/

DM5ZC0E	DI	DM5ZC0E
DM5ZC0E	DN	124I-8H9
DM5ZC0E	MI	TT6CQUM
DM5ZC0E	MN	B7 homolog 3 (CD276)
DM5ZC0E	MT	DTT
DM5ZC0E	RN	National Cancer Institute Drug Dictionary (drug id 722029).
DM5ZC0E	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=722029

DMD751X	DI	DMD751X
DMD751X	DN	1614235 + 2330672
DMD751X	MI	TTPI1M5
DMD751X	MN	Ileal sodium/bile acid cotransporter (SLC10A2)
DMD751X	MT	DTT
DMD751X	MA	Modulator
DMD751X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960).
DMD751X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=960

DMD751X	DI	DMD751X
DMD751X	DN	1614235 + 2330672
DMD751X	MI	TT2UE56
DMD751X	MN	Sodium/glucose cotransporter 1 (SGLT1)
DMD751X	MT	DTT
DMD751X	MA	Modulator
DMD751X	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
DMD751X	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915

DMFG1YA	DI	DMFG1YA
DMFG1YA	DN	177Lu-AMBA
DMFG1YA	MI	TTC1MVT
DMFG1YA	MN	Gastrin-releasing peptide receptor (GRPR)
DMFG1YA	MT	DTT
DMFG1YA	MA	Agonist
DMFG1YA	RN	Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48.
DMFG1YA	RU	https://pubmed.ncbi.nlm.nih.gov/21036718

DMM2V74	DI	DMM2V74
DMM2V74	DN	177Lu-labelled CTT-1403
DMM2V74	MI	TT9G4N0
DMM2V74	MN	Glutamate carboxypeptidase II (GCPII)
DMM2V74	MT	DTT
DMM2V74	RN	Clinical pipeline report, company report or official report of Cancer Targeted Technologies.
DMM2V74	RU	https://www.cancertargetedtechnology.com/pipeline/ctt1403/

DMZ5YMX	DI	DMZ5YMX
DMZ5YMX	DN	18F-FEDAA-1106
DMZ5YMX	MI	TTPTXIN
DMZ5YMX	MN	Translocator protein (TSPO)
DMZ5YMX	MT	DTT
DMZ5YMX	MA	Modulator
DMZ5YMX	RN	Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther. 2003 Sep;306(3):828-37.
DMZ5YMX	RU	https://pubmed.ncbi.nlm.nih.gov/12928523

DMGE3DY	DI	DMGE3DY
DMGE3DY	DN	18-MC
DMGE3DY	MI	TT35UGH
DMGE3DY	MN	Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4)
DMGE3DY	MT	DTT
DMGE3DY	MA	Antagonist
DMGE3DY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGE3DY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMJ1SQY	DI	DMJ1SQY
DMJ1SQY	DN	19-28z T CELLS
DMJ1SQY	MI	TTW640A
DMJ1SQY	MN	B-lymphocyte surface antigen B4 (CD19)
DMJ1SQY	MT	DTT
DMJ1SQY	MA	CAR-T-Cell-Therapy
DMJ1SQY	RN	ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
DMJ1SQY	RU	https://clinicaltrials.gov/ct2/show/NCT01840566

DMQ8NTZ	DI	DMQ8NTZ
DMQ8NTZ	DN	192C86
DMQ8NTZ	MI	TTNVEIR
DMQ8NTZ	MN	Prostaglandin D2 receptor (PTGDR)
DMQ8NTZ	MT	DTT
DMQ8NTZ	MA	Modulator
DMQ8NTZ	RN	Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
DMQ8NTZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795261/

DMN9MPX	DI	DMN9MPX
DMN9MPX	DN	212Pb-labelled DOTAMTATE
DMN9MPX	MI	TTOMNR9
DMN9MPX	MN	Somatostatin receptor (SSTR)
DMN9MPX	MT	DTT
DMN9MPX	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DMN9MPX	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM2SQBF	DI	DM2SQBF
DM2SQBF	DN	225Ac-labelled aCD33
DM2SQBF	MI	TTJVYO3
DM2SQBF	MN	Myeloid cell surface antigen CD33 (CD33)
DM2SQBF	MT	DTT
DM2SQBF	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DM2SQBF	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM3E2IY	DI	DM3E2IY
DM3E2IY	DN	225Ac-labelled aCD38
DM3E2IY	MI	TTPURFN
DM3E2IY	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DM3E2IY	MT	DTT
DM3E2IY	RN	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
DM3E2IY	RU	https://pubmed.ncbi.nlm.nih.gov/32728208

DM1ZY6M	DI	DM1ZY6M
DM1ZY6M	DN	227Th-labelled MSLN-TTC
DM1ZY6M	MI	TT4RXME
DM1ZY6M	MN	Mesothelin (MSLN)
DM1ZY6M	MT	DTT
DM1ZY6M	RN	Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734.
DM1ZY6M	RU	https://pubmed.ncbi.nlm.nih.gov/31064781

DM7L45S	DI	DM7L45S
DM7L45S	DN	227Th-labelled PSMA-TTC
DM7L45S	MI	TT9G4N0
DM7L45S	MN	Glutamate carboxypeptidase II (GCPII)
DM7L45S	MT	DTT
DM7L45S	RN	Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. Clin Cancer Res. 2021 May 25.
DM7L45S	RU	https://pubmed.ncbi.nlm.nih.gov/34035067

DMDFA3E	DI	DMDFA3E
DMDFA3E	DN	349U85.HCL
DMDFA3E	MI	TTZCG4L
DMDFA3E	MN	Phosphodiesterase 3 (PDE3)
DMDFA3E	MT	DTT
DMDFA3E	MA	Modulator
DMDFA3E	RN	Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63.
DMDFA3E	RU	https://pubmed.ncbi.nlm.nih.gov/8299318

DM4Z1CH	DI	DM4Z1CH
DM4Z1CH	DN	4-aminosalicylate sodium
DM4Z1CH	MI	TTK0943
DM4Z1CH	MN	Prostaglandin G/H synthase (COX)
DM4Z1CH	MT	DTT
DM4Z1CH	MA	Modulator
DM4Z1CH	RN	5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202.
DM4Z1CH	RU	https://pubmed.ncbi.nlm.nih.gov/22493349

DM8XMPT	DI	DM8XMPT
DM8XMPT	DN	4SC-203
DM8XMPT	MI	TTGJCWZ
DM8XMPT	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM8XMPT	MT	DTT
DM8XMPT	MA	Modulator
DM8XMPT	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8XMPT	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMG75P3	DI	DMG75P3
DMG75P3	DN	4SC-205
DMG75P3	MI	TTTRP0H
DMG75P3	MN	Kinesin-like protein KIF11 (KIF11)
DMG75P3	MT	DTT
DMG75P3	MA	Inhibitor
DMG75P3	RN	2011 Pipeline of 4SC AG.
DMG75P3	RU	http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html

DM5RLM4	DI	DM5RLM4
DM5RLM4	DN	4SCAR19 cells
DM5RLM4	MI	TTW640A
DM5RLM4	MN	B-lymphocyte surface antigen B4 (CD19)
DM5RLM4	MT	DTT
DM5RLM4	MA	CAR-T-Cell-Therapy
DM5RLM4	RN	ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
DM5RLM4	RU	https://clinicaltrials.gov/ct2/show/NCT02968472

DM0351T	DI	DM0351T
DM0351T	DN	5-FP
DM0351T	MI	TTUTN1I
DM0351T	MN	Human Deoxyribonucleic acid (hDNA)
DM0351T	MT	DTT
DM0351T	MA	Binder
DM0351T	RN	Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9.
DM0351T	RU	https://pubmed.ncbi.nlm.nih.gov/12684389

DMOIE05	DI	DMOIE05
DMOIE05	DN	609A
DMOIE05	MI	TTNBFWK
DMOIE05	MN	Programmed cell death protein 1 (PD-1)
DMOIE05	MT	DTT
DMOIE05	MA	Inhibitor
DMOIE05	RN	Clinical pipeline report, company report or official report of 3SBio.
DMOIE05	RU	http://www.3sbio.com/en/news/details.aspx?id=111

DMQ789Z	DI	DMQ789Z
DMQ789Z	DN	8H9
DMQ789Z	MI	TTUCPMY
DMQ789Z	MN	Tenascin (TNC)
DMQ789Z	MT	DTT
DMQ789Z	RN	In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24.
DMQ789Z	RU	https://pubmed.ncbi.nlm.nih.gov/14973056

DMJR6TC	DI	DMJR6TC
DMJR6TC	DN	90Y-cG250
DMJR6TC	MI	TT2LVK8
DMJR6TC	MN	Carbonic anhydrase IX (CA-IX)
DMJR6TC	MT	DTT
DMJR6TC	RN	Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.
DMJR6TC	RU	https://pubmed.ncbi.nlm.nih.gov/23759990

DMJB6E2	DI	DMJB6E2
DMJB6E2	DN	99mTc-MIP-1405
DMJB6E2	MI	TT9G4N0
DMJB6E2	MN	Glutamate carboxypeptidase II (GCPII)
DMJB6E2	MT	DTT
DMJB6E2	MA	Modulator
DMJB6E2	RN	99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76.
DMJB6E2	RU	https://pubmed.ncbi.nlm.nih.gov/23733925

DMYKPXJ	DI	DMYKPXJ
DMYKPXJ	DN	9cUAB-30
DMYKPXJ	MI	TTH029C
DMYKPXJ	MN	Retinoic acid receptor RXR-gamma (RXRG)
DMYKPXJ	MT	DTT
DMYKPXJ	MA	Modulator
DMYKPXJ	RN	In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64.
DMYKPXJ	RU	https://pubmed.ncbi.nlm.nih.gov/17446266

DMGJ7A4	DI	DMGJ7A4
DMGJ7A4	DN	A/Anhui/05
DMGJ7A4	MI	TTF4CAM
DMGJ7A4	MN	Influenza Hemagglutinin (Influ HA)
DMGJ7A4	MT	DTT
DMGJ7A4	RN	A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989.
DMGJ7A4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302345/

DMRWTFG	DI	DMRWTFG
DMRWTFG	DN	A-337
DMRWTFG	MI	TTUN7MC
DMRWTFG	MN	T-cell surface glycoprotein CD3 (CD3)
DMRWTFG	MT	DTT
DMRWTFG	MA	Inhibitor
DMRWTFG	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMRWTFG	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DMRWTFG	DI	DMRWTFG
DMRWTFG	DN	A-337
DMRWTFG	MI	TTZ8WH4
DMRWTFG	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMRWTFG	MT	DTT
DMRWTFG	MA	Inhibitor
DMRWTFG	RN	Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
DMRWTFG	RU	https://pubmed.ncbi.nlm.nih.gov/31175342

DM25CBW	DI	DM25CBW
DM25CBW	DN	A-348441
DM25CBW	MI	TTOZRK6
DM25CBW	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DM25CBW	MT	DTT
DM25CBW	MA	Inhibitor
DM25CBW	RN	Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90.
DM25CBW	RU	https://pubmed.ncbi.nlm.nih.gov/16987661

DMX0JLI	DI	DMX0JLI
DMX0JLI	DN	A-837093
DMX0JLI	MI	TTMVBWH
DMX0JLI	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMX0JLI	MT	DTT
DMX0JLI	MA	Inhibitor
DMX0JLI	RN	Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19.
DMX0JLI	RU	https://pubmed.ncbi.nlm.nih.gov/18321145

DM92RQT	DI	DM92RQT
DM92RQT	DN	AAB-003/PF-05236812
DM92RQT	MI	TTE4KHA
DM92RQT	MN	Amyloid beta A4 protein (APP)
DM92RQT	MT	DTT
DM92RQT	MA	Modulator
DM92RQT	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM92RQT	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMG4RK0	DI	DMG4RK0
DMG4RK0	DN	AAD-2004
DMG4RK0	MI	TTYLQ8V
DMG4RK0	MN	Prostaglandin E synthase (PTGES)
DMG4RK0	MT	DTT
DMG4RK0	MA	Inhibitor
DMG4RK0	RN	Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61.
DMG4RK0	RU	https://pubmed.ncbi.nlm.nih.gov/22537108

DMIX5HF	DI	DMIX5HF
DMIX5HF	DN	AAV2/8-LSPhGAA
DMIX5HF	MI	TTHCF4J
DMIX5HF	MN	Alpha-glucosidase (GLA)
DMIX5HF	MT	DTT
DMIX5HF	RN	ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
DMIX5HF	RU	https://clinicaltrials.gov/ct2/show/NCT03533673

DMIDEKB	DI	DMIDEKB
DMIDEKB	DN	AAV2-hFIX16
DMIDEKB	MI	TTFEZ5Q
DMIDEKB	MN	Coagulation factor IX (F9)
DMIDEKB	MT	DTT
DMIDEKB	MA	Modulator
DMIDEKB	RN	Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739.
DMIDEKB	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069673/

DMBG9HI	DI	DMBG9HI
DMBG9HI	DN	AB023
DMBG9HI	MI	TTJCPUT
DMBG9HI	MN	Coagulation factor XI (F11)
DMBG9HI	MT	DTT
DMBG9HI	MA	Inhibitor
DMBG9HI	RN	Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809.
DMBG9HI	RU	https://pubmed.ncbi.nlm.nih.gov/30700130

DMGONUE	DI	DMGONUE
DMGONUE	DN	AB680
DMGONUE	MI	TTK0O6Y
DMGONUE	MN	Ecto-5'-nucleotidase (CD73)
DMGONUE	MT	DTT
DMGONUE	MA	Inhibitor
DMGONUE	RN	Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
DMGONUE	RU	https://pubmed.ncbi.nlm.nih.gov/32614585

DMYFB10	DI	DMYFB10
DMYFB10	DN	Abaperidone
DMYFB10	MI	TTJQOD7
DMYFB10	MN	5-HT 2A receptor (HTR2A)
DMYFB10	MT	DTT
DMYFB10	MA	Modulator
DMYFB10	RN	7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9.
DMYFB10	RU	https://www.ncbi.nlm.nih.gov/pubmed/9876110

DMYFB10	DI	DMYFB10
DMYFB10	DN	Abaperidone
DMYFB10	MI	TTEX248
DMYFB10	MN	Dopamine D2 receptor (D2R)
DMYFB10	MT	DTT
DMYFB10	MA	Modulator
DMYFB10	RN	7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9.
DMYFB10	RU	https://www.ncbi.nlm.nih.gov/pubmed/9876110

DMIQXDJ	DI	DMIQXDJ
DMIQXDJ	DN	ABBV-151
DMIQXDJ	MI	TTR9XHZ
DMIQXDJ	MN	Transforming growth factor beta 1 (TGFB1)
DMIQXDJ	MT	DTT
DMIQXDJ	MA	Inhibitor
DMIQXDJ	RN	Clinical pipeline report, company report or official report of AbbVie.
DMIQXDJ	RU	https://www.abbvie.com/our-science/pipeline/abbv-151.html

DM71Q69	DI	DM71Q69
DM71Q69	DN	ABBV-184
DM71Q69	MI	TTUN7MC
DM71Q69	MN	T-cell surface glycoprotein CD3 (CD3)
DM71Q69	MT	DTT
DM71Q69	RN	Clinical pipeline report, company report or official report of AbbVie.
DM71Q69	RU	https://www.abbvie.com/our-science/pipeline/abbv-184.html

DMUCF9L	DI	DMUCF9L
DMUCF9L	DN	ABBV-2451
DMUCF9L	MI	TTRLZHP
DMUCF9L	MN	cAMP-dependent chloride channel (CFTR)
DMUCF9L	MT	DTT
DMUCF9L	MA	Modulator
DMUCF9L	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUCF9L	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMCZI8L	DI	DMCZI8L
DMCZI8L	DN	ABBV-257
DMCZI8L	MI	TTG0MT6
DMCZI8L	MN	Interleukin-17 (IL17)
DMCZI8L	MT	DTT
DMCZI8L	MA	Inhibitor
DMCZI8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCZI8L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCZI8L	DI	DMCZI8L
DMCZI8L	DN	ABBV-257
DMCZI8L	MI	TTF8CQI
DMCZI8L	MN	Tumor necrosis factor (TNF)
DMCZI8L	MT	DTT
DMCZI8L	MA	Inhibitor
DMCZI8L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCZI8L	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMU6K37	DI	DMU6K37
DMU6K37	DN	ABBV-2737
DMU6K37	MI	TTRLZHP
DMU6K37	MN	cAMP-dependent chloride channel (CFTR)
DMU6K37	MT	DTT
DMU6K37	MA	Modulator
DMU6K37	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMU6K37	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMB01L5	DI	DMB01L5
DMB01L5	DN	ABBV-3067
DMB01L5	MI	TTRLZHP
DMB01L5	MN	cAMP-dependent chloride channel (CFTR)
DMB01L5	MT	DTT
DMB01L5	MA	Modulator
DMB01L5	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMB01L5	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM49O6Y	DI	DM49O6Y
DM49O6Y	DN	ABBV-323
DM49O6Y	MI	TTN6Y9A
DM49O6Y	MN	CD40L receptor (CD40)
DM49O6Y	MT	DTT
DM49O6Y	MA	Antagonist
DM49O6Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM49O6Y	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMQGPRE	DI	DMQGPRE
DMQGPRE	DN	ABBV-399
DMQGPRE	MI	TTNDSF4
DMQGPRE	MN	Proto-oncogene c-Met (MET)
DMQGPRE	MT	DTT
DMQGPRE	MA	Inhibitor
DMQGPRE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQGPRE	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPD0KL	DI	DMPD0KL
DMPD0KL	DN	ABBV-428
DMPD0KL	MI	TTIJP3Q
DMPD0KL	MN	TNF related activation protein (CD40LG)
DMPD0KL	MT	DTT
DMPD0KL	MA	Stimulator
DMPD0KL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPD0KL	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM87SM9	DI	DM87SM9
DM87SM9	DN	ABBV-467
DM87SM9	MI	TTL53M6
DM87SM9	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM87SM9	MT	DTT
DM87SM9	MA	Inhibitor
DM87SM9	RN	Clinical pipeline report, company report or official report of AbbVie.
DM87SM9	RU	https://www.abbvie.com/our-science/pipeline/abbv-467.html

DM90EO3	DI	DM90EO3
DM90EO3	DN	ABBV-621
DM90EO3	MI	TTA5MS9
DM90EO3	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM90EO3	MT	DTT
DM90EO3	MA	Agonist
DM90EO3	RN	Clinical pipeline report, company report or official report of AbbVie.
DM90EO3	RU	https://www.abbvie.com/our-science/pipeline/abbv-621.html

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTDP48B
DMTEA9C	MN	Bromodomain-containing protein 2 (BRD2)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTHE657
DMTEA9C	MN	Bromodomain-containing protein 3 (BRD3)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTEA9C	DI	DMTEA9C
DMTEA9C	DN	ABBV-744
DMTEA9C	MI	TTRA6BO
DMTEA9C	MN	Bromodomain-containing protein 4 (BRD4)
DMTEA9C	MT	DTT
DMTEA9C	MA	Inhibitor
DMTEA9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTEA9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZM0T8	DI	DMZM0T8
DMZM0T8	DN	ABBV-838
DMZM0T8	MI	TT7ILZ1
DMZM0T8	MN	SLAM family member 7 SLAMF7 (CS1)
DMZM0T8	MT	DTT
DMZM0T8	MA	Inhibitor
DMZM0T8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZM0T8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMPXDL6	DI	DMPXDL6
DMPXDL6	DN	ABBV-CLS-579
DMPXDL6	MI	TTY8PUS
DMPXDL6	MN	Tyrosine-protein phosphatase non-receptor type 2 (PTPN2)
DMPXDL6	MT	DTT
DMPXDL6	MA	Inhibitor
DMPXDL6	RN	Clinical pipeline report, company report or official report of Calico Life Sciences.
DMPXDL6	RU	https://www.calicolabs.com/press/calico-and-abbvie-share-update-on-early-stage-clinical-programs

DMUSOM9	DI	DMUSOM9
DMUSOM9	DN	ABBV-CX-2029
DMUSOM9	MI	TT8MG4S
DMUSOM9	MN	Transferrin receptor protein 1 (TFRC)
DMUSOM9	MT	DTT
DMUSOM9	RN	Clinical pipeline report, company report or official report of AbbVie.
DMUSOM9	RU	https://www.abbvie.com/our-science/pipeline/abbv-2029.html

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTB8Y9K
DM1KD7U	MN	Angiogenesis (AGG)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTGTQHC
DM1KD7U	MN	DNA topoisomerase I (TOP1)
DM1KD7U	MT	DTT
DM1KD7U	MA	Modulator
DM1KD7U	RN	Company report (Indena)
DM1KD7U	RU	http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TT4V2JM
DM1KD7U	MN	Hepatocyte growth factor (HGF)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTYFKSZ
DM1KD7U	MN	Tubulin beta (TUBB)
DM1KD7U	MT	DTT
DM1KD7U	MA	Modulator
DM1KD7U	RN	Company report (Indena)
DM1KD7U	RU	http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/

DM1KD7U	DI	DM1KD7U
DM1KD7U	DN	ABI-011
DM1KD7U	MI	TTOHSBA
DM1KD7U	MN	Vascular endothelial growth factor A (VEGFA)
DM1KD7U	MT	DTT
DM1KD7U	MA	Inhibitor
DM1KD7U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1KD7U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4TN6W	DI	DM4TN6W
DM4TN6W	DN	ABI-H3733
DM4TN6W	MI	TTM42UJ
DM4TN6W	MN	Hepatitis B virus Capsid protein (HBV C)
DM4TN6W	MT	DTT
DM4TN6W	MA	Inhibitor
DM4TN6W	RN	Clinical pipeline report, company report or official report of Assembly Biosciences.
DM4TN6W	RU	https://www.assemblybio.com/pipeline/

DMS1HR3	DI	DMS1HR3
DMS1HR3	DN	ABM-1310
DMS1HR3	MI	TTWCGQT
DMS1HR3	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMS1HR3	MT	DTT
DMS1HR3	MA	Inhibitor
DMS1HR3	RN	Clinical pipeline report, company report or official report of ABM Therapeutics.
DMS1HR3	RU	http://www.abmtx.com/site/development3

DMA4WEO	DI	DMA4WEO
DMA4WEO	DN	ABSK021
DMA4WEO	MI	TT7MRDV
DMA4WEO	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMA4WEO	MT	DTT
DMA4WEO	MA	Inhibitor
DMA4WEO	RN	Clinical pipeline report, company report or official report of Abbisko Therapeutics.
DMA4WEO	RU	http://www.abbisko.com/page104?_l=en

DMG4H9Y	DI	DMG4H9Y
DMG4H9Y	DN	ABT-072
DMG4H9Y	MI	TTMVBWH
DMG4H9Y	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMG4H9Y	MT	DTT
DMG4H9Y	MA	Inhibitor
DMG4H9Y	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DMG4H9Y	RU	http://www.abbott.com/index2.htm

DMJFWPR	DI	DMJFWPR
DMJFWPR	DN	ABT-102
DMJFWPR	MI	TTMI6F5
DMJFWPR	MN	Transient receptor potential cation channel V1 (TRPV1)
DMJFWPR	MT	DTT
DMJFWPR	MA	Blocker
DMJFWPR	RN	Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6.
DMJFWPR	RU	https://pubmed.ncbi.nlm.nih.gov/19481638

DM1F50I	DI	DM1F50I
DM1F50I	DN	ABT-110
DM1F50I	MI	TTDN3LF
DM1F50I	MN	Nerve growth factor (NGF)
DM1F50I	MT	DTT
DM1F50I	MA	Modulator
DM1F50I	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DM1F50I	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DMQ3O1U	DI	DMQ3O1U
DMQ3O1U	DN	ABT-165
DMQ3O1U	MI	TTV23LH
DMQ3O1U	MN	Delta-like protein 4 (DLL4)
DMQ3O1U	MT	DTT
DMQ3O1U	MA	Inhibitor
DMQ3O1U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ3O1U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ3O1U	DI	DMQ3O1U
DMQ3O1U	DN	ABT-165
DMQ3O1U	MI	TT9HKJA
DMQ3O1U	MN	Vascular endothelial growth factor (VEGF)
DMQ3O1U	MT	DTT
DMQ3O1U	MA	Inhibitor
DMQ3O1U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ3O1U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR7OGL	DI	DMR7OGL
DMR7OGL	DN	ABT-239
DMR7OGL	MI	TT9JNIC
DMR7OGL	MN	Histamine H3 receptor (H3R)
DMR7OGL	MT	DTT
DMR7OGL	MA	Antagonist
DMR7OGL	RN	Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol. 2009 May;157(1):139-49.
DMR7OGL	RU	https://pubmed.ncbi.nlm.nih.gov/19413577

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DES5XRU
DM7TOWX	MN	Cytochrome P450 2C8 (CYP2C8)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DECB0K3
DM7TOWX	MN	Cytochrome P450 2D6 (CYP2D6)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DE4LYSA
DM7TOWX	MN	Cytochrome P450 3A4 (CYP3A4)
DM7TOWX	MT	DME
DM7TOWX	MA	Metabolism
DM7TOWX	RN	Metabolism and disposition of hepatitis C polymerase inhibitor dasabuvir in humans. Drug Metab Dispos. 2016 Aug;44(8):1139-47.
DM7TOWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27179126

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	TTMVBWH
DM7TOWX	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7TOWX	MT	DTT
DM7TOWX	MA	Inhibitor
DM7TOWX	RN	Clinical pipeline report, company report or official report of Abbott Laboratories (2011)
DM7TOWX	RU	http://www.abbott.com/index2.htm

DM7TOWX	DI	DM7TOWX
DM7TOWX	DN	ABT-333
DM7TOWX	MI	DTUGYRD
DM7TOWX	MN	P-glycoprotein 1 (ABCB1)
DM7TOWX	MT	DTP
DM7TOWX	MA	Substrate
DM7TOWX	RN	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
DM7TOWX	RU	https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false

DMWN7D3	DI	DMWN7D3
DMWN7D3	DN	ABT-354
DMWN7D3	MI	TTJS8PY
DMWN7D3	MN	5-HT 6 receptor (HTR6)
DMWN7D3	MT	DTT
DMWN7D3	MA	Modulator
DMWN7D3	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035134)
DMWN7D3	RU	http://adisinsight.springer.com/drugs/800035134

DM4KPV0	DI	DM4KPV0
DM4KPV0	DN	ABT-413
DM4KPV0	MI	TTS9BDA
DM4KPV0	MN	Spectrin non-erythroid beta chain 1 (SPTBN1)
DM4KPV0	MT	DTT
DM4KPV0	RN	The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. International Journal of Medicinal Chemistry Volume 2011 (2011), Article ID 424535, Page(8).
DM4KPV0	RU	http://www.hindawi.com/journals/ijmc/2011/424535/

DMVLPRT	DI	DMVLPRT
DMVLPRT	DN	ABT-700
DMVLPRT	MI	TTNDSF4
DMVLPRT	MN	Proto-oncogene c-Met (MET)
DMVLPRT	MT	DTT
DMVLPRT	MA	Modulator
DMVLPRT	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).
DMVLPRT	RU	http://meetinglibrary.asco.org/content/134301-144

DMFH3JM	DI	DMFH3JM
DMFH3JM	DN	ABT-767
DMFH3JM	MI	TTEBCY8
DMFH3JM	MN	Poly [ADP-ribose] polymerase (PARP)
DMFH3JM	MT	DTT
DMFH3JM	MA	Modulator
DMFH3JM	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMFH3JM	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMB9N4J	DI	DMB9N4J
DMB9N4J	DN	ABT-957
DMB9N4J	MI	TTG5QB7
DMB9N4J	MN	Calpain-2 (CAPN2)
DMB9N4J	MT	DTT
DMB9N4J	MA	Modulator
DMB9N4J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMB9N4J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM9SYVJ	DI	DM9SYVJ
DM9SYVJ	DN	ABX-1431
DM9SYVJ	MI	TTZ963I
DM9SYVJ	MN	Monoglyceride lipase (MAGL)
DM9SYVJ	MT	DTT
DM9SYVJ	MA	Inhibitor
DM9SYVJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SYVJ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMS3915	DI	DMS3915
DMS3915	DN	AC 165198
DMS3915	MI	TTUPB12
DMS3915	MN	Measles virus Fusion glycoprotein (MeV F)
DMS3915	MT	DTT
DMS3915	MA	Modulator
DMS3915	RN	WO patent application no. 2013,1306,83, Xten conjugate compositions and methods of making same.
DMS3915	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130906&CC=WO&NR=2013130683A2&KC=A2

DMB5A63	DI	DMB5A63
DMB5A63	DN	AC0058TA
DMB5A63	MI	TTGM6VW
DMB5A63	MN	Tyrosine-protein kinase BTK (ATK)
DMB5A63	MT	DTT
DMB5A63	MA	Inhibitor
DMB5A63	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB5A63	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM36WTQ	DI	DM36WTQ
DM36WTQ	DN	AC-262271
DM36WTQ	MI	TTZ9SOR
DM36WTQ	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM36WTQ	MT	DTT
DM36WTQ	MA	Agonist
DM36WTQ	RN	Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals.
DM36WTQ	RU	http://www.biocentury.com/products/ac-262271

DMPS6U9	DI	DMPS6U9
DMPS6U9	DN	AC430
DMPS6U9	MI	TTRMX3V
DMPS6U9	MN	Janus kinase 2 (JAK-2)
DMPS6U9	MT	DTT
DMPS6U9	MA	Modulator
DMPS6U9	RN	Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
DMPS6U9	RU	https://pubmed.ncbi.nlm.nih.gov/24818516

DMJ36YH	DI	DMJ36YH
DMJ36YH	DN	ACE-011
DMJ36YH	MI	TTO3HT7
DMJ36YH	MN	Transforming growth factor beta (TGFB)
DMJ36YH	MT	DTT
DMJ36YH	MA	Inhibitor
DMJ36YH	RN	Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
DMJ36YH	RU	http://www.acceleronpharma.com/

DMUBYFM	DI	DMUBYFM
DMUBYFM	DN	ACE-041
DMUBYFM	MI	TTAP4T1
DMUBYFM	MN	Growth/differentiation factor 2 (GDF2)
DMUBYFM	MT	DTT
DMUBYFM	MA	Modulator
DMUBYFM	RN	Company report (Acceleron Pharma)
DMUBYFM	RU	http://www.acceleronpharma.com/products/dalantercept/

DM19UTO	DI	DM19UTO
DM19UTO	DN	Acebilustat
DM19UTO	MI	TTXZEAJ
DM19UTO	MN	Leukotriene A-4 hydrolase (LTA4H)
DM19UTO	MT	DTT
DM19UTO	MA	Inhibitor
DM19UTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM19UTO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMW6X0O	DI	DMW6X0O
DMW6X0O	DN	ACH-2684
DMW6X0O	MI	TTWXB3E
DMW6X0O	MN	Hepatitis C virus NS3 helicase (HCV NS3)
DMW6X0O	MT	DTT
DMW6X0O	MA	Modulator
DMW6X0O	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMW6X0O	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM5SJO9	DI	DM5SJO9
DM5SJO9	DN	ACHN-975
DM5SJO9	MI	TT2D1J6
DM5SJO9	MN	Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC)
DM5SJO9	MT	DTT
DM5SJO9	MA	Modulator
DM5SJO9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5SJO9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMKVE8X	DI	DMKVE8X
DMKVE8X	DN	Acriflavine
DMKVE8X	MI	TT5FH9Y
DMKVE8X	MN	Human immunodeficiency virus Integrase (HIV IN)
DMKVE8X	MT	DTT
DMKVE8X	MA	Modulator
DMKVE8X	RN	Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6.
DMKVE8X	RU	https://pubmed.ncbi.nlm.nih.gov/10665342

DMOZ3AT	DI	DMOZ3AT
DMOZ3AT	DN	ACT-178882
DMOZ3AT	MI	TTB2MXP
DMOZ3AT	MN	Angiotensinogenase renin (REN)
DMOZ3AT	MT	DTT
DMOZ3AT	MA	Inhibitor
DMOZ3AT	RN	Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Clin Drug Investig. 2013 Mar;33(3):207-13.
DMOZ3AT	RU	https://pubmed.ncbi.nlm.nih.gov/23381958

DM5KMYQ	DI	DM5KMYQ
DM5KMYQ	DN	Actimab-M
DM5KMYQ	MI	TTJVYO3
DM5KMYQ	MN	Myeloid cell surface antigen CD33 (CD33)
DM5KMYQ	MT	DTT
DM5KMYQ	MA	Inhibitor
DM5KMYQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5KMYQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMRDY0G	DI	DMRDY0G
DMRDY0G	DN	ACV-1
DMRDY0G	MI	TTJ49OM
DMRDY0G	MN	Neuronal acetylcholine receptor alpha-10 (CHRNA10)
DMRDY0G	MT	DTT
DMRDY0G	MA	Modulator
DMRDY0G	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMRDY0G	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8VQ1S	DI	DM8VQ1S
DM8VQ1S	DN	AD-337
DM8VQ1S	MI	TT3ROYC
DM8VQ1S	MN	Serotonin transporter (SERT)
DM8VQ1S	MT	DTT
DM8VQ1S	MA	Modulator
DM8VQ1S	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8VQ1S	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTEC2T3
DMG82ZA	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTFGZB6
DMG82ZA	MN	Human immunodeficiency virus GAG protein (HIV gag)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TT4NXYM
DMG82ZA	MN	Human immunodeficiency virus Negative factor (HIV nef)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TTF7I5O
DMG82ZA	MN	Human immunodeficiency virus Rev protein (HIV rev)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMG82ZA	DI	DMG82ZA
DMG82ZA	DN	Ad35-GRIN/ENV
DMG82ZA	MI	TT84ETX
DMG82ZA	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMG82ZA	MT	DTT
DMG82ZA	RN	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
DMG82ZA	RU	https://pubmed.ncbi.nlm.nih.gov/22870265

DMFTGHX	DI	DMFTGHX
DMFTGHX	DN	Ad5CMV-NIS
DMFTGHX	MI	TTW7HI9
DMFTGHX	MN	Sodium/iodide cotransporter (SLC5A5)
DMFTGHX	MT	DTT
DMFTGHX	MA	Modulator
DMFTGHX	RN	Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter. Mol Ther. 2009 December; 17(12): 2041-2048.
DMFTGHX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810133/

DMMBQV3	DI	DMMBQV3
DMMBQV3	DN	Ad5-ENVA-48
DMMBQV3	MI	TTEC2T3
DMMBQV3	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMMBQV3	MT	DTT
DMMBQV3	RN	ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
DMMBQV3	RU	https://clinicaltrials.gov/ct2/show/NCT00695877

DM2UMGE	DI	DM2UMGE
DM2UMGE	DN	Ad5-TRAIL
DM2UMGE	MI	TTA5MS9
DM2UMGE	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM2UMGE	MT	DTT
DM2UMGE	MA	Modulator
DM2UMGE	RN	Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006 Jun;13(6):628-32.
DM2UMGE	RU	https://pubmed.ncbi.nlm.nih.gov/16456549

DM16QSG	DI	DM16QSG
DM16QSG	DN	Adaphostin
DM16QSG	MI	TTS7G69
DM16QSG	MN	Fusion protein Bcr-Abl (Bcr-Abl)
DM16QSG	MT	DTT
DM16QSG	MA	Inhibitor
DM16QSG	RN	Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71.
DM16QSG	RU	https://pubmed.ncbi.nlm.nih.gov/11781252

DM59EUY	DI	DM59EUY
DM59EUY	DN	ADCI
DM59EUY	MI	TT9IK2Z
DM59EUY	MN	N-methyl-D-aspartate receptor (NMDAR)
DM59EUY	MT	DTT
DM59EUY	MA	Modulator
DM59EUY	RN	The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
DM59EUY	RU	https://pubmed.ncbi.nlm.nih.gov/10714396

DM59EUY	DI	DM59EUY
DM59EUY	DN	ADCI
DM59EUY	MI	TTRK8B9
DM59EUY	MN	Sodium channel unspecific (NaC)
DM59EUY	MT	DTT
DM59EUY	MA	Modulator
DM59EUY	RN	The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
DM59EUY	RU	https://pubmed.ncbi.nlm.nih.gov/10714396

DMEXT97	DI	DMEXT97
DMEXT97	DN	ADG116
DMEXT97	MI	TTI2S1D
DMEXT97	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMEXT97	MT	DTT
DMEXT97	MA	Inhibitor
DMEXT97	RN	Clinical pipeline report, company report or official report of Adagene.
DMEXT97	RU	https://www.adagene.com/pipeline/adg116/

DMM45P9	DI	DMM45P9
DMM45P9	DN	Ad-IFN-alpha
DMM45P9	MI	TT95SOA
DMM45P9	MN	Interferon alpha (IFNA)
DMM45P9	MT	DTT
DMM45P9	MA	Modulator
DMM45P9	RN	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
DMM45P9	RU	https://pubmed.ncbi.nlm.nih.gov/18246607

DMQVEZB	DI	DMQVEZB
DMQVEZB	DN	Adjustable basal insulin
DMQVEZB	MI	TTZOPHG
DMQVEZB	MN	Insulin (INS)
DMQVEZB	MT	DTT
DMQVEZB	MA	Modulator
DMQVEZB	RN	The future of basal insulin supplementation. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8.
DMQVEZB	RU	https://pubmed.ncbi.nlm.nih.gov/21568722

DM9GLHO	DI	DM9GLHO
DM9GLHO	DN	Ad-OC-hsvTK/valacyclovir
DM9GLHO	MI	TTP3QRF
DM9GLHO	MN	Thymidine kinase 1 (TK1)
DM9GLHO	MT	DTT
DM9GLHO	MA	Inhibitor
DM9GLHO	RN	Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
DM9GLHO	RU	https://pubmed.ncbi.nlm.nih.gov/12639303

DMS6DPF	DI	DMS6DPF
DMS6DPF	DN	ADPT01
DMS6DPF	MI	TTNVXAW
DMS6DPF	MN	Lymphocyte activation gene 3 protein (LAG3)
DMS6DPF	MT	DTT
DMS6DPF	MA	Inhibitor
DMS6DPF	RN	Clinical pipeline report, company report or official report of Novartis.
DMS6DPF	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All

DMS6DPF	DI	DMS6DPF
DMS6DPF	DN	ADPT01
DMS6DPF	MI	TTNBFWK
DMS6DPF	MN	Programmed cell death protein 1 (PD-1)
DMS6DPF	MT	DTT
DMS6DPF	MA	Inhibitor
DMS6DPF	RN	Clinical pipeline report, company report or official report of Novartis.
DMS6DPF	RU	https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All

DM6NUCA	DI	DM6NUCA
DM6NUCA	DN	ADR-851
DM6NUCA	MI	TTNXLKE
DM6NUCA	MN	5-HT 3 receptor (5HT3R)
DM6NUCA	MT	DTT
DM6NUCA	MA	Modulator
DM6NUCA	RN	Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9.
DM6NUCA	RU	https://pubmed.ncbi.nlm.nih.gov/1804661

DMYHIAR	DI	DMYHIAR
DMYHIAR	DN	AdRTVP-1
DMYHIAR	MI	TTEQF1O
DMYHIAR	MN	Glioma pathogenesis-related protein 1 (GLIPR1)
DMYHIAR	MT	DTT
DMYHIAR	MA	Modulator
DMYHIAR	RN	Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63.
DMYHIAR	RU	https://pubmed.ncbi.nlm.nih.gov/16485011

DMHIPF5	DI	DMHIPF5
DMHIPF5	DN	ADV-1002401
DMHIPF5	MI	TTDLNGZ
DMHIPF5	MN	Glucokinase (GCK)
DMHIPF5	MT	DTT
DMHIPF5	MA	Inhibitor
DMHIPF5	RN	The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats. PLoS One. 2014; 9(5): e97139.
DMHIPF5	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032240/

DMH8Z9W	DI	DMH8Z9W
DMH8Z9W	DN	ADVAX
DMH8Z9W	MI	TTRPO9Z
DMH8Z9W	MN	TNF-alpha signaling pathway (TNFA pathway)
DMH8Z9W	MT	DTT
DMH8Z9W	MA	Modulator
DMH8Z9W	RN	Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
DMH8Z9W	RU	https://pubmed.ncbi.nlm.nih.gov/20111582

DMBUOX4	DI	DMBUOX4
DMBUOX4	DN	ADX71149
DMBUOX4	MI	TTXJ47W
DMBUOX4	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMBUOX4	MT	DTT
DMBUOX4	MA	Modulator
DMBUOX4	RN	MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).
DMBUOX4	RU	http://www.researchgate.net/publication/260023632_MGlu2_receptor-mediated_modulation_of_conditioned_avoidance_behavior_in_rats

DM7X2HK	DI	DM7X2HK
DM7X2HK	DN	AE-08
DM7X2HK	MI	TT8MK59
DM7X2HK	MN	Melanocytes lineage-specific antigen GP100 (PMEL)
DM7X2HK	MT	DTT
DM7X2HK	RN	Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
DM7X2HK	RU	https://pubmed.ncbi.nlm.nih.gov/20355185

DMQRKXP	DI	DMQRKXP
DMQRKXP	DN	AEA-35p
DMQRKXP	MI	TTYA75N
DMQRKXP	MN	MHC class II antigen DR (HLA-DR)
DMQRKXP	MT	DTT
DMQRKXP	RN	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
DMQRKXP	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1

DM8I4G0	DI	DM8I4G0
DM8I4G0	DN	AEB701
DM8I4G0	MI	TTYVX59
DM8I4G0	MN	Protein kinase C (PRKC)
DM8I4G0	MT	DTT
DM8I4G0	MA	Inhibitor
DM8I4G0	RN	Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253.
DM8I4G0	RU	http://synapse.koreamed.org/DOIx.php?id=10.4285/jkstn.2012.26.4.248

DMQF982	DI	DMQF982
DMQF982	DN	AEW-541
DMQF982	MI	TTCBFJO
DMQF982	MN	Insulin receptor (INSR)
DMQF982	MT	DTT
DMQF982	MA	Inhibitor
DMQF982	RN	Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009 Aug 27;52(16):4981-5004.
DMQF982	RU	https://pubmed.ncbi.nlm.nih.gov/19610618

DMQF982	DI	DMQF982
DMQF982	DN	AEW-541
DMQF982	MI	TTHRID2
DMQF982	MN	Insulin-like growth factor I receptor (IGF1R)
DMQF982	MT	DTT
DMQF982	MA	Inhibitor
DMQF982	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMQF982	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM8LG2I	DI	DM8LG2I
DM8LG2I	DN	AF-130
DM8LG2I	MI	TT2THBD
DM8LG2I	MN	P2X purinoceptor 3 (P2RX3)
DM8LG2I	MT	DTT
DM8LG2I	MA	Antagonist
DM8LG2I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8LG2I	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMNF3GW	DI	DMNF3GW
DMNF3GW	DN	Afeletecan
DMNF3GW	MI	TTGTQHC
DMNF3GW	MN	DNA topoisomerase I (TOP1)
DMNF3GW	MT	DTT
DMNF3GW	MA	Inhibitor
DMNF3GW	RN	The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Invest New Drugs. 2012 June; 30(3): 1208-1210.
DMNF3GW	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/

DM0I8RZ	DI	DM0I8RZ
DM0I8RZ	DN	Affitope AD-01
DM0I8RZ	MI	TTE4KHA
DM0I8RZ	MN	Amyloid beta A4 protein (APP)
DM0I8RZ	MT	DTT
DM0I8RZ	RN	Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808.
DM0I8RZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313573/

DMIFJZD	DI	DMIFJZD
DMIFJZD	DN	AFM11
DMIFJZD	MI	TTW640A
DMIFJZD	MN	B-lymphocyte surface antigen B4 (CD19)
DMIFJZD	MT	DTT
DMIFJZD	MA	Inhibitor
DMIFJZD	RN	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
DMIFJZD	RU	https://pubmed.ncbi.nlm.nih.gov/25875246

DMIFJZD	DI	DMIFJZD
DMIFJZD	DN	AFM11
DMIFJZD	MI	TTUN7MC
DMIFJZD	MN	T-cell surface glycoprotein CD3 (CD3)
DMIFJZD	MT	DTT
DMIFJZD	MA	Inhibitor
DMIFJZD	RN	A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
DMIFJZD	RU	https://pubmed.ncbi.nlm.nih.gov/25875246

DMSX24U	DI	DMSX24U
DMSX24U	DN	AFO-18
DMSX24U	MI	TT3J5ZI
DMSX24U	MN	Cell mediated immunity response (CMIR)
DMSX24U	MT	DTT
DMSX24U	RN	ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health.
DMSX24U	RU	https://clinicaltrials.gov/ct2/show/NCT01009762

DMHBUMZ	DI	DMHBUMZ
DMHBUMZ	DN	AFP TCR
DMHBUMZ	MI	TT7AKW1
DMHBUMZ	MN	T-cell receptor (TCR)
DMHBUMZ	MT	DTT
DMHBUMZ	MA	Immunomodulator
DMHBUMZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBUMZ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TTH6V3D
DMY4WVK	MN	Cyclin-dependent kinase 1 (CDK1)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TT7HF4W
DMY4WVK	MN	Cyclin-dependent kinase 2 (CDK2)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMY4WVK	DI	DMY4WVK
DMY4WVK	DN	AG-024322
DMY4WVK	MI	TT0PG8F
DMY4WVK	MN	Cyclin-dependent kinase 4 (CDK4)
DMY4WVK	MT	DTT
DMY4WVK	MA	Inhibitor
DMY4WVK	RN	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
DMY4WVK	RU	https://pubmed.ncbi.nlm.nih.gov/19568282

DMFU58V	DI	DMFU58V
DMFU58V	DN	AG2034
DMFU58V	MI	TTCSJBZ
DMFU58V	MN	GAR transformylase (GART)
DMFU58V	MT	DTT
DMFU58V	MA	Modulator
DMFU58V	RN	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7.
DMFU58V	RU	https://pubmed.ncbi.nlm.nih.gov/10803927

DMYTJG7	DI	DMYTJG7
DMYTJG7	DN	AG-270
DMYTJG7	MI	TTSMPXQ
DMYTJG7	MN	S-adenosylmethionine synthase type-2 (MAT2A)
DMYTJG7	MT	DTT
DMYTJG7	MA	Inhibitor
DMYTJG7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYTJG7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZTMEJ	DI	DMZTMEJ
DMZTMEJ	DN	AG-270
DMZTMEJ	MI	TTSMPXQ
DMZTMEJ	MN	S-adenosylmethionine synthase type-2 (MAT2A)
DMZTMEJ	MT	DTT
DMZTMEJ	MA	Inhibitor
DMZTMEJ	RN	Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449.
DMZTMEJ	RU	https://pubmed.ncbi.nlm.nih.gov/33829783

DM7PLMJ	DI	DM7PLMJ
DM7PLMJ	DN	AG-707
DM7PLMJ	MI	TTHYBIX
DM7PLMJ	MN	Heat shock protein 70 (HSP70)
DM7PLMJ	MT	DTT
DM7PLMJ	MA	Modulator
DM7PLMJ	RN	A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41.
DM7PLMJ	RU	https://pubmed.ncbi.nlm.nih.gov/21767588

DMV6JFK	DI	DMV6JFK
DMV6JFK	DN	AGEN1181
DMV6JFK	MI	TTI2S1D
DMV6JFK	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMV6JFK	MT	DTT
DMV6JFK	MA	Inhibitor
DMV6JFK	RN	Clinical pipeline report, company report or official report of Agenus.
DMV6JFK	RU	https://agenusbio.com/agen1181-second-generation-anti-ctla-4/

DMAXVZ1	DI	DMAXVZ1
DMAXVZ1	DN	AGEN2373
DMAXVZ1	MI	TTPW9LJ
DMAXVZ1	MN	Co-stimulatory molecule 4-1BB (CD137)
DMAXVZ1	MT	DTT
DMAXVZ1	MA	Activator
DMAXVZ1	RN	Clinical pipeline report, company report or official report of Agenus.
DMAXVZ1	RU	https://agenusbio.com/agen2373-alpha-cd137/

DMVMIBY	DI	DMVMIBY
DMVMIBY	DN	AGG-523
DMVMIBY	MI	TTXSU2Y
DMVMIBY	MN	Aggrecanase (ADAMTS5)
DMVMIBY	MT	DTT
DMVMIBY	MA	Inhibitor
DMVMIBY	RN	Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23.
DMVMIBY	RU	https://pubmed.ncbi.nlm.nih.gov/21163358

DMVHPOX	DI	DMVHPOX
DMVHPOX	DN	AGN-242266
DMVHPOX	MI	TTS4UGC
DMVHPOX	MN	Farnesoid X-activated receptor (FXR)
DMVHPOX	MT	DTT
DMVHPOX	MA	Agonist
DMVHPOX	RN	Clinical pipeline report, company report or official report of AbbVie.
DMVHPOX	RU	https://www.abbvie.com/our-science/pipeline/agn-242266-fxr-agonist.html

DMU21JF	DI	DMU21JF
DMU21JF	DN	AGS-009
DMU21JF	MI	TT95SOA
DMU21JF	MN	Interferon alpha (IFNA)
DMU21JF	MT	DTT
DMU21JF	RN	Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
DMU21JF	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358492/

DMDUIO4	DI	DMDUIO4
DMDUIO4	DN	AGS-348
DMDUIO4	MI	TTABNSJ
DMDUIO4	MN	Pyruvate kinase (PK)
DMDUIO4	MT	DTT
DMDUIO4	MA	Modulator
DMDUIO4	RN	Clinical pipeline report, company report or official report of Agios Pharmaceuticals.
DMDUIO4	RU	http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=1919588

DML79KE	DI	DML79KE
DML79KE	DN	AGT-182
DML79KE	MI	TTCBFJO
DML79KE	MN	Insulin receptor (INSR)
DML79KE	MT	DTT
DML79KE	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DML79KE	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEAN5EW
DMHMT49	MN	Nitroreductase (NTR)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/9631515

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEX5D46
DMHMT49	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEOWDK1
DMHMT49	MN	Oxygen-insensitive NADPH nitroreductase B (nfsB)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Delamanid is not metabolized by Salmonella or human nitroreductases: a possible mechanism for the lack of mutagenicity. Regul Toxicol Pharmacol. 2017 Mar;84:1-8.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/27988333

DMHMT49	DI	DMHMT49
DMHMT49	DN	AI3-23606
DMHMT49	MI	DEKVGPX
DMHMT49	MN	Retro-nitroreductase (rNR)
DMHMT49	MT	DME
DMHMT49	MA	Metabolism
DMHMT49	RN	Retro-nitroreductase, a putative evolutionary precursor to Enterobacter cloacae strain 96-3 nitroreductase. Antioxid Redox Signal. 2001 Oct;3(5):747-55.
DMHMT49	RU	https://pubmed.ncbi.nlm.nih.gov/11761325

DMDA1UB	DI	DMDA1UB
DMDA1UB	DN	AI-850
DMDA1UB	MI	TTJGNVC
DMDA1UB	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMDA1UB	MT	DTT
DMDA1UB	MA	Modulator
DMDA1UB	RN	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
DMDA1UB	RU	https://pubmed.ncbi.nlm.nih.gov/15835739

DMDA1UB	DI	DMDA1UB
DMDA1UB	DN	AI-850
DMDA1UB	MI	TT63KYR
DMDA1UB	MN	Tubulin beta-1 chain (TUBB1)
DMDA1UB	MT	DTT
DMDA1UB	MA	Modulator
DMDA1UB	RN	Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55.
DMDA1UB	RU	https://pubmed.ncbi.nlm.nih.gov/15835739

DMSPBOW	DI	DMSPBOW
DMSPBOW	DN	AIC100
DMSPBOW	MI	TTCT6F7
DMSPBOW	MN	Intercellular adhesion molecule ICAM-1 (ICAM1)
DMSPBOW	MT	DTT
DMSPBOW	RN	Clinical pipeline report, company report or official report of AffyImmune Therapeutics.
DMSPBOW	RU	https://affyimmune.com/pipeline/

DMNHBMC	DI	DMNHBMC
DMNHBMC	DN	AIC-292
DMNHBMC	MI	TT84ETX
DMNHBMC	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMNHBMC	MT	DTT
DMNHBMC	MA	Inhibitor
DMNHBMC	RN	In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9.
DMNHBMC	RU	https://pubmed.ncbi.nlm.nih.gov/23959304

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TT27RFC
DMW9ZFS	MN	Opioid receptor delta (OPRD1)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Inhibitor
DMW9ZFS	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMW9ZFS	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TTQW87Y
DMW9ZFS	MN	Opioid receptor kappa (OPRK1)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Inhibitor
DMW9ZFS	RN	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
DMW9ZFS	RU	https://pubmed.ncbi.nlm.nih.gov/19027293

DMW9ZFS	DI	DMW9ZFS
DMW9ZFS	DN	AIKO-150
DMW9ZFS	MI	TTKWM86
DMW9ZFS	MN	Opioid receptor mu (MOP)
DMW9ZFS	MT	DTT
DMW9ZFS	MA	Antagonist
DMW9ZFS	RN	Clinical pipeline report, company report or official report of signaturerx.
DMW9ZFS	RU	http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids

DMHCBI0	DI	DMHCBI0
DMHCBI0	DN	AIP-303
DMHCBI0	MI	TT6EO5L
DMHCBI0	MN	Erbb2 tyrosine kinase receptor (HER2)
DMHCBI0	MT	DTT
DMHCBI0	RN	Clinical pipeline report, company report or official report of Adagene.
DMHCBI0	RU	https://www.advancedinnovativepartners.com/technology

DM6PN4H	DI	DM6PN4H
DM6PN4H	DN	AjvW2
DM6PN4H	MI	TT0IHXV
DM6PN4H	MN	DNA topoisomerase II (TOP2)
DM6PN4H	MT	DTT
DM6PN4H	MA	Inhibitor
DM6PN4H	RN	The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82.
DM6PN4H	RU	https://pubmed.ncbi.nlm.nih.gov/12423680

DM6PN4H	DI	DM6PN4H
DM6PN4H	DN	AjvW2
DM6PN4H	MI	TT38RM1
DM6PN4H	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DM6PN4H	MT	DTT
DM6PN4H	RN	Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
DM6PN4H	RU	https://pubmed.ncbi.nlm.nih.gov/11804648

DM4FOX0	DI	DM4FOX0
DM4FOX0	DN	AK107
DM4FOX0	MI	TTV8N19
DM4FOX0	MN	Immune checkpoint (ICH)
DM4FOX0	MT	DTT
DM4FOX0	MA	Inhibitor
DM4FOX0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4FOX0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9JU8L	DI	DM9JU8L
DM9JU8L	DN	AKP-501
DM9JU8L	MI	TT13GFV
DM9JU8L	MN	Follicle stimulating hormone (FSHB)
DM9JU8L	MT	DTT
DM9JU8L	MA	Modulator
DM9JU8L	RN	AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009 Apr;82(4):247-54.
DM9JU8L	RU	https://pubmed.ncbi.nlm.nih.gov/19183407

DMHD615	DI	DMHD615
DMHD615	DN	ALB-109564(a)
DMHD615	MI	TTYFKSZ
DMHD615	MN	Tubulin beta (TUBB)
DMHD615	MT	DTT
DMHD615	MA	Modulator
DMHD615	RN	2010 ASCO Annual Meeting
DMHD615	RU	http://meetinglibrary.asco.org/content/41250-74

DMYTIP4	DI	DMYTIP4
DMYTIP4	DN	Aleplasinin
DMYTIP4	MI	TT5QA2I
DMYTIP4	MN	Plasminogen activator inhibitor (PAI)
DMYTIP4	MT	DTT
DMYTIP4	MA	Inhibitor
DMYTIP4	RN	CN patent application no. 102046168, Pai-1 expression and activity inhibitors for the treatment of ocular disorders.
DMYTIP4	RU	http://www.google.com/patents/CN102046168A?cl=en

DMXMK5S	DI	DMXMK5S
DMXMK5S	DN	Alfa-interferon
DMXMK5S	MI	TTMQB37
DMXMK5S	MN	Interferon alpha/beta receptor 2 (IFNAR2)
DMXMK5S	MT	DTT
DMXMK5S	MA	Stimulator
DMXMK5S	RN	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
DMXMK5S	RU	https://pubmed.ncbi.nlm.nih.gov/18616415

DMGIAND	DI	DMGIAND
DMGIAND	DN	ALLO-501
DMGIAND	MI	TTW640A
DMGIAND	MN	B-lymphocyte surface antigen B4 (CD19)
DMGIAND	MT	DTT
DMGIAND	RN	Clinical pipeline report, company report or official report of Allogene Therapeutics.
DMGIAND	RU	https://www.allogene.com/pipeline#all0-501/501A

DMHE3MD	DI	DMHE3MD
DMHE3MD	DN	ALLO-715
DMHE3MD	MI	TTZ3P4W
DMHE3MD	MN	B-cell maturation protein (TNFRSF17)
DMHE3MD	MT	DTT
DMHE3MD	RN	Clinical pipeline report, company report or official report of Allogene Therapeutics.
DMHE3MD	RU	https://www.allogene.com/pipeline#all0-501/501A

DMCYV26	DI	DMCYV26
DMCYV26	DN	Allogeneic CART-19
DMCYV26	MI	TTW640A
DMCYV26	MN	B-lymphocyte surface antigen B4 (CD19)
DMCYV26	MT	DTT
DMCYV26	MA	CAR-T-Cell-Therapy
DMCYV26	RN	ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
DMCYV26	RU	https://clinicaltrials.gov/ct2/show/NCT02799550

DM4RHM5	DI	DM4RHM5
DM4RHM5	DN	Allogeneic CART-33
DM4RHM5	MI	TTJVYO3
DM4RHM5	MN	Myeloid cell surface antigen CD33 (CD33)
DM4RHM5	MT	DTT
DM4RHM5	MA	CAR-T-Cell-Therapy
DM4RHM5	RN	ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
DM4RHM5	RU	https://clinicaltrials.gov/ct2/show/NCT02799680

DMCSEUY	DI	DMCSEUY
DMCSEUY	DN	ALN-TTR01
DMCSEUY	MI	TTPOYU7
DMCSEUY	MN	Transthyretin messenger RNA (TTR mRNA)
DMCSEUY	MT	DTT
DMCSEUY	MA	Inhibitor
DMCSEUY	RN	Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.
DMCSEUY	RU	https://pubmed.ncbi.nlm.nih.gov/23984729

DM89DHO	DI	DM89DHO
DM89DHO	DN	ALN-VSP
DM89DHO	MI	TTBGTCW
DM89DHO	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DM89DHO	MT	DTT
DM89DHO	RN	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
DM89DHO	RU	http://www.alnylam.com/Programs-and-Pipeline/index.php

DMGFVYL	DI	DMGFVYL
DMGFVYL	DN	ALO-1567
DMGFVYL	MI	TTFBNVI
DMGFVYL	MN	Aldose reductase (AKR1B1)
DMGFVYL	MT	DTT
DMGFVYL	MA	Inhibitor
DMGFVYL	RN	Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol. 1991 Aug;32(2):221-7.
DMGFVYL	RU	https://pubmed.ncbi.nlm.nih.gov/1931471

DMIEKTF	DI	DMIEKTF
DMIEKTF	DN	Alofanib
DMIEKTF	MI	TTGJVQM
DMIEKTF	MN	Fibroblast growth factor receptor 2 (FGFR2)
DMIEKTF	MT	DTT
DMIEKTF	MA	Inhibitor
DMIEKTF	RN	Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156.
DMIEKTF	RU	https://pubmed.ncbi.nlm.nih.gov/27919550

DMP9VXQ	DI	DMP9VXQ
DMP9VXQ	DN	ALPHA-FMH
DMP9VXQ	MI	TTV9GOF
DMP9VXQ	MN	Histidine decarboxylase (HDC)
DMP9VXQ	MT	DTT
DMP9VXQ	MA	Modulator
DMP9VXQ	RN	Alpha-Fluoromethylhistidine. Kinetics of uptake and inhibition of histamine synthesis in basophil (2H3) cell cultures. Mol Pharmacol. 1985 Aug;28(2):191-9.
DMP9VXQ	RU	https://pubmed.ncbi.nlm.nih.gov/2410770

DMBVM1Q	DI	DMBVM1Q
DMBVM1Q	DN	AlphaMedix
DMBVM1Q	MI	TTOMNR9
DMBVM1Q	MN	Somatostatin receptor (SSTR)
DMBVM1Q	MT	DTT
DMBVM1Q	MA	Activator
DMBVM1Q	RN	Clinical pipeline report, company report or official report of Orano Med.
DMBVM1Q	RU	https://www.oranomed.com/en/pipeline

DMTD4EF	DI	DMTD4EF
DMTD4EF	DN	ALPN-202
DMTD4EF	MI	TTI2S1D
DMTD4EF	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMTD4EF	MT	DTT
DMTD4EF	MA	Inhibitor
DMTD4EF	RN	Clinical pipeline report, company report or official report of Alpine Immune Sciences.
DMTD4EF	RU	https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf

DMTD4EF	DI	DMTD4EF
DMTD4EF	DN	ALPN-202
DMTD4EF	MI	TT8ZLTI
DMTD4EF	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMTD4EF	MT	DTT
DMTD4EF	MA	Inhibitor
DMTD4EF	RN	Clinical pipeline report, company report or official report of Alpine Immune Sciences.
DMTD4EF	RU	https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TT9VGXW
DMUJCBT	MN	Angiopoietin 1 receptor (TEK)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTXABCW
DMUJCBT	MN	NT-3 growth factor receptor (TrkC)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMUJCBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTNDSF4
DMUJCBT	MN	Proto-oncogene c-Met (MET)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTTDVOJ
DMUJCBT	MN	Tropomyosin-related kinase A (TrkA)
DMUJCBT	MT	DTT
DMUJCBT	MA	Inhibitor
DMUJCBT	RN	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
DMUJCBT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28270010

DMUJCBT	DI	DMUJCBT
DMUJCBT	DN	Altiratinib
DMUJCBT	MI	TTUTJGQ
DMUJCBT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUJCBT	MT	DTT
DMUJCBT	MA	Antagonist
DMUJCBT	RN	Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
DMUJCBT	RU	http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701

DM6KU93	DI	DM6KU93
DM6KU93	DN	Alvespimycin hydrochloride
DM6KU93	MI	TT78R5H
DM6KU93	MN	Heat shock protein 90 alpha (HSP90A)
DM6KU93	MT	DTT
DM6KU93	MA	Inhibitor
DM6KU93	RN	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41.
DM6KU93	RU	https://pubmed.ncbi.nlm.nih.gov/18260120

DMBGI74	DI	DMBGI74
DMBGI74	DN	ALX-0141
DMBGI74	MI	TT9E8HR
DMBGI74	MN	Osteoclast differentiation factor (ODF)
DMBGI74	MT	DTT
DMBGI74	MA	Inhibitor
DMBGI74	RN	Clinical pipeline report, company report or official report of Ablynx.
DMBGI74	RU	http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0141/

DMIRYM8	DI	DMIRYM8
DMIRYM8	DN	ALX-0651
DMIRYM8	MI	TTBID49
DMIRYM8	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMIRYM8	MT	DTT
DMIRYM8	MA	Inhibitor
DMIRYM8	RN	Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
DMIRYM8	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011214/

DMJ8ACF	DI	DMJ8ACF
DMJ8ACF	DN	ALX-0761
DMJ8ACF	MI	TTG0MT6
DMJ8ACF	MN	Interleukin-17 (IL17)
DMJ8ACF	MT	DTT
DMJ8ACF	MA	Modulator
DMJ8ACF	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMJ8ACF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMJ8ACF	DI	DMJ8ACF
DMJ8ACF	DN	ALX-0761
DMJ8ACF	MI	TTVMO5W
DMJ8ACF	MN	Interleukin-25 (IL25)
DMJ8ACF	MT	DTT
DMJ8ACF	MA	Modulator
DMJ8ACF	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMJ8ACF	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMLJWPN	DI	DMLJWPN
DMLJWPN	DN	Alx-5407
DMLJWPN	MI	TTHJTF7
DMLJWPN	MN	Glycine transporter GlyT-1 (SLC6A9)
DMLJWPN	MT	DTT
DMLJWPN	MA	Blocker
DMLJWPN	RN	ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20.
DMLJWPN	RU	https://pubmed.ncbi.nlm.nih.gov/11723250

DMVXRYC	DI	DMVXRYC
DMVXRYC	DN	AM-211
DMVXRYC	MI	TTQDMX5
DMVXRYC	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DMVXRYC	MT	DTT
DMVXRYC	MA	Antagonist
DMVXRYC	RN	Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 Jul;338(1):290-301.
DMVXRYC	RU	https://pubmed.ncbi.nlm.nih.gov/21487069

DM7Z8NP	DI	DM7Z8NP
DM7Z8NP	DN	AM-461
DM7Z8NP	MI	TTQDMX5
DM7Z8NP	MN	Prostaglandin D2 receptor 2 (PTGDR2)
DM7Z8NP	MT	DTT
DM7Z8NP	MA	Antagonist
DM7Z8NP	RN	A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011 Dec;21(12):1931-6.
DM7Z8NP	RU	https://pubmed.ncbi.nlm.nih.gov/22082220

DM7CD8Z	DI	DM7CD8Z
DM7CD8Z	DN	AMAP-102
DM7CD8Z	MI	TTYSN63
DM7CD8Z	MN	5-HT 2 receptor (5HT2R)
DM7CD8Z	MT	DTT
DM7CD8Z	MA	Antagonist
DM7CD8Z	RN	Clinical pipeline report, company report or official report of Anamar.
DM7CD8Z	RU	http://anamar.com/rd/project-amap102/

DMFELMQ	DI	DMFELMQ
DMFELMQ	DN	AMEP
DMFELMQ	MI	TTH4QIS
DMFELMQ	MN	Integrin alpha-5/beta-1 (ITGA5/B1)
DMFELMQ	MT	DTT
DMFELMQ	MA	Modulator
DMFELMQ	RN	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
DMFELMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25781650

DMFELMQ	DI	DMFELMQ
DMFELMQ	DN	AMEP
DMFELMQ	MI	TT69TQN
DMFELMQ	MN	Integrin alpha-V/beta-3 (ITGAV/B3)
DMFELMQ	MT	DTT
DMFELMQ	MA	Modulator
DMFELMQ	RN	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
DMFELMQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25781650

DMKF1O2	DI	DMKF1O2
DMKF1O2	DN	AMG 119
DMKF1O2	MI	TT1C9K6
DMKF1O2	MN	Delta-like protein 3 (DLL3)
DMKF1O2	MT	DTT
DMKF1O2	MA	Inhibitor
DMKF1O2	RN	Clinical pipeline report, company report or official report of Amgen.
DMKF1O2	RU	https://www.amgenpipeline.com/

DMM0HNF	DI	DMM0HNF
DMM0HNF	DN	AMG 160
DMM0HNF	MI	TT9G4N0
DMM0HNF	MN	Glutamate carboxypeptidase II (GCPII)
DMM0HNF	MT	DTT
DMM0HNF	MA	Inhibitor
DMM0HNF	RN	Clinical pipeline report, company report or official report of Amgen.
DMM0HNF	RU	https://www.amgenpipeline.com/

DMM0HNF	DI	DMM0HNF
DMM0HNF	DN	AMG 160
DMM0HNF	MI	TTUN7MC
DMM0HNF	MN	T-cell surface glycoprotein CD3 (CD3)
DMM0HNF	MT	DTT
DMM0HNF	MA	Inhibitor
DMM0HNF	RN	Clinical pipeline report, company report or official report of Amgen.
DMM0HNF	RU	https://www.amgenpipeline.com/

DMUETI2	DI	DMUETI2
DMUETI2	DN	AMG 167
DMUETI2	MI	TTYRO4F
DMUETI2	MN	Sclerostin (SOST)
DMUETI2	MT	DTT
DMUETI2	MA	Modulator
DMUETI2	RN	Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448.
DMUETI2	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/

DMS72GN	DI	DMS72GN
DMS72GN	DN	AMG 172
DMS72GN	MI	TTNCIE0
DMS72GN	MN	CD70 antigen (CD27-L)
DMS72GN	MT	DTT
DMS72GN	MA	Modulator
DMS72GN	RN	National Cancer Institute Drug Dictionary (drug id 721679).
DMS72GN	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=721679

DM0Q7NO	DI	DM0Q7NO
DM0Q7NO	DN	AMG 176
DM0Q7NO	MI	TTL53M6
DM0Q7NO	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM0Q7NO	MT	DTT
DM0Q7NO	MA	Inhibitor
DM0Q7NO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0Q7NO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMWG2K6	DI	DMWG2K6
DMWG2K6	DN	AMG 199
DMWG2K6	MI	TTVO0JU
DMWG2K6	MN	Mucin-17 (MUC17)
DMWG2K6	MT	DTT
DMWG2K6	MA	Inhibitor
DMWG2K6	RN	Clinical pipeline report, company report or official report of Amgen.
DMWG2K6	RU	https://www.amgenpipeline.com/

DMWG2K6	DI	DMWG2K6
DMWG2K6	DN	AMG 199
DMWG2K6	MI	TTUN7MC
DMWG2K6	MN	T-cell surface glycoprotein CD3 (CD3)
DMWG2K6	MT	DTT
DMWG2K6	MA	Inhibitor
DMWG2K6	RN	Clinical pipeline report, company report or official report of Amgen.
DMWG2K6	RU	https://www.amgenpipeline.com/

DMA1I04	DI	DMA1I04
DMA1I04	DN	AMG 211
DMA1I04	MI	TTY6DTE
DMA1I04	MN	Carcinoembryonic antigen CEA (CD66e)
DMA1I04	MT	DTT
DMA1I04	MA	Immunomodulator
DMA1I04	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA1I04	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMLQJ5P	DI	DMLQJ5P
DMLQJ5P	DN	AMG 228
DMLQJ5P	MI	TTG6LA7
DMLQJ5P	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMLQJ5P	MT	DTT
DMLQJ5P	MA	Agonist
DMLQJ5P	RN	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93.
DMLQJ5P	RU	https://pubmed.ncbi.nlm.nih.gov/30253804

DMXYCZV	DI	DMXYCZV
DMXYCZV	DN	AMG 256
DMXYCZV	MI	TTZO9B0
DMXYCZV	MN	Interleukin 21 receptor (IL21R)
DMXYCZV	MT	DTT
DMXYCZV	MA	Agonist
DMXYCZV	RN	Clinical pipeline report, company report or official report of Amgen.
DMXYCZV	RU	https://www.amgenpipeline.com/

DM92YWD	DI	DM92YWD
DM92YWD	DN	AMG 282
DM92YWD	MI	TT5MD4P
DM92YWD	MN	Interleukin-33 (IL33)
DM92YWD	MT	DTT
DM92YWD	RN	Clinical pipeline report, company report or official report of Amgen.
DM92YWD	RU	http://www.amgenpipeline.com/pipeline/

DM9P0NA	DI	DM9P0NA
DM9P0NA	DN	AMG 319
DM9P0NA	MI	TTGBPJE
DM9P0NA	MN	PI3-kinase delta (PIK3CD)
DM9P0NA	MT	DTT
DM9P0NA	MA	Inhibitor
DM9P0NA	RN	National Cancer Institute Drug Dictionary (drug id 696292).
DM9P0NA	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=696292

DMC3G2E	DI	DMC3G2E
DMC3G2E	DN	AMG 330
DMC3G2E	MI	TTJVYO3
DMC3G2E	MN	Myeloid cell surface antigen CD33 (CD33)
DMC3G2E	MT	DTT
DMC3G2E	MA	Inhibitor
DMC3G2E	RN	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.
DMC3G2E	RU	https://pubmed.ncbi.nlm.nih.gov/24674885

DMC3G2E	DI	DMC3G2E
DMC3G2E	DN	AMG 330
DMC3G2E	MI	TTUN7MC
DMC3G2E	MN	T-cell surface glycoprotein CD3 (CD3)
DMC3G2E	MT	DTT
DMC3G2E	MA	Inhibitor
DMC3G2E	RN	Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.
DMC3G2E	RU	https://pubmed.ncbi.nlm.nih.gov/24674885

DM7CNTG	DI	DM7CNTG
DM7CNTG	DN	AMG 397
DM7CNTG	MI	TTL53M6
DM7CNTG	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM7CNTG	MT	DTT
DM7CNTG	MA	Inhibitor
DM7CNTG	RN	Clinical pipeline report, company report or official report of Amgen.
DM7CNTG	RU	https://www.amgenpipeline.com/

DMVQX5K	DI	DMVQX5K
DMVQX5K	DN	AMG 404
DMVQX5K	MI	TTNBFWK
DMVQX5K	MN	Programmed cell death protein 1 (PD-1)
DMVQX5K	MT	DTT
DMVQX5K	MA	Inhibitor
DMVQX5K	RN	ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.
DMVQX5K	RU	https://clinicaltrials.gov/ct2/show/NCT03853109

DMYFZLA	DI	DMYFZLA
DMYFZLA	DN	AMG 420
DMYFZLA	MI	TTZ3P4W
DMYFZLA	MN	B-cell maturation protein (TNFRSF17)
DMYFZLA	MT	DTT
DMYFZLA	MA	Inhibitor
DMYFZLA	RN	Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.
DMYFZLA	RU	https://pubmed.ncbi.nlm.nih.gov/31895611

DMLAP8F	DI	DMLAP8F
DMLAP8F	DN	AMG 424
DMLAP8F	MI	TTPURFN
DMLAP8F	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMLAP8F	MT	DTT
DMLAP8F	MA	Inhibitor
DMLAP8F	RN	Clinical pipeline report, company report or official report of Amgen.
DMLAP8F	RU	https://www.amgenpipeline.com/

DMLAP8F	DI	DMLAP8F
DMLAP8F	DN	AMG 424
DMLAP8F	MI	TTUN7MC
DMLAP8F	MN	T-cell surface glycoprotein CD3 (CD3)
DMLAP8F	MT	DTT
DMLAP8F	MA	Inhibitor
DMLAP8F	RN	Clinical pipeline report, company report or official report of Amgen.
DMLAP8F	RU	https://www.amgenpipeline.com/

DMI7JO6	DI	DMI7JO6
DMI7JO6	DN	AMG 427
DMI7JO6	MI	TTGJCWZ
DMI7JO6	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMI7JO6	MT	DTT
DMI7JO6	MA	Inhibitor
DMI7JO6	RN	Clinical pipeline report, company report or official report of Amgen.
DMI7JO6	RU	https://www.amgenpipeline.com/

DMI7JO6	DI	DMI7JO6
DMI7JO6	DN	AMG 427
DMI7JO6	MI	TTUN7MC
DMI7JO6	MN	T-cell surface glycoprotein CD3 (CD3)
DMI7JO6	MT	DTT
DMI7JO6	MA	Inhibitor
DMI7JO6	RN	Clinical pipeline report, company report or official report of Amgen.
DMI7JO6	RU	https://www.amgenpipeline.com/

DMG64PE	DI	DMG64PE
DMG64PE	DN	AMG 506
DMG64PE	MI	TTPW9LJ
DMG64PE	MN	Co-stimulatory molecule 4-1BB (CD137)
DMG64PE	MT	DTT
DMG64PE	MA	Inhibitor
DMG64PE	RN	Clinical pipeline report, company report or official report of Amgen.
DMG64PE	RU	https://www.amgenpipeline.com/

DMG64PE	DI	DMG64PE
DMG64PE	DN	AMG 506
DMG64PE	MI	TTGPQ0F
DMG64PE	MN	Prolyl endopeptidase FAP (FAP)
DMG64PE	MT	DTT
DMG64PE	MA	Inhibitor
DMG64PE	RN	Clinical pipeline report, company report or official report of Amgen.
DMG64PE	RU	https://www.amgenpipeline.com/

DM2POGY	DI	DM2POGY
DM2POGY	DN	AMG 509
DM2POGY	MI	TT9E64S
DM2POGY	MN	Metalloreductase STEAP1 (STEAP1)
DM2POGY	MT	DTT
DM2POGY	MA	Inhibitor
DM2POGY	RN	Clinical pipeline report, company report or official report of Amgen.
DM2POGY	RU	https://www.amgenpipeline.com/

DMNEFQ6	DI	DMNEFQ6
DMNEFQ6	DN	AMG 529
DMNEFQ6	MI	TTYM94H
DMNEFQ6	MN	Asialoglycoprotein receptor 1 (ASGR1)
DMNEFQ6	MT	DTT
DMNEFQ6	MA	Inhibitor
DMNEFQ6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNEFQ6	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMQ0N5Z	DI	DMQ0N5Z
DMQ0N5Z	DN	AMG 562
DMQ0N5Z	MI	TTW640A
DMQ0N5Z	MN	B-lymphocyte surface antigen B4 (CD19)
DMQ0N5Z	MT	DTT
DMQ0N5Z	MA	Inhibitor
DMQ0N5Z	RN	Clinical pipeline report, company report or official report of Amgen.
DMQ0N5Z	RU	https://www.amgenpipeline.com/

DMRMC7U	DI	DMRMC7U
DMRMC7U	DN	AMG 579
DMRMC7U	MI	TTJW4LU
DMRMC7U	MN	Phosphodiesterase 10A (PDE10)
DMRMC7U	MT	DTT
DMRMC7U	MA	Inhibitor
DMRMC7U	RN	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.
DMRMC7U	RU	https://pubmed.ncbi.nlm.nih.gov/25062128

DMJFKW3	DI	DMJFKW3
DMJFKW3	DN	AMG 595
DMJFKW3	MI	TTGKNB4
DMJFKW3	MN	Epidermal growth factor receptor (EGFR)
DMJFKW3	MT	DTT
DMJFKW3	MA	Modulator
DMJFKW3	RN	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
DMJFKW3	RU	https://pubmed.ncbi.nlm.nih.gov/25931519

DM4G1SP	DI	DM4G1SP
DM4G1SP	DN	AMG 596
DM4G1SP	MI	TTZ6B2I
DM4G1SP	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM4G1SP	MT	DTT
DM4G1SP	MA	Inhibitor
DM4G1SP	RN	Clinical pipeline report, company report or official report of Amgen.
DM4G1SP	RU	https://www.amgenpipeline.com/

DM4G1SP	DI	DM4G1SP
DM4G1SP	DN	AMG 596
DM4G1SP	MI	TTUN7MC
DM4G1SP	MN	T-cell surface glycoprotein CD3 (CD3)
DM4G1SP	MT	DTT
DM4G1SP	MA	Inhibitor
DM4G1SP	RN	Clinical pipeline report, company report or official report of Amgen.
DM4G1SP	RU	https://www.amgenpipeline.com/

DMA3B9T	DI	DMA3B9T
DMA3B9T	DN	AMG 673
DMA3B9T	MI	TTJVYO3
DMA3B9T	MN	Myeloid cell surface antigen CD33 (CD33)
DMA3B9T	MT	DTT
DMA3B9T	MA	Inhibitor
DMA3B9T	RN	Clinical pipeline report, company report or official report of Amgen.
DMA3B9T	RU	https://www.amgenpipeline.com/

DMA3B9T	DI	DMA3B9T
DMA3B9T	DN	AMG 673
DMA3B9T	MI	TTUN7MC
DMA3B9T	MN	T-cell surface glycoprotein CD3 (CD3)
DMA3B9T	MT	DTT
DMA3B9T	MA	Inhibitor
DMA3B9T	RN	Clinical pipeline report, company report or official report of Amgen.
DMA3B9T	RU	https://www.amgenpipeline.com/

DM6IT3M	DI	DM6IT3M
DM6IT3M	DN	AMG 701
DM6IT3M	MI	TTZ3P4W
DM6IT3M	MN	B-cell maturation protein (TNFRSF17)
DM6IT3M	MT	DTT
DM6IT3M	MA	Inhibitor
DM6IT3M	RN	Clinical pipeline report, company report or official report of Amgen.
DM6IT3M	RU	https://www.amgenpipeline.com/

DM6IT3M	DI	DM6IT3M
DM6IT3M	DN	AMG 701
DM6IT3M	MI	TTUN7MC
DM6IT3M	MN	T-cell surface glycoprotein CD3 (CD3)
DM6IT3M	MT	DTT
DM6IT3M	MA	Inhibitor
DM6IT3M	RN	Clinical pipeline report, company report or official report of Amgen.
DM6IT3M	RU	https://www.amgenpipeline.com/

DMLYP2N	DI	DMLYP2N
DMLYP2N	DN	AMG 757
DMLYP2N	MI	TT1C9K6
DMLYP2N	MN	Delta-like protein 3 (DLL3)
DMLYP2N	MT	DTT
DMLYP2N	MA	Inhibitor
DMLYP2N	RN	Clinical pipeline report, company report or official report of Amgen.
DMLYP2N	RU	https://www.amgenpipeline.com/

DMLYP2N	DI	DMLYP2N
DMLYP2N	DN	AMG 757
DMLYP2N	MI	TTUN7MC
DMLYP2N	MN	T-cell surface glycoprotein CD3 (CD3)
DMLYP2N	MT	DTT
DMLYP2N	MA	Inhibitor
DMLYP2N	RN	Clinical pipeline report, company report or official report of Amgen.
DMLYP2N	RU	https://www.amgenpipeline.com/

DMTGZN8	DI	DMTGZN8
DMTGZN8	DN	AMG 780
DMTGZN8	MI	TTWNQ1T
DMTGZN8	MN	Angiopoietin-1 (ANGPT1)
DMTGZN8	MT	DTT
DMTGZN8	MA	Modulator
DMTGZN8	RN	Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022.
DMTGZN8	RU	http://cancerres.aacrjournals.org/content/74/19_Supplement/1022

DMEIMBP	DI	DMEIMBP
DMEIMBP	DN	AMG 811
DMEIMBP	MI	TT93WF5
DMEIMBP	MN	Interferon-gamma (IFNG)
DMEIMBP	MT	DTT
DMEIMBP	MA	Modulator
DMEIMBP	RN	Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
DMEIMBP	RU	https://pubmed.ncbi.nlm.nih.gov/25213774

DMB6Q19	DI	DMB6Q19
DMB6Q19	DN	AMG 820
DMB6Q19	MI	TT731LW
DMB6Q19	MN	Colony stimulating factor-1 receptor (CSF-1R)
DMB6Q19	MT	DTT
DMB6Q19	MA	Modulator
DMB6Q19	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMB6Q19	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMB6Q19	DI	DMB6Q19
DMB6Q19	DN	AMG 820
DMB6Q19	MI	TTC70AJ
DMB6Q19	MN	Granulocyte colony-stimulating factor receptor (G-CSF-R)
DMB6Q19	MT	DTT
DMB6Q19	MA	Inhibitor
DMB6Q19	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMB6Q19	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM1FJ9C	DI	DM1FJ9C
DM1FJ9C	DN	AMG 876
DM1FJ9C	MI	TTUPB12
DM1FJ9C	MN	Measles virus Fusion glycoprotein (MeV F)
DM1FJ9C	MT	DTT
DM1FJ9C	MA	Modulator
DM1FJ9C	RN	Clinical pipeline report, company report or official report of Amgen.
DM1FJ9C	RU	http://www.amgenpipeline.com/pipeline/

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TTPS3C0
DMASGXJ	MN	Aurora kinase A (AURKA)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TT5LS6T
DMASGXJ	MN	Aurora kinase B (AURKB)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMASGXJ	DI	DMASGXJ
DMASGXJ	DN	AMG 900
DMASGXJ	MI	TTLYXIT
DMASGXJ	MN	Aurora kinase C (AURKC)
DMASGXJ	MT	DTT
DMASGXJ	MA	Modulator
DMASGXJ	RN	Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
DMASGXJ	RU	https://pubmed.ncbi.nlm.nih.gov/20935223

DMCG7XL	DI	DMCG7XL
DMCG7XL	DN	AMG 910
DMCG7XL	MI	TT6PKBX
DMCG7XL	MN	Claudin-18 (CLDN18)
DMCG7XL	MT	DTT
DMCG7XL	MA	Inhibitor
DMCG7XL	RN	Clinical pipeline report, company report or official report of Amgen.
DMCG7XL	RU	https://www.amgenpipeline.com/

DMCG7XL	DI	DMCG7XL
DMCG7XL	DN	AMG 910
DMCG7XL	MI	TTUN7MC
DMCG7XL	MN	T-cell surface glycoprotein CD3 (CD3)
DMCG7XL	MT	DTT
DMCG7XL	MA	Inhibitor
DMCG7XL	RN	Clinical pipeline report, company report or official report of Amgen.
DMCG7XL	RU	https://www.amgenpipeline.com/

DMZQ2DK	DI	DMZQ2DK
DMZQ2DK	DN	AMG 986
DMZQ2DK	MI	TTJ8E43
DMZQ2DK	MN	Apelin receptor (APLNR)
DMZQ2DK	MT	DTT
DMZQ2DK	MA	Agonist
DMZQ2DK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZQ2DK	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMEHOVF	DI	DMEHOVF
DMEHOVF	DN	AMG-139
DMEHOVF	MI	TTC1GLB
DMEHOVF	MN	Interleukin-23 (IL23)
DMEHOVF	MT	DTT
DMEHOVF	RN	Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
DMEHOVF	RU	https://pubmed.ncbi.nlm.nih.gov/25205227

DMSHK23	DI	DMSHK23
DMSHK23	DN	AMG-191
DMSHK23	MI	TTX41N9
DMSHK23	MN	Tyrosine-protein kinase Kit (KIT)
DMSHK23	MT	DTT
DMSHK23	MA	Inhibitor
DMSHK23	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029529)
DMSHK23	RU	http://adisinsight.springer.com/drugs/800029529

DMJQDUC	DI	DMJQDUC
DMJQDUC	DN	Aminoguanidine
DMJQDUC	MI	TTFZYTO
DMJQDUC	MN	C-C chemokine receptor type 2 (CCR2)
DMJQDUC	MT	DTT
DMJQDUC	MA	Antagonist
DMJQDUC	RN	Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005.
DMJQDUC	RU	http://www.aegis.com/news/bw/2005/BW050801.html

DMJQDUC	DI	DMJQDUC
DMJQDUC	DN	Aminoguanidine
DMJQDUC	MI	TTF10I9
DMJQDUC	MN	Nitric-oxide synthase inducible (NOS2)
DMJQDUC	MT	DTT
DMJQDUC	MA	Inhibitor
DMJQDUC	RN	Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.
DMJQDUC	RU	https://pubmed.ncbi.nlm.nih.gov/19572977

DMH9M62	DI	DMH9M62
DMH9M62	DN	AMP-224
DMH9M62	MI	TTNBFWK
DMH9M62	MN	Programmed cell death protein 1 (PD-1)
DMH9M62	MT	DTT
DMH9M62	MA	Modulator
DMH9M62	RN	National Cancer Institute Drug Dictionary (drug id 700595).
DMH9M62	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=700595

DMT27PA	DI	DMT27PA
DMT27PA	DN	AMV564
DMT27PA	MI	TTJVYO3
DMT27PA	MN	Myeloid cell surface antigen CD33 (CD33)
DMT27PA	MT	DTT
DMT27PA	MA	Modulator
DMT27PA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMT27PA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR35U4	DI	DMR35U4
DMR35U4	DN	AMXT1501
DMR35U4	MI	TTJR4Z5
DMR35U4	MN	Polyamine transport (Poly trans)
DMR35U4	MT	DTT
DMR35U4	MA	Inhibitor
DMR35U4	RN	AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. 2013 Sep 15;133(6):1323-33.
DMR35U4	RU	https://pubmed.ncbi.nlm.nih.gov/23457004

DM8B2WQ	DI	DM8B2WQ
DM8B2WQ	DN	AN-2718
DM8B2WQ	MI	TT37GL6
DM8B2WQ	MN	Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS)
DM8B2WQ	MT	DTT
DM8B2WQ	MA	Inhibitor
DM8B2WQ	RN	Metalloid compounds as drugs. Res Pharm Sci. 2013 Jul-Sep; 8(3): 145-158.
DM8B2WQ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764666/

DM67OU4	DI	DM67OU4
DM67OU4	DN	ANAVEX 2-73
DM67OU4	MI	TTZ9SOR
DM67OU4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM67OU4	MT	DTT
DM67OU4	MA	Agonist
DM67OU4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM67OU4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM67OU4	DI	DM67OU4
DM67OU4	DN	ANAVEX 2-73
DM67OU4	MI	TT5TPI6
DM67OU4	MN	Opioid receptor sigma 1 (OPRS1)
DM67OU4	MT	DTT
DM67OU4	MA	Agonist
DM67OU4	RN	2011 Pipeline of Anavex.
DM67OU4	RU	http://anavex.com/pipeline.html

DM39QWN	DI	DM39QWN
DM39QWN	DN	ANS-6637
DM39QWN	MI	TTFLN4T
DM39QWN	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DM39QWN	MT	DTT
DM39QWN	MA	Inhibitor
DM39QWN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM39QWN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3OFZC	DI	DM3OFZC
DM3OFZC	DN	Anti-BCMA CAR T cells
DM3OFZC	MI	TTZ3P4W
DM3OFZC	MN	B-cell maturation protein (TNFRSF17)
DM3OFZC	MT	DTT
DM3OFZC	MA	CAR-T-Cell-Therapy
DM3OFZC	RN	ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma
DM3OFZC	RU	https://clinicaltrials.gov/ct2/show/NCT03559764

DMNFO2B	DI	DMNFO2B
DMNFO2B	DN	Anti-BCMA CAR T cells
DMNFO2B	MI	TTZ3P4W
DMNFO2B	MN	B-cell maturation protein (TNFRSF17)
DMNFO2B	MT	DTT
DMNFO2B	MA	CAR-T-Cell-Therapy
DMNFO2B	RN	ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
DMNFO2B	RU	https://clinicaltrials.gov/ct2/show/NCT02215967

DMUKNDO	DI	DMUKNDO
DMUKNDO	DN	Anti-BCMA CART Cells
DMUKNDO	MI	TTZ3P4W
DMUKNDO	MN	B-cell maturation protein (TNFRSF17)
DMUKNDO	MT	DTT
DMUKNDO	MA	CAR-T-Cell-Therapy
DMUKNDO	RN	ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
DMUKNDO	RU	https://clinicaltrials.gov/ct2/show/NCT03767725

DM2TFUD	DI	DM2TFUD
DM2TFUD	DN	Anti-BCMA CAR-T cells
DM2TFUD	MI	TTZ3P4W
DM2TFUD	MN	B-cell maturation protein (TNFRSF17)
DM2TFUD	MT	DTT
DM2TFUD	MA	CAR-T-Cell-Therapy
DM2TFUD	RN	ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
DM2TFUD	RU	https://clinicaltrials.gov/ct2/show/NCT03093168

DMK25QD	DI	DMK25QD
DMK25QD	DN	Anti-BCMA CAR-T cells
DMK25QD	MI	TTZ3P4W
DMK25QD	MN	B-cell maturation protein (TNFRSF17)
DMK25QD	MT	DTT
DMK25QD	MA	CAR-T-Cell-Therapy
DMK25QD	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMK25QD	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMYIZFW	DI	DMYIZFW
DMYIZFW	DN	Anti-CD123 CAR-T cells
DMYIZFW	MI	TTENHJ0
DMYIZFW	MN	Interleukin 3 receptor alpha (IL3RA)
DMYIZFW	MT	DTT
DMYIZFW	MA	CAR-T-Cell-Therapy
DMYIZFW	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMYIZFW	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DM82OS7	DI	DM82OS7
DM82OS7	DN	Anti-CD123 CAR-T treatment
DM82OS7	MI	TTENHJ0
DM82OS7	MN	Interleukin 3 receptor alpha (IL3RA)
DM82OS7	MT	DTT
DM82OS7	MA	CAR-T-Cell-Therapy
DM82OS7	RN	ClinicalTrials.gov (NCT03672851) Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
DM82OS7	RU	https://clinicaltrials.gov/ct2/show/NCT03672851

DMGUM90	DI	DMGUM90
DMGUM90	DN	Anti-CD133-CAR vector-transduced T cells
DMGUM90	MI	TTXMZ81
DMGUM90	MN	Prominin-1 (PROM1)
DMGUM90	MT	DTT
DMGUM90	MA	CAR-T-Cell-Therapy
DMGUM90	RN	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
DMGUM90	RU	https://clinicaltrials.gov/ct2/show/NCT02541370

DMCABUR	DI	DMCABUR
DMCABUR	DN	Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR	MI	TTW640A
DMCABUR	MN	B-lymphocyte surface antigen B4 (CD19)
DMCABUR	MT	DTT
DMCABUR	MA	CAR-T-Cell-Therapy(Dual specific)
DMCABUR	RN	ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
DMCABUR	RU	https://clinicaltrials.gov/ct2/show/NCT03271515

DMCABUR	DI	DMCABUR
DMCABUR	DN	Anti-CD19 anti-CD20 Bispecific CAR-T
DMCABUR	MI	TTUE541
DMCABUR	MN	Leukocyte surface antigen Leu-16 (CD20)
DMCABUR	MT	DTT
DMCABUR	MA	CAR-T-Cell-Therapy(Dual specific)
DMCABUR	RN	ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
DMCABUR	RU	https://clinicaltrials.gov/ct2/show/NCT03271515

DMH789J	DI	DMH789J
DMH789J	DN	AntiCD19 CART
DMH789J	MI	TTW640A
DMH789J	MN	B-lymphocyte surface antigen B4 (CD19)
DMH789J	MT	DTT
DMH789J	MA	CAR-T-Cell-Therapy
DMH789J	RN	ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
DMH789J	RU	https://clinicaltrials.gov/ct2/show/NCT03434769

DM9W1BS	DI	DM9W1BS
DM9W1BS	DN	Anti-CD19 CAR-T
DM9W1BS	MI	TTW640A
DM9W1BS	MN	B-lymphocyte surface antigen B4 (CD19)
DM9W1BS	MT	DTT
DM9W1BS	MA	CAR-T-Cell-Therapy
DM9W1BS	RN	ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
DM9W1BS	RU	https://clinicaltrials.gov/ct2/show/NCT03110640

DMW549Y	DI	DMW549Y
DMW549Y	DN	Anti-CD19 CART Cells
DMW549Y	MI	TTW640A
DMW549Y	MN	B-lymphocyte surface antigen B4 (CD19)
DMW549Y	MT	DTT
DMW549Y	MA	CAR-T-Cell-Therapy
DMW549Y	RN	ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
DMW549Y	RU	https://clinicaltrials.gov/ct2/show/NCT03767725

DMUQ3C1	DI	DMUQ3C1
DMUQ3C1	DN	Anti-CD19 CAR-T cells
DMUQ3C1	MI	TTW640A
DMUQ3C1	MN	B-lymphocyte surface antigen B4 (CD19)
DMUQ3C1	MT	DTT
DMUQ3C1	MA	CAR-T-Cell-Therapy
DMUQ3C1	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMUQ3C1	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMUVYC5	DI	DMUVYC5
DMUVYC5	DN	Anti-CD19 EBV CTL therapy
DMUVYC5	MI	TTW640A
DMUVYC5	MN	B-lymphocyte surface antigen B4 (CD19)
DMUVYC5	MT	DTT
DMUVYC5	RN	Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia. 2010 May;24(5):1080-4.
DMUVYC5	RU	https://pubmed.ncbi.nlm.nih.gov/20220773

DMF93T2	DI	DMF93T2
DMF93T2	DN	Anti-CD19/BCMA CAR-T cells
DMF93T2	MI	TTZ3P4W
DMF93T2	MN	B-cell maturation protein (TNFRSF17)
DMF93T2	MT	DTT
DMF93T2	MA	CAR-T-Cell-Therapy(Dual specific)
DMF93T2	RN	ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
DMF93T2	RU	https://clinicaltrials.gov/ct2/show/NCT03706547

DMF93T2	DI	DMF93T2
DMF93T2	DN	Anti-CD19/BCMA CAR-T cells
DMF93T2	MI	TTW640A
DMF93T2	MN	B-lymphocyte surface antigen B4 (CD19)
DMF93T2	MT	DTT
DMF93T2	MA	CAR-T-Cell-Therapy(Dual specific)
DMF93T2	RN	ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
DMF93T2	RU	https://clinicaltrials.gov/ct2/show/NCT03706547

DMWKYSM	DI	DMWKYSM
DMWKYSM	DN	Anti-CD19-CAR
DMWKYSM	MI	TTW640A
DMWKYSM	MN	B-lymphocyte surface antigen B4 (CD19)
DMWKYSM	MT	DTT
DMWKYSM	MA	CAR-T-Cell-Therapy
DMWKYSM	RN	ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
DMWKYSM	RU	https://clinicaltrials.gov/ct2/show/NCT01593696

DMMRANJ	DI	DMMRANJ
DMMRANJ	DN	Anti-CD19-CAR T
DMMRANJ	MI	TTW640A
DMMRANJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMRANJ	MT	DTT
DMMRANJ	MA	CAR-T-Cell-Therapy
DMMRANJ	RN	ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
DMMRANJ	RU	https://clinicaltrials.gov/ct2/show/NCT02546739

DMYQFCN	DI	DMYQFCN
DMYQFCN	DN	Anti-CD19-CAR T cells
DMYQFCN	MI	TTW640A
DMYQFCN	MN	B-lymphocyte surface antigen B4 (CD19)
DMYQFCN	MT	DTT
DMYQFCN	MA	CAR-T-Cell-Therapy
DMYQFCN	RN	ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
DMYQFCN	RU	https://clinicaltrials.gov/ct2/show/NCT02659943

DMUFRDK	DI	DMUFRDK
DMUFRDK	DN	Anti-CD22
DMUFRDK	MI	TTM6QSK
DMUFRDK	MN	B-cell receptor CD22 (CD22)
DMUFRDK	MT	DTT
DMUFRDK	RN	2011 Pipeline of Seattle Genetics.
DMUFRDK	RU	http://www.seagen.com/product_pipeline.php

DMKL92E	DI	DMKL92E
DMKL92E	DN	Anti-CD22 CAR-T cells
DMKL92E	MI	TTM6QSK
DMKL92E	MN	B-cell receptor CD22 (CD22)
DMKL92E	MT	DTT
DMKL92E	MA	CAR-T-Cell-Therapy
DMKL92E	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMKL92E	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMTK78L	DI	DMTK78L
DMTK78L	DN	Anti-CD30 CAR-T cells
DMTK78L	MI	TT2GM5R
DMTK78L	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMTK78L	MT	DTT
DMTK78L	MA	CAR-T-Cell-Therapy
DMTK78L	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMTK78L	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DM2IEB7	DI	DM2IEB7
DM2IEB7	DN	Anti-CD30-CAR T cells
DM2IEB7	MI	TT2GM5R
DM2IEB7	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM2IEB7	MT	DTT
DM2IEB7	MA	CAR-T-Cell-Therapy
DM2IEB7	RN	ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
DM2IEB7	RU	https://clinicaltrials.gov/ct2/show/NCT03049449

DMVSPZM	DI	DMVSPZM
DMVSPZM	DN	Anti-CD38 CAR-T cells
DMVSPZM	MI	TTPURFN
DMVSPZM	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMVSPZM	MT	DTT
DMVSPZM	MA	CAR-T-Cell-Therapy
DMVSPZM	RN	ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
DMVSPZM	RU	https://clinicaltrials.gov/ct2/show/NCT03464916

DMZ2D0G	DI	DMZ2D0G
DMZ2D0G	DN	Anti-CD45 mabs
DMZ2D0G	MI	TTUS45N
DMZ2D0G	MN	Leukocyte common antigen (PTPRC)
DMZ2D0G	MT	DTT
DMZ2D0G	RN	CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
DMZ2D0G	RU	https://pubmed.ncbi.nlm.nih.gov/16818275

DMMFL2P	DI	DMMFL2P
DMMFL2P	DN	Anti-CD7 CAR-T cells
DMMFL2P	MI	TTP6B8O
DMMFL2P	MN	T-cell antigen CD7 (CD7)
DMMFL2P	MT	DTT
DMMFL2P	MA	CAR-T-Cell-Therapy
DMMFL2P	RN	ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
DMMFL2P	RU	https://clinicaltrials.gov/ct2/show/NCT03121625

DMDZR0V	DI	DMDZR0V
DMDZR0V	DN	Anti-CEA CAR-T cells
DMDZR0V	MI	TTY6DTE
DMDZR0V	MN	Carcinoembryonic antigen CEA (CD66e)
DMDZR0V	MT	DTT
DMDZR0V	MA	CAR-T-Cell-Therapy
DMDZR0V	RN	ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
DMDZR0V	RU	https://clinicaltrials.gov/ct2/show/NCT03682744

DMA7L3O	DI	DMA7L3O
DMA7L3O	DN	Anti-CEA CAR-T cells
DMA7L3O	MI	TTY6DTE
DMA7L3O	MN	Carcinoembryonic antigen CEA (CD66e)
DMA7L3O	MT	DTT
DMA7L3O	MA	CAR-T-Cell-Therapy
DMA7L3O	RN	ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
DMA7L3O	RU	https://clinicaltrials.gov/ct2/show/NCT02416466

DMJA3H1	DI	DMJA3H1
DMJA3H1	DN	Anti-CEA-CAR T
DMJA3H1	MI	TTY6DTE
DMJA3H1	MN	Carcinoembryonic antigen CEA (CD66e)
DMJA3H1	MT	DTT
DMJA3H1	MA	CAR-T-Cell-Therapy
DMJA3H1	RN	ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
DMJA3H1	RU	https://clinicaltrials.gov/ct2/show/NCT02349724

DM0ZDJ5	DI	DM0ZDJ5
DM0ZDJ5	DN	Anti-EGFL7
DM0ZDJ5	MI	TT7WD0H
DM0ZDJ5	MN	Epidermal growth factor-like protein 7 (EGFL7)
DM0ZDJ5	MT	DTT
DM0ZDJ5	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DM0ZDJ5	RU	http://www.gene.com/gene/pipeline/status/

DMIVUX1	DI	DMIVUX1
DMIVUX1	DN	Anti-EGFR CAR T
DMIVUX1	MI	TTGKNB4
DMIVUX1	MN	Epidermal growth factor receptor (EGFR)
DMIVUX1	MT	DTT
DMIVUX1	MA	CAR-T-Cell-Therapy
DMIVUX1	RN	ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
DMIVUX1	RU	https://clinicaltrials.gov/ct2/show/NCT02331693

DM73920	DI	DM73920
DM73920	DN	Anti-EGFRvIII CAR T cells
DM73920	MI	TTZ6B2I
DM73920	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM73920	MT	DTT
DM73920	MA	CAR-T-Cell-Therapy
DM73920	RN	ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
DM73920	RU	https://clinicaltrials.gov/ct2/show/NCT02844062

DM6QENU	DI	DM6QENU
DM6QENU	DN	Anti-FGFR3
DM6QENU	MI	TTST7KB
DM6QENU	MN	Fibroblast growth factor receptor 3 (FGFR3)
DM6QENU	MT	DTT
DM6QENU	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DM6QENU	RU	http://www.gene.com/gene/index.jsp

DMBVUFL	DI	DMBVUFL
DMBVUFL	DN	Anti-GD2 T-cells (1RG-CART)
DMBVUFL	MI	TT80ARU
DMBVUFL	MN	Ganglioside GD2 (GD2)
DMBVUFL	MT	DTT
DMBVUFL	MA	CAR-T-Cell-Therapy
DMBVUFL	RN	ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
DMBVUFL	RU	https://clinicaltrials.gov/ct2/show/NCT02761915

DMCNFZG	DI	DMCNFZG
DMCNFZG	DN	Anti-GD2-CAR engineered T cells
DMCNFZG	MI	TT80ARU
DMCNFZG	MN	Ganglioside GD2 (GD2)
DMCNFZG	MT	DTT
DMCNFZG	MA	CAR-T-Cell-Therapy
DMCNFZG	RN	ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
DMCNFZG	RU	https://clinicaltrials.gov/ct2/show/NCT02107963

DMUMWFK	DI	DMUMWFK
DMUMWFK	DN	Anti-GPC3 CAR T
DMUMWFK	MI	TTJTSX4
DMUMWFK	MN	Glypican-3 (GPC3)
DMUMWFK	MT	DTT
DMUMWFK	MA	CAR-T-Cell-Therapy
DMUMWFK	RN	ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC
DMUMWFK	RU	https://clinicaltrials.gov/ct2/show/NCT02395250

DMK4GIS	DI	DMK4GIS
DMK4GIS	DN	Anti-hCD70 CAR transduced PBL
DMK4GIS	MI	TTNCIE0
DMK4GIS	MN	CD70 antigen (CD27-L)
DMK4GIS	MT	DTT
DMK4GIS	MA	CAR-T-Cell-Therapy
DMK4GIS	RN	ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
DMK4GIS	RU	https://clinicaltrials.gov/ct2/show/NCT02830724

DMDMNJ6	DI	DMDMNJ6
DMDMNJ6	DN	Anti-HER3/EGFR DAF
DMDMNJ6	MI	TTGKNB4
DMDMNJ6	MN	Epidermal growth factor receptor (EGFR)
DMDMNJ6	MT	DTT
DMDMNJ6	MA	Modulator
DMDMNJ6	RN	Company report (Biooncology)
DMDMNJ6	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMDMNJ6	DI	DMDMNJ6
DMDMNJ6	DN	Anti-HER3/EGFR DAF
DMDMNJ6	MI	TTDC8N2
DMDMNJ6	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMDMNJ6	MT	DTT
DMDMNJ6	MA	Modulator
DMDMNJ6	RN	Company report (Biooncology)
DMDMNJ6	RU	http://www.biooncology.com/pipeline-molecules/anti-her3

DMY2MO4	DI	DMY2MO4
DMY2MO4	DN	Anti-meso-CAR T cells
DMY2MO4	MI	TT4RXME
DMY2MO4	MN	Mesothelin (MSLN)
DMY2MO4	MT	DTT
DMY2MO4	MA	CAR-T-Cell-Therapy
DMY2MO4	RN	ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
DMY2MO4	RU	https://clinicaltrials.gov/ct2/show/NCT02580747

DM5UQA9	DI	DM5UQA9
DM5UQA9	DN	Anti-meso-CAR vector transduced T cells
DM5UQA9	MI	TT4RXME
DM5UQA9	MN	Mesothelin (MSLN)
DM5UQA9	MT	DTT
DM5UQA9	MA	CAR-T-Cell-Therapy
DM5UQA9	RN	ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
DM5UQA9	RU	https://clinicaltrials.gov/ct2/show/NCT02580747

DM5BIM1	DI	DM5BIM1
DM5BIM1	DN	Anti-mesothelin CAR T Cells
DM5BIM1	MI	TT4RXME
DM5BIM1	MN	Mesothelin (MSLN)
DM5BIM1	MT	DTT
DM5BIM1	MA	CAR-T-Cell-Therapy
DM5BIM1	RN	ClinicalTrials.gov (NCT02930993) Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors
DM5BIM1	RU	https://clinicaltrials.gov/ct2/show/NCT02930993

DMUKFCG	DI	DMUKFCG
DMUKFCG	DN	Anti-Mesothelin CAR-T cells
DMUKFCG	MI	TT4RXME
DMUKFCG	MN	Mesothelin (MSLN)
DMUKFCG	MT	DTT
DMUKFCG	MA	CAR-T-Cell-Therapy
DMUKFCG	RN	ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.
DMUKFCG	RU	https://clinicaltrials.gov/ct2/show/NCT03545815

DMQ5ZND	DI	DMQ5ZND
DMQ5ZND	DN	Anti-MUC1 mab
DMQ5ZND	MI	TTBHFYQ
DMQ5ZND	MN	Mucin-1 (MUC1)
DMQ5ZND	MT	DTT
DMQ5ZND	MA	Modulator
DMQ5ZND	RN	Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics. 2001;20(5-6):313-24.
DMQ5ZND	RU	https://pubmed.ncbi.nlm.nih.gov/11839249

DMRWI7E	DI	DMRWI7E
DMRWI7E	DN	Anti-N3pG-Abeta antibody
DMRWI7E	MI	TTE4KHA
DMRWI7E	MN	Amyloid beta A4 protein (APP)
DMRWI7E	MT	DTT
DMRWI7E	RN	LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co.
DMRWI7E	RU	http://www.alzforum.org/therapeutics/ly3002813

DMFZ52G	DI	DMFZ52G
DMFZ52G	DN	Anti-OX40 mab
DMFZ52G	MI	TTL31H0
DMFZ52G	MN	OX40L receptor (CD134)
DMFZ52G	MT	DTT
DMFZ52G	MA	Modulator
DMFZ52G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873).
DMFZ52G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873

DM0UL47	DI	DM0UL47
DM0UL47	DN	Anti-PD-L1
DM0UL47	MI	TT8ZLTI
DM0UL47	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM0UL47	MT	DTT
DM0UL47	RN	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65.
DM0UL47	RU	https://pubmed.ncbi.nlm.nih.gov/22658128

DMWIJL1	DI	DMWIJL1
DMWIJL1	DN	Anti-PD-L1 CSR T cells
DMWIJL1	MI	TT8ZLTI
DMWIJL1	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMWIJL1	MT	DTT
DMWIJL1	MA	CAR-T-Cell-Therapy
DMWIJL1	RN	ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
DMWIJL1	RU	https://clinicaltrials.gov/ct2/show/NCT02937844

DMAESIY	DI	DMAESIY
DMAESIY	DN	ANX005
DMAESIY	MI	TT7LRQH
DMAESIY	MN	Complement C1s component (C1S)
DMAESIY	MT	DTT
DMAESIY	MA	Inhibitor
DMAESIY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAESIY	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM7XES6	DI	DM7XES6
DM7XES6	DN	ANX-042
DM7XES6	MI	TTWVLS6
DM7XES6	MN	Natriuretic peptide receptor (NPR3)
DM7XES6	MT	DTT
DM7XES6	MA	Modulator
DM7XES6	RN	Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation: Novel Therapeutic Concepts to Combat Heart Failure. Circ Heart Fail. 2013 May; 6(3): 594-605.
DM7XES6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981104/

DMGDARN	DI	DMGDARN
DMGDARN	DN	AP32788
DMGDARN	MI	TTGKNB4
DMGDARN	MN	Epidermal growth factor receptor (EGFR)
DMGDARN	MT	DTT
DMGDARN	MA	Inhibitor
DMGDARN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGDARN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM36FOG	DI	DM36FOG
DM36FOG	DN	APD-597
DM36FOG	MI	TT7QNVC
DM36FOG	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM36FOG	MT	DTT
DM36FOG	MA	Agonist
DM36FOG	RN	Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
DM36FOG	RU	https://pubmed.ncbi.nlm.nih.gov/22264481

DMRGF9Q	DI	DMRGF9Q
DMRGF9Q	DN	APD-916
DMRGF9Q	MI	TT9JNIC
DMRGF9Q	MN	Histamine H3 receptor (H3R)
DMRGF9Q	MT	DTT
DMRGF9Q	MA	Antagonist
DMRGF9Q	RN	Identification of biaryl sulfone derivatives as antagonists of the histamine H receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916). Bioorg Med Chem Lett. 2012 Jan 1;22(1):71-5.
DMRGF9Q	RU	https://pubmed.ncbi.nlm.nih.gov/22172695

DMLEKUY	DI	DMLEKUY
DMLEKUY	DN	APG-1387
DMLEKUY	MI	TTS74QB
DMLEKUY	MN	Inhibitor of apoptosis protein (hIAP)
DMLEKUY	MT	DTT
DMLEKUY	MA	Inhibitor
DMLEKUY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLEKUY	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMLEKUY	DI	DMLEKUY
DMLEKUY	DN	APG-1387
DMLEKUY	MI	TTR7B60
DMLEKUY	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMLEKUY	MT	DTT
DMLEKUY	MA	Antagonist
DMLEKUY	RN	XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
DMLEKUY	RU	https://pubmed.ncbi.nlm.nih.gov/29556337

DM6P93J	DI	DM6P93J
DM6P93J	DN	API-023
DM6P93J	MI	TTF1QVM
DM6P93J	MN	Gastric H(+)/K(+) ATPase alpha (ATP4A)
DM6P93J	MT	DTT
DM6P93J	MA	Inhibitor
DM6P93J	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
DM6P93J	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849

DM4WAC2	DI	DM4WAC2
DM4WAC2	DN	APL-501
DM4WAC2	MI	TTNBFWK
DM4WAC2	MN	Programmed cell death protein 1 (PD-1)
DM4WAC2	MT	DTT
DM4WAC2	MA	Inhibitor
DM4WAC2	RN	Clinical pipeline report, company report or official report of Apollomics.
DM4WAC2	RU	https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-501/

DMPJBCR	DI	DMPJBCR
DMPJBCR	DN	APO-010
DMPJBCR	MI	TTF0RCZ
DMPJBCR	MN	Apoptosis mediating surface antigen FAS (FAS)
DMPJBCR	MT	DTT
DMPJBCR	MA	Binder
DMPJBCR	RN	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
DMPJBCR	RU	https://pubmed.ncbi.nlm.nih.gov/21183510

DMU8QD2	DI	DMU8QD2
DMU8QD2	DN	Apramycin
DMU8QD2	MI	TT38DW5
DMU8QD2	MN	Bacterial 16S ribosomal RNA (Bact 16S rRNA)
DMU8QD2	MT	DTT
DMU8QD2	MA	Inhibitor
DMU8QD2	RN	RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
DMU8QD2	RU	https://pubmed.ncbi.nlm.nih.gov/11102874

DMXIKYR	DI	DMXIKYR
DMXIKYR	DN	APTO-253
DMXIKYR	MI	TTTI53X
DMXIKYR	MN	Kruppel like factor 4 (KLF4)
DMXIKYR	MT	DTT
DMXIKYR	MA	Inhibitor
DMXIKYR	RN	Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92.
DMXIKYR	RU	https://pubmed.ncbi.nlm.nih.gov/26268924

DMXDMH5	DI	DMXDMH5
DMXDMH5	DN	APVO414
DMXDMH5	MI	TT9G4N0
DMXDMH5	MN	Glutamate carboxypeptidase II (GCPII)
DMXDMH5	MT	DTT
DMXDMH5	MA	Inhibitor
DMXDMH5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXDMH5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMUAMZY	DI	DMUAMZY
DMUAMZY	DN	APVO436
DMUAMZY	MI	TTENHJ0
DMUAMZY	MN	Interleukin 3 receptor alpha (IL3RA)
DMUAMZY	MT	DTT
DMUAMZY	MA	Inhibitor
DMUAMZY	RN	Clinical pipeline report, company report or official report of Aptevo.
DMUAMZY	RU	https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/

DMUAMZY	DI	DMUAMZY
DMUAMZY	DN	APVO436
DMUAMZY	MI	TTUN7MC
DMUAMZY	MN	T-cell surface glycoprotein CD3 (CD3)
DMUAMZY	MT	DTT
DMUAMZY	MA	Inhibitor
DMUAMZY	RN	Clinical pipeline report, company report or official report of Aptevo.
DMUAMZY	RU	https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/

DMXIMQT	DI	DMXIMQT
DMXIMQT	DN	APX-3330
DMXIMQT	MI	TTHGL48
DMXIMQT	MN	AP endonuclease 1 (APEX1)
DMXIMQT	MT	DTT
DMXIMQT	MA	Inhibitor
DMXIMQT	RN	Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.
DMXIMQT	RU	https://pubmed.ncbi.nlm.nih.gov/20937296

DM4RK6P	DI	DM4RK6P
DM4RK6P	DN	AR-12
DM4RK6P	MI	TT9QBI6
DM4RK6P	MN	Phosphoinositide dependent protein kinase-1 (PDPK1)
DM4RK6P	MT	DTT
DM4RK6P	MA	Modulator
DM4RK6P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM4RK6P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMY0DPM	DI	DMY0DPM
DMY0DPM	DN	ARC-1905
DMY0DPM	MI	TTKANGO
DMY0DPM	MN	Complement C5 (CO5)
DMY0DPM	MT	DTT
DMY0DPM	RN	ClinicalTrials.gov (NCT00950638) A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. U.S. National Institutes of Health.
DMY0DPM	RU	https://clinicaltrials.gov/ct2/show/NCT00950638

DMFJZK3	DI	DMFJZK3
DMFJZK3	DN	Arecoline
DMFJZK3	MI	TTZ9SOR
DMFJZK3	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFJZK3	MT	DTT
DMFJZK3	MA	Inhibitor
DMFJZK3	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMFJZK3	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMPLHBI	DI	DMPLHBI
DMPLHBI	DN	ARI-0001 cells
DMPLHBI	MI	TTW640A
DMPLHBI	MN	B-lymphocyte surface antigen B4 (CD19)
DMPLHBI	MT	DTT
DMPLHBI	MA	CAR-T-Cell-Therapy
DMPLHBI	RN	ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
DMPLHBI	RU	https://clinicaltrials.gov/ct2/show/NCT03144583

DMN4D3A	DI	DMN4D3A
DMN4D3A	DN	ARI-2243
DMN4D3A	MI	TTDIGC1
DMN4D3A	MN	Dipeptidyl peptidase 4 (DPP-4)
DMN4D3A	MT	DTT
DMN4D3A	MA	Modulator
DMN4D3A	RN	Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37.
DMN4D3A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996165/

DMY5IM2	DI	DMY5IM2
DMY5IM2	DN	ARL-67085
DMY5IM2	MI	TTZ1DT0
DMY5IM2	MN	P2Y purinoceptor 12 (P2RY12)
DMY5IM2	MT	DTT
DMY5IM2	MA	Agonist
DMY5IM2	RN	Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
DMY5IM2	RU	https://pubmed.ncbi.nlm.nih.gov/10578132

DMQUFNY	DI	DMQUFNY
DMQUFNY	DN	ARM210
DMQUFNY	MI	TT9YXM1
DMQUFNY	MN	Ryanodine receptor (RYR)
DMQUFNY	MT	DTT
DMQUFNY	MA	Modulator
DMQUFNY	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQUFNY	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DM4D85V	DI	DM4D85V
DM4D85V	DN	ARN-6039
DM4D85V	MI	TTGV6LY
DM4D85V	MN	Nuclear receptor ROR-gamma (RORG)
DM4D85V	MT	DTT
DM4D85V	MA	Agonist
DM4D85V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4D85V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5R7VI	DI	DM5R7VI
DM5R7VI	DN	ARN-6039
DM5R7VI	MI	TTGV6LY
DM5R7VI	MN	Nuclear receptor ROR-gamma (RORG)
DM5R7VI	MT	DTT
DM5R7VI	MA	Agonist
DM5R7VI	RN	Clinical pipeline report, company report or official report of Arrien Pharmaceuticals.
DM5R7VI	RU	https://www.arrienpharma.com/arn-6039.html

DMV5PEK	DI	DMV5PEK
DMV5PEK	DN	ARO-HIF2
DMV5PEK	MI	TTWPA54
DMV5PEK	MN	HIF2-alpha messenger RNA (EPAS1 mRNA)
DMV5PEK	MT	DTT
DMV5PEK	MA	Inhibitor
DMV5PEK	RN	National Cancer Institute Drug Dictionary (drug name ARO-HIF2).
DMV5PEK	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hif2a-rnai-aro-hif2

DMCRLQZ	DI	DMCRLQZ
DMCRLQZ	DN	ARQ 621
DMCRLQZ	MI	TTTRP0H
DMCRLQZ	MN	Kinesin-like protein KIF11 (KIF11)
DMCRLQZ	MT	DTT
DMCRLQZ	MA	Modulator
DMCRLQZ	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DMCRLQZ	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMP9ZT1	DI	DMP9ZT1
DMP9ZT1	DN	ARQ 736
DMP9ZT1	MI	TTWCGQT
DMP9ZT1	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMP9ZT1	MT	DTT
DMP9ZT1	MA	Modulator
DMP9ZT1	RN	National Cancer Institute Drug Dictionary (drug id 688029).
DMP9ZT1	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688029

DM7MWX0	DI	DM7MWX0
DM7MWX0	DN	ARQ 751
DM7MWX0	MI	TTWTSCV
DM7MWX0	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM7MWX0	MT	DTT
DM7MWX0	MA	Inhibitor
DM7MWX0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7MWX0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1FTEC	DI	DM1FTEC
DM1FTEC	DN	ARQ-171
DM1FTEC	MI	TTVJDNB
DM1FTEC	MN	E2F transcription factor 1 (E2F1)
DM1FTEC	MT	DTT
DM1FTEC	MA	Modulator
DM1FTEC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396)
DM1FTEC	RU	http://adisinsight.springer.com/drugs/800025396

DMBQWVR	DI	DMBQWVR
DMBQWVR	DN	ARQ-751
DMBQWVR	MI	TTQ7UAP
DMBQWVR	MN	RAC serine/threonine-protein kinase (AKT)
DMBQWVR	MT	DTT
DMBQWVR	MA	Inhibitor
DMBQWVR	RN	Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479.
DMBQWVR	RU	https://pubmed.ncbi.nlm.nih.gov/26469692

DMMPTCK	DI	DMMPTCK
DMMPTCK	DN	ARRY-300
DMMPTCK	MI	TTROQ37
DMMPTCK	MN	MAPK/ERK kinase kinase (MAP3K)
DMMPTCK	MT	DTT
DMMPTCK	MA	Modulator
DMMPTCK	RN	MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27.
DMMPTCK	RU	https://pubmed.ncbi.nlm.nih.gov/23587417

DMCNV0M	DI	DMCNV0M
DMCNV0M	DN	ARRY-380
DMCNV0M	MI	TT6EO5L
DMCNV0M	MN	Erbb2 tyrosine kinase receptor (HER2)
DMCNV0M	MT	DTT
DMCNV0M	MA	Modulator
DMCNV0M	RN	ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice
DMCNV0M	RU	http://arraybiopharma.com/publications/arry-380-potent-small-molecule-inhibitor-erbb2-increases-survival-intracranial-erbb2-xenograft-models-mice/

DM4CZ2Y	DI	DM4CZ2Y
DM4CZ2Y	DN	ARX-424
DM4CZ2Y	MI	TT4TZ8J
DM4CZ2Y	MN	Interferon-beta (IFNB1)
DM4CZ2Y	MT	DTT
DM4CZ2Y	MA	Modulator
DM4CZ2Y	RN	PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
DM4CZ2Y	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/

DMM9ORD	DI	DMM9ORD
DMM9ORD	DN	ASG-15ME
DMM9ORD	MI	TTTVEKI
DMM9ORD	MN	SLIT and NTRK-like family member 6 (SLITRK6)
DMM9ORD	MT	DTT
DMM9ORD	RN	Clinical pipeline report, company report or official report of Seattle Genetics.
DMM9ORD	RU	http://www.seattlegenetics.com/asg15me

DM0Z3JS	DI	DM0Z3JS
DM0Z3JS	DN	ASG-22ME
DM0Z3JS	MI	TTPO9EG
DM0Z3JS	MN	Nectin cell adhesion molecule 4 (NECTIN4)
DM0Z3JS	MT	DTT
DM0Z3JS	RN	2011 Pipeline of Seattle Genetics.
DM0Z3JS	RU	http://www.seagen.com/product_pipeline.php

DMD0BMN	DI	DMD0BMN
DMD0BMN	DN	ASG-5ME
DMD0BMN	MI	TT0NYDG
DMD0BMN	MN	Choline transporter-like protein 4 (SLC44A4)
DMD0BMN	MT	DTT
DMD0BMN	RN	2011 Pipeline of Seattle Genetics.
DMD0BMN	RU	http://www.seagen.com/product_pipeline.php

DMJCX6D	DI	DMJCX6D
DMJCX6D	DN	ASN003
DMJCX6D	MI	TTWCGQT
DMJCX6D	MN	Serine/threonine-protein kinase B-raf (BRAF)
DMJCX6D	MT	DTT
DMJCX6D	MA	Inhibitor
DMJCX6D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJCX6D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYHEUA	DI	DMYHEUA
DMYHEUA	DN	ASN007
DMYHEUA	MI	TT1MG9E
DMYHEUA	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMYHEUA	MT	DTT
DMYHEUA	MA	Inhibitor
DMYHEUA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYHEUA	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM8DBT6	DI	DM8DBT6
DM8DBT6	DN	ASP-0777
DM8DBT6	MI	TT9IK2Z
DM8DBT6	MN	N-methyl-D-aspartate receptor (NMDAR)
DM8DBT6	MT	DTT
DM8DBT6	MA	Modulator
DM8DBT6	RN	US patent application no. 2011,0262,442, Compositions for treating cns disorders.
DM8DBT6	RU	https://www.google.com/patents/US20110262442

DMC80LV	DI	DMC80LV
DMC80LV	DN	ASP1948
DMC80LV	MI	TTIPJCB
DMC80LV	MN	Neuropilin-1 (NRP1)
DMC80LV	MT	DTT
DMC80LV	MA	Inhibitor
DMC80LV	RN	National Cancer Institute Drug Dictionary (drug name ASP1948).
DMC80LV	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-nrp1-antibody-asp1948

DMX4PWV	DI	DMX4PWV
DMX4PWV	DN	ASP1951
DMX4PWV	MI	TTG6LA7
DMX4PWV	MN	Activation-inducible TNFR family receptor (TNFRSF18)
DMX4PWV	MT	DTT
DMX4PWV	MA	Agonist
DMX4PWV	RN	ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
DMX4PWV	RU	https://clinicaltrials.gov/ct2/show/NCT03799003

DMW72NJ	DI	DMW72NJ
DMW72NJ	DN	ASP3026
DMW72NJ	MI	TTPMQSO
DMW72NJ	MN	ALK tyrosine kinase receptor (ALK)
DMW72NJ	MT	DTT
DMW72NJ	MA	Modulator
DMW72NJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740).
DMW72NJ	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7740

DM1RD0T	DI	DM1RD0T
DM1RD0T	DN	ASP-4058
DM1RD0T	MI	TT9JZCK
DM1RD0T	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DM1RD0T	MT	DTT
DM1RD0T	MA	Modulator
DM1RD0T	RN	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
DM1RD0T	RU	https://pubmed.ncbi.nlm.nih.gov/25347187

DM1RD0T	DI	DM1RD0T
DM1RD0T	DN	ASP-4058
DM1RD0T	MI	TTDZCKV
DM1RD0T	MN	Sphingosine-1-phosphate receptor 5 (S1PR5)
DM1RD0T	MT	DTT
DM1RD0T	MA	Modulator
DM1RD0T	RN	ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819.
DM1RD0T	RU	https://pubmed.ncbi.nlm.nih.gov/25347187

DMA71OL	DI	DMA71OL
DMA71OL	DN	ASP8374
DMA71OL	MI	TTWNL74
DMA71OL	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMA71OL	MT	DTT
DMA71OL	MA	Antagonist
DMA71OL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA71OL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCDMPW	DI	DMCDMPW
DMCDMPW	DN	ASP9801
DMCDMPW	MI	TTF89GD
DMCDMPW	MN	Interleukin-2 (IL2)
DMCDMPW	MT	DTT
DMCDMPW	RN	Clinical pipeline report, company report or official report of Astellas Pharma.
DMCDMPW	RU	https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf

DMCDMPW	DI	DMCDMPW
DMCDMPW	DN	ASP9801
DMCDMPW	MI	TT8FRMO
DMCDMPW	MN	Interleukin-7 (IL7)
DMCDMPW	MT	DTT
DMCDMPW	RN	Clinical pipeline report, company report or official report of Astellas Pharma.
DMCDMPW	RU	https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf

DMCN7WI	DI	DMCN7WI
DMCN7WI	DN	AST-005
DMCN7WI	MI	TTF8CQI
DMCN7WI	MN	Tumor necrosis factor (TNF)
DMCN7WI	MT	DTT
DMCN7WI	MA	Inhibitor
DMCN7WI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCN7WI	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM7C68W	DI	DM7C68W
DM7C68W	DN	AST-008
DM7C68W	MI	TTSHG0T
DM7C68W	MN	Toll-like receptor 9 (TLR9)
DM7C68W	MT	DTT
DM7C68W	MA	Agonist
DM7C68W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7C68W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMD83WO	DI	DMD83WO
DMD83WO	DN	AST-1306
DMD83WO	MI	TTGKNB4
DMD83WO	MN	Epidermal growth factor receptor (EGFR)
DMD83WO	MT	DTT
DMD83WO	MA	Modulator
DMD83WO	RN	AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
DMD83WO	RU	https://pubmed.ncbi.nlm.nih.gov/21789172

DMD2BIT	DI	DMD2BIT
DMD2BIT	DN	AT001/r84
DMD2BIT	MI	TTOHSBA
DMD2BIT	MN	Vascular endothelial growth factor A (VEGFA)
DMD2BIT	MT	DTT
DMD2BIT	RN	Clinical pipeline report, company report or official report of Affitech (2011).
DMD2BIT	RU	http://www.affitech.com/

DMYIPKJ	DI	DMYIPKJ
DMYIPKJ	DN	AT13148
DMYIPKJ	MI	TTMQO60
DMYIPKJ	MN	Rho-associated protein kinase (ROCK)
DMYIPKJ	MT	DTT
DMYIPKJ	MA	Modulator
DMYIPKJ	RN	Company report (Astex)
DMYIPKJ	RU	http://www.astx.com/pipeline/products/clinical

DM2B9E0	DI	DM2B9E0
DM2B9E0	DN	AT13387
DM2B9E0	MI	TT78R5H
DM2B9E0	MN	Heat shock protein 90 alpha (HSP90A)
DM2B9E0	MT	DTT
DM2B9E0	MA	Inhibitor
DM2B9E0	RN	Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008.
DM2B9E0	RU	http://www.drugs.com/clinical_trials/astex-presents-updates-at13387-hsp90-inhibitor-at9283-multi-targeted-kinase-inhibitor-eortc-nci-5775.html

DMCE08M	DI	DMCE08M
DMCE08M	DN	AT7519
DMCE08M	MI	TT7HF4W
DMCE08M	MN	Cyclin-dependent kinase 2 (CDK2)
DMCE08M	MT	DTT
DMCE08M	MA	Inhibitor
DMCE08M	RN	Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32.
DMCE08M	RU	https://pubmed.ncbi.nlm.nih.gov/19174555

DMHYO38	DI	DMHYO38
DMHYO38	DN	AT-787
DMHYO38	MI	TTMVBWH
DMHYO38	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMHYO38	MT	DTT
DMHYO38	MA	Inhibitor
DMHYO38	RN	Clinical pipeline report, company report or official report of Atea Pharmaceuticals.
DMHYO38	RU	https://ateapharma.com/about-us/hepatitis-c/

DM6O0TM	DI	DM6O0TM
DM6O0TM	DN	ATA2271
DM6O0TM	MI	TT4RXME
DM6O0TM	MN	Mesothelin (MSLN)
DM6O0TM	MT	DTT
DM6O0TM	RN	Clinical pipeline report, company report or official report of Atara Biotherapeutics.
DM6O0TM	RU	https://www.atarabio.com/pipeline/ata2271-ata3271/

DMIMH8L	DI	DMIMH8L
DMIMH8L	DN	ATD transdermal gel
DMIMH8L	MI	TTZAYWL
DMIMH8L	MN	Estrogen receptor (ESR)
DMIMH8L	MT	DTT
DMIMH8L	MA	Inhibitor
DMIMH8L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
DMIMH8L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620

DM96JTX	DI	DM96JTX
DM96JTX	DN	ATEVIRDINE
DM96JTX	MI	TT84ETX
DM96JTX	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM96JTX	MT	DTT
DM96JTX	MA	Modulator
DM96JTX	RN	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89.
DM96JTX	RU	https://pubmed.ncbi.nlm.nih.gov/8809165

DMWGKHZ	DI	DMWGKHZ
DMWGKHZ	DN	ATF-936
DMWGKHZ	MI	TTBUYHA
DMWGKHZ	MN	Extracellular calcium-sensing receptor (CASR)
DMWGKHZ	MT	DTT
DMWGKHZ	MA	Antagonist
DMWGKHZ	RN	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
DMWGKHZ	RU	https://pubmed.ncbi.nlm.nih.gov/21514409

DMT5Z84	DI	DMT5Z84
DMT5Z84	DN	ATI-0917
DMT5Z84	MI	TTF7I5O
DMT5Z84	MN	Human immunodeficiency virus Rev protein (HIV rev)
DMT5Z84	MT	DTT
DMT5Z84	MA	Inhibitor
DMT5Z84	RN	Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53.
DMT5Z84	RU	https://pubmed.ncbi.nlm.nih.gov/19335283

DMBKO2W	DI	DMBKO2W
DMBKO2W	DN	ATI-355
DMBKO2W	MI	TT7GXMU
DMBKO2W	MN	Reticulon-4 (RTN4)
DMBKO2W	MT	DTT
DMBKO2W	RN	Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818.
DMBKO2W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589918/

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTJQOD7
DM6GKMU	MN	5-HT 2A receptor (HTR2A)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTO9X1H
DM6GKMU	MN	5-HT 7 receptor (HTR7)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DM6GKMU	DI	DM6GKMU
DM6GKMU	DN	ATI-9242
DM6GKMU	MI	TTEX248
DM6GKMU	MN	Dopamine D2 receptor (D2R)
DM6GKMU	MT	DTT
DM6GKMU	MA	Modulator
DM6GKMU	RN	Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
DM6GKMU	RU	http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12

DMR93S5	DI	DMR93S5
DMR93S5	DN	ATL1103
DMR93S5	MI	TTHJWYD
DMR93S5	MN	GHR messenger RNA (GHR mRNA)
DMR93S5	MT	DTT
DMR93S5	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMR93S5	RU	http://www.isispharm.com/Pipeline/index.htm

DMZI4UX	DI	DMZI4UX
DMZI4UX	DN	ATLCAR.CD30 cells
DMZI4UX	MI	TT2GM5R
DMZI4UX	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DMZI4UX	MT	DTT
DMZI4UX	MA	CAR-T-Cell-Therapy
DMZI4UX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DMZI4UX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DM3IPSX	DI	DM3IPSX
DM3IPSX	DN	ATLCAR.CD30.CCR4 cells
DM3IPSX	MI	TT7HQD0
DM3IPSX	MN	C-C chemokine receptor type 4 (CCR4)
DM3IPSX	MT	DTT
DM3IPSX	MA	CAR-T-Cell-Therapy(Dual specific)
DM3IPSX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DM3IPSX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DM3IPSX	DI	DM3IPSX
DM3IPSX	DN	ATLCAR.CD30.CCR4 cells
DM3IPSX	MI	TT2GM5R
DM3IPSX	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM3IPSX	MT	DTT
DM3IPSX	MA	CAR-T-Cell-Therapy(Dual specific)
DM3IPSX	RN	ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
DM3IPSX	RU	https://clinicaltrials.gov/ct2/show/NCT03602157

DMU67HD	DI	DMU67HD
DMU67HD	DN	ATR-01
DMU67HD	MI	TTK3C21
DMU67HD	MN	Acetoacetyl-CoA thiolase (ACAT1)
DMU67HD	MT	DTT
DMU67HD	MA	Inhibitor
DMU67HD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU67HD	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMUMVXK	DI	DMUMVXK
DMUMVXK	DN	ATR-101
DMUMVXK	MI	TT4V7ST
DMUMVXK	MN	Sterol O-acyltransferase (SOAT)
DMUMVXK	MT	DTT
DMUMVXK	MA	Modulator
DMUMVXK	RN	Company report (Atterocor)
DMUMVXK	RU	http://atterocor.com/pdf/Atterocor-ENDO-PR-61214.pdf

DMBCATZ	DI	DMBCATZ
DMBCATZ	DN	ATR-107
DMBCATZ	MI	TTZO9B0
DMBCATZ	MN	Interleukin 21 receptor (IL21R)
DMBCATZ	MT	DTT
DMBCATZ	RN	Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22.
DMBCATZ	RU	https://pubmed.ncbi.nlm.nih.gov/23913720

DMTG9EV	DI	DMTG9EV
DMTG9EV	DN	ATRC-101
DMTG9EV	MI	TTHC8EF
DMTG9EV	MN	Polyadenylate-binding protein 1 (PABPC1)
DMTG9EV	MT	DTT
DMTG9EV	RN	Clinical pipeline report, company report or official report of Atreca.
DMTG9EV	RU	https://www.atreca.com/pipeline/

DML4SIE	DI	DML4SIE
DML4SIE	DN	Atu-027
DML4SIE	MI	TTW3P4R
DML4SIE	MN	Protein kinase N3 (PKN3)
DML4SIE	MT	DTT
DML4SIE	MA	Modulator
DML4SIE	RN	Company report (Silence Therapeutics)
DML4SIE	RU	http://www.silence-therapeutics.com/pipeline/?doing_wp_cron=1455613779.0401461124420166015625#AboutAtu027

DMKNMAE	DI	DMKNMAE
DMKNMAE	DN	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
DMKNMAE	MI	TTZ3P4W
DMKNMAE	MN	B-cell maturation protein (TNFRSF17)
DMKNMAE	MT	DTT
DMKNMAE	MA	CAR-T-Cell-Therapy
DMKNMAE	RN	ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
DMKNMAE	RU	https://clinicaltrials.gov/ct2/show/NCT03338972

DMQA1VT	DI	DMQA1VT
DMQA1VT	DN	Autologous cell based gene therapy
DMQA1VT	MI	TTCM4B3
DMQA1VT	MN	Nitric-oxide synthase endothelial (NOS3)
DMQA1VT	MT	DTT
DMQA1VT	MA	Modulator
DMQA1VT	RN	Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
DMQA1VT	RU	https://pubmed.ncbi.nlm.nih.gov/12231180

DMJW4TP	DI	DMJW4TP
DMJW4TP	DN	Autologous ET1402L1-CART cells
DMJW4TP	MI	TT3WAD0
DMJW4TP	MN	HLA-A02/AFP complex (HLA-A02/AFP)
DMJW4TP	MT	DTT
DMJW4TP	MA	CAR-T-Cell-Therapy
DMJW4TP	RN	ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
DMJW4TP	RU	https://clinicaltrials.gov/ct2/show/NCT03349255

DMARYFK	DI	DMARYFK
DMARYFK	DN	Autologous melanoma cell vaccine
DMARYFK	MI	TTNYZG2
DMARYFK	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMARYFK	MT	DTT
DMARYFK	MA	Modulator
DMARYFK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMARYFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMZ763A	DI	DMZ763A
DMZ763A	DN	Autologous T Cells Expressing MET scFv CAR
DMZ763A	MI	TTNDSF4
DMZ763A	MN	Proto-oncogene c-Met (MET)
DMZ763A	MT	DTT
DMZ763A	MA	CAR-T-Cell-Therapy
DMZ763A	RN	ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
DMZ763A	RU	https://clinicaltrials.gov/ct2/show/NCT03060356

DMTLU37	DI	DMTLU37
DMTLU37	DN	Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
DMTLU37	MI	TT4RXME
DMTLU37	MN	Mesothelin (MSLN)
DMTLU37	MT	DTT
DMTLU37	MA	CAR-T-Cell-Therapy
DMTLU37	RN	ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
DMTLU37	RU	https://clinicaltrials.gov/ct2/show/NCT01897415

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TT9G4N0
DMOAET3	MN	Glutamate carboxypeptidase II (GCPII)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TTZAT79
DMOAET3	MN	T-cell surface glycoprotein CD3 epsilon (CD3E)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMOAET3	DI	DMOAET3
DMOAET3	DN	Autologous T-cell therapy
DMOAET3	MI	TTV3XPL
DMOAET3	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMOAET3	MT	DTT
DMOAET3	RN	Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
DMOAET3	RU	https://pubmed.ncbi.nlm.nih.gov/23256796

DMZLCTD	DI	DMZLCTD
DMZLCTD	DN	AV-203
DMZLCTD	MI	TTDC8N2
DMZLCTD	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMZLCTD	MT	DTT
DMZLCTD	RN	Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14.
DMZLCTD	RU	https://pubmed.ncbi.nlm.nih.gov/25542901

DME630T	DI	DME630T
DME630T	DN	AV4025
DME630T	MI	TTCJ2X8
DME630T	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DME630T	MT	DTT
DME630T	MA	Modulator
DME630T	RN	Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014 Sep 25;57(18):7716-30.
DME630T	RU	https://pubmed.ncbi.nlm.nih.gov/25148100

DMVL87N	DI	DMVL87N
DMVL87N	DN	AV-965
DMVL87N	MI	TTSQIFT
DMVL87N	MN	5-HT 1A receptor (HTR1A)
DMVL87N	MT	DTT
DMVL87N	MA	Antagonist
DMVL87N	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025412)
DMVL87N	RU	http://adisinsight.springer.com/drugs/800025412

DMKCRMD	DI	DMKCRMD
DMKCRMD	DN	AVB-S6-500
DMKCRMD	MI	TTZPY6J
DMKCRMD	MN	Tyrosine-protein kinase UFO (AXL)
DMKCRMD	MT	DTT
DMKCRMD	MA	Inhibitor
DMKCRMD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKCRMD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMSR91U	DI	DMSR91U
DMSR91U	DN	AVE0118
DMSR91U	MI	TT1VOHK
DMSR91U	MN	Potassium channel unspecific (KC)
DMSR91U	MT	DTT
DMSR91U	MA	Modulator
DMSR91U	RN	Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20.
DMSR91U	RU	https://www.ncbi.nlm.nih.gov/pubmed/24629214

DM56VG2	DI	DM56VG2
DM56VG2	DN	AVE0897
DM56VG2	MI	TTJ584C
DM56VG2	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DM56VG2	MT	DTT
DM56VG2	MA	Agonist
DM56VG2	RN	Pharma & Vaccines. Product Development Pipeline. April 29 2009.
DM56VG2	RU	http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf

DMJY35M	DI	DMJY35M
DMJY35M	DN	AVE1701
DMJY35M	MI	TTC24WT
DMJY35M	MN	C-C chemokine receptor type 1 (CCR1)
DMJY35M	MT	DTT
DMJY35M	MA	Antagonist
DMJY35M	RN	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
DMJY35M	RU	https://pubmed.ncbi.nlm.nih.gov/18321156

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTZ97H5
DMZNTHJ	MN	Phosphodiesterase 4A (PDE4A)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTVIAT9
DMZNTHJ	MN	Phosphodiesterase 4B (PDE4B)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMZNTHJ	DI	DMZNTHJ
DMZNTHJ	DN	AVE-8112
DMZNTHJ	MI	TTSKMI8
DMZNTHJ	MN	Phosphodiesterase 4D (PDE4D)
DMZNTHJ	MT	DTT
DMZNTHJ	MA	Inhibitor
DMZNTHJ	RN	Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33.
DMZNTHJ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/

DMVUW8A	DI	DMVUW8A
DMVUW8A	DN	AVI-6002
DMVUW8A	MI	TTDJLWQ
DMVUW8A	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMVUW8A	MT	DTT
DMVUW8A	MA	Modulator
DMVUW8A	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMVUW8A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMVUW8A	DI	DMVUW8A
DMVUW8A	DN	AVI-6002
DMVUW8A	MI	TT3Z102
DMVUW8A	MN	Ebola virus VP35 messenger RNA (EV VP35 mRNA)
DMVUW8A	MT	DTT
DMVUW8A	MA	Modulator
DMVUW8A	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMVUW8A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMIJSDO	DI	DMIJSDO
DMIJSDO	DN	AVI-6003
DMIJSDO	MI	TTDJLWQ
DMIJSDO	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMIJSDO	MT	DTT
DMIJSDO	MA	Modulator
DMIJSDO	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMIJSDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMIJSDO	DI	DMIJSDO
DMIJSDO	DN	AVI-6003
DMIJSDO	MI	TT3Z102
DMIJSDO	MN	Ebola virus VP35 messenger RNA (EV VP35 mRNA)
DMIJSDO	MT	DTT
DMIJSDO	MA	Modulator
DMIJSDO	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMIJSDO	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMVD327	DI	DMVD327
DMVD327	DN	AVI-7288
DMVD327	MI	TT1E5A4
DMVD327	MN	Marburg virus NP messenger RNA (MV NP mRNA)
DMVD327	MT	DTT
DMVD327	RN	AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med. 2015 Jul 23;373(4):339-48.
DMVD327	RU	https://pubmed.ncbi.nlm.nih.gov/26200980

DMLI9U6	DI	DMLI9U6
DMLI9U6	DN	AVI-7537
DMLI9U6	MI	TTDJLWQ
DMLI9U6	MN	Ebola virus VP24 messenger RNA (EV VP24 mRNA)
DMLI9U6	MT	DTT
DMLI9U6	RN	Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830.
DMLI9U6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/

DMZ39T6	DI	DMZ39T6
DMZ39T6	DN	AVID200
DMZ39T6	MI	TTO3HT7
DMZ39T6	MN	Transforming growth factor beta (TGFB)
DMZ39T6	MT	DTT
DMZ39T6	MA	Inhibitor
DMZ39T6	RN	TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
DMZ39T6	RU	https://pubmed.ncbi.nlm.nih.gov/31211692

DMGAKR9	DI	DMGAKR9
DMGAKR9	DN	AVL-3288
DMGAKR9	MI	TTLA931
DMGAKR9	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMGAKR9	MT	DTT
DMGAKR9	MA	Modulator
DMGAKR9	RN	Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014.
DMGAKR9	RU	https://pubmed.ncbi.nlm.nih.gov/22096516

DMNIVFJ	DI	DMNIVFJ
DMNIVFJ	DN	AVN-322
DMNIVFJ	MI	TTJS8PY
DMNIVFJ	MN	5-HT 6 receptor (HTR6)
DMNIVFJ	MT	DTT
DMNIVFJ	MA	Antagonist
DMNIVFJ	RN	AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Curr Alzheimer Res. 2017;14(3):268-294.
DMNIVFJ	RU	https://pubmed.ncbi.nlm.nih.gov/27829340

DM8CYJ1	DI	DM8CYJ1
DM8CYJ1	DN	AVP-13358
DM8CYJ1	MI	TTYJQTF
DM8CYJ1	MN	Immunoglobulin E (IgE)
DM8CYJ1	MT	DTT
DM8CYJ1	MA	Inhibitor
DM8CYJ1	RN	Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
DM8CYJ1	RU	https://pubmed.ncbi.nlm.nih.gov/15588078

DMMWEH6	DI	DMMWEH6
DMMWEH6	DN	AVP-21D9
DMMWEH6	MI	TT3YGCD
DMMWEH6	MN	Bacterial Protective antigen (Bact pagA)
DMMWEH6	MT	DTT
DMMWEH6	RN	Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625.
DMMWEH6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068543/

DMAKD0I	DI	DMAKD0I
DMAKD0I	DN	AVX-470
DMAKD0I	MI	TTF8CQI
DMAKD0I	MN	Tumor necrosis factor (TNF)
DMAKD0I	MT	DTT
DMAKD0I	MA	Inhibitor
DMAKD0I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAKD0I	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMAKD0I	DI	DMAKD0I
DMAKD0I	DN	AVX-470
DMAKD0I	MI	TTG043C
DMAKD0I	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMAKD0I	MT	DTT
DMAKD0I	RN	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
DMAKD0I	RU	https://pubmed.ncbi.nlm.nih.gov/15507622

DMRQ32K	DI	DMRQ32K
DMRQ32K	DN	AX-024
DMRQ32K	MI	TTMA3VF
DMRQ32K	MN	NCK adaptor protein 1 (NCK1)
DMRQ32K	MT	DTT
DMRQ32K	MA	Modulator
DMRQ32K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ32K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMRQ32K	DI	DMRQ32K
DMRQ32K	DN	AX-024
DMRQ32K	MI	TTXQYT6
DMRQ32K	MN	T-cells (T-cells)
DMRQ32K	MT	DTT
DMRQ32K	MA	Inhibitor
DMRQ32K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRQ32K	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMFBMU7	DI	DMFBMU7
DMFBMU7	DN	Axatilamab
DMFBMU7	MI	TT7MRDV
DMFBMU7	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMFBMU7	MT	DTT
DMFBMU7	MA	Antagonist
DMFBMU7	RN	Clinical pipeline report, company report or official report of Syndax Pharmaceuticals.
DMFBMU7	RU	https://syndax.com/pipeline/axatilimab/

DM6L5IP	DI	DM6L5IP
DM6L5IP	DN	Axitirome
DM6L5IP	MI	TTGER3L
DM6L5IP	MN	Thyroid hormone receptor beta (THRB)
DM6L5IP	MT	DTT
DM6L5IP	MA	Modulator
DM6L5IP	RN	Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253.
DM6L5IP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642162/

DM7ZU3B	DI	DM7ZU3B
DM7ZU3B	DN	AXT-914
DM7ZU3B	MI	TTBUYHA
DM7ZU3B	MN	Extracellular calcium-sensing receptor (CASR)
DM7ZU3B	MT	DTT
DM7ZU3B	MA	Antagonist
DM7ZU3B	RN	AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
DM7ZU3B	RU	https://pubmed.ncbi.nlm.nih.gov/24769332

DMWCJEU	DI	DMWCJEU
DMWCJEU	DN	AZD0156
DMWCJEU	MI	TTKBM7V
DMWCJEU	MN	ATM serine/threonine kinase (ATM)
DMWCJEU	MT	DTT
DMWCJEU	MA	Inhibitor
DMWCJEU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWCJEU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMHBEKM	DI	DMHBEKM
DMHBEKM	DN	AZD0284
DMHBEKM	MI	TTGV6LY
DMHBEKM	MN	Nuclear receptor ROR-gamma (RORG)
DMHBEKM	MT	DTT
DMHBEKM	MA	Agonist
DMHBEKM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHBEKM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMMW72C	DI	DMMW72C
DMMW72C	DN	AZD-1152-HQPA
DMMW72C	MI	TT5LS6T
DMMW72C	MN	Aurora kinase B (AURKB)
DMMW72C	MT	DTT
DMMW72C	MA	Modulator
DMMW72C	RN	Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80.
DMMW72C	RU	https://www.ncbi.nlm.nih.gov/pubmed/22661287

DMBEA6V	DI	DMBEA6V
DMBEA6V	DN	AZD1208
DMBEA6V	MI	TT69J2Z
DMBEA6V	MN	Serine/threonine-protein kinase pim-2 (PIM2)
DMBEA6V	MT	DTT
DMBEA6V	MA	Modulator
DMBEA6V	RN	AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13.
DMBEA6V	RU	https://pubmed.ncbi.nlm.nih.gov/24363397

DMYBX4N	DI	DMYBX4N
DMYBX4N	DN	AZD1390
DMYBX4N	MI	TTKBM7V
DMYBX4N	MN	ATM serine/threonine kinase (ATM)
DMYBX4N	MT	DTT
DMYBX4N	MA	Inhibitor
DMYBX4N	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBX4N	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6UOXF	DI	DM6UOXF
DM6UOXF	DN	AZD1419
DM6UOXF	MI	TTSHG0T
DM6UOXF	MN	Toll-like receptor 9 (TLR9)
DM6UOXF	MT	DTT
DM6UOXF	MA	Agonist
DM6UOXF	RN	Clinical pipeline report, company report or official report of dynavax.
DM6UOXF	RU	http://investors.dynavax.com/releasedetail.cfm?releaseid=611310

DMQ1OX4	DI	DMQ1OX4
DMQ1OX4	DN	AZD1979
DMQ1OX4	MI	TTX4RTB
DMQ1OX4	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMQ1OX4	MT	DTT
DMQ1OX4	MA	Modulator
DMQ1OX4	RN	Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
DMQ1OX4	RU	http://www.biocentury.com/products/azd1979

DMZQEDY	DI	DMZQEDY
DMZQEDY	DN	AZD-2551
DMZQEDY	MI	TTZBFA0
DMZQEDY	MN	Protease unspecific (PRO)
DMZQEDY	MT	DTT
DMZQEDY	MA	Inhibitor
DMZQEDY	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854)
DMZQEDY	RU	http://adisinsight.springer.com/drugs/800029854

DMXFYN0	DI	DMXFYN0
DMXFYN0	DN	AZD-3043
DMXFYN0	MI	TTEX6LM
DMXFYN0	MN	GABA(A) receptor gamma-3 (GABRG3)
DMXFYN0	MT	DTT
DMXFYN0	MA	Modulator
DMXFYN0	RN	AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77.
DMXFYN0	RU	https://pubmed.ncbi.nlm.nih.gov/22531340

DMICW7D	DI	DMICW7D
DMICW7D	DN	AZD-3161
DMICW7D	MI	TTRK8B9
DMICW7D	MN	Sodium channel unspecific (NaC)
DMICW7D	MT	DTT
DMICW7D	MA	Modulator
DMICW7D	RN	Recent progress in sodium channel modulators for pain.Bioorganic & Medicinal Chemistry Letters Volume 24, Issue 16, 15 August 2014, Pages 3690-3699.
DMICW7D	RU	http://www.sciencedirect.com/science/article/pii/S0960894X14006660

DMC1BXV	DI	DMC1BXV
DMC1BXV	DN	AZD-3514
DMC1BXV	MI	TTS64P2
DMC1BXV	MN	Androgen receptor (AR)
DMC1BXV	MT	DTT
DMC1BXV	MA	Antagonist
DMC1BXV	RN	AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27.
DMC1BXV	RU	https://pubmed.ncbi.nlm.nih.gov/23861347

DM72FOD	DI	DM72FOD
DM72FOD	DN	Azd-3839
DM72FOD	MI	TT8JRS7
DM72FOD	MN	Beta-secretase (BACE)
DM72FOD	MT	DTT
DM72FOD	MA	Inhibitor
DM72FOD	RN	Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.
DM72FOD	RU	https://pubmed.ncbi.nlm.nih.gov/23048024

DM72FOD	DI	DM72FOD
DM72FOD	DN	Azd-3839
DM72FOD	MI	DE4LYSA
DM72FOD	MN	Cytochrome P450 3A4 (CYP3A4)
DM72FOD	MT	DME
DM72FOD	MA	Metabolism
DM72FOD	RN	MedChemExpress: AZD3839.
DM72FOD	RU	https://www.medchemexpress.com/AZD3839-free-base.html

DMOYPTK	DI	DMOYPTK
DMOYPTK	DN	AZD4573
DMOYPTK	MI	TT1LVF2
DMOYPTK	MN	Cyclin-dependent kinase 9 (CDK9)
DMOYPTK	MT	DTT
DMOYPTK	MA	Inhibitor
DMOYPTK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOYPTK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM36EY7	DI	DM36EY7
DM36EY7	DN	AZD4721
DM36EY7	MI	TT30C9G
DM36EY7	MN	C-X-C chemokine receptor type 2 (CXCR2)
DM36EY7	MT	DTT
DM36EY7	MA	Antagonist
DM36EY7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038326)
DM36EY7	RU	http://adisinsight.springer.com/drugs/800038326

DMVWMUK	DI	DMVWMUK
DMVWMUK	DN	AZD4785
DMVWMUK	MI	TTB1RA4
DMVWMUK	MN	GTPase KRas (KRAS)
DMVWMUK	MT	DTT
DMVWMUK	MA	Inhibitor
DMVWMUK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVWMUK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRP3N8	DI	DMRP3N8
DMRP3N8	DN	AZD4831
DMRP3N8	MI	TTVCZPI
DMRP3N8	MN	Myeloperoxidase (MPO)
DMRP3N8	MT	DTT
DMRP3N8	MA	Modulator
DMRP3N8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRP3N8	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMQEO4V	DI	DMQEO4V
DMQEO4V	DN	AZD-5122
DMQEO4V	MI	TT30C9G
DMQEO4V	MN	C-X-C chemokine receptor type 2 (CXCR2)
DMQEO4V	MT	DTT
DMQEO4V	MA	Modulator
DMQEO4V	RN	Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589.
DMQEO4V	RU	http://www.mdpi.com/1424-8247/4/4/567

DMW4GM2	DI	DMW4GM2
DMW4GM2	DN	AZD5153
DMW4GM2	MI	TTRA6BO
DMW4GM2	MN	Bromodomain-containing protein 4 (BRD4)
DMW4GM2	MT	DTT
DMW4GM2	MA	Inhibitor
DMW4GM2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW4GM2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMBQ2TF	DI	DMBQ2TF
DMBQ2TF	DN	AZD-5438
DMBQ2TF	MI	TT7HF4W
DMBQ2TF	MN	Cyclin-dependent kinase 2 (CDK2)
DMBQ2TF	MT	DTT
DMBQ2TF	MA	Modulator
DMBQ2TF	RN	AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14.
DMBQ2TF	RU	https://www.ncbi.nlm.nih.gov/pubmed/22795803

DMV6DF3	DI	DMV6DF3
DMV6DF3	DN	AZD5658
DMV6DF3	MI	TTDLNGZ
DMV6DF3	MN	Glucokinase (GCK)
DMV6DF3	MT	DTT
DMV6DF3	MA	Activator
DMV6DF3	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMV6DF3	RU	http://www.astrazeneca.com/Home

DM7QGHO	DI	DM7QGHO
DM7QGHO	DN	AZD5991
DM7QGHO	MI	TTL53M6
DM7QGHO	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DM7QGHO	MT	DTT
DM7QGHO	MA	Inhibitor
DM7QGHO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7QGHO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0WCR4	DI	DM0WCR4
DM0WCR4	DN	AZD-6088
DM0WCR4	MI	TTZ9SOR
DM0WCR4	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0WCR4	MT	DTT
DM0WCR4	MA	Agonist
DM0WCR4	RN	Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints. AAPS J. 2012 December; 14(4): 657-663.
DM0WCR4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475849/

DMW4VQF	DI	DMW4VQF
DMW4VQF	DN	AZD6423
DMW4VQF	MI	TT9IK2Z
DMW4VQF	MN	N-methyl-D-aspartate receptor (NMDAR)
DMW4VQF	MT	DTT
DMW4VQF	MA	Antagonist
DMW4VQF	RN	Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009.
DMW4VQF	RU	http://www.ncbi.nlm.nih.gov/books/NBK5283/

DM84WXZ	DI	DM84WXZ
DM84WXZ	DN	AZD-7295
DM84WXZ	MI	TTCJ2X8
DM84WXZ	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DM84WXZ	MT	DTT
DM84WXZ	MA	Modulator
DM84WXZ	RN	TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711.
DM84WXZ	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/

DMS9I6A	DI	DMS9I6A
DMS9I6A	DN	AZD7687
DMS9I6A	MI	TTF8P9I
DMS9I6A	MN	Diacylglycerol acyltransferase 1 (DGAT1)
DMS9I6A	MT	DTT
DMS9I6A	MA	Inhibitor
DMS9I6A	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMS9I6A	RU	http://www.astrazeneca.com/Home

DM1FW0C	DI	DM1FW0C
DM1FW0C	DN	AZD7762
DM1FW0C	MI	TTTU902
DM1FW0C	MN	Checkpoint kinase-1 (CHK1)
DM1FW0C	MT	DTT
DM1FW0C	MA	Inhibitor
DM1FW0C	RN	Clinical pipeline report, company report or official report of AstraZeneca (2009).
DM1FW0C	RU	http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf

DM8DMI0	DI	DM8DMI0
DM8DMI0	DN	AZD-8165
DM8DMI0	MI	TT6L509
DM8DMI0	MN	Coagulation factor IIa (F2)
DM8DMI0	MT	DTT
DM8DMI0	MA	Inhibitor
DM8DMI0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DM8DMI0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DMWYF1H	DI	DMWYF1H
DMWYF1H	DN	AZD8186
DMWYF1H	MI	TTTHBCA
DMWYF1H	MN	PI3-kinase beta (PIK3CB)
DMWYF1H	MT	DTT
DMWYF1H	MA	Inhibitor
DMWYF1H	RN	National Cancer Institute Drug Dictionary (drug id 751594).
DMWYF1H	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751594

DMWYF1H	DI	DMWYF1H
DMWYF1H	DN	AZD8186
DMWYF1H	MI	TTHBTOP
DMWYF1H	MN	PI3-kinase gamma (PIK3CG)
DMWYF1H	MT	DTT
DMWYF1H	MA	Inhibitor
DMWYF1H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWYF1H	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMTD57A	DI	DMTD57A
DMTD57A	DN	AZD8329
DMTD57A	MI	TTN7BL9
DMTD57A	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMTD57A	MT	DTT
DMTD57A	MA	Inhibitor
DMTD57A	RN	Clinical pipeline report, company report or official report of AstraZeneca (2011).
DMTD57A	RU	http://www.astrazeneca.com/Home

DM9X20P	DI	DM9X20P
DM9X20P	DN	AZD-8418
DM9X20P	MI	TTAN6JD
DM9X20P	MN	Glutamate receptor AMPA (GRIA)
DM9X20P	MT	DTT
DM9X20P	MA	Modulator
DM9X20P	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031633)
DM9X20P	RU	http://adisinsight.springer.com/drugs/800031633

DM3EWUX	DI	DM3EWUX
DM3EWUX	DN	AZD8701
DM3EWUX	MI	TT1X3QF
DM3EWUX	MN	FOXP3 messenger RNA (FOXP3 mRNA)
DM3EWUX	MT	DTT
DM3EWUX	MA	Inhibitor
DM3EWUX	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DM3EWUX	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMPMDTH	DI	DMPMDTH
DMPMDTH	DN	Azd9496
DMPMDTH	MI	DES5XRU
DMPMDTH	MN	Cytochrome P450 2C8 (CYP2C8)
DMPMDTH	MT	DME
DMPMDTH	MA	Metabolism
DMPMDTH	RN	Complete substrate inhibition of cytochrome P450 2C8 by AZD9496, an oral selective estrogen receptor degrader. Drug Metab Dispos. 2018 Sep;46(9):1268-1276.
DMPMDTH	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=29921707

DMPMDTH	DI	DMPMDTH
DMPMDTH	DN	Azd9496
DMPMDTH	MI	TTZAYWL
DMPMDTH	MN	Estrogen receptor (ESR)
DMPMDTH	MT	DTT
DMPMDTH	MA	Antagonist
DMPMDTH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPMDTH	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMAXHC0	DI	DMAXHC0
DMAXHC0	DN	AZD9567
DMAXHC0	MI	TTOZRK6
DMAXHC0	MN	Glucocorticoid receptor messenger RNA (GCR mRNA)
DMAXHC0	MT	DTT
DMAXHC0	MA	Modulator
DMAXHC0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAXHC0	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMWYHXG	DI	DMWYHXG
DMWYHXG	DN	AZD-9819
DMWYHXG	MI	TTPLTSQ
DMWYHXG	MN	Neutrophil elastase (NE)
DMWYHXG	MT	DTT
DMWYHXG	MA	Inhibitor
DMWYHXG	RN	Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
DMWYHXG	RU	https://pubmed.ncbi.nlm.nih.gov/26203069

DM0LKHV	DI	DM0LKHV
DM0LKHV	DN	B7-2/GM-CSF
DM0LKHV	MI	TTZ9SOR
DM0LKHV	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DM0LKHV	MT	DTT
DM0LKHV	MA	Agonist
DM0LKHV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM0LKHV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM0LKHV	DI	DM0LKHV
DM0LKHV	DN	B7-2/GM-CSF
DM0LKHV	MI	TTQWUPT
DM0LKHV	MN	Thyroid hormone receptor (THR)
DM0LKHV	MT	DTT
DM0LKHV	MA	Agonist
DM0LKHV	RN	Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010 Mar;15(2):177-82.
DM0LKHV	RU	https://pubmed.ncbi.nlm.nih.gov/19002578

DM5KU30	DI	DM5KU30
DM5KU30	DN	BAL-30072
DM5KU30	MI	TTJP4SM
DM5KU30	MN	Bacterial Penicillin binding protein (Bact PBP)
DM5KU30	MT	DTT
DM5KU30	MA	Inhibitor
DM5KU30	RN	In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302.
DM5KU30	RU	https://pubmed.ncbi.nlm.nih.gov/20308379

DMAJPOX	DI	DMAJPOX
DMAJPOX	DN	Balapiravir
DMAJPOX	MI	TTMVBWH
DMAJPOX	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAJPOX	MT	DTT
DMAJPOX	MA	Inhibitor
DMAJPOX	RN	R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49.
DMAJPOX	RU	https://pubmed.ncbi.nlm.nih.gov/18828074

DM3415L	DI	DM3415L
DM3415L	DN	BAX-499
DM3415L	MI	TT068JH
DM3415L	MN	Tissue factor pathway inhibitor (TFPI)
DM3415L	MT	DTT
DM3415L	MA	Inhibitor
DM3415L	RN	Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.
DM3415L	RU	https://pubmed.ncbi.nlm.nih.gov/23528042

DMLRGX1	DI	DMLRGX1
DMLRGX1	DN	BAY 1082439
DMLRGX1	MI	TTTHBCA
DMLRGX1	MN	PI3-kinase beta (PIK3CB)
DMLRGX1	MT	DTT
DMLRGX1	MA	Modulator
DMLRGX1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMLRGX1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMYPU8V	DI	DMYPU8V
DMYPU8V	DN	BAY 1238097
DMYPU8V	MI	TTE4BSY
DMYPU8V	MN	Bromodomain and extraterminal domain protein (BET)
DMYPU8V	MT	DTT
DMYPU8V	MA	Inhibitor
DMYPU8V	RN	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948.
DMYPU8V	RU	https://pubmed.ncbi.nlm.nih.gov/28653353

DMF9ALP	DI	DMF9ALP
DMF9ALP	DN	BAY 1817080
DMF9ALP	MI	TT2THBD
DMF9ALP	MN	P2X purinoceptor 3 (P2RX3)
DMF9ALP	MT	DTT
DMF9ALP	MA	Antagonist
DMF9ALP	RN	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
DMF9ALP	RU	https://pubmed.ncbi.nlm.nih.gov/33986030

DMQIKZG	DI	DMQIKZG
DMQIKZG	DN	BAY 1834942
DMQIKZG	MI	TTIGH2W
DMQIKZG	MN	Normal cross-reacting antigen (CD66c)
DMQIKZG	MT	DTT
DMQIKZG	MA	Blocker
DMQIKZG	RN	ClinicalTrials.gov (NCT03596372) Study of BAY1834942 in Patients With Solid Tumors. U.S. National Institutes of Health.
DMQIKZG	RU	https://clinicaltrials.gov/ct2/show/NCT03596372

DMNVPI1	DI	DMNVPI1
DMNVPI1	DN	BAY 1905254
DMNVPI1	MI	TT0R2QD
DMNVPI1	MN	Ig-like domain-containing receptor 2 (ILDR2)
DMNVPI1	MT	DTT
DMNVPI1	MA	Inhibitor
DMNVPI1	RN	Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911.
DMNVPI1	RU	https://pubmed.ncbi.nlm.nih.gov/32312711

DMD9N12	DI	DMD9N12
DMD9N12	DN	BAY 2416964
DMD9N12	MI	TT037IE
DMD9N12	MN	Aryl hydrocarbon receptor (AHR)
DMD9N12	MT	DTT
DMD9N12	MA	Antagonist
DMD9N12	RN	ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health.
DMD9N12	RU	https://clinicaltrials.gov/ct2/show/NCT04069026

DM98EP5	DI	DM98EP5
DM98EP5	DN	BAY 2701439
DM98EP5	MI	TT6EO5L
DM98EP5	MN	Erbb2 tyrosine kinase receptor (HER2)
DM98EP5	MT	DTT
DM98EP5	MA	Inhibitor
DM98EP5	RN	National Cancer Institute Drug Dictionary (drug name BAY2701439).
DM98EP5	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-anti-her2-monoclonal-antibody-bay2701439

DM14XQN	DI	DM14XQN
DM14XQN	DN	BAY 79-4620
DM14XQN	MI	TT2LVK8
DM14XQN	MN	Carbonic anhydrase IX (CA-IX)
DM14XQN	MT	DTT
DM14XQN	RN	Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
DM14XQN	RU	https://pubmed.ncbi.nlm.nih.gov/22147747

DM31RQS	DI	DM31RQS
DM31RQS	DN	BAY 86-8050
DM31RQS	MI	TTYCILE
DM31RQS	MN	Vasopressin receptor (VR)
DM31RQS	MT	DTT
DM31RQS	MA	Modulator
DM31RQS	RN	WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists.
DM31RQS	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20150319&CC=WO&NR=2015036563A1&KC=A1

DMCQEL6	DI	DMCQEL6
DMCQEL6	DN	BAY 94-9343
DMCQEL6	MI	TT4RXME
DMCQEL6	MN	Mesothelin (MSLN)
DMCQEL6	MT	DTT
DMCQEL6	MA	Modulator
DMCQEL6	RN	National Cancer Institute Drug Dictionary (drug id 712853).
DMCQEL6	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=712853

DM8U3Q2	DI	DM8U3Q2
DM8U3Q2	DN	BAY-1075553
DM8U3Q2	MI	TT9G4N0
DM8U3Q2	MN	Glutamate carboxypeptidase II (GCPII)
DM8U3Q2	MT	DTT
DM8U3Q2	MA	Modulator
DM8U3Q2	RN	Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101.
DM8U3Q2	RU	https://pubmed.ncbi.nlm.nih.gov/23955632

DMTB4R8	DI	DMTB4R8
DMTB4R8	DN	BAY1125976
DMTB4R8	MI	TTAZ05C
DMTB4R8	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMTB4R8	MT	DTT
DMTB4R8	MA	Modulator
DMTB4R8	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTB4R8	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMVPAZ7	DI	DMVPAZ7
DMVPAZ7	DN	BAY1143572
DMVPAZ7	MI	TTQ7ABG
DMVPAZ7	MN	Positive transcription elongation factor b (P-TEFb)
DMVPAZ7	MT	DTT
DMVPAZ7	MA	Modulator
DMVPAZ7	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMVPAZ7	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMUK6YM	DI	DMUK6YM
DMUK6YM	DN	BAY1161909
DMUK6YM	MI	TTP7EGM
DMUK6YM	MN	Dual specificity protein kinase TTK (MPS1)
DMUK6YM	MT	DTT
DMUK6YM	MA	Inhibitor
DMUK6YM	RN	National Cancer Institute Drug Dictionary (drug id 761238).
DMUK6YM	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761238

DM7L91K	DI	DM7L91K
DM7L91K	DN	BAY1179470
DM7L91K	MI	TTGJVQM
DM7L91K	MN	Fibroblast growth factor receptor 2 (FGFR2)
DM7L91K	MT	DTT
DM7L91K	MA	Antagonist
DM7L91K	RN	National Cancer Institute Drug Dictionary (drug id 751593).
DM7L91K	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751593

DMCJNRL	DI	DMCJNRL
DMCJNRL	DN	BAY1251152
DMCJNRL	MI	TTQ7ABG
DMCJNRL	MN	Positive transcription elongation factor b (P-TEFb)
DMCJNRL	MT	DTT
DMCJNRL	MA	Inhibitor
DMCJNRL	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCJNRL	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPNBJ1	DI	DMPNBJ1
DMPNBJ1	DN	BAY1436032
DMPNBJ1	MI	TTXDKHT
DMPNBJ1	MN	Mutated oxalosuccinate decarboxylase (mIDH1)
DMPNBJ1	MT	DTT
DMPNBJ1	MA	Inhibitor
DMPNBJ1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPNBJ1	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNL5G7	DI	DMNL5G7
DMNL5G7	DN	BAY-1817080
DMNL5G7	MI	TT2THBD
DMNL5G7	MN	P2X purinoceptor 3 (P2RX3)
DMNL5G7	MT	DTT
DMNL5G7	MA	Inhibitor
DMNL5G7	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMNL5G7	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM8V62T	DI	DM8V62T
DM8V62T	DN	BAY1834845
DM8V62T	MI	TTKFVXR
DM8V62T	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DM8V62T	MT	DTT
DM8V62T	MA	Inhibitor
DM8V62T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM8V62T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DML781M	DI	DML781M
DML781M	DN	BAY1895344
DML781M	MI	TT8ZYBQ
DML781M	MN	Serine/threonine-protein kinase ATR (FRP1)
DML781M	MT	DTT
DML781M	MA	Inhibitor
DML781M	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DML781M	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRL6W5	DI	DMRL6W5
DMRL6W5	DN	BAY2402234
DMRL6W5	MI	TTLVP78
DMRL6W5	MN	Dihydroorotate dehydrogenase (DHODH)
DMRL6W5	MT	DTT
DMRL6W5	MA	Inhibitor
DMRL6W5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRL6W5	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXIDWE	DI	DMXIDWE
DMXIDWE	DN	BAY-60-5521
DMXIDWE	MI	TTFQAYR
DMXIDWE	MN	Cholesteryl ester transfer protein (CETP)
DMXIDWE	MT	DTT
DMXIDWE	MA	Inhibitor
DMXIDWE	RN	Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8.
DMXIDWE	RU	https://pubmed.ncbi.nlm.nih.gov/21838789

DMOUVE7	DI	DMOUVE7
DMOUVE7	DN	BAY-85-8102
DMOUVE7	MI	TTPTXIN
DMOUVE7	MN	Translocator protein (TSPO)
DMOUVE7	MT	DTT
DMOUVE7	MA	Agonist
DMOUVE7	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
DMOUVE7	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879

DM195JA	DI	DM195JA
DM195JA	DN	BAY-86-7548
DM195JA	MI	TTHYDUM
DM195JA	MN	Bombesin receptor (BS)
DM195JA	MT	DTT
DM195JA	MA	Enhancer
DM195JA	RN	Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72.
DM195JA	RU	https://pubmed.ncbi.nlm.nih.gov/23564761

DMSBWAQ	DI	DMSBWAQ
DMSBWAQ	DN	Bb21217
DMSBWAQ	MI	TTZ3P4W
DMSBWAQ	MN	B-cell maturation protein (TNFRSF17)
DMSBWAQ	MT	DTT
DMSBWAQ	MA	CAR-T-Cell-Therapy
DMSBWAQ	RN	ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma
DMSBWAQ	RU	https://clinicaltrials.gov/ct2/show/NCT03274219

DMTG9WM	DI	DMTG9WM
DMTG9WM	DN	BBI-6000
DMTG9WM	MI	TTGV6LY
DMTG9WM	MN	Nuclear receptor ROR-gamma (RORG)
DMTG9WM	MT	DTT
DMTG9WM	MA	Inhibitor
DMTG9WM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMTG9WM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM572ZL	DI	DM572ZL
DM572ZL	DN	BBP-398
DM572ZL	MI	TT7WUAV
DM572ZL	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DM572ZL	MT	DTT
DM572ZL	MA	Inhibitor
DM572ZL	RN	ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
DM572ZL	RU	https://clinicaltrials.gov/ct2/show/NCT04528836

DMGFABM	DI	DMGFABM
DMGFABM	DN	BC-3205
DMGFABM	MI	TTUWYEA
DMGFABM	MN	Bacterial 50S ribosomal RNA (Bact 50S rRNA)
DMGFABM	MT	DTT
DMGFABM	MA	Modulator
DMGFABM	RN	Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. J Clin Microbiol. 2012 October; 50(10): 3361-3364.
DMGFABM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457460/

DMM0VBU	DI	DMM0VBU
DMM0VBU	DN	BCA101
DMM0VBU	MI	TTGKNB4
DMM0VBU	MN	Epidermal growth factor receptor (EGFR)
DMM0VBU	MT	DTT
DMM0VBU	MA	Inhibitor
DMM0VBU	RN	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
DMM0VBU	RU	https://clinicaltrials.gov/ct2/show/NCT04429542

DMM0VBU	DI	DMM0VBU
DMM0VBU	DN	BCA101
DMM0VBU	MI	TTO3HT7
DMM0VBU	MN	Transforming growth factor beta (TGFB)
DMM0VBU	MT	DTT
DMM0VBU	MA	Inhibitor
DMM0VBU	RN	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
DMM0VBU	RU	https://clinicaltrials.gov/ct2/show/NCT04429542

DMZYCWT	DI	DMZYCWT
DMZYCWT	DN	BCI-632
DMZYCWT	MI	TTXJ47W
DMZYCWT	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMZYCWT	MT	DTT
DMZYCWT	MA	Antagonist
DMZYCWT	RN	Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
DMZYCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15317467

DMZYCWT	DI	DMZYCWT
DMZYCWT	DN	BCI-632
DMZYCWT	MI	TT8A9EF
DMZYCWT	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMZYCWT	MT	DTT
DMZYCWT	MA	Modulator
DMZYCWT	RN	Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
DMZYCWT	RU	https://pubmed.ncbi.nlm.nih.gov/15317467

DMRXDN3	DI	DMRXDN3
DMRXDN3	DN	BCI-838
DMRXDN3	MI	TTXJ47W
DMRXDN3	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMRXDN3	MT	DTT
DMRXDN3	MA	Modulator
DMRXDN3	RN	Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
DMRXDN3	RU	http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html

DMRXDN3	DI	DMRXDN3
DMRXDN3	DN	BCI-838
DMRXDN3	MI	TT8A9EF
DMRXDN3	MN	Metabotropic glutamate receptor 3 (mGluR3)
DMRXDN3	MT	DTT
DMRXDN3	MA	Modulator
DMRXDN3	RN	Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
DMRXDN3	RU	http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html

DMQ76B4	DI	DMQ76B4
DMQ76B4	DN	BCL11a shRNA
DMQ76B4	MI	TTPLHYK
DMQ76B4	MN	BCL11A messenger RNA (BCL11A mRNA)
DMQ76B4	MT	DTT
DMQ76B4	MA	Inhibitor
DMQ76B4	RN	Clinical pipeline report, company report or official report of bluebird bio.
DMQ76B4	RU	https://www.bluebirdbio.com/our-science/pipeline

DMZ51EX	DI	DMZ51EX
DMZ51EX	DN	BCL201
DMZ51EX	MI	TTJGNVC
DMZ51EX	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMZ51EX	MT	DTT
DMZ51EX	MA	Inhibitor
DMZ51EX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ51EX	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMJ37LH	DI	DMJ37LH
DMJ37LH	DN	BCMA CART
DMJ37LH	MI	TTZ3P4W
DMJ37LH	MN	B-cell maturation protein (TNFRSF17)
DMJ37LH	MT	DTT
DMJ37LH	MA	CAR-T-Cell-Therapy
DMJ37LH	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DMJ37LH	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DM2V4EO	DI	DM2V4EO
DM2V4EO	DN	BCMA CART and huCART19
DM2V4EO	MI	TTZ3P4W
DM2V4EO	MN	B-cell maturation protein (TNFRSF17)
DM2V4EO	MT	DTT
DM2V4EO	MA	CAR-T-Cell-Therapy(Dual specific)
DM2V4EO	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DM2V4EO	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DM2V4EO	DI	DM2V4EO
DM2V4EO	DN	BCMA CART and huCART19
DM2V4EO	MI	TTW640A
DM2V4EO	MN	B-lymphocyte surface antigen B4 (CD19)
DM2V4EO	MT	DTT
DM2V4EO	MA	CAR-T-Cell-Therapy(Dual specific)
DM2V4EO	RN	ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
DM2V4EO	RU	https://clinicaltrials.gov/ct2/show/NCT03549442

DMJ4W5V	DI	DMJ4W5V
DMJ4W5V	DN	BCMA CAR-T Cells
DMJ4W5V	MI	TTZ3P4W
DMJ4W5V	MN	B-cell maturation protein (TNFRSF17)
DMJ4W5V	MT	DTT
DMJ4W5V	MA	CAR-T-Cell-Therapy
DMJ4W5V	RN	ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
DMJ4W5V	RU	https://clinicaltrials.gov/ct2/show/NCT03661554

DMZDLHV	DI	DMZDLHV
DMZDLHV	DN	BCMA nanobody CAR-T cells
DMZDLHV	MI	TTZ3P4W
DMZDLHV	MN	B-cell maturation protein (TNFRSF17)
DMZDLHV	MT	DTT
DMZDLHV	MA	CAR-T-Cell-Therapy
DMZDLHV	RN	ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
DMZDLHV	RU	https://clinicaltrials.gov/ct2/show/NCT03664661

DMZ13WQ	DI	DMZ13WQ
DMZ13WQ	DN	BCMA-CD19 cCAR
DMZ13WQ	MI	TTZ3P4W
DMZ13WQ	MN	B-cell maturation protein (TNFRSF17)
DMZ13WQ	MT	DTT
DMZ13WQ	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMZ13WQ	RU	https://icellgene.com/our-pipeline.html

DMZ13WQ	DI	DMZ13WQ
DMZ13WQ	DN	BCMA-CD19 cCAR
DMZ13WQ	MI	TTW640A
DMZ13WQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMZ13WQ	MT	DTT
DMZ13WQ	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMZ13WQ	RU	https://icellgene.com/our-pipeline.html

DMEPHMR	DI	DMEPHMR
DMEPHMR	DN	BCMA-CS1 cCAR
DMEPHMR	MI	TTZ3P4W
DMEPHMR	MN	B-cell maturation protein (TNFRSF17)
DMEPHMR	MT	DTT
DMEPHMR	RN	ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
DMEPHMR	RU	https://clinicaltrials.gov/ct2/show/NCT04156269

DMEPHMR	DI	DMEPHMR
DMEPHMR	DN	BCMA-CS1 cCAR
DMEPHMR	MI	TT7ILZ1
DMEPHMR	MN	SLAM family member 7 SLAMF7 (CS1)
DMEPHMR	MT	DTT
DMEPHMR	RN	ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
DMEPHMR	RU	https://clinicaltrials.gov/ct2/show/NCT04156269

DMW0ZDF	DI	DMW0ZDF
DMW0ZDF	DN	BCMA-specific CAR-expressing T Lymphocytes
DMW0ZDF	MI	TTZ3P4W
DMW0ZDF	MN	B-cell maturation protein (TNFRSF17)
DMW0ZDF	MT	DTT
DMW0ZDF	MA	CAR-T-Cell-Therapy
DMW0ZDF	RN	ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma
DMW0ZDF	RU	https://clinicaltrials.gov/ct2/show/NCT03502577

DMGAP53	DI	DMGAP53
DMGAP53	DN	BDD-10103
DMGAP53	MI	TTRK8B9
DMGAP53	MN	Sodium channel unspecific (NaC)
DMGAP53	MT	DTT
DMGAP53	MA	Modulator
DMGAP53	RN	Clinical pipeline report, company report or official report of Birds Pharma AG.
DMGAP53	RU	http://www.birdspharma.com/projects/bdd_10103/

DMUR49N	DI	DMUR49N
DMUR49N	DN	Begacestat
DMUR49N	MI	TT9W8GU
DMUR49N	MN	Gamma-secretase (GS)
DMUR49N	MT	DTT
DMUR49N	MA	Modulator
DMUR49N	RN	Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608.
DMUR49N	RU	https://pubmed.ncbi.nlm.nih.gov/19671883

DM9R0VA	DI	DM9R0VA
DM9R0VA	DN	Belerofon
DM9R0VA	MI	TTSYFMA
DM9R0VA	MN	Interferon alpha/beta receptor 1 (IFNAR1)
DM9R0VA	MT	DTT
DM9R0VA	MA	Modulator
DM9R0VA	RN	WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
DM9R0VA	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2

DM0ZNAR	DI	DM0ZNAR
DM0ZNAR	DN	Belvarafenib
DM0ZNAR	MI	TTB18GJ
DM0ZNAR	MN	Proto-oncogene c-RAF (c-RAF)
DM0ZNAR	MT	DTT
DM0ZNAR	MA	Inhibitor
DM0ZNAR	RN	Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
DM0ZNAR	RU	https://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline

DMN7J43	DI	DMN7J43
DMN7J43	DN	Benzo(a)pyrene
DMN7J43	MI	DTI7UX6
DMN7J43	MN	Breast cancer resistance protein (ABCG2)
DMN7J43	MT	DTP
DMN7J43	MA	Substrate
DMN7J43	RN	A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13.
DMN7J43	RU	https://doi.org/10.1016/j.compbiomed.2011.08.009

DMMW4HV	DI	DMMW4HV
DMMW4HV	DN	Benzoylphenylurea
DMMW4HV	MI	DTI7UX6
DMMW4HV	MN	Breast cancer resistance protein (ABCG2)
DMMW4HV	MT	DTP
DMMW4HV	MA	Substrate
DMMW4HV	RN	American Association for Cancer Research.
DMMW4HV	RU	http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/119-b

DMBUI2A	DI	DMBUI2A
DMBUI2A	DN	BETULINIC ACID
DMBUI2A	MI	TTIU7X1
DMBUI2A	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DMBUI2A	MT	DTT
DMBUI2A	MA	Inhibitor
DMBUI2A	RN	DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3.
DMBUI2A	RU	https://pubmed.ncbi.nlm.nih.gov/10654414

DM7RPSG	DI	DM7RPSG
DM7RPSG	DN	BF-1
DM7RPSG	MI	TT85JO3
DM7RPSG	MN	5-HT receptor (5HTR)
DM7RPSG	MT	DTT
DM7RPSG	MA	Modulator
DM7RPSG	RN	Serotonin (5-HT2B) receptor. SciBX 4(19); doi:10.1038/scibx.2011.534. May 12 2011
DM7RPSG	RU	http://www.nature.com/scibx/journal/v4/n19/full/scibx.2011.534.html

DMHELFU	DI	DMHELFU
DMHELFU	DN	BF-389
DMHELFU	MI	TT2J34L
DMHELFU	MN	Arachidonate 5-lipoxygenase (5-LOX)
DMHELFU	MT	DTT
DMHELFU	MA	Modulator
DMHELFU	RN	Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8.
DMHELFU	RU	https://pubmed.ncbi.nlm.nih.gov/1456184

DM84LXE	DI	DM84LXE
DM84LXE	DN	BGB-10188
DM84LXE	MI	TTGBPJE
DM84LXE	MN	PI3-kinase delta (PIK3CD)
DM84LXE	MT	DTT
DM84LXE	MA	Inhibitor
DM84LXE	RN	ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
DM84LXE	RU	https://clinicaltrials.gov/ct2/show/NCT04282018

DM7QTIC	DI	DM7QTIC
DM7QTIC	DN	BGB-11417
DM7QTIC	MI	TTJGNVC
DM7QTIC	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM7QTIC	MT	DTT
DM7QTIC	MA	Inhibitor
DM7QTIC	RN	Clinical pipeline report, company report or official report of BeiGene.
DM7QTIC	RU	https://www.beigenemedical.com/CongressDocuments/Hu%20BGB-11417%20AACR%20Poster%202020.pdf

DMUP6M5	DI	DMUP6M5
DMUP6M5	DN	BGB-15025
DMUP6M5	MI	TTSHWUP
DMUP6M5	MN	MEK kinase kinase 1 (MAP4K1)
DMUP6M5	MT	DTT
DMUP6M5	MA	Inhibitor
DMUP6M5	RN	ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
DMUP6M5	RU	https://clinicaltrials.gov/ct2/show/NCT04649385

DMIF9DZ	DI	DMIF9DZ
DMIF9DZ	DN	BGB-3113
DMIF9DZ	MI	TTGM6VW
DMIF9DZ	MN	Tyrosine-protein kinase BTK (ATK)
DMIF9DZ	MT	DTT
DMIF9DZ	MA	Inhibitor
DMIF9DZ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMIF9DZ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQMEDH	DI	DMQMEDH
DMQMEDH	DN	BGB-A445
DMQMEDH	MI	TTL31H0
DMQMEDH	MN	OX40L receptor (CD134)
DMQMEDH	MT	DTT
DMQMEDH	RN	Clinical pipeline report, company report or official report of BeiGene.
DMQMEDH	RU	https://www.beigene.com/science-and-product-portfolio/pipeline

DMED4AJ	DI	DMED4AJ
DMED4AJ	DN	BGC-20-1259
DMED4AJ	MI	TT3ROYC
DMED4AJ	MN	Serotonin transporter (SERT)
DMED4AJ	MT	DTT
DMED4AJ	MA	Modulator
DMED4AJ	RN	Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86.
DMED4AJ	RU	https://www.ncbi.nlm.nih.gov/pubmed/21521422

DMM2EZW	DI	DMM2EZW
DMM2EZW	DN	BHV-5000
DMM2EZW	MI	TT9IK2Z
DMM2EZW	MN	N-methyl-D-aspartate receptor (NMDAR)
DMM2EZW	MT	DTT
DMM2EZW	MA	Antagonist
DMM2EZW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM2EZW	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMUJ1EL	DI	DMUJ1EL
DMUJ1EL	DN	BI 113823
DMUJ1EL	MI	TTG5QIA
DMUJ1EL	MN	B1 bradykinin receptor (BDKRB1)
DMUJ1EL	MT	DTT
DMUJ1EL	MA	Modulator
DMUJ1EL	RN	The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42.
DMUJ1EL	RU	https://pubmed.ncbi.nlm.nih.gov/25088373

DMGMFXJ	DI	DMGMFXJ
DMGMFXJ	DN	BI 1701963
DMGMFXJ	MI	TTB1RA4
DMGMFXJ	MN	GTPase KRas (KRAS)
DMGMFXJ	MT	DTT
DMGMFXJ	MA	Inhibitor
DMGMFXJ	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMGMFXJ	RU	https://www.boehringer-ingelheim.com/press-release/first-pan-kras-inhibitor-advances-clinical-testing

DMFJGUL	DI	DMFJGUL
DMFJGUL	DN	BI 3011441
DMFJGUL	MI	TTZCRP3
DMFJGUL	MN	ERK activator kinase (MEK)
DMFJGUL	MT	DTT
DMFJGUL	MA	Inhibitor
DMFJGUL	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMFJGUL	RU	https://www.inoncology.com/ourpipeline/mek-inhibitor

DMWHZFS	DI	DMWHZFS
DMWHZFS	DN	BI 754091
DMWHZFS	MI	TTNBFWK
DMWHZFS	MN	Programmed cell death protein 1 (PD-1)
DMWHZFS	MT	DTT
DMWHZFS	MA	Inhibitor
DMWHZFS	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMWHZFS	RU	https://www.inoncology.com/ourpipeline/pd1-inhibitor

DMZMAOW	DI	DMZMAOW
DMZMAOW	DN	BI 765063
DMZMAOW	MI	TTBRJS9
DMZMAOW	MN	Inhibitory receptor SHPS-1 (SIRPA)
DMZMAOW	MT	DTT
DMZMAOW	MA	Antagonist
DMZMAOW	RN	Clinical pipeline report, company report or official report of OSE Immunotherapeutics.
DMZMAOW	RU	https://ose-immuno.com/en/ose-product/ose-172/

DMRI6YT	DI	DMRI6YT
DMRI6YT	DN	BI 836880
DMRI6YT	MI	TTKLQTJ
DMRI6YT	MN	Angiopoietin-2 (ANGPT2)
DMRI6YT	MT	DTT
DMRI6YT	MA	Blocker
DMRI6YT	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMRI6YT	RU	https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor

DMRI6YT	DI	DMRI6YT
DMRI6YT	DN	BI 836880
DMRI6YT	MI	TT9HKJA
DMRI6YT	MN	Vascular endothelial growth factor (VEGF)
DMRI6YT	MT	DTT
DMRI6YT	MA	Blocker
DMRI6YT	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMRI6YT	RU	https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor

DMMQ12N	DI	DMMQ12N
DMMQ12N	DN	BI 860585
DMMQ12N	MI	TTCJG29
DMMQ12N	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMMQ12N	MT	DTT
DMMQ12N	MA	Inhibitor
DMMQ12N	RN	Clinical pipeline report, company report or official report of tatcongress.
DMMQ12N	RU	http://tatcongress.org/wp-content/uploads/2014/05/tat2014-abstracts-poster-session-6_140217.pdf

DM7W5N2	DI	DM7W5N2
DM7W5N2	DN	BI 894999
DM7W5N2	MI	TTE4BSY
DM7W5N2	MN	Bromodomain and extraterminal domain protein (BET)
DM7W5N2	MT	DTT
DM7W5N2	MA	Inhibitor
DM7W5N2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7W5N2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMEPJ7C	DI	DMEPJ7C
DMEPJ7C	DN	BI 905677
DMEPJ7C	MI	TTSXOWE
DMEPJ7C	MN	LDL receptor related protein-6 (LRP-6)
DMEPJ7C	MT	DTT
DMEPJ7C	MA	Antagonist
DMEPJ7C	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMEPJ7C	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DMEPJ7C	DI	DMEPJ7C
DMEPJ7C	DN	BI 905677
DMEPJ7C	MI	TT7VMG4
DMEPJ7C	MN	Low-density lipoprotein receptor-related protein 5 (LRP5)
DMEPJ7C	MT	DTT
DMEPJ7C	MA	Antagonist
DMEPJ7C	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMEPJ7C	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DMXO3PV	DI	DMXO3PV
DMXO3PV	DN	BI 905681
DMXO3PV	MI	TT7VMG4
DMXO3PV	MN	Low-density lipoprotein receptor-related protein 5 (LRP5)
DMXO3PV	MT	DTT
DMXO3PV	MA	Antagonist
DMXO3PV	RN	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
DMXO3PV	RU	https://www.inoncology.com/ourpipeline/lrp56-antagonist

DME9NYV	DI	DME9NYV
DME9NYV	DN	BI 905711
DME9NYV	MI	TTW20TU
DME9NYV	MN	TRAIL receptor 2 (TRAIL-R2)
DME9NYV	MT	DTT
DME9NYV	MA	Activator
DME9NYV	RN	Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
DME9NYV	RU	https://pubmed.ncbi.nlm.nih.gov/33037135

DM2Z4YQ	DI	DM2Z4YQ
DM2Z4YQ	DN	BI 907828
DM2Z4YQ	MI	TT08GJW
DM2Z4YQ	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DM2Z4YQ	MT	DTT
DM2Z4YQ	MA	Inhibitor
DM2Z4YQ	RN	MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.
DM2Z4YQ	RU	https://pubmed.ncbi.nlm.nih.gov/32651541

DMKQHE5	DI	DMKQHE5
DMKQHE5	DN	BI-11634
DMKQHE5	MI	TTCIHJA
DMKQHE5	MN	Coagulation factor Xa (F10)
DMKQHE5	MT	DTT
DMKQHE5	MA	Inhibitor
DMKQHE5	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMKQHE5	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DMLJOAF	DI	DMLJOAF
DMLJOAF	DN	BI-135585
DMLJOAF	MI	TTN7BL9
DMLJOAF	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DMLJOAF	MT	DTT
DMLJOAF	MA	Modulator
DMLJOAF	RN	New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).
DMLJOAF	RU	https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false

DM2KVM0	DI	DM2KVM0
DM2KVM0	DN	BI-44847
DM2KVM0	MI	TTLWPVF
DM2KVM0	MN	Sodium/glucose cotransporter 2 (SGLT2)
DM2KVM0	MT	DTT
DM2KVM0	MA	Modulator
DM2KVM0	RN	Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
DM2KVM0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437808

DM3JOIX	DI	DM3JOIX
DM3JOIX	DN	BI-754091
DM3JOIX	MI	TTNBFWK
DM3JOIX	MN	Programmed cell death protein 1 (PD-1)
DM3JOIX	MT	DTT
DM3JOIX	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM3JOIX	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMNUY32	DI	DMNUY32
DMNUY32	DN	BI-811283
DMNUY32	MI	TT5LS6T
DMNUY32	MN	Aurora kinase B (AURKB)
DMNUY32	MT	DTT
DMNUY32	MA	Inhibitor
DMNUY32	RN	Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32.
DMNUY32	RU	https://pubmed.ncbi.nlm.nih.gov/22350019

DMOJZUE	DI	DMOJZUE
DMOJZUE	DN	BI-831266
DMOJZUE	MI	TT5LS6T
DMOJZUE	MN	Aurora kinase B (AURKB)
DMOJZUE	MT	DTT
DMOJZUE	MA	Modulator
DMOJZUE	RN	A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22.
DMOJZUE	RU	https://pubmed.ncbi.nlm.nih.gov/25529193

DM4T916	DI	DM4T916
DM4T916	DN	BI-836845
DM4T916	MI	TTT6LOU
DM4T916	MN	Insulin-like growth factor-I (IGF1)
DM4T916	MT	DTT
DM4T916	MA	Modulator
DM4T916	RN	Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409.
DM4T916	RU	https://www.ncbi.nlm.nih.gov/pubmed/24296829

DMGFH7T	DI	DMGFH7T
DMGFH7T	DN	BI-836880
DMGFH7T	MI	TT9HKJA
DMGFH7T	MN	Vascular endothelial growth factor (VEGF)
DMGFH7T	MT	DTT
DMGFH7T	MA	Inhibitor
DMGFH7T	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMGFH7T	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY4B6J	DI	DMY4B6J
DMY4B6J	DN	BI-847325
DMY4B6J	MI	TT5LS6T
DMY4B6J	MN	Aurora kinase B (AURKB)
DMY4B6J	MT	DTT
DMY4B6J	MA	Modulator
DMY4B6J	RN	doi: 10.1158/1535-7163.TARG-13-B281
DMY4B6J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/B281.short

DMY4B6J	DI	DMY4B6J
DMY4B6J	DN	BI-847325
DMY4B6J	MI	TTROQ37
DMY4B6J	MN	MAPK/ERK kinase kinase (MAP3K)
DMY4B6J	MT	DTT
DMY4B6J	MA	Modulator
DMY4B6J	RN	doi: 10.1158/1535-7163.TARG-13-B281
DMY4B6J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/B281.short

DMNOSYW	DI	DMNOSYW
DMNOSYW	DN	BI-853520
DMNOSYW	MI	TTON5IT
DMNOSYW	MN	Focal adhesion kinase 1 (FAK)
DMNOSYW	MT	DTT
DMNOSYW	MA	Modulator
DMNOSYW	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNOSYW	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMP70FI	DI	DMP70FI
DMP70FI	DN	BIBT986
DMP70FI	MI	TTCIHJA
DMP70FI	MN	Coagulation factor Xa (F10)
DMP70FI	MT	DTT
DMP70FI	MA	Inhibitor
DMP70FI	RN	Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9.
DMP70FI	RU	https://pubmed.ncbi.nlm.nih.gov/16839346

DMUBMN5	DI	DMUBMN5
DMUBMN5	DN	BIBV 308
DMUBMN5	MI	TT2O84V
DMUBMN5	MN	Thromboxane A2 receptor (TBXA2R)
DMUBMN5	MT	DTT
DMUBMN5	MA	Antagonist
DMUBMN5	RN	AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
DMUBMN5	RU	https://pubmed.ncbi.nlm.nih.gov/15613065

DM79XGM	DI	DM79XGM
DM79XGM	DN	BIBX-1382
DM79XGM	MI	TTGKNB4
DM79XGM	MN	Epidermal growth factor receptor (EGFR)
DM79XGM	MT	DTT
DM79XGM	MA	Antagonist
DM79XGM	RN	Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
DM79XGM	RU	https://pubmed.ncbi.nlm.nih.gov/12008195

DM5AW7J	DI	DM5AW7J
DM5AW7J	DN	BIIB 015
DM5AW7J	MI	TTN7HMG
DM5AW7J	MN	Teratocarcinoma-derived growth factor 1 (TDGF1)
DM5AW7J	MT	DTT
DM5AW7J	RN	An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46.
DM5AW7J	RU	https://pubmed.ncbi.nlm.nih.gov/21458984

DMZ1V0E	DI	DMZ1V0E
DMZ1V0E	DN	BIIB 022
DMZ1V0E	MI	TTHRID2
DMZ1V0E	MN	Insulin-like growth factor I receptor (IGF1R)
DMZ1V0E	MT	DTT
DMZ1V0E	MA	Antagonist
DMZ1V0E	RN	A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.
DMZ1V0E	RU	https://pubmed.ncbi.nlm.nih.gov/24458261

DMTRF71	DI	DMTRF71
DMTRF71	DN	BIIB 028
DMTRF71	MI	TT78R5H
DMTRF71	MN	Heat shock protein 90 alpha (HSP90A)
DMTRF71	MT	DTT
DMTRF71	MA	Inhibitor
DMTRF71	RN	Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31.
DMTRF71	RU	https://pubmed.ncbi.nlm.nih.gov/23873691

DMVS87W	DI	DMVS87W
DMVS87W	DN	BIIB068
DMVS87W	MI	TTGM6VW
DMVS87W	MN	Tyrosine-protein kinase BTK (ATK)
DMVS87W	MT	DTT
DMVS87W	MA	Inhibitor
DMVS87W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVS87W	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMUC6EP	DI	DMUC6EP
DMUC6EP	DN	BIIB095
DMUC6EP	MI	TT4G2JS
DMUC6EP	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUC6EP	MT	DTT
DMUC6EP	MA	Inhibitor
DMUC6EP	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMUC6EP	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM9UZD7	DI	DM9UZD7
DM9UZD7	DN	Bile acid
DM9UZD7	MI	DEDZRQ1
DM9UZD7	MN	Cytochrome P450 7A1 (CYP7A1)
DM9UZD7	MT	DME
DM9UZD7	MA	Metabolism
DM9UZD7	RN	FGF15 activates Hippo signaling to suppress bile acid metabolism and liver tumorigenesis. Dev Cell. 2019 Feb 25;48(4):460-474.e9.
DM9UZD7	RU	https://pubmed.ncbi.nlm.nih.gov/30745141

DMBTSZD	DI	DMBTSZD
DMBTSZD	DN	BIMU-1
DMBTSZD	MI	TTNXLKE
DMBTSZD	MN	5-HT 3 receptor (5HT3R)
DMBTSZD	MT	DTT
DMBTSZD	MA	Modulator
DMBTSZD	RN	Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
DMBTSZD	RU	https://pubmed.ncbi.nlm.nih.gov/8058105

DMBTSZD	DI	DMBTSZD
DMBTSZD	DN	BIMU-1
DMBTSZD	MI	TT07C3Y
DMBTSZD	MN	5-HT 4 receptor (HTR4)
DMBTSZD	MT	DTT
DMBTSZD	MA	Modulator
DMBTSZD	RN	Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
DMBTSZD	RU	https://pubmed.ncbi.nlm.nih.gov/8058105

DMQ9KZW	DI	DMQ9KZW
DMQ9KZW	DN	Biomed 101
DMQ9KZW	MI	TTN53ZF
DMQ9KZW	MN	Leukotriene B4 receptor 1 (LTB4R)
DMQ9KZW	MT	DTT
DMQ9KZW	MA	Binder
DMQ9KZW	RN	Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
DMQ9KZW	RU	http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101740

DMQ9KZW	DI	DMQ9KZW
DMQ9KZW	DN	Biomed 101
DMQ9KZW	MI	TTVJX54
DMQ9KZW	MN	Leukotriene B4 receptor 2 (LTB4R2)
DMQ9KZW	MT	DTT
DMQ9KZW	MA	Inhibitor
DMQ9KZW	RN	Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993).
DMQ9KZW	RU	http://www.sciencedirect.com/science/article/pii/S0960894X01810003

DMS4P6K	DI	DMS4P6K
DMS4P6K	DN	Biostrophin
DMS4P6K	MI	TT48MP6
DMS4P6K	MN	Dystrophin (DMD)
DMS4P6K	MT	DTT
DMS4P6K	MA	Modulator
DMS4P6K	RN	Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8. 
DMS4P6K	RU	https://pubmed.ncbi.nlm.nih.gov/23609411

DMGAR9Y	DI	DMGAR9Y
DMGAR9Y	DN	BIT225
DMGAR9Y	MI	TT5FNQT
DMGAR9Y	MN	Human immunodeficiency virus Protease (HIV PR)
DMGAR9Y	MT	DTT
DMGAR9Y	MA	Inhibitor
DMGAR9Y	RN	2011 Pipeline of Biotron.
DMGAR9Y	RU	http://www.biotron.com.au/

DM61JH5	DI	DM61JH5
DM61JH5	DN	BIWA 4
DM61JH5	MI	TTWFBT7
DM61JH5	MN	Extracellular matrix receptor III (CD44)
DM61JH5	MT	DTT
DM61JH5	RN	A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72.
DM61JH5	RU	https://pubmed.ncbi.nlm.nih.gov/17062682

DMX9ER7	DI	DMX9ER7
DMX9ER7	DN	BIZELESIN
DMX9ER7	MI	TTUTN1I
DMX9ER7	MN	Human Deoxyribonucleic acid (hDNA)
DMX9ER7	MT	DTT
DMX9ER7	MA	Inhibitor
DMX9ER7	RN	Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30.
DMX9ER7	RU	https://pubmed.ncbi.nlm.nih.gov/8180230

DMAYSFK	DI	DMAYSFK
DMAYSFK	DN	BL-1021
DMAYSFK	MI	TTAWNKZ
DMAYSFK	MN	Norepinephrine transporter (NET)
DMAYSFK	MT	DTT
DMAYSFK	MA	Modulator
DMAYSFK	RN	Company report (BioLineRx)
DMAYSFK	RU	http://www.biolinerx.com/default.asp?pageid=13&itemid=13

DMAYSFK	DI	DMAYSFK
DMAYSFK	DN	BL-1021
DMAYSFK	MI	TT3ROYC
DMAYSFK	MN	Serotonin transporter (SERT)
DMAYSFK	MT	DTT
DMAYSFK	MA	Modulator
DMAYSFK	RN	Company report (BioLineRx)
DMAYSFK	RU	http://www.biolinerx.com/default.asp?pageid=13&itemid=13

DM27J3D	DI	DM27J3D
DM27J3D	DN	BLU-554
DM27J3D	MI	TT1KX2S
DM27J3D	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DM27J3D	MT	DTT
DM27J3D	MA	Inhibitor
DM27J3D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM27J3D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYHNV3	DI	DMYHNV3
DMYHNV3	DN	BLY719
DMYHNV3	MI	TTEUNMR
DMYHNV3	MN	PI3-kinase alpha (PIK3CA)
DMYHNV3	MT	DTT
DMYHNV3	MA	Inhibitor
DMYHNV3	RN	In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82.
DMYHNV3	RU	https://pubmed.ncbi.nlm.nih.gov/25550549

DMIRX3Z	DI	DMIRX3Z
DMIRX3Z	DN	BM-212
DMIRX3Z	MI	TTTLB3R
DMIRX3Z	MN	Mycobacterium Membrane protein mmpL3 (MycB mmpL3)
DMIRX3Z	MT	DTT
DMIRX3Z	MA	Modulator
DMIRX3Z	RN	MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan;56(1):324-31.
DMIRX3Z	RU	https://pubmed.ncbi.nlm.nih.gov/22024828

DM43RV5	DI	DM43RV5
DM43RV5	DN	BM-ca
DM43RV5	MI	TTUE541
DM43RV5	MN	Leukocyte surface antigen Leu-16 (CD20)
DM43RV5	MT	DTT
DM43RV5	RN	BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44.
DM43RV5	RU	https://pubmed.ncbi.nlm.nih.gov/21152859

DMJNFI2	DI	DMJNFI2
DMJNFI2	DN	BMEC-1217B
DMJNFI2	MI	TTFTSHD
DMJNFI2	MN	Cytokine unspecific (CYK)
DMJNFI2	MT	DTT
DMJNFI2	MA	Regulator
DMJNFI2	RN	ClinicalTrials.gov (NCT00425971) Safety Study of Anti-Asthma Agent BMEC-1217B. U.S. National Institutes of Health.
DMJNFI2	RU	https://clinicaltrials.gov/ct2/show/NCT00425971

DMTZ3A6	DI	DMTZ3A6
DMTZ3A6	DN	BMS-196085
DMTZ3A6	MI	TTMXGCW
DMTZ3A6	MN	Adrenergic receptor beta-3 (ADRB3)
DMTZ3A6	MT	DTT
DMTZ3A6	MA	Inhibitor
DMTZ3A6	RN	Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6.
DMTZ3A6	RU	https://pubmed.ncbi.nlm.nih.gov/17533126

DM5M48F	DI	DM5M48F
DM5M48F	DN	BMS214662
DM5M48F	MI	TTXQKM3
DM5M48F	MN	Farnesyl protein transferase (Ftase)
DM5M48F	MT	DTT
DM5M48F	MA	Modulator
DM5M48F	RN	Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604.
DM5M48F	RU	https://www.ncbi.nlm.nih.gov/pubmed/15356656

DMGDJQR	DI	DMGDJQR
DMGDJQR	DN	BMS-394136
DMGDJQR	MI	TTW0CMT
DMGDJQR	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMGDJQR	MT	DTT
DMGDJQR	MA	Modulator
DMGDJQR	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMGDJQR	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMPK32V	DI	DMPK32V
DMPK32V	DN	BMS-754807
DMPK32V	MI	TTWTSCV
DMPK32V	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DMPK32V	MT	DTT
DMPK32V	MA	Inhibitor
DMPK32V	RN	Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3.
DMPK32V	RU	https://pubmed.ncbi.nlm.nih.gov/19778024

DMKR8S1	DI	DMKR8S1
DMKR8S1	DN	BMS-779788
DMKR8S1	MI	TTM1EQF
DMKR8S1	MN	Oxysterols receptor LXR (NR1H)
DMKR8S1	MT	DTT
DMKR8S1	MA	Modulator
DMKR8S1	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMKR8S1	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DM2WMJ7	DI	DM2WMJ7
DM2WMJ7	DN	BMS-816336
DM2WMJ7	MI	TTN7BL9
DM2WMJ7	MN	Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)
DM2WMJ7	MT	DTT
DM2WMJ7	MA	Inhibitor
DM2WMJ7	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027626)
DM2WMJ7	RU	http://adisinsight.springer.com/drugs/800027626

DMCX0H7	DI	DMCX0H7
DMCX0H7	DN	BMS-820132
DMCX0H7	MI	TTDLNGZ
DMCX0H7	MN	Glucokinase (GCK)
DMCX0H7	MT	DTT
DMCX0H7	MA	Inhibitor
DMCX0H7	RN	Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.
DMCX0H7	RU	https://pubmed.ncbi.nlm.nih.gov/26085543

DMPQ5XC	DI	DMPQ5XC
DMPQ5XC	DN	BMS-824383
DMPQ5XC	MI	TTCJ2X8
DMPQ5XC	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMPQ5XC	MT	DTT
DMPQ5XC	MA	Inhibitor
DMPQ5XC	RN	2011 Pipeline of Bristol-Myers Squibb.
DMPQ5XC	RU	http://www.bms.com/pages/default.aspx

DMCW71N	DI	DMCW71N
DMCW71N	DN	BMS-830216
DMCW71N	MI	TTX4RTB
DMCW71N	MN	Melanin-concentrating hormone receptor 1 (MCHR1)
DMCW71N	MT	DTT
DMCW71N	MA	Antagonist
DMCW71N	RN	2011 Pipeline of Bristol-Myers Squibb.
DMCW71N	RU	http://www.bms.com/pages/default.aspx

DMZS1D2	DI	DMZS1D2
DMZS1D2	DN	BMS-852927
DMZS1D2	MI	TTM1EQF
DMZS1D2	MN	Oxysterols receptor LXR (NR1H)
DMZS1D2	MT	DTT
DMZS1D2	MA	Modulator
DMZS1D2	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMZS1D2	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DM7JW0B	DI	DM7JW0B
DM7JW0B	DN	BMS-903452
DM7JW0B	MI	TT7QNVC
DM7JW0B	MN	Glucose-dependent insulinotropic receptor (GPR119)
DM7JW0B	MT	DTT
DM7JW0B	MA	Modulator
DM7JW0B	RN	Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508.
DM7JW0B	RU	https://pubmed.ncbi.nlm.nih.gov/25208139

DM3K8VM	DI	DM3K8VM
DM3K8VM	DN	BMS-908662
DM3K8VM	MI	TTWCGQT
DM3K8VM	MN	Serine/threonine-protein kinase B-raf (BRAF)
DM3K8VM	MT	DTT
DM3K8VM	MA	Inhibitor
DM3K8VM	RN	Clinical pipeline report, company report or official report of Exelixis (2011).
DM3K8VM	RU	http://www.exelixis.com/pipeline

DMG3J6C	DI	DMG3J6C
DMG3J6C	DN	BMS-933043
DMG3J6C	MI	TTLA931
DMG3J6C	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMG3J6C	MT	DTT
DMG3J6C	MA	Modulator
DMG3J6C	RN	Clinical pipeline report, company report or official report of Phrma.org Alzheimers 2012.
DMG3J6C	RU	http://phrma.org/sites/default/files/pdf/alzheimers2012.pdf

DMYIBFM	DI	DMYIBFM
DMYIBFM	DN	BMS-936561
DMYIBFM	MI	TTNCIE0
DMYIBFM	MN	CD70 antigen (CD27-L)
DMYIBFM	MT	DTT
DMYIBFM	MA	Modulator
DMYIBFM	RN	Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
DMYIBFM	RU	https://pubmed.ncbi.nlm.nih.gov/25869904

DMS4H1J	DI	DMS4H1J
DMS4H1J	DN	BMS-936564
DMS4H1J	MI	TTBID49
DMS4H1J	MN	C-X-C chemokine receptor type 4 (CXCR4)
DMS4H1J	MT	DTT
DMS4H1J	MA	Modulator
DMS4H1J	RN	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66.
DMS4H1J	RU	https://pubmed.ncbi.nlm.nih.gov/23213054

DMZ4WMT	DI	DMZ4WMT
DMZ4WMT	DN	BMS-986104
DMZ4WMT	MI	TT9JZCK
DMZ4WMT	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMZ4WMT	MT	DTT
DMZ4WMT	MA	Modulator
DMZ4WMT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ4WMT	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMYLFQR	DI	DMYLFQR
DMYLFQR	DN	BMS-986120
DMYLFQR	MI	TT3I4WV
DMYLFQR	MN	Prostate apoptosis response-4 (PAWR)
DMYLFQR	MT	DTT
DMYLFQR	MA	Antagonist
DMYLFQR	RN	PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456.
DMYLFQR	RU	https://pubmed.ncbi.nlm.nih.gov/29269513

DMXU5FK	DI	DMXU5FK
DMXU5FK	DN	BMS-986189
DMXU5FK	MI	TT8ZLTI
DMXU5FK	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMXU5FK	MT	DTT
DMXU5FK	MA	Inhibitor
DMXU5FK	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMXU5FK	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMHTEZ8	DI	DMHTEZ8
DMHTEZ8	DN	BMS-986249
DMHTEZ8	MI	TTI2S1D
DMHTEZ8	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMHTEZ8	MT	DTT
DMHTEZ8	RN	Clinical pipeline report, company report or official report of CytomX Therapeutics.
DMHTEZ8	RU	https://cytomx.com/pipeline/

DMTMUWJ	DI	DMTMUWJ
DMTMUWJ	DN	BMS-986299
DMTMUWJ	MI	TT4EN8X
DMTMUWJ	MN	Caterpiller protein 1.1 (NLRP3)
DMTMUWJ	MT	DTT
DMTMUWJ	MA	Agonist
DMTMUWJ	RN	National Cancer Institute Drug Dictionary (drug name BMS-986299).
DMTMUWJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nlrp3-agonist-bms-986299

DMM3DBU	DI	DMM3DBU
DMM3DBU	DN	BMS-986301
DMM3DBU	MI	TTT402Y
DMM3DBU	MN	Stimulator of interferon genes protein (TMEM173)
DMM3DBU	MT	DTT
DMM3DBU	MA	Agonist
DMM3DBU	RN	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323.
DMM3DBU	RU	https://pubmed.ncbi.nlm.nih.gov/33081170

DMB6FMH	DI	DMB6FMH
DMB6FMH	DN	BMTP-11
DMB6FMH	MI	TTZPLJS
DMB6FMH	MN	Interleukin 11 receptor alpha (IL11RA)
DMB6FMH	MT	DTT
DMB6FMH	MA	Modulator
DMB6FMH	RN	Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51.
DMB6FMH	RU	https://pubmed.ncbi.nlm.nih.gov/25779950

DMW8VEH	DI	DMW8VEH
DMW8VEH	DN	BMY-43748
DMW8VEH	MI	TT0IHXV
DMW8VEH	MN	DNA topoisomerase II (TOP2)
DMW8VEH	MT	DTT
DMW8VEH	MA	Modulator
DMW8VEH	RN	Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.
DMW8VEH	RU	https://pubmed.ncbi.nlm.nih.gov/20732241

DMSBM6A	DI	DMSBM6A
DMSBM6A	DN	BNC-101
DMSBM6A	MI	TTTSGRH
DMSBM6A	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMSBM6A	MT	DTT
DMSBM6A	MA	Inhibitor
DMSBM6A	RN	Clinical pipeline report, company report or official report of Bionomics.
DMSBM6A	RU	https://www.bionomics.com.au/research-development/pipeline/oncology

DMI4UY3	DI	DMI4UY3
DMI4UY3	DN	BNC375
DMI4UY3	MI	TTLA931
DMI4UY3	MN	Neuronal acetylcholine receptor alpha-7 (CHRNA7)
DMI4UY3	MT	DTT
DMI4UY3	MA	Modulator
DMI4UY3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI4UY3	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMU790L	DI	DMU790L
DMU790L	DN	BOS172722
DMU790L	MI	TTP7EGM
DMU790L	MN	Dual specificity protein kinase TTK (MPS1)
DMU790L	MT	DTT
DMU790L	MA	Inhibitor
DMU790L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMU790L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9L0D8	DI	DM9L0D8
DM9L0D8	DN	BOS172738
DM9L0D8	MI	TT4DXQT
DM9L0D8	MN	Proto-oncogene c-Ret (RET)
DM9L0D8	MT	DTT
DM9L0D8	MA	Inhibitor
DM9L0D8	RN	National Cancer Institute Drug Dictionary (drug name Zeteletinib).
DM9L0D8	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zeteletinib

DMI826O	DI	DMI826O
DMI826O	DN	BP1002
DMI826O	MI	TTFOUV4
DMI826O	MN	BCL-2 messenger RNA (BCL2 mRNA)
DMI826O	MT	DTT
DMI826O	MA	Inhibitor
DMI826O	RN	Clinical pipeline report, company report or official report of Bio-Path Holdings.
DMI826O	RU	http://dnabilize.com/bp1002/

DMNY0U5	DI	DMNY0U5
DMNY0U5	DN	BPI-9016 M
DMNY0U5	MI	TTNDSF4
DMNY0U5	MN	Proto-oncogene c-Met (MET)
DMNY0U5	MT	DTT
DMNY0U5	MA	Inhibitor
DMNY0U5	RN	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
DMNY0U5	RU	https://pubmed.ncbi.nlm.nih.gov/31948451

DMNY0U5	DI	DMNY0U5
DMNY0U5	DN	BPI-9016 M
DMNY0U5	MI	TTZPY6J
DMNY0U5	MN	Tyrosine-protein kinase UFO (AXL)
DMNY0U5	MT	DTT
DMNY0U5	MA	Inhibitor
DMNY0U5	RN	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.
DMNY0U5	RU	https://pubmed.ncbi.nlm.nih.gov/31948451

DM51MSD	DI	DM51MSD
DM51MSD	DN	BPX-101
DM51MSD	MI	TTIJP3Q
DM51MSD	MN	TNF related activation protein (CD40LG)
DM51MSD	MT	DTT
DM51MSD	RN	Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
DM51MSD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/

DMYERSD	DI	DMYERSD
DMYERSD	DN	BPX-701
DMYERSD	MI	TT7AKW1
DMYERSD	MN	T-cell receptor (TCR)
DMYERSD	MT	DTT
DMYERSD	MA	Immunomodulator
DMYERSD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYERSD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMOQ2GB	DI	DMOQ2GB
DMOQ2GB	DN	BR6819
DMOQ2GB	MI	TTYCILE
DMOQ2GB	MN	Vasopressin receptor (VR)
DMOQ2GB	MT	DTT
DMOQ2GB	MA	Antagonist
DMOQ2GB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOQ2GB	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEGPI81
DM4R6UV	MN	Angiotensin-converting enzyme 2 (ACE2)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Nunn's Applied Respiratory Physiology (Eighth Edition). Chapter 11 - Nonrespiratory Functions of the Lung.2017, Pages 203-214.e2
DM4R6UV	RU	https://www.sciencedirect.com/science/article/pii/B9780702062940000113

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEPWYLT
DM4R6UV	MN	Arginine carboxypeptidase (CPN1)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem. 2009 Jan 9;284(2):751-8.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19010784

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	TTGY8IW
DM4R6UV	MN	B2 bradykinin receptor (BDKRB2)
DM4R6UV	MT	DTT
DM4R6UV	MA	Inhibitor
DM4R6UV	RN	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
DM4R6UV	RU	https://pubmed.ncbi.nlm.nih.gov/10882364

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE1TNRG
DM4R6UV	MN	Carboxypeptidase M (CPM)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Interactions between carboxypeptidase M and kinin B1 receptor in endothelial cells. Inflamm Res. 2019 Oct;68(10):845-855.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31218444

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEHEZPI
DM4R6UV	MN	Cathepsin H (CTSH)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Human brain cathepsin H as a neuropeptide and bradykinin metabolizing enzyme. Peptides. 2003 Dec;24(12):1977-84.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15127951

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEG3S8C
DM4R6UV	MN	Cathepsin K (CTSK)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	A cysteine-type carboxypeptidase, cathepsin X, generates peptide receptor agonists. Int Immunopharmacol. 2010 Jan;10(1):134-9.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=19800993

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEIORCK
DM4R6UV	MN	Dipeptidyl peptidase II (DPP7)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 1989 Apr;52(4):1284-93.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=2564425

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEKBXUC
DM4R6UV	MN	PABA peptide hydrolase (MEP1B)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Human and mouse homo-oligomeric meprin A metalloendopeptidase: substrate and inhibitor specificities. Biol Chem. 2007 Nov;388(11):1163-72.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17976009

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DEVSCNZ
DM4R6UV	MN	Prolyl endopeptidase (PREP)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease. Peptides. 2006 Dec;27(12):3363-9.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=17030465

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE8E6X9
DM4R6UV	MN	Soluble aminopeptidase P (sAmp)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese(II)-dependent enzyme. Biochemistry. 2000 Dec 12;39(49):15121-8.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=11106490

DM4R6UV	DI	DM4R6UV
DM4R6UV	DN	Bradykinin
DM4R6UV	MI	DE95LJC
DM4R6UV	MN	Thimet oligopeptidase (THOP1)
DM4R6UV	MT	DME
DM4R6UV	MA	Metabolism
DM4R6UV	RN	Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE). Epilepsia. 2014 May;55(5):754-62.
DM4R6UV	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=24702695

DMK7BND	DI	DMK7BND
DMK7BND	DN	Briciclib
DMK7BND	MI	TTFCJ7S
DMK7BND	MN	G1/S-specific cyclin-D1 (CCND1)
DMK7BND	MT	DTT
DMK7BND	MA	Inhibitor
DMK7BND	RN	Clinical pipeline report, company report or official report of Onconova.
DMK7BND	RU	http://www.onconova.com/product-pipeline/briciclib.php

DM1V9YG	DI	DM1V9YG
DM1V9YG	DN	BRL-52656
DM1V9YG	MI	TTQW87Y
DM1V9YG	MN	Opioid receptor kappa (OPRK1)
DM1V9YG	MT	DTT
DM1V9YG	MA	Agonist
DM1V9YG	RN	Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat. J Pharm Pharmacol. 1999 Nov;51(11):1251-6.
DM1V9YG	RU	https://pubmed.ncbi.nlm.nih.gov/10632082

DMTDWIE	DI	DMTDWIE
DMTDWIE	DN	BRX-005
DMTDWIE	MI	TTHYBIX
DMTDWIE	MN	Heat shock protein 70 (HSP70)
DMTDWIE	MT	DTT
DMTDWIE	MA	Modulator
DMTDWIE	RN	Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9.
DMTDWIE	RU	https://pubmed.ncbi.nlm.nih.gov/11021362

DMS4H30	DI	DMS4H30
DMS4H30	DN	BT-063
DMS4H30	MI	TTDB5IS
DMS4H30	MN	Receptor unspecific (Rec)
DMS4H30	MT	DTT
DMS4H30	RN	Clinical pipeline report, company report or official report of Biotest.
DMS4H30	RU	http://www.biotest.com/de/en/r_d/pipeline/bt063.cfm

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TTFQEMX
DMC8XHQ	MN	Casein kinase I alpha (CSNK1A1)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TTQYF7G
DMC8XHQ	MN	Cyclin-dependent kinase 7 (CDK7)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMC8XHQ	DI	DMC8XHQ
DMC8XHQ	DN	BTX-A51
DMC8XHQ	MI	TT1LVF2
DMC8XHQ	MN	Cyclin-dependent kinase 9 (CDK9)
DMC8XHQ	MT	DTT
DMC8XHQ	MA	Inhibitor
DMC8XHQ	RN	Clinical pipeline report, company report or official report of BioTheryX.
DMC8XHQ	RU	https://www.biotheryx.com/pipeline/

DMJ56MS	DI	DMJ56MS
DMJ56MS	DN	BUTYLATEDHYDROXYTOLUENE
DMJ56MS	MI	TTANPDJ
DMJ56MS	MN	Carbonic anhydrase II (CA-II)
DMJ56MS	MT	DTT
DMJ56MS	MA	Inhibitor
DMJ56MS	RN	Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11.
DMJ56MS	RU	https://pubmed.ncbi.nlm.nih.gov/19231207

DM43GPX	DI	DM43GPX
DM43GPX	DN	BVI-007
DM43GPX	MI	TTCG5PE
DM43GPX	MN	Thrombopoietin (THPO)
DM43GPX	MT	DTT
DM43GPX	MA	Inhibitor
DM43GPX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM43GPX	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM43GPX	DI	DM43GPX
DM43GPX	DN	BVI-007
DM43GPX	MI	TTIHYA4
DM43GPX	MN	Thrombopoietin receptor (MPL)
DM43GPX	MT	DTT
DM43GPX	MA	Antagonist
DM43GPX	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722).
DM43GPX	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722

DMEP321	DI	DMEP321
DMEP321	DN	BVT-74316
DMEP321	MI	TTJS8PY
DMEP321	MN	5-HT 6 receptor (HTR6)
DMEP321	MT	DTT
DMEP321	MA	Antagonist
DMEP321	RN	Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
DMEP321	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/

DMY9L4C	DI	DMY9L4C
DMY9L4C	DN	BXCL702
DMY9L4C	MI	TT3C1VN
DMY9L4C	MN	Enzyme unspecific (Enz)
DMY9L4C	MT	DTT
DMY9L4C	MA	Inhibitor
DMY9L4C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY9L4C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMH6B9J	DI	DMH6B9J
DMH6B9J	DN	BZ-55
DMH6B9J	MI	DE5IED8
DMH6B9J	MN	Cytochrome P450 2C9 (CYP2C9)
DMH6B9J	MT	DME
DMH6B9J	MA	Metabolism
DMH6B9J	RN	Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83.
DMH6B9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232

DMOV2ZD	DI	DMOV2ZD
DMOV2ZD	DN	C188-9
DMOV2ZD	MI	TTHJT3X
DMOV2ZD	MN	STAT3 messenger RNA (STAT3 mRNA)
DMOV2ZD	MT	DTT
DMOV2ZD	MA	Inhibitor
DMOV2ZD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOV2ZD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOFT1V	DI	DMOFT1V
DMOFT1V	DN	C-2507
DMOFT1V	MI	TT5FH9Y
DMOFT1V	MN	Human immunodeficiency virus Integrase (HIV IN)
DMOFT1V	MT	DTT
DMOFT1V	MA	Inhibitor
DMOFT1V	RN	Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85.
DMOFT1V	RU	https://pubmed.ncbi.nlm.nih.gov/19843978

DMR0S8U	DI	DMR0S8U
DMR0S8U	DN	C326
DMR0S8U	MI	TTT1V78
DMR0S8U	MN	Interleukin-6 (IL6)
DMR0S8U	MT	DTT
DMR0S8U	MA	Inhibitor
DMR0S8U	RN	The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009 Jul 9;114(2):437-43.
DMR0S8U	RU	https://pubmed.ncbi.nlm.nih.gov/19383972

DMSO3JA	DI	DMSO3JA
DMSO3JA	DN	C7R-GD2.CART cells
DMSO3JA	MI	TT80ARU
DMSO3JA	MN	Ganglioside GD2 (GD2)
DMSO3JA	MT	DTT
DMSO3JA	MA	CAR-T-Cell-Therapy
DMSO3JA	RN	ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N)
DMSO3JA	RU	https://clinicaltrials.gov/ct2/show/NCT03635632

DMPQ1TM	DI	DMPQ1TM
DMPQ1TM	DN	CA-011
DMPQ1TM	MI	TTMI6F5
DMPQ1TM	MN	Transient receptor potential cation channel V1 (TRPV1)
DMPQ1TM	MT	DTT
DMPQ1TM	MA	Agonist
DMPQ1TM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPQ1TM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMYDNQ2	DI	DMYDNQ2
DMYDNQ2	DN	CA102N
DMYDNQ2	MI	TTVKILB
DMYDNQ2	MN	Prostaglandin G/H synthase 2 (COX-2)
DMYDNQ2	MT	DTT
DMYDNQ2	MA	Inhibitor
DMYDNQ2	RN	National Cancer Institute Drug Dictionary (drug name CA102N).
DMYDNQ2	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nimesulide-hyaluronic-acid-conjugate-ca102n

DMOUHR4	DI	DMOUHR4
DMOUHR4	DN	CA-170
DMOUHR4	MI	TT8ZLTI
DMOUHR4	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMOUHR4	MT	DTT
DMOUHR4	MA	Inhibitor
DMOUHR4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOUHR4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ2OP0	DI	DMQ2OP0
DMQ2OP0	DN	CA-170
DMQ2OP0	MI	TT8ZLTI
DMQ2OP0	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMQ2OP0	MT	DTT
DMQ2OP0	MA	Inhibitor
DMQ2OP0	RN	CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804.
DMQ2OP0	RU	https://pubmed.ncbi.nlm.nih.gov/31374878

DMOUHR4	DI	DMOUHR4
DMOUHR4	DN	CA-170
DMOUHR4	MI	TT51SK8
DMOUHR4	MN	V-set immunoregulatory receptor (VSIR)
DMOUHR4	MT	DTT
DMOUHR4	MA	Inhibitor
DMOUHR4	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMOUHR4	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMWV8C6	DI	DMWV8C6
DMWV8C6	DN	CA-4948
DMWV8C6	MI	TTKFVXR
DMWV8C6	MN	Renal carcinoma antigen NY-REN-64 (IRAK-4)
DMWV8C6	MT	DTT
DMWV8C6	MA	Inhibitor
DMWV8C6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMWV8C6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA1QUC	DI	DMA1QUC
DMA1QUC	DN	CAD-1833
DMA1QUC	MI	TTKU9YD
DMA1QUC	MN	Calcium-activated potassium channel KCa2 (KCNN)
DMA1QUC	MT	DTT
DMA1QUC	MA	Modulator
DMA1QUC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA1QUC	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQ7WJI	DI	DMQ7WJI
DMQ7WJI	DN	CAF-01
DMQ7WJI	MI	TT3J5ZI
DMQ7WJI	MN	Cell mediated immunity response (CMIR)
DMQ7WJI	MT	DTT
DMQ7WJI	MA	Modulator
DMQ7WJI	RN	Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114.
DMQ7WJI	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655441/

DMT4Z5B	DI	DMT4Z5B
DMT4Z5B	DN	CALAA-01
DMT4Z5B	MI	TTBWDI0
DMT4Z5B	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMT4Z5B	MT	DTT
DMT4Z5B	MA	Modulator
DMT4Z5B	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT4Z5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMT4Z5B	DI	DMT4Z5B
DMT4Z5B	DN	CALAA-01
DMT4Z5B	MI	TTV5YEH
DMT4Z5B	MN	Transferrin (TF)
DMT4Z5B	MT	DTT
DMT4Z5B	MA	Modulator
DMT4Z5B	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT4Z5B	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQTUH8	DI	DMQTUH8
DMQTUH8	DN	Calanolide A
DMQTUH8	MI	DE4LYSA
DMQTUH8	MN	Cytochrome P450 3A4 (CYP3A4)
DMQTUH8	MT	DME
DMQTUH8	MA	Metabolism
DMQTUH8	RN	Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol. 2017 Jul 19;8:479.
DMQTUH8	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=28769808

DMQTUH8	DI	DMQTUH8
DMQTUH8	DN	Calanolide A
DMQTUH8	MI	TT84ETX
DMQTUH8	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMQTUH8	MT	DTT
DMQTUH8	MA	Inhibitor
DMQTUH8	RN	Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9.
DMQTUH8	RU	https://pubmed.ncbi.nlm.nih.gov/11366704

DM1FLXD	DI	DM1FLXD
DM1FLXD	DN	CAN04
DM1FLXD	MI	TTWS50K
DM1FLXD	MN	Interleukin 1 receptor accessory protein (IL1RAP)
DM1FLXD	MT	DTT
DM1FLXD	MA	Inhibitor
DM1FLXD	RN	A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)
DM1FLXD	RU	https://clinicaltrials.gov/ct2/show/NCT03267316

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DES5XRU
DM9ERH1	MN	Cytochrome P450 2C8 (CYP2C8)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DE5IED8
DM9ERH1	MN	Cytochrome P450 2C9 (CYP2C9)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DE4LYSA
DM9ERH1	MN	Cytochrome P450 3A4 (CYP3A4)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Identification of enzymes responsible for primary and sequential oxygenation reactions of capravirine in human liver microsomes. Drug Metab Dispos. 2006 Nov;34(11):1798-802.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16914510

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	TT84ETX
DM9ERH1	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DM9ERH1	MT	DTT
DM9ERH1	MA	Inhibitor
DM9ERH1	RN	Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
DM9ERH1	RU	https://pubmed.ncbi.nlm.nih.gov/15205383

DM9ERH1	DI	DM9ERH1
DM9ERH1	DN	Capravirine
DM9ERH1	MI	DEYGVN4
DM9ERH1	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DM9ERH1	MT	DME
DM9ERH1	MA	Metabolism
DM9ERH1	RN	Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98.
DM9ERH1	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=15205383

DM8NLPI	DI	DM8NLPI
DM8NLPI	DN	CAR CD30 T cells
DM8NLPI	MI	TT2GM5R
DM8NLPI	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM8NLPI	MT	DTT
DM8NLPI	MA	CAR-T-Cell-Therapy
DM8NLPI	RN	ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
DM8NLPI	RU	https://clinicaltrials.gov/ct2/show/NCT01316146

DMA9M81	DI	DMA9M81
DMA9M81	DN	CAR138 T Cells
DMA9M81	MI	TTYDSVG
DMA9M81	MN	Syndecan-1 (SDC1)
DMA9M81	MT	DTT
DMA9M81	MA	CAR-T-Cell-Therapy
DMA9M81	RN	ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
DMA9M81	RU	https://clinicaltrials.gov/ct2/show/NCT03672318

DMXD4TC	DI	DMXD4TC
DMXD4TC	DN	CAR19 T cells carrying cytoplasmic activated PD-1
DMXD4TC	MI	TTW640A
DMXD4TC	MN	B-lymphocyte surface antigen B4 (CD19)
DMXD4TC	MT	DTT
DMXD4TC	MA	CAR-T-Cell-Therapy
DMXD4TC	RN	ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
DMXD4TC	RU	https://clinicaltrials.gov/ct2/show/NCT03540303

DM4CXE2	DI	DM4CXE2
DM4CXE2	DN	CAR-20/19-T Cells
DM4CXE2	MI	TTW640A
DM4CXE2	MN	B-lymphocyte surface antigen B4 (CD19)
DM4CXE2	MT	DTT
DM4CXE2	MA	CAR-T-Cell-Therapy(Dual specific)
DM4CXE2	RN	ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
DM4CXE2	RU	https://clinicaltrials.gov/ct2/show/NCT03375619

DM4CXE2	DI	DM4CXE2
DM4CXE2	DN	CAR-20/19-T Cells
DM4CXE2	MI	TTUE541
DM4CXE2	MN	Leukocyte surface antigen Leu-16 (CD20)
DM4CXE2	MT	DTT
DM4CXE2	MA	CAR-T-Cell-Therapy(Dual specific)
DM4CXE2	RN	ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
DM4CXE2	RU	https://clinicaltrials.gov/ct2/show/NCT03375619

DM4SNK8	DI	DM4SNK8
DM4SNK8	DN	CARD-024
DM4SNK8	MI	TTB2MXP
DM4SNK8	MN	Angiotensinogenase renin (REN)
DM4SNK8	MT	DTT
DM4SNK8	MA	Agonist
DM4SNK8	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413).
DM4SNK8	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413

DM5WKU1	DI	DM5WKU1
DM5WKU1	DN	Cardiotrophin-1
DM5WKU1	MI	TTXGTZU
DM5WKU1	MN	Cardiotrophin-1 (CTF1)
DM5WKU1	MT	DTT
DM5WKU1	MA	Stimulator
DM5WKU1	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5WKU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQH2DK	DI	DMQH2DK
DMQH2DK	DN	CAR-GPC3 T Cells
DMQH2DK	MI	TTJTSX4
DMQH2DK	MN	Glypican-3 (GPC3)
DMQH2DK	MT	DTT
DMQH2DK	MA	CAR-T-Cell-Therapy
DMQH2DK	RN	ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
DMQH2DK	RU	https://clinicaltrials.gov/ct2/show/NCT02876978

DMU6ZMX	DI	DMU6ZMX
DMU6ZMX	DN	Carmoxirole
DMU6ZMX	MI	TTEX248
DMU6ZMX	MN	Dopamine D2 receptor (D2R)
DMU6ZMX	MT	DTT
DMU6ZMX	MA	Agonist
DMU6ZMX	RN	Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. Cardiovasc Drugs Ther. 1998 Sep;12(4):387-94.
DMU6ZMX	RU	https://pubmed.ncbi.nlm.nih.gov/9825185

DMC7Y5F	DI	DMC7Y5F
DMC7Y5F	DN	CAR-T cells recognizing EpCAM
DMC7Y5F	MI	TTZ8WH4
DMC7Y5F	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMC7Y5F	MT	DTT
DMC7Y5F	MA	CAR-T-Cell-Therapy
DMC7Y5F	RN	ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer
DMC7Y5F	RU	https://clinicaltrials.gov/ct2/show/NCT02915445

DMTZADW	DI	DMTZADW
DMTZADW	DN	CAR-T cells targeting BCMA
DMTZADW	MI	TTZ3P4W
DMTZADW	MN	B-cell maturation protein (TNFRSF17)
DMTZADW	MT	DTT
DMTZADW	MA	CAR-T-Cell-Therapy
DMTZADW	RN	ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
DMTZADW	RU	https://clinicaltrials.gov/ct2/show/NCT03672253

DM3AHNX	DI	DM3AHNX
DM3AHNX	DN	CAR-T Cells targeting CD19
DM3AHNX	MI	TTW640A
DM3AHNX	MN	B-lymphocyte surface antigen B4 (CD19)
DM3AHNX	MT	DTT
DM3AHNX	MA	CAR-T-Cell-Therapy
DM3AHNX	RN	ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
DM3AHNX	RU	https://clinicaltrials.gov/ct2/show/NCT03186118

DMJK1R0	DI	DMJK1R0
DMJK1R0	DN	CAR-T cells targeting CD19
DMJK1R0	MI	TTW640A
DMJK1R0	MN	B-lymphocyte surface antigen B4 (CD19)
DMJK1R0	MT	DTT
DMJK1R0	MA	CAR-T-Cell-Therapy
DMJK1R0	RN	ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
DMJK1R0	RU	https://clinicaltrials.gov/ct2/show/NCT03086954

DM6Z7AD	DI	DM6Z7AD
DM6Z7AD	DN	CAR-T cells targeting CD80/86
DM6Z7AD	MI	TTFZDNP
DM6Z7AD	MN	Activation B7-1 antigen (CD80)
DM6Z7AD	MT	DTT
DM6Z7AD	MA	CAR-T-Cell-Therapy
DM6Z7AD	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DM6Z7AD	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMX4ZDY	DI	DMX4ZDY
DMX4ZDY	DN	CAR-T Cells targeting CEA
DMX4ZDY	MI	TTY6DTE
DMX4ZDY	MN	Carcinoembryonic antigen CEA (CD66e)
DMX4ZDY	MT	DTT
DMX4ZDY	MA	CAR-T-Cell-Therapy
DMX4ZDY	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMX4ZDY	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMRSG04	DI	DMRSG04
DMRSG04	DN	CAR-T cells targeting EGFRviii
DMRSG04	MI	TTZ6B2I
DMRSG04	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMRSG04	MT	DTT
DMRSG04	MA	CAR-T-Cell-Therapy
DMRSG04	RN	ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
DMRSG04	RU	https://clinicaltrials.gov/ct2/show/NCT03170141

DMWAMNT	DI	DMWAMNT
DMWAMNT	DN	CAR-T Cells targeting EGFRvIII
DMWAMNT	MI	TTZ6B2I
DMWAMNT	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMWAMNT	MT	DTT
DMWAMNT	MA	CAR-T-Cell-Therapy
DMWAMNT	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMWAMNT	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMQ2Y1J	DI	DMQ2Y1J
DMQ2Y1J	DN	CAR-T cells targeting EpCAM
DMQ2Y1J	MI	TTZ8WH4
DMQ2Y1J	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMQ2Y1J	MT	DTT
DMQ2Y1J	MA	CAR-T-Cell-Therapy
DMQ2Y1J	RN	ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
DMQ2Y1J	RU	https://clinicaltrials.gov/ct2/show/NCT03563326

DMYCMNR	DI	DMYCMNR
DMYCMNR	DN	CAR-T Cells targeting HER2
DMYCMNR	MI	TT6EO5L
DMYCMNR	MN	Erbb2 tyrosine kinase receptor (HER2)
DMYCMNR	MT	DTT
DMYCMNR	MA	CAR-T-Cell-Therapy
DMYCMNR	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMYCMNR	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMLI5VG	DI	DMLI5VG
DMLI5VG	DN	CAR-T cells targeting HER2
DMLI5VG	MI	TT6EO5L
DMLI5VG	MN	Erbb2 tyrosine kinase receptor (HER2)
DMLI5VG	MT	DTT
DMLI5VG	MA	CAR-T-Cell-Therapy
DMLI5VG	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMLI5VG	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMGI58S	DI	DMGI58S
DMGI58S	DN	CAR-T cells targeting Lewis-Y
DMGI58S	MI	TTV75BJ
DMGI58S	MN	Carbohydrate antigen Lewis-Y (Lewis-Y)
DMGI58S	MT	DTT
DMGI58S	MA	CAR-T-Cell-Therapy
DMGI58S	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMGI58S	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMTZXSO	DI	DMTZXSO
DMTZXSO	DN	CAR-T cells targeting Mesothelin
DMTZXSO	MI	TT4RXME
DMTZXSO	MN	Mesothelin (MSLN)
DMTZXSO	MT	DTT
DMTZXSO	MA	CAR-T-Cell-Therapy
DMTZXSO	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMTZXSO	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DM6DULC	DI	DM6DULC
DM6DULC	DN	CAR-T Cells targeting Mesothelin
DM6DULC	MI	TT4RXME
DM6DULC	MN	Mesothelin (MSLN)
DM6DULC	MT	DTT
DM6DULC	MA	CAR-T-Cell-Therapy
DM6DULC	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DM6DULC	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DM6GRNC	DI	DM6GRNC
DM6GRNC	DN	CAR-T cells targeting MUC1
DM6GRNC	MI	TTBHFYQ
DM6GRNC	MN	Mucin-1 (MUC1)
DM6GRNC	MT	DTT
DM6GRNC	MA	CAR-T-Cell-Therapy
DM6GRNC	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DM6GRNC	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMNH1Y5	DI	DMNH1Y5
DMNH1Y5	DN	CAR-T Cells targeting MUCI
DMNH1Y5	MI	TTBHFYQ
DMNH1Y5	MN	Mucin-1 (MUC1)
DMNH1Y5	MT	DTT
DMNH1Y5	MA	CAR-T-Cell-Therapy
DMNH1Y5	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMNH1Y5	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMWIXLC	DI	DMWIXLC
DMWIXLC	DN	CAR-T Cells targeting PSCA
DMWIXLC	MI	TT9T4AV
DMWIXLC	MN	Prostate stem cell antigen (PSCA)
DMWIXLC	MT	DTT
DMWIXLC	MA	CAR-T-Cell-Therapy
DMWIXLC	RN	ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
DMWIXLC	RU	https://clinicaltrials.gov/ct2/show/NCT03267173

DMU4G9J	DI	DMU4G9J
DMU4G9J	DN	CAR-T cells targeting PSCA
DMU4G9J	MI	TT9T4AV
DMU4G9J	MN	Prostate stem cell antigen (PSCA)
DMU4G9J	MT	DTT
DMU4G9J	MA	CAR-T-Cell-Therapy
DMU4G9J	RN	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
DMU4G9J	RU	https://clinicaltrials.gov/ct2/show/NCT03198052

DMQ4UJ6	DI	DMQ4UJ6
DMQ4UJ6	DN	CART-10 cells
DMQ4UJ6	MI	TT5TKPM
DMQ4UJ6	MN	Neutral endopeptidase (MME)
DMQ4UJ6	MT	DTT
DMQ4UJ6	MA	CAR-T-Cell-Therapy
DMQ4UJ6	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMQ4UJ6	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMAKZTW	DI	DMAKZTW
DMAKZTW	DN	CART-117 cells
DMAKZTW	MI	TTX41N9
DMAKZTW	MN	Tyrosine-protein kinase Kit (KIT)
DMAKZTW	MT	DTT
DMAKZTW	MA	CAR-T-Cell-Therapy
DMAKZTW	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMAKZTW	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMD0XWR	DI	DMD0XWR
DMD0XWR	DN	CART123 cells
DMD0XWR	MI	TTENHJ0
DMD0XWR	MN	Interleukin 3 receptor alpha (IL3RA)
DMD0XWR	MT	DTT
DMD0XWR	MA	CAR-T-Cell-Therapy
DMD0XWR	RN	ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML
DMD0XWR	RU	https://clinicaltrials.gov/ct2/show/NCT03766126

DMEN6YF	DI	DMEN6YF
DMEN6YF	DN	CART-123 cells
DMEN6YF	MI	TTENHJ0
DMEN6YF	MN	Interleukin 3 receptor alpha (IL3RA)
DMEN6YF	MT	DTT
DMEN6YF	MA	CAR-T-Cell-Therapy
DMEN6YF	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMEN6YF	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM1R8P4	DI	DM1R8P4
DM1R8P4	DN	CART-19
DM1R8P4	MI	TTW640A
DM1R8P4	MN	B-lymphocyte surface antigen B4 (CD19)
DM1R8P4	MT	DTT
DM1R8P4	MA	CAR-T-Cell-Therapy
DM1R8P4	RN	ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
DM1R8P4	RU	https://clinicaltrials.gov/ct2/show/NCT03101709

DM8R2ZX	DI	DM8R2ZX
DM8R2ZX	DN	CART-19
DM8R2ZX	MI	TTW640A
DM8R2ZX	MN	B-lymphocyte surface antigen B4 (CD19)
DM8R2ZX	MT	DTT
DM8R2ZX	MA	CAR-T-Cell-Therapy
DM8R2ZX	RN	ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
DM8R2ZX	RU	https://clinicaltrials.gov/ct2/show/NCT02810223

DMY218P	DI	DMY218P
DMY218P	DN	CART-19 autologous T-cells
DMY218P	MI	TTW640A
DMY218P	MN	B-lymphocyte surface antigen B4 (CD19)
DMY218P	MT	DTT
DMY218P	MA	CAR-T-Cell-Therapy
DMY218P	RN	ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP
DMY218P	RU	https://clinicaltrials.gov/ct2/show/NCT02476734

DMM95XS	DI	DMM95XS
DMM95XS	DN	CART19 cell
DMM95XS	MI	TTW640A
DMM95XS	MN	B-lymphocyte surface antigen B4 (CD19)
DMM95XS	MT	DTT
DMM95XS	MA	CAR-T-Cell-Therapy
DMM95XS	RN	ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
DMM95XS	RU	https://clinicaltrials.gov/ct2/show/NCT03685786

DMHWVY1	DI	DMHWVY1
DMHWVY1	DN	CART-19 cells
DMHWVY1	MI	TTW640A
DMHWVY1	MN	B-lymphocyte surface antigen B4 (CD19)
DMHWVY1	MT	DTT
DMHWVY1	MA	CAR-T-Cell-Therapy
DMHWVY1	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMHWVY1	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMKW27X	DI	DMKW27X
DMKW27X	DN	CART-19 cells
DMKW27X	MI	TTW640A
DMKW27X	MN	B-lymphocyte surface antigen B4 (CD19)
DMKW27X	MT	DTT
DMKW27X	MA	CAR-T-Cell-Therapy
DMKW27X	RN	ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
DMKW27X	RU	https://clinicaltrials.gov/ct2/show/NCT02924753

DMTCB8I	DI	DMTCB8I
DMTCB8I	DN	CART-19 T cells
DMTCB8I	MI	TTW640A
DMTCB8I	MN	B-lymphocyte surface antigen B4 (CD19)
DMTCB8I	MT	DTT
DMTCB8I	MA	CAR-T-Cell-Therapy
DMTCB8I	RN	ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma
DMTCB8I	RU	https://clinicaltrials.gov/ct2/show/NCT02135406

DMR0Z65	DI	DMR0Z65
DMR0Z65	DN	CART-20 cells
DMR0Z65	MI	TTUE541
DMR0Z65	MN	Leukocyte surface antigen Leu-16 (CD20)
DMR0Z65	MT	DTT
DMR0Z65	MA	CAR-T-Cell-Therapy
DMR0Z65	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMR0Z65	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM6X82R	DI	DM6X82R
DM6X82R	DN	CART22 cells
DM6X82R	MI	TTM6QSK
DM6X82R	MN	B-cell receptor CD22 (CD22)
DM6X82R	MT	DTT
DM6X82R	MA	CAR-T-Cell-Therapy
DM6X82R	RN	ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
DM6X82R	RU	https://clinicaltrials.gov/ct2/show/NCT02588456

DMLGJKE	DI	DMLGJKE
DMLGJKE	DN	CART-22 cells
DMLGJKE	MI	TTM6QSK
DMLGJKE	MN	B-cell receptor CD22 (CD22)
DMLGJKE	MT	DTT
DMLGJKE	MA	CAR-T-Cell-Therapy
DMLGJKE	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMLGJKE	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMY3NWK	DI	DMY3NWK
DMY3NWK	DN	CART22 cells expressing anti-CD22 scFv TCRz:41BB
DMY3NWK	MI	TTM6QSK
DMY3NWK	MN	B-cell receptor CD22 (CD22)
DMY3NWK	MT	DTT
DMY3NWK	MA	CAR-T-Cell-Therapy
DMY3NWK	RN	ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
DMY3NWK	RU	https://clinicaltrials.gov/ct2/show/NCT02650414

DM4XT15	DI	DM4XT15
DM4XT15	DN	CART22-65s cells
DM4XT15	MI	TTM6QSK
DM4XT15	MN	B-cell receptor CD22 (CD22)
DM4XT15	MT	DTT
DM4XT15	MA	CAR-T-Cell-Therapy
DM4XT15	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DM4XT15	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMOJ1AH	DI	DMOJ1AH
DMOJ1AH	DN	CART22-65s cells and huCART19 Cells
DMOJ1AH	MI	TTM6QSK
DMOJ1AH	MN	B-cell receptor CD22 (CD22)
DMOJ1AH	MT	DTT
DMOJ1AH	MA	CAR-T-Cell-Therapy(Dual specific)
DMOJ1AH	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DMOJ1AH	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMOJ1AH	DI	DMOJ1AH
DMOJ1AH	DN	CART22-65s cells and huCART19 Cells
DMOJ1AH	MI	TTW640A
DMOJ1AH	MN	B-lymphocyte surface antigen B4 (CD19)
DMOJ1AH	MT	DTT
DMOJ1AH	MA	CAR-T-Cell-Therapy(Dual specific)
DMOJ1AH	RN	ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
DMOJ1AH	RU	https://clinicaltrials.gov/ct2/show/NCT03620058

DMBHCSL	DI	DMBHCSL
DMBHCSL	DN	CART-33 cells
DMBHCSL	MI	TTJVYO3
DMBHCSL	MN	Myeloid cell surface antigen CD33 (CD33)
DMBHCSL	MT	DTT
DMBHCSL	MA	CAR-T-Cell-Therapy
DMBHCSL	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMBHCSL	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMRNIB9	DI	DMRNIB9
DMRNIB9	DN	CART-34 cells
DMRNIB9	MI	TTZAVYN
DMRNIB9	MN	Hematopoietic progenitor cell antigen CD34 (CD34)
DMRNIB9	MT	DTT
DMRNIB9	MA	CAR-T-Cell-Therapy
DMRNIB9	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMRNIB9	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMKN8XD	DI	DMKN8XD
DMKN8XD	DN	CART-38 cells
DMKN8XD	MI	TTPURFN
DMKN8XD	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMKN8XD	MT	DTT
DMKN8XD	MA	CAR-T-Cell-Therapy
DMKN8XD	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMKN8XD	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMQTOBF	DI	DMQTOBF
DMQTOBF	DN	CART-56 cells
DMQTOBF	MI	TTVXPHT
DMQTOBF	MN	Neural cell adhesion molecule 1 (NCAM1)
DMQTOBF	MT	DTT
DMQTOBF	MA	CAR-T-Cell-Therapy
DMQTOBF	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMQTOBF	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DMVK3M2	DI	DMVK3M2
DMVK3M2	DN	CART-BCMA
DMVK3M2	MI	TTZ3P4W
DMVK3M2	MN	B-cell maturation protein (TNFRSF17)
DMVK3M2	MT	DTT
DMVK3M2	MA	CAR-T-Cell-Therapy
DMVK3M2	RN	ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma
DMVK3M2	RU	https://clinicaltrials.gov/ct2/show/NCT02546167

DM4OWJ8	DI	DM4OWJ8
DM4OWJ8	DN	CART-ddBCMA
DM4OWJ8	MI	TTZ3P4W
DM4OWJ8	MN	B-cell maturation protein (TNFRSF17)
DM4OWJ8	MT	DTT
DM4OWJ8	RN	Clinical pipeline report, company report or official report of Arcellx.
DM4OWJ8	RU	https://arcellx.com/pipeline/overview/

DMGPR1C	DI	DMGPR1C
DMGPR1C	DN	CART-EGFRvIII T cells
DMGPR1C	MI	TTZ6B2I
DMGPR1C	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMGPR1C	MT	DTT
DMGPR1C	MA	CAR-T-Cell-Therapy
DMGPR1C	RN	ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
DMGPR1C	RU	https://clinicaltrials.gov/ct2/show/NCT02209376

DM90QPK	DI	DM90QPK
DM90QPK	DN	CART-meso cells
DM90QPK	MI	TT4RXME
DM90QPK	MN	Mesothelin (MSLN)
DM90QPK	MT	DTT
DM90QPK	MA	CAR-T-Cell-Therapy
DM90QPK	RN	ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
DM90QPK	RU	https://clinicaltrials.gov/ct2/show/NCT02159716

DMV84ZR	DI	DMV84ZR
DMV84ZR	DN	CARTmeso/19
DMV84ZR	MI	TTW640A
DMV84ZR	MN	B-lymphocyte surface antigen B4 (CD19)
DMV84ZR	MT	DTT
DMV84ZR	MA	CAR-T-Cell-Therapy(Dual specific)
DMV84ZR	RN	ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
DMV84ZR	RU	https://clinicaltrials.gov/ct2/show/NCT03497819

DMV84ZR	DI	DMV84ZR
DMV84ZR	DN	CARTmeso/19
DMV84ZR	MI	TT4RXME
DMV84ZR	MN	Mesothelin (MSLN)
DMV84ZR	MT	DTT
DMV84ZR	MA	CAR-T-Cell-Therapy(Dual specific)
DMV84ZR	RN	ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
DMV84ZR	RU	https://clinicaltrials.gov/ct2/show/NCT03497819

DMZ4I03	DI	DMZ4I03
DMZ4I03	DN	CART-meso-19 T cells
DMZ4I03	MI	TTW640A
DMZ4I03	MN	B-lymphocyte surface antigen B4 (CD19)
DMZ4I03	MT	DTT
DMZ4I03	MA	CAR-T-Cell-Therapy(Dual specific)
DMZ4I03	RN	ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
DMZ4I03	RU	https://clinicaltrials.gov/ct2/show/NCT02465983

DMZ4I03	DI	DMZ4I03
DMZ4I03	DN	CART-meso-19 T cells
DMZ4I03	MI	TT4RXME
DMZ4I03	MN	Mesothelin (MSLN)
DMZ4I03	MT	DTT
DMZ4I03	MA	CAR-T-Cell-Therapy(Dual specific)
DMZ4I03	RN	ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
DMZ4I03	RU	https://clinicaltrials.gov/ct2/show/NCT02465983

DMOJEXG	DI	DMOJEXG
DMOJEXG	DN	CART-Muc1 cells
DMOJEXG	MI	TTBHFYQ
DMOJEXG	MN	Mucin-1 (MUC1)
DMOJEXG	MT	DTT
DMOJEXG	MA	CAR-T-Cell-Therapy
DMOJEXG	RN	ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
DMOJEXG	RU	https://clinicaltrials.gov/ct2/show/NCT03291444

DM39LPN	DI	DM39LPN
DM39LPN	DN	CarVAC
DM39LPN	MI	TTW640A
DM39LPN	MN	B-lymphocyte surface antigen B4 (CD19)
DM39LPN	MT	DTT
DM39LPN	RN	ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health.
DM39LPN	RU	https://clinicaltrials.gov/ct2/show/NCT04156243

DMO53AD	DI	DMO53AD
DMO53AD	DN	Cavrotolimod
DMO53AD	MI	TTSHG0T
DMO53AD	MN	Toll-like receptor 9 (TLR9)
DMO53AD	MT	DTT
DMO53AD	MA	Agonist
DMO53AD	RN	Clinical pipeline report, company report or official report of Exicure.
DMO53AD	RU	https://www.exicuretx.com/pipeline/index.php

DM12GN7	DI	DM12GN7
DM12GN7	DN	CB-5083
DM12GN7	MI	TTHNLSB
DM12GN7	MN	Valosin-containing protein p97 (VCP)
DM12GN7	MT	DTT
DM12GN7	MA	Inhibitor
DM12GN7	RN	Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479.
DM12GN7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479320/

DMOXDIY	DI	DMOXDIY
DMOXDIY	DN	CB-5339
DMOXDIY	MI	TTHNLSB
DMOXDIY	MN	Valosin-containing protein p97 (VCP)
DMOXDIY	MT	DTT
DMOXDIY	MA	Inhibitor
DMOXDIY	RN	Clinical pipeline report, company report or official report of Cleave Therapeutics.
DMOXDIY	RU	https://www.casipharmaceuticals.com/product-pipeline/cb-5339/

DMXQGKL	DI	DMXQGKL
DMXQGKL	DN	CB-813
DMXQGKL	MI	TTF0EGX
DMXQGKL	MN	Coagulation factor VII (F7)
DMXQGKL	MT	DTT
DMXQGKL	MA	Modulator
DMXQGKL	RN	Clinical pipeline report, company report or official report of Catalyst Biosciences.
DMXQGKL	RU	http://www.catalystbiosciences.com/news/15-06-24/

DMORN60	DI	DMORN60
DMORN60	DN	CBL0137
DMORN60	MI	TTETDKQ
DMORN60	MN	Facilitates chromatin transcription complex (FACT)
DMORN60	MT	DTT
DMORN60	MA	Modulator
DMORN60	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMORN60	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMOTLN4	DI	DMOTLN4
DMOTLN4	DN	CBT-101
DMOTLN4	MI	TTNDSF4
DMOTLN4	MN	Proto-oncogene c-Met (MET)
DMOTLN4	MT	DTT
DMOTLN4	MA	Inhibitor
DMOTLN4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOTLN4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW1OKT	DI	DMW1OKT
DMW1OKT	DN	CBT-501
DMW1OKT	MI	TTNBFWK
DMW1OKT	MN	Programmed cell death protein 1 (PD-1)
DMW1OKT	MT	DTT
DMW1OKT	MA	Modulator
DMW1OKT	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW1OKT	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM0SRAN	DI	DM0SRAN
DM0SRAN	DN	CC-122
DM0SRAN	MI	TTDKGTC
DM0SRAN	MN	Protein cereblon (CRBN)
DM0SRAN	MT	DTT
DM0SRAN	MA	Modulator
DM0SRAN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0SRAN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMAYHT4	DI	DMAYHT4
DMAYHT4	DN	CC-31244
DMAYHT4	MI	TTMVBWH
DMAYHT4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMAYHT4	MT	DTT
DMAYHT4	MA	Inhibitor
DMAYHT4	RN	Clinical pipeline report, company report or official report of Cocrystal Pharma.
DMAYHT4	RU	https://www.cocrystalpharma.com/development-pipeline/hepatitis-c/cc-31244

DMILHMC	DI	DMILHMC
DMILHMC	DN	CC8464
DMILHMC	MI	TT4G2JS
DMILHMC	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMILHMC	MT	DTT
DMILHMC	MA	Inhibitor
DMILHMC	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMILHMC	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMXUT3Z	DI	DMXUT3Z
DMXUT3Z	DN	CC-8490
DMXUT3Z	MI	TTZAYWL
DMXUT3Z	MN	Estrogen receptor (ESR)
DMXUT3Z	MT	DTT
DMXUT3Z	MA	Modulator
DMXUT3Z	RN	Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23.
DMXUT3Z	RU	https://pubmed.ncbi.nlm.nih.gov/15604281

DMK0QDO	DI	DMK0QDO
DMK0QDO	DN	CC-90002
DMK0QDO	MI	TT28S46
DMK0QDO	MN	Leukocyte surface antigen CD47 (CD47)
DMK0QDO	MT	DTT
DMK0QDO	MA	Inhibitor
DMK0QDO	RN	National Cancer Institute Drug Dictionary (drug name CC 90002).
DMK0QDO	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd47-monoclonal-antibody-cc-90002

DMHJLB6	DI	DMHJLB6
DMHJLB6	DN	CC-90006
DMHJLB6	MI	TTNBFWK
DMHJLB6	MN	Programmed cell death protein 1 (PD-1)
DMHJLB6	MT	DTT
DMHJLB6	MA	Antagonist
DMHJLB6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMHJLB6	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMKH3Z9	DI	DMKH3Z9
DMKH3Z9	DN	CC-90010
DMKH3Z9	MI	TTE4BSY
DMKH3Z9	MN	Bromodomain and extraterminal domain protein (BET)
DMKH3Z9	MT	DTT
DMKH3Z9	MA	Inhibitor
DMKH3Z9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMKH3Z9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMO0AJE	DI	DMO0AJE
DMO0AJE	DN	CC-90010
DMO0AJE	MI	TTE4BSY
DMO0AJE	MN	Bromodomain and extraterminal domain protein (BET)
DMO0AJE	MT	DTT
DMO0AJE	MA	Inhibitor
DMO0AJE	RN	Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Ann Oncol. 2020 Jun;31(6):780-788.
DMO0AJE	RU	https://pubmed.ncbi.nlm.nih.gov/32240793

DM1GV6O	DI	DM1GV6O
DM1GV6O	DN	CC-90011
DM1GV6O	MI	TTNR0UQ
DM1GV6O	MN	Lysine-specific histone demethylase 1 (LSD)
DM1GV6O	MT	DTT
DM1GV6O	MA	Inhibitor
DM1GV6O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1GV6O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1M4B8	DI	DM1M4B8
DM1M4B8	DN	CC-93269
DM1M4B8	MI	TTZ3P4W
DM1M4B8	MN	B-cell maturation protein (TNFRSF17)
DM1M4B8	MT	DTT
DM1M4B8	RN	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081.
DM1M4B8	RU	https://pubmed.ncbi.nlm.nih.gov/33227097

DM4581B	DI	DM4581B
DM4581B	DN	CC-94676
DM4581B	MI	TTS64P2
DM4581B	MN	Androgen receptor (AR)
DM4581B	MT	DTT
DM4581B	MA	Degrader
DM4581B	RN	ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
DM4581B	RU	https://clinicaltrials.gov/ct2/show/NCT04428788

DM7E1W0	DI	DM7E1W0
DM7E1W0	DN	CC-95251
DM7E1W0	MI	TTBRJS9
DM7E1W0	MN	Inhibitory receptor SHPS-1 (SIRPA)
DM7E1W0	MT	DTT
DM7E1W0	RN	ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health.
DM7E1W0	RU	https://clinicaltrials.gov/ct2/show/NCT03783403

DMJCIGN	DI	DMJCIGN
DMJCIGN	DN	CC-95775
DMJCIGN	MI	TTE4BSY
DMJCIGN	MN	Bromodomain and extraterminal domain protein (BET)
DMJCIGN	MT	DTT
DMJCIGN	MA	Inhibitor
DMJCIGN	RN	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
DMJCIGN	RU	https://www.bms.com/researchers-and-partners/in-the-pipeline.html

DMLONJG	DI	DMLONJG
DMLONJG	DN	CC-97540
DMLONJG	MI	TTW640A
DMLONJG	MN	B-lymphocyte surface antigen B4 (CD19)
DMLONJG	MT	DTT
DMLONJG	RN	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
DMLONJG	RU	https://clinicaltrials.gov/ct2/show/NCT04231747

DM69YM1	DI	DM69YM1
DM69YM1	DN	CC-98633
DM69YM1	MI	TTZ3P4W
DM69YM1	MN	B-cell maturation protein (TNFRSF17)
DM69YM1	MT	DTT
DM69YM1	RN	ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
DM69YM1	RU	https://clinicaltrials.gov/ct2/show/NCT04394650

DM1UEBR	DI	DM1UEBR
DM1UEBR	DN	CC-99712
DM1UEBR	MI	TTZ3P4W
DM1UEBR	MN	B-cell maturation protein (TNFRSF17)
DM1UEBR	MT	DTT
DM1UEBR	RN	ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
DM1UEBR	RU	https://clinicaltrials.gov/ct2/show/NCT04036461

DM86CZJ	DI	DM86CZJ
DM86CZJ	DN	C-CAR011
DM86CZJ	MI	TTW640A
DM86CZJ	MN	B-lymphocyte surface antigen B4 (CD19)
DM86CZJ	MT	DTT
DM86CZJ	MA	CAR-T-Cell-Therapy
DM86CZJ	RN	ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
DM86CZJ	RU	https://clinicaltrials.gov/ct2/show/NCT03299738

DMT35N2	DI	DMT35N2
DMT35N2	DN	C-CAR088
DMT35N2	MI	TTZ3P4W
DMT35N2	MN	B-cell maturation protein (TNFRSF17)
DMT35N2	MT	DTT
DMT35N2	MA	CAR-T-Cell-Therapy
DMT35N2	RN	ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
DMT35N2	RU	https://clinicaltrials.gov/ct2/show/NCT03751293

DMCFMHR	DI	DMCFMHR
DMCFMHR	DN	CCR5 mab
DMCFMHR	MI	TT2CEJG
DMCFMHR	MN	C-C chemokine receptor type 5 (CCR5)
DMCFMHR	MT	DTT
DMCFMHR	RN	CCR5 Monoclonal Antibodies for HIV-1 Therapy. Curr Opin HIV AIDS. 2009 March; 4(2): 104-111.
DMCFMHR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/

DMPTYE6	DI	DMPTYE6
DMPTYE6	DN	CCW702
DMPTYE6	MI	TT9G4N0
DMPTYE6	MN	Glutamate carboxypeptidase II (GCPII)
DMPTYE6	MT	DTT
DMPTYE6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMPTYE6	RU	https://www.abbvie.com/our-science/pipeline/ccw702.html

DMPTYE6	DI	DMPTYE6
DMPTYE6	DN	CCW702
DMPTYE6	MI	TTUN7MC
DMPTYE6	MN	T-cell surface glycoprotein CD3 (CD3)
DMPTYE6	MT	DTT
DMPTYE6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMPTYE6	RU	https://www.abbvie.com/our-science/pipeline/ccw702.html

DMCWVS7	DI	DMCWVS7
DMCWVS7	DN	CCX-025
DMCWVS7	MI	TTIPS8B
DMCWVS7	MN	C-C chemokine receptor type 9 (CCR9)
DMCWVS7	MT	DTT
DMCWVS7	MA	Antagonist
DMCWVS7	RN	Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29.
DMCWVS7	RU	https://pubmed.ncbi.nlm.nih.gov/22946654

DMO7TES	DI	DMO7TES
DMO7TES	DN	CCX507
DMO7TES	MI	TTIPS8B
DMO7TES	MN	C-C chemokine receptor type 9 (CCR9)
DMO7TES	MT	DTT
DMO7TES	MA	Antagonist
DMO7TES	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO7TES	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DM0XDYT	DI	DM0XDYT
DM0XDYT	DN	CD10-CART
DM0XDYT	MI	TT5TKPM
DM0XDYT	MN	Neutral endopeptidase (MME)
DM0XDYT	MT	DTT
DM0XDYT	MA	CAR-T-Cell-Therapy(Dual specific)
DM0XDYT	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DM0XDYT	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DMDFY1R	DI	DMDFY1R
DMDFY1R	DN	CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
DMDFY1R	MI	TTENHJ0
DMDFY1R	MN	Interleukin 3 receptor alpha (IL3RA)
DMDFY1R	MT	DTT
DMDFY1R	MA	CAR-T-Cell-Therapy
DMDFY1R	RN	ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
DMDFY1R	RU	https://clinicaltrials.gov/ct2/show/NCT03114670

DMUJF9T	DI	DMUJF9T
DMUJF9T	DN	CD123-CD33 Ccar
DMUJF9T	MI	TTENHJ0
DMUJF9T	MN	Interleukin 3 receptor alpha (IL3RA)
DMUJF9T	MT	DTT
DMUJF9T	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUJF9T	RU	http://icellgene.com/our-pipeline.html

DMUJF9T	DI	DMUJF9T
DMUJF9T	DN	CD123-CD33 Ccar
DMUJF9T	MI	TTJVYO3
DMUJF9T	MN	Myeloid cell surface antigen CD33 (CD33)
DMUJF9T	MT	DTT
DMUJF9T	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUJF9T	RU	http://icellgene.com/our-pipeline.html

DM2AHXW	DI	DM2AHXW
DM2AHXW	DN	CD171 specific CAR T cells expressing EGFRt
DM2AHXW	MI	TTC9D3K
DM2AHXW	MN	Neural cell adhesion molecule L1 (L1CAM)
DM2AHXW	MT	DTT
DM2AHXW	MA	CAR-T-Cell-Therapy
DM2AHXW	RN	ClinicalTrials.gov (NCT02311621) Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
DM2AHXW	RU	https://clinicaltrials.gov/ct2/show/NCT02311621

DM4PWNU	DI	DM4PWNU
DM4PWNU	DN	CD19 CAR T
DM4PWNU	MI	TTW640A
DM4PWNU	MN	B-lymphocyte surface antigen B4 (CD19)
DM4PWNU	MT	DTT
DM4PWNU	MA	CAR-T-Cell-Therapy
DM4PWNU	RN	ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
DM4PWNU	RU	https://clinicaltrials.gov/ct2/show/NCT03559439

DMCUBFR	DI	DMCUBFR
DMCUBFR	DN	CD19 CAR T Cells
DMCUBFR	MI	TTW640A
DMCUBFR	MN	B-lymphocyte surface antigen B4 (CD19)
DMCUBFR	MT	DTT
DMCUBFR	MA	CAR-T-Cell-Therapy
DMCUBFR	RN	ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
DMCUBFR	RU	https://clinicaltrials.gov/ct2/show/NCT01853631

DMB8RI6	DI	DMB8RI6
DMB8RI6	DN	CD19 CAR T cells
DMB8RI6	MI	TTW640A
DMB8RI6	MN	B-lymphocyte surface antigen B4 (CD19)
DMB8RI6	MT	DTT
DMB8RI6	MA	CAR-T-Cell-Therapy
DMB8RI6	RN	ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
DMB8RI6	RU	https://clinicaltrials.gov/ct2/show/NCT02975687

DMYFWQT	DI	DMYFWQT
DMYFWQT	DN	CD19 CAR T-cells
DMYFWQT	MI	TTW640A
DMYFWQT	MN	B-lymphocyte surface antigen B4 (CD19)
DMYFWQT	MT	DTT
DMYFWQT	MA	CAR-T-Cell-Therapy
DMYFWQT	RN	ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
DMYFWQT	RU	https://clinicaltrials.gov/ct2/show/NCT03298828

DMJCT6Q	DI	DMJCT6Q
DMJCT6Q	DN	CD19 CAR T-cells
DMJCT6Q	MI	TTW640A
DMJCT6Q	MN	B-lymphocyte surface antigen B4 (CD19)
DMJCT6Q	MT	DTT
DMJCT6Q	MA	CAR-T-Cell-Therapy
DMJCT6Q	RN	ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
DMJCT6Q	RU	https://clinicaltrials.gov/ct2/show/NCT02443831

DM6GNDP	DI	DM6GNDP
DM6GNDP	DN	CD19 CAR-T cells
DM6GNDP	MI	TTW640A
DM6GNDP	MN	B-lymphocyte surface antigen B4 (CD19)
DM6GNDP	MT	DTT
DM6GNDP	MA	CAR-T-Cell-Therapy
DM6GNDP	RN	ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
DM6GNDP	RU	https://clinicaltrials.gov/ct2/show/NCT03671460

DMNDACU	DI	DMNDACU
DMNDACU	DN	CD19 CAR-T cells
DMNDACU	MI	TTW640A
DMNDACU	MN	B-lymphocyte surface antigen B4 (CD19)
DMNDACU	MT	DTT
DMNDACU	MA	CAR-T-Cell-Therapy
DMNDACU	RN	ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
DMNDACU	RU	https://clinicaltrials.gov/ct2/show/NCT03064269

DM49RAT	DI	DM49RAT
DM49RAT	DN	CD19 Redirected Autologous T Cells
DM49RAT	MI	TTW640A
DM49RAT	MN	B-lymphocyte surface antigen B4 (CD19)
DM49RAT	MT	DTT
DM49RAT	MA	CAR-T-Cell-Therapy
DM49RAT	RN	ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
DM49RAT	RU	https://clinicaltrials.gov/ct2/show/NCT03030976

DMMO2EJ	DI	DMMO2EJ
DMMO2EJ	DN	CD19.CAR-aNKT cells
DMMO2EJ	MI	TTW640A
DMMO2EJ	MN	B-lymphocyte surface antigen B4 (CD19)
DMMO2EJ	MT	DTT
DMMO2EJ	MA	CAR-T-Cell-Therapy
DMMO2EJ	RN	ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
DMMO2EJ	RU	https://clinicaltrials.gov/ct2/show/NCT03774654

DMVONF0	DI	DMVONF0
DMVONF0	DN	CD19/CD22 CAR T cells
DMVONF0	MI	TTM6QSK
DMVONF0	MN	B-cell receptor CD22 (CD22)
DMVONF0	MT	DTT
DMVONF0	MA	CAR-T-Cell-Therapy(Dual specific)
DMVONF0	RN	ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
DMVONF0	RU	https://clinicaltrials.gov/ct2/show/NCT03241940

DMVONF0	DI	DMVONF0
DMVONF0	DN	CD19/CD22 CAR T cells
DMVONF0	MI	TTW640A
DMVONF0	MN	B-lymphocyte surface antigen B4 (CD19)
DMVONF0	MT	DTT
DMVONF0	MA	CAR-T-Cell-Therapy(Dual specific)
DMVONF0	RN	ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
DMVONF0	RU	https://clinicaltrials.gov/ct2/show/NCT03241940

DMKA2FL	DI	DMKA2FL
DMKA2FL	DN	CD19/CD22 CAR T-Cells
DMKA2FL	MI	TTM6QSK
DMKA2FL	MN	B-cell receptor CD22 (CD22)
DMKA2FL	MT	DTT
DMKA2FL	MA	CAR-T-Cell-Therapy(Dual specific)
DMKA2FL	RN	ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
DMKA2FL	RU	https://clinicaltrials.gov/ct2/show/NCT03448393

DMKA2FL	DI	DMKA2FL
DMKA2FL	DN	CD19/CD22 CAR T-Cells
DMKA2FL	MI	TTW640A
DMKA2FL	MN	B-lymphocyte surface antigen B4 (CD19)
DMKA2FL	MT	DTT
DMKA2FL	MA	CAR-T-Cell-Therapy(Dual specific)
DMKA2FL	RN	ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
DMKA2FL	RU	https://clinicaltrials.gov/ct2/show/NCT03448393

DMPADR1	DI	DMPADR1
DMPADR1	DN	CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1	MI	TTM6QSK
DMPADR1	MN	B-cell receptor CD22 (CD22)
DMPADR1	MT	DTT
DMPADR1	MA	CAR-T-Cell-Therapy(Dual specific)
DMPADR1	RN	ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
DMPADR1	RU	https://clinicaltrials.gov/ct2/show/NCT03233854

DMPADR1	DI	DMPADR1
DMPADR1	DN	CD19/CD22 Chimeric Antigen Receptor T Cells
DMPADR1	MI	TTW640A
DMPADR1	MN	B-lymphocyte surface antigen B4 (CD19)
DMPADR1	MT	DTT
DMPADR1	MA	CAR-T-Cell-Therapy(Dual specific)
DMPADR1	RN	ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
DMPADR1	RU	https://clinicaltrials.gov/ct2/show/NCT03233854

DMGUQ8V	DI	DMGUQ8V
DMGUQ8V	DN	CD19+ CAR T Cells
DMGUQ8V	MI	TTW640A
DMGUQ8V	MN	B-lymphocyte surface antigen B4 (CD19)
DMGUQ8V	MT	DTT
DMGUQ8V	MA	CAR-T-Cell-Therapy
DMGUQ8V	RN	ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies
DMGUQ8V	RU	https://clinicaltrials.gov/ct2/show/NCT02529813

DMUR1MN	DI	DMUR1MN
DMUR1MN	DN	CD19-CAR and CD28-CAR T Cells
DMUR1MN	MI	TTW640A
DMUR1MN	MN	B-lymphocyte surface antigen B4 (CD19)
DMUR1MN	MT	DTT
DMUR1MN	MA	CAR-T-Cell-Therapy(Dual specific)
DMUR1MN	RN	ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
DMUR1MN	RU	https://clinicaltrials.gov/ct2/show/NCT02146924

DMUR1MN	DI	DMUR1MN
DMUR1MN	DN	CD19-CAR and CD28-CAR T Cells
DMUR1MN	MI	TTQ13FT
DMUR1MN	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMUR1MN	MT	DTT
DMUR1MN	MA	CAR-T-Cell-Therapy(Dual specific)
DMUR1MN	RN	ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
DMUR1MN	RU	https://clinicaltrials.gov/ct2/show/NCT02146924

DMJIW5Z	DI	DMJIW5Z
DMJIW5Z	DN	CD19-CAR-T Cells
DMJIW5Z	MI	TTW640A
DMJIW5Z	MN	B-lymphocyte surface antigen B4 (CD19)
DMJIW5Z	MT	DTT
DMJIW5Z	MA	CAR-T-Cell-Therapy
DMJIW5Z	RN	ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL
DMJIW5Z	RU	https://clinicaltrials.gov/ct2/show/NCT03574168

DML07UZ	DI	DML07UZ
DML07UZ	DN	CD19-CAR-T2 Cells
DML07UZ	MI	TTW640A
DML07UZ	MN	B-lymphocyte surface antigen B4 (CD19)
DML07UZ	MT	DTT
DML07UZ	MA	CAR-T-Cell-Therapy
DML07UZ	RN	ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
DML07UZ	RU	https://clinicaltrials.gov/ct2/show/NCT02822326

DM3LRAF	DI	DM3LRAF
DM3LRAF	DN	CD19CAT-41BBZ CAR T-cells
DM3LRAF	MI	TTW640A
DM3LRAF	MN	B-lymphocyte surface antigen B4 (CD19)
DM3LRAF	MT	DTT
DM3LRAF	MA	CAR-T-Cell-Therapy
DM3LRAF	RN	ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19
DM3LRAF	RU	https://clinicaltrials.gov/ct2/show/NCT02935257

DMETGAQ	DI	DMETGAQ
DMETGAQ	DN	CD19-directed CAR-T cells
DMETGAQ	MI	TTW640A
DMETGAQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMETGAQ	MT	DTT
DMETGAQ	MA	CAR-T-Cell-Therapy
DMETGAQ	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMETGAQ	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DM2OEQ9	DI	DM2OEQ9
DM2OEQ9	DN	CD19-directed CAR-T cells
DM2OEQ9	MI	TTW640A
DM2OEQ9	MN	B-lymphocyte surface antigen B4 (CD19)
DM2OEQ9	MT	DTT
DM2OEQ9	MA	CAR-T-Cell-Therapy
DM2OEQ9	RN	ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
DM2OEQ9	RU	https://clinicaltrials.gov/ct2/show/NCT03483688

DMCZ3A2	DI	DMCZ3A2
DMCZ3A2	DN	CD19-targeted CART cells
DMCZ3A2	MI	TTW640A
DMCZ3A2	MN	B-lymphocyte surface antigen B4 (CD19)
DMCZ3A2	MT	DTT
DMCZ3A2	MA	CAR-T-Cell-Therapy
DMCZ3A2	RN	ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
DMCZ3A2	RU	https://clinicaltrials.gov/ct2/show/NCT03599375

DMT7YOU	DI	DMT7YOU
DMT7YOU	DN	CD19t-haNK
DMT7YOU	MI	TTW640A
DMT7YOU	MN	B-lymphocyte surface antigen B4 (CD19)
DMT7YOU	MT	DTT
DMT7YOU	RN	ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health.
DMT7YOU	RU	https://clinicaltrials.gov/ct2/show/NCT04052061

DMOHACZ	DI	DMOHACZ
DMOHACZ	DN	CD19-TriCAR-T
DMOHACZ	MI	TTW640A
DMOHACZ	MN	B-lymphocyte surface antigen B4 (CD19)
DMOHACZ	MT	DTT
DMOHACZ	MA	CAR-T-Cell-Therapy
DMOHACZ	RN	ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy
DMOHACZ	RU	https://clinicaltrials.gov/ct2/show/NCT03720496

DMGXS8L	DI	DMGXS8L
DMGXS8L	DN	CD20Bi aATC
DMGXS8L	MI	TTUE541
DMGXS8L	MN	Leukocyte surface antigen Leu-16 (CD20)
DMGXS8L	MT	DTT
DMGXS8L	MA	Modulator
DMGXS8L	RN	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
DMGXS8L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/

DMGXS8L	DI	DMGXS8L
DMGXS8L	DN	CD20Bi aATC
DMGXS8L	MI	TTUN7MC
DMGXS8L	MN	T-cell surface glycoprotein CD3 (CD3)
DMGXS8L	MT	DTT
DMGXS8L	MA	Modulator
DMGXS8L	RN	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
DMGXS8L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/

DMSJBUZ	DI	DMSJBUZ
DMSJBUZ	DN	CD20-CART
DMSJBUZ	MI	TTUE541
DMSJBUZ	MN	Leukocyte surface antigen Leu-16 (CD20)
DMSJBUZ	MT	DTT
DMSJBUZ	MA	CAR-T-Cell-Therapy(Dual specific)
DMSJBUZ	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DMSJBUZ	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DM37OJN	DI	DM37OJN
DM37OJN	DN	CD20-CAR-T Cells
DM37OJN	MI	TTUE541
DM37OJN	MN	Leukocyte surface antigen Leu-16 (CD20)
DM37OJN	MT	DTT
DM37OJN	MA	CAR-T-Cell-Therapy
DM37OJN	RN	ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
DM37OJN	RU	https://clinicaltrials.gov/ct2/show/NCT03576807

DMUYTW3	DI	DMUYTW3
DMUYTW3	DN	CD20-CD19 cCAR
DMUYTW3	MI	TTW640A
DMUYTW3	MN	B-lymphocyte surface antigen B4 (CD19)
DMUYTW3	MT	DTT
DMUYTW3	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUYTW3	RU	http://icellgene.com/our-pipeline.html

DMUYTW3	DI	DMUYTW3
DMUYTW3	DN	CD20-CD19 cCAR
DMUYTW3	MI	TTUE541
DMUYTW3	MN	Leukocyte surface antigen Leu-16 (CD20)
DMUYTW3	MT	DTT
DMUYTW3	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DMUYTW3	RU	http://icellgene.com/our-pipeline.html

DMHMPK1	DI	DMHMPK1
DMHMPK1	DN	CD22-CART
DMHMPK1	MI	TTM6QSK
DMHMPK1	MN	B-cell receptor CD22 (CD22)
DMHMPK1	MT	DTT
DMHMPK1	MA	CAR-T-Cell-Therapy(Dual specific)
DMHMPK1	RN	ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
DMHMPK1	RU	https://clinicaltrials.gov/ct2/show/NCT03407859

DMP5V83	DI	DMP5V83
DMP5V83	DN	CD22-specific CAR T-cells also expressing an EGFRt
DMP5V83	MI	TTM6QSK
DMP5V83	MN	B-cell receptor CD22 (CD22)
DMP5V83	MT	DTT
DMP5V83	MA	CAR-T-Cell-Therapy
DMP5V83	RN	ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
DMP5V83	RU	https://clinicaltrials.gov/ct2/show/NCT03244306

DMFGQXB	DI	DMFGQXB
DMFGQXB	DN	CD28 and CD137 CAR-T Cells
DMFGQXB	MI	TTPW9LJ
DMFGQXB	MN	Co-stimulatory molecule 4-1BB (CD137)
DMFGQXB	MT	DTT
DMFGQXB	MA	CAR-T-Cell-Therapy(Dual specific)
DMFGQXB	RN	ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
DMFGQXB	RU	https://clinicaltrials.gov/ct2/show/NCT02186860

DMFGQXB	DI	DMFGQXB
DMFGQXB	DN	CD28 and CD137 CAR-T Cells
DMFGQXB	MI	TTQ13FT
DMFGQXB	MN	T-cell-specific surface glycoprotein CD28 (CD28)
DMFGQXB	MT	DTT
DMFGQXB	MA	CAR-T-Cell-Therapy(Dual specific)
DMFGQXB	RN	ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
DMFGQXB	RU	https://clinicaltrials.gov/ct2/show/NCT02186860

DM4VCJA	DI	DM4VCJA
DM4VCJA	DN	CD30 CAR T Cells
DM4VCJA	MI	TT2GM5R
DM4VCJA	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM4VCJA	MT	DTT
DM4VCJA	MA	CAR-T-Cell-Therapy
DM4VCJA	RN	ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
DM4VCJA	RU	https://clinicaltrials.gov/ct2/show/NCT02917083

DMYD31U	DI	DMYD31U
DMYD31U	DN	CD33-CAR-T Cell
DMYD31U	MI	TTJVYO3
DMYD31U	MN	Myeloid cell surface antigen CD33 (CD33)
DMYD31U	MT	DTT
DMYD31U	MA	CAR-T-Cell-Therapy
DMYD31U	RN	ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
DMYD31U	RU	https://clinicaltrials.gov/ct2/show/NCT03126864

DMNX0V7	DI	DMNX0V7
DMNX0V7	DN	CD38 CAR-T
DMNX0V7	MI	TTPURFN
DMNX0V7	MN	Cyclic ADP-ribose hydrolase 1 (CD38)
DMNX0V7	MT	DTT
DMNX0V7	RN	Clinical pipeline report, company report or official report of Sorrento Therapeutics.
DMNX0V7	RU	https://sorrentotherapeutics.com/research/pipeline/

DM09SW6	DI	DM09SW6
DM09SW6	DN	CD4CAR
DM09SW6	MI	TTN2JFW
DM09SW6	MN	T-cell surface glycoprotein CD4 (CD4)
DM09SW6	MT	DTT
DM09SW6	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM09SW6	RU	https://icellgene.com/our-pipeline.html

DMHTNLJ	DI	DMHTNLJ
DMHTNLJ	DN	CD7.CAR/28zeta CAR T cells
DMHTNLJ	MI	TTP6B8O
DMHTNLJ	MN	T-cell antigen CD7 (CD7)
DMHTNLJ	MT	DTT
DMHTNLJ	MA	CAR-T-Cell-Therapy
DMHTNLJ	RN	ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
DMHTNLJ	RU	https://clinicaltrials.gov/ct2/show/NCT03690011

DM8DWOL	DI	DM8DWOL
DM8DWOL	DN	CDNA vaccine
DM8DWOL	MI	TTNYZG2
DM8DWOL	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DM8DWOL	MT	DTT
DM8DWOL	MA	Modulator
DM8DWOL	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8DWOL	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMN8I5Q	DI	DMN8I5Q
DMN8I5Q	DN	CDP-7657
DMN8I5Q	MI	TTIJP3Q
DMN8I5Q	MN	TNF related activation protein (CD40LG)
DMN8I5Q	MT	DTT
DMN8I5Q	RN	CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
DMN8I5Q	RU	https://pubmed.ncbi.nlm.nih.gov/26335795

DM049IX	DI	DM049IX
DM049IX	DN	CDRI-97/78
DM049IX	MI	TTQ2GJ0
DM049IX	MN	Plasmodial phospholipid metabolism (PPP metab)
DM049IX	MT	DTT
DM049IX	MA	Modulator
DM049IX	RN	Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521.
DM049IX	RU	https://pubmed.ncbi.nlm.nih.gov/24800100

DMKUXB5	DI	DMKUXB5
DMKUXB5	DN	CDT-fenofibrate
DMKUXB5	MI	TTJ584C
DMKUXB5	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMKUXB5	MT	DTT
DMKUXB5	MA	Agonist
DMKUXB5	RN	Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93.
DMKUXB5	RU	https://pubmed.ncbi.nlm.nih.gov/9808609

DMPVUGE	DI	DMPVUGE
DMPVUGE	DN	CDX-1127
DMPVUGE	MI	TTDO1MV
DMPVUGE	MN	T-cell activation antigen CD27 (CD27)
DMPVUGE	MT	DTT
DMPVUGE	MA	Modulator
DMPVUGE	RN	Clinical pipeline report, company report or official report of Celldex Therapeutics.
DMPVUGE	RU	http://www.celldex.com/pipeline/cdx-1127.php

DMS20X6	DI	DMS20X6
DMS20X6	DN	CDX-1135
DMS20X6	MI	TTEA8OW
DMS20X6	MN	Complement receptor type 1 (CR1)
DMS20X6	MT	DTT
DMS20X6	MA	Modulator
DMS20X6	RN	Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013 Nov;56(1-2):91-7.
DMS20X6	RU	https://pubmed.ncbi.nlm.nih.gov/23685261

DMUGN0J	DI	DMUGN0J
DMUGN0J	DN	CDX-1140
DMUGN0J	MI	TTN6Y9A
DMUGN0J	MN	CD40L receptor (CD40)
DMUGN0J	MT	DTT
DMUGN0J	MA	Agonist
DMUGN0J	RN	Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245.
DMUGN0J	RU	https://pubmed.ncbi.nlm.nih.gov/30382327

DMVDIWO	DI	DMVDIWO
DMVDIWO	DN	CDX-527
DMVDIWO	MI	TTNBFWK
DMVDIWO	MN	Programmed cell death protein 1 (PD-1)
DMVDIWO	MT	DTT
DMVDIWO	MA	Inhibitor
DMVDIWO	RN	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
DMVDIWO	RU	https://pubmed.ncbi.nlm.nih.gov/32451681

DMVDIWO	DI	DMVDIWO
DMVDIWO	DN	CDX-527
DMVDIWO	MI	TTDO1MV
DMVDIWO	MN	T-cell activation antigen CD27 (CD27)
DMVDIWO	MT	DTT
DMVDIWO	MA	Activator
DMVDIWO	RN	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.
DMVDIWO	RU	https://pubmed.ncbi.nlm.nih.gov/32451681

DM45BHM	DI	DM45BHM
DM45BHM	DN	CEA CAR-T
DM45BHM	MI	TTY6DTE
DM45BHM	MN	Carcinoembryonic antigen CEA (CD66e)
DM45BHM	MT	DTT
DM45BHM	RN	Clinical pipeline report, company report or official report of Sorrento Therapeutics.
DM45BHM	RU	https://sorrentotherapeutics.com/research/immuno-oncology/car-t/

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TT9VGXW
DMYDTJ6	MN	Angiopoietin 1 receptor (TEK)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Modulator
DMYDTJ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
DMYDTJ6	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TT2Q6G1
DMYDTJ6	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Modulator
DMYDTJ6	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
DMYDTJ6	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8189

DMYDTJ6	DI	DMYDTJ6
DMYDTJ6	DN	CEP-11981
DMYDTJ6	MI	TTUTJGQ
DMYDTJ6	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMYDTJ6	MT	DTT
DMYDTJ6	MA	Inhibitor
DMYDTJ6	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMYDTJ6	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DMYXQBF	DI	DMYXQBF
DMYXQBF	DN	CEP-37251
DMYXQBF	MI	TT9E8HR
DMYXQBF	MN	Osteoclast differentiation factor (ODF)
DMYXQBF	MT	DTT
DMYXQBF	MA	Inhibitor
DMYXQBF	RN	This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010
DMYXQBF	RU	http://www.nature.com/scibx/journal/v3/n40/pdf/scibx.2010.1202.pdf

DMV632P	DI	DMV632P
DMV632P	DN	CEP-37440
DMV632P	MI	TTON5IT
DMV632P	MN	Focal adhesion kinase 1 (FAK)
DMV632P	MT	DTT
DMV632P	MA	Modulator
DMV632P	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMV632P	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMLBKZV	DI	DMLBKZV
DMLBKZV	DN	CER-002
DMLBKZV	MI	TT2JWF6
DMLBKZV	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMLBKZV	MT	DTT
DMLBKZV	MA	Agonist
DMLBKZV	RN	Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
DMLBKZV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997800/

DMGAW0H	DI	DMGAW0H
DMGAW0H	DN	CER-522
DMGAW0H	MI	TT7GN3U
DMGAW0H	MN	Apolipoprotein A-I (APOA1)
DMGAW0H	MT	DTT
DMGAW0H	MA	Modulator
DMGAW0H	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033541)
DMGAW0H	RU	http://adisinsight.springer.com/drugs/800033541

DMH701Q	DI	DMH701Q
DMH701Q	DN	CFI-402257
DMH701Q	MI	TTP7EGM
DMH701Q	MN	Dual specificity protein kinase TTK (MPS1)
DMH701Q	MT	DTT
DMH701Q	MA	Inhibitor
DMH701Q	RN	Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
DMH701Q	RU	https://pubmed.ncbi.nlm.nih.gov/28270606

DM3U2VY	DI	DM3U2VY
DM3U2VY	DN	CG-200745
DM3U2VY	MI	TTBH0VX
DM3U2VY	MN	Histone deacetylase (HDAC)
DM3U2VY	MT	DTT
DM3U2VY	MA	Inhibitor
DM3U2VY	RN	Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.
DM3U2VY	RU	https://pubmed.ncbi.nlm.nih.gov/25781604

DMTCLM3	DI	DMTCLM3
DMTCLM3	DN	CGM097
DMTCLM3	MI	TT7SBF5
DMTCLM3	MN	Cellular tumor antigen p53 (TP53)
DMTCLM3	MT	DTT
DMTCLM3	MA	Modulator
DMTCLM3	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMTCLM3	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMAY8I4	DI	DMAY8I4
DMAY8I4	DN	CGTG-102
DMAY8I4	MI	TTNYZG2
DMAY8I4	MN	Granulocyte-macrophage colony-stimulating factor (CSF2)
DMAY8I4	MT	DTT
DMAY8I4	MA	Modulator
DMAY8I4	RN	Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1;135(3):720-30.
DMAY8I4	RU	https://pubmed.ncbi.nlm.nih.gov/24374597

DMSDNU1	DI	DMSDNU1
DMSDNU1	DN	CHF 5407
DMSDNU1	MI	TTQ13Z5
DMSDNU1	MN	Muscarinic acetylcholine receptor M3 (CHRM3)
DMSDNU1	MT	DTT
DMSDNU1	MA	Modulator
DMSDNU1	RN	Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyc... J Pharmacol Exp Ther. 2010 Dec;335(3):622-35.
DMSDNU1	RU	https://www.ncbi.nlm.nih.gov/pubmed/20805306

DMTE18G	DI	DMTE18G
DMTE18G	DN	CHF-4227
DMTE18G	MI	TTZAYWL
DMTE18G	MN	Estrogen receptor (ESR)
DMTE18G	MT	DTT
DMTE18G	MA	Modulator
DMTE18G	RN	Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. J Pharmacol Exp Ther. 2002 Oct;303(1):196-203.
DMTE18G	RU	https://pubmed.ncbi.nlm.nih.gov/12235251

DMSOB5D	DI	DMSOB5D
DMSOB5D	DN	Chi Lob 7/4
DMSOB5D	MI	TTIJP3Q
DMSOB5D	MN	TNF related activation protein (CD40LG)
DMSOB5D	MT	DTT
DMSOB5D	MA	Modulator
DMSOB5D	RN	Agonistic CD40 antibodies and cancer therapy
DMSOB5D	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590838

DM3L52Q	DI	DM3L52Q
DM3L52Q	DN	Chlorcyclizine
DM3L52Q	MI	DTSYQGK
DM3L52Q	MN	Multidrug resistance-associated protein 1 (ABCC1)
DM3L52Q	MT	DTP
DM3L52Q	MA	Substrate
DM3L52Q	RN	Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
DM3L52Q	RU	http://www.ncbi.nlm.nih.gov/pubmed/15666293

DMJLZ8T	DI	DMJLZ8T
DMJLZ8T	DN	CHT-25
DMJLZ8T	MI	TT10Y9E
DMJLZ8T	MN	Interleukin 2 receptor alpha (IL2RA)
DMJLZ8T	MT	DTT
DMJLZ8T	MA	Modulator
DMJLZ8T	RN	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
DMJLZ8T	RU	https://pubmed.ncbi.nlm.nih.gov/20008855

DM2OB6S	DI	DM2OB6S
DM2OB6S	DN	CI-8993
DM2OB6S	MI	TT51SK8
DM2OB6S	MN	V-set immunoregulatory receptor (VSIR)
DM2OB6S	MT	DTT
DM2OB6S	MA	Antagonist
DM2OB6S	RN	Clinical pipeline report, company report or official report of Curis.
DM2OB6S	RU	https://www.curis.com/pipeline/ci-8993/

DM6SCUK	DI	DM6SCUK
DM6SCUK	DN	CI-959
DM6SCUK	MI	TT4IN7L
DM6SCUK	MN	Histamine release (His rele)
DM6SCUK	MT	DTT
DM6SCUK	MA	Modulator
DM6SCUK	RN	Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33.
DM6SCUK	RU	https://pubmed.ncbi.nlm.nih.gov/7557089

DM8T2KA	DI	DM8T2KA
DM8T2KA	DN	CI-966
DM8T2KA	MI	TTPRKM0
DM8T2KA	MN	GABA transporter GAT-1 (SLC6A1)
DM8T2KA	MT	DTT
DM8T2KA	MA	Modulator
DM8T2KA	RN	Tiagabine, SK&amp;F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24.
DM8T2KA	RU	https://pubmed.ncbi.nlm.nih.gov/7851497

DMB2MKU	DI	DMB2MKU
DMB2MKU	DN	CIGB-128
DMB2MKU	MI	TTSIUJ9
DMB2MKU	MN	Interferon-alpha 2 (IFNA2)
DMB2MKU	MT	DTT
DMB2MKU	MA	Modulator
DMB2MKU	RN	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
DMB2MKU	RU	https://www.ncbi.nlm.nih.gov/pubmed/23272809

DMB2MKU	DI	DMB2MKU
DMB2MKU	DN	CIGB-128
DMB2MKU	MI	TT93WF5
DMB2MKU	MN	Interferon-gamma (IFNG)
DMB2MKU	MT	DTT
DMB2MKU	MA	Modulator
DMB2MKU	RN	Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
DMB2MKU	RU	https://www.ncbi.nlm.nih.gov/pubmed/23272809

DMJFPK6	DI	DMJFPK6
DMJFPK6	DN	CIGB-228
DMJFPK6	MI	TT3CPZW
DMJFPK6	MN	Human papillomavirus protein E7 (HPV E7)
DMJFPK6	MT	DTT
DMJFPK6	RN	Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
DMJFPK6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/

DM8XM72	DI	DM8XM72
DM8XM72	DN	CIGB-500
DM8XM72	MI	TTSTYLU
DM8XM72	MN	Growth hormone secretion (GH secr)
DM8XM72	MT	DTT
DM8XM72	MA	Modulator
DM8XM72	RN	Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 1993 Nov;77(5):1393-7.
DM8XM72	RU	https://pubmed.ncbi.nlm.nih.gov/8077339

DMSGRA7	DI	DMSGRA7
DMSGRA7	DN	CIGB-M3
DMSGRA7	MI	TTY6DTE
DMSGRA7	MN	Carcinoembryonic antigen CEA (CD66e)
DMSGRA7	MT	DTT
DMSGRA7	RN	Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353-63.
DMSGRA7	RU	https://pubmed.ncbi.nlm.nih.gov/21711100

DM7EAG8	DI	DM7EAG8
DM7EAG8	DN	Cilobradine
DM7EAG8	MI	TTKLW9S
DM7EAG8	MN	Hyperpolarization cyclic nucleotide-gated channel (HCN)
DM7EAG8	MT	DTT
DM7EAG8	MA	Modulator
DM7EAG8	RN	Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003 Oct 8;478(2-3):161-71.
DM7EAG8	RU	https://pubmed.ncbi.nlm.nih.gov/14575801

DMJLNEF	DI	DMJLNEF
DMJLNEF	DN	Cipatinib
DMJLNEF	MI	TTGKNB4
DMJLNEF	MN	Epidermal growth factor receptor (EGFR)
DMJLNEF	MT	DTT
DMJLNEF	MA	Modulator
DMJLNEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJLNEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJLNEF	DI	DMJLNEF
DMJLNEF	DN	Cipatinib
DMJLNEF	MI	TT6EO5L
DMJLNEF	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJLNEF	MT	DTT
DMJLNEF	MA	Modulator
DMJLNEF	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMJLNEF	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMQLODU	DI	DMQLODU
DMQLODU	DN	Citarinostat
DMQLODU	MI	TT5ZKDI
DMQLODU	MN	Histone deacetylase 6 (HDAC6)
DMQLODU	MT	DTT
DMQLODU	MA	Inhibitor
DMQLODU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQLODU	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRJF2Q	DI	DMRJF2Q
DMRJF2Q	DN	Citatuzumab bogatox
DMRJF2Q	MI	TTZ8WH4
DMRJF2Q	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DMRJF2Q	MT	DTT
DMRJF2Q	RN	Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92.
DMRJF2Q	RU	https://pubmed.ncbi.nlm.nih.gov/22856424

DMRQX9H	DI	DMRQX9H
DMRQX9H	DN	CJ-12255
DMRQX9H	MI	TTZPO1L
DMRQX9H	MN	Substance-P receptor (TACR1)
DMRQX9H	MT	DTT
DMRQX9H	MA	Antagonist
DMRQX9H	RN	Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype. Life Sci. 2013 Aug 6;93(4):169-77.
DMRQX9H	RU	https://pubmed.ncbi.nlm.nih.gov/23792204

DMGSEB0	DI	DMGSEB0
DMGSEB0	DN	CKD-516
DMGSEB0	MI	TTYFKSZ
DMGSEB0	MN	Tubulin beta (TUBB)
DMGSEB0	MT	DTT
DMGSEB0	MA	Inhibitor
DMGSEB0	RN	CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11.
DMGSEB0	RU	https://pubmed.ncbi.nlm.nih.gov/24202729

DMJX6SM	DI	DMJX6SM
DMJX6SM	DN	CKD-712
DMJX6SM	MI	TTKAWRQ
DMJX6SM	MN	JAK-STAT signaling pathway (JAK-STAT pathway)
DMJX6SM	MT	DTT
DMJX6SM	MA	Inhibitor
DMJX6SM	RN	HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008 Oct;20(10):1839-47.
DMJX6SM	RU	https://pubmed.ncbi.nlm.nih.gov/18634870

DM4UAPD	DI	DM4UAPD
DM4UAPD	DN	Clemizole
DM4UAPD	MI	DE4LYSA
DM4UAPD	MN	Cytochrome P450 3A4 (CYP3A4)
DM4UAPD	MT	DME
DM4UAPD	MA	Metabolism
DM4UAPD	RN	Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther. 2013 Feb;344(2):388-96.
DM4UAPD	RU	https://pubmed.ncbi.nlm.nih.gov/23143674

DM4UAPD	DI	DM4UAPD
DM4UAPD	DN	Clemizole
DM4UAPD	MI	TTALKDS
DM4UAPD	MN	Hepatitis C virus Non-structural 4B (HCV NS4B)
DM4UAPD	MT	DTT
DM4UAPD	MA	Modulator
DM4UAPD	RN	The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74.
DM4UAPD	RU	https://pubmed.ncbi.nlm.nih.gov/20486856

DM5EM04	DI	DM5EM04
DM5EM04	DN	CLL1-CD33 cCART cell therapy
DM5EM04	MI	TTJVYO3
DM5EM04	MN	Myeloid cell surface antigen CD33 (CD33)
DM5EM04	MT	DTT
DM5EM04	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM5EM04	RU	http://icellgene.com/our-pipeline.html

DM5EM04	DI	DM5EM04
DM5EM04	DN	CLL1-CD33 cCART cell therapy
DM5EM04	MI	TT70N8V
DM5EM04	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM5EM04	MT	DTT
DM5EM04	RN	Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
DM5EM04	RU	http://icellgene.com/our-pipeline.html

DM05R4C	DI	DM05R4C
DM05R4C	DN	CLN-081
DM05R4C	MI	TTGKNB4
DM05R4C	MN	Epidermal growth factor receptor (EGFR)
DM05R4C	MT	DTT
DM05R4C	MA	Inhibitor
DM05R4C	RN	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
DM05R4C	RU	https://pubmed.ncbi.nlm.nih.gov/29748209

DM2QBMI	DI	DM2QBMI
DM2QBMI	DN	CLP-1004
DM2QBMI	MI	TT1VOHK
DM2QBMI	MN	Potassium channel unspecific (KC)
DM2QBMI	MT	DTT
DM2QBMI	MA	Binder
DM2QBMI	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)
DM2QBMI	RU	http://adisinsight.springer.com/drugs/800036783

DM674MP	DI	DM674MP
DM674MP	DN	CLT030
DM674MP	MI	TT70N8V
DM674MP	MN	Myeloid inhibitory C-type lectin-like receptor (CD371)
DM674MP	MT	DTT
DM674MP	RN	Clinical pipeline report, company report or official report of Cellerant Therapeutics.
DM674MP	RU	https://www.cellerant.com/programs/clt030/

DMJQG25	DI	DMJQG25
DMJQG25	DN	CLX-0921
DMJQG25	MI	TTZMAO3
DMJQG25	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMJQG25	MT	DTT
DMJQG25	MA	Agonist
DMJQG25	RN	A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8.
DMJQG25	RU	https://pubmed.ncbi.nlm.nih.gov/12898466

DMMC6YR	DI	DMMC6YR
DMMC6YR	DN	CM2489
DMMC6YR	MI	TT5HONZ
DMMC6YR	MN	Calcium channel unspecific (CaC)
DMMC6YR	MT	DTT
DMMC6YR	MA	Modulator
DMMC6YR	RN	Molecular pharmacology of store-operated CRAC channels
DMMC6YR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913763

DMSJVX3	DI	DMSJVX3
DMSJVX3	DN	CM3.1-AC100
DMSJVX3	MI	TTVIMDE
DMSJVX3	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMSJVX3	MT	DTT
DMSJVX3	MA	Agonist
DMSJVX3	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
DMSJVX3	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249

DMY5V4U	DI	DMY5V4U
DMY5V4U	DN	CM-CS1 T-cell
DMY5V4U	MI	TTLRN4A
DMY5V4U	MN	NKG2 D activating NK receptor (KLRK1)
DMY5V4U	MT	DTT
DMY5V4U	MA	CAR-T-Cell-Therapy
DMY5V4U	RN	ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
DMY5V4U	RU	https://clinicaltrials.gov/ct2/show/NCT02203825

DMHBNKP	DI	DMHBNKP
DMHBNKP	DN	C-Met/PD-L1 CAR-T Cell
DMHBNKP	MI	TT8ZLTI
DMHBNKP	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMHBNKP	MT	DTT
DMHBNKP	MA	CAR-T-Cell-Therapy(Dual specific)
DMHBNKP	RN	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
DMHBNKP	RU	https://clinicaltrials.gov/ct2/show/NCT03672305

DMHBNKP	DI	DMHBNKP
DMHBNKP	DN	C-Met/PD-L1 CAR-T Cell
DMHBNKP	MI	TTNDSF4
DMHBNKP	MN	Proto-oncogene c-Met (MET)
DMHBNKP	MT	DTT
DMHBNKP	MA	CAR-T-Cell-Therapy(Dual specific)
DMHBNKP	RN	ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
DMHBNKP	RU	https://clinicaltrials.gov/ct2/show/NCT03672305

DMGMI8P	DI	DMGMI8P
DMGMI8P	DN	CMP-001
DMGMI8P	MI	TTSHG0T
DMGMI8P	MN	Toll-like receptor 9 (TLR9)
DMGMI8P	MT	DTT
DMGMI8P	MA	Agonist
DMGMI8P	RN	Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals.
DMGMI8P	RU	https://checkmatepharma.com/pipeline/

DM6NG3C	DI	DM6NG3C
DM6NG3C	DN	CMV glycoprotein B subunit vaccine
DM6NG3C	MI	TTUR18Y
DM6NG3C	MN	Cytomegalovirus Glycoprotein B (CMV gB)
DM6NG3C	MT	DTT
DM6NG3C	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM6NG3C	RU	http://www.gsk-clinicalstudyregister.com/study/108890#ps

DMMF0J3	DI	DMMF0J3
DMMF0J3	DN	CMX-157
DMMF0J3	MI	TT84ETX
DMMF0J3	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMMF0J3	MT	DTT
DMMF0J3	MA	Inhibitor
DMMF0J3	RN	Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193.
DMMF0J3	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612025/

DM8L36X	DI	DM8L36X
DM8L36X	DN	CNTO-3649
DM8L36X	MI	TTVIMDE
DM8L36X	MN	Glucagon-like peptide 1 receptor (GLP1R)
DM8L36X	MT	DTT
DM8L36X	MA	Agonist
DM8L36X	RN	GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7(11):e49152.
DM8L36X	RU	https://pubmed.ncbi.nlm.nih.gov/23133675

DMF8WAT	DI	DMF8WAT
DMF8WAT	DN	CNTO-5825
DMF8WAT	MI	TT0GVCH
DMF8WAT	MN	Interleukin-13 (IL13)
DMF8WAT	MT	DTT
DMF8WAT	RN	Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
DMF8WAT	RU	https://pubmed.ncbi.nlm.nih.gov/23043368

DMUBP0V	DI	DMUBP0V
DMUBP0V	DN	CNTO888
DMUBP0V	MI	TTNAY0P
DMUBP0V	MN	Monocyte chemotactic and activating factor (CCL2)
DMUBP0V	MT	DTT
DMUBP0V	RN	CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62.
DMUBP0V	RU	https://pubmed.ncbi.nlm.nih.gov/17710158

DMJPEVA	DI	DMJPEVA
DMJPEVA	DN	CNTX-0290
DMJPEVA	MI	TTAE1BR
DMJPEVA	MN	Somatostatin receptor type 4 (SSTR4)
DMJPEVA	MT	DTT
DMJPEVA	MA	Agonist
DMJPEVA	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJPEVA	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMCOJM7	DI	DMCOJM7
DMCOJM7	DN	CNTX-6970
DMCOJM7	MI	TTFZYTO
DMCOJM7	MN	C-C chemokine receptor type 2 (CCR2)
DMCOJM7	MT	DTT
DMCOJM7	MA	Antagonist
DMCOJM7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCOJM7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMMEFO0	DI	DMMEFO0
DMMEFO0	DN	COH29
DMMEFO0	MI	TTX09M4
DMMEFO0	MN	Ribonucleotide reductase (RIR)
DMMEFO0	MT	DTT
DMMEFO0	MA	Inhibitor
DMMEFO0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMEFO0	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXQOHV	DI	DMXQOHV
DMXQOHV	DN	COM701
DMXQOHV	MI	TTOGCNT
DMXQOHV	MN	Transmembrane protein PVRIG (PVRIG)
DMXQOHV	MT	DTT
DMXQOHV	RN	Clinical pipeline report, company report or official report of Compugen.
DMXQOHV	RU	https://cgen.com/pipeline/com701-pvrig/

DMR6T8L	DI	DMR6T8L
DMR6T8L	DN	COM902
DMR6T8L	MI	TTWNL74
DMR6T8L	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DMR6T8L	MT	DTT
DMR6T8L	RN	COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
DMR6T8L	RU	https://pubmed.ncbi.nlm.nih.gov/33903974

DMTLP1N	DI	DMTLP1N
DMTLP1N	DN	Combinectin
DMTLP1N	MI	TTG90S6
DMTLP1N	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DMTLP1N	MT	DTT
DMTLP1N	MA	Inhibitor
DMTLP1N	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMTLP1N	RU	https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf

DMTLP1N	DI	DMTLP1N
DMTLP1N	DN	Combinectin
DMTLP1N	MI	TTN2JFW
DMTLP1N	MN	T-cell surface glycoprotein CD4 (CD4)
DMTLP1N	MT	DTT
DMTLP1N	MA	Inhibitor
DMTLP1N	RN	Clinical pipeline report, company report or official report of ViiV Healthcare.
DMTLP1N	RU	https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf

DMA7PWX	DI	DMA7PWX
DMA7PWX	DN	Combotox
DMA7PWX	MI	TTM6QSK
DMA7PWX	MN	B-cell receptor CD22 (CD22)
DMA7PWX	MT	DTT
DMA7PWX	MA	Modulator
DMA7PWX	RN	A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6.
DMA7PWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/21732928

DMA7PWX	DI	DMA7PWX
DMA7PWX	DN	Combotox
DMA7PWX	MI	TTW640A
DMA7PWX	MN	B-lymphocyte surface antigen B4 (CD19)
DMA7PWX	MT	DTT
DMA7PWX	MA	Modulator
DMA7PWX	RN	A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6.
DMA7PWX	RU	https://www.ncbi.nlm.nih.gov/pubmed/21732928

DMULBZM	DI	DMULBZM
DMULBZM	DN	Cosibelimab
DMULBZM	MI	TT8ZLTI
DMULBZM	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMULBZM	MT	DTT
DMULBZM	RN	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
DMULBZM	RU	https://clinicaltrials.gov/ct2/show/NCT03212404

DM6K3JQ	DI	DM6K3JQ
DM6K3JQ	DN	COTI-2
DM6K3JQ	MI	TT7SBF5
DM6K3JQ	MN	Cellular tumor antigen p53 (TP53)
DM6K3JQ	MT	DTT
DM6K3JQ	MA	Modulator
DM6K3JQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM6K3JQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM32TFO	DI	DM32TFO
DM32TFO	DN	CP-870,893
DM32TFO	MI	TTN6Y9A
DM32TFO	MN	CD40L receptor (CD40)
DM32TFO	MT	DTT
DM32TFO	MA	Agonist
DM32TFO	RN	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83.
DM32TFO	RU	https://pubmed.ncbi.nlm.nih.gov/17327609

DM3J1T9	DI	DM3J1T9
DM3J1T9	DN	CPC-212
DM3J1T9	MI	TT1RS9F
DM3J1T9	MN	Acetylcholinesterase (AChE)
DM3J1T9	MT	DTT
DM3J1T9	MA	Inhibitor
DM3J1T9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3J1T9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMDQG4Y	DI	DMDQG4Y
DMDQG4Y	DN	CPC-250
DMDQG4Y	MI	TT1RS9F
DMDQG4Y	MN	Acetylcholinesterase (AChE)
DMDQG4Y	MT	DTT
DMDQG4Y	MA	Inhibitor
DMDQG4Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDQG4Y	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TTRJ1K4
DMVDYTG	MN	Toll-like receptor 7 (TLR7)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TT8CWFK
DMVDYTG	MN	Toll-like receptor 8 (TLR8)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMVDYTG	DI	DMVDYTG
DMVDYTG	DN	CPG 52364
DMVDYTG	MI	TTSHG0T
DMVDYTG	MN	Toll-like receptor 9 (TLR9)
DMVDYTG	MT	DTT
DMVDYTG	MA	Antagonist
DMVDYTG	RN	Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
DMVDYTG	RU	http://www.lifesciencesworld.com/news/view/51194

DMJSFTX	DI	DMJSFTX
DMJSFTX	DN	CPI-006
DMJSFTX	MI	TTK0O6Y
DMJSFTX	MN	Ecto-5'-nucleotidase (CD73)
DMJSFTX	MT	DTT
DMJSFTX	RN	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
DMJSFTX	RU	https://www.corvuspharma.com/our-science/our-pipeline/

DMMBQ20	DI	DMMBQ20
DMMBQ20	DN	CPI-818
DMMBQ20	MI	TT3C80U
DMMBQ20	MN	T-cell-specific kinase (ITK)
DMMBQ20	MT	DTT
DMMBQ20	MA	Inhibitor
DMMBQ20	RN	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
DMMBQ20	RU	https://www.corvuspharma.com/our-science/our-pipeline/

DMFMGZR	DI	DMFMGZR
DMFMGZR	DN	CPL207-280CA
DMFMGZR	MI	TTB8FUC
DMFMGZR	MN	Free fatty acid receptor 1 (GPR40)
DMFMGZR	MT	DTT
DMFMGZR	MA	Agonist
DMFMGZR	RN	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
DMFMGZR	RU	https://pubmed.ncbi.nlm.nih.gov/31548636

DMQCHU3	DI	DMQCHU3
DMQCHU3	DN	CPP -15
DMQCHU3	MI	TTT2LD9
DMQCHU3	MN	GABA transaminase (ABAT)
DMQCHU3	MT	DTT
DMQCHU3	MA	Modulator
DMQCHU3	RN	Clinical pipeline report, company report or official report of Catalyst Pharma.
DMQCHU3	RU	http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588

DMKWSFI	DI	DMKWSFI
DMKWSFI	DN	CR-002
DMKWSFI	MI	TTQA6SX
DMKWSFI	MN	Platelet-derived growth factor B (PDGFB)
DMKWSFI	MT	DTT
DMKWSFI	MA	Modulator
DMKWSFI	RN	A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44.
DMKWSFI	RU	https://www.ncbi.nlm.nih.gov/pubmed/18538109

DMT7L30	DI	DMT7L30
DMT7L30	DN	CR-3465
DMT7L30	MI	TTGKOY9
DMT7L30	MN	Leukotriene CysLT1 receptor (CYSLTR1)
DMT7L30	MT	DTT
DMT7L30	MA	Modulator
DMT7L30	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMT7L30	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMHDSYF	DI	DMHDSYF
DMHDSYF	DN	CRX-675
DMHDSYF	MI	TTISGCA
DMHDSYF	MN	Toll-like receptor 4 (TLR4)
DMHDSYF	MT	DTT
DMHDSYF	MA	Agonist
DMHDSYF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
DMHDSYF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754

DMG0SPO	DI	DMG0SPO
DMG0SPO	DN	CS-0777
DMG0SPO	MI	TT9JZCK
DMG0SPO	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMG0SPO	MT	DTT
DMG0SPO	MA	Modulator
DMG0SPO	RN	Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72.
DMG0SPO	RU	https://pubmed.ncbi.nlm.nih.gov/24900318

DMU8OCN	DI	DMU8OCN
DMU8OCN	DN	CS1-CAR T Therapy
DMU8OCN	MI	TT7ILZ1
DMU8OCN	MN	SLAM family member 7 SLAMF7 (CS1)
DMU8OCN	MT	DTT
DMU8OCN	MA	CAR-T-Cell-Therapy
DMU8OCN	RN	ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
DMU8OCN	RU	https://clinicaltrials.gov/ct2/show/NCT03710421

DMRH740	DI	DMRH740
DMRH740	DN	CS-8080
DMRH740	MI	TTM1EQF
DMRH740	MN	Oxysterols receptor LXR (NR1H)
DMRH740	MT	DTT
DMRH740	MA	Modulator
DMRH740	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DMRH740	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DMO97RV	DI	DMO97RV
DMO97RV	DN	CSL-362
DMO97RV	MI	TTPYS82
DMO97RV	MN	Interleukin 3 receptor (CSF2RB)
DMO97RV	MT	DTT
DMO97RV	RN	Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.
DMO97RV	RU	https://pubmed.ncbi.nlm.nih.gov/24363400

DM7I39W	DI	DM7I39W
DM7I39W	DN	CSL-362-AML
DM7I39W	MI	TTENHJ0
DM7I39W	MN	Interleukin 3 receptor alpha (IL3RA)
DM7I39W	MT	DTT
DM7I39W	RN	Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.
DM7I39W	RU	https://pubmed.ncbi.nlm.nih.gov/24363400

DMI7XMU	DI	DMI7XMU
DMI7XMU	DN	CT 868
DMI7XMU	MI	TTYMKBE
DMI7XMU	MN	Gastric inhibitory polypeptide receptor (GIPR)
DMI7XMU	MT	DTT
DMI7XMU	MA	Modulator
DMI7XMU	RN	Clinical pipeline report, company report or official report of Carmot Therapeutics.
DMI7XMU	RU	http://carmot-therapeutics.us/pipeline/

DMI7XMU	DI	DMI7XMU
DMI7XMU	DN	CT 868
DMI7XMU	MI	TTVIMDE
DMI7XMU	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMI7XMU	MT	DTT
DMI7XMU	MA	Modulator
DMI7XMU	RN	Clinical pipeline report, company report or official report of Carmot Therapeutics.
DMI7XMU	RU	http://carmot-therapeutics.us/pipeline/

DMBCJW6	DI	DMBCJW6
DMBCJW6	DN	CT053
DMBCJW6	MI	TTZ3P4W
DMBCJW6	MN	B-cell maturation protein (TNFRSF17)
DMBCJW6	MT	DTT
DMBCJW6	RN	ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.
DMBCJW6	RU	https://clinicaltrials.gov/ct2/show/NCT03915184

DMW16VR	DI	DMW16VR
DMW16VR	DN	CT-200
DMW16VR	MI	TTBH0VX
DMW16VR	MN	Histone deacetylase (HDAC)
DMW16VR	MT	DTT
DMW16VR	MA	Inhibitor
DMW16VR	RN	Clinical pipeline report, company report or official report of Celleron.
DMW16VR	RU	http://cellerontherapeutics.com/

DMHBK6L	DI	DMHBK6L
DMHBK6L	DN	CTAP-201
DMHBK6L	MI	TTK59TV
DMHBK6L	MN	Vitamin D3 receptor (VDR)
DMHBK6L	MT	DTT
DMHBK6L	MA	Agonist
DMHBK6L	RN	Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009 April; 156(8): 1267-1278.
DMHBK6L	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697742/

DM2HES0	DI	DM2HES0
DM2HES0	DN	CTCE-0214
DM2HES0	MI	TTBID49
DM2HES0	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM2HES0	MT	DTT
DM2HES0	MA	Agonist
DM2HES0	RN	Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7.
DM2HES0	RU	https://pubmed.ncbi.nlm.nih.gov/21274742

DMIKX01	DI	DMIKX01
DMIKX01	DN	CTP-298
DMIKX01	MI	TT5FNQT
DMIKX01	MN	Human immunodeficiency virus Protease (HIV PR)
DMIKX01	MT	DTT
DMIKX01	MA	Inhibitor
DMIKX01	RN	Avanir Licenses Concert's Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal. Vol 2012 Issue 3 Page(38).
DMIKX01	RU	http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1696/html

DM68I93	DI	DM68I93
DM68I93	DN	CTS-21166
DM68I93	MI	TT8JRS7
DM68I93	MN	Beta-secretase (BACE)
DM68I93	MT	DTT
DM68I93	MA	Inhibitor
DM68I93	RN	ClinicalTrials.gov (NCT00621010) Safety Study of CTS21166 to Treat Alzheimer Disease. U. S. National Institutes of Health. 2008.
DM68I93	RU	https://clinicaltrials.gov/ct2/show/NCT00621010

DMAV86R	DI	DMAV86R
DMAV86R	DN	CTT1403
DMAV86R	MI	TT9G4N0
DMAV86R	MN	Glutamate carboxypeptidase II (GCPII)
DMAV86R	MT	DTT
DMAV86R	MA	Inhibitor
DMAV86R	RN	177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017 Apr 27;7(7):1928-1939.
DMAV86R	RU	https://pubmed.ncbi.nlm.nih.gov/28638478

DMHK9WR	DI	DMHK9WR
DMHK9WR	DN	CTX-101
DMHK9WR	MI	TTW640A
DMHK9WR	MN	B-lymphocyte surface antigen B4 (CD19)
DMHK9WR	MT	DTT
DMHK9WR	RN	Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
DMHK9WR	RU	https://pubmed.ncbi.nlm.nih.gov/31900462

DMWS40H	DI	DMWS40H
DMWS40H	DN	CTX120
DMWS40H	MI	TTZ3P4W
DMWS40H	MN	B-cell maturation protein (TNFRSF17)
DMWS40H	MT	DTT
DMWS40H	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DMWS40H	RU	http://www.crisprtx.com/programs/pipeline

DM926CH	DI	DM926CH
DM926CH	DN	CTX130
DM926CH	MI	TTNCIE0
DM926CH	MN	CD70 antigen (CD27-L)
DM926CH	MT	DTT
DM926CH	RN	Clinical pipeline report, company report or official report of CRISPR Therapeutics.
DM926CH	RU	http://www.crisprtx.com/programs/pipeline

DMMPKN3	DI	DMMPKN3
DMMPKN3	DN	CTX-471
DMMPKN3	MI	TTPW9LJ
DMMPKN3	MN	Co-stimulatory molecule 4-1BB (CD137)
DMMPKN3	MT	DTT
DMMPKN3	MA	Agonist
DMMPKN3	RN	Clinical pipeline report, company report or official report of Compass Therapeutics.
DMMPKN3	RU	https://www.compasstherapeutics.com/candidates/ctx-471-cd137-agonist/

DM9ZOMD	DI	DM9ZOMD
DM9ZOMD	DN	CUDC-101
DM9ZOMD	MI	TTGKNB4
DM9ZOMD	MN	Epidermal growth factor receptor (EGFR)
DM9ZOMD	MT	DTT
DM9ZOMD	MA	Modulator
DM9ZOMD	RN	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
DM9ZOMD	RU	https://pubmed.ncbi.nlm.nih.gov/25573383

DM9ZOMD	DI	DM9ZOMD
DM9ZOMD	DN	CUDC-101
DM9ZOMD	MI	TT6EO5L
DM9ZOMD	MN	Erbb2 tyrosine kinase receptor (HER2)
DM9ZOMD	MT	DTT
DM9ZOMD	MA	Modulator
DM9ZOMD	RN	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
DM9ZOMD	RU	https://pubmed.ncbi.nlm.nih.gov/25573383

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TTVB0O3
DMYD37G	MN	Retinoic acid-inducible gene-1 (RIG-1)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TTRJ1K4
DMYD37G	MN	Toll-like receptor 7 (TLR7)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMYD37G	DI	DMYD37G
DMYD37G	DN	CV8102
DMYD37G	MI	TT8CWFK
DMYD37G	MN	Toll-like receptor 8 (TLR8)
DMYD37G	MT	DTT
DMYD37G	MA	Agonist
DMYD37G	RN	Clinical pipeline report, company report or official report of CureVac.
DMYD37G	RU	https://www.curevac.com/en/pipeline/

DMTSIYZ	DI	DMTSIYZ
DMTSIYZ	DN	CVN058
DMTSIYZ	MI	TTNXLKE
DMTSIYZ	MN	5-HT 3 receptor (5HT3R)
DMTSIYZ	MT	DTT
DMTSIYZ	MA	Antagonist
DMTSIYZ	RN	Clinical pipeline report, company report or official report of Cerevance.
DMTSIYZ	RU	https://cerevance.com/pipeline/

DMY84TW	DI	DMY84TW
DMY84TW	DN	CVT-6883
DMY84TW	MI	TTNE7KG
DMY84TW	MN	Adenosine A2b receptor (ADORA2B)
DMY84TW	MT	DTT
DMY84TW	MA	Modulator
DMY84TW	RN	GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95.
DMY84TW	RU	https://pubmed.ncbi.nlm.nih.gov/22923737

DMO23R0	DI	DMO23R0
DMO23R0	DN	CVX 096
DMO23R0	MI	TTVIMDE
DMO23R0	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMO23R0	MT	DTT
DMO23R0	MA	Modulator
DMO23R0	RN	Chemically programmed antibodies. Trends Biotechnol. 2014 April; 32(4): 186-197.
DMO23R0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978777/

DMV74JC	DI	DMV74JC
DMV74JC	DN	CVX-241
DMV74JC	MI	TTKLQTJ
DMV74JC	MN	Angiopoietin-2 (ANGPT2)
DMV74JC	MT	DTT
DMV74JC	MA	Modulator
DMV74JC	RN	Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616.
DMV74JC	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012461/

DMRD2B0	DI	DMRD2B0
DMRD2B0	DN	CXD-101
DMRD2B0	MI	TTBH0VX
DMRD2B0	MN	Histone deacetylase (HDAC)
DMRD2B0	MT	DTT
DMRD2B0	MA	Inhibitor
DMRD2B0	RN	Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.
DMRD2B0	RU	https://pubmed.ncbi.nlm.nih.gov/20002107

DM4GJ50	DI	DM4GJ50
DM4GJ50	DN	CXR-1002
DM4GJ50	MI	TTTN5QW
DM4GJ50	MN	Serine/threonine-protein kinase pim-1 (PIM1)
DM4GJ50	MT	DTT
DM4GJ50	MA	Inhibitor
DM4GJ50	RN	123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46.
DM4GJ50	RU	http://www.researchgate.net/publication/251668212_123_Antitumor_activity_of_CXR1002_a_novel_anti-cancer_clinical_phase_compound_that_induces_ER_stress_and_inhibits_PIM_kinases_Human_tumor_xenograft_efficacy_and_in_vitro_mode_of_action

DMSM42V	DI	DMSM42V
DMSM42V	DN	CYAD-101
DMSM42V	MI	TTLRN4A
DMSM42V	MN	NKG2 D activating NK receptor (KLRK1)
DMSM42V	MT	DTT
DMSM42V	MA	CAR-T-Cell-Therapy
DMSM42V	RN	ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
DMSM42V	RU	https://clinicaltrials.gov/ct2/show/NCT03692429

DM9ODT6	DI	DM9ODT6
DM9ODT6	DN	CYC065
DM9ODT6	MI	TT7HF4W
DM9ODT6	MN	Cyclin-dependent kinase 2 (CDK2)
DM9ODT6	MT	DTT
DM9ODT6	MA	Inhibitor
DM9ODT6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9ODT6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9ODT6	DI	DM9ODT6
DM9ODT6	DN	CYC065
DM9ODT6	MI	TT1LVF2
DM9ODT6	MN	Cyclin-dependent kinase 9 (CDK9)
DM9ODT6	MT	DTT
DM9ODT6	MA	Inhibitor
DM9ODT6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9ODT6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TTPS3C0
DMUMHXT	MN	Aurora kinase A (AURKA)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TT5LS6T
DMUMHXT	MN	Aurora kinase B (AURKB)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMUMHXT	DI	DMUMHXT
DMUMHXT	DN	CYC116
DMUMHXT	MI	TTUTJGQ
DMUMHXT	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMUMHXT	MT	DTT
DMUMHXT	MA	Inhibitor
DMUMHXT	RN	Clinical pipeline report, company report or official report of Cyclacel.
DMUMHXT	RU	http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011

DMC6PKJ	DI	DMC6PKJ
DMC6PKJ	DN	CYC140
DMC6PKJ	MI	TTIYVQP
DMC6PKJ	MN	Polo-like kinase 1 (PLK1)
DMC6PKJ	MT	DTT
DMC6PKJ	MA	Inhibitor
DMC6PKJ	RN	Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
DMC6PKJ	RU	https://cyclacel.com/research_programs_oncology_cyc140.shtml

DMI6EUB	DI	DMI6EUB
DMI6EUB	DN	Cyclolignan picropodophyllin
DMI6EUB	MI	TTHRID2
DMI6EUB	MN	Insulin-like growth factor I receptor (IGF1R)
DMI6EUB	MT	DTT
DMI6EUB	MA	Inhibitor
DMI6EUB	RN	The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007 Jul;46(1):108-15.
DMI6EUB	RU	https://pubmed.ncbi.nlm.nih.gov/17606126

DMAWVTX	DI	DMAWVTX
DMAWVTX	DN	Cyclopentenylcytosine
DMAWVTX	MI	TTN12BZ
DMAWVTX	MN	CTP synthase (CTPS1)
DMAWVTX	MT	DTT
DMAWVTX	MA	Inhibitor
DMAWVTX	RN	Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
DMAWVTX	RU	https://pubmed.ncbi.nlm.nih.gov/8250543

DMNICD4	DI	DMNICD4
DMNICD4	DN	CYT-013-IL1bQb
DMNICD4	MI	TTRYK0X
DMNICD4	MN	Interleukin-1 beta (IL1B)
DMNICD4	MT	DTT
DMNICD4	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623).
DMNICD4	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623

DMTV09A	DI	DMTV09A
DMTV09A	DN	Cyt-1010
DMTV09A	MI	TTKWM86
DMTV09A	MN	Opioid receptor mu (MOP)
DMTV09A	MT	DTT
DMTV09A	MA	Agonist
DMTV09A	RN	Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188.
DMTV09A	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400840/

DMJ83Z7	DI	DMJ83Z7
DMJ83Z7	DN	CYT-609
DMJ83Z7	MI	TTF8CQI
DMJ83Z7	MN	Tumor necrosis factor (TNF)
DMJ83Z7	MT	DTT
DMJ83Z7	MA	Modulator
DMJ83Z7	RN	Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149.
DMJ83Z7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004980/

DMAY6X2	DI	DMAY6X2
DMAY6X2	DN	CZ-48
DMAY6X2	MI	TTGTQHC
DMAY6X2	MN	DNA topoisomerase I (TOP1)
DMAY6X2	MT	DTT
DMAY6X2	MA	Inhibitor
DMAY6X2	RN	Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23.
DMAY6X2	RU	https://pubmed.ncbi.nlm.nih.gov/11193897

DMGA1DS	DI	DMGA1DS
DMGA1DS	DN	D-0502
DMGA1DS	MI	TTZAYWL
DMGA1DS	MN	Estrogen receptor (ESR)
DMGA1DS	MT	DTT
DMGA1DS	MA	Degrader
DMGA1DS	RN	Clinical pipeline report, company report or official report of InventisBio.
DMGA1DS	RU	http://www.inventisbio.com/en/product.html?id=1

DMTP9ER	DI	DMTP9ER
DMTP9ER	DN	D-20133
DMTP9ER	MI	TT1UZQH
DMTP9ER	MN	Phospholipase C (PLC)
DMTP9ER	MT	DTT
DMTP9ER	MA	Inhibitor
DMTP9ER	RN	Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Curr Med Chem. 2011; 18(18): 2727-2742.
DMTP9ER	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091980/

DMIMK84	DI	DMIMK84
DMIMK84	DN	D2C7
DMIMK84	MI	TTGKNB4
DMIMK84	MN	Epidermal growth factor receptor (EGFR)
DMIMK84	MT	DTT
DMIMK84	RN	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
DMIMK84	RU	https://pubmed.ncbi.nlm.nih.gov/31142380

DMIMK84	DI	DMIMK84
DMIMK84	DN	D2C7
DMIMK84	MI	TTZ6B2I
DMIMK84	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMIMK84	MT	DTT
DMIMK84	RN	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
DMIMK84	RU	https://pubmed.ncbi.nlm.nih.gov/31142380

DM7V2OM	DI	DM7V2OM
DM7V2OM	DN	D-3263
DM7V2OM	MI	TTXDKTO
DM7V2OM	MN	Long transient receptor potential channel 8 (TRPM8)
DM7V2OM	MT	DTT
DM7V2OM	MA	Modulator
DM7V2OM	RN	Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107.
DM7V2OM	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/

DM4OTWL	DI	DM4OTWL
DM4OTWL	DN	DA-1229
DM4OTWL	MI	TTDIGC1
DM4OTWL	MN	Dipeptidyl peptidase 4 (DPP-4)
DM4OTWL	MT	DTT
DM4OTWL	MA	Inhibitor
DM4OTWL	RN	DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9.
DM4OTWL	RU	https://pubmed.ncbi.nlm.nih.gov/22056373

DMPJA64	DI	DMPJA64
DMPJA64	DN	DA-1241
DMPJA64	MI	TT7QNVC
DMPJA64	MN	Glucose-dependent insulinotropic receptor (GPR119)
DMPJA64	MT	DTT
DMPJA64	MA	Agonist
DMPJA64	RN	ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
DMPJA64	RU	https://clinicaltrials.gov/ct2/show/NCT03646721

DM4JG0B	DI	DM4JG0B
DM4JG0B	DN	DA-3607
DM4JG0B	MI	TTA5MS9
DM4JG0B	MN	TNF related apoptosis inducing ligand (TNFSF10)
DM4JG0B	MT	DTT
DM4JG0B	MA	Binder
DM4JG0B	RN	Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 2006 Feb;13(4):330-8.
DM4JG0B	RU	https://pubmed.ncbi.nlm.nih.gov/16195699

DMKPAOD	DI	DMKPAOD
DMKPAOD	DN	DA-6886
DMKPAOD	MI	TT07C3Y
DMKPAOD	MN	5-HT 4 receptor (HTR4)
DMKPAOD	MT	DTT
DMKPAOD	MA	Agonist
DMKPAOD	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMKPAOD	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DMBRN2G	DI	DMBRN2G
DMBRN2G	DN	DA-697b
DMBRN2G	MI	TT3SZBT
DMBRN2G	MN	von Willebrand factor (VWF)
DMBRN2G	MT	DTT
DMBRN2G	MA	Inhibitor
DMBRN2G	RN	A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12.
DMBRN2G	RU	https://pubmed.ncbi.nlm.nih.gov/20062928

DM9KS1A	DI	DM9KS1A
DM9KS1A	DN	DA-727
DM9KS1A	MI	TTGN1ZA
DM9KS1A	MN	Angiotensin II receptor (AGTR)
DM9KS1A	MT	DTT
DM9KS1A	MA	Modulator
DM9KS1A	RN	WO patent application no. 2009,0880,06, Combined pharmaceutical agent.
DM9KS1A	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090716&CC=WO&NR=2009088006A1&KC=A1

DMQR4HA	DI	DMQR4HA
DMQR4HA	DN	DABIS MALEATE
DMQR4HA	MI	TTUTN1I
DMQR4HA	MN	Human Deoxyribonucleic acid (hDNA)
DMQR4HA	MT	DTT
DMQR4HA	MA	Binder
DMQR4HA	RN	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9.
DMQR4HA	RU	https://pubmed.ncbi.nlm.nih.gov/2393411

DM5TB76	DI	DM5TB76
DM5TB76	DN	DACRA 089
DM5TB76	MI	TTAT87F
DM5TB76	MN	Amylin receptor (IAPPR)
DM5TB76	MT	DTT
DM5TB76	MA	Agonist
DM5TB76	RN	A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.
DM5TB76	RU	https://pubmed.ncbi.nlm.nih.gov/28109166

DM5TB76	DI	DM5TB76
DM5TB76	DN	DACRA 089
DM5TB76	MI	TTLWS2O
DM5TB76	MN	Calcitonin receptor (CALCR)
DM5TB76	MT	DTT
DM5TB76	MA	Agonist
DM5TB76	RN	A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602.
DM5TB76	RU	https://pubmed.ncbi.nlm.nih.gov/28109166

DMWT5RS	DI	DMWT5RS
DMWT5RS	DN	Daniquidone
DMWT5RS	MI	TTGTQHC
DMWT5RS	MN	DNA topoisomerase I (TOP1)
DMWT5RS	MT	DTT
DMWT5RS	MA	Modulator
DMWT5RS	RN	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.
DMWT5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23912694

DMWT5RS	DI	DMWT5RS
DMWT5RS	DN	Daniquidone
DMWT5RS	MI	TT0IHXV
DMWT5RS	MN	DNA topoisomerase II (TOP2)
DMWT5RS	MT	DTT
DMWT5RS	MA	Modulator
DMWT5RS	RN	Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23.
DMWT5RS	RU	https://www.ncbi.nlm.nih.gov/pubmed/23912694

DM4A3U7	DI	DM4A3U7
DM4A3U7	DN	DAVLB-HYDRAZIDE
DM4A3U7	MI	TTYFKSZ
DM4A3U7	MN	Tubulin beta (TUBB)
DM4A3U7	MT	DTT
DM4A3U7	MA	Modulator
DM4A3U7	RN	An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971.
DM4A3U7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEBTUZ3
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEHUP0C
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Cloning of D-lactate dehydrogenase genes of Lactobacillus delbrueckii subsp. bulgaricus and their roles in D-lactic acid production. 3 Biotech. 2017 Jul;7(3):194.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/28664378

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DECY6JG
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DEJEWXB
DM1K248	MN	D-Lactate dehydrogenase (ldhA)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Diverse allosteric and catalytic functions of tetrameric d-lactate dehydrogenases from three Gram-negative bacteria. AMB Express. 2014 Oct 28;4:76.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/25401076

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DESR17C
DM1K248	MN	L-Lactate dehydrogenase (ldh)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Purification, properties and immunological relationship of L (+)-lactate dehydrogenase from Lactobacillus casei. Eur J Biochem. 1976 Aug 16;67(2):543-55.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/823016

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DE5DTYB
DM1K248	MN	L-Lactate dehydrogenase (ldh)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Positive selection on D-lactate dehydrogenases of Lactobacillus delbrueckii subspecies bulgaricus. IET Syst Biol. 2015 Aug;9(4):172-9.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/26243834

DM1K248	DI	DM1K248
DM1K248	DN	DB-053072
DM1K248	MI	DE6QXYP
DM1K248	MN	Pyruvate oxidase (pyrO)
DM1K248	MT	DME
DM1K248	MA	Metabolism
DM1K248	RN	Metabolic gene-targeted monitoring of non-starter lactic acid bacteria during cheese ripening. Int J Food Microbiol. 2017 Sep 18;257:276-284.
DM1K248	RU	https://pubmed.ncbi.nlm.nih.gov/28735145

DM6K47B	DI	DM6K47B
DM6K47B	DN	DC/I540/KLH vaccine
DM6K47B	MI	TTUJFD0
DM6K47B	MN	Telomerase reverse transcriptase (TERT)
DM6K47B	MT	DTT
DM6K47B	RN	Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1;10(3):828-39.
DM6K47B	RU	https://pubmed.ncbi.nlm.nih.gov/14871958

DMLVG9D	DI	DMLVG9D
DMLVG9D	DN	DCC-3014
DMLVG9D	MI	TT7MRDV
DMLVG9D	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMLVG9D	MT	DTT
DMLVG9D	MA	Inhibitor
DMLVG9D	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLVG9D	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ8ACY	DI	DMQ8ACY
DMQ8ACY	DN	DCCCyB
DMQ8ACY	MI	TTHJTF7
DMQ8ACY	MN	Glycine transporter GlyT-1 (SLC6A9)
DMQ8ACY	MT	DTT
DMQ8ACY	MA	Modulator
DMQ8ACY	RN	Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354.
DMQ8ACY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007840/

DMQIEFB	DI	DMQIEFB
DMQIEFB	DN	Debio 0827
DMQIEFB	MI	TT5TKPM
DMQIEFB	MN	Neutral endopeptidase (MME)
DMQIEFB	MT	DTT
DMQIEFB	MA	Inhibitor
DMQIEFB	RN	Clinical pipeline report, company report or official report of Debiopharm (2011).
DMQIEFB	RU	http://www.debiopharm.com/our-business/pipeline.html

DMWP3G1	DI	DMWP3G1
DMWP3G1	DN	Debio 0932
DMWP3G1	MI	TT78R5H
DMWP3G1	MN	Heat shock protein 90 alpha (HSP90A)
DMWP3G1	MT	DTT
DMWP3G1	MA	Inhibitor
DMWP3G1	RN	Clinical pipeline report, company report or official report of Debiopharm (2011).
DMWP3G1	RU	http://www.debiopharm.com/our-business/pipeline.html

DMPXLMB	DI	DMPXLMB
DMPXLMB	DN	Demobesin
DMPXLMB	MI	TTHYDUM
DMPXLMB	MN	Bombesin receptor (BS)
DMPXLMB	MT	DTT
DMPXLMB	MA	Antagonist
DMPXLMB	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38).
DMPXLMB	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38

DMTULGS	DI	DMTULGS
DMTULGS	DN	Demogastrin
DMTULGS	MI	TTVFO0U
DMTULGS	MN	Gastrin/cholecystokinin type B receptor (CCKBR)
DMTULGS	MT	DTT
DMTULGS	MA	Modulator
DMTULGS	RN	Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy. Regul Pept. 1999 Oct 22;84(1-3):81-9.
DMTULGS	RU	https://pubmed.ncbi.nlm.nih.gov/10535412

DMURVPF	DI	DMURVPF
DMURVPF	DN	Dendritic cell vaccine
DMURVPF	MI	TT7SBF5
DMURVPF	MN	Cellular tumor antigen p53 (TP53)
DMURVPF	MT	DTT
DMURVPF	RN	Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41.
DMURVPF	RU	https://pubmed.ncbi.nlm.nih.gov/14985857

DMTR7EH	DI	DMTR7EH
DMTR7EH	DN	Desoxypeganine
DMTR7EH	MI	TT1RS9F
DMTR7EH	MN	Acetylcholinesterase (AChE)
DMTR7EH	MT	DTT
DMTR7EH	MA	Modulator
DMTR7EH	RN	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
DMTR7EH	RU	https://pubmed.ncbi.nlm.nih.gov/18560630

DMTR7EH	DI	DMTR7EH
DMTR7EH	DN	Desoxypeganine
DMTR7EH	MI	TT3WG5C
DMTR7EH	MN	Monoamine oxidase type A (MAO-A)
DMTR7EH	MT	DTT
DMTR7EH	MA	Modulator
DMTR7EH	RN	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
DMTR7EH	RU	https://pubmed.ncbi.nlm.nih.gov/18560630

DMAE9I0	DI	DMAE9I0
DMAE9I0	DN	Dexpirronium
DMAE9I0	MI	TTH18TF
DMAE9I0	MN	Muscarinic acetylcholine receptor M5 (CHRM5)
DMAE9I0	MT	DTT
DMAE9I0	MA	Antagonist
DMAE9I0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
DMAE9I0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467

DMI8QNB	DI	DMI8QNB
DMI8QNB	DN	DFP 13318
DMI8QNB	MI	TTGTQHC
DMI8QNB	MN	DNA topoisomerase I (TOP1)
DMI8QNB	MT	DTT
DMI8QNB	MA	Inhibitor
DMI8QNB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMI8QNB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY6QFH	DI	DMY6QFH
DMY6QFH	DN	DFP-11207
DMY6QFH	MI	TTU6BFZ
DMY6QFH	MN	Candida Thymidylate synthase (Candi TMP1)
DMY6QFH	MT	DTT
DMY6QFH	MA	Inhibitor
DMY6QFH	RN	National Cancer Institute Drug Dictionary (drug id 762603).
DMY6QFH	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762603

DMGO4XJ	DI	DMGO4XJ
DMGO4XJ	DN	DFP-14927
DMGO4XJ	MI	TTATL6Y
DMGO4XJ	MN	DNA-dependent DNA polymerase (DPOL)
DMGO4XJ	MT	DTT
DMGO4XJ	MA	Inhibitor
DMGO4XJ	RN	National Cancer Institute Drug Dictionary (drug name DFP14927).
DMGO4XJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927

DMGO4XJ	DI	DMGO4XJ
DMGO4XJ	DN	DFP-14927
DMGO4XJ	MI	TTUTN1I
DMGO4XJ	MN	Human Deoxyribonucleic acid (hDNA)
DMGO4XJ	MT	DTT
DMGO4XJ	MA	Inhibitor
DMGO4XJ	RN	National Cancer Institute Drug Dictionary (drug name DFP14927).
DMGO4XJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927

DM6OJI1	DI	DM6OJI1
DM6OJI1	DN	DIAPLASININ
DM6OJI1	MI	TTTO43N
DM6OJI1	MN	Endothelial plasminogen activator inhibitor (SERPINE1)
DM6OJI1	MT	DTT
DM6OJI1	MA	Inhibitor
DM6OJI1	RN	Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9.
DM6OJI1	RU	https://pubmed.ncbi.nlm.nih.gov/20345708

DMPWOH9	DI	DMPWOH9
DMPWOH9	DN	DKY709
DMPWOH9	MI	TTKT5NV
DMPWOH9	MN	Zinc finger protein Helios (IKZF2)
DMPWOH9	MT	DTT
DMPWOH9	MA	Degrader
DMPWOH9	RN	Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021 Apr;20(4):247-250.
DMPWOH9	RU	https://pubmed.ncbi.nlm.nih.gov/33737725

DMM8GZT	DI	DMM8GZT
DMM8GZT	DN	DL-017
DMM8GZT	MI	TT34BHT
DMM8GZT	MN	Adrenergic receptor alpha-1D (ADRA1D)
DMM8GZT	MT	DTT
DMM8GZT	MA	Modulator
DMM8GZT	RN	Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
DMM8GZT	RU	https://pubmed.ncbi.nlm.nih.gov/11707693

DMCT4BA	DI	DMCT4BA
DMCT4BA	DN	DMUC-5754A
DMCT4BA	MI	TTC1PS3
DMCT4BA	MN	Ovarian carcinoma antigen CA125 (MUC16)
DMCT4BA	MT	DTT
DMCT4BA	RN	Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32.
DMCT4BA	RU	https://pubmed.ncbi.nlm.nih.gov/23629491

DMQFX8R	DI	DMQFX8R
DMQFX8R	DN	DN1406131
DMQFX8R	MI	TTZJYKH
DMQFX8R	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMQFX8R	MT	DTT
DMQFX8R	MA	Inhibitor
DMQFX8R	RN	ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
DMQFX8R	RU	https://clinicaltrials.gov/ct2/show/NCT03641794

DMQFX8R	DI	DMQFX8R
DMQFX8R	DN	DN1406131
DMQFX8R	MI	TTXNCBV
DMQFX8R	MN	Tryptophan 2,3-dioxygenase (TDO)
DMQFX8R	MT	DTT
DMQFX8R	MA	Inhibitor
DMQFX8R	RN	ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
DMQFX8R	RU	https://clinicaltrials.gov/ct2/show/NCT03641794

DM0JT9C	DI	DM0JT9C
DM0JT9C	DN	DN1508052
DM0JT9C	MI	TT8CWFK
DM0JT9C	MN	Toll-like receptor 8 (TLR8)
DM0JT9C	MT	DTT
DM0JT9C	MA	Agonist
DM0JT9C	RN	Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
DM0JT9C	RU	http://www.denovo-sh.com/En/technology.aspx?BaseInfoCateID=48&CateID=48

DMOSCQ9	DI	DMOSCQ9
DMOSCQ9	DN	DNL104
DMOSCQ9	MI	TTAIQSN
DMOSCQ9	MN	Receptor-interacting protein 1 (RIPK1)
DMOSCQ9	MT	DTT
DMOSCQ9	MA	Inhibitor
DMOSCQ9	RN	DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414.
DMOSCQ9	RU	https://pubmed.ncbi.nlm.nih.gov/31437302

DMZT89C	DI	DMZT89C
DMZT89C	DN	DNL151
DMZT89C	MI	TTK0FEA
DMZT89C	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMZT89C	MT	DTT
DMZT89C	MA	Inhibitor
DMZT89C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZT89C	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFEORD	DI	DMFEORD
DMFEORD	DN	DNL201
DMFEORD	MI	TTK0FEA
DMFEORD	MN	Leucine-rich repeat kinase 2 (LRRK2)
DMFEORD	MT	DTT
DMFEORD	MA	Inhibitor
DMFEORD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFEORD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMNSC0O	DI	DMNSC0O
DMNSC0O	DN	DNL747
DMNSC0O	MI	TTAIQSN
DMNSC0O	MN	Receptor-interacting protein 1 (RIPK1)
DMNSC0O	MT	DTT
DMNSC0O	MA	Inhibitor
DMNSC0O	RN	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571.
DMNSC0O	RU	https://pubmed.ncbi.nlm.nih.gov/32669658

DMZS350	DI	DMZS350
DMZS350	DN	Donor-derived CD19/22 bispecific CAR-T cells
DMZS350	MI	TTM6QSK
DMZS350	MN	B-cell receptor CD22 (CD22)
DMZS350	MT	DTT
DMZS350	MA	CAR-T-Cell-Therapy(Dual specific)
DMZS350	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMZS350	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DMZS350	DI	DMZS350
DMZS350	DN	Donor-derived CD19/22 bispecific CAR-T cells
DMZS350	MI	TTW640A
DMZS350	MN	B-lymphocyte surface antigen B4 (CD19)
DMZS350	MT	DTT
DMZS350	MA	CAR-T-Cell-Therapy(Dual specific)
DMZS350	RN	ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
DMZS350	RU	https://clinicaltrials.gov/ct2/show/NCT03463928

DMXZ6A0	DI	DMXZ6A0
DMXZ6A0	DN	DP-4088
DMXZ6A0	MI	TT6L509
DMXZ6A0	MN	Coagulation factor IIa (F2)
DMXZ6A0	MT	DTT
DMXZ6A0	MA	Inhibitor
DMXZ6A0	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
DMXZ6A0	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362

DM4ZDOE	DI	DM4ZDOE
DM4ZDOE	DN	DpC
DM4ZDOE	MI	TTUDR0C
DM4ZDOE	MN	Iron (Fe)
DM4ZDOE	MT	DTT
DM4ZDOE	MA	Chelator
DM4ZDOE	RN	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
DM4ZDOE	RU	https://pubmed.ncbi.nlm.nih.gov/29334758

DMJY9TW	DI	DMJY9TW
DMJY9TW	DN	DRF-1042
DMJY9TW	MI	TTGTQHC
DMJY9TW	MN	DNA topoisomerase I (TOP1)
DMJY9TW	MT	DTT
DMJY9TW	MA	Inhibitor
DMJY9TW	RN	Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60.
DMJY9TW	RU	https://pubmed.ncbi.nlm.nih.gov/15778426

DM0DJPE	DI	DM0DJPE
DM0DJPE	DN	Drug 2838232
DM0DJPE	MI	TTMCA52
DM0DJPE	MN	Viral Maturation (VM)
DM0DJPE	MT	DTT
DM0DJPE	MA	Modulator
DM0DJPE	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762)
DM0DJPE	RU	http://adisinsight.springer.com/drugs/800037762

DMM57CS	DI	DMM57CS
DMM57CS	DN	Drug 2849330
DMM57CS	MI	TTDC8N2
DMM57CS	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DMM57CS	MT	DTT
DMM57CS	RN	National Cancer Institute Drug Dictionary (drug id 754219).
DMM57CS	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754219

DMNFEC6	DI	DMNFEC6
DMNFEC6	DN	Drug 2878175
DMNFEC6	MI	TTMVBWH
DMNFEC6	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMNFEC6	MT	DTT
DMNFEC6	MA	Inhibitor
DMNFEC6	RN	P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY. Journal of Hepatology Volume 60, Issue 1, Supplement, April 2014, Pages S496.
DMNFEC6	RU	http://www.sciencedirect.com/science/article/pii/S0168827814613842

DMWXQC9	DI	DMWXQC9
DMWXQC9	DN	Drug 2881078
DMWXQC9	MI	TTS64P2
DMWXQC9	MN	Androgen receptor (AR)
DMWXQC9	MT	DTT
DMWXQC9	MA	Modulator
DMWXQC9	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743)
DMWXQC9	RU	http://adisinsight.springer.com/drugs/800039743

DMXCN37	DI	DMXCN37
DMXCN37	DN	DS-1040
DMXCN37	MI	TTP18AY
DMXCN37	MN	Carboxypeptidase B2 (CPB2)
DMXCN37	MT	DTT
DMXCN37	MA	Modulator
DMXCN37	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMXCN37	RU	http://www.daiichisankyo.com/rd/pipeline/development_pipeline/index.html#details01

DMPR3A6	DI	DMPR3A6
DMPR3A6	DN	DS-1055
DMPR3A6	MI	TT0FAYT
DMPR3A6	MN	Transforming growth factor beta activator LRRC32 (LRRC32)
DMPR3A6	MT	DTT
DMPR3A6	MA	Inhibitor
DMPR3A6	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DMPR3A6	RU	https://www.daiichisankyo.com/media/press_release/detail/index_4081.html

DM42KZW	DI	DM42KZW
DM42KZW	DN	DS-1093
DM42KZW	MI	TTJQFBG
DM42KZW	MN	HIF-prolyl hydroxylase (HPH)
DM42KZW	MT	DTT
DM42KZW	MA	Modulator
DM42KZW	RN	Company report (Daiichisankyo)
DM42KZW	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM029TQ	DI	DM029TQ
DM029TQ	DN	DS-1150b
DM029TQ	MI	TTP6MT5
DM029TQ	MN	Glucose transporter type 4 (SLC2A4)
DM029TQ	MT	DTT
DM029TQ	MA	Modulator
DM029TQ	RN	Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014
DM029TQ	RU	http://www.nature.com/scibx/journal/v7/n22/full/scibx.2014.633.html

DMXST9F	DI	DMXST9F
DMXST9F	DN	DS-1205
DMXST9F	MI	TTZPY6J
DMXST9F	MN	Tyrosine-protein kinase UFO (AXL)
DMXST9F	MT	DTT
DMXST9F	MA	Inhibitor
DMXST9F	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXST9F	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMNDGPT	DI	DMNDGPT
DMNDGPT	DN	DS-2969
DMNDGPT	MI	TTPBZUO
DMNDGPT	MN	Clostridium difficile DNA gyrase (CD gyr)
DMNDGPT	MT	DTT
DMNDGPT	MA	Inhibitor
DMNDGPT	RN	In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17.
DMNDGPT	RU	https://pubmed.ncbi.nlm.nih.gov/29439962

DMA2B5Y	DI	DMA2B5Y
DMA2B5Y	DN	DS-3032
DMA2B5Y	MI	TT08GJW
DMA2B5Y	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMA2B5Y	MT	DTT
DMA2B5Y	MA	Inhibitor
DMA2B5Y	RN	Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. 
DMA2B5Y	RU	https://pubmed.ncbi.nlm.nih.gov/24577402

DMG7I5J	DI	DMG7I5J
DMG7I5J	DN	DS-3078
DMG7I5J	MI	TTCJG29
DMG7I5J	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMG7I5J	MT	DTT
DMG7I5J	MA	Modulator
DMG7I5J	RN	A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173.
DMG7I5J	RU	http://mct.aacrjournals.org/content/12/11_Supplement/C173.abstract 

DMRLPFG	DI	DMRLPFG
DMRLPFG	DN	DS-3201
DMRLPFG	MI	TTNJA0C
DMRLPFG	MN	Enhancer of zeste homolog 1 (EZH1)
DMRLPFG	MT	DTT
DMRLPFG	MA	Inhibitor
DMRLPFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLPFG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRLPFG	DI	DMRLPFG
DMRLPFG	DN	DS-3201
DMRLPFG	MI	TT9MZCQ
DMRLPFG	MN	Enhancer of zeste homolog 2 (EZH2)
DMRLPFG	MT	DTT
DMRLPFG	MA	Inhibitor
DMRLPFG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRLPFG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6WN9X	DI	DM6WN9X
DM6WN9X	DN	DS-3801
DM6WN9X	MI	TT953CX
DM6WN9X	MN	Motilin receptor (MLNR)
DM6WN9X	MT	DTT
DM6WN9X	MA	Agonist
DM6WN9X	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DM6WN9X	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM0RD4F	DI	DM0RD4F
DM0RD4F	DN	DS-6051
DM0RD4F	MI	TTSZ6Y3
DM0RD4F	MN	Proto-oncogene c-Ros (ROS1)
DM0RD4F	MT	DTT
DM0RD4F	MA	Inhibitor
DM0RD4F	RN	National Cancer Institute Drug Dictionary (drug id 766123).
DM0RD4F	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123

DM0RD4F	DI	DM0RD4F
DM0RD4F	DN	DS-6051
DM0RD4F	MI	TTTDVOJ
DM0RD4F	MN	Tropomyosin-related kinase A (TrkA)
DM0RD4F	MT	DTT
DM0RD4F	MA	Inhibitor
DM0RD4F	RN	National Cancer Institute Drug Dictionary (drug id 766123).
DM0RD4F	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123

DMTKZ1Q	DI	DMTKZ1Q
DMTKZ1Q	DN	DS-6157
DMTKZ1Q	MI	TTGTQHC
DMTKZ1Q	MN	DNA topoisomerase I (TOP1)
DMTKZ1Q	MT	DTT
DMTKZ1Q	MA	Inhibitor
DMTKZ1Q	RN	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.
DMTKZ1Q	RU	https://pubmed.ncbi.nlm.nih.gov/33579785

DMTKZ1Q	DI	DMTKZ1Q
DMTKZ1Q	DN	DS-6157
DMTKZ1Q	MI	TT26C7Z
DMTKZ1Q	MN	G-protein coupled receptor 20 (GPR20)
DMTKZ1Q	MT	DTT
DMTKZ1Q	MA	Inhibitor
DMTKZ1Q	RN	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.
DMTKZ1Q	RU	https://pubmed.ncbi.nlm.nih.gov/33579785

DM7C4U9	DI	DM7C4U9
DM7C4U9	DN	DS-7309
DM7C4U9	MI	TTDLNGZ
DM7C4U9	MN	Glucokinase (GCK)
DM7C4U9	MT	DTT
DM7C4U9	MA	Inhibitor
DM7C4U9	RN	Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013
DM7C4U9	RU	http://www.nature.com/scibx/journal/v6/n45/full/scibx.2013.1279.html

DMCFJM3	DI	DMCFJM3
DMCFJM3	DN	DS-7423
DMCFJM3	MI	TTHBTOP
DMCFJM3	MN	PI3-kinase gamma (PIK3CG)
DMCFJM3	MT	DTT
DMCFJM3	MA	Modulator
DMCFJM3	RN	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
DMCFJM3	RU	https://pubmed.ncbi.nlm.nih.gov/24504419

DMCFJM3	DI	DMCFJM3
DMCFJM3	DN	DS-7423
DMCFJM3	MI	TTCJG29
DMCFJM3	MN	Serine/threonine-protein kinase mTOR (mTOR)
DMCFJM3	MT	DTT
DMCFJM3	MA	Modulator
DMCFJM3	RN	Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
DMCFJM3	RU	https://pubmed.ncbi.nlm.nih.gov/24504419

DMJPUDW	DI	DMJPUDW
DMJPUDW	DN	DS-8273
DMJPUDW	MI	TTW20TU
DMJPUDW	MN	TRAIL receptor 2 (TRAIL-R2)
DMJPUDW	MT	DTT
DMJPUDW	MA	Agonist
DMJPUDW	RN	First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
DMJPUDW	RU	https://pubmed.ncbi.nlm.nih.gov/28050790

DM31VNC	DI	DM31VNC
DM31VNC	DN	DS-8895
DM31VNC	MI	TTRJB2G
DM31VNC	MN	Ephrin type-A receptor 2 (EPHA2)
DM31VNC	MT	DTT
DM31VNC	RN	Clinical pipeline report, company report or official report of Daiichi Sankyo.
DM31VNC	RU	http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf

DM4ZCY0	DI	DM4ZCY0
DM4ZCY0	DN	DSP-0337
DM4ZCY0	MI	TTH8FZW
DM4ZCY0	MN	Signal transducer and activator of transcription 3 (STAT3)
DM4ZCY0	MT	DTT
DM4ZCY0	MA	Inhibitor
DM4ZCY0	RN	Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
DM4ZCY0	RU	https://pubmed.ncbi.nlm.nih.gov/31277685

DMY95MZ	DI	DMY95MZ
DMY95MZ	DN	DSP-0565
DMY95MZ	MI	TT5HONZ
DMY95MZ	MN	Calcium channel unspecific (CaC)
DMY95MZ	MT	DTT
DMY95MZ	MA	Modulator
DMY95MZ	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035668)
DMY95MZ	RU	http://adisinsight.springer.com/drugs/800035668

DMJDP0E	DI	DMJDP0E
DMJDP0E	DN	DSP-1053
DMJDP0E	MI	TTSQIFT
DMJDP0E	MN	5-HT 1A receptor (HTR1A)
DMJDP0E	MT	DTT
DMJDP0E	MA	Antagonist
DMJDP0E	RN	DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect. 2015 Jun;3(3):e00142.
DMJDP0E	RU	https://pubmed.ncbi.nlm.nih.gov/26171224

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTJQOD7
DM4WSHG	MN	5-HT 2A receptor (HTR2A)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTWG9A4
DM4WSHG	MN	Adrenergic receptor alpha-2A (ADRA2A)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM4WSHG	DI	DM4WSHG
DM4WSHG	DN	DSP-1200
DM4WSHG	MI	TTEX248
DM4WSHG	MN	Dopamine D2 receptor (D2R)
DM4WSHG	MT	DTT
DM4WSHG	MA	Antagonist
DM4WSHG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4WSHG	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM0WTMD	DI	DM0WTMD
DM0WTMD	DN	DSP-2230
DM0WTMD	MI	TT4G2JS
DM0WTMD	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DM0WTMD	MT	DTT
DM0WTMD	MA	Inhibitor
DM0WTMD	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0WTMD	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM0WTMD	DI	DM0WTMD
DM0WTMD	DN	DSP-2230
DM0WTMD	MI	TT90XZ8
DM0WTMD	MN	Voltage-gated sodium channel alpha Nav1.8 (SCN10A)
DM0WTMD	MT	DTT
DM0WTMD	MA	Inhibitor
DM0WTMD	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0WTMD	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMYHU24	DI	DMYHU24
DMYHU24	DN	DSP-3905
DMYHU24	MI	TT4G2JS
DMYHU24	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMYHU24	MT	DTT
DMYHU24	MA	Inhibitor
DMYHU24	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMYHU24	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMM86OH	DI	DMM86OH
DMM86OH	DN	DSP-6745
DMM86OH	MI	TT85JO3
DMM86OH	MN	5-HT receptor (5HTR)
DMM86OH	MT	DTT
DMM86OH	MA	Antagonist
DMM86OH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMM86OH	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2PYE0	DI	DM2PYE0
DM2PYE0	DN	DSP-8658
DM2PYE0	MI	TTZMAO3
DM2PYE0	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DM2PYE0	MT	DTT
DM2PYE0	MA	Modulator
DM2PYE0	RN	Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9.
DM2PYE0	RU	https://pubmed.ncbi.nlm.nih.gov/26011171

DM69ZBU	DI	DM69ZBU
DM69ZBU	DN	DST-2970
DM69ZBU	MI	TTRA5BZ
DM69ZBU	MN	Steroid 17-alpha-monooxygenase (S17AH)
DM69ZBU	MT	DTT
DM69ZBU	MA	Inhibitor
DM69ZBU	RN	Clinical pipeline report, company report or official report of DisperSol Technologies.
DM69ZBU	RU	https://www.dispersoltech.com/pipeline/

DMYFOJQ	DI	DMYFOJQ
DMYFOJQ	DN	DT-200
DMYFOJQ	MI	TTS64P2
DMYFOJQ	MN	Androgen receptor (AR)
DMYFOJQ	MT	DTT
DMYFOJQ	MA	Modulator
DMYFOJQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYFOJQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM5AGKV	DI	DM5AGKV
DM5AGKV	DN	DTRMWXHS-12
DM5AGKV	MI	TTGM6VW
DM5AGKV	MN	Tyrosine-protein kinase BTK (ATK)
DM5AGKV	MT	DTT
DM5AGKV	MA	Inhibitor
DM5AGKV	RN	ClinicalTrials.gov (NCT02900716) Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas. U.S. National Institutes of Health.
DM5AGKV	RU	https://clinicaltrials.gov/ct2/show/NCT02900716

DM1FX09	DI	DM1FX09
DM1FX09	DN	DT-TX-30
DM1FX09	MI	TT2O84V
DM1FX09	MN	Thromboxane A2 receptor (TBXA2R)
DM1FX09	MT	DTT
DM1FX09	MA	Antagonist
DM1FX09	RN	DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90.
DM1FX09	RU	https://pubmed.ncbi.nlm.nih.gov/9226103

DM8WBNF	DI	DM8WBNF
DM8WBNF	DN	DTX401
DM8WBNF	MI	TTBQMJ8
DM8WBNF	MN	Glucose-6-phosphatase (G6PC)
DM8WBNF	MT	DTT
DM8WBNF	MA	Replacement
DM8WBNF	RN	Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical.
DM8WBNF	RU	https://www.ultragenyx.com/pipeline/dtx-401-for-gsd1a/

DM3P0H1	DI	DM3P0H1
DM3P0H1	DN	Duvortuxizumab
DM3P0H1	MI	TTW640A
DM3P0H1	MN	B-lymphocyte surface antigen B4 (CD19)
DM3P0H1	MT	DTT
DM3P0H1	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3P0H1	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMDSVRP	DI	DMDSVRP
DMDSVRP	DN	DV-1179
DMDSVRP	MI	TTRJ1K4
DMDSVRP	MN	Toll-like receptor 7 (TLR7)
DMDSVRP	MT	DTT
DMDSVRP	MA	Modulator
DMDSVRP	RN	Company report (Dynavax)
DMDSVRP	RU	http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/

DMDSVRP	DI	DMDSVRP
DMDSVRP	DN	DV-1179
DMDSVRP	MI	TTSHG0T
DMDSVRP	MN	Toll-like receptor 9 (TLR9)
DMDSVRP	MT	DTT
DMDSVRP	MA	Modulator
DMDSVRP	RN	Company report (Dynavax)
DMDSVRP	RU	http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/

DMJ0Y86	DI	DMJ0Y86
DMJ0Y86	DN	DV281
DMJ0Y86	MI	TTSHG0T
DMJ0Y86	MN	Toll-like receptor 9 (TLR9)
DMJ0Y86	MT	DTT
DMJ0Y86	MA	Agonist
DMJ0Y86	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJ0Y86	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQKDJZ	DI	DMQKDJZ
DMQKDJZ	DN	DWJ-208
DMQKDJZ	MI	TT4G2JS
DMQKDJZ	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMQKDJZ	MT	DTT
DMQKDJZ	MA	Antagonist
DMQKDJZ	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DMQKDJZ	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DM4XZY9	DI	DM4XZY9
DM4XZY9	DN	DWP-09031
DM4XZY9	MI	TTE4KHA
DM4XZY9	MN	Amyloid beta A4 protein (APP)
DM4XZY9	MT	DTT
DM4XZY9	MA	Inhibitor
DM4XZY9	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
DM4XZY9	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402

DMS1NC8	DI	DMS1NC8
DMS1NC8	DN	DZ-2640
DMS1NC8	MI	TTJP4SM
DMS1NC8	MN	Bacterial Penicillin binding protein (Bact PBP)
DMS1NC8	MT	DTT
DMS1NC8	MA	Modulator
DMS1NC8	RN	In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8.
DMS1NC8	RU	https://pubmed.ncbi.nlm.nih.gov/10882697

DMEQY4Z	DI	DMEQY4Z
DMEQY4Z	DN	DZD1516
DMEQY4Z	MI	TT6EO5L
DMEQY4Z	MN	Erbb2 tyrosine kinase receptor (HER2)
DMEQY4Z	MT	DTT
DMEQY4Z	MA	Inhibitor
DMEQY4Z	RN	ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health.
DMEQY4Z	RU	https://clinicaltrials.gov/ct2/show/NCT04509596

DM3LOF1	DI	DM3LOF1
DM3LOF1	DN	E 7974
DM3LOF1	MI	TTML2WA
DM3LOF1	MN	Tubulin (TUB)
DM3LOF1	MT	DTT
DM3LOF1	MA	Inhibitor
DM3LOF1	RN	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
DM3LOF1	RU	https://pubmed.ncbi.nlm.nih.gov/18764727

DMNEVKA	DI	DMNEVKA
DMNEVKA	DN	E2012
DMNEVKA	MI	TT9W8GU
DMNEVKA	MN	Gamma-secretase (GS)
DMNEVKA	MT	DTT
DMNEVKA	MA	Modulator
DMNEVKA	RN	Chemical Biology, Molecular Mechanism and Clinical Perspective of -Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol.2011 Dec;9(4):598-622.
DMNEVKA	RU	https://www.ncbi.nlm.nih.gov/pubmed/22798753

DMQDKYV	DI	DMQDKYV
DMQDKYV	DN	E-2212
DMQDKYV	MI	TT9W8GU
DMQDKYV	MN	Gamma-secretase (GS)
DMQDKYV	MT	DTT
DMQDKYV	MA	Modulator
DMQDKYV	RN	Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry. 2013 May 14;52(19):3197-216.
DMQDKYV	RU	https://pubmed.ncbi.nlm.nih.gov/23614767

DM4BD5U	DI	DM4BD5U
DM4BD5U	DN	E2730
DM4BD5U	MI	TTPW8EF
DM4BD5U	MN	Synaptic transmission (ST)
DM4BD5U	MT	DTT
DM4BD5U	MA	Modulator
DM4BD5U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4BD5U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMFVT43	DI	DMFVT43
DMFVT43	DN	E7046
DMFVT43	MI	TT79WV3
DMFVT43	MN	Prostaglandin E2 receptor EP4 (PTGER4)
DMFVT43	MT	DTT
DMFVT43	MA	Antagonist
DMFVT43	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFVT43	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMDOCNW	DI	DMDOCNW
DMDOCNW	DN	E-7050
DMDOCNW	MI	TTNDSF4
DMDOCNW	MN	Proto-oncogene c-Met (MET)
DMDOCNW	MT	DTT
DMDOCNW	MA	Modulator
DMDOCNW	RN	E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
DMDOCNW	RU	https://pubmed.ncbi.nlm.nih.gov/19832844

DMDOCNW	DI	DMDOCNW
DMDOCNW	DN	E-7050
DMDOCNW	MI	TTUTJGQ
DMDOCNW	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMDOCNW	MT	DTT
DMDOCNW	MA	Modulator
DMDOCNW	RN	E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.
DMDOCNW	RU	https://pubmed.ncbi.nlm.nih.gov/19832844

DM8TU5R	DI	DM8TU5R
DM8TU5R	DN	E7766
DM8TU5R	MI	TTT402Y
DM8TU5R	MN	Stimulator of interferon genes protein (TMEM173)
DM8TU5R	MT	DTT
DM8TU5R	MA	Agonist
DM8TU5R	RN	E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743.
DM8TU5R	RU	https://pubmed.ncbi.nlm.nih.gov/33522135

DM8RD4T	DI	DM8RD4T
DM8RD4T	DN	EC0489
DM8RD4T	MI	TTVC37M
DM8RD4T	MN	Folate receptor alpha (FOLR1)
DM8RD4T	MT	DTT
DM8RD4T	MA	Modulator
DM8RD4T	RN	National Cancer Institute Drug Dictionary (drug id 638649).
DM8RD4T	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=638649

DMXW07J	DI	DMXW07J
DMXW07J	DN	EDP-239
DMXW07J	MI	TTCJ2X8
DMXW07J	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMXW07J	MT	DTT
DMXW07J	MA	Modulator
DMXW07J	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMXW07J	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMWTVM1	DI	DMWTVM1
DMWTVM1	DN	EDP-322
DMWTVM1	MI	TT3OT40
DMWTVM1	MN	Multidrug resistance protein 1 (ABCB1)
DMWTVM1	MT	DTT
DMWTVM1	MA	Inhibitor
DMWTVM1	RN	In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7.
DMWTVM1	RU	https://pubmed.ncbi.nlm.nih.gov/25182063

DM8KRA3	DI	DM8KRA3
DM8KRA3	DN	EDP-514
DM8KRA3	MI	TTM42UJ
DM8KRA3	MN	Hepatitis B virus Capsid protein (HBV C)
DM8KRA3	MT	DTT
DM8KRA3	MA	Inhibitor
DM8KRA3	RN	Clinical pipeline report, company report or official report of Enanta Pharmaceuticals.
DM8KRA3	RU	https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Clinical-Trial-Progress-for-EDP-514-its-Lead-Core-Inhibitor-for-Hepatitis-B-Virus/default.aspx

DM3AD65	DI	DM3AD65
DM3AD65	DN	EGFR806-specific CAR T cell
DM3AD65	MI	TTGKNB4
DM3AD65	MN	Epidermal growth factor receptor (EGFR)
DM3AD65	MT	DTT
DM3AD65	MA	CAR-T-Cell-Therapy
DM3AD65	RN	ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
DM3AD65	RU	https://clinicaltrials.gov/ct2/show/NCT03638167

DMZN35T	DI	DMZN35T
DMZN35T	DN	EGFRt/19-28z/4-1BBL CAR T cells
DMZN35T	MI	TTW640A
DMZN35T	MN	B-lymphocyte surface antigen B4 (CD19)
DMZN35T	MT	DTT
DMZN35T	MA	CAR-T-Cell-Therapy
DMZN35T	RN	ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
DMZN35T	RU	https://clinicaltrials.gov/ct2/show/NCT03085173

DM6XWV4	DI	DM6XWV4
DM6XWV4	DN	EGFRvIII CAR T cells
DM6XWV4	MI	TTZ6B2I
DM6XWV4	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DM6XWV4	MT	DTT
DM6XWV4	MA	CAR-T-Cell-Therapy
DM6XWV4	RN	ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
DM6XWV4	RU	https://clinicaltrials.gov/ct2/show/NCT02664363

DMA46RN	DI	DMA46RN
DMA46RN	DN	EGFRvIII-CARs
DMA46RN	MI	TTZ6B2I
DMA46RN	MN	Epidermal growth factor receptor variant III (EGFR vIII)
DMA46RN	MT	DTT
DMA46RN	MA	CAR-T-Cell-Therapy
DMA46RN	RN	ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
DMA46RN	RU	https://clinicaltrials.gov/ct2/show/NCT03283631

DMDPGCS	DI	DMDPGCS
DMDPGCS	DN	EGT-0001474
DMDPGCS	MI	TTLWPVF
DMDPGCS	MN	Sodium/glucose cotransporter 2 (SGLT2)
DMDPGCS	MT	DTT
DMDPGCS	MA	Modulator
DMDPGCS	RN	PhRMA report
DMDPGCS	RU	http://www.phrma.org/sites/default/files/pdf/diabetes2012.pdf

DMXAUB7	DI	DMXAUB7
DMXAUB7	DN	EI1071
DMXAUB7	MI	TT7MRDV
DMXAUB7	MN	Macrophage colony-stimulating factor 1 receptor (CSF1R)
DMXAUB7	MT	DTT
DMXAUB7	MA	Inhibitor
DMXAUB7	RN	Clinical pipeline report, company report or official report of Elixiron Immunotherapeutics.
DMXAUB7	RU	https://www.elixiron.com/

DMA4BRV	DI	DMA4BRV
DMA4BRV	DN	Elinogrel
DMA4BRV	MI	TTZ1DT0
DMA4BRV	MN	P2Y purinoceptor 12 (P2RY12)
DMA4BRV	MT	DTT
DMA4BRV	MA	Antagonist
DMA4BRV	RN	Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
DMA4BRV	RU	https://pubmed.ncbi.nlm.nih.gov/20178048

DMM9S51	DI	DMM9S51
DMM9S51	DN	ELND-002
DMM9S51	MI	TT4BT06
DMM9S51	MN	Integrin alpha-4 (ITGA4)
DMM9S51	MT	DTT
DMM9S51	MA	Antagonist
DMM9S51	RN	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
DMM9S51	RU	https://pubmed.ncbi.nlm.nih.gov/12794117

DMLQYVD	DI	DMLQYVD
DMLQYVD	DN	ELND-004
DMLQYVD	MI	TT4BT06
DMLQYVD	MN	Integrin alpha-4 (ITGA4)
DMLQYVD	MT	DTT
DMLQYVD	MA	Inhibitor
DMLQYVD	RN	Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.
DMLQYVD	RU	https://pubmed.ncbi.nlm.nih.gov/12794117

DMQPI4V	DI	DMQPI4V
DMQPI4V	DN	ELOMOTECAN HYDROCHLORIDE
DMQPI4V	MI	TTGTQHC
DMQPI4V	MN	DNA topoisomerase I (TOP1)
DMQPI4V	MT	DTT
DMQPI4V	MA	Modulator
DMQPI4V	RN	The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci. 2000;922:303-5.
DMQPI4V	RU	https://www.ncbi.nlm.nih.gov/pubmed/11193907

DMIV04R	DI	DMIV04R
DMIV04R	DN	Elpetrigine
DMIV04R	MI	TT5HONZ
DMIV04R	MN	Calcium channel unspecific (CaC)
DMIV04R	MT	DTT
DMIV04R	MA	Blocker
DMIV04R	RN	Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
DMIV04R	RU	http://www.jazzpharma.com/products/

DM4W7Z0	DI	DM4W7Z0
DM4W7Z0	DN	Emactuzumab
DM4W7Z0	MI	TT0IQER
DM4W7Z0	MN	Macrophage colony-stimulating factor 1 (CSF1)
DM4W7Z0	MT	DTT
DM4W7Z0	MA	Antagonist
DM4W7Z0	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4W7Z0	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM6AMKZ	DI	DM6AMKZ
DM6AMKZ	DN	Embeconazole
DM6AMKZ	MI	TTTSOUD
DM6AMKZ	MN	Candida Cytochrome P450 51 (Candi ERG11)
DM6AMKZ	MT	DTT
DM6AMKZ	MA	Inhibitor
DM6AMKZ	RN	CS-758. Antifungal lanosterol 14alpha-demethylase inhibitor, 003, vol28, no3, 217-223.
DM6AMKZ	RU	http://cat.inist.fr/?aModele=afficheN&cpsidt=14796964

DM38JZU	DI	DM38JZU
DM38JZU	DN	EMD-1204831
DM38JZU	MI	TTNDSF4
DM38JZU	MN	Proto-oncogene c-Met (MET)
DM38JZU	MT	DTT
DM38JZU	MA	Inhibitor
DM38JZU	RN	2012 ASCO Annual Meeting.
DM38JZU	RU	http://meetinglibrary.asco.org/subcategories/2012%20ASCO%20Annual%20Meeting

DMQ6YAZ	DI	DMQ6YAZ
DMQ6YAZ	DN	EMD-534085
DMQ6YAZ	MI	TTBGTCW
DMQ6YAZ	MN	Kinesin spindle messenger RNA (KIF11 mRNA)
DMQ6YAZ	MT	DTT
DMQ6YAZ	MA	Inhibitor
DMQ6YAZ	RN	The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5.
DMQ6YAZ	RU	https://pubmed.ncbi.nlm.nih.gov/20149654

DMBIPQL	DI	DMBIPQL
DMBIPQL	DN	Enavatuzumab
DMBIPQL	MI	TTKPS7V
DMBIPQL	MN	TNF superfamily receptor 12A (TNFRSF12A)
DMBIPQL	MT	DTT
DMBIPQL	RN	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.
DMBIPQL	RU	https://pubmed.ncbi.nlm.nih.gov/23073510

DMKPBVX	DI	DMKPBVX
DMKPBVX	DN	Englitazone sodium
DMKPBVX	MI	TTZMAO3
DMKPBVX	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMKPBVX	MT	DTT
DMKPBVX	MA	Agonist
DMKPBVX	RN	PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
DMKPBVX	RU	https://pubmed.ncbi.nlm.nih.gov/12586994

DMGLHYU	DI	DMGLHYU
DMGLHYU	DN	Enkastim-ev
DMGLHYU	MI	TTHYBIX
DMGLHYU	MN	Heat shock protein 70 (HSP70)
DMGLHYU	MT	DTT
DMGLHYU	MA	Modulator
DMGLHYU	RN	Company report (Multimmune)
DMGLHYU	RU	http://www.multimmune.com/mi-THERAPEUTICS-PIPELINE/

DM9BJ3G	DI	DM9BJ3G
DM9BJ3G	DN	ENMD-1198
DM9BJ3G	MI	TTQHWNA
DM9BJ3G	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM9BJ3G	MT	DTT
DM9BJ3G	MA	Inhibitor
DM9BJ3G	RN	ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18.
DM9BJ3G	RU	https://pubmed.ncbi.nlm.nih.gov/20442304

DMMJXAR	DI	DMMJXAR
DMMJXAR	DN	Entolimod
DMMJXAR	MI	TTCXP8J
DMMJXAR	MN	Toll-like receptor 5 (TLR5)
DMMJXAR	MT	DTT
DMMJXAR	MA	Agonist
DMMJXAR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMMJXAR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ6GUY	DI	DMQ6GUY
DMQ6GUY	DN	EOS100850
DMQ6GUY	MI	TTM2AOE
DMQ6GUY	MN	Adenosine A2a receptor (ADORA2A)
DMQ6GUY	MT	DTT
DMQ6GUY	MA	Antagonist
DMQ6GUY	RN	National Cancer Institute Drug Dictionary (drug name EOS100850).
DMQ6GUY	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a2a-receptor-antagonist-eos100850

DMKR3GD	DI	DMKR3GD
DMKR3GD	DN	EP-42675
DMKR3GD	MI	TT6L509
DMKR3GD	MN	Coagulation factor IIa (F2)
DMKR3GD	MT	DTT
DMKR3GD	MA	Modulator
DMKR3GD	RN	EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
DMKR3GD	RU	https://pubmed.ncbi.nlm.nih.gov/24237610

DMKR3GD	DI	DMKR3GD
DMKR3GD	DN	EP-42675
DMKR3GD	MI	TTCIHJA
DMKR3GD	MN	Coagulation factor Xa (F10)
DMKR3GD	MT	DTT
DMKR3GD	MA	Modulator
DMKR3GD	RN	EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33.
DMKR3GD	RU	https://pubmed.ncbi.nlm.nih.gov/24237610

DM49RI7	DI	DM49RI7
DM49RI7	DN	EP-51216
DM49RI7	MI	TTKMAZ6
DM49RI7	MN	Growth hormone receptor (GHR)
DM49RI7	MT	DTT
DM49RI7	MA	Agonist
DM49RI7	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DM49RI7	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMW739O	DI	DMW739O
DMW739O	DN	EP-51389
DMW739O	MI	TTKMAZ6
DMW739O	MN	Growth hormone receptor (GHR)
DMW739O	MT	DTT
DMW739O	MA	Agonist
DMW739O	RN	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
DMW739O	RU	https://pubmed.ncbi.nlm.nih.gov/16634704

DMV0MHI	DI	DMV0MHI
DMV0MHI	DN	EP-7041
DMV0MHI	MI	TTJCPUT
DMV0MHI	MN	Coagulation factor XI (F11)
DMV0MHI	MT	DTT
DMV0MHI	MA	Inhibitor
DMV0MHI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV0MHI	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMUFN29	DI	DMUFN29
DMUFN29	DN	EPI-7386
DMUFN29	MI	TTS64P2
DMUFN29	MN	Androgen receptor (AR)
DMUFN29	MT	DTT
DMUFN29	MA	Inhibitor
DMUFN29	RN	Clinical pipeline report, company report or official report of ESSA Pharma.
DMUFN29	RU	https://www.essapharma.com/pipeline/

DMAQYRL	DI	DMAQYRL
DMAQYRL	DN	Eptacog alfa
DMAQYRL	MI	TTF0EGX
DMAQYRL	MN	Coagulation factor VII (F7)
DMAQYRL	MT	DTT
DMAQYRL	MA	Modulator
DMAQYRL	RN	Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36.
DMAQYRL	RU	https://pubmed.ncbi.nlm.nih.gov/18345709

DMXI9P4	DI	DMXI9P4
DMXI9P4	DN	EPX-100
DMXI9P4	MI	TT85JO3
DMXI9P4	MN	5-HT receptor (5HTR)
DMXI9P4	MT	DTT
DMXI9P4	MA	Modulator
DMXI9P4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXI9P4	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMKMR2X	DI	DMKMR2X
DMKMR2X	DN	ERB-257
DMKMR2X	MI	TTOM3J0
DMKMR2X	MN	Estrogen receptor beta (ESR2)
DMKMR2X	MT	DTT
DMKMR2X	MA	Agonist
DMKMR2X	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030075)
DMKMR2X	RU	http://adisinsight.springer.com/drugs/800030075

DM9YNTO	DI	DM9YNTO
DM9YNTO	DN	ERY974
DM9YNTO	MI	TTJTSX4
DM9YNTO	MN	Glypican-3 (GPC3)
DM9YNTO	MT	DTT
DM9YNTO	MA	Inhibitor
DM9YNTO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9YNTO	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMY0HU6	DI	DMY0HU6
DMY0HU6	DN	ETC-1922159
DMY0HU6	MI	TTNFBTO
DMY0HU6	MN	Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
DMY0HU6	MT	DTT
DMY0HU6	MA	Inhibitor
DMY0HU6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMY0HU6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMS436I	DI	DMS436I
DMS436I	DN	ETX201
DMS436I	MI	TTZXH48
DMS436I	MN	TNF receptor (TNFR)
DMS436I	MT	DTT
DMS436I	MA	Antagonist
DMS436I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS436I	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMY9ZAS	DI	DMY9ZAS
DMY9ZAS	DN	EUK-189
DMY9ZAS	MI	TTPS279
DMY9ZAS	MN	Catalase (CAT)
DMY9ZAS	MT	DTT
DMY9ZAS	MA	Modulator
DMY9ZAS	RN	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
DMY9ZAS	RU	https://pubmed.ncbi.nlm.nih.gov/18569084

DMY9ZAS	DI	DMY9ZAS
DMY9ZAS	DN	EUK-189
DMY9ZAS	MI	TT6RVLG
DMY9ZAS	MN	Superoxide dismutase Cu-Zn (SOD Cu-Zn)
DMY9ZAS	MT	DTT
DMY9ZAS	MA	Modulator
DMY9ZAS	RN	Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90.
DMY9ZAS	RU	https://pubmed.ncbi.nlm.nih.gov/18569084

DMOG8IE	DI	DMOG8IE
DMOG8IE	DN	EVT 401
DMOG8IE	MI	TT473XN
DMOG8IE	MN	P2X purinoceptor 7 (P2RX7)
DMOG8IE	MT	DTT
DMOG8IE	MA	Antagonist
DMOG8IE	RN	Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417.
DMOG8IE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360091/

DMAKWQD	DI	DMAKWQD
DMAKWQD	DN	EVT100
DMAKWQD	MI	TTN9D8E
DMAKWQD	MN	Glutamate receptor ionotropic NMDA 2B (NMDAR2B)
DMAKWQD	MT	DTT
DMAKWQD	MA	Antagonist
DMAKWQD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAKWQD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DM3VC6T	DI	DM3VC6T
DM3VC6T	DN	EW-A-401
DM3VC6T	MI	TT2Q6G1
DM3VC6T	MN	Vascular endothelial growth factor receptor 1 (FLT-1)
DM3VC6T	MT	DTT
DM3VC6T	MA	Modulator
DM3VC6T	RN	DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007
DM3VC6T	RU	http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(14)00160-6

DM2NBC7	DI	DM2NBC7
DM2NBC7	DN	EZN-2968
DM2NBC7	MI	TTQHWNA
DM2NBC7	MN	Hypoxia-inducible factor 1 alpha (HIF-1A)
DM2NBC7	MT	DTT
DM2NBC7	MA	Modulator
DM2NBC7	RN	Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8.
DM2NBC7	RU	https://www.ncbi.nlm.nih.gov/pubmed/24292632

DMXFY18	DI	DMXFY18
DMXFY18	DN	EZN-3042
DMXFY18	MI	TTTPU1G
DMXFY18	MN	Apoptosis inhibitor survivin (BIRC5)
DMXFY18	MT	DTT
DMXFY18	MA	Modulator
DMXFY18	RN	SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45.
DMXFY18	RU	https://www.ncbi.nlm.nih.gov/pubmed/18790754

DMNPS59	DI	DMNPS59
DMNPS59	DN	EZN-4176
DMNPS59	MI	TTKPW01
DMNPS59	MN	Androgen receptor messenger RNA (AR mRNA)
DMNPS59	MT	DTT
DMNPS59	RN	2011 Pipeline of Santaris Pharma.
DMNPS59	RU	http://www.santaris.com/product-pipeline

DMAH12E	DI	DMAH12E
DMAH12E	DN	F-15845
DMAH12E	MI	TTZOVE0
DMAH12E	MN	Voltage-gated sodium channel alpha Nav1.5 (SCN5A)
DMAH12E	MT	DTT
DMAH12E	MA	Inhibitor
DMAH12E	RN	Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91.
DMAH12E	RU	https://pubmed.ncbi.nlm.nih.gov/20718741

DML4JXZ	DI	DML4JXZ
DML4JXZ	DN	F-7TG
DML4JXZ	MI	TTF0EGX
DML4JXZ	MN	Coagulation factor VII (F7)
DML4JXZ	MT	DTT
DML4JXZ	MA	Modulator
DML4JXZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363).
DML4JXZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363

DM71HLX	DI	DM71HLX
DM71HLX	DN	FAZ053
DM71HLX	MI	TT8ZLTI
DM71HLX	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM71HLX	MT	DTT
DM71HLX	MA	Inhibitor
DM71HLX	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM71HLX	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM13YK0	DI	DM13YK0
DM13YK0	DN	Ferroportin mab
DM13YK0	MI	TT6Y1PG
DM13YK0	MN	Solute carrier family 40 member 1 (SLC40A1)
DM13YK0	MT	DTT
DM13YK0	RN	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
DM13YK0	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/

DMS1O56	DI	DMS1O56
DMS1O56	DN	FF-10101-01
DMS1O56	MI	TTGJCWZ
DMS1O56	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMS1O56	MT	DTT
DMS1O56	MA	Inhibitor
DMS1O56	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMS1O56	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMX5290	DI	DMX5290
DMX5290	DN	FF-10502-01
DMX5290	MI	TTUBNVO
DMX5290	MN	DNA synthesis (DNA synth)
DMX5290	MT	DTT
DMX5290	MA	Inhibitor
DMX5290	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMX5290	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM2GHIP	DI	DM2GHIP
DM2GHIP	DN	FFC-14A
DM2GHIP	MI	TTUTN1I
DM2GHIP	MN	Human Deoxyribonucleic acid (hDNA)
DM2GHIP	MT	DTT
DM2GHIP	MA	Binder
DM2GHIP	RN	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21.
DM2GHIP	RU	https://pubmed.ncbi.nlm.nih.gov/16039951

DM8U2IE	DI	DM8U2IE
DM8U2IE	DN	FGI-101-1A6
DM8U2IE	MI	TTHU7JA
DM8U2IE	MN	Tumor susceptibility gene protein 101 (TSG101)
DM8U2IE	MT	DTT
DM8U2IE	RN	ClinicalTrials.gov (NCT01299142) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6). U.S. National Institutes of Health.
DM8U2IE	RU	https://clinicaltrials.gov/ct2/show/NCT01299142

DMY61GX	DI	DMY61GX
DMY61GX	DN	FGLL
DMY61GX	MI	TTUBJQ3
DMY61GX	MN	Neural cell adhesion molecule (NCAM)
DMY61GX	MT	DTT
DMY61GX	MA	Modulator
DMY61GX	RN	An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.
DMY61GX	RU	https://pubmed.ncbi.nlm.nih.gov/23076631

DMLH2Q6	DI	DMLH2Q6
DMLH2Q6	DN	Figopitant
DMLH2Q6	MI	TTZPO1L
DMLH2Q6	MN	Substance-P receptor (TACR1)
DMLH2Q6	MT	DTT
DMLH2Q6	MA	Antagonist
DMLH2Q6	RN	Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos. 2012 Mar;40(3):419-25.
DMLH2Q6	RU	https://pubmed.ncbi.nlm.nih.gov/22184457

DM2SALJ	DI	DM2SALJ
DM2SALJ	DN	Flanvotumab
DM2SALJ	MI	TTFRV98
DM2SALJ	MN	Melanoma antigen gp75 (TYRP1)
DM2SALJ	MT	DTT
DM2SALJ	RN	National Cancer Institute Drug Dictionary (drug id 675217).
DM2SALJ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=675217

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TT7HF4W
DM7BMD6	MN	Cyclin-dependent kinase 2 (CDK2)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TT0PG8F
DM7BMD6	MN	Cyclin-dependent kinase 4 (CDK4)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TTO0FDJ
DM7BMD6	MN	Cyclin-dependent kinase 6 (CDK6)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DM7BMD6	DI	DM7BMD6
DM7BMD6	DN	FN-1501
DM7BMD6	MI	TTGJCWZ
DM7BMD6	MN	Fms-like tyrosine kinase 3 (FLT-3)
DM7BMD6	MT	DTT
DM7BMD6	MA	Inhibitor
DM7BMD6	RN	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
DM7BMD6	RU	https://pubmed.ncbi.nlm.nih.gov/29357250

DMKX174	DI	DMKX174
DMKX174	DN	FOR46
DMKX174	MI	TTMS7DF
DMKX174	MN	Membrane cofactor protein (CD46)
DMKX174	MT	DTT
DMKX174	RN	Clinical pipeline report, company report or official report of Fortis Therapeutics.
DMKX174	RU	https://fortistx.com/for46-pipeline/

DMH1NXO	DI	DMH1NXO
DMH1NXO	DN	FP-025
DMH1NXO	MI	TTXZ0KQ
DMH1NXO	MN	Matrix metalloproteinase-12 (MMP-12)
DMH1NXO	MT	DTT
DMH1NXO	MA	Inhibitor
DMH1NXO	RN	Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7.
DMH1NXO	RU	https://www.ncbi.nlm.nih.gov/pubmed/26174966

DMV9FTH	DI	DMV9FTH
DMV9FTH	DN	FP-045
DMV9FTH	MI	TTFLN4T
DMV9FTH	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMV9FTH	MT	DTT
DMV9FTH	MA	Agonist
DMV9FTH	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMV9FTH	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DM8BG0M	DI	DM8BG0M
DM8BG0M	DN	FP-253-GDEPT
DM8BG0M	MI	TTVYIH7
DM8BG0M	MN	Schistosoma Purine nucleoside phosphorylase (sch PNP)
DM8BG0M	MT	DTT
DM8BG0M	MA	Modulator
DM8BG0M	RN	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57.
DM8BG0M	RU	https://pubmed.ncbi.nlm.nih.gov/15493036

DM1EBRK	DI	DM1EBRK
DM1EBRK	DN	FPA144
DM1EBRK	MI	TTGKIED
DM1EBRK	MN	Fibroblast growth factor-2 (FGF2)
DM1EBRK	MT	DTT
DM1EBRK	MA	Antagonist
DM1EBRK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1EBRK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMI9A1Z	DI	DMI9A1Z
DMI9A1Z	DN	FPI-1434
DMI9A1Z	MI	TTHRID2
DMI9A1Z	MN	Insulin-like growth factor I receptor (IGF1R)
DMI9A1Z	MT	DTT
DMI9A1Z	RN	Clinical pipeline report, company report or official report of Fusion Pharmaceuticals.
DMI9A1Z	RU	https://fusionpharma.com/fusion-pipeline/

DMUI8F3	DI	DMUI8F3
DMUI8F3	DN	Friulimicin
DMUI8F3	MI	TTXT4D5
DMUI8F3	MN	Bacterial Cell membrane (Bact CM)
DMUI8F3	MT	DTT
DMUI8F3	MA	Inhibitor
DMUI8F3	RN	Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60.
DMUI8F3	RU	https://pubmed.ncbi.nlm.nih.gov/21306875

DM0QH9K	DI	DM0QH9K
DM0QH9K	DN	FS118
DM0QH9K	MI	TTNVXAW
DM0QH9K	MN	Lymphocyte activation gene 3 protein (LAG3)
DM0QH9K	MT	DTT
DM0QH9K	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0QH9K	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DM0QH9K	DI	DM0QH9K
DM0QH9K	DN	FS118
DM0QH9K	MI	TT8ZLTI
DM0QH9K	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM0QH9K	MT	DTT
DM0QH9K	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DM0QH9K	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMPENAL	DI	DMPENAL
DMPENAL	DN	FSI-189
DMPENAL	MI	TTBRJS9
DMPENAL	MN	Inhibitory receptor SHPS-1 (SIRPA)
DMPENAL	MT	DTT
DMPENAL	RN	 T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391.
DMPENAL	RU	https://pubmed.ncbi.nlm.nih.gov/32265560

DMZOAT3	DI	DMZOAT3
DMZOAT3	DN	FT-1101
DMZOAT3	MI	TTE4BSY
DMZOAT3	MN	Bromodomain and extraterminal domain protein (BET)
DMZOAT3	MT	DTT
DMZOAT3	MA	Inhibitor
DMZOAT3	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZOAT3	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMCK3OI	DI	DMCK3OI
DMCK3OI	DN	FT-7051
DMCK3OI	MI	TTFRCTK
DMCK3OI	MN	CREB-binding protein (CREBBP)
DMCK3OI	MT	DTT
DMCK3OI	MA	Inhibitor
DMCK3OI	RN	Clinical pipeline report, company report or official report of FORMA Therapeutics.
DMCK3OI	RU	https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/

DMCK3OI	DI	DMCK3OI
DMCK3OI	DN	FT-7051
DMCK3OI	MI	TTGH73N
DMCK3OI	MN	Histone acetyltransferase p300 (EP300)
DMCK3OI	MT	DTT
DMCK3OI	MA	Inhibitor
DMCK3OI	RN	Clinical pipeline report, company report or official report of FORMA Therapeutics.
DMCK3OI	RU	https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/

DMGJNTQ	DI	DMGJNTQ
DMGJNTQ	DN	FT-819
DMGJNTQ	MI	TTW640A
DMGJNTQ	MN	B-lymphocyte surface antigen B4 (CD19)
DMGJNTQ	MT	DTT
DMGJNTQ	RN	Clinical pipeline report, company report or official report of Fate Therapeutics.
DMGJNTQ	RU	https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft819/

DML028U	DI	DML028U
DML028U	DN	G1T28-1
DML028U	MI	TT0PG8F
DML028U	MN	Cyclin-dependent kinase 4 (CDK4)
DML028U	MT	DTT
DML028U	MA	Modulator
DML028U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML028U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DML028U	DI	DML028U
DML028U	DN	G1T28-1
DML028U	MI	TTO0FDJ
DML028U	MN	Cyclin-dependent kinase 6 (CDK6)
DML028U	MT	DTT
DML028U	MA	Modulator
DML028U	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DML028U	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMRGP72	DI	DMRGP72
DMRGP72	DN	G1T-48
DMRGP72	MI	TTZAYWL
DMRGP72	MN	Estrogen receptor (ESR)
DMRGP72	MT	DTT
DMRGP72	MA	Degrader
DMRGP72	RN	G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646.
DMRGP72	RU	https://pubmed.ncbi.nlm.nih.gov/32130619

DM3H6YC	DI	DM3H6YC
DM3H6YC	DN	G-619
DM3H6YC	MI	TT2O84V
DM3H6YC	MN	Thromboxane A2 receptor (TBXA2R)
DM3H6YC	MT	DTT
DM3H6YC	MA	Modulator
DM3H6YC	RN	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
DM3H6YC	RU	https://pubmed.ncbi.nlm.nih.gov/8566149

DM3H6YC	DI	DM3H6YC
DM3H6YC	DN	G-619
DM3H6YC	MI	TTKNWZ4
DM3H6YC	MN	Thromboxane-A synthase (TBXAS1)
DM3H6YC	MT	DTT
DM3H6YC	MA	Modulator
DM3H6YC	RN	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
DM3H6YC	RU	https://pubmed.ncbi.nlm.nih.gov/8566149

DMJLIQ2	DI	DMJLIQ2
DMJLIQ2	DN	GALAMUSTINE HYDROCHLORIDE
DMJLIQ2	MI	TTUTN1I
DMJLIQ2	MN	Human Deoxyribonucleic acid (hDNA)
DMJLIQ2	MT	DTT
DMJLIQ2	MA	Antagonist
DMJLIQ2	RN	6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9.
DMJLIQ2	RU	https://pubmed.ncbi.nlm.nih.gov/3802075

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTV1095
DMG9C4I	MN	COVID-19 RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Blocker
DMG9C4I	RN	BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
DMG9C4I	RU	https://www.biospace.com/article/releases/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid-19/

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTOA6YT
DMG9C4I	MN	MERS-CoV RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Inhibitor
DMG9C4I	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMG9C4I	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMG9C4I	DI	DMG9C4I
DMG9C4I	DN	Galidesivir
DMG9C4I	MI	TTKXI53
DMG9C4I	MN	SARS-CoV RNA-directed RNA polymerase (RdRp)
DMG9C4I	MT	DTT
DMG9C4I	MA	Inhibitor
DMG9C4I	RN	Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
DMG9C4I	RU	https://pubmed.ncbi.nlm.nih.gov/26868298

DMIXMQE	DI	DMIXMQE
DMIXMQE	DN	GAP T cells
DMIXMQE	MI	TTJTSX4
DMIXMQE	MN	Glypican-3 (GPC3)
DMIXMQE	MT	DTT
DMIXMQE	MA	CAR-T-Cell-Therapy
DMIXMQE	RN	ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
DMIXMQE	RU	https://clinicaltrials.gov/ct2/show/NCT02932956

DM52O7W	DI	DM52O7W
DM52O7W	DN	GBR1302
DM52O7W	MI	TT6EO5L
DM52O7W	MN	Erbb2 tyrosine kinase receptor (HER2)
DM52O7W	MT	DTT
DM52O7W	MA	Inhibitor
DM52O7W	RN	Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
DM52O7W	RU	https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf

DM52O7W	DI	DM52O7W
DM52O7W	DN	GBR1302
DM52O7W	MI	TTUN7MC
DM52O7W	MN	T-cell surface glycoprotein CD3 (CD3)
DM52O7W	MT	DTT
DM52O7W	MA	Inhibitor
DM52O7W	RN	Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
DM52O7W	RU	https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf

DMQBEYV	DI	DMQBEYV
DMQBEYV	DN	GC021109
DMQBEYV	MI	TTNVSKA
DMQBEYV	MN	P2Y purinoceptor 6 (P2RY6)
DMQBEYV	MT	DTT
DMQBEYV	MA	Agonist
DMQBEYV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBEYV	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM6R4DO	DI	DM6R4DO
DM6R4DO	DN	GC-1008
DM6R4DO	MI	TT5BDCY
DM6R4DO	MN	TGF-beta receptor (TGFBR)
DM6R4DO	MT	DTT
DM6R4DO	MA	Modulator
DM6R4DO	RN	Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.PLoS One.2014 Mar 11;9(3):e90353.
DM6R4DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/24618589

DMK96CE	DI	DMK96CE
DMK96CE	DN	GC-1113
DMK96CE	MI	TTQG4NR
DMK96CE	MN	Erythropoietin (EPO)
DMK96CE	MT	DTT
DMK96CE	MA	Modulator
DMK96CE	RN	A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.
DMK96CE	RU	https://pubmed.ncbi.nlm.nih.gov/22644842

DMJ7WRI	DI	DMJ7WRI
DMJ7WRI	DN	GCC-1290K
DMJ7WRI	MI	TTYVX59
DMJ7WRI	MN	Protein kinase C (PRKC)
DMJ7WRI	MT	DTT
DMJ7WRI	MA	Modulator
DMJ7WRI	RN	Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
DMJ7WRI	RU	https://pubmed.ncbi.nlm.nih.gov/19428798

DMJ7WRI	DI	DMJ7WRI
DMJ7WRI	DN	GCC-1290K
DMJ7WRI	MI	TTCRJKY
DMJ7WRI	MN	Voltage-gated calcium channel (Cav)
DMJ7WRI	MT	DTT
DMJ7WRI	MA	Modulator
DMJ7WRI	RN	Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34.
DMJ7WRI	RU	https://pubmed.ncbi.nlm.nih.gov/19428798

DMHMZC7	DI	DMHMZC7
DMHMZC7	DN	GCC-4401
DMHMZC7	MI	TTCIHJA
DMHMZC7	MN	Coagulation factor Xa (F10)
DMHMZC7	MT	DTT
DMHMZC7	MA	Inhibitor
DMHMZC7	RN	Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7.
DMHMZC7	RU	https://pubmed.ncbi.nlm.nih.gov/22844656

DM9TD2N	DI	DM9TD2N
DM9TD2N	DN	GD2 T cells
DM9TD2N	MI	TT80ARU
DM9TD2N	MN	Ganglioside GD2 (GD2)
DM9TD2N	MT	DTT
DM9TD2N	MA	CAR-T-Cell-Therapy
DM9TD2N	RN	ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
DM9TD2N	RU	https://clinicaltrials.gov/ct2/show/NCT01953900

DMSE19U	DI	DMSE19U
DMSE19U	DN	GDC0134
DMSE19U	MI	TTF4AVB
DMSE19U	MN	Protein delta homolog 1 (DLK1)
DMSE19U	MT	DTT
DMSE19U	MA	Inhibitor
DMSE19U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSE19U	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM1B3UM	DI	DM1B3UM
DM1B3UM	DN	GDC-0152
DM1B3UM	MI	TTR7B60
DM1B3UM	MN	X-linked inhibitor of apoptosis protein (XIAP)
DM1B3UM	MT	DTT
DM1B3UM	MA	Modulator
DM1B3UM	RN	Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
DM1B3UM	RU	https://pubmed.ncbi.nlm.nih.gov/22413863

DMUNFEP	DI	DMUNFEP
DMUNFEP	DN	GDC0310
DMUNFEP	MI	TT4G2JS
DMUNFEP	MN	Voltage-gated sodium channel alpha Nav1.7 (SCN9A)
DMUNFEP	MT	DTT
DMUNFEP	MA	Inhibitor
DMUNFEP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMUNFEP	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM3Z2JB	DI	DM3Z2JB
DM3Z2JB	DN	GDC-0349
DM3Z2JB	MI	TTCJG29
DM3Z2JB	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM3Z2JB	MT	DTT
DM3Z2JB	MA	Inhibitor
DM3Z2JB	RN	Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7.
DM3Z2JB	RU	https://pubmed.ncbi.nlm.nih.gov/24900569

DMDZ26X	DI	DMDZ26X
DMDZ26X	DN	GDC-0425
DMDZ26X	MI	TTTU902
DMDZ26X	MN	Checkpoint kinase-1 (CHK1)
DMDZ26X	MT	DTT
DMDZ26X	MA	Modulator
DMDZ26X	RN	Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
DMDZ26X	RU	http://cancerres.aacrjournals.org/content/75/15_Supplement/6

DMDY08K	DI	DMDY08K
DMDY08K	DN	GDC-0623
DMDY08K	MI	TTZCRP3
DMDY08K	MN	ERK activator kinase (MEK)
DMDY08K	MT	DTT
DMDY08K	MA	Inhibitor
DMDY08K	RN	Clinical pipeline report, company report or official report of Genentech (2011).
DMDY08K	RU	http://www.gene.com/gene/index.jsp

DMFC2OY	DI	DMFC2OY
DMFC2OY	DN	GDC-0994
DMFC2OY	MI	TT1MG9E
DMFC2OY	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMFC2OY	MT	DTT
DMFC2OY	MA	Modulator
DMFC2OY	RN	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
DMFC2OY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142

DMFC2OY	DI	DMFC2OY
DMFC2OY	DN	GDC-0994
DMFC2OY	MI	TT4TQBX
DMFC2OY	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMFC2OY	MT	DTT
DMFC2OY	MA	Modulator
DMFC2OY	RN	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
DMFC2OY	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142

DMJA27W	DI	DMJA27W
DMJA27W	DN	GDC-5573
DMJA27W	MI	TTB18GJ
DMJA27W	MN	Proto-oncogene c-RAF (c-RAF)
DMJA27W	MT	DTT
DMJA27W	MA	Inhibitor
DMJA27W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMJA27W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMF6UB	DI	DMMF6UB
DMMF6UB	DN	GE-1170A
DMMF6UB	MI	TTYQIFM
DMMF6UB	MN	Staphylococcus Elongation factor Tu (Stap-coc tuf)
DMMF6UB	MT	DTT
DMMF6UB	MA	Inhibitor
DMMF6UB	RN	GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005.
DMMF6UB	RU	https://pubmed.ncbi.nlm.nih.gov/11124042

DMJK7V0	DI	DMJK7V0
DMJK7V0	DN	Ge2270a
DMJK7V0	MI	TTG45NU
DMJK7V0	MN	Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1)
DMJK7V0	MT	DTT
DMJK7V0	MA	Inhibitor
DMJK7V0	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMJK7V0	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMDMKVL	DI	DMDMKVL
DMDMKVL	DN	GEM333
DMDMKVL	MI	TTJVYO3
DMDMKVL	MN	Myeloid cell surface antigen CD33 (CD33)
DMDMKVL	MT	DTT
DMDMKVL	MA	Inhibitor
DMDMKVL	RN	Clinical pipeline report, company report or official report of Gemoab.
DMDMKVL	RU	https://www.gemoab.com/gem333

DMDMKVL	DI	DMDMKVL
DMDMKVL	DN	GEM333
DMDMKVL	MI	TTUN7MC
DMDMKVL	MN	T-cell surface glycoprotein CD3 (CD3)
DMDMKVL	MT	DTT
DMDMKVL	MA	Inhibitor
DMDMKVL	RN	Clinical pipeline report, company report or official report of Gemoab.
DMDMKVL	RU	https://www.gemoab.com/gem333

DM3GSPR	DI	DM3GSPR
DM3GSPR	DN	GEM3PSCA
DM3GSPR	MI	TT9T4AV
DM3GSPR	MN	Prostate stem cell antigen (PSCA)
DM3GSPR	MT	DTT
DM3GSPR	MA	Inhibitor
DM3GSPR	RN	Clinical pipeline report, company report or official report of Gemoab.
DM3GSPR	RU	https://www.gemoab.com/gem3psca

DMV8IWJ	DI	DMV8IWJ
DMV8IWJ	DN	GEN1029
DMV8IWJ	MI	TTW20TU
DMV8IWJ	MN	TRAIL receptor 2 (TRAIL-R2)
DMV8IWJ	MT	DTT
DMV8IWJ	MA	Agonist
DMV8IWJ	RN	National Cancer Institute Drug Dictionary (drug name Tilogotamab).
DMV8IWJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tilogotamab

DMNP6T3	DI	DMNP6T3
DMNP6T3	DN	GEN1042
DMNP6T3	MI	TTN6Y9A
DMNP6T3	MN	CD40L receptor (CD40)
DMNP6T3	MT	DTT
DMNP6T3	MA	Agonist
DMNP6T3	RN	Clinical pipeline report, company report or official report of Genmab.
DMNP6T3	RU	https://www.genmab.com/pipeline/

DMNP6T3	DI	DMNP6T3
DMNP6T3	DN	GEN1042
DMNP6T3	MI	TTPW9LJ
DMNP6T3	MN	Co-stimulatory molecule 4-1BB (CD137)
DMNP6T3	MT	DTT
DMNP6T3	MA	Agonist
DMNP6T3	RN	Clinical pipeline report, company report or official report of Genmab.
DMNP6T3	RU	https://www.genmab.com/pipeline/

DMQ9317	DI	DMQ9317
DMQ9317	DN	GEN1044
DMQ9317	MI	TT70MLA
DMQ9317	MN	Oncotrophoblast glycoprotein 5T4 (TPBG)
DMQ9317	MT	DTT
DMQ9317	RN	Clinical pipeline report, company report or official report of AbbVie.
DMQ9317	RU	https://www.abbvie.com/our-science/pipeline/gen-1044.html

DMQ9317	DI	DMQ9317
DMQ9317	DN	GEN1044
DMQ9317	MI	TTUN7MC
DMQ9317	MN	T-cell surface glycoprotein CD3 (CD3)
DMQ9317	MT	DTT
DMQ9317	RN	Clinical pipeline report, company report or official report of AbbVie.
DMQ9317	RU	https://www.abbvie.com/our-science/pipeline/gen-1044.html

DMEWRNZ	DI	DMEWRNZ
DMEWRNZ	DN	GEN1046
DMEWRNZ	MI	TTPW9LJ
DMEWRNZ	MN	Co-stimulatory molecule 4-1BB (CD137)
DMEWRNZ	MT	DTT
DMEWRNZ	MA	Agonist
DMEWRNZ	RN	Clinical pipeline report, company report or official report of Genmab.
DMEWRNZ	RU	https://www.genmab.com/pipeline/

DMEWRNZ	DI	DMEWRNZ
DMEWRNZ	DN	GEN1046
DMEWRNZ	MI	TT8ZLTI
DMEWRNZ	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMEWRNZ	MT	DTT
DMEWRNZ	MA	Agonist
DMEWRNZ	RN	Clinical pipeline report, company report or official report of Genmab.
DMEWRNZ	RU	https://www.genmab.com/pipeline/

DMWR93D	DI	DMWR93D
DMWR93D	DN	Genaconazole
DMWR93D	MI	TTTSOUD
DMWR93D	MN	Candida Cytochrome P450 51 (Candi ERG11)
DMWR93D	MT	DTT
DMWR93D	MA	Modulator
DMWR93D	RN	New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47.
DMWR93D	RU	https://pubmed.ncbi.nlm.nih.gov/11204162

DMJP83V	DI	DMJP83V
DMJP83V	DN	Gene therapy, IFN-b
DMJP83V	MI	TT4TZ8J
DMJP83V	MN	Interferon-beta (IFNB1)
DMJP83V	MT	DTT
DMJP83V	MA	Modulator
DMJP83V	RN	Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65.
DMJP83V	RU	https://pubmed.ncbi.nlm.nih.gov/15546502

DMTGN0U	DI	DMTGN0U
DMTGN0U	DN	Genz 644282
DMTGN0U	MI	DTUGYRD
DMTGN0U	MN	P-glycoprotein 1 (ABCB1)
DMTGN0U	MT	DTP
DMTGN0U	MA	Substrate
DMTGN0U	RN	Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther. 2011 Aug;10(8):1490-9.
DMTGN0U	RU	https://doi.org/10.1158/1535-7163.MCT-10-1043

DMIXABW	DI	DMIXABW
DMIXABW	DN	Genz-644282
DMIXABW	MI	TTGTQHC
DMIXABW	MN	DNA topoisomerase I (TOP1)
DMIXABW	MT	DTT
DMIXABW	MA	Inhibitor
DMIXABW	RN	Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87.
DMIXABW	RU	https://pubmed.ncbi.nlm.nih.gov/21415217

DMA9UX2	DI	DMA9UX2
DMA9UX2	DN	Gerilimzumab
DMA9UX2	MI	TTT1V78
DMA9UX2	MN	Interleukin-6 (IL6)
DMA9UX2	MT	DTT
DMA9UX2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA9UX2	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMDMPKC	DI	DMDMPKC
DMDMPKC	DN	GGF-2
DMDMPKC	MI	TTEH395
DMDMPKC	MN	Pro-neuregulin-1 (Pro-NRG1)
DMDMPKC	MT	DTT
DMDMPKC	MA	Modulator
DMDMPKC	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMDMPKC	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM8U23L	DI	DM8U23L
DM8U23L	DN	GGTI-2418
DM8U23L	MI	TTXQKM3
DM8U23L	MN	Farnesyl protein transferase (Ftase)
DM8U23L	MT	DTT
DM8U23L	MA	Modulator
DM8U23L	RN	Company report (Prescient)
DM8U23L	RU	http://prescienttherapeutics.com/ptx-100/

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	TTC67I0
DMKY1L4	MN	Bacterial Glucosamine-6-phosphate synthase (Bact glmS)
DMKY1L4	MT	DTT
DMKY1L4	MA	Inhibitor
DMKY1L4	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DMKY1L4	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	DTLHZFU
DMKY1L4	MN	Glucose-6-phosphate translocase (SLC37A4)
DMKY1L4	MT	DTP
DMKY1L4	MA	Substrate
DMKY1L4	RN	A novel mutation (A148V) in the glucose 6-phosphate translocase (SLC37A4) gene in a Korean patient with glycogen storage disease type 1b. J Korean Med Sci. 2005 Jun;20(3):499-501.
DMKY1L4	RU	http://www.ncbi.nlm.nih.gov/pubmed/15953877

DMKY1L4	DI	DMKY1L4
DMKY1L4	DN	Glucose-6-phosphate
DMKY1L4	MI	DTH9SQJ
DMKY1L4	MN	Glycerol-3-phosphate permease (SLC37A1)
DMKY1L4	MT	DTP
DMKY1L4	MA	Substrate
DMKY1L4	RN	SLC37A1 and SLC37A2 are phosphate-linked, glucose-6-phosphate antiporters. PLoS One. 2011;6(9):e23157.
DMKY1L4	RU	http://www.ncbi.nlm.nih.gov/pubmed/21949678

DM1PK0T	DI	DM1PK0T
DM1PK0T	DN	GLYCAR T cells
DM1PK0T	MI	TTJTSX4
DM1PK0T	MN	Glypican-3 (GPC3)
DM1PK0T	MT	DTT
DM1PK0T	MA	CAR-T-Cell-Therapy
DM1PK0T	RN	ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
DM1PK0T	RU	https://clinicaltrials.gov/ct2/show/NCT02905188

DMCKZUT	DI	DMCKZUT
DMCKZUT	DN	GlyT1 PET radiotracers
DMCKZUT	MI	TTHJTF7
DMCKZUT	MN	Glycine transporter GlyT-1 (SLC6A9)
DMCKZUT	MT	DTT
DMCKZUT	MA	Modulator
DMCKZUT	RN	Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19.
DMCKZUT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023951/

DML1KSA	DI	DML1KSA
DML1KSA	DN	GMI-1359
DML1KSA	MI	TTBID49
DML1KSA	MN	C-X-C chemokine receptor type 4 (CXCR4)
DML1KSA	MT	DTT
DML1KSA	MA	Antagonist
DML1KSA	RN	Clinical pipeline report, company report or official report of GlycoMimetics.
DML1KSA	RU	http://glycomimetics.com/pipeline/programs/gmi-1359/

DML1KSA	DI	DML1KSA
DML1KSA	DN	GMI-1359
DML1KSA	MI	TTAU4D6
DML1KSA	MN	E-selectin (SELE)
DML1KSA	MT	DTT
DML1KSA	MA	Antagonist
DML1KSA	RN	Clinical pipeline report, company report or official report of GlycoMimetics.
DML1KSA	RU	http://glycomimetics.com/pipeline/programs/gmi-1359/

DMIFSN2	DI	DMIFSN2
DMIFSN2	DN	GMX1777
DMIFSN2	MI	TTD1WIG
DMIFSN2	MN	Nicotinamide phosphoribosyltransferase (NAMPT)
DMIFSN2	MT	DTT
DMIFSN2	MA	Modulator
DMIFSN2	RN	The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88.
DMIFSN2	RU	https://pubmed.ncbi.nlm.nih.gov/19703994

DMD6H8B	DI	DMD6H8B
DMD6H8B	DN	GMZ-2
DMD6H8B	MI	TT3J5ZI
DMD6H8B	MN	Cell mediated immunity response (CMIR)
DMD6H8B	MT	DTT
DMD6H8B	RN	Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359.
DMD6H8B	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265551/

DMURO94	DI	DMURO94
DMURO94	DN	GNE Lipoplex
DMURO94	MI	TT4DP5S
DMURO94	MN	N-acetylmannosamine kinase (GNE)
DMURO94	MT	DTT
DMURO94	MA	Inhibitor
DMURO94	RN	Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther. 2011 Nov;22(11):1331-41.
DMURO94	RU	https://pubmed.ncbi.nlm.nih.gov/21517694

DMYWDT4	DI	DMYWDT4
DMYWDT4	DN	GNKG-168
DMYWDT4	MI	TTSHG0T
DMYWDT4	MN	Toll-like receptor 9 (TLR9)
DMYWDT4	MT	DTT
DMYWDT4	MA	Modulator
DMYWDT4	RN	National Cancer Institute Drug Dictionary (drug id 662816).
DMYWDT4	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=662816

DMKMU2S	DI	DMKMU2S
DMKMU2S	DN	GNX102
DMKMU2S	MI	TTZUFEL
DMKMU2S	MN	Tumor-associated glycan antigen (TAGA)
DMKMU2S	MT	DTT
DMKMU2S	RN	Clinical pipeline report, company report or official report of GlycoNex.
DMKMU2S	RU	http://www.glyconex.com.tw/index.php/en-us/product-pipeline-us

DM035LO	DI	DM035LO
DM035LO	DN	GP-3269
DM035LO	MI	TTL732K
DM035LO	MN	Adenosine kinase (ADK)
DM035LO	MT	DTT
DM035LO	MA	Inhibitor
DM035LO	RN	Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20.
DM035LO	RU	https://pubmed.ncbi.nlm.nih.gov/16302820

DM9JV80	DI	DM9JV80
DM9JV80	DN	Gp41 HIV-1 vaccine
DM9JV80	MI	TTG90S6
DM9JV80	MN	Human immunodeficiency virus Glycoprotein 41 (HIV gp41)
DM9JV80	MT	DTT
DM9JV80	MA	Modulator
DM9JV80	RN	Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.
DM9JV80	RU	https://pubmed.ncbi.nlm.nih.gov/20111582

DM2MILF	DI	DM2MILF
DM2MILF	DN	GPA-TriMAR-T cells
DM2MILF	MI	TT9VL2N
DM2MILF	MN	Gp100[209-217] peptide (PMEL)
DM2MILF	MT	DTT
DM2MILF	MA	CAR-T-Cell-Therapy
DM2MILF	RN	ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
DM2MILF	RU	https://clinicaltrials.gov/ct2/show/NCT03649529

DMVWHS1	DI	DMVWHS1
DMVWHS1	DN	GPC3 targeting CAR-T cells
DMVWHS1	MI	TTJTSX4
DMVWHS1	MN	Glypican-3 (GPC3)
DMVWHS1	MT	DTT
DMVWHS1	MA	CAR-T-Cell-Therapy
DMVWHS1	RN	ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
DMVWHS1	RU	https://clinicaltrials.gov/ct2/show/NCT03198546

DM0ZQ48	DI	DM0ZQ48
DM0ZQ48	DN	GPI-16072
DM0ZQ48	MI	TT9G4N0
DM0ZQ48	MN	Glutamate carboxypeptidase II (GCPII)
DM0ZQ48	MT	DTT
DM0ZQ48	MA	Inhibitor
DM0ZQ48	RN	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
DM0ZQ48	RU	https://pubmed.ncbi.nlm.nih.gov/17355217

DM8MGSH	DI	DM8MGSH
DM8MGSH	DN	GPRC5D CAR-T cell therapy
DM8MGSH	MI	TTHRAPJ
DM8MGSH	MN	G-protein coupled receptor C 5D (GPRC5D)
DM8MGSH	MT	DTT
DM8MGSH	RN	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746.
DM8MGSH	RU	https://pubmed.ncbi.nlm.nih.gov/30918115

DMFA2XQ	DI	DMFA2XQ
DMFA2XQ	DN	GQ1001
DMFA2XQ	MI	TT6EO5L
DMFA2XQ	MN	Erbb2 tyrosine kinase receptor (HER2)
DMFA2XQ	MT	DTT
DMFA2XQ	RN	Clinical pipeline report, company report or official report of GeneQuantum Healthcare.
DMFA2XQ	RU	http://www.genequantum.com/#/common/product?pid=12&id=13&type=7

DMZ0D3V	DI	DMZ0D3V
DMZ0D3V	DN	GRC-6211
DMZ0D3V	MI	TT0IHXV
DMZ0D3V	MN	DNA topoisomerase II (TOP2)
DMZ0D3V	MT	DTT
DMZ0D3V	MA	Inhibitor
DMZ0D3V	RN	Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6.
DMZ0D3V	RU	https://pubmed.ncbi.nlm.nih.gov/2847647

DMZ0D3V	DI	DMZ0D3V
DMZ0D3V	DN	GRC-6211
DMZ0D3V	MI	TTMI6F5
DMZ0D3V	MN	Transient receptor potential cation channel V1 (TRPV1)
DMZ0D3V	MT	DTT
DMZ0D3V	MA	Antagonist
DMZ0D3V	RN	GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86.
DMZ0D3V	RU	https://pubmed.ncbi.nlm.nih.gov/19010489

DMGF71W	DI	DMGF71W
DMGF71W	DN	GRN163
DMGF71W	MI	TTUJFD0
DMGF71W	MN	Telomerase reverse transcriptase (TERT)
DMGF71W	MT	DTT
DMGF71W	MA	Inhibitor
DMGF71W	RN	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
DMGF71W	RU	https://pubmed.ncbi.nlm.nih.gov/19249983

DMI319T	DI	DMI319T
DMI319T	DN	GS 9667
DMI319T	MI	TTK25J1
DMI319T	MN	Adenosine A1 receptor (ADORA1)
DMI319T	MT	DTT
DMI319T	MA	Agonist
DMI319T	RN	Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92.
DMI319T	RU	https://pubmed.ncbi.nlm.nih.gov/23427000

DMS25DL	DI	DMS25DL
DMS25DL	DN	GS-1423
DMS25DL	MI	TTK0O6Y
DMS25DL	MN	Ecto-5'-nucleotidase (CD73)
DMS25DL	MT	DTT
DMS25DL	RN	Clinical pipeline report, company report or official report of Agenus.
DMS25DL	RU	https://agenusbio.com/pipeline/

DMS25DL	DI	DMS25DL
DMS25DL	DN	GS-1423
DMS25DL	MI	TTO3HT7
DMS25DL	MN	Transforming growth factor beta (TGFB)
DMS25DL	MT	DTT
DMS25DL	RN	Clinical pipeline report, company report or official report of Agenus.
DMS25DL	RU	https://agenusbio.com/pipeline/

DMZVFOQ	DI	DMZVFOQ
DMZVFOQ	DN	GS-5829
DMZVFOQ	MI	TTE4BSY
DMZVFOQ	MN	Bromodomain and extraterminal domain protein (BET)
DMZVFOQ	MT	DTT
DMZVFOQ	MA	Inhibitor
DMZVFOQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZVFOQ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMRDNPC	DI	DMRDNPC
DMRDNPC	DN	GS-6620
DMRDNPC	MI	TTMVBWH
DMRDNPC	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMRDNPC	MT	DTT
DMRDNPC	MA	Inhibitor
DMRDNPC	RN	Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42.
DMRDNPC	RU	https://pubmed.ncbi.nlm.nih.gov/24419349

DMXG3T1	DI	DMXG3T1
DMXG3T1	DN	GS-6637
DMXG3T1	MI	TTFLN4T
DMXG3T1	MN	Mitochondrial aldehyde dehydrogenase (ALDH2)
DMXG3T1	MT	DTT
DMXG3T1	MA	Inhibitor
DMXG3T1	RN	Clinical pipeline report, company report or official report of Gilead.
DMXG3T1	RU	http://www.gilead.com/~/media/Files/pdfs/other/Gilead_Sciences_Company_Overview_FactSheet_080514.pdf

DMNX3US	DI	DMNX3US
DMNX3US	DN	GS-9820
DMNX3US	MI	TTGBPJE
DMNX3US	MN	PI3-kinase delta (PIK3CD)
DMNX3US	MT	DTT
DMNX3US	MA	Inhibitor
DMNX3US	RN	National Cancer Institute Drug Dictionary (drug id 741949).
DMNX3US	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741949

DMMF5IE	DI	DMMF5IE
DMMF5IE	DN	GS-9883
DMMF5IE	MI	DE4LYSA
DMMF5IE	MN	Cytochrome P450 3A4 (CYP3A4)
DMMF5IE	MT	DME
DMMF5IE	MA	Metabolism
DMMF5IE	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DMMF5IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DMMF5IE	DI	DMMF5IE
DMMF5IE	DN	GS-9883
DMMF5IE	MI	DEYGVN4
DMMF5IE	MN	UDP-glucuronosyltransferase 1A1 (UGT1A1)
DMMF5IE	MT	DME
DMMF5IE	MA	Metabolism
DMMF5IE	RN	Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.
DMMF5IE	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31840682

DMGHN98	DI	DMGHN98
DMGHN98	DN	GS-9901
DMGHN98	MI	TTGBPJE
DMGHN98	MN	PI3-kinase delta (PIK3CD)
DMGHN98	MT	DTT
DMGHN98	MA	Inhibitor
DMGHN98	RN	Clinical pipeline report, company report or official report of Gilead.
DMGHN98	RU	http://www.gilead.com/research/pipeline

DMSR5HD	DI	DMSR5HD
DMSR5HD	DN	GSI-136
DMSR5HD	MI	TT9W8GU
DMSR5HD	MN	Gamma-secretase (GS)
DMSR5HD	MT	DTT
DMSR5HD	MA	Modulator
DMSR5HD	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMSR5HD	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMO87YS	DI	DMO87YS
DMO87YS	DN	GSK065
DMO87YS	MI	TTIY56R
DMO87YS	MN	Kynurenine 3-hydroxylase (KMO)
DMO87YS	MT	DTT
DMO87YS	MA	Inhibitor
DMO87YS	RN	Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827.
DMO87YS	RU	https://pubmed.ncbi.nlm.nih.gov/28604669

DMXRPT6	DI	DMXRPT6
DMXRPT6	DN	GSK1070916
DMXRPT6	MI	TT5LS6T
DMXRPT6	MN	Aurora kinase B (AURKB)
DMXRPT6	MT	DTT
DMXRPT6	MA	Modulator
DMXRPT6	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMXRPT6	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMXRPT6	DI	DMXRPT6
DMXRPT6	DN	GSK1070916
DMXRPT6	MI	TTLYXIT
DMXRPT6	MN	Aurora kinase C (AURKC)
DMXRPT6	MT	DTT
DMXRPT6	MA	Modulator
DMXRPT6	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMXRPT6	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMCJUI9	DI	DMCJUI9
DMCJUI9	DN	GSK1070916A
DMCJUI9	MI	TT5LS6T
DMCJUI9	MN	Aurora kinase B (AURKB)
DMCJUI9	MT	DTT
DMCJUI9	MA	Modulator
DMCJUI9	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMCJUI9	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMCJUI9	DI	DMCJUI9
DMCJUI9	DN	GSK1070916A
DMCJUI9	MI	TTLYXIT
DMCJUI9	MN	Aurora kinase C (AURKC)
DMCJUI9	MT	DTT
DMCJUI9	MA	Modulator
DMCJUI9	RN	Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
DMCJUI9	RU	https://pubmed.ncbi.nlm.nih.gov/20420387

DMK3S9J	DI	DMK3S9J
DMK3S9J	DN	GSK1144814
DMK3S9J	MI	TTBPGLU
DMK3S9J	MN	Neuromedin-K receptor (TACR3)
DMK3S9J	MT	DTT
DMK3S9J	MA	Modulator
DMK3S9J	RN	Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
DMK3S9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/23067311

DMK3S9J	DI	DMK3S9J
DMK3S9J	DN	GSK1144814
DMK3S9J	MI	TTZPO1L
DMK3S9J	MN	Substance-P receptor (TACR1)
DMK3S9J	MT	DTT
DMK3S9J	MA	Modulator
DMK3S9J	RN	Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39.
DMK3S9J	RU	https://www.ncbi.nlm.nih.gov/pubmed/23067311

DMNYGB8	DI	DMNYGB8
DMNYGB8	DN	GSK-1322888
DMNYGB8	MI	TT953CX
DMNYGB8	MN	Motilin receptor (MLNR)
DMNYGB8	MT	DTT
DMNYGB8	MA	Agonist
DMNYGB8	RN	ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health.
DMNYGB8	RU	https://clinicaltrials.gov/ct2/show/NCT01294566

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TTVBI8W
DMZC9XU	MN	Dopamine transporter (DAT)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TTAWNKZ
DMZC9XU	MN	Norepinephrine transporter (NET)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMZC9XU	DI	DMZC9XU
DMZC9XU	DN	GSK-1360707
DMZC9XU	MI	TT3ROYC
DMZC9XU	MN	Serotonin transporter (SERT)
DMZC9XU	MT	DTT
DMZC9XU	MA	Inhibitor
DMZC9XU	RN	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
DMZC9XU	RU	https://pubmed.ncbi.nlm.nih.gov/23685546

DMEJMTR	DI	DMEJMTR
DMEJMTR	DN	GSK1440115
DMEJMTR	MI	TTW5UDX
DMEJMTR	MN	Urotensin II receptor (UTS2R)
DMEJMTR	MT	DTT
DMEJMTR	MA	Antagonist
DMEJMTR	RN	Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. Front Pharmacol. 2013; 4: 54.
DMEJMTR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638148/

DMWDQOV	DI	DMWDQOV
DMWDQOV	DN	GSK1482160
DMWDQOV	MI	TT473XN
DMWDQOV	MN	P2X purinoceptor 7 (P2RX7)
DMWDQOV	MT	DTT
DMWDQOV	MA	Antagonist
DMWDQOV	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMWDQOV	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM2L7TH	DI	DM2L7TH
DM2L7TH	DN	GSK1521498
DM2L7TH	MI	TTKWM86
DM2L7TH	MN	Opioid receptor mu (MOP)
DM2L7TH	MT	DTT
DM2L7TH	MA	Agonist
DM2L7TH	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM2L7TH	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DM7I1AQ	DI	DM7I1AQ
DM7I1AQ	DN	GSK1614235
DM7I1AQ	MI	TT2UE56
DM7I1AQ	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM7I1AQ	MT	DTT
DM7I1AQ	MA	Blocker
DM7I1AQ	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM7I1AQ	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMC6QE4	DI	DMC6QE4
DMC6QE4	DN	GSK1795091
DMC6QE4	MI	TTISGCA
DMC6QE4	MN	Toll-like receptor 4 (TLR4)
DMC6QE4	MT	DTT
DMC6QE4	MA	Agonist
DMC6QE4	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC6QE4	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMA41JD	DI	DMA41JD
DMA41JD	DN	GSK-1827771
DMA41JD	MI	TT51DEV
DMA41JD	MN	Interleukin 1 receptor type 2 (IL1R2)
DMA41JD	MT	DTT
DMA41JD	RN	WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne.
DMA41JD	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130117&CC=WO&NR=2013007763A1&KC=A1

DMC14KV	DI	DMC14KV
DMC14KV	DN	GSK1995057
DMC14KV	MI	TTG043C
DMC14KV	MN	Tumor necrosis factor receptor type I (TNF-R1)
DMC14KV	MT	DTT
DMC14KV	RN	Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.
DMC14KV	RU	https://pubmed.ncbi.nlm.nih.gov/23832582

DMRU4YV	DI	DMRU4YV
DMRU4YV	DN	GSK-2018682
DMRU4YV	MI	TT9JZCK
DMRU4YV	MN	Sphingosine-1-phosphate receptor 1 (S1PR1)
DMRU4YV	MT	DTT
DMRU4YV	MA	Agonist
DMRU4YV	RN	Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
DMRU4YV	RU	https://pubmed.ncbi.nlm.nih.gov/23954895

DMM7ZXR	DI	DMM7ZXR
DMM7ZXR	DN	GSK2126458
DMM7ZXR	MI	TTHBTOP
DMM7ZXR	MN	PI3-kinase gamma (PIK3CG)
DMM7ZXR	MT	DTT
DMM7ZXR	MA	Modulator
DMM7ZXR	RN	Company report (GSK)
DMM7ZXR	RU	http://www.gsk-clinicalstudyregister.com/study/113794#ps

DMRXW9P	DI	DMRXW9P
DMRXW9P	DN	GSK-2130579A
DMRXW9P	MI	TTZ8UT4
DMRXW9P	MN	Wilms tumor protein (WT1)
DMRXW9P	MT	DTT
DMRXW9P	RN	Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.
DMRXW9P	RU	http://science.thomsonreuters.com.cn/media/spotlight_on_report_Q22012.pdf

DMUNVXR	DI	DMUNVXR
DMUNVXR	DN	GSK-2239633
DMUNVXR	MI	TT7HQD0
DMUNVXR	MN	C-C chemokine receptor type 4 (CCR4)
DMUNVXR	MT	DTT
DMUNVXR	MA	Antagonist
DMUNVXR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
DMUNVXR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61

DM5VS7B	DI	DM5VS7B
DM5VS7B	DN	GSK-2241658A
DM5VS7B	MI	TTE5ITK
DM5VS7B	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM5VS7B	MT	DTT
DM5VS7B	RN	ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
DM5VS7B	RU	https://clinicaltrials.gov/ct2/show/NCT01213472

DMR24MI	DI	DMR24MI
DMR24MI	DN	GSK-2256098
DMR24MI	MI	TTON5IT
DMR24MI	MN	Focal adhesion kinase 1 (FAK)
DMR24MI	MT	DTT
DMR24MI	MA	Inhibitor
DMR24MI	RN	A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
DMR24MI	RU	https://pubmed.ncbi.nlm.nih.gov/25486573

DM7FN12	DI	DM7FN12
DM7FN12	DN	GSK2256294
DM7FN12	MI	TT7WVHI
DM7FN12	MN	Soluble epoxide hydrolase (EPHX2)
DM7FN12	MT	DTT
DM7FN12	MA	Modulator
DM7FN12	RN	In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
DM7FN12	RU	https://pubmed.ncbi.nlm.nih.gov/23434473

DMOWTRL	DI	DMOWTRL
DMOWTRL	DN	GSK-2315698
DMOWTRL	MI	TTB7VAT
DMOWTRL	MN	Serum amyloid P-component (APCS)
DMOWTRL	MT	DTT
DMOWTRL	RN	Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15.
DMOWTRL	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/

DMZ5A6D	DI	DMZ5A6D
DMZ5A6D	DN	GSK2398852
DMZ5A6D	MI	TTB7VAT
DMZ5A6D	MN	Serum amyloid P-component (APCS)
DMZ5A6D	MT	DTT
DMZ5A6D	RN	ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health.
DMZ5A6D	RU	https://clinicaltrials.gov/ct2/show/NCT01777243

DMIVHDN	DI	DMIVHDN
DMIVHDN	DN	GSK2618960
DMIVHDN	MI	TT8FRMO
DMIVHDN	MN	Interleukin-7 (IL7)
DMIVHDN	MT	DTT
DMIVHDN	MA	Modulator
DMIVHDN	RN	ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health.
DMIVHDN	RU	https://clinicaltrials.gov/ct2/show/NCT02293161

DMCBGLW	DI	DMCBGLW
DMCBGLW	DN	GSK2636771
DMCBGLW	MI	TTTHBCA
DMCBGLW	MN	PI3-kinase beta (PIK3CB)
DMCBGLW	MT	DTT
DMCBGLW	MA	Inhibitor
DMCBGLW	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967).
DMCBGLW	RU	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7967

DMQOM5V	DI	DMQOM5V
DMQOM5V	DN	GSK2646264
DMQOM5V	MI	TTOU65C
DMQOM5V	MN	Tyrosine-protein kinase SYK (SYK)
DMQOM5V	MT	DTT
DMQOM5V	MA	Inhibitor
DMQOM5V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQOM5V	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM3KARJ	DI	DM3KARJ
DM3KARJ	DN	GSK2647544
DM3KARJ	MI	TTDNFMT
DM3KARJ	MN	Platelet-activating factor acetylhydrolase (PLA2G7)
DM3KARJ	MT	DTT
DM3KARJ	MA	Modulator
DM3KARJ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432).
DM3KARJ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432

DMAK89L	DI	DMAK89L
DMAK89L	DN	GSK2661380
DMAK89L	MI	TTNBFWK
DMAK89L	MN	Programmed cell death protein 1 (PD-1)
DMAK89L	MT	DTT
DMAK89L	MA	Inhibitor
DMAK89L	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760).
DMAK89L	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760

DMSGNVK	DI	DMSGNVK
DMSGNVK	DN	GSK2793660
DMSGNVK	MI	TT4H0V2
DMSGNVK	MN	Dipeptidyl peptidase I (CTSC)
DMSGNVK	MT	DTT
DMSGNVK	MA	Modulator
DMSGNVK	RN	ClinicalTrials.gov (NCT02058407) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects. U.S. National Institutes of Health.
DMSGNVK	RU	https://clinicaltrials.gov/ct2/show/NCT02058407

DMJDVW4	DI	DMJDVW4
DMJDVW4	DN	GSK2816126
DMJDVW4	MI	TT9MZCQ
DMJDVW4	MN	Enhancer of zeste homolog 2 (EZH2)
DMJDVW4	MT	DTT
DMJDVW4	MA	Modulator
DMJDVW4	RN	National Cancer Institute Drug Dictionary (drug id 756211).
DMJDVW4	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756211

DMU1X8K	DI	DMU1X8K
DMU1X8K	DN	GSK2820151
DMU1X8K	MI	TTE4BSY
DMU1X8K	MN	Bromodomain and extraterminal domain protein (BET)
DMU1X8K	MT	DTT
DMU1X8K	MA	Inhibitor
DMU1X8K	RN	ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health.
DMU1X8K	RU	https://clinicaltrials.gov/ct2/show/NCT02630251

DMC47M9	DI	DMC47M9
DMC47M9	DN	GSK2831781
DMC47M9	MI	TTNVXAW
DMC47M9	MN	Lymphocyte activation gene 3 protein (LAG3)
DMC47M9	MT	DTT
DMC47M9	MA	Inhibitor
DMC47M9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMC47M9	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM6KE4G	DI	DM6KE4G
DM6KE4G	DN	GSK2849330
DM6KE4G	MI	TTDC8N2
DM6KE4G	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM6KE4G	MT	DTT
DM6KE4G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798).
DM6KE4G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798

DMT3V2W	DI	DMT3V2W
DMT3V2W	DN	GSK2879552
DMT3V2W	MI	TTNR0UQ
DMT3V2W	MN	Lysine-specific histone demethylase 1 (LSD)
DMT3V2W	MT	DTT
DMT3V2W	MA	Inhibitor
DMT3V2W	RN	A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
DMT3V2W	RU	https://pubmed.ncbi.nlm.nih.gov/26175415

DM4ZK6G	DI	DM4ZK6G
DM4ZK6G	DN	GSK3050002
DM4ZK6G	MI	TT2XAZY
DM4ZK6G	MN	Liver and activation-regulated chemokine (CCL20)
DM4ZK6G	MT	DTT
DM4ZK6G	MA	Inhibitor
DM4ZK6G	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4ZK6G	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMCKNJX	DI	DMCKNJX
DMCKNJX	DN	GSK3052230
DMCKNJX	MI	TT5HU6Z
DMCKNJX	MN	Fibroblast growth factor (FGF)
DMCKNJX	MT	DTT
DMCKNJX	MA	Inhibitor
DMCKNJX	RN	National Cancer Institute Drug Dictionary (drug id 599037).
DMCKNJX	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599037

DM70DYV	DI	DM70DYV
DM70DYV	DN	GSK311739
DM70DYV	MI	TTBH0VX
DM70DYV	MN	Histone deacetylase (HDAC)
DM70DYV	MT	DTT
DM70DYV	MA	Modulator
DM70DYV	RN	Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.
DM70DYV	RU	http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf

DMQZSXD	DI	DMQZSXD
DMQZSXD	DN	GSK3117391
DMQZSXD	MI	TTBH0VX
DMQZSXD	MN	Histone deacetylase (HDAC)
DMQZSXD	MT	DTT
DMQZSXD	MA	Modulator
DMQZSXD	RN	The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.
DMQZSXD	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215088/

DM2KCIP	DI	DM2KCIP
DM2KCIP	DN	GSK3179106
DM2KCIP	MI	TT4DXQT
DM2KCIP	MN	Proto-oncogene c-Ret (RET)
DM2KCIP	MT	DTT
DM2KCIP	MA	Inhibitor
DM2KCIP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM2KCIP	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMJAVN7	DI	DMJAVN7
DMJAVN7	DN	GSK3186899
DMJAVN7	MI	TTJ21A9
DMJAVN7	MN	Cyclin-dependent kinase 12 (CDK12)
DMJAVN7	MT	DTT
DMJAVN7	MA	Inhibitor
DMJAVN7	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMJAVN7	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMVEGND	DI	DMVEGND
DMVEGND	DN	GSK3368715
DMVEGND	MI	TTVOJAI
DMVEGND	MN	Protein arginine methyltransferase 1 (PRMT1)
DMVEGND	MT	DTT
DMVEGND	MA	Inhibitor
DMVEGND	RN	National Cancer Institute Drug Dictionary (drug name GSK6097608).
DMVEGND	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt1-inhibitor-gsk3368715

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTZ97H5
DMIEAMU	MN	Phosphodiesterase 4A (PDE4A)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTVIAT9
DMIEAMU	MN	Phosphodiesterase 4B (PDE4B)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMIEAMU	DI	DMIEAMU
DMIEAMU	DN	GSK-356278
DMIEAMU	MI	TTSKMI8
DMIEAMU	MN	Phosphodiesterase 4D (PDE4D)
DMIEAMU	MT	DTT
DMIEAMU	MA	Inhibitor
DMIEAMU	RN	GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63.
DMIEAMU	RU	https://pubmed.ncbi.nlm.nih.gov/24784567

DMRYNJD	DI	DMRYNJD
DMRYNJD	DN	GSK3745417
DMRYNJD	MI	TTT402Y
DMRYNJD	MN	Stimulator of interferon genes protein (TMEM173)
DMRYNJD	MT	DTT
DMRYNJD	MA	Agonist
DMRYNJD	RN	National Cancer Institute Drug Dictionary (drug name GSK3745417).
DMRYNJD	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417

DM1UQ4Y	DI	DM1UQ4Y
DM1UQ4Y	DN	GSK3845097
DM1UQ4Y	MI	TTE5ITK
DM1UQ4Y	MN	Cancer/testis antigen 1 (NY-ESO-1)
DM1UQ4Y	MT	DTT
DM1UQ4Y	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM1UQ4Y	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMN4I7P	DI	DMN4I7P
DMN4I7P	DN	GSK3901961
DMN4I7P	MI	TTE5ITK
DMN4I7P	MN	Cancer/testis antigen 1 (NY-ESO-1)
DMN4I7P	MT	DTT
DMN4I7P	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMN4I7P	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DMI3FU6	DI	DMI3FU6
DMI3FU6	DN	GSK4074386
DMI3FU6	MI	TTNVXAW
DMI3FU6	MN	Lymphocyte activation gene 3 protein (LAG3)
DMI3FU6	MT	DTT
DMI3FU6	MA	Inhibitor
DMI3FU6	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DMI3FU6	RU	https://www.gsk.com/en-gb/research-and-development/our-pipeline/

DM0P729	DI	DM0P729
DM0P729	DN	GSK461364
DM0P729	MI	TTIYVQP
DM0P729	MN	Polo-like kinase 1 (PLK1)
DM0P729	MT	DTT
DM0P729	MA	Inhibitor
DM0P729	RN	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
DM0P729	RU	https://pubmed.ncbi.nlm.nih.gov/19474163

DMPAWBN	DI	DMPAWBN
DMPAWBN	DN	GSK525762
DMPAWBN	MI	TTE4BSY
DMPAWBN	MN	Bromodomain and extraterminal domain protein (BET)
DMPAWBN	MT	DTT
DMPAWBN	MA	Inhibitor
DMPAWBN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMPAWBN	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPAWBN	DI	DMPAWBN
DMPAWBN	DN	GSK525762
DMPAWBN	MI	TTRA6BO
DMPAWBN	MN	Bromodomain-containing protein 4 (BRD4)
DMPAWBN	MT	DTT
DMPAWBN	MA	Modulator
DMPAWBN	RN	Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56.
DMPAWBN	RU	https://www.ncbi.nlm.nih.gov/pubmed/24751816

DM5E9LX	DI	DM5E9LX
DM5E9LX	DN	GSK586529
DM5E9LX	MI	TT7EFHR
DM5E9LX	MN	Corticotropin-releasing factor receptor 1 (CRHR1)
DM5E9LX	MT	DTT
DM5E9LX	MA	Antagonist
DM5E9LX	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DM5E9LX	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMWI0AL	DI	DMWI0AL
DMWI0AL	DN	GSK6097608
DMWI0AL	MI	TT83C4X
DMWI0AL	MN	T-cell surface protein tactile (CD96)
DMWI0AL	MT	DTT
DMWI0AL	MA	Antagonist
DMWI0AL	RN	National Cancer Institute Drug Dictionary (drug name GSK6097608).
DMWI0AL	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd96-monoclonal-antibody-gsk6097608

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	DE3GT9C
DMJPXZ4	MN	Cytochrome P450 4F2 (CYP4F2)
DMJPXZ4	MT	DME
DMJPXZ4	MA	Metabolism
DMJPXZ4	RN	Product information - Gilenya.
DMJPXZ4	RU	http://www.medsafe.govt.nz/profs/datasheet/g/gilenyacap.pdf

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	TT4C8EA
DMJPXZ4	MN	Dopamine D3 receptor (D3R)
DMJPXZ4	MT	DTT
DMJPXZ4	MA	Antagonist
DMJPXZ4	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMJPXZ4	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMJPXZ4	DI	DMJPXZ4
DMJPXZ4	DN	GSK618334
DMJPXZ4	MI	TTOHFIY
DMJPXZ4	MN	Sphingosine kinase 1 (SPHK1)
DMJPXZ4	MT	DTT
DMJPXZ4	MA	Inhibitor
DMJPXZ4	RN	Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. 
DMJPXZ4	RU	https://pubmed.ncbi.nlm.nih.gov/27811359

DM7CIN4	DI	DM7CIN4
DM7CIN4	DN	GSK-625433
DM7CIN4	MI	TTMVBWH
DM7CIN4	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DM7CIN4	MT	DTT
DM7CIN4	MA	Inhibitor
DM7CIN4	RN	Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552.
DM7CIN4	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687230/

DMRBVHE	DI	DMRBVHE
DMRBVHE	DN	GSK690693
DMRBVHE	MI	TTAZ05C
DMRBVHE	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMRBVHE	MT	DTT
DMRBVHE	MA	Modulator
DMRBVHE	RN	Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74.
DMRBVHE	RU	https://www.ncbi.nlm.nih.gov/pubmed/18381444

DM4LR0Y	DI	DM4LR0Y
DM4LR0Y	DN	GSK-958108
DM4LR0Y	MI	TTSQIFT
DM4LR0Y	MN	5-HT 1A receptor (HTR1A)
DM4LR0Y	MT	DTT
DM4LR0Y	MA	Antagonist
DM4LR0Y	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline.
DM4LR0Y	RU	https://gsk.sylogent.com/files/24664.pdf

DMX2J57	DI	DMX2J57
DMX2J57	DN	GT103
DMX2J57	MI	TTUW6OP
DMX2J57	MN	Complement factor H (CFH)
DMX2J57	MT	DTT
DMX2J57	MA	Inhibitor
DMX2J57	RN	Clinical pipeline report, company report or official report of Grid Therapeutics.
DMX2J57	RU	https://gridtherapeutics.com/research-development/gt103/

DM20HS7	DI	DM20HS7
DM20HS7	DN	GTP-004
DM20HS7	MI	TT1RS9F
DM20HS7	MN	Acetylcholinesterase (AChE)
DM20HS7	MT	DTT
DM20HS7	MA	Inhibitor
DM20HS7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM20HS7	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TT1U2YM
DM4T5LH	MN	Cytomegalovirus DNA polymerase (CMV UL54)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TTIU7X1
DM4T5LH	MN	Herpes simplex virus DNA polymerase UL30 (HSV UL30)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DM4T5LH	DI	DM4T5LH
DM4T5LH	DN	Guanosine
DM4T5LH	MI	TTMCF1Y
DM4T5LH	MN	Purine nucleoside phosphorylase (PNP)
DM4T5LH	MT	DTT
DM4T5LH	MA	Inhibitor
DM4T5LH	RN	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
DM4T5LH	RU	https://pubmed.ncbi.nlm.nih.gov/17139284

DMM1RB6	DI	DMM1RB6
DMM1RB6	DN	GW-328267
DMM1RB6	MI	TTM2AOE
DMM1RB6	MN	Adenosine A2a receptor (ADORA2A)
DMM1RB6	MT	DTT
DMM1RB6	MA	Modulator
DMM1RB6	RN	ADENOSINE RECEPTORS AS TARGETS FOR THERAPEUTIC INTERVENTION IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DMM1RB6	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778268

DMOE5SZ	DI	DMOE5SZ
DMOE5SZ	DN	GW-409544
DMOE5SZ	MI	TTJ584C
DMOE5SZ	MN	Peroxisome proliferator-activated receptor alpha (PPARA)
DMOE5SZ	MT	DTT
DMOE5SZ	MA	Modulator
DMOE5SZ	RN	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
DMOE5SZ	RU	https://pubmed.ncbi.nlm.nih.gov/22685582

DMOE5SZ	DI	DMOE5SZ
DMOE5SZ	DN	GW-409544
DMOE5SZ	MI	TTZMAO3
DMOE5SZ	MN	Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
DMOE5SZ	MT	DTT
DMOE5SZ	MA	Modulator
DMOE5SZ	RN	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546.
DMOE5SZ	RU	https://pubmed.ncbi.nlm.nih.gov/22685582

DMBDW93	DI	DMBDW93
DMBDW93	DN	GW-695634
DMBDW93	MI	TT84ETX
DMBDW93	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DMBDW93	MT	DTT
DMBDW93	MA	Inhibitor
DMBDW93	RN	Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35.
DMBDW93	RU	https://pubmed.ncbi.nlm.nih.gov/16499282

DMQ46DN	DI	DMQ46DN
DMQ46DN	DN	GW-796406
DMQ46DN	MI	TTL69WB
DMQ46DN	MN	Angiotensin-converting enzyme (ACE)
DMQ46DN	MT	DTT
DMQ46DN	MA	Modulator
DMQ46DN	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMQ46DN	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMQ46DN	DI	DMQ46DN
DMQ46DN	DN	GW-796406
DMQ46DN	MI	TT5TKPM
DMQ46DN	MN	Neutral endopeptidase (MME)
DMQ46DN	MT	DTT
DMQ46DN	MA	Modulator
DMQ46DN	RN	Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
DMQ46DN	RU	https://pubmed.ncbi.nlm.nih.gov/16144980

DMGO6M1	DI	DMGO6M1
DMGO6M1	DN	GZ402666
DMGO6M1	MI	TTLPC70
DMGO6M1	MN	Lysosomal alpha-glucosidase (GAA)
DMGO6M1	MT	DTT
DMGO6M1	MA	Modulator
DMGO6M1	RN	ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
DMGO6M1	RU	https://clinicaltrials.gov/ct2/show/NCT01898364

DME6VX4	DI	DME6VX4
DME6VX4	DN	GZ402668
DME6VX4	MI	TTQT5S9
DME6VX4	MN	Cambridge pathology 1 antigen (CD52)
DME6VX4	MT	DTT
DME6VX4	RN	Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14.
DME6VX4	RU	http://www.neurology.org/content/84/14_Supplement/S20.006

DMTWNLY	DI	DMTWNLY
DMTWNLY	DN	GZ402674
DMTWNLY	MI	TTGTQHC
DMTWNLY	MN	DNA topoisomerase I (TOP1)
DMTWNLY	MT	DTT
DMTWNLY	MA	Modulator
DMTWNLY	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636).
DMTWNLY	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636

DMRCHOU	DI	DMRCHOU
DMRCHOU	DN	H-103
DMRCHOU	MI	TTHYBIX
DMRCHOU	MN	Heat shock protein 70 (HSP70)
DMRCHOU	MT	DTT
DMRCHOU	MA	Modulator
DMRCHOU	RN	A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82.
DMRCHOU	RU	https://pubmed.ncbi.nlm.nih.gov/19092859

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	DE4LYSA
DMAYTRK	MN	Cytochrome P450 3A4 (CYP3A4)
DMAYTRK	MT	DME
DMAYTRK	MA	Metabolism
DMAYTRK	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DMAYTRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	DEIBDNY
DMAYTRK	MN	Cytochrome P450 3A5 (CYP3A5)
DMAYTRK	MT	DME
DMAYTRK	MA	Metabolism
DMAYTRK	RN	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
DMAYTRK	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=31305210

DMAYTRK	DI	DMAYTRK
DMAYTRK	DN	H3B-6527
DMAYTRK	MI	TT1KX2S
DMAYTRK	MN	FGFR4 messenger RNA (FGFR4 mRNA)
DMAYTRK	MT	DTT
DMAYTRK	MA	Inhibitor
DMAYTRK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAYTRK	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMMVXGR	DI	DMMVXGR
DMMVXGR	DN	H3B-8800
DMMVXGR	MI	TTXR78S
DMMVXGR	MN	SF3b complex (SF3b)
DMMVXGR	MT	DTT
DMMVXGR	MA	Modulator
DMMVXGR	RN	Clinical pipeline report, company report or official report of H3 Biomedicine.
DMMVXGR	RU	https://www.h3biomedicine.com/science/

DMHI8RS	DI	DMHI8RS
DMHI8RS	DN	HCBE-11
DMHI8RS	MI	TTFO0PM
DMHI8RS	MN	Lymphotoxin beta receptor (LTBR)
DMHI8RS	MT	DTT
DMHI8RS	RN	Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33.
DMHI8RS	RU	https://pubmed.ncbi.nlm.nih.gov/22357629

DMVRTCW	DI	DMVRTCW
DMVRTCW	DN	HDM201
DMVRTCW	MI	TT7SBF5
DMVRTCW	MN	Cellular tumor antigen p53 (TP53)
DMVRTCW	MT	DTT
DMVRTCW	MA	Inhibitor
DMVRTCW	RN	National Cancer Institute Drug Dictionary (drug id 761551).
DMVRTCW	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761551

DMVRTCW	DI	DMVRTCW
DMVRTCW	DN	HDM201
DMVRTCW	MI	TT08GJW
DMVRTCW	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMVRTCW	MT	DTT
DMVRTCW	MA	Inhibitor
DMVRTCW	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMVRTCW	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMM7VOB	DI	DMM7VOB
DMM7VOB	DN	Hepapoietin
DMM7VOB	MI	TTNDSF4
DMM7VOB	MN	Proto-oncogene c-Met (MET)
DMM7VOB	MT	DTT
DMM7VOB	MA	Inhibitor
DMM7VOB	RN	Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002.
DMM7VOB	RU	http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2002.01110.x/full

DMBFYSR	DI	DMBFYSR
DMBFYSR	DN	Hepcidin mab
DMBFYSR	MI	TTPCG5T
DMBFYSR	MN	Hepcidin (HAMP)
DMBFYSR	MT	DTT
DMBFYSR	RN	The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161.
DMBFYSR	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/

DMXETUQ	DI	DMXETUQ
DMXETUQ	DN	HER-2/HER-1 vaccine
DMXETUQ	MI	TTGKNB4
DMXETUQ	MN	Epidermal growth factor receptor (EGFR)
DMXETUQ	MT	DTT
DMXETUQ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
DMXETUQ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797

DMZXDBN	DI	DMZXDBN
DMZXDBN	DN	HER2-CAR T Cells
DMZXDBN	MI	TT6EO5L
DMZXDBN	MN	Erbb2 tyrosine kinase receptor (HER2)
DMZXDBN	MT	DTT
DMZXDBN	MA	CAR-T-Cell-Therapy
DMZXDBN	RN	ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases
DMZXDBN	RU	https://clinicaltrials.gov/ct2/show/NCT03696030

DMJ52F9	DI	DMJ52F9
DMJ52F9	DN	HER2p63-71 peptide vaccine
DMJ52F9	MI	TT6EO5L
DMJ52F9	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJ52F9	MT	DTT
DMJ52F9	RN	Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82.
DMJ52F9	RU	https://pubmed.ncbi.nlm.nih.gov/10950153

DMJKBWO	DI	DMJKBWO
DMJKBWO	DN	HER2-specific CAR T cell
DMJKBWO	MI	TT6EO5L
DMJKBWO	MN	Erbb2 tyrosine kinase receptor (HER2)
DMJKBWO	MT	DTT
DMJKBWO	MA	CAR-T-Cell-Therapy
DMJKBWO	RN	ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
DMJKBWO	RU	https://clinicaltrials.gov/ct2/show/NCT03500991

DM7UJ6E	DI	DM7UJ6E
DM7UJ6E	DN	HER2-specific T cells
DM7UJ6E	MI	TT6EO5L
DM7UJ6E	MN	Erbb2 tyrosine kinase receptor (HER2)
DM7UJ6E	MT	DTT
DM7UJ6E	MA	CAR-T-Cell-Therapy
DM7UJ6E	RN	ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
DM7UJ6E	RU	https://clinicaltrials.gov/ct2/show/NCT02442297

DMDZQ23	DI	DMDZQ23
DMDZQ23	DN	HF-0299
DMDZQ23	MI	TTHRID2
DMDZQ23	MN	Insulin-like growth factor I receptor (IGF1R)
DMDZQ23	MT	DTT
DMDZQ23	MA	Modulator
DMDZQ23	RN	A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11.
DMDZQ23	RU	https://pubmed.ncbi.nlm.nih.gov/11162926

DMS9WXG	DI	DMS9WXG
DMS9WXG	DN	HGS-1029
DMS9WXG	MI	TTR7B60
DMS9WXG	MN	X-linked inhibitor of apoptosis protein (XIAP)
DMS9WXG	MT	DTT
DMS9WXG	MA	Antagonist
DMS9WXG	RN	Clinical pipeline report, company report or official report of Aegera Therapeutics Inc.
DMS9WXG	RU	http://www.aegera.com/aeg40826.php

DMQIE58	DI	DMQIE58
DMQIE58	DN	HH2853
DMQIE58	MI	TTNJA0C
DMQIE58	MN	Enhancer of zeste homolog 1 (EZH1)
DMQIE58	MT	DTT
DMQIE58	MA	Inhibitor
DMQIE58	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DMQIE58	RU	https://www.haihepharma.com/en/news/details/215

DMQIE58	DI	DMQIE58
DMQIE58	DN	HH2853
DMQIE58	MI	TT9MZCQ
DMQIE58	MN	Enhancer of zeste homolog 2 (EZH2)
DMQIE58	MT	DTT
DMQIE58	MA	Inhibitor
DMQIE58	RN	Clinical pipeline report, company report or official report of HaiHe Biopharma.
DMQIE58	RU	https://www.haihepharma.com/en/news/details/215

DMRQ4L6	DI	DMRQ4L6
DMRQ4L6	DN	HHCYH33
DMRQ4L6	MI	TTEUNMR
DMRQ4L6	MN	PI3-kinase alpha (PIK3CA)
DMRQ4L6	MT	DTT
DMRQ4L6	MA	Inhibitor
DMRQ4L6	RN	Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85.
DMRQ4L6	RU	https://pubmed.ncbi.nlm.nih.gov/33446653

DM45MR0	DI	DM45MR0
DM45MR0	DN	HIP-2B
DM45MR0	MI	TTL4H8N
DM45MR0	MN	Regenerating human pro-islet peptide (REG3A)
DM45MR0	MT	DTT
DM45MR0	MA	Modulator
DM45MR0	RN	Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33.
DM45MR0	RU	https://pubmed.ncbi.nlm.nih.gov/10550309

DMT3HKZ	DI	DMT3HKZ
DMT3HKZ	DN	HL-018
DMT3HKZ	MI	TT0FYAN
DMT3HKZ	MN	Free fatty acid receptor 2 (FFAR2)
DMT3HKZ	MT	DTT
DMT3HKZ	MA	Inhibitor
DMT3HKZ	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226).
DMT3HKZ	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226

DME4D7H	DI	DME4D7H
DME4D7H	DN	HM71224
DME4D7H	MI	TTGM6VW
DME4D7H	MN	Tyrosine-protein kinase BTK (ATK)
DME4D7H	MT	DTT
DME4D7H	MA	Inhibitor
DME4D7H	RN	HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211.
DME4D7H	RU	https://pubmed.ncbi.nlm.nih.gov/28950886

DMXZ1A8	DI	DMXZ1A8
DMXZ1A8	DN	HMPL-523
DMXZ1A8	MI	TTOU65C
DMXZ1A8	MN	Tyrosine-protein kinase SYK (SYK)
DMXZ1A8	MT	DTT
DMXZ1A8	MA	Inhibitor
DMXZ1A8	RN	Clinical pipeline report, company report or official report of Hutchison MediPharma.
DMXZ1A8	RU	https://www.hutch-med.com/pipeline-and-products/our-pipeline/

DMEGN5I	DI	DMEGN5I
DMEGN5I	DN	HMPL-689
DMEGN5I	MI	TTGBPJE
DMEGN5I	MN	PI3-kinase delta (PIK3CD)
DMEGN5I	MT	DTT
DMEGN5I	MA	Inhibitor
DMEGN5I	RN	Clinical pipeline report, company report or official report of Hutchison MediPharma.
DMEGN5I	RU	https://www.hutch-med.com/pipeline-and-products/our-pipeline/

DM695QT	DI	DM695QT
DM695QT	DN	HMR-1031
DM695QT	MI	TT6S84X
DM695QT	MN	Integrin alpha-4/beta-1 (ITGA4/B1)
DM695QT	MT	DTT
DM695QT	MA	Modulator
DM695QT	RN	Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13.
DM695QT	RU	https://pubmed.ncbi.nlm.nih.gov/14999362

DMRYM03	DI	DMRYM03
DMRYM03	DN	HMS5552
DMRYM03	MI	TTDLNGZ
DMRYM03	MN	Glucokinase (GCK)
DMRYM03	MT	DTT
DMRYM03	MA	Activator
DMRYM03	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMRYM03	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMI0KQW	DI	DMI0KQW
DMI0KQW	DN	HPN217
DMI0KQW	MI	TTZ3P4W
DMI0KQW	MN	B-cell maturation protein (TNFRSF17)
DMI0KQW	MT	DTT
DMI0KQW	RN	Clinical pipeline report, company report or official report of AbbVie.
DMI0KQW	RU	https://www.abbvie.com/our-science/pipeline/hpn-217.html

DMLZDVR	DI	DMLZDVR
DMLZDVR	DN	HPN424
DMLZDVR	MI	TT9G4N0
DMLZDVR	MN	Glutamate carboxypeptidase II (GCPII)
DMLZDVR	MT	DTT
DMLZDVR	RN	Clinical pipeline report, company report or official report of Harpoon Therapeutics.
DMLZDVR	RU	https://www.harpoontx.com/pipeline/

DMUEZ7V	DI	DMUEZ7V
DMUEZ7V	DN	HPP404
DMUEZ7V	MI	TT9JNIC
DMUEZ7V	MN	Histamine H3 receptor (H3R)
DMUEZ7V	MT	DTT
DMUEZ7V	MA	Antagonist
DMUEZ7V	RN	Clinical pipeline report, company report or official report of TransTech Pharma (2011).
DMUEZ7V	RU	http://www.ttpharma.com/

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TTPS3C0
DM5VSZR	MN	Aurora kinase A (AURKA)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TT5LS6T
DM5VSZR	MN	Aurora kinase B (AURKB)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DM5VSZR	DI	DM5VSZR
DM5VSZR	DN	HPP-607
DM5VSZR	MI	TTLYXIT
DM5VSZR	MN	Aurora kinase C (AURKC)
DM5VSZR	MT	DTT
DM5VSZR	MA	Inhibitor
DM5VSZR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
DM5VSZR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936

DMSLDHG	DI	DMSLDHG
DMSLDHG	DN	HPP-854
DMSLDHG	MI	TT8JRS7
DMSLDHG	MN	Beta-secretase (BACE)
DMSLDHG	MT	DTT
DMSLDHG	MA	Modulator
DMSLDHG	RN	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
DMSLDHG	RU	https://pubmed.ncbi.nlm.nih.gov/25621019

DMZXG7Q	DI	DMZXG7Q
DMZXG7Q	DN	HPP971
DMZXG7Q	MI	TTA6ZN2
DMZXG7Q	MN	Nuclear factor erythroid 2-related factor 2 (Nrf2)
DMZXG7Q	MT	DTT
DMZXG7Q	MA	Activator
DMZXG7Q	RN	Clinical pipeline report, company report or official report of vTv Therapeutics.
DMZXG7Q	RU	https://vtvtherapeutics.com/pipeline/nrf2-bach1-program/

DMJG4WR	DI	DMJG4WR
DMJG4WR	DN	HSDB-674
DMJG4WR	MI	DEDPI65
DMJG4WR	MN	Oxygen-insensitive NADPH nitroreductase A (nfsA)
DMJG4WR	MT	DME
DMJG4WR	MA	Metabolism
DMJG4WR	RN	Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract. J Pharm Pharmacol. 1970 Sep;22(9):722-3.
DMJG4WR	RU	https://pubmed.ncbi.nlm.nih.gov/4394772

DML6HP3	DI	DML6HP3
DML6HP3	DN	HSP-990
DML6HP3	MI	DE5IED8
DML6HP3	MN	Cytochrome P450 2C9 (CYP2C9)
DML6HP3	MT	DME
DML6HP3	MA	Metabolism
DML6HP3	RN	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. Br J Cancer. 2015 Feb 17;112(4):650-9.
DML6HP3	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=25625276

DMI4TEC	DI	DMI4TEC
DMI4TEC	DN	HTI-1090
DMI4TEC	MI	TTZJYKH
DMI4TEC	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMI4TEC	MT	DTT
DMI4TEC	MA	Inhibitor
DMI4TEC	RN	Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
DMI4TEC	RU	https://pubmed.ncbi.nlm.nih.gov/30734612

DMI4TEC	DI	DMI4TEC
DMI4TEC	DN	HTI-1090
DMI4TEC	MI	TTXNCBV
DMI4TEC	MN	Tryptophan 2,3-dioxygenase (TDO)
DMI4TEC	MT	DTT
DMI4TEC	MA	Inhibitor
DMI4TEC	RN	Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
DMI4TEC	RU	https://pubmed.ncbi.nlm.nih.gov/30734612

DMB3LQU	DI	DMB3LQU
DMB3LQU	DN	HuA33
DMB3LQU	MI	TT96HUR
DMB3LQU	MN	Cell surface A33 antigen (GPA33)
DMB3LQU	MT	DTT
DMB3LQU	RN	(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80.
DMB3LQU	RU	https://pubmed.ncbi.nlm.nih.gov/21764796

DM9VB4I	DI	DM9VB4I
DM9VB4I	DN	Hu-CART meso cells
DM9VB4I	MI	TT4RXME
DM9VB4I	MN	Mesothelin (MSLN)
DM9VB4I	MT	DTT
DM9VB4I	MA	CAR-T-Cell-Therapy
DM9VB4I	RN	ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers
DM9VB4I	RU	https://clinicaltrials.gov/ct2/show/NCT03054298

DMNAR29	DI	DMNAR29
DMNAR29	DN	HuCART19
DMNAR29	MI	TTW640A
DMNAR29	MN	B-lymphocyte surface antigen B4 (CD19)
DMNAR29	MT	DTT
DMNAR29	MA	CAR-T-Cell-Therapy
DMNAR29	RN	ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
DMNAR29	RU	https://clinicaltrials.gov/ct2/show/NCT02374333

DM4F8AU	DI	DM4F8AU
DM4F8AU	DN	HuCART-meso cells
DM4F8AU	MI	TT4RXME
DM4F8AU	MN	Mesothelin (MSLN)
DM4F8AU	MT	DTT
DM4F8AU	MA	CAR-T-Cell-Therapy
DM4F8AU	RN	ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
DM4F8AU	RU	https://clinicaltrials.gov/ct2/show/NCT03323944

DMDZBTY	DI	DMDZBTY
DMDZBTY	DN	HuM195/rGel
DMDZBTY	MI	TTJVYO3
DMDZBTY	MN	Myeloid cell surface antigen CD33 (CD33)
DMDZBTY	MT	DTT
DMDZBTY	RN	Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21.
DMDZBTY	RU	https://pubmed.ncbi.nlm.nih.gov/22875630

DM0W275	DI	DM0W275
DM0W275	DN	Human CD19 targeted T Cells
DM0W275	MI	TTW640A
DM0W275	MN	B-lymphocyte surface antigen B4 (CD19)
DM0W275	MT	DTT
DM0W275	MA	CAR-T-Cell-Therapy
DM0W275	RN	ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
DM0W275	RU	https://clinicaltrials.gov/ct2/show/NCT03720457

DMVGBA1	DI	DMVGBA1
DMVGBA1	DN	HuMNC2-CAR44 T cells
DMVGBA1	MI	TTBHFYQ
DMVGBA1	MN	Mucin-1 (MUC1)
DMVGBA1	MT	DTT
DMVGBA1	RN	Clinical pipeline report, company report or official report of Minerva Biotechnologies.
DMVGBA1	RU	https://www.minervabio.com/minervabio.com/pipeline/

DMFRM15	DI	DMFRM15
DMFRM15	DN	HX-100
DMFRM15	MI	TTELV3W
DMFRM15	MN	Transformation-sensitive protein p120 (TRPA1)
DMFRM15	MT	DTT
DMFRM15	MA	Inhibitor
DMFRM15	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFRM15	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMRE6UT	DI	DMRE6UT
DMRE6UT	DN	IBC-VS01
DMRE6UT	MI	TTZOPHG
DMRE6UT	MN	Insulin (INS)
DMRE6UT	MT	DTT
DMRE6UT	MA	Modulator
DMRE6UT	RN	Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine. Ther Adv Endocrinol Metab. 2011 February; 2(1): 9-16.
DMRE6UT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474625/

DMXUJ1P	DI	DMXUJ1P
DMXUJ1P	DN	IBI188
DMXUJ1P	MI	TT28S46
DMXUJ1P	MN	Leukocyte surface antigen CD47 (CD47)
DMXUJ1P	MT	DTT
DMXUJ1P	MA	Blocker
DMXUJ1P	RN	Clinical pipeline report, company report or official report of Innovent Biologics.
DMXUJ1P	RU	https://www.innoventbio.com/ScienceAndProducts/Pipeline/ProductRAndD

DMYBHIR	DI	DMYBHIR
DMYBHIR	DN	IBI-20089
DMYBHIR	MI	TTYRL6O
DMYBHIR	MN	Glucocorticoid receptor (NR3C1)
DMYBHIR	MT	DTT
DMYBHIR	MA	Agonist
DMYBHIR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBHIR	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMB83V4	DI	DMB83V4
DMB83V4	DN	IBI318
DMB83V4	MI	TT8ZLTI
DMB83V4	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMB83V4	MT	DTT
DMB83V4	MA	Inhibitor
DMB83V4	RN	Clinical pipeline report, company report or official report of Innovent.
DMB83V4	RU	http://innoventbio.com/#/news/208

DMB83V4	DI	DMB83V4
DMB83V4	DN	IBI318
DMB83V4	MI	TTNBFWK
DMB83V4	MN	Programmed cell death protein 1 (PD-1)
DMB83V4	MT	DTT
DMB83V4	MA	Inhibitor
DMB83V4	RN	Clinical pipeline report, company report or official report of Innovent.
DMB83V4	RU	http://innoventbio.com/#/news/208

DMHS29U	DI	DMHS29U
DMHS29U	DN	Iboctadekin
DMHS29U	MI	TTRICUF
DMHS29U	MN	Interleukin-18 (IL18)
DMHS29U	MT	DTT
DMHS29U	MA	Modulator
DMHS29U	RN	Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78.
DMHS29U	RU	https://pubmed.ncbi.nlm.nih.gov/24777679

DMW1ZAM	DI	DMW1ZAM
DMW1ZAM	DN	Iboctadekin + Doxil
DMW1ZAM	MI	TT0IHXV
DMW1ZAM	MN	DNA topoisomerase II (TOP2)
DMW1ZAM	MT	DTT
DMW1ZAM	MA	Inhibitor
DMW1ZAM	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW1ZAM	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMW1ZAM	DI	DMW1ZAM
DMW1ZAM	DN	Iboctadekin + Doxil
DMW1ZAM	MI	TTRICUF
DMW1ZAM	MN	Interleukin-18 (IL18)
DMW1ZAM	MT	DTT
DMW1ZAM	MA	Modulator
DMW1ZAM	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMW1ZAM	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTRICUF
DMZCBMS	MN	Interleukin-18 (IL18)
DMZCBMS	MT	DTT
DMZCBMS	MA	Modulator
DMZCBMS	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMZCBMS	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTUE541
DMZCBMS	MN	Leukocyte surface antigen Leu-16 (CD20)
DMZCBMS	MT	DTT
DMZCBMS	RN	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
DMZCBMS	RU	http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	DTUGYRD
DMZCBMS	MN	P-glycoprotein 1 (ABCB1)
DMZCBMS	MT	DTP
DMZCBMS	MA	Substrate
DMZCBMS	RN	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
DMZCBMS	RU	http://www.ncbi.nlm.nih.gov/pubmed/26499806

DMZCBMS	DI	DMZCBMS
DMZCBMS	DN	Iboctadekin + Rituximab
DMZCBMS	MI	TTN9VTF
DMZCBMS	MN	Voltage-gated sodium channel alpha Nav1.9 (SCN11A)
DMZCBMS	MT	DTT
DMZCBMS	MA	Blocker
DMZCBMS	RN	New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
DMZCBMS	RU	https://pubmed.ncbi.nlm.nih.gov/15934869

DMMPFZO	DI	DMMPFZO
DMMPFZO	DN	IC9.GD2.CAR.IL-15 T-cells
DMMPFZO	MI	TT80ARU
DMMPFZO	MN	Ganglioside GD2 (GD2)
DMMPFZO	MT	DTT
DMMPFZO	MA	CAR-T-Cell-Therapy
DMMPFZO	RN	ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma
DMMPFZO	RU	https://clinicaltrials.gov/ct2/show/NCT03721068

DMP1ZF8	DI	DMP1ZF8
DMP1ZF8	DN	IC9-CAR19 cells
DMP1ZF8	MI	TTW640A
DMP1ZF8	MN	B-lymphocyte surface antigen B4 (CD19)
DMP1ZF8	MT	DTT
DMP1ZF8	MA	CAR-T-Cell-Therapy
DMP1ZF8	RN	ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
DMP1ZF8	RU	https://clinicaltrials.gov/ct2/show/NCT03016377

DMNCBIU	DI	DMNCBIU
DMNCBIU	DN	IC9-CAR19 T cells
DMNCBIU	MI	TTW640A
DMNCBIU	MN	B-lymphocyte surface antigen B4 (CD19)
DMNCBIU	MT	DTT
DMNCBIU	MA	CAR-T-Cell-Therapy
DMNCBIU	RN	ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
DMNCBIU	RU	https://clinicaltrials.gov/ct2/show/NCT03696784

DMRYHWA	DI	DMRYHWA
DMRYHWA	DN	IC9-GD2-CD28-OX40
DMRYHWA	MI	TT80ARU
DMRYHWA	MN	Ganglioside GD2 (GD2)
DMRYHWA	MT	DTT
DMRYHWA	MA	CAR-T-Cell-Therapy
DMRYHWA	RN	ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
DMRYHWA	RU	https://clinicaltrials.gov/ct2/show/NCT01822652

DMHG4Q9	DI	DMHG4Q9
DMHG4Q9	DN	ICAR19 CAR-T cells
DMHG4Q9	MI	TTW640A
DMHG4Q9	MN	B-lymphocyte surface antigen B4 (CD19)
DMHG4Q9	MT	DTT
DMHG4Q9	MA	CAR-T-Cell-Therapy
DMHG4Q9	RN	ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
DMHG4Q9	RU	https://clinicaltrials.gov/ct2/show/NCT03383952

DM3YZCV	DI	DM3YZCV
DM3YZCV	DN	ICAR30 T cells
DM3YZCV	MI	TT2GM5R
DM3YZCV	MN	Lymphocyte activation antigen CD30 (TNFRSF8)
DM3YZCV	MT	DTT
DM3YZCV	MA	CAR-T-Cell-Therapy
DM3YZCV	RN	ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
DM3YZCV	RU	https://clinicaltrials.gov/ct2/show/NCT03383965

DMY6V5T	DI	DMY6V5T
DMY6V5T	DN	ICasp9M28z T cell
DMY6V5T	MI	TT4RXME
DMY6V5T	MN	Mesothelin (MSLN)
DMY6V5T	MT	DTT
DMY6V5T	MA	CAR-T-Cell-Therapy
DMY6V5T	RN	ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
DMY6V5T	RU	https://clinicaltrials.gov/ct2/show/NCT02414269

DM79W8K	DI	DM79W8K
DM79W8K	DN	ICo-007
DM79W8K	MI	TTAN5W2
DM79W8K	MN	Raf messenger RNA (Raf mRNA)
DM79W8K	MT	DTT
DM79W8K	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DM79W8K	RU	http://www.isispharm.com/Pipeline/index.htm

DM64LVS	DI	DM64LVS
DM64LVS	DN	ICT-121
DM64LVS	MI	TTXMZ81
DM64LVS	MN	Prominin-1 (PROM1)
DM64LVS	MT	DTT
DM64LVS	RN	Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59.
DM64LVS	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322523/

DMNWPMO	DI	DMNWPMO
DMNWPMO	DN	IDH305
DMNWPMO	MI	TTV2A1R
DMNWPMO	MN	Oxalosuccinate decarboxylase (IDH1)
DMNWPMO	MT	DTT
DMNWPMO	MA	Inhibitor
DMNWPMO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNWPMO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1RNT7	DI	DM1RNT7
DM1RNT7	DN	IDR-1018
DM1RNT7	MI	TTXT4D5
DM1RNT7	MN	Bacterial Cell membrane (Bact CM)
DM1RNT7	MT	DTT
DM1RNT7	MA	Regulator
DM1RNT7	RN	Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373.
DM1RNT7	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412849/

DMYG3PZ	DI	DMYG3PZ
DMYG3PZ	DN	IDX-189
DMYG3PZ	MI	TTMVBWH
DMYG3PZ	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMYG3PZ	MT	DTT
DMYG3PZ	MA	Inhibitor
DMYG3PZ	RN	Clinical pipeline report, company report or official report of Idenix (2011).
DMYG3PZ	RU	http://www.idenix.com/

DMMPINS	DI	DMMPINS
DMMPINS	DN	IGM-2323
DMMPINS	MI	TTUE541
DMMPINS	MN	Leukocyte surface antigen Leu-16 (CD20)
DMMPINS	MT	DTT
DMMPINS	MA	Inhibitor
DMMPINS	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMMPINS	RU	https://igmbio.com/pipeline/cd20-x-dc3/

DMMPINS	DI	DMMPINS
DMMPINS	DN	IGM-2323
DMMPINS	MI	TTUN7MC
DMMPINS	MN	T-cell surface glycoprotein CD3 (CD3)
DMMPINS	MT	DTT
DMMPINS	MA	Inhibitor
DMMPINS	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMMPINS	RU	https://igmbio.com/pipeline/cd20-x-dc3/

DMFJXDZ	DI	DMFJXDZ
DMFJXDZ	DN	IGM-8444
DMFJXDZ	MI	TTW20TU
DMFJXDZ	MN	TRAIL receptor 2 (TRAIL-R2)
DMFJXDZ	MT	DTT
DMFJXDZ	MA	Agonist
DMFJXDZ	RN	Clinical pipeline report, company report or official report of IGM Biosciences.
DMFJXDZ	RU	https://igmbio.com/pipeline/death-receptor-5/

DM1MY26	DI	DM1MY26
DM1MY26	DN	IGN523
DM1MY26	MI	TT5CZSM
DM1MY26	MN	Lymphocyte activation antigen 4F2 (SLC3A2)
DM1MY26	MT	DTT
DM1MY26	RN	Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20.
DM1MY26	RU	https://pubmed.ncbi.nlm.nih.gov/25556716

DMDU54Y	DI	DMDU54Y
DMDU54Y	DN	IK-175
DMDU54Y	MI	TT037IE
DMDU54Y	MN	Aryl hydrocarbon receptor (AHR)
DMDU54Y	MT	DTT
DMDU54Y	MA	Antagonist
DMDU54Y	RN	Clinical pipeline report, company report or official report of Ikena Oncology.
DMDU54Y	RU	https://ikenaoncology.com/pipeline/immunotherapy/ahr-antagonist-program/

DMQ01MP	DI	DMQ01MP
DMQ01MP	DN	ILV-095
DMQ01MP	MI	TTLDX4N
DMQ01MP	MN	Interleukin-22 (IL22)
DMQ01MP	MT	DTT
DMQ01MP	RN	Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
DMQ01MP	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/

DM4MY9C	DI	DM4MY9C
DM4MY9C	DN	IM156
DM4MY9C	MI	TTLAFZV
DM4MY9C	MN	AMP-activated protein kinase (AMPK)
DM4MY9C	MT	DTT
DM4MY9C	MA	Inhibitor
DM4MY9C	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM4MY9C	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM43X0Q	DI	DM43X0Q
DM43X0Q	DN	IM19
DM43X0Q	MI	TTW640A
DM43X0Q	MN	B-lymphocyte surface antigen B4 (CD19)
DM43X0Q	MT	DTT
DM43X0Q	MA	CAR-T-Cell-Therapy
DM43X0Q	RN	ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
DM43X0Q	RU	https://clinicaltrials.gov/ct2/show/NCT03528421

DMTNYIB	DI	DMTNYIB
DMTNYIB	DN	IM21 CART
DMTNYIB	MI	TTZ3P4W
DMTNYIB	MN	B-cell maturation protein (TNFRSF17)
DMTNYIB	MT	DTT
DMTNYIB	MA	CAR-T-Cell-Therapy
DMTNYIB	RN	ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
DMTNYIB	RU	https://clinicaltrials.gov/ct2/show/NCT03711864

DML5O7T	DI	DML5O7T
DML5O7T	DN	IM23
DML5O7T	MI	TTENHJ0
DML5O7T	MN	Interleukin 3 receptor alpha (IL3RA)
DML5O7T	MT	DTT
DML5O7T	MA	CAR-T-Cell-Therapy
DML5O7T	RN	ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)
DML5O7T	RU	https://clinicaltrials.gov/ct2/show/NCT03585517

DMD9U5Q	DI	DMD9U5Q
DMD9U5Q	DN	IMA 203
DMD9U5Q	MI	TTPH7T0
DMD9U5Q	MN	Tumor expressed melanoma antigen (PRAME)
DMD9U5Q	MT	DTT
DMD9U5Q	RN	Clinical pipeline report, company report or official report of Immatics.
DMD9U5Q	RU	https://immatics.com/our-pipeline/

DMWSI04	DI	DMWSI04
DMWSI04	DN	IMC-002
DMWSI04	MI	TT28S46
DMWSI04	MN	Leukocyte surface antigen CD47 (CD47)
DMWSI04	MT	DTT
DMWSI04	MA	Blocker
DMWSI04	RN	Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
DMWSI04	RU	http://www.immuneoncia.com/immun/index.php/pipeline/

DMXI5ON	DI	DMXI5ON
DMXI5ON	DN	IMC-3C5
DMXI5ON	MI	TTDCBX5
DMXI5ON	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMXI5ON	MT	DTT
DMXI5ON	MA	Modulator
DMXI5ON	RN	Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414.
DMXI5ON	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464486/

DMUYN26	DI	DMUYN26
DMUYN26	DN	IMC-CS4
DMUYN26	MI	TT731LW
DMUYN26	MN	Colony stimulating factor-1 receptor (CSF-1R)
DMUYN26	MT	DTT
DMUYN26	MA	Modulator
DMUYN26	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMUYN26	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCZQNJ	DI	DMCZQNJ
DMCZQNJ	DN	IMC-EB10
DMCZQNJ	MI	TTGJCWZ
DMCZQNJ	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMCZQNJ	MT	DTT
DMCZQNJ	RN	IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51.
DMCZQNJ	RU	https://pubmed.ncbi.nlm.nih.gov/16651440

DMOFSLE	DI	DMOFSLE
DMOFSLE	DN	IMD-0354
DMOFSLE	MI	TTJ3E9X
DMOFSLE	MN	Inhibitor of nuclear factor kappa-B kinase beta (IKKB)
DMOFSLE	MT	DTT
DMOFSLE	MA	Inhibitor
DMOFSLE	RN	I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
DMOFSLE	RU	https://pubmed.ncbi.nlm.nih.gov/20573155

DMUVLC4	DI	DMUVLC4
DMUVLC4	DN	IMGC936
DMUVLC4	MI	TTTYQNS
DMUVLC4	MN	Cellular disintegrin-related protein (ADAM9)
DMUVLC4	MT	DTT
DMUVLC4	MA	Inhibitor
DMUVLC4	RN	Clinical pipeline report, company report or official report of ImmunoGen.
DMUVLC4	RU	https://www.immunogen.com/category/imgc936/

DMT9MHE	DI	DMT9MHE
DMT9MHE	DN	IMGN289
DMT9MHE	MI	TTGKNB4
DMT9MHE	MN	Epidermal growth factor receptor (EGFR)
DMT9MHE	MT	DTT
DMT9MHE	MA	Inhibitor
DMT9MHE	RN	World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
DMT9MHE	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/

DMSYB83	DI	DMSYB83
DMSYB83	DN	IMGN-388
DMSYB83	MI	TTT1R2L
DMSYB83	MN	Integrin alpha-V (ITGAV)
DMSYB83	MT	DTT
DMSYB83	RN	Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9.
DMSYB83	RU	https://pubmed.ncbi.nlm.nih.gov/20841470

DMR8OG2	DI	DMR8OG2
DMR8OG2	DN	IMGN-853
DMR8OG2	MI	TTVC37M
DMR8OG2	MN	Folate receptor alpha (FOLR1)
DMR8OG2	MT	DTT
DMR8OG2	MA	Inhibitor
DMR8OG2	RN	Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92.
DMR8OG2	RU	https://pubmed.ncbi.nlm.nih.gov/19891424

DMTFUM4	DI	DMTFUM4
DMTFUM4	DN	IMMU-114
DMTFUM4	MI	TTYA75N
DMTFUM4	MN	MHC class II antigen DR (HLA-DR)
DMTFUM4	MT	DTT
DMTFUM4	RN	The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant. 2012 Jul;47(7):967-80.
DMTFUM4	RU	https://pubmed.ncbi.nlm.nih.gov/22020022

DMEHWPC	DI	DMEHWPC
DMEHWPC	DN	IMO-9200
DMEHWPC	MI	TTOK0LR
DMEHWPC	MN	Toll-like receptor (TLR)
DMEHWPC	MT	DTT
DMEHWPC	MA	Antagonist
DMEHWPC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMEHWPC	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMXSMF9	DI	DMXSMF9
DMXSMF9	DN	IMP-701
DMXSMF9	MI	TTNVXAW
DMXSMF9	MN	Lymphocyte activation gene 3 protein (LAG3)
DMXSMF9	MT	DTT
DMXSMF9	RN	IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
DMXSMF9	RU	https://pubmed.ncbi.nlm.nih.gov/17394654

DMPXOVA	DI	DMPXOVA
DMPXOVA	DN	IN10018
DMPXOVA	MI	TTON5IT
DMPXOVA	MN	Focal adhesion kinase 1 (FAK)
DMPXOVA	MT	DTT
DMPXOVA	MA	Inhibitor
DMPXOVA	RN	Clinical pipeline report, company report or official report of InxMed.
DMPXOVA	RU	http://en.inxmed.com/intro/3.html

DMCQTLG	DI	DMCQTLG
DMCQTLG	DN	INB03
DMCQTLG	MI	TTF8CQI
DMCQTLG	MN	Tumor necrosis factor (TNF)
DMCQTLG	MT	DTT
DMCQTLG	MA	Inhibitor
DMCQTLG	RN	Clinical pipeline report, company report or official report of INmune Bio.
DMCQTLG	RU	https://inmunebio.com/index.php/en/science/inb03/overview

DM2FH10	DI	DM2FH10
DM2FH10	DN	INBRX-105
DM2FH10	MI	TTPW9LJ
DM2FH10	MN	Co-stimulatory molecule 4-1BB (CD137)
DM2FH10	MT	DTT
DM2FH10	MA	Agonist
DM2FH10	RN	Clinical pipeline report, company report or official report of Inhibrx.
DM2FH10	RU	https://inhibrx.com/inbrx-105/

DM2FH10	DI	DM2FH10
DM2FH10	DN	INBRX-105
DM2FH10	MI	TT8ZLTI
DM2FH10	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM2FH10	MT	DTT
DM2FH10	MA	Inhibitor
DM2FH10	RN	Clinical pipeline report, company report or official report of Inhibrx.
DM2FH10	RU	https://inhibrx.com/inbrx-105/

DMUNSPI	DI	DMUNSPI
DMUNSPI	DN	INBRX-109
DMUNSPI	MI	TTW20TU
DMUNSPI	MN	TRAIL receptor 2 (TRAIL-R2)
DMUNSPI	MT	DTT
DMUNSPI	RN	Clinical pipeline report, company report or official report of Inhibrx.
DMUNSPI	RU	https://inhibrx.com/inbrx-109/

DMDSZNC	DI	DMDSZNC
DMDSZNC	DN	INCAGN2385
DMDSZNC	MI	TTNVXAW
DMDSZNC	MN	Lymphocyte activation gene 3 protein (LAG3)
DMDSZNC	MT	DTT
DMDSZNC	MA	Inhibitor
DMDSZNC	RN	Clinical pipeline report, company report or official report of Agenus.
DMDSZNC	RU	https://agenusbio.com/pipeline/

DM5SO1T	DI	DM5SO1T
DM5SO1T	DN	INCAGN2390
DM5SO1T	MI	TT1RWL7
DM5SO1T	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM5SO1T	MT	DTT
DM5SO1T	MA	Inhibitor
DM5SO1T	RN	Clinical pipeline report, company report or official report of Agenus.
DM5SO1T	RU	https://agenusbio.com/pipeline/

DMW7CLY	DI	DMW7CLY
DMW7CLY	DN	INCB15050
DMW7CLY	MI	TT2CEJG
DMW7CLY	MN	C-C chemokine receptor type 5 (CCR5)
DMW7CLY	MT	DTT
DMW7CLY	MA	Antagonist
DMW7CLY	RN	Incyte. Product Development Pipeline.
DMW7CLY	RU	http://www.incyte.com/drugs_product_pipeline.html

DMFOXGB	DI	DMFOXGB
DMFOXGB	DN	INCB81776
DMFOXGB	MI	TTO7LKR
DMFOXGB	MN	Tyrosine-protein kinase Mer (MERTK)
DMFOXGB	MT	DTT
DMFOXGB	MA	Inhibitor
DMFOXGB	RN	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
DMFOXGB	RU	https://pubmed.ncbi.nlm.nih.gov/33425754

DMFOXGB	DI	DMFOXGB
DMFOXGB	DN	INCB81776
DMFOXGB	MI	TTZPY6J
DMFOXGB	MN	Tyrosine-protein kinase UFO (AXL)
DMFOXGB	MT	DTT
DMFOXGB	MA	Inhibitor
DMFOXGB	RN	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
DMFOXGB	RU	https://pubmed.ncbi.nlm.nih.gov/33425754

DM5WCBM	DI	DM5WCBM
DM5WCBM	DN	ING-1
DM5WCBM	MI	TTZ8WH4
DM5WCBM	MN	Tumor-associated calcium signal transducer 1 (EPCAM)
DM5WCBM	MT	DTT
DM5WCBM	RN	ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65.
DM5WCBM	RU	https://pubmed.ncbi.nlm.nih.gov/15569986

DM601GL	DI	DM601GL
DM601GL	DN	INNO-105
DM601GL	MI	TT6IEYX
DM601GL	MN	Opioid receptor zeta (OGFR)
DM601GL	MT	DTT
DM601GL	MA	Modulator
DM601GL	RN	National Cancer Institute Drug Dictionary (drug id 428488).
DM601GL	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=428488

DMG6S8U	DI	DMG6S8U
DMG6S8U	DN	INNO-305
DMG6S8U	MI	TTZ8UT4
DMG6S8U	MN	Wilms tumor protein (WT1)
DMG6S8U	MT	DTT
DMG6S8U	MA	Modulator
DMG6S8U	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)
DMG6S8U	RU	http://adisinsight.springer.com/drugs/800023753

DM90P1K	DI	DM90P1K
DM90P1K	DN	INO-3401
DM90P1K	MI	TTUTN1I
DM90P1K	MN	Human Deoxyribonucleic acid (hDNA)
DM90P1K	MT	DTT
DM90P1K	RN	ClinicalTrials.gov (NCT01403155) A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001. U.S. National Institutes of Health.
DM90P1K	RU	https://clinicaltrials.gov/ct2/show/NCT01403155

DMP6I9T	DI	DMP6I9T
DMP6I9T	DN	INO-3510
DMP6I9T	MI	TTUTN1I
DMP6I9T	MN	Human Deoxyribonucleic acid (hDNA)
DMP6I9T	MT	DTT
DMP6I9T	RN	Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine. Inovio. March 26, 2012.
DMP6I9T	RU	http://www.prnewswire.com/news-releases/inovio-receives-us-patent-for-syncon-h1n1-influenza-universal-vaccine-144185625.html

DMA46DO	DI	DMA46DO
DMA46DO	DN	INS-117548
DMA46DO	MI	TTZN7RP
DMA46DO	MN	Rho-associated protein kinase 1 (ROCK1)
DMA46DO	MT	DTT
DMA46DO	MA	Modulator
DMA46DO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA46DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMA46DO	DI	DMA46DO
DMA46DO	DN	INS-117548
DMA46DO	MI	TTGWKQJ
DMA46DO	MN	Rho-associated protein kinase 2 (ROCK2)
DMA46DO	MT	DTT
DMA46DO	MA	Modulator
DMA46DO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMA46DO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMMR7CH	DI	DMMR7CH
DMMR7CH	DN	Insulin oral sublingual
DMMR7CH	MI	TTCBFJO
DMMR7CH	MN	Insulin receptor (INSR)
DMMR7CH	MT	DTT
DMMR7CH	MA	Modulator
DMMR7CH	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).
DMMR7CH	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800

DM93QP2	DI	DM93QP2
DM93QP2	DN	Insulin transdermal
DM93QP2	MI	TTCBFJO
DM93QP2	MN	Insulin receptor (INSR)
DM93QP2	MT	DTT
DM93QP2	MA	Modulator
DM93QP2	RN	Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461-74.
DM93QP2	RU	https://pubmed.ncbi.nlm.nih.gov/12739984

DMXPLMN	DI	DMXPLMN
DMXPLMN	DN	INTOPLICINE
DMXPLMN	MI	TTGTQHC
DMXPLMN	MN	DNA topoisomerase I (TOP1)
DMXPLMN	MT	DTT
DMXPLMN	MA	Modulator
DMXPLMN	RN	Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74.
DMXPLMN	RU	https://www.ncbi.nlm.nih.gov/pubmed/8232227

DMU03WD	DI	DMU03WD
DMU03WD	DN	IO-202
DMU03WD	MI	TTREOKA
DMU03WD	MN	Leukocyte immunoglobulin-like receptor B4 (LILRB4)
DMU03WD	MT	DTT
DMU03WD	MA	Inhibitor
DMU03WD	RN	Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.
DMU03WD	RU	https://www.immune-onc.com/news/2020-09-16-io-202-fpi

DMNBPKS	DI	DMNBPKS
DMNBPKS	DN	Iofolastat I-124
DMNBPKS	MI	TT9G4N0
DMNBPKS	MN	Glutamate carboxypeptidase II (GCPII)
DMNBPKS	MT	DTT
DMNBPKS	MA	Inhibitor
DMNBPKS	RN	123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011 Jul;52(7):1087-93.
DMNBPKS	RU	https://pubmed.ncbi.nlm.nih.gov/21680691

DMY0QL7	DI	DMY0QL7
DMY0QL7	DN	Iomab-ACT
DMY0QL7	MI	TTUS45N
DMY0QL7	MN	Leukocyte common antigen (PTPRC)
DMY0QL7	MT	DTT
DMY0QL7	MA	Inhibitor
DMY0QL7	RN	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
DMY0QL7	RU	https://www.actiniumpharma.com/product-pipeline/iomab-b

DMD7LHM	DI	DMD7LHM
DMD7LHM	DN	ION 224
DMD7LHM	MI	TT8N5V1
DMD7LHM	MN	DGAT2 messenger RNA (DGAT2 mRNA)
DMD7LHM	MT	DTT
DMD7LHM	MA	Inhibitor
DMD7LHM	RN	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
DMD7LHM	RU	https://www.ionispharma.com/ionis-innovation/pipeline/

DMGN96R	DI	DMGN96R
DMGN96R	DN	Ipafricept
DMGN96R	MI	TTVZ87F
DMGN96R	MN	Wnt protein (WNT)
DMGN96R	MT	DTT
DMGN96R	MA	Modulator
DMGN96R	RN	Clinical pipeline report, company report or official report of OncoMed Pharmaceuticals.
DMGN96R	RU	http://www.oncomed.com/Pipeline.html

DMFEI6T	DI	DMFEI6T
DMFEI6T	DN	IPH5201
DMFEI6T	MI	TTYM8DJ
DMFEI6T	MN	Ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
DMFEI6T	MT	DTT
DMFEI6T	MA	Inhibitor
DMFEI6T	RN	ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health.
DMFEI6T	RU	https://clinicaltrials.gov/ct2/show/NCT04261075

DMEIM5G	DI	DMEIM5G
DMEIM5G	DN	IPI-940
DMEIM5G	MI	TTDP1UC
DMEIM5G	MN	Fatty acid amide hydrolase (FAAH)
DMEIM5G	MT	DTT
DMEIM5G	MA	Inhibitor
DMEIM5G	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
DMEIM5G	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400

DMPKH6Y	DI	DMPKH6Y
DMPKH6Y	DN	IPL 550,260
DMPKH6Y	MI	TTO0YVN
DMPKH6Y	MN	Leukocyte (WBC)
DMPKH6Y	MT	DTT
DMPKH6Y	MA	Modulator
DMPKH6Y	RN	WO patent application no. 2005,0792,17, Oligonucleotide decoys and methods of use.
DMPKH6Y	RU	http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050901&CC=WO&NR=2005079217A2&KC=A2

DMHW1LI	DI	DMHW1LI
DMHW1LI	DN	Iptakalim
DMHW1LI	MI	TT1VOHK
DMHW1LI	MN	Potassium channel unspecific (KC)
DMHW1LI	MT	DTT
DMHW1LI	MA	Opener
DMHW1LI	RN	Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
DMHW1LI	RU	https://pubmed.ncbi.nlm.nih.gov/22368410

DMET0H4	DI	DMET0H4
DMET0H4	DN	IQB-9302
DMET0H4	MI	TTW0CMT
DMET0H4	MN	Voltage-gated potassium channel Kv1.5 (KCNA5)
DMET0H4	MT	DTT
DMET0H4	MA	Opener
DMET0H4	RN	Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
DMET0H4	RU	https://pubmed.ncbi.nlm.nih.gov/11159686

DMHP71R	DI	DMHP71R
DMHP71R	DN	IQ-DAA
DMHP71R	MI	TTIQSC1
DMHP71R	MN	Bacterial Lethal factor (Bact lef)
DMHP71R	MT	DTT
DMHP71R	MA	Modulator
DMHP71R	RN	Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
DMHP71R	RU	https://www.ncbi.nlm.nih.gov/pubmed/19207098

DMHP71R	DI	DMHP71R
DMHP71R	DN	IQ-DAA
DMHP71R	MI	TT3YGCD
DMHP71R	MN	Bacterial Protective antigen (Bact pagA)
DMHP71R	MT	DTT
DMHP71R	MA	Modulator
DMHP71R	RN	Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43.
DMHP71R	RU	https://www.ncbi.nlm.nih.gov/pubmed/19207098

DMR3E4L	DI	DMR3E4L
DMR3E4L	DN	Irdabisant
DMR3E4L	MI	TT9JNIC
DMR3E4L	MN	Histamine H3 receptor (H3R)
DMR3E4L	MT	DTT
DMR3E4L	MA	Antagonist
DMR3E4L	RN	CEP-26401 (irdabisant), a potent and selective histamine H receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33.
DMR3E4L	RU	https://pubmed.ncbi.nlm.nih.gov/22001260

DM5YUOM	DI	DM5YUOM
DM5YUOM	DN	Irofulven/Taxotere
DM5YUOM	MI	TTJGNVC
DM5YUOM	MN	Apoptosis regulator Bcl-2 (BCL-2)
DM5YUOM	MT	DTT
DM5YUOM	MA	Modulator
DM5YUOM	RN	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32.
DM5YUOM	RU	https://pubmed.ncbi.nlm.nih.gov/14991863

DM5YUOM	DI	DM5YUOM
DM5YUOM	DN	Irofulven/Taxotere
DM5YUOM	MI	TT63KYR
DM5YUOM	MN	Tubulin beta-1 chain (TUBB1)
DM5YUOM	MT	DTT
DM5YUOM	MA	Modulator
DM5YUOM	RN	Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32.
DM5YUOM	RU	https://pubmed.ncbi.nlm.nih.gov/14991863

DM9SCME	DI	DM9SCME
DM9SCME	DN	IRX4204
DM9SCME	MI	TTP7WQM
DM9SCME	MN	Retinoic acid receptor RXR (RXR)
DM9SCME	MT	DTT
DM9SCME	MA	Agonist
DM9SCME	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9SCME	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9SCME	DI	DM9SCME
DM9SCME	DN	IRX4204
DM9SCME	MI	TTH029C
DM9SCME	MN	Retinoic acid receptor RXR-gamma (RXRG)
DM9SCME	MT	DTT
DM9SCME	MA	Modulator
DM9SCME	RN	Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79.
DM9SCME	RU	https://www.ncbi.nlm.nih.gov/pubmed/26862735

DMCED9U	DI	DMCED9U
DMCED9U	DN	IRX-5183
DMCED9U	MI	TTW38KT
DMCED9U	MN	Retinoic acid receptor alpha (RARA)
DMCED9U	MT	DTT
DMCED9U	MA	Agonist
DMCED9U	RN	Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25.
DMCED9U	RU	https://pubmed.ncbi.nlm.nih.gov/14712350

DMCED9U	DI	DMCED9U
DMCED9U	DN	IRX-5183
DMCED9U	MI	TTP7WQM
DMCED9U	MN	Retinoic acid receptor RXR (RXR)
DMCED9U	MT	DTT
DMCED9U	MA	Agonist
DMCED9U	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCED9U	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMKO7EA	DI	DMKO7EA
DMKO7EA	DN	ISF-402
DMKO7EA	MI	TTCBFJO
DMKO7EA	MN	Insulin receptor (INSR)
DMKO7EA	MT	DTT
DMKO7EA	MA	Modulator
DMKO7EA	RN	Ability of GHTD-amide and analogs to enhance insulin activity through zinc chelation and dispersal of insulin oligomers. Peptides. 2009 Jun;30(6):1088-97.
DMKO7EA	RU	https://pubmed.ncbi.nlm.nih.gov/19463741

DMEJ4B7	DI	DMEJ4B7
DMEJ4B7	DN	ISIS 325568
DMEJ4B7	MI	TTLMJSC
DMEJ4B7	MN	Glucagon receptor messenger RNA (GCGR mRNA)
DMEJ4B7	MT	DTT
DMEJ4B7	RN	Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
DMEJ4B7	RU	http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177

DM9Y51T	DI	DM9Y51T
DM9Y51T	DN	ISIS-ANGPTL3
DM9Y51T	MI	TT59GO7
DM9Y51T	MN	ANGPTL3 messenger RNA (ANGPTL3 mRNA)
DM9Y51T	MT	DTT
DM9Y51T	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM9Y51T	RU	https://www.isispharm.com/pipeline/isis-angptl3rx/

DMX3FN4	DI	DMX3FN4
DMX3FN4	DN	ISIS-APOCIII
DMX3FN4	MI	TTXOZQ1
DMX3FN4	MN	ApoC-III messenger RNA (APOC3 mRNA)
DMX3FN4	MT	DTT
DMX3FN4	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMX3FN4	RU	http://www.isispharm.com/index.htm

DM8P3N5	DI	DM8P3N5
DM8P3N5	DN	ISIS-AR
DM8P3N5	MI	TTKPW01
DM8P3N5	MN	Androgen receptor messenger RNA (AR mRNA)
DM8P3N5	MT	DTT
DM8P3N5	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
DM8P3N5	RU	https://www.isispharm.com/pipeline/isis-arrx/

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TTWRN6M
DMQDUG4	MN	CRP messenger RNA (CRP mRNA)
DMQDUG4	MT	DTT
DMQDUG4	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
DMQDUG4	RU	http://www.isispharm.com/Pipeline/index.htm

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT860QF
DMQDUG4	MN	LCK tyrosine protein kinase (LCK)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT6PKBN
DMQDUG4	MN	Proto-oncogene c-Src (SRC)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TTCQ2E5
DMQDUG4	MN	RIP2 messenger RNA (RIP2 mRNA)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/17850214

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT3PJMV
DMQDUG4	MN	Tyrosine-protein kinase ABL1 (ABL)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/18257513

DMQDUG4	DI	DMQDUG4
DMQDUG4	DN	ISIS-CRP
DMQDUG4	MI	TT6TH8V
DMQDUG4	MN	Tyrosine-protein kinase BRK (PTK6)
DMQDUG4	MT	DTT
DMQDUG4	MA	Inhibitor
DMQDUG4	RN	Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18.
DMQDUG4	RU	https://pubmed.ncbi.nlm.nih.gov/15073106

DMDKAIC	DI	DMDKAIC
DMDKAIC	DN	ISIS-SGLT2
DMDKAIC	MI	TTF8JAT
DMDKAIC	MN	SLC5A2 messenger RNA (SLC5A2 mRNA)
DMDKAIC	MT	DTT
DMDKAIC	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMDKAIC	RU	http://www.isispharm.com/index.htm

DMV1BTP	DI	DMV1BTP
DMV1BTP	DN	ISIS-SOD1
DMV1BTP	MI	TTP9K3Q
DMV1BTP	MN	SOD1 messenger RNA (SOD1 mRNA)
DMV1BTP	MT	DTT
DMV1BTP	RN	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
DMV1BTP	RU	http://www.isispharm.com/index.htm

DMDB7KU	DI	DMDB7KU
DMDB7KU	DN	ISO-1
DMDB7KU	MI	TT2AST1
DMDB7KU	MN	Macrophage migration inhibitory factor (MIF)
DMDB7KU	MT	DTT
DMDB7KU	MA	Inhibitor
DMDB7KU	RN	The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82.
DMDB7KU	RU	https://pubmed.ncbi.nlm.nih.gov/11997397

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEL4UKY
DMBQ8CA	MN	Methylenetetrahydrofolate dehydrogenase (folD)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	nan
DMBQ8CA	RU	nan

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEH3KAT
DMBQ8CA	MN	Methylenetetrahydrofolate reductase (metF)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976.
DMBQ8CA	RU	https://pubmed.ncbi.nlm.nih.gov/30034639

DMBQ8CA	DI	DMBQ8CA
DMBQ8CA	DN	ISO-901
DMBQ8CA	MI	DEOXTPZ
DMBQ8CA	MN	Methylenetetrahydrofolate reductase (MTHFR)
DMBQ8CA	MT	DME
DMBQ8CA	MA	Metabolism
DMBQ8CA	RN	Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40.
DMBQ8CA	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=16187112

DMR17YI	DI	DMR17YI
DMR17YI	DN	Isoquine
DMR17YI	MI	TTVG215
DMR17YI	MN	Debrisoquine 4-hydroxylase (CYP2D6)
DMR17YI	MT	DTT
DMR17YI	MA	Inhibitor
DMR17YI	RN	Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
DMR17YI	RU	https://pubmed.ncbi.nlm.nih.gov/19222165

DMR17YI	DI	DMR17YI
DMR17YI	DN	Isoquine
DMR17YI	MI	TTQ6VDM
DMR17YI	MN	Voltage-gated potassium channel Kv11.1 (KCNH2)
DMR17YI	MT	DTT
DMR17YI	MA	Inhibitor
DMR17YI	RN	Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
DMR17YI	RU	https://pubmed.ncbi.nlm.nih.gov/19222165

DMBPV9W	DI	DMBPV9W
DMBPV9W	DN	IT-139
DMBPV9W	MI	TTW26OG
DMBPV9W	MN	Endoplasmic reticulum chaperone BiP (HSPA5)
DMBPV9W	MT	DTT
DMBPV9W	MA	Inhibitor
DMBPV9W	RN	NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82.
DMBPV9W	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/

DMAYD7O	DI	DMAYD7O
DMAYD7O	DN	IT-141
DMAYD7O	MI	TTGTQHC
DMAYD7O	MN	DNA topoisomerase I (TOP1)
DMAYD7O	MT	DTT
DMAYD7O	MA	Inhibitor
DMAYD7O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAYD7O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMY1DFK	DI	DMY1DFK
DMY1DFK	DN	ITASETRON
DMY1DFK	MI	TTNXLKE
DMY1DFK	MN	5-HT 3 receptor (5HT3R)
DMY1DFK	MT	DTT
DMY1DFK	MA	Modulator
DMY1DFK	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMY1DFK	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DECB0K3
DM702MU	MN	Cytochrome P450 2D6 (CYP2D6)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DE4LYSA
DM702MU	MN	Cytochrome P450 3A4 (CYP3A4)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DEIBDNY
DM702MU	MN	Cytochrome P450 3A5 (CYP3A5)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DM702MU	DI	DM702MU
DM702MU	DN	ITX-5061
DM702MU	MI	DEGTFWK
DM702MU	MN	Mephenytoin 4-hydroxylase (CYP2C19)
DM702MU	MT	DME
DM702MU	MA	Metabolism
DM702MU	RN	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
DM702MU	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22954720

DMSGEU6	DI	DMSGEU6
DMSGEU6	DN	JAB-3068
DMSGEU6	MI	TT7WUAV
DMSGEU6	MN	Protein-tyrosine phosphatase SHP-2 (PTPN11)
DMSGEU6	MT	DTT
DMSGEU6	MA	Inhibitor
DMSGEU6	RN	Clinical pipeline report, company report or official report of AbbVie.
DMSGEU6	RU	https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html

DM7XAV1	DI	DM7XAV1
DM7XAV1	DN	JBH492
DM7XAV1	MI	TT2GIDQ
DM7XAV1	MN	C-C chemokine receptor type 7 (CCR7)
DM7XAV1	MT	DTT
DM7XAV1	RN	ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health.
DM7XAV1	RU	https://clinicaltrials.gov/ct2/show/NCT04240704

DMR3SO5	DI	DMR3SO5
DMR3SO5	DN	JCAR018
DMR3SO5	MI	TTM6QSK
DMR3SO5	MN	B-cell receptor CD22 (CD22)
DMR3SO5	MT	DTT
DMR3SO5	MA	Immunomodulator
DMR3SO5	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMR3SO5	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM1T8KN	DI	DM1T8KN
DM1T8KN	DN	JCAR020
DM1T8KN	MI	TTC1PS3
DM1T8KN	MN	Ovarian carcinoma antigen CA125 (MUC16)
DM1T8KN	MT	DTT
DM1T8KN	MA	Immunomodulator
DM1T8KN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM1T8KN	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM324RM	DI	DM324RM
DM324RM	DN	JCAR023
DM324RM	MI	TTC9D3K
DM324RM	MN	Neural cell adhesion molecule L1 (L1CAM)
DM324RM	MT	DTT
DM324RM	MA	CAR-T-Cell-Therapy
DM324RM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM324RM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMYR3IE	DI	DMYR3IE
DMYR3IE	DN	JES-9501
DMYR3IE	MI	TTEB0GD
DMYR3IE	MN	Cholinesterase (BCHE)
DMYR3IE	MT	DTT
DMYR3IE	MA	Modulator
DMYR3IE	RN	Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5.
DMYR3IE	RU	https://pubmed.ncbi.nlm.nih.gov/11226396

DMMI4XR	DI	DMMI4XR
DMMI4XR	DN	JNJ-17305600
DMMI4XR	MI	TTHJTF7
DMMI4XR	MN	Glycine transporter GlyT-1 (SLC6A9)
DMMI4XR	MT	DTT
DMMI4XR	MA	Inhibitor
DMMI4XR	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935).
DMMI4XR	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TTGKNB4
DMSQ3AZ	MN	Epidermal growth factor receptor (EGFR)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT6EO5L
DMSQ3AZ	MN	Erbb2 tyrosine kinase receptor (HER2)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT0JESD
DMSQ3AZ	MN	Erbb4 tyrosine kinase receptor (Erbb-4)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT2B9KF
DMSQ3AZ	MN	Fyn tyrosine protein kinase (FYN)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT860QF
DMSQ3AZ	MN	LCK tyrosine protein kinase (LCK)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT1RWNJ
DMSQ3AZ	MN	Tyrosine-protein kinase Lyn (JTK8)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TTDCBX5
DMSQ3AZ	MN	Vascular endothelial growth factor receptor 3 (FLT-4)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMSQ3AZ	DI	DMSQ3AZ
DMSQ3AZ	DN	JNJ-26483327
DMSQ3AZ	MI	TT0SQ8J
DMSQ3AZ	MN	Yes tyrosine kinase (YES)
DMSQ3AZ	MT	DTT
DMSQ3AZ	MA	Inhibitor
DMSQ3AZ	RN	National Cancer Institute Drug Dictionary (drug id 596693).
DMSQ3AZ	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693

DMNSJ3C	DI	DMNSJ3C
DMNSJ3C	DN	JNJ-26854165
DMNSJ3C	MI	TT08GJW
DMNSJ3C	MN	Ubiquitin-protein ligase E3 Mdm2 (MDM2)
DMNSJ3C	MT	DTT
DMNSJ3C	MA	Modulator
DMNSJ3C	RN	Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
DMNSJ3C	RU	https://pubmed.ncbi.nlm.nih.gov/24040331

DM49VWQ	DI	DM49VWQ
DM49VWQ	DN	JNJ-3534
DM49VWQ	MI	TTGV6LY
DM49VWQ	MN	Nuclear receptor ROR-gamma (RORG)
DM49VWQ	MT	DTT
DM49VWQ	MA	Modulator
DM49VWQ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM49VWQ	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMDIPW8	DI	DMDIPW8
DMDIPW8	DN	JNJ-38877605
DMDIPW8	MI	TTNDSF4
DMDIPW8	MN	Proto-oncogene c-Met (MET)
DMDIPW8	MT	DTT
DMDIPW8	MA	Inhibitor
DMDIPW8	RN	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304.
DMDIPW8	RU	https://pubmed.ncbi.nlm.nih.gov/25745036

DM45SGE	DI	DM45SGE
DM45SGE	DN	JNJ-39439335
DM45SGE	MI	TTMI6F5
DM45SGE	MN	Transient receptor potential cation channel V1 (TRPV1)
DM45SGE	MT	DTT
DM45SGE	MA	Antagonist
DM45SGE	RN	Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74.
DM45SGE	RU	https://pubmed.ncbi.nlm.nih.gov/25850459

DMOL9JR	DI	DMOL9JR
DMOL9JR	DN	JNJ-42491293
DMOL9JR	MI	TTXJ47W
DMOL9JR	MN	Metabotropic glutamate receptor 2 (mGluR2)
DMOL9JR	MT	DTT
DMOL9JR	MA	Binder
DMOL9JR	RN	Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708. 
DMOL9JR	RU	https://pubmed.ncbi.nlm.nih.gov/25176435

DMQ5ZVK	DI	DMQ5ZVK
DMQ5ZVK	DN	JNJ-54175446
DMQ5ZVK	MI	TT473XN
DMQ5ZVK	MN	P2X purinoceptor 7 (P2RX7)
DMQ5ZVK	MT	DTT
DMQ5ZVK	MA	Antagonist
DMQ5ZVK	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQ5ZVK	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf

DMBV3P8	DI	DMBV3P8
DMBV3P8	DN	JNJ-54728518
DMBV3P8	MI	TTVIMDE
DMBV3P8	MN	Glucagon-like peptide 1 receptor (GLP1R)
DMBV3P8	MT	DTT
DMBV3P8	MA	Agonist
DMBV3P8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMBV3P8	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DM0QZJX	DI	DM0QZJX
DM0QZJX	DN	JNJ-55308942
DM0QZJX	MI	TT473XN
DM0QZJX	MN	P2X purinoceptor 7 (P2RX7)
DM0QZJX	MT	DTT
DM0QZJX	MA	Inhibitor
DM0QZJX	RN	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
DM0QZJX	RU	https://pubmed.ncbi.nlm.nih.gov/30728472

DMSPQDM	DI	DMSPQDM
DMSPQDM	DN	JNJ-61610588
DMSPQDM	MI	TT51SK8
DMSPQDM	MN	V-set immunoregulatory receptor (VSIR)
DMSPQDM	MT	DTT
DMSPQDM	MA	Inhibitor
DMSPQDM	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMSPQDM	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DM5SZAK	DI	DM5SZAK
DM5SZAK	DN	JNJ-63709178
DM5SZAK	MI	TTENHJ0
DM5SZAK	MN	Interleukin 3 receptor alpha (IL3RA)
DM5SZAK	MT	DTT
DM5SZAK	MA	Inhibitor
DM5SZAK	RN	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
DM5SZAK	RU	https://pubmed.ncbi.nlm.nih.gov/29206680

DM5SZAK	DI	DM5SZAK
DM5SZAK	DN	JNJ-63709178
DM5SZAK	MI	TTUN7MC
DM5SZAK	MN	T-cell surface glycoprotein CD3 (CD3)
DM5SZAK	MT	DTT
DM5SZAK	MA	Inhibitor
DM5SZAK	RN	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
DM5SZAK	RU	https://pubmed.ncbi.nlm.nih.gov/29206680

DMJFK6X	DI	DMJFK6X
DMJFK6X	DN	JNJ-63898081
DMJFK6X	MI	TT9G4N0
DMJFK6X	MN	Glutamate carboxypeptidase II (GCPII)
DMJFK6X	MT	DTT
DMJFK6X	MA	Inhibitor
DMJFK6X	RN	Clinical pipeline report, company report or official report of Genmab.
DMJFK6X	RU	https://www.genmab.com/pipeline/

DMLYAGD	DI	DMLYAGD
DMLYAGD	DN	JNJ-64264681
DMLYAGD	MI	TTGM6VW
DMLYAGD	MN	Tyrosine-protein kinase BTK (ATK)
DMLYAGD	MT	DTT
DMLYAGD	MA	Inhibitor
DMLYAGD	RN	A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
DMLYAGD	RU	https://clinicaltrials.gov/ct2/show/NCT04657224

DMYJCUP	DI	DMYJCUP
DMYJCUP	DN	JNJ-64417184
DMYJCUP	MI	TT6275O
DMYJCUP	MN	HRSV RNA-directed RNA polymerase L (HRSV L)
DMYJCUP	MT	DTT
DMYJCUP	MA	Inhibitor
DMYJCUP	RN	Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67.
DMYJCUP	RU	https://pubmed.ncbi.nlm.nih.gov/30974127

DMDBW2N	DI	DMDBW2N
DMDBW2N	DN	JNJ-64619178
DMDBW2N	MI	TTR1D7X
DMDBW2N	MN	Protein arginine methyltransferase 5 (PRMT5)
DMDBW2N	MT	DTT
DMDBW2N	MA	Inhibitor
DMDBW2N	RN	A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114.
DMDBW2N	RU	https://pubmed.ncbi.nlm.nih.gov/30640571

DMQOHRA	DI	DMQOHRA
DMQOHRA	DN	JNJ-67571244
DMQOHRA	MI	TTJVYO3
DMQOHRA	MN	Myeloid cell surface antigen CD33 (CD33)
DMQOHRA	MT	DTT
DMQOHRA	MA	Inhibitor
DMQOHRA	RN	Clinical pipeline report, company report or official report of Genmab.
DMQOHRA	RU	https://www.genmab.com/pipeline/

DM6URNJ	DI	DM6URNJ
DM6URNJ	DN	JNJ-67856633
DM6URNJ	MI	TTCI81G
DM6URNJ	MN	MALT lymphoma-associated translocation (MALT1)
DM6URNJ	MT	DTT
DM6URNJ	MA	Inhibitor
DM6URNJ	RN	National Cancer Institute Drug Dictionary (drug name JNJ67856633).
DM6URNJ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/malt1-inhibitor-jnj-67856633

DM6VR13	DI	DM6VR13
DM6VR13	DN	JNJ-69086420
DM6VR13	MI	TTJLNAW
DM6VR13	MN	Tissue kallikrein (KLK2)
DM6VR13	MT	DTT
DM6VR13	MA	Inhibitor
DM6VR13	RN	ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.
DM6VR13	RU	https://clinicaltrials.gov/ct2/show/NCT04644770

DMY7CW1	DI	DMY7CW1
DMY7CW1	DN	JNJ-74699157
DMY7CW1	MI	TT3LH46
DMY7CW1	MN	KRAS G12C mutant (KRAS G12C)
DMY7CW1	MT	DTT
DMY7CW1	MA	Inhibitor
DMY7CW1	RN	KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070.
DMY7CW1	RU	https://pubmed.ncbi.nlm.nih.gov/32711246

DMFMWLQ	DI	DMFMWLQ
DMFMWLQ	DN	JS004
DMFMWLQ	MI	TTER58P
DMFMWLQ	MN	B- and T-lymphocyte attenuator (BTLA)
DMFMWLQ	MT	DTT
DMFMWLQ	MA	Inhibitor
DMFMWLQ	RN	Clinical pipeline report, company report or official report of Junshi Biosciences.
DMFMWLQ	RU	https://www.junshipharma.com/en/Treatment.html

DMVJWBS	DI	DMVJWBS
DMVJWBS	DN	JSI-1187
DMVJWBS	MI	TT1MG9E
DMVJWBS	MN	Extracellular signal-regulated kinase 1 (ERK1)
DMVJWBS	MT	DTT
DMVJWBS	MA	Inhibitor
DMVJWBS	RN	National Cancer Institute Drug Dictionary (drug name JSI1187).
DMVJWBS	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187

DMVJWBS	DI	DMVJWBS
DMVJWBS	DN	JSI-1187
DMVJWBS	MI	TT4TQBX
DMVJWBS	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMVJWBS	MT	DTT
DMVJWBS	MA	Inhibitor
DMVJWBS	RN	National Cancer Institute Drug Dictionary (drug name JSI1187).
DMVJWBS	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187

DM4QIOH	DI	DM4QIOH
DM4QIOH	DN	JSM 6427
DM4QIOH	MI	TTHIZP9
DM4QIOH	MN	Integrin alpha-5 (ITGA5)
DM4QIOH	MT	DTT
DM4QIOH	MA	Antagonist
DM4QIOH	RN	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
DM4QIOH	RU	https://pubmed.ncbi.nlm.nih.gov/18804537

DM4QIOH	DI	DM4QIOH
DM4QIOH	DN	JSM 6427
DM4QIOH	MI	TTBVIQC
DM4QIOH	MN	Integrin beta-1 (ITGB1)
DM4QIOH	MT	DTT
DM4QIOH	MA	Antagonist
DM4QIOH	RN	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
DM4QIOH	RU	https://pubmed.ncbi.nlm.nih.gov/18804537

DM01JU8	DI	DM01JU8
DM01JU8	DN	JTE-451
DM01JU8	MI	TTGV6LY
DM01JU8	MN	Nuclear receptor ROR-gamma (RORG)
DM01JU8	MT	DTT
DM01JU8	MA	Antagonist
DM01JU8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM01JU8	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DMHMDC0	DI	DMHMDC0
DMHMDC0	DN	JWCAR029
DMHMDC0	MI	TTW640A
DMHMDC0	MN	B-lymphocyte surface antigen B4 (CD19)
DMHMDC0	MT	DTT
DMHMDC0	MA	CAR-T-Cell-Therapy
DMHMDC0	RN	ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
DMHMDC0	RU	https://clinicaltrials.gov/ct2/show/NCT03344367

DMW5J9B	DI	DMW5J9B
DMW5J9B	DN	JX-929
DMW5J9B	MI	TTKRTP6
DMW5J9B	MN	Cytosine deaminase (AICDA)
DMW5J9B	MT	DTT
DMW5J9B	MA	Modulator
DMW5J9B	RN	Micromanaging oncolytic viruses. SciBX 1(42); doi:10.1038/scibx.2008.1014. Nov. 20 2008
DMW5J9B	RU	http://www.nature.com/scibx/journal/v1/n42/full/scibx.2008.1014.html

DMFKEVO	DI	DMFKEVO
DMFKEVO	DN	KA2237
DMFKEVO	MI	TTHBTOP
DMFKEVO	MN	PI3-kinase gamma (PIK3CG)
DMFKEVO	MT	DTT
DMFKEVO	MA	Inhibitor
DMFKEVO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFKEVO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMW0H9Y	DI	DMW0H9Y
DMW0H9Y	DN	KA2507
DMW0H9Y	MI	TT5ZKDI
DMW0H9Y	MN	Histone deacetylase 6 (HDAC6)
DMW0H9Y	MT	DTT
DMW0H9Y	MA	Inhibitor
DMW0H9Y	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMW0H9Y	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMXYN1H	DI	DMXYN1H
DMXYN1H	DN	KAR5585
DMXYN1H	MI	TTZSJHV
DMXYN1H	MN	Tryptophan 5-hydroxylase 1 (TPH1)
DMXYN1H	MT	DTT
DMXYN1H	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMXYN1H	RU	http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf

DMTYNRB	DI	DMTYNRB
DMTYNRB	DN	KD033
DMTYNRB	MI	TT8ZLTI
DMTYNRB	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMTYNRB	MT	DTT
DMTYNRB	MA	Inhibitor
DMTYNRB	RN	Clinical pipeline report, company report or official report of Kadmon.
DMTYNRB	RU	https://kadmon.com/clinical-pipeline/pipeline/kd033/

DMNFDYE	DI	DMNFDYE
DMNFDYE	DN	KD3010
DMNFDYE	MI	TT2JWF6
DMNFDYE	MN	Peroxisome proliferator-activated receptor delta (PPARD)
DMNFDYE	MT	DTT
DMNFDYE	MA	Agonist
DMNFDYE	RN	Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
DMNFDYE	RU	http://www.newsrx.com/newsletters/Health-Business-Week/2006-10-27/102320063331046HBW.html

DMZK7N8	DI	DMZK7N8
DMZK7N8	DN	Keratinocyte growth factor
DMZK7N8	MI	TTFY134
DMZK7N8	MN	Keratinocyte growth factor (FGF7)
DMZK7N8	MT	DTT
DMZK7N8	MA	Modulator
DMZK7N8	RN	Keratinocyte growth factor.Cell Biol Int.1995 May;19(5):399-411.
DMZK7N8	RU	https://www.ncbi.nlm.nih.gov/pubmed/7640656

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTK25J1
DMQ6DLZ	MN	Adenosine A1 receptor (ADORA1)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/11170626

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTM2AOE
DMQ6DLZ	MN	Adenosine A2a receptor (ADORA2A)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/8246243

DMQ6DLZ	DI	DMQ6DLZ
DMQ6DLZ	DN	KF-17837
DMQ6DLZ	MI	TTNE7KG
DMQ6DLZ	MN	Adenosine A2b receptor (ADORA2B)
DMQ6DLZ	MT	DTT
DMQ6DLZ	MA	Inhibitor
DMQ6DLZ	RN	Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3.
DMQ6DLZ	RU	https://pubmed.ncbi.nlm.nih.gov/8246243

DMR14VE	DI	DMR14VE
DMR14VE	DN	KH-901
DMR14VE	MI	TT6MP2Z
DMR14VE	MN	GMCSFR-alpha (CSF2RA)
DMR14VE	MT	DTT
DMR14VE	RN	Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90.
DMR14VE	RU	https://pubmed.ncbi.nlm.nih.gov/17593813

DMLSUQ8	DI	DMLSUQ8
DMLSUQ8	DN	KHK2455
DMLSUQ8	MI	TTZJYKH
DMLSUQ8	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMLSUQ8	MT	DTT
DMLSUQ8	MA	Inhibitor
DMLSUQ8	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLSUQ8	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMR7EF6	DI	DMR7EF6
DMR7EF6	DN	KHK-2866
DMR7EF6	MI	TT15SL0
DMR7EF6	MN	Proheparin-binding EGF-like growth factor (HBEGF)
DMR7EF6	MT	DTT
DMR7EF6	RN	ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health.
DMR7EF6	RU	https://clinicaltrials.gov/ct2/show/NCT01279291

DMIAVBL	DI	DMIAVBL
DMIAVBL	DN	Ki23819
DMIAVBL	MI	TTGJCWZ
DMIAVBL	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMIAVBL	MT	DTT
DMIAVBL	MA	Inhibitor
DMIAVBL	RN	Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia. 2005 Jun;19(6):930-5.
DMIAVBL	RU	https://pubmed.ncbi.nlm.nih.gov/15815726

DMUB3H9	DI	DMUB3H9
DMUB3H9	DN	KITE-439
DMUB3H9	MI	TT3CPZW
DMUB3H9	MN	Human papillomavirus protein E7 (HPV E7)
DMUB3H9	MT	DTT
DMUB3H9	MA	Inhibitor
DMUB3H9	RN	ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.
DMUB3H9	RU	https://clinicaltrials.gov/ct2/show/NCT03912831

DMXR6HI	DI	DMXR6HI
DMXR6HI	DN	KITE-585
DMXR6HI	MI	TTZ3P4W
DMXR6HI	MN	B-cell maturation protein (TNFRSF17)
DMXR6HI	MT	DTT
DMXR6HI	MA	CAR-T-Cell-Therapy
DMXR6HI	RN	ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma
DMXR6HI	RU	https://clinicaltrials.gov/ct2/show/NCT03318861

DMBSI6Y	DI	DMBSI6Y
DMBSI6Y	DN	KITE-718
DMBSI6Y	MI	TTWSKHD
DMBSI6Y	MN	Melanoma-associated antigen 3 (MAGEA3)
DMBSI6Y	MT	DTT
DMBSI6Y	RN	ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
DMBSI6Y	RU	https://clinicaltrials.gov/ct2/show/NCT03139370

DMBSI6Y	DI	DMBSI6Y
DMBSI6Y	DN	KITE-718
DMBSI6Y	MI	TTJIWMO
DMBSI6Y	MN	Melanoma-associated antigen 6 (MAGEA6)
DMBSI6Y	MT	DTT
DMBSI6Y	RN	ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
DMBSI6Y	RU	https://clinicaltrials.gov/ct2/show/NCT03139370

DME8DUV	DI	DME8DUV
DME8DUV	DN	KM-023
DME8DUV	MI	TT84ETX
DME8DUV	MN	Human immunodeficiency virus Reverse transcriptase (HIV RT)
DME8DUV	MT	DTT
DME8DUV	MA	Inhibitor
DME8DUV	RN	Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9.
DME8DUV	RU	https://pubmed.ncbi.nlm.nih.gov/25302016

DMRAWGC	DI	DMRAWGC
DMRAWGC	DN	KM-819
DMRAWGC	MI	TTSKL3G
DMRAWGC	MN	FAS-associated factor 1 (FAF1)
DMRAWGC	MT	DTT
DMRAWGC	MA	Inhibitor
DMRAWGC	RN	A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022.
DMRAWGC	RU	https://pubmed.ncbi.nlm.nih.gov/30992659

DM1D2O0	DI	DM1D2O0
DM1D2O0	DN	KML-001
DM1D2O0	MI	TTUJFD0
DM1D2O0	MN	Telomerase reverse transcriptase (TERT)
DM1D2O0	MT	DTT
DM1D2O0	MA	Inhibitor
DM1D2O0	RN	National Cancer Institute Drug Dictionary (drug id 672554).
DM1D2O0	RU	http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=672554

DMZMSBI	DI	DMZMSBI
DMZMSBI	DN	KO-947
DMZMSBI	MI	TTKPV6O
DMZMSBI	MN	Ephrin type-B receptor 2 (EPHB2)
DMZMSBI	MT	DTT
DMZMSBI	MA	Inhibitor
DMZMSBI	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZMSBI	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM4953W	DI	DM4953W
DM4953W	DN	KOS-2187
DM4953W	MI	TT953CX
DM4953W	MN	Motilin receptor (MLNR)
DM4953W	MT	DTT
DM4953W	MA	Agonist
DM4953W	RN	Kosan Announces Selection of KOS-2187 As Motilide Clinical Candidate at World Congress of Gastroenterology Meeting. Kosan. 2006.
DM4953W	RU	http://www.redorbit.com/news/health/237602/kosan_announces_selection_of_kos2187_as_motilide_clinical_candidate_at/

DMSKI8W	DI	DMSKI8W
DMSKI8W	DN	KPG-121
DMSKI8W	MI	TTEZQ39
DMSKI8W	MN	Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)
DMSKI8W	MT	DTT
DMSKI8W	MA	Modulator
DMSKI8W	RN	Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals.
DMSKI8W	RU	https://www.kangpugroup.com/research_development/pipeline.html

DM1O2X6	DI	DM1O2X6
DM1O2X6	DN	KPG-818
DM1O2X6	MI	TTEZQ39
DM1O2X6	MN	Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase)
DM1O2X6	MT	DTT
DM1O2X6	MA	Modulator
DM1O2X6	RN	Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals.
DM1O2X6	RU	https://www.kangpugroup.com/research_development/pipeline.html

DMYBHER	DI	DMYBHER
DMYBHER	DN	KPL-716
DMYBHER	MI	TT1RJXK
DMYBHER	MN	Interleukin-31 (IL31)
DMYBHER	MT	DTT
DMYBHER	MA	Inhibitor
DMYBHER	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYBHER	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf

DM9JXMD	DI	DM9JXMD
DM9JXMD	DN	KPT-9274
DM9JXMD	MI	TT7Y3BZ
DM9JXMD	MN	PAK-4 protein kinase (PAK4)
DM9JXMD	MT	DTT
DM9JXMD	MA	Inhibitor
DM9JXMD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM9JXMD	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMK0BTN	DI	DMK0BTN
DMK0BTN	DN	KQ-791
DMK0BTN	MI	TTMS7KP
DMK0BTN	MN	Protein-tyrosine phosphatase 1B (PTP1B)
DMK0BTN	MT	DTT
DMK0BTN	MA	Antagonist
DMK0BTN	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMK0BTN	RU	http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf

DMODGJU	DI	DMODGJU
DMODGJU	DN	KRN633
DMODGJU	MI	TTUTJGQ
DMODGJU	MN	Vascular endothelial growth factor receptor 2 (KDR)
DMODGJU	MT	DTT
DMODGJU	MA	Inhibitor
DMODGJU	RN	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
DMODGJU	RU	https://pubmed.ncbi.nlm.nih.gov/17692029

DM8FQPX	DI	DM8FQPX
DM8FQPX	DN	KTN3379
DM8FQPX	MI	TTDC8N2
DM8FQPX	MN	Erbb3 tyrosine kinase receptor (Erbb-3)
DM8FQPX	MT	DTT
DM8FQPX	RN	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750.
DM8FQPX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455348/

DMTFWLE	DI	DMTFWLE
DMTFWLE	DN	KUC-7483
DMTFWLE	MI	TTMXGCW
DMTFWLE	MN	Adrenergic receptor beta-3 (ADRB3)
DMTFWLE	MT	DTT
DMTFWLE	MA	Agonist
DMTFWLE	RN	Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8.
DMTFWLE	RU	https://pubmed.ncbi.nlm.nih.gov/22511202

DMKFVX5	DI	DMKFVX5
DMKFVX5	DN	KUL-7211
DMKFVX5	MI	TT2CJVK
DMKFVX5	MN	Adrenergic receptor beta-2 (ADRB2)
DMKFVX5	MT	DTT
DMKFVX5	MA	Modulator
DMKFVX5	RN	The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
DMKFVX5	RU	https://www.ncbi.nlm.nih.gov/pubmed/16133579

DMKFVX5	DI	DMKFVX5
DMKFVX5	DN	KUL-7211
DMKFVX5	MI	TTMXGCW
DMKFVX5	MN	Adrenergic receptor beta-3 (ADRB3)
DMKFVX5	MT	DTT
DMKFVX5	MA	Modulator
DMKFVX5	RN	The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14.
DMKFVX5	RU	https://www.ncbi.nlm.nih.gov/pubmed/16133579

DMKMN5R	DI	DMKMN5R
DMKMN5R	DN	KUR-501
DMKMN5R	MI	TT80ARU
DMKMN5R	MN	Ganglioside GD2 (GD2)
DMKMN5R	MT	DTT
DMKMN5R	RN	Clinical pipeline report, company report or official report of Kuur Therapeutics.
DMKMN5R	RU	https://kuurtx.com/product-overview/

DMS9LVC	DI	DMS9LVC
DMS9LVC	DN	KUR-502
DMS9LVC	MI	TTW640A
DMS9LVC	MN	B-lymphocyte surface antigen B4 (CD19)
DMS9LVC	MT	DTT
DMS9LVC	RN	Clinical pipeline report, company report or official report of Kuur Therapeutics.
DMS9LVC	RU	https://kuurtx.com/product-overview/

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TTRLW2X
DMFO7RP	MN	Fibroblast growth factor receptor 1 (FGFR1)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TTGJCWZ
DMFO7RP	MN	Fms-like tyrosine kinase 3 (FLT-3)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMFO7RP	DI	DMFO7RP
DMFO7RP	DN	KW-2449
DMFO7RP	MI	TT3PJMV
DMFO7RP	MN	Tyrosine-protein kinase ABL1 (ABL)
DMFO7RP	MT	DTT
DMFO7RP	RN	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
DMFO7RP	RU	https://pubmed.ncbi.nlm.nih.gov/19541823

DMALK7F	DI	DMALK7F
DMALK7F	DN	KW-5092
DMALK7F	MI	TT1RS9F
DMALK7F	MN	Acetylcholinesterase (AChE)
DMALK7F	MT	DTT
DMALK7F	MA	Inhibitor
DMALK7F	RN	Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8.
DMALK7F	RU	https://pubmed.ncbi.nlm.nih.gov/9143009

DML4H05	DI	DML4H05
DML4H05	DN	KX2-361
DML4H05	MI	TT6PKBN
DML4H05	MN	Proto-oncogene c-Src (SRC)
DML4H05	MT	DTT
DML4H05	MA	Inhibitor
DML4H05	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206).
DML4H05	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206

DMWSC5L	DI	DMWSC5L
DMWSC5L	DN	L-778123
DMWSC5L	MI	TTXQKM3
DMWSC5L	MN	Farnesyl protein transferase (Ftase)
DMWSC5L	MT	DTT
DMWSC5L	MA	Modulator
DMWSC5L	RN	Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
DMWSC5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/12479371

DMWSC5L	DI	DMWSC5L
DMWSC5L	DN	L-778123
DMWSC5L	MI	TTX20QP
DMWSC5L	MN	Geranylgeranyl transferase I (GGTase-I)
DMWSC5L	MT	DTT
DMWSC5L	MA	Modulator
DMWSC5L	RN	Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
DMWSC5L	RU	https://www.ncbi.nlm.nih.gov/pubmed/12479371

DMXKO1L	DI	DMXKO1L
DMXKO1L	DN	L-796568
DMXKO1L	MI	TTR6W5O
DMXKO1L	MN	Adrenergic receptor beta-1 (ADRB1)
DMXKO1L	MT	DTT
DMXKO1L	MA	Inhibitor
DMXKO1L	RN	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
DMXKO1L	RU	https://pubmed.ncbi.nlm.nih.gov/20181479

DMXKO1L	DI	DMXKO1L
DMXKO1L	DN	L-796568
DMXKO1L	MI	TT2CJVK
DMXKO1L	MN	Adrenergic receptor beta-2 (ADRB2)
DMXKO1L	MT	DTT
DMXKO1L	MA	Inhibitor
DMXKO1L	RN	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9.
DMXKO1L	RU	https://pubmed.ncbi.nlm.nih.gov/20181479

DM8ANIM	DI	DM8ANIM
DM8ANIM	DN	Lactermin
DM8ANIM	MI	TTDB5IS
DM8ANIM	MN	Receptor unspecific (Rec)
DM8ANIM	MT	DTT
DM8ANIM	MA	Modulator
DM8ANIM	RN	Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75.
DM8ANIM	RU	https://pubmed.ncbi.nlm.nih.gov/16261254

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEQB4LT
DMO4GPK	MN	Beta-galactosidase (bgaB)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Identification and characterization of a novel beta-galactosidase from Victivallis vadensis ATCC BAA-548, an anaerobic fecal bacterium. J Microbiol. 2012 Dec;50(6):1034-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/23274992

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEGLW18
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DENTGJO
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DE4XLDR
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEGBVKJ
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMO4GPK	DI	DMO4GPK
DMO4GPK	DN	Lactose
DMO4GPK	MI	DEDY9F6
DMO4GPK	MN	Cellobiose 2-epimerase (CE)
DMO4GPK	MT	DME
DMO4GPK	MA	Metabolism
DMO4GPK	RN	Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
DMO4GPK	RU	https://pubmed.ncbi.nlm.nih.gov/18710396

DMC0VJF	DI	DMC0VJF
DMC0VJF	DN	Laevo-Bambuterol
DMC0VJF	MI	TTMXGCW
DMC0VJF	MN	Adrenergic receptor beta-3 (ADRB3)
DMC0VJF	MT	DTT
DMC0VJF	MA	Modulator
DMC0VJF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29).
DMC0VJF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29

DM7JNHU	DI	DM7JNHU
DM7JNHU	DN	LAM-001
DM7JNHU	MI	TTCJG29
DM7JNHU	MN	Serine/threonine-protein kinase mTOR (mTOR)
DM7JNHU	MT	DTT
DM7JNHU	MA	Inhibitor
DM7JNHU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM7JNHU	RU	http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf

DMQHWMJ	DI	DMQHWMJ
DMQHWMJ	DN	LAM-003
DMQHWMJ	MI	TTO7FVG
DMQHWMJ	MN	Heat shock protein 90 (HSP90)
DMQHWMJ	MT	DTT
DMQHWMJ	MA	Inhibitor
DMQHWMJ	RN	LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673.
DMQHWMJ	RU	https://pubmed.ncbi.nlm.nih.gov/31751472

DM1C4UM	DI	DM1C4UM
DM1C4UM	DN	LAMB3-transduced autologous epidermal stem cells
DM1C4UM	MI	TT2WOUQ
DM1C4UM	MN	Laminin beta-3 chain (LAMB3)
DM1C4UM	MT	DTT
DM1C4UM	MA	Modulator
DM1C4UM	RN	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006 Dec;12(12):1397-402.
DM1C4UM	RU	https://pubmed.ncbi.nlm.nih.gov/17115047

DMV80DP	DI	DMV80DP
DMV80DP	DN	LAS-186323
DMV80DP	MI	TTLVP78
DMV80DP	MN	Dihydroorotate dehydrogenase (DHODH)
DMV80DP	MT	DTT
DMV80DP	MA	Inhibitor
DMV80DP	RN	Clinical pipeline report, company report or official report of Aslanpharma.
DMV80DP	RU	http://www.aslanpharma.com/download/Press%20Release%20-%20Almirall-ASLAN%20Licensing.pdf

DM4YA0D	DI	DM4YA0D
DM4YA0D	DN	LBR-101
DM4YA0D	MI	TTY6O0Q
DM4YA0D	MN	Calcitonin gene-related peptide receptor (CGRPR)
DM4YA0D	MT	DTT
DM4YA0D	RN	Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.
DM4YA0D	RU	https://pubmed.ncbi.nlm.nih.gov/24366980

DMJEACT	DI	DMJEACT
DMJEACT	DN	LC-1
DMJEACT	MI	TTSXVID
DMJEACT	MN	Nuclear factor NF-kappa-B (NFKB)
DMJEACT	MT	DTT
DMJEACT	MA	Inhibitor
DMJEACT	RN	A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494.
DMJEACT	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982935/

DMHT3CB	DI	DMHT3CB
DMHT3CB	DN	LC-350189
DMHT3CB	MI	TT7RJY8
DMHT3CB	MN	Xanthine dehydrogenase/oxidase (XDH)
DMHT3CB	MT	DTT
DMHT3CB	MA	Inhibitor
DMHT3CB	RN	Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
DMHT3CB	RU	https://pubmed.ncbi.nlm.nih.gov/26357467

DMEY2LK	DI	DMEY2LK
DMEY2LK	DN	LCAR-B4822M CAR-T Cell
DMEY2LK	MI	TTZ3P4W
DMEY2LK	MN	B-cell maturation protein (TNFRSF17)
DMEY2LK	MT	DTT
DMEY2LK	MA	CAR-T-Cell-Therapy
DMEY2LK	RN	ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
DMEY2LK	RU	https://clinicaltrials.gov/ct2/show/NCT03674463

DM9LYXQ	DI	DM9LYXQ
DM9LYXQ	DN	Leflunomide
DM9LYXQ	MI	TT3UY29
DM9LYXQ	MN	HUMAN dihydroorotate dehydrogenase (DHODH)
DM9LYXQ	MT	DTT
DM9LYXQ	MA	Inhibitor
DM9LYXQ	RN	On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w.
DM9LYXQ	RU	https://pubmed.ncbi.nlm.nih.gov/23452331

DMKZVLH	DI	DMKZVLH
DMKZVLH	DN	Lefradafiban
DMKZVLH	MI	TT38RM1
DMKZVLH	MN	Glycoprotein IIb/IIIa receptor (GPIIb/IIIa)
DMKZVLH	MT	DTT
DMKZVLH	MA	Modulator
DMKZVLH	RN	Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.
DMKZVLH	RU	https://pubmed.ncbi.nlm.nih.gov/11250974

DM5INZP	DI	DM5INZP
DM5INZP	DN	LEQ-506
DM5INZP	MI	TT8J1S3
DM5INZP	MN	Smoothened homolog (SMO)
DM5INZP	MT	DTT
DM5INZP	MA	Inhibitor
DM5INZP	RN	Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
DM5INZP	RU	https://pubmed.ncbi.nlm.nih.gov/23821351

DMNHPOT	DI	DMNHPOT
DMNHPOT	DN	LErafAON
DMNHPOT	MI	TTAN5W2
DMNHPOT	MN	Raf messenger RNA (Raf mRNA)
DMNHPOT	MT	DTT
DMNHPOT	RN	Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
DMNHPOT	RU	https://pubmed.ncbi.nlm.nih.gov/15014358

DM2B0TJ	DI	DM2B0TJ
DM2B0TJ	DN	Leukocyte interleukin
DM2B0TJ	MI	TT9721Y
DM2B0TJ	MN	Interleukin 2 receptor beta (IL2RB)
DM2B0TJ	MT	DTT
DM2B0TJ	MA	Modulator
DM2B0TJ	RN	Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64.
DM2B0TJ	RU	https://pubmed.ncbi.nlm.nih.gov/7650289

DMI4O92	DI	DMI4O92
DMI4O92	DN	LFA-102
DMI4O92	MI	TTBPXMA
DMI4O92	MN	Prolactin receptor (PRLR)
DMI4O92	MT	DTT
DMI4O92	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721).
DMI4O92	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1721

DMAG6BV	DI	DMAG6BV
DMAG6BV	DN	LGK974
DMAG6BV	MI	TTNFBTO
DMAG6BV	MN	Protein-serine O-palmitoleoyltransferase porcupine (PORCN)
DMAG6BV	MT	DTT
DMAG6BV	MA	Inhibitor
DMAG6BV	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMAG6BV	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYK52O	DI	DMYK52O
DMYK52O	DN	LHC165
DMYK52O	MI	TTRJ1K4
DMYK52O	MN	Toll-like receptor 7 (TLR7)
DMYK52O	MT	DTT
DMYK52O	MA	Agonist
DMYK52O	RN	Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238.
DMYK52O	RU	https://pubmed.ncbi.nlm.nih.gov/32203790

DMFNSHM	DI	DMFNSHM
DMFNSHM	DN	LHF-535
DMFNSHM	MI	TTD2IK3
DMFNSHM	MN	Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC)
DMFNSHM	MT	DTT
DMFNSHM	MA	Inhibitor
DMFNSHM	RN	A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439.
DMFNSHM	RU	https://pubmed.ncbi.nlm.nih.gov/30576397

DMJRALD	DI	DMJRALD
DMJRALD	DN	LIPO-4
DMJRALD	MI	TTN2JFW
DMJRALD	MN	T-cell surface glycoprotein CD4 (CD4)
DMJRALD	MT	DTT
DMJRALD	RN	Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
DMJRALD	RU	https://pubmed.ncbi.nlm.nih.gov/23850610

DMJRALD	DI	DMJRALD
DMJRALD	DN	LIPO-4
DMJRALD	MI	TTMHA6L
DMJRALD	MN	T-cell surface glycoprotein CD8 (CD8)
DMJRALD	MT	DTT
DMJRALD	RN	Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
DMJRALD	RU	https://pubmed.ncbi.nlm.nih.gov/23850610

DMESZQU	DI	DMESZQU
DMESZQU	DN	Litenimod
DMESZQU	MI	TTSHG0T
DMESZQU	MN	Toll-like receptor 9 (TLR9)
DMESZQU	MT	DTT
DMESZQU	MA	Modulator
DMESZQU	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DMESZQU	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DMR7LKC	DI	DMR7LKC
DMR7LKC	DN	LM-CD45
DMR7LKC	MI	TTUS45N
DMR7LKC	MN	Leukocyte common antigen (PTPRC)
DMR7LKC	MT	DTT
DMR7LKC	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
DMR7LKC	RU	http://adisinsight.springer.com/drugs/800002932

DMU901D	DI	DMU901D
DMU901D	DN	L-MDAM
DMU901D	MI	TTYZVDJ
DMU901D	MN	Dihydrofolate reductase (DHFR)
DMU901D	MT	DTT
DMU901D	MA	Inhibitor
DMU901D	RN	Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
DMU901D	RU	https://pubmed.ncbi.nlm.nih.gov/9816221

DMZU2G1	DI	DMZU2G1
DMZU2G1	DN	LMP-1/LMP-2 CTLs
DMZU2G1	MI	TT0BI4Q
DMZU2G1	MN	Epstein-Barr virus Latent membrane protein 1 (EBV LMP1)
DMZU2G1	MT	DTT
DMZU2G1	MA	Modulator
DMZU2G1	RN	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
DMZU2G1	RU	https://pubmed.ncbi.nlm.nih.gov/16753867

DMZU2G1	DI	DMZU2G1
DMZU2G1	DN	LMP-1/LMP-2 CTLs
DMZU2G1	MI	TTBK351
DMZU2G1	MN	Epstein-Barr virus Latent membrane protein 2 (EBV LMP2)
DMZU2G1	MT	DTT
DMZU2G1	MA	Modulator
DMZU2G1	RN	In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42.
DMZU2G1	RU	https://pubmed.ncbi.nlm.nih.gov/16753867

DM4FW2E	DI	DM4FW2E
DM4FW2E	DN	LMP400
DM4FW2E	MI	TTGTQHC
DM4FW2E	MN	DNA topoisomerase I (TOP1)
DM4FW2E	MT	DTT
DM4FW2E	MA	Inhibitor
DM4FW2E	RN	Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
DM4FW2E	RU	https://pubmed.ncbi.nlm.nih.gov/31227499

DMUCQYW	DI	DMUCQYW
DMUCQYW	DN	LMP744
DMUCQYW	MI	TTGTQHC
DMUCQYW	MN	DNA topoisomerase I (TOP1)
DMUCQYW	MT	DTT
DMUCQYW	MA	Inhibitor
DMUCQYW	RN	Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589.
DMUCQYW	RU	https://pubmed.ncbi.nlm.nih.gov/31227499

DM9OA35	DI	DM9OA35
DM9OA35	DN	Long-acting erythropoietin conjugate
DM9OA35	MI	TTQG4NR
DM9OA35	MN	Erythropoietin (EPO)
DM9OA35	MT	DTT
DM9OA35	MA	Modulator
DM9OA35	RN	Company report (Pharmexcil)
DM9OA35	RU	http://www.pharmexcil.com/v1/docs/KoreanCompanies/hanmi.pdf

DMCKE90	DI	DMCKE90
DMCKE90	DN	Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules
DMCKE90	MI	TT1D53B
DMCKE90	MN	COVID-19 3C-like protease (3CLpro)
DMCKE90	MT	DTT
DMCKE90	MA	Inhibitor
DMCKE90	RN	Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381.
DMCKE90	RU	https://pubmed.ncbi.nlm.nih.gov/32205870

DMDLTCU	DI	DMDLTCU
DMDLTCU	DN	Lotilibcin
DMDLTCU	MI	TTXT4D5
DMDLTCU	MN	Bacterial Cell membrane (Bact CM)
DMDLTCU	MT	DTT
DMDLTCU	MA	Modulator
DMDLTCU	RN	Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287.
DMDLTCU	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468324/

DMDXFBJ	DI	DMDXFBJ
DMDXFBJ	DN	LOXO-195
DMDXFBJ	MI	TTTDVOJ
DMDXFBJ	MN	Tropomyosin-related kinase A (TrkA)
DMDXFBJ	MT	DTT
DMDXFBJ	MA	Inhibitor
DMDXFBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDXFBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYIXQZ	DI	DMYIXQZ
DMYIXQZ	DN	LP-108
DMYIXQZ	MI	TTJGNVC
DMYIXQZ	MN	Apoptosis regulator Bcl-2 (BCL-2)
DMYIXQZ	MT	DTT
DMYIXQZ	RN	National Cancer Institute Drug Dictionary (drug name LP-108).
DMYIXQZ	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-lp-108

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DE0JX6R
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DE8J31V
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEIEY19
DM8VBQJ	MN	Beta-galactosidase (bgaB)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEH2VKT
DM8VBQJ	MN	Glycoside hydrolase (cscA)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEWNRL1
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEDZECR
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM8VBQJ	DI	DM8VBQJ
DM8VBQJ	DN	LS-69767
DM8VBQJ	MI	DEPDE7J
DM8VBQJ	MN	Glycosyl hydrolase (glyH)
DM8VBQJ	MT	DME
DM8VBQJ	MA	Metabolism
DM8VBQJ	RN	In vitro fermentation of fructooligosaccharides with human gut bacteria. Food Funct. 2015 Mar;6(3):947-54.
DM8VBQJ	RU	https://pubmed.ncbi.nlm.nih.gov/25653214

DM94E6W	DI	DM94E6W
DM94E6W	DN	LTT462
DM94E6W	MI	TTVOE6D
DM94E6W	MN	Mitogen-activated protein kinase (MAPK)
DM94E6W	MT	DTT
DM94E6W	MA	Inhibitor
DM94E6W	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM94E6W	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQ0K95	DI	DMQ0K95
DMQ0K95	DN	Lu-02-750
DMQ0K95	MI	TTEX248
DMQ0K95	MN	Dopamine D2 receptor (D2R)
DMQ0K95	MT	DTT
DMQ0K95	MA	Agonist
DMQ0K95	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031195)
DMQ0K95	RU	http://adisinsight.springer.com/drugs/800031195

DMP9UO0	DI	DMP9UO0
DMP9UO0	DN	Lu-AE04621
DMP9UO0	MI	TTEX248
DMP9UO0	MN	Dopamine D2 receptor (D2R)
DMP9UO0	MT	DTT
DMP9UO0	MA	Modulator
DMP9UO0	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031909)
DMP9UO0	RU	http://adisinsight.springer.com/drugs/800031909

DMQI970	DI	DMQI970
DMQI970	DN	Lumoxiti
DMQI970	MI	TTM6QSK
DMQI970	MN	B-cell receptor CD22 (CD22)
DMQI970	MT	DTT
DMQI970	MA	Inhibitor
DMQI970	RN	Clinical pipeline report, company report or official report of Innate Pharma.
DMQI970	RU	https://www.innate-pharma.com/fr/produits/lumoxiti

DMPQE2S	DI	DMPQE2S
DMPQE2S	DN	LVGN6051
DMPQE2S	MI	TTPW9LJ
DMPQE2S	MN	Co-stimulatory molecule 4-1BB (CD137)
DMPQE2S	MT	DTT
DMPQE2S	MA	Activator
DMPQE2S	RN	Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141.
DMPQE2S	RU	https://pubmed.ncbi.nlm.nih.gov/31105267

DM8ZS7T	DI	DM8ZS7T
DM8ZS7T	DN	LX2761
DM8ZS7T	MI	TT2UE56
DM8ZS7T	MN	Sodium/glucose cotransporter 1 (SGLT1)
DM8ZS7T	MT	DTT
DM8ZS7T	MA	Inhibitor
DM8ZS7T	RN	Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
DM8ZS7T	RU	https://www.lexpharma.com/pipeline/lx2761

DMO548K	DI	DMO548K
DMO548K	DN	LX9211
DMO548K	MI	TT0Z32T
DMO548K	MN	Adaptor-associated kinase 1 (AAK1)
DMO548K	MT	DTT
DMO548K	MA	Inhibitor
DMO548K	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMO548K	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMQE9PS	DI	DMQE9PS
DMQE9PS	DN	LXH254
DMQE9PS	MI	TTAN5W2
DMQE9PS	MN	Raf messenger RNA (Raf mRNA)
DMQE9PS	MT	DTT
DMQE9PS	MA	Inhibitor
DMQE9PS	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQE9PS	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3OP41	DI	DM3OP41
DM3OP41	DN	LXR 623
DM3OP41	MI	TTM1EQF
DM3OP41	MN	Oxysterols receptor LXR (NR1H)
DM3OP41	MT	DTT
DM3OP41	MA	Modulator
DM3OP41	RN	Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44.
DM3OP41	RU	https://pubmed.ncbi.nlm.nih.gov/24833295

DMCBV20	DI	DMCBV20
DMCBV20	DN	LY-2334737
DMCBV20	MI	TTUTN1I
DMCBV20	MN	Human Deoxyribonucleic acid (hDNA)
DMCBV20	MT	DTT
DMCBV20	MA	Modulator
DMCBV20	RN	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
DMCBV20	RU	https://pubmed.ncbi.nlm.nih.gov/23616084

DMCBV20	DI	DMCBV20
DMCBV20	DN	LY-2334737
DMCBV20	MI	TTBWDI0
DMCBV20	MN	Ribonucleoside-diphosphate reductase M2 (RRM2)
DMCBV20	MT	DTT
DMCBV20	MA	Modulator
DMCBV20	RN	Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55.
DMCBV20	RU	https://pubmed.ncbi.nlm.nih.gov/23616084

DML8M3B	DI	DML8M3B
DML8M3B	DN	LY-2584702
DML8M3B	MI	TT7M3PI
DML8M3B	MN	Ribosomal protein S6 kinase (S6K)
DML8M3B	MT	DTT
DML8M3B	MA	Modulator
DML8M3B	RN	A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.
DML8M3B	RU	https://www.ncbi.nlm.nih.gov/pubmed/24456794

DM289Z4	DI	DM289Z4
DM289Z4	DN	LY2624587
DM289Z4	MI	TTBID49
DM289Z4	MN	C-X-C chemokine receptor type 4 (CXCR4)
DM289Z4	MT	DTT
DM289Z4	MA	Antagonist
DM289Z4	RN	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585.
DM289Z4	RU	https://pubmed.ncbi.nlm.nih.gov/26954567

DM93AJW	DI	DM93AJW
DM93AJW	DN	LY2780301
DM93AJW	MI	TTAZ05C
DM93AJW	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM93AJW	MT	DTT
DM93AJW	MA	Modulator
DM93AJW	RN	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
DM93AJW	RU	https://pubmed.ncbi.nlm.nih.gov/25902900

DM93AJW	DI	DM93AJW
DM93AJW	DN	LY2780301
DM93AJW	MI	TT7M3PI
DM93AJW	MN	Ribosomal protein S6 kinase (S6K)
DM93AJW	MT	DTT
DM93AJW	MA	Modulator
DM93AJW	RN	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
DM93AJW	RU	https://pubmed.ncbi.nlm.nih.gov/25902900

DM9NYHT	DI	DM9NYHT
DM9NYHT	DN	LY2787106
DM9NYHT	MI	TTPCG5T
DM9NYHT	MN	Hepcidin (HAMP)
DM9NYHT	MT	DTT
DM9NYHT	MA	Inhibitor
DM9NYHT	RN	A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73.
DM9NYHT	RU	https://www.ncbi.nlm.nih.gov/pubmed/28327200

DM8LGWR	DI	DM8LGWR
DM8LGWR	DN	LY-2811376
DM8LGWR	MI	TT8JRS7
DM8LGWR	MN	Beta-secretase (BACE)
DM8LGWR	MT	DTT
DM8LGWR	MA	Inhibitor
DM8LGWR	RN	Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012).
DM8LGWR	RU	http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html

DM8LGWR	DI	DM8LGWR
DM8LGWR	DN	LY-2811376
DM8LGWR	MI	DE4LYSA
DM8LGWR	MN	Cytochrome P450 3A4 (CYP3A4)
DM8LGWR	MT	DME
DM8LGWR	MA	Metabolism
DM8LGWR	RN	Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011 Nov 16;31(46):16507-16.
DM8LGWR	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=22090477

DM5EXJV	DI	DM5EXJV
DM5EXJV	DN	LY-2881835
DM5EXJV	MI	TTB8FUC
DM5EXJV	MN	Free fatty acid receptor 1 (GPR40)
DM5EXJV	MT	DTT
DM5EXJV	MA	Modulator
DM5EXJV	RN	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
DM5EXJV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/

DMGLTE2	DI	DMGLTE2
DMGLTE2	DN	LY2922470
DMGLTE2	MI	TTB8FUC
DMGLTE2	MN	Free fatty acid receptor 1 (GPR40)
DMGLTE2	MT	DTT
DMGLTE2	MA	Agonist
DMGLTE2	RN	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.
DMGLTE2	RU	https://pubmed.ncbi.nlm.nih.gov/27749056

DMY1AFS	DI	DMY1AFS
DMY1AFS	DN	LY294002
DMY1AFS	MI	TTHBTOP
DMY1AFS	MN	PI3-kinase gamma (PIK3CG)
DMY1AFS	MT	DTT
DMY1AFS	MA	Inhibitor
DMY1AFS	RN	Clinical pipeline report, company report or official report of Genentech (2009).
DMY1AFS	RU	http://www.gene.com/gene/pipeline/status/

DM16IX2	DI	DM16IX2
DM16IX2	DN	LY-2979165
DM16IX2	MI	TTXJ47W
DM16IX2	MN	Metabotropic glutamate receptor 2 (mGluR2)
DM16IX2	MT	DTT
DM16IX2	MA	Modulator
DM16IX2	RN	Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
DM16IX2	RU	https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=Annual+Reports+in+Medicinal+Chemistry++LY-2979165&source=bl&ots=oPRAtBeGRL&sig=la4YgUxL9zkXRln2i4EVFFFVzUg&hl=zh-CN&sa=X&ved=0CB4Q6AEwAGoVChMIsbb8qP3FyAIVC1iOCh3bcgiX#v=onepage&q=Annual%20Reports%20in%20Medicinal%20Chemistry%20%20LY-2979165&f=false

DM6PFCN	DI	DM6PFCN
DM6PFCN	DN	LY3009120
DM6PFCN	MI	TTQ9K3Y
DM6PFCN	MN	Serine/threonine-protein kinase Raf (RAF)
DM6PFCN	MT	DTT
DM6PFCN	MA	Modulator
DM6PFCN	RN	Company report (eli lily)
DM6PFCN	RU	http://www.lillyoncologypipeline.com/pan-raf-inhibitor.aspx

DMJPCHK	DI	DMJPCHK
DMJPCHK	DN	LY309887
DMJPCHK	MI	TTEXB9Z
DMJPCHK	MN	Glycinamide ribonucleotide formyltransferase (GART)
DMJPCHK	MT	DTT
DMJPCHK	MA	Inhibitor
DMJPCHK	RN	New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7.
DMJPCHK	RU	https://pubmed.ncbi.nlm.nih.gov/9717984

DM5OP86	DI	DM5OP86
DM5OP86	DN	LY3127804
DM5OP86	MI	TTKLQTJ
DM5OP86	MN	Angiopoietin-2 (ANGPT2)
DM5OP86	MT	DTT
DM5OP86	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM5OP86	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM9RTXM	DI	DM9RTXM
DM9RTXM	DN	LY3164530
DM9RTXM	MI	TTGKNB4
DM9RTXM	MN	Epidermal growth factor receptor (EGFR)
DM9RTXM	MT	DTT
DM9RTXM	MA	Modulator
DM9RTXM	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM9RTXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DM9RTXM	DI	DM9RTXM
DM9RTXM	DN	LY3164530
DM9RTXM	MI	TTNDSF4
DM9RTXM	MN	Proto-oncogene c-Met (MET)
DM9RTXM	MT	DTT
DM9RTXM	MA	Modulator
DM9RTXM	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DM9RTXM	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMQP6VB	DI	DMQP6VB
DMQP6VB	DN	LY3200882
DMQP6VB	MI	TTP4520
DMQP6VB	MN	TGF-beta receptor type I (TGFBR1)
DMQP6VB	MT	DTT
DMQP6VB	MA	Inhibitor
DMQP6VB	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQP6VB	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFDAY7	DI	DMFDAY7
DMFDAY7	DN	LY3214996
DMFDAY7	MI	TT4TQBX
DMFDAY7	MN	Extracellular signal-regulated kinase 2 (ERK2)
DMFDAY7	MT	DTT
DMFDAY7	MA	Inhibitor
DMFDAY7	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFDAY7	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMOV2ML	DI	DMOV2ML
DMOV2ML	DN	LY3300054
DMOV2ML	MI	TT8ZLTI
DMOV2ML	MN	Programmed cell death 1 ligand 1 (PD-L1)
DMOV2ML	MT	DTT
DMOV2ML	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMOV2ML	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMG6HLE	DI	DMG6HLE
DMG6HLE	DN	LY3303560
DMG6HLE	MI	TTS87KH
DMG6HLE	MN	Microtubule-associated protein tau (MAPT)
DMG6HLE	MT	DTT
DMG6HLE	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG6HLE	RU	http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf

DMD51GC	DI	DMD51GC
DMD51GC	DN	LY3321367
DMD51GC	MI	TT1RWL7
DMD51GC	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DMD51GC	MT	DTT
DMD51GC	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMD51GC	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMONZ1L	DI	DMONZ1L
DMONZ1L	DN	LY3381916
DMONZ1L	MI	TTZJYKH
DMONZ1L	MN	Indoleamine 2,3-dioxygenase 1 (IDO1)
DMONZ1L	MT	DTT
DMONZ1L	MA	Inhibitor
DMONZ1L	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMONZ1L	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMB51K2	DI	DMB51K2
DMB51K2	DN	LY3405105
DMB51K2	MI	TTQYF7G
DMB51K2	MN	Cyclin-dependent kinase 7 (CDK7)
DMB51K2	MT	DTT
DMB51K2	MA	Inhibitor
DMB51K2	RN	CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
DMB51K2	RU	https://pubmed.ncbi.nlm.nih.gov/32385714

DMFU0H5	DI	DMFU0H5
DMFU0H5	DN	LY3410738
DMFU0H5	MI	TTV2A1R
DMFU0H5	MN	Oxalosuccinate decarboxylase (IDH1)
DMFU0H5	MT	DTT
DMFU0H5	MA	Inhibitor
DMFU0H5	RN	LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML).  Cancer Res 2020;80(16 Suppl):Abstract nr 6417.
DMFU0H5	RU	https://cancerres.aacrjournals.org/content/80/16_Supplement/6417

DM5QO1A	DI	DM5QO1A
DM5QO1A	DN	LY3415244
DM5QO1A	MI	TT1RWL7
DM5QO1A	MN	Hepatitis A virus cellular receptor 2 (TIM3)
DM5QO1A	MT	DTT
DM5QO1A	MA	Inhibitor
DM5QO1A	RN	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
DM5QO1A	RU	https://pubmed.ncbi.nlm.nih.gov/33441294

DM5QO1A	DI	DM5QO1A
DM5QO1A	DN	LY3415244
DM5QO1A	MI	TT8ZLTI
DM5QO1A	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM5QO1A	MT	DTT
DM5QO1A	MA	Inhibitor
DM5QO1A	RN	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
DM5QO1A	RU	https://pubmed.ncbi.nlm.nih.gov/33441294

DMZLIWX	DI	DMZLIWX
DMZLIWX	DN	LY3475070
DMZLIWX	MI	TTK0O6Y
DMZLIWX	MN	Ecto-5'-nucleotidase (CD73)
DMZLIWX	MT	DTT
DMZLIWX	MA	Inhibitor
DMZLIWX	RN	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
DMZLIWX	RU	https://pubmed.ncbi.nlm.nih.gov/32351498

DMY8W3S	DI	DMY8W3S
DMY8W3S	DN	LY3484356
DMY8W3S	MI	TTZAYWL
DMY8W3S	MN	Estrogen receptor (ESR)
DMY8W3S	MT	DTT
DMY8W3S	MA	Degrader
DMY8W3S	RN	ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health.
DMY8W3S	RU	https://clinicaltrials.gov/ct2/show/NCT04647487

DMLXGAI	DI	DMLXGAI
DMLXGAI	DN	LYS-6KAKT1
DMLXGAI	MI	TTAZ05C
DMLXGAI	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DMLXGAI	MT	DTT
DMLXGAI	MA	Modulator
DMLXGAI	RN	DOI: 10.1016/S1359-6349(10)71767-5
DMLXGAI	RU	https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer

DMLXGAI	DI	DMLXGAI
DMLXGAI	DN	LYS-6KAKT1
DMLXGAI	MI	TT7M3PI
DMLXGAI	MN	Ribosomal protein S6 kinase (S6K)
DMLXGAI	MT	DTT
DMLXGAI	MA	Modulator
DMLXGAI	RN	DOI: 10.1016/S1359-6349(10)71767-5
DMLXGAI	RU	https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer

DMHDCSL	DI	DMHDCSL
DMHDCSL	DN	LZM009
DMHDCSL	MI	TTNBFWK
DMHDCSL	MN	Programmed cell death protein 1 (PD-1)
DMHDCSL	MT	DTT
DMHDCSL	RN	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. 
DMHDCSL	RU	https://pubmed.ncbi.nlm.nih.gov/30247903

DMK7UNL	DI	DMK7UNL
DMK7UNL	DN	M-0004
DMK7UNL	MI	TT07C3Y
DMK7UNL	MN	5-HT 4 receptor (HTR4)
DMK7UNL	MT	DTT
DMK7UNL	MA	Agonist
DMK7UNL	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
DMK7UNL	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9

DME6UNO	DI	DME6UNO
DME6UNO	DN	M012
DME6UNO	MI	TT6Y1PG
DME6UNO	MN	Solute carrier family 40 member 1 (SLC40A1)
DME6UNO	MT	DTT
DME6UNO	MA	Agonist
DME6UNO	RN	Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794.
DME6UNO	RU	https://pubmed.ncbi.nlm.nih.gov/29523504

DMP8QY2	DI	DMP8QY2
DMP8QY2	DN	M1774
DMP8QY2	MI	TT8ZYBQ
DMP8QY2	MN	Serine/threonine-protein kinase ATR (FRP1)
DMP8QY2	MT	DTT
DMP8QY2	MA	Inhibitor
DMP8QY2	RN	National Cancer Institute Drug Dictionary (drug name M1774).
DMP8QY2	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-m1774

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTWTSCV
DM3PVBJ	MN	RAC-alpha serine/threonine-protein kinase (AKT1)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTAZ05C
DM3PVBJ	MN	RAC-gamma serine/threonine-protein kinase (AKT3)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM3PVBJ	DI	DM3PVBJ
DM3PVBJ	DN	M2698
DM3PVBJ	MI	TTG0U4H
DM3PVBJ	MN	Ribosomal protein S6 kinase beta-1 (S6K1)
DM3PVBJ	MT	DTT
DM3PVBJ	MA	Inhibitor
DM3PVBJ	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM3PVBJ	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6PI5B	DI	DM6PI5B
DM6PI5B	DN	M3258
DM6PI5B	MI	TTEAD9J
DM6PI5B	MN	Proteasome beta-8 (PS beta-8)
DM6PI5B	MT	DTT
DM6PI5B	MA	Inhibitor
DM6PI5B	RN	Clinical pipeline report, company report or official report of EMD Serono.
DM6PI5B	RU	https://medical.emdserono.com/en_US/home/oncology/m3258.html

DMG98QO	DI	DMG98QO
DMG98QO	DN	M3541
DMG98QO	MI	TTKBM7V
DMG98QO	MN	ATM serine/threonine kinase (ATM)
DMG98QO	MT	DTT
DMG98QO	MA	Inhibitor
DMG98QO	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMG98QO	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMQBO3V	DI	DMQBO3V
DMQBO3V	DN	M4344
DMQBO3V	MI	TT8ZYBQ
DMQBO3V	MN	Serine/threonine-protein kinase ATR (FRP1)
DMQBO3V	MT	DTT
DMQBO3V	MA	Inhibitor
DMQBO3V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQBO3V	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM6J085	DI	DM6J085
DM6J085	DN	M6223
DM6J085	MI	TTWNL74
DM6J085	MN	V-set and immunoglobulin domain-containing protein 9 (TIGIT)
DM6J085	MT	DTT
DM6J085	MA	Inhibitor
DM6J085	RN	ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.
DM6J085	RU	https://clinicaltrials.gov/ct2/show/NCT04457778

DMDK4MG	DI	DMDK4MG
DMDK4MG	DN	M7583
DMDK4MG	MI	TTGM6VW
DMDK4MG	MN	Tyrosine-protein kinase BTK (ATK)
DMDK4MG	MT	DTT
DMDK4MG	MA	Inhibitor
DMDK4MG	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDK4MG	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM132EG	DI	DM132EG
DM132EG	DN	M802
DM132EG	MI	TT6EO5L
DM132EG	MN	Erbb2 tyrosine kinase receptor (HER2)
DM132EG	MT	DTT
DM132EG	MA	Inhibitor
DM132EG	RN	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
DM132EG	RU	https://pubmed.ncbi.nlm.nih.gov/31412896

DM132EG	DI	DM132EG
DM132EG	DN	M802
DM132EG	MI	TTUN7MC
DM132EG	MN	T-cell surface glycoprotein CD3 (CD3)
DM132EG	MT	DTT
DM132EG	MA	Inhibitor
DM132EG	RN	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
DM132EG	RU	https://pubmed.ncbi.nlm.nih.gov/31412896

DMZ9NVP	DI	DMZ9NVP
DMZ9NVP	DN	M8891
DMZ9NVP	MI	TTZL0OI
DMZ9NVP	MN	Methionine aminopeptidase 2 (METAP2)
DMZ9NVP	MT	DTT
DMZ9NVP	MA	Inhibitor
DMZ9NVP	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMZ9NVP	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMZUM67	DI	DMZUM67
DMZUM67	DN	M9241
DMZUM67	MI	TTG68FB
DMZUM67	MN	Interleukine 12 (IL-12)
DMZUM67	MT	DTT
DMZUM67	MA	Replacement
DMZUM67	RN	Clinical pipeline report, company report or official report of EMD Serono.
DMZUM67	RU	https://medical.emdserono.com/content/healthcare/biopharma/usmi/en_US/home/immuno-oncology/m9241--nhs-il12--.html

DM59TI2	DI	DM59TI2
DM59TI2	DN	M9831
DM59TI2	MI	TTK3PY9
DM59TI2	MN	DNA-dependent protein kinase catalytic (PRKDC)
DM59TI2	MT	DTT
DM59TI2	MA	Inhibitor
DM59TI2	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM59TI2	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0HKU7	DI	DM0HKU7
DM0HKU7	DN	Macozinone
DM0HKU7	MI	TTLOHU4
DM0HKU7	MN	Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1)
DM0HKU7	MT	DTT
DM0HKU7	MA	Inhibitor
DM0HKU7	RN	Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351.
DM0HKU7	RU	https://pubmed.ncbi.nlm.nih.gov/30891138

DM9F15C	DI	DM9F15C
DM9F15C	DN	MAU868
DM9F15C	MI	TT09JLE
DM9F15C	MN	BV virus Major capsid protein VP1 (BKV VP1)
DM9F15C	MT	DTT
DM9F15C	MA	Inhibitor
DM9F15C	RN	Clinical pipeline report, company report or official report of Amplyx Pharmaceuticals.
DM9F15C	RU	https://amplyx.com/our-pipeline/

DMMP7XG	DI	DMMP7XG
DMMP7XG	DN	MAXY-4
DMMP7XG	MI	TTFZDNP
DMMP7XG	MN	Activation B7-1 antigen (CD80)
DMMP7XG	MT	DTT
DMMP7XG	MA	Inhibitor
DMMP7XG	RN	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
DMMP7XG	RU	https://pubmed.ncbi.nlm.nih.gov/21474713

DMMP7XG	DI	DMMP7XG
DMMP7XG	DN	MAXY-4
DMMP7XG	MI	TTHGXBU
DMMP7XG	MN	T-lymphocyte activation antigen CD86 (FUN1)
DMMP7XG	MT	DTT
DMMP7XG	MA	Inhibitor
DMMP7XG	RN	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
DMMP7XG	RU	https://pubmed.ncbi.nlm.nih.gov/21474713

DMSZ8HT	DI	DMSZ8HT
DMSZ8HT	DN	MazF gene therapy
DMSZ8HT	MI	TTRBUYN
DMSZ8HT	MN	Ribonuclease (RNase)
DMSZ8HT	MT	DTT
DMSZ8HT	MA	Modulator
DMSZ8HT	RN	Clinical pipeline report, company report or official report of Takara Bio.
DMSZ8HT	RU	http://www.takara-bio.com/medi_e/

DMLA1QD	DI	DMLA1QD
DMLA1QD	DN	MB-101
DMLA1QD	MI	TTMPZ7V
DMLA1QD	MN	Interleukin 13 receptor alpha-2 (IL13RA2)
DMLA1QD	MT	DTT
DMLA1QD	MA	Immunomodulator
DMLA1QD	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMLA1QD	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMS0P5O	DI	DMS0P5O
DMS0P5O	DN	MB-103
DMS0P5O	MI	TT6EO5L
DMS0P5O	MN	Erbb2 tyrosine kinase receptor (HER2)
DMS0P5O	MT	DTT
DMS0P5O	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMS0P5O	RU	https://www.mustangbio.com/pipeline/

DMRP4BM	DI	DMRP4BM
DMRP4BM	DN	MB-104
DMRP4BM	MI	TT7ILZ1
DMRP4BM	MN	SLAM family member 7 SLAMF7 (CS1)
DMRP4BM	MT	DTT
DMRP4BM	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMRP4BM	RU	https://www.mustangbio.com/pipeline/

DMVGTP6	DI	DMVGTP6
DMVGTP6	DN	MB-105
DMVGTP6	MI	TT9T4AV
DMVGTP6	MN	Prostate stem cell antigen (PSCA)
DMVGTP6	MT	DTT
DMVGTP6	RN	Clinical pipeline report, company report or official report of Mustang Bio.
DMVGTP6	RU	https://www.mustangbio.com/pipeline/

DMPE0KD	DI	DMPE0KD
DMPE0KD	DN	MB-110
DMPE0KD	MI	TTCJ2X8
DMPE0KD	MN	Hepatitis C virus Non-structural 5A (HCV NS5A)
DMPE0KD	MT	DTT
DMPE0KD	MA	Inhibitor
DMPE0KD	RN	Clinical pipeline report, company report or official report of Microbio.
DMPE0KD	RU	https://www.microbio.com.tw/home_03.php?p=7&a=15

DM85AXS	DI	DM85AXS
DM85AXS	DN	MBS301
DM85AXS	MI	TT6EO5L
DM85AXS	MN	Erbb2 tyrosine kinase receptor (HER2)
DM85AXS	MT	DTT
DM85AXS	MA	Inhibitor
DM85AXS	RN	Clinical pipeline report, company report or official report of Beijing Mabworks Biotech.
DM85AXS	RU	http://www.mab-works.com/product/5.html

DMTXIZ1	DI	DMTXIZ1
DMTXIZ1	DN	MBX-700
DMTXIZ1	MI	TTMVBWH
DMTXIZ1	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMTXIZ1	MT	DTT
DMTXIZ1	MA	Inhibitor
DMTXIZ1	RN	Clinical pipeline report, company report or official report of Microbiotix Inc.
DMTXIZ1	RU	http://www.microbiotix.com/therapeutic-programs-hcv.htm

DMFIS4D	DI	DMFIS4D
DMFIS4D	DN	MCD-386
DMFIS4D	MI	TTZ9SOR
DMFIS4D	MN	Muscarinic acetylcholine receptor M1 (CHRM1)
DMFIS4D	MT	DTT
DMFIS4D	MA	Agonist
DMFIS4D	RN	The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5.
DMFIS4D	RU	https://pubmed.ncbi.nlm.nih.gov/16041192

DM8CGUV	DI	DM8CGUV
DM8CGUV	DN	MCLA-145
DM8CGUV	MI	TTPW9LJ
DM8CGUV	MN	Co-stimulatory molecule 4-1BB (CD137)
DM8CGUV	MT	DTT
DM8CGUV	MA	Agonist
DM8CGUV	RN	Clinical pipeline report, company report or official report of Merus.
DM8CGUV	RU	https://merus.nl/publication-category/mcla-145/

DM8CGUV	DI	DM8CGUV
DM8CGUV	DN	MCLA-145
DM8CGUV	MI	TT8ZLTI
DM8CGUV	MN	Programmed cell death 1 ligand 1 (PD-L1)
DM8CGUV	MT	DTT
DM8CGUV	MA	Agonist
DM8CGUV	RN	Clinical pipeline report, company report or official report of Merus.
DM8CGUV	RU	https://merus.nl/pipeline/

DMF0O3X	DI	DMF0O3X
DMF0O3X	DN	MCLA-158
DMF0O3X	MI	TTGKNB4
DMF0O3X	MN	Epidermal growth factor receptor (EGFR)
DMF0O3X	MT	DTT
DMF0O3X	MA	Inhibitor
DMF0O3X	RN	Clinical pipeline report, company report or official report of Merus.
DMF0O3X	RU	https://merus.nl/pipeline/

DMF0O3X	DI	DMF0O3X
DMF0O3X	DN	MCLA-158
DMF0O3X	MI	TTTSGRH
DMF0O3X	MN	Leucine-rich repeat-containing GPCR 5 (LGR5)
DMF0O3X	MT	DTT
DMF0O3X	MA	Inhibitor
DMF0O3X	RN	Clinical pipeline report, company report or official report of Merus.
DMF0O3X	RU	https://merus.nl/pipeline/

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TT27RFC
DMW9YOJ	MN	Opioid receptor delta (OPRD1)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TTQW87Y
DMW9YOJ	MN	Opioid receptor kappa (OPRK1)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DMW9YOJ	DI	DMW9YOJ
DMW9YOJ	DN	MCP-201
DMW9YOJ	MI	TTKWM86
DMW9YOJ	MN	Opioid receptor mu (MOP)
DMW9YOJ	MT	DTT
DMW9YOJ	MA	Agonist
DMW9YOJ	RN	US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same.
DMW9YOJ	RU	http://www.google.com/patents/US6924288

DM65B7G	DI	DM65B7G
DM65B7G	DN	MCP-202
DM65B7G	MI	TT27RFC
DM65B7G	MN	Opioid receptor delta (OPRD1)
DM65B7G	MT	DTT
DM65B7G	MA	Agonist
DM65B7G	RN	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018026)
DM65B7G	RU	http://adisinsight.springer.com/drugs/800018026

DMAESQI	DI	DMAESQI
DMAESQI	DN	MCY-M11
DMAESQI	MI	TT4RXME
DMAESQI	MN	Mesothelin (MSLN)
DMAESQI	MT	DTT
DMAESQI	RN	Clinical pipeline report, company report or official report of MaxCyte.
DMAESQI	RU	https://maxcyte.com/carma-cell-therapies-expands-phase-i-trial-of-anti-mesothelin-mrna-car-pbmc-cell-therapy-mcy-m11/

DM1DISM	DI	DM1DISM
DM1DISM	DN	MDAM (y-methylene-10-deazaaminopterin)
DM1DISM	MI	TTYZVDJ
DM1DISM	MN	Dihydrofolate reductase (DHFR)
DM1DISM	MT	DTT
DM1DISM	MA	Inhibitor
DM1DISM	RN	Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
DM1DISM	RU	https://pubmed.ncbi.nlm.nih.gov/3275776

DMAQ24G	DI	DMAQ24G
DMAQ24G	DN	MDCO-216
DMAQ24G	MI	TT7GN3U
DMAQ24G	MN	Apolipoprotein A-I (APOA1)
DMAQ24G	MT	DTT
DMAQ24G	MA	Modulator
DMAQ24G	RN	MDCO-216 (Apo A-I Milano/POPC Complex) Administered to Cynomolgus Monkeys Induces Pronounced Changes in Plasma Lipids and Apolipoproteins. Circulation. 2011; 124: A10978.
DMAQ24G	RU	https://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A10978

DMC60S8	DI	DMC60S8
DMC60S8	DN	MDL-27531
DMC60S8	MI	TTZ8EM9
DMC60S8	MN	Glycine receptor (GlyR)
DMC60S8	MT	DTT
DMC60S8	MA	Modulator
DMC60S8	RN	MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5.
DMC60S8	RU	https://pubmed.ncbi.nlm.nih.gov/1480315

DML5FX2	DI	DML5FX2
DML5FX2	DN	MDX-018
DML5FX2	MI	TTCTE1G
DML5FX2	MN	Interleukin-8 (IL8)
DML5FX2	MT	DTT
DML5FX2	MA	Modulator
DML5FX2	RN	Company report (Genmab)
DML5FX2	RU	http://www.genmab.com/product-pipeline/products-in-development/humax-il8

DM0RIQF	DI	DM0RIQF
DM0RIQF	DN	MDX-1203
DM0RIQF	MI	TTNCIE0
DM0RIQF	MN	CD70 antigen (CD27-L)
DM0RIQF	MT	DTT
DM0RIQF	RN	J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
DM0RIQF	RU	http://meetinglibrary.asco.org/content/130447-144

DM3402P	DI	DM3402P
DM3402P	DN	MDX-1411
DM3402P	MI	TTNCIE0
DM3402P	MN	CD70 antigen (CD27-L)
DM3402P	MT	DTT
DM3402P	RN	Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
DM3402P	RU	https://pubmed.ncbi.nlm.nih.gov/19741612

DMEMQ5J	DI	DMEMQ5J
DMEMQ5J	DN	ME-1071
DMEMQ5J	MI	TTHI19T
DMEMQ5J	MN	Staphylococcus Beta-lactamase (Stap-coc blaZ)
DMEMQ5J	MT	DTT
DMEMQ5J	MA	Inhibitor
DMEMQ5J	RN	Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
DMEMQ5J	RU	https://pubmed.ncbi.nlm.nih.gov/23489027

DM39PSZ	DI	DM39PSZ
DM39PSZ	DN	ME1100
DM39PSZ	MI	TTOVFH2
DM39PSZ	MN	Bacterial 30S ribosomal RNA (Bact 30S rRNA)
DM39PSZ	MT	DTT
DM39PSZ	MA	Inhibitor
DM39PSZ	RN	ClinicalTrials.gov (NCT01961830) Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers. U.S. National Institutes of Health.
DM39PSZ	RU	https://clinicaltrials.gov/ct2/show/NCT01961830

DMFNYQ9	DI	DMFNYQ9
DMFNYQ9	DN	ME-401
DMFNYQ9	MI	TTGBPJE
DMFNYQ9	MN	PI3-kinase delta (PIK3CD)
DMFNYQ9	MT	DTT
DMFNYQ9	MA	Inhibitor
DMFNYQ9	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFNYQ9	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMYVBU6	DI	DMYVBU6
DMYVBU6	DN	MEDI0562
DMYVBU6	MI	TTL31H0
DMYVBU6	MN	OX40L receptor (CD134)
DMYVBU6	MT	DTT
DMYVBU6	MA	Agonist
DMYVBU6	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMYVBU6	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMPLFBV	DI	DMPLFBV
DMPLFBV	DN	MEDI0680
DMPLFBV	MI	TTNBFWK
DMPLFBV	MN	Programmed cell death protein 1 (PD-1)
DMPLFBV	MT	DTT
DMPLFBV	RN	A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73.
DMPLFBV	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/

DMD9OVI	DI	DMD9OVI
DMD9OVI	DN	MEDI1191
DMD9OVI	MI	TTG68FB
DMD9OVI	MN	Interleukine 12 (IL-12)
DMD9OVI	MT	DTT
DMD9OVI	MA	Replacement
DMD9OVI	RN	Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298.
DMD9OVI	RU	https://pubmed.ncbi.nlm.nih.gov/32817076

DMQDBSU	DI	DMQDBSU
DMQDBSU	DN	MEDI1341
DMQDBSU	MI	TT08OSU
DMQDBSU	MN	Synuclein alpha (SNCA)
DMQDBSU	MT	DTT
DMQDBSU	MA	Inhibitor
DMQDBSU	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMQDBSU	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DMX0DUH	DI	DMX0DUH
DMX0DUH	DN	MEDI2228
DMX0DUH	MI	TTZ3P4W
DMX0DUH	MN	B-cell maturation protein (TNFRSF17)
DMX0DUH	MT	DTT
DMX0DUH	MA	Inhibitor
DMX0DUH	RN	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.
DMX0DUH	RU	https://pubmed.ncbi.nlm.nih.gov/32060401

DMCMYPX	DI	DMCMYPX
DMCMYPX	DN	MEDI-2338
DMCMYPX	MI	TTRICUF
DMCMYPX	MN	Interleukin-18 (IL18)
DMCMYPX	MT	DTT
DMCMYPX	MA	Modulator
DMCMYPX	RN	Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412.
DMCMYPX	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010626/

DM0H5JD	DI	DM0H5JD
DM0H5JD	DN	MEDI3617
DM0H5JD	MI	TTKLQTJ
DM0H5JD	MN	Angiopoietin-2 (ANGPT2)
DM0H5JD	MT	DTT
DM0H5JD	MA	Inhibitor
DM0H5JD	RN	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15;24(12):2749-2757.
DM0H5JD	RU	https://pubmed.ncbi.nlm.nih.gov/29559563

DMBI4EN	DI	DMBI4EN
DMBI4EN	DN	MEDI4212
DMBI4EN	MI	TTYJQTF
DMBI4EN	MN	Immunoglobulin E (IgE)
DMBI4EN	MT	DTT
DMBI4EN	MA	Modulator
DMBI4EN	RN	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
DMBI4EN	RU	https://pubmed.ncbi.nlm.nih.gov/24583620

DMNI60O	DI	DMNI60O
DMNI60O	DN	MEDI4276
DMNI60O	MI	TT6EO5L
DMNI60O	MN	Erbb2 tyrosine kinase receptor (HER2)
DMNI60O	MT	DTT
DMNI60O	MA	Modulator
DMNI60O	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMNI60O	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DME7BMT	DI	DME7BMT
DME7BMT	DN	MEDI4920
DME7BMT	MI	TTIJP3Q
DME7BMT	MN	TNF related activation protein (CD40LG)
DME7BMT	MT	DTT
DME7BMT	MA	Inhibitor
DME7BMT	RN	ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
DME7BMT	RU	https://clinicaltrials.gov/ct2/show/NCT02151110

DM3IJQ5	DI	DM3IJQ5
DM3IJQ5	DN	MEDI5117
DM3IJQ5	MI	TTT1V78
DM3IJQ5	MN	Interleukin-6 (IL6)
DM3IJQ5	MT	DTT
DM3IJQ5	MA	Modulator
DM3IJQ5	RN	Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807.
DM3IJQ5	RU	https://pubmed.ncbi.nlm.nih.gov/21723291

DM3WP70	DI	DM3WP70
DM3WP70	DN	MEDI-547
DM3WP70	MI	TTRJB2G
DM3WP70	MN	Ephrin type-A receptor 2 (EPHA2)
DM3WP70	MT	DTT
DM3WP70	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).
DM3WP70	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1822

DM6ADMG	DI	DM6ADMG
DM6ADMG	DN	MEDI-557
DM6ADMG	MI	TT57ID8
DM6ADMG	MN	Respiratory syncytial virus protein F (RSV F)
DM6ADMG	MT	DTT
DM6ADMG	RN	Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
DM6ADMG	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/

DMFWPLQ	DI	DMFWPLQ
DMFWPLQ	DN	MEDI-565
DMFWPLQ	MI	TTV3XPL
DMFWPLQ	MN	T-cell surface glycoprotein CD3 gamma (CD3G)
DMFWPLQ	MT	DTT
DMFWPLQ	MA	Modulator
DMFWPLQ	RN	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. 
DMFWPLQ	RU	https://www.ncbi.nlm.nih.gov/pubmed/25359367

DMCJFLS	DI	DMCJFLS
DMCJFLS	DN	MEDI-570
DMCJFLS	MI	TTE5VP6
DMCJFLS	MN	Inducible T-cell costimulator (ICOS)
DMCJFLS	MT	DTT
DMCJFLS	MA	Modulator
DMCJFLS	RN	B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4.
DMCJFLS	RU	https://pubmed.ncbi.nlm.nih.gov/23566679

DMNL8MO	DI	DMNL8MO
DMNL8MO	DN	MEDI-573
DMNL8MO	MI	TTT6LOU
DMNL8MO	MN	Insulin-like growth factor-I (IGF1)
DMNL8MO	MT	DTT
DMNL8MO	MA	Modulator
DMNL8MO	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DMNL8MO	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMJ1E24	DI	DMJ1E24
DMJ1E24	DN	MEDI5752
DMJ1E24	MI	TTI2S1D
DMJ1E24	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DMJ1E24	MT	DTT
DMJ1E24	MA	Inhibitor
DMJ1E24	RN	Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
DMJ1E24	RU	https://pubmed.ncbi.nlm.nih.gov/33947716

DMJ1E24	DI	DMJ1E24
DMJ1E24	DN	MEDI5752
DMJ1E24	MI	TTNBFWK
DMJ1E24	MN	Programmed cell death protein 1 (PD-1)
DMJ1E24	MT	DTT
DMJ1E24	MA	Inhibitor
DMJ1E24	RN	Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010.
DMJ1E24	RU	https://pubmed.ncbi.nlm.nih.gov/33947716

DMPW21Z	DI	DMPW21Z
DMPW21Z	DN	MEDI-578
DMPW21Z	MI	TTDN3LF
DMPW21Z	MN	Nerve growth factor (NGF)
DMPW21Z	MT	DTT
DMPW21Z	MA	Modulator
DMPW21Z	RN	Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4.
DMPW21Z	RU	https://www.ncbi.nlm.nih.gov/pubmed/21389990

DM1YSMD	DI	DM1YSMD
DM1YSMD	DN	MEDI6383
DM1YSMD	MI	TTBW580
DM1YSMD	MN	TAX transcriptionally-activated glycoprotein 1 (OX40)
DM1YSMD	MT	DTT
DM1YSMD	RN	J Clin Oncol 33, 2015 (suppl; abstr 3056).
DM1YSMD	RU	http://meetinglibrary.asco.org/content/150554-156

DM8BXDI	DI	DM8BXDI
DM8BXDI	DN	MEDI7814
DM8BXDI	MI	TTKANGO
DM8BXDI	MN	Complement C5 (CO5)
DM8BXDI	MT	DTT
DM8BXDI	MA	Modulator
DM8BXDI	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM8BXDI	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DM0J7UR	DI	DM0J7UR
DM0J7UR	DN	MEDI9197
DM0J7UR	MI	TTRJ1K4
DM0J7UR	MN	Toll-like receptor 7 (TLR7)
DM0J7UR	MT	DTT
DM0J7UR	MA	Agonist
DM0J7UR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0J7UR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM0J7UR	DI	DM0J7UR
DM0J7UR	DN	MEDI9197
DM0J7UR	MI	TT8CWFK
DM0J7UR	MN	Toll-like receptor 8 (TLR8)
DM0J7UR	MT	DTT
DM0J7UR	MA	Agonist
DM0J7UR	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DM0J7UR	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM1ALHT	DI	DM1ALHT
DM1ALHT	DN	MEDl-551
DM1ALHT	MI	TTW640A
DM1ALHT	MN	B-lymphocyte surface antigen B4 (CD19)
DM1ALHT	MT	DTT
DM1ALHT	RN	CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
DM1ALHT	RU	https://pubmed.ncbi.nlm.nih.gov/22820352

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTZ97H5
DMA1KQV	MN	Phosphodiesterase 4A (PDE4A)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTVIAT9
DMA1KQV	MN	Phosphodiesterase 4B (PDE4B)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DMA1KQV	DI	DMA1KQV
DMA1KQV	DN	MEM-1414
DMA1KQV	MI	TTSKMI8
DMA1KQV	MN	Phosphodiesterase 4D (PDE4D)
DMA1KQV	MT	DTT
DMA1KQV	MA	Inhibitor
DMA1KQV	RN	The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166.
DMA1KQV	RU	https://pubmed.ncbi.nlm.nih.gov/25351474

DME18UM	DI	DME18UM
DME18UM	DN	MER-102
DME18UM	MI	TT4QPUL
DME18UM	MN	Antithrombin-III (ATIII)
DME18UM	MT	DTT
DME18UM	MA	Inhibitor
DME18UM	RN	Clinical pipeline report, company report or official report of Merrion's GIPET technology.
DME18UM	RU	http://www.merrionpharma.com/content/portfolio/mer102.asp

DMQSJ9T	DI	DMQSJ9T
DMQSJ9T	DN	Meso-CART
DMQSJ9T	MI	TT4RXME
DMQSJ9T	MN	Mesothelin (MSLN)
DMQSJ9T	MT	DTT
DMQSJ9T	MA	CAR-T-Cell-Therapy
DMQSJ9T	RN	ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
DMQSJ9T	RU	https://clinicaltrials.gov/ct2/show/NCT02706782

DMHXA79	DI	DMHXA79
DMHXA79	DN	Mesothelin-targeted T cells
DMHXA79	MI	TT4RXME
DMHXA79	MN	Mesothelin (MSLN)
DMHXA79	MT	DTT
DMHXA79	MA	CAR-T-Cell-Therapy
DMHXA79	RN	ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer
DMHXA79	RU	https://clinicaltrials.gov/ct2/show/NCT02792114

DMTQ4PN	DI	DMTQ4PN
DMTQ4PN	DN	Metastat
DMTQ4PN	MI	TTLM12X
DMTQ4PN	MN	Matrix metalloproteinase-2 (MMP-2)
DMTQ4PN	MT	DTT
DMTQ4PN	MA	Inhibitor
DMTQ4PN	RN	Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
DMTQ4PN	RU	https://pubmed.ncbi.nlm.nih.gov/12209155

DMQE4IX	DI	DMQE4IX
DMQE4IX	DN	MG-1102
DMQE4IX	MI	TTGUMYS
DMQE4IX	MN	Apolipoprotein(a) (LPA)
DMQE4IX	MT	DTT
DMQE4IX	MA	Modulator
DMQE4IX	RN	Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia. 2012 Apr;14(4):335-43.
DMQE4IX	RU	https://pubmed.ncbi.nlm.nih.gov/22577348

DM2PVLH	DI	DM2PVLH
DM2PVLH	DN	MGA271
DM2PVLH	MI	TT6CQUM
DM2PVLH	MN	B7 homolog 3 (CD276)
DM2PVLH	MT	DTT
DM2PVLH	MA	Modulator
DM2PVLH	RN	T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
DM2PVLH	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107447/

DMQB4VN	DI	DMQB4VN
DMQB4VN	DN	MGD006
DMQB4VN	MI	TTENHJ0
DMQB4VN	MN	Interleukin 3 receptor alpha (IL3RA)
DMQB4VN	MT	DTT
DMQB4VN	MA	Modulator
DMQB4VN	RN	A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82.
DMQB4VN	RU	https://www.ncbi.nlm.nih.gov/pubmed/26019218

DMQB4VN	DI	DMQB4VN
DMQB4VN	DN	MGD006
DMQB4VN	MI	TTUN7MC
DMQB4VN	MN	T-cell surface glycoprotein CD3 (CD3)
DMQB4VN	MT	DTT
DMQB4VN	MA	Modulator
DMQB4VN	RN	A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
DMQB4VN	RU	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288763/

DME4B8I	DI	DME4B8I
DME4B8I	DN	MGD009
DME4B8I	MI	TT6CQUM
DME4B8I	MN	B7 homolog 3 (CD276)
DME4B8I	MT	DTT
DME4B8I	MA	Immunomodulator
DME4B8I	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DME4B8I	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf

DMA368V	DI	DMA368V
DMA368V	DN	MGD010
DMA368V	MI	TTBN5I7
DMA368V	MN	B-cell-specific glycoprotein B29 (CD79B)
DMA368V	MT	DTT
DMA368V	MA	Modulator
DMA368V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA368V	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMA368V	DI	DMA368V
DMA368V	DN	MGD010
DMA368V	MI	TT5RWKQ
DMA368V	MN	Immunoglobulin gamma Fc receptor IIB (FCGR2B)
DMA368V	MT	DTT
DMA368V	MA	Modulator
DMA368V	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMA368V	RU	http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf

DMZN5QX	DI	DMZN5QX
DMZN5QX	DN	MGD014
DMZN5QX	MI	TTEC2T3
DMZN5QX	MN	Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)
DMZN5QX	MT	DTT
DMZN5QX	MA	Inhibitor
DMZN5QX	RN	Clinical pipeline report, company report or official report of MacroGenics.
DMZN5QX	RU	https://www.macrogenics.com/mgd014/

DMZN5QX	DI	DMZN5QX
DMZN5QX	DN	MGD014
DMZN5QX	MI	TTUN7MC
DMZN5QX	MN	T-cell surface glycoprotein CD3 (CD3)
DMZN5QX	MT	DTT
DMZN5QX	MA	Inhibitor
DMZN5QX	RN	Clinical pipeline report, company report or official report of MacroGenics.
DMZN5QX	RU	https://www.macrogenics.com/mgd014/

DM2BYWI	DI	DM2BYWI
DM2BYWI	DN	MGD019
DM2BYWI	MI	TTI2S1D
DM2BYWI	MN	Cytotoxic T-lymphocyte protein 4 (CTLA-4)
DM2BYWI	MT	DTT
DM2BYWI	MA	Inhibitor
DM2BYWI	RN	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
DM2BYWI	RU	https://pubmed.ncbi.nlm.nih.gov/33377134

DM2BYWI	DI	DM2BYWI
DM2BYWI	DN	MGD019
DM2BYWI	MI	TTNBFWK
DM2BYWI	MN	Programmed cell death protein 1 (PD-1)
DM2BYWI	MT	DTT
DM2BYWI	MA	Inhibitor
DM2BYWI	RN	Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163.
DM2BYWI	RU	https://pubmed.ncbi.nlm.nih.gov/33377134

DMTS5VF	DI	DMTS5VF
DMTS5VF	DN	MGN-1706
DMTS5VF	MI	TTSHG0T
DMTS5VF	MN	Toll-like receptor 9 (TLR9)
DMTS5VF	MT	DTT
DMTS5VF	MA	Agonist
DMTS5VF	RN	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759).
DMTS5VF	RU	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	DE4LYSA
DMU9VDS	MN	Cytochrome P450 3A4 (CYP3A4)
DMU9VDS	MT	DME
DMU9VDS	MA	Metabolism
DMU9VDS	RN	Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol. 2003 Oct;43(10):1091-100.
DMU9VDS	RU	https://www.ncbi.nlm.nih.gov/pubmed/?term=14517191

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	DTUGYRD
DMU9VDS	MN	P-glycoprotein 1 (ABCB1)
DMU9VDS	MT	DTP
DMU9VDS	MA	Substrate
DMU9VDS	RN	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
DMU9VDS	RU	https://doi.org/10.1007/s11095-012-0935-x

DMU9VDS	DI	DMU9VDS
DMU9VDS	DN	Mibefradil
DMU9VDS	MI	TTZPWGN
DMU9VDS	MN	Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)
DMU9VDS	MT	DTT
DMU9VDS	MA	Inhibitor
DMU9VDS	RN	Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
DMU9VDS	RU	https://pubmed.ncbi.nlm.nih.gov/10991994

DMTUVCG	DI	DMTUVCG
DMTUVCG	DN	MIK665
DMTUVCG	MI	TTL53M6
DMTUVCG	MN	Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)
DMTUVCG	MT	DTT
DMTUVCG	MA	Inhibitor
DMTUVCG	RN	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
DMTUVCG	RU	https://pubmed.ncbi.nlm.nih.gov/32513939

DMDER9S	DI	DMDER9S
DMDER9S	DN	Minnelide
DMDER9S	MI	TTHYBIX
DMDER9S	MN	Heat shock protein 70 (HSP70)
DMDER9S	MT	DTT
DMDER9S	MA	Inhibitor
DMDER9S	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMDER9S	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DM5VEN9	DI	DM5VEN9
DM5VEN9	DN	Minnelide 001
DM5VEN9	MI	TTHYBIX
DM5VEN9	MN	Heat shock protein 70 (HSP70)
DM5VEN9	MT	DTT
DM5VEN9	MA	Modulator
DM5VEN9	RN	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
DM5VEN9	RU	https://www.ncbi.nlm.nih.gov/pubmed/15950434

DMCPF90	DI	DMCPF90
DMCPF90	DN	Mivebresib
DMCPF90	MI	TTE4BSY
DMCPF90	MN	Bromodomain and extraterminal domain protein (BET)
DMCPF90	MT	DTT
DMCPF90	MA	Inhibitor
DMCPF90	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMCPF90	RU	http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf

DMFLP21	DI	DMFLP21
DMFLP21	DN	MK 8719
DMFLP21	MI	TT2I6UX
DMFLP21	MN	Beta-N-acetylhexosaminidase (OGA)
DMFLP21	MT	DTT
DMFLP21	MA	Inhibitor
DMFLP21	RN	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
DMFLP21	RU	http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf

DM2TAUR	DI	DM2TAUR
DM2TAUR	DN	MK-0731
DM2TAUR	MI	TTTRP0H
DM2TAUR	MN	Kinesin-like protein KIF11 (KIF11)
DM2TAUR	MT	DTT
DM2TAUR	MA	Inhibitor
DM2TAUR	RN	Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39.
DM2TAUR	RU	https://pubmed.ncbi.nlm.nih.gov/22825217

DMHS79I	DI	DMHS79I
DMHS79I	DN	MK-1092
DMHS79I	MI	TTNVEIR
DMHS79I	MN	Prostaglandin D2 receptor (PTGDR)
DMHS79I	MT	DTT
DMHS79I	MA	Antagonist
DMHS79I	RN	The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64.
DMHS79I	RU	https://pubmed.ncbi.nlm.nih.gov/30528099

DME1ZAH	DI	DME1ZAH
DME1ZAH	DN	MK-1496
DME1ZAH	MI	TTIYVQP
DME1ZAH	MN	Polo-like kinase 1 (PLK1)
DME1ZAH	MT	DTT
DME1ZAH	MA	Inhibitor
DME1ZAH	RN	J Clin Oncol 29: 2011 (suppl; abstr 3012).
DME1ZAH	RU	http://meetinglibrary.asco.org/content/73894-102

DMKNH8B	DI	DMKNH8B
DMKNH8B	DN	MK-2118
DMKNH8B	MI	TTT402Y
DMKNH8B	MN	Stimulator of interferon genes protein (TMEM173)
DMKNH8B	MT	DTT
DMKNH8B	MA	Agonist
DMKNH8B	RN	National Cancer Institute Drug Dictionary (drug name ML2118).
DMKNH8B	RU	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-2118

DMUHOJP	DI	DMUHOJP
DMUHOJP	DN	MK-2637
DMUHOJP	MI	TTHJTF7
DMUHOJP	MN	Glycine transporter GlyT-1 (SLC6A9)
DMUHOJP	MT	DTT
DMUHOJP	MA	Modulator
DMUHOJP	RN	Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015 Jan;69(1):33-40.
DMUHOJP	RU	https://pubmed.ncbi.nlm.nih.gov/25196464

DM5EFPS	DI	DM5EFPS
DM5EFPS	DN	MK-3134
DM5EFPS	MI	TT9JNIC
DM5EFPS	MN	Histamine H3 receptor (H3R)
DM5EFPS	MT	DTT
DM5EFPS	MA	Agonist
DM5EFPS	RN	Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24.
DM5EFPS	RU	https://pubmed.ncbi.nlm.nih.gov/21644059

DMG0Q27	DI	DMG0Q27
DMG0Q27	DN	MK-3281
DMG0Q27	MI	TTMVBWH
DMG0Q27	MN	Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B)
DMG0Q27	MT	DTT
DMG0Q27	MA	Inhibitor
DMG0Q27	RN	Clinical pipeline report, company report or official report of Merck (2011).
DMG0Q27	RU	http://www.merck.com/index.html

DMW2O5D	DI	DMW2O5D
DMW2O5D	DN	MK-3328
DMW2O5D	MI	TTHS256
DMW2O5D	MN	Metabotropic glutamate receptor 5 (mGluR5)
DMW2O5D	MT	DTT
DMW2O5D	MA	Modulator
DMW2O5D	RN	URL: http://www.guidetopharmacology.org Nucleic Aci